<SEC-DOCUMENT>0000875045-17-000009.txt : 20170202
<SEC-HEADER>0000875045-17-000009.hdr.sgml : 20170202
<ACCEPTANCE-DATETIME>20170202162400
ACCESSION NUMBER:		0000875045-17-000009
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		185
CONFORMED PERIOD OF REPORT:	20161231
FILED AS OF DATE:		20170202
DATE AS OF CHANGE:		20170202

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOGEN INC.
		CENTRAL INDEX KEY:			0000875045
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				330112644
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19311
		FILM NUMBER:		17568576

	BUSINESS ADDRESS:	
		STREET 1:		225 BINNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		7814642000

	MAIL ADDRESS:	
		STREET 1:		225 BINNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOGEN IDEC INC.
		DATE OF NAME CHANGE:	20070427

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOGEN IDEC INC
		DATE OF NAME CHANGE:	20031112

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	IDEC PHARMACEUTICALS CORP / DE
		DATE OF NAME CHANGE:	19970530
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>biib-20161231x10k.htm
<DESCRIPTION>10-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s2507C85CF481487B7F3E2017068340C8"></a></div><div></div><div><br></div><div style="line-height:100%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:100%;padding-top:4px;text-align:center;font-size:14pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:14pt;font-weight:bold;">UNITED STATES SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:100%;padding-top:4px;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">Washington,&#160;D.C. 20549</font></div><div style="line-height:100%;padding-top:4px;text-align:center;font-size:18pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:18pt;font-weight:bold;">Form&#160;10-K</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:6%;"></td><td style="width:94%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">x</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">For the fiscal year ended December 31, 2016</font></div></td></tr></table></div></div><div style="line-height:100%;padding-top:4px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">or</font></div><div style="line-height:100%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:6%;"></td><td style="width:94%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div></td></tr></table></div></div><div style="line-height:100%;padding-top:4px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Commission file number:&#160;0-19311</font></div><div style="line-height:100%;padding-top:4px;text-align:center;"><img src="biogenlogostandarda06.jpg" alt="biogenlogostandarda06.jpg" style="height:57px;width:173px;"></div><div style="line-height:100%;padding-top:4px;text-align:center;font-size:24pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:24pt;font-weight:bold;">BIOGEN INC.</font></div><div style="line-height:100%;padding-top:4px;text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">(Exact name of registrant as specified in its charter)</font></div><div style="line-height:100%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Delaware</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">33-0112644</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">(State or other jurisdiction of incorporation or organization)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">(I.R.S. Employer Identification No.)</font></div></td></tr></table></div></div><div style="line-height:100%;padding-top:4px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">225 Binney Street, Cambridge, Massachusetts 02142</font></div><div style="line-height:100%;padding-top:4px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">(617)&#160;679-2000</font></div><div style="line-height:100%;padding-top:4px;text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">(Address, including zip code, and telephone number, including area code, of Registrant&#8217;s principal executive offices)</font></div><div style="line-height:100%;padding-top:4px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Securities registered pursuant to Section&#160;12(b) of the Act:</font></div><div style="line-height:100%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Title of Each Class</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Name of Each Exchange on Which Registered</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Common Stock, $0.0005&#160;par value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">The Nasdaq Global Select Market</font></div></td></tr></table></div></div><div style="line-height:100%;padding-top:4px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Securities registered pursuant to Section&#160;12(g) of the Act:</font></div><div style="line-height:100%;padding-top:4px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">None</font></div><div style="line-height:100%;padding-top:4px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.&#160;&#160;&#160;&#160;Yes&#160;</font><font style="font-family:Wingdings;font-size:10pt;">x</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div style="line-height:100%;padding-top:4px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or 15(d) of the Act.&#160;&#160;&#160;&#160;Yes&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No&#160;</font><font style="font-family:Wingdings;font-size:10pt;">x</font></div><div style="line-height:100%;padding-top:4px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;&#160;&#160;Yes&#160;</font><font style="font-family:Wingdings;font-size:10pt;">x</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;No&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div style="line-height:100%;padding-top:4px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule&#160;405 of Regulation&#160;S-T during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit and post such files):&#160;&#160;&#160;&#160;Yes&#160;</font><font style="font-family:Wingdings;font-size:10pt;">x</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div style="line-height:100%;padding-top:4px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indicate by check mark if disclosure of delinquent filers pursuant to Item&#160;405 of Regulation&#160;S-K is not contained herein, and will not be contained, to the best of the registrant&#8217;s knowledge, in definitive proxy or information statements incorporated by reference in Part&#160;III of this Form&#160;10-K or any amendment to this Form&#160;10-K.&#160;&#160;&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">x</font></div><div style="line-height:100%;padding-top:4px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221; and &#8220;smaller reporting company&#8221; in Rule 12b-2 of the Exchange Act.</font></div><div style="line-height:100%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.81481481481481%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:20%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td><td style="width:35%;"></td><td style="width:1%;"></td><td style="width:25%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Large&#160;accelerated&#160;filer&#160;</font><font style="font-family:Wingdings;font-size:10pt;">x</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accelerated&#160;filer </font><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-accelerated&#160;filer </font><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Smaller&#160;reporting&#160;company&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">(Do&#160;not&#160;check&#160;if&#160;a&#160;smaller&#160;reporting&#160;company)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:100%;padding-top:4px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Act).&#160;&#160;&#160;&#160;Yes&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No&#160;</font><font style="font-family:Wingdings;font-size:10pt;">x</font></div><div style="line-height:100%;padding-top:4px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The aggregate market value of the registrant&#8217;s common stock held by non-affiliates of the registrant (without admitting that any person whose shares are not included in such calculation is an affiliate) computed by reference to the price at which the common stock was last sold as of the last business day of the registrant&#8217;s most recently completed second fiscal quarter was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$52,843,669,823</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:100%;padding-top:4px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">January&#160;27, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the registrant had </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">215,951,945</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares of common stock, $0.0005&#160;par value, outstanding.</font></div><div style="line-height:100%;padding-top:4px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">DOCUMENTS INCORPORATED BY REFERENCE</font></div><div style="line-height:100%;padding-top:4px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Portions of the definitive proxy statement for our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Annual Meeting of Stockholders are incorporated by reference into Part&#160;III of this report.</font></div><div style="line-height:100%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="sB46CD385D2FE1C8943A8201706CFE8C9"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">BIOGEN INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">ANNUAL REPORT ON FORM&#160;10-K</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">For the Year Ended December 31, 2016</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">TABLE OF CONTENTS</font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:9%;"></td><td style="width:76%;"></td><td style="width:15%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Page</font></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;" href="#sF71E46622967387263112017077D85D1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">PART&#160;I</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s980F3D57A803760B6204201707AA605E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 1.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s980F3D57A803760B6204201707AA605E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Business</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s980F3D57A803760B6204201707AA605E">1</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s90E7A4539EE0A80EE7AB201709F0C16A"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item&#160;1A.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s90E7A4539EE0A80EE7AB201709F0C16A"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Risk Factors</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s90E7A4539EE0A80EE7AB201709F0C16A">29</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s459292DC67BAB8AD22CE20170A131520"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 1B.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s459292DC67BAB8AD22CE20170A131520"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unresolved Staff Comments</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s459292DC67BAB8AD22CE20170A131520">41</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sE99905CC2A8A59ED6CF420170A439E17"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 2.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sE99905CC2A8A59ED6CF420170A439E17"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Properties</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sE99905CC2A8A59ED6CF420170A439E17">42</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sB414B36729A55C04B2F520170A6D251B"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 3.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sB414B36729A55C04B2F520170A6D251B"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Legal Proceedings</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sB414B36729A55C04B2F520170A6D251B">43</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s299375A7363816F4ECE220170A9725A2"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 4.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s299375A7363816F4ECE220170A9725A2"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mine Safety Disclosures</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s299375A7363816F4ECE220170A9725A2">43</a></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;" href="#s6CFA95DBDE82A948202220170AB9A0CD"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">PART&#160;II</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s1FB62878215C3C11095820166D62D73E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 5.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s1FB62878215C3C11095820166D62D73E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s1FB62878215C3C11095820166D62D73E">44</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sE2566B25C7513ED764422016879AF322"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 6.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sE2566B25C7513ED764422016879AF322"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selected Financial Data</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sE2566B25C7513ED764422016879AF322">46</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s092A7CD20543F5F4464620170B3E42DC"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 7.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s092A7CD20543F5F4464620170B3E42DC"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s092A7CD20543F5F4464620170B3E42DC">48</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sCC38D2DD8152CA3D1F0820170F470F15"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 7A.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sCC38D2DD8152CA3D1F0820170F470F15"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Quantitative and Qualitative Disclosures About Market Risk</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sCC38D2DD8152CA3D1F0820170F470F15">79</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sCA88A35D47BB55E1ECEC20170F7AC1AC"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 8.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sCA88A35D47BB55E1ECEC20170F7AC1AC"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Financial Statements and Supplementary Data</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sCA88A35D47BB55E1ECEC20170F7AC1AC">81</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sA3D5CDED4B09A0FC8BBA20170FABF364"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 9.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sA3D5CDED4B09A0FC8BBA20170FABF364"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sA3D5CDED4B09A0FC8BBA20170FABF364">81</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sDAC09AD994C658BE6C7720170FD43091"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 9A.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sDAC09AD994C658BE6C7720170FD43091"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Controls and Procedures</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sDAC09AD994C658BE6C7720170FD43091">82</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sEBCFB87E1B7347D332B12017100385C2"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 9B.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sEBCFB87E1B7347D332B12017100385C2"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other Information</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sEBCFB87E1B7347D332B12017100385C2">82</a></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;" href="#s53D5B6A6A920BFE6A4B820171021D52E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">PART&#160;III</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sFE0120AC1BF11EBFB1D720171041948D"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 10.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sFE0120AC1BF11EBFB1D720171041948D"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Directors, Executive Officers and Corporate Governance</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sFE0120AC1BF11EBFB1D720171041948D">83</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s6BC898E23C7A3A6E571520171075F6CE"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 11.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s6BC898E23C7A3A6E571520171075F6CE"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Executive Compensation</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s6BC898E23C7A3A6E571520171075F6CE">83</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sD9DA93C4FDFEA74630AB201710A8E79C"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 12.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sD9DA93C4FDFEA74630AB201710A8E79C"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sD9DA93C4FDFEA74630AB201710A8E79C">83</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s29759CFD2E1B09023D91201710C74D49"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 13.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s29759CFD2E1B09023D91201710C74D49"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Certain Relationships and Related Transactions, and Director Independence</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s29759CFD2E1B09023D91201710C74D49">83</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sBFB944790805D270C329201710F0DD8A"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 14.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sBFB944790805D270C329201710F0DD8A"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Principal Accounting Fees and Services</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sBFB944790805D270C329201710F0DD8A">83</a></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;" href="#sFC458658BCC73B87EBF3201711199A3B"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">PART&#160;IV</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sC102002B827A94949B9E2017113C4204"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item&#160;15.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sC102002B827A94949B9E2017113C4204"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Exhibits and Financial Statement Schedules</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sC102002B827A94949B9E2017113C4204">84</a></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s2BF353079D72E44786832017116E7926"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Signatures</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s2BF353079D72E44786832017116E7926">85</a></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s1678D8538B3524784B01201711953BED"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Consolidated Financial Statements</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s1678D8538B3524784B01201711953BED">F- 1</a></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s391239CD1182CE997E4420171877994D"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Exhibit Index</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s391239CD1182CE997E4420171877994D">A- 1</a></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="s92A1ED310ACD5CFCB732201707011FD0"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">NOTE&#160;REGARDING FORWARD-LOOKING STATEMENTS </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">This report contains forward-looking statements that are being made pursuant to the provisions of the Private Securities Litigation Reform Act of 1995 (the Act) with the intention of obtaining the benefits of the &#8220;Safe Harbor&#8221; provisions of the Act. These forward-looking statements may be accompanied by such words as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;forecast,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;project,&#8221; &#8220;target,&#8221; &#8220;will&#8221; and other words and terms of similar meaning. Reference is made in particular to forward-looking statements regarding:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the anticipated amount, timing and accounting of revenues, contingent payments, milestone, royalty and other payments under licensing, collaboration or acquisition agreements, tax positions and contingencies, collectability of receivables, pre-approval inventory, cost of sales, research and development costs, compensation and other selling, general and administrative expenses, amortization of intangible assets, foreign currency exchange risk, estimated fair value of assets and liabilities, and impairment assessments;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">expectations, plans and prospects relating to sales, pricing, growth and launch of our marketed and pipeline products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the potential impact of increased product competition in the markets in which we compete;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the spin off of our hemophilia business, including its anticipated benefits, costs and tax treatment;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the anticipated amount and timing of payments under the Settlement and License Agreement with Forward Pharma A/S (Forward Pharma) and the timing, outcome and impact of administrative, regulatory, legal and other proceedings related to our patents and other proprietary intellectual property rights under our agreement with Forward Pharma;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the costs and timing of potential clinical trials, filing and approvals, and the potential therapeutic scope of the development and commercialization of our and our collaborators&#8217; pipeline products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the drivers for growing our business, including our plans and intent to commit resources relating to business development opportunities and research and development programs;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">potential costs and expenses incurred in connection with corporate restructurings and to execute business transformation and optimization initiatives; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our manufacturing capacity, use of third-party contract manufacturing organizations and plans and timing relating to the expansion of our manufacturing capabilities, including anticipated investments and activities in new manufacturing facilities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the expected financial impact of ceasing manufacturing activities and vacating our biologics manufacturing facility in Cambridge, MA and warehouse space in Somerville, MA;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the potential impact on our results of operations and liquidity of the United Kingdom's (U.K.'s) intent to voluntarily depart from the European Union (E.U.);</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the impact of the continued uncertainty of the credit and economic conditions in certain countries in Europe and our collection of accounts receivable in such countries;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the potential impact of healthcare reform in the United States (U.S.) and measures being taken worldwide designed to reduce healthcare costs to constrain the overall level of government expenditures, including the impact of pricing actions and reduced reimbursement for our products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the timing, outcome and impact of administrative, regulatory, legal and other proceedings related to patents and other proprietary and intellectual property rights, tax audits, assessments and settlements, pricing matters, sales and promotional practices, product liability and other matters;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">lease commitments, purchase obligations and the timing and satisfaction of other contractual obligations;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our ability to finance our operations and business initiatives and obtain funding for such activities; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the impact of new laws and accounting standards.</font></div></td></tr></table><div><br></div><div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These forward-looking statements involve risks and uncertainties, including those that are described in the &#8220;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risk Factors</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8221; section of this report and elsewhere in this report, that could cause actual results to differ materially from those reflected in such statements. You should not place undue reliance on these statements. Forward-looking statements speak only as of the date of this report. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.</font></div><div><a name="sFFA499214554DB8DBA3220170723E8E0"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">NOTE REGARDING COMPANY AND PRODUCT REFERENCES</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">References in this report to:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8220;Biogen,&#8221; the &#8220;company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Biogen Inc. and its consolidated subsidiaries;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8220;RITUXAN&#8221; refers to both RITUXAN (the trade name for rituximab in the U.S., Canada and Japan) and MabThera (the trade name for rituximab outside the U.S., Canada and Japan);</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">"ELOCTATE" refers to both ELOCTATE (the trade name for Antihemophilic Factor (Recombinant), Fc Fusion Protein in the U.S., Canada and Japan) and ELOCTA (the trade name for Antihemophilic Factor (Recombinant), Fc Fusion Protein in the E.U.); and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8220;ANGIOMAX&#8221; refers to both ANGIOMAX (the trade name for bivalirudin in the U.S., Canada and Latin America) and ANGIOX (the trade name for bivalirudin in Europe).</font></div></td></tr></table><div><a name="s42892AA2E101F4C35E8B201707792654"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">NOTE&#160;REGARDING TRADEMARKS</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">AVONEX&#174;, BENEPALI&#174;, FLIXABI&#174;, PLEGRIDY&#174;, RITUXAN&#174;, TECFIDERA&#174;, TYSABRI&#174; and ZINBRYTA&#174; are registered trademarks of Biogen. FUMADERM</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">TM</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and SPINRAZA</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">TM </sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">are trademarks of Biogen. ALPROLIX&#174;, ELOCTATE&#174;, ENBREL&#174;, FAMPYRA</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">TM</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, GAZYVA&#174;, HUMIRA&#174;, OCREVUS&#174;, REMICADE&#174; and other trademarks referenced in this report are the property of their respective owners.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="sF71E46622967387263112017077D85D1"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">PART&#160;I</font></div><div><a name="s980F3D57A803760B6204201707AA605E"></a></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;1. &#160;&#160;&#160;&#160;Business</font></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Overview</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen is a global biopharmaceutical company focused on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). We also have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma and other potential anti-CD20 therapies under a collaboration agreement with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group (Roche Group). </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities, particularly within areas of our scientific, manufacturing and technical capabilities. For nearly two decades we have led in the research and development of new therapies to treat MS, resulting in our leading portfolio of MS treatments. Now our research is focused on additional improvements in the treatment of MS, such as the development of next generation therapies for MS, with a goal to reverse or possibly repair damage caused by the disease. We are also applying our scientific expertise to solve some of the most challenging and complex diseases, including Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis (ALS), and are employing innovative technologies to discover potential treatments for rare and genetic disorders, including new ways of treating diseases through gene therapy.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our innovative drug development and commercialization activities are complemented by our biosimilar therapies that expand access to medicines and reduce the cost burden for healthcare systems. We are leveraging our manufacturing capabilities and know-how to develop, manufacture and market biosimilars through Samsung Bioepis, our joint venture with Samsung BioLogics Co. Ltd. (Samsung Biologics). Under this agreement, we are currently manufacturing and commercializing two anti-tumor necrosis factor (TNF) biosimilars in certain European Union (E.U.) countries.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1</font></div></div><hr style="page-break-after:always"><div><a name="sAD6C6E6CB65D7926F085201707D20595"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Key Developments</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During 2016 we had a number of key developments affecting our business.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Corporate Matters</font></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Hemophilia Spin-Off</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2016 we announced our intention to spin off our hemophilia business, Bioverativ Inc. (Bioverativ), as an independent, publicly traded company. Bioverativ will focus on the discovery, development and commercialization of therapies for treatment of hemophilia and other blood disorders, including ELOCTATE for the treatment of hemophilia A and ALPROLIX for the treatment of hemophilia B. Bioverativ will also assume all of our rights and obligations under our collaboration agreement with Swedish Orphan Biovitrum AB (Sobi) and our collaboration and license agreement with Sangamo Biosciences Inc. (Sangamo).</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On February 1, 2017, we completed the distribution of all the then outstanding shares of common stock of Bioverativ to Biogen stockholders, who received one share of Bioverativ common stock for every two shares of Biogen common stock. As a result of the distribution, Bioverativ is now an independent public company whose shares of common stock are trading under the symbol "BIVV" on the Nasdaq Global Select Market.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The financial results of Bioverativ are included in our consolidated results of operations and financial position in our audited consolidated financial statements for the periods presented in this Form 10-K. The financial results of Bioverativ will be excluded from our consolidated results of operations and financial position commencing February 1, 2017. For additional information regarding the separation of Bioverativ, please read Note 26, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Subsequent Events </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to our consolidated financial statements included in this report</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">.</font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Management Changes </font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During 2016 we appointed several new executives, each of whom has significant experience in the biopharmaceutical industry and is a leader in his or her functional area. These include Michel Vounatsos, Chief Executive Officer, Michael D. Ehlers, Executive Vice President, Research and Development and Paul McKenzie, Executive Vice President, Pharmaceutical Operations and Technology. For additional information related to these and our other Executive Officers, please read "Our Executive Officers" included in this report.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Cost Saving Initiatives</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2016 we initiated cost saving measures intended to realign our organizational structure in anticipation of the changes in roles and workforce resulting from our decision to spin off our hemophilia business, as well as to achieve further targeted cost reductions. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2016 after an evaluation of our manufacturing capacity and needs, we ceased manufacturing at our Cambridge, MA manufacturing facility and subleased our rights to this facility to Brammer Bio MA, LLC (Brammer). In addition to the sublease, Brammer purchased certain leasehold improvements and other assets at this facility and agreed to provide certain manufacturing and other transition and support services to us.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">TECFIDERA Settlement and License Agreement</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2017 we agreed to enter into a settlement and license agreement with Forward Pharma A/S (Forward Pharma). The settlement and license agreement provides us an irrevocable license to all intellectual property owned by Forward Pharma and results in the termination of the German Infringement Litigation. Under the terms of the settlement and license agreement with Forward Pharma, we agreed to pay Forward Pharma $1.25 billion in cash. During the fourth quarter of 2016 we recognized a pre-tax charge of $454.8 million related to this matter. For more information on the settlement and license agreement please read Note 21, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Commitments and Contingencies </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to our consolidated financial statements included in this report</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">.</font></div></div></div><br><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><div><a name="s78294BA71EC49568DCB6201707FBE704"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Product/Pipeline Developments</font></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:5%;"></td><td style="width:95%;"></td></tr><tr><td colspan="2" style="vertical-align:bottom;background-color:#2573ba;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#ffffff;font-weight:bold;">Multiple Sclerosis</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">TYSABRI (natalizumab)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2016 the European Commission (EC) approved a variation to the marketing authorization of TYSABRI, which extended its indication to include relapsing-remitting MS patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy. TYSABRI was previously indicated only for patients who had failed to respond to beta-interferon or glatiramer acetate in the E.U.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">ZINBRYTA (daclizumab)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ZINBRYTA was approved for the treatment of relapsing forms of MS in the U.S. in May 2016 and the E.U. in July 2016.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">Opicinumab (Anti-LINGO-1)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2016 we reported top-line results from SYNERGY, our Phase 2 trial evaluating opicinumab in people with relapsing forms of MS. Opicinumab did not meet the primary endpoint or its secondary efficacy endpoint. However, based on these results, there was a subset of patients within the study that we believe have potential to benefit from treatment, and we are therefore planning another Phase 2 clinical trial related to opicinumab.</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:5%;"></td><td style="width:95%;"></td></tr><tr><td colspan="2" style="vertical-align:bottom;background-color:#679acb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#ffffff;font-weight:bold;">Neurodegeneration</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">Aducanumab (BIIB037)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2016 we announced that aducanumab, our investigational treatment for early Alzheimer&#8217;s disease, was accepted into the European Medicines Agency's (EMA's) Priority Medicines (PRIME) program. PRIME aims to bring treatments to patients more quickly by enhancing the EMA's support for the development of investigational medicines for diseases without available treatments or in need of better treatment options.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In September 2016 aducanumab was granted "Fast Track" designation by the U.S. Food and Drug Administration (FDA). The FDA&#8217;s Fast Track program supports the development of new treatments for serious conditions with an unmet medical need such as Alzheimer&#8217;s disease. </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In September 2016 we announced that efficacy and safety data from an additional interim analysis from our Phase 1b study of aducanumab in early Alzheimer's disease were consistent with results previously reported from the Phase 1b study.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2016 we presented new data from the Phase 1b study of aducanumab, which included interim results from the titration cohort of the placebo-controlled period of the Phase 1b study as well as data from the first year of the long-term extension. The results supported the ongoing Phase 3 studies of aducanumab for early Alzheimer&#8217;s disease.</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:5%;"></td><td style="width:95%;"></td></tr><tr><td colspan="2" style="vertical-align:bottom;background-color:#8fc46e;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#ffffff;font-weight:bold;">Rare Diseases</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">SPINRAZA (nusinersen)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2016 we and Ionis Pharmaceuticals, Inc. (Ionis) announced that SPINRAZA met the primary endpoint for the interim analysis of ENDEAR, the Phase 3 trial evaluating SPINRAZA in infantile-onset (consistent with Type 1) SMA. Based on these results, we exercised our option under our collaboration agreement with Ionis to assume development and commercialization of SPINRAZA, and paid Ionis a $75.0 million license fee in connection with our option exercise.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In September 2016 we completed the rolling submission of a New Drug Application (NDA) to the FDA for the approval of SPINRAZA, and in October 2016 we filed a marketing authorization application (MAA) with the EMA, which had already granted Accelerated Assessment status to SPINRAZA. These applications have been accepted for review by the applicable regulatory authorities.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2016 we dosed our first patient in our infantile-onset SMA Expanded Access Program to provide patient access to SPINRAZA.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2016 we and Ionis announced that SPINRAZA met the primary endpoint for the interim analysis of CHERISH, the Phase 3 trial evaluating SPINRAZA in later-onset (consistent with Type 2) SMA. The analysis found that children receiving SPINRAZA experienced a highly statistically significant improvement in motor function compared to those who did not receive treatment. SPINRAZA demonstrated a favorable safety profile in the study.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2016 SPINRAZA was approved by the FDA for the treatment of SMA in pediatric and adult patients in the U.S. The FDA also issued us a rare pediatric disease priority review voucher with the approval of SPINRAZA, which confers priority review to a subsequent drug application that would not otherwise qualify for priority review.</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:5%;"></td><td style="width:95%;"></td></tr><tr><td colspan="2" style="vertical-align:bottom;background-color:#578196;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#ffffff;font-weight:bold;">Biosimilars (Samsung Bioepis - Biogen's Joint Venture with Samsung Biologics)</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">BENEPALI</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2016 the EC approved Samsung Bioepis' MAA for BENEPALI, an etanercept biosimilar referencing ENBREL, for marketing in the E.U. Under our agreement with Samsung Bioepis, we are manufacturing and commercializing BENEPALI in specified E.U. countries.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">FLIXABI</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2016 the EC approved Samsung Bioepis' MAA for FLIXABI, an infliximab biosimilar candidate referencing REMICADE, for marketing in the E.U. Under our agreement with Samsung Bioepis, we are manufacturing and commercializing FLIXABI in specified E.U. countries.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">Adalimumab (SB5)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2016 the EMA accepted Samsung Bioepis' MAA for SB5, an adalimumab biosimilar candidate referencing HUMIRA.</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:5%;"></td><td style="width:95%;"></td></tr><tr><td colspan="2" style="vertical-align:bottom;background-color:#1c5a7d;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#ffffff;font-weight:bold;">Genentech Relationships</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">GAZYVA (obinutuzumab)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2016 the Roche Group announced that the FDA approved GAZYVA plus bendamustine chemotherapy followed by GAZYVA alone as a new treatment for people with follicular lymphoma who did not respond to a RITUXAN-containing regiment, or whose follicular lymphoma returned after such treatment.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2016 the Roche Group announced positive results from the Phase 3 GALLIUM study, which investigated the efficacy and safety of GAZYVA in combination with chemotherapy followed by maintenance with GAZYVA alone, compared to RITUXAN in combination with chemotherapy followed by maintenance with RITUXAN alone in previously untreated patients with follicular lymphoma. Results from pre-planned interim analysis showed that GAZYVA-based treatment significantly reduced the risk of disease worsening or death compared to RITUXAN-based treatment.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2016 the Roche Group announced that the Phase 3 GOYA study evaluating GAZYVA plus CHOP chemotherapy in people with previously untreated diffuse large B-cell lymphoma did not meet its primary endpoint of significantly reducing the risk of disease worsening or death compared to RITUXAN plus CHOP chemotherapy. Adverse events with GAZYVA and RITUXAN were consistent with those seen in previous clinical trials when each was combined with various chemotherapies.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">OCREVUS (ocrelizumab)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2016 the Roche Group announced that the EMA validated its MAA of OCREVUS for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS) in the E.U. The FDA has also accepted for review the Roche Group's Biologics License Application (BLA) for OCREVUS for the treatment of RMS and PPMS. </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">RITUXAN (rituximab)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2016 Genentech announced the FDA accepted its BLA for a subcutaneous formulation of RITUXAN.</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:5%;"></td><td style="width:95%;"></td></tr><tr><td colspan="2" style="vertical-align:bottom;background-color:#acacac;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Discontinued Programs</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During 2016 we discontinued development of amiselimod (MT-1303) under our agreement with Mitsubishi Tanabe Pharma Corporation, and IONIS-DMPK</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">Rx </sub></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">under one of our collaboration agreements with Ionis. Additionally, we terminated our collaboration agreements with Rodin Therapeutics, Inc. and Ataxion Inc.</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4</font></div></div><hr style="page-break-after:always"><div><a name="sAAC8008BD8BADD47B3342017082677BB"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Marketed Products</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following graphs show our revenues by product and revenues from anti-CD20 therapeutic programs and geography as a percentage of revenue for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;text-align:center;"><img src="principalproductschart.jpg" alt="principalproductschart.jpg" style="height:637px;width:317px;"></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">(1) Interferon includes AVONEX and PLEGRIDY</font></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">(2) Other includes ZINBRYTA, FAMPYRA, ELOCTATE, ALPROLIX, FUMADERM, SPINRAZA, BENEPALI and FLIXABI</font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;text-align:center;"><img src="geographicsaleschart.jpg" alt="geographicsaleschart.jpg" style="height:508px;width:317px;"></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div></div><br><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product sales for TECFIDERA, AVONEX and TYSABRI and anti-CD20 therapeutic programs for RITUXAN each accounted for more than 10% of our total revenue for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. For additional financial information about our product and other revenues and geographic areas in which we operate, please read Note&#160;24, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Segment Information </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to our consolidated financial statements, Item&#160;6. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Selected Financial Data </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">and Item 7. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Management's Discussion and Analysis of Financial Condition and Results of Operations </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">included in this report. A discussion of the risks attendant to our operations is set forth in the &#8220;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risk Factors</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8221; section of this report. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Multiple Sclerosis</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We develop, manufacture and market a number of products designed to treat patients with MS. MS is a progressive neurological disease in which the body loses the ability to transmit messages along nerve cells, leading to a loss of muscle control, paralysis and, in some cases, death. Patients with active relapsing MS experience an uneven pattern of disease progression characterized by periods of stability that are interrupted by flare-ups of the disease after which the patient returns to a new baseline of functioning. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our MS products and major markets include:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:28%;"></td><td style="width:31%;"></td><td style="width:1%;"></td><td style="width:23%;"></td><td style="width:1%;"></td><td style="width:16%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#2573ba;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Product</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#2573ba;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Indication</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#2573ba;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#2573ba;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Collaborator</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#2573ba;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#2573ba;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Major Markets</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;"><img src="tecfidera.jpg" alt="tecfidera.jpg" style="height:37px;width:172px;"></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Relapsing forms of MS in the U.S.</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Relapsing-remitting MS (RRMS) in the E.U.</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">None</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">U.S.</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">France</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Germany</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Italy</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Spain</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">United Kingdom</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;"><img src="avonex.jpg" alt="avonex.jpg" style="height:49px;width:134px;"></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Relapsing forms of MS</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">None</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">U.S.</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">France</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Germany</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Italy</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Spain</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">United Kingdom</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;"><img src="plegridy.jpg" alt="plegridy.jpg" style="height:77px;width:128px;"></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Relapsing forms of MS in the U.S.</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">RRMS in the E.U.</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">None</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">U.S.</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">France</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Germany</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Italy</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Spain</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">United Kingdom</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;"><img src="tysabri.jpg" alt="tysabri.jpg" style="height:62px;width:114px;"></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Relapsing forms of MS</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Crohn's disease in the U.S.</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">None</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">U.S.</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">France</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Germany</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Italy</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Spain</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">United Kingdom</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div><img src="zinbryta.jpg" alt="zinbryta.jpg" style="height:53px;width:144px;"></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Relapsing forms of MS</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">AbbVie Inc. (AbbVie)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">U.S.</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Germany</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;"><img src="fampyra.jpg" alt="fampyra.jpg" style="height:37px;width:133px;"></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Walking ability for patients with MS</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acorda Therapeutics, Inc. (Acorda)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">France</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Germany</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Spain</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Spinal Muscular Atrophy</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">SMA is characterized by loss of motor neurons in the spinal cord and lower brain stem, resulting in severe and progressive muscular atrophy and weakness. Ultimately, individuals with the most severe type of SMA can become paralyzed and have difficulty performing the basic functions of life, like breathing and swallowing. Due to a loss of, or defect in the SMN1 gene, people with SMA do not produce enough survival motor neuron (SMN) protein, which is critical for the maintenance of motor neurons. The severity of SMA correlates with the amount of SMN protein. People with Type 1 SMA, the most severe life-threatening form, produce very little SMN protein and do not achieve the ability to sit without support or live beyond two years without respiratory support. People with Type 2 and Type 3 produce greater amounts of SMN protein and have less severe, but still life-altering, forms of SMA.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2016 the FDA approved SPINRAZA for the treatment of SMA in pediatric and adult patients. We are currently in the early stages of commercial launch in the U.S.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our products for SMA and major markets include: </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:28%;"></td><td style="width:31%;"></td><td style="width:1%;"></td><td style="width:23%;"></td><td style="width:1%;"></td><td style="width:16%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#8fc46e;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Product</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#8fc46e;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Indication</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#8fc46e;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#8fc46e;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Collaborator</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#8fc46e;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#8fc46e;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Major Markets</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><img src="spinrazalogonewa01.jpg" alt="spinrazalogonewa01.jpg" style="height:80px;width:160px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Spinal muscular atrophy</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Ionis</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">U.S.</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:28%;"></td><td style="width:32%;"></td><td style="width:1%;"></td><td style="width:23%;"></td><td style="width:1%;"></td><td style="width:15%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#acacac;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Product</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#acacac;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Indication</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#acacac;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#acacac;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Collaborator</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#acacac;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#acacac;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Major Markets</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;"><img src="fumaderm.jpg" alt="fumaderm.jpg" style="height:45px;width:116px;"></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Moderate to severe plaque psoriasis</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">None</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Germany</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Biosimilars</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biosimilars are a group of biologic medicines that are similar to currently available biologic therapies known as originators. Under our agreement with Samsung Bioepis, we manufacture and commercialize two anti-TNF biosimilars in certain countries in the E.U.: BENEPALI, an etanercept biosimilar referencing ENBREL and FLIXABI, an infliximab biosimilar referencing REMICADE: </font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:28%;"></td><td style="width:56%;"></td><td style="width:1%;"></td><td style="width:15%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#578196;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Product</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#578196;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Indication</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#578196;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#578196;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Major Markets</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;"><img src="benepalia02.jpg" alt="benepalia02.jpg" style="height:49px;width:141px;"></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Moderate to severe rheumatoid arthritis</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Progressive psoriatic arthritis</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Axial spondyloarthritis</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Moderate to severe plaque psoriasis</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Denmark</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Germany</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Netherlands</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Norway</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">United Kingdom</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;"><img src="flixabi.jpg" alt="flixabi.jpg" style="height:49px;width:133px;"></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Rheumatoid arthritis<br>Moderate to severe Crohn's disease<br>Severe ulcerative colitis<br>Severe ankylosing spondylitis<br>Psoriatic arthritis<br>Moderate to severe plaque psoriasis</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Germany</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Netherlands</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">United Kingdom</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Genentech Relationships</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have a collaboration agreement with Genentech that entitles us to certain business and financial rights with respect to RITUXAN, GAZYVA and other anti-CD20 product candidates. Current products include:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:28%;"></td><td style="width:58%;"></td><td style="width:1%;"></td><td style="width:13%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#1c5a7d;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Product</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#1c5a7d;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Indication</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#1c5a7d;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#1c5a7d;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Major Markets</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;"><img src="rituxan.jpg" alt="rituxan.jpg" style="height:46px;width:128px;"></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-Hodgkin's lymphoma</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">CLL</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Rheumatoid arthritis</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Two forms of ANCA-associated vasculitis</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">U.S.</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Canada</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;"><img src="gazyva.jpg" alt="gazyva.jpg" style="height:57px;width:76px;"></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In combination with chlorambucil for previously untreated CLL</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Follicular lymphoma</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">U.S.</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For information about our anti-CD20 therapeutic programs and related agreements with Genentech, please read Note 1, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and Note&#160;19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7</font></div></div><hr style="page-break-after:always"><div><a name="s6A3728A0861E88C7FC5020170856AF3E"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Patient Support and Access</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#32;</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We interact with patients, advocacy organizations and healthcare societies in order to gain insights into unmet needs. The insights gained from these engagements help us support patients with services, programs and applications that are designed to help patients lead better lives. Among other things, we provide customer service and other related programs for our products, such as disease and product specific websites, insurance research services, financial assistance programs, and the facilitation of the procurement of our marketed products. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are dedicated to helping patients obtain access to our therapies. Our patient representatives have access to a comprehensive suite of financial assistance tools. With those tools, we help patients understand their insurance coverage and, if needed, help patients compare and select new insurance options and programs. In the U.S., we have established programs that provide co-pay assistance or free marketed product for qualified uninsured or underinsured patients, based on specific eligibility criteria. We also provide charitable contributions to independent charitable organizations that assist patients with out-of-pocket expenses associated with their therapy.</font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Marketing and Distribution</font></div><div style="line-height:120%;padding-top:6px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Sales Force and Marketing</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We promote our products worldwide, including in the U.S., most of the major countries of the E.U. and Japan, primarily through our own sales forces and marketing groups. In some countries, particularly in areas where we continue to expand into new geographic areas, we partner with third parties. We co-promote ZINBRYTA with AbbVie in the U.S., E.U. and Canadian territories.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We focus our sales and marketing efforts on specialist physicians in private practice or at major medical centers. We use customary pharmaceutical company practices to market our products and to educate physicians, such as sales representatives calling on individual physicians, advertisements, professional symposia, direct mail, public relations and other methods. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Distribution Arrangements</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We distribute our products in the U.S. principally through wholesale distributors of pharmaceutical products, mail order specialty distributors or shipping service providers. In other countries, the distribution of our products varies from country to country, including through wholesale distributors of pharmaceutical products and third-party distribution partners who are responsible for most marketing and distribution activities.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">AbbVie distributes ZINBRYTA in the U.S., and we distribute ZINBRYTA in ex-U.S. markets. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">RITUXAN and GAZYVA are marketed and distributed by the Roche Group and its sublicensees.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our product sales to two wholesale distributors, AmerisourceBergen and McKesson, each accounted for more than 10% of our total revenues for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and on a combined basis, accounted for approximately 60% of our gross product revenues for such years, respectively. For additional information, please read Note 1, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></div></div><br><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8</font></div></div><hr style="page-break-after:always"><div><a name="s131F4F0F4123072A26F920170870BF6F"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Patents and Other Proprietary Rights</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Patents are important to obtaining and protecting exclusive rights in our products and product candidates. We regularly seek patent protection in the U.S.&#160;and in selected countries outside the U.S.&#160;for inventions originating from our research and development efforts. In addition, we license rights to various patents and patent applications. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">U.S.&#160;patents, as well as most foreign patents, are generally effective for 20&#160;years from the date the earliest application was filed; however, U.S.&#160;patents that issue on applications filed before June&#160;8, 1995&#160;may be effective until 17&#160;years from the issue date, if that is later than the 20&#160;year date. In some cases, the patent term may be extended to recapture a portion of the term lost during regulatory review of the claimed therapeutic or, in the case of the U.S., because of U.S.&#160;Patent and Trademark Office (USPTO) delays in prosecuting the application. Specifically, in the U.S., under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act, a patent that covers an FDA-approved drug may be eligible for patent term extension (for up to five years, but not beyond a total of 14 years from the date of product approval) as compensation for patent term lost during the FDA regulatory review process. The duration and extension of the term of foreign patents varies, in accordance with local law. For example, supplementary protection certificates (SPCs) on some of our products have been granted in a number of European countries, compensating in part for delays in obtaining marketing approval.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Regulatory exclusivity, which may consist of regulatory data protection and market protection, also can provide meaningful protection for our products. Regulatory data protection provides to the holder of a drug or biologic marketing authorization, for a set period of time, the exclusive use of the proprietary pre-clinical and clinical data that it created at significant cost and submitted to the applicable regulatory authority to obtain approval of its product. After the applicable set period of time, third parties are then permitted to rely upon our data to file for approval of their abbreviated applications for, and to market (subject to any applicable market protection), their generic drugs and biosimilars referencing our data. Market protection provides to the holder of a drug or biologic marketing authorization the exclusive right to commercialize its product for a set period of </font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">time, thereby preventing the commercialization of another product containing the same active  ingredient(s) during that period. Although the World Trade Organization's agreement on trade-related aspects of intellectual property rights (TRIPS) requires signatory countries to provide regulatory exclusivity to innovative pharmaceutical products, implementation and enforcement varies widely from country to country.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also rely upon other forms of unpatented confidential information to remain competitive. We protect such information principally through confidentiality agreements with our employees, consultants, outside scientific collaborators, scientists whose research we sponsor and other advisers. In the case of our employees, these agreements also provide, in compliance with relevant law, that inventions and other intellectual property conceived by such employees during their employment shall be our exclusive property.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our trademarks are important to us and are generally covered by trademark applications or registrations in the USPTO and the patent or trademark offices of other countries. We also use trademarks licensed from third parties, such as the trademark FAMPYRA which we license from Acorda. Trademark protection varies in accordance with local law, and continues in some countries as long as the trademark is used and in other countries as long as the trademark is registered. Trademark registrations generally are for fixed but renewable terms.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our Patent Portfolio </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table describes our patents in the U.S. and Europe that we currently consider of primary importance to our marketed products, including the territory, patent number, general subject matter and expected expiration dates. Except as otherwise noted, the expected expiration dates include any granted patent term extensions and issued SPCs. In some instances, there are later-expiring patents relating to our products directed to, among other things, particular forms or compositions, methods of manufacturing, or use of the drug in the treatment of particular diseases or conditions. We also continue to pursue additional patents and patent term extensions in the U.S. and other territories covering various aspects of our products that may, if issued, extend exclusivity beyond the expiration of the patents listed in the table.</font></div></div></div><br><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:13%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Product</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Territory</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Patent No.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">General Subject Matter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Patent </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Expiration</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">TECFIDERA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">7,619,001</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Methods of treatment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">7,803,840</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Methods of treatment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">8,399,514</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Methods of treatment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2028</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">8,524,773</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Methods of treatment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">6,509,376</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Formulations of dialkyl fumarates for use in the treatment of autoimmune diseases</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">8,759,393</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Formulations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">7,320,999</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Methods of treatment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2020</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Europe</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">1131065</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Formulations of dialkyl fumarates and their use for treating autoimmune diseases</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(2)</sup></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Europe</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2137537</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Methods of use</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2028</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(3)</sup></font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">AVONEX and PLEGRIDY</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">7,588,755</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Use of recombinant beta interferon for immunomodulation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2026</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">PLEGRIDY</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">7,446,173</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Polymer conjugates of interferon beta-1a</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2022</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">8,524,660</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Methods of treatment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2023</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">8,017,733</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Polymer conjugates of interferon beta-1a</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2025</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Europe</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">1656952</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Polymer conjugates of interferon-beta-1a and uses thereof</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2019</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Europe</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">1476181</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Polymer conjugates of interferon-beta-1a and uses thereof</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2023</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">TYSABRI</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">5,840,299</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Humanized immunoglobulins; nucleic acids; pharmaceutical compositions; methods of use</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">6,602,503</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Humanized recombinant antibodies; nucleic acids and host cells; processes for production; therapeutic compositions; methods of use</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2020</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">7,807,167</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Methods of treatment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2023</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">9,493,567</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Methods of treatment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2027</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Europe</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">0804237</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Humanized immunoglobulins; nucleic acids; pharmaceutical compositions; medical uses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2020</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(4)</sup></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Europe</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">1485127</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Methods of use </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2023</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">FAMPYRA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Europe</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">1732548</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Sustained-release aminopyridine compositions for increasing walking speed in patients with MS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2025</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(5)</sup></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Europe</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">23775536</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Sustained-release aminopyridine compositions for treating MS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2025</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(6)</sup></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">ZINBRYTA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">8,454,965</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Methods of treatment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2024</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">7,258,859</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Methods of treatment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2024</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">9,340,619</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Daclizumab HYP compositions</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2032</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Europe</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">1539200</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2472b9;">Anti-IL-2-receptor antibody for use in a method of treating a subject with MS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2023</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">SPINRAZA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">6,166,197</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2472b9;">Oligomeric Compounds Having Pyrimidine Nucleotide(s)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">6,210,892</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2472b9;">Alteration of Cellular Behavior By Antisense Modulation of MRNA Processing</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">7,101,993</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2472b9;">Oligonucleotides Containing 2&#8217;-O-Modified Purines</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2023</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">7,838,657</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2472b9;">SMA Treatment Via Targeting of SMN2 Splice Site Inhibitory Sequences</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2027</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">8,110,560</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2472b9;">SMA Treatment Via Targeting of SMN2 Splice Site Inhibitory Sequences</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2025</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">8,361,977</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2472b9;">Compositions And Methods For Modulation of SMN2 Splicing</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2030</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">8,980,853</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2472b9;">Compositions And Methods For Modulation of SMN2 Splicing</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2030</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Europe</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">1910395</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2472b9;">Compositions And Methods For Modulation of SMN2 Splicing</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2026</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Europe</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2548560</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2472b9;">Compositions And Methods For Modulation of SMN2 Splicing</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2026</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Footnotes follow on next page.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">In addition to patent protection, certain of our products are entitled to regulatory exclusivity in the U.S. and the E.U. expected until the dates set forth below:</font></div></td></tr></table><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:20%;"></td><td style="width:2%;"></td><td style="width:21%;"></td><td style="width:2%;"></td><td style="width:55%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Product</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Territory</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Expected Expiration</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">TECFIDERA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">E.U.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2024</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">PLEGRIDY</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2026</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">E.U.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2024</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">TYSABRI</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">E.U.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2016</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">FAMPYRA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">E.U.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2021</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">ZINBRYTA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2028</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">E.U.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">*</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">SPINRAZA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2023</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;padding-left:30px;text-indent:-6px;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">*ZINBRYTA was not designated a new active substance at the time of its approval in the E.U. and is not automatically entitled to regulatory exclusivity. Regulatory exclusivity may, however, be available for independent development of known active substances. We intend to assert the protection of its data on this basis.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">This patent is subject to granted SPCs in certain European countries, which extended the patent term in those countries to 2024. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">This patent was revoked in a European opposition. This decision is being appealed. The patent is subject to granted SPCs in certain European countries, which extended the patent term in those countries to 2029.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(4)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Reflects SPCs granted in most European countries.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(5)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">This patent is subject to granted SPCs in certain European countries, which extended the patent term in those countries to 2026.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(6)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">This patent is subject to granted SPCs in certain European countries, which extended the patent term in those countries to 2026.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The existence of patents does not guarantee our right to practice the patented technology or commercialize the patented product. Patents relating to pharmaceutical, biopharmaceutical and biotechnology products, compounds and processes, such as those that cover our existing compounds, products and processes and those that we will likely file in the future, do not always provide complete or adequate protection. Litigation, interferences, oppositions, inter partes reviews or other proceedings are, have been and may in the future be necessary in some instances to determine the validity and scope of certain of our patents, regulatory exclusivities or other proprietary rights, and in other instances to determine the validity, scope or non-infringement of certain patent rights claimed by third parties to be pertinent to the manufacture, use or sale of our products.&#160;We may also face challenges to our patents, regulatory exclusivities and other proprietary rights covering our products by manufacturers of generics and biosimilars. A discussion of certain risks and uncertainties that may affect our patent position, regulatory exclusivities and other proprietary rights is set forth in the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8220;Risk Factors&#8221;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;section of this report, and a discussion of legal proceedings related to certain patents described above is set forth in Note&#160;20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Litigation</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11</font></div></div><hr style="page-break-after:always"><div><a name="s3F37A51FCC504181176E201708A2412F"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Competition</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Competition in the biopharmaceutical industry is intense and comes from many sources, including specialized biotechnology firms and large pharmaceutical companies. Many of our competitors are working to develop products similar to those we are developing or already market and have considerable experience in undertaking clinical trials and in obtaining regulatory approval to market pharmaceutical products. Certain of these companies have substantially greater financial, marketing and research and development resources than we do.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We believe that competition and leadership in the industry is based on managerial and technological excellence and innovation as well as establishing patent and other proprietary positions through research and development. The achievement of a leadership position also depends largely upon our ability to maximize the approval, acceptance and use of products resulting from research and the availability of adequate financial resources to fund facilities, equipment, personnel, clinical testing, manufacturing and marketing. Another key aspect of remaining competitive within the industry is recruiting and retaining leading scientists and technicians. We believe that we have been successful in attracting and retaining skilled and experienced scientific personnel.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Competition among products approved for sale may be based, among other things, on patent position, product efficacy, safety, convenience/delivery devices, reliability, availability and price. In addition, early entry of a new pharmaceutical product into the market may have important advantages in gaining product acceptance and market share. Accordingly, the relative speed with which we can develop products, complete the testing and approval process and supply commercial quantities of products will have a significant impact on our competitive position.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The introduction of new products or technologies, including the development of new processes or technologies by competitors or new information about existing products or technologies, may result in increased competition for our marketed products or pricing pressure on our marketed products. It is also possible that the development of new or improved treatment options or standards of care or cures for the diseases our products treat could reduce or eliminate the use of our products or may limit the utility and application of ongoing clinical trials for our product candidates. We may also face increased competitive pressures as a result of generics and the emergence of biosimilars in the U.S. and E.U. If a generic or biosimilar version of one of our products were approved, it could reduce our sales of that product.</font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Additional information about the competition that our marketed products face is set forth below.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Multiple Sclerosis</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">TECFIDERA, AVONEX, PLEGRIDY, TYSABRI and ZINBRYTA each compete with one or more of the following products: </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:48%;"></td><td style="width:2%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Competing Product</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Competitor</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">AUBAGIO (teriflunomide)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Sanofi</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">BETASERON/BETAFERON (interferon-beta-1b)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Bayer Group</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">COPAXONE </font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(glatiramer acetate)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Teva Pharmaceuticals Industries Ltd.</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">EXTAVIA </font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(interferon-beta-1b)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Novartis AG</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">GLATOPA (glatiramer acetate)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Sandoz, a division of Novartis AG</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">GILENYA (fingolimod)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Novartis AG</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">LEMTRADA (alemtuzumab)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Sanofi</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">REBIF </font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(interferon-beta-1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Merck KGaA (and co-promoted with Pfizer Inc. in the U.S.)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FAMPYRA is indicated as a treatment to improve walking in adult patients with MS who have walking disability and is the first treatment that addresses this unmet medical need with demonstrated efficacy in people with all types of MS. FAMPYRA is currently the only therapy approved to improve walking in patients with MS. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Competition in the MS market is intense.&#160;Along with us, a number of companies are working to develop additional treatments for MS that may in the future compete with our MS products. One such product candidate is OCREVUS, a potential treatment for RMS and PPMS being developed by Genentech. While we have a financial interest in OCREVUS, future sales of our MS products may be adversely affected by the commercialization of OCREVUS, as well as by other MS products we or our competitors are developing</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Future sales may also be negatively impacted</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">by</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the introduction of generics, prodrugs of existing therapeutics or biosimilars of existing products.</font></div></div></div><br><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Spinal Muscular Atrophy</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">SPINRAZA is the only approved treatment for SMA. We are aware of other products in development that, if successfully developed and approved, may compete with SPINRAZA in the SMA market. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Psoriasis</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FUMADERM competes with several different types of therapies in the psoriasis market within Germany, including oral systemics such as methotrexate and cyclosporine.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Biosimilars</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">BENEPALI and FLIXABI, the two biosimilars we currently manufacture and commercialize in the E.U. for Samsung Bioepis, compete with their applicable reference products, ENBREL and REMICADE, respectively, as well as other biosimilars of those reference products. </font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Genentech Relationships in Other Indications</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">RITUXAN and GAZYVA in Oncology</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">RITUXAN and GAZYVA compete with a number of therapies in the oncology market, including TREANDA (bendamustine HCL), ARZERRA (ofatumumab), IMBRUVICA (ibrutinib) and ZYDELIG (idelalisib). </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also expect that over time GAZYVA will increasingly compete with RITUXAN in the oncology market. In addition, we are aware of other anti-CD20 molecules, including biosimilars, in development that, if successfully developed and approved, may compete with RITUXAN and GAZYVA in the oncology market.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">RITUXAN in Rheumatoid Arthritis</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">RITUXAN competes with several different types of therapies in the rheumatoid arthritis market, including, among others, traditional disease-modifying anti-rheumatic drugs such as steroids, methotrexate and cyclosporine, TNF inhibitors, ORENCIA (abatacept), ACTEMRA (tocilizumab) and XELJANZ (tofacitinib).</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are also aware of other products, including biosimilars, in development that, if successfully developed and approved, may compete with RITUXAN in the rheumatoid arthritis market. </font></div></div></div><br><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13</font></div></div><hr style="page-break-after:always"><div><a name="sE3878C3C87C32E9AAE3F201708E97E48"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Research and Development Programs</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A commitment to research is fundamental to our mission. Our research efforts are focused on better understanding the underlying biology of diseases so we can discover and deliver treatments that have the potential to make a real difference in the lives of patients with high unmet medical needs. By applying our expertise in biologics and our growing capabilities in small molecule, antisense, gene therapy, gene editing and other technologies, we target specific medical needs where we believe new or better treatments are needed.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We intend to continue committing significant resources to research and development opportunities.  As part of our ongoing research and development efforts, we have devoted significant resources to conducting clinical studies to advance the development of new pharmaceutical products and technologies and to explore the utility of our existing products in treating disorders beyond those currently approved in their labels.</font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;text-align:center;"><img src="researchanddevelopment.jpg" alt="researchanddevelopment.jpg" style="height:198px;width:317px;"></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The table below highlights our current research and development programs that are in clinical trials and the current phase of such programs. Drug development involves a high degree of risk and investment, and the status, timing and scope of our development programs are subject to change. Important factors that could adversely affect our drug development efforts are discussed in the &#8220;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risk Factors</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8221; section of this report. </font></div></div></div><br><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"></td></tr><tr><td style="width:18%;"></td><td style="width:20%;"></td><td style="width:8%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:5%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Product Candidate</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Collaborator</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#acacac;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">PHASE 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#acacac;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">PHASE 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#acacac;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">PHASE 3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#acacac;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">FILED</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">OCREVUS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Genentech (Roche Group)</font></div></td><td colspan="10" style="vertical-align:bottom;background-color:#1c5a7d;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Primary Progressive &amp; Relapsing Multiple Sclerosis</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Biosimilar adalimumab</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Samsung Bioepis</font></div></td><td colspan="10" style="vertical-align:bottom;background-color:#578196;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Multiple Immunology Indications in Europe</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">GAZYVA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Genentech (Roche Group)</font></div></td><td colspan="7" style="vertical-align:bottom;background-color:#1c5a7d;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Front-Line Indolent Non Hodgkin&#8217;s Lymphoma</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Aducanumab</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Neurimmune SubOne AG</font></div></td><td colspan="7" style="vertical-align:bottom;background-color:#77afe4;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Alzheimer's Disease</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">E2609</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Eisai Co., Ltd. (Eisai)</font></div></td><td colspan="7" style="vertical-align:bottom;background-color:#77afe4;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Alzheimer's Disease</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">BIIB074</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">None</font></div></td><td colspan="5" style="vertical-align:bottom;background-color:#8fc46e;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Trigeminal Neuralgia</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">BIIB074</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">None</font></div></td><td colspan="4" style="vertical-align:bottom;background-color:#8fc46e;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Lumbosacral Radiculopathy</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">BIIB074</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">None</font></div></td><td colspan="4" style="vertical-align:bottom;background-color:#8fc46e;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Erythromelalgia</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">BAN2401</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Eisai</font></div></td><td colspan="4" style="vertical-align:bottom;background-color:#77afe4;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Alzheimer's Disease</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Opicinumab (anti-LINGO-1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">None</font></div></td><td colspan="4" style="vertical-align:bottom;background-color:#2573ba;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Multiple Sclerosis</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">TYSABRI</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">None</font></div></td><td colspan="4" style="vertical-align:bottom;background-color:#8fc46e;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Acute Ischemic Stroke</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">rAAV-XLRS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">AGTC</font></div></td><td colspan="4" style="vertical-align:bottom;background-color:#8fc46e;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">X-linked Juvenile Retinoschisis</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">BG00011 (STX-100)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">None</font></div></td><td colspan="4" style="vertical-align:bottom;background-color:#8fc46e;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Idiopathic Pulmonary Fibrosis</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Dapirolizumab pegol </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">UCB Pharma</font></div></td><td colspan="4" style="vertical-align:bottom;background-color:#8fc46e;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Lupus</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">BIIB059 (Anti-BDCA02)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">None</font></div></td><td colspan="4" style="vertical-align:bottom;background-color:#8fc46e;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Lupus</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">BIIB061</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">None</font></div></td><td style="vertical-align:bottom;background-color:#2573ba;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">MS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">BIIB054</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">None</font></div></td><td style="vertical-align:bottom;background-color:#77afe4;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">PD*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">BIIB067 (IONIS-SOD1</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">Rx</sub></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">)</sub></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Ionis </font></div></td><td style="vertical-align:bottom;background-color:#77afe4;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">ALS**</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">BIIB068 (BTK Inhibitor)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">None</font></div></td><td style="vertical-align:bottom;background-color:#2573ba;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">A***</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">* Parkinson's Disease</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">** Amyotrophic Lateral Sclerosis</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">*** Autoimmune</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For information about certain of our agreements with collaborators and other third parties, please read the subsection entitled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8220;Business Relationships&#8221;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;below and Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">14</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Late Stage Product Candidates</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Additional information about our late stage product candidates, which includes programs in Phase 3 development or in registration stage, is set forth below. </font></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:5%;"></td><td style="width:95%;"></td></tr><tr><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#77afe4;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#ffffff;font-weight:bold;">Neurodegeneration</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">Aducanumab (BIIB037)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Wingdings;font-size:8pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In September 2015 we enrolled our first patient in our two global Phase 3 studies, ENGAGE and EMERGE. ENGAGE and EMERGE will assess the efficacy and safety of aducanumab, our investigational treatment for early Alzheimer's disease, in approximately 2,700 people with early Alzheimer's disease. The studies are identical in design and eligibility criteria. Each study will be conducted in more than 20 countries in North America, Europe and Asia. In October 2015 we announced that we received FDA agreement on a special protocol assessment on the Phase 3 study protocols.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Wingdings;font-size:8pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2016 we announced that aducanumab was accepted into the European Medicines Agency's (EMA's) Priority Medicines (PRIME) program. PRIME aims to bring treatments to patients more quickly by enhancing the EMA's support for the development of investigational medicines for diseases without available treatments or in need of better treatment options.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Wingdings;font-size:8pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In September 2016 aducanumab was granted Fast Track designation by the FDA. The FDA&#8217;s Fast Track program supports the development of new treatments for serious conditions with an unmet medical need such as Alzheimer&#8217;s disease. We also announced that in a recently completed interim analysis from our Phase 1b study of aducanumab in early Alzheimer's disease efficacy and safety data were consistent with results previously reported.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Wingdings;font-size:8pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2016 we presented new data from the Phase 1b study of aducanumab, which included interim results from the titration cohort of the placebo-controlled period of the Phase 1b study as well as data from the first year of the long-term extension. The results supported the ongoing Phase 3 studies of aducanumab for early Alzheimer&#8217;s disease.</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">E2609</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Wingdings;font-size:8pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2016 Eisai announced enrollment has commenced in MISSION&#160;AD, a Phase 3 clinical program of the beta secretase cleaving enzyme (BACE) inhibitor E2609 in patients with early Alzheimer's disease in the U.S.</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:5%;"></td><td style="width:95%;"></td></tr><tr><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#578196;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#ffffff;font-weight:bold;">Biosimilars (Samsung Bioepis - Biogen's Joint Venture with Samsung Biologics)</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">Adalimumab (SB5)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Wingdings;font-size:8pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2016 the EMA accepted Samsung Bioepis' MAA for SB5, an adalimumab biosimilar candidate referencing HUMIRA. If approved by the EC, we will manufacture and commercialize SB5 in specified E.U. countries.</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:5%;"></td><td style="width:95%;"></td></tr><tr><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#1c5a7d;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#ffffff;font-weight:bold;">Genentech Relationships</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">GAZYVA (obinutuzumab)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Wingdings;font-size:8pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The Roche Group is managing GALLIUM, a Phase 3 study examining the efficacy and safety of GAZYVA plus chemotherapy followed by GAZYVA alone for up to two years, as compared head-to-head against RITUXAN plus chemotherapy followed by RITUXAN alone for up to two years. At a pre-planned interim analysis in May 2016, an independent data monitoring committee determined that the study met its primary endpoint early. The results showed GAZYVA-based treatment significantly reduced the risk of disease worsening or death (progression-free survival) compared to RITUXAN-based treatment.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">OCREVUS (ocrelizumab)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Wingdings;font-size:8pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2015 the Roche Group announced positive results from two Phase 3 studies evaluating OCREVUS compared with interferon beta-1a in people with relapsing forms of MS. Treatment with OCREVUS compared with interferon beta-1a significantly reduced the annualized relapse rate over a two-year period; significantly reduced the progression of clinical disability; and led to a significant reduction in the number of lesions in the brain as measured by MRI. </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Wingdings;font-size:8pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In September 2015 the Roche Group announced positive results from a Phase 3 study evaluating OCREVUS in people with PPMS. Treatment with OCREVUS significantly reduced the progression of clinical disability compared with placebo, as measured by the Expanded Disability Status Scale.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Wingdings;font-size:8pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2016 the Roche Group announced that the EMA validated its MAA of OCREVUS for the treatment of RMS and PPMS in the E.U. The FDA has also accepted for review its BLA for OCREVUS for the treatment of RMS and PPMS, and has granted the application priority review designation. Under our agreement with Genentech, if OCREVUS is approved, we will receive tiered royalty payments on sales of OCREVUS in the U.S.</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15</font></div></div><hr style="page-break-after:always"><div><a name="s7326FAA6AD40D2944BDB2017090973CD"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Business Relationships</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As part of our business strategy, we establish business relationships, including joint ventures and collaborative arrangements with other companies, universities and medical research institutions, to assist in the clinical development and/or commercialization of certain of our products and product candidates and to provide support for our research programs. We also evaluate opportunities for acquiring products or rights to products and technologies that are complementary to our business from other companies, universities and medical research institutions.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Below is a brief description of certain business relationships and collaborations that expand our pipeline and provide us with certain rights to existing and potential new products and technologies. For more information regarding certain of these relationships, including their ongoing financial and accounting impact on our business, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">AbbVie, Inc.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have a collaboration agreement with AbbVie aimed at advancing the development and commercialization of ZINBRYTA in MS. Under the agreement, we and AbbVie conduct ZINBRYTA co-promotion activities in the U.S., E.U. and Canadian territories, and we are responsible for manufacturing and research and development activities.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Acorda Therapeutics, Inc.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We collaborate with Acorda to develop and commercialize products containing fampridine, such as FAMPYRA, in markets outside the U.S.&#160;We also have responsibility for regulatory activities and the future clinical development of related products in those markets.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Applied Genetic Technologies Corporation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have a collaboration agreement with Applied Genetic Technologies Corporation (AGTC) to develop gene-based therapies for multiple ophthalmic diseases. The collaboration focuses on the development of a clinical-stage candidate for X-linked Retinoschisis (XLRS) and a preclinical candidate for the treatment of X-linked Retinitis Pigmentosa (XLRP), for which we were granted worldwide commercialization rights. The agreement also provides us with options to early stage discovery programs in two ophthalmic diseases and one non-ophthalmic condition.</font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Eisai Co., Ltd.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have a collaboration with Eisai to jointly develop and commercialize E2609 and BAN2401, two Eisai product candidates for the treatment of Alzheimer&#8217;s disease.&#160;Eisai serves as the global operational and regulatory lead for E2609 and BAN2401 and all costs, including research, development, sales and marketing expenses, are shared equally between us and Eisai. Following marketing approval in major markets, we will co-promote E2609 and BAN2401 with Eisai and share profits equally. In smaller markets, Eisai will distribute these products and pay us a royalty.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The agreement also provides Eisai with options to jointly develop and commercialize two of our candidates for Alzheimer&#8217;s disease, aducanumab and an anti-tau monoclonal antibody, upon the exchange or provision of clinical data. Upon exercise of the applicable option, we will execute a separate collaboration agreement with Eisai on terms and conditions that mirror the financial arrangements we have with Eisai with respect to E2609 and BAN2401.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Genentech (Roche Group)</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have a collaboration agreement with Genentech which entitles us to certain financial and other rights with respect to RITUXAN, GAZYVA and other anti-CD20 product candidates. Additionally, under our agreement with Genentech, if OCREVUS is approved, we will receive tiered royalty payments on sales of OCREVUS in the U.S.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Ionis Pharmaceuticals, Inc.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have an exclusive, worldwide option and collaboration agreement with Ionis relating to the development and commercialization of up to three gene targets, and an exclusive worldwide option and collaboration agreement with Ionis under which both companies are developing and commercializing SPINRAZA for the treatment of SMA. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also have a six-year research collaboration agreement with Ionis, under which both companies perform discovery level research and will develop and commercialize antisense and other therapeutics for the treatment of neurological disorders.</font></div></div></div><br><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Samsung Bioepis</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We and Samsung Biologics established a joint venture, Samsung Bioepis, to develop, manufacture and market biosimilar pharmaceuticals.&#160;We also have an agreement with Samsung Bioepis to commercialize, over a 10-year term, three anti-TNF biosimilar product candidates in specified E.U. countries and, in the case of BENEPALI, Japan.&#160;Under this agreement, we are manufacturing and commercializing BENEPALI, an etanercept biosimilar referencing ENBREL and FLIXABI, an infliximab biosimilar referencing REMICADE. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition to our joint venture and commercialization agreement with Samsung Bioepis, we license certain of our proprietary technology to Samsung Bioepis in connection with Samsung Bioepis' development, manufacture and commercialization of its biosimilar products. We also provide technical development and technology transfer services to Samsung Bioepis, and manufacture clinical and commercial quantities of bulk drug substance of Samsung Bioepis' biosimilar products.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">University of Pennsylvania</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have a collaboration and alliance with the University of Pennsylvania to advance gene therapy and gene editing technologies. The collaboration will primarily focus on the development of therapeutic approaches that target the eye, skeletal muscle and the central nervous system. The alliance is also expected to focus on the research and validation of next-generation gene transfer technology using adeno-associated virus gene delivery vectors and exploring the expanded use of genome editing technology as a potential therapeutic platform.</font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div><a name="sB3B5FF522CB79E39637E2017091A59E9"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Regulatory</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our current and contemplated activities and the products, technologies and processes that result from such activities are subject to substantial government regulation.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Regulation of Pharmaceuticals</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Product Approval and Post-Approval Regulation in the U.S.</font></div><div style="line-height:120%;padding-top:12px;text-align:center;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">APPROVAL PROCESS</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Before new pharmaceutical products may be sold in the U.S., preclinical studies and clinical trials of the products must be conducted and the results submitted to the FDA for approval. With limited exceptions, the FDA requires companies to register both pre-approval and post-approval clinical trials and disclose clinical trial results in public databases. Failure to register a trial or disclose study results within the required time periods could result in penalties, including civil monetary penalties. Clinical trial programs must establish efficacy, determine an appropriate dose and dosing regimen, and define the conditions for safe use. This is a high-risk process that requires stepwise clinical studies in which the candidate product must successfully meet predetermined endpoints. The results of the preclinical and clinical testing of a product are then submitted to the FDA in the form of a BLA or a NDA. In response to a BLA or NDA, the FDA may grant marketing approval, request additional information or deny the application if it determines the application does not provide an adequate basis for approval.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product development and receipt of regulatory approval takes a number of years, involves the expenditure of substantial resources and depends on a number of factors, including the severity of the disease in question, the availability of alternative treatments, potential safety signals observed in preclinical or clinical tests, and the risks and benefits of the product as demonstrated in clinical trials. The FDA has substantial discretion in the product approval process, and it is impossible to predict with any certainty whether and when the FDA will grant marketing approval. The agency may require the sponsor of a BLA or NDA to conduct additional clinical studies or to provide other scientific or technical information about the product, and these additional requirements may lead to unanticipated delay or expense. Furthermore, even if a product is approved, the approval may be subject to limitations based on the FDA's interpretation of the existing pre-clinical or clinical data. </font></div></div></div><br><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">17</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The FDA has developed four distinct approaches intended to make therapeutically important drugs available as rapidly as possible, especially when the drugs are the first available treatment or have advantages over existing treatments: accelerated approval, fast track, breakthrough therapy and priority review.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Accelerated Approval</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">: The FDA may grant &#8220;accelerated approval&#8221; status to products that treat serious or life-threatening illnesses and that provide meaningful therapeutic benefits to patients over existing treatments. Under this pathway, the FDA may approve a product based on surrogate endpoints, or clinical endpoints other than survival or irreversible morbidity. When approval is based on surrogate endpoints or clinical endpoints other than survival or morbidity, the sponsor will be required to conduct additional post-approval clinical studies to verify and describe clinical benefit. Under the agency's accelerated approval regulations, if the FDA concludes that a drug that has been shown to be effective can be safely used only if distribution or use is restricted, it may require certain post-marketing restrictions as necessary to assure safe use. In addition, for products approved under accelerated approval, sponsors may be required to submit all copies of their promotional materials, including advertisements, to the FDA at least thirty days prior to initial dissemination. The FDA may withdraw approval under accelerated approval after a hearing if, for instance, post-marketing studies fail to verify any clinical benefit, it becomes clear that restrictions on the distribution of the product are inadequate to ensure its safe use, or if a sponsor fails to comply with the conditions of the accelerated approval.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Fast Track Status</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">: The FDA may grant "fast track" status to products that treat a serious condition and have data demonstrating the potential to address an unmet medical need or a drug that has been designated as a qualified infectious disease product.</font></div></td></tr></table></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Breakthrough Therapy</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">: The FDA may grant &#8220;breakthrough therapy&#8221; status to drugs designed to treat, alone or in combination with another drug or drugs, a serious or life-threatening disease or condition and for which preliminary clinical evidence suggests a substantial improvement over existing therapies. Such drugs need not address an unmet need, but are nevertheless eligible for expedited review if they offer the potential for an improvement. Breakthrough therapy status entitles the sponsor to earlier and more frequent meetings with the FDA regarding the development of nonclinical and clinical data and permits the FDA to offer product development or regulatory advice for the purpose of shortening the time to product approval. Breakthrough therapy status does not guarantee that a product will be developed or reviewed more quickly and does not ensure FDA approval.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Priority Review</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">: Priority Review only applies to applications (original or efficacy supplement) for a drug that treats a serious condition and, if approved, would provide a significant improvement in safety or effectiveness. Priority Review may also be granted for any supplement that proposes a labeling change due to studies completed in response to a written request from FDA for pediatric studies, for an application for a drug that has been designated as a qualified infectious disease product, or any application or supplement for a drug submitted with a priority review voucher.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:center;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">POST-MARKETING STUDIES</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Regardless of the approval pathway employed, the FDA may require a sponsor to conduct additional post-marketing studies as a condition of approval to provide data on safety and effectiveness. If a sponsor fails to conduct the required studies, the agency may withdraw its approval. In addition, if the FDA concludes that a drug that has been shown to be effective can be safely used only if distribution or use is restricted, it can mandate post-marketing restrictions as necessary to assure safe use. In such a case, the sponsor may be required to establish rigorous systems to assure use of the product under safe conditions. These systems are usually referred to as Risk Evaluation and Mitigation Strategies (REMS). The FDA can impose financial penalties for failing to comply with certain post-marketing commitments, including REMS. In addition, any changes to an approved REMS must be reviewed and approved by the FDA prior to implementation.</font></div></div></div><br><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:center;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">ADVERSE EVENT REPORTING</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We monitor information on side effects and adverse events reported during clinical studies and after marketing approval and report such information and events to regulatory agencies. Non-compliance with the FDA's safety reporting requirements may result in civil or criminal penalties. Side effects or adverse events that are reported during clinical trials can delay, impede, or prevent marketing approval. Based on new safety information that emerges after approval, the FDA can mandate product labeling changes, impose a new REMS or the addition of elements to an existing REMS, require new post-marketing studies (including additional clinical trials), or suspend or withdraw approval of the product. These requirements may affect our ability to maintain marketing approval of our products or require us to make significant expenditures to obtain or maintain such approvals.</font></div><div style="line-height:120%;padding-top:12px;text-align:center;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">APPROVAL OF CHANGES TO AN APPROVED PRODUCT</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">If we seek to make certain types of changes to an approved product, such as adding a new indication, making certain manufacturing changes, or changing manufacturers or suppliers of certain ingredients or components, the FDA will need to review and approve such changes in advance. In the case of a new indication, we are required to demonstrate with additional clinical data that the product is safe and effective for a use other than that initially approved. FDA regulatory review may result in denial or modification of the planned changes, or requirements to conduct additional tests or evaluations that can substantially delay or increase the cost of the planned changes.</font></div><div style="line-height:120%;padding-top:12px;text-align:center;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">REGULATION OF PRODUCT ADVERTISING AND PROMOTION</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The FDA regulates all advertising and promotion activities and communications for products under its jurisdiction both before and after approval. A company can make only those claims relating to safety and efficacy that are approved by the FDA. However, physicians may prescribe legally available drugs for uses that are not described in the drug's labeling. Such off-label uses are common across medical specialties, and often reflect a physician's belief that the off-label use is the best treatment for patients. The FDA does not regulate the behavior of physicians in their choice of treatments, but FDA regulations do impose stringent restrictions on manufacturers' communications regarding off-label uses. Failure to comply with applicable FDA requirements may subject a company to adverse publicity, enforcement action by the FDA, corrective advertising, and the full range of civil and criminal penalties available to the government.</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Regulation of Combination Products</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Combination products are defined by the FDA to include products comprising two or more regulated components (e.g., a biologic and a device). Biologics and devices each have their own regulatory requirements, and combination products may have additional requirements. Some of our marketed products meet this definition and are regulated under this framework and similar regulations outside the U.S., and we expect that some of our pipeline product candidates may be evaluated for regulatory approval under this framework as well. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Product Approval and Post-Approval Regulation Outside the U.S.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We market our products in numerous jurisdictions outside the U.S. Most of these jurisdictions have product approval and post-approval regulatory processes that are similar in principle to those in the U.S. In Europe, for example, where a substantial part of our ex-U.S. efforts are focused, there are several tracks for marketing approval, depending on the type of product for which approval is sought. Under the centralized procedure, a company submits a single application to the EMA. The marketing application is similar to the NDA or BLA in the U.S. and is evaluated by the Committee for Medicinal Products for Human Use (CHMP), the expert scientific committee of the EMA. If the CHMP determines that the marketing application fulfills the requirements for quality, safety, and efficacy, it will submit a favorable opinion to the EC. The CHMP opinion is not binding, but is typically adopted by the EC. A marketing application approved by the EC is valid in all member states. The centralized procedure is required for all biological products, orphan medicinal products, and new treatments for neurodegenerative disorders, and it is available for certain other products, including those which constitute a significant therapeutic, scientific or technical innovation.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition to the centralized procedure, Europe also has: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">a nationalized procedure, which requires a separate application to and approval determination by each country; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">a decentralized procedure, whereby applicants submit identical applications to several countries and receive simultaneous approval; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">a mutual recognition procedure, where applicants submit an application to one country for review and other countries may accept or reject the initial decision. </font></div></td></tr></table></div></div><br><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">19</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Regardless of the approval process employed, various parties share responsibilities for the monitoring, detection, and evaluation of adverse events post-approval, including national authorities, the EMA, the EC, and the marketing authorization holder. In some regions, it is possible to receive an &#8220;accelerated&#8221; review whereby the national regulatory authority will commit to truncated review timelines for products that meet specific medical needs.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Good Manufacturing Practices</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Regulatory agencies regulate and inspect equipment, facilities and processes used in the manufacturing and testing of pharmaceutical and biologic products prior to approving a product. If, after receiving clearance from regulatory agencies, a company makes a material change in manufacturing equipment, location or process, additional regulatory review and approval may be required. We also must adhere to current Good Manufacturing Practices (cGMP) and product-specific regulations enforced by regulatory agencies following product approval. The FDA, the EMA and other regulatory agencies also conduct periodic visits to re-inspect equipment, facilities and processes following the initial approval of a product. If, as a result of these inspections, it is determined that our equipment, facilities or processes do not comply with applicable regulations and conditions of product approval, regulatory agencies may seek civil, criminal or administrative sanctions or remedies against us, including significant financial penalties and the suspension of our manufacturing operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Good Clinical Practices</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The FDA, the EMA and other regulatory agencies promulgate regulations and standards for designing, conducting, monitoring, auditing and reporting the results of clinical trials to ensure that the data and results are accurate and that the rights and welfare of trial participants are adequately protected (commonly referred to as current Good Clinical Practices (cGCP)). Regulatory agencies enforce cGCP through periodic inspections of trial sponsors, principal investigators and trial sites, contract research organizations (CROs), and institutional review boards. If our studies fail to comply with applicable cGCP, the clinical data generated in our clinical trials may be deemed unreliable and relevant regulatory agencies may require us to perform additional clinical trials before approving our marketing applications. Noncompliance can also result in civil or criminal sanctions. We rely on third parties, including CROs, to carry out many of our clinical trial-related activities. Failure of such third parties to comply with cGCP can likewise result in rejection of our clinical trial data or other sanctions.</font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Approval of Biosimilars </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The Patient Protection and Affordable Care Act (PPACA) amended the Public Health Service Act (PHSA) to authorize the FDA to approve biological products, referred to as biosimilars or follow-on biologics, that are shown to be highly similar to previously approved biological products based upon potentially abbreviated data packages.&#160;The biosimilar must show it has no clinically meaningful differences in terms of safety and effectiveness from the reference product, and only minor differences in clinically inactive components are allowable in biosimilars products. The approval pathway for biosimilars does, however, grant a biologics manufacturer a 12-year period of exclusivity from the date of approval of its biological product before biosimilar competition can be introduced. There is uncertainty, however, as the approval framework for biosimilars originally was enacted as part of the PPACA. In 2017, there are likely to be federal legislative and administrative efforts to repeal, substantially modify or invalidate some or all of the provisions of the PPACA. If the PPACA is repealed, substantially modified or invalidated, it is unclear what, if any, impact such action would have on biosimilar regulation.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biosimilars legislation has also been in place in the E.U. since 2003. In December 2012 guidelines issued by the EMA for approving biosimilars of marketed monoclonal antibody products became effective. In the E.U., biosimilars have been approved under a specialized pathway of centralized procedures. The pathway allows sponsors of a biosimilar to seek and obtain regulatory approval based in part on the clinical trial data of an innovator product to which the biosimilar has been demonstrated to be &#8220;similar&#8221;. In many cases, this allows biosimilars to be brought to market without conducting the full complement of clinical trials typically required for novel biologic drugs.</font></div></div></div><br><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">20</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Orphan Drug Act</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the U.S.&#160;Orphan Drug Act, the FDA may grant orphan drug designation to drugs or biologics intended to treat a &#8220;rare disease or condition,&#8221; which generally is a disease or condition that affects fewer than 200,000 individuals in the U.S.&#160;If a product which has an orphan drug designation subsequently receives the first FDA approval for the indication for which it has such designation, the product is entitled to orphan exclusivity, i.e., the FDA may not approve any other applications to market the same drug for the same indication for a period of seven years following marketing approval, except in certain very limited circumstances, such as if the later product is shown to be clinically superior to the orphan product. Legislation similar to the U.S.&#160;Orphan Drug Act has been enacted in other countries to encourage the research, development and marketing of medicines to treat, prevent or diagnose rare diseases. In the E.U., medicinal products intended for diagnosis, prevention or treatment of life-threatening or very serious diseases affecting less than five in 10,000 people receive 10-year market exclusivity, protocol assistance and access to the centralized procedure for marketing authorization. SPINRAZA has been granted orphan drug designation in the U.S., E.U. and Japan.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Regulation Pertaining to Pricing and Reimbursement</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In both domestic and foreign markets, sales of our products depend, in part, on the availability and amount of reimbursement by third-party payors, including governments, private health plans and other organizations. Substantial uncertainty exists regarding the pricing reimbursement of our products, and drug prices continue to receive significant scrutiny. Governments may regulate coverage, reimbursement and pricing of our products to control cost or affect utilization of our products. Challenges to our pricing strategies, by either government or private stakeholders, could harm our business. The U.S.&#160;and foreign governments have enacted and regularly consider additional reform measures that affect health care coverage and costs. Private health plans may also seek to manage cost and utilization by implementing coverage and reimbursement limitations. Other payors, including managed care organizations, health insurers, pharmacy benefit managers, government health administration authorities and private health insurers, seek price discounts or rebates in connection with the placement of our products on their formularies and, in some cases, the imposition of restrictions on access or coverage of particular drugs or pricing determined based on perceived value.</font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Within the U.S.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Medicaid</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">: Medicaid is a joint federal and state program that is administered by the states for low income and disabled beneficiaries. Under the Medicaid Drug Rebate Program, we are required to pay a rebate for each unit of product reimbursed by the state Medicaid programs. The amount of the rebate is established by law and is adjusted upward if average manufacture price (AMP) increases more than inflation (measured by the Consumer Price Index&#160;- Urban). The rebate amount is calculated each quarter based on our report of current AMP and best price for each of our products to the Centers for Medicare&#160;&amp; Medicaid Services (CMS). The requirements for calculating AMP and best price are complex. We are required to report any revisions to AMP or best price previously reported within a certain period, which revisions could affect our rebate liability for prior quarters. In addition, if we fail to provide information timely or we are found to have knowingly submitted false information to the government, the statute governing the Medicaid Drug Rebate Program provides for civil monetary penalties.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Medicare</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">: Medicare is a federal program that is administered by the federal government that covers individuals age&#160;65 and over as well as those with certain disabilities. Medicare Part&#160;B generally covers drugs that must be administered by physicians or other health care practitioners; are provided in connection with certain durable medical equipment; or are certain oral anti-cancer drugs and certain oral immunosuppressive drugs. In addition, clotting factors for hemophilia are typically paid under Medicare Part B. Medicare Part B pays for such drugs under a payment methodology based on the average sales price (ASP) of the drugs. Manufacturers, including us, are required to provide ASP information to the CMS on a quarterly basis. The manufacturer-submitted information is used to calculate Medicare payment rates. If a manufacturer is found to have made a misrepresentation in the reporting of ASP, the governing statute provides for civil monetary penalties.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Medicare Part D provides coverage to enrolled Medicare patients for self-administered drugs (i.e., drugs that are not administered by a physician). Medicare Part D is administered by private prescription drug plans approved by the U.S. government and each drug plan establishes its own Medicare Part D formulary for prescription drug coverage and pricing, which the drug plan may modify from time-to-time. The prescription drug plans negotiate pricing with </font></div></td></tr></table></div></div><br><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-left:30px;padding-top:12px;text-align:left;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">manufacturers and pharmacies, and may condition formulary placement on the availability of manufacturer discounts. In addition, manufacturers, including us, are required to provide to CMS a 50% discount on brand name prescription drugs utilized by Medicare Part D beneficiaries when those beneficiaries reach the coverage gap in their drug benefits.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Federal Agency Discounted Pricing</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">: Our products are subject to discounted pricing when purchased by federal agencies via the Federal Supply Schedule (FSS). FSS participation is required for our products to be covered and reimbursed by the Veterans Administration (VA), Department of Defense, Coast Guard and Public Health Service (PHS). Coverage under Medicaid, Medicare and the PHS pharmaceutical pricing program is also conditioned upon FSS participation. FSS pricing is intended not to exceed the price that we charge our most-favored non-federal customer for a product. In addition, prices for drugs purchased by the VA, Department of Defense (including drugs purchased by military personnel and dependents through the TriCare retail pharmacy program), Coast Guard and PHS are subject to a cap on pricing equal to 76% of the non-federal average manufacturer price (non-FAMP). An additional discount applies if non-FAMP increases more than inflation (measured by the Consumer Price Index&#160;- Urban). In addition, if we fail to provide information timely or we are found to have knowingly submitted false information to the government, the governing statute provides for civil monetary penalties.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">340B Discounted Pricing</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">: To maintain coverage of our products under the Medicaid Drug Rebate Program and Medicare Part B, we are required to extend significant discounts to certain covered entities that purchase products under Section 340B of the PHS pharmaceutical pricing program. Purchasers eligible for discounts include hospitals that serve a disproportionate share of financially needy patients, community health clinics, hemophilia treatment centers and other entities that receive certain types of grants under the PHSA. For all of our products, we must agree to charge a price that will not exceed the amount determined under statute (the &#8220;ceiling price&#8221;) when we sell outpatient drugs to these covered entities. In addition, we may, but are not required to, offer these covered entities a price lower than the 340B ceiling price. The 340B discount formula is based on AMP and is generally similar to the level of rebates calculated under the Medicaid Drug Rebate Program. </font></div></td></tr></table></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Outside the U.S.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Outside the U.S., the E.U. represents a major market. Within the E.U., our products are paid for by a variety of payors, with governments being the primary source of payment. Governments may determine or influence reimbursement of products. Governments may also set prices or otherwise regulate pricing. Negotiating prices with governmental authorities can delay commercialization of our products. Governments may use a variety of cost-containment measures to control the cost of products, including price cuts, mandatory rebates, value-based pricing, and reference pricing (i.e., referencing prices in other countries and using those reference prices to set a price). Budgetary pressures in many E.U. countries are continuing to cause governments to consider or implement various cost-containment measures, such as price freezes, increased price cuts and rebates, and expanded generic substitution and patient cost-sharing. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Regulation Pertaining to Sales and Marketing</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are subject to various federal and state laws pertaining to health care &#8220;fraud and abuse,&#8221; including anti-kickback laws and false claims laws. Anti-kickback laws generally prohibit a prescription drug manufacturer from soliciting, offering, receiving, or paying any remuneration to generate business, including the purchase or prescription of a particular drug. Although the specific provisions of these laws vary, their scope is generally broad and there may be no regulations, guidance or court decisions that clarify how the laws apply to particular industry practices. There is therefore a possibility that our practices might be challenged under the anti-kickback or similar laws. False claims laws prohibit anyone from knowingly and willingly presenting, or causing to be presented for payment to third-party payors (including Medicare and Medicaid) claims for reimbursed drugs or services that are false or fraudulent, claims for items or services not provided as claimed, or claims for medically unnecessary items or services. Our activities relating to the sale and marketing of our products may be subject to scrutiny under these laws. Violations of fraud and abuse laws may be punishable by criminal or civil sanctions, including fines and civil monetary penalties, and exclusion from federal health care programs (including Medicare and Medicaid). In the U.S., federal and state authorities are paying increased attention to enforcement of these laws within the pharmaceutical industry and private individuals have been active in alleging violations of the laws and bringing suits on behalf of the government under the federal civil False Claims Act. If we were subject to allegations concerning, or were convicted of violating, these laws, our business could be harmed.</font></div></div></div><br><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">22</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Laws and regulations have been enacted by the federal government and various states to regulate the sales and marketing practices of pharmaceutical manufacturers. The laws and regulations generally limit financial interactions between manufacturers and health care providers or require disclosure to the government and public of such interactions. The laws include federal &#8220;sunshine&#8221; provisions. The sunshine provisions apply to pharmaceutical manufacturers with products reimbursed under certain government programs and require those manufacturers to disclose annually to the federal government (for re-disclosure to the public) certain payments made to physicians and certain other healthcare practitioners or to teaching hospitals. State laws may also require disclosure of pharmaceutical pricing information and marketing expenditures. Many of these laws and regulations contain ambiguous requirements. Given the lack of clarity in laws and their implementation, our reporting actions could be subject to the penalty provisions of the pertinent federal and state laws and regulations. Outside the U.S., other countries have implemented requirements for disclosure of financial interactions with healthcare providers and additional countries may consider or implement such laws.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Regulations</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Foreign Anti-Corruption</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are subject to various federal and foreign laws that govern our international business practices with respect to payments to government officials. Those laws include the U.S.&#160;Foreign Corrupt Practices Act (FCPA), which prohibits U.S.&#160;companies and their representatives from paying, offering to pay, promising, or authorizing the payment of anything of value to any foreign government official, government staff member, political party, or political candidate for the purpose of obtaining or retaining business or to otherwise obtain favorable treatment or influence a person working in an official capacity. In many countries, the health care professionals we regularly interact with may meet the FCPA's definition of a foreign government official. The FCPA also requires public companies to make and keep books and records that accurately and fairly reflect their transactions and to devise and maintain an adequate system of internal accounting controls.</font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The laws to which we are subject also include the U.K. Bribery Act 2010 (Bribery Act) which proscribes giving and receiving bribes in the public and private sectors, bribing a foreign public official, and failing to have adequate procedures to prevent employees and other agents from giving bribes. U.S. companies that conduct business in the United Kingdom generally will be subject to the Bribery Act. Penalties under the Bribery Act include potentially unlimited fines for companies and criminal sanctions for corporate officers under certain circumstances.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">NIH Guidelines</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We seek to conduct research at our U.S. facilities in compliance with the current U.S.&#160;National Institutes of Health Guidelines for Research Involving Recombinant DNA Molecules (NIH Guidelines). By local ordinance, we are required to, among other things, comply with the NIH Guidelines in relation to our facilities in RTP, North Carolina and are required to operate pursuant to certain permits.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Other Laws</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our present and future business has been and will continue to be subject to various other laws and regulations. Various laws, regulations and recommendations relating to data privacy and protection, safe working conditions, laboratory practices, the experimental use of animals, and the purchase, storage, movement, import, export and use and disposal of hazardous or potentially hazardous substances, including radioactive compounds and infectious disease agents, used in connection with our research work are or may be applicable to our activities. Certain agreements entered into by us involving exclusive license rights may be subject to national or international antitrust regulatory control, the effect of which cannot be predicted. The extent of government regulation, which might result from future legislation or administrative action, cannot accurately be predicted.</font></div><div><a name="sC58674F594F2C8896C7F201709497F1D"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Environmental Matters</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We strive to comply in all material respects with applicable laws and regulations concerning the environment. While it is impossible to predict accurately the future costs associated with environmental compliance and potential remediation activities, compliance with environmental laws is not expected to require significant capital expenditures and has not had, and is not expected to have, a material adverse effect on our operations or competitive position.</font></div></div></div><br><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">23</font></div></div><hr style="page-break-after:always"><div><a name="sA4924D8CF76C9C1822412017096BB34F"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Manufacturing</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are committed to ensuring an uninterrupted supply of medicines to patients around the world. To that end, we continually review our manufacturing capacity, capabilities, processes and facilities. We believe that our manufacturing facilities, together with the third-party contract manufacturing organizations we outsource to, currently provide sufficient capacity for our products and the contract manufacturing services we provide to Samsung Bioepis, our joint venture that develops, manufactures and markets biosimilars, and other strategic contract manufacturing partners. In light of the development of our pipeline, we are expanding our production capacity by building a large-scale biologics manufacturing facility in Solothurn, Switzerland, which is expected to be operational by the end of the decade.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Manufacturing Facilities</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our drug substance manufacturing facilities include:</font></div><div style="line-height:120%;text-align:left;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:49%;"></td><td style="width:2%;"></td><td style="width:49%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Facility</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Drug Substance Manufactured</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">RTP, North Carolina</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">ALPROLIX</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">AVONEX</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">ELOCTATE</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">PLEGRIDY</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">TYSABRI</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">ZINBRYTA</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Other*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Hiller&#248;d, Denmark</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">TYSABRI</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Biosimilars</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:-12px;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">* Other includes products manufactured for contract manufacturing partners</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition to our drug substance manufacturing facilities, we have a drug product manufacturing facility and supporting infrastructure in RTP, North Carolina. This parenteral facility adds capabilities and capacity for filling biologics into vials.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also lease from Eisai an oral solid dose products manufacturing facility in RTP, North Carolina, where we manufacture TECFIDERA and other oral solid dose products, including products for Eisai. This facility supplements our outsourced small molecule manufacturing capabilities. Under our lease arrangement, Eisai may provide us with packaging services for oral solid dose products. In August 2015 we agreed to purchase this facility following the expiration of our current three-year lease in the third quarter of 2018 and Eisai's completion of certain activities.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For a period of time following the spin-off of Bioverativ, we agreed to manufacture and supply, exclusively for Bioverativ, drug substance, drug product and finished goods with respect to ELOCTATE and ALPROLIX and pipeline product candidates.</font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Genentech is responsible for all worldwide manufacturing activities for bulk RITUXAN and GAZYVA and has sourced the manufacture of certain bulk RITUXAN and GAZYVA requirements to a third party, Acorda Therapeutics supplies FAMPYRA to us pursuant to its supply agreement with Alkermes, Inc. and Ionis supplies the active pharmaceutical ingredient (API) for SPINRAZA.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Third-Party Suppliers and Manufacturers</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We principally use third parties to manufacture the API, except as noted above for SPINRAZA, and, to a lesser extent, the final product for our small molecule products and product candidates, including TECFIDERA and FUMADERM and the final drug product for our large molecule products and product candidates, including SPINRAZA. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We source all of our fill-finish and the majority of final product assembly and storage operations for our products, along with a substantial part of our packaging operations, to a concentrated group of third-party contract manufacturing organizations. We have internal label and packaging capability for clinical and commercial products at our Hiller&#248;d facility. Raw materials, delivery devices, such as syringes and auto-injectors, and other supplies required for the production of our products and product candidates are procured from various third-party suppliers and manufacturers in quantities adequate to meet our needs. Continuity of supply of such raw materials, devices and supplies is assured using a strategy of dual sourcing where possible or by a risk-based inventory strategy. Our third-party service providers, suppliers and manufacturers may be subject to routine cGMP inspections by the FDA or comparable agencies in other jurisdictions and undergo assessment and certification by our quality management group.</font></div></div></div><br><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24</font></div></div><hr style="page-break-after:always"><div><a name="s9FF90157800696BB7FA92017099D02D2"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Our Employees</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had approximately 7,400 employees worldwide.</font></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Our Executive Officers (as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">February&#160;2, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:30%;"></td><td style="width:1%;"></td><td style="width:56%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:7%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Officer</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Current Position</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Age</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Year Joined Biogen</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;">Michel Vounatsos</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Chief Executive Officer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">55</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;">Susan H. Alexander</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Executive Vice President, Chief Legal Officer and Corporate Secretary</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">60</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2006</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;">Paul J. Clancy</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Executive Vice President, Finance and Chief Financial Officer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">55</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2001</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;">Gregory F. Covino</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Vice President, Finance and Chief Accounting Officer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">51</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2012</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;">Michael D. Ehlers</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Executive Vice President, Research and Development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">48</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;">Paul McKenzie</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Executive Vice President, Pharmaceutical Operations and Technology</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">51</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;">Kenneth DiPietro</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Executive Vice President, Human Resources</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">58</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2012</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;">Adriana (Andi) Karaboutis</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Executive Vice President, Technology, Business Solutions and Corporate Affairs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">54</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;">Alfred W. Sandrock, Jr., M.D., Ph.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Chief Medical Officer and Executive Vice President of Neurology Discovery and Development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">59</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1998</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:5%;"></td><td style="width:95%;"></td></tr><tr><td colspan="2" style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;">Michel Vounatsos</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Experience</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mr. Vounatsos has served as our Chief Executive Officer since January 2017. Prior to that, from April 2016 to December 2016, Mr. Vounatsos served as our Executive Vice President and Chief Commercial Officer. Prior to joining Biogen, Mr. Vounatsos spent 20 years at Merck where he most recently served as President, Primary Care, Customer Business Line. In this role, he led Merck&#8217;s global primary care business unit, a role which encompassed Merck&#8217;s cardiology-metabolic, general medicine, women&#8217;s health and biosimilars groups and developed and instituted a strategic framework for enhancing the company&#8217;s relationships with key constituents, including the most significant providers, payers and retailers and the world&#8217;s largest governments. Mr. Vounatsos previously held leadership positions across Europe and in China for Merck. Prior to that, Mr. Vounatsos held management positions at Ciba-Geigy.</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Education</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Universite Victor Segalen, Bordeaux II, France, C.S.C.T. Certificate in Medicine</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">HEC School of Management - Paris, M.B.A.</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:5%;"></td><td style="width:95%;"></td></tr><tr><td colspan="2" style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;">Susan H. Alexander</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Experience</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Ms. Alexander has served as our Executive Vice President, Chief Legal Officer and Corporate Secretary since December 2011. Prior to that, from 2006 to December 2011, Ms. Alexander served as our Executive Vice President, General Counsel and Corporate Secretary. From 2003 to January 2006, Ms.&#160;Alexander served as the Senior Vice President, General Counsel and Corporate Secretary of PAREXEL International Corporation, a biopharmaceutical services company. From 2001 to 2003, Ms.&#160;Alexander served as General Counsel of IONA Technologies, a software company. From 1995 to 2001, Ms.&#160;Alexander served as Counsel at Cabot Corporation, a specialty chemicals and performance materials company. Prior to that, Ms.&#160;Alexander was a partner at the law firms of Hinckley, Allen&#160;&amp; Snyder and Fine&#160;&amp; Ambrogne. </font></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Public Company Boards</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Board of Directors of Invacare Corporation, a medical and healthcare product company</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Education</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Wellesley College, B.A</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Boston University School of Law, J.D.</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">25</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:5%;"></td><td style="width:95%;"></td></tr><tr><td colspan="2" style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;">Paul J. Clancy</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Experience</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mr. Clancy has served as our Executive Vice President, Finance and Chief Financial Officer since August 2007. Mr. Clancy joined Biogen, Inc. in 2001 and has held several senior executive positions with us, including Vice President of Business Planning, Portfolio Management and U.S. Marketing, and Senior Vice President of Finance with responsibilities for leading the Treasury, Tax, Investor Relations and Business Planning groups. Prior to that, he spent 13 years at PepsiCo, a food and beverage company, serving in a range of financial and general management positions. </font></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Public Company Boards</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Board of Directors of Agios Pharmaceuticals, Inc., a biopharmaceutical company</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Board of Directors of Incyte Corporation, a biopharmaceutical company </font></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Education</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Babson College, B.S. in Finance</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Columbia University, M.B.A.</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:5%;"></td><td style="width:95%;"></td></tr><tr><td colspan="2" style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;">Gregory F. Covino</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Experience</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mr. Covino has served as our Vice President, Finance and Chief Accounting Officer since April 2012. Prior to that, Mr. Covino served at Boston Scientific Corporation, a medical device company, as Vice President, Corporate Analysis and Control since March 2010, having responsibility for the company's internal audit function, and as Vice President, Finance, International from February 2008 to March 2010, having responsibility for the financial activities of the company's international division. Prior to that, Mr. Covino held several finance positions at Hubbell Incorporated, an electrical products company, including Vice President, Chief Accounting Officer and Controller from 2002 to January 2008, Interim Chief Financial Officer from 2004 to 2005, and Director, Corporate Accounting from 1999 to 2002. </font></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Education</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Bryant University, B.S. in Business Administration</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:5%;"></td><td style="width:95%;"></td></tr><tr><td colspan="2" style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;">Michael D. Ehlers</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Experience</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Dr. Ehlers has served as our Executive Vice President, Head of R&amp;D since May 2016. Prior to joining Biogen, Dr. Ehlers served in leadership positions at Pfizer, Inc., including Senior Vice President &amp; Head BioTherapeutics R&amp;D and Chief Scientific Officer, Neuroscience &amp; Pain. Prior to that, Dr. Ehlers was the George Barth Geller Professor of Neurobiology and an Investigator of the Howard Hughes Medical Institute at Duke University Medical Center. He is the recipient of numerous awards including the Eppendorf &amp; Science Prize in Neurobiology, the John J. Abel Award in Pharmacology, the Society for Neuroscience Young Investigator Award, a National Institute of Mental Health MERIT Award, the National Alliance for Schizophrenia and Depression Distinguished Investigator Award, and the Massachusetts Medical Society Honored Business Leader Award. In 2013, Dr. Ehlers became the 11th recipient of the Thudichum Medal of the Biochemical Society of the United Kingdom. Past recipients include two Nobel laureates. Dr. Ehlers has authored over 100 scientific papers, has served on the Editorial Boards of Annual Reviews in Medicine, Annual Reviews in Pharmacology and Toxicology, the Journal of Neuroscience, the Journal of Biological Chemistry, the Journal of Molecular and Cellular Neuroscience, and has sat on advisory committees of the National Institutes of Health.</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Outside Affiliations</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">PhRMA Foundation Basic Pharmacology Advisory Committee</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Janelia Research Institute Advisory Committee</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">McKnight Endowment Fund for Neuroscience Board</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">World Economic Forum Global Agenda Council on Brain Research</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Education</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">California Institute of Technology, B.S. Chemistry</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The John Hopkins University School of Medicine, M.D.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The John Hopkins University School of Medicine, Ph.D. Neuroscience</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">26</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:5%;"></td><td style="width:95%;"></td></tr><tr><td colspan="2" style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;">Paul McKenzie</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Experience</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Dr. McKenzie has served as our Executive Vice President, Pharmaceutical Operations and Technology since July 2016. Prior to that, from February 2016 to June 2016, he served as our Senior Vice President for Global Biologics Manufacturing &amp; Technical Operations. Prior to joining Biogen, since 2008, Dr. McKenzie held a number of positions of increasing responsibility at Johnson &amp; Johnson (J&amp;J), including Vice President of R&amp;D for J&amp;J&#8217;s Ethicon business where he led the manufacturing and technical operations team responsible for internal and external manufacturing of Janssen&#8217;s pharmaceutical portfolio. He also ran global Development for Janssen R&amp;D, helping to manage pipeline activities from discovery through clinical development and commercialization. Prior to J&amp;J, Dr. McKenzie also held various R&amp;D and manufacturing positions at Bristol-Myers Squibb and Merck &amp; Co.</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Education</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">University of Pennsylvania, B.S. Chemical Engineering</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Carnegie Mellon University, Ph.D. Chemical Engineering</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:5%;"></td><td style="width:95%;"></td></tr><tr><td colspan="2" style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;">Kenneth DiPietro</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Experience</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mr. DiPietro has served as our Executive Vice President, Human Resources since January 2012. Mr. DiPietro joined Biogen from Lenovo Group, a technology company, where he served as Senior Vice President, Human Resources from 2005 to June 2011. From 2003 to 2005, he served as Corporate Vice President, Human Resources at Microsoft Corporation, a technology company. From 1999 to 2002, Mr. DiPietro worked as Vice President, Human Resources at Dell Inc., a technology company. Prior to that, he spent 17 years at PepsiCo, a food and beverage company, serving in a range of human resource and general management positions.</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Public Company Boards</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Board of Directors of InVivo Therapeutics Corporation, a medical device company</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Education</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cornell University, B.S. in Industrial and Labor Relations</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:5%;"></td><td style="width:95%;"></td></tr><tr><td colspan="2" style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;">Adriana (Andi) Karaboutis</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Experience</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Ms. Karaboutis has served as our Executive Vice President, Technology, Business Solutions and Corporate Affairs since December 2015 and prior to that served as our Executive Vice President, Technology and Business Solutions since joining Biogen in September 2014. Prior to that, Ms. Karaboutis was Vice President and Global Chief Information Officer of Dell, Inc., where she was responsible for leading a global IT organization focused on powering Dell as an end-to-end technology solutions provider. Prior to joining Dell in 2010, Ms. Karaboutis spent over 20 years at General Motors and Ford Motor Company in various international leadership positions including computer-integrated manufacturing, supply chain operations, and information technology. </font></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Public Company Boards</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Board of Directors of Advance Auto Parts, an automotive aftermarket parts provider </font></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Education</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Wayne State University, B.S. in Computer Science</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:5%;"></td><td style="width:95%;"></td></tr><tr><td colspan="2" style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;">Alfred W. Sandrock, Jr., M.D., Ph.D.</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Experience</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Dr. Sandrock has served as our Chief Medical Officer and Executive Vice President of Neurology Discovery and Development since November 2015. Prior to that, Dr. Sandrock served as our Chief Medical Officer and Group Senior Vice President from May 2013 to October 2015, and as our Chief Medical Officer and Senior Vice President of Development Sciences from February 2012 to April 2013. Prior to that, Dr. Sandrock held several senior executive positions since joining us in 1998, including Senior Vice President of Neurology Research and Development and Vice President of Clinical Development, Neurology. </font></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Public Company Boards</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Board of Directors of Neurocrine Biosciences, Inc., a life sciences company</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Education</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Stanford University, B.A. in Human Biology</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Harvard Medical School, M.D. </font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Harvard University, Ph.D. in Neurobiology</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Massachusetts General Hospital, internship in Medicine, residency and chief residency in Neurology, and clinical fellowship in Neuromuscular Disease and Clinical Neurophysiology (electromyography)</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">27</font></div></div><hr style="page-break-after:always"><div><a name="s456B4C6A2F6867B83FD7201709E0AE59"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Available Information</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our principal executive offices are located at 225 Binney Street, Cambridge, MA 02142 and our telephone number is (617)&#160;679-2000. Our website address is www.biogen.com. We make available free of charge through the Investors section of our website our Annual Reports on Form&#160;10-K, Quarterly Reports on Form&#160;10-Q, Current Reports on Form&#160;8-K and all amendments to those reports as soon as reasonably practicable after such material is electronically filed with or furnished to the Securities and Exchange Commission (SEC). We include our website address in this report only as an inactive textual reference and do not intend it to be an active link to our website. The contents of our website are not incorporated into this report.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">28</font></div></div><hr style="page-break-after:always"><div><a name="s90E7A4539EE0A80EE7AB201709F0C16A"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;&#160;1A. &#160;&#160;&#160;&#160;Risk Factors</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">We are substantially dependent on revenues from our principal products. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our current revenues depend upon continued sales of our principal products, and, unless we develop or acquire rights to new products and technologies, we may be substantially dependent on sales from our principal products for many years. Further, following the completion of the spin-off of our hemophilia business, our revenues will be further reliant and concentrated on sales of our MS products in an increasingly competitive market, and revenue from sales of our product for spinal muscular atrophy. Any of the following negative developments relating to any of our principal products may adversely affect our revenues and results of operations or could cause a decline in our stock price: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">safety or efficacy issues; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the introduction or greater acceptance of competing products; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">constraints and additional pressures on product pricing or price increases, including those resulting from governmental or regulatory requirements, increased competition, or changes in, or implementation of, reimbursement policies and practices of payors and other third parties; or </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">adverse legal, administrative, regulatory or legislative developments.</font></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">SPINRAZA was recently approved by the FDA, and is in the early stages of commercial launch.&#160;In addition to risks associated with new product launches and the other factors described in these &#8220;Risk Factors&#8221;, our ability to successfully commercialize SPINRAZA may be adversely affected due to:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our limited marketing experience within the spinal muscular atrophy market, which may impact our ability to develop relationships with the associated medical and scientific community; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the lack of readiness of healthcare providers to treat patients with spinal muscular atrophy;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the effectiveness of our commercial strategy for marketing SPINRAZA; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our ability to maintain a positive reputation among patients, healthcare providers and others in the spinal muscular atrophy community, which may be impacted by pricing and reimbursement decisions relating to SPINRAZA. </font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">If we fail to compete effectively, our business and market position would suffer.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The biopharmaceutical industry and the markets in which we operate are intensely competitive. We compete in the marketing and sale of our products, the development of new products and processes, the acquisition of rights to new products with commercial potential and the hiring and retention of personnel. We compete with biotechnology and pharmaceutical companies that have a greater number of products on the market and in the product pipeline, greater financial and other resources and other technological or competitive advantages. One or more of our competitors may benefit from significantly greater sales and marketing capabilities, may develop products that are accepted more widely than ours or may receive patent protection that dominates, blocks or adversely affects our product development or business.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our products are also susceptible to competition from generics and biosimilars in many markets.&#160;Generic versions of drugs and biosimilars are likely to be sold at substantially lower prices than branded products.&#160;Accordingly, the introduction of generic or biosimilar versions of our marketed products likely would significantly reduce both the price that we receive for such marketed products and the volume of products that we sell, which may have an adverse impact on our results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the MS market, we face intense competition as the number of products and competitors continues to expand. Due to our significant reliance on sales of our MS products, our business may be harmed if we are unable to successfully compete in the MS market. More specifically, our ability to compete, maintain and grow our share in the MS market may be adversely affected due to a number of factors, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the introduction of more efficacious, safer, less expensive or more convenient alternatives to our MS products, including our own products and products of our collaborators; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the introduction of lower-cost biosimilars, follow-on products or generic versions of branded MS products sold by our competitors, and the possibility of future competition from generic versions or prodrugs of existing therapeutics or from off-label use by physicians of therapies indicated for other conditions to treat MS patients; </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">29</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">patient dynamics, including the size of the patient population and our ability to attract new patients to our therapies; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">damage to physician and patient confidence in any of our MS products or to our sales and reputation as a result of label changes or adverse experiences or events that may occur with patients treated with our MS products; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">inability to obtain appropriate pricing and reimbursement for our MS products compared to our competitors in key international markets; or </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our ability to obtain and maintain patent, data or market exclusivity for our MS products.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Sales of our products depend, to a significant extent, on adequate coverage, pricing and reimbursement from third-party payors, which are subject to increasing and intense pressure from political, social, competitive and other sources. Our inability to maintain adequate coverage, or a reduction in pricing or reimbursement, could have an adverse effect on our business, revenues and results of operations and could cause a decline in our stock price.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Sales of our products are dependent, in large part, on the availability and extent of coverage, pricing and reimbursement from government health administration authorities, private health insurers and other organizations. When a new pharmaceutical product is approved, the availability of government and private reimbursement for that product may be uncertain, as is the pricing and amount for which that product will be reimbursed. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pricing and reimbursement for our products may be adversely affected by a number of factors, including: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">changes in, and implementation of, federal, state or foreign government regulations or private third-party payors' reimbursement policies; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">pressure by employers on private health insurance plans to reduce costs; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">consolidation and increasing assertiveness of payors, including managed care organizations, health insurers, pharmacy benefit managers, government health administration authorities, private health insurers and other organizations, seeking price discounts or rebates in connection with the placement of our products on their formularies and, in some cases, the imposition of restrictions on access or coverage of particular drugs or pricing determined based on perceived value.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our ability to set the price for our products can vary significantly from country to country and as a result so can the price of our products. Certain countries set prices by reference to the prices in other countries where our products are marketed. Thus, our inability to secure adequate prices in a particular country may not only limit the revenue from our products within that country, but may also adversely affect our ability to obtain acceptable prices in other markets. This may create the opportunity for third-party cross-border trade or influence our decision to sell or not to sell a product, thus adversely affecting our geographic expansion plans and revenues.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our failure to maintain adequate coverage, pricing, or reimbursement for our products would have an adverse effect on our business, revenues and results of operations, could curtail or eliminate our ability to adequately fund research and development programs for the discovery and commercialization of new products and could cause a decline in our stock price.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Drug prices are under significant scrutiny in the markets in which our products are prescribed.&#160;We expect drug pricing and other health care costs to continue to be subject to intense political and societal pressures on a global basis. As a result, our business and reputation may be harmed, our stock price may be adversely impacted and experience periods of volatility, and our results of operations may be adversely impacted.&#160; </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our results of operations may be adversely affected by current and potential future healthcare reforms.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the U.S., federal and state legislatures, health agencies and third-party payors continue to focus on containing the cost of health care. Legislative and regulatory proposals and enactments to reform health care insurance programs could significantly influence the manner in which our products are prescribed and purchased. For example, provisions of the PPACA have resulted in changes in the way health care is paid for by both governmental and private insurers, including increased rebates owed by manufacturers under the Medicaid Drug Rebate Program, annual fees and taxes on manufacturers of certain branded prescription drugs, the requirement that manufacturers participate in a discount program for certain outpatient drugs under Medicare Part D and the expansion of the number of hospitals eligible for discounts under Section 340B of the Public Health Service Act. These changes have had and are expected to continue to have a significant impact on our business. In 2017, we may face uncertainties as a result of likely federal and administrative efforts to repeal, substantially modify or invalidate some or all of the provisions of the PPACA. There is no assurance that the PPACA, as currently enacted or as amended in the future, will not adversely affect our business and financial results, and we cannot predict how future federal or state legislative or administrative changes relating to healthcare reform will affect our business.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">There is also significant economic pressure on state budgets that may result in states increasingly seeking to achieve budget savings through mechanisms that limit coverage or payment for our drugs. In recent years, some states have considered legislation and ballot initiatives that would control the prices of drugs, including laws to allow importation of pharmaceutical products from lower cost jurisdictions outside the U.S. and laws intended to impose price controls on state drug purchases. State Medicaid programs are increasingly requesting manufacturers to pay supplemental rebates and requiring prior authorization by the state program for use of any drug for which supplemental rebates are not being paid. Government efforts to reduce Medicaid expenses may lead to increased use of managed care organizations by Medicaid programs. This may result in managed care organizations influencing prescription decisions for a larger segment of the population and a corresponding constraint on prices and reimbursement for our products. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the E.U. and some other international markets, the government provides health care at low cost to consumers and regulates pharmaceutical prices, patient eligibility or reimbursement levels to control costs for the government-sponsored health care system. Many countries have announced or implemented measures to reduce health care costs to constrain their overall level of government expenditures. These measures vary by country and may include, among other things, patient access restrictions, suspensions on price increases, prospective and possibly retroactive price reductions and other recoupments and increased mandatory discounts or rebates, recoveries of past price increases and greater importation of drugs from lower-cost countries to higher-cost countries. These measures have negatively impacted our revenues, and may continue to adversely affect our revenues and results of operations in the future.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Adverse safety events or restrictions on use and safety warnings for our products can negatively affect our business, product sales and stock price.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adverse safety events involving our marketed products may have a negative impact on our business. Discovery of safety issues with our products could create product liability and could cause additional regulatory scrutiny and requirements for additional labeling or safety monitoring, withdrawal of products from the market and the imposition of fines or criminal penalties. Adverse safety events may also damage physician and patient confidence in our products and our reputation. Any of these could result in liabilities, loss of revenue, material write-offs of inventory, material impairments of intangible assets, goodwill and fixed assets, material restructuring charges and other adverse impacts on our results of operations. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Regulatory authorities are making greater amounts of stand-alone safety information directly available to the public through periodic safety update reports, patient registries and other reporting requirements. The reporting of adverse safety events involving our products or products similar to ours and public rumors about such events may increase claims against us and may also cause our product sales or stock price to decline or experience periods of volatility. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restrictions on use or significant safety warnings that may be required to be included in the label of our products, such as the risk of developing progressive multifocal leukoencephalopathy (PML), a serious brain infection, in the label for certain of our products, may significantly reduce expected revenues for those products and require significant expense and management time. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">If we are unable to obtain and maintain adequate protection for our data, intellectual property and other proprietary rights, our business may be harmed. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our success depends in part on our ability to obtain and defend patent and other intellectual property rights that are important to the commercialization of our products and product candidates. The degree of patent protection that will be afforded to our products and processes in the U.S. and in other important markets remains uncertain and is dependent upon the scope of protection decided upon by the patent offices, courts, administrative bodies and lawmakers in these countries. We can provide no assurance that we will successfully obtain or preserve patent protection for the technologies incorporated into our products and processes, or that the protection obtained will be of sufficient breadth and degree to protect our commercial interests in all countries where we conduct business. If we cannot prevent others from exploiting our inventions, we will not derive the benefit from them that we currently expect. Furthermore, we can provide no assurance that our products will not infringe patents or other intellectual property rights held by third parties.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also rely on regulatory exclusivity for protection of our products. Implementation and enforcement of regulatory exclusivity, which may consist of regulatory data protection and market protection, varies widely from country to country.&#160;Failure to qualify for regulatory exclusivity, or failure to obtain or maintain the extent or duration of such protections that we expect in each of the markets for our products due to challenges, changes or interpretations in the law or otherwise, could affect our revenue for our products or our decision on whether to market our products in a particular country or countries or could otherwise have an adverse impact on our results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Litigation, interferences, oppositions, inter partes reviews or other proceedings are, have been and may in the future be necessary in some instances to determine the validity and scope of certain of our proprietary rights, and in other instances to determine the validity, scope or non-infringement of certain patent rights claimed by third parties to be pertinent to the manufacture, use or sale of our products.&#160;We may also face challenges to our patent and regulatory protections covering our products by third parties, including manufacturers of generics and biosimilars that may choose to launch or attempt to launch their products before the expiration of our patent or regulatory exclusivity.&#160;Litigation, interference, oppositions, inter partes reviews, administrative challenges or other similar types of proceedings are unpredictable and may be protracted, expensive and distracting to management. The outcome of such proceedings could adversely affect the validity and scope of our patent or other proprietary rights, hinder our ability to manufacture and market our products, require us to seek a license for the infringed product or technology or result in the assessment of significant monetary damages against us that may exceed amounts, if any, accrued in our financial statements. An adverse determination in a judicial or administrative proceeding or a failure to obtain necessary licenses could prevent us from manufacturing or selling our products. Furthermore, payments under any licenses that we are able to obtain would reduce our profits derived from the covered products and services.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our long-term success depends upon the successful development of new products and additional indications for existing products. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our long-term viability and growth will depend upon successful development of additional indications for our existing products as well as successful development of new products and technologies from our research and development activities, our biosimilars joint venture with Samsung Biologics or licenses or acquisitions from third parties. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product development is very expensive and involves a high degree of risk. Only a small number of research and development programs result in the commercialization of a product. Clinical trials may indicate that our product candidates lack efficacy, have harmful side effects, result in unexpected adverse events or raise other concerns that may significantly reduce the likelihood of regulatory approval. This may result in terminated programs, significant restrictions on use and safety warnings in an approved label, adverse placement within the treatment paradigm, or significant reduction in the commercial potential of the product candidate.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Clinical trials and the development of biopharmaceutical products is a lengthy and complex process. If we fail to adequately manage our clinical activities, our clinical trials or potential regulatory approvals may be delayed or denied. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Conducting clinical trials is a complex, time-consuming and expensive process. Our ability to complete clinical trials in a timely fashion depends in large part on a number of key factors. These factors include protocol design, regulatory and institutional review board approval, patient enrollment rates and compliance with extensive current Good Clinical Practices. If we or our third-party clinical trial providers or third-party contract research organizations (CROs) do not successfully carry out these clinical activities, our clinical trials or the potential regulatory approval of a product candidate may be delayed or be unsuccessful.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">32</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have opened clinical sites and are enrolling patients in a number of countries where our experience is more limited. In most cases, we use the services of third parties to carry out our clinical trial related activities and rely on such parties to accurately report their results. Our reliance on third parties for these activities may impact our ability to control the timing, conduct, expense and quality of our clinical trials. One CRO has responsibility for a substantial portion of our clinical trial related activities and reporting. If this CRO does not adequately perform, many of our trials may be affected. We may need to replace our CROs. Although we believe there are a number of other CROs we could engage to continue these activities, the replacement of an existing CRO may result in the delay of the affected trials or otherwise adversely affect our efforts to obtain regulatory approvals and commercialize our product candidates.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Successful preclinical work or early stage clinical trials do not ensure success in later stage trials, regulatory approval or commercial viability of a product.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Positive results in a trial may not be replicated in subsequent or confirmatory trials. Additionally, success in preclinical work or early stage clinical trials does not ensure that later stage or larger scale clinical trials will be successful or that regulatory approval will be obtained. In addition, even if later stage clinical trials are successful, regulatory authorities may delay or decline approval of our product candidates. Regulatory authorities may disagree with our view of the data, require additional studies or disagree with our trial design or endpoints. Regulatory authorities may also fail to approve the facilities or the processes used to manufacture a product candidate, our dosing or delivery methods or companion devices. Regulatory authorities may grant marketing approval that is more restricted than anticipated. These restrictions may include limiting indications to narrow patient populations and the imposition of safety monitoring, educational requirements and risk evaluation and mitigation strategies. The occurrence of any of these events could result in significant costs and expenses, have an adverse effect on our business, financial condition and results of operations and cause our stock price to decline or experience periods of volatility.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Even if we are able to successfully develop new products or indications, sales of new products or products with additional indications may not meet investor expectations. We may also make a strategic decision to discontinue development of a product or indication if, for example, we believe commercialization will be difficult relative to the standard of care or other opportunities in our pipeline.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Management and key personnel changes may disrupt our operations, and we may have difficulty retaining key personnel or attracting and retaining qualified replacements on a timely basis for management and other key personnel who may leave the Company.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have experienced changes in management and other key personnel in critical functions across our organization, including our chief executive officer, and heads of research and development and pharmaceutical operations and technology. Changes in management and other key personnel have the potential to disrupt our business, and any such disruption could adversely affect our operations, programs, growth, financial condition and results of operations. Further, new members of management may have different perspectives on programs and opportunities for our business, which may cause us to focus on new business opportunities or reduce or change emphasis on our existing business programs.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our success is dependent upon our ability to attract and retain qualified management and key personnel in a highly competitive environment. Qualified individuals are in high demand, and we may incur significant costs to attract them, particularly at the executive level. We may face difficulty in attracting and retaining key talent for a number of reasons, such as management changes, the underperformance or discontinuation of one or more late stage programs or recruitment by competitors. We cannot assure that we will be able to hire or retain the personnel necessary for our operations or that the loss of any such personnel will not have a material impact on our financial condition and results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Manufacturing issues could substantially increase our costs, limit supply of our products and reduce our revenues.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The process of manufacturing our products is complex, highly regulated and subject to numerous risks, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risk of Product Loss.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;The manufacturing process for our products is extremely susceptible to product loss due to contamination, oxidation, equipment failure or improper installation or operation of equipment, or vendor or operator error. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects and other supply disruptions. If microbial, viral or other contaminations are discovered in our products or manufacturing facilities, we may need to close our manufacturing facilities for an extended period of time to investigate and remediate the contaminant. </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">33</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risks of Reliance on Third Parties and Single Source Providers.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;We rely on third-party suppliers and manufacturers for many aspects of our manufacturing process for our products and product candidates. In some cases, due to the unique manner in which our products are manufactured, we rely on single source providers of several raw materials and manufacturing supplies. These third parties are independent entities subject to their own unique operational and financial risks that are outside of our control. These third parties may not perform their obligations in a timely and cost-effective manner or in compliance with applicable regulations, and they may be unable or unwilling to increase production capacity commensurate with demand for our existing or future products. Finding alternative providers could take a significant amount of time and involve significant expense due to the specialized nature of the services and the need to obtain regulatory approval of any significant changes to our suppliers or manufacturing methods. We cannot be certain that we could reach agreement with alternative providers or that the FDA or other regulatory authorities would approve our use of such alternatives. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Global Bulk Supply Risks.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;We rely on our principal manufacturing facilities for the production of drug substance for our large molecule products and product candidates. Our global bulk supply of these products and product candidates depends on the uninterrupted and efficient operation of these facilities, which could be adversely affected by equipment failures, labor shortages, natural disasters, power failures and numerous other factors.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risks Relating to Compliance with cGMP.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;We and our third-party providers are generally required to maintain compliance with cGMP and other stringent requirements and are subject to inspections by the FDA and comparable agencies in other jurisdictions to confirm such compliance. Any delay, interruption or other issues that arise in the manufacture, fill-finish, packaging or storage of our products as a result of a failure of our facilities or the facilities or operations of third parties to pass any regulatory agency inspection could significantly impair our ability to develop and commercialize our products. Significant noncompliance could also result in the imposition of monetary penalties or other civil or criminal sanctions and damage our reputation.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Any adverse developments affecting our manufacturing operations or the operations of our third-party suppliers and manufacturers may result in shipment delays, inventory shortages, lot failures, product withdrawals or recalls or other interruptions in the commercial supply of our products. We may also have to take inventory write-offs and incur other charges and expenses for products that fail to meet specifications, undertake costly remediation efforts or seek more costly manufacturing alternatives. Such developments could increase our manufacturing costs, cause us to lose revenue or market share as patients and physicians turn to competing therapeutics, diminish our profitability or damage our reputation. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">We depend on relationships with collaborators and other third-parties for revenue, and the development, regulatory approval, commercialization and marketing of certain products, which are outside of our full control.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We rely on a number of significant collaborative relationships for revenue, and the development, regulatory approval, commercialization and marketing of certain of our products and product candidates. We also outsource to third parties certain aspects of our regulatory affairs and clinical development relating to our products and product candidates. Reliance on collaborative and other third-party relationships subjects us to a number of risks, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">we may be unable to control the resources our collaborators or third parties devote to our programs or products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">disputes may arise under the agreement, including with respect to the achievement and payment of milestones or ownership of rights to technology developed with our collaborators or other third parties, and the underlying contract with our collaborators or other third parties may fail to provide significant protection or may fail to be effectively enforced if the collaborators or third parties fail to perform; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the interests of our collaborators or third parties may not always be aligned with our interests, such parties may not pursue regulatory approvals or market a product in the same manner or to the same extent that we would, which could adversely affect our revenues; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">third-party relationships and collaborations often require the parties to cooperate, and failure to do so effectively could adversely affect product sales, or the clinical development or regulatory approvals of products under joint control or could result in termination of the research, development or commercialization of product candidates or result in litigation or arbitration; and</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">34</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">any failure on the part of our collaborators or other third parties to comply with applicable laws and regulatory requirements in the marketing, sale and maintenance of the marketing authorization of our products or to fulfill any responsibilities our collaborators or other third parties may have to protect and enforce any intellectual property rights underlying our products could have an adverse effect on our revenues as well as involve us in possible legal proceedings.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Given these risks, there is considerable uncertainty regarding the success of our current and future collaborative efforts. If these efforts fail, our product development or commercialization of new products could be delayed or revenues from products could decline.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our business may be adversely affected if we do not successfully execute our growth initiatives.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We anticipate growth through internal development projects, commercial initiatives and external opportunities, which may include the acquisition, partnering and in-licensing of products, technologies and companies or the entry into strategic alliances and collaborations. While we believe we have a number of promising programs in our pipeline, failure of internal development projects to advance or difficulties in executing on our commercial initiatives could impact our current and future growth, resulting in additional reliance on external development opportunities for growth. The availability of high quality, cost-effective development opportunities is limited and competitive, and we are not certain that we will be able to identify candidates that we and our shareholders consider suitable or complete transactions on terms that are acceptable to us and our shareholders. We may fail to complete transactions for other reasons, including if we are unable to obtain desired financing on favorable terms, if at all. Even if we are able to successfully identify and complete acquisitions and other strategic alliances and collaborations, we may face unanticipated costs or liabilities in connection with the transaction or we may not be able to integrate them or take full advantage of them or otherwise realize the benefits that we expect.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Supporting our growth initiatives and the further development of our existing products and potential new products in our pipeline will require significant capital expenditures and management resources, including investments in research and development, sales and marketing, manufacturing capabilities and other areas of our business. If we do not successfully manage our growth initiatives, then our business and financial results may be adversely affected and we may incur asset impairment or restructuring charges.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">We may incur operational difficulties or be exposed to claims and liabilities as a result of the separation and distribution of Bioverativ.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On February 1, 2017, we distributed all of the then outstanding shares of Bioverativ common stock to Biogen stockholders in connection with the separation of our hemophilia business. In connection with the distribution, we entered into a separation and distribution agreement and various other agreements (including a transition services agreement, a tax matters agreement, a manufacturing and supply agreement, an employee matters agreement, an intellectual property matters agreement and certain other commercial agreements). These agreements govern the separation and distribution and the relationship between the two companies going forward, including with respect to potential tax-related losses associated with the separation and distribution. They also provide for the performance of services by each company for the benefit of the other for a period of time (including under the manufacturing and supply agreement pursuant to which we will manufacture and supply certain products and materials to Bioverativ). </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">There could be significant liability if the separation and distribution is determined to be a taxable transaction. Bioverativ has agreed to indemnify us for certain potential liabilities that may arise, but we cannot guarantee that Bioverativ will be able to satisfy its indemnification obligations. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The separation and distribution agreement provides for indemnification obligations designed to make Bioverativ financially responsible for many liabilities that may exist relating to its business activities, whether incurred prior to or after the distribution, including any pending or future litigation. It is possible that a court would disregard the allocation agreed to between us and Bioverativ and require us to assume responsibility for obligations allocated to Bioverativ. Third parties could also seek to hold us responsible for any of these liabilities or obligations, and the indemnity rights we have under the separation and distribution agreement may not be sufficient to fully cover all of these liabilities and obligations. Even if we are successful in obtaining indemnification, we may have to bear costs temporarily. In addition, our indemnity obligations to Bioverativ may be significant. These risks could negatively affect our business, financial condition or results of operations. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The separation of Bioverativ continues to involve a number of risks, including, among other things, the indemnification risks described above and the potential that management&#8217;s and our employees&#8217; attention will be significantly diverted by the provision of transitional services. Certain of the agreements described above provide for the performance of services by each company for the benefit of the other for a period of time. If Bioverativ is unable to satisfy its obligations under these agreements, including its indemnification obligations, we could incur losses. These arrangements could also lead to disputes over rights to certain shared property and over the allocation of costs and revenues for products and operations. Our inability to effectively manage the separation activities and related events could adversely affect our business, financial condition or results of operations. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">We may not achieve some or all of the expected benefits of the separation and distribution, and such events may adversely affect our business.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We may not be able to achieve the full strategic and financial benefits expected to result from the separation and distribution, or such benefits may be delayed or not occur at all. If we fail to achieve some or all of the expected benefits of the separation, or if such benefits are delayed, our business, financial condition, results of operations and the value of our stock could be adversely impacted. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">A breakdown or breach of our technology systems could subject us to liability or interrupt the operation of our business.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are increasingly dependent upon technology systems and data. Our computer systems continue to increase in multitude and complexity due to the growth in our business, making them potentially vulnerable to breakdown, malicious intrusion and random attack.&#160;Likewise, data privacy or security breaches by individuals authorized to access our technology systems or others may pose a risk that sensitive data, including intellectual property, trade secrets or personal information belonging to us, our patients, customers or other business partners, may be exposed to unauthorized persons or to the public. Cyber-attacks are increasing in their frequency, sophistication and intensity, and are becoming increasingly difficult to detect. They are often carried out by motivated, well-resourced, skilled and persistent actors including nation states, organized crime groups and "hacktivists." Cyber-attacks could include the deployment of harmful malware and key loggers, a denial-of-service attack, a malicious website, the use of social engineering and other means to affect the confidentiality, integrity and availability of our technology systems and data. Our key business partners face similar risks and any security breach of their systems could adversely affect our security posture. While we continue to build and improve our systems and infrastructure and believe we have taken appropriate security measures to reduce these risks to our data and information technology systems, there can be no assurance that our efforts will prevent breakdowns or breaches in our systems that could adversely affect our business and operations and/or result in the loss of critical or sensitive information, which could result in financial, legal, business or reputational harm to us. In addition, our liability insurance may not be sufficient in type or amount to cover us against claims related to security breaches, cyber-attacks and other related breaches.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">If we fail to comply with the extensive legal and regulatory requirements affecting the health care industry, we could face increased costs, penalties and a loss of business.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our activities, and the activities of our collaborators, distributors and other third-party providers, are subject to extensive government regulation and oversight both in the U.S.&#160;and in foreign jurisdictions. The FDA and comparable agencies in other jurisdictions directly regulate many of our most critical business activities, including the conduct of preclinical and clinical studies, product manufacturing, advertising and promotion, product distribution, adverse event reporting and product risk management. Our interactions in the U.S.&#160;or abroad with physicians and other health care providers that prescribe or purchase our products are also subject to government regulation designed to prevent fraud and abuse in the sale and use of the products and place greater restrictions on the marketing practices of health care companies. Health care companies such as ours are facing heightened scrutiny of their relationships with health care providers from anti-corruption enforcement officials. In addition, health care companies such as ours have been the target of lawsuits and investigations alleging violations of government regulation, including claims asserting submission of incorrect pricing information, impermissible off-label promotion of pharmaceutical products, payments intended to influence the referral of health care business, submission of false claims for government reimbursement, antitrust violations or violations related to environmental matters. There is also enhanced scrutiny of company-sponsored patient assistance programs, including insurance premium and co-pay assistance programs and donations to third party charities that provide such assistance. If we, or our vendors or donation recipients, are deemed to fail to comply with relevant laws, regulations or government guidance in the operation of these programs, we could be subject to significant fines or penalties. Risks relating to compliance with laws and regulations may be heightened as we continue to expand our global operations and enter new therapeutic areas with different patient populations, which may have different product distribution methods, marketing programs or patient assistance programs from those we currently utilize or support. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">36</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Regulations governing the health care industry are subject to change, with possibly retroactive effect, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">new laws, regulations or judicial decisions, or new interpretations of existing laws, regulations or decisions, related to health care availability, pricing or marketing practices, compliance with wage and hour laws and other employment practices, method of delivery, payment for health care products and services, compliance with health information and data privacy and security laws and regulations, tracking and reporting payments and other transfers of value made to physicians and teaching hospitals, extensive anti-bribery and anti-corruption prohibitions, product serialization and labeling requirements and used product take-back requirements; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">changes in the FDA and foreign regulatory approval processes that may delay or prevent the approval of new products and result in lost market opportunity; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">requirements that provide for increased transparency of clinical trial results and quality data, such as the EMA&#8217;s clinical transparency policy, which could impact our ability to protect trade secrets and competitively-sensitive information contained in approval applications or could be misinterpreted leading to reputational damage, misperception or legal action which could harm our business; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">changes in FDA and foreign regulations that may require additional safety monitoring, labeling changes, restrictions on product distribution or use, or other measures after the introduction of our products to market, which could increase our costs of doing business, adversely affect the future permitted uses of approved products, or otherwise adversely affect the market for our products.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Violations of governmental regulation may be punishable by criminal and civil sanctions against us, including fines and civil monetary penalties and exclusion from participation in government programs, including Medicare and Medicaid, as well as against executives overseeing our business. In addition to penalties for violation of laws and regulations, we could be required to repay amounts we received from government payors, or pay additional rebates and interest if we are found to have miscalculated the pricing information we have submitted to the government. We cannot ensure that our compliance controls, policies and procedures will in every instance protect us from acts committed by our employees, collaborators, partners or third-party providers that would violate the laws or regulations of the jurisdictions in which we operate. Whether or not we have complied with the law, an investigation into alleged unlawful conduct could increase our expenses, damage our reputation, divert management time and attention and adversely affect our business.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our effective tax rate may fluctuate and we may incur obligations in tax jurisdictions in excess of accrued amounts.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As a global biopharmaceutical company, we are subject to taxation in numerous countries, states and other jurisdictions. As a result, our effective tax rate is derived from a combination of applicable tax rates in the various places that we operate. In preparing our financial statements, we estimate the amount of tax that will become payable in each of such places. Our effective tax rate, however, may be different than experienced in the past due to numerous factors, including changes in the mix of our profitability from country to country, the results of examinations and audits of our tax filings, adjustments to the value of our uncertain tax positions, changes in accounting for income taxes and changes in tax laws. Any of these factors could cause us to experience an effective tax rate significantly different from previous periods or our current expectations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, our inability to secure or sustain acceptable arrangements with tax authorities and future changes in the tax laws, among other things, may result in tax obligations in excess of amounts accrued in our financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the U.S., there are several proposals under consideration to reform tax law, including proposals that may reduce or eliminate the deferral of U.S.&#160;income tax on our unrepatriated earnings, penalize certain transfer pricing structures, and reduce or eliminate certain foreign or domestic tax credits or deductions. Our future reported financial results may be adversely affected by tax law changes which restrict or eliminate certain foreign tax credits or our ability to deduct expenses attributable to foreign earnings, or otherwise affect the treatment of our unrepatriated earnings.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition to U.S. tax reform proposals, the adoption of some or all of the recommendations set forth in the Organization for Economic Co-operation and Development&#8217;s project on &#8220;Base Erosion and Profit Shifting&#8221; (BEPS) by tax authorities in the countries in which we operate, could negatively impact our effective tax rate.&#160;These recommendations focus on payments from affiliates in high tax jurisdictions to affiliates in lower tax jurisdictions and the activities that give rise to a taxable presence in a particular country.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our indebtedness could adversely affect our business and limit our ability to plan for or respond to changes in our business. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our indebtedness, together with our significant contingent liabilities, including milestone and royalty payment obligations, could have important consequences to our business; for example, such obligations could: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">increase our vulnerability to general adverse economic and industry conditions;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">limit our ability to access capital markets and incur additional debt in the future;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">require us to dedicate a substantial portion of our cash flow from operations to payments on our indebtedness, thereby reducing the availability of our cash flow for other purposes, including business development efforts, research and development and mergers and acquisitions;&#160;and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">limit our flexibility in planning for, or reacting to, changes in our business and the industry in which we operate, thereby placing us at a competitive disadvantage compared to our competitors that have less debt.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our sales and operations are subject to the risks of doing business internationally.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are increasing our presence in international markets, particularly emerging markets, subjecting us to many risks that could adversely affect our business and revenues, such as:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the inability to obtain necessary foreign regulatory or pricing approvals of products in a timely manner; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">collectability of accounts receivable; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">fluctuations in foreign currency exchange rates, in particular the recent strength of the U.S. dollar versus foreign currencies that has adversely impacted our revenues and net income; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">difficulties in staffing and managing international operations; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the imposition of governmental controls; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">less favorable intellectual property or other applicable laws; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">increasingly complex standards for complying with foreign laws and regulations that may differ substantially from country to country and may conflict with corresponding U.S. laws and regulations; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the far-reaching anti-bribery and anti-corruption legislation in the U.K., including the U.K. Bribery Act 2010, and elsewhere and escalation of investigations and prosecutions pursuant to such laws; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">compliance with complex import and export control laws;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">restrictions on direct investments by foreign entities and trade restrictions; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">greater political or economic instability; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">changes in tax laws and tariffs.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, our international operations are subject to regulation under U.S. law. For example, the Foreign Corrupt Practices Act prohibits U.S. companies and their representatives from offering, promising, authorizing or making payments to foreign officials for the purpose of obtaining or retaining business abroad. In many countries, the health care professionals we regularly interact with may meet the definition of a foreign government official for purposes of the Foreign Corrupt Practices Act. Failure to comply with domestic or foreign laws could result in various adverse consequences, including: possible delay in approval or refusal to approve a product; recalls, seizures or withdrawal of an approved product from the market; disruption in the supply or availability of our products or suspension of export or import privileges; the imposition of civil or criminal sanctions; the prosecution of executives overseeing our international operations; and damage to our reputation. Any significant impairment of our ability to sell products outside of the U.S. could adversely impact our business and financial results.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">38</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our operating results are subject to significant fluctuations.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our quarterly revenues, expenses and net income (loss) have fluctuated in the past and are likely to fluctuate significantly in the future due to the risks described in these </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8220;Risk Factors&#8221;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as well as the timing of charges and expenses that we may take. We have recorded, or may be required to record, charges that include:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the cost of restructurings; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">impairments with respect to investments, fixed assets and long-lived assets, including in-process R&amp;D and other intangible assets; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">inventory write-downs for failed quality specifications, charges for excess or obsolete inventory and charges for inventory write downs relating to product suspensions, expirations or recalls; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">changes in the fair value of contingent consideration;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">bad debt expenses and increased bad debt reserves; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">outcomes of litigation and other legal or administrative proceedings, regulatory matters and tax matters;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">milestone payments under license and collaboration agreements; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">payments in connection with acquisitions and other business development activities.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our revenues are also subject to foreign exchange rate fluctuations due to the global nature of our operations. Although we have foreign currency forward contracts to hedge specific forecasted transactions denominated in foreign currencies, our efforts to mitigate the impact of fluctuating currency exchange rates may not be successful. As a result, currency fluctuations among our reporting currency, the U.S.&#160;dollar, and the currencies in which we do business will affect our operating results, often in unpredictable ways. Our net income may also fluctuate due to the impact of charges we may be required to take with respect to foreign currency hedge transactions. In particular, we may incur higher than expected charges from hedge ineffectiveness or from the termination of a hedge relationship.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our operating results during any one period do not necessarily suggest the anticipated results of future periods.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">We are pursuing opportunities to expand our manufacturing capacity for future clinical and commercial requirements for product candidates, which will result in the incurrence of significant investment with no assurance that such investment will be recouped.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">While we believe we currently have sufficient large scale manufacturing capacity to meet our near-term manufacturing requirements, it is probable that we would need additional large scale manufacturing capacity to support future clinical and commercial manufacturing requirements for product candidates in our pipeline, if such candidates are successful and approved. We are building a large scale biologics manufacturing facility in Solothurn, Switzerland and acquired an additional manufacturing facility in Research Triangle Park, North Carolina. Due to the long lead times necessary for the expansion of manufacturing capacity, we expect to incur significant investment to build or expand our facilities or obtain third-party contract manufacturers with no assurance that such investment will be recouped. If we are unable to adequately and timely manufacture and supply our products and product candidates or if we do not fully utilize our manufacturing facilities, our business may be harmed.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our investment in Samsung Bioepis, and our success in commercializing biosimilars developed by Samsung Bioepis, are subject to risks and uncertainties inherent in the development, manufacture and commercialization of biosimilars.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our investment in Samsung Bioepis, and our success in commercializing biosimilars developed by Samsung Bioepis, are subject to a number of risks, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Reliance on Third Parties.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;We are dependent on the efforts of Samsung Bioepis and other third parties over whom we have limited or no control in the development and manufacturing of biosimilars products. If Samsung Bioepis or such other third parties fail to perform successfully, we may not realize the anticipated benefits of our investment in Samsung Bioepis;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Regulatory Compliance.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Biosimilar products may face regulatory hurdles or delays due to the evolving and uncertain regulatory and commercial pathway of biosimilars products in certain jurisdictions; </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">39</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Intellectual Property and Regulatory Challenges.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Biosimilar products may face extensive patent clearances, patent infringement litigation, injunctions or regulatory challenges, which could prevent the commercial launch of a product or delay it for many years; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Failure to Gain Market and Patient Acceptance.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Market success of biosimilar products will be adversely affected if patients, physicians and payers do not accept biosimilar products as safe and efficacious products offering a more competitive price or other benefit over existing therapies; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Ability to Provide Adequate Supply.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;Manufacturing biosimilars is complex.&#160;If we encounter any manufacturing or supply chain difficulties, we may be unable to meet higher than anticipated demand; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Competitive Challenges.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Biosimilar products face significant competition, including from innovator products and from biosimilar products offered by other companies. In some jurisdictions, local tendering processes may restrict biosimilar products from being marketed and sold in those jurisdictions. The number of competitors in a jurisdiction, the timing of approval and the ability to market biosimilar products successfully in a timely and cost-effective matter are additional factors that may impact our success and/or the success of Samsung Bioepis in this business area.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our investments in properties may not be fully realized.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We own or lease real estate primarily consisting of buildings that contain research laboratories, office space and manufacturing operations. For strategic or other operational reasons, we may decide to further consolidate or co-locate certain aspects of our business operations or dispose of one or more of our properties, some of which may be located in markets that are experiencing high vacancy rates and decreasing property values. If we determine that the fair value of any of our owned properties is lower than their book value we may not realize the full investment in these properties and incur significant impairment charges or additional depreciation when the expected useful lives of certain assets have been shortened due to the anticipated closing of facilities. If we decide to fully or partially vacate a leased property, such as ceasing manufacturing at our facility in Cambridge, Massachusetts, we may incur significant cost, including facility closing costs, employee separation and retention expenses, lease termination fees, rent expense in excess of sublease income and impairment of leasehold improvements and accelerated depreciation of assets. Any of these events may have an adverse impact on our results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our portfolio of marketable securities is subject to market, interest and credit risk that may reduce its value.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We maintain a portfolio of marketable securities for investment of our cash. Changes in the value of our portfolio of marketable securities could adversely affect our earnings. In particular, the value of our investments may decline due to increases in interest rates, downgrades of the bonds and other securities included in our portfolio, instability in the global financial markets that reduces the liquidity of securities included in our portfolio, declines in the value of collateral underlying the securities included in our portfolio and other factors. Each of these events may cause us to record charges to reduce the carrying value of our investment portfolio or sell investments for less than our acquisition cost. Although we attempt to mitigate these risks through diversification of our investments and continuous monitoring of our portfolio's overall risk profile, the value of our investments may nevertheless decline.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">There can be no assurance that we will continue to repurchase stock or that we will repurchase stock at favorable prices.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">From time to time our Board of Directors authorizes stock repurchase programs, including most recently a $5.0 billion stock repurchase program in July 2016. The amount and timing of stock repurchases are subject to capital availability and our determination that stock repurchases are in the best interest of our stockholders and are in compliance with all respective laws and our agreements applicable to the repurchase of stock. Our ability to repurchase stock will depend upon, among other factors, our cash balances and potential future capital requirements for strategic transactions, results of operations, financial condition and other factors beyond our control that we may deem relevant. A reduction in, or the completion or expiration of, our stock repurchase programs could have a negative effect on our stock price. We can provide no assurance that we will repurchase stock at favorable prices, if at all.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">40</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">We may not be able to access the capital and credit markets on terms that are favorable to us.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We may seek access to the capital markets to supplement our existing funds and cash generated from operations for working capital, capital expenditure and debt service requirements and other business initiatives. The capital and credit markets have experienced extreme volatility and disruption which leads to uncertainty and liquidity issues for both borrowers and investors. In the event of adverse capital and credit market conditions, we may be unable to obtain capital market financing on favorable terms. Changes in credit ratings issued by nationally recognized credit rating agencies could also adversely affect our cost of financing and the market price of our securities.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our business involves environmental risks, which include the cost of compliance and the risk of contamination or injury.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our business and the business of several of our strategic partners involve the controlled use of hazardous materials, chemicals, biologics and radioactive compounds. Although we believe that our safety procedures for handling and disposing of such materials comply with state, federal and foreign standards, there will always be the risk of accidental contamination or injury. If we were to become liable for an accident, or if we were to suffer an extended facility shutdown, we could incur significant costs, damages and penalties that could harm our business. Manufacturing of our products and product candidates also requires permits from government agencies for water supply and wastewater discharge. If we do not obtain appropriate permits, including permits for sufficient quantities of water and wastewater, we could incur significant costs and limits on our manufacturing volumes that could harm our business.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">The illegal distribution and sale by third parties of counterfeit versions of our products or stolen products could have a negative impact on our reputation and business.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Third parties might illegally distribute and sell counterfeit or unfit versions of our products, which do not meet our rigorous manufacturing, distribution and testing standards. A patient who receives a counterfeit or unfit drug may be at risk for a number of dangerous health consequences. Our reputation and business could suffer harm as a result of counterfeit or unfit drugs sold under our brand name. Stolen inventory that is not properly stored or sold through unauthorized channels could adversely impact patient safety, our reputation and our business. In addition, inventory that is stolen from warehouses, plants or while in-transit, and that is subsequently improperly stored and sold through unauthorized channels, could adversely impact patient safety, our reputation and our business.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">The increasing use of social media platforms presents new risks and challenges.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Social media is increasingly being used to communicate about our products and the diseases our therapies are designed to treat. Social media practices in the biopharmaceutical industry continue to evolve and regulations relating to such use are not always clear. This evolution creates uncertainty and risk of noncompliance with regulations applicable to our business. For example, patients may use social media channels to comment on the effectiveness of a product or to report an alleged adverse event. When such disclosures occur, there is a risk that we fail to monitor and comply with applicable adverse event reporting obligations or we may not be able to defend the company or the public's legitimate interests in the face of the political and market pressures generated by social media due to restrictions on what we may say about our products. There is also a risk of inappropriate disclosure of sensitive information or negative or inaccurate posts or comments about us on any social networking website. If any of these events were to occur or we otherwise fail to comply with applicable regulations, we could incur liability, face overly restrictive regulatory actions or incur other harm to our business.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Some of our collaboration agreements contain change in control provisions that may discourage a third party from attempting to acquire us.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Some of our collaboration agreements include change in control provisions that could reduce the potential acquisition price an acquirer is willing to pay or discourage a takeover attempt that could be viewed as beneficial to shareholders.&#160;Upon a change in control, some of these provisions could trigger reduced milestone, profit or royalty payments to us or give our collaboration partner rights to terminate our collaboration agreement, acquire operational control or force the purchase or sale of the programs that are the subject of the collaboration.&#160; </font></div><div><a name="s459292DC67BAB8AD22CE20170A131520"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;&#160;1B. &#160;&#160;&#160;&#160;Unresolved Staff Comments</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">None.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">41</font></div></div><hr style="page-break-after:always"><div><a name="sE99905CC2A8A59ED6CF420170A439E17"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;&#160;2. &#160;&#160;&#160;&#160;Properties</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Below is a summary of our owned and leased properties as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Massachusetts</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In Cambridge, Massachusetts, we own approximately 508,000&#160;square feet of real estate space, consisting of a building that houses a research laboratory and a cogeneration plant totaling approximately 263,000&#160;square feet and a building that contains research, development and quality laboratories which total approximately 245,000&#160;square feet.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we lease a total of approximately 1,250,000&#160;square feet in Massachusetts, which is summarized as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">893,000&#160;square feet in Cambridge, Massachusetts, which is comprised of a 67,000&#160;square foot biologics manufacturing facility, which is subleased by Brammer, and 826,000&#160;square feet for our corporate headquarters, laboratory and additional office space; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">357,000&#160;square feet of office space in Weston, Massachusetts, of which 175,000 square feet has been subleased through the remaining term of our lease agreement.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our Massachusetts lease agreements expire at various dates through the year 2028.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">North Carolina</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In RTP, North Carolina, we own approximately 834,000&#160;square feet of real estate space, which is summarized as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">357,000&#160;square feet of laboratory and office space;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">175,000&#160;square feet related to a large-scale biologics manufacturing facility;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">105,000&#160;square feet related to a biologics manufacturing facility;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">84,000&#160;square feet of warehouse space and utilities;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">70,000 square feet related to a parenteral fill-finish facility; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">43,000&#160;square feet related to a large-scale purification facility.</font></div></td></tr></table><div style="line-height:120%;padding-left:4px;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we lease 188,000 square feet of a facility in RTP, North Carolina from Eisai to manufacture our and Eisai's oral solid dose products and 40,000 square feet of warehouse space in Durham, North Carolina. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Denmark</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We own a large-scale biologics manufacturing facility totaling approximately 228,000&#160;square feet located in Hiller&#248;d, Denmark. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also own approximately 306,000&#160;square feet of additional space, which is summarized as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">139,000&#160;square feet of warehouse, utilities and support space;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">70,000&#160;square feet related to a label and packaging facility;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50,000&#160;square feet related to a laboratory facility;&#160;and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">47,000&#160;square feet of administrative space.</font></div></td></tr></table><div style="line-height:120%;padding-left:4px;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Switzerland</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2015 we acquired land in Solothurn, Switzerland where we are building a biologics manufacturing facility in the Commune of Luterbach over the next several years.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other International</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We lease office space in Zug, Switzerland, our international headquarters, the U.K., Germany, France, Denmark and numerous other countries. Our international lease agreements expire at various dates through the year 2028.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">42</font></div></div><hr style="page-break-after:always"><div><a name="sB414B36729A55C04B2F520170A6D251B"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;&#160;3. &#160;&#160;&#160;&#160;Legal Proceedings</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For a discussion of legal matters as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, please read Note&#160;20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Litigation</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report, which is incorporated into this item by reference.</font></div><div><a name="s299375A7363816F4ECE220170A9725A2"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;&#160;4. &#160;&#160;&#160;&#160;Mine Safety Disclosures</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Not applicable.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">43</font></div></div><hr style="page-break-after:always"><div><a name="s6CFA95DBDE82A948202220170AB9A0CD"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">PART&#160;II</font></div><div><a name="s1FB62878215C3C11095820166D62D73E"></a></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;5. &#160;&#160;&#160;&#160;Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</font></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Market and Stockholder Information</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our common stock trades on The NASDAQ Global Select Market under the symbol &#8220;BIIB.&#8221; The following table shows the high and low sales price for our common stock as reported by The NASDAQ Global Select Market for each quarter in the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Common Stock Price</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">High</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Low</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">High</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Low</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">First Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">301.02</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">242.07</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">480.18</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">334.40</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Second Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">292.69</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">223.02</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">432.88</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">368.88</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Third Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">333.65</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">240.07</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">412.24</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">265.00</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fourth Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">329.83</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">268.00</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">311.65</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">254.00</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">January&#160;27, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, there were approximately 700 stockholders of record of our common stock.</font></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Dividends</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have not paid cash dividends since our inception. While we historically have not paid cash dividends and do not have a current intention to pay cash dividends, we continually review our capital allocation strategies, including, among other things, payment of cash dividends, stock repurchases or acquisitions.</font></div><div style="line-height:120%;padding-top:18px;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Issuer Purchases of Equity Securities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2016 our Board of Directors authorized a program to repurchase up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of our common stock (2016 Share Repurchase Program). This authorization does not have an expiration date. Repurchased shares will be retired.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;The following table summarizes our common stock repurchase activity under our 2016 Share Repurchase Program during the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">fourth</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;quarter of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:17%;"></td><td style="width:19%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:19%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:19%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Period</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total&#160;Number&#160;of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares&#160;Purchased</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(#)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Average&#160;Price</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Paid&#160;per&#160;Share</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">($)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total&#160;Number&#160;of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares&#160;Purchased</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">as&#160;Part&#160;of&#160;Publicly</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Announced&#160; Programs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(#)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Maximum</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Approximate Dollar Value</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">of Shares That May Yet Be</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Purchased Under</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Our Programs ($ in millions)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">October&#160;2016</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,254,818</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">298.71</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,254,818</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4,276.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">November&#160;2016</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">939,046</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">294.24</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">939,046</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4,000.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;2016</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4,000.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,193,864</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">296.80</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we repurchased and retired approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares of common stock at a cost of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;under the 2016 Share Repurchase Program. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2011 our Board of Directors authorized a program to repurchase up to 20.0 million shares of our common stock (2011 Share Repurchase Program), which has been used principally to offset common stock issuances under our share-based compensation plans. The 2011 Share Repurchase Program does not have an expiration date. We did not repurchase any shares of common stock under our 2011 Share Repurchase Program during the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and have approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares remaining available for repurchase under this authorization.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">44</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Stock Performance Graph</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The graph below compares the five-year cumulative total stockholder return on our common stock, the S&amp;P 500 Index, the Nasdaq Pharmaceutical Index and the Nasdaq Biotechnology Index assuming the investment of $100.00 on December&#160;31, 2011 with dividends being reinvested. The stock price performance in the graph below is not necessarily indicative of future price performance.</font></div><div style="line-height:120%;text-align:center;"><img src="stockperformancechart.jpg" alt="stockperformancechart.jpg" style="height:480px;width:613px;"></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:22%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2011</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2012</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2013</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100.00</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">133.00</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">254.04</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">308.45</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">278.37</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">257.68</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">NASDAQ Pharmaceutical</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100.00</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">114.32</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">155.11</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">188.95</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">199.22</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">197.05</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">S&amp;P 500 Index</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100.00</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">116.00</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">153.57</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">174.60</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">177.01</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">198.18</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">NASDAQ Biotechnology</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100.00</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">132.74</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">220.37</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">296.19</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">331.05</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">260.37</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">45</font></div></div><hr style="page-break-after:always"><div><a name="sE2566B25C7513ED764422016879AF322"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;6. &#160;&#160;&#160;&#160;Selected Financial Data</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">SELECTED FINANCIAL DATA</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td style="width:36%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td colspan="20" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:18px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our results of operations are summarized as follows:</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2012</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except per share amounts)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">(d) (e)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(d)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(f)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(g)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(h)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Results of Operations</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues, net </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">(a)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">9,817.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9,188.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8,203.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,542.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,166.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,314.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,339.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,195.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,126.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,137.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">316.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">236.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">304.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">263.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">212.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">11,448.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10,763.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9,703.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,932.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,516.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total cost and expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6,298.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,872.8</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,747.7</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,441.6</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,707.4</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gain on sale of rights</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">46.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income from operations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5,150.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,891.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,972.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,515.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,855.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense), net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(217.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(123.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(25.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(34.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income before income tax expense and equity in loss of investee, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4,933.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,767.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,946.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,480.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,855.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,237.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,161.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">989.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">601.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">470.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Equity in loss of investee, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">17.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,695.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,593.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,941.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,862.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,380.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income (loss) attributable to noncontrolling interests, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(7.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">46.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,702.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,547.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,934.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,862.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,380.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Diluted Earnings Per Share</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">16.93</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15.34</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12.37</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7.81</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.76</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted-average shares used in calculating diluted earnings per share attributable to Biogen Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">218.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">231.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">237.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">238.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">239.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="20" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our financial condition is summarized as follows:</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2012</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Financial Condition</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash, cash equivalents and marketable securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7,724.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,188.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,316.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,848.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,742.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">22,876.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">19,504.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">14,314.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11,863.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10,130.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes payable and other financing arrangements, less current portion </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">(b)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6,512.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,521.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">580.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">592.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">687.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total Biogen Inc. shareholders&#8217; equity </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">(c)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">12,140.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9,372.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10,809.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8,620.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,961.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition to the following notes, the financial data included within the tables above should be read in conjunction with our consolidated financial statements and related notes and the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;sections of this report and our previously filed Form&#160;10-Ks.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues, net reflect the impact of the following product launches:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:46px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Commercial sales of SPINRAZA began in the fourth quarter of 2016.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">46</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:46px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the terms of our collaboration agreement with AbbVie, we began to recognize revenues on sales of ZINBRYTA to third parties in the E.U. in the third quarter of 2016. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:46px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the terms of our commercial agreement with Samsung Bioepis, we began to recognize revenues on sales of BENEPALI and FLIXABI to third parties in the E.U. in the first quarter of 2016 and third quarter of 2016, respectively. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:46px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Commercial sales of ALPROLIX commenced in the second quarter of 2014 and commercial sales of ELOCTATE and PLEGRIDY commenced in the third quarter of 2014. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:174%;font-size:10pt;padding-left:46px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">TECFIDERA began in April 2013.  </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes payable and other financing arrangements reflects the issuance of our senior unsecured notes for an aggregate principal amount of $6.0 billion in September 2015, and the 2013 repayment of our 6.0%&#160;notes that were issued in 2008 for an aggregate principal amount of $450.0 million.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total Biogen Inc.'s shareholders' equity reflects the repurchase of approximately 32.8 million shares of our common stock at a cost of approximately $8.3 billion between 2012 and 2016:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:46px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During 2016 we repurchased and retired approximately 3.3 million shares of our common stock at a cost of $1.0 billion under our 2016 Share Repurchase Program.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:46px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During 2015 we repurchased and retired approximately 16.8 million shares of our common stock at a cost of $5.0 billion under our 2015 Share Repurchase Program.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:46px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During 2014, 2013 and 2012 we repurchased approximately 2.9 million, 2.0 million and 7.8 million shares, respectively of our common stock at a cost of approximately $2.3 billion under our 2011 Share Repurchase Program of which approximately 3.7 million of these shares were retired.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total cost and expenses for the years ended December 31, 2016 and 2015, include restructuring charges of $33.1 million and $93.4 million, respectively. In addition, total cost and expenses for the year ended December 31, 2016, also include charges to cost of sales totaling $52.4 million of expenses incurred as a result of our determination to vacate and cease manufacturing in our small-scale biologics facility in Cambridge, MA as well as vacate our warehouse in Somerville, MA. Total cost and expenses for year ended December 31, 2016, also include $18.1 million of costs incurred directly related to our separation of our hemophilia business into an independent, publicly traded company.  </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(e)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total cost and expenses for the year ended December 31, 2016, includes a pre-tax charge of $454.8 million related to the January 2017 settlement and license agreement with Forward Pharma A/S (Forward Pharma).</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(f)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2014 AIFA approved a resolution affirming that there is no reimbursement limit from and after February 2013. As a result, we recognized $53.5 million of TYSABRI revenues in the second quarter of 2014 related to the periods beginning February 2013 that were previously deferred.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(g)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our share of revenues from anti-CD20 therapeutic programs reflects charges of $49.7 million in 2013 for damages and interest awarded to Hoechst in Genentech's arbitration with Hoechst for RITUXAN.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(h)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Commencing in the second quarter of 2013 product and total revenues include 100% of net revenues related to sales of TYSABRI as a result of our acquisition of all remaining rights to TYSABRI from Elan Pharma International, Ltd (Elan), an affiliate of Elan Corporation, plc. Upon the closing, our collaboration agreement was terminated, and we no longer record collaboration profit sharing expense. We recognized collaboration profit sharing expense of $85.4 million and $317.9 million during the years ended December 31, 2013 and 2012, respectively. </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">47</font></div></div><hr style="page-break-after:always"><div><a name="s092A7CD20543F5F4464620170B3E42DC"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;7. &#160;&#160;&#160;&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following discussion should be read in conjunction with our consolidated financial statements and related notes beginning on page&#160;F-1 of this report. Certain totals may not sum due to rounding.</font></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Executive Summary</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Introduction</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen is a global biopharmaceutical company focused on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). We also have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other potential anti-CD20 therapies under a collaboration agreement with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2016 we announced our intention to spin off our hemophilia business, Bioverativ Inc. (Bioverativ), as an independent, publicly traded company. Bioverativ will focus on the discovery, development and commercialization of therapies for the treatment of hemophilia and other blood disorders, including ELOCTATE for the treatment of hemophilia A and ALPROLIX for the treatment of hemophilia B. Bioverativ will also assume all of our rights and obligations under our collaboration agreement with Swedish Orphan Biovitrum AB (Sobi) and our collaboration and license agreement with Sangamo Biosciences Inc. (Sangamo).</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On February 1, 2017, we completed the distribution of all the then outstanding shares of common stock of Bioverativ to Biogen stockholders, who received one share of Bioverativ common stock for every two shares of Biogen common stock. As a result of the distribution, Bioverativ is now an independent public company whose shares of common stock are trading under the symbol "BIVV" </font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">on the Nasdaq Global Select Market.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The financial results of Bioverativ are included in our consolidated results of operations and financial position in our audited consolidated financial statements for the periods presented in this Form 10-K. The financial results of Bioverativ will be excluded from our consolidated results of operations and financial position commencing February 1, 2017. For additional information regarding the separation of Bioverativ, please read Note 26, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Subsequent Events </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to our consolidated financial statements included in this report</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our current revenues depend upon continued sales of our principal products and, unless we develop, acquire rights to, and commercialize new products and technologies, we may be substantially dependent on sales from our principal products for many years. Further, following the completion of the spin-off of our hemophilia business, our revenues will be further reliant and concentrated on sales of our MS products in an increasingly competitive market.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;In the longer term, our revenue growth will be dependent upon the successful clinical development, regulatory approval and launch of new commercial products as well as additional indications for our existing products, our ability to obtain and maintain patents and other rights related to our marketed products, assets originating from our research and development efforts and successful execution of external business development opportunities. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities, particularly within areas of our scientific, manufacturing and technical capabilities. For nearly two decades we have led in the research and development of new therapies to treat MS, resulting in our leading portfolio of MS treatments. Now our research is focused on additional improvements in the treatment of MS, such as, the development of next generation therapies for MS with a goal to reverse or possibly repair damage caused by the disease. We are also applying our scientific expertise to solve some of the most challenging and complex diseases, including Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis (ALS), and are employing innovative technologies to discover potential treatments for rare and genetic disorders, including new ways of treating diseases through gene therapy.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our innovative drug development and commercialization activities are complemented by our biosimilar therapies that expand access to medicines and reduce the cost burden for healthcare systems. We are leveraging our manufacturing capabilities and know-how by developing, manufacturing and marketing </font></div></div></div><br><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">48</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">biosimilars through Samsung Bioepis, our joint venture with Samsung BioLogics Co. Ltd. (Samsung Biologics). Under our commercial agreement with Samsung Bioepis, we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, and FLIXABI, an infliximab biosimilar referencing REMICADE, in the European Union (E.U.).</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Financial Highlights</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;"><img src="financialhighlightschart.jpg" alt="financialhighlightschart.jpg" style="height:426px;width:317px;"></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc. were </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$16.93</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing an increase of 10.4% over the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As described below under </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8220;Results of Operations</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">,&#8221; our income from operations for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, reflects the following:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues were </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$11,448.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing an increase of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">6.4%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;over the same period in </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues, net totaled </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$9,817.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing an increase of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">6.8%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;over the same period in </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This increase was driven by a </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">9.1%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;increase in worldwide TECFIDERA revenues, a 52.8% increase in worldwide hemophilia revenues, a </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">4.1%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;increase in worldwide TYSABRI revenues and revenues from BENEPALI. These increases are partially offset by a </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">5.8%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;decrease in worldwide Interferon revenues. Product revenues, net for </font></div></td></tr></table></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-left:30px;padding-top:12px;text-align:left;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, were also negatively impacted by a $167.8 million decrease in hedge gains recognized under our foreign currency hedging program in comparative periods.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs totaled </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1,314.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing a decrease of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">1.8%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;over the same period in </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues totaled </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$316.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing an increase of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">34.0%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;from the same period in </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This increase was primarily driven by an increase in other corporate revenues, which includes amounts earned with respect to our contract manufacturing activities.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total cost and expenses totaled </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$6,298.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing an increase of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">7.2%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This increase was driven by a </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$454.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;litigation settlement and license charge and a </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">19.2%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;increase in cost of sales, which includes a charge of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$45.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for accelerated depreciation as a result of the determination to cease manufacturing in Cambridge, MA and vacate our biologics manufacturing facility in Cambridge, MA and warehouse space in Somerville, MA. These increases were partially offset by a </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">7.8%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;decrease in selling, general and administrative expenses and a decrease in restructuring charges. </font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We generated </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$4,522.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of net cash flows from operations for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which were primarily driven by earnings. Cash, cash equivalents and marketable securities totaled approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$7,724.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we repurchased and retired approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares of common stock at a cost of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;under our share repurchase programs. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Collaborative and Other Relationships</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2016 we entered into a collaboration and alliance with the University of Pennsylvania (UPenn) to advance gene therapy and gene editing technologies. For additional information related to this transaction, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.</font></div></div></div><br><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Restructuring and Cost Saving Initiatives</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the third quarter of 2016 we initiated cost saving measures primarily intended to realign our organizational structure due to the changes in roles and workforce resulting from our decision to spin off our hemophilia business, and to achieve further targeted cost reductions. </font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Additionally, in connection with the transaction to sublease our rights to the manufacturing facility in Cambridge, MA to Brammer Bio MA,&#160;LLC (Brammer), certain employees were separated from Biogen.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information related to our restructuring and cost saving initiatives, please read Note 3, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Restructuring, Business Transformation and Other Cost Saving Initiatives</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.</font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Business Environment</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The biopharmaceutical industry and the markets in which we operate are intensely competitive. Many of our competitors are working to develop or have commercialized products similar to those we market or are developing. In addition, the commercialization of certain of our own approved MS products, products of our collaborators and pipeline product candidates may negatively impact future sales of our existing MS products. Our products may also face increased competitive pressures from the introduction of generic versions, prodrugs of existing therapeutics or biosimilars of existing products and other technologies, such as gene therapies and bispecific antibodies. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, sales of our products are dependent, in large part, on the availability and extent of coverage, pricing and reimbursement from government health administration authorities, private health insurers and other organizations. Drug prices are under significant scrutiny in the markets in which our products are prescribed. Drug pricing and other health care costs continue to be subject to intense political and societal pressures.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information related to our competition and pricing risks that could negatively impact our product sales, please read the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8220;Risk Factors&#8221;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;section of this report.</font></div></div></div><br><div><a name="s6B8DCC4DDF4326A54AB020167F17439B"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Results of Operations</font></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Revenues</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"></td></tr><tr><td style="width:35%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">December 31,</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">% Change</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016 compared to 2015</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015 compared to 2014</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except percentages)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product Revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">United States</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7,050.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,545.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,566.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">17.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Rest of world</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,767.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,642.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,636.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total product revenues</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">9,817.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9,188.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8,203.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,314.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,339.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,195.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">316.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">236.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">304.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">34.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(22.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">11,448.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10,763.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9,703.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Product Revenues</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"></td></tr><tr><td style="width:35%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">December 31,</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">% Change</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016 compared to 2015</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015 compared to 2014</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except percentages)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Multiple Sclerosis:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">TECFIDERA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,968.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,638.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,909.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">9.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">25.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interferon*</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,795.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,968.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,057.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(5.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">TYSABRI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,963.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,886.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,959.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FAMPYRA</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">84.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">89.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">80.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(5.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ZINBRYTA</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">**</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">**</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Hemophilia:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ELOCTATE</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">513.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">319.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">58.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">60.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">447.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ALPROLIX</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">333.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">234.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">76.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">42.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">208.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other product revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FUMADERM</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">45.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">51.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">62.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(10.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(17.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">SPINRAZA</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">**</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">**</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">BENEPALI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">100.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">**</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">**</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FLIXABI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">**</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">**</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total product revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">9,817.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9,188.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8,203.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">* Interferon includes AVONEX and PLEGRIDY.</font></div><div style="line-height:120%;padding-bottom:6px;text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">** Percentage not meaningful.</font></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div><a name="s79A61B7B56A465EE4D2320170B919848"></a></div></div></div><br><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Multiple Sclerosis (MS)</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">TECFIDERA</font></div><div style="line-height:120%;text-align:left;"><img src="tecfiderachart.jpg" alt="tecfiderachart.jpg" style="height:306px;width:317px;"></div><div style="line-height:120%;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in U.S. TECFIDERA revenues was primarily due to price increases, partially offset by higher discounts and allowances and a decrease in unit sales volume of 1%. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in U.S. TECFIDERA revenues was primarily due to increases in unit sales volume of 13% as TECFIDERA penetrated the U.S. market, and increases in gross </font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">price partially offset by higher discounts and allowances.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in rest of world TECFIDERA revenues was primarily due to increases in unit sales volume of 32% in existing markets and new markets where we continue to launch the product and expand our presence around the world. These increases were partially offset by pricing reductions in certain European countries. Rest of world TECFIDERA revenues for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, were also negatively impacted by a $50.2 million decrease in hedge gains recognized under our foreign currency hedging program in the comparative period. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in rest of world TECFIDERA revenues was primarily due to increases in unit sales volume in existing markets and in new markets as we continue to launch the product and expand our presence around the world. These increases were partially offset by pricing reductions in Germany as described below. Rest of world TECFIDERA revenues for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, were also negatively impacted by foreign currency exchange losses totaling $74.1 million. These foreign currency exchange losses were partially offset by comparative net gains recognized under our foreign currency hedging program totaling $47.5 million. </font></div></div></div><br><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">51</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under German legislation related to the pricing of new drug products introduced in the German market, pricing is unregulated for the first 12 months after launch. We launched TECFIDERA in Germany in February 2014 and our unregulated pricing ended in the first quarter of 2015, at which time we began recognizing revenue at the fixed price established through our negotiations with the German regulatory authorities. The negotiated annual price is fixed for three years. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We anticipate relatively stable demand for TECFIDERA in 2017 on a global basis, with patient growth in our international markets offsetting modest patient declines in the U.S. primarily resulting from increasing competition from additional treatments and product candidates for MS, including OCREVUS.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Interferon</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">AVONEX and PLEGRIDY</font></div><div style="line-height:120%;text-align:left;"><img src="avonexchart.jpg" alt="avonexchart.jpg" style="height:306px;width:317px;"></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, U.S. AVONEX revenues totaled $1,675.3 million, $1,790.2 million and $1,956.7 million, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, U.S. PLEGRIDY revenues totaled $305.0 million, $227.1 million and $27.8 million, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in U.S. Interferon revenues was primarily due to an overall decrease in Interferon unit sales volume of 10%, which was attributable to a decrease in AVONEX unit sales volume primarily due to patients transitioning to other oral MS therapies, as well as higher discounts and allowances. These decreases were partially offset by price increases. </font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in U.S. Interferon revenues was primarily due to gross price increases for AVONEX and an increase in PLEGRIDY unit sales volume as sales of PLEGRIDY began in the U.S. in fourth quarter of 2014. These increases were partially offset by a decrease in AVONEX unit sales volume of 17%, which was attributable in part to patients transitioning to other oral MS therapies, including TECFIDERA.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;rest of world AVONEX revenues totaled $638.2 million, $840.0 million and $1,056.4 million, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, rest of world PLEGRIDY revenues totaled $176.7 million, $111.4 million and $16.7 million, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in rest of world Interferon revenues was primarily due to pricing reductions in certain European countries and an overall decrease in AVONEX unit sales volume of 10% due primarily to patients transitioning to other oral MS therapies, including TECFIDERA. Rest of world Interferon revenues for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, were also negatively impacted by a $66.1 million decrease in hedge gains recognized under our hedging program in the comparative period.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in rest of world Interferon revenues was due to a decrease in AVONEX unit sales volume of 11% primarily in Europe attributable to patients transitioning to other oral MS therapies, including TECFIDERA. These increases were partially offset by an increase in PLEGRIDY unit sales volume as sales of PLEGRIDY began in the E.U. in the third quarter of 2014. Rest of world Interferon revenues for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, were also negatively impacted by foreign currency exchange losses of $153.1 million. These foreign currency exchange losses were partially offset by comparative net gains recognized under our foreign currency hedging program of $58.4 million. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We expect that overall Interferon revenues will continue to decline as a result of competition from our other products as well as other MS therapies.</font></div></div></div><br><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">52</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">TYSABRI</font></div><div style="line-height:120%;text-align:left;"><img src="tysabrichart.jpg" alt="tysabrichart.jpg" style="height:306px;width:317px;"></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in U.S. TYSABRI revenues was primarily due to an increase in unit sales volume of 4% and increases in price, partially offset by higher discounts and allowances. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in U.S. TYSABRI revenues was primarily due to an increase in unit sales volume of 4% and increases in gross price, partially offset by higher discounts and allowances. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the slight decrease in rest of world TYSABRI revenues was primarily due to the impact of a $46.1 million decrease in hedge gains recognized under our hedging program in the comparative period. This decrease was partially offset by an increase in unit sales volume of 8%, primarily in Europe.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in rest of world TYSABRI revenues was due to pricing reductions in some European countries and the prior year recognition of $53.5 million of revenue previously deferred in Italy relating to the pricing agreement with the Italian National Medicines Agency (Agenzia Italiana del Farmaco or AIFA) as discussed below.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Rest of world TYSABRI revenues for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, were negatively impacted by foreign currency exchange losses of $136.3 million. These foreign currency exchange losses were partially offset by comparative net gains recognized under our foreign currency hedging program of $45.9 million. </font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the fourth quarter of 2011 Biogen Italia SRL, our Italian subsidiary, received a notice from AIFA that sales of TYSABRI after mid-February 2009 exceeded a reimbursement limit established pursuant to a Price Determination Resolution (Price Resolution) granted by AIFA in December 2006. In January 2017, we negotiated an agreement in principle with AIFA's Price and Reimbursement Committee to settle all of AIFA's existing claims relating to sales of TYSABRI in excess of the reimbursement limit for the periods from February 2009 through January 2013 for an aggregate repayment of EUR</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#231f20;">The agreement is subject to ratification by AIFA.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;If this most recent settlement agreement is accepted, we could recognize approximately EUR</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">42 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in revenue upon resolution of this matter. For information regarding our agreement with AIFA relating to sales of TYSABRI in Italy, please read Note 17, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Other Consolidated Financial Statement Detail</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We anticipate relatively stable demand for TYSABRI in 2017 on a global basis, with patient growth in our international markets offsetting modest patient declines in the U.S. primarily resulting from increasing competition from additional treatments and product candidates for MS, including ZINBRYTA and OCREVUS.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">ZINBRYTA</font></div><div style="line-height:120%;text-align:left;"><img src="zinbrytachart.jpg" alt="zinbrytachart.jpg" style="height:306px;width:317px;"></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the terms of our collaboration agreement with AbbVie, we began to recognize revenues on sales of ZINBRYTA to third parties in the E.U. in the third quarter of 2016.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our relationship with AbbVie, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.</font></div></div></div><br><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">53</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Hemophilia</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">ELOCTATE</font></div><div style="line-height:120%;text-align:left;"><img src="eloctatechart.jpg" alt="eloctatechart.jpg" style="height:306px;width:317px;"></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in U.S. ELOCTATE revenues was primarily due to an increase in unit sales volume of 45%. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in U.S. ELOCTATE revenues was primarily due to increases in unit sales volume. Sales of ELOCTATE in the U.S. began in the third quarter of 2014. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in rest of world ELOCTATE revenues was primarily due to an increase in unit sales volume, primarily in Japan.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in rest of world ELOCTATE revenues was primarily due to increases in unit sales volume. Sales of ELOCTATE in Japan began in the first quarter of 2015. </font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">ALPROLIX</font></div><div style="line-height:120%;text-align:left;"><img src="alprolixchart.jpg" alt="alprolixchart.jpg" style="height:306px;width:317px;"></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in U.S. ALPROLIX revenues was primarily due to an increase in unit sales volume of 28%.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in U.S. ALPROLIX revenues was primarily due to increases in unit sales volume. Sales of ALPROLIX in the U.S. began in the second quarter of 2014. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in rest of world ALPROLIX revenues was primarily due to an increase in unit sales volume, primarily in Japan.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in rest of world ALPROLIX revenues was primarily due to increases in unit sales volume. Sales of ALPROLIX in Japan began in the fourth quarter of 2014. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On February 1, 2017, we completed the distribution of the then outstanding shares of common stock of Bioverativ to Biogen stockholders. As a result of the distribution, Bioverativ will assume discovery, development and commercialization of ELOCTATE and ALPROLIX in the U.S. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on the transaction to separate from and spin off our hemophilia business as a separate independent public company, please read Note 26, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Subsequent Events</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.</font></div></div></div><br><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">54</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Biosimilars</font></div><div style="line-height:120%;"><img src="biosimilarschart.jpg" alt="biosimilarschart.jpg" style="height:306px;width:317px;"></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the terms of our commercial agreement with Samsung Bioepis, we began to recognize revenues on sales of BENEPALI and FLIXABI to third parties in the E.U. in the first quarter of 2016 and third quarter of 2016, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our relationship with Samsung Bioepis, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.</font></div><div><a name="s32D98FCAA39C1ADD43D72016BB869621"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Revenues from Anti-CD20 Therapeutic Programs</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Genentech (Roche Group)</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our share of RITUXAN and GAZYVA operating profits are summarized as follows:</font></div><div style="line-height:120%;"><img src="unconsoljointbusinesschart.jpg" alt="unconsoljointbusinesschart.jpg" style="height:306px;width:317px;"></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Biogen&#8217;s Share of Pre-tax Profits in the U.S. for RITUXAN and GAZYVA</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table provides a summary of amounts comprising our share of pre-tax profits on RITUXAN and GAZYVA in the U.S.:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:33%;"></td><td style="width:1%;"></td><td style="width:19%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:19%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:19%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,941.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,847.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,556.6</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cost and expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">744.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">673.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">771.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pre-tax profits in the U.S.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,197.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,174.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,785.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of pre-tax profits</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,249.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,269.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,117.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our share of RITUXAN pre-tax profits in the U.S. decreased to 39% from 40% as GAZYVA was approved by the FDA in follicular lymphoma in February 2016.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in U.S.&#160;product revenues was primarily due to an increase in GAZYVA unit sales volume of 41%, an increase in RITUXAN unit sales of 1% and selling price increases, partially offset by higher RITUXAN discounts and allowances.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in U.S.&#160;product revenues was primarily due to a 4% increase in RITUXAN unit sales volume and selling price increases, partially offset by higher discounts and allowances.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Collaboration costs and expenses for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;increased primarily due to an increase in RITUXAN product cost of sales.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Collaboration costs and expenses for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;decreased primarily due to the 2014 recognition of $53.9 million of additional Branded Pharmaceutical Drug (BPD) fee expense as well as lower RITUXAN cost of sales, partially offset by higher GAZYVA sales and marketing expenses. During </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;the Internal Revenue Service issued final regulations related to the BPD fee, which had the effect of changing the recognition of the fee for accounting purposes, from the period in which the fee was paid, to the period when the sale occurs. As a result of these final regulations, we recognized an incremental BPD fee in 2014 for the periods 2013 through the end of the third quarter of 2014. The final regulations did not change the timing of payments.</font></div></div></div><br><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">55</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information related to our collaboration with Genentech, including information regarding the pre-tax profit sharing formula and its impact on future revenues from anti-CD20 therapeutic programs, please read Note&#160;19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.</font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Revenue on Sales in the Rest of World for RITUXAN</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenue on sales in the rest of world for RITUXAN primarily consists of our share of pre-tax co-promotion profits on RITUXAN in Canada. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, revenue on sales in the rest of world for RITUXAN decreased as a result of lower pre-tax co-promotion profits on RITUXAN in Canada. </font></div></div></div><br><div><a name="s24B9697416BE62A1741620170BF9C1CC"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Other Revenues</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues are summarized as follows:</font></div><div style="line-height:120%;padding-top:6px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"></td></tr><tr><td style="width:36%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For The Years </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Ended December 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">% Change</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2016 compared to 2015</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015 compared to 2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except percentages)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from collaborative and other relationships</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">39.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">69.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">58.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(43.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other royalty and corporate revenues</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">277.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">167.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">246.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">65.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(32.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">316.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">236.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">304.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">34.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(22.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr></table></div></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Revenues from Collaborative and Other Relationships</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from collaborative and other relationships include revenues earned under our manufacturing services agreement with Sobi on shipments of ELOCTA and ALPROLIX to Sobi, royalties from Sobi on sales of ELOCTA and ALPROLIX in their territory, which includes substantially all of Europe, Russia and certain markets in Northern Africa and the Middle East (the Sobi Territory), our 50% share of the co-promotion profits or losses of ZINBRYTA in the U.S. with AbbVie and revenues from our technical development and manufacturing services agreements with Samsung Bioepis.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in revenues from collaborative and other relationships is primarily due to a net overall loss in the collaboration with AbbVie of $21.9 million within the U.S. territory and lower revenues earned under our manufacturing services agreement with Samsung Bioepis, partially offset by an increase in ELOCTA shipments made under our manufacturing services agreement with Sobi. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in revenues from collaborative and other relationships was primarily due to the start of product shipments to Sobi in relation to our collaboration agreement, as well as increased revenues earned under our manufacturing services agreement with Samsung Bioepis.</font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaborative and other relationships, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Royalty and Corporate Revenues</font></div><div style="line-height:120%;text-align:left;"><img src="otherrevenueschart.jpg" alt="otherrevenueschart.jpg" style="height:306px;width:317px;"></div></div></div><br><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">56</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Royalty Revenues</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We receive royalties from net sales on products related to patents that we have out-licensed. Prior to 2015, our most significant source of royalty revenue had been derived from net worldwide sales of ANGIOMAX, which was out-licensed to The Medicines Company. On December 15, 2014 we ceased recognizing royalty revenues from U.S. sales of ANGIOMAX, contemporaneous with the U.S. patent's expiration.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, royalty revenues were relatively consistent.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, royalty revenues decreased primarily due to the expiration of U.S. patent rights that gave rise to royalty payments related to ANGIOMAX.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Other Corporate Revenues</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our corporate partner revenues include amounts earned under contract manufacturing agreements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, as well as </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to the increase in other corporate revenues was primarily due to higher contract manufacturing revenues related to drug substance manufacturing provided to a strategic partner. </font></div><div><a name="s5DFB901B6BCD56C985C020170C0D410E"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Reserves for Discounts and Allowances</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from product sales are recorded net of reserves established for applicable discounts and allowances, including those associated with the implementation of pricing actions in certain international markets where we operate.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer). Our estimates take into consideration our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Actual amounts may ultimately differ from our estimates. If actual results vary, we adjust these estimates, which will have an effect on earnings in the period of adjustment.</font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Reserves for discounts, contractual adjustments and returns that reduced gross product revenues are summarized as follows:</font></div><div style="line-height:120%;text-align:center;"><img src="reserveschart.jpg" alt="reserveschart.jpg" style="height:328px;width:317px;"></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the years ended December 31, 2016, 2015 and 2014, reserves for discounts and allowances as a percentage of gross product revenues were 21.3%, 19.3% and 16.6%, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Discounts</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Discounts include trade term discounts and wholesaler incentives. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in discounts was primarily driven by increases in gross selling price, contractual discount rates and volume related to our hemophilia products.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in discounts was primarily driven by our recent product additions, gross price increases and increases in contractual rates</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contractual Adjustments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contractual adjustments relate to Medicaid and managed care rebates, co-payment assistance (copay), Veterans Administration (VA), Public Health Service (PHS) discounts, specialty pharmacy program fees and other government rebates or applicable allowances. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in contractual adjustments was primarily due to higher Medicaid and other governmental rebates and allowances in the U.S. and managed care rebates, due in part to an increase in gross selling prices.</font></div></div></div><br><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">57</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in contractual adjustments was primarily due to our recent product additions, higher Medicaid and other governmental rebates and allowances in the U.S. and managed care rebates as a result of an increase in contracted business and gross prices.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Returns</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product return reserves are established for returns made by wholesalers. In accordance with contractual terms, wholesalers are permitted to return product for reasons such as damaged or expired product. The majority of wholesaler returns are due to </font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">product expiration. Provisions for product returns are recorded in the period the related revenue is recognized, resulting in a reduction to product sales. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, return reserves decreased primarily due to a reduction in return rates based on recent experiences of returned products.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information related to our reserves, please read Note 4, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Reserves for Discounts and Allowances</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.</font></div></div></div><br><div><a name="s01E8C988ED85B8C657492016AE6BB56E"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Cost and Expenses</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A summary of total cost and expenses is as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"></td></tr><tr><td style="width:35%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">December 31,</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">% Change</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016 compared to 2015</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015 compared to 2014</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except percentages)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cost of sales, excluding amortization of acquired intangible assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,478.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,240.4</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,171.0</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">19.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,973.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,012.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,893.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(2.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,947.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,113.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,232.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(7.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(5.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amortization of acquired intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">385.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">382.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">489.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(21.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restructuring charges</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">33.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">93.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(64.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">**</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(Gain) loss on fair value remeasurement of contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">14.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(38.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(51.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(178.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Collaboration profit sharing</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">**</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">**</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">TECFIDERA litigation settlement and license charges</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">454.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">**</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">**</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total cost and expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6,298.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,872.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,747.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">** Percentage not meaningful.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">58</font></div></div><hr style="page-break-after:always"><div><a name="s8D950A45FFC9864AF4C420170C6046BB"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Cost of Sales, Excluding Amortization of Acquired Intangible Assets (Cost of Sales)</font></div><div style="line-height:120%;text-align:left;"><img src="costofsaleschart.jpg" alt="costofsaleschart.jpg" style="height:306px;width:317px;"></div><div style="line-height:120%;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Product Cost of Sales</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in product cost of sales was primarily driven by increased contract manufacturing shipments and higher unit sales volume related to our biosimilars and hemophilia products, partially offset by favorable production costs and mix of products. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product cost of sales for 2016 also reflects the recognition of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$45.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of accelerated depreciation as a result of the determination to cease manufacturing in Cambridge, MA and vacate our biologics manufacturing facility in Cambridge, MA and warehouse space in Somerville, MA.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in product cost of sales was primarily driven by increased contract manufacturing production and higher unit sales volume of our marketed products, including newly launched products.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory amounts written down as a result of excess, obsolescence, unmarketability or other reasons totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$48.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$41.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$50.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Royalty Cost of Sales</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in royalty cost of sales was primarily driven by the increase in royalty rates payable to Sobi, increased sales of our hemophilia products and higher royalties on sales of AVONEX and PLEGRIDY in the U.S., partially offset by a decrease in TYSABRI royalties due to the expiration of certain third party royalties.</font></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On June 28, 2016, the U.S. Patent and Trademark Office issued to the Japanese Foundation for Cancer Research (JFCR) a patent related to recombinant interferon-beta protein. This patent, U.S. Patent No. 9,376,478, expires in June 2033. This patent was issued following an interference proceeding between JFCR and us. This patent is relevant to AVONEX and PLEGRIDY, and we will pay royalties in the mid-single digits in relation to this patent during the life of the patent.</font></div><div style="line-height:120%;padding-top:9px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in royalty cost of sales was primarily driven by the increase in royalties due to Sobi on increased sales of our hemophilia products and an increase in the contractual rate of TYSABRI contingent payments due to Perrigo Company plc (Perrigo), which is based on the expected level of annual worldwide net sales of TYSABRI, partially offset by a decrease in TYSABRI revenues and the expiration of certain third-party royalties related to TYSABRI. </font></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our relationship with Sobi, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.</font></div></div></div><br><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">59</font></div></div><hr style="page-break-after:always"><div><a name="s90AC86AE061D5F3A1F1C20170C8D2F58"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Research and Development</font></div><div style="line-height:120%;"><img src="researchanddevelopmentchart.jpg" alt="researchanddevelopmentchart.jpg" style="height:730px;width:317px;"></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;text-align:center;"><img src="rdpiechart2016.jpg" alt="rdpiechart2016.jpg" style="height:281px;width:317px;"></div><div style="line-height:120%;text-align:center;"><img src="rdpiechart2015.jpg" alt="rdpiechart2015.jpg" style="height:281px;width:317px;"></div><div style="line-height:120%;text-align:center;"><img src="rdpiechart2014.jpg" alt="rdpiechart2014.jpg" style="height:281px;width:317px;"></div></div></div><br><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">60</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development expense incurred in support of our marketed products includes costs associated with product lifecycle management activities including, if applicable, costs associated with the development of new indications for existing products. Late stage programs are programs in Phase 3 development or in registration stage. Early stage programs are programs in Phase 1 or Phase 2 development. Research and discovery represents costs incurred to support our discovery research and translational science efforts. Other research and development costs consist of indirect costs incurred in support of overall research and development activities and non-specific programs, including activities that benefit multiple programs, such as management costs as well as depreciation and other facility-based expenses. Costs are reflected in the development stage based upon the program status when incurred. Therefore, the same program could be reflected in different development stages in the same year. For several of our programs, the research and development activities are part of our collaborative and other relationships. Our costs reflect our share of the total costs incurred.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in research and development expense was primarily related to decreases in costs incurred in connection with our early stage programs, marketed products and other research and development costs. These decreases were partially offset by increased costs incurred in connection with our late stage programs and research and discovery.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The decrease in spending associated with our early stage programs for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;was primarily due to the advancement of our aducanumab program for Alzheimer's disease to a late stage program in the third quarter of 2015, decreased costs incurred in connection with opicinumab in MS and the discontinuance of development of anti-TWEAK in lupus nephritis. These decreases were partially offset by increased costs of BIIB074 (formerly known as Raxatrigine) in trigeminal neuralgia (TGN) and increased costs associated with our discontinuance of development of amiselimod in the third quarter of 2016.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The decrease in spending associated with our marketed products for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;was primarily due to the discontinuance of development of TYSABRI and TECFIDERA in secondary primary multiple sclerosis (SPMS) in the third and fourth quarters of 2015, respectively, and decreased costs incurred in connection with our hemophilia products. These decreases were partially offset by the approvals of ZINBRYTA and SPINRAZA in the third and fourth quarters of 2016, respectively.</font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The increase in spending associated with our late stage programs for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;was primarily driven by costs incurred to advance our aducanumab program for Alzheimer's disease, the increased costs incurred to advance our SPINRAZA program for the treatment of SMA and the advancement of E2609 to a late stage program in the fourth quarter of 2016, partially offset by the approval of ZINBRYTA in the third quarter of 2016.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in research and development expense was primarily related to increases in costs incurred in connection with our late and early stage programs and research and discovery, partially offset by a decrease in milestone and upfront expenses and the positive impact of foreign currency translation of $34.0 million.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The increase in spending associated with our late stage programs for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;was primarily driven by costs incurred to advance our aducanumab program for Alzheimer's disease and the SPINRAZA program for the treatment of SMA, partially offset by a decrease in costs related to ZINBRYTA and the approvals of PLEGRIDY and ELOCTATE in 2014.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The increase in spending associated with our early stage programs for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;was primarily due to costs incurred in connection with our aducanumab program for Alzheimer's disease, which advanced to a late stage program during the third quarter of 2015, the BAN2401 program for Alzheimer&#8217;s disease related to our collaboration with Eisai and our BIIB074 program for TGN. These increases were partially offset by a decrease in costs incurred in connection with the SPINRAZA program for the treatment of SMA as the program advanced to a late stage program during the first quarter of 2015.&#160;</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We intend to continue committing significant resources to targeted research and development opportunities where there is a significant unmet need and where the drug candidate has the potential to be highly differentiated. Specifically, we intend to continue to invest in our MS pipeline, our aducanumab program, the BAN2401 and E2609 programs and our BIIB074 program.</font></div></div></div><br><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">61</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Milestone and Upfront Expenses included in Research and Development Expense</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development expense for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;includes a $75.0 million license fee paid to Ionis as we exercised our option to develop and commercialize SPINRAZA from Ionis, a $50.0 million milestone payment due to Eisai related to the initiation of a Phase 3 trial for E2609 and a $20.0 million upfront milestone paid to the UPenn upon entering into a collaboration and alliance. For additional information about these transactions, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development expense for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;includes $60.0 million recorded upon entering into our collaboration with Mitsubishi Tanabe Pharma Corporation (MTPC), $48.1 million recorded upon entering into our collaboration with Applied Genetic Technologies Corporation (AGTC), $30.0 million recorded as milestones in relation to our collaboration agreements with Ionis and $16.0 million paid to AbbVie related to milestones for the development of ZINBRYTA as a result of filing with the FDA and EMA during the year. For additional information about these transactions, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development expense for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;includes $139.3 million recorded in connection with our collaboration agreement with Eisai Co., Ltd. (Eisai), $25.0 million recorded as milestones in relation to our collaboration agreements with Ionis and an aggregate of $60.0 million related to upfront payments made to Sangamo and Google Inc. and for other strategic business arrangements. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These payments are classified as research and development expense as the programs they relate to had not achieved regulatory approval as of the payment date. </font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Selling, General and Administrative</font></div><div style="line-height:120%;"><img src="sellinggeneraladminchart.jpg" alt="sellinggeneraladminchart.jpg" style="height:240px;width:317px;"></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in selling, general and administrative expenses reflects cost savings in connection with our corporate restructuring, which are described below under the heading "Restructuring Charges," partially offset by an increase in costs associated with developing commercial capabilities for ZINBRYTA and SPINRAZA. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in selling, general and administrative expenses was driven by a decrease in corporate giving, incentive compensation and the positive impact of foreign currency translation of $87.6 million, partially offset by an increase of $38.9 million of BPD fee expense. </font></div><div><a name="s51E9AFEB243BCF3CF14E2016ABF33D60"></a></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Amortization of Acquired Intangible Assets</font></div><div style="line-height:120%;"><img src="amortizationchart.jpg" alt="amortizationchart.jpg" style="height:240px;width:317px;"></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our amortization expense is based on the economic consumption of intangible assets. Our most significant intangible assets are related to our AVONEX and TYSABRI products. Annually, during our long-range planning cycle, we perform an analysis of anticipated lifetime revenues of AVONEX and TYSABRI.</font></div></div></div><br><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">62</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our most recent long range planning cycle was completed in the third quarter of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Based upon this analysis, the estimated future amortization of acquired intangible assets is expected to be as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:68%;"></td><td style="width:1%;"></td><td style="width:30%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">As of December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">334.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">312.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">295.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">259.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">242.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We monitor events and expectations regarding product performance. If new information indicates that the assumptions underlying our most recent analysis are substantially different than those utilized in our current estimates, our analysis would be updated and may result in a significant change in the anticipated lifetime revenues of the relevant process. The occurrence of an adverse event could substantially increase the amount of amortization expense associated with our acquired intangible assets as compared to previous periods or our current expectations, which may result in a significant negative impact on our future results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the amortization of acquired intangible assets was relatively consistent as our most recent analysis completed during the third quarter of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;resulted in no significant net change in our expected rate of amortization for acquired intangible assets.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in amortization of acquired intangible assets was primarily driven by a decrease in AVONEX revenues during the comparative periods and the impact of higher expected lifetime revenues of AVONEX due to a slower than previously expected adoption of PLEGRIDY. Amortization of acquired intangible assets during </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;included total impairment charges of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$50.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;related to one of our out-licensed patents and one of our in-process research and development (IPR&amp;D) intangible assets.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information related to the amortization of acquired intangible assets, please read Note 6, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Intangible Assets and Goodwill</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.</font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Impairment of Intangible Assets</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We record charges associated with impairments of intangible assets in amortization of intangible assets.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;we terminated our collaboration agreements with Rodin Therapeutics, Inc. and Ataxion Inc., resulting in impairment losses of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$8.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, related to the IPR&amp;D assets recorded upon entering into the collaboration agreements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Impairment charges related to our intangible assets during </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;were insignificant. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;we recorded a charge of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$34.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;related to the impairment of one of our out-licensed patents to reflect a change in its estimated fair value, due to a change in the underlying competitive market for that product. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;we updated the probabilities of success related to the early stage programs acquired through our recent acquisitions.&#160;This change in probability of success, combined with a delay in one of the projects, resulted in an impairment loss of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$16.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.&#160;</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information, please read Note 6, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Intangible Assets and Goodwill</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">IPR&amp;D</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Overall, the value of our acquired IPR&amp;D assets is dependent upon a number of variables, including estimates of future revenues and the effects of competition, the level of anticipated development costs and the probability and timing of successfully advancing a particular research program from a clinical trial phase to the next.&#160;We are continually reevaluating our estimates concerning these variables and evaluating industry data regarding the productivity of clinical research and the development process.&#160;Changes in our estimates of items may result in a significant change to our valuation of these assets.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The field of developing treatments for forms of neuropathic pain, such as TGN, and idiopathic pulmonary fibrosis (IPF) are highly competitive and can be affected by changes to expected market candidates and changes in timing and the clinical development of our product candidates. There can be no assurance that we will be able to successfully develop BIIB074 for the treatment of TGN or STX-100 for the treatment of IPF, or other indications or that a successfully developed therapy will be able to secure sufficient pricing in a competitive market.&#160;Changes to clinical development plans or life cycle management strategies are evaluated regularly. We review amounts </font></div></div></div><br><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">63</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">capitalized as acquired IPR&amp;D for impairment at least annually, as of October 31, and whenever events or changes in circumstances indicate that the carrying value of the assets might not be recoverable. Our most recent impairment assessment as of October 31, 2016 resulted in no impairments.</font></div><div><a name="sC2ACC7434D43FD5CA20B20170CDE002E"></a></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Restructuring, Business Transformation and Other Cost Saving Initiatives</font></div><div style="line-height:120%;"><img src="restructuringchargeschart.jpg" alt="restructuringchargeschart.jpg" style="height:240px;width:317px;"></div><div style="line-height:120%;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">2015 Cost Saving Initiatives</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">2015 Restructuring Charges</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On October 21, 2015, we announced a corporate restructuring, which included the termination of certain pipeline programs and an </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;reduction in workforce. As a result of these initiatives, we reduced our annual run rate of operating expenses by $250 million and reinvested these savings to support the advancement of our high potential pipeline candidates and key commercial activities. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under this restructuring, cash payments were estimated to total </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$120 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, of which </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;were related to previously accrued 2015 incentive compensation, resulting in net restructuring charges totaling approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$102.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. These amounts were substantially incurred and paid by the end of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized total net restructuring charges of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$8.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$93.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the charges and spending related to our 2015 restructuring program during </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Workforce</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Reduction</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Pipeline</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Programs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restructuring reserve as of December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">33.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">37.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(31.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(9.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(40.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments to previous estimates, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(5.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(2.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restructuring reserve as of December 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">2016 Organizational Changes and Cost Saving Initiatives</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">2016 Restructuring Charges</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the third quarter of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;we initiated additional cost saving measures primarily intended to realign our organizational structure due to the changes in roles and workforce resulting from our decision to spin off our hemophilia business, and to achieve further targeted cost reductions. For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;we recognized charges totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$17.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;related to this effort, which are in addition to, and separate from, the 2015 corporate restructuring described above. These amounts, which were substantially incurred and paid by the end of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, are primarily related to severance and are reflected in restructuring charges in our consolidated statements of income.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Cambridge, MA Manufacturing Facility</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2016 following an evaluation of our current and future manufacturing capabilities and capacity needs, we determined that we intend to vacate and cease manufacturing in our 67,000 square foot small-scale biologics manufacturing facility in Cambridge, MA and also vacate our 46,000 square foot warehouse space in Somerville, MA.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December&#160;2016 we subleased our rights to the manufacturing facility in Cambridge, MA to Brammer. Brammer also purchased from us certain manufacturing equipment, leasehold improvements and other assets in exchange for shares of Brammer common LLC interests and assumed manufacturing operations effective January 1, 2017. In December 2016 we also closed and vacated our warehouse space in Somerville, MA.</font></div></div></div><br><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our departure from these facilities shortened the expected useful lives of certain leasehold improvements and other assets at these facilities. As a result, we recorded additional depreciation expense to reflect the assets' new shorter useful lives. For the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$45.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of this additional depreciation, which was recorded as cost of sales in our consolidated statement of income.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the terms of the agreement, Brammer will also provide manufacturing and other transition and support services to us.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the fourth quarter of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;we recognized charges totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$7.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for severance costs related to certain employees separated from Biogen in connection with this transaction. These amounts will be substantially incurred and paid by the end of the first quarter of 2017 and are reflected in restructuring charges in our consolidated statements of income.</font></div><div><a name="s786423165A5F0681F98820170D553F44"></a></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">(Gain) Loss on Fair Value Remeasurement of Contingent Consideration</font></div><div style="line-height:120%;"><img src="gainlossfairvaluechart.jpg" alt="gainlossfairvaluechart.jpg" style="height:240px;width:317px;"></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The consideration for certain of our business combinations includes future payments that are contingent upon the occurrence of a particular factor or factors. We record an obligation for such contingent consideration payments at fair value on the acquisition date. We then revalue our contingent consideration obligations each reporting period. Changes in the fair value of our contingent consideration obligations, other than changes due to payments, are recognized as a (gain) loss on fair value remeasurement of contingent consideration in our consolidated statements of income. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The loss on fair value remeasurement of contingent consideration for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;was primarily due to changes in the probability of achieving certain developmental milestones and changes in the discount rate.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The loss on fair value remeasurement of contingent consideration for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;was primarily due to changes in the expected timing and probabilities of success related to the achievement of certain developmental milestones and in the discount rate.</font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The gain on fair value remeasurement of contingent consideration for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;was primarily due to an adjustment to the value of our contingent consideration liabilities as we updated the probabilities of success related to the early stage programs acquired through our recent acquisitions. For additional information, please read Note 7, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Fair Value Measurements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.</font></div><div><a name="sD9FDFF631AFEACAE74B320170D00C91D"></a></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Collaboration Profit (Loss) Sharing</font></div><div style="line-height:120%;"><img src="collabprofitsharingchart.jpg" alt="collabprofitsharingchart.jpg" style="height:240px;width:317px;"></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Collaboration profit (loss) sharing includes our 50% share of the profit or loss related to our biosimilars commercial agreement with Samsung Bioepis and our 50% share of the co-promotion profits or losses in the E.U. and Canada related to our collaboration agreement with AbbVie on the commercialization of ZINBRYTA. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We began to recognize revenues on sales of biosimilars in the first quarter of 2016. For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;we recognized net expense of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;related to our biosimilars commercial agreement with Samsung.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We began to recognize revenues on sales of ZINBRYTA in the E.U. in the third quarter of 2016. For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;we also recognized income of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$4.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to reflect AbbVie's 50% share of net collaboration losses in the E.U. and Canada.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;For additional information related to these arrangements, please read Note&#160;19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.</font></div></div></div><br><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">65</font></div></div><hr style="page-break-after:always"><div><a name="sd71f1b53f49b4625a51621667fe42802"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">TECFIDERA Litigation Settlement and License Charges</font></div><div style="line-height:120%;"><img src="teclitigationchart.jpg" alt="teclitigationchart.jpg" style="height:240px;width:317px;"></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2017 we agreed to enter into a settlement and license agreement with Forward Pharma A/S (Forward Pharma) that will provide us an irrevocable license to all intellectual property owned by Forward Pharma and results in the termination of the German Infringement Litigation. Under the terms of the settlement and license agreement with Forward Pharma, we have agreed to pay Forward Pharma </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.25 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in cash. During the fourth quarter of 2016 we recognized a pre-tax charge of $454.8 million related to this matter. This amount represents the fair value of estimated royalties on our sales of TECFIDERA during the period April 2014 through December 31, 2016. For additional information related to the agreement, please read Note 21, Commitments and Contingencies to our consolidated financial statements included in this report.</font></div><div><a name="s3C2135E8628FFF5DCF2620170D5A77E0"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Other Income (Expense), Net</font></div><div style="line-height:120%;"><img src="otherincomeexpensechart.jpg" alt="otherincomeexpensechart.jpg" style="height:240px;width:317px;"></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the change in other income (expense), net was primarily due to an increase in interest expense as a result of the issuance of our senior unsecured notes in the third quarter of 2015. This increase was partially offset by an increase in interest income on higher yields and cash, cash equivalents and marketable securities balances as well as a decrease in foreign exchange losses recognized during the year ended December 31, 2016, compared to the prior year comparative period. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the change in other income (expense), net was primarily due to an increase in interest expense as a result of the issuance of our senior unsecured notes in the third quarter of 2015, higher foreign exchange losses and a decrease in net gains recognized on the sale of our strategic investments and marketable securities. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information related to our senior unsecured notes, please read Note 11, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Indebtedness</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in this report.</font></div></div></div><br><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">66</font></div></div><hr style="page-break-after:always"><div><a name="s4EBAE54402EA74B2165E20170D85A022"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Income Tax Provision</font></div><div style="line-height:120%;"><img src="incometaxchart.jpg" alt="incometaxchart.jpg" style="height:338px;width:317px;"></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our effective tax rate fluctuates from year to year due to the global nature of our operations. The factors that most significantly impact our effective tax rate include variability in the allocation of our taxable earnings among multiple jurisdictions, changes in tax laws, the amount and characterization of our research and development expenses, the levels of certain deductions and credits, acquisitions and licensing transactions.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our effective tax rate for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;increased primarily due to a net state tax benefit in 2015 of $27.0 million resulting from the remeasurement of one of our uncertain tax positions and a higher relative percentage of our earnings being attributed to the U.S., a higher tax jurisdiction.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our effective tax rate for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;benefited from lower anticipated taxes on foreign earnings and reflects a $27.0 million benefit from the 2015 remeasurement of one of our uncertain tax positions.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accounting for Uncertainty in Income Taxes</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For more information on our uncertain tax positions and income tax rate reconciliation for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, please read Note 16, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Income Taxes</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.</font></div><div><a name="s0D3B225DD0BB32D58D2520170DAE0F6D"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Equity in Loss of Investee, Net of Tax</font></div><div style="line-height:120%;"><img src="equitinlossofinvesteechart.jpg" alt="equitinlossofinvesteechart.jpg" style="height:240px;width:317px;"></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2012 we entered into an agreement with Samsung Biologics, establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar pharmaceuticals. We account for this investment under the equity method of accounting. We recognize our share of the results of operations related to our investment in Samsung Bioepis one quarter in arrears. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;our share of losses exceeded the carrying value of our investment. We therefore suspended recognizing additional losses and will continue to do so unless we commit to providing additional funding. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in our equity in loss of investee, net of tax, was due to the suspension of equity method investment losses due to our share of losses exceeding the carrying value of our investment in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and a decrease in our ownership interest. </font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information related to this transaction, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.</font></div><div><a name="s1E02120D9AE57D5DD0C520170DD93D7B"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Noncontrolling Interest</font></div><div style="line-height:120%;"><img src="noncontrollinginterestchart.jpg" alt="noncontrollinginterestchart.jpg" style="height:240px;width:317px;"></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the change in net income (loss) attributable to noncontrolling interests, net of tax, was primarily related to a $60.0 million milestone payment made to Neurimmune SubOne AG (Neurimmune) in 2015.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the change in net income (loss) attributable to noncontrolling interests, net of tax, was primarily related to a $60.0 million milestone payment made to Neurimmune, partially offset by increases in research expenses attributable to noncontrolling interests.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information about Neurimmune, please read Note 18, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Investments in Variable Interest Entities</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.</font></div></div></div><br><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">67</font></div></div><hr style="page-break-after:always"><div><a name="s59AA94ECAFFA5993003520167897D9E2"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Financial Condition, Liquidity and Capital Resources</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our financial condition is summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December&#160;31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">%&#160;Change</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except percentages)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016 compared to 2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Financial assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,326.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,308.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">77.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable securities &#8212; current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,568.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,120.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable securities &#8212; non-current</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,829.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,760.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total cash, cash equivalents and marketable securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7,724.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,188.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Borrowings:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current portion of notes payable and other financing arrangements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes payable and other financing arrangements</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6,512.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,521.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total borrowings</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6,517.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,526.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Working Capital:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">8,732.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,700.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(3,419.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2,577.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">32.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total working capital</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5,312.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,122.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">28.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr></table></div></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div><a name="sA5E31A131D65A3D514D720170E2B566A"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, certain significant cash flows were as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$4.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in net cash flows provided by operating activities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;used for share repurchases;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1.6 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in total net payments for income taxes;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.2 billion in contingent payments made to former shareholders of Fumapharm AG and holders of their rights; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$616.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;used for purchases of property, plant and equipment.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$102.0 million used for upfront and milestone payments to Samsung Bioepis, AbbVie and UPenn; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$75.0 million license fee payment made to Ionis.</font></div></td></tr></table></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, certain significant cash flows were as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$3.7 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in net cash flows provided by operating activities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.9 billion in proceeds from the issuance of our senior unsecured notes;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$5.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;used for share repurchases;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1.7 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in total net payments for income taxes;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$850.0 million in contingent payments made to former shareholders of Fumapharm AG and holders of their rights; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$643.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;used for purchases of property, plant and equipment, including $104.8 million related to the acquisition of Eisai's drug product manufacturing facility in Research Triangle Park (RTP), North Carolina and $62.5 million related to the acquisition of land in Solothurn, Switzerland;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$198.8 million net cash paid for the acquisition of Convergence; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:inherit;font-size:8pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$244.0 million used for upfront and milestone payments to AGTC, MTPC and Neurimmune.</font></div></td></tr></table></div></div><br><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">68</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Overview</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have historically financed our operating and capital expenditures primarily through cash flows earned through our operations. We expect to continue funding our current and planned operating requirements principally through our cash flows from operations, as well as our existing cash resources. We believe that our existing funds, when combined with cash generated from operations and our access to additional financing resources, if needed, are sufficient to satisfy our operating, working capital, strategic alliance, milestone payment, capital expenditure and debt service requirements for the foreseeable future. In addition, we may choose to opportunistically return cash to shareholders and pursue other business initiatives, including acquisition and licensing activities. We may, from time to time, also seek additional funding through a combination of new collaborative agreements, strategic alliances and additional equity and debt financings or from other sources should we identify a significant new opportunity.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The undistributed cumulative foreign earnings of certain of our foreign subsidiaries, exclusive of earnings that would result in little or no net income tax expense under current U.S. tax law or which has already been subject to tax under U.S. tax law, are invested indefinitely outside the U.S. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Of the total cash, cash equivalents and marketable securities at </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, approximately $5.5 billion was generated in foreign jurisdictions and is primarily intended for use in our foreign operations or in connection with business development transactions outside of the U.S. In managing our day-to-day liquidity in the U.S., we do not rely on the unrepatriated earnings as a source of funds and we have not provided for U.S.&#160;federal or state income taxes on these undistributed foreign earnings. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information related to certain risks that could negatively impact our financial position or future results of operations, please read the &#8220;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risk Factors</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8221; and &#8220;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Quantitative and Qualitative Disclosures About Market Risk</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8221; sections of this report.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Share Repurchase Programs</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2016 our Board of Directors authorized a program to repurchase up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of our common stock (2016 Share Repurchase Program). This authorization does not have an expiration date. Repurchased shares will be retired. During the year ended December 31, 2016, we repurchased and retired </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares of common stock at a cost of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;under our 2016 Share Repurchase </font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Program.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2015 our Board of Directors authorized a program to repurchase up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of our common stock (2015 Share Repurchase Program), which was completed as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we repurchased and retired approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares of common stock at a cost of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;under our 2015 Share Repurchase Program.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2011 our Board of Directors authorized a program to repurchase up to 20.0 million of our common stock (2011 Share Repurchase Program), which has been used principally to offset common stock issuances under our share-based compensation plans. The 2011 Share Repurchase Program does not have an expiration date. We did not repurchase any shares of common stock under our 2011 Share Repurchase Program during the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. During the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we purchased approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares of common stock at a cost of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$886.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;under our 2011 Share Repurchase Program. We have approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares remaining available for repurchase under the 2011 Share Repurchase Program.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Cash, Cash Equivalents and Marketable Securities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Until required for another use in our business, we typically invest our cash reserves in bank deposits, certificates of deposit, commercial paper, corporate notes, U.S.&#160;and foreign government instruments and other interest bearing marketable debt instruments in accordance with our investment policy. It is our policy to mitigate credit risk in our cash reserves and marketable securities by maintaining a well-diversified portfolio that limits the amount of exposure as to institution, maturity and investment type. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The net increase in cash, cash equivalents and marketable securities at </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, from </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, is primarily due to net cash flows provided by operating activities, partially offset by purchases of our common stock, payments for income taxes, contingent payments made to former shareholders of Fumapharm AG and holders of their rights, the net purchases of property, plant and equipment and upfront and milestone payments related to our collaboration agreements.</font></div></div></div><br><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">69</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Borrowings</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following is a summary of our principal indebtedness:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$550.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;aggregate principal amount of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">6.875%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes due March&#160;1, 2018;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;aggregate principal amount of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2.90%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes due September 15, 2020;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;aggregate principal amount of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">3.625%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes due September 15, 2022;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1.75 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;aggregate principal amount of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">4.05%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes due September 15, 2025; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1.75 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;aggregate principal amount of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">5.20%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes due September 15,&#160;2045.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These senior unsecured notes were issued at a discount and are amortized as additional interest expense over the period from issuance through maturity.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the third quarter of 2015, we entered into a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">five</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">-year senior unsecured revolving credit facility under which we are permitted to draw funds for working capital and general corporate purposes. The terms of the revolving credit facility include a financial covenant that requires us not to exceed a maximum consolidated leverage ratio. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">no</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;outstanding borrowings and were in compliance with all covenants </font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">under this facility.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our 2006 distribution agreement with Fumedica AG (Fumedica), we issued notes totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">61.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Swiss Francs that were payable to Fumedica in varying amounts from June 2008 through June 2018. Our remaining note payable to Fumedica had a carrying value of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Swiss Francs (</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$6.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Swiss Francs (</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$9.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For a summary of the fair values of our outstanding borrowings as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, please read Note&#160;7, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Fair Value Measurements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Working Capital</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We define working capital as current assets less current liabilities. The increase in working capital at </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, from </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, reflects an increase in total current assets of $2,031.9 million, partially offset by an increase in current liabilities of $842.2 million. The increase in total current assets was primarily driven by an increase in cash, cash equivalents and marketable securities due to net cash flows provided by operating activities. The increase in total current liabilities primarily resulted from litigation settlement and license charges and an increase in accrued collaboration expenses. </font></div></div></div><br><div><a name="s047EA8186E98F8EBBF70201682ABB0DD"></a></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Cash Flows</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our cash flow activity:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"></td></tr><tr><td style="width:35%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">December 31,</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">% Change</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016 compared to 2015</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015 compared to 2014</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except percentages)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net cash flows provided by operating activities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4,522.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,716.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,942.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">21.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">26.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net cash flows used in by investing activities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(2,484.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4,553.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1,543.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(45.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">195.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net cash flows provided by (used in) financing activities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(987.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">986.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(755.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(200.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(230.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr></table></div></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div><a name="s30C07407A44DC00B4ABD20170E7FAF7A"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Operating Activities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash flows from operating activities represent the cash receipts and disbursements related to all of our activities other than investing and financing activities. We expect cash provided from operating activities will continue to be our primary source of funds to finance operating needs and capital expenditures for the foreseeable future.</font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating cash flow is derived by adjusting our net income for:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-cash operating items such as depreciation and amortization, impairment charges and share-based compensation charges;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Changes in operating assets and liabilities which reflect timing differences between the receipt and payment of cash associated with transactions and when they are recognized in results of operations;&#160;and</font></div></td></tr></table></div></div><br><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">70</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Changes associated with the fair value of contingent payments associated with our acquisitions of businesses and payments related to collaborations.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in cash provided by operating activities was primarily driven by higher net income, non-cash charges for depreciation and amortization, a comparative increase in accrued expenses and other liabilities, partially offset by a comparative increase in accounts receivable.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in cash provided by operating activities was primarily driven by higher net income and accounts receivable collections, partially offset by income tax payments.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Investing Activities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in net cash flows used in investing activities was primarily due to a decrease in net purchases of marketable securities and cash paid for the acquisition of Convergence in February 2015, partially offset by an increase in the contingent consideration </font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">related to the Fumapharm AG acquisition. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in net cash flows used in investing activities was primarily due to an increase in net purchases of marketable securities, an increase in the total amount of contingent consideration paid to the former shareholders of Fumapharm AG, an increase in purchases of property, plant and equipment and cash paid for the acquisition of Convergence. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Financing Activities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in net cash flows provided by financing activities was primarily due to the issuance of our senior unsecured notes issued in the third quarter of 2015, partially offset by a decrease in the purchases of common stock.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the change in net cash flows provided by financing activities was primarily due to the issuance of our 2015 Senior Notes, partially offset by an increase in the amount of common stock we repurchased.</font></div></div></div><br><div><a name="s4F7A3AE464C1800B518D201678931914"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Contractual Obligations and Off-Balance Sheet Arrangements</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contractual Obligations</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our contractual obligations as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, excluding amounts related to uncertain tax positions, funding commitments, contingent development, regulatory and commercial milestone payments, TYSABRI contingent payments and contingent consideration related to our business combinations, as described below.</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td style="width:36%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Payments Due by Period</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Less&#160;than</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">1 Year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">1 to 3</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">3 to 5</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">After</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">5&#160;Years</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capital leases (1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">18.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">16.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-cancellable operating leases (2), (3)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">549.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">66.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">108.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">98.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">276.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-term debt obligations (4)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10,281.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">282.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,055.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,939.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7,003.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchase and other obligations (5)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,740.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,598.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">88.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">43.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">9.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Defined benefit obligation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">74.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">74.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total contractual obligations</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">12,663.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,949.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,268.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,082.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7,364.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div><a name="sEFBA25A477A77A7D290520170EE6D64A"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During 2015 we amended our existing lease related to Eisai's oral solid dose products manufacturing facility in RTP, North Carolina, where we manufacture our and Eisai's oral solid dose products. Amounts reflected within the table above include the future contractual commitments. For additional information, please read Note 10, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Property, Plant and Equipment</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.</font></div></td></tr></table></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We lease properties and equipment for use in our operations. Amounts reflected within the table above detail future minimum rental commitments under non-cancelable operating leases as of December&#160;31 for each of the periods presented. In addition to the minimum rental commitments, these leases may require us to pay additional amounts for taxes, insurance, maintenance and other operating expenses. </font></div></td></tr></table></div></div><br><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">71</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Obligations are presented net of sublease income expected to be received for the vacated manufacturing facility in Cambridge, MA, the vacated portion of our Weston, Massachusetts facility and other facilities throughout the world. For additional information related to the sublease of the vacated manufacturing facility in Cambridge, MA, please read Note 3, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Restructuring, Business Transformation and Other Cost Savings Initiatives</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-term debt obligations are primarily related to our Senior Notes, including principal and interest payments. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(5)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchase and other obligations primarily includes our obligations to purchase direct materials, our obligation of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1.25 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;under the litigation settlement and license agreement with Forward Pharma, </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$176.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in contractual commitments for the construction of a biologics manufacturing facility in Solothurn, Switzerland and </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$13.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;related to the fair value of net liabilities on derivative contracts. For additional information on the litigation settlement and license agreement with Forward Pharma please read Note 21, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Commitments and Contingencies</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">TYSABRI Contingent Payments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2013 we acquired from Elan full ownership of all remaining rights to TYSABRI that we did not already own or control. Under the terms of the acquisition agreement, we are obligated to make contingent payments to Elan of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;on annual worldwide net sales up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">25%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;on annual worldwide net sales that exceed </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Royalty payments to Elan and other third parties are recognized as cost of sales in our consolidated statements of income. Elan was acquired by Perrigo in December 2013. Following that acquisition, we began making these royalty payments to Perrigo.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Consideration related to Business Combinations</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisitions of Convergence, Stromedix, Inc. (Stromedix) and Biogen International Neuroscience GmbH (BIN), we agreed to make additional payments based upon the achievement of certain milestone events. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As the acquisitions of Convergence, Stromedix and BIN occurred after January&#160;1, 2009, we record contingent consideration liabilities at their fair value on the acquisition date and revalue these obligations each reporting period. We may pay up to approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.2 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in remaining milestones </font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">related to these acquisitions. For additional information related to our acquisition of Convergence please read Note 2, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in this report.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Fumapharm AG</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2006 we acquired Fumapharm AG. As part of this acquisition we acquired FUMADERM and TECFIDERA (together, Fumapharm Products). We are required to make contingent payments to former shareholders of Fumapharm AG or holders of their rights based on the attainment of certain cumulative sales levels of Fumapharm Products and the level of total net sales of Fumapharm Products in the prior twelve month period, as defined in the acquisition agreement. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;we paid </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.2 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in contingent payments as we reached the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$7.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$8.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$9.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;cumulative sales levels related to the Fumapharm Products in the fourth quarter of 2015 and the first, second and third quarters of 2016, respectively, and accrued </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$300.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;upon reaching </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$11.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in total cumulative sales of Fumapharm Products in the fourth quarter of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We will owe an additional </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$300.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;contingent payment for every additional </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in cumulative sales level of Fumapharm Products reached if the prior 12 months sales of the Fumapharm Products exceed </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, until such time as the cumulative sales level reaches </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$20.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, at which time no further contingent payments shall be due. If the prior 12 months sales of Fumapharm Products are less than </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, contingent payments remain payable on a decreasing tiered basis. These payments will be accounted for as an increase to goodwill as incurred, in accordance with the accounting standard applicable to business combinations when we acquired Fumapharm. Any portion of the payment which is tax deductible will be recorded as a reduction to goodwill. Payments are due within 60&#160;days following the end of the quarter in which the applicable cumulative sales level has been reached.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Development, Regulatory and Commercial Milestone Payments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based on our development plans as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we could make potential future milestone payments to third parties of up to approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.1 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, including approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$0.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in development milestones, approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$0.8 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in regulatory milestones and approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.8 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in commercial milestones as part of our various collaborations, including licensing and development programs. Payments under these agreements generally become due and payable </font></div></div></div><br><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">72</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">upon achievement of certain development, regulatory or commercial milestones. Because the achievement of these milestones had not occurred as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, such contingencies have not been recorded in our financial statements. Amounts related to contingent milestone payments are not considered contractual obligations as they are contingent on the successful achievement of certain development, regulatory approval and commercial milestones. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We anticipate that we may pay approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$157.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of milestone payments in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, provided various development, regulatory or commercial milestones are achieved. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Funding Commitments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we have several on-going clinical studies in various clinical trial stages. Our most significant clinical trial expenditures are to contract research organizations (CROs). The contracts with CROs are generally cancellable, with notice, at our option. We have recorded accrued expenses of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$21.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;on our consolidated balance sheet for expenditures incurred by CROs as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We have approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$500.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in cancellable future commitments based on existing CRO contracts as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Tax Related Obligations</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We exclude liabilities pertaining to uncertain tax positions from our summary of contractual obligations as we cannot make a reliable estimate of the period of cash settlement with the respective taxing authorities. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we have approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$47.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of net liabilities associated with uncertain tax positions. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Off-Balance Sheet Arrangements</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We do not have any relationships with entities often referred to as structured finance or special purpose entities that were established for the purpose of facilitating off-balance sheet arrangements. As such, we are not exposed to any financing, liquidity, market or credit risk that could arise if we had engaged in such relationships. We consolidate variable interest entities if we are the primary beneficiary.</font></div><div><a name="s454267EA15CD9CD62E8B20170EF5FCC1"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Legal Matters</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For a discussion of legal matters as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, please read Note&#160;20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Litigation</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.</font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Critical Accounting Estimates</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The preparation of our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the U.S.&#160;(U.S.&#160;GAAP), requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an on-going basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expenses. Actual results may differ from these estimates under different assumptions or conditions.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Revenue Recognition and Related Allowances</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognize revenue when all of the following criteria are met: persuasive evidence of an arrangement exists; delivery has occurred or services have been rendered; our price to the customer is fixed or determinable; and collectability is reasonably assured. For additional information related to the new accounting standard for revenues from contracts with customers please read Note 1, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies: New Accounting Pronouncements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Product Revenues</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from product sales are recognized when title and risk of loss have passed to the customer, which is typically upon delivery. Product revenues are recorded net of applicable reserves for discounts and allowances. The timing of distributor orders and shipments can cause variability in earnings.</font></div></div></div><br><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">73</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Reserves for Discounts and Allowances</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from product sales are recorded net of reserves established for applicable discounts and allowances, including those associated with the implementation of pricing actions in certain of the international markets in which we operate. These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer). Our estimates take into consideration our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Actual amounts may ultimately differ from our estimates. If actual results vary, we adjust these estimates, which could have an effect on earnings in the period of adjustment. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition to the discounts and rebates described above and classified as a reduction of revenue, we also maintain certain customer service contracts with distributors and other customers in the distribution channel that provide us with inventory management, data and distribution services, which are generally reflected as a reduction of revenue. To the extent we can demonstrate a separable benefit and fair value for these services, we classify these payments within selling, general and administrative expenses.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Revenues from Anti-CD20 Therapeutic Programs</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs consist of:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(i)&#160;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our share of pre-tax profits and losses in the U.S. for RITUXAN and GAZYVA; </font></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:54px;text-indent:-24px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(ii)&#160; reimbursement of our selling and development expenses in the U.S. for RITUXAN; and </font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(iii)</font></div></td><td style="vertical-align:top;padding-left:12px;"><div style="line-height:120%;text-align:left;font-size:10pt;text-indent:-12px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">revenues on sales in the rest of world for RITUXAN, which consist of our share of pre-tax co-promotion profits on RITUXAN in Canada and royalty revenue on RITUXAN sales outside the U.S. and Canada by the Roche Group and its sublicensees. </font></div></td></tr></table></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pre-tax co-promotion profits on RITUXAN and GAZYVA are calculated and paid to us by Genentech in the U.S. Pre-tax co-promotion profits on RITUXAN are calculated and paid to us by the Roche Group in Canada. Pre-tax co-promotion profits consist of U.S. and Canadian net sales to third-party customers less applicable costs to manufacture, third-party royalty expenses, distribution, selling and marketing expenses, and joint development expenses incurred by Genentech, the Roche Group and us. We record our share of the pre-tax co-promotion profits on RITUXAN in Canada and royalty revenues on RITUXAN sales outside the U.S. on a cash basis as we do not have the ability to estimate these profits or royalty revenue in the period incurred. Our share of the pre-tax profits on RITUXAN and GAZYVA in the U.S. includes estimates made by Genentech and those estimates are subject to change. Actual results may differ from our estimates.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Concentrations of Credit Risk</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The majority of our accounts receivable arise from product sales in the U.S. and Europe and are primarily due from wholesale distributors, public hospitals and other government entities. We monitor the financial performance and creditworthiness of our customers so that we can properly assess and respond to changes in their credit profile. We continue to monitor these conditions, including the volatility associated with international economies and the relevant financial markets, and assess their possible impact on our business. Credit and economic conditions in the E.U. continue to remain uncertain, which has, from time to time, led to longer collection periods for our accounts receivable and greater collection risk in certain countries. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Where our collections continue to be subject to significant payment delays due to government funding and reimbursement practices and a portion of these receivables are routinely being collected beyond our contractual payment terms and over periods in excess of one year, we have discounted our receivables and reduced related revenues based on the period of time that we estimate those amounts will be paid, to the extent such period exceeds one year, using the country&#8217;s market-based borrowing rate for such period. The related receivables are classified at the time of sale as non-current assets.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">To date, we have not experienced any significant losses with respect to the collection of our accounts receivable. If economic conditions worsen and/or the financial condition of our customers were to further deteriorate, our risk of collectability may increase, which may result in additional allowances and/or significant bad debts.</font></div></div></div><br><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">74</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information related to our concentration of credit risk associated with our accounts receivable balances, please read the subsection entitled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8220;Credit Risk&#8221;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8220;Quantitative and Qualitative Disclosures About Market Risk&#8221;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;section of this report.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Collaborative and Other Relationships</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our development and commercialization arrangements with Sobi and AbbVie represent collaborative arrangements as each party is an active participant and exposed to significant risks and rewards of the arrangements. Where we are the principal on sales transactions with third parties, we recognize revenue, cost of sales and sales and marketing expenses on a gross basis in their respective lines in our consolidated statements of income. Where we are not the principal on sales transactions with third parties, we record our share of the revenues, cost of sales and sales and marketing expenses on a net basis in collaborative and other relationships in our consolidated statements of income. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information related to our collaborations with Sobi and AbbVie, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Capitalization of Inventory Costs</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We capitalize inventory costs associated with our products prior to regulatory approval, when, based on management&#8217;s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized. We consider numerous attributes in evaluating whether the costs to manufacture a particular product should be capitalized as an asset. We assess the regulatory approval process and where the particular product stands in relation to that approval process, including any known safety or efficacy concerns, potential labeling restrictions and other impediments to approval. We evaluate our anticipated research and development initiatives and constraints relating to the product and the indication in which it will be used. We consider our manufacturing environment including our supply chain in determining logistical constraints that could hamper approval or commercialization. We consider the shelf life of the product in relation to the expected timeline for approval and we consider patent related or contract issues that may prevent or delay commercialization. We also base our judgment on the viability of commercialization, trends in the marketplace and market acceptance criteria. Finally, we consider the reimbursement strategies that may prevail with respect to the product and assess the economic benefit that we are likely to realize. We expense previously capitalized costs related to pre-approval inventory upon a change in such judgment, </font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">due to, among other potential factors, a denial or significant delay of approval by necessary regulatory bodies. All changes in judgment in relation to pre-approval inventory have historically been insignificant.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Acquired Intangible Assets, including In-process Research and Development (IPR&amp;D)</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effective January&#160;1, 2009, when we purchase a business, the acquired IPR&amp;D is measured at fair value, capitalized as an intangible asset and tested for impairment at least annually, as of October 31, until commercialization, after which time the IPR&amp;D is amortized over its estimated useful life. If we acquire an asset or group of assets that do not meet the definition of a business under applicable accounting standards, the acquired IPR&amp;D is expensed on its acquisition date. Future costs to develop these assets are recorded to research and development expense as they are incurred.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have acquired, and expect to continue to acquire, intangible assets through the acquisition of biotechnology companies or through the consolidation of variable interest entities. These intangible assets primarily consist of technology associated with human therapeutic products and IPR&amp;D product candidates. When significant identifiable intangible assets are acquired, we generally engage an independent third-party valuation firm to assist in determining the fair values of these assets as of the acquisition date. Management will determine the fair value of less significant identifiable intangible assets acquired. Discounted cash flow models are typically used in these valuations, and these models require the use of significant estimates and assumptions including but not limited to:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">estimating the timing of and expected costs to complete the in-process projects;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">projecting regulatory approvals;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">estimating future cash flows from product sales resulting from completed products and in process projects;&#160;and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">developing appropriate discount rates and probability rates by project.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We believe the fair values assigned to the intangible assets acquired are based upon reasonable estimates and assumptions given available facts and circumstances as of the acquisition dates.</font></div></div></div><br><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">75</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">If these projects are not successfully developed, the sales and profitability of the company may be adversely affected in future periods. Additionally, the value of the acquired intangible assets may become impaired. We believe that the foregoing assumptions used in the IPR&amp;D analysis were reasonable at the time of the respective acquisition. No assurance can be given that the underlying assumptions used to estimate expected project sales, development costs or profitability, or the events associated with such projects, will transpire as estimated.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Certain IPR&amp;D programs have a fair value that is not significantly in excess of carrying value, including our program for the treatment of TGN. Such programs could become impaired if assumptions used in determining the fair value change.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Impairment and Amortization of Long-lived Assets and Accounting for Goodwill</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Long-lived Assets Other than Goodwill</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-lived assets to be held and used include property, plant and equipment as well as intangible assets, including IPR&amp;D and trademarks. Property, plant and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. We review our intangible assets with indefinite lives for impairment annually, as of October&#160;31, and whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">When performing our impairment assessment, we calculate the fair value using the same methodology as described above under </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">"Acquired Intangible Assets, including In-process Research and Development (IPR&amp;D)"</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. If the carrying value of our intangible assets with indefinite lives exceeds its fair value, then the intangible asset is written-down to its fair value. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our most significant intangible assets are our acquired and in-licensed rights and patents and developed technology. Acquired and in-licensed rights and patents primarily relates to our acquisition of all remaining rights to TYSABRI from Elan. Developed technology primarily relates to our AVONEX product, which was recorded in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003. We amortize the intangible assets related to TYSABRI and AVONEX using the economic consumption method based on revenue generated from the products underlying the related intangible assets. An analysis of the anticipated lifetime revenues of TYSABRI and AVONEX is performed annually during our long range planning cycle, which is generally updated in the third quarter of each year, and whenever events or changes in circumstances </font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">would significantly affect the anticipated lifetime revenues of TYSABRI or AVONEX. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on the impairment charges related to our long-lived assets during </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, please read Note 6, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Intangible Assets and Goodwill</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report. Impairment charges related to our long-lived assets during </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;were insignificant. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Goodwill</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill relates largely to amounts that arose in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003 and amounts that are being paid in connection with the acquisition of Fumapharm AG. Our goodwill balances represent the difference between the purchase price and the fair value of the identifiable tangible and intangible net assets when accounted for using the purchase method of accounting.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We assess our goodwill balance within our single reporting unit annually, as of October&#160;31, and whenever events or changes in circumstances indicate the carrying value of goodwill may not be recoverable to determine whether any impairment in this asset may exist and, if so, the extent of such impairment. We compare the fair value of our reporting unit to its carrying value. If the carrying value of the net assets assigned to the reporting unit exceeds the fair value of our reporting unit, then we would need to determine the implied fair value of our reporting unit&#8217;s goodwill. If the carrying value of our reporting unit&#8217;s goodwill exceeds its implied fair value, then we would record an impairment loss equal to the difference. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We completed our required annual impairment test in the fourth quarters of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, and determined in each of those periods that the carrying value of goodwill was not impaired. In each year, the fair value of our reporting unit, which includes goodwill, was significantly in excess of the carrying value of our reporting unit.</font></div></div></div><br><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">76</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Investments, including Fair Value Measures and Impairments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We invest in various types of securities, including short-term and long-term marketable securities, principally corporate notes, government securities including government sponsored enterprise mortgage-backed securities and credit card and auto loan asset-backed securities, in which our excess cash balances are invested.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In accordance with the accounting standard for fair value measurements, we have classified our financial assets as Level&#160;1, 2 or 3 within the fair value hierarchy. Fair values determined by Level&#160;1 inputs utilize quoted prices (unadjusted) in active markets for identical assets that we have the ability to access. Fair values determined by Level&#160;2 inputs utilize data points that are observable such as quoted prices, interest rates, yield curves and foreign currency spot rates. Fair values determined by Level&#160;3 inputs utilize unobservable data points for the asset.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As noted in Note&#160;7, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Fair Value Measurements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements, a majority of our financial assets have been classified as Level&#160;2. These assets have been initially valued at the transaction price and subsequently valued utilizing third-party pricing services. The pricing services use many observable market inputs to determine value, including reportable trades, benchmark yields, credit spreads, broker/dealer quotes, bids, offers, current spot rates and other industry and economic events. We validate the prices provided by our third-party pricing services by understanding the models used, obtaining market values from other pricing sources and analyzing pricing data in certain instances.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Impairment</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We conduct periodic reviews to identify and evaluate each investment that has an unrealized loss, in accordance with the meaning of other-than-temporary impairment and its application to certain investments. An unrealized loss exists when the current fair value of an individual security is less than its amortized cost basis. Unrealized losses on available-for-sale debt securities that are determined to be temporary, and not related to credit loss, are recorded, net of tax, in accumulated other comprehensive income.</font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For available-for-sale debt securities with unrealized losses, management performs an analysis to assess whether we intend to sell or whether we would more likely than not be required to sell the security before the expected recovery of the amortized cost basis. Where we intend to sell a security, or may be required to do so, the security&#8217;s decline in fair value is deemed to be other-than-temporary and the full amount of the unrealized loss is reflected within earnings as an impairment loss.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Regardless of our intent to sell a security, we perform additional analysis on all securities with unrealized losses to evaluate losses associated with the creditworthiness of the security. Credit losses are identified where we do not expect to receive cash flows sufficient to recover the amortized cost basis of a security and are reflected within earnings as an impairment loss.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Share-Based Compensation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We make certain assumptions in order to value and record expense associated with awards made under our share-based compensation arrangements. Changes in these assumptions may lead to variability with respect to the amount of expense we recognize in connection with share-based payments.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Determining the appropriate valuation model and related assumptions requires judgment, and includes estimating the expected market price of our stock on vesting date and stock price volatility as well as the term of the expected awards. Determining the appropriate amount to expense based on the anticipated achievement of performance targets requires judgment, including forecasting the achievement of future financial targets. The estimate of expense is revised periodically based on the probability of achieving the required performance targets and adjustments are made throughout the term as appropriate. The cumulative impact of any revision is reflected in the period of change.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also estimate forfeitures over the requisite service period when recognizing share-based compensation expense based on historical rates and forward-looking factors. These estimates are adjusted to the extent that actual forfeitures differ, or are expected to materially differ, from our estimates.</font></div></div></div><br><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">77</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Consideration</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For acquisitions completed before January 1, 2009, we record contingent consideration resulting from a business combination when the contingency is resolved. For acquisitions completed after January&#160;1, 2009, we record contingent consideration resulting from a business combination at its fair value on the acquisition date. Each reporting period thereafter, we revalue these obligations and record increases or decreases in their fair value as an adjustment to contingent consideration expense in our consolidated statements of income. Changes in the fair value of the contingent consideration obligations can result from changes to one or multiple inputs including adjustments to the discount rates and achievement and timing of any cumulative sales-based and development milestones, or changes in the probability of certain clinical events and changes in the assumed probability associated with regulatory approval. These fair value measurements represent Level 3 measurements as they are based on significant inputs not observable in the market.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Significant judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, changes in assumptions described above, could have a material impact on the amount of contingent consideration expense we record in any given period.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Restructuring Charges</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have made estimates and judgments regarding the amount and timing of our restructuring expense and liability, including current and future period termination benefits, pipeline program termination costs and other exit costs to be incurred when related actions take place. Severance and other related costs are reflected in our consolidated statements of income as a component of total restructuring charges incurred. Actual results may differ from these estimates.</font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Income Taxes</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We prepare and file income tax returns based on our interpretation of each jurisdiction&#8217;s tax laws and regulations. In preparing our consolidated financial statements, we estimate our income tax liability in each of the jurisdictions in which we operate by estimating our actual current tax expense together with assessing temporary differences resulting from differing treatment of items for tax and financial reporting purposes. These differences result in deferred tax assets and liabilities, which are included in our consolidated balance sheets. Significant management judgment is required in assessing the realizability of our deferred tax assets. In performing this assessment, we consider whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. In making this determination, under the applicable financial accounting standards, we are allowed to consider the scheduled reversal of deferred tax liabilities, projected future taxable income and the effects of tax planning strategies. Our estimates of future taxable income include, among other items, our estimates of future income tax deductions related to the exercise of stock options. In the event that actual results differ from our estimates, we adjust our estimates in future periods and we may need to establish a valuation allowance, which could materially impact our financial position and results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">All tax effects associated with intercompany transfers of assets within our consolidated group, both current and deferred, are recorded as a prepaid tax or deferred charge and recognized through our consolidated statements of income when the asset transferred is sold to a third-party or otherwise recovered through amortization of the asset's remaining economic life.&#160;If the asset transferred becomes impaired, for example through the obsolescence of inventory or the discontinuation of a research program, we will expense any remaining deferred charge or prepaid tax. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, total deferred charges and prepaid taxes were </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$989.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. For additional information related to the new accounting standard on tax effects associated with intercompany transfers of assets within our consolidated group please read Note 1, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies: New Accounting Pronouncements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.</font></div></div></div><br><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">78</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We account for uncertain tax positions using a &#8220;more-likely-than-not&#8221; threshold for recognizing and resolving uncertain tax positions. We evaluate uncertain tax positions on a quarterly basis and consider various factors that include, but are not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, information obtained during in process audit activities and changes in facts or circumstances related to a tax position. We adjust the level of the liability to reflect any subsequent changes in the relevant facts surrounding the uncertain positions. Our liabilities for uncertain tax positions can be relieved only if the contingency becomes legally extinguished, through either payment to the taxing authority or the expiration of the statute of limitations, the recognition of the benefits associated with the position meet the &#8220;more-likely-than-not&#8221; threshold or the liability becomes effectively settled through the examination process. We consider matters to be effectively settled once the taxing authority has completed all of its required or expected examination procedures, including all appeals and administrative reviews, we have no plans to appeal or litigate any aspect of the tax position, and we believe that it is highly unlikely that the taxing authority would examine or re-examine the related tax position. We also accrue for potential interest and penalties related to unrecognized tax benefits in income tax expense.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We earn a significant amount of our operating income outside the U.S.&#160;As a result, a portion of our cash, cash equivalents and marketable securities are held by foreign subsidiaries.&#160;We currently do not intend or foresee a need to repatriate these funds. We expect existing domestic cash, cash equivalents, marketable securities and cash flows from operations to continue to be sufficient to fund our domestic operating activities and cash commitments for investing and financing activities for the foreseeable future.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our non-U.S. subsidiaries&#8217; undistributed foreign earnings included in consolidated retained earnings and other basis differences aggregated to approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$7.6 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.&#160;All undistributed foreign earnings of non-U.S.&#160;subsidiaries, exclusive of earnings that would result in little or no net income tax expense or which were previously taxed under current U.S.&#160;tax law, are reinvested indefinitely in operations outside the U.S.&#160;This determination is made on a jurisdiction-by-jurisdiction basis and takes into the account the liquidity requirements in both the U.S. and within our foreign subsidiaries.&#160; </font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">If we decide to repatriate funds in the future to execute our growth initiatives or to fund any other liquidity needs, the resulting tax consequences would negatively impact our results of operations through a higher effective tax rate and dilution of our earnings.&#160;The residual U.S. tax liability, if cumulative amounts were repatriated, would be between </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.8 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.3 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div><a name="s4A849CDF3BCD16C8F52620170F240DF0"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">New Accounting Standards</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For a discussion of new accounting standards please read Note&#160;1, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Principles</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.</font></div><div><a name="sCC38D2DD8152CA3D1F0820170F470F15"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;7A.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Quantitative and Qualitative Disclosures About Market Risk</font></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Market Risk</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are subject to certain risks which may affect our results of operations, cash flows and fair values of assets and liabilities, including volatility in foreign currency exchange rates, interest rate movements, pricing pressures worldwide and weak economic conditions in the foreign markets in which we operate. We manage the impact of foreign currency exchange rates and interest rates through various financial instruments, including derivative instruments such as foreign currency forward contracts, interest rate lock contracts and interest rate swap contracts. We do not enter into financial instruments for trading or speculative purposes. The counter-parties to these contracts are major financial institutions and there is no significant concentration of exposure with any one counter-party.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Foreign Currency Exchange Risk</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our results of operations are subject to foreign currency exchange rate fluctuations due to the global nature of our operations. We have operations or maintain distribution relationships in the U.S., Europe, Canada, Asia, Central and South America. In addition, we recognize our share of pre-tax co-promotion profits on RITUXAN in Canada. As a result, our financial position, results of operations and cash flows can be affected by market fluctuations in foreign exchange rates, primarily with respect to the Euro, British pound sterling, Canadian dollar, Swiss franc, Danish krone and Japanese yen.</font></div></div></div><br><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">79</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">While the financial results of our global activities are reported in U.S. dollars, the functional currency for most of our foreign subsidiaries is their respective local currency. Fluctuations in the foreign currency exchange rates of the countries in which we do business will affect our operating results, often in ways that are difficult to predict. In particular, as the U.S. dollar strengthens versus other currencies, the value of non-U.S. revenue will decline when reported in U.S. dollars. The impact to net income as a result of a strengthening U.S. dollar will be partially mitigated by the value of non-U.S. expense which will also decline when reported in U.S. dollars. As the U.S. dollar weakens versus other currencies, the value of non-U.S. revenue and expenses will increase when reported in U.S. dollars.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have established revenue and operating expense hedging and balance sheet risk management programs to protect against volatility of future foreign currency cash flows and changes in fair value caused by volatility in foreign exchange rates.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2016 the U.K. voted in a referendum to voluntarily depart from the E.U., known as Brexit. The macroeconomic impact on our results of operations from this vote remains unknown. To date, the foreign exchange impact has been negligible since we hedged the balance sheet foreign currency exchange risk.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Revenue and Operating Expense Hedging Program</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our foreign currency hedging program is designed to mitigate, over time, a portion of the impact resulting from volatility in exchange rate changes on revenues and operating expenses. We use foreign currency forward contracts to manage foreign currency risk, with the majority of our forward contracts used to hedge certain forecasted revenue and operating expense transactions denominated in foreign currencies in the next </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18 months</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We do not engage in currency speculation. For a more detailed disclosure of our revenue and operating expense hedging program, please read Note 9, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Derivative Instruments</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our ability to mitigate the impact of exchange rate changes on revenues and net income diminishes as significant exchange rate fluctuations are sustained over extended periods of time. In particular, devaluation or significant deterioration of foreign currency exchange rates are difficult to mitigate and likely to negatively impact earnings. The cash flows from these contracts are reported as operating activities in our consolidated statements of cash flows.</font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Balance Sheet Risk Management Hedging Program</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also use forward contracts to mitigate the foreign currency exposure related to certain balance sheet items. The primary objective of our balance sheet risk management program is to mitigate the exposure of foreign currency denominated net monetary assets of foreign affiliates. In these instances, we principally utilize currency forward contracts. We have not elected hedge accounting for the balance sheet related items. The cash flows from these contracts are reported as operating activities in our consolidated statement of cash flows.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following quantitative information includes the impact of currency movements on forward contracts used in our revenue, operating expense and balance sheet hedging programs. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, a hypothetical adverse 10% movement in foreign currency rates compared to the U.S. dollar across all maturities would result in a hypothetical decrease in the fair value of forward contracts of approximately $172.0 million and $185.0 million, respectively. The estimated fair value change was determined by measuring the impact of the hypothetical exchange rate movement on outstanding forward contracts. Our use of this methodology to quantify the market risk of such instruments is subject to assumptions and the actual impact could be significantly different. The quantitative information about market risk is limited because it does not take into account all foreign currency operating transactions. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Interest Rate Risk</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our investment portfolio includes cash equivalents and short-term investments. The fair value of our marketable securities is subject to change as a result of potential changes in market interest rates. The potential change in fair value for interest rate sensitive instruments has been assessed on a hypothetical 100 basis point adverse movement across all maturities. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we estimate that such hypothetical 100 basis point adverse movement would result in a hypothetical loss in fair value of approximately $50.0 million and $43.0 million, respectively, to our interest rate sensitive instruments. The fair values of our investments were determined using third-party pricing services or other market observable data.</font></div></div></div><br><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">80</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">To achieve a desired mix of fixed and floating interest rate debt, we entered into interest rate swap contracts during 2015 for certain of our fixed-rate debt. These derivative contracts effectively converted a fixed-rate interest coupon to a floating-rate LIBOR-based coupon over the life of the respective note. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, a 100 basis-point adverse movement (increase in LIBOR) would increase annual interest expense by approximately $6.8&#160;million in each case. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Pricing Pressure</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Governments in some international markets in which we operate have implemented measures aimed at reducing healthcare costs to constrain the overall level of government expenditures. These implemented measures vary by country and include, among other things, mandatory rebates and discounts, prospective and possible retroactive price reductions and suspensions on price increases of pharmaceuticals. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, certain countries set prices by reference to the prices in other countries where our products are marketed. Thus, our inability to secure favorable prices in a particular country may impair our ability to obtain acceptable prices in existing and potential new markets, which may limit market growth. The continued implementation of pricing actions throughout Europe may also lead to higher levels of parallel trade.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the U.S., federal and state legislatures, health agencies and third-party payors continue to focus on containing the cost of health care. Legislative and regulatory proposals, enactments to reform health care insurance programs and increasing pressure from social sources could significantly influence the manner in which our products are prescribed and purchased. It is possible that additional federal health care reform measures will be adopted in the future, which could result in increased pricing pressure and reduced reimbursement for our products and otherwise have an adverse impact on our financial position or results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">There is also significant economic pressure on state budgets that may result in states increasingly seeking to achieve budget savings through mechanisms that limit coverage or payment for our drugs. Managed care organizations are also continuing to seek price discounts and, in some cases, to impose restrictions on the coverage of particular drugs.</font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Credit Risk</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are subject to credit risk from our accounts receivable related to our product sales. The majority of our accounts receivable arise from product sales in the U.S.&#160;and Europe with concentrations of credit risk limited due to the wide variety of customers and markets using our products, as well as their dispersion across many different geographic areas. Our accounts receivable are primarily due from wholesale distributors, public hospitals, specialty pharmacies and other government entities. We monitor the financial performance and creditworthiness of our customers so that we can properly assess and respond to changes in their credit profile. We operate in certain countries where weakness in economic conditions can result in extended collection periods. We continue to monitor these conditions, including the volatility associated with international economies and the relevant financial markets, and assess their possible impact on our business. To date, we have not experienced any significant losses with respect to the collection of our accounts receivable. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Credit and economic conditions in the E.U. continue to remain uncertain, which has, from time to time, led to long collection periods for our accounts receivable and greater collection risk in certain countries. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We believe that our allowance for doubtful accounts was adequate as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. However, if significant changes occur in the availability of government funding or the reimbursement practices of these or other governments, we may not be able to collect on amounts due to us from customers in such countries and our results of operations could be adversely affected.</font></div><div><a name="sCA88A35D47BB55E1ECEC20170F7AC1AC"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;8.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Financial Statements and Supplementary Data</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The information required by this Item&#160;8 is contained on pages F-1 through F-75 of this report and is incorporated herein by reference.</font></div><div><a name="sA3D5CDED4B09A0FC8BBA20170FABF364"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;9.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">None.</font></div></div></div><br><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">81</font></div></div><hr style="page-break-after:always"><div><a name="sDAC09AD994C658BE6C7720170FD43091"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;9A.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Controls and Procedures</font></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Disclosure Controls and Procedures and Internal Control over Financial Reporting</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Controls and Procedures</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules&#160;13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended), as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Based upon that evaluation, our principal executive officer and principal financial officer concluded that, as of the end of the period covered by this report, our disclosure controls and procedures are effective in ensuring that (a)&#160;the information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and (b)&#160;such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, our management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Changes in Internal Control over Financial Reporting</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">There were no changes in our internal control over financial reporting during the quarter ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Management&#8217;s Annual Report on Internal Control over Financial Reporting</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our management is responsible for establishing and maintaining adequate internal control over our financial reporting. Internal control over financial reporting is defined in Rules&#160;13a-15(f) and 15d-15(f) under the Securities Exchange Act as a process designed by, or under the supervision of, a company&#8217;s principal executive and principal financial officers and effected by a company&#8217;s board of directors, management and other personnel to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with </font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">U.S.&#160;GAAP. Our internal control over financial reporting includes those policies and procedures that:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect our transactions and dispositions of our assets;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with U.S.&#160;GAAP, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors;&#160;and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on our financial statements.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our management assessed the effectiveness of our internal control over financial reporting as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in its 2013 Internal Control&#160;&#8212; Integrated Framework.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based on our assessment, our management has concluded that, as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our internal control over financial reporting is effective based on those criteria.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The effectiveness of our internal control over financial reporting as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;has been audited by PricewaterhouseCoopers LLP, an independent registered public accounting firm, as stated in their attestation report, which is included herein.</font></div><div><a name="sEBCFB87E1B7347D332B12017100385C2"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;9B.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Other Information</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">None.</font></div></div></div><br><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">82</font></div></div><hr style="page-break-after:always"><div><a name="s53D5B6A6A920BFE6A4B820171021D52E"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">PART&#160;III</font></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div><a name="sFE0120AC1BF11EBFB1D720171041948D"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;10.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Directors, Executive Officers and Corporate Governance</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The information concerning our executive officers is set forth under the heading </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8220;Our Executive Officers&#8221;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in Part&#160;I of this report. The text of our code of business conduct, which includes the code of ethics that applies to our principal executive officer, principal financial officer, principal accounting officer or controller, and persons performing similar functions, is posted on our website, www.biogen.com, under the &#8220;Corporate Governance&#8221; subsection of the &#8220;About Us&#8221; section of the site. We intend to make all required disclosures regarding any amendments to, or waivers from, provisions of our code of business conduct at the same location of our website. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The response to the remainder of this item is incorporated by reference from the discussion responsive thereto in the sections entitled &#8220;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Proposal&#160;1&#160;- Election of Directors,&#8221; &#8220;Corporate Governance at Biogen,&#8221; &#8220;Stock Ownership&#160;- Section&#160;16(a) Beneficial Ownership Reporting Compliance</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8221; and &#8220;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Miscellaneous&#160;- Stockholder Proposals</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8221; contained in the proxy statement for our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;annual meeting of stockholders.</font></div><div><a name="s6BC898E23C7A3A6E571520171075F6CE"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;11.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Executive Compensation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The response to this item is incorporated by reference from the discussion responsive thereto in the sections entitled &#8220;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Executive Compensation Matters</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8221; and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8220;Corporate Governance at Biogen&#8221;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;contained in the proxy statement for our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;annual meeting of stockholders.</font></div><div><a name="sD9DA93C4FDFEA74630AB201710A8E79C"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;12.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The response to this item is incorporated by reference from the discussion responsive thereto in the sections entitled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8220;Stock Ownership&#8221;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8220;Equity Compensation Plan Information&#8221;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;contained in the proxy statement for our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;annual meeting of stockholders.</font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div><a name="s29759CFD2E1B09023D91201710C74D49"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;13.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Certain Relationships and Related Transactions, and Director Independence</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The response to this item is incorporated by reference from the discussion responsive thereto in the sections entitled &#8220;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Certain Relationships and Related Person Transactions</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8221; and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8220;Corporate Governance at Biogen</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8221; contained in the proxy statement for our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;annual meeting of stockholders.</font></div><div><a name="sBFB944790805D270C329201710F0DD8A"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;14.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Principal Accounting Fees and Services</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The response to this item is incorporated by reference from the discussion responsive thereto in the section entitled &#8220;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Proposal&#160;2&#160;&#8212; Ratification of the Selection of our Independent Registered Public Accounting Firm</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8221; contained in the proxy statement for our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;annual meeting of stockholders.</font></div></div></div><br><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">83</font></div></div><hr style="page-break-after:always"><div><a name="sFC458658BCC73B87EBF3201711199A3B"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">PART&#160;IV</font></div><div><a name="sC102002B827A94949B9E2017113C4204"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;15. &#160;&#160;&#160;&#160;Exhibits and Financial Statement Schedules</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">a. &#160;&#160;&#160;&#160;(1)&#160;Consolidated Financial Statements:</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following financial statements are filed as part of this report:</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:50%;"></td><td style="width:37%;"></td><td style="width:13%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Financial Statements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Page&#160;Number</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Consolidated Statements of Income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F-2</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Consolidated Statements of Comprehensive Income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F-3</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Consolidated Balance Sheets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F-4</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Consolidated Statements of Cash Flows</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F-5</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Consolidated Statements of Equity</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F-6</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes to Consolidated Financial Statements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F-9</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Report of Independent Registered Public Accounting Firm</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F-75</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Certain totals may not sum due to rounding.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;(2) Financial Statement Schedules</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Schedules are omitted because they are not applicable, or are not required, or because the information is included in the consolidated financial statements and notes thereto.</font></div><div style="line-height:120%;padding-top:12px;text-indent:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">(3) Exhibits</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The exhibits listed on the Exhibit&#160;Index beginning on page&#160;A-1, which is incorporated herein by reference, are filed or furnished as part of this report or are incorporated into this report by reference.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">84</font></div></div><hr style="page-break-after:always"><div><a name="s2BF353079D72E44786832017116E7926"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">SIGNATURES</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></div><div style="line-height:120%;font-size:18pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:18pt;">&#160;</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:316px;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="2"></td></tr><tr><td style="width:50px;"></td><td style="width:265px;"></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">BIOGEN INC.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">S</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/&#160;&#160;&#160;&#160;M</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">ICHEL</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;V</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">OUNATSOS</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Michel Vounatsos</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Chief Executive Officer</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Date: </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">February&#160;2, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">85</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:42%;"></td><td style="width:3%;"></td><td style="width:34%;"></td><td style="width:3%;"></td><td style="width:18%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Name</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Capacity</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Date</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">S</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/&#160;&#160;&#160;&#160;M</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">ICHEL</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;V</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">OUNATSOS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Director&#160;and&#160;Chief&#160;Executive&#160;Officer (principal&#160;executive&#160;officer)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">February&#160;2, 2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Michel Vounatsos</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">S</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/&#160;&#160;&#160;&#160;P</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">AUL</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;J. C</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">LANCY</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Executive&#160;Vice&#160;President,&#160;Finance&#160;and Chief Financial Officer (principal financial officer)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">February&#160;2, 2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Paul J. Clancy</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">S</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/&#160;&#160;&#160;&#160;G</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">REGORY</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;F. C</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">OVINO</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Vice President, Finance, Chief Accounting Officer (principal accounting officer)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">February&#160;2, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gregory F. Covino</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">S</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/&#160;&#160;&#160;&#160;S</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">TELIOS</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;P</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">APADOPOULOS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Director&#160;and&#160;Chairman&#160;of&#160;the&#160;Board&#160;of Directors</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">February&#160;2, 2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Stelios Papadopoulos</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">S</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/&#160;&#160;&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">LEXANDER </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">J</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">D</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">ENNER</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">February&#160;2, 2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;Alexander J. Denner</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">S</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/&#160;&#160;&#160;&#160;C</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">AROLINE</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;D. D</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">ORSA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">February&#160;2, 2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Caroline D. Dorsa</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">S</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/&#160;&#160;&#160;&#160;N</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">ANCY</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;L. L</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">EAMING</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">February&#160;2, 2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Nancy L. Leaming</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">S</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/&#160;&#160;&#160;&#160;R</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">ICHARD </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">C</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">M</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">ULLIGAN</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">February&#160;2, 2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Richard C. Mulligan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">S</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/&#160;&#160;&#160;&#160;R</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">OBERT</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;W. P</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">ANGIA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">February&#160;2, 2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Robert W. Pangia</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">S</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/&#160;&#160;&#160;&#160;B</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">RIAN</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;S. P</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">OSNER</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">February&#160;2, 2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Brian S. Posner</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">S</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/&#160;&#160;&#160;&#160;E</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">RIC</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;K. R</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">OWINSKY</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">February&#160;2, 2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Eric K. Rowinsky</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">S</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/&#160;&#160;&#160;&#160;L</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">YNN</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;S</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">CHENK</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">February&#160;2, 2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Lynn Schenk</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">S</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/&#160;&#160;&#160;&#160;S</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">TEPHEN</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;A. S</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">HERWIN</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">February&#160;2, 2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Stephen A. Sherwin</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">86</font></div></div><hr style="page-break-after:always"><div><a name="s1678D8538B3524784B01201711953BED"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:50%;"></td><td style="width:37%;"></td><td style="width:13%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Page&#160;Number</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Consolidated Statements of Income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F-2</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Consolidated Statements of Comprehensive Income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F-3</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Consolidated Balance Sheets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F-4</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Consolidated Statements of Cash Flows</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F-5</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Consolidated Statements of Equity</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F-6</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes to Consolidated Financial Statements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F-9</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Report of Independent Registered Public Accounting Firm</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F-75</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:300px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 1</font></div></div><hr style="page-break-after:always"><div><a name="s85EFC898A1DF3C5E8C4F20166D62A773"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONSOLIDATED STATEMENTS OF INCOME</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">(In millions, except per share amounts)</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:56%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">9,817.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9,188.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8,203.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,314.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,339.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,195.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">316.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">236.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">304.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">11,448.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10,763.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9,703.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cost and expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cost of sales, excluding amortization of acquired intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,478.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,240.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,171.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,973.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,012.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,893.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,947.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,113.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,232.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amortization of acquired intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">385.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">382.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">489.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restructuring charges</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">33.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">93.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Loss (gain) on fair value remeasurement of contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">14.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(38.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Collaboration profit (loss) sharing</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">TECFIDERA litigation settlement and license charges</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">454.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total cost and expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6,298.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,872.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,747.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gain on sale of rights</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income from operations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5,150.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,891.0</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,972.4</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense), net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(217.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(123.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(25.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income before income tax expense and equity in loss of investee, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4,933.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,767.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,946.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,237.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,161.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">989.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Equity in loss of investee, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,695.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,593.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,941.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net (loss) income attributable to noncontrolling interests, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(7.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">46.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,702.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,547.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,934.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income per share:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">16.96</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15.38</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12.42</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">16.93</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15.34</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12.37</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted-average shares used in calculating:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share attributable to Biogen Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">218.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">230.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">236.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">218.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">231.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">237.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:120px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">See accompanying notes to these consolidated financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 2</font></div></div><hr style="page-break-after:always"><div><a name="s694BD8453171193BA39720166D717F6F"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">(In millions)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:56%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,702.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,547.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,934.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unrealized gains (losses) on securities available for sale:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unrealized gains (losses) recognized during the period, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(10.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Less: reclassification adjustment for (gains) losses included in net income, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(6.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unrealized gains (losses) on securities available for sale, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(10.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(6.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unrealized gains (losses) on cash flow hedges:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unrealized gains (losses) recognized during the period, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">51.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">110.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">101.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Less: reclassification adjustment for (gains) losses included in net income, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(4.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(172.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(6.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unrealized gains (losses) on cash flow hedges, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">47.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(61.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">95.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unrealized gains (losses) on pension benefit obligation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(6.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(12.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Currency translation adjustment</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(138.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(96.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(109.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other comprehensive income (loss), net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(95.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(164.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(31.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Comprehensive income attributable to Biogen Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,606.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,382.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,903.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Comprehensive income (loss) attributable to noncontrolling interests, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(7.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">46.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Comprehensive income</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,599.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,428.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,909.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">See accompanying notes to these consolidated financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 3</font></div></div><hr style="page-break-after:always"><div><a name="sA1259B69170D00A0145E20166D81202C"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONSOLIDATED BALANCE SHEETS</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">(In millions, except per share amounts)</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:67%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td colspan="8" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">ASSETS</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,326.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,308.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,568.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,120.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accounts receivable, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,441.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,227.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due from anti-CD20 therapeutic programs, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">300.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">314.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,001.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">893.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,093.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">836.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total current assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">8,732.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,700.3</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,829.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,760.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Property, plant and equipment, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,501.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,187.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,808.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,085.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,669.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,663.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,335.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,107.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">22,876.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">19,504.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td colspan="8" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">LIABILITIES AND EQUITY</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current portion of notes payable and other financing arrangements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Taxes payable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">231.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">208.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accounts payable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">279.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">267.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,903.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,096.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,419.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,577.7</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes payable and other financing arrangements</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6,512.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,521.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferred tax liability</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">93.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">124.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">722.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">905.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10,748.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10,129.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Commitments and contingencies</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Equity:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Inc. shareholders&#8217; equity</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Preferred stock, par value $0.001 per share</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Common stock, par value $0.0005 per share</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Additional paid-in capital</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accumulated other comprehensive loss</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(319.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(224.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Retained earnings</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">15,071.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12,208.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Treasury stock, at cost; 22.6 million shares, respectively</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(2,611.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2,611.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total Biogen Inc. shareholders&#8217; equity</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">12,140.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9,372.8</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Noncontrolling interests</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(11.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total equity</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">12,128.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9,374.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total liabilities and equity</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">22,876.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">19,504.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">See accompanying notes to these consolidated financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 4</font></div></div><hr style="page-break-after:always"><div><a name="sE93A51BD0E007536A2C620166D900974"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONSOLIDATED STATEMENTS OF CASH FLOWS</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">(In millions)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:62%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash flows from operating activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,695.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,593.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,941.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments to reconcile net income to net cash flows from operating activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">682.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">600.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">688.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">154.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">161.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">155.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferred income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(175.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(145.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(308.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">91.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">82.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(50.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Changes in operating assets and liabilities, net:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accounts receivable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(241.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">29.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(512.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due from anti-CD20 therapeutic programs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">13.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(31.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(30.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(165.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(174.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(185.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">59.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(127.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(108.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">570.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">74.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">244.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax assets and liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(232.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(429.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">40.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">69.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">83.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">68.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net cash flows provided by operating activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4,522.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,716.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,942.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash flows from investing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Proceeds from sales and maturities of marketable securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7,378.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,063.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,718.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchases of marketable securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(7,913.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(6,864.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3,583.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration related to Fumapharm AG acquisition</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1,200.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(850.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(375.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquisitions of businesses, net of cash acquired</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(198.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchases of property, plant and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(616.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(643.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(287.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquisitions of intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(111.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(15.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(28.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(22.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(44.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net cash flows used in investing activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(2,484.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4,553.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1,543.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash flows from financing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchases of treasury stock</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1,000.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(5,000.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(886.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Proceeds from issuance of stock for share-based compensation arrangements</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">43.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">54.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">54.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Proceeds from borrowings</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,930.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Repayments of borrowings</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(2.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Excess tax benefit from share-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">12.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">78.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">96.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration payments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(38.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(13.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(20.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(2.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(61.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net cash flows provided by (used in) financing activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(987.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">986.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(755.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net increase in cash and cash equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,049.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">148.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">643.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effect of exchange rate changes on cash and cash equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(31.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(45.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(40.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash and cash equivalents, beginning of the year</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,308.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,204.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">602.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash and cash equivalents, end of the year</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,326.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,308.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,204.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">See accompanying notes to these consolidated financial statements.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 5</font></div></div><hr style="page-break-after:always"><div><a name="s45201670F7FF60DDDB4D20166DB01279"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONSOLIDATED STATEMENTS OF EQUITY</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">(In millions)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="45"></td></tr><tr><td style="width:11%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Preferred stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Additional</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">paid-in</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">capital</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">comprehensive</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Retained</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">earnings</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Treasury stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Biogen Inc.</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">shareholders&#8217;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">equity</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Noncontrolling</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">interests</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">equity</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Balance, December 31, 2015</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">241.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(224.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">12,208.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(22.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(2,611.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">9,372.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">9,374.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,702.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,702.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(7.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,695.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss), net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(95.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(95.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(95.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquisition of noncontrolling interests</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(0.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(0.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capital contribution to noncontrolling interests</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deconsolidation of noncontrolling interests</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(7.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(7.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Repurchase of common stock pursuant to the 2016 Share Repurchase Program, at cost</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(3.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1,000.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1,000.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1,000.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Retirement of common stock pursuant to the 2016 Share Repurchase Program, at cost</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(3.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(164.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(835.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,000.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Issuance of common stock under stock option and stock purchase plans</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">43.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">43.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">43.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Issuance of common stock under stock award plan</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(47.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(4.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(52.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(52.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Compensation expense related to share-based payments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">169.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">169.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">169.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Tax benefit from share-based payments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(0.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(0.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(0.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Balance, December 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">238.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(319.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">15,071.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(22.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(2,611.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">12,140.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(11.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">12,128.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">See accompanying notes to these consolidated financial statements.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 6</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONSOLIDATED STATEMENTS OF EQUITY - (Continued)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">(In millions)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="45"></td></tr><tr><td style="width:11%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Preferred stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Additional</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">paid-in</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">capital</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">comprehensive</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Retained</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">earnings</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Treasury stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Biogen Inc.</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">shareholders&#8217;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">equity</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Noncontrolling</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">interests</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">equity</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Balance, December 31, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">257.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,196.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(59.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9,283.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(22.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2,611.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10,809.0</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.0</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10,814.0</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,547.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,547.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">46.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,593.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss), net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(164.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(164.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(164.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Distribution to noncontrolling interests</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(60.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(60.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquisition of noncontrolling interests</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Repurchase of common stock pursuant to the 2015 Share Repurchase Program, at cost</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(16.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(5,000.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(5,000.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(5,000.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Retirement of common stock pursuant to the 2015 Share Repurchase Program, at cost</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(16.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4,377.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(622.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,000.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Issuance of common stock under stock option and stock purchase plans</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">54.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">54.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">54.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Issuance of common stock under stock award plan</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(125.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(125.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(125.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Compensation expense related to share-based payments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">183.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">183.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">183.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Tax benefit from share-based payments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">69.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">69.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">69.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Balance, December 31, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">241.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(224.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12,208.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(22.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2,611.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9,372.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9,374.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">See accompanying notes to these consolidated financial statements.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 7</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONSOLIDATED STATEMENTS OF EQUITY - (Continued)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">(In millions)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="45"></td></tr><tr><td style="width:11%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Preferred stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Additional</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">paid-in</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">capital</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">comprehensive</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Retained</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">earnings</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Treasury stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Biogen Inc.</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">shareholders&#8217;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">equity</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Noncontrolling</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">interests</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">equity</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Balance, December 31, 2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">256.0</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,023.6</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(27.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,349.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(19.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1,724.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8,620.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.6</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8,620.8</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,934.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,934.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,941.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss), net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(31.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(31.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(31.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Distribution to noncontrolling interests</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(9.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(9.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other transactions with noncontrolling interests</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Repurchase of common stock for Treasury pursuant to the 2011 Share Repurchase Program, at cost</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(886.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(886.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(886.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Issuance of common stock under stock option and stock purchase plans</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">54.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">54.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">54.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Issuance of common stock under stock award plan</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(140.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(140.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(140.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Compensation expense related to share-based payments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">165.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">165.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">165.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Tax benefit from share-based payments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">93.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">93.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">93.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Balance, December 31, 2014</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">257.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,196.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(59.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9,283.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(22.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2,611.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10,809.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10,814.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">See accompanying notes to these consolidated financial statements.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 8</font></div></div><hr style="page-break-after:always"><div><a name="sECE2A069CEC8D9B9B281201712C1392F"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div><a name="s398F499846C8A6636ED720166DFE937E"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">1. &#160;&#160;&#160;&#160;Summary of Significant Accounting Policies</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Business Overview</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen is a global biopharmaceutical company focused on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). We also have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other potential anti-CD20 therapies under a collaboration agreement with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group (Roche Group).</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities, particularly within areas of our scientific, manufacturing and technical capabilities. Our research is currently focused on additional improvements in the treatment of MS, solving some of the most challenging and complex diseases, including Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis (ALS), and employing innovative technologies to discover potential treatments for rare and genetic disorders, including new ways of treating diseases through gene therapy.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our innovative drug development and commercialization activities are complemented by our biosimilar therapies that expand access to medicines and reduce the cost burden for healthcare systems. We are leveraging our manufacturing capabilities and know-how to develop, manufacture and market biosimilars through Samsung Bioepis, our joint venture with Samsung BioLogics Co. Ltd. (Samsung Biologics). Under this agreement, we are currently manufacturing and commercializing BENEPALI, an etanercept biosimilar referencing ENBREL, and FLIXABI, an infliximab biosimilar referencing REMICADE, in the European Union (E.U.).</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Hemophilia Spin-Off</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2016 we announced our intention to spin off our hemophilia business, Bioverativ Inc. (Bioverativ), as an independent, publicly traded company. Bioverativ, will focus on the discovery, development and commercialization of therapies for treatment of hemophilia and other blood disorders, including ELOCTATE for the treatment of hemophilia A and ALPROLIX for the treatment of hemophilia B. Bioverativ will also assume all of our rights and obligations under our collaboration agreement with Swedish Orphan Biovitrum AB (Sobi) and our collaboration and license agreement with Sangamo Biosciences Inc. (Sangamo).</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On February 1, 2017, we completed the distribution of all the then outstanding shares of common stock of Bioverativ to Biogen stockholders, who received one share of Bioverativ common stock for every two shares of Biogen common stock. As a result of the distribution, Bioverativ is now an independent public company whose shares of common stock are trading under the symbol "BIVV" on the Nasdaq Global Select Market.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The financial results of Bioverativ are reflected in our consolidated results of operations and financial position included in these audited consolidated financial statements for the periods presented in this Form 10-K. The financial results of Bioverativ will be excluded from our consolidated results of operations and financial position commencing February 1, 2017. For additional information regarding the separation of Bioverativ, please read Note 26, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Subsequent Events</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Consolidation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of the economics, we record net income (loss) attributable to noncontrolling interests in our consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In determining whether we are the primary beneficiary of an entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 9</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The preparation of our consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an on-going basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates under different assumptions or conditions.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Revenue Recognition</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognize revenue when all of the following criteria are met: persuasive evidence of an arrangement exists; delivery has occurred or services have been rendered; our price to the customer is fixed or determinable; and collectability is reasonably assured.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Product Revenues</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from product sales are recognized when title and risk of loss have passed to the customer, which is typically upon delivery. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Reserves for Discounts and Allowances</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from product sales are recorded net of reserves established for applicable discounts and allowances, including those associated with the implementation of pricing actions in certain of the international markets in which we operate. These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer). Our estimates take into consideration our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Actual amounts may ultimately differ from our estimates. If actual results vary, we adjust these estimates, which could have an effect on earnings in the period of adjustment. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenue reserves are categorized as follows: discounts, contractual adjustments and returns.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Discounts include trade term discounts and wholesaler incentives. Trade term discounts and wholesaler incentives primarily relate to estimated obligations for credits to be granted to wholesalers for remitting payment on their purchases within established incentive periods and credits to be granted to wholesalers for compliance with various contractually-defined inventory management practices, respectively. We determine these reserves based on our historical experience, including the timing of customer payments.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contractual adjustments primarily relate to Medicaid and managed care rebates, co-payment (copay) assistance, Veterans Administration (VA) and Public Health Service (PHS) discounts, specialty pharmacy program fees and other governmental rebates or applicable allowances.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Medicaid rebates relate to our estimated obligations to states under established reimbursement arrangements. Rebate accruals are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a liability which is included in other current liabilities. Our liability for Medicaid rebates consists of estimates for claims that a state will make for the current quarter, claims for prior quarters that have been estimated for which an invoice has not been received, invoices received for claims from the prior quarters that have not been paid, and an estimate of potential claims that will be made for inventory that exists in the distribution channel at period end.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Governmental rebates or chargebacks, including VA and PHS discounts, represent our estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices we charge to wholesalers which provide those products. The wholesaler charges us for the </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 10</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-left:30px;padding-top:12px;text-align:left;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">difference between what the wholesaler pays for the products and the ultimate selling price to the qualified healthcare providers. Rebate and chargeback reserves are established in the same period as the related revenue is recognized, resulting in a reduction in product revenue and accounts receivable. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider from the wholesaler, and we generally issue credits for such amounts within a few weeks of the wholesaler notifying us about the resale. Our reserves for VA, PHS and chargebacks consist of amounts that we expect to issue for inventory that exists at the wholesalers that we expect will be sold to qualified healthcare providers and chargebacks that wholesalers have claimed for which we have not issued a credit.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Managed care rebates represent our estimated obligations to third parties, primarily pharmacy benefit managers. Rebate accruals are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a liability which is included in accrued expenses and other current liabilities. These rebates result from performance-based goals, formulary position and price increase limit allowances (price protection). The calculation of the accrual for these rebates is based on an estimate of the customer&#8217;s buying patterns and the resulting applicable contractual rebate rate(s) to be earned over a contractual period.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Copay assistance represents financial assistance to qualified patients, assisting them with prescription drug co-payments required by insurance. The calculation of the accrual for copay is based on an estimate of claims and the cost per claim that we expect to receive associated with inventory that exists in the distribution channel at period end.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other governmental rebates or applicable allowances primarily relate to mandatory rebates and discounts in international markets where government-sponsored healthcare systems are the primary payors for healthcare.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product returns are established for returns expected to be made by wholesalers and are recorded in the period the related revenue is recognized, resulting in a reduction to product sales. In accordance with contractual terms, wholesalers are permitted to return product for reasons such as damaged or expired product. The majority of wholesaler returns are due to product expiration. Expired product return reserves are estimated through a comparison of historical return data to their related sales on a production lot basis. Historical rates of return are determined for each product and are adjusted for known or expected changes in the marketplace specific to each product.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition to the discounts, rebates and product returns described above and classified as a reduction of revenue, we also maintain certain customer service contracts with distributors and other customers in the distribution channel that provide us with inventory management, data and distribution services, which are generally reflected as a reduction of revenue. To the extent we can demonstrate a separable benefit and fair value for these services, we classify these payments in selling, general and administrative expenses.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Revenues from Anti-CD20 Therapeutic Programs</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs consist of:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(i)&#160;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our share of pre-tax profits and losses in the U.S. for RITUXAN and GAZYVA; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(ii)&#160; </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">reimbursement of our selling and development expenses in the U.S. for RITUXAN; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(iii)&#160;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">revenues on sales in the rest of world for RITUXAN, which consist of our share of pre-tax co-promotion profits on RITUXAN in Canada and royalty revenue on RITUXAN sales outside the U.S. and Canada by the Roche Group and its sublicensees. </font></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pre-tax co-promotion profits on RITUXAN and GAZYVA are calculated and paid to us by Genentech in the U.S. Pre-tax co-promotion profits on RITUXAN are calculated and paid to us by the Roche Group in Canada. Pre-tax co-promotion profits consist of U.S. and Canadian net sales to third-party customers less applicable costs to manufacture, third-party royalty expenses, distribution, selling and marketing expenses, and joint development expenses incurred by Genentech, the Roche Group and us. We record our share of the pre-tax co-promotion profits on RITUXAN in Canada and royalty revenues on RITUXAN sales outside the U.S. on a cash basis as we do not have the ability to estimate these profits or royalty revenue in the period incurred. Our share of the pre-tax profits on RITUXAN and GAZYVA in the U.S. includes estimates made by Genentech and those estimates are subject to change. Actual results may differ from our estimates. For additional information related to our collaboration with Genentech, please read Note&#160;19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 11</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Royalty Revenues</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We receive royalty revenues on sales by our licensees of other products covered under patents that we own. We do not have future performance obligations under these license arrangements. We record these revenues based on estimates of the sales that occurred during the relevant period as a component of other revenues. The relevant period estimates of sales are based on interim data provided by licensees and analysis of historical royalties that have been paid to us, adjusted for any changes in facts and circumstances, as appropriate. Differences between actual and estimated royalty revenues are adjusted for in the period in which they become known, typically the following quarter. Historically, adjustments have not been material when compared to actual amounts paid by licensees. If we are unable to reasonably estimate royalty revenue or do not have access to the information, then we record royalty revenues on a cash basis. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Multiple-Element Revenue Arrangements</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We may enter into transactions that involve the sale of products and related services under multiple element arrangements.&#160;In accounting for these transactions, we assess the elements of the contract and whether each element has standalone value and allocate revenue to the various elements based on their estimated selling price as a component of total revenues.&#160;The selling price of a revenue generating element can be based on current selling prices offered by us or another party for current products or management&#8217;s best estimate of a selling price. Revenue allocated to an individual element is recognized when all other revenue recognition criteria are met for that element.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Collaborative and Other Relationships</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our development and commercialization arrangements with Sobi and AbbVie Inc. (AbbVie) represent collaborative arrangements as each party is an active participant and exposed to significant risks and rewards of the arrangements. Where we are the principal on sales transactions with third parties, we recognize revenue, cost of sales and operating expenses on a gross basis in their respective lines in our consolidated statements of income. Where we are not the principal on sales transactions with third parties, we record our share of the revenues, cost of sales and operating expenses on a net basis in collaborative and other relationships included in other revenue in our consolidated statements of income. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information related to our collaborations with Sobi and AbbVie, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Fair Value Measurements</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have certain financial assets and liabilities recorded at fair value which have been classified as Level&#160;1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Level&#160;1</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#8212; Fair values are determined utilizing quoted prices (unadjusted) in active markets for identical assets or liabilities that we have the ability to access;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Level&#160;2</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#8212; Fair values are determined by utilizing quoted prices for identical or similar assets and liabilities in active markets or other market observable inputs such as interest rates, yield curves and foreign currency spot rates;&#160;and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Level&#160;3</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#8212; Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The majority of our financial assets have been classified as Level&#160;2. Our financial assets (which include our cash equivalents, derivative contracts, marketable debt securities and plan assets for deferred compensation) have been initially valued at the transaction price and subsequently valued, at the end of each reporting period, utilizing third-party pricing services or other market observable data. The pricing services utilize industry standard valuation models, including both income and market-based approaches and observable market inputs to determine value. These observable market inputs include reportable trades, benchmark yields, credit spreads, broker/dealer quotes, bids, offers, current spot rates and other industry and economic events.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We validate the prices provided by our third-party pricing services by reviewing their pricing methods and matrices, obtaining market values from other pricing sources and analyzing pricing data in certain instances. After completing our validation procedures, we did not adjust or override any fair value measurements provided by our pricing services as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Other Assets and Liabilities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The carrying amounts reflected in the consolidated balance sheets for current accounts receivable, due from anti-CD20 therapeutic programs, other current assets, accounts payable and accrued expenses and other, approximate fair value due to their short-term maturities.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Cash and Cash Equivalents</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We consider only those investments which are highly liquid, readily convertible to cash and that mature within three months from date of purchase to be cash equivalents. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, cash equivalents were comprised of money market funds and commercial paper, overnight reverse repurchase agreements and other debt securities with maturities less than 90 days from the date of purchase.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accounts Receivable</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The majority of our accounts receivable arise from product sales and primarily represent amounts due from our wholesale distributors, public hospitals and other government entities. We monitor the financial performance and creditworthiness of our customers so that we can properly assess and respond to changes in their credit profile. We provide reserves against trade receivables for estimated losses that may result from a customer&#8217;s inability to pay. Amounts determined to be uncollectible are charged or written-off against the reserve. To date, our historical reserves and write-offs of accounts receivable have not been significant.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In countries where we have experienced a pattern of payments extending beyond our contractual payment term and we expect to collect receivables greater than one year from the time of sale, we have discounted our receivables and reduced related revenues over the period of time that we estimate those amounts will be paid using the country&#8217;s market-based borrowing rate for such period. The related receivables are classified at the time of sale as non-current assets. We accrete interest income on these receivables, which is recognized as a component of other income (expense), net in our consolidated statements of income.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Concentration of Credit Risk</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Financial instruments that potentially subject us to concentrations of credit risk include cash and cash equivalents, investments, derivatives and accounts receivable. We attempt to minimize the risks related to cash and cash equivalents and investments by investing in a broad and diverse range of financial instruments as previously defined by us. We have established guidelines related to credit ratings and maturities intended to safeguard principal balances and maintain liquidity. Our investment portfolio is maintained in accordance with our investment policy, which defines allowable investments, specifies credit quality standards and limits the credit exposure of any single issuer. We minimize credit risk resulting from derivative instruments by choosing only highly rated financial institutions as counterparties.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Concentrations of credit risk with respect to receivables, which are typically unsecured, are somewhat mitigated due to the wide variety of customers and markets using our products, as well as their dispersion across many different geographic areas. The majority of our accounts receivable arise from product sales in the U.S. and Europe and have standard payment terms which generally require payment within </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30 to 90 days</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We monitor the financial performance and creditworthiness of our customers so that we can properly assess and respond to changes in their credit profile. We continue to monitor these conditions and assess their possible impact on our business. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, two wholesale distributors individually accounted for approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.2%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">19.2%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35.4%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">23.1%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, of accounts receivable, net, respectively. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Marketable Securities and Other Investments</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Marketable Debt Securities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Available-for-sale debt securities are recorded at fair market value and unrealized gains and losses are included in accumulated other comprehensive income (loss) in equity, net of related tax effects, unless the security has experienced a credit loss, we have determined that we have the intent to sell the security or we have determined that it is more likely than not that we will have to sell the security before its expected recovery. Realized gains and losses are reported in other income (expense), net, on a specific identification basis.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 13</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Marketable Equity Securities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our marketable equity securities represent investments in publicly traded equity securities and are included in investments and other assets in our consolidated balance sheet. When assessing whether a decline in the fair value of a marketable equity security is other-than-temporary, we consider the fair market value of the security, the duration of the security&#8217;s decline and prospects for the underlying business, including favorable or adverse clinical trial results, new product initiatives and new collaborative agreements with the companies in which we have invested.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Non-Marketable Equity Securities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also invest in equity securities of companies whose securities are not publicly traded and where fair value is not readily available. These investments are recorded using either the cost method or the equity method of accounting, depending on our ownership percentage and other factors that suggest we have significant influence. We monitor these investments to evaluate whether any decline in their value has occurred that would be other-than-temporary, based on the implied value of recent company financings, public market prices of comparable companies and general market conditions and are included in investments and other assets in our consolidated balance sheet.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Evaluating Investments for Other-than-Temporary Impairments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We conduct periodic reviews to identify and evaluate each investment that has an unrealized loss, in accordance with the meaning of other-than-temporary impairment and its application to certain investments. An unrealized loss exists when the current fair value of an individual security is less than its amortized cost basis. Unrealized losses on available-for-sale securities that are determined to be temporary, and not related to credit loss, are recorded, net of tax, in accumulated other comprehensive income.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For available-for-sale debt securities with unrealized losses, management performs an analysis to assess whether we intend to sell or whether we would more likely than not be required to sell the security before the expected recovery of the amortized cost basis. Where we intend to sell a security, or may be required to do so, the security&#8217;s decline in fair value is deemed to be other-than-temporary and the full amount of the unrealized loss is reflected in earnings as an impairment loss.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Regardless of our intent to sell a security, we perform additional analysis on all securities with unrealized losses to evaluate losses associated with the creditworthiness of the security. Credit losses are identified where we do not expect to receive cash flows sufficient to recover the amortized cost basis of a security.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For equity securities, when assessing whether a decline in value is other-than-temporary, we consider the fair market value of the security, the duration of the security&#8217;s decline, and the financial condition of the issuer. We then consider our intent and ability to hold the equity security for a period of time sufficient to recover our carrying value. Where we have determined that we lack the intent and ability to hold an equity security to its expected recovery, the security&#8217;s decline in fair value is deemed to be other-than-temporary and is reflected in earnings as an impairment loss.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Equity Method of Accounting</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In circumstances where we have the ability to exercise significant influence over the operating and financial policies of a company in which we have an investment, we utilize the equity method of accounting for recording investment activity.&#160;In assessing whether we exercise significant influence, we consider the nature and magnitude of our investment, the voting and protective rights we hold, any participation in the governance of the other company, and other relevant factors such as the presence of a collaboration or other business relationship.&#160;Under the equity method of accounting, we record in our results of operations our share of income or loss of the other company. If our share of losses exceeds the carrying value of our investment, we will suspend recognizing additional losses and will continue to do so unless we commit to providing additional funding. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Inventory</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventories are stated at the lower of cost or market with cost based on the first-in, first-out (FIFO) method. We classify our inventory costs as long-term when we expect to utilize the inventory beyond our normal operating cycle and include these costs in investments and other assets in our consolidated balance sheets. Inventory that can be used in either the production of clinical or commercial products is expensed as research and development costs when identified for use in a clinical manufacturing campaign.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 14</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Capitalization of Inventory Costs</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We capitalize inventory costs associated with our products prior to regulatory approval, when, based on management&#8217;s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized. We consider numerous attributes in evaluating whether the costs to manufacture a particular product should be capitalized as an asset. We assess the regulatory approval process and where the particular product stands in relation to that approval process, including any known safety or efficacy concerns, potential labeling restrictions and other impediments to approval. We evaluate our anticipated research and development initiatives and constraints relating to the product and the indication in which it will be used. We consider our manufacturing environment including our supply chain in determining logistical constraints that could hamper approval or commercialization. We consider the shelf life of the product in relation to the expected timeline for approval and we consider patent related or contract issues that may prevent or delay commercialization. We also base our judgment on the viability of commercialization, trends in the marketplace and market acceptance criteria. Finally, we consider the reimbursement strategies that may prevail with respect to the product and assess the economic benefit that we are likely to realize. We expense previously capitalized costs related to pre-approval inventory upon a change in such judgment, due to, among other potential factors, a denial or significant delay of approval by necessary regulatory bodies.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Obsolescence and Unmarketable Inventory</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We periodically review our inventories for excess or obsolescence and write-down obsolete or otherwise unmarketable inventory to its estimated net realizable value. If the actual net realizable value is less than that estimated by us, or if it is determined that inventory utilization will further diminish based on estimates of demand, additional inventory write-downs may be required. Additionally, our products are subject to strict quality control and monitoring which we perform throughout the manufacturing process. In the event that certain batches or units of product no longer meet quality specifications, we will record a charge to cost of sales to write-down any unmarketable inventory to its estimated net realizable value. In all cases, product inventory is carried at the lower of cost or its estimated net realizable value. Amounts written-down due to unmarketable inventory are charged to cost of sales.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Property, Plant and Equipment</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Property, plant and equipment are carried at cost, subject to review for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. The cost of normal, recurring, or periodic repairs and maintenance activities related to property, plant and equipment are expensed as incurred. The cost for planned major maintenance activities, including the related acquisition or construction of assets, is capitalized if the repair will result in future economic benefits.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest costs incurred during the construction of major capital projects are capitalized until the underlying asset is ready for its intended use, at which point the interest costs are amortized as depreciation expense over the life of the underlying asset. We also capitalize certain direct and incremental costs associated with the validation effort required for licensing by regulatory agencies of new manufacturing equipment for the production of a commercially approved drug. These costs primarily include direct labor and material and are incurred in preparing the equipment for its intended use. The validation costs are either amortized over the life of the related equipment or expensed as cost of sales when the product produced in the validation process is sold.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we capitalize certain internal use computer software development costs. If the software is an integral part of production assets, these costs are included in machinery and equipment and are amortized on a straight-line basis over the estimated useful lives of the related software, which generally range from </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three to five years</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 15</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We generally depreciate or amortize the cost of our property, plant and equipment using the straight-line method over the estimated useful lives of the respective assets, which are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:50%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Asset Category</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Useful Lives</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Land</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Not depreciated</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Buildings</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">15 to 40&#160;years</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Leasehold Improvements</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Lesser of the useful life or the term of the respective lease</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Furniture and Fixtures</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5 to 7&#160;years</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Machinery and Equipment</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5 to 20&#160;years</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Computer&#160;Software&#160;and&#160;Hardware</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3 to 5&#160;years</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">When we dispose of property, plant and equipment, we remove the associated cost and accumulated depreciation from the related accounts on our consolidated balance sheet and include any resulting gain or loss in our consolidated statement of income.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Intangible Assets</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our intangible assets consist of acquired and in-licensed rights and patents, developed technology, out-licensed patents, in-process research and development acquired after January&#160;1, 2009, trademarks and trade names. Our intangible assets are recorded at fair value at the time of their acquisition and are stated in our consolidated balance sheets net of accumulated amortization and impairments, if applicable.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets related to acquired and in-licensed rights and patents, developed technology and out-licensed patents are amortized over their estimated useful lives using the economic consumption method if anticipated future revenues can be reasonably estimated. The straight-line method is used when revenues cannot be reasonably estimated. Amortization is recorded as amortization of acquired intangible assets in our consolidated statements of income.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired and in-licensed rights and patents primarily relate to our acquisition of all remaining rights to TYSABRI from Elan Pharma International, Ltd (Elan), an affiliate of Elan Corporation, plc. Developed technology primarily relates to our AVONEX product, which was recorded in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003. We amortize the intangible assets related to TYSABRI and AVONEX using the economic consumption method based on revenue generated from the products underlying the related intangible assets. An analysis of the anticipated lifetime revenues of TYSABRI and AVONEX is performed annually during our long range planning cycle, which is generally updated in the third quarter of each year, and whenever events or changes in circumstances would significantly affect the anticipated lifetime revenues of TYSABRI or AVONEX.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets related to trademarks, trade names and in-process research and development prior to commercialization are not amortized because they have indefinite lives; however, they are subject to review for impairment. We review our intangible assets with indefinite lives for impairment annually, as of October&#160;31, and whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Acquired In-process Research and Development (IPR&amp;D)</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired IPR&amp;D represents the fair value assigned to research and development assets that have not reached technological feasibility. The value assigned to acquired IPR&amp;D is determined by estimating the costs to develop the acquired technology into commercially viable products, estimating the resulting revenue from the projects and discounting the net cash flows to present value. The revenue and costs projections used to value acquired IPR&amp;D are, as applicable, reduced based on the probability of success of developing a new drug. Additionally, the projections consider the relevant market sizes and growth factors, expected trends in technology and the nature and expected timing of new product introductions by us and our competitors. The rates utilized to discount the net cash flows to their present value are commensurate with the stage of development of the projects and uncertainties in the economic estimates used in the projections. Upon the acquisition of IPR&amp;D, we complete an assessment of whether our acquisition constitutes the purchase of a single asset or a group of assets. We consider multiple factors in this assessment, including the nature of the technology acquired, the presence or absence of separate cash flows, the development process and stage of completion, quantitative significance and our rationale for entering into the transaction.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 16</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">If we acquire a business as defined under applicable accounting standards, then the acquired IPR&amp;D is capitalized as an intangible asset. If we acquire an asset or group of assets that do not meet the definition of a business, then the acquired IPR&amp;D is expensed on its acquisition date. Future costs to develop these assets are recorded to research and development expense as they are incurred. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">When performing our impairment assessment, we calculate the fair value using the same methodology as described above. If the carrying value of our acquired IPR&amp;D exceeds its fair value, then the intangible asset is written-down to its fair value. Certain IPR&amp;D programs have a fair value that is not significantly in excess of carrying value, including our program for the treatment of trigeminal neuralgia (TGN). Such programs could become impaired if assumptions used in determining the fair value change.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Goodwill</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill represents the difference between the purchase price and the fair value of the identifiable tangible and intangible net assets when accounted for using the purchase method of accounting. Goodwill is not amortized, but reviewed for impairment. Goodwill is reviewed annually, as of October&#160;31, and whenever events or changes in circumstances indicate that the carrying value of the goodwill might not be recoverable.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We compare the fair value of our reporting unit to its carrying value. If the carrying value of the net assets assigned to the reporting unit exceeds the fair value of our reporting unit, then we would need to determine the implied fair value of our reporting unit&#8217;s goodwill. If the carrying value of our reporting unit&#8217;s goodwill exceeds its implied fair value, then we would record an impairment loss equal to the difference. As described in Note&#160;24, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Segment Information</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements, we operate in one operating segment which we consider our only reporting unit.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Impairment of Long-Lived Assets</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-lived assets to be held and used, including property, plant and equipment and definite-lived intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets or asset group may not be recoverable.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written-down to their fair values. Long-lived assets to be disposed of are carried at fair value less costs to sell.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Consideration</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The consideration for our acquisitions often includes future payments that are contingent upon the occurrence of a particular event. For acquisitions completed before January 1, 2009, we record contingent consideration resulting from a business combination when the contingency is resolved. For acquisitions that qualify as business combinations completed after January&#160;1, 2009, we record an obligation for such contingent payments at fair value on the acquisition date. We estimate the fair value of contingent consideration obligations through valuation models that incorporate probability-adjusted assumptions related to the achievement of the milestones and thus likelihood of making related payments. We revalue these contingent consideration obligations each reporting period. Changes in the fair value of our contingent consideration obligations are recognized in our consolidated statements of income. Changes in the fair value of the contingent consideration obligations can result from changes to one or multiple inputs, including adjustments to the discount rates, changes in the amount or timing of expected expenditures associated with product development, changes in the amount or timing of cash flows and reserves associated with products upon commercialization, changes in the assumed achievement or timing of any cumulative sales-based and development milestones, changes in the probability of certain clinical events and changes in the assumed probability associated with regulatory approval. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 17</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Discount rates in our valuation models represent a measure of the credit risk associated with settling the liability. The period over which we discount our contingent obligations is based on the current development stage of the product candidates, our specific development plan for that product candidate adjusted for the probability of completing the development step, and when the contingent payments would be triggered. In estimating the probability of success, we utilize data regarding similar milestone events from several sources, including industry studies and our own experience. These fair value measurements are based on significant inputs not observable in the market. Significant judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, changes in assumptions could have a material impact on the amount of contingent consideration expense we record in any given period.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Derivative Instruments and Hedging Activities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognize all derivative instruments as either assets or liabilities at fair value in our consolidated balance sheets. Changes in the fair value of derivatives are recorded each period in current earnings or accumulated other comprehensive income (loss), depending on whether a derivative is designated as part of a hedge transaction and, if so, the type of hedge transaction. We classify the cash flows from these instruments in the same category as the cash flows from the hedged items. We do not hold or issue derivative instruments for trading or speculative purposes.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We assess, both at inception and on an ongoing basis, whether the derivatives that are used in hedging transactions are highly effective in offsetting the changes in cash flows or fair values of the hedged items. We also assess hedge ineffectiveness on a quarterly basis and record the gain or loss related to the ineffective portion to current earnings. If we determine that a forecasted transaction is no longer probable of occurring, we discontinue hedge accounting for the affected portion of the hedge instrument, and any related unrealized gain or loss on the contract is recognized in current earnings.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Translation of Foreign Currencies</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The functional currency for most of our foreign subsidiaries is their local currency. For our non-U.S. subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the average foreign exchange rates for the period. Adjustments resulting from the translation of the financial statements of our foreign operations into U.S.&#160;dollars are excluded from the determination of net income and are recorded in accumulated other comprehensive income, a separate component of equity. For subsidiaries where the functional currency of the assets and liabilities differ from the local currency, non-monetary assets and liabilities are translated at the rate of exchange in effect on the date assets were acquired while monetary assets and liabilities are translated at current rates of exchange as of the balance sheet date. Income and expense items are translated at the average foreign currency rates for the period. Translation adjustments of these subsidiaries are included in other income (expense), net, in our consolidated statements of income.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Royalty Cost of Sales</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We make royalty payments to a number of third parties under license or purchase agreements associated with our acquisition of intellectual property. These royalty payments are typically calculated as a percentage (royalty rate) of the sales of our products in a particular year.&#160;That royalty rate may remain constant, increase or decrease within each year based on the total amount of sales during the annual period. Each quarterly period, we estimate our total royalty obligation for the full year and recognize the proportional amount as cost of sales based on actual quarterly sales as a percentage of full year estimated sales. For example, if the level of net sales in any calendar year increases the royalty rate within the year, we will record our cost of sales at an even rate over the year, based on the estimated blended royalty rate. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accounting for Share-Based Compensation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our share-based compensation programs grant awards that have included stock options, restricted stock units which vest based on stock performance known as market stock units (MSUs), performance-vested restricted stock units which settle in cash (CSPUs), time-vested restricted stock units (RSUs), performance-vested restricted stock units which can be settled in cash or shares of our common stock (PUs) at the sole discretion of the Compensation and Management Development Committee of the Board of Directors and shares issued under our employee stock purchase plan (ESPP). We charge the estimated fair value of awards against income over the requisite service period, which is generally the vesting period. Where awards are made with non-substantive vesting periods (for instance, </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 18</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">where a portion of the award vests upon retirement eligibility), we estimate and recognize expense based on the period from the grant date to the date on which the employee is retirement eligible.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair values of our stock option grants are estimated as of the date of grant using a Black-Scholes option valuation model. The estimated fair values of the stock options are then expensed over the options&#8217; vesting periods.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair values of our MSUs are estimated using a lattice model with a Monte Carlo simulation. We apply an accelerated attribution method to recognize share-based compensation expense over the applicable service period, net of estimated forfeitures, when accounting for our MSUs. The probability of actual shares expected to be earned is considered in the grant date valuation, therefore the expense is not adjusted to reflect the actual units earned.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair values of our RSUs are based on the market value of our stock on the date of grant. Compensation expense for RSUs is recognized straight-line over the applicable service period.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We apply an accelerated attribution method to recognize share-based compensation expense when accounting for our CSPUs and PUs and the fair value of the liability is remeasured at the end of each reporting period through expected settlement. Compensation expense associated with CSPUs and PUs are based upon the stock price and the number of units expected to be earned after assessing the probability that certain performance criteria will be met and the associated targeted payout level that is forecasted will be achieved, net of estimated forfeitures. Cumulative adjustments are recorded each quarter to reflect changes in the stock price and estimated outcome of the performance-related conditions until the date results are determined and settled.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The purchase price of common stock under our ESPP is equal to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">85%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of the lesser of (i)&#160;the fair market value per share of the common stock on the first business day of an offering period and (ii)&#160;the fair market value per share of the common stock on the purchase date. The fair value of the discounted purchases made under our ESPP is calculated using the Black-Scholes model. The fair value of the look-back provision plus the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;discount is recognized as compensation expense over the 90 day purchase period. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Research and Development Expenses</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development expenses consist of upfront fees and milestones paid to collaborators and expenses incurred in performing research and development activities, which include compensation and benefits, facilities and overhead expenses, clinical trial expenses and fees paid to contract research organizations (CROs), clinical supply and manufacturing expenses, write-offs of inventory that was previously capitalized in anticipation of product launch and determined to no longer be realizable, and other outside expenses. Research and development expenses are expensed as incurred. Payments we make for research and development services prior to the services being rendered are recorded as prepaid assets on our consolidated balance sheets and are expensed as the services are provided. We also accrue the costs of ongoing clinical trials associated with programs that have been terminated or discontinued for which there is no future economic benefit at the time the decision is made to terminate or discontinue the program.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">From time to time, we enter into development agreements in which we share expenses with a collaborative partner. We record payments received from our collaborative partners for their share of the development costs as a reduction of research and development expense, except as discussed in Note&#160;19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements. Because an initial indication has been approved for both RITUXAN and GAZYVA, expenses incurred by Genentech in the ongoing development of RITUXAN and GAZYVA are not recorded as research and development expense, but rather reduce our share of profits recorded as a component of revenues from anti-CD20 therapeutic programs.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For collaborations with commercialized products, if we are the principal, we record revenue and the corresponding operating costs in their respective line items in our consolidated statements of income. If we are not the principal, we record operating costs as a reduction of revenue.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Selling, General and Administrative Expenses</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative expenses are primarily comprised of compensation and benefits associated with sales and marketing, finance, human resources, legal, information technology and other administrative personnel, outside marketing, advertising and legal expenses and other general and administrative costs.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Advertising costs are expensed as incurred. For the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, advertising costs totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$106.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$108.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$92.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 19</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Income Taxes</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The provision for income taxes includes federal, state, local and foreign taxes. Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences of temporary differences between the financial statement carrying amounts and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which the temporary differences are expected to be recovered or settled. We evaluate the realizability of our deferred tax assets and establish a valuation allowance when it is more likely than not that all or a portion of deferred tax assets will not be realized.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">All tax effects associated with intercompany transfers of assets in our consolidated group, both current and deferred, are recorded as a prepaid tax or deferred charge and recognized through the consolidated statement of income when the asset transferred is sold to a third party or otherwise recovered through amortization of the asset's remaining economic life.&#160;If the asset transferred becomes impaired, for example through the discontinuation of a research program, we will expense any remaining deferred charge or prepaid tax.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We account for uncertain tax positions using a &#8220;more-likely-than-not&#8221; threshold for recognizing and resolving uncertain tax positions. We evaluate uncertain tax positions on a quarterly basis and consider various factors including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, information obtained during in process audit activities and changes in facts or circumstances related to a tax position. We also accrue for potential interest and penalties related to unrecognized tax benefits in income tax expense.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingencies</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are currently involved in various claims and legal proceedings. Loss contingency provisions are recorded if the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount can be reasonably estimated or a range of loss can be determined. These accruals represent management&#8217;s best estimate of probable loss. Disclosure also is provided when it is reasonably possible that a loss will be incurred or when it is reasonably possible that the amount of a loss will exceed the recorded provision. On a quarterly basis, we review the status of each significant matter and assess its potential financial exposure.&#160;Significant judgment is required in both the determination of probability and the determination as to whether an exposure is reasonably estimable. Because of uncertainties related to these matters, accruals are based only on the best information available at the time. As additional information becomes available, we reassess the potential liability related to pending claims and litigation and may change our estimates. These changes in the estimates of the potential liabilities could have a material impact on our consolidated results of operations and financial position.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Earnings per Share</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share is computed by dividing undistributed net income attributable to Biogen Inc. by the weighted-average number of common shares outstanding during the period. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">New Accounting Pronouncements</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed, we do not believe that the impact of recently issued standards that are not yet effective will have a material impact on our financial position or results of operations upon adoption.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2014 the FASB issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers (Topic 606), which supersedes all existing revenue recognition requirements, including most industry-specific guidance. The new standard requires a company to recognize revenue when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. The FASB has subsequently issued the following amendments to ASU 2014-09 which have the same effective date and transition date of January 1, 2018:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2015 the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date, which delayed the effective date of the new standard from January 1, 2017 to January 1, 2018. The FASB also agreed to allow entities to choose to adopt the standard as of the original effective date. </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 20</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2016 the FASB issued ASU No. 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations, which clarifies the implementation guidance on principal versus agent considerations. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In April 2016 the FASB issued ASU No. 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing, which clarifies certain aspects of identifying performance obligations and licensing implementation guidance. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2016 the FASB issued ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients related to disclosures of remaining performance obligations, as well as other amendments to guidance on collectability, non-cash consideration and the presentation of sales and other similar taxes collected from customers. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2016 the FASB issued ASU No. 2016-20, Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers, which amends certain narrow aspects of the guidance issued in ASU 2014-09 including guidance related to the disclosure of remaining performance obligations and prior-period performance obligations, as well as other amendments to the guidance on loan guarantee fees, contract costs, refund liabilities, advertising costs and the clarification of certain examples. </font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are currently evaluating the method of adoption and the potential impact that Topic 606 may have on our financial position and results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In April 2015 the FASB issued ASU No. 2015-05, Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Customer's Accounting for Fees Paid in a Cloud Computing Arrangement. Under this standard, if a cloud computing arrangement includes a software license, the software license element of the arrangement should be accounted for consistent with the acquisition of other software licenses. If a cloud computing arrangement does not include a software license, the arrangement should be accounted for as a service contract. We adopted this standard as of January 1, 2016, which did not have an impact on our financial position or results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2015 the FASB issued ASU No. 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory. The new standard applies only to inventory for which cost is determined by methods other than last-in, first-out and the retail inventory method, which includes inventory that is measured using first-in, first-out or average cost. Inventory within the scope of this standard is required to be measured at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. We adopted this standard as of January 1, 2016, which did not have an impact on our financial position or results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In September 2015 the FASB issued ASU No. 2015-16, Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments. The new standard requires that an acquirer recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined and sets forth new disclosure requirements related to the adjustments. We adopted this standard as of January 1, 2016, which did not have an impact on our financial position or results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2016 the FASB issued ASU No. 2016-01, Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. This new standard amends certain aspects of accounting and disclosure requirements of financial instruments, including the requirement that equity investments with readily determinable fair values be measured at fair value with changes in fair value recognized in our results of operations. This new standard does not apply to investments accounted for under the equity method of accounting or those that result in consolidation of the investee. Equity investments that do not have readily determinable fair values may be measured at fair value or at cost minus impairment adjusted for changes in observable prices. A financial liability that is measured at fair value in accordance with the fair value option is required to be presented separately in other comprehensive income for the portion of the total change in the fair value resulting from change in the instrument-specific credit risk. In addition, a valuation allowance should be evaluated on deferred tax assets related to available-for-sale debt securities in combination with other deferred tax assets. This new standard will be effective for us on January 1, 2018. The adoption of this standard is not expected to have a material impact on our financial position or results of operations.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 21</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2016 the FASB issued ASU No. 2016-02, Leases (Topic 842). This new standard requires that all lessees recognize the assets and liabilities that arise from leases on the balance sheet and disclose qualitative and quantitative information about its leasing arrangements. This new standard will be effective for us on January 1, 2019. The adoption of this standard is not expected to have a material impact on our net financial position, but will impact the amount of our assets and liabilities. We are currently evaluating the potential impact that this standard may have on our results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2016 the FASB issued ASU No. 2016-06, Derivatives and Hedging (Topic 815): Contingent Put and Call Options in Debt Instruments. This new standard simplifies the embedded derivative analysis for debt instruments containing contingent call or put options by removing the requirement to assess whether a contingent event is related to interest rates or credit risks. This new standard will be effective for us on January 1, 2017. The adoption of this standard is not expected to have an impact on our financial position or results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2016 the FASB issued ASU No. 2016-07, Investments - Equity Method and Joint Ventures (Topic 323): Simplifying the Transition to the Equity Method of Accounting. This new standard eliminates the requirement that when an investment qualifies for use of the equity method as a result of an increase in the level of ownership interest or degree of influence, an adjustment must be made to the investment, results of operations and retained earnings retroactively on a step-by-step basis as if the equity method had been in effect during all previous periods that the investment has been held. This new standard will be effective for us on January 1, 2017. The adoption of this standard is not expected to have a material impact on our financial position or results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2016 the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. This new standard requires recognition of the income tax effects of vested or settled awards in the income statement and involves several other aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities and classification on the statement of cash flows. This new standard will be effective for us on January 1, 2017. The adoption of this standard is not expected to have a material impact on our financial position, results of operations or statements of cash flows upon adoption.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2016 the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. This new standard changes the impairment model for most financial assets and certain other instruments. Under the new standard, entities holding financial assets and net investment in leases that are not accounted for at fair value through net income to be presented at the net amount expected to be collected. An allowance for credit losses will be a valuation account that will be deducted from the amortized cost basis of the financial asset to present the net carrying value at the amount expected to be collected on the financial asset. This new standard will be effective for us on January 1, 2020. The adoption of this standard is not expected to have a material impact on our financial position or results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2016 the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. This new standard clarifies certain aspects of the statement of cash flows, including the classification of debt prepayment or debt extinguishment costs or other debt instruments with coupon interest rates that are insignificant in relation to the effective interest rate of the borrowing, contingent consideration payments made after a business combination, proceeds from the settlement of insurance claims, proceeds from the settlement of corporate-owned life insurance policies, distributions received from equity method investees and beneficial interests in securitization transactions. This new standard also clarifies that an entity should determine each separately identifiable source of use within the cash receipts and payments on the basis of the nature of the underlying cash flows. In situations in which cash receipts and payments have aspects of more than one class of cash flows and cannot be separated by source or use, the appropriate classification should depend on the activity that is likely to be the predominant source or use of cash flows for the item. This new standard will be effective for us on January 1, 2018. The adoption of this standard is not expected to have a material impact on our statements of cash flows upon adoption.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2016 the FASB issued ASU No. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfer of Assets Other Than Inventory. This new standard eliminates the exception for an intra-entity transfer of an asset other than inventory. Under the new standard, entities should recognize the income tax consequences on an intra-entity transfer of an asset other than inventory when the transfer occurs. This new standard will be effective for us on January 1, 2018 and will be applied on a modified retrospective basis through a cumulative-effect adjustment directly to retained earnings as of the beginning of the period of adoption. We are currently evaluating the potential impact this standard may have on our financial position and results of operations.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 22</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2017 the FASB issued ASU No. 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business. This new standard clarifies the definition of a business and provides a screen to determine when an integrated set of assets and activities is not a business. The screen requires that when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the set is not a business. This new standard will be effective for us on January 1, 2018. However, we have adopted this standard as of January 1, 2017, with prospective application to any business development transaction.</font></div><div><a name="s6CDE90853F459E62521720166E2C4903"></a></div><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Acquisitions</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Convergence Pharmaceuticals</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On February 12, 2015, we completed our acquisition of all of the outstanding stock of Convergence Pharmaceuticals (Convergence), a clinical-stage biopharmaceutical company with a focus on developing product candidates for neuropathic pain. Convergence&#8217;s lead candidate was a Phase 2 clinical candidate BIIB074 (CNV1014802), which had demonstrated clinical activity in proof-of-concept studies for TGN. Additionally, BIIB074 had potential applicability in several other neuropathic pain states, including lumbosacral radiculopathy and erythromelalgia. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The purchase price consisted of a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$200.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;cash payment at closing, plus contingent consideration in the form of development and approval milestones up to a maximum of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$450.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, of which </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$350.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;was associated with the development and approval of BIIB074 for the treatment of TGN. The acquisition was funded from our existing cash on hand and was accounted for as the acquisition of a business. In addition to obtaining the rights to BIIB074 and additional product candidates in preclinical development, we retained the services of key employees of Convergence. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisition of Convergence, we recorded a liability of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$274.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;representing the fair value of the contingent consideration.&#160;This amount was estimated through a valuation model that incorporated industry-based probability adjusted assumptions relating to the achievement of these milestones and thus the likelihood of making the contingent payments. This fair value measurement was based upon significant inputs not observable in the market and therefore represented a Level 3 measurement. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The purchase price, as adjusted, consisted of the following:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:87%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash portion of consideration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">200.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">274.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total purchase price</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">474.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the second quarter of 2015 we adjusted our preliminary estimate of the fair value of the assets acquired and contingent consideration as of the date of acquisition as a result of finalizing the purchase price accounting. This resulted in an increase in the value of our estimated contingent consideration and goodwill by </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$36.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Our revised purchase price allocation is reflected in the chart below. Our purchase price allocation is complete.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subsequent changes in the fair value of the contingent consideration obligation will be recognized as adjustments to contingent consideration and reflected in our consolidated statements of income. In the fourth quarter of 2016 a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$50.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;milestone related to BIIB074 in an additional neuropathic pain indication was earned and paid, resulting in a reduction to the contingent consideration. For additional information related to the fair value of this obligation, please read Note 7,&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Fair Value Measurements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;to these consolidated financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 23</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the estimated fair values of the separately identifiable assets acquired and liabilities assumed as of February&#160;12, 2015, as adjusted:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:87%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In-process research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">424.6</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">128.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferred tax liability</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(84.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total purchase price</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">474.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our estimate of the fair value of the IPR&amp;D programs acquired was determined through a probability adjusted discounted cash flow analysis utilizing a discount rate of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This valuation was primarily driven by the value associated with the lead candidate, BIIB074, which is in development for the treatment of TGN and was expected to be completed no earlier than 2020, at a remaining cost of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$145.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The fair value associated with BIIB074 for the treatment of TGN was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$200.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We recorded additional IPR&amp;D assets related to the use of BIIB074 in two additional neuropathic pain indications, with a total estimated value of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$220.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The remaining cost of development for these two indications was approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$415.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, with an expected completion date of no earlier than 2021. These fair value measurements were based on significant inputs not observable in the market and thus represented Level 3 fair value measurements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We attributed the goodwill recognized to the Convergence workforce's expertise in chronic pain research and clinical development and to establishing a deferred tax liability for the acquired IPR&amp;D intangible assets which had no tax basis. The goodwill was not tax deductible.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pro forma results of operations would not be materially different as a result of the acquisition of Convergence and therefore are not presented. Subsequent to the acquisition date, our results of operations include the results of operations of Convergence.</font></div><div><a name="s76D32627F533578F8C6920166E4C4AA6"></a></div><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Restructuring, Business Transformation and Other Cost Saving Initiatives</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">2015 Cost Saving Initiatives</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">2015 Restructuring Charges</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On October 21, 2015, we announced a corporate restructuring, which included the termination of certain pipeline programs and an </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;reduction in workforce. Under this restructuring, cash payments were estimated to total approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$120.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, of which </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;were related to previously accrued 2015 incentive compensation, resulting in net restructuring charges totaling approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$102.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. These amounts were substantially paid by the end of 2016.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized total net restructuring charges of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$8.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We previously recognized </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$93.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of restructuring charges in our consolidated statements of income during the fourth quarter of 2015.&#160;Our restructuring reserve is included in accrued expenses and other in our consolidated balance sheets.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the charges and spending related to our 2015 restructuring program during 2016:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:53%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Workforce</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Reduction</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Pipeline</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Programs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restructuring reserve as of December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">33.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">37.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(31.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(9.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(40.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments to previous estimates, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(5.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(2.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restructuring reserve as of December 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 24</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">2016 Organizational Changes and Cost Saving Initiatives</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">2016 Restructuring Charges</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the third quarter of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;we initiated cost saving measures primarily intended to realign our organizational structure due to the changes in roles and workforce resulting from our decision to spin off our hemophilia business, and to achieve further targeted cost reductions. For the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized charges totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$17.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;related to this effort, which are in addition to, and separate from, the 2015 corporate restructuring described above. These amounts, which were substantially incurred and paid by the end of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, are primarily related to severance and are reflected in restructuring charges in our consolidated statements of income.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Cambridge, MA Manufacturing Facility</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2016 following an evaluation of our current and future manufacturing capabilities and capacity needs, we determined that we intend to vacate and cease manufacturing in our 67,000 square foot small-scale biologics manufacturing facility in Cambridge, MA and also vacate our 46,000 square foot warehouse space in Somerville, MA.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December&#160;2016 we subleased our rights to the manufacturing facility in Cambridge, MA to Brammer Bio MA,&#160;LLC (Brammer). Brammer also purchased from us certain manufacturing equipment, leasehold improvements and other assets in exchange for shares of Brammer common LLC interests and assumed manufacturing operations effective January 1, 2017. In December 2016 we also closed and vacated our warehouse space in Somerville, MA.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our departure from these facilities shortened the expected useful lives of certain leasehold improvements and other assets at these facilities. As a result, we recorded additional depreciation expense to reflect the assets' new shorter useful lives. For the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$45.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of this additional depreciation, which was recorded as cost of sales in our consolidated statements of income.</font></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the terms of the agreement, Brammer will also provide manufacturing and other transition and support services to us.</font></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the fourth quarter of 2016 we recognized charges totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$7.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for severance costs related to certain employees separated from Biogen in connection with this transaction. These amounts will be substantially incurred and paid by the end of first quarter of 2017 and are reflected in restructuring charges in our consolidated statements of income.</font></div><div><a name="s90A962E2A56A3C2E95A220166E5B5AF6"></a></div><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">4.&#160;&#160;&#160;&#160;Reserves for Discounts and Allowances</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">An analysis of the change in reserves for discounts and allowances is summarized as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Discounts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Returns</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Beginning balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">56.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">548.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">57.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">662.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current provisions relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">592.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,044.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">30.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,668.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments relating to prior years</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(16.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(16.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/returns relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(522.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1,576.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(2,099.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/returns relating to sales in prior years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(53.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(536.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(19.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(609.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Ending balance</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">71.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">482.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">51.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">605.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 25</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Discounts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Returns</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">2015</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Beginning balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">47.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">387.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">483.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current provisions relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">459.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,732.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,229.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments relating to prior years</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(16.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(14.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(32.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/returns relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(405.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1,258.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1,666.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/returns relating to sales in prior years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(44.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(296.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(11.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(351.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Ending balance</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">56.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">548.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">57.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">662.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Discounts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Returns</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">2014</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Beginning balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">47.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">345.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">33.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">426.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current provisions relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">347.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,265.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">39.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,651.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments relating to prior years</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(28.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(16.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/returns relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(299.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(933.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1,237.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/returns relating to sales in prior years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(46.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(261.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(33.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(341.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Ending balance</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">47.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">387.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">483.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The total revenue-related reserves above, included in our consolidated balance sheets, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:67%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Reduction of accounts receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">166.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">144.6</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Component of accrued expenses and other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">438.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">518.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenue-related reserves</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">605.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">662.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><a name="s52B980E90E700E51565120166E7A53E1"></a></div><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Inventory</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The components of inventory are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:67%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Raw materials</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">170.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">213.0</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Work in process</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">698.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">577.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Finished goods</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">170.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">143.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total inventory</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,039.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">933.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Balance Sheet Classification:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,001.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">893.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">37.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">40.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total inventory</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,039.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">933.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-term inventory, which primarily consists of work in process, is included in investments and other assets in our consolidated balance sheets.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 26</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our inventory included </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$24.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;associated with our ZINBRYTA program, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$24.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;associated with our FLIXABI program and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$18.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;associated with our BENEPALI program, which had been capitalized in advance of regulatory approval. The European Commission (EC) approved the marketing authorization applications for BENEPALI and FLIXABI, two anti-tumor necrosis factor (TNF) biosimilars, for marketing in the E.U. in January 2016 and May 2016, respectively. In addition, ZINBRYTA was approved for the treatment of relapsing forms of MS in the U.S. in May 2016 and in the E.U. in July 2016. For information on our pre-approval inventory policy, please read Note 1,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#32;Summary of Significant Accounting Policies</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory amounts written down as a result of excess, obsolescence, unmarketability or other reasons are charged to cost of sales, and totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$48.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$41.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$50.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div><a name="s60D5E1A171A38F59201420166E7A97FD"></a></div><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">6.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Intangible Assets and Goodwill</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Intangible Assets</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets, net of accumulated amortization, impairment charges and adjustments, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="26"></td></tr><tr><td style="width:21%;"></td><td style="width:17%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">As of December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated Life</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Out-licensed patents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13-23 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">543.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(523.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">19.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">543.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(506.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Developed technology</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15-23 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,005.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(2,634.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">371.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,005.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2,552.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">452.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In-process research and development</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indefinite until commercialization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">648.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">648.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">730.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">730.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Trademarks and trade names</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indefinite</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">64.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">64.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired and in-licensed rights and patents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6-18 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,481.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(776.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,705.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,303.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(502.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,800.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total intangible assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7,742.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(3,934.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,808.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7,646.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3,561.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,085.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amortization of acquired intangible assets totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$385.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$382.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$489.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Amortization of acquired intangible assets during 2016 included impairment charges of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$12.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;related to two of our IPR&amp;D intangible assets. Amortization of acquired intangible assets during </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;included impairment charges of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$34.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;related to one of our out-licensed patents and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$16.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;related to one of our IPR&amp;D intangible assets. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Out-licensed Patents</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Out-licensed patents to third-parties primarily relate to patents acquired in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003. During 2014 we recorded a charge of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$34.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;related to the impairment of one of our out-licensed patents to reflect a change in its estimated fair value due to a change in the underlying competitive market for that product. The charge was included in amortization of acquired intangible assets in our consolidated statements of income. The fair value of the intangible asset was based on a discounted cash flow calculated using Level 3 fair value measurements and inputs including estimated revenues. There were no impairment charges related to our out-licensed patents during </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;or </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Developed Technology</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Developed technology primarily relates to our AVONEX product, which was recorded in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003. The net book value of this asset as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$363.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 27</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">IPR&amp;D</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">IPR&amp;D represents the fair value assigned to research and development assets that we acquire and have not reached technological feasibility at the date of acquisition. Upon commercialization, we will determine the estimated useful life. In connection with our acquisition of Convergence in February 2015, we acquired IPR&amp;D programs with an estimated fair value of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$424.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This amount has and will be adjusted for foreign exchange rate fluctuations. For a more detailed description of this transaction, please read Note 2, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">An analysis of anticipated lifetime revenues and anticipated development costs is performed annually during our long- range planning cycle, which was updated in the third quarter of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.&#160;This analysis is based upon certain assumptions that we evaluate on a periodic basis, including anticipated future product sales, the expected impact of changes in the amount of development costs and the probabilities of our programs succeeding, the introduction of new products by our competitors and changes in our commercial and pipeline product candidates.&#160;&#160; </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the fourth quarter of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;we terminated our collaboration agreements with Rodin Therapeutics, Inc. and Ataxion Inc., resulting in impairment losses of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$8.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, reflecting the full value of the assets recorded upon entering into the collaboration agreements. These impairment losses are included in amortization of acquired intangible assets in our consolidated statements of income.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the third quarter of 2014 we updated the probabilities of success related to the early stage programs acquired through our recent acquisitions.&#160;The change in probability of success, combined with a delay in one of the projects, resulted in an impairment loss of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$16.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in one of our IPR&amp;D assets during 2014.&#160;This impairment is included in amortization of acquired intangible assets in our consolidated statements of income.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Acquired and In-licensed Rights and Patents</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired and in-licensed rights and patents primarily relate to our acquisition of all remaining rights to TYSABRI from Elan Corporation plc (Elan). The net book value of this asset as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2,493.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The net change in acquired and in-licensed rights and patents during the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, reflects:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$60.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;milestone payment due to Ionis Pharmaceuticals, Inc. (Ionis) for the approval of SPINRAZA in the U.S. in December 2016;</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$50.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in total milestone payments due to Samsung Bioepis, which became payable upon the approval of BENEPALI and FLIXABI in the E.U. in January 2016 and May 2016, respectively;</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$32.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in total milestone payments due to AbbVie, Inc. (AbbVie), which became payable upon the approval of ZINBRYTA in the U.S. in May 2016 and the E.U. in July 2016; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$26.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;upon the approval of ALPROLIX in the E.U. in May 2016 which is comprised of a </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$20.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;contingent payment due to the former owners of Syntonix Pharmaceuticals, Inc. (Syntonix) and </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$6.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;related to the establishment of a corresponding deferred tax liability.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our relationships with Samsung Bioepis, AbbVie and Ionis, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Estimated Future Amortization of Intangible Assets</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;">&#32;</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our amortization expense is based on the economic consumption of intangible assets. Our most significant intangible assets are related to our AVONEX and TYSABRI products. Annually, during our long-range planning cycle, we perform an analysis of anticipated lifetime revenues of AVONEX and TYSABRI. This analysis is also updated whenever events or changes in circumstances would significantly affect the anticipated lifetime revenues of either product.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 28</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our most recent long range planning cycle was completed in the third quarter of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Based upon this analysis, the estimated future amortization of acquired intangible assets is expected to be as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:81%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">As of December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">334.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">312.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">295.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">259.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">242.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Goodwill</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table provides a roll forward of the changes in our goodwill balance:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:67%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill, beginning of year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,663.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,760.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Increase to goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,026.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">908.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(21.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill, end of year</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,669.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,663.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The increase in goodwill during </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;was related to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.2 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in contingent milestones achieved (exclusive of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$173.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in tax benefits) and payable to the former shareholders of Fumapharm AG or holders of their rights. Other includes changes related to foreign exchange rate fluctuations. The increase in goodwill during </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;was related to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$900.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in contingent milestones achieved (exclusive of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$120.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in tax benefits) and payable to the former shareholders of Fumapharm AG or holders of their rights and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$128.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;related to our acquisition of Convergence.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information related to future contingent payments to the former shareholders of Fumapharm AG or holders of their rights, please read Note 21, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Commitments and Contingencies</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements. For additional information related to our acquisition of Convergence, please read Note 2, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">no</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;accumulated impairment losses related to goodwill.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 29</font></div></div><hr style="page-break-after:always"><div><a name="s25C8DB44620E1B21268120166EA9917F"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">7.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Fair Value Measurements</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br>December 31, <br>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quoted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Prices in</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Active</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level&#160;1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Observable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level&#160;2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level&#160;3)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,039.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,039.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable debt securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,663.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,663.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,172.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,172.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">561.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">561.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">24.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">24.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">61.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">61.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Plan assets for deferred compensation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">34.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">34.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7,558.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">24.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7,533.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">13.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">13.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration obligations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">467.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">467.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">481.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">13.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">467.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br>December 31, <br>2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quoted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Prices</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">in&#160;Active</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Observable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">909.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">909.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable debt securities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,510.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,510.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,875.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,875.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">494.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">494.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">27.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">27.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Plan assets for deferred compensation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">40.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">40.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,895.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,857.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">14.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">14.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration obligations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">506.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">506.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">520.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">14.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">506.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair value of Level 2 instruments classified as cash equivalents and marketable debt securities were determined through third-party pricing services. For a description of our validation procedures related to prices provided by third-party pricing services, refer to Note 1, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies: Fair Value Measurements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 30</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Debt Instruments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:67%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes payable to Fumedica</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.875% Senior Notes due March 1, 2018</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">583.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">602.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.900% Senior Notes due September 15, 2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,521.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,497.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.625% Senior Notes due September 15, 2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,026.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,014.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.050% Senior Notes due September 15, 2025</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,796.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,764.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.200% Senior Notes due September 15, 2045</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,874.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,757.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6,808.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,645.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair value of our notes payable to Fumedica was estimated using market observable inputs, including current interest and foreign currency exchange rates. The fair values of each of our series of Senior Notes were determined through market, observable, and corroborated sources. For additional information related to our debt instruments, please read Note 11, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Indebtedness</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Consideration Obligations</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table provides a roll forward of the fair values of our contingent consideration obligations which includes Level 3 measurements:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:67%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As&#160;of&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value, beginning of year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">506.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">215.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Additions</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">274.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Changes in fair value</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">14.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments and other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(53.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(14.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value, end of year</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">467.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">506.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$246.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$301.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, of the fair value of our total contingent consideration obligations was reflected as a component of other long-term liabilities in our consolidated balance sheets with the remaining balance reflected as a component of accrued expenses and other. Payments and other for 2016 includes </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$7.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of a Convergence milestone converted to a short-term obligation under the terms of the acquisition agreement.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">There were </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">no</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;changes in valuation techniques or transfers between fair value measurement levels during the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The fair values of the intangible assets and contingent consideration liabilities were based on a probability-adjusted discounted cash flow calculation using Level 3 fair value measurements and inputs including estimated revenues and probabilities of success. For additional information related to the valuation techniques and inputs utilized in valuation of our financial assets and liabilities, please read Note 1, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Convergence</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisition of Convergence in February 2015 we recorded a contingent consideration obligation of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$274.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This valuation was based on probability weighted net cash outflow projections of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$450.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, discounted using a rate of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.0%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which was the estimated cost of debt financing for market participants. This liability reflected the revised estimate from the date of acquisition for our initial clinical development plans, resulting probabilities of success and the timing of certain milestone payments. For a more detailed description of this transaction, please read Note 2, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the fair value of this contingent consideration obligation was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$258.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$297.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Our most recent valuation was determined based upon probability weighted net cash flow projections of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$400.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, discounted using a rate of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.7%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which is a measure of the credit risk associated with settling the liability. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 31</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the net decrease in the fair value of this obligation was primarily due to achievement of a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$50.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;milestone related to a second indication, partially offset by changes in the discount rate and an increase in the probability of success related to the achievement of certain developmental milestones. Approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$148.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;is reflected as a component of accrued expenses and other in our consolidated balance sheets as we expect to make the payment within one year.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Stromedix Inc.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisition of Stromedix Inc. (Stromedix) in March 2012 we recorded a contingent consideration obligation of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$122.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the fair value of this contingent consideration obligation was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$133.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$131.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Our most recent valuation was determined based upon probability weighted net cash outflow projections of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$419.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, discounted using a rate of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.2%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which is a measure of the credit risk associated with settling the liability. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the net increase in the fair value of this obligation was primarily due to changes in the discount rate, partially offset by changes in the expected timing related to the achievement of certain remaining developmental milestones. Approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$56.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;is reflected as a component of accrued expenses and other in our consolidated balance sheets as we expect to make the payment within one year.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Biogen Idec International Neuroscience GmbH</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisition of Biogen Idec International Neuroscience GmbH (BIN), formerly Panima Pharmaceuticals AG (Panima), in December 2010 we recorded a contingent consideration obligation of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$81.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the fair value of this contingent consideration obligation was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$75.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$77.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Our most recent valuation was determined based upon probability weighted net cash outflow projections of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$361.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, discounted using a rate of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.7%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which is a measure of the credit risk associated with settling the liability. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the net decrease in the fair value of this obligation was primarily due to payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in developmental milestones, partially offset by changes in the discount rate. Approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;is reflected as a component of accrued expenses and other in our consolidated balance sheets as we expect to make the payment within one year.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Acquired IPR&amp;D</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisition of Convergence, we also allocated </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$424.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of the total purchase price to acquired IPR&amp;D, which was capitalized as an intangible asset. The amount allocated to acquired IPR&amp;D was based on significant inputs not observable in the market and thus represented a Level 3 fair value measurement. This estimate was also adjusted from our preliminary estimate as of the date of acquisition to reflect revised estimates to our initial clinical development plans, resulting probabilities of success and the timing of certain milestone payments. These assets will be tested for impairment annually until commercialization, after which time the IPR&amp;D will be amortized over its estimated useful life. For a more detailed description of this transaction, please read Note 2, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements.</font></div><div><a name="s4E29929A2C57470F3C9920166EE86923"></a></div><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">8.&#160;&#160;&#160;&#160;Financial Instruments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our financial assets with maturities of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">less than 90&#160;days</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;from the date of purchase included in cash and cash equivalents on the accompanying consolidated balance sheet:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:67%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Commercial paper</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">31.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Overnight reverse repurchase agreements</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">134.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Money market funds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">741.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">673.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Short-term debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,266.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">79.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,039.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">909.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 32</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The carrying values of our commercial paper, including accrued interest, overnight reverse repurchase agreements, money market funds and our short-term debt securities approximate fair value due to their short term maturities. Our overnight reverse repurchase agreements were collateralized with agency-guaranteed mortgage-backed securities and represented approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.7%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of total assets as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables summarize our marketable debt and equity securities, classified as available for sale:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2016 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,408.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(0.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,409.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,255.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(4.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,258.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,156.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,156.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,016.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(3.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,019.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">557.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(2.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">559.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total marketable debt securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5,398.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(11.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5,406.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities, non-current</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">24.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(9.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">33.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2015 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">394.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">394.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,116.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,120.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,723.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,724.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,152.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,155.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">491.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">493.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total marketable debt securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,880.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(10.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,891.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities, non-current</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">28.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Summary of Contractual Maturities: Available-for-Sale Securities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">As of December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair&#160; Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair&#160; Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due in one year or less</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,568.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,569.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,120.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,122.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due after one year through five years</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,552.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,559.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,575.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,583.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due after five years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">276.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">277.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">184.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">185.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total available-for-sale securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5,398.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5,406.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,880.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,891.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The average maturity of our marketable debt securities available-for-sale as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;months and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months, respectively.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 33</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Proceeds from Marketable Debt Securities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:53%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Proceeds from maturities and sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7,378.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,063.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,718.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Realized gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Realized losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Realized losses for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, primarily relate to sales of corporate bonds, agency mortgage-backed securities and other asset-backed securities. Realized losses for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, primarily relate to sales of corporate bonds, agency mortgage-backed securities and other asset-backed securities. Realized losses for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, primarily relate to sales of agency mortgage-backed securities and government securities.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Strategic Investments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our strategic investment portfolio was comprised of investments totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$99.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$96.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, which are included in investments and other assets in our consolidated balance sheets. Our strategic investment portfolio includes investments in equity securities of certain biotechnology companies and investments in venture capital funds where the underlying investments are in equity securities of biotechnology companies. </font></div><div><a name="sE1087E1EAE8E7B820D0120166F16CCA0"></a></div><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">9.&#160;&#160;&#160;&#160;Derivative Instruments</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Foreign Currency Forward Contracts - Hedging Instruments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due to the global nature of our operations, portions of our revenues and operating expenses are recorded in currencies other than the U.S.&#160;dollar. The value of revenues and operating expenses measured in U.S.&#160;dollars is therefore subject to changes in foreign currency exchange rates. In order to mitigate these changes we use foreign currency forward contracts to lock in exchange rates associated with a portion of our forecasted international revenues and operating expenses.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign currency forward contracts in effect as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, had durations of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18 months</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. These contracts have been designated as cash flow hedges and accordingly, to the extent effective, any unrealized gains or losses on these foreign currency forward contracts are reported in accumulated other comprehensive income (loss) (referred to as AOCI in the tables below). Realized gains and losses for the effective portion of such contracts are recognized in revenue when the sale of product in the currency being hedged is recognized and, beginning in the fourth quarter of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, in operating expenses when the expense in the currency being hedged is recorded. To the extent ineffective, hedge transaction gains and losses are reported in other income (expense), net.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenues and operating expenses is summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:67%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Notional Amount</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As&#160;of&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Foreign Currency: (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Euro</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">871.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">945.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Swiss francs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">80.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Canadian dollar</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">76.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total foreign currency forward contracts</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">871.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,103.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 34</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The portion of the fair value of these foreign currency forward contracts that was included in accumulated other comprehensive income (loss) in total equity reflected net gains of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$49.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$72.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. We expect all contracts to be settled over the next </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18 months</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and any amounts in accumulated other comprehensive income (loss) to be reported as an adjustment to revenue or operating expense. We consider the impact of our and our counterparties&#8217; credit risk on the fair value of the contracts as well as the ability of each party to execute its contractual obligations. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, credit risk did not change the fair value of our foreign currency forward contracts.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the effect of foreign currency forward contracts designated as hedging instruments on our consolidated statements of income:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="27"></td></tr><tr><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td colspan="27" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December 31,</font></div></td></tr><tr><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Reclassified from AOCI into Net Income</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;">(Effective Portion)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized into Net Income</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;">(Ineffective Portion)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">173.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.8</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Interest Rate Contracts - Hedging Instruments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have entered into interest rate lock contracts or interest rate swap contracts on certain borrowing transactions to manage our exposure to interest rate changes and to reduce our overall cost of borrowing. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Interest Rate Lock Contracts</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;we entered into treasury rate locks, with an aggregated notional amount of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.1 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which were designated as cash flow hedges to hedge against changes in the 10-year and 30-year U.S. treasury interest rates that could have impacted our anticipated debt offering. In connection with the issuance of our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.05%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.20%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes, as described in Note 11, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Indebtedness</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we settled the treasury rate locks and realized an </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$8.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;gain. As the hedging relationship was effective, the gain was recorded in AOCI and will be recognized in other income (expense), net over the life of the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.05%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.20%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Interest Rate Swap Contracts</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the issuance of our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.90%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes, as described in Note 11, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Indebtedness</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we entered into interest rate swaps with an aggregate notional amount of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$675.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which expire on September 15, 2020. The interest rate swap contracts are designated as hedges of the fair value changes in the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.90%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes attributable to changes in interest rates. Since the specific terms and notional amount of the swaps match the debt being hedged, it is assumed to be a highly effective hedge and all changes in the fair value of the swaps are recorded as a component of the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.90%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes with no net impact recorded in income. Any net interest payments made or received on the interest rate swap contracts are recognized as a component of interest expense in our consolidated statements of income.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Foreign Currency Forward Contracts - Other Derivatives</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also enter into other foreign currency forward contracts, usually with durations of one month or less, to mitigate the foreign currency risk related to certain balance sheet positions. We have not elected hedge accounting for these transactions.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The aggregate notional amount of these outstanding foreign currency contracts was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$902.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$721.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Net losses of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$29.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$23.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;related to these contracts were recognized as a component of other income (expense), net, for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Summary of Derivatives</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">While certain of our derivatives are subject to netting arrangements with our counterparties, we do not offset derivative assets and liabilities in our consolidated balance sheets.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 35</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the fair value and presentation in our consolidated balance sheets of our outstanding derivatives including those designated as hedging instruments:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.61013645224172%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:40%;"></td><td style="width:40%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance&#160;Sheet&#160;Location</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">Fair Value<br>As of December 31, 2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hedging Instruments:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">50.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Other Derivatives:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued&#160;expenses&#160;and&#160;other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">9.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.61013645224172%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:40%;"></td><td style="width:40%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance Sheet Location</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value<br>As of December 31, 2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hedging Instruments:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued&#160;expenses&#160;and&#160;other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Other Derivatives:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued&#160;expenses&#160;and&#160;other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><a name="sB08AC59F3420BA8656DA20166F458AD9"></a></div><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">10.&#160;&#160;&#160;&#160;&#160;&#160;Property, Plant and Equipment</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Property, plant and equipment are recorded at historical cost, net of accumulated depreciation. Components of property, plant and equipment, net are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:67%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Land</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">137.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">74.7</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Buildings</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,107.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,035.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Leasehold improvements</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">123.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">166.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Machinery and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,105.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,079.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Computer software and hardware</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">746.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">647.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Furniture and fixtures</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">60.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">72.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Construction in progress</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">658.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">441.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total cost</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,941.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,517.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Less: accumulated depreciation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1,439.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1,330.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total property, plant and equipment, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,501.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,187.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Depreciation expense totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$309.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$217.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$198.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we capitalized interest costs related to construction in progress totaling approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$12.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$6.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Solothurn, Switzerland Facility</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the first quarter of 2016 we closed on the purchase of land in Solothurn, Switzerland for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Swiss Francs (approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$62.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">). We are building a biologics manufacturing facility on this land in the Commune of Luterbach over the next several years. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$481.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$99.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, capitalized as construction in progress related to the construction of this facility. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 36</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Research Triangle Park Facility Purchase</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On August 24, 2015, we purchased from Eisai, Inc. (Eisai) its drug product manufacturing facility and supporting infrastructure in Research Triangle Park (RTP), North Carolina for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$104.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The purchase price consisted of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$58.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for buildings, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$25.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for machinery and equipment and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$20.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for land.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On August 24, 2015, we also amended our existing </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">-year lease related to Eisai's oral solid dose products manufacturing facility in RTP, North Carolina where we manufacture our and Eisai's oral solid dose products. As amended, the lease provides for a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">-year term and our agreement to purchase the facility upon expiration of the lease term and Eisai's completion of certain activities. Accordingly, we recorded the assets along with a corresponding financing obligation on our consolidated balance sheet for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$20.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the net present value of the future minimum lease payments. The assets were recorded as a component of buildings and machinery and equipment. We expect to complete the purchase of the oral solid products manufacturing facility at the end of the lease term in the third quarter of 2018.</font></div><div><a name="s705B4F31DE94E08E9BD320166F55BEF6"></a></div><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">11.&#160;&#160;&#160;&#160;&#160;Indebtedness</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our indebtedness is summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:67%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Current portion:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes payable to Fumedica</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Financing arrangement for the purchase of the RTP facility</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current portion of notes payable and other financing arrangements</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Non-current portion:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.875% Senior Notes due March 1, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">558.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">565.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.900% Senior Notes due September 15, 2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,485.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,485.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.625% Senior Notes due September 15, 2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">993.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">992.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.050% Senior Notes due September 15, 2025</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,734.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,733.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.200% Senior Notes due September 15, 2045</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,721.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,721.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes payable to Fumedica</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Financing arrangement for the purchase of the RTP facility</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">16.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current portion of notes payable and other financing arrangements</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6,512.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,521.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following is a summary of our principal indebtedness as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$550.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;aggregate principal amount of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">6.875%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes due March 1, 2018, valued at </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">99.184%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of par;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;aggregate principal amount of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2.90%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes due September 15, 2020, valued at </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">99.792%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of par;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;aggregate principal amount of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">3.625%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes due September 15, 2022, valued at </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">99.920%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of par;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1.75 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;aggregate principal amount of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">4.05%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes due September 15, 2025, valued at </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">99.764%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of par; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1.75 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;aggregate principal amount of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">5.20%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes due September 15,&#160;2045, valued at </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">99.294%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of par.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The costs associated with these offerings of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$52.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;have been recorded as a reduction to the carrying amount of the debt on our consolidated balance sheet. These costs along with the discounts will be amortized as additional interest expense using the effective interest rate method over the period from issuance through maturity. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These notes are senior unsecured obligations. The notes may be redeemed at our option at any time at </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of the principal amount plus accrued interest and a specified make-whole amount. The </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.875%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes due in </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 37</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018 contain a change of control provision that may require us to purchase the notes under certain circumstances. There is also an interest rate adjustment feature that requires us to pay interest at an increased rate on the notes if the credit rating on the notes declines below investment grade. The remaining Senior Notes contain a change of control provision that may require us to purchase the notes at a price equal to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">101%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of the principal amount plus accrued and unpaid interest to the date of purchase under certain circumstances.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.90%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes offering due in 2020, we entered into interest rate swap contracts. The carrying value of the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.90%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes includes approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$4.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;related to changes in the fair value of these contracts. For additional information, please read Note 9, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Derivative Instruments, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.875%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;Senior Notes due in 2018, we entered into interest rate swap contracts where we received a fixed rate and paid a variable rate. These contracts were terminated in December 2008. Upon termination of these swaps, the carrying amount of the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.875%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;Senior Notes due in 2018 was increased by </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$62.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and is being amortized using the effective interest rate method over the remaining life of the Senior Notes and is being recognized as a reduction of interest expense. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$9.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;remains to be amortized. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Notes Payable to Fumedica</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our 2006 distribution agreement with Fumedica, we issued notes totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">61.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Swiss Francs which were payable to Fumedica in varying amounts from June 2008 through June 2018. Our remaining note payable to Fumedica had a carrying value of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Swiss Francs (</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$6.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Swiss Francs (</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$9.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Credit Facility</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2015 we entered into a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">five</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">-year senior unsecured revolving credit facility under which we are permitted to draw funds for working capital and general corporate purposes. The terms of the revolving credit facility include a financial covenant that requires us not to exceed a maximum consolidated leverage ratio. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">no</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;outstanding borrowings and were in compliance with all covenants under this facility.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Financing Arrangement</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During 2015 we recorded a financing obligation in relation to the amendment of our lease agreement of Eisai's oral solid dose products manufacturing facility in RTP, North Carolina where we manufacture our and Eisai's oral solid dose products. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the financing obligation totaled approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$18.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$19.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. For additional information, please read Note 10, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Property, Plant and Equipment</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Debt Maturity</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The total gross payments, excluding our financing arrangement, due under our debt arrangements are as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.4375%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:80%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">As of December 31, 2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">553.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,500.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2022 and thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4,500.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6,556.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair value of our debt is disclosed in Note&#160;7, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Fair Value Measurements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 38</font></div></div><hr style="page-break-after:always"><div><a name="sA0FB5C2B9951465C239320166F74C22B"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">12.&#160;&#160;&#160;&#160;&#160; Equity</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Preferred Stock</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;shares of Preferred Stock authorized, of which </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.75 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares are authorized as Series A, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares are authorized as Series X junior participating and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.25 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares are undesignated. Shares may be issued without a vote or action of stockholders from time to time in classes or series with the designations, powers, preferences, and the relative, participating, optional or other special rights of the shares of each such class or series and any qualifications, limitations or restrictions thereon as set forth in the instruments governing such shares. Any such Preferred Stock may rank prior to common stock as to dividend rights, liquidation preference or both, and may have full or limited voting rights and may be convertible into shares of common stock. No shares of Preferred Stock were issued and outstanding during </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Common Stock</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table describes the number of shares authorized, issued and outstanding of our common stock as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"></td></tr><tr><td style="width:24%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">As of December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Authorized</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Issued</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Authorized</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Issued</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Outstanding</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Common stock</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,000.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">238.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">215.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,000.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">241.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">218.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Share Repurchases</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2016 our Board of Directors authorized a program to repurchase up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of our common stock (2016 Share Repurchase Program). This authorization does not have an expiration date. Repurchased shares will be retired. As of December 31, 2016, we repurchased and retired </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares of common stock at a cost of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;under our 2016 Share Repurchase Program.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2015 our Board of Directors authorized a program to repurchase up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of our common stock (2015 Share Repurchase Program), which was completed as of December&#160;31, 2015. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we repurchased and retired approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares of common stock at a cost of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;under our 2015 Share Repurchase Program.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2011 our Board of Directors authorized a program to repurchase up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">20.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares of our common stock (2011 Share Repurchase Program), which has been used principally to offset common stock issuances under our share-based compensation plans. The 2011 Share Repurchase Program does not have an expiration date. We did not repurchase any shares of common stock under our 2011 Share Repurchase Program during the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. During </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;we purchased approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares of common stock at a cost of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$886.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;under our 2011 Share Repurchase Program. We have approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares remaining available for repurchase under this authorization.</font></div><div><a name="sFF911103C7BA7EC2064E20166F7463A4"></a></div><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">13.&#160;&#160;&#160;&#160;&#160;&#160;Accumulated Other Comprehensive Income (Loss)</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the changes in accumulated other comprehensive income (loss), net of tax by component:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td style="width:26%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Translation Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(0.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(37.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(195.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(224.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(10.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">51.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(138.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(92.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(4.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(3.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(10.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">47.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(138.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(95.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(10.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">57.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(32.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(334.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(319.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 39</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td style="width:26%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Translation Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">71.7</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(31.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(99.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(59.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">110.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(6.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(96.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(172.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(171.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(61.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(6.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(96.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(164.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(37.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(195.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(224.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td style="width:26%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Translation Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.6</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(23.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(19.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.0</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(27.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">101.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(12.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(109.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(19.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(6.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(6.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(12.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(6.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">95.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(12.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(109.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(31.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2014</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">71.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(31.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(99.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(59.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the amounts reclassified from accumulated other comprehensive income:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:28%;"></td><td style="width:25%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Income Statement Location</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amounts Reclassified from</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated Other Comprehensive Income</font></div></td></tr><tr><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended December&#160;31,</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on securities available for sale</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(0.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on cash flow hedges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">173.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total reclassifications, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">171.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 40</font></div></div><hr style="page-break-after:always"><div><a name="sB4034169AE6D10706AD420166FA36CE2"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">14.&#160;&#160;&#160;&#160;&#160;&#160;Earnings&#160;per Share</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic and diluted earnings per share are calculated as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:53%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Numerator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,702.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,547.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,934.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Denominator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted average number of common shares outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">218.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">230.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">236.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effect of dilutive securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Stock options and employee stock purchase plan</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Time-vested restricted stock units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Market stock units</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Dilutive potential common shares</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Shares used in calculating diluted earnings per share</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">218.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">231.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">237.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts excluded from the calculation of net income per diluted share because their effects were anti-dilutive were insignificant.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Earnings per share for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, reflects, on a weighted average basis, the repurchase of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares, respectively, of our common stock under our share repurchase authorizations.</font></div><div><a name="s36AC6E6A559AA26DA10320166FB2417E"></a></div><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">15.&#160;&#160;&#160;&#160;&#160;Share-based Payments</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Share-based Compensation Expense</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes share-based compensation expense included in our consolidated statements of income:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:55%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">84.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">88.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">102.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">121.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">127.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">150.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restructuring charges</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(8.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">204.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">207.3</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">252.4</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capitalized share-based compensation costs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(14.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(11.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(10.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in total cost and expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">189.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">196.3</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">242.4</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax effect</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(54.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(55.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(72.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">135.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">140.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">170.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 41</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:55%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Market stock units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">38.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">38.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Time-vested restricted stock units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">120.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">119.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">115.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash settled performance units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">16.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">22.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">65.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">18.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee stock purchase plan</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">11.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">204.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">207.3</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">252.4</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capitalized share-based compensation costs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(14.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(11.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(10.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in total cost and expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">189.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">196.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">242.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Windfall tax benefits from vesting of stock awards, exercises of stock options and ESPP participation were </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$12.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$78.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$96.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. These amounts have been calculated under the alternative transition method. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, unrecognized compensation cost related to unvested share-based compensation was approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$189.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, net of estimated forfeitures. We expect to recognize the cost of these unvested awards over a weighted-average period of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.9</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;years.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Share-Based Compensation Plans</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;share-based compensation plans pursuant to which awards are currently being made: (i)&#160;the Biogen Inc. 2006 Non-Employee Directors Equity Plan (2006&#160;Directors Plan); (ii)&#160;the Biogen Inc. 2008 Amended and Restated Omnibus Equity Plan (2008 Omnibus Plan); and (iii)&#160;the Biogen Inc. 2015 Employee Stock Purchase Plan (ESPP). </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Directors Plan</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2006 our stockholders approved the 2006&#160;Directors Plan for share-based awards to our directors. Awards granted from the 2006&#160;Directors Plan may include stock options, shares of restricted stock, restricted stock units, stock appreciation rights and other awards in such amounts and with such terms and conditions as may be determined by a committee of our Board of Directors, subject to the provisions of the plan. We have reserved a total of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares of common stock for issuance under the 2006&#160;Directors Plan. The 2006&#160;Directors Plan provides that awards other than stock options and stock appreciation rights will be counted against the total number of shares reserved under the plan in a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.5-to-1</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;ratio. In June 2015 our stockholders approved an amendment to extend the term of the 2006 Directors Plan until June 2025.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Omnibus Plans</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2008 our stockholders approved the 2008 Omnibus Plan for share-based awards to our employees. Awards granted from the 2008 Omnibus Plan may include stock options, shares of restricted stock, restricted stock units, performance shares, shares of phantom stock, stock appreciation rights and other awards in such amounts and with such terms and conditions as may be determined by a committee of our Board of Directors, subject to the provisions of the plan. Shares of common stock available for issuance under the 2008 Omnibus Plan consist of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares reserved for this purpose, plus shares of common stock that remained available for issuance under our 2005 Omnibus Equity Plan on the date that our stockholders approved the 2008 Omnibus Plan, plus shares that were subject to awards under the 2005 Omnibus Equity Plan that remain unissued upon the cancellation, surrender, exchange or termination of such awards. The 2008 Omnibus Equity Plan provides that awards other than stock options and stock appreciation rights will be counted against the total number of shares available under the plan in a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.5-to-1</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;ratio.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have not made any awards pursuant to the 2005 Omnibus Equity Plan since our stockholders approved the 2008 Omnibus Plan, and do not intend to make any awards pursuant to the 2005 Omnibus Equity Plan in the future, except that unused shares under the 2005 Omnibus Equity Plan have been carried over for use under the 2008 Omnibus Plan.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 42</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Stock Options</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We currently do not grant stock options to our employees or directors. Outstanding stock options previously granted to our employees and directors generally have a ten-year term and vest over a period of between one and four years, provided the individual continues to serve at Biogen through the vesting dates. Options granted under all plans are exercisable at a price per share not less than the fair market value of the underlying common stock on the date of grant. The estimated fair value of options, including the effect of estimated forfeitures, is recognized over the options&#8217; vesting periods. The fair value of the stock options granted in 2010 was estimated as of the date of grant using a Black-Scholes option valuation model. There were </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">no</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;grants of stock options made in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, all outstanding options were exercisable.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The expected life of options granted is derived using assumed exercise rates based on historical exercise patterns and represents the period of time that options granted are expected to be outstanding. Expected stock price volatility is based upon implied volatility for our exchange-traded options and other factors, including historical volatility. After assessing all available information on either historical volatility, implied volatility, or both, we have concluded that a combination of both historical and implied volatility provides the best estimate of expected volatility. The risk-free interest rate used is determined by the market yield curve based upon risk-free interest rates established by the Federal Reserve, or non-coupon bonds that have maturities equal to the expected term. The dividend yield of zero is based upon the fact that we have not historically granted cash dividends, and do not expect to issue dividends in the foreseeable future. Stock options granted prior to January&#160;1, 2006 were valued based on the grant date fair value of those awards, using the Black-Scholes option pricing model, as previously calculated for pro-forma disclosures.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our stock option activity:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:67%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Exercise</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Price</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Outstanding at December 31, 2015</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">107,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">53.94</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(41,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">53.75</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cancelled</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Outstanding at December 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">66,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">54.06</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The total intrinsic values of options exercised in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$38.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$42.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. The aggregate intrinsic values of options outstanding as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The weighted average remaining contractual term for options outstanding as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.0</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;years. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the amount of tax benefit realized for stock options and cash received from the exercise of stock options:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:53%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Tax benefit realized for stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash received from the exercise of stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Market Stock Units (MSUs)</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">MSUs awarded to employees prior to 2014 vested in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">four</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;equal annual increments beginning on the first anniversary of the grant date. Participants may ultimately earn between </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">150%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of the target number of units granted based on actual stock performance. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">MSUs awarded to employees in 2014, 2015 and 2016 vest in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;equal annual increments beginning on the first anniversary of the grant date, and participants may ultimately earn between </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">200%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of the target number of units granted based on actual stock performance. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 43</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The vesting of these awards is subject to the respective employee&#8217;s continued employment. The number of MSUs granted represents the target number of units that are eligible to be earned based on the attainment of certain market-based criteria involving our stock price. The number of MSUs earned is calculated at each annual anniversary from the date of grant over the respective vesting periods, resulting in multiple performance periods. Accordingly, additional MSUs may be issued or currently outstanding MSUs may be cancelled upon final determination of the number of awards earned. Compensation expense, including the effect of forfeitures, is recognized over the applicable service period.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our MSU activity:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:67%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Grant&#160;Date</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2015</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">269,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">339.89</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Granted (a)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">168,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">328.03</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(155,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">244.68</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(52,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">371.62</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">230,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">355.60</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">MSUs granted in 2016 include approximately </font><font style="font-family:Franklin Gothic Book;font-size:9pt;">15,000</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#32;and </font><font style="font-family:Franklin Gothic Book;font-size:9pt;">20,000</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#32;MSUs issued in 2016 based upon the attainment of performance criteria set for 2013 and 2012, respectively, in relation to awards granted in those years. The remainder of MSUs granted during 2016 include awards granted in conjunction with our annual awards made in February 2016 and MSUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We value grants of MSUs using a lattice model with a Monte Carlo simulation. This valuation methodology utilizes several key assumptions, including the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">60</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;calendar day average closing stock price on grant date for MSUs awarded prior to 2014, the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;calendar day average closing stock price on the date of grant for MSUs awarded in 2014, 2015 and 2016, expected volatility of our stock price, risk-free rates of return and expected dividend yield.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;The assumptions used in our valuation are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:44%;"></td><td style="width:18%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td><td style="width:18%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Range of expected stock price volatility</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">38.2% - 40.7%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31.0% - 33.2%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31.7% - 35.1%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Range of risk-free interest rates</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.6% - 0.9%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2% - 1.0%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1% - 0.7%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30 calendar day average stock price on grant date</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$260.67 - $304.86</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$277.35 - $426.27</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$280.88 - $335.65</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted-average per share grant date fair value</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$328.03</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$493.43</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$395.22</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The total fair values of MSUs vested in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$39.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$109.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$117.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Cash Settled Performance Units (CSPUs)</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">CSPUs awarded to employees vest in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;equal annual increments beginning on the first anniversary of the grant date. The vesting of these awards is subject to the respective employee&#8217;s continued employment with such awards settled in cash. The number of CSPUs granted represents the target number of units that are eligible to be earned based on the attainment of certain performance measures established at the beginning of the performance period, which ends on December&#160;31 of each year. Participants may ultimately earn between </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">200%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of the target number of units granted based on the degree of actual performance metric achievement. Accordingly, additional CSPUs may be issued or currently outstanding CSPUs may be cancelled upon final determination of the number of units earned. CSPUs awarded prior to 2014 are settled in cash based on the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">60</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;calendar day average closing stock price through each vesting date once the actual vested and earned number of units is known. CSPUs awarded in 2014, 2015 and 2016 will be settled in cash based on the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;calendar day average closing stock price through each vesting date, once the actual vested and earned number of units is known. Since no shares are issued, these awards do not dilute equity. Compensation expense, including the effect of forfeitures, is recognized over the applicable service period.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 44</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our CSPU activity:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:82%;"></td><td style="width:17%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2015</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">192,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Granted (a)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">86,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(117,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(39,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">122,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">CSPUs granted in 2016 include awards granted in conjunction with our annual awards made in February 2016 and CSPUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The total cash paid in settlement of CSPUs vested in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$31.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$79.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$92.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.&#160; </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Performance-vested Restricted Stock Units (PUs)</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2014 we revised our long term incentive program to include a new type of award granted to certain employees in the form of restricted stock units that may be settled in cash or shares of our common stock at the sole discretion of the Compensation and Management Development Committee of our Board of Directors. These awards are structured and accounted for the same way as the cash settled performance units, and vest in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;equal annual increments beginning on the first anniversary of the grant date. The number of PUs granted represents the target number of units that are eligible to be earned based on the attainment of certain performance measures established at the beginning of the performance period, which ends on December 31 of each year. Participants may ultimately earn between </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">200%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of the target number of units granted based on the degree of actual performance metric achievement. Accordingly, additional PUs may be issued or currently outstanding PUs may be cancelled upon final determination of the number of units earned. PUs settling in cash are based on the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;calendar day average closing stock price through each vesting date once the actual vested and earned number of units is known. Compensation expense, including the effect of forfeitures, is recognized over the applicable service period.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our PU activity:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:82%;"></td><td style="width:17%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2015</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">103,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Granted (a)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">55,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(31,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(17,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">110,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">PUs granted in 2016 include awards granted in conjunction with our annual awards made in February 2016 and PUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">32,000</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;PU were converted to share settlements, of which approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11,000</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares were vested and issued. All other PUs that vested in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;were settled in cash totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$12.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">All PUs that vested in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;were settled in cash totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$8.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Time-Vested Restricted Stock Units (RSUs)</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">RSUs awarded to employees generally vest no sooner than </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">one-third per year over three years</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;on the anniversary of the date of grant, or upon the third anniversary of the date of the grant, provided the employee remains continuously employed with us, except as otherwise provided in the plan. Shares of our common stock will be delivered to the employee upon vesting, subject to payment of applicable withholding taxes. RSUs awarded to directors for service on our Board of Directors vest on the first anniversary of the date of grant, provided in each case that the director continues to serve on our Board of Directors through the vesting date. Shares of our common stock will be delivered to the director upon vesting and are not subject to any withholding taxes. The fair value of all RSUs is based on the market value of our stock on the date of grant. Compensation expense, including the effect of forfeitures, is recognized over the applicable service period.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 45</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our RSU activity:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:67%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Grant&#160;Date</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2015</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">810,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">323.87</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Granted (a)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">649,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">268.52</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(406,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">285.13</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(165,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">310.30</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">888,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">303.49</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">RSUs granted in 2016 primarily represent RSUs granted in conjunction with our annual awards made in February 2016 and awards made in conjunction with the hiring of new employees. RSUs granted in 2016 also include approximately </font><font style="font-family:Franklin Gothic Book;font-size:9pt;">11,000</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#32;RSUs granted to our Board of Directors.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">RSUs granted in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;had weighted average grant date fair values of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$388.88</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$321.72</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The total fair values of RSUs vested in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$104.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$239.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$281.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.&#160; </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Employee Stock Purchase Plan (ESPP)</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2015 our stockholders approved the Biogen Inc. 2015 ESPP (2015 ESPP). The 2015 ESPP, which became effective on July 1, 2015, replaced the Biogen Idec Inc. 1995 ESPP (1995 ESPP), which expired on June&#160;30, 2015. The maximum aggregate number of shares of our common stock that may be purchased under the 2015 ESPP is </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our ESPP activity:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:53%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except share amounts)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Shares issued under the 2015 ESPP</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">190,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">78,000</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">**</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Shares issued under the 1995 ESPP</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">98,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">180,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash received under the 2015 ESPP</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">41.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">19.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">**</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash received under the 1995 ESPP</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">46.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 46</font></div></div><hr style="page-break-after:always"><div><a name="s7E07590119C5E641939920167000050E"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">16.&#160;&#160;&#160;&#160;&#160;&#160;Income Taxes</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Income Tax Expense</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income before income tax provision and the income tax expense consist of the following:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:53%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Income before income taxes (benefit):</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Domestic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,655.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,386.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,557.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,277.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,380.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,389.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4,933.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,767.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,946.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Income tax expense (benefit):</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Federal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,304.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,214.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,159.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">State</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">55.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">38.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">65.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">52.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">54.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">73.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,412.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,307.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,298.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferred:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Federal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(125.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(129.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(280.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">State</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(3.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(21.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(45.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(14.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(6.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(175.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(145.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(308.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total income tax expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,237.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,161.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">989.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Deferred Tax Assets and Liabilities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Significant components of our deferred tax assets and liabilities are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:67%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As&#160;of&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Deferred tax assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Tax credits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">201.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">189.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory, other reserves and accruals</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">250.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">243.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangibles, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">459.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">328.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net operating loss</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">65.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">61.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">63.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">49.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(16.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(14.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total deferred tax assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,071.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">871.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Deferred tax liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchased intangible assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(376.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(440.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Depreciation, amortization and other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(113.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(102.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total deferred tax liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(490.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(542.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition to deferred tax assets and liabilities, we have recorded prepaid tax and deferred charges related to intercompany transactions. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the total deferred charges and prepaid taxes were </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$989.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$697.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 47</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Tax Rate</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:55%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Statutory rate</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">35.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">State taxes</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Taxes on foreign earnings</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(9.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(10.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(9.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Credits and net operating loss utilization</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchased intangible assets</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Manufacturing deduction</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other permanent items</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effective tax rate</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">25.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">25.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our effective tax rate for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;increased primarily due to a net state tax benefit in 2015 resulting from the remeasurement of one of our uncertain tax positions, described below, and a higher relative percentage of our earnings being attributed to the U.S., a higher tax jurisdiction.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our effective tax rate for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;benefited from lower taxes on foreign earnings and reflects a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$27.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;benefit from the 2015 remeasurement of one of our uncertain tax positions.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had net operating losses and general business credit carry forwards for federal income tax purposes of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$22.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$140.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, which begin to expire in 2020. Additionally, for state income tax purposes, we had net operating loss carry forwards of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$86.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which begin to expire in 2017. For state income tax purposes, we also had research and investment credit carry forwards of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$126.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which begin to expire in 2017. For foreign income tax purposes, we had </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$489.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of net operating loss carryforwards, which begin to expire in 2021.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In assessing the realizability of our deferred tax assets, we have considered whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. In making this determination, under the applicable financial reporting standards, we are allowed to consider the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies. Our estimates of future taxable income take into consideration, among other items, our estimates of future income tax deductions related to the exercise of stock options. Based upon the level of historical taxable income and income tax liability and projections for future taxable income over the periods in which the deferred tax assets are utilizable, we believe it is more likely than not that we will realize the net benefits of the deferred tax assets of our wholly owned subsidiaries. In the event that actual results differ from our estimates or we adjust our estimates in future periods, we may need to establish a valuation allowance, which could materially impact our financial position and results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, undistributed foreign earnings of non-U.S.&#160;subsidiaries included in consolidated retained earnings and other basis differences aggregated approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$7.6 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We intend to reinvest these earnings indefinitely in operations outside the U.S.&#160;The residual U.S. tax liability, if cumulative amounts were repatriated, would be between </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.8 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.3 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 48</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accounting for Uncertainty in Income Taxes</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A reconciliation of the beginning and ending amount of our unrecognized tax benefits is summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:56%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance at January&#160;1,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">67.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">131.5</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">110.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Additions based on tax positions related to the current period</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">20.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Additions for tax positions of prior periods</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">36.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">19.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">86.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Reductions for tax positions of prior periods</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(13.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(49.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(23.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Statute expirations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Settlements</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(64.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(42.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(60.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance at December&#160;31,</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">32.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">67.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">131.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We and our subsidiaries are routinely examined by various taxing authorities. We file income tax returns in the U.S.&#160;federal jurisdiction, various U.S. states, and foreign jurisdictions. With few exceptions, including the proposed disallowance we discuss below, we are no longer subject to U.S.&#160;federal tax examination for years before 2013 or state, local, or non-U.S.&#160;income tax examinations for years before 2005. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Included in the balance of unrecognized tax benefits as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;are </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$26.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$53.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;(net of the federal benefit on state issues), respectively, of unrecognized tax benefits that, if recognized, would affect the effective income tax rate in future periods. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognize potential interest and penalties accrued related to unrecognized tax benefits in income tax expense. In </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;we recognized a net interest expense of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$9.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. In </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;we recognized net interest expense of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. In </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;we recognized a net interest expense of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$4.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We have accrued approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$25.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$12.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for the payment of interest as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2015 we received a final assessment from the Danish Tax Authority (SKAT) for fiscal 2009 regarding withholding taxes and the treatment of certain intercompany transactions involving a Danish affiliate and another of our affiliates.&#160;In April 2016 we received final assessments from the SKAT for 2011 and 2013 regarding withholding taxes for similar intercompany transactions. The total amount assessed for 2009, 2011 and 2013 is estimated to be </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$58.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, including interest. For the assessments related to 2011 and 2013 we have made payments to SKAT totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$12.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We continue to dispute the assessments for all of these periods and believe that the positions taken in our historical filings are valid. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Federal Uncertain Tax Positions</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the year ended December 31, 2015, the net effect of adjustments to one of our uncertain tax positions was a net benefit of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$27.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, primarily related to the state impact of a federal uncertain tax item.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">It is reasonably possible that we will adjust the value of our uncertain tax positions related to our revenues from anti-CD20 therapeutic programs and certain transfer pricing issues as we receive additional information from various taxing authorities, including reaching settlements with the authorities. In addition, the IRS and other national tax authorities routinely examine our intercompany transfer pricing with respect to intellectual property related transactions and it is possible that they may disagree with one or more positions we have taken with respect to such valuations.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 49</font></div></div><hr style="page-break-after:always"><div><a name="sE5B9D9F97FB5BBBD60972016702F0169"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">17.&#160;&#160;&#160;&#160;&#160;&#160;Other Consolidated Financial Statement Detail</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Supplemental Cash Flow Information</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Supplemental disclosure of cash flow information for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, is as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:51%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash paid during the year for:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">281.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">39.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">41.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,642.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,674.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,163.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Non-cash Operating, Investing and Financing Activity</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2016 we accrued </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$454.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;related to the recent settlement and license agreement with Forward Pharma A/S (Forward Pharma). For additional information related to this transaction, please read Note 21, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Commitment and Contingencies</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the fourth quarter of 2016 we accrued </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$300.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;upon reaching </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$11.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in total cumulative sales of Fumapharm Products. The amount, net of tax benefit, was accounted for as an increase to goodwill in accordance with the accounting standard applicable to business combinations when we acquired Fumapharm and is expected to be paid in the first quarter of 2017. For additional information related to this transaction, please read Note 21, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Commitments and Contingencies</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the construction of our manufacturing facility in Solothurn, Switzerland, we accrued charges related to processing equipment and engineering services of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$100.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in our consolidated balance sheet. For additional information related to this transaction, please read Note 10,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#32;Property, Plant and Equipment</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2015 upon completion of our acquisition of Convergence, we recorded a contingent consideration obligation of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$274.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as part of the purchase price. For additional information related to this transaction, please read Note 2, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Income (Expense), Net</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Components of other income (expense), net, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:53%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">63.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">22.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(260.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(95.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(29.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gain (loss) on investments, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign exchange gains (losses), net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(9.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(32.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(11.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(17.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(13.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(8.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other income (expense), net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(217.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(123.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(25.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Current Assets</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets include prepaid taxes totaling approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$817.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$550.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 50</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accrued Expenses and Other</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other consists of the following:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:67%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current portion of contingent consideration obligations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">580.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">504.7</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued TECFIDERA litigation settlement and license charges</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">454.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenue-related reserves for discounts and allowances</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">438.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">518.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee compensation and benefits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">282.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">270.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Royalties and licensing fees</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">195.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">167.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Construction in progress</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">134.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">87.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Collaboration expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">130.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">685.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">516.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total accrued expenses and other</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,903.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,096.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Pricing of TYSABRI in Italy - AIFA</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the fourth quarter of 2011 Biogen Italia SRL, our Italian subsidiary,&#160;received a notice from the Italian National Medicines Agency (Agenzia Italiana del Farmaco or AIFA) that sales of TYSABRI after mid-February 2009 through mid-February 2011 exceeded by EUR</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;a reimbursement limit established pursuant to a Price Determination Resolution granted by AIFA in December 2006. In January 2012 we filed an appeal against AIFA in administrative court in Rome, Italy seeking a ruling that the reimbursement limit in the Price Determination Resolution should apply as written to only &#8220;the first </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months&#8221; of TYSABRI sales, which ended in mid-February 2009. That appeal is still pending. Since being notified in the fourth quarter of 2011 that AIFA believed a reimbursement limit was still in effect, we deferred revenue on sales of TYSABRI as if the reimbursement limit were in effect for each biannual period beginning in mid-February 2009. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2013 we negotiated an agreement in principle with AIFA's Price and Reimbursement Committee that would have resolved all of AIFA's claims relating to sales of TYSABRI in excess of the reimbursement limit for the periods from February 2009 through January 2013 for an aggregate repayment of EUR</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">33.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. As a result of this agreement in principle, we recorded a liability and reduction to revenue of EUR</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;at June 30, 2013, which approximated </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of the claim related to the period from mid-February 2009 through mid-February 2011. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we have approximately EUR</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">79 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;recorded as accrued expenses and other in our consolidated balance sheets for the periods mid-February 2009 through January 2013, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2014 AIFA approved a resolution affirming that there is no reimbursement limit from and after February 2013. As a result, we recognized </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$53.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of TYSABRI revenues related to the periods February 2013 through June 2014 that were previously deferred. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2017 we negotiated an agreement in principle with AIFA's Price and Reimbursement Committee to settle all of AIFA's existing claims relating to sales of TYSABRI in excess of the reimbursement limit for the periods from February 2009 through January 2013 for an aggregate repayment of EUR</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The agreement is subject to ratification by AIFA. If this most recent settlement agreement is accepted, we will recognize approximately EUR</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">42 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in revenue upon final resolution of this matter. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 51</font></div></div><hr style="page-break-after:always"><div><a name="sD1DFBDCC71887A1B2E892016704EE32A"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">18.&#160;&#160;&#160;&#160;&#160;Investments in Variable Interest Entities</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Consolidated Variable Interest Entities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our consolidated financial statements include the financial results of variable interest entities in which we are the primary beneficiary. The following are our significant variable interest entities.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Neurimmune SubOne AG</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2007 we entered into a collaboration agreement with Neurimmune SubOne AG (Neurimmune), a subsidiary of Neurimmune AG, for the development and commercialization of antibodies for the treatment of Alzheimer&#8217;s disease. Neurimmune conducts research to identify potential therapeutic antibodies and we are responsible for the development, manufacturing and commercialization of all products. Our anti-amyloid beta antibody, aducanumab, for the treatment of Alzheimer&#8217;s disease resulted from this collaboration. In September 2015 we announced that the first patient had been enrolled in a Phase 3 trial for aducanumab, which triggered a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$60.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;milestone payment due to Neurimmune. As we consolidate the financial results of Neurimmune, we recognized this payment as a charge to noncontrolling interest in the third quarter of 2015. Based upon our current development plans for aducanumab, we may pay Neurimmune up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$275.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in remaining milestone payments. We may also pay royalties in the low-to-mid-teens on sales of any resulting commercial products.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We determined that we are the primary beneficiary of Neurimmune because we have the power through the collaboration to direct the activities that most significantly impact the entity&#8217;s economic performance and are required to fund </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of the research and development costs incurred in support of the collaboration agreement. Accordingly, we consolidate the results of Neurimmune.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are required to reimburse Neurimmune for amounts that are incurred by Neurimmune for research and development expenses in support of the collaboration. Amounts reimbursed are reflected in research and development expense in our consolidated statements of income. During the years ending </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, these amounts were immaterial. Future milestone payments and royalties, if any, will be reflected in our consolidated statements of income as a charge to noncontrolling interest, net of tax, when such milestones are achieved. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The assets and liabilities of Neurimmune are not significant to our financial position or results of operations as it is a research and development organization. We have provided no financing to Neurimmune other than previously contractually required amounts.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Rodin Therapeutics, Inc.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2015 we paid </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$8.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for preferred stock in Rodin Therapeutics, Inc. (Rodin) and entered into an option and collaboration agreement which gave us the right to purchase all remaining outstanding shares of Rodin at any time until 35 days after acceptance of an Investigational New Drug (IND) application by the FDA. As we determined that we were the primary beneficiary of Rodin, we consolidated the results of Rodin and recorded an IPR&amp;D intangible asset of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$8.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and assigned approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to noncontrolling interest.  </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the fourth quarter of 2016 we terminated our collaboration agreement with Rodin. Upon termination of the collaboration agreement, we deconsolidated the results of Rodin and impaired the IPR&amp;D asset, resulting in an impairment loss of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$8.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;related to the IPR&amp;D asset recorded upon entering into the collaboration agreement. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The assets and liabilities of Rodin were not significant to our financial position or results of operations as Rodin is a research and development organization. We had provided no financing to Rodin other than the contractually required amounts disclosed above.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Ataxion Inc.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2014 we paid </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for preferred stock in Ataxion, Inc. (Ataxion) and entered into an option and collaboration agreement which gave us the right to purchase all outstanding shares of Ataxion at any time until 30 days after delivery of a Phase 1 clinical trial study report. As we determined that we were the primary beneficiary of Ataxion, we consolidated the results of Ataxion and recorded an IPR&amp;D intangible asset of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and assigned that amount to noncontrolling interest.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 52</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the fourth quarter of 2016 we terminated our option agreement with Ataxion. Upon termination of the collaboration agreement, we deconsolidated the results of Ataxion and impaired the IPR&amp;D asset, resulting in an impairment loss of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;related to the IPR&amp;D asset recorded upon entering into the collaboration agreement.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The assets and liabilities of Ataxion were not significant to our financial position or results of operations as Ataxion is a research and development organization. We had provided no financing to Ataxion other than the contractually required amounts disclosed above.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Unconsolidated Variable Interest Entities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have relationships with other variable interest entities that we do not consolidate as we lack the power to direct the activities that significantly impact the economic success of these entities. These relationships include investments in certain biotechnology companies and research collaboration agreements. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the total carrying value of our investments in biotechnology companies totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$47.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$29.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Our maximum exposure to loss related to these variable interest entities is limited to the carrying value of our investments.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have also entered into research collaboration agreements with certain variable interest entities where we are required to fund certain development activities. These development activities are included in research and development expense in our consolidated statements of income, as they are incurred. We have provided no financing to these variable interest entities other than previously contractually required amounts. </font></div><div><a name="s4B75A6CEA330B3A8ED4A2016704EC966"></a></div><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">19.&#160;&#160;&#160;&#160;&#160;&#160;Collaborative and Other Relationships</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our business strategy, we have entered into various collaboration agreements which provide us with rights to develop, produce and market products using certain know-how, technology and patent rights maintained by our collaborative partners. Terms of the various collaboration agreements may require us to make milestone payments upon the achievement of certain product research and development objectives and pay royalties on future sales, if any, of commercial products resulting from the collaboration.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Depending on the collaborative arrangement, we may record funding receivable or payable balances with our partners, based on the nature of the cost-sharing mechanism and activity within the collaboration. Our significant collaboration arrangements are discussed below.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Genentech (Roche Group)</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other potential anti-CD20 therapies under a collaboration agreement with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group. The Roche Group and its sub-licensees maintain sole responsibility for the development, manufacturing and commercialization of GAZYVA in the U.S. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our collaboration agreement will continue in effect until we mutually agree to terminate the collaboration, except that if we undergo a change in control, as defined in the collaboration agreement, Genentech has the right to present an offer to buy the rights to RITUXAN and we must either accept Genentech&#8217;s offer or purchase Genentech&#8217;s rights on the same terms as its offer. Genentech will also be deemed concurrently to have purchased our rights to any other anti-CD20 products in development in exchange for a royalty and our rights to GAZYVA in exchange for the compensation described in the table below. Our collaboration with Genentech was created through a contractual arrangement and not through a joint venture or other legal entity.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">RITUXAN</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Genentech is responsible for the worldwide manufacturing of RITUXAN. Development and commercialization rights and responsibilities under this collaboration are divided as follows:</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">U.S.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We share with Genentech co-exclusive rights to develop, commercialize and market RITUXAN in the U.S.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 53</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Canada</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We and Genentech have assigned our rights under our collaboration agreement with respect to Canada to the Roche Group.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">GAZYVA</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognize our share of the development and commercialization expenses of GAZYVA as a reduction of our share of pre-tax profits in revenues from anti-CD20 therapeutic programs. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Commercialization of GAZYVA impacts our percentage of the co-promotion profits for RITUXAN, as summarized in the table below.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">OCREVUS (Ocrelizumab)</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Genentech is solely responsible for development and commercialization of OCREVUS, a humanized anti-CD20 monoclonal antibody currently in development for MS, and funding future costs. Genentech cannot develop OCREVUS in CLL, NHL or Rheumatoid Arthritis (RA). We will receive tiered royalties between </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.5%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;on U.S. net sales of OCREVUS if approved for commercial sale by the FDA. The FDA has accepted for review the Biologics License Application for OCREVUS for the treatment of relapsing multiple sclerosis (RMS) and primary-progressive multiple sclerosis (PPMS), and has granted the application Priority Review Designation. There will be a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;reduction to these royalties if a biosimilar to OCREVUS is approved in the U.S. In addition, we will receive a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;royalty on net sales of OCREVUS outside the U.S., with the royalty period lasting </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;years from the first commercial sale of OCREVUS on a country-by-country basis. In June 2016 the European Medicines Agency (EMA) validated its marketing authorization application (MAA) of OCREVUS for the treatment of RMS and PPMS in the E.U. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Commercialization of OCREVUS will not impact the percentage of the co-promotion profits we receive for RITUXAN or GAZYVA.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Profit-sharing Formulas</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">RITUXAN Profit Share</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our current pretax co-promotion profit-sharing formula for RITUXAN provides for a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;share on the first </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$50.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of co-promotion operating profits earned each calendar year. Our share of annual co-promotion profits in excess of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$50.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;varies, as summarized in the table below, upon the following events:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:82%;"></td><td style="width:17%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Until GAZYVA First Non-CLL FDA Approval</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">40.0</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">After GAZYVA First Non-CLL FDA Approval until First GAZYVA Threshold Date</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">39.0</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">After First GAZYVA Threshold Date until Second GAZYVA Threshold Date</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">37.5</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">After Second GAZYVA Threshold Date</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">35.0</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;">First Non-CLL GAZYVA FDA Approval</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;means the FDA&#8217;s first approval of GAZYVA in an indication other than CLL.</font></div><div style="line-height:120%;padding-top:12px;padding-left:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;">First GAZYVA Threshold Date</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;means the earlier of (1)&#160;the date of the First Non-CLL GAZYVA FDA approval if U.S. gross sales of GAZYVA for the preceding consecutive 12 month period were at least </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$150.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;or (2)&#160;the first day of the calendar quarter after the date of the First Non-CLL GAZYVA FDA Approval that U.S. gross sales of GAZYVA within any consecutive 12 month period have reached </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$150.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;">Second GAZYVA Threshold Date</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;means the first day of the calendar quarter after U.S. gross sales of GAZYVA within any consecutive 12 month period have reached </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$500.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The Second GAZYVA Threshold Date can be achieved regardless of whether GAZYVA has been approved in a non-CLL indication.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our share of RITUXAN pre-tax profits in the U.S. decreased to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">39%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;from </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">40%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as GAZYVA was approved by the FDA in follicular lymphoma in February 2016. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, should the FDA approve an anti-CD20 product other than OCREVUS or GAZYVA that is acquired or developed by Genentech and subject to the collaboration agreement, our share of the co-promotion operating profits would be between </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">38%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;based on certain events.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 54</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">GAZYVA Profit Share</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our current pretax profit-sharing formula for GAZYVA provides for a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;share on the first </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$50.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of operating profits earned each calendar year. Our share of annual profits in excess of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$50.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;varies, as summarized in the table below, upon the following events:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:82%;"></td><td style="width:17%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Until First GAZYVA Threshold Date</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">39.0</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">After First GAZYVA Threshold Date until Second GAZYVA Threshold Date</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">37.5</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">After Second GAZYVA Threshold Date</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">35.0</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our share of operating losses on GAZYVA was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Revenues from Anti-CD20 Therapeutic Programs</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:53%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,249.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,269.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,117.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenue on sales in the rest of world for RITUXAN</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">65.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">69.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">78.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues from anti-CD20 therapeutic programs</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,314.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,339.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,195.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">39%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;profit-sharing threshold was met during the first quarter. In </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">40%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;profit-sharing threshold was met during the first quarter.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Prior to regulatory approval, we record our share of the expenses incurred by the collaboration for the development of anti-CD20 products in research and development expense in our consolidated statements of income. After an anti-CD20 product is approved, we record our share of the development expenses related to that product as a reduction of our share of pre-tax profits in revenues from anti-CD20 therapeutic programs. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Acorda</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2009 we entered into a collaboration and license agreement with Acorda Therapeutics, Inc. (Acorda) to develop and commercialize products containing fampridine in markets outside the U.S, including FAMPYRA.&#160;We also have responsibility for regulatory activities and the future clinical development of related products in those markets. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the terms of the collaboration and license agreement, we pay Acorda tiered royalties based on the level of ex-U.S. net sales. We may pay up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$375.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of additional milestone payments to Acorda based on the successful achievement of certain regulatory and commercial milestones. The next expected milestone would be </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, due if ex-U.S. net sales reach </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$100.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;over a period of four consecutive quarters. We will capitalize these additional milestones as intangible assets upon achievement of the milestone which will then be amortized utilizing an economic consumption model and recognized as amortization of acquired intangible assets. Royalty payments are recognized as a cost of goods sold.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the collaboration and license agreement, we have also entered into a supply agreement with Acorda for the commercial supply of FAMPYRA. This agreement is a sublicense arrangement of an existing agreement between Acorda and Alkermes, who acquired Elan Drug Technologies, the original party to the license with Acorda. During the years ending </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, total cost of sales related to royalties and commercial supply of FAMPRYA reflected in our consolidated statements of income were </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$31.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$30.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$29.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 55</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">AbbVie</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have a collaboration agreement with AbbVie aimed at advancing the development and commercialization of ZINBRYTA in MS, which was approved for the treatment of relapsing forms of MS in the U.S. in May 2016 and the E.U. in July 2016. We made milestone payments totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$32.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;related to these approvals, which were capitalized as intangible assets, net in our consolidated balance sheets. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the agreement, we and AbbVie conduct ZINBRYTA co-promotion activities in the U.S., E.U. and Canadian territories (Collaboration Territory), where development and commercialization costs and profits are shared equally. Outside of the Collaboration Territory, we are solely responsible for development and commercialization of ZINBRYTA and will pay a tiered royalty to AbbVie as a percentage of net sales in the low to high teens.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;We are responsible for manufacturing and research and development activities in both the Collaboration Territory and outside the Collaboration Territory and will record these activities within their respective lines in our consolidated statements of income, net of any reimbursement of research and development expenditures received from AbbVie.&#160;For the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the collaboration incurred </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$48.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$113.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$117.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for research and development activities, for which we recognized </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$24.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$60.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$67.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in our consolidated statements of income. During </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;we made milestone payments of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$16.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for the development of ZINBRYTA as a result of filing for regulatory approval in the U.S. and E.U. during the year. These payments were recorded as research and development expense in our consolidated statements of income.  </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Prior to regulatory approval, we also recognized </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$22.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of pre-commercialization expenses within our selling, general and administrative expense, which represents </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of the collaboration's pre-commercialization costs for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. After ZINBRYTA was approved by the FDA and EMA in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we began to recognize our share of the collaboration activities within the U.S., E.U. and Canadian territories as described below.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Co-promotion Profits and Losses</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the U.S., AbbVie recognizes revenues on sales to third parties and we recognize our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;share of the co-promotion profits or losses as a component of total revenues in our consolidated statements of income. The collaboration began selling ZINBRYTA in the U.S. in the third quarter of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. For the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized a net reduction in revenue of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$21.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to reflect our share of an overall net loss within the collaboration.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table provides a summary of the U.S. collaboration and our share of the co-promotion losses on ZINBRYTA in the U.S.:</font></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:84%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Year Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Costs and expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">50.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Co-promotion losses in the U.S.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">43.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of co-promotion losses in the U.S.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">21.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the E.U. and Canada, we recognize revenues on sales to third parties in product revenues, net in our consolidated statements of income. We also record the related cost of revenues and sales and marketing expenses to their respective line items in our consolidated statements of income as these costs are incurred. We reimburse AbbVie for their </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;share of the co-promotion profits or losses in the E.U. and Canada. This reimbursement is recognized in collaboration profit (loss) sharing in our consolidated statements of income. We began to recognize product revenues on sales of ZINBRYTA in the E.U. in the third quarter of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. For the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized income of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$4.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to reflect AbbVie's </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;sharing of the net collaboration losses in the E.U. and Canada. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 56</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Swedish Orphan Biovitrum AB (publ)</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2007 we acquired </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of the stock of Syntonix. Syntonix, now known as Bioverativ Therapeutics Inc. (formerly Biogen Hemophilia Inc.), had previously entered into a collaboration agreement with Swedish Orphan Biovitrum AB (publ) (Sobi) to jointly develop and commercialize Factor VIII and Factor IX hemophilia products, including ELOCTATE and ALPROLIX. Under an amended and restated collaboration agreement, we have commercial rights for North America (the Biogen North America Territory) and for rest of the world markets outside of the Sobi Territory, as defined below (the Biogen Direct Territory).&#160;Subject to the exercise of an option right that Sobi controls, Sobi has commercial rights in substantially all of Europe, Russia and certain countries in Northern Africa and the Middle East (the Sobi Territory). The collaboration agreement was amended and restated in April 2014. (References to the collaboration agreement refer to the amended and restated collaboration agreement).</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2014 Sobi exercised its option to assume final development and commercialization activities in the Sobi Territory for ELOCTA (the trade name for ELOCTATE in the E.U.). In July 2015 Sobi exercised its option to assume final development and commercialization of ALPROLIX in the Sobi Territory. Upon each exercise of opt-in right under the terms of the collaboration agreement, Sobi made a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;payment in escrow. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ELOCTA was approved by the EC in November 2015 and Sobi had its first commercial sale of ELOCTA in January 2016. In March 2016 the EC approved the transfer of the marketing authorization for ELOCTA in the E.U. from Biogen to Sobi, making Sobi the marketing authorization holder of ELOCTA in the E.U. As the marketing authorization holder, Sobi assumes full legal responsibility for ELOCTA, from a regulatory perspective, during its entire life cycle in the E.U. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$144.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in expenditures for ELOCTA, net of the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;escrow payment and other royalty adjustments as described in the table and its footnote (3) below, are reimbursable by Sobi under the collaboration agreement due to its election to assume final development and commercialization of ELOCTA within the Sobi Territory, which is the Opt-In Consideration for ELOCTA. This reimbursement will be recognized by us as royalty revenue in proportion to collaboration revenues, over a ten-year period, consistent with the initial patent term of the product.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ALPROLIX was approved in the E.U. by the EC in May 2016 and Sobi had its first commercial sale in June 2016. In September 2016 the EC approved the transfer of the marketing authorization for ALPROLIX in the E.U. from Biogen to Sobi, making Sobi the marketing authorization holder of ALPROLIX in the E.U. As the marketing authorization holder, Sobi assumes full legal responsibility for ALPROLIX, from a regulatory perspective, during its entire life cycle in the E.U. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$123.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in expenditures for ALPROLIX, net of the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;escrow payment and other royalty adjustments as described in the table and its footnote (3) below, are reimbursable to us by Sobi under the collaboration agreement due to Sobi's election to assume final development and commercialization of ALPROLIX in the Sobi Territory, which is the Opt-In Consideration for ALPROLIX. This reimbursement will be recognized by us as royalty revenue in proportion to collaboration revenues, over a ten-year period, consistent with the initial patent term of the product. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The Opt-In Consideration for each product will be paid by Sobi using a cross-royalty cash payment structure for sales in each company&#8217;s respective territories as an adjustment to the Base Rate in the table below. Under the collaboration agreement, cash payments are as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:51%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td><td style="width:16%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rates post Sobi Opt-In</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(3)</sup></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Royalty and Net Revenue Share Rates:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Method</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Base Rate following</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">1st&#160;commercial&#160;sale&#160;in</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">the Sobi Territory:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rate during the</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Reimbursement</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Period:</font></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Sobi rate to Biogen on net sales in the Sobi Territory</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Royalty</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">12%</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Base&#160;Rate<br>plus 5%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Biogen rate to Sobi on net sales in the Biogen North America Territory</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Royalty</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">12%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Base Rate<br>less 5%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Biogen rate to Sobi on net sales in the Biogen Direct Territory</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Royalty</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">17%</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Base Rate<br>less 5%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Biogen rate to Sobi on net revenue</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">from the Biogen Distributor Territory</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(2)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Net<br>Revenue<br>Share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">50%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Base Rate<br>less 15%</font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Net revenue represents Biogen&#8217;s pre-tax receipts from third-party distributors, less expenses incurred by Biogen in the conduct of commercialization activities supporting the distributor activities.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">The Biogen Distributor Territory represents Biogen territories where sales are derived utilizing a third-party distributor.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 57</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">A credit will be issued to Sobi against its reimbursement of the Opt-in Consideration for each product in an amount equal to the difference in the rate paid by Biogen to Sobi on sales in the Biogen territories for certain periods prior to the first commercial sale in the Sobi Territory versus the rate that otherwise would have been payable on such sales.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are recording revenue at the effective royalty rate expected over the term of the agreement of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">14%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and recording cost of sales at the effective royalty rate expected over the term of the agreement of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">If the reimbursement of the Opt-in Consideration has not been achieved within </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six years</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of the first commercial sale of such product, we maintain the right to require Sobi to pay any remaining balances due to us within </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">90 days</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of the six-year anniversary date of the first commercial sale.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Following the spin-off of our hemophilia business, this collaboration agreement with Sobi will continue with Bioverativ, an independent public company. For additional information about the spin-off, please see Note 1, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">and Note 26, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Subsequent Events </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Ionis Pharmaceuticals, Inc. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Long-Term Strategic Research Collaboration</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In September 2013 we entered into a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">-year research collaboration with Ionis, formerly known as Isis Pharmaceuticals Inc. under which both companies collaborate to perform discovery level research and then develop and commercialize antisense or other therapeutics for the treatment of neurological disorders.&#160;Under the collaboration, Ionis will perform research on a set of neurological targets identified within the agreement. Once the research has reached a specific stage of development, we will make the determination whether antisense is the preferred approach to develop a therapeutic candidate or whether another modality is preferred. If antisense is selected, Ionis will continue development and identify a product candidate. If another modality is used, we will assume the responsibility for identifying a product candidate and developing it. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the terms of this agreement, we paid Ionis an upfront amount of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$100.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.&#160;Of this payment, we recorded prepaid research and discovery services of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$25.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing the value of the Ionis full time equivalent employee resources which are required by the collaboration to provide research and discovery services to us over the term.&#160;The remaining </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$75.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of the upfront payment was recorded as research and development expense as it represented the purchase of intellectual property that had not reached technological feasibility.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Ionis is also eligible to receive milestone payments, license fees and royalty payments for all product candidates developed through this collaboration, with the specific amount dependent upon the modality of the product candidate advanced by us. During the years ending </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we triggered milestones of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$20.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$20.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, related to the advancement of IONIS-SOD1</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">Rx</sub></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for the treatment of ALS and other neurological targets identified.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For non-ALS antisense product candidates, Ionis will be responsible for global development through the completion of a Phase 2 trial and we will provide advice on the clinical trial design and regulatory strategy. For ALS antisense product candidates, we are responsible for global development, clinical trial design and regulatory strategy. We have an option to license a product candidate until completion of the Phase 2 trial. If we exercise our option, we will pay Ionis up to a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$70.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;license fee and assume global development, regulatory and commercialization responsibilities. Ionis could receive additional milestone payments upon the achievement of certain regulatory milestones of up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$130.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, plus additional amounts related to the cost of clinical trials conducted by Ionis under the collaboration, and royalties on future sales if we successfully develop the product candidate after option exercise. &#160;&#160;</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For product candidates using a different modality, we will be responsible for global development through all stages and will pay Ionis up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$90.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;upon the achievement of certain regulatory milestones and royalties on future sales if we successfully develop the product candidate. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 58</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Product Collaborations </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2012 we entered into three separate exclusive worldwide option and collaboration agreements with Ionis under which both companies will develop and commercialize SPINRAZA (nusinersen) for the treatment of SMA, antisense therapeutics for up to three gene targets and IONIS-DMPK</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">RX</sub></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for the treatment of myotonic dystrophy type 1 (DM1), respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">SPINRAZA (nusinersen)</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2012 we entered into an exclusive worldwide option and collaboration agreement with Ionis under which both companies will develop and commercialize the antisense investigational drug candidate, SPINRAZA, for the treatment of SMA. Under the terms of this agreement, we paid Ionis </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$29.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as an upfront payment. During 2014 we amended the agreement to adjust the amount of potential additional payments and terms of the exercise of our opt-in right to license SPINRAZA, which included providing for additional opt-in scenarios, based on the filing or acceptance of a new drug application (NDA) or marketing authorization application with the FDA or EMA. Consistent with the initial agreement, Ionis remained responsible for conducting the pivotal/Phase 3 trials and we provided input on the clinical trial design and regulatory strategy for the development of SPINRAZA.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we triggered clinical trial payments of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$35.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$42.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$57.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, related to the advancement of the program. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2016 we and Ionis announced that SPINRAZA met the primary endpoint for the interim analysis of the Phase 3 trial evaluating SPINRAZA in infantile-onset SMA. In November 2016 we and Ionis announced that SPINRAZA met the primary endpoint for the interim analysis of the Phase 3 trial evaluating SPINRAZA in later-onset SMA. During the third quarter of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;we exercised our option to develop and commercialize SPINRAZA and paid Ionis a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$75.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;license fee in connection with the option exercise. This amount was recognized as research and development expense in our consolidated statements of income. In December 2016 SPINRAZA was approved by the FDA for the treatment of SMA in pediatric and adult patients in the U.S. During the fourth quarter of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;we accrued a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$60.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;milestone payment due to Ionis for the approval of SPINRAZA in the U.S. This amount was capitalized in intangible assets, net in our consolidated balance sheets.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the years ending </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$257.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$74.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$27.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, were reflected in research and development expense in our consolidated statements of income related to the advancement of the program. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We may pay Ionis up to approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$90.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in additional milestone payments upon the achievement of certain regulatory milestones as well as a royalty rate in the mid-teens on future sales of SPINRAZA.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Antisense Therapeutics</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the terms of the December 2012 agreement relating to the development and commercialization of up to three gene targets we provided Ionis with an upfront payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$30.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and agreed to make potential additional payments, prior to licensing, of up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;based on the development of the selected product candidate as well as a mark-up of the cost estimate of the Phase 1 and Phase 2 trials. During </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;we triggered a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;milestone payment. Ionis will be responsible for global development of any product candidate</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt"> </sub></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">through the completion of a Phase 2 trial and we will provide advice on the clinical trial design and regulatory strategy. We have an option to license the product candidate</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt"> </sub></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">until completion of the Phase 2 trial. If we exercise our option, we will pay Ionis up to a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$70.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;license fee and assume global development, regulatory and commercialization responsibilities. Ionis could receive up to another </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$130.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in milestone payments upon the achievement of certain regulatory milestones as well as royalties on future sales</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt"> </sub></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">if we successfully develop the product candidate after option exercise. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">IONIS-DMPK</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">Rx</sub>&#160;</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the terms of the June 2012 agreement for the DM1 candidate, we provided Ionis with an upfront payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$12.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and agreed to make potential additional payments, prior to licensing, of up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$59.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;based on the development of the selected product candidate. During </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;we amended the agreement to adjust the amount of potential additional payments by an additional </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$4.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;due to changes in the clinical trial design. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 59</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;we terminated the development of the IONIS-DMPK</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">Rx </sub></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">product candidate to treat DM1 and returned the product to Ionis. During the years ending </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.1 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$9.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, were reflected in research and development expense in our consolidated statements of income. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Eisai Co., Ltd. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">BAN2401 and E2609 Collaboration</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2014 we entered into a collaboration agreement with Eisai Co., Ltd. (Eisai) (Eisai Collaboration Agreement) to jointly develop and commercialize two Eisai product candidates for the treatment of Alzheimer&#8217;s disease, BAN2401, a monoclonal antibody that targets amyloid-beta aggregates, and E2609, a BACE inhibitor.&#160;Under the Eisai Collaboration Agreement, Eisai serves as the global operational and regulatory lead for both compounds and all costs, including research, development, sales and marketing expenses, will be shared equally by us and Eisai. Following marketing approval in major markets, such as the U.S., the E.U. and Japan, we will co-promote BAN2401 and E2609 with Eisai and share profits equally. In smaller markets, Eisai will distribute these products and pay us a royalty. The Eisai Collaboration Agreement also provides the parties with certain rights and obligations in the event of a change in control of either party. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The Eisai Collaboration Agreement also provides Eisai an option to jointly develop and commercialize aducanumab, our anti-amyloid beta antibody candidate for Alzheimer&#8217;s disease (Aducanumab Option) and an option to jointly develop and commercialize one of our anti-tau monoclonal antibodies (Anti-Tau Option). Upon exercise of each of the Aducanumab Option and the Anti-Tau Option, we will execute a separate collaboration agreement with Eisai on terms and conditions that mirror the Eisai Collaboration Agreement.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Aducanumab Option</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Eisai may exercise the Aducanumab Option after either (i) the Phase 1b clinical trial for aducanumab and the Phase 2 clinical trial for BAN2401 (Post-Phase 2 Aducanumab Option), or (ii) completion of the Phase 3 clinical trial for aducanumab (Post-Phase 3 Aducanumab Option) under certain conditions. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The consideration we will receive if Eisai exercises the Post-Phase 2 Aducanumab Option depends on the development status of BAN2401. If BAN2401 is then determined to advance to Phase 3, we will be entitled to receive a single payment from Eisai upon regulatory approval of aducanumab and we will no longer be required to pay Eisai any milestone payments for products containing BAN2401 under the Eisai Collaboration Agreement. If the development of BAN2401 has instead been terminated, we will receive development and commercial milestone payments from Eisai (Post-Phase 2 Aducanumab Milestone Payments). If Eisai does not exercise its Post-Phase 2 Aducanumab Option, we may elect to terminate the Eisai Collaboration Agreement with respect to BAN2401 but, under certain conditions, will have the option to reinstate the Eisai Collaboration Agreement after completion of a BAN2401 Phase 3 clinical trial.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">If Eisai exercises its Post-Phase 3 Aducanumab Option, Eisai will be required to pay us all Phase 3 development and commercialization costs plus a mark-up and an amount equal to any unpaid Post-Phase 2 Aducanumab Milestone Payments that would have been payable if Eisai had exercised its Post-Phase 2 Aducanumab Option. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Anti-Tau Option</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Eisai may exercise the Anti-Tau Option after completion of the Phase 1 clinical trial of such anti-tau monoclonal antibody. If Eisai exercises its Anti-Tau Option, we will receive an upfront payment from Eisai and will be entitled to additional development and commercial milestone payments.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Upon the effective date of the Eisai Collaboration Agreement, we paid Eisai </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$100.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and recorded </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$17.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, reflecting the fair value of the options granted under the Eisai Collaboration Agreement, both of which were classified as research and development expense in our consolidated statements of income. During the second quarter of 2014 Eisai exercised its option under the Eisai Collaboration Agreement to expand the joint development and commercialization activities to include Japan. Upon such exercise, we paid Eisai an additional </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$35.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and recorded </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$21.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as research and development expense in our consolidated statements of income, which represented the difference between the payment made upon exercise of the option and the fair value of that option recorded as research and development expense upon closing of the agreement in the first quarter of 2014. During the fourth quarter of 2016 we recognized a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$50.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;milestone payment related to the initiation of a phase 3 </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 60</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">trial for E2609, which is included in research and development expense in our consolidated statements of income. We could pay Eisai up to an additional </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;under the Eisai Collaboration Agreement based on the future achievement of certain development, regulatory and commercial milestones.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition to our arrangements with Eisai, Neurimmune is entitled to milestone and royalty payments related to the development and commercialization of aducanumab and certain anti-tau antibodies. For additional information regarding our agreement with Neurimmune, please see Note 18, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Investments in Variable Interest Entities</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A summary of activity related to our collaboration with Eisai is as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:56%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total development expense incurred by the collaboration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">95.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">84.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">57.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen&#8217;s share of development expense, excluding upfront and milestone payments, reflected in our consolidated statements of income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">50.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">40.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">29.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Applied Genetic Technologies Corporation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2015 we announced a collaboration and license agreement to develop gene-based therapies for multiple ophthalmic diseases with Applied Genetic Technologies Corporation (AGTC). The collaboration will focus on the development of a portfolio of AGTC&#8217;s therapeutic programs, including both a clinical-stage candidate for X-linked Retinoschisis (XLRS) and a pre-clinical candidate for the treatment of X-Linked Retinitis Pigmentosa (XLRP). The agreement also includes options for early stage discovery programs in two ophthalmic diseases and one non-ophthalmic condition, as well as an equity investment in AGTC.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the third quarter of 2015 we made an upfront payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$124.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which included a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$30.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;equity investment in AGTC, prepaid research and development expenditures of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$58.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and total licensing and other fees of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$35.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$58.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of prepaid research and development expenditures were recorded in investments and other assets in our consolidated balance sheets and will be expensed as the services are provided. During </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;we recorded </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$54.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as research and development expense associated with AGTC in our consolidated statements of income, including the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$35.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;total licensing and other fees, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$6.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in research and development services, a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$7.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;premium on our equity investment and a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;clinical development milestone related to XLRS. During </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;we recorded </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$26.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in research and development services in research and development expense in our consolidated statements of income.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">AGTC is eligible to receive development, regulatory and commercial milestone payments aggregating in excess of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.1 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which includes up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$472.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;collectively for the two lead programs and up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$592.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;across the discovery programs. AGTC is also eligible to receive royalties in the mid-single digit to mid-teen percentages of annual net sales. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We were granted worldwide commercialization rights for the XLRS and XLRP programs. AGTC has an option to share development costs and profits after the initial clinical trial data are available, and an option to co-promote the second of these products to be approved in the U.S. AGTC will lead the clinical development programs of XLRS through product approval and of XLRP through the completion of first-in-human trials. We will support the clinical development costs, subject to certain conditions, following the first-in-human study for XLRS and IND-enabling studies for XLRP. Under the manufacturing license, we have received an exclusive license to use AGTC&#8217;s proprietary technology platform to make AAV vectors for up to six genes, three of which are in AGTC&#8217;s discretion, in exchange for payment of milestones and royalties.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">University of Pennsylvania</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2016 we entered into a collaboration and alliance with the University of Pennsylvania (UPenn) to advance gene therapy and gene editing technologies. The collaboration will primarily focus on the development of therapeutic approaches that target the eye, skeletal muscle and the central nervous system. The alliance is also expected to focus on the research and validation of next-generation gene transfer technology using adeno-associated virus gene delivery vectors and exploring the expanded use of genome editing technology as a potential therapeutic platform.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 61</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the second quarter of 2016 we paid Penn an upfront fee of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$20.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which was recorded as research and development expense in our consolidated statements of income, and prepaid research and development expenditures of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which was recorded in investments and other assets in our consolidated balance sheets. We also expect to fund an additional </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$47.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in the aggregate in research and development costs extending over the next three to five years in seven preclinical research and development programs, as well as the exploration of genome-editing technology.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">If all of the collaborations programs are successful and we exercise all of our options under the Penn collaboration and alliance, we may be required to make future payments of over </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in research funding, options and milestone payments, in addition to royalties payable on net sales of products.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Sangamo BioSciences, Inc. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2014 we completed an exclusive worldwide research, development and commercialization collaboration and license agreement with Sangamo under which both companies will develop and commercialize product candidates for the treatment of two inherited blood disorders, sickle cell disease and beta-thalassemia.&#160;The collaboration is currently in the research stage of development.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the terms of the agreement, we paid Sangamo an upfront payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$20.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in cash, with additional payments of up to approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$300.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;based on the achievement of certain development, regulatory and commercial milestones, plus royalties based on sales.&#160;We recorded the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$20.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;upfront payment as research and development expense in our consolidated statements of income. Under this arrangement, Sangamo will be responsible for identifying a product candidate for the treatment of beta-thalassemia and advancing that candidate through a completed Phase 1 human clinical trial, at which point we would assume responsibility for development.&#160;We will jointly develop a sickle cell disease candidate through the potential filing of an investigative new drug application, after which we would assume clinical responsibilities. We will lead the global development and commercialization efforts and Sangamo will have the option to assume co-promotion responsibilities in the U.S.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the years ending </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$13.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$13.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$28.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, of expense was reflected in our consolidated statements of income.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Following the spin-off of our hemophilia business, this collaboration and license agreement with Sangamo will continue with Bioverativ, an independent public company. For additional information about the spin-off, please see Note 1, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and Note 26, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Subsequent Events </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Mitsubishi Tanabe Pharma Corporation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In September 2015 we announced an agreement with Mitsubishi Tanabe Pharma Corporation (MTPC) to exclusively license amiselimod (MT-1303), a late stage experimental medicine with potential in multiple autoimmune indications. Amiselimod is an oral compound that targets the sphingosine 1-phosphate receptor. During the fourth quarter of 2015 the agreement became effective and we made an upfront payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$60.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which was recorded as research and development expense in our consolidated statements of income. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the third quarter of 2016 we discontinued our development of amiselimod. We expect to formally terminate the agreement and return the program to MTPC in the first quarter of 2017. We will have no further license to or continuing involvement in the development of this compound. For the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$22.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;was reflected in research and development expense in our consolidated statements of income.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Research and Discovery Arrangements </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we entered into several research, discovery and other related arrangements that resulted in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$9.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$40.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, recorded as research and development expense in our consolidated statements of income. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These additional arrangements include the potential for future milestone payments based on clinical and commercial development over a period of several years. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 62</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Samsung Bioepis</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Joint Venture Agreement</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2012 we entered into a joint venture agreement with Samsung BioLogics Co. Ltd. (Samsung Biologics), establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar pharmaceuticals.&#160;Samsung Biologics contributed </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">280.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;South Korean won (approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$250.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) for an </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">85%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;stake in Samsung Bioepis and we contributed approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;South Korean won (approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$45.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) for the remaining </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;ownership interest.&#160;Under the joint venture agreement, we have no obligation to provide any additional funding and our ownership interest may be diluted due to financings in which we do not participate. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our ownership interest is approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.5%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which reflects the effect of additional equity financings in which we did not participate. We maintain an option to purchase additional stock in Samsung Bioepis that would allow us to increase our ownership percentage up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49.9%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.&#160;The exercise of this option is within our control and is based on paying for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49.9%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of the total investment made by Samsung Biologics into Samsung Bioepis in excess of what we have already contributed under the agreement plus a rate that will represent their return on capital. If we do not exercise this option by a date in 2018 determined pursuant to the joint venture agreement, this option will expire and Samsung Biologics will have the right to purchase all of Samsung Bioepis&#8217; shares then held by us.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Samsung Biologics has the power to direct the activities of Samsung Bioepis which will most significantly and directly impact its economic performance.&#160;We account for this investment under the equity method of accounting as we maintain the ability to exercise significant influence over Samsung Bioepis through a presence on the entity&#8217;s Board of Directors and our contractual relationship.&#160;Under the equity method, we recorded our original investment at cost and subsequently adjust the carrying value of our investment for our share of equity in the entity&#8217;s income or losses according to our percentage of ownership. We recognize our share of the results of operations related to our investment in Samsung Bioepis one quarter in arrears when the results of the entity become available, which is reflected as equity in loss of investee, net of tax in our consolidated statements of income. During the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized a loss on our investment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$12.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. During </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, as our share of losses exceeded the carrying value of our investment, we suspended recognizing additional losses and will continue to do so unless we commit to providing additional funding.</font></div><div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Commercial Agreement</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2013 pursuant to our rights under the joint venture agreement with Samsung Biologics, we entered into an agreement with Samsung Bioepis to commercialize, over a 10-year term, three anti-tumor necrosis factor (TNF) biosimilar product candidates in Europe and in the case of one anti-TNF biosimilar, Japan.&#160;Under the terms of this agreement, we have made total upfront and clinical development milestone payments of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$46.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, all of which have been recorded as research and development expense in our consolidated statements of income as the programs they relate to had not achieved regulatory approval. We also agreed to make additional milestone payments of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$25.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;upon regulatory approval in the E.U. for each of the three anti-TNF biosimilar product candidates. During the year ended December 31, 2016, we paid </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$50.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in milestone payments, which have been capitalized in intangible assets, net in our consolidated balance sheets as BENEPALI received regulatory approval in the E.U. in January 2016 and FLIXABI received regulatory approval in the E.U. in May 2016. In July 2016 the EMA accepted Samsung Bioepis' MAA for SB5, an adalimumab biosimilar candidate referencing HUMIRA.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We began to recognize revenue on sales of BENEPALI in the E.U. in the first quarter of 2016 and FLIXABI in the E.U. in the third quarter of 2016. We reflect revenues on sales of BENEPALI and FLIXABI to third parties in product revenues, net in our consolidated statements of income and record the related cost of revenues and sales and marketing expenses in our consolidated statements of income to their respective line items when these costs are incurred. We share </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of the profit or loss related to our commercial agreement with Samsung Bioepis. This profit sharing with Samsung Bioepis is recognized in collaboration profit (loss) sharing in our consolidated statements of income. For the year ended December 31, 2016, we recognized a net expense of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;related to the collaboration profit share. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 63</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Other Services</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Simultaneous with the formation of Samsung Bioepis, we also entered into a license agreement, a technical development services agreement and a manufacturing agreement with Samsung Bioepis. Under the terms of the license agreement, we granted Samsung Bioepis an exclusive license to use, develop, manufacture and commercialize biosimilar products created by Samsung Bioepis using Biogen product-specific technology. In exchange, we will receive single digit royalties on all biosimilar products developed and commercialized by Samsung Bioepis. Under the terms of the technical development services agreement, we provide Samsung Bioepis technical development and technology transfer services, which include, but are not limited to, cell culture development, purification process development, formulation development and analytical development. Under the terms of our manufacturing agreement, we manufacture clinical and commercial quantities of bulk drug substance of biosimilar products for Samsung Bioepis pursuant to contractual terms.&#160;Under limited circumstances, we may also supply Samsung Bioepis with quantities of drug product of biosimilar products for use in clinical trials through arrangements with third-party contract manufacturers. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$20.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$62.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$58.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in revenues in relation to these services, which is reflected as a component of other revenues in our consolidated statements of income. </font></div><div><a name="sCAF63F0EF878A519C0A2201670CBBEFC"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">20.&#160;&#160;&#160;&#160;Litigation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are currently involved in various claims and legal proceedings, including the matters described below. For information as to our accounting policies relating to claims and legal proceedings, including use of estimates and contingencies, please read Note 1, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">With respect to some loss contingencies, an estimate of the possible loss or range of loss cannot be made until management has further information, including, for example, (i) which claims, if any, will survive dispositive motion practice; (ii) information to be obtained through discovery; (iii) information as to the parties' damages claims and supporting evidence; (iv) the parties&#8217; legal theories; and (v) the parties' settlement positions. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The claims and legal proceedings in which we are involved also include challenges to the scope, validity or enforceability of the patents relating to our products, pipeline or processes, and challenges to the scope, validity or enforceability of the patents held by others. These include claims by third parties that we infringe their patents. An adverse outcome in any of these proceedings could result in one or more of the following and have a material impact on our business or consolidated results of operations and financial position: (i) loss of patent protection; (ii) inability to continue to engage in certain activities; and (iii) payment of significant damages, royalties, penalties and/or license fees to third parties.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Loss Contingencies </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Forward Pharma German Patent Litigation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On November 18, 2014, Forward Pharma A/S (Forward Pharma) filed suit against us in the Regional Court of D&#252;sseldorf, Germany (the German Infringement Litigation) alleging that TECFIDERA infringes German Utility Model DE&#160;20 2005 022 112&#160;U1 (the utility model), which was issued in April 2014 and expired in October 2015. Forward Pharma subsequently&#160;extended its allegations&#160;to assert that TECFIDERA infringes Forward Pharma's European Patent No. 2,801,355 (the '355 patent), which was issued in May 2015 and expires in October 2025. We have entered a settlement and license agreement with Forward Pharma that will provide us an irrevocable license to all intellectual property owned by Forward Pharma and result in the termination of the German Infringement Litigation. For more information on the settlement and license agreement please read Note 21, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Commitments and Contingencies</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 64</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Italian National Medicines Agency</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the fourth quarter of 2011 Biogen Italia SRL&#160;received notice from the Italian National Medicines Agency (Agenzia Italiana del Farmaco or AIFA) that sales of TYSABRI after mid-February 2009 exceeded a reimbursement limit established pursuant to a Price Determination Resolution (Price Resolution) granted by AIFA in December 2006. On January&#160;12, 2012, we filed an appeal in the Regional Administrative Tribunal of Lazio (Il Tribunale Amministrativo Regionale per il Lazio) in Rome, Italy seeking a ruling that the reimbursement limit in the Price Resolution should apply as written to only &#8220;the first </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months&#8221; of TYSABRI sales, which ended in mid-February 2009. The appeal is still pending. In June 2014 AIFA approved a resolution affirming that there is no reimbursement limit from and after February 2013. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#231f20;">In January 2017 we negotiated an agreement in principle with AIFA's Price and Reimbursement Committee to settle all of AIFA's existing claims relating to sales of TYSABRI in excess of the reimbursement limit for the periods from February 2009 through January 2013 for an aggregate repayment of EUR</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#231f20;">. The agreement is subject to ratification by AIFA.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information regarding this matter, please read Note 17, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Other Consolidated Financial Statement Detail </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Qui Tam Litigation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On July 6, 2015, a qui tam action filed on behalf of the United States and certain states were unsealed by the U.S. District Court for the District of Massachusetts. The action alleges sales and promotional activities in violation of the federal False Claims Act and state law counterparts, and seeks single and treble damages, civil penalties, interest, attorneys&#8217; fees and costs. Our motion to dismiss is pending. The United States has not made an intervention decision. An estimate of the possible loss or range of loss cannot be made at this time.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Securities Litigation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We and certain current and former officers are defendants in In re Biogen Inc. Securities Litigation, filed by a shareholder on August 18, 2015 in the U.S. District Court for the District of Massachusetts. The amended complaint alleges violations of federal securities laws under 15 U.S.C. &#167;78j(b) and &#167;78t(a) and 17 C.F.R. &#167;240.10b-5. The lead plaintiff sought a declaration of the action as a class action, certification as a representative of the class and its counsel as class counsel, and an award of damages, interest and attorneys' fees. On July 1, 2016, the U.S. District Court dismissed the case and in September 2016 denied the plaintiff's motion to vacate the order of dismissal. The plaintiff has appealed. An estimate of the possible loss or range of loss cannot be made at this time.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We and certain current and former officers are also defendants in an action filed by another shareholder on October 20, 2016 in the U.S. District Court for the District of Massachusetts, related to the matter described above. The complaint alleges violations of federal securities laws under 15 U.S.C. &#167;78j(b) and &#167;78t(a) and 17 C.F.R. &#167;240.10b-5 and seeks a declaration of the action as a class action and an award of damages, interest and attorney's fees. An estimate of the possible loss or range of loss cannot be made at this time.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Matters</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Interference Proceeding with Forward Pharma</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In April 2015 the U.S. Patent and Trademark Office (USPTO) declared an interference between Forward Pharma&#8217;s pending U.S. Patent Application No. 11/576,871 and our U.S. Patent No. 8,399,514 (the '514 patent). The '514 patent includes claims covering the treatment of multiple sclerosis with 480 mg of dimethyl fumarate as provided for in our TECFIDERA label. We are awaiting a decision in this matter.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Inter Partes Review Proceeding</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On March 22, 2016, the USPTO instituted </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">inter partes</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;review of the '514 patent on the petition of the Coalition for Affordable Drugs V LLC, an entity associated with a hedge fund. We are awaiting a decision in this matter.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On April 18, 2016, Swiss Pharma International AG filed petitions in the USPTO for inter partes review of U.S. Patent Nos. 8,349,321 and 8,900,577, relating to specific formulations of natalizumab (TYSABRI), and U.S. Patent No. 8,815,236, relating to methods for treating MS and Crohn's disease using specific formulations of natalizumab (TYSABRI). In October 2016 the USPTO declined to institute proceedings under all three petitions. Swiss Pharma filed requests for rehearing, which are pending.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 65</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">European Patent Office Oppositions</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2016 the European Patent Office issued a written decision confirming its earlier revocation of our European patent number 2 137 537 (the '537 patent), which we have appealed. The '537 patent includes claims covering the treatment of MS with 480 mg of dimethyl fumarate as provided for in our TECFIDERA label.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Patent Revocation Matter</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2015 Swiss Pharma International AG brought an action in the Patents Court of the United Kingdom to revoke the UK counterpart of our European Patent Number 1 485 127&#160;(&#8220;Administration of agents to treat inflammation&#8221;) (the '127 patent), which was issued in June 2011 and concerns administration of natalizumab (TYSABRI) to treat MS. The patent expires in February 2023.&#160;Subsequently, the same entity brought an actions in the District Court of The Hague (on January 11, 2016) and the German Patents Court (on March 3, 2016) to invalidate the Dutch and German counterparts of the '127 patent. In September 2016 we resolved the UK action by agreeing to revocation of the UK patent. A hearing has been scheduled in the Dutch action for early 2017 and the German action for early 2018.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">'755 Patent Litigation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On May&#160;28, 2010, Biogen MA Inc. (formerly Biogen Idec MA Inc.) filed a complaint in the U.S.&#160;District Court for the District of New Jersey alleging infringement by Bayer Healthcare Pharmaceuticals Inc. (Bayer) (manufacturer, marketer and seller of BETASERON and manufacturer of EXTAVIA), EMD Serono, Inc. (EMD Serono) (manufacturer, marketer and seller of REBIF), Pfizer Inc. (co-marketer of REBIF) and Novartis Pharmaceuticals Corp. (Novartis) (marketer and seller of EXTAVIA) of our U.S. Patent No. 7,588,755 ('755 Patent), which claims the use of interferon beta for immunomodulation or treating a viral condition, viral disease, cancers or tumors. The complaint seeks monetary damages, including lost profits and royalties. Bayer had previously filed a complaint against us in the same court, on May 27, 2010, seeking a declaratory judgment that it does not infringe the '755 Patent and that the patent is invalid, and seeking monetary relief in the form of attorneys' fees, costs and expenses. The court has consolidated the two lawsuits, and we refer to the two actions as the &#8220;Consolidated '755 Patent Actions.&#8221;</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Bayer, Pfizer, Novartis and EMD Serono have all filed counterclaims in the Consolidated '755 Patent Actions seeking declaratory judgments of patent invalidity and non-infringement, and seeking monetary relief in the form of costs and attorneys' fees, and EMD Serono and Bayer have each filed a counterclaim seeking a declaratory judgment that the '755 Patent is unenforceable based on alleged inequitable conduct. Bayer has also amended its complaint to seek such a declaration. Trial has been set for September 2017.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Government Matters</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have learned that state and federal governmental authorities are investigating our sales and promotional practices and have received related subpoenas. We are cooperating with the government. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On March 4, 2016, we received a subpoena from the federal government for documents relating to our relationship with non-profit organizations that provide assistance to patients taking drugs sold by Biogen. We are cooperating with the government.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On July 1, 2016, we received a civil investigative demand from the federal government for documents and information relating to our treatment of certain service agreements with wholesalers when calculating and reporting Average Manufacturer Prices in connection with the Medicaid Drug Rebate Program. We are cooperating with the government.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On December 5, 2016, we received a subpoena from the federal government for documents relating to government price reporting, rebate payments and Biogen's co-pay assistance programs for AVONEX, TECFIDERA, TYSABRI and PLEGRIDY. We are cooperating with the government.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On December 29, 2016, we received a civil investigative demand from the federal government for documents and information relating to our relationships with entities providing clinical education and reimbursement support services. We are cooperating with the government.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 66</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Product Liability and Other Legal Proceedings</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are also involved in product liability claims and other legal proceedings generally incidental to our normal business activities. While the outcome of any of these proceedings cannot be accurately predicted, we do not believe the ultimate resolution of any of these existing matters would have a material adverse effect on our business or financial condition.</font></div><div><a name="s47C21E0996556DC06696201670CBA502"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">21.&#160;&#160;&#160;&#160;Commitments and Contingencies</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">TECFIDERA Litigation Settlement and License Agreement</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2017 we agreed to enter into a settlement and license agreement with Forward Pharma that will provide us an irrevocable license to all intellectual property owned by Forward Pharma and results in the termination of the German Infringement Litigation. Under the terms of the settlement and license agreement with Forward Pharma, we have agreed to pay Forward Pharma </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.25 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in cash. Under certain circumstances outlined in the agreement, we will pay Forward Pharma royalties on net sales of our products for the treatment of multiple sclerosis that are covered by a Forward Pharma patent and have dimethyl fumarate (&#8220;DMF&#8221;) as an active pharmaceutical ingredient.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the fourth quarter of 2016 we recognized a pre-tax charge of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$454.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;related to this matter. This amount represents the fair value of estimated royalties on our sales of TECFIDERA during the period April 2014 through December 31, 2016. When the cash payment is made following approval of the settlement and license agreement, we will recognize assets of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$656.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$138.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, reflecting the estimated fair value of the license acquired that is attributable to the U.S. and E.U., respectively. If Forward Pharma does not receive a patent in either the Interference Proceeding pending in the U.S. or the pending European Opposition Proceeding (which proceedings are defined in the settlement and license agreement), we would likely recognize an immediate impairment charge equal to the value of the license that is attributable to that jurisdiction as additional litigation expense and we would not be obligated to pay Forward Pharma royalties in such jurisdiction. If Forward Pharma receives a patent in either the U.S. Interference Proceeding or the E.U. Opposition Proceeding, we would amortize the assets related to a license of intellectual property in the related jurisdiction utilizing an economic consumption model and we may be obligated to royalties on a country by country basis in Europe and other ex-U.S. markets. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information with respect to the terms of this agreement, including potential royalties payable, please read the Settlement and License Agreement dated January 17, 2017,&#160;between Biogen Swiss Manufacturing GmbH, Biogen International Holding Ltd, Forward Pharma A/S and the other parties thereto which is filed as Exhibit 10.41 to this 2016 Form 10-K. For additional information related to the ongoing Interference Proceeding with Forward Pharma in the U.S. or the European Office Opposition in the E.U., please read Note 20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Litigation</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">TYSABRI Contingent Payments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2013 we acquired from Elan full ownership of all remaining rights to TYSABRI that we did not already own or control. Under the terms of the acquisition agreement, we are obligated to make contingent payments to Elan of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;on annual worldwide net sales up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">25%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;on annual worldwide net sales that exceed </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Royalty payments to Elan and other third parties are recognized as cost of sales in our consolidated statements of income. Elan was acquired by Perrigo Company plc (Perrigo) in December 2013. Following that acquisition, we began making these royalty payments to Perrigo.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Consideration related to Business Combinations</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisitions of Convergence, Stromedix and Biogen International Neuroscience GmbH (BIN), we agreed to make additional payments based upon the achievement of certain milestone events. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As the acquisitions of Convergence, Stromedix and BIN, formerly Panima Pharmaceuticals AG, occurred after January&#160;1, 2009, we record contingent consideration liabilities at their fair value on the acquisition date and revalue these obligations each reporting period. We may pay up to approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.2 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in remaining milestones related to these acquisitions. For additional information related to our acquisition of Convergence please read Note 2, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 67</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Fumapharm AG</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2006 we acquired Fumapharm AG. As part of this acquisition we acquired FUMADERM and TECFIDERA (together, Fumapharm Products). We paid </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$220.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;upon closing of the transaction and agreed to pay an additional </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;if a Fumapharm Product was approved for MS in the U.S.&#160;or E.U. In the second quarter of 2013 we paid this </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;contingent payment as TECFIDERA was approved in the U.S. for MS by the FDA. We are also required to make additional contingent payments to former shareholders of Fumapharm AG or holders of their rights based on the attainment of certain cumulative sales levels of Fumapharm Products and the level of total net sales of Fumapharm Products in the prior twelve month period, as defined in the acquisition agreement. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;we paid </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.2 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in contingent payments as we reached the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$7.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$8.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$9.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;cumulative sales levels related to the Fumapharm Products in the fourth quarter of 2015 and the first, second and third quarters of 2016, respectively, and accrued </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$300.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;upon reaching </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$11.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in total cumulative sales of Fumapharm Products in the fourth quarter of 2016.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We will owe an additional </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$300.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;contingent payment for every additional </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in cumulative sales level of Fumapharm Products reached if the prior 12 months sales of the Fumapharm Products exceed </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, until such time as the cumulative sales level reaches </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$20.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, at which time no further contingent payments shall be due. If the prior 12 months sales of Fumapharm Products are less than </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, contingent payments remain payable on a decreasing tiered basis. These payments will be accounted for as an increase to goodwill as incurred, in accordance with the accounting standard applicable to business combinations when we acquired Fumapharm. Any portion of the payment which is tax deductible will be recorded as a reduction to goodwill. Payments are due within 60&#160;days following the end of the quarter in which the applicable cumulative sales level has been reached. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Development, Regulatory and Commercial Milestone Payments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based on our development plans as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we could make potential future milestone payments to third parties of up to approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.1 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, including approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$0.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in development milestones, approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$0.8 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in regulatory milestones and approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.8 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in commercial milestones as part of our various collaborations, including licensing and development programs. Payments under these agreements generally become due and payable upon achievement of certain development, regulatory or commercial milestones. Because the achievement of these milestones had not occurred as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, such contingencies have not been recorded in our financial statements. Amounts related to contingent milestone payments are not considered contractual obligations as they are contingent on the successful achievement of certain development, regulatory approval and commercial milestones. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Funding Commitments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we have several on-going clinical studies in various clinical trial stages. Our most significant clinical trial expenditures are to contract research organizations (CROs). The contracts with CROs are generally cancellable, with notice, at our option. We have recorded accrued expenses of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$21.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;on our consolidated balance sheet for expenditures incurred by CROs as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We have approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$500.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in cancellable future commitments based on existing CRO contracts as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Tax Related Obligations</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We exclude liabilities pertaining to uncertain tax positions from our summary of contractual obligations as we cannot make a reliable estimate of the period of cash settlement with the respective taxing authorities. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we have approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$47.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of net liabilities associated with uncertain tax positions.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Solothurn, Switzerland Facility</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On December 1, 2015, we purchased land in Solothurn, Switzerland where we are building a biologics manufacturing facility over the next several years. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had contractual commitments of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$176.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for the construction of this facility.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 68</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Leases</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We rent laboratory and office space and certain equipment under non-cancelable operating leases. These lease agreements contain various clauses for renewal at our option and, in certain cases, escalation clauses typically linked to rates of inflation. Rental expense under these leases, net of amounts recognized in relation to exiting our manufacturing facility in Cambridge, Massachusetts and our Weston, Massachusetts facility, which terminate at various dates through 2028, amounted to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$68.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$68.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$62.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. In addition to rent, the leases may require us to pay additional amounts for taxes, insurance, maintenance and other operating expenses.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, minimum rental commitments under non-cancelable leases, net of income from subleases, for each of the next five years and total thereafter were as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="28"></td></tr><tr><td style="width:31%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2021</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Thereafter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Minimum lease payments </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">75.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">69.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">69.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">65.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">64.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">331.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">676.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Less: income from subleases (1)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(8.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(15.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(15.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(15.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(16.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(55.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(126.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net minimum lease payments</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">66.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">54.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">53.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">50.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">48.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">276.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">549.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Represents sublease income expected to be received for the vacated manufacturing facility in Cambridge, MA, the vacated portion of our Weston, Massachusetts facility and other facilities throughout the world. For additional information related to the sublease of the vacated manufacturing facility in Cambridge, MA, please read Note 3, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-style:italic;">Restructuring, Business Transformation and Other Cost Savings Initiatives</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#32;to these consolidated financial statements.</font></div></td></tr></table><div style="line-height:120%;padding-left:4px;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under certain of our lease agreements, we are contractually obligated to return leased space to its original condition upon termination of the lease agreement. At the inception of a lease with such conditions, we record an asset retirement obligation liability and a corresponding capital asset in an amount equal to the estimated fair value of the obligation. In subsequent periods, for each such lease, we record interest expense to accrete the asset retirement obligation liability to full value and depreciate each capitalized asset retirement obligation asset, both over the term of the associated lease agreement. Our asset retirement obligations were not significant as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;or </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-left:4px;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Eisai Financing Arrangement</font></div><div style="line-height:120%;padding-left:4px;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During 2015 we amended our existing lease related to Eisai's oral solid dose products manufacturing facility in RTP, North Carolina where we manufacture our and Eisai's oral solid dose products. For additional information, please read Note 10, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Property, Plant and Equipment</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the net present values of the future minimum lease payments were as follows:</font></div><div style="line-height:120%;padding-left:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:79%;"></td><td style="width:1%;"></td><td style="width:19%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">As of December 31, 2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">16.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">18.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Less: interest</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(0.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net present value of the future minimum lease payments</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">18.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><a name="s1851AC4E6E388EEEF25C201670EA691A"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">22.&#160;&#160;&#160;&#160;&#160;&#160;Guarantees</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we did not have significant liabilities recorded for guarantees.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We enter into indemnification provisions under our agreements with other companies in the ordinary course of business, typically with business partners, contractors, clinical sites and customers. Under these provisions, we generally indemnify and hold harmless the indemnified party for losses suffered or incurred by the indemnified party as a result of our activities. These indemnification provisions generally survive termination of the underlying agreement. The maximum potential amount of future payments we could be required to make under these indemnification provisions is unlimited. However, to date we have not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. As a result, the estimated fair value of these agreements is minimal. Accordingly, we have no liabilities recorded for these agreements as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 69</font></div></div><hr style="page-break-after:always"><div><a name="sC38C808F4CB4277573F7201670EAE08D"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">23.&#160;&#160;&#160;&#160;&#160;&#160;Employee Benefit Plans</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We sponsor various retirement and pension plans. Our estimates of liabilities and expenses for these plans incorporate a number of assumptions, including expected rates of return on plan assets and interest rates used to discount future benefits.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">401(k) Savings Plan</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We maintain a 401(k) Savings Plan, which is available to substantially all regular employees in the U.S. over the age of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Participants may make voluntary contributions. We make matching contributions according to the 401(k) Savings Plan&#8217;s matching formula. All matching contributions and participant contributions vest immediately. The 401(k) Savings Plan also holds certain transition contributions on behalf of participants who previously participated in the Biogen, Inc. Retirement Plan. The expense related to our 401(k) Savings Plan primarily consists of our matching contributions.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Expense related to our 401(k) Savings Plan totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$45.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$51.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$49.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Deferred Compensation Plan</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We maintain a non-qualified deferred compensation plan, known as the Supplemental Savings Plan (SSP), which allows a select group of management employees in the U.S. to defer a portion of their compensation. The SSP also provides certain credits to highly compensated U.S. employees, which are paid by the company. These credits are known as the Restoration Match. The deferred compensation amounts are accrued when earned. Such deferred compensation is distributable in cash in accordance with the rules of the SSP. Deferred compensation amounts under such plan as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, totaled approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$128.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$126.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, and are included in other long-term liabilities in our consolidated balance sheets. The SSP also holds certain transition contributions on behalf of participants who previously participated in the Biogen, Inc. Retirement Plan. The Restoration Match and participant contributions vest immediately. Distributions to participants can be either in one lump sum payment or annual installments as elected by the participants.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Pension Plans</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our retiree benefit plans include defined benefit plans for employees in our affiliates in Switzerland and Germany as well as other insignificant defined benefit plans in certain other countries in which we maintain an operating presence.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our Swiss plan is a government-mandated retirement fund that provides employees with a minimum investment return. The minimum investment return is determined annually by the Swiss government and was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.25%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in 2016 and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.75%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Under the Swiss plan, both we and certain of our employees with annual earnings in excess of government determined amounts are required to make contributions into a fund managed by an independent investment fiduciary. Employer contributions must be in an amount at least equal to the employee&#8217;s contribution. Minimum employee contributions are based on the respective employee&#8217;s age, salary and gender. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the Swiss plan had an unfunded net pension obligation of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$39.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$42.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, and plan assets which totaled approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$68.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$63.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. In </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized expense totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$12.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$9.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, related to our Swiss plan.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The obligations under the German plans are unfunded and totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$35.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$27.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Net periodic pension cost related to the German plans totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$4.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$4.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 70</font></div></div><hr style="page-break-after:always"><div><a name="sA475A314CAC4CDCFA8CD201670FAF308"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">24.&#160;&#160;&#160;&#160;&#160;&#160;Segment Information</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We operate as </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">one</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;operating segment, which is discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. Our Chief Executive Officer (CEO), as the chief operating decision-maker, manages and allocates resources to the operations of our company on a total company basis. Our research and development organization is responsible for the research and discovery of new product candidates and supports development and registration efforts for potential future products. Our pharmaceutical, operations and technology organization manages the development of the manufacturing processes, clinical trial supply, commercial product supply, distribution, buildings and facilities. Our commercial organization is responsible for U.S. and international development of our commercial products. The company is also supported by corporate staff functions. Managing and allocating resources on a total company basis enables our CEO to assess the overall level of resources available and how to best deploy these resources across functions, therapeutic areas, and research and development projects that are in line with our long-term company-wide strategic goals. Consistent with this decision-making process, our CEO uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Enterprise-wide disclosures about product revenues, other revenues and long-lived assets by geographic area and information relating to major customers are presented below. Revenues are primarily attributed to individual countries based on location of the customer or licensee.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenue by product is summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="36"></td></tr><tr><td style="width:18%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="35" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">States</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">World</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">States</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">World</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">States</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">World</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Multiple Sclerosis (MS):</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">TECFIDERA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">3,169.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">798.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">3,968.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">2,908.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">730.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">3,638.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">2,426.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">482.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">2,909.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">AVONEX</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">1,675.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">638.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">2,313.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,790.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">840.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">2,630.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,956.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,056.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">3,013.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">PLEGRIDY</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">305.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">176.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">481.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">227.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">111.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">338.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">27.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">16.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">44.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">TYSABRI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">1,182.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">780.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">1,963.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,103.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">783.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,886.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,025.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">934.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,959.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">FAMPYRA</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">84.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">84.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">89.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">89.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">80.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">80.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">ZINBRYTA</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">7.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">7.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Hemophilia:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">ELOCTATE</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">445.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">68.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">513.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">308.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">11.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">319.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">58.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">58.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">ALPROLIX</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">268.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">65.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">333.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">208.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">25.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">234.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">72.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">3.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">76.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Other product revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">FUMADERM</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">45.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">45.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">51.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">51.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">62.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">62.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">SPINRAZA</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">4.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">4.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">BENEPALI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">100.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">100.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">FLIXABI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total product revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">7,050.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">2,767.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">9,817.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">6,545.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">2,642.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">9,188.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">5,566.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">2,636.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">8,203.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 71</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Geographic Information</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables contain certain financial information by geographic area:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"></td></tr><tr><td style="width:29%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">December 31, 2016 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Europe</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Germany</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Asia</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues from external customers</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7,050.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,533.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">703.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">217.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">313.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">9,817.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,249.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">63.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,314.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues from external customers</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">224.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">70.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">20.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">316.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-lived assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,272.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,219.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,501.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">December 31, 2015 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Europe</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Germany</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Asia</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues from external customers</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,545.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,497.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">668.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">143.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">333.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9,188.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,269.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">65.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,339.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues from external customers</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">142.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">29.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">62.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">236.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-lived assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,296.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">879.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,187.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">December 31, 2014 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Europe</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Germany</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Asia</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues from external customers</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,566.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,383.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">811.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">112.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">328.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8,203.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,117.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">70.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,195.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues from external customers</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">212.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">58.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">304.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-lived assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,055.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">701.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,765.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Represents amounts related to Europe less those attributable to Germany.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Revenues from Anti-CD20 Therapeutic Programs</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of our total revenues in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, are derived from our collaboration agreement with Genentech. For additional information related to our collaboration with Genentech, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Significant Customers</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recorded revenue from two wholesalers accounting for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">22%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of gross product revenues in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">34%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">26%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of gross product revenues in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">33%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">27%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of gross product revenues in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$643.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$684.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$676.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, of our long-lived assets were related to our manufacturing facilities in Denmark. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$545.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$161.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, of our long-lived assets were related to the construction of a biologics manufacturing facility in Solothurn, Switzerland.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information related to our manufacturing facility in Solothurn, Switzerland, please read Note 10, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Property, plant and equipment</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 72</font></div></div><hr style="page-break-after:always"><div><a name="s84A1AE749FEB7FE9FB11201671578D92"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">25.&#160;&#160;&#160;&#160;&#160;&#160;Quarterly Financial Data (Unaudited)</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td style="width:36%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except per share amounts)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">First</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Second</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Third</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fourth</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Year</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2016</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(a)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(b)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(b) (c)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(b) (d) (e)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,309.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,466.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,539.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,502.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">9,817.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">329.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">349.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">317.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">318.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,314.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">87.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">79.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">98.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">50.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">316.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,726.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,894.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,955.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,872.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">11,448.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gross profit (1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,413.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,523.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,538.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,493.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">9,970.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">969.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,048.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,030.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">647.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,695.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">970.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,049.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,032.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">649.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,702.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income per share:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.44</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.79</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.72</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.00</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">16.96</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.43</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.79</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.71</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2.99</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">16.93</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted-average shares used in calculating:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share attributable to Biogen Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">218.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">219.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">218.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">216.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">218.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">219.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">219.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">219.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">217.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">218.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td style="width:36%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except per share amounts)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">First</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Second</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Third</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fourth</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Year</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">2015</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(f) (g)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(a) (h)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,172.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,198.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,391.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,425.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9,188.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">330.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">337.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">337.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">333.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,339.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">52.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">55.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">79.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">236.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,555.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,591.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,777.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,839.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10,763.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gross profit (1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,242.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,305.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,467.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,507.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9,523.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">820.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">924.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,019.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">828.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,593.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">822.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">927.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">965.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">831.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,547.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income per share:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.50</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.94</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.16</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.77</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15.38</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.49</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.93</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.15</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.77</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15.34</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted-average shares used in calculating:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share attributable to Biogen Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">235.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">235.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">232.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">220.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">230.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">235.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">235.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">232.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">220.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">231.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(1) Gross profit is calculated as total revenues less cost of sales, excluding amortization of acquired intangible assets.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc., for the first quarter of 2016 and the fourth quarter of 2015, includes pre-tax restructuring charges totaling </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$9.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$93.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively related to the 2015 corporate restructuring program.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 73</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for the second, third and fourth quarters of 2016 includes pre-tax additional depreciation expense totaling </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$15.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$15.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$14.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, as part of our determination to cease manufacturing in our small-scale biologics manufacturing facility in Cambridge, MA as well as vacate our warehouse space in Somerville, MA. Our departure from these facilities has shortened the expected useful lives of certain leasehold improvements and other assets at these facilities.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for the third quarter of 2016 includes a pre-tax charge to research and development expense of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$75.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for a license fee paid to Ionis as we exercised our option to develop and commercialize SPINRAZA.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for the fourth quarter of 2016 includes a pre-tax charge to research and development expense of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$50.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for a milestone payment due to Eisai related to the initiation of a phase 3 trial for E2609.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(e)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for the fourth quarter of 2016 includes a pre-tax charge of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$454.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;related to the January 2017 settlement and license agreement with Forward Pharma.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(f)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for the third quarter of 2015 includes a pre-tax charge to research and development expense of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$48.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;recorded upon entering into the collaboration agreement with AGTC.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(g)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc. for the third quarter of 2015 reflects the attribution of a </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$60.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;charge to noncontrolling interests, net of tax, related to a milestone payment due Neurimmune upon the enrollment of the first patient in a Phase 3 trial for aducanumab.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(h)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for the fourth quarter of 2015 includes a pre-tax charge to research and development expense of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$60.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;recorded upon entering into the collaboration agreement with MTPC.</font></div></td></tr></table><div><a name="sc3bf5ba8deae495e94b9793dca7ab112"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">26.&#160;&#160;&#160;&#160;&#160;&#160;Subsequent Events</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On February 1, 2017, we completed the distribution of the issued and outstanding common stock of Bioverativ to Biogen stockholders. For additional information related to the distribution of Bioverativ, please read Note 1, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the distribution, we entered into a separation and distribution agreement and various other agreements (including a transition services agreement, a tax matters agreement, a manufacturing and supply agreement, an employee matters agreement, an intellectual property matters agreement and certain other commercial agreements). These agreements govern the separation and distribution and the relationship between the two companies going forward. They also provide for the performance of services by each company for the benefit of the other for a period of time (including under the manufacturing and supply agreement pursuant to which we will manufacture and supply certain products and materials to Bioverativ).</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 74</font></div></div><hr style="page-break-after:always"><div><a name="s021224D10E0E3A12F3F9201718762BB9"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">To the Board of Directors and Shareholders of Biogen Inc.</font></div><div style="line-height:120%;padding-top:18px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In our opinion, the accompanying consolidated balance sheets and the related consolidated statements of income, comprehensive income, equity and cash flows present fairly, in all material respects, the financial position of Biogen Inc. and its subsidiaries  at December 31, 2016 and December 31, 2015, and the results of their operations and their cash flows for each of the three years in the period ended December 31, 2016 in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2016, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission  (COSO).The Company's  management is responsible for these financial statements, for maintaining effective internal control over financial reporting and for its assessment  of the effectiveness of internal control over financial reporting, included in Management's  Report on Internal Control over Financial Reporting under item 9A. Our responsibility is to express opinions on these financial statements and on the Company's internal control over financial reporting based on our integrated audits. We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement and whether effective internal control over financial reporting was maintained in all material respects. Our audits of the financial statements included examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial statement presentation. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions  of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</font></div><div style="line-height:120%;padding-top:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/s/ PricewaterhouseCoopers LLP</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Boston, Massachusetts</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">February&#160;2, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 75</font></div></div><hr style="page-break-after:always"><div><a name="s391239CD1182CE997E4420171877994D"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">EXHIBIT INDEX</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:16%;"></td><td style="width:7%;"></td><td style="width:77%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Exhibit&#160;No.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Description</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.1&#8224;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset Purchase Agreement among Biogen Idec International Holding Ltd., Elan Pharma International Limited and Elan Pharmaceuticals, Inc., dated as of February 5, 2013. Filed as Exhibit 2.1 to our Current Report on Form 8-K/A filed on February 12, 2013.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Separation Agreement between Biogen Inc. and Bioverativ Inc. Filed as Exhibit 2.1 to our Current Report on Form 8-K filed on February 2, 2017.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amended and Restated Certificate of Incorporation, as amended. Filed as Exhibit 3.1 to our Quarterly Report on Form 10-Q for the quarter ended June 30, 2012.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Certificate of Amendment to the Certificate of Incorporation. Filed as Exhibit 3.1 to our Current Report on Form 8-K filed on March 27, 2015.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Third Amended and Restated Bylaws. Filed as Exhibit 3.2 to our Current Report on Form 8-K filed on March 27, 2015.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Reference is made to Exhibit 3.1 for a description of the rights, preferences and privileges of our Series A Preferred Stock and Series X Junior Participating Preferred Stock.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indenture between Biogen Idec and The Bank of New York Trust Company, N.A. dated as of February 26, 2008. Filed as Exhibit 4.1 to our Registration Statement on Form S-3 (File No. 333-149379).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">First Supplemental Indenture between Biogen Idec and The Bank of New York Trust Company, N.A. dated as of March 4, 2008. Filed as Exhibit 4.1 to our Current Report on Form 8-K filed on March 4, 2008.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indenture, dated September 15, 2015, between Biogen Inc. and U.S. Bank National Association. Filed as Exhibit 4.1 to our Current Report on Form 8-K filed on September 16, 2015.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">First Supplemental Indenture, dated September 15, 2015, between Biogen Inc. and U.S. Bank National Association. Filed as Exhibit 4.2 to our Current Report on Form 8-K filed on September 16, 2015.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Credit Agreement, dated August 28, 2015, between Biogen Inc., Bank of America, N.A., as administrative agent, swing line lender and an L/C issuer, and the other lenders party thereto. Filed as Exhibit 10.1 to our Current Report on Form 8-K filed on September 1, 2015.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.2&#8224;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Expression Technology Agreement between Biogen Idec and Genentech. Inc. dated March 16, 1995. Filed as an exhibit to Biogen Idec&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 1995.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Letter Agreement between Biogen Idec and Genentech, Inc. dated May 21, 1996. Filed as Exhibit 10.1 to our Current Report on Form 8-K filed on June 6, 1996.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.4&#8224;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Second Amended and Restated Collaboration Agreement between Biogen Idec and Genentech, Inc. dated as of October 18, 2010. Filed as Exhibit 10.5 to our Annual Report on Form 10-K for the year ended December 31, 2010.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.5&#8224;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Letter agreement regarding GA101 financial terms between Biogen Idec and Genentech, Inc. dated October 18, 2010. Filed as Exhibit 10.6 to our Annual Report on Form 10-K for the year ended December 31, 2010.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.6*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Idec Inc. 2008 Amended and Restated Omnibus Equity Plan. Filed as Exhibit 10.1 to our Quarterly Report on Form 10-Q for the quarter ended March 31, 2014.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.7*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Form of performance unit award agreement under the Biogen Idec Inc. 2008 Omnibus Equity Plan. Filed as Exhibit 10.2 to our Quarterly Report on Form 10-Q for the quarter ended March 31, 2014.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.8*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Form of market stock unit award agreement under the Biogen Idec Inc. 2008 Omnibus Equity Plan. Filed as Exhibit 10.3 to our Quarterly Report on Form 10-Q for the quarter ended March 31, 2014.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.9*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Form of restricted stock unit award agreement under the Biogen Idec Inc. 2008 Omnibus Equity Plan. Filed as Exhibit 10.1 to our Current Report on Form 8-K filed on August 1, 2008.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.10*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Form of nonqualified stock option award agreement under the Biogen Idec Inc. 2008 Omnibus Equity Plan. Filed as Exhibit 10.2 to our Current Report on Form 8-K filed on August 1, 2008.</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A- 1</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:16%;"></td><td style="width:7%;"></td><td style="width:77%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Exhibit&#160;No.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Description</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.11*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Form of cash-settled performance shares award agreement under the Biogen Idec Inc. 2008 Omnibus Equity Plan. Filed as Exhibit 10.1 to our Quarterly Report on Form 10-Q for the quarter ended March&#160;31, 2010.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.12*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Form of performance shares award agreement under the Biogen Idec Inc. 2008 Omnibus Equity Plan. Filed as Exhibit 10.12 to our Annual Report on Form 10-K for the year ended December 31, 2013.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.13*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Form of market stock unit award agreement under the Biogen Idec Inc. 2008 Omnibus Equity Plan. Filed as Exhibit 10.2 to our Quarterly Report on Form 10-Q for the quarter ended March 31, 2010.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.14*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Inc. 2006 Non-Employee Directors Equity Plan, as amended. Filed as Exhibit 10.1 to our Quarterly Report on Form 10-Q for the quarter ended March 31, 2015.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.15*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Idec Inc. 2005 Omnibus Equity Plan. Filed as Appendix A to our Definitive Proxy Statement on Schedule 14A filed on April 15, 2005.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.16*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amendment No. 1 to the Biogen Idec Inc. 2005 Omnibus Equity Plan dated April 4, 2006. Filed as Exhibit 10.1 to our Quarterly Report on Form 10-Q for the quarter ended March 31, 2007.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.17*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amendment No. 2 to the Biogen Idec Inc. 2005 Omnibus Equity Plan dated February 12, 2007. Filed as Exhibit 10.2 to our Quarterly Report on Form 10-Q for the quarter ended March 31, 2007.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.18*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amendment to the Biogen Idec Inc. 2005 Omnibus Equity Plan dated April 18, 2008. Filed as Exhibit 10.7 to our Quarterly Report on Form 10-Q for the quarter ended June 30, 2008.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.19*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amendment to Biogen Idec Inc. 2005 Omnibus Equity Plan dated October 13, 2008. Filed as Exhibit 10.30 to our Annual Report on Form 10-K for the year ended December 31, 2008.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.20*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Inc. 2015 Employee Stock Purchase Plan. Filed as Appendix A to Biogen's Definitive Proxy Statement on Schedule 14A filed on April 30, 2015.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.21*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Idec Inc. 2008 Performance-Based Management Incentive Plan. Filed as Appendix B to Biogen Idec&#8217;s Definitive Proxy Statement on Schedule 14A filed on May 8, 2008.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.22*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Voluntary Executive Supplemental Savings Plan, as amended and restated effective January 1, 2004. Filed as Exhibit 10.13 to our Annual Report on Form 10-K for the year ended December 31, 2003.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.23*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Supplemental Savings Plan, as amended. Filed as Exhibit 10.23 to our Annual Report on Form 10-K for the year ended December 31, 2015.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.24*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Voluntary Board of Directors Savings Plan, as amended. Filed as Exhibit 10.24 to our Annual Report on Form 10-K for the year ended December 31, 2015.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.25*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Idec Inc. Executive Severance Policy &#8212; U.S. Executive Vice President, as amended effective January 1, 2014. Filed as Exhibit 10.39 to our Annual Report on Form 10-K for the year ended December 31, 2013.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.26*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Idec Inc. Executive Severance Policy &#8212; International Executive Vice President, as amended effective January 1, 2014. Filed as Exhibit 10.40 Annual Report on Form 10-K for the year ended December 31, 2013.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.27*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Idec Inc. Executive Severance Policy &#8212; U.S. Senior Vice President, as amended effective October 13, 2008. Filed as Exhibit 10.53 to our Annual Report on Form 10-K for the year ended December 31, 2008.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.28*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Idec Inc. Executive Severance Policy &#8212; International Senior Vice President, as amended effective October 13, 2008. Filed as Exhibit 10.54 to our Annual Report on Form 10-K for the year ended December 31, 2008.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.29*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Annual Retainer Summary for Board of Directors. Filed as Exhibit 10.1 to our Quarterly Report on Form 10-Q for the quarter ended September 30, 2014.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.30*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Form of indemnification agreement for directors and executive officers. Filed as Exhibit 10.1 to our Current Report on Form 8-K filed on June 7, 2011.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.31*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employment Agreement between Biogen Idec and George A. Scangos amended as of August 23, 2013. Filed as Exhibit 10.1 to our Current Report on Form 8-K filed on August 26, 2013.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.32*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Letter regarding employment arrangement of Paul J. Clancy dated August 17, 2007. Filed as Exhibit 10.49 to our Annual Report on Form 10-K for the year ended December 31, 2007.</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A- 2</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sB46CD385D2FE1C8943A8201706CFE8C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:17%;"></td><td style="width:6%;"></td><td style="width:77%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Exhibit&#160;No.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Description</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.33*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employment Agreement between Biogen Inc. and Michel Vounatsos dated December 18, 2016. Filed as Exhibit 10.1 to our Current Report on Form 8-K filed on December 19, 2016.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.34*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Letter regarding employment arrangement of Kenneth DiPietro dated December 12, 2011. Filed as Exhibit 10.49 to our Annual Report on Form 10-K for the year ended December 31, 2012.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.35*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Letter regarding employment arrangement of Alfred Sandrock dated May 7, 2013. Filed as Exhibit 10.1 to our Quarterly Report on Form 10-Q for the quarter ended June 30, 2013.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.36*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Letter regarding employment arrangement of Alfred Sandrock dated October 19, 2015. Filed as Exhibit 10.37 to our Annual Report on Form 10-K for the year ended December 31, 2015.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.37*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Letter regarding employment arrangement of Susan Alexander dated December&#160;13, 2005. Filed as Exhibit&#160;10.58 to our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2009.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.38*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Letter regarding employment arrangement of Adriana Karaboutis dated August 7, 2014. Filed as Exhibit 10.44 to our Annual Report on Form 10-K for the year ended December 31, 2014.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.39*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Letter regarding employment arrangement of John Cox dated May 19, 2016. Filed as Exhibit 10.1 to our Quarterly Report on Form 10-Q for the quarter ended June 30, 2016. </font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.40*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Letter regarding separation arrangement of Tony Kingsley dated November 12, 2015. Filed as Exhibit 10.42 to our Annual Report on Form 10-K for the year ended December 31, 2015.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.41</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Settlement and License Agreement,&#160;dated January 17, 2017,&#160;between Biogen Swiss Manufacturing GmbH, Biogen International Holding Ltd, Forward Pharma A/S and the other parties thereto. Filed as Exhibit 10.1 to our Current Report on Form 8-K filed on February 1, 2017.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subsidiaries. </font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">23+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Consent of PricewaterhouseCoopers LLP, an Independent Registered Public Accounting Firm.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31.1+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Certification of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31.2+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Certification of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">32.1++</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Certification of the Chief Executive Officer and the Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">101++</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following materials from Biogen Inc.&#8217;s Annual Report on Form 10-K for the year ended December 31, 2016, formatted in XBRL (Extensible Business Reporting Language): (i) the Consolidated Statements of Income, (ii) the Consolidated Statements of Comprehensive Income, (iii) the Consolidated Balance Sheets, (iv) the Consolidated Statements of Cash Flows, (v) the Consolidated Statements of Equity and (vi) Notes to Consolidated Financial Statements.</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:6%;"></td><td style="width:94%;"></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">^</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">References to &#8220;our&#8221; filings mean filings made by Biogen Inc. and filings made by IDEC Pharmaceuticals Corporation prior to the merger with Biogen, Inc. Unless otherwise indicated exhibits were previously filed with the Securities and Exchange Commission under Commission File Number 0-19311 and are incorporated herein by reference.</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:6%;"></td><td style="width:94%;"></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">*</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Management contract or compensatory plan or arrangement.</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:6%;"></td><td style="width:94%;"></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8224;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Confidential treatment has been granted or requested with respect to portions of this exhibit.</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:6%;"></td><td style="width:94%;"></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">+</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Filed herewith.</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.0234375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:2%;"></td><td style="width:4%;"></td><td style="width:94%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">+</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">+</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Furnished herewith.</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A- 3</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21
<SEQUENCE>2
<FILENAME>biib-20161231xex21.htm
<DESCRIPTION>EXHIBIT 21
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s275266524A4224C33BC82016E6EA6F13"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Exhibit 21</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">BIOGEN INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following is a list of subsidiaries of Biogen Inc. as of December 31, 2016, omitting some subsidiaries which, considered in the aggregate, would not constitute a significant subsidiary.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">SUBSIDIARY</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">STATE OR OTHER JURISDICTION OF INCORPORATION OR ORGANIZATION</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen MA Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Massachusetts</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Realty Corporation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Massachusetts</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Realty Limited Partnership</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Massachusetts</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen U.S. Corporation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Massachusetts</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen U.S. Limited Partnership</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Massachusetts</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Foundation Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Massachusetts</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen (RTP) Realty LLC</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Holding I LLC</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Holding II LLC</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Idec Nobel Research Center, LLC</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Manufacturing Holding LLC</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen New Ventures Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen SRO Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Therapeutics Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen U.S. Pacific LLC</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen U.S. West Corporation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Bioverativ Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Bioverativ Therapeutics Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Bioverativ U.S. LLC</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Bioverativ Pacific LLC</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Conforma Therapeutics Corporation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Stromedix, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen (Argentina) SRL</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Argentina</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Australia PTY Ltd</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Australia</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Austria GmbH</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Austria</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Belgium N.V./S.A.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Belgium</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen International Holding Limited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Bermuda</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Brasil Produtos Farmaceuticos LTDA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Brazil</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Canada Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Canada</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Chile Spa</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Chile</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Idec Pharmaceutical Consultancy (Shanghai) Co., Ltd.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">China</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen (Czech Republic) s.r.o.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Czech Republic</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen (Denmark) A/S</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Denmark</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen (Denmark) Manufacturing ApS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Denmark</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Holding APS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Denmark</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen (Denmark) New Manufacturing ApS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Denmark</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Finland OY</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Finland</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen France S.A.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">France</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen GmbH</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Germany</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Idec (Hong Kong) Limited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Hong Kong</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Hungary KFT</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Hungary</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Idec Biotech India Pvt. Ltd.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">India</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Idec (Ireland) Ltd.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Ireland</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Italia SRL</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Italy</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Japan Ltd.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Japan</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Luxembourg Holding SARL</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Luxembourg</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Mexico S. DE R.L. DE C.V.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mexico</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen NZ Biopharma Ltd.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">New Zealand</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Norway AS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Norway</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Poland Sp. z.o.o</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Poland</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Portugal Sociedade Farmaceutica, Unipessoal, Lda.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Portugal</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen (Singapore) Pte Ltd</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Singapore</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Slovakia s.r.o.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Slovak Republic</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Pharma, farmacevtska in biotehnoloska druzba d.o.o</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Slovenia</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Spain, S.L.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Spain</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fundacion Biogen</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Spain</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Sweden AB</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Sweden</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen International GmbH</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Switzerland</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen International Neuroscience GmbH</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Switzerland</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Management Services GmbH</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Switzerland</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Swiss Manufacturing GmbH</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Switzerland</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Switzerland AG</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Switzerland</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Switzerland Holdings GmbH</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Switzerland</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Eidetica Biopharma GmbH</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Switzerland</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen B.V.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The Netherlands</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Netherlands B.V.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The Netherlands</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Idec Ltd.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">UK</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Idec Research Ltd.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">UK</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Convergence Pharmaceuticals Ltd.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">UK</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Convergence Pharmaceuticals Holdings Ltd.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">UK</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Old Convergence Pharmaceuticals Ltd.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">UK</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Panion Ltd.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">UK</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Silver Acquisition Co. Ltd.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">UK</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Idec Uruguay SA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Uruguay</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Bioverativ Canada</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Canada</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Bioverativ Japan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Japan</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23
<SEQUENCE>3
<FILENAME>biib-20161231xex23.htm
<DESCRIPTION>EXHIBIT 23
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sACC8163D61A25070B5792016E7900206"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Exhibit 23</font></div><div style="line-height:120%;padding-bottom:32px;padding-top:32px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We hereby consent to the incorporation by reference in the Registration Statement on Form S-3 (No. 333-206799) and Registration Statements on Forms S-8 (Nos. 333-205254, 333-110432, 333-128339, 333-152456, 333-140817 and 333-170133) of Biogen Inc. of our report</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt"> </sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">dated February 2, 2017 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10&#8209;K.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/s/ PricewaterhouseCoopers LLP</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Boston, Massachusetts</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">February 2, 2017</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>biib-20161231xex311.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sE7BFC774941D936624AC2016E8389065"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Exhibit 31.1</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO</font></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">I, Michel Vounatsos, certify that:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1. </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">I have reviewed this annual report of Biogen Inc.;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">b) </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">c) </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5. </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">b) </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div></td></tr></table><div style="line-height:120%;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:76%;"></td><td style="width:24%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Date: February&#160;2, 2017</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/s/ Michel Vounatsos</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Michel Vounatsos</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Chief Executive Officer</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>biib-20161231xex312.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sB48EA59BA154EA5307D22016E8DE95C7"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Exhibit 31.2</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO</font></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">I, Paul J. Clancy, certify that:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1. </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">I have reviewed this annual report of Biogen Inc.;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">a) </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">b) </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">d) </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5. </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">a) </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">b) </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div></td></tr></table><div style="line-height:120%;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:75%;"></td><td style="width:25%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Date: February&#160;2, 2017</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/s/ Paul J. Clancy</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Paul J. Clancy</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Executive Vice President and</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Chief Financial Officer</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>biib-20161231xex321.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sAD28208AC4411837FE472016E98CCA53"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Exhibit 32.1</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">CERTIFICATION</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a)&#160;and (b)&#160;of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Biogen Inc., a Delaware corporation (the &#8220;Company&#8221;), does hereby certify, to such officer&#8217;s knowledge, that:</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The Annual Report on Form 10-K for the year ended December&#160;31, 2016 (the &#8220;Form 10-K&#8221;) of the Company fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-K fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:75%;"></td><td style="width:25%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Dated: February&#160;2, 2017</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/s/ Michel Vounatsos &#160;&#160;&#160;&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Michel Vounatsos</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Chief Executive Officer</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">[principal executive officer]</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:75%;"></td><td style="width:25%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Dated: February 2, 2017</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/s/ Paul J. Clancy</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Paul J. Clancy</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Executive Vice President</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">and Chief Financial Officer</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">[principal financial officer]</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A signed original of this written statement required by Section&#160;906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>7
<FILENAME>biib-20161231.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:4f3ca0d7c04348978c4be18cf73a0aa9,x:dda8348d6051450a9926a65427e78724-->
<xbrli:xbrl xmlns:biib="http://www.biogenidec.com/20161231" xmlns:country="http://xbrl.sec.gov/country/2016-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2016-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2016-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2016-01-31" xmlns:us-roles="http://fasb.org/us-roles/2016-01-31" xmlns:us-types="http://fasb.org/us-types/2016-01-31" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
	<link:schemaRef xlink:href="biib-20161231.xsd" xlink:type="simple" />
	<xbrli:context id="FD2016Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-01-27</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q2">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_biib_MajorDistributorAxis_biib_DistributorTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:MajorDistributorAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_biib_MajorDistributorAxis_biib_DistributorOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:MajorDistributorAxis">biib:DistributorOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_biib_MajorDistributorAxis_biib_DistributorOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:MajorDistributorAxis">biib:DistributorOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_biib_MajorDistributorAxis_biib_DistributorTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:MajorDistributorAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q1_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ConvergencePharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-02-01</xbrli:startDate>
			<xbrli:endDate>2015-02-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4QTD_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ConvergencePharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-10-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q1ConvergencePharma_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_biib_BIIB074Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ConvergencePharmaceuticalsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:BIIB074Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-02-12</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q1ConvergencePharma_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ConvergencePharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-02-12</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q1ConvergencePharma_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_biib_NeuropathicpainindicationsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ConvergencePharmaceuticalsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:NeuropathicpainindicationsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-02-12</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q1_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_biib_BIIB074Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ConvergencePharmaceuticalsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:BIIB074Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-02-01</xbrli:startDate>
			<xbrli:endDate>2015-02-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_biib_FacilityLocationAxis_biib_CambridgeMAMember_us-gaap_RestructuringPlanAxis_biib_A2016RestructuringChargesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:CambridgeMAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2016RestructuringChargesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_RestructuringPlanAxis_biib_A2015RestructuringChargesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2015RestructuringChargesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4QTD_us-gaap_RestructuringPlanAxis_biib_A2015RestructuringChargesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2015RestructuringChargesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-10-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_RestructuringPlanAxis_biib_A2015RestructuringChargesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2015RestructuringChargesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_RestructuringPlanAxis_biib_A2016RestructuringChargesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2016RestructuringChargesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_biib_FacilityLocationAxis_biib_CambridgeMAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:CambridgeMAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ContractTerminationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ContractTerminationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ContractTerminationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ReserveForCashDiscountMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ReserveForCashDiscountMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ReserveForCashDiscountMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ReserveForCashDiscountMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ReserveForCashDiscountMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ReserveForCashDiscountMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ReserveForCashDiscountMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_ProductOrServiceAxis_biib_ZINBRYTAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_ProductOrServiceAxis_biib_BENEPALIMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_ProductOrServiceAxis_biib_FLIXABIMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember_us-gaap_ProductOrServiceAxis_biib_BiosimilarsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_ProductOrServiceAxis_biib_AVONEXMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember_us-gaap_ProductOrServiceAxis_biib_ZINBRYTAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember_us-gaap_ProductOrServiceAxis_biib_ALPROLIXMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ALPROLIXMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_AtaxionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VariableInterestEntitiesByClassificationOfEntityAxis">biib:AtaxionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember_us-gaap_ProductOrServiceAxis_biib_ALPROLIXMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ALPROLIXMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_RodinTherapeuticsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VariableInterestEntitiesByClassificationOfEntityAxis">biib:RodinTherapeuticsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember_us-gaap_ProductOrServiceAxis_biib_TysabriProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_BusinessAcquisitionAxis_biib_StromedixMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:StromedixMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ConvergencePharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_BusinessAcquisitionAxis_biib_BiogenIdecInternationalNeuroscienceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:BiogenIdecInternationalNeuroscienceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_BusinessAcquisitionAxis_biib_StromedixMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:StromedixMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_BusinessAcquisitionAxis_biib_BiogenIdecInternationalNeuroscienceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:BiogenIdecInternationalNeuroscienceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_BusinessAcquisitionAxis_biib_StromedixMember_us-gaap_ContingentConsiderationByTypeAxis_us-gaap_AccruedLiabilitiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:StromedixMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_BusinessAcquisitionAxis_biib_StromedixMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:StromedixMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ConvergencePharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2012Q1QTD_us-gaap_BusinessAcquisitionAxis_biib_StromedixMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:StromedixMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2012-01-01</xbrli:startDate>
			<xbrli:endDate>2012-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember_us-gaap_ContingentConsiderationByTypeAxis_us-gaap_AccruedLiabilitiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ConvergencePharmaceuticalsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_ContingentConsiderationByTypeAxis_us-gaap_OtherNoncurrentLiabilitiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_BusinessAcquisitionAxis_biib_BiogenIdecInternationalNeuroscienceMember_us-gaap_ContingentConsiderationByTypeAxis_us-gaap_AccruedLiabilitiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:BiogenIdecInternationalNeuroscienceMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_ContingentConsiderationByTypeAxis_us-gaap_OtherNoncurrentLiabilitiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2010Q4QTD_us-gaap_BusinessAcquisitionAxis_biib_BiogenIdecInternationalNeuroscienceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:BiogenIdecInternationalNeuroscienceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2010-10-01</xbrli:startDate>
			<xbrli:endDate>2010-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_BusinessAcquisitionAxis_biib_BiogenIdecInternationalNeuroscienceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:BiogenIdecInternationalNeuroscienceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ConvergencePharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_NotesPayableToFumedicaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:NotesPayableToFumedicaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_DebtInstrumentAxis_biib_NotesPayableToFumedicaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:NotesPayableToFumedicaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_InvestmentTypeAxis_us-gaap_DebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_InvestmentTypeAxis_us-gaap_RepurchaseAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_InvestmentTypeAxis_us-gaap_RepurchaseAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_InvestmentTypeAxis_us-gaap_DebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_StrategicInvestmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:StrategicInvestmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_StrategicInvestmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:StrategicInvestmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:CorporateDebtSecuritiesCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:GovernmentSecuritiesCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesNonCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:GovernmentSecuritiesNonCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesNonCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:CorporateDebtSecuritiesNonCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:MortgageAndOtherAssetBackedSecuritiesCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MarketableEquitySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:MarketableEquitySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:CorporateDebtSecuritiesCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesNonCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:GovernmentSecuritiesNonCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MarketableEquitySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:MarketableEquitySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesNonCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:CorporateDebtSecuritiesNonCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:GovernmentSecuritiesCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:MortgageAndOtherAssetBackedSecuritiesCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherInvestmentsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherInvestmentsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_CurrencyAxis_currency_CAD_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_CurrencyAxis_currency_CHF_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_CurrencyAxis_currency_CAD_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_CurrencyAxis_currency_EUR_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_CurrencyAxis_currency_EUR_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_CurrencyAxis_currency_CHF_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_biib_FacilityLocationAxis_biib_SolothurnMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:SolothurnMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3QTD_us-gaap_BusinessAcquisitionAxis_biib_EisaiMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:EisaiMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1QTD_biib_FacilityLocationAxis_biib_SolothurnMember_us-gaap_CurrencyAxis_currency_USD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:SolothurnMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:CurrencyAxis">currency:USD</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3QTD_us-gaap_BusinessAcquisitionAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_BusinessAcquisitionAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1QTD_biib_FacilityLocationAxis_biib_SolothurnMember_us-gaap_CurrencyAxis_currency_CHF_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:SolothurnMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_biib_FacilityLocationAxis_biib_SolothurnMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:SolothurnMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3QTD_us-gaap_BusinessAcquisitionAxis_biib_EisaiMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:EisaiMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3QTD_us-gaap_BusinessAcquisitionAxis_biib_EisaiMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:EisaiMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableOtherPayablesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_BusinessAcquisitionAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2006Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableOtherPayablesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2006-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2008Q1SD_us-gaap_LongtermDebtTypeAxis_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">biib:SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2008-12-01</xbrli:startDate>
			<xbrli:endDate>2008-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_LongtermDebtTypeAxis_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">biib:SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableOtherPayablesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2008Q1SD_us-gaap_LongtermDebtTypeAxis_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">biib:SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2008-03-04</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2008Q1SD_us-gaap_DebtInstrumentAxis_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2008-03-04</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_BusinessAcquisitionAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementClassOfStockAxis_biib_SeriesXPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">biib:SeriesXPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q3">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementClassOfStockAxis_biib_UndesignatedPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">biib:UndesignatedPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q2">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2011Q1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2011-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:StockOptionsAndEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:StockOptionsAndEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:StockOptionsAndEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_RestructuringChargesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_RestructuringChargesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_RestructuringChargesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_PlanNameAxis_biib_A1995ESPPMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:A1995ESPPMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_PlanNameAxis_biib_A2015ESPPMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:A2015ESPPMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_PlanNameAxis_biib_A1995ESPPMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:A1995ESPPMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_PlanNameAxis_biib_A2015ESPPMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:A2015ESPPMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_PlanNameAxis_biib_A1995ESPPMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:A1995ESPPMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_biib_ShareBasedCompensationPlanAxis_biib_AttainmentOfPerformanceCriteriain2012Member_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:ShareBasedCompensationPlanAxis">biib:AttainmentOfPerformanceCriteriain2012Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_biib_ShareBasedCompensationPlanAxis_biib_AttainmentOfPerformanceCriteriain2013Member_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:ShareBasedCompensationPlanAxis">biib:AttainmentOfPerformanceCriteriain2013Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_biib_ShareBasedCompensationPlanAxis_biib_DirectorsPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:ShareBasedCompensationPlanAxis">biib:DirectorsPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_biib_ShareBasedCompensationPlanAxis_biib_OmnibusPlansMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:ShareBasedCompensationPlanAxis">biib:OmnibusPlansMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember_us-gaap_TitleOfIndividualAxis_us-gaap_DirectorMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_PlanNameAxis_biib_EmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_PlanNameAxis_biib_PerformanceUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:PerformanceUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_PlanNameAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_PlanNameAxis_biib_PerformanceUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:PerformanceUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_PlanNameAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_PlanNameAxis_biib_EmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_PlanNameAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_PlanNameAxis_biib_CashSettledPerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_PlanNameAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_PlanNameAxis_biib_EmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_PlanNameAxis_biib_CashSettledPerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_PlanNameAxis_biib_CashSettledPerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_PlanNameAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_PlanNameAxis_biib_PerformanceUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:PerformanceUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_PlanNameAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q1YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_GeneralBusinessMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:GeneralBusinessMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_GeneralBusinessMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:GeneralBusinessMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_GeneralBusinessMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:GeneralBusinessMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q2QTD_us-gaap_StatementGeographicalAxis_country_IT">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:IT</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-04-01</xbrli:startDate>
			<xbrli:endDate>2014-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementGeographicalAxis_country_IT">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:IT</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q2_us-gaap_StatementGeographicalAxis_country_IT">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:IT</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_biib_CumulativeSalesLevelAxis_biib_ElevenbillionMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:CumulativeSalesLevelAxis">biib:ElevenbillionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementGeographicalAxis_country_IT">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:IT</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_biib_CumulativeSalesLevelAxis_biib_ElevenbillionMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:CumulativeSalesLevelAxis">biib:ElevenbillionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2011Q4_us-gaap_StatementGeographicalAxis_country_IT">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:IT</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2011-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4QTD_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_RodinTherapeuticsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:VariableInterestEntitiesByClassificationOfEntityAxis">biib:RodinTherapeuticsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-10-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_NeurimmuneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:VariableInterestEntitiesByClassificationOfEntityAxis">biib:NeurimmuneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3QTD_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_NeurimmuneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:VariableInterestEntitiesByClassificationOfEntityAxis">biib:NeurimmuneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q1QTD_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_AtaxionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:VariableInterestEntitiesByClassificationOfEntityAxis">biib:AtaxionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_RodinTherapeuticsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:VariableInterestEntitiesByClassificationOfEntityAxis">biib:RodinTherapeuticsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_ProductOrServiceAxis_biib_RituxanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:RituxanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_biib_SobiRateToBiogenOnNetSalesInSobiTerritoryMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:RoyaltyAndNetRevenueShareRatesByTerritoryAxis">biib:SobiRateToBiogenOnNetSalesInSobiTerritoryMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_biib_BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:RoyaltyAndNetRevenueShareRatesByTerritoryAxis">biib:BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_biib_BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember_us-gaap_StatementGeographicalAxis_biib_SobiTerritoryMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:RoyaltyAndNetRevenueShareRatesByTerritoryAxis">biib:BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">biib:SobiTerritoryMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_biib_BiogenRateToSobiOnNetRevenueFromBiogenDistributorTerritoryMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:RoyaltyAndNetRevenueShareRatesByTerritoryAxis">biib:BiogenRateToSobiOnNetRevenueFromBiogenDistributorTerritoryMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_biib_BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:RoyaltyAndNetRevenueShareRatesByTerritoryAxis">biib:BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_biib_BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember_us-gaap_StatementGeographicalAxis_biib_SobiTerritoryMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:RoyaltyAndNetRevenueShareRatesByTerritoryAxis">biib:BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">biib:SobiTerritoryMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_biib_BiogenRateToSobiOnNetRevenueFromBiogenDistributorTerritoryMember_us-gaap_StatementGeographicalAxis_biib_SobiTerritoryMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:RoyaltyAndNetRevenueShareRatesByTerritoryAxis">biib:BiogenRateToSobiOnNetRevenueFromBiogenDistributorTerritoryMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">biib:SobiTerritoryMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AbbVieMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_TypeOfArrangementAxis_biib_RocheGroupGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_biib_RocheGroupGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_biib_RocheGroupGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_RituxanMember_us-gaap_StatementGeographicalAxis_us-gaap_ForeignCountryMember_us-gaap_TypeOfArrangementAxis_biib_RocheGroupGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:RituxanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_TypeOfArrangementAxis_biib_RocheGroupGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_biib_RocheGroupGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_TypeOfArrangementAxis_biib_RocheGroupGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_RituxanMember_us-gaap_StatementGeographicalAxis_us-gaap_ForeignCountryMember_us-gaap_TypeOfArrangementAxis_biib_RocheGroupGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:RituxanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_RituxanMember_us-gaap_StatementGeographicalAxis_us-gaap_ForeignCountryMember_us-gaap_TypeOfArrangementAxis_biib_RocheGroupGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:RituxanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_ProductOrServiceAxis_biib_RituxanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:RituxanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_TypeOfArrangementAxis_biib_AcordaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AcordaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_TypeOfArrangementAxis_biib_SangamoBioSciencesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SangamoBioSciencesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q3_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q2_us-gaap_TypeOfArrangementAxis_biib_UniversityofPennsylvaniaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UniversityofPennsylvaniaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2YTD_us-gaap_TypeOfArrangementAxis_biib_UniversityofPennsylvaniaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UniversityofPennsylvaniaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AGTCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AGTCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_TypeOfArrangementAxis_biib_SwedishOrphanBiovitrumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SwedishOrphanBiovitrumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q1_us-gaap_TypeOfArrangementAxis_biib_SangamoBioSciencesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SangamoBioSciencesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4QTD_us-gaap_TypeOfArrangementAxis_biib_MitsubishiTanabePharmaCorporationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-10-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q2QTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-04-01</xbrli:startDate>
			<xbrli:endDate>2014-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2012Q1QTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2012-01-01</xbrli:startDate>
			<xbrli:endDate>2012-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3QTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AbbVieMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2007Q1SD_us-gaap_BusinessAcquisitionAxis_biib_BiogenIdecHemophiliaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:BiogenIdecHemophiliaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2007-01-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_GAZYVAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:GAZYVAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_TypeOfArrangementAxis_biib_AGTCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AGTCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AcordaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AcordaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_OcrelizumabMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:OcrelizumabMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_TypeOfArrangementAxis_biib_OtherresearchanddiscoveryMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:OtherresearchanddiscoveryMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_TypeOfArrangementAxis_biib_AGTCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AGTCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AcordaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AcordaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2012Q1SD2_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2012-02-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_TypeOfArrangementAxis_biib_OtherresearchanddiscoveryMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:OtherresearchanddiscoveryMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_ZINBRYTAMember_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AbbVieMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_us-gaap_TypeOfArrangementAxis_biib_SwedishOrphanBiovitrumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SwedishOrphanBiovitrumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_OcrelizumabMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:OcrelizumabMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AbbVieMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_TypeOfArrangementAxis_biib_OtherresearchanddiscoveryMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:OtherresearchanddiscoveryMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_TypeOfArrangementAxis_biib_SangamoBioSciencesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SangamoBioSciencesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q1_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_DMPKMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:DMPKMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AbbVieMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesRevenueNetMember_us-gaap_TypeOfArrangementAxis_biib_SwedishOrphanBiovitrumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SwedishOrphanBiovitrumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2012Q2QTD_us-gaap_ProductOrServiceAxis_biib_DMPKMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:DMPKMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2012-04-01</xbrli:startDate>
			<xbrli:endDate>2012-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_TypeOfArrangementAxis_biib_UniversityofPennsylvaniaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UniversityofPennsylvaniaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_ProductOrServiceAxis_biib_GAZYVAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:GAZYVAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q3QTD_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-07-01</xbrli:startDate>
			<xbrli:endDate>2013-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_TypeOfArrangementAxis_biib_SangamoBioSciencesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SangamoBioSciencesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_ZINBRYTAMember_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AbbVieMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AGTCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AGTCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AcordaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AcordaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_ELOCTATEMember_us-gaap_TypeOfArrangementAxis_biib_SwedishOrphanBiovitrumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ELOCTATEMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SwedishOrphanBiovitrumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_DMPKMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:DMPKMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2012Q4QTD_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2012-10-01</xbrli:startDate>
			<xbrli:endDate>2012-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_ALPROLIXMember_us-gaap_TypeOfArrangementAxis_biib_SwedishOrphanBiovitrumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ALPROLIXMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SwedishOrphanBiovitrumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_ZINBRYTAMember_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AbbVieMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementGeographicalAxis_us-gaap_EuropeMember_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:EuropeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AbbVieMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q1_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3QTD_us-gaap_TypeOfArrangementAxis_biib_AGTCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AGTCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_LeadprogramsMember_us-gaap_TypeOfArrangementAxis_biib_AGTCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:LeadprogramsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AGTCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2012Q1Feb_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2012-02-01</xbrli:startDate>
			<xbrli:endDate>2012-02-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_OcrelizumabMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:OcrelizumabMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AbbVieMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_OcrelizumabMember_us-gaap_StatementGeographicalAxis_us-gaap_ForeignCountryMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:OcrelizumabMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2012Q2_us-gaap_ProductOrServiceAxis_biib_DMPKMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:DMPKMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2012-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_SOD1Member_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:SOD1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_ProductOrServiceAxis_biib_DMPKMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:DMPKMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_TypeOfArrangementAxis_biib_MitsubishiTanabePharmaCorporationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4QTD_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-10-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_ProductOrServiceAxis_biib_ZINBRYTAMember_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AbbVieMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_NewAntiCd20Member_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:NewAntiCd20Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_ZINBRYTAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_ProductOrServiceAxis_biib_DiscoveryprogramsMember_us-gaap_TypeOfArrangementAxis_biib_AGTCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:DiscoveryprogramsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AGTCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_ProductOrServiceAxis_biib_LeadprogramsMember_us-gaap_TypeOfArrangementAxis_biib_AGTCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:LeadprogramsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AGTCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_TypeOfArrangementAxis_biib_SangamoBioSciencesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SangamoBioSciencesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_NewAntiCd20Member_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:NewAntiCd20Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_DMPKMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:DMPKMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_ProductOrServiceAxis_biib_RituxanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:RituxanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2011Q4QTD_us-gaap_StatementGeographicalAxis_country_IT">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:IT</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2011-10-01</xbrli:startDate>
			<xbrli:endDate>2011-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_biib_CumulativeSalesLevelAxis_biib_EachAdditionalOneBillionUpToTwentyBillionMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:CumulativeSalesLevelAxis">biib:EachAdditionalOneBillionUpToTwentyBillionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_biib_CumulativeSalesLevelAxis_biib_EachAdditionalOneBillionUpToTwentyBillionMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:CumulativeSalesLevelAxis">biib:EachAdditionalOneBillionUpToTwentyBillionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_biib_FutureContingentMilestoneTypesAxis_biib_RegulatoryMilestonesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:RegulatoryMilestonesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2013Q2SD_us-gaap_BusinessAcquisitionAxis_biib_TysabriProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:TysabriProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-04-02</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_biib_CumulativeSalesLevelAxis_biib_ThreeBillionMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:CumulativeSalesLevelAxis">biib:ThreeBillionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_biib_FutureContingentMilestoneTypesAxis_biib_CommercialMilestonesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:CommercialMilestonesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_biib_CumulativeSalesLevelAxis_biib_SevenbillionMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:CumulativeSalesLevelAxis">biib:SevenbillionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q2_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_biib_FutureContingentMilestoneTypesAxis_biib_DevelopmentMilestonesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:DevelopmentMilestonesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_biib_CumulativeSalesLevelAxis_biib_NinebillionMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:CumulativeSalesLevelAxis">biib:NinebillionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementGeographicalAxis_us-gaap_EuropeanUnionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:EuropeanUnionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_biib_CumulativeSalesLevelAxis_biib_EightbillionMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:CumulativeSalesLevelAxis">biib:EightbillionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_biib_CumulativeSalesLevelAxis_biib_TenbillionMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:CumulativeSalesLevelAxis">biib:TenbillionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_biib_CumulativeSalesLevelAxis_biib_OneBillionMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:CumulativeSalesLevelAxis">biib:OneBillionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_biib_CumulativeSalesLevelAxis_biib_TenbillionMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:CumulativeSalesLevelAxis">biib:TenbillionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2006Q4YTD_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2006-01-01</xbrli:startDate>
			<xbrli:endDate>2006-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_us-gaap_ForeignPensionPlansDefinedBenefitMember_us-gaap_StatementGeographicalAxis_country_CH">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis">us-gaap:ForeignPensionPlansDefinedBenefitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:CH</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_DefinedContributionPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedContributionPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_us-gaap_ForeignPensionPlansDefinedBenefitMember_us-gaap_StatementGeographicalAxis_country_DE">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis">us-gaap:ForeignPensionPlansDefinedBenefitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_us-gaap_ForeignPensionPlansDefinedBenefitMember_us-gaap_StatementGeographicalAxis_country_DE">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis">us-gaap:ForeignPensionPlansDefinedBenefitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_us-gaap_ForeignPensionPlansDefinedBenefitMember_us-gaap_StatementGeographicalAxis_country_CH">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis">us-gaap:ForeignPensionPlansDefinedBenefitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:CH</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_us-gaap_ForeignPensionPlansDefinedBenefitMember_us-gaap_StatementGeographicalAxis_country_CH">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis">us-gaap:ForeignPensionPlansDefinedBenefitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:CH</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_DefinedContributionPlanTypeAxis_us-gaap_UnitedStatesPostretirementBenefitPlansOfUSEntityDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedContributionPlanTypeAxis">us-gaap:UnitedStatesPostretirementBenefitPlansOfUSEntityDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_us-gaap_ForeignPensionPlansDefinedBenefitMember_us-gaap_StatementGeographicalAxis_country_DE">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis">us-gaap:ForeignPensionPlansDefinedBenefitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_us-gaap_ForeignPensionPlansDefinedBenefitMember_us-gaap_StatementGeographicalAxis_country_CH">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis">us-gaap:ForeignPensionPlansDefinedBenefitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:CH</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_DefinedContributionPlanTypeAxis_us-gaap_UnitedStatesPostretirementBenefitPlansOfUSEntityDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedContributionPlanTypeAxis">us-gaap:UnitedStatesPostretirementBenefitPlansOfUSEntityDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_us-gaap_ForeignPensionPlansDefinedBenefitMember_us-gaap_StatementGeographicalAxis_country_CH">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis">us-gaap:ForeignPensionPlansDefinedBenefitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:CH</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_us-gaap_ForeignPensionPlansDefinedBenefitMember_us-gaap_StatementGeographicalAxis_country_DE">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis">us-gaap:ForeignPensionPlansDefinedBenefitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_DefinedContributionPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedContributionPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_us-gaap_ForeignPensionPlansDefinedBenefitMember_us-gaap_StatementGeographicalAxis_country_DE">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis">us-gaap:ForeignPensionPlansDefinedBenefitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_DefinedContributionPlanTypeAxis_us-gaap_UnitedStatesPostretirementBenefitPlansOfUSEntityDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedContributionPlanTypeAxis">us-gaap:UnitedStatesPostretirementBenefitPlansOfUSEntityDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementGeographicalAxis_country_DE">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">biib:SegmentGeographicalGroupsOfCountriesGroupOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementGeographicalAxis_us-gaap_EuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:EuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">biib:SegmentGeographicalGroupsOfCountriesGroupOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementGeographicalAxis_us-gaap_AsiaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:AsiaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementGeographicalAxis_country_DE">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">biib:SegmentGeographicalGroupsOfCountriesGroupOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_StatementGeographicalAxis_country_DE">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementGeographicalAxis_us-gaap_AsiaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:AsiaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_StatementGeographicalAxis_us-gaap_AsiaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:AsiaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">biib:SegmentGeographicalGroupsOfCountriesGroupOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">biib:SegmentGeographicalGroupsOfCountriesGroupOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_StatementGeographicalAxis_us-gaap_EuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:EuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementGeographicalAxis_country_DE">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementGeographicalAxis_country_DE">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementGeographicalAxis_us-gaap_EuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:EuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">biib:SegmentGeographicalGroupsOfCountriesGroupOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementGeographicalAxis_us-gaap_EuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:EuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementGeographicalAxis_us-gaap_AsiaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:AsiaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementGeographicalAxis_country_DE">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementGeographicalAxis_us-gaap_AsiaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:AsiaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementGeographicalAxis_us-gaap_EuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:EuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementGeographicalAxis_us-gaap_AsiaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:AsiaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementGeographicalAxis_us-gaap_EuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:EuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_PLEGRIDYMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_BENEPALIMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_AVONEXMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_BENEPALIMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_FLIXABIMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_BENEPALIMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_TecfideraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_FUMADERMMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_ELOCTATEMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ELOCTATEMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_FAMPYRAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_FLIXABIMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_FUMADERMMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_ALPROLIXProductMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ALPROLIXProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_FUMADERMMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_BENEPALIMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_ZINBRYTAMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_BENEPALIMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_PLEGRIDYMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_ELOCTATEMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ELOCTATEMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_TysabriMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TysabriMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_AVONEXMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_FAMPYRAMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_ZINBRYTAMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_ALPROLIXProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ALPROLIXProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_BENEPALIMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_FUMADERMMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_ALPROLIXProductMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ALPROLIXProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_FLIXABIMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_FLIXABIMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_FUMADERMMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_ALPROLIXProductMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ALPROLIXProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_PLEGRIDYMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_PLEGRIDYMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_FAMPYRAMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_BENEPALIMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_AVONEXMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_ALPROLIXProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ALPROLIXProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_FUMADERMMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_TysabriMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TysabriMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_TysabriMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TysabriMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_FAMPYRAMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_AVONEXMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_ALPROLIXProductMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ALPROLIXProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_TysabriMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TysabriMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_ELOCTATEMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ELOCTATEMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_FAMPYRAMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_ALPROLIXProductMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ALPROLIXProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_FUMADERMMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_ZINBRYTAMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_FAMPYRAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_ZINBRYTAMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_PLEGRIDYMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_AVONEXMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_FLIXABIMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_PLEGRIDYMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_FUMADERMMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_ELOCTATEMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ELOCTATEMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_AVONEXMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_BENEPALIMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_TysabriMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TysabriMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_ZINBRYTAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_ZINBRYTAMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_FLIXABIMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_TysabriMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TysabriMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_FLIXABIMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_ELOCTATEMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ELOCTATEMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_FLIXABIMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_FUMADERMMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_ALPROLIXProductMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ALPROLIXProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_TysabriMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TysabriMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_AVONEXMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_TecfideraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_AVONEXMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_ELOCTATEMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ELOCTATEMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_TysabriMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TysabriMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_BENEPALIMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_PLEGRIDYMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_PLEGRIDYMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_ZINBRYTAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_AVONEXMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_TecfideraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_FAMPYRAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_ZINBRYTAMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_FAMPYRAMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_ALPROLIXProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ALPROLIXProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_TysabriMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TysabriMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_ELOCTATEMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ELOCTATEMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_ELOCTATEMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ELOCTATEMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_FLIXABIMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_ELOCTATEMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ELOCTATEMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_PLEGRIDYMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_FAMPYRAMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_biib_MajorDistributorAxis_biib_DistributorOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:MajorDistributorAxis">biib:DistributorOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_biib_MajorDistributorAxis_biib_DistributorTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:MajorDistributorAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_biib_MajorDistributorAxis_biib_DistributorTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:MajorDistributorAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementGeographicalAxis_biib_SolothurnMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">biib:SolothurnMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementGeographicalAxis_country_DK">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:DK</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_biib_MajorDistributorAxis_biib_DistributorOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:MajorDistributorAxis">biib:DistributorOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_biib_MajorDistributorAxis_biib_DistributorTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:MajorDistributorAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementGeographicalAxis_country_DK">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:DK</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_biib_MajorDistributorAxis_biib_DistributorOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:MajorDistributorAxis">biib:DistributorOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementGeographicalAxis_biib_SolothurnMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">biib:SolothurnMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementGeographicalAxis_country_DK">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:DK</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-10-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-04-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-10-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q2QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-04-01</xbrli:startDate>
			<xbrli:endDate>2015-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3QTD_biib_FacilityLocationAxis_biib_CambridgeMAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:CambridgeMAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2QTD_biib_FacilityLocationAxis_biib_CambridgeMAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:CambridgeMAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-04-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1QTD_us-gaap_RestructuringPlanAxis_biib_A2015RestructuringChargesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2015RestructuringChargesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4QTD_biib_FacilityLocationAxis_biib_CambridgeMAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:CambridgeMAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-10-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:unit id="number">
		<xbrli:measure>xbrli:pure</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="shares">
		<xbrli:measure>xbrli:shares</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="usdPerShare">
		<xbrli:divide>
			<xbrli:unitNumerator>
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unitNumerator>
			<xbrli:unitDenominator>
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unitDenominator>
		</xbrli:divide>
	</xbrli:unit>
	<xbrli:unit id="usd">
		<xbrli:measure>iso4217:USD</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="Plan">
		<xbrli:measure>biib:Plan</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="Increment">
		<xbrli:measure>biib:Increment</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="chf">
		<xbrli:measure>iso4217:CHF</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="EUR">
		<xbrli:measure>iso4217:EUR</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="segment">
		<xbrli:measure>biib:segment</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="KRW">
		<xbrli:measure>iso4217:KRW</xbrli:measure>
	</xbrli:unit>
	<biib:AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch contextRef="FI2016Q4" decimals="-5" id="Fact-22C8D86808B463A0F25B7411DFB8F1D5" unitRef="usd">21000000</biib:AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch>
	<biib:AdditionalMilestonePayment contextRef="FI2012Q2_us-gaap_ProductOrServiceAxis_biib_DMPKMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-2B7C9720B9A6677EF00C281CCFAFC0DD" unitRef="usd">59000000</biib:AdditionalMilestonePayment>
	<biib:AdditionalMilestonePayment contextRef="FI2015Q4_us-gaap_ProductOrServiceAxis_biib_DMPKMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-A4A39B6F57D7569B4099281D500DD2FD" unitRef="usd">4200000</biib:AdditionalMilestonePayment>
	<biib:AdditionalMilestonePayment contextRef="FI2016Q4_us-gaap_ProductOrServiceAxis_biib_DiscoveryprogramsMember_us-gaap_TypeOfArrangementAxis_biib_AGTCMember" decimals="-5" id="Fact-43E370AFD3EB0AE04AA37411DFC63D6E" unitRef="usd">592500000</biib:AdditionalMilestonePayment>
	<biib:AdditionalMilestonePayment contextRef="FI2016Q4_us-gaap_ProductOrServiceAxis_biib_LeadprogramsMember_us-gaap_TypeOfArrangementAxis_biib_AGTCMember" decimals="-5" id="Fact-7167D9F31315998736267411DFC4EF9D" unitRef="usd">472500000</biib:AdditionalMilestonePayment>
	<biib:AdditionalMilestonePayment contextRef="FI2016Q4_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="-5" id="Fact-64058FF9C35AC1CBE7F027F0CC18B074" unitRef="usd">25000000</biib:AdditionalMilestonePayment>
	<biib:AdditionalMilestonePayment contextRef="FI2016Q4_us-gaap_TypeOfArrangementAxis_biib_AGTCMember" decimals="-8" id="Fact-B36DCE57C316F469EDA47411DFC46AD2" unitRef="usd">1100000000</biib:AdditionalMilestonePayment>
	<biib:AdditionalMilestonePayment contextRef="FI2016Q4_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" decimals="-8" id="Fact-DC0FCBCA1D75798F19267411DFE509CB" unitRef="usd">1000000000</biib:AdditionalMilestonePayment>
	<biib:AdditionalMilestonePayment contextRef="FI2016Q4_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-BA37BCAF88DB81EF793CD6105F85627D" unitRef="usd">10000000</biib:AdditionalMilestonePayment>
	<biib:AdditionalMilestonePayment contextRef="FI2016Q4_us-gaap_TypeOfArrangementAxis_biib_SangamoBioSciencesMember" decimals="-5" id="Fact-AE34B9DFCD14CEDFA18527EE2548C9D8" unitRef="usd">300000000</biib:AdditionalMilestonePayment>
	<biib:Additionalmilestonepaymentsforproductcandidateusingadifferentmodality contextRef="FD2016Q4YTD_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-2458E01B80632D62EB3D7411DFE13945" unitRef="usd">90000000</biib:Additionalmilestonepaymentsforproductcandidateusingadifferentmodality>
	<biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears contextRef="FD2014Q4YTD" decimals="-5" id="Fact-F05B6DAAD81831C9C3367411DFF5F0EA" unitRef="usd">16000000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
	<biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears contextRef="FD2014Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-9D8FEA5ED92C16D9EC507411DFF45332" unitRef="usd">28500000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
	<biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears contextRef="FD2014Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember" decimals="-5" id="Fact-D114141676832BD141107411DFF49032" unitRef="usd">1000000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
	<biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears contextRef="FD2014Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-0D0A9D614B1FA890D91D7411DFF5A3BE" unitRef="usd">-13500000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
	<biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears contextRef="FD2015Q4YTD" decimals="-5" id="Fact-23E26EC95FE24C6E6A097411DFDF2A3C" unitRef="usd">32300000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
	<biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears contextRef="FD2015Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-2F648E819C79544207BB7411DFDFED3B" unitRef="usd">16300000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
	<biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears contextRef="FD2015Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember" decimals="-5" id="Fact-AE0181D993973C7E77647411DFE14FDE" unitRef="usd">1300000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
	<biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears contextRef="FD2015Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-9BA726E42C9CD9D279CE7411DFDD726D" unitRef="usd">14700000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
	<biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears contextRef="FD2016Q4YTD" decimals="-5" id="Fact-D4D809907F58C25D31867411DFE4F538" unitRef="usd">16700000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
	<biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears contextRef="FD2016Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-CCBF24CEB96B52CEBEB97411E017C142" unitRef="usd">-1500000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
	<biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears contextRef="FD2016Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember" decimals="-5" id="Fact-32C5C992BF7533AE57317411DFE1E1C6" unitRef="usd">1400000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
	<biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears contextRef="FD2016Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-895E7047122055C8BE987411DFE14CEB" unitRef="usd">16800000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
	<biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost contextRef="FI2015Q4" decimals="-5" id="Fact-3491702936A82581B1327411E02E5B82" unitRef="usd">185300000</biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost>
	<biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost contextRef="FI2016Q4" decimals="-5" id="Fact-96BDAB53FEA72D98232B7411E02F4D3E" unitRef="usd">277500000</biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost>
	<biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue contextRef="FI2015Q4" decimals="-5" id="Fact-B5DDDB0024E7DF712A7D7411E02E27FE" unitRef="usd">184500000</biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue>
	<biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue contextRef="FI2016Q4" decimals="-5" id="Fact-B30396564D6B79F231727411E02E1012" unitRef="usd">276800000</biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue>
	<biib:AverageMaturityOfMarketableSecurities contextRef="FD2015Q4YTD" id="Fact-E6018D8B28B5A71DAAFC7411E002011A">P16M</biib:AverageMaturityOfMarketableSecurities>
	<biib:AverageMaturityOfMarketableSecurities contextRef="FD2016Q4YTD" id="Fact-0C235D8B13DAC6E35A3A7411E016A2DF">P12M</biib:AverageMaturityOfMarketableSecurities>
	<biib:AverageStockPriceOnGrantDateInDollarsMaximum contextRef="FD2014Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="2" id="Fact-F8B4A56E07A7679F098EFBA4B9E34966" unitRef="usd">335.65</biib:AverageStockPriceOnGrantDateInDollarsMaximum>
	<biib:AverageStockPriceOnGrantDateInDollarsMaximum contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="2" id="Fact-68BEB68838770787301F7411E01BAD29" unitRef="usd">426.27</biib:AverageStockPriceOnGrantDateInDollarsMaximum>
	<biib:AverageStockPriceOnGrantDateInDollarsMaximum contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="2" id="Fact-C986A83CB5761C48E9FA7411E02096DF" unitRef="usd">304.86</biib:AverageStockPriceOnGrantDateInDollarsMaximum>
	<biib:AverageStockPriceOnGrantDateInDollarsMinimum contextRef="FD2014Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="2" id="Fact-A84EA81A0A45AA515648FBA4A264B492" unitRef="usd">280.88</biib:AverageStockPriceOnGrantDateInDollarsMinimum>
	<biib:AverageStockPriceOnGrantDateInDollarsMinimum contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="2" id="Fact-1DBDB9FBCFCC311A9A117411DFC9E077" unitRef="usd">227.35</biib:AverageStockPriceOnGrantDateInDollarsMinimum>
	<biib:AverageStockPriceOnGrantDateInDollarsMinimum contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="2" id="Fact-2F9CF5503EAB28D0AEA57411E0212C35" unitRef="usd">260.67</biib:AverageStockPriceOnGrantDateInDollarsMinimum>
	<biib:BaseRateAfterFirstCommercialSale contextRef="FD2016Q4YTD_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_biib_BiogenRateToSobiOnNetRevenueFromBiogenDistributorTerritoryMember_us-gaap_StatementGeographicalAxis_biib_SobiTerritoryMember" decimals="2" id="Fact-26157C066AA584769A817411E0064C7B" unitRef="number">0.50</biib:BaseRateAfterFirstCommercialSale>
	<biib:BaseRateAfterFirstCommercialSale contextRef="FD2016Q4YTD_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_biib_BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember_us-gaap_StatementGeographicalAxis_biib_SobiTerritoryMember" decimals="INF" id="Fact-D074FAC9A33B005BA9348C86BFB4A4E5" unitRef="number">0.17</biib:BaseRateAfterFirstCommercialSale>
	<biib:BaseRateAfterFirstCommercialSale contextRef="FD2016Q4YTD_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_biib_BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember_us-gaap_StatementGeographicalAxis_biib_SobiTerritoryMember" decimals="2" id="Fact-C7A58E252A2585D3C4A88C8680C9E5ED" unitRef="number">0.12</biib:BaseRateAfterFirstCommercialSale>
	<biib:BaseRateAfterFirstCommercialSale contextRef="FD2016Q4YTD_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_biib_SobiRateToBiogenOnNetSalesInSobiTerritoryMember" decimals="2" id="Fact-C07982F1719A81B5940E8C8642EC1FAE" unitRef="number">0.12</biib:BaseRateAfterFirstCommercialSale>
	<biib:Biogeneffectiveroyaltyrate contextRef="FD2016Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_us-gaap_TypeOfArrangementAxis_biib_SwedishOrphanBiovitrumMember" id="Fact-9E3E48E66FDBA47140198C8BE25A1667">0.11</biib:Biogeneffectiveroyaltyrate>
	<biib:Biogeneffectiveroyaltyrate contextRef="FD2016Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesRevenueNetMember_us-gaap_TypeOfArrangementAxis_biib_SwedishOrphanBiovitrumMember" id="Fact-8D092BADDB51139AFB698C8B8F2DB33C">0.14</biib:Biogeneffectiveroyaltyrate>
	<biib:Biogenshareofcopromotionprofitsorlosses contextRef="FD2016Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember" decimals="2" id="Fact-74357E560EA70EFCA6E2D6263A8C85AE" unitRef="number">0.50</biib:Biogenshareofcopromotionprofitsorlosses>
	<biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment contextRef="FI2016Q4_us-gaap_ProductOrServiceAxis_biib_GAZYVAMember" decimals="-5" id="Fact-F44A3986825060EC6E617411DFFF07D3" unitRef="usd">50000000</biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment>
	<biib:CollaborationProfitSharing contextRef="FD2014Q4YTD" decimals="-5" id="Fact-574527D07DF8213164507411DFF8FFFA" unitRef="usd">0</biib:CollaborationProfitSharing>
	<biib:CollaborationProfitSharing contextRef="FD2015Q4YTD" decimals="-5" id="Fact-BE4253FDCD119C10CFCF7411E00209A0" unitRef="usd">0</biib:CollaborationProfitSharing>
	<biib:CollaborationProfitSharing contextRef="FD2016Q4YTD" decimals="-5" id="Fact-F444E625817E746BBFE57411DFDF5925" unitRef="usd">10200000</biib:CollaborationProfitSharing>
	<biib:Collaborationexpensesaccrual contextRef="FI2015Q4" decimals="-5" id="Fact-E829173F7DC3DBA0ADB4D16FF80C16A3" unitRef="usd">31200000</biib:Collaborationexpensesaccrual>
	<biib:Collaborationexpensesaccrual contextRef="FI2016Q4" decimals="-5" id="Fact-4B0852EA4F452353F18ED16F3860EE85" unitRef="usd">130900000</biib:Collaborationexpensesaccrual>
	<biib:Collaborationprofitlosssharing contextRef="FD2016Q4YTD_us-gaap_StatementGeographicalAxis_us-gaap_EuropeMember_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember" decimals="-5" id="Fact-D2BD89853CC91A58BD2D8CB1D371F928" unitRef="usd">4900000</biib:Collaborationprofitlosssharing>
	<biib:Collaborationprofitlosssharing contextRef="FD2016Q4YTD_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember" decimals="-5" id="Fact-F4F75B34EFCA972BF4A18CFE40A902D4" unitRef="usd">15100000</biib:Collaborationprofitlosssharing>
	<biib:CompensationExpenseOverPurchasePeriod contextRef="FD2016Q4YTD" id="Fact-3A68FF7784F9BB0834667411E000649D">The fair value of the look-back provision plus the 15% discount</biib:CompensationExpenseOverPurchasePeriod>
	<biib:ComputerSoftwareAndHardware contextRef="FI2015Q4" decimals="-5" id="Fact-EB03BA98D5994FD548567411DFD9A4AC" unitRef="usd">647100000</biib:ComputerSoftwareAndHardware>
	<biib:ComputerSoftwareAndHardware contextRef="FI2016Q4" decimals="-5" id="Fact-A631F89E55575C48D3B17411DFD883C1" unitRef="usd">746800000</biib:ComputerSoftwareAndHardware>
	<biib:ConsiderationPerProductDeveloped contextRef="FD2016Q4YTD_us-gaap_TypeOfArrangementAxis_biib_SwedishOrphanBiovitrumMember" decimals="-5" id="Fact-047C33B7BD020D36C53D7411DFE39878" unitRef="usd">10000000</biib:ConsiderationPerProductDeveloped>
	<biib:Copromotionprofitsandlosses contextRef="FD2016Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember" decimals="-5" id="Fact-FC0718C5C35BA223FF6ED621C0AACD0D" unitRef="usd">43900000</biib:Copromotionprofitsandlosses>
	<biib:CumulativeSalesLevel contextRef="FI2016Q4_biib_CumulativeSalesLevelAxis_biib_EachAdditionalOneBillionUpToTwentyBillionMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember" decimals="-8" id="Fact-7525F45D13677F4EFC8DD25AA9926D51" unitRef="usd">20000000000</biib:CumulativeSalesLevel>
	<biib:CumulativeSalesLevel contextRef="FI2016Q4_biib_CumulativeSalesLevelAxis_biib_EightbillionMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember" decimals="-8" id="Fact-A5FC6926A619DBB45AA3D2460F93A49C" unitRef="usd">8000000000</biib:CumulativeSalesLevel>
	<biib:CumulativeSalesLevel contextRef="FI2016Q4_biib_CumulativeSalesLevelAxis_biib_ElevenbillionMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember" decimals="-8" id="Fact-F0D29D99305CB8C38CAED23A1BB74F13" unitRef="usd">11000000000</biib:CumulativeSalesLevel>
	<biib:CumulativeSalesLevel contextRef="FI2016Q4_biib_CumulativeSalesLevelAxis_biib_NinebillionMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember" decimals="-8" id="Fact-0DE98CFE4C66ABAF24B9D250B61CFCEC" unitRef="usd">9000000000</biib:CumulativeSalesLevel>
	<biib:CumulativeSalesLevel contextRef="FI2016Q4_biib_CumulativeSalesLevelAxis_biib_OneBillionMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember" decimals="-8" id="Fact-9705C8A15E1B6BAEE3A6D24549CDB416" unitRef="usd">1000000000</biib:CumulativeSalesLevel>
	<biib:CumulativeSalesLevel contextRef="FI2016Q4_biib_CumulativeSalesLevelAxis_biib_SevenbillionMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember" decimals="-8" id="Fact-188996B6B08C2794C6B8D2506E67B202" unitRef="usd">7000000000</biib:CumulativeSalesLevel>
	<biib:CumulativeSalesLevel contextRef="FI2016Q4_biib_CumulativeSalesLevelAxis_biib_TenbillionMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember" decimals="-8" id="Fact-F34B53907CDB4699A8BAD24FEBDCED60" unitRef="usd">10000000000</biib:CumulativeSalesLevel>
	<biib:CumulativeSalesLevel contextRef="FI2016Q4_biib_CumulativeSalesLevelAxis_biib_ThreeBillionMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember" decimals="-8" id="Fact-D72B77FC05F4EC373143D250FE364E80" unitRef="usd">3000000000</biib:CumulativeSalesLevel>
	<biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear contextRef="FD2014Q4YTD" decimals="-5" id="Fact-ABCE8A83E1F6EC2E4AEA7411DFF4FCD2" unitRef="usd">1651800000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
	<biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear contextRef="FD2014Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-84D98FC621635DFF3A517411DFF47569" unitRef="usd">1265400000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
	<biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear contextRef="FD2014Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember" decimals="-5" id="Fact-CADACA1D6CDF8878C6737411DFF56495" unitRef="usd">347300000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
	<biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear contextRef="FD2014Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-84B1586F7DB6502B81C87411DFF68359" unitRef="usd">39100000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
	<biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear contextRef="FD2015Q4YTD" decimals="-5" id="Fact-4264E3239E22291639837411DFDD3A6D" unitRef="usd">2229400000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
	<biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear contextRef="FD2015Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-3DB79B5EC56E9F4A4A5A7411DFE00A5A" unitRef="usd">1732100000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
	<biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear contextRef="FD2015Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember" decimals="-5" id="Fact-3842169E536411228F9B7411DFE3CBAF" unitRef="usd">459700000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
	<biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear contextRef="FD2015Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-B1426A841FC61513BAF27411DFE0C648" unitRef="usd">37600000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
	<biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear contextRef="FD2016Q4YTD" decimals="-5" id="Fact-86CFB16CD586CE76479C7411DFE03008" unitRef="usd">2668000000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
	<biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear contextRef="FD2016Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-021090CC839AC187FCE77411DFDEBF8D" unitRef="usd">2044500000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
	<biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear contextRef="FD2016Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember" decimals="-5" id="Fact-191C5990035E4B9328027411E0139085" unitRef="usd">592600000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
	<biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear contextRef="FD2016Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-37A844DEC1348C0069387411DFE0C56D" unitRef="usd">30900000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
	<biib:DebtInstrumentMakeWholeProvisionRedemptionPricePercentage contextRef="FD2016Q4YTD" decimals="INF" id="Fact-71EDF3B58E937F882D047411DFF04907" unitRef="number">1.01</biib:DebtInstrumentMakeWholeProvisionRedemptionPricePercentage>
	<biib:DebtInstrumentUnamortizedInterestOnDebt contextRef="FI2016Q4_us-gaap_LongtermDebtTypeAxis_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" decimals="-5" id="Fact-45A3B78A4532296D4FDE7411DFF1DE35" unitRef="usd">9900000</biib:DebtInstrumentUnamortizedInterestOnDebt>
	<biib:DeferredTaxLiabilitiesDepreciationAmortizationOther contextRef="FI2015Q4" decimals="-5" id="Fact-F6184388D28E89B356C07411E006566E" unitRef="usd">102700000</biib:DeferredTaxLiabilitiesDepreciationAmortizationOther>
	<biib:DeferredTaxLiabilitiesDepreciationAmortizationOther contextRef="FI2016Q4" decimals="-5" id="Fact-E563616A5F9C94A409F77411DFC43452" unitRef="usd">113500000</biib:DeferredTaxLiabilitiesDepreciationAmortizationOther>
	<biib:DiscountRateRecognizedInCompensationExpense contextRef="FD2016Q4YTD" decimals="2" id="Fact-264DF7D99792386D42AA7411DFDB8676" unitRef="number">0.15</biib:DiscountRateRecognizedInCompensationExpense>
	<biib:DueFromUnconsolidatedJointBusiness contextRef="FI2015Q4" decimals="-5" id="Fact-59CA5A7B2838D24D01FD7411DFB8D080" unitRef="usd">314500000</biib:DueFromUnconsolidatedJointBusiness>
	<biib:DueFromUnconsolidatedJointBusiness contextRef="FI2016Q4" decimals="-5" id="Fact-EA126FE50957D2E881557411DFDBBDBD" unitRef="usd">300600000</biib:DueFromUnconsolidatedJointBusiness>
	<biib:EffectiveIncomeTaxRateReconciliationContingentConsideration contextRef="FD2014Q4YTD" decimals="3" id="Fact-17341F6A07ECB074CE1C7411E02642C2" unitRef="number">-0.004</biib:EffectiveIncomeTaxRateReconciliationContingentConsideration>
	<biib:EffectiveIncomeTaxRateReconciliationContingentConsideration contextRef="FD2015Q4YTD" decimals="3" id="Fact-26BCDBA067836DC7EF157411E024D69C" unitRef="number">0.003</biib:EffectiveIncomeTaxRateReconciliationContingentConsideration>
	<biib:EffectiveIncomeTaxRateReconciliationContingentConsideration contextRef="FD2016Q4YTD" decimals="3" id="Fact-4F4A2C283BA3D6B34DAD7411DFF8E4FB" unitRef="number">0.004</biib:EffectiveIncomeTaxRateReconciliationContingentConsideration>
	<biib:EffectiveIncomeTaxRateReconciliationManufacturingDeduction contextRef="FD2014Q4YTD" decimals="3" id="Fact-12F1A5202F6CD3CE979A7411E023C48E" unitRef="number">-0.018</biib:EffectiveIncomeTaxRateReconciliationManufacturingDeduction>
	<biib:EffectiveIncomeTaxRateReconciliationManufacturingDeduction contextRef="FD2015Q4YTD" decimals="3" id="Fact-C22B7DBAF5FFF73AA8497411E012F682" unitRef="number">-0.018</biib:EffectiveIncomeTaxRateReconciliationManufacturingDeduction>
	<biib:EffectiveIncomeTaxRateReconciliationManufacturingDeduction contextRef="FD2016Q4YTD" decimals="3" id="Fact-2A04DB7D6C2AFC8AFAFE7411DFC565EE" unitRef="number">-0.019</biib:EffectiveIncomeTaxRateReconciliationManufacturingDeduction>
	<biib:EmployeeServiceSharebasedCompensationSharesUsedtoSettleAwards contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" decimals="0" id="Fact-16D337DCA99699497983D15FC4C4213D" unitRef="shares">32000</biib:EmployeeServiceSharebasedCompensationSharesUsedtoSettleAwards>
	<biib:EmployeeServiceSharebasedCompensationSharesUsedtoSettleAwards contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember" decimals="0" id="Fact-53510ED05F14E2621E35D160F05BC4AF" unitRef="shares">11000</biib:EmployeeServiceSharebasedCompensationSharesUsedtoSettleAwards>
	<biib:EntityWidePercentageOfRevenueFromMajorDistributors contextRef="FD2014Q4YTD_biib_MajorDistributorAxis_biib_DistributorOneMember" decimals="2" id="Fact-DCBEAC39FD09505295707411DFB84E5C" unitRef="number">0.33</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
	<biib:EntityWidePercentageOfRevenueFromMajorDistributors contextRef="FD2014Q4YTD_biib_MajorDistributorAxis_biib_DistributorTwoMember" decimals="2" id="Fact-DD5504AEB6E3D7ED07A47411DFBA3F6D" unitRef="number">0.27</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
	<biib:EntityWidePercentageOfRevenueFromMajorDistributors contextRef="FD2015Q4YTD_biib_MajorDistributorAxis_biib_DistributorOneMember" decimals="2" id="Fact-4AE4F11EBD323FDC14D57411DFB954F4" unitRef="number">0.34</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
	<biib:EntityWidePercentageOfRevenueFromMajorDistributors contextRef="FD2015Q4YTD_biib_MajorDistributorAxis_biib_DistributorTwoMember" decimals="2" id="Fact-37D4797796B31A64D8CD7411DFB9440C" unitRef="number">0.26</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
	<biib:EntityWidePercentageOfRevenueFromMajorDistributors contextRef="FD2016Q4YTD_biib_MajorDistributorAxis_biib_DistributorOneMember" decimals="2" id="Fact-88ADADF11AA8EF9A055F7411DFB9CC36" unitRef="number">0.35</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
	<biib:EntityWidePercentageOfRevenueFromMajorDistributors contextRef="FD2016Q4YTD_biib_MajorDistributorAxis_biib_DistributorTwoMember" decimals="2" id="Fact-EBA00783FB7513BDA6E47411DFBA69C9" unitRef="number">0.22</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
	<biib:EquityMethodInvestmentOwnershipPercentageMaximum contextRef="D2012Q1Feb_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="INF" id="Fact-AE50DFCED195B8EB35A27411DFE34F86" unitRef="number">0.499</biib:EquityMethodInvestmentOwnershipPercentageMaximum>
	<biib:EquityMethodInvestmentsExpectedProfitShare contextRef="FD2016Q4YTD_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember" decimals="INF" id="Fact-A1EC4241D96107B547C57411DFBD6FC6" unitRef="number">0.5</biib:EquityMethodInvestmentsExpectedProfitShare>
	<biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones contextRef="FI2016Q4_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-FE0EC7740D4D39AC98E3281AFED8D545" unitRef="usd">90000000</biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones>
	<biib:EstimatedTaxLiabilityOnUndistributedEarningsOfForeignSubsidiaries contextRef="FI2016Q4_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="-8" id="Fact-40C6A95B302A21EF14FA7411DFEC9128" unitRef="usd">2300000000</biib:EstimatedTaxLiabilityOnUndistributedEarningsOfForeignSubsidiaries>
	<biib:EstimatedTaxLiabilityOnUndistributedEarningsOfForeignSubsidiaries contextRef="FI2016Q4_us-gaap_RangeAxis_us-gaap_MinimumMember" decimals="-8" id="Fact-56A1011EB121A756CF3C7411DFED0668" unitRef="usd">1800000000</biib:EstimatedTaxLiabilityOnUndistributedEarningsOfForeignSubsidiaries>
	<biib:EstimatedUsefulLivesOfLeaseholdImprovements contextRef="FD2016Q4YTD" id="Fact-DECAE121C7CD7291C6157411E022C3DE">Lesser of the useful life or the term of the respective lease</biib:EstimatedUsefulLivesOfLeaseholdImprovements>
	<biib:ExpectedAdditionalMilestonePaymentsOnSuccessfulAchievementOfRegulatoryAndCommercialSalesMilestones contextRef="FI2016Q4_us-gaap_TypeOfArrangementAxis_biib_AcordaMember" decimals="-5" id="Fact-8C2D27F557E361DDD0C77411DFD913B6" unitRef="usd">375000000</biib:ExpectedAdditionalMilestonePaymentsOnSuccessfulAchievementOfRegulatoryAndCommercialSalesMilestones>
	<biib:ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold contextRef="FI2016Q4_us-gaap_TypeOfArrangementAxis_biib_AcordaMember" decimals="-5" id="Fact-6AD401A7D4029BDCFFD07411DFE4DF9C" unitRef="usd">15000000</biib:ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold>
	<biib:ExpectedLicenseFeeAndRegulatoryMilestonePayments contextRef="FI2016Q4_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-8964995A230F675EA1DBD60A88757B1A" unitRef="usd">130000000</biib:ExpectedLicenseFeeAndRegulatoryMilestonePayments>
	<biib:ExpenseIncurredByCollaboration contextRef="FD2014Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember" decimals="-5" id="Fact-2C073B8A473F7C2D10A727F7D32D7087" unitRef="usd">117800000</biib:ExpenseIncurredByCollaboration>
	<biib:ExpenseIncurredByCollaboration contextRef="FD2014Q4YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" decimals="-5" id="Fact-FB837858B221551B5A497411DFE59E05" unitRef="usd">57500000</biib:ExpenseIncurredByCollaboration>
	<biib:ExpenseIncurredByCollaboration contextRef="FD2015Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember" decimals="-5" id="Fact-022618F27DC19D6487C527F5AED75669" unitRef="usd">113800000</biib:ExpenseIncurredByCollaboration>
	<biib:ExpenseIncurredByCollaboration contextRef="FD2015Q4YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" decimals="-5" id="Fact-22324438F74A88A9A2767411DFD74D18" unitRef="usd">84100000</biib:ExpenseIncurredByCollaboration>
	<biib:ExpenseIncurredByCollaboration contextRef="FD2016Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember" decimals="-5" id="Fact-836A4CFDB8950B92C82527F83CF76682" unitRef="usd">48600000</biib:ExpenseIncurredByCollaboration>
	<biib:ExpenseIncurredByCollaboration contextRef="FD2016Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember" decimals="-5" id="Fact-44A57AF1351FABBF018928307645CAD9" unitRef="usd">50000000</biib:ExpenseIncurredByCollaboration>
	<biib:ExpenseIncurredByCollaboration contextRef="FD2016Q4YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" decimals="-5" id="Fact-F3BA7E1CABF59C9E45BD7411DFDA14C7" unitRef="usd">95100000</biib:ExpenseIncurredByCollaboration>
	<biib:ExpenseReflectedWithinStatementsOfIncome contextRef="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_DMPKMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-F300C840CDBA5DFD5E727411DFD7149C" unitRef="usd">10900000</biib:ExpenseReflectedWithinStatementsOfIncome>
	<biib:ExpenseReflectedWithinStatementsOfIncome contextRef="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-23D971295DB8A864AE737411DFD24A1B" unitRef="usd">27700000</biib:ExpenseReflectedWithinStatementsOfIncome>
	<biib:ExpenseReflectedWithinStatementsOfIncome contextRef="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_ZINBRYTAMember_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember" decimals="-5" id="Fact-3D0B95EAC3930FF01057281739226F64" unitRef="usd">67400000</biib:ExpenseReflectedWithinStatementsOfIncome>
	<biib:ExpenseReflectedWithinStatementsOfIncome contextRef="FD2014Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AcordaMember" decimals="-5" id="Fact-67FE1EC9D1654CEF26777411DFEAE27D" unitRef="usd">29200000</biib:ExpenseReflectedWithinStatementsOfIncome>
	<biib:ExpenseReflectedWithinStatementsOfIncome contextRef="FD2014Q4YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" decimals="-5" id="Fact-D73E56862C33394928537411DFD800E1" unitRef="usd">29100000</biib:ExpenseReflectedWithinStatementsOfIncome>
	<biib:ExpenseReflectedWithinStatementsOfIncome contextRef="FD2014Q4YTD_us-gaap_TypeOfArrangementAxis_biib_SangamoBioSciencesMember" decimals="-5" id="Fact-40C785DFDCA1ABED2B6B27ECF13B8244" unitRef="usd">28900000</biib:ExpenseReflectedWithinStatementsOfIncome>
	<biib:ExpenseReflectedWithinStatementsOfIncome contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_DMPKMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-62220B94016DBF2BD3B67411E017D9B3" unitRef="usd">9000000</biib:ExpenseReflectedWithinStatementsOfIncome>
	<biib:ExpenseReflectedWithinStatementsOfIncome contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-280F4F82B9943BDD4ADB7411DFD1E50E" unitRef="usd">74900000</biib:ExpenseReflectedWithinStatementsOfIncome>
	<biib:ExpenseReflectedWithinStatementsOfIncome contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_ZINBRYTAMember_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember" decimals="-5" id="Fact-B894E9D0AA3602546D872816F9DED7EB" unitRef="usd">60800000</biib:ExpenseReflectedWithinStatementsOfIncome>
	<biib:ExpenseReflectedWithinStatementsOfIncome contextRef="FD2015Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AcordaMember" decimals="-5" id="Fact-1976EB6137CD98C302047411DFC5800B" unitRef="usd">30600000</biib:ExpenseReflectedWithinStatementsOfIncome>
	<biib:ExpenseReflectedWithinStatementsOfIncome contextRef="FD2015Q4YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" decimals="-5" id="Fact-FB86C0120D7EAE8EC1F77411DFD83914" unitRef="usd">40400000</biib:ExpenseReflectedWithinStatementsOfIncome>
	<biib:ExpenseReflectedWithinStatementsOfIncome contextRef="FD2015Q4YTD_us-gaap_TypeOfArrangementAxis_biib_SangamoBioSciencesMember" decimals="-5" id="Fact-9A72949330F1E8C1999E27EF5E1AE6A4" unitRef="usd">13600000</biib:ExpenseReflectedWithinStatementsOfIncome>
	<biib:ExpenseReflectedWithinStatementsOfIncome contextRef="FD2016Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_ProductOrServiceAxis_biib_ZINBRYTAMember_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember" decimals="-5" id="Fact-75A1D24FFB428A7B3B2C28147A624900" unitRef="usd">22000000</biib:ExpenseReflectedWithinStatementsOfIncome>
	<biib:ExpenseReflectedWithinStatementsOfIncome contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_DMPKMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-29536585B7F25CFA21127411DFBD08CF" unitRef="usd">3100000</biib:ExpenseReflectedWithinStatementsOfIncome>
	<biib:ExpenseReflectedWithinStatementsOfIncome contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-151B4B31D8E03C67835F7411DFBC22B0" unitRef="usd">257800000</biib:ExpenseReflectedWithinStatementsOfIncome>
	<biib:ExpenseReflectedWithinStatementsOfIncome contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_ZINBRYTAMember_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember" decimals="-5" id="Fact-73C57355DD9952B1D8E727FC1E0A126F" unitRef="usd">24300000</biib:ExpenseReflectedWithinStatementsOfIncome>
	<biib:ExpenseReflectedWithinStatementsOfIncome contextRef="FD2016Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AcordaMember" decimals="-5" id="Fact-32C7BE2C9E4F82B38AE77411DFBDF59E" unitRef="usd">31500000</biib:ExpenseReflectedWithinStatementsOfIncome>
	<biib:ExpenseReflectedWithinStatementsOfIncome contextRef="FD2016Q4YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" decimals="-5" id="Fact-36AB641E7FA26236F51B7411DFD9E0D4" unitRef="usd">50500000</biib:ExpenseReflectedWithinStatementsOfIncome>
	<biib:ExpenseReflectedWithinStatementsOfIncome contextRef="FD2016Q4YTD_us-gaap_TypeOfArrangementAxis_biib_SangamoBioSciencesMember" decimals="-5" id="Fact-6E02FABAEB801BFBE99527EFF0944CBA" unitRef="usd">13400000</biib:ExpenseReflectedWithinStatementsOfIncome>
	<biib:ForeignSalesRequiredToTriggerMilestone contextRef="FD2016Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AcordaMember" decimals="-5" id="Fact-CE01CED472004A8DDD3D7411DFBE1D4D" unitRef="usd">100000000</biib:ForeignSalesRequiredToTriggerMilestone>
	<biib:FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion contextRef="I2013Q2SD_us-gaap_BusinessAcquisitionAxis_biib_TysabriProductMember" decimals="2" id="Fact-B2B38989651F5CA26ED6D244BCD1125D" unitRef="number">0.25</biib:FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion>
	<biib:FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion contextRef="I2013Q2SD_us-gaap_BusinessAcquisitionAxis_biib_TysabriProductMember" decimals="2" id="Fact-980D3B8AC62410E378A4D2446CE81E88" unitRef="number">0.18</biib:FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion>
	<biib:FutureContingentPaymentThreshold contextRef="I2013Q2SD_us-gaap_BusinessAcquisitionAxis_biib_TysabriProductMember" decimals="-8" id="Fact-7F2E51447F454FDD96C2D2424C50F651" unitRef="usd">2000000000</biib:FutureContingentPaymentThreshold>
	<biib:FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_OcrelizumabMember_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="2" id="Fact-B0186B79E492B3E80E887411DFBD1C9C" unitRef="number">0.24</biib:FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct>
	<biib:FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_OcrelizumabMember_us-gaap_RangeAxis_us-gaap_MinimumMember" decimals="3" id="Fact-3B16EC6360DA3AC207A17411DFBDB8B9" unitRef="number">0.135</biib:FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct>
	<biib:FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_OcrelizumabMember_us-gaap_StatementGeographicalAxis_us-gaap_ForeignCountryMember" decimals="2" id="Fact-307E7F26159AC86D9A327411DFC502D4" unitRef="number">0.03</biib:FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct>
	<biib:Futurepercentageofcopromotionoperatingprofits contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_NewAntiCd20Member_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="2" id="Fact-A796F12240CB1BD0E3417411DFE5C470" unitRef="number">0.38</biib:Futurepercentageofcopromotionoperatingprofits>
	<biib:Futurepercentageofcopromotionoperatingprofits contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_NewAntiCd20Member_us-gaap_RangeAxis_us-gaap_MinimumMember" decimals="2" id="Fact-B3BA4EDB6F0446A784107411DFD04A87" unitRef="number">0.30</biib:Futurepercentageofcopromotionoperatingprofits>
	<biib:Futureresearchanddevelopmentcommitment contextRef="FI2016Q4_us-gaap_TypeOfArrangementAxis_biib_UniversityofPennsylvaniaMember" decimals="-5" id="Fact-C4D0C370CF229BC1BEDE8CFA8DE8A6C1" unitRef="usd">47500000</biib:Futureresearchanddevelopmentcommitment>
	<biib:GainOnSaleOfRights contextRef="FD2014Q4YTD" decimals="-5" id="Fact-F56558F7E5EF9CE8ED907411DFDEDF08" unitRef="usd">16800000</biib:GainOnSaleOfRights>
	<biib:GainOnSaleOfRights contextRef="FD2015Q4YTD" decimals="-5" id="Fact-9D00002CF1C849DDD82D7411DFF6705D" unitRef="usd">0</biib:GainOnSaleOfRights>
	<biib:GainOnSaleOfRights contextRef="FD2016Q4YTD" decimals="-5" id="Fact-1090196F24F9350947E77411DFE32127" unitRef="usd">0</biib:GainOnSaleOfRights>
	<biib:IncreasedCarryingAmountOfSeniorNotes contextRef="D2008Q1SD_us-gaap_LongtermDebtTypeAxis_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" decimals="-5" id="Fact-54BA88C45683B092C9B47411E0095240" unitRef="usd">62800000</biib:IncreasedCarryingAmountOfSeniorNotes>
	<biib:IndefiniteLivedIntangibleAssetsUsefulLife contextRef="FD2016Q4YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" id="Fact-48E39CA6D4DE545BC9337411E02F57A3">Indefinite</biib:IndefiniteLivedIntangibleAssetsUsefulLife>
	<biib:IndefiniteLivedIntangibleAssetsUsefulLife contextRef="FD2016Q4YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember" id="Fact-51639B7762EF228C29F37411E028EB70">Indefinite</biib:IndefiniteLivedIntangibleAssetsUsefulLife>
	<biib:InterestInSubsidiary contextRef="FD2016Q4YTD" decimals="2" id="Fact-1210B4776C0155F51EA97411DFDE723B" unitRef="number">1.00</biib:InterestInSubsidiary>
	<biib:Inventorynetcurrentandnoncurrent contextRef="FI2015Q4" decimals="-5" id="Fact-7B29CEE7D4AC95640DF37411E02636CE" unitRef="usd">933600000</biib:Inventorynetcurrentandnoncurrent>
	<biib:Inventorynetcurrentandnoncurrent contextRef="FI2016Q4" decimals="-5" id="Fact-AB28BAB5FF7B0776480D7411E027B61F" unitRef="usd">1039400000</biib:Inventorynetcurrentandnoncurrent>
	<biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities contextRef="FI2015Q4" decimals="-5" id="Fact-032253CD53CAF0D8E1957411E0259328" unitRef="usd">29200000</biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities>
	<biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities contextRef="FI2016Q4" decimals="-5" id="Fact-FEABA0725202DCFCBC857411E0254A7B" unitRef="usd">47400000</biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities>
	<biib:InvestmentsByThirdPartyInJointVentureAsPerAgreement contextRef="I2012Q1SD2_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="-8" id="Fact-F95B243889D5A48316437411DFBCFD8F" unitRef="KRW">280500000000</biib:InvestmentsByThirdPartyInJointVentureAsPerAgreement>
	<biib:InvestmentsByThirdPartyInJointVentureAsPerAgreement contextRef="I2012Q1SD2_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="-5" id="Fact-271EE25A2E32846EA7C67411DFC51B40" unitRef="usd">250000000</biib:InvestmentsByThirdPartyInJointVentureAsPerAgreement>
	<biib:JointVentureOwnerShipPercentageByThirdParty contextRef="D2012Q1Feb_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="2" id="Fact-C64DCD18983B58A44CE87411DFE3D204" unitRef="number">0.85</biib:JointVentureOwnerShipPercentageByThirdParty>
	<biib:LiabilityForFairValueOfOptionsGrantedUnderAgreement contextRef="FI2014Q1_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" decimals="-5" id="Fact-B3BE0E236BEF41F5E2877411DFD70835" unitRef="usd">17700000</biib:LiabilityForFairValueOfOptionsGrantedUnderAgreement>
	<biib:LicenseFee contextRef="FD2016Q3QTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsInc.Member" decimals="-5" id="Fact-39329AC8C095B4A0F77C8CC595DCB155" unitRef="usd">75000000</biib:LicenseFee>
	<biib:LicenseFee contextRef="FD2016Q4YTD_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-F968E8FDA0C55F16BD3D7411DFD9957A" unitRef="usd">70000000</biib:LicenseFee>
	<biib:LossContingencyAdjustmentRelatedToClaimAmountPercent contextRef="FI2013Q2_us-gaap_StatementGeographicalAxis_country_IT" decimals="INF" id="Fact-7826C52D748C6878970B7411E0158107" unitRef="number">0.5</biib:LossContingencyAdjustmentRelatedToClaimAmountPercent>
	<biib:MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent contextRef="FD2013Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="2" id="Fact-8EC326DA2E33947EB71F7411E0216B91" unitRef="number">1.50</biib:MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent>
	<biib:MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember" decimals="2" id="Fact-248E88F868581A4D1EF17411E0136721" unitRef="number">2.00</biib:MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent>
	<biib:MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="2" id="Fact-51120454CA29325C80C77411E013BA5B" unitRef="number">2.00</biib:MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent>
	<biib:MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" decimals="2" id="Fact-CB861C15C7303D41FF517411DFC7C2DB" unitRef="number">2.00</biib:MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent>
	<biib:MilestonePaymentsMadeDuringPeriod contextRef="FD2014Q2QTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" decimals="-5" id="Fact-E6D79E8FF04EA206CD137411DFBD3457" unitRef="usd">35000000</biib:MilestonePaymentsMadeDuringPeriod>
	<biib:MilestonePaymentsMadeDuringPeriod contextRef="FD2016Q4QTD_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember" decimals="-5" id="Fact-A3EC2A9409FCF348B029D11E64A55111" unitRef="usd">50000000</biib:MilestonePaymentsMadeDuringPeriod>
	<biib:MilestonePaymentsMadeDuringPeriod contextRef="FD2016Q4YTD_us-gaap_BusinessAcquisitionAxis_biib_BiogenIdecInternationalNeuroscienceMember" decimals="-5" id="Fact-C06F88777133B7BCE53BD70818BBE06C" unitRef="usd">3300000</biib:MilestonePaymentsMadeDuringPeriod>
	<biib:MilestonePaymentsMadeDuringPeriod contextRef="FD2016Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember_us-gaap_ProductOrServiceAxis_biib_ALPROLIXMember" decimals="-5" id="Fact-3836DBD8CF4E58B950B3184948D9E52A" unitRef="usd">20000000</biib:MilestonePaymentsMadeDuringPeriod>
	<biib:MinimumQualifyingAgeForEmployeeBenefitPlan contextRef="FD2016Q4YTD_us-gaap_DefinedContributionPlanTypeAxis_us-gaap_UnitedStatesPostretirementBenefitPlansOfUSEntityDefinedBenefitMember" id="Fact-51500D9B8E4FF627B84B7411DFEC27D3">P21Y</biib:MinimumQualifyingAgeForEmployeeBenefitPlan>
	<biib:MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent contextRef="FD2013Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="2" id="Fact-8EB0F1F8FD09BDF5850E7411DFC87769" unitRef="number">0.00</biib:MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent>
	<biib:MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember" decimals="2" id="Fact-6B46C4459CA7A112CBEF7411E02863D5" unitRef="number">0.00</biib:MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent>
	<biib:MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="2" id="Fact-A0AE24501BC96FB1FD407411E0153936" unitRef="number">0.00</biib:MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent>
	<biib:MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" decimals="2" id="Fact-195DE46981DA7ADB1B827411DFC7BEA3" unitRef="number">0.00</biib:MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent>
	<biib:NetMinimumLeasePayments contextRef="FI2016Q4" decimals="-5" id="Fact-46E24363BDB8DEF3D5047411E0192ACD" unitRef="usd">549500000</biib:NetMinimumLeasePayments>
	<biib:NetMinimumLeasePaymentsThereafter contextRef="FI2016Q4" decimals="-5" id="Fact-B6CB1CD8682CEA99794B7411E01976C0" unitRef="usd">276500000</biib:NetMinimumLeasePaymentsThereafter>
	<biib:NetMinimumLeasePaymentsWithInFiveYear contextRef="FI2016Q4" decimals="-5" id="Fact-3CCE55B7AE571982F5597411E0192B79" unitRef="usd">48400000</biib:NetMinimumLeasePaymentsWithInFiveYear>
	<biib:NetMinimumLeasePaymentsWithInFourYear contextRef="FI2016Q4" decimals="-5" id="Fact-156DE925AA4CE7C1DF417411E019EF76" unitRef="usd">50000000</biib:NetMinimumLeasePaymentsWithInFourYear>
	<biib:NetMinimumLeasePaymentsWithInOneYear contextRef="FI2016Q4" decimals="-5" id="Fact-E668B6956625510C9F987411E0197E5B" unitRef="usd">66400000</biib:NetMinimumLeasePaymentsWithInOneYear>
	<biib:NetMinimumLeasePaymentsWithInThreeYear contextRef="FI2016Q4" decimals="-5" id="Fact-C66292265189CB780D577411E0192AC3" unitRef="usd">53600000</biib:NetMinimumLeasePaymentsWithInThreeYear>
	<biib:NetMinimumLeasePaymentsWithInTwoYear contextRef="FI2016Q4" decimals="-5" id="Fact-4863A19502689A5721A67411E019AA87" unitRef="usd">54600000</biib:NetMinimumLeasePaymentsWithInTwoYear>
	<biib:Noncontrollinginterestincreasedecreaseother contextRef="FD2014Q4YTD" decimals="-5" id="Fact-73787B6CFC521DB1E94FD6FD42CFE002" unitRef="usd">6700000</biib:Noncontrollinginterestincreasedecreaseother>
	<biib:Noncontrollinginterestincreasedecreaseother contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" decimals="-5" id="Fact-05581EE07E05FCF99603D6FCF3ED3298" unitRef="usd">6700000</biib:Noncontrollinginterestincreasedecreaseother>
	<biib:Noncontrollinginterestincreasedecreaseother contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" decimals="-5" id="Fact-8AA358547666E6C5BC8ED6FCAF4B7B0E" unitRef="usd">0</biib:Noncontrollinginterestincreasedecreaseother>
	<biib:NumberOfDaysForCalculationOfAverageClosingStockPrice contextRef="FD2013Q4YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember" id="Fact-69EE3FE45DDE7D9798097411DFC87BF0">P60D</biib:NumberOfDaysForCalculationOfAverageClosingStockPrice>
	<biib:NumberOfDaysForCalculationOfAverageClosingStockPrice contextRef="FD2013Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" id="Fact-680D78648C842DA41980188B20C6A6D3">P60D</biib:NumberOfDaysForCalculationOfAverageClosingStockPrice>
	<biib:NumberOfDaysForCalculationOfAverageClosingStockPrice contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember" id="Fact-71664A80F53DFB242A1B7411DFC7ACEE">P30D</biib:NumberOfDaysForCalculationOfAverageClosingStockPrice>
	<biib:NumberOfDaysForCalculationOfAverageClosingStockPrice contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" id="Fact-B0BF4DB70CDBE493DFA27411DFCF0E5E">P30D</biib:NumberOfDaysForCalculationOfAverageClosingStockPrice>
	<biib:NumberOfDaysForCalculationOfAverageClosingStockPrice contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" id="Fact-D8717E7D54B166845C077411DFC7D98F">P30D</biib:NumberOfDaysForCalculationOfAverageClosingStockPrice>
	<biib:NumberOfEqualAnnualIncrements contextRef="FD2013Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="INF" id="Fact-71BD608FD5E8FF2C8D687411DFC8A5CE" unitRef="Increment">4</biib:NumberOfEqualAnnualIncrements>
	<biib:NumberOfEqualAnnualIncrements contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember" decimals="INF" id="Fact-124073517605D67B410D7411DFC7DB04" unitRef="Increment">3</biib:NumberOfEqualAnnualIncrements>
	<biib:NumberOfEqualAnnualIncrements contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="INF" id="Fact-2A8E20115354AB3172207411E0148AC4" unitRef="Increment">3</biib:NumberOfEqualAnnualIncrements>
	<biib:NumberOfEqualAnnualIncrements contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" decimals="INF" id="Fact-22931E747513FA3011D67411DFCF7F04" unitRef="Increment">3</biib:NumberOfEqualAnnualIncrements>
	<biib:NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade contextRef="FD2016Q4YTD" decimals="INF" id="Fact-36F54BFD092663CBAE4B7411DFEEADB3" unitRef="Plan">3</biib:NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade>
	<biib:NumberOfSharesOfCommonStockForIssuance contextRef="FD2016Q4YTD_biib_ShareBasedCompensationPlanAxis_biib_DirectorsPlanMember" decimals="-5" id="Fact-A56DBF9B8FA3BCAD14867411E014E0F5" unitRef="shares">1600000</biib:NumberOfSharesOfCommonStockForIssuance>
	<biib:NumberOfSharesOfCommonStockForIssuance contextRef="FD2016Q4YTD_biib_ShareBasedCompensationPlanAxis_biib_OmnibusPlansMember" decimals="-5" id="Fact-AA913CC25A03D202CE867411E014B40D" unitRef="shares">15000000</biib:NumberOfSharesOfCommonStockForIssuance>
	<biib:OtherIncomeExpenseNet contextRef="FD2014Q4YTD" decimals="-5" id="Fact-563FDBF1819FCDE4DFB07411DFBC4606" unitRef="usd">-8700000</biib:OtherIncomeExpenseNet>
	<biib:OtherIncomeExpenseNet contextRef="FD2015Q4YTD" decimals="-5" id="Fact-3E4CB9D68455D7961E037411E0223FB2" unitRef="usd">-13800000</biib:OtherIncomeExpenseNet>
	<biib:OtherIncomeExpenseNet contextRef="FD2016Q4YTD" decimals="-5" id="Fact-4FD0966FCD38FAEDBCB27411E02592AB" unitRef="usd">-17000000</biib:OtherIncomeExpenseNet>
	<biib:Overnightreverserepurchaseagreementspercentoftotalassets contextRef="FI2015Q4" decimals="INF" id="Fact-914A5DC1E2DF4357BB917411DFB7AE8C" unitRef="number">0.0071</biib:Overnightreverserepurchaseagreementspercentoftotalassets>
	<biib:ParValueOfNotesPayable contextRef="FI2015Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableOtherPayablesMember" decimals="-5" id="Fact-F1CEFA889C663E8E0F5C7411DFC75CEB" unitRef="usd">9000000</biib:ParValueOfNotesPayable>
	<biib:ParValueOfNotesPayable contextRef="FI2015Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableOtherPayablesMember" decimals="-5" id="Fact-56F556CA1C9D974302847411DFF34BC0" unitRef="chf">8900000</biib:ParValueOfNotesPayable>
	<biib:ParValueOfNotesPayable contextRef="FI2016Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableOtherPayablesMember" decimals="-5" id="Fact-ED43F945DDDE0B36B1C27411DFF4E159" unitRef="chf">6200000</biib:ParValueOfNotesPayable>
	<biib:ParValueOfNotesPayable contextRef="FI2016Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableOtherPayablesMember" decimals="-5" id="Fact-E71AAF71BF5FEDC625C17411DFEFF95B" unitRef="usd">6000000</biib:ParValueOfNotesPayable>
	<biib:PaymentTermsOfAccountsReceivable contextRef="FD2016Q4YTD" id="Fact-C66EB27D4DED08C063967411E018393B">30 to 90 days</biib:PaymentTermsOfAccountsReceivable>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear contextRef="FD2014Q4YTD" decimals="-5" id="Fact-4B64179313B6A9A116C27411DFF402EE" unitRef="usd">1237200000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear contextRef="FD2014Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-0C9735C13F5473F3C36B7411DFF5E16E" unitRef="usd">933400000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear contextRef="FD2014Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember" decimals="-5" id="Fact-FD3F92004580D00D21077411DFF50D35" unitRef="usd">299700000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear contextRef="FD2014Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-17801B5B0D7B58BB6A507411DFF44FED" unitRef="usd">4100000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear contextRef="FD2015Q4YTD" decimals="-5" id="Fact-273C0F38AC0BC23F9C017411DFE1E961" unitRef="usd">1666600000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear contextRef="FD2015Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-1A0DE22593548A7208D57411DFDD7BBB" unitRef="usd">1258100000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear contextRef="FD2015Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember" decimals="-5" id="Fact-E3EE1D9751ADEDDB85E67411DFDE15E7" unitRef="usd">405900000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear contextRef="FD2015Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-88E18C6D49BFAAC237057411DFDD995A" unitRef="usd">2600000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear contextRef="FD2016Q4YTD" decimals="-5" id="Fact-8A4F7AFCEF7BDEC29F497411DFE1C95A" unitRef="usd">2099500000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear contextRef="FD2016Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-F4F6835806554E8F1CFF7411DFDFEB8C" unitRef="usd">1576000000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear contextRef="FD2016Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember" decimals="-5" id="Fact-CB79C55C046EA237E8D17411DFE2850B" unitRef="usd">522500000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear contextRef="FD2016Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-2D67CCF3B7F084DBD6C27411DFE1BB87" unitRef="usd">1000000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear contextRef="FD2014Q4YTD" decimals="-5" id="Fact-FA4194E547EDC383CC8D7411DFF5882D" unitRef="usd">341000000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear contextRef="FD2014Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-38BC8C94E2A6686CD4A67411DFF6CFF0" unitRef="usd">261900000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear contextRef="FD2014Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember" decimals="-5" id="Fact-EBDAA5BD50BB97D7F5797411DFF42A7A" unitRef="usd">46000000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear contextRef="FD2014Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-2B9F0729D4F3E27304EA7411DFF4E1C8" unitRef="usd">33100000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear contextRef="FD2015Q4YTD" decimals="-5" id="Fact-EA0D008CB9A0CA43E25D7411DFE2E668" unitRef="usd">351600000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear contextRef="FD2015Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-C7D9BCC09C1B9ACFA82F7411DFDB5ED9" unitRef="usd">296100000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear contextRef="FD2015Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember" decimals="-5" id="Fact-638939112303884698C57411DFE44981" unitRef="usd">44000000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear contextRef="FD2015Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-4C2FE9652BAB7B18CAB27411DFE05C09" unitRef="usd">11500000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear contextRef="FD2016Q4YTD" decimals="-5" id="Fact-B576E66D672A7050B1757411DFE0A947" unitRef="usd">609000000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear contextRef="FD2016Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-3038F1DE6349A63A1DCC7411E0181047" unitRef="usd">536000000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear contextRef="FD2016Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember" decimals="-5" id="Fact-BC371C60A132696FCC277411DFE0A3FC" unitRef="usd">53200000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear contextRef="FD2016Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-3312928529D730DF09D97411E01761A4" unitRef="usd">19800000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
	<biib:PercentageOfCoPromotionOperatingLosses contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_GAZYVAMember" decimals="2" id="Fact-3697B7BA7F340A71488E7411DFE4048E" unitRef="number">0.35</biib:PercentageOfCoPromotionOperatingLosses>
	<biib:PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion contextRef="FI2016Q4_us-gaap_ProductOrServiceAxis_biib_GAZYVAMember" decimals="2" id="Fact-E4687980525D3AC580B77411DFDAA20C" unitRef="number">0.35</biib:PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion>
	<biib:PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion contextRef="FI2016Q4_us-gaap_ProductOrServiceAxis_biib_RituxanMember" decimals="2" id="Fact-D6BDC74B704E14FDB50F7411E017975B" unitRef="number">0.30</biib:PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion>
	<biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillion contextRef="FI2014Q4_us-gaap_ProductOrServiceAxis_biib_RituxanMember" decimals="2" id="Fact-E4A27D8F43B69EFEA4127411DFBBEA03" unitRef="number">0.40</biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillion>
	<biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillion contextRef="FI2015Q4_us-gaap_ProductOrServiceAxis_biib_RituxanMember" decimals="2" id="Fact-F66B121E81050D7C10B67411DFBBC6D8" unitRef="number">0.40</biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillion>
	<biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillion contextRef="FI2016Q4_us-gaap_ProductOrServiceAxis_biib_RituxanMember" decimals="2" id="Fact-38E862B701031D7AD2407411DFC49101" unitRef="number">0.39</biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillion>
	<biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne contextRef="FI2016Q4_us-gaap_ProductOrServiceAxis_biib_RituxanMember" decimals="3" id="Fact-EFE1B38AB3941C18F2977411DFC78F11" unitRef="number">0.400</biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne>
	<biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne contextRef="FI2016Q4_us-gaap_ProductOrServiceAxis_biib_GAZYVAMember" decimals="3" id="Fact-9CD1676516971CB1DFE27411E000C9BE" unitRef="number">0.390</biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne>
	<biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne contextRef="FI2016Q4_us-gaap_ProductOrServiceAxis_biib_RituxanMember" decimals="3" id="Fact-5EB58422FFC41194DD2E7411DFC70D4C" unitRef="number">0.390</biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne>
	<biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree contextRef="FI2016Q4_us-gaap_ProductOrServiceAxis_biib_GAZYVAMember" decimals="3" id="Fact-9D77E2E71EE09C8EAFC77411E0006892" unitRef="number">0.350</biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree>
	<biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree contextRef="FI2016Q4_us-gaap_ProductOrServiceAxis_biib_RituxanMember" decimals="3" id="Fact-E81D87323500BFAF86E97411DFC9E019" unitRef="number">0.350</biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree>
	<biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo contextRef="FI2016Q4_us-gaap_ProductOrServiceAxis_biib_GAZYVAMember" decimals="3" id="Fact-6B154967FBEAC2AC3DE67411E000D1F1" unitRef="number">0.375</biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo>
	<biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo contextRef="FI2016Q4_us-gaap_ProductOrServiceAxis_biib_RituxanMember" decimals="3" id="Fact-30F2EFD350706730490B7411DFC78916" unitRef="number">0.375</biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo>
	<biib:PercentageOfMarketValuePerShareOfCommonStock contextRef="FD2016Q4YTD" decimals="2" id="Fact-B171AC16B13774BD3A557411DFDECE0A" unitRef="usdPerShare">0.85</biib:PercentageOfMarketValuePerShareOfCommonStock>
	<biib:PercentageOfMinimumInvestmentReturn contextRef="FD2014Q4YTD_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_us-gaap_ForeignPensionPlansDefinedBenefitMember_us-gaap_StatementGeographicalAxis_country_CH" decimals="4" id="Fact-CB86ECCB16DDA3EADC697411DFEB84CF" unitRef="number">0.0175</biib:PercentageOfMinimumInvestmentReturn>
	<biib:PercentageOfMinimumInvestmentReturn contextRef="FD2015Q4YTD_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_us-gaap_ForeignPensionPlansDefinedBenefitMember_us-gaap_StatementGeographicalAxis_country_CH" decimals="4" id="Fact-250105CE6902DC2073F57411DFF3CE98" unitRef="number">0.0175</biib:PercentageOfMinimumInvestmentReturn>
	<biib:PercentageOfMinimumInvestmentReturn contextRef="FD2016Q4YTD_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_us-gaap_ForeignPensionPlansDefinedBenefitMember_us-gaap_StatementGeographicalAxis_country_CH" decimals="4" id="Fact-FBDB33D6E7C1F0094BCA7411DFEC2C86" unitRef="number">0.0125</biib:PercentageOfMinimumInvestmentReturn>
	<biib:PercentageParValueOfSeniorNotes contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" decimals="INF" id="Fact-F4BC0652A2B9DAADF4B4883F436C1F8F" unitRef="number">0.99294</biib:PercentageParValueOfSeniorNotes>
	<biib:PercentageParValueOfSeniorNotes contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" decimals="INF" id="Fact-0F3375EF5E227A71F3E38840113574D6" unitRef="number">0.99764</biib:PercentageParValueOfSeniorNotes>
	<biib:PercentageParValueOfSeniorNotes contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" decimals="INF" id="Fact-4C624ECD8B5D3EA9E39488416161ACAD" unitRef="number">0.9992</biib:PercentageParValueOfSeniorNotes>
	<biib:PercentageParValueOfSeniorNotes contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" decimals="INF" id="Fact-5272E8DB2D85933AB5D48840B32B24FB" unitRef="number">0.99792</biib:PercentageParValueOfSeniorNotes>
	<biib:PercentageParValueOfSeniorNotes contextRef="I2008Q1SD_us-gaap_LongtermDebtTypeAxis_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" decimals="INF" id="Fact-EF516FA97BB5FF5BC92E1872182A3DC9" unitRef="number">0.99184</biib:PercentageParValueOfSeniorNotes>
	<biib:PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables contextRef="FI2015Q4_biib_MajorDistributorAxis_biib_DistributorOneMember" decimals="3" id="Fact-54ACC45A90CCC2E8AB397411DFE0F471" unitRef="number">0.354</biib:PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables>
	<biib:PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables contextRef="FI2015Q4_biib_MajorDistributorAxis_biib_DistributorTwoMember" decimals="3" id="Fact-05CFF792721EAAC764257411DFDF66D6" unitRef="number">0.231</biib:PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables>
	<biib:PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables contextRef="FI2016Q4_biib_MajorDistributorAxis_biib_DistributorOneMember" decimals="3" id="Fact-D61290A0F0857533BF3E7411DFDCC7C3" unitRef="number">0.372</biib:PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables>
	<biib:PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables contextRef="FI2016Q4_biib_MajorDistributorAxis_biib_DistributorTwoMember" decimals="3" id="Fact-DA3B58BE09C24F0DEA477411DFDF35FC" unitRef="number">0.192</biib:PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables>
	<biib:PeriodOfCollaborationAgreement contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_OcrelizumabMember" id="Fact-A68593413FB5A0C9E129D6285DEDA1BF">P11Y</biib:PeriodOfCollaborationAgreement>
	<biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-D24C7ECD1522FFCA57D87411DFB8AA63" unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
	<biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-CE21EEDEB6EE69D7DAF37411E02803E8" unitRef="usd">40100000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
	<biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-9D4FD091C77B544E02247411DFB7D7E7" unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
	<biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-9170AA16E369DAA185C27411E02E5D37" unitRef="usd">40100000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
	<biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-468305E755640B86CEB97411E0130381" unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
	<biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-7D05918D8FBB5C48F3DD7411E0020A33" unitRef="usd">34500000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
	<biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-FF8ED5B13A2856411FE77411DFC7FFF8" unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
	<biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-B593FF8147816EE5CB927411DFD7E7B2" unitRef="usd">34500000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
	<biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately contextRef="FI2016Q4" decimals="-8" id="Fact-0E4B62385E38E85A2B657411E00102A3" unitRef="usd">3100000000</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
	<biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately contextRef="FI2016Q4_biib_FutureContingentMilestoneTypesAxis_biib_CommercialMilestonesMember" decimals="-8" id="Fact-D50622BA3266601867F8D24F7F244026" unitRef="usd">1800000000</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
	<biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately contextRef="FI2016Q4_biib_FutureContingentMilestoneTypesAxis_biib_DevelopmentMilestonesMember" decimals="-8" id="Fact-75B920B07DEA8DF5EC25D24F322A70A5" unitRef="usd">500000000</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
	<biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately contextRef="FI2016Q4_biib_FutureContingentMilestoneTypesAxis_biib_RegulatoryMilestonesMember" decimals="-8" id="Fact-9C886D52E04A8855D2FBD2481DAE5F63" unitRef="usd">800000000</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
	<biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately contextRef="FI2016Q4_us-gaap_TypeOfArrangementAxis_biib_UniversityofPennsylvaniaMember" decimals="-8" id="Fact-6A7C7490C48837CE56B98CFADC66CAAC" unitRef="usd">2000000000</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
	<biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately contextRef="I2015Q1ConvergencePharma_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember" decimals="-5" id="Fact-DB4D7B9C825592718CC187582A27629F" unitRef="usd">450000000</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
	<biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately contextRef="I2015Q1ConvergencePharma_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_biib_BIIB074Member" decimals="-5" id="Fact-96D27F29E5F0571E2E668758B906C112" unitRef="usd">350000000</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
	<biib:Preapprovalinventory contextRef="FI2015Q4_us-gaap_ProductOrServiceAxis_biib_BENEPALIMember" decimals="-5" id="Fact-C78F0827342E96DE4EA687AC640A7754" unitRef="usd">18400000</biib:Preapprovalinventory>
	<biib:Preapprovalinventory contextRef="FI2015Q4_us-gaap_ProductOrServiceAxis_biib_FLIXABIMember" decimals="-5" id="Fact-07E660B716601ED3EE1687ACF05618BA" unitRef="usd">24200000</biib:Preapprovalinventory>
	<biib:Preapprovalinventory contextRef="FI2015Q4_us-gaap_ProductOrServiceAxis_biib_ZINBRYTAMember" decimals="-5" id="Fact-3C785AF943EB6C136F317411DFDFCF01" unitRef="usd">24700000</biib:Preapprovalinventory>
	<biib:Premiumonequityinvestment contextRef="FD2015Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AGTCMember" decimals="-5" id="Fact-3AA38C2197D72974FED17411DFBDEB23" unitRef="usd">7500000</biib:Premiumonequityinvestment>
	<biib:PurchasePriceOfCommonStockUnderEspp contextRef="FD2016Q4YTD" id="Fact-226F2B44B47F08255F027411E01887AE">85% of the lower of (i) the market value per share of the common stock on the participant's entry date into an offering period or (ii) the market value per share of the common stock on the purchase date</biib:PurchasePriceOfCommonStockUnderEspp>
	<biib:Purchaseofcommonstock contextRef="FD2015Q3QTD_us-gaap_TypeOfArrangementAxis_biib_AGTCMember" decimals="-5" id="Fact-521FEE272039EB4DFD747411DFD99DEA" unitRef="usd">30000000</biib:Purchaseofcommonstock>
	<biib:RateDuringReimbursementPeriod contextRef="FD2016Q4YTD_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_biib_BiogenRateToSobiOnNetRevenueFromBiogenDistributorTerritoryMember" id="Fact-7868629071C4E2E44AB27411E005126B">Base Rate
less 15%</biib:RateDuringReimbursementPeriod>
	<biib:RateDuringReimbursementPeriod contextRef="FD2016Q4YTD_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_biib_BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember" id="Fact-2338F62463E4890570327411E006B32E">Base Rate
less 5%</biib:RateDuringReimbursementPeriod>
	<biib:RateDuringReimbursementPeriod contextRef="FD2016Q4YTD_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_biib_BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember" id="Fact-760425DD3D1CE703E2EB7411E0064735">Base Rate
less 5%</biib:RateDuringReimbursementPeriod>
	<biib:RateDuringReimbursementPeriod contextRef="FD2016Q4YTD_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_biib_SobiRateToBiogenOnNetSalesInSobiTerritoryMember" id="Fact-B85B0919EFABA59765B67411E006FD7D">Base&#160;Rate
plus 5%</biib:RateDuringReimbursementPeriod>
	<biib:RatioOfNumberOfSharesReservedUnderPlan contextRef="FD2016Q4YTD_biib_ShareBasedCompensationPlanAxis_biib_DirectorsPlanMember" id="Fact-A5145600D832C8AF0BD37411E0213719">1.5-to-1</biib:RatioOfNumberOfSharesReservedUnderPlan>
	<biib:RatioOfNumberOfSharesReservedUnderPlan contextRef="FD2016Q4YTD_biib_ShareBasedCompensationPlanAxis_biib_OmnibusPlansMember" id="Fact-CDB938582BC8DA1410CC7411E0149214">1.5-to-1</biib:RatioOfNumberOfSharesReservedUnderPlan>
	<biib:Reductioninroyaltyrate contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_OcrelizumabMember" decimals="INF" id="Fact-7D5C3017E845A4E197607411DFBDDBCA" unitRef="number">0.5</biib:Reductioninroyaltyrate>
	<biib:ReimbursementCostAchievingPeriod contextRef="FD2016Q4YTD_us-gaap_TypeOfArrangementAxis_biib_SwedishOrphanBiovitrumMember" id="Fact-BD298F7423A9C397428C7411DFC540A7">P6Y</biib:ReimbursementCostAchievingPeriod>
	<biib:ReimbursementLimitStatedInResolution contextRef="FD2011Q4QTD_us-gaap_StatementGeographicalAxis_country_IT" id="Fact-E05FDC839398CEF4288688A53E656C19">P24D</biib:ReimbursementLimitStatedInResolution>
	<biib:ReimbursementLimitStatedInResolution contextRef="FD2014Q2QTD_us-gaap_StatementGeographicalAxis_country_IT" id="Fact-3E7943CC433D025EEF3C189848869A45">P24D</biib:ReimbursementLimitStatedInResolution>
	<biib:ReimbursementUnderAmendedAgreementMethod contextRef="FD2016Q4YTD_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_biib_BiogenRateToSobiOnNetRevenueFromBiogenDistributorTerritoryMember" id="Fact-7FA0B71A6C77A3A300247411E0053AC7">Net
Revenue
Share</biib:ReimbursementUnderAmendedAgreementMethod>
	<biib:ReimbursementUnderAmendedAgreementMethod contextRef="FD2016Q4YTD_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_biib_BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember" id="Fact-E010430BA88A35A1E1767411E0052CFF">Royalty</biib:ReimbursementUnderAmendedAgreementMethod>
	<biib:ReimbursementUnderAmendedAgreementMethod contextRef="FD2016Q4YTD_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_biib_BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember" id="Fact-ABCDBC1C6DC024D06E047411E0069F9A">Royalty</biib:ReimbursementUnderAmendedAgreementMethod>
	<biib:ReimbursementUnderAmendedAgreementMethod contextRef="FD2016Q4YTD_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_biib_SobiRateToBiogenOnNetSalesInSobiTerritoryMember" id="Fact-F093268DB7EFCDC586DA7411E005061F">Royalty</biib:ReimbursementUnderAmendedAgreementMethod>
	<biib:RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement contextRef="FD2016Q4YTD_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_NeurimmuneMember" decimals="-5" id="Fact-A26C78E2ECD5E232F20D7411E0251E25" unitRef="usd">275000000</biib:RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement>
	<biib:ResearchAndDevelopmentCostInSupportOfCollaborationAgreement contextRef="FD2016Q4YTD_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_NeurimmuneMember" decimals="2" id="Fact-77BCB4082303C03205917411E025EFA7" unitRef="number">1.00</biib:ResearchAndDevelopmentCostInSupportOfCollaborationAgreement>
	<biib:Researchanddevelopmentservices contextRef="FD2015Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AGTCMember" decimals="-5" id="Fact-71F0F9DB4AE7591B18537411DFC300BB" unitRef="usd">6500000</biib:Researchanddevelopmentservices>
	<biib:RestructuringandRelatedCostExpectedCashPayments contextRef="FI2015Q4_us-gaap_RestructuringPlanAxis_biib_A2015RestructuringChargesMember" decimals="-5" id="Fact-46E3DF87AD2EDC228627878FB022A263" unitRef="usd">120000000</biib:RestructuringandRelatedCostExpectedCashPayments>
	<biib:Restructuringandrelatedcostexpectedpercentageofpositionseliminated contextRef="FD2015Q4QTD_us-gaap_RestructuringPlanAxis_biib_A2015RestructuringChargesMember" decimals="2" id="Fact-F6D04A659919C5A7CA1B87901887382F" unitRef="number">0.11</biib:Restructuringandrelatedcostexpectedpercentageofpositionseliminated>
	<biib:RevenuesInPercentageFromAntiCD20TherapeuticPrograms contextRef="FD2014Q4YTD" decimals="2" id="Fact-E0193FCE6FB3A407DC097411DFB9E678" unitRef="number">0.12</biib:RevenuesInPercentageFromAntiCD20TherapeuticPrograms>
	<biib:RevenuesInPercentageFromAntiCD20TherapeuticPrograms contextRef="FD2015Q4YTD" decimals="2" id="Fact-16C95EF56362DBA822D17411DFB95FED" unitRef="number">0.12</biib:RevenuesInPercentageFromAntiCD20TherapeuticPrograms>
	<biib:RevenuesInPercentageFromAntiCD20TherapeuticPrograms contextRef="FD2016Q4YTD" decimals="2" id="Fact-4C3A5D829DE1FC742E807411DFB94B78" unitRef="number">0.11</biib:RevenuesInPercentageFromAntiCD20TherapeuticPrograms>
	<biib:RevenuesfromantiCD20therapeuticprograms contextRef="FD2014Q4YTD" decimals="-5" id="Fact-228F2DCE10036B84B7E17411DFDBAFAD" unitRef="usd">1195400000</biib:RevenuesfromantiCD20therapeuticprograms>
	<biib:RevenuesfromantiCD20therapeuticprograms contextRef="FD2014Q4YTD_us-gaap_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember" decimals="-5" id="Fact-42D4B69E55747C5441FC7411E004D3B0" unitRef="usd">70600000</biib:RevenuesfromantiCD20therapeuticprograms>
	<biib:RevenuesfromantiCD20therapeuticprograms contextRef="FD2014Q4YTD_us-gaap_StatementGeographicalAxis_country_DE" decimals="-5" id="Fact-5C73BFAE1A9C6972E64D7411E0080433" unitRef="usd">0</biib:RevenuesfromantiCD20therapeuticprograms>
	<biib:RevenuesfromantiCD20therapeuticprograms contextRef="FD2014Q4YTD_us-gaap_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-CDD4E08B195E797F194D7411E0059D66" unitRef="usd">1117100000</biib:RevenuesfromantiCD20therapeuticprograms>
	<biib:RevenuesfromantiCD20therapeuticprograms contextRef="FD2014Q4YTD_us-gaap_StatementGeographicalAxis_us-gaap_AsiaMember" decimals="-5" id="Fact-5C95FF3F1462553A6F577411E027B5D7" unitRef="usd">0</biib:RevenuesfromantiCD20therapeuticprograms>
	<biib:RevenuesfromantiCD20therapeuticprograms contextRef="FD2014Q4YTD_us-gaap_StatementGeographicalAxis_us-gaap_EuropeMember" decimals="-5" id="Fact-35EBA901C69FBC2031297411E0238647" unitRef="usd">7700000</biib:RevenuesfromantiCD20therapeuticprograms>
	<biib:RevenuesfromantiCD20therapeuticprograms contextRef="FD2014Q4YTD_us-gaap_TypeOfArrangementAxis_biib_RocheGroupGenentechMember" decimals="-5" id="Fact-3E939183FC3A13B604407411DFB7A7C4" unitRef="usd">1195400000</biib:RevenuesfromantiCD20therapeuticprograms>
	<biib:RevenuesfromantiCD20therapeuticprograms contextRef="FD2015Q1YTD" decimals="-5" id="Fact-4F6EE4B7864E295E6FB87411DFCC8E45" unitRef="usd">330600000</biib:RevenuesfromantiCD20therapeuticprograms>
	<biib:RevenuesfromantiCD20therapeuticprograms contextRef="FD2015Q2QTD" decimals="-5" id="Fact-548553C8A0566611865D7411DFCA3F7B" unitRef="usd">337500000</biib:RevenuesfromantiCD20therapeuticprograms>
	<biib:RevenuesfromantiCD20therapeuticprograms contextRef="FD2015Q3QTD" decimals="-5" id="Fact-D04EA6048972411ADF0D7411DFCAA634" unitRef="usd">337200000</biib:RevenuesfromantiCD20therapeuticprograms>
	<biib:RevenuesfromantiCD20therapeuticprograms contextRef="FD2015Q4QTD" decimals="-5" id="Fact-1CB6D2E8FDC01768AA8D7411DFC803C6" unitRef="usd">333900000</biib:RevenuesfromantiCD20therapeuticprograms>
	<biib:RevenuesfromantiCD20therapeuticprograms contextRef="FD2015Q4YTD" decimals="-5" id="Fact-8926A7759C4BB2B9E9687411DFDFB7BA" unitRef="usd">1339200000</biib:RevenuesfromantiCD20therapeuticprograms>
	<biib:RevenuesfromantiCD20therapeuticprograms contextRef="FD2015Q4YTD_us-gaap_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember" decimals="-5" id="Fact-5669F6FF1B20E3A1B03C7411E003D49E" unitRef="usd">65900000</biib:RevenuesfromantiCD20therapeuticprograms>
	<biib:RevenuesfromantiCD20therapeuticprograms contextRef="FD2015Q4YTD_us-gaap_StatementGeographicalAxis_country_DE" decimals="-5" id="Fact-7E867FDB03381A83B6997411DFE45243" unitRef="usd">0</biib:RevenuesfromantiCD20therapeuticprograms>
	<biib:RevenuesfromantiCD20therapeuticprograms contextRef="FD2015Q4YTD_us-gaap_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-F363A3AAF08880F1F94C7411DFD96D85" unitRef="usd">1269800000</biib:RevenuesfromantiCD20therapeuticprograms>
	<biib:RevenuesfromantiCD20therapeuticprograms contextRef="FD2015Q4YTD_us-gaap_StatementGeographicalAxis_us-gaap_AsiaMember" decimals="-5" id="Fact-65B411EE6F2AEF3833D67411E022D969" unitRef="usd">0</biib:RevenuesfromantiCD20therapeuticprograms>
	<biib:RevenuesfromantiCD20therapeuticprograms contextRef="FD2015Q4YTD_us-gaap_StatementGeographicalAxis_us-gaap_EuropeMember" decimals="-5" id="Fact-F487BE0E1D57619825DF7411DFDB1ED5" unitRef="usd">3500000</biib:RevenuesfromantiCD20therapeuticprograms>
	<biib:RevenuesfromantiCD20therapeuticprograms contextRef="FD2015Q4YTD_us-gaap_TypeOfArrangementAxis_biib_RocheGroupGenentechMember" decimals="-5" id="Fact-2DC3FDE945C34483FA437411E012C29C" unitRef="usd">1339200000</biib:RevenuesfromantiCD20therapeuticprograms>
	<biib:RevenuesfromantiCD20therapeuticprograms contextRef="FD2016Q1QTD" decimals="-5" id="Fact-05661D9E7FECB9D1615E7411E006CF94" unitRef="usd">329500000</biib:RevenuesfromantiCD20therapeuticprograms>
	<biib:RevenuesfromantiCD20therapeuticprograms contextRef="FD2016Q2QTD" decimals="-5" id="Fact-F9782FCF0C89DA8954C47411E008321D" unitRef="usd">349200000</biib:RevenuesfromantiCD20therapeuticprograms>
	<biib:RevenuesfromantiCD20therapeuticprograms contextRef="FD2016Q3QTD" decimals="-5" id="Fact-0D327F143B200E8C01387411DFF8AAA5" unitRef="usd">317600000</biib:RevenuesfromantiCD20therapeuticprograms>
	<biib:RevenuesfromantiCD20therapeuticprograms contextRef="FD2016Q4QTD" decimals="-5" id="Fact-D8CC63127E38B8B731E77411DFF8BBE5" unitRef="usd">318200000</biib:RevenuesfromantiCD20therapeuticprograms>
	<biib:RevenuesfromantiCD20therapeuticprograms contextRef="FD2016Q4YTD" decimals="-5" id="Fact-3B912308B8D199F0CC347411DFCD6612" unitRef="usd">1314500000</biib:RevenuesfromantiCD20therapeuticprograms>
	<biib:RevenuesfromantiCD20therapeuticprograms contextRef="FD2016Q4YTD_us-gaap_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember" decimals="-5" id="Fact-D252BB98D6F4CE038C5C7411DFDD0F52" unitRef="usd">63100000</biib:RevenuesfromantiCD20therapeuticprograms>
	<biib:RevenuesfromantiCD20therapeuticprograms contextRef="FD2016Q4YTD_us-gaap_StatementGeographicalAxis_country_DE" decimals="-5" id="Fact-2BFD2D87BF1A5793C7417411DFCF78BD" unitRef="usd">0</biib:RevenuesfromantiCD20therapeuticprograms>
	<biib:RevenuesfromantiCD20therapeuticprograms contextRef="FD2016Q4YTD_us-gaap_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-6C5E057E4067E8E4D8827411E0276ACC" unitRef="usd">1249500000</biib:RevenuesfromantiCD20therapeuticprograms>
	<biib:RevenuesfromantiCD20therapeuticprograms contextRef="FD2016Q4YTD_us-gaap_StatementGeographicalAxis_us-gaap_AsiaMember" decimals="-5" id="Fact-B85CAE26404057F7FE527411E02700B3" unitRef="usd">0</biib:RevenuesfromantiCD20therapeuticprograms>
	<biib:RevenuesfromantiCD20therapeuticprograms contextRef="FD2016Q4YTD_us-gaap_StatementGeographicalAxis_us-gaap_EuropeMember" decimals="-5" id="Fact-6B588F2139659A5DD6FB7411E027C4A1" unitRef="usd">1900000</biib:RevenuesfromantiCD20therapeuticprograms>
	<biib:RevenuesfromantiCD20therapeuticprograms contextRef="FD2016Q4YTD_us-gaap_TypeOfArrangementAxis_biib_RocheGroupGenentechMember" decimals="-5" id="Fact-A6F23E54E13872A3AA677411DFB94EBF" unitRef="usd">1314500000</biib:RevenuesfromantiCD20therapeuticprograms>
	<biib:SalesTriggerGrossSalesThreshold contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_GAZYVAMember" decimals="-5" id="Fact-7FD1CCADEABD8567500B7411DFBD4989" unitRef="usd">500000000</biib:SalesTriggerGrossSalesThreshold>
	<biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses contextRef="FD2014Q4YTD" decimals="-5" id="Fact-145FAF66CC2018AE3F857411E008FC40" unitRef="usd">242400000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
	<biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses contextRef="FD2015Q4YTD" decimals="-5" id="Fact-0A81C5AD864532876C347411E008ED24" unitRef="usd">196300000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
	<biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses contextRef="FD2016Q4YTD" decimals="-5" id="Fact-827BA960EA668360E17D7411E009ADC0" unitRef="usd">189800000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
	<biib:ShareOfCoPromotionProfits contextRef="FD2014Q4YTD_us-gaap_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_biib_RocheGroupGenentechMember" decimals="-5" id="Fact-4AC4C56D934C625704927411DFB7A4F8" unitRef="usd">1117100000</biib:ShareOfCoPromotionProfits>
	<biib:ShareOfCoPromotionProfits contextRef="FD2015Q4YTD_us-gaap_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_biib_RocheGroupGenentechMember" decimals="-5" id="Fact-A73A93214EE2ABBC63E17411DFB86391" unitRef="usd">1269800000</biib:ShareOfCoPromotionProfits>
	<biib:ShareOfCoPromotionProfits contextRef="FD2016Q4YTD_us-gaap_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_biib_RocheGroupGenentechMember" decimals="-5" id="Fact-721C9D3696E70AFBE5267411DFB84526" unitRef="usd">1249500000</biib:ShareOfCoPromotionProfits>
	<biib:ShareOfCoPromotionProfits contextRef="FD2016Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember" decimals="-5" id="Fact-299C8869FFD42223CE9DD621C0A74DC4" unitRef="usd">21900000</biib:ShareOfCoPromotionProfits>
	<biib:StrategicInvestmentPortfolio contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_StrategicInvestmentsMember" decimals="-5" id="Fact-A728622431CF81F23DBA7411E0162446" unitRef="usd">96000000</biib:StrategicInvestmentPortfolio>
	<biib:StrategicInvestmentPortfolio contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_StrategicInvestmentsMember" decimals="-5" id="Fact-C9632818DCBFEBD991A17411DFB8F667" unitRef="usd">99900000</biib:StrategicInvestmentPortfolio>
	<biib:TermOfLease contextRef="FD2015Q3QTD_us-gaap_BusinessAcquisitionAxis_biib_EisaiMember" id="Fact-A937224650D9AC89E1207411E0253F09">P3Y</biib:TermOfLease>
	<biib:Termofcollaborationagreement contextRef="FD2013Q3QTD_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" id="Fact-3A89B9719C4F98A2ACFF7411DFC4C39C">P6Y</biib:Termofcollaborationagreement>
	<biib:ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_GAZYVAMember" decimals="-5" id="Fact-02297AEDB3A2AF91691F7411DFC34B65" unitRef="usd">150000000</biib:ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne>
	<biib:ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_GAZYVAMember" decimals="-5" id="Fact-47B9216E68900D02C8B97411DFBCDEFE" unitRef="usd">150000000</biib:ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne>
	<biib:TimePeriodForPayingRemainingBalanceDue contextRef="FD2016Q4YTD_us-gaap_TypeOfArrangementAxis_biib_SwedishOrphanBiovitrumMember" id="Fact-89AA51579A2B5128206E7411DFBD0A31">P90D</biib:TimePeriodForPayingRemainingBalanceDue>
	<biib:Totaldeferredchargesandprepaidtaxes contextRef="FI2015Q4" decimals="-5" id="Fact-66192A8966B51AEBBB577411DFEC0EF9" unitRef="usd">697900000</biib:Totaldeferredchargesandprepaidtaxes>
	<biib:Totaldeferredchargesandprepaidtaxes contextRef="FI2016Q4" decimals="-5" id="Fact-F9A4156C5806DF0084C27411DFEDD034" unitRef="usd">989800000</biib:Totaldeferredchargesandprepaidtaxes>
	<biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner contextRef="FI2013Q3_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-15870ABF8EB7D3E832B67411DFBBE1A3" unitRef="usd">100000000</biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
	<biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner contextRef="FI2014Q1_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" decimals="-5" id="Fact-67FD76E265376B3159927411DFBC0DA7" unitRef="usd">100000000</biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
	<biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner contextRef="FI2014Q1_us-gaap_TypeOfArrangementAxis_biib_SangamoBioSciencesMember" decimals="-5" id="Fact-5DFB2446B2FBFD02585D27EECC6539A1" unitRef="usd">20000000</biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
	<biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner contextRef="FI2015Q3_us-gaap_TypeOfArrangementAxis_biib_AGTCMember" decimals="-5" id="Fact-F190F31609C4BCEAF34D7411DFC54CA9" unitRef="usd">124000000</biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
	<biib:WeightedAveragePeriodToRecognizeCostOfNonvestedAwards contextRef="FD2016Q4YTD" id="Fact-7C1B630A787733C6A236D1559965E9CD">P1Y11M</biib:WeightedAveragePeriodToRecognizeCostOfNonvestedAwards>
	<biib:WindfallTaxBenefitsFromVestingOfStockAwardsExercisesOfStockOptionsAndEsppParticipation contextRef="FD2014Q4YTD" decimals="-5" id="Fact-CB2BF8F04EABD4EA0AFF7411E015D8AE" unitRef="usd">96400000</biib:WindfallTaxBenefitsFromVestingOfStockAwardsExercisesOfStockOptionsAndEsppParticipation>
	<biib:WindfallTaxBenefitsFromVestingOfStockAwardsExercisesOfStockOptionsAndEsppParticipation contextRef="FD2015Q4YTD" decimals="-5" id="Fact-4D05F8CC5BFA96425F547411E0095E99" unitRef="usd">78200000</biib:WindfallTaxBenefitsFromVestingOfStockAwardsExercisesOfStockOptionsAndEsppParticipation>
	<biib:WindfallTaxBenefitsFromVestingOfStockAwardsExercisesOfStockOptionsAndEsppParticipation contextRef="FD2016Q4YTD" decimals="-5" id="Fact-03450C68027AAB7A9DD77411E014F66F" unitRef="usd">12600000</biib:WindfallTaxBenefitsFromVestingOfStockAwardsExercisesOfStockOptionsAndEsppParticipation>
	<dei:AmendmentFlag contextRef="FD2016Q4YTD" id="Fact-63E78065D9B69FC13E2E7411DFC5A781">false</dei:AmendmentFlag>
	<dei:CurrentFiscalYearEndDate contextRef="FD2016Q4YTD" id="Fact-63D42E7B4470210B55E97411DFC5DE85">--12-31</dei:CurrentFiscalYearEndDate>
	<dei:DocumentFiscalPeriodFocus contextRef="FD2016Q4YTD" id="Fact-63757540FB75B88DA9407411DFF69749">FY</dei:DocumentFiscalPeriodFocus>
	<dei:DocumentFiscalYearFocus contextRef="FD2016Q4YTD" id="Fact-A161431D348B4A74005B7411DFC3C564">2016</dei:DocumentFiscalYearFocus>
	<dei:DocumentPeriodEndDate contextRef="FD2016Q4YTD" id="Fact-66CC0A604B2D4BC665C77411DFFF5D10">2016-12-31</dei:DocumentPeriodEndDate>
	<dei:DocumentType contextRef="FD2016Q4YTD" id="Fact-559C198E6A84476117517411DFC59EAB">10-K</dei:DocumentType>
	<dei:EntityCentralIndexKey contextRef="FD2016Q4YTD" id="Fact-EEAE1D425CCDC1A1CDA87411DFC39417">0000875045</dei:EntityCentralIndexKey>
	<dei:EntityCommonStockSharesOutstanding contextRef="I2016Q4" decimals="0" id="Fact-2C6CFFF7014608A2E2FE7411DFC5BE62" unitRef="shares">215951945</dei:EntityCommonStockSharesOutstanding>
	<dei:EntityCurrentReportingStatus contextRef="FD2016Q4YTD" id="Fact-7283502183ABA907B88C7411DFC30A97">Yes</dei:EntityCurrentReportingStatus>
	<dei:EntityFilerCategory contextRef="FD2016Q4YTD" id="Fact-7A2682D717D2825980E67411DFD15670">Large Accelerated Filer</dei:EntityFilerCategory>
	<dei:EntityPublicFloat contextRef="FI2016Q2" decimals="0" id="Fact-461076E8EBB32BAAF4477411DFC409AC" unitRef="usd">52843669823</dei:EntityPublicFloat>
	<dei:EntityRegistrantName contextRef="FD2016Q4YTD" id="Fact-7380DEA5A78EDF693DBB7411E01A5412">BIOGEN INC.</dei:EntityRegistrantName>
	<dei:EntityVoluntaryFilers contextRef="FD2016Q4YTD" id="Fact-A488533C998A30A63CE37411DFF6FDC0">No</dei:EntityVoluntaryFilers>
	<dei:EntityWellKnownSeasonedIssuer contextRef="FD2016Q4YTD" id="Fact-FEF2DBB9E92B5AB33EAF7411E01A1CBC">Yes</dei:EntityWellKnownSeasonedIssuer>
	<invest:DerivativeNotionalAmount contextRef="FI2015Q4_us-gaap_CurrencyAxis_currency_CAD_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-FE3AA3D6907F4760B95E7411DFB91570" unitRef="usd">76700000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2015Q4_us-gaap_CurrencyAxis_currency_CHF_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-8456B655B4B47CD611317411DFB9CF5A" unitRef="usd">80800000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2015Q4_us-gaap_CurrencyAxis_currency_EUR_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-52C79D0655DA7487C37B7411DFB91CD7" unitRef="usd">945500000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2015Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-8" id="Fact-2E80306310DAE51A58527411DFF68EAB" unitRef="usd">1100000000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2015Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-DFD403D69F4820EB7C7A881EEA16796B" unitRef="usd">675000000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2015Q4_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-C035362FFE0099FAA3737411DFB9F465" unitRef="usd">1103000000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2015Q4_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" decimals="-5" id="Fact-A2B23101B340818DB1C27411DFF65368" unitRef="usd">721000000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2016Q4_us-gaap_CurrencyAxis_currency_CAD_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-9DCE117DEA76B54FB5FB7411DFBA0FEA" unitRef="usd">0</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2016Q4_us-gaap_CurrencyAxis_currency_CHF_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-C131E17E6B485960A7F57411DFB991EA" unitRef="usd">0</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2016Q4_us-gaap_CurrencyAxis_currency_EUR_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-AA4FF73D9CAFA7BC74247411DFB9E69A" unitRef="usd">871700000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2016Q4_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-2DCEB1EC5B720EB2B7417411DFB9C373" unitRef="usd">871700000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2016Q4_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" decimals="-5" id="Fact-7DED9C2299A41B2197117411DFF68DFB" unitRef="usd">902100000</invest:DerivativeNotionalAmount>
	<us-gaap:AccountsPayableCurrent contextRef="FI2015Q4" decimals="-5" id="Fact-751E1E6017041698533D7411E006EF88" unitRef="usd">267400000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccountsPayableCurrent contextRef="FI2016Q4" decimals="-5" id="Fact-EFF04112AD6216496E227411DFF1CD23" unitRef="usd">279800000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccountsReceivableNetCurrent contextRef="FI2015Q4" decimals="-5" id="Fact-9E6B6051D6AD681E4EE27411DFDBE76D" unitRef="usd">1227000000</us-gaap:AccountsReceivableNetCurrent>
	<us-gaap:AccountsReceivableNetCurrent contextRef="FI2016Q4" decimals="-5" id="Fact-DC05EFE0680AB6C7A9807411DFD9377D" unitRef="usd">1441600000</us-gaap:AccountsReceivableNetCurrent>
	<us-gaap:AccruedRoyaltiesCurrent contextRef="FI2015Q4" decimals="-5" id="Fact-3AB3EF127CC29550E13E7411DFD1F2DD" unitRef="usd">167900000</us-gaap:AccruedRoyaltiesCurrent>
	<us-gaap:AccruedRoyaltiesCurrent contextRef="FI2016Q4" decimals="-5" id="Fact-4772170EA9C064E063297411DFD12669" unitRef="usd">195800000</us-gaap:AccruedRoyaltiesCurrent>
	<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="FI2015Q4" decimals="-5" id="Fact-C7862E6DD4298C609D767411DFD70F86" unitRef="usd">1330100000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
	<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="FI2016Q4" decimals="-5" id="Fact-8B1F0EDE1504B0B0BD647411DFD94462" unitRef="usd">1439300000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2013Q4" decimals="-5" id="Fact-58143AF74559F7F97F247411E008B161" unitRef="usd">-27700000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-D284B66149E16F62B0797411E00B3B76" unitRef="usd">-19600000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-2ADEC7382EE498DB1A1D7411E00C9424" unitRef="usd">-23700000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-0AA938FE6216F42C0D497411E0072894" unitRef="usd">5600000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-14A3EC4C81B5F22665FF7411E00CFD3C" unitRef="usd">10000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2014Q4" decimals="-5" id="Fact-45EC92254C4255610BB47411E00C1D6F" unitRef="usd">-59500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-014668742C0D8A7FE1D87411E008EDD0" unitRef="usd">-31600000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-313FAA83A6FBA8B6088B7411E0095A1C" unitRef="usd">71700000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-D46979C9971CF433E4FC7411E0094907" unitRef="usd">-400000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-DFF8AD1C2B5E1A6ADAFD7411E0090904" unitRef="usd">-99200000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2015Q4" decimals="-5" id="Fact-8376273CB34310ADF5DB7411DFE0782D" unitRef="usd">-224000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-8870B66661D2C06D21087411DFCC50FF" unitRef="usd">-37800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-4620A8442B822A0849E27411E00CC3B9" unitRef="usd">10200000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-9942F74BE08B14A32C807411DFCC3D3D" unitRef="usd">-800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-AD7A15FB7E646EF598B97411DFCCCC94" unitRef="usd">-195600000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2016Q4" decimals="-5" id="Fact-0910355E278B1648E17B7411DFD0EC36" unitRef="usd">-319900000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-9DE8065476772D1258E57411E00ADE18" unitRef="usd">-32700000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-54D33D6DD3D6F295E4E37411DFE15B86" unitRef="usd">57800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-AD04E60CF01CAA788B9D7411DFD0D3CD" unitRef="usd">-10800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-41CBAD262DB6D5AE69CA7411E00ACABA" unitRef="usd">-334200000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AdditionalPaidInCapital contextRef="FI2015Q4" decimals="-5" id="Fact-316D876E2893499590CC7411DFE1591C" unitRef="usd">0</us-gaap:AdditionalPaidInCapital>
	<us-gaap:AdditionalPaidInCapital contextRef="FI2016Q4" decimals="-5" id="Fact-3892416FAA8BEBB825537411DFD8A08B" unitRef="usd">0</us-gaap:AdditionalPaidInCapital>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation contextRef="FD2014Q4YTD" decimals="-5" id="Fact-4DE573BC1B15D63284BF7411DFF1FD55" unitRef="usd">93000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-5" id="Fact-F85CC9B43B7EF34731CA7411DFF1DF48" unitRef="usd">93000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation contextRef="FD2015Q4YTD" decimals="-5" id="Fact-DB0394C716F9F7F728877411DFBB1FFA" unitRef="usd">69000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-5" id="Fact-E6915AF02510759D0F297411DFEC9AF6" unitRef="usd">69000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation contextRef="FD2016Q4YTD" decimals="-5" id="Fact-FEE177BE708EDCC9239E7411DFF08EFD" unitRef="usd">600000</us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-5" id="Fact-9E0E122EBDE6C86DDA6B7411DFEE3A04" unitRef="usd">-600000</us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation>
	<us-gaap:AdvertisingExpense contextRef="FD2014Q4YTD" decimals="-5" id="Fact-0F540EED9D3679B44B207411DFDC7322" unitRef="usd">92900000</us-gaap:AdvertisingExpense>
	<us-gaap:AdvertisingExpense contextRef="FD2015Q4YTD" decimals="-5" id="Fact-EF8BA8BC9C4B3C6323857411DFDCF513" unitRef="usd">108600000</us-gaap:AdvertisingExpense>
	<us-gaap:AdvertisingExpense contextRef="FD2016Q4YTD" decimals="-5" id="Fact-58D89E533E8F3DC5D0C57411DFDDC1DE" unitRef="usd">106300000</us-gaap:AdvertisingExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2014Q4YTD" decimals="-5" id="Fact-D015C12FB3C98671C4627411E02204E2" unitRef="usd">165000000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2014Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember" decimals="-5" id="Fact-27EF80C802DB5229889D7411E0197DC1" unitRef="usd">170200000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2014Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-5" id="Fact-37156217B532A6180D6F7411E00783F9" unitRef="usd">102100000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2014Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_RestructuringChargesMember" decimals="-5" id="Fact-4D04E70B1494E69C4FAA7411E0072894" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2014Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-5" id="Fact-0CB404F793400230C7027411E0075806" unitRef="usd">150300000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2014Q4YTD_us-gaap_PlanNameAxis_biib_CashSettledPerformanceSharesMember" decimals="-5" id="Fact-16DBA096F9DFBC88CA397411DFCDC2F0" unitRef="usd">65500000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2014Q4YTD_us-gaap_PlanNameAxis_biib_EmployeeStockPurchasePlanMember" decimals="-5" id="Fact-321B1D924990B75253677411E00834EE" unitRef="usd">12200000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2014Q4YTD_us-gaap_PlanNameAxis_biib_MarketStockUnitsMember" decimals="-5" id="Fact-3AA8A3C7F326F5731BDE7411DFCC08CA" unitRef="usd">37400000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2014Q4YTD_us-gaap_PlanNameAxis_biib_PerformanceUnitsMember" decimals="-5" id="Fact-E8D519079D5973172C0A7411DFC8F0A1" unitRef="usd">21900000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2014Q4YTD_us-gaap_PlanNameAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="-5" id="Fact-A2AED910DC44821FFF8B7411E00A385B" unitRef="usd">115400000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-5" id="Fact-B99F2247833E5C5930757411DFEFB03B" unitRef="usd">165000000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q4YTD" decimals="-5" id="Fact-61A213F65675D3F465947411DFBC7491" unitRef="usd">183200000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember" decimals="-5" id="Fact-6BDD7C16227572E57D417411E00CC04B" unitRef="usd">140500000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-5" id="Fact-9CC381A33A24255F96807411E008526C" unitRef="usd">88600000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_RestructuringChargesMember" decimals="-5" id="Fact-5E0515EE86743DE8BD397411E012153F" unitRef="usd">-8600000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-5" id="Fact-42D9AB024FD91044D2297411DFC8852F" unitRef="usd">127300000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q4YTD_us-gaap_PlanNameAxis_biib_CashSettledPerformanceSharesMember" decimals="-5" id="Fact-67E9B838B2CD23626F807411DFCD3A39" unitRef="usd">22400000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q4YTD_us-gaap_PlanNameAxis_biib_EmployeeStockPurchasePlanMember" decimals="-5" id="Fact-8BD25EE7C2D2E41681A17411DFCA02A0" unitRef="usd">13900000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q4YTD_us-gaap_PlanNameAxis_biib_MarketStockUnitsMember" decimals="-5" id="Fact-D7E34520536B22EC66977411DFCB4243" unitRef="usd">38100000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q4YTD_us-gaap_PlanNameAxis_biib_PerformanceUnitsMember" decimals="-5" id="Fact-4ECF87C1276ED2EFD7CC7411DFCD9601" unitRef="usd">13900000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q4YTD_us-gaap_PlanNameAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="-5" id="Fact-3D5B782E9E7FE8906E697411DFCAB28C" unitRef="usd">119000000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-5" id="Fact-49AAB2ECA51177F9E5427411DFB89C12" unitRef="usd">183200000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q4YTD" decimals="-5" id="Fact-B0B815710631754D38137411DFF0D66A" unitRef="usd">169400000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember" decimals="-5" id="Fact-15FCFB6971EDE63E41137411E008831B" unitRef="usd">135800000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-5" id="Fact-362F70EE0D36CF40562A7411E008AE63" unitRef="usd">84500000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_RestructuringChargesMember" decimals="-5" id="Fact-DC839F07BB6791D2431F7411E0079D0D" unitRef="usd">1800000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-5" id="Fact-1ECD2D34180015B3F6357411E001750A" unitRef="usd">121700000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q4YTD_us-gaap_PlanNameAxis_biib_CashSettledPerformanceSharesMember" decimals="-5" id="Fact-B6A033C507BE17CEEE827411DFCC79B2" unitRef="usd">16300000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q4YTD_us-gaap_PlanNameAxis_biib_EmployeeStockPurchasePlanMember" decimals="-5" id="Fact-555E99E45C965FBC0FB07411DFCE75C7" unitRef="usd">11100000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q4YTD_us-gaap_PlanNameAxis_biib_MarketStockUnitsMember" decimals="-5" id="Fact-22CE3DB895ACE4B0FE627411DFCB8F10" unitRef="usd">38400000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q4YTD_us-gaap_PlanNameAxis_biib_PerformanceUnitsMember" decimals="-5" id="Fact-1BF97A245705B0A80D997411DFCDE84B" unitRef="usd">18600000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q4YTD_us-gaap_PlanNameAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="-5" id="Fact-779BF0F21211C32594537411DFCDEC0A" unitRef="usd">120000000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-5" id="Fact-3D906DB78DED9F55B9E77411DFEEFA6D" unitRef="usd">169400000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="FD2014Q4YTD" decimals="-5" id="Fact-05ABB9B9C390809B2BDC7411E00CBBE6" unitRef="usd">252400000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
	<us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="FD2015Q4YTD" decimals="-5" id="Fact-4BE72D6910D719BD83E67411E0080747" unitRef="usd">207300000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
	<us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="FD2016Q4YTD" decimals="-5" id="Fact-604792AFB1C03A10336B7411E00AF672" unitRef="usd">204400000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
	<us-gaap:AmortizationOfIntangibleAssets contextRef="FD2014Q4YTD" decimals="-5" id="Fact-83C59E5801D276BEF20F7411DFF6F5AD" unitRef="usd">489800000</us-gaap:AmortizationOfIntangibleAssets>
	<us-gaap:AmortizationOfIntangibleAssets contextRef="FD2015Q4YTD" decimals="-5" id="Fact-035964A00768300D29567411DFDF8C2B" unitRef="usd">382600000</us-gaap:AmortizationOfIntangibleAssets>
	<us-gaap:AmortizationOfIntangibleAssets contextRef="FD2016Q4YTD" decimals="-5" id="Fact-7F1D4CE7A7F86B72C8B87411E025C3F5" unitRef="usd">385600000</us-gaap:AmortizationOfIntangibleAssets>
	<us-gaap:Assets contextRef="FI2015Q4" decimals="-5" id="Fact-8A70F3DBE9C6F85A50D87411DFC67D3D" unitRef="usd">19504800000</us-gaap:Assets>
	<us-gaap:Assets contextRef="FI2016Q4" decimals="-5" id="Fact-12C93AEF35F5D84416C37411DFE21345" unitRef="usd">22876800000</us-gaap:Assets>
	<us-gaap:AssetsCurrent contextRef="FI2015Q4" decimals="-5" id="Fact-A212FB4056D773581EA27411DFD15D42" unitRef="usd">6700300000</us-gaap:AssetsCurrent>
	<us-gaap:AssetsCurrent contextRef="FI2016Q4" decimals="-5" id="Fact-2BF5EEDB7A341F1A01857411DFDD103D" unitRef="usd">8732200000</us-gaap:AssetsCurrent>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-824CDA6BAEFAA5ADEB3B7411E028C5D5" unitRef="usd">37500000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-7FD091FC71084C362D937411DFB7D285" unitRef="usd">5857700000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-63D739AA064F0161E83D7411E0289317" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-FB565F83DB0C41FE8EAB7411E0281344" unitRef="usd">5895200000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-7673FA3F2CCACAC4CA187411E002EF73" unitRef="usd">24900000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-C866EED1938706C4EE017411E022B867" unitRef="usd">7533100000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-6DD08981155FB3716DDD7411E00125D2" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-5EF47BB8B7250F48A6B97411E018F7DE" unitRef="usd">7558000000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2015Q4" decimals="-5" id="Fact-32F6817AF4DBD87D76A47411E02EA2CE" unitRef="usd">4891200000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2016Q4" decimals="-5" id="Fact-21F23DEF2B9A8D4500BA7411E02ECC78" unitRef="usd">5406300000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q4" decimals="-5" id="Fact-C0C9259183E316DFF2F57411E02FC2AE" unitRef="usd">4880900000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-ED0674021C803AEED7857411DFB7A6FC" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-F9877DC00270B93071FE7411DFB7D720" unitRef="usd">494100000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-83F8C47D25CF376A54A77411E0297F3C" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-0F15369ECF40BD415B947411E029C278" unitRef="usd">494100000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-F1395A4500C5FEF239DA7411E0286E83" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-C66484E00828EC4F7E007411E02800E5" unitRef="usd">1510900000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-DD32C0871196688EB2F77411E0298745" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-DBED85FB02327DEAB36A7411E02F7454" unitRef="usd">1510900000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-75A6F258CB001B9757D27411E028FEF4" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-97EAE0273497C58603C47411DFB70FC1" unitRef="usd">2875900000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-1FEF7119FEDA111CAE3E7411E0291CC3" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-47935BBCD9FC5B7399DC7411E02E212D" unitRef="usd">2875900000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesCurrentMember" decimals="-5" id="Fact-82C527C0CA06CFFD66B07411DFCF9203" unitRef="usd">394300000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesNonCurrentMember" decimals="-5" id="Fact-465AF2CFE0F0B577777A7411DFCECFDA" unitRef="usd">1116600000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesCurrentMember" decimals="-5" id="Fact-CDC858AA46B98A4E16AB7411DFCF7149" unitRef="usd">1723400000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesNonCurrentMember" decimals="-5" id="Fact-7F517EAAE9067CC7EC787411DFCE520B" unitRef="usd">1152500000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MarketableEquitySecuritiesMember" decimals="-5" id="Fact-0A05229DFBBAFD8904FA7411DFCF3EF4" unitRef="usd">37500000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" decimals="-5" id="Fact-0EA048DDBAFB74C148477411DFCEB174" unitRef="usd">2800000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" decimals="-5" id="Fact-0005FF2C9E93565C3F837411DFCE08F8" unitRef="usd">491300000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4" decimals="-5" id="Fact-7120EA26B70055B10C6B7411E02F4423" unitRef="usd">5398000000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-387DB9179F0BF7CA55CD7411DFF7E93A" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-25FE0696DBEEC9AACDF37411DFD9979C" unitRef="usd">561700000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-1485121F508B0F56ADEA7411E023B026" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-FF2732370BF01F9BDD807411E021F625" unitRef="usd">561700000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-246397EF594D022A604E7411E018FD43" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-471A94A0CC1CB31B4DD47411E0275C74" unitRef="usd">2663800000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-13C9205D469E3FD9F8267411E029BAD0" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-5FAB78FD4FB2068380117411E00272CA" unitRef="usd">2663800000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-64A2F3F28DB4BCE1B4697411E018FC95" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-1775CC889D42487245447411E001F30D" unitRef="usd">2172500000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-2B6CADF9FAAE2DE1E7D97411E01918B3" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-D714892FD7950DB833707411E0213F44" unitRef="usd">2172500000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesCurrentMember" decimals="-5" id="Fact-00B916BFF3072ABA57257411DFCD4D15" unitRef="usd">1408600000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesNonCurrentMember" decimals="-5" id="Fact-DE53CFF83FAE4C244D417411DFCAD940" unitRef="usd">1255200000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesCurrentMember" decimals="-5" id="Fact-59ADA72C6783DC8AB8457411DFC9C94F" unitRef="usd">1156000000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesNonCurrentMember" decimals="-5" id="Fact-3BDFC47D453B9F2879E97411DFCBDB54" unitRef="usd">1016500000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MarketableEquitySecuritiesMember" decimals="-5" id="Fact-4E454BA6A907F488FFB57411DFC96C1E" unitRef="usd">24900000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" decimals="-5" id="Fact-4D71329A21F4CEE895BF7411DFCDA94A" unitRef="usd">4000000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" decimals="-5" id="Fact-AEF275A517D746668F357411DFCC6B08" unitRef="usd">557700000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2015Q4" decimals="-5" id="Fact-F80ED89BC1AFDA25CD527411DFD052C5" unitRef="usd">300000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesCurrentMember" decimals="-5" id="Fact-6C44B0BB0F05A75ECCF37411DFD02FAF" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesNonCurrentMember" decimals="-5" id="Fact-DC5E5DF8D0848798D00B7411DFCE2080" unitRef="usd">100000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesCurrentMember" decimals="-5" id="Fact-077A205586ED96F8028C7411DFD0E947" unitRef="usd">100000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesNonCurrentMember" decimals="-5" id="Fact-FFD9A4BCA386153A4FB47411DFD0994E" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MarketableEquitySecuritiesMember" decimals="-5" id="Fact-6FB7DCAB06EA6A943A2A7411DFCF6DB1" unitRef="usd">9200000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" decimals="-5" id="Fact-8C8F454A6C9F2AD6949A7411DFCF4E89" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" decimals="-5" id="Fact-2F5907661C982A15E1987411DFCE5C2D" unitRef="usd">100000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2016Q4" decimals="-5" id="Fact-49B8FD841FA8C362B6847411DFCB55D8" unitRef="usd">2900000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesCurrentMember" decimals="-5" id="Fact-F7C20C51C1DB063F736C7411DFCDD55A" unitRef="usd">200000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesNonCurrentMember" decimals="-5" id="Fact-E4B484A2F45BE3CA15F07411DFCD2EC4" unitRef="usd">1200000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesCurrentMember" decimals="-5" id="Fact-4EFCB22225A8CD330E4D7411DFCA5428" unitRef="usd">200000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesNonCurrentMember" decimals="-5" id="Fact-462F72AE4A72CF7C781A7411DFCBE75C" unitRef="usd">500000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MarketableEquitySecuritiesMember" decimals="-5" id="Fact-F4425C8B3B3869BC14597411DFCBD7F7" unitRef="usd">700000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" decimals="-5" id="Fact-1E2242AA77F1E7B7AAED7411DFCD0438" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" decimals="-5" id="Fact-A635B7A5E615E2DFF10C7411DFC9AC7C" unitRef="usd">800000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2015Q4" decimals="-5" id="Fact-6AE34AF4219BA3FEB84E7411DFCE94EF" unitRef="usd">10600000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesCurrentMember" decimals="-5" id="Fact-85F525983E9F6B25D77C7411DFCF575E" unitRef="usd">500000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesNonCurrentMember" decimals="-5" id="Fact-4AD7E805EB3CFC63CF117411DFD005A0" unitRef="usd">4100000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesCurrentMember" decimals="-5" id="Fact-11CF1304138BB482F4247411DFCFE322" unitRef="usd">1100000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesNonCurrentMember" decimals="-5" id="Fact-CB08191B8E03A738EAF77411DFCED8C6" unitRef="usd">3100000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MarketableEquitySecuritiesMember" decimals="-5" id="Fact-D770B61E6A4DC7FB3EEB7411DFCFAAFE" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" decimals="-5" id="Fact-8A71657E3DB75AFC56687411DFCF78FC" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" decimals="-5" id="Fact-3F8E38B948EC399211837411DFCF9EE3" unitRef="usd">1800000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2016Q4" decimals="-5" id="Fact-9241EF0DE56FDEFDB2D47411DFCB8B5F" unitRef="usd">11200000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesCurrentMember" decimals="-5" id="Fact-767D8AB1F22001F9D2AF7411DFCEC8B8" unitRef="usd">600000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesNonCurrentMember" decimals="-5" id="Fact-5E4E510F32A9DBE939327411DFCD7C70" unitRef="usd">4700000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesCurrentMember" decimals="-5" id="Fact-56D67500E481D44508F77411DFCD4EF4" unitRef="usd">300000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesNonCurrentMember" decimals="-5" id="Fact-1FB3D8663557993BC3567411DFC8AFE5" unitRef="usd">3400000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MarketableEquitySecuritiesMember" decimals="-5" id="Fact-DB002B9B6259F0D8E0E77411DFC82ABE" unitRef="usd">9300000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" decimals="-5" id="Fact-26A6C88E5BA6E98EE43F7411DFC81DEC" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" decimals="-5" id="Fact-685797E53A2BE7B694F07411DFCAE2AC" unitRef="usd">2200000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2015Q4" decimals="-5" id="Fact-A629528FB026316BC7437411DFCF9EB2" unitRef="usd">4891200000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesCurrentMember" decimals="-5" id="Fact-2B61C406BA8742FCCEF07411DFCFA331" unitRef="usd">394800000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesNonCurrentMember" decimals="-5" id="Fact-6D4B25216E9FD3CD886D7411DFCF274B" unitRef="usd">1120600000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesCurrentMember" decimals="-5" id="Fact-30AA54EBAF83A7A718EA7411DFCE1BE1" unitRef="usd">1724400000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesNonCurrentMember" decimals="-5" id="Fact-76EC46F53D32F10B314D7411DFCF773B" unitRef="usd">1155600000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MarketableEquitySecuritiesMember" decimals="-5" id="Fact-F71657EA1F895FFDF04B7411DFCF6F40" unitRef="usd">28300000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" decimals="-5" id="Fact-122B6FD5EE0084962B8D7411DFD0C2A5" unitRef="usd">2800000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" decimals="-5" id="Fact-E6F35987CC6EF06F83FD7411DFD0E5EB" unitRef="usd">493000000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2016Q4" decimals="-5" id="Fact-E6AD1DE7A1019510B98F7411DFC78826" unitRef="usd">5406300000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesCurrentMember" decimals="-5" id="Fact-D3E47D5D183C6678B1A57411DFC7EAE8" unitRef="usd">1409000000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesNonCurrentMember" decimals="-5" id="Fact-F6431600C51122312B587411DFCA0B44" unitRef="usd">1258700000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesCurrentMember" decimals="-5" id="Fact-E7902E53C9C6B626D97A7411DFC8F311" unitRef="usd">1156100000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesNonCurrentMember" decimals="-5" id="Fact-D743951AFB7850D6D6DB7411DFCB5E04" unitRef="usd">1019400000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MarketableEquitySecuritiesMember" decimals="-5" id="Fact-8F249D924356DB88A7147411DFC9E957" unitRef="usd">33500000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" decimals="-5" id="Fact-DF97C9CB5109D1EFFF107411DFC901DA" unitRef="usd">4000000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" decimals="-5" id="Fact-40DD3AC42B54EA30EA4B7411DFCD1726" unitRef="usd">559100000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesCurrent contextRef="FI2015Q4" decimals="-5" id="Fact-3C12B628144C4FA842E37411E025AE7F" unitRef="usd">2120500000</us-gaap:AvailableForSaleSecuritiesCurrent>
	<us-gaap:AvailableForSaleSecuritiesCurrent contextRef="FI2016Q4" decimals="-5" id="Fact-F7C45B0126893A9535837411E027410E" unitRef="usd">2568600000</us-gaap:AvailableForSaleSecuritiesCurrent>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost contextRef="FI2015Q4" decimals="-5" id="Fact-3ED4658B85568D102EC87411E02E0CAF" unitRef="usd">2583900000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost contextRef="FI2016Q4" decimals="-5" id="Fact-02D28C795A8A6203C7E57411E02E7AA4" unitRef="usd">2559700000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue contextRef="FI2015Q4" decimals="-5" id="Fact-2F7E7B0B65B3D2BDD12D7411E02F09EA" unitRef="usd">2575900000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue contextRef="FI2016Q4" decimals="-5" id="Fact-3EB48E944026928F71D07411E02E1B5A" unitRef="usd">2552600000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost contextRef="FI2015Q4" decimals="-5" id="Fact-EB3B1213448A602704B47411E02F8FD9" unitRef="usd">2122000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost contextRef="FI2016Q4" decimals="-5" id="Fact-D3A0DB7ADCDD918C8F1B7411DFB7B57B" unitRef="usd">2569100000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="FI2015Q4" decimals="-5" id="Fact-B603DCAF1329C7E35DCE7411E02EB571" unitRef="usd">2120500000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="FI2016Q4" decimals="-5" id="Fact-50E5ED661D457BB8CF7F7411E02EF179" unitRef="usd">2568600000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
	<us-gaap:AvailableForSaleSecuritiesGrossRealizedGains contextRef="FD2014Q4YTD" decimals="-5" id="Fact-A2D6CE32ACD8EE4859467411DFFF76CA" unitRef="usd">700000</us-gaap:AvailableForSaleSecuritiesGrossRealizedGains>
	<us-gaap:AvailableForSaleSecuritiesGrossRealizedGains contextRef="FD2015Q4YTD" decimals="-5" id="Fact-BF83471C3BDA733036A57411DFFFC221" unitRef="usd">1500000</us-gaap:AvailableForSaleSecuritiesGrossRealizedGains>
	<us-gaap:AvailableForSaleSecuritiesGrossRealizedGains contextRef="FD2016Q4YTD" decimals="-5" id="Fact-AD36D9F228E4F2A91D1A7411DFFFF5FC" unitRef="usd">3300000</us-gaap:AvailableForSaleSecuritiesGrossRealizedGains>
	<us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses contextRef="FD2014Q4YTD" decimals="-5" id="Fact-CF1ABE0EE22B717FA4FF7411DFFFCCE6" unitRef="usd">500000</us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses>
	<us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses contextRef="FD2015Q4YTD" decimals="-5" id="Fact-AC4791BB25296F2C91BE7411DFFEA8B6" unitRef="usd">3500000</us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses>
	<us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses contextRef="FD2016Q4YTD" decimals="-5" id="Fact-C58A10193B9A87DEF5697411DFFF1600" unitRef="usd">4300000</us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses>
	<us-gaap:AvailableForSaleSecuritiesNoncurrent contextRef="FI2015Q4" decimals="-5" id="Fact-10ED99E5C5AE9055C26F7411DFDACE19" unitRef="usd">2760400000</us-gaap:AvailableForSaleSecuritiesNoncurrent>
	<us-gaap:AvailableForSaleSecuritiesNoncurrent contextRef="FI2016Q4" decimals="-5" id="Fact-2E2C717D9F9E09A200E37411DFF35D3B" unitRef="usd">2829400000</us-gaap:AvailableForSaleSecuritiesNoncurrent>
	<us-gaap:BuildingsAndImprovementsGross contextRef="FI2015Q4" decimals="-5" id="Fact-9470D01D048189A5A1EF7411DFD95639" unitRef="usd">1035600000</us-gaap:BuildingsAndImprovementsGross>
	<us-gaap:BuildingsAndImprovementsGross contextRef="FI2016Q4" decimals="-5" id="Fact-1F0B312C5483B42A1DBE7411DFD84116" unitRef="usd">1107800000</us-gaap:BuildingsAndImprovementsGross>
	<us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired contextRef="I2007Q1SD_us-gaap_BusinessAcquisitionAxis_biib_BiogenIdecHemophiliaMember" decimals="2" id="Fact-6E2874C21C97779474A77411DFD12EAF" unitRef="number">1.00</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
	<us-gaap:BusinessCombinationConsiderationTransferred1 contextRef="D2015Q1_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember" decimals="-5" id="Fact-6ACF1C530451965B7ED3FA812ACEA78B" unitRef="usd">474600000</us-gaap:BusinessCombinationConsiderationTransferred1>
	<us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="D2015Q1_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember" decimals="-5" id="Fact-2F09DB4C4B470FEF34CF8769675F3C9B" unitRef="usd">36000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
	<us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh contextRef="FI2013Q2_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember" decimals="-5" id="Fact-8304C5731059D800F283D24781EA0907" unitRef="usd">15000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
	<us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh contextRef="FI2016Q4" decimals="-8" id="Fact-7D37E3789A0939F992C87411E01AD418" unitRef="usd">1200000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
	<us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh contextRef="FI2016Q4_us-gaap_BusinessAcquisitionAxis_biib_BiogenIdecInternationalNeuroscienceMember" decimals="-5" id="Fact-089EA808DDA3F10A67EF7411DFF3A87E" unitRef="usd">361700000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
	<us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh contextRef="FI2016Q4_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember" decimals="-5" id="Fact-B9FE4C804DFE650D43B618585BE982B5" unitRef="usd">400000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
	<us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh contextRef="FI2016Q4_us-gaap_BusinessAcquisitionAxis_biib_StromedixMember" decimals="-5" id="Fact-8B865A57EC2161C088CC7411DFF38404" unitRef="usd">419000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
	<us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh contextRef="I2015Q1ConvergencePharma_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_biib_BIIB074Member" decimals="-5" id="Fact-812688BB22BA9F8E46C587751508AF89" unitRef="usd">145000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
	<us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh contextRef="I2015Q1ConvergencePharma_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_biib_NeuropathicpainindicationsMember" decimals="-5" id="Fact-82D5C59CCA54385CD41E8764F02A52FC" unitRef="usd">415000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2014Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-F5441D6AE3791484FD407411DFD1E4C2" unitRef="usd">215500000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2015Q4_us-gaap_BusinessAcquisitionAxis_biib_BiogenIdecInternationalNeuroscienceMember" decimals="-5" id="Fact-2C9FAF7646DDDA1DD1437411E02033CF" unitRef="usd">77000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2015Q4_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember" decimals="-5" id="Fact-2675168F02DEA77AFE19184FBF967275" unitRef="usd">297500000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2015Q4_us-gaap_BusinessAcquisitionAxis_biib_StromedixMember" decimals="-5" id="Fact-755A500BFC7CBEBD2B0F7411DFF3139A" unitRef="usd">131500000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-19F888C4B902E3D260E67411E028355A" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-42A936C4C94C2200454F7411E02F72FA" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-F03E5E35BFBDFA89B62A7411DFB7FB19" unitRef="usd">506000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2015Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-EF8311307203E78EE2937411E02F3E99" unitRef="usd">506000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2016Q4_us-gaap_BusinessAcquisitionAxis_biib_BiogenIdecInternationalNeuroscienceMember" decimals="-5" id="Fact-9C5F0954C699F1165CC57411DFF3A39E" unitRef="usd">75500000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2016Q4_us-gaap_BusinessAcquisitionAxis_biib_BiogenIdecInternationalNeuroscienceMember_us-gaap_ContingentConsiderationByTypeAxis_us-gaap_AccruedLiabilitiesMember" decimals="-5" id="Fact-1F2022885E2AF62885D718541DF506DC" unitRef="usd">15500000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2016Q4_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember" decimals="-5" id="Fact-93BE43CBE3E25D0E773D184E3D37D95F" unitRef="usd">258900000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2016Q4_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember_us-gaap_ContingentConsiderationByTypeAxis_us-gaap_AccruedLiabilitiesMember" decimals="-5" id="Fact-42C056DD5C2B972137BC7411E0218B26" unitRef="usd">148400000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2016Q4_us-gaap_BusinessAcquisitionAxis_biib_StromedixMember" decimals="-5" id="Fact-1DF6F9A803FF86AF944D7411DFF49802" unitRef="usd">133200000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2016Q4_us-gaap_BusinessAcquisitionAxis_biib_StromedixMember_us-gaap_ContingentConsiderationByTypeAxis_us-gaap_AccruedLiabilitiesMember" decimals="-5" id="Fact-D0B76632CF30978403C918539F7AF4C3" unitRef="usd">56900000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-55182CE809E0305473047411E0194B7D" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-38724D3DECBE67C3ACD47411DFE3FAF3" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-9F14B151A029F63229C67411E01616EF" unitRef="usd">467600000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2016Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-FB5DDC17A7BA5CF89A2B7411DFEE7D21" unitRef="usd">467600000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent contextRef="FI2015Q4" decimals="-5" id="Fact-13870E5A25499E595C237411DFD100C8" unitRef="usd">504700000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
	<us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent contextRef="FI2016Q4" decimals="-5" id="Fact-DBCD38F39D7EC09099FE7411DFD1A9A3" unitRef="usd">580800000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
	<us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="FI2015Q4_us-gaap_ContingentConsiderationByTypeAxis_us-gaap_OtherNoncurrentLiabilitiesMember" decimals="-5" id="Fact-7BD2B6E0519789E98BAD7411DFF3EA65" unitRef="usd">301300000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
	<us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="FI2016Q4_us-gaap_ContingentConsiderationByTypeAxis_us-gaap_OtherNoncurrentLiabilitiesMember" decimals="-5" id="Fact-1B35B3D5AF6DC342F7437411E0212278" unitRef="usd">246800000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent contextRef="I2015Q1ConvergencePharma_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember" decimals="-5" id="Fact-6CE0DB142B156F5323B5FA81ACC73E95" unitRef="usd">84900000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets contextRef="I2015Q1ConvergencePharma_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember" decimals="-5" id="Fact-DCC89D06E2F046953EA587C2A381ADD7" unitRef="usd">424600000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets contextRef="I2015Q1ConvergencePharma_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_biib_BIIB074Member" decimals="-5" id="Fact-B8F20896E88BBD893C0787681D3A9587" unitRef="usd">200000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets contextRef="I2015Q1ConvergencePharma_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_biib_NeuropathicpainindicationsMember" decimals="-5" id="Fact-49A275F3B6F4D5013EFB8766AF145D49" unitRef="usd">220000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="I2015Q1ConvergencePharma_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember" decimals="-5" id="Fact-BFE90C96DFD928C9B308FA81ACDAD728" unitRef="usd">7600000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet contextRef="I2015Q1ConvergencePharma_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember" decimals="-5" id="Fact-D20EFD0674D55E24E455FA81ACCF08B5" unitRef="usd">474600000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets contextRef="I2015Q1ConvergencePharma_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember" decimals="-5" id="Fact-F3A82669A7D5ACB55BEBFA81ACD644F4" unitRef="usd">1000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets>
	<us-gaap:CapitalLeaseObligations contextRef="FI2015Q3_us-gaap_BusinessAcquisitionAxis_biib_EisaiMember" decimals="-5" id="Fact-EBDDDA6D260E521F2DF488299AEBD562" unitRef="usd">20300000</us-gaap:CapitalLeaseObligations>
	<us-gaap:CapitalLeaseObligations contextRef="FI2015Q4_us-gaap_BusinessAcquisitionAxis_biib_EisaiMember" decimals="-5" id="Fact-0790809DB6638A58527418737C579502" unitRef="usd">19800000</us-gaap:CapitalLeaseObligations>
	<us-gaap:CapitalLeaseObligations contextRef="FI2016Q4_us-gaap_BusinessAcquisitionAxis_biib_EisaiMember" decimals="-5" id="Fact-EED3EEEC293A4F7708217411DFF01AA5" unitRef="usd">18100000</us-gaap:CapitalLeaseObligations>
	<us-gaap:CapitalLeasesFutureMinimumPaymentsDue contextRef="FI2016Q4" decimals="-5" id="Fact-6604EF08859EC2B577E67411E0266A43" unitRef="usd">18700000</us-gaap:CapitalLeasesFutureMinimumPaymentsDue>
	<us-gaap:CapitalLeasesFutureMinimumPaymentsDueCurrent contextRef="FI2016Q4" decimals="-5" id="Fact-F9259D609E651D7C94077411E02684B4" unitRef="usd">2000000</us-gaap:CapitalLeasesFutureMinimumPaymentsDueCurrent>
	<us-gaap:CapitalLeasesFutureMinimumPaymentsDueInTwoYears contextRef="FI2016Q4" decimals="-5" id="Fact-C576A2315365AEE8E98D7411E0265965" unitRef="usd">16700000</us-gaap:CapitalLeasesFutureMinimumPaymentsDueInTwoYears>
	<us-gaap:CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments contextRef="FI2016Q4" decimals="-5" id="Fact-C699B192B57DDC445E657411E02602CA" unitRef="usd">600000</us-gaap:CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments>
	<us-gaap:CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments contextRef="FI2016Q4" decimals="-5" id="Fact-AF0EED598FBB2705FD937411E02603B2" unitRef="usd">18100000</us-gaap:CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2013Q4" decimals="-5" id="Fact-67A3743BB9CACA469B117411E017F25E" unitRef="usd">602600000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2014Q4" decimals="-5" id="Fact-8C3488E6E751B1C0D3CF7411E01886F1" unitRef="usd">1204900000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2015Q4" decimals="-5" id="Fact-1EF8329569AC1168D0277411E0237EC1" unitRef="usd">1308000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2016Q4" decimals="-5" id="Fact-471C3798F7542C5D30447411DFD9870E" unitRef="usd">2326500000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-D820417DA6E84CEC62417411E028FF8F" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-AB73B2DC2DBE21679A8B7411E028B8B1" unitRef="usd">909500000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-35C4D3C58766C19EBA8D7411E0282ADB" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-B6BB9EE5B5494A52B1767411E02959F2" unitRef="usd">909500000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-EB3DAA45FD45F1C4F93B7411E0243F03" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-30BE38C41C71B7B910837411E006E3E6" unitRef="usd">2039600000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-016F8CB44ADBB6C845517411DFF76BB3" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-063DE7198AB1F24F9FAC7411E021B23B" unitRef="usd">2039600000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="FD2014Q4YTD" decimals="-5" id="Fact-0945D99EEDD01DAE631C7411E0168BDE" unitRef="usd">643200000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="FD2015Q4YTD" decimals="-5" id="Fact-4FABD79EE00FACB59F067411E016D3AF" unitRef="usd">148900000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="FD2016Q4YTD" decimals="-5" id="Fact-BDFC1A38845632B9F0427411E019F329" unitRef="usd">1049800000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2015Q4" decimals="-5" id="Fact-9B1B162E20DD9AD1D1367411DFE1E717" unitRef="usd">909500000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2015Q4_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember" decimals="-5" id="Fact-5642A7AD0602A3A280B77411E024DBE4" unitRef="usd">21900000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2015Q4_us-gaap_InvestmentTypeAxis_us-gaap_DebtSecuritiesMember" decimals="-5" id="Fact-179DAF4CB59A3CC968187411E006DE73" unitRef="usd">79100000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2015Q4_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember" decimals="-5" id="Fact-778FE11F0FD09B700DC47411DFE322FA" unitRef="usd">673800000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2015Q4_us-gaap_InvestmentTypeAxis_us-gaap_RepurchaseAgreementsMember" decimals="-5" id="Fact-CA267610FD35521BA61C7411E00B3F40" unitRef="usd">134700000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2016Q4" decimals="-5" id="Fact-F0FBDD9581FF0F4792017411E0264FDE" unitRef="usd">2039600000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2016Q4_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember" decimals="-5" id="Fact-3A4239C0E15656BB3ED97411DFFE7825" unitRef="usd">31000000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2016Q4_us-gaap_InvestmentTypeAxis_us-gaap_DebtSecuritiesMember" decimals="-5" id="Fact-856E131E9DE34FB12B877411DFFF76B1" unitRef="usd">1266900000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2016Q4_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember" decimals="-5" id="Fact-97C8C7231125B73B29837411DFC59A1D" unitRef="usd">741700000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2016Q4_us-gaap_InvestmentTypeAxis_us-gaap_RepurchaseAgreementsMember" decimals="-5" id="Fact-BFB4019FE6AB11A2DA6D7411DFBDDEE7" unitRef="usd">0</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CommitmentsAndContingencies contextRef="FI2015Q4" id="Fact-A73AB8C67CCA6D2982BA7411DFE2740F" unitRef="usd" xsi:nil="true" />
	<us-gaap:CommitmentsAndContingencies contextRef="FI2016Q4" id="Fact-792882A445DB556BC7EF7411DFBA6E57" unitRef="usd" xsi:nil="true" />
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2015Q4" decimals="4" id="Fact-BAF7F175D5AB75E3A9167411DFFF18D0" unitRef="usdPerShare">0.0005</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2016Q4" decimals="4" id="Fact-D802318B523E5D7A8C897411E001DCD1" unitRef="usdPerShare">0.0005</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockSharesAuthorized contextRef="FI2015Q4" decimals="-5" id="Fact-A6091ABAE2C68036695B7411E00B572F" unitRef="shares">1000000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesAuthorized contextRef="FI2016Q4" decimals="-5" id="Fact-44436121BA68A861AF6E7411E00A72B6" unitRef="shares">1000000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesIssued contextRef="FI2015Q4" decimals="-5" id="Fact-02D300337B1325B875C27411E00BB702" unitRef="shares">241200000</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesIssued contextRef="FI2016Q4" decimals="-5" id="Fact-43B770A5E9B2895217317411DFC8C8E4" unitRef="shares">238500000</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2015Q4" decimals="-5" id="Fact-B937D2A7327B002040E57411E008FDD5" unitRef="shares">218600000</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2016Q4" decimals="-5" id="Fact-9EB5612AADD783CC79C27411DFC8928D" unitRef="shares">215900000</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockValue contextRef="FI2015Q4" decimals="-5" id="Fact-E9DA849FB8E1E68D96447411DFF06FB7" unitRef="usd">100000</us-gaap:CommonStockValue>
	<us-gaap:CommonStockValue contextRef="FI2016Q4" decimals="-5" id="Fact-9244951801F4C482611D7411E0271E69" unitRef="usd">100000</us-gaap:CommonStockValue>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2014Q4YTD" decimals="-5" id="Fact-2D64E503F46BEF4BA4F27411E0251ED7" unitRef="usd">2903000000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2015Q4YTD" decimals="-5" id="Fact-17A89A43E0BBB62C0EA87411E020D7D6" unitRef="usd">3382500000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2016Q4YTD" decimals="-5" id="Fact-5D83A19B54D062F74D657411E00B1C15" unitRef="usd">3606900000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="FD2014Q4YTD" decimals="-5" id="Fact-AD3DD37F073C0112B9BB7411E02787A3" unitRef="usd">-6800000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
	<us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="FD2015Q4YTD" decimals="-5" id="Fact-CAEED51DECBB5478DAD37411E0269F55" unitRef="usd">-46200000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
	<us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="FD2016Q4YTD" decimals="-5" id="Fact-D343EA3C62E1CE9041DE7411DFC57ACC" unitRef="usd">7100000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
	<us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="FD2014Q4YTD" decimals="-5" id="Fact-B4C0015DF54645D3B8EC7411E0254E5A" unitRef="usd">2909800000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="FD2015Q4YTD" decimals="-5" id="Fact-D825C1470ABACE331F0B7411E020CF02" unitRef="usd">3428700000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="FD2016Q4YTD" decimals="-5" id="Fact-6B1FE28B3CECC29ECEA17411E02150DF" unitRef="usd">3599800000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:ConstructionInProgressGross contextRef="FI2015Q4" decimals="-5" id="Fact-EFCFC67736A84814422F7411DFD75E5E" unitRef="usd">441200000</us-gaap:ConstructionInProgressGross>
	<us-gaap:ConstructionInProgressGross contextRef="FI2015Q4_biib_FacilityLocationAxis_biib_SolothurnMember" decimals="-5" id="Fact-C96625CC55C249200A0C186E003F58EA" unitRef="usd">99000000</us-gaap:ConstructionInProgressGross>
	<us-gaap:ConstructionInProgressGross contextRef="FI2016Q4" decimals="-5" id="Fact-A80660CCAB0799C58EB07411DFD9E406" unitRef="usd">658600000</us-gaap:ConstructionInProgressGross>
	<us-gaap:ConstructionInProgressGross contextRef="FI2016Q4_biib_FacilityLocationAxis_biib_SolothurnMember" decimals="-5" id="Fact-65A9D06FFAC970261B98186DB98F9BB5" unitRef="usd">481500000</us-gaap:ConstructionInProgressGross>
	<us-gaap:ConstructionPayableCurrentAndNoncurrent contextRef="FI2015Q4" decimals="-5" id="Fact-6E120CF45897E3C44548D16BD106BA93" unitRef="usd">87900000</us-gaap:ConstructionPayableCurrentAndNoncurrent>
	<us-gaap:ConstructionPayableCurrentAndNoncurrent contextRef="FI2016Q4" decimals="-5" id="Fact-1E2FE5FCFF7ECCAA8337D16809D6F88B" unitRef="usd">134000000</us-gaap:ConstructionPayableCurrentAndNoncurrent>
	<us-gaap:ConstructionPayableCurrentAndNoncurrent contextRef="FI2016Q4_biib_FacilityLocationAxis_biib_SolothurnMember" decimals="-5" id="Fact-F85587AE2757EF1C5166D24D0BD1B672" unitRef="usd">100000000</us-gaap:ConstructionPayableCurrentAndNoncurrent>
	<us-gaap:CostOfGoodsSold contextRef="FD2014Q4YTD" decimals="-5" id="Fact-4D1E7DF7A77000EC4C4B7411DFC4CC5C" unitRef="usd">1171000000</us-gaap:CostOfGoodsSold>
	<us-gaap:CostOfGoodsSold contextRef="FD2015Q4YTD" decimals="-5" id="Fact-ACCDBDCCAB3048CF86017411DFDC3474" unitRef="usd">1240400000</us-gaap:CostOfGoodsSold>
	<us-gaap:CostOfGoodsSold contextRef="FD2016Q4YTD" decimals="-5" id="Fact-628D2531F6E97545E3F67411DFFF1609" unitRef="usd">1478700000</us-gaap:CostOfGoodsSold>
	<us-gaap:CostsAndExpenses contextRef="FD2014Q4YTD" decimals="-5" id="Fact-0A6A424E8B6148B37D3E7411E001CC17" unitRef="usd">5747700000</us-gaap:CostsAndExpenses>
	<us-gaap:CostsAndExpenses contextRef="FD2015Q4YTD" decimals="-5" id="Fact-B694B86D556AC0183DF97411E0237A27" unitRef="usd">5872800000</us-gaap:CostsAndExpenses>
	<us-gaap:CostsAndExpenses contextRef="FD2016Q4YTD" decimals="-5" id="Fact-EFC588D7B5A6EFBC56197411E000FD64" unitRef="usd">6298400000</us-gaap:CostsAndExpenses>
	<us-gaap:CurrentFederalTaxExpenseBenefit contextRef="FD2014Q4YTD" decimals="-5" id="Fact-97E8CF321750FC5B87FA7411E01526DB" unitRef="usd">1159500000</us-gaap:CurrentFederalTaxExpenseBenefit>
	<us-gaap:CurrentFederalTaxExpenseBenefit contextRef="FD2015Q4YTD" decimals="-5" id="Fact-A6BBB1F0829E546581DD7411E01692DA" unitRef="usd">1214100000</us-gaap:CurrentFederalTaxExpenseBenefit>
	<us-gaap:CurrentFederalTaxExpenseBenefit contextRef="FD2016Q4YTD" decimals="-5" id="Fact-29187139ECB1365B2CE57411E0160C14" unitRef="usd">1304300000</us-gaap:CurrentFederalTaxExpenseBenefit>
	<us-gaap:CurrentForeignTaxExpenseBenefit contextRef="FD2014Q4YTD" decimals="-5" id="Fact-4DA6DEB5E75252C0977E7411E016B959" unitRef="usd">73400000</us-gaap:CurrentForeignTaxExpenseBenefit>
	<us-gaap:CurrentForeignTaxExpenseBenefit contextRef="FD2015Q4YTD" decimals="-5" id="Fact-E7D15920F8D5426A98797411DFFFDD88" unitRef="usd">54500000</us-gaap:CurrentForeignTaxExpenseBenefit>
	<us-gaap:CurrentForeignTaxExpenseBenefit contextRef="FD2016Q4YTD" decimals="-5" id="Fact-BD7785617741600D3F4A7411E016E23D" unitRef="usd">52900000</us-gaap:CurrentForeignTaxExpenseBenefit>
	<us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="FD2014Q4YTD" decimals="-5" id="Fact-DC2ADB532FC5B5A697CF7411E029C0BC" unitRef="usd">1298100000</us-gaap:CurrentIncomeTaxExpenseBenefit>
	<us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="FD2015Q4YTD" decimals="-5" id="Fact-2ED3E21AA9005F390E007411E02451BD" unitRef="usd">1307200000</us-gaap:CurrentIncomeTaxExpenseBenefit>
	<us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="FD2016Q4YTD" decimals="-5" id="Fact-68BCEE9D09EEE1593C877411E002DD23" unitRef="usd">1412300000</us-gaap:CurrentIncomeTaxExpenseBenefit>
	<us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="FD2014Q4YTD" decimals="-5" id="Fact-C7DFD624A9AB0BED718C7411E01515E7" unitRef="usd">65200000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
	<us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="FD2015Q4YTD" decimals="-5" id="Fact-04EF4872095265A4139D7411DFFFB58A" unitRef="usd">38600000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
	<us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="FD2016Q4YTD" decimals="-5" id="Fact-0CE5ED336275423AB7EB7411E022E4E8" unitRef="usd">55100000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
	<us-gaap:DebtCurrent contextRef="FI2015Q4" decimals="-5" id="Fact-A86299482A02A83EF73F7411DFF26A5C" unitRef="usd">4800000</us-gaap:DebtCurrent>
	<us-gaap:DebtCurrent contextRef="FI2016Q4" decimals="-5" id="Fact-376104D78E8629C7CBDD7411DFD98581" unitRef="usd">4700000</us-gaap:DebtCurrent>
	<us-gaap:DebtInstrumentFaceAmount contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" decimals="-7" id="Fact-1C37FD4CBAF0CCE04C45883D6AAECDE4" unitRef="usd">1750000000</us-gaap:DebtInstrumentFaceAmount>
	<us-gaap:DebtInstrumentFaceAmount contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" decimals="-7" id="Fact-3149D9D7B137E6D31A208840EBB9C25F" unitRef="usd">1750000000</us-gaap:DebtInstrumentFaceAmount>
	<us-gaap:DebtInstrumentFaceAmount contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" decimals="-8" id="Fact-BADC204F34698B0083D1883BE2A9B05C" unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
	<us-gaap:DebtInstrumentFaceAmount contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" decimals="-8" id="Fact-50B5969070EF6276A55D883E750E34F6" unitRef="usd">1500000000</us-gaap:DebtInstrumentFaceAmount>
	<us-gaap:DebtInstrumentFaceAmount contextRef="I2008Q1SD_us-gaap_LongtermDebtTypeAxis_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" decimals="-5" id="Fact-966F8FD85C2B26FBFDB4186FACD54AB2" unitRef="usd">550000000</us-gaap:DebtInstrumentFaceAmount>
	<us-gaap:DebtInstrumentFairValue contextRef="FI2015Q4" decimals="-5" id="Fact-4DA0C75DC67FB0753D8D7411E0246C02" unitRef="usd">6645900000</us-gaap:DebtInstrumentFairValue>
	<us-gaap:DebtInstrumentFairValue contextRef="FI2016Q4" decimals="-5" id="Fact-F080E4C3C1BF397BB7837411E0249859" unitRef="usd">6808400000</us-gaap:DebtInstrumentFairValue>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" decimals="4" id="Fact-9AFC676A9B1F1F587B408820DF6067F4" unitRef="number">0.0520</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" decimals="4" id="Fact-6866B68FA8AEDD07565288228553B2EC" unitRef="number">0.0405</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" decimals="INF" id="Fact-BEAB0DBEAB4831F3A611883D27ABBDFF" unitRef="number">0.03625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" decimals="4" id="Fact-785222456463A8D886C2881FDECA42E2" unitRef="number">0.0290</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" decimals="INF" id="Fact-E748DEF94019A8AAE5137411E027FC50" unitRef="number">0.052</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" decimals="INF" id="Fact-825569E2E686E035D1777411E0277834" unitRef="number">0.0405</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" decimals="5" id="Fact-7B4CB14D65D83DBA5B7A7411DFEE6B9E" unitRef="number">0.06875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" decimals="INF" id="Fact-D802B79408B2D4BB8F087411E0132E85" unitRef="number">0.03625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" decimals="INF" id="Fact-AA358EB9728015AACC5B7411E013732A" unitRef="number">0.029</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="I2008Q1SD_us-gaap_DebtInstrumentAxis_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" decimals="INF" id="Fact-8750D713D444BCD9B213186FD3C3AF3F" unitRef="number">0.06875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentMaturityDateDescription contextRef="FD2016Q4YTD" id="Fact-3A35B114A0E369AA03AF7411E0121485">less than 90&#160;days</us-gaap:DebtInstrumentMaturityDateDescription>
	<us-gaap:DebtInstrumentRedemptionPricePercentage contextRef="FD2016Q4YTD" decimals="INF" id="Fact-E657B74564E5B8A3E79018774B67B925" unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
	<us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent contextRef="FI2015Q4_us-gaap_DefinedContributionPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" decimals="-5" id="Fact-59D04201D5D3FAFFB8717411DFE5C160" unitRef="usd">126900000</us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent>
	<us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent contextRef="FI2016Q4_us-gaap_DefinedContributionPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" decimals="-5" id="Fact-CDE1E4839B915C2EBA4B7411DFE5C4B0" unitRef="usd">128500000</us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent>
	<us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="FD2014Q4YTD" decimals="-5" id="Fact-980DA7E6F530AC80987B7411E028F885" unitRef="usd">-280900000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
	<us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="FD2015Q4YTD" decimals="-5" id="Fact-2B6D270D364876C5675A7411DFBC1576" unitRef="usd">-129600000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
	<us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="FD2016Q4YTD" decimals="-5" id="Fact-F9E9C9EC707A7E8A4E897411E0212846" unitRef="usd">-125600000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
	<us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="FD2014Q4YTD" decimals="-5" id="Fact-E265B63CDB1251FC504C7411E02725E4" unitRef="usd">-6300000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
	<us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="FD2015Q4YTD" decimals="-5" id="Fact-41F03C5E96DE04D17CC67411E004B454" unitRef="usd">-14100000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
	<us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="FD2016Q4YTD" decimals="-5" id="Fact-AEA6D85330CB4CC64C1E7411E01352DC" unitRef="usd">-45600000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
	<us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="FD2014Q4YTD" decimals="-5" id="Fact-9DCDD425DEAE7EF17A1A7411E01AE905" unitRef="usd">-308200000</us-gaap:DeferredIncomeTaxExpenseBenefit>
	<us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="FD2015Q4YTD" decimals="-5" id="Fact-60F1C6FC76CEB45DD5737411E0157B08" unitRef="usd">-145600000</us-gaap:DeferredIncomeTaxExpenseBenefit>
	<us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="FD2016Q4YTD" decimals="-5" id="Fact-8AEF5FBE2289E66A2E1A7411E01A37C0" unitRef="usd">-175000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
	<us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="FD2014Q4YTD" decimals="-5" id="Fact-34321C0EF6A82FAC58007411E01B8A00" unitRef="usd">-21000000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
	<us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="FD2015Q4YTD" decimals="-5" id="Fact-41363C09C6429898EC8E7411E0284BDC" unitRef="usd">-1900000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
	<us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="FD2016Q4YTD" decimals="-5" id="Fact-AE30D1FCC9F1105F0F997411DFC5810E" unitRef="usd">-3800000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
	<us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="FI2015Q4" decimals="-5" id="Fact-5ED5D5EE83C5380E62427411E0248D56" unitRef="usd">328300000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
	<us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="FI2016Q4" decimals="-5" id="Fact-C70C436557CB7D8761357411DFBC856C" unitRef="usd">459800000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
	<us-gaap:DeferredTaxAssetsInventory contextRef="FI2015Q4" decimals="-5" id="Fact-54F8CCFE21A6183082277411E01AB6B1" unitRef="usd">243900000</us-gaap:DeferredTaxAssetsInventory>
	<us-gaap:DeferredTaxAssetsInventory contextRef="FI2016Q4" decimals="-5" id="Fact-5251CDF642A6FEFEF34A7411DFBC0F54" unitRef="usd">250600000</us-gaap:DeferredTaxAssetsInventory>
	<us-gaap:DeferredTaxAssetsNet contextRef="FI2015Q4" decimals="-5" id="Fact-F0ACE7156EF588EB8FB67411E0064825" unitRef="usd">871700000</us-gaap:DeferredTaxAssetsNet>
	<us-gaap:DeferredTaxAssetsNet contextRef="FI2016Q4" decimals="-5" id="Fact-E8AA860192C85E84A6EE7411E000ED83" unitRef="usd">1071800000</us-gaap:DeferredTaxAssetsNet>
	<us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="FI2015Q4" decimals="-5" id="Fact-C1980EFF70DF3273BE5A7411E005DB8B" unitRef="usd">24700000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
	<us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="FI2016Q4" decimals="-5" id="Fact-E771DD5BB5F5E76C09C77411E0045D3A" unitRef="usd">65900000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
	<us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal contextRef="FI2016Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_GeneralBusinessMember" decimals="-5" id="Fact-F3BC63BCFC63BCD274B27411DFEB6513" unitRef="usd">86400000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
	<us-gaap:DeferredTaxAssetsOther contextRef="FI2015Q4" decimals="-5" id="Fact-F4FAE7FDD501B4E42E197411DFBC11BD" unitRef="usd">35800000</us-gaap:DeferredTaxAssetsOther>
	<us-gaap:DeferredTaxAssetsOther contextRef="FI2016Q4" decimals="-5" id="Fact-8093D5DC5F60626111737411DFB773C2" unitRef="usd">49000000</us-gaap:DeferredTaxAssetsOther>
	<us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="FI2015Q4" decimals="-5" id="Fact-88296EE5F4A92DA897F47411DFF47279" unitRef="usd">189300000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
	<us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="FI2016Q4" decimals="-5" id="Fact-2AAF1BC9C1758C69E93B7411DFBC9734" unitRef="usd">201100000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
	<us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="FI2015Q4" decimals="-5" id="Fact-CFC78AF1D8AF0D0019C77411E008873D" unitRef="usd">63800000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
	<us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="FI2016Q4" decimals="-5" id="Fact-543453ADDF5D5C1A990F7411DFBA6007" unitRef="usd">61500000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
	<us-gaap:DeferredTaxAssetsValuationAllowance contextRef="FI2015Q4" decimals="-5" id="Fact-FB7E4358737EBEC912637411DFBBF451" unitRef="usd">14100000</us-gaap:DeferredTaxAssetsValuationAllowance>
	<us-gaap:DeferredTaxAssetsValuationAllowance contextRef="FI2016Q4" decimals="-5" id="Fact-D78E7D7B346949F513EE7411DFBB1AD6" unitRef="usd">16100000</us-gaap:DeferredTaxAssetsValuationAllowance>
	<us-gaap:DeferredTaxLiabilities contextRef="FI2015Q4" decimals="-5" id="Fact-322AF499A74732424D997411DFB9C98B" unitRef="usd">542800000</us-gaap:DeferredTaxLiabilities>
	<us-gaap:DeferredTaxLiabilities contextRef="FI2016Q4" decimals="-5" id="Fact-A19D8E53925046434CB57411DFC39C7D" unitRef="usd">490100000</us-gaap:DeferredTaxLiabilities>
	<us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets contextRef="FI2015Q4" decimals="-5" id="Fact-83E1293C8514254CD8847411E006D849" unitRef="usd">440100000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
	<us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets contextRef="FI2016Q4" decimals="-5" id="Fact-6F49BC4A3A2B11422A017411E025F2C5" unitRef="usd">376600000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
	<us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets contextRef="FI2016Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember_us-gaap_ProductOrServiceAxis_biib_ALPROLIXMember" decimals="-5" id="Fact-7D80DAD7A9AF58781EC618497A728746" unitRef="usd">6500000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
	<us-gaap:DeferredTaxLiabilitiesNoncurrent contextRef="FI2015Q4" decimals="-5" id="Fact-5FF546BBEDD2930F5BE67411DFF31354" unitRef="usd">124900000</us-gaap:DeferredTaxLiabilitiesNoncurrent>
	<us-gaap:DeferredTaxLiabilitiesNoncurrent contextRef="FI2016Q4" decimals="-5" id="Fact-5D05D9F96847451CFC6C7411DFE1C471" unitRef="usd">93100000</us-gaap:DeferredTaxLiabilitiesNoncurrent>
	<us-gaap:DefinedBenefitPlanBenefitObligation contextRef="FI2015Q4_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_us-gaap_ForeignPensionPlansDefinedBenefitMember_us-gaap_StatementGeographicalAxis_country_CH" decimals="-5" id="Fact-D55AD5E623CF11E2BF867411DFEC2964" unitRef="usd">63900000</us-gaap:DefinedBenefitPlanBenefitObligation>
	<us-gaap:DefinedBenefitPlanBenefitObligation contextRef="FI2015Q4_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_us-gaap_ForeignPensionPlansDefinedBenefitMember_us-gaap_StatementGeographicalAxis_country_DE" decimals="-5" id="Fact-888401C924E33418CDF27411DFF07351" unitRef="usd">27600000</us-gaap:DefinedBenefitPlanBenefitObligation>
	<us-gaap:DefinedBenefitPlanBenefitObligation contextRef="FI2016Q4_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_us-gaap_ForeignPensionPlansDefinedBenefitMember_us-gaap_StatementGeographicalAxis_country_CH" decimals="-5" id="Fact-D250FDE78636960E4C657411DFEA2E1F" unitRef="usd">68600000</us-gaap:DefinedBenefitPlanBenefitObligation>
	<us-gaap:DefinedBenefitPlanBenefitObligation contextRef="FI2016Q4_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_us-gaap_ForeignPensionPlansDefinedBenefitMember_us-gaap_StatementGeographicalAxis_country_DE" decimals="-5" id="Fact-0C9AFE7E4984F896A7957411DFC78F2D" unitRef="usd">35400000</us-gaap:DefinedBenefitPlanBenefitObligation>
	<us-gaap:DefinedBenefitPlanFundedStatusOfPlan contextRef="FI2015Q4_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_us-gaap_ForeignPensionPlansDefinedBenefitMember_us-gaap_StatementGeographicalAxis_country_CH" decimals="-5" id="Fact-B001EEC38EE412EBB7C87411DFEAD06F" unitRef="usd">42400000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
	<us-gaap:DefinedBenefitPlanFundedStatusOfPlan contextRef="FI2016Q4_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_us-gaap_ForeignPensionPlansDefinedBenefitMember_us-gaap_StatementGeographicalAxis_country_CH" decimals="-5" id="Fact-BD6C5099649E045BC5777411DFEA6E62" unitRef="usd">39100000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
	<us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost contextRef="FD2014Q4YTD_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_us-gaap_ForeignPensionPlansDefinedBenefitMember_us-gaap_StatementGeographicalAxis_country_DE" decimals="-5" id="Fact-A3279883B4013158DC467411DFC72154" unitRef="usd">3500000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
	<us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost contextRef="FD2015Q4YTD_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_us-gaap_ForeignPensionPlansDefinedBenefitMember_us-gaap_StatementGeographicalAxis_country_DE" decimals="-5" id="Fact-8F4690403A7CB2C9BF477411DFE5ED62" unitRef="usd">4000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
	<us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost contextRef="FD2016Q4YTD_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_us-gaap_ForeignPensionPlansDefinedBenefitMember_us-gaap_StatementGeographicalAxis_country_DE" decimals="-5" id="Fact-599400E5F2FD3F0150497411DFEAFB04" unitRef="usd">4200000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
	<us-gaap:DefinedContributionPlanCostRecognized contextRef="FD2014Q4YTD_us-gaap_DefinedContributionPlanTypeAxis_us-gaap_UnitedStatesPostretirementBenefitPlansOfUSEntityDefinedBenefitMember" decimals="-5" id="Fact-11DDE8C0469926D999EF7411DFECD0B5" unitRef="usd">49300000</us-gaap:DefinedContributionPlanCostRecognized>
	<us-gaap:DefinedContributionPlanCostRecognized contextRef="FD2015Q4YTD_us-gaap_DefinedContributionPlanTypeAxis_us-gaap_UnitedStatesPostretirementBenefitPlansOfUSEntityDefinedBenefitMember" decimals="-5" id="Fact-E1DF2AAD52C6C80BE1D37411DFECD51E" unitRef="usd">51800000</us-gaap:DefinedContributionPlanCostRecognized>
	<us-gaap:DefinedContributionPlanCostRecognized contextRef="FD2016Q4YTD_us-gaap_DefinedContributionPlanTypeAxis_us-gaap_UnitedStatesPostretirementBenefitPlansOfUSEntityDefinedBenefitMember" decimals="-5" id="Fact-45AA2A3A77FD13B4715D7411DFEB2409" unitRef="usd">45200000</us-gaap:DefinedContributionPlanCostRecognized>
	<us-gaap:Depreciation contextRef="FD2014Q4YTD" decimals="-5" id="Fact-9BF2366F21945C5445A77411E026DF70" unitRef="usd">198400000</us-gaap:Depreciation>
	<us-gaap:Depreciation contextRef="FD2015Q4YTD" decimals="-5" id="Fact-3B4E0A5743136B87FB4E7411E0253C3C" unitRef="usd">217900000</us-gaap:Depreciation>
	<us-gaap:Depreciation contextRef="FD2016Q4YTD" decimals="-5" id="Fact-C2C0162F132B5CA487717411E0265CE4" unitRef="usd">309300000</us-gaap:Depreciation>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2014Q4YTD" decimals="-5" id="Fact-703D878FB5DB7132A3737411E019BBF2" unitRef="usd">688100000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2015Q4YTD" decimals="-5" id="Fact-231FB3CDA36D7EE938F37411E017E940" unitRef="usd">600400000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2016Q4YTD" decimals="-5" id="Fact-184FB97843E139EAF81F7411E0195AB1" unitRef="usd">682700000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="FI2015Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-A297982FA284AE9D2FE67411DFE3CF41" unitRef="usd">16600000</us-gaap:DerivativeFairValueOfDerivativeAsset>
	<us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="FI2015Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" decimals="-5" id="Fact-BC15CD219CDA84F23AA67411DFE5C879" unitRef="usd">10300000</us-gaap:DerivativeFairValueOfDerivativeAsset>
	<us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="FI2015Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherInvestmentsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-4BAC11D6DF37E7A49F1E7411DFE5B962" unitRef="usd">300000</us-gaap:DerivativeFairValueOfDerivativeAsset>
	<us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember" decimals="-5" id="Fact-3154654D59EE6C97938D7411DFEF3C35" unitRef="usd">4600000</us-gaap:DerivativeFairValueOfDerivativeAsset>
	<us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-741BB4E06616D03458787411DFF41395" unitRef="usd">50400000</us-gaap:DerivativeFairValueOfDerivativeAsset>
	<us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" decimals="-5" id="Fact-D113DD45E904520F5CB47411DFF406C0" unitRef="usd">4000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
	<us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherInvestmentsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-53FC0A99FCD0D906033D7411DFF4C9D1" unitRef="usd">6600000</us-gaap:DerivativeFairValueOfDerivativeAsset>
	<us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="FI2015Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-6D891FD9FCBD4DEDAD21186570F568E3" unitRef="usd">10200000</us-gaap:DerivativeFairValueOfDerivativeLiability>
	<us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="FI2015Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" decimals="-5" id="Fact-EEC8275FEDE024436B3B7411E0229797" unitRef="usd">2000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
	<us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="FI2015Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-2E1F79BEA81D102A68B11865C4D43EC1" unitRef="usd">2500000</us-gaap:DerivativeFairValueOfDerivativeLiability>
	<us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" decimals="-5" id="Fact-0AEA15982ACB83CBB7ED7411DFF36E49" unitRef="usd">9000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
	<us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-79F720729E2139FE1FD27411DFF39AB9" unitRef="usd">4600000</us-gaap:DerivativeFairValueOfDerivativeLiability>
	<us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet contextRef="FD2014Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember" decimals="-5" id="Fact-633C73CABB2A92DFA535186225A449A6" unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
	<us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet contextRef="FD2014Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember" decimals="-5" id="Fact-39F91B016B72BFD070AA7411E000CB2A" unitRef="usd">6800000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
	<us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet contextRef="FD2015Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember" decimals="-5" id="Fact-EAB49EE6EA695AA3B0E11861D197BFFA" unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
	<us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet contextRef="FD2015Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember" decimals="-5" id="Fact-D993EF2A973AFE6FFFC47411E0000719" unitRef="usd">173200000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
	<us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet contextRef="FD2016Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember" decimals="-5" id="Fact-EDDF6E205486128F3D0C1860AF67665F" unitRef="usd">-1500000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
	<us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet contextRef="FD2016Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember" decimals="-5" id="Fact-F507E5D8586629F3091E7411E000C0CE" unitRef="usd">5300000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
	<us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet contextRef="FD2014Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" decimals="-5" id="Fact-9C25979F62F4C88A0B051863ED4BF6FB" unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
	<us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet contextRef="FD2014Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" decimals="-5" id="Fact-F26B8C5D451597985D7F7411E001B3F3" unitRef="usd">-1500000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
	<us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet contextRef="FD2015Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" decimals="-5" id="Fact-49CCBE63454ABF2800721863B673D826" unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
	<us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet contextRef="FD2015Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" decimals="-5" id="Fact-F2A20BE600DC7B94651C7411DFFF5A5E" unitRef="usd">4900000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
	<us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet contextRef="FD2016Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" decimals="-5" id="Fact-E93B7B8C9BC7872806FF186354CA6A21" unitRef="usd">100000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
	<us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet contextRef="FD2016Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" decimals="-5" id="Fact-05F583A0FB949B4E577F7411DFFFBA66" unitRef="usd">2900000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
	<us-gaap:DerivativeRemainingMaturity1 contextRef="FD2015Q4YTD_us-gaap_RangeAxis_us-gaap_MaximumMember" id="Fact-91995F6294A0D2EDA17B7411DFF6E08B">P18M</us-gaap:DerivativeRemainingMaturity1>
	<us-gaap:DerivativeRemainingMaturity1 contextRef="FD2015Q4YTD_us-gaap_RangeAxis_us-gaap_MinimumMember" id="Fact-5AC927B91C6013DB704E7411DFF654FC">P1M</us-gaap:DerivativeRemainingMaturity1>
	<us-gaap:DerivativeRemainingMaturity1 contextRef="FD2016Q4YTD_us-gaap_RangeAxis_us-gaap_MaximumMember" id="Fact-9EC01D177120CFAF386A7411DFF63BF3">P18M</us-gaap:DerivativeRemainingMaturity1>
	<us-gaap:DerivativeRemainingMaturity1 contextRef="FD2016Q4YTD_us-gaap_RangeAxis_us-gaap_MinimumMember" id="Fact-DE44BFD25FE19A0551B57411DFF6114C">P1M</us-gaap:DerivativeRemainingMaturity1>
	<us-gaap:EarningsPerShareBasic contextRef="FD2014Q4YTD" decimals="2" id="Fact-A62E961B4F1A6CF7D62F7411DFD10024" unitRef="usdPerShare">12.42</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2015Q1YTD" decimals="2" id="Fact-E2943B03BB221A1B88F37411DFCAAA3E" unitRef="usdPerShare">3.50</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2015Q2QTD" decimals="2" id="Fact-667991878D1C1FDFF35B7411DFCBC0EE" unitRef="usdPerShare">3.94</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2015Q3QTD" decimals="2" id="Fact-489F2EA2DBE0404FE4597411DFC7811F" unitRef="usdPerShare">4.16</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2015Q4QTD" decimals="2" id="Fact-5AE45B2C1E44224963167411DFCA5910" unitRef="usdPerShare">3.77</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2015Q4YTD" decimals="2" id="Fact-029934AB615E287D1CEA7411DFB816AE" unitRef="usdPerShare">15.38</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2016Q1QTD" decimals="2" id="Fact-D21C25A4C9EC92E7E9077411DFF8ADC1" unitRef="usdPerShare">4.44</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2016Q2QTD" decimals="2" id="Fact-7285D01D77F2FBFFCDF87411DFF3997E" unitRef="usdPerShare">4.79</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2016Q3QTD" decimals="2" id="Fact-214A074D44D160A4CCA47411E024304F" unitRef="usdPerShare">4.72</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2016Q4QTD" decimals="2" id="Fact-6895F09475FE3E5395B07411E0098F65" unitRef="usdPerShare">3.00</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2016Q4YTD" decimals="2" id="Fact-85DBBEC109395377E52E7411E026F1D2" unitRef="usdPerShare">16.96</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2014Q4YTD" decimals="2" id="Fact-E638F1F55C65ACA7F54F7411DFF62E21" unitRef="usdPerShare">12.37</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2015Q1YTD" decimals="2" id="Fact-D953E68A8A92A7BA52D97411DFCBB01F" unitRef="usdPerShare">3.49</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2015Q2QTD" decimals="2" id="Fact-D7BB355FAB06B69FF8607411DFC7A7C1" unitRef="usdPerShare">3.93</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2015Q3QTD" decimals="2" id="Fact-AF035CF6CBE5DF9C39597411DFCD3804" unitRef="usdPerShare">4.15</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2015Q4QTD" decimals="2" id="Fact-9E10D6BFFB898CDE07337411DFC9C0D7" unitRef="usdPerShare">3.77</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2015Q4YTD" decimals="2" id="Fact-AE9211652921F7DAD5C27411DFE13C47" unitRef="usdPerShare">15.34</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2016Q1QTD" decimals="2" id="Fact-46BBBEF2809823F37E8C7411DFF725F3" unitRef="usdPerShare">4.43</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2016Q2QTD" decimals="2" id="Fact-1CBE51FDF3C31899A2687411DFFE9B5A" unitRef="usdPerShare">4.79</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2016Q3QTD" decimals="2" id="Fact-4A73BA769439D9BB6FD07411E02991DC" unitRef="usdPerShare">4.71</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2016Q4QTD" decimals="2" id="Fact-50A59A399A9330FF51787411E0079E19" unitRef="usdPerShare">2.99</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2016Q4YTD" decimals="2" id="Fact-16DC423FEC37DAC1831F7411DFE32AA1" unitRef="usdPerShare">16.93</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="FD2014Q4YTD" decimals="-5" id="Fact-60E9CE39AE512B3A7E097411E01A5A8E" unitRef="usd">-40900000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
	<us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="FD2015Q4YTD" decimals="-5" id="Fact-07904D870588E4FB7B6F7411E0173591" unitRef="usd">-45800000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
	<us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="FD2016Q4YTD" decimals="-5" id="Fact-CE142295054C0CC20F327411E0175812" unitRef="usd">-31300000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
	<us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="FD2014Q4YTD" decimals="3" id="Fact-4040F3F9C26F55DDDE757411DFF8A63F" unitRef="number">0.251</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
	<us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="FD2015Q4YTD" decimals="3" id="Fact-77FDA425F274F925EC2F7411E025E2E4" unitRef="number">0.244</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
	<us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="FD2016Q4YTD" decimals="3" id="Fact-97C983DE321E4B8397357411E022DA1D" unitRef="number">0.251</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
	<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="FD2014Q4YTD" decimals="3" id="Fact-3016DD9BCFB4D462CE707411E009B773" unitRef="number">0.350</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
	<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="FD2015Q4YTD" decimals="3" id="Fact-19E5B0915E3809BD71B17411E00B3CEB" unitRef="number">0.350</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
	<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="FD2016Q4YTD" decimals="3" id="Fact-5F64AF82A4B53B3252C67411DFB749AE" unitRef="number">0.350</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
	<us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="FD2014Q4YTD" decimals="3" id="Fact-EC9BE3BC00C5CA8C89857411E0156590" unitRef="number">-0.095</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
	<us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="FD2015Q4YTD" decimals="3" id="Fact-FFEE86DDE03C730396227411DFB8D635" unitRef="number">-0.100</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
	<us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="FD2016Q4YTD" decimals="3" id="Fact-4468938FAB372D6CC9707411E00CE263" unitRef="number">-0.096</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
	<us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization contextRef="FD2014Q4YTD" decimals="3" id="Fact-1DC46B9CCAF3FA11A40D7411E02224A3" unitRef="number">0.012</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization>
	<us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization contextRef="FD2015Q4YTD" decimals="3" id="Fact-EA05D21F13D9C52196A17411E0084872" unitRef="number">0.010</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization>
	<us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization contextRef="FD2016Q4YTD" decimals="3" id="Fact-6082A6D13972F45C82FE7411E0231EC1" unitRef="number">0.012</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization>
	<us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther contextRef="FD2014Q4YTD" decimals="3" id="Fact-3C2F6C3F4592AD8CF8327411E009D4DA" unitRef="number">0.005</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
	<us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther contextRef="FD2015Q4YTD" decimals="3" id="Fact-60A09A0290AF4AA556977411E00C9BD2" unitRef="number">0.007</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
	<us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther contextRef="FD2016Q4YTD" decimals="3" id="Fact-C5C31505EF09AC84BE9A7411DFFE6861" unitRef="number">0.005</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
	<us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="FD2014Q4YTD" decimals="3" id="Fact-FE328AF7491D8B49ADF07411DFBCC438" unitRef="number">0.012</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
	<us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="FD2015Q4YTD" decimals="3" id="Fact-65C0E4AEA9A3084139857411E0233555" unitRef="number">0.005</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
	<us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="FD2016Q4YTD" decimals="3" id="Fact-57CBF096EF824CFDD61B7411E022EDF1" unitRef="number">0.009</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
	<us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="FD2014Q4YTD" decimals="3" id="Fact-D0FD35517E6EF3D03F427411E003C01D" unitRef="number">0.011</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
	<us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="FD2015Q4YTD" decimals="3" id="Fact-8F3C49A60276D28096187411E00734C9" unitRef="number">0.013</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
	<us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="FD2016Q4YTD" decimals="3" id="Fact-1BE44CA3CF97B47AEE057411E02EF732" unitRef="number">0.014</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
	<us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="FI2015Q4" decimals="-5" id="Fact-7C8B5BB36AAA3B22F3317411DFD1474D" unitRef="usd">270800000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
	<us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="FI2016Q4" decimals="-5" id="Fact-7A396090F607CA13EA577411DFB78321" unitRef="usd">282900000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
	<us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount contextRef="FD2014Q4YTD" decimals="-5" id="Fact-AD0ABD26702E0B8653DD7411E009505D" unitRef="usd">-10000000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
	<us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount contextRef="FD2015Q4YTD" decimals="-5" id="Fact-783680E2217EE46099D97411E00748EA" unitRef="usd">-11000000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
	<us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount contextRef="FD2016Q4YTD" decimals="-5" id="Fact-EFB9A7ACCD52674CCBF37411E025FFEF" unitRef="usd">-14600000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
	<us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards contextRef="FD2014Q4YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember" decimals="-5" id="Fact-DA12C57D2B27221605547411E021B44C" unitRef="usd">92800000</us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards>
	<us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember" decimals="-5" id="Fact-7A860627F01E7E8098427411DFC736C5" unitRef="usd">79800000</us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards>
	<us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" decimals="-5" id="Fact-2593F0A6D69C25F88A77D15CD8DA129E" unitRef="usd">12400000</us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards>
	<us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember" decimals="-5" id="Fact-53D4A0BA363E3578B3547411E013F72C" unitRef="usd">31900000</us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards>
	<us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" decimals="-5" id="Fact-AA5EFD3C485C5684D2A77411E0144CCB" unitRef="usd">8100000</us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards>
	<us-gaap:EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions contextRef="FD2014Q4YTD" decimals="-5" id="Fact-48E547F68262FED388E27411E0035C6C" unitRef="usd">8500000</us-gaap:EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions>
	<us-gaap:EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions contextRef="FD2015Q4YTD" decimals="-5" id="Fact-D8211ADB5BB764B9F1917411E0027C2D" unitRef="usd">6300000</us-gaap:EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions>
	<us-gaap:EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions contextRef="FD2016Q4YTD" decimals="-5" id="Fact-309C759A2A718B74BC257411E0256FF5" unitRef="usd">2200000</us-gaap:EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="FI2016Q4" decimals="-5" id="Fact-15A537A0BBA8E4A84B577411DFC77B77" unitRef="usd">189800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
	<us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="FD2014Q4YTD" decimals="-5" id="Fact-1FA61A08C060DA568E0B7411E008F7AD" unitRef="usd">72200000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
	<us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="FD2015Q4YTD" decimals="-5" id="Fact-79A245FB739F068BDD287411E00A0DC3" unitRef="usd">55800000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
	<us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="FD2016Q4YTD" decimals="-5" id="Fact-34A6B55077E0A9784C4B7411E007B4C1" unitRef="usd">54000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
	<us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions contextRef="FD2014Q4YTD" decimals="-5" id="Fact-F85D54438D3FD09F822F7411DFD0E8F4" unitRef="usd">13000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions>
	<us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions contextRef="FD2015Q4YTD" decimals="-5" id="Fact-83E0E8589EB305F4709A7411DFD06FD7" unitRef="usd">11900000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions>
	<us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions contextRef="FD2016Q4YTD" decimals="-5" id="Fact-4095EEE8F5877F0FC46E7411E00387E8" unitRef="usd">4000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions>
	<us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="FI2016Q4_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="3" id="Fact-5576ADF78048DDA7A50F7411DFD70663" unitRef="number">0.065</us-gaap:EquityMethodInvestmentOwnershipPercentage>
	<us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="I2012Q1SD2_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="2" id="Fact-D59006D0C1918E33AD797411DFE43D9B" unitRef="number">0.15</us-gaap:EquityMethodInvestmentOwnershipPercentage>
	<us-gaap:EquityMethodInvestments contextRef="I2012Q1SD2_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="-5" id="Fact-28C907A743971A7067007411DFC6CB63" unitRef="usd">45000000</us-gaap:EquityMethodInvestments>
	<us-gaap:EquityMethodInvestments contextRef="I2012Q1SD2_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="-8" id="Fact-AC1AB04ECF0CBFD0CB567411DFBD9992" unitRef="KRW">49500000000</us-gaap:EquityMethodInvestments>
	<us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities contextRef="FD2014Q4YTD" decimals="-5" id="Fact-7979658A27780BCDA7377411E01AF82F" unitRef="usd">96400000</us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities>
	<us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities contextRef="FD2015Q4YTD" decimals="-5" id="Fact-35E567F9B7DFA7CF5EF47411DFF0E72B" unitRef="usd">78200000</us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities>
	<us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities contextRef="FD2016Q4YTD" decimals="-5" id="Fact-55E6AE58EBBD7BEFCC987411E0173E30" unitRef="usd">12600000</us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities>
	<us-gaap:FairValueInputsDiscountRate contextRef="D2015Q1_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember" decimals="3" id="Fact-A809F767520CAFFD562B880107D0AFD0" unitRef="number">0.020</us-gaap:FairValueInputsDiscountRate>
	<us-gaap:FairValueInputsDiscountRate contextRef="D2015Q1_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_biib_BIIB074Member" decimals="2" id="Fact-A65555BD5EBE093A8EDC875C5E165A60" unitRef="number">0.11</us-gaap:FairValueInputsDiscountRate>
	<us-gaap:FairValueInputsDiscountRate contextRef="FD2016Q4YTD_us-gaap_BusinessAcquisitionAxis_biib_BiogenIdecInternationalNeuroscienceMember" decimals="3" id="Fact-96F71EBD3CC75D53DB0D7411E0201F09" unitRef="number">0.027</us-gaap:FairValueInputsDiscountRate>
	<us-gaap:FairValueInputsDiscountRate contextRef="FD2016Q4YTD_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember" decimals="3" id="Fact-3FEDE96775636F58FC64184EB4DCE4B8" unitRef="number">0.027</us-gaap:FairValueInputsDiscountRate>
	<us-gaap:FairValueInputsDiscountRate contextRef="FD2016Q4YTD_us-gaap_BusinessAcquisitionAxis_biib_StromedixMember" decimals="INF" id="Fact-8346DBD40C6C8274052C7411DFF4FD25" unitRef="number">0.022</us-gaap:FairValueInputsDiscountRate>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="FD2014Q4YTD" decimals="-5" id="Fact-0FDF4A8D4A65860D59008D75530B6FFC" unitRef="usd">38900000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="FD2015Q4YTD" decimals="-5" id="Fact-27ADABE1C4CE6008B3F78D7530AAFE8B" unitRef="usd">-30500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="FD2016Q4YTD" decimals="-5" id="Fact-7552AC896E77B7642A6B8D750D6370F0" unitRef="usd">-14800000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases contextRef="D2015Q1_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember" decimals="-5" id="Fact-1C130236DEC59D03BD00FA812AD7E446" unitRef="usd">274500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases contextRef="FD2010Q4QTD_us-gaap_BusinessAcquisitionAxis_biib_BiogenIdecInternationalNeuroscienceMember" decimals="-5" id="Fact-74089F3E99760EF963497411DFF34272" unitRef="usd">81200000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases contextRef="FD2012Q1QTD_us-gaap_BusinessAcquisitionAxis_biib_StromedixMember" decimals="-5" id="Fact-A23AD24FC9B30CDB5BF28808F2983DDA" unitRef="usd">122200000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases contextRef="FD2015Q4YTD" decimals="-5" id="Fact-2A261DECE8E318B19CDA7411DFD1710D" unitRef="usd">274500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases contextRef="FD2016Q4YTD" decimals="-5" id="Fact-8BC61AD95543E8F9FFBB7411DFD7ABAA" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements contextRef="FD2015Q4YTD" decimals="-5" id="Fact-FE5309AD5187916AE0FA7411DFD1EA39" unitRef="usd">14500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements contextRef="FD2016Q4YTD" decimals="-5" id="Fact-1734EBC6A995728B35AF7411DFD1F95A" unitRef="usd">53200000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
	<us-gaap:FairValueMeasurementsChangesInValuationTechniques contextRef="FD2015Q4YTD" id="Fact-8E6B5C612E12DE50730D7411E022ED04">0</us-gaap:FairValueMeasurementsChangesInValuationTechniques>
	<us-gaap:FairValueMeasurementsChangesInValuationTechniques contextRef="FD2016Q4YTD" id="Fact-0E02A264B438AD451C117411DFF30637">0</us-gaap:FairValueMeasurementsChangesInValuationTechniques>
	<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="FD2016Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember_us-gaap_RangeAxis_us-gaap_MaximumMember" id="Fact-620D463616302C1315F27411E02E3127">P18Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
	<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="FD2016Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember_us-gaap_RangeAxis_us-gaap_MinimumMember" id="Fact-FD8CE7C03A7220B170F27411E02827AF">P6Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
	<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="FD2016Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember_us-gaap_RangeAxis_us-gaap_MaximumMember" id="Fact-630762D96FDD2AA656237411E028C28E">P23Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
	<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="FD2016Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember_us-gaap_RangeAxis_us-gaap_MinimumMember" id="Fact-36F1AD649FE28F70784E7411E0283DF8">P13Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
	<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="FD2016Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_RangeAxis_us-gaap_MaximumMember" id="Fact-6403F562671C81DE672E7411E028A90E">P23Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
	<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="FD2016Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_RangeAxis_us-gaap_MinimumMember" id="Fact-C3F17A61226BCDC60DD57411E028A83D">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2015Q4" decimals="-5" id="Fact-60C6812A27F32996D1317411DFF62B57" unitRef="usd">3561200000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2015Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" decimals="-5" id="Fact-3A09ABF623706987ED777411E0005714" unitRef="usd">502300000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2015Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" decimals="-5" id="Fact-FDF34DFCB753D238C85C7411E027EEFB" unitRef="usd">506000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2015Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" decimals="-5" id="Fact-E8BA5CB3757ABDB2B6767411E00114C0" unitRef="usd">2552900000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2015Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" decimals="-5" id="Fact-2AD1A10FB972816FBEDA7411DFB81098" unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2015Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember" decimals="-5" id="Fact-2B68E4BE198CD8F6D69B7411DFF8A1CA" unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2016Q4" decimals="-5" id="Fact-B2C3D89536927E5AF5137411DFF3A116" unitRef="usd">3934000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2016Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" decimals="-5" id="Fact-0C547525B24A7A8585EF7411E0029846" unitRef="usd">776100000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2016Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" decimals="-5" id="Fact-D4B4FA1CFB78FBF650C47411E0024233" unitRef="usd">523600000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2016Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" decimals="-5" id="Fact-DF16577BF5051DE513C17411E025C560" unitRef="usd">2634300000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2016Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" decimals="-5" id="Fact-23A3B3398F8B9D6C773C7411E023C1AF" unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2016Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember" decimals="-5" id="Fact-20CE8FD58C2E4AF32F6D7411E026BEEB" unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="FI2016Q4" decimals="-5" id="Fact-41E4A83326E5BC8CD0F17411E002B47A" unitRef="usd">334800000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="FI2016Q4" decimals="-5" id="Fact-64581F7722CAB06A60D47411DFFF8811" unitRef="usd">242800000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="FI2016Q4" decimals="-5" id="Fact-E8B65EA2FCD1E570F99E7411DFC50CD2" unitRef="usd">259700000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="FI2016Q4" decimals="-5" id="Fact-9F701BFBF7B8E592A92C7411E01BB3D5" unitRef="usd">295200000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="FI2016Q4" decimals="-5" id="Fact-90E92AAD91C80CE1C74C7411E0197CC0" unitRef="usd">312700000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
	<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="FI2015Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" decimals="-5" id="Fact-96119DB6C767AB38F6AD7411E0282E4F" unitRef="usd">3303200000</us-gaap:FiniteLivedIntangibleAssetsGross>
	<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="FI2015Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" decimals="-5" id="Fact-8030F0D41DD9776AA1187411DFF7012E" unitRef="usd">543300000</us-gaap:FiniteLivedIntangibleAssetsGross>
	<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="FI2015Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" decimals="-5" id="Fact-BC29A46C171D29A742A47411DFC3AAFF" unitRef="usd">3005300000</us-gaap:FiniteLivedIntangibleAssetsGross>
	<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="FI2016Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" decimals="-5" id="Fact-07D6638AC8A15C338D277411E022A757" unitRef="usd">3481700000</us-gaap:FiniteLivedIntangibleAssetsGross>
	<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="FI2016Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" decimals="-5" id="Fact-EC6845E555BF4C9E327F7411DFC451BF" unitRef="usd">543300000</us-gaap:FiniteLivedIntangibleAssetsGross>
	<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="FI2016Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" decimals="-5" id="Fact-BD37BADF8242D85650467411E000015A" unitRef="usd">3005300000</us-gaap:FiniteLivedIntangibleAssetsGross>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2015Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" decimals="-5" id="Fact-76FAD6768FD6500A7B687411E0262887" unitRef="usd">2800900000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2015Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" decimals="-5" id="Fact-E20B868020C8FD36AC407411E002702E" unitRef="usd">37300000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2015Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" decimals="-5" id="Fact-0872853897CC5A13517C7411DFF81FA6" unitRef="usd">452400000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2016Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" decimals="-5" id="Fact-A124923AED34BC22107F7411E026DF70" unitRef="usd">2705600000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2016Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember_us-gaap_ProductOrServiceAxis_biib_TysabriProductMember" decimals="-5" id="Fact-00CCEBD128FD84E3808B7411DFF6E353" unitRef="usd">2493200000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2016Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" decimals="-5" id="Fact-80DB0D2B2BAE5231DBE47411DFF8E6D8" unitRef="usd">19700000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2016Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" decimals="-5" id="Fact-B689F95D8F63EEC086C17411DFFFF3A4" unitRef="usd">371000000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2016Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_ProductOrServiceAxis_biib_AVONEXMember" decimals="-5" id="Fact-650BC150A88DB9F559F57411DFF5EC1E" unitRef="usd">363300000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease contextRef="FD2016Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember_us-gaap_ProductOrServiceAxis_biib_ALPROLIXMember" decimals="-5" id="Fact-BD046A2F6D41321CAC1718490DB2A5EB" unitRef="usd">26500000</us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease>
	<us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease contextRef="FD2016Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember_us-gaap_ProductOrServiceAxis_biib_BiosimilarsMember" decimals="-5" id="Fact-51D76311E760596006B91848800D2499" unitRef="usd">50000000</us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease>
	<us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease contextRef="FD2016Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember" decimals="-5" id="Fact-6573D19BB238F923394AD1235DD2161B" unitRef="usd">60000000</us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease>
	<us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease contextRef="FD2016Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember_us-gaap_ProductOrServiceAxis_biib_ZINBRYTAMember" decimals="-5" id="Fact-CB1D959FE49960C778DF1848C45BE7C2" unitRef="usd">32000000</us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease>
	<us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-6217E804839750A1FBD47411E02FEEBE" unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-F085B010F034812A5E547411E028B915" unitRef="usd">27200000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-1DC0F468C79AF4A1C38C7411E02E650F" unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-B9E1CE3B41B3193022B47411E02F156B" unitRef="usd">27200000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-967573612A809627009F7411E01B6144" unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-80CD93E4E0C2D5D067437411E0187B3B" unitRef="usd">61000000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-7401451B51A52C02A6447411E0187827" unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-1757A923369ED62429BB7411DFD90F14" unitRef="usd">61000000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-A7C918B814FAF3F25F467411DFB75883" unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-6442E69C2C0BB5B809CD7411E02EC45D" unitRef="usd">14700000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-07678438E77FB7E5E38C7411E0292188" unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-57496372F80AA57267487411E02E0954" unitRef="usd">14700000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-D838E2991C745F8831057411E0011511" unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-2E90007E65EC9B70096D7411DFDB7B7C" unitRef="usd">13600000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-7F828A6D516FDD0032037411DFF59458" unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-933A4A5CD09220D3CF797411E0199A2A" unitRef="usd">13600000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
	<us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="FD2014Q4YTD" decimals="-5" id="Fact-82E9EAD8B6BE4C0037657411E024337D" unitRef="usd">-11600000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
	<us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="FD2015Q4YTD" decimals="-5" id="Fact-C0DFCA67E7B082D722417411DFBC3F23" unitRef="usd">-32700000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
	<us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="FD2016Q4YTD" decimals="-5" id="Fact-71EEE1FB0644347D32017411E025708E" unitRef="usd">-9800000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
	<us-gaap:FurnitureAndFixturesGross contextRef="FI2015Q4" decimals="-5" id="Fact-710294EA6172C8B9523D7411E0286080" unitRef="usd">72900000</us-gaap:FurnitureAndFixturesGross>
	<us-gaap:FurnitureAndFixturesGross contextRef="FI2016Q4" decimals="-5" id="Fact-EC2DCF49538EC3BDAE027411E0294766" unitRef="usd">60600000</us-gaap:FurnitureAndFixturesGross>
	<us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactions contextRef="FI2016Q4" decimals="-5" id="Fact-AED74A30C6BA48309C207411E01884D7" unitRef="usd">126900000</us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactions>
	<us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter contextRef="FI2016Q4" decimals="-5" id="Fact-AD62A00E41CC4CE68D3C7411E01BE03B" unitRef="usd">55400000</us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter>
	<us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears contextRef="FI2016Q4" decimals="-5" id="Fact-2CD8D0A4AA55A8A1FCCE7411E01ACACC" unitRef="usd">16200000</us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears>
	<us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears contextRef="FI2016Q4" decimals="-5" id="Fact-20C54AA5A51D8A96F4C87411E01A08B9" unitRef="usd">15700000</us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears>
	<us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear contextRef="FI2016Q4" decimals="-5" id="Fact-333EF9C01483C0E36A227411E0193FA2" unitRef="usd">8900000</us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear>
	<us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears contextRef="FI2016Q4" decimals="-5" id="Fact-F98B26011BC9508E52057411E0194260" unitRef="usd">15500000</us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears>
	<us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears contextRef="FI2016Q4" decimals="-5" id="Fact-306BE32C78C729B043DF7411E01A4440" unitRef="usd">15200000</us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears>
	<us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments contextRef="FD2014Q4YTD" decimals="-5" id="Fact-F1F1E7A0A58338BB95D17411DFF6CF6C" unitRef="usd">15500000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
	<us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments contextRef="FD2015Q4YTD" decimals="-5" id="Fact-E066E8DFC947A68C0FBB7411DFF67C14" unitRef="usd">23800000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
	<us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments contextRef="FD2016Q4YTD" decimals="-5" id="Fact-74FA1B074467292D20237411DFF5A8C3" unitRef="usd">29200000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
	<us-gaap:GainLossOnSaleOfInvestments contextRef="FD2014Q4YTD" decimals="-5" id="Fact-BC6DF463A16AC3F348247411E00B2829" unitRef="usd">11800000</us-gaap:GainLossOnSaleOfInvestments>
	<us-gaap:GainLossOnSaleOfInvestments contextRef="FD2015Q4YTD" decimals="-5" id="Fact-62076D3904D468054E7A7411E02353F8" unitRef="usd">-3800000</us-gaap:GainLossOnSaleOfInvestments>
	<us-gaap:GainLossOnSaleOfInvestments contextRef="FD2016Q4YTD" decimals="-5" id="Fact-F9556980A5E4B5F5B4B57411E005D9C7" unitRef="usd">6000000</us-gaap:GainLossOnSaleOfInvestments>
	<us-gaap:Goodwill contextRef="FI2014Q4" decimals="-5" id="Fact-B75BA4EA90165B67D7847411DFD1D82A" unitRef="usd">1760200000</us-gaap:Goodwill>
	<us-gaap:Goodwill contextRef="FI2015Q4" decimals="-5" id="Fact-0408DABBA3205EFF22AF7411DFE1C17D" unitRef="usd">2663800000</us-gaap:Goodwill>
	<us-gaap:Goodwill contextRef="FI2016Q4" decimals="-5" id="Fact-D1723B914DF5CF3296BC7411DFDD8586" unitRef="usd">3669300000</us-gaap:Goodwill>
	<us-gaap:Goodwill contextRef="I2015Q1ConvergencePharma_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember" decimals="-5" id="Fact-CD93EF900AF2D8CF93B987C6BB4CB56C" unitRef="usd">128300000</us-gaap:Goodwill>
	<us-gaap:GoodwillAcquiredDuringPeriod contextRef="FD2015Q4YTD" decimals="-5" id="Fact-61AAC048B772B10C9A0F7411DFD8DB23" unitRef="usd">908100000</us-gaap:GoodwillAcquiredDuringPeriod>
	<us-gaap:GoodwillAcquiredDuringPeriod contextRef="FD2015Q4YTD_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember" decimals="-5" id="Fact-B77B40BF02CAC9642A9587C5EE368572" unitRef="usd">900000000</us-gaap:GoodwillAcquiredDuringPeriod>
	<us-gaap:GoodwillAcquiredDuringPeriod contextRef="FD2016Q4YTD" decimals="-5" id="Fact-9E07B1F27313CC63794C7411DFD1EFC0" unitRef="usd">1026900000</us-gaap:GoodwillAcquiredDuringPeriod>
	<us-gaap:GoodwillAcquiredDuringPeriod contextRef="FD2016Q4YTD_biib_CumulativeSalesLevelAxis_biib_EachAdditionalOneBillionUpToTwentyBillionMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember" decimals="-5" id="Fact-D0915D55291554351DCDD25B2204AF1D" unitRef="usd">300000000</us-gaap:GoodwillAcquiredDuringPeriod>
	<us-gaap:GoodwillAcquiredDuringPeriod contextRef="FD2016Q4YTD_biib_CumulativeSalesLevelAxis_biib_ElevenbillionMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember" decimals="-5" id="Fact-7C27143E4EC6E6D305557411E01452A1" unitRef="usd">300000000</us-gaap:GoodwillAcquiredDuringPeriod>
	<us-gaap:GoodwillAcquiredDuringPeriod contextRef="FD2016Q4YTD_biib_CumulativeSalesLevelAxis_biib_TenbillionMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember" decimals="-8" id="Fact-D70C95A0AAE5708627707411E0151838" unitRef="usd">1200000000</us-gaap:GoodwillAcquiredDuringPeriod>
	<us-gaap:GoodwillAcquiredDuringPeriod contextRef="FD2016Q4YTD_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember" decimals="-8" id="Fact-9614A649B006B30FBEC77411DFF4A89E" unitRef="usd">1200000000</us-gaap:GoodwillAcquiredDuringPeriod>
	<us-gaap:GoodwillImpairedAccumulatedImpairmentLoss contextRef="FI2016Q4" decimals="-6" id="Fact-11DC056139E89905437E7411DFF42728" unitRef="usd">0</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
	<us-gaap:GoodwillOtherIncreaseDecrease contextRef="FD2015Q4YTD" decimals="-5" id="Fact-791C7E4FD0835B2B571B7411DFD75E40" unitRef="usd">-4500000</us-gaap:GoodwillOtherIncreaseDecrease>
	<us-gaap:GoodwillOtherIncreaseDecrease contextRef="FD2016Q4YTD" decimals="-5" id="Fact-B32A11C025C4D4087C127411DFD1F47E" unitRef="usd">-21400000</us-gaap:GoodwillOtherIncreaseDecrease>
	<us-gaap:GrossProfit contextRef="FD2015Q1YTD" decimals="-5" id="Fact-2A505653B69036077A507411DFCB9910" unitRef="usd">2242600000</us-gaap:GrossProfit>
	<us-gaap:GrossProfit contextRef="FD2015Q2QTD" decimals="-5" id="Fact-9B346987E74EDA4D4C427411DFC95154" unitRef="usd">2305500000</us-gaap:GrossProfit>
	<us-gaap:GrossProfit contextRef="FD2015Q3QTD" decimals="-5" id="Fact-666BD7B77AE5645655E87411DFE42535" unitRef="usd">2467900000</us-gaap:GrossProfit>
	<us-gaap:GrossProfit contextRef="FD2015Q4QTD" decimals="-5" id="Fact-D1D84D33F2FDB54543597411DFCB9944" unitRef="usd">2507500000</us-gaap:GrossProfit>
	<us-gaap:GrossProfit contextRef="FD2015Q4YTD" decimals="-5" id="Fact-F44085B6841B0A6022DF7411DFCBC150" unitRef="usd">9523400000</us-gaap:GrossProfit>
	<us-gaap:GrossProfit contextRef="FD2016Q1QTD" decimals="-5" id="Fact-47F276ACFDE047C99AB07411E0135F2A" unitRef="usd">2413800000</us-gaap:GrossProfit>
	<us-gaap:GrossProfit contextRef="FD2016Q2QTD" decimals="-5" id="Fact-5B73FA20397DB68D48B37411E027547A" unitRef="usd">2523900000</us-gaap:GrossProfit>
	<us-gaap:GrossProfit contextRef="FD2016Q3QTD" decimals="-5" id="Fact-29F80FF72328B505EA9A7411E025A3CF" unitRef="usd">2538900000</us-gaap:GrossProfit>
	<us-gaap:GrossProfit contextRef="FD2016Q4QTD" decimals="-5" id="Fact-CB707F400C141F4399D57411DFF6AC23" unitRef="usd">2493500000</us-gaap:GrossProfit>
	<us-gaap:GrossProfit contextRef="FD2016Q4YTD" decimals="-5" id="Fact-6D8953DD9007BD392F557411DFEB79DB" unitRef="usd">9970100000</us-gaap:GrossProfit>
	<us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="FD2014Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" decimals="-5" id="Fact-6EB15E9BEB8BF04901BB87BF9AD394A9" unitRef="usd">34700000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
	<us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="FD2014Q4YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" decimals="-5" id="Fact-AB96D6A5EED737BE446387C05CF56960" unitRef="usd">16200000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
	<us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="FD2016Q4YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" decimals="-5" id="Fact-9881598155B6C9388A7DD122C0CAED5B" unitRef="usd">12200000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
	<us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="FD2016Q4YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_AtaxionMember" decimals="-5" id="Fact-58210B86C49BDE4F94EFD12143CC9632" unitRef="usd">3500000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
	<us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="FD2016Q4YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_RodinTherapeuticsMember" decimals="-5" id="Fact-DE462DDF5A21BF844736D1221C9869F1" unitRef="usd">8700000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="FD2014Q4YTD" decimals="-5" id="Fact-D4F4A0CD3C591BB36B707411DFC4D93A" unitRef="usd">2557400000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="FD2015Q4YTD" decimals="-5" id="Fact-4F288C52F21063CC7F597411DFF8B8F9" unitRef="usd">3386700000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="FD2016Q4YTD" decimals="-5" id="Fact-7E49AB19244F4C0CC3667411E0263EE4" unitRef="usd">3655400000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="FD2014Q4YTD" decimals="-5" id="Fact-CF951F7FCDAB8C64E1F37411DFC62D7D" unitRef="usd">1389200000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="FD2015Q4YTD" decimals="-5" id="Fact-B2FAE6586FF7BC6809117411E02613AE" unitRef="usd">1380600000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="FD2016Q4YTD" decimals="-5" id="Fact-21E20150AD23AC98DBCA7411E0221C52" unitRef="usd">1277600000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="FD2014Q4YTD" decimals="-5" id="Fact-83962699E71D0F53EC417411DFDF62AB" unitRef="usd">3946600000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="FD2015Q4YTD" decimals="-5" id="Fact-2F7A3DA6DE2B3EB7348A7411DFE31CA8" unitRef="usd">4767300000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="FD2016Q4YTD" decimals="-5" id="Fact-4290C5B4DEB3DAF84F407411DFFFF043" unitRef="usd">4933000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeLossFromEquityMethodInvestments contextRef="FD2014Q4YTD" decimals="-5" id="Fact-3892D0FA002B2CA6B7E07411DFF751FC" unitRef="usd">-15100000</us-gaap:IncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeLossFromEquityMethodInvestments contextRef="FD2015Q4YTD" decimals="-5" id="Fact-FA6DC4450F8B6DE71EED7411DFE476A8" unitRef="usd">-12500000</us-gaap:IncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeLossFromEquityMethodInvestments contextRef="FD2016Q4YTD" decimals="-5" id="Fact-D5646DE3E200DBD5DCFE7411E02283E5" unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued contextRef="FI2016Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember" decimals="-5" id="Fact-22C2BBA94C6DF8D66DCF1892FDB8FDB4" unitRef="usd">58300000</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2014Q4YTD" decimals="-5" id="Fact-A83422215027AB4B56F57411DFD2007C" unitRef="usd">989900000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2014Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-B8E06732BBB442A5E0157411DFBCDDDA" unitRef="usd">-500000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2014Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-8E49A7FE6D579D0C6C2C7411E0051A47" unitRef="usd">-3500000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2015Q4YTD" decimals="-5" id="Fact-D8BF41E90DF604BED58D7411E0223503" unitRef="usd">1161600000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2015Q4YTD_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember" decimals="-5" id="Fact-EFBAA72FE70B8127100187C6199A4290" unitRef="usd">120200000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2015Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-489CB533CA31D46670C87411DFD98A2C" unitRef="usd">-800000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2015Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-AFD5D728BCA33846C3DE7411E012846C" unitRef="usd">700000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2016Q4YTD" decimals="-5" id="Fact-12BD804E87CEC5BEF4657411DFF43908" unitRef="usd">1237300000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2016Q4YTD_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember" decimals="-5" id="Fact-519739E117CF9D2799767411DFF5740B" unitRef="usd">173100000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2016Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-749134A738C7569427137411DFD8A30D" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2016Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-6BE9F8CC86DBFFF1A5167411E0093609" unitRef="usd">300000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxesPaidNet contextRef="FD2014Q4YTD" decimals="-5" id="Fact-37E61E65D61DAD3790827411E027D74C" unitRef="usd">1163200000</us-gaap:IncomeTaxesPaidNet>
	<us-gaap:IncomeTaxesPaidNet contextRef="FD2015Q4YTD" decimals="-5" id="Fact-1D22C9A119191EFCD0817411E026BCD6" unitRef="usd">1674800000</us-gaap:IncomeTaxesPaidNet>
	<us-gaap:IncomeTaxesPaidNet contextRef="FD2016Q4YTD" decimals="-5" id="Fact-3FF17CDC741373C4EE337411E0266167" unitRef="usd">1642200000</us-gaap:IncomeTaxesPaidNet>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="FD2014Q4YTD" decimals="-5" id="Fact-C5DD3702DA2998A411B17411E018D06E" unitRef="usd">512400000</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="FD2015Q4YTD" decimals="-5" id="Fact-DD31A1B6804BAA4D666E7411E018B1FD" unitRef="usd">-29000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="FD2016Q4YTD" decimals="-5" id="Fact-22233C825A095491EBED7411E0173A78" unitRef="usd">241400000</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable contextRef="FD2014Q4YTD" decimals="-5" id="Fact-7279B947A55C049AE7467411E0175A5A" unitRef="usd">40300000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
	<us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable contextRef="FD2015Q4YTD" decimals="-5" id="Fact-96BAFB5BC9D7F4B593727411E0154903" unitRef="usd">-429400000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
	<us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable contextRef="FD2016Q4YTD" decimals="-5" id="Fact-E6505C04FB608F80594A7411E01A76EC" unitRef="usd">-232600000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
	<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="FD2014Q4YTD" decimals="-5" id="Fact-7C6132E2FC541AD1BC4F7411E01621EF" unitRef="usd">244300000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="FD2015Q4YTD" decimals="-5" id="Fact-07D90C6A27D7F2E39FF27411E016946F" unitRef="usd">74200000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="FD2016Q4YTD" decimals="-5" id="Fact-8C7A199BC91C9A6DBEFA7411E01AD4C6" unitRef="usd">570100000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInInventories contextRef="FD2014Q4YTD" decimals="-5" id="Fact-AB3F252C23E108C633AD7411E014F03B" unitRef="usd">185900000</us-gaap:IncreaseDecreaseInInventories>
	<us-gaap:IncreaseDecreaseInInventories contextRef="FD2015Q4YTD" decimals="-5" id="Fact-13C35AC5630D2EE419217411E016F6D3" unitRef="usd">174400000</us-gaap:IncreaseDecreaseInInventories>
	<us-gaap:IncreaseDecreaseInInventories contextRef="FD2016Q4YTD" decimals="-5" id="Fact-573518014AA92C98F6CB7411E016D7B9" unitRef="usd">165600000</us-gaap:IncreaseDecreaseInInventories>
	<us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="FD2014Q4YTD" decimals="-5" id="Fact-DACBD052DAAB07B185B97411E015569D" unitRef="usd">108700000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
	<us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="FD2015Q4YTD" decimals="-5" id="Fact-6837895930D2708CB7BB7411E0161A83" unitRef="usd">127000000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
	<us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="FD2016Q4YTD" decimals="-5" id="Fact-F178569A8D685B287A3F7411E019F25E" unitRef="usd">-59100000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
	<us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet contextRef="FD2014Q4YTD" decimals="-5" id="Fact-657220F29DB429BBA92B7411E0201127" unitRef="usd">30700000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
	<us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet contextRef="FD2015Q4YTD" decimals="-5" id="Fact-D3EA8946B12AFE4AC6527411E016C863" unitRef="usd">31100000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
	<us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet contextRef="FD2016Q4YTD" decimals="-5" id="Fact-A7A8903E0AE4D1E485527411E01605D4" unitRef="usd">-13900000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
	<us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="FD2014Q4YTD" decimals="-5" id="Fact-6A6F2A291B91CC1C2F647411E0160571" unitRef="usd">68700000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
	<us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="FD2015Q4YTD" decimals="-5" id="Fact-48758E6205522EAA45BC7411E0193FAB" unitRef="usd">83200000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
	<us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="FD2016Q4YTD" decimals="-5" id="Fact-FE1D887AE87D42629ADA7411E0199BAC" unitRef="usd">69500000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2014Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember" decimals="-5" id="Fact-722109907C00DCE6FB777411DFDA22F3" unitRef="shares">200000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2014Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember" decimals="-5" id="Fact-6F4F03A511E0C53C942A7411DFDA0F49" unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2014Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="-5" id="Fact-B11A5A687E1FFC2FD01F7411DFDB30A7" unitRef="shares">500000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2015Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember" decimals="-5" id="Fact-E34F0E69261D8086CCBF7411DFDA3CEC" unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2015Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember" decimals="-5" id="Fact-B6C17DD76E8962E34C6E7411DFDE87A7" unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2015Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="-5" id="Fact-7FB5C2B818D7C94A69FA7411DFDA77D9" unitRef="shares">300000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2016Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember" decimals="-5" id="Fact-3CB99C9ADA41F874DAB97411DFDBB05C" unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2016Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember" decimals="-5" id="Fact-140A0C8626829F7D14777411DFDB139D" unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2016Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="-5" id="Fact-8280377BEAF2086911D17411DFDBACF6" unitRef="shares">200000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="FI2015Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" decimals="-5" id="Fact-01413056D46D6AF144917411E0262E8D" unitRef="usd">730500000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
	<us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="FI2015Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember" decimals="-5" id="Fact-381829FD7E70D96DE4197411DFFE15F9" unitRef="usd">64000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
	<us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="FI2016Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" decimals="-5" id="Fact-D6603FE6D3FB2031D0817411DFF79108" unitRef="usd">648000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
	<us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="FI2016Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember" decimals="-5" id="Fact-FEB8EBC37EAA4C99F4A87411DFF56047" unitRef="usd">64000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
	<us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="FI2015Q4" decimals="-5" id="Fact-39B3CBE809B62296E9D57411E0017E7E" unitRef="usd">7646300000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
	<us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="FI2016Q4" decimals="-5" id="Fact-87D968258A83FA8B84C17411E0267347" unitRef="usd">7742300000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
	<us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="FI2015Q4" decimals="-5" id="Fact-9FA622D99004EEE22F167411DFD98910" unitRef="usd">4085100000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
	<us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="FI2016Q4" decimals="-5" id="Fact-F0AAC719AA864F700E667411DFF2AD57" unitRef="usd">3808300000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
	<us-gaap:InterestCostsCapitalized contextRef="FD2014Q4YTD" decimals="-5" id="Fact-1D8CFE4CC10F8BB4F5E07411E026CEDF" unitRef="usd">6400000</us-gaap:InterestCostsCapitalized>
	<us-gaap:InterestCostsCapitalized contextRef="FD2015Q4YTD" decimals="-5" id="Fact-59DB43A60DDE7C1B15177411E0252D42" unitRef="usd">10400000</us-gaap:InterestCostsCapitalized>
	<us-gaap:InterestCostsCapitalized contextRef="FD2016Q4YTD" decimals="-5" id="Fact-F9CC4098BB0C5545542F7411E025CC38" unitRef="usd">12900000</us-gaap:InterestCostsCapitalized>
	<us-gaap:InterestExpense contextRef="FD2014Q4YTD" decimals="-5" id="Fact-688C14199BD6A50FCB327411E025C322" unitRef="usd">29500000</us-gaap:InterestExpense>
	<us-gaap:InterestExpense contextRef="FD2015Q4YTD" decimals="-5" id="Fact-0C800F034F4D877E60187411E01214A3" unitRef="usd">95500000</us-gaap:InterestExpense>
	<us-gaap:InterestExpense contextRef="FD2016Q4YTD" decimals="-5" id="Fact-1FB164CBF1F8301C015C7411E027F699" unitRef="usd">260000000</us-gaap:InterestExpense>
	<us-gaap:InterestPaidNet contextRef="FD2014Q4YTD" decimals="-5" id="Fact-BD83BCF9F2B70AB809987411E02679AD" unitRef="usd">41200000</us-gaap:InterestPaidNet>
	<us-gaap:InterestPaidNet contextRef="FD2015Q4YTD" decimals="-5" id="Fact-0C409BB9F26370007B537411E0275E86" unitRef="usd">39100000</us-gaap:InterestPaidNet>
	<us-gaap:InterestPaidNet contextRef="FD2016Q4YTD" decimals="-5" id="Fact-22A0C465BBD84B5D20337411E0260BA2" unitRef="usd">281200000</us-gaap:InterestPaidNet>
	<us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="FI2015Q4" decimals="-5" id="Fact-299E6AE331EEED14CDA67411E0269176" unitRef="usd">143000000</us-gaap:InventoryFinishedGoodsNetOfReserves>
	<us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="FI2016Q4" decimals="-5" id="Fact-983690F504EEDBC36A117411E026AA1C" unitRef="usd">170300000</us-gaap:InventoryFinishedGoodsNetOfReserves>
	<us-gaap:InventoryNet contextRef="FI2015Q4" decimals="-5" id="Fact-C3D32E16F5E02FF3DDDB7411DFDAB831" unitRef="usd">893400000</us-gaap:InventoryNet>
	<us-gaap:InventoryNet contextRef="FI2016Q4" decimals="-5" id="Fact-EFD7FD3915F09A817BE27411DFDF51CD" unitRef="usd">1001600000</us-gaap:InventoryNet>
	<us-gaap:InventoryNoncurrent contextRef="FI2015Q4" decimals="-5" id="Fact-935E9509CF5E5C36A6F97411E0276556" unitRef="usd">40200000</us-gaap:InventoryNoncurrent>
	<us-gaap:InventoryNoncurrent contextRef="FI2016Q4" decimals="-5" id="Fact-DB8CEE29CC2B1F9F22597411E0267FED" unitRef="usd">37800000</us-gaap:InventoryNoncurrent>
	<us-gaap:InventoryRawMaterialsNetOfReserves contextRef="FI2015Q4" decimals="-5" id="Fact-5DF237D73D368239251D7411E0269F73" unitRef="usd">213000000</us-gaap:InventoryRawMaterialsNetOfReserves>
	<us-gaap:InventoryRawMaterialsNetOfReserves contextRef="FI2016Q4" decimals="-5" id="Fact-85460BCC4853D81A3A917411E02764D5" unitRef="usd">170400000</us-gaap:InventoryRawMaterialsNetOfReserves>
	<us-gaap:InventoryWorkInProcessNetOfReserves contextRef="FI2015Q4" decimals="-5" id="Fact-09A930EBD01B254D366A7411E0269196" unitRef="usd">577600000</us-gaap:InventoryWorkInProcessNetOfReserves>
	<us-gaap:InventoryWorkInProcessNetOfReserves contextRef="FI2016Q4" decimals="-5" id="Fact-C5F8E191BBDBC01AD65B7411E0266F26" unitRef="usd">698700000</us-gaap:InventoryWorkInProcessNetOfReserves>
	<us-gaap:InventoryWriteDown contextRef="FD2014Q4YTD" decimals="-5" id="Fact-50C9EF472C91899DAE217411DFE1A727" unitRef="usd">50600000</us-gaap:InventoryWriteDown>
	<us-gaap:InventoryWriteDown contextRef="FD2015Q4YTD" decimals="-5" id="Fact-D2E7E6E62D7AB6163E327411DFE3F80C" unitRef="usd">41900000</us-gaap:InventoryWriteDown>
	<us-gaap:InventoryWriteDown contextRef="FD2016Q4YTD" decimals="-5" id="Fact-2C89BF6F6CFEF8CEFE6A7411DFDFB563" unitRef="usd">48200000</us-gaap:InventoryWriteDown>
	<us-gaap:InvestmentIncomeInterest contextRef="FD2014Q4YTD" decimals="-5" id="Fact-C7E620A6206FE698BB4A7411DFBBE1B9" unitRef="usd">12200000</us-gaap:InvestmentIncomeInterest>
	<us-gaap:InvestmentIncomeInterest contextRef="FD2015Q4YTD" decimals="-5" id="Fact-F714576CA146F8D8F74B7411E0245631" unitRef="usd">22100000</us-gaap:InvestmentIncomeInterest>
	<us-gaap:InvestmentIncomeInterest contextRef="FD2016Q4YTD" decimals="-5" id="Fact-2ABF636EE9252C9A07357411DFBBE263" unitRef="usd">63400000</us-gaap:InvestmentIncomeInterest>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-6F697C907240402289937411DFB70CCA" unitRef="usd">37500000</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-1AB6C870AB8BF03CE18F7411E0284011" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-A716F2C295380311C2C17411E0281E04" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-8DA0FC226C89953411877411DFB7CD61" unitRef="usd">37500000</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-D9625FC4E4FFB561B57C7411E01AE421" unitRef="usd">24900000</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-3CDBA8865D58177FB45C7411E018B0F8" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-5B268288D20DFE3FFBA57411E019E881" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-AE04A59E6E8E4B07AC937411E028C49D" unitRef="usd">24900000</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:Land contextRef="FI2015Q4" decimals="-5" id="Fact-DF76C633CF9217B048AA7411DFD8D0C5" unitRef="usd">74700000</us-gaap:Land>
	<us-gaap:Land contextRef="FI2016Q4" decimals="-5" id="Fact-44F3D3A1879EDC0B96847411DFD739FB" unitRef="usd">137800000</us-gaap:Land>
	<us-gaap:LeaseAndRentalExpense contextRef="FD2014Q4YTD" decimals="-5" id="Fact-52E62F43918D04A1EE2B7411DFF016D3" unitRef="usd">62400000</us-gaap:LeaseAndRentalExpense>
	<us-gaap:LeaseAndRentalExpense contextRef="FD2015Q4YTD" decimals="-5" id="Fact-FA9356B069F2B4550A867411E022CCEB" unitRef="usd">68600000</us-gaap:LeaseAndRentalExpense>
	<us-gaap:LeaseAndRentalExpense contextRef="FD2016Q4YTD" decimals="-5" id="Fact-52717105B1FE1B761E207411E02453DB" unitRef="usd">68700000</us-gaap:LeaseAndRentalExpense>
	<us-gaap:LeaseholdImprovementsGross contextRef="FI2015Q4" decimals="-5" id="Fact-F38F580B1F01788A9D497411DFD95F76" unitRef="usd">166600000</us-gaap:LeaseholdImprovementsGross>
	<us-gaap:LeaseholdImprovementsGross contextRef="FI2016Q4" decimals="-5" id="Fact-CC829CEE0348ACAD33667411DFD8D9C7" unitRef="usd">123700000</us-gaap:LeaseholdImprovementsGross>
	<us-gaap:LesseeLeasingArrangementsOperatingLeasesTermOfContract contextRef="FD2015Q3QTD_us-gaap_BusinessAcquisitionAxis_biib_EisaiMember" id="Fact-020F86F74B5B22C304A37411E02533DF">P10Y</us-gaap:LesseeLeasingArrangementsOperatingLeasesTermOfContract>
	<us-gaap:Liabilities contextRef="FI2015Q4" decimals="-5" id="Fact-20C3EDD4CC713BE7175C7411DFDFBD22" unitRef="usd">10129900000</us-gaap:Liabilities>
	<us-gaap:Liabilities contextRef="FI2016Q4" decimals="-5" id="Fact-900408C3E0247B8DB9B37411DFE31E22" unitRef="usd">10748200000</us-gaap:Liabilities>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2015Q4" decimals="-5" id="Fact-E703421369CD7F6C5BFB7411DFDD0CF5" unitRef="usd">19504800000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2016Q4" decimals="-5" id="Fact-B143E18EF8AF42A649617411DFD84C4F" unitRef="usd">22876800000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesCurrent contextRef="FI2015Q4" decimals="-5" id="Fact-15A02F925CA73148CFA47411DFD99822" unitRef="usd">2577700000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LiabilitiesCurrent contextRef="FI2016Q4" decimals="-5" id="Fact-42DDC17FF9C06D7B2DF57411DFD8292F" unitRef="usd">3419900000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-4744F56B27210DA8D7EC7411E028B9A3" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-8F06B22A193766A8C4787411E02E2C77" unitRef="usd">14700000</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-BD3F75CF8BEDBC08B0077411E0281E35" unitRef="usd">506000000</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-CC50E3E1D18AAD2077567411E029A843" unitRef="usd">520700000</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-57602B0FEC8EE6215EFC7411E00014BD" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-874E4431642F5B4B37B57411E0216CB9" unitRef="usd">13600000</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-48604578BA2C7CB06E757411DFFF307C" unitRef="usd">467600000</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-05204665F6A2BFA3F7927411E0015ACB" unitRef="usd">481200000</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilityForUncertainTaxPositionsCurrent contextRef="FI2016Q4" decimals="-5" id="Fact-4EC8F32DA35325E165597411E0170D66" unitRef="usd">47800000</us-gaap:LiabilityForUncertainTaxPositionsCurrent>
	<us-gaap:LicenseCosts contextRef="FD2015Q3QTD_us-gaap_TypeOfArrangementAxis_biib_AGTCMember" decimals="-5" id="Fact-2F0E5BF940C86C20E7247411DFE59F61" unitRef="usd">35600000</us-gaap:LicenseCosts>
	<us-gaap:LineOfCreditFacilityExpirationPeriod contextRef="FD2015Q4YTD" id="Fact-1CD28545746106F5396E7411E0099FF8">P5Y</us-gaap:LineOfCreditFacilityExpirationPeriod>
	<us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding contextRef="FI2016Q4" decimals="0" id="Fact-2623828D6B462E4ECDD67411DFF1F17D" unitRef="usd">0</us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding>
	<us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="FI2015Q4" decimals="-8" id="Fact-E2AEC86E9D725E00C2E4884858B79CEA" unitRef="usd">1000000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
	<us-gaap:LitigationReserve contextRef="FI2015Q4" decimals="-5" id="Fact-F42D92B6BC8AFF2B78E97411DFD16522" unitRef="usd">0</us-gaap:LitigationReserve>
	<us-gaap:LitigationReserve contextRef="FI2016Q4" decimals="-5" id="Fact-457C84A716775AD1AFC07411DFD1128D" unitRef="usd">454800000</us-gaap:LitigationReserve>
	<us-gaap:LitigationSettlementAmount contextRef="FD2016Q4YTD" decimals="-7" id="Fact-EBBA8973CF9D3F8735EAD2410639F98A" unitRef="usd">1250000000</us-gaap:LitigationSettlementAmount>
	<us-gaap:LitigationSettlementExpense contextRef="FD2014Q4YTD" decimals="-5" id="Fact-4D273281E99EFFC6005AD0D34849DDF0" unitRef="usd">0</us-gaap:LitigationSettlementExpense>
	<us-gaap:LitigationSettlementExpense contextRef="FD2015Q4YTD" decimals="-5" id="Fact-FDBBBB68D30BDFCCD6E8D0D322D51E25" unitRef="usd">0</us-gaap:LitigationSettlementExpense>
	<us-gaap:LitigationSettlementExpense contextRef="FD2016Q4YTD" decimals="-5" id="Fact-FFDDBC438B02D87D2F8DD0D2EB8D23F5" unitRef="usd">454800000</us-gaap:LitigationSettlementExpense>
	<us-gaap:LitigationSettlementExpense contextRef="FD2016Q4YTD_us-gaap_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-E102A373DC69C8A0FF6BD718AE3ABDF2" unitRef="usd">656300000</us-gaap:LitigationSettlementExpense>
	<us-gaap:LitigationSettlementExpense contextRef="FD2016Q4YTD_us-gaap_StatementGeographicalAxis_us-gaap_EuropeanUnionMember" decimals="-5" id="Fact-C9E2B4AA79FA06960BA4D718BACB7C54" unitRef="usd">138900000</us-gaap:LitigationSettlementExpense>
	<us-gaap:LongTermDebt contextRef="FI2015Q4" decimals="-5" id="Fact-FF94CDD7D0B894D24CCD7411DFDEEBE0" unitRef="usd">6521500000</us-gaap:LongTermDebt>
	<us-gaap:LongTermDebt contextRef="FI2016Q4" decimals="-5" id="Fact-91975BA0C5656A88B4737411DFE03D45" unitRef="usd">6512700000</us-gaap:LongTermDebt>
	<us-gaap:LongTermDebtAndCapitalLeaseObligations contextRef="FI2015Q4" decimals="-5" id="Fact-A1484D5734C2A71E94277411E012B90A" unitRef="usd">18100000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
	<us-gaap:LongTermDebtAndCapitalLeaseObligations contextRef="FI2016Q4" decimals="-5" id="Fact-A83CD51F2D61758A2D417411E00C669F" unitRef="usd">16400000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
	<us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent contextRef="FI2015Q4" decimals="-5" id="Fact-A54ACADA5D053B2FEAA47411E0126FB7" unitRef="usd">1700000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
	<us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent contextRef="FI2016Q4" decimals="-5" id="Fact-DBCFEB5EB0A0BB522A5B7411E00BE176" unitRef="usd">1700000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
	<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive contextRef="FI2016Q4" decimals="-5" id="Fact-3E109266B80BE5C1D2F37411DFCEFC5B" unitRef="usd">4500000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive>
	<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths contextRef="FI2016Q4" decimals="-5" id="Fact-6BD4D6C4651C0B83685D7411DFCEDBFB" unitRef="usd">3100000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
	<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive contextRef="FI2016Q4" decimals="-5" id="Fact-2D35F03FA60B85FB749E885509B1C50E" unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
	<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour contextRef="FI2016Q4" decimals="-5" id="Fact-A623C169EFD628B224227411DFCFA95E" unitRef="usd">1500000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
	<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree contextRef="FI2016Q4" decimals="-5" id="Fact-AD1D64E93EBC00B979477411DFCEDB32" unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
	<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo contextRef="FI2016Q4" decimals="-5" id="Fact-88B143006363E6C2F9D97411DFCFC958" unitRef="usd">553100000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
	<us-gaap:LongTermNotesPayable contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" decimals="-5" id="Fact-087C0592D48B1CCEE64C7411DFE38EB3" unitRef="usd">1721100000</us-gaap:LongTermNotesPayable>
	<us-gaap:LongTermNotesPayable contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" decimals="-5" id="Fact-9946F3FAC24A491166387411E00BA8C9" unitRef="usd">1733400000</us-gaap:LongTermNotesPayable>
	<us-gaap:LongTermNotesPayable contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" decimals="-5" id="Fact-2550849998A4BBD4D9CA7411E012EC19" unitRef="usd">565300000</us-gaap:LongTermNotesPayable>
	<us-gaap:LongTermNotesPayable contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" decimals="-5" id="Fact-DF1B4A8C2455F051E6B67411E0076F9B" unitRef="usd">992200000</us-gaap:LongTermNotesPayable>
	<us-gaap:LongTermNotesPayable contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" decimals="-5" id="Fact-47345FCC0606CC1B86F87411E0074057" unitRef="usd">1485500000</us-gaap:LongTermNotesPayable>
	<us-gaap:LongTermNotesPayable contextRef="FI2015Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableOtherPayablesMember" decimals="-5" id="Fact-FDA5BA15109775361FA47411DFD71FAA" unitRef="usd">5900000</us-gaap:LongTermNotesPayable>
	<us-gaap:LongTermNotesPayable contextRef="FI2016Q4" decimals="-5" id="Fact-CC5145E97AA55877A1347411DFCE264B" unitRef="usd">6556200000</us-gaap:LongTermNotesPayable>
	<us-gaap:LongTermNotesPayable contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" decimals="-5" id="Fact-0DFAF15C671C612237BB7411DFE57902" unitRef="usd">1721500000</us-gaap:LongTermNotesPayable>
	<us-gaap:LongTermNotesPayable contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" decimals="-5" id="Fact-3E8FEB1D50EF167AF6447411E0035C8E" unitRef="usd">1734800000</us-gaap:LongTermNotesPayable>
	<us-gaap:LongTermNotesPayable contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" decimals="-5" id="Fact-A5BF4D4EC2F8A99F50967411E0129F7E" unitRef="usd">558500000</us-gaap:LongTermNotesPayable>
	<us-gaap:LongTermNotesPayable contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" decimals="-5" id="Fact-059DF9EA3C58E83444107411DFCFD265" unitRef="usd">993200000</us-gaap:LongTermNotesPayable>
	<us-gaap:LongTermNotesPayable contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" decimals="-5" id="Fact-CA01C4FE4A99DE91B8047411E00B58CE" unitRef="usd">1485300000</us-gaap:LongTermNotesPayable>
	<us-gaap:LongTermNotesPayable contextRef="FI2016Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableOtherPayablesMember" decimals="-5" id="Fact-0E5FD024B35203BF50407411E017DB95" unitRef="usd">3000000</us-gaap:LongTermNotesPayable>
	<us-gaap:LongTermNotesPayable contextRef="I2006Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableOtherPayablesMember" decimals="-5" id="Fact-07E58A2AED2AB32963507411DFEF3469" unitRef="chf">61400000</us-gaap:LongTermNotesPayable>
	<us-gaap:LossContingencyAccrualAtCarryingValue contextRef="FI2013Q2_us-gaap_StatementGeographicalAxis_country_IT" decimals="-5" id="Fact-943F375754A97180EDFF88A0EF7F39BD" unitRef="usd">15400000</us-gaap:LossContingencyAccrualAtCarryingValue>
	<us-gaap:LossContingencyEstimateOfPossibleLoss contextRef="FI2011Q4_us-gaap_StatementGeographicalAxis_country_IT" decimals="-5" id="Fact-347EB694FBBB1A71D656889FD532ABC0" unitRef="usd">30700000</us-gaap:LossContingencyEstimateOfPossibleLoss>
	<us-gaap:LossContingencyEstimateOfPossibleLoss contextRef="FI2013Q2_us-gaap_StatementGeographicalAxis_country_IT" decimals="-5" id="Fact-1391029A09318CCE3ED888A02D91281E" unitRef="usd">33300000</us-gaap:LossContingencyEstimateOfPossibleLoss>
	<us-gaap:LossContingencyEstimateOfPossibleLoss contextRef="FI2016Q4_us-gaap_StatementGeographicalAxis_country_IT" decimals="-5" id="Fact-48501A639D9328F596FCD782EDFF2486" unitRef="usd">37400000</us-gaap:LossContingencyEstimateOfPossibleLoss>
	<us-gaap:MachineryAndEquipmentGross contextRef="FI2015Q4" decimals="-5" id="Fact-E28B74129E3F2FAE8D467411DFD76474" unitRef="usd">1079600000</us-gaap:MachineryAndEquipmentGross>
	<us-gaap:MachineryAndEquipmentGross contextRef="FI2016Q4" decimals="-5" id="Fact-5B3E3316BE4EB60E9F397411DFDB96C3" unitRef="usd">1105800000</us-gaap:MachineryAndEquipmentGross>
	<us-gaap:MaximumRemainingMaturityOfForeignCurrencyDerivatives1 contextRef="FD2016Q4YTD" id="Fact-2CD8312D9408790478127411DFF6CF0D">P18M</us-gaap:MaximumRemainingMaturityOfForeignCurrencyDerivatives1>
	<us-gaap:MinorityInterest contextRef="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" decimals="-5" id="Fact-E110D9452C6D8748F90A7411DFF108CA" unitRef="usd">600000</us-gaap:MinorityInterest>
	<us-gaap:MinorityInterest contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" decimals="-5" id="Fact-0432DA6F80F599A95B4C7411DFEE588E" unitRef="usd">5000000</us-gaap:MinorityInterest>
	<us-gaap:MinorityInterest contextRef="FI2015Q4" decimals="-5" id="Fact-4C459A28784353F32D557411DFD8B575" unitRef="usd">2100000</us-gaap:MinorityInterest>
	<us-gaap:MinorityInterest contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" decimals="-5" id="Fact-92806A0C16687B1541247411DFEE82D3" unitRef="usd">2100000</us-gaap:MinorityInterest>
	<us-gaap:MinorityInterest contextRef="FI2016Q4" decimals="-5" id="Fact-4EF0F066CD46C120F6217411DFDFE863" unitRef="usd">-11500000</us-gaap:MinorityInterest>
	<us-gaap:MinorityInterest contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" decimals="-5" id="Fact-42B1E951176F771476D37411DFEEFB0E" unitRef="usd">-11500000</us-gaap:MinorityInterest>
	<us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders contextRef="FD2014Q4YTD" decimals="-5" id="Fact-9D6BC9CD3524C75594547411DFEF29AD" unitRef="usd">9100000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
	<us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" decimals="-5" id="Fact-BA1773218FC119F6D01E7411DFF26F63" unitRef="usd">9100000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
	<us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" decimals="-5" id="Fact-E7D249857B3AC865A8BC7411DFF09E34" unitRef="usd">0</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
	<us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders contextRef="FD2015Q4YTD" decimals="-5" id="Fact-5123BD30B5050C37B4618D86FD9AA41C" unitRef="usd">60000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
	<us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" decimals="-5" id="Fact-C320555E662012F1E8C98D867BFE83CB" unitRef="usd">-60000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
	<us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" decimals="-5" id="Fact-C57151E0224D8F91905E8D867C08CF91" unitRef="usd">0</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
	<us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders contextRef="FD2016Q4YTD" decimals="-5" id="Fact-2DCF1FF8E22E0B0B9EA07411DFEE2839" unitRef="usd">1500000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
	<us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" decimals="-5" id="Fact-5C4F4426B2BBA8FC083A7411DFE27CE6" unitRef="usd">-1500000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
	<us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" decimals="-5" id="Fact-F9F80DBB4789526EE0407411E00800D6" unitRef="usd">0</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2014Q4YTD" decimals="-5" id="Fact-C632771762F10C64DF7B7411E0155576" unitRef="usd">-755900000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2015Q4YTD" decimals="-5" id="Fact-D5B2BD85C326394EED587411E0162633" unitRef="usd">986400000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2016Q4YTD" decimals="-5" id="Fact-AEF563A6315A41DF862F7411E016E1C9" unitRef="usd">-987800000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2014Q4YTD" decimals="-5" id="Fact-483DEB69FABEB09C41187411E019E565" unitRef="usd">-1543000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2015Q4YTD" decimals="-5" id="Fact-D4CF5253DD1E5E917CB67411E01A5BF2" unitRef="usd">-4553600000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2016Q4YTD" decimals="-5" id="Fact-E20A22FD6A01A3CE3CF57411E0198741" unitRef="usd">-2484800000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2014Q4YTD" decimals="-5" id="Fact-9A2394CE149E7625CE4D7411E01902EF" unitRef="usd">2942100000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2015Q4YTD" decimals="-5" id="Fact-B4D7D81E2F7B927296D77411E0179026" unitRef="usd">3716100000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2016Q4YTD" decimals="-5" id="Fact-6F7F21A5C6E73E3F10797411E01792D4" unitRef="usd">4522400000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetIncomeLoss contextRef="FD2014Q4YTD" decimals="-5" id="Fact-574C57C062E50BE6BEEB7411DFE144DB" unitRef="usd">2934800000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2014Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" decimals="-5" id="Fact-79777330845F1A7ACF107411E0111E08" unitRef="usd">12700000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-5" id="Fact-755B209DAD396FB74A107411DFF1D1AA" unitRef="usd">2934800000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2015Q1YTD" decimals="-5" id="Fact-6BD2FF8FF21ED0F9BE797411DFE59EE6" unitRef="usd">822500000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2015Q2QTD" decimals="-5" id="Fact-47205F414760EC1DAACD7411DFC9EF20" unitRef="usd">927300000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2015Q3QTD" decimals="-5" id="Fact-B16F150E99C47C35C86E7411DFCBB594" unitRef="usd">965600000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2015Q4QTD" decimals="-5" id="Fact-5B15086706C577C6AF8F7411DFE58F77" unitRef="usd">831600000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2015Q4YTD" decimals="-5" id="Fact-DB307911A952B9219A8D7411DFCE20F3" unitRef="usd">3547000000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2015Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" decimals="-5" id="Fact-34FDEDDAF412773F22E57411E00A437B" unitRef="usd">171000000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-5" id="Fact-F2A03B4396630701F0947411DFBAC04B" unitRef="usd">3547000000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2016Q1QTD" decimals="-5" id="Fact-5DF069E1B4397DCCF2467411E0076018" unitRef="usd">970900000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2016Q2QTD" decimals="-5" id="Fact-ED691BC1381DE4F3ABF07411DFFECA7D" unitRef="usd">1049800000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2016Q3QTD" decimals="-5" id="Fact-8A51E551082BA991E5187411DFB872AA" unitRef="usd">1032900000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2016Q4QTD" decimals="-5" id="Fact-925DC70EF2FB3FBF80697411E00775D5" unitRef="usd">649200000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2016Q4YTD" decimals="-5" id="Fact-3445D0112A0DC02E7F937411DFE0FDDF" unitRef="usd">3702800000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2016Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" decimals="-5" id="Fact-6805089AC783B1FF91A17411E00B70BF" unitRef="usd">3400000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-5" id="Fact-7AA5FBCA9DF712438AB97411DFF20B2F" unitRef="usd">3702800000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="FD2014Q4YTD" decimals="-5" id="Fact-03A65104AF789F16A5F17411E02571C6" unitRef="usd">6800000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
	<us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" decimals="-5" id="Fact-CAB38BF43498CB4FD14A7411DFEF2A46" unitRef="usd">6800000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
	<us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="FD2015Q3QTD_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_NeurimmuneMember" decimals="-5" id="Fact-B7B2B7ABDB2EBF0AB02F7411E0257E43" unitRef="usd">60000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
	<us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="FD2015Q4YTD" decimals="-5" id="Fact-0D94F4785DAB61AC877D7411DFE1E3D1" unitRef="usd">46200000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
	<us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" decimals="-5" id="Fact-F9B36A6DC634C1F917777411DFB92866" unitRef="usd">46200000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
	<us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="FD2016Q4YTD" decimals="-5" id="Fact-6431C8644ABF1E57E4107411DFC74958" unitRef="usd">-7100000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
	<us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" decimals="-5" id="Fact-30D8C5BFB4CC47BE16597411DFEF96F1" unitRef="usd">-7100000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
	<us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation contextRef="FD2016Q4YTD" decimals="-5" id="Fact-5533DCE7B4FD5A293B95D1174F054E21" unitRef="usd">7500000</us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation>
	<us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" decimals="-5" id="Fact-2B2B6EC2CA702B264D99D1171871B9CC" unitRef="usd">7500000</us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation>
	<us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" decimals="-5" id="Fact-86D4D34D2DFD8BD19906D1168A624CAD" unitRef="usd">0</us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation>
	<us-gaap:NoncontrollingInterestInVariableInterestEntity contextRef="FI2015Q4_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_RodinTherapeuticsMember" decimals="-5" id="Fact-BD28CD6C1A3108A359FB189E89D3590B" unitRef="usd">10900000</us-gaap:NoncontrollingInterestInVariableInterestEntity>
	<us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination contextRef="FD2015Q4YTD" decimals="-5" id="Fact-0B7CEBBEE734C984CA0E7411DFBAAFF2" unitRef="usd">10900000</us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination>
	<us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" decimals="-5" id="Fact-89CF7D1E145A429F4C917411DFB9B389" unitRef="usd">10900000</us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination>
	<us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" decimals="-5" id="Fact-91966A069C5C71B18E967411DFB96A4E" unitRef="usd">0</us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination>
	<us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination contextRef="FD2016Q4YTD" decimals="-5" id="Fact-992F717F129A52247DE57411DFEF9B03" unitRef="usd">600000</us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination>
	<us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" decimals="-5" id="Fact-044459B9EE9FD97691867411DFEE6C6A" unitRef="usd">-600000</us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination>
	<us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" decimals="-5" id="Fact-5DF957FBF5F91FF51A687411DFEC53B2" unitRef="usd">0</us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination>
	<us-gaap:NoncurrentAssets contextRef="FI2014Q4" decimals="-5" id="Fact-8EB250DE458437FB6E697411E0238B44" unitRef="usd">1765700000</us-gaap:NoncurrentAssets>
	<us-gaap:NoncurrentAssets contextRef="FI2014Q4_us-gaap_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember" decimals="-5" id="Fact-D71902AB523461EE44197411DFF673E2" unitRef="usd">3200000</us-gaap:NoncurrentAssets>
	<us-gaap:NoncurrentAssets contextRef="FI2014Q4_us-gaap_StatementGeographicalAxis_country_DE" decimals="-5" id="Fact-26759A76EDBA01BE9EAF7411E024543C" unitRef="usd">2500000</us-gaap:NoncurrentAssets>
	<us-gaap:NoncurrentAssets contextRef="FI2014Q4_us-gaap_StatementGeographicalAxis_country_DK" decimals="-5" id="Fact-3F3980A4BD2C10E6BF8E7411DFB9C86F" unitRef="usd">676000000</us-gaap:NoncurrentAssets>
	<us-gaap:NoncurrentAssets contextRef="FI2014Q4_us-gaap_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-64310251648CF937288C7411E0096850" unitRef="usd">1055500000</us-gaap:NoncurrentAssets>
	<us-gaap:NoncurrentAssets contextRef="FI2014Q4_us-gaap_StatementGeographicalAxis_us-gaap_AsiaMember" decimals="-5" id="Fact-FB85DE971AFECCB930DE7411E028ACCE" unitRef="usd">2600000</us-gaap:NoncurrentAssets>
	<us-gaap:NoncurrentAssets contextRef="FI2014Q4_us-gaap_StatementGeographicalAxis_us-gaap_EuropeMember" decimals="-5" id="Fact-7445B803AB132A7E14DE7411E0222411" unitRef="usd">701900000</us-gaap:NoncurrentAssets>
	<us-gaap:NoncurrentAssets contextRef="FI2015Q4" decimals="-5" id="Fact-F1E60819D275BBA29A6D7411DFD86C87" unitRef="usd">2187600000</us-gaap:NoncurrentAssets>
	<us-gaap:NoncurrentAssets contextRef="FI2015Q4_us-gaap_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember" decimals="-5" id="Fact-CFA597DE45695A97FEDD7411E01239A7" unitRef="usd">1700000</us-gaap:NoncurrentAssets>
	<us-gaap:NoncurrentAssets contextRef="FI2015Q4_us-gaap_StatementGeographicalAxis_biib_SolothurnMember" decimals="-5" id="Fact-6D3FEE4565E9BD21076BD6450EB9794E" unitRef="usd">161500000</us-gaap:NoncurrentAssets>
	<us-gaap:NoncurrentAssets contextRef="FI2015Q4_us-gaap_StatementGeographicalAxis_country_DE" decimals="-5" id="Fact-0CC0AD60C7FA8AA11CAD7411E003430C" unitRef="usd">2300000</us-gaap:NoncurrentAssets>
	<us-gaap:NoncurrentAssets contextRef="FI2015Q4_us-gaap_StatementGeographicalAxis_country_DK" decimals="-5" id="Fact-AD633213C4F5E07001507411DFBB0FDC" unitRef="usd">684900000</us-gaap:NoncurrentAssets>
	<us-gaap:NoncurrentAssets contextRef="FI2015Q4_us-gaap_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-38C4F7116C4766F7A6F67411E0259467" unitRef="usd">1296500000</us-gaap:NoncurrentAssets>
	<us-gaap:NoncurrentAssets contextRef="FI2015Q4_us-gaap_StatementGeographicalAxis_us-gaap_AsiaMember" decimals="-5" id="Fact-1C3E668E5B98BC09B3657411E006CF32" unitRef="usd">7700000</us-gaap:NoncurrentAssets>
	<us-gaap:NoncurrentAssets contextRef="FI2015Q4_us-gaap_StatementGeographicalAxis_us-gaap_EuropeMember" decimals="-5" id="Fact-23CDB8F58AEC88F990C77411E002D31D" unitRef="usd">879400000</us-gaap:NoncurrentAssets>
	<us-gaap:NoncurrentAssets contextRef="FI2016Q4" decimals="-5" id="Fact-B7DAE3E37FE3FDD1D05C7411DFE500DD" unitRef="usd">2501800000</us-gaap:NoncurrentAssets>
	<us-gaap:NoncurrentAssets contextRef="FI2016Q4_us-gaap_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember" decimals="-5" id="Fact-DB9B20029F2C64E319937411E0271EC2" unitRef="usd">1400000</us-gaap:NoncurrentAssets>
	<us-gaap:NoncurrentAssets contextRef="FI2016Q4_us-gaap_StatementGeographicalAxis_biib_SolothurnMember" decimals="-5" id="Fact-562EAC5C636B8CB8C072D6447ACE90CD" unitRef="usd">545500000</us-gaap:NoncurrentAssets>
	<us-gaap:NoncurrentAssets contextRef="FI2016Q4_us-gaap_StatementGeographicalAxis_country_DE" decimals="-5" id="Fact-2A408473337D0C331CED7411E026E363" unitRef="usd">1800000</us-gaap:NoncurrentAssets>
	<us-gaap:NoncurrentAssets contextRef="FI2016Q4_us-gaap_StatementGeographicalAxis_country_DK" decimals="-5" id="Fact-282C7D433FDEF3073EA07411DFB908CD" unitRef="usd">643600000</us-gaap:NoncurrentAssets>
	<us-gaap:NoncurrentAssets contextRef="FI2016Q4_us-gaap_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-6074AC6ECBAF469DF1DE7411E027AB83" unitRef="usd">1272300000</us-gaap:NoncurrentAssets>
	<us-gaap:NoncurrentAssets contextRef="FI2016Q4_us-gaap_StatementGeographicalAxis_us-gaap_AsiaMember" decimals="-5" id="Fact-36116D785923C8AE09D97411E0233D63" unitRef="usd">7000000</us-gaap:NoncurrentAssets>
	<us-gaap:NoncurrentAssets contextRef="FI2016Q4_us-gaap_StatementGeographicalAxis_us-gaap_EuropeMember" decimals="-5" id="Fact-54F40D534FE85FAE151F7411E002D2AC" unitRef="usd">1219300000</us-gaap:NoncurrentAssets>
	<us-gaap:NotesPayableCurrent contextRef="FI2015Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableOtherPayablesMember" decimals="-5" id="Fact-510C0888AA6C2DFBC42A7411E007F726" unitRef="usd">3100000</us-gaap:NotesPayableCurrent>
	<us-gaap:NotesPayableCurrent contextRef="FI2016Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableOtherPayablesMember" decimals="-5" id="Fact-66B4ACF9E11A5FD1295E7411E00A9003" unitRef="usd">3000000</us-gaap:NotesPayableCurrent>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_NotesPayableToFumedicaMember" decimals="-5" id="Fact-1BB49AE0AE989C970A307411E0243D31" unitRef="usd">9400000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" decimals="-5" id="Fact-B04866D530C00B809ED17411E0243C56" unitRef="usd">1757600000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" decimals="-5" id="Fact-4FB8177922A90E1F8D6C7411E0242D28" unitRef="usd">1764600000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" decimals="-5" id="Fact-CAC10D800242DDC5F7FA7411E0244A5E" unitRef="usd">602600000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" decimals="-5" id="Fact-7BE8D5E4649F3A13159B7411E024D925" unitRef="usd">1014200000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" decimals="-5" id="Fact-DDDA005FD2655819F6557411E024AE4D" unitRef="usd">1497500000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_biib_NotesPayableToFumedicaMember" decimals="-5" id="Fact-7FE704A8992FC8A2678D7411E024CE2F" unitRef="usd">6100000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" decimals="-5" id="Fact-974688B4600C33551E4A7411E0246590" unitRef="usd">1874500000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" decimals="-5" id="Fact-A889D6D393EB546057C87411E024E302" unitRef="usd">1796000000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" decimals="-5" id="Fact-F82205E5335484FD127F7411E0249C9C" unitRef="usd">583700000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" decimals="-5" id="Fact-5DDC611C8B469A6376B47411E0243086" unitRef="usd">1026600000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" decimals="-5" id="Fact-CED205EA129BFFDA470E7411E024F56A" unitRef="usd">1521500000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NumberOfReportableSegments contextRef="FD2016Q4YTD" decimals="0" id="Fact-B464A84FDE33DF670C157411DFB9B74E" unitRef="segment">1</us-gaap:NumberOfReportableSegments>
	<us-gaap:OperatingExpenses contextRef="FD2014Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-0CD11D75723E9B6F462B188814B1B2BA" unitRef="usd">0</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2015Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-343312C05B638636169F1887D695E261" unitRef="usd">0</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2016Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-E9DE7E8F6FFD1596B4CF18876998DEBE" unitRef="usd">1500000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingIncomeLoss contextRef="FD2014Q4YTD" decimals="-5" id="Fact-7CDEE1D3F505168B76877411DFF8AA12" unitRef="usd">3972400000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2015Q4YTD" decimals="-5" id="Fact-D8389A9CCC9BCBDF27B37411DFBB0D85" unitRef="usd">4891000000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2016Q4YTD" decimals="-5" id="Fact-15CD36535F25DE7821C57411DFE53566" unitRef="usd">5150400000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="FI2016Q4" decimals="-5" id="Fact-E80DE0A9AFA66638D0A57411E01A8C42" unitRef="usd">676400000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="FI2016Q4" decimals="-5" id="Fact-BF72D7439D71B63984D07411E01B12D3" unitRef="usd">75300000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears contextRef="FI2016Q4" decimals="-5" id="Fact-E8F5F26158309F77F6CE7411E01A7626" unitRef="usd">64600000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears contextRef="FI2016Q4" decimals="-5" id="Fact-AD2EC31740FC11054BFC7411E01B84AA" unitRef="usd">65700000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="FI2016Q4" decimals="-5" id="Fact-2A80796B4E028BCA2B217411E01A994A" unitRef="usd">69100000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="FI2016Q4" decimals="-5" id="Fact-94FDB61B830F211E47C37411E019D154" unitRef="usd">69800000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter contextRef="FI2016Q4" decimals="-5" id="Fact-1E4EBFF216E39A367A527411E0190C74" unitRef="usd">331900000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter>
	<us-gaap:OperatingLossCarryforwards contextRef="FI2016Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_GeneralBusinessMember" decimals="-5" id="Fact-B33C435971CBA399299C7411DFEB866F" unitRef="usd">22500000</us-gaap:OperatingLossCarryforwards>
	<us-gaap:OperatingLossCarryforwards contextRef="FI2016Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_GeneralBusinessMember" decimals="-5" id="Fact-9995F1F26563BB8260467411DFED4477" unitRef="usd">489400000</us-gaap:OperatingLossCarryforwards>
	<us-gaap:OtherAccruedLiabilitiesCurrent contextRef="FI2015Q4" decimals="-5" id="Fact-5902BBB5137E856991957411DFD15CC0" unitRef="usd">516200000</us-gaap:OtherAccruedLiabilitiesCurrent>
	<us-gaap:OtherAccruedLiabilitiesCurrent contextRef="FI2016Q4" decimals="-5" id="Fact-CE34EB98AC7762E5C82F7411DFD23CE8" unitRef="usd">685700000</us-gaap:OtherAccruedLiabilitiesCurrent>
	<us-gaap:OtherAssetsCurrent contextRef="FI2015Q4" decimals="-5" id="Fact-537A028AD5952598EFF87411DFD0FAB4" unitRef="usd">836900000</us-gaap:OtherAssetsCurrent>
	<us-gaap:OtherAssetsCurrent contextRef="FI2016Q4" decimals="-5" id="Fact-BF7431E63428322B14D27411DFDA4AC1" unitRef="usd">1093300000</us-gaap:OtherAssetsCurrent>
	<us-gaap:OtherAssetsNoncurrent contextRef="FI2015Q4" decimals="-5" id="Fact-AE974F69C7205E6B2B717411DFEFE20B" unitRef="usd">1107600000</us-gaap:OtherAssetsNoncurrent>
	<us-gaap:OtherAssetsNoncurrent contextRef="FI2016Q2_us-gaap_TypeOfArrangementAxis_biib_UniversityofPennsylvaniaMember" decimals="-5" id="Fact-719AC1BC97EF5A79E1BB8CFA5628DD60" unitRef="usd">15000000</us-gaap:OtherAssetsNoncurrent>
	<us-gaap:OtherAssetsNoncurrent contextRef="FI2016Q4" decimals="-5" id="Fact-CDADBFD904AD183D05E07411DFF311F9" unitRef="usd">1335800000</us-gaap:OtherAssetsNoncurrent>
	<us-gaap:OtherCommitment contextRef="FI2016Q4" decimals="-5" id="Fact-AD063F3EC4E8DB1E25E47411E01AB34A" unitRef="usd">500000000</us-gaap:OtherCommitment>
	<us-gaap:OtherCommitment contextRef="FI2016Q4_biib_FacilityLocationAxis_biib_SolothurnMember" decimals="-5" id="Fact-508331387E1776DB478FD239C01FFEAE" unitRef="usd">176300000</us-gaap:OtherCommitment>
	<us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="FD2014Q4YTD" decimals="-5" id="Fact-84C09B36DBD0952B6EF77411E01B5280" unitRef="usd">-6000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="FD2015Q4YTD" decimals="-5" id="Fact-C5D0F34A79650BAFEBE57411DFCDC511" unitRef="usd">-400000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="FD2016Q4YTD" decimals="-5" id="Fact-D0BECE9B825A6487FA4A7411E02101EC" unitRef="usd">-10000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2014Q4YTD" decimals="-5" id="Fact-B4B62872FD582C7B51277411E006770F" unitRef="usd">-19100000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-AEF9BF5F2B7EE98E85CB7411E0073CFF" unitRef="usd">-12000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-F52C7E8ED275B0FA4BAE7411E009B872" unitRef="usd">101700000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-6D48B1240BF729132A257411E009D0E7" unitRef="usd">400000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-3C5A45BAF9FA320983B67411DFFE0A5C" unitRef="usd">-109200000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2015Q4YTD" decimals="-5" id="Fact-ACC8F16B646F8A5277307411DFCD939D" unitRef="usd">6500000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2015Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember" decimals="-5" id="Fact-9184ECB4A646007D730F882244FAA8F5" unitRef="usd">8500000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-194B71538F1BAAD135BC7411DFCDC240" unitRef="usd">-6200000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-35DDFF35FE9F1402DA8E7411E009114E" unitRef="usd">110800000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-D669FEB283EEB4CC43EA7411E0077A83" unitRef="usd">-1700000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-3985DEB01A22C127412E7411DFCDF342" unitRef="usd">-96400000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2016Q4YTD" decimals="-5" id="Fact-79160EC0194577867E2F7411E0051E8E" unitRef="usd">-92500000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-AFD64866E78E3062064A7411DFE17C58" unitRef="usd">5100000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-1B1437FF90C4BD1A96FC7411DFE3BE51" unitRef="usd">51600000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-12CB68BA4DC92D14C3207411E009C04F" unitRef="usd">-10600000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-CDA707A571BC8D4D2C9D7411E009FA25" unitRef="usd">-138600000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax contextRef="FD2014Q4YTD" decimals="-5" id="Fact-E066AAA1D61A84E627AC7411E025E0D5" unitRef="usd">95400000</us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax contextRef="FD2015Q4YTD" decimals="-5" id="Fact-45C3D082CE8C2AF0994C7411E01B7487" unitRef="usd">-61500000</us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax contextRef="FD2016Q4YTD" decimals="-5" id="Fact-D774FA629A544AF2CEB17411DFF2AD20" unitRef="usd">47600000</us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="FD2014Q4YTD" decimals="-5" id="Fact-F1EEFCBFC300531FBE4A7411E020B582" unitRef="usd">-109200000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="FD2015Q4YTD" decimals="-5" id="Fact-230F5260ACA6AC37C7257411E01BF1ED" unitRef="usd">-96400000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="FD2016Q4YTD" decimals="-5" id="Fact-9543CB696A64F05E57B37411E021DF4F" unitRef="usd">-138600000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2014Q4YTD" decimals="-5" id="Fact-B006C72BFFAE0B3835FF7411DFF0CB69" unitRef="usd">31800000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" decimals="-5" id="Fact-3AE79D320ED3538C5C617411DFF11B9D" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2015Q4YTD" decimals="-5" id="Fact-8D07AA94E9E962DEBE2A7411E0065AB4" unitRef="usd">-164500000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" decimals="-5" id="Fact-56B3EC7BD61AE3AC6E047411DFBBFBF3" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2016Q4YTD" decimals="-5" id="Fact-D15BA14707C500E3787A7411E0130A81" unitRef="usd">95800000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" decimals="-5" id="Fact-B20211AC8F590C8693AA7411DFEE693A" unitRef="usd">100000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="FD2014Q4YTD" decimals="-5" id="Fact-CCBCE2F460AA619B92ED7411DFC3AC42" unitRef="usd">-31800000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-28127AF7256B2C93653C7411E00BA6F5" unitRef="usd">-12000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-716DD0A6D512F143C1247411E0085AFB" unitRef="usd">95400000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-64C9D70A3A26E936AF597411E0098218" unitRef="usd">-6000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-5" id="Fact-106A57F94F452EE0A6407411DFF2C2AE" unitRef="usd">-31800000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-670ACF67C192F140B4B87411E00BD9F6" unitRef="usd">-109200000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="FD2015Q4YTD" decimals="-5" id="Fact-ACF0C3E0C398EE1D54AB7411E020AF1D" unitRef="usd">-164500000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-4CFB71AD1F2622D733837411DFC7861F" unitRef="usd">-6200000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-02F5C394F64BB14F72347411E00A7FA6" unitRef="usd">-61500000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-16DA6267CFA4353B0BC37411DFC7F8F8" unitRef="usd">-400000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-5" id="Fact-321262FF3C799C80155C7411E0182ACB" unitRef="usd">-164500000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-F7589C77BC90E9EC1F317411DFC79240" unitRef="usd">-96400000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="FD2016Q4YTD" decimals="-5" id="Fact-02BBEC888FE5A71B12517411E021B977" unitRef="usd">-95900000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-B45211F04F83E7D03F337411E00A3B69" unitRef="usd">5100000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-26B747D87B0AEEFFFC377411E00714BE" unitRef="usd">47600000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-C3B8AA3E80FA3CBA52077411DFE23625" unitRef="usd">-10000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-5" id="Fact-1AA4A86C8D5E7A37796B7411E004E693" unitRef="usd">-95900000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-FC7FC964E1E4799A9E557411DFE2BF38" unitRef="usd">-138600000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax contextRef="FD2014Q4YTD" decimals="-5" id="Fact-70174E89D189AB88FE837411E00AA325" unitRef="usd">12000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax contextRef="FD2015Q4YTD" decimals="-5" id="Fact-CCD2E5637F1A5DCED5617411E02144E3" unitRef="usd">6200000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax contextRef="FD2016Q4YTD" decimals="-5" id="Fact-0C325D5BE28B75ED26F57411E02115ED" unitRef="usd">-5100000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax contextRef="FD2014Q4YTD" decimals="-5" id="Fact-E96D34C0E312BFCB7A207411DFC5D920" unitRef="usd">6400000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax contextRef="FD2015Q4YTD" decimals="-5" id="Fact-57C348C2C0441A6ED5957411E01BF37A" unitRef="usd">-1300000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax contextRef="FD2016Q4YTD" decimals="-5" id="Fact-D3101906551E933016457411E021DAB8" unitRef="usd">-600000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax contextRef="FD2014Q4YTD" decimals="-5" id="Fact-33B4026CC941E362A7157411E0212AEF" unitRef="usd">6300000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax contextRef="FD2015Q4YTD" decimals="-5" id="Fact-D24CDCAE94207F524DB17411E02039DB" unitRef="usd">172300000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax contextRef="FD2016Q4YTD" decimals="-5" id="Fact-6CAD5BE588E7A2F0FB107411DFC54BF7" unitRef="usd">4000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax>
	<us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax contextRef="FD2014Q4YTD" decimals="-5" id="Fact-DEF0980529FA73998F557411E0205485" unitRef="usd">101700000</us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax contextRef="FD2015Q4YTD" decimals="-5" id="Fact-1552D1F10DD3944AF4927411E020DAFF" unitRef="usd">110800000</us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax contextRef="FD2016Q4YTD" decimals="-5" id="Fact-43C5787E331CA6A2CB337411DFBD3CA4" unitRef="usd">51600000</us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="FD2014Q4YTD" decimals="-5" id="Fact-F8924701F29D7EFACCDF7411E01B86DB" unitRef="usd">400000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="FD2015Q4YTD" decimals="-5" id="Fact-243CE6C4A1E7A57C0F9E7411DFF2C84C" unitRef="usd">-1700000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="FD2016Q4YTD" decimals="-5" id="Fact-9EBBA71F98EBEAD7D48C7411E0268555" unitRef="usd">-10600000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherLiabilities contextRef="FI2016Q4_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember" decimals="-5" id="Fact-0435B8D5C0C2D24D5A1FD135ADC399DD" unitRef="usd">7900000</us-gaap:OtherLiabilities>
	<us-gaap:OtherLiabilitiesCurrent contextRef="FI2015Q4" decimals="-5" id="Fact-1A5882CDF66AEEE060E47411DFDBCCB2" unitRef="usd">2096800000</us-gaap:OtherLiabilitiesCurrent>
	<us-gaap:OtherLiabilitiesCurrent contextRef="FI2016Q4" decimals="-5" id="Fact-59160B9DA16A191982B27411DFDDDF4F" unitRef="usd">2903500000</us-gaap:OtherLiabilitiesCurrent>
	<us-gaap:OtherLiabilitiesNoncurrent contextRef="FI2015Q4" decimals="-5" id="Fact-DDA654789964C2CB7B9F7411DFE19819" unitRef="usd">905800000</us-gaap:OtherLiabilitiesNoncurrent>
	<us-gaap:OtherLiabilitiesNoncurrent contextRef="FI2016Q4" decimals="-5" id="Fact-5C96D7FF9188B11019677411DFDED1DC" unitRef="usd">722500000</us-gaap:OtherLiabilitiesNoncurrent>
	<us-gaap:OtherLiabilitiesNoncurrent contextRef="FI2016Q4_us-gaap_StatementGeographicalAxis_country_IT" decimals="-6" id="Fact-F31AAA0FC1A459520096D77FE07834AE" unitRef="EUR">79000000</us-gaap:OtherLiabilitiesNoncurrent>
	<us-gaap:OtherNoncashIncomeExpense contextRef="FD2014Q4YTD" decimals="-5" id="Fact-FBC72A3FC02964004FB87411E0163CDD" unitRef="usd">50300000</us-gaap:OtherNoncashIncomeExpense>
	<us-gaap:OtherNoncashIncomeExpense contextRef="FD2015Q4YTD" decimals="-5" id="Fact-9B1DA3E401DF0C2862AE7411E017ACAE" unitRef="usd">-82200000</us-gaap:OtherNoncashIncomeExpense>
	<us-gaap:OtherNoncashIncomeExpense contextRef="FD2016Q4YTD" decimals="-5" id="Fact-648991A452A7D3A777BD7411E0165803" unitRef="usd">-91200000</us-gaap:OtherNoncashIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2014Q4YTD" decimals="-5" id="Fact-0A9D328C40B548462C107411DFDDDF0E" unitRef="usd">-25800000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2014Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-4509460D037A181911937411E012E58B" unitRef="usd">0</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2014Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-84C37D10E562E84BA6E97411DFF80F8A" unitRef="usd">9900000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2015Q4YTD" decimals="-5" id="Fact-032B010DE6FAE68A43007411DFDDAFC7" unitRef="usd">-123700000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2015Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-10F7D4429B12F449DFBC7411DFCF3A89" unitRef="usd">-100000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2015Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-D115F5BB9C9DF0F0AB827411E01AE391" unitRef="usd">-2000000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2016Q4YTD" decimals="-5" id="Fact-E49FCD4F9EF19D7F02707411DFCCC587" unitRef="usd">-217400000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2016Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-A909A917082BC8E0530E7411DFE3B920" unitRef="usd">200000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2016Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-371267580DDDD07F2EB87411E00AD559" unitRef="usd">-900000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2014Q4YTD" decimals="-5" id="Fact-96B686C72977CB6EAAB27411E00516BE" unitRef="usd">304500000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2014Q4YTD_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="-5" id="Fact-2C778611466E00EC07257411DFE5183B" unitRef="usd">58500000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2014Q4YTD_us-gaap_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember" decimals="-5" id="Fact-8D67A669271448A604E37411E00950A1" unitRef="usd">0</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2014Q4YTD_us-gaap_StatementGeographicalAxis_country_DE" decimals="-5" id="Fact-DD593CA07B3DDF71394B7411E023C6A0" unitRef="usd">1800000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2014Q4YTD_us-gaap_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-626BD88F1B157C63D5237411E00CC220" unitRef="usd">212600000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2014Q4YTD_us-gaap_StatementGeographicalAxis_us-gaap_AsiaMember" decimals="-5" id="Fact-B41FFE8C9DF2B5877E7C7411DFDDD288" unitRef="usd">58500000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2014Q4YTD_us-gaap_StatementGeographicalAxis_us-gaap_EuropeMember" decimals="-5" id="Fact-2EC1A3B107A255BA3E427411E0030A47" unitRef="usd">31600000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2015Q1YTD" decimals="-5" id="Fact-C4EBB7C458057D634B927411DFCA894B" unitRef="usd">52000000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2015Q2QTD" decimals="-5" id="Fact-DBDDACED892FCF5E957B7411DFCB90A4" unitRef="usd">55600000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2015Q3QTD" decimals="-5" id="Fact-CF25F959AD45E02AA8AB7411DFC98265" unitRef="usd">49000000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2015Q4QTD" decimals="-5" id="Fact-263496BAAC5D48700B767411DFC90850" unitRef="usd">79500000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2015Q4YTD" decimals="-5" id="Fact-632981BA7ED82825F9AC7411DFD85290" unitRef="usd">236100000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2015Q4YTD_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="-5" id="Fact-B8F9E8C24928BA49E0408CFF077E29D9" unitRef="usd">62900000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2015Q4YTD_us-gaap_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember" decimals="-5" id="Fact-F3D27647101867B895C67411E027E2AF" unitRef="usd">0</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2015Q4YTD_us-gaap_StatementGeographicalAxis_country_DE" decimals="-5" id="Fact-228D98B92606FE5C12B97411E027E1F8" unitRef="usd">1600000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2015Q4YTD_us-gaap_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-92C0649C1CE31C450CD27411E0014D84" unitRef="usd">142000000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2015Q4YTD_us-gaap_StatementGeographicalAxis_us-gaap_AsiaMember" decimals="-5" id="Fact-5C9CDF86E4F34B9CDCEA7411E027AA1E" unitRef="usd">62900000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2015Q4YTD_us-gaap_StatementGeographicalAxis_us-gaap_EuropeMember" decimals="-5" id="Fact-A66EA1FE285B2EA2C3117411E0033821" unitRef="usd">29600000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2016Q1QTD" decimals="-5" id="Fact-845196AD273B94ED5C607411E005B962" unitRef="usd">87900000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2016Q2QTD" decimals="-5" id="Fact-653E751ED9CB1AFBED197411E0256299" unitRef="usd">79000000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2016Q3QTD" decimals="-5" id="Fact-146748FFC0796F9D6D637411DFF7084B" unitRef="usd">98600000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2016Q4QTD" decimals="-5" id="Fact-6E63FBCEB997A19FA1897411E0053AF9" unitRef="usd">50900000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2016Q4YTD" decimals="-5" id="Fact-A9F361F6F8FF21EDAE617411DFC3C1C5" unitRef="usd">316400000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2016Q4YTD_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="-5" id="Fact-0F48BBD5A4C5FE848AB87411DFBC8FB0" unitRef="usd">20200000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2016Q4YTD_us-gaap_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember" decimals="-5" id="Fact-808113C066173BAD6CAB7411E0234014" unitRef="usd">0</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2016Q4YTD_us-gaap_StatementGeographicalAxis_country_DE" decimals="-5" id="Fact-218479F4BA07DD1CA1277411DFF397A9" unitRef="usd">1500000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2016Q4YTD_us-gaap_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-BD539E5ADA9B360092417411DFFE56FC" unitRef="usd">224700000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2016Q4YTD_us-gaap_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember" decimals="-5" id="Fact-3EB5C47B5CB315A1037F8CB0CB0C2E09" unitRef="usd">21900000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2016Q4YTD_us-gaap_StatementGeographicalAxis_us-gaap_AsiaMember" decimals="-5" id="Fact-76B9F3342CD6D7BB294B7411E00082B5" unitRef="usd">20200000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2016Q4YTD_us-gaap_StatementGeographicalAxis_us-gaap_EuropeMember" decimals="-5" id="Fact-C0540DD17AF96B22EB8C7411E027A558" unitRef="usd">70000000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:PaymentsForOtherTaxes contextRef="FD2016Q4YTD_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember" decimals="-5" id="Fact-82C33712DB2352C477161893840E83C6" unitRef="usd">12200000</us-gaap:PaymentsForOtherTaxes>
	<us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="FD2014Q4YTD" decimals="-5" id="Fact-8A1CD7FB8AF33F6AD0FF7411DFF07BEC" unitRef="usd">-12200000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
	<us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="FD2015Q4YTD" decimals="-5" id="Fact-2F55448B34CF4F562A247411E018ACBC" unitRef="usd">44500000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
	<us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="FD2016Q4YTD" decimals="-5" id="Fact-A0BF742E7A47381B9B997411E024D1F8" unitRef="usd">22800000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
	<us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="FD2014Q4YTD" decimals="-5" id="Fact-861B2467987AECD15DDF7411E017F5F6" unitRef="usd">886800000</us-gaap:PaymentsForRepurchaseOfCommonStock>
	<us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="FD2015Q4YTD" decimals="-8" id="Fact-DA48054ABFC2C4E02B48885B612E0505" unitRef="usd">5000000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
	<us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="FD2015Q4YTD" decimals="-5" id="Fact-901DE4A2E008DDE2411F7411E0196622" unitRef="usd">5000000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
	<us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="FD2016Q4YTD" decimals="-8" id="Fact-8C45C8F806F66E356D23885CA7D44167" unitRef="usd">1000000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
	<us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="FD2016Q4YTD" decimals="-5" id="Fact-54774C78F77058B5FD3A7411E0182928" unitRef="usd">1000000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
	<us-gaap:PaymentsForRestructuring contextRef="FD2016Q4YTD" decimals="-5" id="Fact-95BB608775AF4D8992538798C24E6921" unitRef="usd">40200000</us-gaap:PaymentsForRestructuring>
	<us-gaap:PaymentsForRestructuring contextRef="FD2016Q4YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember" decimals="-5" id="Fact-77A91D83E8B98EA7EF728798A8774F6F" unitRef="usd">9000000</us-gaap:PaymentsForRestructuring>
	<us-gaap:PaymentsForRestructuring contextRef="FD2016Q4YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember" decimals="-5" id="Fact-3D6F10CA11479FFA3041879886CF8FA4" unitRef="usd">31200000</us-gaap:PaymentsForRestructuring>
	<us-gaap:PaymentsOfFinancingCosts contextRef="FD2015Q4YTD" decimals="-5" id="Fact-4D45E683B823343E96271872E535CF14" unitRef="usd">52000000</us-gaap:PaymentsOfFinancingCosts>
	<us-gaap:PaymentsToAcquireAvailableForSaleSecurities contextRef="FD2014Q4YTD" decimals="-5" id="Fact-70C780AFAAC95EEC72167411E0189F6E" unitRef="usd">3583100000</us-gaap:PaymentsToAcquireAvailableForSaleSecurities>
	<us-gaap:PaymentsToAcquireAvailableForSaleSecurities contextRef="FD2015Q4YTD" decimals="-5" id="Fact-C7DB24DD0348F33A38A27411E01582F5" unitRef="usd">6864900000</us-gaap:PaymentsToAcquireAvailableForSaleSecurities>
	<us-gaap:PaymentsToAcquireAvailableForSaleSecurities contextRef="FD2016Q4YTD" decimals="-5" id="Fact-8A773979A67F41DD24D27411E019BB14" unitRef="usd">7913200000</us-gaap:PaymentsToAcquireAvailableForSaleSecurities>
	<us-gaap:PaymentsToAcquireBusinessesGross contextRef="D2006Q4YTD_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember" decimals="-5" id="Fact-4205FF4ED629050CCBD9D255ED2D5977" unitRef="usd">220000000</us-gaap:PaymentsToAcquireBusinessesGross>
	<us-gaap:PaymentsToAcquireBusinessesGross contextRef="D2015Q1_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember" decimals="-5" id="Fact-1196C91FFA3A4207C077FA812ADF29B4" unitRef="usd">200100000</us-gaap:PaymentsToAcquireBusinessesGross>
	<us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="FD2014Q4YTD" decimals="-5" id="Fact-D49FB2FAA95FFB2013DA7411E017CD46" unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
	<us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="FD2015Q4YTD" decimals="-5" id="Fact-E7AC7FC5E0AEA8E1B74B7411E0183F40" unitRef="usd">198800000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
	<us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="FD2016Q4YTD" decimals="-5" id="Fact-03CDFB01F0C35647D6587411E0210E73" unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
	<us-gaap:PaymentsToAcquireIntangibleAssets contextRef="FD2014Q4YTD" decimals="-5" id="Fact-7D10B374E407920EA9F6D0D516D94A68" unitRef="usd">28200000</us-gaap:PaymentsToAcquireIntangibleAssets>
	<us-gaap:PaymentsToAcquireIntangibleAssets contextRef="FD2015Q4YTD" decimals="-5" id="Fact-64DD24839D22C8E82A40D0D4F89495CB" unitRef="usd">15400000</us-gaap:PaymentsToAcquireIntangibleAssets>
	<us-gaap:PaymentsToAcquireIntangibleAssets contextRef="FD2016Q4YTD" decimals="-5" id="Fact-EBC6E595596868481E05D0D4C97D1A38" unitRef="usd">111600000</us-gaap:PaymentsToAcquireIntangibleAssets>
	<us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates contextRef="FD2014Q1QTD_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_AtaxionMember" decimals="-5" id="Fact-1F2C0DCD17EA3D4FDBC618A150648EAA" unitRef="usd">1600000</us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates>
	<us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates contextRef="FD2015Q4QTD_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_RodinTherapeuticsMember" decimals="-5" id="Fact-CBE2BC922C85DC8E4BA0189AA216C38B" unitRef="usd">8000000</us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates>
	<us-gaap:PaymentsToAcquireOtherProductiveAssets contextRef="FD2014Q4YTD" decimals="-5" id="Fact-877591D57AB8F8B00F497411E0188EEB" unitRef="usd">375000000</us-gaap:PaymentsToAcquireOtherProductiveAssets>
	<us-gaap:PaymentsToAcquireOtherProductiveAssets contextRef="FD2015Q4YTD" decimals="-5" id="Fact-9C607F94B22112D4C08B7411E0151A1B" unitRef="usd">850000000</us-gaap:PaymentsToAcquireOtherProductiveAssets>
	<us-gaap:PaymentsToAcquireOtherProductiveAssets contextRef="FD2016Q4YTD" decimals="-5" id="Fact-5F84B1BE9377C2183A597411E020FDFE" unitRef="usd">1200000000</us-gaap:PaymentsToAcquireOtherProductiveAssets>
	<us-gaap:PaymentsToAcquireProductiveAssets contextRef="FD2014Q4YTD" decimals="-5" id="Fact-B449AB66CF14553E86D7D0F1F6AB3700" unitRef="usd">20500000</us-gaap:PaymentsToAcquireProductiveAssets>
	<us-gaap:PaymentsToAcquireProductiveAssets contextRef="FD2015Q4YTD" decimals="-5" id="Fact-DE43567EFCBBF2554E3DD0F1D47E3B81" unitRef="usd">13100000</us-gaap:PaymentsToAcquireProductiveAssets>
	<us-gaap:PaymentsToAcquireProductiveAssets contextRef="FD2016Q4YTD" decimals="-5" id="Fact-9AE771C8D9C65397DA59D0F18D072208" unitRef="usd">38600000</us-gaap:PaymentsToAcquireProductiveAssets>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2014Q4YTD" decimals="-5" id="Fact-CF8473B0732B6EE5AD2E7411E017FD6A" unitRef="usd">287800000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2015Q4YTD" decimals="-5" id="Fact-7FA1854967A07608F6BD7411E016D2A2" unitRef="usd">643000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2016Q4YTD" decimals="-5" id="Fact-41D02C150CEE46F591BA7411DFEFB17E" unitRef="usd">616100000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PensionExpense contextRef="FD2014Q4YTD_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_us-gaap_ForeignPensionPlansDefinedBenefitMember_us-gaap_StatementGeographicalAxis_country_CH" decimals="-5" id="Fact-5F08716D13CDB5AF0DDF7411DFECEE4C" unitRef="usd">9800000</us-gaap:PensionExpense>
	<us-gaap:PensionExpense contextRef="FD2015Q4YTD_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_us-gaap_ForeignPensionPlansDefinedBenefitMember_us-gaap_StatementGeographicalAxis_country_CH" decimals="-5" id="Fact-729CE3219732859833937411DFC6C0F9" unitRef="usd">12900000</us-gaap:PensionExpense>
	<us-gaap:PensionExpense contextRef="FD2016Q4YTD_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_us-gaap_ForeignPensionPlansDefinedBenefitMember_us-gaap_StatementGeographicalAxis_country_CH" decimals="-5" id="Fact-C99F2BB3E32AC777C04C7411DFEC3DD0" unitRef="usd">15300000</us-gaap:PensionExpense>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2015Q4" decimals="3" id="Fact-2B96ABD9F3BBA924739E7411E0067B86" unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2016Q4" decimals="3" id="Fact-13807934B850E855D1647411E0076CDA" unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2016Q4" decimals="-5" id="Fact-B933976DA4C0F0A936747411DFE513B3" unitRef="shares">8000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_biib_SeriesXPreferredStockMember" decimals="-5" id="Fact-2C44D6E82CD451F473FF7411DFE52454" unitRef="shares">1000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_biib_UndesignatedPreferredStockMember" decimals="-4" id="Fact-05CEF957321310CD87667411E00AB869" unitRef="shares">5250000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="-4" id="Fact-7053A80BE1B86F34AD617411E00A4C7D" unitRef="shares">1750000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockValue contextRef="FI2015Q4" decimals="-5" id="Fact-C0392AEE17894108830E7411DFC679DD" unitRef="usd">0</us-gaap:PreferredStockValue>
	<us-gaap:PreferredStockValue contextRef="FI2016Q4" decimals="-5" id="Fact-38C930C56077E3072B237411DFE17121" unitRef="usd">0</us-gaap:PreferredStockValue>
	<us-gaap:PrepaidExpenseAndOtherAssets contextRef="FI2013Q3_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-FA643FB6FF895D14F7D47411DFE35105" unitRef="usd">25000000</us-gaap:PrepaidExpenseAndOtherAssets>
	<us-gaap:PrepaidExpenseAndOtherAssets contextRef="FI2015Q3_us-gaap_TypeOfArrangementAxis_biib_AGTCMember" decimals="-5" id="Fact-0DC60958D7D7C19150347411E017E7DA" unitRef="usd">58400000</us-gaap:PrepaidExpenseAndOtherAssets>
	<us-gaap:PrepaidTaxes contextRef="FI2015Q4" decimals="-5" id="Fact-C4B8E56CC52D1326A3D07411E015325D" unitRef="usd">550600000</us-gaap:PrepaidTaxes>
	<us-gaap:PrepaidTaxes contextRef="FI2016Q4" decimals="-5" id="Fact-E0004CFA60115A04D8717411E0148F5F" unitRef="usd">817000000</us-gaap:PrepaidTaxes>
	<us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="FD2014Q4YTD" decimals="-5" id="Fact-3785A55E7014CAC2B2157411E01974AA" unitRef="usd">54900000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
	<us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="FD2015Q4YTD" decimals="-5" id="Fact-862B37EF63BCF293661E7411E017B220" unitRef="usd">54200000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
	<us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="FD2016Q4YTD" decimals="-5" id="Fact-F46DFA8DD75E7688F3A27411E01A51C1" unitRef="usd">43700000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
	<us-gaap:ProceedsFromNotesPayable contextRef="FD2014Q4YTD" decimals="-5" id="Fact-73ABD6FE735BA3DB69E67411E01AC867" unitRef="usd">0</us-gaap:ProceedsFromNotesPayable>
	<us-gaap:ProceedsFromNotesPayable contextRef="FD2015Q4YTD" decimals="-5" id="Fact-CF13FDD75ADD781000EF7411E018DD72" unitRef="usd">5930500000</us-gaap:ProceedsFromNotesPayable>
	<us-gaap:ProceedsFromNotesPayable contextRef="FD2016Q4YTD" decimals="-5" id="Fact-3619664D0F0BB20D472A7411E016C59B" unitRef="usd">0</us-gaap:ProceedsFromNotesPayable>
	<us-gaap:ProceedsFromPaymentsForOtherFinancingActivities contextRef="FD2014Q4YTD" decimals="-5" id="Fact-8D43C26254F5B2F570E47411E01AD5AB" unitRef="usd">2800000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
	<us-gaap:ProceedsFromPaymentsForOtherFinancingActivities contextRef="FD2015Q4YTD" decimals="-5" id="Fact-F72082427D512BECFDB07411E016786A" unitRef="usd">-61300000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
	<us-gaap:ProceedsFromPaymentsForOtherFinancingActivities contextRef="FD2016Q4YTD" decimals="-5" id="Fact-E869B3C206EBDB0144A27411E018492B" unitRef="usd">-2800000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
	<us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="FD2014Q4YTD" decimals="-5" id="Fact-C50E794DCB20E93E7D847411E0197808" unitRef="usd">2718900000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
	<us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="FD2015Q4YTD" decimals="-5" id="Fact-79AA1A1D54F9F6E0073E7411E0195F81" unitRef="usd">4063000000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
	<us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="FD2016Q4YTD" decimals="-5" id="Fact-3DF7C6B8BAE8E9E58DA17411E015EA18" unitRef="usd">7378900000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
	<us-gaap:ProfitLoss contextRef="FD2014Q4YTD" decimals="-5" id="Fact-808C459014F62BA318137411DFDFD070" unitRef="usd">2941600000</us-gaap:ProfitLoss>
	<us-gaap:ProfitLoss contextRef="FD2015Q1YTD" decimals="-5" id="Fact-D920F6525BDC4E75E8B97411DFE53D26" unitRef="usd">820200000</us-gaap:ProfitLoss>
	<us-gaap:ProfitLoss contextRef="FD2015Q2QTD" decimals="-5" id="Fact-13F00D094A5482B9A7E97411DFCBA9BC" unitRef="usd">924800000</us-gaap:ProfitLoss>
	<us-gaap:ProfitLoss contextRef="FD2015Q3QTD" decimals="-5" id="Fact-D13FF17EA1A64B03C1FC7411DFCD7AE9" unitRef="usd">1019500000</us-gaap:ProfitLoss>
	<us-gaap:ProfitLoss contextRef="FD2015Q4QTD" decimals="-5" id="Fact-0CD06C5781E7384A15507411DFC9B4DB" unitRef="usd">828700000</us-gaap:ProfitLoss>
	<us-gaap:ProfitLoss contextRef="FD2015Q4YTD" decimals="-5" id="Fact-C31A37F1D3EADF440C587411DFFF6BAA" unitRef="usd">3593200000</us-gaap:ProfitLoss>
	<us-gaap:ProfitLoss contextRef="FD2016Q1QTD" decimals="-5" id="Fact-F994F79D8121ECED63D27411DFCADC6F" unitRef="usd">969200000</us-gaap:ProfitLoss>
	<us-gaap:ProfitLoss contextRef="FD2016Q2QTD" decimals="-5" id="Fact-47E5067AA09A162721CD7411DFF75898" unitRef="usd">1048400000</us-gaap:ProfitLoss>
	<us-gaap:ProfitLoss contextRef="FD2016Q3QTD" decimals="-5" id="Fact-0AC2574987BF8B7C897C7411DFF6269C" unitRef="usd">1030200000</us-gaap:ProfitLoss>
	<us-gaap:ProfitLoss contextRef="FD2016Q4QTD" decimals="-5" id="Fact-FAD73755D443A4E1A2D37411DFF7D762" unitRef="usd">647900000</us-gaap:ProfitLoss>
	<us-gaap:ProfitLoss contextRef="FD2016Q4YTD" decimals="-5" id="Fact-F5A621B9ECF28D39FC197411DFF4476B" unitRef="usd">3695700000</us-gaap:ProfitLoss>
	<us-gaap:PropertyPlantAndEquipmentAdditions contextRef="FD2015Q3QTD_us-gaap_BusinessAcquisitionAxis_biib_EisaiMember" decimals="-5" id="Fact-A81638A2520482B5AB0888278962EFF0" unitRef="usd">104800000</us-gaap:PropertyPlantAndEquipmentAdditions>
	<us-gaap:PropertyPlantAndEquipmentAdditions contextRef="FD2015Q3QTD_us-gaap_BusinessAcquisitionAxis_biib_EisaiMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember" decimals="-5" id="Fact-6F13C5C1955A15D2A7FA8827DD1E3473" unitRef="usd">58600000</us-gaap:PropertyPlantAndEquipmentAdditions>
	<us-gaap:PropertyPlantAndEquipmentAdditions contextRef="FD2015Q3QTD_us-gaap_BusinessAcquisitionAxis_biib_EisaiMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember" decimals="-5" id="Fact-D7B58C54E61A980A28A6882909FEC222" unitRef="usd">20300000</us-gaap:PropertyPlantAndEquipmentAdditions>
	<us-gaap:PropertyPlantAndEquipmentAdditions contextRef="FD2015Q3QTD_us-gaap_BusinessAcquisitionAxis_biib_EisaiMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember" decimals="-5" id="Fact-DD4553933024E46C2B1B88289F1B8C1A" unitRef="usd">25900000</us-gaap:PropertyPlantAndEquipmentAdditions>
	<us-gaap:PropertyPlantAndEquipmentAdditions contextRef="FD2016Q1QTD_biib_FacilityLocationAxis_biib_SolothurnMember_us-gaap_CurrencyAxis_currency_CHF_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember" decimals="-5" id="Fact-362CD90678A0CE3FD7E4186CAE908981" unitRef="usd">64400000</us-gaap:PropertyPlantAndEquipmentAdditions>
	<us-gaap:PropertyPlantAndEquipmentAdditions contextRef="FD2016Q1QTD_biib_FacilityLocationAxis_biib_SolothurnMember_us-gaap_CurrencyAxis_currency_USD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember" decimals="-5" id="Fact-37848FF8C2006ED86AA2186D04BDE378" unitRef="usd">62500000</us-gaap:PropertyPlantAndEquipmentAdditions>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2015Q4" decimals="-5" id="Fact-B781A2F89B87C74AAF427411DFD7B862" unitRef="usd">3517700000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2016Q4" decimals="-5" id="Fact-0D43A6BF184E85DCE81E7411DFD72576" unitRef="usd">3941100000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2015Q4" decimals="-5" id="Fact-8AFD7F2B7CE696B00FA87411DFDB0F2E" unitRef="usd">2187600000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2016Q4" decimals="-5" id="Fact-7B42AFD5095856672D3C7411DFDF2AA2" unitRef="usd">2501800000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="FD2016Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember_us-gaap_RangeAxis_us-gaap_MaximumMember" id="Fact-CF86743AD6596BD5BDBA7411E0248E82">P40Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="FD2016Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember_us-gaap_RangeAxis_us-gaap_MinimumMember" id="Fact-A1F9FCD3EA7A90294C217411E0266E4A">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="FD2016Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_us-gaap_RangeAxis_us-gaap_MaximumMember" id="Fact-594B991E70A71BB5EAB07411DFD90D5F">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="FD2016Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_us-gaap_RangeAxis_us-gaap_MinimumMember" id="Fact-C4B29D67E656A65CAA097411DFD8A7F5">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="FD2016Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_us-gaap_RangeAxis_us-gaap_MaximumMember" id="Fact-E83D9EDC6B452BC7B3917411DFF4CE4E">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="FD2016Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_us-gaap_RangeAxis_us-gaap_MinimumMember" id="Fact-4CEC0A6C008BF9F02AD67411DFFE4A1B">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="FD2016Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_us-gaap_RangeAxis_us-gaap_MaximumMember" id="Fact-CEAF5C2E963C92D2BC537411DFD8FE41">P20Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="FD2016Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_us-gaap_RangeAxis_us-gaap_MinimumMember" id="Fact-89C8CF628CE28D527D577411DFF6AB34">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2014Q4YTD" decimals="-5" id="Fact-F7B14E6E026AF827DEDC7411E0064ADC" unitRef="usd">-12700000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-39920355FE182BA92E5D7411E00C6AEF" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-1FE7530CA4240DADCE687411E007F31E" unitRef="usd">-6300000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-CAF1FACB7E973AFC20567411E0072603" unitRef="usd">-6400000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-73CE24A9A02809DA6BE17411E00B2F00" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2015Q4YTD" decimals="-5" id="Fact-4D2B51F5F980B216F3C37411E00CA345" unitRef="usd">-171000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-D5667A708F4FAE2395DA7411DFCDADBC" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-232EAF0704BBA1B6B2D07411DFCB83D7" unitRef="usd">-172300000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-C15331891F377DD85CD57411E0115FFC" unitRef="usd">1300000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-1E214A39B1EFC52465AC7411E00B4D77" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2016Q4YTD" decimals="-5" id="Fact-A302FEB668F5EB1350DB7411E009FF55" unitRef="usd">-3400000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-3120B3AF8DAA395BB8D77411DFE3A740" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-1E18A949E49914E8CAA27411E00959B8" unitRef="usd">-4000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-673C492704FDCA2FCB097411E009B8EC" unitRef="usd">600000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-6A5DBF1597350A905FB37411E00B153D" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:RepaymentsOfDebt contextRef="FD2014Q4YTD" decimals="-5" id="Fact-8AAA67A6C3B44066D8B27411E019E999" unitRef="usd">2700000</us-gaap:RepaymentsOfDebt>
	<us-gaap:RepaymentsOfDebt contextRef="FD2015Q4YTD" decimals="-5" id="Fact-7F9AF84F6FF7384E448A7411E015C992" unitRef="usd">2100000</us-gaap:RepaymentsOfDebt>
	<us-gaap:RepaymentsOfDebt contextRef="FD2016Q4YTD" decimals="-5" id="Fact-FF3EC8AB55ADE799AAE67411E01A4897" unitRef="usd">2700000</us-gaap:RepaymentsOfDebt>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2012Q1QTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-CA525FF14455F83F7A977411DFCF2307" unitRef="usd">29000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2012Q2QTD_us-gaap_ProductOrServiceAxis_biib_DMPKMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-B3AEEE46DBECD1FB9852281BF5A1E2EE" unitRef="usd">12000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2012Q4QTD_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-EA2B9ED68B549439E3DFD60F9E5EC3FD" unitRef="usd">30000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2013Q3QTD_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-879A7B565F033F575E667411DFD93E82" unitRef="usd">75000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2013Q4QTD_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember" decimals="-5" id="Fact-EBF9406CC1E965FEEA4A7411DFBDC211" unitRef="usd">46000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2014Q2QTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" decimals="-5" id="Fact-1B482159043EF856F15E7411DFE19D4A" unitRef="usd">21600000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2014Q4YTD" decimals="-5" id="Fact-2467208FA1A4005259187411E025B828" unitRef="usd">1893400000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-6C91A4B9F6547E42D7F58CCC032B0FA4" unitRef="usd">57300000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2014Q4YTD_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-58642172041E9559D32E28198FB755F9" unitRef="usd">20000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2014Q4YTD_us-gaap_TypeOfArrangementAxis_biib_OtherresearchanddiscoveryMember" decimals="-5" id="Fact-45DD11A84A95DC0593CE8CF91ADE8AD0" unitRef="usd">40000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2015Q3QTD_us-gaap_TypeOfArrangementAxis_biib_AGTCMember" decimals="-5" id="Fact-5FABB6A957B8119B6C0F7411DFF8D403" unitRef="usd">48100000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2015Q4QTD_us-gaap_TypeOfArrangementAxis_biib_MitsubishiTanabePharmaCorporationMember" decimals="-5" id="Fact-12D02F62A77340E9D8E77411DFBB2278" unitRef="usd">60000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2015Q4YTD" decimals="-5" id="Fact-057C5C80BC29AA8125717411DFB947CF" unitRef="usd">2012800000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_LeadprogramsMember_us-gaap_TypeOfArrangementAxis_biib_AGTCMember" decimals="-5" id="Fact-6E6D6AB1E59C5844C76C7411DFE396B2" unitRef="usd">5000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_SOD1Member_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-99AF444039536F005BD5D610F21905FC" unitRef="usd">10000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-8B79CAC7460AFD78ECC17411E01792D0" unitRef="usd">42800000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_ZINBRYTAMember" decimals="-5" id="Fact-EDEC0D19E8D35A1D122E27FA446E6401" unitRef="usd">16000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2015Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AGTCMember" decimals="-5" id="Fact-8B5D756653BC0311E8577411E0171ACD" unitRef="usd">54500000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2015Q4YTD_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-0EE2209F0B59F3A268707411DFE30DAE" unitRef="usd">20000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2015Q4YTD_us-gaap_TypeOfArrangementAxis_biib_OtherresearchanddiscoveryMember" decimals="-5" id="Fact-5337F510C3BD3BAEF3F17411DFC53B24" unitRef="usd">9700000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2016Q2YTD_us-gaap_TypeOfArrangementAxis_biib_UniversityofPennsylvaniaMember" decimals="-5" id="Fact-DBC21A4A0FE5B28A6F638CF9E2646D8F" unitRef="usd">20000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2016Q4YTD" decimals="-5" id="Fact-1D5ACBB16CF3823D65097411DFDAA1E5" unitRef="usd">1973300000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_ALPROLIXMember_us-gaap_TypeOfArrangementAxis_biib_SwedishOrphanBiovitrumMember" decimals="-5" id="Fact-BF63F87C445DB6471C507411DFC58B76" unitRef="usd">123000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_ELOCTATEMember_us-gaap_TypeOfArrangementAxis_biib_SwedishOrphanBiovitrumMember" decimals="-5" id="Fact-6D0CEEFD45B3E9E6599C7411DFC3C618" unitRef="usd">144000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-C92EAB7ED1367686EE667411DFE49263" unitRef="usd">35300000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2016Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AGTCMember" decimals="-5" id="Fact-2D64429ADE6C1E512DF5D6176BEB722D" unitRef="usd">26500000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2016Q4YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" decimals="-5" id="Fact-60153F09A84618B0834FD618B90B93EA" unitRef="usd">50000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2016Q4YTD_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-FBC84468AF6D2FB9D1407411DFE12FC1" unitRef="usd">5500000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2016Q4YTD_us-gaap_TypeOfArrangementAxis_biib_MitsubishiTanabePharmaCorporationMember" decimals="-5" id="Fact-F1EC2AA5565499D1FCD58CF429350D1D" unitRef="usd">22800000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2016Q4YTD_us-gaap_TypeOfArrangementAxis_biib_OtherresearchanddiscoveryMember" decimals="-5" id="Fact-5A744A685DBC1B0D12D47411DFDD39DE" unitRef="usd">10300000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentInProcess contextRef="FD2014Q1QTD_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_AtaxionMember" decimals="-5" id="Fact-A73FE9948B72DC8766E118A57085CEF2" unitRef="usd">3500000</us-gaap:ResearchAndDevelopmentInProcess>
	<us-gaap:ResearchAndDevelopmentInProcess contextRef="FD2015Q4QTD_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_RodinTherapeuticsMember" decimals="-5" id="Fact-29FB22D6D6D110198D6F189C41A3CF69" unitRef="usd">8700000</us-gaap:ResearchAndDevelopmentInProcess>
	<us-gaap:RestructuringAndRelatedCostExpectedCost1 contextRef="FI2015Q4_us-gaap_RestructuringPlanAxis_biib_A2015RestructuringChargesMember" decimals="-5" id="Fact-A2EE592E6F50CAA3C492878F768F220A" unitRef="usd">102000000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
	<us-gaap:RestructuringCharges contextRef="FD2014Q4YTD" decimals="-5" id="Fact-14993B7A51D31E48A0148D74A6594EC5" unitRef="usd">0</us-gaap:RestructuringCharges>
	<us-gaap:RestructuringCharges contextRef="FD2015Q4QTD_us-gaap_RestructuringPlanAxis_biib_A2015RestructuringChargesMember" decimals="-5" id="Fact-8334C026976D228E757B878E82AFD99E" unitRef="usd">93400000</us-gaap:RestructuringCharges>
	<us-gaap:RestructuringCharges contextRef="FD2015Q4YTD" decimals="-5" id="Fact-D0D4E0F5BB14A22637FD8D74916AB3F2" unitRef="usd">93400000</us-gaap:RestructuringCharges>
	<us-gaap:RestructuringCharges contextRef="FD2016Q1QTD_us-gaap_RestructuringPlanAxis_biib_A2015RestructuringChargesMember" decimals="-5" id="Fact-CA17F42FA68628EC9DA7D6493E504C0A" unitRef="usd">9700000</us-gaap:RestructuringCharges>
	<us-gaap:RestructuringCharges contextRef="FD2016Q4YTD" decimals="-5" id="Fact-2A5B9ACC4C6FB6A2D7078D74510D9D42" unitRef="usd">33100000</us-gaap:RestructuringCharges>
	<us-gaap:RestructuringCharges contextRef="FD2016Q4YTD_biib_FacilityLocationAxis_biib_CambridgeMAMember_us-gaap_RestructuringPlanAxis_biib_A2016RestructuringChargesMember" decimals="-5" id="Fact-C5F447550DDFC68D5B5D183D2D974389" unitRef="usd">7400000</us-gaap:RestructuringCharges>
	<us-gaap:RestructuringCharges contextRef="FD2016Q4YTD_us-gaap_RestructuringPlanAxis_biib_A2015RestructuringChargesMember" decimals="-5" id="Fact-839C9118AC3B0B6A2C8A879321B116CE" unitRef="usd">8000000</us-gaap:RestructuringCharges>
	<us-gaap:RestructuringCharges contextRef="FD2016Q4YTD_us-gaap_RestructuringPlanAxis_biib_A2016RestructuringChargesMember" decimals="-5" id="Fact-1B6BB28E9E6FF0BBA51A7411DFDB707C" unitRef="usd">17700000</us-gaap:RestructuringCharges>
	<us-gaap:RestructuringCosts contextRef="FD2016Q4YTD" decimals="-5" id="Fact-09F367A30A368D6D18118798585F3118" unitRef="usd">10300000</us-gaap:RestructuringCosts>
	<us-gaap:RestructuringCosts contextRef="FD2016Q4YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember" decimals="-5" id="Fact-400AE6967710C42506868798433E8568" unitRef="usd">5400000</us-gaap:RestructuringCosts>
	<us-gaap:RestructuringCosts contextRef="FD2016Q4YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember" decimals="-5" id="Fact-F1E145BA52DDCA3B0B58879821DE16CD" unitRef="usd">4900000</us-gaap:RestructuringCosts>
	<us-gaap:RestructuringReserve contextRef="FI2015Q4" decimals="-5" id="Fact-969DCAE00C3A47FB76147411DFE28680" unitRef="usd">37300000</us-gaap:RestructuringReserve>
	<us-gaap:RestructuringReserve contextRef="FI2015Q4_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember" decimals="-5" id="Fact-A3A79F51547D52F2D0B97411DFDDB834" unitRef="usd">3600000</us-gaap:RestructuringReserve>
	<us-gaap:RestructuringReserve contextRef="FI2015Q4_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember" decimals="-5" id="Fact-40B0583ABAAE04AAB7B97411DFE09F0E" unitRef="usd">33700000</us-gaap:RestructuringReserve>
	<us-gaap:RestructuringReserve contextRef="FI2016Q4" decimals="-5" id="Fact-AFBDB5F9F3659076A4D987994E0122D6" unitRef="usd">5100000</us-gaap:RestructuringReserve>
	<us-gaap:RestructuringReserve contextRef="FI2016Q4_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember" decimals="-5" id="Fact-206CF360CD523BC7A4D3879938FE5527" unitRef="usd">2900000</us-gaap:RestructuringReserve>
	<us-gaap:RestructuringReserve contextRef="FI2016Q4_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember" decimals="-5" id="Fact-D4D45BD258050448A95D879924465312" unitRef="usd">2200000</us-gaap:RestructuringReserve>
	<us-gaap:RestructuringReserveAcceleratedDepreciation contextRef="FD2016Q2QTD_biib_FacilityLocationAxis_biib_CambridgeMAMember" decimals="-5" id="Fact-7BB9E18A1D67AE819C14D6463B2C5CE8" unitRef="usd">15800000</us-gaap:RestructuringReserveAcceleratedDepreciation>
	<us-gaap:RestructuringReserveAcceleratedDepreciation contextRef="FD2016Q3QTD_biib_FacilityLocationAxis_biib_CambridgeMAMember" decimals="-5" id="Fact-43B3B1B0DAEDB3068475D646B999C3F0" unitRef="usd">15700000</us-gaap:RestructuringReserveAcceleratedDepreciation>
	<us-gaap:RestructuringReserveAcceleratedDepreciation contextRef="FD2016Q4QTD_biib_FacilityLocationAxis_biib_CambridgeMAMember" decimals="-5" id="Fact-A25A616E98EE515F94BBD64A31334B53" unitRef="usd">14000000</us-gaap:RestructuringReserveAcceleratedDepreciation>
	<us-gaap:RestructuringReserveAcceleratedDepreciation contextRef="FD2016Q4YTD_biib_FacilityLocationAxis_biib_CambridgeMAMember" decimals="-5" id="Fact-5C82540AFD8858217B5B183C4ED5C907" unitRef="usd">45500000</us-gaap:RestructuringReserveAcceleratedDepreciation>
	<us-gaap:RestructuringReserveAccrualAdjustment1 contextRef="FD2015Q4QTD_us-gaap_RestructuringPlanAxis_biib_A2015RestructuringChargesMember" decimals="-5" id="Fact-C857A423377E08B627037411DFDAB59B" unitRef="usd">15900000</us-gaap:RestructuringReserveAccrualAdjustment1>
	<us-gaap:RestructuringReserveAccrualAdjustment1 contextRef="FD2016Q4YTD" decimals="-5" id="Fact-78FA2E35ABAFD57D352E7411DFDEB3CA" unitRef="usd">-2300000</us-gaap:RestructuringReserveAccrualAdjustment1>
	<us-gaap:RestructuringReserveAccrualAdjustment1 contextRef="FD2016Q4YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember" decimals="-5" id="Fact-C7759837032616961F6E7411DFDFA950" unitRef="usd">2900000</us-gaap:RestructuringReserveAccrualAdjustment1>
	<us-gaap:RestructuringReserveAccrualAdjustment1 contextRef="FD2016Q4YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember" decimals="-5" id="Fact-8BAD78B3E977D65C3EBF7411DFDF5BA4" unitRef="usd">-5200000</us-gaap:RestructuringReserveAccrualAdjustment1>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2015Q4" decimals="-5" id="Fact-C99862FB09D824629FA17411E02E53C9" unitRef="usd">12208400000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2016Q4" decimals="-5" id="Fact-FB93F0BB61DAD4699DC57411DFE26675" unitRef="usd">15071600000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:Revenues contextRef="FD2014Q4YTD" decimals="-5" id="Fact-E168E115D5E06C9871537411DFBBE2BC" unitRef="usd">9703300000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2015Q1YTD" decimals="-5" id="Fact-2A6DCC4657E44831FBF17411DFCA14E8" unitRef="usd">2555000000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2015Q2QTD" decimals="-5" id="Fact-81BEB5E1356AAFBA43A67411DFE4BBF6" unitRef="usd">2591600000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2015Q3QTD" decimals="-5" id="Fact-2A12C8DDC32ACFA45E467411DFE51E28" unitRef="usd">2777900000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2015Q4QTD" decimals="-5" id="Fact-3244B3D26360BF7F48407411DFCC5A82" unitRef="usd">2839300000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2015Q4YTD" decimals="-5" id="Fact-DA923B7ABF77E94356EF7411DFC4E741" unitRef="usd">10763800000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q1QTD" decimals="-5" id="Fact-2062FD266C1E1AA7814F7411DFFFC6CB" unitRef="usd">2726800000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q2QTD" decimals="-5" id="Fact-648C146A863A74F04D7F7411DFFEEF53" unitRef="usd">2894200000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q3QTD" decimals="-5" id="Fact-80FEE3C26BF0DEEEEDF87411DFF687E8" unitRef="usd">2955800000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q4QTD" decimals="-5" id="Fact-520F1B891C3B4F6324E07411DFF7079D" unitRef="usd">2872000000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q4YTD" decimals="-5" id="Fact-E0FB4E88FA1BF68C89A27411DFC5D677" unitRef="usd">11448800000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember" decimals="-5" id="Fact-4EBED6709CA9CFE1DB51282F58869376" unitRef="usd">6100000</us-gaap:Revenues>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2014Q2QTD_us-gaap_StatementGeographicalAxis_country_IT" decimals="-5" id="Fact-AA5A33B5E3D546D47D6D7411E015A36A" unitRef="usd">53500000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2014Q4YTD" decimals="-5" id="Fact-445F15DC89EDCE28FB827411DFC6B5CC" unitRef="usd">8203400000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_ALPROLIXProductMember" decimals="-5" id="Fact-60785DC4E8FEE2E4BE8A7411E022E255" unitRef="usd">76000000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_ALPROLIXProductMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-AE0849DFB969127AE2287411E0043C88" unitRef="usd">3900000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_ALPROLIXProductMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-99F6C5218AC8C37C56187411E00143F2" unitRef="usd">72100000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_AVONEXMember" decimals="-5" id="Fact-4C667A33130C543975A97411E01BE781" unitRef="usd">3013100000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_AVONEXMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-361075275C8CEBBF611F7411E003A606" unitRef="usd">1056400000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_AVONEXMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-6B7881867DB5B2F804DD7411E0236D68" unitRef="usd">1956700000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_BENEPALIMember" decimals="-5" id="Fact-F757A2DCC115693E06E418C4DB5E3C11" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_BENEPALIMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-F300EDA44874EBE5A18918C498A53574" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_BENEPALIMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-860B13F457AC3E6647C718C4515B4604" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_ELOCTATEMember" decimals="-5" id="Fact-C944A6C09C70369D87F77411E000958E" unitRef="usd">58400000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_ELOCTATEMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-01797FF77946FE79450D7411E0026F40" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_ELOCTATEMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-AA5F03A5734E27FAC4097411E0132B91" unitRef="usd">58400000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_FAMPYRAMember" decimals="-5" id="Fact-10B72BEE005CF6E79F8D7411E00240B0" unitRef="usd">80200000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_FAMPYRAMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-25EC5163EBF39A6434267411E0224901" unitRef="usd">80200000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_FAMPYRAMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-FA2AE5D92DF3D150AE2F7411E004FD59" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_FLIXABIMember" decimals="-5" id="Fact-3F22050A49ED3A61ADA1D643EDA4F956" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_FLIXABIMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-2DB582BB0DF1C296FB5DD643ADCD7ACA" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_FLIXABIMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-574FFA25AEC32C29CE2BD64347926F2E" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_FUMADERMMember" decimals="-5" id="Fact-F767663402D451A93F717411E022629B" unitRef="usd">62500000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_FUMADERMMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-9EE11B736EA021C4D1087411E02431EC" unitRef="usd">62500000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_FUMADERMMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-F4F0F78FE40A5183AEB77411E01BE0A0" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_PLEGRIDYMember" decimals="-5" id="Fact-A8E530DCFADD556509987411E020DB3D" unitRef="usd">44500000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_PLEGRIDYMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-C0CAF17B65E51E6F9ED07411E0046AA5" unitRef="usd">16700000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_PLEGRIDYMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-6BC17BB7A6ED5C257D907411E01BB7EE" unitRef="usd">27800000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_RituxanMember_us-gaap_StatementGeographicalAxis_us-gaap_ForeignCountryMember_us-gaap_TypeOfArrangementAxis_biib_RocheGroupGenentechMember" decimals="-5" id="Fact-40D0352CB7ACDA9AFDA87411DFB730CD" unitRef="usd">78300000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember" decimals="-5" id="Fact-897BFEE875EE36CA4B43D6415231957B" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-8F2E7C4BD7620CDDCB0FD640FFF4AFD1" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-3886489203B6852765D1D640ADFD2022" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_TecfideraMember" decimals="-5" id="Fact-A37203097A1DF0F015927411E02382A8" unitRef="usd">2909200000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-A089F5C46E6B768DE54F7411E0235219" unitRef="usd">482600000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-210ACD300FE2C813410F7411E0233F8B" unitRef="usd">2426600000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_TysabriMember" decimals="-5" id="Fact-D0D5EF03389D4A7AE1DC7411DFFF8CE7" unitRef="usd">1959500000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_TysabriMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-C5424BB5E1796C5D8B167411E00231A1" unitRef="usd">934400000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_TysabriMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-746B983B3A7FB022FA9C7411E017DD7A" unitRef="usd">1025100000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_ZINBRYTAMember" decimals="-5" id="Fact-08002D81E505896BBD2A18B5CF01D9CA" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_ZINBRYTAMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-52B3DE25852A17F9E0DD18B56BD7E286" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_ZINBRYTAMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-C312D217D5D6AFFF5E3E18B50DECE5B1" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2014Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-63ACA688BE02FFF5C6D67411E008CA84" unitRef="usd">6800000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2014Q4YTD_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-84178E57A2F0BD3255EB7411E01BF176" unitRef="usd">2636700000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2014Q4YTD_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-DA9A80975D4EA5E7269A7411E0238B11" unitRef="usd">5566700000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2014Q4YTD_us-gaap_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember" decimals="-5" id="Fact-D93C55F6E4A8228348847411E0042690" unitRef="usd">328200000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2014Q4YTD_us-gaap_StatementGeographicalAxis_country_DE" decimals="-5" id="Fact-415B103E08B1717B6D257411DFBCBF88" unitRef="usd">811800000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2014Q4YTD_us-gaap_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-05922AB9E49DA90ED6967411E0083E5E" unitRef="usd">5566700000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2014Q4YTD_us-gaap_StatementGeographicalAxis_us-gaap_AsiaMember" decimals="-5" id="Fact-2304D5A93D43C61D8B4D7411E027F244" unitRef="usd">112800000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2014Q4YTD_us-gaap_StatementGeographicalAxis_us-gaap_EuropeMember" decimals="-5" id="Fact-862519685A99AF98F0F47411DFD8A0E5" unitRef="usd">1383900000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q1YTD" decimals="-5" id="Fact-23759BF453722229CF187411DFC909DC" unitRef="usd">2172300000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q2QTD" decimals="-5" id="Fact-5B559527866B2D8D8F117411DFCD6B30" unitRef="usd">2198600000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q3QTD" decimals="-5" id="Fact-94594408B158A403E9597411DFCC1C97" unitRef="usd">2391700000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4QTD" decimals="-5" id="Fact-48E41AB8D3EA32FC5EDF7411DFCB9A8E" unitRef="usd">2425900000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD" decimals="-5" id="Fact-44B30A30E19A962D95637411DFBD8956" unitRef="usd">9188500000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_ALPROLIXProductMember" decimals="-5" id="Fact-3EFB17403A60117BAFF77411E000ADB1" unitRef="usd">234500000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_ALPROLIXProductMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-C4C0FC795176D990B7537411E0235660" unitRef="usd">25600000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_ALPROLIXProductMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-34EF5ABEC3C167EA44FC7411E0233506" unitRef="usd">208900000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_AVONEXMember" decimals="-5" id="Fact-293A35EBCDA5A67C80657411E00375D2" unitRef="usd">2630200000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_AVONEXMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-7969572161B351D970E07411E0017D33" unitRef="usd">840000000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_AVONEXMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-D8C284CC6E45739E98297411E0013B43" unitRef="usd">1790200000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_BENEPALIMember" decimals="-5" id="Fact-4F836685457C2307FE0418C3EC549329" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_BENEPALIMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-E1BB2D2EA41BC2EE102818C35EF828D9" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_BENEPALIMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-EADA4E252AB50A6D93AB18C0F697A589" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_ELOCTATEMember" decimals="-5" id="Fact-B79926D576206D6177E47411E00460ED" unitRef="usd">319700000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_ELOCTATEMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-2E2554E4E08912A8F7A07411E023E2D2" unitRef="usd">11400000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_ELOCTATEMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-6830A57D13F353451BFA7411E012BD8A" unitRef="usd">308300000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_FAMPYRAMember" decimals="-5" id="Fact-84DEDCF859AA8CC084D47411E017FA4D" unitRef="usd">89700000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_FAMPYRAMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-DA47DB9B329F3AE320A27411E023A9F3" unitRef="usd">89700000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_FAMPYRAMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-84CF05BE3A899FDCADD77411E003101C" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_FLIXABIMember" decimals="-5" id="Fact-C554569D3F9E63DFEA69D6430A220E06" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_FLIXABIMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-E451DEA5444D79C3F9B1D642C2FCAE5E" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_FLIXABIMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-F66C6F6A44E4EC7A4405D6427E64A114" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_FUMADERMMember" decimals="-5" id="Fact-BEAABBCE55C281BCE7E37411E02320E7" unitRef="usd">51400000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_FUMADERMMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-29F735D2D1E158FAA20E7411E000A8E2" unitRef="usd">51400000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_FUMADERMMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-1619170EB356911EF38F7411E0001349" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_PLEGRIDYMember" decimals="-5" id="Fact-53E9A9E21CD6C731656C7411E0054239" unitRef="usd">338500000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_PLEGRIDYMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-1B7ACDE6365867D5C48A7411E003FA5F" unitRef="usd">111400000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_PLEGRIDYMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-B26978F4EDA8CC8290167411E01B4C4A" unitRef="usd">227100000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_RituxanMember_us-gaap_StatementGeographicalAxis_us-gaap_ForeignCountryMember_us-gaap_TypeOfArrangementAxis_biib_RocheGroupGenentechMember" decimals="-5" id="Fact-647D8CE424FF8C02E6CE7411DFB7838C" unitRef="usd">69400000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember" decimals="-5" id="Fact-41C46599C0D8ECC073A6D2789B30A16A" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-A8293C12F914221BB9DCD278565360A9" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-BADA4C7796C6335D7DB6D27814CF2D3D" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_TecfideraMember" decimals="-5" id="Fact-9D31A8D8998554DD39507411E001B0A9" unitRef="usd">3638400000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-EA176EA8BCF41F24C5E77411E0015176" unitRef="usd">730200000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-7503F438D01F570EBC1A7411E0006C25" unitRef="usd">2908200000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_TysabriMember" decimals="-5" id="Fact-E851D82C0CC64F99EF1E7411E020A4BF" unitRef="usd">1886100000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_TysabriMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-2F47A6646423F29D401B7411E0032707" unitRef="usd">783000000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_TysabriMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-82CACCBE24EB6933FBCA7411E005DBD1" unitRef="usd">1103100000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_ZINBRYTAMember" decimals="-5" id="Fact-34BCED76E9EEA7A2061818B4BADA81DA" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_ZINBRYTAMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-8730D6096609FE6B1C7118B2CC62FB77" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_ZINBRYTAMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-3BB0B8A704A4D48A217318B24D0238FB" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-BA87312156A23B4576597411E00AE51E" unitRef="usd">173200000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-4A68B53B0DEFC071A6C97411E021E457" unitRef="usd">2642700000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-B7870F1EFECD71B49BE37411E001E1F3" unitRef="usd">6545800000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember" decimals="-5" id="Fact-A8B684DB76BD5D9AD48B7411E0265428" unitRef="usd">333300000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_StatementGeographicalAxis_country_DE" decimals="-5" id="Fact-66C52FDE01123D6D91527411E001B5BC" unitRef="usd">668100000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-82CDBBBC4A2C1A2D02947411DFE498AF" unitRef="usd">6545800000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_StatementGeographicalAxis_us-gaap_AsiaMember" decimals="-5" id="Fact-A58627C82262B3FC7E717411E0092D98" unitRef="usd">143700000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_StatementGeographicalAxis_us-gaap_EuropeMember" decimals="-5" id="Fact-6AD09A37CCAB563DFA7F7411DFE36E8F" unitRef="usd">1497600000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q1QTD" decimals="-5" id="Fact-9C1C4E4BDF2D12DCDC877411DFF7B5DE" unitRef="usd">2309400000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q2QTD" decimals="-5" id="Fact-36F563DB5E40A6C2198C7411E0053D89" unitRef="usd">2466000000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q3QTD" decimals="-5" id="Fact-67F28EEB5716EFC15C467411E023FCC2" unitRef="usd">2539600000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4QTD" decimals="-5" id="Fact-39196447E7E7101121E77411DFF731BA" unitRef="usd">2502900000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD" decimals="-5" id="Fact-3774C6312D87CF5AF2217411DFC6A21B" unitRef="usd">9817900000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_ALPROLIXProductMember" decimals="-5" id="Fact-2EBFCA3F85456B39A65F7411E023253B" unitRef="usd">333700000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_ALPROLIXProductMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-20EDF284ACB2BB19689A7411E017FED7" unitRef="usd">65700000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_ALPROLIXProductMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-B59B4560F644AD2F26BB7411E01AE25D" unitRef="usd">268000000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_AVONEXMember" decimals="-5" id="Fact-586E7C59231814BD6E427411E025BD80" unitRef="usd">2313500000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_AVONEXMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-C232C3DFC0408096E68E7411E01515A2" unitRef="usd">638200000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_AVONEXMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-CC6119F84BFD797D40CA7411E004CA22" unitRef="usd">1675300000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_BENEPALIMember" decimals="-5" id="Fact-8369C199B604952E714C18C078ED1390" unitRef="usd">100600000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_BENEPALIMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-E7DA1E7962088F6642A218C00445FD23" unitRef="usd">100600000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_BENEPALIMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-CB51BADFA327137DE39018BF7251F4E3" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_ELOCTATEMember" decimals="-5" id="Fact-131FF391A4708245F5DD7411E00217B3" unitRef="usd">513200000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_ELOCTATEMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-6A44452FCF01F4DBB89C7411E0018C6C" unitRef="usd">68000000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_ELOCTATEMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-12554A3A26CA263A60D57411E0033962" unitRef="usd">445200000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_FAMPYRAMember" decimals="-5" id="Fact-0DC5AC0E41288697D5797411E001AF25" unitRef="usd">84900000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_FAMPYRAMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-2A5631FEA34EC13EFF797411E023AC6E" unitRef="usd">84900000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_FAMPYRAMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-BB119F0F95449A274BEF7411E0238A43" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_FLIXABIMember" decimals="-5" id="Fact-4E7430A585EDF2943D8DD6423A5E1AD8" unitRef="usd">100000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_FLIXABIMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-DD5A0AB6A95AAE40F438D641F46A7205" unitRef="usd">100000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_FLIXABIMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-3D2BBE3D18308F054E55D641B6E4148D" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_FUMADERMMember" decimals="-5" id="Fact-3466633E43B88E8E40ED7411E001704B" unitRef="usd">45900000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_FUMADERMMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-8F21860439DE415269817411E0176083" unitRef="usd">45900000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_FUMADERMMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-A385D545EC046EF668B77411E02286A1" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_PLEGRIDYMember" decimals="-5" id="Fact-C97D1A4C8BF757AD6F3B7411E0040E6E" unitRef="usd">481700000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_PLEGRIDYMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-EACB9525F3B690998B287411E003FDAD" unitRef="usd">176700000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_PLEGRIDYMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-FDEA559144EBF68D9E227411E005737B" unitRef="usd">305000000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_RituxanMember_us-gaap_StatementGeographicalAxis_us-gaap_ForeignCountryMember_us-gaap_TypeOfArrangementAxis_biib_RocheGroupGenentechMember" decimals="-5" id="Fact-4C7EFC5C1292DE8278D57411DFB8817B" unitRef="usd">65000000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember" decimals="-5" id="Fact-6794185D353D4A7D9638D277B92E9599" unitRef="usd">4600000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-3DDC661D9D6A0F263AC4D2776A2C5162" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-BFCEA29772B91235512CD277035910D0" unitRef="usd">4600000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_TecfideraMember" decimals="-5" id="Fact-BE6A21CCE3404D508A1B7411E01825DF" unitRef="usd">3968100000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-E94123262467E2EF1E857411E00269DA" unitRef="usd">798700000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-9F36C4E57E58564798807411E005258C" unitRef="usd">3169400000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_TysabriMember" decimals="-5" id="Fact-A96FACAC1EBDDC6643C17411E0047CD0" unitRef="usd">1963800000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_TysabriMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-5C77C2683C0EAE5657B87411E01AFE27" unitRef="usd">780900000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_TysabriMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-E95C8D35B2A62ABA6A517411E0246895" unitRef="usd">1182900000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_ZINBRYTAMember" decimals="-5" id="Fact-F87AEF52DCB0F0A2FD7118ADD304714F" unitRef="usd">7800000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_ZINBRYTAMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-900C1718D3F36A638AB518AD80028BAE" unitRef="usd">7800000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD_us-gaap_ProductOrServiceAxis_biib_ZINBRYTAMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-B730C77F8FCFB32CD71A18AD0E4D8D62" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-B0CB7D7491045B1DFC9D7411E019BEF5" unitRef="usd">5300000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-DC88F04D525C13A2E7DC7411E0209ABA" unitRef="usd">2767500000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-DBAF46A0836D494888E47411E0002863" unitRef="usd">7050400000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD_us-gaap_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember" decimals="-5" id="Fact-48A9C4E01F9C93CF03E87411DFDA7FBC" unitRef="usd">313000000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD_us-gaap_StatementGeographicalAxis_country_DE" decimals="-5" id="Fact-6EE08E346A6FF8BB7A867411E02745A5" unitRef="usd">703700000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD_us-gaap_StatementGeographicalAxis_country_IT" decimals="-6" id="Fact-8F44CCBA6F0820DBA507D7841066BD9E" unitRef="usd">42000000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD_us-gaap_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-F3B49C89FFEBAE0670D27411E0276C08" unitRef="usd">7050400000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD_us-gaap_StatementGeographicalAxis_us-gaap_AsiaMember" decimals="-5" id="Fact-030D80629B951AAE26F67411DFB8E624" unitRef="usd">217300000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q4YTD_us-gaap_StatementGeographicalAxis_us-gaap_EuropeMember" decimals="-5" id="Fact-DD37641534FB3861A3EE7411DFCFBE52" unitRef="usd">1533500000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="FD2014Q4YTD" decimals="-5" id="Fact-A1340B9E347D50B7B8047411DFDD1024" unitRef="usd">2232300000</us-gaap:SellingGeneralAndAdministrativeExpense>
	<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="FD2015Q4YTD" decimals="-5" id="Fact-920C05E91A23FF15D40E7411DFD8D80F" unitRef="usd">2113100000</us-gaap:SellingGeneralAndAdministrativeExpense>
	<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="FD2016Q4YTD" decimals="-5" id="Fact-465E5AAFF89E0265C5F07411DFF810F9" unitRef="usd">1947900000</us-gaap:SellingGeneralAndAdministrativeExpense>
	<us-gaap:ShareBasedCompensation contextRef="FD2014Q4YTD" decimals="-5" id="Fact-0C555471BE361C553FC87411E01AF33B" unitRef="usd">155300000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2015Q4YTD" decimals="-5" id="Fact-32D8B7E453D65889E4B87411E01A21C4" unitRef="usd">161400000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2016Q4YTD" decimals="-5" id="Fact-D70F09006C4FB8E492EB7411E01A2F04" unitRef="usd">154800000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember" decimals="INF" id="Fact-6BACBA86EA3B884518317411DFC7CE50" unitRef="shares">39000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="INF" id="Fact-5372C4595853C8C7EDA27411E016874D" unitRef="shares">52000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="INF" id="Fact-D932664093F170B0D1127411E0283EE7" unitRef="shares">165000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" decimals="INF" id="Fact-B0634D41E3338DC30CC07411E00BF892" unitRef="shares">17000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="2" id="Fact-18F2296D1CC1C9D0E8EE7411E0164608" unitRef="usdPerShare">371.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="2" id="Fact-B819CFF4F4D6682DA72B7411E028ADBF" unitRef="usdPerShare">310.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="FD2016Q4YTD_biib_ShareBasedCompensationPlanAxis_biib_AttainmentOfPerformanceCriteriain2012Member_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="INF" id="Fact-07AFF127153B667A17F87411DFC767AB" unitRef="shares">20000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="FD2016Q4YTD_biib_ShareBasedCompensationPlanAxis_biib_AttainmentOfPerformanceCriteriain2013Member_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="INF" id="Fact-AF0A6D8D06FB950985997411E013E6E0" unitRef="shares">15000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember" decimals="INF" id="Fact-0656FE8E0BD71BD9C4EF7411E00B6E7E" unitRef="shares">86000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="INF" id="Fact-42EE05ECC18C65EFE72D7411E0163C3C" unitRef="shares">168000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="INF" id="Fact-33905F796C44F1C055ED7411E028D91F" unitRef="shares">649000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember_us-gaap_TitleOfIndividualAxis_us-gaap_DirectorMember" decimals="INF" id="Fact-392D4AB732EBED959FA57411E014CFB9" unitRef="shares">11000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" decimals="INF" id="Fact-042CE7ADAEC1CBE16B747411E011ECC9" unitRef="shares">55000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2014Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="2" id="Fact-A80C3C40F4468392A1067411E0242DCA" unitRef="usdPerShare">395.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2014Q4YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="2" id="Fact-870B03C4D92042B698C77411E015CB46" unitRef="usdPerShare">321.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="2" id="Fact-6770B6F49DA5215934337411E024693F" unitRef="usdPerShare">493.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="2" id="Fact-A76B73E662D5B253E0147411E0145DD5" unitRef="usdPerShare">388.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="2" id="Fact-46320FA19AF69BA1336D7411E02447E9" unitRef="usdPerShare">328.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="2" id="Fact-E8558476094CD433787B7411E028876E" unitRef="usdPerShare">268.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="FI2015Q4_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember" decimals="INF" id="Fact-0E3BDE471CB2C8C497287411E00B3E6B" unitRef="shares">192000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="FI2015Q4_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="INF" id="Fact-A8B7B3FBC00EC523DEC47411E017DBCE" unitRef="shares">269000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="FI2015Q4_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="INF" id="Fact-47AC9C7CE459740CF7A37411E0285DC8" unitRef="shares">810000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="FI2015Q4_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" decimals="INF" id="Fact-2ABDB83FB2B5F91464747411E00BDEBC" unitRef="shares">103000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="FI2016Q4_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember" decimals="INF" id="Fact-6C0DBE3B671285F397AC7411E012F4BE" unitRef="shares">122000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="FI2016Q4_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="INF" id="Fact-B2E88E700336548653547411E0167FD6" unitRef="shares">230000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="FI2016Q4_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="INF" id="Fact-007DD5D339CD0DC8156C7411E0281DB5" unitRef="shares">888000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="FI2016Q4_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" decimals="INF" id="Fact-CA5E157AC455B63E68C57411E00C6D0B" unitRef="shares">110000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="FI2015Q4_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="2" id="Fact-5E0CC2A00DDBF98C0D457411E0160993" unitRef="usdPerShare">339.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="FI2015Q4_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="2" id="Fact-C399104751BB586C64BA7411E02883D1" unitRef="usdPerShare">323.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="FI2016Q4_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="2" id="Fact-D4ADD12AF854EA3D4BF87411E016ABE7" unitRef="usdPerShare">355.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="FI2016Q4_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="2" id="Fact-8EB567BC6C1718D375FD7411E0283C4B" unitRef="usdPerShare">303.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember" decimals="INF" id="Fact-A63FEBA51C75E2E30F1D7411E00B4574" unitRef="shares">117000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="INF" id="Fact-E232E130C0662A8FFDAC7411E0163D29" unitRef="shares">155000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="INF" id="Fact-218CBAD6CF6ED18D8AA57411E02870C6" unitRef="shares">406000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" decimals="INF" id="Fact-3D3909AD4F5FC2A56DCE7411E00B6249" unitRef="shares">31000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="FD2014Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="-5" id="Fact-58DD1185E113C6B575587411E017691F" unitRef="usd">117400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="FD2014Q4YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="-5" id="Fact-6B68B9C7B45BF04ECE6D7411DFF30663" unitRef="usd">281100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="-5" id="Fact-26DE8F17FE26922F93887411E015D1CB" unitRef="usd">109000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="-5" id="Fact-AAF145C489B4BB9EF7F67411E022DA4A" unitRef="usd">239700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="-5" id="Fact-9AA68F867603C1AC702E7411E0148DA1" unitRef="usd">39300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="-5" id="Fact-2D1CEF72F1B812ED7FE47411E01462EB" unitRef="usd">104600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="2" id="Fact-909821E11793100B54647411E016F366" unitRef="usdPerShare">244.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="2" id="Fact-10B39091711A8001FD9C7411E02877C5" unitRef="usdPerShare">285.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2014Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="2" id="Fact-A60E3351BB16ADA8A5067411E024B5F2" unitRef="number">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="2" id="Fact-5613D079969CA8B6B5917411E024BFA7" unitRef="number">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="2" id="Fact-3FA8411F11AAD9A4CB3B7411E0241A19" unitRef="number">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2014Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="3" id="Fact-1F0EA23C9BABA9CCF8C27411DFCD7CCE" unitRef="number">0.351</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2014Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember_us-gaap_RangeAxis_us-gaap_MinimumMember" decimals="3" id="Fact-38EFD7EE13D411B84CD67411E0216303" unitRef="number">0.317</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="3" id="Fact-6EC112D1E4EA2A7FB11A7411DFC91B33" unitRef="number">0.332</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember_us-gaap_RangeAxis_us-gaap_MinimumMember" decimals="3" id="Fact-45E76ABD4611E57909267411DFCB8AB0" unitRef="number">0.310</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="3" id="Fact-9A3BEE614812739A9E227411DFCCE643" unitRef="number">0.407</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember_us-gaap_RangeAxis_us-gaap_MinimumMember" decimals="3" id="Fact-22264A6FC7459F635C1A7411E01BDA65" unitRef="number">0.382</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="FD2014Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="3" id="Fact-782B7BFA3ABA3C18B7077411DFCB1448" unitRef="number">0.007</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="3" id="Fact-89F06470B003CB5FE0197411DFCD40D7" unitRef="number">0.010</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="3" id="Fact-29D29828B0BBF9F797937411E02041DB" unitRef="number">0.009</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="FD2014Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="3" id="Fact-064B75AC6DA0CB6AC0667411E022AE81" unitRef="number">0.001</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="3" id="Fact-E2C05536A221E0A53EC67411E021B57E" unitRef="number">0.002</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="3" id="Fact-7D836A5DDC1944B0EE2C7411DFC87A1D" unitRef="number">0.006</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="FI2014Q4" decimals="INF" id="Fact-73611353C4794643F06E7411E0044589" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="FI2015Q4" decimals="INF" id="Fact-C4A2C725A8317FAA3FCC7411E0045798" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="FI2016Q4" decimals="INF" id="Fact-939F3F2C2BCA802F4A9B7411E0139DED" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="FD2014Q4YTD" decimals="-5" id="Fact-7F98B84E98081579AB967411E01205E3" unitRef="usd">42700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="FD2015Q4YTD" decimals="-5" id="Fact-AE82C2FBDF9F83FBD2D17411E0130111" unitRef="usd">38000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="FD2016Q4YTD" decimals="-5" id="Fact-1E43AB8364EF69317D787411E0149ADB" unitRef="usd">10400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="FD2016Q4YTD" decimals="INF" id="Fact-4919CE1E9854349354047411E004D0AB" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="FD2016Q4YTD" decimals="INF" id="Fact-B63F58ACE722CF0B2E107411E0195B07" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="FI2016Q4" decimals="-5" id="Fact-BC40FA83894C39E490577411DFD150E5" unitRef="usd">15000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2015Q4" decimals="INF" id="Fact-490F69FEC2C9251DB96A7411DFC5BB40" unitRef="shares">107000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2016Q4" decimals="INF" id="Fact-726939F033CD4AE6D58A7411E02F105A" unitRef="shares">66000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2015Q4" decimals="2" id="Fact-DDB094FD61C10CD9B3C27411DFC5BD16" unitRef="usdPerShare">53.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2016Q4" decimals="2" id="Fact-64DADE2CCA8A81C752787411E0177F55" unitRef="usdPerShare">54.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="FD2016Q4YTD" decimals="2" id="Fact-94562A99ECCEE2A307867411E02FFF7C" unitRef="usdPerShare">53.75</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="FD2016Q4YTD" decimals="2" id="Fact-7E1A9E4D99B816A7736C7411E0055CAD" unitRef="usdPerShare">0.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="FD2016Q4YTD" decimals="2" id="Fact-6D305A7EB3A2B4458A067411E0198A9D" unitRef="usdPerShare">0.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="FD2016Q4YTD" id="Fact-0ED55C226B7700F5C4AB7411DFC9E28D">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
	<us-gaap:SharesIssued contextRef="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-7504489AEB459E9B2E317411DFF284B2" unitRef="shares">256000000</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-5" id="Fact-D2F8F805BD8D781DE9FE7411DFF0EF92" unitRef="shares">0</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-69717C6D9C34E3EF9DB37411E0221C4E" unitRef="shares">19700000</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-325910D50C65427DB8367411DFBCAB99" unitRef="shares">257100000</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-5" id="Fact-3F1C2C5213574D89532F7411DFBCAFFA" unitRef="shares">0</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-39E860FCAD56FD91C0517411DFBD7254" unitRef="shares">22600000</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-5BB76A21E6BDBC28074A7411DFEE5B12" unitRef="shares">241200000</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-5" id="Fact-A3AB5EC89658AE7ABF817411DFEE95F9" unitRef="shares">0</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-4E142BB54E339AEA7D6D7411E005ABE9" unitRef="shares">22600000</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-E7008C19CDE2B487871F7411DFEE285D" unitRef="shares">238500000</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-5" id="Fact-DF9FC332D3C5489DDC507411DFED1916" unitRef="shares">0</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-F365221EF8EA4600A2CE7411DFF0B490" unitRef="shares">22600000</us-gaap:SharesIssued>
	<us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="FD2014Q4YTD_us-gaap_PlanNameAxis_biib_A1995ESPPMember" decimals="INF" id="Fact-E1DDB3FB14C1F0D9C2647411DFC915DE" unitRef="shares">180000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
	<us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="FD2015Q4YTD_us-gaap_PlanNameAxis_biib_A1995ESPPMember" decimals="INF" id="Fact-FAD69DD30BE739A386947411E0123688" unitRef="shares">98000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
	<us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="FD2015Q4YTD_us-gaap_PlanNameAxis_biib_A2015ESPPMember" decimals="INF" id="Fact-45BDE2ADACA2C2A4A2B38883845A5AEE" unitRef="shares">78000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
	<us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="FD2016Q4YTD" decimals="-5" id="Fact-719CA52CC9A24147F6F97411E0144A60" unitRef="shares">6200000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
	<us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="FD2016Q4YTD_us-gaap_PlanNameAxis_biib_A1995ESPPMember" decimals="INF" id="Fact-05A21D1DB1F43E6298677411E00C62DB" unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
	<us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="FD2016Q4YTD_us-gaap_PlanNameAxis_biib_A2015ESPPMember" decimals="INF" id="Fact-A65301E0671548A7F9AC7411DFC8D556" unitRef="shares">190000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-ED748548E9CC88CAA1EF7411DFF10EB1" unitRef="shares">800000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-B7FE56B31C2BCF300FB67411DFBA5B13" unitRef="shares">600000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2016Q4YTD" decimals="INF" id="Fact-E0071C2ECB28415B0AB67411E013252C" unitRef="shares">41000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-888B8C754B64FF4BC3797411DFEDB6D0" unitRef="shares">400000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-2BCD38DCE3092CBEDF007411DFF0860B" unitRef="shares">300000</us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued>
	<us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-72BFB51CFE7734F84E2E7411DFE176C5" unitRef="shares">300000</us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued>
	<us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-A3555D45414CB80182367411DFE4F9BD" unitRef="shares">200000</us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued>
	<us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="FD2014Q4YTD_us-gaap_PlanNameAxis_biib_A1995ESPPMember" decimals="-5" id="Fact-AF725E9B2C485FC0F85D7411DFC9A705" unitRef="usd">46400000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
	<us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="FD2015Q4YTD_us-gaap_PlanNameAxis_biib_A1995ESPPMember" decimals="-5" id="Fact-82F41645EC5A8D89C41D7411E0126E3F" unitRef="usd">30000000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
	<us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="FD2015Q4YTD_us-gaap_PlanNameAxis_biib_A2015ESPPMember" decimals="-5" id="Fact-14C5CE7527DFB830DA198883B470C2C2" unitRef="usd">19300000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
	<us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="FD2016Q4YTD_us-gaap_PlanNameAxis_biib_A1995ESPPMember" decimals="-5" id="Fact-10EA4DF9D2FFACA3AFEC7411DFC9A7AE" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
	<us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="FD2016Q4YTD_us-gaap_PlanNameAxis_biib_A2015ESPPMember" decimals="-5" id="Fact-81AE8D5CD5C3EECB791F7411DFC91375" unitRef="usd">41500000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2014Q4YTD" decimals="-5" id="Fact-EA07BCECFF177BA15C437411DFF21CF2" unitRef="usd">140300000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-5" id="Fact-99D38743767505A612817411DFF124ED" unitRef="usd">140300000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-665209787EC84CA363A97411DFF02B5A" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2015Q4YTD" decimals="-5" id="Fact-D4D7F3FD3A724B85FFF97411DFBD0784" unitRef="usd">125100000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-5" id="Fact-EAF90017A0466EC8AEC07411DFBBDF19" unitRef="usd">125100000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-0011794A45696E8FFD1B7411E002339A" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2016Q4YTD" decimals="-5" id="Fact-7CB914253529ED0465B77411DFE1F03C" unitRef="usd">52100000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-5" id="Fact-2EFCF6DDD3DF4A4EA1447411DFF2CC90" unitRef="usd">47600000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-2350953CA628F26EDA0F7411DFF02F4D" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-5" id="Fact-FE1CFFE0A3828E3DE293D6F4FD5BBD91" unitRef="usd">4500000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued contextRef="FD2014Q4YTD" decimals="-5" id="Fact-5240EEC6D9C156C726997411DFF283B2" unitRef="usd">54900000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
	<us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-5" id="Fact-086B4D453A5984C35CA47411DFF06B17" unitRef="usd">54900000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
	<us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-B03C9D2721E406B919687411DFF212CF" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
	<us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued contextRef="FD2015Q4YTD" decimals="-5" id="Fact-D697CA7AAAB85EEE993D7411DFBBD0F6" unitRef="usd">54200000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
	<us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-5" id="Fact-1A3BD4ACDC78B7A766C17411DFBAD4C6" unitRef="usd">54200000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
	<us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-327838FCC3F0F12E26217411DFBCBE4F" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
	<us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued contextRef="FD2016Q4YTD" decimals="-5" id="Fact-83F5DDBC21D274F07DB77411DFEE68CB" unitRef="usd">43700000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
	<us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-5" id="Fact-2A77FF636203C7AF11837411DFEDC2E8" unitRef="usd">43700000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
	<us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-4F334428CD1341F0CB637411DFEF31A2" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
	<us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-5" id="Fact-312E301589C7AC582994D6F4858D0D62" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
	<us-gaap:StockRepurchaseProgramAuthorizedAmount1 contextRef="FI2015Q2" decimals="-8" id="Fact-77419A8401071C0DAA6B8859F3880B11" unitRef="usd">5000000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
	<us-gaap:StockRepurchaseProgramAuthorizedAmount1 contextRef="FI2016Q3" decimals="-8" id="Fact-72AA29FB2FB1DE37AFE17411E00A3D7E" unitRef="usd">5000000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
	<us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased contextRef="FI2011Q1" decimals="-5" id="Fact-E6734F8C6B004564E8547411E00AFFCA" unitRef="shares">20000000</us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased>
	<us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased contextRef="FI2016Q4" decimals="-5" id="Fact-FFD30D9C64B14AB476CB7411E00AE4EE" unitRef="shares">1300000</us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased>
	<us-gaap:StockRepurchasedAndRetiredDuringPeriodShares contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-4746241A476E45067472D6F3627A4583" unitRef="shares">16800000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
	<us-gaap:StockRepurchasedAndRetiredDuringPeriodShares contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-8209C1FC99EB604A9F27D6F2305B322A" unitRef="shares">16800000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
	<us-gaap:StockRepurchasedAndRetiredDuringPeriodShares contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-115E265A9F54B305E67E7411DFEDB0E6" unitRef="shares">3300000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
	<us-gaap:StockRepurchasedAndRetiredDuringPeriodShares contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-316FAE2C303D43D37D4F7411DFEDD234" unitRef="shares">3300000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
	<us-gaap:StockholdersEquity contextRef="FI2013Q4" decimals="-5" id="Fact-FDACA9846D2D4B5EFE777411DFF29220" unitRef="usd">8620200000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2014Q4" decimals="-5" id="Fact-C6BE2F162FC5F0903ADB7411DFBD5519" unitRef="usd">10809000000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2015Q4" decimals="-5" id="Fact-160B485327415E7910EE7411DFDB3C56" unitRef="usd">9372800000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2016Q4" decimals="-5" id="Fact-A534D05DD4F8D6DBC72F7411DFDD48E7" unitRef="usd">12140100000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2013Q4" decimals="-5" id="Fact-C46F39CC9E835E6FD7BF7411E0229065" unitRef="usd">8620800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-5" id="Fact-2280B8413803865D067B7411DFF0B951" unitRef="usd">-27700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-5" id="Fact-88678DB1B7FA8CF0973F7411DFF2D6A4" unitRef="usd">4023600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-9D658B8EC7A8C62E1E617411DFF15029" unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-5" id="Fact-E95F07BE089D0D73E2147411DFF1563C" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-5" id="Fact-DC6F67DAE6114319D2E47411E0227E71" unitRef="usd">6349100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-D3F35E7A3D598BC4250C7411DFEFCB34" unitRef="usd">1724900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2014Q4" decimals="-5" id="Fact-8381983C366EDC428BFE7411DFBAD24B" unitRef="usd">10814000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-5" id="Fact-944BF52E063D020C5EA87411DFB93A75" unitRef="usd">59500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-5" id="Fact-F95B64756199329AF6237411DFBC70DF" unitRef="usd">4196200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-E38B7CC0C1AA20506E7E7411DFBDC48C" unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-5" id="Fact-56D5413AE550FB34BC257411DFBBD7C5" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-5" id="Fact-1377CF65E613C258889A7411DFBB06E4" unitRef="usd">9283900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-612C65204A9DFCC727577411DFEB25E4" unitRef="usd">2611700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2015Q4" decimals="-5" id="Fact-6A5699FF864E696AEC377411DFF76B8C" unitRef="usd">9374900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-5" id="Fact-696DADB8FF7F571297B17411DFEEFABF" unitRef="usd">224000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-5" id="Fact-45E0A70231EDD0F2DC9A7411DFEBE79A" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-034697E2C404A793A1637411DFED725C" unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-5" id="Fact-2BD2ED89D68D13E790867411DFEFA660" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-5" id="Fact-EEDB586BA3645F3BE6367411DFEF9602" unitRef="usd">12208400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-2F497B93878F9758CF327411DFE4DADF" unitRef="usd">2611700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2016Q4" decimals="-5" id="Fact-D3C9A42C45AB7DE20E9C7411DFD91FFD" unitRef="usd">12128600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-5" id="Fact-3177EDAB872D280B48A67411DFEC1E04" unitRef="usd">319900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-5" id="Fact-00831FFFD1615F1D27AD7411DFEF7297" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-41EF251A86B23F1C61F97411E0038445" unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-5" id="Fact-8637E1FEC754981378427411DFF1BCA6" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-5" id="Fact-A96D131F8D70E8A0A4D57411DFF0830A" unitRef="usd">15071600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-D0F286EC39952B82663E7411DFEE80A9" unitRef="usd">2611700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:TaxCreditCarryforwardAmount contextRef="FI2016Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_GeneralBusinessMember" decimals="-5" id="Fact-5AC8C51FD90436FFE83F7411DFED56A3" unitRef="usd">140000000</us-gaap:TaxCreditCarryforwardAmount>
	<us-gaap:TaxCreditCarryforwardAmount contextRef="FI2016Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember" decimals="-5" id="Fact-71DDAF950B888186A3EF7411DFED618E" unitRef="usd">126600000</us-gaap:TaxCreditCarryforwardAmount>
	<us-gaap:TaxesPayableCurrent contextRef="FI2015Q4" decimals="-5" id="Fact-6F259FC6E7E73A2EA4957411DFDF17C5" unitRef="usd">208700000</us-gaap:TaxesPayableCurrent>
	<us-gaap:TaxesPayableCurrent contextRef="FI2016Q4" decimals="-5" id="Fact-AEB684EB68E0197DEA907411E023F8C9" unitRef="usd">231900000</us-gaap:TaxesPayableCurrent>
	<us-gaap:TreasuryStockRetiredCostMethodAmount contextRef="FD2015Q4YTD" decimals="-5" id="Fact-C89E6F40E9904F8A9124D6F29BD8794B" unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
	<us-gaap:TreasuryStockRetiredCostMethodAmount contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-5" id="Fact-47D107C8E25180C0B5A1D6F394BBC262" unitRef="usd">4377500000</us-gaap:TreasuryStockRetiredCostMethodAmount>
	<us-gaap:TreasuryStockRetiredCostMethodAmount contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-A9D902AF81610CBB08ABD6F560EFAEEC" unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
	<us-gaap:TreasuryStockRetiredCostMethodAmount contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-5" id="Fact-71735AA04EF68AE88A92D6F1E440DD38" unitRef="usd">622500000</us-gaap:TreasuryStockRetiredCostMethodAmount>
	<us-gaap:TreasuryStockRetiredCostMethodAmount contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-403DCFF0ED92F9309ADED6F26AA16B1F" unitRef="usd">5000000000</us-gaap:TreasuryStockRetiredCostMethodAmount>
	<us-gaap:TreasuryStockRetiredCostMethodAmount contextRef="FD2016Q4YTD" decimals="-5" id="Fact-3DCB3795C0CA067324C47411E00652B9" unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
	<us-gaap:TreasuryStockRetiredCostMethodAmount contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-5" id="Fact-78D174553F4871BD4DD47411DFEDA2C2" unitRef="usd">164900000</us-gaap:TreasuryStockRetiredCostMethodAmount>
	<us-gaap:TreasuryStockRetiredCostMethodAmount contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-DDDF62DD2D98E60F72987411DFEE721A" unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
	<us-gaap:TreasuryStockRetiredCostMethodAmount contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-5" id="Fact-1C08B359130CAAF2C3827411DFEE26E2" unitRef="usd">835100000</us-gaap:TreasuryStockRetiredCostMethodAmount>
	<us-gaap:TreasuryStockRetiredCostMethodAmount contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-BAF19380CA2A8EE685057411DFEBD011" unitRef="usd">1000000000</us-gaap:TreasuryStockRetiredCostMethodAmount>
	<us-gaap:TreasuryStockShares contextRef="FI2015Q4" decimals="-5" id="Fact-CC28F7C2422891C857247411E025D384" unitRef="shares">22600000</us-gaap:TreasuryStockShares>
	<us-gaap:TreasuryStockShares contextRef="FI2016Q4" decimals="-5" id="Fact-48F36D6AD697EE2A68187411E021E2AD" unitRef="shares">22600000</us-gaap:TreasuryStockShares>
	<us-gaap:TreasuryStockSharesAcquired contextRef="FD2014Q4YTD" decimals="-5" id="Fact-F6113AAE6861E4510D68885BC44D76DA" unitRef="shares">2900000</us-gaap:TreasuryStockSharesAcquired>
	<us-gaap:TreasuryStockSharesAcquired contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-E4E32B9369F93CA383567411DFF22BFA" unitRef="shares">2900000</us-gaap:TreasuryStockSharesAcquired>
	<us-gaap:TreasuryStockSharesAcquired contextRef="FD2015Q4YTD" decimals="-5" id="Fact-E25E4A760B14A99AFF6B885B195C2836" unitRef="shares">16800000</us-gaap:TreasuryStockSharesAcquired>
	<us-gaap:TreasuryStockSharesAcquired contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-56695C701E73034F8680D6F10500A247" unitRef="shares">16800000</us-gaap:TreasuryStockSharesAcquired>
	<us-gaap:TreasuryStockSharesAcquired contextRef="FD2016Q4YTD" decimals="-5" id="Fact-F4AAB0A07F035141ADBC885C685B3A83" unitRef="shares">3300000</us-gaap:TreasuryStockSharesAcquired>
	<us-gaap:TreasuryStockSharesAcquired contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-04CEA33A6D0976398C097411DFEFD917" unitRef="shares">3300000</us-gaap:TreasuryStockSharesAcquired>
	<us-gaap:TreasuryStockValue contextRef="FI2015Q4" decimals="-5" id="Fact-A4E03EAAE210A342D6417411DFDF152D" unitRef="usd">2611700000</us-gaap:TreasuryStockValue>
	<us-gaap:TreasuryStockValue contextRef="FI2016Q4" decimals="-5" id="Fact-F084675D31037CCFA2C67411DFDC26F3" unitRef="usd">2611700000</us-gaap:TreasuryStockValue>
	<us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="FD2014Q4YTD" decimals="-5" id="Fact-9A6F61CB5E6DBC7B96417411DFF23D02" unitRef="usd">886800000</us-gaap:TreasuryStockValueAcquiredCostMethod>
	<us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-0D31EAF4D013E82258CB7411E022D49C" unitRef="usd">886800000</us-gaap:TreasuryStockValueAcquiredCostMethod>
	<us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="FD2015Q4YTD" decimals="-5" id="Fact-6563C5848B917E6C2010D6F2EB0539F1" unitRef="usd">5000000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
	<us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-7A738AA6D5182BCEBFE1D6F15CC92727" unitRef="usd">5000000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
	<us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="FD2016Q4YTD" decimals="-5" id="Fact-0B45F86F926FC6AF42087411E004D86A" unitRef="usd">1000000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
	<us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-976BAB377CE1AE652BE37411DFEE515D" unitRef="usd">1000000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
	<us-gaap:UndistributedEarningsOfForeignSubsidiaries contextRef="FI2016Q4" decimals="-8" id="Fact-4B0CAD9DF9C562B90FD97411DFED2334" unitRef="usd">7600000000</us-gaap:UndistributedEarningsOfForeignSubsidiaries>
	<us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax contextRef="FD2014Q4YTD" decimals="-5" id="Fact-BABD0C80008C945F78AC7411DFF67C74" unitRef="usd">72100000</us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax>
	<us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax contextRef="FD2015Q4YTD" decimals="-5" id="Fact-8EE6E6EF6D909076B13E7411DFF6A6D7" unitRef="usd">-1800000</us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax>
	<us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax contextRef="FD2016Q4YTD" decimals="-5" id="Fact-2F525344EF3BAEFC99B67411DFF6020A" unitRef="usd">49800000</us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax>
	<us-gaap:UnrecognizedTaxBenefits contextRef="FI2013Q4" decimals="-5" id="Fact-AFAD0FCFEB9EEACC4EF57411E0184850" unitRef="usd">110100000</us-gaap:UnrecognizedTaxBenefits>
	<us-gaap:UnrecognizedTaxBenefits contextRef="FI2014Q4" decimals="-5" id="Fact-E095064AFFF02726B2287411E017BB0B" unitRef="usd">131500000</us-gaap:UnrecognizedTaxBenefits>
	<us-gaap:UnrecognizedTaxBenefits contextRef="FI2015Q4" decimals="-5" id="Fact-D445D500722C4275FC8C7411E0187596" unitRef="usd">67900000</us-gaap:UnrecognizedTaxBenefits>
	<us-gaap:UnrecognizedTaxBenefits contextRef="FI2016Q4" decimals="-5" id="Fact-3BAF6AD5F64CF1D970557411E01860C2" unitRef="usd">32400000</us-gaap:UnrecognizedTaxBenefits>
	<us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions contextRef="FD2015Q1YTD" decimals="-5" id="Fact-83F7F514C47E786A0AAED651520D0CCE" unitRef="usd">27000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions>
	<us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="FD2014Q4YTD" decimals="-5" id="Fact-D89408D7283EA103ADB47411E019BD96" unitRef="usd">23400000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
	<us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="FD2015Q4YTD" decimals="-5" id="Fact-301A598557F7472400527411E018BE70" unitRef="usd">49900000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
	<us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="FD2016Q4YTD" decimals="-5" id="Fact-3BC321F4003EBBAAB41D7411E018B54B" unitRef="usd">13300000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
	<us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities contextRef="FD2014Q4YTD" decimals="-5" id="Fact-895357C79FF592B7C69D7411E017CD07" unitRef="usd">60500000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
	<us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities contextRef="FD2015Q4YTD" decimals="-5" id="Fact-46AAF64B1E3AFDFB85A77411E01862CF" unitRef="usd">42500000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
	<us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities contextRef="FD2016Q4YTD" decimals="-5" id="Fact-BE92B65112F5F72518A07411E017E2CF" unitRef="usd">64300000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
	<us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense contextRef="FD2014Q4YTD" decimals="-5" id="Fact-8C81428FE267004D3F8A7411DFEE4C76" unitRef="usd">4100000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
	<us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense contextRef="FD2015Q4YTD" decimals="-5" id="Fact-DA9C892CFF08412269FC7411DFEC247A" unitRef="usd">3100000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
	<us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense contextRef="FD2016Q4YTD" decimals="-5" id="Fact-B288C3C198D8D66FEB9A7411DFED0A26" unitRef="usd">9100000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
	<us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="FD2014Q4YTD" decimals="-5" id="Fact-B6150FA44162DAFFB3777411E018EF98" unitRef="usd">20800000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
	<us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="FD2015Q4YTD" decimals="-5" id="Fact-098265C4D4009FFD54E87411E01827CA" unitRef="usd">10500000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
	<us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="FD2016Q4YTD" decimals="-5" id="Fact-4A1CF33C6FF245AE8B887411E0186AFA" unitRef="usd">7200000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
	<us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="FD2014Q4YTD" decimals="-5" id="Fact-31363BD08FEC836A447E7411E018E1A7" unitRef="usd">86100000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
	<us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="FD2015Q4YTD" decimals="-5" id="Fact-83372533073F54EF5A2E7411E017B187" unitRef="usd">19500000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
	<us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="FD2016Q4YTD" decimals="-5" id="Fact-0665424E38AEB174B4957411E018C5E4" unitRef="usd">36300000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
	<us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued contextRef="FI2015Q4" decimals="-5" id="Fact-E83EE4B2E14CAA76D73A7411DFED6F94" unitRef="usd">12500000</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued>
	<us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued contextRef="FI2016Q4" decimals="-5" id="Fact-7A415FE400B3C75F0B847411DFEC8472" unitRef="usd">25200000</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued>
	<us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations contextRef="FD2014Q4YTD" decimals="-5" id="Fact-47E091A0DF4E4B35EDE17411E0179163" unitRef="usd">1600000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
	<us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations contextRef="FD2015Q4YTD" decimals="-5" id="Fact-C0481430698C3C8407B67411E0182C7D" unitRef="usd">1200000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
	<us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations contextRef="FD2016Q4YTD" decimals="-5" id="Fact-C824C6956E7E902EACED7411E0189CD6" unitRef="usd">1400000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
	<us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate contextRef="FI2014Q4" decimals="-5" id="Fact-5CE2A45FC6D63FEEFCB97411DFEC94F8" unitRef="usd">53600000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
	<us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate contextRef="FI2015Q4" decimals="-5" id="Fact-DDD8BC8337B2345145E47411DFECCE99" unitRef="usd">15700000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
	<us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate contextRef="FI2016Q4" decimals="-5" id="Fact-180F7B606FBF72E86DA27411DFEC456A" unitRef="usd">26900000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2013Q4" decimals="-5" id="Fact-53841250445C7737A5227411DFF67123" unitRef="usd">426200000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2013Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-5B4B916095B4F098B12B7411DFF5D37F" unitRef="usd">345500000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2013Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember" decimals="-5" id="Fact-0542D8DB7A6BE83B31287411DFF40499" unitRef="usd">47000000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2013Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-52974797991D308A5F927411DFF428A2" unitRef="usd">33700000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2014Q4" decimals="-5" id="Fact-BE540200DEDB2DF5F63F7411DFE1833D" unitRef="usd">483800000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2014Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-EF8084ABFD635D11C0307411DFE40405" unitRef="usd">387100000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2014Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember" decimals="-5" id="Fact-D976CE7BA5C6DFF549BE7411DFDADECA" unitRef="usd">47600000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2014Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-BBD08D7AB2877B95A0CF7411DFDEAAA0" unitRef="usd">49100000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2015Q4" decimals="-5" id="Fact-2A5E0DAB4AB3FAD9D79B7411DFDD1DD4" unitRef="usd">662700000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2015Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember" decimals="-5" id="Fact-615A3954593E722AE43C7411DFBA9D48" unitRef="usd">144600000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2015Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember" decimals="-5" id="Fact-4E4FBEF8E822554645837411DFBAD76A" unitRef="usd">518100000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2015Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-A515C4DF0EAF647B53E47411DFDD6C7F" unitRef="usd">548700000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2015Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember" decimals="-5" id="Fact-F574483B4A2E5A2E09AB7411DFDC2AC0" unitRef="usd">56100000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2015Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-A93EBEC78C9FD4BF7E927411DFDDA6BD" unitRef="usd">57900000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2016Q4" decimals="-5" id="Fact-D9508D1BEE192801C7AE7411DFDF0D92" unitRef="usd">605500000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember" decimals="-5" id="Fact-6A812EE49811DE6E64B37411DFBA3DA8" unitRef="usd">166900000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember" decimals="-5" id="Fact-80501D7B893495BB3B387411DFBB71DE" unitRef="usd">438600000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2016Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-D878A438D4D331BAF4D87411DFE0CEA8" unitRef="usd">482700000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2016Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember" decimals="-5" id="Fact-5FE985B0FF85E2F4ADE77411E017970E" unitRef="usd">71600000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2016Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-681DE6364EF9297871E57411E01551A4" unitRef="usd">51200000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="FD2014Q4YTD" decimals="-5" id="Fact-9577A0CB6E9B1A58BEC27411DFDA07B6" unitRef="shares">800000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
	<us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="FD2015Q4YTD" decimals="-5" id="Fact-EC3B81BCAEC0BCC40CF47411DFDB1F3E" unitRef="shares">500000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
	<us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="FD2016Q4YTD" decimals="-5" id="Fact-3CA9550F0F920EEA071D7411DFDBD647" unitRef="shares">400000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="FD2014Q4YTD" decimals="-5" id="Fact-30AB7410A53301FDCE6E7411DFE3BA3B" unitRef="shares">237200000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="FD2015Q1YTD" decimals="-5" id="Fact-59A9EBA376D60F20EB1E7411DFCDB535" unitRef="shares">235600000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="FD2015Q2QTD" decimals="-5" id="Fact-80EE43DA66AC2C88D7787411DFCBBEBD" unitRef="shares">235700000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="FD2015Q3QTD" decimals="-5" id="Fact-A483D18EE499151C66107411DFC75311" unitRef="shares">232600000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="FD2015Q4QTD" decimals="-5" id="Fact-8A12D1BC71A0D4DBA4567411DFCA35B3" unitRef="shares">220800000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="FD2015Q4YTD" decimals="-5" id="Fact-BBC2364B9B8EC23C7CCF7411DFDC60C8" unitRef="shares">231200000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="FD2016Q1QTD" decimals="-5" id="Fact-AF78E3C0A0DD3C21B7D77411DFE5E988" unitRef="shares">219300000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="FD2016Q2QTD" decimals="-5" id="Fact-6D5A7DA5624C1EBD21167411E004B989" unitRef="shares">219400000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="FD2016Q3QTD" decimals="-5" id="Fact-B46146A16FEE9968B7F27411E003E51E" unitRef="shares">219400000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="FD2016Q4QTD" decimals="-5" id="Fact-5D21AEFB8880E9C3A3277411E00589A9" unitRef="shares">217000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="FD2016Q4YTD" decimals="-5" id="Fact-4C7B82D2F47009A052047411DFE0B057" unitRef="shares">218800000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation contextRef="FD2014Q4YTD" decimals="-5" id="Fact-A5F2F76E4B89BB9877F87411DFC98176" unitRef="shares">1000000</us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation>
	<us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation contextRef="FD2015Q4YTD" decimals="-5" id="Fact-3A90F957FCCC2B02E69D7411DFC97AA8" unitRef="shares">4600000</us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation>
	<us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation contextRef="FD2016Q4YTD" decimals="-5" id="Fact-AA3C7BC47AB7ECC60C007411DFCA8F04" unitRef="shares">700000</us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2014Q4YTD" decimals="-5" id="Fact-804C80E10BACDAA2B9197411E0222C16" unitRef="shares">236400000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2015Q1YTD" decimals="-5" id="Fact-83BB1D90BEDA5E5C81E67411DFC93A24" unitRef="shares">235000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2015Q2QTD" decimals="-5" id="Fact-DFE1D9F174BF5303CCF07411DFC70016" unitRef="shares">235300000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2015Q3QTD" decimals="-5" id="Fact-108554D09AC0B05993D67411DFCBF17E" unitRef="shares">232200000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2015Q4QTD" decimals="-5" id="Fact-AF1DD600866953AA2BEC7411DFCB275F" unitRef="shares">220400000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2015Q4YTD" decimals="-5" id="Fact-72EC34BBFC64E47E25337411DFC51737" unitRef="shares">230700000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2016Q1QTD" decimals="-5" id="Fact-60BAAB2CD2A848D07AD47411DFF84C1A" unitRef="shares">218900000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2016Q2QTD" decimals="-5" id="Fact-A26DD5BF6F5D4D5101AB7411DFFED467" unitRef="shares">219100000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2016Q3QTD" decimals="-5" id="Fact-4CDACC707248D4D9C03F7411E0075497" unitRef="shares">218900000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2016Q4QTD" decimals="-5" id="Fact-D4EC3B23395CB07872CC7411DFDBF125" unitRef="shares">216600000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2016Q4YTD" decimals="-5" id="Fact-AFB12D56316DC168C4537411E00361D3" unitRef="shares">218400000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock contextRef="FD2016Q4YTD" id="Fact-486EDABB30699477F47F7411DFC58594">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Discounts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Contractual&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Returns&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Beginning balance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;56.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;548.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;57.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;662.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current provisions relating to sales in current year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;592.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,044.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;30.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,668.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Adjustments relating to prior years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(1.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(16.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(16.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/returns relating to sales in current year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(522.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(1,576.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(1.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(2,099.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/returns relating to sales in prior years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(53.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(536.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(19.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(609.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Ending balance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;71.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;482.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;51.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;605.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Discounts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Contractual&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Returns&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Beginning balance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;47.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;387.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;49.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;483.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current provisions relating to sales in current year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;459.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,732.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;37.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,229.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Adjustments relating to prior years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(16.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(14.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(32.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/returns relating to sales in current year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(405.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1,258.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(2.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1,666.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/returns relating to sales in prior years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(44.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(296.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(11.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(351.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Ending balance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;56.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;548.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;57.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;662.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Discounts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Contractual&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Returns&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Beginning balance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;47.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;345.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;33.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;426.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current provisions relating to sales in current year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;347.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,265.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;39.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,651.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Adjustments relating to prior years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(28.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;13.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(16.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/returns relating to sales in current year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(299.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(933.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(4.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1,237.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/returns relating to sales in prior years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(46.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(261.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(33.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(341.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Ending balance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;47.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;387.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;49.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;483.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock>
	<biib:AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock contextRef="FD2016Q4YTD" id="Fact-80F63FC983E3E722A0667411E0139F09">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Expected dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Range of expected stock price volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;38.2% - 40.7%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;31.0% - 33.2%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;31.7% - 35.1%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Range of risk-free interest rates&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.6% - 0.9%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.2% - 1.0%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1% - 0.7%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;30 calendar day average stock price on grant date&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$260.67 - $304.86&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$277.35 - $426.27&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$280.88 - $335.65&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Weighted-average per share grant date fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$328.03&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$493.43&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$395.22&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock>
	<biib:BusinessOverviewPolicyTextBlock contextRef="FD2016Q4YTD" id="Fact-E54B306C0F5004B882077411DFDE674E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen is a global biopharmaceutical company focused on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). We also have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other potential anti-CD20 therapies under a collaboration agreement with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group (Roche Group).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities, particularly within areas of our scientific, manufacturing and technical capabilities. Our research is currently focused on additional improvements in the treatment of MS, solving some of the most challenging and complex diseases, including Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis (ALS), and employing innovative technologies to discover potential treatments for rare and genetic disorders, including new ways of treating diseases through gene therapy.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our innovative drug development and commercialization activities are complemented by our biosimilar therapies that expand access to medicines and reduce the cost burden for healthcare systems. We are leveraging our manufacturing capabilities and know-how to develop, manufacture and market biosimilars through Samsung Bioepis, our joint venture with Samsung BioLogics Co. Ltd. (Samsung Biologics). Under this agreement, we are currently manufacturing and commercializing BENEPALI, an etanercept biosimilar referencing ENBREL, and FLIXABI, an infliximab biosimilar referencing REMICADE, in the European Union (E.U.).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Hemophilia Spin-Off&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In May 2016 we announced our intention to spin off our hemophilia business, Bioverativ Inc. (Bioverativ), as an independent, publicly traded company. Bioverativ, will focus on the discovery, development and commercialization of therapies for treatment of hemophilia and other blood disorders, including ELOCTATE for the treatment of hemophilia A and ALPROLIX for the treatment of hemophilia B. Bioverativ will also assume all of our rights and obligations under our collaboration agreement with Swedish Orphan Biovitrum AB (Sobi) and our collaboration and license agreement with Sangamo Biosciences Inc. (Sangamo).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On February 1, 2017, we completed the distribution of all the then outstanding shares of common stock of Bioverativ to Biogen stockholders, who received one share of Bioverativ common stock for every two shares of Biogen common stock. As a result of the distribution, Bioverativ is now an independent public company whose shares of common stock are trading under the symbol "BIVV" on the Nasdaq Global Select Market.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The financial results of Bioverativ are reflected in our consolidated results of operations and financial position included in these audited consolidated financial statements for the periods presented in this Form 10-K. The financial results of Bioverativ will be excluded from our consolidated results of operations and financial position commencing February 1, 2017. For additional information regarding the separation of Bioverativ, please read Note 26, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Subsequent Events&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</biib:BusinessOverviewPolicyTextBlock>
	<biib:CoPromotionProfitSharingFormulaTableTextBlock contextRef="FD2016Q4YTD" id="Fact-32E445557C6A68B107537411DFBB30FF">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:82%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Until GAZYVA First Non-CLL FDA Approval&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;40.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;After GAZYVA First Non-CLL FDA Approval until First GAZYVA Threshold Date&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;39.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;After First GAZYVA Threshold Date until Second GAZYVA Threshold Date&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;37.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;After Second GAZYVA Threshold Date&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;35.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;"&gt;First Non-CLL GAZYVA FDA Approval&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; means the FDA&amp;#8217;s first approval of GAZYVA in an indication other than CLL.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;padding-left:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;"&gt;First GAZYVA Threshold Date&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; means the earlier of (1)&amp;#160;the date of the First Non-CLL GAZYVA FDA approval if U.S. gross sales of GAZYVA for the preceding consecutive 12 month period were at least &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$150.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; or (2)&amp;#160;the first day of the calendar quarter after the date of the First Non-CLL GAZYVA FDA Approval that U.S. gross sales of GAZYVA within any consecutive 12 month period have reached &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$150.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;"&gt;Second GAZYVA Threshold Date&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; means the first day of the calendar quarter after U.S. gross sales of GAZYVA within any consecutive 12 month period have reached &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$500.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. The Second GAZYVA Threshold Date can be achieved regardless of whether GAZYVA has been approved in a non-CLL indication.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</biib:CoPromotionProfitSharingFormulaTableTextBlock>
	<biib:CollaborativeandOtherRelationshipsPolicyTextBlock contextRef="FD2016Q4YTD" id="Fact-98C1BC38EBB0FC04FAD31835FFEE47E6">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our development and commercialization arrangements with Sobi and AbbVie Inc. (AbbVie) represent collaborative arrangements as each party is an active participant and exposed to significant risks and rewards of the arrangements. Where we are the principal on sales transactions with third parties, we recognize revenue, cost of sales and operating expenses on a gross basis in their respective lines in our consolidated statements of income. Where we are not the principal on sales transactions with third parties, we record our share of the revenues, cost of sales and operating expenses on a net basis in collaborative and other relationships included in other revenue in our consolidated statements of income. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information related to our collaborations with Sobi and AbbVie, please read Note 19, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</biib:CollaborativeandOtherRelationshipsPolicyTextBlock>
	<biib:IntangibleAssetsExcludingGoodwillTableTextBlock contextRef="FD2016Q4YTD" id="Fact-AF4435E36D2709CF82397411DFF556A8">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="26" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:21%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;As of December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Estimated Life&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Accumulated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Accumulated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Out-licensed patents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;13-23 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;543.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(523.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;19.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;543.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(506.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;37.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Developed technology&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;15-23 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3,005.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(2,634.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;371.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,005.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(2,552.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;452.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In-process research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Indefinite until commercialization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;648.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;648.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;730.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;730.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Trademarks and trade names&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Indefinite&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;64.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;64.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;64.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;64.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Acquired and in-licensed rights and patents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6-18 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3,481.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(776.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,705.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,303.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(502.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,800.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total intangible assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;7,742.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(3,934.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3,808.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;7,646.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(3,561.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4,085.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:IntangibleAssetsExcludingGoodwillTableTextBlock>
	<biib:PerformanceunitsactivityTableTextBlock contextRef="FD2016Q4YTD" id="Fact-ACF5D52D6F4D73D822237411E022C1D3">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:82%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;103,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Granted (a)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;55,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Vested&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(31,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(17,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;110,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:PerformanceunitsactivityTableTextBlock>
	<biib:PretaxProfitSharingFormulaTableTextBlock contextRef="FD2016Q4YTD" id="Fact-6C29B0B346BEF1B9C9657411DFBEBCB4">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:82%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Until First GAZYVA Threshold Date&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;39.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;After First GAZYVA Threshold Date until Second GAZYVA Threshold Date&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;37.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;After Second GAZYVA Threshold Date&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;35.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:PretaxProfitSharingFormulaTableTextBlock>
	<biib:ReimbursementUnderAmendedAgreementAmountsPayableTableTextBlock contextRef="FD2016Q4YTD" id="Fact-F4708C126580F0D819767411DFEA3F14">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.609375%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:51%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:16%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Rates post Sobi Opt-In&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(3)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Royalty and Net Revenue Share Rates:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Method&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Base Rate following&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;1st&amp;#160;commercial&amp;#160;sale&amp;#160;in&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;the Sobi Territory:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Rate during the&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Reimbursement&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Period:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Sobi rate to Biogen on net sales in the Sobi Territory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Royalty&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;12%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Base&amp;#160;Rate&lt;br clear="none"/&gt;plus 5%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Biogen rate to Sobi on net sales in the Biogen North America Territory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Royalty&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;12%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Base Rate&lt;br clear="none"/&gt;less 5%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Biogen rate to Sobi on net sales in the Biogen Direct Territory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Royalty&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;17%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Base Rate&lt;br clear="none"/&gt;less 5%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Biogen rate to Sobi on net revenue&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(1)&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;from the Biogen Distributor Territory&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(2)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Net&lt;br clear="none"/&gt;Revenue&lt;br clear="none"/&gt;Share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;50%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Base Rate&lt;br clear="none"/&gt;less 15%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt;Net revenue represents Biogen&amp;#8217;s pre-tax receipts from third-party distributors, less expenses incurred by Biogen in the conduct of commercialization activities supporting the distributor activities.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt;The Biogen Distributor Territory represents Biogen territories where sales are derived utilizing a third-party distributor.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt;A credit will be issued to Sobi against its reimbursement of the Opt-in Consideration for each product in an amount equal to the difference in the rate paid by Biogen to Sobi on sales in the Biogen territories for certain periods prior to the first commercial sale in the Sobi Territory versus the rate that otherwise would have been payable on such sales.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:ReimbursementUnderAmendedAgreementAmountsPayableTableTextBlock>
	<biib:RevenuesFromUnconsolidatedJointBusinessTableTextBlock contextRef="FD2016Q4YTD" id="Fact-A997010958C7491DDF1E7411DFD9E13F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,249.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,269.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,117.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenue on sales in the rest of world for RITUXAN&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;65.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;69.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;78.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total revenues from anti-CD20 therapeutic programs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,314.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,339.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,195.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:RevenuesFromUnconsolidatedJointBusinessTableTextBlock>
	<biib:RoyaltyCostofSalesPolicyTextBlock contextRef="FD2016Q4YTD" id="Fact-457845B30AEFB42695F97411DFDEE040">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We make royalty payments to a number of third parties under license or purchase agreements associated with our acquisition of intellectual property. These royalty payments are typically calculated as a percentage (royalty rate) of the sales of our products in a particular year.&amp;#160;That royalty rate may remain constant, increase or decrease within each year based on the total amount of sales during the annual period. Each quarterly period, we estimate our total royalty obligation for the full year and recognize the proportional amount as cost of sales based on actual quarterly sales as a percentage of full year estimated sales. For example, if the level of net sales in any calendar year increases the royalty rate within the year, we will record our cost of sales at an even rate over the year, based on the estimated blended royalty rate.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</biib:RoyaltyCostofSalesPolicyTextBlock>
	<biib:ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock contextRef="FD2016Q4YTD" id="Fact-35D7EE8EA82F271FB17B7411E0157980">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:82%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;192,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Granted (a)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;86,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Vested&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(117,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(39,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;122,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock>
	<biib:ScheduleOfMarketStockUnitsActivityTableTextBlock contextRef="FD2016Q4YTD" id="Fact-B8480688F65A61531C477411E0151DEC">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Grant&amp;#160;Date&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;269,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;339.89&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Granted (a)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;168,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;328.03&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Vested&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(155,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;244.68&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(52,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;371.62&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;230,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;355.60&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:ScheduleOfMarketStockUnitsActivityTableTextBlock>
	<biib:ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock contextRef="FD2016Q4YTD" id="Fact-50627C7CBE9CD4AA0BBF7411DFDBA3B8">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="2" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:50%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:50%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;"&gt;Asset Category&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;"&gt;Useful Lives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Land&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Not depreciated&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Buildings&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;15 to 40&amp;#160;years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Leasehold Improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Lesser of the useful life or the term of the respective lease&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Furniture and Fixtures&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5 to 7&amp;#160;years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Machinery and Equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5 to 20&amp;#160;years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Computer&amp;#160;Software&amp;#160;and&amp;#160;Hardware&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3 to 5&amp;#160;years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock>
	<biib:SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock contextRef="FD2016Q4YTD" id="Fact-0390DDE42874C82716627411E0154023">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions, except share amounts)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Shares issued under the 2015 ESPP&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;190,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;78,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;**&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Shares issued under the 1995 ESPP&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;98,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;180,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash received under the 2015 ESPP&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;41.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;19.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;**&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash received under the 1995 ESPP&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;30.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;46.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock>
	<biib:SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock contextRef="FD2016Q4YTD" id="Fact-1391DE0BEBB12EFFAD557411DFE3CD28">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:56%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Years Ended&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total development expense incurred by the collaboration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;95.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;84.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;57.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen&amp;#8217;s share of development expense, excluding upfront and milestone payments, reflected in our consolidated statements of income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;50.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;40.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;29.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock>
	<biib:SummaryOfActivityRelatedToCollaborationWithCompanySevenTableTextBlock contextRef="FD2016Q4YTD" id="Fact-318EDB0BCCA6A20F4C53D62DF616A5A5">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:84%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Year Ended December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Product revenues, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;6.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Costs and expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;50.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Co-promotion losses in the U.S.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;43.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen's share of co-promotion losses in the U.S.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;21.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:SummaryOfActivityRelatedToCollaborationWithCompanySevenTableTextBlock>
	<biib:SummaryOfCommonStockTableTextBlock contextRef="FD2016Q4YTD" id="Fact-5F608E03FD5F3C19F1AA7411E0121EAA">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="18" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:24%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;As of December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Authorized&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Issued&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Authorized&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Issued&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Common stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,000.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;238.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;215.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,000.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;241.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;218.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:SummaryOfCommonStockTableTextBlock>
	<biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock contextRef="FD2016Q4YTD" id="Fact-1569ED0A092796EE412A7411DFC42153">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Reduction of accounts receivable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;166.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;144.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Component of accrued expenses and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;438.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;518.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total revenue-related reserves&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;605.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;662.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock>
	<biib:TimeVestedRestrictedStockUnitsActivityTableTextBlock contextRef="FD2016Q4YTD" id="Fact-453DA9B3605BC6E2A90F7411DFEE2E9B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Grant&amp;#160;Date&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;810,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;323.87&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Granted (a)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;649,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;268.52&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Vested&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(406,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;285.13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(165,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;310.30&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;888,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;303.49&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:TimeVestedRestrictedStockUnitsActivityTableTextBlock>
	<us-gaap:AdditionalFinancialInformationDisclosureTextBlock contextRef="FD2016Q4YTD" id="Fact-E9CFC536FCEF636A153D7411E0131958">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Other Consolidated Financial Statement Detail&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Supplemental Cash Flow Information&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Supplemental disclosure of cash flow information for the years ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, is as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:51%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash paid during the year for:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;281.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;39.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;41.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,642.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,674.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,163.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Non-cash Operating, Investing and Financing Activity&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In December 2016 we accrued &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$454.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to the recent settlement and license agreement with Forward Pharma A/S (Forward Pharma). For additional information related to this transaction, please read Note 21, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Commitment and Contingencies&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In the fourth quarter of 2016 we accrued &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$300.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; upon reaching &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$11.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in total cumulative sales of Fumapharm Products. The amount, net of tax benefit, was accounted for as an increase to goodwill in accordance with the accounting standard applicable to business combinations when we acquired Fumapharm and is expected to be paid in the first quarter of 2017. For additional information related to this transaction, please read Note 21, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Commitments and Contingencies&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with the construction of our manufacturing facility in Solothurn, Switzerland, we accrued charges related to processing equipment and engineering services of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$100.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in our consolidated balance sheet. For additional information related to this transaction, please read Note 10,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt; Property, Plant and Equipment&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In February 2015 upon completion of our acquisition of Convergence, we recorded a contingent consideration obligation of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$274.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as part of the purchase price. For additional information related to this transaction, please read Note 2, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Acquisitions&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Other Income (Expense), Net&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Components of other income (expense), net, are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;63.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;22.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;12.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(260.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(95.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(29.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gain (loss) on investments, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;6.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(3.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;11.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Foreign exchange gains (losses), net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(9.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(32.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(11.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(17.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(13.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(8.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total other income (expense), net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(217.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(123.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(25.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Other Current Assets&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets include prepaid taxes totaling approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$817.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$550.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Accrued Expenses and Other&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other consists of the following:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current portion of contingent consideration obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;580.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;504.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued TECFIDERA litigation settlement and license charges&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;454.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenue-related reserves for discounts and allowances&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;438.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;518.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Employee compensation and benefits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;282.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;270.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Royalties and licensing fees&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;195.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;167.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Construction in progress&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;134.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;87.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Collaboration expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;130.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;31.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;685.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;516.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total accrued expenses and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,903.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,096.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Pricing of TYSABRI in Italy - AIFA&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In the fourth quarter of 2011 Biogen Italia SRL, our Italian subsidiary,&amp;#160;received a notice from the Italian National Medicines Agency (Agenzia Italiana del Farmaco or AIFA) that sales of TYSABRI after mid-February 2009 through mid-February 2011 exceeded by EUR&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;30.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; a reimbursement limit established pursuant to a Price Determination Resolution granted by AIFA in December 2006. In January 2012 we filed an appeal against AIFA in administrative court in Rome, Italy seeking a ruling that the reimbursement limit in the Price Determination Resolution should apply as written to only &amp;#8220;the first &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;24&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months&amp;#8221; of TYSABRI sales, which ended in mid-February 2009. That appeal is still pending. Since being notified in the fourth quarter of 2011 that AIFA believed a reimbursement limit was still in effect, we deferred revenue on sales of TYSABRI as if the reimbursement limit were in effect for each biannual period beginning in mid-February 2009. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In July 2013 we negotiated an agreement in principle with AIFA's Price and Reimbursement Committee that would have resolved all of AIFA's claims relating to sales of TYSABRI in excess of the reimbursement limit for the periods from February 2009 through January 2013 for an aggregate repayment of EUR&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;33.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. As a result of this agreement in principle, we recorded a liability and reduction to revenue of EUR&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;15.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; at June 30, 2013, which approximated &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;50%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the claim related to the period from mid-February 2009 through mid-February 2011. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we have approximately EUR&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;79 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; recorded as accrued expenses and other in our consolidated balance sheets for the periods mid-February 2009 through January 2013, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In June 2014 AIFA approved a resolution affirming that there is no reimbursement limit from and after February 2013. As a result, we recognized &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$53.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of TYSABRI revenues related to the periods February 2013 through June 2014 that were previously deferred. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In January 2017 we negotiated an agreement in principle with AIFA's Price and Reimbursement Committee to settle all of AIFA's existing claims relating to sales of TYSABRI in excess of the reimbursement limit for the periods from February 2009 through January 2013 for an aggregate repayment of EUR&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;37.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. The agreement is subject to ratification by AIFA. If this most recent settlement agreement is accepted, we will recognize approximately EUR&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;42 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in revenue upon final resolution of this matter.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:AdditionalFinancialInformationDisclosureTextBlock>
	<us-gaap:AvailableForSaleSecuritiesTextBlock contextRef="FD2016Q4YTD" id="Fact-FBA3869496E99491D48E7411DFF46D32">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2016 (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,408.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(0.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,409.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,255.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(4.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,258.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,156.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,156.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,016.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(3.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,019.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;4.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;4.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;557.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(2.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;559.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total marketable debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5,398.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(11.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5,406.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities, non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;24.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(9.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;33.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2015 (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;394.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;394.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,116.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(4.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,120.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,723.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,724.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,152.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(3.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,155.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;491.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;493.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total marketable debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4,880.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(10.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4,891.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities, non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;37.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;9.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;28.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:AvailableForSaleSecuritiesTextBlock>
	<us-gaap:BusinessCombinationsPolicy contextRef="FD2016Q4YTD" id="Fact-C6A648607F9050C1B1327411DFDC7A6E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The consideration for our acquisitions often includes future payments that are contingent upon the occurrence of a particular event. For acquisitions completed before January 1, 2009, we record contingent consideration resulting from a business combination when the contingency is resolved. For acquisitions that qualify as business combinations completed after January&amp;#160;1, 2009, we record an obligation for such contingent payments at fair value on the acquisition date. We estimate the fair value of contingent consideration obligations through valuation models that incorporate probability-adjusted assumptions related to the achievement of the milestones and thus likelihood of making related payments. We revalue these contingent consideration obligations each reporting period. Changes in the fair value of our contingent consideration obligations are recognized in our consolidated statements of income. Changes in the fair value of the contingent consideration obligations can result from changes to one or multiple inputs, including adjustments to the discount rates, changes in the amount or timing of expected expenditures associated with product development, changes in the amount or timing of cash flows and reserves associated with products upon commercialization, changes in the assumed achievement or timing of any cumulative sales-based and development milestones, changes in the probability of certain clinical events and changes in the assumed probability associated with regulatory approval. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Discount rates in our valuation models represent a measure of the credit risk associated with settling the liability. The period over which we discount our contingent obligations is based on the current development stage of the product candidates, our specific development plan for that product candidate adjusted for the probability of completing the development step, and when the contingent payments would be triggered. In estimating the probability of success, we utilize data regarding similar milestone events from several sources, including industry studies and our own experience. These fair value measurements are based on significant inputs not observable in the market. Significant judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, changes in assumptions could have a material impact on the amount of contingent consideration expense we record in any given period.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BusinessCombinationsPolicy>
	<us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="FD2016Q4YTD" id="Fact-36EC0421483C7EBDF7567411DFDF1EDA">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We consider only those investments which are highly liquid, readily convertible to cash and that mature within three months from date of purchase to be cash equivalents. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, cash equivalents were comprised of money market funds and commercial paper, overnight reverse repurchase agreements and other debt securities with maturities less than 90 days from the date of purchase.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
	<us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock contextRef="FD2016Q4YTD" id="Fact-3D097AB4EB43D5F5AF6D7411DFFE81F1">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Financial Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our financial assets with maturities of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;less than 90&amp;#160;days&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; from the date of purchase included in cash and cash equivalents on the accompanying consolidated balance sheet:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Commercial paper&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;31.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;21.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Overnight reverse repurchase agreements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;134.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;741.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;673.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Short-term debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,266.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;79.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,039.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;909.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The carrying values of our commercial paper, including accrued interest, overnight reverse repurchase agreements, money market funds and our short-term debt securities approximate fair value due to their short term maturities. Our overnight reverse repurchase agreements were collateralized with agency-guaranteed mortgage-backed securities and represented approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.7%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of total assets as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following tables summarize our marketable debt and equity securities, classified as available for sale:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2016 (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,408.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(0.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,409.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,255.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(4.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,258.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,156.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,156.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,016.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(3.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,019.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;4.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;4.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;557.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(2.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;559.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total marketable debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5,398.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(11.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5,406.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities, non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;24.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(9.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;33.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2015 (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;394.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;394.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,116.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(4.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,120.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,723.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,724.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,152.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(3.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,155.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;491.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;493.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total marketable debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4,880.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(10.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4,891.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities, non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;37.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;9.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;28.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Summary of Contractual Maturities: Available-for-Sale Securities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;As of December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Estimated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&amp;#160; Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Estimated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&amp;#160; Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due in one year or less&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,568.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,569.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,120.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,122.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due after one year through five years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,552.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,559.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,575.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,583.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due after five years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;276.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;277.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;184.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;185.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total available-for-sale securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5,398.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5,406.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4,880.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4,891.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The average maturity of our marketable debt securities available-for-sale as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; was &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;12&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;months and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;16&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Proceeds from Marketable Debt Securities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Proceeds from maturities and sales&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;7,378.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4,063.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,718.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Realized gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Realized losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;4.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Realized losses for the year ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, primarily relate to sales of corporate bonds, agency mortgage-backed securities and other asset-backed securities. Realized losses for the year ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, primarily relate to sales of corporate bonds, agency mortgage-backed securities and other asset-backed securities. Realized losses for the year ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, primarily relate to sales of agency mortgage-backed securities and government securities.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Strategic Investments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, our strategic investment portfolio was comprised of investments totaling &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$99.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$96.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, which are included in investments and other assets in our consolidated balance sheets. Our strategic investment portfolio includes investments in equity securities of certain biotechnology companies and investments in venture capital funds where the underlying investments are in equity securities of biotechnology companies.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock>
	<us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="FD2016Q4YTD" id="Fact-E5FDC7E08F26EDE01CED7411DFE3AC34">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Collaborative and Other Relationships&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with our business strategy, we have entered into various collaboration agreements which provide us with rights to develop, produce and market products using certain know-how, technology and patent rights maintained by our collaborative partners. Terms of the various collaboration agreements may require us to make milestone payments upon the achievement of certain product research and development objectives and pay royalties on future sales, if any, of commercial products resulting from the collaboration.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Depending on the collaborative arrangement, we may record funding receivable or payable balances with our partners, based on the nature of the cost-sharing mechanism and activity within the collaboration. Our significant collaboration arrangements are discussed below.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Genentech (Roche Group)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other potential anti-CD20 therapies under a collaboration agreement with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group. The Roche Group and its sub-licensees maintain sole responsibility for the development, manufacturing and commercialization of GAZYVA in the U.S. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our collaboration agreement will continue in effect until we mutually agree to terminate the collaboration, except that if we undergo a change in control, as defined in the collaboration agreement, Genentech has the right to present an offer to buy the rights to RITUXAN and we must either accept Genentech&amp;#8217;s offer or purchase Genentech&amp;#8217;s rights on the same terms as its offer. Genentech will also be deemed concurrently to have purchased our rights to any other anti-CD20 products in development in exchange for a royalty and our rights to GAZYVA in exchange for the compensation described in the table below. Our collaboration with Genentech was created through a contractual arrangement and not through a joint venture or other legal entity.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;RITUXAN&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Genentech is responsible for the worldwide manufacturing of RITUXAN. Development and commercialization rights and responsibilities under this collaboration are divided as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;U.S.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We share with Genentech co-exclusive rights to develop, commercialize and market RITUXAN in the U.S.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Canada&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We and Genentech have assigned our rights under our collaboration agreement with respect to Canada to the Roche Group.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;GAZYVA&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We recognize our share of the development and commercialization expenses of GAZYVA as a reduction of our share of pre-tax profits in revenues from anti-CD20 therapeutic programs. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Commercialization of GAZYVA impacts our percentage of the co-promotion profits for RITUXAN, as summarized in the table below.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;OCREVUS (Ocrelizumab)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Genentech is solely responsible for development and commercialization of OCREVUS, a humanized anti-CD20 monoclonal antibody currently in development for MS, and funding future costs. Genentech cannot develop OCREVUS in CLL, NHL or Rheumatoid Arthritis (RA). We will receive tiered royalties between &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;13.5%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;24%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; on U.S. net sales of OCREVUS if approved for commercial sale by the FDA. The FDA has accepted for review the Biologics License Application for OCREVUS for the treatment of relapsing multiple sclerosis (RMS) and primary-progressive multiple sclerosis (PPMS), and has granted the application Priority Review Designation. There will be a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;50%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; reduction to these royalties if a biosimilar to OCREVUS is approved in the U.S. In addition, we will receive a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; royalty on net sales of OCREVUS outside the U.S., with the royalty period lasting &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;11&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; years from the first commercial sale of OCREVUS on a country-by-country basis. In June 2016 the European Medicines Agency (EMA) validated its marketing authorization application (MAA) of OCREVUS for the treatment of RMS and PPMS in the E.U. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Commercialization of OCREVUS will not impact the percentage of the co-promotion profits we receive for RITUXAN or GAZYVA.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Profit-sharing Formulas&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;RITUXAN Profit Share&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our current pretax co-promotion profit-sharing formula for RITUXAN provides for a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;30%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; share on the first &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$50.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of co-promotion operating profits earned each calendar year. Our share of annual co-promotion profits in excess of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$50.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; varies, as summarized in the table below, upon the following events:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:82%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Until GAZYVA First Non-CLL FDA Approval&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;40.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;After GAZYVA First Non-CLL FDA Approval until First GAZYVA Threshold Date&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;39.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;After First GAZYVA Threshold Date until Second GAZYVA Threshold Date&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;37.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;After Second GAZYVA Threshold Date&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;35.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;"&gt;First Non-CLL GAZYVA FDA Approval&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; means the FDA&amp;#8217;s first approval of GAZYVA in an indication other than CLL.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;padding-left:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;"&gt;First GAZYVA Threshold Date&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; means the earlier of (1)&amp;#160;the date of the First Non-CLL GAZYVA FDA approval if U.S. gross sales of GAZYVA for the preceding consecutive 12 month period were at least &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$150.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; or (2)&amp;#160;the first day of the calendar quarter after the date of the First Non-CLL GAZYVA FDA Approval that U.S. gross sales of GAZYVA within any consecutive 12 month period have reached &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$150.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;"&gt;Second GAZYVA Threshold Date&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; means the first day of the calendar quarter after U.S. gross sales of GAZYVA within any consecutive 12 month period have reached &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$500.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. The Second GAZYVA Threshold Date can be achieved regardless of whether GAZYVA has been approved in a non-CLL indication.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our share of RITUXAN pre-tax profits in the U.S. decreased to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;39%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; from &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;40%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as GAZYVA was approved by the FDA in follicular lymphoma in February 2016. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In addition, should the FDA approve an anti-CD20 product other than OCREVUS or GAZYVA that is acquired or developed by Genentech and subject to the collaboration agreement, our share of the co-promotion operating profits would be between &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;30%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;38%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; based on certain events.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;GAZYVA Profit Share&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our current pretax profit-sharing formula for GAZYVA provides for a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;35%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; share on the first &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$50.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of operating profits earned each calendar year. Our share of annual profits in excess of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$50.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; varies, as summarized in the table below, upon the following events:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:82%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Until First GAZYVA Threshold Date&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;39.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;After First GAZYVA Threshold Date until Second GAZYVA Threshold Date&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;37.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;After Second GAZYVA Threshold Date&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;35.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, our share of operating losses on GAZYVA was &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;35%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Revenues from Anti-CD20 Therapeutic Programs&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from anti-CD20 therapeutic programs are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,249.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,269.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,117.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenue on sales in the rest of world for RITUXAN&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;65.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;69.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;78.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total revenues from anti-CD20 therapeutic programs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,314.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,339.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,195.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;39%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; profit-sharing threshold was met during the first quarter. In &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;40%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; profit-sharing threshold was met during the first quarter.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Prior to regulatory approval, we record our share of the expenses incurred by the collaboration for the development of anti-CD20 products in research and development expense in our consolidated statements of income. After an anti-CD20 product is approved, we record our share of the development expenses related to that product as a reduction of our share of pre-tax profits in revenues from anti-CD20 therapeutic programs. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Acorda&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In 2009 we entered into a collaboration and license agreement with Acorda Therapeutics, Inc. (Acorda) to develop and commercialize products containing fampridine in markets outside the U.S, including FAMPYRA.&amp;#160;We also have responsibility for regulatory activities and the future clinical development of related products in those markets. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Under the terms of the collaboration and license agreement, we pay Acorda tiered royalties based on the level of ex-U.S. net sales. We may pay up to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$375.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of additional milestone payments to Acorda based on the successful achievement of certain regulatory and commercial milestones. The next expected milestone would be &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$15.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, due if ex-U.S. net sales reach &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$100.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; over a period of four consecutive quarters. We will capitalize these additional milestones as intangible assets upon achievement of the milestone which will then be amortized utilizing an economic consumption model and recognized as amortization of acquired intangible assets. Royalty payments are recognized as a cost of goods sold.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with the collaboration and license agreement, we have also entered into a supply agreement with Acorda for the commercial supply of FAMPYRA. This agreement is a sublicense arrangement of an existing agreement between Acorda and Alkermes, who acquired Elan Drug Technologies, the original party to the license with Acorda. During the years ending &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, total cost of sales related to royalties and commercial supply of FAMPRYA reflected in our consolidated statements of income were &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$31.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$30.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$29.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;AbbVie&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have a collaboration agreement with AbbVie aimed at advancing the development and commercialization of ZINBRYTA in MS, which was approved for the treatment of relapsing forms of MS in the U.S. in May 2016 and the E.U. in July 2016. We made milestone payments totaling &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$32.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to these approvals, which were capitalized as intangible assets, net in our consolidated balance sheets. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Under the agreement, we and AbbVie conduct ZINBRYTA co-promotion activities in the U.S., E.U. and Canadian territories (Collaboration Territory), where development and commercialization costs and profits are shared equally. Outside of the Collaboration Territory, we are solely responsible for development and commercialization of ZINBRYTA and will pay a tiered royalty to AbbVie as a percentage of net sales in the low to high teens.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; We are responsible for manufacturing and research and development activities in both the Collaboration Territory and outside the Collaboration Territory and will record these activities within their respective lines in our consolidated statements of income, net of any reimbursement of research and development expenditures received from AbbVie.&amp;#160;For the years ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the collaboration incurred &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$48.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$113.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$117.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for research and development activities, for which we recognized &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$24.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$60.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$67.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, in our consolidated statements of income. During &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; we made milestone payments of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$16.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for the development of ZINBRYTA as a result of filing for regulatory approval in the U.S. and E.U. during the year. These payments were recorded as research and development expense in our consolidated statements of income.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Prior to regulatory approval, we also recognized &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$22.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of pre-commercialization expenses within our selling, general and administrative expense, which represents &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;50%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the collaboration's pre-commercialization costs for &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. After ZINBRYTA was approved by the FDA and EMA in &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we began to recognize our share of the collaboration activities within the U.S., E.U. and Canadian territories as described below.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Co-promotion Profits and Losses&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In the U.S., AbbVie recognizes revenues on sales to third parties and we recognize our &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;50%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; share of the co-promotion profits or losses as a component of total revenues in our consolidated statements of income. The collaboration began selling ZINBRYTA in the U.S. in the third quarter of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. For the year ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recognized a net reduction in revenue of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$21.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to reflect our share of an overall net loss within the collaboration.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table provides a summary of the U.S. collaboration and our share of the co-promotion losses on ZINBRYTA in the U.S.:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:84%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Year Ended December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Product revenues, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;6.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Costs and expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;50.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Co-promotion losses in the U.S.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;43.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen's share of co-promotion losses in the U.S.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;21.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In the E.U. and Canada, we recognize revenues on sales to third parties in product revenues, net in our consolidated statements of income. We also record the related cost of revenues and sales and marketing expenses to their respective line items in our consolidated statements of income as these costs are incurred. We reimburse AbbVie for their &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;50%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; share of the co-promotion profits or losses in the E.U. and Canada. This reimbursement is recognized in collaboration profit (loss) sharing in our consolidated statements of income. We began to recognize product revenues on sales of ZINBRYTA in the E.U. in the third quarter of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. For the year ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recognized income of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$4.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to reflect AbbVie's &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;50%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; sharing of the net collaboration losses in the E.U. and Canada. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Swedish Orphan Biovitrum AB (publ)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In January 2007 we acquired &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;100%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the stock of Syntonix. Syntonix, now known as Bioverativ Therapeutics Inc. (formerly Biogen Hemophilia Inc.), had previously entered into a collaboration agreement with Swedish Orphan Biovitrum AB (publ) (Sobi) to jointly develop and commercialize Factor VIII and Factor IX hemophilia products, including ELOCTATE and ALPROLIX. Under an amended and restated collaboration agreement, we have commercial rights for North America (the Biogen North America Territory) and for rest of the world markets outside of the Sobi Territory, as defined below (the Biogen Direct Territory).&amp;#160;Subject to the exercise of an option right that Sobi controls, Sobi has commercial rights in substantially all of Europe, Russia and certain countries in Northern Africa and the Middle East (the Sobi Territory). The collaboration agreement was amended and restated in April 2014. (References to the collaboration agreement refer to the amended and restated collaboration agreement).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In November 2014 Sobi exercised its option to assume final development and commercialization activities in the Sobi Territory for ELOCTA (the trade name for ELOCTATE in the E.U.). In July 2015 Sobi exercised its option to assume final development and commercialization of ALPROLIX in the Sobi Territory. Upon each exercise of opt-in right under the terms of the collaboration agreement, Sobi made a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$10.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; payment in escrow. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;ELOCTA was approved by the EC in November 2015 and Sobi had its first commercial sale of ELOCTA in January 2016. In March 2016 the EC approved the transfer of the marketing authorization for ELOCTA in the E.U. from Biogen to Sobi, making Sobi the marketing authorization holder of ELOCTA in the E.U. As the marketing authorization holder, Sobi assumes full legal responsibility for ELOCTA, from a regulatory perspective, during its entire life cycle in the E.U. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$144.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in expenditures for ELOCTA, net of the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$10.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; escrow payment and other royalty adjustments as described in the table and its footnote (3) below, are reimbursable by Sobi under the collaboration agreement due to its election to assume final development and commercialization of ELOCTA within the Sobi Territory, which is the Opt-In Consideration for ELOCTA. This reimbursement will be recognized by us as royalty revenue in proportion to collaboration revenues, over a ten-year period, consistent with the initial patent term of the product.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;ALPROLIX was approved in the E.U. by the EC in May 2016 and Sobi had its first commercial sale in June 2016. In September 2016 the EC approved the transfer of the marketing authorization for ALPROLIX in the E.U. from Biogen to Sobi, making Sobi the marketing authorization holder of ALPROLIX in the E.U. As the marketing authorization holder, Sobi assumes full legal responsibility for ALPROLIX, from a regulatory perspective, during its entire life cycle in the E.U. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$123.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in expenditures for ALPROLIX, net of the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$10.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; escrow payment and other royalty adjustments as described in the table and its footnote (3) below, are reimbursable to us by Sobi under the collaboration agreement due to Sobi's election to assume final development and commercialization of ALPROLIX in the Sobi Territory, which is the Opt-In Consideration for ALPROLIX. This reimbursement will be recognized by us as royalty revenue in proportion to collaboration revenues, over a ten-year period, consistent with the initial patent term of the product. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The Opt-In Consideration for each product will be paid by Sobi using a cross-royalty cash payment structure for sales in each company&amp;#8217;s respective territories as an adjustment to the Base Rate in the table below. Under the collaboration agreement, cash payments are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.609375%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:51%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:16%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Rates post Sobi Opt-In&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(3)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Royalty and Net Revenue Share Rates:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Method&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Base Rate following&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;1st&amp;#160;commercial&amp;#160;sale&amp;#160;in&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;the Sobi Territory:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Rate during the&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Reimbursement&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Period:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Sobi rate to Biogen on net sales in the Sobi Territory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Royalty&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;12%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Base&amp;#160;Rate&lt;br clear="none"/&gt;plus 5%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Biogen rate to Sobi on net sales in the Biogen North America Territory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Royalty&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;12%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Base Rate&lt;br clear="none"/&gt;less 5%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Biogen rate to Sobi on net sales in the Biogen Direct Territory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Royalty&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;17%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Base Rate&lt;br clear="none"/&gt;less 5%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Biogen rate to Sobi on net revenue&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(1)&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;from the Biogen Distributor Territory&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(2)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Net&lt;br clear="none"/&gt;Revenue&lt;br clear="none"/&gt;Share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;50%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Base Rate&lt;br clear="none"/&gt;less 15%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt;Net revenue represents Biogen&amp;#8217;s pre-tax receipts from third-party distributors, less expenses incurred by Biogen in the conduct of commercialization activities supporting the distributor activities.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt;The Biogen Distributor Territory represents Biogen territories where sales are derived utilizing a third-party distributor.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt;A credit will be issued to Sobi against its reimbursement of the Opt-in Consideration for each product in an amount equal to the difference in the rate paid by Biogen to Sobi on sales in the Biogen territories for certain periods prior to the first commercial sale in the Sobi Territory versus the rate that otherwise would have been payable on such sales.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We are recording revenue at the effective royalty rate expected over the term of the agreement of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;14%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and recording cost of sales at the effective royalty rate expected over the term of the agreement of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;11%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;If the reimbursement of the Opt-in Consideration has not been achieved within &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;six years&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the first commercial sale of such product, we maintain the right to require Sobi to pay any remaining balances due to us within &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;90 days&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the six-year anniversary date of the first commercial sale.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Following the spin-off of our hemophilia business, this collaboration agreement with Sobi will continue with Bioverativ, an independent public company. For additional information about the spin-off, please see Note 1, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Summary of Significant Accounting Policies &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;and Note 26, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Subsequent Events &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Ionis Pharmaceuticals, Inc. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Long-Term Strategic Research Collaboration&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In September 2013 we entered into a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;six&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;-year research collaboration with Ionis, formerly known as Isis Pharmaceuticals Inc. under which both companies collaborate to perform discovery level research and then develop and commercialize antisense or other therapeutics for the treatment of neurological disorders.&amp;#160;Under the collaboration, Ionis will perform research on a set of neurological targets identified within the agreement. Once the research has reached a specific stage of development, we will make the determination whether antisense is the preferred approach to develop a therapeutic candidate or whether another modality is preferred. If antisense is selected, Ionis will continue development and identify a product candidate. If another modality is used, we will assume the responsibility for identifying a product candidate and developing it. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Under the terms of this agreement, we paid Ionis an upfront amount of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$100.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&amp;#160;Of this payment, we recorded prepaid research and discovery services of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$25.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, representing the value of the Ionis full time equivalent employee resources which are required by the collaboration to provide research and discovery services to us over the term.&amp;#160;The remaining &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$75.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the upfront payment was recorded as research and development expense as it represented the purchase of intellectual property that had not reached technological feasibility.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Ionis is also eligible to receive milestone payments, license fees and royalty payments for all product candidates developed through this collaboration, with the specific amount dependent upon the modality of the product candidate advanced by us. During the years ending &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we triggered milestones of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$5.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$20.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$20.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, related to the advancement of IONIS-SOD1&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;sub style="vertical-align:bottom;line-height:120%;font-size:pt"&gt;Rx&lt;/sub&gt;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for the treatment of ALS and other neurological targets identified.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For non-ALS antisense product candidates, Ionis will be responsible for global development through the completion of a Phase 2 trial and we will provide advice on the clinical trial design and regulatory strategy. For ALS antisense product candidates, we are responsible for global development, clinical trial design and regulatory strategy. We have an option to license a product candidate until completion of the Phase 2 trial. If we exercise our option, we will pay Ionis up to a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$70.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; license fee and assume global development, regulatory and commercialization responsibilities. Ionis could receive additional milestone payments upon the achievement of certain regulatory milestones of up to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$130.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, plus additional amounts related to the cost of clinical trials conducted by Ionis under the collaboration, and royalties on future sales if we successfully develop the product candidate after option exercise. &amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For product candidates using a different modality, we will be responsible for global development through all stages and will pay Ionis up to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$90.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; upon the achievement of certain regulatory milestones and royalties on future sales if we successfully develop the product candidate. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Product Collaborations &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In 2012 we entered into three separate exclusive worldwide option and collaboration agreements with Ionis under which both companies will develop and commercialize SPINRAZA (nusinersen) for the treatment of SMA, antisense therapeutics for up to three gene targets and IONIS-DMPK&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;sub style="vertical-align:bottom;line-height:120%;font-size:pt"&gt;RX&lt;/sub&gt;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for the treatment of myotonic dystrophy type 1 (DM1), respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;SPINRAZA (nusinersen)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In January 2012 we entered into an exclusive worldwide option and collaboration agreement with Ionis under which both companies will develop and commercialize the antisense investigational drug candidate, SPINRAZA, for the treatment of SMA. Under the terms of this agreement, we paid Ionis &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$29.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as an upfront payment. During 2014 we amended the agreement to adjust the amount of potential additional payments and terms of the exercise of our opt-in right to license SPINRAZA, which included providing for additional opt-in scenarios, based on the filing or acceptance of a new drug application (NDA) or marketing authorization application with the FDA or EMA. Consistent with the initial agreement, Ionis remained responsible for conducting the pivotal/Phase 3 trials and we provided input on the clinical trial design and regulatory strategy for the development of SPINRAZA.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we triggered clinical trial payments of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$35.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$42.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$57.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, related to the advancement of the program. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In August 2016 we and Ionis announced that SPINRAZA met the primary endpoint for the interim analysis of the Phase 3 trial evaluating SPINRAZA in infantile-onset SMA. In November 2016 we and Ionis announced that SPINRAZA met the primary endpoint for the interim analysis of the Phase 3 trial evaluating SPINRAZA in later-onset SMA. During the third quarter of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; we exercised our option to develop and commercialize SPINRAZA and paid Ionis a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$75.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; license fee in connection with the option exercise. This amount was recognized as research and development expense in our consolidated statements of income. In December 2016 SPINRAZA was approved by the FDA for the treatment of SMA in pediatric and adult patients in the U.S. During the fourth quarter of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; we accrued a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$60.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; milestone payment due to Ionis for the approval of SPINRAZA in the U.S. This amount was capitalized in intangible assets, net in our consolidated balance sheets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During the years ending &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$257.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$74.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$27.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, were reflected in research and development expense in our consolidated statements of income related to the advancement of the program. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We may pay Ionis up to approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$90.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in additional milestone payments upon the achievement of certain regulatory milestones as well as a royalty rate in the mid-teens on future sales of SPINRAZA.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Antisense Therapeutics&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Under the terms of the December 2012 agreement relating to the development and commercialization of up to three gene targets we provided Ionis with an upfront payment of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$30.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and agreed to make potential additional payments, prior to licensing, of up to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$10.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; based on the development of the selected product candidate as well as a mark-up of the cost estimate of the Phase 1 and Phase 2 trials. During &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; we triggered a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$10.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; milestone payment. Ionis will be responsible for global development of any product candidate&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;sub style="vertical-align:bottom;line-height:120%;font-size:pt"&gt; &lt;/sub&gt;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;through the completion of a Phase 2 trial and we will provide advice on the clinical trial design and regulatory strategy. We have an option to license the product candidate&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;sub style="vertical-align:bottom;line-height:120%;font-size:pt"&gt; &lt;/sub&gt;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;until completion of the Phase 2 trial. If we exercise our option, we will pay Ionis up to a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$70.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; license fee and assume global development, regulatory and commercialization responsibilities. Ionis could receive up to another &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$130.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in milestone payments upon the achievement of certain regulatory milestones as well as royalties on future sales&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;sub style="vertical-align:bottom;line-height:120%;font-size:pt"&gt; &lt;/sub&gt;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;if we successfully develop the product candidate after option exercise. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;IONIS-DMPK&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;&lt;sub style="vertical-align:bottom;line-height:120%;font-size:pt"&gt;Rx&lt;/sub&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Under the terms of the June 2012 agreement for the DM1 candidate, we provided Ionis with an upfront payment of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$12.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and agreed to make potential additional payments, prior to licensing, of up to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$59.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; based on the development of the selected product candidate. During &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; we amended the agreement to adjust the amount of potential additional payments by an additional &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$4.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; due to changes in the clinical trial design. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; we terminated the development of the IONIS-DMPK&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;sub style="vertical-align:bottom;line-height:120%;font-size:pt"&gt;Rx &lt;/sub&gt;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;product candidate to treat DM1 and returned the product to Ionis. During the years ending &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$3.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$9.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$10.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, were reflected in research and development expense in our consolidated statements of income. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Eisai Co., Ltd. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;BAN2401 and E2609 Collaboration&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In March 2014 we entered into a collaboration agreement with Eisai Co., Ltd. (Eisai) (Eisai Collaboration Agreement) to jointly develop and commercialize two Eisai product candidates for the treatment of Alzheimer&amp;#8217;s disease, BAN2401, a monoclonal antibody that targets amyloid-beta aggregates, and E2609, a BACE inhibitor.&amp;#160;Under the Eisai Collaboration Agreement, Eisai serves as the global operational and regulatory lead for both compounds and all costs, including research, development, sales and marketing expenses, will be shared equally by us and Eisai. Following marketing approval in major markets, such as the U.S., the E.U. and Japan, we will co-promote BAN2401 and E2609 with Eisai and share profits equally. In smaller markets, Eisai will distribute these products and pay us a royalty. The Eisai Collaboration Agreement also provides the parties with certain rights and obligations in the event of a change in control of either party. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The Eisai Collaboration Agreement also provides Eisai an option to jointly develop and commercialize aducanumab, our anti-amyloid beta antibody candidate for Alzheimer&amp;#8217;s disease (Aducanumab Option) and an option to jointly develop and commercialize one of our anti-tau monoclonal antibodies (Anti-Tau Option). Upon exercise of each of the Aducanumab Option and the Anti-Tau Option, we will execute a separate collaboration agreement with Eisai on terms and conditions that mirror the Eisai Collaboration Agreement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Aducanumab Option&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Eisai may exercise the Aducanumab Option after either (i) the Phase 1b clinical trial for aducanumab and the Phase 2 clinical trial for BAN2401 (Post-Phase 2 Aducanumab Option), or (ii) completion of the Phase 3 clinical trial for aducanumab (Post-Phase 3 Aducanumab Option) under certain conditions. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The consideration we will receive if Eisai exercises the Post-Phase 2 Aducanumab Option depends on the development status of BAN2401. If BAN2401 is then determined to advance to Phase 3, we will be entitled to receive a single payment from Eisai upon regulatory approval of aducanumab and we will no longer be required to pay Eisai any milestone payments for products containing BAN2401 under the Eisai Collaboration Agreement. If the development of BAN2401 has instead been terminated, we will receive development and commercial milestone payments from Eisai (Post-Phase 2 Aducanumab Milestone Payments). If Eisai does not exercise its Post-Phase 2 Aducanumab Option, we may elect to terminate the Eisai Collaboration Agreement with respect to BAN2401 but, under certain conditions, will have the option to reinstate the Eisai Collaboration Agreement after completion of a BAN2401 Phase 3 clinical trial.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;If Eisai exercises its Post-Phase 3 Aducanumab Option, Eisai will be required to pay us all Phase 3 development and commercialization costs plus a mark-up and an amount equal to any unpaid Post-Phase 2 Aducanumab Milestone Payments that would have been payable if Eisai had exercised its Post-Phase 2 Aducanumab Option. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Anti-Tau Option&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Eisai may exercise the Anti-Tau Option after completion of the Phase 1 clinical trial of such anti-tau monoclonal antibody. If Eisai exercises its Anti-Tau Option, we will receive an upfront payment from Eisai and will be entitled to additional development and commercial milestone payments.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Upon the effective date of the Eisai Collaboration Agreement, we paid Eisai &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$100.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and recorded &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$17.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, reflecting the fair value of the options granted under the Eisai Collaboration Agreement, both of which were classified as research and development expense in our consolidated statements of income. During the second quarter of 2014 Eisai exercised its option under the Eisai Collaboration Agreement to expand the joint development and commercialization activities to include Japan. Upon such exercise, we paid Eisai an additional &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$35.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, and recorded &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$21.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as research and development expense in our consolidated statements of income, which represented the difference between the payment made upon exercise of the option and the fair value of that option recorded as research and development expense upon closing of the agreement in the first quarter of 2014. During the fourth quarter of 2016 we recognized a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$50.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; milestone payment related to the initiation of a phase 3 trial for E2609, which is included in research and development expense in our consolidated statements of income. We could pay Eisai up to an additional &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; under the Eisai Collaboration Agreement based on the future achievement of certain development, regulatory and commercial milestones.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In addition to our arrangements with Eisai, Neurimmune is entitled to milestone and royalty payments related to the development and commercialization of aducanumab and certain anti-tau antibodies. For additional information regarding our agreement with Neurimmune, please see Note 18, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Investments in Variable Interest Entities&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;A summary of activity related to our collaboration with Eisai is as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:56%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Years Ended&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total development expense incurred by the collaboration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;95.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;84.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;57.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen&amp;#8217;s share of development expense, excluding upfront and milestone payments, reflected in our consolidated statements of income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;50.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;40.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;29.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Applied Genetic Technologies Corporation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In July 2015 we announced a collaboration and license agreement to develop gene-based therapies for multiple ophthalmic diseases with Applied Genetic Technologies Corporation (AGTC). The collaboration will focus on the development of a portfolio of AGTC&amp;#8217;s therapeutic programs, including both a clinical-stage candidate for X-linked Retinoschisis (XLRS) and a pre-clinical candidate for the treatment of X-Linked Retinitis Pigmentosa (XLRP). The agreement also includes options for early stage discovery programs in two ophthalmic diseases and one non-ophthalmic condition, as well as an equity investment in AGTC.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During the third quarter of 2015 we made an upfront payment of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$124.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which included a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$30.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; equity investment in AGTC, prepaid research and development expenditures of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$58.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and total licensing and other fees of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$35.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. The &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$58.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of prepaid research and development expenditures were recorded in investments and other assets in our consolidated balance sheets and will be expensed as the services are provided. During &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; we recorded &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$54.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as research and development expense associated with AGTC in our consolidated statements of income, including the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$35.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; total licensing and other fees, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$6.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in research and development services, a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$7.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; premium on our equity investment and a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$5.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; clinical development milestone related to XLRS. During &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; we recorded &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$26.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in research and development services in research and development expense in our consolidated statements of income.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;AGTC is eligible to receive development, regulatory and commercial milestone payments aggregating in excess of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.1 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which includes up to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$472.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; collectively for the two lead programs and up to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$592.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; across the discovery programs. AGTC is also eligible to receive royalties in the mid-single digit to mid-teen percentages of annual net sales. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We were granted worldwide commercialization rights for the XLRS and XLRP programs. AGTC has an option to share development costs and profits after the initial clinical trial data are available, and an option to co-promote the second of these products to be approved in the U.S. AGTC will lead the clinical development programs of XLRS through product approval and of XLRP through the completion of first-in-human trials. We will support the clinical development costs, subject to certain conditions, following the first-in-human study for XLRS and IND-enabling studies for XLRP. Under the manufacturing license, we have received an exclusive license to use AGTC&amp;#8217;s proprietary technology platform to make AAV vectors for up to six genes, three of which are in AGTC&amp;#8217;s discretion, in exchange for payment of milestones and royalties.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;University of Pennsylvania&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In May 2016 we entered into a collaboration and alliance with the University of Pennsylvania (UPenn) to advance gene therapy and gene editing technologies. The collaboration will primarily focus on the development of therapeutic approaches that target the eye, skeletal muscle and the central nervous system. The alliance is also expected to focus on the research and validation of next-generation gene transfer technology using adeno-associated virus gene delivery vectors and exploring the expanded use of genome editing technology as a potential therapeutic platform.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During the second quarter of 2016 we paid Penn an upfront fee of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$20.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which was recorded as research and development expense in our consolidated statements of income, and prepaid research and development expenditures of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$15.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which was recorded in investments and other assets in our consolidated balance sheets. We also expect to fund an additional &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$47.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in the aggregate in research and development costs extending over the next three to five years in seven preclinical research and development programs, as well as the exploration of genome-editing technology.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;If all of the collaborations programs are successful and we exercise all of our options under the Penn collaboration and alliance, we may be required to make future payments of over &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$2.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in research funding, options and milestone payments, in addition to royalties payable on net sales of products.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Sangamo BioSciences, Inc. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In February 2014 we completed an exclusive worldwide research, development and commercialization collaboration and license agreement with Sangamo under which both companies will develop and commercialize product candidates for the treatment of two inherited blood disorders, sickle cell disease and beta-thalassemia.&amp;#160;The collaboration is currently in the research stage of development.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Under the terms of the agreement, we paid Sangamo an upfront payment of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$20.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in cash, with additional payments of up to approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$300.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; based on the achievement of certain development, regulatory and commercial milestones, plus royalties based on sales.&amp;#160;We recorded the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$20.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; upfront payment as research and development expense in our consolidated statements of income. Under this arrangement, Sangamo will be responsible for identifying a product candidate for the treatment of beta-thalassemia and advancing that candidate through a completed Phase 1 human clinical trial, at which point we would assume responsibility for development.&amp;#160;We will jointly develop a sickle cell disease candidate through the potential filing of an investigative new drug application, after which we would assume clinical responsibilities. We will lead the global development and commercialization efforts and Sangamo will have the option to assume co-promotion responsibilities in the U.S.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During the years ending &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$13.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$13.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$28.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, of expense was reflected in our consolidated statements of income.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Following the spin-off of our hemophilia business, this collaboration and license agreement with Sangamo will continue with Bioverativ, an independent public company. For additional information about the spin-off, please see Note 1, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Summary of Significant Accounting Policies&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and Note 26, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Subsequent Events &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Mitsubishi Tanabe Pharma Corporation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In September 2015 we announced an agreement with Mitsubishi Tanabe Pharma Corporation (MTPC) to exclusively license amiselimod (MT-1303), a late stage experimental medicine with potential in multiple autoimmune indications. Amiselimod is an oral compound that targets the sphingosine 1-phosphate receptor. During the fourth quarter of 2015 the agreement became effective and we made an upfront payment of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$60.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which was recorded as research and development expense in our consolidated statements of income. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During the third quarter of 2016 we discontinued our development of amiselimod. We expect to formally terminate the agreement and return the program to MTPC in the first quarter of 2017. We will have no further license to or continuing involvement in the development of this compound. For the year ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$22.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; was reflected in research and development expense in our consolidated statements of income.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Other Research and Discovery Arrangements &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During the years ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we entered into several research, discovery and other related arrangements that resulted in &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$10.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$9.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$40.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, recorded as research and development expense in our consolidated statements of income. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;These additional arrangements include the potential for future milestone payments based on clinical and commercial development over a period of several years. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Samsung Bioepis&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Joint Venture Agreement&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In February 2012 we entered into a joint venture agreement with Samsung BioLogics Co. Ltd. (Samsung Biologics), establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar pharmaceuticals.&amp;#160;Samsung Biologics contributed &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;280.5 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; South Korean won (approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$250.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;) for an &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;85%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; stake in Samsung Bioepis and we contributed approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;49.5 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; South Korean won (approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$45.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;) for the remaining &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;15%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; ownership interest.&amp;#160;Under the joint venture agreement, we have no obligation to provide any additional funding and our ownership interest may be diluted due to financings in which we do not participate. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, our ownership interest is approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.5%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which reflects the effect of additional equity financings in which we did not participate. We maintain an option to purchase additional stock in Samsung Bioepis that would allow us to increase our ownership percentage up to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;49.9%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&amp;#160;The exercise of this option is within our control and is based on paying for &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;49.9%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the total investment made by Samsung Biologics into Samsung Bioepis in excess of what we have already contributed under the agreement plus a rate that will represent their return on capital. If we do not exercise this option by a date in 2018 determined pursuant to the joint venture agreement, this option will expire and Samsung Biologics will have the right to purchase all of Samsung Bioepis&amp;#8217; shares then held by us.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Samsung Biologics has the power to direct the activities of Samsung Bioepis which will most significantly and directly impact its economic performance.&amp;#160;We account for this investment under the equity method of accounting as we maintain the ability to exercise significant influence over Samsung Bioepis through a presence on the entity&amp;#8217;s Board of Directors and our contractual relationship.&amp;#160;Under the equity method, we recorded our original investment at cost and subsequently adjust the carrying value of our investment for our share of equity in the entity&amp;#8217;s income or losses according to our percentage of ownership. We recognize our share of the results of operations related to our investment in Samsung Bioepis one quarter in arrears when the results of the entity become available, which is reflected as equity in loss of investee, net of tax in our consolidated statements of income. During the years ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recognized a loss on our investment of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$12.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$15.1 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. During &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, as our share of losses exceeded the carrying value of our investment, we suspended recognizing additional losses and will continue to do so unless we commit to providing additional funding.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Commercial Agreement&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In December 2013 pursuant to our rights under the joint venture agreement with Samsung Biologics, we entered into an agreement with Samsung Bioepis to commercialize, over a 10-year term, three anti-tumor necrosis factor (TNF) biosimilar product candidates in Europe and in the case of one anti-TNF biosimilar, Japan.&amp;#160;Under the terms of this agreement, we have made total upfront and clinical development milestone payments of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$46.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, all of which have been recorded as research and development expense in our consolidated statements of income as the programs they relate to had not achieved regulatory approval. We also agreed to make additional milestone payments of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$25.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; upon regulatory approval in the E.U. for each of the three anti-TNF biosimilar product candidates. During the year ended December 31, 2016, we paid &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$50.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in milestone payments, which have been capitalized in intangible assets, net in our consolidated balance sheets as BENEPALI received regulatory approval in the E.U. in January 2016 and FLIXABI received regulatory approval in the E.U. in May 2016. In July 2016 the EMA accepted Samsung Bioepis' MAA for SB5, an adalimumab biosimilar candidate referencing HUMIRA.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We began to recognize revenue on sales of BENEPALI in the E.U. in the first quarter of 2016 and FLIXABI in the E.U. in the third quarter of 2016. We reflect revenues on sales of BENEPALI and FLIXABI to third parties in product revenues, net in our consolidated statements of income and record the related cost of revenues and sales and marketing expenses in our consolidated statements of income to their respective line items when these costs are incurred. We share &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;50%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the profit or loss related to our commercial agreement with Samsung Bioepis. This profit sharing with Samsung Bioepis is recognized in collaboration profit (loss) sharing in our consolidated statements of income. For the year ended December 31, 2016, we recognized a net expense of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$15.1 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to the collaboration profit share. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Other Services&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Simultaneous with the formation of Samsung Bioepis, we also entered into a license agreement, a technical development services agreement and a manufacturing agreement with Samsung Bioepis. Under the terms of the license agreement, we granted Samsung Bioepis an exclusive license to use, develop, manufacture and commercialize biosimilar products created by Samsung Bioepis using Biogen product-specific technology. In exchange, we will receive single digit royalties on all biosimilar products developed and commercialized by Samsung Bioepis. Under the terms of the technical development services agreement, we provide Samsung Bioepis technical development and technology transfer services, which include, but are not limited to, cell culture development, purification process development, formulation development and analytical development. Under the terms of our manufacturing agreement, we manufacture clinical and commercial quantities of bulk drug substance of biosimilar products for Samsung Bioepis pursuant to contractual terms.&amp;#160;Under limited circumstances, we may also supply Samsung Bioepis with quantities of drug product of biosimilar products for use in clinical trials through arrangements with third-party contract manufacturers. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the years ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recognized &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$20.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$62.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$58.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, in revenues in relation to these services, which is reflected as a component of other revenues in our consolidated statements of income.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
	<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="FD2016Q4YTD" id="Fact-3DD7C8C04521280BD2E37411E008DBAC">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Commitments and Contingencies&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;TECFIDERA Litigation Settlement and License Agreement&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In January 2017 we agreed to enter into a settlement and license agreement with Forward Pharma that will provide us an irrevocable license to all intellectual property owned by Forward Pharma and results in the termination of the German Infringement Litigation. Under the terms of the settlement and license agreement with Forward Pharma, we have agreed to pay Forward Pharma &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.25 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in cash. Under certain circumstances outlined in the agreement, we will pay Forward Pharma royalties on net sales of our products for the treatment of multiple sclerosis that are covered by a Forward Pharma patent and have dimethyl fumarate (&amp;#8220;DMF&amp;#8221;) as an active pharmaceutical ingredient.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During the fourth quarter of 2016 we recognized a pre-tax charge of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$454.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to this matter. This amount represents the fair value of estimated royalties on our sales of TECFIDERA during the period April 2014 through December 31, 2016. When the cash payment is made following approval of the settlement and license agreement, we will recognize assets of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$656.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$138.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, reflecting the estimated fair value of the license acquired that is attributable to the U.S. and E.U., respectively. If Forward Pharma does not receive a patent in either the Interference Proceeding pending in the U.S. or the pending European Opposition Proceeding (which proceedings are defined in the settlement and license agreement), we would likely recognize an immediate impairment charge equal to the value of the license that is attributable to that jurisdiction as additional litigation expense and we would not be obligated to pay Forward Pharma royalties in such jurisdiction. If Forward Pharma receives a patent in either the U.S. Interference Proceeding or the E.U. Opposition Proceeding, we would amortize the assets related to a license of intellectual property in the related jurisdiction utilizing an economic consumption model and we may be obligated to royalties on a country by country basis in Europe and other ex-U.S. markets. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information with respect to the terms of this agreement, including potential royalties payable, please read the Settlement and License Agreement dated January 17, 2017,&amp;#160;between Biogen Swiss Manufacturing GmbH, Biogen International Holding Ltd, Forward Pharma A/S and the other parties thereto which is filed as Exhibit 10.41 to this 2016 Form 10-K. For additional information related to the ongoing Interference Proceeding with Forward Pharma in the U.S. or the European Office Opposition in the E.U., please read Note 20, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Litigation&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;TYSABRI Contingent Payments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In 2013 we acquired from Elan full ownership of all remaining rights to TYSABRI that we did not already own or control. Under the terms of the acquisition agreement, we are obligated to make contingent payments to Elan of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;18%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; on annual worldwide net sales up to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$2.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;25%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; on annual worldwide net sales that exceed &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$2.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. Royalty payments to Elan and other third parties are recognized as cost of sales in our consolidated statements of income. Elan was acquired by Perrigo Company plc (Perrigo) in December 2013. Following that acquisition, we began making these royalty payments to Perrigo.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Contingent Consideration related to Business Combinations&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with our acquisitions of Convergence, Stromedix and Biogen International Neuroscience GmbH (BIN), we agreed to make additional payments based upon the achievement of certain milestone events. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As the acquisitions of Convergence, Stromedix and BIN, formerly Panima Pharmaceuticals AG, occurred after January&amp;#160;1, 2009, we record contingent consideration liabilities at their fair value on the acquisition date and revalue these obligations each reporting period. We may pay up to approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.2 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in remaining milestones related to these acquisitions. For additional information related to our acquisition of Convergence please read Note 2, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Acquisitions&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Fumapharm AG&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In 2006 we acquired Fumapharm AG. As part of this acquisition we acquired FUMADERM and TECFIDERA (together, Fumapharm Products). We paid &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$220.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; upon closing of the transaction and agreed to pay an additional &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$15.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; if a Fumapharm Product was approved for MS in the U.S.&amp;#160;or E.U. In the second quarter of 2013 we paid this &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$15.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; contingent payment as TECFIDERA was approved in the U.S. for MS by the FDA. We are also required to make additional contingent payments to former shareholders of Fumapharm AG or holders of their rights based on the attainment of certain cumulative sales levels of Fumapharm Products and the level of total net sales of Fumapharm Products in the prior twelve month period, as defined in the acquisition agreement. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; we paid &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.2 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in contingent payments as we reached the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$7.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$8.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$9.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$10.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; cumulative sales levels related to the Fumapharm Products in the fourth quarter of 2015 and the first, second and third quarters of 2016, respectively, and accrued &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$300.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; upon reaching &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$11.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in total cumulative sales of Fumapharm Products in the fourth quarter of 2016.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We will owe an additional &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$300.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; contingent payment for every additional &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in cumulative sales level of Fumapharm Products reached if the prior 12 months sales of the Fumapharm Products exceed &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$3.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, until such time as the cumulative sales level reaches &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$20.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, at which time no further contingent payments shall be due. If the prior 12 months sales of Fumapharm Products are less than &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$3.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, contingent payments remain payable on a decreasing tiered basis. These payments will be accounted for as an increase to goodwill as incurred, in accordance with the accounting standard applicable to business combinations when we acquired Fumapharm. Any portion of the payment which is tax deductible will be recorded as a reduction to goodwill. Payments are due within 60&amp;#160;days following the end of the quarter in which the applicable cumulative sales level has been reached. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Contingent Development, Regulatory and Commercial Milestone Payments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Based on our development plans as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we could make potential future milestone payments to third parties of up to approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$3.1 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, including approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$0.5 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in development milestones, approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$0.8 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in regulatory milestones and approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.8 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in commercial milestones as part of our various collaborations, including licensing and development programs. Payments under these agreements generally become due and payable upon achievement of certain development, regulatory or commercial milestones. Because the achievement of these milestones had not occurred as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, such contingencies have not been recorded in our financial statements. Amounts related to contingent milestone payments are not considered contractual obligations as they are contingent on the successful achievement of certain development, regulatory approval and commercial milestones. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Other Funding Commitments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we have several on-going clinical studies in various clinical trial stages. Our most significant clinical trial expenditures are to contract research organizations (CROs). The contracts with CROs are generally cancellable, with notice, at our option. We have recorded accrued expenses of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$21.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; on our consolidated balance sheet for expenditures incurred by CROs as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. We have approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$500.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in cancellable future commitments based on existing CRO contracts as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Tax Related Obligations&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We exclude liabilities pertaining to uncertain tax positions from our summary of contractual obligations as we cannot make a reliable estimate of the period of cash settlement with the respective taxing authorities. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we have approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$47.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of net liabilities associated with uncertain tax positions.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Solothurn, Switzerland Facility&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On December 1, 2015, we purchased land in Solothurn, Switzerland where we are building a biologics manufacturing facility over the next several years. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we had contractual commitments of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$176.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for the construction of this facility.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Leases&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We rent laboratory and office space and certain equipment under non-cancelable operating leases. These lease agreements contain various clauses for renewal at our option and, in certain cases, escalation clauses typically linked to rates of inflation. Rental expense under these leases, net of amounts recognized in relation to exiting our manufacturing facility in Cambridge, Massachusetts and our Weston, Massachusetts facility, which terminate at various dates through 2028, amounted to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$68.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$68.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$62.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. In addition to rent, the leases may require us to pay additional amounts for taxes, insurance, maintenance and other operating expenses.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, minimum rental commitments under non-cancelable leases, net of income from subleases, for each of the next five years and total thereafter were as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="28" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:31%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Thereafter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Minimum lease payments &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;75.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;69.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;69.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;65.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;64.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;331.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;676.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Less: income from subleases (1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(8.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(15.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(15.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(15.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(16.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(55.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(126.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net minimum lease payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;66.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;54.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;53.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;50.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;48.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;276.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;549.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt;(1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt;Represents sublease income expected to be received for the vacated manufacturing facility in Cambridge, MA, the vacated portion of our Weston, Massachusetts facility and other facilities throughout the world. For additional information related to the sublease of the vacated manufacturing facility in Cambridge, MA, please read Note 3, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-style:italic;"&gt;Restructuring, Business Transformation and Other Cost Savings Initiatives&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt; to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-left:4px;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Under certain of our lease agreements, we are contractually obligated to return leased space to its original condition upon termination of the lease agreement. At the inception of a lease with such conditions, we record an asset retirement obligation liability and a corresponding capital asset in an amount equal to the estimated fair value of the obligation. In subsequent periods, for each such lease, we record interest expense to accrete the asset retirement obligation liability to full value and depreciate each capitalized asset retirement obligation asset, both over the term of the associated lease agreement. Our asset retirement obligations were not significant as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; or &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:4px;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Eisai Financing Arrangement&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:4px;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During 2015 we amended our existing lease related to Eisai's oral solid dose products manufacturing facility in RTP, North Carolina where we manufacture our and Eisai's oral solid dose products. For additional information, please read Note 10, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Property, Plant and Equipment&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the net present values of the future minimum lease payments were as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:4px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:79%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:19%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;As of December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;16.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;18.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Less: interest&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(0.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net present value of the future minimum lease payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;18.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
	<us-gaap:CommitmentsAndContingenciesPolicyTextBlock contextRef="FD2016Q4YTD" id="Fact-05F41B069C73C44337DC7411DFDFA957">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We are currently involved in various claims and legal proceedings. Loss contingency provisions are recorded if the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount can be reasonably estimated or a range of loss can be determined. These accruals represent management&amp;#8217;s best estimate of probable loss. Disclosure also is provided when it is reasonably possible that a loss will be incurred or when it is reasonably possible that the amount of a loss will exceed the recorded provision. On a quarterly basis, we review the status of each significant matter and assess its potential financial exposure.&amp;#160;Significant judgment is required in both the determination of probability and the determination as to whether an exposure is reasonably estimable. Because of uncertainties related to these matters, accruals are based only on the best information available at the time. As additional information becomes available, we reassess the potential liability related to pending claims and litigation and may change our estimates. These changes in the estimates of the potential liabilities could have a material impact on our consolidated results of operations and financial position.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
	<us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="FD2016Q4YTD" id="Fact-55D2D150D6DF9EEAD80B7411DFDF436E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our share-based compensation programs grant awards that have included stock options, restricted stock units which vest based on stock performance known as market stock units (MSUs), performance-vested restricted stock units which settle in cash (CSPUs), time-vested restricted stock units (RSUs), performance-vested restricted stock units which can be settled in cash or shares of our common stock (PUs) at the sole discretion of the Compensation and Management Development Committee of the Board of Directors and shares issued under our employee stock purchase plan (ESPP). We charge the estimated fair value of awards against income over the requisite service period, which is generally the vesting period. Where awards are made with non-substantive vesting periods (for instance, where a portion of the award vests upon retirement eligibility), we estimate and recognize expense based on the period from the grant date to the date on which the employee is retirement eligible.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The fair values of our stock option grants are estimated as of the date of grant using a Black-Scholes option valuation model. The estimated fair values of the stock options are then expensed over the options&amp;#8217; vesting periods.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The fair values of our MSUs are estimated using a lattice model with a Monte Carlo simulation. We apply an accelerated attribution method to recognize share-based compensation expense over the applicable service period, net of estimated forfeitures, when accounting for our MSUs. The probability of actual shares expected to be earned is considered in the grant date valuation, therefore the expense is not adjusted to reflect the actual units earned.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The fair values of our RSUs are based on the market value of our stock on the date of grant. Compensation expense for RSUs is recognized straight-line over the applicable service period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We apply an accelerated attribution method to recognize share-based compensation expense when accounting for our CSPUs and PUs and the fair value of the liability is remeasured at the end of each reporting period through expected settlement. Compensation expense associated with CSPUs and PUs are based upon the stock price and the number of units expected to be earned after assessing the probability that certain performance criteria will be met and the associated targeted payout level that is forecasted will be achieved, net of estimated forfeitures. Cumulative adjustments are recorded each quarter to reflect changes in the stock price and estimated outcome of the performance-related conditions until the date results are determined and settled.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The purchase price of common stock under our ESPP is equal to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;85%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the lesser of (i)&amp;#160;the fair market value per share of the common stock on the first business day of an offering period and (ii)&amp;#160;the fair market value per share of the common stock on the purchase date. The fair value of the discounted purchases made under our ESPP is calculated using the Black-Scholes model. The fair value of the look-back provision plus the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;15%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; discount is recognized as compensation expense over the 90 day purchase period. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
	<us-gaap:ComprehensiveIncomeNoteTextBlock contextRef="FD2016Q4YTD" id="Fact-2E31EBB9D4CA338CA04A7411E005CEEC">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Accumulated Other Comprehensive Income (Loss)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the changes in accumulated other comprehensive income (loss), net of tax by component:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="20" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:26%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Securities Available for Sale&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Cash Flow Hedges&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unfunded Status of Postretirement Benefit Plans&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Translation Adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;10.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(37.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(195.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(224.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other comprehensive income (loss) before reclassifications&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(10.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;51.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(138.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(92.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(4.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(3.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net current period other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(10.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;47.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(138.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(95.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(10.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;57.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(32.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(334.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(319.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="20" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:26%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Securities Available for Sale&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Cash Flow Hedges&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unfunded Status of Postretirement Benefit Plans&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Translation Adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, December 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;71.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(31.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(99.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(59.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other comprehensive income (loss) before reclassifications&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;110.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(6.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(96.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(172.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(171.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net current period other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(61.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(6.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(96.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(164.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;10.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(37.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(195.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(224.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="20" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:26%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Securities Available for Sale&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Cash Flow Hedges&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unfunded Status of Postretirement Benefit Plans&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Translation Adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, December 31, 2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(23.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(19.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;10.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(27.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other comprehensive income (loss) before reclassifications&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;101.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(12.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(109.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(19.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(6.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(6.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(12.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net current period other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(6.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;95.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(12.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(109.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(31.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, December 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;71.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(31.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(99.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(59.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the amounts reclassified from accumulated other comprehensive income:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:28%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:25%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Income Statement Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amounts Reclassified from&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Accumulated Other Comprehensive Income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Years Ended December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on securities available for sale&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(0.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(2.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;9.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income tax benefit (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(3.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on cash flow hedges&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;173.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(1.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income tax benefit (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total reclassifications, net of tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;171.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;12.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomeNoteTextBlock>
	<us-gaap:ConcentrationRiskCreditRisk contextRef="FD2016Q4YTD" id="Fact-0FA5030EED1757B7D3D57411DFDDE8E2">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Financial instruments that potentially subject us to concentrations of credit risk include cash and cash equivalents, investments, derivatives and accounts receivable. We attempt to minimize the risks related to cash and cash equivalents and investments by investing in a broad and diverse range of financial instruments as previously defined by us. We have established guidelines related to credit ratings and maturities intended to safeguard principal balances and maintain liquidity. Our investment portfolio is maintained in accordance with our investment policy, which defines allowable investments, specifies credit quality standards and limits the credit exposure of any single issuer. We minimize credit risk resulting from derivative instruments by choosing only highly rated financial institutions as counterparties.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Concentrations of credit risk with respect to receivables, which are typically unsecured, are somewhat mitigated due to the wide variety of customers and markets using our products, as well as their dispersion across many different geographic areas. The majority of our accounts receivable arise from product sales in the U.S. and Europe and have standard payment terms which generally require payment within &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;30 to 90 days&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. We monitor the financial performance and creditworthiness of our customers so that we can properly assess and respond to changes in their credit profile. We continue to monitor these conditions and assess their possible impact on our business. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, two wholesale distributors individually accounted for approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;37.2%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;19.2%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;35.4%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;23.1%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, of accounts receivable, net, respectively. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
	<us-gaap:ConsolidationPolicyTextBlock contextRef="FD2016Q4YTD" id="Fact-C62DBEAEF2884767E6E17411DFDFBD47">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;100%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the economics, we record net income (loss) attributable to noncontrolling interests in our consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In determining whether we are the primary beneficiary of an entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
	<us-gaap:DebtDisclosureTextBlock contextRef="FD2016Q4YTD" id="Fact-40C8174FB4F53879BDF77411DFEFEC2F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Indebtedness&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our indebtedness is summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Current portion:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Notes payable to Fumedica&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Financing arrangement for the purchase of the RTP facility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current portion of notes payable and other financing arrangements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;4.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Non-current portion:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.875% Senior Notes due March 1, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;558.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;565.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.900% Senior Notes due September 15, 2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,485.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,485.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.625% Senior Notes due September 15, 2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;993.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;992.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.050% Senior Notes due September 15, 2025&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,734.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,733.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.200% Senior Notes due September 15, 2045&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,721.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,721.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Notes payable to Fumedica&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Financing arrangement for the purchase of the RTP facility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;16.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;18.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current portion of notes payable and other financing arrangements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;6,512.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6,521.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following is a summary of our principal indebtedness as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$550.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; aggregate principal amount of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;6.875%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes due March 1, 2018, valued at &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;99.184%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of par;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$1.5 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; aggregate principal amount of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;2.90%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes due September 15, 2020, valued at &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;99.792%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of par;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$1.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; aggregate principal amount of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;3.625%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes due September 15, 2022, valued at &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;99.920%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of par;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$1.75 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; aggregate principal amount of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;4.05%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes due September 15, 2025, valued at &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;99.764%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of par; and&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$1.75 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; aggregate principal amount of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;5.20%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes due September 15,&amp;#160;2045, valued at &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;99.294%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of par.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The costs associated with these offerings of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$52.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; have been recorded as a reduction to the carrying amount of the debt on our consolidated balance sheet. These costs along with the discounts will be amortized as additional interest expense using the effective interest rate method over the period from issuance through maturity. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;These notes are senior unsecured obligations. The notes may be redeemed at our option at any time at &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;100%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the principal amount plus accrued interest and a specified make-whole amount. The &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.875%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes due in 2018 contain a change of control provision that may require us to purchase the notes under certain circumstances. There is also an interest rate adjustment feature that requires us to pay interest at an increased rate on the notes if the credit rating on the notes declines below investment grade. The remaining Senior Notes contain a change of control provision that may require us to purchase the notes at a price equal to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;101%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the principal amount plus accrued and unpaid interest to the date of purchase under certain circumstances.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.90%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes offering due in 2020, we entered into interest rate swap contracts. The carrying value of the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.90%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes includes approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$4.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to changes in the fair value of these contracts. For additional information, please read Note 9, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Derivative Instruments, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.875%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;Senior Notes due in 2018, we entered into interest rate swap contracts where we received a fixed rate and paid a variable rate. These contracts were terminated in December 2008. Upon termination of these swaps, the carrying amount of the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.875%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;Senior Notes due in 2018 was increased by &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$62.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and is being amortized using the effective interest rate method over the remaining life of the Senior Notes and is being recognized as a reduction of interest expense. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$9.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; remains to be amortized. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Notes Payable to Fumedica&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with our 2006 distribution agreement with Fumedica, we issued notes totaling &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;61.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Swiss Francs which were payable to Fumedica in varying amounts from June 2008 through June 2018. Our remaining note payable to Fumedica had a carrying value of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Swiss Francs (&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$6.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;) and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;8.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Swiss Francs (&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$9.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;) as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Credit Facility&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In August 2015 we entered into a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;five&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;-year senior unsecured revolving credit facility under which we are permitted to draw funds for working capital and general corporate purposes. The terms of the revolving credit facility include a financial covenant that requires us not to exceed a maximum consolidated leverage ratio. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we had &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; outstanding borrowings and were in compliance with all covenants under this facility.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Financing Arrangement&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During 2015 we recorded a financing obligation in relation to the amendment of our lease agreement of Eisai's oral solid dose products manufacturing facility in RTP, North Carolina where we manufacture our and Eisai's oral solid dose products. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the financing obligation totaled approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$18.1 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$19.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. For additional information, please read Note 10, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Property, Plant and Equipment&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Debt Maturity&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The total gross payments, excluding our financing arrangement, due under our debt arrangements are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.4375%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:80%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;As of December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;553.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,500.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2022 and thereafter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;4,500.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;6,556.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The fair value of our debt is disclosed in Note&amp;#160;7, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Fair Value Measurements&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
	<us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock contextRef="FD2016Q4YTD" id="Fact-A53AB21555A069A9B2EC7411DFF67A23">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Derivative Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Foreign Currency Forward Contracts - Hedging Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due to the global nature of our operations, portions of our revenues and operating expenses are recorded in currencies other than the U.S.&amp;#160;dollar. The value of revenues and operating expenses measured in U.S.&amp;#160;dollars is therefore subject to changes in foreign currency exchange rates. In order to mitigate these changes we use foreign currency forward contracts to lock in exchange rates associated with a portion of our forecasted international revenues and operating expenses.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Foreign currency forward contracts in effect as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, had durations of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;18 months&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. These contracts have been designated as cash flow hedges and accordingly, to the extent effective, any unrealized gains or losses on these foreign currency forward contracts are reported in accumulated other comprehensive income (loss) (referred to as AOCI in the tables below). Realized gains and losses for the effective portion of such contracts are recognized in revenue when the sale of product in the currency being hedged is recognized and, beginning in the fourth quarter of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, in operating expenses when the expense in the currency being hedged is recorded. To the extent ineffective, hedge transaction gains and losses are reported in other income (expense), net.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenues and operating expenses is summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Notional Amount&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As&amp;#160;of&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Foreign Currency: (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Euro&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;871.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;945.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Swiss francs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;80.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Canadian dollar&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;76.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total foreign currency forward contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;871.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,103.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The portion of the fair value of these foreign currency forward contracts that was included in accumulated other comprehensive income (loss) in total equity reflected net gains of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$49.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$72.1 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for the years ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. We expect all contracts to be settled over the next &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;18 months&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and any amounts in accumulated other comprehensive income (loss) to be reported as an adjustment to revenue or operating expense. We consider the impact of our and our counterparties&amp;#8217; credit risk on the fair value of the contracts as well as the ability of each party to execute its contractual obligations. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, credit risk did not change the fair value of our foreign currency forward contracts.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the effect of foreign currency forward contracts designated as hedging instruments on our consolidated statements of income:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="27" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="27" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Reclassified from AOCI into Net Income&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;"&gt;(Effective Portion)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized into Net Income&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;"&gt;(Ineffective Portion)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;173.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(1.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Interest Rate Contracts - Hedging Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have entered into interest rate lock contracts or interest rate swap contracts on certain borrowing transactions to manage our exposure to interest rate changes and to reduce our overall cost of borrowing. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Interest Rate Lock Contracts&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; we entered into treasury rate locks, with an aggregated notional amount of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.1 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which were designated as cash flow hedges to hedge against changes in the 10-year and 30-year U.S. treasury interest rates that could have impacted our anticipated debt offering. In connection with the issuance of our &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.05%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.20%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes, as described in Note 11, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Indebtedness&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we settled the treasury rate locks and realized an &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$8.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; gain. As the hedging relationship was effective, the gain was recorded in AOCI and will be recognized in other income (expense), net over the life of the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.05%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.20%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Interest Rate Swap Contracts&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with the issuance of our &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.90%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes, as described in Note 11, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Indebtedness&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we entered into interest rate swaps with an aggregate notional amount of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$675.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which expire on September 15, 2020. The interest rate swap contracts are designated as hedges of the fair value changes in the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.90%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes attributable to changes in interest rates. Since the specific terms and notional amount of the swaps match the debt being hedged, it is assumed to be a highly effective hedge and all changes in the fair value of the swaps are recorded as a component of the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.90%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes with no net impact recorded in income. Any net interest payments made or received on the interest rate swap contracts are recognized as a component of interest expense in our consolidated statements of income.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Foreign Currency Forward Contracts - Other Derivatives&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We also enter into other foreign currency forward contracts, usually with durations of one month or less, to mitigate the foreign currency risk related to certain balance sheet positions. We have not elected hedge accounting for these transactions.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The aggregate notional amount of these outstanding foreign currency contracts was &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$902.1 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$721.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. Net losses of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$29.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$23.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$15.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to these contracts were recognized as a component of other income (expense), net, for the years ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Summary of Derivatives&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;While certain of our derivatives are subject to netting arrangements with our counterparties, we do not offset derivative assets and liabilities in our consolidated balance sheets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the fair value and presentation in our consolidated balance sheets of our outstanding derivatives including those designated as hedging instruments:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.61013645224172%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:40%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:40%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Balance&amp;#160;Sheet&amp;#160;Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;Fair Value&lt;br clear="none"/&gt;As of December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Hedging Instruments:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;50.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Investments and other assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;6.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other long-term liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;4.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Other Derivatives:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;4.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued&amp;#160;expenses&amp;#160;and&amp;#160;other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;9.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.61013645224172%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:40%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:40%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Balance Sheet Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;br clear="none"/&gt;As of December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Hedging Instruments:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;16.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Investments and other assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued&amp;#160;expenses&amp;#160;and&amp;#160;other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;10.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other long-term liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Other Derivatives:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;10.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued&amp;#160;expenses&amp;#160;and&amp;#160;other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
	<us-gaap:DerivativesPolicyTextBlock contextRef="FD2016Q4YTD" id="Fact-D6455924FECBF06202407411DFDF1C09">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We recognize all derivative instruments as either assets or liabilities at fair value in our consolidated balance sheets. Changes in the fair value of derivatives are recorded each period in current earnings or accumulated other comprehensive income (loss), depending on whether a derivative is designated as part of a hedge transaction and, if so, the type of hedge transaction. We classify the cash flows from these instruments in the same category as the cash flows from the hedged items. We do not hold or issue derivative instruments for trading or speculative purposes.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We assess, both at inception and on an ongoing basis, whether the derivatives that are used in hedging transactions are highly effective in offsetting the changes in cash flows or fair values of the hedged items. We also assess hedge ineffectiveness on a quarterly basis and record the gain or loss related to the ineffective portion to current earnings. If we determine that a forecasted transaction is no longer probable of occurring, we discontinue hedge accounting for the affected portion of the hedge instrument, and any related unrealized gain or loss on the contract is recognized in current earnings.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
	<us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="FD2016Q4YTD" id="Fact-58FF69AA80C91A16CF4B7411E015981F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Share-based Payments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Share-based Compensation Expense&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes share-based compensation expense included in our consolidated statements of income:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:55%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;84.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;88.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;102.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Selling, general and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;121.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;127.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;150.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Restructuring charges&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(1.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(8.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Subtotal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;204.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;207.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;252.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Capitalized share-based compensation costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(14.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(11.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(10.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Share-based compensation expense included in total cost and expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;189.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;196.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;242.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income tax effect&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(54.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(55.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(72.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Share-based compensation expense included in net income attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;135.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;140.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;170.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:55%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Market stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;38.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;38.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;37.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Time-vested restricted stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;120.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;119.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;115.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash settled performance units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;16.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;22.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;65.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Performance units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;18.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;13.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;21.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Employee stock purchase plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;11.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;13.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;12.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Subtotal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;204.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;207.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;252.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Capitalized share-based compensation costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(14.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(11.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(10.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Share-based compensation expense included in total cost and expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;189.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;196.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;242.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Windfall tax benefits from vesting of stock awards, exercises of stock options and ESPP participation were &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$12.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$78.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$96.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. These amounts have been calculated under the alternative transition method. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, unrecognized compensation cost related to unvested share-based compensation was approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$189.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, net of estimated forfeitures. We expect to recognize the cost of these unvested awards over a weighted-average period of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.9&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; years.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Share-Based Compensation Plans&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; share-based compensation plans pursuant to which awards are currently being made: (i)&amp;#160;the Biogen Inc. 2006 Non-Employee Directors Equity Plan (2006&amp;#160;Directors Plan); (ii)&amp;#160;the Biogen Inc. 2008 Amended and Restated Omnibus Equity Plan (2008 Omnibus Plan); and (iii)&amp;#160;the Biogen Inc. 2015 Employee Stock Purchase Plan (ESPP). &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Directors Plan&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In May 2006 our stockholders approved the 2006&amp;#160;Directors Plan for share-based awards to our directors. Awards granted from the 2006&amp;#160;Directors Plan may include stock options, shares of restricted stock, restricted stock units, stock appreciation rights and other awards in such amounts and with such terms and conditions as may be determined by a committee of our Board of Directors, subject to the provisions of the plan. We have reserved a total of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares of common stock for issuance under the 2006&amp;#160;Directors Plan. The 2006&amp;#160;Directors Plan provides that awards other than stock options and stock appreciation rights will be counted against the total number of shares reserved under the plan in a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.5-to-1&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; ratio. In June 2015 our stockholders approved an amendment to extend the term of the 2006 Directors Plan until June 2025.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Omnibus Plans&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In June 2008 our stockholders approved the 2008 Omnibus Plan for share-based awards to our employees. Awards granted from the 2008 Omnibus Plan may include stock options, shares of restricted stock, restricted stock units, performance shares, shares of phantom stock, stock appreciation rights and other awards in such amounts and with such terms and conditions as may be determined by a committee of our Board of Directors, subject to the provisions of the plan. Shares of common stock available for issuance under the 2008 Omnibus Plan consist of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;15.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares reserved for this purpose, plus shares of common stock that remained available for issuance under our 2005 Omnibus Equity Plan on the date that our stockholders approved the 2008 Omnibus Plan, plus shares that were subject to awards under the 2005 Omnibus Equity Plan that remain unissued upon the cancellation, surrender, exchange or termination of such awards. The 2008 Omnibus Equity Plan provides that awards other than stock options and stock appreciation rights will be counted against the total number of shares available under the plan in a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.5-to-1&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; ratio.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have not made any awards pursuant to the 2005 Omnibus Equity Plan since our stockholders approved the 2008 Omnibus Plan, and do not intend to make any awards pursuant to the 2005 Omnibus Equity Plan in the future, except that unused shares under the 2005 Omnibus Equity Plan have been carried over for use under the 2008 Omnibus Plan.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Stock Options&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We currently do not grant stock options to our employees or directors. Outstanding stock options previously granted to our employees and directors generally have a ten-year term and vest over a period of between one and four years, provided the individual continues to serve at Biogen through the vesting dates. Options granted under all plans are exercisable at a price per share not less than the fair market value of the underlying common stock on the date of grant. The estimated fair value of options, including the effect of estimated forfeitures, is recognized over the options&amp;#8217; vesting periods. The fair value of the stock options granted in 2010 was estimated as of the date of grant using a Black-Scholes option valuation model. There were &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; grants of stock options made in &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, all outstanding options were exercisable.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The expected life of options granted is derived using assumed exercise rates based on historical exercise patterns and represents the period of time that options granted are expected to be outstanding. Expected stock price volatility is based upon implied volatility for our exchange-traded options and other factors, including historical volatility. After assessing all available information on either historical volatility, implied volatility, or both, we have concluded that a combination of both historical and implied volatility provides the best estimate of expected volatility. The risk-free interest rate used is determined by the market yield curve based upon risk-free interest rates established by the Federal Reserve, or non-coupon bonds that have maturities equal to the expected term. The dividend yield of zero is based upon the fact that we have not historically granted cash dividends, and do not expect to issue dividends in the foreseeable future. Stock options granted prior to January&amp;#160;1, 2006 were valued based on the grant date fair value of those awards, using the Black-Scholes option pricing model, as previously calculated for pro-forma disclosures.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our stock option activity:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Exercise&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Outstanding at December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;107,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;53.94&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(41,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;53.75&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cancelled&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Outstanding at December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;66,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;54.06&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The total intrinsic values of options exercised in &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; totaled &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$10.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$38.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$42.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. The aggregate intrinsic values of options outstanding as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; totaled &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$15.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. The weighted average remaining contractual term for options outstanding as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; was &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.0&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;years. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the amount of tax benefit realized for stock options and cash received from the exercise of stock options:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Tax benefit realized for stock options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;4.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;11.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;13.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash received from the exercise of stock options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;8.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Market Stock Units (MSUs)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;MSUs awarded to employees prior to 2014 vested in &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;four&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; equal annual increments beginning on the first anniversary of the grant date. Participants may ultimately earn between &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;150%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the target number of units granted based on actual stock performance. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;MSUs awarded to employees in 2014, 2015 and 2016 vest in &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; equal annual increments beginning on the first anniversary of the grant date, and participants may ultimately earn between &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;200%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the target number of units granted based on actual stock performance. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The vesting of these awards is subject to the respective employee&amp;#8217;s continued employment. The number of MSUs granted represents the target number of units that are eligible to be earned based on the attainment of certain market-based criteria involving our stock price. The number of MSUs earned is calculated at each annual anniversary from the date of grant over the respective vesting periods, resulting in multiple performance periods. Accordingly, additional MSUs may be issued or currently outstanding MSUs may be cancelled upon final determination of the number of awards earned. Compensation expense, including the effect of forfeitures, is recognized over the applicable service period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our MSU activity:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Grant&amp;#160;Date&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;269,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;339.89&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Granted (a)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;168,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;328.03&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Vested&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(155,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;244.68&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(52,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;371.62&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;230,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;355.60&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(a)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt;MSUs granted in 2016 include approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:9pt;"&gt;15,000&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:9pt;"&gt;20,000&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt; MSUs issued in 2016 based upon the attainment of performance criteria set for 2013 and 2012, respectively, in relation to awards granted in those years. The remainder of MSUs granted during 2016 include awards granted in conjunction with our annual awards made in February 2016 and MSUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We value grants of MSUs using a lattice model with a Monte Carlo simulation. This valuation methodology utilizes several key assumptions, including the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;60&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; calendar day average closing stock price on grant date for MSUs awarded prior to 2014, the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;30&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; calendar day average closing stock price on the date of grant for MSUs awarded in 2014, 2015 and 2016, expected volatility of our stock price, risk-free rates of return and expected dividend yield.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; The assumptions used in our valuation are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Expected dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Range of expected stock price volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;38.2% - 40.7%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;31.0% - 33.2%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;31.7% - 35.1%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Range of risk-free interest rates&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.6% - 0.9%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.2% - 1.0%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1% - 0.7%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;30 calendar day average stock price on grant date&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$260.67 - $304.86&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$277.35 - $426.27&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$280.88 - $335.65&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Weighted-average per share grant date fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$328.03&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$493.43&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$395.22&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The total fair values of MSUs vested in &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; totaled &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$39.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$109.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$117.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Cash Settled Performance Units (CSPUs)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;CSPUs awarded to employees vest in &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; equal annual increments beginning on the first anniversary of the grant date. The vesting of these awards is subject to the respective employee&amp;#8217;s continued employment with such awards settled in cash. The number of CSPUs granted represents the target number of units that are eligible to be earned based on the attainment of certain performance measures established at the beginning of the performance period, which ends on December&amp;#160;31 of each year. Participants may ultimately earn between &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;200%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the target number of units granted based on the degree of actual performance metric achievement. Accordingly, additional CSPUs may be issued or currently outstanding CSPUs may be cancelled upon final determination of the number of units earned. CSPUs awarded prior to 2014 are settled in cash based on the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;60&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; calendar day average closing stock price through each vesting date once the actual vested and earned number of units is known. CSPUs awarded in 2014, 2015 and 2016 will be settled in cash based on the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;30&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; calendar day average closing stock price through each vesting date, once the actual vested and earned number of units is known. Since no shares are issued, these awards do not dilute equity. Compensation expense, including the effect of forfeitures, is recognized over the applicable service period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our CSPU activity:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:82%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;192,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Granted (a)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;86,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Vested&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(117,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(39,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;122,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(a)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt;CSPUs granted in 2016 include awards granted in conjunction with our annual awards made in February 2016 and CSPUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The total cash paid in settlement of CSPUs vested in &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; totaled &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$31.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$79.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$92.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&amp;#160; &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Performance-vested Restricted Stock Units (PUs)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In 2014 we revised our long term incentive program to include a new type of award granted to certain employees in the form of restricted stock units that may be settled in cash or shares of our common stock at the sole discretion of the Compensation and Management Development Committee of our Board of Directors. These awards are structured and accounted for the same way as the cash settled performance units, and vest in &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; equal annual increments beginning on the first anniversary of the grant date. The number of PUs granted represents the target number of units that are eligible to be earned based on the attainment of certain performance measures established at the beginning of the performance period, which ends on December 31 of each year. Participants may ultimately earn between &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;200%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the target number of units granted based on the degree of actual performance metric achievement. Accordingly, additional PUs may be issued or currently outstanding PUs may be cancelled upon final determination of the number of units earned. PUs settling in cash are based on the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;30&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; calendar day average closing stock price through each vesting date once the actual vested and earned number of units is known. Compensation expense, including the effect of forfeitures, is recognized over the applicable service period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our PU activity:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:82%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;103,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Granted (a)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;55,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Vested&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(31,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(17,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;110,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt;(a)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt;PUs granted in 2016 include awards granted in conjunction with our annual awards made in February 2016 and PUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;32,000&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; PU were converted to share settlements, of which approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;11,000&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares were vested and issued. All other PUs that vested in &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; were settled in cash totaling &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$12.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;All PUs that vested in &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; were settled in cash totaling &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$8.1 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Time-Vested Restricted Stock Units (RSUs)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;RSUs awarded to employees generally vest no sooner than &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;one-third per year over three years&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; on the anniversary of the date of grant, or upon the third anniversary of the date of the grant, provided the employee remains continuously employed with us, except as otherwise provided in the plan. Shares of our common stock will be delivered to the employee upon vesting, subject to payment of applicable withholding taxes. RSUs awarded to directors for service on our Board of Directors vest on the first anniversary of the date of grant, provided in each case that the director continues to serve on our Board of Directors through the vesting date. Shares of our common stock will be delivered to the director upon vesting and are not subject to any withholding taxes. The fair value of all RSUs is based on the market value of our stock on the date of grant. Compensation expense, including the effect of forfeitures, is recognized over the applicable service period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our RSU activity:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Grant&amp;#160;Date&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;810,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;323.87&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Granted (a)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;649,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;268.52&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Vested&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(406,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;285.13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(165,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;310.30&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;888,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;303.49&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(a)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt;RSUs granted in 2016 primarily represent RSUs granted in conjunction with our annual awards made in February 2016 and awards made in conjunction with the hiring of new employees. RSUs granted in 2016 also include approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:9pt;"&gt;11,000&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt; RSUs granted to our Board of Directors.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;RSUs granted in &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; had weighted average grant date fair values of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$388.88&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$321.72&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The total fair values of RSUs vested in &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; totaled &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$104.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$239.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$281.1 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&amp;#160; &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Employee Stock Purchase Plan (ESPP)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In June 2015 our stockholders approved the Biogen Inc. 2015 ESPP (2015 ESPP). The 2015 ESPP, which became effective on July 1, 2015, replaced the Biogen Idec Inc. 1995 ESPP (1995 ESPP), which expired on June&amp;#160;30, 2015. The maximum aggregate number of shares of our common stock that may be purchased under the 2015 ESPP is &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our ESPP activity:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions, except share amounts)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Shares issued under the 2015 ESPP&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;190,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;78,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;**&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Shares issued under the 1995 ESPP&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;98,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;180,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash received under the 2015 ESPP&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;41.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;19.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;**&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash received under the 1995 ESPP&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;30.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;46.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
	<us-gaap:EarningsPerSharePolicyTextBlock contextRef="FD2016Q4YTD" id="Fact-E92F385A549E992E45C07411DFDDCFC9">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Basic earnings per share is computed by dividing undistributed net income attributable to Biogen Inc. by the weighted-average number of common shares outstanding during the period. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
	<us-gaap:EarningsPerShareTextBlock contextRef="FD2016Q4YTD" id="Fact-CE7F82103AC16F9A8EC67411DFC9B90D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Earnings&amp;#160;per Share&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Basic and diluted earnings per share are calculated as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Years Ended December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Numerator:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3,702.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,547.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,934.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Denominator:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Weighted average number of common shares outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;218.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;230.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;236.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Effect of dilutive securities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Stock options and employee stock purchase plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Time-vested restricted stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Market stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Dilutive potential common shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Shares used in calculating diluted earnings per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;218.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;231.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;237.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts excluded from the calculation of net income per diluted share because their effects were anti-dilutive were insignificant.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Earnings per share for the years ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, reflects, on a weighted average basis, the repurchase of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares, respectively, of our common stock under our share repurchase authorizations.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
	<us-gaap:EquityMethodInvestmentsPolicy contextRef="FD2016Q4YTD" id="Fact-16CA5D05BC1E997AEE247411DFE043CE">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In circumstances where we have the ability to exercise significant influence over the operating and financial policies of a company in which we have an investment, we utilize the equity method of accounting for recording investment activity.&amp;#160;In assessing whether we exercise significant influence, we consider the nature and magnitude of our investment, the voting and protective rights we hold, any participation in the governance of the other company, and other relevant factors such as the presence of a collaboration or other business relationship.&amp;#160;Under the equity method of accounting, we record in our results of operations our share of income or loss of the other company. If our share of losses exceeds the carrying value of our investment, we will suspend recognizing additional losses and will continue to do so unless we commit to providing additional funding. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsPolicy>
	<us-gaap:FairValueByBalanceSheetGroupingTextBlock contextRef="FD2016Q4YTD" id="Fact-11604CBB0B08FB8F75BC7411E02145AD">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Notes payable to Fumedica&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;6.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;9.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.875% Senior Notes due March 1, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;583.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;602.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.900% Senior Notes due September 15, 2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,521.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,497.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.625% Senior Notes due September 15, 2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,026.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,014.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.050% Senior Notes due September 15, 2025&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,796.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,764.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.200% Senior Notes due September 15, 2045&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,874.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,757.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;6,808.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6,645.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueByBalanceSheetGroupingTextBlock>
	<us-gaap:FairValueDisclosuresTextBlock contextRef="FD2016Q4YTD" id="Fact-6E2F3767C271C74258D77411E0219B14">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Fair Value Measurements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;December 31, &lt;br clear="none"/&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quoted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Prices in&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Active&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Markets&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level&amp;#160;1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Observable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level&amp;#160;2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unobservable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level&amp;#160;3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,039.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,039.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable debt securities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,663.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,663.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,172.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,172.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;561.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;561.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;24.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;24.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;61.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;61.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Plan assets for deferred compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;34.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;34.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;7,558.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;24.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;7,533.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;13.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;13.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Contingent consideration obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;467.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;467.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;481.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;13.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;467.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;December 31, &lt;br clear="none"/&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quoted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Prices&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;in&amp;#160;Active&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Markets&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Observable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unobservable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;909.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;909.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable debt securities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,510.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,510.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,875.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,875.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;494.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;494.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;37.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;37.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;27.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;27.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Plan assets for deferred compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;40.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;40.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5,895.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;37.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5,857.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;14.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;14.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Contingent consideration obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;506.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;506.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;520.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;14.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;506.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The fair value of Level 2 instruments classified as cash equivalents and marketable debt securities were determined through third-party pricing services. For a description of our validation procedures related to prices provided by third-party pricing services, refer to Note 1, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Summary of Significant Accounting Policies: Fair Value Measurements&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Debt Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The fair values of our debt instruments, which are Level&amp;#160;2 liabilities, are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Notes payable to Fumedica&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;6.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;9.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.875% Senior Notes due March 1, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;583.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;602.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.900% Senior Notes due September 15, 2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,521.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,497.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.625% Senior Notes due September 15, 2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,026.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,014.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.050% Senior Notes due September 15, 2025&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,796.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,764.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.200% Senior Notes due September 15, 2045&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,874.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,757.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;6,808.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6,645.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The fair value of our notes payable to Fumedica was estimated using market observable inputs, including current interest and foreign currency exchange rates. The fair values of each of our series of Senior Notes were determined through market, observable, and corroborated sources. For additional information related to our debt instruments, please read Note 11, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Indebtedness&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Contingent Consideration Obligations&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table provides a roll forward of the fair values of our contingent consideration obligations which includes Level 3 measurements:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As&amp;#160;of&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Fair value, beginning of year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;506.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;215.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Additions&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;274.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Changes in fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;14.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;30.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(53.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(14.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Fair value, end of year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;467.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;506.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$246.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$301.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, of the fair value of our total contingent consideration obligations was reflected as a component of other long-term liabilities in our consolidated balance sheets with the remaining balance reflected as a component of accrued expenses and other. Payments and other for 2016 includes &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$7.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of a Convergence milestone converted to a short-term obligation under the terms of the acquisition agreement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;There were &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; changes in valuation techniques or transfers between fair value measurement levels during the years ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. The fair values of the intangible assets and contingent consideration liabilities were based on a probability-adjusted discounted cash flow calculation using Level 3 fair value measurements and inputs including estimated revenues and probabilities of success. For additional information related to the valuation techniques and inputs utilized in valuation of our financial assets and liabilities, please read Note 1, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Summary of Significant Accounting Policies&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Convergence&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with our acquisition of Convergence in February 2015 we recorded a contingent consideration obligation of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$274.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This valuation was based on probability weighted net cash outflow projections of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$450.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, discounted using a rate of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.0%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which was the estimated cost of debt financing for market participants. This liability reflected the revised estimate from the date of acquisition for our initial clinical development plans, resulting probabilities of success and the timing of certain milestone payments. For a more detailed description of this transaction, please read Note 2, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Acquisitions&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the fair value of this contingent consideration obligation was &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$258.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$297.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. Our most recent valuation was determined based upon probability weighted net cash flow projections of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$400.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, discounted using a rate of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.7%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which is a measure of the credit risk associated with settling the liability. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; compared to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the net decrease in the fair value of this obligation was primarily due to achievement of a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$50.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; milestone related to a second indication, partially offset by changes in the discount rate and an increase in the probability of success related to the achievement of certain developmental milestones. Approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$148.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; is reflected as a component of accrued expenses and other in our consolidated balance sheets as we expect to make the payment within one year.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Stromedix Inc.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with our acquisition of Stromedix Inc. (Stromedix) in March 2012 we recorded a contingent consideration obligation of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$122.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the fair value of this contingent consideration obligation was &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$133.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$131.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. Our most recent valuation was determined based upon probability weighted net cash outflow projections of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$419.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, discounted using a rate of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.2%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which is a measure of the credit risk associated with settling the liability. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; compared to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the net increase in the fair value of this obligation was primarily due to changes in the discount rate, partially offset by changes in the expected timing related to the achievement of certain remaining developmental milestones. Approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$56.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; is reflected as a component of accrued expenses and other in our consolidated balance sheets as we expect to make the payment within one year.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Biogen Idec International Neuroscience GmbH&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with our acquisition of Biogen Idec International Neuroscience GmbH (BIN), formerly Panima Pharmaceuticals AG (Panima), in December 2010 we recorded a contingent consideration obligation of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$81.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the fair value of this contingent consideration obligation was &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$75.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$77.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. Our most recent valuation was determined based upon probability weighted net cash outflow projections of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$361.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, discounted using a rate of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.7%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which is a measure of the credit risk associated with settling the liability. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; compared to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the net decrease in the fair value of this obligation was primarily due to payment of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$3.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in developmental milestones, partially offset by changes in the discount rate. Approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$15.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; is reflected as a component of accrued expenses and other in our consolidated balance sheets as we expect to make the payment within one year.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Acquired IPR&amp;amp;D&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with our acquisition of Convergence, we also allocated &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$424.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the total purchase price to acquired IPR&amp;amp;D, which was capitalized as an intangible asset. The amount allocated to acquired IPR&amp;amp;D was based on significant inputs not observable in the market and thus represented a Level 3 fair value measurement. This estimate was also adjusted from our preliminary estimate as of the date of acquisition to reflect revised estimates to our initial clinical development plans, resulting probabilities of success and the timing of certain milestone payments. These assets will be tested for impairment annually until commercialization, after which time the IPR&amp;amp;D will be amortized over its estimated useful life. For a more detailed description of this transaction, please read Note 2, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Acquisitions&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
	<us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="FD2016Q4YTD" id="Fact-DDEBD8681F48030DEB857411E021AF6B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As&amp;#160;of&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Fair value, beginning of year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;506.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;215.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Additions&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;274.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Changes in fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;14.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;30.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(53.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(14.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Fair value, end of year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;467.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;506.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
	<us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="FD2016Q4YTD" id="Fact-0F7E8E13F907545BFE017411DFDD9E21">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have certain financial assets and liabilities recorded at fair value which have been classified as Level&amp;#160;1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements.&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Level&amp;#160;1&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;&amp;#8212; Fair values are determined utilizing quoted prices (unadjusted) in active markets for identical assets or liabilities that we have the ability to access;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Level&amp;#160;2&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;&amp;#8212; Fair values are determined by utilizing quoted prices for identical or similar assets and liabilities in active markets or other market observable inputs such as interest rates, yield curves and foreign currency spot rates;&amp;#160;and&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Level&amp;#160;3&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;&amp;#8212; Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The majority of our financial assets have been classified as Level&amp;#160;2. Our financial assets (which include our cash equivalents, derivative contracts, marketable debt securities and plan assets for deferred compensation) have been initially valued at the transaction price and subsequently valued, at the end of each reporting period, utilizing third-party pricing services or other market observable data. The pricing services utilize industry standard valuation models, including both income and market-based approaches and observable market inputs to determine value. These observable market inputs include reportable trades, benchmark yields, credit spreads, broker/dealer quotes, bids, offers, current spot rates and other industry and economic events.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We validate the prices provided by our third-party pricing services by reviewing their pricing methods and matrices, obtaining market values from other pricing sources and analyzing pricing data in certain instances. After completing our validation procedures, we did not adjust or override any fair value measurements provided by our pricing services as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Other Assets and Liabilities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The carrying amounts reflected in the consolidated balance sheets for current accounts receivable, due from anti-CD20 therapeutic programs, other current assets, accounts payable and accrued expenses and other, approximate fair value due to their short-term maturities.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
	<us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="FD2016Q4YTD" id="Fact-1E216312767CFDBE5D7A7411DFDC44A8">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The functional currency for most of our foreign subsidiaries is their local currency. For our non-U.S. subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the average foreign exchange rates for the period. Adjustments resulting from the translation of the financial statements of our foreign operations into U.S.&amp;#160;dollars are excluded from the determination of net income and are recorded in accumulated other comprehensive income, a separate component of equity. For subsidiaries where the functional currency of the assets and liabilities differ from the local currency, non-monetary assets and liabilities are translated at the rate of exchange in effect on the date assets were acquired while monetary assets and liabilities are translated at current rates of exchange as of the balance sheet date. Income and expense items are translated at the average foreign currency rates for the period. Translation adjustments of these subsidiaries are included in other income (expense), net, in our consolidated statements of income.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
	<us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="FD2016Q4YTD" id="Fact-A3193D945ECF7C7C908B7411DFF4805B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Intangible Assets and Goodwill&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Intangible Assets&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Intangible assets, net of accumulated amortization, impairment charges and adjustments, are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="26" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:21%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;As of December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Estimated Life&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Accumulated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Accumulated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Out-licensed patents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;13-23 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;543.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(523.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;19.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;543.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(506.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;37.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Developed technology&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;15-23 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3,005.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(2,634.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;371.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,005.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(2,552.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;452.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In-process research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Indefinite until commercialization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;648.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;648.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;730.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;730.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Trademarks and trade names&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Indefinite&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;64.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;64.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;64.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;64.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Acquired and in-licensed rights and patents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6-18 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3,481.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(776.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,705.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,303.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(502.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,800.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total intangible assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;7,742.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(3,934.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3,808.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;7,646.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(3,561.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4,085.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amortization of acquired intangible assets totaled &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$385.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$382.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$489.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for the years ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. Amortization of acquired intangible assets during 2016 included impairment charges of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$12.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to two of our IPR&amp;amp;D intangible assets. Amortization of acquired intangible assets during &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; included impairment charges of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$34.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to one of our out-licensed patents and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$16.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to one of our IPR&amp;amp;D intangible assets. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Out-licensed Patents&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Out-licensed patents to third-parties primarily relate to patents acquired in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003. During 2014 we recorded a charge of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$34.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to the impairment of one of our out-licensed patents to reflect a change in its estimated fair value due to a change in the underlying competitive market for that product. The charge was included in amortization of acquired intangible assets in our consolidated statements of income. The fair value of the intangible asset was based on a discounted cash flow calculated using Level 3 fair value measurements and inputs including estimated revenues. There were no impairment charges related to our out-licensed patents during &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; or &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Developed Technology&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Developed technology primarily relates to our AVONEX product, which was recorded in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003. The net book value of this asset as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, was &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$363.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;IPR&amp;amp;D&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;IPR&amp;amp;D represents the fair value assigned to research and development assets that we acquire and have not reached technological feasibility at the date of acquisition. Upon commercialization, we will determine the estimated useful life. In connection with our acquisition of Convergence in February 2015, we acquired IPR&amp;amp;D programs with an estimated fair value of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$424.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This amount has and will be adjusted for foreign exchange rate fluctuations. For a more detailed description of this transaction, please read Note 2, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Acquisitions&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;An analysis of anticipated lifetime revenues and anticipated development costs is performed annually during our long- range planning cycle, which was updated in the third quarter of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&amp;#160;This analysis is based upon certain assumptions that we evaluate on a periodic basis, including anticipated future product sales, the expected impact of changes in the amount of development costs and the probabilities of our programs succeeding, the introduction of new products by our competitors and changes in our commercial and pipeline product candidates.&amp;#160;&amp;#160; &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During the fourth quarter of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; we terminated our collaboration agreements with Rodin Therapeutics, Inc. and Ataxion Inc., resulting in impairment losses of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$8.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$3.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, reflecting the full value of the assets recorded upon entering into the collaboration agreements. These impairment losses are included in amortization of acquired intangible assets in our consolidated statements of income.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During the third quarter of 2014 we updated the probabilities of success related to the early stage programs acquired through our recent acquisitions.&amp;#160;The change in probability of success, combined with a delay in one of the projects, resulted in an impairment loss of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$16.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in one of our IPR&amp;amp;D assets during 2014.&amp;#160;This impairment is included in amortization of acquired intangible assets in our consolidated statements of income.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Acquired and In-licensed Rights and Patents&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Acquired and in-licensed rights and patents primarily relate to our acquisition of all remaining rights to TYSABRI from Elan Corporation plc (Elan). The net book value of this asset as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, was &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$2,493.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The net change in acquired and in-licensed rights and patents during the year ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, reflects:&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$60.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; milestone payment due to Ionis Pharmaceuticals, Inc. (Ionis) for the approval of SPINRAZA in the U.S. in December 2016;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$50.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in total milestone payments due to Samsung Bioepis, which became payable upon the approval of BENEPALI and FLIXABI in the E.U. in January 2016 and May 2016, respectively;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$32.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in total milestone payments due to AbbVie, Inc. (AbbVie), which became payable upon the approval of ZINBRYTA in the U.S. in May 2016 and the E.U. in July 2016; and&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$26.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; upon the approval of ALPROLIX in the E.U. in May 2016 which is comprised of a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$20.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; contingent payment due to the former owners of Syntonix Pharmaceuticals, Inc. (Syntonix) and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$6.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to the establishment of a corresponding deferred tax liability.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on our relationships with Samsung Bioepis, AbbVie and Ionis, please read Note 19, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Estimated Future Amortization of Intangible Assets&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;"&gt; &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our amortization expense is based on the economic consumption of intangible assets. Our most significant intangible assets are related to our AVONEX and TYSABRI products. Annually, during our long-range planning cycle, we perform an analysis of anticipated lifetime revenues of AVONEX and TYSABRI. This analysis is also updated whenever events or changes in circumstances would significantly affect the anticipated lifetime revenues of either product.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our most recent long range planning cycle was completed in the third quarter of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. Based upon this analysis, the estimated future amortization of acquired intangible assets is expected to be as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:81%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;As of December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;334.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;312.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;295.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;259.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;242.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Goodwill&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table provides a roll forward of the changes in our goodwill balance:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill, beginning of year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,663.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,760.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Increase to goodwill&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,026.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;908.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(21.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(4.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill, end of year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3,669.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,663.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The increase in goodwill during &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; was related to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.2 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in contingent milestones achieved (exclusive of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$173.1 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in tax benefits) and payable to the former shareholders of Fumapharm AG or holders of their rights. Other includes changes related to foreign exchange rate fluctuations. The increase in goodwill during &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; was related to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$900.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in contingent milestones achieved (exclusive of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$120.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in tax benefits) and payable to the former shareholders of Fumapharm AG or holders of their rights and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$128.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to our acquisition of Convergence.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information related to future contingent payments to the former shareholders of Fumapharm AG or holders of their rights, please read Note 21, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Commitments and Contingencies&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements. For additional information related to our acquisition of Convergence, please read Note 2, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Acquisitions&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we had &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; accumulated impairment losses related to goodwill.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
	<us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy contextRef="FD2016Q4YTD" id="Fact-F458B5BB1805276215B97411DFDF0705">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill represents the difference between the purchase price and the fair value of the identifiable tangible and intangible net assets when accounted for using the purchase method of accounting. Goodwill is not amortized, but reviewed for impairment. Goodwill is reviewed annually, as of October&amp;#160;31, and whenever events or changes in circumstances indicate that the carrying value of the goodwill might not be recoverable.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We compare the fair value of our reporting unit to its carrying value. If the carrying value of the net assets assigned to the reporting unit exceeds the fair value of our reporting unit, then we would need to determine the implied fair value of our reporting unit&amp;#8217;s goodwill. If the carrying value of our reporting unit&amp;#8217;s goodwill exceeds its implied fair value, then we would record an impairment loss equal to the difference. As described in Note&amp;#160;24, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Segment Information&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements, we operate in one operating segment which we consider our only reporting unit.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
	<us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy contextRef="FD2016Q4YTD" id="Fact-DF86C72EE70C36E117777411DFDE7B6E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our intangible assets consist of acquired and in-licensed rights and patents, developed technology, out-licensed patents, in-process research and development acquired after January&amp;#160;1, 2009, trademarks and trade names. Our intangible assets are recorded at fair value at the time of their acquisition and are stated in our consolidated balance sheets net of accumulated amortization and impairments, if applicable.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Intangible assets related to acquired and in-licensed rights and patents, developed technology and out-licensed patents are amortized over their estimated useful lives using the economic consumption method if anticipated future revenues can be reasonably estimated. The straight-line method is used when revenues cannot be reasonably estimated. Amortization is recorded as amortization of acquired intangible assets in our consolidated statements of income.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Acquired and in-licensed rights and patents primarily relate to our acquisition of all remaining rights to TYSABRI from Elan Pharma International, Ltd (Elan), an affiliate of Elan Corporation, plc. Developed technology primarily relates to our AVONEX product, which was recorded in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003. We amortize the intangible assets related to TYSABRI and AVONEX using the economic consumption method based on revenue generated from the products underlying the related intangible assets. An analysis of the anticipated lifetime revenues of TYSABRI and AVONEX is performed annually during our long range planning cycle, which is generally updated in the third quarter of each year, and whenever events or changes in circumstances would significantly affect the anticipated lifetime revenues of TYSABRI or AVONEX.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Intangible assets related to trademarks, trade names and in-process research and development prior to commercialization are not amortized because they have indefinite lives; however, they are subject to review for impairment. We review our intangible assets with indefinite lives for impairment annually, as of October&amp;#160;31, and whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy>
	<us-gaap:GuaranteesTextBlock contextRef="FD2016Q4YTD" id="Fact-32A13A161807B088777A7411DFB87711">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Guarantees&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we did not have significant liabilities recorded for guarantees.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We enter into indemnification provisions under our agreements with other companies in the ordinary course of business, typically with business partners, contractors, clinical sites and customers. Under these provisions, we generally indemnify and hold harmless the indemnified party for losses suffered or incurred by the indemnified party as a result of our activities. These indemnification provisions generally survive termination of the underlying agreement. The maximum potential amount of future payments we could be required to make under these indemnification provisions is unlimited. However, to date we have not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. As a result, the estimated fair value of these agreements is minimal. Accordingly, we have no liabilities recorded for these agreements as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:GuaranteesTextBlock>
	<us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="FD2016Q4YTD" id="Fact-92DABE3771A7D561ED617411DFDF7774">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Long-lived assets to be held and used, including property, plant and equipment and definite-lived intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets or asset group may not be recoverable.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written-down to their fair values. Long-lived assets to be disposed of are carried at fair value less costs to sell.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
	<us-gaap:InProcessResearchAndDevelopmentPolicy contextRef="FD2016Q4YTD" id="Fact-13A3FD9CCFCF73E694F07411DFDC7119">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Acquired IPR&amp;amp;D represents the fair value assigned to research and development assets that have not reached technological feasibility. The value assigned to acquired IPR&amp;amp;D is determined by estimating the costs to develop the acquired technology into commercially viable products, estimating the resulting revenue from the projects and discounting the net cash flows to present value. The revenue and costs projections used to value acquired IPR&amp;amp;D are, as applicable, reduced based on the probability of success of developing a new drug. Additionally, the projections consider the relevant market sizes and growth factors, expected trends in technology and the nature and expected timing of new product introductions by us and our competitors. The rates utilized to discount the net cash flows to their present value are commensurate with the stage of development of the projects and uncertainties in the economic estimates used in the projections. Upon the acquisition of IPR&amp;amp;D, we complete an assessment of whether our acquisition constitutes the purchase of a single asset or a group of assets. We consider multiple factors in this assessment, including the nature of the technology acquired, the presence or absence of separate cash flows, the development process and stage of completion, quantitative significance and our rationale for entering into the transaction.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;If we acquire a business as defined under applicable accounting standards, then the acquired IPR&amp;amp;D is capitalized as an intangible asset. If we acquire an asset or group of assets that do not meet the definition of a business, then the acquired IPR&amp;amp;D is expensed on its acquisition date. Future costs to develop these assets are recorded to research and development expense as they are incurred. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;When performing our impairment assessment, we calculate the fair value using the same methodology as described above. If the carrying value of our acquired IPR&amp;amp;D exceeds its fair value, then the intangible asset is written-down to its fair value. Certain IPR&amp;amp;D programs have a fair value that is not significantly in excess of carrying value, including our program for the treatment of trigeminal neuralgia (TGN). Such programs could become impaired if assumptions used in determining the fair value change.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InProcessResearchAndDevelopmentPolicy>
	<us-gaap:IncomeTaxDisclosureTextBlock contextRef="FD2016Q4YTD" id="Fact-37AE3A20A6D595C92EB97411DFEC9459">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Income Taxes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Income Tax Expense&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income before income tax provision and the income tax expense consist of the following:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Income before income taxes (benefit):&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Domestic&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3,655.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,386.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,557.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Foreign&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,277.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,380.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,389.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;4,933.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4,767.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,946.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Income tax expense (benefit):&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Federal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,304.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,214.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,159.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;State&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;55.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;38.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;65.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Foreign&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;52.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;54.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;73.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,412.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,307.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,298.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Deferred:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Federal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(125.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(129.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(280.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;State&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(3.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(21.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Foreign&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(45.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(14.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(6.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(175.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(145.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(308.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total income tax expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,237.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,161.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;989.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Deferred Tax Assets and Liabilities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Significant components of our deferred tax assets and liabilities are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As&amp;#160;of&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Deferred tax assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Tax credits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;201.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;189.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Inventory, other reserves and accruals&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;250.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;243.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Intangibles, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;459.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;328.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net operating loss&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;65.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;24.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Share-based compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;61.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;63.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;49.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;35.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Valuation allowance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(16.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(14.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total deferred tax assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,071.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;871.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Deferred tax liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Purchased intangible assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(376.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(440.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Depreciation, amortization and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(113.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(102.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total deferred tax liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(490.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(542.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In addition to deferred tax assets and liabilities, we have recorded prepaid tax and deferred charges related to intercompany transactions. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the total deferred charges and prepaid taxes were &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$989.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$697.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Tax Rate&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;A reconciliation between the U.S.&amp;#160;federal statutory tax rate and our effective tax rate is summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:55%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Statutory rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;35.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;35.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;35.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;State taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Taxes on foreign earnings&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(9.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(10.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(9.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Credits and net operating loss utilization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(1.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Purchased intangible assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Manufacturing deduction&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(1.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other permanent items&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Effective tax rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;25.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;24.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;25.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our effective tax rate for &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; compared to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; increased primarily due to a net state tax benefit in 2015 resulting from the remeasurement of one of our uncertain tax positions, described below, and a higher relative percentage of our earnings being attributed to the U.S., a higher tax jurisdiction.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our effective tax rate for &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; compared to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; benefited from lower taxes on foreign earnings and reflects a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$27.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; benefit from the 2015 remeasurement of one of our uncertain tax positions.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we had net operating losses and general business credit carry forwards for federal income tax purposes of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$22.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$140.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, which begin to expire in 2020. Additionally, for state income tax purposes, we had net operating loss carry forwards of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$86.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which begin to expire in 2017. For state income tax purposes, we also had research and investment credit carry forwards of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$126.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which begin to expire in 2017. For foreign income tax purposes, we had &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$489.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of net operating loss carryforwards, which begin to expire in 2021.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In assessing the realizability of our deferred tax assets, we have considered whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. In making this determination, under the applicable financial reporting standards, we are allowed to consider the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies. Our estimates of future taxable income take into consideration, among other items, our estimates of future income tax deductions related to the exercise of stock options. Based upon the level of historical taxable income and income tax liability and projections for future taxable income over the periods in which the deferred tax assets are utilizable, we believe it is more likely than not that we will realize the net benefits of the deferred tax assets of our wholly owned subsidiaries. In the event that actual results differ from our estimates or we adjust our estimates in future periods, we may need to establish a valuation allowance, which could materially impact our financial position and results of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, undistributed foreign earnings of non-U.S.&amp;#160;subsidiaries included in consolidated retained earnings and other basis differences aggregated approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$7.6 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. We intend to reinvest these earnings indefinitely in operations outside the U.S.&amp;#160;The residual U.S. tax liability, if cumulative amounts were repatriated, would be between &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.8 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$2.3 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Accounting for Uncertainty in Income Taxes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;A reconciliation of the beginning and ending amount of our unrecognized tax benefits is summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:56%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance at January&amp;#160;1,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;67.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;131.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;110.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Additions based on tax positions related to the current period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;7.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;10.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;20.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Additions for tax positions of prior periods&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;36.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;19.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;86.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Reductions for tax positions of prior periods&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(13.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(49.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(23.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Statute expirations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(1.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Settlements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(64.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(42.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(60.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance at December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;32.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;67.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;131.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We and our subsidiaries are routinely examined by various taxing authorities. We file income tax returns in the U.S.&amp;#160;federal jurisdiction, various U.S. states, and foreign jurisdictions. With few exceptions, including the proposed disallowance we discuss below, we are no longer subject to U.S.&amp;#160;federal tax examination for years before 2013 or state, local, or non-U.S.&amp;#160;income tax examinations for years before 2005. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Included in the balance of unrecognized tax benefits as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; are &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$26.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$15.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$53.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; (net of the federal benefit on state issues), respectively, of unrecognized tax benefits that, if recognized, would affect the effective income tax rate in future periods. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We recognize potential interest and penalties accrued related to unrecognized tax benefits in income tax expense. In &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; we recognized a net interest expense of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$9.1 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. In &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; we recognized net interest expense of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$3.1 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. In &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; we recognized a net interest expense of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$4.1 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. We have accrued approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$25.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$12.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for the payment of interest as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In March 2015 we received a final assessment from the Danish Tax Authority (SKAT) for fiscal 2009 regarding withholding taxes and the treatment of certain intercompany transactions involving a Danish affiliate and another of our affiliates.&amp;#160;In April 2016 we received final assessments from the SKAT for 2011 and 2013 regarding withholding taxes for similar intercompany transactions. The total amount assessed for 2009, 2011 and 2013 is estimated to be &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$58.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, including interest. For the assessments related to 2011 and 2013 we have made payments to SKAT totaling &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$12.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. We continue to dispute the assessments for all of these periods and believe that the positions taken in our historical filings are valid. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Federal Uncertain Tax Positions&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During the year ended December 31, 2015, the net effect of adjustments to one of our uncertain tax positions was a net benefit of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$27.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, primarily related to the state impact of a federal uncertain tax item.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;It is reasonably possible that we will adjust the value of our uncertain tax positions related to our revenues from anti-CD20 therapeutic programs and certain transfer pricing issues as we receive additional information from various taxing authorities, including reaching settlements with the authorities. In addition, the IRS and other national tax authorities routinely examine our intercompany transfer pricing with respect to intellectual property related transactions and it is possible that they may disagree with one or more positions we have taken with respect to such valuations.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
	<us-gaap:IncomeTaxPolicyTextBlock contextRef="FD2016Q4YTD" id="Fact-6114E2EDD56BF57344D57411DFDDEC47">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The provision for income taxes includes federal, state, local and foreign taxes. Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences of temporary differences between the financial statement carrying amounts and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which the temporary differences are expected to be recovered or settled. We evaluate the realizability of our deferred tax assets and establish a valuation allowance when it is more likely than not that all or a portion of deferred tax assets will not be realized.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;All tax effects associated with intercompany transfers of assets in our consolidated group, both current and deferred, are recorded as a prepaid tax or deferred charge and recognized through the consolidated statement of income when the asset transferred is sold to a third party or otherwise recovered through amortization of the asset's remaining economic life.&amp;#160;If the asset transferred becomes impaired, for example through the discontinuation of a research program, we will expense any remaining deferred charge or prepaid tax.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We account for uncertain tax positions using a &amp;#8220;more-likely-than-not&amp;#8221; threshold for recognizing and resolving uncertain tax positions. We evaluate uncertain tax positions on a quarterly basis and consider various factors including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, information obtained during in process audit activities and changes in facts or circumstances related to a tax position. We also accrue for potential interest and penalties related to unrecognized tax benefits in income tax expense.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
	<us-gaap:InventoryDisclosureTextBlock contextRef="FD2016Q4YTD" id="Fact-7173D71EBD3D68C235FB7411DFE0EC18">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Inventory&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The components of inventory are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Raw materials&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;170.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;213.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Work in process&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;698.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;577.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Finished goods&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;170.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;143.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total inventory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,039.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;933.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Balance Sheet Classification:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Inventory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,001.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;893.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Investments and other assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;37.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;40.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total inventory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,039.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;933.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Long-term inventory, which primarily consists of work in process, is included in investments and other assets in our consolidated balance sheets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, our inventory included &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$24.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; associated with our ZINBRYTA program, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$24.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; associated with our FLIXABI program and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$18.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; associated with our BENEPALI program, which had been capitalized in advance of regulatory approval. The European Commission (EC) approved the marketing authorization applications for BENEPALI and FLIXABI, two anti-tumor necrosis factor (TNF) biosimilars, for marketing in the E.U. in January 2016 and May 2016, respectively. In addition, ZINBRYTA was approved for the treatment of relapsing forms of MS in the U.S. in May 2016 and in the E.U. in July 2016. For information on our pre-approval inventory policy, please read Note 1,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt; Summary of Significant Accounting Policies&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Inventory amounts written down as a result of excess, obsolescence, unmarketability or other reasons are charged to cost of sales, and totaled &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$48.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$41.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$50.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for the years ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
	<us-gaap:InventoryPolicyTextBlock contextRef="FD2016Q4YTD" id="Fact-F3F08C64C979848FF89D7411DFDE0694">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Inventories are stated at the lower of cost or market with cost based on the first-in, first-out (FIFO) method. We classify our inventory costs as long-term when we expect to utilize the inventory beyond our normal operating cycle and include these costs in investments and other assets in our consolidated balance sheets. Inventory that can be used in either the production of clinical or commercial products is expensed as research and development costs when identified for use in a clinical manufacturing campaign.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Capitalization of Inventory Costs&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We capitalize inventory costs associated with our products prior to regulatory approval, when, based on management&amp;#8217;s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized. We consider numerous attributes in evaluating whether the costs to manufacture a particular product should be capitalized as an asset. We assess the regulatory approval process and where the particular product stands in relation to that approval process, including any known safety or efficacy concerns, potential labeling restrictions and other impediments to approval. We evaluate our anticipated research and development initiatives and constraints relating to the product and the indication in which it will be used. We consider our manufacturing environment including our supply chain in determining logistical constraints that could hamper approval or commercialization. We consider the shelf life of the product in relation to the expected timeline for approval and we consider patent related or contract issues that may prevent or delay commercialization. We also base our judgment on the viability of commercialization, trends in the marketplace and market acceptance criteria. Finally, we consider the reimbursement strategies that may prevail with respect to the product and assess the economic benefit that we are likely to realize. We expense previously capitalized costs related to pre-approval inventory upon a change in such judgment, due to, among other potential factors, a denial or significant delay of approval by necessary regulatory bodies.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Obsolescence and Unmarketable Inventory&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We periodically review our inventories for excess or obsolescence and write-down obsolete or otherwise unmarketable inventory to its estimated net realizable value. If the actual net realizable value is less than that estimated by us, or if it is determined that inventory utilization will further diminish based on estimates of demand, additional inventory write-downs may be required. Additionally, our products are subject to strict quality control and monitoring which we perform throughout the manufacturing process. In the event that certain batches or units of product no longer meet quality specifications, we will record a charge to cost of sales to write-down any unmarketable inventory to its estimated net realizable value. In all cases, product inventory is carried at the lower of cost or its estimated net realizable value. Amounts written-down due to unmarketable inventory are charged to cost of sales.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
	<us-gaap:InvestmentPolicyTextBlock contextRef="FD2016Q4YTD" id="Fact-55448DB230AE23FF89847411DFDD1340">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Marketable Debt Securities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Available-for-sale debt securities are recorded at fair market value and unrealized gains and losses are included in accumulated other comprehensive income (loss) in equity, net of related tax effects, unless the security has experienced a credit loss, we have determined that we have the intent to sell the security or we have determined that it is more likely than not that we will have to sell the security before its expected recovery. Realized gains and losses are reported in other income (expense), net, on a specific identification basis.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Marketable Equity Securities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our marketable equity securities represent investments in publicly traded equity securities and are included in investments and other assets in our consolidated balance sheet. When assessing whether a decline in the fair value of a marketable equity security is other-than-temporary, we consider the fair market value of the security, the duration of the security&amp;#8217;s decline and prospects for the underlying business, including favorable or adverse clinical trial results, new product initiatives and new collaborative agreements with the companies in which we have invested.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Non-Marketable Equity Securities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We also invest in equity securities of companies whose securities are not publicly traded and where fair value is not readily available. These investments are recorded using either the cost method or the equity method of accounting, depending on our ownership percentage and other factors that suggest we have significant influence. We monitor these investments to evaluate whether any decline in their value has occurred that would be other-than-temporary, based on the implied value of recent company financings, public market prices of comparable companies and general market conditions and are included in investments and other assets in our consolidated balance sheet.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Evaluating Investments for Other-than-Temporary Impairments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We conduct periodic reviews to identify and evaluate each investment that has an unrealized loss, in accordance with the meaning of other-than-temporary impairment and its application to certain investments. An unrealized loss exists when the current fair value of an individual security is less than its amortized cost basis. Unrealized losses on available-for-sale securities that are determined to be temporary, and not related to credit loss, are recorded, net of tax, in accumulated other comprehensive income.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For available-for-sale debt securities with unrealized losses, management performs an analysis to assess whether we intend to sell or whether we would more likely than not be required to sell the security before the expected recovery of the amortized cost basis. Where we intend to sell a security, or may be required to do so, the security&amp;#8217;s decline in fair value is deemed to be other-than-temporary and the full amount of the unrealized loss is reflected in earnings as an impairment loss.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Regardless of our intent to sell a security, we perform additional analysis on all securities with unrealized losses to evaluate losses associated with the creditworthiness of the security. Credit losses are identified where we do not expect to receive cash flows sufficient to recover the amortized cost basis of a security.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For equity securities, when assessing whether a decline in value is other-than-temporary, we consider the fair market value of the security, the duration of the security&amp;#8217;s decline, and the financial condition of the issuer. We then consider our intent and ability to hold the equity security for a period of time sufficient to recover our carrying value. Where we have determined that we lack the intent and ability to hold an equity security to its expected recovery, the security&amp;#8217;s decline in fair value is deemed to be other-than-temporary and is reflected in earnings as an impairment loss.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InvestmentPolicyTextBlock>
	<us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock contextRef="FD2016Q4YTD" id="Fact-A0F68ACE2E3363D0F8FF7411DFF8414D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;As of December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Estimated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&amp;#160; Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Estimated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&amp;#160; Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due in one year or less&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,568.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,569.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,120.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,122.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due after one year through five years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,552.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,559.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,575.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,583.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due after five years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;276.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;277.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;184.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;185.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total available-for-sale securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5,398.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5,406.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4,880.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4,891.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
	<us-gaap:LegalMattersAndContingenciesTextBlock contextRef="FD2016Q4YTD" id="Fact-7F01BF9EF441F52CD6257411E012F986">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Litigation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We are currently involved in various claims and legal proceedings, including the matters described below. For information as to our accounting policies relating to claims and legal proceedings, including use of estimates and contingencies, please read Note 1, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Summary of Significant Accounting Policies&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;With respect to some loss contingencies, an estimate of the possible loss or range of loss cannot be made until management has further information, including, for example, (i) which claims, if any, will survive dispositive motion practice; (ii) information to be obtained through discovery; (iii) information as to the parties' damages claims and supporting evidence; (iv) the parties&amp;#8217; legal theories; and (v) the parties' settlement positions. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The claims and legal proceedings in which we are involved also include challenges to the scope, validity or enforceability of the patents relating to our products, pipeline or processes, and challenges to the scope, validity or enforceability of the patents held by others. These include claims by third parties that we infringe their patents. An adverse outcome in any of these proceedings could result in one or more of the following and have a material impact on our business or consolidated results of operations and financial position: (i) loss of patent protection; (ii) inability to continue to engage in certain activities; and (iii) payment of significant damages, royalties, penalties and/or license fees to third parties.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Loss Contingencies &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Forward Pharma German Patent Litigation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On November 18, 2014, Forward Pharma A/S (Forward Pharma) filed suit against us in the Regional Court of D&amp;#252;sseldorf, Germany (the German Infringement Litigation) alleging that TECFIDERA infringes German Utility Model DE&amp;#160;20 2005 022 112&amp;#160;U1 (the utility model), which was issued in April 2014 and expired in October 2015. Forward Pharma subsequently&amp;#160;extended its allegations&amp;#160;to assert that TECFIDERA infringes Forward Pharma's European Patent No. 2,801,355 (the '355 patent), which was issued in May 2015 and expires in October 2025. We have entered a settlement and license agreement with Forward Pharma that will provide us an irrevocable license to all intellectual property owned by Forward Pharma and result in the termination of the German Infringement Litigation. For more information on the settlement and license agreement please read Note 21, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Commitments and Contingencies&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Italian National Medicines Agency&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In the fourth quarter of 2011 Biogen Italia SRL&amp;#160;received notice from the Italian National Medicines Agency (Agenzia Italiana del Farmaco or AIFA) that sales of TYSABRI after mid-February 2009 exceeded a reimbursement limit established pursuant to a Price Determination Resolution (Price Resolution) granted by AIFA in December 2006. On January&amp;#160;12, 2012, we filed an appeal in the Regional Administrative Tribunal of Lazio (Il Tribunale Amministrativo Regionale per il Lazio) in Rome, Italy seeking a ruling that the reimbursement limit in the Price Resolution should apply as written to only &amp;#8220;the first &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;24&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months&amp;#8221; of TYSABRI sales, which ended in mid-February 2009. The appeal is still pending. In June 2014 AIFA approved a resolution affirming that there is no reimbursement limit from and after February 2013. &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#231f20;"&gt;In January 2017 we negotiated an agreement in principle with AIFA's Price and Reimbursement Committee to settle all of AIFA's existing claims relating to sales of TYSABRI in excess of the reimbursement limit for the periods from February 2009 through January 2013 for an aggregate repayment of EUR&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;37.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#231f20;"&gt;. The agreement is subject to ratification by AIFA.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information regarding this matter, please read Note 17, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Other Consolidated Financial Statement Detail &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Qui Tam Litigation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On July 6, 2015, a qui tam action filed on behalf of the United States and certain states were unsealed by the U.S. District Court for the District of Massachusetts. The action alleges sales and promotional activities in violation of the federal False Claims Act and state law counterparts, and seeks single and treble damages, civil penalties, interest, attorneys&amp;#8217; fees and costs. Our motion to dismiss is pending. The United States has not made an intervention decision. An estimate of the possible loss or range of loss cannot be made at this time.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Securities Litigation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We and certain current and former officers are defendants in In re Biogen Inc. Securities Litigation, filed by a shareholder on August 18, 2015 in the U.S. District Court for the District of Massachusetts. The amended complaint alleges violations of federal securities laws under 15 U.S.C. &amp;#167;78j(b) and &amp;#167;78t(a) and 17 C.F.R. &amp;#167;240.10b-5. The lead plaintiff sought a declaration of the action as a class action, certification as a representative of the class and its counsel as class counsel, and an award of damages, interest and attorneys' fees. On July 1, 2016, the U.S. District Court dismissed the case and in September 2016 denied the plaintiff's motion to vacate the order of dismissal. The plaintiff has appealed. An estimate of the possible loss or range of loss cannot be made at this time.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We and certain current and former officers are also defendants in an action filed by another shareholder on October 20, 2016 in the U.S. District Court for the District of Massachusetts, related to the matter described above. The complaint alleges violations of federal securities laws under 15 U.S.C. &amp;#167;78j(b) and &amp;#167;78t(a) and 17 C.F.R. &amp;#167;240.10b-5 and seeks a declaration of the action as a class action and an award of damages, interest and attorney's fees. An estimate of the possible loss or range of loss cannot be made at this time.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Other Matters&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Interference Proceeding with Forward Pharma&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In April 2015 the U.S. Patent and Trademark Office (USPTO) declared an interference between Forward Pharma&amp;#8217;s pending U.S. Patent Application No. 11/576,871 and our U.S. Patent No. 8,399,514 (the '514 patent). The '514 patent includes claims covering the treatment of multiple sclerosis with 480 mg of dimethyl fumarate as provided for in our TECFIDERA label. We are awaiting a decision in this matter.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Inter Partes Review Proceeding&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On March 22, 2016, the USPTO instituted &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;inter partes&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; review of the '514 patent on the petition of the Coalition for Affordable Drugs V LLC, an entity associated with a hedge fund. We are awaiting a decision in this matter.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On April 18, 2016, Swiss Pharma International AG filed petitions in the USPTO for inter partes review of U.S. Patent Nos. 8,349,321 and 8,900,577, relating to specific formulations of natalizumab (TYSABRI), and U.S. Patent No. 8,815,236, relating to methods for treating MS and Crohn's disease using specific formulations of natalizumab (TYSABRI). In October 2016 the USPTO declined to institute proceedings under all three petitions. Swiss Pharma filed requests for rehearing, which are pending.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;European Patent Office Oppositions&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In June 2016 the European Patent Office issued a written decision confirming its earlier revocation of our European patent number 2 137 537 (the '537 patent), which we have appealed. The '537 patent includes claims covering the treatment of MS with 480 mg of dimethyl fumarate as provided for in our TECFIDERA label.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Patent Revocation Matter&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In December 2015 Swiss Pharma International AG brought an action in the Patents Court of the United Kingdom to revoke the UK counterpart of our European Patent Number 1 485 127&amp;#160;(&amp;#8220;Administration of agents to treat inflammation&amp;#8221;) (the '127 patent), which was issued in June 2011 and concerns administration of natalizumab (TYSABRI) to treat MS. The patent expires in February 2023.&amp;#160;Subsequently, the same entity brought an actions in the District Court of The Hague (on January 11, 2016) and the German Patents Court (on March 3, 2016) to invalidate the Dutch and German counterparts of the '127 patent. In September 2016 we resolved the UK action by agreeing to revocation of the UK patent. A hearing has been scheduled in the Dutch action for early 2017 and the German action for early 2018.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;'755 Patent Litigation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On May&amp;#160;28, 2010, Biogen MA Inc. (formerly Biogen Idec MA Inc.) filed a complaint in the U.S.&amp;#160;District Court for the District of New Jersey alleging infringement by Bayer Healthcare Pharmaceuticals Inc. (Bayer) (manufacturer, marketer and seller of BETASERON and manufacturer of EXTAVIA), EMD Serono, Inc. (EMD Serono) (manufacturer, marketer and seller of REBIF), Pfizer Inc. (co-marketer of REBIF) and Novartis Pharmaceuticals Corp. (Novartis) (marketer and seller of EXTAVIA) of our U.S. Patent No. 7,588,755 ('755 Patent), which claims the use of interferon beta for immunomodulation or treating a viral condition, viral disease, cancers or tumors. The complaint seeks monetary damages, including lost profits and royalties. Bayer had previously filed a complaint against us in the same court, on May 27, 2010, seeking a declaratory judgment that it does not infringe the '755 Patent and that the patent is invalid, and seeking monetary relief in the form of attorneys' fees, costs and expenses. The court has consolidated the two lawsuits, and we refer to the two actions as the &amp;#8220;Consolidated '755 Patent Actions.&amp;#8221;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Bayer, Pfizer, Novartis and EMD Serono have all filed counterclaims in the Consolidated '755 Patent Actions seeking declaratory judgments of patent invalidity and non-infringement, and seeking monetary relief in the form of costs and attorneys' fees, and EMD Serono and Bayer have each filed a counterclaim seeking a declaratory judgment that the '755 Patent is unenforceable based on alleged inequitable conduct. Bayer has also amended its complaint to seek such a declaration. Trial has been set for September 2017.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Government Matters&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have learned that state and federal governmental authorities are investigating our sales and promotional practices and have received related subpoenas. We are cooperating with the government. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On March 4, 2016, we received a subpoena from the federal government for documents relating to our relationship with non-profit organizations that provide assistance to patients taking drugs sold by Biogen. We are cooperating with the government.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On July 1, 2016, we received a civil investigative demand from the federal government for documents and information relating to our treatment of certain service agreements with wholesalers when calculating and reporting Average Manufacturer Prices in connection with the Medicaid Drug Rebate Program. We are cooperating with the government.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On December 5, 2016, we received a subpoena from the federal government for documents relating to government price reporting, rebate payments and Biogen's co-pay assistance programs for AVONEX, TECFIDERA, TYSABRI and PLEGRIDY. We are cooperating with the government.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On December 29, 2016, we received a civil investigative demand from the federal government for documents and information relating to our relationships with entities providing clinical education and reimbursement support services. We are cooperating with the government.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Product Liability and Other Legal Proceedings&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We are also involved in product liability claims and other legal proceedings generally incidental to our normal business activities. While the outcome of any of these proceedings cannot be accurately predicted, we do not believe the ultimate resolution of any of these existing matters would have a material adverse effect on our business or financial condition.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:LegalMattersAndContingenciesTextBlock>
	<us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock contextRef="FD2016Q4YTD" id="Fact-B2C047DC2252D1429D037411E0274E5D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Acquisitions&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Convergence Pharmaceuticals&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On February 12, 2015, we completed our acquisition of all of the outstanding stock of Convergence Pharmaceuticals (Convergence), a clinical-stage biopharmaceutical company with a focus on developing product candidates for neuropathic pain. Convergence&amp;#8217;s lead candidate was a Phase 2 clinical candidate BIIB074 (CNV1014802), which had demonstrated clinical activity in proof-of-concept studies for TGN. Additionally, BIIB074 had potential applicability in several other neuropathic pain states, including lumbosacral radiculopathy and erythromelalgia. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The purchase price consisted of a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$200.1 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; cash payment at closing, plus contingent consideration in the form of development and approval milestones up to a maximum of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$450.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, of which &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$350.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; was associated with the development and approval of BIIB074 for the treatment of TGN. The acquisition was funded from our existing cash on hand and was accounted for as the acquisition of a business. In addition to obtaining the rights to BIIB074 and additional product candidates in preclinical development, we retained the services of key employees of Convergence. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with our acquisition of Convergence, we recorded a liability of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$274.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; representing the fair value of the contingent consideration.&amp;#160;This amount was estimated through a valuation model that incorporated industry-based probability adjusted assumptions relating to the achievement of these milestones and thus the likelihood of making the contingent payments. This fair value measurement was based upon significant inputs not observable in the market and therefore represented a Level 3 measurement. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The purchase price, as adjusted, consisted of the following:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:87%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash portion of consideration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;200.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Contingent consideration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;274.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total purchase price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;474.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During the second quarter of 2015 we adjusted our preliminary estimate of the fair value of the assets acquired and contingent consideration as of the date of acquisition as a result of finalizing the purchase price accounting. This resulted in an increase in the value of our estimated contingent consideration and goodwill by &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$36.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. Our revised purchase price allocation is reflected in the chart below. Our purchase price allocation is complete.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Subsequent changes in the fair value of the contingent consideration obligation will be recognized as adjustments to contingent consideration and reflected in our consolidated statements of income. In the fourth quarter of 2016 a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$50.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; milestone related to BIIB074 in an additional neuropathic pain indication was earned and paid, resulting in a reduction to the contingent consideration. For additional information related to the fair value of this obligation, please read Note 7,&amp;#160;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Fair Value Measurements&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the estimated fair values of the separately identifiable assets acquired and liabilities assumed as of February&amp;#160;12, 2015, as adjusted:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:87%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In-process research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;424.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other intangible assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;7.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;128.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Deferred tax liability&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(84.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total purchase price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;474.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our estimate of the fair value of the IPR&amp;amp;D programs acquired was determined through a probability adjusted discounted cash flow analysis utilizing a discount rate of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;11%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This valuation was primarily driven by the value associated with the lead candidate, BIIB074, which is in development for the treatment of TGN and was expected to be completed no earlier than 2020, at a remaining cost of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$145.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. The fair value associated with BIIB074 for the treatment of TGN was &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$200.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. We recorded additional IPR&amp;amp;D assets related to the use of BIIB074 in two additional neuropathic pain indications, with a total estimated value of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$220.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. The remaining cost of development for these two indications was approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$415.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, with an expected completion date of no earlier than 2021. These fair value measurements were based on significant inputs not observable in the market and thus represented Level 3 fair value measurements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We attributed the goodwill recognized to the Convergence workforce's expertise in chronic pain research and clinical development and to establishing a deferred tax liability for the acquired IPR&amp;amp;D intangible assets which had no tax basis. The goodwill was not tax deductible.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Pro forma results of operations would not be materially different as a result of the acquisition of Convergence and therefore are not presented. Subsequent to the acquisition date, our results of operations include the results of operations of Convergence.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock>
	<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="FD2016Q4YTD" id="Fact-C8AF04EB6509998583DE7411DFDC11FB">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed, we do not believe that the impact of recently issued standards that are not yet effective will have a material impact on our financial position or results of operations upon adoption.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In May 2014 the FASB issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers (Topic 606), which supersedes all existing revenue recognition requirements, including most industry-specific guidance. The new standard requires a company to recognize revenue when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. The FASB has subsequently issued the following amendments to ASU 2014-09 which have the same effective date and transition date of January 1, 2018:&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In August 2015 the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date, which delayed the effective date of the new standard from January 1, 2017 to January 1, 2018. The FASB also agreed to allow entities to choose to adopt the standard as of the original effective date. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In March 2016 the FASB issued ASU No. 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations, which clarifies the implementation guidance on principal versus agent considerations. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In April 2016 the FASB issued ASU No. 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing, which clarifies certain aspects of identifying performance obligations and licensing implementation guidance. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In May 2016 the FASB issued ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients related to disclosures of remaining performance obligations, as well as other amendments to guidance on collectability, non-cash consideration and the presentation of sales and other similar taxes collected from customers. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In December 2016 the FASB issued ASU No. 2016-20, Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers, which amends certain narrow aspects of the guidance issued in ASU 2014-09 including guidance related to the disclosure of remaining performance obligations and prior-period performance obligations, as well as other amendments to the guidance on loan guarantee fees, contract costs, refund liabilities, advertising costs and the clarification of certain examples. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We are currently evaluating the method of adoption and the potential impact that Topic 606 may have on our financial position and results of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In April 2015 the FASB issued ASU No. 2015-05, Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Customer's Accounting for Fees Paid in a Cloud Computing Arrangement. Under this standard, if a cloud computing arrangement includes a software license, the software license element of the arrangement should be accounted for consistent with the acquisition of other software licenses. If a cloud computing arrangement does not include a software license, the arrangement should be accounted for as a service contract. We adopted this standard as of January 1, 2016, which did not have an impact on our financial position or results of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In July 2015 the FASB issued ASU No. 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory. The new standard applies only to inventory for which cost is determined by methods other than last-in, first-out and the retail inventory method, which includes inventory that is measured using first-in, first-out or average cost. Inventory within the scope of this standard is required to be measured at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. We adopted this standard as of January 1, 2016, which did not have an impact on our financial position or results of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In September 2015 the FASB issued ASU No. 2015-16, Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments. The new standard requires that an acquirer recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined and sets forth new disclosure requirements related to the adjustments. We adopted this standard as of January 1, 2016, which did not have an impact on our financial position or results of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In January 2016 the FASB issued ASU No. 2016-01, Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. This new standard amends certain aspects of accounting and disclosure requirements of financial instruments, including the requirement that equity investments with readily determinable fair values be measured at fair value with changes in fair value recognized in our results of operations. This new standard does not apply to investments accounted for under the equity method of accounting or those that result in consolidation of the investee. Equity investments that do not have readily determinable fair values may be measured at fair value or at cost minus impairment adjusted for changes in observable prices. A financial liability that is measured at fair value in accordance with the fair value option is required to be presented separately in other comprehensive income for the portion of the total change in the fair value resulting from change in the instrument-specific credit risk. In addition, a valuation allowance should be evaluated on deferred tax assets related to available-for-sale debt securities in combination with other deferred tax assets. This new standard will be effective for us on January 1, 2018. The adoption of this standard is not expected to have a material impact on our financial position or results of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In February 2016 the FASB issued ASU No. 2016-02, Leases (Topic 842). This new standard requires that all lessees recognize the assets and liabilities that arise from leases on the balance sheet and disclose qualitative and quantitative information about its leasing arrangements. This new standard will be effective for us on January 1, 2019. The adoption of this standard is not expected to have a material impact on our net financial position, but will impact the amount of our assets and liabilities. We are currently evaluating the potential impact that this standard may have on our results of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In March 2016 the FASB issued ASU No. 2016-06, Derivatives and Hedging (Topic 815): Contingent Put and Call Options in Debt Instruments. This new standard simplifies the embedded derivative analysis for debt instruments containing contingent call or put options by removing the requirement to assess whether a contingent event is related to interest rates or credit risks. This new standard will be effective for us on January 1, 2017. The adoption of this standard is not expected to have an impact on our financial position or results of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In March 2016 the FASB issued ASU No. 2016-07, Investments - Equity Method and Joint Ventures (Topic 323): Simplifying the Transition to the Equity Method of Accounting. This new standard eliminates the requirement that when an investment qualifies for use of the equity method as a result of an increase in the level of ownership interest or degree of influence, an adjustment must be made to the investment, results of operations and retained earnings retroactively on a step-by-step basis as if the equity method had been in effect during all previous periods that the investment has been held. This new standard will be effective for us on January 1, 2017. The adoption of this standard is not expected to have a material impact on our financial position or results of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In March 2016 the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. This new standard requires recognition of the income tax effects of vested or settled awards in the income statement and involves several other aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities and classification on the statement of cash flows. This new standard will be effective for us on January 1, 2017. The adoption of this standard is not expected to have a material impact on our financial position, results of operations or statements of cash flows upon adoption.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In June 2016 the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. This new standard changes the impairment model for most financial assets and certain other instruments. Under the new standard, entities holding financial assets and net investment in leases that are not accounted for at fair value through net income to be presented at the net amount expected to be collected. An allowance for credit losses will be a valuation account that will be deducted from the amortized cost basis of the financial asset to present the net carrying value at the amount expected to be collected on the financial asset. This new standard will be effective for us on January 1, 2020. The adoption of this standard is not expected to have a material impact on our financial position or results of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In August 2016 the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. This new standard clarifies certain aspects of the statement of cash flows, including the classification of debt prepayment or debt extinguishment costs or other debt instruments with coupon interest rates that are insignificant in relation to the effective interest rate of the borrowing, contingent consideration payments made after a business combination, proceeds from the settlement of insurance claims, proceeds from the settlement of corporate-owned life insurance policies, distributions received from equity method investees and beneficial interests in securitization transactions. This new standard also clarifies that an entity should determine each separately identifiable source of use within the cash receipts and payments on the basis of the nature of the underlying cash flows. In situations in which cash receipts and payments have aspects of more than one class of cash flows and cannot be separated by source or use, the appropriate classification should depend on the activity that is likely to be the predominant source or use of cash flows for the item. This new standard will be effective for us on January 1, 2018. The adoption of this standard is not expected to have a material impact on our statements of cash flows upon adoption.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In October 2016 the FASB issued ASU No. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfer of Assets Other Than Inventory. This new standard eliminates the exception for an intra-entity transfer of an asset other than inventory. Under the new standard, entities should recognize the income tax consequences on an intra-entity transfer of an asset other than inventory when the transfer occurs. This new standard will be effective for us on January 1, 2018 and will be applied on a modified retrospective basis through a cumulative-effect adjustment directly to retained earnings as of the beginning of the period of adoption. We are currently evaluating the potential impact this standard may have on our financial position and results of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In January 2017 the FASB issued ASU No. 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business. This new standard clarifies the definition of a business and provides a screen to determine when an integrated set of assets and activities is not a business. The screen requires that when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the set is not a business. This new standard will be effective for us on January 1, 2018. However, we have adopted this standard as of January 1, 2017, with prospective application to any business development transaction.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
	<us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock contextRef="FD2016Q4YTD" id="Fact-FEE1D65AA7A7A0022F857411DFDE5E8E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Summary of Significant Accounting Policies&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Business Overview&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen is a global biopharmaceutical company focused on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). We also have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other potential anti-CD20 therapies under a collaboration agreement with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group (Roche Group).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities, particularly within areas of our scientific, manufacturing and technical capabilities. Our research is currently focused on additional improvements in the treatment of MS, solving some of the most challenging and complex diseases, including Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis (ALS), and employing innovative technologies to discover potential treatments for rare and genetic disorders, including new ways of treating diseases through gene therapy.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our innovative drug development and commercialization activities are complemented by our biosimilar therapies that expand access to medicines and reduce the cost burden for healthcare systems. We are leveraging our manufacturing capabilities and know-how to develop, manufacture and market biosimilars through Samsung Bioepis, our joint venture with Samsung BioLogics Co. Ltd. (Samsung Biologics). Under this agreement, we are currently manufacturing and commercializing BENEPALI, an etanercept biosimilar referencing ENBREL, and FLIXABI, an infliximab biosimilar referencing REMICADE, in the European Union (E.U.).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Hemophilia Spin-Off&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In May 2016 we announced our intention to spin off our hemophilia business, Bioverativ Inc. (Bioverativ), as an independent, publicly traded company. Bioverativ, will focus on the discovery, development and commercialization of therapies for treatment of hemophilia and other blood disorders, including ELOCTATE for the treatment of hemophilia A and ALPROLIX for the treatment of hemophilia B. Bioverativ will also assume all of our rights and obligations under our collaboration agreement with Swedish Orphan Biovitrum AB (Sobi) and our collaboration and license agreement with Sangamo Biosciences Inc. (Sangamo).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On February 1, 2017, we completed the distribution of all the then outstanding shares of common stock of Bioverativ to Biogen stockholders, who received one share of Bioverativ common stock for every two shares of Biogen common stock. As a result of the distribution, Bioverativ is now an independent public company whose shares of common stock are trading under the symbol "BIVV" on the Nasdaq Global Select Market.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The financial results of Bioverativ are reflected in our consolidated results of operations and financial position included in these audited consolidated financial statements for the periods presented in this Form 10-K. The financial results of Bioverativ will be excluded from our consolidated results of operations and financial position commencing February 1, 2017. For additional information regarding the separation of Bioverativ, please read Note 26, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Subsequent Events&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Consolidation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;100%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the economics, we record net income (loss) attributable to noncontrolling interests in our consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In determining whether we are the primary beneficiary of an entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Use of Estimates&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The preparation of our consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an on-going basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates under different assumptions or conditions.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Revenue Recognition&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We recognize revenue when all of the following criteria are met: persuasive evidence of an arrangement exists; delivery has occurred or services have been rendered; our price to the customer is fixed or determinable; and collectability is reasonably assured.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Product Revenues&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from product sales are recognized when title and risk of loss have passed to the customer, which is typically upon delivery. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Reserves for Discounts and Allowances&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from product sales are recorded net of reserves established for applicable discounts and allowances, including those associated with the implementation of pricing actions in certain of the international markets in which we operate. These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer). Our estimates take into consideration our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Actual amounts may ultimately differ from our estimates. If actual results vary, we adjust these estimates, which could have an effect on earnings in the period of adjustment. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Product revenue reserves are categorized as follows: discounts, contractual adjustments and returns.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Discounts include trade term discounts and wholesaler incentives. Trade term discounts and wholesaler incentives primarily relate to estimated obligations for credits to be granted to wholesalers for remitting payment on their purchases within established incentive periods and credits to be granted to wholesalers for compliance with various contractually-defined inventory management practices, respectively. We determine these reserves based on our historical experience, including the timing of customer payments.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Contractual adjustments primarily relate to Medicaid and managed care rebates, co-payment (copay) assistance, Veterans Administration (VA) and Public Health Service (PHS) discounts, specialty pharmacy program fees and other governmental rebates or applicable allowances.&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Medicaid rebates relate to our estimated obligations to states under established reimbursement arrangements. Rebate accruals are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a liability which is included in other current liabilities. Our liability for Medicaid rebates consists of estimates for claims that a state will make for the current quarter, claims for prior quarters that have been estimated for which an invoice has not been received, invoices received for claims from the prior quarters that have not been paid, and an estimate of potential claims that will be made for inventory that exists in the distribution channel at period end.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Governmental rebates or chargebacks, including VA and PHS discounts, represent our estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices we charge to wholesalers which provide those products. The wholesaler charges us for the difference between what the wholesaler pays for the products and the ultimate selling price to the qualified healthcare providers. Rebate and chargeback reserves are established in the same period as the related revenue is recognized, resulting in a reduction in product revenue and accounts receivable. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider from the wholesaler, and we generally issue credits for such amounts within a few weeks of the wholesaler notifying us about the resale. Our reserves for VA, PHS and chargebacks consist of amounts that we expect to issue for inventory that exists at the wholesalers that we expect will be sold to qualified healthcare providers and chargebacks that wholesalers have claimed for which we have not issued a credit.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Managed care rebates represent our estimated obligations to third parties, primarily pharmacy benefit managers. Rebate accruals are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a liability which is included in accrued expenses and other current liabilities. These rebates result from performance-based goals, formulary position and price increase limit allowances (price protection). The calculation of the accrual for these rebates is based on an estimate of the customer&amp;#8217;s buying patterns and the resulting applicable contractual rebate rate(s) to be earned over a contractual period.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Copay assistance represents financial assistance to qualified patients, assisting them with prescription drug co-payments required by insurance. The calculation of the accrual for copay is based on an estimate of claims and the cost per claim that we expect to receive associated with inventory that exists in the distribution channel at period end.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other governmental rebates or applicable allowances primarily relate to mandatory rebates and discounts in international markets where government-sponsored healthcare systems are the primary payors for healthcare.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Product returns are established for returns expected to be made by wholesalers and are recorded in the period the related revenue is recognized, resulting in a reduction to product sales. In accordance with contractual terms, wholesalers are permitted to return product for reasons such as damaged or expired product. The majority of wholesaler returns are due to product expiration. Expired product return reserves are estimated through a comparison of historical return data to their related sales on a production lot basis. Historical rates of return are determined for each product and are adjusted for known or expected changes in the marketplace specific to each product.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In addition to the discounts, rebates and product returns described above and classified as a reduction of revenue, we also maintain certain customer service contracts with distributors and other customers in the distribution channel that provide us with inventory management, data and distribution services, which are generally reflected as a reduction of revenue. To the extent we can demonstrate a separable benefit and fair value for these services, we classify these payments in selling, general and administrative expenses.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Revenues from Anti-CD20 Therapeutic Programs&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from anti-CD20 therapeutic programs consist of:&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(i)&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;our share of pre-tax profits and losses in the U.S. for RITUXAN and GAZYVA; &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(ii)&amp;#160; &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;reimbursement of our selling and development expenses in the U.S. for RITUXAN; and &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(iii)&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;revenues on sales in the rest of world for RITUXAN, which consist of our share of pre-tax co-promotion profits on RITUXAN in Canada and royalty revenue on RITUXAN sales outside the U.S. and Canada by the Roche Group and its sublicensees. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Pre-tax co-promotion profits on RITUXAN and GAZYVA are calculated and paid to us by Genentech in the U.S. Pre-tax co-promotion profits on RITUXAN are calculated and paid to us by the Roche Group in Canada. Pre-tax co-promotion profits consist of U.S. and Canadian net sales to third-party customers less applicable costs to manufacture, third-party royalty expenses, distribution, selling and marketing expenses, and joint development expenses incurred by Genentech, the Roche Group and us. We record our share of the pre-tax co-promotion profits on RITUXAN in Canada and royalty revenues on RITUXAN sales outside the U.S. on a cash basis as we do not have the ability to estimate these profits or royalty revenue in the period incurred. Our share of the pre-tax profits on RITUXAN and GAZYVA in the U.S. includes estimates made by Genentech and those estimates are subject to change. Actual results may differ from our estimates. For additional information related to our collaboration with Genentech, please read Note&amp;#160;19, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Royalty Revenues&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We receive royalty revenues on sales by our licensees of other products covered under patents that we own. We do not have future performance obligations under these license arrangements. We record these revenues based on estimates of the sales that occurred during the relevant period as a component of other revenues. The relevant period estimates of sales are based on interim data provided by licensees and analysis of historical royalties that have been paid to us, adjusted for any changes in facts and circumstances, as appropriate. Differences between actual and estimated royalty revenues are adjusted for in the period in which they become known, typically the following quarter. Historically, adjustments have not been material when compared to actual amounts paid by licensees. If we are unable to reasonably estimate royalty revenue or do not have access to the information, then we record royalty revenues on a cash basis. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Multiple-Element Revenue Arrangements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We may enter into transactions that involve the sale of products and related services under multiple element arrangements.&amp;#160;In accounting for these transactions, we assess the elements of the contract and whether each element has standalone value and allocate revenue to the various elements based on their estimated selling price as a component of total revenues.&amp;#160;The selling price of a revenue generating element can be based on current selling prices offered by us or another party for current products or management&amp;#8217;s best estimate of a selling price. Revenue allocated to an individual element is recognized when all other revenue recognition criteria are met for that element.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Collaborative and Other Relationships&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our development and commercialization arrangements with Sobi and AbbVie Inc. (AbbVie) represent collaborative arrangements as each party is an active participant and exposed to significant risks and rewards of the arrangements. Where we are the principal on sales transactions with third parties, we recognize revenue, cost of sales and operating expenses on a gross basis in their respective lines in our consolidated statements of income. Where we are not the principal on sales transactions with third parties, we record our share of the revenues, cost of sales and operating expenses on a net basis in collaborative and other relationships included in other revenue in our consolidated statements of income. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information related to our collaborations with Sobi and AbbVie, please read Note 19, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Fair Value Measurements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have certain financial assets and liabilities recorded at fair value which have been classified as Level&amp;#160;1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements.&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Level&amp;#160;1&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;&amp;#8212; Fair values are determined utilizing quoted prices (unadjusted) in active markets for identical assets or liabilities that we have the ability to access;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Level&amp;#160;2&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;&amp;#8212; Fair values are determined by utilizing quoted prices for identical or similar assets and liabilities in active markets or other market observable inputs such as interest rates, yield curves and foreign currency spot rates;&amp;#160;and&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Level&amp;#160;3&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;&amp;#8212; Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The majority of our financial assets have been classified as Level&amp;#160;2. Our financial assets (which include our cash equivalents, derivative contracts, marketable debt securities and plan assets for deferred compensation) have been initially valued at the transaction price and subsequently valued, at the end of each reporting period, utilizing third-party pricing services or other market observable data. The pricing services utilize industry standard valuation models, including both income and market-based approaches and observable market inputs to determine value. These observable market inputs include reportable trades, benchmark yields, credit spreads, broker/dealer quotes, bids, offers, current spot rates and other industry and economic events.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We validate the prices provided by our third-party pricing services by reviewing their pricing methods and matrices, obtaining market values from other pricing sources and analyzing pricing data in certain instances. After completing our validation procedures, we did not adjust or override any fair value measurements provided by our pricing services as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Other Assets and Liabilities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The carrying amounts reflected in the consolidated balance sheets for current accounts receivable, due from anti-CD20 therapeutic programs, other current assets, accounts payable and accrued expenses and other, approximate fair value due to their short-term maturities.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Cash and Cash Equivalents&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We consider only those investments which are highly liquid, readily convertible to cash and that mature within three months from date of purchase to be cash equivalents. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, cash equivalents were comprised of money market funds and commercial paper, overnight reverse repurchase agreements and other debt securities with maturities less than 90 days from the date of purchase.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Accounts Receivable&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The majority of our accounts receivable arise from product sales and primarily represent amounts due from our wholesale distributors, public hospitals and other government entities. We monitor the financial performance and creditworthiness of our customers so that we can properly assess and respond to changes in their credit profile. We provide reserves against trade receivables for estimated losses that may result from a customer&amp;#8217;s inability to pay. Amounts determined to be uncollectible are charged or written-off against the reserve. To date, our historical reserves and write-offs of accounts receivable have not been significant.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In countries where we have experienced a pattern of payments extending beyond our contractual payment term and we expect to collect receivables greater than one year from the time of sale, we have discounted our receivables and reduced related revenues over the period of time that we estimate those amounts will be paid using the country&amp;#8217;s market-based borrowing rate for such period. The related receivables are classified at the time of sale as non-current assets. We accrete interest income on these receivables, which is recognized as a component of other income (expense), net in our consolidated statements of income.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Concentration of Credit Risk&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Financial instruments that potentially subject us to concentrations of credit risk include cash and cash equivalents, investments, derivatives and accounts receivable. We attempt to minimize the risks related to cash and cash equivalents and investments by investing in a broad and diverse range of financial instruments as previously defined by us. We have established guidelines related to credit ratings and maturities intended to safeguard principal balances and maintain liquidity. Our investment portfolio is maintained in accordance with our investment policy, which defines allowable investments, specifies credit quality standards and limits the credit exposure of any single issuer. We minimize credit risk resulting from derivative instruments by choosing only highly rated financial institutions as counterparties.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Concentrations of credit risk with respect to receivables, which are typically unsecured, are somewhat mitigated due to the wide variety of customers and markets using our products, as well as their dispersion across many different geographic areas. The majority of our accounts receivable arise from product sales in the U.S. and Europe and have standard payment terms which generally require payment within &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;30 to 90 days&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. We monitor the financial performance and creditworthiness of our customers so that we can properly assess and respond to changes in their credit profile. We continue to monitor these conditions and assess their possible impact on our business. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, two wholesale distributors individually accounted for approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;37.2%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;19.2%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;35.4%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;23.1%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, of accounts receivable, net, respectively. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Marketable Securities and Other Investments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Marketable Debt Securities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Available-for-sale debt securities are recorded at fair market value and unrealized gains and losses are included in accumulated other comprehensive income (loss) in equity, net of related tax effects, unless the security has experienced a credit loss, we have determined that we have the intent to sell the security or we have determined that it is more likely than not that we will have to sell the security before its expected recovery. Realized gains and losses are reported in other income (expense), net, on a specific identification basis.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Marketable Equity Securities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our marketable equity securities represent investments in publicly traded equity securities and are included in investments and other assets in our consolidated balance sheet. When assessing whether a decline in the fair value of a marketable equity security is other-than-temporary, we consider the fair market value of the security, the duration of the security&amp;#8217;s decline and prospects for the underlying business, including favorable or adverse clinical trial results, new product initiatives and new collaborative agreements with the companies in which we have invested.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Non-Marketable Equity Securities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We also invest in equity securities of companies whose securities are not publicly traded and where fair value is not readily available. These investments are recorded using either the cost method or the equity method of accounting, depending on our ownership percentage and other factors that suggest we have significant influence. We monitor these investments to evaluate whether any decline in their value has occurred that would be other-than-temporary, based on the implied value of recent company financings, public market prices of comparable companies and general market conditions and are included in investments and other assets in our consolidated balance sheet.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Evaluating Investments for Other-than-Temporary Impairments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We conduct periodic reviews to identify and evaluate each investment that has an unrealized loss, in accordance with the meaning of other-than-temporary impairment and its application to certain investments. An unrealized loss exists when the current fair value of an individual security is less than its amortized cost basis. Unrealized losses on available-for-sale securities that are determined to be temporary, and not related to credit loss, are recorded, net of tax, in accumulated other comprehensive income.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For available-for-sale debt securities with unrealized losses, management performs an analysis to assess whether we intend to sell or whether we would more likely than not be required to sell the security before the expected recovery of the amortized cost basis. Where we intend to sell a security, or may be required to do so, the security&amp;#8217;s decline in fair value is deemed to be other-than-temporary and the full amount of the unrealized loss is reflected in earnings as an impairment loss.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Regardless of our intent to sell a security, we perform additional analysis on all securities with unrealized losses to evaluate losses associated with the creditworthiness of the security. Credit losses are identified where we do not expect to receive cash flows sufficient to recover the amortized cost basis of a security.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For equity securities, when assessing whether a decline in value is other-than-temporary, we consider the fair market value of the security, the duration of the security&amp;#8217;s decline, and the financial condition of the issuer. We then consider our intent and ability to hold the equity security for a period of time sufficient to recover our carrying value. Where we have determined that we lack the intent and ability to hold an equity security to its expected recovery, the security&amp;#8217;s decline in fair value is deemed to be other-than-temporary and is reflected in earnings as an impairment loss.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Equity Method of Accounting&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In circumstances where we have the ability to exercise significant influence over the operating and financial policies of a company in which we have an investment, we utilize the equity method of accounting for recording investment activity.&amp;#160;In assessing whether we exercise significant influence, we consider the nature and magnitude of our investment, the voting and protective rights we hold, any participation in the governance of the other company, and other relevant factors such as the presence of a collaboration or other business relationship.&amp;#160;Under the equity method of accounting, we record in our results of operations our share of income or loss of the other company. If our share of losses exceeds the carrying value of our investment, we will suspend recognizing additional losses and will continue to do so unless we commit to providing additional funding. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Inventory&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Inventories are stated at the lower of cost or market with cost based on the first-in, first-out (FIFO) method. We classify our inventory costs as long-term when we expect to utilize the inventory beyond our normal operating cycle and include these costs in investments and other assets in our consolidated balance sheets. Inventory that can be used in either the production of clinical or commercial products is expensed as research and development costs when identified for use in a clinical manufacturing campaign.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Capitalization of Inventory Costs&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We capitalize inventory costs associated with our products prior to regulatory approval, when, based on management&amp;#8217;s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized. We consider numerous attributes in evaluating whether the costs to manufacture a particular product should be capitalized as an asset. We assess the regulatory approval process and where the particular product stands in relation to that approval process, including any known safety or efficacy concerns, potential labeling restrictions and other impediments to approval. We evaluate our anticipated research and development initiatives and constraints relating to the product and the indication in which it will be used. We consider our manufacturing environment including our supply chain in determining logistical constraints that could hamper approval or commercialization. We consider the shelf life of the product in relation to the expected timeline for approval and we consider patent related or contract issues that may prevent or delay commercialization. We also base our judgment on the viability of commercialization, trends in the marketplace and market acceptance criteria. Finally, we consider the reimbursement strategies that may prevail with respect to the product and assess the economic benefit that we are likely to realize. We expense previously capitalized costs related to pre-approval inventory upon a change in such judgment, due to, among other potential factors, a denial or significant delay of approval by necessary regulatory bodies.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Obsolescence and Unmarketable Inventory&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We periodically review our inventories for excess or obsolescence and write-down obsolete or otherwise unmarketable inventory to its estimated net realizable value. If the actual net realizable value is less than that estimated by us, or if it is determined that inventory utilization will further diminish based on estimates of demand, additional inventory write-downs may be required. Additionally, our products are subject to strict quality control and monitoring which we perform throughout the manufacturing process. In the event that certain batches or units of product no longer meet quality specifications, we will record a charge to cost of sales to write-down any unmarketable inventory to its estimated net realizable value. In all cases, product inventory is carried at the lower of cost or its estimated net realizable value. Amounts written-down due to unmarketable inventory are charged to cost of sales.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Property, Plant and Equipment&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Property, plant and equipment are carried at cost, subject to review for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. The cost of normal, recurring, or periodic repairs and maintenance activities related to property, plant and equipment are expensed as incurred. The cost for planned major maintenance activities, including the related acquisition or construction of assets, is capitalized if the repair will result in future economic benefits.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest costs incurred during the construction of major capital projects are capitalized until the underlying asset is ready for its intended use, at which point the interest costs are amortized as depreciation expense over the life of the underlying asset. We also capitalize certain direct and incremental costs associated with the validation effort required for licensing by regulatory agencies of new manufacturing equipment for the production of a commercially approved drug. These costs primarily include direct labor and material and are incurred in preparing the equipment for its intended use. The validation costs are either amortized over the life of the related equipment or expensed as cost of sales when the product produced in the validation process is sold.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In addition, we capitalize certain internal use computer software development costs. If the software is an integral part of production assets, these costs are included in machinery and equipment and are amortized on a straight-line basis over the estimated useful lives of the related software, which generally range from &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three to five years&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We generally depreciate or amortize the cost of our property, plant and equipment using the straight-line method over the estimated useful lives of the respective assets, which are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="2" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:50%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:50%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;"&gt;Asset Category&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;"&gt;Useful Lives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Land&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Not depreciated&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Buildings&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;15 to 40&amp;#160;years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Leasehold Improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Lesser of the useful life or the term of the respective lease&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Furniture and Fixtures&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5 to 7&amp;#160;years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Machinery and Equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5 to 20&amp;#160;years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Computer&amp;#160;Software&amp;#160;and&amp;#160;Hardware&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3 to 5&amp;#160;years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;When we dispose of property, plant and equipment, we remove the associated cost and accumulated depreciation from the related accounts on our consolidated balance sheet and include any resulting gain or loss in our consolidated statement of income.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Intangible Assets&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our intangible assets consist of acquired and in-licensed rights and patents, developed technology, out-licensed patents, in-process research and development acquired after January&amp;#160;1, 2009, trademarks and trade names. Our intangible assets are recorded at fair value at the time of their acquisition and are stated in our consolidated balance sheets net of accumulated amortization and impairments, if applicable.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Intangible assets related to acquired and in-licensed rights and patents, developed technology and out-licensed patents are amortized over their estimated useful lives using the economic consumption method if anticipated future revenues can be reasonably estimated. The straight-line method is used when revenues cannot be reasonably estimated. Amortization is recorded as amortization of acquired intangible assets in our consolidated statements of income.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Acquired and in-licensed rights and patents primarily relate to our acquisition of all remaining rights to TYSABRI from Elan Pharma International, Ltd (Elan), an affiliate of Elan Corporation, plc. Developed technology primarily relates to our AVONEX product, which was recorded in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003. We amortize the intangible assets related to TYSABRI and AVONEX using the economic consumption method based on revenue generated from the products underlying the related intangible assets. An analysis of the anticipated lifetime revenues of TYSABRI and AVONEX is performed annually during our long range planning cycle, which is generally updated in the third quarter of each year, and whenever events or changes in circumstances would significantly affect the anticipated lifetime revenues of TYSABRI or AVONEX.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Intangible assets related to trademarks, trade names and in-process research and development prior to commercialization are not amortized because they have indefinite lives; however, they are subject to review for impairment. We review our intangible assets with indefinite lives for impairment annually, as of October&amp;#160;31, and whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Acquired In-process Research and Development (IPR&amp;amp;D)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Acquired IPR&amp;amp;D represents the fair value assigned to research and development assets that have not reached technological feasibility. The value assigned to acquired IPR&amp;amp;D is determined by estimating the costs to develop the acquired technology into commercially viable products, estimating the resulting revenue from the projects and discounting the net cash flows to present value. The revenue and costs projections used to value acquired IPR&amp;amp;D are, as applicable, reduced based on the probability of success of developing a new drug. Additionally, the projections consider the relevant market sizes and growth factors, expected trends in technology and the nature and expected timing of new product introductions by us and our competitors. The rates utilized to discount the net cash flows to their present value are commensurate with the stage of development of the projects and uncertainties in the economic estimates used in the projections. Upon the acquisition of IPR&amp;amp;D, we complete an assessment of whether our acquisition constitutes the purchase of a single asset or a group of assets. We consider multiple factors in this assessment, including the nature of the technology acquired, the presence or absence of separate cash flows, the development process and stage of completion, quantitative significance and our rationale for entering into the transaction.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;If we acquire a business as defined under applicable accounting standards, then the acquired IPR&amp;amp;D is capitalized as an intangible asset. If we acquire an asset or group of assets that do not meet the definition of a business, then the acquired IPR&amp;amp;D is expensed on its acquisition date. Future costs to develop these assets are recorded to research and development expense as they are incurred. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;When performing our impairment assessment, we calculate the fair value using the same methodology as described above. If the carrying value of our acquired IPR&amp;amp;D exceeds its fair value, then the intangible asset is written-down to its fair value. Certain IPR&amp;amp;D programs have a fair value that is not significantly in excess of carrying value, including our program for the treatment of trigeminal neuralgia (TGN). Such programs could become impaired if assumptions used in determining the fair value change.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Goodwill&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill represents the difference between the purchase price and the fair value of the identifiable tangible and intangible net assets when accounted for using the purchase method of accounting. Goodwill is not amortized, but reviewed for impairment. Goodwill is reviewed annually, as of October&amp;#160;31, and whenever events or changes in circumstances indicate that the carrying value of the goodwill might not be recoverable.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We compare the fair value of our reporting unit to its carrying value. If the carrying value of the net assets assigned to the reporting unit exceeds the fair value of our reporting unit, then we would need to determine the implied fair value of our reporting unit&amp;#8217;s goodwill. If the carrying value of our reporting unit&amp;#8217;s goodwill exceeds its implied fair value, then we would record an impairment loss equal to the difference. As described in Note&amp;#160;24, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Segment Information&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements, we operate in one operating segment which we consider our only reporting unit.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Impairment of Long-Lived Assets&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Long-lived assets to be held and used, including property, plant and equipment and definite-lived intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets or asset group may not be recoverable.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written-down to their fair values. Long-lived assets to be disposed of are carried at fair value less costs to sell.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Contingent Consideration&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The consideration for our acquisitions often includes future payments that are contingent upon the occurrence of a particular event. For acquisitions completed before January 1, 2009, we record contingent consideration resulting from a business combination when the contingency is resolved. For acquisitions that qualify as business combinations completed after January&amp;#160;1, 2009, we record an obligation for such contingent payments at fair value on the acquisition date. We estimate the fair value of contingent consideration obligations through valuation models that incorporate probability-adjusted assumptions related to the achievement of the milestones and thus likelihood of making related payments. We revalue these contingent consideration obligations each reporting period. Changes in the fair value of our contingent consideration obligations are recognized in our consolidated statements of income. Changes in the fair value of the contingent consideration obligations can result from changes to one or multiple inputs, including adjustments to the discount rates, changes in the amount or timing of expected expenditures associated with product development, changes in the amount or timing of cash flows and reserves associated with products upon commercialization, changes in the assumed achievement or timing of any cumulative sales-based and development milestones, changes in the probability of certain clinical events and changes in the assumed probability associated with regulatory approval. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Discount rates in our valuation models represent a measure of the credit risk associated with settling the liability. The period over which we discount our contingent obligations is based on the current development stage of the product candidates, our specific development plan for that product candidate adjusted for the probability of completing the development step, and when the contingent payments would be triggered. In estimating the probability of success, we utilize data regarding similar milestone events from several sources, including industry studies and our own experience. These fair value measurements are based on significant inputs not observable in the market. Significant judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, changes in assumptions could have a material impact on the amount of contingent consideration expense we record in any given period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Derivative Instruments and Hedging Activities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We recognize all derivative instruments as either assets or liabilities at fair value in our consolidated balance sheets. Changes in the fair value of derivatives are recorded each period in current earnings or accumulated other comprehensive income (loss), depending on whether a derivative is designated as part of a hedge transaction and, if so, the type of hedge transaction. We classify the cash flows from these instruments in the same category as the cash flows from the hedged items. We do not hold or issue derivative instruments for trading or speculative purposes.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We assess, both at inception and on an ongoing basis, whether the derivatives that are used in hedging transactions are highly effective in offsetting the changes in cash flows or fair values of the hedged items. We also assess hedge ineffectiveness on a quarterly basis and record the gain or loss related to the ineffective portion to current earnings. If we determine that a forecasted transaction is no longer probable of occurring, we discontinue hedge accounting for the affected portion of the hedge instrument, and any related unrealized gain or loss on the contract is recognized in current earnings.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Translation of Foreign Currencies&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The functional currency for most of our foreign subsidiaries is their local currency. For our non-U.S. subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the average foreign exchange rates for the period. Adjustments resulting from the translation of the financial statements of our foreign operations into U.S.&amp;#160;dollars are excluded from the determination of net income and are recorded in accumulated other comprehensive income, a separate component of equity. For subsidiaries where the functional currency of the assets and liabilities differ from the local currency, non-monetary assets and liabilities are translated at the rate of exchange in effect on the date assets were acquired while monetary assets and liabilities are translated at current rates of exchange as of the balance sheet date. Income and expense items are translated at the average foreign currency rates for the period. Translation adjustments of these subsidiaries are included in other income (expense), net, in our consolidated statements of income.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Royalty Cost of Sales&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We make royalty payments to a number of third parties under license or purchase agreements associated with our acquisition of intellectual property. These royalty payments are typically calculated as a percentage (royalty rate) of the sales of our products in a particular year.&amp;#160;That royalty rate may remain constant, increase or decrease within each year based on the total amount of sales during the annual period. Each quarterly period, we estimate our total royalty obligation for the full year and recognize the proportional amount as cost of sales based on actual quarterly sales as a percentage of full year estimated sales. For example, if the level of net sales in any calendar year increases the royalty rate within the year, we will record our cost of sales at an even rate over the year, based on the estimated blended royalty rate. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Accounting for Share-Based Compensation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our share-based compensation programs grant awards that have included stock options, restricted stock units which vest based on stock performance known as market stock units (MSUs), performance-vested restricted stock units which settle in cash (CSPUs), time-vested restricted stock units (RSUs), performance-vested restricted stock units which can be settled in cash or shares of our common stock (PUs) at the sole discretion of the Compensation and Management Development Committee of the Board of Directors and shares issued under our employee stock purchase plan (ESPP). We charge the estimated fair value of awards against income over the requisite service period, which is generally the vesting period. Where awards are made with non-substantive vesting periods (for instance, where a portion of the award vests upon retirement eligibility), we estimate and recognize expense based on the period from the grant date to the date on which the employee is retirement eligible.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The fair values of our stock option grants are estimated as of the date of grant using a Black-Scholes option valuation model. The estimated fair values of the stock options are then expensed over the options&amp;#8217; vesting periods.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The fair values of our MSUs are estimated using a lattice model with a Monte Carlo simulation. We apply an accelerated attribution method to recognize share-based compensation expense over the applicable service period, net of estimated forfeitures, when accounting for our MSUs. The probability of actual shares expected to be earned is considered in the grant date valuation, therefore the expense is not adjusted to reflect the actual units earned.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The fair values of our RSUs are based on the market value of our stock on the date of grant. Compensation expense for RSUs is recognized straight-line over the applicable service period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We apply an accelerated attribution method to recognize share-based compensation expense when accounting for our CSPUs and PUs and the fair value of the liability is remeasured at the end of each reporting period through expected settlement. Compensation expense associated with CSPUs and PUs are based upon the stock price and the number of units expected to be earned after assessing the probability that certain performance criteria will be met and the associated targeted payout level that is forecasted will be achieved, net of estimated forfeitures. Cumulative adjustments are recorded each quarter to reflect changes in the stock price and estimated outcome of the performance-related conditions until the date results are determined and settled.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The purchase price of common stock under our ESPP is equal to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;85%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the lesser of (i)&amp;#160;the fair market value per share of the common stock on the first business day of an offering period and (ii)&amp;#160;the fair market value per share of the common stock on the purchase date. The fair value of the discounted purchases made under our ESPP is calculated using the Black-Scholes model. The fair value of the look-back provision plus the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;15%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; discount is recognized as compensation expense over the 90 day purchase period. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Research and Development Expenses&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Research and development expenses consist of upfront fees and milestones paid to collaborators and expenses incurred in performing research and development activities, which include compensation and benefits, facilities and overhead expenses, clinical trial expenses and fees paid to contract research organizations (CROs), clinical supply and manufacturing expenses, write-offs of inventory that was previously capitalized in anticipation of product launch and determined to no longer be realizable, and other outside expenses. Research and development expenses are expensed as incurred. Payments we make for research and development services prior to the services being rendered are recorded as prepaid assets on our consolidated balance sheets and are expensed as the services are provided. We also accrue the costs of ongoing clinical trials associated with programs that have been terminated or discontinued for which there is no future economic benefit at the time the decision is made to terminate or discontinue the program.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;From time to time, we enter into development agreements in which we share expenses with a collaborative partner. We record payments received from our collaborative partners for their share of the development costs as a reduction of research and development expense, except as discussed in Note&amp;#160;19, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements. Because an initial indication has been approved for both RITUXAN and GAZYVA, expenses incurred by Genentech in the ongoing development of RITUXAN and GAZYVA are not recorded as research and development expense, but rather reduce our share of profits recorded as a component of revenues from anti-CD20 therapeutic programs.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For collaborations with commercialized products, if we are the principal, we record revenue and the corresponding operating costs in their respective line items in our consolidated statements of income. If we are not the principal, we record operating costs as a reduction of revenue.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Selling, General and Administrative Expenses&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Selling, general and administrative expenses are primarily comprised of compensation and benefits associated with sales and marketing, finance, human resources, legal, information technology and other administrative personnel, outside marketing, advertising and legal expenses and other general and administrative costs.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Advertising costs are expensed as incurred. For the years ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, advertising costs totaled &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$106.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$108.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$92.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Income Taxes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The provision for income taxes includes federal, state, local and foreign taxes. Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences of temporary differences between the financial statement carrying amounts and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which the temporary differences are expected to be recovered or settled. We evaluate the realizability of our deferred tax assets and establish a valuation allowance when it is more likely than not that all or a portion of deferred tax assets will not be realized.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;All tax effects associated with intercompany transfers of assets in our consolidated group, both current and deferred, are recorded as a prepaid tax or deferred charge and recognized through the consolidated statement of income when the asset transferred is sold to a third party or otherwise recovered through amortization of the asset's remaining economic life.&amp;#160;If the asset transferred becomes impaired, for example through the discontinuation of a research program, we will expense any remaining deferred charge or prepaid tax.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We account for uncertain tax positions using a &amp;#8220;more-likely-than-not&amp;#8221; threshold for recognizing and resolving uncertain tax positions. We evaluate uncertain tax positions on a quarterly basis and consider various factors including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, information obtained during in process audit activities and changes in facts or circumstances related to a tax position. We also accrue for potential interest and penalties related to unrecognized tax benefits in income tax expense.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Contingencies&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We are currently involved in various claims and legal proceedings. Loss contingency provisions are recorded if the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount can be reasonably estimated or a range of loss can be determined. These accruals represent management&amp;#8217;s best estimate of probable loss. Disclosure also is provided when it is reasonably possible that a loss will be incurred or when it is reasonably possible that the amount of a loss will exceed the recorded provision. On a quarterly basis, we review the status of each significant matter and assess its potential financial exposure.&amp;#160;Significant judgment is required in both the determination of probability and the determination as to whether an exposure is reasonably estimable. Because of uncertainties related to these matters, accruals are based only on the best information available at the time. As additional information becomes available, we reassess the potential liability related to pending claims and litigation and may change our estimates. These changes in the estimates of the potential liabilities could have a material impact on our consolidated results of operations and financial position.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Earnings per Share&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Basic earnings per share is computed by dividing undistributed net income attributable to Biogen Inc. by the weighted-average number of common shares outstanding during the period. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;New Accounting Pronouncements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed, we do not believe that the impact of recently issued standards that are not yet effective will have a material impact on our financial position or results of operations upon adoption.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In May 2014 the FASB issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers (Topic 606), which supersedes all existing revenue recognition requirements, including most industry-specific guidance. The new standard requires a company to recognize revenue when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. The FASB has subsequently issued the following amendments to ASU 2014-09 which have the same effective date and transition date of January 1, 2018:&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In August 2015 the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date, which delayed the effective date of the new standard from January 1, 2017 to January 1, 2018. The FASB also agreed to allow entities to choose to adopt the standard as of the original effective date. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In March 2016 the FASB issued ASU No. 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations, which clarifies the implementation guidance on principal versus agent considerations. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In April 2016 the FASB issued ASU No. 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing, which clarifies certain aspects of identifying performance obligations and licensing implementation guidance. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In May 2016 the FASB issued ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients related to disclosures of remaining performance obligations, as well as other amendments to guidance on collectability, non-cash consideration and the presentation of sales and other similar taxes collected from customers. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In December 2016 the FASB issued ASU No. 2016-20, Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers, which amends certain narrow aspects of the guidance issued in ASU 2014-09 including guidance related to the disclosure of remaining performance obligations and prior-period performance obligations, as well as other amendments to the guidance on loan guarantee fees, contract costs, refund liabilities, advertising costs and the clarification of certain examples. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We are currently evaluating the method of adoption and the potential impact that Topic 606 may have on our financial position and results of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In April 2015 the FASB issued ASU No. 2015-05, Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Customer's Accounting for Fees Paid in a Cloud Computing Arrangement. Under this standard, if a cloud computing arrangement includes a software license, the software license element of the arrangement should be accounted for consistent with the acquisition of other software licenses. If a cloud computing arrangement does not include a software license, the arrangement should be accounted for as a service contract. We adopted this standard as of January 1, 2016, which did not have an impact on our financial position or results of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In July 2015 the FASB issued ASU No. 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory. The new standard applies only to inventory for which cost is determined by methods other than last-in, first-out and the retail inventory method, which includes inventory that is measured using first-in, first-out or average cost. Inventory within the scope of this standard is required to be measured at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. We adopted this standard as of January 1, 2016, which did not have an impact on our financial position or results of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In September 2015 the FASB issued ASU No. 2015-16, Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments. The new standard requires that an acquirer recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined and sets forth new disclosure requirements related to the adjustments. We adopted this standard as of January 1, 2016, which did not have an impact on our financial position or results of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In January 2016 the FASB issued ASU No. 2016-01, Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. This new standard amends certain aspects of accounting and disclosure requirements of financial instruments, including the requirement that equity investments with readily determinable fair values be measured at fair value with changes in fair value recognized in our results of operations. This new standard does not apply to investments accounted for under the equity method of accounting or those that result in consolidation of the investee. Equity investments that do not have readily determinable fair values may be measured at fair value or at cost minus impairment adjusted for changes in observable prices. A financial liability that is measured at fair value in accordance with the fair value option is required to be presented separately in other comprehensive income for the portion of the total change in the fair value resulting from change in the instrument-specific credit risk. In addition, a valuation allowance should be evaluated on deferred tax assets related to available-for-sale debt securities in combination with other deferred tax assets. This new standard will be effective for us on January 1, 2018. The adoption of this standard is not expected to have a material impact on our financial position or results of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In February 2016 the FASB issued ASU No. 2016-02, Leases (Topic 842). This new standard requires that all lessees recognize the assets and liabilities that arise from leases on the balance sheet and disclose qualitative and quantitative information about its leasing arrangements. This new standard will be effective for us on January 1, 2019. The adoption of this standard is not expected to have a material impact on our net financial position, but will impact the amount of our assets and liabilities. We are currently evaluating the potential impact that this standard may have on our results of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In March 2016 the FASB issued ASU No. 2016-06, Derivatives and Hedging (Topic 815): Contingent Put and Call Options in Debt Instruments. This new standard simplifies the embedded derivative analysis for debt instruments containing contingent call or put options by removing the requirement to assess whether a contingent event is related to interest rates or credit risks. This new standard will be effective for us on January 1, 2017. The adoption of this standard is not expected to have an impact on our financial position or results of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In March 2016 the FASB issued ASU No. 2016-07, Investments - Equity Method and Joint Ventures (Topic 323): Simplifying the Transition to the Equity Method of Accounting. This new standard eliminates the requirement that when an investment qualifies for use of the equity method as a result of an increase in the level of ownership interest or degree of influence, an adjustment must be made to the investment, results of operations and retained earnings retroactively on a step-by-step basis as if the equity method had been in effect during all previous periods that the investment has been held. This new standard will be effective for us on January 1, 2017. The adoption of this standard is not expected to have a material impact on our financial position or results of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In March 2016 the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. This new standard requires recognition of the income tax effects of vested or settled awards in the income statement and involves several other aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities and classification on the statement of cash flows. This new standard will be effective for us on January 1, 2017. The adoption of this standard is not expected to have a material impact on our financial position, results of operations or statements of cash flows upon adoption.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In June 2016 the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. This new standard changes the impairment model for most financial assets and certain other instruments. Under the new standard, entities holding financial assets and net investment in leases that are not accounted for at fair value through net income to be presented at the net amount expected to be collected. An allowance for credit losses will be a valuation account that will be deducted from the amortized cost basis of the financial asset to present the net carrying value at the amount expected to be collected on the financial asset. This new standard will be effective for us on January 1, 2020. The adoption of this standard is not expected to have a material impact on our financial position or results of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In August 2016 the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. This new standard clarifies certain aspects of the statement of cash flows, including the classification of debt prepayment or debt extinguishment costs or other debt instruments with coupon interest rates that are insignificant in relation to the effective interest rate of the borrowing, contingent consideration payments made after a business combination, proceeds from the settlement of insurance claims, proceeds from the settlement of corporate-owned life insurance policies, distributions received from equity method investees and beneficial interests in securitization transactions. This new standard also clarifies that an entity should determine each separately identifiable source of use within the cash receipts and payments on the basis of the nature of the underlying cash flows. In situations in which cash receipts and payments have aspects of more than one class of cash flows and cannot be separated by source or use, the appropriate classification should depend on the activity that is likely to be the predominant source or use of cash flows for the item. This new standard will be effective for us on January 1, 2018. The adoption of this standard is not expected to have a material impact on our statements of cash flows upon adoption.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In October 2016 the FASB issued ASU No. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfer of Assets Other Than Inventory. This new standard eliminates the exception for an intra-entity transfer of an asset other than inventory. Under the new standard, entities should recognize the income tax consequences on an intra-entity transfer of an asset other than inventory when the transfer occurs. This new standard will be effective for us on January 1, 2018 and will be applied on a modified retrospective basis through a cumulative-effect adjustment directly to retained earnings as of the beginning of the period of adoption. We are currently evaluating the potential impact this standard may have on our financial position and results of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In January 2017 the FASB issued ASU No. 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business. This new standard clarifies the definition of a business and provides a screen to determine when an integrated set of assets and activities is not a business. The screen requires that when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the set is not a business. This new standard will be effective for us on January 1, 2018. However, we have adopted this standard as of January 1, 2017, with prospective application to any business development transaction.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
	<us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="FD2016Q4YTD" id="Fact-2C779EF067ECABB10D827411DFE5A323">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Employee Benefit Plans&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We sponsor various retirement and pension plans. Our estimates of liabilities and expenses for these plans incorporate a number of assumptions, including expected rates of return on plan assets and interest rates used to discount future benefits.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;401(k) Savings Plan&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We maintain a 401(k) Savings Plan, which is available to substantially all regular employees in the U.S. over the age of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;21&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. Participants may make voluntary contributions. We make matching contributions according to the 401(k) Savings Plan&amp;#8217;s matching formula. All matching contributions and participant contributions vest immediately. The 401(k) Savings Plan also holds certain transition contributions on behalf of participants who previously participated in the Biogen, Inc. Retirement Plan. The expense related to our 401(k) Savings Plan primarily consists of our matching contributions.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Expense related to our 401(k) Savings Plan totaled &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$45.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$51.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$49.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for the years ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Deferred Compensation Plan&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We maintain a non-qualified deferred compensation plan, known as the Supplemental Savings Plan (SSP), which allows a select group of management employees in the U.S. to defer a portion of their compensation. The SSP also provides certain credits to highly compensated U.S. employees, which are paid by the company. These credits are known as the Restoration Match. The deferred compensation amounts are accrued when earned. Such deferred compensation is distributable in cash in accordance with the rules of the SSP. Deferred compensation amounts under such plan as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, totaled approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$128.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$126.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, and are included in other long-term liabilities in our consolidated balance sheets. The SSP also holds certain transition contributions on behalf of participants who previously participated in the Biogen, Inc. Retirement Plan. The Restoration Match and participant contributions vest immediately. Distributions to participants can be either in one lump sum payment or annual installments as elected by the participants.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Pension Plans&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our retiree benefit plans include defined benefit plans for employees in our affiliates in Switzerland and Germany as well as other insignificant defined benefit plans in certain other countries in which we maintain an operating presence.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our Swiss plan is a government-mandated retirement fund that provides employees with a minimum investment return. The minimum investment return is determined annually by the Swiss government and was &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.25%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in 2016 and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.75%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. Under the Swiss plan, both we and certain of our employees with annual earnings in excess of government determined amounts are required to make contributions into a fund managed by an independent investment fiduciary. Employer contributions must be in an amount at least equal to the employee&amp;#8217;s contribution. Minimum employee contributions are based on the respective employee&amp;#8217;s age, salary and gender. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the Swiss plan had an unfunded net pension obligation of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$39.1 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$42.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, and plan assets which totaled approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$68.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$63.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. In &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recognized expense totaling &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$15.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$12.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$9.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, related to our Swiss plan.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The obligations under the German plans are unfunded and totaled &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$35.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$27.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. Net periodic pension cost related to the German plans totaled &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$4.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$4.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$3.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for the years ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
	<us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="FD2016Q4YTD" id="Fact-AE8DE92B23DA175F99D97411E025B144">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Property, Plant and Equipment&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Property, plant and equipment are recorded at historical cost, net of accumulated depreciation. Components of property, plant and equipment, net are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Land&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;137.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;74.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Buildings&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,107.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,035.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Leasehold improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;123.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;166.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Machinery and equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,105.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,079.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Computer software and hardware&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;746.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;647.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Furniture and fixtures&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;60.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;72.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Construction in progress&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;658.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;441.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3,941.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,517.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Less: accumulated depreciation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(1,439.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1,330.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total property, plant and equipment, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,501.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,187.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Depreciation expense totaled &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$309.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$217.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$198.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we capitalized interest costs related to construction in progress totaling approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$12.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$10.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$6.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Solothurn, Switzerland Facility&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During the first quarter of 2016 we closed on the purchase of land in Solothurn, Switzerland for &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;64.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Swiss Francs (approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$62.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;). We are building a biologics manufacturing facility on this land in the Commune of Luterbach over the next several years. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we had approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$481.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$99.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, capitalized as construction in progress related to the construction of this facility. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Research Triangle Park Facility Purchase&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On August 24, 2015, we purchased from Eisai, Inc. (Eisai) its drug product manufacturing facility and supporting infrastructure in Research Triangle Park (RTP), North Carolina for &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$104.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. The purchase price consisted of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$58.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for buildings, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$25.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for machinery and equipment and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$20.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for land.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On August 24, 2015, we also amended our existing &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;10&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;-year lease related to Eisai's oral solid dose products manufacturing facility in RTP, North Carolina where we manufacture our and Eisai's oral solid dose products. As amended, the lease provides for a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;-year term and our agreement to purchase the facility upon expiration of the lease term and Eisai's completion of certain activities. Accordingly, we recorded the assets along with a corresponding financing obligation on our consolidated balance sheet for &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$20.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the net present value of the future minimum lease payments. The assets were recorded as a component of buildings and machinery and equipment. We expect to complete the purchase of the oral solid products manufacturing facility at the end of the lease term in the third quarter of 2018.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
	<us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="FD2016Q4YTD" id="Fact-9E2D81EEA366B98CA78E7411DFDFE137">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Property, plant and equipment are carried at cost, subject to review for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. The cost of normal, recurring, or periodic repairs and maintenance activities related to property, plant and equipment are expensed as incurred. The cost for planned major maintenance activities, including the related acquisition or construction of assets, is capitalized if the repair will result in future economic benefits.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest costs incurred during the construction of major capital projects are capitalized until the underlying asset is ready for its intended use, at which point the interest costs are amortized as depreciation expense over the life of the underlying asset. We also capitalize certain direct and incremental costs associated with the validation effort required for licensing by regulatory agencies of new manufacturing equipment for the production of a commercially approved drug. These costs primarily include direct labor and material and are incurred in preparing the equipment for its intended use. The validation costs are either amortized over the life of the related equipment or expensed as cost of sales when the product produced in the validation process is sold.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In addition, we capitalize certain internal use computer software development costs. If the software is an integral part of production assets, these costs are included in machinery and equipment and are amortized on a straight-line basis over the estimated useful lives of the related software, which generally range from &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three to five years&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We generally depreciate or amortize the cost of our property, plant and equipment using the straight-line method over the estimated useful lives of the respective assets, which are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="2" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:50%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:50%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;"&gt;Asset Category&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;"&gt;Useful Lives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Land&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Not depreciated&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Buildings&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;15 to 40&amp;#160;years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Leasehold Improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Lesser of the useful life or the term of the respective lease&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Furniture and Fixtures&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5 to 7&amp;#160;years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Machinery and Equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5 to 20&amp;#160;years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Computer&amp;#160;Software&amp;#160;and&amp;#160;Hardware&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3 to 5&amp;#160;years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;When we dispose of property, plant and equipment, we remove the associated cost and accumulated depreciation from the related accounts on our consolidated balance sheet and include any resulting gain or loss in our consolidated statement of income.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
	<us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="FD2016Q4YTD" id="Fact-A61EF1E3B5C0097C0FBD7411E025A184">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Land&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;137.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;74.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Buildings&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,107.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,035.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Leasehold improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;123.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;166.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Machinery and equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,105.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,079.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Computer software and hardware&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;746.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;647.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Furniture and fixtures&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;60.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;72.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Construction in progress&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;658.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;441.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3,941.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,517.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Less: accumulated depreciation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(1,439.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1,330.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total property, plant and equipment, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,501.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,187.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
	<us-gaap:QuarterlyFinancialInformationTextBlock contextRef="FD2016Q4YTD" id="Fact-B8196A6D78FAE9C8E1FA7411DFF80C01">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Quarterly Financial Data (Unaudited)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="20" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:36%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions, except per share amounts)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;First&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quarter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Second&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quarter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Third&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quarter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fourth&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quarter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(a)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(b)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(b) (c)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(b) (d) (e)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Product revenues, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,309.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,466.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,539.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,502.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;9,817.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from anti-CD20 therapeutic programs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;329.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;349.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;317.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;318.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,314.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;87.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;79.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;98.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;50.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;316.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,726.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,894.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,955.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,872.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;11,448.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gross profit (1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,413.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,523.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,538.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,493.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;9,970.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;969.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,048.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,030.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;647.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3,695.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;970.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,049.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,032.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;649.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3,702.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income per share:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Basic earnings per share attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;4.44&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;4.79&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;4.72&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;16.96&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Diluted earnings per share attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;4.43&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;4.79&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;4.71&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2.99&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;16.93&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Weighted-average shares used in calculating:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Basic earnings per share attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;218.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;219.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;218.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;216.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;218.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Diluted earnings per share attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;219.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;219.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;219.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;217.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;218.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="20" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:36%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions, except per share amounts)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;First&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quarter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Second&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quarter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Third&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quarter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fourth&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quarter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(f) (g)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(a) (h)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Product revenues, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,172.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,198.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,391.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,425.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;9,188.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from anti-CD20 therapeutic programs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;330.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;337.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;337.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;333.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,339.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;52.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;55.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;49.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;79.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;236.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,555.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,591.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,777.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,839.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;10,763.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gross profit (1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,242.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,305.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,467.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,507.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;9,523.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;820.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;924.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,019.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;828.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,593.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;822.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;927.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;965.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;831.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,547.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income per share:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Basic earnings per share attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.50&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.94&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.16&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.77&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;15.38&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Diluted earnings per share attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.49&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.93&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.15&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.77&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;15.34&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Weighted-average shares used in calculating:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Basic earnings per share attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;235.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;235.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;232.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;220.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;230.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Diluted earnings per share attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;235.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;235.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;232.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;220.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;231.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:4px;text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt;(1) Gross profit is calculated as total revenues less cost of sales, excluding amortization of acquired intangible assets.&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(a)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income and net income attributable to Biogen Inc., for the first quarter of 2016 and the fourth quarter of 2015, includes pre-tax restructuring charges totaling &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$9.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$93.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively related to the 2015 corporate restructuring program.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(b)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income and net income attributable to Biogen Inc. for the second, third and fourth quarters of 2016 includes pre-tax additional depreciation expense totaling &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$15.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$15.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$14.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, as part of our determination to cease manufacturing in our small-scale biologics manufacturing facility in Cambridge, MA as well as vacate our warehouse space in Somerville, MA. Our departure from these facilities has shortened the expected useful lives of certain leasehold improvements and other assets at these facilities.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(c)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income and net income attributable to Biogen Inc. for the third quarter of 2016 includes a pre-tax charge to research and development expense of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$75.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for a license fee paid to Ionis as we exercised our option to develop and commercialize SPINRAZA.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(d)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income and net income attributable to Biogen Inc. for the fourth quarter of 2016 includes a pre-tax charge to research and development expense of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$50.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for a milestone payment due to Eisai related to the initiation of a phase 3 trial for E2609.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(e)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income and net income attributable to Biogen Inc. for the fourth quarter of 2016 includes a pre-tax charge of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$454.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to the January 2017 settlement and license agreement with Forward Pharma.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(f)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income and net income attributable to Biogen Inc. for the third quarter of 2015 includes a pre-tax charge to research and development expense of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$48.1 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; recorded upon entering into the collaboration agreement with AGTC.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(g)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income attributable to Biogen Inc. for the third quarter of 2015 reflects the attribution of a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$60.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; charge to noncontrolling interests, net of tax, related to a milestone payment due Neurimmune upon the enrollment of the first patient in a Phase 3 trial for aducanumab.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(h)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income and net income attributable to Biogen Inc. for the fourth quarter of 2015 includes a pre-tax charge to research and development expense of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$60.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; recorded upon entering into the collaboration agreement with MTPC.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:QuarterlyFinancialInformationTextBlock>
	<us-gaap:RealizedGainLossOnInvestmentsTableTextBlock contextRef="FD2016Q4YTD" id="Fact-4EA6AE1560219084A7E57411DFFFFA40">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Proceeds from maturities and sales&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;7,378.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4,063.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,718.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Realized gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Realized losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;4.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RealizedGainLossOnInvestmentsTableTextBlock>
	<us-gaap:ReceivablesPolicyTextBlock contextRef="FD2016Q4YTD" id="Fact-D30B961A92674F0ABCFC7411DFDC6749">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The majority of our accounts receivable arise from product sales and primarily represent amounts due from our wholesale distributors, public hospitals and other government entities. We monitor the financial performance and creditworthiness of our customers so that we can properly assess and respond to changes in their credit profile. We provide reserves against trade receivables for estimated losses that may result from a customer&amp;#8217;s inability to pay. Amounts determined to be uncollectible are charged or written-off against the reserve. To date, our historical reserves and write-offs of accounts receivable have not been significant.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In countries where we have experienced a pattern of payments extending beyond our contractual payment term and we expect to collect receivables greater than one year from the time of sale, we have discounted our receivables and reduced related revenues over the period of time that we estimate those amounts will be paid using the country&amp;#8217;s market-based borrowing rate for such period. The related receivables are classified at the time of sale as non-current assets. We accrete interest income on these receivables, which is recognized as a component of other income (expense), net in our consolidated statements of income.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ReceivablesPolicyTextBlock>
	<us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock contextRef="FD2016Q4YTD" id="Fact-F29B28B27B96D4BE18CC7411E0052156">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:28%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:25%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Income Statement Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amounts Reclassified from&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Accumulated Other Comprehensive Income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Years Ended December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on securities available for sale&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(0.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(2.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;9.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income tax benefit (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(3.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on cash flow hedges&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;173.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(1.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income tax benefit (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total reclassifications, net of tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;171.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;12.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock>
	<us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock contextRef="FD2016Q4YTD" id="Fact-63DF9356B950454134807411DFE02746">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Research and development expenses consist of upfront fees and milestones paid to collaborators and expenses incurred in performing research and development activities, which include compensation and benefits, facilities and overhead expenses, clinical trial expenses and fees paid to contract research organizations (CROs), clinical supply and manufacturing expenses, write-offs of inventory that was previously capitalized in anticipation of product launch and determined to no longer be realizable, and other outside expenses. Research and development expenses are expensed as incurred. Payments we make for research and development services prior to the services being rendered are recorded as prepaid assets on our consolidated balance sheets and are expensed as the services are provided. We also accrue the costs of ongoing clinical trials associated with programs that have been terminated or discontinued for which there is no future economic benefit at the time the decision is made to terminate or discontinue the program.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;From time to time, we enter into development agreements in which we share expenses with a collaborative partner. We record payments received from our collaborative partners for their share of the development costs as a reduction of research and development expense, except as discussed in Note&amp;#160;19, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements. Because an initial indication has been approved for both RITUXAN and GAZYVA, expenses incurred by Genentech in the ongoing development of RITUXAN and GAZYVA are not recorded as research and development expense, but rather reduce our share of profits recorded as a component of revenues from anti-CD20 therapeutic programs.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For collaborations with commercialized products, if we are the principal, we record revenue and the corresponding operating costs in their respective line items in our consolidated statements of income. If we are not the principal, we record operating costs as a reduction of revenue.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock>
	<us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock contextRef="FD2016Q4YTD" id="Fact-CCB282F05A0A7B05F2EB7411DFDAF97B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Restructuring, Business Transformation and Other Cost Saving Initiatives&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;2015 Cost Saving Initiatives&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;2015 Restructuring Charges&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On October 21, 2015, we announced a corporate restructuring, which included the termination of certain pipeline programs and an &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;11%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; reduction in workforce. Under this restructuring, cash payments were estimated to total approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$120.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, of which &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$15.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; were related to previously accrued 2015 incentive compensation, resulting in net restructuring charges totaling approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$102.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. These amounts were substantially paid by the end of 2016.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the year ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recognized total net restructuring charges of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$8.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. We previously recognized &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$93.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of restructuring charges in our consolidated statements of income during the fourth quarter of 2015.&amp;#160;Our restructuring reserve is included in accrued expenses and other in our consolidated balance sheets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the charges and spending related to our 2015 restructuring program during 2016:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Workforce&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Reduction&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Pipeline&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Programs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Restructuring reserve as of December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;33.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;37.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;4.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;10.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(31.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(9.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(40.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Adjustments to previous estimates, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(5.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(2.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Restructuring reserve as of December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;2016 Organizational Changes and Cost Saving Initiatives&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;2016 Restructuring Charges&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During the third quarter of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; we initiated cost saving measures primarily intended to realign our organizational structure due to the changes in roles and workforce resulting from our decision to spin off our hemophilia business, and to achieve further targeted cost reductions. For the year ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recognized charges totaling &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$17.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to this effort, which are in addition to, and separate from, the 2015 corporate restructuring described above. These amounts, which were substantially incurred and paid by the end of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, are primarily related to severance and are reflected in restructuring charges in our consolidated statements of income.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Cambridge, MA Manufacturing Facility&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In June 2016 following an evaluation of our current and future manufacturing capabilities and capacity needs, we determined that we intend to vacate and cease manufacturing in our 67,000 square foot small-scale biologics manufacturing facility in Cambridge, MA and also vacate our 46,000 square foot warehouse space in Somerville, MA.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In December&amp;#160;2016 we subleased our rights to the manufacturing facility in Cambridge, MA to Brammer Bio MA,&amp;#160;LLC (Brammer). Brammer also purchased from us certain manufacturing equipment, leasehold improvements and other assets in exchange for shares of Brammer common LLC interests and assumed manufacturing operations effective January 1, 2017. In December 2016 we also closed and vacated our warehouse space in Somerville, MA.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our departure from these facilities shortened the expected useful lives of certain leasehold improvements and other assets at these facilities. As a result, we recorded additional depreciation expense to reflect the assets' new shorter useful lives. For the year ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recognized approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$45.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of this additional depreciation, which was recorded as cost of sales in our consolidated statements of income.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Under the terms of the agreement, Brammer will also provide manufacturing and other transition and support services to us.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In the fourth quarter of 2016 we recognized charges totaling &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$7.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for severance costs related to certain employees separated from Biogen in connection with this transaction. These amounts will be substantially incurred and paid by the end of first quarter of 2017 and are reflected in restructuring charges in our consolidated statements of income.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
	<us-gaap:RevenueRecognitionPolicyTextBlock contextRef="FD2016Q4YTD" id="Fact-EE273B25418C742E59207411DFDFF90E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We recognize revenue when all of the following criteria are met: persuasive evidence of an arrangement exists; delivery has occurred or services have been rendered; our price to the customer is fixed or determinable; and collectability is reasonably assured.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Product Revenues&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from product sales are recognized when title and risk of loss have passed to the customer, which is typically upon delivery. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Reserves for Discounts and Allowances&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from product sales are recorded net of reserves established for applicable discounts and allowances, including those associated with the implementation of pricing actions in certain of the international markets in which we operate. These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer). Our estimates take into consideration our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Actual amounts may ultimately differ from our estimates. If actual results vary, we adjust these estimates, which could have an effect on earnings in the period of adjustment. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Product revenue reserves are categorized as follows: discounts, contractual adjustments and returns.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Discounts include trade term discounts and wholesaler incentives. Trade term discounts and wholesaler incentives primarily relate to estimated obligations for credits to be granted to wholesalers for remitting payment on their purchases within established incentive periods and credits to be granted to wholesalers for compliance with various contractually-defined inventory management practices, respectively. We determine these reserves based on our historical experience, including the timing of customer payments.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Contractual adjustments primarily relate to Medicaid and managed care rebates, co-payment (copay) assistance, Veterans Administration (VA) and Public Health Service (PHS) discounts, specialty pharmacy program fees and other governmental rebates or applicable allowances.&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Medicaid rebates relate to our estimated obligations to states under established reimbursement arrangements. Rebate accruals are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a liability which is included in other current liabilities. Our liability for Medicaid rebates consists of estimates for claims that a state will make for the current quarter, claims for prior quarters that have been estimated for which an invoice has not been received, invoices received for claims from the prior quarters that have not been paid, and an estimate of potential claims that will be made for inventory that exists in the distribution channel at period end.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Governmental rebates or chargebacks, including VA and PHS discounts, represent our estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices we charge to wholesalers which provide those products. The wholesaler charges us for the difference between what the wholesaler pays for the products and the ultimate selling price to the qualified healthcare providers. Rebate and chargeback reserves are established in the same period as the related revenue is recognized, resulting in a reduction in product revenue and accounts receivable. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider from the wholesaler, and we generally issue credits for such amounts within a few weeks of the wholesaler notifying us about the resale. Our reserves for VA, PHS and chargebacks consist of amounts that we expect to issue for inventory that exists at the wholesalers that we expect will be sold to qualified healthcare providers and chargebacks that wholesalers have claimed for which we have not issued a credit.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Managed care rebates represent our estimated obligations to third parties, primarily pharmacy benefit managers. Rebate accruals are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a liability which is included in accrued expenses and other current liabilities. These rebates result from performance-based goals, formulary position and price increase limit allowances (price protection). The calculation of the accrual for these rebates is based on an estimate of the customer&amp;#8217;s buying patterns and the resulting applicable contractual rebate rate(s) to be earned over a contractual period.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Copay assistance represents financial assistance to qualified patients, assisting them with prescription drug co-payments required by insurance. The calculation of the accrual for copay is based on an estimate of claims and the cost per claim that we expect to receive associated with inventory that exists in the distribution channel at period end.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other governmental rebates or applicable allowances primarily relate to mandatory rebates and discounts in international markets where government-sponsored healthcare systems are the primary payors for healthcare.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Product returns are established for returns expected to be made by wholesalers and are recorded in the period the related revenue is recognized, resulting in a reduction to product sales. In accordance with contractual terms, wholesalers are permitted to return product for reasons such as damaged or expired product. The majority of wholesaler returns are due to product expiration. Expired product return reserves are estimated through a comparison of historical return data to their related sales on a production lot basis. Historical rates of return are determined for each product and are adjusted for known or expected changes in the marketplace specific to each product.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In addition to the discounts, rebates and product returns described above and classified as a reduction of revenue, we also maintain certain customer service contracts with distributors and other customers in the distribution channel that provide us with inventory management, data and distribution services, which are generally reflected as a reduction of revenue. To the extent we can demonstrate a separable benefit and fair value for these services, we classify these payments in selling, general and administrative expenses.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Revenues from Anti-CD20 Therapeutic Programs&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from anti-CD20 therapeutic programs consist of:&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(i)&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;our share of pre-tax profits and losses in the U.S. for RITUXAN and GAZYVA; &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(ii)&amp;#160; &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;reimbursement of our selling and development expenses in the U.S. for RITUXAN; and &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(iii)&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;revenues on sales in the rest of world for RITUXAN, which consist of our share of pre-tax co-promotion profits on RITUXAN in Canada and royalty revenue on RITUXAN sales outside the U.S. and Canada by the Roche Group and its sublicensees. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Pre-tax co-promotion profits on RITUXAN and GAZYVA are calculated and paid to us by Genentech in the U.S. Pre-tax co-promotion profits on RITUXAN are calculated and paid to us by the Roche Group in Canada. Pre-tax co-promotion profits consist of U.S. and Canadian net sales to third-party customers less applicable costs to manufacture, third-party royalty expenses, distribution, selling and marketing expenses, and joint development expenses incurred by Genentech, the Roche Group and us. We record our share of the pre-tax co-promotion profits on RITUXAN in Canada and royalty revenues on RITUXAN sales outside the U.S. on a cash basis as we do not have the ability to estimate these profits or royalty revenue in the period incurred. Our share of the pre-tax profits on RITUXAN and GAZYVA in the U.S. includes estimates made by Genentech and those estimates are subject to change. Actual results may differ from our estimates. For additional information related to our collaboration with Genentech, please read Note&amp;#160;19, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Royalty Revenues&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We receive royalty revenues on sales by our licensees of other products covered under patents that we own. We do not have future performance obligations under these license arrangements. We record these revenues based on estimates of the sales that occurred during the relevant period as a component of other revenues. The relevant period estimates of sales are based on interim data provided by licensees and analysis of historical royalties that have been paid to us, adjusted for any changes in facts and circumstances, as appropriate. Differences between actual and estimated royalty revenues are adjusted for in the period in which they become known, typically the following quarter. Historically, adjustments have not been material when compared to actual amounts paid by licensees. If we are unable to reasonably estimate royalty revenue or do not have access to the information, then we record royalty revenues on a cash basis. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Multiple-Element Revenue Arrangements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We may enter into transactions that involve the sale of products and related services under multiple element arrangements.&amp;#160;In accounting for these transactions, we assess the elements of the contract and whether each element has standalone value and allocate revenue to the various elements based on their estimated selling price as a component of total revenues.&amp;#160;The selling price of a revenue generating element can be based on current selling prices offered by us or another party for current products or management&amp;#8217;s best estimate of a selling price. Revenue allocated to an individual element is recognized when all other revenue recognition criteria are met for that element.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
	<us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="FD2016Q4YTD" id="Fact-17AD76C67AB8E65F92787411E014CD8F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current portion of contingent consideration obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;580.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;504.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued TECFIDERA litigation settlement and license charges&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;454.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenue-related reserves for discounts and allowances&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;438.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;518.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Employee compensation and benefits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;282.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;270.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Royalties and licensing fees&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;195.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;167.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Construction in progress&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;134.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;87.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Collaboration expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;130.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;31.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;685.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;516.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total accrued expenses and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,903.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,096.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
	<us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock contextRef="FD2016Q4YTD" id="Fact-84202E24F644E2DE78AA7411E00521B6">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="20" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:26%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Securities Available for Sale&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Cash Flow Hedges&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unfunded Status of Postretirement Benefit Plans&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Translation Adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;10.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(37.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(195.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(224.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other comprehensive income (loss) before reclassifications&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(10.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;51.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(138.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(92.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(4.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(3.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net current period other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(10.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;47.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(138.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(95.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(10.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;57.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(32.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(334.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(319.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="20" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:26%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Securities Available for Sale&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Cash Flow Hedges&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unfunded Status of Postretirement Benefit Plans&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Translation Adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, December 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;71.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(31.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(99.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(59.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other comprehensive income (loss) before reclassifications&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;110.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(6.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(96.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(172.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(171.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net current period other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(61.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(6.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(96.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(164.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;10.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(37.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(195.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(224.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="20" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:26%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Securities Available for Sale&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Cash Flow Hedges&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unfunded Status of Postretirement Benefit Plans&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Translation Adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, December 31, 2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(23.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(19.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;10.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(27.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other comprehensive income (loss) before reclassifications&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;101.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(12.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(109.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(19.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(6.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(6.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(12.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net current period other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(6.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;95.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(12.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(109.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(31.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, December 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;71.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(31.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(99.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(59.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
	<us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock contextRef="FD2015Q4YTD" id="Fact-7ACB5D04F46A3EFD30FB7411DFB9FF30">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:87%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash portion of consideration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;200.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Contingent consideration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;274.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total purchase price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;474.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock>
	<us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock contextRef="FD2016Q4YTD" id="Fact-A305AE8038BA9B1FFD6A7411E015BE65">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Commercial paper&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;31.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;21.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Overnight reverse repurchase agreements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;134.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;741.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;673.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Short-term debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,266.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;79.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,039.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;909.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
	<us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock contextRef="FD2016Q4YTD" id="Fact-FB8FB27D7FDCA35B449B7411E01333BE">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:51%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash paid during the year for:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;281.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;39.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;41.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,642.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,674.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,163.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock>
	<us-gaap:ScheduleOfCashProceedsReceivedFromShareBasedPaymentAwardsTableTextBlock contextRef="FD2016Q4YTD" id="Fact-BDFBFCBB50A63194BDEB7411E01593EF">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Tax benefit realized for stock options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;4.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;11.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;13.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash received from the exercise of stock options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;8.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashProceedsReceivedFromShareBasedPaymentAwardsTableTextBlock>
	<us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock contextRef="FD2016Q4YTD" id="Fact-6C240856FC236CF769F67411E0229F98">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:55%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Market stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;38.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;38.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;37.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Time-vested restricted stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;120.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;119.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;115.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash settled performance units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;16.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;22.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;65.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Performance units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;18.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;13.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;21.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Employee stock purchase plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;11.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;13.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;12.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Subtotal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;204.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;207.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;252.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Capitalized share-based compensation costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(14.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(11.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(10.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Share-based compensation expense included in total cost and expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;189.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;196.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;242.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
	<us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="FD2016Q4YTD" id="Fact-361D182C7CC4D9967E097411DFEC335A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Income before income taxes (benefit):&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Domestic&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3,655.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,386.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,557.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Foreign&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,277.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,380.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,389.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;4,933.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4,767.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,946.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Income tax expense (benefit):&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Federal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,304.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,214.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,159.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;State&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;55.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;38.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;65.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Foreign&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;52.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;54.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;73.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,412.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,307.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,298.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Deferred:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Federal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(125.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(129.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(280.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;State&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(3.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(21.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Foreign&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(45.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(14.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(6.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(175.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(145.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(308.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total income tax expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,237.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,161.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;989.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
	<us-gaap:ScheduleOfDebtTableTextBlock contextRef="FD2016Q4YTD" id="Fact-9166FB0215654ED06CE27411DFEFEC8C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Current portion:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Notes payable to Fumedica&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Financing arrangement for the purchase of the RTP facility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current portion of notes payable and other financing arrangements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;4.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Non-current portion:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.875% Senior Notes due March 1, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;558.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;565.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.900% Senior Notes due September 15, 2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,485.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,485.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.625% Senior Notes due September 15, 2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;993.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;992.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.050% Senior Notes due September 15, 2025&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,734.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,733.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.200% Senior Notes due September 15, 2045&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,721.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,721.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Notes payable to Fumedica&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Financing arrangement for the purchase of the RTP facility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;16.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;18.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current portion of notes payable and other financing arrangements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;6,512.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6,521.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
	<us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="FD2016Q4YTD" id="Fact-4D341BDAA97F877D6B697411DFECAA17">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As&amp;#160;of&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Deferred tax assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Tax credits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;201.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;189.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Inventory, other reserves and accruals&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;250.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;243.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Intangibles, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;459.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;328.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net operating loss&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;65.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;24.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Share-based compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;61.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;63.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;49.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;35.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Valuation allowance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(16.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(14.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total deferred tax assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,071.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;871.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Deferred tax liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Purchased intangible assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(376.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(440.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Depreciation, amortization and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(113.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(102.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total deferred tax liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(490.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(542.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
	<us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock contextRef="FD2016Q4YTD" id="Fact-1B26E8D2A55942E7ABA27411DFF61433">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="27" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="27" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Reclassified from AOCI into Net Income&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;"&gt;(Effective Portion)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized into Net Income&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;"&gt;(Ineffective Portion)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;173.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(1.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock>
	<us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock contextRef="FD2016Q4YTD" id="Fact-739696AD7CD83BD680D07411DFF51759">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.61013645224172%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:40%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:40%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Balance&amp;#160;Sheet&amp;#160;Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;Fair Value&lt;br clear="none"/&gt;As of December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Hedging Instruments:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;50.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Investments and other assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;6.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other long-term liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;4.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Other Derivatives:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;4.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued&amp;#160;expenses&amp;#160;and&amp;#160;other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;9.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.61013645224172%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:40%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:40%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Balance Sheet Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;br clear="none"/&gt;As of December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Hedging Instruments:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;16.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Investments and other assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued&amp;#160;expenses&amp;#160;and&amp;#160;other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;10.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other long-term liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Other Derivatives:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;10.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued&amp;#160;expenses&amp;#160;and&amp;#160;other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock>
	<us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="FD2016Q4YTD" id="Fact-379647A5852A538805CF7411DFC9AC2E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Years Ended December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Numerator:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3,702.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,547.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,934.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Denominator:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Weighted average number of common shares outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;218.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;230.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;236.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Effect of dilutive securities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Stock options and employee stock purchase plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Time-vested restricted stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Market stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Dilutive potential common shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Shares used in calculating diluted earnings per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;218.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;231.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;237.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
	<us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="FD2016Q4YTD" id="Fact-D3D05D9673771BDAC04A7411DFECD723">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:55%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Statutory rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;35.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;35.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;35.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;State taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Taxes on foreign earnings&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(9.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(10.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(9.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Credits and net operating loss utilization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(1.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Purchased intangible assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Manufacturing deduction&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(1.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other permanent items&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Effective tax rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;25.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;24.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;25.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
	<us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="FD2016Q4YTD" id="Fact-747AD3CDF2CCC241D0FA7411DFC7DDDC">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:55%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;84.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;88.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;102.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Selling, general and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;121.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;127.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;150.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Restructuring charges&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(1.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(8.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Subtotal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;204.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;207.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;252.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Capitalized share-based compensation costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(14.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(11.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(10.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Share-based compensation expense included in total cost and expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;189.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;196.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;242.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income tax effect&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(54.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(55.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(72.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Share-based compensation expense included in net income attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;135.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;140.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;170.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
	<us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock contextRef="FD2016Q4YTD" id="Fact-AF9B48957282CD11F3877411DFBAD7A7">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="36" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:6%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:6%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:6%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:6%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:6%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:6%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:6%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="35" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Years Ended December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;United&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;States&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Rest of&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;World&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;United&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;States&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Rest of&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;World&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;United&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;States&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Rest of&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;World&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Multiple Sclerosis (MS):&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;TECFIDERA&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;3,169.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;798.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;3,968.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;2,908.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;730.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;3,638.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;2,426.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;482.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;2,909.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;AVONEX&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;1,675.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;638.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;2,313.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;1,790.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;840.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;2,630.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;1,956.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;1,056.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;3,013.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;PLEGRIDY&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;305.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;176.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;481.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;227.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;111.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;338.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;27.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;16.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;44.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;TYSABRI&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;1,182.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;780.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;1,963.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;1,103.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;783.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;1,886.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;1,025.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;934.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;1,959.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;FAMPYRA&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;84.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;84.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;89.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;89.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;80.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;80.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;ZINBRYTA&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;7.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;7.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Hemophilia:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;ELOCTATE&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;445.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;68.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;513.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;308.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;11.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;319.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;58.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;58.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;ALPROLIX&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;268.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;65.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;333.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;208.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;25.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;234.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;72.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;3.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;76.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Other product revenues:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;FUMADERM&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;45.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;45.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;51.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;51.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;62.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;62.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;SPINRAZA&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;4.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;4.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;BENEPALI&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;100.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;100.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;FLIXABI&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Total product revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;7,050.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;2,767.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;9,817.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;6,545.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;2,642.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;9,188.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;5,566.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;2,636.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;8,203.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock>
	<us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="FD2016Q4YTD" id="Fact-9565AD9B93FA8D78DFCB7411E021224D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;December 31, &lt;br clear="none"/&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quoted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Prices in&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Active&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Markets&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level&amp;#160;1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Observable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level&amp;#160;2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unobservable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level&amp;#160;3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,039.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,039.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable debt securities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,663.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,663.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,172.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,172.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;561.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;561.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;24.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;24.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;61.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;61.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Plan assets for deferred compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;34.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;34.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;7,558.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;24.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;7,533.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;13.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;13.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Contingent consideration obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;467.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;467.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;481.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;13.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;467.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;December 31, &lt;br clear="none"/&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quoted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Prices&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;in&amp;#160;Active&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Markets&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Observable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unobservable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;909.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;909.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable debt securities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,510.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,510.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,875.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,875.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;494.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;494.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;37.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;37.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;27.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;27.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Plan assets for deferred compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;40.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;40.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5,895.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;37.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5,857.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;14.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;14.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Contingent consideration obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;506.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;506.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;520.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;14.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;506.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
	<us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock contextRef="FD2016Q4YTD" id="Fact-1CC735E4A973F38271607411E01AFD97">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-left:4px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:79%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:19%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;As of December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;16.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;18.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Less: interest&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(0.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net present value of the future minimum lease payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;18.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock>
	<us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="FD2016Q4YTD" id="Fact-AC8A1752FBF2B06704FC7411E01BB33E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="28" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:31%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Thereafter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Minimum lease payments &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;75.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;69.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;69.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;65.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;64.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;331.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;676.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Less: income from subleases (1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(8.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(15.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(15.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(15.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(16.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(55.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(126.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net minimum lease payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;66.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;54.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;53.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;50.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;48.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;276.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;549.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
	<us-gaap:ScheduleOfGoodwillTextBlock contextRef="FD2016Q4YTD" id="Fact-3B293149BB8BA8F044487411DFF5D205">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill, beginning of year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,663.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,760.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Increase to goodwill&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,026.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;908.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(21.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(4.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill, end of year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3,669.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,663.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
	<us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="FD2016Q4YTD" id="Fact-61926D7FA8B467C545D27411DFE1DAA8">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Raw materials&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;170.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;213.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Work in process&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;698.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;577.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Finished goods&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;170.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;143.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total inventory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,039.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;933.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Balance Sheet Classification:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Inventory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,001.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;893.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Investments and other assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;37.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;40.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total inventory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,039.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;933.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
	<us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock contextRef="FD2016Q4YTD" id="Fact-83C71ACA41BB6DF9E9A57411DFEF9817">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.4375%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:80%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;As of December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;553.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,500.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2022 and thereafter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;4,500.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;6,556.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
	<us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock contextRef="FD2016Q4YTD" id="Fact-8E952DCD4E47C60E372D7411DFF681BD">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Notional Amount&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As&amp;#160;of&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Foreign Currency: (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Euro&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;871.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;945.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Swiss francs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;80.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Canadian dollar&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;76.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total foreign currency forward contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;871.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,103.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock>
	<us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock contextRef="FD2016Q4YTD" id="Fact-A7C05D2CD8E14D96963A7411E014BDF3">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;63.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;22.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;12.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(260.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(95.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(29.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gain (loss) on investments, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;6.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(3.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;11.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Foreign exchange gains (losses), net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(9.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(32.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(11.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(17.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(13.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(8.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total other income (expense), net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(217.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(123.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(25.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
	<us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock contextRef="FD2016Q4YTD" id="Fact-1C59EAFBA0CC76C11D7A7411DFF8D241">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="20" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:36%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions, except per share amounts)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;First&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quarter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Second&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quarter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Third&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quarter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fourth&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quarter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(a)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(b)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(b) (c)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(b) (d) (e)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Product revenues, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,309.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,466.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,539.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,502.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;9,817.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from anti-CD20 therapeutic programs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;329.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;349.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;317.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;318.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,314.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;87.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;79.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;98.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;50.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;316.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,726.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,894.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,955.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,872.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;11,448.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gross profit (1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,413.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,523.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,538.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,493.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;9,970.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;969.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,048.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,030.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;647.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3,695.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;970.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,049.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,032.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;649.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3,702.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income per share:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Basic earnings per share attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;4.44&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;4.79&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;4.72&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;16.96&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Diluted earnings per share attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;4.43&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;4.79&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;4.71&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2.99&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;16.93&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Weighted-average shares used in calculating:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Basic earnings per share attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;218.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;219.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;218.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;216.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;218.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Diluted earnings per share attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;219.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;219.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;219.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;217.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;218.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="20" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:36%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions, except per share amounts)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;First&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quarter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Second&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quarter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Third&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quarter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fourth&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quarter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(f) (g)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(a) (h)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Product revenues, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,172.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,198.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,391.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,425.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;9,188.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from anti-CD20 therapeutic programs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;330.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;337.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;337.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;333.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,339.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;52.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;55.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;49.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;79.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;236.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,555.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,591.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,777.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,839.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;10,763.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gross profit (1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,242.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,305.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,467.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,507.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;9,523.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;820.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;924.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,019.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;828.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,593.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;822.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;927.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;965.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;831.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,547.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income per share:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Basic earnings per share attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.50&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.94&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.16&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.77&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;15.38&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Diluted earnings per share attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.49&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.93&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.15&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.77&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;15.34&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Weighted-average shares used in calculating:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Basic earnings per share attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;235.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;235.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;232.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;220.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;230.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Diluted earnings per share attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;235.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;235.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;232.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;220.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;231.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:4px;text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt;(1) Gross profit is calculated as total revenues less cost of sales, excluding amortization of acquired intangible assets.&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(a)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income and net income attributable to Biogen Inc., for the first quarter of 2016 and the fourth quarter of 2015, includes pre-tax restructuring charges totaling &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$9.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$93.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively related to the 2015 corporate restructuring program.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(b)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income and net income attributable to Biogen Inc. for the second, third and fourth quarters of 2016 includes pre-tax additional depreciation expense totaling &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$15.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$15.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$14.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, as part of our determination to cease manufacturing in our small-scale biologics manufacturing facility in Cambridge, MA as well as vacate our warehouse space in Somerville, MA. Our departure from these facilities has shortened the expected useful lives of certain leasehold improvements and other assets at these facilities.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(c)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income and net income attributable to Biogen Inc. for the third quarter of 2016 includes a pre-tax charge to research and development expense of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$75.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for a license fee paid to Ionis as we exercised our option to develop and commercialize SPINRAZA.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(d)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income and net income attributable to Biogen Inc. for the fourth quarter of 2016 includes a pre-tax charge to research and development expense of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$50.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for a milestone payment due to Eisai related to the initiation of a phase 3 trial for E2609.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(e)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income and net income attributable to Biogen Inc. for the fourth quarter of 2016 includes a pre-tax charge of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$454.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to the January 2017 settlement and license agreement with Forward Pharma.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(f)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income and net income attributable to Biogen Inc. for the third quarter of 2015 includes a pre-tax charge to research and development expense of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$48.1 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; recorded upon entering into the collaboration agreement with AGTC.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(g)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income attributable to Biogen Inc. for the third quarter of 2015 reflects the attribution of a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$60.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; charge to noncontrolling interests, net of tax, related to a milestone payment due Neurimmune upon the enrollment of the first patient in a Phase 3 trial for aducanumab.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(h)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income and net income attributable to Biogen Inc. for the fourth quarter of 2015 includes a pre-tax charge to research and development expense of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$60.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; recorded upon entering into the collaboration agreement with MTPC.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock>
	<us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock contextRef="FD2015Q4YTD" id="Fact-091A904FB7E7251B7AD07411DFBE22B5">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:87%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In-process research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;424.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other intangible assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;7.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;128.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Deferred tax liability&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(84.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total purchase price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;474.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
	<us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock contextRef="FD2016Q4YTD" id="Fact-C80DF42E6AF7650DDEA87411DFDA7766">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Workforce&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Reduction&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Pipeline&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Programs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Restructuring reserve as of December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;33.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;37.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;4.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;10.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(31.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(9.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(40.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Adjustments to previous estimates, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(5.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(2.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Restructuring reserve as of December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock>
	<us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock contextRef="FD2016Q4YTD" id="Fact-CDCA2C439020DE77CBE37411DFB9DE8E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="24" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:29%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;December 31, 2016 (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;U.S.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Europe&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(1)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Germany&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Asia&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Product revenues from external customers&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;7,050.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,533.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;703.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;217.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;313.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;9,817.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from anti-CD20 therapeutic programs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,249.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;63.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,314.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other revenues from external customers&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;224.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;70.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;20.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;316.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Long-lived assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,272.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,219.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;7.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,501.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;December 31, 2015 (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;U.S.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Europe&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(1)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Germany&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Asia&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Product revenues from external customers&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6,545.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,497.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;668.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;143.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;333.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;9,188.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from anti-CD20 therapeutic programs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,269.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;65.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,339.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other revenues from external customers&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;142.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;29.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;62.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;236.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Long-lived assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,296.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;879.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;7.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,187.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;December 31, 2014 (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;U.S.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Europe&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(1)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Germany&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Asia&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Product revenues from external customers&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5,566.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,383.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;811.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;112.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;328.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;8,203.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from anti-CD20 therapeutic programs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,117.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;7.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;70.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,195.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other revenues from external customers&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;212.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;31.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;58.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;304.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Long-lived assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,055.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;701.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,765.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock>
	<us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="FD2016Q4YTD" id="Fact-31D9461B29F805A3C2BF7411DFD0DAE0">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Exercise&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Outstanding at December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;107,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;53.94&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(41,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;53.75&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cancelled&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Outstanding at December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;66,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;54.06&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
	<us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock contextRef="FD2016Q4YTD" id="Fact-35257262F5BB5D6F5EFB7411DFEC615A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:56%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance at January&amp;#160;1,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;67.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;131.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;110.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Additions based on tax positions related to the current period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;7.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;10.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;20.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Additions for tax positions of prior periods&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;36.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;19.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;86.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Reductions for tax positions of prior periods&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(13.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(49.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(23.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Statute expirations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(1.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Settlements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(64.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(42.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(60.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance at December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;32.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;67.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;131.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
	<us-gaap:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock contextRef="FD2016Q4YTD" id="Fact-F5D323369D89E3B33A4F7411DFC5CF76">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Reserves for Discounts and Allowances&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;An analysis of the change in reserves for discounts and allowances is summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Discounts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Contractual&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Returns&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Beginning balance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;56.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;548.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;57.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;662.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current provisions relating to sales in current year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;592.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,044.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;30.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,668.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Adjustments relating to prior years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(1.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(16.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(16.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/returns relating to sales in current year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(522.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(1,576.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(1.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(2,099.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/returns relating to sales in prior years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(53.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(536.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(19.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(609.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Ending balance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;71.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;482.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;51.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;605.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Discounts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Contractual&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Returns&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Beginning balance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;47.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;387.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;49.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;483.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current provisions relating to sales in current year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;459.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,732.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;37.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,229.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Adjustments relating to prior years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(16.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(14.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(32.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/returns relating to sales in current year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(405.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1,258.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(2.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1,666.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/returns relating to sales in prior years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(44.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(296.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(11.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(351.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Ending balance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;56.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;548.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;57.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;662.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Discounts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Contractual&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Returns&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Beginning balance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;47.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;345.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;33.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;426.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current provisions relating to sales in current year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;347.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,265.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;39.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,651.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Adjustments relating to prior years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(28.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;13.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(16.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/returns relating to sales in current year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(299.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(933.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(4.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1,237.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/returns relating to sales in prior years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(46.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(261.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(33.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(341.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Ending balance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;47.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;387.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;49.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;483.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The total revenue-related reserves above, included in our consolidated balance sheets, are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Reduction of accounts receivable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;166.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;144.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Component of accrued expenses and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;438.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;518.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total revenue-related reserves&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;605.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;662.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock>
	<us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="FD2016Q4YTD" id="Fact-7B9B2AF2731A05D732CE7411DFF5CC77">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:81%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;As of December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;334.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;312.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;295.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;259.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;242.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
	<us-gaap:SegmentReportingDisclosureTextBlock contextRef="FD2016Q4YTD" id="Fact-65699A38DC14B816DC817411DFBA5B78">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Segment Information&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We operate as &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; operating segment, which is discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. Our Chief Executive Officer (CEO), as the chief operating decision-maker, manages and allocates resources to the operations of our company on a total company basis. Our research and development organization is responsible for the research and discovery of new product candidates and supports development and registration efforts for potential future products. Our pharmaceutical, operations and technology organization manages the development of the manufacturing processes, clinical trial supply, commercial product supply, distribution, buildings and facilities. Our commercial organization is responsible for U.S. and international development of our commercial products. The company is also supported by corporate staff functions. Managing and allocating resources on a total company basis enables our CEO to assess the overall level of resources available and how to best deploy these resources across functions, therapeutic areas, and research and development projects that are in line with our long-term company-wide strategic goals. Consistent with this decision-making process, our CEO uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Enterprise-wide disclosures about product revenues, other revenues and long-lived assets by geographic area and information relating to major customers are presented below. Revenues are primarily attributed to individual countries based on location of the customer or licensee.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenue by product is summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="36" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:6%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:6%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:6%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:6%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:6%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:6%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:6%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="35" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Years Ended December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;United&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;States&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Rest of&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;World&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;United&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;States&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Rest of&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;World&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;United&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;States&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Rest of&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;World&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Multiple Sclerosis (MS):&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;TECFIDERA&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;3,169.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;798.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;3,968.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;2,908.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;730.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;3,638.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;2,426.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;482.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;2,909.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;AVONEX&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;1,675.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;638.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;2,313.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;1,790.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;840.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;2,630.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;1,956.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;1,056.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;3,013.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;PLEGRIDY&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;305.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;176.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;481.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;227.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;111.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;338.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;27.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;16.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;44.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;TYSABRI&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;1,182.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;780.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;1,963.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;1,103.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;783.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;1,886.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;1,025.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;934.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;1,959.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;FAMPYRA&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;84.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;84.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;89.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;89.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;80.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;80.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;ZINBRYTA&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;7.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;7.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Hemophilia:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;ELOCTATE&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;445.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;68.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;513.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;308.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;11.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;319.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;58.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;58.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;ALPROLIX&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;268.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;65.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;333.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;208.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;25.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;234.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;72.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;3.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;76.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Other product revenues:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;FUMADERM&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;45.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;45.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;51.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;51.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;62.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;62.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;SPINRAZA&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;4.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;4.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;BENEPALI&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;100.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;100.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;FLIXABI&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Total product revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;7,050.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;2,767.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;9,817.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;6,545.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;2,642.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;9,188.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;5,566.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;2,636.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;8,203.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Geographic Information&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following tables contain certain financial information by geographic area:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="24" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:29%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;December 31, 2016 (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;U.S.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Europe&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(1)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Germany&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Asia&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Product revenues from external customers&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;7,050.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,533.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;703.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;217.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;313.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;9,817.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from anti-CD20 therapeutic programs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,249.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;63.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,314.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other revenues from external customers&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;224.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;70.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;20.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;316.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Long-lived assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,272.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,219.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;7.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,501.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;December 31, 2015 (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;U.S.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Europe&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(1)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Germany&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Asia&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Product revenues from external customers&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6,545.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,497.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;668.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;143.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;333.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;9,188.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from anti-CD20 therapeutic programs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,269.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;65.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,339.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other revenues from external customers&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;142.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;29.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;62.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;236.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Long-lived assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,296.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;879.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;7.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,187.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;December 31, 2014 (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;U.S.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Europe&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(1)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Germany&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Asia&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Product revenues from external customers&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5,566.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,383.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;811.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;112.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;328.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;8,203.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from anti-CD20 therapeutic programs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,117.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;7.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;70.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,195.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other revenues from external customers&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;212.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;31.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;58.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;304.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Long-lived assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,055.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;701.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,765.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt;(1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt;Represents amounts related to Europe less those attributable to Germany.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Revenues from Anti-CD20 Therapeutic Programs&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;11%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;12%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;12%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of our total revenues in &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, are derived from our collaboration agreement with Genentech. For additional information related to our collaboration with Genentech, please read Note 19, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Significant Customers&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We recorded revenue from two wholesalers accounting for &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;35%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;22%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of gross product revenues in &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;34%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;26%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of gross product revenues in &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;33%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;27%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of gross product revenues in &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$643.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$684.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$676.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, of our long-lived assets were related to our manufacturing facilities in Denmark. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$545.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$161.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, of our long-lived assets were related to the construction of a biologics manufacturing facility in Solothurn, Switzerland.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information related to our manufacturing facility in Solothurn, Switzerland, please read Note 10, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Property, plant and equipment&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
	<us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock contextRef="FD2016Q4YTD" id="Fact-3502909EFB5299899C9E7411DFDD6A60">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Selling, general and administrative expenses are primarily comprised of compensation and benefits associated with sales and marketing, finance, human resources, legal, information technology and other administrative personnel, outside marketing, advertising and legal expenses and other general and administrative costs.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Advertising costs are expensed as incurred. For the years ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, advertising costs totaled &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$106.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$108.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$92.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
	<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="FD2016Q4YTD" id="Fact-E126143D86D6BF1B398A7411E00A0487">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Equity&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Preferred Stock&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;8.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;shares of Preferred Stock authorized, of which &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.75 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares are authorized as Series A, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares are authorized as Series X junior participating and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.25 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares are undesignated. Shares may be issued without a vote or action of stockholders from time to time in classes or series with the designations, powers, preferences, and the relative, participating, optional or other special rights of the shares of each such class or series and any qualifications, limitations or restrictions thereon as set forth in the instruments governing such shares. Any such Preferred Stock may rank prior to common stock as to dividend rights, liquidation preference or both, and may have full or limited voting rights and may be convertible into shares of common stock. No shares of Preferred Stock were issued and outstanding during &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Common Stock&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table describes the number of shares authorized, issued and outstanding of our common stock as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="18" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:24%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;As of December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Authorized&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Issued&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Authorized&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Issued&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Common stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,000.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;238.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;215.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,000.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;241.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;218.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Share Repurchases&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In July 2016 our Board of Directors authorized a program to repurchase up to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$5.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of our common stock (2016 Share Repurchase Program). This authorization does not have an expiration date. Repurchased shares will be retired. As of December 31, 2016, we repurchased and retired &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares of common stock at a cost of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; under our 2016 Share Repurchase Program.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In May 2015 our Board of Directors authorized a program to repurchase up to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$5.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of our common stock (2015 Share Repurchase Program), which was completed as of December&amp;#160;31, 2015. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we repurchased and retired approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;16.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares of common stock at a cost of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$5.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; under our 2015 Share Repurchase Program.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In February 2011 our Board of Directors authorized a program to repurchase up to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;20.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares of our common stock (2011 Share Repurchase Program), which has been used principally to offset common stock issuances under our share-based compensation plans. The 2011 Share Repurchase Program does not have an expiration date. We did not repurchase any shares of common stock under our 2011 Share Repurchase Program during the years ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. During &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; we purchased approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares of common stock at a cost of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$886.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; under our 2011 Share Repurchase Program. We have approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares remaining available for repurchase under this authorization.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
	<us-gaap:SubsequentEventsTextBlock contextRef="FD2016Q4YTD" id="Fact-8A0B9F7B415768ED58CBD65623E7D8C9">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Subsequent Events&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On February 1, 2017, we completed the distribution of the issued and outstanding common stock of Bioverativ to Biogen stockholders. For additional information related to the distribution of Bioverativ, please read Note 1, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Summary of Significant Accounting Policies&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with the distribution, we entered into a separation and distribution agreement and various other agreements (including a transition services agreement, a tax matters agreement, a manufacturing and supply agreement, an employee matters agreement, an intellectual property matters agreement and certain other commercial agreements). These agreements govern the separation and distribution and the relationship between the two companies going forward. They also provide for the performance of services by each company for the benefit of the other for a period of time (including under the manufacturing and supply agreement pursuant to which we will manufacture and supply certain products and materials to Bioverativ).&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
	<us-gaap:UseOfEstimates contextRef="FD2016Q4YTD" id="Fact-C9D0BF107091A7C4A09D7411DFDCD194">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The preparation of our consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an on-going basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates under different assumptions or conditions.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
	<us-gaap:VariableInterestEntityDisclosureTextBlock contextRef="FD2016Q4YTD" id="Fact-3FFED220F7861772CC507411E025FAC1">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Investments in Variable Interest Entities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Consolidated Variable Interest Entities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our consolidated financial statements include the financial results of variable interest entities in which we are the primary beneficiary. The following are our significant variable interest entities.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Neurimmune SubOne AG&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In 2007 we entered into a collaboration agreement with Neurimmune SubOne AG (Neurimmune), a subsidiary of Neurimmune AG, for the development and commercialization of antibodies for the treatment of Alzheimer&amp;#8217;s disease. Neurimmune conducts research to identify potential therapeutic antibodies and we are responsible for the development, manufacturing and commercialization of all products. Our anti-amyloid beta antibody, aducanumab, for the treatment of Alzheimer&amp;#8217;s disease resulted from this collaboration. In September 2015 we announced that the first patient had been enrolled in a Phase 3 trial for aducanumab, which triggered a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$60.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; milestone payment due to Neurimmune. As we consolidate the financial results of Neurimmune, we recognized this payment as a charge to noncontrolling interest in the third quarter of 2015. Based upon our current development plans for aducanumab, we may pay Neurimmune up to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$275.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in remaining milestone payments. We may also pay royalties in the low-to-mid-teens on sales of any resulting commercial products.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We determined that we are the primary beneficiary of Neurimmune because we have the power through the collaboration to direct the activities that most significantly impact the entity&amp;#8217;s economic performance and are required to fund &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;100%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the research and development costs incurred in support of the collaboration agreement. Accordingly, we consolidate the results of Neurimmune.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We are required to reimburse Neurimmune for amounts that are incurred by Neurimmune for research and development expenses in support of the collaboration. Amounts reimbursed are reflected in research and development expense in our consolidated statements of income. During the years ending &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, these amounts were immaterial. Future milestone payments and royalties, if any, will be reflected in our consolidated statements of income as a charge to noncontrolling interest, net of tax, when such milestones are achieved. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The assets and liabilities of Neurimmune are not significant to our financial position or results of operations as it is a research and development organization. We have provided no financing to Neurimmune other than previously contractually required amounts.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Rodin Therapeutics, Inc.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In December 2015 we paid &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$8.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for preferred stock in Rodin Therapeutics, Inc. (Rodin) and entered into an option and collaboration agreement which gave us the right to purchase all remaining outstanding shares of Rodin at any time until 35 days after acceptance of an Investigational New Drug (IND) application by the FDA. As we determined that we were the primary beneficiary of Rodin, we consolidated the results of Rodin and recorded an IPR&amp;amp;D intangible asset of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$8.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and assigned approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$10.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to noncontrolling interest.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During the fourth quarter of 2016 we terminated our collaboration agreement with Rodin. Upon termination of the collaboration agreement, we deconsolidated the results of Rodin and impaired the IPR&amp;amp;D asset, resulting in an impairment loss of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$8.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to the IPR&amp;amp;D asset recorded upon entering into the collaboration agreement. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The assets and liabilities of Rodin were not significant to our financial position or results of operations as Rodin is a research and development organization. We had provided no financing to Rodin other than the contractually required amounts disclosed above.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Ataxion Inc.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In February 2014 we paid &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for preferred stock in Ataxion, Inc. (Ataxion) and entered into an option and collaboration agreement which gave us the right to purchase all outstanding shares of Ataxion at any time until 30 days after delivery of a Phase 1 clinical trial study report. As we determined that we were the primary beneficiary of Ataxion, we consolidated the results of Ataxion and recorded an IPR&amp;amp;D intangible asset of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$3.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and assigned that amount to noncontrolling interest.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During the fourth quarter of 2016 we terminated our option agreement with Ataxion. Upon termination of the collaboration agreement, we deconsolidated the results of Ataxion and impaired the IPR&amp;amp;D asset, resulting in an impairment loss of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$3.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to the IPR&amp;amp;D asset recorded upon entering into the collaboration agreement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The assets and liabilities of Ataxion were not significant to our financial position or results of operations as Ataxion is a research and development organization. We had provided no financing to Ataxion other than the contractually required amounts disclosed above.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Unconsolidated Variable Interest Entities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have relationships with other variable interest entities that we do not consolidate as we lack the power to direct the activities that significantly impact the economic success of these entities. These relationships include investments in certain biotechnology companies and research collaboration agreements. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the total carrying value of our investments in biotechnology companies totaled &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$47.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$29.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. Our maximum exposure to loss related to these variable interest entities is limited to the carrying value of our investments.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have also entered into research collaboration agreements with certain variable interest entities where we are required to fund certain development activities. These development activities are included in research and development expense in our consolidated statements of income, as they are incurred. We have provided no financing to these variable interest entities other than previously contractually required amounts.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:VariableInterestEntityDisclosureTextBlock>
	<link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
		<link:loc xlink:href="#Fact-042CE7ADAEC1CBE16B747411E011ECC9" xlink:label="Fact-042CE7ADAEC1CBE16B747411E011ECC9_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-0656FE8E0BD71BD9C4EF7411E00B6E7E" xlink:label="Fact-0656FE8E0BD71BD9C4EF7411E00B6E7E_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-07AFF127153B667A17F87411DFC767AB" xlink:label="Fact-07AFF127153B667A17F87411DFC767AB_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-20C54AA5A51D8A96F4C87411E01A08B9" xlink:label="Fact-20C54AA5A51D8A96F4C87411E01A08B9_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-2338F62463E4890570327411E006B32E" xlink:label="Fact-2338F62463E4890570327411E006B32E_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-23CDB8F58AEC88F990C77411E002D31D" xlink:label="Fact-23CDB8F58AEC88F990C77411E002D31D_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-26157C066AA584769A817411E0064C7B" xlink:label="Fact-26157C066AA584769A817411E0064C7B_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-29F80FF72328B505EA9A7411E025A3CF" xlink:label="Fact-29F80FF72328B505EA9A7411E025A3CF_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-2A505653B69036077A507411DFCB9910" xlink:label="Fact-2A505653B69036077A507411DFCB9910_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-2CD8D0A4AA55A8A1FCCE7411E01ACACC" xlink:label="Fact-2CD8D0A4AA55A8A1FCCE7411E01ACACC_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-2EC1A3B107A255BA3E427411E0030A47" xlink:label="Fact-2EC1A3B107A255BA3E427411E0030A47_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-306BE32C78C729B043DF7411E01A4440" xlink:label="Fact-306BE32C78C729B043DF7411E01A4440_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-333EF9C01483C0E36A227411E0193FA2" xlink:label="Fact-333EF9C01483C0E36A227411E0193FA2_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-33905F796C44F1C055ED7411E028D91F" xlink:label="Fact-33905F796C44F1C055ED7411E028D91F_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-35EBA901C69FBC2031297411E0238647" xlink:label="Fact-35EBA901C69FBC2031297411E0238647_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-392D4AB732EBED959FA57411E014CFB9" xlink:label="Fact-392D4AB732EBED959FA57411E014CFB9_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-42EE05ECC18C65EFE72D7411E0163C3C" xlink:label="Fact-42EE05ECC18C65EFE72D7411E0163C3C_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-46320FA19AF69BA1336D7411E02447E9" xlink:label="Fact-46320FA19AF69BA1336D7411E02447E9_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-47F276ACFDE047C99AB07411E0135F2A" xlink:label="Fact-47F276ACFDE047C99AB07411E0135F2A_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-54F40D534FE85FAE151F7411E002D2AC" xlink:label="Fact-54F40D534FE85FAE151F7411E002D2AC_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-5B73FA20397DB68D48B37411E027547A" xlink:label="Fact-5B73FA20397DB68D48B37411E027547A_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-666BD7B77AE5645655E87411DFE42535" xlink:label="Fact-666BD7B77AE5645655E87411DFE42535_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-6AD09A37CCAB563DFA7F7411DFE36E8F" xlink:label="Fact-6AD09A37CCAB563DFA7F7411DFE36E8F_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-6B588F2139659A5DD6FB7411E027C4A1" xlink:label="Fact-6B588F2139659A5DD6FB7411E027C4A1_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-6D8953DD9007BD392F557411DFEB79DB" xlink:label="Fact-6D8953DD9007BD392F557411DFEB79DB_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-7445B803AB132A7E14DE7411E0222411" xlink:label="Fact-7445B803AB132A7E14DE7411E0222411_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-760425DD3D1CE703E2EB7411E0064735" xlink:label="Fact-760425DD3D1CE703E2EB7411E0064735_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-7868629071C4E2E44AB27411E005126B" xlink:label="Fact-7868629071C4E2E44AB27411E005126B_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-7FA0B71A6C77A3A300247411E0053AC7" xlink:label="Fact-7FA0B71A6C77A3A300247411E0053AC7_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-862519685A99AF98F0F47411DFD8A0E5" xlink:label="Fact-862519685A99AF98F0F47411DFD8A0E5_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-9B346987E74EDA4D4C427411DFC95154" xlink:label="Fact-9B346987E74EDA4D4C427411DFC95154_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-A66EA1FE285B2EA2C3117411E0033821" xlink:label="Fact-A66EA1FE285B2EA2C3117411E0033821_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-AD62A00E41CC4CE68D3C7411E01BE03B" xlink:label="Fact-AD62A00E41CC4CE68D3C7411E01BE03B_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-AED74A30C6BA48309C207411E01884D7" xlink:label="Fact-AED74A30C6BA48309C207411E01884D7_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-AF0A6D8D06FB950985997411E013E6E0" xlink:label="Fact-AF0A6D8D06FB950985997411E013E6E0_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-B85B0919EFABA59765B67411E006FD7D" xlink:label="Fact-B85B0919EFABA59765B67411E006FD7D_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-C0540DD17AF96B22EB8C7411E027A558" xlink:label="Fact-C0540DD17AF96B22EB8C7411E027A558_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-CB707F400C141F4399D57411DFF6AC23" xlink:label="Fact-CB707F400C141F4399D57411DFF6AC23_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-D1D84D33F2FDB54543597411DFCB9944" xlink:label="Fact-D1D84D33F2FDB54543597411DFCB9944_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-DD37641534FB3861A3EE7411DFCFBE52" xlink:label="Fact-DD37641534FB3861A3EE7411DFCFBE52_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-E8558476094CD433787B7411E028876E" xlink:label="Fact-E8558476094CD433787B7411E028876E_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-F44085B6841B0A6022DF7411DFCBC150" xlink:label="Fact-F44085B6841B0A6022DF7411DFCBC150_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-F487BE0E1D57619825DF7411DFDB1ED5" xlink:label="Fact-F487BE0E1D57619825DF7411DFDB1ED5_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-F98B26011BC9508E52057411E0194260" xlink:label="Fact-F98B26011BC9508E52057411E0194260_lbl" xlink:type="locator" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-042CE7ADAEC1CBE16B747411E011ECC9_lbl" xlink:to="Footnote-415A9C2F434C01C68AB57411E034EAA7_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-0656FE8E0BD71BD9C4EF7411E00B6E7E_lbl" xlink:to="Footnote-415A9C2F434C01C68AB57411E034EAA7_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-07AFF127153B667A17F87411DFC767AB_lbl" xlink:to="Footnote-C56711A3B4BCFD6B477D7411E034432D_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-20C54AA5A51D8A96F4C87411E01A08B9_lbl" xlink:to="Footnote-FF4BB382E131F38EC1C67411E0354E70_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-2338F62463E4890570327411E006B32E_lbl" xlink:to="Footnote-9BE8171211D5CF79F8DF7411E0355F88_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-23CDB8F58AEC88F990C77411E002D31D_lbl" xlink:to="Footnote-FFDDAAA7168BFEA87A3F7411E035839D_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-26157C066AA584769A817411E0064C7B_lbl" xlink:to="Footnote-4DAA0DE6DC9B8D0E3BB77411E035E52C_lbl" xlink:type="arc" />
		<link:footnoteArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-26157C066AA584769A817411E0064C7B_lbl" xlink:to="Footnote-9BE8171211D5CF79F8DF7411E0355F88_lbl" xlink:type="arc" />
		<link:footnoteArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-26157C066AA584769A817411E0064C7B_lbl" xlink:to="Footnote-C15584C77536A58E218C7411E03537E7_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-29F80FF72328B505EA9A7411E025A3CF_lbl" xlink:to="Footnote-8030EE4ECFEC0D68FF02D7219D4B6266_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-2A505653B69036077A507411DFCB9910_lbl" xlink:to="Footnote-8030EE4ECFEC0D68FF02D7219D4B6266_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-2CD8D0A4AA55A8A1FCCE7411E01ACACC_lbl" xlink:to="Footnote-FF4BB382E131F38EC1C67411E0354E70_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-2EC1A3B107A255BA3E427411E0030A47_lbl" xlink:to="Footnote-FFDDAAA7168BFEA87A3F7411E035839D_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-306BE32C78C729B043DF7411E01A4440_lbl" xlink:to="Footnote-FF4BB382E131F38EC1C67411E0354E70_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-333EF9C01483C0E36A227411E0193FA2_lbl" xlink:to="Footnote-FF4BB382E131F38EC1C67411E0354E70_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-33905F796C44F1C055ED7411E028D91F_lbl" xlink:to="Footnote-EBC5D9AA3EBE2C08DCE27411E034E22E_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-35EBA901C69FBC2031297411E0238647_lbl" xlink:to="Footnote-FFDDAAA7168BFEA87A3F7411E035839D_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-392D4AB732EBED959FA57411E014CFB9_lbl" xlink:to="Footnote-EBC5D9AA3EBE2C08DCE27411E034E22E_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-42EE05ECC18C65EFE72D7411E0163C3C_lbl" xlink:to="Footnote-C56711A3B4BCFD6B477D7411E034432D_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-46320FA19AF69BA1336D7411E02447E9_lbl" xlink:to="Footnote-C56711A3B4BCFD6B477D7411E034432D_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-47F276ACFDE047C99AB07411E0135F2A_lbl" xlink:to="Footnote-8030EE4ECFEC0D68FF02D7219D4B6266_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-54F40D534FE85FAE151F7411E002D2AC_lbl" xlink:to="Footnote-FFDDAAA7168BFEA87A3F7411E035839D_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-5B73FA20397DB68D48B37411E027547A_lbl" xlink:to="Footnote-8030EE4ECFEC0D68FF02D7219D4B6266_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-666BD7B77AE5645655E87411DFE42535_lbl" xlink:to="Footnote-8030EE4ECFEC0D68FF02D7219D4B6266_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-6AD09A37CCAB563DFA7F7411DFE36E8F_lbl" xlink:to="Footnote-FFDDAAA7168BFEA87A3F7411E035839D_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-6B588F2139659A5DD6FB7411E027C4A1_lbl" xlink:to="Footnote-FFDDAAA7168BFEA87A3F7411E035839D_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-6D8953DD9007BD392F557411DFEB79DB_lbl" xlink:to="Footnote-8030EE4ECFEC0D68FF02D7219D4B6266_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-7445B803AB132A7E14DE7411E0222411_lbl" xlink:to="Footnote-FFDDAAA7168BFEA87A3F7411E035839D_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-760425DD3D1CE703E2EB7411E0064735_lbl" xlink:to="Footnote-9BE8171211D5CF79F8DF7411E0355F88_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-7868629071C4E2E44AB27411E005126B_lbl" xlink:to="Footnote-4DAA0DE6DC9B8D0E3BB77411E035E52C_lbl" xlink:type="arc" />
		<link:footnoteArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-7868629071C4E2E44AB27411E005126B_lbl" xlink:to="Footnote-9BE8171211D5CF79F8DF7411E0355F88_lbl" xlink:type="arc" />
		<link:footnoteArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-7868629071C4E2E44AB27411E005126B_lbl" xlink:to="Footnote-C15584C77536A58E218C7411E03537E7_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-7FA0B71A6C77A3A300247411E0053AC7_lbl" xlink:to="Footnote-4DAA0DE6DC9B8D0E3BB77411E035E52C_lbl" xlink:type="arc" />
		<link:footnoteArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-7FA0B71A6C77A3A300247411E0053AC7_lbl" xlink:to="Footnote-C15584C77536A58E218C7411E03537E7_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-862519685A99AF98F0F47411DFD8A0E5_lbl" xlink:to="Footnote-FFDDAAA7168BFEA87A3F7411E035839D_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-9B346987E74EDA4D4C427411DFC95154_lbl" xlink:to="Footnote-8030EE4ECFEC0D68FF02D7219D4B6266_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-A66EA1FE285B2EA2C3117411E0033821_lbl" xlink:to="Footnote-FFDDAAA7168BFEA87A3F7411E035839D_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-AD62A00E41CC4CE68D3C7411E01BE03B_lbl" xlink:to="Footnote-FF4BB382E131F38EC1C67411E0354E70_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-AED74A30C6BA48309C207411E01884D7_lbl" xlink:to="Footnote-FF4BB382E131F38EC1C67411E0354E70_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-AF0A6D8D06FB950985997411E013E6E0_lbl" xlink:to="Footnote-C56711A3B4BCFD6B477D7411E034432D_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-B85B0919EFABA59765B67411E006FD7D_lbl" xlink:to="Footnote-9BE8171211D5CF79F8DF7411E0355F88_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-C0540DD17AF96B22EB8C7411E027A558_lbl" xlink:to="Footnote-FFDDAAA7168BFEA87A3F7411E035839D_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-CB707F400C141F4399D57411DFF6AC23_lbl" xlink:to="Footnote-8030EE4ECFEC0D68FF02D7219D4B6266_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-D1D84D33F2FDB54543597411DFCB9944_lbl" xlink:to="Footnote-8030EE4ECFEC0D68FF02D7219D4B6266_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-DD37641534FB3861A3EE7411DFCFBE52_lbl" xlink:to="Footnote-FFDDAAA7168BFEA87A3F7411E035839D_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-E8558476094CD433787B7411E028876E_lbl" xlink:to="Footnote-EBC5D9AA3EBE2C08DCE27411E034E22E_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-F44085B6841B0A6022DF7411DFCBC150_lbl" xlink:to="Footnote-8030EE4ECFEC0D68FF02D7219D4B6266_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-F487BE0E1D57619825DF7411DFDB1ED5_lbl" xlink:to="Footnote-FFDDAAA7168BFEA87A3F7411E035839D_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-F98B26011BC9508E52057411E0194260_lbl" xlink:to="Footnote-FF4BB382E131F38EC1C67411E0354E70_lbl" xlink:type="arc" />
		<link:footnote xlink:label="Footnote-415A9C2F434C01C68AB57411E034EAA7_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">CSPUs granted in 2016 include awards granted in conjunction with our annual awards made in February 2016 and CSPUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant.</link:footnote>
		<link:footnote xlink:label="Footnote-4DAA0DE6DC9B8D0E3BB77411E035E52C_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The Biogen Distributor Territory represents Biogen territories where sales are derived utilizing a third-party distributor.</link:footnote>
		<link:footnote xlink:label="Footnote-8030EE4ECFEC0D68FF02D7219D4B6266_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">(1) Gross profit is calculated as total revenues less cost of sales, excluding amortization of acquired intangible assets.</link:footnote>
		<link:footnote xlink:label="Footnote-9BE8171211D5CF79F8DF7411E0355F88_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">A credit will be issued to Sobi against its reimbursement of the Opt-in Consideration for each product in an amount equal to the difference in the rate paid by Biogen to Sobi on sales in the Biogen territories for certain periods prior to the first commercial sale in the Sobi Territory versus the rate that otherwise would have been payable on such sales.</link:footnote>
		<link:footnote xlink:label="Footnote-C15584C77536A58E218C7411E03537E7_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Net revenue represents Biogen&#8217;s pre-tax receipts from third-party distributors, less expenses incurred by Biogen in the conduct of commercialization activities supporting the distributor activities.</link:footnote>
		<link:footnote xlink:label="Footnote-C56711A3B4BCFD6B477D7411E034432D_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">MSUs granted in 2016 include approximately 15,000 and 20,000 MSUs issued in 2016 based upon the attainment of performance criteria set for 2013 and 2012, respectively, in relation to awards granted in those years. The remainder of MSUs granted during 2016 include awards granted in conjunction with our annual awards made in February 2016 and MSUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant.</link:footnote>
		<link:footnote xlink:label="Footnote-EBC5D9AA3EBE2C08DCE27411E034E22E_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">RSUs granted in 2016 primarily represent RSUs granted in conjunction with our annual awards made in February 2016 and awards made in conjunction with the hiring of new employees. RSUs granted in 2016 also include approximately 11,000 RSUs granted to our Board of Directors.</link:footnote>
		<link:footnote xlink:label="Footnote-FF4BB382E131F38EC1C67411E0354E70_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">(1)</link:footnote>
		<link:footnote xlink:label="Footnote-FFDDAAA7168BFEA87A3F7411E035839D_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Represents amounts related to Europe less those attributable to Germany.</link:footnote>
	</link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>biib-20161231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.biogenidec.com/20161231" xmlns:biib="http://www.biogenidec.com/20161231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2016-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/us-gaap/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-roles-2016-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-types-2016-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2016-01-31" schemaLocation="http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2016-01-31" schemaLocation="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2016-01-31" schemaLocation="http://xbrl.sec.gov/exch/2016/exch-2016-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20161231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20161231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20161231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20161231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="AccumulatedOtherComprehensiveIncomeLoss" roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLoss">
        <link:definition>2116100 - Disclosure - Accumulated Other Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncomeLossDetails" roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails">
        <link:definition>2416402 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncomeLossDetails1" roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails1">
        <link:definition>2416403 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncomeLossTables" roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables">
        <link:definition>2316301 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Acquisitions" roleURI="http://www.biogenidec.com/role/Acquisitions">
        <link:definition>2102100 - Disclosure - Acquisitions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsAcquisitionsDetails" roleURI="http://www.biogenidec.com/role/AcquisitionsAcquisitionsDetails">
        <link:definition>2402402 - Disclosure - Acquisitions Acquisitions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsAcquisitionsDetails1" roleURI="http://www.biogenidec.com/role/AcquisitionsAcquisitionsDetails1">
        <link:definition>2402403 - Disclosure - Acquisitions Acquisitions (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsAcquisitionsTables" roleURI="http://www.biogenidec.com/role/AcquisitionsAcquisitionsTables">
        <link:definition>2302301 - Disclosure - Acquisitions Acquisitions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsDetailsTextual" roleURI="http://www.biogenidec.com/role/AcquisitionsDetailsTextual">
        <link:definition>2402404 - Disclosure - Acquisitions (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAndOtherRelationships" roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships">
        <link:definition>2122100 - Disclosure - Collaborative and Other Relationships</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsDetails3" roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsDetails3">
        <link:definition>2422405 - Disclosure - Collaborative and Other Relationships Collaborative and Other Relationships (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAndOtherRelationshipsDetails" roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetails">
        <link:definition>2422402 - Disclosure - Collaborative and Other Relationships (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAndOtherRelationshipsDetails1" roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetails1">
        <link:definition>2422403 - Disclosure - Collaborative and Other Relationships (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAndOtherRelationshipsDetails2" roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetails2">
        <link:definition>2422404 - Disclosure - Collaborative and Other Relationships (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAndOtherRelationshipsDetailsTextual" roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual">
        <link:definition>2422406 - Disclosure - Collaborative and Other Relationships (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAndOtherRelationshipsTables" roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables">
        <link:definition>2322301 - Disclosure - Collaborative and Other Relationships (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingencies" roleURI="http://www.biogenidec.com/role/CommitmentsAndContingencies">
        <link:definition>2124100 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesCommitmentsAndContingenciesDetails1" roleURI="http://www.biogenidec.com/role/CommitmentsAndContingenciesCommitmentsAndContingenciesDetails1">
        <link:definition>2424403 - Disclosure - Commitments and Contingencies Commitments and Contingencies (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesDetails" roleURI="http://www.biogenidec.com/role/CommitmentsAndContingenciesDetails">
        <link:definition>2424402 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesDetailsTextual" roleURI="http://www.biogenidec.com/role/CommitmentsAndContingenciesDetailsTextual">
        <link:definition>2424404 - Disclosure - Commitments and Contingencies (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesTables" roleURI="http://www.biogenidec.com/role/CommitmentsAndContingenciesTables">
        <link:definition>2324301 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.biogenidec.com/role/ConsolidatedBalanceSheets">
        <link:definition>1003000 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.biogenidec.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>1003501 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfCashFlows" roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows">
        <link:definition>1004000 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfComprehensiveIncome" roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsOfComprehensiveIncome">
        <link:definition>1002000 - Statement - Consolidated Statements of Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfEquity" roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsOfEquity">
        <link:definition>1005000 - Statement - Consolidated Statements of Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfIncome" roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsOfIncome">
        <link:definition>1001000 - Statement - Consolidated Statements of Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstruments" roleURI="http://www.biogenidec.com/role/DerivativeInstruments">
        <link:definition>2112100 - Disclosure - Derivative Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsDetails" roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails">
        <link:definition>2412402 - Disclosure - Derivative Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsDetails1" roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails1">
        <link:definition>2412403 - Disclosure - Derivative Instruments (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsDetailsTextual" roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetailsTextual">
        <link:definition>2412404 - Disclosure - Derivative Instruments (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsTables" roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsTables">
        <link:definition>2312301 - Disclosure - Derivative Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DocumentAndEntityInformation" roleURI="http://www.biogenidec.com/role/DocumentAndEntityInformation">
        <link:definition>0001000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShare" roleURI="http://www.biogenidec.com/role/EarningsPerShare">
        <link:definition>2117100 - Disclosure - Earnings per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareDetails" roleURI="http://www.biogenidec.com/role/EarningsPerShareDetails">
        <link:definition>2417402 - Disclosure - Earnings per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareTables" roleURI="http://www.biogenidec.com/role/EarningsPerShareTables">
        <link:definition>2317301 - Disclosure - Earnings per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlans" roleURI="http://www.biogenidec.com/role/EmployeeBenefitPlans">
        <link:definition>2126100 - Disclosure - Employee Benefit Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlansDetails1" roleURI="http://www.biogenidec.com/role/EmployeeBenefitPlansDetails1">
        <link:definition>2426402 - Disclosure - Employee Benefit Plans (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlansEmployeeBenefitPlansDetails" roleURI="http://www.biogenidec.com/role/EmployeeBenefitPlansEmployeeBenefitPlansDetails">
        <link:definition>2426401 - Disclosure - Employee Benefit Plans Employee Benefit Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Equity" roleURI="http://www.biogenidec.com/role/Equity">
        <link:definition>2115100 - Disclosure - Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityDetails" roleURI="http://www.biogenidec.com/role/EquityDetails">
        <link:definition>2415402 - Disclosure - Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityDetailsTextual" roleURI="http://www.biogenidec.com/role/EquityDetailsTextual">
        <link:definition>2415403 - Disclosure - Equity (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityTables" roleURI="http://www.biogenidec.com/role/EquityTables">
        <link:definition>2315301 - Disclosure - Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.biogenidec.com/role/FairValueMeasurements">
        <link:definition>2110100 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails">
        <link:definition>2410402 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails1" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails1">
        <link:definition>2410403 - Disclosure - Fair Value Measurements (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails2" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails2">
        <link:definition>2410404 - Disclosure - Fair Value Measurements (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetailsTextual" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual">
        <link:definition>2410405 - Disclosure - Fair Value Measurements (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsTables">
        <link:definition>2310301 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstruments" roleURI="http://www.biogenidec.com/role/FinancialInstruments">
        <link:definition>2111100 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails">
        <link:definition>2411402 - Disclosure - Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails1" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1">
        <link:definition>2411403 - Disclosure - Financial Instruments (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails2" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails2">
        <link:definition>2411404 - Disclosure - Financial Instruments (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails3" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails3">
        <link:definition>2411405 - Disclosure - Financial Instruments (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetailsTextual1" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual1">
        <link:definition>2411406 - Disclosure - Financial Instruments (Details Textual 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetailsTextual2" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual2">
        <link:definition>2411407 - Disclosure - Financial Instruments (Details Textual 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsTables" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsTables">
        <link:definition>2311301 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Guarantees" roleURI="http://www.biogenidec.com/role/Guarantees">
        <link:definition>2125100 - Disclosure - Guarantees</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.biogenidec.com/role/IncomeTaxes">
        <link:definition>2119100 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails">
        <link:definition>2419402 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails1" roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails1">
        <link:definition>2419403 - Disclosure - Income Taxes (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails2" roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails2">
        <link:definition>2419404 - Disclosure - Income Taxes (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails3" roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails3">
        <link:definition>2419405 - Disclosure - Income Taxes (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetailsTextual" roleURI="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual">
        <link:definition>2419406 - Disclosure - Income Taxes (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.biogenidec.com/role/IncomeTaxesTables">
        <link:definition>2319301 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Indebtedness" roleURI="http://www.biogenidec.com/role/Indebtedness">
        <link:definition>2114100 - Disclosure - Indebtedness</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IndebtednessDetails" roleURI="http://www.biogenidec.com/role/IndebtednessDetails">
        <link:definition>2414402 - Disclosure - Indebtedness (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IndebtednessDetails1" roleURI="http://www.biogenidec.com/role/IndebtednessDetails1">
        <link:definition>2414403 - Disclosure - Indebtedness (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IndebtednessDetailsTextual" roleURI="http://www.biogenidec.com/role/IndebtednessDetailsTextual">
        <link:definition>2414404 - Disclosure - Indebtedness (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IndebtednessTables" roleURI="http://www.biogenidec.com/role/IndebtednessTables">
        <link:definition>2314301 - Disclosure - Indebtedness (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsAndGoodwill" roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill">
        <link:definition>2109100 - Disclosure - Intangible Assets and Goodwill</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsAndGoodwillDetails" roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails">
        <link:definition>2409402 - Disclosure - Intangible Assets and Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsAndGoodwillDetails1" roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1">
        <link:definition>2409403 - Disclosure - Intangible Assets and Goodwill (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsAndGoodwillTables" roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables">
        <link:definition>2309301 - Disclosure - Intangible Assets and Goodwill (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventory" roleURI="http://www.biogenidec.com/role/Inventory">
        <link:definition>2108100 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryDetails" roleURI="http://www.biogenidec.com/role/InventoryDetails">
        <link:definition>2408402 - Disclosure - Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryDetailsTextual" roleURI="http://www.biogenidec.com/role/InventoryDetailsTextual">
        <link:definition>2408403 - Disclosure - Inventory (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryTables" roleURI="http://www.biogenidec.com/role/InventoryTables">
        <link:definition>2308301 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsInVariableInterestEntities" roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities">
        <link:definition>2121100 - Disclosure - Investments in Variable Interest Entities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsInVariableInterestEntitiesDetails" roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails">
        <link:definition>2421401 - Disclosure - Investments in Variable Interest Entities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Litigation" roleURI="http://www.biogenidec.com/role/Litigation">
        <link:definition>2123100 - Disclosure - Litigation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LitigationDetails" roleURI="http://www.biogenidec.com/role/LitigationDetails">
        <link:definition>2423401 - Disclosure - Litigation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetail" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail">
        <link:definition>2120100 - Disclosure - Other Consolidated Financial Statement Detail</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetailDetails" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails">
        <link:definition>2420402 - Disclosure - Other Consolidated Financial Statement Detail (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetailDetailsTextual" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetailsTextual">
        <link:definition>2420403 - Disclosure - Other Consolidated Financial Statement Detail (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetailTables" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables">
        <link:definition>2320301 - Disclosure - Other Consolidated Financial Statement Detail (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantAndEquipment" roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipment">
        <link:definition>2113100 - Disclosure - Property, Plant and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantAndEquipmentDetails" roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails">
        <link:definition>2413402 - Disclosure - Property, Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantAndEquipmentDetailsTextual" roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetailsTextual">
        <link:definition>2413403 - Disclosure - Property, Plant and Equipment (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantAndEquipmentTables" roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentTables">
        <link:definition>2313301 - Disclosure - Property, Plant and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="QuarterlyFinancialDataUnaudited" roleURI="http://www.biogenidec.com/role/QuarterlyFinancialDataUnaudited">
        <link:definition>2128100 - Disclosure - Quarterly Financial Data (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="QuarterlyFinancialDataUnauditedDetails" roleURI="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetails">
        <link:definition>2428402 - Disclosure - Quarterly Financial Data (Unaudited) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="QuarterlyFinancialDataUnauditedDetailsTextual" roleURI="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetailsTextual">
        <link:definition>2428403 - Disclosure - Quarterly Financial Data (Unaudited) (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="QuarterlyFinancialDataUnauditedTables" roleURI="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedTables">
        <link:definition>2328301 - Disclosure - Quarterly Financial Data (Unaudited) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringRestructuring" roleURI="http://www.biogenidec.com/role/RestructuringRestructuring">
        <link:definition>2106100 - Disclosure - Restructuring Restructuring</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringRestructuringDetails" roleURI="http://www.biogenidec.com/role/RestructuringRestructuringDetails">
        <link:definition>2406402 - Disclosure - Restructuring Restructuring (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringRestructuringDetailsTextual" roleURI="http://www.biogenidec.com/role/RestructuringRestructuringDetailsTextual">
        <link:definition>2406403 - Disclosure - Restructuring Restructuring (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringRestructuringTables" roleURI="http://www.biogenidec.com/role/RestructuringRestructuringTables">
        <link:definition>2306301 - Disclosure - Restructuring Restructuring (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueReserves" roleURI="http://www.biogenidec.com/role/RevenueReserves">
        <link:definition>2107100 - Disclosure - Revenue Reserves</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueReservesDetails" roleURI="http://www.biogenidec.com/role/RevenueReservesDetails">
        <link:definition>2407402 - Disclosure - Revenue Reserves (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueReservesDetails1" roleURI="http://www.biogenidec.com/role/RevenueReservesDetails1">
        <link:definition>2407403 - Disclosure - Revenue Reserves (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueReservesTables" roleURI="http://www.biogenidec.com/role/RevenueReservesTables">
        <link:definition>2307301 - Disclosure - Revenue Reserves (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformation" roleURI="http://www.biogenidec.com/role/SegmentInformation">
        <link:definition>2127100 - Disclosure - Segment Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationDetails" roleURI="http://www.biogenidec.com/role/SegmentInformationDetails">
        <link:definition>2427402 - Disclosure - Segment Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationDetails1" roleURI="http://www.biogenidec.com/role/SegmentInformationDetails1">
        <link:definition>2427403 - Disclosure - Segment Information (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationDetailsTextual" roleURI="http://www.biogenidec.com/role/SegmentInformationDetailsTextual">
        <link:definition>2427404 - Disclosure - Segment Information (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationTables" roleURI="http://www.biogenidec.com/role/SegmentInformationTables">
        <link:definition>2327301 - Disclosure - Segment Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPayments" roleURI="http://www.biogenidec.com/role/ShareBasedPayments">
        <link:definition>2118100 - Disclosure - Share-based Payments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetails" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails">
        <link:definition>2418402 - Disclosure - Share-Based Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetails1" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1">
        <link:definition>2418403 - Disclosure - Share-Based Payments (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetails2" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails2">
        <link:definition>2418404 - Disclosure - Share-Based Payments (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetails3" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails3">
        <link:definition>2418405 - Disclosure - Share-Based Payments (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetails4" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails4">
        <link:definition>2418406 - Disclosure - Share-Based Payments (Details 4)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetails5" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails5">
        <link:definition>2418407 - Disclosure - Share-Based Payments (Details 5)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetails6" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails6">
        <link:definition>2418408 - Disclosure - Share-Based Payments (Details 6)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetails8" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails8">
        <link:definition>2418410 - Disclosure - Share-Based Payments (Details 8)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetails9" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails9">
        <link:definition>2418411 - Disclosure - Share-Based Payments (Details 9)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetailsTextual" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetailsTextual">
        <link:definition>2418412 - Disclosure - Share-Based Payments (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsShareBasedPaymentsDetails7" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedPaymentsDetails7">
        <link:definition>2418409 - Disclosure - Share-based Payments Share-Based Payments (Details 7)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsTables" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTables">
        <link:definition>2318301 - Disclosure - Share-Based Payments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsNotes" roleURI="http://www.biogenidec.com/role/SubsequentEventsNotes">
        <link:definition>2129100 - Disclosure - Subsequent Events (Notes)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPolicies" roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies">
        <link:definition>2101100 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesDetails" roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails">
        <link:definition>2401403 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>2201201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesTables">
        <link:definition>2301302 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element abstract="true" id="biib_A1995ESPPMember" name="A1995ESPPMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_A2015ESPPMember" name="A2015ESPPMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_A2015RestructuringChargesMember" name="A2015RestructuringChargesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_A2016RestructuringChargesMember" name="A2016RestructuringChargesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_AGTCMember" name="AGTCMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ALPROLIXMember" name="ALPROLIXMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ALPROLIXProductMember" name="ALPROLIXProductMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_AVONEXMember" name="AVONEXMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_AbbVieMember" name="AbbVieMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch" name="AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_AcordaMember" name="AcordaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_AdditionalMilestonePayment" name="AdditionalMilestonePayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_AdditionalProductsAxis" name="AdditionalProductsAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_AdditionalProductsDomain" name="AdditionalProductsDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Additionalmilestonepaymentsforproductcandidateusingadifferentmodality" name="Additionalmilestonepaymentsforproductcandidateusingadifferentmodality" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" name="AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract" name="AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" name="AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock" name="AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_AtaxionMember" name="AtaxionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_AttainmentOfPerformanceCriteriain2012Member" name="AttainmentOfPerformanceCriteriain2012Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_AttainmentOfPerformanceCriteriain2013Member" name="AttainmentOfPerformanceCriteriain2013Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" name="AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" name="AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_AverageMaturityOfMarketableSecurities" name="AverageMaturityOfMarketableSecurities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_AverageStockPriceOnGrantDateInDollarsMaximum" name="AverageStockPriceOnGrantDateInDollarsMaximum" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_AverageStockPriceOnGrantDateInDollarsMinimum" name="AverageStockPriceOnGrantDateInDollarsMinimum" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_BENEPALIMember" name="BENEPALIMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_BIIB074Member" name="BIIB074Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_BaseRateAfterFirstCommercialSale" name="BaseRateAfterFirstCommercialSale" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_BasicAndDilutedEarningsPerShareAbstract" name="BasicAndDilutedEarningsPerShareAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_BiogenIdecHemophiliaMember" name="BiogenIdecHemophiliaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_BiogenIdecInternationalNeuroscienceMember" name="BiogenIdecInternationalNeuroscienceMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_BiogenRateToSobiOnNetRevenueFromBiogenDistributorTerritoryMember" name="BiogenRateToSobiOnNetRevenueFromBiogenDistributorTerritoryMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember" name="BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember" name="BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Biogeneffectiveroyaltyrate" name="Biogeneffectiveroyaltyrate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Biogenshareofcopromotionprofitsorlosses" name="Biogenshareofcopromotionprofitsorlosses" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_BiosimilarsMember" name="BiosimilarsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_BusinessOverviewPolicyTextBlock" name="BusinessOverviewPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_BusinessTextualAbstract" name="BusinessTextualAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CambridgeMAMember" name="CambridgeMAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CashSettledPerformanceSharesAbstract" name="CashSettledPerformanceSharesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CashSettledPerformanceSharesMember" name="CashSettledPerformanceSharesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CashflowsoperatingexpensesMember" name="CashflowsoperatingexpensesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CashflowsrevenueMember" name="CashflowsrevenueMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" name="CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_CoPromotionProfitSharingFormulaAbstract" name="CoPromotionProfitSharingFormulaAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_CoPromotionProfitSharingFormulaTableTextBlock" name="CoPromotionProfitSharingFormulaTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_CollaborationProfitSharing" name="CollaborationProfitSharing" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_Collaborationexpensesaccrual" name="Collaborationexpensesaccrual" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_Collaborationprofitlosssharing" name="Collaborationprofitlosssharing" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CollaborationsTextualAbstract" name="CollaborationsTextualAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_CollaborativeandOtherRelationshipsPolicyTextBlock" name="CollaborativeandOtherRelationshipsPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CommercialMilestonesMember" name="CommercialMilestonesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CommitmentsAndContingenciesTextualAbstract" name="CommitmentsAndContingenciesTextualAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_CompensationExpenseOverPurchasePeriod" name="CompensationExpenseOverPurchasePeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_ComputerSoftwareAndHardware" name="ComputerSoftwareAndHardware" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_ConsiderationPerProductDeveloped" name="ConsiderationPerProductDeveloped" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ContractualAdjustmentsMember" name="ContractualAdjustmentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ConvergencePharmaceuticalsMember" name="ConvergencePharmaceuticalsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Copromotionprofitsandlosses" name="Copromotionprofitsandlosses" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CorporateDebtSecuritiesCurrentMember" name="CorporateDebtSecuritiesCurrentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CorporateDebtSecuritiesNonCurrentMember" name="CorporateDebtSecuritiesNonCurrentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_CumulativeSalesLevel" name="CumulativeSalesLevel" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_CumulativeSalesLevelAxis" name="CumulativeSalesLevelAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CumulativeSalesLevelDomain" name="CumulativeSalesLevelDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" name="CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_DMPKMember" name="DMPKMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage" name="DebtInstrumentMakeWholeProvisionRedemptionPricePercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_DebtInstrumentUnamortizedInterestOnDebt" name="DebtInstrumentUnamortizedInterestOnDebt" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_DeferredTaxLiabilitiesDepreciationAmortizationOther" name="DeferredTaxLiabilitiesDepreciationAmortizationOther" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_DenominatorAbstract" name="DenominatorAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_DevelopmentMilestonesMember" name="DevelopmentMilestonesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_DirectorsPlanMember" name="DirectorsPlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_DiscountRateRecognizedInCompensationExpense" name="DiscountRateRecognizedInCompensationExpense" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_DiscoveryprogramsMember" name="DiscoveryprogramsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_DistributorOneMember" name="DistributorOneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_DistributorTwoMember" name="DistributorTwoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_DueFromUnconsolidatedJointBusiness" name="DueFromUnconsolidatedJointBusiness" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_ELOCTATEMember" name="ELOCTATEMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_EachAdditionalOneBillionUpToTwentyBillionMember" name="EachAdditionalOneBillionUpToTwentyBillionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_EarningsPerShareTextualAbstract" name="EarningsPerShareTextualAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_EffectiveIncomeTaxRateReconciliationContingentConsideration" name="EffectiveIncomeTaxRateReconciliationContingentConsideration" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction" name="EffectiveIncomeTaxRateReconciliationManufacturingDeduction" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_EightbillionMember" name="EightbillionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_EisaiMember" name="EisaiMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ElevenbillionMember" name="ElevenbillionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_EmployeeBenefitPlansTextualAbstract" name="EmployeeBenefitPlansTextualAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_EmployeeServiceSharebasedCompensationSharesUsedtoSettleAwards" name="EmployeeServiceSharebasedCompensationSharesUsedtoSettleAwards" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_EmployeeStockPurchasePlanMember" name="EmployeeStockPurchasePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_EntityWidePercentageOfRevenueFromMajorDistributors" name="EntityWidePercentageOfRevenueFromMajorDistributors" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_EquityMethodInvestmentOwnershipPercentageMaximum" name="EquityMethodInvestmentOwnershipPercentageMaximum" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_EquityMethodInvestmentsExpectedProfitShare" name="EquityMethodInvestmentsExpectedProfitShare" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_EquityTextualAbstract" name="EquityTextualAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" name="EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_EstimatedTaxLiabilityOnUndistributedEarningsOfForeignSubsidiaries" name="EstimatedTaxLiabilityOnUndistributedEarningsOfForeignSubsidiaries" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_EstimatedUsefulLivesOfLeaseholdImprovements" name="EstimatedUsefulLivesOfLeaseholdImprovements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_ExpectedAdditionalMilestonePaymentsOnSuccessfulAchievementOfRegulatoryAndCommercialSalesMilestones" name="ExpectedAdditionalMilestonePaymentsOnSuccessfulAchievementOfRegulatoryAndCommercialSalesMilestones" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold" name="ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments" name="ExpectedLicenseFeeAndRegulatoryMilestonePayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_ExpenseIncurredByCollaboration" name="ExpenseIncurredByCollaboration" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_ExpenseReflectedWithinStatementsOfIncome" name="ExpenseReflectedWithinStatementsOfIncome" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FAMPYRAMember" name="FAMPYRAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FLIXABIMember" name="FLIXABIMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FUMADERMMember" name="FUMADERMMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FacilityLocationAxis" name="FacilityLocationAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FacilityLocationDomain" name="FacilityLocationDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FinancialInstrumentsTextualAbstract" name="FinancialInstrumentsTextualAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_ForeignSalesRequiredToTriggerMilestone" name="ForeignSalesRequiredToTriggerMilestone" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FumapharmAgMember" name="FumapharmAgMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FutureContingentMilestoneTypesAxis" name="FutureContingentMilestoneTypesAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FutureContingentMilestoneTypesDomain" name="FutureContingentMilestoneTypesDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion" name="FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion" name="FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="biib_FutureContingentPaymentThreshold" name="FutureContingentPaymentThreshold" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct" name="FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Futurepercentageofcopromotionoperatingprofits" name="Futurepercentageofcopromotionoperatingprofits" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Futureresearchanddevelopmentcommitment" name="Futureresearchanddevelopmentcommitment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_GAZYVAMember" name="GAZYVAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_GainOnSaleOfRights" name="GainOnSaleOfRights" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_GovernmentSecuritiesCurrentMember" name="GovernmentSecuritiesCurrentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_GovernmentSecuritiesNonCurrentMember" name="GovernmentSecuritiesNonCurrentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_InLicensedPatentsMember" name="InLicensedPatentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_IncomeTaxesTextualAbstract" name="IncomeTaxesTextualAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_IncreasedCarryingAmountOfSeniorNotes" name="IncreasedCarryingAmountOfSeniorNotes" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="biib_IndefiniteLivedIntangibleAssetsUsefulLife" name="IndefiniteLivedIntangibleAssetsUsefulLife" nillable="true" substitutionGroup="xbrli:item" type="us-types:durationStringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract" name="IntangibleAssetsAndGoodwillAdditionalTextualAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_IntangibleAssetsExcludingGoodwillTableTextBlock" name="IntangibleAssetsExcludingGoodwillTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_InterestInSubsidiary" name="InterestInSubsidiary" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Inventorynetcurrentandnoncurrent" name="Inventorynetcurrentandnoncurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" name="InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_InvestmentInVariableInterestEntitiesTextualAbstract" name="InvestmentInVariableInterestEntitiesTextualAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement" name="InvestmentsByThirdPartyInJointVentureAsPerAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_InvestmentsInVariableInterestEntitiesAbstract" name="InvestmentsInVariableInterestEntitiesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_IonisPharmaceuticalsInc.Member" name="IonisPharmaceuticalsInc.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_IonisPharmaceuticalsMember" name="IonisPharmaceuticalsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_JointVentureOwnerShipPercentageByThirdParty" name="JointVentureOwnerShipPercentageByThirdParty" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_LeadprogramsMember" name="LeadprogramsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_LiabilityForFairValueOfOptionsGrantedUnderAgreement" name="LiabilityForFairValueOfOptionsGrantedUnderAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_LicenseFee" name="LicenseFee" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_LossContingencyAdjustmentRelatedToClaimAmountPercent" name="LossContingencyAdjustmentRelatedToClaimAmountPercent" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_MajorDistributorAxis" name="MajorDistributorAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_MajorDistributorDomain" name="MajorDistributorDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_MarketStockUnitsActivityAbstract" name="MarketStockUnitsActivityAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_MarketStockUnitsMember" name="MarketStockUnitsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_MarketableEquitySecuritiesMember" name="MarketableEquitySecuritiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" name="MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_MilestonePaymentsMadeDuringPeriod" name="MilestonePaymentsMadeDuringPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_MinimumQualifyingAgeForEmployeeBenefitPlan" name="MinimumQualifyingAgeForEmployeeBenefitPlan" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract" name="MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" name="MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_MitsubishiTanabePharmaCorporationMember" name="MitsubishiTanabePharmaCorporationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" name="MortgageAndOtherAssetBackedSecuritiesCurrentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" name="MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_NetMinimumLeasePayments" name="NetMinimumLeasePayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_NetMinimumLeasePaymentsThereafter" name="NetMinimumLeasePaymentsThereafter" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_NetMinimumLeasePaymentsWithInFiveYear" name="NetMinimumLeasePaymentsWithInFiveYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_NetMinimumLeasePaymentsWithInFourYear" name="NetMinimumLeasePaymentsWithInFourYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_NetMinimumLeasePaymentsWithInOneYear" name="NetMinimumLeasePaymentsWithInOneYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_NetMinimumLeasePaymentsWithInThreeYear" name="NetMinimumLeasePaymentsWithInThreeYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_NetMinimumLeasePaymentsWithInTwoYear" name="NetMinimumLeasePaymentsWithInTwoYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_NeurimmuneMember" name="NeurimmuneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_NeuropathicpainindicationsMember" name="NeuropathicpainindicationsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_NewAntiCd20Member" name="NewAntiCd20Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_NinebillionMember" name="NinebillionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Noncontrollinginterestincreasedecreaseother" name="Noncontrollinginterestincreasedecreaseother" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_NotesPayableToFumedicaMember" name="NotesPayableToFumedicaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_NumberOfDaysForCalculationOfAverageClosingStockPrice" name="NumberOfDaysForCalculationOfAverageClosingStockPrice" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_NumberOfEqualAnnualIncrements" name="NumberOfEqualAnnualIncrements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade" name="NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_NumberOfSharesOfCommonStockForIssuance" name="NumberOfSharesOfCommonStockForIssuance" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_NumeratorAbstract" name="NumeratorAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_OcrelizumabMember" name="OcrelizumabMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_OmnibusPlansMember" name="OmnibusPlansMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_OneBillionMember" name="OneBillionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_OtherIncomeExpenseNet" name="OtherIncomeExpenseNet" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_OtherresearchanddiscoveryMember" name="OtherresearchanddiscoveryMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_OutLicensedPatentsMember" name="OutLicensedPatentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Overnightreverserepurchaseagreementspercentoftotalassets" name="Overnightreverserepurchaseagreementspercentoftotalassets" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_PLEGRIDYMember" name="PLEGRIDYMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_ParValueOfNotesPayable" name="ParValueOfNotesPayable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_PaymentTermsOfAccountsReceivable" name="PaymentTermsOfAccountsReceivable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" name="PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" name="PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_PercentageOfCoPromotionOperatingLosses" name="PercentageOfCoPromotionOperatingLosses" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion" name="PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillion" name="PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillion" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne" name="PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract" name="PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne" name="PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree" name="PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo" name="PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="biib_PercentageOfMarketValuePerShareOfCommonStock" name="PercentageOfMarketValuePerShareOfCommonStock" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_PercentageOfMinimumInvestmentReturn" name="PercentageOfMinimumInvestmentReturn" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_PercentageParValueOfSeniorNotes" name="PercentageParValueOfSeniorNotes" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables" name="PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_PerformanceUnitsMember" name="PerformanceUnitsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_PerformanceunitsactivityTableTextBlock" name="PerformanceunitsactivityTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_PeriodOfCollaborationAgreement" name="PeriodOfCollaborationAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_PlanAssetsForDeferredCompensationFairValueDisclosure" name="PlanAssetsForDeferredCompensationFairValueDisclosure" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" name="PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_Preapprovalinventory" name="Preapprovalinventory" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_Premiumonequityinvestment" name="Premiumonequityinvestment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_PretaxProfitSharingFormulaTableTextBlock" name="PretaxProfitSharingFormulaTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ProceedsFromMarketableDebtSecuritiesAbstract" name="ProceedsFromMarketableDebtSecuritiesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_PurchasePriceOfCommonStockUnderEspp" name="PurchasePriceOfCommonStockUnderEspp" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Purchaseofcommonstock" name="Purchaseofcommonstock" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="biib_RateDuringReimbursementPeriod" name="RateDuringReimbursementPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_RatioOfNumberOfSharesReservedUnderPlan" name="RatioOfNumberOfSharesReservedUnderPlan" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Reductioninroyaltyrate" name="Reductioninroyaltyrate" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_RegulatoryMilestonesMember" name="RegulatoryMilestonesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_ReimbursementCostAchievingPeriod" name="ReimbursementCostAchievingPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_ReimbursementLimitStatedInResolution" name="ReimbursementLimitStatedInResolution" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ReimbursementUnderAmendedAgreementAmountsPayableAbstract" name="ReimbursementUnderAmendedAgreementAmountsPayableAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_ReimbursementUnderAmendedAgreementAmountsPayableTableTextBlock" name="ReimbursementUnderAmendedAgreementAmountsPayableTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_ReimbursementUnderAmendedAgreementMethod" name="ReimbursementUnderAmendedAgreementMethod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement" name="RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement" name="ResearchAndDevelopmentCostInSupportOfCollaborationAgreement" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Researchanddevelopmentservices" name="Researchanddevelopmentservices" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ReservesForDiscountsAndAllowancesAbstract" name="ReservesForDiscountsAndAllowancesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_RestOfWorldMember" name="RestOfWorldMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_RestrictedStockUnitsActivityAbstract" name="RestrictedStockUnitsActivityAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_RestructuringandRelatedCostExpectedCashPayments" name="RestructuringandRelatedCostExpectedCashPayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_Restructuringandrelatedcostexpectedpercentageofpositionseliminated" name="Restructuringandrelatedcostexpectedpercentageofpositionseliminated" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_RevenuesFromUnconsolidatedJointBusinessAbstract" name="RevenuesFromUnconsolidatedJointBusinessAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_RevenuesFromUnconsolidatedJointBusinessTableTextBlock" name="RevenuesFromUnconsolidatedJointBusinessTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms" name="RevenuesInPercentageFromAntiCD20TherapeuticPrograms" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_RevenuesfromantiCD20therapeuticprograms" name="RevenuesfromantiCD20therapeuticprograms" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_RituxanMember" name="RituxanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_RocheGroupGenentechMember" name="RocheGroupGenentechMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_RodinTherapeuticsMember" name="RodinTherapeuticsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis" name="RoyaltyAndNetRevenueShareRatesByTerritoryAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_RoyaltyAndNetRevenueShareRatesByTerritoryDomain" name="RoyaltyAndNetRevenueShareRatesByTerritoryDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_RoyaltyCostofSalesPolicyTextBlock" name="RoyaltyCostofSalesPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SOD1Member" name="SOD1Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SPINRAZAMember" name="SPINRAZAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_SalesTriggerGrossSalesThreshold" name="SalesTriggerGrossSalesThreshold" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SamsungBiosimilarAgreementMember" name="SamsungBiosimilarAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SangamoBioSciencesMember" name="SangamoBioSciencesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock" name="ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems" name="ScheduleOfDevelopmentMilestoneAndCollaborationLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable" name="ScheduleOfDevelopmentMilestoneAndCollaborationTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_ScheduleOfMarketStockUnitsActivityTableTextBlock" name="ScheduleOfMarketStockUnitsActivityTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" name="ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember" name="SegmentGeographicalGroupsOfCountriesGroupOtherMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SegmentInformationTextualAbstract" name="SegmentInformationTextualAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" name="SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" name="SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" name="SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" name="SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" name="SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_SeriesXPreferredStockMember" name="SeriesXPreferredStockMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SevenbillionMember" name="SevenbillionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" name="ShareBasedCompensationExpenseIncludedInCostsAndExpenses" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ShareBasedCompensationPlanAxis" name="ShareBasedCompensationPlanAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ShareBasedCompensationPlanDomain" name="ShareBasedCompensationPlanDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ShareBasedPaymentsTextualAbstract" name="ShareBasedPaymentsTextualAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_ShareOfCoPromotionProfits" name="ShareOfCoPromotionProfits" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock" name="SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SobiRateToBiogenOnNetSalesInSobiTerritoryMember" name="SobiRateToBiogenOnNetSalesInSobiTerritoryMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SobiTerritoryMember" name="SobiTerritoryMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SolothurnMember" name="SolothurnMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_StockOptionActivityAbstract" name="StockOptionActivityAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_StockOptionsAndEmployeeStockPurchasePlanMember" name="StockOptionsAndEmployeeStockPurchasePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_StrategicInvestmentPortfolio" name="StrategicInvestmentPortfolio" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_StrategicInvestmentsMember" name="StrategicInvestmentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_StromedixMember" name="StromedixMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock" name="SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_SummaryOfActivityRelatedToCollaborationWithCompanySevenTableTextBlock" name="SummaryOfActivityRelatedToCollaborationWithCompanySevenTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_SummaryOfCommonStockTableTextBlock" name="SummaryOfCommonStockTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SummaryOfFairAndCarryingValueOfDebtInstrumentsAbstract" name="SummaryOfFairAndCarryingValueOfDebtInstrumentsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" name="SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" name="SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SwedishOrphanBiovitrumMember" name="SwedishOrphanBiovitrumMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_TaxBenefitAndCashReceivedFromStockOptionAbstract" name="TaxBenefitAndCashReceivedFromStockOptionAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_TecfideraMember" name="TecfideraMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_TenbillionMember" name="TenbillionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_TermOfLease" name="TermOfLease" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Termofcollaborationagreement" name="Termofcollaborationagreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ThreeBillionMember" name="ThreeBillionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne" name="ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne" name="ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="biib_TimePeriodForPayingRemainingBalanceDue" name="TimePeriodForPayingRemainingBalanceDue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock" name="TimeVestedRestrictedStockUnitsActivityTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_TimeVestedRestrictedStockUnitsMember" name="TimeVestedRestrictedStockUnitsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Totaldeferredchargesandprepaidtaxes" name="Totaldeferredchargesandprepaidtaxes" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_TysabriMember" name="TysabriMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_TysabriProductMember" name="TysabriProductMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_UndesignatedPreferredStockMember" name="UndesignatedPreferredStockMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_UniversityofPennsylvaniaMember" name="UniversityofPennsylvaniaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" name="UpfrontAndMilestonePaymentsMadeToCollaborativePartner" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_ValuationOfGrantedStockUnitsAbstract" name="ValuationOfGrantedStockUnitsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards" name="WeightedAveragePeriodToRecognizeCostOfNonvestedAwards" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_WindfallTaxBenefitsFromVestingOfStockAwardsExercisesOfStockOptionsAndEsppParticipation" name="WindfallTaxBenefitsFromVestingOfStockAwardsExercisesOfStockOptionsAndEsppParticipation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ZINBRYTAMember" name="ZINBRYTAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>biib-20161231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLoss" xlink:href="biib-20161231.xsd#AccumulatedOtherComprehensiveIncomeLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:href="biib-20161231.xsd#AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails1" xlink:href="biib-20161231.xsd#AccumulatedOtherComprehensiveIncomeLossDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:href="biib-20161231.xsd#AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Acquisitions" xlink:href="biib-20161231.xsd#Acquisitions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsAcquisitionsDetails" xlink:href="biib-20161231.xsd#AcquisitionsAcquisitionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsAcquisitionsDetails1" xlink:href="biib-20161231.xsd#AcquisitionsAcquisitionsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsAcquisitionsTables" xlink:href="biib-20161231.xsd#AcquisitionsAcquisitionsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsDetailsTextual" xlink:href="biib-20161231.xsd#AcquisitionsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships" xlink:href="biib-20161231.xsd#CollaborativeAndOtherRelationships" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsDetails3" xlink:href="biib-20161231.xsd#CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetails" xlink:href="biib-20161231.xsd#CollaborativeAndOtherRelationshipsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetails1" xlink:href="biib-20161231.xsd#CollaborativeAndOtherRelationshipsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetails2" xlink:href="biib-20161231.xsd#CollaborativeAndOtherRelationshipsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual" xlink:href="biib-20161231.xsd#CollaborativeAndOtherRelationshipsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables" xlink:href="biib-20161231.xsd#CollaborativeAndOtherRelationshipsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CommitmentsAndContingencies" xlink:href="biib-20161231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CommitmentsAndContingenciesCommitmentsAndContingenciesDetails1" xlink:href="biib-20161231.xsd#CommitmentsAndContingenciesCommitmentsAndContingenciesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CommitmentsAndContingenciesDetails" xlink:href="biib-20161231.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CommitmentsAndContingenciesDetailsTextual" xlink:href="biib-20161231.xsd#CommitmentsAndContingenciesDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CommitmentsAndContingenciesTables" xlink:href="biib-20161231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedBalanceSheets" xlink:href="biib-20161231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="biib-20161231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="biib-20161231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsOfComprehensiveIncome" xlink:href="biib-20161231.xsd#ConsolidatedStatementsOfComprehensiveIncome" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsOfEquity" xlink:href="biib-20161231.xsd#ConsolidatedStatementsOfEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsOfIncome" xlink:href="biib-20161231.xsd#ConsolidatedStatementsOfIncome" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstruments" xlink:href="biib-20161231.xsd#DerivativeInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:href="biib-20161231.xsd#DerivativeInstrumentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails1" xlink:href="biib-20161231.xsd#DerivativeInstrumentsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetailsTextual" xlink:href="biib-20161231.xsd#DerivativeInstrumentsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:href="biib-20161231.xsd#DerivativeInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DocumentAndEntityInformation" xlink:href="biib-20161231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShare" xlink:href="biib-20161231.xsd#EarningsPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShareDetails" xlink:href="biib-20161231.xsd#EarningsPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShareTables" xlink:href="biib-20161231.xsd#EarningsPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EmployeeBenefitPlans" xlink:href="biib-20161231.xsd#EmployeeBenefitPlans" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EmployeeBenefitPlansDetails1" xlink:href="biib-20161231.xsd#EmployeeBenefitPlansDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EmployeeBenefitPlansEmployeeBenefitPlansDetails" xlink:href="biib-20161231.xsd#EmployeeBenefitPlansEmployeeBenefitPlansDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Equity" xlink:href="biib-20161231.xsd#Equity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityDetails" xlink:href="biib-20161231.xsd#EquityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityDetailsTextual" xlink:href="biib-20161231.xsd#EquityDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityTables" xlink:href="biib-20161231.xsd#EquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurements" xlink:href="biib-20161231.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:href="biib-20161231.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:href="biib-20161231.xsd#FairValueMeasurementsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:href="biib-20161231.xsd#FairValueMeasurementsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:href="biib-20161231.xsd#FairValueMeasurementsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:href="biib-20161231.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstruments" xlink:href="biib-20161231.xsd#FinancialInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:href="biib-20161231.xsd#FinancialInstrumentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:href="biib-20161231.xsd#FinancialInstrumentsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:href="biib-20161231.xsd#FinancialInstrumentsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:href="biib-20161231.xsd#FinancialInstrumentsDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual1" xlink:href="biib-20161231.xsd#FinancialInstrumentsDetailsTextual1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual2" xlink:href="biib-20161231.xsd#FinancialInstrumentsDetailsTextual2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:href="biib-20161231.xsd#FinancialInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Guarantees" xlink:href="biib-20161231.xsd#Guarantees" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxes" xlink:href="biib-20161231.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:href="biib-20161231.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails1" xlink:href="biib-20161231.xsd#IncomeTaxesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails2" xlink:href="biib-20161231.xsd#IncomeTaxesDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails3" xlink:href="biib-20161231.xsd#IncomeTaxesDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:href="biib-20161231.xsd#IncomeTaxesDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:href="biib-20161231.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Indebtedness" xlink:href="biib-20161231.xsd#Indebtedness" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessDetails" xlink:href="biib-20161231.xsd#IndebtednessDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessDetails1" xlink:href="biib-20161231.xsd#IndebtednessDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessDetailsTextual" xlink:href="biib-20161231.xsd#IndebtednessDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessTables" xlink:href="biib-20161231.xsd#IndebtednessTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill" xlink:href="biib-20161231.xsd#IntangibleAssetsAndGoodwill" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails" xlink:href="biib-20161231.xsd#IntangibleAssetsAndGoodwillDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:href="biib-20161231.xsd#IntangibleAssetsAndGoodwillDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables" xlink:href="biib-20161231.xsd#IntangibleAssetsAndGoodwillTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Inventory" xlink:href="biib-20161231.xsd#Inventory" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryDetails" xlink:href="biib-20161231.xsd#InventoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryDetailsTextual" xlink:href="biib-20161231.xsd#InventoryDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryTables" xlink:href="biib-20161231.xsd#InventoryTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities" xlink:href="biib-20161231.xsd#InvestmentsInVariableInterestEntities" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails" xlink:href="biib-20161231.xsd#InvestmentsInVariableInterestEntitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Litigation" xlink:href="biib-20161231.xsd#Litigation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/LitigationDetails" xlink:href="biib-20161231.xsd#LitigationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:href="biib-20161231.xsd#OtherConsolidatedFinancialStatementDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:href="biib-20161231.xsd#OtherConsolidatedFinancialStatementDetailDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetailsTextual" xlink:href="biib-20161231.xsd#OtherConsolidatedFinancialStatementDetailDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:href="biib-20161231.xsd#OtherConsolidatedFinancialStatementDetailTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipment" xlink:href="biib-20161231.xsd#PropertyPlantAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails" xlink:href="biib-20161231.xsd#PropertyPlantAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetailsTextual" xlink:href="biib-20161231.xsd#PropertyPlantAndEquipmentDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentTables" xlink:href="biib-20161231.xsd#PropertyPlantAndEquipmentTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/QuarterlyFinancialDataUnaudited" xlink:href="biib-20161231.xsd#QuarterlyFinancialDataUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetails" xlink:href="biib-20161231.xsd#QuarterlyFinancialDataUnauditedDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetailsTextual" xlink:href="biib-20161231.xsd#QuarterlyFinancialDataUnauditedDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedTables" xlink:href="biib-20161231.xsd#QuarterlyFinancialDataUnauditedTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RestructuringRestructuring" xlink:href="biib-20161231.xsd#RestructuringRestructuring" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RestructuringRestructuringDetails" xlink:href="biib-20161231.xsd#RestructuringRestructuringDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RestructuringRestructuringDetailsTextual" xlink:href="biib-20161231.xsd#RestructuringRestructuringDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RestructuringRestructuringTables" xlink:href="biib-20161231.xsd#RestructuringRestructuringTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenueReserves" xlink:href="biib-20161231.xsd#RevenueReserves" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenueReservesDetails" xlink:href="biib-20161231.xsd#RevenueReservesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenueReservesDetails1" xlink:href="biib-20161231.xsd#RevenueReservesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenueReservesTables" xlink:href="biib-20161231.xsd#RevenueReservesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SegmentInformation" xlink:href="biib-20161231.xsd#SegmentInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SegmentInformationDetails" xlink:href="biib-20161231.xsd#SegmentInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SegmentInformationDetails1" xlink:href="biib-20161231.xsd#SegmentInformationDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SegmentInformationDetailsTextual" xlink:href="biib-20161231.xsd#SegmentInformationDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SegmentInformationTables" xlink:href="biib-20161231.xsd#SegmentInformationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPayments" xlink:href="biib-20161231.xsd#ShareBasedPayments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:href="biib-20161231.xsd#ShareBasedPaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:href="biib-20161231.xsd#ShareBasedPaymentsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails2" xlink:href="biib-20161231.xsd#ShareBasedPaymentsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails3" xlink:href="biib-20161231.xsd#ShareBasedPaymentsDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails4" xlink:href="biib-20161231.xsd#ShareBasedPaymentsDetails4" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails5" xlink:href="biib-20161231.xsd#ShareBasedPaymentsDetails5" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails6" xlink:href="biib-20161231.xsd#ShareBasedPaymentsDetails6" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails8" xlink:href="biib-20161231.xsd#ShareBasedPaymentsDetails8" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails9" xlink:href="biib-20161231.xsd#ShareBasedPaymentsDetails9" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetailsTextual" xlink:href="biib-20161231.xsd#ShareBasedPaymentsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedPaymentsDetails7" xlink:href="biib-20161231.xsd#ShareBasedPaymentsShareBasedPaymentsDetails7" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:href="biib-20161231.xsd#ShareBasedPaymentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SubsequentEventsNotes" xlink:href="biib-20161231.xsd#SubsequentEventsNotes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="biib-20161231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:href="biib-20161231.xsd#SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="biib-20161231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="biib-20161231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLoss" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails1" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/Acquisitions" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/AcquisitionsAcquisitionsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/AcquisitionsAcquisitionsDetails1" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/AcquisitionsAcquisitionsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/AcquisitionsDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsDetails3" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetails" xlink:type="extended">
    <link:loc xlink:href="biib-20161231.xsd#biib_RevenuesfromantiCD20therapeuticprograms" xlink:label="loc_biib_RevenuesfromantiCD20therapeuticprograms_ccb7b808-8f93-67cc-494d-bd9e53d6ff0a" xlink:type="locator" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ShareOfCoPromotionProfits" xlink:label="loc_biib_ShareOfCoPromotionProfits_ef682c5c-2c58-3237-de89-7411f73c704b" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_RevenuesfromantiCD20therapeuticprograms_ccb7b808-8f93-67cc-494d-bd9e53d6ff0a" xlink:to="loc_biib_ShareOfCoPromotionProfits_ef682c5c-2c58-3237-de89-7411f73c704b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_dec93aa4-b03e-3954-a272-eeb250ead290" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_RevenuesfromantiCD20therapeuticprograms_ccb7b808-8f93-67cc-494d-bd9e53d6ff0a" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_dec93aa4-b03e-3954-a272-eeb250ead290" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetails1" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetails2" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CommitmentsAndContingenciesCommitmentsAndContingenciesDetails1" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CommitmentsAndContingenciesDetails" xlink:type="extended">
    <link:loc xlink:href="biib-20161231.xsd#biib_NetMinimumLeasePaymentsWithInTwoYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInTwoYear_06d914c3-9c7f-fd3d-0f36-7411f728f71a" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_5519a64c-2a56-b1d5-2ab3-ee16d7d2a7a5" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInTwoYear_06d914c3-9c7f-fd3d-0f36-7411f728f71a" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_5519a64c-2a56-b1d5-2ab3-ee16d7d2a7a5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_07bfd5c6-3827-f7f1-39c4-c9370ee0e136" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInTwoYear_06d914c3-9c7f-fd3d-0f36-7411f728f71a" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_07bfd5c6-3827-f7f1-39c4-c9370ee0e136" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_NetMinimumLeasePaymentsThereafter" xlink:label="loc_biib_NetMinimumLeasePaymentsThereafter_aa8dc011-16d7-467f-f5ba-7411f621cdf6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_b89e7a90-e5d1-031a-5e13-781005c7ec6e" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsThereafter_aa8dc011-16d7-467f-f5ba-7411f621cdf6" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_b89e7a90-e5d1-031a-5e13-781005c7ec6e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_f2660b03-ee3f-0c19-f66f-3f0b78187b65" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsThereafter_aa8dc011-16d7-467f-f5ba-7411f621cdf6" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_f2660b03-ee3f-0c19-f66f-3f0b78187b65" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_NetMinimumLeasePaymentsWithInThreeYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInThreeYear_d44dff50-8a06-0a6f-a687-7411f5c313ef" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_2154b0cd-b6a4-a252-5801-385edf9d9702" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInThreeYear_d44dff50-8a06-0a6f-a687-7411f5c313ef" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_2154b0cd-b6a4-a252-5801-385edf9d9702" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_959fc161-66d3-9372-3953-05cd602239b5" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInThreeYear_d44dff50-8a06-0a6f-a687-7411f5c313ef" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_959fc161-66d3-9372-3953-05cd602239b5" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_NetMinimumLeasePayments" xlink:label="loc_biib_NetMinimumLeasePayments_afcf1b49-215a-42f4-e8af-7411f59f69c0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_ab95e8f2-93e0-6140-6e56-a79823c16c0d" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePayments_afcf1b49-215a-42f4-e8af-7411f59f69c0" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_ab95e8f2-93e0-6140-6e56-a79823c16c0d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_122eee87-59d8-02dd-5e15-5913ea32e487" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePayments_afcf1b49-215a-42f4-e8af-7411f59f69c0" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_122eee87-59d8-02dd-5e15-5913ea32e487" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_NetMinimumLeasePaymentsWithInFiveYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInFiveYear_05bbb881-451f-f383-f3c4-7411f5098f73" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_d7e45dda-b3de-1974-4726-54d18939cd1c" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInFiveYear_05bbb881-451f-f383-f3c4-7411f5098f73" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_d7e45dda-b3de-1974-4726-54d18939cd1c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_fcaf9c44-5f9f-e7cc-37bf-302bc442eaa2" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInFiveYear_05bbb881-451f-f383-f3c4-7411f5098f73" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_fcaf9c44-5f9f-e7cc-37bf-302bc442eaa2" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_NetMinimumLeasePaymentsWithInOneYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInOneYear_9d8cfc5b-0d98-6c8e-d403-7411f8171fe8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_00eaf688-6963-ad8a-03b8-e257d107b9c7" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInOneYear_9d8cfc5b-0d98-6c8e-d403-7411f8171fe8" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_00eaf688-6963-ad8a-03b8-e257d107b9c7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_1045d438-6948-b8c9-46a1-ee4f3580e222" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInOneYear_9d8cfc5b-0d98-6c8e-d403-7411f8171fe8" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_1045d438-6948-b8c9-46a1-ee4f3580e222" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_NetMinimumLeasePaymentsWithInFourYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInFourYear_a9bb1050-6cae-906c-a8a0-7411f57b6df2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_c2ad5d03-49c6-819a-1ac6-e6584eea34ff" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInFourYear_a9bb1050-6cae-906c-a8a0-7411f57b6df2" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_c2ad5d03-49c6-819a-1ac6-e6584eea34ff" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_563d4555-e41a-7792-78fc-2aad5331dd09" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInFourYear_a9bb1050-6cae-906c-a8a0-7411f57b6df2" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_563d4555-e41a-7792-78fc-2aad5331dd09" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CommitmentsAndContingenciesDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CommitmentsAndContingenciesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_04e17fb3-9b77-1c98-f460-7f5dd0c01008" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_48ae1e41-8bb7-d139-f404-61b44b37e179" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_04e17fb3-9b77-1c98-f460-7f5dd0c01008" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_48ae1e41-8bb7-d139-f404-61b44b37e179" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_48ae1e41-8bb7-d139-f404-61b44b37e179" xlink:to="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_3c8f3df4-466c-f78c-b021-17337fc4a147" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:to="loc_us-gaap_PreferredStockValue_3c8f3df4-466c-f78c-b021-17337fc4a147" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_d53388e7-4c8c-4e6d-6e90-7a6e0a100b74" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:to="loc_us-gaap_CommonStockValue_d53388e7-4c8c-4e6d-6e90-7a6e0a100b74" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_27e98f68-fe6c-3420-5b5a-861a4dc60800" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:to="loc_us-gaap_AdditionalPaidInCapital_27e98f68-fe6c-3420-5b5a-861a4dc60800" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_aeb1020a-508a-a8c1-f34c-bafff16c26cb" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_aeb1020a-508a-a8c1-f34c-bafff16c26cb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f759e73e-9f4f-941e-1138-49bc44f6b118" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f759e73e-9f4f-941e-1138-49bc44f6b118" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_d36dfcc8-b62a-1868-1a67-2bd77655103a" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:to="loc_us-gaap_TreasuryStockValue_d36dfcc8-b62a-1868-1a67-2bd77655103a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_0b2dda0f-483d-415e-b849-61eb9013050d" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_48ae1e41-8bb7-d139-f404-61b44b37e179" xlink:to="loc_us-gaap_MinorityInterest_0b2dda0f-483d-415e-b849-61eb9013050d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_6d3ec995-5062-ef92-dd72-b570c1eafdc8" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_04e17fb3-9b77-1c98-f460-7f5dd0c01008" xlink:to="loc_us-gaap_Liabilities_6d3ec995-5062-ef92-dd72-b570c1eafdc8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6d3ec995-5062-ef92-dd72-b570c1eafdc8" xlink:to="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_222239a2-3ddd-5e4f-4ae1-b11c60b29d92" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:to="loc_us-gaap_AccountsPayableCurrent_222239a2-3ddd-5e4f-4ae1-b11c60b29d92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaap_TaxesPayableCurrent_09c3afb8-38a1-4889-4c3b-0ee54f55be27" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:to="loc_us-gaap_TaxesPayableCurrent_09c3afb8-38a1-4889-4c3b-0ee54f55be27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_0ff25fd8-f6de-e7fa-c6c3-85d94f17f57b" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_0ff25fd8-f6de-e7fa-c6c3-85d94f17f57b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_8730cf6f-d6e3-789a-4435-85747cc6a847" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:to="loc_us-gaap_DebtCurrent_8730cf6f-d6e3-789a-4435-85747cc6a847" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_69e5de31-e379-3d10-54e1-db1271f781f0" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6d3ec995-5062-ef92-dd72-b570c1eafdc8" xlink:to="loc_us-gaap_LongTermDebt_69e5de31-e379-3d10-54e1-db1271f781f0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_3b38d8c3-335c-53c8-5510-f59766fb81d5" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6d3ec995-5062-ef92-dd72-b570c1eafdc8" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_3b38d8c3-335c-53c8-5510-f59766fb81d5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_b65887e3-1865-ef3e-c8ae-81780cbff9ee" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6d3ec995-5062-ef92-dd72-b570c1eafdc8" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_b65887e3-1865-ef3e-c8ae-81780cbff9ee" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:to="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_a5201305-cb63-d1e5-f4e7-e25409fb5d3a" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:to="loc_us-gaap_InventoryNet_a5201305-cb63-d1e5-f4e7-e25409fb5d3a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ec544f28-9c7b-137c-e428-9ae47c2375fc" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ec544f28-9c7b-137c-e428-9ae47c2375fc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesCurrent_30444800-bccf-94eb-16a7-6eb32a0bf8df" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesCurrent_30444800-bccf-94eb-16a7-6eb32a0bf8df" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_d28874fa-4543-5746-c91a-559d7ab47f77" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_d28874fa-4543-5746-c91a-559d7ab47f77" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_DueFromUnconsolidatedJointBusiness" xlink:label="loc_biib_DueFromUnconsolidatedJointBusiness_3e105e43-1819-e37b-45ec-7411f4eec456" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:to="loc_biib_DueFromUnconsolidatedJointBusiness_3e105e43-1819-e37b-45ec-7411f4eec456" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_fdb77e30-ba68-0e41-abc1-70858b11de5b" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:to="loc_us-gaap_OtherAssetsCurrent_fdb77e30-ba68-0e41-abc1-70858b11de5b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesNoncurrent_b3d12002-79e5-47db-0a4d-77b30be5f00c" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesNoncurrent_b3d12002-79e5-47db-0a4d-77b30be5f00c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_68e7c3c1-9b8d-84fe-3a5c-d69c15dfe7a2" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_68e7c3c1-9b8d-84fe-3a5c-d69c15dfe7a2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_27b15389-386a-f983-c189-731d6d3c3fbb" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_27b15389-386a-f983-c189-731d6d3c3fbb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_d723083e-f7a3-6d89-9926-32afaa010d8a" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:to="loc_us-gaap_Goodwill_d723083e-f7a3-6d89-9926-32afaa010d8a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_e6ade192-0839-bdd8-d08b-20387a0e8201" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_e6ade192-0839-bdd8-d08b-20387a0e8201" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_104af714-3829-5d79-3fb3-059f86c366da" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_104af714-3829-5d79-3fb3-059f86c366da" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_00a475d0-9ed4-5ca4-8e09-183f13a0aa46" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_ProfitLoss_00a475d0-9ed4-5ca4-8e09-183f13a0aa46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_b0d6e80b-2a71-4b3d-5167-6e414c6a123b" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_b0d6e80b-2a71-4b3d-5167-6e414c6a123b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_432488d8-28ca-5b8d-679b-29be120957b5" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_ShareBasedCompensation_432488d8-28ca-5b8d-679b-29be120957b5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_91674616-989d-90e8-1302-b52ff7a33098" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_91674616-989d-90e8-1302-b52ff7a33098" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_ef024267-fc04-b9fd-6e4e-38d399da963a" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_ef024267-fc04-b9fd-6e4e-38d399da963a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ffe19198-61f8-be6a-6111-42f645804604" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ffe19198-61f8-be6a-6111-42f645804604" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_fdbab275-b995-9f6e-4d30-38c2b0ed44dd" xlink:type="locator" />
    <link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_fdbab275-b995-9f6e-4d30-38c2b0ed44dd" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_bae7c33e-3fd3-413e-0f2e-aaa9daaa49d7" xlink:type="locator" />
    <link:calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_bae7c33e-3fd3-413e-0f2e-aaa9daaa49d7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_d8c0a214-0b0d-1fc8-686b-ed5eca49895f" xlink:type="locator" />
    <link:calculationArc order="9" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_d8c0a214-0b0d-1fc8-686b-ed5eca49895f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_ce728eee-c863-e8aa-a864-1d7a3b12d862" xlink:type="locator" />
    <link:calculationArc order="10" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_ce728eee-c863-e8aa-a864-1d7a3b12d862" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_7a016eeb-d472-4272-2fad-97e749a6fbc2" xlink:type="locator" />
    <link:calculationArc order="11" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_7a016eeb-d472-4272-2fad-97e749a6fbc2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_7141899e-1a56-24a9-9015-497ee51d7b39" xlink:type="locator" />
    <link:calculationArc order="12" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_7141899e-1a56-24a9-9015-497ee51d7b39" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_95f67350-d3ec-5d41-e3b2-a4fe7a19e15b" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_104af714-3829-5d79-3fb3-059f86c366da" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_95f67350-d3ec-5d41-e3b2-a4fe7a19e15b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_3d4b15de-b1bf-181b-e3f1-91381ce35d3d" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_95f67350-d3ec-5d41-e3b2-a4fe7a19e15b" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_3d4b15de-b1bf-181b-e3f1-91381ce35d3d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_c02ad689-0839-347f-dbb5-560ba41e6864" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_95f67350-d3ec-5d41-e3b2-a4fe7a19e15b" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_c02ad689-0839-347f-dbb5-560ba41e6864" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_c094319f-e455-d1ac-bba2-987bc5dff7e6" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_95f67350-d3ec-5d41-e3b2-a4fe7a19e15b" xlink:to="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_c094319f-e455-d1ac-bba2-987bc5dff7e6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_4a851329-dac2-753a-9238-81894caa8647" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_95f67350-d3ec-5d41-e3b2-a4fe7a19e15b" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_4a851329-dac2-753a-9238-81894caa8647" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_991d89e2-25f7-1061-f5f8-86acc91f176b" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_95f67350-d3ec-5d41-e3b2-a4fe7a19e15b" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_991d89e2-25f7-1061-f5f8-86acc91f176b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_fd30e334-9842-e274-9b27-bbbf9eeb6080" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_95f67350-d3ec-5d41-e3b2-a4fe7a19e15b" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_fd30e334-9842-e274-9b27-bbbf9eeb6080" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_f727506e-917a-c7f2-effd-742269ec6604" xlink:type="locator" />
    <link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_95f67350-d3ec-5d41-e3b2-a4fe7a19e15b" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_f727506e-917a-c7f2-effd-742269ec6604" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08614f0c-c3a2-4c92-7c1d-aed5de18fe70" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_104af714-3829-5d79-3fb3-059f86c366da" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08614f0c-c3a2-4c92-7c1d-aed5de18fe70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_fc2ca57d-dc62-7ce6-b2c4-25896bddd1fc" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08614f0c-c3a2-4c92-7c1d-aed5de18fe70" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_fc2ca57d-dc62-7ce6-b2c4-25896bddd1fc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_c1508a6a-babd-3ec7-9349-b4d44aab4c91" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08614f0c-c3a2-4c92-7c1d-aed5de18fe70" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_c1508a6a-babd-3ec7-9349-b4d44aab4c91" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_44a700f6-fd76-d81b-18cc-566e56087517" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08614f0c-c3a2-4c92-7c1d-aed5de18fe70" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_44a700f6-fd76-d81b-18cc-566e56087517" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaap_RepaymentsOfDebt_7deebd9e-3e56-a0b1-a928-708a4a76b360" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08614f0c-c3a2-4c92-7c1d-aed5de18fe70" xlink:to="loc_us-gaap_RepaymentsOfDebt_7deebd9e-3e56-a0b1-a928-708a4a76b360" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities" xlink:label="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities_11b1e641-cd86-3d66-b07d-893757bffb5e" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08614f0c-c3a2-4c92-7c1d-aed5de18fe70" xlink:to="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities_11b1e641-cd86-3d66-b07d-893757bffb5e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_4bfb598c-5b20-1fea-5801-a6da79e5a964" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08614f0c-c3a2-4c92-7c1d-aed5de18fe70" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_4bfb598c-5b20-1fea-5801-a6da79e5a964" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_7e341d9c-b561-17b2-6b84-9236041ffef0" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08614f0c-c3a2-4c92-7c1d-aed5de18fe70" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_7e341d9c-b561-17b2-6b84-9236041ffef0" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ConsolidatedStatementsOfComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_d23b2d61-1407-f3f5-ba7b-69860a5b50dd" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_663a641c-b103-1e10-d3ec-c078ec7a031b" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_d23b2d61-1407-f3f5-ba7b-69860a5b50dd" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_663a641c-b103-1e10-d3ec-c078ec7a031b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_663a641c-b103-1e10-d3ec-c078ec7a031b" xlink:to="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_fc027bcf-19a3-7936-be65-3ec1deb94fb4" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_663a641c-b103-1e10-d3ec-c078ec7a031b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_fc027bcf-19a3-7936-be65-3ec1deb94fb4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_0f105a40-393d-896e-47b8-344549074b13" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_fc027bcf-19a3-7936-be65-3ec1deb94fb4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_0f105a40-393d-896e-47b8-344549074b13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_045a7791-44b8-d416-a735-af6ac83e7eb3" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_0f105a40-393d-896e-47b8-344549074b13" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_045a7791-44b8-d416-a735-af6ac83e7eb3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_2295fde9-6004-04c5-d6d3-8f045ad42e78" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_0f105a40-393d-896e-47b8-344549074b13" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_2295fde9-6004-04c5-d6d3-8f045ad42e78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_7888ca55-4b2a-9f3e-262a-d47103cbdac1" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_fc027bcf-19a3-7936-be65-3ec1deb94fb4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_7888ca55-4b2a-9f3e-262a-d47103cbdac1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax_d9de8ce9-57ed-333b-718c-8618608550c0" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_7888ca55-4b2a-9f3e-262a-d47103cbdac1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax_d9de8ce9-57ed-333b-718c-8618608550c0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax_767808f1-67e4-3a9e-d369-91823cb4cb6e" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_7888ca55-4b2a-9f3e-262a-d47103cbdac1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax_767808f1-67e4-3a9e-d369-91823cb4cb6e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_d8bc96e3-060f-f5ff-d324-c7cecf3273f4" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_fc027bcf-19a3-7936-be65-3ec1deb94fb4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_d8bc96e3-060f-f5ff-d324-c7cecf3273f4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_7263cb18-5b58-9955-8575-e8eaa5dac989" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_fc027bcf-19a3-7936-be65-3ec1deb94fb4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_7263cb18-5b58-9955-8575-e8eaa5dac989" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_eddbf4fa-a79b-3699-85e9-ca7ce5eef536" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_d23b2d61-1407-f3f5-ba7b-69860a5b50dd" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_eddbf4fa-a79b-3699-85e9-ca7ce5eef536" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ConsolidatedStatementsOfEquity" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ConsolidatedStatementsOfIncome" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_00a475d0-9ed4-5ca4-8e09-183f13a0aa46" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:to="loc_us-gaap_ProfitLoss_00a475d0-9ed4-5ca4-8e09-183f13a0aa46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_5ba85eae-c4c2-72cc-f9e5-b0edc41783e5" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_00a475d0-9ed4-5ca4-8e09-183f13a0aa46" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_5ba85eae-c4c2-72cc-f9e5-b0edc41783e5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_800dbb3e-0416-e0ab-a30e-cfaeb17b8c4c" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_5ba85eae-c4c2-72cc-f9e5-b0edc41783e5" xlink:to="loc_us-gaap_OperatingIncomeLoss_800dbb3e-0416-e0ab-a30e-cfaeb17b8c4c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_4ce4747e-ba05-83d9-3458-6f9d1635c2ec" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_800dbb3e-0416-e0ab-a30e-cfaeb17b8c4c" xlink:to="loc_us-gaap_Revenues_4ce4747e-ba05-83d9-3458-6f9d1635c2ec" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_dec93aa4-b03e-3954-a272-eeb250ead290" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_4ce4747e-ba05-83d9-3458-6f9d1635c2ec" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_dec93aa4-b03e-3954-a272-eeb250ead290" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_RevenuesfromantiCD20therapeuticprograms" xlink:label="loc_biib_RevenuesfromantiCD20therapeuticprograms_ccb7b808-8f93-67cc-494d-bd9e53d6ff0a" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_4ce4747e-ba05-83d9-3458-6f9d1635c2ec" xlink:to="loc_biib_RevenuesfromantiCD20therapeuticprograms_ccb7b808-8f93-67cc-494d-bd9e53d6ff0a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherSalesRevenueNet" xlink:label="loc_us-gaap_OtherSalesRevenueNet_888a521b-fa37-b5b1-8e28-b2ce12b7ced6" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_4ce4747e-ba05-83d9-3458-6f9d1635c2ec" xlink:to="loc_us-gaap_OtherSalesRevenueNet_888a521b-fa37-b5b1-8e28-b2ce12b7ced6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_ba9c144a-a131-2335-7bef-6a9a2f344885" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_800dbb3e-0416-e0ab-a30e-cfaeb17b8c4c" xlink:to="loc_us-gaap_CostsAndExpenses_ba9c144a-a131-2335-7bef-6a9a2f344885" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_us-gaap_CostOfGoodsSold_758fda00-4ec6-2a1a-3601-b22661c1a7ff" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_ba9c144a-a131-2335-7bef-6a9a2f344885" xlink:to="loc_us-gaap_CostOfGoodsSold_758fda00-4ec6-2a1a-3601-b22661c1a7ff" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_c100c3d5-921a-ee55-568b-f12db1e8f91f" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_ba9c144a-a131-2335-7bef-6a9a2f344885" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_c100c3d5-921a-ee55-568b-f12db1e8f91f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_33158828-aa18-5ead-beab-c284c08cb606" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_ba9c144a-a131-2335-7bef-6a9a2f344885" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_33158828-aa18-5ead-beab-c284c08cb606" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_45782c94-912f-fb4e-76bf-199e35f3c27b" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_ba9c144a-a131-2335-7bef-6a9a2f344885" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_45782c94-912f-fb4e-76bf-199e35f3c27b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_08c2928f-d1d5-f97a-10aa-389716958b98" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_ba9c144a-a131-2335-7bef-6a9a2f344885" xlink:to="loc_us-gaap_RestructuringCharges_08c2928f-d1d5-f97a-10aa-389716958b98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_01f2b122-3157-76d4-112e-c7b272fecbb3" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_ba9c144a-a131-2335-7bef-6a9a2f344885" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_01f2b122-3157-76d4-112e-c7b272fecbb3" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_CollaborationProfitSharing" xlink:label="loc_biib_CollaborationProfitSharing_b5072886-56d1-7b23-2dcb-7411f8ca9edd" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_ba9c144a-a131-2335-7bef-6a9a2f344885" xlink:to="loc_biib_CollaborationProfitSharing_b5072886-56d1-7b23-2dcb-7411f8ca9edd" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationSettlementExpense" xlink:label="loc_us-gaap_LitigationSettlementExpense_8544f683-c313-b777-1cd9-9892732f0a30" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_ba9c144a-a131-2335-7bef-6a9a2f344885" xlink:to="loc_us-gaap_LitigationSettlementExpense_8544f683-c313-b777-1cd9-9892732f0a30" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_GainOnSaleOfRights" xlink:label="loc_biib_GainOnSaleOfRights_d0e38a11-b0dd-f65a-bf9f-bd9e5508e240" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_800dbb3e-0416-e0ab-a30e-cfaeb17b8c4c" xlink:to="loc_biib_GainOnSaleOfRights_d0e38a11-b0dd-f65a-bf9f-bd9e5508e240" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_b936f21a-1a1f-465e-d82c-5e014c9c5399" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_5ba85eae-c4c2-72cc-f9e5-b0edc41783e5" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_b936f21a-1a1f-465e-d82c-5e014c9c5399" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_9b166675-b7b2-1067-1806-03b1ee0126f1" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_00a475d0-9ed4-5ca4-8e09-183f13a0aa46" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_9b166675-b7b2-1067-1806-03b1ee0126f1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_359134c0-3512-0437-07c4-28574636fc79" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_00a475d0-9ed4-5ca4-8e09-183f13a0aa46" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_359134c0-3512-0437-07c4-28574636fc79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_57932a93-02bc-f4e7-4538-5a7fc65a1b5b" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_57932a93-02bc-f4e7-4538-5a7fc65a1b5b" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstruments" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsDetails1" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EarningsPerShare" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ae404dc0-76bc-cd1d-811f-e233c07e0569" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e841a58a-f12e-0adc-36de-0299a43719a9" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ae404dc0-76bc-cd1d-811f-e233c07e0569" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e841a58a-f12e-0adc-36de-0299a43719a9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_e24f9d55-d9ef-3f95-c65d-cbc9febefcb3" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ae404dc0-76bc-cd1d-811f-e233c07e0569" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_e24f9d55-d9ef-3f95-c65d-cbc9febefcb3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_9dba38ce-5067-b4c4-09f7-0cf74e4693de" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_e24f9d55-d9ef-3f95-c65d-cbc9febefcb3" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_9dba38ce-5067-b4c4-09f7-0cf74e4693de" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EarningsPerShareTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EmployeeBenefitPlans" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EmployeeBenefitPlansDetails1" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EmployeeBenefitPlansEmployeeBenefitPlansDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/Equity" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EquityDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EquityDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EquityTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurements" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_4f567ef5-b8d7-6688-bab2-00271c822568" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_794fc482-f400-6856-2d15-b80c897f0bac" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_4f567ef5-b8d7-6688-bab2-00271c822568" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_794fc482-f400-6856-2d15-b80c897f0bac" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_e5ea9848-5ffb-0a59-3b02-d214338777c4" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_4f567ef5-b8d7-6688-bab2-00271c822568" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_e5ea9848-5ffb-0a59-3b02-d214338777c4" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstruments" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_bca7edb8-274e-a972-85d8-811b7da33e90" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_64878df4-a4bb-ba61-aacb-ed249b31f694" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_bca7edb8-274e-a972-85d8-811b7da33e90" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_64878df4-a4bb-ba61-aacb-ed249b31f694" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_59295b7e-c316-eccf-27db-e84d9ca58730" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_bca7edb8-274e-a972-85d8-811b7da33e90" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_59295b7e-c316-eccf-27db-e84d9ca58730" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_74826df9-1290-2e5d-1476-bd9e533dee23" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_bca7edb8-274e-a972-85d8-811b7da33e90" xlink:to="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_74826df9-1290-2e5d-1476-bd9e533dee23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_01be169b-08cc-7c30-55f5-941791d17ef8" xlink:type="locator" />
    <link:loc xlink:href="biib-20161231.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_3913e100-ff62-4129-cd9e-bd9e557cbc90" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecurities_01be169b-08cc-7c30-55f5-941791d17ef8" xlink:to="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_3913e100-ff62-4129-cd9e-bd9e557cbc90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_db3b580e-d182-4945-7c2e-ce877e78a106" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecurities_01be169b-08cc-7c30-55f5-941791d17ef8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_db3b580e-d182-4945-7c2e-ce877e78a106" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_73f419d8-d119-3f34-15a6-338e4455cd96" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecurities_01be169b-08cc-7c30-55f5-941791d17ef8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_73f419d8-d119-3f34-15a6-338e4455cd96" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual1" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual2" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/Guarantees" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxes" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_5ba85eae-c4c2-72cc-f9e5-b0edc41783e5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_1681e6de-4e66-20b4-2a19-d146b2f65c02" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_5ba85eae-c4c2-72cc-f9e5-b0edc41783e5" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_1681e6de-4e66-20b4-2a19-d146b2f65c02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_a0805b6e-967d-7844-2bfa-2e63ee48cdb6" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_5ba85eae-c4c2-72cc-f9e5-b0edc41783e5" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_a0805b6e-967d-7844-2bfa-2e63ee48cdb6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_9b166675-b7b2-1067-1806-03b1ee0126f1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_7107f7ad-ea23-072c-c2a3-7b97b29553fc" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_9b166675-b7b2-1067-1806-03b1ee0126f1" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_7107f7ad-ea23-072c-c2a3-7b97b29553fc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_b8476f99-9bab-21a6-d61d-02a9c0661176" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_7107f7ad-ea23-072c-c2a3-7b97b29553fc" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_b8476f99-9bab-21a6-d61d-02a9c0661176" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_3ab57836-244f-310a-5a92-cb6b846a6a17" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_7107f7ad-ea23-072c-c2a3-7b97b29553fc" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_3ab57836-244f-310a-5a92-cb6b846a6a17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_4ecf0d1c-66f0-0be9-cfb9-ecdef8184a9e" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_7107f7ad-ea23-072c-c2a3-7b97b29553fc" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_4ecf0d1c-66f0-0be9-cfb9-ecdef8184a9e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_91674616-989d-90e8-1302-b52ff7a33098" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_9b166675-b7b2-1067-1806-03b1ee0126f1" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_91674616-989d-90e8-1302-b52ff7a33098" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_f316d4eb-12c7-f1d0-fd3d-ba8b892345ca" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_91674616-989d-90e8-1302-b52ff7a33098" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_f316d4eb-12c7-f1d0-fd3d-ba8b892345ca" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_88730b7a-f2f4-51cb-d8a1-7a903025ce13" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_91674616-989d-90e8-1302-b52ff7a33098" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_88730b7a-f2f4-51cb-d8a1-7a903025ce13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_79489ccf-36b3-815d-b6db-f2a6ac50099c" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_91674616-989d-90e8-1302-b52ff7a33098" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_79489ccf-36b3-815d-b6db-f2a6ac50099c" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_f549ecdb-d466-ac37-840e-8410ff9e5017" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_fa726c85-83ac-b28f-66e2-0281dd3b7026" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_f549ecdb-d466-ac37-840e-8410ff9e5017" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_fa726c85-83ac-b28f-66e2-0281dd3b7026" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_DeferredTaxLiabilitiesDepreciationAmortizationOther" xlink:label="loc_biib_DeferredTaxLiabilitiesDepreciationAmortizationOther_bdf1b380-7319-b8f7-a7cc-7411f904ab47" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_f549ecdb-d466-ac37-840e-8410ff9e5017" xlink:to="loc_biib_DeferredTaxLiabilitiesDepreciationAmortizationOther_bdf1b380-7319-b8f7-a7cc-7411f904ab47" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_dad43eb1-2d05-8e6b-1503-6a61e00404ca" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_f1177a25-1e80-13fd-0827-beddb4de2232" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_dad43eb1-2d05-8e6b-1503-6a61e00404ca" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_f1177a25-1e80-13fd-0827-beddb4de2232" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_8b88b249-eaff-c7db-3189-f3f8348e1a59" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_dad43eb1-2d05-8e6b-1503-6a61e00404ca" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_8b88b249-eaff-c7db-3189-f3f8348e1a59" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_9086bb49-e21d-2fdd-c7ce-32e56ffef9d8" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_dad43eb1-2d05-8e6b-1503-6a61e00404ca" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_9086bb49-e21d-2fdd-c7ce-32e56ffef9d8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_6826a434-0eba-a280-99df-92eaa6c3f055" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_dad43eb1-2d05-8e6b-1503-6a61e00404ca" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_6826a434-0eba-a280-99df-92eaa6c3f055" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_87cdbec2-773d-bc5a-3050-f979513ecb7f" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_dad43eb1-2d05-8e6b-1503-6a61e00404ca" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_87cdbec2-773d-bc5a-3050-f979513ecb7f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_bdc6598b-bd97-4cc7-9f4f-5d5ac82ed0ed" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_dad43eb1-2d05-8e6b-1503-6a61e00404ca" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_bdc6598b-bd97-4cc7-9f4f-5d5ac82ed0ed" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_36eb2c32-e98d-f713-df5d-5d9e7e50b88d" xlink:type="locator" />
    <link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_dad43eb1-2d05-8e6b-1503-6a61e00404ca" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_36eb2c32-e98d-f713-df5d-5d9e7e50b88d" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_9d686b75-f9ca-45e9-dcb7-a314128deba9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_8e6be169-09a9-5661-71bb-cb6bce1f56f7" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_9d686b75-f9ca-45e9-dcb7-a314128deba9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_8e6be169-09a9-5661-71bb-cb6bce1f56f7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_a476c969-d3fd-cf02-0d56-ac5fad2f8a34" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_9d686b75-f9ca-45e9-dcb7-a314128deba9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_a476c969-d3fd-cf02-0d56-ac5fad2f8a34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_592bc0e7-9233-a559-98bd-046511cfe2a6" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_9d686b75-f9ca-45e9-dcb7-a314128deba9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_592bc0e7-9233-a559-98bd-046511cfe2a6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_0d763afc-4281-0204-2391-400c96ae6714" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_9d686b75-f9ca-45e9-dcb7-a314128deba9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_0d763afc-4281-0204-2391-400c96ae6714" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_854996b2-91af-6409-f56d-aae3ba36eff1" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_9d686b75-f9ca-45e9-dcb7-a314128deba9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_854996b2-91af-6409-f56d-aae3ba36eff1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_56e289e1-500c-c77f-97ba-e406a6be2593" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_9d686b75-f9ca-45e9-dcb7-a314128deba9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_56e289e1-500c-c77f-97ba-e406a6be2593" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_EffectiveIncomeTaxRateReconciliationContingentConsideration" xlink:label="loc_biib_EffectiveIncomeTaxRateReconciliationContingentConsideration_eb6a0d4e-1ec1-3d72-fdc0-7411f8a7920a" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_9d686b75-f9ca-45e9-dcb7-a314128deba9" xlink:to="loc_biib_EffectiveIncomeTaxRateReconciliationContingentConsideration_eb6a0d4e-1ec1-3d72-fdc0-7411f8a7920a" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction" xlink:label="loc_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_72b442ab-dd2f-23d7-ec24-bd9e533c7d55" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_9d686b75-f9ca-45e9-dcb7-a314128deba9" xlink:to="loc_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_72b442ab-dd2f-23d7-ec24-bd9e533c7d55" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails3" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/Indebtedness" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IndebtednessDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IndebtednessDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaap_LongTermNotesPayable_1a54c9c9-504a-3600-d358-4e7e40235d41" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_be4c6cb2-c102-b108-bfb6-0404d740f001" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermNotesPayable_1a54c9c9-504a-3600-d358-4e7e40235d41" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_be4c6cb2-c102-b108-bfb6-0404d740f001" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_fff555d3-22e2-1be9-15a7-f79f0064a4bb" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermNotesPayable_1a54c9c9-504a-3600-d358-4e7e40235d41" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_fff555d3-22e2-1be9-15a7-f79f0064a4bb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_c5420c55-b70f-9186-5b0e-88de7d1b3712" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermNotesPayable_1a54c9c9-504a-3600-d358-4e7e40235d41" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_c5420c55-b70f-9186-5b0e-88de7d1b3712" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_7b82936a-3efa-d722-acea-fbe08d94cdb3" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermNotesPayable_1a54c9c9-504a-3600-d358-4e7e40235d41" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_7b82936a-3efa-d722-acea-fbe08d94cdb3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_6231296c-2b9b-a710-fe01-a01a31f4eeb8" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermNotesPayable_1a54c9c9-504a-3600-d358-4e7e40235d41" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_6231296c-2b9b-a710-fe01-a01a31f4eeb8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_4ce000ca-0272-5539-8854-56410906b97f" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermNotesPayable_1a54c9c9-504a-3600-d358-4e7e40235d41" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_4ce000ca-0272-5539-8854-56410906b97f" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IndebtednessDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IndebtednessTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_70724be1-cf82-e50d-0cc7-fa6194f78b70" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_7ea689db-170d-242a-aadc-096d31f6a174" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_70724be1-cf82-e50d-0cc7-fa6194f78b70" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_7ea689db-170d-242a-aadc-096d31f6a174" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_d981c90e-1b35-63c2-c258-b2af7bf5b3e0" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_70724be1-cf82-e50d-0cc7-fa6194f78b70" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_d981c90e-1b35-63c2-c258-b2af7bf5b3e0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_20da5796-2b47-ef11-689a-589894b52fb4" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_70724be1-cf82-e50d-0cc7-fa6194f78b70" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_20da5796-2b47-ef11-689a-589894b52fb4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_27b15389-386a-f983-c189-731d6d3c3fbb" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_2497ccf0-783f-7384-a80c-38649f384646" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_27b15389-386a-f983-c189-731d6d3c3fbb" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_2497ccf0-783f-7384-a80c-38649f384646" xlink:type="arc" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_27b15389-386a-f983-c189-731d6d3c3fbb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_d981c90e-1b35-63c2-c258-b2af7bf5b3e0" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/Inventory" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:href="biib-20161231.xsd#biib_Inventorynetcurrentandnoncurrent" xlink:label="loc_biib_Inventorynetcurrentandnoncurrent_68666644-b813-08f4-eca9-be4209690838" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_5e2f7e41-cc2d-1880-9908-a0f60d8dacca" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_Inventorynetcurrentandnoncurrent_68666644-b813-08f4-eca9-be4209690838" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_5e2f7e41-cc2d-1880-9908-a0f60d8dacca" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_7b711a15-f1f0-530a-4653-51844577a7f7" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_Inventorynetcurrentandnoncurrent_68666644-b813-08f4-eca9-be4209690838" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_7b711a15-f1f0-530a-4653-51844577a7f7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_f925ebd3-061a-e984-2203-e9a7cc583900" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_Inventorynetcurrentandnoncurrent_68666644-b813-08f4-eca9-be4209690838" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_f925ebd3-061a-e984-2203-e9a7cc583900" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/InventoryDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/InventoryTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/Litigation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/LitigationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_b936f21a-1a1f-465e-d82c-5e014c9c5399" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_ed735562-dfa2-f50c-cfbd-c90d6a562718" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_b936f21a-1a1f-465e-d82c-5e014c9c5399" xlink:to="loc_us-gaap_InvestmentIncomeInterest_ed735562-dfa2-f50c-cfbd-c90d6a562718" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_4b6ddf50-6253-3349-fa29-8fc77f744f58" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_b936f21a-1a1f-465e-d82c-5e014c9c5399" xlink:to="loc_us-gaap_InterestExpense_4b6ddf50-6253-3349-fa29-8fc77f744f58" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnSaleOfInvestments" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments_72f8dbcf-d3e6-9f03-ee3e-0ffce77f6746" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_b936f21a-1a1f-465e-d82c-5e014c9c5399" xlink:to="loc_us-gaap_GainLossOnSaleOfInvestments_72f8dbcf-d3e6-9f03-ee3e-0ffce77f6746" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_8bd26a17-2466-c9ca-826d-1c7167e5c7f9" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_b936f21a-1a1f-465e-d82c-5e014c9c5399" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_8bd26a17-2466-c9ca-826d-1c7167e5c7f9" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_OtherIncomeExpenseNet" xlink:label="loc_biib_OtherIncomeExpenseNet_29cc14b5-c693-8a7c-4835-7411f8aef2ea" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_b936f21a-1a1f-465e-d82c-5e014c9c5399" xlink:to="loc_biib_OtherIncomeExpenseNet_29cc14b5-c693-8a7c-4835-7411f8aef2ea" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_0ff25fd8-f6de-e7fa-c6c3-85d94f17f57b" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_e33aee43-c0e5-8860-8918-3d1a7a9d15e4" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_0ff25fd8-f6de-e7fa-c6c3-85d94f17f57b" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_e33aee43-c0e5-8860-8918-3d1a7a9d15e4" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipment" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_68e7c3c1-9b8d-84fe-3a5c-d69c15dfe7a2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_8c99d26c-e257-b8ba-86ee-4f792a9452ce" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_68e7c3c1-9b8d-84fe-3a5c-d69c15dfe7a2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_8c99d26c-e257-b8ba-86ee-4f792a9452ce" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Land" xlink:label="loc_us-gaap_Land_667d1a41-669f-3aab-72f7-e84c123c2e4e" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_8c99d26c-e257-b8ba-86ee-4f792a9452ce" xlink:to="loc_us-gaap_Land_667d1a41-669f-3aab-72f7-e84c123c2e4e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BuildingsAndImprovementsGross" xlink:label="loc_us-gaap_BuildingsAndImprovementsGross_d9fefc5a-548b-350e-f762-77b33f08d379" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_8c99d26c-e257-b8ba-86ee-4f792a9452ce" xlink:to="loc_us-gaap_BuildingsAndImprovementsGross_d9fefc5a-548b-350e-f762-77b33f08d379" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="loc_us-gaap_LeaseholdImprovementsGross_b8b5e24d-4f2b-947a-b2e9-4e7f6d8ed99e" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_8c99d26c-e257-b8ba-86ee-4f792a9452ce" xlink:to="loc_us-gaap_LeaseholdImprovementsGross_b8b5e24d-4f2b-947a-b2e9-4e7f6d8ed99e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MachineryAndEquipmentGross" xlink:label="loc_us-gaap_MachineryAndEquipmentGross_4e601ab2-1dbc-5423-fb86-c88684959076" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_8c99d26c-e257-b8ba-86ee-4f792a9452ce" xlink:to="loc_us-gaap_MachineryAndEquipmentGross_4e601ab2-1dbc-5423-fb86-c88684959076" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ComputerSoftwareAndHardware" xlink:label="loc_biib_ComputerSoftwareAndHardware_46f13f8f-1da3-bdca-f2ec-7411f57988ae" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_8c99d26c-e257-b8ba-86ee-4f792a9452ce" xlink:to="loc_biib_ComputerSoftwareAndHardware_46f13f8f-1da3-bdca-f2ec-7411f57988ae" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FurnitureAndFixturesGross" xlink:label="loc_us-gaap_FurnitureAndFixturesGross_8a7add33-d764-1525-b16a-1946a4946e85" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_8c99d26c-e257-b8ba-86ee-4f792a9452ce" xlink:to="loc_us-gaap_FurnitureAndFixturesGross_8a7add33-d764-1525-b16a-1946a4946e85" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConstructionInProgressGross" xlink:label="loc_us-gaap_ConstructionInProgressGross_f5c6dffb-00d4-b12e-a7e2-d03265a1fd19" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_8c99d26c-e257-b8ba-86ee-4f792a9452ce" xlink:to="loc_us-gaap_ConstructionInProgressGross_f5c6dffb-00d4-b12e-a7e2-d03265a1fd19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_95ebcb07-1c4a-1ded-365f-edc9cd2fa101" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_68e7c3c1-9b8d-84fe-3a5c-d69c15dfe7a2" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_95ebcb07-1c4a-1ded-365f-edc9cd2fa101" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/QuarterlyFinancialDataUnaudited" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/RestructuringRestructuring" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/RestructuringRestructuringDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/RestructuringRestructuringDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/RestructuringRestructuringTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/RevenueReserves" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/RevenueReservesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/RevenueReservesDetails1" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/RevenueReservesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/SegmentInformation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/SegmentInformationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/SegmentInformationDetails1" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/SegmentInformationDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/SegmentInformationTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPayments" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:type="extended">
    <link:loc xlink:href="biib-20161231.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_44ed1d14-371c-5f9d-c158-bd9e537d91ca" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_7a3e2b9e-239b-1138-f935-4aa4335a528f" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_44ed1d14-371c-5f9d-c158-bd9e537d91ca" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_7a3e2b9e-239b-1138-f935-4aa4335a528f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_cd8f1afb-536b-0ff3-edb0-41d6faa7aebc" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_44ed1d14-371c-5f9d-c158-bd9e537d91ca" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_cd8f1afb-536b-0ff3-edb0-41d6faa7aebc" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails2" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails3" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails4" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails5" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails6" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails8" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails9" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedPaymentsDetails7" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/SubsequentEventsNotes" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>biib-20161231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLoss" xlink:href="biib-20161231.xsd#AccumulatedOtherComprehensiveIncomeLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:href="biib-20161231.xsd#AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails1" xlink:href="biib-20161231.xsd#AccumulatedOtherComprehensiveIncomeLossDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:href="biib-20161231.xsd#AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Acquisitions" xlink:href="biib-20161231.xsd#Acquisitions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsAcquisitionsDetails" xlink:href="biib-20161231.xsd#AcquisitionsAcquisitionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsAcquisitionsDetails1" xlink:href="biib-20161231.xsd#AcquisitionsAcquisitionsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsAcquisitionsTables" xlink:href="biib-20161231.xsd#AcquisitionsAcquisitionsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsDetailsTextual" xlink:href="biib-20161231.xsd#AcquisitionsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships" xlink:href="biib-20161231.xsd#CollaborativeAndOtherRelationships" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsDetails3" xlink:href="biib-20161231.xsd#CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetails" xlink:href="biib-20161231.xsd#CollaborativeAndOtherRelationshipsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetails1" xlink:href="biib-20161231.xsd#CollaborativeAndOtherRelationshipsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetails2" xlink:href="biib-20161231.xsd#CollaborativeAndOtherRelationshipsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual" xlink:href="biib-20161231.xsd#CollaborativeAndOtherRelationshipsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables" xlink:href="biib-20161231.xsd#CollaborativeAndOtherRelationshipsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CommitmentsAndContingencies" xlink:href="biib-20161231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CommitmentsAndContingenciesCommitmentsAndContingenciesDetails1" xlink:href="biib-20161231.xsd#CommitmentsAndContingenciesCommitmentsAndContingenciesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CommitmentsAndContingenciesDetails" xlink:href="biib-20161231.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CommitmentsAndContingenciesDetailsTextual" xlink:href="biib-20161231.xsd#CommitmentsAndContingenciesDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CommitmentsAndContingenciesTables" xlink:href="biib-20161231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedBalanceSheets" xlink:href="biib-20161231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="biib-20161231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="biib-20161231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsOfComprehensiveIncome" xlink:href="biib-20161231.xsd#ConsolidatedStatementsOfComprehensiveIncome" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsOfEquity" xlink:href="biib-20161231.xsd#ConsolidatedStatementsOfEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsOfIncome" xlink:href="biib-20161231.xsd#ConsolidatedStatementsOfIncome" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstruments" xlink:href="biib-20161231.xsd#DerivativeInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:href="biib-20161231.xsd#DerivativeInstrumentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails1" xlink:href="biib-20161231.xsd#DerivativeInstrumentsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetailsTextual" xlink:href="biib-20161231.xsd#DerivativeInstrumentsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:href="biib-20161231.xsd#DerivativeInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DocumentAndEntityInformation" xlink:href="biib-20161231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShare" xlink:href="biib-20161231.xsd#EarningsPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShareDetails" xlink:href="biib-20161231.xsd#EarningsPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShareTables" xlink:href="biib-20161231.xsd#EarningsPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EmployeeBenefitPlans" xlink:href="biib-20161231.xsd#EmployeeBenefitPlans" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EmployeeBenefitPlansDetails1" xlink:href="biib-20161231.xsd#EmployeeBenefitPlansDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EmployeeBenefitPlansEmployeeBenefitPlansDetails" xlink:href="biib-20161231.xsd#EmployeeBenefitPlansEmployeeBenefitPlansDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Equity" xlink:href="biib-20161231.xsd#Equity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityDetails" xlink:href="biib-20161231.xsd#EquityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityDetailsTextual" xlink:href="biib-20161231.xsd#EquityDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityTables" xlink:href="biib-20161231.xsd#EquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurements" xlink:href="biib-20161231.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:href="biib-20161231.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:href="biib-20161231.xsd#FairValueMeasurementsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:href="biib-20161231.xsd#FairValueMeasurementsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:href="biib-20161231.xsd#FairValueMeasurementsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:href="biib-20161231.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstruments" xlink:href="biib-20161231.xsd#FinancialInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:href="biib-20161231.xsd#FinancialInstrumentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:href="biib-20161231.xsd#FinancialInstrumentsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:href="biib-20161231.xsd#FinancialInstrumentsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:href="biib-20161231.xsd#FinancialInstrumentsDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual1" xlink:href="biib-20161231.xsd#FinancialInstrumentsDetailsTextual1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual2" xlink:href="biib-20161231.xsd#FinancialInstrumentsDetailsTextual2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:href="biib-20161231.xsd#FinancialInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Guarantees" xlink:href="biib-20161231.xsd#Guarantees" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxes" xlink:href="biib-20161231.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:href="biib-20161231.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails1" xlink:href="biib-20161231.xsd#IncomeTaxesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails2" xlink:href="biib-20161231.xsd#IncomeTaxesDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails3" xlink:href="biib-20161231.xsd#IncomeTaxesDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:href="biib-20161231.xsd#IncomeTaxesDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:href="biib-20161231.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Indebtedness" xlink:href="biib-20161231.xsd#Indebtedness" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessDetails" xlink:href="biib-20161231.xsd#IndebtednessDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessDetails1" xlink:href="biib-20161231.xsd#IndebtednessDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessDetailsTextual" xlink:href="biib-20161231.xsd#IndebtednessDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessTables" xlink:href="biib-20161231.xsd#IndebtednessTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill" xlink:href="biib-20161231.xsd#IntangibleAssetsAndGoodwill" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails" xlink:href="biib-20161231.xsd#IntangibleAssetsAndGoodwillDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:href="biib-20161231.xsd#IntangibleAssetsAndGoodwillDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables" xlink:href="biib-20161231.xsd#IntangibleAssetsAndGoodwillTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Inventory" xlink:href="biib-20161231.xsd#Inventory" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryDetails" xlink:href="biib-20161231.xsd#InventoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryDetailsTextual" xlink:href="biib-20161231.xsd#InventoryDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryTables" xlink:href="biib-20161231.xsd#InventoryTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities" xlink:href="biib-20161231.xsd#InvestmentsInVariableInterestEntities" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails" xlink:href="biib-20161231.xsd#InvestmentsInVariableInterestEntitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Litigation" xlink:href="biib-20161231.xsd#Litigation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/LitigationDetails" xlink:href="biib-20161231.xsd#LitigationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:href="biib-20161231.xsd#OtherConsolidatedFinancialStatementDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:href="biib-20161231.xsd#OtherConsolidatedFinancialStatementDetailDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetailsTextual" xlink:href="biib-20161231.xsd#OtherConsolidatedFinancialStatementDetailDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:href="biib-20161231.xsd#OtherConsolidatedFinancialStatementDetailTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipment" xlink:href="biib-20161231.xsd#PropertyPlantAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails" xlink:href="biib-20161231.xsd#PropertyPlantAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetailsTextual" xlink:href="biib-20161231.xsd#PropertyPlantAndEquipmentDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentTables" xlink:href="biib-20161231.xsd#PropertyPlantAndEquipmentTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/QuarterlyFinancialDataUnaudited" xlink:href="biib-20161231.xsd#QuarterlyFinancialDataUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetails" xlink:href="biib-20161231.xsd#QuarterlyFinancialDataUnauditedDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetailsTextual" xlink:href="biib-20161231.xsd#QuarterlyFinancialDataUnauditedDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedTables" xlink:href="biib-20161231.xsd#QuarterlyFinancialDataUnauditedTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RestructuringRestructuring" xlink:href="biib-20161231.xsd#RestructuringRestructuring" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RestructuringRestructuringDetails" xlink:href="biib-20161231.xsd#RestructuringRestructuringDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RestructuringRestructuringDetailsTextual" xlink:href="biib-20161231.xsd#RestructuringRestructuringDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RestructuringRestructuringTables" xlink:href="biib-20161231.xsd#RestructuringRestructuringTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenueReserves" xlink:href="biib-20161231.xsd#RevenueReserves" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenueReservesDetails" xlink:href="biib-20161231.xsd#RevenueReservesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenueReservesDetails1" xlink:href="biib-20161231.xsd#RevenueReservesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenueReservesTables" xlink:href="biib-20161231.xsd#RevenueReservesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SegmentInformation" xlink:href="biib-20161231.xsd#SegmentInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SegmentInformationDetails" xlink:href="biib-20161231.xsd#SegmentInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SegmentInformationDetails1" xlink:href="biib-20161231.xsd#SegmentInformationDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SegmentInformationDetailsTextual" xlink:href="biib-20161231.xsd#SegmentInformationDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SegmentInformationTables" xlink:href="biib-20161231.xsd#SegmentInformationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPayments" xlink:href="biib-20161231.xsd#ShareBasedPayments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:href="biib-20161231.xsd#ShareBasedPaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:href="biib-20161231.xsd#ShareBasedPaymentsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails2" xlink:href="biib-20161231.xsd#ShareBasedPaymentsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails3" xlink:href="biib-20161231.xsd#ShareBasedPaymentsDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails4" xlink:href="biib-20161231.xsd#ShareBasedPaymentsDetails4" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails5" xlink:href="biib-20161231.xsd#ShareBasedPaymentsDetails5" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails6" xlink:href="biib-20161231.xsd#ShareBasedPaymentsDetails6" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails8" xlink:href="biib-20161231.xsd#ShareBasedPaymentsDetails8" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails9" xlink:href="biib-20161231.xsd#ShareBasedPaymentsDetails9" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetailsTextual" xlink:href="biib-20161231.xsd#ShareBasedPaymentsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedPaymentsDetails7" xlink:href="biib-20161231.xsd#ShareBasedPaymentsShareBasedPaymentsDetails7" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:href="biib-20161231.xsd#ShareBasedPaymentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SubsequentEventsNotes" xlink:href="biib-20161231.xsd#SubsequentEventsNotes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="biib-20161231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:href="biib-20161231.xsd#SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="biib-20161231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="biib-20161231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLoss" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_DCC6E30B8F0E016F7415FB6C3B138862" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_EB081C83F342BF2C3B8EFB6C3B122DF0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_DCC6E30B8F0E016F7415FB6C3B138862" xlink:to="loc_us-gaap_StatementTable_EB081C83F342BF2C3B8EFB6C3B122DF0" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_ABA2B54464736C4E76F4FB6C3B12BA51" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_EB081C83F342BF2C3B8EFB6C3B122DF0" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_ABA2B54464736C4E76F4FB6C3B12BA51" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_ACBEE212638E5DFCB6DBFB6C3B122373_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ABA2B54464736C4E76F4FB6C3B12BA51" xlink:to="loc_us-gaap_EquityComponentDomain_ACBEE212638E5DFCB6DBFB6C3B122373_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_ACBEE212638E5DFCB6DBFB6C3B122373" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ABA2B54464736C4E76F4FB6C3B12BA51" xlink:to="loc_us-gaap_EquityComponentDomain_ACBEE212638E5DFCB6DBFB6C3B122373" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_ED5ED3B5D36FBFA653D7FB6C3B126504" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ACBEE212638E5DFCB6DBFB6C3B122373" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_ED5ED3B5D36FBFA653D7FB6C3B126504" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_974E821DE07252F39823FB6C3B13D894" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ACBEE212638E5DFCB6DBFB6C3B122373" xlink:to="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_974E821DE07252F39823FB6C3B13D894" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_2F923B0CE5A4BBEE6EC9FB6C3B13281A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ACBEE212638E5DFCB6DBFB6C3B122373" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_2F923B0CE5A4BBEE6EC9FB6C3B13281A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_FAB61E2B105812ECF5C7FB6C3B13B50E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ACBEE212638E5DFCB6DBFB6C3B122373" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_FAB61E2B105812ECF5C7FB6C3B13B50E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_CDF92BFD30E696D57A71FB6C3B137C2B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_DCC6E30B8F0E016F7415FB6C3B138862" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_CDF92BFD30E696D57A71FB6C3B137C2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_A55550F976AA6321C4EEFB6C3B13FFF4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_DCC6E30B8F0E016F7415FB6C3B138862" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_A55550F976AA6321C4EEFB6C3B13FFF4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_4AF63ABFDC7C9493F6C5FB6C3B13DEA3" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_DCC6E30B8F0E016F7415FB6C3B138862" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_4AF63ABFDC7C9493F6C5FB6C3B13DEA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_9B7AB4B53C702D648A1EFB6C3B135A90" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_DCC6E30B8F0E016F7415FB6C3B138862" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_9B7AB4B53C702D648A1EFB6C3B135A90" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_C48AE22503D3D984571CFB6C3B0D01BB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_0FC85EB3EB54CF197601FB6C3B0CE699" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_C48AE22503D3D984571CFB6C3B0D01BB" xlink:to="loc_us-gaap_StatementTable_0FC85EB3EB54CF197601FB6C3B0CE699" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_9312D5F108CDA6E9CDA2FB6C3B0CF0BE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_0FC85EB3EB54CF197601FB6C3B0CE699" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_9312D5F108CDA6E9CDA2FB6C3B0CF0BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_5D75B19D012F93A8142EFB6C3B0DAB5F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9312D5F108CDA6E9CDA2FB6C3B0CF0BE" xlink:to="loc_us-gaap_EquityComponentDomain_5D75B19D012F93A8142EFB6C3B0DAB5F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_5D75B19D012F93A8142EFB6C3B0DAB5F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9312D5F108CDA6E9CDA2FB6C3B0CF0BE" xlink:to="loc_us-gaap_EquityComponentDomain_5D75B19D012F93A8142EFB6C3B0DAB5F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_E12D2ED6320B9F73DCF9FB6C3B0DCE38" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5D75B19D012F93A8142EFB6C3B0DAB5F" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_E12D2ED6320B9F73DCF9FB6C3B0DCE38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_CC50E506EE5506B6375BFB6C3B0D3A64" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5D75B19D012F93A8142EFB6C3B0DAB5F" xlink:to="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_CC50E506EE5506B6375BFB6C3B0D3A64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_1DD56B741810089DFB0DFB6C3B0D7E66" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_0FC85EB3EB54CF197601FB6C3B0CE699" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_1DD56B741810089DFB0DFB6C3B0D7E66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_A4F64A839DA875EF31BCFB6C3B0D026E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_1DD56B741810089DFB0DFB6C3B0D7E66" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_A4F64A839DA875EF31BCFB6C3B0D026E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_A4F64A839DA875EF31BCFB6C3B0D026E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_1DD56B741810089DFB0DFB6C3B0D7E66" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_A4F64A839DA875EF31BCFB6C3B0D026E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_3B9FE05BB0A1881F4187FB6C3B0D5B1B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_A4F64A839DA875EF31BCFB6C3B0D026E" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_3B9FE05BB0A1881F4187FB6C3B0D5B1B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_C5BBBB03F1CE459EA245FB6C3B0DD212" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_C48AE22503D3D984571CFB6C3B0D01BB" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_C5BBBB03F1CE459EA245FB6C3B0DD212" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_9611A906585BADFEDA0DFB6C3B0D25AC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_C48AE22503D3D984571CFB6C3B0D01BB" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_9611A906585BADFEDA0DFB6C3B0D25AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_C7D49731C883E8DC3994FB6C3B0D5378" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_C48AE22503D3D984571CFB6C3B0D01BB" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_C7D49731C883E8DC3994FB6C3B0D5378" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_3C6FC0337FE5637B4CD1FB6C3B0DB563" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_C48AE22503D3D984571CFB6C3B0D01BB" xlink:to="loc_us-gaap_OperatingExpenses_3C6FC0337FE5637B4CD1FB6C3B0DB563" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_3B5340F17A2322430F8AFB6C3B0DC907" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_C48AE22503D3D984571CFB6C3B0D01BB" xlink:to="loc_us-gaap_NetIncomeLoss_3B5340F17A2322430F8AFB6C3B0DC907" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/Acquisitions" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/AcquisitionsAcquisitionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_4CA94FD31B17B54C908AFA4EA5DA05DF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_09D0F7B30BCC15C3D539FA4EA5DA81E3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4CA94FD31B17B54C908AFA4EA5DA05DF" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_09D0F7B30BCC15C3D539FA4EA5DA81E3" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_F986DBCB87C8A79192C0FA4EA5DA10EE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_09D0F7B30BCC15C3D539FA4EA5DA81E3" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_F986DBCB87C8A79192C0FA4EA5DA10EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6629848242E045951958FA4EA5DA9750_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_F986DBCB87C8A79192C0FA4EA5DA10EE" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6629848242E045951958FA4EA5DA9750_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6629848242E045951958FA4EA5DA9750" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_F986DBCB87C8A79192C0FA4EA5DA10EE" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6629848242E045951958FA4EA5DA9750" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ConvergencePharmaceuticalsMember" xlink:label="loc_biib_ConvergencePharmaceuticalsMember_9C0846778CCA1F308477FA4EA5DA00FF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6629848242E045951958FA4EA5DA9750" xlink:to="loc_biib_ConvergencePharmaceuticalsMember_9C0846778CCA1F308477FA4EA5DA00FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_EF5129B9ACDD65A2B739FA4EA5DA07FE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4CA94FD31B17B54C908AFA4EA5DA05DF" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_EF5129B9ACDD65A2B739FA4EA5DA07FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_7BAE254052D5EAC525D3FA4EA5DA8B83" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4CA94FD31B17B54C908AFA4EA5DA05DF" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_7BAE254052D5EAC525D3FA4EA5DA8B83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_FD1F057F2C70004B24A2FA4EA5DA3DBE" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4CA94FD31B17B54C908AFA4EA5DA05DF" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_FD1F057F2C70004B24A2FA4EA5DA3DBE" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/AcquisitionsAcquisitionsDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_D273B22EFA3D52255B45FCCBDD05A4BE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_120DACFA5B491B9B9F4EFCCBDD04DB05" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_D273B22EFA3D52255B45FCCBDD05A4BE" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_120DACFA5B491B9B9F4EFCCBDD04DB05" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_7CB346EB751FC5DB12B3FCCBDD04C51B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_120DACFA5B491B9B9F4EFCCBDD04DB05" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_7CB346EB751FC5DB12B3FCCBDD04C51B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_92BFFA03C94605B78D3DFCCBDD05D825_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7CB346EB751FC5DB12B3FCCBDD04C51B" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_92BFFA03C94605B78D3DFCCBDD05D825_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_92BFFA03C94605B78D3DFCCBDD05D825" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7CB346EB751FC5DB12B3FCCBDD04C51B" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_92BFFA03C94605B78D3DFCCBDD05D825" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ConvergencePharmaceuticalsMember" xlink:label="loc_biib_ConvergencePharmaceuticalsMember_DC466AB0D0BFEC1A1A9DFCCBDD058C83" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_92BFFA03C94605B78D3DFCCBDD05D825" xlink:to="loc_biib_ConvergencePharmaceuticalsMember_DC466AB0D0BFEC1A1A9DFCCBDD058C83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_B1732C67456B3983DD40FCCBDD053791" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_D273B22EFA3D52255B45FCCBDD05A4BE" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_B1732C67456B3983DD40FCCBDD053791" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_3EF243BBBF5A5FDAF2ADFCCBDD05BA2B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_D273B22EFA3D52255B45FCCBDD05A4BE" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_3EF243BBBF5A5FDAF2ADFCCBDD05BA2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_01BC5B0BC3FCB8A70D76FCCBDD052812" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_D273B22EFA3D52255B45FCCBDD05A4BE" xlink:to="loc_us-gaap_Goodwill_01BC5B0BC3FCB8A70D76FCCBDD052812" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_0603AA20E7F9C0CDD106FCCBDD051A1E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_D273B22EFA3D52255B45FCCBDD05A4BE" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_0603AA20E7F9C0CDD106FCCBDD051A1E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_2CA66B5E1AF1F38B1D7DFCCBDD055703" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_D273B22EFA3D52255B45FCCBDD05A4BE" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_2CA66B5E1AF1F38B1D7DFCCBDD055703" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_5EAA6BE85D3FC1EB3B7CFCCBDD05FDB4" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_D273B22EFA3D52255B45FCCBDD05A4BE" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_5EAA6BE85D3FC1EB3B7CFCCBDD05FDB4" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/AcquisitionsAcquisitionsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/AcquisitionsDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_150FB150C3552FF59522FD3DC927922B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_12A1011813AB1F87DF3EFD3DC924EC7E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_150FB150C3552FF59522FD3DC927922B" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_12A1011813AB1F87DF3EFD3DC924EC7E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_EE9DFDCAA197F44FD5C6FD3DC925F122" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_12A1011813AB1F87DF3EFD3DC924EC7E" xlink:to="loc_us-gaap_ProductOrServiceAxis_EE9DFDCAA197F44FD5C6FD3DC925F122" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_E63B6D792A662D7F3BBAFD3DC9255B36_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProductOrServiceAxis_EE9DFDCAA197F44FD5C6FD3DC925F122" xlink:to="loc_us-gaap_ProductsAndServicesDomain_E63B6D792A662D7F3BBAFD3DC9255B36_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_E63B6D792A662D7F3BBAFD3DC9255B36" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProductOrServiceAxis_EE9DFDCAA197F44FD5C6FD3DC925F122" xlink:to="loc_us-gaap_ProductsAndServicesDomain_E63B6D792A662D7F3BBAFD3DC9255B36" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_BIIB074Member" xlink:label="loc_biib_BIIB074Member_A2EBDAC15163137BA4D1FD3DC9254946" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_E63B6D792A662D7F3BBAFD3DC9255B36" xlink:to="loc_biib_BIIB074Member_A2EBDAC15163137BA4D1FD3DC9254946" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_NeuropathicpainindicationsMember" xlink:label="loc_biib_NeuropathicpainindicationsMember_BD49A3ECFA87A1355AC6FD3DC9265243" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_E63B6D792A662D7F3BBAFD3DC9255B36" xlink:to="loc_biib_NeuropathicpainindicationsMember_BD49A3ECFA87A1355AC6FD3DC9265243" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_132D476A4607A43F69FCFD3DC9265C68" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_12A1011813AB1F87DF3EFD3DC924EC7E" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_132D476A4607A43F69FCFD3DC9265C68" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FFFBEA96F84473AD64ADFD3DC9266206_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_132D476A4607A43F69FCFD3DC9265C68" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FFFBEA96F84473AD64ADFD3DC9266206_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FFFBEA96F84473AD64ADFD3DC9266206" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_132D476A4607A43F69FCFD3DC9265C68" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FFFBEA96F84473AD64ADFD3DC9266206" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ConvergencePharmaceuticalsMember" xlink:label="loc_biib_ConvergencePharmaceuticalsMember_6A9895973D8D839791A7FD3DC9277A0F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FFFBEA96F84473AD64ADFD3DC9266206" xlink:to="loc_biib_ConvergencePharmaceuticalsMember_6A9895973D8D839791A7FD3DC9277A0F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_28413A84D79639B99BE3FD3DC927A81A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_150FB150C3552FF59522FD3DC927922B" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_28413A84D79639B99BE3FD3DC927A81A" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_6416E2D6F7721CB3EDE8FD3DC9274C38" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_150FB150C3552FF59522FD3DC927922B" xlink:to="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_6416E2D6F7721CB3EDE8FD3DC9274C38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_CA19F6C2570D36AF9FCFFD3DC9273AF8" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_150FB150C3552FF59522FD3DC927922B" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_CA19F6C2570D36AF9FCFFD3DC9273AF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_980208237E0BFFEF941EFD3DC92729DA" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_150FB150C3552FF59522FD3DC927922B" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_980208237E0BFFEF941EFD3DC92729DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsDiscountRate" xlink:label="loc_us-gaap_FairValueInputsDiscountRate_A334150E342C32996D66FD3DC927AC5C" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_150FB150C3552FF59522FD3DC927922B" xlink:to="loc_us-gaap_FairValueInputsDiscountRate_A334150E342C32996D66FD3DC927AC5C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_CB6F12FA47E2D2FFF004FD3DC927B704" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_150FB150C3552FF59522FD3DC927922B" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_CB6F12FA47E2D2FFF004FD3DC927B704" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_892EFDC5AAE5EE1682BFFD3DC9273792" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_150FB150C3552FF59522FD3DC927922B" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_892EFDC5AAE5EE1682BFFD3DC9273792" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_MilestonePaymentsMadeDuringPeriod" xlink:label="loc_biib_MilestonePaymentsMadeDuringPeriod_21F177B976CF2AFDDE95FD3DC9280E6B" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_150FB150C3552FF59522FD3DC927922B" xlink:to="loc_biib_MilestonePaymentsMadeDuringPeriod_21F177B976CF2AFDDE95FD3DC9280E6B" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsDetails3" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_522A612EEFB75027B507FC923B9226C0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_27D20259CB130454FC74FC923B905349" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_522A612EEFB75027B507FC923B9226C0" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_27D20259CB130454FC74FC923B905349" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_C892D04C0057280FC3F1FC923B903FD4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_27D20259CB130454FC74FC923B905349" xlink:to="loc_us-gaap_TypeOfArrangementAxis_C892D04C0057280FC3F1FC923B903FD4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_04E64AD700EA3E88557CFC923B91A035_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_C892D04C0057280FC3F1FC923B903FD4" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_04E64AD700EA3E88557CFC923B91A035_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_04E64AD700EA3E88557CFC923B91A035" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_C892D04C0057280FC3F1FC923B903FD4" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_04E64AD700EA3E88557CFC923B91A035" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_EisaiMember" xlink:label="loc_biib_EisaiMember_0F7D5B507EE58070FC0FFC923B920483" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_04E64AD700EA3E88557CFC923B91A035" xlink:to="loc_biib_EisaiMember_0F7D5B507EE58070FC0FFC923B920483" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ExpenseIncurredByCollaboration" xlink:label="loc_biib_ExpenseIncurredByCollaboration_322EAE643162663B292AFC923B92A53B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_522A612EEFB75027B507FC923B9226C0" xlink:to="loc_biib_ExpenseIncurredByCollaboration_322EAE643162663B292AFC923B92A53B" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ExpenseReflectedWithinStatementsOfIncome" xlink:label="loc_biib_ExpenseReflectedWithinStatementsOfIncome_56E603325A5DE3DC29BFFC923B92C51D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_522A612EEFB75027B507FC923B9226C0" xlink:to="loc_biib_ExpenseReflectedWithinStatementsOfIncome_56E603325A5DE3DC29BFFC923B92C51D" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_AD580251C011CE01922CFCCBDB4AC2B0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_24F0DCBC60D9174F0F0DFCCBDB494280" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_AD580251C011CE01922CFCCBDB4AC2B0" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_24F0DCBC60D9174F0F0DFCCBDB494280" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_47591CCE961B7B438163FCCBDB49034F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_24F0DCBC60D9174F0F0DFCCBDB494280" xlink:to="loc_us-gaap_ProductOrServiceAxis_47591CCE961B7B438163FCCBDB49034F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_EFCB5161C79B50A0AEFCFCCBDB49409F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProductOrServiceAxis_47591CCE961B7B438163FCCBDB49034F" xlink:to="loc_us-gaap_ProductsAndServicesDomain_EFCB5161C79B50A0AEFCFCCBDB49409F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_EFCB5161C79B50A0AEFCFCCBDB49409F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProductOrServiceAxis_47591CCE961B7B438163FCCBDB49034F" xlink:to="loc_us-gaap_ProductsAndServicesDomain_EFCB5161C79B50A0AEFCFCCBDB49409F" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_GAZYVAMember" xlink:label="loc_biib_GAZYVAMember_366E910026E23722C08CFCCBDB4A6306" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_EFCB5161C79B50A0AEFCFCCBDB49409F" xlink:to="loc_biib_GAZYVAMember_366E910026E23722C08CFCCBDB4A6306" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_RituxanMember" xlink:label="loc_biib_RituxanMember_0941647EFD7572C0F09FFCCBDB4AA9B6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_EFCB5161C79B50A0AEFCFCCBDB49409F" xlink:to="loc_biib_RituxanMember_0941647EFD7572C0F09FFCCBDB4AA9B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_CFCEF90D9E832E402940FCCBDB4A6DF3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_24F0DCBC60D9174F0F0DFCCBDB494280" xlink:to="loc_us-gaap_TypeOfArrangementAxis_CFCEF90D9E832E402940FCCBDB4A6DF3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_716B58F2ADEEEC34951AFCCBDB4AF28A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_CFCEF90D9E832E402940FCCBDB4A6DF3" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_716B58F2ADEEEC34951AFCCBDB4AF28A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_716B58F2ADEEEC34951AFCCBDB4AF28A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_CFCEF90D9E832E402940FCCBDB4A6DF3" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_716B58F2ADEEEC34951AFCCBDB4AF28A" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_RocheGroupGenentechMember" xlink:label="loc_biib_RocheGroupGenentechMember_D5B2104DFD28235DF39DFCCBDB4A88BD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_716B58F2ADEEEC34951AFCCBDB4AF28A" xlink:to="loc_biib_RocheGroupGenentechMember_D5B2104DFD28235DF39DFCCBDB4A88BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_153324260F611F59A15BFCCBDB4AB71E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_24F0DCBC60D9174F0F0DFCCBDB494280" xlink:to="loc_us-gaap_StatementGeographicalAxis_153324260F611F59A15BFCCBDB4AB71E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_A1F461703C20423626D2FCCBDB4A47B4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementGeographicalAxis_153324260F611F59A15BFCCBDB4AB71E" xlink:to="loc_us-gaap_SegmentGeographicalDomain_A1F461703C20423626D2FCCBDB4A47B4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_A1F461703C20423626D2FCCBDB4A47B4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementGeographicalAxis_153324260F611F59A15BFCCBDB4AB71E" xlink:to="loc_us-gaap_SegmentGeographicalDomain_A1F461703C20423626D2FCCBDB4A47B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd#country_US" xlink:label="loc_country_US_E6AEAAA62A2D82DF6F5DFCCBDB4A317C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_A1F461703C20423626D2FCCBDB4A47B4" xlink:to="loc_country_US_E6AEAAA62A2D82DF6F5DFCCBDB4A317C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember_1953C986A0F612DE3319FCCBDB4A6C62" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_A1F461703C20423626D2FCCBDB4A47B4" xlink:to="loc_us-gaap_ForeignCountryMember_1953C986A0F612DE3319FCCBDB4A6C62" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_CoPromotionProfitSharingFormulaAbstract" xlink:label="loc_biib_CoPromotionProfitSharingFormulaAbstract_3B1573BD06472B7BFC56FCCBDB4AD84B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_AD580251C011CE01922CFCCBDB4AC2B0" xlink:to="loc_biib_CoPromotionProfitSharingFormulaAbstract_3B1573BD06472B7BFC56FCCBDB4AD84B" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_7D23513C0B1999CC70ABFCCBDB4AB38F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CoPromotionProfitSharingFormulaAbstract_3B1573BD06472B7BFC56FCCBDB4AD84B" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_7D23513C0B1999CC70ABFCCBDB4AB38F" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_B5623F03315DCFF62C87FCCBDB4A53BC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CoPromotionProfitSharingFormulaAbstract_3B1573BD06472B7BFC56FCCBDB4AD84B" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_B5623F03315DCFF62C87FCCBDB4A53BC" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_D1DBFD1A286513D8B20FFCCBDB4A5776" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_B5623F03315DCFF62C87FCCBDB4A53BC" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_D1DBFD1A286513D8B20FFCCBDB4A5776" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_370B69E102EC9B2D5F53FCCBDB4BCE87" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_B5623F03315DCFF62C87FCCBDB4A53BC" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_370B69E102EC9B2D5F53FCCBDB4BCE87" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_560A019BE4B4229A8DA4FCCBDB4B51E2" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_B5623F03315DCFF62C87FCCBDB4A53BC" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_560A019BE4B4229A8DA4FCCBDB4B51E2" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_RevenuesFromUnconsolidatedJointBusinessAbstract" xlink:label="loc_biib_RevenuesFromUnconsolidatedJointBusinessAbstract_3E7405A87940B30E3C75FCCBDB4BAFBE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_AD580251C011CE01922CFCCBDB4AC2B0" xlink:to="loc_biib_RevenuesFromUnconsolidatedJointBusinessAbstract_3E7405A87940B30E3C75FCCBDB4BAFBE" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ShareOfCoPromotionProfits" xlink:label="loc_biib_ShareOfCoPromotionProfits_7FDF39A1BF1023E1C467FCCBDB4B9065" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_RevenuesFromUnconsolidatedJointBusinessAbstract_3E7405A87940B30E3C75FCCBDB4BAFBE" xlink:to="loc_biib_ShareOfCoPromotionProfits_7FDF39A1BF1023E1C467FCCBDB4B9065" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_1C8748C56E10DA39C733FCCBDB4B2743" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_RevenuesFromUnconsolidatedJointBusinessAbstract_3E7405A87940B30E3C75FCCBDB4BAFBE" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_1C8748C56E10DA39C733FCCBDB4B2743" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_RevenuesfromantiCD20therapeuticprograms" xlink:label="loc_biib_RevenuesfromantiCD20therapeuticprograms_CB1F7B8A8C53BC5C114CFD0ABF103979" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_RevenuesFromUnconsolidatedJointBusinessAbstract_3E7405A87940B30E3C75FCCBDB4BAFBE" xlink:to="loc_biib_RevenuesfromantiCD20therapeuticprograms_CB1F7B8A8C53BC5C114CFD0ABF103979" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1CAB3AF003A0978B73BEFC923B36A041" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_D481F2725702754F5145FC923B3593BD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1CAB3AF003A0978B73BEFC923B36A041" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_D481F2725702754F5145FC923B3593BD" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_EAFFF3931575E2971A6CFC923B35F715" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_D481F2725702754F5145FC923B3593BD" xlink:to="loc_us-gaap_TypeOfArrangementAxis_EAFFF3931575E2971A6CFC923B35F715" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B4B1D4AF273F73E99D23FC923B36AC09_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_EAFFF3931575E2971A6CFC923B35F715" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B4B1D4AF273F73E99D23FC923B36AC09_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B4B1D4AF273F73E99D23FC923B36AC09" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_EAFFF3931575E2971A6CFC923B35F715" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B4B1D4AF273F73E99D23FC923B36AC09" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_AbbVieMember" xlink:label="loc_biib_AbbVieMember_33B6612D9C11B6FF287DFC923B36F196" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B4B1D4AF273F73E99D23FC923B36AC09" xlink:to="loc_biib_AbbVieMember_33B6612D9C11B6FF287DFC923B36F196" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_97C85A5C1EDC9F1C8DA0FC923B3658B0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1CAB3AF003A0978B73BEFC923B36A041" xlink:to="loc_us-gaap_Revenues_97C85A5C1EDC9F1C8DA0FC923B3658B0" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ExpenseIncurredByCollaboration" xlink:label="loc_biib_ExpenseIncurredByCollaboration_ED7E43115B58978914BAFC923B36967A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1CAB3AF003A0978B73BEFC923B36A041" xlink:to="loc_biib_ExpenseIncurredByCollaboration_ED7E43115B58978914BAFC923B36967A" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_Copromotionprofitsandlosses" xlink:label="loc_biib_Copromotionprofitsandlosses_3844388B1DDCB546D761FC923B36B1C3" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1CAB3AF003A0978B73BEFC923B36A041" xlink:to="loc_biib_Copromotionprofitsandlosses_3844388B1DDCB546D761FC923B36B1C3" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ShareOfCoPromotionProfits" xlink:label="loc_biib_ShareOfCoPromotionProfits_38396503935BF02F0784FC923B36C048" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1CAB3AF003A0978B73BEFC923B36A041" xlink:to="loc_biib_ShareOfCoPromotionProfits_38396503935BF02F0784FC923B36C048" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_65AA1B8C6F80743F9A32FCCBDB3FA184" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_DD890341D4784DD039A1FCCBDB3EFFE6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_65AA1B8C6F80743F9A32FCCBDB3FA184" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_DD890341D4784DD039A1FCCBDB3EFFE6" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="biib-20161231.xsd#biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis" xlink:label="loc_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_86B8A232126DDF0F2AE0FCCBDB3EC7E9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_DD890341D4784DD039A1FCCBDB3EFFE6" xlink:to="loc_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_86B8A232126DDF0F2AE0FCCBDB3EC7E9" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_RoyaltyAndNetRevenueShareRatesByTerritoryDomain" xlink:label="loc_biib_RoyaltyAndNetRevenueShareRatesByTerritoryDomain_33401B3A33201BDAF1DAFCCBDB3E102E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_86B8A232126DDF0F2AE0FCCBDB3EC7E9" xlink:to="loc_biib_RoyaltyAndNetRevenueShareRatesByTerritoryDomain_33401B3A33201BDAF1DAFCCBDB3E102E_default" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_RoyaltyAndNetRevenueShareRatesByTerritoryDomain" xlink:label="loc_biib_RoyaltyAndNetRevenueShareRatesByTerritoryDomain_33401B3A33201BDAF1DAFCCBDB3E102E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_86B8A232126DDF0F2AE0FCCBDB3EC7E9" xlink:to="loc_biib_RoyaltyAndNetRevenueShareRatesByTerritoryDomain_33401B3A33201BDAF1DAFCCBDB3E102E" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_SobiRateToBiogenOnNetSalesInSobiTerritoryMember" xlink:label="loc_biib_SobiRateToBiogenOnNetSalesInSobiTerritoryMember_5F8EC1B9821E9B199F30FCCBDB3E684E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_RoyaltyAndNetRevenueShareRatesByTerritoryDomain_33401B3A33201BDAF1DAFCCBDB3E102E" xlink:to="loc_biib_SobiRateToBiogenOnNetSalesInSobiTerritoryMember_5F8EC1B9821E9B199F30FCCBDB3E684E" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember" xlink:label="loc_biib_BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember_73A065A4BBF0C082C1E4FCCBDB3E9CAE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_RoyaltyAndNetRevenueShareRatesByTerritoryDomain_33401B3A33201BDAF1DAFCCBDB3E102E" xlink:to="loc_biib_BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember_73A065A4BBF0C082C1E4FCCBDB3E9CAE" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember" xlink:label="loc_biib_BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember_FA30F299DB42322C2DEBFCCBDB3FB61C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_RoyaltyAndNetRevenueShareRatesByTerritoryDomain_33401B3A33201BDAF1DAFCCBDB3E102E" xlink:to="loc_biib_BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember_FA30F299DB42322C2DEBFCCBDB3FB61C" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_BiogenRateToSobiOnNetRevenueFromBiogenDistributorTerritoryMember" xlink:label="loc_biib_BiogenRateToSobiOnNetRevenueFromBiogenDistributorTerritoryMember_2C3F18FCE71516776831FCCBDB3F714C" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_RoyaltyAndNetRevenueShareRatesByTerritoryDomain_33401B3A33201BDAF1DAFCCBDB3E102E" xlink:to="loc_biib_BiogenRateToSobiOnNetRevenueFromBiogenDistributorTerritoryMember_2C3F18FCE71516776831FCCBDB3F714C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_175DF9355EE0AC81DDA8FCCBDB3F39CF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_DD890341D4784DD039A1FCCBDB3EFFE6" xlink:to="loc_us-gaap_StatementGeographicalAxis_175DF9355EE0AC81DDA8FCCBDB3F39CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_8DB7219D3E5CC66FC806FCCBDB3FDB6C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementGeographicalAxis_175DF9355EE0AC81DDA8FCCBDB3F39CF" xlink:to="loc_us-gaap_SegmentGeographicalDomain_8DB7219D3E5CC66FC806FCCBDB3FDB6C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_8DB7219D3E5CC66FC806FCCBDB3FDB6C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementGeographicalAxis_175DF9355EE0AC81DDA8FCCBDB3F39CF" xlink:to="loc_us-gaap_SegmentGeographicalDomain_8DB7219D3E5CC66FC806FCCBDB3FDB6C" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_SobiTerritoryMember" xlink:label="loc_biib_SobiTerritoryMember_476C5BCB37E416AA5292FCCBDB3FC4B8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_8DB7219D3E5CC66FC806FCCBDB3FDB6C" xlink:to="loc_biib_SobiTerritoryMember_476C5BCB37E416AA5292FCCBDB3FC4B8" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ReimbursementUnderAmendedAgreementAmountsPayableAbstract" xlink:label="loc_biib_ReimbursementUnderAmendedAgreementAmountsPayableAbstract_3752608623C78099CBDCFCCBDB3F96A3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_65AA1B8C6F80743F9A32FCCBDB3FA184" xlink:to="loc_biib_ReimbursementUnderAmendedAgreementAmountsPayableAbstract_3752608623C78099CBDCFCCBDB3F96A3" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ReimbursementUnderAmendedAgreementMethod" xlink:label="loc_biib_ReimbursementUnderAmendedAgreementMethod_E664502ED6062B9EF56DFCCBDB3FD6E0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ReimbursementUnderAmendedAgreementAmountsPayableAbstract_3752608623C78099CBDCFCCBDB3F96A3" xlink:to="loc_biib_ReimbursementUnderAmendedAgreementMethod_E664502ED6062B9EF56DFCCBDB3FD6E0" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_BaseRateAfterFirstCommercialSale" xlink:label="loc_biib_BaseRateAfterFirstCommercialSale_D44839A14833FCE53BD1FCCBDB3F7501" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ReimbursementUnderAmendedAgreementAmountsPayableAbstract_3752608623C78099CBDCFCCBDB3F96A3" xlink:to="loc_biib_BaseRateAfterFirstCommercialSale_D44839A14833FCE53BD1FCCBDB3F7501" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_RateDuringReimbursementPeriod" xlink:label="loc_biib_RateDuringReimbursementPeriod_7C48F47BAA151A887E11FCCBDB3F79A6" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ReimbursementUnderAmendedAgreementAmountsPayableAbstract_3752608623C78099CBDCFCCBDB3F96A3" xlink:to="loc_biib_RateDuringReimbursementPeriod_7C48F47BAA151A887E11FCCBDB3F79A6" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8500CE652AEB38DB084C00324DDA4806" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_83F11A9AA2E1B252D41B00324DCA6E29" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8500CE652AEB38DB084C00324DDA4806" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_83F11A9AA2E1B252D41B00324DCA6E29" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9BF9AA2B03E70FEC962200324DCB6F92" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_83F11A9AA2E1B252D41B00324DCA6E29" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9BF9AA2B03E70FEC962200324DCB6F92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6B488D7C781AC336320900324DCB5474_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9BF9AA2B03E70FEC962200324DCB6F92" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6B488D7C781AC336320900324DCB5474_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6B488D7C781AC336320900324DCB5474" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9BF9AA2B03E70FEC962200324DCB6F92" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6B488D7C781AC336320900324DCB5474" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_InLicensedPatentsMember" xlink:label="loc_biib_InLicensedPatentsMember_A39CFC9ECB683CCC089100324DCBEAB9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6B488D7C781AC336320900324DCB5474" xlink:to="loc_biib_InLicensedPatentsMember_A39CFC9ECB683CCC089100324DCBEAB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_750A0FB44430DC047C8100324DCB79CA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_83F11A9AA2E1B252D41B00324DCA6E29" xlink:to="loc_us-gaap_StatementGeographicalAxis_750A0FB44430DC047C8100324DCB79CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_71BF79D567627B36FE1600324DCB6BBD_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementGeographicalAxis_750A0FB44430DC047C8100324DCB79CA" xlink:to="loc_us-gaap_SegmentGeographicalDomain_71BF79D567627B36FE1600324DCB6BBD_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_71BF79D567627B36FE1600324DCB6BBD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementGeographicalAxis_750A0FB44430DC047C8100324DCB79CA" xlink:to="loc_us-gaap_SegmentGeographicalDomain_71BF79D567627B36FE1600324DCB6BBD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd#country_US" xlink:label="loc_country_US_0F749EF60FCE4F7716B700324DCBE4AC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_71BF79D567627B36FE1600324DCB6BBD" xlink:to="loc_country_US_0F749EF60FCE4F7716B700324DCBE4AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember_E45CD6D0477B9C2CA4A300324DCB01B2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_71BF79D567627B36FE1600324DCB6BBD" xlink:to="loc_us-gaap_ForeignCountryMember_E45CD6D0477B9C2CA4A300324DCB01B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EuropeMember" xlink:label="loc_us-gaap_EuropeMember_E8477B18E3AC86F4D3BD00324DD0ACBB" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_71BF79D567627B36FE1600324DCB6BBD" xlink:to="loc_us-gaap_EuropeMember_E8477B18E3AC86F4D3BD00324DD0ACBB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_A92CC2CE08C48D60E3DC00324DD06BC7" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_83F11A9AA2E1B252D41B00324DCA6E29" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_A92CC2CE08C48D60E3DC00324DD06BC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_EC16ED80BEAA3751FD0D00324DD08A31_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_A92CC2CE08C48D60E3DC00324DD06BC7" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_EC16ED80BEAA3751FD0D00324DD08A31_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_EC16ED80BEAA3751FD0D00324DD08A31" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_A92CC2CE08C48D60E3DC00324DD06BC7" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_EC16ED80BEAA3751FD0D00324DD08A31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaap_SalesRevenueNetMember_5D660DE5CAB20B8D191E00324DD07B87" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_EC16ED80BEAA3751FD0D00324DD08A31" xlink:to="loc_us-gaap_SalesRevenueNetMember_5D660DE5CAB20B8D191E00324DD07B87" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="loc_us-gaap_CostOfSalesMember_5320C9E11E1530B2BC6300324DD1DF6C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_EC16ED80BEAA3751FD0D00324DD08A31" xlink:to="loc_us-gaap_CostOfSalesMember_5320C9E11E1530B2BC6300324DD1DF6C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_E95895140AD94EADF44C00324DD107D4" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_EC16ED80BEAA3751FD0D00324DD08A31" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_E95895140AD94EADF44C00324DD107D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_C9E1DEAC603022C9C9F400324DD1EDBB" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_EC16ED80BEAA3751FD0D00324DD08A31" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_C9E1DEAC603022C9C9F400324DD1EDBB" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_AdditionalProductsAxis" xlink:label="loc_biib_AdditionalProductsAxis_74422684264CE974068E00324DD122C0" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_83F11A9AA2E1B252D41B00324DCA6E29" xlink:to="loc_biib_AdditionalProductsAxis_74422684264CE974068E00324DD122C0" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_AdditionalProductsDomain" xlink:label="loc_biib_AdditionalProductsDomain_C75638621B5D25F8E82400324DD1617A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_AdditionalProductsAxis_74422684264CE974068E00324DD122C0" xlink:to="loc_biib_AdditionalProductsDomain_C75638621B5D25F8E82400324DD1617A_default" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_AdditionalProductsDomain" xlink:label="loc_biib_AdditionalProductsDomain_C75638621B5D25F8E82400324DD1617A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_AdditionalProductsAxis_74422684264CE974068E00324DD122C0" xlink:to="loc_biib_AdditionalProductsDomain_C75638621B5D25F8E82400324DD1617A" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_NewAntiCd20Member" xlink:label="loc_biib_NewAntiCd20Member_18AE8EC249DE8BF1766600324DD1EBF7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_AdditionalProductsDomain_C75638621B5D25F8E82400324DD1617A" xlink:to="loc_biib_NewAntiCd20Member_18AE8EC249DE8BF1766600324DD1EBF7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_0995FC3D5831CC80831600324DD18A99" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_83F11A9AA2E1B252D41B00324DCA6E29" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_0995FC3D5831CC80831600324DD18A99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="loc_us-gaap_EquityMethodInvesteeNameDomain_BA64F908B187457F672900324DD128CB_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_0995FC3D5831CC80831600324DD18A99" xlink:to="loc_us-gaap_EquityMethodInvesteeNameDomain_BA64F908B187457F672900324DD128CB_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="loc_us-gaap_EquityMethodInvesteeNameDomain_BA64F908B187457F672900324DD128CB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_0995FC3D5831CC80831600324DD18A99" xlink:to="loc_us-gaap_EquityMethodInvesteeNameDomain_BA64F908B187457F672900324DD128CB" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_SamsungBiosimilarAgreementMember" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_BF251F7DD9F663C84AB700324DD21B6F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvesteeNameDomain_BA64F908B187457F672900324DD128CB" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_BF251F7DD9F663C84AB700324DD21B6F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_25746087DD181BDF7AD400324DD25624" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_83F11A9AA2E1B252D41B00324DCA6E29" xlink:to="loc_us-gaap_ProductOrServiceAxis_25746087DD181BDF7AD400324DD25624" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_E7F20544B2F02CC7FFCB00324DD2FAEF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProductOrServiceAxis_25746087DD181BDF7AD400324DD25624" xlink:to="loc_us-gaap_ProductsAndServicesDomain_E7F20544B2F02CC7FFCB00324DD2FAEF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_E7F20544B2F02CC7FFCB00324DD2FAEF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProductOrServiceAxis_25746087DD181BDF7AD400324DD25624" xlink:to="loc_us-gaap_ProductsAndServicesDomain_E7F20544B2F02CC7FFCB00324DD2FAEF" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_RituxanMember" xlink:label="loc_biib_RituxanMember_FB4F1ED3E65A3F74231400324DD2184B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_E7F20544B2F02CC7FFCB00324DD2FAEF" xlink:to="loc_biib_RituxanMember_FB4F1ED3E65A3F74231400324DD2184B" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_GAZYVAMember" xlink:label="loc_biib_GAZYVAMember_04E9F78DCDD9D8A0164900324DD23492" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_E7F20544B2F02CC7FFCB00324DD2FAEF" xlink:to="loc_biib_GAZYVAMember_04E9F78DCDD9D8A0164900324DD23492" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_NewAntiCd20Member" xlink:label="loc_biib_NewAntiCd20Member_B5EB9EA7C24056BA698000324DD29B8F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_E7F20544B2F02CC7FFCB00324DD2FAEF" xlink:to="loc_biib_NewAntiCd20Member_B5EB9EA7C24056BA698000324DD29B8F" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_OcrelizumabMember" xlink:label="loc_biib_OcrelizumabMember_404530F02145F035EAA300324DD22A7C" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_E7F20544B2F02CC7FFCB00324DD2FAEF" xlink:to="loc_biib_OcrelizumabMember_404530F02145F035EAA300324DD22A7C" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ZINBRYTAMember" xlink:label="loc_biib_ZINBRYTAMember_F6D9425B6B1E3D56D8FD00324DD2B5A5" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_E7F20544B2F02CC7FFCB00324DD2FAEF" xlink:to="loc_biib_ZINBRYTAMember_F6D9425B6B1E3D56D8FD00324DD2B5A5" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ELOCTATEMember" xlink:label="loc_biib_ELOCTATEMember_3ADEC812E75C9838CA5500324DD22723" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_E7F20544B2F02CC7FFCB00324DD2FAEF" xlink:to="loc_biib_ELOCTATEMember_3ADEC812E75C9838CA5500324DD22723" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ALPROLIXMember" xlink:label="loc_biib_ALPROLIXMember_74308065C231A2E3D9D800324DD24BE4" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_E7F20544B2F02CC7FFCB00324DD2FAEF" xlink:to="loc_biib_ALPROLIXMember_74308065C231A2E3D9D800324DD24BE4" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_SPINRAZAMember" xlink:label="loc_biib_SPINRAZAMember_4C0A4712FA47DEDB8C8800324DD2B9F0" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_E7F20544B2F02CC7FFCB00324DD2FAEF" xlink:to="loc_biib_SPINRAZAMember_4C0A4712FA47DEDB8C8800324DD2B9F0" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_SOD1Member" xlink:label="loc_biib_SOD1Member_979693D25EBCC47B156900324DD36CFC" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_E7F20544B2F02CC7FFCB00324DD2FAEF" xlink:to="loc_biib_SOD1Member_979693D25EBCC47B156900324DD36CFC" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_DMPKMember" xlink:label="loc_biib_DMPKMember_CFCE29079AC59A436DD700324DD34D71" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_E7F20544B2F02CC7FFCB00324DD2FAEF" xlink:to="loc_biib_DMPKMember_CFCE29079AC59A436DD700324DD34D71" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_LeadprogramsMember" xlink:label="loc_biib_LeadprogramsMember_8574A41E9F896F6B5A1800324DD39546" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_E7F20544B2F02CC7FFCB00324DD2FAEF" xlink:to="loc_biib_LeadprogramsMember_8574A41E9F896F6B5A1800324DD39546" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_DiscoveryprogramsMember" xlink:label="loc_biib_DiscoveryprogramsMember_E697510F3EA7F15431C500324DD3F580" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_E7F20544B2F02CC7FFCB00324DD2FAEF" xlink:to="loc_biib_DiscoveryprogramsMember_E697510F3EA7F15431C500324DD3F580" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_BiosimilarsMember" xlink:label="loc_biib_BiosimilarsMember_ADCD38E2FF68E371DACA00324DD3533A" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_E7F20544B2F02CC7FFCB00324DD2FAEF" xlink:to="loc_biib_BiosimilarsMember_ADCD38E2FF68E371DACA00324DD3533A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_9E704D9DBDBF3BF1FE8000324DD37E7B" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_83F11A9AA2E1B252D41B00324DCA6E29" xlink:to="loc_us-gaap_TypeOfArrangementAxis_9E704D9DBDBF3BF1FE8000324DD37E7B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_BEB6C3837D1E6F5A3EB000324DD34692_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_9E704D9DBDBF3BF1FE8000324DD37E7B" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_BEB6C3837D1E6F5A3EB000324DD34692_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_BEB6C3837D1E6F5A3EB000324DD34692" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_9E704D9DBDBF3BF1FE8000324DD37E7B" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_BEB6C3837D1E6F5A3EB000324DD34692" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_RocheGroupGenentechMember" xlink:label="loc_biib_RocheGroupGenentechMember_2A98A4A6553C4185DFF700324DD3912B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_BEB6C3837D1E6F5A3EB000324DD34692" xlink:to="loc_biib_RocheGroupGenentechMember_2A98A4A6553C4185DFF700324DD3912B" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_AcordaMember" xlink:label="loc_biib_AcordaMember_F0C5FC1F383F3FCA9F3400324DD3705C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_BEB6C3837D1E6F5A3EB000324DD34692" xlink:to="loc_biib_AcordaMember_F0C5FC1F383F3FCA9F3400324DD3705C" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_AbbVieMember" xlink:label="loc_biib_AbbVieMember_F57E7CE71593D3CBB6DE00324DD8DC14" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_BEB6C3837D1E6F5A3EB000324DD34692" xlink:to="loc_biib_AbbVieMember_F57E7CE71593D3CBB6DE00324DD8DC14" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_SwedishOrphanBiovitrumMember" xlink:label="loc_biib_SwedishOrphanBiovitrumMember_CFF749ECE4A5DC222F6A00324DD82147" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_BEB6C3837D1E6F5A3EB000324DD34692" xlink:to="loc_biib_SwedishOrphanBiovitrumMember_CFF749ECE4A5DC222F6A00324DD82147" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_IonisPharmaceuticalsMember" xlink:label="loc_biib_IonisPharmaceuticalsMember_9B0BE632DEB5B4EDA98700324DD87277" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_BEB6C3837D1E6F5A3EB000324DD34692" xlink:to="loc_biib_IonisPharmaceuticalsMember_9B0BE632DEB5B4EDA98700324DD87277" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_EisaiMember" xlink:label="loc_biib_EisaiMember_097BCEA9C7B9AB31BAFA00324DD8F253" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_BEB6C3837D1E6F5A3EB000324DD34692" xlink:to="loc_biib_EisaiMember_097BCEA9C7B9AB31BAFA00324DD8F253" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_AGTCMember" xlink:label="loc_biib_AGTCMember_4AB37C498E34121983D100324DD8C619" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_BEB6C3837D1E6F5A3EB000324DD34692" xlink:to="loc_biib_AGTCMember_4AB37C498E34121983D100324DD8C619" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_UniversityofPennsylvaniaMember" xlink:label="loc_biib_UniversityofPennsylvaniaMember_30D7BCA7EC9D29C0130700324DD9EC5D" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_BEB6C3837D1E6F5A3EB000324DD34692" xlink:to="loc_biib_UniversityofPennsylvaniaMember_30D7BCA7EC9D29C0130700324DD9EC5D" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_SangamoBioSciencesMember" xlink:label="loc_biib_SangamoBioSciencesMember_25F4D8CA2177B310FE8900324DD95135" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_BEB6C3837D1E6F5A3EB000324DD34692" xlink:to="loc_biib_SangamoBioSciencesMember_25F4D8CA2177B310FE8900324DD95135" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_MitsubishiTanabePharmaCorporationMember" xlink:label="loc_biib_MitsubishiTanabePharmaCorporationMember_F4D28A9293E5ECE26F4600324DD9D8A7" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_BEB6C3837D1E6F5A3EB000324DD34692" xlink:to="loc_biib_MitsubishiTanabePharmaCorporationMember_F4D28A9293E5ECE26F4600324DD9D8A7" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_OtherresearchanddiscoveryMember" xlink:label="loc_biib_OtherresearchanddiscoveryMember_93DB9A2685A190A9488200324DD9329D" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_BEB6C3837D1E6F5A3EB000324DD34692" xlink:to="loc_biib_OtherresearchanddiscoveryMember_93DB9A2685A190A9488200324DD9329D" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_SamsungBiosimilarAgreementMember" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_E1325B66930D686B366B00324DD958DC" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_BEB6C3837D1E6F5A3EB000324DD34692" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_E1325B66930D686B366B00324DD958DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_80BFB9B1C7A6C7AACC9200324DD90524" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_83F11A9AA2E1B252D41B00324DCA6E29" xlink:to="loc_us-gaap_RangeAxis_80BFB9B1C7A6C7AACC9200324DD90524" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_5D863C2192BB1A280D2700324DD95D6C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_80BFB9B1C7A6C7AACC9200324DD90524" xlink:to="loc_us-gaap_RangeMember_5D863C2192BB1A280D2700324DD95D6C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_5D863C2192BB1A280D2700324DD95D6C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_80BFB9B1C7A6C7AACC9200324DD90524" xlink:to="loc_us-gaap_RangeMember_5D863C2192BB1A280D2700324DD95D6C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_880A9AFBD6FC615C9AA900324DD93522" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_5D863C2192BB1A280D2700324DD95D6C" xlink:to="loc_us-gaap_MinimumMember_880A9AFBD6FC615C9AA900324DD93522" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_16F191A93001216B20B000324DD9079F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_5D863C2192BB1A280D2700324DD95D6C" xlink:to="loc_us-gaap_MaximumMember_16F191A93001216B20B000324DD9079F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_99096B337C7CF3A1BE1000324DD9D6F6" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_83F11A9AA2E1B252D41B00324DCA6E29" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_99096B337C7CF3A1BE1000324DD9D6F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_23A578236E5C977EFC1800324DDA2887_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_99096B337C7CF3A1BE1000324DD9D6F6" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_23A578236E5C977EFC1800324DDA2887_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_23A578236E5C977EFC1800324DDA2887" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_99096B337C7CF3A1BE1000324DD9D6F6" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_23A578236E5C977EFC1800324DDA2887" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_BiogenIdecHemophiliaMember" xlink:label="loc_biib_BiogenIdecHemophiliaMember_4DA3E4E00A0D9AB9744300324DDA0DA9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_23A578236E5C977EFC1800324DDA2887" xlink:to="loc_biib_BiogenIdecHemophiliaMember_4DA3E4E00A0D9AB9744300324DDA0DA9" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_Biogeneffectiveroyaltyrate" xlink:label="loc_biib_Biogeneffectiveroyaltyrate_F8BBA80074C61031E3FB00324DDA8F61" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8500CE652AEB38DB084C00324DDA4806" xlink:to="loc_biib_Biogeneffectiveroyaltyrate_F8BBA80074C61031E3FB00324DDA8F61" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_CollaborationsTextualAbstract" xlink:label="loc_biib_CollaborationsTextualAbstract_77B6CB9A30BA7410DA2800324DDA5228" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8500CE652AEB38DB084C00324DDA4806" xlink:to="loc_biib_CollaborationsTextualAbstract_77B6CB9A30BA7410DA2800324DDA5228" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct" xlink:label="loc_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_3527DD33D244067D81C300324DDA3817" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_77B6CB9A30BA7410DA2800324DDA5228" xlink:to="loc_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_3527DD33D244067D81C300324DDA3817" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_Reductioninroyaltyrate" xlink:label="loc_biib_Reductioninroyaltyrate_90988B2EEB2DC40C960300324DDAA555" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_77B6CB9A30BA7410DA2800324DDA5228" xlink:to="loc_biib_Reductioninroyaltyrate_90988B2EEB2DC40C960300324DDAA555" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_PeriodOfCollaborationAgreement" xlink:label="loc_biib_PeriodOfCollaborationAgreement_9AA9CF475DC0BD381C0700324DDAB86A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_77B6CB9A30BA7410DA2800324DDA5228" xlink:to="loc_biib_PeriodOfCollaborationAgreement_9AA9CF475DC0BD381C0700324DDAB86A" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_DE47CF2AD4047A0869BC00324DDA2799" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_77B6CB9A30BA7410DA2800324DDA5228" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_DE47CF2AD4047A0869BC00324DDA2799" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" xlink:label="loc_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_9AC0EEDD08A40C73D71800324DDA9AFC" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_77B6CB9A30BA7410DA2800324DDA5228" xlink:to="loc_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_9AC0EEDD08A40C73D71800324DDA9AFC" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne" xlink:label="loc_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_A8CE0B9D1C7AD331083B00324DDA4A12" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_77B6CB9A30BA7410DA2800324DDA5228" xlink:to="loc_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_A8CE0B9D1C7AD331083B00324DDA4A12" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne" xlink:label="loc_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_90F2A898F7178B3EED3000324DDB1B09" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_77B6CB9A30BA7410DA2800324DDA5228" xlink:to="loc_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_90F2A898F7178B3EED3000324DDB1B09" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_SalesTriggerGrossSalesThreshold" xlink:label="loc_biib_SalesTriggerGrossSalesThreshold_D80AAAC27B4CA3F9288C00324DDB6EC3" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_77B6CB9A30BA7410DA2800324DDA5228" xlink:to="loc_biib_SalesTriggerGrossSalesThreshold_D80AAAC27B4CA3F9288C00324DDB6EC3" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_Futurepercentageofcopromotionoperatingprofits" xlink:label="loc_biib_Futurepercentageofcopromotionoperatingprofits_630C4EAEF3E53229614B00324DDB8375" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_77B6CB9A30BA7410DA2800324DDA5228" xlink:to="loc_biib_Futurepercentageofcopromotionoperatingprofits_630C4EAEF3E53229614B00324DDB8375" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_PercentageOfCoPromotionOperatingLosses" xlink:label="loc_biib_PercentageOfCoPromotionOperatingLosses_1DF59DD3C200469B1F1600324DDBFC76" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_77B6CB9A30BA7410DA2800324DDA5228" xlink:to="loc_biib_PercentageOfCoPromotionOperatingLosses_1DF59DD3C200469B1F1600324DDBFC76" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ShareOfCoPromotionProfits" xlink:label="loc_biib_ShareOfCoPromotionProfits_9C3DEAC96FE3008073AE00324DDBA43B" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_77B6CB9A30BA7410DA2800324DDA5228" xlink:to="loc_biib_ShareOfCoPromotionProfits_9C3DEAC96FE3008073AE00324DDBA43B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_C1059B7306DF6572489900324DDBDD8A" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_77B6CB9A30BA7410DA2800324DDA5228" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_C1059B7306DF6572489900324DDBDD8A" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillion" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillion_50C192F6DB2CE13DC04600324DDB87A5" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_77B6CB9A30BA7410DA2800324DDA5228" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillion_50C192F6DB2CE13DC04600324DDB87A5" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ExpectedAdditionalMilestonePaymentsOnSuccessfulAchievementOfRegulatoryAndCommercialSalesMilestones" xlink:label="loc_biib_ExpectedAdditionalMilestonePaymentsOnSuccessfulAchievementOfRegulatoryAndCommercialSalesMilestones_4458AFD1322B607B83D900324DDB2AA7" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_77B6CB9A30BA7410DA2800324DDA5228" xlink:to="loc_biib_ExpectedAdditionalMilestonePaymentsOnSuccessfulAchievementOfRegulatoryAndCommercialSalesMilestones_4458AFD1322B607B83D900324DDB2AA7" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold" xlink:label="loc_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold_4EFD3D2323A8653C5F0C00324DDBB2D6" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_77B6CB9A30BA7410DA2800324DDA5228" xlink:to="loc_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold_4EFD3D2323A8653C5F0C00324DDBB2D6" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ForeignSalesRequiredToTriggerMilestone" xlink:label="loc_biib_ForeignSalesRequiredToTriggerMilestone_8ADC23FCB12FA4F33DA900324DDB1912" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_77B6CB9A30BA7410DA2800324DDA5228" xlink:to="loc_biib_ForeignSalesRequiredToTriggerMilestone_8ADC23FCB12FA4F33DA900324DDB1912" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ExpenseReflectedWithinStatementsOfIncome" xlink:label="loc_biib_ExpenseReflectedWithinStatementsOfIncome_EE20D7686732BBE9366B00324DE02A50" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_77B6CB9A30BA7410DA2800324DDA5228" xlink:to="loc_biib_ExpenseReflectedWithinStatementsOfIncome_EE20D7686732BBE9366B00324DE02A50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_D22A63805907E2D34ADF00324DE0221B" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_77B6CB9A30BA7410DA2800324DDA5228" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_D22A63805907E2D34ADF00324DE0221B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_8C5D906AA0B920A9ACF700324DE01BA8" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_77B6CB9A30BA7410DA2800324DDA5228" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_8C5D906AA0B920A9ACF700324DE01BA8" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ConsiderationPerProductDeveloped" xlink:label="loc_biib_ConsiderationPerProductDeveloped_3E421C6B325C6616DB6600324DE0C64A" xlink:type="locator" />
    <link:definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_77B6CB9A30BA7410DA2800324DDA5228" xlink:to="loc_biib_ConsiderationPerProductDeveloped_3E421C6B325C6616DB6600324DE0C64A" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ReimbursementCostAchievingPeriod" xlink:label="loc_biib_ReimbursementCostAchievingPeriod_D6335F0418B321A856EF00324DE07AC1" xlink:type="locator" />
    <link:definitionArc order="21" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_77B6CB9A30BA7410DA2800324DDA5228" xlink:to="loc_biib_ReimbursementCostAchievingPeriod_D6335F0418B321A856EF00324DE07AC1" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_TimePeriodForPayingRemainingBalanceDue" xlink:label="loc_biib_TimePeriodForPayingRemainingBalanceDue_4BAB6D58A857BEA2378800324DE19069" xlink:type="locator" />
    <link:definitionArc order="22" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_77B6CB9A30BA7410DA2800324DDA5228" xlink:to="loc_biib_TimePeriodForPayingRemainingBalanceDue_4BAB6D58A857BEA2378800324DE19069" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_D0C9445048DD9CCDB8BD00324DE1BD34" xlink:type="locator" />
    <link:definitionArc order="23" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_77B6CB9A30BA7410DA2800324DDA5228" xlink:to="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_D0C9445048DD9CCDB8BD00324DE1BD34" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_DBEAD684EA24A72B73DA00324DE1C4DD" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8500CE652AEB38DB084C00324DDA4806" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_DBEAD684EA24A72B73DA00324DE1C4DD" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_1EC8215D31D9BCF042DB00324DE13634" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8500CE652AEB38DB084C00324DDA4806" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_1EC8215D31D9BCF042DB00324DE13634" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_5A21B6843D8A93A6FF2D00324DE1E34C" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8500CE652AEB38DB084C00324DDA4806" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_5A21B6843D8A93A6FF2D00324DE1E34C" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ExpenseIncurredByCollaboration" xlink:label="loc_biib_ExpenseIncurredByCollaboration_5F763A9CD5B07A71AF9300324DE140D8" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8500CE652AEB38DB084C00324DDA4806" xlink:to="loc_biib_ExpenseIncurredByCollaboration_5F763A9CD5B07A71AF9300324DE140D8" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_Biogenshareofcopromotionprofitsorlosses" xlink:label="loc_biib_Biogenshareofcopromotionprofitsorlosses_2663182AD7A449ACAE6E00324DE1CEA9" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8500CE652AEB38DB084C00324DDA4806" xlink:to="loc_biib_Biogenshareofcopromotionprofitsorlosses_2663182AD7A449ACAE6E00324DE1CEA9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherSalesRevenueNet" xlink:label="loc_us-gaap_OtherSalesRevenueNet_D910D345D98E68C3E8D800324DE13F8A" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8500CE652AEB38DB084C00324DDA4806" xlink:to="loc_us-gaap_OtherSalesRevenueNet_D910D345D98E68C3E8D800324DE13F8A" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_Collaborationprofitlosssharing" xlink:label="loc_biib_Collaborationprofitlosssharing_2ABF537BC43F84A7580100324DE1826E" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8500CE652AEB38DB084C00324DDA4806" xlink:to="loc_biib_Collaborationprofitlosssharing_2ABF537BC43F84A7580100324DE1826E" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_Termofcollaborationagreement" xlink:label="loc_biib_Termofcollaborationagreement_C2B4FBE56DB41C96FD1200324DE19CB6" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8500CE652AEB38DB084C00324DDA4806" xlink:to="loc_biib_Termofcollaborationagreement_C2B4FBE56DB41C96FD1200324DE19CB6" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:label="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_536A518791C22AB1104300324DE11B61" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8500CE652AEB38DB084C00324DDA4806" xlink:to="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_536A518791C22AB1104300324DE11B61" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_1CBED0CFEAF65F9CB0BE00324DE1E538" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8500CE652AEB38DB084C00324DDA4806" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssets_1CBED0CFEAF65F9CB0BE00324DE1E538" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_LicenseFee" xlink:label="loc_biib_LicenseFee_A0CFE3932900F1657BEC00324DE15392" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8500CE652AEB38DB084C00324DDA4806" xlink:to="loc_biib_LicenseFee_A0CFE3932900F1657BEC00324DE15392" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments" xlink:label="loc_biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments_B4D8C5EA889F6C16E1BB00324DE2037F" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8500CE652AEB38DB084C00324DDA4806" xlink:to="loc_biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments_B4D8C5EA889F6C16E1BB00324DE2037F" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_Additionalmilestonepaymentsforproductcandidateusingadifferentmodality" xlink:label="loc_biib_Additionalmilestonepaymentsforproductcandidateusingadifferentmodality_3923CDAE5F1D5A8CE13B00324DE2B6E0" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8500CE652AEB38DB084C00324DDA4806" xlink:to="loc_biib_Additionalmilestonepaymentsforproductcandidateusingadifferentmodality_3923CDAE5F1D5A8CE13B00324DE2B6E0" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_AdditionalMilestonePayment" xlink:label="loc_biib_AdditionalMilestonePayment_E2E88E157D7F29F7C87500324DE2CE01" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8500CE652AEB38DB084C00324DDA4806" xlink:to="loc_biib_AdditionalMilestonePayment_E2E88E157D7F29F7C87500324DE2CE01" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_LiabilityForFairValueOfOptionsGrantedUnderAgreement" xlink:label="loc_biib_LiabilityForFairValueOfOptionsGrantedUnderAgreement_51EBA597E391D6EDE5EE00324DE206E5" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8500CE652AEB38DB084C00324DDA4806" xlink:to="loc_biib_LiabilityForFairValueOfOptionsGrantedUnderAgreement_51EBA597E391D6EDE5EE00324DE206E5" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_MilestonePaymentsMadeDuringPeriod" xlink:label="loc_biib_MilestonePaymentsMadeDuringPeriod_F2527F2DCDA44D8055E800324DE20416" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8500CE652AEB38DB084C00324DDA4806" xlink:to="loc_biib_MilestonePaymentsMadeDuringPeriod_F2527F2DCDA44D8055E800324DE20416" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_Purchaseofcommonstock" xlink:label="loc_biib_Purchaseofcommonstock_249C20275405AA0E721A00324DE2BAD5" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8500CE652AEB38DB084C00324DDA4806" xlink:to="loc_biib_Purchaseofcommonstock_249C20275405AA0E721A00324DE2BAD5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LicenseCosts" xlink:label="loc_us-gaap_LicenseCosts_ED9A445A208C875E7D4900324DE28F6A" xlink:type="locator" />
    <link:definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8500CE652AEB38DB084C00324DDA4806" xlink:to="loc_us-gaap_LicenseCosts_ED9A445A208C875E7D4900324DE28F6A" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_Researchanddevelopmentservices" xlink:label="loc_biib_Researchanddevelopmentservices_8C46E510086ACD5EAFAC00324DE2F46D" xlink:type="locator" />
    <link:definitionArc order="21" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8500CE652AEB38DB084C00324DDA4806" xlink:to="loc_biib_Researchanddevelopmentservices_8C46E510086ACD5EAFAC00324DE2F46D" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_Premiumonequityinvestment" xlink:label="loc_biib_Premiumonequityinvestment_D9D020046C9C59946EBC00324DE2E4F6" xlink:type="locator" />
    <link:definitionArc order="22" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8500CE652AEB38DB084C00324DDA4806" xlink:to="loc_biib_Premiumonequityinvestment_D9D020046C9C59946EBC00324DE2E4F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_F7E55C2A28A43E701BA700324DE21A4D" xlink:type="locator" />
    <link:definitionArc order="23" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8500CE652AEB38DB084C00324DDA4806" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_F7E55C2A28A43E701BA700324DE21A4D" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_Futureresearchanddevelopmentcommitment" xlink:label="loc_biib_Futureresearchanddevelopmentcommitment_5241B29C582E8D603E7E00324DE22676" xlink:type="locator" />
    <link:definitionArc order="24" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8500CE652AEB38DB084C00324DDA4806" xlink:to="loc_biib_Futureresearchanddevelopmentcommitment_5241B29C582E8D603E7E00324DE22676" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_635065C50F261783F48F00324DE29844" xlink:type="locator" />
    <link:definitionArc order="25" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8500CE652AEB38DB084C00324DDA4806" xlink:to="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_635065C50F261783F48F00324DE29844" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement" xlink:label="loc_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_CF61670E1DEA0DE5C64200324DE2F7D5" xlink:type="locator" />
    <link:definitionArc order="26" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8500CE652AEB38DB084C00324DDA4806" xlink:to="loc_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_CF61670E1DEA0DE5C64200324DE2F7D5" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_JointVentureOwnerShipPercentageByThirdParty" xlink:label="loc_biib_JointVentureOwnerShipPercentageByThirdParty_FEC319DD1A2485F7937D00324DE3767C" xlink:type="locator" />
    <link:definitionArc order="27" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8500CE652AEB38DB084C00324DDA4806" xlink:to="loc_biib_JointVentureOwnerShipPercentageByThirdParty_FEC319DD1A2485F7937D00324DE3767C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_4FF82632107F0293166600324DE389B6" xlink:type="locator" />
    <link:definitionArc order="28" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8500CE652AEB38DB084C00324DDA4806" xlink:to="loc_us-gaap_EquityMethodInvestments_4FF82632107F0293166600324DE389B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_FA6D2531D7294ED5324F00324DE31B81" xlink:type="locator" />
    <link:definitionArc order="29" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8500CE652AEB38DB084C00324DDA4806" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_FA6D2531D7294ED5324F00324DE31B81" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_EquityMethodInvestmentOwnershipPercentageMaximum" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageMaximum_DAA75F3E6E807D80566900324DE31FDF" xlink:type="locator" />
    <link:definitionArc order="30" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8500CE652AEB38DB084C00324DDA4806" xlink:to="loc_biib_EquityMethodInvestmentOwnershipPercentageMaximum_DAA75F3E6E807D80566900324DE31FDF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_C77E6B4454DCC78F0C5000324DE37A71" xlink:type="locator" />
    <link:definitionArc order="31" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8500CE652AEB38DB084C00324DDA4806" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_C77E6B4454DCC78F0C5000324DE37A71" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_EquityMethodInvestmentsExpectedProfitShare" xlink:label="loc_biib_EquityMethodInvestmentsExpectedProfitShare_B9ADC2A21EB64914C9C500324DE38086" xlink:type="locator" />
    <link:definitionArc order="32" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8500CE652AEB38DB084C00324DDA4806" xlink:to="loc_biib_EquityMethodInvestmentsExpectedProfitShare_B9ADC2A21EB64914C9C500324DE38086" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CommitmentsAndContingenciesCommitmentsAndContingenciesDetails1" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CommitmentsAndContingenciesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CommitmentsAndContingenciesDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_3F88748D37747DDA5562FCCBDB03F53E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_54814CBF69A87D818242FCCBDB001A9D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3F88748D37747DDA5562FCCBDB03F53E" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_54814CBF69A87D818242FCCBDB001A9D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="biib-20161231.xsd#biib_FutureContingentMilestoneTypesAxis" xlink:label="loc_biib_FutureContingentMilestoneTypesAxis_5FF89936066A288377E5FCCBDB018D9E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_54814CBF69A87D818242FCCBDB001A9D" xlink:to="loc_biib_FutureContingentMilestoneTypesAxis_5FF89936066A288377E5FCCBDB018D9E" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_FutureContingentMilestoneTypesDomain" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_A2F87FF556DD670E99E8FCCBDB01692E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_5FF89936066A288377E5FCCBDB018D9E" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_A2F87FF556DD670E99E8FCCBDB01692E_default" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_FutureContingentMilestoneTypesDomain" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_A2F87FF556DD670E99E8FCCBDB01692E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_5FF89936066A288377E5FCCBDB018D9E" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_A2F87FF556DD670E99E8FCCBDB01692E" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_DevelopmentMilestonesMember" xlink:label="loc_biib_DevelopmentMilestonesMember_3965AD6BCF8A16F3727AFCCBDB01E682" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_A2F87FF556DD670E99E8FCCBDB01692E" xlink:to="loc_biib_DevelopmentMilestonesMember_3965AD6BCF8A16F3727AFCCBDB01E682" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_RegulatoryMilestonesMember" xlink:label="loc_biib_RegulatoryMilestonesMember_0CD9D5E266FDC9D4C84DFCCBDB02C17C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_A2F87FF556DD670E99E8FCCBDB01692E" xlink:to="loc_biib_RegulatoryMilestonesMember_0CD9D5E266FDC9D4C84DFCCBDB02C17C" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_CommercialMilestonesMember" xlink:label="loc_biib_CommercialMilestonesMember_4AB828CEF55151D5B1B0FCCBDB02206E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_A2F87FF556DD670E99E8FCCBDB01692E" xlink:to="loc_biib_CommercialMilestonesMember_4AB828CEF55151D5B1B0FCCBDB02206E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_D590FC76B6CCFBD15FF0FCCBDB008ADA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_54814CBF69A87D818242FCCBDB001A9D" xlink:to="loc_us-gaap_StatementGeographicalAxis_D590FC76B6CCFBD15FF0FCCBDB008ADA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_791D9BB5460B8A07E1C4FCCBDB004413_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementGeographicalAxis_D590FC76B6CCFBD15FF0FCCBDB008ADA" xlink:to="loc_us-gaap_SegmentGeographicalDomain_791D9BB5460B8A07E1C4FCCBDB004413_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_791D9BB5460B8A07E1C4FCCBDB004413" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementGeographicalAxis_D590FC76B6CCFBD15FF0FCCBDB008ADA" xlink:to="loc_us-gaap_SegmentGeographicalDomain_791D9BB5460B8A07E1C4FCCBDB004413" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd#country_US" xlink:label="loc_country_US_626133589F752EB96A0FFCCBDB012FBB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_791D9BB5460B8A07E1C4FCCBDB004413" xlink:to="loc_country_US_626133589F752EB96A0FFCCBDB012FBB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EuropeanUnionMember" xlink:label="loc_us-gaap_EuropeanUnionMember_64E9420A8F4E79A2B0DCFCCBDB01937C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_791D9BB5460B8A07E1C4FCCBDB004413" xlink:to="loc_us-gaap_EuropeanUnionMember_64E9420A8F4E79A2B0DCFCCBDB01937C" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_CumulativeSalesLevelAxis" xlink:label="loc_biib_CumulativeSalesLevelAxis_5DA6BB9546DA847D079DFCCBDB023514" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_54814CBF69A87D818242FCCBDB001A9D" xlink:to="loc_biib_CumulativeSalesLevelAxis_5DA6BB9546DA847D079DFCCBDB023514" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_CumulativeSalesLevelDomain" xlink:label="loc_biib_CumulativeSalesLevelDomain_685C71E853F24FEDCC9AFCCBDB02CCF0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_CumulativeSalesLevelAxis_5DA6BB9546DA847D079DFCCBDB023514" xlink:to="loc_biib_CumulativeSalesLevelDomain_685C71E853F24FEDCC9AFCCBDB02CCF0_default" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_CumulativeSalesLevelDomain" xlink:label="loc_biib_CumulativeSalesLevelDomain_685C71E853F24FEDCC9AFCCBDB02CCF0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_CumulativeSalesLevelAxis_5DA6BB9546DA847D079DFCCBDB023514" xlink:to="loc_biib_CumulativeSalesLevelDomain_685C71E853F24FEDCC9AFCCBDB02CCF0" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_TenbillionMember" xlink:label="loc_biib_TenbillionMember_BD5C684B53F08C1DCA5FFCCBDB0292D2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CumulativeSalesLevelDomain_685C71E853F24FEDCC9AFCCBDB02CCF0" xlink:to="loc_biib_TenbillionMember_BD5C684B53F08C1DCA5FFCCBDB0292D2" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_SevenbillionMember" xlink:label="loc_biib_SevenbillionMember_1EDACFACECFDEB6DD4C3FCCBDB02A590" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CumulativeSalesLevelDomain_685C71E853F24FEDCC9AFCCBDB02CCF0" xlink:to="loc_biib_SevenbillionMember_1EDACFACECFDEB6DD4C3FCCBDB02A590" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_EightbillionMember" xlink:label="loc_biib_EightbillionMember_3416099A6FDB6C4073C5FCCBDB023F08" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CumulativeSalesLevelDomain_685C71E853F24FEDCC9AFCCBDB02CCF0" xlink:to="loc_biib_EightbillionMember_3416099A6FDB6C4073C5FCCBDB023F08" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_NinebillionMember" xlink:label="loc_biib_NinebillionMember_2245531DE5BAEF26359CFCCBDB021AD4" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CumulativeSalesLevelDomain_685C71E853F24FEDCC9AFCCBDB02CCF0" xlink:to="loc_biib_NinebillionMember_2245531DE5BAEF26359CFCCBDB021AD4" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ElevenbillionMember" xlink:label="loc_biib_ElevenbillionMember_04A8D50FDF0C5C95BC8BFCCBDB024077" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CumulativeSalesLevelDomain_685C71E853F24FEDCC9AFCCBDB02CCF0" xlink:to="loc_biib_ElevenbillionMember_04A8D50FDF0C5C95BC8BFCCBDB024077" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_OneBillionMember" xlink:label="loc_biib_OneBillionMember_A676BD77F5A6F4BD2F7AFCCBDB02B434" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CumulativeSalesLevelDomain_685C71E853F24FEDCC9AFCCBDB02CCF0" xlink:to="loc_biib_OneBillionMember_A676BD77F5A6F4BD2F7AFCCBDB02B434" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_EachAdditionalOneBillionUpToTwentyBillionMember" xlink:label="loc_biib_EachAdditionalOneBillionUpToTwentyBillionMember_5C1CD92EB5BE3D83BC1DFCCBDB0214CC" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CumulativeSalesLevelDomain_685C71E853F24FEDCC9AFCCBDB02CCF0" xlink:to="loc_biib_EachAdditionalOneBillionUpToTwentyBillionMember_5C1CD92EB5BE3D83BC1DFCCBDB0214CC" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ThreeBillionMember" xlink:label="loc_biib_ThreeBillionMember_3D0B8D041A6DBAD55E41FCCBDB026885" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CumulativeSalesLevelDomain_685C71E853F24FEDCC9AFCCBDB02CCF0" xlink:to="loc_biib_ThreeBillionMember_3D0B8D041A6DBAD55E41FCCBDB026885" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_27AB6CDA50E3EC7FF352FCCBDB02C5DF" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_54814CBF69A87D818242FCCBDB001A9D" xlink:to="loc_us-gaap_ProductOrServiceAxis_27AB6CDA50E3EC7FF352FCCBDB02C5DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_F6674D01C458A00BA290FCCBDB02B5D3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProductOrServiceAxis_27AB6CDA50E3EC7FF352FCCBDB02C5DF" xlink:to="loc_us-gaap_ProductsAndServicesDomain_F6674D01C458A00BA290FCCBDB02B5D3_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_F6674D01C458A00BA290FCCBDB02B5D3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProductOrServiceAxis_27AB6CDA50E3EC7FF352FCCBDB02C5DF" xlink:to="loc_us-gaap_ProductsAndServicesDomain_F6674D01C458A00BA290FCCBDB02B5D3" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_8CB995C5F30A9951805EFCCBDB0394DC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_F6674D01C458A00BA290FCCBDB02B5D3" xlink:to="loc_biib_TecfideraMember_8CB995C5F30A9951805EFCCBDB0394DC" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_FacilityLocationAxis" xlink:label="loc_biib_FacilityLocationAxis_F057B8CBCFB194FBCC28FCCBDB039A55" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_54814CBF69A87D818242FCCBDB001A9D" xlink:to="loc_biib_FacilityLocationAxis_F057B8CBCFB194FBCC28FCCBDB039A55" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_C44374ED04CE5F26A4D9FCCBDB038829_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_FacilityLocationAxis_F057B8CBCFB194FBCC28FCCBDB039A55" xlink:to="loc_biib_FacilityLocationDomain_C44374ED04CE5F26A4D9FCCBDB038829_default" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_C44374ED04CE5F26A4D9FCCBDB038829" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_FacilityLocationAxis_F057B8CBCFB194FBCC28FCCBDB039A55" xlink:to="loc_biib_FacilityLocationDomain_C44374ED04CE5F26A4D9FCCBDB038829" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_SolothurnMember" xlink:label="loc_biib_SolothurnMember_8D4DCE9A15554E0EDE18FCCBDB038080" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FacilityLocationDomain_C44374ED04CE5F26A4D9FCCBDB038829" xlink:to="loc_biib_SolothurnMember_8D4DCE9A15554E0EDE18FCCBDB038080" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_55C1090D40644F695BACFCCBDB03B61E" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_54814CBF69A87D818242FCCBDB001A9D" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_55C1090D40644F695BACFCCBDB03B61E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5A85283DEFBDDA90D196FCCBDB0343DD_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_55C1090D40644F695BACFCCBDB03B61E" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5A85283DEFBDDA90D196FCCBDB0343DD_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5A85283DEFBDDA90D196FCCBDB0343DD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_55C1090D40644F695BACFCCBDB03B61E" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5A85283DEFBDDA90D196FCCBDB0343DD" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_TysabriProductMember" xlink:label="loc_biib_TysabriProductMember_D7EE40229FC45FE4F42AFCCBDB039EDD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5A85283DEFBDDA90D196FCCBDB0343DD" xlink:to="loc_biib_TysabriProductMember_D7EE40229FC45FE4F42AFCCBDB039EDD" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_FumapharmAgMember" xlink:label="loc_biib_FumapharmAgMember_4698B823E08F2C1FBCCEFCCBDB037BA7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5A85283DEFBDDA90D196FCCBDB0343DD" xlink:to="loc_biib_FumapharmAgMember_4698B823E08F2C1FBCCEFCCBDB037BA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationSettlementAmount" xlink:label="loc_us-gaap_LitigationSettlementAmount_C6F13F5B8BED3F4AB517FCCBDB032AA2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3F88748D37747DDA5562FCCBDB03F53E" xlink:to="loc_us-gaap_LitigationSettlementAmount_C6F13F5B8BED3F4AB517FCCBDB032AA2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationSettlementExpense" xlink:label="loc_us-gaap_LitigationSettlementExpense_E7A6939CF4EF10B6C2EBFCCBDB044305" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3F88748D37747DDA5562FCCBDB03F53E" xlink:to="loc_us-gaap_LitigationSettlementExpense_E7A6939CF4EF10B6C2EBFCCBDB044305" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion" xlink:label="loc_biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion_3D9C63E8B139FBE74DD0FCCBDB04F3CD" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3F88748D37747DDA5562FCCBDB03F53E" xlink:to="loc_biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion_3D9C63E8B139FBE74DD0FCCBDB04F3CD" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_FutureContingentPaymentThreshold" xlink:label="loc_biib_FutureContingentPaymentThreshold_76B614BA5AC785A41EF2FCCBDB045DFF" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3F88748D37747DDA5562FCCBDB03F53E" xlink:to="loc_biib_FutureContingentPaymentThreshold_76B614BA5AC785A41EF2FCCBDB045DFF" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion" xlink:label="loc_biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion_32A2609B9027D57287A3FCCBDB04C1D0" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3F88748D37747DDA5562FCCBDB03F53E" xlink:to="loc_biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion_32A2609B9027D57287A3FCCBDB04C1D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_19886BCD224CA5AD4D70FCCBDB04536C" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3F88748D37747DDA5562FCCBDB03F53E" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_19886BCD224CA5AD4D70FCCBDB04536C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_DF774469DE10512A6CB4FCCBDB044207" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3F88748D37747DDA5562FCCBDB03F53E" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_DF774469DE10512A6CB4FCCBDB044207" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_BA32A84CF1709C65C0C4FCCBDB0446D0" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3F88748D37747DDA5562FCCBDB03F53E" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_BA32A84CF1709C65C0C4FCCBDB0446D0" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_CumulativeSalesLevel" xlink:label="loc_biib_CumulativeSalesLevel_EEE4CDAB35A8BB67EA41FCCBDB046324" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3F88748D37747DDA5562FCCBDB03F53E" xlink:to="loc_biib_CumulativeSalesLevel_EEE4CDAB35A8BB67EA41FCCBDB046324" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_A7E33FE1D7E9052CFAB7FCCBDB043642" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3F88748D37747DDA5562FCCBDB03F53E" xlink:to="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_A7E33FE1D7E9052CFAB7FCCBDB043642" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCommitment" xlink:label="loc_us-gaap_OtherCommitment_0BF58AEF4406DD44967FFCCBDB048D3A" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3F88748D37747DDA5562FCCBDB03F53E" xlink:to="loc_us-gaap_OtherCommitment_0BF58AEF4406DD44967FFCCBDB048D3A" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CommitmentsAndContingenciesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ConsolidatedBalanceSheets" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ConsolidatedStatementsOfComprehensiveIncome" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ConsolidatedStatementsOfEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0E3E948FEE5940CA0E8DFA4E86C3120B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_F1B1636431E4D753C2F2FA4E86C1C9EB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0E3E948FEE5940CA0E8DFA4E86C3120B" xlink:to="loc_us-gaap_StatementTable_F1B1636431E4D753C2F2FA4E86C1C9EB" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_81C7029D1B460705560EFA4E86C2CDC6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_F1B1636431E4D753C2F2FA4E86C1C9EB" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_81C7029D1B460705560EFA4E86C2CDC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_32A038D2E1D8CFE6EBF9FA4E86C24E66_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_81C7029D1B460705560EFA4E86C2CDC6" xlink:to="loc_us-gaap_EquityComponentDomain_32A038D2E1D8CFE6EBF9FA4E86C24E66_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_32A038D2E1D8CFE6EBF9FA4E86C24E66" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_81C7029D1B460705560EFA4E86C2CDC6" xlink:to="loc_us-gaap_EquityComponentDomain_32A038D2E1D8CFE6EBF9FA4E86C24E66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_E1776E1F7E83050BCE5FFA4E86C2F785" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_32A038D2E1D8CFE6EBF9FA4E86C24E66" xlink:to="loc_us-gaap_PreferredStockMember_E1776E1F7E83050BCE5FFA4E86C2F785" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1D1E6199649AD9888512FA4E86C2DE64" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_32A038D2E1D8CFE6EBF9FA4E86C24E66" xlink:to="loc_us-gaap_CommonStockMember_1D1E6199649AD9888512FA4E86C2DE64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_19C2E1AC3A51C1CEB3E4FA4E86C3DB6C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_32A038D2E1D8CFE6EBF9FA4E86C24E66" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_19C2E1AC3A51C1CEB3E4FA4E86C3DB6C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_BABC4C5C1C3FA7B99E4EFA4E86C34AC1" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_32A038D2E1D8CFE6EBF9FA4E86C24E66" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_BABC4C5C1C3FA7B99E4EFA4E86C34AC1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_008DA1F1E23C1A25C588FA4E86C3DDB4" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_32A038D2E1D8CFE6EBF9FA4E86C24E66" xlink:to="loc_us-gaap_RetainedEarningsMember_008DA1F1E23C1A25C588FA4E86C3DDB4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_CAC8C58E0CDEDE3D37BDFA4E86C3A59E" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_32A038D2E1D8CFE6EBF9FA4E86C24E66" xlink:to="loc_us-gaap_TreasuryStockMember_CAC8C58E0CDEDE3D37BDFA4E86C3A59E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember_22A64331B46162E2978DFA4E86C377CD" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_32A038D2E1D8CFE6EBF9FA4E86C24E66" xlink:to="loc_us-gaap_NoncontrollingInterestMember_22A64331B46162E2978DFA4E86C377CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaap_ParentMember_88515E9A8C01CD047681FA4E86C329B1" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_32A038D2E1D8CFE6EBF9FA4E86C24E66" xlink:to="loc_us-gaap_ParentMember_88515E9A8C01CD047681FA4E86C329B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3ED9F2B165CAC7A177FEFA4E86C369AC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0E3E948FEE5940CA0E8DFA4E86C3120B" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3ED9F2B165CAC7A177FEFA4E86C369AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_E82A5BF5FD36BF565D3FFA4E86C34B1E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0E3E948FEE5940CA0E8DFA4E86C3120B" xlink:to="loc_us-gaap_StockholdersEquity_E82A5BF5FD36BF565D3FFA4E86C34B1E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_B35244305D5432355132FA62E1F363A2" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0E3E948FEE5940CA0E8DFA4E86C3120B" xlink:to="loc_us-gaap_MinorityInterest_B35244305D5432355132FA62E1F363A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_09ED34115D0DB2C5C9A8FA4E86C39260" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0E3E948FEE5940CA0E8DFA4E86C3120B" xlink:to="loc_us-gaap_SharesIssued_09ED34115D0DB2C5C9A8FA4E86C39260" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_F65CAA5A74AAB75EE499FA4E86C9E04E" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0E3E948FEE5940CA0E8DFA4E86C3120B" xlink:to="loc_us-gaap_NetIncomeLoss_F65CAA5A74AAB75EE499FA4E86C9E04E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_19FB94CADBFECE313C68FA4E86C98BC5" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0E3E948FEE5940CA0E8DFA4E86C3120B" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_19FB94CADBFECE313C68FA4E86C98BC5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_330255D061562EF2059EFA4E86C906FA" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0E3E948FEE5940CA0E8DFA4E86C3120B" xlink:to="loc_us-gaap_ProfitLoss_330255D061562EF2059EFA4E86C906FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_B617B661C12A79FAE5D7FA4E86CB4038" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0E3E948FEE5940CA0E8DFA4E86C3120B" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_B617B661C12A79FAE5D7FA4E86CB4038" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_4E5583132B126B4296B4FA4E86C9A5F4" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0E3E948FEE5940CA0E8DFA4E86C3120B" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_4E5583132B126B4296B4FA4E86C9A5F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_B759C8A3EB036466340FFA4E86CCA3EF" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0E3E948FEE5940CA0E8DFA4E86C3120B" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_B759C8A3EB036466340FFA4E86CCA3EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_BC00FB0592BDEF6D0CBCFA4E86CBAD02" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0E3E948FEE5940CA0E8DFA4E86C3120B" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_BC00FB0592BDEF6D0CBCFA4E86CBAD02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:label="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_075FB79A363488CE31FCFA4E86CBEE64" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0E3E948FEE5940CA0E8DFA4E86C3120B" xlink:to="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_075FB79A363488CE31FCFA4E86CBEE64" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_Noncontrollinginterestincreasedecreaseother" xlink:label="loc_biib_Noncontrollinginterestincreasedecreaseother_12AA7CD3387443EF5FE2FA702CB186D7" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0E3E948FEE5940CA0E8DFA4E86C3120B" xlink:to="loc_biib_Noncontrollinginterestincreasedecreaseother_12AA7CD3387443EF5FE2FA702CB186D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_EB0C7D9BD72EDDFD46CFFA4E86CC17B0" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0E3E948FEE5940CA0E8DFA4E86C3120B" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_EB0C7D9BD72EDDFD46CFFA4E86CC17B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_BD3ABF5978070366FA10FA4E86CC80A3" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0E3E948FEE5940CA0E8DFA4E86C3120B" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_BD3ABF5978070366FA10FA4E86CC80A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_F21AC471FB0200E0D930FA4E86CCFADF" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0E3E948FEE5940CA0E8DFA4E86C3120B" xlink:to="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_F21AC471FB0200E0D930FA4E86CCFADF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_9384811AD3563D189F83FA4E86CCED92" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0E3E948FEE5940CA0E8DFA4E86C3120B" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_9384811AD3563D189F83FA4E86CCED92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_45014191A8381260DF58FA4E86CCB485" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0E3E948FEE5940CA0E8DFA4E86C3120B" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_45014191A8381260DF58FA4E86CCB485" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_AD648C8DA2170A77E93BFA4E86CC01C0" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0E3E948FEE5940CA0E8DFA4E86C3120B" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_AD648C8DA2170A77E93BFA4E86CC01C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_EEB50A234E79C0DFC401FA4E86CCD2D6" xlink:type="locator" />
    <link:definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0E3E948FEE5940CA0E8DFA4E86C3120B" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_EEB50A234E79C0DFC401FA4E86CCD2D6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_693CA36EE6B80BF11F63FA4E86CC9975" xlink:type="locator" />
    <link:definitionArc order="21" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0E3E948FEE5940CA0E8DFA4E86C3120B" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_693CA36EE6B80BF11F63FA4E86CC9975" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_03C8D66D222607E8FB17FA4E86CC214F" xlink:type="locator" />
    <link:definitionArc order="22" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0E3E948FEE5940CA0E8DFA4E86C3120B" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_03C8D66D222607E8FB17FA4E86CC214F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_6951C9FFFB846813412AFA4E86CCB444" xlink:type="locator" />
    <link:definitionArc order="23" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0E3E948FEE5940CA0E8DFA4E86C3120B" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_6951C9FFFB846813412AFA4E86CCB444" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ConsolidatedStatementsOfIncome" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DerivativeInstruments" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativesFairValueLineItems" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_1179AEFBD10892F1480E186112F489A5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_E44222346ECE99266A93186112ED8AAE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_1179AEFBD10892F1480E186112F489A5" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_E44222346ECE99266A93186112ED8AAE" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrencyAxis" xlink:label="loc_us-gaap_CurrencyAxis_B51BED92C483DC215186186112EDB970" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_E44222346ECE99266A93186112ED8AAE" xlink:to="loc_us-gaap_CurrencyAxis_B51BED92C483DC215186186112EDB970" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_AA6E6542DD5A025958E0186112ED6FBD_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CurrencyAxis_B51BED92C483DC215186186112EDB970" xlink:to="loc_currency_AllCurrenciesDomain_AA6E6542DD5A025958E0186112ED6FBD_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_AA6E6542DD5A025958E0186112ED6FBD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CurrencyAxis_B51BED92C483DC215186186112EDB970" xlink:to="loc_currency_AllCurrenciesDomain_AA6E6542DD5A025958E0186112ED6FBD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd#currency_EUR" xlink:label="loc_currency_EUR_BBDAE1D78EB0878F04C3186112EDE3C8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_AA6E6542DD5A025958E0186112ED6FBD" xlink:to="loc_currency_EUR_BBDAE1D78EB0878F04C3186112EDE3C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd#currency_CHF" xlink:label="loc_currency_CHF_A8DD31A1A2099CD86D9E186112ED9FAB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_AA6E6542DD5A025958E0186112ED6FBD" xlink:to="loc_currency_CHF_A8DD31A1A2099CD86D9E186112ED9FAB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd#currency_CAD" xlink:label="loc_currency_CAD_6CBE88D1FA60149A95C9186112ED8B0C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_AA6E6542DD5A025958E0186112ED6FBD" xlink:to="loc_currency_CAD_6CBE88D1FA60149A95C9186112ED8B0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_657B9A6846DAC536C718186112EEC7B0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_E44222346ECE99266A93186112ED8AAE" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_657B9A6846DAC536C718186112EEC7B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_255C0D941A39BFAE286B186112EEF440_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_657B9A6846DAC536C718186112EEC7B0" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_255C0D941A39BFAE286B186112EEF440_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_255C0D941A39BFAE286B186112EEF440" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_657B9A6846DAC536C718186112EEC7B0" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_255C0D941A39BFAE286B186112EEF440" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="loc_us-gaap_ForeignExchangeContractMember_740A43694E7991786FCE186112EEF80A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_255C0D941A39BFAE286B186112EEF440" xlink:to="loc_us-gaap_ForeignExchangeContractMember_740A43694E7991786FCE186112EEF80A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_E9F7B9CB4F5C9A0F57B2186112EEAD69" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_E44222346ECE99266A93186112ED8AAE" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_E9F7B9CB4F5C9A0F57B2186112EEAD69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_7F7BE59861405F5F9A03186112EE1034_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_E9F7B9CB4F5C9A0F57B2186112EEAD69" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_7F7BE59861405F5F9A03186112EE1034_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_7F7BE59861405F5F9A03186112EE1034" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_E9F7B9CB4F5C9A0F57B2186112EEAD69" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_7F7BE59861405F5F9A03186112EE1034" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_5745D7DD90C294934703186112EEB39E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7F7BE59861405F5F9A03186112EE1034" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_5745D7DD90C294934703186112EEB39E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherInvestmentsMember" xlink:label="loc_us-gaap_OtherInvestmentsMember_B914893C190F339B7D97186112F305F3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7F7BE59861405F5F9A03186112EE1034" xlink:to="loc_us-gaap_OtherInvestmentsMember_B914893C190F339B7D97186112F305F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_379BCDD7D1C024696773186112F4157A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7F7BE59861405F5F9A03186112EE1034" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_379BCDD7D1C024696773186112F4157A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_D0E5A657A5AA1E6BA426186112F43986" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7F7BE59861405F5F9A03186112EE1034" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_D0E5A657A5AA1E6BA426186112F43986" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_592EC7CDF857F6D24008186112F44962" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_E44222346ECE99266A93186112ED8AAE" xlink:to="loc_us-gaap_HedgingDesignationAxis_592EC7CDF857F6D24008186112F44962" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_F8ED8A5ACD0D211BF31D186112F476D2_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_592EC7CDF857F6D24008186112F44962" xlink:to="loc_us-gaap_HedgingDesignationDomain_F8ED8A5ACD0D211BF31D186112F476D2_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_F8ED8A5ACD0D211BF31D186112F476D2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_592EC7CDF857F6D24008186112F44962" xlink:to="loc_us-gaap_HedgingDesignationDomain_F8ED8A5ACD0D211BF31D186112F476D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_4D3F532F0A3E8C8D4101186112F44698" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_F8ED8A5ACD0D211BF31D186112F476D2" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_4D3F532F0A3E8C8D4101186112F44698" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="loc_us-gaap_NondesignatedMember_44035CF15944EB78A8FD186112F47D25" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_F8ED8A5ACD0D211BF31D186112F476D2" xlink:to="loc_us-gaap_NondesignatedMember_44035CF15944EB78A8FD186112F47D25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_DerivativeNotionalAmount" xlink:label="loc_invest_DerivativeNotionalAmount_3B164CC99080F2DF68B5186112F41CF0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_1179AEFBD10892F1480E186112F489A5" xlink:to="loc_invest_DerivativeNotionalAmount_3B164CC99080F2DF68B5186112F41CF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeAssetFairValueNetAbstract" xlink:label="loc_us-gaap_DerivativeAssetFairValueNetAbstract_26230DFBF28AD02C4F65186112F46324" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_1179AEFBD10892F1480E186112F489A5" xlink:to="loc_us-gaap_DerivativeAssetFairValueNetAbstract_26230DFBF28AD02C4F65186112F46324" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_8A7B461A78C70294B3EB186112F4066A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeAssetFairValueNetAbstract_26230DFBF28AD02C4F65186112F46324" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_8A7B461A78C70294B3EB186112F4066A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_00ECC430F1245E830914186112F4AB13" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeAssetFairValueNetAbstract_26230DFBF28AD02C4F65186112F46324" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_00ECC430F1245E830914186112F4AB13" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_A39CC300AEA523911224FB6680133AB7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_34DCD7F960B80F9D1E97FB668012FAF6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_A39CC300AEA523911224FB6680133AB7" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_34DCD7F960B80F9D1E97FB668012FAF6" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_7BBFC8975BC9C4B99053FB668012D9AB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_34DCD7F960B80F9D1E97FB668012FAF6" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_7BBFC8975BC9C4B99053FB668012D9AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_A280D04F8E21772ED805FB66801288EA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_7BBFC8975BC9C4B99053FB668012D9AB" xlink:to="loc_us-gaap_HedgingRelationshipDomain_A280D04F8E21772ED805FB66801288EA_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_A280D04F8E21772ED805FB66801288EA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_7BBFC8975BC9C4B99053FB668012D9AB" xlink:to="loc_us-gaap_HedgingRelationshipDomain_A280D04F8E21772ED805FB66801288EA" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_CashflowsrevenueMember" xlink:label="loc_biib_CashflowsrevenueMember_507D7556AA9E08361F15FB668012D7E8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_A280D04F8E21772ED805FB66801288EA" xlink:to="loc_biib_CashflowsrevenueMember_507D7556AA9E08361F15FB668012D7E8" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_CashflowsoperatingexpensesMember" xlink:label="loc_biib_CashflowsoperatingexpensesMember_DDA91E7A320E5EE7E18EFB668012F39E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_A280D04F8E21772ED805FB66801288EA" xlink:to="loc_biib_CashflowsoperatingexpensesMember_DDA91E7A320E5EE7E18EFB668012F39E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_F290BE8C00DB34944206FB6680120083" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_34DCD7F960B80F9D1E97FB668012FAF6" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_F290BE8C00DB34944206FB6680120083" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_2CECFC135AD170E8F1B6FB668013A6CC_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_F290BE8C00DB34944206FB6680120083" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_2CECFC135AD170E8F1B6FB668013A6CC_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_2CECFC135AD170E8F1B6FB668013A6CC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_F290BE8C00DB34944206FB6680120083" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_2CECFC135AD170E8F1B6FB668013A6CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="loc_us-gaap_ForeignExchangeContractMember_8DB4036B1D96E28AEC3EFB668013BF12" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_2CECFC135AD170E8F1B6FB668013A6CC" xlink:to="loc_us-gaap_ForeignExchangeContractMember_8DB4036B1D96E28AEC3EFB668013BF12" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1A9D6CD01BC85D8D1249FB668013E198" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_34DCD7F960B80F9D1E97FB668012FAF6" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1A9D6CD01BC85D8D1249FB668013E198" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_C20CF2A963C92219A81CFB6680135339_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1A9D6CD01BC85D8D1249FB668013E198" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_C20CF2A963C92219A81CFB6680135339_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_C20CF2A963C92219A81CFB6680135339" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1A9D6CD01BC85D8D1249FB668013E198" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_C20CF2A963C92219A81CFB6680135339" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesMember" xlink:label="loc_us-gaap_SalesMember_FFE7E1FBAABDAD0D85BCFB6680136F66" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_C20CF2A963C92219A81CFB6680135339" xlink:to="loc_us-gaap_SalesMember_FFE7E1FBAABDAD0D85BCFB6680136F66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_69973FCE9F74433E7CABFB668013D4BF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_C20CF2A963C92219A81CFB6680135339" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_69973FCE9F74433E7CABFB668013D4BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenseMember" xlink:label="loc_us-gaap_OperatingExpenseMember_8CEE66D007DD8283F373FB6680135FF8" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_C20CF2A963C92219A81CFB6680135339" xlink:to="loc_us-gaap_OperatingExpenseMember_8CEE66D007DD8283F373FB6680135FF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNetAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNetAbstract_3F3A7C17B1A3BE73F461FB668013ABDA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_A39CC300AEA523911224FB6680133AB7" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNetAbstract_3F3A7C17B1A3BE73F461FB668013ABDA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_16AF03C759DF2C58D130FB6680136A5A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNetAbstract_3F3A7C17B1A3BE73F461FB668013ABDA" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_16AF03C759DF2C58D130FB6680136A5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_D2AB121D2B1355043A4FFB6680149A4F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNetAbstract_3F3A7C17B1A3BE73F461FB668013ABDA" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_D2AB121D2B1355043A4FFB6680149A4F" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativesFairValueLineItems" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_F0D72898DA7CC956EEDCFB6680068D64" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_8BF6C47D5795C29BD852FB668003AC5E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_F0D72898DA7CC956EEDCFB6680068D64" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_8BF6C47D5795C29BD852FB668003AC5E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_22F7A5A2E8AF9C633972FB66800438B5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_8BF6C47D5795C29BD852FB668003AC5E" xlink:to="loc_us-gaap_RangeAxis_22F7A5A2E8AF9C633972FB66800438B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_48A68AE7842B3D831AA5FB668004C539_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_22F7A5A2E8AF9C633972FB66800438B5" xlink:to="loc_us-gaap_RangeMember_48A68AE7842B3D831AA5FB668004C539_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_48A68AE7842B3D831AA5FB668004C539" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_22F7A5A2E8AF9C633972FB66800438B5" xlink:to="loc_us-gaap_RangeMember_48A68AE7842B3D831AA5FB668004C539" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_9489C7419AC4A154B011FB6680045D99" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_48A68AE7842B3D831AA5FB668004C539" xlink:to="loc_us-gaap_MinimumMember_9489C7419AC4A154B011FB6680045D99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_D76683016A8DE77B3954FB668004071E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_48A68AE7842B3D831AA5FB668004C539" xlink:to="loc_us-gaap_MaximumMember_D76683016A8DE77B3954FB668004071E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_C6BC7FEBC00234FDC2AAFB6680056C67" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_8BF6C47D5795C29BD852FB668003AC5E" xlink:to="loc_us-gaap_DebtInstrumentAxis_C6BC7FEBC00234FDC2AAFB6680056C67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8EF21CBD550D7C1BFB7BFB668005E155_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_C6BC7FEBC00234FDC2AAFB6680056C67" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8EF21CBD550D7C1BFB7BFB668005E155_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8EF21CBD550D7C1BFB7BFB668005E155" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_C6BC7FEBC00234FDC2AAFB6680056C67" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8EF21CBD550D7C1BFB7BFB668005E155" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_EB5D5AF8F1DDF80D8FA1FB668005FECC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8EF21CBD550D7C1BFB7BFB668005E155" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_EB5D5AF8F1DDF80D8FA1FB668005FECC" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_AE349128F8900B42E8F5FB6680057E8C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8EF21CBD550D7C1BFB7BFB668005E155" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_AE349128F8900B42E8F5FB6680057E8C" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_06D2CA3ED529EED137C4FB6680055156" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8EF21CBD550D7C1BFB7BFB668005E155" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_06D2CA3ED529EED137C4FB6680055156" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_20C6C0BB40981E6AF767FB6680055CBD" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_8BF6C47D5795C29BD852FB668003AC5E" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_20C6C0BB40981E6AF767FB6680055CBD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_A3C34263A548BA4DFFABFB6680056163_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_20C6C0BB40981E6AF767FB6680055CBD" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_A3C34263A548BA4DFFABFB6680056163_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_A3C34263A548BA4DFFABFB6680056163" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_20C6C0BB40981E6AF767FB6680055CBD" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_A3C34263A548BA4DFFABFB6680056163" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestRateContractMember" xlink:label="loc_us-gaap_InterestRateContractMember_0BC792B987CE7F40A565FB6680054D0C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_A3C34263A548BA4DFFABFB6680056163" xlink:to="loc_us-gaap_InterestRateContractMember_0BC792B987CE7F40A565FB6680054D0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember_F13D63C6AFD3ACAC3980FB6680055877" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_A3C34263A548BA4DFFABFB6680056163" xlink:to="loc_us-gaap_InterestRateSwapMember_F13D63C6AFD3ACAC3980FB6680055877" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_52BBBC171EE38D0B4667FB6680053378" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_8BF6C47D5795C29BD852FB668003AC5E" xlink:to="loc_us-gaap_HedgingDesignationAxis_52BBBC171EE38D0B4667FB6680053378" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_0D221CDC070FEFEC0C9CFB6680056B80_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_52BBBC171EE38D0B4667FB6680053378" xlink:to="loc_us-gaap_HedgingDesignationDomain_0D221CDC070FEFEC0C9CFB6680056B80_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_0D221CDC070FEFEC0C9CFB6680056B80" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_52BBBC171EE38D0B4667FB6680053378" xlink:to="loc_us-gaap_HedgingDesignationDomain_0D221CDC070FEFEC0C9CFB6680056B80" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_77C57B707FA5DDF57596FB668006FF6E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_0D221CDC070FEFEC0C9CFB6680056B80" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_77C57B707FA5DDF57596FB668006FF6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="loc_us-gaap_NondesignatedMember_B0E1373503EA2087430BFB6680060024" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_0D221CDC070FEFEC0C9CFB6680056B80" xlink:to="loc_us-gaap_NondesignatedMember_B0E1373503EA2087430BFB6680060024" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeRemainingMaturity1" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1_955D089587F4AA09DAF2FB66800649BC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_F0D72898DA7CC956EEDCFB6680068D64" xlink:to="loc_us-gaap_DerivativeRemainingMaturity1_955D089587F4AA09DAF2FB66800649BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_DerivativeNotionalAmount" xlink:label="loc_invest_DerivativeNotionalAmount_30CB92F9D52F45BFAAAFFB6680065E7B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_F0D72898DA7CC956EEDCFB6680068D64" xlink:to="loc_invest_DerivativeNotionalAmount_30CB92F9D52F45BFAAAFFB6680065E7B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_06CDF68D16D3273F45BAFB66800636E3" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_F0D72898DA7CC956EEDCFB6680068D64" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_06CDF68D16D3273F45BAFB66800636E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_2C73426F798D539A9817FB66800645D7" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_F0D72898DA7CC956EEDCFB6680068D64" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_2C73426F798D539A9817FB66800645D7" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EarningsPerShare" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_B3C5EDA290A7207E19A774128546FC8A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_405885FB801A26F6CD28741285461380" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_B3C5EDA290A7207E19A774128546FC8A" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_405885FB801A26F6CD28741285461380" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3D6521F7DE12D3604596741285468FD2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_405885FB801A26F6CD28741285461380" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3D6521F7DE12D3604596741285468FD2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0B122B3CFECA999F5C45741285468C47_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3D6521F7DE12D3604596741285468FD2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0B122B3CFECA999F5C45741285468C47_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0B122B3CFECA999F5C45741285468C47" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3D6521F7DE12D3604596741285468FD2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0B122B3CFECA999F5C45741285468C47" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_StockOptionsAndEmployeeStockPurchasePlanMember" xlink:label="loc_biib_StockOptionsAndEmployeeStockPurchasePlanMember_E78A59C52EEDABD124E674128546A36F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0B122B3CFECA999F5C45741285468C47" xlink:to="loc_biib_StockOptionsAndEmployeeStockPurchasePlanMember_E78A59C52EEDABD124E674128546A36F" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_233C56A82D092AFD36FC7412854645F5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0B122B3CFECA999F5C45741285468C47" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_233C56A82D092AFD36FC7412854645F5" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_0B7D95AF5AF21DDDE7EF74128546B1BC" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0B122B3CFECA999F5C45741285468C47" xlink:to="loc_biib_MarketStockUnitsMember_0B7D95AF5AF21DDDE7EF74128546B1BC" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_BasicAndDilutedEarningsPerShareAbstract" xlink:label="loc_biib_BasicAndDilutedEarningsPerShareAbstract_4C0290AF0CD79276F6997412854641C9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_B3C5EDA290A7207E19A774128546FC8A" xlink:to="loc_biib_BasicAndDilutedEarningsPerShareAbstract_4C0290AF0CD79276F6997412854641C9" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_NumeratorAbstract" xlink:label="loc_biib_NumeratorAbstract_6715CC6AD8F213A757397412854646AC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_4C0290AF0CD79276F6997412854641C9" xlink:to="loc_biib_NumeratorAbstract_6715CC6AD8F213A757397412854646AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_0F1DE0E8F05F3EE856F47412854697F0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_NumeratorAbstract_6715CC6AD8F213A757397412854646AC" xlink:to="loc_us-gaap_NetIncomeLoss_0F1DE0E8F05F3EE856F47412854697F0" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_DenominatorAbstract" xlink:label="loc_biib_DenominatorAbstract_440A9944CF67CDD0BBBA741285463724" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_4C0290AF0CD79276F6997412854641C9" xlink:to="loc_biib_DenominatorAbstract_440A9944CF67CDD0BBBA741285463724" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_C5E1F5F301F2613EE0A674128546F32E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_DenominatorAbstract_440A9944CF67CDD0BBBA741285463724" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_C5E1F5F301F2613EE0A674128546F32E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_0F494F54B561DEC4FE4974128546CDB7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_DenominatorAbstract_440A9944CF67CDD0BBBA741285463724" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_0F494F54B561DEC4FE4974128546CDB7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_114DB08C90AEEC8432C574128546E076" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_0F494F54B561DEC4FE4974128546CDB7" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_114DB08C90AEEC8432C574128546E076" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_5496007EB242490CE16B741285471985" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_0F494F54B561DEC4FE4974128546CDB7" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_5496007EB242490CE16B741285471985" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_24B4B2C04F281ABB404374128547D45A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_DenominatorAbstract_440A9944CF67CDD0BBBA741285463724" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_24B4B2C04F281ABB404374128547D45A" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EarningsPerShareTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EmployeeBenefitPlans" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EmployeeBenefitPlansDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_13479C04743014554B3FFD60F5C184FB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_9AB432A796BA545F439EFD60F5C0A275" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_13479C04743014554B3FFD60F5C184FB" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_9AB432A796BA545F439EFD60F5C0A275" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis" xlink:label="loc_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_6F29096E529B1F29FED9FD60F5C168EF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_9AB432A796BA545F439EFD60F5C0A275" xlink:to="loc_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_6F29096E529B1F29FED9FD60F5C168EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefinedBenefitPlansDomain" xlink:label="loc_us-gaap_DefinedBenefitPlansDomain_2D6164896BA60719C29AFD60F5C19D5B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_6F29096E529B1F29FED9FD60F5C168EF" xlink:to="loc_us-gaap_DefinedBenefitPlansDomain_2D6164896BA60719C29AFD60F5C19D5B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefinedBenefitPlansDomain" xlink:label="loc_us-gaap_DefinedBenefitPlansDomain_2D6164896BA60719C29AFD60F5C19D5B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_6F29096E529B1F29FED9FD60F5C168EF" xlink:to="loc_us-gaap_DefinedBenefitPlansDomain_2D6164896BA60719C29AFD60F5C19D5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignPensionPlansDefinedBenefitMember" xlink:label="loc_us-gaap_ForeignPensionPlansDefinedBenefitMember_F21ADBC6EDDE7D137A5CFD6419EBF273" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansDomain_2D6164896BA60719C29AFD60F5C19D5B" xlink:to="loc_us-gaap_ForeignPensionPlansDefinedBenefitMember_F21ADBC6EDDE7D137A5CFD6419EBF273" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_67C5FB5D02E7E9D86146FD66B9F28C3C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_9AB432A796BA545F439EFD60F5C0A275" xlink:to="loc_us-gaap_StatementGeographicalAxis_67C5FB5D02E7E9D86146FD66B9F28C3C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_098044288CA921EA5970FD66BAAC8841_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementGeographicalAxis_67C5FB5D02E7E9D86146FD66B9F28C3C" xlink:to="loc_us-gaap_SegmentGeographicalDomain_098044288CA921EA5970FD66BAAC8841_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_098044288CA921EA5970FD66BAAC8841" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementGeographicalAxis_67C5FB5D02E7E9D86146FD66B9F28C3C" xlink:to="loc_us-gaap_SegmentGeographicalDomain_098044288CA921EA5970FD66BAAC8841" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd#country_CH" xlink:label="loc_country_CH_0EAA89673D11D8FB27C9FD6742C94FEB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_098044288CA921EA5970FD66BAAC8841" xlink:to="loc_country_CH_0EAA89673D11D8FB27C9FD6742C94FEB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd#country_DE" xlink:label="loc_country_DE_BE99447F614882305BD6FD688657C73A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_098044288CA921EA5970FD66BAAC8841" xlink:to="loc_country_DE_BE99447F614882305BD6FD688657C73A" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_EmployeeBenefitPlansTextualAbstract" xlink:label="loc_biib_EmployeeBenefitPlansTextualAbstract_7A70FCB58BEB71A72903FD60F5C14026" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_13479C04743014554B3FFD60F5C184FB" xlink:to="loc_biib_EmployeeBenefitPlansTextualAbstract_7A70FCB58BEB71A72903FD60F5C14026" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_PercentageOfMinimumInvestmentReturn" xlink:label="loc_biib_PercentageOfMinimumInvestmentReturn_B803952E3AC6721C66B7FD60F5C168C8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_EmployeeBenefitPlansTextualAbstract_7A70FCB58BEB71A72903FD60F5C14026" xlink:to="loc_biib_PercentageOfMinimumInvestmentReturn_B803952E3AC6721C66B7FD60F5C168C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_E9A909DCC0F31FA6C863FD60F5C208A7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_EmployeeBenefitPlansTextualAbstract_7A70FCB58BEB71A72903FD60F5C14026" xlink:to="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_E9A909DCC0F31FA6C863FD60F5C208A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_152647AA8B6CA2F0F7D3FD60F5C22261" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_EmployeeBenefitPlansTextualAbstract_7A70FCB58BEB71A72903FD60F5C14026" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_152647AA8B6CA2F0F7D3FD60F5C22261" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PensionExpense" xlink:label="loc_us-gaap_PensionExpense_2396CA64D497F4D40453FD60F5C25E4F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_EmployeeBenefitPlansTextualAbstract_7A70FCB58BEB71A72903FD60F5C14026" xlink:to="loc_us-gaap_PensionExpense_2396CA64D497F4D40453FD60F5C25E4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_CC3BAFC54E0950244E81FD60F5C23CED" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_EmployeeBenefitPlansTextualAbstract_7A70FCB58BEB71A72903FD60F5C14026" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_CC3BAFC54E0950244E81FD60F5C23CED" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EmployeeBenefitPlansEmployeeBenefitPlansDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_60F954C5A78454392A34FD645195A226" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="loc_us-gaap_DefinedContributionPlanTable_C4C775A7D36A0F609D51FD64519486FE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_60F954C5A78454392A34FD645195A226" xlink:to="loc_us-gaap_DefinedContributionPlanTable_C4C775A7D36A0F609D51FD64519486FE" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefinedContributionPlanTypeAxis" xlink:label="loc_us-gaap_DefinedContributionPlanTypeAxis_3D839D87DF83F0AB7DF7FD6451952CA5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedContributionPlanTable_C4C775A7D36A0F609D51FD64519486FE" xlink:to="loc_us-gaap_DefinedContributionPlanTypeAxis_3D839D87DF83F0AB7DF7FD6451952CA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefinedContributionPlanTypeDomain" xlink:label="loc_us-gaap_DefinedContributionPlanTypeDomain_3DF3F09439BE8A680A6CFD645195EB5B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DefinedContributionPlanTypeAxis_3D839D87DF83F0AB7DF7FD6451952CA5" xlink:to="loc_us-gaap_DefinedContributionPlanTypeDomain_3DF3F09439BE8A680A6CFD645195EB5B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefinedContributionPlanTypeDomain" xlink:label="loc_us-gaap_DefinedContributionPlanTypeDomain_3DF3F09439BE8A680A6CFD645195EB5B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DefinedContributionPlanTypeAxis_3D839D87DF83F0AB7DF7FD6451952CA5" xlink:to="loc_us-gaap_DefinedContributionPlanTypeDomain_3DF3F09439BE8A680A6CFD645195EB5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnitedStatesPostretirementBenefitPlansOfUSEntityDefinedBenefitMember" xlink:label="loc_us-gaap_UnitedStatesPostretirementBenefitPlansOfUSEntityDefinedBenefitMember_F8051DF1BA9540C14AE8FD64519560F5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedContributionPlanTypeDomain_3DF3F09439BE8A680A6CFD645195EB5B" xlink:to="loc_us-gaap_UnitedStatesPostretirementBenefitPlansOfUSEntityDefinedBenefitMember_F8051DF1BA9540C14AE8FD64519560F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_136486EEEF0CD6313610FD6BA62FDA67" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedContributionPlanTypeDomain_3DF3F09439BE8A680A6CFD645195EB5B" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_136486EEEF0CD6313610FD6BA62FDA67" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_MinimumQualifyingAgeForEmployeeBenefitPlan" xlink:label="loc_biib_MinimumQualifyingAgeForEmployeeBenefitPlan_1634074B30605814AFF0FD645195979B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_60F954C5A78454392A34FD645195A226" xlink:to="loc_biib_MinimumQualifyingAgeForEmployeeBenefitPlan_1634074B30605814AFF0FD645195979B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_E17AD2B62461B01A77F1FD6451951985" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_60F954C5A78454392A34FD645195A226" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_E17AD2B62461B01A77F1FD6451951985" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:label="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_4A360062E9362E8FB324FD6451959BDC" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_60F954C5A78454392A34FD645195A226" xlink:to="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_4A360062E9362E8FB324FD6451959BDC" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/Equity" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EquityDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EquityDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_FACBFD4C48C6B6B40D70885D71DA4DF9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_B25930ABFB3B1B06F7D9885D71D9E738" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_FACBFD4C48C6B6B40D70885D71DA4DF9" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_B25930ABFB3B1B06F7D9885D71D9E738" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_BED900729CBA0DB819F6885D71D9455B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_B25930ABFB3B1B06F7D9885D71D9E738" xlink:to="loc_us-gaap_StatementClassOfStockAxis_BED900729CBA0DB819F6885D71D9455B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_B0E001EB0DA96B832B6E885D71D9E4AD_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_BED900729CBA0DB819F6885D71D9455B" xlink:to="loc_us-gaap_ClassOfStockDomain_B0E001EB0DA96B832B6E885D71D9E4AD_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_B0E001EB0DA96B832B6E885D71D9E4AD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_BED900729CBA0DB819F6885D71D9455B" xlink:to="loc_us-gaap_ClassOfStockDomain_B0E001EB0DA96B832B6E885D71D9E4AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_A2CFEEB2754F29240CFF885D71D9BD58" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_B0E001EB0DA96B832B6E885D71D9E4AD" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_A2CFEEB2754F29240CFF885D71D9BD58" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_SeriesXPreferredStockMember" xlink:label="loc_biib_SeriesXPreferredStockMember_4817424A7F71C9DFF7C2885D71DADE28" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_B0E001EB0DA96B832B6E885D71D9E4AD" xlink:to="loc_biib_SeriesXPreferredStockMember_4817424A7F71C9DFF7C2885D71DADE28" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_UndesignatedPreferredStockMember" xlink:label="loc_biib_UndesignatedPreferredStockMember_1E5BD6E086FF1C15BAA7885D71DA954A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_B0E001EB0DA96B832B6E885D71D9E4AD" xlink:to="loc_biib_UndesignatedPreferredStockMember_1E5BD6E086FF1C15BAA7885D71DA954A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_188C0B99672A470C7EEB885D71DA4B2A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_FACBFD4C48C6B6B40D70885D71DA4DF9" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_188C0B99672A470C7EEB885D71DA4B2A" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EquityTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurements" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_D0B12C1FE3D48CC43B8C741289654F67" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3CCB0A2AB40DAF2E2F9B741289630065" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_D0B12C1FE3D48CC43B8C741289654F67" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3CCB0A2AB40DAF2E2F9B741289630065" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_327672A363745DB84C9F74128964607C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3CCB0A2AB40DAF2E2F9B741289630065" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_327672A363745DB84C9F74128964607C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1DDEEFDCD55F1D744C83741289643D96_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_327672A363745DB84C9F74128964607C" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1DDEEFDCD55F1D744C83741289643D96_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1DDEEFDCD55F1D744C83741289643D96" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_327672A363745DB84C9F74128964607C" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1DDEEFDCD55F1D744C83741289643D96" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_9D9C356F0EFCB93ECEDF74128964A4A4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1DDEEFDCD55F1D744C83741289643D96" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_9D9C356F0EFCB93ECEDF74128964A4A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_DB096D52768136F61AF974128964987C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1DDEEFDCD55F1D744C83741289643D96" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_DB096D52768136F61AF974128964987C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_3EEE1517D2B327599B6A741289647B8C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1DDEEFDCD55F1D744C83741289643D96" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_3EEE1517D2B327599B6A741289647B8C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_73C9E29BF6AEB9D30F2A741289643C76" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3CCB0A2AB40DAF2E2F9B741289630065" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_73C9E29BF6AEB9D30F2A741289643C76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_406003CA77C8EF712832741289644A6A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_73C9E29BF6AEB9D30F2A741289643C76" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_406003CA77C8EF712832741289644A6A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_406003CA77C8EF712832741289644A6A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_73C9E29BF6AEB9D30F2A741289643C76" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_406003CA77C8EF712832741289644A6A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_8FCAF976D552BC56841C74128964499B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_406003CA77C8EF712832741289644A6A" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_8FCAF976D552BC56841C74128964499B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_D94706AFE6497BB12B3274128964AB8F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3CCB0A2AB40DAF2E2F9B741289630065" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_D94706AFE6497BB12B3274128964AB8F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_036C5ED6840CCBCC63DB74128964ED11_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_D94706AFE6497BB12B3274128964AB8F" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_036C5ED6840CCBCC63DB74128964ED11_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_036C5ED6840CCBCC63DB74128964ED11" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_D94706AFE6497BB12B3274128964AB8F" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_036C5ED6840CCBCC63DB74128964ED11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_67889AE4268160F0FE6D74128965752D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_036C5ED6840CCBCC63DB74128964ED11" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_67889AE4268160F0FE6D74128965752D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_DEF1CB5B47F0DEF646C974128965E928" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_036C5ED6840CCBCC63DB74128964ED11" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_DEF1CB5B47F0DEF646C974128965E928" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_7F50926FDE3AB1CEF983741289658F24" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_036C5ED6840CCBCC63DB74128964ED11" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_7F50926FDE3AB1CEF983741289658F24" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_4E1AEE1C863591E840CB74128965E970" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_D0B12C1FE3D48CC43B8C741289654F67" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_4E1AEE1C863591E840CB74128965E970" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_5FCC9271109AD25A7E0074128965442F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_4E1AEE1C863591E840CB74128965E970" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_5FCC9271109AD25A7E0074128965442F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_10CAD8AF675AB0EFA3B874128965A54A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_5FCC9271109AD25A7E0074128965442F" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_10CAD8AF675AB0EFA3B874128965A54A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_AE74DF41AF5479492ECB74128965820A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_5FCC9271109AD25A7E0074128965442F" xlink:to="loc_us-gaap_AvailableForSaleSecurities_AE74DF41AF5479492ECB74128965820A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_AD5E170D5A8B38B9977F741289652F71" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_5FCC9271109AD25A7E0074128965442F" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_AD5E170D5A8B38B9977F741289652F71" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_E4EEF57A4D4FE7A07D4E741289659AFF" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_5FCC9271109AD25A7E0074128965442F" xlink:to="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_E4EEF57A4D4FE7A07D4E741289659AFF" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:label="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_C8C1BB0AD6F0093A41BC7412896585C0" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_5FCC9271109AD25A7E0074128965442F" xlink:to="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_C8C1BB0AD6F0093A41BC7412896585C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_B2AD5C745A88A43189FC74128965BA58" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_5FCC9271109AD25A7E0074128965442F" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_B2AD5C745A88A43189FC74128965BA58" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_11F3CF729521E65566BE74128965979B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_4E1AEE1C863591E840CB74128965E970" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_11F3CF729521E65566BE74128965979B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_42B408E63F6A1660B2A274128965C053" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_11F3CF729521E65566BE74128965979B" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_42B408E63F6A1660B2A274128965C053" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_F7B45837B03645D7C2157412896529B4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_11F3CF729521E65566BE74128965979B" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_F7B45837B03645D7C2157412896529B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_D11E3591EC46CA7F13FC74128966E035" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_11F3CF729521E65566BE74128965979B" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_D11E3591EC46CA7F13FC74128966E035" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_7E2CBB85700DB8BB77347412859F50BC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_7BE162E006E5D581FC297412859EA504" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7E2CBB85700DB8BB77347412859F50BC" xlink:to="loc_us-gaap_DebtInstrumentTable_7BE162E006E5D581FC297412859EA504" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_ADDE80E33EC568A8608C7412859EA3B2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_7BE162E006E5D581FC297412859EA504" xlink:to="loc_us-gaap_DebtInstrumentAxis_ADDE80E33EC568A8608C7412859EA3B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_90FDF59E18AF3798FADE7412859EB6E3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_ADDE80E33EC568A8608C7412859EA3B2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_90FDF59E18AF3798FADE7412859EB6E3_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_90FDF59E18AF3798FADE7412859EB6E3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_ADDE80E33EC568A8608C7412859EA3B2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_90FDF59E18AF3798FADE7412859EB6E3" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_NotesPayableToFumedicaMember" xlink:label="loc_biib_NotesPayableToFumedicaMember_4E4617E10B794EDCC7D47412859E0241" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_90FDF59E18AF3798FADE7412859EB6E3" xlink:to="loc_biib_NotesPayableToFumedicaMember_4E4617E10B794EDCC7D47412859E0241" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" xlink:label="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_4084E52831D341B78D767412859EF3FA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_90FDF59E18AF3798FADE7412859EB6E3" xlink:to="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_4084E52831D341B78D767412859EF3FA" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_DBE602EE205B351E28E37412859E52DD" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_90FDF59E18AF3798FADE7412859EB6E3" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_DBE602EE205B351E28E37412859E52DD" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_F12C83D12ABD9C31696A7412859E776B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_90FDF59E18AF3798FADE7412859EB6E3" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_F12C83D12ABD9C31696A7412859E776B" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_292B8878B2255D249CD67412859F1224" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_90FDF59E18AF3798FADE7412859EB6E3" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_292B8878B2255D249CD67412859F1224" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_FD9DF289EED4A6D3B0997412859F25B2" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_90FDF59E18AF3798FADE7412859EB6E3" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_FD9DF289EED4A6D3B0997412859F25B2" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_SummaryOfFairAndCarryingValueOfDebtInstrumentsAbstract" xlink:label="loc_biib_SummaryOfFairAndCarryingValueOfDebtInstrumentsAbstract_6B4FCE642438FE521A5B7412859F4EC2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7E2CBB85700DB8BB77347412859F50BC" xlink:to="loc_biib_SummaryOfFairAndCarryingValueOfDebtInstrumentsAbstract_6B4FCE642438FE521A5B7412859F4EC2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_5252426369D9D3D944287412859F99AE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfFairAndCarryingValueOfDebtInstrumentsAbstract_6B4FCE642438FE521A5B7412859F4EC2" xlink:to="loc_us-gaap_NotesPayableFairValueDisclosure_5252426369D9D3D944287412859F99AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue_0282930666FA3A4788087412859F35F5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfFairAndCarryingValueOfDebtInstrumentsAbstract_6B4FCE642438FE521A5B7412859F4EC2" xlink:to="loc_us-gaap_DebtInstrumentFairValue_0282930666FA3A4788087412859F35F5" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_1B4B38B37E52C5C969AEFA4EA53E6D9F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_FB7B8C5DDC8492BAE5BAFA4EA53D5F5F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_1B4B38B37E52C5C969AEFA4EA53E6D9F" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_FB7B8C5DDC8492BAE5BAFA4EA53D5F5F" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_B329E351399F2ED734B3FA4EA53ED875" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_FB7B8C5DDC8492BAE5BAFA4EA53D5F5F" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_B329E351399F2ED734B3FA4EA53ED875" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_E7ACDDB1850C0A4A3932FA4EA53E907E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_B329E351399F2ED734B3FA4EA53ED875" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_E7ACDDB1850C0A4A3932FA4EA53E907E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_E7ACDDB1850C0A4A3932FA4EA53E907E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_B329E351399F2ED734B3FA4EA53ED875" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_E7ACDDB1850C0A4A3932FA4EA53E907E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_1D3CF788F24BD52B7303FA4EA53E2C83" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_E7ACDDB1850C0A4A3932FA4EA53E907E" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_1D3CF788F24BD52B7303FA4EA53E2C83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_412E1EE25FF8A4D8C00AFA4EA53E8F3B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_1B4B38B37E52C5C969AEFA4EA53E6D9F" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_412E1EE25FF8A4D8C00AFA4EA53E8F3B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_EE50A41D540140D05341FA4EA53E768A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_1B4B38B37E52C5C969AEFA4EA53E6D9F" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_EE50A41D540140D05341FA4EA53E768A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_86ED79D9FA5087E3162DFA4EA53FFEE2" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_1B4B38B37E52C5C969AEFA4EA53E6D9F" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_86ED79D9FA5087E3162DFA4EA53FFEE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_A2F47AECA9BA45E88510FA4EA53FB925" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_1B4B38B37E52C5C969AEFA4EA53E6D9F" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_A2F47AECA9BA45E88510FA4EA53FB925" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_4EF1E1805E3186E4199AFA4EA5379C6E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_78ECBFDD8E3BDE88A018FA4EA5368038" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_4EF1E1805E3186E4199AFA4EA5379C6E" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_78ECBFDD8E3BDE88A018FA4EA5368038" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_D125E2B5A79F770352BFFA4EA5369282" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_78ECBFDD8E3BDE88A018FA4EA5368038" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_D125E2B5A79F770352BFFA4EA5369282" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_D2B4DB4C6D0F7CF954CEFA4EA536C51E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_D125E2B5A79F770352BFFA4EA5369282" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_D2B4DB4C6D0F7CF954CEFA4EA536C51E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_D2B4DB4C6D0F7CF954CEFA4EA536C51E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_D125E2B5A79F770352BFFA4EA5369282" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_D2B4DB4C6D0F7CF954CEFA4EA536C51E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_8B6D9933976C20040909FA4EA53614A6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_D2B4DB4C6D0F7CF954CEFA4EA536C51E" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_8B6D9933976C20040909FA4EA53614A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_5BE0BAE2E6313D435495FA4EA536ACA6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_D2B4DB4C6D0F7CF954CEFA4EA536C51E" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_5BE0BAE2E6313D435495FA4EA536ACA6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_83E88747D6223C3930C8FA4EA536754B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_78ECBFDD8E3BDE88A018FA4EA5368038" xlink:to="loc_us-gaap_DebtInstrumentAxis_83E88747D6223C3930C8FA4EA536754B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_B4F142E23D2B19044F93FA4EA536AC22_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_83E88747D6223C3930C8FA4EA536754B" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_B4F142E23D2B19044F93FA4EA536AC22_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_B4F142E23D2B19044F93FA4EA536AC22" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_83E88747D6223C3930C8FA4EA536754B" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_B4F142E23D2B19044F93FA4EA536AC22" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" xlink:label="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_E385C0A2922D4B9DEAB6FA4EA536F876" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_B4F142E23D2B19044F93FA4EA536AC22" xlink:to="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_E385C0A2922D4B9DEAB6FA4EA536F876" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_D3CC7B27317746D5FB44FA4EA536CDFA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_B4F142E23D2B19044F93FA4EA536AC22" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_D3CC7B27317746D5FB44FA4EA536CDFA" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_088698FF8E92E1CE60FFFA4EA5369D45" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_B4F142E23D2B19044F93FA4EA536AC22" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_088698FF8E92E1CE60FFFA4EA5369D45" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_54130BA99456F081A158FA4EA5375F8E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_B4F142E23D2B19044F93FA4EA536AC22" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_54130BA99456F081A158FA4EA5375F8E" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_6F1C36A012A1FF654A3AFA4EA53740E9" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_B4F142E23D2B19044F93FA4EA536AC22" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_6F1C36A012A1FF654A3AFA4EA53740E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_4EA20B08800657F7990CFA4EA537DC10" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_78ECBFDD8E3BDE88A018FA4EA5368038" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_4EA20B08800657F7990CFA4EA537DC10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_17F6054F3BE813882AF0FA4EA537B559_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4EA20B08800657F7990CFA4EA537DC10" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_17F6054F3BE813882AF0FA4EA537B559_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_17F6054F3BE813882AF0FA4EA537B559" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4EA20B08800657F7990CFA4EA537DC10" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_17F6054F3BE813882AF0FA4EA537B559" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ConvergencePharmaceuticalsMember" xlink:label="loc_biib_ConvergencePharmaceuticalsMember_D2E70236A4084E26A09CFA4EA5373EC9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_17F6054F3BE813882AF0FA4EA537B559" xlink:to="loc_biib_ConvergencePharmaceuticalsMember_D2E70236A4084E26A09CFA4EA5373EC9" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_StromedixMember" xlink:label="loc_biib_StromedixMember_784859EF897FF5D52BB5FA4EA5374ABF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_17F6054F3BE813882AF0FA4EA537B559" xlink:to="loc_biib_StromedixMember_784859EF897FF5D52BB5FA4EA5374ABF" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_BiogenIdecInternationalNeuroscienceMember" xlink:label="loc_biib_BiogenIdecInternationalNeuroscienceMember_0A875F6FBFBB38E9FF52FA4EA537B4AF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_17F6054F3BE813882AF0FA4EA537B559" xlink:to="loc_biib_BiogenIdecInternationalNeuroscienceMember_0A875F6FBFBB38E9FF52FA4EA537B4AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_8D32529963D92B94907CFA4EA537EEEC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_4EF1E1805E3186E4199AFA4EA5379C6E" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_8D32529963D92B94907CFA4EA537EEEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_66B267C10EB54D203109FA4EA5370DCF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_4EF1E1805E3186E4199AFA4EA5379C6E" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_66B267C10EB54D203109FA4EA5370DCF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilities" xlink:label="loc_us-gaap_OtherLiabilities_0C3AFECB77D6E3B39895FB4679C40AA2" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_4EF1E1805E3186E4199AFA4EA5379C6E" xlink:to="loc_us-gaap_OtherLiabilities_0C3AFECB77D6E3B39895FB4679C40AA2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsChangesInValuationTechniques" xlink:label="loc_us-gaap_FairValueMeasurementsChangesInValuationTechniques_7AA68F08FD585028A6B4FA4EA537A0A2" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_4EF1E1805E3186E4199AFA4EA5379C6E" xlink:to="loc_us-gaap_FairValueMeasurementsChangesInValuationTechniques_7AA68F08FD585028A6B4FA4EA537A0A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_673F71BAFC271E72CD2BFA4EA5380797" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_4EF1E1805E3186E4199AFA4EA5379C6E" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_673F71BAFC271E72CD2BFA4EA5380797" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_C68A841C4CC5E052385FFA4EA538F6F7" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_4EF1E1805E3186E4199AFA4EA5379C6E" xlink:to="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_C68A841C4CC5E052385FFA4EA538F6F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_62A6C02D296D7D6E9655FA4EA538825A" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_4EF1E1805E3186E4199AFA4EA5379C6E" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_62A6C02D296D7D6E9655FA4EA538825A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_DFC8E9C90B07E21FD0A5FA4EA538CA1F" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_4EF1E1805E3186E4199AFA4EA5379C6E" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_DFC8E9C90B07E21FD0A5FA4EA538CA1F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsDiscountRate" xlink:label="loc_us-gaap_FairValueInputsDiscountRate_CB159300AD6FAA01224CFA4EA5386A30" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_4EF1E1805E3186E4199AFA4EA5379C6E" xlink:to="loc_us-gaap_FairValueInputsDiscountRate_CB159300AD6FAA01224CFA4EA5386A30" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_MilestonePaymentsMadeDuringPeriod" xlink:label="loc_biib_MilestonePaymentsMadeDuringPeriod_0EA421F0C707B691E719FA4EA538BEAD" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_4EF1E1805E3186E4199AFA4EA5379C6E" xlink:to="loc_biib_MilestonePaymentsMadeDuringPeriod_0EA421F0C707B691E719FA4EA538BEAD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_CC3C5579E5A659874F61FA4EA53858E4" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_4EF1E1805E3186E4199AFA4EA5379C6E" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_CC3C5579E5A659874F61FA4EA53858E4" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstruments" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_1DB70DD5DD3D25B62DE6741285700C88" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_1F721FFCC55D9C3F555C7412857086EF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_1DB70DD5DD3D25B62DE6741285700C88" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_1F721FFCC55D9C3F555C7412857086EF" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_E256350D4D10EC26D713741285704312" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_1F721FFCC55D9C3F555C7412857086EF" xlink:to="loc_us-gaap_InvestmentTypeAxis_E256350D4D10EC26D713741285704312" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_07ABD2017CF721E7DAB874128570B8B1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_E256350D4D10EC26D713741285704312" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_07ABD2017CF721E7DAB874128570B8B1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_07ABD2017CF721E7DAB874128570B8B1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_E256350D4D10EC26D713741285704312" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_07ABD2017CF721E7DAB874128570B8B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_5926A2C99DC4B2E701F274128570409E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_07ABD2017CF721E7DAB874128570B8B1" xlink:to="loc_us-gaap_CommercialPaperMember_5926A2C99DC4B2E701F274128570409E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementsMember" xlink:label="loc_us-gaap_RepurchaseAgreementsMember_AE2A18DBD3EC6D4BCAF974128570C971" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_07ABD2017CF721E7DAB874128570B8B1" xlink:to="loc_us-gaap_RepurchaseAgreementsMember_AE2A18DBD3EC6D4BCAF974128570C971" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_46297473E91FFF47EDD6741285700F59" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_07ABD2017CF721E7DAB874128570B8B1" xlink:to="loc_us-gaap_MoneyMarketFundsMember_46297473E91FFF47EDD6741285700F59" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtSecuritiesMember" xlink:label="loc_us-gaap_DebtSecuritiesMember_AC62169F04661A22BB73741285702627" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_07ABD2017CF721E7DAB874128570B8B1" xlink:to="loc_us-gaap_DebtSecuritiesMember_AC62169F04661A22BB73741285702627" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_E7D62A8A1CE96EBF1FED7412857046E5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_1DB70DD5DD3D25B62DE6741285700C88" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_E7D62A8A1CE96EBF1FED7412857046E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_A7BCD403C336965C9FC17412857045E9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_E7D62A8A1CE96EBF1FED7412857046E5" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_A7BCD403C336965C9FC17412857045E9" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6CD19605095FA7A9674D741285868C19" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_596407D89492CC68970474128585C4CC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6CD19605095FA7A9674D741285868C19" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_596407D89492CC68970474128585C4CC" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_F1E3BB0484B23F6355B374128585849E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_596407D89492CC68970474128585C4CC" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_F1E3BB0484B23F6355B374128585849E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_06161575FD6348E04CEF7412858510D5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_F1E3BB0484B23F6355B374128585849E" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_06161575FD6348E04CEF7412858510D5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_06161575FD6348E04CEF7412858510D5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_F1E3BB0484B23F6355B374128585849E" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_06161575FD6348E04CEF7412858510D5" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_CorporateDebtSecuritiesCurrentMember" xlink:label="loc_biib_CorporateDebtSecuritiesCurrentMember_6CF6A3A250B7A7A9B3547412858645AB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_06161575FD6348E04CEF7412858510D5" xlink:to="loc_biib_CorporateDebtSecuritiesCurrentMember_6CF6A3A250B7A7A9B3547412858645AB" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_CorporateDebtSecuritiesNonCurrentMember" xlink:label="loc_biib_CorporateDebtSecuritiesNonCurrentMember_BB2E8A25CA6755B8582074128586B6BE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_06161575FD6348E04CEF7412858510D5" xlink:to="loc_biib_CorporateDebtSecuritiesNonCurrentMember_BB2E8A25CA6755B8582074128586B6BE" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_GovernmentSecuritiesCurrentMember" xlink:label="loc_biib_GovernmentSecuritiesCurrentMember_00E27231AF31E7477BAF74128586111B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_06161575FD6348E04CEF7412858510D5" xlink:to="loc_biib_GovernmentSecuritiesCurrentMember_00E27231AF31E7477BAF74128586111B" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_GovernmentSecuritiesNonCurrentMember" xlink:label="loc_biib_GovernmentSecuritiesNonCurrentMember_0BFBD90AAAE3A16AF5B07412858638B2" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_06161575FD6348E04CEF7412858510D5" xlink:to="loc_biib_GovernmentSecuritiesNonCurrentMember_0BFBD90AAAE3A16AF5B07412858638B2" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_246BCFD4EB74A6553C78741285868DCC" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_06161575FD6348E04CEF7412858510D5" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_246BCFD4EB74A6553C78741285868DCC" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_771D1BCDE326C09FA3DD74128586B467" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_06161575FD6348E04CEF7412858510D5" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_771D1BCDE326C09FA3DD74128586B467" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_MarketableEquitySecuritiesMember" xlink:label="loc_biib_MarketableEquitySecuritiesMember_FA1D45C965E0157B77D37412858685AC" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_06161575FD6348E04CEF7412858510D5" xlink:to="loc_biib_MarketableEquitySecuritiesMember_FA1D45C965E0157B77D37412858685AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_FFE3243587A7C40D1B96741285863E21" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6CD19605095FA7A9674D741285868C19" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_FFE3243587A7C40D1B96741285863E21" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_8B6EB25C110BDA5A9479741285866C03" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_FFE3243587A7C40D1B96741285863E21" xlink:to="loc_us-gaap_AvailableForSaleSecurities_8B6EB25C110BDA5A9479741285866C03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_58736ABFF3033C279061741285866A88" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_FFE3243587A7C40D1B96741285863E21" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_58736ABFF3033C279061741285866A88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_93884E10312B9D6FCF0474128586BF6E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_FFE3243587A7C40D1B96741285863E21" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_93884E10312B9D6FCF0474128586BF6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_4599C1B6F0250B95BC1D74128586BBB3" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_FFE3243587A7C40D1B96741285863E21" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_4599C1B6F0250B95BC1D74128586BBB3" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual1" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_4B2010F92FBE1938FF967412892D594C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_19DAD7DC54B2DC0DF9C17412892D15C3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4B2010F92FBE1938FF967412892D594C" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_19DAD7DC54B2DC0DF9C17412892D15C3" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_239F68ED15E0CEFF272F7412892D9E9C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_19DAD7DC54B2DC0DF9C17412892D15C3" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_239F68ED15E0CEFF272F7412892D9E9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_3FD54EFB30E9436DB6897412892DEBE2_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_239F68ED15E0CEFF272F7412892D9E9C" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_3FD54EFB30E9436DB6897412892DEBE2_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_3FD54EFB30E9436DB6897412892DEBE2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_239F68ED15E0CEFF272F7412892D9E9C" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_3FD54EFB30E9436DB6897412892DEBE2" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_StrategicInvestmentsMember" xlink:label="loc_biib_StrategicInvestmentsMember_3A56DF22F59F5DDF8DA27412892D5151" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_3FD54EFB30E9436DB6897412892DEBE2" xlink:to="loc_biib_StrategicInvestmentsMember_3A56DF22F59F5DDF8DA27412892D5151" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_StrategicInvestmentPortfolio" xlink:label="loc_biib_StrategicInvestmentPortfolio_9CD6A3EA0986DD668F157412892D8E5F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4B2010F92FBE1938FF967412892D594C" xlink:to="loc_biib_StrategicInvestmentPortfolio_9CD6A3EA0986DD668F157412892D8E5F" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/Guarantees" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxes" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails1" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails2" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails3" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_00E0B3716ACF582B5EA0FB6C3A9493FA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxCreditCarryforwardTable" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_D57276560D19C41D50F7FB6C3A9367D1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_00E0B3716ACF582B5EA0FB6C3A9493FA" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_D57276560D19C41D50F7FB6C3A9367D1" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_E11EC0C22E1883BEC9AEFB6C3A93B7EB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_D57276560D19C41D50F7FB6C3A9367D1" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_E11EC0C22E1883BEC9AEFB6C3A93B7EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_2B58F2608EBA3640FA55FB6C3A93193C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_E11EC0C22E1883BEC9AEFB6C3A93B7EB" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_2B58F2608EBA3640FA55FB6C3A93193C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_2B58F2608EBA3640FA55FB6C3A93193C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_E11EC0C22E1883BEC9AEFB6C3A93B7EB" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_2B58F2608EBA3640FA55FB6C3A93193C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralBusinessMember" xlink:label="loc_us-gaap_GeneralBusinessMember_2543008807CF7B4EF9A1FB6C3A9498A8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_2B58F2608EBA3640FA55FB6C3A93193C" xlink:to="loc_us-gaap_GeneralBusinessMember_2543008807CF7B4EF9A1FB6C3A9498A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaap_ResearchMember_4DBDF5E2704A4CE40BA7FB6C3A943A1D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_2B58F2608EBA3640FA55FB6C3A93193C" xlink:to="loc_us-gaap_ResearchMember_4DBDF5E2704A4CE40BA7FB6C3A943A1D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_07A5337131E57B86ACE7FB6C3A94B15F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_D57276560D19C41D50F7FB6C3A9367D1" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_07A5337131E57B86ACE7FB6C3A94B15F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_26593EAF62DE347B1BBCFB6C3A9423E2_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_07A5337131E57B86ACE7FB6C3A94B15F" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_26593EAF62DE347B1BBCFB6C3A9423E2_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_26593EAF62DE347B1BBCFB6C3A9423E2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_07A5337131E57B86ACE7FB6C3A94B15F" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_26593EAF62DE347B1BBCFB6C3A9423E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_2AB747F1F5878B670DE6FB6C3A9434B7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_26593EAF62DE347B1BBCFB6C3A9423E2" xlink:to="loc_us-gaap_DomesticCountryMember_2AB747F1F5878B670DE6FB6C3A9434B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_663494817860BFA82613FB6C3A9484E6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_26593EAF62DE347B1BBCFB6C3A9423E2" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_663494817860BFA82613FB6C3A9484E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember_64F033248F252C04694DFB6C3A94EC7B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_26593EAF62DE347B1BBCFB6C3A9423E2" xlink:to="loc_us-gaap_ForeignCountryMember_64F033248F252C04694DFB6C3A94EC7B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_9234C749B3FF2908F622FB6C3A945D4D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_D57276560D19C41D50F7FB6C3A9367D1" xlink:to="loc_us-gaap_RangeAxis_9234C749B3FF2908F622FB6C3A945D4D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_8B9AC74B131A1D034804FB6C3A946CE9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_9234C749B3FF2908F622FB6C3A945D4D" xlink:to="loc_us-gaap_RangeMember_8B9AC74B131A1D034804FB6C3A946CE9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_8B9AC74B131A1D034804FB6C3A946CE9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_9234C749B3FF2908F622FB6C3A945D4D" xlink:to="loc_us-gaap_RangeMember_8B9AC74B131A1D034804FB6C3A946CE9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_E7207E82EF97ED817AEEFB6C3A94D0EF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_8B9AC74B131A1D034804FB6C3A946CE9" xlink:to="loc_us-gaap_MinimumMember_E7207E82EF97ED817AEEFB6C3A94D0EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_8CC9083D6471A8848333FB6C3A94DB6B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_8B9AC74B131A1D034804FB6C3A946CE9" xlink:to="loc_us-gaap_MaximumMember_8CC9083D6471A8848333FB6C3A94DB6B" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_Totaldeferredchargesandprepaidtaxes" xlink:label="loc_biib_Totaldeferredchargesandprepaidtaxes_2E0ADAB25257D49EB115FB6C3A957FB2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_00E0B3716ACF582B5EA0FB6C3A9493FA" xlink:to="loc_biib_Totaldeferredchargesandprepaidtaxes_2E0ADAB25257D49EB115FB6C3A957FB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_38AFF590486AB590C0B9FB6C3A956F3D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_00E0B3716ACF582B5EA0FB6C3A9493FA" xlink:to="loc_us-gaap_OperatingLossCarryforwards_38AFF590486AB590C0B9FB6C3A956F3D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_8610CCAFA874187D1B4BFB6C3A955530" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_00E0B3716ACF582B5EA0FB6C3A9493FA" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_8610CCAFA874187D1B4BFB6C3A955530" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_0D009D03ECAED24684B2FB6C3A956205" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_00E0B3716ACF582B5EA0FB6C3A9493FA" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_0D009D03ECAED24684B2FB6C3A956205" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_EstimatedTaxLiabilityOnUndistributedEarningsOfForeignSubsidiaries" xlink:label="loc_biib_EstimatedTaxLiabilityOnUndistributedEarningsOfForeignSubsidiaries_E54A5FDFD81D0E0D90E3FB6C3A9502EF" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_00E0B3716ACF582B5EA0FB6C3A9493FA" xlink:to="loc_biib_EstimatedTaxLiabilityOnUndistributedEarningsOfForeignSubsidiaries_E54A5FDFD81D0E0D90E3FB6C3A9502EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_6B106CD6D6215CB73F9CFB6C3A9512C6" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_00E0B3716ACF582B5EA0FB6C3A9493FA" xlink:to="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_6B106CD6D6215CB73F9CFB6C3A9512C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForOtherTaxes" xlink:label="loc_us-gaap_PaymentsForOtherTaxes_AA28A789123BF1CD05C6FB6C3A959E3E" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_00E0B3716ACF582B5EA0FB6C3A9493FA" xlink:to="loc_us-gaap_PaymentsForOtherTaxes_AA28A789123BF1CD05C6FB6C3A959E3E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_D60AD832F51E83D8A8EDFB6C3A9521FE" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_00E0B3716ACF582B5EA0FB6C3A9493FA" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_D60AD832F51E83D8A8EDFB6C3A9521FE" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/Indebtedness" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IndebtednessDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_BC28B9D17ECAB81729CC741288AA5DA2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_23F9140F38F65B1DDB2E741288A9EE20" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_BC28B9D17ECAB81729CC741288AA5DA2" xlink:to="loc_us-gaap_DebtInstrumentTable_23F9140F38F65B1DDB2E741288A9EE20" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_B430770893D0DB9F3C13741288A97DE2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_23F9140F38F65B1DDB2E741288A9EE20" xlink:to="loc_us-gaap_DebtInstrumentAxis_B430770893D0DB9F3C13741288A97DE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4FFF00931BE31D2A41B6741288A9B039_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_B430770893D0DB9F3C13741288A97DE2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4FFF00931BE31D2A41B6741288A9B039_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4FFF00931BE31D2A41B6741288A9B039" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_B430770893D0DB9F3C13741288A97DE2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4FFF00931BE31D2A41B6741288A9B039" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" xlink:label="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_5A34F004F545210CD412741288A9369A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4FFF00931BE31D2A41B6741288A9B039" xlink:to="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_5A34F004F545210CD412741288A9369A" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_4806B7808167A366B9EB741288AAA67C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4FFF00931BE31D2A41B6741288A9B039" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_4806B7808167A366B9EB741288AAA67C" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_EF8D4829394D0B581ABC741288AA5501" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4FFF00931BE31D2A41B6741288A9B039" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_EF8D4829394D0B581ABC741288AA5501" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_81E00D5E1B6671A18FBB741288AAFDE7" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4FFF00931BE31D2A41B6741288A9B039" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_81E00D5E1B6671A18FBB741288AAFDE7" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_566786B39A46B984EFE1741288AA18D3" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4FFF00931BE31D2A41B6741288A9B039" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_566786B39A46B984EFE1741288AA18D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_4717E0D33EA9E282914D741288AAD767" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_23F9140F38F65B1DDB2E741288A9EE20" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_4717E0D33EA9E282914D741288AAD767" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_09E296E8F6ED8F373242741288AAD493_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_4717E0D33EA9E282914D741288AAD767" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_09E296E8F6ED8F373242741288AAD493_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_09E296E8F6ED8F373242741288AAD493" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_4717E0D33EA9E282914D741288AAD767" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_09E296E8F6ED8F373242741288AAD493" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_F23C5DB4BBDFE5956646741288AAEC7A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_09E296E8F6ED8F373242741288AAD493" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_F23C5DB4BBDFE5956646741288AAEC7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtCurrentAbstract" xlink:label="loc_us-gaap_LongTermDebtCurrentAbstract_A6EE826FFB2C467AA233741288AA0965" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_BC28B9D17ECAB81729CC741288AA5DA2" xlink:to="loc_us-gaap_LongTermDebtCurrentAbstract_A6EE826FFB2C467AA233741288AA0965" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent_C31B1000A917B2A5C089741288AA281D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtCurrentAbstract_A6EE826FFB2C467AA233741288AA0965" xlink:to="loc_us-gaap_NotesPayableCurrent_C31B1000A917B2A5C089741288AA281D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_6DFFAFF1E404547E719A741288AA4E43" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtCurrentAbstract_A6EE826FFB2C467AA233741288AA0965" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_6DFFAFF1E404547E719A741288AA4E43" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_3C7D1573FDEBA5ED8472741288AB984F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtCurrentAbstract_A6EE826FFB2C467AA233741288AA0965" xlink:to="loc_us-gaap_DebtCurrent_3C7D1573FDEBA5ED8472741288AB984F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtNoncurrentAbstract" xlink:label="loc_us-gaap_LongTermDebtNoncurrentAbstract_93443A2C22ECD0C39F07741288ABCDDA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_BC28B9D17ECAB81729CC741288AA5DA2" xlink:to="loc_us-gaap_LongTermDebtNoncurrentAbstract_93443A2C22ECD0C39F07741288ABCDDA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaap_LongTermNotesPayable_FD3ABB6E93C3F750EEE4741288AB5B0F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtNoncurrentAbstract_93443A2C22ECD0C39F07741288ABCDDA" xlink:to="loc_us-gaap_LongTermNotesPayable_FD3ABB6E93C3F750EEE4741288AB5B0F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_FAFDE133BE7A727291CE741288ABB2AC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtNoncurrentAbstract_93443A2C22ECD0C39F07741288ABCDDA" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_FAFDE133BE7A727291CE741288ABB2AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_1BF3B6344A87BA76F58D741288AB31AA" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtNoncurrentAbstract_93443A2C22ECD0C39F07741288ABCDDA" xlink:to="loc_us-gaap_LongTermDebt_1BF3B6344A87BA76F58D741288AB31AA" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IndebtednessDetails1" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IndebtednessDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_5752CFAD9689FE6191B7FB6C3B2D530F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_D02E8ABC39633BDC6620FB6C3B2BC381" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5752CFAD9689FE6191B7FB6C3B2D530F" xlink:to="loc_us-gaap_DebtInstrumentTable_D02E8ABC39633BDC6620FB6C3B2BC381" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_A17D36DD43378FDA977AFB6C3B2B1A64" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_D02E8ABC39633BDC6620FB6C3B2BC381" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_A17D36DD43378FDA977AFB6C3B2B1A64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F0E0D0B2A3072779215EFB6C3B2CAA86_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_A17D36DD43378FDA977AFB6C3B2B1A64" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F0E0D0B2A3072779215EFB6C3B2CAA86_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F0E0D0B2A3072779215EFB6C3B2CAA86" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_A17D36DD43378FDA977AFB6C3B2B1A64" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F0E0D0B2A3072779215EFB6C3B2CAA86" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_EisaiMember" xlink:label="loc_biib_EisaiMember_862C7250210EF6500D67FB6C3B2CA88E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F0E0D0B2A3072779215EFB6C3B2CAA86" xlink:to="loc_biib_EisaiMember_862C7250210EF6500D67FB6C3B2CA88E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_348D41DAD7599358180DFB6C3B2C2C50" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_D02E8ABC39633BDC6620FB6C3B2BC381" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_348D41DAD7599358180DFB6C3B2C2C50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_2554A9C66B380B3904E4FB6C3B2C8D98_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_348D41DAD7599358180DFB6C3B2C2C50" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_2554A9C66B380B3904E4FB6C3B2C8D98_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_2554A9C66B380B3904E4FB6C3B2C8D98" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_348D41DAD7599358180DFB6C3B2C2C50" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_2554A9C66B380B3904E4FB6C3B2C8D98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember_34748199695F03984D23FB6C3B2C68D6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_2554A9C66B380B3904E4FB6C3B2C8D98" xlink:to="loc_us-gaap_InterestRateSwapMember_34748199695F03984D23FB6C3B2C68D6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_9F4E5C22383D81478732FB6C3B2CCCF1" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_D02E8ABC39633BDC6620FB6C3B2BC381" xlink:to="loc_us-gaap_DebtInstrumentAxis_9F4E5C22383D81478732FB6C3B2CCCF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4966CEBD113955EC117DFB6C3B2C4CC1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_9F4E5C22383D81478732FB6C3B2CCCF1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4966CEBD113955EC117DFB6C3B2C4CC1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4966CEBD113955EC117DFB6C3B2C4CC1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_9F4E5C22383D81478732FB6C3B2CCCF1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4966CEBD113955EC117DFB6C3B2C4CC1" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" xlink:label="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_E06656F60997175D66ACFB6C3B2D2E5F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4966CEBD113955EC117DFB6C3B2C4CC1" xlink:to="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_E06656F60997175D66ACFB6C3B2D2E5F" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_922BBC27FB74C86B3203FB6C3B2C95AC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4966CEBD113955EC117DFB6C3B2C4CC1" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_922BBC27FB74C86B3203FB6C3B2C95AC" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_11AE3B411779C35DC2D1FB6C3B2C38AD" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4966CEBD113955EC117DFB6C3B2C4CC1" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_11AE3B411779C35DC2D1FB6C3B2C38AD" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_7696055F354DD5BBB4C2FB6C3B2C1E1B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4966CEBD113955EC117DFB6C3B2C4CC1" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_7696055F354DD5BBB4C2FB6C3B2C1E1B" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_E141CCBD9CD21A414615FB6C3B2DE27F" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4966CEBD113955EC117DFB6C3B2C4CC1" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_E141CCBD9CD21A414615FB6C3B2DE27F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_4D512F1DE9CC41220EC3FB6C3B2D7AAE" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_D02E8ABC39633BDC6620FB6C3B2BC381" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_4D512F1DE9CC41220EC3FB6C3B2D7AAE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_E0EE637A77F1FD013EB4FB6C3B2DBB5D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_4D512F1DE9CC41220EC3FB6C3B2D7AAE" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_E0EE637A77F1FD013EB4FB6C3B2DBB5D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_E0EE637A77F1FD013EB4FB6C3B2DBB5D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_4D512F1DE9CC41220EC3FB6C3B2D7AAE" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_E0EE637A77F1FD013EB4FB6C3B2DBB5D" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" xlink:label="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_F460B26AD7CCE0039BC4FB6C3B2D2BF7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_E0EE637A77F1FD013EB4FB6C3B2DBB5D" xlink:to="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_F460B26AD7CCE0039BC4FB6C3B2D2BF7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_C377AD0DACDA89BDFF77FB6C3B2DD741" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_E0EE637A77F1FD013EB4FB6C3B2DBB5D" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_C377AD0DACDA89BDFF77FB6C3B2DD741" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_B5B9DD9F22A0B43D16EDFB6C3B2D5AA9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5752CFAD9689FE6191B7FB6C3B2D530F" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_B5B9DD9F22A0B43D16EDFB6C3B2D5AA9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7996C1D6E355B21926FEFB6C3B2D9D04" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5752CFAD9689FE6191B7FB6C3B2D530F" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7996C1D6E355B21926FEFB6C3B2D9D04" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_PercentageParValueOfSeniorNotes" xlink:label="loc_biib_PercentageParValueOfSeniorNotes_E17B1A73F4DD56062176FB6C3B2D1F28" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5752CFAD9689FE6191B7FB6C3B2D530F" xlink:to="loc_biib_PercentageParValueOfSeniorNotes_E17B1A73F4DD56062176FB6C3B2D1F28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_7EE34F6F1CEF32E9E451FB6C3B2DF9A8" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5752CFAD9689FE6191B7FB6C3B2D530F" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_7EE34F6F1CEF32E9E451FB6C3B2DF9A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_6EE391E5E954B296E080FB6C3B2D47C7" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5752CFAD9689FE6191B7FB6C3B2D530F" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_6EE391E5E954B296E080FB6C3B2D47C7" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage" xlink:label="loc_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_EE511399A391A897CE62FB6C3B2DA09E" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5752CFAD9689FE6191B7FB6C3B2D530F" xlink:to="loc_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_EE511399A391A897CE62FB6C3B2DA09E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_A2269BFCD9DFFAE512CFFB6C3B2DAE9E" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5752CFAD9689FE6191B7FB6C3B2D530F" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_A2269BFCD9DFFAE512CFFB6C3B2DAE9E" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_IncreasedCarryingAmountOfSeniorNotes" xlink:label="loc_biib_IncreasedCarryingAmountOfSeniorNotes_A6F9FEA410774AB1EDE8FB6C3B2D91E5" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5752CFAD9689FE6191B7FB6C3B2D530F" xlink:to="loc_biib_IncreasedCarryingAmountOfSeniorNotes_A6F9FEA410774AB1EDE8FB6C3B2D91E5" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_DebtInstrumentUnamortizedInterestOnDebt" xlink:label="loc_biib_DebtInstrumentUnamortizedInterestOnDebt_71176A85CAD91D7BC8ABFB6C3B2EC1FA" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5752CFAD9689FE6191B7FB6C3B2D530F" xlink:to="loc_biib_DebtInstrumentUnamortizedInterestOnDebt_71176A85CAD91D7BC8ABFB6C3B2EC1FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaap_LongTermNotesPayable_D86392754D2EA82DEA91FB6C3B2E8DB1" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5752CFAD9689FE6191B7FB6C3B2D530F" xlink:to="loc_us-gaap_LongTermNotesPayable_D86392754D2EA82DEA91FB6C3B2E8DB1" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ParValueOfNotesPayable" xlink:label="loc_biib_ParValueOfNotesPayable_5B4F5A729633222018C4FB6C3B2E5127" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5752CFAD9689FE6191B7FB6C3B2D530F" xlink:to="loc_biib_ParValueOfNotesPayable_5B4F5A729633222018C4FB6C3B2E5127" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_E9CD763E2F6FE6E78D65FB6C3B2E7DFB" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5752CFAD9689FE6191B7FB6C3B2D530F" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_E9CD763E2F6FE6E78D65FB6C3B2E7DFB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:label="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_990D5D30089F47B7C6CAFB6C3B2EE2F4" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5752CFAD9689FE6191B7FB6C3B2D530F" xlink:to="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_990D5D30089F47B7C6CAFB6C3B2EE2F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" xlink:label="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_62720ECD59E7A105B580FB6C3B2E9D4D" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5752CFAD9689FE6191B7FB6C3B2D530F" xlink:to="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_62720ECD59E7A105B580FB6C3B2E9D4D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalLeaseObligations" xlink:label="loc_us-gaap_CapitalLeaseObligations_24683F64C9594DEE4071FB6C3B2E9B9C" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5752CFAD9689FE6191B7FB6C3B2D530F" xlink:to="loc_us-gaap_CapitalLeaseObligations_24683F64C9594DEE4071FB6C3B2E9B9C" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IndebtednessTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_C95FCA0A99D01B9DF1A7FA4EA5692355" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_D482A3637939C6007F8DFA4EA5662371" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_C95FCA0A99D01B9DF1A7FA4EA5692355" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_D482A3637939C6007F8DFA4EA5662371" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:label="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_9571EB206C38718E9A32FA4EA566847A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_D482A3637939C6007F8DFA4EA5662371" xlink:to="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_9571EB206C38718E9A32FA4EA566847A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:label="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_4D521F71344B6FA0A530FA4EA566F134_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_9571EB206C38718E9A32FA4EA566847A" xlink:to="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_4D521F71344B6FA0A530FA4EA566F134_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:label="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_4D521F71344B6FA0A530FA4EA566F134" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_9571EB206C38718E9A32FA4EA566847A" xlink:to="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_4D521F71344B6FA0A530FA4EA566F134" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_RodinTherapeuticsMember" xlink:label="loc_biib_RodinTherapeuticsMember_D47F17B4A3B4ED539DAAFA4EA566E194" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_4D521F71344B6FA0A530FA4EA566F134" xlink:to="loc_biib_RodinTherapeuticsMember_D47F17B4A3B4ED539DAAFA4EA566E194" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_AtaxionMember" xlink:label="loc_biib_AtaxionMember_45D4F6F4E9C1F53ADDF0FA4EA5668E55" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_4D521F71344B6FA0A530FA4EA566F134" xlink:to="loc_biib_AtaxionMember_45D4F6F4E9C1F53ADDF0FA4EA5668E55" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_D729CC80798A0C1AF420FA4EA566A740" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_D482A3637939C6007F8DFA4EA5662371" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_D729CC80798A0C1AF420FA4EA566A740" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_755DA58CD94666FFF0E5FA4EA56617E9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_D729CC80798A0C1AF420FA4EA566A740" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_755DA58CD94666FFF0E5FA4EA56617E9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_755DA58CD94666FFF0E5FA4EA56617E9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_D729CC80798A0C1AF420FA4EA566A740" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_755DA58CD94666FFF0E5FA4EA56617E9" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ConvergencePharmaceuticalsMember" xlink:label="loc_biib_ConvergencePharmaceuticalsMember_B4AA3F1C7F5BC186F547FA4EA5662E50" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_755DA58CD94666FFF0E5FA4EA56617E9" xlink:to="loc_biib_ConvergencePharmaceuticalsMember_B4AA3F1C7F5BC186F547FA4EA5662E50" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_FumapharmAgMember" xlink:label="loc_biib_FumapharmAgMember_718F7CFAED742A741E4DFA4EA567F58A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_755DA58CD94666FFF0E5FA4EA56617E9" xlink:to="loc_biib_FumapharmAgMember_718F7CFAED742A741E4DFA4EA567F58A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_B99380799C21A0B54886FA4EA567FE44" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_D482A3637939C6007F8DFA4EA5662371" xlink:to="loc_us-gaap_ProductOrServiceAxis_B99380799C21A0B54886FA4EA567FE44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_88D951F6EB60560F5A28FA4EA5677E4A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProductOrServiceAxis_B99380799C21A0B54886FA4EA567FE44" xlink:to="loc_us-gaap_ProductsAndServicesDomain_88D951F6EB60560F5A28FA4EA5677E4A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_88D951F6EB60560F5A28FA4EA5677E4A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProductOrServiceAxis_B99380799C21A0B54886FA4EA567FE44" xlink:to="loc_us-gaap_ProductsAndServicesDomain_88D951F6EB60560F5A28FA4EA5677E4A" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_AVONEXMember" xlink:label="loc_biib_AVONEXMember_7870E220AA7EAE6E577EFA4EA56761DA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_88D951F6EB60560F5A28FA4EA5677E4A" xlink:to="loc_biib_AVONEXMember_7870E220AA7EAE6E577EFA4EA56761DA" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_TysabriProductMember" xlink:label="loc_biib_TysabriProductMember_B4BA9D2D422AA49F85B6FA4EA5679D1D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_88D951F6EB60560F5A28FA4EA5677E4A" xlink:to="loc_biib_TysabriProductMember_B4BA9D2D422AA49F85B6FA4EA5679D1D" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_SPINRAZAMember" xlink:label="loc_biib_SPINRAZAMember_E6C645BEAE1F3AA442CAFA4EA567F477" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_88D951F6EB60560F5A28FA4EA5677E4A" xlink:to="loc_biib_SPINRAZAMember_E6C645BEAE1F3AA442CAFA4EA567F477" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_BiosimilarsMember" xlink:label="loc_biib_BiosimilarsMember_E12D59C42DA0F0715779FA4EA567955E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_88D951F6EB60560F5A28FA4EA5677E4A" xlink:to="loc_biib_BiosimilarsMember_E12D59C42DA0F0715779FA4EA567955E" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ZINBRYTAMember" xlink:label="loc_biib_ZINBRYTAMember_5461BBCC6A5B80477BFFFA4EA5673C4B" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_88D951F6EB60560F5A28FA4EA5677E4A" xlink:to="loc_biib_ZINBRYTAMember_5461BBCC6A5B80477BFFFA4EA5673C4B" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ALPROLIXMember" xlink:label="loc_biib_ALPROLIXMember_7BEEC76BE0B4D5A4F5E0FA4EA5673A0A" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_88D951F6EB60560F5A28FA4EA5677E4A" xlink:to="loc_biib_ALPROLIXMember_7BEEC76BE0B4D5A4F5E0FA4EA5673A0A" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_0B13F5CFBAA3BC5F6A0CFA4EA5675070" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_88D951F6EB60560F5A28FA4EA5677E4A" xlink:to="loc_biib_TecfideraMember_0B13F5CFBAA3BC5F6A0CFA4EA5675070" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_DF6DB2AD6DE068351AC8FA4EA567EE67" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_D482A3637939C6007F8DFA4EA5662371" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_DF6DB2AD6DE068351AC8FA4EA567EE67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_FA7F0C10BBC676532FD0FA4EA567DF98_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_DF6DB2AD6DE068351AC8FA4EA567EE67" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_FA7F0C10BBC676532FD0FA4EA567DF98_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_FA7F0C10BBC676532FD0FA4EA567DF98" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_DF6DB2AD6DE068351AC8FA4EA567EE67" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_FA7F0C10BBC676532FD0FA4EA567DF98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_883C2E327BC7EAFD2020FA4EA568E9AA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_FA7F0C10BBC676532FD0FA4EA567DF98" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_883C2E327BC7EAFD2020FA4EA568E9AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_A069B136347BACE6EF79FA4EA5689F22" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_FA7F0C10BBC676532FD0FA4EA567DF98" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_A069B136347BACE6EF79FA4EA5689F22" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3A77B573F189966822CAFA4EA568479A" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_D482A3637939C6007F8DFA4EA5662371" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3A77B573F189966822CAFA4EA568479A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4CFF285E3BED4B15CE9DFA4EA5682C9B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3A77B573F189966822CAFA4EA568479A" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4CFF285E3BED4B15CE9DFA4EA5682C9B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4CFF285E3BED4B15CE9DFA4EA5682C9B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3A77B573F189966822CAFA4EA568479A" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4CFF285E3BED4B15CE9DFA4EA5682C9B" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_OutLicensedPatentsMember" xlink:label="loc_biib_OutLicensedPatentsMember_B0AE17218424D421D4F4FA4EA568F926" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4CFF285E3BED4B15CE9DFA4EA5682C9B" xlink:to="loc_biib_OutLicensedPatentsMember_B0AE17218424D421D4F4FA4EA568F926" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_EC4FE92223CD4ACE0E8FFA4EA568338A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4CFF285E3BED4B15CE9DFA4EA5682C9B" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_EC4FE92223CD4ACE0E8FFA4EA568338A" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_InLicensedPatentsMember" xlink:label="loc_biib_InLicensedPatentsMember_4F03EF38B05FBF13C07FFA4EA5689712" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4CFF285E3BED4B15CE9DFA4EA5682C9B" xlink:to="loc_biib_InLicensedPatentsMember_4F03EF38B05FBF13C07FFA4EA5689712" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_9570C071FC13D3C8A406FA4EA56892A6" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_D482A3637939C6007F8DFA4EA5662371" xlink:to="loc_us-gaap_RangeAxis_9570C071FC13D3C8A406FA4EA56892A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_10376B02C73034E9AC1EFA4EA56977D1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_9570C071FC13D3C8A406FA4EA56892A6" xlink:to="loc_us-gaap_RangeMember_10376B02C73034E9AC1EFA4EA56977D1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_10376B02C73034E9AC1EFA4EA56977D1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_9570C071FC13D3C8A406FA4EA56892A6" xlink:to="loc_us-gaap_RangeMember_10376B02C73034E9AC1EFA4EA56977D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_198B75AFA09405F8212FFA4EA569478E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_10376B02C73034E9AC1EFA4EA56977D1" xlink:to="loc_us-gaap_MinimumMember_198B75AFA09405F8212FFA4EA569478E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_1B1F0E0106FFFE7F90A3FA4EA56913CC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_10376B02C73034E9AC1EFA4EA56977D1" xlink:to="loc_us-gaap_MaximumMember_1B1F0E0106FFFE7F90A3FA4EA56913CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_238640EE7A862943D437FA4EA569696D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_C95FCA0A99D01B9DF1A7FA4EA5692355" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_238640EE7A862943D437FA4EA569696D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_A29B57FC344DCAC48CE6FA4EA5691754" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_C95FCA0A99D01B9DF1A7FA4EA5692355" xlink:to="loc_us-gaap_Goodwill_A29B57FC344DCAC48CE6FA4EA5691754" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_C5638768CFA6E40E605AFA4EA569C628" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_C95FCA0A99D01B9DF1A7FA4EA5692355" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_C5638768CFA6E40E605AFA4EA569C628" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_9F7FB4B9002A04739509FA4EA5695DA5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_C5638768CFA6E40E605AFA4EA569C628" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_9F7FB4B9002A04739509FA4EA5695DA5" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_IndefiniteLivedIntangibleAssetsUsefulLife" xlink:label="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_EABE525958F1D684A851FA4EA5697F53" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_C5638768CFA6E40E605AFA4EA569C628" xlink:to="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_EABE525958F1D684A851FA4EA5697F53" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_09AFB774F9270418D372FA4EA5698256" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_C5638768CFA6E40E605AFA4EA569C628" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_09AFB774F9270418D372FA4EA5698256" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_B28F4E22F8595B80D9DEFA4EA56AB87D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_C5638768CFA6E40E605AFA4EA569C628" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_B28F4E22F8595B80D9DEFA4EA56AB87D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_016DD484F130E93016A9FA4EA56A7B50" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_C5638768CFA6E40E605AFA4EA569C628" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_016DD484F130E93016A9FA4EA56A7B50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9A75AC0F6DB0FE13818CFA4EA56A6641" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_C5638768CFA6E40E605AFA4EA569C628" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9A75AC0F6DB0FE13818CFA4EA56A6641" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_9D42B46898876CD1B454FA4EA56A84FA" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_C5638768CFA6E40E605AFA4EA569C628" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_9D42B46898876CD1B454FA4EA56A84FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_D1A76CD50BA8CB402E03FA4EA56ADFCE" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_C5638768CFA6E40E605AFA4EA569C628" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_D1A76CD50BA8CB402E03FA4EA56ADFCE" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract" xlink:label="loc_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_29FD9B87D1DD80B3CB79FA4EA56AEBBC" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_C95FCA0A99D01B9DF1A7FA4EA5692355" xlink:to="loc_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_29FD9B87D1DD80B3CB79FA4EA56AEBBC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_08608861291CC0CADB77FA4EA56ABD03" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_29FD9B87D1DD80B3CB79FA4EA56AEBBC" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_08608861291CC0CADB77FA4EA56ABD03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_25BA715290654A34933CFA4EA56A2953" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_29FD9B87D1DD80B3CB79FA4EA56AEBBC" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_25BA715290654A34933CFA4EA56A2953" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_E726D53C151763F6DC85FA4EA56ABE9E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_29FD9B87D1DD80B3CB79FA4EA56AEBBC" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_E726D53C151763F6DC85FA4EA56ABE9E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_EB71C2D975CE7DC733E7FA4EA56A551E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_29FD9B87D1DD80B3CB79FA4EA56AEBBC" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_EB71C2D975CE7DC733E7FA4EA56A551E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_3063EF10D969D201069FFA4EA56A164F" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_29FD9B87D1DD80B3CB79FA4EA56AEBBC" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_3063EF10D969D201069FFA4EA56A164F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_43E1686ECC9C1656DA43FA4EA56A3C50" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_C95FCA0A99D01B9DF1A7FA4EA5692355" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_43E1686ECC9C1656DA43FA4EA56A3C50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_EC4D94D43C4F25DB9DC7FA4EA56A6E5C" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_C95FCA0A99D01B9DF1A7FA4EA5692355" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_EC4D94D43C4F25DB9DC7FA4EA56A6E5C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_AF511DF43B9C4BA90E88FA4EA56A75A8" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_C95FCA0A99D01B9DF1A7FA4EA5692355" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_AF511DF43B9C4BA90E88FA4EA56A75A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_6445ECC3E6EE14771830FA4EA56A2905" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_C95FCA0A99D01B9DF1A7FA4EA5692355" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_6445ECC3E6EE14771830FA4EA56A2905" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_MilestonePaymentsMadeDuringPeriod" xlink:label="loc_biib_MilestonePaymentsMadeDuringPeriod_518533EDC445F5CE2D71FA4EA56AF71A" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_C95FCA0A99D01B9DF1A7FA4EA5692355" xlink:to="loc_biib_MilestonePaymentsMadeDuringPeriod_518533EDC445F5CE2D71FA4EA56AF71A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_4184BF8ACCE7F88664D2FA4EA56AD3ED" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_C95FCA0A99D01B9DF1A7FA4EA5692355" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_4184BF8ACCE7F88664D2FA4EA56AD3ED" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillLineItems" xlink:label="loc_us-gaap_GoodwillLineItems_8AEA97134254380E3CEA87BF3B2AE537" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_EA940FBA93144EFE1E7487BF3B29D862" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_8AEA97134254380E3CEA87BF3B2AE537" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_EA940FBA93144EFE1E7487BF3B29D862" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1D4C47B303104186CDD987BF3B2979BF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_EA940FBA93144EFE1E7487BF3B29D862" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1D4C47B303104186CDD987BF3B2979BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_969D8966B6BFB1C0262287BF3B2A80B7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1D4C47B303104186CDD987BF3B2979BF" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_969D8966B6BFB1C0262287BF3B2A80B7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_969D8966B6BFB1C0262287BF3B2A80B7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1D4C47B303104186CDD987BF3B2979BF" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_969D8966B6BFB1C0262287BF3B2A80B7" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_FumapharmAgMember" xlink:label="loc_biib_FumapharmAgMember_BD8A0BD79ED07843716B87BF3B2A1185" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_969D8966B6BFB1C0262287BF3B2A80B7" xlink:to="loc_biib_FumapharmAgMember_BD8A0BD79ED07843716B87BF3B2A1185" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ConvergencePharmaceuticalsMember" xlink:label="loc_biib_ConvergencePharmaceuticalsMember_81CCFAAC11B5E2B2B25787BF3B2A5B1A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_969D8966B6BFB1C0262287BF3B2A80B7" xlink:to="loc_biib_ConvergencePharmaceuticalsMember_81CCFAAC11B5E2B2B25787BF3B2A5B1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_E5EA64CCE23D194102EA87BF3B2A0B07" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_EA940FBA93144EFE1E7487BF3B29D862" xlink:to="loc_us-gaap_ProductOrServiceAxis_E5EA64CCE23D194102EA87BF3B2A0B07" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_2A7C3E518EA8DD65BD5887BF3B2AC2EA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProductOrServiceAxis_E5EA64CCE23D194102EA87BF3B2A0B07" xlink:to="loc_us-gaap_ProductsAndServicesDomain_2A7C3E518EA8DD65BD5887BF3B2AC2EA_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_2A7C3E518EA8DD65BD5887BF3B2AC2EA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProductOrServiceAxis_E5EA64CCE23D194102EA87BF3B2A0B07" xlink:to="loc_us-gaap_ProductsAndServicesDomain_2A7C3E518EA8DD65BD5887BF3B2AC2EA" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_1118904958EDA2238F7687BF3B2A4B9F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_2A7C3E518EA8DD65BD5887BF3B2AC2EA" xlink:to="loc_biib_TecfideraMember_1118904958EDA2238F7687BF3B2A4B9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_F0528CC32E758AB7A44387BF3B2ADD4B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_8AEA97134254380E3CEA87BF3B2AE537" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_F0528CC32E758AB7A44387BF3B2ADD4B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_2C5F2DB47884536A4FFD87BF3B2ADFDE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_8AEA97134254380E3CEA87BF3B2AE537" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_2C5F2DB47884536A4FFD87BF3B2ADFDE" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/Inventory" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/InventoryDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/InventoryDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryLineItems" xlink:label="loc_us-gaap_InventoryLineItems_305528DEBE90E366EF97FA4EA575481F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AirlineProductsAndServicesTable" xlink:label="loc_us-gaap_AirlineProductsAndServicesTable_F9BE3E575610995DFE86FA4EA5747988" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InventoryLineItems_305528DEBE90E366EF97FA4EA575481F" xlink:to="loc_us-gaap_AirlineProductsAndServicesTable_F9BE3E575610995DFE86FA4EA5747988" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_B4FCFC950B150F3BADB9FA4EA5744761" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AirlineProductsAndServicesTable_F9BE3E575610995DFE86FA4EA5747988" xlink:to="loc_us-gaap_ProductOrServiceAxis_B4FCFC950B150F3BADB9FA4EA5744761" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_745DA2D409B793DA4F46FA4EA574DF6D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProductOrServiceAxis_B4FCFC950B150F3BADB9FA4EA5744761" xlink:to="loc_us-gaap_ProductsAndServicesDomain_745DA2D409B793DA4F46FA4EA574DF6D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_745DA2D409B793DA4F46FA4EA574DF6D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProductOrServiceAxis_B4FCFC950B150F3BADB9FA4EA5744761" xlink:to="loc_us-gaap_ProductsAndServicesDomain_745DA2D409B793DA4F46FA4EA574DF6D" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ZINBRYTAMember" xlink:label="loc_biib_ZINBRYTAMember_5B5607FF8AFAB5049888FA4EA5750FF1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_745DA2D409B793DA4F46FA4EA574DF6D" xlink:to="loc_biib_ZINBRYTAMember_5B5607FF8AFAB5049888FA4EA5750FF1" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_FLIXABIMember" xlink:label="loc_biib_FLIXABIMember_2306DB88289A58D8113EFA4EA5751589" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_745DA2D409B793DA4F46FA4EA574DF6D" xlink:to="loc_biib_FLIXABIMember_2306DB88289A58D8113EFA4EA5751589" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_BENEPALIMember" xlink:label="loc_biib_BENEPALIMember_B09D4C84C9A62C145A5DFA4EA575E81B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_745DA2D409B793DA4F46FA4EA574DF6D" xlink:to="loc_biib_BENEPALIMember_B09D4C84C9A62C145A5DFA4EA575E81B" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_Preapprovalinventory" xlink:label="loc_biib_Preapprovalinventory_9AFB9E710795E7A71CDEFA4EA5752B17" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_305528DEBE90E366EF97FA4EA575481F" xlink:to="loc_biib_Preapprovalinventory_9AFB9E710795E7A71CDEFA4EA5752B17" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/InventoryTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableInterestEntityLineItems" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_D749D4FC817F1D4B08E8FB6C3A6F2AF7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_A9511272C46777E782BAFB6C3A6EE6B3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_D749D4FC817F1D4B08E8FB6C3A6F2AF7" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_A9511272C46777E782BAFB6C3A6EE6B3" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_F9D984D2409EB6869042FB6C3A6EE9A0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_A9511272C46777E782BAFB6C3A6EE6B3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_F9D984D2409EB6869042FB6C3A6EE9A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_77F973F31DFF86B3C4E1FB6C3A6FC0FE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_F9D984D2409EB6869042FB6C3A6EE9A0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_77F973F31DFF86B3C4E1FB6C3A6FC0FE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_77F973F31DFF86B3C4E1FB6C3A6FC0FE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_F9D984D2409EB6869042FB6C3A6EE9A0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_77F973F31DFF86B3C4E1FB6C3A6FC0FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_B10D2936A3C04D38EC9BFB6C3A6FB17A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_77F973F31DFF86B3C4E1FB6C3A6FC0FE" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_B10D2936A3C04D38EC9BFB6C3A6FB17A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:label="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_02E2121797B058EAA30DFB6C3A6F7A5F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_A9511272C46777E782BAFB6C3A6EE6B3" xlink:to="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_02E2121797B058EAA30DFB6C3A6F7A5F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:label="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_90D8249C6B9956EF840BFB6C3A6F9A60_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_02E2121797B058EAA30DFB6C3A6F7A5F" xlink:to="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_90D8249C6B9956EF840BFB6C3A6F9A60_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:label="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_90D8249C6B9956EF840BFB6C3A6F9A60" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_02E2121797B058EAA30DFB6C3A6F7A5F" xlink:to="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_90D8249C6B9956EF840BFB6C3A6F9A60" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_NeurimmuneMember" xlink:label="loc_biib_NeurimmuneMember_9DD675C4915E938A271EFB6C3A6F23EF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_90D8249C6B9956EF840BFB6C3A6F9A60" xlink:to="loc_biib_NeurimmuneMember_9DD675C4915E938A271EFB6C3A6F23EF" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_RodinTherapeuticsMember" xlink:label="loc_biib_RodinTherapeuticsMember_4895BE54026B721A9706FB6C3A6F5AB3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_90D8249C6B9956EF840BFB6C3A6F9A60" xlink:to="loc_biib_RodinTherapeuticsMember_4895BE54026B721A9706FB6C3A6F5AB3" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_AtaxionMember" xlink:label="loc_biib_AtaxionMember_A2AC2BBB54308E41566EFB6C3A6F71CD" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_90D8249C6B9956EF840BFB6C3A6F9A60" xlink:to="loc_biib_AtaxionMember_A2AC2BBB54308E41566EFB6C3A6F71CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_DE19D1C78A0A7ADA62CAFB6C3A6FAD3B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_D749D4FC817F1D4B08E8FB6C3A6F2AF7" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_DE19D1C78A0A7ADA62CAFB6C3A6FAD3B" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_InvestmentInVariableInterestEntitiesTextualAbstract" xlink:label="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_077D275A6430BD65E4B1FB6C3A6FBFF2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_D749D4FC817F1D4B08E8FB6C3A6F2AF7" xlink:to="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_077D275A6430BD65E4B1FB6C3A6FBFF2" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement" xlink:label="loc_biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement_E51BC98ADC77575FBE8EFB6C3A709C63" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_077D275A6430BD65E4B1FB6C3A6FBFF2" xlink:to="loc_biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement_E51BC98ADC77575FBE8EFB6C3A709C63" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement" xlink:label="loc_biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement_CDC4BD9DA9249EC557E1FB6C3A703CA7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_077D275A6430BD65E4B1FB6C3A6FBFF2" xlink:to="loc_biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement_CDC4BD9DA9249EC557E1FB6C3A703CA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_B9B2E0F8F520ED2F8788FB6C3A7052DD" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_077D275A6430BD65E4B1FB6C3A6FBFF2" xlink:to="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_B9B2E0F8F520ED2F8788FB6C3A7052DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_CB74C091903190AA71FCFB6C3A70124C" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_077D275A6430BD65E4B1FB6C3A6FBFF2" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_CB74C091903190AA71FCFB6C3A70124C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NoncontrollingInterestInVariableInterestEntity" xlink:label="loc_us-gaap_NoncontrollingInterestInVariableInterestEntity_8CDA4892E5DFFF9798B6FB6C3A704EDF" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_077D275A6430BD65E4B1FB6C3A6FBFF2" xlink:to="loc_us-gaap_NoncontrollingInterestInVariableInterestEntity_8CDA4892E5DFFF9798B6FB6C3A704EDF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_7AE815B77CF6B967F862FB6C3A700A97" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_077D275A6430BD65E4B1FB6C3A6FBFF2" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_7AE815B77CF6B967F862FB6C3A700A97" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:label="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_3C3C50D7A085BD91B647FB6C3A7023D4" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_077D275A6430BD65E4B1FB6C3A6FBFF2" xlink:to="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_3C3C50D7A085BD91B647FB6C3A7023D4" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/Litigation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/LitigationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_E1218D3754D6593F72E7FCCAD8F24890" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_CE23F5EB8675F207A859FCCAD8F1EFDB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_E1218D3754D6593F72E7FCCAD8F24890" xlink:to="loc_us-gaap_LossContingenciesTable_CE23F5EB8675F207A859FCCAD8F1EFDB" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_9871C956DAEBAF712F29FCCAD8F11184" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_CE23F5EB8675F207A859FCCAD8F1EFDB" xlink:to="loc_us-gaap_StatementGeographicalAxis_9871C956DAEBAF712F29FCCAD8F11184" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_C721FDD84A1313C1DFA5FCCAD8F1DF5A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementGeographicalAxis_9871C956DAEBAF712F29FCCAD8F11184" xlink:to="loc_us-gaap_SegmentGeographicalDomain_C721FDD84A1313C1DFA5FCCAD8F1DF5A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_C721FDD84A1313C1DFA5FCCAD8F1DF5A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementGeographicalAxis_9871C956DAEBAF712F29FCCAD8F11184" xlink:to="loc_us-gaap_SegmentGeographicalDomain_C721FDD84A1313C1DFA5FCCAD8F1DF5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd#country_IT" xlink:label="loc_country_IT_6C56232AED5E0666E7A7FCCAD8F1F8B4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_C721FDD84A1313C1DFA5FCCAD8F1DF5A" xlink:to="loc_country_IT_6C56232AED5E0666E7A7FCCAD8F1F8B4" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ReimbursementLimitStatedInResolution" xlink:label="loc_biib_ReimbursementLimitStatedInResolution_9ECCB5AAD6F7CF31DFC9FCCAD8F24F60" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_E1218D3754D6593F72E7FCCAD8F24890" xlink:to="loc_biib_ReimbursementLimitStatedInResolution_9ECCB5AAD6F7CF31DFC9FCCAD8F24F60" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_C4083F241F0D1BD03A9DFCCAD8F27140" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_E1218D3754D6593F72E7FCCAD8F24890" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_C4083F241F0D1BD03A9DFCCAD8F27140" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_A42FA2D960549E2AB32EFB6C3A854558" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_F5018EEA7FAE61CF11CFFB6C3A85EDEE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_A42FA2D960549E2AB32EFB6C3A854558" xlink:to="loc_us-gaap_StatementTable_F5018EEA7FAE61CF11CFFB6C3A85EDEE" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_DA5CA3A0DB2A65F331DFFB6C3A85B94A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_F5018EEA7FAE61CF11CFFB6C3A85EDEE" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_DA5CA3A0DB2A65F331DFFB6C3A85B94A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_85FBA75FE9291149FD8CFB6C3A851BE4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_DA5CA3A0DB2A65F331DFFB6C3A85B94A" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_85FBA75FE9291149FD8CFB6C3A851BE4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_85FBA75FE9291149FD8CFB6C3A851BE4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_DA5CA3A0DB2A65F331DFFB6C3A85B94A" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_85FBA75FE9291149FD8CFB6C3A851BE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_6BAAB45C376C946753E2FB6C3A856C14" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_85FBA75FE9291149FD8CFB6C3A851BE4" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_6BAAB45C376C946753E2FB6C3A856C14" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_4342839C9E9EB11919FDFB6C3A853624" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_A42FA2D960549E2AB32EFB6C3A854558" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_4342839C9E9EB11919FDFB6C3A853624" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_818E713A0D6967D4B9D4FB6C3A7CF643" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_C6C4AA17ADE20EB1DE6CFB6C3A7A249B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_818E713A0D6967D4B9D4FB6C3A7CF643" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_C6C4AA17ADE20EB1DE6CFB6C3A7A249B" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_0C528E6E7E6A74EDD0DCFB6C3A7A1265" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_C6C4AA17ADE20EB1DE6CFB6C3A7A249B" xlink:to="loc_us-gaap_StatementGeographicalAxis_0C528E6E7E6A74EDD0DCFB6C3A7A1265" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_F8CC8DB532DAD514734FFB6C3A7ADBC2_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementGeographicalAxis_0C528E6E7E6A74EDD0DCFB6C3A7A1265" xlink:to="loc_us-gaap_SegmentGeographicalDomain_F8CC8DB532DAD514734FFB6C3A7ADBC2_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_F8CC8DB532DAD514734FFB6C3A7ADBC2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementGeographicalAxis_0C528E6E7E6A74EDD0DCFB6C3A7A1265" xlink:to="loc_us-gaap_SegmentGeographicalDomain_F8CC8DB532DAD514734FFB6C3A7ADBC2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd#country_IT" xlink:label="loc_country_IT_A3D617FBC9AE3E88202AFB6C3A7A76A7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_F8CC8DB532DAD514734FFB6C3A7ADBC2" xlink:to="loc_country_IT_A3D617FBC9AE3E88202AFB6C3A7A76A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_6D5C446F1C15A7800AF3FB6C3A7B9206" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_C6C4AA17ADE20EB1DE6CFB6C3A7A249B" xlink:to="loc_us-gaap_ProductOrServiceAxis_6D5C446F1C15A7800AF3FB6C3A7B9206" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_3026F79808E98109B16EFB6C3A7B498B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProductOrServiceAxis_6D5C446F1C15A7800AF3FB6C3A7B9206" xlink:to="loc_us-gaap_ProductsAndServicesDomain_3026F79808E98109B16EFB6C3A7B498B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_3026F79808E98109B16EFB6C3A7B498B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProductOrServiceAxis_6D5C446F1C15A7800AF3FB6C3A7B9206" xlink:to="loc_us-gaap_ProductsAndServicesDomain_3026F79808E98109B16EFB6C3A7B498B" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_DC6B9DBCB0C99121CF87FB6C3A7B37A0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_3026F79808E98109B16EFB6C3A7B498B" xlink:to="loc_biib_TecfideraMember_DC6B9DBCB0C99121CF87FB6C3A7B37A0" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_CumulativeSalesLevelAxis" xlink:label="loc_biib_CumulativeSalesLevelAxis_307D3D3893BBBAF6C9ECFB6C3A7B8756" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_C6C4AA17ADE20EB1DE6CFB6C3A7A249B" xlink:to="loc_biib_CumulativeSalesLevelAxis_307D3D3893BBBAF6C9ECFB6C3A7B8756" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_CumulativeSalesLevelDomain" xlink:label="loc_biib_CumulativeSalesLevelDomain_4FB6EEB520BB1657F312FB6C3A7BF198_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_CumulativeSalesLevelAxis_307D3D3893BBBAF6C9ECFB6C3A7B8756" xlink:to="loc_biib_CumulativeSalesLevelDomain_4FB6EEB520BB1657F312FB6C3A7BF198_default" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_CumulativeSalesLevelDomain" xlink:label="loc_biib_CumulativeSalesLevelDomain_4FB6EEB520BB1657F312FB6C3A7BF198" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_CumulativeSalesLevelAxis_307D3D3893BBBAF6C9ECFB6C3A7B8756" xlink:to="loc_biib_CumulativeSalesLevelDomain_4FB6EEB520BB1657F312FB6C3A7BF198" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ElevenbillionMember" xlink:label="loc_biib_ElevenbillionMember_9F9AC15002436D034960FB6C3A7B568D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CumulativeSalesLevelDomain_4FB6EEB520BB1657F312FB6C3A7BF198" xlink:to="loc_biib_ElevenbillionMember_9F9AC15002436D034960FB6C3A7B568D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_C5F8E25C7C340703C061FB6C3A7BAD75" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_C6C4AA17ADE20EB1DE6CFB6C3A7A249B" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_C5F8E25C7C340703C061FB6C3A7BAD75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_AB37326A5FE5473795CBFB6C3A7BA6B1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_C5F8E25C7C340703C061FB6C3A7BAD75" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_AB37326A5FE5473795CBFB6C3A7BA6B1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_AB37326A5FE5473795CBFB6C3A7BA6B1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_C5F8E25C7C340703C061FB6C3A7BAD75" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_AB37326A5FE5473795CBFB6C3A7BA6B1" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_FumapharmAgMember" xlink:label="loc_biib_FumapharmAgMember_D2B1B793D81F312FA855FB6C3A7C4106" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_AB37326A5FE5473795CBFB6C3A7BA6B1" xlink:to="loc_biib_FumapharmAgMember_D2B1B793D81F312FA855FB6C3A7C4106" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ConvergencePharmaceuticalsMember" xlink:label="loc_biib_ConvergencePharmaceuticalsMember_D99BA0E8217D8EA15DA0FB6C3A7C524F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_AB37326A5FE5473795CBFB6C3A7BA6B1" xlink:to="loc_biib_ConvergencePharmaceuticalsMember_D99BA0E8217D8EA15DA0FB6C3A7C524F" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_FacilityLocationAxis" xlink:label="loc_biib_FacilityLocationAxis_6357BD1E932CB5C1E74CFB6C3A7CA068" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_C6C4AA17ADE20EB1DE6CFB6C3A7A249B" xlink:to="loc_biib_FacilityLocationAxis_6357BD1E932CB5C1E74CFB6C3A7CA068" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_64D750ECCACBD74194B9FB6C3A7C9CE5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_FacilityLocationAxis_6357BD1E932CB5C1E74CFB6C3A7CA068" xlink:to="loc_biib_FacilityLocationDomain_64D750ECCACBD74194B9FB6C3A7C9CE5_default" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_64D750ECCACBD74194B9FB6C3A7C9CE5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_FacilityLocationAxis_6357BD1E932CB5C1E74CFB6C3A7CA068" xlink:to="loc_biib_FacilityLocationDomain_64D750ECCACBD74194B9FB6C3A7C9CE5" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_SolothurnMember" xlink:label="loc_biib_SolothurnMember_35273543728AA07E2BDDFB6C3A7C2074" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FacilityLocationDomain_64D750ECCACBD74194B9FB6C3A7C9CE5" xlink:to="loc_biib_SolothurnMember_35273543728AA07E2BDDFB6C3A7C2074" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationSettlementExpense" xlink:label="loc_us-gaap_LitigationSettlementExpense_4524B2A259A0974CC6EBFB6C3A7CA717" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_818E713A0D6967D4B9D4FB6C3A7CF643" xlink:to="loc_us-gaap_LitigationSettlementExpense_4524B2A259A0974CC6EBFB6C3A7CA717" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_502880A06042CF43D120FB6C3A7C510C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_818E713A0D6967D4B9D4FB6C3A7CF643" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_502880A06042CF43D120FB6C3A7C510C" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_CumulativeSalesLevel" xlink:label="loc_biib_CumulativeSalesLevel_8EFDC8FC90D214139B9DFB6C3A7DEE48" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_818E713A0D6967D4B9D4FB6C3A7CF643" xlink:to="loc_biib_CumulativeSalesLevel_8EFDC8FC90D214139B9DFB6C3A7DEE48" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConstructionPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent_1D736EE70810393C06D4FBBFB7A802BD" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_818E713A0D6967D4B9D4FB6C3A7CF643" xlink:to="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent_1D736EE70810393C06D4FBBFB7A802BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_173FF5BE27589843D7E1FB6C3A7DE364" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_818E713A0D6967D4B9D4FB6C3A7CF643" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_173FF5BE27589843D7E1FB6C3A7DE364" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidTaxes" xlink:label="loc_us-gaap_PrepaidTaxes_16BCC52584BEED3645FBFB6C3A7DA321" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_818E713A0D6967D4B9D4FB6C3A7CF643" xlink:to="loc_us-gaap_PrepaidTaxes_16BCC52584BEED3645FBFB6C3A7DA321" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_22F8E760669A78A5DC89FB6C3A7D9597" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_818E713A0D6967D4B9D4FB6C3A7CF643" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_22F8E760669A78A5DC89FB6C3A7D9597" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ReimbursementLimitStatedInResolution" xlink:label="loc_biib_ReimbursementLimitStatedInResolution_6E8014F8D75FCB28EB30FB6C3A7DAB05" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_818E713A0D6967D4B9D4FB6C3A7CF643" xlink:to="loc_biib_ReimbursementLimitStatedInResolution_6E8014F8D75FCB28EB30FB6C3A7DAB05" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_CCFE86255E01399D9E5FFB6C3A7D30BC" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_818E713A0D6967D4B9D4FB6C3A7CF643" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_CCFE86255E01399D9E5FFB6C3A7D30BC" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_LossContingencyAdjustmentRelatedToClaimAmountPercent" xlink:label="loc_biib_LossContingencyAdjustmentRelatedToClaimAmountPercent_E53392492F4F75200048FB6C3A7D1749" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_818E713A0D6967D4B9D4FB6C3A7CF643" xlink:to="loc_biib_LossContingencyAdjustmentRelatedToClaimAmountPercent_E53392492F4F75200048FB6C3A7D1749" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_46110BB3A1600EBDE0E5FB6C3A7D621E" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_818E713A0D6967D4B9D4FB6C3A7CF643" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_46110BB3A1600EBDE0E5FB6C3A7D621E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_C90D4BB660FE9CBDF6A0FB6C3A7DDACA" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_818E713A0D6967D4B9D4FB6C3A7CF643" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_C90D4BB660FE9CBDF6A0FB6C3A7DDACA" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipment" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_EC0C8926DE2938ADB2F3FA4EA4BF5D26" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_06817BABE672F9B4C485FA4EA4BEA452" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_EC0C8926DE2938ADB2F3FA4EA4BF5D26" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_06817BABE672F9B4C485FA4EA4BEA452" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrencyAxis" xlink:label="loc_us-gaap_CurrencyAxis_89E315A9DE4ABD0FEAA0FA4EA4BE27DC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_06817BABE672F9B4C485FA4EA4BEA452" xlink:to="loc_us-gaap_CurrencyAxis_89E315A9DE4ABD0FEAA0FA4EA4BE27DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_DF848F43B464F2E7C07AFA4EA4BEA272_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CurrencyAxis_89E315A9DE4ABD0FEAA0FA4EA4BE27DC" xlink:to="loc_currency_AllCurrenciesDomain_DF848F43B464F2E7C07AFA4EA4BEA272_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_DF848F43B464F2E7C07AFA4EA4BEA272" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CurrencyAxis_89E315A9DE4ABD0FEAA0FA4EA4BE27DC" xlink:to="loc_currency_AllCurrenciesDomain_DF848F43B464F2E7C07AFA4EA4BEA272" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd#currency_CHF" xlink:label="loc_currency_CHF_1422E3ABF05D9928DDE7FA4EA4BE1A85" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_DF848F43B464F2E7C07AFA4EA4BEA272" xlink:to="loc_currency_CHF_1422E3ABF05D9928DDE7FA4EA4BE1A85" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd#currency_USD" xlink:label="loc_currency_USD_5DCBBF9C02779CC13F8BFA4EA4BEC338" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_DF848F43B464F2E7C07AFA4EA4BEA272" xlink:to="loc_currency_USD_5DCBBF9C02779CC13F8BFA4EA4BEC338" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_A8DE4DA358BA42F02131FA4EA4BE06E0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_06817BABE672F9B4C485FA4EA4BEA452" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_A8DE4DA358BA42F02131FA4EA4BE06E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_20FEF50E048C85BD0526FA4EA4BE80C7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_A8DE4DA358BA42F02131FA4EA4BE06E0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_20FEF50E048C85BD0526FA4EA4BE80C7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_20FEF50E048C85BD0526FA4EA4BE80C7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_A8DE4DA358BA42F02131FA4EA4BE06E0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_20FEF50E048C85BD0526FA4EA4BE80C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BuildingMember" xlink:label="loc_us-gaap_BuildingMember_EF2AD1EA31FA14BC7DD9FA4EA4BE95E4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_20FEF50E048C85BD0526FA4EA4BE80C7" xlink:to="loc_us-gaap_BuildingMember_EF2AD1EA31FA14BC7DD9FA4EA4BE95E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_69FD1E648E437808EF2EFA4EA4BF4A37" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_20FEF50E048C85BD0526FA4EA4BE80C7" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_69FD1E648E437808EF2EFA4EA4BF4A37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LandMember" xlink:label="loc_us-gaap_LandMember_894D830F5CD78D669735FA4EA4BFD82B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_20FEF50E048C85BD0526FA4EA4BE80C7" xlink:to="loc_us-gaap_LandMember_894D830F5CD78D669735FA4EA4BFD82B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_01F7CB7AF10A096C9A36FA4EA4BF0643" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_06817BABE672F9B4C485FA4EA4BEA452" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_01F7CB7AF10A096C9A36FA4EA4BF0643" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_66C0C7DEC4DDCF9593A7FA4EA4BF64AE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_01F7CB7AF10A096C9A36FA4EA4BF0643" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_66C0C7DEC4DDCF9593A7FA4EA4BF64AE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_66C0C7DEC4DDCF9593A7FA4EA4BF64AE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_01F7CB7AF10A096C9A36FA4EA4BF0643" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_66C0C7DEC4DDCF9593A7FA4EA4BF64AE" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_EisaiMember" xlink:label="loc_biib_EisaiMember_7284362A5D52773CACB7FA4EA4BF7A69" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_66C0C7DEC4DDCF9593A7FA4EA4BF64AE" xlink:to="loc_biib_EisaiMember_7284362A5D52773CACB7FA4EA4BF7A69" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_FacilityLocationAxis" xlink:label="loc_biib_FacilityLocationAxis_74D61367D05743380EF1FA4EA4BF0B74" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_06817BABE672F9B4C485FA4EA4BEA452" xlink:to="loc_biib_FacilityLocationAxis_74D61367D05743380EF1FA4EA4BF0B74" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_94BC43AE99B5AF6925C4FA4EA4BF36F6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_FacilityLocationAxis_74D61367D05743380EF1FA4EA4BF0B74" xlink:to="loc_biib_FacilityLocationDomain_94BC43AE99B5AF6925C4FA4EA4BF36F6_default" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_94BC43AE99B5AF6925C4FA4EA4BF36F6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_FacilityLocationAxis_74D61367D05743380EF1FA4EA4BF0B74" xlink:to="loc_biib_FacilityLocationDomain_94BC43AE99B5AF6925C4FA4EA4BF36F6" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_SolothurnMember" xlink:label="loc_biib_SolothurnMember_F226F2D866627C19B19CFA4EA4BF5E5D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FacilityLocationDomain_94BC43AE99B5AF6925C4FA4EA4BF36F6" xlink:to="loc_biib_SolothurnMember_F226F2D866627C19B19CFA4EA4BF5E5D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_E917D5DCDAE6C53D41F7FA4EA4BFA2F9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_EC0C8926DE2938ADB2F3FA4EA4BF5D26" xlink:to="loc_us-gaap_Depreciation_E917D5DCDAE6C53D41F7FA4EA4BFA2F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestCostsCapitalized" xlink:label="loc_us-gaap_InterestCostsCapitalized_01359CEC34A7EE743104FA4EA4BF65DE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_EC0C8926DE2938ADB2F3FA4EA4BF5D26" xlink:to="loc_us-gaap_InterestCostsCapitalized_01359CEC34A7EE743104FA4EA4BF65DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAdditions" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAdditions_FDAC12C5DC82EDB3C9BDFA4EA4BF4275" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_EC0C8926DE2938ADB2F3FA4EA4BF5D26" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAdditions_FDAC12C5DC82EDB3C9BDFA4EA4BF4275" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConstructionInProgressGross" xlink:label="loc_us-gaap_ConstructionInProgressGross_5C51B16F78EBD6F3D08DFA4EA4C0C18E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_EC0C8926DE2938ADB2F3FA4EA4BF5D26" xlink:to="loc_us-gaap_ConstructionInProgressGross_5C51B16F78EBD6F3D08DFA4EA4C0C18E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:label="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_A169EC780FFBB76DCA2CFA4EA4C0B98F" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_EC0C8926DE2938ADB2F3FA4EA4BF5D26" xlink:to="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_A169EC780FFBB76DCA2CFA4EA4C0B98F" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_TermOfLease" xlink:label="loc_biib_TermOfLease_4684C66542187739F454FA4EA4C0B882" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_EC0C8926DE2938ADB2F3FA4EA4BF5D26" xlink:to="loc_biib_TermOfLease_4684C66542187739F454FA4EA4C0B882" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalLeaseObligations" xlink:label="loc_us-gaap_CapitalLeaseObligations_6DDC589EBC8E538467CCFA4EA4C023D2" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_EC0C8926DE2938ADB2F3FA4EA4BF5D26" xlink:to="loc_us-gaap_CapitalLeaseObligations_6DDC589EBC8E538467CCFA4EA4C023D2" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/QuarterlyFinancialDataUnaudited" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="biib-20161231.xsd#biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems" xlink:label="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_8D61436B050E51C22A74FCCBDA9EDFA0" xlink:type="locator" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable" xlink:label="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_DD90BBCBFD70B10B3C91FCCBDA9677F8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_8D61436B050E51C22A74FCCBDA9EDFA0" xlink:to="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_DD90BBCBFD70B10B3C91FCCBDA9677F8" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_842679059329E7BC7E03FCCBDA961A46" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_DD90BBCBFD70B10B3C91FCCBDA9677F8" xlink:to="loc_us-gaap_ProductOrServiceAxis_842679059329E7BC7E03FCCBDA961A46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_C228479EF900150D1EBCFCCBDA978CB6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProductOrServiceAxis_842679059329E7BC7E03FCCBDA961A46" xlink:to="loc_us-gaap_ProductsAndServicesDomain_C228479EF900150D1EBCFCCBDA978CB6_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_C228479EF900150D1EBCFCCBDA978CB6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProductOrServiceAxis_842679059329E7BC7E03FCCBDA961A46" xlink:to="loc_us-gaap_ProductsAndServicesDomain_C228479EF900150D1EBCFCCBDA978CB6" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_SPINRAZAMember" xlink:label="loc_biib_SPINRAZAMember_A597A5BB090FCE733603FCCBDA97A7BE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_C228479EF900150D1EBCFCCBDA978CB6" xlink:to="loc_biib_SPINRAZAMember_A597A5BB090FCE733603FCCBDA97A7BE" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_FacilityLocationAxis" xlink:label="loc_biib_FacilityLocationAxis_0FD623E7A2F2978A7BB3FCCBDA9748F4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_DD90BBCBFD70B10B3C91FCCBDA9677F8" xlink:to="loc_biib_FacilityLocationAxis_0FD623E7A2F2978A7BB3FCCBDA9748F4" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_F5FBF2E48B4F457F79E3FCCBDA97A499_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_FacilityLocationAxis_0FD623E7A2F2978A7BB3FCCBDA9748F4" xlink:to="loc_biib_FacilityLocationDomain_F5FBF2E48B4F457F79E3FCCBDA97A499_default" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_F5FBF2E48B4F457F79E3FCCBDA97A499" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_FacilityLocationAxis_0FD623E7A2F2978A7BB3FCCBDA9748F4" xlink:to="loc_biib_FacilityLocationDomain_F5FBF2E48B4F457F79E3FCCBDA97A499" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_CambridgeMAMember" xlink:label="loc_biib_CambridgeMAMember_9F7A0D3D9DFED50D21C6FCCBDA97E788" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FacilityLocationDomain_F5FBF2E48B4F457F79E3FCCBDA97A499" xlink:to="loc_biib_CambridgeMAMember_9F7A0D3D9DFED50D21C6FCCBDA97E788" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringPlanAxis" xlink:label="loc_us-gaap_RestructuringPlanAxis_9E3C71DF67BEA010D6C9FCCBDA974768" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_DD90BBCBFD70B10B3C91FCCBDA9677F8" xlink:to="loc_us-gaap_RestructuringPlanAxis_9E3C71DF67BEA010D6C9FCCBDA974768" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringPlanDomain" xlink:label="loc_us-gaap_RestructuringPlanDomain_4A6E345E0224F5483195FCCBDA976257_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_9E3C71DF67BEA010D6C9FCCBDA974768" xlink:to="loc_us-gaap_RestructuringPlanDomain_4A6E345E0224F5483195FCCBDA976257_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringPlanDomain" xlink:label="loc_us-gaap_RestructuringPlanDomain_4A6E345E0224F5483195FCCBDA976257" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_9E3C71DF67BEA010D6C9FCCBDA974768" xlink:to="loc_us-gaap_RestructuringPlanDomain_4A6E345E0224F5483195FCCBDA976257" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_A2015RestructuringChargesMember" xlink:label="loc_biib_A2015RestructuringChargesMember_EB06A8254A161B8B1EA3FCCBDA97C4F0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_4A6E345E0224F5483195FCCBDA976257" xlink:to="loc_biib_A2015RestructuringChargesMember_EB06A8254A161B8B1EA3FCCBDA97C4F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:label="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_517001ABA83BD333B12DFCCBDA98971F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_DD90BBCBFD70B10B3C91FCCBDA9677F8" xlink:to="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_517001ABA83BD333B12DFCCBDA98971F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:label="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_895A00F3D4AB3BD88309FCCBDA98D490_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_517001ABA83BD333B12DFCCBDA98971F" xlink:to="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_895A00F3D4AB3BD88309FCCBDA98D490_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:label="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_895A00F3D4AB3BD88309FCCBDA98D490" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_517001ABA83BD333B12DFCCBDA98971F" xlink:to="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_895A00F3D4AB3BD88309FCCBDA98D490" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_NeurimmuneMember" xlink:label="loc_biib_NeurimmuneMember_87A6135A4C1A251156ACFCCBDA98D7CE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_895A00F3D4AB3BD88309FCCBDA98D490" xlink:to="loc_biib_NeurimmuneMember_87A6135A4C1A251156ACFCCBDA98D7CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_653F5C675DA02922DFB5FCCBDA98EFD9" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_DD90BBCBFD70B10B3C91FCCBDA9677F8" xlink:to="loc_us-gaap_TypeOfArrangementAxis_653F5C675DA02922DFB5FCCBDA98EFD9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ABEFCDBDC21F0533DC69FCCBDA984AEF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_653F5C675DA02922DFB5FCCBDA98EFD9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ABEFCDBDC21F0533DC69FCCBDA984AEF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ABEFCDBDC21F0533DC69FCCBDA984AEF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_653F5C675DA02922DFB5FCCBDA98EFD9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ABEFCDBDC21F0533DC69FCCBDA984AEF" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_IonisPharmaceuticalsInc.Member" xlink:label="loc_biib_IonisPharmaceuticalsInc.Member_029D1FC1B26E6FB2597BFCCBDA9DEA6E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ABEFCDBDC21F0533DC69FCCBDA984AEF" xlink:to="loc_biib_IonisPharmaceuticalsInc.Member_029D1FC1B26E6FB2597BFCCBDA9DEA6E" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_EisaiMember" xlink:label="loc_biib_EisaiMember_A737BCB44D1537AF7D96FCCBDA9D7E0D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ABEFCDBDC21F0533DC69FCCBDA984AEF" xlink:to="loc_biib_EisaiMember_A737BCB44D1537AF7D96FCCBDA9D7E0D" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_AGTCMember" xlink:label="loc_biib_AGTCMember_B6F3FE2551930753DC63FCCBDA98D175" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ABEFCDBDC21F0533DC69FCCBDA984AEF" xlink:to="loc_biib_AGTCMember_B6F3FE2551930753DC63FCCBDA98D175" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_MitsubishiTanabePharmaCorporationMember" xlink:label="loc_biib_MitsubishiTanabePharmaCorporationMember_26F6B8E4E4F33FCDCBBEFCCBDA9DC3B0" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ABEFCDBDC21F0533DC69FCCBDA984AEF" xlink:to="loc_biib_MitsubishiTanabePharmaCorporationMember_26F6B8E4E4F33FCDCBBEFCCBDA9DC3B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_8F6728B08721A77F9C1EFCCBDA9ECECA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_8D61436B050E51C22A74FCCBDA9EDFA0" xlink:to="loc_us-gaap_RestructuringCharges_8F6728B08721A77F9C1EFCCBDA9ECECA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:label="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_9C667E06869B8B51983BFCCBDA9E7DAD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_8D61436B050E51C22A74FCCBDA9EDFA0" xlink:to="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_9C667E06869B8B51983BFCCBDA9E7DAD" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_LicenseFee" xlink:label="loc_biib_LicenseFee_2B82C6267B65D2B2F27EFCCBDA9EAB75" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_8D61436B050E51C22A74FCCBDA9EDFA0" xlink:to="loc_biib_LicenseFee_2B82C6267B65D2B2F27EFCCBDA9EAB75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_8CA086F2C3B2A0583B4EFCCBDA9E31E3" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_8D61436B050E51C22A74FCCBDA9EDFA0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_8CA086F2C3B2A0583B4EFCCBDA9E31E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationSettlementExpense" xlink:label="loc_us-gaap_LitigationSettlementExpense_56E62808A3F2885A7425FCCBDA9EAF06" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_8D61436B050E51C22A74FCCBDA9EDFA0" xlink:to="loc_us-gaap_LitigationSettlementExpense_56E62808A3F2885A7425FCCBDA9EAF06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_7A33040AF70ACFB45EF5FCCBDA9E2F66" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_8D61436B050E51C22A74FCCBDA9EDFA0" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_7A33040AF70ACFB45EF5FCCBDA9E2F66" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RestructuringRestructuring" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RestructuringRestructuringDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_4D4ADC8CE5D34B08C7C8FA4EA5C47B04" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8846F3EA4F344CC8EB24FA4EA5C33A90" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_4D4ADC8CE5D34B08C7C8FA4EA5C47B04" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8846F3EA4F344CC8EB24FA4EA5C33A90" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_D12C194F276AEACBF7B0FA4EA5C45A09" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8846F3EA4F344CC8EB24FA4EA5C33A90" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_D12C194F276AEACBF7B0FA4EA5C45A09" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_B97E74C8BAF2E4A1E822FA4EA5C4AD56_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_D12C194F276AEACBF7B0FA4EA5C45A09" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_B97E74C8BAF2E4A1E822FA4EA5C4AD56_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_B97E74C8BAF2E4A1E822FA4EA5C4AD56" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_D12C194F276AEACBF7B0FA4EA5C45A09" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_B97E74C8BAF2E4A1E822FA4EA5C4AD56" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="loc_us-gaap_EmployeeSeveranceMember_892B946708C514E5728CFA4EA5C49DF4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_B97E74C8BAF2E4A1E822FA4EA5C4AD56" xlink:to="loc_us-gaap_EmployeeSeveranceMember_892B946708C514E5728CFA4EA5C49DF4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractTerminationMember" xlink:label="loc_us-gaap_ContractTerminationMember_1C7835881F9C8BB4C3C2FA4EA5C42FEC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_B97E74C8BAF2E4A1E822FA4EA5C4AD56" xlink:to="loc_us-gaap_ContractTerminationMember_1C7835881F9C8BB4C3C2FA4EA5C42FEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve_F98E011F465E7C6E1F06FA4EA5C456B5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_4D4ADC8CE5D34B08C7C8FA4EA5C47B04" xlink:to="loc_us-gaap_RestructuringReserve_F98E011F465E7C6E1F06FA4EA5C456B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringCosts" xlink:label="loc_us-gaap_RestructuringCosts_8C8A6227327B7F4CE4DFFA4EA5C5DA64" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_4D4ADC8CE5D34B08C7C8FA4EA5C47B04" xlink:to="loc_us-gaap_RestructuringCosts_8C8A6227327B7F4CE4DFFA4EA5C5DA64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForRestructuring" xlink:label="loc_us-gaap_PaymentsForRestructuring_1DAC998E1EC73EF1021CFA4EA5C4EEC3" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_4D4ADC8CE5D34B08C7C8FA4EA5C47B04" xlink:to="loc_us-gaap_PaymentsForRestructuring_1DAC998E1EC73EF1021CFA4EA5C4EEC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringReserveAccrualAdjustment1" xlink:label="loc_us-gaap_RestructuringReserveAccrualAdjustment1_7437DEE17F0945E2D236FA4EA5C432AD" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_4D4ADC8CE5D34B08C7C8FA4EA5C47B04" xlink:to="loc_us-gaap_RestructuringReserveAccrualAdjustment1_7437DEE17F0945E2D236FA4EA5C432AD" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RestructuringRestructuringDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_EC5C3494D051AFB0CF82FA4EA5BFF493" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_087A087A8E3CC64BB59AFA4EA5BD2D35" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_EC5C3494D051AFB0CF82FA4EA5BFF493" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_087A087A8E3CC64BB59AFA4EA5BD2D35" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="biib-20161231.xsd#biib_FacilityLocationAxis" xlink:label="loc_biib_FacilityLocationAxis_D88BF99C7DD80632BFE8FA4EA5BE494B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_087A087A8E3CC64BB59AFA4EA5BD2D35" xlink:to="loc_biib_FacilityLocationAxis_D88BF99C7DD80632BFE8FA4EA5BE494B" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_D0B46BE437119D940BE6FA4EA5BEC9B4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_FacilityLocationAxis_D88BF99C7DD80632BFE8FA4EA5BE494B" xlink:to="loc_biib_FacilityLocationDomain_D0B46BE437119D940BE6FA4EA5BEC9B4_default" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_D0B46BE437119D940BE6FA4EA5BEC9B4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_FacilityLocationAxis_D88BF99C7DD80632BFE8FA4EA5BE494B" xlink:to="loc_biib_FacilityLocationDomain_D0B46BE437119D940BE6FA4EA5BEC9B4" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_CambridgeMAMember" xlink:label="loc_biib_CambridgeMAMember_70B30548757135BB71F0FA4EA5BEDC28" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FacilityLocationDomain_D0B46BE437119D940BE6FA4EA5BEC9B4" xlink:to="loc_biib_CambridgeMAMember_70B30548757135BB71F0FA4EA5BEDC28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringPlanAxis" xlink:label="loc_us-gaap_RestructuringPlanAxis_F0EF9EF6AE038BD6A0BFFA4EA5BE8FD7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_087A087A8E3CC64BB59AFA4EA5BD2D35" xlink:to="loc_us-gaap_RestructuringPlanAxis_F0EF9EF6AE038BD6A0BFFA4EA5BE8FD7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringPlanDomain" xlink:label="loc_us-gaap_RestructuringPlanDomain_4773AB87B787A78453D2FA4EA5BE9A0C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_F0EF9EF6AE038BD6A0BFFA4EA5BE8FD7" xlink:to="loc_us-gaap_RestructuringPlanDomain_4773AB87B787A78453D2FA4EA5BE9A0C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringPlanDomain" xlink:label="loc_us-gaap_RestructuringPlanDomain_4773AB87B787A78453D2FA4EA5BE9A0C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_F0EF9EF6AE038BD6A0BFFA4EA5BE8FD7" xlink:to="loc_us-gaap_RestructuringPlanDomain_4773AB87B787A78453D2FA4EA5BE9A0C" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_A2015RestructuringChargesMember" xlink:label="loc_biib_A2015RestructuringChargesMember_35527C5B4B6B83711063FA4EA5BEAE85" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_4773AB87B787A78453D2FA4EA5BE9A0C" xlink:to="loc_biib_A2015RestructuringChargesMember_35527C5B4B6B83711063FA4EA5BEAE85" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_A2016RestructuringChargesMember" xlink:label="loc_biib_A2016RestructuringChargesMember_939EF3D923298797CFE6FA4EA5BE45B4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_4773AB87B787A78453D2FA4EA5BE9A0C" xlink:to="loc_biib_A2016RestructuringChargesMember_939EF3D923298797CFE6FA4EA5BE45B4" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_Restructuringandrelatedcostexpectedpercentageofpositionseliminated" xlink:label="loc_biib_Restructuringandrelatedcostexpectedpercentageofpositionseliminated_A7963B3270BA73D76483FA4EA5BF9007" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_EC5C3494D051AFB0CF82FA4EA5BFF493" xlink:to="loc_biib_Restructuringandrelatedcostexpectedpercentageofpositionseliminated_A7963B3270BA73D76483FA4EA5BF9007" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_RestructuringandRelatedCostExpectedCashPayments" xlink:label="loc_biib_RestructuringandRelatedCostExpectedCashPayments_9AD883F3037E741C1C08FA4EA5BF94FE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_EC5C3494D051AFB0CF82FA4EA5BFF493" xlink:to="loc_biib_RestructuringandRelatedCostExpectedCashPayments_9AD883F3037E741C1C08FA4EA5BF94FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringReserveAccrualAdjustment1" xlink:label="loc_us-gaap_RestructuringReserveAccrualAdjustment1_F792AC8F0796450B7A7EFA4EA5BFFA77" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_EC5C3494D051AFB0CF82FA4EA5BFF493" xlink:to="loc_us-gaap_RestructuringReserveAccrualAdjustment1_F792AC8F0796450B7A7EFA4EA5BFFA77" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_38BE0210DFD11C5640CDFA4EA5BF5F5A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_EC5C3494D051AFB0CF82FA4EA5BFF493" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_38BE0210DFD11C5640CDFA4EA5BF5F5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_204BC0BD4E63BF5CFAA3FA4EA5BFCDF2" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_EC5C3494D051AFB0CF82FA4EA5BFF493" xlink:to="loc_us-gaap_RestructuringCharges_204BC0BD4E63BF5CFAA3FA4EA5BFCDF2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:label="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_99B935F2C070CC4CCCD0FA4EA5BFBF9C" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_EC5C3494D051AFB0CF82FA4EA5BFF493" xlink:to="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_99B935F2C070CC4CCCD0FA4EA5BFBF9C" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RestructuringRestructuringTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenueReserves" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenueReservesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_C97D500E00A90B8F27387412860F9DDB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_F22B8E0CDA4C75DE58FA7412860F7902" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_C97D500E00A90B8F27387412860F9DDB" xlink:to="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_F22B8E0CDA4C75DE58FA7412860F7902" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_6C3AEB43EC27BF0E6E597412860FA81D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_F22B8E0CDA4C75DE58FA7412860F7902" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_6C3AEB43EC27BF0E6E597412860FA81D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_2E67798B5F6F9E086F7C7412860FFF43_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_6C3AEB43EC27BF0E6E597412860FA81D" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_2E67798B5F6F9E086F7C7412860FFF43_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_2E67798B5F6F9E086F7C7412860FFF43" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_6C3AEB43EC27BF0E6E597412860FA81D" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_2E67798B5F6F9E086F7C7412860FFF43" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReserveForCashDiscountMember" xlink:label="loc_us-gaap_ReserveForCashDiscountMember_BC7C0170ACC231ACADD97412860F2087" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_2E67798B5F6F9E086F7C7412860FFF43" xlink:to="loc_us-gaap_ReserveForCashDiscountMember_BC7C0170ACC231ACADD97412860F2087" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ContractualAdjustmentsMember" xlink:label="loc_biib_ContractualAdjustmentsMember_760BA8657469537B49AD7412860F41A4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_2E67798B5F6F9E086F7C7412860FFF43" xlink:to="loc_biib_ContractualAdjustmentsMember_760BA8657469537B49AD7412860F41A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember_FE0DC58AD709CDABE5C27412860FACFA" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_2E67798B5F6F9E086F7C7412860FFF43" xlink:to="loc_us-gaap_SalesReturnsAndAllowancesMember_FE0DC58AD709CDABE5C27412860FACFA" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract" xlink:label="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_518129311F902B2564A67412860F3F49" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_C97D500E00A90B8F27387412860F9DDB" xlink:to="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_518129311F902B2564A67412860F3F49" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_0AB80A908396C2913C477412860FEFA8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_518129311F902B2564A67412860F3F49" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_0AB80A908396C2913C477412860FEFA8" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:label="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_70C3699B3A02F341F710741286109150" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_518129311F902B2564A67412860F3F49" xlink:to="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_70C3699B3A02F341F710741286109150" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:label="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_569B038F3DDF3940872374128610336B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_518129311F902B2564A67412860F3F49" xlink:to="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_569B038F3DDF3940872374128610336B" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_54882D79CC37482823DD74128610D2CB" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_518129311F902B2564A67412860F3F49" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_54882D79CC37482823DD74128610D2CB" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_389E80FE308C3DC0B06074128610C2A1" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_518129311F902B2564A67412860F3F49" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_389E80FE308C3DC0B06074128610C2A1" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenueReservesDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_E4AE9B8C3471305904FE7412856BCC04" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_427F5F77EB7F27AC13F77412856B5E0B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_E4AE9B8C3471305904FE7412856BCC04" xlink:to="loc_us-gaap_StatementTable_427F5F77EB7F27AC13F77412856B5E0B" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_6661E1B537003DFBEDE97412856BB501" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_427F5F77EB7F27AC13F77412856B5E0B" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_6661E1B537003DFBEDE97412856BB501" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_C8BE19C77706966D6F427412856B97F2_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_6661E1B537003DFBEDE97412856BB501" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_C8BE19C77706966D6F427412856B97F2_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_C8BE19C77706966D6F427412856B97F2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_6661E1B537003DFBEDE97412856BB501" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_C8BE19C77706966D6F427412856B97F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_201986558ECDB33345607412856B30B6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_C8BE19C77706966D6F427412856B97F2" xlink:to="loc_us-gaap_AccountsReceivableMember_201986558ECDB33345607412856B30B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_9F3EAFCAECEBF769D40E7412856B5086" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_C8BE19C77706966D6F427412856B97F2" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_9F3EAFCAECEBF769D40E7412856B5086" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_2E891048FD0FC444334C7412856B5C92" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_E4AE9B8C3471305904FE7412856BCC04" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_2E891048FD0FC444334C7412856B5C92" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenueReservesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SegmentInformation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SegmentInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_F4B182F3456C3DA39C30D6253303538E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_E72281390FDBEAEF0D33D6253303FCEB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_F4B182F3456C3DA39C30D6253303538E" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_E72281390FDBEAEF0D33D6253303FCEB" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_0F24FA10BF0E2218A04AD6253303C5DF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_E72281390FDBEAEF0D33D6253303FCEB" xlink:to="loc_us-gaap_ProductOrServiceAxis_0F24FA10BF0E2218A04AD6253303C5DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_7BB229E8315B32F01391D6253303898A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProductOrServiceAxis_0F24FA10BF0E2218A04AD6253303C5DF" xlink:to="loc_us-gaap_ProductsAndServicesDomain_7BB229E8315B32F01391D6253303898A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_7BB229E8315B32F01391D6253303898A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProductOrServiceAxis_0F24FA10BF0E2218A04AD6253303C5DF" xlink:to="loc_us-gaap_ProductsAndServicesDomain_7BB229E8315B32F01391D6253303898A" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_15C54AA4E0531D12CAE7D6253303170D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_7BB229E8315B32F01391D6253303898A" xlink:to="loc_biib_TecfideraMember_15C54AA4E0531D12CAE7D6253303170D" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_AVONEXMember" xlink:label="loc_biib_AVONEXMember_A5BFAECC376C2C81987AD6253303C48C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_7BB229E8315B32F01391D6253303898A" xlink:to="loc_biib_AVONEXMember_A5BFAECC376C2C81987AD6253303C48C" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_PLEGRIDYMember" xlink:label="loc_biib_PLEGRIDYMember_E0F2867121121025D50DD6253303324B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_7BB229E8315B32F01391D6253303898A" xlink:to="loc_biib_PLEGRIDYMember_E0F2867121121025D50DD6253303324B" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_TysabriMember" xlink:label="loc_biib_TysabriMember_FAD340642C25E4B77D63D6253303F27C" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_7BB229E8315B32F01391D6253303898A" xlink:to="loc_biib_TysabriMember_FAD340642C25E4B77D63D6253303F27C" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_FAMPYRAMember" xlink:label="loc_biib_FAMPYRAMember_84620BD3AE6BF6F8F39BD625330314E7" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_7BB229E8315B32F01391D6253303898A" xlink:to="loc_biib_FAMPYRAMember_84620BD3AE6BF6F8F39BD625330314E7" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ZINBRYTAMember" xlink:label="loc_biib_ZINBRYTAMember_6E9313E6CFD79283560AD62533034FBB" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_7BB229E8315B32F01391D6253303898A" xlink:to="loc_biib_ZINBRYTAMember_6E9313E6CFD79283560AD62533034FBB" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ELOCTATEMember" xlink:label="loc_biib_ELOCTATEMember_932ED9441F65ADA90FE3D62533039E8D" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_7BB229E8315B32F01391D6253303898A" xlink:to="loc_biib_ELOCTATEMember_932ED9441F65ADA90FE3D62533039E8D" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ALPROLIXProductMember" xlink:label="loc_biib_ALPROLIXProductMember_48E09595890D1E5A5905D6253303EBA3" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_7BB229E8315B32F01391D6253303898A" xlink:to="loc_biib_ALPROLIXProductMember_48E09595890D1E5A5905D6253303EBA3" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_FUMADERMMember" xlink:label="loc_biib_FUMADERMMember_B1930264832021B16508D62533034645" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_7BB229E8315B32F01391D6253303898A" xlink:to="loc_biib_FUMADERMMember_B1930264832021B16508D62533034645" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_SPINRAZAMember" xlink:label="loc_biib_SPINRAZAMember_12C191FF1826722F7B57D6253303E598" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_7BB229E8315B32F01391D6253303898A" xlink:to="loc_biib_SPINRAZAMember_12C191FF1826722F7B57D6253303E598" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_BENEPALIMember" xlink:label="loc_biib_BENEPALIMember_DC6CDDF5CEF0600A66DCD6253303965D" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_7BB229E8315B32F01391D6253303898A" xlink:to="loc_biib_BENEPALIMember_DC6CDDF5CEF0600A66DCD6253303965D" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_FLIXABIMember" xlink:label="loc_biib_FLIXABIMember_0A7D1DDE9C9E279DEB88D641DB278DF0" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_7BB229E8315B32F01391D6253303898A" xlink:to="loc_biib_FLIXABIMember_0A7D1DDE9C9E279DEB88D641DB278DF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_C5A46EC3601644616EAED62533030D78" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_E72281390FDBEAEF0D33D6253303FCEB" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_C5A46EC3601644616EAED62533030D78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_C833D7DB5645675FE15BD6253303188C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_C5A46EC3601644616EAED62533030D78" xlink:to="loc_us-gaap_SegmentDomain_C833D7DB5645675FE15BD6253303188C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_C833D7DB5645675FE15BD6253303188C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_C5A46EC3601644616EAED62533030D78" xlink:to="loc_us-gaap_SegmentDomain_C833D7DB5645675FE15BD6253303188C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd#country_US" xlink:label="loc_country_US_9737309753D323FCA3B4D625330302F9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_C833D7DB5645675FE15BD6253303188C" xlink:to="loc_country_US_9737309753D323FCA3B4D625330302F9" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_RestOfWorldMember" xlink:label="loc_biib_RestOfWorldMember_79B1664F14E3F27452DCD62533030BA1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_C833D7DB5645675FE15BD6253303188C" xlink:to="loc_biib_RestOfWorldMember_79B1664F14E3F27452DCD62533030BA1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNetAbstract" xlink:label="loc_us-gaap_SalesRevenueGoodsNetAbstract_2E0EFA6AC25B666C97F1D6253303E494" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_F4B182F3456C3DA39C30D6253303538E" xlink:to="loc_us-gaap_SalesRevenueGoodsNetAbstract_2E0EFA6AC25B666C97F1D6253303E494" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_5AC660AC0AEED2B78CAED6253303FA8A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SalesRevenueGoodsNetAbstract_2E0EFA6AC25B666C97F1D6253303E494" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_5AC660AC0AEED2B78CAED6253303FA8A" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SegmentInformationDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_0D4046DFB38E0125FC38FCCBDAD8870C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_92D3F3966936A27A585CFCCBDAD7C583" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_0D4046DFB38E0125FC38FCCBDAD8870C" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_92D3F3966936A27A585CFCCBDAD7C583" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_CB2D09A6E40FCB4CFDC4FCCBDAD7EA6F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_92D3F3966936A27A585CFCCBDAD7C583" xlink:to="loc_us-gaap_StatementGeographicalAxis_CB2D09A6E40FCB4CFDC4FCCBDAD7EA6F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_64AF6D8AD308C7498449FCCBDAD7F7CC_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementGeographicalAxis_CB2D09A6E40FCB4CFDC4FCCBDAD7EA6F" xlink:to="loc_us-gaap_SegmentGeographicalDomain_64AF6D8AD308C7498449FCCBDAD7F7CC_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_64AF6D8AD308C7498449FCCBDAD7F7CC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementGeographicalAxis_CB2D09A6E40FCB4CFDC4FCCBDAD7EA6F" xlink:to="loc_us-gaap_SegmentGeographicalDomain_64AF6D8AD308C7498449FCCBDAD7F7CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd#country_US" xlink:label="loc_country_US_2070A85DA878947C21D3FCCBDAD757DB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_64AF6D8AD308C7498449FCCBDAD7F7CC" xlink:to="loc_country_US_2070A85DA878947C21D3FCCBDAD757DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EuropeMember" xlink:label="loc_us-gaap_EuropeMember_287DD1D37D55C3F9BB16FCCBDAD7926C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_64AF6D8AD308C7498449FCCBDAD7F7CC" xlink:to="loc_us-gaap_EuropeMember_287DD1D37D55C3F9BB16FCCBDAD7926C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd#country_DE" xlink:label="loc_country_DE_33ED03D7F031EF18B13BFCCBDAD84518" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_64AF6D8AD308C7498449FCCBDAD7F7CC" xlink:to="loc_country_DE_33ED03D7F031EF18B13BFCCBDAD84518" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AsiaMember" xlink:label="loc_us-gaap_AsiaMember_3D02FA0D16C77E390DB6FCCBDAD8B98E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_64AF6D8AD308C7498449FCCBDAD7F7CC" xlink:to="loc_us-gaap_AsiaMember_3D02FA0D16C77E390DB6FCCBDAD8B98E" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember" xlink:label="loc_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember_2B71F906AE0E6DC5B173FCCBDAD8E0C7" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_64AF6D8AD308C7498449FCCBDAD7F7CC" xlink:to="loc_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember_2B71F906AE0E6DC5B173FCCBDAD8E0C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentsGeographicalAreasAbstract" xlink:label="loc_us-gaap_SegmentsGeographicalAreasAbstract_85F38EC10D32DCF3A0E4FCCBDAD8125A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_0D4046DFB38E0125FC38FCCBDAD8870C" xlink:to="loc_us-gaap_SegmentsGeographicalAreasAbstract_85F38EC10D32DCF3A0E4FCCBDAD8125A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_9F56E840AF7CF4A87CBAFCCBDAD8F7DE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentsGeographicalAreasAbstract_85F38EC10D32DCF3A0E4FCCBDAD8125A" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_9F56E840AF7CF4A87CBAFCCBDAD8F7DE" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_RevenuesfromantiCD20therapeuticprograms" xlink:label="loc_biib_RevenuesfromantiCD20therapeuticprograms_35A3EFD597512058F4C1FCE261DA5FA4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentsGeographicalAreasAbstract_85F38EC10D32DCF3A0E4FCCBDAD8125A" xlink:to="loc_biib_RevenuesfromantiCD20therapeuticprograms_35A3EFD597512058F4C1FCE261DA5FA4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherSalesRevenueNet" xlink:label="loc_us-gaap_OtherSalesRevenueNet_E5031EDA988972BCD522FCCBDAD8EF75" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentsGeographicalAreasAbstract_85F38EC10D32DCF3A0E4FCCBDAD8125A" xlink:to="loc_us-gaap_OtherSalesRevenueNet_E5031EDA988972BCD522FCCBDAD8EF75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NoncurrentAssets" xlink:label="loc_us-gaap_NoncurrentAssets_8E874CC2DD3FA532A570FCCBDAD83975" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentsGeographicalAreasAbstract_85F38EC10D32DCF3A0E4FCCBDAD8125A" xlink:to="loc_us-gaap_NoncurrentAssets_8E874CC2DD3FA532A570FCCBDAD83975" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SegmentInformationDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_C00646353A7BBA92F040FCCBDAC9FDAE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_9BD4DBCFCBD52B1929B2FCCBDAC9889D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_C00646353A7BBA92F040FCCBDAC9FDAE" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_9BD4DBCFCBD52B1929B2FCCBDAC9889D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_A2E8E8C54EBF49DE76B1FCCBDAC98AF2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_9BD4DBCFCBD52B1929B2FCCBDAC9889D" xlink:to="loc_us-gaap_StatementGeographicalAxis_A2E8E8C54EBF49DE76B1FCCBDAC98AF2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_6F87343CA8C5F1A54E66FCCBDAC913AE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementGeographicalAxis_A2E8E8C54EBF49DE76B1FCCBDAC98AF2" xlink:to="loc_us-gaap_SegmentGeographicalDomain_6F87343CA8C5F1A54E66FCCBDAC913AE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_6F87343CA8C5F1A54E66FCCBDAC913AE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementGeographicalAxis_A2E8E8C54EBF49DE76B1FCCBDAC98AF2" xlink:to="loc_us-gaap_SegmentGeographicalDomain_6F87343CA8C5F1A54E66FCCBDAC913AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd#country_DK" xlink:label="loc_country_DK_37D00F9C0B052EE7CBBEFCCBDAC96594" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_6F87343CA8C5F1A54E66FCCBDAC913AE" xlink:to="loc_country_DK_37D00F9C0B052EE7CBBEFCCBDAC96594" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_SolothurnMember" xlink:label="loc_biib_SolothurnMember_4E07644CE08344D83290FCCBDAC9ACE9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_6F87343CA8C5F1A54E66FCCBDAC913AE" xlink:to="loc_biib_SolothurnMember_4E07644CE08344D83290FCCBDAC9ACE9" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_MajorDistributorAxis" xlink:label="loc_biib_MajorDistributorAxis_4CE345720BAD7FAF95F2FCCBDAC9C69B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_9BD4DBCFCBD52B1929B2FCCBDAC9889D" xlink:to="loc_biib_MajorDistributorAxis_4CE345720BAD7FAF95F2FCCBDAC9C69B" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_MajorDistributorDomain" xlink:label="loc_biib_MajorDistributorDomain_732AB2608F8CC55B7B07FCCBDAC98BA5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_MajorDistributorAxis_4CE345720BAD7FAF95F2FCCBDAC9C69B" xlink:to="loc_biib_MajorDistributorDomain_732AB2608F8CC55B7B07FCCBDAC98BA5_default" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_MajorDistributorDomain" xlink:label="loc_biib_MajorDistributorDomain_732AB2608F8CC55B7B07FCCBDAC98BA5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_MajorDistributorAxis_4CE345720BAD7FAF95F2FCCBDAC9C69B" xlink:to="loc_biib_MajorDistributorDomain_732AB2608F8CC55B7B07FCCBDAC98BA5" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_DistributorOneMember" xlink:label="loc_biib_DistributorOneMember_F178FF845BE66F5A057FFCCBDAC9478C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_MajorDistributorDomain_732AB2608F8CC55B7B07FCCBDAC98BA5" xlink:to="loc_biib_DistributorOneMember_F178FF845BE66F5A057FFCCBDAC9478C" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_DistributorTwoMember" xlink:label="loc_biib_DistributorTwoMember_884E0803F9274A505BF0FCCBDAC9172B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_MajorDistributorDomain_732AB2608F8CC55B7B07FCCBDAC98BA5" xlink:to="loc_biib_DistributorTwoMember_884E0803F9274A505BF0FCCBDAC9172B" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms" xlink:label="loc_biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms_1BBECB4198EE9ACB6956FCE69BFAFF51" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_C00646353A7BBA92F040FCCBDAC9FDAE" xlink:to="loc_biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms_1BBECB4198EE9ACB6956FCE69BFAFF51" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:label="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_258A6514AF60758796C1FCCBDAC97752" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_C00646353A7BBA92F040FCCBDAC9FDAE" xlink:to="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_258A6514AF60758796C1FCCBDAC97752" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NoncurrentAssets" xlink:label="loc_us-gaap_NoncurrentAssets_546F5ACCDE8D8EFF0914FCCBDACA4BDC" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_C00646353A7BBA92F040FCCBDAC9FDAE" xlink:to="loc_us-gaap_NoncurrentAssets_546F5ACCDE8D8EFF0914FCCBDACA4BDC" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SegmentInformationTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPayments" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3673719AA25E849D2CEBFB6C3AF449AB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_F51E8C4065F378FB4403FB6C3AF48C3B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3673719AA25E849D2CEBFB6C3AF449AB" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_F51E8C4065F378FB4403FB6C3AF48C3B" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_A61B9E7665CC3749D8AFFB6C3AF4BCAC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_F51E8C4065F378FB4403FB6C3AF48C3B" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_A61B9E7665CC3749D8AFFB6C3AF4BCAC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8B753C9D7E38F6C098B9FB6C3AF46075_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_A61B9E7665CC3749D8AFFB6C3AF4BCAC" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8B753C9D7E38F6C098B9FB6C3AF46075_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8B753C9D7E38F6C098B9FB6C3AF46075" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_A61B9E7665CC3749D8AFFB6C3AF4BCAC" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8B753C9D7E38F6C098B9FB6C3AF46075" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_C1BBB5E5A84FB1E4EE65FB6C3AF4DB6C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8B753C9D7E38F6C098B9FB6C3AF46075" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_C1BBB5E5A84FB1E4EE65FB6C3AF4DB6C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_AB5A9E1AF72E880E5071FB6C3AF4E91D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8B753C9D7E38F6C098B9FB6C3AF46075" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_AB5A9E1AF72E880E5071FB6C3AF4E91D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringChargesMember" xlink:label="loc_us-gaap_RestructuringChargesMember_861D34FD216488DE6A06FB6C3AF40ACC" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8B753C9D7E38F6C098B9FB6C3AF46075" xlink:to="loc_us-gaap_RestructuringChargesMember_861D34FD216488DE6A06FB6C3AF40ACC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaap_ParentMember_853662D2FFA4CE3A0451FB6C3AF4A819" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8B753C9D7E38F6C098B9FB6C3AF46075" xlink:to="loc_us-gaap_ParentMember_853662D2FFA4CE3A0451FB6C3AF4A819" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_C7EF5191E5F2FE25056AFB6C3AF44AEA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3673719AA25E849D2CEBFB6C3AF449AB" xlink:to="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_C7EF5191E5F2FE25056AFB6C3AF44AEA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_BA6D979ACACEB4E62C82FB6C3AF552C1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_C7EF5191E5F2FE25056AFB6C3AF44AEA" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_BA6D979ACACEB4E62C82FB6C3AF552C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_28847CE0E13B593D63B2FB6C3AF5A1DE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_C7EF5191E5F2FE25056AFB6C3AF44AEA" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_28847CE0E13B593D63B2FB6C3AF5A1DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_16D86BEA17B7C9154F18FB6C3AF56008" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_C7EF5191E5F2FE25056AFB6C3AF44AEA" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_16D86BEA17B7C9154F18FB6C3AF56008" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_23B7ED9669D453AB7CC8FB6C3AF53405" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_C7EF5191E5F2FE25056AFB6C3AF44AEA" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_23B7ED9669D453AB7CC8FB6C3AF53405" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_F3CDEEA12A6D67B5FF1CFB6C3AF5871F" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_C7EF5191E5F2FE25056AFB6C3AF44AEA" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_F3CDEEA12A6D67B5FF1CFB6C3AF5871F" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5327E5FA35DE914A0418FCCBDBF9AB7A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_ED4F42753DB211D679D2FCCBDBF932F0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5327E5FA35DE914A0418FCCBDBF9AB7A" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_ED4F42753DB211D679D2FCCBDBF932F0" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_526C5F4D461F6E8F64E7FCCBDBF9750A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_ED4F42753DB211D679D2FCCBDBF932F0" xlink:to="loc_us-gaap_PlanNameAxis_526C5F4D461F6E8F64E7FCCBDBF9750A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_BBA12AB6B3E3D2008B1EFCCBDBF90E80_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_526C5F4D461F6E8F64E7FCCBDBF9750A" xlink:to="loc_us-gaap_PlanNameDomain_BBA12AB6B3E3D2008B1EFCCBDBF90E80_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_BBA12AB6B3E3D2008B1EFCCBDBF90E80" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_526C5F4D461F6E8F64E7FCCBDBF9750A" xlink:to="loc_us-gaap_PlanNameDomain_BBA12AB6B3E3D2008B1EFCCBDBF90E80" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_5BE8DDDE9284359E782BFCCBDBF97D56" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_BBA12AB6B3E3D2008B1EFCCBDBF90E80" xlink:to="loc_biib_MarketStockUnitsMember_5BE8DDDE9284359E782BFCCBDBF97D56" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_2CF622EA7C88A4E9CDC2FCCBDBF9178D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_BBA12AB6B3E3D2008B1EFCCBDBF90E80" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_2CF622EA7C88A4E9CDC2FCCBDBF9178D" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_CashSettledPerformanceSharesMember" xlink:label="loc_biib_CashSettledPerformanceSharesMember_07DB1ED188101A2572AEFCCBDBF9FE15" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_BBA12AB6B3E3D2008B1EFCCBDBF90E80" xlink:to="loc_biib_CashSettledPerformanceSharesMember_07DB1ED188101A2572AEFCCBDBF9FE15" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_PerformanceUnitsMember" xlink:label="loc_biib_PerformanceUnitsMember_0B35579AF2D99A91D3F9FCCBDBF9B11A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_BBA12AB6B3E3D2008B1EFCCBDBF90E80" xlink:to="loc_biib_PerformanceUnitsMember_0B35579AF2D99A91D3F9FCCBDBF9B11A" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_EmployeeStockPurchasePlanMember" xlink:label="loc_biib_EmployeeStockPurchasePlanMember_420AB1F2642296763C40FCCBDBF95CEF" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_BBA12AB6B3E3D2008B1EFCCBDBF90E80" xlink:to="loc_biib_EmployeeStockPurchasePlanMember_420AB1F2642296763C40FCCBDBF95CEF" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:label="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_4C5DB6279FA0D67FA030FCCBDBF9BB4B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5327E5FA35DE914A0418FCCBDBF9AB7A" xlink:to="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_4C5DB6279FA0D67FA030FCCBDBF9BB4B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_FD0AD41CD2C18315A39AFCCBDBF9E79E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_4C5DB6279FA0D67FA030FCCBDBF9BB4B" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_FD0AD41CD2C18315A39AFCCBDBF9E79E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_B59F0208579375A23CE4FCCBDBF97B57" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_4C5DB6279FA0D67FA030FCCBDBF9BB4B" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_B59F0208579375A23CE4FCCBDBF97B57" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_CE72565E6683CE0D2336FCCBDBF9F6C0" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_4C5DB6279FA0D67FA030FCCBDBF9BB4B" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_CE72565E6683CE0D2336FCCBDBF9F6C0" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_68A457065EA3B81A3828FCCBDBFAAC0B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_4C5DB6279FA0D67FA030FCCBDBF9BB4B" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_68A457065EA3B81A3828FCCBDBFAAC0B" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails2" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails3" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails4" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_10FA2251D793D993B5D67412882D1DED" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_18801415804C0709608D7412882CE0F9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_10FA2251D793D993B5D67412882D1DED" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_18801415804C0709608D7412882CE0F9" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_68BDA0B0AED75AC406657412882C99C1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_18801415804C0709608D7412882CE0F9" xlink:to="loc_us-gaap_AwardTypeAxis_68BDA0B0AED75AC406657412882C99C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6B5FEE71662A7AFABDC27412882C8CE7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_68BDA0B0AED75AC406657412882C99C1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6B5FEE71662A7AFABDC27412882C8CE7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6B5FEE71662A7AFABDC27412882C8CE7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_68BDA0B0AED75AC406657412882C99C1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6B5FEE71662A7AFABDC27412882C8CE7" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_9FE60F77DB962B5CD1D27412882C770B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6B5FEE71662A7AFABDC27412882C8CE7" xlink:to="loc_biib_MarketStockUnitsMember_9FE60F77DB962B5CD1D27412882C770B" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_MarketStockUnitsActivityAbstract" xlink:label="loc_biib_MarketStockUnitsActivityAbstract_EB0B9D4F3BA062C2AD067412882DAEE2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_10FA2251D793D993B5D67412882D1DED" xlink:to="loc_biib_MarketStockUnitsActivityAbstract_EB0B9D4F3BA062C2AD067412882DAEE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4BB21F8CE6F0C63187D37412882D5626" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_EB0B9D4F3BA062C2AD067412882DAEE2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4BB21F8CE6F0C63187D37412882D5626" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6063B783674D6381F89C7412882D400B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_EB0B9D4F3BA062C2AD067412882DAEE2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6063B783674D6381F89C7412882D400B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2062511BC52E337205867412882D7309" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_EB0B9D4F3BA062C2AD067412882DAEE2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2062511BC52E337205867412882D7309" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_D3B73801144B40130E437412882DCD0A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_EB0B9D4F3BA062C2AD067412882DAEE2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_D3B73801144B40130E437412882DCD0A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_54EEAF6623742D53F7497412882D7C9F" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_EB0B9D4F3BA062C2AD067412882DAEE2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_54EEAF6623742D53F7497412882D7C9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_F5A2A4A6D44F141A03077412882D970A" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_EB0B9D4F3BA062C2AD067412882DAEE2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_F5A2A4A6D44F141A03077412882D970A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_C2050BC33A50C40072537412882DDB10" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_EB0B9D4F3BA062C2AD067412882DAEE2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_C2050BC33A50C40072537412882DDB10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_6492CF2A6FEB1AF9D75F7412882D852F" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_EB0B9D4F3BA062C2AD067412882DAEE2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_6492CF2A6FEB1AF9D75F7412882D852F" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails5" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8EF275847D972757B64AFB6C3ADA4A2D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_641BF024B801A2A15CF6FB6C3ADA4EBF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8EF275847D972757B64AFB6C3ADA4A2D" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_641BF024B801A2A15CF6FB6C3ADA4EBF" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_06DC7333E17FE1485B53FB6C3ADAD803" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_641BF024B801A2A15CF6FB6C3ADA4EBF" xlink:to="loc_us-gaap_AwardTypeAxis_06DC7333E17FE1485B53FB6C3ADAD803" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_913CF6D82CA7E2A4CBD7FB6C3ADAF552_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_06DC7333E17FE1485B53FB6C3ADAD803" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_913CF6D82CA7E2A4CBD7FB6C3ADAF552_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_913CF6D82CA7E2A4CBD7FB6C3ADAF552" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_06DC7333E17FE1485B53FB6C3ADAD803" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_913CF6D82CA7E2A4CBD7FB6C3ADAF552" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_9ADFE3A9AC8E8D5132D8FB6C3ADAF787" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_913CF6D82CA7E2A4CBD7FB6C3ADAF552" xlink:to="loc_biib_MarketStockUnitsMember_9ADFE3A9AC8E8D5132D8FB6C3ADAF787" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_5E20694293916A4CA961FB6C3ADA361D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_641BF024B801A2A15CF6FB6C3ADA4EBF" xlink:to="loc_us-gaap_RangeAxis_5E20694293916A4CA961FB6C3ADA361D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_102BD134AD4882E977B9FB6C3ADA8F1F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_5E20694293916A4CA961FB6C3ADA361D" xlink:to="loc_us-gaap_RangeMember_102BD134AD4882E977B9FB6C3ADA8F1F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_102BD134AD4882E977B9FB6C3ADA8F1F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_5E20694293916A4CA961FB6C3ADA361D" xlink:to="loc_us-gaap_RangeMember_102BD134AD4882E977B9FB6C3ADA8F1F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_89665EFA87A0227E56D0FB6C3ADA5EBB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_102BD134AD4882E977B9FB6C3ADA8F1F" xlink:to="loc_us-gaap_MinimumMember_89665EFA87A0227E56D0FB6C3ADA5EBB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_57F5F80375041EE3600FFB6C3ADA2277" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_102BD134AD4882E977B9FB6C3ADA8F1F" xlink:to="loc_us-gaap_MaximumMember_57F5F80375041EE3600FFB6C3ADA2277" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ValuationOfGrantedStockUnitsAbstract" xlink:label="loc_biib_ValuationOfGrantedStockUnitsAbstract_FB2EC3965B7896849E93FB6C3ADB8E00" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8EF275847D972757B64AFB6C3ADA4A2D" xlink:to="loc_biib_ValuationOfGrantedStockUnitsAbstract_FB2EC3965B7896849E93FB6C3ADB8E00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_61CB6AD25C6385BDF790FB6C3ADBAABC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ValuationOfGrantedStockUnitsAbstract_FB2EC3965B7896849E93FB6C3ADB8E00" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_61CB6AD25C6385BDF790FB6C3ADBAABC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_5CBB127508B0202ECF86FB6C3ADBACE4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ValuationOfGrantedStockUnitsAbstract_FB2EC3965B7896849E93FB6C3ADB8E00" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_5CBB127508B0202ECF86FB6C3ADBACE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_B296757E39549928EB1BFB6C3ADBD156" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ValuationOfGrantedStockUnitsAbstract_FB2EC3965B7896849E93FB6C3ADB8E00" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_B296757E39549928EB1BFB6C3ADBD156" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_0C126A384E819793B300FB6C3ADB8383" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ValuationOfGrantedStockUnitsAbstract_FB2EC3965B7896849E93FB6C3ADB8E00" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_0C126A384E819793B300FB6C3ADB8383" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_AverageStockPriceOnGrantDateInDollarsMinimum" xlink:label="loc_biib_AverageStockPriceOnGrantDateInDollarsMinimum_31DCF42228DC7E3F4957FB6C3ADBB518" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ValuationOfGrantedStockUnitsAbstract_FB2EC3965B7896849E93FB6C3ADB8E00" xlink:to="loc_biib_AverageStockPriceOnGrantDateInDollarsMinimum_31DCF42228DC7E3F4957FB6C3ADBB518" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_AverageStockPriceOnGrantDateInDollarsMaximum" xlink:label="loc_biib_AverageStockPriceOnGrantDateInDollarsMaximum_FD5C768ECF8625BFB681FB6C3ADBCEA9" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ValuationOfGrantedStockUnitsAbstract_FB2EC3965B7896849E93FB6C3ADB8E00" xlink:to="loc_biib_AverageStockPriceOnGrantDateInDollarsMaximum_FD5C768ECF8625BFB681FB6C3ADBCEA9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_C3CF65BAB3363B652D06FB6C3ADB6678" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ValuationOfGrantedStockUnitsAbstract_FB2EC3965B7896849E93FB6C3ADB8E00" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_C3CF65BAB3363B652D06FB6C3ADB6678" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails6" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B037F8FE4018249D6562741286F5BF5A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_52C766BF8869984412AD741286F424FF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B037F8FE4018249D6562741286F5BF5A" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_52C766BF8869984412AD741286F424FF" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_30CA20BB01B9775C0187741286F42BB2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_52C766BF8869984412AD741286F424FF" xlink:to="loc_us-gaap_AwardTypeAxis_30CA20BB01B9775C0187741286F42BB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3E397BC6F4D662901608741286F4E683_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_30CA20BB01B9775C0187741286F42BB2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3E397BC6F4D662901608741286F4E683_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3E397BC6F4D662901608741286F4E683" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_30CA20BB01B9775C0187741286F42BB2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3E397BC6F4D662901608741286F4E683" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_CashSettledPerformanceSharesMember" xlink:label="loc_biib_CashSettledPerformanceSharesMember_528682C21A819A76A6AE741286F5BDCE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3E397BC6F4D662901608741286F4E683" xlink:to="loc_biib_CashSettledPerformanceSharesMember_528682C21A819A76A6AE741286F5BDCE" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_CashSettledPerformanceSharesAbstract" xlink:label="loc_biib_CashSettledPerformanceSharesAbstract_C8B0513E210CDCD3A606741286F5A57C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B037F8FE4018249D6562741286F5BF5A" xlink:to="loc_biib_CashSettledPerformanceSharesAbstract_C8B0513E210CDCD3A606741286F5A57C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_EAF171D1AD935D09BF1A741286F54506" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CashSettledPerformanceSharesAbstract_C8B0513E210CDCD3A606741286F5A57C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_EAF171D1AD935D09BF1A741286F54506" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_B8B02B2E5353C727629A741286F58965" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CashSettledPerformanceSharesAbstract_C8B0513E210CDCD3A606741286F5A57C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_B8B02B2E5353C727629A741286F58965" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_FDD2AF720A28E86A873F741286F539F9" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CashSettledPerformanceSharesAbstract_C8B0513E210CDCD3A606741286F5A57C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_FDD2AF720A28E86A873F741286F539F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_EF47A5BE56FC6379F104741286F52E5A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CashSettledPerformanceSharesAbstract_C8B0513E210CDCD3A606741286F5A57C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_EF47A5BE56FC6379F104741286F52E5A" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails8" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_251C89B8F19660BEF5897412873FC80C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5046C72D39C35117E7357412873E7E14" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_251C89B8F19660BEF5897412873FC80C" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5046C72D39C35117E7357412873E7E14" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_667671D70CAD4E446BE07412873EFB28" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5046C72D39C35117E7357412873E7E14" xlink:to="loc_us-gaap_AwardTypeAxis_667671D70CAD4E446BE07412873EFB28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_33E397BBFF5436C22D227412873F7416_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_667671D70CAD4E446BE07412873EFB28" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_33E397BBFF5436C22D227412873F7416_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_33E397BBFF5436C22D227412873F7416" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_667671D70CAD4E446BE07412873EFB28" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_33E397BBFF5436C22D227412873F7416" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_E67F7C3572C4F46D1A7B7412873F2D8A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_33E397BBFF5436C22D227412873F7416" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_E67F7C3572C4F46D1A7B7412873F2D8A" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_RestrictedStockUnitsActivityAbstract" xlink:label="loc_biib_RestrictedStockUnitsActivityAbstract_F27C758B5D2570FBFF197412873F3509" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_251C89B8F19660BEF5897412873FC80C" xlink:to="loc_biib_RestrictedStockUnitsActivityAbstract_F27C758B5D2570FBFF197412873F3509" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8466604ABA6CB2DF63057412873FA437" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_F27C758B5D2570FBFF197412873F3509" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8466604ABA6CB2DF63057412873FA437" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6FE2C5F528C471B40D1E7412873F6923" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_F27C758B5D2570FBFF197412873F3509" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6FE2C5F528C471B40D1E7412873F6923" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_8C0B20A50D4F82FE9EC074128740BAE5" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_F27C758B5D2570FBFF197412873F3509" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_8C0B20A50D4F82FE9EC074128740BAE5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_36BDB20C404FB45E3733741287403541" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_F27C758B5D2570FBFF197412873F3509" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_36BDB20C404FB45E3733741287403541" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_DC4690F6FC8AFF60799A741287404FD7" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_F27C758B5D2570FBFF197412873F3509" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_DC4690F6FC8AFF60799A741287404FD7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_2CFD9C1EC8C55AB37E71741287406675" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_F27C758B5D2570FBFF197412873F3509" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_2CFD9C1EC8C55AB37E71741287406675" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_CDA41B0670AA14519C66741287403329" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_F27C758B5D2570FBFF197412873F3509" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_CDA41B0670AA14519C66741287403329" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_F679596BE59C9EC7B7BC741287409B0E" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_F27C758B5D2570FBFF197412873F3509" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_F679596BE59C9EC7B7BC741287409B0E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails9" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_4AB6710A9DE9758EEDA8886F76652946" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_D0E2863E35C7BD077131886F76652E6A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_4AB6710A9DE9758EEDA8886F76652946" xlink:to="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_D0E2863E35C7BD077131886F76652E6A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_936C2D906EC05AB3CD22886F76655298" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_D0E2863E35C7BD077131886F76652E6A" xlink:to="loc_us-gaap_PlanNameAxis_936C2D906EC05AB3CD22886F76655298" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_24B094D3E1C41F11157C886F76658D07_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_936C2D906EC05AB3CD22886F76655298" xlink:to="loc_us-gaap_PlanNameDomain_24B094D3E1C41F11157C886F76658D07_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_24B094D3E1C41F11157C886F76658D07" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_936C2D906EC05AB3CD22886F76655298" xlink:to="loc_us-gaap_PlanNameDomain_24B094D3E1C41F11157C886F76658D07" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_A2015ESPPMember" xlink:label="loc_biib_A2015ESPPMember_A211A5E6775E8F7601E4886F7665FD00" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_24B094D3E1C41F11157C886F76658D07" xlink:to="loc_biib_A2015ESPPMember_A211A5E6775E8F7601E4886F7665FD00" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_A1995ESPPMember" xlink:label="loc_biib_A1995ESPPMember_47480A7C219297A899A3886F76655F6D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_24B094D3E1C41F11157C886F76658D07" xlink:to="loc_biib_A1995ESPPMember_47480A7C219297A899A3886F76655F6D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_AB912E158D0F3D191D51886F766B1BF9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_4AB6710A9DE9758EEDA8886F76652946" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_AB912E158D0F3D191D51886F766B1BF9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_A8A79E123689DBA46648886F766B403B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_4AB6710A9DE9758EEDA8886F76652946" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_A8A79E123689DBA46648886F766B403B" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8642D524F792DB30754EFB6C3ABED5B7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_73C35A5BDE91FDEDB644FB6C3ABCDB25" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8642D524F792DB30754EFB6C3ABED5B7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_73C35A5BDE91FDEDB644FB6C3ABCDB25" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_13FC1BD3227FED52E914FB6C3ABCE306" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_73C35A5BDE91FDEDB644FB6C3ABCDB25" xlink:to="loc_us-gaap_VestingAxis_13FC1BD3227FED52E914FB6C3ABCE306" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_320AE8B6E933D76CE29EFB6C3ABC7229_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_13FC1BD3227FED52E914FB6C3ABCE306" xlink:to="loc_us-gaap_VestingDomain_320AE8B6E933D76CE29EFB6C3ABC7229_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_320AE8B6E933D76CE29EFB6C3ABC7229" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_13FC1BD3227FED52E914FB6C3ABCE306" xlink:to="loc_us-gaap_VestingDomain_320AE8B6E933D76CE29EFB6C3ABC7229" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_DBD87A2CFE74972CED60FB6C3ABC17E3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_320AE8B6E933D76CE29EFB6C3ABC7229" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_DBD87A2CFE74972CED60FB6C3ABC17E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_6877531E0B7D765B3954FB6C3ABC65D1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_73C35A5BDE91FDEDB644FB6C3ABCDB25" xlink:to="loc_us-gaap_TitleOfIndividualAxis_6877531E0B7D765B3954FB6C3ABC65D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_172857DB172052692648FB6C3ABCF04B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_6877531E0B7D765B3954FB6C3ABC65D1" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_172857DB172052692648FB6C3ABCF04B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_172857DB172052692648FB6C3ABCF04B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_6877531E0B7D765B3954FB6C3ABC65D1" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_172857DB172052692648FB6C3ABCF04B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DirectorMember" xlink:label="loc_us-gaap_DirectorMember_54D488B4764A8620FB33FB6C3ABCB917" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_172857DB172052692648FB6C3ABCF04B" xlink:to="loc_us-gaap_DirectorMember_54D488B4764A8620FB33FB6C3ABCB917" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ShareBasedCompensationPlanAxis" xlink:label="loc_biib_ShareBasedCompensationPlanAxis_693C1B162F6843BB9BF4FB6C3ABC9981" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_73C35A5BDE91FDEDB644FB6C3ABCDB25" xlink:to="loc_biib_ShareBasedCompensationPlanAxis_693C1B162F6843BB9BF4FB6C3ABC9981" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ShareBasedCompensationPlanDomain" xlink:label="loc_biib_ShareBasedCompensationPlanDomain_0661520A83D58ADD79EDFB6C3ABDA209_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_ShareBasedCompensationPlanAxis_693C1B162F6843BB9BF4FB6C3ABC9981" xlink:to="loc_biib_ShareBasedCompensationPlanDomain_0661520A83D58ADD79EDFB6C3ABDA209_default" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ShareBasedCompensationPlanDomain" xlink:label="loc_biib_ShareBasedCompensationPlanDomain_0661520A83D58ADD79EDFB6C3ABDA209" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_ShareBasedCompensationPlanAxis_693C1B162F6843BB9BF4FB6C3ABC9981" xlink:to="loc_biib_ShareBasedCompensationPlanDomain_0661520A83D58ADD79EDFB6C3ABDA209" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_DirectorsPlanMember" xlink:label="loc_biib_DirectorsPlanMember_9FA25E1B95FAB2302BBDFB6C3ABDBF74" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ShareBasedCompensationPlanDomain_0661520A83D58ADD79EDFB6C3ABDA209" xlink:to="loc_biib_DirectorsPlanMember_9FA25E1B95FAB2302BBDFB6C3ABDBF74" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_OmnibusPlansMember" xlink:label="loc_biib_OmnibusPlansMember_A7FF3A038E92A3ACB5A9FB6C3ABD2724" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ShareBasedCompensationPlanDomain_0661520A83D58ADD79EDFB6C3ABDA209" xlink:to="loc_biib_OmnibusPlansMember_A7FF3A038E92A3ACB5A9FB6C3ABD2724" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_AttainmentOfPerformanceCriteriain2013Member" xlink:label="loc_biib_AttainmentOfPerformanceCriteriain2013Member_EBF663E1E30148C70E48FB6C3ABDE2E3" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ShareBasedCompensationPlanDomain_0661520A83D58ADD79EDFB6C3ABDA209" xlink:to="loc_biib_AttainmentOfPerformanceCriteriain2013Member_EBF663E1E30148C70E48FB6C3ABDE2E3" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_AttainmentOfPerformanceCriteriain2012Member" xlink:label="loc_biib_AttainmentOfPerformanceCriteriain2012Member_FE978AD1E2853A5EC6AEFB6C3ABD3F2C" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ShareBasedCompensationPlanDomain_0661520A83D58ADD79EDFB6C3ABDA209" xlink:to="loc_biib_AttainmentOfPerformanceCriteriain2012Member_FE978AD1E2853A5EC6AEFB6C3ABD3F2C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_80B6F04B1E582FE480B2FB6C3ABEB31F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_73C35A5BDE91FDEDB644FB6C3ABCDB25" xlink:to="loc_us-gaap_AwardTypeAxis_80B6F04B1E582FE480B2FB6C3ABEB31F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_92811D27273A1D199FFAFB6C3ABEFAF1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_80B6F04B1E582FE480B2FB6C3ABEB31F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_92811D27273A1D199FFAFB6C3ABEFAF1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_92811D27273A1D199FFAFB6C3ABEFAF1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_80B6F04B1E582FE480B2FB6C3ABEB31F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_92811D27273A1D199FFAFB6C3ABEFAF1" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_01DB996B3E072ECC5EC4FB6C3ABE5FF0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_92811D27273A1D199FFAFB6C3ABEFAF1" xlink:to="loc_biib_MarketStockUnitsMember_01DB996B3E072ECC5EC4FB6C3ABE5FF0" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_CashSettledPerformanceSharesMember" xlink:label="loc_biib_CashSettledPerformanceSharesMember_5788B0B8E876590EF60FFB6C3ABEDDF0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_92811D27273A1D199FFAFB6C3ABEFAF1" xlink:to="loc_biib_CashSettledPerformanceSharesMember_5788B0B8E876590EF60FFB6C3ABEDDF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_BE37102DA20E931910BFFB6C3ABE955C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_92811D27273A1D199FFAFB6C3ABEFAF1" xlink:to="loc_us-gaap_PerformanceSharesMember_BE37102DA20E931910BFFB6C3ABE955C" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_F1CD908540A804D55240FB6C3ABEDCAC" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_92811D27273A1D199FFAFB6C3ABEFAF1" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_F1CD908540A804D55240FB6C3ABEDCAC" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_NumberOfSharesOfCommonStockForIssuance" xlink:label="loc_biib_NumberOfSharesOfCommonStockForIssuance_9385B2452E59EC90DA0EFB6C3ABE9279" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8642D524F792DB30754EFB6C3ABED5B7" xlink:to="loc_biib_NumberOfSharesOfCommonStockForIssuance_9385B2452E59EC90DA0EFB6C3ABE9279" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_RatioOfNumberOfSharesReservedUnderPlan" xlink:label="loc_biib_RatioOfNumberOfSharesReservedUnderPlan_EF9774C4143A5FC116B0FB6C3ABEBAD7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8642D524F792DB30754EFB6C3ABED5B7" xlink:to="loc_biib_RatioOfNumberOfSharesReservedUnderPlan_EF9774C4143A5FC116B0FB6C3ABEBAD7" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_NumberOfEqualAnnualIncrements" xlink:label="loc_biib_NumberOfEqualAnnualIncrements_FED7351DD2CF1D71E8BBFB6C3ABE0AA3" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8642D524F792DB30754EFB6C3ABED5B7" xlink:to="loc_biib_NumberOfEqualAnnualIncrements_FED7351DD2CF1D71E8BBFB6C3ABE0AA3" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" xlink:label="loc_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_93F1735E18862861C0D6FB6C3ABE4733" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8642D524F792DB30754EFB6C3ABED5B7" xlink:to="loc_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_93F1735E18862861C0D6FB6C3ABE4733" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" xlink:label="loc_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_012D665CA003490616B2FB6C3ABFBE61" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8642D524F792DB30754EFB6C3ABED5B7" xlink:to="loc_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_012D665CA003490616B2FB6C3ABFBE61" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5A1F588ECE37683E6921FB6C3ABFCC36" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8642D524F792DB30754EFB6C3ABED5B7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5A1F588ECE37683E6921FB6C3ABFCC36" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_EmployeeServiceSharebasedCompensationSharesUsedtoSettleAwards" xlink:label="loc_biib_EmployeeServiceSharebasedCompensationSharesUsedtoSettleAwards_A867212FFCB6FD1AFC02FB6C3ABFB492" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8642D524F792DB30754EFB6C3ABED5B7" xlink:to="loc_biib_EmployeeServiceSharebasedCompensationSharesUsedtoSettleAwards_A867212FFCB6FD1AFC02FB6C3ABFB492" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_NumberOfDaysForCalculationOfAverageClosingStockPrice" xlink:label="loc_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice_29E946ED3485878ED861FB6C3ABFA5E2" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8642D524F792DB30754EFB6C3ABED5B7" xlink:to="loc_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice_29E946ED3485878ED861FB6C3ABFA5E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_C9A2D292A3C6BC70D612FB6C3ABF3CAF" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8642D524F792DB30754EFB6C3ABED5B7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_C9A2D292A3C6BC70D612FB6C3ABF3CAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_ED8CF59300C2A24F2B5FFB6C3ABF8960" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8642D524F792DB30754EFB6C3ABED5B7" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_ED8CF59300C2A24F2B5FFB6C3ABF8960" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_C965FABDE23F547930BDFB6C3ABFEC00" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8642D524F792DB30754EFB6C3ABED5B7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_C965FABDE23F547930BDFB6C3ABFEC00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_EF43722CBE330ACF957CFB6C3ABFABC5" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8642D524F792DB30754EFB6C3ABED5B7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_EF43722CBE330ACF957CFB6C3ABFABC5" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedPaymentsDetails7" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A157320CEE791243E1B3741285C79024" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_737368393D87DBC9DE8E741285C6913F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A157320CEE791243E1B3741285C79024" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_737368393D87DBC9DE8E741285C6913F" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2D6E4801F5DEDD51C91C741285C69561" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_737368393D87DBC9DE8E741285C6913F" xlink:to="loc_us-gaap_AwardTypeAxis_2D6E4801F5DEDD51C91C741285C69561" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2A23EE2FA3B0D63C59B3741285C61499_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2D6E4801F5DEDD51C91C741285C69561" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2A23EE2FA3B0D63C59B3741285C61499_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2A23EE2FA3B0D63C59B3741285C61499" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2D6E4801F5DEDD51C91C741285C69561" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2A23EE2FA3B0D63C59B3741285C61499" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_256F088A5EF62C5A3B9A741285C6240B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2A23EE2FA3B0D63C59B3741285C61499" xlink:to="loc_us-gaap_PerformanceSharesMember_256F088A5EF62C5A3B9A741285C6240B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5AED1D7A81C904DBCE80741285C74715" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A157320CEE791243E1B3741285C79024" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5AED1D7A81C904DBCE80741285C74715" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_CFB86F0FFA5CC3D781EF741285C7AF05" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A157320CEE791243E1B3741285C79024" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_CFB86F0FFA5CC3D781EF741285C7AF05" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_432CCB86D89DBA20487F741285C7B256" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A157320CEE791243E1B3741285C79024" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_432CCB86D89DBA20487F741285C7B256" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_DDEC41701D2A3974EF72741285C762F9" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A157320CEE791243E1B3741285C79024" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_DDEC41701D2A3974EF72741285C762F9" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SubsequentEventsNotes" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_C340C1736CFB9C480174FD6455B7FD73" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_FFC379CA953923695574FD6455B52934" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_C340C1736CFB9C480174FD6455B7FD73" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_FFC379CA953923695574FD6455B52934" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="biib-20161231.xsd#biib_MajorDistributorAxis" xlink:label="loc_biib_MajorDistributorAxis_0C617459372D0287C764FD6455B53D20" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_FFC379CA953923695574FD6455B52934" xlink:to="loc_biib_MajorDistributorAxis_0C617459372D0287C764FD6455B53D20" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_MajorDistributorDomain" xlink:label="loc_biib_MajorDistributorDomain_618A118D84C9D3C6979AFD6455B5B322_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_MajorDistributorAxis_0C617459372D0287C764FD6455B53D20" xlink:to="loc_biib_MajorDistributorDomain_618A118D84C9D3C6979AFD6455B5B322_default" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_MajorDistributorDomain" xlink:label="loc_biib_MajorDistributorDomain_618A118D84C9D3C6979AFD6455B5B322" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_MajorDistributorAxis_0C617459372D0287C764FD6455B53D20" xlink:to="loc_biib_MajorDistributorDomain_618A118D84C9D3C6979AFD6455B5B322" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_DistributorOneMember" xlink:label="loc_biib_DistributorOneMember_22E99E9D740EDFB6B6BEFD6455B6E07C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_MajorDistributorDomain_618A118D84C9D3C6979AFD6455B5B322" xlink:to="loc_biib_DistributorOneMember_22E99E9D740EDFB6B6BEFD6455B6E07C" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_DistributorTwoMember" xlink:label="loc_biib_DistributorTwoMember_5A50F69B599D584F1C04FD6455B67FFE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_MajorDistributorDomain_618A118D84C9D3C6979AFD6455B5B322" xlink:to="loc_biib_DistributorTwoMember_5A50F69B599D584F1C04FD6455B67FFE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_FA6775DA937575ABDDE9FD6455B6550D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_FFC379CA953923695574FD6455B52934" xlink:to="loc_us-gaap_RangeAxis_FA6775DA937575ABDDE9FD6455B6550D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_7AB54C06CE2BD698E040FD6455B622FC_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_FA6775DA937575ABDDE9FD6455B6550D" xlink:to="loc_us-gaap_RangeMember_7AB54C06CE2BD698E040FD6455B622FC_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_7AB54C06CE2BD698E040FD6455B622FC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_FA6775DA937575ABDDE9FD6455B6550D" xlink:to="loc_us-gaap_RangeMember_7AB54C06CE2BD698E040FD6455B622FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_B002776E3D783143D648FD6455B62FC3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_7AB54C06CE2BD698E040FD6455B622FC" xlink:to="loc_us-gaap_MinimumMember_B002776E3D783143D648FD6455B62FC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_E50660221DD02361D2F0FD6455B6FF0B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_7AB54C06CE2BD698E040FD6455B622FC" xlink:to="loc_us-gaap_MaximumMember_E50660221DD02361D2F0FD6455B6FF0B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5EC3A36315AF9FBB018EFD6455B68766" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_FFC379CA953923695574FD6455B52934" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5EC3A36315AF9FBB018EFD6455B68766" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_F19D4C59A615F3586A34FD6455B6F1B5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5EC3A36315AF9FBB018EFD6455B68766" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_F19D4C59A615F3586A34FD6455B6F1B5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_F19D4C59A615F3586A34FD6455B6F1B5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5EC3A36315AF9FBB018EFD6455B68766" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_F19D4C59A615F3586A34FD6455B6F1B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BuildingMember" xlink:label="loc_us-gaap_BuildingMember_36B74441F3065935CA3CFD6455B62F30" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_F19D4C59A615F3586A34FD6455B6F1B5" xlink:to="loc_us-gaap_BuildingMember_36B74441F3065935CA3CFD6455B62F30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_F43F3E47CD3075DDB6B5FD6455B6B77D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_F19D4C59A615F3586A34FD6455B6F1B5" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_F43F3E47CD3075DDB6B5FD6455B6B77D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_02C03DA302A7E2EC3DA9FD6455B6AB21" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_F19D4C59A615F3586A34FD6455B6F1B5" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_02C03DA302A7E2EC3DA9FD6455B6AB21" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_6DD451FA08BDA8CE0645FD6455B7FF52" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_F19D4C59A615F3586A34FD6455B6F1B5" xlink:to="loc_us-gaap_ComputerEquipmentMember_6DD451FA08BDA8CE0645FD6455B7FF52" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables" xlink:label="loc_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables_0213699FEAA841A1133CFD6455B7064C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_C340C1736CFB9C480174FD6455B7FD73" xlink:to="loc_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables_0213699FEAA841A1133CFD6455B7064C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_E82E394D507DA2A5F92EFD6455B7211E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_C340C1736CFB9C480174FD6455B7FD73" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_E82E394D507DA2A5F92EFD6455B7211E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>biib-20161231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_743D37E640CD3A4604B3FA4EA5BDD34B_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_743D37E640CD3A4604B3FA4EA5BDD34B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_743D37E640CD3A4604B3FA4EA5BDD34B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_743D37E640CD3A4604B3FA4EA5BDD34B" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_743D37E640CD3A4604B3FA4EA5BDD34B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_087A087A8E3CC64BB59AFA4EA5BD2D35_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_087A087A8E3CC64BB59AFA4EA5BD2D35" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_087A087A8E3CC64BB59AFA4EA5BD2D35_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_087A087A8E3CC64BB59AFA4EA5BD2D35" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_087A087A8E3CC64BB59AFA4EA5BD2D35" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_087A087A8E3CC64BB59AFA4EA5BD2D35" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_087A087A8E3CC64BB59AFA4EA5BD2D35" xlink:type="arc" />
    <link:label id="lab_biib_FacilityLocationAxis_D88BF99C7DD80632BFE8FA4EA5BE494B_terseLabel_en-US" xlink:label="lab_biib_FacilityLocationAxis_D88BF99C7DD80632BFE8FA4EA5BE494B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Facility Location [Axis]</link:label>
    <link:label id="lab_biib_FacilityLocationAxis_D88BF99C7DD80632BFE8FA4EA5BE494B_label_en-US" xlink:label="lab_biib_FacilityLocationAxis_D88BF99C7DD80632BFE8FA4EA5BE494B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Facility Location [Axis]</link:label>
    <link:label id="lab_biib_FacilityLocationAxis_D88BF99C7DD80632BFE8FA4EA5BE494B_documentation_en-US" xlink:label="lab_biib_FacilityLocationAxis_D88BF99C7DD80632BFE8FA4EA5BE494B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_FacilityLocationAxis" xlink:label="loc_biib_FacilityLocationAxis_D88BF99C7DD80632BFE8FA4EA5BE494B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FacilityLocationAxis_D88BF99C7DD80632BFE8FA4EA5BE494B" xlink:to="lab_biib_FacilityLocationAxis_D88BF99C7DD80632BFE8FA4EA5BE494B" xlink:type="arc" />
    <link:label id="lab_biib_FacilityLocationDomain_D0B46BE437119D940BE6FA4EA5BEC9B4_terseLabel_en-US" xlink:label="lab_biib_FacilityLocationDomain_D0B46BE437119D940BE6FA4EA5BEC9B4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Facility Location [Domain]</link:label>
    <link:label id="lab_biib_FacilityLocationDomain_D0B46BE437119D940BE6FA4EA5BEC9B4_label_en-US" xlink:label="lab_biib_FacilityLocationDomain_D0B46BE437119D940BE6FA4EA5BEC9B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Facility Location [Domain]</link:label>
    <link:label id="lab_biib_FacilityLocationDomain_D0B46BE437119D940BE6FA4EA5BEC9B4_documentation_en-US" xlink:label="lab_biib_FacilityLocationDomain_D0B46BE437119D940BE6FA4EA5BEC9B4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_D0B46BE437119D940BE6FA4EA5BEC9B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FacilityLocationDomain_D0B46BE437119D940BE6FA4EA5BEC9B4" xlink:to="lab_biib_FacilityLocationDomain_D0B46BE437119D940BE6FA4EA5BEC9B4" xlink:type="arc" />
    <link:label id="lab_biib_CambridgeMAMember_70B30548757135BB71F0FA4EA5BEDC28_terseLabel_en-US" xlink:label="lab_biib_CambridgeMAMember_70B30548757135BB71F0FA4EA5BEDC28" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cambridge, MA</link:label>
    <link:label id="lab_biib_CambridgeMAMember_70B30548757135BB71F0FA4EA5BEDC28_label_en-US" xlink:label="lab_biib_CambridgeMAMember_70B30548757135BB71F0FA4EA5BEDC28" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cambridge, MA [Member]</link:label>
    <link:label id="lab_biib_CambridgeMAMember_70B30548757135BB71F0FA4EA5BEDC28_documentation_en-US" xlink:label="lab_biib_CambridgeMAMember_70B30548757135BB71F0FA4EA5BEDC28" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cambridge, MA [Member]</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_CambridgeMAMember" xlink:label="loc_biib_CambridgeMAMember_70B30548757135BB71F0FA4EA5BEDC28" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CambridgeMAMember_70B30548757135BB71F0FA4EA5BEDC28" xlink:to="lab_biib_CambridgeMAMember_70B30548757135BB71F0FA4EA5BEDC28" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringPlanAxis_F0EF9EF6AE038BD6A0BFFA4EA5BE8FD7_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis_F0EF9EF6AE038BD6A0BFFA4EA5BE8FD7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_F0EF9EF6AE038BD6A0BFFA4EA5BE8FD7_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis_F0EF9EF6AE038BD6A0BFFA4EA5BE8FD7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringPlanAxis" xlink:label="loc_us-gaap_RestructuringPlanAxis_F0EF9EF6AE038BD6A0BFFA4EA5BE8FD7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanAxis_F0EF9EF6AE038BD6A0BFFA4EA5BE8FD7" xlink:to="lab_us-gaap_RestructuringPlanAxis_F0EF9EF6AE038BD6A0BFFA4EA5BE8FD7" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringPlanDomain_4773AB87B787A78453D2FA4EA5BE9A0C_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain_4773AB87B787A78453D2FA4EA5BE9A0C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_4773AB87B787A78453D2FA4EA5BE9A0C_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain_4773AB87B787A78453D2FA4EA5BE9A0C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringPlanDomain" xlink:label="loc_us-gaap_RestructuringPlanDomain_4773AB87B787A78453D2FA4EA5BE9A0C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanDomain_4773AB87B787A78453D2FA4EA5BE9A0C" xlink:to="lab_us-gaap_RestructuringPlanDomain_4773AB87B787A78453D2FA4EA5BE9A0C" xlink:type="arc" />
    <link:label id="lab_biib_A2015RestructuringChargesMember_35527C5B4B6B83711063FA4EA5BEAE85_terseLabel_en-US" xlink:label="lab_biib_A2015RestructuringChargesMember_35527C5B4B6B83711063FA4EA5BEAE85" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2015 Restructuring Charges</link:label>
    <link:label id="lab_biib_A2015RestructuringChargesMember_35527C5B4B6B83711063FA4EA5BEAE85_label_en-US" xlink:label="lab_biib_A2015RestructuringChargesMember_35527C5B4B6B83711063FA4EA5BEAE85" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2015 Restructuring Charges [Member]</link:label>
    <link:label id="lab_biib_A2015RestructuringChargesMember_35527C5B4B6B83711063FA4EA5BEAE85_documentation_en-US" xlink:label="lab_biib_A2015RestructuringChargesMember_35527C5B4B6B83711063FA4EA5BEAE85" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2015 Restructuring Charges [Member]</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_A2015RestructuringChargesMember" xlink:label="loc_biib_A2015RestructuringChargesMember_35527C5B4B6B83711063FA4EA5BEAE85" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A2015RestructuringChargesMember_35527C5B4B6B83711063FA4EA5BEAE85" xlink:to="lab_biib_A2015RestructuringChargesMember_35527C5B4B6B83711063FA4EA5BEAE85" xlink:type="arc" />
    <link:label id="lab_biib_A2016RestructuringChargesMember_939EF3D923298797CFE6FA4EA5BE45B4_terseLabel_en-US" xlink:label="lab_biib_A2016RestructuringChargesMember_939EF3D923298797CFE6FA4EA5BE45B4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2016 Restructuring Charges</link:label>
    <link:label id="lab_biib_A2016RestructuringChargesMember_939EF3D923298797CFE6FA4EA5BE45B4_label_en-US" xlink:label="lab_biib_A2016RestructuringChargesMember_939EF3D923298797CFE6FA4EA5BE45B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2016 Restructuring Charges [Member]</link:label>
    <link:label id="lab_biib_A2016RestructuringChargesMember_939EF3D923298797CFE6FA4EA5BE45B4_documentation_en-US" xlink:label="lab_biib_A2016RestructuringChargesMember_939EF3D923298797CFE6FA4EA5BE45B4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2016 Restructuring Charges [Member]</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_A2016RestructuringChargesMember" xlink:label="loc_biib_A2016RestructuringChargesMember_939EF3D923298797CFE6FA4EA5BE45B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A2016RestructuringChargesMember_939EF3D923298797CFE6FA4EA5BE45B4" xlink:to="lab_biib_A2016RestructuringChargesMember_939EF3D923298797CFE6FA4EA5BE45B4" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_EC5C3494D051AFB0CF82FA4EA5BFF493_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems_EC5C3494D051AFB0CF82FA4EA5BFF493" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_EC5C3494D051AFB0CF82FA4EA5BFF493_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems_EC5C3494D051AFB0CF82FA4EA5BFF493" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_EC5C3494D051AFB0CF82FA4EA5BFF493" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_EC5C3494D051AFB0CF82FA4EA5BFF493" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems_EC5C3494D051AFB0CF82FA4EA5BFF493" xlink:type="arc" />
    <link:label id="lab_biib_Restructuringandrelatedcostexpectedpercentageofpositionseliminated_A7963B3270BA73D76483FA4EA5BF9007_terseLabel_en-US" xlink:label="lab_biib_Restructuringandrelatedcostexpectedpercentageofpositionseliminated_A7963B3270BA73D76483FA4EA5BF9007" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring and related cost, expected percentage of positions eliminated</link:label>
    <link:label id="lab_biib_Restructuringandrelatedcostexpectedpercentageofpositionseliminated_A7963B3270BA73D76483FA4EA5BF9007_label_en-US" xlink:label="lab_biib_Restructuringandrelatedcostexpectedpercentageofpositionseliminated_A7963B3270BA73D76483FA4EA5BF9007" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and related cost, expected percentage of positions eliminated</link:label>
    <link:label id="lab_biib_Restructuringandrelatedcostexpectedpercentageofpositionseliminated_A7963B3270BA73D76483FA4EA5BF9007_documentation_en-US" xlink:label="lab_biib_Restructuringandrelatedcostexpectedpercentageofpositionseliminated_A7963B3270BA73D76483FA4EA5BF9007" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restructuring and related cost, expected percentage of positions eliminated</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_Restructuringandrelatedcostexpectedpercentageofpositionseliminated" xlink:label="loc_biib_Restructuringandrelatedcostexpectedpercentageofpositionseliminated_A7963B3270BA73D76483FA4EA5BF9007" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Restructuringandrelatedcostexpectedpercentageofpositionseliminated_A7963B3270BA73D76483FA4EA5BF9007" xlink:to="lab_biib_Restructuringandrelatedcostexpectedpercentageofpositionseliminated_A7963B3270BA73D76483FA4EA5BF9007" xlink:type="arc" />
    <link:label id="lab_biib_RestructuringandRelatedCostExpectedCashPayments_9AD883F3037E741C1C08FA4EA5BF94FE_terseLabel_en-US" xlink:label="lab_biib_RestructuringandRelatedCostExpectedCashPayments_9AD883F3037E741C1C08FA4EA5BF94FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Previously accrued incentive compensation</link:label>
    <link:label id="lab_biib_RestructuringandRelatedCostExpectedCashPayments_9AD883F3037E741C1C08FA4EA5BF94FE_label_en-US" xlink:label="lab_biib_RestructuringandRelatedCostExpectedCashPayments_9AD883F3037E741C1C08FA4EA5BF94FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Expected Cash Payments</link:label>
    <link:label id="lab_biib_RestructuringandRelatedCostExpectedCashPayments_9AD883F3037E741C1C08FA4EA5BF94FE_documentation_en-US" xlink:label="lab_biib_RestructuringandRelatedCostExpectedCashPayments_9AD883F3037E741C1C08FA4EA5BF94FE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Expected Cash Payments</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_RestructuringandRelatedCostExpectedCashPayments" xlink:label="loc_biib_RestructuringandRelatedCostExpectedCashPayments_9AD883F3037E741C1C08FA4EA5BF94FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RestructuringandRelatedCostExpectedCashPayments_9AD883F3037E741C1C08FA4EA5BF94FE" xlink:to="lab_biib_RestructuringandRelatedCostExpectedCashPayments_9AD883F3037E741C1C08FA4EA5BF94FE" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringReserveAccrualAdjustment1_F792AC8F0796450B7A7EFA4EA5BFFA77_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveAccrualAdjustment1_F792AC8F0796450B7A7EFA4EA5BFFA77" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to previous estimates, net</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveAccrualAdjustment1_F792AC8F0796450B7A7EFA4EA5BFFA77_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveAccrualAdjustment1_F792AC8F0796450B7A7EFA4EA5BFFA77" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Reserve, Accrual Adjustment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringReserveAccrualAdjustment1" xlink:label="loc_us-gaap_RestructuringReserveAccrualAdjustment1_F792AC8F0796450B7A7EFA4EA5BFFA77" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveAccrualAdjustment1_F792AC8F0796450B7A7EFA4EA5BFFA77" xlink:to="lab_us-gaap_RestructuringReserveAccrualAdjustment1_F792AC8F0796450B7A7EFA4EA5BFFA77" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_38BE0210DFD11C5640CDFA4EA5BF5F5A_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_38BE0210DFD11C5640CDFA4EA5BF5F5A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total restructuring charges expected</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_38BE0210DFD11C5640CDFA4EA5BF5F5A_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_38BE0210DFD11C5640CDFA4EA5BF5F5A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Expected Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_38BE0210DFD11C5640CDFA4EA5BF5F5A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_38BE0210DFD11C5640CDFA4EA5BF5F5A" xlink:to="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_38BE0210DFD11C5640CDFA4EA5BF5F5A" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringCharges_204BC0BD4E63BF5CFAA3FA4EA5BFCDF2_verboseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges_204BC0BD4E63BF5CFAA3FA4EA5BFCDF2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Restructuring charges</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_204BC0BD4E63BF5CFAA3FA4EA5BFCDF2_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges_204BC0BD4E63BF5CFAA3FA4EA5BFCDF2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_204BC0BD4E63BF5CFAA3FA4EA5BFCDF2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges_204BC0BD4E63BF5CFAA3FA4EA5BFCDF2" xlink:to="lab_us-gaap_RestructuringCharges_204BC0BD4E63BF5CFAA3FA4EA5BFCDF2" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringReserveAcceleratedDepreciation_99B935F2C070CC4CCCD0FA4EA5BFBF9C_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveAcceleratedDepreciation_99B935F2C070CC4CCCD0FA4EA5BFBF9C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accelerated depreciation</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveAcceleratedDepreciation_99B935F2C070CC4CCCD0FA4EA5BFBF9C_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveAcceleratedDepreciation_99B935F2C070CC4CCCD0FA4EA5BFBF9C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Accelerated Depreciation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:label="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_99B935F2C070CC4CCCD0FA4EA5BFBF9C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_99B935F2C070CC4CCCD0FA4EA5BFBF9C" xlink:to="lab_us-gaap_RestructuringReserveAcceleratedDepreciation_99B935F2C070CC4CCCD0FA4EA5BFBF9C" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_F40690FC5DE5BE82C32F7412861D03B2_label_en-US" xlink:label="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_F40690FC5DE5BE82C32F7412861D03B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, All Other Investments [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_F40690FC5DE5BE82C32F7412861D03B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_F40690FC5DE5BE82C32F7412861D03B2" xlink:to="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_F40690FC5DE5BE82C32F7412861D03B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_73E02659880127AE79A57412861DF614_verboseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_73E02659880127AE79A57412861DF614" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_73E02659880127AE79A57412861DF614_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_73E02659880127AE79A57412861DF614" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, and Marketable Securities [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_73E02659880127AE79A57412861DF614" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_73E02659880127AE79A57412861DF614" xlink:to="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_73E02659880127AE79A57412861DF614" xlink:type="arc" />
    <link:label id="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_344E893259392665568B7412856C6381_label_en-US" xlink:label="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_344E893259392665568B7412856C6381" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments in Variable Interest Entities [Abstract]</link:label>
    <link:label id="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_344E893259392665568B7412856C6381_documentation_en-US" xlink:label="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_344E893259392665568B7412856C6381" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Investments In Variable Interest Entities.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:label="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_344E893259392665568B7412856C6381" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_344E893259392665568B7412856C6381" xlink:to="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_344E893259392665568B7412856C6381" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_C4F3FECEAA13F25C1B507412856C4E64_verboseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_C4F3FECEAA13F25C1B507412856C4E64" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Investments in Variable Interest Entities</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_C4F3FECEAA13F25C1B507412856C4E64_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_C4F3FECEAA13F25C1B507412856C4E64" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Interest Entity Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_C4F3FECEAA13F25C1B507412856C4E64" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_C4F3FECEAA13F25C1B507412856C4E64" xlink:to="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_C4F3FECEAA13F25C1B507412856C4E64" xlink:type="arc" />
    <link:label id="lab_biib_ReservesForDiscountsAndAllowancesAbstract_7BBDCA9A6D4DCA49E6DE7412853A84AF_label_en-US" xlink:label="lab_biib_ReservesForDiscountsAndAllowancesAbstract_7BBDCA9A6D4DCA49E6DE7412853A84AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reserves for Discounts and Allowances [Abstract]</link:label>
    <link:label id="lab_biib_ReservesForDiscountsAndAllowancesAbstract_7BBDCA9A6D4DCA49E6DE7412853A84AF_documentation_en-US" xlink:label="lab_biib_ReservesForDiscountsAndAllowancesAbstract_7BBDCA9A6D4DCA49E6DE7412853A84AF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue reserves.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_ReservesForDiscountsAndAllowancesAbstract" xlink:label="loc_biib_ReservesForDiscountsAndAllowancesAbstract_7BBDCA9A6D4DCA49E6DE7412853A84AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ReservesForDiscountsAndAllowancesAbstract_7BBDCA9A6D4DCA49E6DE7412853A84AF" xlink:to="lab_biib_ReservesForDiscountsAndAllowancesAbstract_7BBDCA9A6D4DCA49E6DE7412853A84AF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_E41E7A8D8B861F809BE07412853AE111_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_E41E7A8D8B861F809BE07412853AE111" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Reserves for Discounts and Allowances</link:label>
    <link:label id="lab_us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_E41E7A8D8B861F809BE07412853AE111_label_en-US" xlink:label="lab_us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_E41E7A8D8B861F809BE07412853AE111" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:label="loc_us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_E41E7A8D8B861F809BE07412853AE111" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_E41E7A8D8B861F809BE07412853AE111" xlink:to="lab_us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_E41E7A8D8B861F809BE07412853AE111" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_EFCE884F2BA5BA04200A7412871002FE_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_EFCE884F2BA5BA04200A7412871002FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_EFCE884F2BA5BA04200A7412871002FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_EFCE884F2BA5BA04200A7412871002FE" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_EFCE884F2BA5BA04200A7412871002FE" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_99755ABF3A0AD3776EAF741287107808_verboseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_99755ABF3A0AD3776EAF741287107808" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Collaborative and Other Relationships</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_99755ABF3A0AD3776EAF741287107808_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_99755ABF3A0AD3776EAF741287107808" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_99755ABF3A0AD3776EAF741287107808" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_99755ABF3A0AD3776EAF741287107808" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_99755ABF3A0AD3776EAF741287107808" xlink:type="arc" />
    <link:label id="lab_us-gaap_GuaranteesAbstract_6B7A961749CF64535CCB7412862FAF48_label_en-US" xlink:label="lab_us-gaap_GuaranteesAbstract_6B7A961749CF64535CCB7412862FAF48" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Guarantees [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GuaranteesAbstract" xlink:label="loc_us-gaap_GuaranteesAbstract_6B7A961749CF64535CCB7412862FAF48" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GuaranteesAbstract_6B7A961749CF64535CCB7412862FAF48" xlink:to="lab_us-gaap_GuaranteesAbstract_6B7A961749CF64535CCB7412862FAF48" xlink:type="arc" />
    <link:label id="lab_us-gaap_GuaranteesTextBlock_A2B7DA4C9C169A7B96477412862F11C1_verboseLabel_en-US" xlink:label="lab_us-gaap_GuaranteesTextBlock_A2B7DA4C9C169A7B96477412862F11C1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Guarantees</link:label>
    <link:label id="lab_us-gaap_GuaranteesTextBlock_A2B7DA4C9C169A7B96477412862F11C1_label_en-US" xlink:label="lab_us-gaap_GuaranteesTextBlock_A2B7DA4C9C169A7B96477412862F11C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Guarantees [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GuaranteesTextBlock" xlink:label="loc_us-gaap_GuaranteesTextBlock_A2B7DA4C9C169A7B96477412862F11C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GuaranteesTextBlock_A2B7DA4C9C169A7B96477412862F11C1" xlink:to="lab_us-gaap_GuaranteesTextBlock_A2B7DA4C9C169A7B96477412862F11C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_A9511272C46777E782BAFB6C3A6EE6B3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_A9511272C46777E782BAFB6C3A6EE6B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_A9511272C46777E782BAFB6C3A6EE6B3_label_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_A9511272C46777E782BAFB6C3A6EE6B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_A9511272C46777E782BAFB6C3A6EE6B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_A9511272C46777E782BAFB6C3A6EE6B3" xlink:to="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_A9511272C46777E782BAFB6C3A6EE6B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_F9D984D2409EB6869042FB6C3A6EE9A0_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_F9D984D2409EB6869042FB6C3A6EE9A0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_F9D984D2409EB6869042FB6C3A6EE9A0_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_F9D984D2409EB6869042FB6C3A6EE9A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_F9D984D2409EB6869042FB6C3A6EE9A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_F9D984D2409EB6869042FB6C3A6EE9A0" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_F9D984D2409EB6869042FB6C3A6EE9A0" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_77F973F31DFF86B3C4E1FB6C3A6FC0FE_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_77F973F31DFF86B3C4E1FB6C3A6FC0FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_77F973F31DFF86B3C4E1FB6C3A6FC0FE_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_77F973F31DFF86B3C4E1FB6C3A6FC0FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_77F973F31DFF86B3C4E1FB6C3A6FC0FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_77F973F31DFF86B3C4E1FB6C3A6FC0FE" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_77F973F31DFF86B3C4E1FB6C3A6FC0FE" xlink:type="arc" />
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_B10D2936A3C04D38EC9BFB6C3A6FB17A_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember_B10D2936A3C04D38EC9BFB6C3A6FB17A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_B10D2936A3C04D38EC9BFB6C3A6FB17A_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember_B10D2936A3C04D38EC9BFB6C3A6FB17A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_B10D2936A3C04D38EC9BFB6C3A6FB17A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember_B10D2936A3C04D38EC9BFB6C3A6FB17A" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember_B10D2936A3C04D38EC9BFB6C3A6FB17A" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_02E2121797B058EAA30DFB6C3A6F7A5F_verboseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_02E2121797B058EAA30DFB6C3A6F7A5F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Variable Interest Entities by Classification of Entity [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_02E2121797B058EAA30DFB6C3A6F7A5F_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_02E2121797B058EAA30DFB6C3A6F7A5F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Interest Entities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:label="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_02E2121797B058EAA30DFB6C3A6F7A5F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_02E2121797B058EAA30DFB6C3A6F7A5F" xlink:to="lab_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_02E2121797B058EAA30DFB6C3A6F7A5F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassificationOfVariableInterestEntityDomain_90D8249C6B9956EF840BFB6C3A6F9A60_terseLabel_en-US" xlink:label="lab_us-gaap_ClassificationOfVariableInterestEntityDomain_90D8249C6B9956EF840BFB6C3A6F9A60" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Interest Entity, Classification [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassificationOfVariableInterestEntityDomain_90D8249C6B9956EF840BFB6C3A6F9A60_label_en-US" xlink:label="lab_us-gaap_ClassificationOfVariableInterestEntityDomain_90D8249C6B9956EF840BFB6C3A6F9A60" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Interest Entity, Classification [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:label="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_90D8249C6B9956EF840BFB6C3A6F9A60" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_90D8249C6B9956EF840BFB6C3A6F9A60" xlink:to="lab_us-gaap_ClassificationOfVariableInterestEntityDomain_90D8249C6B9956EF840BFB6C3A6F9A60" xlink:type="arc" />
    <link:label id="lab_biib_NeurimmuneMember_9DD675C4915E938A271EFB6C3A6F23EF_verboseLabel_en-US" xlink:label="lab_biib_NeurimmuneMember_9DD675C4915E938A271EFB6C3A6F23EF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Neurimmune</link:label>
    <link:label id="lab_biib_NeurimmuneMember_9DD675C4915E938A271EFB6C3A6F23EF_label_en-US" xlink:label="lab_biib_NeurimmuneMember_9DD675C4915E938A271EFB6C3A6F23EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Neurimmune [Member]</link:label>
    <link:label id="lab_biib_NeurimmuneMember_9DD675C4915E938A271EFB6C3A6F23EF_documentation_en-US" xlink:label="lab_biib_NeurimmuneMember_9DD675C4915E938A271EFB6C3A6F23EF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Neurimmune.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_NeurimmuneMember" xlink:label="loc_biib_NeurimmuneMember_9DD675C4915E938A271EFB6C3A6F23EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NeurimmuneMember_9DD675C4915E938A271EFB6C3A6F23EF" xlink:to="lab_biib_NeurimmuneMember_9DD675C4915E938A271EFB6C3A6F23EF" xlink:type="arc" />
    <link:label id="lab_biib_RodinTherapeuticsMember_4895BE54026B721A9706FB6C3A6F5AB3_terseLabel_en-US" xlink:label="lab_biib_RodinTherapeuticsMember_4895BE54026B721A9706FB6C3A6F5AB3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rodin Therapeutics</link:label>
    <link:label id="lab_biib_RodinTherapeuticsMember_4895BE54026B721A9706FB6C3A6F5AB3_label_en-US" xlink:label="lab_biib_RodinTherapeuticsMember_4895BE54026B721A9706FB6C3A6F5AB3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rodin Therapeutics [Member]</link:label>
    <link:label id="lab_biib_RodinTherapeuticsMember_4895BE54026B721A9706FB6C3A6F5AB3_documentation_en-US" xlink:label="lab_biib_RodinTherapeuticsMember_4895BE54026B721A9706FB6C3A6F5AB3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Rodin Therapeutics [Member]</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_RodinTherapeuticsMember" xlink:label="loc_biib_RodinTherapeuticsMember_4895BE54026B721A9706FB6C3A6F5AB3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RodinTherapeuticsMember_4895BE54026B721A9706FB6C3A6F5AB3" xlink:to="lab_biib_RodinTherapeuticsMember_4895BE54026B721A9706FB6C3A6F5AB3" xlink:type="arc" />
    <link:label id="lab_biib_AtaxionMember_A2AC2BBB54308E41566EFB6C3A6F71CD_terseLabel_en-US" xlink:label="lab_biib_AtaxionMember_A2AC2BBB54308E41566EFB6C3A6F71CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ataxion</link:label>
    <link:label id="lab_biib_AtaxionMember_A2AC2BBB54308E41566EFB6C3A6F71CD_label_en-US" xlink:label="lab_biib_AtaxionMember_A2AC2BBB54308E41566EFB6C3A6F71CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ataxion [Member]</link:label>
    <link:label id="lab_biib_AtaxionMember_A2AC2BBB54308E41566EFB6C3A6F71CD_documentation_en-US" xlink:label="lab_biib_AtaxionMember_A2AC2BBB54308E41566EFB6C3A6F71CD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ataxion [Member]</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_AtaxionMember" xlink:label="loc_biib_AtaxionMember_A2AC2BBB54308E41566EFB6C3A6F71CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AtaxionMember_A2AC2BBB54308E41566EFB6C3A6F71CD" xlink:to="lab_biib_AtaxionMember_A2AC2BBB54308E41566EFB6C3A6F71CD" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_D749D4FC817F1D4B08E8FB6C3A6F2AF7_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems_D749D4FC817F1D4B08E8FB6C3A6F2AF7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_D749D4FC817F1D4B08E8FB6C3A6F2AF7_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems_D749D4FC817F1D4B08E8FB6C3A6F2AF7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableInterestEntityLineItems" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_D749D4FC817F1D4B08E8FB6C3A6F2AF7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_D749D4FC817F1D4B08E8FB6C3A6F2AF7" xlink:to="lab_us-gaap_VariableInterestEntityLineItems_D749D4FC817F1D4B08E8FB6C3A6F2AF7" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_DE19D1C78A0A7ADA62CAFB6C3A6FAD3B_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_DE19D1C78A0A7ADA62CAFB6C3A6FAD3B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net (loss) income attributable to noncontrolling interests, net of tax</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_DE19D1C78A0A7ADA62CAFB6C3A6FAD3B_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_DE19D1C78A0A7ADA62CAFB6C3A6FAD3B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_DE19D1C78A0A7ADA62CAFB6C3A6FAD3B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_DE19D1C78A0A7ADA62CAFB6C3A6FAD3B" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_DE19D1C78A0A7ADA62CAFB6C3A6FAD3B" xlink:type="arc" />
    <link:label id="lab_biib_InvestmentInVariableInterestEntitiesTextualAbstract_077D275A6430BD65E4B1FB6C3A6FBFF2_verboseLabel_en-US" xlink:label="lab_biib_InvestmentInVariableInterestEntitiesTextualAbstract_077D275A6430BD65E4B1FB6C3A6FBFF2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Investment in Variable Interest Entities (Textual)</link:label>
    <link:label id="lab_biib_InvestmentInVariableInterestEntitiesTextualAbstract_077D275A6430BD65E4B1FB6C3A6FBFF2_label_en-US" xlink:label="lab_biib_InvestmentInVariableInterestEntitiesTextualAbstract_077D275A6430BD65E4B1FB6C3A6FBFF2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment in Variable Interest Entities (Textual) [Abstract]</link:label>
    <link:label id="lab_biib_InvestmentInVariableInterestEntitiesTextualAbstract_077D275A6430BD65E4B1FB6C3A6FBFF2_documentation_en-US" xlink:label="lab_biib_InvestmentInVariableInterestEntitiesTextualAbstract_077D275A6430BD65E4B1FB6C3A6FBFF2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Investment in Variable Interest Entities.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_InvestmentInVariableInterestEntitiesTextualAbstract" xlink:label="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_077D275A6430BD65E4B1FB6C3A6FBFF2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_077D275A6430BD65E4B1FB6C3A6FBFF2" xlink:to="lab_biib_InvestmentInVariableInterestEntitiesTextualAbstract_077D275A6430BD65E4B1FB6C3A6FBFF2" xlink:type="arc" />
    <link:label id="lab_biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement_E51BC98ADC77575FBE8EFB6C3A709C63_verboseLabel_en-US" xlink:label="lab_biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement_E51BC98ADC77575FBE8EFB6C3A709C63" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Remaining potential development milestone payments and royalties on commercial sales under the terms of collaboration agreement</link:label>
    <link:label id="lab_biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement_E51BC98ADC77575FBE8EFB6C3A709C63_label_en-US" xlink:label="lab_biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement_E51BC98ADC77575FBE8EFB6C3A709C63" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Remaining Potential Development Milestone Payments And Royalties On Commercial Sales Under Terms Of Collaboration Agreement</link:label>
    <link:label id="lab_biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement_E51BC98ADC77575FBE8EFB6C3A709C63_documentation_en-US" xlink:label="lab_biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement_E51BC98ADC77575FBE8EFB6C3A709C63" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expected total payments including upfront and milestone payments as well as the greater of an annual maintenance fee or usage-based royalty payments under the terms of collaboration agreement.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement" xlink:label="loc_biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement_E51BC98ADC77575FBE8EFB6C3A709C63" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement_E51BC98ADC77575FBE8EFB6C3A709C63" xlink:to="lab_biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement_E51BC98ADC77575FBE8EFB6C3A709C63" xlink:type="arc" />
    <link:label id="lab_biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement_CDC4BD9DA9249EC557E1FB6C3A703CA7_verboseLabel_en-US" xlink:label="lab_biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement_CDC4BD9DA9249EC557E1FB6C3A703CA7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Percentage of funding for R&amp;D cost required in support of the collaboration agreement</link:label>
    <link:label id="lab_biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement_CDC4BD9DA9249EC557E1FB6C3A703CA7_label_en-US" xlink:label="lab_biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement_CDC4BD9DA9249EC557E1FB6C3A703CA7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Cost In Support Of Collaboration Agreement</link:label>
    <link:label id="lab_biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement_CDC4BD9DA9249EC557E1FB6C3A703CA7_documentation_en-US" xlink:label="lab_biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement_CDC4BD9DA9249EC557E1FB6C3A703CA7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research and development cost in support of the collaboration agreement.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement" xlink:label="loc_biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement_CDC4BD9DA9249EC557E1FB6C3A703CA7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement_CDC4BD9DA9249EC557E1FB6C3A703CA7" xlink:to="lab_biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement_CDC4BD9DA9249EC557E1FB6C3A703CA7" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_B9B2E0F8F520ED2F8788FB6C3A7052DD_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_B9B2E0F8F520ED2F8788FB6C3A7052DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments to acquire interest in peferred stock of an affiliates</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_B9B2E0F8F520ED2F8788FB6C3A7052DD_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_B9B2E0F8F520ED2F8788FB6C3A7052DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Interest in Subsidiaries and Affiliates</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_B9B2E0F8F520ED2F8788FB6C3A7052DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_B9B2E0F8F520ED2F8788FB6C3A7052DD" xlink:to="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_B9B2E0F8F520ED2F8788FB6C3A7052DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_CB74C091903190AA71FCFB6C3A70124C_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess_CB74C091903190AA71FCFB6C3A70124C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">In-process research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_CB74C091903190AA71FCFB6C3A70124C_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess_CB74C091903190AA71FCFB6C3A70124C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development in Process</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_CB74C091903190AA71FCFB6C3A70124C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentInProcess_CB74C091903190AA71FCFB6C3A70124C" xlink:to="lab_us-gaap_ResearchAndDevelopmentInProcess_CB74C091903190AA71FCFB6C3A70124C" xlink:type="arc" />
    <link:label id="lab_us-gaap_NoncontrollingInterestInVariableInterestEntity_8CDA4892E5DFFF9798B6FB6C3A704EDF_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestInVariableInterestEntity_8CDA4892E5DFFF9798B6FB6C3A704EDF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minority interest in our stockholder's equity</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestInVariableInterestEntity_8CDA4892E5DFFF9798B6FB6C3A704EDF_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestInVariableInterestEntity_8CDA4892E5DFFF9798B6FB6C3A704EDF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest in Variable Interest Entity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NoncontrollingInterestInVariableInterestEntity" xlink:label="loc_us-gaap_NoncontrollingInterestInVariableInterestEntity_8CDA4892E5DFFF9798B6FB6C3A704EDF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestInVariableInterestEntity_8CDA4892E5DFFF9798B6FB6C3A704EDF" xlink:to="lab_us-gaap_NoncontrollingInterestInVariableInterestEntity_8CDA4892E5DFFF9798B6FB6C3A704EDF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_7AE815B77CF6B967F862FB6C3A700A97_negatedLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_7AE815B77CF6B967F862FB6C3A700A97" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Impairment of Intangible Assets, Finite-lived</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_7AE815B77CF6B967F862FB6C3A700A97_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_7AE815B77CF6B967F862FB6C3A700A97" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment of Intangible Assets, Finite-lived</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_7AE815B77CF6B967F862FB6C3A700A97" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_7AE815B77CF6B967F862FB6C3A700A97" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_7AE815B77CF6B967F862FB6C3A700A97" xlink:type="arc" />
    <link:label id="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_3C3C50D7A085BD91B647FB6C3A7023D4_verboseLabel_en-US" xlink:label="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_3C3C50D7A085BD91B647FB6C3A7023D4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities</link:label>
    <link:label id="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_3C3C50D7A085BD91B647FB6C3A7023D4_label_en-US" xlink:label="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_3C3C50D7A085BD91B647FB6C3A7023D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities</link:label>
    <link:label id="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_3C3C50D7A085BD91B647FB6C3A7023D4_documentation_en-US" xlink:label="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_3C3C50D7A085BD91B647FB6C3A7023D4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:label="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_3C3C50D7A085BD91B647FB6C3A7023D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_3C3C50D7A085BD91B647FB6C3A7023D4" xlink:to="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_3C3C50D7A085BD91B647FB6C3A7023D4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_27D20259CB130454FC74FC923B905349_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_27D20259CB130454FC74FC923B905349" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_27D20259CB130454FC74FC923B905349_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_27D20259CB130454FC74FC923B905349" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_27D20259CB130454FC74FC923B905349" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_27D20259CB130454FC74FC923B905349" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_27D20259CB130454FC74FC923B905349" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_C892D04C0057280FC3F1FC923B903FD4_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_C892D04C0057280FC3F1FC923B903FD4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangements [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_C892D04C0057280FC3F1FC923B903FD4_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_C892D04C0057280FC3F1FC923B903FD4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_C892D04C0057280FC3F1FC923B903FD4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis_C892D04C0057280FC3F1FC923B903FD4" xlink:to="lab_us-gaap_TypeOfArrangementAxis_C892D04C0057280FC3F1FC923B903FD4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_04E64AD700EA3E88557CFC923B91A035_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_04E64AD700EA3E88557CFC923B91A035" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_04E64AD700EA3E88557CFC923B91A035_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_04E64AD700EA3E88557CFC923B91A035" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_04E64AD700EA3E88557CFC923B91A035" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_04E64AD700EA3E88557CFC923B91A035" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_04E64AD700EA3E88557CFC923B91A035" xlink:type="arc" />
    <link:label id="lab_biib_EisaiMember_0F7D5B507EE58070FC0FFC923B920483_terseLabel_en-US" xlink:label="lab_biib_EisaiMember_0F7D5B507EE58070FC0FFC923B920483" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Eisai</link:label>
    <link:label id="lab_biib_EisaiMember_0F7D5B507EE58070FC0FFC923B920483_label_en-US" xlink:label="lab_biib_EisaiMember_0F7D5B507EE58070FC0FFC923B920483" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Eisai [Member]</link:label>
    <link:label id="lab_biib_EisaiMember_0F7D5B507EE58070FC0FFC923B920483_documentation_en-US" xlink:label="lab_biib_EisaiMember_0F7D5B507EE58070FC0FFC923B920483" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Eisai [Member]</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_EisaiMember" xlink:label="loc_biib_EisaiMember_0F7D5B507EE58070FC0FFC923B920483" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EisaiMember_0F7D5B507EE58070FC0FFC923B920483" xlink:to="lab_biib_EisaiMember_0F7D5B507EE58070FC0FFC923B920483" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_522A612EEFB75027B507FC923B9226C0_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_522A612EEFB75027B507FC923B9226C0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative arrangements and non-collaborative arrangement transactions</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_522A612EEFB75027B507FC923B9226C0_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_522A612EEFB75027B507FC923B9226C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_522A612EEFB75027B507FC923B9226C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_522A612EEFB75027B507FC923B9226C0" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_522A612EEFB75027B507FC923B9226C0" xlink:type="arc" />
    <link:label id="lab_biib_ExpenseIncurredByCollaboration_322EAE643162663B292AFC923B92A53B_terseLabel_en-US" xlink:label="lab_biib_ExpenseIncurredByCollaboration_322EAE643162663B292AFC923B92A53B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total expense incurred by collaboration</link:label>
    <link:label id="lab_biib_ExpenseIncurredByCollaboration_322EAE643162663B292AFC923B92A53B_label_en-US" xlink:label="lab_biib_ExpenseIncurredByCollaboration_322EAE643162663B292AFC923B92A53B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense Incurred By Collaboration</link:label>
    <link:label id="lab_biib_ExpenseIncurredByCollaboration_322EAE643162663B292AFC923B92A53B_documentation_en-US" xlink:label="lab_biib_ExpenseIncurredByCollaboration_322EAE643162663B292AFC923B92A53B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total expense incurred by collaboration.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_ExpenseIncurredByCollaboration" xlink:label="loc_biib_ExpenseIncurredByCollaboration_322EAE643162663B292AFC923B92A53B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ExpenseIncurredByCollaboration_322EAE643162663B292AFC923B92A53B" xlink:to="lab_biib_ExpenseIncurredByCollaboration_322EAE643162663B292AFC923B92A53B" xlink:type="arc" />
    <link:label id="lab_biib_ExpenseReflectedWithinStatementsOfIncome_56E603325A5DE3DC29BFFC923B92C51D_terseLabel_en-US" xlink:label="lab_biib_ExpenseReflectedWithinStatementsOfIncome_56E603325A5DE3DC29BFFC923B92C51D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Biogen's share of expense reflected within our consolidation statements of income</link:label>
    <link:label id="lab_biib_ExpenseReflectedWithinStatementsOfIncome_56E603325A5DE3DC29BFFC923B92C51D_label_en-US" xlink:label="lab_biib_ExpenseReflectedWithinStatementsOfIncome_56E603325A5DE3DC29BFFC923B92C51D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense Reflected Within Statements Of Income</link:label>
    <link:label id="lab_biib_ExpenseReflectedWithinStatementsOfIncome_56E603325A5DE3DC29BFFC923B92C51D_documentation_en-US" xlink:label="lab_biib_ExpenseReflectedWithinStatementsOfIncome_56E603325A5DE3DC29BFFC923B92C51D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Biogen Idec's share of expense reflected within our consolidated statements of income.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_ExpenseReflectedWithinStatementsOfIncome" xlink:label="loc_biib_ExpenseReflectedWithinStatementsOfIncome_56E603325A5DE3DC29BFFC923B92C51D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ExpenseReflectedWithinStatementsOfIncome_56E603325A5DE3DC29BFFC923B92C51D" xlink:to="lab_biib_ExpenseReflectedWithinStatementsOfIncome_56E603325A5DE3DC29BFFC923B92C51D" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_C3A309E5C37E8518D6AF74128649A570_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract_C3A309E5C37E8518D6AF74128649A570" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_C3A309E5C37E8518D6AF74128649A570" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_C3A309E5C37E8518D6AF74128649A570" xlink:to="lab_us-gaap_BusinessCombinationsAbstract_C3A309E5C37E8518D6AF74128649A570" xlink:type="arc" />
    <link:label id="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_6409925C1B4692E184577412865A70C9_verboseLabel_en-US" xlink:label="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_6409925C1B4692E184577412865A70C9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_6409925C1B4692E184577412865A70C9_label_en-US" xlink:label="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_6409925C1B4692E184577412865A70C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mergers, Acquisitions and Dispositions Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:label="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_6409925C1B4692E184577412865A70C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_6409925C1B4692E184577412865A70C9" xlink:to="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_6409925C1B4692E184577412865A70C9" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_54A085C6BCAEDE1EDE607412885E9AA6_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_54A085C6BCAEDE1EDE607412885E9AA6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_54A085C6BCAEDE1EDE607412885E9AA6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_54A085C6BCAEDE1EDE607412885E9AA6" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_54A085C6BCAEDE1EDE607412885E9AA6" xlink:type="arc" />
    <link:label id="lab_biib_TaxBenefitAndCashReceivedFromStockOptionAbstract_FE69185DC09BA2C8BF9B7412885EE90F_verboseLabel_en-US" xlink:label="lab_biib_TaxBenefitAndCashReceivedFromStockOptionAbstract_FE69185DC09BA2C8BF9B7412885EE90F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Tax benefit and cash received from stock option</link:label>
    <link:label id="lab_biib_TaxBenefitAndCashReceivedFromStockOptionAbstract_FE69185DC09BA2C8BF9B7412885EE90F_label_en-US" xlink:label="lab_biib_TaxBenefitAndCashReceivedFromStockOptionAbstract_FE69185DC09BA2C8BF9B7412885EE90F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Benefit And Cash Received From Stock Option [Abstract]</link:label>
    <link:label id="lab_biib_TaxBenefitAndCashReceivedFromStockOptionAbstract_FE69185DC09BA2C8BF9B7412885EE90F_documentation_en-US" xlink:label="lab_biib_TaxBenefitAndCashReceivedFromStockOptionAbstract_FE69185DC09BA2C8BF9B7412885EE90F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax benefit and cash received from stock option.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_TaxBenefitAndCashReceivedFromStockOptionAbstract" xlink:label="loc_biib_TaxBenefitAndCashReceivedFromStockOptionAbstract_FE69185DC09BA2C8BF9B7412885EE90F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TaxBenefitAndCashReceivedFromStockOptionAbstract_FE69185DC09BA2C8BF9B7412885EE90F" xlink:to="lab_biib_TaxBenefitAndCashReceivedFromStockOptionAbstract_FE69185DC09BA2C8BF9B7412885EE90F" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions_29A59EF6EAEDDF20F4FF7412885E26C2_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions_29A59EF6EAEDDF20F4FF7412885E26C2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Tax benefit realized for stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions_29A59EF6EAEDDF20F4FF7412885E26C2_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions_29A59EF6EAEDDF20F4FF7412885E26C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Tax Benefit Realized from Exercise of Stock Options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions_29A59EF6EAEDDF20F4FF7412885E26C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions_29A59EF6EAEDDF20F4FF7412885E26C2" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions_29A59EF6EAEDDF20F4FF7412885E26C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions_C54135149F619543D6D07412885EB409_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions_C54135149F619543D6D07412885EB409" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash received from the exercise of stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions_C54135149F619543D6D07412885EB409_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions_C54135149F619543D6D07412885EB409" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Cash Received from Exercise of Stock Options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions_C54135149F619543D6D07412885EB409" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions_C54135149F619543D6D07412885EB409" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions_C54135149F619543D6D07412885EB409" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_A716CF5AD670A1CA3FDA741285AD7121_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract_A716CF5AD670A1CA3FDA741285AD7121" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_A716CF5AD670A1CA3FDA741285AD7121" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_A716CF5AD670A1CA3FDA741285AD7121" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract_A716CF5AD670A1CA3FDA741285AD7121" xlink:type="arc" />
    <link:label id="lab_us-gaap_Land_DB98DD13CE2844966A5A741285AD0E6D_terseLabel_en-US" xlink:label="lab_us-gaap_Land_DB98DD13CE2844966A5A741285AD0E6D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Land</link:label>
    <link:label id="lab_us-gaap_Land_DB98DD13CE2844966A5A741285AD0E6D_label_en-US" xlink:label="lab_us-gaap_Land_DB98DD13CE2844966A5A741285AD0E6D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Land</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Land" xlink:label="loc_us-gaap_Land_DB98DD13CE2844966A5A741285AD0E6D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Land_DB98DD13CE2844966A5A741285AD0E6D" xlink:to="lab_us-gaap_Land_DB98DD13CE2844966A5A741285AD0E6D" xlink:type="arc" />
    <link:label id="lab_us-gaap_BuildingsAndImprovementsGross_896444DCD382CCC964B5741285ADBDC1_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingsAndImprovementsGross_896444DCD382CCC964B5741285ADBDC1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Buildings</link:label>
    <link:label id="lab_us-gaap_BuildingsAndImprovementsGross_896444DCD382CCC964B5741285ADBDC1_label_en-US" xlink:label="lab_us-gaap_BuildingsAndImprovementsGross_896444DCD382CCC964B5741285ADBDC1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Buildings and Improvements, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BuildingsAndImprovementsGross" xlink:label="loc_us-gaap_BuildingsAndImprovementsGross_896444DCD382CCC964B5741285ADBDC1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingsAndImprovementsGross_896444DCD382CCC964B5741285ADBDC1" xlink:to="lab_us-gaap_BuildingsAndImprovementsGross_896444DCD382CCC964B5741285ADBDC1" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseholdImprovementsGross_5B1DE702061BE3B2AECC741285ADC99B_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsGross_5B1DE702061BE3B2AECC741285ADC99B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsGross_5B1DE702061BE3B2AECC741285ADC99B_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsGross_5B1DE702061BE3B2AECC741285ADC99B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="loc_us-gaap_LeaseholdImprovementsGross_5B1DE702061BE3B2AECC741285ADC99B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsGross_5B1DE702061BE3B2AECC741285ADC99B" xlink:to="lab_us-gaap_LeaseholdImprovementsGross_5B1DE702061BE3B2AECC741285ADC99B" xlink:type="arc" />
    <link:label id="lab_us-gaap_MachineryAndEquipmentGross_88E85845253AD50A0AE9741285AD11AD_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentGross_88E85845253AD50A0AE9741285AD11AD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Machinery and equipment</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentGross_88E85845253AD50A0AE9741285AD11AD_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentGross_88E85845253AD50A0AE9741285AD11AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Machinery and Equipment, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MachineryAndEquipmentGross" xlink:label="loc_us-gaap_MachineryAndEquipmentGross_88E85845253AD50A0AE9741285AD11AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentGross_88E85845253AD50A0AE9741285AD11AD" xlink:to="lab_us-gaap_MachineryAndEquipmentGross_88E85845253AD50A0AE9741285AD11AD" xlink:type="arc" />
    <link:label id="lab_biib_ComputerSoftwareAndHardware_A0836A8A58508A60D1FE741285AD54BB_terseLabel_en-US" xlink:label="lab_biib_ComputerSoftwareAndHardware_A0836A8A58508A60D1FE741285AD54BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer software and hardware</link:label>
    <link:label id="lab_biib_ComputerSoftwareAndHardware_A0836A8A58508A60D1FE741285AD54BB_label_en-US" xlink:label="lab_biib_ComputerSoftwareAndHardware_A0836A8A58508A60D1FE741285AD54BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer software and hardware</link:label>
    <link:label id="lab_biib_ComputerSoftwareAndHardware_A0836A8A58508A60D1FE741285AD54BB_documentation_en-US" xlink:label="lab_biib_ComputerSoftwareAndHardware_A0836A8A58508A60D1FE741285AD54BB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Computer software and hardware</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_ComputerSoftwareAndHardware" xlink:label="loc_biib_ComputerSoftwareAndHardware_A0836A8A58508A60D1FE741285AD54BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ComputerSoftwareAndHardware_A0836A8A58508A60D1FE741285AD54BB" xlink:to="lab_biib_ComputerSoftwareAndHardware_A0836A8A58508A60D1FE741285AD54BB" xlink:type="arc" />
    <link:label id="lab_us-gaap_FurnitureAndFixturesGross_DCC6EEC10FE5ECA2A0C0741285AE0DC7_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesGross_DCC6EEC10FE5ECA2A0C0741285AE0DC7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesGross_DCC6EEC10FE5ECA2A0C0741285AE0DC7_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesGross_DCC6EEC10FE5ECA2A0C0741285AE0DC7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FurnitureAndFixturesGross" xlink:label="loc_us-gaap_FurnitureAndFixturesGross_DCC6EEC10FE5ECA2A0C0741285AE0DC7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesGross_DCC6EEC10FE5ECA2A0C0741285AE0DC7" xlink:to="lab_us-gaap_FurnitureAndFixturesGross_DCC6EEC10FE5ECA2A0C0741285AE0DC7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConstructionInProgressGross_F3B033946DAE7A28B5A2741285AE3DC1_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross_F3B033946DAE7A28B5A2741285AE3DC1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_F3B033946DAE7A28B5A2741285AE3DC1_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross_F3B033946DAE7A28B5A2741285AE3DC1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction in Progress, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConstructionInProgressGross" xlink:label="loc_us-gaap_ConstructionInProgressGross_F3B033946DAE7A28B5A2741285AE3DC1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressGross_F3B033946DAE7A28B5A2741285AE3DC1" xlink:to="lab_us-gaap_ConstructionInProgressGross_F3B033946DAE7A28B5A2741285AE3DC1" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_C2E1774E2A90A7B4E83E741285AE6DF4_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross_C2E1774E2A90A7B4E83E741285AE6DF4" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total cost</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_C2E1774E2A90A7B4E83E741285AE6DF4_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross_C2E1774E2A90A7B4E83E741285AE6DF4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_C2E1774E2A90A7B4E83E741285AE6DF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_C2E1774E2A90A7B4E83E741285AE6DF4" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross_C2E1774E2A90A7B4E83E741285AE6DF4" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_5177FFE974E9FBD96B34741285AECD5D_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_5177FFE974E9FBD96B34741285AECD5D" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_5177FFE974E9FBD96B34741285AECD5D_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_5177FFE974E9FBD96B34741285AECD5D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_5177FFE974E9FBD96B34741285AECD5D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_5177FFE974E9FBD96B34741285AECD5D" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_5177FFE974E9FBD96B34741285AECD5D" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_273ED9F81EE043739078741285AEBCEF_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_273ED9F81EE043739078741285AEBCEF" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_273ED9F81EE043739078741285AEBCEF_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_273ED9F81EE043739078741285AEBCEF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_273ED9F81EE043739078741285AEBCEF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_273ED9F81EE043739078741285AEBCEF" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_273ED9F81EE043739078741285AEBCEF" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_1E78396BE0876AC2616F74128573A54C_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_1E78396BE0876AC2616F74128573A54C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1E78396BE0876AC2616F74128573A54C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1E78396BE0876AC2616F74128573A54C" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_1E78396BE0876AC2616F74128573A54C" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_E870D908C4AEAB07C9897412857491DB_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_E870D908C4AEAB07C9897412857491DB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_E870D908C4AEAB07C9897412857491DB_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_E870D908C4AEAB07C9897412857491DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_E870D908C4AEAB07C9897412857491DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_E870D908C4AEAB07C9897412857491DB" xlink:to="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_E870D908C4AEAB07C9897412857491DB" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityAbstract_9180C6F99C377148FEF1885D71D4FED3_label_en-US" xlink:label="lab_us-gaap_EquityAbstract_9180C6F99C377148FEF1885D71D4FED3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_9180C6F99C377148FEF1885D71D4FED3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract_9180C6F99C377148FEF1885D71D4FED3" xlink:to="lab_us-gaap_EquityAbstract_9180C6F99C377148FEF1885D71D4FED3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_B25930ABFB3B1B06F7D9885D71D9E738_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_B25930ABFB3B1B06F7D9885D71D9E738" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_B25930ABFB3B1B06F7D9885D71D9E738_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_B25930ABFB3B1B06F7D9885D71D9E738" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_B25930ABFB3B1B06F7D9885D71D9E738" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_B25930ABFB3B1B06F7D9885D71D9E738" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable_B25930ABFB3B1B06F7D9885D71D9E738" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_BED900729CBA0DB819F6885D71D9455B_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis_BED900729CBA0DB819F6885D71D9455B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_BED900729CBA0DB819F6885D71D9455B_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis_BED900729CBA0DB819F6885D71D9455B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_BED900729CBA0DB819F6885D71D9455B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis_BED900729CBA0DB819F6885D71D9455B" xlink:to="lab_us-gaap_StatementClassOfStockAxis_BED900729CBA0DB819F6885D71D9455B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfStockDomain_B0E001EB0DA96B832B6E885D71D9E4AD_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain_B0E001EB0DA96B832B6E885D71D9E4AD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_B0E001EB0DA96B832B6E885D71D9E4AD_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain_B0E001EB0DA96B832B6E885D71D9E4AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_B0E001EB0DA96B832B6E885D71D9E4AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain_B0E001EB0DA96B832B6E885D71D9E4AD" xlink:to="lab_us-gaap_ClassOfStockDomain_B0E001EB0DA96B832B6E885D71D9E4AD" xlink:type="arc" />
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_A2CFEEB2754F29240CFF885D71D9BD58_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember_A2CFEEB2754F29240CFF885D71D9BD58" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series A</link:label>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_A2CFEEB2754F29240CFF885D71D9BD58_label_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember_A2CFEEB2754F29240CFF885D71D9BD58" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_A2CFEEB2754F29240CFF885D71D9BD58" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesAPreferredStockMember_A2CFEEB2754F29240CFF885D71D9BD58" xlink:to="lab_us-gaap_SeriesAPreferredStockMember_A2CFEEB2754F29240CFF885D71D9BD58" xlink:type="arc" />
    <link:label id="lab_biib_SeriesXPreferredStockMember_4817424A7F71C9DFF7C2885D71DADE28_terseLabel_en-US" xlink:label="lab_biib_SeriesXPreferredStockMember_4817424A7F71C9DFF7C2885D71DADE28" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series X junior participating</link:label>
    <link:label id="lab_biib_SeriesXPreferredStockMember_4817424A7F71C9DFF7C2885D71DADE28_label_en-US" xlink:label="lab_biib_SeriesXPreferredStockMember_4817424A7F71C9DFF7C2885D71DADE28" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series X Preferred Stock [Member]</link:label>
    <link:label id="lab_biib_SeriesXPreferredStockMember_4817424A7F71C9DFF7C2885D71DADE28_documentation_en-US" xlink:label="lab_biib_SeriesXPreferredStockMember_4817424A7F71C9DFF7C2885D71DADE28" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series X preferred stock.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_SeriesXPreferredStockMember" xlink:label="loc_biib_SeriesXPreferredStockMember_4817424A7F71C9DFF7C2885D71DADE28" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeriesXPreferredStockMember_4817424A7F71C9DFF7C2885D71DADE28" xlink:to="lab_biib_SeriesXPreferredStockMember_4817424A7F71C9DFF7C2885D71DADE28" xlink:type="arc" />
    <link:label id="lab_biib_UndesignatedPreferredStockMember_1E5BD6E086FF1C15BAA7885D71DA954A_terseLabel_en-US" xlink:label="lab_biib_UndesignatedPreferredStockMember_1E5BD6E086FF1C15BAA7885D71DA954A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Undesignated</link:label>
    <link:label id="lab_biib_UndesignatedPreferredStockMember_1E5BD6E086FF1C15BAA7885D71DA954A_label_en-US" xlink:label="lab_biib_UndesignatedPreferredStockMember_1E5BD6E086FF1C15BAA7885D71DA954A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Undesignated Preferred Stock [Member]</link:label>
    <link:label id="lab_biib_UndesignatedPreferredStockMember_1E5BD6E086FF1C15BAA7885D71DA954A_documentation_en-US" xlink:label="lab_biib_UndesignatedPreferredStockMember_1E5BD6E086FF1C15BAA7885D71DA954A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Undesignated preferred stock.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_UndesignatedPreferredStockMember" xlink:label="loc_biib_UndesignatedPreferredStockMember_1E5BD6E086FF1C15BAA7885D71DA954A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_UndesignatedPreferredStockMember_1E5BD6E086FF1C15BAA7885D71DA954A" xlink:to="lab_biib_UndesignatedPreferredStockMember_1E5BD6E086FF1C15BAA7885D71DA954A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfStockLineItems_FACBFD4C48C6B6B40D70885D71DA4DF9_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_FACBFD4C48C6B6B40D70885D71DA4DF9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_FACBFD4C48C6B6B40D70885D71DA4DF9_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_FACBFD4C48C6B6B40D70885D71DA4DF9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_FACBFD4C48C6B6B40D70885D71DA4DF9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems_FACBFD4C48C6B6B40D70885D71DA4DF9" xlink:to="lab_us-gaap_ClassOfStockLineItems_FACBFD4C48C6B6B40D70885D71DA4DF9" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_188C0B99672A470C7EEB885D71DA4B2A_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_188C0B99672A470C7EEB885D71DA4B2A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_188C0B99672A470C7EEB885D71DA4B2A_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_188C0B99672A470C7EEB885D71DA4B2A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_188C0B99672A470C7EEB885D71DA4B2A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized_188C0B99672A470C7EEB885D71DA4B2A" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized_188C0B99672A470C7EEB885D71DA4B2A" xlink:type="arc" />
    <link:label id="lab_biib_EquityTextualAbstract_C3180DBF4C88F59446A0885D71DAE66D_verboseLabel_en-US" xlink:label="lab_biib_EquityTextualAbstract_C3180DBF4C88F59446A0885D71DAE66D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Equity (Textual)</link:label>
    <link:label id="lab_biib_EquityTextualAbstract_C3180DBF4C88F59446A0885D71DAE66D_label_en-US" xlink:label="lab_biib_EquityTextualAbstract_C3180DBF4C88F59446A0885D71DAE66D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity (Textual) [Abstract]</link:label>
    <link:label id="lab_biib_EquityTextualAbstract_C3180DBF4C88F59446A0885D71DAE66D_documentation_en-US" xlink:label="lab_biib_EquityTextualAbstract_C3180DBF4C88F59446A0885D71DAE66D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_EquityTextualAbstract" xlink:label="loc_biib_EquityTextualAbstract_C3180DBF4C88F59446A0885D71DAE66D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EquityTextualAbstract_C3180DBF4C88F59446A0885D71DAE66D" xlink:to="lab_biib_EquityTextualAbstract_C3180DBF4C88F59446A0885D71DAE66D" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_E0E3A28F27926F563495885D71F1DCA5_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_E0E3A28F27926F563495885D71F1DCA5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Authorized amount of share repurchases under the 2015 Share Repurchase Program</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_E0E3A28F27926F563495885D71F1DCA5_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_E0E3A28F27926F563495885D71F1DCA5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_E0E3A28F27926F563495885D71F1DCA5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_E0E3A28F27926F563495885D71F1DCA5" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_E0E3A28F27926F563495885D71F1DCA5" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_64BC21E348D04C12287C885D71F1D852_verboseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired_64BC21E348D04C12287C885D71F1D852" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Repurchase of common stock, shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_64BC21E348D04C12287C885D71F1D852_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired_64BC21E348D04C12287C885D71F1D852" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_64BC21E348D04C12287C885D71F1D852" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired_64BC21E348D04C12287C885D71F1D852" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired_64BC21E348D04C12287C885D71F1D852" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_AB799FEC70DC92CB719B885D71F17EBA_verboseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_AB799FEC70DC92CB719B885D71F17EBA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Repurchase of common stock, value</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_AB799FEC70DC92CB719B885D71F17EBA_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_AB799FEC70DC92CB719B885D71F17EBA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_AB799FEC70DC92CB719B885D71F17EBA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_AB799FEC70DC92CB719B885D71F17EBA" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_AB799FEC70DC92CB719B885D71F17EBA" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_62653CD603211D471394885D71F13A31_verboseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_62653CD603211D471394885D71F13A31" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock shares authorized for repurchase</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_62653CD603211D471394885D71F13A31_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_62653CD603211D471394885D71F13A31" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchase Program, Number of Shares Authorized to be Repurchased</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:label="loc_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_62653CD603211D471394885D71F13A31" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_62653CD603211D471394885D71F13A31" xlink:to="lab_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_62653CD603211D471394885D71F13A31" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5046C72D39C35117E7357412873E7E14_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5046C72D39C35117E7357412873E7E14" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5046C72D39C35117E7357412873E7E14_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5046C72D39C35117E7357412873E7E14" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5046C72D39C35117E7357412873E7E14" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5046C72D39C35117E7357412873E7E14" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5046C72D39C35117E7357412873E7E14" xlink:type="arc" />
    <link:label id="lab_us-gaap_AwardTypeAxis_667671D70CAD4E446BE07412873EFB28_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_667671D70CAD4E446BE07412873EFB28" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Award Type and Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_667671D70CAD4E446BE07412873EFB28_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_667671D70CAD4E446BE07412873EFB28" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_667671D70CAD4E446BE07412873EFB28" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis_667671D70CAD4E446BE07412873EFB28" xlink:to="lab_us-gaap_AwardTypeAxis_667671D70CAD4E446BE07412873EFB28" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_33E397BBFF5436C22D227412873F7416_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_33E397BBFF5436C22D227412873F7416" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Award Type and Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_33E397BBFF5436C22D227412873F7416_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_33E397BBFF5436C22D227412873F7416" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_33E397BBFF5436C22D227412873F7416" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_33E397BBFF5436C22D227412873F7416" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_33E397BBFF5436C22D227412873F7416" xlink:type="arc" />
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsMember_E67F7C3572C4F46D1A7B7412873F2D8A_verboseLabel_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsMember_E67F7C3572C4F46D1A7B7412873F2D8A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Time-vested restricted stock units</link:label>
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsMember_E67F7C3572C4F46D1A7B7412873F2D8A_label_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsMember_E67F7C3572C4F46D1A7B7412873F2D8A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Time Vested Restricted Stock Units [Member]</link:label>
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsMember_E67F7C3572C4F46D1A7B7412873F2D8A_documentation_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsMember_E67F7C3572C4F46D1A7B7412873F2D8A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Time vested restricted stock units.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_E67F7C3572C4F46D1A7B7412873F2D8A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TimeVestedRestrictedStockUnitsMember_E67F7C3572C4F46D1A7B7412873F2D8A" xlink:to="lab_biib_TimeVestedRestrictedStockUnitsMember_E67F7C3572C4F46D1A7B7412873F2D8A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_251C89B8F19660BEF5897412873FC80C_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_251C89B8F19660BEF5897412873FC80C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_251C89B8F19660BEF5897412873FC80C_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_251C89B8F19660BEF5897412873FC80C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_251C89B8F19660BEF5897412873FC80C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_251C89B8F19660BEF5897412873FC80C" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_251C89B8F19660BEF5897412873FC80C" xlink:type="arc" />
    <link:label id="lab_biib_RestrictedStockUnitsActivityAbstract_F27C758B5D2570FBFF197412873F3509_verboseLabel_en-US" xlink:label="lab_biib_RestrictedStockUnitsActivityAbstract_F27C758B5D2570FBFF197412873F3509" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Time-vested restricted stock units</link:label>
    <link:label id="lab_biib_RestrictedStockUnitsActivityAbstract_F27C758B5D2570FBFF197412873F3509_label_en-US" xlink:label="lab_biib_RestrictedStockUnitsActivityAbstract_F27C758B5D2570FBFF197412873F3509" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units Activity [Abstract]</link:label>
    <link:label id="lab_biib_RestrictedStockUnitsActivityAbstract_F27C758B5D2570FBFF197412873F3509_documentation_en-US" xlink:label="lab_biib_RestrictedStockUnitsActivityAbstract_F27C758B5D2570FBFF197412873F3509" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restricted stock units activity.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_RestrictedStockUnitsActivityAbstract" xlink:label="loc_biib_RestrictedStockUnitsActivityAbstract_F27C758B5D2570FBFF197412873F3509" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_F27C758B5D2570FBFF197412873F3509" xlink:to="lab_biib_RestrictedStockUnitsActivityAbstract_F27C758B5D2570FBFF197412873F3509" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8466604ABA6CB2DF63057412873FA437_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8466604ABA6CB2DF63057412873FA437" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance, Unvested, Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8466604ABA6CB2DF63057412873FA437_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8466604ABA6CB2DF63057412873FA437" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8466604ABA6CB2DF63057412873FA437" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8466604ABA6CB2DF63057412873FA437" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8466604ABA6CB2DF63057412873FA437" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6FE2C5F528C471B40D1E7412873F6923_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6FE2C5F528C471B40D1E7412873F6923" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6FE2C5F528C471B40D1E7412873F6923_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6FE2C5F528C471B40D1E7412873F6923" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6FE2C5F528C471B40D1E7412873F6923" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6FE2C5F528C471B40D1E7412873F6923" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6FE2C5F528C471B40D1E7412873F6923" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_8C0B20A50D4F82FE9EC074128740BAE5_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_8C0B20A50D4F82FE9EC074128740BAE5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Shares, Granted</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_8C0B20A50D4F82FE9EC074128740BAE5_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_8C0B20A50D4F82FE9EC074128740BAE5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_8C0B20A50D4F82FE9EC074128740BAE5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_8C0B20A50D4F82FE9EC074128740BAE5" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_8C0B20A50D4F82FE9EC074128740BAE5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_36BDB20C404FB45E3733741287403541_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_36BDB20C404FB45E3733741287403541" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Grant Date Fair Value, Granted</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_36BDB20C404FB45E3733741287403541_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_36BDB20C404FB45E3733741287403541" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_36BDB20C404FB45E3733741287403541" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_36BDB20C404FB45E3733741287403541" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_36BDB20C404FB45E3733741287403541" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_DC4690F6FC8AFF60799A741287404FD7_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_DC4690F6FC8AFF60799A741287404FD7" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Shares, Vested</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_DC4690F6FC8AFF60799A741287404FD7_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_DC4690F6FC8AFF60799A741287404FD7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_DC4690F6FC8AFF60799A741287404FD7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_DC4690F6FC8AFF60799A741287404FD7" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_DC4690F6FC8AFF60799A741287404FD7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_2CFD9C1EC8C55AB37E71741287406675_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_2CFD9C1EC8C55AB37E71741287406675" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Grant Date Fair Value, Vested</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_2CFD9C1EC8C55AB37E71741287406675_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_2CFD9C1EC8C55AB37E71741287406675" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_2CFD9C1EC8C55AB37E71741287406675" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_2CFD9C1EC8C55AB37E71741287406675" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_2CFD9C1EC8C55AB37E71741287406675" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_CDA41B0670AA14519C66741287403329_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_CDA41B0670AA14519C66741287403329" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Shares, Forfeited</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_CDA41B0670AA14519C66741287403329_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_CDA41B0670AA14519C66741287403329" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_CDA41B0670AA14519C66741287403329" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_CDA41B0670AA14519C66741287403329" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_CDA41B0670AA14519C66741287403329" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_F679596BE59C9EC7B7BC741287409B0E_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_F679596BE59C9EC7B7BC741287409B0E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Grant Date Fair Value, Forfeited</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_F679596BE59C9EC7B7BC741287409B0E_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_F679596BE59C9EC7B7BC741287409B0E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_F679596BE59C9EC7B7BC741287409B0E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_F679596BE59C9EC7B7BC741287409B0E" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_F679596BE59C9EC7B7BC741287409B0E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5F5DCBF71E10B8060790741287409237_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5F5DCBF71E10B8060790741287409237" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance, Unvested, Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5F5DCBF71E10B8060790741287409237" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5F5DCBF71E10B8060790741287409237" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5F5DCBF71E10B8060790741287409237" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2D314A9CAD8E4488871574128740264B_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2D314A9CAD8E4488871574128740264B" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2D314A9CAD8E4488871574128740264B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2D314A9CAD8E4488871574128740264B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2D314A9CAD8E4488871574128740264B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_FFC379CA953923695574FD6455B52934_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_FFC379CA953923695574FD6455B52934" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_FFC379CA953923695574FD6455B52934_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_FFC379CA953923695574FD6455B52934" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_FFC379CA953923695574FD6455B52934" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_FFC379CA953923695574FD6455B52934" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_FFC379CA953923695574FD6455B52934" xlink:type="arc" />
    <link:label id="lab_biib_MajorDistributorAxis_0C617459372D0287C764FD6455B53D20_terseLabel_en-US" xlink:label="lab_biib_MajorDistributorAxis_0C617459372D0287C764FD6455B53D20" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Major Distributor [Axis]</link:label>
    <link:label id="lab_biib_MajorDistributorAxis_0C617459372D0287C764FD6455B53D20_label_en-US" xlink:label="lab_biib_MajorDistributorAxis_0C617459372D0287C764FD6455B53D20" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major Distributor [Axis]</link:label>
    <link:label id="lab_biib_MajorDistributorAxis_0C617459372D0287C764FD6455B53D20_documentation_en-US" xlink:label="lab_biib_MajorDistributorAxis_0C617459372D0287C764FD6455B53D20" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Major Distributor.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_MajorDistributorAxis" xlink:label="loc_biib_MajorDistributorAxis_0C617459372D0287C764FD6455B53D20" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MajorDistributorAxis_0C617459372D0287C764FD6455B53D20" xlink:to="lab_biib_MajorDistributorAxis_0C617459372D0287C764FD6455B53D20" xlink:type="arc" />
    <link:label id="lab_biib_MajorDistributorDomain_618A118D84C9D3C6979AFD6455B5B322_terseLabel_en-US" xlink:label="lab_biib_MajorDistributorDomain_618A118D84C9D3C6979AFD6455B5B322" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Major Distributor [Domain]</link:label>
    <link:label id="lab_biib_MajorDistributorDomain_618A118D84C9D3C6979AFD6455B5B322_label_en-US" xlink:label="lab_biib_MajorDistributorDomain_618A118D84C9D3C6979AFD6455B5B322" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major Distributor [Domain]</link:label>
    <link:label id="lab_biib_MajorDistributorDomain_618A118D84C9D3C6979AFD6455B5B322_documentation_en-US" xlink:label="lab_biib_MajorDistributorDomain_618A118D84C9D3C6979AFD6455B5B322" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Major Distributor.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_MajorDistributorDomain" xlink:label="loc_biib_MajorDistributorDomain_618A118D84C9D3C6979AFD6455B5B322" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MajorDistributorDomain_618A118D84C9D3C6979AFD6455B5B322" xlink:to="lab_biib_MajorDistributorDomain_618A118D84C9D3C6979AFD6455B5B322" xlink:type="arc" />
    <link:label id="lab_biib_DistributorOneMember_22E99E9D740EDFB6B6BEFD6455B6E07C_terseLabel_en-US" xlink:label="lab_biib_DistributorOneMember_22E99E9D740EDFB6B6BEFD6455B6E07C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Distributor One</link:label>
    <link:label id="lab_biib_DistributorOneMember_22E99E9D740EDFB6B6BEFD6455B6E07C_label_en-US" xlink:label="lab_biib_DistributorOneMember_22E99E9D740EDFB6B6BEFD6455B6E07C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Distributor One [Member]</link:label>
    <link:label id="lab_biib_DistributorOneMember_22E99E9D740EDFB6B6BEFD6455B6E07C_documentation_en-US" xlink:label="lab_biib_DistributorOneMember_22E99E9D740EDFB6B6BEFD6455B6E07C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Distributor one.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_DistributorOneMember" xlink:label="loc_biib_DistributorOneMember_22E99E9D740EDFB6B6BEFD6455B6E07C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DistributorOneMember_22E99E9D740EDFB6B6BEFD6455B6E07C" xlink:to="lab_biib_DistributorOneMember_22E99E9D740EDFB6B6BEFD6455B6E07C" xlink:type="arc" />
    <link:label id="lab_biib_DistributorTwoMember_5A50F69B599D584F1C04FD6455B67FFE_terseLabel_en-US" xlink:label="lab_biib_DistributorTwoMember_5A50F69B599D584F1C04FD6455B67FFE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Distributor Two</link:label>
    <link:label id="lab_biib_DistributorTwoMember_5A50F69B599D584F1C04FD6455B67FFE_label_en-US" xlink:label="lab_biib_DistributorTwoMember_5A50F69B599D584F1C04FD6455B67FFE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Distributor Two [Member]</link:label>
    <link:label id="lab_biib_DistributorTwoMember_5A50F69B599D584F1C04FD6455B67FFE_documentation_en-US" xlink:label="lab_biib_DistributorTwoMember_5A50F69B599D584F1C04FD6455B67FFE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Distributor two.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_DistributorTwoMember" xlink:label="loc_biib_DistributorTwoMember_5A50F69B599D584F1C04FD6455B67FFE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DistributorTwoMember_5A50F69B599D584F1C04FD6455B67FFE" xlink:to="lab_biib_DistributorTwoMember_5A50F69B599D584F1C04FD6455B67FFE" xlink:type="arc" />
    <link:label id="lab_us-gaap_RangeAxis_FA6775DA937575ABDDE9FD6455B6550D_terseLabel_en-US" xlink:label="lab_us-gaap_RangeAxis_FA6775DA937575ABDDE9FD6455B6550D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_us-gaap_RangeAxis_FA6775DA937575ABDDE9FD6455B6550D_label_en-US" xlink:label="lab_us-gaap_RangeAxis_FA6775DA937575ABDDE9FD6455B6550D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_FA6775DA937575ABDDE9FD6455B6550D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeAxis_FA6775DA937575ABDDE9FD6455B6550D" xlink:to="lab_us-gaap_RangeAxis_FA6775DA937575ABDDE9FD6455B6550D" xlink:type="arc" />
    <link:label id="lab_us-gaap_RangeMember_7AB54C06CE2BD698E040FD6455B622FC_terseLabel_en-US" xlink:label="lab_us-gaap_RangeMember_7AB54C06CE2BD698E040FD6455B622FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_us-gaap_RangeMember_7AB54C06CE2BD698E040FD6455B622FC_label_en-US" xlink:label="lab_us-gaap_RangeMember_7AB54C06CE2BD698E040FD6455B622FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_7AB54C06CE2BD698E040FD6455B622FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeMember_7AB54C06CE2BD698E040FD6455B622FC" xlink:to="lab_us-gaap_RangeMember_7AB54C06CE2BD698E040FD6455B622FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinimumMember_B002776E3D783143D648FD6455B62FC3_verboseLabel_en-US" xlink:label="lab_us-gaap_MinimumMember_B002776E3D783143D648FD6455B62FC3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_us-gaap_MinimumMember_B002776E3D783143D648FD6455B62FC3_label_en-US" xlink:label="lab_us-gaap_MinimumMember_B002776E3D783143D648FD6455B62FC3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_B002776E3D783143D648FD6455B62FC3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinimumMember_B002776E3D783143D648FD6455B62FC3" xlink:to="lab_us-gaap_MinimumMember_B002776E3D783143D648FD6455B62FC3" xlink:type="arc" />
    <link:label id="lab_us-gaap_MaximumMember_E50660221DD02361D2F0FD6455B6FF0B_verboseLabel_en-US" xlink:label="lab_us-gaap_MaximumMember_E50660221DD02361D2F0FD6455B6FF0B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_us-gaap_MaximumMember_E50660221DD02361D2F0FD6455B6FF0B_label_en-US" xlink:label="lab_us-gaap_MaximumMember_E50660221DD02361D2F0FD6455B6FF0B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_E50660221DD02361D2F0FD6455B6FF0B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaximumMember_E50660221DD02361D2F0FD6455B6FF0B" xlink:to="lab_us-gaap_MaximumMember_E50660221DD02361D2F0FD6455B6FF0B" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5EC3A36315AF9FBB018EFD6455B68766_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5EC3A36315AF9FBB018EFD6455B68766" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5EC3A36315AF9FBB018EFD6455B68766_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5EC3A36315AF9FBB018EFD6455B68766" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5EC3A36315AF9FBB018EFD6455B68766" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5EC3A36315AF9FBB018EFD6455B68766" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5EC3A36315AF9FBB018EFD6455B68766" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_F19D4C59A615F3586A34FD6455B6F1B5_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_F19D4C59A615F3586A34FD6455B6F1B5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_F19D4C59A615F3586A34FD6455B6F1B5_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_F19D4C59A615F3586A34FD6455B6F1B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_F19D4C59A615F3586A34FD6455B6F1B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_F19D4C59A615F3586A34FD6455B6F1B5" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_F19D4C59A615F3586A34FD6455B6F1B5" xlink:type="arc" />
    <link:label id="lab_us-gaap_BuildingMember_36B74441F3065935CA3CFD6455B62F30_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingMember_36B74441F3065935CA3CFD6455B62F30" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Building</link:label>
    <link:label id="lab_us-gaap_BuildingMember_36B74441F3065935CA3CFD6455B62F30_label_en-US" xlink:label="lab_us-gaap_BuildingMember_36B74441F3065935CA3CFD6455B62F30" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Building [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BuildingMember" xlink:label="loc_us-gaap_BuildingMember_36B74441F3065935CA3CFD6455B62F30" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingMember_36B74441F3065935CA3CFD6455B62F30" xlink:to="lab_us-gaap_BuildingMember_36B74441F3065935CA3CFD6455B62F30" xlink:type="arc" />
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_F43F3E47CD3075DDB6B5FD6455B6B77D_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember_F43F3E47CD3075DDB6B5FD6455B6B77D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_F43F3E47CD3075DDB6B5FD6455B6B77D_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember_F43F3E47CD3075DDB6B5FD6455B6B77D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_F43F3E47CD3075DDB6B5FD6455B6B77D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember_F43F3E47CD3075DDB6B5FD6455B6B77D" xlink:to="lab_us-gaap_FurnitureAndFixturesMember_F43F3E47CD3075DDB6B5FD6455B6B77D" xlink:type="arc" />
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_02C03DA302A7E2EC3DA9FD6455B6AB21_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember_02C03DA302A7E2EC3DA9FD6455B6AB21" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Machinery and Equipment</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_02C03DA302A7E2EC3DA9FD6455B6AB21_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember_02C03DA302A7E2EC3DA9FD6455B6AB21" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Machinery and Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_02C03DA302A7E2EC3DA9FD6455B6AB21" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentMember_02C03DA302A7E2EC3DA9FD6455B6AB21" xlink:to="lab_us-gaap_MachineryAndEquipmentMember_02C03DA302A7E2EC3DA9FD6455B6AB21" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComputerEquipmentMember_6DD451FA08BDA8CE0645FD6455B7FF52_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember_6DD451FA08BDA8CE0645FD6455B7FF52" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer Equipment</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_6DD451FA08BDA8CE0645FD6455B7FF52_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember_6DD451FA08BDA8CE0645FD6455B7FF52" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_6DD451FA08BDA8CE0645FD6455B7FF52" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember_6DD451FA08BDA8CE0645FD6455B7FF52" xlink:to="lab_us-gaap_ComputerEquipmentMember_6DD451FA08BDA8CE0645FD6455B7FF52" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_C340C1736CFB9C480174FD6455B7FD73_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_C340C1736CFB9C480174FD6455B7FD73" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_C340C1736CFB9C480174FD6455B7FD73_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_C340C1736CFB9C480174FD6455B7FD73" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_C340C1736CFB9C480174FD6455B7FD73" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_C340C1736CFB9C480174FD6455B7FD73" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems_C340C1736CFB9C480174FD6455B7FD73" xlink:type="arc" />
    <link:label id="lab_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables_0213699FEAA841A1133CFD6455B7064C_terseLabel_en-US" xlink:label="lab_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables_0213699FEAA841A1133CFD6455B7064C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage receivables of wholesale distributor accounted in consolidated receivables</link:label>
    <link:label id="lab_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables_0213699FEAA841A1133CFD6455B7064C_label_en-US" xlink:label="lab_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables_0213699FEAA841A1133CFD6455B7064C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Receivables Of Wholesale Distributor Accounted In Consolidated Receivables</link:label>
    <link:label id="lab_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables_0213699FEAA841A1133CFD6455B7064C_documentation_en-US" xlink:label="lab_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables_0213699FEAA841A1133CFD6455B7064C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage receivables of wholesale distributor accounted in consolidated receivables.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables" xlink:label="loc_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables_0213699FEAA841A1133CFD6455B7064C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables_0213699FEAA841A1133CFD6455B7064C" xlink:to="lab_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables_0213699FEAA841A1133CFD6455B7064C" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_E82E394D507DA2A5F92EFD6455B7211E_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_E82E394D507DA2A5F92EFD6455B7211E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_E82E394D507DA2A5F92EFD6455B7211E_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_E82E394D507DA2A5F92EFD6455B7211E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_E82E394D507DA2A5F92EFD6455B7211E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_E82E394D507DA2A5F92EFD6455B7211E" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_E82E394D507DA2A5F92EFD6455B7211E" xlink:type="arc" />
    <link:label id="lab_biib_BusinessTextualAbstract_F2F790AB569569D52FACFD6455B7B738_terseLabel_en-US" xlink:label="lab_biib_BusinessTextualAbstract_F2F790AB569569D52FACFD6455B7B738" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business (Textual)</link:label>
    <link:label id="lab_biib_BusinessTextualAbstract_F2F790AB569569D52FACFD6455B7B738_label_en-US" xlink:label="lab_biib_BusinessTextualAbstract_F2F790AB569569D52FACFD6455B7B738" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business (Textual) [Abstract]</link:label>
    <link:label id="lab_biib_BusinessTextualAbstract_F2F790AB569569D52FACFD6455B7B738_documentation_en-US" xlink:label="lab_biib_BusinessTextualAbstract_F2F790AB569569D52FACFD6455B7B738" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_BusinessTextualAbstract" xlink:label="loc_biib_BusinessTextualAbstract_F2F790AB569569D52FACFD6455B7B738" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BusinessTextualAbstract_F2F790AB569569D52FACFD6455B7B738" xlink:to="lab_biib_BusinessTextualAbstract_F2F790AB569569D52FACFD6455B7B738" xlink:type="arc" />
    <link:label id="lab_biib_InterestInSubsidiary_85A64598858CA72579F2FD6455B723C9_terseLabel_en-US" xlink:label="lab_biib_InterestInSubsidiary_85A64598858CA72579F2FD6455B723C9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest in subsidiary (less than given percentage)</link:label>
    <link:label id="lab_biib_InterestInSubsidiary_85A64598858CA72579F2FD6455B723C9_label_en-US" xlink:label="lab_biib_InterestInSubsidiary_85A64598858CA72579F2FD6455B723C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest In Subsidiary</link:label>
    <link:label id="lab_biib_InterestInSubsidiary_85A64598858CA72579F2FD6455B723C9_documentation_en-US" xlink:label="lab_biib_InterestInSubsidiary_85A64598858CA72579F2FD6455B723C9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest in subsidiary.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_InterestInSubsidiary" xlink:label="loc_biib_InterestInSubsidiary_85A64598858CA72579F2FD6455B723C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InterestInSubsidiary_85A64598858CA72579F2FD6455B723C9" xlink:to="lab_biib_InterestInSubsidiary_85A64598858CA72579F2FD6455B723C9" xlink:type="arc" />
    <link:label id="lab_biib_PaymentTermsOfAccountsReceivable_3024DF3BCF6143708E66FD6455B72294_verboseLabel_en-US" xlink:label="lab_biib_PaymentTermsOfAccountsReceivable_3024DF3BCF6143708E66FD6455B72294" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Payment terms of accounts receivable arising from product sales</link:label>
    <link:label id="lab_biib_PaymentTermsOfAccountsReceivable_3024DF3BCF6143708E66FD6455B72294_label_en-US" xlink:label="lab_biib_PaymentTermsOfAccountsReceivable_3024DF3BCF6143708E66FD6455B72294" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment Terms Of Accounts Receivable</link:label>
    <link:label id="lab_biib_PaymentTermsOfAccountsReceivable_3024DF3BCF6143708E66FD6455B72294_documentation_en-US" xlink:label="lab_biib_PaymentTermsOfAccountsReceivable_3024DF3BCF6143708E66FD6455B72294" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payment  terms of accounts receivable.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_PaymentTermsOfAccountsReceivable" xlink:label="loc_biib_PaymentTermsOfAccountsReceivable_3024DF3BCF6143708E66FD6455B72294" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PaymentTermsOfAccountsReceivable_3024DF3BCF6143708E66FD6455B72294" xlink:to="lab_biib_PaymentTermsOfAccountsReceivable_3024DF3BCF6143708E66FD6455B72294" xlink:type="arc" />
    <link:label id="lab_biib_EstimatedUsefulLivesOfLeaseholdImprovements_870271B4C148845B3851FD6455B7D37D_terseLabel_en-US" xlink:label="lab_biib_EstimatedUsefulLivesOfLeaseholdImprovements_870271B4C148845B3851FD6455B7D37D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated useful lives of leasehold improvements</link:label>
    <link:label id="lab_biib_EstimatedUsefulLivesOfLeaseholdImprovements_870271B4C148845B3851FD6455B7D37D_label_en-US" xlink:label="lab_biib_EstimatedUsefulLivesOfLeaseholdImprovements_870271B4C148845B3851FD6455B7D37D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated Useful Lives Of Leasehold Improvements</link:label>
    <link:label id="lab_biib_EstimatedUsefulLivesOfLeaseholdImprovements_870271B4C148845B3851FD6455B7D37D_documentation_en-US" xlink:label="lab_biib_EstimatedUsefulLivesOfLeaseholdImprovements_870271B4C148845B3851FD6455B7D37D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Estimated useful lives of leasehold improvements.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_EstimatedUsefulLivesOfLeaseholdImprovements" xlink:label="loc_biib_EstimatedUsefulLivesOfLeaseholdImprovements_870271B4C148845B3851FD6455B7D37D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EstimatedUsefulLivesOfLeaseholdImprovements_870271B4C148845B3851FD6455B7D37D" xlink:to="lab_biib_EstimatedUsefulLivesOfLeaseholdImprovements_870271B4C148845B3851FD6455B7D37D" xlink:type="arc" />
    <link:label id="lab_biib_PurchasePriceOfCommonStockUnderEspp_87CAB256082CBC5D11F2FD6455B72CF3_terseLabel_en-US" xlink:label="lab_biib_PurchasePriceOfCommonStockUnderEspp_87CAB256082CBC5D11F2FD6455B72CF3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase price of common stock under ESPP</link:label>
    <link:label id="lab_biib_PurchasePriceOfCommonStockUnderEspp_87CAB256082CBC5D11F2FD6455B72CF3_label_en-US" xlink:label="lab_biib_PurchasePriceOfCommonStockUnderEspp_87CAB256082CBC5D11F2FD6455B72CF3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Price Of Common Stock Under ESPP</link:label>
    <link:label id="lab_biib_PurchasePriceOfCommonStockUnderEspp_87CAB256082CBC5D11F2FD6455B72CF3_documentation_en-US" xlink:label="lab_biib_PurchasePriceOfCommonStockUnderEspp_87CAB256082CBC5D11F2FD6455B72CF3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Purchase Price Of Common Stock Under ESPP.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_PurchasePriceOfCommonStockUnderEspp" xlink:label="loc_biib_PurchasePriceOfCommonStockUnderEspp_87CAB256082CBC5D11F2FD6455B72CF3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PurchasePriceOfCommonStockUnderEspp_87CAB256082CBC5D11F2FD6455B72CF3" xlink:to="lab_biib_PurchasePriceOfCommonStockUnderEspp_87CAB256082CBC5D11F2FD6455B72CF3" xlink:type="arc" />
    <link:label id="lab_biib_PercentageOfMarketValuePerShareOfCommonStock_17F2E1E1E771AC0D430EFD6455B759F7_terseLabel_en-US" xlink:label="lab_biib_PercentageOfMarketValuePerShareOfCommonStock_17F2E1E1E771AC0D430EFD6455B759F7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of market value per share of common stock</link:label>
    <link:label id="lab_biib_PercentageOfMarketValuePerShareOfCommonStock_17F2E1E1E771AC0D430EFD6455B759F7_label_en-US" xlink:label="lab_biib_PercentageOfMarketValuePerShareOfCommonStock_17F2E1E1E771AC0D430EFD6455B759F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Market Value Per Share Of Common Stock</link:label>
    <link:label id="lab_biib_PercentageOfMarketValuePerShareOfCommonStock_17F2E1E1E771AC0D430EFD6455B759F7_documentation_en-US" xlink:label="lab_biib_PercentageOfMarketValuePerShareOfCommonStock_17F2E1E1E771AC0D430EFD6455B759F7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of market value per share of common stock.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_PercentageOfMarketValuePerShareOfCommonStock" xlink:label="loc_biib_PercentageOfMarketValuePerShareOfCommonStock_17F2E1E1E771AC0D430EFD6455B759F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageOfMarketValuePerShareOfCommonStock_17F2E1E1E771AC0D430EFD6455B759F7" xlink:to="lab_biib_PercentageOfMarketValuePerShareOfCommonStock_17F2E1E1E771AC0D430EFD6455B759F7" xlink:type="arc" />
    <link:label id="lab_biib_CompensationExpenseOverPurchasePeriod_B91C5A91FFCE90C1D2F8FD6455B7AB5A_terseLabel_en-US" xlink:label="lab_biib_CompensationExpenseOverPurchasePeriod_B91C5A91FFCE90C1D2F8FD6455B7AB5A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation expense over purchase period</link:label>
    <link:label id="lab_biib_CompensationExpenseOverPurchasePeriod_B91C5A91FFCE90C1D2F8FD6455B7AB5A_label_en-US" xlink:label="lab_biib_CompensationExpenseOverPurchasePeriod_B91C5A91FFCE90C1D2F8FD6455B7AB5A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Expense Over Purchase Period</link:label>
    <link:label id="lab_biib_CompensationExpenseOverPurchasePeriod_B91C5A91FFCE90C1D2F8FD6455B7AB5A_documentation_en-US" xlink:label="lab_biib_CompensationExpenseOverPurchasePeriod_B91C5A91FFCE90C1D2F8FD6455B7AB5A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Compensation expense over purchase period.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_CompensationExpenseOverPurchasePeriod" xlink:label="loc_biib_CompensationExpenseOverPurchasePeriod_B91C5A91FFCE90C1D2F8FD6455B7AB5A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CompensationExpenseOverPurchasePeriod_B91C5A91FFCE90C1D2F8FD6455B7AB5A" xlink:to="lab_biib_CompensationExpenseOverPurchasePeriod_B91C5A91FFCE90C1D2F8FD6455B7AB5A" xlink:type="arc" />
    <link:label id="lab_biib_DiscountRateRecognizedInCompensationExpense_B868EDE20548C7CC7946FD6455B7657C_terseLabel_en-US" xlink:label="lab_biib_DiscountRateRecognizedInCompensationExpense_B868EDE20548C7CC7946FD6455B7657C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discount rate recognized in compensation expense</link:label>
    <link:label id="lab_biib_DiscountRateRecognizedInCompensationExpense_B868EDE20548C7CC7946FD6455B7657C_label_en-US" xlink:label="lab_biib_DiscountRateRecognizedInCompensationExpense_B868EDE20548C7CC7946FD6455B7657C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discount Rate Recognized In Compensation Expense</link:label>
    <link:label id="lab_biib_DiscountRateRecognizedInCompensationExpense_B868EDE20548C7CC7946FD6455B7657C_documentation_en-US" xlink:label="lab_biib_DiscountRateRecognizedInCompensationExpense_B868EDE20548C7CC7946FD6455B7657C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Discount rate recognized in compensation expense.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_DiscountRateRecognizedInCompensationExpense" xlink:label="loc_biib_DiscountRateRecognizedInCompensationExpense_B868EDE20548C7CC7946FD6455B7657C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DiscountRateRecognizedInCompensationExpense_B868EDE20548C7CC7946FD6455B7657C" xlink:to="lab_biib_DiscountRateRecognizedInCompensationExpense_B868EDE20548C7CC7946FD6455B7657C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdvertisingExpense_E4F0DE0E609A8569A20AFD6455B7ABF8_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingExpense_E4F0DE0E609A8569A20AFD6455B7ABF8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Advertising costs</link:label>
    <link:label id="lab_us-gaap_AdvertisingExpense_E4F0DE0E609A8569A20AFD6455B7ABF8_label_en-US" xlink:label="lab_us-gaap_AdvertisingExpense_E4F0DE0E609A8569A20AFD6455B7ABF8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advertising Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdvertisingExpense" xlink:label="loc_us-gaap_AdvertisingExpense_E4F0DE0E609A8569A20AFD6455B7ABF8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingExpense_E4F0DE0E609A8569A20AFD6455B7ABF8" xlink:to="lab_us-gaap_AdvertisingExpense_E4F0DE0E609A8569A20AFD6455B7ABF8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_F22B8E0CDA4C75DE58FA7412860F7902_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_F22B8E0CDA4C75DE58FA7412860F7902" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:label id="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_F22B8E0CDA4C75DE58FA7412860F7902_label_en-US" xlink:label="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_F22B8E0CDA4C75DE58FA7412860F7902" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_F22B8E0CDA4C75DE58FA7412860F7902" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_F22B8E0CDA4C75DE58FA7412860F7902" xlink:to="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_F22B8E0CDA4C75DE58FA7412860F7902" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_6C3AEB43EC27BF0E6E597412860FA81D_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_6C3AEB43EC27BF0E6E597412860FA81D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_6C3AEB43EC27BF0E6E597412860FA81D_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_6C3AEB43EC27BF0E6E597412860FA81D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_6C3AEB43EC27BF0E6E597412860FA81D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_6C3AEB43EC27BF0E6E597412860FA81D" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_6C3AEB43EC27BF0E6E597412860FA81D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_2E67798B5F6F9E086F7C7412860FFF43_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain_2E67798B5F6F9E086F7C7412860FFF43" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation Allowances and Reserves [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_2E67798B5F6F9E086F7C7412860FFF43_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain_2E67798B5F6F9E086F7C7412860FFF43" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_2E67798B5F6F9E086F7C7412860FFF43" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_2E67798B5F6F9E086F7C7412860FFF43" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain_2E67798B5F6F9E086F7C7412860FFF43" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReserveForCashDiscountMember_BC7C0170ACC231ACADD97412860F2087_verboseLabel_en-US" xlink:label="lab_us-gaap_ReserveForCashDiscountMember_BC7C0170ACC231ACADD97412860F2087" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Discounts</link:label>
    <link:label id="lab_us-gaap_ReserveForCashDiscountMember_BC7C0170ACC231ACADD97412860F2087_label_en-US" xlink:label="lab_us-gaap_ReserveForCashDiscountMember_BC7C0170ACC231ACADD97412860F2087" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reserve for Cash Discount [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReserveForCashDiscountMember" xlink:label="loc_us-gaap_ReserveForCashDiscountMember_BC7C0170ACC231ACADD97412860F2087" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReserveForCashDiscountMember_BC7C0170ACC231ACADD97412860F2087" xlink:to="lab_us-gaap_ReserveForCashDiscountMember_BC7C0170ACC231ACADD97412860F2087" xlink:type="arc" />
    <link:label id="lab_biib_ContractualAdjustmentsMember_760BA8657469537B49AD7412860F41A4_verboseLabel_en-US" xlink:label="lab_biib_ContractualAdjustmentsMember_760BA8657469537B49AD7412860F41A4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Contractual Adjustments</link:label>
    <link:label id="lab_biib_ContractualAdjustmentsMember_760BA8657469537B49AD7412860F41A4_label_en-US" xlink:label="lab_biib_ContractualAdjustmentsMember_760BA8657469537B49AD7412860F41A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual Adjustments [Member]</link:label>
    <link:label id="lab_biib_ContractualAdjustmentsMember_760BA8657469537B49AD7412860F41A4_documentation_en-US" xlink:label="lab_biib_ContractualAdjustmentsMember_760BA8657469537B49AD7412860F41A4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contractual adjustments.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_ContractualAdjustmentsMember" xlink:label="loc_biib_ContractualAdjustmentsMember_760BA8657469537B49AD7412860F41A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ContractualAdjustmentsMember_760BA8657469537B49AD7412860F41A4" xlink:to="lab_biib_ContractualAdjustmentsMember_760BA8657469537B49AD7412860F41A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesReturnsAndAllowancesMember_FE0DC58AD709CDABE5C27412860FACFA_verboseLabel_en-US" xlink:label="lab_us-gaap_SalesReturnsAndAllowancesMember_FE0DC58AD709CDABE5C27412860FACFA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Returns</link:label>
    <link:label id="lab_us-gaap_SalesReturnsAndAllowancesMember_FE0DC58AD709CDABE5C27412860FACFA_label_en-US" xlink:label="lab_us-gaap_SalesReturnsAndAllowancesMember_FE0DC58AD709CDABE5C27412860FACFA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Returns and Allowances [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember_FE0DC58AD709CDABE5C27412860FACFA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesReturnsAndAllowancesMember_FE0DC58AD709CDABE5C27412860FACFA" xlink:to="lab_us-gaap_SalesReturnsAndAllowancesMember_FE0DC58AD709CDABE5C27412860FACFA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_C97D500E00A90B8F27387412860F9DDB_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_C97D500E00A90B8F27387412860F9DDB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_C97D500E00A90B8F27387412860F9DDB_label_en-US" xlink:label="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_C97D500E00A90B8F27387412860F9DDB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_C97D500E00A90B8F27387412860F9DDB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_C97D500E00A90B8F27387412860F9DDB" xlink:to="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_C97D500E00A90B8F27387412860F9DDB" xlink:type="arc" />
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_518129311F902B2564A67412860F3F49_verboseLabel_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_518129311F902B2564A67412860F3F49" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Analysis of the amount of, and change in, reserves</link:label>
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_518129311F902B2564A67412860F3F49_label_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_518129311F902B2564A67412860F3F49" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Analysis Of Amount Of And Change In Product Revenue Reserves [Abstract]</link:label>
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_518129311F902B2564A67412860F3F49_documentation_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_518129311F902B2564A67412860F3F49" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Analysis of the amount of, and change in product revenue reserves.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract" xlink:label="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_518129311F902B2564A67412860F3F49" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_518129311F902B2564A67412860F3F49" xlink:to="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_518129311F902B2564A67412860F3F49" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_0AB80A908396C2913C477412860FEFA8_periodStartLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance_0AB80A908396C2913C477412860FEFA8" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_0AB80A908396C2913C477412860FEFA8_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance_0AB80A908396C2913C477412860FEFA8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowances and Reserves, Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_0AB80A908396C2913C477412860FEFA8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance_0AB80A908396C2913C477412860FEFA8" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance_0AB80A908396C2913C477412860FEFA8" xlink:type="arc" />
    <link:label id="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_70C3699B3A02F341F710741286109150_verboseLabel_en-US" xlink:label="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_70C3699B3A02F341F710741286109150" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current provisions relating to sales in current year</link:label>
    <link:label id="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_70C3699B3A02F341F710741286109150_label_en-US" xlink:label="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_70C3699B3A02F341F710741286109150" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Provisions To Product Revenue Reserves Relating To Sales In Current Year</link:label>
    <link:label id="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_70C3699B3A02F341F710741286109150_documentation_en-US" xlink:label="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_70C3699B3A02F341F710741286109150" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Current provisions to product revenue reserves relating to sales in current year.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:label="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_70C3699B3A02F341F710741286109150" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_70C3699B3A02F341F710741286109150" xlink:to="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_70C3699B3A02F341F710741286109150" xlink:type="arc" />
    <link:label id="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_569B038F3DDF3940872374128610336B_negatedLabel_en-US" xlink:label="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_569B038F3DDF3940872374128610336B" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Adjustments relating to prior years</link:label>
    <link:label id="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_569B038F3DDF3940872374128610336B_label_en-US" xlink:label="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_569B038F3DDF3940872374128610336B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments To Product Revenue Reserves Relating To Sales In Prior Years</link:label>
    <link:label id="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_569B038F3DDF3940872374128610336B_documentation_en-US" xlink:label="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_569B038F3DDF3940872374128610336B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments to product revenue reserves relating to sales in prior years.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:label="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_569B038F3DDF3940872374128610336B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_569B038F3DDF3940872374128610336B" xlink:to="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_569B038F3DDF3940872374128610336B" xlink:type="arc" />
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_54882D79CC37482823DD74128610D2CB_negatedLabel_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_54882D79CC37482823DD74128610D2CB" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments/returns relating to sales in current year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_54882D79CC37482823DD74128610D2CB_label_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_54882D79CC37482823DD74128610D2CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments Returns Applied Against Product Revenue Reserves Relating To Current Year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_54882D79CC37482823DD74128610D2CB_documentation_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_54882D79CC37482823DD74128610D2CB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments/ returns applied against product revenue reserves relating to current year.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_54882D79CC37482823DD74128610D2CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_54882D79CC37482823DD74128610D2CB" xlink:to="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_54882D79CC37482823DD74128610D2CB" xlink:type="arc" />
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_389E80FE308C3DC0B06074128610C2A1_negatedLabel_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_389E80FE308C3DC0B06074128610C2A1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments/returns relating to sales in prior years</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_389E80FE308C3DC0B06074128610C2A1_label_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_389E80FE308C3DC0B06074128610C2A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments Returns Applied Against Product Revenue Reserves Relating To Prior Year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_389E80FE308C3DC0B06074128610C2A1_documentation_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_389E80FE308C3DC0B06074128610C2A1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments/ returns applied against product revenue reserves relating to prior year.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_389E80FE308C3DC0B06074128610C2A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_389E80FE308C3DC0B06074128610C2A1" xlink:to="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_389E80FE308C3DC0B06074128610C2A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_C55244427442ED04BFD7741286105CC5_periodEndLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance_C55244427442ED04BFD7741286105CC5" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_C55244427442ED04BFD7741286105CC5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance_C55244427442ED04BFD7741286105CC5" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance_C55244427442ED04BFD7741286105CC5" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_9516F4B18AC4C884EF307412858BA364_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract_9516F4B18AC4C884EF307412858BA364" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_9516F4B18AC4C884EF307412858BA364" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract_9516F4B18AC4C884EF307412858BA364" xlink:to="lab_us-gaap_DebtDisclosureAbstract_9516F4B18AC4C884EF307412858BA364" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_37EC383BF4A289CFD77F7412858B5CE5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock_37EC383BF4A289CFD77F7412858B5CE5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Indebtedness</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_37EC383BF4A289CFD77F7412858B5CE5_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock_37EC383BF4A289CFD77F7412858B5CE5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Debt [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_37EC383BF4A289CFD77F7412858B5CE5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock_37EC383BF4A289CFD77F7412858B5CE5" xlink:to="lab_us-gaap_ScheduleOfDebtTableTextBlock_37EC383BF4A289CFD77F7412858B5CE5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_CB335014BEB5A8D720207412858BF906_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_CB335014BEB5A8D720207412858BF906" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total debt maturities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_CB335014BEB5A8D720207412858BF906_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_CB335014BEB5A8D720207412858BF906" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_CB335014BEB5A8D720207412858BF906" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_CB335014BEB5A8D720207412858BF906" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_CB335014BEB5A8D720207412858BF906" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementTable_427F5F77EB7F27AC13F77412856B5E0B_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable_427F5F77EB7F27AC13F77412856B5E0B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_427F5F77EB7F27AC13F77412856B5E0B_label_en-US" xlink:label="lab_us-gaap_StatementTable_427F5F77EB7F27AC13F77412856B5E0B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_427F5F77EB7F27AC13F77412856B5E0B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_427F5F77EB7F27AC13F77412856B5E0B" xlink:to="lab_us-gaap_StatementTable_427F5F77EB7F27AC13F77412856B5E0B" xlink:type="arc" />
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_6661E1B537003DFBEDE97412856BB501_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis_6661E1B537003DFBEDE97412856BB501" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_6661E1B537003DFBEDE97412856BB501_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis_6661E1B537003DFBEDE97412856BB501" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_6661E1B537003DFBEDE97412856BB501" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_6661E1B537003DFBEDE97412856BB501" xlink:to="lab_us-gaap_BalanceSheetLocationAxis_6661E1B537003DFBEDE97412856BB501" xlink:type="arc" />
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_C8BE19C77706966D6F427412856B97F2_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain_C8BE19C77706966D6F427412856B97F2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_C8BE19C77706966D6F427412856B97F2_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain_C8BE19C77706966D6F427412856B97F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_C8BE19C77706966D6F427412856B97F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_C8BE19C77706966D6F427412856B97F2" xlink:to="lab_us-gaap_BalanceSheetLocationDomain_C8BE19C77706966D6F427412856B97F2" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableMember_201986558ECDB33345607412856B30B6_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember_201986558ECDB33345607412856B30B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reduction of accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_201986558ECDB33345607412856B30B6_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember_201986558ECDB33345607412856B30B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_201986558ECDB33345607412856B30B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember_201986558ECDB33345607412856B30B6" xlink:to="lab_us-gaap_AccountsReceivableMember_201986558ECDB33345607412856B30B6" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_9F3EAFCAECEBF769D40E7412856B5086_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember_9F3EAFCAECEBF769D40E7412856B5086" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Component of accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_9F3EAFCAECEBF769D40E7412856B5086_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember_9F3EAFCAECEBF769D40E7412856B5086" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Current Liabilities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_9F3EAFCAECEBF769D40E7412856B5086" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesMember_9F3EAFCAECEBF769D40E7412856B5086" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesMember_9F3EAFCAECEBF769D40E7412856B5086" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementLineItems_E4AE9B8C3471305904FE7412856BCC04_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems_E4AE9B8C3471305904FE7412856BCC04" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_E4AE9B8C3471305904FE7412856BCC04_label_en-US" xlink:label="lab_us-gaap_StatementLineItems_E4AE9B8C3471305904FE7412856BCC04" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_E4AE9B8C3471305904FE7412856BCC04" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_E4AE9B8C3471305904FE7412856BCC04" xlink:to="lab_us-gaap_StatementLineItems_E4AE9B8C3471305904FE7412856BCC04" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_2E891048FD0FC444334C7412856B5C92_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance_2E891048FD0FC444334C7412856B5C92" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_2E891048FD0FC444334C7412856B5C92" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance_2E891048FD0FC444334C7412856B5C92" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance_2E891048FD0FC444334C7412856B5C92" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_50EAD4201C713231F55774128862917E_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_50EAD4201C713231F55774128862917E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of Contractual Maturities: Available-for-Sale Securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_50EAD4201C713231F55774128862917E_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_50EAD4201C713231F55774128862917E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Debt Maturities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_50EAD4201C713231F55774128862917E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_50EAD4201C713231F55774128862917E" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_50EAD4201C713231F55774128862917E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_9BD61D05DD67F66FC9827412886207AD_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_9BD61D05DD67F66FC9827412886207AD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due in one year or less, Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_9BD61D05DD67F66FC9827412886207AD_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_9BD61D05DD67F66FC9827412886207AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Debt Maturities, Next Twelve Months, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_9BD61D05DD67F66FC9827412886207AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_9BD61D05DD67F66FC9827412886207AD" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_9BD61D05DD67F66FC9827412886207AD" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_717EFF9F6109710071FD74128862009B_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_717EFF9F6109710071FD74128862009B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due in one year or less, Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_717EFF9F6109710071FD74128862009B_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_717EFF9F6109710071FD74128862009B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Debt Maturities, Next Twelve Months, Amortized Cost Basis</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_717EFF9F6109710071FD74128862009B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_717EFF9F6109710071FD74128862009B" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_717EFF9F6109710071FD74128862009B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_CAE91BAF5177044AD5D4741288625D39_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_CAE91BAF5177044AD5D4741288625D39" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due after one year through five years, Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_CAE91BAF5177044AD5D4741288625D39_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_CAE91BAF5177044AD5D4741288625D39" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Debt Maturities, Year Two Through Five, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_CAE91BAF5177044AD5D4741288625D39" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_CAE91BAF5177044AD5D4741288625D39" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_CAE91BAF5177044AD5D4741288625D39" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_0204508C72F04343FA0774128867FF95_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_0204508C72F04343FA0774128867FF95" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due after one year through five years, Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_0204508C72F04343FA0774128867FF95_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_0204508C72F04343FA0774128867FF95" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Debt Maturities, Year Two Through Five, Amortized Cost Basis</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_0204508C72F04343FA0774128867FF95" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_0204508C72F04343FA0774128867FF95" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_0204508C72F04343FA0774128867FF95" xlink:type="arc" />
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_50466D71A427E88FF92F741288683A67_verboseLabel_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_50466D71A427E88FF92F741288683A67" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due after five years, Estimated Fair Value</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_50466D71A427E88FF92F741288683A67_label_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_50466D71A427E88FF92F741288683A67" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available For Sale Securities Debt Maturities After Five Years Fair Value</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_50466D71A427E88FF92F741288683A67_documentation_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_50466D71A427E88FF92F741288683A67" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This item represents the fair value of debt securities, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_50466D71A427E88FF92F741288683A67" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_50466D71A427E88FF92F741288683A67" xlink:to="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_50466D71A427E88FF92F741288683A67" xlink:type="arc" />
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_FBD1B5C6A46AF42C540274128868D9FA_verboseLabel_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_FBD1B5C6A46AF42C540274128868D9FA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due after five years, Amortized Cost</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_FBD1B5C6A46AF42C540274128868D9FA_label_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_FBD1B5C6A46AF42C540274128868D9FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available For Sale Securities Debt Maturities After Five Years Amortized Cost</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_FBD1B5C6A46AF42C540274128868D9FA_documentation_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_FBD1B5C6A46AF42C540274128868D9FA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This item represents debt securities, at cost, net of adjustments made for accretion, amortization, other-than-temporary impairments, and hedging, if any, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_FBD1B5C6A46AF42C540274128868D9FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_FBD1B5C6A46AF42C540274128868D9FA" xlink:to="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_FBD1B5C6A46AF42C540274128868D9FA" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_1DB87E3F612961436103741288687D1A_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities_1DB87E3F612961436103741288687D1A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total available-for-sale securities, Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_1DB87E3F612961436103741288687D1A_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities_1DB87E3F612961436103741288687D1A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_1DB87E3F612961436103741288687D1A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecurities_1DB87E3F612961436103741288687D1A" xlink:to="lab_us-gaap_AvailableForSaleSecurities_1DB87E3F612961436103741288687D1A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_B0EAD00535E14A301F2474128868A766_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_B0EAD00535E14A301F2474128868A766" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total available-for-sale securities, Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_B0EAD00535E14A301F2474128868A766_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_B0EAD00535E14A301F2474128868A766" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Debt Securities, Amortized Cost Basis</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_B0EAD00535E14A301F2474128868A766" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_B0EAD00535E14A301F2474128868A766" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_B0EAD00535E14A301F2474128868A766" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProductOrServiceAxis_47591CCE961B7B438163FCCBDB49034F_terseLabel_en-US" xlink:label="lab_us-gaap_ProductOrServiceAxis_47591CCE961B7B438163FCCBDB49034F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Products and Services [Axis]</link:label>
    <link:label id="lab_us-gaap_ProductOrServiceAxis_47591CCE961B7B438163FCCBDB49034F_label_en-US" xlink:label="lab_us-gaap_ProductOrServiceAxis_47591CCE961B7B438163FCCBDB49034F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products and Services [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_47591CCE961B7B438163FCCBDB49034F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductOrServiceAxis_47591CCE961B7B438163FCCBDB49034F" xlink:to="lab_us-gaap_ProductOrServiceAxis_47591CCE961B7B438163FCCBDB49034F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProductsAndServicesDomain_EFCB5161C79B50A0AEFCFCCBDB49409F_terseLabel_en-US" xlink:label="lab_us-gaap_ProductsAndServicesDomain_EFCB5161C79B50A0AEFCFCCBDB49409F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Products and Services [Domain]</link:label>
    <link:label id="lab_us-gaap_ProductsAndServicesDomain_EFCB5161C79B50A0AEFCFCCBDB49409F_label_en-US" xlink:label="lab_us-gaap_ProductsAndServicesDomain_EFCB5161C79B50A0AEFCFCCBDB49409F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products and Services [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_EFCB5161C79B50A0AEFCFCCBDB49409F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductsAndServicesDomain_EFCB5161C79B50A0AEFCFCCBDB49409F" xlink:to="lab_us-gaap_ProductsAndServicesDomain_EFCB5161C79B50A0AEFCFCCBDB49409F" xlink:type="arc" />
    <link:label id="lab_biib_GAZYVAMember_366E910026E23722C08CFCCBDB4A6306_terseLabel_en-US" xlink:label="lab_biib_GAZYVAMember_366E910026E23722C08CFCCBDB4A6306" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GAZYVA</link:label>
    <link:label id="lab_biib_GAZYVAMember_366E910026E23722C08CFCCBDB4A6306_label_en-US" xlink:label="lab_biib_GAZYVAMember_366E910026E23722C08CFCCBDB4A6306" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">GAZYVA [Member]</link:label>
    <link:label id="lab_biib_GAZYVAMember_366E910026E23722C08CFCCBDB4A6306_documentation_en-US" xlink:label="lab_biib_GAZYVAMember_366E910026E23722C08CFCCBDB4A6306" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">GAZYVA [Member]</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_GAZYVAMember" xlink:label="loc_biib_GAZYVAMember_366E910026E23722C08CFCCBDB4A6306" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GAZYVAMember_366E910026E23722C08CFCCBDB4A6306" xlink:to="lab_biib_GAZYVAMember_366E910026E23722C08CFCCBDB4A6306" xlink:type="arc" />
    <link:label id="lab_biib_RituxanMember_0941647EFD7572C0F09FFCCBDB4AA9B6_verboseLabel_en-US" xlink:label="lab_biib_RituxanMember_0941647EFD7572C0F09FFCCBDB4AA9B6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">RITUXAN</link:label>
    <link:label id="lab_biib_RituxanMember_0941647EFD7572C0F09FFCCBDB4AA9B6_label_en-US" xlink:label="lab_biib_RituxanMember_0941647EFD7572C0F09FFCCBDB4AA9B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">RITUXAN [Member]</link:label>
    <link:label id="lab_biib_RituxanMember_0941647EFD7572C0F09FFCCBDB4AA9B6_documentation_en-US" xlink:label="lab_biib_RituxanMember_0941647EFD7572C0F09FFCCBDB4AA9B6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">RITUXAN.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_RituxanMember" xlink:label="loc_biib_RituxanMember_0941647EFD7572C0F09FFCCBDB4AA9B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RituxanMember_0941647EFD7572C0F09FFCCBDB4AA9B6" xlink:to="lab_biib_RituxanMember_0941647EFD7572C0F09FFCCBDB4AA9B6" xlink:type="arc" />
    <link:label id="lab_biib_RocheGroupGenentechMember_D5B2104DFD28235DF39DFCCBDB4A88BD_verboseLabel_en-US" xlink:label="lab_biib_RocheGroupGenentechMember_D5B2104DFD28235DF39DFCCBDB4A88BD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Roche Group - Genentech</link:label>
    <link:label id="lab_biib_RocheGroupGenentechMember_D5B2104DFD28235DF39DFCCBDB4A88BD_label_en-US" xlink:label="lab_biib_RocheGroupGenentechMember_D5B2104DFD28235DF39DFCCBDB4A88BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Roche Group Genentech Member</link:label>
    <link:label id="lab_biib_RocheGroupGenentechMember_D5B2104DFD28235DF39DFCCBDB4A88BD_documentation_en-US" xlink:label="lab_biib_RocheGroupGenentechMember_D5B2104DFD28235DF39DFCCBDB4A88BD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Roche group Genentech.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_RocheGroupGenentechMember" xlink:label="loc_biib_RocheGroupGenentechMember_D5B2104DFD28235DF39DFCCBDB4A88BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RocheGroupGenentechMember_D5B2104DFD28235DF39DFCCBDB4A88BD" xlink:to="lab_biib_RocheGroupGenentechMember_D5B2104DFD28235DF39DFCCBDB4A88BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementGeographicalAxis_153324260F611F59A15BFCCBDB4AB71E_terseLabel_en-US" xlink:label="lab_us-gaap_StatementGeographicalAxis_153324260F611F59A15BFCCBDB4AB71E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementGeographicalAxis_153324260F611F59A15BFCCBDB4AB71E_label_en-US" xlink:label="lab_us-gaap_StatementGeographicalAxis_153324260F611F59A15BFCCBDB4AB71E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_153324260F611F59A15BFCCBDB4AB71E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementGeographicalAxis_153324260F611F59A15BFCCBDB4AB71E" xlink:to="lab_us-gaap_StatementGeographicalAxis_153324260F611F59A15BFCCBDB4AB71E" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentGeographicalDomain_A1F461703C20423626D2FCCBDB4A47B4_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentGeographicalDomain_A1F461703C20423626D2FCCBDB4A47B4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentGeographicalDomain_A1F461703C20423626D2FCCBDB4A47B4_label_en-US" xlink:label="lab_us-gaap_SegmentGeographicalDomain_A1F461703C20423626D2FCCBDB4A47B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_A1F461703C20423626D2FCCBDB4A47B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentGeographicalDomain_A1F461703C20423626D2FCCBDB4A47B4" xlink:to="lab_us-gaap_SegmentGeographicalDomain_A1F461703C20423626D2FCCBDB4A47B4" xlink:type="arc" />
    <link:label id="lab_country_US_E6AEAAA62A2D82DF6F5DFCCBDB4A317C_verboseLabel_en-US" xlink:label="lab_country_US_E6AEAAA62A2D82DF6F5DFCCBDB4A317C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">U.S</link:label>
    <link:label id="lab_country_US_E6AEAAA62A2D82DF6F5DFCCBDB4A317C_label_en-US" xlink:label="lab_country_US_E6AEAAA62A2D82DF6F5DFCCBDB4A317C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd#country_US" xlink:label="loc_country_US_E6AEAAA62A2D82DF6F5DFCCBDB4A317C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US_E6AEAAA62A2D82DF6F5DFCCBDB4A317C" xlink:to="lab_country_US_E6AEAAA62A2D82DF6F5DFCCBDB4A317C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCountryMember_1953C986A0F612DE3319FCCBDB4A6C62_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember_1953C986A0F612DE3319FCCBDB4A6C62" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Outside the U.S</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_1953C986A0F612DE3319FCCBDB4A6C62_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember_1953C986A0F612DE3319FCCBDB4A6C62" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember_1953C986A0F612DE3319FCCBDB4A6C62" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember_1953C986A0F612DE3319FCCBDB4A6C62" xlink:to="lab_us-gaap_ForeignCountryMember_1953C986A0F612DE3319FCCBDB4A6C62" xlink:type="arc" />
    <link:label id="lab_biib_CoPromotionProfitSharingFormulaAbstract_3B1573BD06472B7BFC56FCCBDB4AD84B_verboseLabel_en-US" xlink:label="lab_biib_CoPromotionProfitSharingFormulaAbstract_3B1573BD06472B7BFC56FCCBDB4AD84B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Co-promotion profit sharing formula</link:label>
    <link:label id="lab_biib_CoPromotionProfitSharingFormulaAbstract_3B1573BD06472B7BFC56FCCBDB4AD84B_label_en-US" xlink:label="lab_biib_CoPromotionProfitSharingFormulaAbstract_3B1573BD06472B7BFC56FCCBDB4AD84B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Co Promotion Profit Sharing Formula [Abstract]</link:label>
    <link:label id="lab_biib_CoPromotionProfitSharingFormulaAbstract_3B1573BD06472B7BFC56FCCBDB4AD84B_documentation_en-US" xlink:label="lab_biib_CoPromotionProfitSharingFormulaAbstract_3B1573BD06472B7BFC56FCCBDB4AD84B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Co-promotion profit sharing formula.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_CoPromotionProfitSharingFormulaAbstract" xlink:label="loc_biib_CoPromotionProfitSharingFormulaAbstract_3B1573BD06472B7BFC56FCCBDB4AD84B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CoPromotionProfitSharingFormulaAbstract_3B1573BD06472B7BFC56FCCBDB4AD84B" xlink:to="lab_biib_CoPromotionProfitSharingFormulaAbstract_3B1573BD06472B7BFC56FCCBDB4AD84B" xlink:type="arc" />
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_7D23513C0B1999CC70ABFCCBDB4AB38F_verboseLabel_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_7D23513C0B1999CC70ABFCCBDB4AB38F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Until GAZYVA First Non-CLL FDA Approval</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_7D23513C0B1999CC70ABFCCBDB4AB38F_label_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_7D23513C0B1999CC70ABFCCBDB4AB38F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option One</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_7D23513C0B1999CC70ABFCCBDB4AB38F_documentation_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_7D23513C0B1999CC70ABFCCBDB4AB38F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of co promotion operating profits greater than first fifty million option one.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_7D23513C0B1999CC70ABFCCBDB4AB38F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_7D23513C0B1999CC70ABFCCBDB4AB38F" xlink:to="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_7D23513C0B1999CC70ABFCCBDB4AB38F" xlink:type="arc" />
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_B5623F03315DCFF62C87FCCBDB4A53BC_verboseLabel_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_B5623F03315DCFF62C87FCCBDB4A53BC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">After First GA101 Threshold Date</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_B5623F03315DCFF62C87FCCBDB4A53BC_label_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_B5623F03315DCFF62C87FCCBDB4A53BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two [Abstract]</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_B5623F03315DCFF62C87FCCBDB4A53BC_documentation_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_B5623F03315DCFF62C87FCCBDB4A53BC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of co promotion operating profits greater than first fifty million option two.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_B5623F03315DCFF62C87FCCBDB4A53BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_B5623F03315DCFF62C87FCCBDB4A53BC" xlink:to="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_B5623F03315DCFF62C87FCCBDB4A53BC" xlink:type="arc" />
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_D1DBFD1A286513D8B20FFCCBDB4A5776_verboseLabel_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_D1DBFD1A286513D8B20FFCCBDB4A5776" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Until First GAZYVA Threshold Date</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_D1DBFD1A286513D8B20FFCCBDB4A5776_label_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_D1DBFD1A286513D8B20FFCCBDB4A5776" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Sub Option One</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_D1DBFD1A286513D8B20FFCCBDB4A5776_documentation_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_D1DBFD1A286513D8B20FFCCBDB4A5776" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of co promotion operating profits greater than first fifty million option two sub option one.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_D1DBFD1A286513D8B20FFCCBDB4A5776" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_D1DBFD1A286513D8B20FFCCBDB4A5776" xlink:to="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_D1DBFD1A286513D8B20FFCCBDB4A5776" xlink:type="arc" />
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_370B69E102EC9B2D5F53FCCBDB4BCE87_verboseLabel_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_370B69E102EC9B2D5F53FCCBDB4BCE87" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">After First Threshold Date and until Second Threshold Date</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_370B69E102EC9B2D5F53FCCBDB4BCE87_label_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_370B69E102EC9B2D5F53FCCBDB4BCE87" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Sub Option Two</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_370B69E102EC9B2D5F53FCCBDB4BCE87_documentation_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_370B69E102EC9B2D5F53FCCBDB4BCE87" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of co promotion operating profits greater than first fifty million option two sub option two.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_370B69E102EC9B2D5F53FCCBDB4BCE87" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_370B69E102EC9B2D5F53FCCBDB4BCE87" xlink:to="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_370B69E102EC9B2D5F53FCCBDB4BCE87" xlink:type="arc" />
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_560A019BE4B4229A8DA4FCCBDB4B51E2_verboseLabel_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_560A019BE4B4229A8DA4FCCBDB4B51E2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">After Second Threshold Date</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_560A019BE4B4229A8DA4FCCBDB4B51E2_label_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_560A019BE4B4229A8DA4FCCBDB4B51E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Sub Option Three</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_560A019BE4B4229A8DA4FCCBDB4B51E2_documentation_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_560A019BE4B4229A8DA4FCCBDB4B51E2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of co promotion operating profits greater than first fifty million option two sub option three.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_560A019BE4B4229A8DA4FCCBDB4B51E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_560A019BE4B4229A8DA4FCCBDB4B51E2" xlink:to="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_560A019BE4B4229A8DA4FCCBDB4B51E2" xlink:type="arc" />
    <link:label id="lab_biib_RevenuesFromUnconsolidatedJointBusinessAbstract_3E7405A87940B30E3C75FCCBDB4BAFBE_verboseLabel_en-US" xlink:label="lab_biib_RevenuesFromUnconsolidatedJointBusinessAbstract_3E7405A87940B30E3C75FCCBDB4BAFBE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenues from unconsolidated joint business</link:label>
    <link:label id="lab_biib_RevenuesFromUnconsolidatedJointBusinessAbstract_3E7405A87940B30E3C75FCCBDB4BAFBE_label_en-US" xlink:label="lab_biib_RevenuesFromUnconsolidatedJointBusinessAbstract_3E7405A87940B30E3C75FCCBDB4BAFBE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues From Unconsolidated Joint Business [Abstract]</link:label>
    <link:label id="lab_biib_RevenuesFromUnconsolidatedJointBusinessAbstract_3E7405A87940B30E3C75FCCBDB4BAFBE_documentation_en-US" xlink:label="lab_biib_RevenuesFromUnconsolidatedJointBusinessAbstract_3E7405A87940B30E3C75FCCBDB4BAFBE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenues from unconsolidated joint business.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_RevenuesFromUnconsolidatedJointBusinessAbstract" xlink:label="loc_biib_RevenuesFromUnconsolidatedJointBusinessAbstract_3E7405A87940B30E3C75FCCBDB4BAFBE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RevenuesFromUnconsolidatedJointBusinessAbstract_3E7405A87940B30E3C75FCCBDB4BAFBE" xlink:to="lab_biib_RevenuesFromUnconsolidatedJointBusinessAbstract_3E7405A87940B30E3C75FCCBDB4BAFBE" xlink:type="arc" />
    <link:label id="lab_biib_ShareOfCoPromotionProfits_7FDF39A1BF1023E1C467FCCBDB4B9065_verboseLabel_en-US" xlink:label="lab_biib_ShareOfCoPromotionProfits_7FDF39A1BF1023E1C467FCCBDB4B9065" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses</link:label>
    <link:label id="lab_biib_ShareOfCoPromotionProfits_7FDF39A1BF1023E1C467FCCBDB4B9065_label_en-US" xlink:label="lab_biib_ShareOfCoPromotionProfits_7FDF39A1BF1023E1C467FCCBDB4B9065" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Of Co Promotion Profits</link:label>
    <link:label id="lab_biib_ShareOfCoPromotionProfits_7FDF39A1BF1023E1C467FCCBDB4B9065_documentation_en-US" xlink:label="lab_biib_ShareOfCoPromotionProfits_7FDF39A1BF1023E1C467FCCBDB4B9065" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share of co promotion profits.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_ShareOfCoPromotionProfits" xlink:label="loc_biib_ShareOfCoPromotionProfits_7FDF39A1BF1023E1C467FCCBDB4B9065" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ShareOfCoPromotionProfits_7FDF39A1BF1023E1C467FCCBDB4B9065" xlink:to="lab_biib_ShareOfCoPromotionProfits_7FDF39A1BF1023E1C467FCCBDB4B9065" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesRevenueGoodsNet_1C8748C56E10DA39C733FCCBDB4B2743_verboseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueGoodsNet_1C8748C56E10DA39C733FCCBDB4B2743" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenue on sales in the rest of world for RITUXAN</link:label>
    <link:label id="lab_us-gaap_SalesRevenueGoodsNet_1C8748C56E10DA39C733FCCBDB4B2743_label_en-US" xlink:label="lab_us-gaap_SalesRevenueGoodsNet_1C8748C56E10DA39C733FCCBDB4B2743" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Revenue, Goods, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_1C8748C56E10DA39C733FCCBDB4B2743" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueGoodsNet_1C8748C56E10DA39C733FCCBDB4B2743" xlink:to="lab_us-gaap_SalesRevenueGoodsNet_1C8748C56E10DA39C733FCCBDB4B2743" xlink:type="arc" />
    <link:label id="lab_biib_RevenuesfromantiCD20therapeuticprograms_CB1F7B8A8C53BC5C114CFD0ABF103979_totalLabel_en-US" xlink:label="lab_biib_RevenuesfromantiCD20therapeuticprograms_CB1F7B8A8C53BC5C114CFD0ABF103979" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total revenues from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_RevenuesfromantiCD20therapeuticprograms_CB1F7B8A8C53BC5C114CFD0ABF103979_label_en-US" xlink:label="lab_biib_RevenuesfromantiCD20therapeuticprograms_CB1F7B8A8C53BC5C114CFD0ABF103979" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_RevenuesfromantiCD20therapeuticprograms_CB1F7B8A8C53BC5C114CFD0ABF103979_documentation_en-US" xlink:label="lab_biib_RevenuesfromantiCD20therapeuticprograms_CB1F7B8A8C53BC5C114CFD0ABF103979" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenues from anti-CD20 therapeutic programs consists of our share of pre-tax co-promotion profits in the U.S.; reimbursement of selling and development expense in the U.S.; and revenue on sales of RITUXAN outside the U.S., which consist of our share of pre-tax co-promotion profits in Canada.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_RevenuesfromantiCD20therapeuticprograms" xlink:label="loc_biib_RevenuesfromantiCD20therapeuticprograms_CB1F7B8A8C53BC5C114CFD0ABF103979" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RevenuesfromantiCD20therapeuticprograms_CB1F7B8A8C53BC5C114CFD0ABF103979" xlink:to="lab_biib_RevenuesfromantiCD20therapeuticprograms_CB1F7B8A8C53BC5C114CFD0ABF103979" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_28A1BB26CB8EB5805CD5741287D33F64_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract_28A1BB26CB8EB5805CD5741287D33F64" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_28A1BB26CB8EB5805CD5741287D33F64" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_28A1BB26CB8EB5805CD5741287D33F64" xlink:to="lab_us-gaap_InventoryDisclosureAbstract_28A1BB26CB8EB5805CD5741287D33F64" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNetAbstract_7638E650219C0D7BC906741287D3662E_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNetAbstract_7638E650219C0D7BC906741287D3662E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Components of inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNetAbstract_7638E650219C0D7BC906741287D3662E_label_en-US" xlink:label="lab_us-gaap_InventoryNetAbstract_7638E650219C0D7BC906741287D3662E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNetAbstract" xlink:label="loc_us-gaap_InventoryNetAbstract_7638E650219C0D7BC906741287D3662E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNetAbstract_7638E650219C0D7BC906741287D3662E" xlink:to="lab_us-gaap_InventoryNetAbstract_7638E650219C0D7BC906741287D3662E" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_51BDE1562471CCE8691F741287D37F78_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves_51BDE1562471CCE8691F741287D37F78" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_51BDE1562471CCE8691F741287D37F78_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves_51BDE1562471CCE8691F741287D37F78" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_51BDE1562471CCE8691F741287D37F78" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves_51BDE1562471CCE8691F741287D37F78" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves_51BDE1562471CCE8691F741287D37F78" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_27513D91F545418F1C48741287D38075_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves_27513D91F545418F1C48741287D38075" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_27513D91F545418F1C48741287D38075_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves_27513D91F545418F1C48741287D38075" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_27513D91F545418F1C48741287D38075" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves_27513D91F545418F1C48741287D38075" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves_27513D91F545418F1C48741287D38075" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_19AC6750A5A43A805F22741287D30B21_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_19AC6750A5A43A805F22741287D30B21" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_19AC6750A5A43A805F22741287D30B21_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_19AC6750A5A43A805F22741287D30B21" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_19AC6750A5A43A805F22741287D30B21" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_19AC6750A5A43A805F22741287D30B21" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_19AC6750A5A43A805F22741287D30B21" xlink:type="arc" />
    <link:label id="lab_biib_Inventorynetcurrentandnoncurrent_CCF031A5E78C60AEAD6D741287D36754_totalLabel_en-US" xlink:label="lab_biib_Inventorynetcurrentandnoncurrent_CCF031A5E78C60AEAD6D741287D36754" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total inventory</link:label>
    <link:label id="lab_biib_Inventorynetcurrentandnoncurrent_CCF031A5E78C60AEAD6D741287D36754_label_en-US" xlink:label="lab_biib_Inventorynetcurrentandnoncurrent_CCF031A5E78C60AEAD6D741287D36754" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, net current and noncurrent</link:label>
    <link:label id="lab_biib_Inventorynetcurrentandnoncurrent_CCF031A5E78C60AEAD6D741287D36754_documentation_en-US" xlink:label="lab_biib_Inventorynetcurrentandnoncurrent_CCF031A5E78C60AEAD6D741287D36754" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Inventory, net current and noncurrent</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_Inventorynetcurrentandnoncurrent" xlink:label="loc_biib_Inventorynetcurrentandnoncurrent_CCF031A5E78C60AEAD6D741287D36754" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Inventorynetcurrentandnoncurrent_CCF031A5E78C60AEAD6D741287D36754" xlink:to="lab_biib_Inventorynetcurrentandnoncurrent_CCF031A5E78C60AEAD6D741287D36754" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNet_A25D533272BCC66D806E741287D386CA_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet_A25D533272BCC66D806E741287D386CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, current</link:label>
    <link:label id="lab_us-gaap_InventoryNet_A25D533272BCC66D806E741287D386CA_label_en-US" xlink:label="lab_us-gaap_InventoryNet_A25D533272BCC66D806E741287D386CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_A25D533272BCC66D806E741287D386CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet_A25D533272BCC66D806E741287D386CA" xlink:to="lab_us-gaap_InventoryNet_A25D533272BCC66D806E741287D386CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNoncurrent_5852560715BFF17C5B46741287D3F0D2_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent_5852560715BFF17C5B46741287D3F0D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, noncurrent</link:label>
    <link:label id="lab_us-gaap_InventoryNoncurrent_5852560715BFF17C5B46741287D3F0D2_label_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent_5852560715BFF17C5B46741287D3F0D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNoncurrent" xlink:label="loc_us-gaap_InventoryNoncurrent_5852560715BFF17C5B46741287D3F0D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNoncurrent_5852560715BFF17C5B46741287D3F0D2" xlink:to="lab_us-gaap_InventoryNoncurrent_5852560715BFF17C5B46741287D3F0D2" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementAbstract_D34F471616F41BD6D58CFCCBDD5E76C5_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract_D34F471616F41BD6D58CFCCBDD5E76C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_D34F471616F41BD6D58CFCCBDD5E76C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_D34F471616F41BD6D58CFCCBDD5E76C5" xlink:to="lab_us-gaap_IncomeStatementAbstract_D34F471616F41BD6D58CFCCBDD5E76C5" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenuesAbstract_FCB0662899306CD6EB98FCCBDD5E32B6_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract_FCB0662899306CD6EB98FCCBDD5E32B6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_FCB0662899306CD6EB98FCCBDD5E32B6_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract_FCB0662899306CD6EB98FCCBDD5E32B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_FCB0662899306CD6EB98FCCBDD5E32B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract_FCB0662899306CD6EB98FCCBDD5E32B6" xlink:to="lab_us-gaap_RevenuesAbstract_FCB0662899306CD6EB98FCCBDD5E32B6" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesRevenueGoodsNet_9DFDD4F2C995A28FD2AFFCCBDD5E3297_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueGoodsNet_9DFDD4F2C995A28FD2AFFCCBDD5E3297" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product, net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_9DFDD4F2C995A28FD2AFFCCBDD5E3297" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueGoodsNet_9DFDD4F2C995A28FD2AFFCCBDD5E3297" xlink:to="lab_us-gaap_SalesRevenueGoodsNet_9DFDD4F2C995A28FD2AFFCCBDD5E3297" xlink:type="arc" />
    <link:label id="lab_biib_RevenuesfromantiCD20therapeuticprograms_6A24DDE376B18C2166B4FCE0F7BFC8DC_terseLabel_en-US" xlink:label="lab_biib_RevenuesfromantiCD20therapeuticprograms_6A24DDE376B18C2166B4FCE0F7BFC8DC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues from anti-CD20 therapeutic programs</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_RevenuesfromantiCD20therapeuticprograms" xlink:label="loc_biib_RevenuesfromantiCD20therapeuticprograms_6A24DDE376B18C2166B4FCE0F7BFC8DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RevenuesfromantiCD20therapeuticprograms_6A24DDE376B18C2166B4FCE0F7BFC8DC" xlink:to="lab_biib_RevenuesfromantiCD20therapeuticprograms_6A24DDE376B18C2166B4FCE0F7BFC8DC" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherSalesRevenueNet_527FB59A974B4F706400FCCBDD5EC604_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherSalesRevenueNet_527FB59A974B4F706400FCCBDD5EC604" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherSalesRevenueNet_527FB59A974B4F706400FCCBDD5EC604_label_en-US" xlink:label="lab_us-gaap_OtherSalesRevenueNet_527FB59A974B4F706400FCCBDD5EC604" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Revenue, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherSalesRevenueNet" xlink:label="loc_us-gaap_OtherSalesRevenueNet_527FB59A974B4F706400FCCBDD5EC604" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherSalesRevenueNet_527FB59A974B4F706400FCCBDD5EC604" xlink:to="lab_us-gaap_OtherSalesRevenueNet_527FB59A974B4F706400FCCBDD5EC604" xlink:type="arc" />
    <link:label id="lab_us-gaap_Revenues_A939D15791375375C38DFCCBDD5F974F_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues_A939D15791375375C38DFCCBDD5F974F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_A939D15791375375C38DFCCBDD5F974F_label_en-US" xlink:label="lab_us-gaap_Revenues_A939D15791375375C38DFCCBDD5F974F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_A939D15791375375C38DFCCBDD5F974F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_A939D15791375375C38DFCCBDD5F974F" xlink:to="lab_us-gaap_Revenues_A939D15791375375C38DFCCBDD5F974F" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_FD93560E4CE731EA26ADFCCBDD5FCBF5_verboseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract_FD93560E4CE731EA26ADFCCBDD5FCBF5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cost and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_FD93560E4CE731EA26ADFCCBDD5FCBF5_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract_FD93560E4CE731EA26ADFCCBDD5FCBF5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_FD93560E4CE731EA26ADFCCBDD5FCBF5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_FD93560E4CE731EA26ADFCCBDD5FCBF5" xlink:to="lab_us-gaap_CostsAndExpensesAbstract_FD93560E4CE731EA26ADFCCBDD5FCBF5" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostOfGoodsSold_F5910B16AF0C87D33AB9FCCBDD5F6D9A_negatedLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsSold_F5910B16AF0C87D33AB9FCCBDD5F6D9A" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Cost of sales, excluding amortization of acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsSold_F5910B16AF0C87D33AB9FCCBDD5F6D9A_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsSold_F5910B16AF0C87D33AB9FCCBDD5F6D9A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods Sold</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_us-gaap_CostOfGoodsSold_F5910B16AF0C87D33AB9FCCBDD5F6D9A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsSold_F5910B16AF0C87D33AB9FCCBDD5F6D9A" xlink:to="lab_us-gaap_CostOfGoodsSold_F5910B16AF0C87D33AB9FCCBDD5F6D9A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_B1AE8F7EA2277EEF8827FCCBDD5F7D33_negatedLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_B1AE8F7EA2277EEF8827FCCBDD5F7D33" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_B1AE8F7EA2277EEF8827FCCBDD5F7D33_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_B1AE8F7EA2277EEF8827FCCBDD5F7D33" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_B1AE8F7EA2277EEF8827FCCBDD5F7D33" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_B1AE8F7EA2277EEF8827FCCBDD5F7D33" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_B1AE8F7EA2277EEF8827FCCBDD5F7D33" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_21D2217831FE5468C6E6FCCBDD5FE99F_negatedLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_21D2217831FE5468C6E6FCCBDD5FE99F" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_21D2217831FE5468C6E6FCCBDD5FE99F_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_21D2217831FE5468C6E6FCCBDD5FE99F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_21D2217831FE5468C6E6FCCBDD5FE99F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense_21D2217831FE5468C6E6FCCBDD5FE99F" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense_21D2217831FE5468C6E6FCCBDD5FE99F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_17C95568C4778DD6928CFCCBDD5F3088_negatedLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets_17C95568C4778DD6928CFCCBDD5F3088" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Amortization of acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_17C95568C4778DD6928CFCCBDD5F3088_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets_17C95568C4778DD6928CFCCBDD5F3088" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_17C95568C4778DD6928CFCCBDD5F3088" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets_17C95568C4778DD6928CFCCBDD5F3088" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets_17C95568C4778DD6928CFCCBDD5F3088" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringCharges_856D9F349D2D90D2819BFCCBDD5F4385_negatedLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges_856D9F349D2D90D2819BFCCBDD5F4385" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Restructuring charges</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_856D9F349D2D90D2819BFCCBDD5F4385" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges_856D9F349D2D90D2819BFCCBDD5F4385" xlink:to="lab_us-gaap_RestructuringCharges_856D9F349D2D90D2819BFCCBDD5F4385" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_3F4C4F5DA9626C4430B2FCCBDD5FBFE8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_3F4C4F5DA9626C4430B2FCCBDD5FBFE8" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loss (gain) on fair value remeasurement of contingent consideration</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_3F4C4F5DA9626C4430B2FCCBDD5FBFE8_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_3F4C4F5DA9626C4430B2FCCBDD5FBFE8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_3F4C4F5DA9626C4430B2FCCBDD5FBFE8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_3F4C4F5DA9626C4430B2FCCBDD5FBFE8" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_3F4C4F5DA9626C4430B2FCCBDD5FBFE8" xlink:type="arc" />
    <link:label id="lab_biib_CollaborationProfitSharing_BE122485326C843BE687FCCBDD5F03A8_negatedLabel_en-US" xlink:label="lab_biib_CollaborationProfitSharing_BE122485326C843BE687FCCBDD5F03A8" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Collaboration profit (loss) sharing</link:label>
    <link:label id="lab_biib_CollaborationProfitSharing_BE122485326C843BE687FCCBDD5F03A8_label_en-US" xlink:label="lab_biib_CollaborationProfitSharing_BE122485326C843BE687FCCBDD5F03A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration profit sharing</link:label>
    <link:label id="lab_biib_CollaborationProfitSharing_BE122485326C843BE687FCCBDD5F03A8_documentation_en-US" xlink:label="lab_biib_CollaborationProfitSharing_BE122485326C843BE687FCCBDD5F03A8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments are made to Elan for their share of rest of world net operating profits to effect an equal sharing of collaboration operating profit. These payments include the reimbursement of our portion of third-party royalties that Elan pays on behalf of the collaboration, relating to sales outside of the U.S. These amounts are reflected in the collaboration profit sharing line in our consolidated statement of income. As sales of TYSABRI outside the U.S. increase, our collaboration profit sharing expense will increase.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_CollaborationProfitSharing" xlink:label="loc_biib_CollaborationProfitSharing_BE122485326C843BE687FCCBDD5F03A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CollaborationProfitSharing_BE122485326C843BE687FCCBDD5F03A8" xlink:to="lab_biib_CollaborationProfitSharing_BE122485326C843BE687FCCBDD5F03A8" xlink:type="arc" />
    <link:label id="lab_us-gaap_LitigationSettlementExpense_98BBE6559AB72B39BB5EFCCBDD5F6343_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense_98BBE6559AB72B39BB5EFCCBDD5F6343" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">TECFIDERA litigation settlement and license charges</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_98BBE6559AB72B39BB5EFCCBDD5F6343_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense_98BBE6559AB72B39BB5EFCCBDD5F6343" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Settlement, Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationSettlementExpense" xlink:label="loc_us-gaap_LitigationSettlementExpense_98BBE6559AB72B39BB5EFCCBDD5F6343" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementExpense_98BBE6559AB72B39BB5EFCCBDD5F6343" xlink:to="lab_us-gaap_LitigationSettlementExpense_98BBE6559AB72B39BB5EFCCBDD5F6343" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostsAndExpenses_965F66C724B6060765D1FCCBDD600DA5_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses_965F66C724B6060765D1FCCBDD600DA5" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total cost and expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_965F66C724B6060765D1FCCBDD600DA5_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses_965F66C724B6060765D1FCCBDD600DA5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_965F66C724B6060765D1FCCBDD600DA5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses_965F66C724B6060765D1FCCBDD600DA5" xlink:to="lab_us-gaap_CostsAndExpenses_965F66C724B6060765D1FCCBDD600DA5" xlink:type="arc" />
    <link:label id="lab_biib_GainOnSaleOfRights_6F9BE092AD4ACAD03193FCCBDD6037E8_terseLabel_en-US" xlink:label="lab_biib_GainOnSaleOfRights_6F9BE092AD4ACAD03193FCCBDD6037E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain on sale of rights</link:label>
    <link:label id="lab_biib_GainOnSaleOfRights_6F9BE092AD4ACAD03193FCCBDD6037E8_label_en-US" xlink:label="lab_biib_GainOnSaleOfRights_6F9BE092AD4ACAD03193FCCBDD6037E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain on sale of rights</link:label>
    <link:label id="lab_biib_GainOnSaleOfRights_6F9BE092AD4ACAD03193FCCBDD6037E8_documentation_en-US" xlink:label="lab_biib_GainOnSaleOfRights_6F9BE092AD4ACAD03193FCCBDD6037E8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gain on sale of our royalty and other rights related to future sales of BENLYSTA recognized in our consolidated statement of income.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_GainOnSaleOfRights" xlink:label="loc_biib_GainOnSaleOfRights_6F9BE092AD4ACAD03193FCCBDD6037E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GainOnSaleOfRights_6F9BE092AD4ACAD03193FCCBDD6037E8" xlink:to="lab_biib_GainOnSaleOfRights_6F9BE092AD4ACAD03193FCCBDD6037E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_060696BD2C6E8788D691FCCBDD60208C_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_060696BD2C6E8788D691FCCBDD60208C" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_060696BD2C6E8788D691FCCBDD60208C_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_060696BD2C6E8788D691FCCBDD60208C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_060696BD2C6E8788D691FCCBDD60208C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_060696BD2C6E8788D691FCCBDD60208C" xlink:to="lab_us-gaap_OperatingIncomeLoss_060696BD2C6E8788D691FCCBDD60208C" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_D8677AC82452763B19A3FCCBDD6006F5_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_D8677AC82452763B19A3FCCBDD6006F5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_D8677AC82452763B19A3FCCBDD6006F5_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_D8677AC82452763B19A3FCCBDD6006F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_D8677AC82452763B19A3FCCBDD6006F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_D8677AC82452763B19A3FCCBDD6006F5" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense_D8677AC82452763B19A3FCCBDD6006F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_308659B57A79C833AD1CFCCBDD603E62_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_308659B57A79C833AD1CFCCBDD603E62" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income before income tax expense and equity in loss of investee, net of tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_308659B57A79C833AD1CFCCBDD603E62_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_308659B57A79C833AD1CFCCBDD603E62" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_308659B57A79C833AD1CFCCBDD603E62" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_308659B57A79C833AD1CFCCBDD603E62" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_308659B57A79C833AD1CFCCBDD603E62" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_E459415AC6FB9C9D93D8FCCBDD60AB8D_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_E459415AC6FB9C9D93D8FCCBDD60AB8D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_E459415AC6FB9C9D93D8FCCBDD60AB8D_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_E459415AC6FB9C9D93D8FCCBDD60AB8D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_E459415AC6FB9C9D93D8FCCBDD60AB8D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_E459415AC6FB9C9D93D8FCCBDD60AB8D" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_E459415AC6FB9C9D93D8FCCBDD60AB8D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_82BAB6CEE9EBCFE58B89FCCBDD6005FF_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments_82BAB6CEE9EBCFE58B89FCCBDD6005FF" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Equity in loss of investee, net of tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_82BAB6CEE9EBCFE58B89FCCBDD6005FF_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments_82BAB6CEE9EBCFE58B89FCCBDD6005FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_82BAB6CEE9EBCFE58B89FCCBDD6005FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments_82BAB6CEE9EBCFE58B89FCCBDD6005FF" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments_82BAB6CEE9EBCFE58B89FCCBDD6005FF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProfitLoss_3469D66CF9BBF1F1834FFCCBDD605EC2_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss_3469D66CF9BBF1F1834FFCCBDD605EC2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_3469D66CF9BBF1F1834FFCCBDD605EC2_label_en-US" xlink:label="lab_us-gaap_ProfitLoss_3469D66CF9BBF1F1834FFCCBDD605EC2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_3469D66CF9BBF1F1834FFCCBDD605EC2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_3469D66CF9BBF1F1834FFCCBDD605EC2" xlink:to="lab_us-gaap_ProfitLoss_3469D66CF9BBF1F1834FFCCBDD605EC2" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_B6F3A8DA5BF7E05ECAF6FCCBDD603284_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_B6F3A8DA5BF7E05ECAF6FCCBDD603284" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_B6F3A8DA5BF7E05ECAF6FCCBDD603284_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_B6F3A8DA5BF7E05ECAF6FCCBDD603284" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_B6F3A8DA5BF7E05ECAF6FCCBDD603284" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_B6F3A8DA5BF7E05ECAF6FCCBDD603284" xlink:to="lab_us-gaap_NetIncomeLoss_B6F3A8DA5BF7E05ECAF6FCCBDD603284" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_BF2F3EE85FF499B55B90FCCBDD606B24_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_BF2F3EE85FF499B55B90FCCBDD606B24" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_BF2F3EE85FF499B55B90FCCBDD606B24_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_BF2F3EE85FF499B55B90FCCBDD606B24" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_BF2F3EE85FF499B55B90FCCBDD606B24" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_BF2F3EE85FF499B55B90FCCBDD606B24" xlink:to="lab_us-gaap_EarningsPerShareAbstract_BF2F3EE85FF499B55B90FCCBDD606B24" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasic_8FB422F5AC92D4A25632FCCBDD60EF45_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_8FB422F5AC92D4A25632FCCBDD60EF45" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic earnings per share attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_8FB422F5AC92D4A25632FCCBDD60EF45_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_8FB422F5AC92D4A25632FCCBDD60EF45" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_8FB422F5AC92D4A25632FCCBDD60EF45" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_8FB422F5AC92D4A25632FCCBDD60EF45" xlink:to="lab_us-gaap_EarningsPerShareBasic_8FB422F5AC92D4A25632FCCBDD60EF45" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_8423D4CD597EF24A7069FCCBDD6030C5_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted_8423D4CD597EF24A7069FCCBDD6030C5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Diluted earnings per share attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_8423D4CD597EF24A7069FCCBDD6030C5_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted_8423D4CD597EF24A7069FCCBDD6030C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_8423D4CD597EF24A7069FCCBDD6030C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted_8423D4CD597EF24A7069FCCBDD6030C5" xlink:to="lab_us-gaap_EarningsPerShareDiluted_8423D4CD597EF24A7069FCCBDD6030C5" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_AD67AA00460A2457EE2FFCCBDD614B95_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_AD67AA00460A2457EE2FFCCBDD614B95" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average shares used in calculating:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_AD67AA00460A2457EE2FFCCBDD614B95_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_AD67AA00460A2457EE2FFCCBDD614B95" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_AD67AA00460A2457EE2FFCCBDD614B95" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_AD67AA00460A2457EE2FFCCBDD614B95" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_AD67AA00460A2457EE2FFCCBDD614B95" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_375F9D29E158306C7405FCCBDD6113BB_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_375F9D29E158306C7405FCCBDD6113BB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic earnings per share attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_375F9D29E158306C7405FCCBDD6113BB_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_375F9D29E158306C7405FCCBDD6113BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_375F9D29E158306C7405FCCBDD6113BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_375F9D29E158306C7405FCCBDD6113BB" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_375F9D29E158306C7405FCCBDD6113BB" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_D22321FD29756E5832DFFCCBDD615E2F_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_D22321FD29756E5832DFFCCBDD615E2F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted earnings per share attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_D22321FD29756E5832DFFCCBDD615E2F_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_D22321FD29756E5832DFFCCBDD615E2F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_D22321FD29756E5832DFFCCBDD615E2F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_D22321FD29756E5832DFFCCBDD615E2F" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_D22321FD29756E5832DFFCCBDD615E2F" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_D12C194F276AEACBF7B0FA4EA5C45A09_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis_D12C194F276AEACBF7B0FA4EA5C45A09" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_D12C194F276AEACBF7B0FA4EA5C45A09_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis_D12C194F276AEACBF7B0FA4EA5C45A09" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_D12C194F276AEACBF7B0FA4EA5C45A09" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_D12C194F276AEACBF7B0FA4EA5C45A09" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis_D12C194F276AEACBF7B0FA4EA5C45A09" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_B97E74C8BAF2E4A1E822FA4EA5C4AD56_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain_B97E74C8BAF2E4A1E822FA4EA5C4AD56" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_B97E74C8BAF2E4A1E822FA4EA5C4AD56_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain_B97E74C8BAF2E4A1E822FA4EA5C4AD56" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_B97E74C8BAF2E4A1E822FA4EA5C4AD56" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_B97E74C8BAF2E4A1E822FA4EA5C4AD56" xlink:to="lab_us-gaap_TypeOfRestructuringDomain_B97E74C8BAF2E4A1E822FA4EA5C4AD56" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_892B946708C514E5728CFA4EA5C49DF4_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember_892B946708C514E5728CFA4EA5C49DF4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Workforce reduction</link:label>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_892B946708C514E5728CFA4EA5C49DF4_label_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember_892B946708C514E5728CFA4EA5C49DF4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Severance [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="loc_us-gaap_EmployeeSeveranceMember_892B946708C514E5728CFA4EA5C49DF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeSeveranceMember_892B946708C514E5728CFA4EA5C49DF4" xlink:to="lab_us-gaap_EmployeeSeveranceMember_892B946708C514E5728CFA4EA5C49DF4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractTerminationMember_1C7835881F9C8BB4C3C2FA4EA5C42FEC_terseLabel_en-US" xlink:label="lab_us-gaap_ContractTerminationMember_1C7835881F9C8BB4C3C2FA4EA5C42FEC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pipeline programs</link:label>
    <link:label id="lab_us-gaap_ContractTerminationMember_1C7835881F9C8BB4C3C2FA4EA5C42FEC_label_en-US" xlink:label="lab_us-gaap_ContractTerminationMember_1C7835881F9C8BB4C3C2FA4EA5C42FEC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract Termination [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractTerminationMember" xlink:label="loc_us-gaap_ContractTerminationMember_1C7835881F9C8BB4C3C2FA4EA5C42FEC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractTerminationMember_1C7835881F9C8BB4C3C2FA4EA5C42FEC" xlink:to="lab_us-gaap_ContractTerminationMember_1C7835881F9C8BB4C3C2FA4EA5C42FEC" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringReserve_F98E011F465E7C6E1F06FA4EA5C456B5_periodStartLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve_F98E011F465E7C6E1F06FA4EA5C456B5" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Restructuring reserve, beginning period</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_F98E011F465E7C6E1F06FA4EA5C456B5_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve_F98E011F465E7C6E1F06FA4EA5C456B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve_F98E011F465E7C6E1F06FA4EA5C456B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve_F98E011F465E7C6E1F06FA4EA5C456B5" xlink:to="lab_us-gaap_RestructuringReserve_F98E011F465E7C6E1F06FA4EA5C456B5" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringCosts_8C8A6227327B7F4CE4DFFA4EA5C5DA64_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCosts_8C8A6227327B7F4CE4DFFA4EA5C5DA64" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expense</link:label>
    <link:label id="lab_us-gaap_RestructuringCosts_8C8A6227327B7F4CE4DFFA4EA5C5DA64_label_en-US" xlink:label="lab_us-gaap_RestructuringCosts_8C8A6227327B7F4CE4DFFA4EA5C5DA64" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringCosts" xlink:label="loc_us-gaap_RestructuringCosts_8C8A6227327B7F4CE4DFFA4EA5C5DA64" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCosts_8C8A6227327B7F4CE4DFFA4EA5C5DA64" xlink:to="lab_us-gaap_RestructuringCosts_8C8A6227327B7F4CE4DFFA4EA5C5DA64" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForRestructuring_1DAC998E1EC73EF1021CFA4EA5C4EEC3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring_1DAC998E1EC73EF1021CFA4EA5C4EEC3" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payments</link:label>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_1DAC998E1EC73EF1021CFA4EA5C4EEC3_label_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring_1DAC998E1EC73EF1021CFA4EA5C4EEC3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Restructuring</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForRestructuring" xlink:label="loc_us-gaap_PaymentsForRestructuring_1DAC998E1EC73EF1021CFA4EA5C4EEC3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRestructuring_1DAC998E1EC73EF1021CFA4EA5C4EEC3" xlink:to="lab_us-gaap_PaymentsForRestructuring_1DAC998E1EC73EF1021CFA4EA5C4EEC3" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringReserve_2D4129A94F11085DC892FA854417BA72_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve_2D4129A94F11085DC892FA854417BA72" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Restructuring reserve, ending period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve_2D4129A94F11085DC892FA854417BA72" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve_2D4129A94F11085DC892FA854417BA72" xlink:to="lab_us-gaap_RestructuringReserve_2D4129A94F11085DC892FA854417BA72" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtByMaturityAbstract_3460EC8D39E5918E957CD13AF2F6BA07_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtByMaturityAbstract_3460EC8D39E5918E957CD13AF2F6BA07" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total debt maturities</link:label>
    <link:label id="lab_us-gaap_LongTermDebtByMaturityAbstract_3460EC8D39E5918E957CD13AF2F6BA07_label_en-US" xlink:label="lab_us-gaap_LongTermDebtByMaturityAbstract_3460EC8D39E5918E957CD13AF2F6BA07" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtByMaturityAbstract" xlink:label="loc_us-gaap_LongTermDebtByMaturityAbstract_3460EC8D39E5918E957CD13AF2F6BA07" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_3460EC8D39E5918E957CD13AF2F6BA07" xlink:to="lab_us-gaap_LongTermDebtByMaturityAbstract_3460EC8D39E5918E957CD13AF2F6BA07" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_2BFE0615A33D5D4CE90AD13F815CAD83_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_2BFE0615A33D5D4CE90AD13F815CAD83" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2017</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_2BFE0615A33D5D4CE90AD13F815CAD83_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_2BFE0615A33D5D4CE90AD13F815CAD83" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_2BFE0615A33D5D4CE90AD13F815CAD83" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_2BFE0615A33D5D4CE90AD13F815CAD83" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_2BFE0615A33D5D4CE90AD13F815CAD83" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_322850FE789B539075B2D13FEEDCF142_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_322850FE789B539075B2D13FEEDCF142" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2018</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_322850FE789B539075B2D13FEEDCF142_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_322850FE789B539075B2D13FEEDCF142" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_322850FE789B539075B2D13FEEDCF142" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_322850FE789B539075B2D13FEEDCF142" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_322850FE789B539075B2D13FEEDCF142" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_3DCC9AFE2E9DD541B35AD1404F15BBA2_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_3DCC9AFE2E9DD541B35AD1404F15BBA2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2019</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_3DCC9AFE2E9DD541B35AD1404F15BBA2_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_3DCC9AFE2E9DD541B35AD1404F15BBA2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_3DCC9AFE2E9DD541B35AD1404F15BBA2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_3DCC9AFE2E9DD541B35AD1404F15BBA2" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_3DCC9AFE2E9DD541B35AD1404F15BBA2" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_9F436DC06146B076AF56D140A48E24FC_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_9F436DC06146B076AF56D140A48E24FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_9F436DC06146B076AF56D140A48E24FC_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_9F436DC06146B076AF56D140A48E24FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_9F436DC06146B076AF56D140A48E24FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_9F436DC06146B076AF56D140A48E24FC" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_9F436DC06146B076AF56D140A48E24FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_2488AC957999C343CE9BD13AF2F66FBB_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_2488AC957999C343CE9BD13AF2F66FBB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_2488AC957999C343CE9BD13AF2F66FBB_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_2488AC957999C343CE9BD13AF2F66FBB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_2488AC957999C343CE9BD13AF2F66FBB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_2488AC957999C343CE9BD13AF2F66FBB" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_2488AC957999C343CE9BD13AF2F66FBB" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_28E1592F4C825515435CD13AF2F61DE4_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_28E1592F4C825515435CD13AF2F61DE4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2022 and thereafter</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_28E1592F4C825515435CD13AF2F61DE4_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_28E1592F4C825515435CD13AF2F61DE4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal after Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_28E1592F4C825515435CD13AF2F61DE4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_28E1592F4C825515435CD13AF2F61DE4" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_28E1592F4C825515435CD13AF2F61DE4" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermNotesPayable_2763671CF633C0C4CA4CD13AF2F66364_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermNotesPayable_2763671CF633C0C4CA4CD13AF2F66364" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LongTermNotesPayable_2763671CF633C0C4CA4CD13AF2F66364_label_en-US" xlink:label="lab_us-gaap_LongTermNotesPayable_2763671CF633C0C4CA4CD13AF2F66364" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaap_LongTermNotesPayable_2763671CF633C0C4CA4CD13AF2F66364" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermNotesPayable_2763671CF633C0C4CA4CD13AF2F66364" xlink:to="lab_us-gaap_LongTermNotesPayable_2763671CF633C0C4CA4CD13AF2F66364" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentTable_D02E8ABC39633BDC6620FB6C3B2BC381_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_D02E8ABC39633BDC6620FB6C3B2BC381" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_D02E8ABC39633BDC6620FB6C3B2BC381_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_D02E8ABC39633BDC6620FB6C3B2BC381" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_D02E8ABC39633BDC6620FB6C3B2BC381" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable_D02E8ABC39633BDC6620FB6C3B2BC381" xlink:to="lab_us-gaap_DebtInstrumentTable_D02E8ABC39633BDC6620FB6C3B2BC381" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_A17D36DD43378FDA977AFB6C3B2B1A64_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_A17D36DD43378FDA977AFB6C3B2B1A64" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_A17D36DD43378FDA977AFB6C3B2B1A64_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_A17D36DD43378FDA977AFB6C3B2B1A64" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_A17D36DD43378FDA977AFB6C3B2B1A64" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_A17D36DD43378FDA977AFB6C3B2B1A64" xlink:to="lab_us-gaap_BusinessAcquisitionAxis_A17D36DD43378FDA977AFB6C3B2B1A64" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_F0E0D0B2A3072779215EFB6C3B2CAA86_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_F0E0D0B2A3072779215EFB6C3B2CAA86" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_F0E0D0B2A3072779215EFB6C3B2CAA86_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_F0E0D0B2A3072779215EFB6C3B2CAA86" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F0E0D0B2A3072779215EFB6C3B2CAA86" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F0E0D0B2A3072779215EFB6C3B2CAA86" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain_F0E0D0B2A3072779215EFB6C3B2CAA86" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_348D41DAD7599358180DFB6C3B2C2C50_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis_348D41DAD7599358180DFB6C3B2C2C50" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instrument Risk [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_348D41DAD7599358180DFB6C3B2C2C50_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis_348D41DAD7599358180DFB6C3B2C2C50" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_348D41DAD7599358180DFB6C3B2C2C50" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_348D41DAD7599358180DFB6C3B2C2C50" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis_348D41DAD7599358180DFB6C3B2C2C50" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_2554A9C66B380B3904E4FB6C3B2C8D98_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain_2554A9C66B380B3904E4FB6C3B2C8D98" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Contract Type [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_2554A9C66B380B3904E4FB6C3B2C8D98_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain_2554A9C66B380B3904E4FB6C3B2C8D98" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_2554A9C66B380B3904E4FB6C3B2C8D98" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_2554A9C66B380B3904E4FB6C3B2C8D98" xlink:to="lab_us-gaap_DerivativeContractTypeDomain_2554A9C66B380B3904E4FB6C3B2C8D98" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestRateSwapMember_34748199695F03984D23FB6C3B2C68D6_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember_34748199695F03984D23FB6C3B2C68D6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate swap</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_34748199695F03984D23FB6C3B2C68D6_label_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember_34748199695F03984D23FB6C3B2C68D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Rate Swap [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember_34748199695F03984D23FB6C3B2C68D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateSwapMember_34748199695F03984D23FB6C3B2C68D6" xlink:to="lab_us-gaap_InterestRateSwapMember_34748199695F03984D23FB6C3B2C68D6" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentAxis_9F4E5C22383D81478732FB6C3B2CCCF1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_9F4E5C22383D81478732FB6C3B2CCCF1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_9F4E5C22383D81478732FB6C3B2CCCF1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_9F4E5C22383D81478732FB6C3B2CCCF1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_9F4E5C22383D81478732FB6C3B2CCCF1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis_9F4E5C22383D81478732FB6C3B2CCCF1" xlink:to="lab_us-gaap_DebtInstrumentAxis_9F4E5C22383D81478732FB6C3B2CCCF1" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_4966CEBD113955EC117DFB6C3B2C4CC1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_4966CEBD113955EC117DFB6C3B2C4CC1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_4966CEBD113955EC117DFB6C3B2C4CC1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_4966CEBD113955EC117DFB6C3B2C4CC1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4966CEBD113955EC117DFB6C3B2C4CC1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4966CEBD113955EC117DFB6C3B2C4CC1" xlink:to="lab_us-gaap_DebtInstrumentNameDomain_4966CEBD113955EC117DFB6C3B2C4CC1" xlink:type="arc" />
    <link:label id="lab_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_E06656F60997175D66ACFB6C3B2D2E5F_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_E06656F60997175D66ACFB6C3B2D2E5F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">6.875% Senior Notes due 2018</link:label>
    <link:label id="lab_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_E06656F60997175D66ACFB6C3B2D2E5F_label_en-US" xlink:label="lab_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_E06656F60997175D66ACFB6C3B2D2E5F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes Six Point Eight Seven Five Percent Due Twenty Eighteen [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_E06656F60997175D66ACFB6C3B2D2E5F_documentation_en-US" xlink:label="lab_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_E06656F60997175D66ACFB6C3B2D2E5F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes Six Point Eight Seven Five Percent Due Twenty Eighteen.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" xlink:label="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_E06656F60997175D66ACFB6C3B2D2E5F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_E06656F60997175D66ACFB6C3B2D2E5F" xlink:to="lab_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_E06656F60997175D66ACFB6C3B2D2E5F" xlink:type="arc" />
    <link:label id="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_922BBC27FB74C86B3203FB6C3B2C95AC_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_922BBC27FB74C86B3203FB6C3B2C95AC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2.90% Senior Notes due 2020</link:label>
    <link:label id="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_922BBC27FB74C86B3203FB6C3B2C95AC_label_en-US" xlink:label="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_922BBC27FB74C86B3203FB6C3B2C95AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes Two Point Nine Percent Due Twenty Twenty [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_922BBC27FB74C86B3203FB6C3B2C95AC_documentation_en-US" xlink:label="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_922BBC27FB74C86B3203FB6C3B2C95AC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes Two Point Nine Percent Due Twenty Twenty [Member]</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_922BBC27FB74C86B3203FB6C3B2C95AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_922BBC27FB74C86B3203FB6C3B2C95AC" xlink:to="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_922BBC27FB74C86B3203FB6C3B2C95AC" xlink:type="arc" />
    <link:label id="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_11AE3B411779C35DC2D1FB6C3B2C38AD_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_11AE3B411779C35DC2D1FB6C3B2C38AD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">3.625% Senior Notes due 2022</link:label>
    <link:label id="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_11AE3B411779C35DC2D1FB6C3B2C38AD_label_en-US" xlink:label="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_11AE3B411779C35DC2D1FB6C3B2C38AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes Three Point Six Two Five Percent Due Twenty Twenty Two [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_11AE3B411779C35DC2D1FB6C3B2C38AD_documentation_en-US" xlink:label="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_11AE3B411779C35DC2D1FB6C3B2C38AD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes Three Point Six Two Five Percent Due Twenty Twenty Two [Member]</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_11AE3B411779C35DC2D1FB6C3B2C38AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_11AE3B411779C35DC2D1FB6C3B2C38AD" xlink:to="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_11AE3B411779C35DC2D1FB6C3B2C38AD" xlink:type="arc" />
    <link:label id="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_7696055F354DD5BBB4C2FB6C3B2C1E1B_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_7696055F354DD5BBB4C2FB6C3B2C1E1B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">4.05% Senior Notes due 2025</link:label>
    <link:label id="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_7696055F354DD5BBB4C2FB6C3B2C1E1B_label_en-US" xlink:label="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_7696055F354DD5BBB4C2FB6C3B2C1E1B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes Four Point Zero Five Percent Due Twenty Twenty Five [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_7696055F354DD5BBB4C2FB6C3B2C1E1B_documentation_en-US" xlink:label="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_7696055F354DD5BBB4C2FB6C3B2C1E1B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes Four Point Zero Five Percent Due Twenty Twenty Five [Member]</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_7696055F354DD5BBB4C2FB6C3B2C1E1B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_7696055F354DD5BBB4C2FB6C3B2C1E1B" xlink:to="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_7696055F354DD5BBB4C2FB6C3B2C1E1B" xlink:type="arc" />
    <link:label id="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_E141CCBD9CD21A414615FB6C3B2DE27F_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_E141CCBD9CD21A414615FB6C3B2DE27F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">5.20% Senior Notes due 2045</link:label>
    <link:label id="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_E141CCBD9CD21A414615FB6C3B2DE27F_label_en-US" xlink:label="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_E141CCBD9CD21A414615FB6C3B2DE27F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes Five Point Two Percent Due Twenty Forty Five [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_E141CCBD9CD21A414615FB6C3B2DE27F_documentation_en-US" xlink:label="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_E141CCBD9CD21A414615FB6C3B2DE27F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes Five Point Two Percent Due Twenty Forty Five [Member]</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_E141CCBD9CD21A414615FB6C3B2DE27F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_E141CCBD9CD21A414615FB6C3B2DE27F" xlink:to="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_E141CCBD9CD21A414615FB6C3B2DE27F" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_4D512F1DE9CC41220EC3FB6C3B2D7AAE_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis_4D512F1DE9CC41220EC3FB6C3B2D7AAE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_4D512F1DE9CC41220EC3FB6C3B2D7AAE_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis_4D512F1DE9CC41220EC3FB6C3B2D7AAE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_4D512F1DE9CC41220EC3FB6C3B2D7AAE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_4D512F1DE9CC41220EC3FB6C3B2D7AAE" xlink:to="lab_us-gaap_LongtermDebtTypeAxis_4D512F1DE9CC41220EC3FB6C3B2D7AAE" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_E0EE637A77F1FD013EB4FB6C3B2DBB5D_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain_E0EE637A77F1FD013EB4FB6C3B2DBB5D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_E0EE637A77F1FD013EB4FB6C3B2DBB5D_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain_E0EE637A77F1FD013EB4FB6C3B2DBB5D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_E0EE637A77F1FD013EB4FB6C3B2DBB5D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_E0EE637A77F1FD013EB4FB6C3B2DBB5D" xlink:to="lab_us-gaap_LongtermDebtTypeDomain_E0EE637A77F1FD013EB4FB6C3B2DBB5D" xlink:type="arc" />
    <link:label id="lab_us-gaap_NotesPayableOtherPayablesMember_C377AD0DACDA89BDFF77FB6C3B2DD741_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableOtherPayablesMember_C377AD0DACDA89BDFF77FB6C3B2DD741" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Note payable to Fumedica</link:label>
    <link:label id="lab_us-gaap_NotesPayableOtherPayablesMember_C377AD0DACDA89BDFF77FB6C3B2DD741_label_en-US" xlink:label="lab_us-gaap_NotesPayableOtherPayablesMember_C377AD0DACDA89BDFF77FB6C3B2DD741" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable, Other Payables [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_C377AD0DACDA89BDFF77FB6C3B2DD741" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableOtherPayablesMember_C377AD0DACDA89BDFF77FB6C3B2DD741" xlink:to="lab_us-gaap_NotesPayableOtherPayablesMember_C377AD0DACDA89BDFF77FB6C3B2DD741" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_5752CFAD9689FE6191B7FB6C3B2D530F_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_5752CFAD9689FE6191B7FB6C3B2D530F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_5752CFAD9689FE6191B7FB6C3B2D530F_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_5752CFAD9689FE6191B7FB6C3B2D530F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_5752CFAD9689FE6191B7FB6C3B2D530F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5752CFAD9689FE6191B7FB6C3B2D530F" xlink:to="lab_us-gaap_DebtInstrumentLineItems_5752CFAD9689FE6191B7FB6C3B2D530F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_B5B9DD9F22A0B43D16EDFB6C3B2D5AA9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_B5B9DD9F22A0B43D16EDFB6C3B2D5AA9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principal amount of senior notes</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_B5B9DD9F22A0B43D16EDFB6C3B2D5AA9_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_B5B9DD9F22A0B43D16EDFB6C3B2D5AA9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_B5B9DD9F22A0B43D16EDFB6C3B2D5AA9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount_B5B9DD9F22A0B43D16EDFB6C3B2D5AA9" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount_B5B9DD9F22A0B43D16EDFB6C3B2D5AA9" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_7996C1D6E355B21926FEFB6C3B2D9D04_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_7996C1D6E355B21926FEFB6C3B2D9D04" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Interest rate on senior notes</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_7996C1D6E355B21926FEFB6C3B2D9D04_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_7996C1D6E355B21926FEFB6C3B2D9D04" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7996C1D6E355B21926FEFB6C3B2D9D04" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7996C1D6E355B21926FEFB6C3B2D9D04" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_7996C1D6E355B21926FEFB6C3B2D9D04" xlink:type="arc" />
    <link:label id="lab_biib_PercentageParValueOfSeniorNotes_E17B1A73F4DD56062176FB6C3B2D1F28_terseLabel_en-US" xlink:label="lab_biib_PercentageParValueOfSeniorNotes_E17B1A73F4DD56062176FB6C3B2D1F28" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redemption percentage par value of senior notes</link:label>
    <link:label id="lab_biib_PercentageParValueOfSeniorNotes_E17B1A73F4DD56062176FB6C3B2D1F28_label_en-US" xlink:label="lab_biib_PercentageParValueOfSeniorNotes_E17B1A73F4DD56062176FB6C3B2D1F28" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Par Value Of Senior Notes</link:label>
    <link:label id="lab_biib_PercentageParValueOfSeniorNotes_E17B1A73F4DD56062176FB6C3B2D1F28_documentation_en-US" xlink:label="lab_biib_PercentageParValueOfSeniorNotes_E17B1A73F4DD56062176FB6C3B2D1F28" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage Par Value Of Senior Notes</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_PercentageParValueOfSeniorNotes" xlink:label="loc_biib_PercentageParValueOfSeniorNotes_E17B1A73F4DD56062176FB6C3B2D1F28" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageParValueOfSeniorNotes_E17B1A73F4DD56062176FB6C3B2D1F28" xlink:to="lab_biib_PercentageParValueOfSeniorNotes_E17B1A73F4DD56062176FB6C3B2D1F28" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsOfFinancingCosts_7EE34F6F1CEF32E9E451FB6C3B2DF9A8_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts_7EE34F6F1CEF32E9E451FB6C3B2DF9A8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Costs associated with the Senior Notes offerings</link:label>
    <link:label id="lab_us-gaap_PaymentsOfFinancingCosts_7EE34F6F1CEF32E9E451FB6C3B2DF9A8_label_en-US" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts_7EE34F6F1CEF32E9E451FB6C3B2DF9A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Financing Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_7EE34F6F1CEF32E9E451FB6C3B2DF9A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfFinancingCosts_7EE34F6F1CEF32E9E451FB6C3B2DF9A8" xlink:to="lab_us-gaap_PaymentsOfFinancingCosts_7EE34F6F1CEF32E9E451FB6C3B2DF9A8" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_6EE391E5E954B296E080FB6C3B2D47C7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_6EE391E5E954B296E080FB6C3B2D47C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redemptions percentage of 2015 notes</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_6EE391E5E954B296E080FB6C3B2D47C7_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_6EE391E5E954B296E080FB6C3B2D47C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_6EE391E5E954B296E080FB6C3B2D47C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_6EE391E5E954B296E080FB6C3B2D47C7" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_6EE391E5E954B296E080FB6C3B2D47C7" xlink:type="arc" />
    <link:label id="lab_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_EE511399A391A897CE62FB6C3B2DA09E_terseLabel_en-US" xlink:label="lab_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_EE511399A391A897CE62FB6C3B2DA09E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redemption percentage for change in control provision on the 2015 Senior Notes</link:label>
    <link:label id="lab_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_EE511399A391A897CE62FB6C3B2DA09E_label_en-US" xlink:label="lab_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_EE511399A391A897CE62FB6C3B2DA09E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Make Whole Provision Redemption Price, Percentage</link:label>
    <link:label id="lab_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_EE511399A391A897CE62FB6C3B2DA09E_documentation_en-US" xlink:label="lab_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_EE511399A391A897CE62FB6C3B2DA09E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Make Whole Provision Redemption Price, Percentage</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage" xlink:label="loc_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_EE511399A391A897CE62FB6C3B2DA09E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_EE511399A391A897CE62FB6C3B2DA09E" xlink:to="lab_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_EE511399A391A897CE62FB6C3B2DA09E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_A2269BFCD9DFFAE512CFFB6C3B2DAE9E_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_A2269BFCD9DFFAE512CFFB6C3B2DAE9E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of the interest rate swaps</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_A2269BFCD9DFFAE512CFFB6C3B2DAE9E_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_A2269BFCD9DFFAE512CFFB6C3B2DAE9E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Asset, Fair Value, Gross Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_A2269BFCD9DFFAE512CFFB6C3B2DAE9E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_A2269BFCD9DFFAE512CFFB6C3B2DAE9E" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_A2269BFCD9DFFAE512CFFB6C3B2DAE9E" xlink:type="arc" />
    <link:label id="lab_biib_IncreasedCarryingAmountOfSeniorNotes_A6F9FEA410774AB1EDE8FB6C3B2D91E5_terseLabel_en-US" xlink:label="lab_biib_IncreasedCarryingAmountOfSeniorNotes_A6F9FEA410774AB1EDE8FB6C3B2D91E5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increased carrying amount of interest rate swap</link:label>
    <link:label id="lab_biib_IncreasedCarryingAmountOfSeniorNotes_A6F9FEA410774AB1EDE8FB6C3B2D91E5_label_en-US" xlink:label="lab_biib_IncreasedCarryingAmountOfSeniorNotes_A6F9FEA410774AB1EDE8FB6C3B2D91E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increased Carrying Amount Of Senior Notes</link:label>
    <link:label id="lab_biib_IncreasedCarryingAmountOfSeniorNotes_A6F9FEA410774AB1EDE8FB6C3B2D91E5_documentation_en-US" xlink:label="lab_biib_IncreasedCarryingAmountOfSeniorNotes_A6F9FEA410774AB1EDE8FB6C3B2D91E5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increased carrying amount of senior notes.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_IncreasedCarryingAmountOfSeniorNotes" xlink:label="loc_biib_IncreasedCarryingAmountOfSeniorNotes_A6F9FEA410774AB1EDE8FB6C3B2D91E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IncreasedCarryingAmountOfSeniorNotes_A6F9FEA410774AB1EDE8FB6C3B2D91E5" xlink:to="lab_biib_IncreasedCarryingAmountOfSeniorNotes_A6F9FEA410774AB1EDE8FB6C3B2D91E5" xlink:type="arc" />
    <link:label id="lab_biib_DebtInstrumentUnamortizedInterestOnDebt_71176A85CAD91D7BC8ABFB6C3B2EC1FA_terseLabel_en-US" xlink:label="lab_biib_DebtInstrumentUnamortizedInterestOnDebt_71176A85CAD91D7BC8ABFB6C3B2EC1FA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest to be amortized on debt</link:label>
    <link:label id="lab_biib_DebtInstrumentUnamortizedInterestOnDebt_71176A85CAD91D7BC8ABFB6C3B2EC1FA_label_en-US" xlink:label="lab_biib_DebtInstrumentUnamortizedInterestOnDebt_71176A85CAD91D7BC8ABFB6C3B2EC1FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument Unamortized Interest On Debt</link:label>
    <link:label id="lab_biib_DebtInstrumentUnamortizedInterestOnDebt_71176A85CAD91D7BC8ABFB6C3B2EC1FA_documentation_en-US" xlink:label="lab_biib_DebtInstrumentUnamortizedInterestOnDebt_71176A85CAD91D7BC8ABFB6C3B2EC1FA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt instrument unamortized interest on debt.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_DebtInstrumentUnamortizedInterestOnDebt" xlink:label="loc_biib_DebtInstrumentUnamortizedInterestOnDebt_71176A85CAD91D7BC8ABFB6C3B2EC1FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DebtInstrumentUnamortizedInterestOnDebt_71176A85CAD91D7BC8ABFB6C3B2EC1FA" xlink:to="lab_biib_DebtInstrumentUnamortizedInterestOnDebt_71176A85CAD91D7BC8ABFB6C3B2EC1FA" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermNotesPayable_D86392754D2EA82DEA91FB6C3B2E8DB1_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermNotesPayable_D86392754D2EA82DEA91FB6C3B2E8DB1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Notes payable and other financing arrangements</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaap_LongTermNotesPayable_D86392754D2EA82DEA91FB6C3B2E8DB1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermNotesPayable_D86392754D2EA82DEA91FB6C3B2E8DB1" xlink:to="lab_us-gaap_LongTermNotesPayable_D86392754D2EA82DEA91FB6C3B2E8DB1" xlink:type="arc" />
    <link:label id="lab_biib_ParValueOfNotesPayable_5B4F5A729633222018C4FB6C3B2E5127_terseLabel_en-US" xlink:label="lab_biib_ParValueOfNotesPayable_5B4F5A729633222018C4FB6C3B2E5127" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Par value of notes payable</link:label>
    <link:label id="lab_biib_ParValueOfNotesPayable_5B4F5A729633222018C4FB6C3B2E5127_label_en-US" xlink:label="lab_biib_ParValueOfNotesPayable_5B4F5A729633222018C4FB6C3B2E5127" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Par Value Of Notes Payable</link:label>
    <link:label id="lab_biib_ParValueOfNotesPayable_5B4F5A729633222018C4FB6C3B2E5127_documentation_en-US" xlink:label="lab_biib_ParValueOfNotesPayable_5B4F5A729633222018C4FB6C3B2E5127" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Par value of notes payable.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_ParValueOfNotesPayable" xlink:label="loc_biib_ParValueOfNotesPayable_5B4F5A729633222018C4FB6C3B2E5127" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ParValueOfNotesPayable_5B4F5A729633222018C4FB6C3B2E5127" xlink:to="lab_biib_ParValueOfNotesPayable_5B4F5A729633222018C4FB6C3B2E5127" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_E9CD763E2F6FE6E78D65FB6C3B2E7DFB_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_E9CD763E2F6FE6E78D65FB6C3B2E7DFB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior unsecured revolving credit facility maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_E9CD763E2F6FE6E78D65FB6C3B2E7DFB_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_E9CD763E2F6FE6E78D65FB6C3B2E7DFB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_E9CD763E2F6FE6E78D65FB6C3B2E7DFB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_E9CD763E2F6FE6E78D65FB6C3B2E7DFB" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_E9CD763E2F6FE6E78D65FB6C3B2E7DFB" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCreditFacilityExpirationPeriod_990D5D30089F47B7C6CAFB6C3B2EE2F4_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityExpirationPeriod_990D5D30089F47B7C6CAFB6C3B2EE2F4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term of credit facility</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityExpirationPeriod_990D5D30089F47B7C6CAFB6C3B2EE2F4_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityExpirationPeriod_990D5D30089F47B7C6CAFB6C3B2EE2F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Expiration Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:label="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_990D5D30089F47B7C6CAFB6C3B2EE2F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_990D5D30089F47B7C6CAFB6C3B2EE2F4" xlink:to="lab_us-gaap_LineOfCreditFacilityExpirationPeriod_990D5D30089F47B7C6CAFB6C3B2EE2F4" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_62720ECD59E7A105B580FB6C3B2E9D4D_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_62720ECD59E7A105B580FB6C3B2E9D4D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount outstanding under the credit facility</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_62720ECD59E7A105B580FB6C3B2E9D4D_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_62720ECD59E7A105B580FB6C3B2E9D4D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Fair Value of Amount Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" xlink:label="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_62720ECD59E7A105B580FB6C3B2E9D4D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_62720ECD59E7A105B580FB6C3B2E9D4D" xlink:to="lab_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_62720ECD59E7A105B580FB6C3B2E9D4D" xlink:type="arc" />
    <link:label id="lab_us-gaap_CapitalLeaseObligations_24683F64C9594DEE4071FB6C3B2E9B9C_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLeaseObligations_24683F64C9594DEE4071FB6C3B2E9B9C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital lease obligation</link:label>
    <link:label id="lab_us-gaap_CapitalLeaseObligations_24683F64C9594DEE4071FB6C3B2E9B9C_label_en-US" xlink:label="lab_us-gaap_CapitalLeaseObligations_24683F64C9594DEE4071FB6C3B2E9B9C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Lease Obligations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalLeaseObligations" xlink:label="loc_us-gaap_CapitalLeaseObligations_24683F64C9594DEE4071FB6C3B2E9B9C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeaseObligations_24683F64C9594DEE4071FB6C3B2E9B9C" xlink:to="lab_us-gaap_CapitalLeaseObligations_24683F64C9594DEE4071FB6C3B2E9B9C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_F51E8C4065F378FB4403FB6C3AF48C3B_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_F51E8C4065F378FB4403FB6C3AF48C3B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_F51E8C4065F378FB4403FB6C3AF48C3B_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_F51E8C4065F378FB4403FB6C3AF48C3B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_F51E8C4065F378FB4403FB6C3AF48C3B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_F51E8C4065F378FB4403FB6C3AF48C3B" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_F51E8C4065F378FB4403FB6C3AF48C3B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_A61B9E7665CC3749D8AFFB6C3AF4BCAC_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_A61B9E7665CC3749D8AFFB6C3AF4BCAC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_A61B9E7665CC3749D8AFFB6C3AF4BCAC_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_A61B9E7665CC3749D8AFFB6C3AF4BCAC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_A61B9E7665CC3749D8AFFB6C3AF4BCAC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_A61B9E7665CC3749D8AFFB6C3AF4BCAC" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_A61B9E7665CC3749D8AFFB6C3AF4BCAC" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_8B753C9D7E38F6C098B9FB6C3AF46075_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_8B753C9D7E38F6C098B9FB6C3AF46075" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_8B753C9D7E38F6C098B9FB6C3AF46075_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_8B753C9D7E38F6C098B9FB6C3AF46075" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8B753C9D7E38F6C098B9FB6C3AF46075" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8B753C9D7E38F6C098B9FB6C3AF46075" xlink:to="lab_us-gaap_IncomeStatementLocationDomain_8B753C9D7E38F6C098B9FB6C3AF46075" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_C1BBB5E5A84FB1E4EE65FB6C3AF4DB6C_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_C1BBB5E5A84FB1E4EE65FB6C3AF4DB6C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_C1BBB5E5A84FB1E4EE65FB6C3AF4DB6C_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_C1BBB5E5A84FB1E4EE65FB6C3AF4DB6C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_C1BBB5E5A84FB1E4EE65FB6C3AF4DB6C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_C1BBB5E5A84FB1E4EE65FB6C3AF4DB6C" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_C1BBB5E5A84FB1E4EE65FB6C3AF4DB6C" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_AB5A9E1AF72E880E5071FB6C3AF4E91D_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_AB5A9E1AF72E880E5071FB6C3AF4E91D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_AB5A9E1AF72E880E5071FB6C3AF4E91D_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_AB5A9E1AF72E880E5071FB6C3AF4E91D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_AB5A9E1AF72E880E5071FB6C3AF4E91D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_AB5A9E1AF72E880E5071FB6C3AF4E91D" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_AB5A9E1AF72E880E5071FB6C3AF4E91D" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringChargesMember_861D34FD216488DE6A06FB6C3AF40ACC_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringChargesMember_861D34FD216488DE6A06FB6C3AF40ACC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring charges</link:label>
    <link:label id="lab_us-gaap_RestructuringChargesMember_861D34FD216488DE6A06FB6C3AF40ACC_label_en-US" xlink:label="lab_us-gaap_RestructuringChargesMember_861D34FD216488DE6A06FB6C3AF40ACC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringChargesMember" xlink:label="loc_us-gaap_RestructuringChargesMember_861D34FD216488DE6A06FB6C3AF40ACC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringChargesMember_861D34FD216488DE6A06FB6C3AF40ACC" xlink:to="lab_us-gaap_RestructuringChargesMember_861D34FD216488DE6A06FB6C3AF40ACC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ParentMember_853662D2FFA4CE3A0451FB6C3AF4A819_verboseLabel_en-US" xlink:label="lab_us-gaap_ParentMember_853662D2FFA4CE3A0451FB6C3AF4A819" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total share-based compensation expense, net of tax</link:label>
    <link:label id="lab_us-gaap_ParentMember_853662D2FFA4CE3A0451FB6C3AF4A819_label_en-US" xlink:label="lab_us-gaap_ParentMember_853662D2FFA4CE3A0451FB6C3AF4A819" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaap_ParentMember_853662D2FFA4CE3A0451FB6C3AF4A819" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ParentMember_853662D2FFA4CE3A0451FB6C3AF4A819" xlink:to="lab_us-gaap_ParentMember_853662D2FFA4CE3A0451FB6C3AF4A819" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3673719AA25E849D2CEBFB6C3AF449AB_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3673719AA25E849D2CEBFB6C3AF449AB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3673719AA25E849D2CEBFB6C3AF449AB_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3673719AA25E849D2CEBFB6C3AF449AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3673719AA25E849D2CEBFB6C3AF449AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3673719AA25E849D2CEBFB6C3AF449AB" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3673719AA25E849D2CEBFB6C3AF449AB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_C7EF5191E5F2FE25056AFB6C3AF44AEA_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_C7EF5191E5F2FE25056AFB6C3AF44AEA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Expense included in consolidated statements of income</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_C7EF5191E5F2FE25056AFB6C3AF44AEA_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_C7EF5191E5F2FE25056AFB6C3AF44AEA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Allocation and Classification in Financial Statements [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_C7EF5191E5F2FE25056AFB6C3AF44AEA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_C7EF5191E5F2FE25056AFB6C3AF44AEA" xlink:to="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_C7EF5191E5F2FE25056AFB6C3AF44AEA" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_BA6D979ACACEB4E62C82FB6C3AF552C1_negatedLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_BA6D979ACACEB4E62C82FB6C3AF552C1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_BA6D979ACACEB4E62C82FB6C3AF552C1_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_BA6D979ACACEB4E62C82FB6C3AF552C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allocated Share-based Compensation Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_BA6D979ACACEB4E62C82FB6C3AF552C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_BA6D979ACACEB4E62C82FB6C3AF552C1" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_BA6D979ACACEB4E62C82FB6C3AF552C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_28847CE0E13B593D63B2FB6C3AF5A1DE_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_28847CE0E13B593D63B2FB6C3AF5A1DE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Subtotal</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_28847CE0E13B593D63B2FB6C3AF5A1DE_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_28847CE0E13B593D63B2FB6C3AF5A1DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allocated Share-based Compensation Expense, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_28847CE0E13B593D63B2FB6C3AF5A1DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_28847CE0E13B593D63B2FB6C3AF5A1DE" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_28847CE0E13B593D63B2FB6C3AF5A1DE" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_16D86BEA17B7C9154F18FB6C3AF56008_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_16D86BEA17B7C9154F18FB6C3AF56008" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capitalized share-based compensation costs</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_16D86BEA17B7C9154F18FB6C3AF56008_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_16D86BEA17B7C9154F18FB6C3AF56008" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Capitalized Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_16D86BEA17B7C9154F18FB6C3AF56008" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_16D86BEA17B7C9154F18FB6C3AF56008" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_16D86BEA17B7C9154F18FB6C3AF56008" xlink:type="arc" />
    <link:label id="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_23B7ED9669D453AB7CC8FB6C3AF53405_totalLabel_en-US" xlink:label="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_23B7ED9669D453AB7CC8FB6C3AF53405" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense included in total costs and expenses</link:label>
    <link:label id="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_23B7ED9669D453AB7CC8FB6C3AF53405_label_en-US" xlink:label="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_23B7ED9669D453AB7CC8FB6C3AF53405" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Expense Included In Costs And Expenses</link:label>
    <link:label id="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_23B7ED9669D453AB7CC8FB6C3AF53405_documentation_en-US" xlink:label="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_23B7ED9669D453AB7CC8FB6C3AF53405" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share based compensation expense included in costs and expenses.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_23B7ED9669D453AB7CC8FB6C3AF53405" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_23B7ED9669D453AB7CC8FB6C3AF53405" xlink:to="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_23B7ED9669D453AB7CC8FB6C3AF53405" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_F3CDEEA12A6D67B5FF1CFB6C3AF5871F_negatedLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_F3CDEEA12A6D67B5FF1CFB6C3AF5871F" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Income tax effect</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_F3CDEEA12A6D67B5FF1CFB6C3AF5871F_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_F3CDEEA12A6D67B5FF1CFB6C3AF5871F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Tax Benefit from Compensation Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_F3CDEEA12A6D67B5FF1CFB6C3AF5871F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_F3CDEEA12A6D67B5FF1CFB6C3AF5871F" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_F3CDEEA12A6D67B5FF1CFB6C3AF5871F" xlink:type="arc" />
    <link:label id="lab_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_86B8A232126DDF0F2AE0FCCBDB3EC7E9_terseLabel_en-US" xlink:label="lab_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_86B8A232126DDF0F2AE0FCCBDB3EC7E9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty And Net Revenue Share Rates By Territory [Axis]</link:label>
    <link:label id="lab_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_86B8A232126DDF0F2AE0FCCBDB3EC7E9_label_en-US" xlink:label="lab_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_86B8A232126DDF0F2AE0FCCBDB3EC7E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty And Net Revenue Share Rates By Territory [Axis]</link:label>
    <link:label id="lab_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_86B8A232126DDF0F2AE0FCCBDB3EC7E9_documentation_en-US" xlink:label="lab_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_86B8A232126DDF0F2AE0FCCBDB3EC7E9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty and net revenue share rates by territory.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis" xlink:label="loc_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_86B8A232126DDF0F2AE0FCCBDB3EC7E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_86B8A232126DDF0F2AE0FCCBDB3EC7E9" xlink:to="lab_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_86B8A232126DDF0F2AE0FCCBDB3EC7E9" xlink:type="arc" />
    <link:label id="lab_biib_RoyaltyAndNetRevenueShareRatesByTerritoryDomain_33401B3A33201BDAF1DAFCCBDB3E102E_terseLabel_en-US" xlink:label="lab_biib_RoyaltyAndNetRevenueShareRatesByTerritoryDomain_33401B3A33201BDAF1DAFCCBDB3E102E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty And Net Revenue Share Rates By Territory [Domain]</link:label>
    <link:label id="lab_biib_RoyaltyAndNetRevenueShareRatesByTerritoryDomain_33401B3A33201BDAF1DAFCCBDB3E102E_label_en-US" xlink:label="lab_biib_RoyaltyAndNetRevenueShareRatesByTerritoryDomain_33401B3A33201BDAF1DAFCCBDB3E102E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty And Net Revenue Share Rates By Territory [Domain]</link:label>
    <link:label id="lab_biib_RoyaltyAndNetRevenueShareRatesByTerritoryDomain_33401B3A33201BDAF1DAFCCBDB3E102E_documentation_en-US" xlink:label="lab_biib_RoyaltyAndNetRevenueShareRatesByTerritoryDomain_33401B3A33201BDAF1DAFCCBDB3E102E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty and net revenue share rates by territory.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_RoyaltyAndNetRevenueShareRatesByTerritoryDomain" xlink:label="loc_biib_RoyaltyAndNetRevenueShareRatesByTerritoryDomain_33401B3A33201BDAF1DAFCCBDB3E102E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RoyaltyAndNetRevenueShareRatesByTerritoryDomain_33401B3A33201BDAF1DAFCCBDB3E102E" xlink:to="lab_biib_RoyaltyAndNetRevenueShareRatesByTerritoryDomain_33401B3A33201BDAF1DAFCCBDB3E102E" xlink:type="arc" />
    <link:label id="lab_biib_SobiRateToBiogenOnNetSalesInSobiTerritoryMember_5F8EC1B9821E9B199F30FCCBDB3E684E_verboseLabel_en-US" xlink:label="lab_biib_SobiRateToBiogenOnNetSalesInSobiTerritoryMember_5F8EC1B9821E9B199F30FCCBDB3E684E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Sobi rate to Biogen on net sales in the Sobi Territory [Member]</link:label>
    <link:label id="lab_biib_SobiRateToBiogenOnNetSalesInSobiTerritoryMember_5F8EC1B9821E9B199F30FCCBDB3E684E_label_en-US" xlink:label="lab_biib_SobiRateToBiogenOnNetSalesInSobiTerritoryMember_5F8EC1B9821E9B199F30FCCBDB3E684E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sobi Rate To Biogen On Net Sales In The Sobi Territory [Member]</link:label>
    <link:label id="lab_biib_SobiRateToBiogenOnNetSalesInSobiTerritoryMember_5F8EC1B9821E9B199F30FCCBDB3E684E_documentation_en-US" xlink:label="lab_biib_SobiRateToBiogenOnNetSalesInSobiTerritoryMember_5F8EC1B9821E9B199F30FCCBDB3E684E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sobi rate to Biogen on net sales in the sobi territory.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_SobiRateToBiogenOnNetSalesInSobiTerritoryMember" xlink:label="loc_biib_SobiRateToBiogenOnNetSalesInSobiTerritoryMember_5F8EC1B9821E9B199F30FCCBDB3E684E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SobiRateToBiogenOnNetSalesInSobiTerritoryMember_5F8EC1B9821E9B199F30FCCBDB3E684E" xlink:to="lab_biib_SobiRateToBiogenOnNetSalesInSobiTerritoryMember_5F8EC1B9821E9B199F30FCCBDB3E684E" xlink:type="arc" />
    <link:label id="lab_biib_BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember_73A065A4BBF0C082C1E4FCCBDB3E9CAE_verboseLabel_en-US" xlink:label="lab_biib_BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember_73A065A4BBF0C082C1E4FCCBDB3E9CAE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Biogen rate to sobi on net sales in the Biogen North America Territory [Member]</link:label>
    <link:label id="lab_biib_BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember_73A065A4BBF0C082C1E4FCCBDB3E9CAE_label_en-US" xlink:label="lab_biib_BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember_73A065A4BBF0C082C1E4FCCBDB3E9CAE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Biogen Rate To Sobi On Net Sales In The Biogen North America Territory [Member]</link:label>
    <link:label id="lab_biib_BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember_73A065A4BBF0C082C1E4FCCBDB3E9CAE_documentation_en-US" xlink:label="lab_biib_BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember_73A065A4BBF0C082C1E4FCCBDB3E9CAE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Biogen rate to sobi on net sales in the Biogen North America territory.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember" xlink:label="loc_biib_BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember_73A065A4BBF0C082C1E4FCCBDB3E9CAE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember_73A065A4BBF0C082C1E4FCCBDB3E9CAE" xlink:to="lab_biib_BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember_73A065A4BBF0C082C1E4FCCBDB3E9CAE" xlink:type="arc" />
    <link:label id="lab_biib_BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember_FA30F299DB42322C2DEBFCCBDB3FB61C_verboseLabel_en-US" xlink:label="lab_biib_BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember_FA30F299DB42322C2DEBFCCBDB3FB61C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Biogen rate to sobi on net sales in the Biogen direct Territory [Member]</link:label>
    <link:label id="lab_biib_BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember_FA30F299DB42322C2DEBFCCBDB3FB61C_label_en-US" xlink:label="lab_biib_BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember_FA30F299DB42322C2DEBFCCBDB3FB61C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Biogen Rate To Sobi On Net Sales In The Biogen Direct Territory [Member]</link:label>
    <link:label id="lab_biib_BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember_FA30F299DB42322C2DEBFCCBDB3FB61C_documentation_en-US" xlink:label="lab_biib_BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember_FA30F299DB42322C2DEBFCCBDB3FB61C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Biogen rate to sobi on net sales in the Biogen direct Territory.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember" xlink:label="loc_biib_BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember_FA30F299DB42322C2DEBFCCBDB3FB61C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember_FA30F299DB42322C2DEBFCCBDB3FB61C" xlink:to="lab_biib_BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember_FA30F299DB42322C2DEBFCCBDB3FB61C" xlink:type="arc" />
    <link:label id="lab_biib_BiogenRateToSobiOnNetRevenueFromBiogenDistributorTerritoryMember_2C3F18FCE71516776831FCCBDB3F714C_verboseLabel_en-US" xlink:label="lab_biib_BiogenRateToSobiOnNetRevenueFromBiogenDistributorTerritoryMember_2C3F18FCE71516776831FCCBDB3F714C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Biogen rate to Sobi on net revenue from the Biogen distributor Territory [Member]</link:label>
    <link:label id="lab_biib_BiogenRateToSobiOnNetRevenueFromBiogenDistributorTerritoryMember_2C3F18FCE71516776831FCCBDB3F714C_label_en-US" xlink:label="lab_biib_BiogenRateToSobiOnNetRevenueFromBiogenDistributorTerritoryMember_2C3F18FCE71516776831FCCBDB3F714C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Biogen Rate To Sobi On Net Revenue From The Biogen Distributor Territory Member</link:label>
    <link:label id="lab_biib_BiogenRateToSobiOnNetRevenueFromBiogenDistributorTerritoryMember_2C3F18FCE71516776831FCCBDB3F714C_documentation_en-US" xlink:label="lab_biib_BiogenRateToSobiOnNetRevenueFromBiogenDistributorTerritoryMember_2C3F18FCE71516776831FCCBDB3F714C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Biogen rate to Sobi on net revenue(1) from the Biogen distributor territory(2).</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_BiogenRateToSobiOnNetRevenueFromBiogenDistributorTerritoryMember" xlink:label="loc_biib_BiogenRateToSobiOnNetRevenueFromBiogenDistributorTerritoryMember_2C3F18FCE71516776831FCCBDB3F714C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BiogenRateToSobiOnNetRevenueFromBiogenDistributorTerritoryMember_2C3F18FCE71516776831FCCBDB3F714C" xlink:to="lab_biib_BiogenRateToSobiOnNetRevenueFromBiogenDistributorTerritoryMember_2C3F18FCE71516776831FCCBDB3F714C" xlink:type="arc" />
    <link:label id="lab_biib_SobiTerritoryMember_476C5BCB37E416AA5292FCCBDB3FC4B8_verboseLabel_en-US" xlink:label="lab_biib_SobiTerritoryMember_476C5BCB37E416AA5292FCCBDB3FC4B8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Sobi Territory [Member]</link:label>
    <link:label id="lab_biib_SobiTerritoryMember_476C5BCB37E416AA5292FCCBDB3FC4B8_label_en-US" xlink:label="lab_biib_SobiTerritoryMember_476C5BCB37E416AA5292FCCBDB3FC4B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sobi Territory [Member]</link:label>
    <link:label id="lab_biib_SobiTerritoryMember_476C5BCB37E416AA5292FCCBDB3FC4B8_documentation_en-US" xlink:label="lab_biib_SobiTerritoryMember_476C5BCB37E416AA5292FCCBDB3FC4B8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sobi territory.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_SobiTerritoryMember" xlink:label="loc_biib_SobiTerritoryMember_476C5BCB37E416AA5292FCCBDB3FC4B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SobiTerritoryMember_476C5BCB37E416AA5292FCCBDB3FC4B8" xlink:to="lab_biib_SobiTerritoryMember_476C5BCB37E416AA5292FCCBDB3FC4B8" xlink:type="arc" />
    <link:label id="lab_biib_ReimbursementUnderAmendedAgreementAmountsPayableAbstract_3752608623C78099CBDCFCCBDB3F96A3_verboseLabel_en-US" xlink:label="lab_biib_ReimbursementUnderAmendedAgreementAmountsPayableAbstract_3752608623C78099CBDCFCCBDB3F96A3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Mechanism for reimbursement, under the amended agreement amounts payable</link:label>
    <link:label id="lab_biib_ReimbursementUnderAmendedAgreementAmountsPayableAbstract_3752608623C78099CBDCFCCBDB3F96A3_label_en-US" xlink:label="lab_biib_ReimbursementUnderAmendedAgreementAmountsPayableAbstract_3752608623C78099CBDCFCCBDB3F96A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reimbursement Under The Amended Agreement Amounts Payable [Abstract]</link:label>
    <link:label id="lab_biib_ReimbursementUnderAmendedAgreementAmountsPayableAbstract_3752608623C78099CBDCFCCBDB3F96A3_documentation_en-US" xlink:label="lab_biib_ReimbursementUnderAmendedAgreementAmountsPayableAbstract_3752608623C78099CBDCFCCBDB3F96A3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Mechanism for reimbursement, under the amended agreement amounts payable.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_ReimbursementUnderAmendedAgreementAmountsPayableAbstract" xlink:label="loc_biib_ReimbursementUnderAmendedAgreementAmountsPayableAbstract_3752608623C78099CBDCFCCBDB3F96A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ReimbursementUnderAmendedAgreementAmountsPayableAbstract_3752608623C78099CBDCFCCBDB3F96A3" xlink:to="lab_biib_ReimbursementUnderAmendedAgreementAmountsPayableAbstract_3752608623C78099CBDCFCCBDB3F96A3" xlink:type="arc" />
    <link:label id="lab_biib_ReimbursementUnderAmendedAgreementMethod_E664502ED6062B9EF56DFCCBDB3FD6E0_verboseLabel_en-US" xlink:label="lab_biib_ReimbursementUnderAmendedAgreementMethod_E664502ED6062B9EF56DFCCBDB3FD6E0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Reimbursement, under the amended agreement, Method</link:label>
    <link:label id="lab_biib_ReimbursementUnderAmendedAgreementMethod_E664502ED6062B9EF56DFCCBDB3FD6E0_label_en-US" xlink:label="lab_biib_ReimbursementUnderAmendedAgreementMethod_E664502ED6062B9EF56DFCCBDB3FD6E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reimbursement Under The Amended Agreement Method</link:label>
    <link:label id="lab_biib_ReimbursementUnderAmendedAgreementMethod_E664502ED6062B9EF56DFCCBDB3FD6E0_documentation_en-US" xlink:label="lab_biib_ReimbursementUnderAmendedAgreementMethod_E664502ED6062B9EF56DFCCBDB3FD6E0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reimbursement, under the amended agreement, method.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_ReimbursementUnderAmendedAgreementMethod" xlink:label="loc_biib_ReimbursementUnderAmendedAgreementMethod_E664502ED6062B9EF56DFCCBDB3FD6E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ReimbursementUnderAmendedAgreementMethod_E664502ED6062B9EF56DFCCBDB3FD6E0" xlink:to="lab_biib_ReimbursementUnderAmendedAgreementMethod_E664502ED6062B9EF56DFCCBDB3FD6E0" xlink:type="arc" />
    <link:label id="lab_biib_BaseRateAfterFirstCommercialSale_D44839A14833FCE53BD1FCCBDB3F7501_verboseLabel_en-US" xlink:label="lab_biib_BaseRateAfterFirstCommercialSale_D44839A14833FCE53BD1FCCBDB3F7501" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Base rate following first commercial sale in the territory</link:label>
    <link:label id="lab_biib_BaseRateAfterFirstCommercialSale_D44839A14833FCE53BD1FCCBDB3F7501_label_en-US" xlink:label="lab_biib_BaseRateAfterFirstCommercialSale_D44839A14833FCE53BD1FCCBDB3F7501" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Base Rate After First Commercial Sale</link:label>
    <link:label id="lab_biib_BaseRateAfterFirstCommercialSale_D44839A14833FCE53BD1FCCBDB3F7501_documentation_en-US" xlink:label="lab_biib_BaseRateAfterFirstCommercialSale_D44839A14833FCE53BD1FCCBDB3F7501" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Base rate after first commercial sale.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_BaseRateAfterFirstCommercialSale" xlink:label="loc_biib_BaseRateAfterFirstCommercialSale_D44839A14833FCE53BD1FCCBDB3F7501" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BaseRateAfterFirstCommercialSale_D44839A14833FCE53BD1FCCBDB3F7501" xlink:to="lab_biib_BaseRateAfterFirstCommercialSale_D44839A14833FCE53BD1FCCBDB3F7501" xlink:type="arc" />
    <link:label id="lab_biib_RateDuringReimbursementPeriod_7C48F47BAA151A887E11FCCBDB3F79A6_verboseLabel_en-US" xlink:label="lab_biib_RateDuringReimbursementPeriod_7C48F47BAA151A887E11FCCBDB3F79A6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Rate during the reimbursement period</link:label>
    <link:label id="lab_biib_RateDuringReimbursementPeriod_7C48F47BAA151A887E11FCCBDB3F79A6_label_en-US" xlink:label="lab_biib_RateDuringReimbursementPeriod_7C48F47BAA151A887E11FCCBDB3F79A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rate During Reimbursement Period</link:label>
    <link:label id="lab_biib_RateDuringReimbursementPeriod_7C48F47BAA151A887E11FCCBDB3F79A6_documentation_en-US" xlink:label="lab_biib_RateDuringReimbursementPeriod_7C48F47BAA151A887E11FCCBDB3F79A6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Rate during the reimbursement period.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_RateDuringReimbursementPeriod" xlink:label="loc_biib_RateDuringReimbursementPeriod_7C48F47BAA151A887E11FCCBDB3F79A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RateDuringReimbursementPeriod_7C48F47BAA151A887E11FCCBDB3F79A6" xlink:to="lab_biib_RateDuringReimbursementPeriod_7C48F47BAA151A887E11FCCBDB3F79A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_044C5C253184537B43B4FCCBDA962932_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_044C5C253184537B43B4FCCBDA962932" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Quarterly Financial Information Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_044C5C253184537B43B4FCCBDA962932" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_044C5C253184537B43B4FCCBDA962932" xlink:to="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_044C5C253184537B43B4FCCBDA962932" xlink:type="arc" />
    <link:label id="lab_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_DD90BBCBFD70B10B3C91FCCBDA9677F8_terseLabel_en-US" xlink:label="lab_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_DD90BBCBFD70B10B3C91FCCBDA9677F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Development Milestone And Collaboration [Table]</link:label>
    <link:label id="lab_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_DD90BBCBFD70B10B3C91FCCBDA9677F8_label_en-US" xlink:label="lab_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_DD90BBCBFD70B10B3C91FCCBDA9677F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Development Milestone And Collaboration [Table]</link:label>
    <link:label id="lab_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_DD90BBCBFD70B10B3C91FCCBDA9677F8_documentation_en-US" xlink:label="lab_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_DD90BBCBFD70B10B3C91FCCBDA9677F8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of development milestone and collaboration.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable" xlink:label="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_DD90BBCBFD70B10B3C91FCCBDA9677F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_DD90BBCBFD70B10B3C91FCCBDA9677F8" xlink:to="lab_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_DD90BBCBFD70B10B3C91FCCBDA9677F8" xlink:type="arc" />
    <link:label id="lab_biib_SPINRAZAMember_A597A5BB090FCE733603FCCBDA97A7BE_terseLabel_en-US" xlink:label="lab_biib_SPINRAZAMember_A597A5BB090FCE733603FCCBDA97A7BE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SPINRAZA</link:label>
    <link:label id="lab_biib_SPINRAZAMember_A597A5BB090FCE733603FCCBDA97A7BE_label_en-US" xlink:label="lab_biib_SPINRAZAMember_A597A5BB090FCE733603FCCBDA97A7BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SPINRAZA [Member]</link:label>
    <link:label id="lab_biib_SPINRAZAMember_A597A5BB090FCE733603FCCBDA97A7BE_documentation_en-US" xlink:label="lab_biib_SPINRAZAMember_A597A5BB090FCE733603FCCBDA97A7BE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">SPINRAZA [Member]</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_SPINRAZAMember" xlink:label="loc_biib_SPINRAZAMember_A597A5BB090FCE733603FCCBDA97A7BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SPINRAZAMember_A597A5BB090FCE733603FCCBDA97A7BE" xlink:to="lab_biib_SPINRAZAMember_A597A5BB090FCE733603FCCBDA97A7BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_517001ABA83BD333B12DFCCBDA98971F_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_517001ABA83BD333B12DFCCBDA98971F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Interest Entities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:label="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_517001ABA83BD333B12DFCCBDA98971F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_517001ABA83BD333B12DFCCBDA98971F" xlink:to="lab_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_517001ABA83BD333B12DFCCBDA98971F" xlink:type="arc" />
    <link:label id="lab_biib_NeurimmuneMember_87A6135A4C1A251156ACFCCBDA98D7CE_terseLabel_en-US" xlink:label="lab_biib_NeurimmuneMember_87A6135A4C1A251156ACFCCBDA98D7CE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Neurimmune</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_NeurimmuneMember" xlink:label="loc_biib_NeurimmuneMember_87A6135A4C1A251156ACFCCBDA98D7CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NeurimmuneMember_87A6135A4C1A251156ACFCCBDA98D7CE" xlink:to="lab_biib_NeurimmuneMember_87A6135A4C1A251156ACFCCBDA98D7CE" xlink:type="arc" />
    <link:label id="lab_biib_IonisPharmaceuticalsInc.Member_029D1FC1B26E6FB2597BFCCBDA9DEA6E_terseLabel_en-US" xlink:label="lab_biib_IonisPharmaceuticalsInc.Member_029D1FC1B26E6FB2597BFCCBDA9DEA6E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ionis Pharmaceuticals, Inc. [Member]</link:label>
    <link:label id="lab_biib_IonisPharmaceuticalsInc.Member_029D1FC1B26E6FB2597BFCCBDA9DEA6E_label_en-US" xlink:label="lab_biib_IonisPharmaceuticalsInc.Member_029D1FC1B26E6FB2597BFCCBDA9DEA6E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ionis Pharmaceuticals, Inc. [Member]</link:label>
    <link:label id="lab_biib_IonisPharmaceuticalsInc.Member_029D1FC1B26E6FB2597BFCCBDA9DEA6E_documentation_en-US" xlink:label="lab_biib_IonisPharmaceuticalsInc.Member_029D1FC1B26E6FB2597BFCCBDA9DEA6E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ionis Pharmaceuticals, Inc. [Member]</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_IonisPharmaceuticalsInc.Member" xlink:label="loc_biib_IonisPharmaceuticalsInc.Member_029D1FC1B26E6FB2597BFCCBDA9DEA6E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IonisPharmaceuticalsInc.Member_029D1FC1B26E6FB2597BFCCBDA9DEA6E" xlink:to="lab_biib_IonisPharmaceuticalsInc.Member_029D1FC1B26E6FB2597BFCCBDA9DEA6E" xlink:type="arc" />
    <link:label id="lab_biib_AGTCMember_B6F3FE2551930753DC63FCCBDA98D175_terseLabel_en-US" xlink:label="lab_biib_AGTCMember_B6F3FE2551930753DC63FCCBDA98D175" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AGTC</link:label>
    <link:label id="lab_biib_AGTCMember_B6F3FE2551930753DC63FCCBDA98D175_label_en-US" xlink:label="lab_biib_AGTCMember_B6F3FE2551930753DC63FCCBDA98D175" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AGTC [Member]</link:label>
    <link:label id="lab_biib_AGTCMember_B6F3FE2551930753DC63FCCBDA98D175_documentation_en-US" xlink:label="lab_biib_AGTCMember_B6F3FE2551930753DC63FCCBDA98D175" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AGTC [Member]</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_AGTCMember" xlink:label="loc_biib_AGTCMember_B6F3FE2551930753DC63FCCBDA98D175" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AGTCMember_B6F3FE2551930753DC63FCCBDA98D175" xlink:to="lab_biib_AGTCMember_B6F3FE2551930753DC63FCCBDA98D175" xlink:type="arc" />
    <link:label id="lab_biib_MitsubishiTanabePharmaCorporationMember_26F6B8E4E4F33FCDCBBEFCCBDA9DC3B0_terseLabel_en-US" xlink:label="lab_biib_MitsubishiTanabePharmaCorporationMember_26F6B8E4E4F33FCDCBBEFCCBDA9DC3B0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Mitsubishi Tanabe Pharma Corporation</link:label>
    <link:label id="lab_biib_MitsubishiTanabePharmaCorporationMember_26F6B8E4E4F33FCDCBBEFCCBDA9DC3B0_label_en-US" xlink:label="lab_biib_MitsubishiTanabePharmaCorporationMember_26F6B8E4E4F33FCDCBBEFCCBDA9DC3B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mitsubishi Tanabe Pharma Corporation [Member]</link:label>
    <link:label id="lab_biib_MitsubishiTanabePharmaCorporationMember_26F6B8E4E4F33FCDCBBEFCCBDA9DC3B0_documentation_en-US" xlink:label="lab_biib_MitsubishiTanabePharmaCorporationMember_26F6B8E4E4F33FCDCBBEFCCBDA9DC3B0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Mitsubishi Tanabe Pharmaceutical Corporation [Member]</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_MitsubishiTanabePharmaCorporationMember" xlink:label="loc_biib_MitsubishiTanabePharmaCorporationMember_26F6B8E4E4F33FCDCBBEFCCBDA9DC3B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MitsubishiTanabePharmaCorporationMember_26F6B8E4E4F33FCDCBBEFCCBDA9DC3B0" xlink:to="lab_biib_MitsubishiTanabePharmaCorporationMember_26F6B8E4E4F33FCDCBBEFCCBDA9DC3B0" xlink:type="arc" />
    <link:label id="lab_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_8D61436B050E51C22A74FCCBDA9EDFA0_terseLabel_en-US" xlink:label="lab_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_8D61436B050E51C22A74FCCBDA9EDFA0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Development Milestone And Collaboration [Line Items]</link:label>
    <link:label id="lab_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_8D61436B050E51C22A74FCCBDA9EDFA0_label_en-US" xlink:label="lab_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_8D61436B050E51C22A74FCCBDA9EDFA0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Development Milestone And Collaboration [Line Items]</link:label>
    <link:label id="lab_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_8D61436B050E51C22A74FCCBDA9EDFA0_documentation_en-US" xlink:label="lab_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_8D61436B050E51C22A74FCCBDA9EDFA0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Development Milestone And Collaboration.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems" xlink:label="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_8D61436B050E51C22A74FCCBDA9EDFA0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_8D61436B050E51C22A74FCCBDA9EDFA0" xlink:to="lab_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_8D61436B050E51C22A74FCCBDA9EDFA0" xlink:type="arc" />
    <link:label id="lab_biib_LicenseFee_2B82C6267B65D2B2F27EFCCBDA9EAB75_terseLabel_en-US" xlink:label="lab_biib_LicenseFee_2B82C6267B65D2B2F27EFCCBDA9EAB75" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License Fee</link:label>
    <link:label id="lab_biib_LicenseFee_2B82C6267B65D2B2F27EFCCBDA9EAB75_label_en-US" xlink:label="lab_biib_LicenseFee_2B82C6267B65D2B2F27EFCCBDA9EAB75" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Fee</link:label>
    <link:label id="lab_biib_LicenseFee_2B82C6267B65D2B2F27EFCCBDA9EAB75_documentation_en-US" xlink:label="lab_biib_LicenseFee_2B82C6267B65D2B2F27EFCCBDA9EAB75" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License Fee</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_LicenseFee" xlink:label="loc_biib_LicenseFee_2B82C6267B65D2B2F27EFCCBDA9EAB75" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_LicenseFee_2B82C6267B65D2B2F27EFCCBDA9EAB75" xlink:to="lab_biib_LicenseFee_2B82C6267B65D2B2F27EFCCBDA9EAB75" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_8CA086F2C3B2A0583B4EFCCBDA9E31E3_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_8CA086F2C3B2A0583B4EFCCBDA9E31E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_8CA086F2C3B2A0583B4EFCCBDA9E31E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_8CA086F2C3B2A0583B4EFCCBDA9E31E3" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_8CA086F2C3B2A0583B4EFCCBDA9E31E3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_D562851649E94D4190F17412858AE074_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_D562851649E94D4190F17412858AE074" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase price</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_D562851649E94D4190F17412858AE074_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_D562851649E94D4190F17412858AE074" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_D562851649E94D4190F17412858AE074" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_D562851649E94D4190F17412858AE074" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_D562851649E94D4190F17412858AE074" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_B73DFAAF4E101BAFCA3F7412858A6FE2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_B73DFAAF4E101BAFCA3F7412858A6FE2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated fair values of separately identifiable assets acquired and liabilities assumed</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_B73DFAAF4E101BAFCA3F7412858A6FE2_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_B73DFAAF4E101BAFCA3F7412858A6FE2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_B73DFAAF4E101BAFCA3F7412858A6FE2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_B73DFAAF4E101BAFCA3F7412858A6FE2" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_B73DFAAF4E101BAFCA3F7412858A6FE2" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_20D527F0871241049B20FA3C6A7F33A2_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_20D527F0871241049B20FA3C6A7F33A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_20D527F0871241049B20FA3C6A7F33A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_20D527F0871241049B20FA3C6A7F33A2" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_20D527F0871241049B20FA3C6A7F33A2" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_158D11B3367370A54F4EFA3C6A80BBD3_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_158D11B3367370A54F4EFA3C6A80BBD3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_158D11B3367370A54F4EFA3C6A80BBD3_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_158D11B3367370A54F4EFA3C6A80BBD3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_158D11B3367370A54F4EFA3C6A80BBD3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_158D11B3367370A54F4EFA3C6A80BBD3" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_158D11B3367370A54F4EFA3C6A80BBD3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProfitLoss_57DB28BC89F13D2ACFFFFA3C6A80650E_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss_57DB28BC89F13D2ACFFFFA3C6A80650E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_57DB28BC89F13D2ACFFFFA3C6A80650E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_57DB28BC89F13D2ACFFFFA3C6A80650E" xlink:to="lab_us-gaap_ProfitLoss_57DB28BC89F13D2ACFFFFA3C6A80650E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_E6A3547D67A31AFC7811FA3C6A8078CC_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_E6A3547D67A31AFC7811FA3C6A8078CC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net income to net cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_E6A3547D67A31AFC7811FA3C6A8078CC_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_E6A3547D67A31AFC7811FA3C6A8078CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_E6A3547D67A31AFC7811FA3C6A8078CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_E6A3547D67A31AFC7811FA3C6A8078CC" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_E6A3547D67A31AFC7811FA3C6A8078CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_71350998FF7AB811690DFA3C6A80BC18_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_71350998FF7AB811690DFA3C6A80BC18" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_71350998FF7AB811690DFA3C6A80BC18_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_71350998FF7AB811690DFA3C6A80BC18" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_71350998FF7AB811690DFA3C6A80BC18" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization_71350998FF7AB811690DFA3C6A80BC18" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization_71350998FF7AB811690DFA3C6A80BC18" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensation_74335836FE74462160BBFA3C6A8026BA_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_74335836FE74462160BBFA3C6A8026BA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_74335836FE74462160BBFA3C6A8026BA_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_74335836FE74462160BBFA3C6A8026BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_74335836FE74462160BBFA3C6A8026BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_74335836FE74462160BBFA3C6A8026BA" xlink:to="lab_us-gaap_ShareBasedCompensation_74335836FE74462160BBFA3C6A8026BA" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_7F0845890384B51B44C2FA3C6A80D75A_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_7F0845890384B51B44C2FA3C6A80D75A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_7F0845890384B51B44C2FA3C6A80D75A_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_7F0845890384B51B44C2FA3C6A80D75A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_7F0845890384B51B44C2FA3C6A80D75A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_7F0845890384B51B44C2FA3C6A80D75A" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_7F0845890384B51B44C2FA3C6A80D75A" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_82D4ECADECFF8461A6D7FA3C6A803FFC_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense_82D4ECADECFF8461A6D7FA3C6A803FFC" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_82D4ECADECFF8461A6D7FA3C6A803FFC_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense_82D4ECADECFF8461A6D7FA3C6A803FFC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_82D4ECADECFF8461A6D7FA3C6A803FFC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense_82D4ECADECFF8461A6D7FA3C6A803FFC" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense_82D4ECADECFF8461A6D7FA3C6A803FFC" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_42C2D3FDA29062537AE8FA3C6A807DA0_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_42C2D3FDA29062537AE8FA3C6A807DA0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities, net:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_42C2D3FDA29062537AE8FA3C6A807DA0_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_42C2D3FDA29062537AE8FA3C6A807DA0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_42C2D3FDA29062537AE8FA3C6A807DA0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_42C2D3FDA29062537AE8FA3C6A807DA0" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_42C2D3FDA29062537AE8FA3C6A807DA0" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_041BA8DE6CE9F5AA66E4FA3C6A80DFCA_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_041BA8DE6CE9F5AA66E4FA3C6A80DFCA" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_041BA8DE6CE9F5AA66E4FA3C6A80DFCA_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_041BA8DE6CE9F5AA66E4FA3C6A80DFCA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_041BA8DE6CE9F5AA66E4FA3C6A80DFCA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_041BA8DE6CE9F5AA66E4FA3C6A80DFCA" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_041BA8DE6CE9F5AA66E4FA3C6A80DFCA" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_C6924A04301FBEDCAD11FA3C6A816021_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_C6924A04301FBEDCAD11FA3C6A816021" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Due from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_C6924A04301FBEDCAD11FA3C6A816021_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_C6924A04301FBEDCAD11FA3C6A816021" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Assets and Liabilities, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_C6924A04301FBEDCAD11FA3C6A816021" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_C6924A04301FBEDCAD11FA3C6A816021" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_C6924A04301FBEDCAD11FA3C6A816021" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_21421CBE960CBBF30B55FA3C6A8017DA_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_21421CBE960CBBF30B55FA3C6A8017DA" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_21421CBE960CBBF30B55FA3C6A8017DA_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_21421CBE960CBBF30B55FA3C6A8017DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_21421CBE960CBBF30B55FA3C6A8017DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories_21421CBE960CBBF30B55FA3C6A8017DA" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories_21421CBE960CBBF30B55FA3C6A8017DA" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_3A98B7C20E7B72F81D04FA3C6A807854_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_3A98B7C20E7B72F81D04FA3C6A807854" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_3A98B7C20E7B72F81D04FA3C6A807854_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_3A98B7C20E7B72F81D04FA3C6A807854" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_3A98B7C20E7B72F81D04FA3C6A807854" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_3A98B7C20E7B72F81D04FA3C6A807854" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_3A98B7C20E7B72F81D04FA3C6A807854" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_4EB2F9329F7EDEA17E1DFA3C6A80DE4C_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_4EB2F9329F7EDEA17E1DFA3C6A80DE4C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_4EB2F9329F7EDEA17E1DFA3C6A80DE4C_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_4EB2F9329F7EDEA17E1DFA3C6A80DE4C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_4EB2F9329F7EDEA17E1DFA3C6A80DE4C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_4EB2F9329F7EDEA17E1DFA3C6A80DE4C" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_4EB2F9329F7EDEA17E1DFA3C6A80DE4C" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_B45D3B804659458985A5FA3C6A801B0F_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_B45D3B804659458985A5FA3C6A801B0F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax assets and liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_B45D3B804659458985A5FA3C6A801B0F_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_B45D3B804659458985A5FA3C6A801B0F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_B45D3B804659458985A5FA3C6A801B0F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_B45D3B804659458985A5FA3C6A801B0F" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_B45D3B804659458985A5FA3C6A801B0F" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_9BE5090FA78850ADE4BFFA3C6A81CA99_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_9BE5090FA78850ADE4BFFA3C6A81CA99" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_9BE5090FA78850ADE4BFFA3C6A81CA99_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_9BE5090FA78850ADE4BFFA3C6A81CA99" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_9BE5090FA78850ADE4BFFA3C6A81CA99" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_9BE5090FA78850ADE4BFFA3C6A81CA99" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_9BE5090FA78850ADE4BFFA3C6A81CA99" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_5D8B873FB2833FC61724FA3C6A81C159_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_5D8B873FB2833FC61724FA3C6A81C159" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash flows provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_5D8B873FB2833FC61724FA3C6A81C159_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_5D8B873FB2833FC61724FA3C6A81C159" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5D8B873FB2833FC61724FA3C6A81C159" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5D8B873FB2833FC61724FA3C6A81C159" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_5D8B873FB2833FC61724FA3C6A81C159" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_FB9AD60121FCFA545899FA3C6A81B80F_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_FB9AD60121FCFA545899FA3C6A81B80F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_FB9AD60121FCFA545899FA3C6A81B80F_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_FB9AD60121FCFA545899FA3C6A81B80F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_FB9AD60121FCFA545899FA3C6A81B80F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_FB9AD60121FCFA545899FA3C6A81B80F" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_FB9AD60121FCFA545899FA3C6A81B80F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_30CB034E054E2E049A1EFA3C6A81C179_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_30CB034E054E2E049A1EFA3C6A81C179" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sales and maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_30CB034E054E2E049A1EFA3C6A81C179_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_30CB034E054E2E049A1EFA3C6A81C179" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale and Maturity of Available-for-sale Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_30CB034E054E2E049A1EFA3C6A81C179" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_30CB034E054E2E049A1EFA3C6A81C179" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_30CB034E054E2E049A1EFA3C6A81C179" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_CA06DC1D51B9DCEC6C01FA3C6A813FCF_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_CA06DC1D51B9DCEC6C01FA3C6A813FCF" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_CA06DC1D51B9DCEC6C01FA3C6A813FCF_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_CA06DC1D51B9DCEC6C01FA3C6A813FCF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Available-for-sale Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_CA06DC1D51B9DCEC6C01FA3C6A813FCF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_CA06DC1D51B9DCEC6C01FA3C6A813FCF" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_CA06DC1D51B9DCEC6C01FA3C6A813FCF" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_C30BCD1ACCEA0075B0CAFA3C6A81A342_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_C30BCD1ACCEA0075B0CAFA3C6A81A342" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration related to Fumapharm AG acquisition</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_C30BCD1ACCEA0075B0CAFA3C6A81A342_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_C30BCD1ACCEA0075B0CAFA3C6A81A342" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Other Productive Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_C30BCD1ACCEA0075B0CAFA3C6A81A342" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_C30BCD1ACCEA0075B0CAFA3C6A81A342" xlink:to="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_C30BCD1ACCEA0075B0CAFA3C6A81A342" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_4627D2DD633EDB327E3FFA3C6A818A22_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_4627D2DD633EDB327E3FFA3C6A818A22" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Acquisitions of businesses, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_4627D2DD633EDB327E3FFA3C6A818A22_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_4627D2DD633EDB327E3FFA3C6A818A22" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_4627D2DD633EDB327E3FFA3C6A818A22" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_4627D2DD633EDB327E3FFA3C6A818A22" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_4627D2DD633EDB327E3FFA3C6A818A22" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ED212E4ABBE3397D5099FA3C6A81203B_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ED212E4ABBE3397D5099FA3C6A81203B" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ED212E4ABBE3397D5099FA3C6A81203B_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ED212E4ABBE3397D5099FA3C6A81203B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ED212E4ABBE3397D5099FA3C6A81203B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ED212E4ABBE3397D5099FA3C6A81203B" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ED212E4ABBE3397D5099FA3C6A81203B" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_A67A989AD8BBF7062697FA3C6A818D86_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets_A67A989AD8BBF7062697FA3C6A818D86" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions of intangible assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_A67A989AD8BBF7062697FA3C6A818D86_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets_A67A989AD8BBF7062697FA3C6A818D86" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_A67A989AD8BBF7062697FA3C6A818D86" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets_A67A989AD8BBF7062697FA3C6A818D86" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets_A67A989AD8BBF7062697FA3C6A818D86" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_9B2761B204B1B4B90B0AFA3C6A819CC8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_9B2761B204B1B4B90B0AFA3C6A819CC8" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_9B2761B204B1B4B90B0AFA3C6A819CC8_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_9B2761B204B1B4B90B0AFA3C6A819CC8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_9B2761B204B1B4B90B0AFA3C6A819CC8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_9B2761B204B1B4B90B0AFA3C6A819CC8" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_9B2761B204B1B4B90B0AFA3C6A819CC8" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_059F6839B852AFF97D8BFA3C6A813167_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_059F6839B852AFF97D8BFA3C6A813167" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash flows used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_059F6839B852AFF97D8BFA3C6A813167_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_059F6839B852AFF97D8BFA3C6A813167" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_059F6839B852AFF97D8BFA3C6A813167" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_059F6839B852AFF97D8BFA3C6A813167" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_059F6839B852AFF97D8BFA3C6A813167" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0EB7899DEDF87E024881FA3C6A810549_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0EB7899DEDF87E024881FA3C6A810549" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0EB7899DEDF87E024881FA3C6A810549_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0EB7899DEDF87E024881FA3C6A810549" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0EB7899DEDF87E024881FA3C6A810549" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0EB7899DEDF87E024881FA3C6A810549" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0EB7899DEDF87E024881FA3C6A810549" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_C6708D623F9DFEA644DCFA3C6A8125BF_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_C6708D623F9DFEA644DCFA3C6A8125BF" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of treasury stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_C6708D623F9DFEA644DCFA3C6A8125BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_C6708D623F9DFEA644DCFA3C6A8125BF" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_C6708D623F9DFEA644DCFA3C6A8125BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_C36510AAF636CD372935FA3C6A8192E0_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_C36510AAF636CD372935FA3C6A8192E0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of stock for share-based compensation arrangements</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_C36510AAF636CD372935FA3C6A8192E0_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_C36510AAF636CD372935FA3C6A8192E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Shares under Incentive and Share-based Compensation Plans, Including Stock Options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_C36510AAF636CD372935FA3C6A8192E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_C36510AAF636CD372935FA3C6A8192E0" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_C36510AAF636CD372935FA3C6A8192E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromNotesPayable_4EDEF56FA3A537DB0B85FA3C6A825CCD_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromNotesPayable_4EDEF56FA3A537DB0B85FA3C6A825CCD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from borrowings</link:label>
    <link:label id="lab_us-gaap_ProceedsFromNotesPayable_4EDEF56FA3A537DB0B85FA3C6A825CCD_label_en-US" xlink:label="lab_us-gaap_ProceedsFromNotesPayable_4EDEF56FA3A537DB0B85FA3C6A825CCD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Notes Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_4EDEF56FA3A537DB0B85FA3C6A825CCD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromNotesPayable_4EDEF56FA3A537DB0B85FA3C6A825CCD" xlink:to="lab_us-gaap_ProceedsFromNotesPayable_4EDEF56FA3A537DB0B85FA3C6A825CCD" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepaymentsOfDebt_678D707A4169C048E0C2FA3C6A825B85_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt_678D707A4169C048E0C2FA3C6A825B85" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repayments of borrowings</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_678D707A4169C048E0C2FA3C6A825B85_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt_678D707A4169C048E0C2FA3C6A825B85" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaap_RepaymentsOfDebt_678D707A4169C048E0C2FA3C6A825B85" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebt_678D707A4169C048E0C2FA3C6A825B85" xlink:to="lab_us-gaap_RepaymentsOfDebt_678D707A4169C048E0C2FA3C6A825B85" xlink:type="arc" />
    <link:label id="lab_us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities_FF07CC051F19F4D7CBDFFA3C6A82CCD7_terseLabel_en-US" xlink:label="lab_us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities_FF07CC051F19F4D7CBDFFA3C6A82CCD7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Excess tax benefit from share-based compensation</link:label>
    <link:label id="lab_us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities_FF07CC051F19F4D7CBDFFA3C6A82CCD7_label_en-US" xlink:label="lab_us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities_FF07CC051F19F4D7CBDFFA3C6A82CCD7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Excess Tax Benefit from Share-based Compensation, Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities" xlink:label="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities_FF07CC051F19F4D7CBDFFA3C6A82CCD7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities_FF07CC051F19F4D7CBDFFA3C6A82CCD7" xlink:to="lab_us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities_FF07CC051F19F4D7CBDFFA3C6A82CCD7" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_2B1A901B977CC0FBD6CAFA3C6A82759E_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets_2B1A901B977CC0FBD6CAFA3C6A82759E" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration payments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_2B1A901B977CC0FBD6CAFA3C6A82759E_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets_2B1A901B977CC0FBD6CAFA3C6A82759E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Productive Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_2B1A901B977CC0FBD6CAFA3C6A82759E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireProductiveAssets_2B1A901B977CC0FBD6CAFA3C6A82759E" xlink:to="lab_us-gaap_PaymentsToAcquireProductiveAssets_2B1A901B977CC0FBD6CAFA3C6A82759E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_9395B585664B62DD921BFA3C6A8244AA_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_9395B585664B62DD921BFA3C6A8244AA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_9395B585664B62DD921BFA3C6A8244AA_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_9395B585664B62DD921BFA3C6A8244AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_9395B585664B62DD921BFA3C6A8244AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_9395B585664B62DD921BFA3C6A8244AA" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_9395B585664B62DD921BFA3C6A8244AA" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_40D54524EB9C30D7701BFA3C6A826A1E_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_40D54524EB9C30D7701BFA3C6A826A1E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash flows provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_40D54524EB9C30D7701BFA3C6A826A1E_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_40D54524EB9C30D7701BFA3C6A826A1E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_40D54524EB9C30D7701BFA3C6A826A1E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_40D54524EB9C30D7701BFA3C6A826A1E" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_40D54524EB9C30D7701BFA3C6A826A1E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_88F9ADFB136CBBD39D21FA3C6A82391B_totalLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_88F9ADFB136CBBD39D21FA3C6A82391B" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_88F9ADFB136CBBD39D21FA3C6A82391B_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_88F9ADFB136CBBD39D21FA3C6A82391B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_88F9ADFB136CBBD39D21FA3C6A82391B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_88F9ADFB136CBBD39D21FA3C6A82391B" xlink:to="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_88F9ADFB136CBBD39D21FA3C6A82391B" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_3DBA04B4518DC0F8850AFA3C6A824D91_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_3DBA04B4518DC0F8850AFA3C6A824D91" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_3DBA04B4518DC0F8850AFA3C6A824D91_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_3DBA04B4518DC0F8850AFA3C6A824D91" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash and Cash Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_3DBA04B4518DC0F8850AFA3C6A824D91" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_3DBA04B4518DC0F8850AFA3C6A824D91" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_3DBA04B4518DC0F8850AFA3C6A824D91" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_73AB53D0BE4D003782DCFA3C6A822A47_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_73AB53D0BE4D003782DCFA3C6A822A47" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, beginning of the year</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_73AB53D0BE4D003782DCFA3C6A822A47_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_73AB53D0BE4D003782DCFA3C6A822A47" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_73AB53D0BE4D003782DCFA3C6A822A47" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_73AB53D0BE4D003782DCFA3C6A822A47" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_73AB53D0BE4D003782DCFA3C6A822A47" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_F80F8EA146621F71D853FA3C6A8226EA_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_F80F8EA146621F71D853FA3C6A8226EA" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, end of the year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_F80F8EA146621F71D853FA3C6A8226EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_F80F8EA146621F71D853FA3C6A8226EA" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_F80F8EA146621F71D853FA3C6A8226EA" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_D8571DDA0FD9E9CA6E67FCCBDB08BD27_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_D8571DDA0FD9E9CA6E67FCCBDB08BD27" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_D8571DDA0FD9E9CA6E67FCCBDB08BD27" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_D8571DDA0FD9E9CA6E67FCCBDB08BD27" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_D8571DDA0FD9E9CA6E67FCCBDB08BD27" xlink:type="arc" />
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_C601848522D0FD08508CFCCBDB08078D_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_C601848522D0FD08508CFCCBDB08078D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital leases, future minimum payments due in 2017</link:label>
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_C601848522D0FD08508CFCCBDB08078D_label_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_C601848522D0FD08508CFCCBDB08078D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Leases, Future Minimum Payments Due, Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_C601848522D0FD08508CFCCBDB08078D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_C601848522D0FD08508CFCCBDB08078D" xlink:to="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_C601848522D0FD08508CFCCBDB08078D" xlink:type="arc" />
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_5AF9F70C229C82284191FCCBDB08D779_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_5AF9F70C229C82284191FCCBDB08D779" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital leases, future minimum payments due in 2018</link:label>
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_5AF9F70C229C82284191FCCBDB08D779_label_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_5AF9F70C229C82284191FCCBDB08D779" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Leases, Future Minimum Payments Due in Two Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_5AF9F70C229C82284191FCCBDB08D779" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_5AF9F70C229C82284191FCCBDB08D779" xlink:to="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_5AF9F70C229C82284191FCCBDB08D779" xlink:type="arc" />
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDue_ABA7C901EFE234F86D4CFCCBDB08BD9C_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDue_ABA7C901EFE234F86D4CFCCBDB08BD9C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital leases, future minimum payments due total</link:label>
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDue_ABA7C901EFE234F86D4CFCCBDB08BD9C_label_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDue_ABA7C901EFE234F86D4CFCCBDB08BD9C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Leases, Future Minimum Payments Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDue_ABA7C901EFE234F86D4CFCCBDB08BD9C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDue_ABA7C901EFE234F86D4CFCCBDB08BD9C" xlink:to="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDue_ABA7C901EFE234F86D4CFCCBDB08BD9C" xlink:type="arc" />
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments_B502AE9617ECB046EC34FCCBDB083B83_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments_B502AE9617ECB046EC34FCCBDB083B83" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: interest on capital lease</link:label>
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments_B502AE9617ECB046EC34FCCBDB083B83_label_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments_B502AE9617ECB046EC34FCCBDB083B83" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Leases, Future Minimum Payments, Interest Included in Payments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments_B502AE9617ECB046EC34FCCBDB083B83" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments_B502AE9617ECB046EC34FCCBDB083B83" xlink:to="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments_B502AE9617ECB046EC34FCCBDB083B83" xlink:type="arc" />
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments_BED88C35F6FEBD234766FCCBDB08AE0A_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments_BED88C35F6FEBD234766FCCBDB08AE0A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net present value of the future minimum lease payments</link:label>
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments_BED88C35F6FEBD234766FCCBDB08AE0A_label_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments_BED88C35F6FEBD234766FCCBDB08AE0A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Leases, Future Minimum Payments, Present Value of Net Minimum Payments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments_BED88C35F6FEBD234766FCCBDB08AE0A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments_BED88C35F6FEBD234766FCCBDB08AE0A" xlink:to="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments_BED88C35F6FEBD234766FCCBDB08AE0A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_19DAD7DC54B2DC0DF9C17412892D15C3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_19DAD7DC54B2DC0DF9C17412892D15C3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_19DAD7DC54B2DC0DF9C17412892D15C3_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_19DAD7DC54B2DC0DF9C17412892D15C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_19DAD7DC54B2DC0DF9C17412892D15C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_19DAD7DC54B2DC0DF9C17412892D15C3" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_19DAD7DC54B2DC0DF9C17412892D15C3" xlink:type="arc" />
    <link:label id="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_239F68ED15E0CEFF272F7412892D9E9C_terseLabel_en-US" xlink:label="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_239F68ED15E0CEFF272F7412892D9E9C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Major Types of Debt and Equity Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_239F68ED15E0CEFF272F7412892D9E9C_label_en-US" xlink:label="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_239F68ED15E0CEFF272F7412892D9E9C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major Types of Debt and Equity Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_239F68ED15E0CEFF272F7412892D9E9C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_239F68ED15E0CEFF272F7412892D9E9C" xlink:to="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_239F68ED15E0CEFF272F7412892D9E9C" xlink:type="arc" />
    <link:label id="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_3FD54EFB30E9436DB6897412892DEBE2_terseLabel_en-US" xlink:label="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_3FD54EFB30E9436DB6897412892DEBE2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Major Types of Debt and Equity Securities [Domain]</link:label>
    <link:label id="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_3FD54EFB30E9436DB6897412892DEBE2_label_en-US" xlink:label="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_3FD54EFB30E9436DB6897412892DEBE2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major Types of Debt and Equity Securities [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_3FD54EFB30E9436DB6897412892DEBE2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_3FD54EFB30E9436DB6897412892DEBE2" xlink:to="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_3FD54EFB30E9436DB6897412892DEBE2" xlink:type="arc" />
    <link:label id="lab_biib_StrategicInvestmentsMember_3A56DF22F59F5DDF8DA27412892D5151_terseLabel_en-US" xlink:label="lab_biib_StrategicInvestmentsMember_3A56DF22F59F5DDF8DA27412892D5151" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Strategic Investments</link:label>
    <link:label id="lab_biib_StrategicInvestmentsMember_3A56DF22F59F5DDF8DA27412892D5151_label_en-US" xlink:label="lab_biib_StrategicInvestmentsMember_3A56DF22F59F5DDF8DA27412892D5151" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Strategic Investments [Member]</link:label>
    <link:label id="lab_biib_StrategicInvestmentsMember_3A56DF22F59F5DDF8DA27412892D5151_documentation_en-US" xlink:label="lab_biib_StrategicInvestmentsMember_3A56DF22F59F5DDF8DA27412892D5151" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Strategic investments.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_StrategicInvestmentsMember" xlink:label="loc_biib_StrategicInvestmentsMember_3A56DF22F59F5DDF8DA27412892D5151" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_StrategicInvestmentsMember_3A56DF22F59F5DDF8DA27412892D5151" xlink:to="lab_biib_StrategicInvestmentsMember_3A56DF22F59F5DDF8DA27412892D5151" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_4B2010F92FBE1938FF967412892D594C_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems_4B2010F92FBE1938FF967412892D594C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_4B2010F92FBE1938FF967412892D594C_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems_4B2010F92FBE1938FF967412892D594C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_4B2010F92FBE1938FF967412892D594C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4B2010F92FBE1938FF967412892D594C" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems_4B2010F92FBE1938FF967412892D594C" xlink:type="arc" />
    <link:label id="lab_biib_StrategicInvestmentPortfolio_9CD6A3EA0986DD668F157412892D8E5F_verboseLabel_en-US" xlink:label="lab_biib_StrategicInvestmentPortfolio_9CD6A3EA0986DD668F157412892D8E5F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Strategic investment portfolio</link:label>
    <link:label id="lab_biib_StrategicInvestmentPortfolio_9CD6A3EA0986DD668F157412892D8E5F_label_en-US" xlink:label="lab_biib_StrategicInvestmentPortfolio_9CD6A3EA0986DD668F157412892D8E5F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Strategic Investment Portfolio</link:label>
    <link:label id="lab_biib_StrategicInvestmentPortfolio_9CD6A3EA0986DD668F157412892D8E5F_documentation_en-US" xlink:label="lab_biib_StrategicInvestmentPortfolio_9CD6A3EA0986DD668F157412892D8E5F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Strategic investment portfolio.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_StrategicInvestmentPortfolio" xlink:label="loc_biib_StrategicInvestmentPortfolio_9CD6A3EA0986DD668F157412892D8E5F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_StrategicInvestmentPortfolio_9CD6A3EA0986DD668F157412892D8E5F" xlink:to="lab_biib_StrategicInvestmentPortfolio_9CD6A3EA0986DD668F157412892D8E5F" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_D5BEFA375996064EEB5974128890BF8D_label_en-US" xlink:label="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_D5BEFA375996064EEB5974128890BF8D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Information about Litigation Matters [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:label="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_D5BEFA375996064EEB5974128890BF8D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_D5BEFA375996064EEB5974128890BF8D" xlink:to="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_D5BEFA375996064EEB5974128890BF8D" xlink:type="arc" />
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_CFE7BF3D427C0D89F572741288912A24_verboseLabel_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock_CFE7BF3D427C0D89F572741288912A24" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Litigation</link:label>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_CFE7BF3D427C0D89F572741288912A24_label_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock_CFE7BF3D427C0D89F572741288912A24" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Matters and Contingencies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_CFE7BF3D427C0D89F572741288912A24" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalMattersAndContingenciesTextBlock_CFE7BF3D427C0D89F572741288912A24" xlink:to="lab_us-gaap_LegalMattersAndContingenciesTextBlock_CFE7BF3D427C0D89F572741288912A24" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentReportingAbstract_C80BC235D2A1D18B179E7412887E1443_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract_C80BC235D2A1D18B179E7412887E1443" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_C80BC235D2A1D18B179E7412887E1443" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract_C80BC235D2A1D18B179E7412887E1443" xlink:to="lab_us-gaap_SegmentReportingAbstract_C80BC235D2A1D18B179E7412887E1443" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_102AF70286EE64762A887412887EBEA8_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock_102AF70286EE64762A887412887EBEA8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_102AF70286EE64762A887412887EBEA8_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock_102AF70286EE64762A887412887EBEA8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_102AF70286EE64762A887412887EBEA8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock_102AF70286EE64762A887412887EBEA8" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock_102AF70286EE64762A887412887EBEA8" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtCurrentAbstract_A6EE826FFB2C467AA233741288AA0965_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrentAbstract_A6EE826FFB2C467AA233741288AA0965" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion:</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrentAbstract_A6EE826FFB2C467AA233741288AA0965_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrentAbstract_A6EE826FFB2C467AA233741288AA0965" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Current Maturities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtCurrentAbstract" xlink:label="loc_us-gaap_LongTermDebtCurrentAbstract_A6EE826FFB2C467AA233741288AA0965" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrentAbstract_A6EE826FFB2C467AA233741288AA0965" xlink:to="lab_us-gaap_LongTermDebtCurrentAbstract_A6EE826FFB2C467AA233741288AA0965" xlink:type="arc" />
    <link:label id="lab_us-gaap_NotesPayableCurrent_C31B1000A917B2A5C089741288AA281D_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent_C31B1000A917B2A5C089741288AA281D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes payable to Fumedica</link:label>
    <link:label id="lab_us-gaap_NotesPayableCurrent_C31B1000A917B2A5C089741288AA281D_label_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent_C31B1000A917B2A5C089741288AA281D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent_C31B1000A917B2A5C089741288AA281D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableCurrent_C31B1000A917B2A5C089741288AA281D" xlink:to="lab_us-gaap_NotesPayableCurrent_C31B1000A917B2A5C089741288AA281D" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_6DFFAFF1E404547E719A741288AA4E43_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_6DFFAFF1E404547E719A741288AA4E43" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing arrangement for the purchase of the RTP facility</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_6DFFAFF1E404547E719A741288AA4E43_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_6DFFAFF1E404547E719A741288AA4E43" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt and Capital Lease Obligations, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_6DFFAFF1E404547E719A741288AA4E43" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_6DFFAFF1E404547E719A741288AA4E43" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_6DFFAFF1E404547E719A741288AA4E43" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtCurrent_3C7D1573FDEBA5ED8472741288AB984F_terseLabel_en-US" xlink:label="lab_us-gaap_DebtCurrent_3C7D1573FDEBA5ED8472741288AB984F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion of notes payable and other financing arrangements</link:label>
    <link:label id="lab_us-gaap_DebtCurrent_3C7D1573FDEBA5ED8472741288AB984F_label_en-US" xlink:label="lab_us-gaap_DebtCurrent_3C7D1573FDEBA5ED8472741288AB984F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_3C7D1573FDEBA5ED8472741288AB984F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtCurrent_3C7D1573FDEBA5ED8472741288AB984F" xlink:to="lab_us-gaap_DebtCurrent_3C7D1573FDEBA5ED8472741288AB984F" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtNoncurrentAbstract_93443A2C22ECD0C39F07741288ABCDDA_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrentAbstract_93443A2C22ECD0C39F07741288ABCDDA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current portion:</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrentAbstract_93443A2C22ECD0C39F07741288ABCDDA_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrentAbstract_93443A2C22ECD0C39F07741288ABCDDA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Excluding Current Maturities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtNoncurrentAbstract" xlink:label="loc_us-gaap_LongTermDebtNoncurrentAbstract_93443A2C22ECD0C39F07741288ABCDDA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrentAbstract_93443A2C22ECD0C39F07741288ABCDDA" xlink:to="lab_us-gaap_LongTermDebtNoncurrentAbstract_93443A2C22ECD0C39F07741288ABCDDA" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermNotesPayable_FD3ABB6E93C3F750EEE4741288AB5B0F_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermNotesPayable_FD3ABB6E93C3F750EEE4741288AB5B0F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current notes payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaap_LongTermNotesPayable_FD3ABB6E93C3F750EEE4741288AB5B0F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermNotesPayable_FD3ABB6E93C3F750EEE4741288AB5B0F" xlink:to="lab_us-gaap_LongTermNotesPayable_FD3ABB6E93C3F750EEE4741288AB5B0F" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_FAFDE133BE7A727291CE741288ABB2AC_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_FAFDE133BE7A727291CE741288ABB2AC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing arrangement for the purchase of the RTP facility</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_FAFDE133BE7A727291CE741288ABB2AC_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_FAFDE133BE7A727291CE741288ABB2AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt and Capital Lease Obligations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_FAFDE133BE7A727291CE741288ABB2AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_FAFDE133BE7A727291CE741288ABB2AC" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_FAFDE133BE7A727291CE741288ABB2AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebt_1BF3B6344A87BA76F58D741288AB31AA_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt_1BF3B6344A87BA76F58D741288AB31AA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current portion of notes payable and other financing arrangements</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_1BF3B6344A87BA76F58D741288AB31AA_label_en-US" xlink:label="lab_us-gaap_LongTermDebt_1BF3B6344A87BA76F58D741288AB31AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_1BF3B6344A87BA76F58D741288AB31AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt_1BF3B6344A87BA76F58D741288AB31AA" xlink:to="lab_us-gaap_LongTermDebt_1BF3B6344A87BA76F58D741288AB31AA" xlink:type="arc" />
    <link:label id="lab_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_BD09442F3C0EB9A54D86FCCBDB1182F9_verboseLabel_en-US" xlink:label="lab_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_BD09442F3C0EB9A54D86FCCBDB1182F9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Minimum rental commitments under non-cancelable leases</link:label>
    <link:label id="lab_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_BD09442F3C0EB9A54D86FCCBDB1182F9_label_en-US" xlink:label="lab_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_BD09442F3C0EB9A54D86FCCBDB1182F9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum Rental Commitments Under Noncancellable Leases [Abstract]</link:label>
    <link:label id="lab_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_BD09442F3C0EB9A54D86FCCBDB1182F9_documentation_en-US" xlink:label="lab_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_BD09442F3C0EB9A54D86FCCBDB1182F9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Minimum rental commitments under noncancellable leases.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract" xlink:label="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_BD09442F3C0EB9A54D86FCCBDB1182F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_BD09442F3C0EB9A54D86FCCBDB1182F9" xlink:to="lab_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_BD09442F3C0EB9A54D86FCCBDB1182F9" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_3BA706F6C55680FDE605FCCBDB12E123_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_3BA706F6C55680FDE605FCCBDB12E123" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Minimum lease payments, 2017</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_3BA706F6C55680FDE605FCCBDB12E123_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_3BA706F6C55680FDE605FCCBDB12E123" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_3BA706F6C55680FDE605FCCBDB12E123" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_3BA706F6C55680FDE605FCCBDB12E123" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_3BA706F6C55680FDE605FCCBDB12E123" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_EF49597FC0B80C186853FCCBDB1206DF_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_EF49597FC0B80C186853FCCBDB1206DF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Minimum lease payments, 2018</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_EF49597FC0B80C186853FCCBDB1206DF_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_EF49597FC0B80C186853FCCBDB1206DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Two Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_EF49597FC0B80C186853FCCBDB1206DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_EF49597FC0B80C186853FCCBDB1206DF" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_EF49597FC0B80C186853FCCBDB1206DF" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_EEC0E54505AC7247780BFCCBDB126316_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_EEC0E54505AC7247780BFCCBDB126316" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Minimum lease payments, 2019</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_EEC0E54505AC7247780BFCCBDB126316_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_EEC0E54505AC7247780BFCCBDB126316" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Three Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_EEC0E54505AC7247780BFCCBDB126316" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_EEC0E54505AC7247780BFCCBDB126316" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_EEC0E54505AC7247780BFCCBDB126316" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_EEC1923A1588BEF0CEFEFCCBDB125C85_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_EEC1923A1588BEF0CEFEFCCBDB125C85" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Minimum lease payments, 2020</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_EEC1923A1588BEF0CEFEFCCBDB125C85_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_EEC1923A1588BEF0CEFEFCCBDB125C85" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Four Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_EEC1923A1588BEF0CEFEFCCBDB125C85" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_EEC1923A1588BEF0CEFEFCCBDB125C85" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_EEC1923A1588BEF0CEFEFCCBDB125C85" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_B770D8638394C03E35ADFCCBDB12E7C1_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_B770D8638394C03E35ADFCCBDB12E7C1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Minimum lease payments, 2021</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_B770D8638394C03E35ADFCCBDB12E7C1_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_B770D8638394C03E35ADFCCBDB12E7C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Five Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_B770D8638394C03E35ADFCCBDB12E7C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_B770D8638394C03E35ADFCCBDB12E7C1" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_B770D8638394C03E35ADFCCBDB12E7C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_0D8237DC63B31443DB5BFCCBDB124496_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_0D8237DC63B31443DB5BFCCBDB124496" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Minimum lease payments, Thereafter</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_0D8237DC63B31443DB5BFCCBDB124496_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_0D8237DC63B31443DB5BFCCBDB124496" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due Thereafter</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_0D8237DC63B31443DB5BFCCBDB124496" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_0D8237DC63B31443DB5BFCCBDB124496" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_0D8237DC63B31443DB5BFCCBDB124496" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_381FE6E685D46EA38891FCCBDB12390D_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_381FE6E685D46EA38891FCCBDB12390D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum lease payments, Total</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_381FE6E685D46EA38891FCCBDB12390D_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_381FE6E685D46EA38891FCCBDB12390D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_381FE6E685D46EA38891FCCBDB12390D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_381FE6E685D46EA38891FCCBDB12390D" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_381FE6E685D46EA38891FCCBDB12390D" xlink:type="arc" />
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_665D61F6138B179FC2EAFCCBDB1238D8_negatedLabel_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_665D61F6138B179FC2EAFCCBDB1238D8" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: income from subleases, 2017</link:label>
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_665D61F6138B179FC2EAFCCBDB1238D8_label_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_665D61F6138B179FC2EAFCCBDB1238D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Minimum Sublease Rentals, Sale Leaseback Transactions, Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_665D61F6138B179FC2EAFCCBDB1238D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_665D61F6138B179FC2EAFCCBDB1238D8" xlink:to="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_665D61F6138B179FC2EAFCCBDB1238D8" xlink:type="arc" />
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_022D2C9D6570691FFD59FCCBDB123FD4_negatedLabel_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_022D2C9D6570691FFD59FCCBDB123FD4" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: income from subleases, 2018</link:label>
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_022D2C9D6570691FFD59FCCBDB123FD4_label_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_022D2C9D6570691FFD59FCCBDB123FD4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Minimum Sublease Rentals, Sale Leaseback Transactions, within Two Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_022D2C9D6570691FFD59FCCBDB123FD4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_022D2C9D6570691FFD59FCCBDB123FD4" xlink:to="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_022D2C9D6570691FFD59FCCBDB123FD4" xlink:type="arc" />
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_9523C8FDA1A1ED2292ADFCCBDB124130_negatedLabel_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_9523C8FDA1A1ED2292ADFCCBDB124130" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: income from subleases, 2019</link:label>
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_9523C8FDA1A1ED2292ADFCCBDB124130_label_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_9523C8FDA1A1ED2292ADFCCBDB124130" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Minimum Sublease Rentals, Sale Leaseback Transactions, within Three Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_9523C8FDA1A1ED2292ADFCCBDB124130" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_9523C8FDA1A1ED2292ADFCCBDB124130" xlink:to="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_9523C8FDA1A1ED2292ADFCCBDB124130" xlink:type="arc" />
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_14C8E6D79E1C6047183CFCCBDB128136_negatedLabel_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_14C8E6D79E1C6047183CFCCBDB128136" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: income from subleases, 2020</link:label>
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_14C8E6D79E1C6047183CFCCBDB128136_label_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_14C8E6D79E1C6047183CFCCBDB128136" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Minimum Sublease Rentals, Sale Leaseback Transactions, within Four Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_14C8E6D79E1C6047183CFCCBDB128136" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_14C8E6D79E1C6047183CFCCBDB128136" xlink:to="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_14C8E6D79E1C6047183CFCCBDB128136" xlink:type="arc" />
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_B748E0ADD7A4B7036744FCCBDB124C5F_negatedLabel_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_B748E0ADD7A4B7036744FCCBDB124C5F" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: income from subleases, 2021</link:label>
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_B748E0ADD7A4B7036744FCCBDB124C5F_label_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_B748E0ADD7A4B7036744FCCBDB124C5F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Minimum Sublease Rentals, Sale Leaseback Transactions, within Five Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_B748E0ADD7A4B7036744FCCBDB124C5F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_B748E0ADD7A4B7036744FCCBDB124C5F" xlink:to="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_B748E0ADD7A4B7036744FCCBDB124C5F" xlink:type="arc" />
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_B8C1181999B741436D78FCCBDB12F60C_negatedLabel_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_B8C1181999B741436D78FCCBDB12F60C" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: income from subleases, Thereafter</link:label>
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_B8C1181999B741436D78FCCBDB12F60C_label_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_B8C1181999B741436D78FCCBDB12F60C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Minimum Sublease Rentals, Sale Leaseback Transactions, Thereafter</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_B8C1181999B741436D78FCCBDB12F60C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_B8C1181999B741436D78FCCBDB12F60C" xlink:to="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_B8C1181999B741436D78FCCBDB12F60C" xlink:type="arc" />
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_0A38B9FA6C1A4D896B76FCCBDB12BCEF_negatedLabel_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_0A38B9FA6C1A4D896B76FCCBDB12BCEF" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: income from subleases, Total</link:label>
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_0A38B9FA6C1A4D896B76FCCBDB12BCEF_label_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_0A38B9FA6C1A4D896B76FCCBDB12BCEF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Minimum Sublease Rentals, Sale Leaseback Transactions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_0A38B9FA6C1A4D896B76FCCBDB12BCEF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_0A38B9FA6C1A4D896B76FCCBDB12BCEF" xlink:to="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_0A38B9FA6C1A4D896B76FCCBDB12BCEF" xlink:type="arc" />
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInOneYear_DC7230A433E4957FC2FDFCCBDB1254DB_totalLabel_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInOneYear_DC7230A433E4957FC2FDFCCBDB1254DB" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net minimum lease payments, 2017</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInOneYear_DC7230A433E4957FC2FDFCCBDB1254DB_label_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInOneYear_DC7230A433E4957FC2FDFCCBDB1254DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Minimum Lease Payments With In One Year</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInOneYear_DC7230A433E4957FC2FDFCCBDB1254DB_documentation_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInOneYear_DC7230A433E4957FC2FDFCCBDB1254DB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net minimum lease payments with in one year.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_NetMinimumLeasePaymentsWithInOneYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInOneYear_DC7230A433E4957FC2FDFCCBDB1254DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInOneYear_DC7230A433E4957FC2FDFCCBDB1254DB" xlink:to="lab_biib_NetMinimumLeasePaymentsWithInOneYear_DC7230A433E4957FC2FDFCCBDB1254DB" xlink:type="arc" />
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInTwoYear_DB4B939286D7930F885CFCCBDB127751_totalLabel_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInTwoYear_DB4B939286D7930F885CFCCBDB127751" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net minimum lease payments, 2018</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInTwoYear_DB4B939286D7930F885CFCCBDB127751_label_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInTwoYear_DB4B939286D7930F885CFCCBDB127751" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Minimum Lease Payments With In Two Year</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInTwoYear_DB4B939286D7930F885CFCCBDB127751_documentation_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInTwoYear_DB4B939286D7930F885CFCCBDB127751" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net minimum lease payments with in two year.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_NetMinimumLeasePaymentsWithInTwoYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInTwoYear_DB4B939286D7930F885CFCCBDB127751" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInTwoYear_DB4B939286D7930F885CFCCBDB127751" xlink:to="lab_biib_NetMinimumLeasePaymentsWithInTwoYear_DB4B939286D7930F885CFCCBDB127751" xlink:type="arc" />
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInThreeYear_3776589AD4DCDA250691FCCBDB137165_totalLabel_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInThreeYear_3776589AD4DCDA250691FCCBDB137165" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net minimum lease payments, 2019</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInThreeYear_3776589AD4DCDA250691FCCBDB137165_label_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInThreeYear_3776589AD4DCDA250691FCCBDB137165" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Minimum Lease Payments With In Three Year</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInThreeYear_3776589AD4DCDA250691FCCBDB137165_documentation_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInThreeYear_3776589AD4DCDA250691FCCBDB137165" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net minimum lease payments with in three year.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_NetMinimumLeasePaymentsWithInThreeYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInThreeYear_3776589AD4DCDA250691FCCBDB137165" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInThreeYear_3776589AD4DCDA250691FCCBDB137165" xlink:to="lab_biib_NetMinimumLeasePaymentsWithInThreeYear_3776589AD4DCDA250691FCCBDB137165" xlink:type="arc" />
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInFourYear_E7F180FB4168C0BF8504FCCBDB130ED9_totalLabel_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInFourYear_E7F180FB4168C0BF8504FCCBDB130ED9" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net minimum lease payments, 2020</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInFourYear_E7F180FB4168C0BF8504FCCBDB130ED9_label_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInFourYear_E7F180FB4168C0BF8504FCCBDB130ED9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Minimum Lease Payments With In Four Year</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInFourYear_E7F180FB4168C0BF8504FCCBDB130ED9_documentation_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInFourYear_E7F180FB4168C0BF8504FCCBDB130ED9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net minimum lease payments with in four year.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_NetMinimumLeasePaymentsWithInFourYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInFourYear_E7F180FB4168C0BF8504FCCBDB130ED9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInFourYear_E7F180FB4168C0BF8504FCCBDB130ED9" xlink:to="lab_biib_NetMinimumLeasePaymentsWithInFourYear_E7F180FB4168C0BF8504FCCBDB130ED9" xlink:type="arc" />
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInFiveYear_B6F4E54D28C88EA6DA78FCCBDB130B00_totalLabel_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInFiveYear_B6F4E54D28C88EA6DA78FCCBDB130B00" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net minimum lease payments, 2021</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInFiveYear_B6F4E54D28C88EA6DA78FCCBDB130B00_label_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInFiveYear_B6F4E54D28C88EA6DA78FCCBDB130B00" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Minimum Lease Payments With In Five Year</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInFiveYear_B6F4E54D28C88EA6DA78FCCBDB130B00_documentation_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInFiveYear_B6F4E54D28C88EA6DA78FCCBDB130B00" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net minimum lease payments with in five year.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_NetMinimumLeasePaymentsWithInFiveYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInFiveYear_B6F4E54D28C88EA6DA78FCCBDB130B00" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInFiveYear_B6F4E54D28C88EA6DA78FCCBDB130B00" xlink:to="lab_biib_NetMinimumLeasePaymentsWithInFiveYear_B6F4E54D28C88EA6DA78FCCBDB130B00" xlink:type="arc" />
    <link:label id="lab_biib_NetMinimumLeasePaymentsThereafter_9176C0DC5938574116BBFCCBDB133E38_totalLabel_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsThereafter_9176C0DC5938574116BBFCCBDB133E38" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net minimum lease payments, Thereafter</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsThereafter_9176C0DC5938574116BBFCCBDB133E38_label_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsThereafter_9176C0DC5938574116BBFCCBDB133E38" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Minimum Lease Payments Thereafter</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsThereafter_9176C0DC5938574116BBFCCBDB133E38_documentation_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsThereafter_9176C0DC5938574116BBFCCBDB133E38" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net minimum lease payments thereafter.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_NetMinimumLeasePaymentsThereafter" xlink:label="loc_biib_NetMinimumLeasePaymentsThereafter_9176C0DC5938574116BBFCCBDB133E38" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NetMinimumLeasePaymentsThereafter_9176C0DC5938574116BBFCCBDB133E38" xlink:to="lab_biib_NetMinimumLeasePaymentsThereafter_9176C0DC5938574116BBFCCBDB133E38" xlink:type="arc" />
    <link:label id="lab_biib_NetMinimumLeasePayments_8253FE7EF3E20B152CF9FCCBDB13FA05_totalLabel_en-US" xlink:label="lab_biib_NetMinimumLeasePayments_8253FE7EF3E20B152CF9FCCBDB13FA05" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net minimum lease payments, Total</link:label>
    <link:label id="lab_biib_NetMinimumLeasePayments_8253FE7EF3E20B152CF9FCCBDB13FA05_label_en-US" xlink:label="lab_biib_NetMinimumLeasePayments_8253FE7EF3E20B152CF9FCCBDB13FA05" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Minimum Lease Payments</link:label>
    <link:label id="lab_biib_NetMinimumLeasePayments_8253FE7EF3E20B152CF9FCCBDB13FA05_documentation_en-US" xlink:label="lab_biib_NetMinimumLeasePayments_8253FE7EF3E20B152CF9FCCBDB13FA05" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net minimum lease payments total.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_NetMinimumLeasePayments" xlink:label="loc_biib_NetMinimumLeasePayments_8253FE7EF3E20B152CF9FCCBDB13FA05" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NetMinimumLeasePayments_8253FE7EF3E20B152CF9FCCBDB13FA05" xlink:to="lab_biib_NetMinimumLeasePayments_8253FE7EF3E20B152CF9FCCBDB13FA05" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingenciesTable_CE23F5EB8675F207A859FCCAD8F1EFDB_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable_CE23F5EB8675F207A859FCCAD8F1EFDB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_CE23F5EB8675F207A859FCCAD8F1EFDB_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable_CE23F5EB8675F207A859FCCAD8F1EFDB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_CE23F5EB8675F207A859FCCAD8F1EFDB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable_CE23F5EB8675F207A859FCCAD8F1EFDB" xlink:to="lab_us-gaap_LossContingenciesTable_CE23F5EB8675F207A859FCCAD8F1EFDB" xlink:type="arc" />
    <link:label id="lab_country_IT_6C56232AED5E0666E7A7FCCAD8F1F8B4_terseLabel_en-US" xlink:label="lab_country_IT_6C56232AED5E0666E7A7FCCAD8F1F8B4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ITALY</link:label>
    <link:label id="lab_country_IT_6C56232AED5E0666E7A7FCCAD8F1F8B4_label_en-US" xlink:label="lab_country_IT_6C56232AED5E0666E7A7FCCAD8F1F8B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ITALY</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd#country_IT" xlink:label="loc_country_IT_6C56232AED5E0666E7A7FCCAD8F1F8B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_IT_6C56232AED5E0666E7A7FCCAD8F1F8B4" xlink:to="lab_country_IT_6C56232AED5E0666E7A7FCCAD8F1F8B4" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingenciesLineItems_E1218D3754D6593F72E7FCCAD8F24890_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems_E1218D3754D6593F72E7FCCAD8F24890" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_E1218D3754D6593F72E7FCCAD8F24890_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems_E1218D3754D6593F72E7FCCAD8F24890" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_E1218D3754D6593F72E7FCCAD8F24890" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems_E1218D3754D6593F72E7FCCAD8F24890" xlink:to="lab_us-gaap_LossContingenciesLineItems_E1218D3754D6593F72E7FCCAD8F24890" xlink:type="arc" />
    <link:label id="lab_biib_ReimbursementLimitStatedInResolution_9ECCB5AAD6F7CF31DFC9FCCAD8F24F60_terseLabel_en-US" xlink:label="lab_biib_ReimbursementLimitStatedInResolution_9ECCB5AAD6F7CF31DFC9FCCAD8F24F60" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reimbursement Limit Stated In Resolution</link:label>
    <link:label id="lab_biib_ReimbursementLimitStatedInResolution_9ECCB5AAD6F7CF31DFC9FCCAD8F24F60_label_en-US" xlink:label="lab_biib_ReimbursementLimitStatedInResolution_9ECCB5AAD6F7CF31DFC9FCCAD8F24F60" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reimbursement Limit Stated In Resolution</link:label>
    <link:label id="lab_biib_ReimbursementLimitStatedInResolution_9ECCB5AAD6F7CF31DFC9FCCAD8F24F60_documentation_en-US" xlink:label="lab_biib_ReimbursementLimitStatedInResolution_9ECCB5AAD6F7CF31DFC9FCCAD8F24F60" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reimbursement limit stated in the resolution.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_ReimbursementLimitStatedInResolution" xlink:label="loc_biib_ReimbursementLimitStatedInResolution_9ECCB5AAD6F7CF31DFC9FCCAD8F24F60" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ReimbursementLimitStatedInResolution_9ECCB5AAD6F7CF31DFC9FCCAD8F24F60" xlink:to="lab_biib_ReimbursementLimitStatedInResolution_9ECCB5AAD6F7CF31DFC9FCCAD8F24F60" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_C4083F241F0D1BD03A9DFCCAD8F27140_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_C4083F241F0D1BD03A9DFCCAD8F27140" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proposed settlement</link:label>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_C4083F241F0D1BD03A9DFCCAD8F27140_label_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_C4083F241F0D1BD03A9DFCCAD8F27140" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_C4083F241F0D1BD03A9DFCCAD8F27140" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_C4083F241F0D1BD03A9DFCCAD8F27140" xlink:to="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_C4083F241F0D1BD03A9DFCCAD8F27140" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_859F38EC5184DB2340A77412857221E5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_859F38EC5184DB2340A77412857221E5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_859F38EC5184DB2340A77412857221E5_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_859F38EC5184DB2340A77412857221E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_859F38EC5184DB2340A77412857221E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_859F38EC5184DB2340A77412857221E5" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_859F38EC5184DB2340A77412857221E5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_186D6D9753D3BB1D65D97412857225B9_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_186D6D9753D3BB1D65D97412857225B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_186D6D9753D3BB1D65D97412857225B9_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_186D6D9753D3BB1D65D97412857225B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_186D6D9753D3BB1D65D97412857225B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_186D6D9753D3BB1D65D97412857225B9" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_186D6D9753D3BB1D65D97412857225B9" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_28513005836CD22FDC4FFB668011C771_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_28513005836CD22FDC4FFB668011C771" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_28513005836CD22FDC4FFB668011C771" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_28513005836CD22FDC4FFB668011C771" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_28513005836CD22FDC4FFB668011C771" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_34DCD7F960B80F9D1E97FB668012FAF6_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_34DCD7F960B80F9D1E97FB668012FAF6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) by Hedging Relationship, by Income Statement Location, by Derivative Instrument Risk [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_34DCD7F960B80F9D1E97FB668012FAF6_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_34DCD7F960B80F9D1E97FB668012FAF6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_34DCD7F960B80F9D1E97FB668012FAF6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_34DCD7F960B80F9D1E97FB668012FAF6" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_34DCD7F960B80F9D1E97FB668012FAF6" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_7BBFC8975BC9C4B99053FB668012D9AB_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_7BBFC8975BC9C4B99053FB668012D9AB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_7BBFC8975BC9C4B99053FB668012D9AB_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_7BBFC8975BC9C4B99053FB668012D9AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_7BBFC8975BC9C4B99053FB668012D9AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_7BBFC8975BC9C4B99053FB668012D9AB" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_7BBFC8975BC9C4B99053FB668012D9AB" xlink:type="arc" />
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_A280D04F8E21772ED805FB66801288EA_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain_A280D04F8E21772ED805FB66801288EA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_A280D04F8E21772ED805FB66801288EA_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain_A280D04F8E21772ED805FB66801288EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_A280D04F8E21772ED805FB66801288EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain_A280D04F8E21772ED805FB66801288EA" xlink:to="lab_us-gaap_HedgingRelationshipDomain_A280D04F8E21772ED805FB66801288EA" xlink:type="arc" />
    <link:label id="lab_biib_CashflowsrevenueMember_507D7556AA9E08361F15FB668012D7E8_terseLabel_en-US" xlink:label="lab_biib_CashflowsrevenueMember_507D7556AA9E08361F15FB668012D7E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows, revenue</link:label>
    <link:label id="lab_biib_CashflowsrevenueMember_507D7556AA9E08361F15FB668012D7E8_label_en-US" xlink:label="lab_biib_CashflowsrevenueMember_507D7556AA9E08361F15FB668012D7E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows, revenue [Member]</link:label>
    <link:label id="lab_biib_CashflowsrevenueMember_507D7556AA9E08361F15FB668012D7E8_documentation_en-US" xlink:label="lab_biib_CashflowsrevenueMember_507D7556AA9E08361F15FB668012D7E8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash flows, revenue [Member]</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_CashflowsrevenueMember" xlink:label="loc_biib_CashflowsrevenueMember_507D7556AA9E08361F15FB668012D7E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CashflowsrevenueMember_507D7556AA9E08361F15FB668012D7E8" xlink:to="lab_biib_CashflowsrevenueMember_507D7556AA9E08361F15FB668012D7E8" xlink:type="arc" />
    <link:label id="lab_biib_CashflowsoperatingexpensesMember_DDA91E7A320E5EE7E18EFB668012F39E_terseLabel_en-US" xlink:label="lab_biib_CashflowsoperatingexpensesMember_DDA91E7A320E5EE7E18EFB668012F39E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows, operating expenses</link:label>
    <link:label id="lab_biib_CashflowsoperatingexpensesMember_DDA91E7A320E5EE7E18EFB668012F39E_label_en-US" xlink:label="lab_biib_CashflowsoperatingexpensesMember_DDA91E7A320E5EE7E18EFB668012F39E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows, operating expenses [Member]</link:label>
    <link:label id="lab_biib_CashflowsoperatingexpensesMember_DDA91E7A320E5EE7E18EFB668012F39E_documentation_en-US" xlink:label="lab_biib_CashflowsoperatingexpensesMember_DDA91E7A320E5EE7E18EFB668012F39E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash flows, operating expenses [Member]</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_CashflowsoperatingexpensesMember" xlink:label="loc_biib_CashflowsoperatingexpensesMember_DDA91E7A320E5EE7E18EFB668012F39E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CashflowsoperatingexpensesMember_DDA91E7A320E5EE7E18EFB668012F39E" xlink:to="lab_biib_CashflowsoperatingexpensesMember_DDA91E7A320E5EE7E18EFB668012F39E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_8DB4036B1D96E28AEC3EFB668013BF12_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember_8DB4036B1D96E28AEC3EFB668013BF12" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign Exchange Contract</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_8DB4036B1D96E28AEC3EFB668013BF12_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember_8DB4036B1D96E28AEC3EFB668013BF12" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="loc_us-gaap_ForeignExchangeContractMember_8DB4036B1D96E28AEC3EFB668013BF12" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember_8DB4036B1D96E28AEC3EFB668013BF12" xlink:to="lab_us-gaap_ForeignExchangeContractMember_8DB4036B1D96E28AEC3EFB668013BF12" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_1A9D6CD01BC85D8D1249FB668013E198_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_1A9D6CD01BC85D8D1249FB668013E198" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1A9D6CD01BC85D8D1249FB668013E198" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1A9D6CD01BC85D8D1249FB668013E198" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_1A9D6CD01BC85D8D1249FB668013E198" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_C20CF2A963C92219A81CFB6680135339_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_C20CF2A963C92219A81CFB6680135339" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_C20CF2A963C92219A81CFB6680135339" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_C20CF2A963C92219A81CFB6680135339" xlink:to="lab_us-gaap_IncomeStatementLocationDomain_C20CF2A963C92219A81CFB6680135339" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesMember_FFE7E1FBAABDAD0D85BCFB6680136F66_verboseLabel_en-US" xlink:label="lab_us-gaap_SalesMember_FFE7E1FBAABDAD0D85BCFB6680136F66" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_SalesMember_FFE7E1FBAABDAD0D85BCFB6680136F66_label_en-US" xlink:label="lab_us-gaap_SalesMember_FFE7E1FBAABDAD0D85BCFB6680136F66" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesMember" xlink:label="loc_us-gaap_SalesMember_FFE7E1FBAABDAD0D85BCFB6680136F66" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesMember_FFE7E1FBAABDAD0D85BCFB6680136F66" xlink:to="lab_us-gaap_SalesMember_FFE7E1FBAABDAD0D85BCFB6680136F66" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_69973FCE9F74433E7CABFB668013D4BF_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_69973FCE9F74433E7CABFB668013D4BF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense)</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_69973FCE9F74433E7CABFB668013D4BF_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_69973FCE9F74433E7CABFB668013D4BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense) [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_69973FCE9F74433E7CABFB668013D4BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_69973FCE9F74433E7CABFB668013D4BF" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_69973FCE9F74433E7CABFB668013D4BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpenseMember_8CEE66D007DD8283F373FB6680135FF8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenseMember_8CEE66D007DD8283F373FB6680135FF8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Expense</link:label>
    <link:label id="lab_us-gaap_OperatingExpenseMember_8CEE66D007DD8283F373FB6680135FF8_label_en-US" xlink:label="lab_us-gaap_OperatingExpenseMember_8CEE66D007DD8283F373FB6680135FF8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenseMember" xlink:label="loc_us-gaap_OperatingExpenseMember_8CEE66D007DD8283F373FB6680135FF8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenseMember_8CEE66D007DD8283F373FB6680135FF8" xlink:to="lab_us-gaap_OperatingExpenseMember_8CEE66D007DD8283F373FB6680135FF8" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_A39CC300AEA523911224FB6680133AB7_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_A39CC300AEA523911224FB6680133AB7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_A39CC300AEA523911224FB6680133AB7_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_A39CC300AEA523911224FB6680133AB7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_A39CC300AEA523911224FB6680133AB7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_A39CC300AEA523911224FB6680133AB7" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_A39CC300AEA523911224FB6680133AB7" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNetAbstract_3F3A7C17B1A3BE73F461FB668013ABDA_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNetAbstract_3F3A7C17B1A3BE73F461FB668013ABDA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of the effect of derivatives designated as hedging instruments on the consolidated statements of income</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNetAbstract_3F3A7C17B1A3BE73F461FB668013ABDA_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNetAbstract_3F3A7C17B1A3BE73F461FB668013ABDA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) Recognized in Other Comprehensive Income (Loss), Effective Portion, Net [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNetAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNetAbstract_3F3A7C17B1A3BE73F461FB668013ABDA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNetAbstract_3F3A7C17B1A3BE73F461FB668013ABDA" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNetAbstract_3F3A7C17B1A3BE73F461FB668013ABDA" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_16AF03C759DF2C58D130FB6680136A5A_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_16AF03C759DF2C58D130FB6680136A5A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Amount Reclassified from Accumulated Other Comprehensive Income into Income Gain/(Loss) (Effective Portion)</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_16AF03C759DF2C58D130FB6680136A5A_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_16AF03C759DF2C58D130FB6680136A5A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_16AF03C759DF2C58D130FB6680136A5A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_16AF03C759DF2C58D130FB6680136A5A" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_16AF03C759DF2C58D130FB6680136A5A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_D2AB121D2B1355043A4FFB6680149A4F_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_D2AB121D2B1355043A4FFB6680149A4F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net gains (losses) in earnings of foreign currency forward contracts due to hedge ineffectiveness</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_D2AB121D2B1355043A4FFB6680149A4F_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_D2AB121D2B1355043A4FFB6680149A4F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_D2AB121D2B1355043A4FFB6680149A4F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_D2AB121D2B1355043A4FFB6680149A4F" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_D2AB121D2B1355043A4FFB6680149A4F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_4C1A22F2310E33F4645CD6D80CA4B913_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_4C1A22F2310E33F4645CD6D80CA4B913" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplementary cash flow information</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_4C1A22F2310E33F4645CD6D80CA4B913_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_4C1A22F2310E33F4645CD6D80CA4B913" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_4C1A22F2310E33F4645CD6D80CA4B913" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_4C1A22F2310E33F4645CD6D80CA4B913" xlink:to="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_4C1A22F2310E33F4645CD6D80CA4B913" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_463E2ABAB28F8474B7A6D6D80CA47F8E_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_463E2ABAB28F8474B7A6D6D80CA47F8E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_463E2ABAB28F8474B7A6D6D80CA47F8E_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_463E2ABAB28F8474B7A6D6D80CA47F8E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Other Nonoperating Income (Expense) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_463E2ABAB28F8474B7A6D6D80CA47F8E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_463E2ABAB28F8474B7A6D6D80CA47F8E" xlink:to="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_463E2ABAB28F8474B7A6D6D80CA47F8E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_3728B5EE5AD5FECB26E9D6D80CA4F3A2_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_3728B5EE5AD5FECB26E9D6D80CA4F3A2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_3728B5EE5AD5FECB26E9D6D80CA4F3A2_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_3728B5EE5AD5FECB26E9D6D80CA4F3A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_3728B5EE5AD5FECB26E9D6D80CA4F3A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_3728B5EE5AD5FECB26E9D6D80CA4F3A2" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_3728B5EE5AD5FECB26E9D6D80CA4F3A2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_50240BAA7FDB0B532A177412859AB3E9_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_50240BAA7FDB0B532A177412859AB3E9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss) Note</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_50240BAA7FDB0B532A177412859AB3E9_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_50240BAA7FDB0B532A177412859AB3E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss) Note [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_50240BAA7FDB0B532A177412859AB3E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_50240BAA7FDB0B532A177412859AB3E9" xlink:to="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_50240BAA7FDB0B532A177412859AB3E9" xlink:type="arc" />
    <link:label id="lab_biib_ConvergencePharmaceuticalsMember_9C0846778CCA1F308477FA4EA5DA00FF_terseLabel_en-US" xlink:label="lab_biib_ConvergencePharmaceuticalsMember_9C0846778CCA1F308477FA4EA5DA00FF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convergence Pharmaceuticals</link:label>
    <link:label id="lab_biib_ConvergencePharmaceuticalsMember_9C0846778CCA1F308477FA4EA5DA00FF_label_en-US" xlink:label="lab_biib_ConvergencePharmaceuticalsMember_9C0846778CCA1F308477FA4EA5DA00FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convergence Pharmaceuticals [Member]</link:label>
    <link:label id="lab_biib_ConvergencePharmaceuticalsMember_9C0846778CCA1F308477FA4EA5DA00FF_documentation_en-US" xlink:label="lab_biib_ConvergencePharmaceuticalsMember_9C0846778CCA1F308477FA4EA5DA00FF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Convergence Pharmaceuticals [Member]</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_ConvergencePharmaceuticalsMember" xlink:label="loc_biib_ConvergencePharmaceuticalsMember_9C0846778CCA1F308477FA4EA5DA00FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ConvergencePharmaceuticalsMember_9C0846778CCA1F308477FA4EA5DA00FF" xlink:to="lab_biib_ConvergencePharmaceuticalsMember_9C0846778CCA1F308477FA4EA5DA00FF" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_EF5129B9ACDD65A2B739FA4EA5DA07FE_verboseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross_EF5129B9ACDD65A2B739FA4EA5DA07FE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash portion of consideration</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_EF5129B9ACDD65A2B739FA4EA5DA07FE_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross_EF5129B9ACDD65A2B739FA4EA5DA07FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_EF5129B9ACDD65A2B739FA4EA5DA07FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross_EF5129B9ACDD65A2B739FA4EA5DA07FE" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross_EF5129B9ACDD65A2B739FA4EA5DA07FE" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_7BAE254052D5EAC525D3FA4EA5DA8B83_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_7BAE254052D5EAC525D3FA4EA5DA8B83" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration obligation</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_7BAE254052D5EAC525D3FA4EA5DA8B83_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_7BAE254052D5EAC525D3FA4EA5DA8B83" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_7BAE254052D5EAC525D3FA4EA5DA8B83" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_7BAE254052D5EAC525D3FA4EA5DA8B83" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_7BAE254052D5EAC525D3FA4EA5DA8B83" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_FD1F057F2C70004B24A2FA4EA5DA3DBE_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1_FD1F057F2C70004B24A2FA4EA5DA3DBE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total purchase price</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_FD1F057F2C70004B24A2FA4EA5DA3DBE_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1_FD1F057F2C70004B24A2FA4EA5DA3DBE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_FD1F057F2C70004B24A2FA4EA5DA3DBE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_FD1F057F2C70004B24A2FA4EA5DA3DBE" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1_FD1F057F2C70004B24A2FA4EA5DA3DBE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_2888EB03FA2E01B02F5D7412884D03D5_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_2888EB03FA2E01B02F5D7412884D03D5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense included in consolidated statements of income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_2888EB03FA2E01B02F5D7412884D03D5_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_2888EB03FA2E01B02F5D7412884D03D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_2888EB03FA2E01B02F5D7412884D03D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_2888EB03FA2E01B02F5D7412884D03D5" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_2888EB03FA2E01B02F5D7412884D03D5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_F8E1177C68655A3DABAC7412884D4999_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_F8E1177C68655A3DABAC7412884D4999" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of share-based compensation expense associated with each of our share-based compensating programs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_F8E1177C68655A3DABAC7412884D4999_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_F8E1177C68655A3DABAC7412884D4999" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_F8E1177C68655A3DABAC7412884D4999" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_F8E1177C68655A3DABAC7412884D4999" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_F8E1177C68655A3DABAC7412884D4999" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_F09BA77671235D9A07A97412884DE7B5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_F09BA77671235D9A07A97412884DE7B5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock option activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_F09BA77671235D9A07A97412884DE7B5_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_F09BA77671235D9A07A97412884DE7B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_F09BA77671235D9A07A97412884DE7B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_F09BA77671235D9A07A97412884DE7B5" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_F09BA77671235D9A07A97412884DE7B5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCashProceedsReceivedFromShareBasedPaymentAwardsTableTextBlock_0A3DE9C6D60261AC97E47412884D08B8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashProceedsReceivedFromShareBasedPaymentAwardsTableTextBlock_0A3DE9C6D60261AC97E47412884D08B8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax benefit and cash received from stock option exercises</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashProceedsReceivedFromShareBasedPaymentAwardsTableTextBlock_0A3DE9C6D60261AC97E47412884D08B8_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashProceedsReceivedFromShareBasedPaymentAwardsTableTextBlock_0A3DE9C6D60261AC97E47412884D08B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Cash Proceeds Received from Share-based Payment Awards [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCashProceedsReceivedFromShareBasedPaymentAwardsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashProceedsReceivedFromShareBasedPaymentAwardsTableTextBlock_0A3DE9C6D60261AC97E47412884D08B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashProceedsReceivedFromShareBasedPaymentAwardsTableTextBlock_0A3DE9C6D60261AC97E47412884D08B8" xlink:to="lab_us-gaap_ScheduleOfCashProceedsReceivedFromShareBasedPaymentAwardsTableTextBlock_0A3DE9C6D60261AC97E47412884D08B8" xlink:type="arc" />
    <link:label id="lab_biib_ScheduleOfMarketStockUnitsActivityTableTextBlock_E09E95E30AED98E4CF237412884DF243_terseLabel_en-US" xlink:label="lab_biib_ScheduleOfMarketStockUnitsActivityTableTextBlock_E09E95E30AED98E4CF237412884DF243" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Market stock units activity</link:label>
    <link:label id="lab_biib_ScheduleOfMarketStockUnitsActivityTableTextBlock_E09E95E30AED98E4CF237412884DF243_label_en-US" xlink:label="lab_biib_ScheduleOfMarketStockUnitsActivityTableTextBlock_E09E95E30AED98E4CF237412884DF243" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Market Stock Units Activity [Table Text Block]</link:label>
    <link:label id="lab_biib_ScheduleOfMarketStockUnitsActivityTableTextBlock_E09E95E30AED98E4CF237412884DF243_documentation_en-US" xlink:label="lab_biib_ScheduleOfMarketStockUnitsActivityTableTextBlock_E09E95E30AED98E4CF237412884DF243" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Market Stock Units Activity.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_ScheduleOfMarketStockUnitsActivityTableTextBlock" xlink:label="loc_biib_ScheduleOfMarketStockUnitsActivityTableTextBlock_E09E95E30AED98E4CF237412884DF243" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ScheduleOfMarketStockUnitsActivityTableTextBlock_E09E95E30AED98E4CF237412884DF243" xlink:to="lab_biib_ScheduleOfMarketStockUnitsActivityTableTextBlock_E09E95E30AED98E4CF237412884DF243" xlink:type="arc" />
    <link:label id="lab_biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock_1CC208B869C71CCF07537412884D0016_terseLabel_en-US" xlink:label="lab_biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock_1CC208B869C71CCF07537412884D0016" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assumptions used in valuation of market based stock units</link:label>
    <link:label id="lab_biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock_1CC208B869C71CCF07537412884D0016_label_en-US" xlink:label="lab_biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock_1CC208B869C71CCF07537412884D0016" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assumptions Used In Valuation Of Market Based Stock Units [Table Text Block]</link:label>
    <link:label id="lab_biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock_1CC208B869C71CCF07537412884D0016_documentation_en-US" xlink:label="lab_biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock_1CC208B869C71CCF07537412884D0016" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Assumptions used in valuation of market based stock units.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock" xlink:label="loc_biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock_1CC208B869C71CCF07537412884D0016" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock_1CC208B869C71CCF07537412884D0016" xlink:to="lab_biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock_1CC208B869C71CCF07537412884D0016" xlink:type="arc" />
    <link:label id="lab_biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock_08E0B6873219E6A0F2AD7412884D6ECA_terseLabel_en-US" xlink:label="lab_biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock_08E0B6873219E6A0F2AD7412884D6ECA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash settled performance shares activity</link:label>
    <link:label id="lab_biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock_08E0B6873219E6A0F2AD7412884D6ECA_label_en-US" xlink:label="lab_biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock_08E0B6873219E6A0F2AD7412884D6ECA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Cash Settled Performance Shares Activity [Table Text Block]</link:label>
    <link:label id="lab_biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock_08E0B6873219E6A0F2AD7412884D6ECA_documentation_en-US" xlink:label="lab_biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock_08E0B6873219E6A0F2AD7412884D6ECA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Cash Settled Performance Shares Activity.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock" xlink:label="loc_biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock_08E0B6873219E6A0F2AD7412884D6ECA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock_08E0B6873219E6A0F2AD7412884D6ECA" xlink:to="lab_biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock_08E0B6873219E6A0F2AD7412884D6ECA" xlink:type="arc" />
    <link:label id="lab_biib_PerformanceunitsactivityTableTextBlock_4305236B8E5A1C8037497412884DE645_terseLabel_en-US" xlink:label="lab_biib_PerformanceunitsactivityTableTextBlock_4305236B8E5A1C8037497412884DE645" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance units activity</link:label>
    <link:label id="lab_biib_PerformanceunitsactivityTableTextBlock_4305236B8E5A1C8037497412884DE645_label_en-US" xlink:label="lab_biib_PerformanceunitsactivityTableTextBlock_4305236B8E5A1C8037497412884DE645" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance units activity [Table Text Block]</link:label>
    <link:label id="lab_biib_PerformanceunitsactivityTableTextBlock_4305236B8E5A1C8037497412884DE645_documentation_en-US" xlink:label="lab_biib_PerformanceunitsactivityTableTextBlock_4305236B8E5A1C8037497412884DE645" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Performance units activity [Table Text Block]</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_PerformanceunitsactivityTableTextBlock" xlink:label="loc_biib_PerformanceunitsactivityTableTextBlock_4305236B8E5A1C8037497412884DE645" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PerformanceunitsactivityTableTextBlock_4305236B8E5A1C8037497412884DE645" xlink:to="lab_biib_PerformanceunitsactivityTableTextBlock_4305236B8E5A1C8037497412884DE645" xlink:type="arc" />
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock_9F487BC84A6571B12E257412884EF2A0_terseLabel_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock_9F487BC84A6571B12E257412884EF2A0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Time-vested restricted stock units activity</link:label>
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock_9F487BC84A6571B12E257412884EF2A0_label_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock_9F487BC84A6571B12E257412884EF2A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Time Vested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock_9F487BC84A6571B12E257412884EF2A0_documentation_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock_9F487BC84A6571B12E257412884EF2A0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Time Vested Restricted Stock Units Activity.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock_9F487BC84A6571B12E257412884EF2A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock_9F487BC84A6571B12E257412884EF2A0" xlink:to="lab_biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock_9F487BC84A6571B12E257412884EF2A0" xlink:type="arc" />
    <link:label id="lab_biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock_5ED042AEA7BA2576FF767412884E93E8_terseLabel_en-US" xlink:label="lab_biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock_5ED042AEA7BA2576FF767412884E93E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued under employee stock purchase plan</link:label>
    <link:label id="lab_biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock_5ED042AEA7BA2576FF767412884E93E8_label_en-US" xlink:label="lab_biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock_5ED042AEA7BA2576FF767412884E93E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued Under Employee Stock Purchase Plan [Table Text Block]</link:label>
    <link:label id="lab_biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock_5ED042AEA7BA2576FF767412884E93E8_documentation_en-US" xlink:label="lab_biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock_5ED042AEA7BA2576FF767412884E93E8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shares issued under employee stock purchase plan.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock" xlink:label="loc_biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock_5ED042AEA7BA2576FF767412884E93E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock_5ED042AEA7BA2576FF767412884E93E8" xlink:to="lab_biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock_5ED042AEA7BA2576FF767412884E93E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_5A2BAA23B58000FC72BAFA4EA53DEEB0_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract_5A2BAA23B58000FC72BAFA4EA53DEEB0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_5A2BAA23B58000FC72BAFA4EA53DEEB0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_5A2BAA23B58000FC72BAFA4EA53DEEB0" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract_5A2BAA23B58000FC72BAFA4EA53DEEB0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_FB7B8C5DDC8492BAE5BAFA4EA53D5F5F_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_FB7B8C5DDC8492BAE5BAFA4EA53D5F5F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_FB7B8C5DDC8492BAE5BAFA4EA53D5F5F_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_FB7B8C5DDC8492BAE5BAFA4EA53D5F5F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_FB7B8C5DDC8492BAE5BAFA4EA53D5F5F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_FB7B8C5DDC8492BAE5BAFA4EA53D5F5F" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_FB7B8C5DDC8492BAE5BAFA4EA53D5F5F" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_B329E351399F2ED734B3FA4EA53ED875_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_B329E351399F2ED734B3FA4EA53ED875" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value by Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_B329E351399F2ED734B3FA4EA53ED875_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_B329E351399F2ED734B3FA4EA53ED875" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_B329E351399F2ED734B3FA4EA53ED875" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_B329E351399F2ED734B3FA4EA53ED875" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis_B329E351399F2ED734B3FA4EA53ED875" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_E7ACDDB1850C0A4A3932FA4EA53E907E_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_E7ACDDB1850C0A4A3932FA4EA53E907E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_E7ACDDB1850C0A4A3932FA4EA53E907E_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_E7ACDDB1850C0A4A3932FA4EA53E907E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_E7ACDDB1850C0A4A3932FA4EA53E907E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_E7ACDDB1850C0A4A3932FA4EA53E907E" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain_E7ACDDB1850C0A4A3932FA4EA53E907E" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_1D3CF788F24BD52B7303FA4EA53E2C83_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_1D3CF788F24BD52B7303FA4EA53E2C83" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_1D3CF788F24BD52B7303FA4EA53E2C83_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_1D3CF788F24BD52B7303FA4EA53E2C83" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Recurring [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_1D3CF788F24BD52B7303FA4EA53E2C83" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember_1D3CF788F24BD52B7303FA4EA53E2C83" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember_1D3CF788F24BD52B7303FA4EA53E2C83" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_1B4B38B37E52C5C969AEFA4EA53E6D9F_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_1B4B38B37E52C5C969AEFA4EA53E6D9F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Contingent Consideration [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_1B4B38B37E52C5C969AEFA4EA53E6D9F_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_1B4B38B37E52C5C969AEFA4EA53E6D9F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Contingent Consideration [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_1B4B38B37E52C5C969AEFA4EA53E6D9F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_1B4B38B37E52C5C969AEFA4EA53E6D9F" xlink:to="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_1B4B38B37E52C5C969AEFA4EA53E6D9F" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_412E1EE25FF8A4D8C00AFA4EA53E8F3B_periodStartLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_412E1EE25FF8A4D8C00AFA4EA53E8F3B" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Fair value, beginning of period</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_412E1EE25FF8A4D8C00AFA4EA53E8F3B_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_412E1EE25FF8A4D8C00AFA4EA53E8F3B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_412E1EE25FF8A4D8C00AFA4EA53E8F3B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_412E1EE25FF8A4D8C00AFA4EA53E8F3B" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_412E1EE25FF8A4D8C00AFA4EA53E8F3B" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_EE50A41D540140D05341FA4EA53E768A_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_EE50A41D540140D05341FA4EA53E768A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Additions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_EE50A41D540140D05341FA4EA53E768A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_EE50A41D540140D05341FA4EA53E768A" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_EE50A41D540140D05341FA4EA53E768A" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_A2F47AECA9BA45E88510FA4EA53FB925_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_A2F47AECA9BA45E88510FA4EA53FB925" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_A2F47AECA9BA45E88510FA4EA53FB925_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_A2F47AECA9BA45E88510FA4EA53FB925" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_A2F47AECA9BA45E88510FA4EA53FB925" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_A2F47AECA9BA45E88510FA4EA53FB925" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_A2F47AECA9BA45E88510FA4EA53FB925" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_A9B35EA0800B560FA52EFA4EA53FA261_periodEndLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_A9B35EA0800B560FA52EFA4EA53FA261" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Fair value, end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_A9B35EA0800B560FA52EFA4EA53FA261" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_A9B35EA0800B560FA52EFA4EA53FA261" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_A9B35EA0800B560FA52EFA4EA53FA261" xlink:type="arc" />
    <link:label id="lab_biib_BIIB074Member_A2EBDAC15163137BA4D1FD3DC9254946_terseLabel_en-US" xlink:label="lab_biib_BIIB074Member_A2EBDAC15163137BA4D1FD3DC9254946" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BIIB074</link:label>
    <link:label id="lab_biib_BIIB074Member_A2EBDAC15163137BA4D1FD3DC9254946_label_en-US" xlink:label="lab_biib_BIIB074Member_A2EBDAC15163137BA4D1FD3DC9254946" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BIIB074 [Member]</link:label>
    <link:label id="lab_biib_BIIB074Member_A2EBDAC15163137BA4D1FD3DC9254946_documentation_en-US" xlink:label="lab_biib_BIIB074Member_A2EBDAC15163137BA4D1FD3DC9254946" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BIIB074 [Member]</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_BIIB074Member" xlink:label="loc_biib_BIIB074Member_A2EBDAC15163137BA4D1FD3DC9254946" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BIIB074Member_A2EBDAC15163137BA4D1FD3DC9254946" xlink:to="lab_biib_BIIB074Member_A2EBDAC15163137BA4D1FD3DC9254946" xlink:type="arc" />
    <link:label id="lab_biib_NeuropathicpainindicationsMember_BD49A3ECFA87A1355AC6FD3DC9265243_terseLabel_en-US" xlink:label="lab_biib_NeuropathicpainindicationsMember_BD49A3ECFA87A1355AC6FD3DC9265243" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Neuropathic pain indications</link:label>
    <link:label id="lab_biib_NeuropathicpainindicationsMember_BD49A3ECFA87A1355AC6FD3DC9265243_label_en-US" xlink:label="lab_biib_NeuropathicpainindicationsMember_BD49A3ECFA87A1355AC6FD3DC9265243" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Neuropathic pain indications [Member]</link:label>
    <link:label id="lab_biib_NeuropathicpainindicationsMember_BD49A3ECFA87A1355AC6FD3DC9265243_documentation_en-US" xlink:label="lab_biib_NeuropathicpainindicationsMember_BD49A3ECFA87A1355AC6FD3DC9265243" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Neuropathic pain indications [Member]</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_NeuropathicpainindicationsMember" xlink:label="loc_biib_NeuropathicpainindicationsMember_BD49A3ECFA87A1355AC6FD3DC9265243" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NeuropathicpainindicationsMember_BD49A3ECFA87A1355AC6FD3DC9265243" xlink:to="lab_biib_NeuropathicpainindicationsMember_BD49A3ECFA87A1355AC6FD3DC9265243" xlink:type="arc" />
    <link:label id="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_6416E2D6F7721CB3EDE8FD3DC9274C38_terseLabel_en-US" xlink:label="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_6416E2D6F7721CB3EDE8FD3DC9274C38" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential future milestone payments</link:label>
    <link:label id="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_6416E2D6F7721CB3EDE8FD3DC9274C38_label_en-US" xlink:label="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_6416E2D6F7721CB3EDE8FD3DC9274C38" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential Future Milestone Payments Commitment To Third Party Approximately</link:label>
    <link:label id="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_6416E2D6F7721CB3EDE8FD3DC9274C38_documentation_en-US" xlink:label="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_6416E2D6F7721CB3EDE8FD3DC9274C38" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Potential future milestone payments commitment to third party approximately.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_6416E2D6F7721CB3EDE8FD3DC9274C38" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_6416E2D6F7721CB3EDE8FD3DC9274C38" xlink:to="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_6416E2D6F7721CB3EDE8FD3DC9274C38" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_980208237E0BFFEF941EFD3DC92729DA_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_980208237E0BFFEF941EFD3DC92729DA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in contingent consideration liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_980208237E0BFFEF941EFD3DC92729DA_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_980208237E0BFFEF941EFD3DC92729DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_980208237E0BFFEF941EFD3DC92729DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_980208237E0BFFEF941EFD3DC92729DA" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_980208237E0BFFEF941EFD3DC92729DA" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsDiscountRate_A334150E342C32996D66FD3DC927AC5C_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsDiscountRate_A334150E342C32996D66FD3DC927AC5C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_FairValueInputsDiscountRate_A334150E342C32996D66FD3DC927AC5C_label_en-US" xlink:label="lab_us-gaap_FairValueInputsDiscountRate_A334150E342C32996D66FD3DC927AC5C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Inputs, Discount Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsDiscountRate" xlink:label="loc_us-gaap_FairValueInputsDiscountRate_A334150E342C32996D66FD3DC927AC5C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsDiscountRate_A334150E342C32996D66FD3DC927AC5C" xlink:to="lab_us-gaap_FairValueInputsDiscountRate_A334150E342C32996D66FD3DC927AC5C" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_CB6F12FA47E2D2FFF004FD3DC927B704_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_CB6F12FA47E2D2FFF004FD3DC927B704" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum contingent consideration in the form of development and approval milestones</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_CB6F12FA47E2D2FFF004FD3DC927B704_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_CB6F12FA47E2D2FFF004FD3DC927B704" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_CB6F12FA47E2D2FFF004FD3DC927B704" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_CB6F12FA47E2D2FFF004FD3DC927B704" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_CB6F12FA47E2D2FFF004FD3DC927B704" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_892EFDC5AAE5EE1682BFFD3DC9273792_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_892EFDC5AAE5EE1682BFFD3DC9273792" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">In-process research and development</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_892EFDC5AAE5EE1682BFFD3DC9273792_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_892EFDC5AAE5EE1682BFFD3DC9273792" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_892EFDC5AAE5EE1682BFFD3DC9273792" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_892EFDC5AAE5EE1682BFFD3DC9273792" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_892EFDC5AAE5EE1682BFFD3DC9273792" xlink:type="arc" />
    <link:label id="lab_biib_MilestonePaymentsMadeDuringPeriod_21F177B976CF2AFDDE95FD3DC9280E6B_terseLabel_en-US" xlink:label="lab_biib_MilestonePaymentsMadeDuringPeriod_21F177B976CF2AFDDE95FD3DC9280E6B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payment made during period</link:label>
    <link:label id="lab_biib_MilestonePaymentsMadeDuringPeriod_21F177B976CF2AFDDE95FD3DC9280E6B_label_en-US" xlink:label="lab_biib_MilestonePaymentsMadeDuringPeriod_21F177B976CF2AFDDE95FD3DC9280E6B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Payments Made During Period</link:label>
    <link:label id="lab_biib_MilestonePaymentsMadeDuringPeriod_21F177B976CF2AFDDE95FD3DC9280E6B_documentation_en-US" xlink:label="lab_biib_MilestonePaymentsMadeDuringPeriod_21F177B976CF2AFDDE95FD3DC9280E6B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone Payments Made During Period.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_MilestonePaymentsMadeDuringPeriod" xlink:label="loc_biib_MilestonePaymentsMadeDuringPeriod_21F177B976CF2AFDDE95FD3DC9280E6B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MilestonePaymentsMadeDuringPeriod_21F177B976CF2AFDDE95FD3DC9280E6B" xlink:to="lab_biib_MilestonePaymentsMadeDuringPeriod_21F177B976CF2AFDDE95FD3DC9280E6B" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3CCB0A2AB40DAF2E2F9B741289630065_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3CCB0A2AB40DAF2E2F9B741289630065" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3CCB0A2AB40DAF2E2F9B741289630065_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3CCB0A2AB40DAF2E2F9B741289630065" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3CCB0A2AB40DAF2E2F9B741289630065" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3CCB0A2AB40DAF2E2F9B741289630065" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3CCB0A2AB40DAF2E2F9B741289630065" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_327672A363745DB84C9F74128964607C_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_327672A363745DB84C9F74128964607C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_327672A363745DB84C9F74128964607C_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_327672A363745DB84C9F74128964607C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_327672A363745DB84C9F74128964607C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_327672A363745DB84C9F74128964607C" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_327672A363745DB84C9F74128964607C" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1DDEEFDCD55F1D744C83741289643D96_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1DDEEFDCD55F1D744C83741289643D96" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1DDEEFDCD55F1D744C83741289643D96_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1DDEEFDCD55F1D744C83741289643D96" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1DDEEFDCD55F1D744C83741289643D96" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1DDEEFDCD55F1D744C83741289643D96" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1DDEEFDCD55F1D744C83741289643D96" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_9D9C356F0EFCB93ECEDF74128964A4A4_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_9D9C356F0EFCB93ECEDF74128964A4A4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Quoted Prices in Active Markets (Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_9D9C356F0EFCB93ECEDF74128964A4A4_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_9D9C356F0EFCB93ECEDF74128964A4A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_9D9C356F0EFCB93ECEDF74128964A4A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member_9D9C356F0EFCB93ECEDF74128964A4A4" xlink:to="lab_us-gaap_FairValueInputsLevel1Member_9D9C356F0EFCB93ECEDF74128964A4A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_DB096D52768136F61AF974128964987C_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_DB096D52768136F61AF974128964987C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Significant Other Observable Inputs (Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_DB096D52768136F61AF974128964987C_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_DB096D52768136F61AF974128964987C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_DB096D52768136F61AF974128964987C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member_DB096D52768136F61AF974128964987C" xlink:to="lab_us-gaap_FairValueInputsLevel2Member_DB096D52768136F61AF974128964987C" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_3EEE1517D2B327599B6A741289647B8C_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_3EEE1517D2B327599B6A741289647B8C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Significant Unobservable Inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_3EEE1517D2B327599B6A741289647B8C_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_3EEE1517D2B327599B6A741289647B8C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_3EEE1517D2B327599B6A741289647B8C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member_3EEE1517D2B327599B6A741289647B8C" xlink:to="lab_us-gaap_FairValueInputsLevel3Member_3EEE1517D2B327599B6A741289647B8C" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_8FCAF976D552BC56841C74128964499B_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_8FCAF976D552BC56841C74128964499B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_8FCAF976D552BC56841C74128964499B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember_8FCAF976D552BC56841C74128964499B" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember_8FCAF976D552BC56841C74128964499B" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_D94706AFE6497BB12B3274128964AB8F_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis_D94706AFE6497BB12B3274128964AB8F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value by Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_D94706AFE6497BB12B3274128964AB8F_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis_D94706AFE6497BB12B3274128964AB8F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_D94706AFE6497BB12B3274128964AB8F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_D94706AFE6497BB12B3274128964AB8F" xlink:to="lab_us-gaap_FairValueByAssetClassAxis_D94706AFE6497BB12B3274128964AB8F" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_036C5ED6840CCBCC63DB74128964ED11_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_036C5ED6840CCBCC63DB74128964ED11" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, by Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_036C5ED6840CCBCC63DB74128964ED11_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_036C5ED6840CCBCC63DB74128964ED11" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_036C5ED6840CCBCC63DB74128964ED11" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_036C5ED6840CCBCC63DB74128964ED11" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_036C5ED6840CCBCC63DB74128964ED11" xlink:type="arc" />
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_67889AE4268160F0FE6D74128965752D_verboseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember_67889AE4268160F0FE6D74128965752D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_67889AE4268160F0FE6D74128965752D_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember_67889AE4268160F0FE6D74128965752D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_67889AE4268160F0FE6D74128965752D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember_67889AE4268160F0FE6D74128965752D" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember_67889AE4268160F0FE6D74128965752D" xlink:type="arc" />
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_DEF1CB5B47F0DEF646C974128965E928_verboseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember_DEF1CB5B47F0DEF646C974128965E928" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Government securities</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_DEF1CB5B47F0DEF646C974128965E928_label_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember_DEF1CB5B47F0DEF646C974128965E928" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Treasury and Government [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_DEF1CB5B47F0DEF646C974128965E928" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryAndGovernmentMember_DEF1CB5B47F0DEF646C974128965E928" xlink:to="lab_us-gaap_USTreasuryAndGovernmentMember_DEF1CB5B47F0DEF646C974128965E928" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_7F50926FDE3AB1CEF983741289658F24_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember_7F50926FDE3AB1CEF983741289658F24" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Mortgage and other asset backed securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_7F50926FDE3AB1CEF983741289658F24_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember_7F50926FDE3AB1CEF983741289658F24" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset-backed Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_7F50926FDE3AB1CEF983741289658F24" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember_7F50926FDE3AB1CEF983741289658F24" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember_7F50926FDE3AB1CEF983741289658F24" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_D0B12C1FE3D48CC43B8C741289654F67_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_D0B12C1FE3D48CC43B8C741289654F67" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_D0B12C1FE3D48CC43B8C741289654F67_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_D0B12C1FE3D48CC43B8C741289654F67" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_D0B12C1FE3D48CC43B8C741289654F67" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_D0B12C1FE3D48CC43B8C741289654F67" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_D0B12C1FE3D48CC43B8C741289654F67" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_4E1AEE1C863591E840CB74128965E970_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_4E1AEE1C863591E840CB74128965E970" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of assets and liabilities recorded at fair value</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_4E1AEE1C863591E840CB74128965E970_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_4E1AEE1C863591E840CB74128965E970" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets, Liabilities and Stockholders' Equity Measured on Recurring Basis [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_4E1AEE1C863591E840CB74128965E970" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_4E1AEE1C863591E840CB74128965E970" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_4E1AEE1C863591E840CB74128965E970" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_5FCC9271109AD25A7E0074128965442F_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract_5FCC9271109AD25A7E0074128965442F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_5FCC9271109AD25A7E0074128965442F_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract_5FCC9271109AD25A7E0074128965442F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_5FCC9271109AD25A7E0074128965442F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_5FCC9271109AD25A7E0074128965442F" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract_5FCC9271109AD25A7E0074128965442F" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_10CAD8AF675AB0EFA3B874128965A54A_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_10CAD8AF675AB0EFA3B874128965A54A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_10CAD8AF675AB0EFA3B874128965A54A_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_10CAD8AF675AB0EFA3B874128965A54A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_10CAD8AF675AB0EFA3B874128965A54A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_10CAD8AF675AB0EFA3B874128965A54A" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_10CAD8AF675AB0EFA3B874128965A54A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_AE74DF41AF5479492ECB74128965820A_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities_AE74DF41AF5479492ECB74128965820A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable debt securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_AE74DF41AF5479492ECB74128965820A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecurities_AE74DF41AF5479492ECB74128965820A" xlink:to="lab_us-gaap_AvailableForSaleSecurities_AE74DF41AF5479492ECB74128965820A" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_AD5E170D5A8B38B9977F741289652F71_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure_AD5E170D5A8B38B9977F741289652F71" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_AD5E170D5A8B38B9977F741289652F71_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure_AD5E170D5A8B38B9977F741289652F71" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_AD5E170D5A8B38B9977F741289652F71" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure_AD5E170D5A8B38B9977F741289652F71" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure_AD5E170D5A8B38B9977F741289652F71" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_E4EEF57A4D4FE7A07D4E741289659AFF_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_E4EEF57A4D4FE7A07D4E741289659AFF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Derivative contracts</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_E4EEF57A4D4FE7A07D4E741289659AFF_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_E4EEF57A4D4FE7A07D4E741289659AFF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Contract, Asset, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_E4EEF57A4D4FE7A07D4E741289659AFF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_E4EEF57A4D4FE7A07D4E741289659AFF" xlink:to="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_E4EEF57A4D4FE7A07D4E741289659AFF" xlink:type="arc" />
    <link:label id="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_C8C1BB0AD6F0093A41BC7412896585C0_verboseLabel_en-US" xlink:label="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_C8C1BB0AD6F0093A41BC7412896585C0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Plan assets for deferred compensation</link:label>
    <link:label id="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_C8C1BB0AD6F0093A41BC7412896585C0_label_en-US" xlink:label="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_C8C1BB0AD6F0093A41BC7412896585C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Assets For Deferred Compensation Fair Value Disclosure</link:label>
    <link:label id="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_C8C1BB0AD6F0093A41BC7412896585C0_documentation_en-US" xlink:label="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_C8C1BB0AD6F0093A41BC7412896585C0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair values as of the balance sheet date of all assets of deferred compensation plans.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:label="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_C8C1BB0AD6F0093A41BC7412896585C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_C8C1BB0AD6F0093A41BC7412896585C0" xlink:to="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_C8C1BB0AD6F0093A41BC7412896585C0" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_B2AD5C745A88A43189FC74128965BA58_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure_B2AD5C745A88A43189FC74128965BA58" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_B2AD5C745A88A43189FC74128965BA58_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure_B2AD5C745A88A43189FC74128965BA58" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_B2AD5C745A88A43189FC74128965BA58" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_B2AD5C745A88A43189FC74128965BA58" xlink:to="lab_us-gaap_AssetsFairValueDisclosure_B2AD5C745A88A43189FC74128965BA58" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_11F3CF729521E65566BE74128965979B_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_11F3CF729521E65566BE74128965979B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_11F3CF729521E65566BE74128965979B_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_11F3CF729521E65566BE74128965979B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_11F3CF729521E65566BE74128965979B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_11F3CF729521E65566BE74128965979B" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_11F3CF729521E65566BE74128965979B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_42B408E63F6A1660B2A274128965C053_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_42B408E63F6A1660B2A274128965C053" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Derivative contracts</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_42B408E63F6A1660B2A274128965C053_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_42B408E63F6A1660B2A274128965C053" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Contracts, Liability, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_42B408E63F6A1660B2A274128965C053" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_42B408E63F6A1660B2A274128965C053" xlink:to="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_42B408E63F6A1660B2A274128965C053" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_F7B45837B03645D7C2157412896529B4_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_F7B45837B03645D7C2157412896529B4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration obligations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_F7B45837B03645D7C2157412896529B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_F7B45837B03645D7C2157412896529B4" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_F7B45837B03645D7C2157412896529B4" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_D11E3591EC46CA7F13FC74128966E035_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure_D11E3591EC46CA7F13FC74128966E035" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_D11E3591EC46CA7F13FC74128966E035_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure_D11E3591EC46CA7F13FC74128966E035" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_D11E3591EC46CA7F13FC74128966E035" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_D11E3591EC46CA7F13FC74128966E035" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure_D11E3591EC46CA7F13FC74128966E035" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_43D49CCE297C1372A032FA4EA566D521_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_43D49CCE297C1372A032FA4EA566D521" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_43D49CCE297C1372A032FA4EA566D521" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_43D49CCE297C1372A032FA4EA566D521" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_43D49CCE297C1372A032FA4EA566D521" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_D482A3637939C6007F8DFA4EA5662371_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_D482A3637939C6007F8DFA4EA5662371" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_D482A3637939C6007F8DFA4EA5662371_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_D482A3637939C6007F8DFA4EA5662371" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_D482A3637939C6007F8DFA4EA5662371" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_D482A3637939C6007F8DFA4EA5662371" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_D482A3637939C6007F8DFA4EA5662371" xlink:type="arc" />
    <link:label id="lab_biib_FumapharmAgMember_718F7CFAED742A741E4DFA4EA567F58A_terseLabel_en-US" xlink:label="lab_biib_FumapharmAgMember_718F7CFAED742A741E4DFA4EA567F58A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fumapharm AG</link:label>
    <link:label id="lab_biib_FumapharmAgMember_718F7CFAED742A741E4DFA4EA567F58A_label_en-US" xlink:label="lab_biib_FumapharmAgMember_718F7CFAED742A741E4DFA4EA567F58A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fumapharm AG [Member]</link:label>
    <link:label id="lab_biib_FumapharmAgMember_718F7CFAED742A741E4DFA4EA567F58A_documentation_en-US" xlink:label="lab_biib_FumapharmAgMember_718F7CFAED742A741E4DFA4EA567F58A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fumapharm AG [Member]</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_FumapharmAgMember" xlink:label="loc_biib_FumapharmAgMember_718F7CFAED742A741E4DFA4EA567F58A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FumapharmAgMember_718F7CFAED742A741E4DFA4EA567F58A" xlink:to="lab_biib_FumapharmAgMember_718F7CFAED742A741E4DFA4EA567F58A" xlink:type="arc" />
    <link:label id="lab_biib_AVONEXMember_7870E220AA7EAE6E577EFA4EA56761DA_terseLabel_en-US" xlink:label="lab_biib_AVONEXMember_7870E220AA7EAE6E577EFA4EA56761DA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AVONEX</link:label>
    <link:label id="lab_biib_AVONEXMember_7870E220AA7EAE6E577EFA4EA56761DA_label_en-US" xlink:label="lab_biib_AVONEXMember_7870E220AA7EAE6E577EFA4EA56761DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AVONEX [Member]</link:label>
    <link:label id="lab_biib_AVONEXMember_7870E220AA7EAE6E577EFA4EA56761DA_documentation_en-US" xlink:label="lab_biib_AVONEXMember_7870E220AA7EAE6E577EFA4EA56761DA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AVONEX</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_AVONEXMember" xlink:label="loc_biib_AVONEXMember_7870E220AA7EAE6E577EFA4EA56761DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AVONEXMember_7870E220AA7EAE6E577EFA4EA56761DA" xlink:to="lab_biib_AVONEXMember_7870E220AA7EAE6E577EFA4EA56761DA" xlink:type="arc" />
    <link:label id="lab_biib_TysabriProductMember_B4BA9D2D422AA49F85B6FA4EA5679D1D_terseLabel_en-US" xlink:label="lab_biib_TysabriProductMember_B4BA9D2D422AA49F85B6FA4EA5679D1D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">TYSABRI</link:label>
    <link:label id="lab_biib_TysabriProductMember_B4BA9D2D422AA49F85B6FA4EA5679D1D_label_en-US" xlink:label="lab_biib_TysabriProductMember_B4BA9D2D422AA49F85B6FA4EA5679D1D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">TYSABRI product [Member]</link:label>
    <link:label id="lab_biib_TysabriProductMember_B4BA9D2D422AA49F85B6FA4EA5679D1D_documentation_en-US" xlink:label="lab_biib_TysabriProductMember_B4BA9D2D422AA49F85B6FA4EA5679D1D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">TYSABRI product [Member]</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_TysabriProductMember" xlink:label="loc_biib_TysabriProductMember_B4BA9D2D422AA49F85B6FA4EA5679D1D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TysabriProductMember_B4BA9D2D422AA49F85B6FA4EA5679D1D" xlink:to="lab_biib_TysabriProductMember_B4BA9D2D422AA49F85B6FA4EA5679D1D" xlink:type="arc" />
    <link:label id="lab_biib_BiosimilarsMember_E12D59C42DA0F0715779FA4EA567955E_terseLabel_en-US" xlink:label="lab_biib_BiosimilarsMember_E12D59C42DA0F0715779FA4EA567955E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Biosimilars</link:label>
    <link:label id="lab_biib_BiosimilarsMember_E12D59C42DA0F0715779FA4EA567955E_label_en-US" xlink:label="lab_biib_BiosimilarsMember_E12D59C42DA0F0715779FA4EA567955E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Biosimilars [Member]</link:label>
    <link:label id="lab_biib_BiosimilarsMember_E12D59C42DA0F0715779FA4EA567955E_documentation_en-US" xlink:label="lab_biib_BiosimilarsMember_E12D59C42DA0F0715779FA4EA567955E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Biosimilars [Member]</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_BiosimilarsMember" xlink:label="loc_biib_BiosimilarsMember_E12D59C42DA0F0715779FA4EA567955E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BiosimilarsMember_E12D59C42DA0F0715779FA4EA567955E" xlink:to="lab_biib_BiosimilarsMember_E12D59C42DA0F0715779FA4EA567955E" xlink:type="arc" />
    <link:label id="lab_biib_ZINBRYTAMember_5461BBCC6A5B80477BFFFA4EA5673C4B_terseLabel_en-US" xlink:label="lab_biib_ZINBRYTAMember_5461BBCC6A5B80477BFFFA4EA5673C4B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ZINBRYTA</link:label>
    <link:label id="lab_biib_ZINBRYTAMember_5461BBCC6A5B80477BFFFA4EA5673C4B_label_en-US" xlink:label="lab_biib_ZINBRYTAMember_5461BBCC6A5B80477BFFFA4EA5673C4B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ZINBRYTA [Member]</link:label>
    <link:label id="lab_biib_ZINBRYTAMember_5461BBCC6A5B80477BFFFA4EA5673C4B_documentation_en-US" xlink:label="lab_biib_ZINBRYTAMember_5461BBCC6A5B80477BFFFA4EA5673C4B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ZINBRYTA [Member]</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_ZINBRYTAMember" xlink:label="loc_biib_ZINBRYTAMember_5461BBCC6A5B80477BFFFA4EA5673C4B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ZINBRYTAMember_5461BBCC6A5B80477BFFFA4EA5673C4B" xlink:to="lab_biib_ZINBRYTAMember_5461BBCC6A5B80477BFFFA4EA5673C4B" xlink:type="arc" />
    <link:label id="lab_biib_ALPROLIXMember_7BEEC76BE0B4D5A4F5E0FA4EA5673A0A_terseLabel_en-US" xlink:label="lab_biib_ALPROLIXMember_7BEEC76BE0B4D5A4F5E0FA4EA5673A0A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ALPROLIX</link:label>
    <link:label id="lab_biib_ALPROLIXMember_7BEEC76BE0B4D5A4F5E0FA4EA5673A0A_label_en-US" xlink:label="lab_biib_ALPROLIXMember_7BEEC76BE0B4D5A4F5E0FA4EA5673A0A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ALPROLIX [Member]</link:label>
    <link:label id="lab_biib_ALPROLIXMember_7BEEC76BE0B4D5A4F5E0FA4EA5673A0A_documentation_en-US" xlink:label="lab_biib_ALPROLIXMember_7BEEC76BE0B4D5A4F5E0FA4EA5673A0A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ALPROLIX [Member]</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_ALPROLIXMember" xlink:label="loc_biib_ALPROLIXMember_7BEEC76BE0B4D5A4F5E0FA4EA5673A0A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ALPROLIXMember_7BEEC76BE0B4D5A4F5E0FA4EA5673A0A" xlink:to="lab_biib_ALPROLIXMember_7BEEC76BE0B4D5A4F5E0FA4EA5673A0A" xlink:type="arc" />
    <link:label id="lab_biib_TecfideraMember_0B13F5CFBAA3BC5F6A0CFA4EA5675070_terseLabel_en-US" xlink:label="lab_biib_TecfideraMember_0B13F5CFBAA3BC5F6A0CFA4EA5675070" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">TECFIDERA</link:label>
    <link:label id="lab_biib_TecfideraMember_0B13F5CFBAA3BC5F6A0CFA4EA5675070_label_en-US" xlink:label="lab_biib_TecfideraMember_0B13F5CFBAA3BC5F6A0CFA4EA5675070" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">TECFIDERA [Member]</link:label>
    <link:label id="lab_biib_TecfideraMember_0B13F5CFBAA3BC5F6A0CFA4EA5675070_documentation_en-US" xlink:label="lab_biib_TecfideraMember_0B13F5CFBAA3BC5F6A0CFA4EA5675070" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">TECFIDERA [Member]</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_0B13F5CFBAA3BC5F6A0CFA4EA5675070" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TecfideraMember_0B13F5CFBAA3BC5F6A0CFA4EA5675070" xlink:to="lab_biib_TecfideraMember_0B13F5CFBAA3BC5F6A0CFA4EA5675070" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_DF6DB2AD6DE068351AC8FA4EA567EE67_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_DF6DB2AD6DE068351AC8FA4EA567EE67" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_DF6DB2AD6DE068351AC8FA4EA567EE67_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_DF6DB2AD6DE068351AC8FA4EA567EE67" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_DF6DB2AD6DE068351AC8FA4EA567EE67" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_DF6DB2AD6DE068351AC8FA4EA567EE67" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_DF6DB2AD6DE068351AC8FA4EA567EE67" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_FA7F0C10BBC676532FD0FA4EA567DF98_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_FA7F0C10BBC676532FD0FA4EA567DF98" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_FA7F0C10BBC676532FD0FA4EA567DF98_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_FA7F0C10BBC676532FD0FA4EA567DF98" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_FA7F0C10BBC676532FD0FA4EA567DF98" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_FA7F0C10BBC676532FD0FA4EA567DF98" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_FA7F0C10BBC676532FD0FA4EA567DF98" xlink:type="arc" />
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_883C2E327BC7EAFD2020FA4EA568E9AA_verboseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember_883C2E327BC7EAFD2020FA4EA568E9AA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">In-process research and development</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_883C2E327BC7EAFD2020FA4EA568E9AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember_883C2E327BC7EAFD2020FA4EA568E9AA" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember_883C2E327BC7EAFD2020FA4EA568E9AA" xlink:type="arc" />
    <link:label id="lab_us-gaap_TrademarksAndTradeNamesMember_A069B136347BACE6EF79FA4EA5689F22_verboseLabel_en-US" xlink:label="lab_us-gaap_TrademarksAndTradeNamesMember_A069B136347BACE6EF79FA4EA5689F22" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Trademarks and trade names</link:label>
    <link:label id="lab_us-gaap_TrademarksAndTradeNamesMember_A069B136347BACE6EF79FA4EA5689F22_label_en-US" xlink:label="lab_us-gaap_TrademarksAndTradeNamesMember_A069B136347BACE6EF79FA4EA5689F22" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trademarks and Trade Names [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_A069B136347BACE6EF79FA4EA5689F22" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TrademarksAndTradeNamesMember_A069B136347BACE6EF79FA4EA5689F22" xlink:to="lab_us-gaap_TrademarksAndTradeNamesMember_A069B136347BACE6EF79FA4EA5689F22" xlink:type="arc" />
    <link:label id="lab_biib_OutLicensedPatentsMember_B0AE17218424D421D4F4FA4EA568F926_terseLabel_en-US" xlink:label="lab_biib_OutLicensedPatentsMember_B0AE17218424D421D4F4FA4EA568F926" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Out-licensed patents</link:label>
    <link:label id="lab_biib_OutLicensedPatentsMember_B0AE17218424D421D4F4FA4EA568F926_label_en-US" xlink:label="lab_biib_OutLicensedPatentsMember_B0AE17218424D421D4F4FA4EA568F926" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Out Licensed Patents [Member]</link:label>
    <link:label id="lab_biib_OutLicensedPatentsMember_B0AE17218424D421D4F4FA4EA568F926_documentation_en-US" xlink:label="lab_biib_OutLicensedPatentsMember_B0AE17218424D421D4F4FA4EA568F926" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Out-licensed patents.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_OutLicensedPatentsMember" xlink:label="loc_biib_OutLicensedPatentsMember_B0AE17218424D421D4F4FA4EA568F926" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OutLicensedPatentsMember_B0AE17218424D421D4F4FA4EA568F926" xlink:to="lab_biib_OutLicensedPatentsMember_B0AE17218424D421D4F4FA4EA568F926" xlink:type="arc" />
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_EC4FE92223CD4ACE0E8FFA4EA568338A_terseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember_EC4FE92223CD4ACE0E8FFA4EA568338A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Developed technology</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_EC4FE92223CD4ACE0E8FFA4EA568338A_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember_EC4FE92223CD4ACE0E8FFA4EA568338A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_EC4FE92223CD4ACE0E8FFA4EA568338A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember_EC4FE92223CD4ACE0E8FFA4EA568338A" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember_EC4FE92223CD4ACE0E8FFA4EA568338A" xlink:type="arc" />
    <link:label id="lab_biib_InLicensedPatentsMember_4F03EF38B05FBF13C07FFA4EA5689712_terseLabel_en-US" xlink:label="lab_biib_InLicensedPatentsMember_4F03EF38B05FBF13C07FFA4EA5689712" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquired and in-licensed rights and patents</link:label>
    <link:label id="lab_biib_InLicensedPatentsMember_4F03EF38B05FBF13C07FFA4EA5689712_label_en-US" xlink:label="lab_biib_InLicensedPatentsMember_4F03EF38B05FBF13C07FFA4EA5689712" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">In Licensed Patents [Member]</link:label>
    <link:label id="lab_biib_InLicensedPatentsMember_4F03EF38B05FBF13C07FFA4EA5689712_documentation_en-US" xlink:label="lab_biib_InLicensedPatentsMember_4F03EF38B05FBF13C07FFA4EA5689712" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">In-licensed patents.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_InLicensedPatentsMember" xlink:label="loc_biib_InLicensedPatentsMember_4F03EF38B05FBF13C07FFA4EA5689712" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InLicensedPatentsMember_4F03EF38B05FBF13C07FFA4EA5689712" xlink:to="lab_biib_InLicensedPatentsMember_4F03EF38B05FBF13C07FFA4EA5689712" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_C95FCA0A99D01B9DF1A7FA4EA5692355_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_C95FCA0A99D01B9DF1A7FA4EA5692355" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_C95FCA0A99D01B9DF1A7FA4EA5692355_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_C95FCA0A99D01B9DF1A7FA4EA5692355" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_C95FCA0A99D01B9DF1A7FA4EA5692355" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_C95FCA0A99D01B9DF1A7FA4EA5692355" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_C95FCA0A99D01B9DF1A7FA4EA5692355" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_238640EE7A862943D437FA4EA569696D_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod_238640EE7A862943D437FA4EA569696D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase to goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_238640EE7A862943D437FA4EA569696D_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod_238640EE7A862943D437FA4EA569696D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_238640EE7A862943D437FA4EA569696D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod_238640EE7A862943D437FA4EA569696D" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod_238640EE7A862943D437FA4EA569696D" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_A29B57FC344DCAC48CE6FA4EA5691754_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill_A29B57FC344DCAC48CE6FA4EA5691754" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_A29B57FC344DCAC48CE6FA4EA5691754_label_en-US" xlink:label="lab_us-gaap_Goodwill_A29B57FC344DCAC48CE6FA4EA5691754" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_A29B57FC344DCAC48CE6FA4EA5691754" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_A29B57FC344DCAC48CE6FA4EA5691754" xlink:to="lab_us-gaap_Goodwill_A29B57FC344DCAC48CE6FA4EA5691754" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_C5638768CFA6E40E605AFA4EA569C628_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_C5638768CFA6E40E605AFA4EA569C628" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_C5638768CFA6E40E605AFA4EA569C628_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_C5638768CFA6E40E605AFA4EA569C628" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_C5638768CFA6E40E605AFA4EA569C628" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_C5638768CFA6E40E605AFA4EA569C628" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_C5638768CFA6E40E605AFA4EA569C628" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_9F7FB4B9002A04739509FA4EA5695DA5_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_9F7FB4B9002A04739509FA4EA5695DA5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Estimated life, (In Years)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_9F7FB4B9002A04739509FA4EA5695DA5_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_9F7FB4B9002A04739509FA4EA5695DA5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_9F7FB4B9002A04739509FA4EA5695DA5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_9F7FB4B9002A04739509FA4EA5695DA5" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_9F7FB4B9002A04739509FA4EA5695DA5" xlink:type="arc" />
    <link:label id="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_EABE525958F1D684A851FA4EA5697F53_terseLabel_en-US" xlink:label="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_EABE525958F1D684A851FA4EA5697F53" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite lived intangible assets useful life</link:label>
    <link:label id="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_EABE525958F1D684A851FA4EA5697F53_label_en-US" xlink:label="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_EABE525958F1D684A851FA4EA5697F53" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite Lived Intangible Assets Useful Life</link:label>
    <link:label id="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_EABE525958F1D684A851FA4EA5697F53_documentation_en-US" xlink:label="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_EABE525958F1D684A851FA4EA5697F53" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Indefinite lived intangible assets useful life.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_IndefiniteLivedIntangibleAssetsUsefulLife" xlink:label="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_EABE525958F1D684A851FA4EA5697F53" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_EABE525958F1D684A851FA4EA5697F53" xlink:to="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_EABE525958F1D684A851FA4EA5697F53" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_09AFB774F9270418D372FA4EA5698256_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross_09AFB774F9270418D372FA4EA5698256" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_09AFB774F9270418D372FA4EA5698256_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross_09AFB774F9270418D372FA4EA5698256" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_09AFB774F9270418D372FA4EA5698256" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross_09AFB774F9270418D372FA4EA5698256" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross_09AFB774F9270418D372FA4EA5698256" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_B28F4E22F8595B80D9DEFA4EA56AB87D_verboseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_B28F4E22F8595B80D9DEFA4EA56AB87D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cost and net</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_B28F4E22F8595B80D9DEFA4EA56AB87D_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_B28F4E22F8595B80D9DEFA4EA56AB87D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_B28F4E22F8595B80D9DEFA4EA56AB87D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_B28F4E22F8595B80D9DEFA4EA56AB87D" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_B28F4E22F8595B80D9DEFA4EA56AB87D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_016DD484F130E93016A9FA4EA56A7B50_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_016DD484F130E93016A9FA4EA56A7B50" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total intangible assets, gross</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_016DD484F130E93016A9FA4EA56A7B50_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_016DD484F130E93016A9FA4EA56A7B50" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_016DD484F130E93016A9FA4EA56A7B50" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_016DD484F130E93016A9FA4EA56A7B50" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_016DD484F130E93016A9FA4EA56A7B50" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9A75AC0F6DB0FE13818CFA4EA56A6641_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9A75AC0F6DB0FE13818CFA4EA56A6641" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9A75AC0F6DB0FE13818CFA4EA56A6641_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9A75AC0F6DB0FE13818CFA4EA56A6641" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9A75AC0F6DB0FE13818CFA4EA56A6641" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9A75AC0F6DB0FE13818CFA4EA56A6641" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9A75AC0F6DB0FE13818CFA4EA56A6641" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_9D42B46898876CD1B454FA4EA56A84FA_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet_9D42B46898876CD1B454FA4EA56A84FA" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_9D42B46898876CD1B454FA4EA56A84FA_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet_9D42B46898876CD1B454FA4EA56A84FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_9D42B46898876CD1B454FA4EA56A84FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_9D42B46898876CD1B454FA4EA56A84FA" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet_9D42B46898876CD1B454FA4EA56A84FA" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_D1A76CD50BA8CB402E03FA4EA56ADFCE_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_D1A76CD50BA8CB402E03FA4EA56ADFCE" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_D1A76CD50BA8CB402E03FA4EA56ADFCE_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_D1A76CD50BA8CB402E03FA4EA56ADFCE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_D1A76CD50BA8CB402E03FA4EA56ADFCE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_D1A76CD50BA8CB402E03FA4EA56ADFCE" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_D1A76CD50BA8CB402E03FA4EA56ADFCE" xlink:type="arc" />
    <link:label id="lab_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_29FD9B87D1DD80B3CB79FA4EA56AEBBC_verboseLabel_en-US" xlink:label="lab_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_29FD9B87D1DD80B3CB79FA4EA56AEBBC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets and Goodwill (Additional Textual)</link:label>
    <link:label id="lab_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_29FD9B87D1DD80B3CB79FA4EA56AEBBC_label_en-US" xlink:label="lab_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_29FD9B87D1DD80B3CB79FA4EA56AEBBC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets And Goodwill (Additional Textual) [Abstract]</link:label>
    <link:label id="lab_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_29FD9B87D1DD80B3CB79FA4EA56AEBBC_documentation_en-US" xlink:label="lab_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_29FD9B87D1DD80B3CB79FA4EA56AEBBC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Intangible assets and goodwill additional.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract" xlink:label="loc_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_29FD9B87D1DD80B3CB79FA4EA56AEBBC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_29FD9B87D1DD80B3CB79FA4EA56AEBBC" xlink:to="lab_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_29FD9B87D1DD80B3CB79FA4EA56AEBBC" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_08608861291CC0CADB77FA4EA56ABD03_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_08608861291CC0CADB77FA4EA56ABD03" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected future amortization expense, 2017</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_08608861291CC0CADB77FA4EA56ABD03_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_08608861291CC0CADB77FA4EA56ABD03" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_08608861291CC0CADB77FA4EA56ABD03" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_08608861291CC0CADB77FA4EA56ABD03" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_08608861291CC0CADB77FA4EA56ABD03" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_25BA715290654A34933CFA4EA56A2953_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_25BA715290654A34933CFA4EA56A2953" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected future amortization expense, 2018</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_25BA715290654A34933CFA4EA56A2953_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_25BA715290654A34933CFA4EA56A2953" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_25BA715290654A34933CFA4EA56A2953" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_25BA715290654A34933CFA4EA56A2953" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_25BA715290654A34933CFA4EA56A2953" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_E726D53C151763F6DC85FA4EA56ABE9E_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_E726D53C151763F6DC85FA4EA56ABE9E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected future amortization expense, 2019</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_E726D53C151763F6DC85FA4EA56ABE9E_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_E726D53C151763F6DC85FA4EA56ABE9E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_E726D53C151763F6DC85FA4EA56ABE9E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_E726D53C151763F6DC85FA4EA56ABE9E" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_E726D53C151763F6DC85FA4EA56ABE9E" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_EB71C2D975CE7DC733E7FA4EA56A551E_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_EB71C2D975CE7DC733E7FA4EA56A551E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected future amortization expense, 2020</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_EB71C2D975CE7DC733E7FA4EA56A551E_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_EB71C2D975CE7DC733E7FA4EA56A551E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_EB71C2D975CE7DC733E7FA4EA56A551E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_EB71C2D975CE7DC733E7FA4EA56A551E" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_EB71C2D975CE7DC733E7FA4EA56A551E" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_3063EF10D969D201069FFA4EA56A164F_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_3063EF10D969D201069FFA4EA56A164F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected future amortization expense, 2021</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_3063EF10D969D201069FFA4EA56A164F_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_3063EF10D969D201069FFA4EA56A164F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_3063EF10D969D201069FFA4EA56A164F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_3063EF10D969D201069FFA4EA56A164F" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_3063EF10D969D201069FFA4EA56A164F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_EC4D94D43C4F25DB9DC7FA4EA56A6E5C_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_EC4D94D43C4F25DB9DC7FA4EA56A6E5C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of out-licensed patent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_EC4D94D43C4F25DB9DC7FA4EA56A6E5C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_EC4D94D43C4F25DB9DC7FA4EA56A6E5C" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_EC4D94D43C4F25DB9DC7FA4EA56A6E5C" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_6445ECC3E6EE14771830FA4EA56A2905_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_6445ECC3E6EE14771830FA4EA56A2905" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net change in acquired and in-licensed rights and patents</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_6445ECC3E6EE14771830FA4EA56A2905_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_6445ECC3E6EE14771830FA4EA56A2905" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Period Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_6445ECC3E6EE14771830FA4EA56A2905" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_6445ECC3E6EE14771830FA4EA56A2905" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_6445ECC3E6EE14771830FA4EA56A2905" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_4184BF8ACCE7F88664D2FA4EA56AD3ED_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_4184BF8ACCE7F88664D2FA4EA56AD3ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_4184BF8ACCE7F88664D2FA4EA56AD3ED_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_4184BF8ACCE7F88664D2FA4EA56AD3ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_4184BF8ACCE7F88664D2FA4EA56AD3ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_4184BF8ACCE7F88664D2FA4EA56AD3ED" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_4184BF8ACCE7F88664D2FA4EA56AD3ED" xlink:type="arc" />
    <link:label id="lab_country_US_0F749EF60FCE4F7716B700324DCBE4AC_terseLabel_en-US" xlink:label="lab_country_US_0F749EF60FCE4F7716B700324DCBE4AC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd#country_US" xlink:label="loc_country_US_0F749EF60FCE4F7716B700324DCBE4AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US_0F749EF60FCE4F7716B700324DCBE4AC" xlink:to="lab_country_US_0F749EF60FCE4F7716B700324DCBE4AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_EuropeMember_E8477B18E3AC86F4D3BD00324DD0ACBB_terseLabel_en-US" xlink:label="lab_us-gaap_EuropeMember_E8477B18E3AC86F4D3BD00324DD0ACBB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Europe</link:label>
    <link:label id="lab_us-gaap_EuropeMember_E8477B18E3AC86F4D3BD00324DD0ACBB_label_en-US" xlink:label="lab_us-gaap_EuropeMember_E8477B18E3AC86F4D3BD00324DD0ACBB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Europe [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EuropeMember" xlink:label="loc_us-gaap_EuropeMember_E8477B18E3AC86F4D3BD00324DD0ACBB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EuropeMember_E8477B18E3AC86F4D3BD00324DD0ACBB" xlink:to="lab_us-gaap_EuropeMember_E8477B18E3AC86F4D3BD00324DD0ACBB" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesRevenueNetMember_5D660DE5CAB20B8D191E00324DD07B87_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember_5D660DE5CAB20B8D191E00324DD07B87" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_5D660DE5CAB20B8D191E00324DD07B87_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember_5D660DE5CAB20B8D191E00324DD07B87" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Revenue, Net [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaap_SalesRevenueNetMember_5D660DE5CAB20B8D191E00324DD07B87" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember_5D660DE5CAB20B8D191E00324DD07B87" xlink:to="lab_us-gaap_SalesRevenueNetMember_5D660DE5CAB20B8D191E00324DD07B87" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostOfSalesMember_5320C9E11E1530B2BC6300324DD1DF6C_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember_5320C9E11E1530B2BC6300324DD1DF6C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_5320C9E11E1530B2BC6300324DD1DF6C_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember_5320C9E11E1530B2BC6300324DD1DF6C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="loc_us-gaap_CostOfSalesMember_5320C9E11E1530B2BC6300324DD1DF6C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember_5320C9E11E1530B2BC6300324DD1DF6C" xlink:to="lab_us-gaap_CostOfSalesMember_5320C9E11E1530B2BC6300324DD1DF6C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_E95895140AD94EADF44C00324DD107D4_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_E95895140AD94EADF44C00324DD107D4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_E95895140AD94EADF44C00324DD107D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_E95895140AD94EADF44C00324DD107D4" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_E95895140AD94EADF44C00324DD107D4" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_C9E1DEAC603022C9C9F400324DD1EDBB_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_C9E1DEAC603022C9C9F400324DD1EDBB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_C9E1DEAC603022C9C9F400324DD1EDBB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_C9E1DEAC603022C9C9F400324DD1EDBB" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_C9E1DEAC603022C9C9F400324DD1EDBB" xlink:type="arc" />
    <link:label id="lab_biib_AdditionalProductsAxis_74422684264CE974068E00324DD122C0_terseLabel_en-US" xlink:label="lab_biib_AdditionalProductsAxis_74422684264CE974068E00324DD122C0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Products [Axis]</link:label>
    <link:label id="lab_biib_AdditionalProductsAxis_74422684264CE974068E00324DD122C0_label_en-US" xlink:label="lab_biib_AdditionalProductsAxis_74422684264CE974068E00324DD122C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Products [Axis]</link:label>
    <link:label id="lab_biib_AdditionalProductsAxis_74422684264CE974068E00324DD122C0_documentation_en-US" xlink:label="lab_biib_AdditionalProductsAxis_74422684264CE974068E00324DD122C0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional products.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_AdditionalProductsAxis" xlink:label="loc_biib_AdditionalProductsAxis_74422684264CE974068E00324DD122C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AdditionalProductsAxis_74422684264CE974068E00324DD122C0" xlink:to="lab_biib_AdditionalProductsAxis_74422684264CE974068E00324DD122C0" xlink:type="arc" />
    <link:label id="lab_biib_AdditionalProductsDomain_C75638621B5D25F8E82400324DD1617A_terseLabel_en-US" xlink:label="lab_biib_AdditionalProductsDomain_C75638621B5D25F8E82400324DD1617A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Products [Domain]</link:label>
    <link:label id="lab_biib_AdditionalProductsDomain_C75638621B5D25F8E82400324DD1617A_label_en-US" xlink:label="lab_biib_AdditionalProductsDomain_C75638621B5D25F8E82400324DD1617A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Products [Domain]</link:label>
    <link:label id="lab_biib_AdditionalProductsDomain_C75638621B5D25F8E82400324DD1617A_documentation_en-US" xlink:label="lab_biib_AdditionalProductsDomain_C75638621B5D25F8E82400324DD1617A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional products.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_AdditionalProductsDomain" xlink:label="loc_biib_AdditionalProductsDomain_C75638621B5D25F8E82400324DD1617A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AdditionalProductsDomain_C75638621B5D25F8E82400324DD1617A" xlink:to="lab_biib_AdditionalProductsDomain_C75638621B5D25F8E82400324DD1617A" xlink:type="arc" />
    <link:label id="lab_biib_NewAntiCd20Member_18AE8EC249DE8BF1766600324DD1EBF7_verboseLabel_en-US" xlink:label="lab_biib_NewAntiCd20Member_18AE8EC249DE8BF1766600324DD1EBF7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">New Anti-CD20</link:label>
    <link:label id="lab_biib_NewAntiCd20Member_18AE8EC249DE8BF1766600324DD1EBF7_label_en-US" xlink:label="lab_biib_NewAntiCd20Member_18AE8EC249DE8BF1766600324DD1EBF7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Anti Cd20 [Member]</link:label>
    <link:label id="lab_biib_NewAntiCd20Member_18AE8EC249DE8BF1766600324DD1EBF7_documentation_en-US" xlink:label="lab_biib_NewAntiCd20Member_18AE8EC249DE8BF1766600324DD1EBF7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">New Anti-CD20.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_NewAntiCd20Member" xlink:label="loc_biib_NewAntiCd20Member_18AE8EC249DE8BF1766600324DD1EBF7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NewAntiCd20Member_18AE8EC249DE8BF1766600324DD1EBF7" xlink:to="lab_biib_NewAntiCd20Member_18AE8EC249DE8BF1766600324DD1EBF7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_0995FC3D5831CC80831600324DD18A99_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_0995FC3D5831CC80831600324DD18A99" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Method Investee, Name [Axis]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_0995FC3D5831CC80831600324DD18A99_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_0995FC3D5831CC80831600324DD18A99" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_0995FC3D5831CC80831600324DD18A99" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_0995FC3D5831CC80831600324DD18A99" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_0995FC3D5831CC80831600324DD18A99" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvesteeNameDomain_BA64F908B187457F672900324DD128CB_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvesteeNameDomain_BA64F908B187457F672900324DD128CB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Method Investee, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvesteeNameDomain_BA64F908B187457F672900324DD128CB_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvesteeNameDomain_BA64F908B187457F672900324DD128CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="loc_us-gaap_EquityMethodInvesteeNameDomain_BA64F908B187457F672900324DD128CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvesteeNameDomain_BA64F908B187457F672900324DD128CB" xlink:to="lab_us-gaap_EquityMethodInvesteeNameDomain_BA64F908B187457F672900324DD128CB" xlink:type="arc" />
    <link:label id="lab_biib_SamsungBiosimilarAgreementMember_BF251F7DD9F663C84AB700324DD21B6F_terseLabel_en-US" xlink:label="lab_biib_SamsungBiosimilarAgreementMember_BF251F7DD9F663C84AB700324DD21B6F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Samsung Biosimilar Agreement</link:label>
    <link:label id="lab_biib_SamsungBiosimilarAgreementMember_BF251F7DD9F663C84AB700324DD21B6F_label_en-US" xlink:label="lab_biib_SamsungBiosimilarAgreementMember_BF251F7DD9F663C84AB700324DD21B6F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Samsung Biosimilar Agreement [Member]</link:label>
    <link:label id="lab_biib_SamsungBiosimilarAgreementMember_BF251F7DD9F663C84AB700324DD21B6F_documentation_en-US" xlink:label="lab_biib_SamsungBiosimilarAgreementMember_BF251F7DD9F663C84AB700324DD21B6F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Samsung bio-similar agreement.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_SamsungBiosimilarAgreementMember" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_BF251F7DD9F663C84AB700324DD21B6F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SamsungBiosimilarAgreementMember_BF251F7DD9F663C84AB700324DD21B6F" xlink:to="lab_biib_SamsungBiosimilarAgreementMember_BF251F7DD9F663C84AB700324DD21B6F" xlink:type="arc" />
    <link:label id="lab_biib_OcrelizumabMember_404530F02145F035EAA300324DD22A7C_verboseLabel_en-US" xlink:label="lab_biib_OcrelizumabMember_404530F02145F035EAA300324DD22A7C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Ocrelizumab</link:label>
    <link:label id="lab_biib_OcrelizumabMember_404530F02145F035EAA300324DD22A7C_label_en-US" xlink:label="lab_biib_OcrelizumabMember_404530F02145F035EAA300324DD22A7C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ocrelizumab [Member]</link:label>
    <link:label id="lab_biib_OcrelizumabMember_404530F02145F035EAA300324DD22A7C_documentation_en-US" xlink:label="lab_biib_OcrelizumabMember_404530F02145F035EAA300324DD22A7C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ocrelizumab.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_OcrelizumabMember" xlink:label="loc_biib_OcrelizumabMember_404530F02145F035EAA300324DD22A7C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OcrelizumabMember_404530F02145F035EAA300324DD22A7C" xlink:to="lab_biib_OcrelizumabMember_404530F02145F035EAA300324DD22A7C" xlink:type="arc" />
    <link:label id="lab_biib_ELOCTATEMember_3ADEC812E75C9838CA5500324DD22723_terseLabel_en-US" xlink:label="lab_biib_ELOCTATEMember_3ADEC812E75C9838CA5500324DD22723" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ELOCTATE</link:label>
    <link:label id="lab_biib_ELOCTATEMember_3ADEC812E75C9838CA5500324DD22723_label_en-US" xlink:label="lab_biib_ELOCTATEMember_3ADEC812E75C9838CA5500324DD22723" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ELOCTATE [Member]</link:label>
    <link:label id="lab_biib_ELOCTATEMember_3ADEC812E75C9838CA5500324DD22723_documentation_en-US" xlink:label="lab_biib_ELOCTATEMember_3ADEC812E75C9838CA5500324DD22723" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ELOCTATE [Member]</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_ELOCTATEMember" xlink:label="loc_biib_ELOCTATEMember_3ADEC812E75C9838CA5500324DD22723" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ELOCTATEMember_3ADEC812E75C9838CA5500324DD22723" xlink:to="lab_biib_ELOCTATEMember_3ADEC812E75C9838CA5500324DD22723" xlink:type="arc" />
    <link:label id="lab_biib_SOD1Member_979693D25EBCC47B156900324DD36CFC_terseLabel_en-US" xlink:label="lab_biib_SOD1Member_979693D25EBCC47B156900324DD36CFC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SOD1</link:label>
    <link:label id="lab_biib_SOD1Member_979693D25EBCC47B156900324DD36CFC_label_en-US" xlink:label="lab_biib_SOD1Member_979693D25EBCC47B156900324DD36CFC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SOD1 [Member]</link:label>
    <link:label id="lab_biib_SOD1Member_979693D25EBCC47B156900324DD36CFC_documentation_en-US" xlink:label="lab_biib_SOD1Member_979693D25EBCC47B156900324DD36CFC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">SOD1 [Member]</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_SOD1Member" xlink:label="loc_biib_SOD1Member_979693D25EBCC47B156900324DD36CFC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SOD1Member_979693D25EBCC47B156900324DD36CFC" xlink:to="lab_biib_SOD1Member_979693D25EBCC47B156900324DD36CFC" xlink:type="arc" />
    <link:label id="lab_biib_DMPKMember_CFCE29079AC59A436DD700324DD34D71_terseLabel_en-US" xlink:label="lab_biib_DMPKMember_CFCE29079AC59A436DD700324DD34D71" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">DMPK</link:label>
    <link:label id="lab_biib_DMPKMember_CFCE29079AC59A436DD700324DD34D71_label_en-US" xlink:label="lab_biib_DMPKMember_CFCE29079AC59A436DD700324DD34D71" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">DMPK [Member]</link:label>
    <link:label id="lab_biib_DMPKMember_CFCE29079AC59A436DD700324DD34D71_documentation_en-US" xlink:label="lab_biib_DMPKMember_CFCE29079AC59A436DD700324DD34D71" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">DMPK [Member]</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_DMPKMember" xlink:label="loc_biib_DMPKMember_CFCE29079AC59A436DD700324DD34D71" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DMPKMember_CFCE29079AC59A436DD700324DD34D71" xlink:to="lab_biib_DMPKMember_CFCE29079AC59A436DD700324DD34D71" xlink:type="arc" />
    <link:label id="lab_biib_LeadprogramsMember_8574A41E9F896F6B5A1800324DD39546_terseLabel_en-US" xlink:label="lab_biib_LeadprogramsMember_8574A41E9F896F6B5A1800324DD39546" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lead programs</link:label>
    <link:label id="lab_biib_LeadprogramsMember_8574A41E9F896F6B5A1800324DD39546_label_en-US" xlink:label="lab_biib_LeadprogramsMember_8574A41E9F896F6B5A1800324DD39546" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lead programs [Member]</link:label>
    <link:label id="lab_biib_LeadprogramsMember_8574A41E9F896F6B5A1800324DD39546_documentation_en-US" xlink:label="lab_biib_LeadprogramsMember_8574A41E9F896F6B5A1800324DD39546" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lead programs [Member]</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_LeadprogramsMember" xlink:label="loc_biib_LeadprogramsMember_8574A41E9F896F6B5A1800324DD39546" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_LeadprogramsMember_8574A41E9F896F6B5A1800324DD39546" xlink:to="lab_biib_LeadprogramsMember_8574A41E9F896F6B5A1800324DD39546" xlink:type="arc" />
    <link:label id="lab_biib_DiscoveryprogramsMember_E697510F3EA7F15431C500324DD3F580_terseLabel_en-US" xlink:label="lab_biib_DiscoveryprogramsMember_E697510F3EA7F15431C500324DD3F580" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discovery programs</link:label>
    <link:label id="lab_biib_DiscoveryprogramsMember_E697510F3EA7F15431C500324DD3F580_label_en-US" xlink:label="lab_biib_DiscoveryprogramsMember_E697510F3EA7F15431C500324DD3F580" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discovery programs [Member]</link:label>
    <link:label id="lab_biib_DiscoveryprogramsMember_E697510F3EA7F15431C500324DD3F580_documentation_en-US" xlink:label="lab_biib_DiscoveryprogramsMember_E697510F3EA7F15431C500324DD3F580" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Discovery programs [Member]</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_DiscoveryprogramsMember" xlink:label="loc_biib_DiscoveryprogramsMember_E697510F3EA7F15431C500324DD3F580" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DiscoveryprogramsMember_E697510F3EA7F15431C500324DD3F580" xlink:to="lab_biib_DiscoveryprogramsMember_E697510F3EA7F15431C500324DD3F580" xlink:type="arc" />
    <link:label id="lab_biib_AcordaMember_F0C5FC1F383F3FCA9F3400324DD3705C_terseLabel_en-US" xlink:label="lab_biib_AcordaMember_F0C5FC1F383F3FCA9F3400324DD3705C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acorda</link:label>
    <link:label id="lab_biib_AcordaMember_F0C5FC1F383F3FCA9F3400324DD3705C_label_en-US" xlink:label="lab_biib_AcordaMember_F0C5FC1F383F3FCA9F3400324DD3705C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acorda [Member]</link:label>
    <link:label id="lab_biib_AcordaMember_F0C5FC1F383F3FCA9F3400324DD3705C_documentation_en-US" xlink:label="lab_biib_AcordaMember_F0C5FC1F383F3FCA9F3400324DD3705C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Acorda.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_AcordaMember" xlink:label="loc_biib_AcordaMember_F0C5FC1F383F3FCA9F3400324DD3705C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AcordaMember_F0C5FC1F383F3FCA9F3400324DD3705C" xlink:to="lab_biib_AcordaMember_F0C5FC1F383F3FCA9F3400324DD3705C" xlink:type="arc" />
    <link:label id="lab_biib_AbbVieMember_F57E7CE71593D3CBB6DE00324DD8DC14_verboseLabel_en-US" xlink:label="lab_biib_AbbVieMember_F57E7CE71593D3CBB6DE00324DD8DC14" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">AbbVie</link:label>
    <link:label id="lab_biib_AbbVieMember_F57E7CE71593D3CBB6DE00324DD8DC14_label_en-US" xlink:label="lab_biib_AbbVieMember_F57E7CE71593D3CBB6DE00324DD8DC14" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AbbVie [Member]</link:label>
    <link:label id="lab_biib_AbbVieMember_F57E7CE71593D3CBB6DE00324DD8DC14_documentation_en-US" xlink:label="lab_biib_AbbVieMember_F57E7CE71593D3CBB6DE00324DD8DC14" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AbbVie</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_AbbVieMember" xlink:label="loc_biib_AbbVieMember_F57E7CE71593D3CBB6DE00324DD8DC14" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AbbVieMember_F57E7CE71593D3CBB6DE00324DD8DC14" xlink:to="lab_biib_AbbVieMember_F57E7CE71593D3CBB6DE00324DD8DC14" xlink:type="arc" />
    <link:label id="lab_biib_SwedishOrphanBiovitrumMember_CFF749ECE4A5DC222F6A00324DD82147_verboseLabel_en-US" xlink:label="lab_biib_SwedishOrphanBiovitrumMember_CFF749ECE4A5DC222F6A00324DD82147" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Swedish Orphan Biovitrum</link:label>
    <link:label id="lab_biib_SwedishOrphanBiovitrumMember_CFF749ECE4A5DC222F6A00324DD82147_label_en-US" xlink:label="lab_biib_SwedishOrphanBiovitrumMember_CFF749ECE4A5DC222F6A00324DD82147" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Swedish Orphan Biovitrum [Member]</link:label>
    <link:label id="lab_biib_SwedishOrphanBiovitrumMember_CFF749ECE4A5DC222F6A00324DD82147_documentation_en-US" xlink:label="lab_biib_SwedishOrphanBiovitrumMember_CFF749ECE4A5DC222F6A00324DD82147" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Swedish orphan biovitrum.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_SwedishOrphanBiovitrumMember" xlink:label="loc_biib_SwedishOrphanBiovitrumMember_CFF749ECE4A5DC222F6A00324DD82147" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SwedishOrphanBiovitrumMember_CFF749ECE4A5DC222F6A00324DD82147" xlink:to="lab_biib_SwedishOrphanBiovitrumMember_CFF749ECE4A5DC222F6A00324DD82147" xlink:type="arc" />
    <link:label id="lab_biib_IonisPharmaceuticalsMember_9B0BE632DEB5B4EDA98700324DD87277_terseLabel_en-US" xlink:label="lab_biib_IonisPharmaceuticalsMember_9B0BE632DEB5B4EDA98700324DD87277" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ionis Pharmaceuticals, Inc.</link:label>
    <link:label id="lab_biib_IonisPharmaceuticalsMember_9B0BE632DEB5B4EDA98700324DD87277_label_en-US" xlink:label="lab_biib_IonisPharmaceuticalsMember_9B0BE632DEB5B4EDA98700324DD87277" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ionis Pharmaceuticals [Member]</link:label>
    <link:label id="lab_biib_IonisPharmaceuticalsMember_9B0BE632DEB5B4EDA98700324DD87277_documentation_en-US" xlink:label="lab_biib_IonisPharmaceuticalsMember_9B0BE632DEB5B4EDA98700324DD87277" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ionis Pharmaceuticals [Member]</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_IonisPharmaceuticalsMember" xlink:label="loc_biib_IonisPharmaceuticalsMember_9B0BE632DEB5B4EDA98700324DD87277" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IonisPharmaceuticalsMember_9B0BE632DEB5B4EDA98700324DD87277" xlink:to="lab_biib_IonisPharmaceuticalsMember_9B0BE632DEB5B4EDA98700324DD87277" xlink:type="arc" />
    <link:label id="lab_biib_UniversityofPennsylvaniaMember_30D7BCA7EC9D29C0130700324DD9EC5D_terseLabel_en-US" xlink:label="lab_biib_UniversityofPennsylvaniaMember_30D7BCA7EC9D29C0130700324DD9EC5D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">University of Pennsylvania</link:label>
    <link:label id="lab_biib_UniversityofPennsylvaniaMember_30D7BCA7EC9D29C0130700324DD9EC5D_label_en-US" xlink:label="lab_biib_UniversityofPennsylvaniaMember_30D7BCA7EC9D29C0130700324DD9EC5D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">University of Pennsylvania [Member]</link:label>
    <link:label id="lab_biib_UniversityofPennsylvaniaMember_30D7BCA7EC9D29C0130700324DD9EC5D_documentation_en-US" xlink:label="lab_biib_UniversityofPennsylvaniaMember_30D7BCA7EC9D29C0130700324DD9EC5D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">University of Pennsylvania [Member]</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_UniversityofPennsylvaniaMember" xlink:label="loc_biib_UniversityofPennsylvaniaMember_30D7BCA7EC9D29C0130700324DD9EC5D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_UniversityofPennsylvaniaMember_30D7BCA7EC9D29C0130700324DD9EC5D" xlink:to="lab_biib_UniversityofPennsylvaniaMember_30D7BCA7EC9D29C0130700324DD9EC5D" xlink:type="arc" />
    <link:label id="lab_biib_SangamoBioSciencesMember_25F4D8CA2177B310FE8900324DD95135_terseLabel_en-US" xlink:label="lab_biib_SangamoBioSciencesMember_25F4D8CA2177B310FE8900324DD95135" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sangamo BioSciences</link:label>
    <link:label id="lab_biib_SangamoBioSciencesMember_25F4D8CA2177B310FE8900324DD95135_label_en-US" xlink:label="lab_biib_SangamoBioSciencesMember_25F4D8CA2177B310FE8900324DD95135" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sangamo BioSciences [Member]</link:label>
    <link:label id="lab_biib_SangamoBioSciencesMember_25F4D8CA2177B310FE8900324DD95135_documentation_en-US" xlink:label="lab_biib_SangamoBioSciencesMember_25F4D8CA2177B310FE8900324DD95135" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sangamo BioSciences [Member]</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_SangamoBioSciencesMember" xlink:label="loc_biib_SangamoBioSciencesMember_25F4D8CA2177B310FE8900324DD95135" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SangamoBioSciencesMember_25F4D8CA2177B310FE8900324DD95135" xlink:to="lab_biib_SangamoBioSciencesMember_25F4D8CA2177B310FE8900324DD95135" xlink:type="arc" />
    <link:label id="lab_biib_OtherresearchanddiscoveryMember_93DB9A2685A190A9488200324DD9329D_terseLabel_en-US" xlink:label="lab_biib_OtherresearchanddiscoveryMember_93DB9A2685A190A9488200324DD9329D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other research and discovery</link:label>
    <link:label id="lab_biib_OtherresearchanddiscoveryMember_93DB9A2685A190A9488200324DD9329D_label_en-US" xlink:label="lab_biib_OtherresearchanddiscoveryMember_93DB9A2685A190A9488200324DD9329D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other research and discovery [Member]</link:label>
    <link:label id="lab_biib_OtherresearchanddiscoveryMember_93DB9A2685A190A9488200324DD9329D_documentation_en-US" xlink:label="lab_biib_OtherresearchanddiscoveryMember_93DB9A2685A190A9488200324DD9329D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other research and discovery [Member]</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_OtherresearchanddiscoveryMember" xlink:label="loc_biib_OtherresearchanddiscoveryMember_93DB9A2685A190A9488200324DD9329D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OtherresearchanddiscoveryMember_93DB9A2685A190A9488200324DD9329D" xlink:to="lab_biib_OtherresearchanddiscoveryMember_93DB9A2685A190A9488200324DD9329D" xlink:type="arc" />
    <link:label id="lab_biib_BiogenIdecHemophiliaMember_4DA3E4E00A0D9AB9744300324DDA0DA9_terseLabel_en-US" xlink:label="lab_biib_BiogenIdecHemophiliaMember_4DA3E4E00A0D9AB9744300324DDA0DA9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Biogen Hemophilia</link:label>
    <link:label id="lab_biib_BiogenIdecHemophiliaMember_4DA3E4E00A0D9AB9744300324DDA0DA9_label_en-US" xlink:label="lab_biib_BiogenIdecHemophiliaMember_4DA3E4E00A0D9AB9744300324DDA0DA9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Biogen Idec Hemophilia [Member]</link:label>
    <link:label id="lab_biib_BiogenIdecHemophiliaMember_4DA3E4E00A0D9AB9744300324DDA0DA9_documentation_en-US" xlink:label="lab_biib_BiogenIdecHemophiliaMember_4DA3E4E00A0D9AB9744300324DDA0DA9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Biogen Idec Hemophilia.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_BiogenIdecHemophiliaMember" xlink:label="loc_biib_BiogenIdecHemophiliaMember_4DA3E4E00A0D9AB9744300324DDA0DA9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BiogenIdecHemophiliaMember_4DA3E4E00A0D9AB9744300324DDA0DA9" xlink:to="lab_biib_BiogenIdecHemophiliaMember_4DA3E4E00A0D9AB9744300324DDA0DA9" xlink:type="arc" />
    <link:label id="lab_biib_Biogeneffectiveroyaltyrate_F8BBA80074C61031E3FB00324DDA8F61_terseLabel_en-US" xlink:label="lab_biib_Biogeneffectiveroyaltyrate_F8BBA80074C61031E3FB00324DDA8F61" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Biogen effective royalty rate</link:label>
    <link:label id="lab_biib_Biogeneffectiveroyaltyrate_F8BBA80074C61031E3FB00324DDA8F61_label_en-US" xlink:label="lab_biib_Biogeneffectiveroyaltyrate_F8BBA80074C61031E3FB00324DDA8F61" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Biogen effective royalty rate</link:label>
    <link:label id="lab_biib_Biogeneffectiveroyaltyrate_F8BBA80074C61031E3FB00324DDA8F61_documentation_en-US" xlink:label="lab_biib_Biogeneffectiveroyaltyrate_F8BBA80074C61031E3FB00324DDA8F61" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Biogen effective royalty rate</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_Biogeneffectiveroyaltyrate" xlink:label="loc_biib_Biogeneffectiveroyaltyrate_F8BBA80074C61031E3FB00324DDA8F61" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Biogeneffectiveroyaltyrate_F8BBA80074C61031E3FB00324DDA8F61" xlink:to="lab_biib_Biogeneffectiveroyaltyrate_F8BBA80074C61031E3FB00324DDA8F61" xlink:type="arc" />
    <link:label id="lab_biib_CollaborationsTextualAbstract_77B6CB9A30BA7410DA2800324DDA5228_verboseLabel_en-US" xlink:label="lab_biib_CollaborationsTextualAbstract_77B6CB9A30BA7410DA2800324DDA5228" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Collaborative and Other Relationships (Textual)</link:label>
    <link:label id="lab_biib_CollaborationsTextualAbstract_77B6CB9A30BA7410DA2800324DDA5228_label_en-US" xlink:label="lab_biib_CollaborationsTextualAbstract_77B6CB9A30BA7410DA2800324DDA5228" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborations (Textual) [Abstract]</link:label>
    <link:label id="lab_biib_CollaborationsTextualAbstract_77B6CB9A30BA7410DA2800324DDA5228_documentation_en-US" xlink:label="lab_biib_CollaborationsTextualAbstract_77B6CB9A30BA7410DA2800324DDA5228" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborations.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_CollaborationsTextualAbstract" xlink:label="loc_biib_CollaborationsTextualAbstract_77B6CB9A30BA7410DA2800324DDA5228" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CollaborationsTextualAbstract_77B6CB9A30BA7410DA2800324DDA5228" xlink:to="lab_biib_CollaborationsTextualAbstract_77B6CB9A30BA7410DA2800324DDA5228" xlink:type="arc" />
    <link:label id="lab_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_3527DD33D244067D81C300324DDA3817_verboseLabel_en-US" xlink:label="lab_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_3527DD33D244067D81C300324DDA3817" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Future royalties percentage to be received on sale of ocrelizumab</link:label>
    <link:label id="lab_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_3527DD33D244067D81C300324DDA3817_label_en-US" xlink:label="lab_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_3527DD33D244067D81C300324DDA3817" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Royalties Percentage To Be Received On Sale Of Product</link:label>
    <link:label id="lab_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_3527DD33D244067D81C300324DDA3817_documentation_en-US" xlink:label="lab_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_3527DD33D244067D81C300324DDA3817" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Future royalties percentage to be received on sale of product.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct" xlink:label="loc_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_3527DD33D244067D81C300324DDA3817" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_3527DD33D244067D81C300324DDA3817" xlink:to="lab_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_3527DD33D244067D81C300324DDA3817" xlink:type="arc" />
    <link:label id="lab_biib_Reductioninroyaltyrate_90988B2EEB2DC40C960300324DDAA555_terseLabel_en-US" xlink:label="lab_biib_Reductioninroyaltyrate_90988B2EEB2DC40C960300324DDAA555" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reduction in royalty rate</link:label>
    <link:label id="lab_biib_Reductioninroyaltyrate_90988B2EEB2DC40C960300324DDAA555_label_en-US" xlink:label="lab_biib_Reductioninroyaltyrate_90988B2EEB2DC40C960300324DDAA555" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reduction in royalty rate</link:label>
    <link:label id="lab_biib_Reductioninroyaltyrate_90988B2EEB2DC40C960300324DDAA555_documentation_en-US" xlink:label="lab_biib_Reductioninroyaltyrate_90988B2EEB2DC40C960300324DDAA555" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reduction in royalty rate</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_Reductioninroyaltyrate" xlink:label="loc_biib_Reductioninroyaltyrate_90988B2EEB2DC40C960300324DDAA555" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Reductioninroyaltyrate_90988B2EEB2DC40C960300324DDAA555" xlink:to="lab_biib_Reductioninroyaltyrate_90988B2EEB2DC40C960300324DDAA555" xlink:type="arc" />
    <link:label id="lab_biib_PeriodOfCollaborationAgreement_9AA9CF475DC0BD381C0700324DDAB86A_verboseLabel_en-US" xlink:label="lab_biib_PeriodOfCollaborationAgreement_9AA9CF475DC0BD381C0700324DDAB86A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Period of collaboration agreement</link:label>
    <link:label id="lab_biib_PeriodOfCollaborationAgreement_9AA9CF475DC0BD381C0700324DDAB86A_label_en-US" xlink:label="lab_biib_PeriodOfCollaborationAgreement_9AA9CF475DC0BD381C0700324DDAB86A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Period Of Collaboration Agreement</link:label>
    <link:label id="lab_biib_PeriodOfCollaborationAgreement_9AA9CF475DC0BD381C0700324DDAB86A_documentation_en-US" xlink:label="lab_biib_PeriodOfCollaborationAgreement_9AA9CF475DC0BD381C0700324DDAB86A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period of collaboration agreement.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_PeriodOfCollaborationAgreement" xlink:label="loc_biib_PeriodOfCollaborationAgreement_9AA9CF475DC0BD381C0700324DDAB86A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PeriodOfCollaborationAgreement_9AA9CF475DC0BD381C0700324DDAB86A" xlink:to="lab_biib_PeriodOfCollaborationAgreement_9AA9CF475DC0BD381C0700324DDAB86A" xlink:type="arc" />
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_DE47CF2AD4047A0869BC00324DDA2799_terseLabel_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_DE47CF2AD4047A0869BC00324DDA2799" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of Co promotion Operating Profits first fifty million</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_DE47CF2AD4047A0869BC00324DDA2799_label_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_DE47CF2AD4047A0869BC00324DDA2799" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Co Promotion Operating Profits First Fifty Million</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_DE47CF2AD4047A0869BC00324DDA2799_documentation_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_DE47CF2AD4047A0869BC00324DDA2799" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of co promotion operating profits first fifty million.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_DE47CF2AD4047A0869BC00324DDA2799" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_DE47CF2AD4047A0869BC00324DDA2799" xlink:to="lab_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_DE47CF2AD4047A0869BC00324DDA2799" xlink:type="arc" />
    <link:label id="lab_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_9AC0EEDD08A40C73D71800324DDA9AFC_verboseLabel_en-US" xlink:label="lab_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_9AC0EEDD08A40C73D71800324DDA9AFC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Co-promotion operating profit threshold for Rituxan in U S and Canada to determine share of co promotion operating profit prior to amendment</link:label>
    <link:label id="lab_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_9AC0EEDD08A40C73D71800324DDA9AFC_label_en-US" xlink:label="lab_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_9AC0EEDD08A40C73D71800324DDA9AFC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Co Promotion Operating Profit Threshold To Determine Share Of Co Promotion Operating Profit Prior To Amendment</link:label>
    <link:label id="lab_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_9AC0EEDD08A40C73D71800324DDA9AFC_documentation_en-US" xlink:label="lab_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_9AC0EEDD08A40C73D71800324DDA9AFC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Co promotion operating profit threshold to determine share of co promotion operating profit prior to amendment.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" xlink:label="loc_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_9AC0EEDD08A40C73D71800324DDA9AFC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_9AC0EEDD08A40C73D71800324DDA9AFC" xlink:to="lab_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_9AC0EEDD08A40C73D71800324DDA9AFC" xlink:type="arc" />
    <link:label id="lab_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_A8CE0B9D1C7AD331083B00324DDA4A12_verboseLabel_en-US" xlink:label="lab_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_A8CE0B9D1C7AD331083B00324DDA4A12" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Limit of gross sale of GAZYVA to be achieved in preceding 12 months under option one</link:label>
    <link:label id="lab_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_A8CE0B9D1C7AD331083B00324DDA4A12_label_en-US" xlink:label="lab_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_A8CE0B9D1C7AD331083B00324DDA4A12" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Threshold Of Gross Sales Of To Be Achieved In Preceding Twelve Consecutive Months Under Option One</link:label>
    <link:label id="lab_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_A8CE0B9D1C7AD331083B00324DDA4A12_documentation_en-US" xlink:label="lab_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_A8CE0B9D1C7AD331083B00324DDA4A12" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Threshold of gross sales of to be achieved in preceding twelve consecutive months under option one.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne" xlink:label="loc_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_A8CE0B9D1C7AD331083B00324DDA4A12" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_A8CE0B9D1C7AD331083B00324DDA4A12" xlink:to="lab_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_A8CE0B9D1C7AD331083B00324DDA4A12" xlink:type="arc" />
    <link:label id="lab_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_90F2A898F7178B3EED3000324DDB1B09_verboseLabel_en-US" xlink:label="lab_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_90F2A898F7178B3EED3000324DDB1B09" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Limit of gross sale of GAZYVA to be achieved in any 12 months under option one</link:label>
    <link:label id="lab_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_90F2A898F7178B3EED3000324DDB1B09_label_en-US" xlink:label="lab_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_90F2A898F7178B3EED3000324DDB1B09" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Threshold Of Gross Sales To Be Achieved In Any Twelve Consecutive Months Under Option One</link:label>
    <link:label id="lab_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_90F2A898F7178B3EED3000324DDB1B09_documentation_en-US" xlink:label="lab_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_90F2A898F7178B3EED3000324DDB1B09" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Threshold of gross sales to be achieved in any twelve consecutive months under option one.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne" xlink:label="loc_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_90F2A898F7178B3EED3000324DDB1B09" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_90F2A898F7178B3EED3000324DDB1B09" xlink:to="lab_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_90F2A898F7178B3EED3000324DDB1B09" xlink:type="arc" />
    <link:label id="lab_biib_SalesTriggerGrossSalesThreshold_D80AAAC27B4CA3F9288C00324DDB6EC3_terseLabel_en-US" xlink:label="lab_biib_SalesTriggerGrossSalesThreshold_D80AAAC27B4CA3F9288C00324DDB6EC3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales Trigger Gross Sales Threshold</link:label>
    <link:label id="lab_biib_SalesTriggerGrossSalesThreshold_D80AAAC27B4CA3F9288C00324DDB6EC3_label_en-US" xlink:label="lab_biib_SalesTriggerGrossSalesThreshold_D80AAAC27B4CA3F9288C00324DDB6EC3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Trigger Gross Sales Threshold</link:label>
    <link:label id="lab_biib_SalesTriggerGrossSalesThreshold_D80AAAC27B4CA3F9288C00324DDB6EC3_documentation_en-US" xlink:label="lab_biib_SalesTriggerGrossSalesThreshold_D80AAAC27B4CA3F9288C00324DDB6EC3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sales trigger gross sales threshold.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_SalesTriggerGrossSalesThreshold" xlink:label="loc_biib_SalesTriggerGrossSalesThreshold_D80AAAC27B4CA3F9288C00324DDB6EC3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SalesTriggerGrossSalesThreshold_D80AAAC27B4CA3F9288C00324DDB6EC3" xlink:to="lab_biib_SalesTriggerGrossSalesThreshold_D80AAAC27B4CA3F9288C00324DDB6EC3" xlink:type="arc" />
    <link:label id="lab_biib_Futurepercentageofcopromotionoperatingprofits_630C4EAEF3E53229614B00324DDB8375_terseLabel_en-US" xlink:label="lab_biib_Futurepercentageofcopromotionoperatingprofits_630C4EAEF3E53229614B00324DDB8375" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future percentage of co-promotion operating profits</link:label>
    <link:label id="lab_biib_Futurepercentageofcopromotionoperatingprofits_630C4EAEF3E53229614B00324DDB8375_label_en-US" xlink:label="lab_biib_Futurepercentageofcopromotionoperatingprofits_630C4EAEF3E53229614B00324DDB8375" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future percentage of co-promotion operating profits</link:label>
    <link:label id="lab_biib_Futurepercentageofcopromotionoperatingprofits_630C4EAEF3E53229614B00324DDB8375_documentation_en-US" xlink:label="lab_biib_Futurepercentageofcopromotionoperatingprofits_630C4EAEF3E53229614B00324DDB8375" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Future percentage of co-promotion operating profits</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_Futurepercentageofcopromotionoperatingprofits" xlink:label="loc_biib_Futurepercentageofcopromotionoperatingprofits_630C4EAEF3E53229614B00324DDB8375" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Futurepercentageofcopromotionoperatingprofits_630C4EAEF3E53229614B00324DDB8375" xlink:to="lab_biib_Futurepercentageofcopromotionoperatingprofits_630C4EAEF3E53229614B00324DDB8375" xlink:type="arc" />
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingLosses_1DF59DD3C200469B1F1600324DDBFC76_terseLabel_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingLosses_1DF59DD3C200469B1F1600324DDBFC76" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage Of Co Promotion Operating Losses</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingLosses_1DF59DD3C200469B1F1600324DDBFC76_label_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingLosses_1DF59DD3C200469B1F1600324DDBFC76" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Co Promotion Operating Losses</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingLosses_1DF59DD3C200469B1F1600324DDBFC76_documentation_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingLosses_1DF59DD3C200469B1F1600324DDBFC76" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage Of Co Promotion Operating Losses</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_PercentageOfCoPromotionOperatingLosses" xlink:label="loc_biib_PercentageOfCoPromotionOperatingLosses_1DF59DD3C200469B1F1600324DDBFC76" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageOfCoPromotionOperatingLosses_1DF59DD3C200469B1F1600324DDBFC76" xlink:to="lab_biib_PercentageOfCoPromotionOperatingLosses_1DF59DD3C200469B1F1600324DDBFC76" xlink:type="arc" />
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillion_50C192F6DB2CE13DC04600324DDB87A5_terseLabel_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillion_50C192F6DB2CE13DC04600324DDB87A5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of share of Co promotion profits exceeding $50 million</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillion_50C192F6DB2CE13DC04600324DDB87A5_label_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillion_50C192F6DB2CE13DC04600324DDB87A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillion_50C192F6DB2CE13DC04600324DDB87A5_documentation_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillion_50C192F6DB2CE13DC04600324DDB87A5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of co promotion operating profits greater than first fifty million.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillion" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillion_50C192F6DB2CE13DC04600324DDB87A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillion_50C192F6DB2CE13DC04600324DDB87A5" xlink:to="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillion_50C192F6DB2CE13DC04600324DDB87A5" xlink:type="arc" />
    <link:label id="lab_biib_ExpectedAdditionalMilestonePaymentsOnSuccessfulAchievementOfRegulatoryAndCommercialSalesMilestones_4458AFD1322B607B83D900324DDB2AA7_verboseLabel_en-US" xlink:label="lab_biib_ExpectedAdditionalMilestonePaymentsOnSuccessfulAchievementOfRegulatoryAndCommercialSalesMilestones_4458AFD1322B607B83D900324DDB2AA7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected additional milestone payments for successful achievement of regulatory and commercial sales milestones</link:label>
    <link:label id="lab_biib_ExpectedAdditionalMilestonePaymentsOnSuccessfulAchievementOfRegulatoryAndCommercialSalesMilestones_4458AFD1322B607B83D900324DDB2AA7_label_en-US" xlink:label="lab_biib_ExpectedAdditionalMilestonePaymentsOnSuccessfulAchievementOfRegulatoryAndCommercialSalesMilestones_4458AFD1322B607B83D900324DDB2AA7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected Additional Milestone Payments On Successful Achievement Of Regulatory And Commercial Sales Milestones</link:label>
    <link:label id="lab_biib_ExpectedAdditionalMilestonePaymentsOnSuccessfulAchievementOfRegulatoryAndCommercialSalesMilestones_4458AFD1322B607B83D900324DDB2AA7_documentation_en-US" xlink:label="lab_biib_ExpectedAdditionalMilestonePaymentsOnSuccessfulAchievementOfRegulatoryAndCommercialSalesMilestones_4458AFD1322B607B83D900324DDB2AA7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expected additional milestone payments on successful achievement of regulatory and commercial sales milestones.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_ExpectedAdditionalMilestonePaymentsOnSuccessfulAchievementOfRegulatoryAndCommercialSalesMilestones" xlink:label="loc_biib_ExpectedAdditionalMilestonePaymentsOnSuccessfulAchievementOfRegulatoryAndCommercialSalesMilestones_4458AFD1322B607B83D900324DDB2AA7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ExpectedAdditionalMilestonePaymentsOnSuccessfulAchievementOfRegulatoryAndCommercialSalesMilestones_4458AFD1322B607B83D900324DDB2AA7" xlink:to="lab_biib_ExpectedAdditionalMilestonePaymentsOnSuccessfulAchievementOfRegulatoryAndCommercialSalesMilestones_4458AFD1322B607B83D900324DDB2AA7" xlink:type="arc" />
    <link:label id="lab_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold_4EFD3D2323A8653C5F0C00324DDBB2D6_verboseLabel_en-US" xlink:label="lab_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold_4EFD3D2323A8653C5F0C00324DDBB2D6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected additional milestone payments when certain sales threshold is met</link:label>
    <link:label id="lab_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold_4EFD3D2323A8653C5F0C00324DDBB2D6_label_en-US" xlink:label="lab_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold_4EFD3D2323A8653C5F0C00324DDBB2D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected Additional Milestone Payments When Meeting Certain Sales Threshold</link:label>
    <link:label id="lab_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold_4EFD3D2323A8653C5F0C00324DDBB2D6_documentation_en-US" xlink:label="lab_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold_4EFD3D2323A8653C5F0C00324DDBB2D6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expected additional milestone payments when meeting certain sales threshold.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold" xlink:label="loc_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold_4EFD3D2323A8653C5F0C00324DDBB2D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold_4EFD3D2323A8653C5F0C00324DDBB2D6" xlink:to="lab_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold_4EFD3D2323A8653C5F0C00324DDBB2D6" xlink:type="arc" />
    <link:label id="lab_biib_ForeignSalesRequiredToTriggerMilestone_8ADC23FCB12FA4F33DA900324DDB1912_verboseLabel_en-US" xlink:label="lab_biib_ForeignSalesRequiredToTriggerMilestone_8ADC23FCB12FA4F33DA900324DDB1912" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign sales required to trigger milestone</link:label>
    <link:label id="lab_biib_ForeignSalesRequiredToTriggerMilestone_8ADC23FCB12FA4F33DA900324DDB1912_label_en-US" xlink:label="lab_biib_ForeignSalesRequiredToTriggerMilestone_8ADC23FCB12FA4F33DA900324DDB1912" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Sales Required To Trigger Milestone</link:label>
    <link:label id="lab_biib_ForeignSalesRequiredToTriggerMilestone_8ADC23FCB12FA4F33DA900324DDB1912_documentation_en-US" xlink:label="lab_biib_ForeignSalesRequiredToTriggerMilestone_8ADC23FCB12FA4F33DA900324DDB1912" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Foreign sales required to trigger milestone.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_ForeignSalesRequiredToTriggerMilestone" xlink:label="loc_biib_ForeignSalesRequiredToTriggerMilestone_8ADC23FCB12FA4F33DA900324DDB1912" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ForeignSalesRequiredToTriggerMilestone_8ADC23FCB12FA4F33DA900324DDB1912" xlink:to="lab_biib_ForeignSalesRequiredToTriggerMilestone_8ADC23FCB12FA4F33DA900324DDB1912" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_D22A63805907E2D34ADF00324DE0221B_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_D22A63805907E2D34ADF00324DE0221B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_D22A63805907E2D34ADF00324DE0221B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_D22A63805907E2D34ADF00324DE0221B" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_D22A63805907E2D34ADF00324DE0221B" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_8C5D906AA0B920A9ACF700324DE01BA8_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_8C5D906AA0B920A9ACF700324DE01BA8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock acquired in acquisition</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_8C5D906AA0B920A9ACF700324DE01BA8_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_8C5D906AA0B920A9ACF700324DE01BA8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Percentage of Voting Interests Acquired</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_8C5D906AA0B920A9ACF700324DE01BA8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_8C5D906AA0B920A9ACF700324DE01BA8" xlink:to="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_8C5D906AA0B920A9ACF700324DE01BA8" xlink:type="arc" />
    <link:label id="lab_biib_ConsiderationPerProductDeveloped_3E421C6B325C6616DB6600324DE0C64A_verboseLabel_en-US" xlink:label="lab_biib_ConsiderationPerProductDeveloped_3E421C6B325C6616DB6600324DE0C64A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Consideration per product</link:label>
    <link:label id="lab_biib_ConsiderationPerProductDeveloped_3E421C6B325C6616DB6600324DE0C64A_label_en-US" xlink:label="lab_biib_ConsiderationPerProductDeveloped_3E421C6B325C6616DB6600324DE0C64A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consideration Per Product Developed</link:label>
    <link:label id="lab_biib_ConsiderationPerProductDeveloped_3E421C6B325C6616DB6600324DE0C64A_documentation_en-US" xlink:label="lab_biib_ConsiderationPerProductDeveloped_3E421C6B325C6616DB6600324DE0C64A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Consideration Per Product Developed</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_ConsiderationPerProductDeveloped" xlink:label="loc_biib_ConsiderationPerProductDeveloped_3E421C6B325C6616DB6600324DE0C64A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ConsiderationPerProductDeveloped_3E421C6B325C6616DB6600324DE0C64A" xlink:to="lab_biib_ConsiderationPerProductDeveloped_3E421C6B325C6616DB6600324DE0C64A" xlink:type="arc" />
    <link:label id="lab_biib_ReimbursementCostAchievingPeriod_D6335F0418B321A856EF00324DE07AC1_verboseLabel_en-US" xlink:label="lab_biib_ReimbursementCostAchievingPeriod_D6335F0418B321A856EF00324DE07AC1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Reimbursement cost achieving period</link:label>
    <link:label id="lab_biib_ReimbursementCostAchievingPeriod_D6335F0418B321A856EF00324DE07AC1_label_en-US" xlink:label="lab_biib_ReimbursementCostAchievingPeriod_D6335F0418B321A856EF00324DE07AC1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reimbursement Cost Achieving Period</link:label>
    <link:label id="lab_biib_ReimbursementCostAchievingPeriod_D6335F0418B321A856EF00324DE07AC1_documentation_en-US" xlink:label="lab_biib_ReimbursementCostAchievingPeriod_D6335F0418B321A856EF00324DE07AC1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reimbursement cost achieving period.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_ReimbursementCostAchievingPeriod" xlink:label="loc_biib_ReimbursementCostAchievingPeriod_D6335F0418B321A856EF00324DE07AC1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ReimbursementCostAchievingPeriod_D6335F0418B321A856EF00324DE07AC1" xlink:to="lab_biib_ReimbursementCostAchievingPeriod_D6335F0418B321A856EF00324DE07AC1" xlink:type="arc" />
    <link:label id="lab_biib_TimePeriodForPayingRemainingBalanceDue_4BAB6D58A857BEA2378800324DE19069_verboseLabel_en-US" xlink:label="lab_biib_TimePeriodForPayingRemainingBalanceDue_4BAB6D58A857BEA2378800324DE19069" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Time period for paying remaining balance due</link:label>
    <link:label id="lab_biib_TimePeriodForPayingRemainingBalanceDue_4BAB6D58A857BEA2378800324DE19069_label_en-US" xlink:label="lab_biib_TimePeriodForPayingRemainingBalanceDue_4BAB6D58A857BEA2378800324DE19069" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Time Period For Paying Remaining Balance Due</link:label>
    <link:label id="lab_biib_TimePeriodForPayingRemainingBalanceDue_4BAB6D58A857BEA2378800324DE19069_documentation_en-US" xlink:label="lab_biib_TimePeriodForPayingRemainingBalanceDue_4BAB6D58A857BEA2378800324DE19069" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Time period for paying remaining balance due.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_TimePeriodForPayingRemainingBalanceDue" xlink:label="loc_biib_TimePeriodForPayingRemainingBalanceDue_4BAB6D58A857BEA2378800324DE19069" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TimePeriodForPayingRemainingBalanceDue_4BAB6D58A857BEA2378800324DE19069" xlink:to="lab_biib_TimePeriodForPayingRemainingBalanceDue_4BAB6D58A857BEA2378800324DE19069" xlink:type="arc" />
    <link:label id="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_D0C9445048DD9CCDB8BD00324DE1BD34_verboseLabel_en-US" xlink:label="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_D0C9445048DD9CCDB8BD00324DE1BD34" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Estimated additional payments upon achievement of development and commercial milestones.</link:label>
    <link:label id="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_D0C9445048DD9CCDB8BD00324DE1BD34_label_en-US" xlink:label="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_D0C9445048DD9CCDB8BD00324DE1BD34" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated Additional Payments Upon Achievement Of Development And Commercial Milestones</link:label>
    <link:label id="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_D0C9445048DD9CCDB8BD00324DE1BD34_documentation_en-US" xlink:label="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_D0C9445048DD9CCDB8BD00324DE1BD34" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Estimated additional payments upon achievement of development and commercial milestones.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_D0C9445048DD9CCDB8BD00324DE1BD34" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_D0C9445048DD9CCDB8BD00324DE1BD34" xlink:to="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_D0C9445048DD9CCDB8BD00324DE1BD34" xlink:type="arc" />
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_DBEAD684EA24A72B73DA00324DE1C4DD_terseLabel_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_DBEAD684EA24A72B73DA00324DE1C4DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Sub Option One</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_DBEAD684EA24A72B73DA00324DE1C4DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_DBEAD684EA24A72B73DA00324DE1C4DD" xlink:to="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_DBEAD684EA24A72B73DA00324DE1C4DD" xlink:type="arc" />
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_1EC8215D31D9BCF042DB00324DE13634_terseLabel_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_1EC8215D31D9BCF042DB00324DE13634" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option One</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_1EC8215D31D9BCF042DB00324DE13634" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_1EC8215D31D9BCF042DB00324DE13634" xlink:to="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_1EC8215D31D9BCF042DB00324DE13634" xlink:type="arc" />
    <link:label id="lab_biib_Biogenshareofcopromotionprofitsorlosses_2663182AD7A449ACAE6E00324DE1CEA9_terseLabel_en-US" xlink:label="lab_biib_Biogenshareofcopromotionprofitsorlosses_2663182AD7A449ACAE6E00324DE1CEA9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Biogen share of co-promotion profits or losses</link:label>
    <link:label id="lab_biib_Biogenshareofcopromotionprofitsorlosses_2663182AD7A449ACAE6E00324DE1CEA9_label_en-US" xlink:label="lab_biib_Biogenshareofcopromotionprofitsorlosses_2663182AD7A449ACAE6E00324DE1CEA9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Biogen share of co-promotion profits or losses</link:label>
    <link:label id="lab_biib_Biogenshareofcopromotionprofitsorlosses_2663182AD7A449ACAE6E00324DE1CEA9_documentation_en-US" xlink:label="lab_biib_Biogenshareofcopromotionprofitsorlosses_2663182AD7A449ACAE6E00324DE1CEA9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Biogen share of co-promotion profits or losses</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_Biogenshareofcopromotionprofitsorlosses" xlink:label="loc_biib_Biogenshareofcopromotionprofitsorlosses_2663182AD7A449ACAE6E00324DE1CEA9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Biogenshareofcopromotionprofitsorlosses_2663182AD7A449ACAE6E00324DE1CEA9" xlink:to="lab_biib_Biogenshareofcopromotionprofitsorlosses_2663182AD7A449ACAE6E00324DE1CEA9" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherSalesRevenueNet_D910D345D98E68C3E8D800324DE13F8A_terseLabel_en-US" xlink:label="lab_us-gaap_OtherSalesRevenueNet_D910D345D98E68C3E8D800324DE13F8A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other revenues from external customers</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherSalesRevenueNet" xlink:label="loc_us-gaap_OtherSalesRevenueNet_D910D345D98E68C3E8D800324DE13F8A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherSalesRevenueNet_D910D345D98E68C3E8D800324DE13F8A" xlink:to="lab_us-gaap_OtherSalesRevenueNet_D910D345D98E68C3E8D800324DE13F8A" xlink:type="arc" />
    <link:label id="lab_biib_Collaborationprofitlosssharing_2ABF537BC43F84A7580100324DE1826E_terseLabel_en-US" xlink:label="lab_biib_Collaborationprofitlosssharing_2ABF537BC43F84A7580100324DE1826E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration profit (loss) sharing</link:label>
    <link:label id="lab_biib_Collaborationprofitlosssharing_2ABF537BC43F84A7580100324DE1826E_label_en-US" xlink:label="lab_biib_Collaborationprofitlosssharing_2ABF537BC43F84A7580100324DE1826E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration profit (loss) sharing</link:label>
    <link:label id="lab_biib_Collaborationprofitlosssharing_2ABF537BC43F84A7580100324DE1826E_documentation_en-US" xlink:label="lab_biib_Collaborationprofitlosssharing_2ABF537BC43F84A7580100324DE1826E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration profit (loss) sharing</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_Collaborationprofitlosssharing" xlink:label="loc_biib_Collaborationprofitlosssharing_2ABF537BC43F84A7580100324DE1826E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Collaborationprofitlosssharing_2ABF537BC43F84A7580100324DE1826E" xlink:to="lab_biib_Collaborationprofitlosssharing_2ABF537BC43F84A7580100324DE1826E" xlink:type="arc" />
    <link:label id="lab_biib_Termofcollaborationagreement_C2B4FBE56DB41C96FD1200324DE19CB6_terseLabel_en-US" xlink:label="lab_biib_Termofcollaborationagreement_C2B4FBE56DB41C96FD1200324DE19CB6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term of collaboration agreement</link:label>
    <link:label id="lab_biib_Termofcollaborationagreement_C2B4FBE56DB41C96FD1200324DE19CB6_label_en-US" xlink:label="lab_biib_Termofcollaborationagreement_C2B4FBE56DB41C96FD1200324DE19CB6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term of collaboration agreement</link:label>
    <link:label id="lab_biib_Termofcollaborationagreement_C2B4FBE56DB41C96FD1200324DE19CB6_documentation_en-US" xlink:label="lab_biib_Termofcollaborationagreement_C2B4FBE56DB41C96FD1200324DE19CB6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Term of collaboration agreement</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_Termofcollaborationagreement" xlink:label="loc_biib_Termofcollaborationagreement_C2B4FBE56DB41C96FD1200324DE19CB6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Termofcollaborationagreement_C2B4FBE56DB41C96FD1200324DE19CB6" xlink:to="lab_biib_Termofcollaborationagreement_C2B4FBE56DB41C96FD1200324DE19CB6" xlink:type="arc" />
    <link:label id="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_536A518791C22AB1104300324DE11B61_terseLabel_en-US" xlink:label="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_536A518791C22AB1104300324DE11B61" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total upfront and milestone payments made to collaborative partner</link:label>
    <link:label id="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_536A518791C22AB1104300324DE11B61_label_en-US" xlink:label="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_536A518791C22AB1104300324DE11B61" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upfront And Milestone Payments Made To Collaborative Partner</link:label>
    <link:label id="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_536A518791C22AB1104300324DE11B61_documentation_en-US" xlink:label="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_536A518791C22AB1104300324DE11B61" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total upfront and milestone payments made to collaborative partner.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:label="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_536A518791C22AB1104300324DE11B61" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_536A518791C22AB1104300324DE11B61" xlink:to="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_536A518791C22AB1104300324DE11B61" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssets_1CBED0CFEAF65F9CB0BE00324DE1E538_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssets_1CBED0CFEAF65F9CB0BE00324DE1E538" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid research and discovery services</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssets_1CBED0CFEAF65F9CB0BE00324DE1E538_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssets_1CBED0CFEAF65F9CB0BE00324DE1E538" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_1CBED0CFEAF65F9CB0BE00324DE1E538" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssets_1CBED0CFEAF65F9CB0BE00324DE1E538" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssets_1CBED0CFEAF65F9CB0BE00324DE1E538" xlink:type="arc" />
    <link:label id="lab_biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments_B4D8C5EA889F6C16E1BB00324DE2037F_terseLabel_en-US" xlink:label="lab_biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments_B4D8C5EA889F6C16E1BB00324DE2037F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected License Fee And Regulatory Milestone Payments</link:label>
    <link:label id="lab_biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments_B4D8C5EA889F6C16E1BB00324DE2037F_label_en-US" xlink:label="lab_biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments_B4D8C5EA889F6C16E1BB00324DE2037F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected License Fee And Regulatory Milestone Payments</link:label>
    <link:label id="lab_biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments_B4D8C5EA889F6C16E1BB00324DE2037F_documentation_en-US" xlink:label="lab_biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments_B4D8C5EA889F6C16E1BB00324DE2037F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expected license fee and regulatory milestone payments.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments" xlink:label="loc_biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments_B4D8C5EA889F6C16E1BB00324DE2037F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments_B4D8C5EA889F6C16E1BB00324DE2037F" xlink:to="lab_biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments_B4D8C5EA889F6C16E1BB00324DE2037F" xlink:type="arc" />
    <link:label id="lab_biib_Additionalmilestonepaymentsforproductcandidateusingadifferentmodality_3923CDAE5F1D5A8CE13B00324DE2B6E0_terseLabel_en-US" xlink:label="lab_biib_Additionalmilestonepaymentsforproductcandidateusingadifferentmodality_3923CDAE5F1D5A8CE13B00324DE2B6E0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional milestone payments for product candidate using a different modality</link:label>
    <link:label id="lab_biib_Additionalmilestonepaymentsforproductcandidateusingadifferentmodality_3923CDAE5F1D5A8CE13B00324DE2B6E0_label_en-US" xlink:label="lab_biib_Additionalmilestonepaymentsforproductcandidateusingadifferentmodality_3923CDAE5F1D5A8CE13B00324DE2B6E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional milestone payments for product candidate using a different modality</link:label>
    <link:label id="lab_biib_Additionalmilestonepaymentsforproductcandidateusingadifferentmodality_3923CDAE5F1D5A8CE13B00324DE2B6E0_documentation_en-US" xlink:label="lab_biib_Additionalmilestonepaymentsforproductcandidateusingadifferentmodality_3923CDAE5F1D5A8CE13B00324DE2B6E0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional milestone payments for product candidate using a different modality</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_Additionalmilestonepaymentsforproductcandidateusingadifferentmodality" xlink:label="loc_biib_Additionalmilestonepaymentsforproductcandidateusingadifferentmodality_3923CDAE5F1D5A8CE13B00324DE2B6E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Additionalmilestonepaymentsforproductcandidateusingadifferentmodality_3923CDAE5F1D5A8CE13B00324DE2B6E0" xlink:to="lab_biib_Additionalmilestonepaymentsforproductcandidateusingadifferentmodality_3923CDAE5F1D5A8CE13B00324DE2B6E0" xlink:type="arc" />
    <link:label id="lab_biib_AdditionalMilestonePayment_E2E88E157D7F29F7C87500324DE2CE01_terseLabel_en-US" xlink:label="lab_biib_AdditionalMilestonePayment_E2E88E157D7F29F7C87500324DE2CE01" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional milestone payment</link:label>
    <link:label id="lab_biib_AdditionalMilestonePayment_E2E88E157D7F29F7C87500324DE2CE01_label_en-US" xlink:label="lab_biib_AdditionalMilestonePayment_E2E88E157D7F29F7C87500324DE2CE01" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Milestone Payment</link:label>
    <link:label id="lab_biib_AdditionalMilestonePayment_E2E88E157D7F29F7C87500324DE2CE01_documentation_en-US" xlink:label="lab_biib_AdditionalMilestonePayment_E2E88E157D7F29F7C87500324DE2CE01" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional milestone payment.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_AdditionalMilestonePayment" xlink:label="loc_biib_AdditionalMilestonePayment_E2E88E157D7F29F7C87500324DE2CE01" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AdditionalMilestonePayment_E2E88E157D7F29F7C87500324DE2CE01" xlink:to="lab_biib_AdditionalMilestonePayment_E2E88E157D7F29F7C87500324DE2CE01" xlink:type="arc" />
    <link:label id="lab_biib_LiabilityForFairValueOfOptionsGrantedUnderAgreement_51EBA597E391D6EDE5EE00324DE206E5_terseLabel_en-US" xlink:label="lab_biib_LiabilityForFairValueOfOptionsGrantedUnderAgreement_51EBA597E391D6EDE5EE00324DE206E5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount recorded to reflect fair value of options granted</link:label>
    <link:label id="lab_biib_LiabilityForFairValueOfOptionsGrantedUnderAgreement_51EBA597E391D6EDE5EE00324DE206E5_label_en-US" xlink:label="lab_biib_LiabilityForFairValueOfOptionsGrantedUnderAgreement_51EBA597E391D6EDE5EE00324DE206E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability For Fair Value Of Options Granted Under Agreement</link:label>
    <link:label id="lab_biib_LiabilityForFairValueOfOptionsGrantedUnderAgreement_51EBA597E391D6EDE5EE00324DE206E5_documentation_en-US" xlink:label="lab_biib_LiabilityForFairValueOfOptionsGrantedUnderAgreement_51EBA597E391D6EDE5EE00324DE206E5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Liability For Fair Value Of Options Granted Under Agreement</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_LiabilityForFairValueOfOptionsGrantedUnderAgreement" xlink:label="loc_biib_LiabilityForFairValueOfOptionsGrantedUnderAgreement_51EBA597E391D6EDE5EE00324DE206E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_LiabilityForFairValueOfOptionsGrantedUnderAgreement_51EBA597E391D6EDE5EE00324DE206E5" xlink:to="lab_biib_LiabilityForFairValueOfOptionsGrantedUnderAgreement_51EBA597E391D6EDE5EE00324DE206E5" xlink:type="arc" />
    <link:label id="lab_biib_Purchaseofcommonstock_249C20275405AA0E721A00324DE2BAD5_terseLabel_en-US" xlink:label="lab_biib_Purchaseofcommonstock_249C20275405AA0E721A00324DE2BAD5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase of common stock</link:label>
    <link:label id="lab_biib_Purchaseofcommonstock_249C20275405AA0E721A00324DE2BAD5_label_en-US" xlink:label="lab_biib_Purchaseofcommonstock_249C20275405AA0E721A00324DE2BAD5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase of common stock</link:label>
    <link:label id="lab_biib_Purchaseofcommonstock_249C20275405AA0E721A00324DE2BAD5_documentation_en-US" xlink:label="lab_biib_Purchaseofcommonstock_249C20275405AA0E721A00324DE2BAD5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Purchase of common stock</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_Purchaseofcommonstock" xlink:label="loc_biib_Purchaseofcommonstock_249C20275405AA0E721A00324DE2BAD5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Purchaseofcommonstock_249C20275405AA0E721A00324DE2BAD5" xlink:to="lab_biib_Purchaseofcommonstock_249C20275405AA0E721A00324DE2BAD5" xlink:type="arc" />
    <link:label id="lab_us-gaap_LicenseCosts_ED9A445A208C875E7D4900324DE28F6A_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseCosts_ED9A445A208C875E7D4900324DE28F6A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total licensing and other fees</link:label>
    <link:label id="lab_us-gaap_LicenseCosts_ED9A445A208C875E7D4900324DE28F6A_label_en-US" xlink:label="lab_us-gaap_LicenseCosts_ED9A445A208C875E7D4900324DE28F6A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LicenseCosts" xlink:label="loc_us-gaap_LicenseCosts_ED9A445A208C875E7D4900324DE28F6A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseCosts_ED9A445A208C875E7D4900324DE28F6A" xlink:to="lab_us-gaap_LicenseCosts_ED9A445A208C875E7D4900324DE28F6A" xlink:type="arc" />
    <link:label id="lab_biib_Researchanddevelopmentservices_8C46E510086ACD5EAFAC00324DE2F46D_terseLabel_en-US" xlink:label="lab_biib_Researchanddevelopmentservices_8C46E510086ACD5EAFAC00324DE2F46D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development services</link:label>
    <link:label id="lab_biib_Researchanddevelopmentservices_8C46E510086ACD5EAFAC00324DE2F46D_label_en-US" xlink:label="lab_biib_Researchanddevelopmentservices_8C46E510086ACD5EAFAC00324DE2F46D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development services</link:label>
    <link:label id="lab_biib_Researchanddevelopmentservices_8C46E510086ACD5EAFAC00324DE2F46D_documentation_en-US" xlink:label="lab_biib_Researchanddevelopmentservices_8C46E510086ACD5EAFAC00324DE2F46D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research and development services</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_Researchanddevelopmentservices" xlink:label="loc_biib_Researchanddevelopmentservices_8C46E510086ACD5EAFAC00324DE2F46D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Researchanddevelopmentservices_8C46E510086ACD5EAFAC00324DE2F46D" xlink:to="lab_biib_Researchanddevelopmentservices_8C46E510086ACD5EAFAC00324DE2F46D" xlink:type="arc" />
    <link:label id="lab_biib_Premiumonequityinvestment_D9D020046C9C59946EBC00324DE2E4F6_terseLabel_en-US" xlink:label="lab_biib_Premiumonequityinvestment_D9D020046C9C59946EBC00324DE2E4F6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Premium on equity investment</link:label>
    <link:label id="lab_biib_Premiumonequityinvestment_D9D020046C9C59946EBC00324DE2E4F6_label_en-US" xlink:label="lab_biib_Premiumonequityinvestment_D9D020046C9C59946EBC00324DE2E4F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Premium on equity investment</link:label>
    <link:label id="lab_biib_Premiumonequityinvestment_D9D020046C9C59946EBC00324DE2E4F6_documentation_en-US" xlink:label="lab_biib_Premiumonequityinvestment_D9D020046C9C59946EBC00324DE2E4F6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Premium on equity investment</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_Premiumonequityinvestment" xlink:label="loc_biib_Premiumonequityinvestment_D9D020046C9C59946EBC00324DE2E4F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Premiumonequityinvestment_D9D020046C9C59946EBC00324DE2E4F6" xlink:to="lab_biib_Premiumonequityinvestment_D9D020046C9C59946EBC00324DE2E4F6" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_F7E55C2A28A43E701BA700324DE21A4D_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_F7E55C2A28A43E701BA700324DE21A4D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid research and development</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_F7E55C2A28A43E701BA700324DE21A4D_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_F7E55C2A28A43E701BA700324DE21A4D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_F7E55C2A28A43E701BA700324DE21A4D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_F7E55C2A28A43E701BA700324DE21A4D" xlink:to="lab_us-gaap_OtherAssetsNoncurrent_F7E55C2A28A43E701BA700324DE21A4D" xlink:type="arc" />
    <link:label id="lab_biib_Futureresearchanddevelopmentcommitment_5241B29C582E8D603E7E00324DE22676_terseLabel_en-US" xlink:label="lab_biib_Futureresearchanddevelopmentcommitment_5241B29C582E8D603E7E00324DE22676" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future research and development commitment</link:label>
    <link:label id="lab_biib_Futureresearchanddevelopmentcommitment_5241B29C582E8D603E7E00324DE22676_label_en-US" xlink:label="lab_biib_Futureresearchanddevelopmentcommitment_5241B29C582E8D603E7E00324DE22676" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future research and development commitment</link:label>
    <link:label id="lab_biib_Futureresearchanddevelopmentcommitment_5241B29C582E8D603E7E00324DE22676_documentation_en-US" xlink:label="lab_biib_Futureresearchanddevelopmentcommitment_5241B29C582E8D603E7E00324DE22676" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Future research and development commitment</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_Futureresearchanddevelopmentcommitment" xlink:label="loc_biib_Futureresearchanddevelopmentcommitment_5241B29C582E8D603E7E00324DE22676" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Futureresearchanddevelopmentcommitment_5241B29C582E8D603E7E00324DE22676" xlink:to="lab_biib_Futureresearchanddevelopmentcommitment_5241B29C582E8D603E7E00324DE22676" xlink:type="arc" />
    <link:label id="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_635065C50F261783F48F00324DE29844_verboseLabel_en-US" xlink:label="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_635065C50F261783F48F00324DE29844" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Potential future milestone payments commitment, approximately</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_635065C50F261783F48F00324DE29844" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_635065C50F261783F48F00324DE29844" xlink:to="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_635065C50F261783F48F00324DE29844" xlink:type="arc" />
    <link:label id="lab_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_CF61670E1DEA0DE5C64200324DE2F7D5_terseLabel_en-US" xlink:label="lab_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_CF61670E1DEA0DE5C64200324DE2F7D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments By Third Party In Joint Venture As Per Agreement.</link:label>
    <link:label id="lab_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_CF61670E1DEA0DE5C64200324DE2F7D5_label_en-US" xlink:label="lab_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_CF61670E1DEA0DE5C64200324DE2F7D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments By Third Party In Joint Venture As Per Agreement.</link:label>
    <link:label id="lab_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_CF61670E1DEA0DE5C64200324DE2F7D5_documentation_en-US" xlink:label="lab_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_CF61670E1DEA0DE5C64200324DE2F7D5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Investments by third party in joint venture as per agreement</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement" xlink:label="loc_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_CF61670E1DEA0DE5C64200324DE2F7D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_CF61670E1DEA0DE5C64200324DE2F7D5" xlink:to="lab_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_CF61670E1DEA0DE5C64200324DE2F7D5" xlink:type="arc" />
    <link:label id="lab_biib_JointVentureOwnerShipPercentageByThirdParty_FEC319DD1A2485F7937D00324DE3767C_terseLabel_en-US" xlink:label="lab_biib_JointVentureOwnerShipPercentageByThirdParty_FEC319DD1A2485F7937D00324DE3767C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Joint Venture Owner Ship Percentage By Third Party.</link:label>
    <link:label id="lab_biib_JointVentureOwnerShipPercentageByThirdParty_FEC319DD1A2485F7937D00324DE3767C_label_en-US" xlink:label="lab_biib_JointVentureOwnerShipPercentageByThirdParty_FEC319DD1A2485F7937D00324DE3767C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Joint Venture Owner Ship Percentage By Third Party.</link:label>
    <link:label id="lab_biib_JointVentureOwnerShipPercentageByThirdParty_FEC319DD1A2485F7937D00324DE3767C_documentation_en-US" xlink:label="lab_biib_JointVentureOwnerShipPercentageByThirdParty_FEC319DD1A2485F7937D00324DE3767C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Joint venture owner ship percentage by third party.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_JointVentureOwnerShipPercentageByThirdParty" xlink:label="loc_biib_JointVentureOwnerShipPercentageByThirdParty_FEC319DD1A2485F7937D00324DE3767C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_JointVentureOwnerShipPercentageByThirdParty_FEC319DD1A2485F7937D00324DE3767C" xlink:to="lab_biib_JointVentureOwnerShipPercentageByThirdParty_FEC319DD1A2485F7937D00324DE3767C" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestments_4FF82632107F0293166600324DE389B6_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments_4FF82632107F0293166600324DE389B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Method Investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_4FF82632107F0293166600324DE389B6_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments_4FF82632107F0293166600324DE389B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_4FF82632107F0293166600324DE389B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments_4FF82632107F0293166600324DE389B6" xlink:to="lab_us-gaap_EquityMethodInvestments_4FF82632107F0293166600324DE389B6" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_FA6D2531D7294ED5324F00324DE31B81_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_FA6D2531D7294ED5324F00324DE31B81" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of equity interest to the portion of total capital stock</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_FA6D2531D7294ED5324F00324DE31B81_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_FA6D2531D7294ED5324F00324DE31B81" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_FA6D2531D7294ED5324F00324DE31B81" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_FA6D2531D7294ED5324F00324DE31B81" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_FA6D2531D7294ED5324F00324DE31B81" xlink:type="arc" />
    <link:label id="lab_biib_EquityMethodInvestmentOwnershipPercentageMaximum_DAA75F3E6E807D80566900324DE31FDF_terseLabel_en-US" xlink:label="lab_biib_EquityMethodInvestmentOwnershipPercentageMaximum_DAA75F3E6E807D80566900324DE31FDF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Method Investment Ownership Percentage Maximum</link:label>
    <link:label id="lab_biib_EquityMethodInvestmentOwnershipPercentageMaximum_DAA75F3E6E807D80566900324DE31FDF_label_en-US" xlink:label="lab_biib_EquityMethodInvestmentOwnershipPercentageMaximum_DAA75F3E6E807D80566900324DE31FDF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment Ownership Percentage Maximum</link:label>
    <link:label id="lab_biib_EquityMethodInvestmentOwnershipPercentageMaximum_DAA75F3E6E807D80566900324DE31FDF_documentation_en-US" xlink:label="lab_biib_EquityMethodInvestmentOwnershipPercentageMaximum_DAA75F3E6E807D80566900324DE31FDF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity method investment ownership percentage maximum.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_EquityMethodInvestmentOwnershipPercentageMaximum" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageMaximum_DAA75F3E6E807D80566900324DE31FDF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EquityMethodInvestmentOwnershipPercentageMaximum_DAA75F3E6E807D80566900324DE31FDF" xlink:to="lab_biib_EquityMethodInvestmentOwnershipPercentageMaximum_DAA75F3E6E807D80566900324DE31FDF" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_C77E6B4454DCC78F0C5000324DE37A71_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments_C77E6B4454DCC78F0C5000324DE37A71" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_C77E6B4454DCC78F0C5000324DE37A71" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments_C77E6B4454DCC78F0C5000324DE37A71" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments_C77E6B4454DCC78F0C5000324DE37A71" xlink:type="arc" />
    <link:label id="lab_biib_EquityMethodInvestmentsExpectedProfitShare_B9ADC2A21EB64914C9C500324DE38086_terseLabel_en-US" xlink:label="lab_biib_EquityMethodInvestmentsExpectedProfitShare_B9ADC2A21EB64914C9C500324DE38086" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Method Investments, Expected Profit Share</link:label>
    <link:label id="lab_biib_EquityMethodInvestmentsExpectedProfitShare_B9ADC2A21EB64914C9C500324DE38086_label_en-US" xlink:label="lab_biib_EquityMethodInvestmentsExpectedProfitShare_B9ADC2A21EB64914C9C500324DE38086" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments, Expected Profit Share</link:label>
    <link:label id="lab_biib_EquityMethodInvestmentsExpectedProfitShare_B9ADC2A21EB64914C9C500324DE38086_documentation_en-US" xlink:label="lab_biib_EquityMethodInvestmentsExpectedProfitShare_B9ADC2A21EB64914C9C500324DE38086" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Method Investments, Expected Profit Share</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_EquityMethodInvestmentsExpectedProfitShare" xlink:label="loc_biib_EquityMethodInvestmentsExpectedProfitShare_B9ADC2A21EB64914C9C500324DE38086" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EquityMethodInvestmentsExpectedProfitShare_B9ADC2A21EB64914C9C500324DE38086" xlink:to="lab_biib_EquityMethodInvestmentsExpectedProfitShare_B9ADC2A21EB64914C9C500324DE38086" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_69A827D5E992A87FD89FFCCBDA7FFCB7_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract_69A827D5E992A87FD89FFCCBDA7FFCB7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_69A827D5E992A87FD89FFCCBDA7FFCB7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract_69A827D5E992A87FD89FFCCBDA7FFCB7" xlink:to="lab_us-gaap_SubsequentEventsAbstract_69A827D5E992A87FD89FFCCBDA7FFCB7" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_1980AA37463A6D680C6DFCF6322304BF_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_1980AA37463A6D680C6DFCF6322304BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_1980AA37463A6D680C6DFCF6322304BF_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_1980AA37463A6D680C6DFCF6322304BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_1980AA37463A6D680C6DFCF6322304BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock_1980AA37463A6D680C6DFCF6322304BF" xlink:to="lab_us-gaap_SubsequentEventsTextBlock_1980AA37463A6D680C6DFCF6322304BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_9312D5F108CDA6E9CDA2FB6C3B0CF0BE_netLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_9312D5F108CDA6E9CDA2FB6C3B0CF0BE" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_9312D5F108CDA6E9CDA2FB6C3B0CF0BE_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_9312D5F108CDA6E9CDA2FB6C3B0CF0BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_9312D5F108CDA6E9CDA2FB6C3B0CF0BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9312D5F108CDA6E9CDA2FB6C3B0CF0BE" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_9312D5F108CDA6E9CDA2FB6C3B0CF0BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityComponentDomain_5D75B19D012F93A8142EFB6C3B0DAB5F_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_5D75B19D012F93A8142EFB6C3B0DAB5F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_5D75B19D012F93A8142EFB6C3B0DAB5F_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_5D75B19D012F93A8142EFB6C3B0DAB5F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_5D75B19D012F93A8142EFB6C3B0DAB5F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain_5D75B19D012F93A8142EFB6C3B0DAB5F" xlink:to="lab_us-gaap_EquityComponentDomain_5D75B19D012F93A8142EFB6C3B0DAB5F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_E12D2ED6320B9F73DCF9FB6C3B0DCE38_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_E12D2ED6320B9F73DCF9FB6C3B0DCE38" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized Gains (Losses) on Securities Available for Sale</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_E12D2ED6320B9F73DCF9FB6C3B0DCE38_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_E12D2ED6320B9F73DCF9FB6C3B0DCE38" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Net Investment Gain (Loss) Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_E12D2ED6320B9F73DCF9FB6C3B0DCE38" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_E12D2ED6320B9F73DCF9FB6C3B0DCE38" xlink:to="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_E12D2ED6320B9F73DCF9FB6C3B0DCE38" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_CC50E506EE5506B6375BFB6C3B0D3A64_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_CC50E506EE5506B6375BFB6C3B0D3A64" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized Gains (Losses) on Cash Flow Hedges</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_CC50E506EE5506B6375BFB6C3B0D3A64_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_CC50E506EE5506B6375BFB6C3B0D3A64" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Net Gain (Loss) from Cash Flow Hedges Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_CC50E506EE5506B6375BFB6C3B0D3A64" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_CC50E506EE5506B6375BFB6C3B0D3A64" xlink:to="lab_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_CC50E506EE5506B6375BFB6C3B0D3A64" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_1DD56B741810089DFB0DFB6C3B0D7E66_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_1DD56B741810089DFB0DFB6C3B0D7E66" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_1DD56B741810089DFB0DFB6C3B0D7E66_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_1DD56B741810089DFB0DFB6C3B0D7E66" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_1DD56B741810089DFB0DFB6C3B0D7E66" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_1DD56B741810089DFB0DFB6C3B0D7E66" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_1DD56B741810089DFB0DFB6C3B0D7E66" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_A4F64A839DA875EF31BCFB6C3B0D026E_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_A4F64A839DA875EF31BCFB6C3B0D026E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_A4F64A839DA875EF31BCFB6C3B0D026E_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_A4F64A839DA875EF31BCFB6C3B0D026E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_A4F64A839DA875EF31BCFB6C3B0D026E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_A4F64A839DA875EF31BCFB6C3B0D026E" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_A4F64A839DA875EF31BCFB6C3B0D026E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_3B9FE05BB0A1881F4187FB6C3B0D5B1B_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_3B9FE05BB0A1881F4187FB6C3B0D5B1B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Member]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_3B9FE05BB0A1881F4187FB6C3B0D5B1B_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_3B9FE05BB0A1881F4187FB6C3B0D5B1B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_3B9FE05BB0A1881F4187FB6C3B0D5B1B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_3B9FE05BB0A1881F4187FB6C3B0D5B1B" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_3B9FE05BB0A1881F4187FB6C3B0D5B1B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_C48AE22503D3D984571CFB6C3B0D01BB_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_C48AE22503D3D984571CFB6C3B0D01BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</link:label>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_C48AE22503D3D984571CFB6C3B0D01BB_label_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_C48AE22503D3D984571CFB6C3B0D01BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_C48AE22503D3D984571CFB6C3B0D01BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_C48AE22503D3D984571CFB6C3B0D01BB" xlink:to="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_C48AE22503D3D984571CFB6C3B0D01BB" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_C5BBBB03F1CE459EA245FB6C3B0DD212_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_C5BBBB03F1CE459EA245FB6C3B0DD212" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_C5BBBB03F1CE459EA245FB6C3B0DD212" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_C5BBBB03F1CE459EA245FB6C3B0DD212" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense_C5BBBB03F1CE459EA245FB6C3B0DD212" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_9611A906585BADFEDA0DFB6C3B0D25AC_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_9611A906585BADFEDA0DFB6C3B0D25AC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_9611A906585BADFEDA0DFB6C3B0D25AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_9611A906585BADFEDA0DFB6C3B0D25AC" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_9611A906585BADFEDA0DFB6C3B0D25AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpenses_3C6FC0337FE5637B4CD1FB6C3B0DB563_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses_3C6FC0337FE5637B4CD1FB6C3B0DB563" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_3C6FC0337FE5637B4CD1FB6C3B0DB563_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses_3C6FC0337FE5637B4CD1FB6C3B0DB563" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_3C6FC0337FE5637B4CD1FB6C3B0DB563" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_3C6FC0337FE5637B4CD1FB6C3B0DB563" xlink:to="lab_us-gaap_OperatingExpenses_3C6FC0337FE5637B4CD1FB6C3B0DB563" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_3B5340F17A2322430F8AFB6C3B0DC907_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_3B5340F17A2322430F8AFB6C3B0DC907" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income attributable to Biogen Inc.</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_3B5340F17A2322430F8AFB6C3B0DC907" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_3B5340F17A2322430F8AFB6C3B0DC907" xlink:to="lab_us-gaap_NetIncomeLoss_3B5340F17A2322430F8AFB6C3B0DC907" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_3EF243BBBF5A5FDAF2ADFCCBDD05BA2B_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_3EF243BBBF5A5FDAF2ADFCCBDD05BA2B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other intangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_3EF243BBBF5A5FDAF2ADFCCBDD05BA2B_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_3EF243BBBF5A5FDAF2ADFCCBDD05BA2B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_3EF243BBBF5A5FDAF2ADFCCBDD05BA2B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_3EF243BBBF5A5FDAF2ADFCCBDD05BA2B" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_3EF243BBBF5A5FDAF2ADFCCBDD05BA2B" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_0603AA20E7F9C0CDD106FCCBDD051A1E_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_0603AA20E7F9C0CDD106FCCBDD051A1E" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_0603AA20E7F9C0CDD106FCCBDD051A1E_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_0603AA20E7F9C0CDD106FCCBDD051A1E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_0603AA20E7F9C0CDD106FCCBDD051A1E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_0603AA20E7F9C0CDD106FCCBDD051A1E" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_0603AA20E7F9C0CDD106FCCBDD051A1E" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_2CA66B5E1AF1F38B1D7DFCCBDD055703_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_2CA66B5E1AF1F38B1D7DFCCBDD055703" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_2CA66B5E1AF1F38B1D7DFCCBDD055703_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_2CA66B5E1AF1F38B1D7DFCCBDD055703" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_2CA66B5E1AF1F38B1D7DFCCBDD055703" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_2CA66B5E1AF1F38B1D7DFCCBDD055703" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_2CA66B5E1AF1F38B1D7DFCCBDD055703" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_5EAA6BE85D3FC1EB3B7CFCCBDD05FDB4_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_5EAA6BE85D3FC1EB3B7CFCCBDD05FDB4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total purchase price</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_5EAA6BE85D3FC1EB3B7CFCCBDD05FDB4_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_5EAA6BE85D3FC1EB3B7CFCCBDD05FDB4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_5EAA6BE85D3FC1EB3B7CFCCBDD05FDB4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_5EAA6BE85D3FC1EB3B7CFCCBDD05FDB4" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_5EAA6BE85D3FC1EB3B7CFCCBDD05FDB4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_4917FB441C891725F5FD741285921167_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_4917FB441C891725F5FD741285921167" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of assets and liabilities recorded at fair value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_4917FB441C891725F5FD741285921167_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_4917FB441C891725F5FD741285921167" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_4917FB441C891725F5FD741285921167" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_4917FB441C891725F5FD741285921167" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_4917FB441C891725F5FD741285921167" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_D14BE826585B07573C26741285928172_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_D14BE826585B07573C26741285928172" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of fair and carrying value of debt instruments</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_D14BE826585B07573C26741285928172_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_D14BE826585B07573C26741285928172" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_D14BE826585B07573C26741285928172" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_D14BE826585B07573C26741285928172" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_D14BE826585B07573C26741285928172" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_706BC9FEE7F65268708A7412859273DD_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_706BC9FEE7F65268708A7412859273DD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair value of contingent consideration obligations</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_706BC9FEE7F65268708A7412859273DD_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_706BC9FEE7F65268708A7412859273DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_706BC9FEE7F65268708A7412859273DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_706BC9FEE7F65268708A7412859273DD" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_706BC9FEE7F65268708A7412859273DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_2E12FE2E286790A29E7A7412863C2652_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_2E12FE2E286790A29E7A7412863C2652" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Components of inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_2E12FE2E286790A29E7A7412863C2652_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_2E12FE2E286790A29E7A7412863C2652" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_2E12FE2E286790A29E7A7412863C2652" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_2E12FE2E286790A29E7A7412863C2652" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_2E12FE2E286790A29E7A7412863C2652" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_88CD8057C402FDC255D2FA4E86BE668F_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract_88CD8057C402FDC255D2FA4E86BE668F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_88CD8057C402FDC255D2FA4E86BE668F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_88CD8057C402FDC255D2FA4E86BE668F" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract_88CD8057C402FDC255D2FA4E86BE668F" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_81C7029D1B460705560EFA4E86C2CDC6_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_81C7029D1B460705560EFA4E86C2CDC6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement, Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_81C7029D1B460705560EFA4E86C2CDC6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_81C7029D1B460705560EFA4E86C2CDC6" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_81C7029D1B460705560EFA4E86C2CDC6" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockMember_E1776E1F7E83050BCE5FFA4E86C2F785_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember_E1776E1F7E83050BCE5FFA4E86C2F785" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_E1776E1F7E83050BCE5FFA4E86C2F785_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember_E1776E1F7E83050BCE5FFA4E86C2F785" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_E1776E1F7E83050BCE5FFA4E86C2F785" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember_E1776E1F7E83050BCE5FFA4E86C2F785" xlink:to="lab_us-gaap_PreferredStockMember_E1776E1F7E83050BCE5FFA4E86C2F785" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockMember_1D1E6199649AD9888512FA4E86C2DE64_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember_1D1E6199649AD9888512FA4E86C2DE64" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_1D1E6199649AD9888512FA4E86C2DE64_label_en-US" xlink:label="lab_us-gaap_CommonStockMember_1D1E6199649AD9888512FA4E86C2DE64" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1D1E6199649AD9888512FA4E86C2DE64" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_1D1E6199649AD9888512FA4E86C2DE64" xlink:to="lab_us-gaap_CommonStockMember_1D1E6199649AD9888512FA4E86C2DE64" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_19C2E1AC3A51C1CEB3E4FA4E86C3DB6C_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_19C2E1AC3A51C1CEB3E4FA4E86C3DB6C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_19C2E1AC3A51C1CEB3E4FA4E86C3DB6C_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_19C2E1AC3A51C1CEB3E4FA4E86C3DB6C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_19C2E1AC3A51C1CEB3E4FA4E86C3DB6C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_19C2E1AC3A51C1CEB3E4FA4E86C3DB6C" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_19C2E1AC3A51C1CEB3E4FA4E86C3DB6C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_BABC4C5C1C3FA7B99E4EFA4E86C34AC1_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_BABC4C5C1C3FA7B99E4EFA4E86C34AC1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_BABC4C5C1C3FA7B99E4EFA4E86C34AC1_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_BABC4C5C1C3FA7B99E4EFA4E86C34AC1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_BABC4C5C1C3FA7B99E4EFA4E86C34AC1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_BABC4C5C1C3FA7B99E4EFA4E86C34AC1" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_BABC4C5C1C3FA7B99E4EFA4E86C34AC1" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsMember_008DA1F1E23C1A25C588FA4E86C3DDB4_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_008DA1F1E23C1A25C588FA4E86C3DDB4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_008DA1F1E23C1A25C588FA4E86C3DDB4_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_008DA1F1E23C1A25C588FA4E86C3DDB4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_008DA1F1E23C1A25C588FA4E86C3DDB4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_008DA1F1E23C1A25C588FA4E86C3DDB4" xlink:to="lab_us-gaap_RetainedEarningsMember_008DA1F1E23C1A25C588FA4E86C3DDB4" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockMember_CAC8C58E0CDEDE3D37BDFA4E86C3A59E_verboseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember_CAC8C58E0CDEDE3D37BDFA4E86C3A59E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Treasury stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_CAC8C58E0CDEDE3D37BDFA4E86C3A59E_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember_CAC8C58E0CDEDE3D37BDFA4E86C3A59E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_CAC8C58E0CDEDE3D37BDFA4E86C3A59E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember_CAC8C58E0CDEDE3D37BDFA4E86C3A59E" xlink:to="lab_us-gaap_TreasuryStockMember_CAC8C58E0CDEDE3D37BDFA4E86C3A59E" xlink:type="arc" />
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_22A64331B46162E2978DFA4E86C377CD_verboseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember_22A64331B46162E2978DFA4E86C377CD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_22A64331B46162E2978DFA4E86C377CD_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember_22A64331B46162E2978DFA4E86C377CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember_22A64331B46162E2978DFA4E86C377CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember_22A64331B46162E2978DFA4E86C377CD" xlink:to="lab_us-gaap_NoncontrollingInterestMember_22A64331B46162E2978DFA4E86C377CD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ParentMember_88515E9A8C01CD047681FA4E86C329B1_terseLabel_en-US" xlink:label="lab_us-gaap_ParentMember_88515E9A8C01CD047681FA4E86C329B1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaap_ParentMember_88515E9A8C01CD047681FA4E86C329B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ParentMember_88515E9A8C01CD047681FA4E86C329B1" xlink:to="lab_us-gaap_ParentMember_88515E9A8C01CD047681FA4E86C329B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3ED9F2B165CAC7A177FEFA4E86C369AC_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3ED9F2B165CAC7A177FEFA4E86C369AC" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3ED9F2B165CAC7A177FEFA4E86C369AC_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3ED9F2B165CAC7A177FEFA4E86C369AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3ED9F2B165CAC7A177FEFA4E86C369AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3ED9F2B165CAC7A177FEFA4E86C369AC" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3ED9F2B165CAC7A177FEFA4E86C369AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_E82A5BF5FD36BF565D3FFA4E86C34B1E_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_E82A5BF5FD36BF565D3FFA4E86C34B1E" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_E82A5BF5FD36BF565D3FFA4E86C34B1E_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity_E82A5BF5FD36BF565D3FFA4E86C34B1E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_E82A5BF5FD36BF565D3FFA4E86C34B1E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_E82A5BF5FD36BF565D3FFA4E86C34B1E" xlink:to="lab_us-gaap_StockholdersEquity_E82A5BF5FD36BF565D3FFA4E86C34B1E" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinorityInterest_B35244305D5432355132FA62E1F363A2_periodStartLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest_B35244305D5432355132FA62E1F363A2" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_B35244305D5432355132FA62E1F363A2_label_en-US" xlink:label="lab_us-gaap_MinorityInterest_B35244305D5432355132FA62E1F363A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_B35244305D5432355132FA62E1F363A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest_B35244305D5432355132FA62E1F363A2" xlink:to="lab_us-gaap_MinorityInterest_B35244305D5432355132FA62E1F363A2" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesIssued_09ED34115D0DB2C5C9A8FA4E86C39260_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_SharesIssued_09ED34115D0DB2C5C9A8FA4E86C39260" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance, shares</link:label>
    <link:label id="lab_us-gaap_SharesIssued_09ED34115D0DB2C5C9A8FA4E86C39260_label_en-US" xlink:label="lab_us-gaap_SharesIssued_09ED34115D0DB2C5C9A8FA4E86C39260" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_09ED34115D0DB2C5C9A8FA4E86C39260" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued_09ED34115D0DB2C5C9A8FA4E86C39260" xlink:to="lab_us-gaap_SharesIssued_09ED34115D0DB2C5C9A8FA4E86C39260" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_B617B661C12A79FAE5D7FA4E86CB4038_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_B617B661C12A79FAE5D7FA4E86CB4038" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_B617B661C12A79FAE5D7FA4E86CB4038_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_B617B661C12A79FAE5D7FA4E86CB4038" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_B617B661C12A79FAE5D7FA4E86CB4038" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_B617B661C12A79FAE5D7FA4E86CB4038" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_B617B661C12A79FAE5D7FA4E86CB4038" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_4E5583132B126B4296B4FA4E86C9A5F4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_4E5583132B126B4296B4FA4E86C9A5F4" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_4E5583132B126B4296B4FA4E86C9A5F4_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_4E5583132B126B4296B4FA4E86C9A5F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_4E5583132B126B4296B4FA4E86C9A5F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_4E5583132B126B4296B4FA4E86C9A5F4" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_4E5583132B126B4296B4FA4E86C9A5F4" xlink:type="arc" />
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_B759C8A3EB036466340FFA4E86CCA3EF_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_B759C8A3EB036466340FFA4E86CCA3EF" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Acquisition of noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_B759C8A3EB036466340FFA4E86CCA3EF_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_B759C8A3EB036466340FFA4E86CCA3EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest, Increase from Business Combination</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_B759C8A3EB036466340FFA4E86CCA3EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_B759C8A3EB036466340FFA4E86CCA3EF" xlink:to="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_B759C8A3EB036466340FFA4E86CCA3EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_BC00FB0592BDEF6D0CBCFA4E86CBAD02_negatedLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_BC00FB0592BDEF6D0CBCFA4E86CBAD02" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Distribution or Capital contribution to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_BC00FB0592BDEF6D0CBCFA4E86CBAD02_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_BC00FB0592BDEF6D0CBCFA4E86CBAD02" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_BC00FB0592BDEF6D0CBCFA4E86CBAD02" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_BC00FB0592BDEF6D0CBCFA4E86CBAD02" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_BC00FB0592BDEF6D0CBCFA4E86CBAD02" xlink:type="arc" />
    <link:label id="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_075FB79A363488CE31FCFA4E86CBEE64_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_075FB79A363488CE31FCFA4E86CBEE64" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deconsolidation of noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_075FB79A363488CE31FCFA4E86CBEE64_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_075FB79A363488CE31FCFA4E86CBEE64" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest, Decrease from Deconsolidation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:label="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_075FB79A363488CE31FCFA4E86CBEE64" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_075FB79A363488CE31FCFA4E86CBEE64" xlink:to="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_075FB79A363488CE31FCFA4E86CBEE64" xlink:type="arc" />
    <link:label id="lab_biib_Noncontrollinginterestincreasedecreaseother_12AA7CD3387443EF5FE2FA702CB186D7_terseLabel_en-US" xlink:label="lab_biib_Noncontrollinginterestincreasedecreaseother_12AA7CD3387443EF5FE2FA702CB186D7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling interest, increase (decrease) other</link:label>
    <link:label id="lab_biib_Noncontrollinginterestincreasedecreaseother_12AA7CD3387443EF5FE2FA702CB186D7_label_en-US" xlink:label="lab_biib_Noncontrollinginterestincreasedecreaseother_12AA7CD3387443EF5FE2FA702CB186D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling interest, increase (decrease) other</link:label>
    <link:label id="lab_biib_Noncontrollinginterestincreasedecreaseother_12AA7CD3387443EF5FE2FA702CB186D7_documentation_en-US" xlink:label="lab_biib_Noncontrollinginterestincreasedecreaseother_12AA7CD3387443EF5FE2FA702CB186D7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Noncontrolling interest, increase (decrease) other</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_Noncontrollinginterestincreasedecreaseother" xlink:label="loc_biib_Noncontrollinginterestincreasedecreaseother_12AA7CD3387443EF5FE2FA702CB186D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Noncontrollinginterestincreasedecreaseother_12AA7CD3387443EF5FE2FA702CB186D7" xlink:to="lab_biib_Noncontrollinginterestincreasedecreaseother_12AA7CD3387443EF5FE2FA702CB186D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_EB0C7D9BD72EDDFD46CFFA4E86CC17B0_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_EB0C7D9BD72EDDFD46CFFA4E86CC17B0" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Repurchase of common stock, at cost</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_EB0C7D9BD72EDDFD46CFFA4E86CC17B0_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_EB0C7D9BD72EDDFD46CFFA4E86CC17B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_EB0C7D9BD72EDDFD46CFFA4E86CC17B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_EB0C7D9BD72EDDFD46CFFA4E86CC17B0" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_EB0C7D9BD72EDDFD46CFFA4E86CC17B0" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_BD3ABF5978070366FA10FA4E86CC80A3_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired_BD3ABF5978070366FA10FA4E86CC80A3" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Repurchase of common stock, at cost, shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_BD3ABF5978070366FA10FA4E86CC80A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired_BD3ABF5978070366FA10FA4E86CC80A3" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired_BD3ABF5978070366FA10FA4E86CC80A3" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_F21AC471FB0200E0D930FA4E86CCFADF_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_F21AC471FB0200E0D930FA4E86CCFADF" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Retirement of common stock pursuant to the 2016 Share Repurchase Program, at cost</link:label>
    <link:label id="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_F21AC471FB0200E0D930FA4E86CCFADF_label_en-US" xlink:label="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_F21AC471FB0200E0D930FA4E86CCFADF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Retired, Cost Method, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_F21AC471FB0200E0D930FA4E86CCFADF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_F21AC471FB0200E0D930FA4E86CCFADF" xlink:to="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_F21AC471FB0200E0D930FA4E86CCFADF" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_9384811AD3563D189F83FA4E86CCED92_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_9384811AD3563D189F83FA4E86CCED92" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Retirement of common stock pursuant to the 2015 Share Repurchase Program, at cost, shares</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_9384811AD3563D189F83FA4E86CCED92_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_9384811AD3563D189F83FA4E86CCED92" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchased and Retired During Period, Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_9384811AD3563D189F83FA4E86CCED92" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_9384811AD3563D189F83FA4E86CCED92" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_9384811AD3563D189F83FA4E86CCED92" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_45014191A8381260DF58FA4E86CCB485_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_45014191A8381260DF58FA4E86CCB485" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under stock option and stock purchase plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_45014191A8381260DF58FA4E86CCB485_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_45014191A8381260DF58FA4E86CCB485" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Treasury Stock Reissued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_45014191A8381260DF58FA4E86CCB485" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_45014191A8381260DF58FA4E86CCB485" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_45014191A8381260DF58FA4E86CCB485" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_AD648C8DA2170A77E93BFA4E86CC01C0_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_AD648C8DA2170A77E93BFA4E86CC01C0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under stock option and stock purchase plans, shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_AD648C8DA2170A77E93BFA4E86CC01C0_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_AD648C8DA2170A77E93BFA4E86CC01C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Treasury Stock Reissued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_AD648C8DA2170A77E93BFA4E86CC01C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_AD648C8DA2170A77E93BFA4E86CC01C0" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_AD648C8DA2170A77E93BFA4E86CC01C0" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_EEB50A234E79C0DFC401FA4E86CCD2D6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_EEB50A234E79C0DFC401FA4E86CCD2D6" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under stock award plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_EEB50A234E79C0DFC401FA4E86CCD2D6_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_EEB50A234E79C0DFC401FA4E86CCD2D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_EEB50A234E79C0DFC401FA4E86CCD2D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_EEB50A234E79C0DFC401FA4E86CCD2D6" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_EEB50A234E79C0DFC401FA4E86CCD2D6" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_693CA36EE6B80BF11F63FA4E86CC9975_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_693CA36EE6B80BF11F63FA4E86CC9975" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under stock award plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_693CA36EE6B80BF11F63FA4E86CC9975_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_693CA36EE6B80BF11F63FA4E86CC9975" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_693CA36EE6B80BF11F63FA4E86CC9975" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_693CA36EE6B80BF11F63FA4E86CC9975" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_693CA36EE6B80BF11F63FA4E86CC9975" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_03C8D66D222607E8FB17FA4E86CC214F_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_03C8D66D222607E8FB17FA4E86CC214F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation expense related to share-based payments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_03C8D66D222607E8FB17FA4E86CC214F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_03C8D66D222607E8FB17FA4E86CC214F" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_03C8D66D222607E8FB17FA4E86CC214F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_6951C9FFFB846813412AFA4E86CCB444_negatedLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_6951C9FFFB846813412AFA4E86CCB444" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Tax benefit from share-based payments</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_6951C9FFFB846813412AFA4E86CCB444_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_6951C9FFFB846813412AFA4E86CCB444" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_6951C9FFFB846813412AFA4E86CCB444" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_6951C9FFFB846813412AFA4E86CCB444" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_6951C9FFFB846813412AFA4E86CCB444" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_84FD5A09ECCE070EC6CFFA4E86CC46E5_negatedPeriodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_84FD5A09ECCE070EC6CFFA4E86CC46E5" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_84FD5A09ECCE070EC6CFFA4E86CC46E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_84FD5A09ECCE070EC6CFFA4E86CC46E5" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_84FD5A09ECCE070EC6CFFA4E86CC46E5" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_C2C248EE9C8CA2BCAB4CFA64A3BBB0D2_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_C2C248EE9C8CA2BCAB4CFA64A3BBB0D2" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_C2C248EE9C8CA2BCAB4CFA64A3BBB0D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_C2C248EE9C8CA2BCAB4CFA64A3BBB0D2" xlink:to="lab_us-gaap_StockholdersEquity_C2C248EE9C8CA2BCAB4CFA64A3BBB0D2" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinorityInterest_524D13A8E08AEB619744FA4E86CD6AA6_periodEndLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest_524D13A8E08AEB619744FA4E86CD6AA6" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_524D13A8E08AEB619744FA4E86CD6AA6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest_524D13A8E08AEB619744FA4E86CD6AA6" xlink:to="lab_us-gaap_MinorityInterest_524D13A8E08AEB619744FA4E86CD6AA6" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesIssued_5F4D6AC4F8A73EA83728FA4E86CC51EF_negatedPeriodEndLabel_en-US" xlink:label="lab_us-gaap_SharesIssued_5F4D6AC4F8A73EA83728FA4E86CC51EF" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance, shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_5F4D6AC4F8A73EA83728FA4E86CC51EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued_5F4D6AC4F8A73EA83728FA4E86CC51EF" xlink:to="lab_us-gaap_SharesIssued_5F4D6AC4F8A73EA83728FA4E86CC51EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrencyAxis_89E315A9DE4ABD0FEAA0FA4EA4BE27DC_terseLabel_en-US" xlink:label="lab_us-gaap_CurrencyAxis_89E315A9DE4ABD0FEAA0FA4EA4BE27DC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency [Axis]</link:label>
    <link:label id="lab_us-gaap_CurrencyAxis_89E315A9DE4ABD0FEAA0FA4EA4BE27DC_label_en-US" xlink:label="lab_us-gaap_CurrencyAxis_89E315A9DE4ABD0FEAA0FA4EA4BE27DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrencyAxis" xlink:label="loc_us-gaap_CurrencyAxis_89E315A9DE4ABD0FEAA0FA4EA4BE27DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrencyAxis_89E315A9DE4ABD0FEAA0FA4EA4BE27DC" xlink:to="lab_us-gaap_CurrencyAxis_89E315A9DE4ABD0FEAA0FA4EA4BE27DC" xlink:type="arc" />
    <link:label id="lab_currency_AllCurrenciesDomain_DF848F43B464F2E7C07AFA4EA4BEA272_terseLabel_en-US" xlink:label="lab_currency_AllCurrenciesDomain_DF848F43B464F2E7C07AFA4EA4BEA272" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:label id="lab_currency_AllCurrenciesDomain_DF848F43B464F2E7C07AFA4EA4BEA272_label_en-US" xlink:label="lab_currency_AllCurrenciesDomain_DF848F43B464F2E7C07AFA4EA4BEA272" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_DF848F43B464F2E7C07AFA4EA4BEA272" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_AllCurrenciesDomain_DF848F43B464F2E7C07AFA4EA4BEA272" xlink:to="lab_currency_AllCurrenciesDomain_DF848F43B464F2E7C07AFA4EA4BEA272" xlink:type="arc" />
    <link:label id="lab_currency_CHF_1422E3ABF05D9928DDE7FA4EA4BE1A85_terseLabel_en-US" xlink:label="lab_currency_CHF_1422E3ABF05D9928DDE7FA4EA4BE1A85" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Swiss francs</link:label>
    <link:label id="lab_currency_CHF_1422E3ABF05D9928DDE7FA4EA4BE1A85_label_en-US" xlink:label="lab_currency_CHF_1422E3ABF05D9928DDE7FA4EA4BE1A85" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Switzerland, Francs</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd#currency_CHF" xlink:label="loc_currency_CHF_1422E3ABF05D9928DDE7FA4EA4BE1A85" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_CHF_1422E3ABF05D9928DDE7FA4EA4BE1A85" xlink:to="lab_currency_CHF_1422E3ABF05D9928DDE7FA4EA4BE1A85" xlink:type="arc" />
    <link:label id="lab_currency_USD_5DCBBF9C02779CC13F8BFA4EA4BEC338_terseLabel_en-US" xlink:label="lab_currency_USD_5DCBBF9C02779CC13F8BFA4EA4BEC338" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">United States of America, Dollars</link:label>
    <link:label id="lab_currency_USD_5DCBBF9C02779CC13F8BFA4EA4BEC338_label_en-US" xlink:label="lab_currency_USD_5DCBBF9C02779CC13F8BFA4EA4BEC338" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">United States of America, Dollars</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd#currency_USD" xlink:label="loc_currency_USD_5DCBBF9C02779CC13F8BFA4EA4BEC338" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_USD_5DCBBF9C02779CC13F8BFA4EA4BEC338" xlink:to="lab_currency_USD_5DCBBF9C02779CC13F8BFA4EA4BEC338" xlink:type="arc" />
    <link:label id="lab_us-gaap_LandMember_894D830F5CD78D669735FA4EA4BFD82B_terseLabel_en-US" xlink:label="lab_us-gaap_LandMember_894D830F5CD78D669735FA4EA4BFD82B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Land</link:label>
    <link:label id="lab_us-gaap_LandMember_894D830F5CD78D669735FA4EA4BFD82B_label_en-US" xlink:label="lab_us-gaap_LandMember_894D830F5CD78D669735FA4EA4BFD82B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Land [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LandMember" xlink:label="loc_us-gaap_LandMember_894D830F5CD78D669735FA4EA4BFD82B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandMember_894D830F5CD78D669735FA4EA4BFD82B" xlink:to="lab_us-gaap_LandMember_894D830F5CD78D669735FA4EA4BFD82B" xlink:type="arc" />
    <link:label id="lab_biib_SolothurnMember_F226F2D866627C19B19CFA4EA4BF5E5D_terseLabel_en-US" xlink:label="lab_biib_SolothurnMember_F226F2D866627C19B19CFA4EA4BF5E5D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Solothurn</link:label>
    <link:label id="lab_biib_SolothurnMember_F226F2D866627C19B19CFA4EA4BF5E5D_label_en-US" xlink:label="lab_biib_SolothurnMember_F226F2D866627C19B19CFA4EA4BF5E5D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Solothurn [Member]</link:label>
    <link:label id="lab_biib_SolothurnMember_F226F2D866627C19B19CFA4EA4BF5E5D_documentation_en-US" xlink:label="lab_biib_SolothurnMember_F226F2D866627C19B19CFA4EA4BF5E5D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Solothurn [Member]</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_SolothurnMember" xlink:label="loc_biib_SolothurnMember_F226F2D866627C19B19CFA4EA4BF5E5D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SolothurnMember_F226F2D866627C19B19CFA4EA4BF5E5D" xlink:to="lab_biib_SolothurnMember_F226F2D866627C19B19CFA4EA4BF5E5D" xlink:type="arc" />
    <link:label id="lab_us-gaap_Depreciation_E917D5DCDAE6C53D41F7FA4EA4BFA2F9_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation_E917D5DCDAE6C53D41F7FA4EA4BFA2F9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_E917D5DCDAE6C53D41F7FA4EA4BFA2F9_label_en-US" xlink:label="lab_us-gaap_Depreciation_E917D5DCDAE6C53D41F7FA4EA4BFA2F9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_E917D5DCDAE6C53D41F7FA4EA4BFA2F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation_E917D5DCDAE6C53D41F7FA4EA4BFA2F9" xlink:to="lab_us-gaap_Depreciation_E917D5DCDAE6C53D41F7FA4EA4BFA2F9" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestCostsCapitalized_01359CEC34A7EE743104FA4EA4BF65DE_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestCostsCapitalized_01359CEC34A7EE743104FA4EA4BF65DE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Interest cost capitalization related to construction in progress</link:label>
    <link:label id="lab_us-gaap_InterestCostsCapitalized_01359CEC34A7EE743104FA4EA4BF65DE_label_en-US" xlink:label="lab_us-gaap_InterestCostsCapitalized_01359CEC34A7EE743104FA4EA4BF65DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Costs Capitalized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestCostsCapitalized" xlink:label="loc_us-gaap_InterestCostsCapitalized_01359CEC34A7EE743104FA4EA4BF65DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestCostsCapitalized_01359CEC34A7EE743104FA4EA4BF65DE" xlink:to="lab_us-gaap_InterestCostsCapitalized_01359CEC34A7EE743104FA4EA4BF65DE" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAdditions_FDAC12C5DC82EDB3C9BDFA4EA4BF4275_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAdditions_FDAC12C5DC82EDB3C9BDFA4EA4BF4275" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Facility Purchase</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAdditions_FDAC12C5DC82EDB3C9BDFA4EA4BF4275_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAdditions_FDAC12C5DC82EDB3C9BDFA4EA4BF4275" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Additions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAdditions" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAdditions_FDAC12C5DC82EDB3C9BDFA4EA4BF4275" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAdditions_FDAC12C5DC82EDB3C9BDFA4EA4BF4275" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAdditions_FDAC12C5DC82EDB3C9BDFA4EA4BF4275" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_A169EC780FFBB76DCA2CFA4EA4C0B98F_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_A169EC780FFBB76DCA2CFA4EA4C0B98F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term of original lease</link:label>
    <link:label id="lab_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_A169EC780FFBB76DCA2CFA4EA4C0B98F_label_en-US" xlink:label="lab_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_A169EC780FFBB76DCA2CFA4EA4C0B98F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee Leasing Arrangements, Operating Leases, Term of Contract</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:label="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_A169EC780FFBB76DCA2CFA4EA4C0B98F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_A169EC780FFBB76DCA2CFA4EA4C0B98F" xlink:to="lab_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_A169EC780FFBB76DCA2CFA4EA4C0B98F" xlink:type="arc" />
    <link:label id="lab_biib_TermOfLease_4684C66542187739F454FA4EA4C0B882_terseLabel_en-US" xlink:label="lab_biib_TermOfLease_4684C66542187739F454FA4EA4C0B882" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term of amended lease</link:label>
    <link:label id="lab_biib_TermOfLease_4684C66542187739F454FA4EA4C0B882_label_en-US" xlink:label="lab_biib_TermOfLease_4684C66542187739F454FA4EA4C0B882" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term Of Lease</link:label>
    <link:label id="lab_biib_TermOfLease_4684C66542187739F454FA4EA4C0B882_documentation_en-US" xlink:label="lab_biib_TermOfLease_4684C66542187739F454FA4EA4C0B882" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Term Of Lease.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_TermOfLease" xlink:label="loc_biib_TermOfLease_4684C66542187739F454FA4EA4C0B882" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TermOfLease_4684C66542187739F454FA4EA4C0B882" xlink:to="lab_biib_TermOfLease_4684C66542187739F454FA4EA4C0B882" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_D125E2B5A79F770352BFFA4EA5369282_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis_D125E2B5A79F770352BFFA4EA5369282" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_D125E2B5A79F770352BFFA4EA5369282_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis_D125E2B5A79F770352BFFA4EA5369282" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_D125E2B5A79F770352BFFA4EA5369282" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_D125E2B5A79F770352BFFA4EA5369282" xlink:to="lab_us-gaap_ContingentConsiderationByTypeAxis_D125E2B5A79F770352BFFA4EA5369282" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_D2B4DB4C6D0F7CF954CEFA4EA536C51E_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain_D2B4DB4C6D0F7CF954CEFA4EA536C51E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_D2B4DB4C6D0F7CF954CEFA4EA536C51E_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain_D2B4DB4C6D0F7CF954CEFA4EA536C51E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_D2B4DB4C6D0F7CF954CEFA4EA536C51E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_D2B4DB4C6D0F7CF954CEFA4EA536C51E" xlink:to="lab_us-gaap_ContingentConsiderationTypeDomain_D2B4DB4C6D0F7CF954CEFA4EA536C51E" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_8B6D9933976C20040909FA4EA53614A6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember_8B6D9933976C20040909FA4EA53614A6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_8B6D9933976C20040909FA4EA53614A6_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember_8B6D9933976C20040909FA4EA53614A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_8B6D9933976C20040909FA4EA53614A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesMember_8B6D9933976C20040909FA4EA53614A6" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesMember_8B6D9933976C20040909FA4EA53614A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_5BE0BAE2E6313D435495FA4EA536ACA6_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember_5BE0BAE2E6313D435495FA4EA536ACA6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_5BE0BAE2E6313D435495FA4EA536ACA6_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember_5BE0BAE2E6313D435495FA4EA536ACA6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_5BE0BAE2E6313D435495FA4EA536ACA6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesMember_5BE0BAE2E6313D435495FA4EA536ACA6" xlink:to="lab_us-gaap_AccruedLiabilitiesMember_5BE0BAE2E6313D435495FA4EA536ACA6" xlink:type="arc" />
    <link:label id="lab_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_E385C0A2922D4B9DEAB6FA4EA536F876_verboseLabel_en-US" xlink:label="lab_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_E385C0A2922D4B9DEAB6FA4EA536F876" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">6.875% Senior Notes due 2018</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" xlink:label="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_E385C0A2922D4B9DEAB6FA4EA536F876" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_E385C0A2922D4B9DEAB6FA4EA536F876" xlink:to="lab_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_E385C0A2922D4B9DEAB6FA4EA536F876" xlink:type="arc" />
    <link:label id="lab_biib_StromedixMember_784859EF897FF5D52BB5FA4EA5374ABF_verboseLabel_en-US" xlink:label="lab_biib_StromedixMember_784859EF897FF5D52BB5FA4EA5374ABF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stromedix, Inc.</link:label>
    <link:label id="lab_biib_StromedixMember_784859EF897FF5D52BB5FA4EA5374ABF_label_en-US" xlink:label="lab_biib_StromedixMember_784859EF897FF5D52BB5FA4EA5374ABF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stromedix [Member]</link:label>
    <link:label id="lab_biib_StromedixMember_784859EF897FF5D52BB5FA4EA5374ABF_documentation_en-US" xlink:label="lab_biib_StromedixMember_784859EF897FF5D52BB5FA4EA5374ABF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stromedix.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_StromedixMember" xlink:label="loc_biib_StromedixMember_784859EF897FF5D52BB5FA4EA5374ABF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_StromedixMember_784859EF897FF5D52BB5FA4EA5374ABF" xlink:to="lab_biib_StromedixMember_784859EF897FF5D52BB5FA4EA5374ABF" xlink:type="arc" />
    <link:label id="lab_biib_BiogenIdecInternationalNeuroscienceMember_0A875F6FBFBB38E9FF52FA4EA537B4AF_terseLabel_en-US" xlink:label="lab_biib_BiogenIdecInternationalNeuroscienceMember_0A875F6FBFBB38E9FF52FA4EA537B4AF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Biogen Idec International Neuroscience GmbH</link:label>
    <link:label id="lab_biib_BiogenIdecInternationalNeuroscienceMember_0A875F6FBFBB38E9FF52FA4EA537B4AF_label_en-US" xlink:label="lab_biib_BiogenIdecInternationalNeuroscienceMember_0A875F6FBFBB38E9FF52FA4EA537B4AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Biogen Idec International Neuroscience Member</link:label>
    <link:label id="lab_biib_BiogenIdecInternationalNeuroscienceMember_0A875F6FBFBB38E9FF52FA4EA537B4AF_documentation_en-US" xlink:label="lab_biib_BiogenIdecInternationalNeuroscienceMember_0A875F6FBFBB38E9FF52FA4EA537B4AF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Biogen idec international neuroscience.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_BiogenIdecInternationalNeuroscienceMember" xlink:label="loc_biib_BiogenIdecInternationalNeuroscienceMember_0A875F6FBFBB38E9FF52FA4EA537B4AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BiogenIdecInternationalNeuroscienceMember_0A875F6FBFBB38E9FF52FA4EA537B4AF" xlink:to="lab_biib_BiogenIdecInternationalNeuroscienceMember_0A875F6FBFBB38E9FF52FA4EA537B4AF" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_8D32529963D92B94907CFA4EA537EEEC_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_8D32529963D92B94907CFA4EA537EEEC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate on senior notes</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_8D32529963D92B94907CFA4EA537EEEC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_8D32529963D92B94907CFA4EA537EEEC" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_8D32529963D92B94907CFA4EA537EEEC" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_66B267C10EB54D203109FA4EA5370DCF_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_66B267C10EB54D203109FA4EA5370DCF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration obligations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_66B267C10EB54D203109FA4EA5370DCF_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_66B267C10EB54D203109FA4EA5370DCF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_66B267C10EB54D203109FA4EA5370DCF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_66B267C10EB54D203109FA4EA5370DCF" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_66B267C10EB54D203109FA4EA5370DCF" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilities_0C3AFECB77D6E3B39895FB4679C40AA2_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilities_0C3AFECB77D6E3B39895FB4679C40AA2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Milestone converted to short-term obligation</link:label>
    <link:label id="lab_us-gaap_OtherLiabilities_0C3AFECB77D6E3B39895FB4679C40AA2_label_en-US" xlink:label="lab_us-gaap_OtherLiabilities_0C3AFECB77D6E3B39895FB4679C40AA2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilities" xlink:label="loc_us-gaap_OtherLiabilities_0C3AFECB77D6E3B39895FB4679C40AA2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilities_0C3AFECB77D6E3B39895FB4679C40AA2" xlink:to="lab_us-gaap_OtherLiabilities_0C3AFECB77D6E3B39895FB4679C40AA2" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsChangesInValuationTechniques_7AA68F08FD585028A6B4FA4EA537A0A2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsChangesInValuationTechniques_7AA68F08FD585028A6B4FA4EA537A0A2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value measurements, changes in valuation techniques</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsChangesInValuationTechniques_7AA68F08FD585028A6B4FA4EA537A0A2_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsChangesInValuationTechniques_7AA68F08FD585028A6B4FA4EA537A0A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Changes in Valuation Techniques</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsChangesInValuationTechniques" xlink:label="loc_us-gaap_FairValueMeasurementsChangesInValuationTechniques_7AA68F08FD585028A6B4FA4EA537A0A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsChangesInValuationTechniques_7AA68F08FD585028A6B4FA4EA537A0A2" xlink:to="lab_us-gaap_FairValueMeasurementsChangesInValuationTechniques_7AA68F08FD585028A6B4FA4EA537A0A2" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_62A6C02D296D7D6E9655FA4EA538825A_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_62A6C02D296D7D6E9655FA4EA538825A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration obligations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_62A6C02D296D7D6E9655FA4EA538825A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_62A6C02D296D7D6E9655FA4EA538825A" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_62A6C02D296D7D6E9655FA4EA538825A" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsDiscountRate_CB159300AD6FAA01224CFA4EA5386A30_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsDiscountRate_CB159300AD6FAA01224CFA4EA5386A30" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Discount rate used for net cash outflow projections for fair value measurement</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsDiscountRate" xlink:label="loc_us-gaap_FairValueInputsDiscountRate_CB159300AD6FAA01224CFA4EA5386A30" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsDiscountRate_CB159300AD6FAA01224CFA4EA5386A30" xlink:to="lab_us-gaap_FairValueInputsDiscountRate_CB159300AD6FAA01224CFA4EA5386A30" xlink:type="arc" />
    <link:label id="lab_biib_MilestonePaymentsMadeDuringPeriod_0EA421F0C707B691E719FA4EA538BEAD_verboseLabel_en-US" xlink:label="lab_biib_MilestonePaymentsMadeDuringPeriod_0EA421F0C707B691E719FA4EA538BEAD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Milestone payments made during period</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_MilestonePaymentsMadeDuringPeriod" xlink:label="loc_biib_MilestonePaymentsMadeDuringPeriod_0EA421F0C707B691E719FA4EA538BEAD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MilestonePaymentsMadeDuringPeriod_0EA421F0C707B691E719FA4EA538BEAD" xlink:to="lab_biib_MilestonePaymentsMadeDuringPeriod_0EA421F0C707B691E719FA4EA538BEAD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_9BD4DBCFCBD52B1929B2FCCBDAC9889D_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_9BD4DBCFCBD52B1929B2FCCBDAC9889D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_9BD4DBCFCBD52B1929B2FCCBDAC9889D_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_9BD4DBCFCBD52B1929B2FCCBDAC9889D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_9BD4DBCFCBD52B1929B2FCCBDAC9889D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_9BD4DBCFCBD52B1929B2FCCBDAC9889D" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_9BD4DBCFCBD52B1929B2FCCBDAC9889D" xlink:type="arc" />
    <link:label id="lab_country_DK_37D00F9C0B052EE7CBBEFCCBDAC96594_terseLabel_en-US" xlink:label="lab_country_DK_37D00F9C0B052EE7CBBEFCCBDAC96594" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">DENMARK</link:label>
    <link:label id="lab_country_DK_37D00F9C0B052EE7CBBEFCCBDAC96594_label_en-US" xlink:label="lab_country_DK_37D00F9C0B052EE7CBBEFCCBDAC96594" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">DENMARK</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd#country_DK" xlink:label="loc_country_DK_37D00F9C0B052EE7CBBEFCCBDAC96594" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_DK_37D00F9C0B052EE7CBBEFCCBDAC96594" xlink:to="lab_country_DK_37D00F9C0B052EE7CBBEFCCBDAC96594" xlink:type="arc" />
    <link:label id="lab_biib_DistributorOneMember_F178FF845BE66F5A057FFCCBDAC9478C_verboseLabel_en-US" xlink:label="lab_biib_DistributorOneMember_F178FF845BE66F5A057FFCCBDAC9478C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Distributor One</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_DistributorOneMember" xlink:label="loc_biib_DistributorOneMember_F178FF845BE66F5A057FFCCBDAC9478C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DistributorOneMember_F178FF845BE66F5A057FFCCBDAC9478C" xlink:to="lab_biib_DistributorOneMember_F178FF845BE66F5A057FFCCBDAC9478C" xlink:type="arc" />
    <link:label id="lab_biib_DistributorTwoMember_884E0803F9274A505BF0FCCBDAC9172B_verboseLabel_en-US" xlink:label="lab_biib_DistributorTwoMember_884E0803F9274A505BF0FCCBDAC9172B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Distributor Two</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_DistributorTwoMember" xlink:label="loc_biib_DistributorTwoMember_884E0803F9274A505BF0FCCBDAC9172B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DistributorTwoMember_884E0803F9274A505BF0FCCBDAC9172B" xlink:to="lab_biib_DistributorTwoMember_884E0803F9274A505BF0FCCBDAC9172B" xlink:type="arc" />
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_C00646353A7BBA92F040FCCBDAC9FDAE_terseLabel_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_C00646353A7BBA92F040FCCBDAC9FDAE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_C00646353A7BBA92F040FCCBDAC9FDAE_label_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_C00646353A7BBA92F040FCCBDAC9FDAE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_C00646353A7BBA92F040FCCBDAC9FDAE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_C00646353A7BBA92F040FCCBDAC9FDAE" xlink:to="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_C00646353A7BBA92F040FCCBDAC9FDAE" xlink:type="arc" />
    <link:label id="lab_biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms_1BBECB4198EE9ACB6956FCE69BFAFF51_verboseLabel_en-US" xlink:label="lab_biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms_1BBECB4198EE9ACB6956FCE69BFAFF51" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenues from unconsolidated joint business in percentage</link:label>
    <link:label id="lab_biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms_1BBECB4198EE9ACB6956FCE69BFAFF51_label_en-US" xlink:label="lab_biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms_1BBECB4198EE9ACB6956FCE69BFAFF51" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues In Percentage From Anti-CD20 Therapeutic Programs</link:label>
    <link:label id="lab_biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms_1BBECB4198EE9ACB6956FCE69BFAFF51_documentation_en-US" xlink:label="lab_biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms_1BBECB4198EE9ACB6956FCE69BFAFF51" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenues In Percentage From Anti-CD20 Therapeutic Programs</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms" xlink:label="loc_biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms_1BBECB4198EE9ACB6956FCE69BFAFF51" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms_1BBECB4198EE9ACB6956FCE69BFAFF51" xlink:to="lab_biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms_1BBECB4198EE9ACB6956FCE69BFAFF51" xlink:type="arc" />
    <link:label id="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_258A6514AF60758796C1FCCBDAC97752_verboseLabel_en-US" xlink:label="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_258A6514AF60758796C1FCCBDAC97752" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Entity wide percentage of revenue from major distributors</link:label>
    <link:label id="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_258A6514AF60758796C1FCCBDAC97752_label_en-US" xlink:label="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_258A6514AF60758796C1FCCBDAC97752" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Wide Percentage Of Revenue From Major Distributors</link:label>
    <link:label id="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_258A6514AF60758796C1FCCBDAC97752_documentation_en-US" xlink:label="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_258A6514AF60758796C1FCCBDAC97752" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Entity wide percentage of revenue from major distributors.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:label="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_258A6514AF60758796C1FCCBDAC97752" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_258A6514AF60758796C1FCCBDAC97752" xlink:to="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_258A6514AF60758796C1FCCBDAC97752" xlink:type="arc" />
    <link:label id="lab_us-gaap_NoncurrentAssets_546F5ACCDE8D8EFF0914FCCBDACA4BDC_terseLabel_en-US" xlink:label="lab_us-gaap_NoncurrentAssets_546F5ACCDE8D8EFF0914FCCBDACA4BDC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-lived assets related to operations in Denmark</link:label>
    <link:label id="lab_us-gaap_NoncurrentAssets_546F5ACCDE8D8EFF0914FCCBDACA4BDC_label_en-US" xlink:label="lab_us-gaap_NoncurrentAssets_546F5ACCDE8D8EFF0914FCCBDACA4BDC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NoncurrentAssets" xlink:label="loc_us-gaap_NoncurrentAssets_546F5ACCDE8D8EFF0914FCCBDACA4BDC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncurrentAssets_546F5ACCDE8D8EFF0914FCCBDACA4BDC" xlink:to="lab_us-gaap_NoncurrentAssets_546F5ACCDE8D8EFF0914FCCBDACA4BDC" xlink:type="arc" />
    <link:label id="lab_biib_SegmentInformationTextualAbstract_1FD70DFF1534541CEB1FFCCBDACA2707_verboseLabel_en-US" xlink:label="lab_biib_SegmentInformationTextualAbstract_1FD70DFF1534541CEB1FFCCBDACA2707" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Segment Information (Textual) [Abstract]</link:label>
    <link:label id="lab_biib_SegmentInformationTextualAbstract_1FD70DFF1534541CEB1FFCCBDACA2707_label_en-US" xlink:label="lab_biib_SegmentInformationTextualAbstract_1FD70DFF1534541CEB1FFCCBDACA2707" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Information (Textual) [Abstract]</link:label>
    <link:label id="lab_biib_SegmentInformationTextualAbstract_1FD70DFF1534541CEB1FFCCBDACA2707_documentation_en-US" xlink:label="lab_biib_SegmentInformationTextualAbstract_1FD70DFF1534541CEB1FFCCBDACA2707" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Segment Information.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_SegmentInformationTextualAbstract" xlink:label="loc_biib_SegmentInformationTextualAbstract_1FD70DFF1534541CEB1FFCCBDACA2707" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SegmentInformationTextualAbstract_1FD70DFF1534541CEB1FFCCBDACA2707" xlink:to="lab_biib_SegmentInformationTextualAbstract_1FD70DFF1534541CEB1FFCCBDACA2707" xlink:type="arc" />
    <link:label id="lab_us-gaap_NumberOfReportableSegments_5E9147CB31329628DAE3FCCBDACA2721_verboseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments_5E9147CB31329628DAE3FCCBDACA2721" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number of reportable segment</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_5E9147CB31329628DAE3FCCBDACA2721_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments_5E9147CB31329628DAE3FCCBDACA2721" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaap_NumberOfReportableSegments_5E9147CB31329628DAE3FCCBDACA2721" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments_5E9147CB31329628DAE3FCCBDACA2721" xlink:to="lab_us-gaap_NumberOfReportableSegments_5E9147CB31329628DAE3FCCBDACA2721" xlink:type="arc" />
    <link:label id="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_C1937652D8054560F4ED741285DAAD7F_verboseLabel_en-US" xlink:label="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_C1937652D8054560F4ED741285DAAD7F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_C1937652D8054560F4ED741285DAAD7F_label_en-US" xlink:label="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_C1937652D8054560F4ED741285DAAD7F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets Excluding Goodwill [Table Text Block]</link:label>
    <link:label id="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_C1937652D8054560F4ED741285DAAD7F_documentation_en-US" xlink:label="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_C1937652D8054560F4ED741285DAAD7F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Intangible assets excluding goodwill.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:label="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_C1937652D8054560F4ED741285DAAD7F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_C1937652D8054560F4ED741285DAAD7F" xlink:to="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_C1937652D8054560F4ED741285DAAD7F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_3311B4AD738F881B814C741285DA6C0E_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_3311B4AD738F881B814C741285DA6C0E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated future amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_3311B4AD738F881B814C741285DA6C0E_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_3311B4AD738F881B814C741285DA6C0E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_3311B4AD738F881B814C741285DA6C0E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_3311B4AD738F881B814C741285DA6C0E" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_3311B4AD738F881B814C741285DA6C0E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_04E78B019CC94BDB82A5741285DA6135_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock_04E78B019CC94BDB82A5741285DA6135" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of roll forward of the changes in goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_04E78B019CC94BDB82A5741285DA6135_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock_04E78B019CC94BDB82A5741285DA6135" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_04E78B019CC94BDB82A5741285DA6135" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock_04E78B019CC94BDB82A5741285DA6135" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock_04E78B019CC94BDB82A5741285DA6135" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_EFC1C7390C4CD7AE0568F4AB01422D56_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_EFC1C7390C4CD7AE0568F4AB01422D56" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_EFC1C7390C4CD7AE0568F4AB01422D56" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_EFC1C7390C4CD7AE0568F4AB01422D56" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_EFC1C7390C4CD7AE0568F4AB01422D56" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_2C4F5F3AD50032C7EBFFF4AB014205E5_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_2C4F5F3AD50032C7EBFFF4AB014205E5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_2C4F5F3AD50032C7EBFFF4AB014205E5_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_2C4F5F3AD50032C7EBFFF4AB014205E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_2C4F5F3AD50032C7EBFFF4AB014205E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_2C4F5F3AD50032C7EBFFF4AB014205E5" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_2C4F5F3AD50032C7EBFFF4AB014205E5" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_761AE55E3F7E0E81071CF4AB014204C7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_761AE55E3F7E0E81071CF4AB014204C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains (losses) recognized during the period, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_761AE55E3F7E0E81071CF4AB014204C7_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_761AE55E3F7E0E81071CF4AB014204C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_761AE55E3F7E0E81071CF4AB014204C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_761AE55E3F7E0E81071CF4AB014204C7" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_761AE55E3F7E0E81071CF4AB014204C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_0DBB8C7411F6EA2EDF63F4AB0143233B_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_0DBB8C7411F6EA2EDF63F4AB0143233B" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: reclassification adjustment for (gains) losses included in net income, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_0DBB8C7411F6EA2EDF63F4AB0143233B_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_0DBB8C7411F6EA2EDF63F4AB0143233B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_0DBB8C7411F6EA2EDF63F4AB0143233B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_0DBB8C7411F6EA2EDF63F4AB0143233B" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_0DBB8C7411F6EA2EDF63F4AB0143233B" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_2715EC25AF3B0B19A0D6F4AB01435324_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_2715EC25AF3B0B19A0D6F4AB01435324" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains (losses) on securities available for sale, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_2715EC25AF3B0B19A0D6F4AB01435324_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_2715EC25AF3B0B19A0D6F4AB01435324" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_2715EC25AF3B0B19A0D6F4AB01435324" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_2715EC25AF3B0B19A0D6F4AB01435324" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_2715EC25AF3B0B19A0D6F4AB01435324" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax_030CF917F8DCCBBF7750F4AB01438D27_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax_030CF917F8DCCBBF7750F4AB01438D27" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains (losses) recognized during the period, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax_030CF917F8DCCBBF7750F4AB01438D27_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax_030CF917F8DCCBBF7750F4AB01438D27" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax_030CF917F8DCCBBF7750F4AB01438D27" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax_030CF917F8DCCBBF7750F4AB01438D27" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax_030CF917F8DCCBBF7750F4AB01438D27" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax_41B4C8477BC336F6F82CF4AB01438924_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax_41B4C8477BC336F6F82CF4AB01438924" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: reclassification adjustment for (gains) losses included in net income, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax_41B4C8477BC336F6F82CF4AB01438924_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax_41B4C8477BC336F6F82CF4AB01438924" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax_41B4C8477BC336F6F82CF4AB01438924" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax_41B4C8477BC336F6F82CF4AB01438924" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax_41B4C8477BC336F6F82CF4AB01438924" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_B773831B3AC34E652295F4AB0143D18D_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_B773831B3AC34E652295F4AB0143D18D" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains (losses) on cash flow hedges, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_B773831B3AC34E652295F4AB0143D18D_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_B773831B3AC34E652295F4AB0143D18D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_B773831B3AC34E652295F4AB0143D18D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_B773831B3AC34E652295F4AB0143D18D" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_B773831B3AC34E652295F4AB0143D18D" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_F96B0ECA59856DBE981EF4AB0143DBED_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_F96B0ECA59856DBE981EF4AB0143DBED" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains (losses) on pension benefit obligation</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_F96B0ECA59856DBE981EF4AB0143DBED_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_F96B0ECA59856DBE981EF4AB0143DBED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Adjustment, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_F96B0ECA59856DBE981EF4AB0143DBED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_F96B0ECA59856DBE981EF4AB0143DBED" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_F96B0ECA59856DBE981EF4AB0143DBED" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_109500D8867D56133DE9F4AB01438DA9_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_109500D8867D56133DE9F4AB01438DA9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_109500D8867D56133DE9F4AB01438DA9_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_109500D8867D56133DE9F4AB01438DA9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_109500D8867D56133DE9F4AB01438DA9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_109500D8867D56133DE9F4AB01438DA9" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_109500D8867D56133DE9F4AB01438DA9" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_B34E3E1EAEE894FA2EC5F4AB0143ECEE_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_B34E3E1EAEE894FA2EC5F4AB0143ECEE" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other comprehensive income (loss), net of tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_B34E3E1EAEE894FA2EC5F4AB0143ECEE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_B34E3E1EAEE894FA2EC5F4AB0143ECEE" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_B34E3E1EAEE894FA2EC5F4AB0143ECEE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_A7306DC5AE572E033A67F4AB0143415F_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_A7306DC5AE572E033A67F4AB0143415F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_A7306DC5AE572E033A67F4AB0143415F_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_A7306DC5AE572E033A67F4AB0143415F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_A7306DC5AE572E033A67F4AB0143415F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_A7306DC5AE572E033A67F4AB0143415F" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax_A7306DC5AE572E033A67F4AB0143415F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_4268B49B7AEE5C858327F4AB014365B3_negatedLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_4268B49B7AEE5C858327F4AB014365B3" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income (loss) attributable to noncontrolling interests, net of tax</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_4268B49B7AEE5C858327F4AB014365B3_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_4268B49B7AEE5C858327F4AB014365B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_4268B49B7AEE5C858327F4AB014365B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_4268B49B7AEE5C858327F4AB014365B3" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_4268B49B7AEE5C858327F4AB014365B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_9093D6E5185A2665EDA6F4AB0143A41A_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_9093D6E5185A2665EDA6F4AB0143A41A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_9093D6E5185A2665EDA6F4AB0143A41A_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_9093D6E5185A2665EDA6F4AB0143A41A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_9093D6E5185A2665EDA6F4AB0143A41A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_9093D6E5185A2665EDA6F4AB0143A41A" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_9093D6E5185A2665EDA6F4AB0143A41A" xlink:type="arc" />
    <link:label id="lab_biib_CoPromotionProfitSharingFormulaTableTextBlock_869996A6E20420520A13D6D80C65F8BC_verboseLabel_en-US" xlink:label="lab_biib_CoPromotionProfitSharingFormulaTableTextBlock_869996A6E20420520A13D6D80C65F8BC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Co-promotion profit sharing formula</link:label>
    <link:label id="lab_biib_CoPromotionProfitSharingFormulaTableTextBlock_869996A6E20420520A13D6D80C65F8BC_label_en-US" xlink:label="lab_biib_CoPromotionProfitSharingFormulaTableTextBlock_869996A6E20420520A13D6D80C65F8BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Co Promotion Profit Sharing Formula [Table Text Block]</link:label>
    <link:label id="lab_biib_CoPromotionProfitSharingFormulaTableTextBlock_869996A6E20420520A13D6D80C65F8BC_documentation_en-US" xlink:label="lab_biib_CoPromotionProfitSharingFormulaTableTextBlock_869996A6E20420520A13D6D80C65F8BC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Co-promotion profit sharing formula.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_CoPromotionProfitSharingFormulaTableTextBlock" xlink:label="loc_biib_CoPromotionProfitSharingFormulaTableTextBlock_869996A6E20420520A13D6D80C65F8BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CoPromotionProfitSharingFormulaTableTextBlock_869996A6E20420520A13D6D80C65F8BC" xlink:to="lab_biib_CoPromotionProfitSharingFormulaTableTextBlock_869996A6E20420520A13D6D80C65F8BC" xlink:type="arc" />
    <link:label id="lab_biib_PretaxProfitSharingFormulaTableTextBlock_988303FB6EC24990D50FD6D80C65B6A5_terseLabel_en-US" xlink:label="lab_biib_PretaxProfitSharingFormulaTableTextBlock_988303FB6EC24990D50FD6D80C65B6A5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pretax profit sharing formula</link:label>
    <link:label id="lab_biib_PretaxProfitSharingFormulaTableTextBlock_988303FB6EC24990D50FD6D80C65B6A5_label_en-US" xlink:label="lab_biib_PretaxProfitSharingFormulaTableTextBlock_988303FB6EC24990D50FD6D80C65B6A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pretax Profit Sharing Formula [Table Text Block]</link:label>
    <link:label id="lab_biib_PretaxProfitSharingFormulaTableTextBlock_988303FB6EC24990D50FD6D80C65B6A5_documentation_en-US" xlink:label="lab_biib_PretaxProfitSharingFormulaTableTextBlock_988303FB6EC24990D50FD6D80C65B6A5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pretax Profit Sharing Formula [Table Text Block]</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_PretaxProfitSharingFormulaTableTextBlock" xlink:label="loc_biib_PretaxProfitSharingFormulaTableTextBlock_988303FB6EC24990D50FD6D80C65B6A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PretaxProfitSharingFormulaTableTextBlock_988303FB6EC24990D50FD6D80C65B6A5" xlink:to="lab_biib_PretaxProfitSharingFormulaTableTextBlock_988303FB6EC24990D50FD6D80C65B6A5" xlink:type="arc" />
    <link:label id="lab_biib_RevenuesFromUnconsolidatedJointBusinessTableTextBlock_F191D80D1C1004DEA0B4D6D80C65A040_verboseLabel_en-US" xlink:label="lab_biib_RevenuesFromUnconsolidatedJointBusinessTableTextBlock_F191D80D1C1004DEA0B4D6D80C65A040" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenues from unconsolidated joint business</link:label>
    <link:label id="lab_biib_RevenuesFromUnconsolidatedJointBusinessTableTextBlock_F191D80D1C1004DEA0B4D6D80C65A040_label_en-US" xlink:label="lab_biib_RevenuesFromUnconsolidatedJointBusinessTableTextBlock_F191D80D1C1004DEA0B4D6D80C65A040" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues From Unconsolidated Joint Business [Table Text Block]</link:label>
    <link:label id="lab_biib_RevenuesFromUnconsolidatedJointBusinessTableTextBlock_F191D80D1C1004DEA0B4D6D80C65A040_documentation_en-US" xlink:label="lab_biib_RevenuesFromUnconsolidatedJointBusinessTableTextBlock_F191D80D1C1004DEA0B4D6D80C65A040" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenues from unconsolidated joint business.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_RevenuesFromUnconsolidatedJointBusinessTableTextBlock" xlink:label="loc_biib_RevenuesFromUnconsolidatedJointBusinessTableTextBlock_F191D80D1C1004DEA0B4D6D80C65A040" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RevenuesFromUnconsolidatedJointBusinessTableTextBlock_F191D80D1C1004DEA0B4D6D80C65A040" xlink:to="lab_biib_RevenuesFromUnconsolidatedJointBusinessTableTextBlock_F191D80D1C1004DEA0B4D6D80C65A040" xlink:type="arc" />
    <link:label id="lab_biib_ReimbursementUnderAmendedAgreementAmountsPayableTableTextBlock_03A6B37655C26F6D3A00D6D80C656EE9_verboseLabel_en-US" xlink:label="lab_biib_ReimbursementUnderAmendedAgreementAmountsPayableTableTextBlock_03A6B37655C26F6D3A00D6D80C656EE9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Mechanism for reimbursement, under the amended agreement amounts payable</link:label>
    <link:label id="lab_biib_ReimbursementUnderAmendedAgreementAmountsPayableTableTextBlock_03A6B37655C26F6D3A00D6D80C656EE9_label_en-US" xlink:label="lab_biib_ReimbursementUnderAmendedAgreementAmountsPayableTableTextBlock_03A6B37655C26F6D3A00D6D80C656EE9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reimbursement Under The Amended Agreement Amounts Payable [Table Text Block]</link:label>
    <link:label id="lab_biib_ReimbursementUnderAmendedAgreementAmountsPayableTableTextBlock_03A6B37655C26F6D3A00D6D80C656EE9_documentation_en-US" xlink:label="lab_biib_ReimbursementUnderAmendedAgreementAmountsPayableTableTextBlock_03A6B37655C26F6D3A00D6D80C656EE9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Mechanism for reimbursement, under the amended agreement amounts payable.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_ReimbursementUnderAmendedAgreementAmountsPayableTableTextBlock" xlink:label="loc_biib_ReimbursementUnderAmendedAgreementAmountsPayableTableTextBlock_03A6B37655C26F6D3A00D6D80C656EE9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ReimbursementUnderAmendedAgreementAmountsPayableTableTextBlock_03A6B37655C26F6D3A00D6D80C656EE9" xlink:to="lab_biib_ReimbursementUnderAmendedAgreementAmountsPayableTableTextBlock_03A6B37655C26F6D3A00D6D80C656EE9" xlink:type="arc" />
    <link:label id="lab_biib_SummaryOfActivityRelatedToCollaborationWithCompanySevenTableTextBlock_0C201848E3DDD15DF183D6D80C658ECB_verboseLabel_en-US" xlink:label="lab_biib_SummaryOfActivityRelatedToCollaborationWithCompanySevenTableTextBlock_0C201848E3DDD15DF183D6D80C658ECB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of activity related to collaboration with AbbVie Inc.</link:label>
    <link:label id="lab_biib_SummaryOfActivityRelatedToCollaborationWithCompanySevenTableTextBlock_0C201848E3DDD15DF183D6D80C658ECB_label_en-US" xlink:label="lab_biib_SummaryOfActivityRelatedToCollaborationWithCompanySevenTableTextBlock_0C201848E3DDD15DF183D6D80C658ECB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary Of Activity Related To Collaboration With Company Seven [Table Text Block]</link:label>
    <link:label id="lab_biib_SummaryOfActivityRelatedToCollaborationWithCompanySevenTableTextBlock_0C201848E3DDD15DF183D6D80C658ECB_documentation_en-US" xlink:label="lab_biib_SummaryOfActivityRelatedToCollaborationWithCompanySevenTableTextBlock_0C201848E3DDD15DF183D6D80C658ECB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary of activity related to collaboration with company seven.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_SummaryOfActivityRelatedToCollaborationWithCompanySevenTableTextBlock" xlink:label="loc_biib_SummaryOfActivityRelatedToCollaborationWithCompanySevenTableTextBlock_0C201848E3DDD15DF183D6D80C658ECB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryOfActivityRelatedToCollaborationWithCompanySevenTableTextBlock_0C201848E3DDD15DF183D6D80C658ECB" xlink:to="lab_biib_SummaryOfActivityRelatedToCollaborationWithCompanySevenTableTextBlock_0C201848E3DDD15DF183D6D80C658ECB" xlink:type="arc" />
    <link:label id="lab_biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock_14760211647C293785B7D6D80C651A7B_terseLabel_en-US" xlink:label="lab_biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock_14760211647C293785B7D6D80C651A7B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of activity related to collaboration with Eisai</link:label>
    <link:label id="lab_biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock_14760211647C293785B7D6D80C651A7B_label_en-US" xlink:label="lab_biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock_14760211647C293785B7D6D80C651A7B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary Of Activity Related To Collaboration With Company Eight [Table Text Block] [Table Text Block]</link:label>
    <link:label id="lab_biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock_14760211647C293785B7D6D80C651A7B_documentation_en-US" xlink:label="lab_biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock_14760211647C293785B7D6D80C651A7B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary Of Activity Related To Collaboration With Company Eight [Table Text Block] [Table Text Block]</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock" xlink:label="loc_biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock_14760211647C293785B7D6D80C651A7B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock_14760211647C293785B7D6D80C651A7B" xlink:to="lab_biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock_14760211647C293785B7D6D80C651A7B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_DE47BD3E94FA0D53063BFCCBDBB11D55_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract_DE47BD3E94FA0D53063BFCCBDBB11D55" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_DE47BD3E94FA0D53063BFCCBDBB11D55" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_DE47BD3E94FA0D53063BFCCBDBB11D55" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract_DE47BD3E94FA0D53063BFCCBDBB11D55" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_C2DFF3E3118DF58C9D9BFCCBDBB19441_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_C2DFF3E3118DF58C9D9BFCCBDBB19441" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation between the U.S. federal statutory tax rate and effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_C2DFF3E3118DF58C9D9BFCCBDBB19441_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_C2DFF3E3118DF58C9D9BFCCBDBB19441" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_C2DFF3E3118DF58C9D9BFCCBDBB19441" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_C2DFF3E3118DF58C9D9BFCCBDBB19441" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_C2DFF3E3118DF58C9D9BFCCBDBB19441" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_160FE3F0D351623EBA00FCCBDBB1F09F_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_160FE3F0D351623EBA00FCCBDBB1F09F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Statutory rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_160FE3F0D351623EBA00FCCBDBB1F09F_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_160FE3F0D351623EBA00FCCBDBB1F09F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_160FE3F0D351623EBA00FCCBDBB1F09F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_160FE3F0D351623EBA00FCCBDBB1F09F" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_160FE3F0D351623EBA00FCCBDBB1F09F" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_C363BC7FBCE94DDD6B36FCCBDBB1A74A_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_C363BC7FBCE94DDD6B36FCCBDBB1A74A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">State taxes</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_C363BC7FBCE94DDD6B36FCCBDBB1A74A_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_C363BC7FBCE94DDD6B36FCCBDBB1A74A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_C363BC7FBCE94DDD6B36FCCBDBB1A74A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_C363BC7FBCE94DDD6B36FCCBDBB1A74A" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_C363BC7FBCE94DDD6B36FCCBDBB1A74A" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_BEE896DA696F9EA4DA72FCCBDBB1C75C_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_BEE896DA696F9EA4DA72FCCBDBB1C75C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Taxes on foreign earnings</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_BEE896DA696F9EA4DA72FCCBDBB1C75C_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_BEE896DA696F9EA4DA72FCCBDBB1C75C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_BEE896DA696F9EA4DA72FCCBDBB1C75C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_BEE896DA696F9EA4DA72FCCBDBB1C75C" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_BEE896DA696F9EA4DA72FCCBDBB1C75C" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_BB4E62F1443136934D4BFCCBDBB131E1_negatedLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_BB4E62F1443136934D4BFCCBDBB131E1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Credits and net operating loss utilization</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_BB4E62F1443136934D4BFCCBDBB131E1_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_BB4E62F1443136934D4BFCCBDBB131E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_BB4E62F1443136934D4BFCCBDBB131E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_BB4E62F1443136934D4BFCCBDBB131E1" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_BB4E62F1443136934D4BFCCBDBB131E1" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_CCFEF370E37CD7EB9A8EFCCBDBB10FB3_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_CCFEF370E37CD7EB9A8EFCCBDBB10FB3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Purchased intangible assets</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_CCFEF370E37CD7EB9A8EFCCBDBB10FB3_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_CCFEF370E37CD7EB9A8EFCCBDBB10FB3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Depreciation and Amortization, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_CCFEF370E37CD7EB9A8EFCCBDBB10FB3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_CCFEF370E37CD7EB9A8EFCCBDBB10FB3" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_CCFEF370E37CD7EB9A8EFCCBDBB10FB3" xlink:type="arc" />
    <link:label id="lab_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_F689E5F4ED03AB68A094FCCBDBB1C033_terseLabel_en-US" xlink:label="lab_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_F689E5F4ED03AB68A094FCCBDBB1C033" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Manufacturing deduction</link:label>
    <link:label id="lab_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_F689E5F4ED03AB68A094FCCBDBB1C033_label_en-US" xlink:label="lab_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_F689E5F4ED03AB68A094FCCBDBB1C033" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective income tax rate reconciliation manufacturing deduction</link:label>
    <link:label id="lab_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_F689E5F4ED03AB68A094FCCBDBB1C033_documentation_en-US" xlink:label="lab_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_F689E5F4ED03AB68A094FCCBDBB1C033" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective income tax rate reconciliation manufacturing deduction</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction" xlink:label="loc_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_F689E5F4ED03AB68A094FCCBDBB1C033" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_F689E5F4ED03AB68A094FCCBDBB1C033" xlink:to="lab_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_F689E5F4ED03AB68A094FCCBDBB1C033" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_443C4121CE014887BEC2FCCBDBB1AC0E_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_443C4121CE014887BEC2FCCBDBB1AC0E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Permanent items</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_443C4121CE014887BEC2FCCBDBB1AC0E_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_443C4121CE014887BEC2FCCBDBB1AC0E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_443C4121CE014887BEC2FCCBDBB1AC0E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_443C4121CE014887BEC2FCCBDBB1AC0E" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_443C4121CE014887BEC2FCCBDBB1AC0E" xlink:type="arc" />
    <link:label id="lab_biib_EffectiveIncomeTaxRateReconciliationContingentConsideration_D830CC20EA0B9986027AFCCBDBB1D409_verboseLabel_en-US" xlink:label="lab_biib_EffectiveIncomeTaxRateReconciliationContingentConsideration_D830CC20EA0B9986027AFCCBDBB1D409" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_biib_EffectiveIncomeTaxRateReconciliationContingentConsideration_D830CC20EA0B9986027AFCCBDBB1D409_label_en-US" xlink:label="lab_biib_EffectiveIncomeTaxRateReconciliationContingentConsideration_D830CC20EA0B9986027AFCCBDBB1D409" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation Contingent Consideration</link:label>
    <link:label id="lab_biib_EffectiveIncomeTaxRateReconciliationContingentConsideration_D830CC20EA0B9986027AFCCBDBB1D409_documentation_en-US" xlink:label="lab_biib_EffectiveIncomeTaxRateReconciliationContingentConsideration_D830CC20EA0B9986027AFCCBDBB1D409" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective income tax rate reconciliation contingent consideration.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_EffectiveIncomeTaxRateReconciliationContingentConsideration" xlink:label="loc_biib_EffectiveIncomeTaxRateReconciliationContingentConsideration_D830CC20EA0B9986027AFCCBDBB1D409" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EffectiveIncomeTaxRateReconciliationContingentConsideration_D830CC20EA0B9986027AFCCBDBB1D409" xlink:to="lab_biib_EffectiveIncomeTaxRateReconciliationContingentConsideration_D830CC20EA0B9986027AFCCBDBB1D409" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1B6847EE7F34AD39A0ADFCCBDBB1C3F0_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1B6847EE7F34AD39A0ADFCCBDBB1C3F0" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1B6847EE7F34AD39A0ADFCCBDBB1C3F0_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1B6847EE7F34AD39A0ADFCCBDBB1C3F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1B6847EE7F34AD39A0ADFCCBDBB1C3F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1B6847EE7F34AD39A0ADFCCBDBB1C3F0" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1B6847EE7F34AD39A0ADFCCBDBB1C3F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_2824576FE30FF765D7E274128580453B_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_2824576FE30FF765D7E274128580453B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenue by product</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_2824576FE30FF765D7E274128580453B_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_2824576FE30FF765D7E274128580453B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from External Customers by Products and Services [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_2824576FE30FF765D7E274128580453B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_2824576FE30FF765D7E274128580453B" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_2824576FE30FF765D7E274128580453B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_79934338A91A46E766C17412858125F5_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_79934338A91A46E766C17412858125F5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Geographic information</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_79934338A91A46E766C17412858125F5_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_79934338A91A46E766C17412858125F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:label="loc_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_79934338A91A46E766C17412858125F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_79934338A91A46E766C17412858125F5" xlink:to="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_79934338A91A46E766C17412858125F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_7912E4FF9ADB36C54777741285DE0A6B_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_7912E4FF9ADB36C54777741285DE0A6B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of financial assets with maturities of less than 90 days included within cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_7912E4FF9ADB36C54777741285DE0A6B_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_7912E4FF9ADB36C54777741285DE0A6B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_7912E4FF9ADB36C54777741285DE0A6B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_7912E4FF9ADB36C54777741285DE0A6B" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_7912E4FF9ADB36C54777741285DE0A6B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_A68A284FAE15909FA237741285DE9D01_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_A68A284FAE15909FA237741285DE9D01" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities including strategic investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_A68A284FAE15909FA237741285DE9D01_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_A68A284FAE15909FA237741285DE9D01" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_A68A284FAE15909FA237741285DE9D01" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_A68A284FAE15909FA237741285DE9D01" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_A68A284FAE15909FA237741285DE9D01" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_44308A501203545369B5741285DE88A0_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_44308A501203545369B5741285DE88A0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of contractual maturities: Available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_44308A501203545369B5741285DE88A0_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_44308A501203545369B5741285DE88A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_44308A501203545369B5741285DE88A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_44308A501203545369B5741285DE88A0" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_44308A501203545369B5741285DE88A0" xlink:type="arc" />
    <link:label id="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_DAA6813D3BA140507BBC741285DE1217_verboseLabel_en-US" xlink:label="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_DAA6813D3BA140507BBC741285DE1217" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from marketable securities, excluding strategic investments</link:label>
    <link:label id="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_DAA6813D3BA140507BBC741285DE1217_label_en-US" xlink:label="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_DAA6813D3BA140507BBC741285DE1217" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Realized Gain (Loss) on Investments [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RealizedGainLossOnInvestmentsTableTextBlock" xlink:label="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_DAA6813D3BA140507BBC741285DE1217" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_DAA6813D3BA140507BBC741285DE1217" xlink:to="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_DAA6813D3BA140507BBC741285DE1217" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_7B672CBCA8F28885979C741288362640_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_7B672CBCA8F28885979C741288362640" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency forward contracts that were entered into to hedge forecasted revenue</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_7B672CBCA8F28885979C741288362640_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_7B672CBCA8F28885979C741288362640" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_7B672CBCA8F28885979C741288362640" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_7B672CBCA8F28885979C741288362640" xlink:to="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_7B672CBCA8F28885979C741288362640" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_655EA3463ADB73E0289474128836F1BF_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_655EA3463ADB73E0289474128836F1BF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of the effect of derivatives designated as hedging instruments on our consolidated statements of income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_655EA3463ADB73E0289474128836F1BF_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_655EA3463ADB73E0289474128836F1BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_655EA3463ADB73E0289474128836F1BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_655EA3463ADB73E0289474128836F1BF" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_655EA3463ADB73E0289474128836F1BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_718BDE7B59B1007EF1F0741288372165_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_718BDE7B59B1007EF1F0741288372165" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of the fair value for our outstanding derivatives</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_718BDE7B59B1007EF1F0741288372165_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_718BDE7B59B1007EF1F0741288372165" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_718BDE7B59B1007EF1F0741288372165" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_718BDE7B59B1007EF1F0741288372165" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_718BDE7B59B1007EF1F0741288372165" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_4342839C9E9EB11919FDFB6C3A853624_verboseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance_4342839C9E9EB11919FDFB6C3A853624" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenue-related reserves for discounts and allowances</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_4342839C9E9EB11919FDFB6C3A853624" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance_4342839C9E9EB11919FDFB6C3A853624" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance_4342839C9E9EB11919FDFB6C3A853624" xlink:type="arc" />
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_401A5A7A0772D376535AFB6C3A85D57F_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_401A5A7A0772D376535AFB6C3A85D57F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash Paid During the Year</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_401A5A7A0772D376535AFB6C3A85D57F_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_401A5A7A0772D376535AFB6C3A85D57F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_401A5A7A0772D376535AFB6C3A85D57F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_401A5A7A0772D376535AFB6C3A85D57F" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract_401A5A7A0772D376535AFB6C3A85D57F" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestPaidNet_40B5B122F87E1F10FF32FB6C3A85BBD5_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet_40B5B122F87E1F10FF32FB6C3A85BBD5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_40B5B122F87E1F10FF32FB6C3A85BBD5_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet_40B5B122F87E1F10FF32FB6C3A85BBD5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_40B5B122F87E1F10FF32FB6C3A85BBD5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet_40B5B122F87E1F10FF32FB6C3A85BBD5" xlink:to="lab_us-gaap_InterestPaidNet_40B5B122F87E1F10FF32FB6C3A85BBD5" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_619DE04A88276891C555FB6C3A85111D_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet_619DE04A88276891C555FB6C3A85111D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_619DE04A88276891C555FB6C3A85111D_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet_619DE04A88276891C555FB6C3A85111D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_619DE04A88276891C555FB6C3A85111D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet_619DE04A88276891C555FB6C3A85111D" xlink:to="lab_us-gaap_IncomeTaxesPaidNet_619DE04A88276891C555FB6C3A85111D" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract_B2D7A1719DDC0DC86B2AFB6C3A85F734_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract_B2D7A1719DDC0DC86B2AFB6C3A85F734" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_B2D7A1719DDC0DC86B2AFB6C3A85F734" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_B2D7A1719DDC0DC86B2AFB6C3A85F734" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract_B2D7A1719DDC0DC86B2AFB6C3A85F734" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_4830AFF7636950969FCBFB6C3A8500AE_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest_4830AFF7636950969FCBFB6C3A8500AE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_4830AFF7636950969FCBFB6C3A8500AE_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest_4830AFF7636950969FCBFB6C3A8500AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_4830AFF7636950969FCBFB6C3A8500AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest_4830AFF7636950969FCBFB6C3A8500AE" xlink:to="lab_us-gaap_InvestmentIncomeInterest_4830AFF7636950969FCBFB6C3A8500AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestExpense_61DA2F09D53281FDC87AFB6C3A862B6D_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense_61DA2F09D53281FDC87AFB6C3A862B6D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_61DA2F09D53281FDC87AFB6C3A862B6D_label_en-US" xlink:label="lab_us-gaap_InterestExpense_61DA2F09D53281FDC87AFB6C3A862B6D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_61DA2F09D53281FDC87AFB6C3A862B6D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense_61DA2F09D53281FDC87AFB6C3A862B6D" xlink:to="lab_us-gaap_InterestExpense_61DA2F09D53281FDC87AFB6C3A862B6D" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainLossOnSaleOfInvestments_990B6444814F3DE87296FB6C3A86A56F_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfInvestments_990B6444814F3DE87296FB6C3A86A56F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain (loss) on investments, net</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfInvestments_990B6444814F3DE87296FB6C3A86A56F_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfInvestments_990B6444814F3DE87296FB6C3A86A56F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Sale of Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnSaleOfInvestments" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments_990B6444814F3DE87296FB6C3A86A56F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfInvestments_990B6444814F3DE87296FB6C3A86A56F" xlink:to="lab_us-gaap_GainLossOnSaleOfInvestments_990B6444814F3DE87296FB6C3A86A56F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_A89D6F73061AC9B88A47FB6C3A8600AE_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_A89D6F73061AC9B88A47FB6C3A8600AE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign exchange gains (losses), net</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_A89D6F73061AC9B88A47FB6C3A8600AE_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_A89D6F73061AC9B88A47FB6C3A8600AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_A89D6F73061AC9B88A47FB6C3A8600AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_A89D6F73061AC9B88A47FB6C3A8600AE" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_A89D6F73061AC9B88A47FB6C3A8600AE" xlink:type="arc" />
    <link:label id="lab_biib_OtherIncomeExpenseNet_01AC010B6F8DD062F390FB6C3A868CAB_terseLabel_en-US" xlink:label="lab_biib_OtherIncomeExpenseNet_01AC010B6F8DD062F390FB6C3A868CAB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_biib_OtherIncomeExpenseNet_01AC010B6F8DD062F390FB6C3A868CAB_label_en-US" xlink:label="lab_biib_OtherIncomeExpenseNet_01AC010B6F8DD062F390FB6C3A868CAB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Income Expense Net</link:label>
    <link:label id="lab_biib_OtherIncomeExpenseNet_01AC010B6F8DD062F390FB6C3A868CAB_documentation_en-US" xlink:label="lab_biib_OtherIncomeExpenseNet_01AC010B6F8DD062F390FB6C3A868CAB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of other nonoperating income and expense, which does not qualify for separate disclosure on the income statement.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_OtherIncomeExpenseNet" xlink:label="loc_biib_OtherIncomeExpenseNet_01AC010B6F8DD062F390FB6C3A868CAB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OtherIncomeExpenseNet_01AC010B6F8DD062F390FB6C3A868CAB" xlink:to="lab_biib_OtherIncomeExpenseNet_01AC010B6F8DD062F390FB6C3A868CAB" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_32D3E7B0194FA8F2B604FB6C3A86B24F_totalLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_32D3E7B0194FA8F2B604FB6C3A86B24F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other income (expense), net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_32D3E7B0194FA8F2B604FB6C3A86B24F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_32D3E7B0194FA8F2B604FB6C3A86B24F" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense_32D3E7B0194FA8F2B604FB6C3A86B24F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_65965AD395E0BFE79CD4FB6C3A865D83_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_65965AD395E0BFE79CD4FB6C3A865D83" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_65965AD395E0BFE79CD4FB6C3A865D83" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_65965AD395E0BFE79CD4FB6C3A865D83" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_65965AD395E0BFE79CD4FB6C3A865D83" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_35C5BDE1D363DDF837C7FB6C3A86F383_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_35C5BDE1D363DDF837C7FB6C3A86F383" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current portion of contingent consideration obligations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_35C5BDE1D363DDF837C7FB6C3A86F383_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_35C5BDE1D363DDF837C7FB6C3A86F383" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_35C5BDE1D363DDF837C7FB6C3A86F383" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_35C5BDE1D363DDF837C7FB6C3A86F383" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_35C5BDE1D363DDF837C7FB6C3A86F383" xlink:type="arc" />
    <link:label id="lab_us-gaap_LitigationReserve_C095AB38E5F7A2E6F241FB6C3A86750E_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationReserve_C095AB38E5F7A2E6F241FB6C3A86750E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued TECFIDERA litigation settlement and license charges</link:label>
    <link:label id="lab_us-gaap_LitigationReserve_C095AB38E5F7A2E6F241FB6C3A86750E_label_en-US" xlink:label="lab_us-gaap_LitigationReserve_C095AB38E5F7A2E6F241FB6C3A86750E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated Litigation Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationReserve" xlink:label="loc_us-gaap_LitigationReserve_C095AB38E5F7A2E6F241FB6C3A86750E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationReserve_C095AB38E5F7A2E6F241FB6C3A86750E" xlink:to="lab_us-gaap_LitigationReserve_C095AB38E5F7A2E6F241FB6C3A86750E" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_2D60653B7294B1261D94FB6C3A86FDCB_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_2D60653B7294B1261D94FB6C3A86FDCB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Employee compensation and benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_2D60653B7294B1261D94FB6C3A86FDCB_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_2D60653B7294B1261D94FB6C3A86FDCB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_2D60653B7294B1261D94FB6C3A86FDCB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_2D60653B7294B1261D94FB6C3A86FDCB" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_2D60653B7294B1261D94FB6C3A86FDCB" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_4374CE5FB5DDEA44FA79FB6C3A86ED55_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent_4374CE5FB5DDEA44FA79FB6C3A86ED55" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Royalties and licensing fees</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_4374CE5FB5DDEA44FA79FB6C3A86ED55_label_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent_4374CE5FB5DDEA44FA79FB6C3A86ED55" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Royalties, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_4374CE5FB5DDEA44FA79FB6C3A86ED55" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrent_4374CE5FB5DDEA44FA79FB6C3A86ED55" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrent_4374CE5FB5DDEA44FA79FB6C3A86ED55" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConstructionPayableCurrentAndNoncurrent_02746E28D90BFFFB8120FB6C3A86AA61_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionPayableCurrentAndNoncurrent_02746E28D90BFFFB8120FB6C3A86AA61" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionPayableCurrentAndNoncurrent_02746E28D90BFFFB8120FB6C3A86AA61_label_en-US" xlink:label="lab_us-gaap_ConstructionPayableCurrentAndNoncurrent_02746E28D90BFFFB8120FB6C3A86AA61" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConstructionPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent_02746E28D90BFFFB8120FB6C3A86AA61" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent_02746E28D90BFFFB8120FB6C3A86AA61" xlink:to="lab_us-gaap_ConstructionPayableCurrentAndNoncurrent_02746E28D90BFFFB8120FB6C3A86AA61" xlink:type="arc" />
    <link:label id="lab_biib_Collaborationexpensesaccrual_E5A3341D74D9E65A64DCFBC387FDF5F8_terseLabel_en-US" xlink:label="lab_biib_Collaborationexpensesaccrual_E5A3341D74D9E65A64DCFBC387FDF5F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration expenses</link:label>
    <link:label id="lab_biib_Collaborationexpensesaccrual_E5A3341D74D9E65A64DCFBC387FDF5F8_label_en-US" xlink:label="lab_biib_Collaborationexpensesaccrual_E5A3341D74D9E65A64DCFBC387FDF5F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration expenses accrual</link:label>
    <link:label id="lab_biib_Collaborationexpensesaccrual_E5A3341D74D9E65A64DCFBC387FDF5F8_documentation_en-US" xlink:label="lab_biib_Collaborationexpensesaccrual_E5A3341D74D9E65A64DCFBC387FDF5F8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration expenses accrual</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_Collaborationexpensesaccrual" xlink:label="loc_biib_Collaborationexpensesaccrual_E5A3341D74D9E65A64DCFBC387FDF5F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Collaborationexpensesaccrual_E5A3341D74D9E65A64DCFBC387FDF5F8" xlink:to="lab_biib_Collaborationexpensesaccrual_E5A3341D74D9E65A64DCFBC387FDF5F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_7F9DB389DB03A2A40D20FB6C3A873723_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_7F9DB389DB03A2A40D20FB6C3A873723" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_7F9DB389DB03A2A40D20FB6C3A873723_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_7F9DB389DB03A2A40D20FB6C3A873723" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_7F9DB389DB03A2A40D20FB6C3A873723" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent_7F9DB389DB03A2A40D20FB6C3A873723" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent_7F9DB389DB03A2A40D20FB6C3A873723" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_B2E02A1EA03CF1B90BC1FB6C3A873A6B_totalLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_B2E02A1EA03CF1B90BC1FB6C3A873A6B" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_B2E02A1EA03CF1B90BC1FB6C3A873A6B_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_B2E02A1EA03CF1B90BC1FB6C3A873A6B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_B2E02A1EA03CF1B90BC1FB6C3A873A6B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_B2E02A1EA03CF1B90BC1FB6C3A873A6B" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent_B2E02A1EA03CF1B90BC1FB6C3A873A6B" xlink:type="arc" />
    <link:label id="lab_biib_SummaryOfCommonStockTableTextBlock_A7C3745096884837CFBF7412882FBEB7_terseLabel_en-US" xlink:label="lab_biib_SummaryOfCommonStockTableTextBlock_A7C3745096884837CFBF7412882FBEB7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of common stock</link:label>
    <link:label id="lab_biib_SummaryOfCommonStockTableTextBlock_A7C3745096884837CFBF7412882FBEB7_label_en-US" xlink:label="lab_biib_SummaryOfCommonStockTableTextBlock_A7C3745096884837CFBF7412882FBEB7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary Of Common Stock [Table Text Block]</link:label>
    <link:label id="lab_biib_SummaryOfCommonStockTableTextBlock_A7C3745096884837CFBF7412882FBEB7_documentation_en-US" xlink:label="lab_biib_SummaryOfCommonStockTableTextBlock_A7C3745096884837CFBF7412882FBEB7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary of common stock.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_SummaryOfCommonStockTableTextBlock" xlink:label="loc_biib_SummaryOfCommonStockTableTextBlock_A7C3745096884837CFBF7412882FBEB7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryOfCommonStockTableTextBlock_A7C3745096884837CFBF7412882FBEB7" xlink:to="lab_biib_SummaryOfCommonStockTableTextBlock_A7C3745096884837CFBF7412882FBEB7" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_A7DF48A8C4E0E99F7BE674128598937F_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_A7DF48A8C4E0E99F7BE674128598937F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_A7DF48A8C4E0E99F7BE674128598937F_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_A7DF48A8C4E0E99F7BE674128598937F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_A7DF48A8C4E0E99F7BE674128598937F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_A7DF48A8C4E0E99F7BE674128598937F" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_A7DF48A8C4E0E99F7BE674128598937F" xlink:type="arc" />
    <link:label id="lab_us-gaap_VestingAxis_13FC1BD3227FED52E914FB6C3ABCE306_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis_13FC1BD3227FED52E914FB6C3ABCE306" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_13FC1BD3227FED52E914FB6C3ABCE306_label_en-US" xlink:label="lab_us-gaap_VestingAxis_13FC1BD3227FED52E914FB6C3ABCE306" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_13FC1BD3227FED52E914FB6C3ABCE306" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis_13FC1BD3227FED52E914FB6C3ABCE306" xlink:to="lab_us-gaap_VestingAxis_13FC1BD3227FED52E914FB6C3ABCE306" xlink:type="arc" />
    <link:label id="lab_us-gaap_VestingDomain_320AE8B6E933D76CE29EFB6C3ABC7229_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain_320AE8B6E933D76CE29EFB6C3ABC7229" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_320AE8B6E933D76CE29EFB6C3ABC7229_label_en-US" xlink:label="lab_us-gaap_VestingDomain_320AE8B6E933D76CE29EFB6C3ABC7229" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_320AE8B6E933D76CE29EFB6C3ABC7229" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain_320AE8B6E933D76CE29EFB6C3ABC7229" xlink:to="lab_us-gaap_VestingDomain_320AE8B6E933D76CE29EFB6C3ABC7229" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_DBD87A2CFE74972CED60FB6C3ABC17E3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_DBD87A2CFE74972CED60FB6C3ABC17E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Settlement of PUs</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_DBD87A2CFE74972CED60FB6C3ABC17E3_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_DBD87A2CFE74972CED60FB6C3ABC17E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Award, Tranche One [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_DBD87A2CFE74972CED60FB6C3ABC17E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_DBD87A2CFE74972CED60FB6C3ABC17E3" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_DBD87A2CFE74972CED60FB6C3ABC17E3" xlink:type="arc" />
    <link:label id="lab_us-gaap_TitleOfIndividualAxis_6877531E0B7D765B3954FB6C3ABC65D1_terseLabel_en-US" xlink:label="lab_us-gaap_TitleOfIndividualAxis_6877531E0B7D765B3954FB6C3ABC65D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_us-gaap_TitleOfIndividualAxis_6877531E0B7D765B3954FB6C3ABC65D1_label_en-US" xlink:label="lab_us-gaap_TitleOfIndividualAxis_6877531E0B7D765B3954FB6C3ABC65D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_6877531E0B7D765B3954FB6C3ABC65D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TitleOfIndividualAxis_6877531E0B7D765B3954FB6C3ABC65D1" xlink:to="lab_us-gaap_TitleOfIndividualAxis_6877531E0B7D765B3954FB6C3ABC65D1" xlink:type="arc" />
    <link:label id="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_172857DB172052692648FB6C3ABCF04B_terseLabel_en-US" xlink:label="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_172857DB172052692648FB6C3ABCF04B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Relationship to Entity [Domain]</link:label>
    <link:label id="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_172857DB172052692648FB6C3ABCF04B_label_en-US" xlink:label="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_172857DB172052692648FB6C3ABCF04B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Relationship to Entity [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_172857DB172052692648FB6C3ABCF04B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_172857DB172052692648FB6C3ABCF04B" xlink:to="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_172857DB172052692648FB6C3ABCF04B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DirectorMember_54D488B4764A8620FB33FB6C3ABCB917_terseLabel_en-US" xlink:label="lab_us-gaap_DirectorMember_54D488B4764A8620FB33FB6C3ABCB917" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Director</link:label>
    <link:label id="lab_us-gaap_DirectorMember_54D488B4764A8620FB33FB6C3ABCB917_label_en-US" xlink:label="lab_us-gaap_DirectorMember_54D488B4764A8620FB33FB6C3ABCB917" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DirectorMember" xlink:label="loc_us-gaap_DirectorMember_54D488B4764A8620FB33FB6C3ABCB917" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DirectorMember_54D488B4764A8620FB33FB6C3ABCB917" xlink:to="lab_us-gaap_DirectorMember_54D488B4764A8620FB33FB6C3ABCB917" xlink:type="arc" />
    <link:label id="lab_biib_ShareBasedCompensationPlanAxis_693C1B162F6843BB9BF4FB6C3ABC9981_terseLabel_en-US" xlink:label="lab_biib_ShareBasedCompensationPlanAxis_693C1B162F6843BB9BF4FB6C3ABC9981" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Based Compensation Plan [Axis]</link:label>
    <link:label id="lab_biib_ShareBasedCompensationPlanAxis_693C1B162F6843BB9BF4FB6C3ABC9981_label_en-US" xlink:label="lab_biib_ShareBasedCompensationPlanAxis_693C1B162F6843BB9BF4FB6C3ABC9981" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Plan [Axis]</link:label>
    <link:label id="lab_biib_ShareBasedCompensationPlanAxis_693C1B162F6843BB9BF4FB6C3ABC9981_documentation_en-US" xlink:label="lab_biib_ShareBasedCompensationPlanAxis_693C1B162F6843BB9BF4FB6C3ABC9981" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share based compensation plan.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_ShareBasedCompensationPlanAxis" xlink:label="loc_biib_ShareBasedCompensationPlanAxis_693C1B162F6843BB9BF4FB6C3ABC9981" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ShareBasedCompensationPlanAxis_693C1B162F6843BB9BF4FB6C3ABC9981" xlink:to="lab_biib_ShareBasedCompensationPlanAxis_693C1B162F6843BB9BF4FB6C3ABC9981" xlink:type="arc" />
    <link:label id="lab_biib_ShareBasedCompensationPlanDomain_0661520A83D58ADD79EDFB6C3ABDA209_terseLabel_en-US" xlink:label="lab_biib_ShareBasedCompensationPlanDomain_0661520A83D58ADD79EDFB6C3ABDA209" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Based Compensation Plan [Domain]</link:label>
    <link:label id="lab_biib_ShareBasedCompensationPlanDomain_0661520A83D58ADD79EDFB6C3ABDA209_label_en-US" xlink:label="lab_biib_ShareBasedCompensationPlanDomain_0661520A83D58ADD79EDFB6C3ABDA209" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Plan [Domain]</link:label>
    <link:label id="lab_biib_ShareBasedCompensationPlanDomain_0661520A83D58ADD79EDFB6C3ABDA209_documentation_en-US" xlink:label="lab_biib_ShareBasedCompensationPlanDomain_0661520A83D58ADD79EDFB6C3ABDA209" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share based compensation plan.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_ShareBasedCompensationPlanDomain" xlink:label="loc_biib_ShareBasedCompensationPlanDomain_0661520A83D58ADD79EDFB6C3ABDA209" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ShareBasedCompensationPlanDomain_0661520A83D58ADD79EDFB6C3ABDA209" xlink:to="lab_biib_ShareBasedCompensationPlanDomain_0661520A83D58ADD79EDFB6C3ABDA209" xlink:type="arc" />
    <link:label id="lab_biib_DirectorsPlanMember_9FA25E1B95FAB2302BBDFB6C3ABDBF74_verboseLabel_en-US" xlink:label="lab_biib_DirectorsPlanMember_9FA25E1B95FAB2302BBDFB6C3ABDBF74" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Directors Plan</link:label>
    <link:label id="lab_biib_DirectorsPlanMember_9FA25E1B95FAB2302BBDFB6C3ABDBF74_label_en-US" xlink:label="lab_biib_DirectorsPlanMember_9FA25E1B95FAB2302BBDFB6C3ABDBF74" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Directors Plan [Member]</link:label>
    <link:label id="lab_biib_DirectorsPlanMember_9FA25E1B95FAB2302BBDFB6C3ABDBF74_documentation_en-US" xlink:label="lab_biib_DirectorsPlanMember_9FA25E1B95FAB2302BBDFB6C3ABDBF74" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Directors plan.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_DirectorsPlanMember" xlink:label="loc_biib_DirectorsPlanMember_9FA25E1B95FAB2302BBDFB6C3ABDBF74" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DirectorsPlanMember_9FA25E1B95FAB2302BBDFB6C3ABDBF74" xlink:to="lab_biib_DirectorsPlanMember_9FA25E1B95FAB2302BBDFB6C3ABDBF74" xlink:type="arc" />
    <link:label id="lab_biib_OmnibusPlansMember_A7FF3A038E92A3ACB5A9FB6C3ABD2724_terseLabel_en-US" xlink:label="lab_biib_OmnibusPlansMember_A7FF3A038E92A3ACB5A9FB6C3ABD2724" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Omnibus Plans</link:label>
    <link:label id="lab_biib_OmnibusPlansMember_A7FF3A038E92A3ACB5A9FB6C3ABD2724_label_en-US" xlink:label="lab_biib_OmnibusPlansMember_A7FF3A038E92A3ACB5A9FB6C3ABD2724" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Omnibus Plans [Member]</link:label>
    <link:label id="lab_biib_OmnibusPlansMember_A7FF3A038E92A3ACB5A9FB6C3ABD2724_documentation_en-US" xlink:label="lab_biib_OmnibusPlansMember_A7FF3A038E92A3ACB5A9FB6C3ABD2724" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Omnibus plans.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_OmnibusPlansMember" xlink:label="loc_biib_OmnibusPlansMember_A7FF3A038E92A3ACB5A9FB6C3ABD2724" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OmnibusPlansMember_A7FF3A038E92A3ACB5A9FB6C3ABD2724" xlink:to="lab_biib_OmnibusPlansMember_A7FF3A038E92A3ACB5A9FB6C3ABD2724" xlink:type="arc" />
    <link:label id="lab_biib_AttainmentOfPerformanceCriteriain2013Member_EBF663E1E30148C70E48FB6C3ABDE2E3_terseLabel_en-US" xlink:label="lab_biib_AttainmentOfPerformanceCriteriain2013Member_EBF663E1E30148C70E48FB6C3ABDE2E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Attainment Of Performance Criteria in 2013</link:label>
    <link:label id="lab_biib_AttainmentOfPerformanceCriteriain2013Member_EBF663E1E30148C70E48FB6C3ABDE2E3_label_en-US" xlink:label="lab_biib_AttainmentOfPerformanceCriteriain2013Member_EBF663E1E30148C70E48FB6C3ABDE2E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Attainment Of Performance Criteria in 2013 [Member]</link:label>
    <link:label id="lab_biib_AttainmentOfPerformanceCriteriain2013Member_EBF663E1E30148C70E48FB6C3ABDE2E3_documentation_en-US" xlink:label="lab_biib_AttainmentOfPerformanceCriteriain2013Member_EBF663E1E30148C70E48FB6C3ABDE2E3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Attainment Of Performance Criteria in 2013</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_AttainmentOfPerformanceCriteriain2013Member" xlink:label="loc_biib_AttainmentOfPerformanceCriteriain2013Member_EBF663E1E30148C70E48FB6C3ABDE2E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AttainmentOfPerformanceCriteriain2013Member_EBF663E1E30148C70E48FB6C3ABDE2E3" xlink:to="lab_biib_AttainmentOfPerformanceCriteriain2013Member_EBF663E1E30148C70E48FB6C3ABDE2E3" xlink:type="arc" />
    <link:label id="lab_biib_AttainmentOfPerformanceCriteriain2012Member_FE978AD1E2853A5EC6AEFB6C3ABD3F2C_terseLabel_en-US" xlink:label="lab_biib_AttainmentOfPerformanceCriteriain2012Member_FE978AD1E2853A5EC6AEFB6C3ABD3F2C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Attainment Of Performance Criteria in 2012</link:label>
    <link:label id="lab_biib_AttainmentOfPerformanceCriteriain2012Member_FE978AD1E2853A5EC6AEFB6C3ABD3F2C_label_en-US" xlink:label="lab_biib_AttainmentOfPerformanceCriteriain2012Member_FE978AD1E2853A5EC6AEFB6C3ABD3F2C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Attainment Of Performance Criteria in 2012 [Member]</link:label>
    <link:label id="lab_biib_AttainmentOfPerformanceCriteriain2012Member_FE978AD1E2853A5EC6AEFB6C3ABD3F2C_documentation_en-US" xlink:label="lab_biib_AttainmentOfPerformanceCriteriain2012Member_FE978AD1E2853A5EC6AEFB6C3ABD3F2C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Attainment Of Performance Criteria in 2012 [Member]</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_AttainmentOfPerformanceCriteriain2012Member" xlink:label="loc_biib_AttainmentOfPerformanceCriteriain2012Member_FE978AD1E2853A5EC6AEFB6C3ABD3F2C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AttainmentOfPerformanceCriteriain2012Member_FE978AD1E2853A5EC6AEFB6C3ABD3F2C" xlink:to="lab_biib_AttainmentOfPerformanceCriteriain2012Member_FE978AD1E2853A5EC6AEFB6C3ABD3F2C" xlink:type="arc" />
    <link:label id="lab_biib_MarketStockUnitsMember_01DB996B3E072ECC5EC4FB6C3ABE5FF0_verboseLabel_en-US" xlink:label="lab_biib_MarketStockUnitsMember_01DB996B3E072ECC5EC4FB6C3ABE5FF0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Market stock units</link:label>
    <link:label id="lab_biib_MarketStockUnitsMember_01DB996B3E072ECC5EC4FB6C3ABE5FF0_label_en-US" xlink:label="lab_biib_MarketStockUnitsMember_01DB996B3E072ECC5EC4FB6C3ABE5FF0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Market Stock Units [Member]</link:label>
    <link:label id="lab_biib_MarketStockUnitsMember_01DB996B3E072ECC5EC4FB6C3ABE5FF0_documentation_en-US" xlink:label="lab_biib_MarketStockUnitsMember_01DB996B3E072ECC5EC4FB6C3ABE5FF0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Market stock units.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_01DB996B3E072ECC5EC4FB6C3ABE5FF0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MarketStockUnitsMember_01DB996B3E072ECC5EC4FB6C3ABE5FF0" xlink:to="lab_biib_MarketStockUnitsMember_01DB996B3E072ECC5EC4FB6C3ABE5FF0" xlink:type="arc" />
    <link:label id="lab_biib_CashSettledPerformanceSharesMember_5788B0B8E876590EF60FFB6C3ABEDDF0_terseLabel_en-US" xlink:label="lab_biib_CashSettledPerformanceSharesMember_5788B0B8E876590EF60FFB6C3ABEDDF0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash settled performance units</link:label>
    <link:label id="lab_biib_CashSettledPerformanceSharesMember_5788B0B8E876590EF60FFB6C3ABEDDF0_label_en-US" xlink:label="lab_biib_CashSettledPerformanceSharesMember_5788B0B8E876590EF60FFB6C3ABEDDF0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash settled performance shares [Member]</link:label>
    <link:label id="lab_biib_CashSettledPerformanceSharesMember_5788B0B8E876590EF60FFB6C3ABEDDF0_documentation_en-US" xlink:label="lab_biib_CashSettledPerformanceSharesMember_5788B0B8E876590EF60FFB6C3ABEDDF0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash settled performance shares [Member]</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_CashSettledPerformanceSharesMember" xlink:label="loc_biib_CashSettledPerformanceSharesMember_5788B0B8E876590EF60FFB6C3ABEDDF0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CashSettledPerformanceSharesMember_5788B0B8E876590EF60FFB6C3ABEDDF0" xlink:to="lab_biib_CashSettledPerformanceSharesMember_5788B0B8E876590EF60FFB6C3ABEDDF0" xlink:type="arc" />
    <link:label id="lab_us-gaap_PerformanceSharesMember_BE37102DA20E931910BFFB6C3ABE955C_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember_BE37102DA20E931910BFFB6C3ABE955C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance units</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_BE37102DA20E931910BFFB6C3ABE955C_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember_BE37102DA20E931910BFFB6C3ABE955C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_BE37102DA20E931910BFFB6C3ABE955C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember_BE37102DA20E931910BFFB6C3ABE955C" xlink:to="lab_us-gaap_PerformanceSharesMember_BE37102DA20E931910BFFB6C3ABE955C" xlink:type="arc" />
    <link:label id="lab_biib_NumberOfSharesOfCommonStockForIssuance_9385B2452E59EC90DA0EFB6C3ABE9279_verboseLabel_en-US" xlink:label="lab_biib_NumberOfSharesOfCommonStockForIssuance_9385B2452E59EC90DA0EFB6C3ABE9279" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total number of shares of common stock for issuance</link:label>
    <link:label id="lab_biib_NumberOfSharesOfCommonStockForIssuance_9385B2452E59EC90DA0EFB6C3ABE9279_label_en-US" xlink:label="lab_biib_NumberOfSharesOfCommonStockForIssuance_9385B2452E59EC90DA0EFB6C3ABE9279" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Shares Of Common Stock For Issuance</link:label>
    <link:label id="lab_biib_NumberOfSharesOfCommonStockForIssuance_9385B2452E59EC90DA0EFB6C3ABE9279_documentation_en-US" xlink:label="lab_biib_NumberOfSharesOfCommonStockForIssuance_9385B2452E59EC90DA0EFB6C3ABE9279" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total number of shares of common stock for issuance.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_NumberOfSharesOfCommonStockForIssuance" xlink:label="loc_biib_NumberOfSharesOfCommonStockForIssuance_9385B2452E59EC90DA0EFB6C3ABE9279" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NumberOfSharesOfCommonStockForIssuance_9385B2452E59EC90DA0EFB6C3ABE9279" xlink:to="lab_biib_NumberOfSharesOfCommonStockForIssuance_9385B2452E59EC90DA0EFB6C3ABE9279" xlink:type="arc" />
    <link:label id="lab_biib_RatioOfNumberOfSharesReservedUnderPlan_EF9774C4143A5FC116B0FB6C3ABEBAD7_verboseLabel_en-US" xlink:label="lab_biib_RatioOfNumberOfSharesReservedUnderPlan_EF9774C4143A5FC116B0FB6C3ABEBAD7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Ratio of total number of shares reserved under the plan</link:label>
    <link:label id="lab_biib_RatioOfNumberOfSharesReservedUnderPlan_EF9774C4143A5FC116B0FB6C3ABEBAD7_label_en-US" xlink:label="lab_biib_RatioOfNumberOfSharesReservedUnderPlan_EF9774C4143A5FC116B0FB6C3ABEBAD7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ratio Of Number Of Shares Reserved Under Plan</link:label>
    <link:label id="lab_biib_RatioOfNumberOfSharesReservedUnderPlan_EF9774C4143A5FC116B0FB6C3ABEBAD7_documentation_en-US" xlink:label="lab_biib_RatioOfNumberOfSharesReservedUnderPlan_EF9774C4143A5FC116B0FB6C3ABEBAD7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ratio of total number of shares reserved under the plan.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_RatioOfNumberOfSharesReservedUnderPlan" xlink:label="loc_biib_RatioOfNumberOfSharesReservedUnderPlan_EF9774C4143A5FC116B0FB6C3ABEBAD7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RatioOfNumberOfSharesReservedUnderPlan_EF9774C4143A5FC116B0FB6C3ABEBAD7" xlink:to="lab_biib_RatioOfNumberOfSharesReservedUnderPlan_EF9774C4143A5FC116B0FB6C3ABEBAD7" xlink:type="arc" />
    <link:label id="lab_biib_NumberOfEqualAnnualIncrements_FED7351DD2CF1D71E8BBFB6C3ABE0AA3_verboseLabel_en-US" xlink:label="lab_biib_NumberOfEqualAnnualIncrements_FED7351DD2CF1D71E8BBFB6C3ABE0AA3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number of equal annual increments</link:label>
    <link:label id="lab_biib_NumberOfEqualAnnualIncrements_FED7351DD2CF1D71E8BBFB6C3ABE0AA3_label_en-US" xlink:label="lab_biib_NumberOfEqualAnnualIncrements_FED7351DD2CF1D71E8BBFB6C3ABE0AA3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Equal Annual Increments</link:label>
    <link:label id="lab_biib_NumberOfEqualAnnualIncrements_FED7351DD2CF1D71E8BBFB6C3ABE0AA3_documentation_en-US" xlink:label="lab_biib_NumberOfEqualAnnualIncrements_FED7351DD2CF1D71E8BBFB6C3ABE0AA3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of equal annual increments.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_NumberOfEqualAnnualIncrements" xlink:label="loc_biib_NumberOfEqualAnnualIncrements_FED7351DD2CF1D71E8BBFB6C3ABE0AA3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NumberOfEqualAnnualIncrements_FED7351DD2CF1D71E8BBFB6C3ABE0AA3" xlink:to="lab_biib_NumberOfEqualAnnualIncrements_FED7351DD2CF1D71E8BBFB6C3ABE0AA3" xlink:type="arc" />
    <link:label id="lab_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_93F1735E18862861C0D6FB6C3ABE4733_verboseLabel_en-US" xlink:label="lab_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_93F1735E18862861C0D6FB6C3ABE4733" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Percentage of earnings of the target number of units granted based on actual stock performance (Minimum)</link:label>
    <link:label id="lab_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_93F1735E18862861C0D6FB6C3ABE4733_label_en-US" xlink:label="lab_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_93F1735E18862861C0D6FB6C3ABE4733" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum Target Number Of Market Stock Units Granted Based On Stock Performance In Percent</link:label>
    <link:label id="lab_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_93F1735E18862861C0D6FB6C3ABE4733_documentation_en-US" xlink:label="lab_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_93F1735E18862861C0D6FB6C3ABE4733" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Minimum target number of market stock units granted based on stock performance in percent.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" xlink:label="loc_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_93F1735E18862861C0D6FB6C3ABE4733" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_93F1735E18862861C0D6FB6C3ABE4733" xlink:to="lab_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_93F1735E18862861C0D6FB6C3ABE4733" xlink:type="arc" />
    <link:label id="lab_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_012D665CA003490616B2FB6C3ABFBE61_verboseLabel_en-US" xlink:label="lab_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_012D665CA003490616B2FB6C3ABFBE61" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Percentage of earnings of the target number of units granted based on actual stock performance (Maximum)</link:label>
    <link:label id="lab_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_012D665CA003490616B2FB6C3ABFBE61_label_en-US" xlink:label="lab_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_012D665CA003490616B2FB6C3ABFBE61" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum Target Number Of Market Stock Units Granted Based On Stock Performance In Percent</link:label>
    <link:label id="lab_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_012D665CA003490616B2FB6C3ABFBE61_documentation_en-US" xlink:label="lab_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_012D665CA003490616B2FB6C3ABFBE61" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maximum target number of market stock units granted based on stock performance in percent.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" xlink:label="loc_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_012D665CA003490616B2FB6C3ABFBE61" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_012D665CA003490616B2FB6C3ABFBE61" xlink:to="lab_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_012D665CA003490616B2FB6C3ABFBE61" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5A1F588ECE37683E6921FB6C3ABFCC36_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5A1F588ECE37683E6921FB6C3ABFCC36" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares granted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5A1F588ECE37683E6921FB6C3ABFCC36" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5A1F588ECE37683E6921FB6C3ABFCC36" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5A1F588ECE37683E6921FB6C3ABFCC36" xlink:type="arc" />
    <link:label id="lab_biib_EmployeeServiceSharebasedCompensationSharesUsedtoSettleAwards_A867212FFCB6FD1AFC02FB6C3ABFB492_terseLabel_en-US" xlink:label="lab_biib_EmployeeServiceSharebasedCompensationSharesUsedtoSettleAwards_A867212FFCB6FD1AFC02FB6C3ABFB492" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PUs converted to share settlements</link:label>
    <link:label id="lab_biib_EmployeeServiceSharebasedCompensationSharesUsedtoSettleAwards_A867212FFCB6FD1AFC02FB6C3ABFB492_label_en-US" xlink:label="lab_biib_EmployeeServiceSharebasedCompensationSharesUsedtoSettleAwards_A867212FFCB6FD1AFC02FB6C3ABFB492" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Shares Used to Settle Awards</link:label>
    <link:label id="lab_biib_EmployeeServiceSharebasedCompensationSharesUsedtoSettleAwards_A867212FFCB6FD1AFC02FB6C3ABFB492_documentation_en-US" xlink:label="lab_biib_EmployeeServiceSharebasedCompensationSharesUsedtoSettleAwards_A867212FFCB6FD1AFC02FB6C3ABFB492" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Shares Used to Settle Awards</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_EmployeeServiceSharebasedCompensationSharesUsedtoSettleAwards" xlink:label="loc_biib_EmployeeServiceSharebasedCompensationSharesUsedtoSettleAwards_A867212FFCB6FD1AFC02FB6C3ABFB492" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EmployeeServiceSharebasedCompensationSharesUsedtoSettleAwards_A867212FFCB6FD1AFC02FB6C3ABFB492" xlink:to="lab_biib_EmployeeServiceSharebasedCompensationSharesUsedtoSettleAwards_A867212FFCB6FD1AFC02FB6C3ABFB492" xlink:type="arc" />
    <link:label id="lab_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice_29E946ED3485878ED861FB6C3ABFA5E2_verboseLabel_en-US" xlink:label="lab_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice_29E946ED3485878ED861FB6C3ABFA5E2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number of days for calculation of average closing stock price</link:label>
    <link:label id="lab_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice_29E946ED3485878ED861FB6C3ABFA5E2_label_en-US" xlink:label="lab_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice_29E946ED3485878ED861FB6C3ABFA5E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Days For Calculation Of Average Closing Stock Price</link:label>
    <link:label id="lab_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice_29E946ED3485878ED861FB6C3ABFA5E2_documentation_en-US" xlink:label="lab_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice_29E946ED3485878ED861FB6C3ABFA5E2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of days for calculation of average closing stock price.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_NumberOfDaysForCalculationOfAverageClosingStockPrice" xlink:label="loc_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice_29E946ED3485878ED861FB6C3ABFA5E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice_29E946ED3485878ED861FB6C3ABFA5E2" xlink:to="lab_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice_29E946ED3485878ED861FB6C3ABFA5E2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_C9A2D292A3C6BC70D612FB6C3ABF3CAF_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_C9A2D292A3C6BC70D612FB6C3ABF3CAF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total fair value of vested awards</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_C9A2D292A3C6BC70D612FB6C3ABF3CAF_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_C9A2D292A3C6BC70D612FB6C3ABF3CAF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_C9A2D292A3C6BC70D612FB6C3ABF3CAF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_C9A2D292A3C6BC70D612FB6C3ABF3CAF" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_C9A2D292A3C6BC70D612FB6C3ABF3CAF" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_ED8CF59300C2A24F2B5FFB6C3ABF8960_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_ED8CF59300C2A24F2B5FFB6C3ABF8960" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash in settlement of CSPS awards upon vesting</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_ED8CF59300C2A24F2B5FFB6C3ABF8960_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_ED8CF59300C2A24F2B5FFB6C3ABF8960" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Cash Flow Effect, Cash Used to Settle Awards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_ED8CF59300C2A24F2B5FFB6C3ABF8960" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_ED8CF59300C2A24F2B5FFB6C3ABF8960" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_ED8CF59300C2A24F2B5FFB6C3ABF8960" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_C965FABDE23F547930BDFB6C3ABFEC00_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_C965FABDE23F547930BDFB6C3ABFEC00" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average grant date fair value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_C965FABDE23F547930BDFB6C3ABFEC00" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_C965FABDE23F547930BDFB6C3ABFEC00" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_C965FABDE23F547930BDFB6C3ABFEC00" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_EF43722CBE330ACF957CFB6C3ABFABC5_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_EF43722CBE330ACF957CFB6C3ABFABC5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued under ESPP</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_EF43722CBE330ACF957CFB6C3ABFABC5_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_EF43722CBE330ACF957CFB6C3ABFABC5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_EF43722CBE330ACF957CFB6C3ABFABC5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_EF43722CBE330ACF957CFB6C3ABFABC5" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_EF43722CBE330ACF957CFB6C3ABFABC5" xlink:type="arc" />
    <link:label id="lab_biib_ShareBasedPaymentsTextualAbstract_15496D6D0235C502459EFB6C3ABF2F73_terseLabel_en-US" xlink:label="lab_biib_ShareBasedPaymentsTextualAbstract_15496D6D0235C502459EFB6C3ABF2F73" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payments (Textual)</link:label>
    <link:label id="lab_biib_ShareBasedPaymentsTextualAbstract_15496D6D0235C502459EFB6C3ABF2F73_label_en-US" xlink:label="lab_biib_ShareBasedPaymentsTextualAbstract_15496D6D0235C502459EFB6C3ABF2F73" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payments (Textual) [Abstract]</link:label>
    <link:label id="lab_biib_ShareBasedPaymentsTextualAbstract_15496D6D0235C502459EFB6C3ABF2F73_documentation_en-US" xlink:label="lab_biib_ShareBasedPaymentsTextualAbstract_15496D6D0235C502459EFB6C3ABF2F73" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Based Payments.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_ShareBasedPaymentsTextualAbstract" xlink:label="loc_biib_ShareBasedPaymentsTextualAbstract_15496D6D0235C502459EFB6C3ABF2F73" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ShareBasedPaymentsTextualAbstract_15496D6D0235C502459EFB6C3ABF2F73" xlink:to="lab_biib_ShareBasedPaymentsTextualAbstract_15496D6D0235C502459EFB6C3ABF2F73" xlink:type="arc" />
    <link:label id="lab_biib_WindfallTaxBenefitsFromVestingOfStockAwardsExercisesOfStockOptionsAndEsppParticipation_B758B8655DEF6C2C54CAFB6C3ABF1845_verboseLabel_en-US" xlink:label="lab_biib_WindfallTaxBenefitsFromVestingOfStockAwardsExercisesOfStockOptionsAndEsppParticipation_B758B8655DEF6C2C54CAFB6C3ABF1845" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Windfall tax benefits from vesting of stock awards, exercises of stock options and ESPP participation</link:label>
    <link:label id="lab_biib_WindfallTaxBenefitsFromVestingOfStockAwardsExercisesOfStockOptionsAndEsppParticipation_B758B8655DEF6C2C54CAFB6C3ABF1845_label_en-US" xlink:label="lab_biib_WindfallTaxBenefitsFromVestingOfStockAwardsExercisesOfStockOptionsAndEsppParticipation_B758B8655DEF6C2C54CAFB6C3ABF1845" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Windfall Tax Benefits From Vesting Of Stock Awards Exercises Of Stock Options And ESPP Participation</link:label>
    <link:label id="lab_biib_WindfallTaxBenefitsFromVestingOfStockAwardsExercisesOfStockOptionsAndEsppParticipation_B758B8655DEF6C2C54CAFB6C3ABF1845_documentation_en-US" xlink:label="lab_biib_WindfallTaxBenefitsFromVestingOfStockAwardsExercisesOfStockOptionsAndEsppParticipation_B758B8655DEF6C2C54CAFB6C3ABF1845" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Windfall tax benefits from vesting of stock awards, exercises of stock options and ESPP participation.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_WindfallTaxBenefitsFromVestingOfStockAwardsExercisesOfStockOptionsAndEsppParticipation" xlink:label="loc_biib_WindfallTaxBenefitsFromVestingOfStockAwardsExercisesOfStockOptionsAndEsppParticipation_B758B8655DEF6C2C54CAFB6C3ABF1845" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_WindfallTaxBenefitsFromVestingOfStockAwardsExercisesOfStockOptionsAndEsppParticipation_B758B8655DEF6C2C54CAFB6C3ABF1845" xlink:to="lab_biib_WindfallTaxBenefitsFromVestingOfStockAwardsExercisesOfStockOptionsAndEsppParticipation_B758B8655DEF6C2C54CAFB6C3ABF1845" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_0E973089056F76FC2010FB6C3ABFBB78_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_0E973089056F76FC2010FB6C3ABFBB78" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation cost related to unvested share-based compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_0E973089056F76FC2010FB6C3ABFBB78_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_0E973089056F76FC2010FB6C3ABFBB78" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_0E973089056F76FC2010FB6C3ABFBB78" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_0E973089056F76FC2010FB6C3ABFBB78" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_0E973089056F76FC2010FB6C3ABFBB78" xlink:type="arc" />
    <link:label id="lab_biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards_DB646783595BD4B6FA37FB6C3ABF4EDB_verboseLabel_en-US" xlink:label="lab_biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards_DB646783595BD4B6FA37FB6C3ABF4EDB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average period to recognize the cost of unvested awards</link:label>
    <link:label id="lab_biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards_DB646783595BD4B6FA37FB6C3ABF4EDB_label_en-US" xlink:label="lab_biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards_DB646783595BD4B6FA37FB6C3ABF4EDB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Period To Recognize Cost Of Nonvested Awards</link:label>
    <link:label id="lab_biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards_DB646783595BD4B6FA37FB6C3ABF4EDB_documentation_en-US" xlink:label="lab_biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards_DB646783595BD4B6FA37FB6C3ABF4EDB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted-average period to recognize the cost of nonvested awards.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards" xlink:label="loc_biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards_DB646783595BD4B6FA37FB6C3ABF4EDB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards_DB646783595BD4B6FA37FB6C3ABF4EDB" xlink:to="lab_biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards_DB646783595BD4B6FA37FB6C3ABF4EDB" xlink:type="arc" />
    <link:label id="lab_biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade_92A015FC5A6BB10A3C19FB6C3AC089D2_verboseLabel_en-US" xlink:label="lab_biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade_92A015FC5A6BB10A3C19FB6C3AC089D2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number of share-based compensation plans pursuant to which awards are currently being made</link:label>
    <link:label id="lab_biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade_92A015FC5A6BB10A3C19FB6C3AC089D2_label_en-US" xlink:label="lab_biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade_92A015FC5A6BB10A3C19FB6C3AC089D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Share Based Compensation Plans Pursuant To Which Awards Are Currently Being Made</link:label>
    <link:label id="lab_biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade_92A015FC5A6BB10A3C19FB6C3AC089D2_documentation_en-US" xlink:label="lab_biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade_92A015FC5A6BB10A3C19FB6C3AC089D2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of share-based compensation plans pursuant to which awards are currently being made.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade" xlink:label="loc_biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade_92A015FC5A6BB10A3C19FB6C3AC089D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade_92A015FC5A6BB10A3C19FB6C3AC089D2" xlink:to="lab_biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade_92A015FC5A6BB10A3C19FB6C3AC089D2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_6AC4960BF1C9A3AE6609FB6C3AC0CCE1_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_6AC4960BF1C9A3AE6609FB6C3AC0CCE1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number of shares granted under stock options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_6AC4960BF1C9A3AE6609FB6C3AC0CCE1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_6AC4960BF1C9A3AE6609FB6C3AC0CCE1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_6AC4960BF1C9A3AE6609FB6C3AC0CCE1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_6AC4960BF1C9A3AE6609FB6C3AC0CCE1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_6AC4960BF1C9A3AE6609FB6C3AC0CCE1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_C7DB8E7F29D6C642EF6CFB6C3AC08941_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_C7DB8E7F29D6C642EF6CFB6C3AC08941" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_C7DB8E7F29D6C642EF6CFB6C3AC08941_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_C7DB8E7F29D6C642EF6CFB6C3AC08941" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_C7DB8E7F29D6C642EF6CFB6C3AC08941" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_C7DB8E7F29D6C642EF6CFB6C3AC08941" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_C7DB8E7F29D6C642EF6CFB6C3AC08941" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_C29A18095AAABCB46C3EFB6C3AC05391_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_C29A18095AAABCB46C3EFB6C3AC05391" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic values of options outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_C29A18095AAABCB46C3EFB6C3AC05391_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_C29A18095AAABCB46C3EFB6C3AC05391" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_C29A18095AAABCB46C3EFB6C3AC05391" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_C29A18095AAABCB46C3EFB6C3AC05391" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_C29A18095AAABCB46C3EFB6C3AC05391" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_281DC2A06026F7A88730FB6C3AC0EFC1_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_281DC2A06026F7A88730FB6C3AC0EFC1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average remaining contractual term for options outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_281DC2A06026F7A88730FB6C3AC0EFC1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_281DC2A06026F7A88730FB6C3AC0EFC1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_281DC2A06026F7A88730FB6C3AC0EFC1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_281DC2A06026F7A88730FB6C3AC0EFC1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_281DC2A06026F7A88730FB6C3AC0EFC1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_E73DE8F1400F988F6C05FA4EA5C76E44_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_E73DE8F1400F988F6C05FA4EA5C76E44" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Charges and spending related to our 2015 restructuring program</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_E73DE8F1400F988F6C05FA4EA5C76E44_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_E73DE8F1400F988F6C05FA4EA5C76E44" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_E73DE8F1400F988F6C05FA4EA5C76E44" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_E73DE8F1400F988F6C05FA4EA5C76E44" xlink:to="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_E73DE8F1400F988F6C05FA4EA5C76E44" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_E44222346ECE99266A93186112ED8AAE_terseLabel_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_E44222346ECE99266A93186112ED8AAE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_E44222346ECE99266A93186112ED8AAE_label_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_E44222346ECE99266A93186112ED8AAE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_E44222346ECE99266A93186112ED8AAE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_E44222346ECE99266A93186112ED8AAE" xlink:to="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_E44222346ECE99266A93186112ED8AAE" xlink:type="arc" />
    <link:label id="lab_currency_EUR_BBDAE1D78EB0878F04C3186112EDE3C8_verboseLabel_en-US" xlink:label="lab_currency_EUR_BBDAE1D78EB0878F04C3186112EDE3C8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Euro</link:label>
    <link:label id="lab_currency_EUR_BBDAE1D78EB0878F04C3186112EDE3C8_label_en-US" xlink:label="lab_currency_EUR_BBDAE1D78EB0878F04C3186112EDE3C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Euro Member Countries, Euro</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd#currency_EUR" xlink:label="loc_currency_EUR_BBDAE1D78EB0878F04C3186112EDE3C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_EUR_BBDAE1D78EB0878F04C3186112EDE3C8" xlink:to="lab_currency_EUR_BBDAE1D78EB0878F04C3186112EDE3C8" xlink:type="arc" />
    <link:label id="lab_currency_CAD_6CBE88D1FA60149A95C9186112ED8B0C_verboseLabel_en-US" xlink:label="lab_currency_CAD_6CBE88D1FA60149A95C9186112ED8B0C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Canadian dollar</link:label>
    <link:label id="lab_currency_CAD_6CBE88D1FA60149A95C9186112ED8B0C_label_en-US" xlink:label="lab_currency_CAD_6CBE88D1FA60149A95C9186112ED8B0C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Canada, Dollars</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd#currency_CAD" xlink:label="loc_currency_CAD_6CBE88D1FA60149A95C9186112ED8B0C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_CAD_6CBE88D1FA60149A95C9186112ED8B0C" xlink:to="lab_currency_CAD_6CBE88D1FA60149A95C9186112ED8B0C" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_5745D7DD90C294934703186112EEB39E_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember_5745D7DD90C294934703186112EEB39E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_5745D7DD90C294934703186112EEB39E_label_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember_5745D7DD90C294934703186112EEB39E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Current Assets [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_5745D7DD90C294934703186112EEB39E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentAssetsMember_5745D7DD90C294934703186112EEB39E" xlink:to="lab_us-gaap_OtherCurrentAssetsMember_5745D7DD90C294934703186112EEB39E" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherInvestmentsMember_B914893C190F339B7D97186112F305F3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInvestmentsMember_B914893C190F339B7D97186112F305F3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments and other assets</link:label>
    <link:label id="lab_us-gaap_OtherInvestmentsMember_B914893C190F339B7D97186112F305F3_label_en-US" xlink:label="lab_us-gaap_OtherInvestmentsMember_B914893C190F339B7D97186112F305F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Investments [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherInvestmentsMember" xlink:label="loc_us-gaap_OtherInvestmentsMember_B914893C190F339B7D97186112F305F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInvestmentsMember_B914893C190F339B7D97186112F305F3" xlink:to="lab_us-gaap_OtherInvestmentsMember_B914893C190F339B7D97186112F305F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_HedgingDesignationAxis_592EC7CDF857F6D24008186112F44962_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis_592EC7CDF857F6D24008186112F44962" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_592EC7CDF857F6D24008186112F44962_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis_592EC7CDF857F6D24008186112F44962" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_592EC7CDF857F6D24008186112F44962" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis_592EC7CDF857F6D24008186112F44962" xlink:to="lab_us-gaap_HedgingDesignationAxis_592EC7CDF857F6D24008186112F44962" xlink:type="arc" />
    <link:label id="lab_us-gaap_HedgingDesignationDomain_F8ED8A5ACD0D211BF31D186112F476D2_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain_F8ED8A5ACD0D211BF31D186112F476D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_F8ED8A5ACD0D211BF31D186112F476D2_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain_F8ED8A5ACD0D211BF31D186112F476D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_F8ED8A5ACD0D211BF31D186112F476D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain_F8ED8A5ACD0D211BF31D186112F476D2" xlink:to="lab_us-gaap_HedgingDesignationDomain_F8ED8A5ACD0D211BF31D186112F476D2" xlink:type="arc" />
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_4D3F532F0A3E8C8D4101186112F44698_verboseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember_4D3F532F0A3E8C8D4101186112F44698" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_4D3F532F0A3E8C8D4101186112F44698_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember_4D3F532F0A3E8C8D4101186112F44698" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_4D3F532F0A3E8C8D4101186112F44698" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember_4D3F532F0A3E8C8D4101186112F44698" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember_4D3F532F0A3E8C8D4101186112F44698" xlink:type="arc" />
    <link:label id="lab_us-gaap_NondesignatedMember_44035CF15944EB78A8FD186112F47D25_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember_44035CF15944EB78A8FD186112F47D25" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Not Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_44035CF15944EB78A8FD186112F47D25_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember_44035CF15944EB78A8FD186112F47D25" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="loc_us-gaap_NondesignatedMember_44035CF15944EB78A8FD186112F47D25" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember_44035CF15944EB78A8FD186112F47D25" xlink:to="lab_us-gaap_NondesignatedMember_44035CF15944EB78A8FD186112F47D25" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_1179AEFBD10892F1480E186112F489A5_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems_1179AEFBD10892F1480E186112F489A5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_1179AEFBD10892F1480E186112F489A5_label_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems_1179AEFBD10892F1480E186112F489A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativesFairValueLineItems" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_1179AEFBD10892F1480E186112F489A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_1179AEFBD10892F1480E186112F489A5" xlink:to="lab_us-gaap_DerivativesFairValueLineItems_1179AEFBD10892F1480E186112F489A5" xlink:type="arc" />
    <link:label id="lab_invest_DerivativeNotionalAmount_3B164CC99080F2DF68B5186112F41CF0_terseLabel_en-US" xlink:label="lab_invest_DerivativeNotionalAmount_3B164CC99080F2DF68B5186112F41CF0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate notional amount</link:label>
    <link:label id="lab_invest_DerivativeNotionalAmount_3B164CC99080F2DF68B5186112F41CF0_label_en-US" xlink:label="lab_invest_DerivativeNotionalAmount_3B164CC99080F2DF68B5186112F41CF0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_DerivativeNotionalAmount" xlink:label="loc_invest_DerivativeNotionalAmount_3B164CC99080F2DF68B5186112F41CF0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_invest_DerivativeNotionalAmount_3B164CC99080F2DF68B5186112F41CF0" xlink:to="lab_invest_DerivativeNotionalAmount_3B164CC99080F2DF68B5186112F41CF0" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeAssetFairValueNetAbstract_26230DFBF28AD02C4F65186112F46324_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueNetAbstract_26230DFBF28AD02C4F65186112F46324" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of derivatives designated as hedging instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueNetAbstract_26230DFBF28AD02C4F65186112F46324_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueNetAbstract_26230DFBF28AD02C4F65186112F46324" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Asset, Fair Value, Amount Not Offset Against Collateral [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeAssetFairValueNetAbstract" xlink:label="loc_us-gaap_DerivativeAssetFairValueNetAbstract_26230DFBF28AD02C4F65186112F46324" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetFairValueNetAbstract_26230DFBF28AD02C4F65186112F46324" xlink:to="lab_us-gaap_DerivativeAssetFairValueNetAbstract_26230DFBF28AD02C4F65186112F46324" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_8A7B461A78C70294B3EB186112F4066A_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_8A7B461A78C70294B3EB186112F4066A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Asset derivatives</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_8A7B461A78C70294B3EB186112F4066A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_8A7B461A78C70294B3EB186112F4066A" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_8A7B461A78C70294B3EB186112F4066A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_00ECC430F1245E830914186112F4AB13_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_00ECC430F1245E830914186112F4AB13" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability derivatives</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_00ECC430F1245E830914186112F4AB13_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_00ECC430F1245E830914186112F4AB13" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liability, Fair Value, Gross Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_00ECC430F1245E830914186112F4AB13" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_00ECC430F1245E830914186112F4AB13" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_00ECC430F1245E830914186112F4AB13" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_B30DC78CB621AD1EBB5B741287AA35EC_verboseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_B30DC78CB621AD1EBB5B741287AA35EC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payments</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_B30DC78CB621AD1EBB5B741287AA35EC_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_B30DC78CB621AD1EBB5B741287AA35EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_B30DC78CB621AD1EBB5B741287AA35EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_B30DC78CB621AD1EBB5B741287AA35EC" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_B30DC78CB621AD1EBB5B741287AA35EC" xlink:type="arc" />
    <link:label id="lab_biib_DocumentAndEntityInformationAbstract_2E9C329A656DE6A45C21F60DFFBB4217_label_en-US" xlink:label="lab_biib_DocumentAndEntityInformationAbstract_2E9C329A656DE6A45C21F60DFFBB4217" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document and Entity Information [Abstract]</link:label>
    <link:label id="lab_biib_DocumentAndEntityInformationAbstract_2E9C329A656DE6A45C21F60DFFBB4217_documentation_en-US" xlink:label="lab_biib_DocumentAndEntityInformationAbstract_2E9C329A656DE6A45C21F60DFFBB4217" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Document and Entity Information.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_DocumentAndEntityInformationAbstract" xlink:label="loc_biib_DocumentAndEntityInformationAbstract_2E9C329A656DE6A45C21F60DFFBB4217" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_2E9C329A656DE6A45C21F60DFFBB4217" xlink:to="lab_biib_DocumentAndEntityInformationAbstract_2E9C329A656DE6A45C21F60DFFBB4217" xlink:type="arc" />
    <link:label id="lab_dei_EntityRegistrantName_00F29C0724315EA9D3E3F60DFFBBF5DC_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName_00F29C0724315EA9D3E3F60DFFBBF5DC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_00F29C0724315EA9D3E3F60DFFBBF5DC_label_en-US" xlink:label="lab_dei_EntityRegistrantName_00F29C0724315EA9D3E3F60DFFBBF5DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_00F29C0724315EA9D3E3F60DFFBBF5DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_00F29C0724315EA9D3E3F60DFFBBF5DC" xlink:to="lab_dei_EntityRegistrantName_00F29C0724315EA9D3E3F60DFFBBF5DC" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_FB51DC7CDB37BEF66026F60DFFBB2925_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey_FB51DC7CDB37BEF66026F60DFFBB2925" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_FB51DC7CDB37BEF66026F60DFFBB2925_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_FB51DC7CDB37BEF66026F60DFFBB2925" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_FB51DC7CDB37BEF66026F60DFFBB2925" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_FB51DC7CDB37BEF66026F60DFFBB2925" xlink:to="lab_dei_EntityCentralIndexKey_FB51DC7CDB37BEF66026F60DFFBB2925" xlink:type="arc" />
    <link:label id="lab_dei_CurrentFiscalYearEndDate_B8DB82CB7E46059910F5F60DFFBBC7D5_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_B8DB82CB7E46059910F5F60DFFBBC7D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_B8DB82CB7E46059910F5F60DFFBBC7D5_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_B8DB82CB7E46059910F5F60DFFBBC7D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_B8DB82CB7E46059910F5F60DFFBBC7D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_B8DB82CB7E46059910F5F60DFFBBC7D5" xlink:to="lab_dei_CurrentFiscalYearEndDate_B8DB82CB7E46059910F5F60DFFBBC7D5" xlink:type="arc" />
    <link:label id="lab_dei_EntityFilerCategory_D7923CDE99A53FB86196F60DFFBB4460_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory_D7923CDE99A53FB86196F60DFFBB4460" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_D7923CDE99A53FB86196F60DFFBB4460_label_en-US" xlink:label="lab_dei_EntityFilerCategory_D7923CDE99A53FB86196F60DFFBB4460" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_D7923CDE99A53FB86196F60DFFBB4460" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_D7923CDE99A53FB86196F60DFFBB4460" xlink:to="lab_dei_EntityFilerCategory_D7923CDE99A53FB86196F60DFFBB4460" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_411C797853B1B34B6546F60DFFBB0CC6_terseLabel_en-US" xlink:label="lab_dei_DocumentType_411C797853B1B34B6546F60DFFBB0CC6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_411C797853B1B34B6546F60DFFBB0CC6_label_en-US" xlink:label="lab_dei_DocumentType_411C797853B1B34B6546F60DFFBB0CC6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_411C797853B1B34B6546F60DFFBB0CC6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_411C797853B1B34B6546F60DFFBB0CC6" xlink:to="lab_dei_DocumentType_411C797853B1B34B6546F60DFFBB0CC6" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_B311D47439E0D100C915F60DFFBB7741_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_B311D47439E0D100C915F60DFFBB7741" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_B311D47439E0D100C915F60DFFBB7741_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_B311D47439E0D100C915F60DFFBB7741" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_B311D47439E0D100C915F60DFFBB7741" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_B311D47439E0D100C915F60DFFBB7741" xlink:to="lab_dei_DocumentPeriodEndDate_B311D47439E0D100C915F60DFFBB7741" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalYearFocus_3A02C104290A8AED2CC6F60DFFBB80E2_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_3A02C104290A8AED2CC6F60DFFBB80E2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_3A02C104290A8AED2CC6F60DFFBB80E2_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_3A02C104290A8AED2CC6F60DFFBB80E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_3A02C104290A8AED2CC6F60DFFBB80E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_3A02C104290A8AED2CC6F60DFFBB80E2" xlink:to="lab_dei_DocumentFiscalYearFocus_3A02C104290A8AED2CC6F60DFFBB80E2" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_31DB33FEFF0917E11805F60DFFBB2867_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_31DB33FEFF0917E11805F60DFFBB2867" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_31DB33FEFF0917E11805F60DFFBB2867_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_31DB33FEFF0917E11805F60DFFBB2867" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_31DB33FEFF0917E11805F60DFFBB2867" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_31DB33FEFF0917E11805F60DFFBB2867" xlink:to="lab_dei_DocumentFiscalPeriodFocus_31DB33FEFF0917E11805F60DFFBB2867" xlink:type="arc" />
    <link:label id="lab_dei_AmendmentFlag_9BA082B1875FEB4C8029F60DFFBB6D17_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag_9BA082B1875FEB4C8029F60DFFBB6D17" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_9BA082B1875FEB4C8029F60DFFBB6D17_label_en-US" xlink:label="lab_dei_AmendmentFlag_9BA082B1875FEB4C8029F60DFFBB6D17" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_9BA082B1875FEB4C8029F60DFFBB6D17" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_9BA082B1875FEB4C8029F60DFFBB6D17" xlink:to="lab_dei_AmendmentFlag_9BA082B1875FEB4C8029F60DFFBB6D17" xlink:type="arc" />
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_8F100A8CD69F5A0E8023F60DFFBB4C63_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_8F100A8CD69F5A0E8023F60DFFBB4C63" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_8F100A8CD69F5A0E8023F60DFFBB4C63_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_8F100A8CD69F5A0E8023F60DFFBB4C63" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_8F100A8CD69F5A0E8023F60DFFBB4C63" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_8F100A8CD69F5A0E8023F60DFFBB4C63" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_8F100A8CD69F5A0E8023F60DFFBB4C63" xlink:type="arc" />
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_951346FB54666DBCF607F60DFFBBC125_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer_951346FB54666DBCF607F60DFFBBC125" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_951346FB54666DBCF607F60DFFBBC125_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer_951346FB54666DBCF607F60DFFBBC125" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_951346FB54666DBCF607F60DFFBBC125" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer_951346FB54666DBCF607F60DFFBBC125" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer_951346FB54666DBCF607F60DFFBBC125" xlink:type="arc" />
    <link:label id="lab_dei_EntityVoluntaryFilers_4E98B5DA9083436BDA70F60DFFBBC87A_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers_4E98B5DA9083436BDA70F60DFFBBC87A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_4E98B5DA9083436BDA70F60DFFBBC87A_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers_4E98B5DA9083436BDA70F60DFFBBC87A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_4E98B5DA9083436BDA70F60DFFBBC87A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers_4E98B5DA9083436BDA70F60DFFBBC87A" xlink:to="lab_dei_EntityVoluntaryFilers_4E98B5DA9083436BDA70F60DFFBBC87A" xlink:type="arc" />
    <link:label id="lab_dei_EntityCurrentReportingStatus_AB0C57CC23789B480FD4F60DFFBB2551_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_AB0C57CC23789B480FD4F60DFFBB2551" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_AB0C57CC23789B480FD4F60DFFBB2551_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_AB0C57CC23789B480FD4F60DFFBB2551" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_AB0C57CC23789B480FD4F60DFFBB2551" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus_AB0C57CC23789B480FD4F60DFFBB2551" xlink:to="lab_dei_EntityCurrentReportingStatus_AB0C57CC23789B480FD4F60DFFBB2551" xlink:type="arc" />
    <link:label id="lab_dei_EntityPublicFloat_4F0202F19F5AE05DFCC1F60DFFBBC3E4_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat_4F0202F19F5AE05DFCC1F60DFFBBC3E4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_4F0202F19F5AE05DFCC1F60DFFBBC3E4_label_en-US" xlink:label="lab_dei_EntityPublicFloat_4F0202F19F5AE05DFCC1F60DFFBBC3E4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_4F0202F19F5AE05DFCC1F60DFFBBC3E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat_4F0202F19F5AE05DFCC1F60DFFBBC3E4" xlink:to="lab_dei_EntityPublicFloat_4F0202F19F5AE05DFCC1F60DFFBBC3E4" xlink:type="arc" />
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_E720D6CCDB917D80092C741285871D4E_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_E720D6CCDB917D80092C741285871D4E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation and Retirement Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_E720D6CCDB917D80092C741285871D4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_E720D6CCDB917D80092C741285871D4E" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_E720D6CCDB917D80092C741285871D4E" xlink:type="arc" />
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_EE4D83818B9DC6E34A307412858731FC_verboseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_EE4D83818B9DC6E34A307412858731FC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Employee Benefit Plans</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_EE4D83818B9DC6E34A307412858731FC_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_EE4D83818B9DC6E34A307412858731FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension and Other Postretirement Benefits Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_EE4D83818B9DC6E34A307412858731FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_EE4D83818B9DC6E34A307412858731FC" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_EE4D83818B9DC6E34A307412858731FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedContributionPlanTable_C4C775A7D36A0F609D51FD64519486FE_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanTable_C4C775A7D36A0F609D51FD64519486FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan [Table]</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanTable_C4C775A7D36A0F609D51FD64519486FE_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanTable_C4C775A7D36A0F609D51FD64519486FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="loc_us-gaap_DefinedContributionPlanTable_C4C775A7D36A0F609D51FD64519486FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanTable_C4C775A7D36A0F609D51FD64519486FE" xlink:to="lab_us-gaap_DefinedContributionPlanTable_C4C775A7D36A0F609D51FD64519486FE" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedContributionPlanTypeAxis_3D839D87DF83F0AB7DF7FD6451952CA5_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanTypeAxis_3D839D87DF83F0AB7DF7FD6451952CA5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan Type [Axis]</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanTypeAxis_3D839D87DF83F0AB7DF7FD6451952CA5_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanTypeAxis_3D839D87DF83F0AB7DF7FD6451952CA5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefinedContributionPlanTypeAxis" xlink:label="loc_us-gaap_DefinedContributionPlanTypeAxis_3D839D87DF83F0AB7DF7FD6451952CA5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanTypeAxis_3D839D87DF83F0AB7DF7FD6451952CA5" xlink:to="lab_us-gaap_DefinedContributionPlanTypeAxis_3D839D87DF83F0AB7DF7FD6451952CA5" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedContributionPlanTypeDomain_3DF3F09439BE8A680A6CFD645195EB5B_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanTypeDomain_3DF3F09439BE8A680A6CFD645195EB5B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan Type [Domain]</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanTypeDomain_3DF3F09439BE8A680A6CFD645195EB5B_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanTypeDomain_3DF3F09439BE8A680A6CFD645195EB5B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefinedContributionPlanTypeDomain" xlink:label="loc_us-gaap_DefinedContributionPlanTypeDomain_3DF3F09439BE8A680A6CFD645195EB5B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanTypeDomain_3DF3F09439BE8A680A6CFD645195EB5B" xlink:to="lab_us-gaap_DefinedContributionPlanTypeDomain_3DF3F09439BE8A680A6CFD645195EB5B" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnitedStatesPostretirementBenefitPlansOfUSEntityDefinedBenefitMember_F8051DF1BA9540C14AE8FD64519560F5_terseLabel_en-US" xlink:label="lab_us-gaap_UnitedStatesPostretirementBenefitPlansOfUSEntityDefinedBenefitMember_F8051DF1BA9540C14AE8FD64519560F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">401k</link:label>
    <link:label id="lab_us-gaap_UnitedStatesPostretirementBenefitPlansOfUSEntityDefinedBenefitMember_F8051DF1BA9540C14AE8FD64519560F5_label_en-US" xlink:label="lab_us-gaap_UnitedStatesPostretirementBenefitPlansOfUSEntityDefinedBenefitMember_F8051DF1BA9540C14AE8FD64519560F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">United States Postretirement Benefit Plan of US Entity [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnitedStatesPostretirementBenefitPlansOfUSEntityDefinedBenefitMember" xlink:label="loc_us-gaap_UnitedStatesPostretirementBenefitPlansOfUSEntityDefinedBenefitMember_F8051DF1BA9540C14AE8FD64519560F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnitedStatesPostretirementBenefitPlansOfUSEntityDefinedBenefitMember_F8051DF1BA9540C14AE8FD64519560F5" xlink:to="lab_us-gaap_UnitedStatesPostretirementBenefitPlansOfUSEntityDefinedBenefitMember_F8051DF1BA9540C14AE8FD64519560F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_136486EEEF0CD6313610FD6BA62FDA67_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_136486EEEF0CD6313610FD6BA62FDA67" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Compensation Plan</link:label>
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_136486EEEF0CD6313610FD6BA62FDA67_label_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_136486EEEF0CD6313610FD6BA62FDA67" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Postretirement Benefit Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_136486EEEF0CD6313610FD6BA62FDA67" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_136486EEEF0CD6313610FD6BA62FDA67" xlink:to="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_136486EEEF0CD6313610FD6BA62FDA67" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedContributionPlanDisclosureLineItems_60F954C5A78454392A34FD645195A226_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanDisclosureLineItems_60F954C5A78454392A34FD645195A226" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanDisclosureLineItems_60F954C5A78454392A34FD645195A226_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanDisclosureLineItems_60F954C5A78454392A34FD645195A226" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan Disclosure [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_60F954C5A78454392A34FD645195A226" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_60F954C5A78454392A34FD645195A226" xlink:to="lab_us-gaap_DefinedContributionPlanDisclosureLineItems_60F954C5A78454392A34FD645195A226" xlink:type="arc" />
    <link:label id="lab_biib_MinimumQualifyingAgeForEmployeeBenefitPlan_1634074B30605814AFF0FD645195979B_terseLabel_en-US" xlink:label="lab_biib_MinimumQualifyingAgeForEmployeeBenefitPlan_1634074B30605814AFF0FD645195979B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum Qualifying Age For Employee Benefit Plan</link:label>
    <link:label id="lab_biib_MinimumQualifyingAgeForEmployeeBenefitPlan_1634074B30605814AFF0FD645195979B_label_en-US" xlink:label="lab_biib_MinimumQualifyingAgeForEmployeeBenefitPlan_1634074B30605814AFF0FD645195979B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum Qualifying Age For Employee Benefit Plan</link:label>
    <link:label id="lab_biib_MinimumQualifyingAgeForEmployeeBenefitPlan_1634074B30605814AFF0FD645195979B_documentation_en-US" xlink:label="lab_biib_MinimumQualifyingAgeForEmployeeBenefitPlan_1634074B30605814AFF0FD645195979B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Minimum qualifying age for employee benefit plan.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_MinimumQualifyingAgeForEmployeeBenefitPlan" xlink:label="loc_biib_MinimumQualifyingAgeForEmployeeBenefitPlan_1634074B30605814AFF0FD645195979B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MinimumQualifyingAgeForEmployeeBenefitPlan_1634074B30605814AFF0FD645195979B" xlink:to="lab_biib_MinimumQualifyingAgeForEmployeeBenefitPlan_1634074B30605814AFF0FD645195979B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_E17AD2B62461B01A77F1FD6451951985_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized_E17AD2B62461B01A77F1FD6451951985" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expenses related to savings plan</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_E17AD2B62461B01A77F1FD6451951985_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized_E17AD2B62461B01A77F1FD6451951985" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Cost Recognized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_E17AD2B62461B01A77F1FD6451951985" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized_E17AD2B62461B01A77F1FD6451951985" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized_E17AD2B62461B01A77F1FD6451951985" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_4A360062E9362E8FB324FD6451959BDC_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_4A360062E9362E8FB324FD6451959BDC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred compensation liability</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_4A360062E9362E8FB324FD6451959BDC_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_4A360062E9362E8FB324FD6451959BDC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Compensation Liability, Classified, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:label="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_4A360062E9362E8FB324FD6451959BDC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_4A360062E9362E8FB324FD6451959BDC" xlink:to="lab_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_4A360062E9362E8FB324FD6451959BDC" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_1B19D95009801A545C74741285521463_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_1B19D95009801A545C74741285521463" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_1B19D95009801A545C74741285521463_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_1B19D95009801A545C74741285521463" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_1B19D95009801A545C74741285521463" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock_1B19D95009801A545C74741285521463" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock_1B19D95009801A545C74741285521463" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_CBEF66339F5F537A2CFB741287EDB2C3_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_CBEF66339F5F537A2CFB741287EDB2C3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets and Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_CBEF66339F5F537A2CFB741287EDB2C3_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_CBEF66339F5F537A2CFB741287EDB2C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_CBEF66339F5F537A2CFB741287EDB2C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_CBEF66339F5F537A2CFB741287EDB2C3" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_CBEF66339F5F537A2CFB741287EDB2C3" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxCreditCarryforwardTable_D57276560D19C41D50F7FB6C3A9367D1_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardTable_D57276560D19C41D50F7FB6C3A9367D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Table]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardTable_D57276560D19C41D50F7FB6C3A9367D1_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardTable_D57276560D19C41D50F7FB6C3A9367D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxCreditCarryforwardTable" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_D57276560D19C41D50F7FB6C3A9367D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_D57276560D19C41D50F7FB6C3A9367D1" xlink:to="lab_us-gaap_TaxCreditCarryforwardTable_D57276560D19C41D50F7FB6C3A9367D1" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_E11EC0C22E1883BEC9AEFB6C3A93B7EB_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis_E11EC0C22E1883BEC9AEFB6C3A93B7EB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_E11EC0C22E1883BEC9AEFB6C3A93B7EB_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis_E11EC0C22E1883BEC9AEFB6C3A93B7EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_E11EC0C22E1883BEC9AEFB6C3A93B7EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_E11EC0C22E1883BEC9AEFB6C3A93B7EB" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis_E11EC0C22E1883BEC9AEFB6C3A93B7EB" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_2B58F2608EBA3640FA55FB6C3A93193C_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain_2B58F2608EBA3640FA55FB6C3A93193C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_2B58F2608EBA3640FA55FB6C3A93193C_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain_2B58F2608EBA3640FA55FB6C3A93193C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_2B58F2608EBA3640FA55FB6C3A93193C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_2B58F2608EBA3640FA55FB6C3A93193C" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain_2B58F2608EBA3640FA55FB6C3A93193C" xlink:type="arc" />
    <link:label id="lab_us-gaap_GeneralBusinessMember_2543008807CF7B4EF9A1FB6C3A9498A8_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralBusinessMember_2543008807CF7B4EF9A1FB6C3A9498A8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General Business</link:label>
    <link:label id="lab_us-gaap_GeneralBusinessMember_2543008807CF7B4EF9A1FB6C3A9498A8_label_en-US" xlink:label="lab_us-gaap_GeneralBusinessMember_2543008807CF7B4EF9A1FB6C3A9498A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General Business Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralBusinessMember" xlink:label="loc_us-gaap_GeneralBusinessMember_2543008807CF7B4EF9A1FB6C3A9498A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralBusinessMember_2543008807CF7B4EF9A1FB6C3A9498A8" xlink:to="lab_us-gaap_GeneralBusinessMember_2543008807CF7B4EF9A1FB6C3A9498A8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchMember_4DBDF5E2704A4CE40BA7FB6C3A943A1D_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchMember_4DBDF5E2704A4CE40BA7FB6C3A943A1D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research</link:label>
    <link:label id="lab_us-gaap_ResearchMember_4DBDF5E2704A4CE40BA7FB6C3A943A1D_label_en-US" xlink:label="lab_us-gaap_ResearchMember_4DBDF5E2704A4CE40BA7FB6C3A943A1D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaap_ResearchMember_4DBDF5E2704A4CE40BA7FB6C3A943A1D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchMember_4DBDF5E2704A4CE40BA7FB6C3A943A1D" xlink:to="lab_us-gaap_ResearchMember_4DBDF5E2704A4CE40BA7FB6C3A943A1D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_07A5337131E57B86ACE7FB6C3A94B15F_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis_07A5337131E57B86ACE7FB6C3A94B15F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_07A5337131E57B86ACE7FB6C3A94B15F_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis_07A5337131E57B86ACE7FB6C3A94B15F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_07A5337131E57B86ACE7FB6C3A94B15F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_07A5337131E57B86ACE7FB6C3A94B15F" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis_07A5337131E57B86ACE7FB6C3A94B15F" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_26593EAF62DE347B1BBCFB6C3A9423E2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain_26593EAF62DE347B1BBCFB6C3A9423E2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_26593EAF62DE347B1BBCFB6C3A9423E2_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain_26593EAF62DE347B1BBCFB6C3A9423E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_26593EAF62DE347B1BBCFB6C3A9423E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_26593EAF62DE347B1BBCFB6C3A9423E2" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain_26593EAF62DE347B1BBCFB6C3A9423E2" xlink:type="arc" />
    <link:label id="lab_us-gaap_DomesticCountryMember_2AB747F1F5878B670DE6FB6C3A9434B7_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember_2AB747F1F5878B670DE6FB6C3A9434B7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Domestic Country</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_2AB747F1F5878B670DE6FB6C3A9434B7_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember_2AB747F1F5878B670DE6FB6C3A9434B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_2AB747F1F5878B670DE6FB6C3A9434B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember_2AB747F1F5878B670DE6FB6C3A9434B7" xlink:to="lab_us-gaap_DomesticCountryMember_2AB747F1F5878B670DE6FB6C3A9434B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_663494817860BFA82613FB6C3A9484E6_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember_663494817860BFA82613FB6C3A9484E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_663494817860BFA82613FB6C3A9484E6_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember_663494817860BFA82613FB6C3A9484E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_663494817860BFA82613FB6C3A9484E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember_663494817860BFA82613FB6C3A9484E6" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember_663494817860BFA82613FB6C3A9484E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCountryMember_64F033248F252C04694DFB6C3A94EC7B_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember_64F033248F252C04694DFB6C3A94EC7B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember_64F033248F252C04694DFB6C3A94EC7B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember_64F033248F252C04694DFB6C3A94EC7B" xlink:to="lab_us-gaap_ForeignCountryMember_64F033248F252C04694DFB6C3A94EC7B" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_00E0B3716ACF582B5EA0FB6C3A9493FA_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems_00E0B3716ACF582B5EA0FB6C3A9493FA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Line Items]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_00E0B3716ACF582B5EA0FB6C3A9493FA_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems_00E0B3716ACF582B5EA0FB6C3A9493FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_00E0B3716ACF582B5EA0FB6C3A9493FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_00E0B3716ACF582B5EA0FB6C3A9493FA" xlink:to="lab_us-gaap_TaxCreditCarryforwardLineItems_00E0B3716ACF582B5EA0FB6C3A9493FA" xlink:type="arc" />
    <link:label id="lab_biib_Totaldeferredchargesandprepaidtaxes_2E0ADAB25257D49EB115FB6C3A957FB2_terseLabel_en-US" xlink:label="lab_biib_Totaldeferredchargesandprepaidtaxes_2E0ADAB25257D49EB115FB6C3A957FB2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total deferred charges and prepaid taxes</link:label>
    <link:label id="lab_biib_Totaldeferredchargesandprepaidtaxes_2E0ADAB25257D49EB115FB6C3A957FB2_label_en-US" xlink:label="lab_biib_Totaldeferredchargesandprepaidtaxes_2E0ADAB25257D49EB115FB6C3A957FB2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total deferred charges and prepaid taxes</link:label>
    <link:label id="lab_biib_Totaldeferredchargesandprepaidtaxes_2E0ADAB25257D49EB115FB6C3A957FB2_documentation_en-US" xlink:label="lab_biib_Totaldeferredchargesandprepaidtaxes_2E0ADAB25257D49EB115FB6C3A957FB2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total deferred charges and prepaid taxes</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_Totaldeferredchargesandprepaidtaxes" xlink:label="loc_biib_Totaldeferredchargesandprepaidtaxes_2E0ADAB25257D49EB115FB6C3A957FB2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Totaldeferredchargesandprepaidtaxes_2E0ADAB25257D49EB115FB6C3A957FB2" xlink:to="lab_biib_Totaldeferredchargesandprepaidtaxes_2E0ADAB25257D49EB115FB6C3A957FB2" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_38AFF590486AB590C0B9FB6C3A956F3D_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards_38AFF590486AB590C0B9FB6C3A956F3D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_38AFF590486AB590C0B9FB6C3A956F3D_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards_38AFF590486AB590C0B9FB6C3A956F3D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_38AFF590486AB590C0B9FB6C3A956F3D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards_38AFF590486AB590C0B9FB6C3A956F3D" xlink:to="lab_us-gaap_OperatingLossCarryforwards_38AFF590486AB590C0B9FB6C3A956F3D" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_8610CCAFA874187D1B4BFB6C3A955530_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount_8610CCAFA874187D1B4BFB6C3A955530" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_8610CCAFA874187D1B4BFB6C3A955530_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount_8610CCAFA874187D1B4BFB6C3A955530" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_8610CCAFA874187D1B4BFB6C3A955530" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount_8610CCAFA874187D1B4BFB6C3A955530" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount_8610CCAFA874187D1B4BFB6C3A955530" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_0D009D03ECAED24684B2FB6C3A956205_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_0D009D03ECAED24684B2FB6C3A956205" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_0D009D03ECAED24684B2FB6C3A956205_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_0D009D03ECAED24684B2FB6C3A956205" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_0D009D03ECAED24684B2FB6C3A956205" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_0D009D03ECAED24684B2FB6C3A956205" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_0D009D03ECAED24684B2FB6C3A956205" xlink:type="arc" />
    <link:label id="lab_biib_EstimatedTaxLiabilityOnUndistributedEarningsOfForeignSubsidiaries_E54A5FDFD81D0E0D90E3FB6C3A9502EF_terseLabel_en-US" xlink:label="lab_biib_EstimatedTaxLiabilityOnUndistributedEarningsOfForeignSubsidiaries_E54A5FDFD81D0E0D90E3FB6C3A9502EF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated Tax Liability On Undistributed Earnings Of Foreign Subsidiaries</link:label>
    <link:label id="lab_biib_EstimatedTaxLiabilityOnUndistributedEarningsOfForeignSubsidiaries_E54A5FDFD81D0E0D90E3FB6C3A9502EF_label_en-US" xlink:label="lab_biib_EstimatedTaxLiabilityOnUndistributedEarningsOfForeignSubsidiaries_E54A5FDFD81D0E0D90E3FB6C3A9502EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated Tax Liability On Undistributed Earnings Of Foreign Subsidiaries</link:label>
    <link:label id="lab_biib_EstimatedTaxLiabilityOnUndistributedEarningsOfForeignSubsidiaries_E54A5FDFD81D0E0D90E3FB6C3A9502EF_documentation_en-US" xlink:label="lab_biib_EstimatedTaxLiabilityOnUndistributedEarningsOfForeignSubsidiaries_E54A5FDFD81D0E0D90E3FB6C3A9502EF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Estimated tax liability on undistributed earnings of foreign subsidiaries.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_EstimatedTaxLiabilityOnUndistributedEarningsOfForeignSubsidiaries" xlink:label="loc_biib_EstimatedTaxLiabilityOnUndistributedEarningsOfForeignSubsidiaries_E54A5FDFD81D0E0D90E3FB6C3A9502EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EstimatedTaxLiabilityOnUndistributedEarningsOfForeignSubsidiaries_E54A5FDFD81D0E0D90E3FB6C3A9502EF" xlink:to="lab_biib_EstimatedTaxLiabilityOnUndistributedEarningsOfForeignSubsidiaries_E54A5FDFD81D0E0D90E3FB6C3A9502EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_6B106CD6D6215CB73F9CFB6C3A9512C6_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_6B106CD6D6215CB73F9CFB6C3A9512C6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Notice of assessment of corporate withholding tax including penalties and interest</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_6B106CD6D6215CB73F9CFB6C3A9512C6_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_6B106CD6D6215CB73F9CFB6C3A9512C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Examination, Penalties and Interest Accrued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_6B106CD6D6215CB73F9CFB6C3A9512C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_6B106CD6D6215CB73F9CFB6C3A9512C6" xlink:to="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_6B106CD6D6215CB73F9CFB6C3A9512C6" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForOtherTaxes_AA28A789123BF1CD05C6FB6C3A959E3E_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForOtherTaxes_AA28A789123BF1CD05C6FB6C3A959E3E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments for Other Taxes</link:label>
    <link:label id="lab_us-gaap_PaymentsForOtherTaxes_AA28A789123BF1CD05C6FB6C3A959E3E_label_en-US" xlink:label="lab_us-gaap_PaymentsForOtherTaxes_AA28A789123BF1CD05C6FB6C3A959E3E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Other Taxes</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForOtherTaxes" xlink:label="loc_us-gaap_PaymentsForOtherTaxes_AA28A789123BF1CD05C6FB6C3A959E3E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForOtherTaxes_AA28A789123BF1CD05C6FB6C3A959E3E" xlink:to="lab_us-gaap_PaymentsForOtherTaxes_AA28A789123BF1CD05C6FB6C3A959E3E" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_D60AD832F51E83D8A8EDFB6C3A9521FE_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_D60AD832F51E83D8A8EDFB6C3A9521FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net effect of adjustments to our uncertain tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_D60AD832F51E83D8A8EDFB6C3A9521FE_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_D60AD832F51E83D8A8EDFB6C3A9521FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_D60AD832F51E83D8A8EDFB6C3A9521FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_D60AD832F51E83D8A8EDFB6C3A9521FE" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_D60AD832F51E83D8A8EDFB6C3A9521FE" xlink:type="arc" />
    <link:label id="lab_biib_IncomeTaxesTextualAbstract_9D57ADF06678AF6C508CFB6C3A95CBD1_verboseLabel_en-US" xlink:label="lab_biib_IncomeTaxesTextualAbstract_9D57ADF06678AF6C508CFB6C3A95CBD1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes (Textual)</link:label>
    <link:label id="lab_biib_IncomeTaxesTextualAbstract_9D57ADF06678AF6C508CFB6C3A95CBD1_label_en-US" xlink:label="lab_biib_IncomeTaxesTextualAbstract_9D57ADF06678AF6C508CFB6C3A95CBD1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes (Textual) [Abstract]</link:label>
    <link:label id="lab_biib_IncomeTaxesTextualAbstract_9D57ADF06678AF6C508CFB6C3A95CBD1_documentation_en-US" xlink:label="lab_biib_IncomeTaxesTextualAbstract_9D57ADF06678AF6C508CFB6C3A95CBD1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income Taxes.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_IncomeTaxesTextualAbstract" xlink:label="loc_biib_IncomeTaxesTextualAbstract_9D57ADF06678AF6C508CFB6C3A95CBD1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IncomeTaxesTextualAbstract_9D57ADF06678AF6C508CFB6C3A95CBD1" xlink:to="lab_biib_IncomeTaxesTextualAbstract_9D57ADF06678AF6C508CFB6C3A95CBD1" xlink:type="arc" />
    <link:label id="lab_us-gaap_UndistributedEarningsOfForeignSubsidiaries_FE677785951A64866093FB6C3A95FB34_terseLabel_en-US" xlink:label="lab_us-gaap_UndistributedEarningsOfForeignSubsidiaries_FE677785951A64866093FB6C3A95FB34" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Undistributed Foreign Earnings Of Non Us Subsidiaries</link:label>
    <link:label id="lab_us-gaap_UndistributedEarningsOfForeignSubsidiaries_FE677785951A64866093FB6C3A95FB34_label_en-US" xlink:label="lab_us-gaap_UndistributedEarningsOfForeignSubsidiaries_FE677785951A64866093FB6C3A95FB34" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Undistributed Earnings of Foreign Subsidiaries</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UndistributedEarningsOfForeignSubsidiaries" xlink:label="loc_us-gaap_UndistributedEarningsOfForeignSubsidiaries_FE677785951A64866093FB6C3A95FB34" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UndistributedEarningsOfForeignSubsidiaries_FE677785951A64866093FB6C3A95FB34" xlink:to="lab_us-gaap_UndistributedEarningsOfForeignSubsidiaries_FE677785951A64866093FB6C3A95FB34" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_1482ED81FE2CEE029BCEFB6C3A957588_verboseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_1482ED81FE2CEE029BCEFB6C3A957588" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefit</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_1482ED81FE2CEE029BCEFB6C3A957588_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_1482ED81FE2CEE029BCEFB6C3A957588" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_1482ED81FE2CEE029BCEFB6C3A957588" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_1482ED81FE2CEE029BCEFB6C3A957588" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_1482ED81FE2CEE029BCEFB6C3A957588" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_FCF8EE553950DD812519FB6C3A950230_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_FCF8EE553950DD812519FB6C3A950230" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net interest expense</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_FCF8EE553950DD812519FB6C3A950230_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_FCF8EE553950DD812519FB6C3A950230" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_FCF8EE553950DD812519FB6C3A950230" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_FCF8EE553950DD812519FB6C3A950230" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_FCF8EE553950DD812519FB6C3A950230" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_69A3D7A0BED79C843304FB6C3A95B9F8_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_69A3D7A0BED79C843304FB6C3A95B9F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Interest on Income Taxes Accrued</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_69A3D7A0BED79C843304FB6C3A95B9F8_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_69A3D7A0BED79C843304FB6C3A95B9F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Interest on Income Taxes Accrued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_69A3D7A0BED79C843304FB6C3A95B9F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_69A3D7A0BED79C843304FB6C3A95B9F8" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_69A3D7A0BED79C843304FB6C3A95B9F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_EA940FBA93144EFE1E7487BF3B29D862_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable_EA940FBA93144EFE1E7487BF3B29D862" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_EA940FBA93144EFE1E7487BF3B29D862_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable_EA940FBA93144EFE1E7487BF3B29D862" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_EA940FBA93144EFE1E7487BF3B29D862" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_EA940FBA93144EFE1E7487BF3B29D862" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable_EA940FBA93144EFE1E7487BF3B29D862" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillLineItems_8AEA97134254380E3CEA87BF3B2AE537_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems_8AEA97134254380E3CEA87BF3B2AE537" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_8AEA97134254380E3CEA87BF3B2AE537_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems_8AEA97134254380E3CEA87BF3B2AE537" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillLineItems" xlink:label="loc_us-gaap_GoodwillLineItems_8AEA97134254380E3CEA87BF3B2AE537" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems_8AEA97134254380E3CEA87BF3B2AE537" xlink:to="lab_us-gaap_GoodwillLineItems_8AEA97134254380E3CEA87BF3B2AE537" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_2C5F2DB47884536A4FFD87BF3B2ADFDE_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_2C5F2DB47884536A4FFD87BF3B2ADFDE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated impairment losses related to goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_2C5F2DB47884536A4FFD87BF3B2ADFDE_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_2C5F2DB47884536A4FFD87BF3B2ADFDE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_2C5F2DB47884536A4FFD87BF3B2ADFDE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_2C5F2DB47884536A4FFD87BF3B2ADFDE" xlink:to="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_2C5F2DB47884536A4FFD87BF3B2ADFDE" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillRollForward_F42EEE2993604665D2F387BF3B2A6BCA_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward_F42EEE2993604665D2F387BF3B2A6BCA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of roll forward of the changes in goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_F42EEE2993604665D2F387BF3B2A6BCA_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward_F42EEE2993604665D2F387BF3B2A6BCA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillRollForward" xlink:label="loc_us-gaap_GoodwillRollForward_F42EEE2993604665D2F387BF3B2A6BCA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward_F42EEE2993604665D2F387BF3B2A6BCA" xlink:to="lab_us-gaap_GoodwillRollForward_F42EEE2993604665D2F387BF3B2A6BCA" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_097E00B64063F9CC41F987BF3B2A7189_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill_097E00B64063F9CC41F987BF3B2A7189" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Goodwill, beginning of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_097E00B64063F9CC41F987BF3B2A7189" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_097E00B64063F9CC41F987BF3B2A7189" xlink:to="lab_us-gaap_Goodwill_097E00B64063F9CC41F987BF3B2A7189" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_35BBF5D516E49D800AF787BF3B2A5C66_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod_35BBF5D516E49D800AF787BF3B2A5C66" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Increase to goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_35BBF5D516E49D800AF787BF3B2A5C66" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod_35BBF5D516E49D800AF787BF3B2A5C66" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod_35BBF5D516E49D800AF787BF3B2A5C66" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_C7021BCFD0F9EB3A933E87BF3B2A6860_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease_C7021BCFD0F9EB3A933E87BF3B2A6860" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other goodwill adjustments</link:label>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_C7021BCFD0F9EB3A933E87BF3B2A6860_label_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease_C7021BCFD0F9EB3A933E87BF3B2A6860" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Other Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillOtherIncreaseDecrease" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_C7021BCFD0F9EB3A933E87BF3B2A6860" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillOtherIncreaseDecrease_C7021BCFD0F9EB3A933E87BF3B2A6860" xlink:to="lab_us-gaap_GoodwillOtherIncreaseDecrease_C7021BCFD0F9EB3A933E87BF3B2A6860" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_734F832DE97B917DB97787BF3B2A6072_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill_734F832DE97B917DB97787BF3B2A6072" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Goodwill, end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_734F832DE97B917DB97787BF3B2A6072" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_734F832DE97B917DB97787BF3B2A6072" xlink:to="lab_us-gaap_Goodwill_734F832DE97B917DB97787BF3B2A6072" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_29D8FB4DE8FB45613543741285BC94F4_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_29D8FB4DE8FB45613543741285BC94F4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Components of deferred tax assets and liabilities</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_29D8FB4DE8FB45613543741285BC94F4_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_29D8FB4DE8FB45613543741285BC94F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of Deferred Tax Assets and Liabilities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_29D8FB4DE8FB45613543741285BC94F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_29D8FB4DE8FB45613543741285BC94F4" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_29D8FB4DE8FB45613543741285BC94F4" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_976232192BFB527D4BAB741285BCD225_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_976232192BFB527D4BAB741285BCD225" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax credits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_976232192BFB527D4BAB741285BCD225_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_976232192BFB527D4BAB741285BCD225" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_976232192BFB527D4BAB741285BCD225" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_976232192BFB527D4BAB741285BCD225" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_976232192BFB527D4BAB741285BCD225" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsInventory_6EAAE85FA1B930E14FA1741285BD74F5_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInventory_6EAAE85FA1B930E14FA1741285BD74F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, other reserves, and accruals</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInventory_6EAAE85FA1B930E14FA1741285BD74F5_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInventory_6EAAE85FA1B930E14FA1741285BD74F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Inventory</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_6EAAE85FA1B930E14FA1741285BD74F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInventory_6EAAE85FA1B930E14FA1741285BD74F5" xlink:to="lab_us-gaap_DeferredTaxAssetsInventory_6EAAE85FA1B930E14FA1741285BD74F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_F4F6EF72CB966621B9FC741285BD7154_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_F4F6EF72CB966621B9FC741285BD7154" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangibles, net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_F4F6EF72CB966621B9FC741285BD7154_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_F4F6EF72CB966621B9FC741285BD7154" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_F4F6EF72CB966621B9FC741285BD7154" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_F4F6EF72CB966621B9FC741285BD7154" xlink:to="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_F4F6EF72CB966621B9FC741285BD7154" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_AD7997AEA0D71912DC93741285BD41D6_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_AD7997AEA0D71912DC93741285BD41D6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_AD7997AEA0D71912DC93741285BD41D6_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_AD7997AEA0D71912DC93741285BD41D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_AD7997AEA0D71912DC93741285BD41D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_AD7997AEA0D71912DC93741285BD41D6" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_AD7997AEA0D71912DC93741285BD41D6" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_E6EF74F7B76A7485DD7F741285BD6D8B_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_E6EF74F7B76A7485DD7F741285BD6D8B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_E6EF74F7B76A7485DD7F741285BD6D8B_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_E6EF74F7B76A7485DD7F741285BD6D8B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_E6EF74F7B76A7485DD7F741285BD6D8B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_E6EF74F7B76A7485DD7F741285BD6D8B" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_E6EF74F7B76A7485DD7F741285BD6D8B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_36F0BC779783F9883E7E741285BD6642_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther_36F0BC779783F9883E7E741285BD6642" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_36F0BC779783F9883E7E741285BD6642_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther_36F0BC779783F9883E7E741285BD6642" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_36F0BC779783F9883E7E741285BD6642" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther_36F0BC779783F9883E7E741285BD6642" xlink:to="lab_us-gaap_DeferredTaxAssetsOther_36F0BC779783F9883E7E741285BD6642" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_D85C2B8AE911B4459102741285BDF10C_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_D85C2B8AE911B4459102741285BDF10C" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_D85C2B8AE911B4459102741285BDF10C_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_D85C2B8AE911B4459102741285BDF10C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_D85C2B8AE911B4459102741285BDF10C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance_D85C2B8AE911B4459102741285BDF10C" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance_D85C2B8AE911B4459102741285BDF10C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_074AC8687960D447536F741285BD4822_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet_074AC8687960D447536F741285BD4822" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_074AC8687960D447536F741285BD4822_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet_074AC8687960D447536F741285BD4822" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_074AC8687960D447536F741285BD4822" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_074AC8687960D447536F741285BD4822" xlink:to="lab_us-gaap_DeferredTaxAssetsNet_074AC8687960D447536F741285BD4822" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_583B3255D0C7527E0BB3741285BD1BD2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_583B3255D0C7527E0BB3741285BD1BD2" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchased intangible assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_583B3255D0C7527E0BB3741285BD1BD2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_583B3255D0C7527E0BB3741285BD1BD2" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_583B3255D0C7527E0BB3741285BD1BD2" xlink:type="arc" />
    <link:label id="lab_biib_DeferredTaxLiabilitiesDepreciationAmortizationOther_64B0E38F7245D7C08C25741285BDE65D_negatedTerseLabel_en-US" xlink:label="lab_biib_DeferredTaxLiabilitiesDepreciationAmortizationOther_64B0E38F7245D7C08C25741285BDE65D" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Depreciation, amortization and other</link:label>
    <link:label id="lab_biib_DeferredTaxLiabilitiesDepreciationAmortizationOther_64B0E38F7245D7C08C25741285BDE65D_label_en-US" xlink:label="lab_biib_DeferredTaxLiabilitiesDepreciationAmortizationOther_64B0E38F7245D7C08C25741285BDE65D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities Depreciation Amortization Other</link:label>
    <link:label id="lab_biib_DeferredTaxLiabilitiesDepreciationAmortizationOther_64B0E38F7245D7C08C25741285BDE65D_documentation_en-US" xlink:label="lab_biib_DeferredTaxLiabilitiesDepreciationAmortizationOther_64B0E38F7245D7C08C25741285BDE65D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities depreciation amortization other.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_DeferredTaxLiabilitiesDepreciationAmortizationOther" xlink:label="loc_biib_DeferredTaxLiabilitiesDepreciationAmortizationOther_64B0E38F7245D7C08C25741285BDE65D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DeferredTaxLiabilitiesDepreciationAmortizationOther_64B0E38F7245D7C08C25741285BDE65D" xlink:to="lab_biib_DeferredTaxLiabilitiesDepreciationAmortizationOther_64B0E38F7245D7C08C25741285BDE65D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_AA759D6CB7AE73DAEE36741285BD48FC_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities_AA759D6CB7AE73DAEE36741285BD48FC" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_AA759D6CB7AE73DAEE36741285BD48FC_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities_AA759D6CB7AE73DAEE36741285BD48FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_AA759D6CB7AE73DAEE36741285BD48FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities_AA759D6CB7AE73DAEE36741285BD48FC" xlink:to="lab_us-gaap_DeferredTaxLiabilities_AA759D6CB7AE73DAEE36741285BD48FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_596407D89492CC68970474128585C4CC_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_596407D89492CC68970474128585C4CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_596407D89492CC68970474128585C4CC_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_596407D89492CC68970474128585C4CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_596407D89492CC68970474128585C4CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_596407D89492CC68970474128585C4CC" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_596407D89492CC68970474128585C4CC" xlink:type="arc" />
    <link:label id="lab_biib_CorporateDebtSecuritiesCurrentMember_6CF6A3A250B7A7A9B3547412858645AB_verboseLabel_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesCurrentMember_6CF6A3A250B7A7A9B3547412858645AB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Corporate debt securities Current</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesCurrentMember_6CF6A3A250B7A7A9B3547412858645AB_label_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesCurrentMember_6CF6A3A250B7A7A9B3547412858645AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities Current [Member]</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesCurrentMember_6CF6A3A250B7A7A9B3547412858645AB_documentation_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesCurrentMember_6CF6A3A250B7A7A9B3547412858645AB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Corporate debt securities Current.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_CorporateDebtSecuritiesCurrentMember" xlink:label="loc_biib_CorporateDebtSecuritiesCurrentMember_6CF6A3A250B7A7A9B3547412858645AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CorporateDebtSecuritiesCurrentMember_6CF6A3A250B7A7A9B3547412858645AB" xlink:to="lab_biib_CorporateDebtSecuritiesCurrentMember_6CF6A3A250B7A7A9B3547412858645AB" xlink:type="arc" />
    <link:label id="lab_biib_CorporateDebtSecuritiesNonCurrentMember_BB2E8A25CA6755B8582074128586B6BE_verboseLabel_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesNonCurrentMember_BB2E8A25CA6755B8582074128586B6BE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Corporate debt securities Non-current</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesNonCurrentMember_BB2E8A25CA6755B8582074128586B6BE_label_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesNonCurrentMember_BB2E8A25CA6755B8582074128586B6BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities Non Current [Member]</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesNonCurrentMember_BB2E8A25CA6755B8582074128586B6BE_documentation_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesNonCurrentMember_BB2E8A25CA6755B8582074128586B6BE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities Non Current.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_CorporateDebtSecuritiesNonCurrentMember" xlink:label="loc_biib_CorporateDebtSecuritiesNonCurrentMember_BB2E8A25CA6755B8582074128586B6BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CorporateDebtSecuritiesNonCurrentMember_BB2E8A25CA6755B8582074128586B6BE" xlink:to="lab_biib_CorporateDebtSecuritiesNonCurrentMember_BB2E8A25CA6755B8582074128586B6BE" xlink:type="arc" />
    <link:label id="lab_biib_GovernmentSecuritiesCurrentMember_00E27231AF31E7477BAF74128586111B_verboseLabel_en-US" xlink:label="lab_biib_GovernmentSecuritiesCurrentMember_00E27231AF31E7477BAF74128586111B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Government securities Current</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesCurrentMember_00E27231AF31E7477BAF74128586111B_label_en-US" xlink:label="lab_biib_GovernmentSecuritiesCurrentMember_00E27231AF31E7477BAF74128586111B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government Securities Current [Member]</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesCurrentMember_00E27231AF31E7477BAF74128586111B_documentation_en-US" xlink:label="lab_biib_GovernmentSecuritiesCurrentMember_00E27231AF31E7477BAF74128586111B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Government securities Current.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_GovernmentSecuritiesCurrentMember" xlink:label="loc_biib_GovernmentSecuritiesCurrentMember_00E27231AF31E7477BAF74128586111B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GovernmentSecuritiesCurrentMember_00E27231AF31E7477BAF74128586111B" xlink:to="lab_biib_GovernmentSecuritiesCurrentMember_00E27231AF31E7477BAF74128586111B" xlink:type="arc" />
    <link:label id="lab_biib_GovernmentSecuritiesNonCurrentMember_0BFBD90AAAE3A16AF5B07412858638B2_verboseLabel_en-US" xlink:label="lab_biib_GovernmentSecuritiesNonCurrentMember_0BFBD90AAAE3A16AF5B07412858638B2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Government securities Non-current</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesNonCurrentMember_0BFBD90AAAE3A16AF5B07412858638B2_label_en-US" xlink:label="lab_biib_GovernmentSecuritiesNonCurrentMember_0BFBD90AAAE3A16AF5B07412858638B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government Securities Non-current [Member]</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesNonCurrentMember_0BFBD90AAAE3A16AF5B07412858638B2_documentation_en-US" xlink:label="lab_biib_GovernmentSecuritiesNonCurrentMember_0BFBD90AAAE3A16AF5B07412858638B2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Government Securities Non Current.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_GovernmentSecuritiesNonCurrentMember" xlink:label="loc_biib_GovernmentSecuritiesNonCurrentMember_0BFBD90AAAE3A16AF5B07412858638B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GovernmentSecuritiesNonCurrentMember_0BFBD90AAAE3A16AF5B07412858638B2" xlink:to="lab_biib_GovernmentSecuritiesNonCurrentMember_0BFBD90AAAE3A16AF5B07412858638B2" xlink:type="arc" />
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_246BCFD4EB74A6553C78741285868DCC_verboseLabel_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_246BCFD4EB74A6553C78741285868DCC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Mortgage and other asset backed securities Current</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_246BCFD4EB74A6553C78741285868DCC_label_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_246BCFD4EB74A6553C78741285868DCC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mortgage And Other Asset Backed Securities Current [Member]</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_246BCFD4EB74A6553C78741285868DCC_documentation_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_246BCFD4EB74A6553C78741285868DCC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Mortgage and other asset backed securities Current.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_246BCFD4EB74A6553C78741285868DCC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_246BCFD4EB74A6553C78741285868DCC" xlink:to="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_246BCFD4EB74A6553C78741285868DCC" xlink:type="arc" />
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_771D1BCDE326C09FA3DD74128586B467_verboseLabel_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_771D1BCDE326C09FA3DD74128586B467" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Mortgage and other asset backed securities Non-current</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_771D1BCDE326C09FA3DD74128586B467_label_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_771D1BCDE326C09FA3DD74128586B467" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mortgage And Other Asset Backed Securities Non Current [Member]</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_771D1BCDE326C09FA3DD74128586B467_documentation_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_771D1BCDE326C09FA3DD74128586B467" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Mortgage And Other Asset Backed Securities Non Current.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_771D1BCDE326C09FA3DD74128586B467" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_771D1BCDE326C09FA3DD74128586B467" xlink:to="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_771D1BCDE326C09FA3DD74128586B467" xlink:type="arc" />
    <link:label id="lab_biib_MarketableEquitySecuritiesMember_FA1D45C965E0157B77D37412858685AC_verboseLabel_en-US" xlink:label="lab_biib_MarketableEquitySecuritiesMember_FA1D45C965E0157B77D37412858685AC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Marketable equity securities</link:label>
    <link:label id="lab_biib_MarketableEquitySecuritiesMember_FA1D45C965E0157B77D37412858685AC_label_en-US" xlink:label="lab_biib_MarketableEquitySecuritiesMember_FA1D45C965E0157B77D37412858685AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Equity Securities [Member]</link:label>
    <link:label id="lab_biib_MarketableEquitySecuritiesMember_FA1D45C965E0157B77D37412858685AC_documentation_en-US" xlink:label="lab_biib_MarketableEquitySecuritiesMember_FA1D45C965E0157B77D37412858685AC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Marketable equity securities.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_MarketableEquitySecuritiesMember" xlink:label="loc_biib_MarketableEquitySecuritiesMember_FA1D45C965E0157B77D37412858685AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MarketableEquitySecuritiesMember_FA1D45C965E0157B77D37412858685AC" xlink:to="lab_biib_MarketableEquitySecuritiesMember_FA1D45C965E0157B77D37412858685AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6CD19605095FA7A9674D741285868C19_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6CD19605095FA7A9674D741285868C19" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6CD19605095FA7A9674D741285868C19_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6CD19605095FA7A9674D741285868C19" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6CD19605095FA7A9674D741285868C19" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6CD19605095FA7A9674D741285868C19" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6CD19605095FA7A9674D741285868C19" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_FFE3243587A7C40D1B96741285863E21_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract_FFE3243587A7C40D1B96741285863E21" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Marketable Debt and Equity Securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_FFE3243587A7C40D1B96741285863E21_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract_FFE3243587A7C40D1B96741285863E21" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_FFE3243587A7C40D1B96741285863E21" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_FFE3243587A7C40D1B96741285863E21" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAbstract_FFE3243587A7C40D1B96741285863E21" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_8B6EB25C110BDA5A9479741285866C03_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities_8B6EB25C110BDA5A9479741285866C03" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_8B6EB25C110BDA5A9479741285866C03" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecurities_8B6EB25C110BDA5A9479741285866C03" xlink:to="lab_us-gaap_AvailableForSaleSecurities_8B6EB25C110BDA5A9479741285866C03" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_58736ABFF3033C279061741285866A88_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_58736ABFF3033C279061741285866A88" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_58736ABFF3033C279061741285866A88_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_58736ABFF3033C279061741285866A88" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_58736ABFF3033C279061741285866A88" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_58736ABFF3033C279061741285866A88" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_58736ABFF3033C279061741285866A88" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_93884E10312B9D6FCF0474128586BF6E_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_93884E10312B9D6FCF0474128586BF6E" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_93884E10312B9D6FCF0474128586BF6E_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_93884E10312B9D6FCF0474128586BF6E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_93884E10312B9D6FCF0474128586BF6E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_93884E10312B9D6FCF0474128586BF6E" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_93884E10312B9D6FCF0474128586BF6E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_4599C1B6F0250B95BC1D74128586BBB3_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_4599C1B6F0250B95BC1D74128586BBB3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_4599C1B6F0250B95BC1D74128586BBB3_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_4599C1B6F0250B95BC1D74128586BBB3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Amortized Cost Basis</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_4599C1B6F0250B95BC1D74128586BBB3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_4599C1B6F0250B95BC1D74128586BBB3" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_4599C1B6F0250B95BC1D74128586BBB3" xlink:type="arc" />
    <link:label id="lab_biib_NotesPayableToFumedicaMember_4E4617E10B794EDCC7D47412859E0241_verboseLabel_en-US" xlink:label="lab_biib_NotesPayableToFumedicaMember_4E4617E10B794EDCC7D47412859E0241" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Notes Payable to Fumedica</link:label>
    <link:label id="lab_biib_NotesPayableToFumedicaMember_4E4617E10B794EDCC7D47412859E0241_label_en-US" xlink:label="lab_biib_NotesPayableToFumedicaMember_4E4617E10B794EDCC7D47412859E0241" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable To Fumedica [Member]</link:label>
    <link:label id="lab_biib_NotesPayableToFumedicaMember_4E4617E10B794EDCC7D47412859E0241_documentation_en-US" xlink:label="lab_biib_NotesPayableToFumedicaMember_4E4617E10B794EDCC7D47412859E0241" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Notes payable.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_NotesPayableToFumedicaMember" xlink:label="loc_biib_NotesPayableToFumedicaMember_4E4617E10B794EDCC7D47412859E0241" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NotesPayableToFumedicaMember_4E4617E10B794EDCC7D47412859E0241" xlink:to="lab_biib_NotesPayableToFumedicaMember_4E4617E10B794EDCC7D47412859E0241" xlink:type="arc" />
    <link:label id="lab_biib_SummaryOfFairAndCarryingValueOfDebtInstrumentsAbstract_6B4FCE642438FE521A5B7412859F4EC2_verboseLabel_en-US" xlink:label="lab_biib_SummaryOfFairAndCarryingValueOfDebtInstrumentsAbstract_6B4FCE642438FE521A5B7412859F4EC2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of fair and carrying value of debt instruments</link:label>
    <link:label id="lab_biib_SummaryOfFairAndCarryingValueOfDebtInstrumentsAbstract_6B4FCE642438FE521A5B7412859F4EC2_label_en-US" xlink:label="lab_biib_SummaryOfFairAndCarryingValueOfDebtInstrumentsAbstract_6B4FCE642438FE521A5B7412859F4EC2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of fair and carrying value of debt instruments [Abstract]</link:label>
    <link:label id="lab_biib_SummaryOfFairAndCarryingValueOfDebtInstrumentsAbstract_6B4FCE642438FE521A5B7412859F4EC2_documentation_en-US" xlink:label="lab_biib_SummaryOfFairAndCarryingValueOfDebtInstrumentsAbstract_6B4FCE642438FE521A5B7412859F4EC2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary of fair and carrying value of debt instruments.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_SummaryOfFairAndCarryingValueOfDebtInstrumentsAbstract" xlink:label="loc_biib_SummaryOfFairAndCarryingValueOfDebtInstrumentsAbstract_6B4FCE642438FE521A5B7412859F4EC2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryOfFairAndCarryingValueOfDebtInstrumentsAbstract_6B4FCE642438FE521A5B7412859F4EC2" xlink:to="lab_biib_SummaryOfFairAndCarryingValueOfDebtInstrumentsAbstract_6B4FCE642438FE521A5B7412859F4EC2" xlink:type="arc" />
    <link:label id="lab_us-gaap_NotesPayableFairValueDisclosure_5252426369D9D3D944287412859F99AE_verboseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableFairValueDisclosure_5252426369D9D3D944287412859F99AE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Notes payable, fair value</link:label>
    <link:label id="lab_us-gaap_NotesPayableFairValueDisclosure_5252426369D9D3D944287412859F99AE_label_en-US" xlink:label="lab_us-gaap_NotesPayableFairValueDisclosure_5252426369D9D3D944287412859F99AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_5252426369D9D3D944287412859F99AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableFairValueDisclosure_5252426369D9D3D944287412859F99AE" xlink:to="lab_us-gaap_NotesPayableFairValueDisclosure_5252426369D9D3D944287412859F99AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_0282930666FA3A4788087412859F35F5_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue_0282930666FA3A4788087412859F35F5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total fair value</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_0282930666FA3A4788087412859F35F5_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue_0282930666FA3A4788087412859F35F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue_0282930666FA3A4788087412859F35F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue_0282930666FA3A4788087412859F35F5" xlink:to="lab_us-gaap_DebtInstrumentFairValue_0282930666FA3A4788087412859F35F5" xlink:type="arc" />
    <link:label id="lab_biib_MarketStockUnitsActivityAbstract_EB0B9D4F3BA062C2AD067412882DAEE2_verboseLabel_en-US" xlink:label="lab_biib_MarketStockUnitsActivityAbstract_EB0B9D4F3BA062C2AD067412882DAEE2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Market stock units activity</link:label>
    <link:label id="lab_biib_MarketStockUnitsActivityAbstract_EB0B9D4F3BA062C2AD067412882DAEE2_label_en-US" xlink:label="lab_biib_MarketStockUnitsActivityAbstract_EB0B9D4F3BA062C2AD067412882DAEE2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Market Stock Units Activity [Abstract]</link:label>
    <link:label id="lab_biib_MarketStockUnitsActivityAbstract_EB0B9D4F3BA062C2AD067412882DAEE2_documentation_en-US" xlink:label="lab_biib_MarketStockUnitsActivityAbstract_EB0B9D4F3BA062C2AD067412882DAEE2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Market stock units activity.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_MarketStockUnitsActivityAbstract" xlink:label="loc_biib_MarketStockUnitsActivityAbstract_EB0B9D4F3BA062C2AD067412882DAEE2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_EB0B9D4F3BA062C2AD067412882DAEE2" xlink:to="lab_biib_MarketStockUnitsActivityAbstract_EB0B9D4F3BA062C2AD067412882DAEE2" xlink:type="arc" />
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_6062B72096C355CD7F50741289698D2F_verboseLabel_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_6062B72096C355CD7F50741289698D2F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Analysis of the change in reserves</link:label>
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_6062B72096C355CD7F50741289698D2F_label_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_6062B72096C355CD7F50741289698D2F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Analysis Of Amount Of And Change In Product Revenue Reserves [Table Text Block]</link:label>
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_6062B72096C355CD7F50741289698D2F_documentation_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_6062B72096C355CD7F50741289698D2F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Analysis of amount of and change in product revenue reserves.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:label="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_6062B72096C355CD7F50741289698D2F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_6062B72096C355CD7F50741289698D2F" xlink:to="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_6062B72096C355CD7F50741289698D2F" xlink:type="arc" />
    <link:label id="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_563BBDB65902B3FC4329741289698C87_verboseLabel_en-US" xlink:label="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_563BBDB65902B3FC4329741289698C87" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total reserves, included in consolidated balance sheets</link:label>
    <link:label id="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_563BBDB65902B3FC4329741289698C87_label_en-US" xlink:label="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_563BBDB65902B3FC4329741289698C87" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary Of Product Revenue Reserves Included In Consolidated Balance Sheets [Table Text Block]</link:label>
    <link:label id="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_563BBDB65902B3FC4329741289698C87_documentation_en-US" xlink:label="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_563BBDB65902B3FC4329741289698C87" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary of total product revenue reserves included in consolidated balance sheets.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:label="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_563BBDB65902B3FC4329741289698C87" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_563BBDB65902B3FC4329741289698C87" xlink:to="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_563BBDB65902B3FC4329741289698C87" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_D0E2863E35C7BD077131886F76652E6A_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_D0E2863E35C7BD077131886F76652E6A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Employee Stock Ownership Plan (ESOP) Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_D0E2863E35C7BD077131886F76652E6A_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_D0E2863E35C7BD077131886F76652E6A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Stock Ownership Plan (ESOP) Disclosures [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_D0E2863E35C7BD077131886F76652E6A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_D0E2863E35C7BD077131886F76652E6A" xlink:to="lab_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_D0E2863E35C7BD077131886F76652E6A" xlink:type="arc" />
    <link:label id="lab_us-gaap_PlanNameAxis_936C2D906EC05AB3CD22886F76655298_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis_936C2D906EC05AB3CD22886F76655298" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_936C2D906EC05AB3CD22886F76655298_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis_936C2D906EC05AB3CD22886F76655298" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_936C2D906EC05AB3CD22886F76655298" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis_936C2D906EC05AB3CD22886F76655298" xlink:to="lab_us-gaap_PlanNameAxis_936C2D906EC05AB3CD22886F76655298" xlink:type="arc" />
    <link:label id="lab_us-gaap_PlanNameDomain_24B094D3E1C41F11157C886F76658D07_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain_24B094D3E1C41F11157C886F76658D07" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_24B094D3E1C41F11157C886F76658D07_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain_24B094D3E1C41F11157C886F76658D07" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_24B094D3E1C41F11157C886F76658D07" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain_24B094D3E1C41F11157C886F76658D07" xlink:to="lab_us-gaap_PlanNameDomain_24B094D3E1C41F11157C886F76658D07" xlink:type="arc" />
    <link:label id="lab_biib_A2015ESPPMember_A211A5E6775E8F7601E4886F7665FD00_terseLabel_en-US" xlink:label="lab_biib_A2015ESPPMember_A211A5E6775E8F7601E4886F7665FD00" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2015 ESPP</link:label>
    <link:label id="lab_biib_A2015ESPPMember_A211A5E6775E8F7601E4886F7665FD00_label_en-US" xlink:label="lab_biib_A2015ESPPMember_A211A5E6775E8F7601E4886F7665FD00" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2015 ESPP [Member]</link:label>
    <link:label id="lab_biib_A2015ESPPMember_A211A5E6775E8F7601E4886F7665FD00_documentation_en-US" xlink:label="lab_biib_A2015ESPPMember_A211A5E6775E8F7601E4886F7665FD00" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2015 ESPP [Member]</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_A2015ESPPMember" xlink:label="loc_biib_A2015ESPPMember_A211A5E6775E8F7601E4886F7665FD00" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A2015ESPPMember_A211A5E6775E8F7601E4886F7665FD00" xlink:to="lab_biib_A2015ESPPMember_A211A5E6775E8F7601E4886F7665FD00" xlink:type="arc" />
    <link:label id="lab_biib_A1995ESPPMember_47480A7C219297A899A3886F76655F6D_terseLabel_en-US" xlink:label="lab_biib_A1995ESPPMember_47480A7C219297A899A3886F76655F6D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">1995 ESPP</link:label>
    <link:label id="lab_biib_A1995ESPPMember_47480A7C219297A899A3886F76655F6D_label_en-US" xlink:label="lab_biib_A1995ESPPMember_47480A7C219297A899A3886F76655F6D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">1995 ESPP [Member]</link:label>
    <link:label id="lab_biib_A1995ESPPMember_47480A7C219297A899A3886F76655F6D_documentation_en-US" xlink:label="lab_biib_A1995ESPPMember_47480A7C219297A899A3886F76655F6D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">1995 ESPP [Member]</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_A1995ESPPMember" xlink:label="loc_biib_A1995ESPPMember_47480A7C219297A899A3886F76655F6D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A1995ESPPMember_47480A7C219297A899A3886F76655F6D" xlink:to="lab_biib_A1995ESPPMember_47480A7C219297A899A3886F76655F6D" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_4AB6710A9DE9758EEDA8886F76652946_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_4AB6710A9DE9758EEDA8886F76652946" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_4AB6710A9DE9758EEDA8886F76652946_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_4AB6710A9DE9758EEDA8886F76652946" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_4AB6710A9DE9758EEDA8886F76652946" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_4AB6710A9DE9758EEDA8886F76652946" xlink:to="lab_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_4AB6710A9DE9758EEDA8886F76652946" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_A8A79E123689DBA46648886F766B403B_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_A8A79E123689DBA46648886F766B403B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash received under ESPP</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_A8A79E123689DBA46648886F766B403B_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_A8A79E123689DBA46648886F766B403B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_A8A79E123689DBA46648886F766B403B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_A8A79E123689DBA46648886F766B403B" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_A8A79E123689DBA46648886F766B403B" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_87BA5A3CA40A268D630D741285DC1395_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_87BA5A3CA40A268D630D741285DC1395" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_87BA5A3CA40A268D630D741285DC1395" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_87BA5A3CA40A268D630D741285DC1395" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_87BA5A3CA40A268D630D741285DC1395" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_28E06002BD8F9E095FE6741285DC645F_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_28E06002BD8F9E095FE6741285DC645F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_28E06002BD8F9E095FE6741285DC645F_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_28E06002BD8F9E095FE6741285DC645F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_28E06002BD8F9E095FE6741285DC645F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare_28E06002BD8F9E095FE6741285DC645F" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare_28E06002BD8F9E095FE6741285DC645F" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_EFF28A2144A6F8085D6B741285DCEC2B_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_EFF28A2144A6F8085D6B741285DCEC2B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_EFF28A2144A6F8085D6B741285DCEC2B_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_EFF28A2144A6F8085D6B741285DCEC2B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_EFF28A2144A6F8085D6B741285DCEC2B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_EFF28A2144A6F8085D6B741285DCEC2B" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_EFF28A2144A6F8085D6B741285DCEC2B" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockShares_A7E431562B3CBAB2589F741285DCB72A_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares_A7E431562B3CBAB2589F741285DCB72A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury stock at cost, shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_A7E431562B3CBAB2589F741285DCB72A_label_en-US" xlink:label="lab_us-gaap_TreasuryStockShares_A7E431562B3CBAB2589F741285DCB72A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="loc_us-gaap_TreasuryStockShares_A7E431562B3CBAB2589F741285DCB72A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockShares_A7E431562B3CBAB2589F741285DCB72A" xlink:to="lab_us-gaap_TreasuryStockShares_A7E431562B3CBAB2589F741285DCB72A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_29A3EF5CC10644D90B057412876898FE_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_29A3EF5CC10644D90B057412876898FE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other Consolidated Financial Statement Detail</link:label>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_29A3EF5CC10644D90B057412876898FE_label_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_29A3EF5CC10644D90B057412876898FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Financial Information Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_29A3EF5CC10644D90B057412876898FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_29A3EF5CC10644D90B057412876898FE" xlink:to="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_29A3EF5CC10644D90B057412876898FE" xlink:type="arc" />
    <link:label id="lab_biib_ValuationOfGrantedStockUnitsAbstract_FB2EC3965B7896849E93FB6C3ADB8E00_verboseLabel_en-US" xlink:label="lab_biib_ValuationOfGrantedStockUnitsAbstract_FB2EC3965B7896849E93FB6C3ADB8E00" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Assumptions used in valuation of market based stock units</link:label>
    <link:label id="lab_biib_ValuationOfGrantedStockUnitsAbstract_FB2EC3965B7896849E93FB6C3ADB8E00_label_en-US" xlink:label="lab_biib_ValuationOfGrantedStockUnitsAbstract_FB2EC3965B7896849E93FB6C3ADB8E00" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation of Granted Stock Units [Abstract]</link:label>
    <link:label id="lab_biib_ValuationOfGrantedStockUnitsAbstract_FB2EC3965B7896849E93FB6C3ADB8E00_documentation_en-US" xlink:label="lab_biib_ValuationOfGrantedStockUnitsAbstract_FB2EC3965B7896849E93FB6C3ADB8E00" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Valuation of granted stock units.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_ValuationOfGrantedStockUnitsAbstract" xlink:label="loc_biib_ValuationOfGrantedStockUnitsAbstract_FB2EC3965B7896849E93FB6C3ADB8E00" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ValuationOfGrantedStockUnitsAbstract_FB2EC3965B7896849E93FB6C3ADB8E00" xlink:to="lab_biib_ValuationOfGrantedStockUnitsAbstract_FB2EC3965B7896849E93FB6C3ADB8E00" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_61CB6AD25C6385BDF790FB6C3ADBAABC_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_61CB6AD25C6385BDF790FB6C3ADBAABC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_61CB6AD25C6385BDF790FB6C3ADBAABC_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_61CB6AD25C6385BDF790FB6C3ADBAABC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_61CB6AD25C6385BDF790FB6C3ADBAABC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_61CB6AD25C6385BDF790FB6C3ADBAABC" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_61CB6AD25C6385BDF790FB6C3ADBAABC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_5CBB127508B0202ECF86FB6C3ADBACE4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_5CBB127508B0202ECF86FB6C3ADBACE4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range of expected stock price volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_5CBB127508B0202ECF86FB6C3ADBACE4_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_5CBB127508B0202ECF86FB6C3ADBACE4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_5CBB127508B0202ECF86FB6C3ADBACE4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_5CBB127508B0202ECF86FB6C3ADBACE4" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_5CBB127508B0202ECF86FB6C3ADBACE4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_B296757E39549928EB1BFB6C3ADBD156_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_B296757E39549928EB1BFB6C3ADBD156" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Minimum range of risk-free interest rates</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_B296757E39549928EB1BFB6C3ADBD156_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_B296757E39549928EB1BFB6C3ADBD156" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_B296757E39549928EB1BFB6C3ADBD156" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_B296757E39549928EB1BFB6C3ADBD156" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_B296757E39549928EB1BFB6C3ADBD156" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_0C126A384E819793B300FB6C3ADB8383_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_0C126A384E819793B300FB6C3ADB8383" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Maximum range of risk-free interest rates</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_0C126A384E819793B300FB6C3ADB8383_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_0C126A384E819793B300FB6C3ADB8383" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_0C126A384E819793B300FB6C3ADB8383" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_0C126A384E819793B300FB6C3ADB8383" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_0C126A384E819793B300FB6C3ADB8383" xlink:type="arc" />
    <link:label id="lab_biib_AverageStockPriceOnGrantDateInDollarsMinimum_31DCF42228DC7E3F4957FB6C3ADBB518_verboseLabel_en-US" xlink:label="lab_biib_AverageStockPriceOnGrantDateInDollarsMinimum_31DCF42228DC7E3F4957FB6C3ADBB518" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Average stock price on grant date minimum</link:label>
    <link:label id="lab_biib_AverageStockPriceOnGrantDateInDollarsMinimum_31DCF42228DC7E3F4957FB6C3ADBB518_label_en-US" xlink:label="lab_biib_AverageStockPriceOnGrantDateInDollarsMinimum_31DCF42228DC7E3F4957FB6C3ADBB518" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Average Stock Price On Grant Date In Dollars Minimum</link:label>
    <link:label id="lab_biib_AverageStockPriceOnGrantDateInDollarsMinimum_31DCF42228DC7E3F4957FB6C3ADBB518_documentation_en-US" xlink:label="lab_biib_AverageStockPriceOnGrantDateInDollarsMinimum_31DCF42228DC7E3F4957FB6C3ADBB518" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Average stock price on grant date in dollars minimum.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_AverageStockPriceOnGrantDateInDollarsMinimum" xlink:label="loc_biib_AverageStockPriceOnGrantDateInDollarsMinimum_31DCF42228DC7E3F4957FB6C3ADBB518" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AverageStockPriceOnGrantDateInDollarsMinimum_31DCF42228DC7E3F4957FB6C3ADBB518" xlink:to="lab_biib_AverageStockPriceOnGrantDateInDollarsMinimum_31DCF42228DC7E3F4957FB6C3ADBB518" xlink:type="arc" />
    <link:label id="lab_biib_AverageStockPriceOnGrantDateInDollarsMaximum_FD5C768ECF8625BFB681FB6C3ADBCEA9_verboseLabel_en-US" xlink:label="lab_biib_AverageStockPriceOnGrantDateInDollarsMaximum_FD5C768ECF8625BFB681FB6C3ADBCEA9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Average stock price on grant date maximum</link:label>
    <link:label id="lab_biib_AverageStockPriceOnGrantDateInDollarsMaximum_FD5C768ECF8625BFB681FB6C3ADBCEA9_label_en-US" xlink:label="lab_biib_AverageStockPriceOnGrantDateInDollarsMaximum_FD5C768ECF8625BFB681FB6C3ADBCEA9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Average Stock Price On Grant Date In Dollars Maximum</link:label>
    <link:label id="lab_biib_AverageStockPriceOnGrantDateInDollarsMaximum_FD5C768ECF8625BFB681FB6C3ADBCEA9_documentation_en-US" xlink:label="lab_biib_AverageStockPriceOnGrantDateInDollarsMaximum_FD5C768ECF8625BFB681FB6C3ADBCEA9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Average stock price on grant date in dollars maximum.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_AverageStockPriceOnGrantDateInDollarsMaximum" xlink:label="loc_biib_AverageStockPriceOnGrantDateInDollarsMaximum_FD5C768ECF8625BFB681FB6C3ADBCEA9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AverageStockPriceOnGrantDateInDollarsMaximum_FD5C768ECF8625BFB681FB6C3ADBCEA9" xlink:to="lab_biib_AverageStockPriceOnGrantDateInDollarsMaximum_FD5C768ECF8625BFB681FB6C3ADBCEA9" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinimumMember_9489C7419AC4A154B011FB6680045D99_terseLabel_en-US" xlink:label="lab_us-gaap_MinimumMember_9489C7419AC4A154B011FB6680045D99" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_9489C7419AC4A154B011FB6680045D99" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinimumMember_9489C7419AC4A154B011FB6680045D99" xlink:to="lab_us-gaap_MinimumMember_9489C7419AC4A154B011FB6680045D99" xlink:type="arc" />
    <link:label id="lab_us-gaap_MaximumMember_D76683016A8DE77B3954FB668004071E_terseLabel_en-US" xlink:label="lab_us-gaap_MaximumMember_D76683016A8DE77B3954FB668004071E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_D76683016A8DE77B3954FB668004071E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaximumMember_D76683016A8DE77B3954FB668004071E" xlink:to="lab_us-gaap_MaximumMember_D76683016A8DE77B3954FB668004071E" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestRateContractMember_0BC792B987CE7F40A565FB6680054D0C_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateContractMember_0BC792B987CE7F40A565FB6680054D0C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate lock</link:label>
    <link:label id="lab_us-gaap_InterestRateContractMember_0BC792B987CE7F40A565FB6680054D0C_label_en-US" xlink:label="lab_us-gaap_InterestRateContractMember_0BC792B987CE7F40A565FB6680054D0C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Rate Contract [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestRateContractMember" xlink:label="loc_us-gaap_InterestRateContractMember_0BC792B987CE7F40A565FB6680054D0C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateContractMember_0BC792B987CE7F40A565FB6680054D0C" xlink:to="lab_us-gaap_InterestRateContractMember_0BC792B987CE7F40A565FB6680054D0C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_77C57B707FA5DDF57596FB668006FF6E_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember_77C57B707FA5DDF57596FB668006FF6E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Designated as Hedging Instrument</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_77C57B707FA5DDF57596FB668006FF6E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember_77C57B707FA5DDF57596FB668006FF6E" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember_77C57B707FA5DDF57596FB668006FF6E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeRemainingMaturity1_955D089587F4AA09DAF2FB66800649BC_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeRemainingMaturity1_955D089587F4AA09DAF2FB66800649BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative, Remaining Maturity</link:label>
    <link:label id="lab_us-gaap_DerivativeRemainingMaturity1_955D089587F4AA09DAF2FB66800649BC_label_en-US" xlink:label="lab_us-gaap_DerivativeRemainingMaturity1_955D089587F4AA09DAF2FB66800649BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Remaining Maturity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeRemainingMaturity1" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1_955D089587F4AA09DAF2FB66800649BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeRemainingMaturity1_955D089587F4AA09DAF2FB66800649BC" xlink:to="lab_us-gaap_DerivativeRemainingMaturity1_955D089587F4AA09DAF2FB66800649BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_2C73426F798D539A9817FB66800645D7_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_2C73426F798D539A9817FB66800645D7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Gain on treasury rate lock settlement</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_2C73426F798D539A9817FB66800645D7_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_2C73426F798D539A9817FB66800645D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_2C73426F798D539A9817FB66800645D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_2C73426F798D539A9817FB66800645D7" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_2C73426F798D539A9817FB66800645D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_90AFF56FC9C3F2358358FB668006D3FA_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_90AFF56FC9C3F2358358FB668006D3FA" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gain/Loss on fair value of foreign currency forward contracts</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_90AFF56FC9C3F2358358FB668006D3FA_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_90AFF56FC9C3F2358358FB668006D3FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized Gain (Loss) on Foreign Currency Derivatives, Net, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" xlink:label="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_90AFF56FC9C3F2358358FB668006D3FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_90AFF56FC9C3F2358358FB668006D3FA" xlink:to="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_90AFF56FC9C3F2358358FB668006D3FA" xlink:type="arc" />
    <link:label id="lab_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1_4E4F19E46316DC86F90AFB668006498B_verboseLabel_en-US" xlink:label="lab_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1_4E4F19E46316DC86F90AFB668006498B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected settlement time for contracts, in months</link:label>
    <link:label id="lab_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1_4E4F19E46316DC86F90AFB668006498B_label_en-US" xlink:label="lab_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1_4E4F19E46316DC86F90AFB668006498B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum Remaining Maturity of Foreign Currency Derivatives</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1" xlink:label="loc_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1_4E4F19E46316DC86F90AFB668006498B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1_4E4F19E46316DC86F90AFB668006498B" xlink:to="lab_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1_4E4F19E46316DC86F90AFB668006498B" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_7A84FAEB44F64E1A4260FB668006FF65_verboseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_7A84FAEB44F64E1A4260FB668006FF65" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net gains (losses) of other income (expense) related to foreign currency forward contracts</link:label>
    <link:label id="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_7A84FAEB44F64E1A4260FB668006FF65_label_en-US" xlink:label="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_7A84FAEB44F64E1A4260FB668006FF65" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_7A84FAEB44F64E1A4260FB668006FF65" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_7A84FAEB44F64E1A4260FB668006FF65" xlink:to="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_7A84FAEB44F64E1A4260FB668006FF65" xlink:type="arc" />
    <link:label id="lab_us-gaap_Revenues_97C85A5C1EDC9F1C8DA0FC923B3658B0_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues_97C85A5C1EDC9F1C8DA0FC923B3658B0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_97C85A5C1EDC9F1C8DA0FC923B3658B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_97C85A5C1EDC9F1C8DA0FC923B3658B0" xlink:to="lab_us-gaap_Revenues_97C85A5C1EDC9F1C8DA0FC923B3658B0" xlink:type="arc" />
    <link:label id="lab_biib_Copromotionprofitsandlosses_3844388B1DDCB546D761FC923B36B1C3_terseLabel_en-US" xlink:label="lab_biib_Copromotionprofitsandlosses_3844388B1DDCB546D761FC923B36B1C3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Co-promotion profits and losses</link:label>
    <link:label id="lab_biib_Copromotionprofitsandlosses_3844388B1DDCB546D761FC923B36B1C3_label_en-US" xlink:label="lab_biib_Copromotionprofitsandlosses_3844388B1DDCB546D761FC923B36B1C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Co-promotion profits and losses</link:label>
    <link:label id="lab_biib_Copromotionprofitsandlosses_3844388B1DDCB546D761FC923B36B1C3_documentation_en-US" xlink:label="lab_biib_Copromotionprofitsandlosses_3844388B1DDCB546D761FC923B36B1C3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Co-promotion profits and losses</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_Copromotionprofitsandlosses" xlink:label="loc_biib_Copromotionprofitsandlosses_3844388B1DDCB546D761FC923B36B1C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Copromotionprofitsandlosses_3844388B1DDCB546D761FC923B36B1C3" xlink:to="lab_biib_Copromotionprofitsandlosses_3844388B1DDCB546D761FC923B36B1C3" xlink:type="arc" />
    <link:label id="lab_biib_ShareOfCoPromotionProfits_38396503935BF02F0784FC923B36C048_terseLabel_en-US" xlink:label="lab_biib_ShareOfCoPromotionProfits_38396503935BF02F0784FC923B36C048" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Biogen's share of co-promotion losses</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_ShareOfCoPromotionProfits" xlink:label="loc_biib_ShareOfCoPromotionProfits_38396503935BF02F0784FC923B36C048" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ShareOfCoPromotionProfits_38396503935BF02F0784FC923B36C048" xlink:to="lab_biib_ShareOfCoPromotionProfits_38396503935BF02F0784FC923B36C048" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_ABA2B54464736C4E76F4FB6C3B12BA51_verboseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_ABA2B54464736C4E76F4FB6C3B12BA51" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_ABA2B54464736C4E76F4FB6C3B12BA51" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ABA2B54464736C4E76F4FB6C3B12BA51" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_ABA2B54464736C4E76F4FB6C3B12BA51" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_2F923B0CE5A4BBEE6EC9FB6C3B13281A_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_2F923B0CE5A4BBEE6EC9FB6C3B13281A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unfunded Status of Postretirement Benefit Plans</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_2F923B0CE5A4BBEE6EC9FB6C3B13281A_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_2F923B0CE5A4BBEE6EC9FB6C3B13281A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_2F923B0CE5A4BBEE6EC9FB6C3B13281A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_2F923B0CE5A4BBEE6EC9FB6C3B13281A" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_2F923B0CE5A4BBEE6EC9FB6C3B13281A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_FAB61E2B105812ECF5C7FB6C3B13B50E_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember_FAB61E2B105812ECF5C7FB6C3B13B50E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Translation Adjustments</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_FAB61E2B105812ECF5C7FB6C3B13B50E_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember_FAB61E2B105812ECF5C7FB6C3B13B50E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_FAB61E2B105812ECF5C7FB6C3B13B50E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember_FAB61E2B105812ECF5C7FB6C3B13B50E" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember_FAB61E2B105812ECF5C7FB6C3B13B50E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_DCC6E30B8F0E016F7415FB6C3B138862_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_DCC6E30B8F0E016F7415FB6C3B138862" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_DCC6E30B8F0E016F7415FB6C3B138862_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_DCC6E30B8F0E016F7415FB6C3B138862" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_DCC6E30B8F0E016F7415FB6C3B138862" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_DCC6E30B8F0E016F7415FB6C3B138862" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_DCC6E30B8F0E016F7415FB6C3B138862" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_CDF92BFD30E696D57A71FB6C3B137C2B_periodStartLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_CDF92BFD30E696D57A71FB6C3B137C2B" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income (loss), net of tax beginning balance</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_CDF92BFD30E696D57A71FB6C3B137C2B_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_CDF92BFD30E696D57A71FB6C3B137C2B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_CDF92BFD30E696D57A71FB6C3B137C2B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_CDF92BFD30E696D57A71FB6C3B137C2B" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_CDF92BFD30E696D57A71FB6C3B137C2B" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_A55550F976AA6321C4EEFB6C3B13FFF4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_A55550F976AA6321C4EEFB6C3B13FFF4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss), before reclassifications</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_A55550F976AA6321C4EEFB6C3B13FFF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_A55550F976AA6321C4EEFB6C3B13FFF4" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_A55550F976AA6321C4EEFB6C3B13FFF4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_4AF63ABFDC7C9493F6C5FB6C3B13DEA3_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_4AF63ABFDC7C9493F6C5FB6C3B13DEA3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amounts reclassified from accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_4AF63ABFDC7C9493F6C5FB6C3B13DEA3_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_4AF63ABFDC7C9493F6C5FB6C3B13DEA3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_4AF63ABFDC7C9493F6C5FB6C3B13DEA3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_4AF63ABFDC7C9493F6C5FB6C3B13DEA3" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_4AF63ABFDC7C9493F6C5FB6C3B13DEA3" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_9B7AB4B53C702D648A1EFB6C3B135A90_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_9B7AB4B53C702D648A1EFB6C3B135A90" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net current period other comprehensive income (loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_9B7AB4B53C702D648A1EFB6C3B135A90" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_9B7AB4B53C702D648A1EFB6C3B135A90" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_9B7AB4B53C702D648A1EFB6C3B135A90" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2C96B4AFAB9BE384850BFB6C3B137306_periodEndLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2C96B4AFAB9BE384850BFB6C3B137306" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income (loss), net of tax ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2C96B4AFAB9BE384850BFB6C3B137306" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2C96B4AFAB9BE384850BFB6C3B137306" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2C96B4AFAB9BE384850BFB6C3B137306" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_367A2BFD273EBF00AF7B741285683182_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_367A2BFD273EBF00AF7B741285683182" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income before income tax provision and the income tax expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_367A2BFD273EBF00AF7B741285683182_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_367A2BFD273EBF00AF7B741285683182" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_367A2BFD273EBF00AF7B741285683182" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_367A2BFD273EBF00AF7B741285683182" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_367A2BFD273EBF00AF7B741285683182" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_8DA5E4F7EFE6DA231EA6741285687E13_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_8DA5E4F7EFE6DA231EA6741285687E13" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Components of deferred tax assets and liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_8DA5E4F7EFE6DA231EA6741285687E13_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_8DA5E4F7EFE6DA231EA6741285687E13" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_8DA5E4F7EFE6DA231EA6741285687E13" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_8DA5E4F7EFE6DA231EA6741285687E13" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_8DA5E4F7EFE6DA231EA6741285687E13" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_982811AC6F51690EA967741285689D74_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_982811AC6F51690EA967741285689D74" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation between the U.S. federal statutory tax rate and effective tax rate</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_982811AC6F51690EA967741285689D74_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_982811AC6F51690EA967741285689D74" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_982811AC6F51690EA967741285689D74" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_982811AC6F51690EA967741285689D74" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_982811AC6F51690EA967741285689D74" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_1768E1E533026D7B638A741285681D83_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_1768E1E533026D7B638A741285681D83" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of beginning and ending amount of unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_1768E1E533026D7B638A741285681D83_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_1768E1E533026D7B638A741285681D83" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_1768E1E533026D7B638A741285681D83" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_1768E1E533026D7B638A741285681D83" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_1768E1E533026D7B638A741285681D83" xlink:type="arc" />
    <link:label id="lab_biib_StockOptionActivityAbstract_63FFD68403502708E7D174128550C563_verboseLabel_en-US" xlink:label="lab_biib_StockOptionActivityAbstract_63FFD68403502708E7D174128550C563" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock Option Activity</link:label>
    <link:label id="lab_biib_StockOptionActivityAbstract_63FFD68403502708E7D174128550C563_label_en-US" xlink:label="lab_biib_StockOptionActivityAbstract_63FFD68403502708E7D174128550C563" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Option Activity [Abstract]</link:label>
    <link:label id="lab_biib_StockOptionActivityAbstract_63FFD68403502708E7D174128550C563_documentation_en-US" xlink:label="lab_biib_StockOptionActivityAbstract_63FFD68403502708E7D174128550C563" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock option activity.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_StockOptionActivityAbstract" xlink:label="loc_biib_StockOptionActivityAbstract_63FFD68403502708E7D174128550C563" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_StockOptionActivityAbstract_63FFD68403502708E7D174128550C563" xlink:to="lab_biib_StockOptionActivityAbstract_63FFD68403502708E7D174128550C563" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_D04CBCACD8673358DA44741285501914_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_D04CBCACD8673358DA44741285501914" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance, Outstanding shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_D04CBCACD8673358DA44741285501914_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_D04CBCACD8673358DA44741285501914" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_D04CBCACD8673358DA44741285501914" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_D04CBCACD8673358DA44741285501914" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_D04CBCACD8673358DA44741285501914" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_D457F3D198DA02C474E7741285504A00_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_D457F3D198DA02C474E7741285504A00" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance, Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_D457F3D198DA02C474E7741285504A00_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_D457F3D198DA02C474E7741285504A00" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_D457F3D198DA02C474E7741285504A00" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_D457F3D198DA02C474E7741285504A00" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_D457F3D198DA02C474E7741285504A00" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_4411824CB83C23E1D088741285502061_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_4411824CB83C23E1D088741285502061" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares, Granted</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_4411824CB83C23E1D088741285502061_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_4411824CB83C23E1D088741285502061" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_4411824CB83C23E1D088741285502061" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_4411824CB83C23E1D088741285502061" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_4411824CB83C23E1D088741285502061" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_D6242A16E59967BB739074128550AD7C_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_D6242A16E59967BB739074128550AD7C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price, Granted</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_D6242A16E59967BB739074128550AD7C_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_D6242A16E59967BB739074128550AD7C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_D6242A16E59967BB739074128550AD7C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_D6242A16E59967BB739074128550AD7C" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_D6242A16E59967BB739074128550AD7C" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6898291F4B1AB630FA7274128550EFE9_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6898291F4B1AB630FA7274128550EFE9" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Shares, Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6898291F4B1AB630FA7274128550EFE9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6898291F4B1AB630FA7274128550EFE9" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6898291F4B1AB630FA7274128550EFE9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_0B59B0D59B87C40E9E8F74128550B90B_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_0B59B0D59B87C40E9E8F74128550B90B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price, Exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_0B59B0D59B87C40E9E8F74128550B90B_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_0B59B0D59B87C40E9E8F74128550B90B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_0B59B0D59B87C40E9E8F74128550B90B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_0B59B0D59B87C40E9E8F74128550B90B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_0B59B0D59B87C40E9E8F74128550B90B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2409E4B93EFCF98A6522741285501AC6_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2409E4B93EFCF98A6522741285501AC6" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Shares, Cancelled</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2409E4B93EFCF98A6522741285501AC6_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2409E4B93EFCF98A6522741285501AC6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2409E4B93EFCF98A6522741285501AC6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2409E4B93EFCF98A6522741285501AC6" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2409E4B93EFCF98A6522741285501AC6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_8F6586DA4A1FE2A61ABC741285511758_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_8F6586DA4A1FE2A61ABC741285511758" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price, Cancelled</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_8F6586DA4A1FE2A61ABC741285511758_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_8F6586DA4A1FE2A61ABC741285511758" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_8F6586DA4A1FE2A61ABC741285511758" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_8F6586DA4A1FE2A61ABC741285511758" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_8F6586DA4A1FE2A61ABC741285511758" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_EBCBC870FFD6D440968074128551B58E_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_EBCBC870FFD6D440968074128551B58E" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance, Outstanding shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_EBCBC870FFD6D440968074128551B58E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_EBCBC870FFD6D440968074128551B58E" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_EBCBC870FFD6D440968074128551B58E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_38B7568935F828AC060074128551D302_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_38B7568935F828AC060074128551D302" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_38B7568935F828AC060074128551D302" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_38B7568935F828AC060074128551D302" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_38B7568935F828AC060074128551D302" xlink:type="arc" />
    <link:label id="lab_biib_BusinessOverviewPolicyTextBlock_0C66D3DE0492CF21543AFA4EA5F1B30A_terseLabel_en-US" xlink:label="lab_biib_BusinessOverviewPolicyTextBlock_0C66D3DE0492CF21543AFA4EA5F1B30A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Overview</link:label>
    <link:label id="lab_biib_BusinessOverviewPolicyTextBlock_0C66D3DE0492CF21543AFA4EA5F1B30A_label_en-US" xlink:label="lab_biib_BusinessOverviewPolicyTextBlock_0C66D3DE0492CF21543AFA4EA5F1B30A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Overview [Policy Text Block]</link:label>
    <link:label id="lab_biib_BusinessOverviewPolicyTextBlock_0C66D3DE0492CF21543AFA4EA5F1B30A_documentation_en-US" xlink:label="lab_biib_BusinessOverviewPolicyTextBlock_0C66D3DE0492CF21543AFA4EA5F1B30A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Describes an overview of the company and its operations.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_BusinessOverviewPolicyTextBlock" xlink:label="loc_biib_BusinessOverviewPolicyTextBlock_0C66D3DE0492CF21543AFA4EA5F1B30A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BusinessOverviewPolicyTextBlock_0C66D3DE0492CF21543AFA4EA5F1B30A" xlink:to="lab_biib_BusinessOverviewPolicyTextBlock_0C66D3DE0492CF21543AFA4EA5F1B30A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_AD3BA4B53FC32530B02DFA4EA5F2FB0C_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_AD3BA4B53FC32530B02DFA4EA5F2FB0C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_AD3BA4B53FC32530B02DFA4EA5F2FB0C_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_AD3BA4B53FC32530B02DFA4EA5F2FB0C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_AD3BA4B53FC32530B02DFA4EA5F2FB0C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock_AD3BA4B53FC32530B02DFA4EA5F2FB0C" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock_AD3BA4B53FC32530B02DFA4EA5F2FB0C" xlink:type="arc" />
    <link:label id="lab_us-gaap_UseOfEstimates_99A969F1682B8F034EF0FA4EA5F2E511_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates_99A969F1682B8F034EF0FA4EA5F2E511" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_99A969F1682B8F034EF0FA4EA5F2E511_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates_99A969F1682B8F034EF0FA4EA5F2E511" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_99A969F1682B8F034EF0FA4EA5F2E511" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates_99A969F1682B8F034EF0FA4EA5F2E511" xlink:to="lab_us-gaap_UseOfEstimates_99A969F1682B8F034EF0FA4EA5F2E511" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_7AD9BDDD6B306F362656FA4EA5F229BE_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock_7AD9BDDD6B306F362656FA4EA5F229BE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_7AD9BDDD6B306F362656FA4EA5F229BE_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock_7AD9BDDD6B306F362656FA4EA5F229BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_7AD9BDDD6B306F362656FA4EA5F229BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock_7AD9BDDD6B306F362656FA4EA5F229BE" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock_7AD9BDDD6B306F362656FA4EA5F229BE" xlink:type="arc" />
    <link:label id="lab_biib_CollaborativeandOtherRelationshipsPolicyTextBlock_B5AD5C9FBBB12E210C11FA4EA5F23561_terseLabel_en-US" xlink:label="lab_biib_CollaborativeandOtherRelationshipsPolicyTextBlock_B5AD5C9FBBB12E210C11FA4EA5F23561" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative and Other Relationships</link:label>
    <link:label id="lab_biib_CollaborativeandOtherRelationshipsPolicyTextBlock_B5AD5C9FBBB12E210C11FA4EA5F23561_label_en-US" xlink:label="lab_biib_CollaborativeandOtherRelationshipsPolicyTextBlock_B5AD5C9FBBB12E210C11FA4EA5F23561" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative and Other Relationships [Policy Text Block]</link:label>
    <link:label id="lab_biib_CollaborativeandOtherRelationshipsPolicyTextBlock_B5AD5C9FBBB12E210C11FA4EA5F23561_documentation_en-US" xlink:label="lab_biib_CollaborativeandOtherRelationshipsPolicyTextBlock_B5AD5C9FBBB12E210C11FA4EA5F23561" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative and Other Relationships [Policy Text Block]</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_CollaborativeandOtherRelationshipsPolicyTextBlock" xlink:label="loc_biib_CollaborativeandOtherRelationshipsPolicyTextBlock_B5AD5C9FBBB12E210C11FA4EA5F23561" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CollaborativeandOtherRelationshipsPolicyTextBlock_B5AD5C9FBBB12E210C11FA4EA5F23561" xlink:to="lab_biib_CollaborativeandOtherRelationshipsPolicyTextBlock_B5AD5C9FBBB12E210C11FA4EA5F23561" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_C6167CA2E65167BD8523FA4EA5F243E7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_C6167CA2E65167BD8523FA4EA5F243E7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_C6167CA2E65167BD8523FA4EA5F243E7_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_C6167CA2E65167BD8523FA4EA5F243E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_C6167CA2E65167BD8523FA4EA5F243E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_C6167CA2E65167BD8523FA4EA5F243E7" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_C6167CA2E65167BD8523FA4EA5F243E7" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_A2E3533CC6D77782AD04FA4EA5F22B39_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_A2E3533CC6D77782AD04FA4EA5F22B39" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_A2E3533CC6D77782AD04FA4EA5F22B39_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_A2E3533CC6D77782AD04FA4EA5F22B39" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_A2E3533CC6D77782AD04FA4EA5F22B39" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_A2E3533CC6D77782AD04FA4EA5F22B39" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_A2E3533CC6D77782AD04FA4EA5F22B39" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReceivablesPolicyTextBlock_47010DDB6425AA410848FA4EA5F2B68B_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock_47010DDB6425AA410848FA4EA5F2B68B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_ReceivablesPolicyTextBlock_47010DDB6425AA410848FA4EA5F2B68B_label_en-US" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock_47010DDB6425AA410848FA4EA5F2B68B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivables, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock_47010DDB6425AA410848FA4EA5F2B68B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesPolicyTextBlock_47010DDB6425AA410848FA4EA5F2B68B" xlink:to="lab_us-gaap_ReceivablesPolicyTextBlock_47010DDB6425AA410848FA4EA5F2B68B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_539D186664ADBA562802FA4EA5F2265B_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk_539D186664ADBA562802FA4EA5F2265B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_539D186664ADBA562802FA4EA5F2265B_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk_539D186664ADBA562802FA4EA5F2265B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_539D186664ADBA562802FA4EA5F2265B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk_539D186664ADBA562802FA4EA5F2265B" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk_539D186664ADBA562802FA4EA5F2265B" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_7905AE6274F095ABB806FA4EA5F2D71B_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock_7905AE6274F095ABB806FA4EA5F2D71B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable Securities and Other Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_7905AE6274F095ABB806FA4EA5F2D71B_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock_7905AE6274F095ABB806FA4EA5F2D71B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_7905AE6274F095ABB806FA4EA5F2D71B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock_7905AE6274F095ABB806FA4EA5F2D71B" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock_7905AE6274F095ABB806FA4EA5F2D71B" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_283B5D89A6B5A8382134FA4EA5F25927_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy_283B5D89A6B5A8382134FA4EA5F25927" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Method of Accounting</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_283B5D89A6B5A8382134FA4EA5F25927_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy_283B5D89A6B5A8382134FA4EA5F25927" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityMethodInvestmentsPolicy" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy_283B5D89A6B5A8382134FA4EA5F25927" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsPolicy_283B5D89A6B5A8382134FA4EA5F25927" xlink:to="lab_us-gaap_EquityMethodInvestmentsPolicy_283B5D89A6B5A8382134FA4EA5F25927" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_79546CC2596F29419D7FFA4EA5F3C940_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock_79546CC2596F29419D7FFA4EA5F3C940" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_79546CC2596F29419D7FFA4EA5F3C940_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock_79546CC2596F29419D7FFA4EA5F3C940" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_79546CC2596F29419D7FFA4EA5F3C940" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock_79546CC2596F29419D7FFA4EA5F3C940" xlink:to="lab_us-gaap_InventoryPolicyTextBlock_79546CC2596F29419D7FFA4EA5F3C940" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_428B3D918160E8A020C8FA4EA5F3D06A_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_428B3D918160E8A020C8FA4EA5F3D06A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_428B3D918160E8A020C8FA4EA5F3D06A_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_428B3D918160E8A020C8FA4EA5F3D06A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_428B3D918160E8A020C8FA4EA5F3D06A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_428B3D918160E8A020C8FA4EA5F3D06A" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_428B3D918160E8A020C8FA4EA5F3D06A" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_A2C37BFB65CC4EA1D81AFA4EA5F37AD7_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_A2C37BFB65CC4EA1D81AFA4EA5F37AD7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_A2C37BFB65CC4EA1D81AFA4EA5F37AD7_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_A2C37BFB65CC4EA1D81AFA4EA5F37AD7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_A2C37BFB65CC4EA1D81AFA4EA5F37AD7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_A2C37BFB65CC4EA1D81AFA4EA5F37AD7" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_A2C37BFB65CC4EA1D81AFA4EA5F37AD7" xlink:type="arc" />
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentPolicy_81A53C16AC7ACFC08867FA4EA5F37B69_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentPolicy_81A53C16AC7ACFC08867FA4EA5F37B69" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquired In-process Research and Development (IPR&amp;D)</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentPolicy_81A53C16AC7ACFC08867FA4EA5F37B69_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentPolicy_81A53C16AC7ACFC08867FA4EA5F37B69" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">In Process Research and Development, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentPolicy_81A53C16AC7ACFC08867FA4EA5F37B69" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentPolicy_81A53C16AC7ACFC08867FA4EA5F37B69" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentPolicy_81A53C16AC7ACFC08867FA4EA5F37B69" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_336971FF93DCF2C0E541FA4EA5F3F551_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_336971FF93DCF2C0E541FA4EA5F3F551" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_336971FF93DCF2C0E541FA4EA5F3F551_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_336971FF93DCF2C0E541FA4EA5F3F551" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_336971FF93DCF2C0E541FA4EA5F3F551" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_336971FF93DCF2C0E541FA4EA5F3F551" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_336971FF93DCF2C0E541FA4EA5F3F551" xlink:type="arc" />
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_65ABCD5004CED5C5010EFA4EA5F34FCA_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_65ABCD5004CED5C5010EFA4EA5F34FCA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_65ABCD5004CED5C5010EFA4EA5F34FCA_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_65ABCD5004CED5C5010EFA4EA5F34FCA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_65ABCD5004CED5C5010EFA4EA5F34FCA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_65ABCD5004CED5C5010EFA4EA5F34FCA" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_65ABCD5004CED5C5010EFA4EA5F34FCA" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_EF825907F05187C98951FA4EA5F330CB_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy_EF825907F05187C98951FA4EA5F330CB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent Consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_EF825907F05187C98951FA4EA5F330CB_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy_EF825907F05187C98951FA4EA5F330CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_EF825907F05187C98951FA4EA5F330CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy_EF825907F05187C98951FA4EA5F330CB" xlink:to="lab_us-gaap_BusinessCombinationsPolicy_EF825907F05187C98951FA4EA5F330CB" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_44640B7F8B8B6F5B1D21FA4EA5F37DA3_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock_44640B7F8B8B6F5B1D21FA4EA5F37DA3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_44640B7F8B8B6F5B1D21FA4EA5F37DA3_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock_44640B7F8B8B6F5B1D21FA4EA5F37DA3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_44640B7F8B8B6F5B1D21FA4EA5F37DA3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock_44640B7F8B8B6F5B1D21FA4EA5F37DA3" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock_44640B7F8B8B6F5B1D21FA4EA5F37DA3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_9030579F663589326000FA4EA5F37B4C_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_9030579F663589326000FA4EA5F37B4C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Translation of Foreign Currencies</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_9030579F663589326000FA4EA5F37B4C_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_9030579F663589326000FA4EA5F37B4C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_9030579F663589326000FA4EA5F37B4C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_9030579F663589326000FA4EA5F37B4C" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_9030579F663589326000FA4EA5F37B4C" xlink:type="arc" />
    <link:label id="lab_biib_RoyaltyCostofSalesPolicyTextBlock_96F5FB333FFEE77F1DACFA4EA5F3FB27_terseLabel_en-US" xlink:label="lab_biib_RoyaltyCostofSalesPolicyTextBlock_96F5FB333FFEE77F1DACFA4EA5F3FB27" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty Cost of Sales</link:label>
    <link:label id="lab_biib_RoyaltyCostofSalesPolicyTextBlock_96F5FB333FFEE77F1DACFA4EA5F3FB27_label_en-US" xlink:label="lab_biib_RoyaltyCostofSalesPolicyTextBlock_96F5FB333FFEE77F1DACFA4EA5F3FB27" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Cost of Sales [Policy Text Block]</link:label>
    <link:label id="lab_biib_RoyaltyCostofSalesPolicyTextBlock_96F5FB333FFEE77F1DACFA4EA5F3FB27_documentation_en-US" xlink:label="lab_biib_RoyaltyCostofSalesPolicyTextBlock_96F5FB333FFEE77F1DACFA4EA5F3FB27" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty Cost of Sales [Policy Text Block]</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_RoyaltyCostofSalesPolicyTextBlock" xlink:label="loc_biib_RoyaltyCostofSalesPolicyTextBlock_96F5FB333FFEE77F1DACFA4EA5F3FB27" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RoyaltyCostofSalesPolicyTextBlock_96F5FB333FFEE77F1DACFA4EA5F3FB27" xlink:to="lab_biib_RoyaltyCostofSalesPolicyTextBlock_96F5FB333FFEE77F1DACFA4EA5F3FB27" xlink:type="arc" />
    <link:label id="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_6D735E2E558A5F9E638CFA4EA5F3BEA2_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_6D735E2E558A5F9E638CFA4EA5F3BEA2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting for Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_6D735E2E558A5F9E638CFA4EA5F3BEA2_label_en-US" xlink:label="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_6D735E2E558A5F9E638CFA4EA5F3BEA2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Related Costs, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_6D735E2E558A5F9E638CFA4EA5F3BEA2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_6D735E2E558A5F9E638CFA4EA5F3BEA2" xlink:to="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_6D735E2E558A5F9E638CFA4EA5F3BEA2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_F2C983F9508734B978EFFA4EA5F4BC60_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_F2C983F9508734B978EFFA4EA5F4BC60" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_F2C983F9508734B978EFFA4EA5F4BC60_label_en-US" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_F2C983F9508734B978EFFA4EA5F4BC60" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research, Development, and Computer Software, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_F2C983F9508734B978EFFA4EA5F4BC60" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_F2C983F9508734B978EFFA4EA5F4BC60" xlink:to="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_F2C983F9508734B978EFFA4EA5F4BC60" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_F8AE32562D9B06E76E2CFA4EA5F46C9A_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_F8AE32562D9B06E76E2CFA4EA5F46C9A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_F8AE32562D9B06E76E2CFA4EA5F46C9A_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_F8AE32562D9B06E76E2CFA4EA5F46C9A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_F8AE32562D9B06E76E2CFA4EA5F46C9A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_F8AE32562D9B06E76E2CFA4EA5F46C9A" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_F8AE32562D9B06E76E2CFA4EA5F46C9A" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_36A115D6637679A4222DFA4EA5F49539_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_36A115D6637679A4222DFA4EA5F49539" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_36A115D6637679A4222DFA4EA5F49539_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_36A115D6637679A4222DFA4EA5F49539" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_36A115D6637679A4222DFA4EA5F49539" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock_36A115D6637679A4222DFA4EA5F49539" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock_36A115D6637679A4222DFA4EA5F49539" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_EADD7AB6BE8085EC7ECEFA4EA5F46221_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_EADD7AB6BE8085EC7ECEFA4EA5F46221" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_EADD7AB6BE8085EC7ECEFA4EA5F46221_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_EADD7AB6BE8085EC7ECEFA4EA5F46221" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_EADD7AB6BE8085EC7ECEFA4EA5F46221" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_EADD7AB6BE8085EC7ECEFA4EA5F46221" xlink:to="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_EADD7AB6BE8085EC7ECEFA4EA5F46221" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_44E584C92EF1EA17530DFA4EA5F417CF_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_44E584C92EF1EA17530DFA4EA5F417CF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_44E584C92EF1EA17530DFA4EA5F417CF_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_44E584C92EF1EA17530DFA4EA5F417CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_44E584C92EF1EA17530DFA4EA5F417CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock_44E584C92EF1EA17530DFA4EA5F417CF" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock_44E584C92EF1EA17530DFA4EA5F417CF" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_5B0BD681D0AE71C31A82FA4EA5F49F11_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_5B0BD681D0AE71C31A82FA4EA5F49F11" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_5B0BD681D0AE71C31A82FA4EA5F49F11_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_5B0BD681D0AE71C31A82FA4EA5F49F11" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_5B0BD681D0AE71C31A82FA4EA5F49F11" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_5B0BD681D0AE71C31A82FA4EA5F49F11" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_5B0BD681D0AE71C31A82FA4EA5F49F11" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_92D3F3966936A27A585CFCCBDAD7C583_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_92D3F3966936A27A585CFCCBDAD7C583" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Revenue by Major Customers, by Reporting Segments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_92D3F3966936A27A585CFCCBDAD7C583_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_92D3F3966936A27A585CFCCBDAD7C583" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Revenue by Major Customers, by Reporting Segments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_92D3F3966936A27A585CFCCBDAD7C583" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_92D3F3966936A27A585CFCCBDAD7C583" xlink:to="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_92D3F3966936A27A585CFCCBDAD7C583" xlink:type="arc" />
    <link:label id="lab_us-gaap_EuropeMember_287DD1D37D55C3F9BB16FCCBDAD7926C_verboseLabel_en-US" xlink:label="lab_us-gaap_EuropeMember_287DD1D37D55C3F9BB16FCCBDAD7926C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Europe</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EuropeMember" xlink:label="loc_us-gaap_EuropeMember_287DD1D37D55C3F9BB16FCCBDAD7926C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EuropeMember_287DD1D37D55C3F9BB16FCCBDAD7926C" xlink:to="lab_us-gaap_EuropeMember_287DD1D37D55C3F9BB16FCCBDAD7926C" xlink:type="arc" />
    <link:label id="lab_country_DE_33ED03D7F031EF18B13BFCCBDAD84518_verboseLabel_en-US" xlink:label="lab_country_DE_33ED03D7F031EF18B13BFCCBDAD84518" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Germany</link:label>
    <link:label id="lab_country_DE_33ED03D7F031EF18B13BFCCBDAD84518_label_en-US" xlink:label="lab_country_DE_33ED03D7F031EF18B13BFCCBDAD84518" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">GERMANY</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd#country_DE" xlink:label="loc_country_DE_33ED03D7F031EF18B13BFCCBDAD84518" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_DE_33ED03D7F031EF18B13BFCCBDAD84518" xlink:to="lab_country_DE_33ED03D7F031EF18B13BFCCBDAD84518" xlink:type="arc" />
    <link:label id="lab_us-gaap_AsiaMember_3D02FA0D16C77E390DB6FCCBDAD8B98E_verboseLabel_en-US" xlink:label="lab_us-gaap_AsiaMember_3D02FA0D16C77E390DB6FCCBDAD8B98E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Asia</link:label>
    <link:label id="lab_us-gaap_AsiaMember_3D02FA0D16C77E390DB6FCCBDAD8B98E_label_en-US" xlink:label="lab_us-gaap_AsiaMember_3D02FA0D16C77E390DB6FCCBDAD8B98E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asia [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AsiaMember" xlink:label="loc_us-gaap_AsiaMember_3D02FA0D16C77E390DB6FCCBDAD8B98E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AsiaMember_3D02FA0D16C77E390DB6FCCBDAD8B98E" xlink:to="lab_us-gaap_AsiaMember_3D02FA0D16C77E390DB6FCCBDAD8B98E" xlink:type="arc" />
    <link:label id="lab_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember_2B71F906AE0E6DC5B173FCCBDAD8E0C7_verboseLabel_en-US" xlink:label="lab_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember_2B71F906AE0E6DC5B173FCCBDAD8E0C7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember_2B71F906AE0E6DC5B173FCCBDAD8E0C7_label_en-US" xlink:label="lab_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember_2B71F906AE0E6DC5B173FCCBDAD8E0C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Geographical Groups Of Countries Group Other [Member]</link:label>
    <link:label id="lab_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember_2B71F906AE0E6DC5B173FCCBDAD8E0C7_documentation_en-US" xlink:label="lab_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember_2B71F906AE0E6DC5B173FCCBDAD8E0C7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Segment geographical groups of countries group other.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember" xlink:label="loc_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember_2B71F906AE0E6DC5B173FCCBDAD8E0C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember_2B71F906AE0E6DC5B173FCCBDAD8E0C7" xlink:to="lab_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember_2B71F906AE0E6DC5B173FCCBDAD8E0C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_0D4046DFB38E0125FC38FCCBDAD8870C_terseLabel_en-US" xlink:label="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_0D4046DFB38E0125FC38FCCBDAD8870C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, Major Customer [Line Items]</link:label>
    <link:label id="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_0D4046DFB38E0125FC38FCCBDAD8870C_label_en-US" xlink:label="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_0D4046DFB38E0125FC38FCCBDAD8870C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Major Customer [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_0D4046DFB38E0125FC38FCCBDAD8870C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_0D4046DFB38E0125FC38FCCBDAD8870C" xlink:to="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_0D4046DFB38E0125FC38FCCBDAD8870C" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentsGeographicalAreasAbstract_85F38EC10D32DCF3A0E4FCCBDAD8125A_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentsGeographicalAreasAbstract_85F38EC10D32DCF3A0E4FCCBDAD8125A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Geographic information</link:label>
    <link:label id="lab_us-gaap_SegmentsGeographicalAreasAbstract_85F38EC10D32DCF3A0E4FCCBDAD8125A_label_en-US" xlink:label="lab_us-gaap_SegmentsGeographicalAreasAbstract_85F38EC10D32DCF3A0E4FCCBDAD8125A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments, Geographical Areas [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentsGeographicalAreasAbstract" xlink:label="loc_us-gaap_SegmentsGeographicalAreasAbstract_85F38EC10D32DCF3A0E4FCCBDAD8125A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentsGeographicalAreasAbstract_85F38EC10D32DCF3A0E4FCCBDAD8125A" xlink:to="lab_us-gaap_SegmentsGeographicalAreasAbstract_85F38EC10D32DCF3A0E4FCCBDAD8125A" xlink:type="arc" />
    <link:label id="lab_us-gaap_NoncurrentAssets_8E874CC2DD3FA532A570FCCBDAD83975_verboseLabel_en-US" xlink:label="lab_us-gaap_NoncurrentAssets_8E874CC2DD3FA532A570FCCBDAD83975" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Long-lived assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NoncurrentAssets" xlink:label="loc_us-gaap_NoncurrentAssets_8E874CC2DD3FA532A570FCCBDAD83975" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncurrentAssets_8E874CC2DD3FA532A570FCCBDAD83975" xlink:to="lab_us-gaap_NoncurrentAssets_8E874CC2DD3FA532A570FCCBDAD83975" xlink:type="arc" />
    <link:label id="lab_biib_ProceedsFromMarketableDebtSecuritiesAbstract_9E5A0952B81FC024BB557412887D6137_verboseLabel_en-US" xlink:label="lab_biib_ProceedsFromMarketableDebtSecuritiesAbstract_9E5A0952B81FC024BB557412887D6137" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Marketable Debt Securities</link:label>
    <link:label id="lab_biib_ProceedsFromMarketableDebtSecuritiesAbstract_9E5A0952B81FC024BB557412887D6137_label_en-US" xlink:label="lab_biib_ProceedsFromMarketableDebtSecuritiesAbstract_9E5A0952B81FC024BB557412887D6137" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Marketable Debt Securities [Abstract]</link:label>
    <link:label id="lab_biib_ProceedsFromMarketableDebtSecuritiesAbstract_9E5A0952B81FC024BB557412887D6137_documentation_en-US" xlink:label="lab_biib_ProceedsFromMarketableDebtSecuritiesAbstract_9E5A0952B81FC024BB557412887D6137" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds from marketable debt securities.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_ProceedsFromMarketableDebtSecuritiesAbstract" xlink:label="loc_biib_ProceedsFromMarketableDebtSecuritiesAbstract_9E5A0952B81FC024BB557412887D6137" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ProceedsFromMarketableDebtSecuritiesAbstract_9E5A0952B81FC024BB557412887D6137" xlink:to="lab_biib_ProceedsFromMarketableDebtSecuritiesAbstract_9E5A0952B81FC024BB557412887D6137" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_B909BBB1C1E1A293CFC17412887D6CC3_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_B909BBB1C1E1A293CFC17412887D6CC3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from maturities and sales</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_B909BBB1C1E1A293CFC17412887D6CC3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_B909BBB1C1E1A293CFC17412887D6CC3" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_B909BBB1C1E1A293CFC17412887D6CC3" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_4441DF522A524225764D7412887DD2FC_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_4441DF522A524225764D7412887DD2FC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Realized gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_4441DF522A524225764D7412887DD2FC_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_4441DF522A524225764D7412887DD2FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Gross Realized Gains</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedGains" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_4441DF522A524225764D7412887DD2FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_4441DF522A524225764D7412887DD2FC" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_4441DF522A524225764D7412887DD2FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_BD090D05B53C3C3020137412887D41EA_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_BD090D05B53C3C3020137412887D41EA" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Realized losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_BD090D05B53C3C3020137412887D41EA_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_BD090D05B53C3C3020137412887D41EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Gross Realized Losses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_BD090D05B53C3C3020137412887D41EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_BD090D05B53C3C3020137412887D41EA" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_BD090D05B53C3C3020137412887D41EA" xlink:type="arc" />
    <link:label id="lab_us-gaap_SelectedQuarterlyFinancialInformationAbstract_B2B82078E3250991C858FCCBDAA90A2F_terseLabel_en-US" xlink:label="lab_us-gaap_SelectedQuarterlyFinancialInformationAbstract_B2B82078E3250991C858FCCBDAA90A2F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selected Quarterly Financial Information [Abstract]</link:label>
    <link:label id="lab_us-gaap_SelectedQuarterlyFinancialInformationAbstract_B2B82078E3250991C858FCCBDAA90A2F_label_en-US" xlink:label="lab_us-gaap_SelectedQuarterlyFinancialInformationAbstract_B2B82078E3250991C858FCCBDAA90A2F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selected Quarterly Financial Information [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SelectedQuarterlyFinancialInformationAbstract" xlink:label="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_B2B82078E3250991C858FCCBDAA90A2F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_B2B82078E3250991C858FCCBDAA90A2F" xlink:to="lab_us-gaap_SelectedQuarterlyFinancialInformationAbstract_B2B82078E3250991C858FCCBDAA90A2F" xlink:type="arc" />
    <link:label id="lab_us-gaap_Revenues_FDDD39B8961D98D36F15FCCBDAA93423_verboseLabel_en-US" xlink:label="lab_us-gaap_Revenues_FDDD39B8961D98D36F15FCCBDAA93423" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_FDDD39B8961D98D36F15FCCBDAA93423" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_FDDD39B8961D98D36F15FCCBDAA93423" xlink:to="lab_us-gaap_Revenues_FDDD39B8961D98D36F15FCCBDAA93423" xlink:type="arc" />
    <link:label id="lab_us-gaap_GrossProfit_8ED741BFCFAC58431C46FCCBDAA9BE5C_verboseLabel_en-US" xlink:label="lab_us-gaap_GrossProfit_8ED741BFCFAC58431C46FCCBDAA9BE5C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Gross Profit</link:label>
    <link:label id="lab_us-gaap_GrossProfit_8ED741BFCFAC58431C46FCCBDAA9BE5C_label_en-US" xlink:label="lab_us-gaap_GrossProfit_8ED741BFCFAC58431C46FCCBDAA9BE5C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_8ED741BFCFAC58431C46FCCBDAA9BE5C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit_8ED741BFCFAC58431C46FCCBDAA9BE5C" xlink:to="lab_us-gaap_GrossProfit_8ED741BFCFAC58431C46FCCBDAA9BE5C" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_E860CBA5718194256389FCCBDAAE5A13_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_E860CBA5718194256389FCCBDAAE5A13" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income attributable to Biogen Idec Inc</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_E860CBA5718194256389FCCBDAAE5A13" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_E860CBA5718194256389FCCBDAAE5A13" xlink:to="lab_us-gaap_NetIncomeLoss_E860CBA5718194256389FCCBDAAE5A13" xlink:type="arc" />
    <link:label id="lab_biib_PLEGRIDYMember_E0F2867121121025D50DD6253303324B_terseLabel_en-US" xlink:label="lab_biib_PLEGRIDYMember_E0F2867121121025D50DD6253303324B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PLEGRIDY</link:label>
    <link:label id="lab_biib_PLEGRIDYMember_E0F2867121121025D50DD6253303324B_label_en-US" xlink:label="lab_biib_PLEGRIDYMember_E0F2867121121025D50DD6253303324B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PLEGRIDY [Member]</link:label>
    <link:label id="lab_biib_PLEGRIDYMember_E0F2867121121025D50DD6253303324B_documentation_en-US" xlink:label="lab_biib_PLEGRIDYMember_E0F2867121121025D50DD6253303324B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">PLEGRIDY [Member]</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_PLEGRIDYMember" xlink:label="loc_biib_PLEGRIDYMember_E0F2867121121025D50DD6253303324B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PLEGRIDYMember_E0F2867121121025D50DD6253303324B" xlink:to="lab_biib_PLEGRIDYMember_E0F2867121121025D50DD6253303324B" xlink:type="arc" />
    <link:label id="lab_biib_TysabriMember_FAD340642C25E4B77D63D6253303F27C_verboseLabel_en-US" xlink:label="lab_biib_TysabriMember_FAD340642C25E4B77D63D6253303F27C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">TYSABRI</link:label>
    <link:label id="lab_biib_TysabriMember_FAD340642C25E4B77D63D6253303F27C_label_en-US" xlink:label="lab_biib_TysabriMember_FAD340642C25E4B77D63D6253303F27C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">TYSABRI [Member]</link:label>
    <link:label id="lab_biib_TysabriMember_FAD340642C25E4B77D63D6253303F27C_documentation_en-US" xlink:label="lab_biib_TysabriMember_FAD340642C25E4B77D63D6253303F27C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tysabri.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_TysabriMember" xlink:label="loc_biib_TysabriMember_FAD340642C25E4B77D63D6253303F27C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TysabriMember_FAD340642C25E4B77D63D6253303F27C" xlink:to="lab_biib_TysabriMember_FAD340642C25E4B77D63D6253303F27C" xlink:type="arc" />
    <link:label id="lab_biib_FAMPYRAMember_84620BD3AE6BF6F8F39BD625330314E7_terseLabel_en-US" xlink:label="lab_biib_FAMPYRAMember_84620BD3AE6BF6F8F39BD625330314E7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FAMPYRA</link:label>
    <link:label id="lab_biib_FAMPYRAMember_84620BD3AE6BF6F8F39BD625330314E7_label_en-US" xlink:label="lab_biib_FAMPYRAMember_84620BD3AE6BF6F8F39BD625330314E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">FAMPYRA [Member]</link:label>
    <link:label id="lab_biib_FAMPYRAMember_84620BD3AE6BF6F8F39BD625330314E7_documentation_en-US" xlink:label="lab_biib_FAMPYRAMember_84620BD3AE6BF6F8F39BD625330314E7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">FAMPYRA [Member]</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_FAMPYRAMember" xlink:label="loc_biib_FAMPYRAMember_84620BD3AE6BF6F8F39BD625330314E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FAMPYRAMember_84620BD3AE6BF6F8F39BD625330314E7" xlink:to="lab_biib_FAMPYRAMember_84620BD3AE6BF6F8F39BD625330314E7" xlink:type="arc" />
    <link:label id="lab_biib_ALPROLIXProductMember_48E09595890D1E5A5905D6253303EBA3_terseLabel_en-US" xlink:label="lab_biib_ALPROLIXProductMember_48E09595890D1E5A5905D6253303EBA3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ALPROLIX</link:label>
    <link:label id="lab_biib_ALPROLIXProductMember_48E09595890D1E5A5905D6253303EBA3_label_en-US" xlink:label="lab_biib_ALPROLIXProductMember_48E09595890D1E5A5905D6253303EBA3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ALPROLIX Product [Member]</link:label>
    <link:label id="lab_biib_ALPROLIXProductMember_48E09595890D1E5A5905D6253303EBA3_documentation_en-US" xlink:label="lab_biib_ALPROLIXProductMember_48E09595890D1E5A5905D6253303EBA3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ALPROLIX Product [Member]</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_ALPROLIXProductMember" xlink:label="loc_biib_ALPROLIXProductMember_48E09595890D1E5A5905D6253303EBA3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ALPROLIXProductMember_48E09595890D1E5A5905D6253303EBA3" xlink:to="lab_biib_ALPROLIXProductMember_48E09595890D1E5A5905D6253303EBA3" xlink:type="arc" />
    <link:label id="lab_biib_FUMADERMMember_B1930264832021B16508D62533034645_terseLabel_en-US" xlink:label="lab_biib_FUMADERMMember_B1930264832021B16508D62533034645" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FUMADERM</link:label>
    <link:label id="lab_biib_FUMADERMMember_B1930264832021B16508D62533034645_label_en-US" xlink:label="lab_biib_FUMADERMMember_B1930264832021B16508D62533034645" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">FUMADERM [Member]</link:label>
    <link:label id="lab_biib_FUMADERMMember_B1930264832021B16508D62533034645_documentation_en-US" xlink:label="lab_biib_FUMADERMMember_B1930264832021B16508D62533034645" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">FUMADERM [Member]</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_FUMADERMMember" xlink:label="loc_biib_FUMADERMMember_B1930264832021B16508D62533034645" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FUMADERMMember_B1930264832021B16508D62533034645" xlink:to="lab_biib_FUMADERMMember_B1930264832021B16508D62533034645" xlink:type="arc" />
    <link:label id="lab_biib_BENEPALIMember_DC6CDDF5CEF0600A66DCD6253303965D_terseLabel_en-US" xlink:label="lab_biib_BENEPALIMember_DC6CDDF5CEF0600A66DCD6253303965D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BENEPALI</link:label>
    <link:label id="lab_biib_BENEPALIMember_DC6CDDF5CEF0600A66DCD6253303965D_label_en-US" xlink:label="lab_biib_BENEPALIMember_DC6CDDF5CEF0600A66DCD6253303965D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BENEPALI [Member]</link:label>
    <link:label id="lab_biib_BENEPALIMember_DC6CDDF5CEF0600A66DCD6253303965D_documentation_en-US" xlink:label="lab_biib_BENEPALIMember_DC6CDDF5CEF0600A66DCD6253303965D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BENEPALI [Member]</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_BENEPALIMember" xlink:label="loc_biib_BENEPALIMember_DC6CDDF5CEF0600A66DCD6253303965D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BENEPALIMember_DC6CDDF5CEF0600A66DCD6253303965D" xlink:to="lab_biib_BENEPALIMember_DC6CDDF5CEF0600A66DCD6253303965D" xlink:type="arc" />
    <link:label id="lab_biib_FLIXABIMember_0A7D1DDE9C9E279DEB88D641DB278DF0_terseLabel_en-US" xlink:label="lab_biib_FLIXABIMember_0A7D1DDE9C9E279DEB88D641DB278DF0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FLIXABI</link:label>
    <link:label id="lab_biib_FLIXABIMember_0A7D1DDE9C9E279DEB88D641DB278DF0_label_en-US" xlink:label="lab_biib_FLIXABIMember_0A7D1DDE9C9E279DEB88D641DB278DF0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">FLIXABI [Member]</link:label>
    <link:label id="lab_biib_FLIXABIMember_0A7D1DDE9C9E279DEB88D641DB278DF0_documentation_en-US" xlink:label="lab_biib_FLIXABIMember_0A7D1DDE9C9E279DEB88D641DB278DF0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">FLIXABI [Member]</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_FLIXABIMember" xlink:label="loc_biib_FLIXABIMember_0A7D1DDE9C9E279DEB88D641DB278DF0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FLIXABIMember_0A7D1DDE9C9E279DEB88D641DB278DF0" xlink:to="lab_biib_FLIXABIMember_0A7D1DDE9C9E279DEB88D641DB278DF0" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_C5A46EC3601644616EAED62533030D78_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis_C5A46EC3601644616EAED62533030D78" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement, Business Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_C5A46EC3601644616EAED62533030D78_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis_C5A46EC3601644616EAED62533030D78" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_C5A46EC3601644616EAED62533030D78" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_C5A46EC3601644616EAED62533030D78" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis_C5A46EC3601644616EAED62533030D78" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentDomain_C833D7DB5645675FE15BD6253303188C_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain_C833D7DB5645675FE15BD6253303188C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_C833D7DB5645675FE15BD6253303188C_label_en-US" xlink:label="lab_us-gaap_SegmentDomain_C833D7DB5645675FE15BD6253303188C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_C833D7DB5645675FE15BD6253303188C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain_C833D7DB5645675FE15BD6253303188C" xlink:to="lab_us-gaap_SegmentDomain_C833D7DB5645675FE15BD6253303188C" xlink:type="arc" />
    <link:label id="lab_biib_RestOfWorldMember_79B1664F14E3F27452DCD62533030BA1_verboseLabel_en-US" xlink:label="lab_biib_RestOfWorldMember_79B1664F14E3F27452DCD62533030BA1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Rest of world</link:label>
    <link:label id="lab_biib_RestOfWorldMember_79B1664F14E3F27452DCD62533030BA1_label_en-US" xlink:label="lab_biib_RestOfWorldMember_79B1664F14E3F27452DCD62533030BA1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rest Of World [Member]</link:label>
    <link:label id="lab_biib_RestOfWorldMember_79B1664F14E3F27452DCD62533030BA1_documentation_en-US" xlink:label="lab_biib_RestOfWorldMember_79B1664F14E3F27452DCD62533030BA1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Rest of world.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_RestOfWorldMember" xlink:label="loc_biib_RestOfWorldMember_79B1664F14E3F27452DCD62533030BA1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RestOfWorldMember_79B1664F14E3F27452DCD62533030BA1" xlink:to="lab_biib_RestOfWorldMember_79B1664F14E3F27452DCD62533030BA1" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesRevenueGoodsNetAbstract_2E0EFA6AC25B666C97F1D6253303E494_verboseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueGoodsNetAbstract_2E0EFA6AC25B666C97F1D6253303E494" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenue by product</link:label>
    <link:label id="lab_us-gaap_SalesRevenueGoodsNetAbstract_2E0EFA6AC25B666C97F1D6253303E494_label_en-US" xlink:label="lab_us-gaap_SalesRevenueGoodsNetAbstract_2E0EFA6AC25B666C97F1D6253303E494" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Revenue, Goods, Net [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNetAbstract" xlink:label="loc_us-gaap_SalesRevenueGoodsNetAbstract_2E0EFA6AC25B666C97F1D6253303E494" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueGoodsNetAbstract_2E0EFA6AC25B666C97F1D6253303E494" xlink:to="lab_us-gaap_SalesRevenueGoodsNetAbstract_2E0EFA6AC25B666C97F1D6253303E494" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_A7BDEDDD3365807A25E67412868E67C0_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_A7BDEDDD3365807A25E67412868E67C0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_A7BDEDDD3365807A25E67412868E67C0_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_A7BDEDDD3365807A25E67412868E67C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_A7BDEDDD3365807A25E67412868E67C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock_A7BDEDDD3365807A25E67412868E67C0" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock_A7BDEDDD3365807A25E67412868E67C0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_1F721FFCC55D9C3F555C7412857086EF_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_1F721FFCC55D9C3F555C7412857086EF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_1F721FFCC55D9C3F555C7412857086EF_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_1F721FFCC55D9C3F555C7412857086EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_1F721FFCC55D9C3F555C7412857086EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_1F721FFCC55D9C3F555C7412857086EF" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_1F721FFCC55D9C3F555C7412857086EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentTypeAxis_E256350D4D10EC26D713741285704312_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis_E256350D4D10EC26D713741285704312" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_E256350D4D10EC26D713741285704312_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis_E256350D4D10EC26D713741285704312" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_E256350D4D10EC26D713741285704312" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis_E256350D4D10EC26D713741285704312" xlink:to="lab_us-gaap_InvestmentTypeAxis_E256350D4D10EC26D713741285704312" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_07ABD2017CF721E7DAB874128570B8B1_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember_07ABD2017CF721E7DAB874128570B8B1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment Type Categorization [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_07ABD2017CF721E7DAB874128570B8B1_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember_07ABD2017CF721E7DAB874128570B8B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_07ABD2017CF721E7DAB874128570B8B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_07ABD2017CF721E7DAB874128570B8B1" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember_07ABD2017CF721E7DAB874128570B8B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommercialPaperMember_5926A2C99DC4B2E701F274128570409E_verboseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember_5926A2C99DC4B2E701F274128570409E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Commercial Paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_5926A2C99DC4B2E701F274128570409E_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember_5926A2C99DC4B2E701F274128570409E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_5926A2C99DC4B2E701F274128570409E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember_5926A2C99DC4B2E701F274128570409E" xlink:to="lab_us-gaap_CommercialPaperMember_5926A2C99DC4B2E701F274128570409E" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepurchaseAgreementsMember_AE2A18DBD3EC6D4BCAF974128570C971_verboseLabel_en-US" xlink:label="lab_us-gaap_RepurchaseAgreementsMember_AE2A18DBD3EC6D4BCAF974128570C971" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Overnight Reverse Repurchase Agreements</link:label>
    <link:label id="lab_us-gaap_RepurchaseAgreementsMember_AE2A18DBD3EC6D4BCAF974128570C971_label_en-US" xlink:label="lab_us-gaap_RepurchaseAgreementsMember_AE2A18DBD3EC6D4BCAF974128570C971" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repurchase Agreements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementsMember" xlink:label="loc_us-gaap_RepurchaseAgreementsMember_AE2A18DBD3EC6D4BCAF974128570C971" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepurchaseAgreementsMember_AE2A18DBD3EC6D4BCAF974128570C971" xlink:to="lab_us-gaap_RepurchaseAgreementsMember_AE2A18DBD3EC6D4BCAF974128570C971" xlink:type="arc" />
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_46297473E91FFF47EDD6741285700F59_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_46297473E91FFF47EDD6741285700F59" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money Market Funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_46297473E91FFF47EDD6741285700F59_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_46297473E91FFF47EDD6741285700F59" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_46297473E91FFF47EDD6741285700F59" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember_46297473E91FFF47EDD6741285700F59" xlink:to="lab_us-gaap_MoneyMarketFundsMember_46297473E91FFF47EDD6741285700F59" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesMember_AC62169F04661A22BB73741285702627_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember_AC62169F04661A22BB73741285702627" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Short-term Debt Securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesMember_AC62169F04661A22BB73741285702627_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember_AC62169F04661A22BB73741285702627" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtSecuritiesMember" xlink:label="loc_us-gaap_DebtSecuritiesMember_AC62169F04661A22BB73741285702627" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesMember_AC62169F04661A22BB73741285702627" xlink:to="lab_us-gaap_DebtSecuritiesMember_AC62169F04661A22BB73741285702627" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_1DB70DD5DD3D25B62DE6741285700C88_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems_1DB70DD5DD3D25B62DE6741285700C88" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_1DB70DD5DD3D25B62DE6741285700C88_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems_1DB70DD5DD3D25B62DE6741285700C88" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_1DB70DD5DD3D25B62DE6741285700C88" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_1DB70DD5DD3D25B62DE6741285700C88" xlink:to="lab_us-gaap_CashAndCashEquivalentsLineItems_1DB70DD5DD3D25B62DE6741285700C88" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_E7D62A8A1CE96EBF1FED7412857046E5_verboseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_E7D62A8A1CE96EBF1FED7412857046E5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_E7D62A8A1CE96EBF1FED7412857046E5_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_E7D62A8A1CE96EBF1FED7412857046E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Equivalents, at Carrying Value [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_E7D62A8A1CE96EBF1FED7412857046E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_E7D62A8A1CE96EBF1FED7412857046E5" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_E7D62A8A1CE96EBF1FED7412857046E5" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_A7BCD403C336965C9FC17412857045E9_verboseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue_A7BCD403C336965C9FC17412857045E9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_A7BCD403C336965C9FC17412857045E9_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue_A7BCD403C336965C9FC17412857045E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_A7BCD403C336965C9FC17412857045E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValue_A7BCD403C336965C9FC17412857045E9" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValue_A7BCD403C336965C9FC17412857045E9" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsAbstract_F9490E985D4B7F7E8298D0DB24225323_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract_F9490E985D4B7F7E8298D0DB24225323" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_F9490E985D4B7F7E8298D0DB24225323_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract_F9490E985D4B7F7E8298D0DB24225323" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_F9490E985D4B7F7E8298D0DB24225323" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_F9490E985D4B7F7E8298D0DB24225323" xlink:to="lab_us-gaap_AssetsAbstract_F9490E985D4B7F7E8298D0DB24225323" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_E874B274DD05602615B4D0DB24228537_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_E874B274DD05602615B4D0DB24228537" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_E874B274DD05602615B4D0DB24228537_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_E874B274DD05602615B4D0DB24228537" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_E874B274DD05602615B4D0DB24228537" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_E874B274DD05602615B4D0DB24228537" xlink:to="lab_us-gaap_AssetsCurrentAbstract_E874B274DD05602615B4D0DB24228537" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_9421F3E8303FA32693D6D0DB242282D2_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_9421F3E8303FA32693D6D0DB242282D2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9421F3E8303FA32693D6D0DB242282D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9421F3E8303FA32693D6D0DB242282D2" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_9421F3E8303FA32693D6D0DB242282D2" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesCurrent_9420DA0D7C5338400CF9D0DB2422F1E7_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesCurrent_9420DA0D7C5338400CF9D0DB2422F1E7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesCurrent_9420DA0D7C5338400CF9D0DB2422F1E7_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesCurrent_9420DA0D7C5338400CF9D0DB2422F1E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesCurrent_9420DA0D7C5338400CF9D0DB2422F1E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesCurrent_9420DA0D7C5338400CF9D0DB2422F1E7" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesCurrent_9420DA0D7C5338400CF9D0DB2422F1E7" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_4E6BF41F1352A65F3F4FD0DB24227D72_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_4E6BF41F1352A65F3F4FD0DB24227D72" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_4E6BF41F1352A65F3F4FD0DB24227D72_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_4E6BF41F1352A65F3F4FD0DB24227D72" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Net, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_4E6BF41F1352A65F3F4FD0DB24227D72" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_4E6BF41F1352A65F3F4FD0DB24227D72" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent_4E6BF41F1352A65F3F4FD0DB24227D72" xlink:type="arc" />
    <link:label id="lab_biib_DueFromUnconsolidatedJointBusiness_F39A5878B535F6D4744BD0DB2423F5EE_verboseLabel_en-US" xlink:label="lab_biib_DueFromUnconsolidatedJointBusiness_F39A5878B535F6D4744BD0DB2423F5EE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due from anti-CD20 therapeutic programs, net</link:label>
    <link:label id="lab_biib_DueFromUnconsolidatedJointBusiness_F39A5878B535F6D4744BD0DB2423F5EE_label_en-US" xlink:label="lab_biib_DueFromUnconsolidatedJointBusiness_F39A5878B535F6D4744BD0DB2423F5EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Due from unconsolidated joint business</link:label>
    <link:label id="lab_biib_DueFromUnconsolidatedJointBusiness_F39A5878B535F6D4744BD0DB2423F5EE_documentation_en-US" xlink:label="lab_biib_DueFromUnconsolidatedJointBusiness_F39A5878B535F6D4744BD0DB2423F5EE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Receivable from unconsolidated joint business for our share of the pre-tax co-promotion profits generated from our co-promotion arrangement for sales of RITUXAN.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_DueFromUnconsolidatedJointBusiness" xlink:label="loc_biib_DueFromUnconsolidatedJointBusiness_F39A5878B535F6D4744BD0DB2423F5EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DueFromUnconsolidatedJointBusiness_F39A5878B535F6D4744BD0DB2423F5EE" xlink:to="lab_biib_DueFromUnconsolidatedJointBusiness_F39A5878B535F6D4744BD0DB2423F5EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNet_6F02786CC6A3020527D5D0DB2423F718_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet_6F02786CC6A3020527D5D0DB2423F718" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_6F02786CC6A3020527D5D0DB2423F718" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet_6F02786CC6A3020527D5D0DB2423F718" xlink:to="lab_us-gaap_InventoryNet_6F02786CC6A3020527D5D0DB2423F718" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsCurrent_1C33231B7FE0EFD65783D0DB24233B9E_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent_1C33231B7FE0EFD65783D0DB24233B9E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_1C33231B7FE0EFD65783D0DB24233B9E_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent_1C33231B7FE0EFD65783D0DB24233B9E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_1C33231B7FE0EFD65783D0DB24233B9E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent_1C33231B7FE0EFD65783D0DB24233B9E" xlink:to="lab_us-gaap_OtherAssetsCurrent_1C33231B7FE0EFD65783D0DB24233B9E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrent_BBF5714B52B6DB35EAB2D0DB24236181_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent_BBF5714B52B6DB35EAB2D0DB24236181" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_BBF5714B52B6DB35EAB2D0DB24236181_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent_BBF5714B52B6DB35EAB2D0DB24236181" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_BBF5714B52B6DB35EAB2D0DB24236181" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_BBF5714B52B6DB35EAB2D0DB24236181" xlink:to="lab_us-gaap_AssetsCurrent_BBF5714B52B6DB35EAB2D0DB24236181" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesNoncurrent_D7E5B8ACF699B42CA742D0DB242320A5_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesNoncurrent_D7E5B8ACF699B42CA742D0DB242320A5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesNoncurrent_D7E5B8ACF699B42CA742D0DB242320A5_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesNoncurrent_D7E5B8ACF699B42CA742D0DB242320A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesNoncurrent_D7E5B8ACF699B42CA742D0DB242320A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesNoncurrent_D7E5B8ACF699B42CA742D0DB242320A5" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesNoncurrent_D7E5B8ACF699B42CA742D0DB242320A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_DEDF7501791A050C3306D0DB2423A0AD_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_DEDF7501791A050C3306D0DB2423A0AD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_DEDF7501791A050C3306D0DB2423A0AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_DEDF7501791A050C3306D0DB2423A0AD" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_DEDF7501791A050C3306D0DB2423A0AD" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_0024F277E1769D1E62F1D0DB24289784_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_0024F277E1769D1E62F1D0DB24289784" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_0024F277E1769D1E62F1D0DB24289784" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_0024F277E1769D1E62F1D0DB24289784" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_0024F277E1769D1E62F1D0DB24289784" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_0895FD405EFF4152BED7D0DB2428F70B_verboseLabel_en-US" xlink:label="lab_us-gaap_Goodwill_0895FD405EFF4152BED7D0DB2428F70B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_0895FD405EFF4152BED7D0DB2428F70B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_0895FD405EFF4152BED7D0DB2428F70B" xlink:to="lab_us-gaap_Goodwill_0895FD405EFF4152BED7D0DB2428F70B" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_6A65C744AFD6514AFF28D0DB24280A2D_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_6A65C744AFD6514AFF28D0DB24280A2D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Investments and other assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_6A65C744AFD6514AFF28D0DB24280A2D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_6A65C744AFD6514AFF28D0DB24280A2D" xlink:to="lab_us-gaap_OtherAssetsNoncurrent_6A65C744AFD6514AFF28D0DB24280A2D" xlink:type="arc" />
    <link:label id="lab_us-gaap_Assets_23CDDFB9C859F885ABC1D0DB24297E89_totalLabel_en-US" xlink:label="lab_us-gaap_Assets_23CDDFB9C859F885ABC1D0DB24297E89" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_23CDDFB9C859F885ABC1D0DB24297E89_label_en-US" xlink:label="lab_us-gaap_Assets_23CDDFB9C859F885ABC1D0DB24297E89" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_23CDDFB9C859F885ABC1D0DB24297E89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_23CDDFB9C859F885ABC1D0DB24297E89" xlink:to="lab_us-gaap_Assets_23CDDFB9C859F885ABC1D0DB24297E89" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1A6C2C75D57AF755E2B6D0DB24297E76_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1A6C2C75D57AF755E2B6D0DB24297E76" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1A6C2C75D57AF755E2B6D0DB24297E76_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1A6C2C75D57AF755E2B6D0DB24297E76" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1A6C2C75D57AF755E2B6D0DB24297E76" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1A6C2C75D57AF755E2B6D0DB24297E76" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1A6C2C75D57AF755E2B6D0DB24297E76" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_3B88EF6148A7E2EA393ED0DB24292B15_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_3B88EF6148A7E2EA393ED0DB24292B15" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_3B88EF6148A7E2EA393ED0DB24292B15_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_3B88EF6148A7E2EA393ED0DB24292B15" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_3B88EF6148A7E2EA393ED0DB24292B15" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_3B88EF6148A7E2EA393ED0DB24292B15" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_3B88EF6148A7E2EA393ED0DB24292B15" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtCurrent_02DE8209DDA7A26A1F7CD0DB242927FB_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtCurrent_02DE8209DDA7A26A1F7CD0DB242927FB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current portion of notes payable and other financing arrangements</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_02DE8209DDA7A26A1F7CD0DB242927FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtCurrent_02DE8209DDA7A26A1F7CD0DB242927FB" xlink:to="lab_us-gaap_DebtCurrent_02DE8209DDA7A26A1F7CD0DB242927FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxesPayableCurrent_19FBAF11AA6FDC5D2A87D0DB24292973_verboseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent_19FBAF11AA6FDC5D2A87D0DB24292973" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Taxes payable</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_19FBAF11AA6FDC5D2A87D0DB24292973_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent_19FBAF11AA6FDC5D2A87D0DB24292973" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaap_TaxesPayableCurrent_19FBAF11AA6FDC5D2A87D0DB24292973" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent_19FBAF11AA6FDC5D2A87D0DB24292973" xlink:to="lab_us-gaap_TaxesPayableCurrent_19FBAF11AA6FDC5D2A87D0DB24292973" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableCurrent_8C48E082AAC4684CD778D0DB24299899_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_8C48E082AAC4684CD778D0DB24299899" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_8C48E082AAC4684CD778D0DB24299899_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_8C48E082AAC4684CD778D0DB24299899" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_8C48E082AAC4684CD778D0DB24299899" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_8C48E082AAC4684CD778D0DB24299899" xlink:to="lab_us-gaap_AccountsPayableCurrent_8C48E082AAC4684CD778D0DB24299899" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_6D89F8EAA8742F292BEAD0DB24292D33_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_6D89F8EAA8742F292BEAD0DB24292D33" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_6D89F8EAA8742F292BEAD0DB24292D33" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_6D89F8EAA8742F292BEAD0DB24292D33" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent_6D89F8EAA8742F292BEAD0DB24292D33" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrent_156833D7A489C2A0E40AD0DB2429B20D_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_156833D7A489C2A0E40AD0DB2429B20D" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_156833D7A489C2A0E40AD0DB2429B20D_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_156833D7A489C2A0E40AD0DB2429B20D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_156833D7A489C2A0E40AD0DB2429B20D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_156833D7A489C2A0E40AD0DB2429B20D" xlink:to="lab_us-gaap_LiabilitiesCurrent_156833D7A489C2A0E40AD0DB2429B20D" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebt_692C01555AD02271092AD0DB242975E3_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt_692C01555AD02271092AD0DB242975E3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Notes payable and other financing arrangements</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_692C01555AD02271092AD0DB242975E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt_692C01555AD02271092AD0DB242975E3" xlink:to="lab_us-gaap_LongTermDebt_692C01555AD02271092AD0DB242975E3" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_C3624648DFB988E4A182D0DB2429809A_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_C3624648DFB988E4A182D0DB2429809A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_C3624648DFB988E4A182D0DB2429809A_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_C3624648DFB988E4A182D0DB2429809A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Net, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_C3624648DFB988E4A182D0DB2429809A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_C3624648DFB988E4A182D0DB2429809A" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_C3624648DFB988E4A182D0DB2429809A" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_370AA9F611C90244C406D0DB2429C64B_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_370AA9F611C90244C406D0DB2429C64B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_370AA9F611C90244C406D0DB2429C64B_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_370AA9F611C90244C406D0DB2429C64B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_370AA9F611C90244C406D0DB2429C64B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_370AA9F611C90244C406D0DB2429C64B" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent_370AA9F611C90244C406D0DB2429C64B" xlink:type="arc" />
    <link:label id="lab_us-gaap_Liabilities_55C16DD95EC785E95EB4D0DB24290E2D_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities_55C16DD95EC785E95EB4D0DB24290E2D" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_55C16DD95EC785E95EB4D0DB24290E2D_label_en-US" xlink:label="lab_us-gaap_Liabilities_55C16DD95EC785E95EB4D0DB24290E2D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_55C16DD95EC785E95EB4D0DB24290E2D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_55C16DD95EC785E95EB4D0DB24290E2D" xlink:to="lab_us-gaap_Liabilities_55C16DD95EC785E95EB4D0DB24290E2D" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_22EF07F4350F3DC18843D0DB242910D5_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_22EF07F4350F3DC18843D0DB242910D5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_22EF07F4350F3DC18843D0DB242910D5_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_22EF07F4350F3DC18843D0DB242910D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_22EF07F4350F3DC18843D0DB242910D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_22EF07F4350F3DC18843D0DB242910D5" xlink:to="lab_us-gaap_CommitmentsAndContingencies_22EF07F4350F3DC18843D0DB242910D5" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_FC79F69E7EFA78557C2AD0DB24296692_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_FC79F69E7EFA78557C2AD0DB24296692" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_FC79F69E7EFA78557C2AD0DB24296692_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_FC79F69E7EFA78557C2AD0DB24296692" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_FC79F69E7EFA78557C2AD0DB24296692" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_FC79F69E7EFA78557C2AD0DB24296692" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_FC79F69E7EFA78557C2AD0DB24296692" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_530FE173F09D7A066AEAD0DB24293778_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_530FE173F09D7A066AEAD0DB24293778" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Biogen Idec Inc. shareholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_530FE173F09D7A066AEAD0DB24293778_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_530FE173F09D7A066AEAD0DB24293778" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_530FE173F09D7A066AEAD0DB24293778" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_530FE173F09D7A066AEAD0DB24293778" xlink:to="lab_us-gaap_StockholdersEquityAbstract_530FE173F09D7A066AEAD0DB24293778" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockValue_26A790E10F477CEE0BB6D0DB242A1BCC_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue_26A790E10F477CEE0BB6D0DB242A1BCC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value $0.001 per share</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_26A790E10F477CEE0BB6D0DB242A1BCC_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue_26A790E10F477CEE0BB6D0DB242A1BCC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_26A790E10F477CEE0BB6D0DB242A1BCC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue_26A790E10F477CEE0BB6D0DB242A1BCC" xlink:to="lab_us-gaap_PreferredStockValue_26A790E10F477CEE0BB6D0DB242A1BCC" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockValue_D6106F7074703304D05ED0DB242AD87E_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue_D6106F7074703304D05ED0DB242AD87E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value $0.0005 per share</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_D6106F7074703304D05ED0DB242AD87E_label_en-US" xlink:label="lab_us-gaap_CommonStockValue_D6106F7074703304D05ED0DB242AD87E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_D6106F7074703304D05ED0DB242AD87E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_D6106F7074703304D05ED0DB242AD87E" xlink:to="lab_us-gaap_CommonStockValue_D6106F7074703304D05ED0DB242AD87E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_7795E33A05CDD7D1BF40D0DB242AD48C_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_7795E33A05CDD7D1BF40D0DB242AD48C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_7795E33A05CDD7D1BF40D0DB242AD48C_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_7795E33A05CDD7D1BF40D0DB242AD48C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_7795E33A05CDD7D1BF40D0DB242AD48C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital_7795E33A05CDD7D1BF40D0DB242AD48C" xlink:to="lab_us-gaap_AdditionalPaidInCapital_7795E33A05CDD7D1BF40D0DB242AD48C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_E9C76EDBC7AFF3B89248D0DB242AD113_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_E9C76EDBC7AFF3B89248D0DB242AD113" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_E9C76EDBC7AFF3B89248D0DB242AD113" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_E9C76EDBC7AFF3B89248D0DB242AD113" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_E9C76EDBC7AFF3B89248D0DB242AD113" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_1057A67800D65090314AD0DB242AA0AC_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_1057A67800D65090314AD0DB242AA0AC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_1057A67800D65090314AD0DB242AA0AC_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_1057A67800D65090314AD0DB242AA0AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1057A67800D65090314AD0DB242AA0AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1057A67800D65090314AD0DB242AA0AC" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_1057A67800D65090314AD0DB242AA0AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockValue_8B68B5D0BF91EC52F72FD0DB242A068B_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue_8B68B5D0BF91EC52F72FD0DB242A068B" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Treasury stock, at cost; 22.6 million shares, respectively</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_8B68B5D0BF91EC52F72FD0DB242A068B_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue_8B68B5D0BF91EC52F72FD0DB242A068B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_8B68B5D0BF91EC52F72FD0DB242A068B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue_8B68B5D0BF91EC52F72FD0DB242A068B" xlink:to="lab_us-gaap_TreasuryStockValue_8B68B5D0BF91EC52F72FD0DB242A068B" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_6AABAE74EB19CB658887D0DB242AB432_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_6AABAE74EB19CB658887D0DB242AB432" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Biogen Inc. shareholders&#8217; equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_6AABAE74EB19CB658887D0DB242AB432" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_6AABAE74EB19CB658887D0DB242AB432" xlink:to="lab_us-gaap_StockholdersEquity_6AABAE74EB19CB658887D0DB242AB432" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinorityInterest_4DF9557B9A486E03CD4BD0DB242A671C_verboseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest_4DF9557B9A486E03CD4BD0DB242A671C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_4DF9557B9A486E03CD4BD0DB242A671C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest_4DF9557B9A486E03CD4BD0DB242A671C" xlink:to="lab_us-gaap_MinorityInterest_4DF9557B9A486E03CD4BD0DB242A671C" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_E767A175B5E934146078D0DB242AF735_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_E767A175B5E934146078D0DB242AF735" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_E767A175B5E934146078D0DB242AF735" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_E767A175B5E934146078D0DB242AF735" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_E767A175B5E934146078D0DB242AF735" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_C18288F4F6E73CD9E9AED0DB242A7B7D_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_C18288F4F6E73CD9E9AED0DB242A7B7D" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_C18288F4F6E73CD9E9AED0DB242A7B7D_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_C18288F4F6E73CD9E9AED0DB242A7B7D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_C18288F4F6E73CD9E9AED0DB242A7B7D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_C18288F4F6E73CD9E9AED0DB242A7B7D" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_C18288F4F6E73CD9E9AED0DB242A7B7D" xlink:type="arc" />
    <link:label id="lab_biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_3C390512AB33B60D48FD74128843AE5A_terseLabel_en-US" xlink:label="lab_biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_3C390512AB33B60D48FD74128843AE5A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment estimated useful lives</link:label>
    <link:label id="lab_biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_3C390512AB33B60D48FD74128843AE5A_label_en-US" xlink:label="lab_biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_3C390512AB33B60D48FD74128843AE5A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Property Plant And Equipment Useful Lives [Table Text Block]</link:label>
    <link:label id="lab_biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_3C390512AB33B60D48FD74128843AE5A_documentation_en-US" xlink:label="lab_biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_3C390512AB33B60D48FD74128843AE5A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of property plant and equipment useful lives.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" xlink:label="loc_biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_3C390512AB33B60D48FD74128843AE5A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_3C390512AB33B60D48FD74128843AE5A" xlink:to="lab_biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_3C390512AB33B60D48FD74128843AE5A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_2499CAB9C43B751A232FFCCBDB15E33B_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_2499CAB9C43B751A232FFCCBDB15E33B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Minimum rental commitments under non-cancelable leases</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_2499CAB9C43B751A232FFCCBDB15E33B_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_2499CAB9C43B751A232FFCCBDB15E33B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_2499CAB9C43B751A232FFCCBDB15E33B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_2499CAB9C43B751A232FFCCBDB15E33B" xlink:to="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_2499CAB9C43B751A232FFCCBDB15E33B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock_7ADB87DE8FEB5D9BE6BCFCCBDB160567_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock_7ADB87DE8FEB5D9BE6BCFCCBDB160567" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future minimum lease payments for capital leases</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock_7ADB87DE8FEB5D9BE6BCFCCBDB160567_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock_7ADB87DE8FEB5D9BE6BCFCCBDB160567" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Future Minimum Lease Payments for Capital Leases [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock_7ADB87DE8FEB5D9BE6BCFCCBDB160567" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock_7ADB87DE8FEB5D9BE6BCFCCBDB160567" xlink:to="lab_us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock_7ADB87DE8FEB5D9BE6BCFCCBDB160567" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsAbstract_27B31ABAAAEE4BC3BA00741287C8ACF2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsAbstract_27B31ABAAAEE4BC3BA00741287C8ACF2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsAbstract_27B31ABAAAEE4BC3BA00741287C8ACF2_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsAbstract_27B31ABAAAEE4BC3BA00741287C8ACF2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsAbstract" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsAbstract_27B31ABAAAEE4BC3BA00741287C8ACF2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsAbstract_27B31ABAAAEE4BC3BA00741287C8ACF2" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsAbstract_27B31ABAAAEE4BC3BA00741287C8ACF2" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_11AD9491DDD4750AB7D1741287C80BE5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_11AD9491DDD4750AB7D1741287C80BE5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income before income taxes (benefit):</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_11AD9491DDD4750AB7D1741287C80BE5_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_11AD9491DDD4750AB7D1741287C80BE5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_11AD9491DDD4750AB7D1741287C80BE5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_11AD9491DDD4750AB7D1741287C80BE5" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_11AD9491DDD4750AB7D1741287C80BE5" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_62ACE3D9AE5F3E13B65E741287C8395E_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_62ACE3D9AE5F3E13B65E741287C8395E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Domestic</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_62ACE3D9AE5F3E13B65E741287C8395E_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_62ACE3D9AE5F3E13B65E741287C8395E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_62ACE3D9AE5F3E13B65E741287C8395E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_62ACE3D9AE5F3E13B65E741287C8395E" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_62ACE3D9AE5F3E13B65E741287C8395E" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_063DAC2307739C134EAC741287C800C6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_063DAC2307739C134EAC741287C800C6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_063DAC2307739C134EAC741287C800C6_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_063DAC2307739C134EAC741287C800C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_063DAC2307739C134EAC741287C800C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_063DAC2307739C134EAC741287C800C6" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_063DAC2307739C134EAC741287C800C6" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_253906626C54F6F2AE12741287C838B7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_253906626C54F6F2AE12741287C838B7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense (benefit):</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_253906626C54F6F2AE12741287C838B7_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_253906626C54F6F2AE12741287C838B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_253906626C54F6F2AE12741287C838B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_253906626C54F6F2AE12741287C838B7" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_253906626C54F6F2AE12741287C838B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_3C22CFDDAE006CC90693741287C88981_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_3C22CFDDAE006CC90693741287C88981" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_3C22CFDDAE006CC90693741287C88981_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_3C22CFDDAE006CC90693741287C88981" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_3C22CFDDAE006CC90693741287C88981" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_3C22CFDDAE006CC90693741287C88981" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_3C22CFDDAE006CC90693741287C88981" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_D813E68252FF3AEB55D1741287C98092_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit_D813E68252FF3AEB55D1741287C98092" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_D813E68252FF3AEB55D1741287C98092_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit_D813E68252FF3AEB55D1741287C98092" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_D813E68252FF3AEB55D1741287C98092" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit_D813E68252FF3AEB55D1741287C98092" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit_D813E68252FF3AEB55D1741287C98092" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_C9DDFC92B11C6E3D99ED741287C9F510_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_C9DDFC92B11C6E3D99ED741287C9F510" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_C9DDFC92B11C6E3D99ED741287C9F510_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_C9DDFC92B11C6E3D99ED741287C9F510" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_C9DDFC92B11C6E3D99ED741287C9F510" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_C9DDFC92B11C6E3D99ED741287C9F510" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_C9DDFC92B11C6E3D99ED741287C9F510" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_4844BD8AE816E27F5F4E741287C94D15_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit_4844BD8AE816E27F5F4E741287C94D15" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_4844BD8AE816E27F5F4E741287C94D15_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit_4844BD8AE816E27F5F4E741287C94D15" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_4844BD8AE816E27F5F4E741287C94D15" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit_4844BD8AE816E27F5F4E741287C94D15" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit_4844BD8AE816E27F5F4E741287C94D15" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_E58354977A86488070A2741287C99E97_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_E58354977A86488070A2741287C99E97" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_E58354977A86488070A2741287C99E97_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_E58354977A86488070A2741287C99E97" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_E58354977A86488070A2741287C99E97" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_E58354977A86488070A2741287C99E97" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_E58354977A86488070A2741287C99E97" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_5094EE50E8A66A199E0A741287C9EA89_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_5094EE50E8A66A199E0A741287C9EA89" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_5094EE50E8A66A199E0A741287C9EA89_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_5094EE50E8A66A199E0A741287C9EA89" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_5094EE50E8A66A199E0A741287C9EA89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_5094EE50E8A66A199E0A741287C9EA89" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_5094EE50E8A66A199E0A741287C9EA89" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_2BC0DE047EEA4B058E1F741287C93110_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_2BC0DE047EEA4B058E1F741287C93110" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_2BC0DE047EEA4B058E1F741287C93110_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_2BC0DE047EEA4B058E1F741287C93110" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_2BC0DE047EEA4B058E1F741287C93110" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_2BC0DE047EEA4B058E1F741287C93110" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_2BC0DE047EEA4B058E1F741287C93110" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_C06395115D97EEF0C26F741287C90DA9_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_C06395115D97EEF0C26F741287C90DA9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_C06395115D97EEF0C26F741287C90DA9_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_C06395115D97EEF0C26F741287C90DA9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_C06395115D97EEF0C26F741287C90DA9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_C06395115D97EEF0C26F741287C90DA9" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_C06395115D97EEF0C26F741287C90DA9" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_5120469C3498ACE3CE6B741287C9C099_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_5120469C3498ACE3CE6B741287C9C099" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_5120469C3498ACE3CE6B741287C9C099_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_5120469C3498ACE3CE6B741287C9C099" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_5120469C3498ACE3CE6B741287C9C099" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_5120469C3498ACE3CE6B741287C9C099" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_5120469C3498ACE3CE6B741287C9C099" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_61FF8A76906EE8FD39D6741287CA3409_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_61FF8A76906EE8FD39D6741287CA3409" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_61FF8A76906EE8FD39D6741287CA3409" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_61FF8A76906EE8FD39D6741287CA3409" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_61FF8A76906EE8FD39D6741287CA3409" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_3C280754D761BD17CAFD741287CA37CD_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_3C280754D761BD17CAFD741287CA37CD" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total income tax expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_3C280754D761BD17CAFD741287CA37CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_3C280754D761BD17CAFD741287CA37CD" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_3C280754D761BD17CAFD741287CA37CD" xlink:type="arc" />
    <link:label id="lab_us-gaap_AirlineProductsAndServicesTable_F9BE3E575610995DFE86FA4EA5747988_terseLabel_en-US" xlink:label="lab_us-gaap_AirlineProductsAndServicesTable_F9BE3E575610995DFE86FA4EA5747988" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Products and Services [Table]</link:label>
    <link:label id="lab_us-gaap_AirlineProductsAndServicesTable_F9BE3E575610995DFE86FA4EA5747988_label_en-US" xlink:label="lab_us-gaap_AirlineProductsAndServicesTable_F9BE3E575610995DFE86FA4EA5747988" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products and Services [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AirlineProductsAndServicesTable" xlink:label="loc_us-gaap_AirlineProductsAndServicesTable_F9BE3E575610995DFE86FA4EA5747988" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AirlineProductsAndServicesTable_F9BE3E575610995DFE86FA4EA5747988" xlink:to="lab_us-gaap_AirlineProductsAndServicesTable_F9BE3E575610995DFE86FA4EA5747988" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryLineItems_305528DEBE90E366EF97FA4EA575481F_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryLineItems_305528DEBE90E366EF97FA4EA575481F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:label id="lab_us-gaap_InventoryLineItems_305528DEBE90E366EF97FA4EA575481F_label_en-US" xlink:label="lab_us-gaap_InventoryLineItems_305528DEBE90E366EF97FA4EA575481F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryLineItems" xlink:label="loc_us-gaap_InventoryLineItems_305528DEBE90E366EF97FA4EA575481F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryLineItems_305528DEBE90E366EF97FA4EA575481F" xlink:to="lab_us-gaap_InventoryLineItems_305528DEBE90E366EF97FA4EA575481F" xlink:type="arc" />
    <link:label id="lab_biib_Preapprovalinventory_9AFB9E710795E7A71CDEFA4EA5752B17_terseLabel_en-US" xlink:label="lab_biib_Preapprovalinventory_9AFB9E710795E7A71CDEFA4EA5752B17" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-approval inventory</link:label>
    <link:label id="lab_biib_Preapprovalinventory_9AFB9E710795E7A71CDEFA4EA5752B17_label_en-US" xlink:label="lab_biib_Preapprovalinventory_9AFB9E710795E7A71CDEFA4EA5752B17" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-approval inventory</link:label>
    <link:label id="lab_biib_Preapprovalinventory_9AFB9E710795E7A71CDEFA4EA5752B17_documentation_en-US" xlink:label="lab_biib_Preapprovalinventory_9AFB9E710795E7A71CDEFA4EA5752B17" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pre-approval inventory</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_Preapprovalinventory" xlink:label="loc_biib_Preapprovalinventory_9AFB9E710795E7A71CDEFA4EA5752B17" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Preapprovalinventory_9AFB9E710795E7A71CDEFA4EA5752B17" xlink:to="lab_biib_Preapprovalinventory_9AFB9E710795E7A71CDEFA4EA5752B17" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryWriteDown_515486300E3C8EF55E7BFA4EA575F043_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryWriteDown_515486300E3C8EF55E7BFA4EA575F043" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Write-downs on excess, obsolete, unmarketable or other inventory</link:label>
    <link:label id="lab_us-gaap_InventoryWriteDown_515486300E3C8EF55E7BFA4EA575F043_label_en-US" xlink:label="lab_us-gaap_InventoryWriteDown_515486300E3C8EF55E7BFA4EA575F043" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Write-down</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="loc_us-gaap_InventoryWriteDown_515486300E3C8EF55E7BFA4EA575F043" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWriteDown_515486300E3C8EF55E7BFA4EA575F043" xlink:to="lab_us-gaap_InventoryWriteDown_515486300E3C8EF55E7BFA4EA575F043" xlink:type="arc" />
    <link:label id="lab_biib_CumulativeSalesLevelAxis_307D3D3893BBBAF6C9ECFB6C3A7B8756_terseLabel_en-US" xlink:label="lab_biib_CumulativeSalesLevelAxis_307D3D3893BBBAF6C9ECFB6C3A7B8756" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cumulative sales level [Axis]</link:label>
    <link:label id="lab_biib_CumulativeSalesLevelAxis_307D3D3893BBBAF6C9ECFB6C3A7B8756_label_en-US" xlink:label="lab_biib_CumulativeSalesLevelAxis_307D3D3893BBBAF6C9ECFB6C3A7B8756" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cumulative sales level [Axis]</link:label>
    <link:label id="lab_biib_CumulativeSalesLevelAxis_307D3D3893BBBAF6C9ECFB6C3A7B8756_documentation_en-US" xlink:label="lab_biib_CumulativeSalesLevelAxis_307D3D3893BBBAF6C9ECFB6C3A7B8756" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cumulative sales level [Axis]</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_CumulativeSalesLevelAxis" xlink:label="loc_biib_CumulativeSalesLevelAxis_307D3D3893BBBAF6C9ECFB6C3A7B8756" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CumulativeSalesLevelAxis_307D3D3893BBBAF6C9ECFB6C3A7B8756" xlink:to="lab_biib_CumulativeSalesLevelAxis_307D3D3893BBBAF6C9ECFB6C3A7B8756" xlink:type="arc" />
    <link:label id="lab_biib_CumulativeSalesLevelDomain_4FB6EEB520BB1657F312FB6C3A7BF198_terseLabel_en-US" xlink:label="lab_biib_CumulativeSalesLevelDomain_4FB6EEB520BB1657F312FB6C3A7BF198" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cumulative sales level [Domain]</link:label>
    <link:label id="lab_biib_CumulativeSalesLevelDomain_4FB6EEB520BB1657F312FB6C3A7BF198_label_en-US" xlink:label="lab_biib_CumulativeSalesLevelDomain_4FB6EEB520BB1657F312FB6C3A7BF198" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cumulative sales level [Domain]</link:label>
    <link:label id="lab_biib_CumulativeSalesLevelDomain_4FB6EEB520BB1657F312FB6C3A7BF198_documentation_en-US" xlink:label="lab_biib_CumulativeSalesLevelDomain_4FB6EEB520BB1657F312FB6C3A7BF198" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Cumulative sales level [Axis]</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_CumulativeSalesLevelDomain" xlink:label="loc_biib_CumulativeSalesLevelDomain_4FB6EEB520BB1657F312FB6C3A7BF198" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CumulativeSalesLevelDomain_4FB6EEB520BB1657F312FB6C3A7BF198" xlink:to="lab_biib_CumulativeSalesLevelDomain_4FB6EEB520BB1657F312FB6C3A7BF198" xlink:type="arc" />
    <link:label id="lab_biib_ElevenbillionMember_9F9AC15002436D034960FB6C3A7B568D_terseLabel_en-US" xlink:label="lab_biib_ElevenbillionMember_9F9AC15002436D034960FB6C3A7B568D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Eleven billion</link:label>
    <link:label id="lab_biib_ElevenbillionMember_9F9AC15002436D034960FB6C3A7B568D_label_en-US" xlink:label="lab_biib_ElevenbillionMember_9F9AC15002436D034960FB6C3A7B568D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Eleven billion [Member]</link:label>
    <link:label id="lab_biib_ElevenbillionMember_9F9AC15002436D034960FB6C3A7B568D_documentation_en-US" xlink:label="lab_biib_ElevenbillionMember_9F9AC15002436D034960FB6C3A7B568D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Eleven billion [Member]</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_ElevenbillionMember" xlink:label="loc_biib_ElevenbillionMember_9F9AC15002436D034960FB6C3A7B568D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ElevenbillionMember_9F9AC15002436D034960FB6C3A7B568D" xlink:to="lab_biib_ElevenbillionMember_9F9AC15002436D034960FB6C3A7B568D" xlink:type="arc" />
    <link:label id="lab_biib_CumulativeSalesLevel_8EFDC8FC90D214139B9DFB6C3A7DEE48_terseLabel_en-US" xlink:label="lab_biib_CumulativeSalesLevel_8EFDC8FC90D214139B9DFB6C3A7DEE48" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cumulative sales level</link:label>
    <link:label id="lab_biib_CumulativeSalesLevel_8EFDC8FC90D214139B9DFB6C3A7DEE48_label_en-US" xlink:label="lab_biib_CumulativeSalesLevel_8EFDC8FC90D214139B9DFB6C3A7DEE48" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cumulative sales level</link:label>
    <link:label id="lab_biib_CumulativeSalesLevel_8EFDC8FC90D214139B9DFB6C3A7DEE48_documentation_en-US" xlink:label="lab_biib_CumulativeSalesLevel_8EFDC8FC90D214139B9DFB6C3A7DEE48" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cumulative sales level</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_CumulativeSalesLevel" xlink:label="loc_biib_CumulativeSalesLevel_8EFDC8FC90D214139B9DFB6C3A7DEE48" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CumulativeSalesLevel_8EFDC8FC90D214139B9DFB6C3A7DEE48" xlink:to="lab_biib_CumulativeSalesLevel_8EFDC8FC90D214139B9DFB6C3A7DEE48" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidTaxes_16BCC52584BEED3645FBFB6C3A7DA321_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidTaxes_16BCC52584BEED3645FBFB6C3A7DA321" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid taxes</link:label>
    <link:label id="lab_us-gaap_PrepaidTaxes_16BCC52584BEED3645FBFB6C3A7DA321_label_en-US" xlink:label="lab_us-gaap_PrepaidTaxes_16BCC52584BEED3645FBFB6C3A7DA321" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Taxes</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidTaxes" xlink:label="loc_us-gaap_PrepaidTaxes_16BCC52584BEED3645FBFB6C3A7DA321" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidTaxes_16BCC52584BEED3645FBFB6C3A7DA321" xlink:to="lab_us-gaap_PrepaidTaxes_16BCC52584BEED3645FBFB6C3A7DA321" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_22F8E760669A78A5DC89FB6C3A7D9597_negatedLabel_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_22F8E760669A78A5DC89FB6C3A7D9597" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Proposed settlement</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_22F8E760669A78A5DC89FB6C3A7D9597" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_22F8E760669A78A5DC89FB6C3A7D9597" xlink:to="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_22F8E760669A78A5DC89FB6C3A7D9597" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_CCFE86255E01399D9E5FFB6C3A7D30BC_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue_CCFE86255E01399D9E5FFB6C3A7D30BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss contingency accrual</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_CCFE86255E01399D9E5FFB6C3A7D30BC_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue_CCFE86255E01399D9E5FFB6C3A7D30BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_CCFE86255E01399D9E5FFB6C3A7D30BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue_CCFE86255E01399D9E5FFB6C3A7D30BC" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue_CCFE86255E01399D9E5FFB6C3A7D30BC" xlink:type="arc" />
    <link:label id="lab_biib_LossContingencyAdjustmentRelatedToClaimAmountPercent_E53392492F4F75200048FB6C3A7D1749_terseLabel_en-US" xlink:label="lab_biib_LossContingencyAdjustmentRelatedToClaimAmountPercent_E53392492F4F75200048FB6C3A7D1749" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss contingency, adjustment related to claim amount, percent</link:label>
    <link:label id="lab_biib_LossContingencyAdjustmentRelatedToClaimAmountPercent_E53392492F4F75200048FB6C3A7D1749_label_en-US" xlink:label="lab_biib_LossContingencyAdjustmentRelatedToClaimAmountPercent_E53392492F4F75200048FB6C3A7D1749" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Adjustment Related To Claim Amount, Percent</link:label>
    <link:label id="lab_biib_LossContingencyAdjustmentRelatedToClaimAmountPercent_E53392492F4F75200048FB6C3A7D1749_documentation_en-US" xlink:label="lab_biib_LossContingencyAdjustmentRelatedToClaimAmountPercent_E53392492F4F75200048FB6C3A7D1749" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Loss Contingency, Adjustment Related To Claim Amount, Percent</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_LossContingencyAdjustmentRelatedToClaimAmountPercent" xlink:label="loc_biib_LossContingencyAdjustmentRelatedToClaimAmountPercent_E53392492F4F75200048FB6C3A7D1749" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_LossContingencyAdjustmentRelatedToClaimAmountPercent_E53392492F4F75200048FB6C3A7D1749" xlink:to="lab_biib_LossContingencyAdjustmentRelatedToClaimAmountPercent_E53392492F4F75200048FB6C3A7D1749" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_C90D4BB660FE9CBDF6A0FB6C3A7DDACA_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_C90D4BB660FE9CBDF6A0FB6C3A7DDACA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other long-term deferred revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_C90D4BB660FE9CBDF6A0FB6C3A7DDACA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_C90D4BB660FE9CBDF6A0FB6C3A7DDACA" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent_C90D4BB660FE9CBDF6A0FB6C3A7DDACA" xlink:type="arc" />
    <link:label id="lab_biib_PerformanceUnitsMember_0B35579AF2D99A91D3F9FCCBDBF9B11A_terseLabel_en-US" xlink:label="lab_biib_PerformanceUnitsMember_0B35579AF2D99A91D3F9FCCBDBF9B11A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance Units [Member]</link:label>
    <link:label id="lab_biib_PerformanceUnitsMember_0B35579AF2D99A91D3F9FCCBDBF9B11A_label_en-US" xlink:label="lab_biib_PerformanceUnitsMember_0B35579AF2D99A91D3F9FCCBDBF9B11A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Units [Member]</link:label>
    <link:label id="lab_biib_PerformanceUnitsMember_0B35579AF2D99A91D3F9FCCBDBF9B11A_documentation_en-US" xlink:label="lab_biib_PerformanceUnitsMember_0B35579AF2D99A91D3F9FCCBDBF9B11A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Performance Units [Member]</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_PerformanceUnitsMember" xlink:label="loc_biib_PerformanceUnitsMember_0B35579AF2D99A91D3F9FCCBDBF9B11A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PerformanceUnitsMember_0B35579AF2D99A91D3F9FCCBDBF9B11A" xlink:to="lab_biib_PerformanceUnitsMember_0B35579AF2D99A91D3F9FCCBDBF9B11A" xlink:type="arc" />
    <link:label id="lab_biib_EmployeeStockPurchasePlanMember_420AB1F2642296763C40FCCBDBF95CEF_verboseLabel_en-US" xlink:label="lab_biib_EmployeeStockPurchasePlanMember_420AB1F2642296763C40FCCBDBF95CEF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Employee stock purchase plan</link:label>
    <link:label id="lab_biib_EmployeeStockPurchasePlanMember_420AB1F2642296763C40FCCBDBF95CEF_label_en-US" xlink:label="lab_biib_EmployeeStockPurchasePlanMember_420AB1F2642296763C40FCCBDBF95CEF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_biib_EmployeeStockPurchasePlanMember_420AB1F2642296763C40FCCBDBF95CEF_documentation_en-US" xlink:label="lab_biib_EmployeeStockPurchasePlanMember_420AB1F2642296763C40FCCBDBF95CEF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee stock purchase plan.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_EmployeeStockPurchasePlanMember" xlink:label="loc_biib_EmployeeStockPurchasePlanMember_420AB1F2642296763C40FCCBDBF95CEF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EmployeeStockPurchasePlanMember_420AB1F2642296763C40FCCBDBF95CEF" xlink:to="lab_biib_EmployeeStockPurchasePlanMember_420AB1F2642296763C40FCCBDBF95CEF" xlink:type="arc" />
    <link:label id="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_4C5DB6279FA0D67FA030FCCBDBF9BB4B_verboseLabel_en-US" xlink:label="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_4C5DB6279FA0D67FA030FCCBDBF9BB4B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of share based compensation expense associated with different programs</link:label>
    <link:label id="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_4C5DB6279FA0D67FA030FCCBDBF9BB4B_label_en-US" xlink:label="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_4C5DB6279FA0D67FA030FCCBDBF9BB4B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of share based compensation expense associated with different programs [Abstract]</link:label>
    <link:label id="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_4C5DB6279FA0D67FA030FCCBDBF9BB4B_documentation_en-US" xlink:label="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_4C5DB6279FA0D67FA030FCCBDBF9BB4B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary of share-based compensation expense associated with different programs.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:label="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_4C5DB6279FA0D67FA030FCCBDBF9BB4B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_4C5DB6279FA0D67FA030FCCBDBF9BB4B" xlink:to="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_4C5DB6279FA0D67FA030FCCBDBF9BB4B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_FD0AD41CD2C18315A39AFCCBDBF9E79E_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_FD0AD41CD2C18315A39AFCCBDBF9E79E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_FD0AD41CD2C18315A39AFCCBDBF9E79E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_FD0AD41CD2C18315A39AFCCBDBF9E79E" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_FD0AD41CD2C18315A39AFCCBDBF9E79E" xlink:type="arc" />
    <link:label id="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_68A457065EA3B81A3828FCCBDBFAAC0B_terseLabel_en-US" xlink:label="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_68A457065EA3B81A3828FCCBDBFAAC0B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense included in total costs and expenses</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_68A457065EA3B81A3828FCCBDBFAAC0B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_68A457065EA3B81A3828FCCBDBFAAC0B" xlink:to="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_68A457065EA3B81A3828FCCBDBFAAC0B" xlink:type="arc" />
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_D6A9AB60E31A1DC3A7B174128945023F_verboseLabel_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock_D6A9AB60E31A1DC3A7B174128945023F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Quarterly Financial Data (Unaudited)</link:label>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_D6A9AB60E31A1DC3A7B174128945023F_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock_D6A9AB60E31A1DC3A7B174128945023F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Quarterly Financial Information [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock_D6A9AB60E31A1DC3A7B174128945023F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationTextBlock_D6A9AB60E31A1DC3A7B174128945023F" xlink:to="lab_us-gaap_QuarterlyFinancialInformationTextBlock_D6A9AB60E31A1DC3A7B174128945023F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_ACF66F1417A596214540741286EBC6FB_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_ACF66F1417A596214540741286EBC6FB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Quarterly Financial Data (Unaudited)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_ACF66F1417A596214540741286EBC6FB_label_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_ACF66F1417A596214540741286EBC6FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Quarterly Financial Information [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_ACF66F1417A596214540741286EBC6FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_ACF66F1417A596214540741286EBC6FB" xlink:to="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_ACF66F1417A596214540741286EBC6FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_405885FB801A26F6CD28741285461380_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_405885FB801A26F6CD28741285461380" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_405885FB801A26F6CD28741285461380_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_405885FB801A26F6CD28741285461380" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_405885FB801A26F6CD28741285461380" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_405885FB801A26F6CD28741285461380" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_405885FB801A26F6CD28741285461380" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3D6521F7DE12D3604596741285468FD2_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3D6521F7DE12D3604596741285468FD2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, by Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3D6521F7DE12D3604596741285468FD2_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3D6521F7DE12D3604596741285468FD2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3D6521F7DE12D3604596741285468FD2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3D6521F7DE12D3604596741285468FD2" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3D6521F7DE12D3604596741285468FD2" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_0B122B3CFECA999F5C45741285468C47_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_0B122B3CFECA999F5C45741285468C47" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_0B122B3CFECA999F5C45741285468C47_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_0B122B3CFECA999F5C45741285468C47" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0B122B3CFECA999F5C45741285468C47" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0B122B3CFECA999F5C45741285468C47" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain_0B122B3CFECA999F5C45741285468C47" xlink:type="arc" />
    <link:label id="lab_biib_StockOptionsAndEmployeeStockPurchasePlanMember_E78A59C52EEDABD124E674128546A36F_verboseLabel_en-US" xlink:label="lab_biib_StockOptionsAndEmployeeStockPurchasePlanMember_E78A59C52EEDABD124E674128546A36F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock options and employee stock purchase plan</link:label>
    <link:label id="lab_biib_StockOptionsAndEmployeeStockPurchasePlanMember_E78A59C52EEDABD124E674128546A36F_label_en-US" xlink:label="lab_biib_StockOptionsAndEmployeeStockPurchasePlanMember_E78A59C52EEDABD124E674128546A36F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock options and employee stock purchase plan [Member]</link:label>
    <link:label id="lab_biib_StockOptionsAndEmployeeStockPurchasePlanMember_E78A59C52EEDABD124E674128546A36F_documentation_en-US" xlink:label="lab_biib_StockOptionsAndEmployeeStockPurchasePlanMember_E78A59C52EEDABD124E674128546A36F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock options and employee stock purchase plan.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_StockOptionsAndEmployeeStockPurchasePlanMember" xlink:label="loc_biib_StockOptionsAndEmployeeStockPurchasePlanMember_E78A59C52EEDABD124E674128546A36F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_StockOptionsAndEmployeeStockPurchasePlanMember_E78A59C52EEDABD124E674128546A36F" xlink:to="lab_biib_StockOptionsAndEmployeeStockPurchasePlanMember_E78A59C52EEDABD124E674128546A36F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_B3C5EDA290A7207E19A774128546FC8A_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_B3C5EDA290A7207E19A774128546FC8A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_B3C5EDA290A7207E19A774128546FC8A_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_B3C5EDA290A7207E19A774128546FC8A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_B3C5EDA290A7207E19A774128546FC8A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_B3C5EDA290A7207E19A774128546FC8A" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_B3C5EDA290A7207E19A774128546FC8A" xlink:type="arc" />
    <link:label id="lab_biib_BasicAndDilutedEarningsPerShareAbstract_4C0290AF0CD79276F6997412854641C9_verboseLabel_en-US" xlink:label="lab_biib_BasicAndDilutedEarningsPerShareAbstract_4C0290AF0CD79276F6997412854641C9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted earnings per share</link:label>
    <link:label id="lab_biib_BasicAndDilutedEarningsPerShareAbstract_4C0290AF0CD79276F6997412854641C9_label_en-US" xlink:label="lab_biib_BasicAndDilutedEarningsPerShareAbstract_4C0290AF0CD79276F6997412854641C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic And Diluted Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_biib_BasicAndDilutedEarningsPerShareAbstract_4C0290AF0CD79276F6997412854641C9_documentation_en-US" xlink:label="lab_biib_BasicAndDilutedEarningsPerShareAbstract_4C0290AF0CD79276F6997412854641C9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Basic and diluted earnings per share.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_BasicAndDilutedEarningsPerShareAbstract" xlink:label="loc_biib_BasicAndDilutedEarningsPerShareAbstract_4C0290AF0CD79276F6997412854641C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_4C0290AF0CD79276F6997412854641C9" xlink:to="lab_biib_BasicAndDilutedEarningsPerShareAbstract_4C0290AF0CD79276F6997412854641C9" xlink:type="arc" />
    <link:label id="lab_biib_NumeratorAbstract_6715CC6AD8F213A757397412854646AC_verboseLabel_en-US" xlink:label="lab_biib_NumeratorAbstract_6715CC6AD8F213A757397412854646AC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_biib_NumeratorAbstract_6715CC6AD8F213A757397412854646AC_label_en-US" xlink:label="lab_biib_NumeratorAbstract_6715CC6AD8F213A757397412854646AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Numerator [Abstract]</link:label>
    <link:label id="lab_biib_NumeratorAbstract_6715CC6AD8F213A757397412854646AC_documentation_en-US" xlink:label="lab_biib_NumeratorAbstract_6715CC6AD8F213A757397412854646AC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Numerator.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_NumeratorAbstract" xlink:label="loc_biib_NumeratorAbstract_6715CC6AD8F213A757397412854646AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NumeratorAbstract_6715CC6AD8F213A757397412854646AC" xlink:to="lab_biib_NumeratorAbstract_6715CC6AD8F213A757397412854646AC" xlink:type="arc" />
    <link:label id="lab_biib_DenominatorAbstract_440A9944CF67CDD0BBBA741285463724_verboseLabel_en-US" xlink:label="lab_biib_DenominatorAbstract_440A9944CF67CDD0BBBA741285463724" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_biib_DenominatorAbstract_440A9944CF67CDD0BBBA741285463724_label_en-US" xlink:label="lab_biib_DenominatorAbstract_440A9944CF67CDD0BBBA741285463724" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Denominator [Abstract]</link:label>
    <link:label id="lab_biib_DenominatorAbstract_440A9944CF67CDD0BBBA741285463724_documentation_en-US" xlink:label="lab_biib_DenominatorAbstract_440A9944CF67CDD0BBBA741285463724" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Denominator.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_DenominatorAbstract" xlink:label="loc_biib_DenominatorAbstract_440A9944CF67CDD0BBBA741285463724" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DenominatorAbstract_440A9944CF67CDD0BBBA741285463724" xlink:to="lab_biib_DenominatorAbstract_440A9944CF67CDD0BBBA741285463724" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_C5E1F5F301F2613EE0A674128546F32E_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_C5E1F5F301F2613EE0A674128546F32E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average number of common shares outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_C5E1F5F301F2613EE0A674128546F32E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_C5E1F5F301F2613EE0A674128546F32E" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_C5E1F5F301F2613EE0A674128546F32E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_0F494F54B561DEC4FE4974128546CDB7_verboseLabel_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract_0F494F54B561DEC4FE4974128546CDB7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Effect of dilutive securities:</link:label>
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_0F494F54B561DEC4FE4974128546CDB7_label_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract_0F494F54B561DEC4FE4974128546CDB7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_0F494F54B561DEC4FE4974128546CDB7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_0F494F54B561DEC4FE4974128546CDB7" xlink:to="lab_us-gaap_DilutiveSecuritiesAbstract_0F494F54B561DEC4FE4974128546CDB7" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_114DB08C90AEEC8432C574128546E076_verboseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_114DB08C90AEEC8432C574128546E076" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock options and employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_114DB08C90AEEC8432C574128546E076_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_114DB08C90AEEC8432C574128546E076" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_114DB08C90AEEC8432C574128546E076" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_114DB08C90AEEC8432C574128546E076" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_114DB08C90AEEC8432C574128546E076" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_5496007EB242490CE16B741285471985_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_5496007EB242490CE16B741285471985" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Dilutive potential common shares</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_5496007EB242490CE16B741285471985_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_5496007EB242490CE16B741285471985" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_5496007EB242490CE16B741285471985" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_5496007EB242490CE16B741285471985" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_5496007EB242490CE16B741285471985" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_24B4B2C04F281ABB404374128547D45A_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_24B4B2C04F281ABB404374128547D45A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Shares used in calculating diluted earnings per share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_24B4B2C04F281ABB404374128547D45A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_24B4B2C04F281ABB404374128547D45A" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_24B4B2C04F281ABB404374128547D45A" xlink:type="arc" />
    <link:label id="lab_biib_EarningsPerShareTextualAbstract_9E70D23636B7662ADEF7741285475A0F_terseLabel_en-US" xlink:label="lab_biib_EarningsPerShareTextualAbstract_9E70D23636B7662ADEF7741285475A0F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings per share (Textual)</link:label>
    <link:label id="lab_biib_EarningsPerShareTextualAbstract_9E70D23636B7662ADEF7741285475A0F_label_en-US" xlink:label="lab_biib_EarningsPerShareTextualAbstract_9E70D23636B7662ADEF7741285475A0F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share (Textual) [Abstract]</link:label>
    <link:label id="lab_biib_EarningsPerShareTextualAbstract_9E70D23636B7662ADEF7741285475A0F_documentation_en-US" xlink:label="lab_biib_EarningsPerShareTextualAbstract_9E70D23636B7662ADEF7741285475A0F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Earnings per share.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_EarningsPerShareTextualAbstract" xlink:label="loc_biib_EarningsPerShareTextualAbstract_9E70D23636B7662ADEF7741285475A0F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EarningsPerShareTextualAbstract_9E70D23636B7662ADEF7741285475A0F" xlink:to="lab_biib_EarningsPerShareTextualAbstract_9E70D23636B7662ADEF7741285475A0F" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_09F30CF3ADB6E2C9846E74128547E20F_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_09F30CF3ADB6E2C9846E74128547E20F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_09F30CF3ADB6E2C9846E74128547E20F_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_09F30CF3ADB6E2C9846E74128547E20F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares, Common Stock Subject to Repurchase or Cancellation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_09F30CF3ADB6E2C9846E74128547E20F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_09F30CF3ADB6E2C9846E74128547E20F" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_09F30CF3ADB6E2C9846E74128547E20F" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_F834A14464F81AADCB707412862B21D9_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_F834A14464F81AADCB707412862B21D9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Earnings per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_F834A14464F81AADCB707412862B21D9_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_F834A14464F81AADCB707412862B21D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_F834A14464F81AADCB707412862B21D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock_F834A14464F81AADCB707412862B21D9" xlink:to="lab_us-gaap_EarningsPerShareTextBlock_F834A14464F81AADCB707412862B21D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_FB1E2F4BAE47D4508BE5741285F82F22_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_FB1E2F4BAE47D4508BE5741285F82F22" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted earnings per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_FB1E2F4BAE47D4508BE5741285F82F22_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_FB1E2F4BAE47D4508BE5741285F82F22" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_FB1E2F4BAE47D4508BE5741285F82F22" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_FB1E2F4BAE47D4508BE5741285F82F22" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_FB1E2F4BAE47D4508BE5741285F82F22" xlink:type="arc" />
    <link:label id="lab_biib_CashSettledPerformanceSharesAbstract_C8B0513E210CDCD3A606741286F5A57C_verboseLabel_en-US" xlink:label="lab_biib_CashSettledPerformanceSharesAbstract_C8B0513E210CDCD3A606741286F5A57C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash settled performance shares</link:label>
    <link:label id="lab_biib_CashSettledPerformanceSharesAbstract_C8B0513E210CDCD3A606741286F5A57C_label_en-US" xlink:label="lab_biib_CashSettledPerformanceSharesAbstract_C8B0513E210CDCD3A606741286F5A57C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Settled Performance Shares [Abstract]</link:label>
    <link:label id="lab_biib_CashSettledPerformanceSharesAbstract_C8B0513E210CDCD3A606741286F5A57C_documentation_en-US" xlink:label="lab_biib_CashSettledPerformanceSharesAbstract_C8B0513E210CDCD3A606741286F5A57C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash settled performance shares.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_CashSettledPerformanceSharesAbstract" xlink:label="loc_biib_CashSettledPerformanceSharesAbstract_C8B0513E210CDCD3A606741286F5A57C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CashSettledPerformanceSharesAbstract_C8B0513E210CDCD3A606741286F5A57C" xlink:to="lab_biib_CashSettledPerformanceSharesAbstract_C8B0513E210CDCD3A606741286F5A57C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_9AB432A796BA545F439EFD60F5C0A275_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_9AB432A796BA545F439EFD60F5C0A275" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_9AB432A796BA545F439EFD60F5C0A275_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_9AB432A796BA545F439EFD60F5C0A275" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_9AB432A796BA545F439EFD60F5C0A275" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_9AB432A796BA545F439EFD60F5C0A275" xlink:to="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_9AB432A796BA545F439EFD60F5C0A275" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_6F29096E529B1F29FED9FD60F5C168EF_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_6F29096E529B1F29FED9FD60F5C168EF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Axis]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_6F29096E529B1F29FED9FD60F5C168EF_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_6F29096E529B1F29FED9FD60F5C168EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plans and Other Postretirement Benefit Plans [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis" xlink:label="loc_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_6F29096E529B1F29FED9FD60F5C168EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_6F29096E529B1F29FED9FD60F5C168EF" xlink:to="lab_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_6F29096E529B1F29FED9FD60F5C168EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlansDomain_2D6164896BA60719C29AFD60F5C19D5B_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlansDomain_2D6164896BA60719C29AFD60F5C19D5B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Benefit Plans and Other Postretirement Benefit Plans [Domain]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlansDomain_2D6164896BA60719C29AFD60F5C19D5B_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlansDomain_2D6164896BA60719C29AFD60F5C19D5B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan and Other Postretirement Benefit Plan [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefinedBenefitPlansDomain" xlink:label="loc_us-gaap_DefinedBenefitPlansDomain_2D6164896BA60719C29AFD60F5C19D5B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlansDomain_2D6164896BA60719C29AFD60F5C19D5B" xlink:to="lab_us-gaap_DefinedBenefitPlansDomain_2D6164896BA60719C29AFD60F5C19D5B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignPensionPlansDefinedBenefitMember_F21ADBC6EDDE7D137A5CFD6419EBF273_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignPensionPlansDefinedBenefitMember_F21ADBC6EDDE7D137A5CFD6419EBF273" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Pension Plan</link:label>
    <link:label id="lab_us-gaap_ForeignPensionPlansDefinedBenefitMember_F21ADBC6EDDE7D137A5CFD6419EBF273_label_en-US" xlink:label="lab_us-gaap_ForeignPensionPlansDefinedBenefitMember_F21ADBC6EDDE7D137A5CFD6419EBF273" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Pension Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignPensionPlansDefinedBenefitMember" xlink:label="loc_us-gaap_ForeignPensionPlansDefinedBenefitMember_F21ADBC6EDDE7D137A5CFD6419EBF273" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignPensionPlansDefinedBenefitMember_F21ADBC6EDDE7D137A5CFD6419EBF273" xlink:to="lab_us-gaap_ForeignPensionPlansDefinedBenefitMember_F21ADBC6EDDE7D137A5CFD6419EBF273" xlink:type="arc" />
    <link:label id="lab_country_CH_0EAA89673D11D8FB27C9FD6742C94FEB_terseLabel_en-US" xlink:label="lab_country_CH_0EAA89673D11D8FB27C9FD6742C94FEB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SWITZERLAND</link:label>
    <link:label id="lab_country_CH_0EAA89673D11D8FB27C9FD6742C94FEB_label_en-US" xlink:label="lab_country_CH_0EAA89673D11D8FB27C9FD6742C94FEB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SWITZERLAND</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd#country_CH" xlink:label="loc_country_CH_0EAA89673D11D8FB27C9FD6742C94FEB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CH_0EAA89673D11D8FB27C9FD6742C94FEB" xlink:to="lab_country_CH_0EAA89673D11D8FB27C9FD6742C94FEB" xlink:type="arc" />
    <link:label id="lab_country_DE_BE99447F614882305BD6FD688657C73A_terseLabel_en-US" xlink:label="lab_country_DE_BE99447F614882305BD6FD688657C73A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GERMANY</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd#country_DE" xlink:label="loc_country_DE_BE99447F614882305BD6FD688657C73A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_DE_BE99447F614882305BD6FD688657C73A" xlink:to="lab_country_DE_BE99447F614882305BD6FD688657C73A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_13479C04743014554B3FFD60F5C184FB_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_13479C04743014554B3FFD60F5C184FB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_13479C04743014554B3FFD60F5C184FB_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_13479C04743014554B3FFD60F5C184FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_13479C04743014554B3FFD60F5C184FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_13479C04743014554B3FFD60F5C184FB" xlink:to="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_13479C04743014554B3FFD60F5C184FB" xlink:type="arc" />
    <link:label id="lab_biib_EmployeeBenefitPlansTextualAbstract_7A70FCB58BEB71A72903FD60F5C14026_verboseLabel_en-US" xlink:label="lab_biib_EmployeeBenefitPlansTextualAbstract_7A70FCB58BEB71A72903FD60F5C14026" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Employee Benefit Plans (Textual) [Abstract]</link:label>
    <link:label id="lab_biib_EmployeeBenefitPlansTextualAbstract_7A70FCB58BEB71A72903FD60F5C14026_label_en-US" xlink:label="lab_biib_EmployeeBenefitPlansTextualAbstract_7A70FCB58BEB71A72903FD60F5C14026" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Benefit Plans (Textual) [Abstract]</link:label>
    <link:label id="lab_biib_EmployeeBenefitPlansTextualAbstract_7A70FCB58BEB71A72903FD60F5C14026_documentation_en-US" xlink:label="lab_biib_EmployeeBenefitPlansTextualAbstract_7A70FCB58BEB71A72903FD60F5C14026" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee benefit plans.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_EmployeeBenefitPlansTextualAbstract" xlink:label="loc_biib_EmployeeBenefitPlansTextualAbstract_7A70FCB58BEB71A72903FD60F5C14026" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EmployeeBenefitPlansTextualAbstract_7A70FCB58BEB71A72903FD60F5C14026" xlink:to="lab_biib_EmployeeBenefitPlansTextualAbstract_7A70FCB58BEB71A72903FD60F5C14026" xlink:type="arc" />
    <link:label id="lab_biib_PercentageOfMinimumInvestmentReturn_B803952E3AC6721C66B7FD60F5C168C8_verboseLabel_en-US" xlink:label="lab_biib_PercentageOfMinimumInvestmentReturn_B803952E3AC6721C66B7FD60F5C168C8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Percentage of minimum investment return</link:label>
    <link:label id="lab_biib_PercentageOfMinimumInvestmentReturn_B803952E3AC6721C66B7FD60F5C168C8_label_en-US" xlink:label="lab_biib_PercentageOfMinimumInvestmentReturn_B803952E3AC6721C66B7FD60F5C168C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Minimum Investment Return</link:label>
    <link:label id="lab_biib_PercentageOfMinimumInvestmentReturn_B803952E3AC6721C66B7FD60F5C168C8_documentation_en-US" xlink:label="lab_biib_PercentageOfMinimumInvestmentReturn_B803952E3AC6721C66B7FD60F5C168C8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of minimum investment return.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_PercentageOfMinimumInvestmentReturn" xlink:label="loc_biib_PercentageOfMinimumInvestmentReturn_B803952E3AC6721C66B7FD60F5C168C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageOfMinimumInvestmentReturn_B803952E3AC6721C66B7FD60F5C168C8" xlink:to="lab_biib_PercentageOfMinimumInvestmentReturn_B803952E3AC6721C66B7FD60F5C168C8" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_E9A909DCC0F31FA6C863FD60F5C208A7_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_E9A909DCC0F31FA6C863FD60F5C208A7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Unfunded net pension</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_E9A909DCC0F31FA6C863FD60F5C208A7_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_E9A909DCC0F31FA6C863FD60F5C208A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Funded Status of Plan</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_E9A909DCC0F31FA6C863FD60F5C208A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_E9A909DCC0F31FA6C863FD60F5C208A7" xlink:to="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_E9A909DCC0F31FA6C863FD60F5C208A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_152647AA8B6CA2F0F7D3FD60F5C22261_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation_152647AA8B6CA2F0F7D3FD60F5C22261" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Employee Benefit Plan obligations</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_152647AA8B6CA2F0F7D3FD60F5C22261_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation_152647AA8B6CA2F0F7D3FD60F5C22261" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_152647AA8B6CA2F0F7D3FD60F5C22261" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanBenefitObligation_152647AA8B6CA2F0F7D3FD60F5C22261" xlink:to="lab_us-gaap_DefinedBenefitPlanBenefitObligation_152647AA8B6CA2F0F7D3FD60F5C22261" xlink:type="arc" />
    <link:label id="lab_us-gaap_PensionExpense_2396CA64D497F4D40453FD60F5C25E4F_terseLabel_en-US" xlink:label="lab_us-gaap_PensionExpense_2396CA64D497F4D40453FD60F5C25E4F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Expense</link:label>
    <link:label id="lab_us-gaap_PensionExpense_2396CA64D497F4D40453FD60F5C25E4F_label_en-US" xlink:label="lab_us-gaap_PensionExpense_2396CA64D497F4D40453FD60F5C25E4F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PensionExpense" xlink:label="loc_us-gaap_PensionExpense_2396CA64D497F4D40453FD60F5C25E4F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionExpense_2396CA64D497F4D40453FD60F5C25E4F" xlink:to="lab_us-gaap_PensionExpense_2396CA64D497F4D40453FD60F5C25E4F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_CC3BAFC54E0950244E81FD60F5C23CED_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_CC3BAFC54E0950244E81FD60F5C23CED" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Periodic pension cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_CC3BAFC54E0950244E81FD60F5C23CED_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_CC3BAFC54E0950244E81FD60F5C23CED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_CC3BAFC54E0950244E81FD60F5C23CED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_CC3BAFC54E0950244E81FD60F5C23CED" xlink:to="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_CC3BAFC54E0950244E81FD60F5C23CED" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_7BDEE2B8F885C6CD7AE8D6D80DED445D_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_7BDEE2B8F885C6CD7AE8D6D80DED445D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Components of property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_7BDEE2B8F885C6CD7AE8D6D80DED445D_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_7BDEE2B8F885C6CD7AE8D6D80DED445D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_7BDEE2B8F885C6CD7AE8D6D80DED445D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_7BDEE2B8F885C6CD7AE8D6D80DED445D" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_7BDEE2B8F885C6CD7AE8D6D80DED445D" xlink:type="arc" />
    <link:label id="lab_biib_FutureContingentMilestoneTypesAxis_5FF89936066A288377E5FCCBDB018D9E_terseLabel_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesAxis_5FF89936066A288377E5FCCBDB018D9E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future Contingent Milestone Types [Axis]</link:label>
    <link:label id="lab_biib_FutureContingentMilestoneTypesAxis_5FF89936066A288377E5FCCBDB018D9E_label_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesAxis_5FF89936066A288377E5FCCBDB018D9E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Contingent Milestone Types [Axis]</link:label>
    <link:label id="lab_biib_FutureContingentMilestoneTypesAxis_5FF89936066A288377E5FCCBDB018D9E_documentation_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesAxis_5FF89936066A288377E5FCCBDB018D9E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Future Contingent Milestone Types [Axis]</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_FutureContingentMilestoneTypesAxis" xlink:label="loc_biib_FutureContingentMilestoneTypesAxis_5FF89936066A288377E5FCCBDB018D9E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_5FF89936066A288377E5FCCBDB018D9E" xlink:to="lab_biib_FutureContingentMilestoneTypesAxis_5FF89936066A288377E5FCCBDB018D9E" xlink:type="arc" />
    <link:label id="lab_biib_FutureContingentMilestoneTypesDomain_A2F87FF556DD670E99E8FCCBDB01692E_terseLabel_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesDomain_A2F87FF556DD670E99E8FCCBDB01692E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future Contingent Milestone Types [Domain]</link:label>
    <link:label id="lab_biib_FutureContingentMilestoneTypesDomain_A2F87FF556DD670E99E8FCCBDB01692E_label_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesDomain_A2F87FF556DD670E99E8FCCBDB01692E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Contingent Milestone Types [Domain]</link:label>
    <link:label id="lab_biib_FutureContingentMilestoneTypesDomain_A2F87FF556DD670E99E8FCCBDB01692E_documentation_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesDomain_A2F87FF556DD670E99E8FCCBDB01692E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Future Contingent Milestone Types [Axis]</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_FutureContingentMilestoneTypesDomain" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_A2F87FF556DD670E99E8FCCBDB01692E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_A2F87FF556DD670E99E8FCCBDB01692E" xlink:to="lab_biib_FutureContingentMilestoneTypesDomain_A2F87FF556DD670E99E8FCCBDB01692E" xlink:type="arc" />
    <link:label id="lab_biib_DevelopmentMilestonesMember_3965AD6BCF8A16F3727AFCCBDB01E682_terseLabel_en-US" xlink:label="lab_biib_DevelopmentMilestonesMember_3965AD6BCF8A16F3727AFCCBDB01E682" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Development Milestones [Member]</link:label>
    <link:label id="lab_biib_DevelopmentMilestonesMember_3965AD6BCF8A16F3727AFCCBDB01E682_label_en-US" xlink:label="lab_biib_DevelopmentMilestonesMember_3965AD6BCF8A16F3727AFCCBDB01E682" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Development Milestones [Member]</link:label>
    <link:label id="lab_biib_DevelopmentMilestonesMember_3965AD6BCF8A16F3727AFCCBDB01E682_documentation_en-US" xlink:label="lab_biib_DevelopmentMilestonesMember_3965AD6BCF8A16F3727AFCCBDB01E682" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Development Milestones [Member]</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_DevelopmentMilestonesMember" xlink:label="loc_biib_DevelopmentMilestonesMember_3965AD6BCF8A16F3727AFCCBDB01E682" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DevelopmentMilestonesMember_3965AD6BCF8A16F3727AFCCBDB01E682" xlink:to="lab_biib_DevelopmentMilestonesMember_3965AD6BCF8A16F3727AFCCBDB01E682" xlink:type="arc" />
    <link:label id="lab_biib_RegulatoryMilestonesMember_0CD9D5E266FDC9D4C84DFCCBDB02C17C_terseLabel_en-US" xlink:label="lab_biib_RegulatoryMilestonesMember_0CD9D5E266FDC9D4C84DFCCBDB02C17C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Regulatory Milestones [Member]</link:label>
    <link:label id="lab_biib_RegulatoryMilestonesMember_0CD9D5E266FDC9D4C84DFCCBDB02C17C_label_en-US" xlink:label="lab_biib_RegulatoryMilestonesMember_0CD9D5E266FDC9D4C84DFCCBDB02C17C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Regulatory Milestones [Member]</link:label>
    <link:label id="lab_biib_RegulatoryMilestonesMember_0CD9D5E266FDC9D4C84DFCCBDB02C17C_documentation_en-US" xlink:label="lab_biib_RegulatoryMilestonesMember_0CD9D5E266FDC9D4C84DFCCBDB02C17C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Regulatory Milestones [Member]</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_RegulatoryMilestonesMember" xlink:label="loc_biib_RegulatoryMilestonesMember_0CD9D5E266FDC9D4C84DFCCBDB02C17C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RegulatoryMilestonesMember_0CD9D5E266FDC9D4C84DFCCBDB02C17C" xlink:to="lab_biib_RegulatoryMilestonesMember_0CD9D5E266FDC9D4C84DFCCBDB02C17C" xlink:type="arc" />
    <link:label id="lab_biib_CommercialMilestonesMember_4AB828CEF55151D5B1B0FCCBDB02206E_terseLabel_en-US" xlink:label="lab_biib_CommercialMilestonesMember_4AB828CEF55151D5B1B0FCCBDB02206E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial Milestones [Member]</link:label>
    <link:label id="lab_biib_CommercialMilestonesMember_4AB828CEF55151D5B1B0FCCBDB02206E_label_en-US" xlink:label="lab_biib_CommercialMilestonesMember_4AB828CEF55151D5B1B0FCCBDB02206E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Milestones [Member]</link:label>
    <link:label id="lab_biib_CommercialMilestonesMember_4AB828CEF55151D5B1B0FCCBDB02206E_documentation_en-US" xlink:label="lab_biib_CommercialMilestonesMember_4AB828CEF55151D5B1B0FCCBDB02206E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commercial Milestones [Member]</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_CommercialMilestonesMember" xlink:label="loc_biib_CommercialMilestonesMember_4AB828CEF55151D5B1B0FCCBDB02206E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CommercialMilestonesMember_4AB828CEF55151D5B1B0FCCBDB02206E" xlink:to="lab_biib_CommercialMilestonesMember_4AB828CEF55151D5B1B0FCCBDB02206E" xlink:type="arc" />
    <link:label id="lab_us-gaap_EuropeanUnionMember_64E9420A8F4E79A2B0DCFCCBDB01937C_terseLabel_en-US" xlink:label="lab_us-gaap_EuropeanUnionMember_64E9420A8F4E79A2B0DCFCCBDB01937C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">European Union</link:label>
    <link:label id="lab_us-gaap_EuropeanUnionMember_64E9420A8F4E79A2B0DCFCCBDB01937C_label_en-US" xlink:label="lab_us-gaap_EuropeanUnionMember_64E9420A8F4E79A2B0DCFCCBDB01937C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">European Union [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EuropeanUnionMember" xlink:label="loc_us-gaap_EuropeanUnionMember_64E9420A8F4E79A2B0DCFCCBDB01937C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EuropeanUnionMember_64E9420A8F4E79A2B0DCFCCBDB01937C" xlink:to="lab_us-gaap_EuropeanUnionMember_64E9420A8F4E79A2B0DCFCCBDB01937C" xlink:type="arc" />
    <link:label id="lab_biib_TenbillionMember_BD5C684B53F08C1DCA5FFCCBDB0292D2_terseLabel_en-US" xlink:label="lab_biib_TenbillionMember_BD5C684B53F08C1DCA5FFCCBDB0292D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ten billion</link:label>
    <link:label id="lab_biib_TenbillionMember_BD5C684B53F08C1DCA5FFCCBDB0292D2_label_en-US" xlink:label="lab_biib_TenbillionMember_BD5C684B53F08C1DCA5FFCCBDB0292D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ten billion [Member]</link:label>
    <link:label id="lab_biib_TenbillionMember_BD5C684B53F08C1DCA5FFCCBDB0292D2_documentation_en-US" xlink:label="lab_biib_TenbillionMember_BD5C684B53F08C1DCA5FFCCBDB0292D2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ten billion [Member]</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_TenbillionMember" xlink:label="loc_biib_TenbillionMember_BD5C684B53F08C1DCA5FFCCBDB0292D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TenbillionMember_BD5C684B53F08C1DCA5FFCCBDB0292D2" xlink:to="lab_biib_TenbillionMember_BD5C684B53F08C1DCA5FFCCBDB0292D2" xlink:type="arc" />
    <link:label id="lab_biib_SevenbillionMember_1EDACFACECFDEB6DD4C3FCCBDB02A590_terseLabel_en-US" xlink:label="lab_biib_SevenbillionMember_1EDACFACECFDEB6DD4C3FCCBDB02A590" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Seven billion</link:label>
    <link:label id="lab_biib_SevenbillionMember_1EDACFACECFDEB6DD4C3FCCBDB02A590_label_en-US" xlink:label="lab_biib_SevenbillionMember_1EDACFACECFDEB6DD4C3FCCBDB02A590" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Seven billion [Member]</link:label>
    <link:label id="lab_biib_SevenbillionMember_1EDACFACECFDEB6DD4C3FCCBDB02A590_documentation_en-US" xlink:label="lab_biib_SevenbillionMember_1EDACFACECFDEB6DD4C3FCCBDB02A590" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Seven billion [Member]</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_SevenbillionMember" xlink:label="loc_biib_SevenbillionMember_1EDACFACECFDEB6DD4C3FCCBDB02A590" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SevenbillionMember_1EDACFACECFDEB6DD4C3FCCBDB02A590" xlink:to="lab_biib_SevenbillionMember_1EDACFACECFDEB6DD4C3FCCBDB02A590" xlink:type="arc" />
    <link:label id="lab_biib_EightbillionMember_3416099A6FDB6C4073C5FCCBDB023F08_terseLabel_en-US" xlink:label="lab_biib_EightbillionMember_3416099A6FDB6C4073C5FCCBDB023F08" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Eight billion</link:label>
    <link:label id="lab_biib_EightbillionMember_3416099A6FDB6C4073C5FCCBDB023F08_label_en-US" xlink:label="lab_biib_EightbillionMember_3416099A6FDB6C4073C5FCCBDB023F08" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Eight billion [Member]</link:label>
    <link:label id="lab_biib_EightbillionMember_3416099A6FDB6C4073C5FCCBDB023F08_documentation_en-US" xlink:label="lab_biib_EightbillionMember_3416099A6FDB6C4073C5FCCBDB023F08" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Eight billion</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_EightbillionMember" xlink:label="loc_biib_EightbillionMember_3416099A6FDB6C4073C5FCCBDB023F08" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EightbillionMember_3416099A6FDB6C4073C5FCCBDB023F08" xlink:to="lab_biib_EightbillionMember_3416099A6FDB6C4073C5FCCBDB023F08" xlink:type="arc" />
    <link:label id="lab_biib_NinebillionMember_2245531DE5BAEF26359CFCCBDB021AD4_terseLabel_en-US" xlink:label="lab_biib_NinebillionMember_2245531DE5BAEF26359CFCCBDB021AD4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nine billion</link:label>
    <link:label id="lab_biib_NinebillionMember_2245531DE5BAEF26359CFCCBDB021AD4_label_en-US" xlink:label="lab_biib_NinebillionMember_2245531DE5BAEF26359CFCCBDB021AD4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nine billion [Member]</link:label>
    <link:label id="lab_biib_NinebillionMember_2245531DE5BAEF26359CFCCBDB021AD4_documentation_en-US" xlink:label="lab_biib_NinebillionMember_2245531DE5BAEF26359CFCCBDB021AD4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Nine billion [Member]</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_NinebillionMember" xlink:label="loc_biib_NinebillionMember_2245531DE5BAEF26359CFCCBDB021AD4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NinebillionMember_2245531DE5BAEF26359CFCCBDB021AD4" xlink:to="lab_biib_NinebillionMember_2245531DE5BAEF26359CFCCBDB021AD4" xlink:type="arc" />
    <link:label id="lab_biib_OneBillionMember_A676BD77F5A6F4BD2F7AFCCBDB02B434_terseLabel_en-US" xlink:label="lab_biib_OneBillionMember_A676BD77F5A6F4BD2F7AFCCBDB02B434" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">One billion</link:label>
    <link:label id="lab_biib_OneBillionMember_A676BD77F5A6F4BD2F7AFCCBDB02B434_label_en-US" xlink:label="lab_biib_OneBillionMember_A676BD77F5A6F4BD2F7AFCCBDB02B434" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">One billion [Member]</link:label>
    <link:label id="lab_biib_OneBillionMember_A676BD77F5A6F4BD2F7AFCCBDB02B434_documentation_en-US" xlink:label="lab_biib_OneBillionMember_A676BD77F5A6F4BD2F7AFCCBDB02B434" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">One billion [Member]</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_OneBillionMember" xlink:label="loc_biib_OneBillionMember_A676BD77F5A6F4BD2F7AFCCBDB02B434" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OneBillionMember_A676BD77F5A6F4BD2F7AFCCBDB02B434" xlink:to="lab_biib_OneBillionMember_A676BD77F5A6F4BD2F7AFCCBDB02B434" xlink:type="arc" />
    <link:label id="lab_biib_EachAdditionalOneBillionUpToTwentyBillionMember_5C1CD92EB5BE3D83BC1DFCCBDB0214CC_terseLabel_en-US" xlink:label="lab_biib_EachAdditionalOneBillionUpToTwentyBillionMember_5C1CD92EB5BE3D83BC1DFCCBDB0214CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Each additional one billion up to twenty billion</link:label>
    <link:label id="lab_biib_EachAdditionalOneBillionUpToTwentyBillionMember_5C1CD92EB5BE3D83BC1DFCCBDB0214CC_label_en-US" xlink:label="lab_biib_EachAdditionalOneBillionUpToTwentyBillionMember_5C1CD92EB5BE3D83BC1DFCCBDB0214CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Each additional one billion up to twenty billion [Member]</link:label>
    <link:label id="lab_biib_EachAdditionalOneBillionUpToTwentyBillionMember_5C1CD92EB5BE3D83BC1DFCCBDB0214CC_documentation_en-US" xlink:label="lab_biib_EachAdditionalOneBillionUpToTwentyBillionMember_5C1CD92EB5BE3D83BC1DFCCBDB0214CC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Each additional one billion up to twenty billion [Member]</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_EachAdditionalOneBillionUpToTwentyBillionMember" xlink:label="loc_biib_EachAdditionalOneBillionUpToTwentyBillionMember_5C1CD92EB5BE3D83BC1DFCCBDB0214CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EachAdditionalOneBillionUpToTwentyBillionMember_5C1CD92EB5BE3D83BC1DFCCBDB0214CC" xlink:to="lab_biib_EachAdditionalOneBillionUpToTwentyBillionMember_5C1CD92EB5BE3D83BC1DFCCBDB0214CC" xlink:type="arc" />
    <link:label id="lab_biib_ThreeBillionMember_3D0B8D041A6DBAD55E41FCCBDB026885_terseLabel_en-US" xlink:label="lab_biib_ThreeBillionMember_3D0B8D041A6DBAD55E41FCCBDB026885" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Three billion</link:label>
    <link:label id="lab_biib_ThreeBillionMember_3D0B8D041A6DBAD55E41FCCBDB026885_label_en-US" xlink:label="lab_biib_ThreeBillionMember_3D0B8D041A6DBAD55E41FCCBDB026885" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Three billion [Member]</link:label>
    <link:label id="lab_biib_ThreeBillionMember_3D0B8D041A6DBAD55E41FCCBDB026885_documentation_en-US" xlink:label="lab_biib_ThreeBillionMember_3D0B8D041A6DBAD55E41FCCBDB026885" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Three billion [Member]</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_ThreeBillionMember" xlink:label="loc_biib_ThreeBillionMember_3D0B8D041A6DBAD55E41FCCBDB026885" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ThreeBillionMember_3D0B8D041A6DBAD55E41FCCBDB026885" xlink:to="lab_biib_ThreeBillionMember_3D0B8D041A6DBAD55E41FCCBDB026885" xlink:type="arc" />
    <link:label id="lab_us-gaap_LitigationSettlementAmount_C6F13F5B8BED3F4AB517FCCBDB032AA2_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmount_C6F13F5B8BED3F4AB517FCCBDB032AA2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation settlement and license agreement amount</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementAmount_C6F13F5B8BED3F4AB517FCCBDB032AA2_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmount_C6F13F5B8BED3F4AB517FCCBDB032AA2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Settlement, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationSettlementAmount" xlink:label="loc_us-gaap_LitigationSettlementAmount_C6F13F5B8BED3F4AB517FCCBDB032AA2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementAmount_C6F13F5B8BED3F4AB517FCCBDB032AA2" xlink:to="lab_us-gaap_LitigationSettlementAmount_C6F13F5B8BED3F4AB517FCCBDB032AA2" xlink:type="arc" />
    <link:label id="lab_biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion_3D9C63E8B139FBE74DD0FCCBDB04F3CD_terseLabel_en-US" xlink:label="lab_biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion_3D9C63E8B139FBE74DD0FCCBDB04F3CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future contingent payment for annual worldwide net sales up to $2.0 billion</link:label>
    <link:label id="lab_biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion_3D9C63E8B139FBE74DD0FCCBDB04F3CD_label_en-US" xlink:label="lab_biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion_3D9C63E8B139FBE74DD0FCCBDB04F3CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future contingent payment for annual worldwide net sales up to $2.0 billion</link:label>
    <link:label id="lab_biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion_3D9C63E8B139FBE74DD0FCCBDB04F3CD_documentation_en-US" xlink:label="lab_biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion_3D9C63E8B139FBE74DD0FCCBDB04F3CD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Future contingent payment for annual worldwide net sales up to $2.0 billion</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion" xlink:label="loc_biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion_3D9C63E8B139FBE74DD0FCCBDB04F3CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion_3D9C63E8B139FBE74DD0FCCBDB04F3CD" xlink:to="lab_biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion_3D9C63E8B139FBE74DD0FCCBDB04F3CD" xlink:type="arc" />
    <link:label id="lab_biib_FutureContingentPaymentThreshold_76B614BA5AC785A41EF2FCCBDB045DFF_terseLabel_en-US" xlink:label="lab_biib_FutureContingentPaymentThreshold_76B614BA5AC785A41EF2FCCBDB045DFF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future contingent payment threshold</link:label>
    <link:label id="lab_biib_FutureContingentPaymentThreshold_76B614BA5AC785A41EF2FCCBDB045DFF_label_en-US" xlink:label="lab_biib_FutureContingentPaymentThreshold_76B614BA5AC785A41EF2FCCBDB045DFF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future contingent payment threshold</link:label>
    <link:label id="lab_biib_FutureContingentPaymentThreshold_76B614BA5AC785A41EF2FCCBDB045DFF_documentation_en-US" xlink:label="lab_biib_FutureContingentPaymentThreshold_76B614BA5AC785A41EF2FCCBDB045DFF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Future contingent payment threshold</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_FutureContingentPaymentThreshold" xlink:label="loc_biib_FutureContingentPaymentThreshold_76B614BA5AC785A41EF2FCCBDB045DFF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FutureContingentPaymentThreshold_76B614BA5AC785A41EF2FCCBDB045DFF" xlink:to="lab_biib_FutureContingentPaymentThreshold_76B614BA5AC785A41EF2FCCBDB045DFF" xlink:type="arc" />
    <link:label id="lab_biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion_32A2609B9027D57287A3FCCBDB04C1D0_terseLabel_en-US" xlink:label="lab_biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion_32A2609B9027D57287A3FCCBDB04C1D0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future contingent payment for annual worldwide net sales that exceed $2.0 billion</link:label>
    <link:label id="lab_biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion_32A2609B9027D57287A3FCCBDB04C1D0_label_en-US" xlink:label="lab_biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion_32A2609B9027D57287A3FCCBDB04C1D0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future contingent payment for annual worldwide net sales that exceed $2.0 billion</link:label>
    <link:label id="lab_biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion_32A2609B9027D57287A3FCCBDB04C1D0_documentation_en-US" xlink:label="lab_biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion_32A2609B9027D57287A3FCCBDB04C1D0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Future contingent payment for annual worldwide net sales that exceed $2.0 billion</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion" xlink:label="loc_biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion_32A2609B9027D57287A3FCCBDB04C1D0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion_32A2609B9027D57287A3FCCBDB04C1D0" xlink:to="lab_biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion_32A2609B9027D57287A3FCCBDB04C1D0" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_DF774469DE10512A6CB4FCCBDB044207_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross_DF774469DE10512A6CB4FCCBDB044207" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount paid in cash</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_DF774469DE10512A6CB4FCCBDB044207" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross_DF774469DE10512A6CB4FCCBDB044207" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross_DF774469DE10512A6CB4FCCBDB044207" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherCommitment_0BF58AEF4406DD44967FFCCBDB048D3A_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitment_0BF58AEF4406DD44967FFCCBDB048D3A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cancellable future commitments</link:label>
    <link:label id="lab_us-gaap_OtherCommitment_0BF58AEF4406DD44967FFCCBDB048D3A_label_en-US" xlink:label="lab_us-gaap_OtherCommitment_0BF58AEF4406DD44967FFCCBDB048D3A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCommitment" xlink:label="loc_us-gaap_OtherCommitment_0BF58AEF4406DD44967FFCCBDB048D3A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitment_0BF58AEF4406DD44967FFCCBDB048D3A" xlink:to="lab_us-gaap_OtherCommitment_0BF58AEF4406DD44967FFCCBDB048D3A" xlink:type="arc" />
    <link:label id="lab_biib_CommitmentsAndContingenciesTextualAbstract_68F891822C35C2DD0BBDFCCBDB04F524_terseLabel_en-US" xlink:label="lab_biib_CommitmentsAndContingenciesTextualAbstract_68F891822C35C2DD0BBDFCCBDB04F524" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments And Contingencies (Textual)</link:label>
    <link:label id="lab_biib_CommitmentsAndContingenciesTextualAbstract_68F891822C35C2DD0BBDFCCBDB04F524_label_en-US" xlink:label="lab_biib_CommitmentsAndContingenciesTextualAbstract_68F891822C35C2DD0BBDFCCBDB04F524" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments And Contingencies (Textual) [Abstract]</link:label>
    <link:label id="lab_biib_CommitmentsAndContingenciesTextualAbstract_68F891822C35C2DD0BBDFCCBDB04F524_documentation_en-US" xlink:label="lab_biib_CommitmentsAndContingenciesTextualAbstract_68F891822C35C2DD0BBDFCCBDB04F524" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commitments And Contingencies.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_CommitmentsAndContingenciesTextualAbstract" xlink:label="loc_biib_CommitmentsAndContingenciesTextualAbstract_68F891822C35C2DD0BBDFCCBDB04F524" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CommitmentsAndContingenciesTextualAbstract_68F891822C35C2DD0BBDFCCBDB04F524" xlink:to="lab_biib_CommitmentsAndContingenciesTextualAbstract_68F891822C35C2DD0BBDFCCBDB04F524" xlink:type="arc" />
    <link:label id="lab_biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch_BDFC4391A41944D39003FCCBDB04EC7F_verboseLabel_en-US" xlink:label="lab_biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch_BDFC4391A41944D39003FCCBDB04EC7F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch_BDFC4391A41944D39003FCCBDB04EC7F_label_en-US" xlink:label="lab_biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch_BDFC4391A41944D39003FCCBDB04EC7F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Expenses On Funding Commitment Related To Clinical Research</link:label>
    <link:label id="lab_biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch_BDFC4391A41944D39003FCCBDB04EC7F_documentation_en-US" xlink:label="lab_biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch_BDFC4391A41944D39003FCCBDB04EC7F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued expenses on funding commitment related to clinical research.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch" xlink:label="loc_biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch_BDFC4391A41944D39003FCCBDB04EC7F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch_BDFC4391A41944D39003FCCBDB04EC7F" xlink:to="lab_biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch_BDFC4391A41944D39003FCCBDB04EC7F" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilityForUncertainTaxPositionsCurrent_ED4C2A5AB443DAA8C891FCCBDB0458AF_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUncertainTaxPositionsCurrent_ED4C2A5AB443DAA8C891FCCBDB0458AF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Liabilities associated with uncertain tax positions</link:label>
    <link:label id="lab_us-gaap_LiabilityForUncertainTaxPositionsCurrent_ED4C2A5AB443DAA8C891FCCBDB0458AF_label_en-US" xlink:label="lab_us-gaap_LiabilityForUncertainTaxPositionsCurrent_ED4C2A5AB443DAA8C891FCCBDB0458AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability for Uncertainty in Income Taxes, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:label="loc_us-gaap_LiabilityForUncertainTaxPositionsCurrent_ED4C2A5AB443DAA8C891FCCBDB0458AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUncertainTaxPositionsCurrent_ED4C2A5AB443DAA8C891FCCBDB0458AF" xlink:to="lab_us-gaap_LiabilityForUncertainTaxPositionsCurrent_ED4C2A5AB443DAA8C891FCCBDB0458AF" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseAndRentalExpense_206A249A9ABCFD3D352DFCCBDB049EEC_verboseLabel_en-US" xlink:label="lab_us-gaap_LeaseAndRentalExpense_206A249A9ABCFD3D352DFCCBDB049EEC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Lease rent expense which terminates at various dates through 2028</link:label>
    <link:label id="lab_us-gaap_LeaseAndRentalExpense_206A249A9ABCFD3D352DFCCBDB049EEC_label_en-US" xlink:label="lab_us-gaap_LeaseAndRentalExpense_206A249A9ABCFD3D352DFCCBDB049EEC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Rent Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaap_LeaseAndRentalExpense_206A249A9ABCFD3D352DFCCBDB049EEC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseAndRentalExpense_206A249A9ABCFD3D352DFCCBDB049EEC" xlink:to="lab_us-gaap_LeaseAndRentalExpense_206A249A9ABCFD3D352DFCCBDB049EEC" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_7FC3DA7A2E04CF9278727412863B6686_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_7FC3DA7A2E04CF9278727412863B6686" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Indebtedness</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_7FC3DA7A2E04CF9278727412863B6686_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_7FC3DA7A2E04CF9278727412863B6686" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_7FC3DA7A2E04CF9278727412863B6686" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock_7FC3DA7A2E04CF9278727412863B6686" xlink:to="lab_us-gaap_DebtDisclosureTextBlock_7FC3DA7A2E04CF9278727412863B6686" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_57B95B6C9BB26B78810E741289472C8E_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_57B95B6C9BB26B78810E741289472C8E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_57B95B6C9BB26B78810E741289472C8E_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_57B95B6C9BB26B78810E741289472C8E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_57B95B6C9BB26B78810E741289472C8E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_57B95B6C9BB26B78810E741289472C8E" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_57B95B6C9BB26B78810E741289472C8E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_9410AB11770103BE3DBB741285C8A311_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_9410AB11770103BE3DBB741285C8A311" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_9410AB11770103BE3DBB741285C8A311_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_9410AB11770103BE3DBB741285C8A311" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_9410AB11770103BE3DBB741285C8A311" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_9410AB11770103BE3DBB741285C8A311" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_9410AB11770103BE3DBB741285C8A311" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_5600D24BBB4CCD7FAFF4741287224D53_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_5600D24BBB4CCD7FAFF4741287224D53" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_5600D24BBB4CCD7FAFF4741287224D53_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_5600D24BBB4CCD7FAFF4741287224D53" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_5600D24BBB4CCD7FAFF4741287224D53" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_5600D24BBB4CCD7FAFF4741287224D53" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_5600D24BBB4CCD7FAFF4741287224D53" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_1BCFD0CBEBC2A5F68282741285FAE103_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_1BCFD0CBEBC2A5F68282741285FAE103" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_1BCFD0CBEBC2A5F68282741285FAE103_label_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_1BCFD0CBEBC2A5F68282741285FAE103" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_1BCFD0CBEBC2A5F68282741285FAE103" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_1BCFD0CBEBC2A5F68282741285FAE103" xlink:to="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_1BCFD0CBEBC2A5F68282741285FAE103" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_8F64AE470796D326ED11741285FAE98B_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_8F64AE470796D326ED11741285FAE98B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_8F64AE470796D326ED11741285FAE98B_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_8F64AE470796D326ED11741285FAE98B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_8F64AE470796D326ED11741285FAE98B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_8F64AE470796D326ED11741285FAE98B" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_8F64AE470796D326ED11741285FAE98B" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesIssued_BC08D84117549A61703B741285FAAE9C_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_BC08D84117549A61703B741285FAAE9C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_BC08D84117549A61703B741285FAAE9C_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_BC08D84117549A61703B741285FAAE9C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_BC08D84117549A61703B741285FAAE9C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_BC08D84117549A61703B741285FAAE9C" xlink:to="lab_us-gaap_CommonStockSharesIssued_BC08D84117549A61703B741285FAAE9C" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_C8D6D2906F3358D6496B741285FA91BF_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_C8D6D2906F3358D6496B741285FA91BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_C8D6D2906F3358D6496B741285FA91BF_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_C8D6D2906F3358D6496B741285FA91BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_C8D6D2906F3358D6496B741285FA91BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_C8D6D2906F3358D6496B741285FA91BF" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_C8D6D2906F3358D6496B741285FA91BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_5D086E97061320707C8C7412892AD231_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock_5D086E97061320707C8C7412892AD231" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_5D086E97061320707C8C7412892AD231_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock_5D086E97061320707C8C7412892AD231" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_5D086E97061320707C8C7412892AD231" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock_5D086E97061320707C8C7412892AD231" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock_5D086E97061320707C8C7412892AD231" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_116D803BA6268CD3C88F741286B2E6A6_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_116D803BA6268CD3C88F741286B2E6A6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_116D803BA6268CD3C88F741286B2E6A6_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_116D803BA6268CD3C88F741286B2E6A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_116D803BA6268CD3C88F741286B2E6A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_116D803BA6268CD3C88F741286B2E6A6" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_116D803BA6268CD3C88F741286B2E6A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract_A147A3BED54DF704CA43F15B085360CE_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract_A147A3BED54DF704CA43F15B085360CE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of the beginning and ending of unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract_A147A3BED54DF704CA43F15B085360CE_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract_A147A3BED54DF704CA43F15B085360CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract_A147A3BED54DF704CA43F15B085360CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract_A147A3BED54DF704CA43F15B085360CE" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract_A147A3BED54DF704CA43F15B085360CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_4767749A06685A276054F15B0853742A_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_4767749A06685A276054F15B0853742A" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at January 1</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_4767749A06685A276054F15B0853742A_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_4767749A06685A276054F15B0853742A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_4767749A06685A276054F15B0853742A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits_4767749A06685A276054F15B0853742A" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits_4767749A06685A276054F15B0853742A" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_3C391CFCC6B5A43B423EF15B0853E013_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_3C391CFCC6B5A43B423EF15B0853E013" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions based on tax positions related to the current period</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_3C391CFCC6B5A43B423EF15B0853E013_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_3C391CFCC6B5A43B423EF15B0853E013" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_3C391CFCC6B5A43B423EF15B0853E013" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_3C391CFCC6B5A43B423EF15B0853E013" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_3C391CFCC6B5A43B423EF15B0853E013" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_E0963A3C083530F8A83AF15B08538927_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_E0963A3C083530F8A83AF15B08538927" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions for tax positions of prior periods</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_E0963A3C083530F8A83AF15B08538927_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_E0963A3C083530F8A83AF15B08538927" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_E0963A3C083530F8A83AF15B08538927" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_E0963A3C083530F8A83AF15B08538927" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_E0963A3C083530F8A83AF15B08538927" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_B0617FE81610C5FFD16AF15B0853EA32_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_B0617FE81610C5FFD16AF15B0853EA32" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Reductions for tax positions of prior periods</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_B0617FE81610C5FFD16AF15B0853EA32_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_B0617FE81610C5FFD16AF15B0853EA32" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_B0617FE81610C5FFD16AF15B0853EA32" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_B0617FE81610C5FFD16AF15B0853EA32" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_B0617FE81610C5FFD16AF15B0853EA32" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_C6E6A72E332904A0B1E5F15B08537CE5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_C6E6A72E332904A0B1E5F15B08537CE5" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Statute expirations</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_C6E6A72E332904A0B1E5F15B08537CE5_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_C6E6A72E332904A0B1E5F15B08537CE5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_C6E6A72E332904A0B1E5F15B08537CE5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_C6E6A72E332904A0B1E5F15B08537CE5" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_C6E6A72E332904A0B1E5F15B08537CE5" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_F91CD49D9C388E76FAD3F15B0853A3C3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_F91CD49D9C388E76FAD3F15B0853A3C3" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Settlements</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_F91CD49D9C388E76FAD3F15B0853A3C3_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_F91CD49D9C388E76FAD3F15B0853A3C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_F91CD49D9C388E76FAD3F15B0853A3C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_F91CD49D9C388E76FAD3F15B0853A3C3" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_F91CD49D9C388E76FAD3F15B0853A3C3" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_3930ABAD8EED3AD61816F15B0853B35A_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_3930ABAD8EED3AD61816F15B0853B35A" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at December 31</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_3930ABAD8EED3AD61816F15B0853B35A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits_3930ABAD8EED3AD61816F15B0853B35A" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits_3930ABAD8EED3AD61816F15B0853B35A" xlink:type="arc" />
    <link:label id="lab_biib_FinancialInstrumentsTextualAbstract_84051641C72F24ACD2A6F4AB0037FA0C_terseLabel_en-US" xlink:label="lab_biib_FinancialInstrumentsTextualAbstract_84051641C72F24ACD2A6F4AB0037FA0C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments (Textual)</link:label>
    <link:label id="lab_biib_FinancialInstrumentsTextualAbstract_84051641C72F24ACD2A6F4AB0037FA0C_label_en-US" xlink:label="lab_biib_FinancialInstrumentsTextualAbstract_84051641C72F24ACD2A6F4AB0037FA0C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments (Textual) [Abstract]</link:label>
    <link:label id="lab_biib_FinancialInstrumentsTextualAbstract_84051641C72F24ACD2A6F4AB0037FA0C_documentation_en-US" xlink:label="lab_biib_FinancialInstrumentsTextualAbstract_84051641C72F24ACD2A6F4AB0037FA0C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Financial Instruments.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_FinancialInstrumentsTextualAbstract" xlink:label="loc_biib_FinancialInstrumentsTextualAbstract_84051641C72F24ACD2A6F4AB0037FA0C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FinancialInstrumentsTextualAbstract_84051641C72F24ACD2A6F4AB0037FA0C" xlink:to="lab_biib_FinancialInstrumentsTextualAbstract_84051641C72F24ACD2A6F4AB0037FA0C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentMaturityDateDescription_F7D6028B7E3F34C65CB7F4AB0037C598_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentMaturityDateDescription_F7D6028B7E3F34C65CB7F4AB0037C598" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Original maturities of commercial paper and short-term debt securities</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentMaturityDateDescription_F7D6028B7E3F34C65CB7F4AB0037C598_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentMaturityDateDescription_F7D6028B7E3F34C65CB7F4AB0037C598" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Maturity Date, Description</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentMaturityDateDescription" xlink:label="loc_us-gaap_DebtInstrumentMaturityDateDescription_F7D6028B7E3F34C65CB7F4AB0037C598" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentMaturityDateDescription_F7D6028B7E3F34C65CB7F4AB0037C598" xlink:to="lab_us-gaap_DebtInstrumentMaturityDateDescription_F7D6028B7E3F34C65CB7F4AB0037C598" xlink:type="arc" />
    <link:label id="lab_biib_Overnightreverserepurchaseagreementspercentoftotalassets_FD80643A04A2853980A3F4AB0038ACBC_terseLabel_en-US" xlink:label="lab_biib_Overnightreverserepurchaseagreementspercentoftotalassets_FD80643A04A2853980A3F4AB0038ACBC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Overnight reverse repurchase agreements, percent of total assets</link:label>
    <link:label id="lab_biib_Overnightreverserepurchaseagreementspercentoftotalassets_FD80643A04A2853980A3F4AB0038ACBC_label_en-US" xlink:label="lab_biib_Overnightreverserepurchaseagreementspercentoftotalassets_FD80643A04A2853980A3F4AB0038ACBC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Overnight reverse repurchase agreements, percent of total assets</link:label>
    <link:label id="lab_biib_Overnightreverserepurchaseagreementspercentoftotalassets_FD80643A04A2853980A3F4AB0038ACBC_documentation_en-US" xlink:label="lab_biib_Overnightreverserepurchaseagreementspercentoftotalassets_FD80643A04A2853980A3F4AB0038ACBC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Overnight reverse repurchase agreements, percent of total assets</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_Overnightreverserepurchaseagreementspercentoftotalassets" xlink:label="loc_biib_Overnightreverserepurchaseagreementspercentoftotalassets_FD80643A04A2853980A3F4AB0038ACBC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Overnightreverserepurchaseagreementspercentoftotalassets_FD80643A04A2853980A3F4AB0038ACBC" xlink:to="lab_biib_Overnightreverserepurchaseagreementspercentoftotalassets_FD80643A04A2853980A3F4AB0038ACBC" xlink:type="arc" />
    <link:label id="lab_biib_AverageMaturityOfMarketableSecurities_B3753617F7991C0BDF7AF4AB0038D869_verboseLabel_en-US" xlink:label="lab_biib_AverageMaturityOfMarketableSecurities_B3753617F7991C0BDF7AF4AB0038D869" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Average maturity of marketable securities, months</link:label>
    <link:label id="lab_biib_AverageMaturityOfMarketableSecurities_B3753617F7991C0BDF7AF4AB0038D869_label_en-US" xlink:label="lab_biib_AverageMaturityOfMarketableSecurities_B3753617F7991C0BDF7AF4AB0038D869" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Average Maturity Of Marketable Securities</link:label>
    <link:label id="lab_biib_AverageMaturityOfMarketableSecurities_B3753617F7991C0BDF7AF4AB0038D869_documentation_en-US" xlink:label="lab_biib_AverageMaturityOfMarketableSecurities_B3753617F7991C0BDF7AF4AB0038D869" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Average remaining time to maturity of marketable debt securities, available-for-sale securities.</link:label>
    <link:loc xlink:href="biib-20161231.xsd#biib_AverageMaturityOfMarketableSecurities" xlink:label="loc_biib_AverageMaturityOfMarketableSecurities_B3753617F7991C0BDF7AF4AB0038D869" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AverageMaturityOfMarketableSecurities_B3753617F7991C0BDF7AF4AB0038D869" xlink:to="lab_biib_AverageMaturityOfMarketableSecurities_B3753617F7991C0BDF7AF4AB0038D869" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>biib-20161231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLoss" xlink:href="biib-20161231.xsd#AccumulatedOtherComprehensiveIncomeLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:href="biib-20161231.xsd#AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails1" xlink:href="biib-20161231.xsd#AccumulatedOtherComprehensiveIncomeLossDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:href="biib-20161231.xsd#AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Acquisitions" xlink:href="biib-20161231.xsd#Acquisitions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsAcquisitionsDetails" xlink:href="biib-20161231.xsd#AcquisitionsAcquisitionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsAcquisitionsDetails1" xlink:href="biib-20161231.xsd#AcquisitionsAcquisitionsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsAcquisitionsTables" xlink:href="biib-20161231.xsd#AcquisitionsAcquisitionsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsDetailsTextual" xlink:href="biib-20161231.xsd#AcquisitionsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships" xlink:href="biib-20161231.xsd#CollaborativeAndOtherRelationships" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsDetails3" xlink:href="biib-20161231.xsd#CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetails" xlink:href="biib-20161231.xsd#CollaborativeAndOtherRelationshipsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetails1" xlink:href="biib-20161231.xsd#CollaborativeAndOtherRelationshipsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetails2" xlink:href="biib-20161231.xsd#CollaborativeAndOtherRelationshipsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual" xlink:href="biib-20161231.xsd#CollaborativeAndOtherRelationshipsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables" xlink:href="biib-20161231.xsd#CollaborativeAndOtherRelationshipsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CommitmentsAndContingencies" xlink:href="biib-20161231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CommitmentsAndContingenciesCommitmentsAndContingenciesDetails1" xlink:href="biib-20161231.xsd#CommitmentsAndContingenciesCommitmentsAndContingenciesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CommitmentsAndContingenciesDetails" xlink:href="biib-20161231.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CommitmentsAndContingenciesDetailsTextual" xlink:href="biib-20161231.xsd#CommitmentsAndContingenciesDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CommitmentsAndContingenciesTables" xlink:href="biib-20161231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedBalanceSheets" xlink:href="biib-20161231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="biib-20161231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="biib-20161231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsOfComprehensiveIncome" xlink:href="biib-20161231.xsd#ConsolidatedStatementsOfComprehensiveIncome" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsOfEquity" xlink:href="biib-20161231.xsd#ConsolidatedStatementsOfEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsOfIncome" xlink:href="biib-20161231.xsd#ConsolidatedStatementsOfIncome" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstruments" xlink:href="biib-20161231.xsd#DerivativeInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:href="biib-20161231.xsd#DerivativeInstrumentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails1" xlink:href="biib-20161231.xsd#DerivativeInstrumentsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetailsTextual" xlink:href="biib-20161231.xsd#DerivativeInstrumentsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:href="biib-20161231.xsd#DerivativeInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DocumentAndEntityInformation" xlink:href="biib-20161231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShare" xlink:href="biib-20161231.xsd#EarningsPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShareDetails" xlink:href="biib-20161231.xsd#EarningsPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShareTables" xlink:href="biib-20161231.xsd#EarningsPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EmployeeBenefitPlans" xlink:href="biib-20161231.xsd#EmployeeBenefitPlans" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EmployeeBenefitPlansDetails1" xlink:href="biib-20161231.xsd#EmployeeBenefitPlansDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EmployeeBenefitPlansEmployeeBenefitPlansDetails" xlink:href="biib-20161231.xsd#EmployeeBenefitPlansEmployeeBenefitPlansDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Equity" xlink:href="biib-20161231.xsd#Equity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityDetails" xlink:href="biib-20161231.xsd#EquityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityDetailsTextual" xlink:href="biib-20161231.xsd#EquityDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityTables" xlink:href="biib-20161231.xsd#EquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurements" xlink:href="biib-20161231.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:href="biib-20161231.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:href="biib-20161231.xsd#FairValueMeasurementsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:href="biib-20161231.xsd#FairValueMeasurementsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:href="biib-20161231.xsd#FairValueMeasurementsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:href="biib-20161231.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstruments" xlink:href="biib-20161231.xsd#FinancialInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:href="biib-20161231.xsd#FinancialInstrumentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:href="biib-20161231.xsd#FinancialInstrumentsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:href="biib-20161231.xsd#FinancialInstrumentsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:href="biib-20161231.xsd#FinancialInstrumentsDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual1" xlink:href="biib-20161231.xsd#FinancialInstrumentsDetailsTextual1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual2" xlink:href="biib-20161231.xsd#FinancialInstrumentsDetailsTextual2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:href="biib-20161231.xsd#FinancialInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Guarantees" xlink:href="biib-20161231.xsd#Guarantees" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxes" xlink:href="biib-20161231.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:href="biib-20161231.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails1" xlink:href="biib-20161231.xsd#IncomeTaxesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails2" xlink:href="biib-20161231.xsd#IncomeTaxesDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails3" xlink:href="biib-20161231.xsd#IncomeTaxesDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:href="biib-20161231.xsd#IncomeTaxesDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:href="biib-20161231.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Indebtedness" xlink:href="biib-20161231.xsd#Indebtedness" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessDetails" xlink:href="biib-20161231.xsd#IndebtednessDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessDetails1" xlink:href="biib-20161231.xsd#IndebtednessDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessDetailsTextual" xlink:href="biib-20161231.xsd#IndebtednessDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessTables" xlink:href="biib-20161231.xsd#IndebtednessTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill" xlink:href="biib-20161231.xsd#IntangibleAssetsAndGoodwill" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails" xlink:href="biib-20161231.xsd#IntangibleAssetsAndGoodwillDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:href="biib-20161231.xsd#IntangibleAssetsAndGoodwillDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables" xlink:href="biib-20161231.xsd#IntangibleAssetsAndGoodwillTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Inventory" xlink:href="biib-20161231.xsd#Inventory" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryDetails" xlink:href="biib-20161231.xsd#InventoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryDetailsTextual" xlink:href="biib-20161231.xsd#InventoryDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryTables" xlink:href="biib-20161231.xsd#InventoryTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities" xlink:href="biib-20161231.xsd#InvestmentsInVariableInterestEntities" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails" xlink:href="biib-20161231.xsd#InvestmentsInVariableInterestEntitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Litigation" xlink:href="biib-20161231.xsd#Litigation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/LitigationDetails" xlink:href="biib-20161231.xsd#LitigationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:href="biib-20161231.xsd#OtherConsolidatedFinancialStatementDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:href="biib-20161231.xsd#OtherConsolidatedFinancialStatementDetailDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetailsTextual" xlink:href="biib-20161231.xsd#OtherConsolidatedFinancialStatementDetailDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:href="biib-20161231.xsd#OtherConsolidatedFinancialStatementDetailTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipment" xlink:href="biib-20161231.xsd#PropertyPlantAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails" xlink:href="biib-20161231.xsd#PropertyPlantAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetailsTextual" xlink:href="biib-20161231.xsd#PropertyPlantAndEquipmentDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentTables" xlink:href="biib-20161231.xsd#PropertyPlantAndEquipmentTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/QuarterlyFinancialDataUnaudited" xlink:href="biib-20161231.xsd#QuarterlyFinancialDataUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetails" xlink:href="biib-20161231.xsd#QuarterlyFinancialDataUnauditedDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetailsTextual" xlink:href="biib-20161231.xsd#QuarterlyFinancialDataUnauditedDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedTables" xlink:href="biib-20161231.xsd#QuarterlyFinancialDataUnauditedTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RestructuringRestructuring" xlink:href="biib-20161231.xsd#RestructuringRestructuring" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RestructuringRestructuringDetails" xlink:href="biib-20161231.xsd#RestructuringRestructuringDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RestructuringRestructuringDetailsTextual" xlink:href="biib-20161231.xsd#RestructuringRestructuringDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RestructuringRestructuringTables" xlink:href="biib-20161231.xsd#RestructuringRestructuringTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenueReserves" xlink:href="biib-20161231.xsd#RevenueReserves" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenueReservesDetails" xlink:href="biib-20161231.xsd#RevenueReservesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenueReservesDetails1" xlink:href="biib-20161231.xsd#RevenueReservesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenueReservesTables" xlink:href="biib-20161231.xsd#RevenueReservesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SegmentInformation" xlink:href="biib-20161231.xsd#SegmentInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SegmentInformationDetails" xlink:href="biib-20161231.xsd#SegmentInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SegmentInformationDetails1" xlink:href="biib-20161231.xsd#SegmentInformationDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SegmentInformationDetailsTextual" xlink:href="biib-20161231.xsd#SegmentInformationDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SegmentInformationTables" xlink:href="biib-20161231.xsd#SegmentInformationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPayments" xlink:href="biib-20161231.xsd#ShareBasedPayments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:href="biib-20161231.xsd#ShareBasedPaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:href="biib-20161231.xsd#ShareBasedPaymentsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails2" xlink:href="biib-20161231.xsd#ShareBasedPaymentsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails3" xlink:href="biib-20161231.xsd#ShareBasedPaymentsDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails4" xlink:href="biib-20161231.xsd#ShareBasedPaymentsDetails4" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails5" xlink:href="biib-20161231.xsd#ShareBasedPaymentsDetails5" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails6" xlink:href="biib-20161231.xsd#ShareBasedPaymentsDetails6" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails8" xlink:href="biib-20161231.xsd#ShareBasedPaymentsDetails8" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails9" xlink:href="biib-20161231.xsd#ShareBasedPaymentsDetails9" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetailsTextual" xlink:href="biib-20161231.xsd#ShareBasedPaymentsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedPaymentsDetails7" xlink:href="biib-20161231.xsd#ShareBasedPaymentsShareBasedPaymentsDetails7" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:href="biib-20161231.xsd#ShareBasedPaymentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SubsequentEventsNotes" xlink:href="biib-20161231.xsd#SubsequentEventsNotes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="biib-20161231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:href="biib-20161231.xsd#SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="biib-20161231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="biib-20161231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_BC7C78AF85C6ECEE717C7412859A3CE7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_50240BAA7FDB0B532A177412859AB3E9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_BC7C78AF85C6ECEE717C7412859A3CE7" xlink:to="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_50240BAA7FDB0B532A177412859AB3E9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_DE72257DA1C3291AB7FAFB6C3B12461D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_EB081C83F342BF2C3B8EFB6C3B122DF0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_DE72257DA1C3291AB7FAFB6C3B12461D" xlink:to="loc_us-gaap_StatementTable_EB081C83F342BF2C3B8EFB6C3B122DF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_ABA2B54464736C4E76F4FB6C3B12BA51" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_EB081C83F342BF2C3B8EFB6C3B122DF0" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_ABA2B54464736C4E76F4FB6C3B12BA51" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_ACBEE212638E5DFCB6DBFB6C3B122373" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ABA2B54464736C4E76F4FB6C3B12BA51" xlink:to="loc_us-gaap_EquityComponentDomain_ACBEE212638E5DFCB6DBFB6C3B122373" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_ED5ED3B5D36FBFA653D7FB6C3B126504" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ACBEE212638E5DFCB6DBFB6C3B122373" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_ED5ED3B5D36FBFA653D7FB6C3B126504" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_974E821DE07252F39823FB6C3B13D894" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ACBEE212638E5DFCB6DBFB6C3B122373" xlink:to="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_974E821DE07252F39823FB6C3B13D894" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_2F923B0CE5A4BBEE6EC9FB6C3B13281A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ACBEE212638E5DFCB6DBFB6C3B122373" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_2F923B0CE5A4BBEE6EC9FB6C3B13281A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_FAB61E2B105812ECF5C7FB6C3B13B50E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ACBEE212638E5DFCB6DBFB6C3B122373" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_FAB61E2B105812ECF5C7FB6C3B13B50E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_DCC6E30B8F0E016F7415FB6C3B138862" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_EB081C83F342BF2C3B8EFB6C3B122DF0" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_DCC6E30B8F0E016F7415FB6C3B138862" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_CDF92BFD30E696D57A71FB6C3B137C2B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_DCC6E30B8F0E016F7415FB6C3B138862" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_CDF92BFD30E696D57A71FB6C3B137C2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_A55550F976AA6321C4EEFB6C3B13FFF4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_DCC6E30B8F0E016F7415FB6C3B138862" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_A55550F976AA6321C4EEFB6C3B13FFF4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_4AF63ABFDC7C9493F6C5FB6C3B13DEA3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_DCC6E30B8F0E016F7415FB6C3B138862" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_4AF63ABFDC7C9493F6C5FB6C3B13DEA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_9B7AB4B53C702D648A1EFB6C3B135A90" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_DCC6E30B8F0E016F7415FB6C3B138862" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_9B7AB4B53C702D648A1EFB6C3B135A90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2C96B4AFAB9BE384850BFB6C3B137306" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_DCC6E30B8F0E016F7415FB6C3B138862" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2C96B4AFAB9BE384850BFB6C3B137306" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_24E8B7676442AE3B1DE8FB6C3B0CDE17" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_0FC85EB3EB54CF197601FB6C3B0CE699" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_24E8B7676442AE3B1DE8FB6C3B0CDE17" xlink:to="loc_us-gaap_StatementTable_0FC85EB3EB54CF197601FB6C3B0CE699" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_9312D5F108CDA6E9CDA2FB6C3B0CF0BE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/netLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0FC85EB3EB54CF197601FB6C3B0CE699" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_9312D5F108CDA6E9CDA2FB6C3B0CF0BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_5D75B19D012F93A8142EFB6C3B0DAB5F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9312D5F108CDA6E9CDA2FB6C3B0CF0BE" xlink:to="loc_us-gaap_EquityComponentDomain_5D75B19D012F93A8142EFB6C3B0DAB5F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_E12D2ED6320B9F73DCF9FB6C3B0DCE38" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5D75B19D012F93A8142EFB6C3B0DAB5F" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_E12D2ED6320B9F73DCF9FB6C3B0DCE38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_CC50E506EE5506B6375BFB6C3B0D3A64" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5D75B19D012F93A8142EFB6C3B0DAB5F" xlink:to="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_CC50E506EE5506B6375BFB6C3B0D3A64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_1DD56B741810089DFB0DFB6C3B0D7E66" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0FC85EB3EB54CF197601FB6C3B0CE699" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_1DD56B741810089DFB0DFB6C3B0D7E66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_A4F64A839DA875EF31BCFB6C3B0D026E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_1DD56B741810089DFB0DFB6C3B0D7E66" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_A4F64A839DA875EF31BCFB6C3B0D026E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_3B9FE05BB0A1881F4187FB6C3B0D5B1B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_A4F64A839DA875EF31BCFB6C3B0D026E" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_3B9FE05BB0A1881F4187FB6C3B0D5B1B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_C48AE22503D3D984571CFB6C3B0D01BB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0FC85EB3EB54CF197601FB6C3B0CE699" xlink:to="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_C48AE22503D3D984571CFB6C3B0D01BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_C5BBBB03F1CE459EA245FB6C3B0DD212" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_C48AE22503D3D984571CFB6C3B0D01BB" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_C5BBBB03F1CE459EA245FB6C3B0DD212" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_9611A906585BADFEDA0DFB6C3B0D25AC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_C48AE22503D3D984571CFB6C3B0D01BB" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_9611A906585BADFEDA0DFB6C3B0D25AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_C7D49731C883E8DC3994FB6C3B0D5378" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_C48AE22503D3D984571CFB6C3B0D01BB" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_C7D49731C883E8DC3994FB6C3B0D5378" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_3C6FC0337FE5637B4CD1FB6C3B0DB563" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_C48AE22503D3D984571CFB6C3B0D01BB" xlink:to="loc_us-gaap_OperatingExpenses_3C6FC0337FE5637B4CD1FB6C3B0DB563" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_3B5340F17A2322430F8AFB6C3B0DC907" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_C48AE22503D3D984571CFB6C3B0D01BB" xlink:to="loc_us-gaap_NetIncomeLoss_3B5340F17A2322430F8AFB6C3B0DC907" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_49B45CB81A472FB169FE741285727253" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_859F38EC5184DB2340A77412857221E5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_49B45CB81A472FB169FE741285727253" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_859F38EC5184DB2340A77412857221E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_186D6D9753D3BB1D65D97412857225B9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_49B45CB81A472FB169FE741285727253" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_186D6D9753D3BB1D65D97412857225B9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Acquisitions" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_C3A309E5C37E8518D6AF74128649A570" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:label="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_6409925C1B4692E184577412865A70C9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_C3A309E5C37E8518D6AF74128649A570" xlink:to="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_6409925C1B4692E184577412865A70C9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/AcquisitionsAcquisitionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_85F326CA435B8FDB9F91FA4EA5D9EBA9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_09D0F7B30BCC15C3D539FA4EA5DA81E3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_85F326CA435B8FDB9F91FA4EA5D9EBA9" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_09D0F7B30BCC15C3D539FA4EA5DA81E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_F986DBCB87C8A79192C0FA4EA5DA10EE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_09D0F7B30BCC15C3D539FA4EA5DA81E3" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_F986DBCB87C8A79192C0FA4EA5DA10EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6629848242E045951958FA4EA5DA9750" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_F986DBCB87C8A79192C0FA4EA5DA10EE" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6629848242E045951958FA4EA5DA9750" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ConvergencePharmaceuticalsMember" xlink:label="loc_biib_ConvergencePharmaceuticalsMember_9C0846778CCA1F308477FA4EA5DA00FF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6629848242E045951958FA4EA5DA9750" xlink:to="loc_biib_ConvergencePharmaceuticalsMember_9C0846778CCA1F308477FA4EA5DA00FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_4CA94FD31B17B54C908AFA4EA5DA05DF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_09D0F7B30BCC15C3D539FA4EA5DA81E3" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_4CA94FD31B17B54C908AFA4EA5DA05DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_EF5129B9ACDD65A2B739FA4EA5DA07FE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4CA94FD31B17B54C908AFA4EA5DA05DF" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_EF5129B9ACDD65A2B739FA4EA5DA07FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_7BAE254052D5EAC525D3FA4EA5DA8B83" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4CA94FD31B17B54C908AFA4EA5DA05DF" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_7BAE254052D5EAC525D3FA4EA5DA8B83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_FD1F057F2C70004B24A2FA4EA5DA3DBE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4CA94FD31B17B54C908AFA4EA5DA05DF" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_FD1F057F2C70004B24A2FA4EA5DA3DBE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/AcquisitionsAcquisitionsDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_1D1791F197AA502BD712FCCBDD04AA40" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_120DACFA5B491B9B9F4EFCCBDD04DB05" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_1D1791F197AA502BD712FCCBDD04AA40" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_120DACFA5B491B9B9F4EFCCBDD04DB05" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_7CB346EB751FC5DB12B3FCCBDD04C51B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_120DACFA5B491B9B9F4EFCCBDD04DB05" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_7CB346EB751FC5DB12B3FCCBDD04C51B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_92BFFA03C94605B78D3DFCCBDD05D825" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7CB346EB751FC5DB12B3FCCBDD04C51B" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_92BFFA03C94605B78D3DFCCBDD05D825" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ConvergencePharmaceuticalsMember" xlink:label="loc_biib_ConvergencePharmaceuticalsMember_DC466AB0D0BFEC1A1A9DFCCBDD058C83" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_92BFFA03C94605B78D3DFCCBDD05D825" xlink:to="loc_biib_ConvergencePharmaceuticalsMember_DC466AB0D0BFEC1A1A9DFCCBDD058C83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_D273B22EFA3D52255B45FCCBDD05A4BE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_120DACFA5B491B9B9F4EFCCBDD04DB05" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_D273B22EFA3D52255B45FCCBDD05A4BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_B1732C67456B3983DD40FCCBDD053791" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_D273B22EFA3D52255B45FCCBDD05A4BE" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_B1732C67456B3983DD40FCCBDD053791" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_3EF243BBBF5A5FDAF2ADFCCBDD05BA2B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_D273B22EFA3D52255B45FCCBDD05A4BE" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_3EF243BBBF5A5FDAF2ADFCCBDD05BA2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_01BC5B0BC3FCB8A70D76FCCBDD052812" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_D273B22EFA3D52255B45FCCBDD05A4BE" xlink:to="loc_us-gaap_Goodwill_01BC5B0BC3FCB8A70D76FCCBDD052812" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_0603AA20E7F9C0CDD106FCCBDD051A1E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_D273B22EFA3D52255B45FCCBDD05A4BE" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_0603AA20E7F9C0CDD106FCCBDD051A1E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_2CA66B5E1AF1F38B1D7DFCCBDD055703" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_D273B22EFA3D52255B45FCCBDD05A4BE" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_2CA66B5E1AF1F38B1D7DFCCBDD055703" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_5EAA6BE85D3FC1EB3B7CFCCBDD05FDB4" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_D273B22EFA3D52255B45FCCBDD05A4BE" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_5EAA6BE85D3FC1EB3B7CFCCBDD05FDB4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/AcquisitionsAcquisitionsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_70BE9D8E7E7016072DE07412858AB67A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_D562851649E94D4190F17412858AE074" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_70BE9D8E7E7016072DE07412858AB67A" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_D562851649E94D4190F17412858AE074" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_B73DFAAF4E101BAFCA3F7412858A6FE2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_70BE9D8E7E7016072DE07412858AB67A" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_B73DFAAF4E101BAFCA3F7412858A6FE2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/AcquisitionsDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_4524D1247B02038B7B65FD3DC92249B3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_12A1011813AB1F87DF3EFD3DC924EC7E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_4524D1247B02038B7B65FD3DC92249B3" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_12A1011813AB1F87DF3EFD3DC924EC7E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_EE9DFDCAA197F44FD5C6FD3DC925F122" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_12A1011813AB1F87DF3EFD3DC924EC7E" xlink:to="loc_us-gaap_ProductOrServiceAxis_EE9DFDCAA197F44FD5C6FD3DC925F122" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_E63B6D792A662D7F3BBAFD3DC9255B36" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductOrServiceAxis_EE9DFDCAA197F44FD5C6FD3DC925F122" xlink:to="loc_us-gaap_ProductsAndServicesDomain_E63B6D792A662D7F3BBAFD3DC9255B36" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_BIIB074Member" xlink:label="loc_biib_BIIB074Member_A2EBDAC15163137BA4D1FD3DC9254946" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_E63B6D792A662D7F3BBAFD3DC9255B36" xlink:to="loc_biib_BIIB074Member_A2EBDAC15163137BA4D1FD3DC9254946" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_NeuropathicpainindicationsMember" xlink:label="loc_biib_NeuropathicpainindicationsMember_BD49A3ECFA87A1355AC6FD3DC9265243" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_E63B6D792A662D7F3BBAFD3DC9255B36" xlink:to="loc_biib_NeuropathicpainindicationsMember_BD49A3ECFA87A1355AC6FD3DC9265243" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_132D476A4607A43F69FCFD3DC9265C68" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_12A1011813AB1F87DF3EFD3DC924EC7E" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_132D476A4607A43F69FCFD3DC9265C68" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FFFBEA96F84473AD64ADFD3DC9266206" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_132D476A4607A43F69FCFD3DC9265C68" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FFFBEA96F84473AD64ADFD3DC9266206" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ConvergencePharmaceuticalsMember" xlink:label="loc_biib_ConvergencePharmaceuticalsMember_6A9895973D8D839791A7FD3DC9277A0F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FFFBEA96F84473AD64ADFD3DC9266206" xlink:to="loc_biib_ConvergencePharmaceuticalsMember_6A9895973D8D839791A7FD3DC9277A0F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_150FB150C3552FF59522FD3DC927922B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_12A1011813AB1F87DF3EFD3DC924EC7E" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_150FB150C3552FF59522FD3DC927922B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_28413A84D79639B99BE3FD3DC927A81A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_150FB150C3552FF59522FD3DC927922B" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_28413A84D79639B99BE3FD3DC927A81A" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_6416E2D6F7721CB3EDE8FD3DC9274C38" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_150FB150C3552FF59522FD3DC927922B" xlink:to="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_6416E2D6F7721CB3EDE8FD3DC9274C38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_CA19F6C2570D36AF9FCFFD3DC9273AF8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_150FB150C3552FF59522FD3DC927922B" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_CA19F6C2570D36AF9FCFFD3DC9273AF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_980208237E0BFFEF941EFD3DC92729DA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_150FB150C3552FF59522FD3DC927922B" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_980208237E0BFFEF941EFD3DC92729DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsDiscountRate" xlink:label="loc_us-gaap_FairValueInputsDiscountRate_A334150E342C32996D66FD3DC927AC5C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_150FB150C3552FF59522FD3DC927922B" xlink:to="loc_us-gaap_FairValueInputsDiscountRate_A334150E342C32996D66FD3DC927AC5C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_CB6F12FA47E2D2FFF004FD3DC927B704" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_150FB150C3552FF59522FD3DC927922B" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_CB6F12FA47E2D2FFF004FD3DC927B704" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_892EFDC5AAE5EE1682BFFD3DC9273792" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_150FB150C3552FF59522FD3DC927922B" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_892EFDC5AAE5EE1682BFFD3DC9273792" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_MilestonePaymentsMadeDuringPeriod" xlink:label="loc_biib_MilestonePaymentsMadeDuringPeriod_21F177B976CF2AFDDE95FD3DC9280E6B" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_150FB150C3552FF59522FD3DC927922B" xlink:to="loc_biib_MilestonePaymentsMadeDuringPeriod_21F177B976CF2AFDDE95FD3DC9280E6B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_EFCE884F2BA5BA04200A7412871002FE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_99755ABF3A0AD3776EAF741287107808" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_EFCE884F2BA5BA04200A7412871002FE" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_99755ABF3A0AD3776EAF741287107808" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsDetails3" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_DA168F5E01B616038714FC923B903416" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_27D20259CB130454FC74FC923B905349" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_DA168F5E01B616038714FC923B903416" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_27D20259CB130454FC74FC923B905349" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_C892D04C0057280FC3F1FC923B903FD4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_27D20259CB130454FC74FC923B905349" xlink:to="loc_us-gaap_TypeOfArrangementAxis_C892D04C0057280FC3F1FC923B903FD4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_04E64AD700EA3E88557CFC923B91A035" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_C892D04C0057280FC3F1FC923B903FD4" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_04E64AD700EA3E88557CFC923B91A035" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_EisaiMember" xlink:label="loc_biib_EisaiMember_0F7D5B507EE58070FC0FFC923B920483" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_04E64AD700EA3E88557CFC923B91A035" xlink:to="loc_biib_EisaiMember_0F7D5B507EE58070FC0FFC923B920483" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_522A612EEFB75027B507FC923B9226C0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_27D20259CB130454FC74FC923B905349" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_522A612EEFB75027B507FC923B9226C0" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ExpenseIncurredByCollaboration" xlink:label="loc_biib_ExpenseIncurredByCollaboration_322EAE643162663B292AFC923B92A53B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_522A612EEFB75027B507FC923B9226C0" xlink:to="loc_biib_ExpenseIncurredByCollaboration_322EAE643162663B292AFC923B92A53B" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ExpenseReflectedWithinStatementsOfIncome" xlink:label="loc_biib_ExpenseReflectedWithinStatementsOfIncome_56E603325A5DE3DC29BFFC923B92C51D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_522A612EEFB75027B507FC923B9226C0" xlink:to="loc_biib_ExpenseReflectedWithinStatementsOfIncome_56E603325A5DE3DC29BFFC923B92C51D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_DBEFE233D138BC91799DFCCBDB49B7A5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_24F0DCBC60D9174F0F0DFCCBDB494280" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_DBEFE233D138BC91799DFCCBDB49B7A5" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_24F0DCBC60D9174F0F0DFCCBDB494280" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_47591CCE961B7B438163FCCBDB49034F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_24F0DCBC60D9174F0F0DFCCBDB494280" xlink:to="loc_us-gaap_ProductOrServiceAxis_47591CCE961B7B438163FCCBDB49034F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_EFCB5161C79B50A0AEFCFCCBDB49409F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductOrServiceAxis_47591CCE961B7B438163FCCBDB49034F" xlink:to="loc_us-gaap_ProductsAndServicesDomain_EFCB5161C79B50A0AEFCFCCBDB49409F" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_GAZYVAMember" xlink:label="loc_biib_GAZYVAMember_366E910026E23722C08CFCCBDB4A6306" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_EFCB5161C79B50A0AEFCFCCBDB49409F" xlink:to="loc_biib_GAZYVAMember_366E910026E23722C08CFCCBDB4A6306" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_RituxanMember" xlink:label="loc_biib_RituxanMember_0941647EFD7572C0F09FFCCBDB4AA9B6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_EFCB5161C79B50A0AEFCFCCBDB49409F" xlink:to="loc_biib_RituxanMember_0941647EFD7572C0F09FFCCBDB4AA9B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_CFCEF90D9E832E402940FCCBDB4A6DF3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_24F0DCBC60D9174F0F0DFCCBDB494280" xlink:to="loc_us-gaap_TypeOfArrangementAxis_CFCEF90D9E832E402940FCCBDB4A6DF3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_716B58F2ADEEEC34951AFCCBDB4AF28A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_CFCEF90D9E832E402940FCCBDB4A6DF3" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_716B58F2ADEEEC34951AFCCBDB4AF28A" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_RocheGroupGenentechMember" xlink:label="loc_biib_RocheGroupGenentechMember_D5B2104DFD28235DF39DFCCBDB4A88BD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_716B58F2ADEEEC34951AFCCBDB4AF28A" xlink:to="loc_biib_RocheGroupGenentechMember_D5B2104DFD28235DF39DFCCBDB4A88BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_153324260F611F59A15BFCCBDB4AB71E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_24F0DCBC60D9174F0F0DFCCBDB494280" xlink:to="loc_us-gaap_StatementGeographicalAxis_153324260F611F59A15BFCCBDB4AB71E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_A1F461703C20423626D2FCCBDB4A47B4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementGeographicalAxis_153324260F611F59A15BFCCBDB4AB71E" xlink:to="loc_us-gaap_SegmentGeographicalDomain_A1F461703C20423626D2FCCBDB4A47B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd#country_US" xlink:label="loc_country_US_E6AEAAA62A2D82DF6F5DFCCBDB4A317C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_A1F461703C20423626D2FCCBDB4A47B4" xlink:to="loc_country_US_E6AEAAA62A2D82DF6F5DFCCBDB4A317C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember_1953C986A0F612DE3319FCCBDB4A6C62" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_A1F461703C20423626D2FCCBDB4A47B4" xlink:to="loc_us-gaap_ForeignCountryMember_1953C986A0F612DE3319FCCBDB4A6C62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_AD580251C011CE01922CFCCBDB4AC2B0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_24F0DCBC60D9174F0F0DFCCBDB494280" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_AD580251C011CE01922CFCCBDB4AC2B0" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_CoPromotionProfitSharingFormulaAbstract" xlink:label="loc_biib_CoPromotionProfitSharingFormulaAbstract_3B1573BD06472B7BFC56FCCBDB4AD84B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_AD580251C011CE01922CFCCBDB4AC2B0" xlink:to="loc_biib_CoPromotionProfitSharingFormulaAbstract_3B1573BD06472B7BFC56FCCBDB4AD84B" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_7D23513C0B1999CC70ABFCCBDB4AB38F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CoPromotionProfitSharingFormulaAbstract_3B1573BD06472B7BFC56FCCBDB4AD84B" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_7D23513C0B1999CC70ABFCCBDB4AB38F" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_B5623F03315DCFF62C87FCCBDB4A53BC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CoPromotionProfitSharingFormulaAbstract_3B1573BD06472B7BFC56FCCBDB4AD84B" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_B5623F03315DCFF62C87FCCBDB4A53BC" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_D1DBFD1A286513D8B20FFCCBDB4A5776" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_B5623F03315DCFF62C87FCCBDB4A53BC" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_D1DBFD1A286513D8B20FFCCBDB4A5776" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_370B69E102EC9B2D5F53FCCBDB4BCE87" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_B5623F03315DCFF62C87FCCBDB4A53BC" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_370B69E102EC9B2D5F53FCCBDB4BCE87" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_560A019BE4B4229A8DA4FCCBDB4B51E2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_B5623F03315DCFF62C87FCCBDB4A53BC" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_560A019BE4B4229A8DA4FCCBDB4B51E2" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_RevenuesFromUnconsolidatedJointBusinessAbstract" xlink:label="loc_biib_RevenuesFromUnconsolidatedJointBusinessAbstract_3E7405A87940B30E3C75FCCBDB4BAFBE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_AD580251C011CE01922CFCCBDB4AC2B0" xlink:to="loc_biib_RevenuesFromUnconsolidatedJointBusinessAbstract_3E7405A87940B30E3C75FCCBDB4BAFBE" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ShareOfCoPromotionProfits" xlink:label="loc_biib_ShareOfCoPromotionProfits_7FDF39A1BF1023E1C467FCCBDB4B9065" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_RevenuesFromUnconsolidatedJointBusinessAbstract_3E7405A87940B30E3C75FCCBDB4BAFBE" xlink:to="loc_biib_ShareOfCoPromotionProfits_7FDF39A1BF1023E1C467FCCBDB4B9065" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_1C8748C56E10DA39C733FCCBDB4B2743" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_RevenuesFromUnconsolidatedJointBusinessAbstract_3E7405A87940B30E3C75FCCBDB4BAFBE" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_1C8748C56E10DA39C733FCCBDB4B2743" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_RevenuesfromantiCD20therapeuticprograms" xlink:label="loc_biib_RevenuesfromantiCD20therapeuticprograms_CB1F7B8A8C53BC5C114CFD0ABF103979" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_RevenuesFromUnconsolidatedJointBusinessAbstract_3E7405A87940B30E3C75FCCBDB4BAFBE" xlink:to="loc_biib_RevenuesfromantiCD20therapeuticprograms_CB1F7B8A8C53BC5C114CFD0ABF103979" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_45D03BB62A9E64BC9C2DFC923B356963" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_D481F2725702754F5145FC923B3593BD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_45D03BB62A9E64BC9C2DFC923B356963" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_D481F2725702754F5145FC923B3593BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_EAFFF3931575E2971A6CFC923B35F715" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_D481F2725702754F5145FC923B3593BD" xlink:to="loc_us-gaap_TypeOfArrangementAxis_EAFFF3931575E2971A6CFC923B35F715" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B4B1D4AF273F73E99D23FC923B36AC09" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_EAFFF3931575E2971A6CFC923B35F715" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B4B1D4AF273F73E99D23FC923B36AC09" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_AbbVieMember" xlink:label="loc_biib_AbbVieMember_33B6612D9C11B6FF287DFC923B36F196" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B4B1D4AF273F73E99D23FC923B36AC09" xlink:to="loc_biib_AbbVieMember_33B6612D9C11B6FF287DFC923B36F196" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1CAB3AF003A0978B73BEFC923B36A041" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_D481F2725702754F5145FC923B3593BD" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1CAB3AF003A0978B73BEFC923B36A041" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_97C85A5C1EDC9F1C8DA0FC923B3658B0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1CAB3AF003A0978B73BEFC923B36A041" xlink:to="loc_us-gaap_Revenues_97C85A5C1EDC9F1C8DA0FC923B3658B0" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ExpenseIncurredByCollaboration" xlink:label="loc_biib_ExpenseIncurredByCollaboration_ED7E43115B58978914BAFC923B36967A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1CAB3AF003A0978B73BEFC923B36A041" xlink:to="loc_biib_ExpenseIncurredByCollaboration_ED7E43115B58978914BAFC923B36967A" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_Copromotionprofitsandlosses" xlink:label="loc_biib_Copromotionprofitsandlosses_3844388B1DDCB546D761FC923B36B1C3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1CAB3AF003A0978B73BEFC923B36A041" xlink:to="loc_biib_Copromotionprofitsandlosses_3844388B1DDCB546D761FC923B36B1C3" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ShareOfCoPromotionProfits" xlink:label="loc_biib_ShareOfCoPromotionProfits_38396503935BF02F0784FC923B36C048" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1CAB3AF003A0978B73BEFC923B36A041" xlink:to="loc_biib_ShareOfCoPromotionProfits_38396503935BF02F0784FC923B36C048" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3D7646A23FB81A880898FCCBDB3EF0D8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_DD890341D4784DD039A1FCCBDB3EFFE6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3D7646A23FB81A880898FCCBDB3EF0D8" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_DD890341D4784DD039A1FCCBDB3EFFE6" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis" xlink:label="loc_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_86B8A232126DDF0F2AE0FCCBDB3EC7E9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_DD890341D4784DD039A1FCCBDB3EFFE6" xlink:to="loc_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_86B8A232126DDF0F2AE0FCCBDB3EC7E9" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_RoyaltyAndNetRevenueShareRatesByTerritoryDomain" xlink:label="loc_biib_RoyaltyAndNetRevenueShareRatesByTerritoryDomain_33401B3A33201BDAF1DAFCCBDB3E102E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_86B8A232126DDF0F2AE0FCCBDB3EC7E9" xlink:to="loc_biib_RoyaltyAndNetRevenueShareRatesByTerritoryDomain_33401B3A33201BDAF1DAFCCBDB3E102E" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_SobiRateToBiogenOnNetSalesInSobiTerritoryMember" xlink:label="loc_biib_SobiRateToBiogenOnNetSalesInSobiTerritoryMember_5F8EC1B9821E9B199F30FCCBDB3E684E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_RoyaltyAndNetRevenueShareRatesByTerritoryDomain_33401B3A33201BDAF1DAFCCBDB3E102E" xlink:to="loc_biib_SobiRateToBiogenOnNetSalesInSobiTerritoryMember_5F8EC1B9821E9B199F30FCCBDB3E684E" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember" xlink:label="loc_biib_BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember_73A065A4BBF0C082C1E4FCCBDB3E9CAE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_RoyaltyAndNetRevenueShareRatesByTerritoryDomain_33401B3A33201BDAF1DAFCCBDB3E102E" xlink:to="loc_biib_BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember_73A065A4BBF0C082C1E4FCCBDB3E9CAE" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember" xlink:label="loc_biib_BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember_FA30F299DB42322C2DEBFCCBDB3FB61C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_RoyaltyAndNetRevenueShareRatesByTerritoryDomain_33401B3A33201BDAF1DAFCCBDB3E102E" xlink:to="loc_biib_BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember_FA30F299DB42322C2DEBFCCBDB3FB61C" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_BiogenRateToSobiOnNetRevenueFromBiogenDistributorTerritoryMember" xlink:label="loc_biib_BiogenRateToSobiOnNetRevenueFromBiogenDistributorTerritoryMember_2C3F18FCE71516776831FCCBDB3F714C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_RoyaltyAndNetRevenueShareRatesByTerritoryDomain_33401B3A33201BDAF1DAFCCBDB3E102E" xlink:to="loc_biib_BiogenRateToSobiOnNetRevenueFromBiogenDistributorTerritoryMember_2C3F18FCE71516776831FCCBDB3F714C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_175DF9355EE0AC81DDA8FCCBDB3F39CF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_DD890341D4784DD039A1FCCBDB3EFFE6" xlink:to="loc_us-gaap_StatementGeographicalAxis_175DF9355EE0AC81DDA8FCCBDB3F39CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_8DB7219D3E5CC66FC806FCCBDB3FDB6C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementGeographicalAxis_175DF9355EE0AC81DDA8FCCBDB3F39CF" xlink:to="loc_us-gaap_SegmentGeographicalDomain_8DB7219D3E5CC66FC806FCCBDB3FDB6C" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_SobiTerritoryMember" xlink:label="loc_biib_SobiTerritoryMember_476C5BCB37E416AA5292FCCBDB3FC4B8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_8DB7219D3E5CC66FC806FCCBDB3FDB6C" xlink:to="loc_biib_SobiTerritoryMember_476C5BCB37E416AA5292FCCBDB3FC4B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_65AA1B8C6F80743F9A32FCCBDB3FA184" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_DD890341D4784DD039A1FCCBDB3EFFE6" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_65AA1B8C6F80743F9A32FCCBDB3FA184" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ReimbursementUnderAmendedAgreementAmountsPayableAbstract" xlink:label="loc_biib_ReimbursementUnderAmendedAgreementAmountsPayableAbstract_3752608623C78099CBDCFCCBDB3F96A3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_65AA1B8C6F80743F9A32FCCBDB3FA184" xlink:to="loc_biib_ReimbursementUnderAmendedAgreementAmountsPayableAbstract_3752608623C78099CBDCFCCBDB3F96A3" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ReimbursementUnderAmendedAgreementMethod" xlink:label="loc_biib_ReimbursementUnderAmendedAgreementMethod_E664502ED6062B9EF56DFCCBDB3FD6E0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ReimbursementUnderAmendedAgreementAmountsPayableAbstract_3752608623C78099CBDCFCCBDB3F96A3" xlink:to="loc_biib_ReimbursementUnderAmendedAgreementMethod_E664502ED6062B9EF56DFCCBDB3FD6E0" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_BaseRateAfterFirstCommercialSale" xlink:label="loc_biib_BaseRateAfterFirstCommercialSale_D44839A14833FCE53BD1FCCBDB3F7501" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ReimbursementUnderAmendedAgreementAmountsPayableAbstract_3752608623C78099CBDCFCCBDB3F96A3" xlink:to="loc_biib_BaseRateAfterFirstCommercialSale_D44839A14833FCE53BD1FCCBDB3F7501" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_RateDuringReimbursementPeriod" xlink:label="loc_biib_RateDuringReimbursementPeriod_7C48F47BAA151A887E11FCCBDB3F79A6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ReimbursementUnderAmendedAgreementAmountsPayableAbstract_3752608623C78099CBDCFCCBDB3F96A3" xlink:to="loc_biib_RateDuringReimbursementPeriod_7C48F47BAA151A887E11FCCBDB3F79A6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_41E962784A00BE4599E700324DCAAEAF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_83F11A9AA2E1B252D41B00324DCA6E29" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_41E962784A00BE4599E700324DCAAEAF" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_83F11A9AA2E1B252D41B00324DCA6E29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9BF9AA2B03E70FEC962200324DCB6F92" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_83F11A9AA2E1B252D41B00324DCA6E29" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9BF9AA2B03E70FEC962200324DCB6F92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6B488D7C781AC336320900324DCB5474" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9BF9AA2B03E70FEC962200324DCB6F92" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6B488D7C781AC336320900324DCB5474" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_InLicensedPatentsMember" xlink:label="loc_biib_InLicensedPatentsMember_A39CFC9ECB683CCC089100324DCBEAB9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6B488D7C781AC336320900324DCB5474" xlink:to="loc_biib_InLicensedPatentsMember_A39CFC9ECB683CCC089100324DCBEAB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_750A0FB44430DC047C8100324DCB79CA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_83F11A9AA2E1B252D41B00324DCA6E29" xlink:to="loc_us-gaap_StatementGeographicalAxis_750A0FB44430DC047C8100324DCB79CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_71BF79D567627B36FE1600324DCB6BBD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementGeographicalAxis_750A0FB44430DC047C8100324DCB79CA" xlink:to="loc_us-gaap_SegmentGeographicalDomain_71BF79D567627B36FE1600324DCB6BBD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd#country_US" xlink:label="loc_country_US_0F749EF60FCE4F7716B700324DCBE4AC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_71BF79D567627B36FE1600324DCB6BBD" xlink:to="loc_country_US_0F749EF60FCE4F7716B700324DCBE4AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember_E45CD6D0477B9C2CA4A300324DCB01B2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_71BF79D567627B36FE1600324DCB6BBD" xlink:to="loc_us-gaap_ForeignCountryMember_E45CD6D0477B9C2CA4A300324DCB01B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EuropeMember" xlink:label="loc_us-gaap_EuropeMember_E8477B18E3AC86F4D3BD00324DD0ACBB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_71BF79D567627B36FE1600324DCB6BBD" xlink:to="loc_us-gaap_EuropeMember_E8477B18E3AC86F4D3BD00324DD0ACBB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_A92CC2CE08C48D60E3DC00324DD06BC7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_83F11A9AA2E1B252D41B00324DCA6E29" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_A92CC2CE08C48D60E3DC00324DD06BC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_EC16ED80BEAA3751FD0D00324DD08A31" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_A92CC2CE08C48D60E3DC00324DD06BC7" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_EC16ED80BEAA3751FD0D00324DD08A31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaap_SalesRevenueNetMember_5D660DE5CAB20B8D191E00324DD07B87" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_EC16ED80BEAA3751FD0D00324DD08A31" xlink:to="loc_us-gaap_SalesRevenueNetMember_5D660DE5CAB20B8D191E00324DD07B87" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="loc_us-gaap_CostOfSalesMember_5320C9E11E1530B2BC6300324DD1DF6C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_EC16ED80BEAA3751FD0D00324DD08A31" xlink:to="loc_us-gaap_CostOfSalesMember_5320C9E11E1530B2BC6300324DD1DF6C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_E95895140AD94EADF44C00324DD107D4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_EC16ED80BEAA3751FD0D00324DD08A31" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_E95895140AD94EADF44C00324DD107D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_C9E1DEAC603022C9C9F400324DD1EDBB" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_EC16ED80BEAA3751FD0D00324DD08A31" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_C9E1DEAC603022C9C9F400324DD1EDBB" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_AdditionalProductsAxis" xlink:label="loc_biib_AdditionalProductsAxis_74422684264CE974068E00324DD122C0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_83F11A9AA2E1B252D41B00324DCA6E29" xlink:to="loc_biib_AdditionalProductsAxis_74422684264CE974068E00324DD122C0" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_AdditionalProductsDomain" xlink:label="loc_biib_AdditionalProductsDomain_C75638621B5D25F8E82400324DD1617A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_AdditionalProductsAxis_74422684264CE974068E00324DD122C0" xlink:to="loc_biib_AdditionalProductsDomain_C75638621B5D25F8E82400324DD1617A" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_NewAntiCd20Member" xlink:label="loc_biib_NewAntiCd20Member_18AE8EC249DE8BF1766600324DD1EBF7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_AdditionalProductsDomain_C75638621B5D25F8E82400324DD1617A" xlink:to="loc_biib_NewAntiCd20Member_18AE8EC249DE8BF1766600324DD1EBF7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_0995FC3D5831CC80831600324DD18A99" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_83F11A9AA2E1B252D41B00324DCA6E29" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_0995FC3D5831CC80831600324DD18A99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="loc_us-gaap_EquityMethodInvesteeNameDomain_BA64F908B187457F672900324DD128CB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_0995FC3D5831CC80831600324DD18A99" xlink:to="loc_us-gaap_EquityMethodInvesteeNameDomain_BA64F908B187457F672900324DD128CB" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_SamsungBiosimilarAgreementMember" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_BF251F7DD9F663C84AB700324DD21B6F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvesteeNameDomain_BA64F908B187457F672900324DD128CB" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_BF251F7DD9F663C84AB700324DD21B6F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_25746087DD181BDF7AD400324DD25624" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_83F11A9AA2E1B252D41B00324DCA6E29" xlink:to="loc_us-gaap_ProductOrServiceAxis_25746087DD181BDF7AD400324DD25624" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_E7F20544B2F02CC7FFCB00324DD2FAEF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductOrServiceAxis_25746087DD181BDF7AD400324DD25624" xlink:to="loc_us-gaap_ProductsAndServicesDomain_E7F20544B2F02CC7FFCB00324DD2FAEF" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_RituxanMember" xlink:label="loc_biib_RituxanMember_FB4F1ED3E65A3F74231400324DD2184B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_E7F20544B2F02CC7FFCB00324DD2FAEF" xlink:to="loc_biib_RituxanMember_FB4F1ED3E65A3F74231400324DD2184B" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_GAZYVAMember" xlink:label="loc_biib_GAZYVAMember_04E9F78DCDD9D8A0164900324DD23492" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_E7F20544B2F02CC7FFCB00324DD2FAEF" xlink:to="loc_biib_GAZYVAMember_04E9F78DCDD9D8A0164900324DD23492" xlink:type="arc" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_E7F20544B2F02CC7FFCB00324DD2FAEF" xlink:to="loc_biib_NewAntiCd20Member_18AE8EC249DE8BF1766600324DD1EBF7" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_OcrelizumabMember" xlink:label="loc_biib_OcrelizumabMember_404530F02145F035EAA300324DD22A7C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_E7F20544B2F02CC7FFCB00324DD2FAEF" xlink:to="loc_biib_OcrelizumabMember_404530F02145F035EAA300324DD22A7C" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ZINBRYTAMember" xlink:label="loc_biib_ZINBRYTAMember_F6D9425B6B1E3D56D8FD00324DD2B5A5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_E7F20544B2F02CC7FFCB00324DD2FAEF" xlink:to="loc_biib_ZINBRYTAMember_F6D9425B6B1E3D56D8FD00324DD2B5A5" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ELOCTATEMember" xlink:label="loc_biib_ELOCTATEMember_3ADEC812E75C9838CA5500324DD22723" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_E7F20544B2F02CC7FFCB00324DD2FAEF" xlink:to="loc_biib_ELOCTATEMember_3ADEC812E75C9838CA5500324DD22723" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ALPROLIXMember" xlink:label="loc_biib_ALPROLIXMember_74308065C231A2E3D9D800324DD24BE4" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_E7F20544B2F02CC7FFCB00324DD2FAEF" xlink:to="loc_biib_ALPROLIXMember_74308065C231A2E3D9D800324DD24BE4" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_SPINRAZAMember" xlink:label="loc_biib_SPINRAZAMember_4C0A4712FA47DEDB8C8800324DD2B9F0" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_E7F20544B2F02CC7FFCB00324DD2FAEF" xlink:to="loc_biib_SPINRAZAMember_4C0A4712FA47DEDB8C8800324DD2B9F0" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_SOD1Member" xlink:label="loc_biib_SOD1Member_979693D25EBCC47B156900324DD36CFC" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_E7F20544B2F02CC7FFCB00324DD2FAEF" xlink:to="loc_biib_SOD1Member_979693D25EBCC47B156900324DD36CFC" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_DMPKMember" xlink:label="loc_biib_DMPKMember_CFCE29079AC59A436DD700324DD34D71" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_E7F20544B2F02CC7FFCB00324DD2FAEF" xlink:to="loc_biib_DMPKMember_CFCE29079AC59A436DD700324DD34D71" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_LeadprogramsMember" xlink:label="loc_biib_LeadprogramsMember_8574A41E9F896F6B5A1800324DD39546" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_E7F20544B2F02CC7FFCB00324DD2FAEF" xlink:to="loc_biib_LeadprogramsMember_8574A41E9F896F6B5A1800324DD39546" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_DiscoveryprogramsMember" xlink:label="loc_biib_DiscoveryprogramsMember_E697510F3EA7F15431C500324DD3F580" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_E7F20544B2F02CC7FFCB00324DD2FAEF" xlink:to="loc_biib_DiscoveryprogramsMember_E697510F3EA7F15431C500324DD3F580" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_BiosimilarsMember" xlink:label="loc_biib_BiosimilarsMember_ADCD38E2FF68E371DACA00324DD3533A" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_E7F20544B2F02CC7FFCB00324DD2FAEF" xlink:to="loc_biib_BiosimilarsMember_ADCD38E2FF68E371DACA00324DD3533A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_9E704D9DBDBF3BF1FE8000324DD37E7B" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_83F11A9AA2E1B252D41B00324DCA6E29" xlink:to="loc_us-gaap_TypeOfArrangementAxis_9E704D9DBDBF3BF1FE8000324DD37E7B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_BEB6C3837D1E6F5A3EB000324DD34692" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_9E704D9DBDBF3BF1FE8000324DD37E7B" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_BEB6C3837D1E6F5A3EB000324DD34692" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_RocheGroupGenentechMember" xlink:label="loc_biib_RocheGroupGenentechMember_2A98A4A6553C4185DFF700324DD3912B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_BEB6C3837D1E6F5A3EB000324DD34692" xlink:to="loc_biib_RocheGroupGenentechMember_2A98A4A6553C4185DFF700324DD3912B" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_AcordaMember" xlink:label="loc_biib_AcordaMember_F0C5FC1F383F3FCA9F3400324DD3705C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_BEB6C3837D1E6F5A3EB000324DD34692" xlink:to="loc_biib_AcordaMember_F0C5FC1F383F3FCA9F3400324DD3705C" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_AbbVieMember" xlink:label="loc_biib_AbbVieMember_F57E7CE71593D3CBB6DE00324DD8DC14" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_BEB6C3837D1E6F5A3EB000324DD34692" xlink:to="loc_biib_AbbVieMember_F57E7CE71593D3CBB6DE00324DD8DC14" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_SwedishOrphanBiovitrumMember" xlink:label="loc_biib_SwedishOrphanBiovitrumMember_CFF749ECE4A5DC222F6A00324DD82147" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_BEB6C3837D1E6F5A3EB000324DD34692" xlink:to="loc_biib_SwedishOrphanBiovitrumMember_CFF749ECE4A5DC222F6A00324DD82147" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_IonisPharmaceuticalsMember" xlink:label="loc_biib_IonisPharmaceuticalsMember_9B0BE632DEB5B4EDA98700324DD87277" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_BEB6C3837D1E6F5A3EB000324DD34692" xlink:to="loc_biib_IonisPharmaceuticalsMember_9B0BE632DEB5B4EDA98700324DD87277" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_EisaiMember" xlink:label="loc_biib_EisaiMember_097BCEA9C7B9AB31BAFA00324DD8F253" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_BEB6C3837D1E6F5A3EB000324DD34692" xlink:to="loc_biib_EisaiMember_097BCEA9C7B9AB31BAFA00324DD8F253" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_AGTCMember" xlink:label="loc_biib_AGTCMember_4AB37C498E34121983D100324DD8C619" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_BEB6C3837D1E6F5A3EB000324DD34692" xlink:to="loc_biib_AGTCMember_4AB37C498E34121983D100324DD8C619" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_UniversityofPennsylvaniaMember" xlink:label="loc_biib_UniversityofPennsylvaniaMember_30D7BCA7EC9D29C0130700324DD9EC5D" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_BEB6C3837D1E6F5A3EB000324DD34692" xlink:to="loc_biib_UniversityofPennsylvaniaMember_30D7BCA7EC9D29C0130700324DD9EC5D" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_SangamoBioSciencesMember" xlink:label="loc_biib_SangamoBioSciencesMember_25F4D8CA2177B310FE8900324DD95135" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_BEB6C3837D1E6F5A3EB000324DD34692" xlink:to="loc_biib_SangamoBioSciencesMember_25F4D8CA2177B310FE8900324DD95135" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_MitsubishiTanabePharmaCorporationMember" xlink:label="loc_biib_MitsubishiTanabePharmaCorporationMember_F4D28A9293E5ECE26F4600324DD9D8A7" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_BEB6C3837D1E6F5A3EB000324DD34692" xlink:to="loc_biib_MitsubishiTanabePharmaCorporationMember_F4D28A9293E5ECE26F4600324DD9D8A7" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_OtherresearchanddiscoveryMember" xlink:label="loc_biib_OtherresearchanddiscoveryMember_93DB9A2685A190A9488200324DD9329D" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_BEB6C3837D1E6F5A3EB000324DD34692" xlink:to="loc_biib_OtherresearchanddiscoveryMember_93DB9A2685A190A9488200324DD9329D" xlink:type="arc" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_BEB6C3837D1E6F5A3EB000324DD34692" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_BF251F7DD9F663C84AB700324DD21B6F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_80BFB9B1C7A6C7AACC9200324DD90524" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_83F11A9AA2E1B252D41B00324DCA6E29" xlink:to="loc_us-gaap_RangeAxis_80BFB9B1C7A6C7AACC9200324DD90524" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_5D863C2192BB1A280D2700324DD95D6C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_80BFB9B1C7A6C7AACC9200324DD90524" xlink:to="loc_us-gaap_RangeMember_5D863C2192BB1A280D2700324DD95D6C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_880A9AFBD6FC615C9AA900324DD93522" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_5D863C2192BB1A280D2700324DD95D6C" xlink:to="loc_us-gaap_MinimumMember_880A9AFBD6FC615C9AA900324DD93522" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_16F191A93001216B20B000324DD9079F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_5D863C2192BB1A280D2700324DD95D6C" xlink:to="loc_us-gaap_MaximumMember_16F191A93001216B20B000324DD9079F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_99096B337C7CF3A1BE1000324DD9D6F6" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_83F11A9AA2E1B252D41B00324DCA6E29" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_99096B337C7CF3A1BE1000324DD9D6F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_23A578236E5C977EFC1800324DDA2887" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_99096B337C7CF3A1BE1000324DD9D6F6" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_23A578236E5C977EFC1800324DDA2887" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_BiogenIdecHemophiliaMember" xlink:label="loc_biib_BiogenIdecHemophiliaMember_4DA3E4E00A0D9AB9744300324DDA0DA9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_23A578236E5C977EFC1800324DDA2887" xlink:to="loc_biib_BiogenIdecHemophiliaMember_4DA3E4E00A0D9AB9744300324DDA0DA9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8500CE652AEB38DB084C00324DDA4806" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_83F11A9AA2E1B252D41B00324DCA6E29" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8500CE652AEB38DB084C00324DDA4806" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_Biogeneffectiveroyaltyrate" xlink:label="loc_biib_Biogeneffectiveroyaltyrate_F8BBA80074C61031E3FB00324DDA8F61" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8500CE652AEB38DB084C00324DDA4806" xlink:to="loc_biib_Biogeneffectiveroyaltyrate_F8BBA80074C61031E3FB00324DDA8F61" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_CollaborationsTextualAbstract" xlink:label="loc_biib_CollaborationsTextualAbstract_77B6CB9A30BA7410DA2800324DDA5228" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8500CE652AEB38DB084C00324DDA4806" xlink:to="loc_biib_CollaborationsTextualAbstract_77B6CB9A30BA7410DA2800324DDA5228" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct" xlink:label="loc_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_3527DD33D244067D81C300324DDA3817" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_77B6CB9A30BA7410DA2800324DDA5228" xlink:to="loc_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_3527DD33D244067D81C300324DDA3817" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_Reductioninroyaltyrate" xlink:label="loc_biib_Reductioninroyaltyrate_90988B2EEB2DC40C960300324DDAA555" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_77B6CB9A30BA7410DA2800324DDA5228" xlink:to="loc_biib_Reductioninroyaltyrate_90988B2EEB2DC40C960300324DDAA555" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_PeriodOfCollaborationAgreement" xlink:label="loc_biib_PeriodOfCollaborationAgreement_9AA9CF475DC0BD381C0700324DDAB86A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_77B6CB9A30BA7410DA2800324DDA5228" xlink:to="loc_biib_PeriodOfCollaborationAgreement_9AA9CF475DC0BD381C0700324DDAB86A" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_DE47CF2AD4047A0869BC00324DDA2799" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_77B6CB9A30BA7410DA2800324DDA5228" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_DE47CF2AD4047A0869BC00324DDA2799" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" xlink:label="loc_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_9AC0EEDD08A40C73D71800324DDA9AFC" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_77B6CB9A30BA7410DA2800324DDA5228" xlink:to="loc_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_9AC0EEDD08A40C73D71800324DDA9AFC" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne" xlink:label="loc_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_A8CE0B9D1C7AD331083B00324DDA4A12" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_77B6CB9A30BA7410DA2800324DDA5228" xlink:to="loc_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_A8CE0B9D1C7AD331083B00324DDA4A12" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne" xlink:label="loc_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_90F2A898F7178B3EED3000324DDB1B09" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_77B6CB9A30BA7410DA2800324DDA5228" xlink:to="loc_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_90F2A898F7178B3EED3000324DDB1B09" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_SalesTriggerGrossSalesThreshold" xlink:label="loc_biib_SalesTriggerGrossSalesThreshold_D80AAAC27B4CA3F9288C00324DDB6EC3" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_77B6CB9A30BA7410DA2800324DDA5228" xlink:to="loc_biib_SalesTriggerGrossSalesThreshold_D80AAAC27B4CA3F9288C00324DDB6EC3" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_Futurepercentageofcopromotionoperatingprofits" xlink:label="loc_biib_Futurepercentageofcopromotionoperatingprofits_630C4EAEF3E53229614B00324DDB8375" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_77B6CB9A30BA7410DA2800324DDA5228" xlink:to="loc_biib_Futurepercentageofcopromotionoperatingprofits_630C4EAEF3E53229614B00324DDB8375" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_PercentageOfCoPromotionOperatingLosses" xlink:label="loc_biib_PercentageOfCoPromotionOperatingLosses_1DF59DD3C200469B1F1600324DDBFC76" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_77B6CB9A30BA7410DA2800324DDA5228" xlink:to="loc_biib_PercentageOfCoPromotionOperatingLosses_1DF59DD3C200469B1F1600324DDBFC76" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ShareOfCoPromotionProfits" xlink:label="loc_biib_ShareOfCoPromotionProfits_9C3DEAC96FE3008073AE00324DDBA43B" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_77B6CB9A30BA7410DA2800324DDA5228" xlink:to="loc_biib_ShareOfCoPromotionProfits_9C3DEAC96FE3008073AE00324DDBA43B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_C1059B7306DF6572489900324DDBDD8A" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_77B6CB9A30BA7410DA2800324DDA5228" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_C1059B7306DF6572489900324DDBDD8A" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillion" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillion_50C192F6DB2CE13DC04600324DDB87A5" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_77B6CB9A30BA7410DA2800324DDA5228" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillion_50C192F6DB2CE13DC04600324DDB87A5" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ExpectedAdditionalMilestonePaymentsOnSuccessfulAchievementOfRegulatoryAndCommercialSalesMilestones" xlink:label="loc_biib_ExpectedAdditionalMilestonePaymentsOnSuccessfulAchievementOfRegulatoryAndCommercialSalesMilestones_4458AFD1322B607B83D900324DDB2AA7" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_77B6CB9A30BA7410DA2800324DDA5228" xlink:to="loc_biib_ExpectedAdditionalMilestonePaymentsOnSuccessfulAchievementOfRegulatoryAndCommercialSalesMilestones_4458AFD1322B607B83D900324DDB2AA7" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold" xlink:label="loc_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold_4EFD3D2323A8653C5F0C00324DDBB2D6" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_77B6CB9A30BA7410DA2800324DDA5228" xlink:to="loc_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold_4EFD3D2323A8653C5F0C00324DDBB2D6" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ForeignSalesRequiredToTriggerMilestone" xlink:label="loc_biib_ForeignSalesRequiredToTriggerMilestone_8ADC23FCB12FA4F33DA900324DDB1912" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_77B6CB9A30BA7410DA2800324DDA5228" xlink:to="loc_biib_ForeignSalesRequiredToTriggerMilestone_8ADC23FCB12FA4F33DA900324DDB1912" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ExpenseReflectedWithinStatementsOfIncome" xlink:label="loc_biib_ExpenseReflectedWithinStatementsOfIncome_EE20D7686732BBE9366B00324DE02A50" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_77B6CB9A30BA7410DA2800324DDA5228" xlink:to="loc_biib_ExpenseReflectedWithinStatementsOfIncome_EE20D7686732BBE9366B00324DE02A50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_D22A63805907E2D34ADF00324DE0221B" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_77B6CB9A30BA7410DA2800324DDA5228" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_D22A63805907E2D34ADF00324DE0221B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_8C5D906AA0B920A9ACF700324DE01BA8" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_77B6CB9A30BA7410DA2800324DDA5228" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_8C5D906AA0B920A9ACF700324DE01BA8" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ConsiderationPerProductDeveloped" xlink:label="loc_biib_ConsiderationPerProductDeveloped_3E421C6B325C6616DB6600324DE0C64A" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_77B6CB9A30BA7410DA2800324DDA5228" xlink:to="loc_biib_ConsiderationPerProductDeveloped_3E421C6B325C6616DB6600324DE0C64A" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ReimbursementCostAchievingPeriod" xlink:label="loc_biib_ReimbursementCostAchievingPeriod_D6335F0418B321A856EF00324DE07AC1" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_77B6CB9A30BA7410DA2800324DDA5228" xlink:to="loc_biib_ReimbursementCostAchievingPeriod_D6335F0418B321A856EF00324DE07AC1" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_TimePeriodForPayingRemainingBalanceDue" xlink:label="loc_biib_TimePeriodForPayingRemainingBalanceDue_4BAB6D58A857BEA2378800324DE19069" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_77B6CB9A30BA7410DA2800324DDA5228" xlink:to="loc_biib_TimePeriodForPayingRemainingBalanceDue_4BAB6D58A857BEA2378800324DE19069" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_D0C9445048DD9CCDB8BD00324DE1BD34" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_77B6CB9A30BA7410DA2800324DDA5228" xlink:to="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_D0C9445048DD9CCDB8BD00324DE1BD34" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_DBEAD684EA24A72B73DA00324DE1C4DD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8500CE652AEB38DB084C00324DDA4806" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_DBEAD684EA24A72B73DA00324DE1C4DD" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_1EC8215D31D9BCF042DB00324DE13634" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8500CE652AEB38DB084C00324DDA4806" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_1EC8215D31D9BCF042DB00324DE13634" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_5A21B6843D8A93A6FF2D00324DE1E34C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8500CE652AEB38DB084C00324DDA4806" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_5A21B6843D8A93A6FF2D00324DE1E34C" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ExpenseIncurredByCollaboration" xlink:label="loc_biib_ExpenseIncurredByCollaboration_5F763A9CD5B07A71AF9300324DE140D8" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8500CE652AEB38DB084C00324DDA4806" xlink:to="loc_biib_ExpenseIncurredByCollaboration_5F763A9CD5B07A71AF9300324DE140D8" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_Biogenshareofcopromotionprofitsorlosses" xlink:label="loc_biib_Biogenshareofcopromotionprofitsorlosses_2663182AD7A449ACAE6E00324DE1CEA9" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8500CE652AEB38DB084C00324DDA4806" xlink:to="loc_biib_Biogenshareofcopromotionprofitsorlosses_2663182AD7A449ACAE6E00324DE1CEA9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherSalesRevenueNet" xlink:label="loc_us-gaap_OtherSalesRevenueNet_D910D345D98E68C3E8D800324DE13F8A" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8500CE652AEB38DB084C00324DDA4806" xlink:to="loc_us-gaap_OtherSalesRevenueNet_D910D345D98E68C3E8D800324DE13F8A" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_Collaborationprofitlosssharing" xlink:label="loc_biib_Collaborationprofitlosssharing_2ABF537BC43F84A7580100324DE1826E" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8500CE652AEB38DB084C00324DDA4806" xlink:to="loc_biib_Collaborationprofitlosssharing_2ABF537BC43F84A7580100324DE1826E" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_Termofcollaborationagreement" xlink:label="loc_biib_Termofcollaborationagreement_C2B4FBE56DB41C96FD1200324DE19CB6" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8500CE652AEB38DB084C00324DDA4806" xlink:to="loc_biib_Termofcollaborationagreement_C2B4FBE56DB41C96FD1200324DE19CB6" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:label="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_536A518791C22AB1104300324DE11B61" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8500CE652AEB38DB084C00324DDA4806" xlink:to="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_536A518791C22AB1104300324DE11B61" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_1CBED0CFEAF65F9CB0BE00324DE1E538" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8500CE652AEB38DB084C00324DDA4806" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssets_1CBED0CFEAF65F9CB0BE00324DE1E538" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_LicenseFee" xlink:label="loc_biib_LicenseFee_A0CFE3932900F1657BEC00324DE15392" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8500CE652AEB38DB084C00324DDA4806" xlink:to="loc_biib_LicenseFee_A0CFE3932900F1657BEC00324DE15392" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments" xlink:label="loc_biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments_B4D8C5EA889F6C16E1BB00324DE2037F" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8500CE652AEB38DB084C00324DDA4806" xlink:to="loc_biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments_B4D8C5EA889F6C16E1BB00324DE2037F" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_Additionalmilestonepaymentsforproductcandidateusingadifferentmodality" xlink:label="loc_biib_Additionalmilestonepaymentsforproductcandidateusingadifferentmodality_3923CDAE5F1D5A8CE13B00324DE2B6E0" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8500CE652AEB38DB084C00324DDA4806" xlink:to="loc_biib_Additionalmilestonepaymentsforproductcandidateusingadifferentmodality_3923CDAE5F1D5A8CE13B00324DE2B6E0" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_AdditionalMilestonePayment" xlink:label="loc_biib_AdditionalMilestonePayment_E2E88E157D7F29F7C87500324DE2CE01" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8500CE652AEB38DB084C00324DDA4806" xlink:to="loc_biib_AdditionalMilestonePayment_E2E88E157D7F29F7C87500324DE2CE01" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_LiabilityForFairValueOfOptionsGrantedUnderAgreement" xlink:label="loc_biib_LiabilityForFairValueOfOptionsGrantedUnderAgreement_51EBA597E391D6EDE5EE00324DE206E5" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8500CE652AEB38DB084C00324DDA4806" xlink:to="loc_biib_LiabilityForFairValueOfOptionsGrantedUnderAgreement_51EBA597E391D6EDE5EE00324DE206E5" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_MilestonePaymentsMadeDuringPeriod" xlink:label="loc_biib_MilestonePaymentsMadeDuringPeriod_F2527F2DCDA44D8055E800324DE20416" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8500CE652AEB38DB084C00324DDA4806" xlink:to="loc_biib_MilestonePaymentsMadeDuringPeriod_F2527F2DCDA44D8055E800324DE20416" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_Purchaseofcommonstock" xlink:label="loc_biib_Purchaseofcommonstock_249C20275405AA0E721A00324DE2BAD5" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8500CE652AEB38DB084C00324DDA4806" xlink:to="loc_biib_Purchaseofcommonstock_249C20275405AA0E721A00324DE2BAD5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LicenseCosts" xlink:label="loc_us-gaap_LicenseCosts_ED9A445A208C875E7D4900324DE28F6A" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8500CE652AEB38DB084C00324DDA4806" xlink:to="loc_us-gaap_LicenseCosts_ED9A445A208C875E7D4900324DE28F6A" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_Researchanddevelopmentservices" xlink:label="loc_biib_Researchanddevelopmentservices_8C46E510086ACD5EAFAC00324DE2F46D" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8500CE652AEB38DB084C00324DDA4806" xlink:to="loc_biib_Researchanddevelopmentservices_8C46E510086ACD5EAFAC00324DE2F46D" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_Premiumonequityinvestment" xlink:label="loc_biib_Premiumonequityinvestment_D9D020046C9C59946EBC00324DE2E4F6" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8500CE652AEB38DB084C00324DDA4806" xlink:to="loc_biib_Premiumonequityinvestment_D9D020046C9C59946EBC00324DE2E4F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_F7E55C2A28A43E701BA700324DE21A4D" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8500CE652AEB38DB084C00324DDA4806" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_F7E55C2A28A43E701BA700324DE21A4D" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_Futureresearchanddevelopmentcommitment" xlink:label="loc_biib_Futureresearchanddevelopmentcommitment_5241B29C582E8D603E7E00324DE22676" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8500CE652AEB38DB084C00324DDA4806" xlink:to="loc_biib_Futureresearchanddevelopmentcommitment_5241B29C582E8D603E7E00324DE22676" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_635065C50F261783F48F00324DE29844" xlink:type="locator" />
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8500CE652AEB38DB084C00324DDA4806" xlink:to="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_635065C50F261783F48F00324DE29844" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement" xlink:label="loc_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_CF61670E1DEA0DE5C64200324DE2F7D5" xlink:type="locator" />
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8500CE652AEB38DB084C00324DDA4806" xlink:to="loc_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_CF61670E1DEA0DE5C64200324DE2F7D5" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_JointVentureOwnerShipPercentageByThirdParty" xlink:label="loc_biib_JointVentureOwnerShipPercentageByThirdParty_FEC319DD1A2485F7937D00324DE3767C" xlink:type="locator" />
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8500CE652AEB38DB084C00324DDA4806" xlink:to="loc_biib_JointVentureOwnerShipPercentageByThirdParty_FEC319DD1A2485F7937D00324DE3767C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_4FF82632107F0293166600324DE389B6" xlink:type="locator" />
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8500CE652AEB38DB084C00324DDA4806" xlink:to="loc_us-gaap_EquityMethodInvestments_4FF82632107F0293166600324DE389B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_FA6D2531D7294ED5324F00324DE31B81" xlink:type="locator" />
    <link:presentationArc order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8500CE652AEB38DB084C00324DDA4806" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_FA6D2531D7294ED5324F00324DE31B81" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_EquityMethodInvestmentOwnershipPercentageMaximum" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageMaximum_DAA75F3E6E807D80566900324DE31FDF" xlink:type="locator" />
    <link:presentationArc order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8500CE652AEB38DB084C00324DDA4806" xlink:to="loc_biib_EquityMethodInvestmentOwnershipPercentageMaximum_DAA75F3E6E807D80566900324DE31FDF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_C77E6B4454DCC78F0C5000324DE37A71" xlink:type="locator" />
    <link:presentationArc order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8500CE652AEB38DB084C00324DDA4806" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_C77E6B4454DCC78F0C5000324DE37A71" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_EquityMethodInvestmentsExpectedProfitShare" xlink:label="loc_biib_EquityMethodInvestmentsExpectedProfitShare_B9ADC2A21EB64914C9C500324DE38086" xlink:type="locator" />
    <link:presentationArc order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8500CE652AEB38DB084C00324DDA4806" xlink:to="loc_biib_EquityMethodInvestmentsExpectedProfitShare_B9ADC2A21EB64914C9C500324DE38086" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_143BE5C7BDBBBCB9CFCDD6D80C658446" xlink:type="locator" />
    <link:loc xlink:href="biib-20161231.xsd#biib_CoPromotionProfitSharingFormulaTableTextBlock" xlink:label="loc_biib_CoPromotionProfitSharingFormulaTableTextBlock_869996A6E20420520A13D6D80C65F8BC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_143BE5C7BDBBBCB9CFCDD6D80C658446" xlink:to="loc_biib_CoPromotionProfitSharingFormulaTableTextBlock_869996A6E20420520A13D6D80C65F8BC" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_PretaxProfitSharingFormulaTableTextBlock" xlink:label="loc_biib_PretaxProfitSharingFormulaTableTextBlock_988303FB6EC24990D50FD6D80C65B6A5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_143BE5C7BDBBBCB9CFCDD6D80C658446" xlink:to="loc_biib_PretaxProfitSharingFormulaTableTextBlock_988303FB6EC24990D50FD6D80C65B6A5" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_RevenuesFromUnconsolidatedJointBusinessTableTextBlock" xlink:label="loc_biib_RevenuesFromUnconsolidatedJointBusinessTableTextBlock_F191D80D1C1004DEA0B4D6D80C65A040" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_143BE5C7BDBBBCB9CFCDD6D80C658446" xlink:to="loc_biib_RevenuesFromUnconsolidatedJointBusinessTableTextBlock_F191D80D1C1004DEA0B4D6D80C65A040" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ReimbursementUnderAmendedAgreementAmountsPayableTableTextBlock" xlink:label="loc_biib_ReimbursementUnderAmendedAgreementAmountsPayableTableTextBlock_03A6B37655C26F6D3A00D6D80C656EE9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_143BE5C7BDBBBCB9CFCDD6D80C658446" xlink:to="loc_biib_ReimbursementUnderAmendedAgreementAmountsPayableTableTextBlock_03A6B37655C26F6D3A00D6D80C656EE9" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_SummaryOfActivityRelatedToCollaborationWithCompanySevenTableTextBlock" xlink:label="loc_biib_SummaryOfActivityRelatedToCollaborationWithCompanySevenTableTextBlock_0C201848E3DDD15DF183D6D80C658ECB" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_143BE5C7BDBBBCB9CFCDD6D80C658446" xlink:to="loc_biib_SummaryOfActivityRelatedToCollaborationWithCompanySevenTableTextBlock_0C201848E3DDD15DF183D6D80C658ECB" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock" xlink:label="loc_biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock_14760211647C293785B7D6D80C651A7B" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_143BE5C7BDBBBCB9CFCDD6D80C658446" xlink:to="loc_biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock_14760211647C293785B7D6D80C651A7B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CommitmentsAndContingencies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_24BB4DFCDDBF049B0A5D741285C84794" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_9410AB11770103BE3DBB741285C8A311" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_24BB4DFCDDBF049B0A5D741285C84794" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_9410AB11770103BE3DBB741285C8A311" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CommitmentsAndContingenciesCommitmentsAndContingenciesDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_D8571DDA0FD9E9CA6E67FCCBDB08BD27" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_C601848522D0FD08508CFCCBDB08078D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_D8571DDA0FD9E9CA6E67FCCBDB08BD27" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_C601848522D0FD08508CFCCBDB08078D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_5AF9F70C229C82284191FCCBDB08D779" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_D8571DDA0FD9E9CA6E67FCCBDB08BD27" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_5AF9F70C229C82284191FCCBDB08D779" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDue_ABA7C901EFE234F86D4CFCCBDB08BD9C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_D8571DDA0FD9E9CA6E67FCCBDB08BD27" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDue_ABA7C901EFE234F86D4CFCCBDB08BD9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments_B502AE9617ECB046EC34FCCBDB083B83" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_D8571DDA0FD9E9CA6E67FCCBDB08BD27" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments_B502AE9617ECB046EC34FCCBDB083B83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments_BED88C35F6FEBD234766FCCBDB08AE0A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_D8571DDA0FD9E9CA6E67FCCBDB08BD27" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments_BED88C35F6FEBD234766FCCBDB08AE0A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CommitmentsAndContingenciesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_79DE1ECDE1867B18AC6EFCCBDB110926" xlink:type="locator" />
    <link:loc xlink:href="biib-20161231.xsd#biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract" xlink:label="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_BD09442F3C0EB9A54D86FCCBDB1182F9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_79DE1ECDE1867B18AC6EFCCBDB110926" xlink:to="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_BD09442F3C0EB9A54D86FCCBDB1182F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_3BA706F6C55680FDE605FCCBDB12E123" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_BD09442F3C0EB9A54D86FCCBDB1182F9" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_3BA706F6C55680FDE605FCCBDB12E123" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_EF49597FC0B80C186853FCCBDB1206DF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_BD09442F3C0EB9A54D86FCCBDB1182F9" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_EF49597FC0B80C186853FCCBDB1206DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_EEC0E54505AC7247780BFCCBDB126316" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_BD09442F3C0EB9A54D86FCCBDB1182F9" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_EEC0E54505AC7247780BFCCBDB126316" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_EEC1923A1588BEF0CEFEFCCBDB125C85" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_BD09442F3C0EB9A54D86FCCBDB1182F9" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_EEC1923A1588BEF0CEFEFCCBDB125C85" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_B770D8638394C03E35ADFCCBDB12E7C1" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_BD09442F3C0EB9A54D86FCCBDB1182F9" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_B770D8638394C03E35ADFCCBDB12E7C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_0D8237DC63B31443DB5BFCCBDB124496" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_BD09442F3C0EB9A54D86FCCBDB1182F9" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_0D8237DC63B31443DB5BFCCBDB124496" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_381FE6E685D46EA38891FCCBDB12390D" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_BD09442F3C0EB9A54D86FCCBDB1182F9" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_381FE6E685D46EA38891FCCBDB12390D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_665D61F6138B179FC2EAFCCBDB1238D8" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_BD09442F3C0EB9A54D86FCCBDB1182F9" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_665D61F6138B179FC2EAFCCBDB1238D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_022D2C9D6570691FFD59FCCBDB123FD4" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_BD09442F3C0EB9A54D86FCCBDB1182F9" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_022D2C9D6570691FFD59FCCBDB123FD4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_9523C8FDA1A1ED2292ADFCCBDB124130" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_BD09442F3C0EB9A54D86FCCBDB1182F9" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_9523C8FDA1A1ED2292ADFCCBDB124130" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_14C8E6D79E1C6047183CFCCBDB128136" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_BD09442F3C0EB9A54D86FCCBDB1182F9" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_14C8E6D79E1C6047183CFCCBDB128136" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_B748E0ADD7A4B7036744FCCBDB124C5F" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_BD09442F3C0EB9A54D86FCCBDB1182F9" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_B748E0ADD7A4B7036744FCCBDB124C5F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_B8C1181999B741436D78FCCBDB12F60C" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_BD09442F3C0EB9A54D86FCCBDB1182F9" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_B8C1181999B741436D78FCCBDB12F60C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_0A38B9FA6C1A4D896B76FCCBDB12BCEF" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_BD09442F3C0EB9A54D86FCCBDB1182F9" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_0A38B9FA6C1A4D896B76FCCBDB12BCEF" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_NetMinimumLeasePaymentsWithInOneYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInOneYear_DC7230A433E4957FC2FDFCCBDB1254DB" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_BD09442F3C0EB9A54D86FCCBDB1182F9" xlink:to="loc_biib_NetMinimumLeasePaymentsWithInOneYear_DC7230A433E4957FC2FDFCCBDB1254DB" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_NetMinimumLeasePaymentsWithInTwoYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInTwoYear_DB4B939286D7930F885CFCCBDB127751" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_BD09442F3C0EB9A54D86FCCBDB1182F9" xlink:to="loc_biib_NetMinimumLeasePaymentsWithInTwoYear_DB4B939286D7930F885CFCCBDB127751" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_NetMinimumLeasePaymentsWithInThreeYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInThreeYear_3776589AD4DCDA250691FCCBDB137165" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_BD09442F3C0EB9A54D86FCCBDB1182F9" xlink:to="loc_biib_NetMinimumLeasePaymentsWithInThreeYear_3776589AD4DCDA250691FCCBDB137165" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_NetMinimumLeasePaymentsWithInFourYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInFourYear_E7F180FB4168C0BF8504FCCBDB130ED9" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_BD09442F3C0EB9A54D86FCCBDB1182F9" xlink:to="loc_biib_NetMinimumLeasePaymentsWithInFourYear_E7F180FB4168C0BF8504FCCBDB130ED9" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_NetMinimumLeasePaymentsWithInFiveYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInFiveYear_B6F4E54D28C88EA6DA78FCCBDB130B00" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_BD09442F3C0EB9A54D86FCCBDB1182F9" xlink:to="loc_biib_NetMinimumLeasePaymentsWithInFiveYear_B6F4E54D28C88EA6DA78FCCBDB130B00" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_NetMinimumLeasePaymentsThereafter" xlink:label="loc_biib_NetMinimumLeasePaymentsThereafter_9176C0DC5938574116BBFCCBDB133E38" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_BD09442F3C0EB9A54D86FCCBDB1182F9" xlink:to="loc_biib_NetMinimumLeasePaymentsThereafter_9176C0DC5938574116BBFCCBDB133E38" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_NetMinimumLeasePayments" xlink:label="loc_biib_NetMinimumLeasePayments_8253FE7EF3E20B152CF9FCCBDB13FA05" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_BD09442F3C0EB9A54D86FCCBDB1182F9" xlink:to="loc_biib_NetMinimumLeasePayments_8253FE7EF3E20B152CF9FCCBDB13FA05" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CommitmentsAndContingenciesDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0B7D44DAE8AA68B3DB88FCCBDB000B0A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_54814CBF69A87D818242FCCBDB001A9D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0B7D44DAE8AA68B3DB88FCCBDB000B0A" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_54814CBF69A87D818242FCCBDB001A9D" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_FutureContingentMilestoneTypesAxis" xlink:label="loc_biib_FutureContingentMilestoneTypesAxis_5FF89936066A288377E5FCCBDB018D9E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_54814CBF69A87D818242FCCBDB001A9D" xlink:to="loc_biib_FutureContingentMilestoneTypesAxis_5FF89936066A288377E5FCCBDB018D9E" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_FutureContingentMilestoneTypesDomain" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_A2F87FF556DD670E99E8FCCBDB01692E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_5FF89936066A288377E5FCCBDB018D9E" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_A2F87FF556DD670E99E8FCCBDB01692E" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_DevelopmentMilestonesMember" xlink:label="loc_biib_DevelopmentMilestonesMember_3965AD6BCF8A16F3727AFCCBDB01E682" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_A2F87FF556DD670E99E8FCCBDB01692E" xlink:to="loc_biib_DevelopmentMilestonesMember_3965AD6BCF8A16F3727AFCCBDB01E682" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_RegulatoryMilestonesMember" xlink:label="loc_biib_RegulatoryMilestonesMember_0CD9D5E266FDC9D4C84DFCCBDB02C17C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_A2F87FF556DD670E99E8FCCBDB01692E" xlink:to="loc_biib_RegulatoryMilestonesMember_0CD9D5E266FDC9D4C84DFCCBDB02C17C" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_CommercialMilestonesMember" xlink:label="loc_biib_CommercialMilestonesMember_4AB828CEF55151D5B1B0FCCBDB02206E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_A2F87FF556DD670E99E8FCCBDB01692E" xlink:to="loc_biib_CommercialMilestonesMember_4AB828CEF55151D5B1B0FCCBDB02206E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_D590FC76B6CCFBD15FF0FCCBDB008ADA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_54814CBF69A87D818242FCCBDB001A9D" xlink:to="loc_us-gaap_StatementGeographicalAxis_D590FC76B6CCFBD15FF0FCCBDB008ADA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_791D9BB5460B8A07E1C4FCCBDB004413" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementGeographicalAxis_D590FC76B6CCFBD15FF0FCCBDB008ADA" xlink:to="loc_us-gaap_SegmentGeographicalDomain_791D9BB5460B8A07E1C4FCCBDB004413" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd#country_US" xlink:label="loc_country_US_626133589F752EB96A0FFCCBDB012FBB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_791D9BB5460B8A07E1C4FCCBDB004413" xlink:to="loc_country_US_626133589F752EB96A0FFCCBDB012FBB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EuropeanUnionMember" xlink:label="loc_us-gaap_EuropeanUnionMember_64E9420A8F4E79A2B0DCFCCBDB01937C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_791D9BB5460B8A07E1C4FCCBDB004413" xlink:to="loc_us-gaap_EuropeanUnionMember_64E9420A8F4E79A2B0DCFCCBDB01937C" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_CumulativeSalesLevelAxis" xlink:label="loc_biib_CumulativeSalesLevelAxis_5DA6BB9546DA847D079DFCCBDB023514" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_54814CBF69A87D818242FCCBDB001A9D" xlink:to="loc_biib_CumulativeSalesLevelAxis_5DA6BB9546DA847D079DFCCBDB023514" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_CumulativeSalesLevelDomain" xlink:label="loc_biib_CumulativeSalesLevelDomain_685C71E853F24FEDCC9AFCCBDB02CCF0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CumulativeSalesLevelAxis_5DA6BB9546DA847D079DFCCBDB023514" xlink:to="loc_biib_CumulativeSalesLevelDomain_685C71E853F24FEDCC9AFCCBDB02CCF0" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_TenbillionMember" xlink:label="loc_biib_TenbillionMember_BD5C684B53F08C1DCA5FFCCBDB0292D2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CumulativeSalesLevelDomain_685C71E853F24FEDCC9AFCCBDB02CCF0" xlink:to="loc_biib_TenbillionMember_BD5C684B53F08C1DCA5FFCCBDB0292D2" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_SevenbillionMember" xlink:label="loc_biib_SevenbillionMember_1EDACFACECFDEB6DD4C3FCCBDB02A590" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CumulativeSalesLevelDomain_685C71E853F24FEDCC9AFCCBDB02CCF0" xlink:to="loc_biib_SevenbillionMember_1EDACFACECFDEB6DD4C3FCCBDB02A590" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_EightbillionMember" xlink:label="loc_biib_EightbillionMember_3416099A6FDB6C4073C5FCCBDB023F08" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CumulativeSalesLevelDomain_685C71E853F24FEDCC9AFCCBDB02CCF0" xlink:to="loc_biib_EightbillionMember_3416099A6FDB6C4073C5FCCBDB023F08" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_NinebillionMember" xlink:label="loc_biib_NinebillionMember_2245531DE5BAEF26359CFCCBDB021AD4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CumulativeSalesLevelDomain_685C71E853F24FEDCC9AFCCBDB02CCF0" xlink:to="loc_biib_NinebillionMember_2245531DE5BAEF26359CFCCBDB021AD4" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ElevenbillionMember" xlink:label="loc_biib_ElevenbillionMember_04A8D50FDF0C5C95BC8BFCCBDB024077" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CumulativeSalesLevelDomain_685C71E853F24FEDCC9AFCCBDB02CCF0" xlink:to="loc_biib_ElevenbillionMember_04A8D50FDF0C5C95BC8BFCCBDB024077" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_OneBillionMember" xlink:label="loc_biib_OneBillionMember_A676BD77F5A6F4BD2F7AFCCBDB02B434" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CumulativeSalesLevelDomain_685C71E853F24FEDCC9AFCCBDB02CCF0" xlink:to="loc_biib_OneBillionMember_A676BD77F5A6F4BD2F7AFCCBDB02B434" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_EachAdditionalOneBillionUpToTwentyBillionMember" xlink:label="loc_biib_EachAdditionalOneBillionUpToTwentyBillionMember_5C1CD92EB5BE3D83BC1DFCCBDB0214CC" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CumulativeSalesLevelDomain_685C71E853F24FEDCC9AFCCBDB02CCF0" xlink:to="loc_biib_EachAdditionalOneBillionUpToTwentyBillionMember_5C1CD92EB5BE3D83BC1DFCCBDB0214CC" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ThreeBillionMember" xlink:label="loc_biib_ThreeBillionMember_3D0B8D041A6DBAD55E41FCCBDB026885" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CumulativeSalesLevelDomain_685C71E853F24FEDCC9AFCCBDB02CCF0" xlink:to="loc_biib_ThreeBillionMember_3D0B8D041A6DBAD55E41FCCBDB026885" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_27AB6CDA50E3EC7FF352FCCBDB02C5DF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_54814CBF69A87D818242FCCBDB001A9D" xlink:to="loc_us-gaap_ProductOrServiceAxis_27AB6CDA50E3EC7FF352FCCBDB02C5DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_F6674D01C458A00BA290FCCBDB02B5D3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductOrServiceAxis_27AB6CDA50E3EC7FF352FCCBDB02C5DF" xlink:to="loc_us-gaap_ProductsAndServicesDomain_F6674D01C458A00BA290FCCBDB02B5D3" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_8CB995C5F30A9951805EFCCBDB0394DC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_F6674D01C458A00BA290FCCBDB02B5D3" xlink:to="loc_biib_TecfideraMember_8CB995C5F30A9951805EFCCBDB0394DC" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_FacilityLocationAxis" xlink:label="loc_biib_FacilityLocationAxis_F057B8CBCFB194FBCC28FCCBDB039A55" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_54814CBF69A87D818242FCCBDB001A9D" xlink:to="loc_biib_FacilityLocationAxis_F057B8CBCFB194FBCC28FCCBDB039A55" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_C44374ED04CE5F26A4D9FCCBDB038829" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityLocationAxis_F057B8CBCFB194FBCC28FCCBDB039A55" xlink:to="loc_biib_FacilityLocationDomain_C44374ED04CE5F26A4D9FCCBDB038829" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_SolothurnMember" xlink:label="loc_biib_SolothurnMember_8D4DCE9A15554E0EDE18FCCBDB038080" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityLocationDomain_C44374ED04CE5F26A4D9FCCBDB038829" xlink:to="loc_biib_SolothurnMember_8D4DCE9A15554E0EDE18FCCBDB038080" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_55C1090D40644F695BACFCCBDB03B61E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_54814CBF69A87D818242FCCBDB001A9D" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_55C1090D40644F695BACFCCBDB03B61E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5A85283DEFBDDA90D196FCCBDB0343DD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_55C1090D40644F695BACFCCBDB03B61E" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5A85283DEFBDDA90D196FCCBDB0343DD" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_TysabriProductMember" xlink:label="loc_biib_TysabriProductMember_D7EE40229FC45FE4F42AFCCBDB039EDD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5A85283DEFBDDA90D196FCCBDB0343DD" xlink:to="loc_biib_TysabriProductMember_D7EE40229FC45FE4F42AFCCBDB039EDD" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_FumapharmAgMember" xlink:label="loc_biib_FumapharmAgMember_4698B823E08F2C1FBCCEFCCBDB037BA7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5A85283DEFBDDA90D196FCCBDB0343DD" xlink:to="loc_biib_FumapharmAgMember_4698B823E08F2C1FBCCEFCCBDB037BA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_3F88748D37747DDA5562FCCBDB03F53E" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_54814CBF69A87D818242FCCBDB001A9D" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_3F88748D37747DDA5562FCCBDB03F53E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationSettlementAmount" xlink:label="loc_us-gaap_LitigationSettlementAmount_C6F13F5B8BED3F4AB517FCCBDB032AA2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3F88748D37747DDA5562FCCBDB03F53E" xlink:to="loc_us-gaap_LitigationSettlementAmount_C6F13F5B8BED3F4AB517FCCBDB032AA2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationSettlementExpense" xlink:label="loc_us-gaap_LitigationSettlementExpense_E7A6939CF4EF10B6C2EBFCCBDB044305" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3F88748D37747DDA5562FCCBDB03F53E" xlink:to="loc_us-gaap_LitigationSettlementExpense_E7A6939CF4EF10B6C2EBFCCBDB044305" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion" xlink:label="loc_biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion_3D9C63E8B139FBE74DD0FCCBDB04F3CD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3F88748D37747DDA5562FCCBDB03F53E" xlink:to="loc_biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion_3D9C63E8B139FBE74DD0FCCBDB04F3CD" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_FutureContingentPaymentThreshold" xlink:label="loc_biib_FutureContingentPaymentThreshold_76B614BA5AC785A41EF2FCCBDB045DFF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3F88748D37747DDA5562FCCBDB03F53E" xlink:to="loc_biib_FutureContingentPaymentThreshold_76B614BA5AC785A41EF2FCCBDB045DFF" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion" xlink:label="loc_biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion_32A2609B9027D57287A3FCCBDB04C1D0" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3F88748D37747DDA5562FCCBDB03F53E" xlink:to="loc_biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion_32A2609B9027D57287A3FCCBDB04C1D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_19886BCD224CA5AD4D70FCCBDB04536C" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3F88748D37747DDA5562FCCBDB03F53E" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_19886BCD224CA5AD4D70FCCBDB04536C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_DF774469DE10512A6CB4FCCBDB044207" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3F88748D37747DDA5562FCCBDB03F53E" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_DF774469DE10512A6CB4FCCBDB044207" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_BA32A84CF1709C65C0C4FCCBDB0446D0" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3F88748D37747DDA5562FCCBDB03F53E" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_BA32A84CF1709C65C0C4FCCBDB0446D0" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_CumulativeSalesLevel" xlink:label="loc_biib_CumulativeSalesLevel_EEE4CDAB35A8BB67EA41FCCBDB046324" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3F88748D37747DDA5562FCCBDB03F53E" xlink:to="loc_biib_CumulativeSalesLevel_EEE4CDAB35A8BB67EA41FCCBDB046324" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_A7E33FE1D7E9052CFAB7FCCBDB043642" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3F88748D37747DDA5562FCCBDB03F53E" xlink:to="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_A7E33FE1D7E9052CFAB7FCCBDB043642" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCommitment" xlink:label="loc_us-gaap_OtherCommitment_0BF58AEF4406DD44967FFCCBDB048D3A" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3F88748D37747DDA5562FCCBDB03F53E" xlink:to="loc_us-gaap_OtherCommitment_0BF58AEF4406DD44967FFCCBDB048D3A" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_CommitmentsAndContingenciesTextualAbstract" xlink:label="loc_biib_CommitmentsAndContingenciesTextualAbstract_68F891822C35C2DD0BBDFCCBDB04F524" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0B7D44DAE8AA68B3DB88FCCBDB000B0A" xlink:to="loc_biib_CommitmentsAndContingenciesTextualAbstract_68F891822C35C2DD0BBDFCCBDB04F524" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch" xlink:label="loc_biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch_BDFC4391A41944D39003FCCBDB04EC7F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CommitmentsAndContingenciesTextualAbstract_68F891822C35C2DD0BBDFCCBDB04F524" xlink:to="loc_biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch_BDFC4391A41944D39003FCCBDB04EC7F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:label="loc_us-gaap_LiabilityForUncertainTaxPositionsCurrent_ED4C2A5AB443DAA8C891FCCBDB0458AF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CommitmentsAndContingenciesTextualAbstract_68F891822C35C2DD0BBDFCCBDB04F524" xlink:to="loc_us-gaap_LiabilityForUncertainTaxPositionsCurrent_ED4C2A5AB443DAA8C891FCCBDB0458AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaap_LeaseAndRentalExpense_206A249A9ABCFD3D352DFCCBDB049EEC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CommitmentsAndContingenciesTextualAbstract_68F891822C35C2DD0BBDFCCBDB04F524" xlink:to="loc_us-gaap_LeaseAndRentalExpense_206A249A9ABCFD3D352DFCCBDB049EEC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CommitmentsAndContingenciesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_25B196B8B2D263FB0118FCCBDB153B50" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_2499CAB9C43B751A232FFCCBDB15E33B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_25B196B8B2D263FB0118FCCBDB153B50" xlink:to="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_2499CAB9C43B751A232FFCCBDB15E33B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock_7ADB87DE8FEB5D9BE6BCFCCBDB160567" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_25B196B8B2D263FB0118FCCBDB153B50" xlink:to="loc_us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock_7ADB87DE8FEB5D9BE6BCFCCBDB160567" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_99298CFC43D36EB8BFE9D0DB2422CB21" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_F9490E985D4B7F7E8298D0DB24225323" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_99298CFC43D36EB8BFE9D0DB2422CB21" xlink:to="loc_us-gaap_AssetsAbstract_F9490E985D4B7F7E8298D0DB24225323" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_E874B274DD05602615B4D0DB24228537" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_F9490E985D4B7F7E8298D0DB24225323" xlink:to="loc_us-gaap_AssetsCurrentAbstract_E874B274DD05602615B4D0DB24228537" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9421F3E8303FA32693D6D0DB242282D2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_E874B274DD05602615B4D0DB24228537" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9421F3E8303FA32693D6D0DB242282D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesCurrent_9420DA0D7C5338400CF9D0DB2422F1E7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_E874B274DD05602615B4D0DB24228537" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesCurrent_9420DA0D7C5338400CF9D0DB2422F1E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_4E6BF41F1352A65F3F4FD0DB24227D72" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_E874B274DD05602615B4D0DB24228537" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_4E6BF41F1352A65F3F4FD0DB24227D72" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_DueFromUnconsolidatedJointBusiness" xlink:label="loc_biib_DueFromUnconsolidatedJointBusiness_F39A5878B535F6D4744BD0DB2423F5EE" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_E874B274DD05602615B4D0DB24228537" xlink:to="loc_biib_DueFromUnconsolidatedJointBusiness_F39A5878B535F6D4744BD0DB2423F5EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_6F02786CC6A3020527D5D0DB2423F718" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_E874B274DD05602615B4D0DB24228537" xlink:to="loc_us-gaap_InventoryNet_6F02786CC6A3020527D5D0DB2423F718" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_1C33231B7FE0EFD65783D0DB24233B9E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_E874B274DD05602615B4D0DB24228537" xlink:to="loc_us-gaap_OtherAssetsCurrent_1C33231B7FE0EFD65783D0DB24233B9E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_BBF5714B52B6DB35EAB2D0DB24236181" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_E874B274DD05602615B4D0DB24228537" xlink:to="loc_us-gaap_AssetsCurrent_BBF5714B52B6DB35EAB2D0DB24236181" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesNoncurrent_D7E5B8ACF699B42CA742D0DB242320A5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_F9490E985D4B7F7E8298D0DB24225323" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesNoncurrent_D7E5B8ACF699B42CA742D0DB242320A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_DEDF7501791A050C3306D0DB2423A0AD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_F9490E985D4B7F7E8298D0DB24225323" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_DEDF7501791A050C3306D0DB2423A0AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_0024F277E1769D1E62F1D0DB24289784" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_F9490E985D4B7F7E8298D0DB24225323" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_0024F277E1769D1E62F1D0DB24289784" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_0895FD405EFF4152BED7D0DB2428F70B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_F9490E985D4B7F7E8298D0DB24225323" xlink:to="loc_us-gaap_Goodwill_0895FD405EFF4152BED7D0DB2428F70B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_6A65C744AFD6514AFF28D0DB24280A2D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_F9490E985D4B7F7E8298D0DB24225323" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_6A65C744AFD6514AFF28D0DB24280A2D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_23CDDFB9C859F885ABC1D0DB24297E89" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_F9490E985D4B7F7E8298D0DB24225323" xlink:to="loc_us-gaap_Assets_23CDDFB9C859F885ABC1D0DB24297E89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1A6C2C75D57AF755E2B6D0DB24297E76" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_99298CFC43D36EB8BFE9D0DB2422CB21" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1A6C2C75D57AF755E2B6D0DB24297E76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_3B88EF6148A7E2EA393ED0DB24292B15" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1A6C2C75D57AF755E2B6D0DB24297E76" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_3B88EF6148A7E2EA393ED0DB24292B15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_02DE8209DDA7A26A1F7CD0DB242927FB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_3B88EF6148A7E2EA393ED0DB24292B15" xlink:to="loc_us-gaap_DebtCurrent_02DE8209DDA7A26A1F7CD0DB242927FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaap_TaxesPayableCurrent_19FBAF11AA6FDC5D2A87D0DB24292973" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_3B88EF6148A7E2EA393ED0DB24292B15" xlink:to="loc_us-gaap_TaxesPayableCurrent_19FBAF11AA6FDC5D2A87D0DB24292973" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_8C48E082AAC4684CD778D0DB24299899" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_3B88EF6148A7E2EA393ED0DB24292B15" xlink:to="loc_us-gaap_AccountsPayableCurrent_8C48E082AAC4684CD778D0DB24299899" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_6D89F8EAA8742F292BEAD0DB24292D33" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_3B88EF6148A7E2EA393ED0DB24292B15" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_6D89F8EAA8742F292BEAD0DB24292D33" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_156833D7A489C2A0E40AD0DB2429B20D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_3B88EF6148A7E2EA393ED0DB24292B15" xlink:to="loc_us-gaap_LiabilitiesCurrent_156833D7A489C2A0E40AD0DB2429B20D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_692C01555AD02271092AD0DB242975E3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1A6C2C75D57AF755E2B6D0DB24297E76" xlink:to="loc_us-gaap_LongTermDebt_692C01555AD02271092AD0DB242975E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_C3624648DFB988E4A182D0DB2429809A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1A6C2C75D57AF755E2B6D0DB24297E76" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_C3624648DFB988E4A182D0DB2429809A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_370AA9F611C90244C406D0DB2429C64B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1A6C2C75D57AF755E2B6D0DB24297E76" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_370AA9F611C90244C406D0DB2429C64B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_55C16DD95EC785E95EB4D0DB24290E2D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1A6C2C75D57AF755E2B6D0DB24297E76" xlink:to="loc_us-gaap_Liabilities_55C16DD95EC785E95EB4D0DB24290E2D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_22EF07F4350F3DC18843D0DB242910D5" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1A6C2C75D57AF755E2B6D0DB24297E76" xlink:to="loc_us-gaap_CommitmentsAndContingencies_22EF07F4350F3DC18843D0DB242910D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_FC79F69E7EFA78557C2AD0DB24296692" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1A6C2C75D57AF755E2B6D0DB24297E76" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_FC79F69E7EFA78557C2AD0DB24296692" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_530FE173F09D7A066AEAD0DB24293778" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_FC79F69E7EFA78557C2AD0DB24296692" xlink:to="loc_us-gaap_StockholdersEquityAbstract_530FE173F09D7A066AEAD0DB24293778" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_26A790E10F477CEE0BB6D0DB242A1BCC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_530FE173F09D7A066AEAD0DB24293778" xlink:to="loc_us-gaap_PreferredStockValue_26A790E10F477CEE0BB6D0DB242A1BCC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_D6106F7074703304D05ED0DB242AD87E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_530FE173F09D7A066AEAD0DB24293778" xlink:to="loc_us-gaap_CommonStockValue_D6106F7074703304D05ED0DB242AD87E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_7795E33A05CDD7D1BF40D0DB242AD48C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_530FE173F09D7A066AEAD0DB24293778" xlink:to="loc_us-gaap_AdditionalPaidInCapital_7795E33A05CDD7D1BF40D0DB242AD48C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_E9C76EDBC7AFF3B89248D0DB242AD113" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_530FE173F09D7A066AEAD0DB24293778" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_E9C76EDBC7AFF3B89248D0DB242AD113" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1057A67800D65090314AD0DB242AA0AC" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_530FE173F09D7A066AEAD0DB24293778" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1057A67800D65090314AD0DB242AA0AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_8B68B5D0BF91EC52F72FD0DB242A068B" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_530FE173F09D7A066AEAD0DB24293778" xlink:to="loc_us-gaap_TreasuryStockValue_8B68B5D0BF91EC52F72FD0DB242A068B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_6AABAE74EB19CB658887D0DB242AB432" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_530FE173F09D7A066AEAD0DB24293778" xlink:to="loc_us-gaap_StockholdersEquity_6AABAE74EB19CB658887D0DB242AB432" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_4DF9557B9A486E03CD4BD0DB242A671C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_FC79F69E7EFA78557C2AD0DB24296692" xlink:to="loc_us-gaap_MinorityInterest_4DF9557B9A486E03CD4BD0DB242A671C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_E767A175B5E934146078D0DB242AF735" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_FC79F69E7EFA78557C2AD0DB24296692" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_E767A175B5E934146078D0DB242AF735" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_C18288F4F6E73CD9E9AED0DB242A7B7D" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1A6C2C75D57AF755E2B6D0DB24297E76" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_C18288F4F6E73CD9E9AED0DB242A7B7D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_87BA5A3CA40A268D630D741285DC1395" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_28E06002BD8F9E095FE6741285DC645F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_87BA5A3CA40A268D630D741285DC1395" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_28E06002BD8F9E095FE6741285DC645F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_EFF28A2144A6F8085D6B741285DCEC2B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_87BA5A3CA40A268D630D741285DC1395" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_EFF28A2144A6F8085D6B741285DCEC2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="loc_us-gaap_TreasuryStockShares_A7E431562B3CBAB2589F741285DCB72A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_87BA5A3CA40A268D630D741285DC1395" xlink:to="loc_us-gaap_TreasuryStockShares_A7E431562B3CBAB2589F741285DCB72A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_20D527F0871241049B20FA3C6A7F33A2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_158D11B3367370A54F4EFA3C6A80BBD3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_20D527F0871241049B20FA3C6A7F33A2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_158D11B3367370A54F4EFA3C6A80BBD3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_57DB28BC89F13D2ACFFFFA3C6A80650E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_158D11B3367370A54F4EFA3C6A80BBD3" xlink:to="loc_us-gaap_ProfitLoss_57DB28BC89F13D2ACFFFFA3C6A80650E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_E6A3547D67A31AFC7811FA3C6A8078CC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_158D11B3367370A54F4EFA3C6A80BBD3" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_E6A3547D67A31AFC7811FA3C6A8078CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_71350998FF7AB811690DFA3C6A80BC18" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_E6A3547D67A31AFC7811FA3C6A8078CC" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_71350998FF7AB811690DFA3C6A80BC18" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_74335836FE74462160BBFA3C6A8026BA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_E6A3547D67A31AFC7811FA3C6A8078CC" xlink:to="loc_us-gaap_ShareBasedCompensation_74335836FE74462160BBFA3C6A8026BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_7F0845890384B51B44C2FA3C6A80D75A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_E6A3547D67A31AFC7811FA3C6A8078CC" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_7F0845890384B51B44C2FA3C6A80D75A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_82D4ECADECFF8461A6D7FA3C6A803FFC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_E6A3547D67A31AFC7811FA3C6A8078CC" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_82D4ECADECFF8461A6D7FA3C6A803FFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_42C2D3FDA29062537AE8FA3C6A807DA0" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_E6A3547D67A31AFC7811FA3C6A8078CC" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_42C2D3FDA29062537AE8FA3C6A807DA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_041BA8DE6CE9F5AA66E4FA3C6A80DFCA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_42C2D3FDA29062537AE8FA3C6A807DA0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_041BA8DE6CE9F5AA66E4FA3C6A80DFCA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_C6924A04301FBEDCAD11FA3C6A816021" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_42C2D3FDA29062537AE8FA3C6A807DA0" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_C6924A04301FBEDCAD11FA3C6A816021" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_21421CBE960CBBF30B55FA3C6A8017DA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_42C2D3FDA29062537AE8FA3C6A807DA0" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_21421CBE960CBBF30B55FA3C6A8017DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_3A98B7C20E7B72F81D04FA3C6A807854" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_42C2D3FDA29062537AE8FA3C6A807DA0" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_3A98B7C20E7B72F81D04FA3C6A807854" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_4EB2F9329F7EDEA17E1DFA3C6A80DE4C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_42C2D3FDA29062537AE8FA3C6A807DA0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_4EB2F9329F7EDEA17E1DFA3C6A80DE4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_B45D3B804659458985A5FA3C6A801B0F" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_42C2D3FDA29062537AE8FA3C6A807DA0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_B45D3B804659458985A5FA3C6A801B0F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_9BE5090FA78850ADE4BFFA3C6A81CA99" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_42C2D3FDA29062537AE8FA3C6A807DA0" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_9BE5090FA78850ADE4BFFA3C6A81CA99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5D8B873FB2833FC61724FA3C6A81C159" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_E6A3547D67A31AFC7811FA3C6A8078CC" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5D8B873FB2833FC61724FA3C6A81C159" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_FB9AD60121FCFA545899FA3C6A81B80F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_20D527F0871241049B20FA3C6A7F33A2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_FB9AD60121FCFA545899FA3C6A81B80F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_30CB034E054E2E049A1EFA3C6A81C179" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_FB9AD60121FCFA545899FA3C6A81B80F" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_30CB034E054E2E049A1EFA3C6A81C179" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_CA06DC1D51B9DCEC6C01FA3C6A813FCF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_FB9AD60121FCFA545899FA3C6A81B80F" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_CA06DC1D51B9DCEC6C01FA3C6A813FCF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_C30BCD1ACCEA0075B0CAFA3C6A81A342" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_FB9AD60121FCFA545899FA3C6A81B80F" xlink:to="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_C30BCD1ACCEA0075B0CAFA3C6A81A342" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_4627D2DD633EDB327E3FFA3C6A818A22" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_FB9AD60121FCFA545899FA3C6A81B80F" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_4627D2DD633EDB327E3FFA3C6A818A22" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ED212E4ABBE3397D5099FA3C6A81203B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_FB9AD60121FCFA545899FA3C6A81B80F" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ED212E4ABBE3397D5099FA3C6A81203B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_A67A989AD8BBF7062697FA3C6A818D86" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_FB9AD60121FCFA545899FA3C6A81B80F" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_A67A989AD8BBF7062697FA3C6A818D86" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_9B2761B204B1B4B90B0AFA3C6A819CC8" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_FB9AD60121FCFA545899FA3C6A81B80F" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_9B2761B204B1B4B90B0AFA3C6A819CC8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_059F6839B852AFF97D8BFA3C6A813167" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_FB9AD60121FCFA545899FA3C6A81B80F" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_059F6839B852AFF97D8BFA3C6A813167" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0EB7899DEDF87E024881FA3C6A810549" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_20D527F0871241049B20FA3C6A7F33A2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0EB7899DEDF87E024881FA3C6A810549" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_C6708D623F9DFEA644DCFA3C6A8125BF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0EB7899DEDF87E024881FA3C6A810549" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_C6708D623F9DFEA644DCFA3C6A8125BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_C36510AAF636CD372935FA3C6A8192E0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0EB7899DEDF87E024881FA3C6A810549" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_C36510AAF636CD372935FA3C6A8192E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_4EDEF56FA3A537DB0B85FA3C6A825CCD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0EB7899DEDF87E024881FA3C6A810549" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_4EDEF56FA3A537DB0B85FA3C6A825CCD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaap_RepaymentsOfDebt_678D707A4169C048E0C2FA3C6A825B85" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0EB7899DEDF87E024881FA3C6A810549" xlink:to="loc_us-gaap_RepaymentsOfDebt_678D707A4169C048E0C2FA3C6A825B85" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities" xlink:label="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities_FF07CC051F19F4D7CBDFFA3C6A82CCD7" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0EB7899DEDF87E024881FA3C6A810549" xlink:to="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities_FF07CC051F19F4D7CBDFFA3C6A82CCD7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_2B1A901B977CC0FBD6CAFA3C6A82759E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0EB7899DEDF87E024881FA3C6A810549" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_2B1A901B977CC0FBD6CAFA3C6A82759E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_9395B585664B62DD921BFA3C6A8244AA" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0EB7899DEDF87E024881FA3C6A810549" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_9395B585664B62DD921BFA3C6A8244AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_40D54524EB9C30D7701BFA3C6A826A1E" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0EB7899DEDF87E024881FA3C6A810549" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_40D54524EB9C30D7701BFA3C6A826A1E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_88F9ADFB136CBBD39D21FA3C6A82391B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_20D527F0871241049B20FA3C6A7F33A2" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_88F9ADFB136CBBD39D21FA3C6A82391B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_3DBA04B4518DC0F8850AFA3C6A824D91" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_20D527F0871241049B20FA3C6A7F33A2" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_3DBA04B4518DC0F8850AFA3C6A824D91" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_73AB53D0BE4D003782DCFA3C6A822A47" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_20D527F0871241049B20FA3C6A7F33A2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_73AB53D0BE4D003782DCFA3C6A822A47" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_F80F8EA146621F71D853FA3C6A8226EA" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_20D527F0871241049B20FA3C6A7F33A2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_F80F8EA146621F71D853FA3C6A8226EA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ConsolidatedStatementsOfComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_EFC1C7390C4CD7AE0568F4AB01422D56" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1E870ED77EA1C3EE200BF4AB0142E251" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_EFC1C7390C4CD7AE0568F4AB01422D56" xlink:to="loc_us-gaap_NetIncomeLoss_1E870ED77EA1C3EE200BF4AB0142E251" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_2C4F5F3AD50032C7EBFFF4AB014205E5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_EFC1C7390C4CD7AE0568F4AB01422D56" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_2C4F5F3AD50032C7EBFFF4AB014205E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_761AE55E3F7E0E81071CF4AB014204C7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_2C4F5F3AD50032C7EBFFF4AB014205E5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_761AE55E3F7E0E81071CF4AB014204C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_0DBB8C7411F6EA2EDF63F4AB0143233B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_2C4F5F3AD50032C7EBFFF4AB014205E5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_0DBB8C7411F6EA2EDF63F4AB0143233B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_2715EC25AF3B0B19A0D6F4AB01435324" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_2C4F5F3AD50032C7EBFFF4AB014205E5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_2715EC25AF3B0B19A0D6F4AB01435324" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax_030CF917F8DCCBBF7750F4AB01438D27" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_2C4F5F3AD50032C7EBFFF4AB014205E5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax_030CF917F8DCCBBF7750F4AB01438D27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax_41B4C8477BC336F6F82CF4AB01438924" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_2C4F5F3AD50032C7EBFFF4AB014205E5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax_41B4C8477BC336F6F82CF4AB01438924" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_B773831B3AC34E652295F4AB0143D18D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_2C4F5F3AD50032C7EBFFF4AB014205E5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_B773831B3AC34E652295F4AB0143D18D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_F96B0ECA59856DBE981EF4AB0143DBED" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_2C4F5F3AD50032C7EBFFF4AB014205E5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_F96B0ECA59856DBE981EF4AB0143DBED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_109500D8867D56133DE9F4AB01438DA9" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_2C4F5F3AD50032C7EBFFF4AB014205E5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_109500D8867D56133DE9F4AB01438DA9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_B34E3E1EAEE894FA2EC5F4AB0143ECEE" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_2C4F5F3AD50032C7EBFFF4AB014205E5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_B34E3E1EAEE894FA2EC5F4AB0143ECEE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_A7306DC5AE572E033A67F4AB0143415F" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_2C4F5F3AD50032C7EBFFF4AB014205E5" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_A7306DC5AE572E033A67F4AB0143415F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_4268B49B7AEE5C858327F4AB014365B3" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_2C4F5F3AD50032C7EBFFF4AB014205E5" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_4268B49B7AEE5C858327F4AB014365B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_9093D6E5185A2665EDA6F4AB0143A41A" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_2C4F5F3AD50032C7EBFFF4AB014205E5" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_9093D6E5185A2665EDA6F4AB0143A41A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ConsolidatedStatementsOfEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_88CD8057C402FDC255D2FA4E86BE668F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_F1B1636431E4D753C2F2FA4E86C1C9EB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_88CD8057C402FDC255D2FA4E86BE668F" xlink:to="loc_us-gaap_StatementTable_F1B1636431E4D753C2F2FA4E86C1C9EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_81C7029D1B460705560EFA4E86C2CDC6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_F1B1636431E4D753C2F2FA4E86C1C9EB" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_81C7029D1B460705560EFA4E86C2CDC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_32A038D2E1D8CFE6EBF9FA4E86C24E66" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_81C7029D1B460705560EFA4E86C2CDC6" xlink:to="loc_us-gaap_EquityComponentDomain_32A038D2E1D8CFE6EBF9FA4E86C24E66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_E1776E1F7E83050BCE5FFA4E86C2F785" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_32A038D2E1D8CFE6EBF9FA4E86C24E66" xlink:to="loc_us-gaap_PreferredStockMember_E1776E1F7E83050BCE5FFA4E86C2F785" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1D1E6199649AD9888512FA4E86C2DE64" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_32A038D2E1D8CFE6EBF9FA4E86C24E66" xlink:to="loc_us-gaap_CommonStockMember_1D1E6199649AD9888512FA4E86C2DE64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_19C2E1AC3A51C1CEB3E4FA4E86C3DB6C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_32A038D2E1D8CFE6EBF9FA4E86C24E66" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_19C2E1AC3A51C1CEB3E4FA4E86C3DB6C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_BABC4C5C1C3FA7B99E4EFA4E86C34AC1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_32A038D2E1D8CFE6EBF9FA4E86C24E66" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_BABC4C5C1C3FA7B99E4EFA4E86C34AC1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_008DA1F1E23C1A25C588FA4E86C3DDB4" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_32A038D2E1D8CFE6EBF9FA4E86C24E66" xlink:to="loc_us-gaap_RetainedEarningsMember_008DA1F1E23C1A25C588FA4E86C3DDB4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_CAC8C58E0CDEDE3D37BDFA4E86C3A59E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_32A038D2E1D8CFE6EBF9FA4E86C24E66" xlink:to="loc_us-gaap_TreasuryStockMember_CAC8C58E0CDEDE3D37BDFA4E86C3A59E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember_22A64331B46162E2978DFA4E86C377CD" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_32A038D2E1D8CFE6EBF9FA4E86C24E66" xlink:to="loc_us-gaap_NoncontrollingInterestMember_22A64331B46162E2978DFA4E86C377CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaap_ParentMember_88515E9A8C01CD047681FA4E86C329B1" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_32A038D2E1D8CFE6EBF9FA4E86C24E66" xlink:to="loc_us-gaap_ParentMember_88515E9A8C01CD047681FA4E86C329B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0E3E948FEE5940CA0E8DFA4E86C3120B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_F1B1636431E4D753C2F2FA4E86C1C9EB" xlink:to="loc_us-gaap_StatementLineItems_0E3E948FEE5940CA0E8DFA4E86C3120B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3ED9F2B165CAC7A177FEFA4E86C369AC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0E3E948FEE5940CA0E8DFA4E86C3120B" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3ED9F2B165CAC7A177FEFA4E86C369AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_E82A5BF5FD36BF565D3FFA4E86C34B1E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0E3E948FEE5940CA0E8DFA4E86C3120B" xlink:to="loc_us-gaap_StockholdersEquity_E82A5BF5FD36BF565D3FFA4E86C34B1E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_B35244305D5432355132FA62E1F363A2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0E3E948FEE5940CA0E8DFA4E86C3120B" xlink:to="loc_us-gaap_MinorityInterest_B35244305D5432355132FA62E1F363A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_09ED34115D0DB2C5C9A8FA4E86C39260" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0E3E948FEE5940CA0E8DFA4E86C3120B" xlink:to="loc_us-gaap_SharesIssued_09ED34115D0DB2C5C9A8FA4E86C39260" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_F65CAA5A74AAB75EE499FA4E86C9E04E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0E3E948FEE5940CA0E8DFA4E86C3120B" xlink:to="loc_us-gaap_NetIncomeLoss_F65CAA5A74AAB75EE499FA4E86C9E04E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_19FB94CADBFECE313C68FA4E86C98BC5" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0E3E948FEE5940CA0E8DFA4E86C3120B" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_19FB94CADBFECE313C68FA4E86C98BC5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_330255D061562EF2059EFA4E86C906FA" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0E3E948FEE5940CA0E8DFA4E86C3120B" xlink:to="loc_us-gaap_ProfitLoss_330255D061562EF2059EFA4E86C906FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_B617B661C12A79FAE5D7FA4E86CB4038" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0E3E948FEE5940CA0E8DFA4E86C3120B" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_B617B661C12A79FAE5D7FA4E86CB4038" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_4E5583132B126B4296B4FA4E86C9A5F4" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0E3E948FEE5940CA0E8DFA4E86C3120B" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_4E5583132B126B4296B4FA4E86C9A5F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_B759C8A3EB036466340FFA4E86CCA3EF" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0E3E948FEE5940CA0E8DFA4E86C3120B" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_B759C8A3EB036466340FFA4E86CCA3EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_BC00FB0592BDEF6D0CBCFA4E86CBAD02" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0E3E948FEE5940CA0E8DFA4E86C3120B" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_BC00FB0592BDEF6D0CBCFA4E86CBAD02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:label="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_075FB79A363488CE31FCFA4E86CBEE64" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0E3E948FEE5940CA0E8DFA4E86C3120B" xlink:to="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_075FB79A363488CE31FCFA4E86CBEE64" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_Noncontrollinginterestincreasedecreaseother" xlink:label="loc_biib_Noncontrollinginterestincreasedecreaseother_12AA7CD3387443EF5FE2FA702CB186D7" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0E3E948FEE5940CA0E8DFA4E86C3120B" xlink:to="loc_biib_Noncontrollinginterestincreasedecreaseother_12AA7CD3387443EF5FE2FA702CB186D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_EB0C7D9BD72EDDFD46CFFA4E86CC17B0" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0E3E948FEE5940CA0E8DFA4E86C3120B" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_EB0C7D9BD72EDDFD46CFFA4E86CC17B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_BD3ABF5978070366FA10FA4E86CC80A3" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0E3E948FEE5940CA0E8DFA4E86C3120B" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_BD3ABF5978070366FA10FA4E86CC80A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_F21AC471FB0200E0D930FA4E86CCFADF" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0E3E948FEE5940CA0E8DFA4E86C3120B" xlink:to="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_F21AC471FB0200E0D930FA4E86CCFADF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_9384811AD3563D189F83FA4E86CCED92" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0E3E948FEE5940CA0E8DFA4E86C3120B" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_9384811AD3563D189F83FA4E86CCED92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_45014191A8381260DF58FA4E86CCB485" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0E3E948FEE5940CA0E8DFA4E86C3120B" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_45014191A8381260DF58FA4E86CCB485" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_AD648C8DA2170A77E93BFA4E86CC01C0" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0E3E948FEE5940CA0E8DFA4E86C3120B" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_AD648C8DA2170A77E93BFA4E86CC01C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_EEB50A234E79C0DFC401FA4E86CCD2D6" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0E3E948FEE5940CA0E8DFA4E86C3120B" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_EEB50A234E79C0DFC401FA4E86CCD2D6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_693CA36EE6B80BF11F63FA4E86CC9975" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0E3E948FEE5940CA0E8DFA4E86C3120B" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_693CA36EE6B80BF11F63FA4E86CC9975" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_03C8D66D222607E8FB17FA4E86CC214F" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0E3E948FEE5940CA0E8DFA4E86C3120B" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_03C8D66D222607E8FB17FA4E86CC214F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_6951C9FFFB846813412AFA4E86CCB444" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0E3E948FEE5940CA0E8DFA4E86C3120B" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_6951C9FFFB846813412AFA4E86CCB444" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_84FD5A09ECCE070EC6CFFA4E86CC46E5" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0E3E948FEE5940CA0E8DFA4E86C3120B" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_84FD5A09ECCE070EC6CFFA4E86CC46E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_C2C248EE9C8CA2BCAB4CFA64A3BBB0D2" xlink:type="locator" />
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0E3E948FEE5940CA0E8DFA4E86C3120B" xlink:to="loc_us-gaap_StockholdersEquity_C2C248EE9C8CA2BCAB4CFA64A3BBB0D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_524D13A8E08AEB619744FA4E86CD6AA6" xlink:type="locator" />
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0E3E948FEE5940CA0E8DFA4E86C3120B" xlink:to="loc_us-gaap_MinorityInterest_524D13A8E08AEB619744FA4E86CD6AA6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_5F4D6AC4F8A73EA83728FA4E86CC51EF" xlink:type="locator" />
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0E3E948FEE5940CA0E8DFA4E86C3120B" xlink:to="loc_us-gaap_SharesIssued_5F4D6AC4F8A73EA83728FA4E86CC51EF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ConsolidatedStatementsOfIncome" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_D34F471616F41BD6D58CFCCBDD5E76C5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_FCB0662899306CD6EB98FCCBDD5E32B6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_D34F471616F41BD6D58CFCCBDD5E76C5" xlink:to="loc_us-gaap_RevenuesAbstract_FCB0662899306CD6EB98FCCBDD5E32B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_9DFDD4F2C995A28FD2AFFCCBDD5E3297" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_FCB0662899306CD6EB98FCCBDD5E32B6" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_9DFDD4F2C995A28FD2AFFCCBDD5E3297" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_RevenuesfromantiCD20therapeuticprograms" xlink:label="loc_biib_RevenuesfromantiCD20therapeuticprograms_6A24DDE376B18C2166B4FCE0F7BFC8DC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_FCB0662899306CD6EB98FCCBDD5E32B6" xlink:to="loc_biib_RevenuesfromantiCD20therapeuticprograms_6A24DDE376B18C2166B4FCE0F7BFC8DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherSalesRevenueNet" xlink:label="loc_us-gaap_OtherSalesRevenueNet_527FB59A974B4F706400FCCBDD5EC604" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_FCB0662899306CD6EB98FCCBDD5E32B6" xlink:to="loc_us-gaap_OtherSalesRevenueNet_527FB59A974B4F706400FCCBDD5EC604" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_A939D15791375375C38DFCCBDD5F974F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_FCB0662899306CD6EB98FCCBDD5E32B6" xlink:to="loc_us-gaap_Revenues_A939D15791375375C38DFCCBDD5F974F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_FD93560E4CE731EA26ADFCCBDD5FCBF5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_D34F471616F41BD6D58CFCCBDD5E76C5" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_FD93560E4CE731EA26ADFCCBDD5FCBF5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_us-gaap_CostOfGoodsSold_F5910B16AF0C87D33AB9FCCBDD5F6D9A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_FD93560E4CE731EA26ADFCCBDD5FCBF5" xlink:to="loc_us-gaap_CostOfGoodsSold_F5910B16AF0C87D33AB9FCCBDD5F6D9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_B1AE8F7EA2277EEF8827FCCBDD5F7D33" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_FD93560E4CE731EA26ADFCCBDD5FCBF5" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_B1AE8F7EA2277EEF8827FCCBDD5F7D33" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_21D2217831FE5468C6E6FCCBDD5FE99F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_FD93560E4CE731EA26ADFCCBDD5FCBF5" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_21D2217831FE5468C6E6FCCBDD5FE99F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_17C95568C4778DD6928CFCCBDD5F3088" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_FD93560E4CE731EA26ADFCCBDD5FCBF5" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_17C95568C4778DD6928CFCCBDD5F3088" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_856D9F349D2D90D2819BFCCBDD5F4385" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_FD93560E4CE731EA26ADFCCBDD5FCBF5" xlink:to="loc_us-gaap_RestructuringCharges_856D9F349D2D90D2819BFCCBDD5F4385" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_3F4C4F5DA9626C4430B2FCCBDD5FBFE8" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_FD93560E4CE731EA26ADFCCBDD5FCBF5" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_3F4C4F5DA9626C4430B2FCCBDD5FBFE8" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_CollaborationProfitSharing" xlink:label="loc_biib_CollaborationProfitSharing_BE122485326C843BE687FCCBDD5F03A8" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_FD93560E4CE731EA26ADFCCBDD5FCBF5" xlink:to="loc_biib_CollaborationProfitSharing_BE122485326C843BE687FCCBDD5F03A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationSettlementExpense" xlink:label="loc_us-gaap_LitigationSettlementExpense_98BBE6559AB72B39BB5EFCCBDD5F6343" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_FD93560E4CE731EA26ADFCCBDD5FCBF5" xlink:to="loc_us-gaap_LitigationSettlementExpense_98BBE6559AB72B39BB5EFCCBDD5F6343" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_965F66C724B6060765D1FCCBDD600DA5" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_FD93560E4CE731EA26ADFCCBDD5FCBF5" xlink:to="loc_us-gaap_CostsAndExpenses_965F66C724B6060765D1FCCBDD600DA5" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_GainOnSaleOfRights" xlink:label="loc_biib_GainOnSaleOfRights_6F9BE092AD4ACAD03193FCCBDD6037E8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_D34F471616F41BD6D58CFCCBDD5E76C5" xlink:to="loc_biib_GainOnSaleOfRights_6F9BE092AD4ACAD03193FCCBDD6037E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_060696BD2C6E8788D691FCCBDD60208C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_D34F471616F41BD6D58CFCCBDD5E76C5" xlink:to="loc_us-gaap_OperatingIncomeLoss_060696BD2C6E8788D691FCCBDD60208C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_D8677AC82452763B19A3FCCBDD6006F5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_D34F471616F41BD6D58CFCCBDD5E76C5" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_D8677AC82452763B19A3FCCBDD6006F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_308659B57A79C833AD1CFCCBDD603E62" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_D34F471616F41BD6D58CFCCBDD5E76C5" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_308659B57A79C833AD1CFCCBDD603E62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_E459415AC6FB9C9D93D8FCCBDD60AB8D" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_D34F471616F41BD6D58CFCCBDD5E76C5" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_E459415AC6FB9C9D93D8FCCBDD60AB8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_82BAB6CEE9EBCFE58B89FCCBDD6005FF" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_D34F471616F41BD6D58CFCCBDD5E76C5" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_82BAB6CEE9EBCFE58B89FCCBDD6005FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_3469D66CF9BBF1F1834FFCCBDD605EC2" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_D34F471616F41BD6D58CFCCBDD5E76C5" xlink:to="loc_us-gaap_ProfitLoss_3469D66CF9BBF1F1834FFCCBDD605EC2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_7D8FDC226FFA67387C20FCCBDD60A2E3" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_D34F471616F41BD6D58CFCCBDD5E76C5" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_7D8FDC226FFA67387C20FCCBDD60A2E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_B6F3A8DA5BF7E05ECAF6FCCBDD603284" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_D34F471616F41BD6D58CFCCBDD5E76C5" xlink:to="loc_us-gaap_NetIncomeLoss_B6F3A8DA5BF7E05ECAF6FCCBDD603284" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_BF2F3EE85FF499B55B90FCCBDD606B24" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_D34F471616F41BD6D58CFCCBDD5E76C5" xlink:to="loc_us-gaap_EarningsPerShareAbstract_BF2F3EE85FF499B55B90FCCBDD606B24" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_8FB422F5AC92D4A25632FCCBDD60EF45" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_BF2F3EE85FF499B55B90FCCBDD606B24" xlink:to="loc_us-gaap_EarningsPerShareBasic_8FB422F5AC92D4A25632FCCBDD60EF45" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_8423D4CD597EF24A7069FCCBDD6030C5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_BF2F3EE85FF499B55B90FCCBDD606B24" xlink:to="loc_us-gaap_EarningsPerShareDiluted_8423D4CD597EF24A7069FCCBDD6030C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_AD67AA00460A2457EE2FFCCBDD614B95" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_D34F471616F41BD6D58CFCCBDD5E76C5" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_AD67AA00460A2457EE2FFCCBDD614B95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_375F9D29E158306C7405FCCBDD6113BB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_AD67AA00460A2457EE2FFCCBDD614B95" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_375F9D29E158306C7405FCCBDD6113BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_D22321FD29756E5832DFFCCBDD615E2F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_AD67AA00460A2457EE2FFCCBDD614B95" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_D22321FD29756E5832DFFCCBDD615E2F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstruments" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_142A40A25596CA7CE43F741286B2453E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_116D803BA6268CD3C88F741286B2E6A6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_142A40A25596CA7CE43F741286B2453E" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_116D803BA6268CD3C88F741286B2E6A6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0CAB9E02CB66B21C4D22186112EDC250" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_E44222346ECE99266A93186112ED8AAE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0CAB9E02CB66B21C4D22186112EDC250" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_E44222346ECE99266A93186112ED8AAE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrencyAxis" xlink:label="loc_us-gaap_CurrencyAxis_B51BED92C483DC215186186112EDB970" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_E44222346ECE99266A93186112ED8AAE" xlink:to="loc_us-gaap_CurrencyAxis_B51BED92C483DC215186186112EDB970" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_AA6E6542DD5A025958E0186112ED6FBD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrencyAxis_B51BED92C483DC215186186112EDB970" xlink:to="loc_currency_AllCurrenciesDomain_AA6E6542DD5A025958E0186112ED6FBD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd#currency_EUR" xlink:label="loc_currency_EUR_BBDAE1D78EB0878F04C3186112EDE3C8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_AA6E6542DD5A025958E0186112ED6FBD" xlink:to="loc_currency_EUR_BBDAE1D78EB0878F04C3186112EDE3C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd#currency_CHF" xlink:label="loc_currency_CHF_A8DD31A1A2099CD86D9E186112ED9FAB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_AA6E6542DD5A025958E0186112ED6FBD" xlink:to="loc_currency_CHF_A8DD31A1A2099CD86D9E186112ED9FAB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd#currency_CAD" xlink:label="loc_currency_CAD_6CBE88D1FA60149A95C9186112ED8B0C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_AA6E6542DD5A025958E0186112ED6FBD" xlink:to="loc_currency_CAD_6CBE88D1FA60149A95C9186112ED8B0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_657B9A6846DAC536C718186112EEC7B0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_E44222346ECE99266A93186112ED8AAE" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_657B9A6846DAC536C718186112EEC7B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_255C0D941A39BFAE286B186112EEF440" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_657B9A6846DAC536C718186112EEC7B0" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_255C0D941A39BFAE286B186112EEF440" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="loc_us-gaap_ForeignExchangeContractMember_740A43694E7991786FCE186112EEF80A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_255C0D941A39BFAE286B186112EEF440" xlink:to="loc_us-gaap_ForeignExchangeContractMember_740A43694E7991786FCE186112EEF80A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_E9F7B9CB4F5C9A0F57B2186112EEAD69" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_E44222346ECE99266A93186112ED8AAE" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_E9F7B9CB4F5C9A0F57B2186112EEAD69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_7F7BE59861405F5F9A03186112EE1034" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_E9F7B9CB4F5C9A0F57B2186112EEAD69" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_7F7BE59861405F5F9A03186112EE1034" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_5745D7DD90C294934703186112EEB39E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7F7BE59861405F5F9A03186112EE1034" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_5745D7DD90C294934703186112EEB39E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherInvestmentsMember" xlink:label="loc_us-gaap_OtherInvestmentsMember_B914893C190F339B7D97186112F305F3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7F7BE59861405F5F9A03186112EE1034" xlink:to="loc_us-gaap_OtherInvestmentsMember_B914893C190F339B7D97186112F305F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_379BCDD7D1C024696773186112F4157A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7F7BE59861405F5F9A03186112EE1034" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_379BCDD7D1C024696773186112F4157A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_D0E5A657A5AA1E6BA426186112F43986" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7F7BE59861405F5F9A03186112EE1034" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_D0E5A657A5AA1E6BA426186112F43986" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_592EC7CDF857F6D24008186112F44962" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_E44222346ECE99266A93186112ED8AAE" xlink:to="loc_us-gaap_HedgingDesignationAxis_592EC7CDF857F6D24008186112F44962" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_F8ED8A5ACD0D211BF31D186112F476D2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_592EC7CDF857F6D24008186112F44962" xlink:to="loc_us-gaap_HedgingDesignationDomain_F8ED8A5ACD0D211BF31D186112F476D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_4D3F532F0A3E8C8D4101186112F44698" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_F8ED8A5ACD0D211BF31D186112F476D2" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_4D3F532F0A3E8C8D4101186112F44698" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="loc_us-gaap_NondesignatedMember_44035CF15944EB78A8FD186112F47D25" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_F8ED8A5ACD0D211BF31D186112F476D2" xlink:to="loc_us-gaap_NondesignatedMember_44035CF15944EB78A8FD186112F47D25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativesFairValueLineItems" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_1179AEFBD10892F1480E186112F489A5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_E44222346ECE99266A93186112ED8AAE" xlink:to="loc_us-gaap_DerivativesFairValueLineItems_1179AEFBD10892F1480E186112F489A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_DerivativeNotionalAmount" xlink:label="loc_invest_DerivativeNotionalAmount_3B164CC99080F2DF68B5186112F41CF0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_1179AEFBD10892F1480E186112F489A5" xlink:to="loc_invest_DerivativeNotionalAmount_3B164CC99080F2DF68B5186112F41CF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeAssetFairValueNetAbstract" xlink:label="loc_us-gaap_DerivativeAssetFairValueNetAbstract_26230DFBF28AD02C4F65186112F46324" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_1179AEFBD10892F1480E186112F489A5" xlink:to="loc_us-gaap_DerivativeAssetFairValueNetAbstract_26230DFBF28AD02C4F65186112F46324" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_8A7B461A78C70294B3EB186112F4066A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeAssetFairValueNetAbstract_26230DFBF28AD02C4F65186112F46324" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_8A7B461A78C70294B3EB186112F4066A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_00ECC430F1245E830914186112F4AB13" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeAssetFairValueNetAbstract_26230DFBF28AD02C4F65186112F46324" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_00ECC430F1245E830914186112F4AB13" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_28513005836CD22FDC4FFB668011C771" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_34DCD7F960B80F9D1E97FB668012FAF6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_28513005836CD22FDC4FFB668011C771" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_34DCD7F960B80F9D1E97FB668012FAF6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_7BBFC8975BC9C4B99053FB668012D9AB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_34DCD7F960B80F9D1E97FB668012FAF6" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_7BBFC8975BC9C4B99053FB668012D9AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_A280D04F8E21772ED805FB66801288EA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_7BBFC8975BC9C4B99053FB668012D9AB" xlink:to="loc_us-gaap_HedgingRelationshipDomain_A280D04F8E21772ED805FB66801288EA" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_CashflowsrevenueMember" xlink:label="loc_biib_CashflowsrevenueMember_507D7556AA9E08361F15FB668012D7E8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_A280D04F8E21772ED805FB66801288EA" xlink:to="loc_biib_CashflowsrevenueMember_507D7556AA9E08361F15FB668012D7E8" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_CashflowsoperatingexpensesMember" xlink:label="loc_biib_CashflowsoperatingexpensesMember_DDA91E7A320E5EE7E18EFB668012F39E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_A280D04F8E21772ED805FB66801288EA" xlink:to="loc_biib_CashflowsoperatingexpensesMember_DDA91E7A320E5EE7E18EFB668012F39E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_F290BE8C00DB34944206FB6680120083" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_34DCD7F960B80F9D1E97FB668012FAF6" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_F290BE8C00DB34944206FB6680120083" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_2CECFC135AD170E8F1B6FB668013A6CC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_F290BE8C00DB34944206FB6680120083" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_2CECFC135AD170E8F1B6FB668013A6CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="loc_us-gaap_ForeignExchangeContractMember_8DB4036B1D96E28AEC3EFB668013BF12" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_2CECFC135AD170E8F1B6FB668013A6CC" xlink:to="loc_us-gaap_ForeignExchangeContractMember_8DB4036B1D96E28AEC3EFB668013BF12" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1A9D6CD01BC85D8D1249FB668013E198" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_34DCD7F960B80F9D1E97FB668012FAF6" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1A9D6CD01BC85D8D1249FB668013E198" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_C20CF2A963C92219A81CFB6680135339" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1A9D6CD01BC85D8D1249FB668013E198" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_C20CF2A963C92219A81CFB6680135339" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesMember" xlink:label="loc_us-gaap_SalesMember_FFE7E1FBAABDAD0D85BCFB6680136F66" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_C20CF2A963C92219A81CFB6680135339" xlink:to="loc_us-gaap_SalesMember_FFE7E1FBAABDAD0D85BCFB6680136F66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_69973FCE9F74433E7CABFB668013D4BF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_C20CF2A963C92219A81CFB6680135339" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_69973FCE9F74433E7CABFB668013D4BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenseMember" xlink:label="loc_us-gaap_OperatingExpenseMember_8CEE66D007DD8283F373FB6680135FF8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_C20CF2A963C92219A81CFB6680135339" xlink:to="loc_us-gaap_OperatingExpenseMember_8CEE66D007DD8283F373FB6680135FF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_A39CC300AEA523911224FB6680133AB7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_34DCD7F960B80F9D1E97FB668012FAF6" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_A39CC300AEA523911224FB6680133AB7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNetAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNetAbstract_3F3A7C17B1A3BE73F461FB668013ABDA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_A39CC300AEA523911224FB6680133AB7" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNetAbstract_3F3A7C17B1A3BE73F461FB668013ABDA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_16AF03C759DF2C58D130FB6680136A5A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNetAbstract_3F3A7C17B1A3BE73F461FB668013ABDA" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_16AF03C759DF2C58D130FB6680136A5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_D2AB121D2B1355043A4FFB6680149A4F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNetAbstract_3F3A7C17B1A3BE73F461FB668013ABDA" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_D2AB121D2B1355043A4FFB6680149A4F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_35DA316B13DA2BFA7D14FB668003998C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_8BF6C47D5795C29BD852FB668003AC5E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_35DA316B13DA2BFA7D14FB668003998C" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_8BF6C47D5795C29BD852FB668003AC5E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_22F7A5A2E8AF9C633972FB66800438B5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_8BF6C47D5795C29BD852FB668003AC5E" xlink:to="loc_us-gaap_RangeAxis_22F7A5A2E8AF9C633972FB66800438B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_48A68AE7842B3D831AA5FB668004C539" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_22F7A5A2E8AF9C633972FB66800438B5" xlink:to="loc_us-gaap_RangeMember_48A68AE7842B3D831AA5FB668004C539" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_9489C7419AC4A154B011FB6680045D99" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_48A68AE7842B3D831AA5FB668004C539" xlink:to="loc_us-gaap_MinimumMember_9489C7419AC4A154B011FB6680045D99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_D76683016A8DE77B3954FB668004071E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_48A68AE7842B3D831AA5FB668004C539" xlink:to="loc_us-gaap_MaximumMember_D76683016A8DE77B3954FB668004071E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_C6BC7FEBC00234FDC2AAFB6680056C67" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_8BF6C47D5795C29BD852FB668003AC5E" xlink:to="loc_us-gaap_DebtInstrumentAxis_C6BC7FEBC00234FDC2AAFB6680056C67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8EF21CBD550D7C1BFB7BFB668005E155" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_C6BC7FEBC00234FDC2AAFB6680056C67" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8EF21CBD550D7C1BFB7BFB668005E155" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_EB5D5AF8F1DDF80D8FA1FB668005FECC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8EF21CBD550D7C1BFB7BFB668005E155" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_EB5D5AF8F1DDF80D8FA1FB668005FECC" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_AE349128F8900B42E8F5FB6680057E8C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8EF21CBD550D7C1BFB7BFB668005E155" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_AE349128F8900B42E8F5FB6680057E8C" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_06D2CA3ED529EED137C4FB6680055156" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8EF21CBD550D7C1BFB7BFB668005E155" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_06D2CA3ED529EED137C4FB6680055156" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_20C6C0BB40981E6AF767FB6680055CBD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_8BF6C47D5795C29BD852FB668003AC5E" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_20C6C0BB40981E6AF767FB6680055CBD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_A3C34263A548BA4DFFABFB6680056163" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_20C6C0BB40981E6AF767FB6680055CBD" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_A3C34263A548BA4DFFABFB6680056163" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestRateContractMember" xlink:label="loc_us-gaap_InterestRateContractMember_0BC792B987CE7F40A565FB6680054D0C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_A3C34263A548BA4DFFABFB6680056163" xlink:to="loc_us-gaap_InterestRateContractMember_0BC792B987CE7F40A565FB6680054D0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember_F13D63C6AFD3ACAC3980FB6680055877" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_A3C34263A548BA4DFFABFB6680056163" xlink:to="loc_us-gaap_InterestRateSwapMember_F13D63C6AFD3ACAC3980FB6680055877" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_52BBBC171EE38D0B4667FB6680053378" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_8BF6C47D5795C29BD852FB668003AC5E" xlink:to="loc_us-gaap_HedgingDesignationAxis_52BBBC171EE38D0B4667FB6680053378" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_0D221CDC070FEFEC0C9CFB6680056B80" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_52BBBC171EE38D0B4667FB6680053378" xlink:to="loc_us-gaap_HedgingDesignationDomain_0D221CDC070FEFEC0C9CFB6680056B80" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_77C57B707FA5DDF57596FB668006FF6E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_0D221CDC070FEFEC0C9CFB6680056B80" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_77C57B707FA5DDF57596FB668006FF6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="loc_us-gaap_NondesignatedMember_B0E1373503EA2087430BFB6680060024" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_0D221CDC070FEFEC0C9CFB6680056B80" xlink:to="loc_us-gaap_NondesignatedMember_B0E1373503EA2087430BFB6680060024" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativesFairValueLineItems" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_F0D72898DA7CC956EEDCFB6680068D64" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_8BF6C47D5795C29BD852FB668003AC5E" xlink:to="loc_us-gaap_DerivativesFairValueLineItems_F0D72898DA7CC956EEDCFB6680068D64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeRemainingMaturity1" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1_955D089587F4AA09DAF2FB66800649BC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_F0D72898DA7CC956EEDCFB6680068D64" xlink:to="loc_us-gaap_DerivativeRemainingMaturity1_955D089587F4AA09DAF2FB66800649BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_DerivativeNotionalAmount" xlink:label="loc_invest_DerivativeNotionalAmount_30CB92F9D52F45BFAAAFFB6680065E7B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_F0D72898DA7CC956EEDCFB6680068D64" xlink:to="loc_invest_DerivativeNotionalAmount_30CB92F9D52F45BFAAAFFB6680065E7B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_06CDF68D16D3273F45BAFB66800636E3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_F0D72898DA7CC956EEDCFB6680068D64" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_06CDF68D16D3273F45BAFB66800636E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_2C73426F798D539A9817FB66800645D7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_F0D72898DA7CC956EEDCFB6680068D64" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_2C73426F798D539A9817FB66800645D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" xlink:label="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_90AFF56FC9C3F2358358FB668006D3FA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_35DA316B13DA2BFA7D14FB668003998C" xlink:to="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_90AFF56FC9C3F2358358FB668006D3FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1" xlink:label="loc_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1_4E4F19E46316DC86F90AFB668006498B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_35DA316B13DA2BFA7D14FB668003998C" xlink:to="loc_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1_4E4F19E46316DC86F90AFB668006498B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_7A84FAEB44F64E1A4260FB668006FF65" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_35DA316B13DA2BFA7D14FB668003998C" xlink:to="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_7A84FAEB44F64E1A4260FB668006FF65" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_CA2B19929CCCDCC66CD674128836B88A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_7B672CBCA8F28885979C741288362640" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_CA2B19929CCCDCC66CD674128836B88A" xlink:to="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_7B672CBCA8F28885979C741288362640" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_655EA3463ADB73E0289474128836F1BF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_CA2B19929CCCDCC66CD674128836B88A" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_655EA3463ADB73E0289474128836F1BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_718BDE7B59B1007EF1F0741288372165" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_CA2B19929CCCDCC66CD674128836B88A" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_718BDE7B59B1007EF1F0741288372165" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <link:loc xlink:href="biib-20161231.xsd#biib_DocumentAndEntityInformationAbstract" xlink:label="loc_biib_DocumentAndEntityInformationAbstract_2E9C329A656DE6A45C21F60DFFBB4217" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_00F29C0724315EA9D3E3F60DFFBBF5DC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_2E9C329A656DE6A45C21F60DFFBB4217" xlink:to="loc_dei_EntityRegistrantName_00F29C0724315EA9D3E3F60DFFBBF5DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_FB51DC7CDB37BEF66026F60DFFBB2925" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_2E9C329A656DE6A45C21F60DFFBB4217" xlink:to="loc_dei_EntityCentralIndexKey_FB51DC7CDB37BEF66026F60DFFBB2925" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_B8DB82CB7E46059910F5F60DFFBBC7D5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_2E9C329A656DE6A45C21F60DFFBB4217" xlink:to="loc_dei_CurrentFiscalYearEndDate_B8DB82CB7E46059910F5F60DFFBBC7D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_D7923CDE99A53FB86196F60DFFBB4460" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_2E9C329A656DE6A45C21F60DFFBB4217" xlink:to="loc_dei_EntityFilerCategory_D7923CDE99A53FB86196F60DFFBB4460" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_411C797853B1B34B6546F60DFFBB0CC6" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_2E9C329A656DE6A45C21F60DFFBB4217" xlink:to="loc_dei_DocumentType_411C797853B1B34B6546F60DFFBB0CC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_B311D47439E0D100C915F60DFFBB7741" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_2E9C329A656DE6A45C21F60DFFBB4217" xlink:to="loc_dei_DocumentPeriodEndDate_B311D47439E0D100C915F60DFFBB7741" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_3A02C104290A8AED2CC6F60DFFBB80E2" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_2E9C329A656DE6A45C21F60DFFBB4217" xlink:to="loc_dei_DocumentFiscalYearFocus_3A02C104290A8AED2CC6F60DFFBB80E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_31DB33FEFF0917E11805F60DFFBB2867" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_2E9C329A656DE6A45C21F60DFFBB4217" xlink:to="loc_dei_DocumentFiscalPeriodFocus_31DB33FEFF0917E11805F60DFFBB2867" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_9BA082B1875FEB4C8029F60DFFBB6D17" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_2E9C329A656DE6A45C21F60DFFBB4217" xlink:to="loc_dei_AmendmentFlag_9BA082B1875FEB4C8029F60DFFBB6D17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_8F100A8CD69F5A0E8023F60DFFBB4C63" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_2E9C329A656DE6A45C21F60DFFBB4217" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_8F100A8CD69F5A0E8023F60DFFBB4C63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_951346FB54666DBCF607F60DFFBBC125" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_2E9C329A656DE6A45C21F60DFFBB4217" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_951346FB54666DBCF607F60DFFBBC125" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_4E98B5DA9083436BDA70F60DFFBBC87A" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_2E9C329A656DE6A45C21F60DFFBB4217" xlink:to="loc_dei_EntityVoluntaryFilers_4E98B5DA9083436BDA70F60DFFBBC87A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_AB0C57CC23789B480FD4F60DFFBB2551" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_2E9C329A656DE6A45C21F60DFFBB4217" xlink:to="loc_dei_EntityCurrentReportingStatus_AB0C57CC23789B480FD4F60DFFBB2551" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_4F0202F19F5AE05DFCC1F60DFFBBC3E4" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_2E9C329A656DE6A45C21F60DFFBB4217" xlink:to="loc_dei_EntityPublicFloat_4F0202F19F5AE05DFCC1F60DFFBBC3E4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EarningsPerShare" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_803A2E5B6F9C2E2E5EAB7412862B31CC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_F834A14464F81AADCB707412862B21D9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_803A2E5B6F9C2E2E5EAB7412862B31CC" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_F834A14464F81AADCB707412862B21D9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_4A5295A91E10A8D0C67C74128545B43D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_405885FB801A26F6CD28741285461380" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4A5295A91E10A8D0C67C74128545B43D" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_405885FB801A26F6CD28741285461380" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3D6521F7DE12D3604596741285468FD2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_405885FB801A26F6CD28741285461380" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3D6521F7DE12D3604596741285468FD2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0B122B3CFECA999F5C45741285468C47" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3D6521F7DE12D3604596741285468FD2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0B122B3CFECA999F5C45741285468C47" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_StockOptionsAndEmployeeStockPurchasePlanMember" xlink:label="loc_biib_StockOptionsAndEmployeeStockPurchasePlanMember_E78A59C52EEDABD124E674128546A36F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0B122B3CFECA999F5C45741285468C47" xlink:to="loc_biib_StockOptionsAndEmployeeStockPurchasePlanMember_E78A59C52EEDABD124E674128546A36F" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_233C56A82D092AFD36FC7412854645F5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0B122B3CFECA999F5C45741285468C47" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_233C56A82D092AFD36FC7412854645F5" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_0B7D95AF5AF21DDDE7EF74128546B1BC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0B122B3CFECA999F5C45741285468C47" xlink:to="loc_biib_MarketStockUnitsMember_0B7D95AF5AF21DDDE7EF74128546B1BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_B3C5EDA290A7207E19A774128546FC8A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_405885FB801A26F6CD28741285461380" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_B3C5EDA290A7207E19A774128546FC8A" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_BasicAndDilutedEarningsPerShareAbstract" xlink:label="loc_biib_BasicAndDilutedEarningsPerShareAbstract_4C0290AF0CD79276F6997412854641C9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_B3C5EDA290A7207E19A774128546FC8A" xlink:to="loc_biib_BasicAndDilutedEarningsPerShareAbstract_4C0290AF0CD79276F6997412854641C9" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_NumeratorAbstract" xlink:label="loc_biib_NumeratorAbstract_6715CC6AD8F213A757397412854646AC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_4C0290AF0CD79276F6997412854641C9" xlink:to="loc_biib_NumeratorAbstract_6715CC6AD8F213A757397412854646AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_0F1DE0E8F05F3EE856F47412854697F0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_NumeratorAbstract_6715CC6AD8F213A757397412854646AC" xlink:to="loc_us-gaap_NetIncomeLoss_0F1DE0E8F05F3EE856F47412854697F0" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_DenominatorAbstract" xlink:label="loc_biib_DenominatorAbstract_440A9944CF67CDD0BBBA741285463724" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_4C0290AF0CD79276F6997412854641C9" xlink:to="loc_biib_DenominatorAbstract_440A9944CF67CDD0BBBA741285463724" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_C5E1F5F301F2613EE0A674128546F32E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DenominatorAbstract_440A9944CF67CDD0BBBA741285463724" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_C5E1F5F301F2613EE0A674128546F32E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_0F494F54B561DEC4FE4974128546CDB7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DenominatorAbstract_440A9944CF67CDD0BBBA741285463724" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_0F494F54B561DEC4FE4974128546CDB7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_114DB08C90AEEC8432C574128546E076" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_0F494F54B561DEC4FE4974128546CDB7" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_114DB08C90AEEC8432C574128546E076" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_5496007EB242490CE16B741285471985" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_0F494F54B561DEC4FE4974128546CDB7" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_5496007EB242490CE16B741285471985" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_24B4B2C04F281ABB404374128547D45A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DenominatorAbstract_440A9944CF67CDD0BBBA741285463724" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_24B4B2C04F281ABB404374128547D45A" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_EarningsPerShareTextualAbstract" xlink:label="loc_biib_EarningsPerShareTextualAbstract_9E70D23636B7662ADEF7741285475A0F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4A5295A91E10A8D0C67C74128545B43D" xlink:to="loc_biib_EarningsPerShareTextualAbstract_9E70D23636B7662ADEF7741285475A0F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_09F30CF3ADB6E2C9846E74128547E20F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_EarningsPerShareTextualAbstract_9E70D23636B7662ADEF7741285475A0F" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_09F30CF3ADB6E2C9846E74128547E20F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EarningsPerShareTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1A736A9B4BC96C4D945B741285F8FF60" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_FB1E2F4BAE47D4508BE5741285F82F22" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1A736A9B4BC96C4D945B741285F8FF60" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_FB1E2F4BAE47D4508BE5741285F82F22" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EmployeeBenefitPlans" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_E720D6CCDB917D80092C741285871D4E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_EE4D83818B9DC6E34A307412858731FC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_E720D6CCDB917D80092C741285871D4E" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_EE4D83818B9DC6E34A307412858731FC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EmployeeBenefitPlansDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_034ABD604878E4296477FD60F5C0B51E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_9AB432A796BA545F439EFD60F5C0A275" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_034ABD604878E4296477FD60F5C0B51E" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_9AB432A796BA545F439EFD60F5C0A275" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis" xlink:label="loc_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_6F29096E529B1F29FED9FD60F5C168EF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_9AB432A796BA545F439EFD60F5C0A275" xlink:to="loc_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_6F29096E529B1F29FED9FD60F5C168EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefinedBenefitPlansDomain" xlink:label="loc_us-gaap_DefinedBenefitPlansDomain_2D6164896BA60719C29AFD60F5C19D5B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_6F29096E529B1F29FED9FD60F5C168EF" xlink:to="loc_us-gaap_DefinedBenefitPlansDomain_2D6164896BA60719C29AFD60F5C19D5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignPensionPlansDefinedBenefitMember" xlink:label="loc_us-gaap_ForeignPensionPlansDefinedBenefitMember_F21ADBC6EDDE7D137A5CFD6419EBF273" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansDomain_2D6164896BA60719C29AFD60F5C19D5B" xlink:to="loc_us-gaap_ForeignPensionPlansDefinedBenefitMember_F21ADBC6EDDE7D137A5CFD6419EBF273" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_67C5FB5D02E7E9D86146FD66B9F28C3C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_9AB432A796BA545F439EFD60F5C0A275" xlink:to="loc_us-gaap_StatementGeographicalAxis_67C5FB5D02E7E9D86146FD66B9F28C3C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_098044288CA921EA5970FD66BAAC8841" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementGeographicalAxis_67C5FB5D02E7E9D86146FD66B9F28C3C" xlink:to="loc_us-gaap_SegmentGeographicalDomain_098044288CA921EA5970FD66BAAC8841" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd#country_CH" xlink:label="loc_country_CH_0EAA89673D11D8FB27C9FD6742C94FEB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_098044288CA921EA5970FD66BAAC8841" xlink:to="loc_country_CH_0EAA89673D11D8FB27C9FD6742C94FEB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd#country_DE" xlink:label="loc_country_DE_BE99447F614882305BD6FD688657C73A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_098044288CA921EA5970FD66BAAC8841" xlink:to="loc_country_DE_BE99447F614882305BD6FD688657C73A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_13479C04743014554B3FFD60F5C184FB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_9AB432A796BA545F439EFD60F5C0A275" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_13479C04743014554B3FFD60F5C184FB" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_EmployeeBenefitPlansTextualAbstract" xlink:label="loc_biib_EmployeeBenefitPlansTextualAbstract_7A70FCB58BEB71A72903FD60F5C14026" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_13479C04743014554B3FFD60F5C184FB" xlink:to="loc_biib_EmployeeBenefitPlansTextualAbstract_7A70FCB58BEB71A72903FD60F5C14026" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_PercentageOfMinimumInvestmentReturn" xlink:label="loc_biib_PercentageOfMinimumInvestmentReturn_B803952E3AC6721C66B7FD60F5C168C8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_EmployeeBenefitPlansTextualAbstract_7A70FCB58BEB71A72903FD60F5C14026" xlink:to="loc_biib_PercentageOfMinimumInvestmentReturn_B803952E3AC6721C66B7FD60F5C168C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_E9A909DCC0F31FA6C863FD60F5C208A7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_EmployeeBenefitPlansTextualAbstract_7A70FCB58BEB71A72903FD60F5C14026" xlink:to="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_E9A909DCC0F31FA6C863FD60F5C208A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_152647AA8B6CA2F0F7D3FD60F5C22261" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_EmployeeBenefitPlansTextualAbstract_7A70FCB58BEB71A72903FD60F5C14026" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_152647AA8B6CA2F0F7D3FD60F5C22261" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PensionExpense" xlink:label="loc_us-gaap_PensionExpense_2396CA64D497F4D40453FD60F5C25E4F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_EmployeeBenefitPlansTextualAbstract_7A70FCB58BEB71A72903FD60F5C14026" xlink:to="loc_us-gaap_PensionExpense_2396CA64D497F4D40453FD60F5C25E4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_CC3BAFC54E0950244E81FD60F5C23CED" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_EmployeeBenefitPlansTextualAbstract_7A70FCB58BEB71A72903FD60F5C14026" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_CC3BAFC54E0950244E81FD60F5C23CED" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EmployeeBenefitPlansEmployeeBenefitPlansDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_5B857C1253846B7A1257FD6451947DB9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="loc_us-gaap_DefinedContributionPlanTable_C4C775A7D36A0F609D51FD64519486FE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_5B857C1253846B7A1257FD6451947DB9" xlink:to="loc_us-gaap_DefinedContributionPlanTable_C4C775A7D36A0F609D51FD64519486FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefinedContributionPlanTypeAxis" xlink:label="loc_us-gaap_DefinedContributionPlanTypeAxis_3D839D87DF83F0AB7DF7FD6451952CA5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanTable_C4C775A7D36A0F609D51FD64519486FE" xlink:to="loc_us-gaap_DefinedContributionPlanTypeAxis_3D839D87DF83F0AB7DF7FD6451952CA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefinedContributionPlanTypeDomain" xlink:label="loc_us-gaap_DefinedContributionPlanTypeDomain_3DF3F09439BE8A680A6CFD645195EB5B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanTypeAxis_3D839D87DF83F0AB7DF7FD6451952CA5" xlink:to="loc_us-gaap_DefinedContributionPlanTypeDomain_3DF3F09439BE8A680A6CFD645195EB5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnitedStatesPostretirementBenefitPlansOfUSEntityDefinedBenefitMember" xlink:label="loc_us-gaap_UnitedStatesPostretirementBenefitPlansOfUSEntityDefinedBenefitMember_F8051DF1BA9540C14AE8FD64519560F5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanTypeDomain_3DF3F09439BE8A680A6CFD645195EB5B" xlink:to="loc_us-gaap_UnitedStatesPostretirementBenefitPlansOfUSEntityDefinedBenefitMember_F8051DF1BA9540C14AE8FD64519560F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_136486EEEF0CD6313610FD6BA62FDA67" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanTypeDomain_3DF3F09439BE8A680A6CFD645195EB5B" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_136486EEEF0CD6313610FD6BA62FDA67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_60F954C5A78454392A34FD645195A226" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanTable_C4C775A7D36A0F609D51FD64519486FE" xlink:to="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_60F954C5A78454392A34FD645195A226" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_MinimumQualifyingAgeForEmployeeBenefitPlan" xlink:label="loc_biib_MinimumQualifyingAgeForEmployeeBenefitPlan_1634074B30605814AFF0FD645195979B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_60F954C5A78454392A34FD645195A226" xlink:to="loc_biib_MinimumQualifyingAgeForEmployeeBenefitPlan_1634074B30605814AFF0FD645195979B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_E17AD2B62461B01A77F1FD6451951985" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_60F954C5A78454392A34FD645195A226" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_E17AD2B62461B01A77F1FD6451951985" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:label="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_4A360062E9362E8FB324FD6451959BDC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_60F954C5A78454392A34FD645195A226" xlink:to="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_4A360062E9362E8FB324FD6451959BDC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Equity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_9937BFE277EC9989AB6774128598C691" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_A7DF48A8C4E0E99F7BE674128598937F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_9937BFE277EC9989AB6774128598C691" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_A7DF48A8C4E0E99F7BE674128598937F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EquityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_AE1EBAD1F58F6D2DBC81741285FAF6E3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_1BCFD0CBEBC2A5F68282741285FAE103" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_AE1EBAD1F58F6D2DBC81741285FAF6E3" xlink:to="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_1BCFD0CBEBC2A5F68282741285FAE103" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_8F64AE470796D326ED11741285FAE98B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_1BCFD0CBEBC2A5F68282741285FAE103" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_8F64AE470796D326ED11741285FAE98B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_BC08D84117549A61703B741285FAAE9C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_1BCFD0CBEBC2A5F68282741285FAE103" xlink:to="loc_us-gaap_CommonStockSharesIssued_BC08D84117549A61703B741285FAAE9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_C8D6D2906F3358D6496B741285FA91BF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_1BCFD0CBEBC2A5F68282741285FAE103" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_C8D6D2906F3358D6496B741285FA91BF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EquityDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_9180C6F99C377148FEF1885D71D4FED3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_B25930ABFB3B1B06F7D9885D71D9E738" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_9180C6F99C377148FEF1885D71D4FED3" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_B25930ABFB3B1B06F7D9885D71D9E738" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_BED900729CBA0DB819F6885D71D9455B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_B25930ABFB3B1B06F7D9885D71D9E738" xlink:to="loc_us-gaap_StatementClassOfStockAxis_BED900729CBA0DB819F6885D71D9455B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_B0E001EB0DA96B832B6E885D71D9E4AD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_BED900729CBA0DB819F6885D71D9455B" xlink:to="loc_us-gaap_ClassOfStockDomain_B0E001EB0DA96B832B6E885D71D9E4AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_A2CFEEB2754F29240CFF885D71D9BD58" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_B0E001EB0DA96B832B6E885D71D9E4AD" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_A2CFEEB2754F29240CFF885D71D9BD58" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_SeriesXPreferredStockMember" xlink:label="loc_biib_SeriesXPreferredStockMember_4817424A7F71C9DFF7C2885D71DADE28" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_B0E001EB0DA96B832B6E885D71D9E4AD" xlink:to="loc_biib_SeriesXPreferredStockMember_4817424A7F71C9DFF7C2885D71DADE28" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_UndesignatedPreferredStockMember" xlink:label="loc_biib_UndesignatedPreferredStockMember_1E5BD6E086FF1C15BAA7885D71DA954A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_B0E001EB0DA96B832B6E885D71D9E4AD" xlink:to="loc_biib_UndesignatedPreferredStockMember_1E5BD6E086FF1C15BAA7885D71DA954A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_FACBFD4C48C6B6B40D70885D71DA4DF9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_B25930ABFB3B1B06F7D9885D71D9E738" xlink:to="loc_us-gaap_ClassOfStockLineItems_FACBFD4C48C6B6B40D70885D71DA4DF9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_188C0B99672A470C7EEB885D71DA4B2A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_FACBFD4C48C6B6B40D70885D71DA4DF9" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_188C0B99672A470C7EEB885D71DA4B2A" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_EquityTextualAbstract" xlink:label="loc_biib_EquityTextualAbstract_C3180DBF4C88F59446A0885D71DAE66D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_9180C6F99C377148FEF1885D71D4FED3" xlink:to="loc_biib_EquityTextualAbstract_C3180DBF4C88F59446A0885D71DAE66D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_E0E3A28F27926F563495885D71F1DCA5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_EquityTextualAbstract_C3180DBF4C88F59446A0885D71DAE66D" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_E0E3A28F27926F563495885D71F1DCA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_64BC21E348D04C12287C885D71F1D852" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_EquityTextualAbstract_C3180DBF4C88F59446A0885D71DAE66D" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_64BC21E348D04C12287C885D71F1D852" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_AB799FEC70DC92CB719B885D71F17EBA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_EquityTextualAbstract_C3180DBF4C88F59446A0885D71DAE66D" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_AB799FEC70DC92CB719B885D71F17EBA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:label="loc_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_62653CD603211D471394885D71F13A31" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_EquityTextualAbstract_C3180DBF4C88F59446A0885D71DAE66D" xlink:to="loc_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_62653CD603211D471394885D71F13A31" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EquityTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_59B309AD064B9CBCC4ED7412882F0C50" xlink:type="locator" />
    <link:loc xlink:href="biib-20161231.xsd#biib_SummaryOfCommonStockTableTextBlock" xlink:label="loc_biib_SummaryOfCommonStockTableTextBlock_A7C3745096884837CFBF7412882FBEB7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_59B309AD064B9CBCC4ED7412882F0C50" xlink:to="loc_biib_SummaryOfCommonStockTableTextBlock_A7C3745096884837CFBF7412882FBEB7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_95193A67A185A989E3827412868E024E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_A7BDEDDD3365807A25E67412868E67C0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_95193A67A185A989E3827412868E024E" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_A7BDEDDD3365807A25E67412868E67C0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_434971C0056778009BB4741289630E97" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3CCB0A2AB40DAF2E2F9B741289630065" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_434971C0056778009BB4741289630E97" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3CCB0A2AB40DAF2E2F9B741289630065" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_327672A363745DB84C9F74128964607C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3CCB0A2AB40DAF2E2F9B741289630065" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_327672A363745DB84C9F74128964607C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1DDEEFDCD55F1D744C83741289643D96" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_327672A363745DB84C9F74128964607C" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1DDEEFDCD55F1D744C83741289643D96" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_9D9C356F0EFCB93ECEDF74128964A4A4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1DDEEFDCD55F1D744C83741289643D96" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_9D9C356F0EFCB93ECEDF74128964A4A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_DB096D52768136F61AF974128964987C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1DDEEFDCD55F1D744C83741289643D96" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_DB096D52768136F61AF974128964987C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_3EEE1517D2B327599B6A741289647B8C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1DDEEFDCD55F1D744C83741289643D96" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_3EEE1517D2B327599B6A741289647B8C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_73C9E29BF6AEB9D30F2A741289643C76" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3CCB0A2AB40DAF2E2F9B741289630065" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_73C9E29BF6AEB9D30F2A741289643C76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_406003CA77C8EF712832741289644A6A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_73C9E29BF6AEB9D30F2A741289643C76" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_406003CA77C8EF712832741289644A6A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_8FCAF976D552BC56841C74128964499B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_406003CA77C8EF712832741289644A6A" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_8FCAF976D552BC56841C74128964499B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_D94706AFE6497BB12B3274128964AB8F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3CCB0A2AB40DAF2E2F9B741289630065" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_D94706AFE6497BB12B3274128964AB8F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_036C5ED6840CCBCC63DB74128964ED11" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_D94706AFE6497BB12B3274128964AB8F" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_036C5ED6840CCBCC63DB74128964ED11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_67889AE4268160F0FE6D74128965752D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_036C5ED6840CCBCC63DB74128964ED11" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_67889AE4268160F0FE6D74128965752D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_DEF1CB5B47F0DEF646C974128965E928" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_036C5ED6840CCBCC63DB74128964ED11" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_DEF1CB5B47F0DEF646C974128965E928" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_7F50926FDE3AB1CEF983741289658F24" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_036C5ED6840CCBCC63DB74128964ED11" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_7F50926FDE3AB1CEF983741289658F24" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_D0B12C1FE3D48CC43B8C741289654F67" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3CCB0A2AB40DAF2E2F9B741289630065" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_D0B12C1FE3D48CC43B8C741289654F67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_4E1AEE1C863591E840CB74128965E970" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_D0B12C1FE3D48CC43B8C741289654F67" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_4E1AEE1C863591E840CB74128965E970" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_5FCC9271109AD25A7E0074128965442F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_4E1AEE1C863591E840CB74128965E970" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_5FCC9271109AD25A7E0074128965442F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_10CAD8AF675AB0EFA3B874128965A54A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_5FCC9271109AD25A7E0074128965442F" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_10CAD8AF675AB0EFA3B874128965A54A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_AE74DF41AF5479492ECB74128965820A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_5FCC9271109AD25A7E0074128965442F" xlink:to="loc_us-gaap_AvailableForSaleSecurities_AE74DF41AF5479492ECB74128965820A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_AD5E170D5A8B38B9977F741289652F71" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_5FCC9271109AD25A7E0074128965442F" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_AD5E170D5A8B38B9977F741289652F71" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_E4EEF57A4D4FE7A07D4E741289659AFF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_5FCC9271109AD25A7E0074128965442F" xlink:to="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_E4EEF57A4D4FE7A07D4E741289659AFF" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:label="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_C8C1BB0AD6F0093A41BC7412896585C0" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_5FCC9271109AD25A7E0074128965442F" xlink:to="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_C8C1BB0AD6F0093A41BC7412896585C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_B2AD5C745A88A43189FC74128965BA58" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_5FCC9271109AD25A7E0074128965442F" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_B2AD5C745A88A43189FC74128965BA58" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_11F3CF729521E65566BE74128965979B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_4E1AEE1C863591E840CB74128965E970" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_11F3CF729521E65566BE74128965979B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_42B408E63F6A1660B2A274128965C053" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_11F3CF729521E65566BE74128965979B" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_42B408E63F6A1660B2A274128965C053" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_F7B45837B03645D7C2157412896529B4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_11F3CF729521E65566BE74128965979B" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_F7B45837B03645D7C2157412896529B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_D11E3591EC46CA7F13FC74128966E035" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_11F3CF729521E65566BE74128965979B" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_D11E3591EC46CA7F13FC74128966E035" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_39B769DBB89FCBDDA8107412859E01DF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_7BE162E006E5D581FC297412859EA504" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_39B769DBB89FCBDDA8107412859E01DF" xlink:to="loc_us-gaap_DebtInstrumentTable_7BE162E006E5D581FC297412859EA504" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_ADDE80E33EC568A8608C7412859EA3B2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_7BE162E006E5D581FC297412859EA504" xlink:to="loc_us-gaap_DebtInstrumentAxis_ADDE80E33EC568A8608C7412859EA3B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_90FDF59E18AF3798FADE7412859EB6E3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_ADDE80E33EC568A8608C7412859EA3B2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_90FDF59E18AF3798FADE7412859EB6E3" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_NotesPayableToFumedicaMember" xlink:label="loc_biib_NotesPayableToFumedicaMember_4E4617E10B794EDCC7D47412859E0241" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_90FDF59E18AF3798FADE7412859EB6E3" xlink:to="loc_biib_NotesPayableToFumedicaMember_4E4617E10B794EDCC7D47412859E0241" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" xlink:label="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_4084E52831D341B78D767412859EF3FA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_90FDF59E18AF3798FADE7412859EB6E3" xlink:to="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_4084E52831D341B78D767412859EF3FA" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_DBE602EE205B351E28E37412859E52DD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_90FDF59E18AF3798FADE7412859EB6E3" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_DBE602EE205B351E28E37412859E52DD" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_F12C83D12ABD9C31696A7412859E776B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_90FDF59E18AF3798FADE7412859EB6E3" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_F12C83D12ABD9C31696A7412859E776B" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_292B8878B2255D249CD67412859F1224" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_90FDF59E18AF3798FADE7412859EB6E3" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_292B8878B2255D249CD67412859F1224" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_FD9DF289EED4A6D3B0997412859F25B2" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_90FDF59E18AF3798FADE7412859EB6E3" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_FD9DF289EED4A6D3B0997412859F25B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_7E2CBB85700DB8BB77347412859F50BC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_7BE162E006E5D581FC297412859EA504" xlink:to="loc_us-gaap_DebtInstrumentLineItems_7E2CBB85700DB8BB77347412859F50BC" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_SummaryOfFairAndCarryingValueOfDebtInstrumentsAbstract" xlink:label="loc_biib_SummaryOfFairAndCarryingValueOfDebtInstrumentsAbstract_6B4FCE642438FE521A5B7412859F4EC2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7E2CBB85700DB8BB77347412859F50BC" xlink:to="loc_biib_SummaryOfFairAndCarryingValueOfDebtInstrumentsAbstract_6B4FCE642438FE521A5B7412859F4EC2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_5252426369D9D3D944287412859F99AE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfFairAndCarryingValueOfDebtInstrumentsAbstract_6B4FCE642438FE521A5B7412859F4EC2" xlink:to="loc_us-gaap_NotesPayableFairValueDisclosure_5252426369D9D3D944287412859F99AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue_0282930666FA3A4788087412859F35F5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfFairAndCarryingValueOfDebtInstrumentsAbstract_6B4FCE642438FE521A5B7412859F4EC2" xlink:to="loc_us-gaap_DebtInstrumentFairValue_0282930666FA3A4788087412859F35F5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_5A2BAA23B58000FC72BAFA4EA53DEEB0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_FB7B8C5DDC8492BAE5BAFA4EA53D5F5F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_5A2BAA23B58000FC72BAFA4EA53DEEB0" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_FB7B8C5DDC8492BAE5BAFA4EA53D5F5F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_B329E351399F2ED734B3FA4EA53ED875" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_FB7B8C5DDC8492BAE5BAFA4EA53D5F5F" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_B329E351399F2ED734B3FA4EA53ED875" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_E7ACDDB1850C0A4A3932FA4EA53E907E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_B329E351399F2ED734B3FA4EA53ED875" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_E7ACDDB1850C0A4A3932FA4EA53E907E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_1D3CF788F24BD52B7303FA4EA53E2C83" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_E7ACDDB1850C0A4A3932FA4EA53E907E" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_1D3CF788F24BD52B7303FA4EA53E2C83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_1B4B38B37E52C5C969AEFA4EA53E6D9F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_FB7B8C5DDC8492BAE5BAFA4EA53D5F5F" xlink:to="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_1B4B38B37E52C5C969AEFA4EA53E6D9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_412E1EE25FF8A4D8C00AFA4EA53E8F3B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_1B4B38B37E52C5C969AEFA4EA53E6D9F" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_412E1EE25FF8A4D8C00AFA4EA53E8F3B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_EE50A41D540140D05341FA4EA53E768A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_1B4B38B37E52C5C969AEFA4EA53E6D9F" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_EE50A41D540140D05341FA4EA53E768A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_86ED79D9FA5087E3162DFA4EA53FFEE2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_1B4B38B37E52C5C969AEFA4EA53E6D9F" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_86ED79D9FA5087E3162DFA4EA53FFEE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_A2F47AECA9BA45E88510FA4EA53FB925" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_1B4B38B37E52C5C969AEFA4EA53E6D9F" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_A2F47AECA9BA45E88510FA4EA53FB925" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_A9B35EA0800B560FA52EFA4EA53FA261" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_1B4B38B37E52C5C969AEFA4EA53E6D9F" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_A9B35EA0800B560FA52EFA4EA53FA261" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_DDE73616EC87166E8DB5FA4EA53548E6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_78ECBFDD8E3BDE88A018FA4EA5368038" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_DDE73616EC87166E8DB5FA4EA53548E6" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_78ECBFDD8E3BDE88A018FA4EA5368038" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_D125E2B5A79F770352BFFA4EA5369282" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_78ECBFDD8E3BDE88A018FA4EA5368038" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_D125E2B5A79F770352BFFA4EA5369282" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_D2B4DB4C6D0F7CF954CEFA4EA536C51E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_D125E2B5A79F770352BFFA4EA5369282" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_D2B4DB4C6D0F7CF954CEFA4EA536C51E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_8B6D9933976C20040909FA4EA53614A6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_D2B4DB4C6D0F7CF954CEFA4EA536C51E" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_8B6D9933976C20040909FA4EA53614A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_5BE0BAE2E6313D435495FA4EA536ACA6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_D2B4DB4C6D0F7CF954CEFA4EA536C51E" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_5BE0BAE2E6313D435495FA4EA536ACA6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_83E88747D6223C3930C8FA4EA536754B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_78ECBFDD8E3BDE88A018FA4EA5368038" xlink:to="loc_us-gaap_DebtInstrumentAxis_83E88747D6223C3930C8FA4EA536754B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_B4F142E23D2B19044F93FA4EA536AC22" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_83E88747D6223C3930C8FA4EA536754B" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_B4F142E23D2B19044F93FA4EA536AC22" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" xlink:label="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_E385C0A2922D4B9DEAB6FA4EA536F876" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_B4F142E23D2B19044F93FA4EA536AC22" xlink:to="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_E385C0A2922D4B9DEAB6FA4EA536F876" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_D3CC7B27317746D5FB44FA4EA536CDFA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_B4F142E23D2B19044F93FA4EA536AC22" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_D3CC7B27317746D5FB44FA4EA536CDFA" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_088698FF8E92E1CE60FFFA4EA5369D45" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_B4F142E23D2B19044F93FA4EA536AC22" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_088698FF8E92E1CE60FFFA4EA5369D45" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_54130BA99456F081A158FA4EA5375F8E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_B4F142E23D2B19044F93FA4EA536AC22" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_54130BA99456F081A158FA4EA5375F8E" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_6F1C36A012A1FF654A3AFA4EA53740E9" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_B4F142E23D2B19044F93FA4EA536AC22" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_6F1C36A012A1FF654A3AFA4EA53740E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_4EA20B08800657F7990CFA4EA537DC10" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_78ECBFDD8E3BDE88A018FA4EA5368038" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_4EA20B08800657F7990CFA4EA537DC10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_17F6054F3BE813882AF0FA4EA537B559" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4EA20B08800657F7990CFA4EA537DC10" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_17F6054F3BE813882AF0FA4EA537B559" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ConvergencePharmaceuticalsMember" xlink:label="loc_biib_ConvergencePharmaceuticalsMember_D2E70236A4084E26A09CFA4EA5373EC9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_17F6054F3BE813882AF0FA4EA537B559" xlink:to="loc_biib_ConvergencePharmaceuticalsMember_D2E70236A4084E26A09CFA4EA5373EC9" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_StromedixMember" xlink:label="loc_biib_StromedixMember_784859EF897FF5D52BB5FA4EA5374ABF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_17F6054F3BE813882AF0FA4EA537B559" xlink:to="loc_biib_StromedixMember_784859EF897FF5D52BB5FA4EA5374ABF" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_BiogenIdecInternationalNeuroscienceMember" xlink:label="loc_biib_BiogenIdecInternationalNeuroscienceMember_0A875F6FBFBB38E9FF52FA4EA537B4AF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_17F6054F3BE813882AF0FA4EA537B559" xlink:to="loc_biib_BiogenIdecInternationalNeuroscienceMember_0A875F6FBFBB38E9FF52FA4EA537B4AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_4EF1E1805E3186E4199AFA4EA5379C6E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_78ECBFDD8E3BDE88A018FA4EA5368038" xlink:to="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_4EF1E1805E3186E4199AFA4EA5379C6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_8D32529963D92B94907CFA4EA537EEEC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_4EF1E1805E3186E4199AFA4EA5379C6E" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_8D32529963D92B94907CFA4EA537EEEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_66B267C10EB54D203109FA4EA5370DCF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_4EF1E1805E3186E4199AFA4EA5379C6E" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_66B267C10EB54D203109FA4EA5370DCF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilities" xlink:label="loc_us-gaap_OtherLiabilities_0C3AFECB77D6E3B39895FB4679C40AA2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_4EF1E1805E3186E4199AFA4EA5379C6E" xlink:to="loc_us-gaap_OtherLiabilities_0C3AFECB77D6E3B39895FB4679C40AA2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsChangesInValuationTechniques" xlink:label="loc_us-gaap_FairValueMeasurementsChangesInValuationTechniques_7AA68F08FD585028A6B4FA4EA537A0A2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_4EF1E1805E3186E4199AFA4EA5379C6E" xlink:to="loc_us-gaap_FairValueMeasurementsChangesInValuationTechniques_7AA68F08FD585028A6B4FA4EA537A0A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_673F71BAFC271E72CD2BFA4EA5380797" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_4EF1E1805E3186E4199AFA4EA5379C6E" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_673F71BAFC271E72CD2BFA4EA5380797" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_C68A841C4CC5E052385FFA4EA538F6F7" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_4EF1E1805E3186E4199AFA4EA5379C6E" xlink:to="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_C68A841C4CC5E052385FFA4EA538F6F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_62A6C02D296D7D6E9655FA4EA538825A" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_4EF1E1805E3186E4199AFA4EA5379C6E" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_62A6C02D296D7D6E9655FA4EA538825A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_DFC8E9C90B07E21FD0A5FA4EA538CA1F" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_4EF1E1805E3186E4199AFA4EA5379C6E" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_DFC8E9C90B07E21FD0A5FA4EA538CA1F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsDiscountRate" xlink:label="loc_us-gaap_FairValueInputsDiscountRate_CB159300AD6FAA01224CFA4EA5386A30" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_4EF1E1805E3186E4199AFA4EA5379C6E" xlink:to="loc_us-gaap_FairValueInputsDiscountRate_CB159300AD6FAA01224CFA4EA5386A30" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_MilestonePaymentsMadeDuringPeriod" xlink:label="loc_biib_MilestonePaymentsMadeDuringPeriod_0EA421F0C707B691E719FA4EA538BEAD" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_4EF1E1805E3186E4199AFA4EA5379C6E" xlink:to="loc_biib_MilestonePaymentsMadeDuringPeriod_0EA421F0C707B691E719FA4EA538BEAD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_CC3C5579E5A659874F61FA4EA53858E4" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_4EF1E1805E3186E4199AFA4EA5379C6E" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_CC3C5579E5A659874F61FA4EA53858E4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_5ED948AE1F6B9783BEB774128591921A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_4917FB441C891725F5FD741285921167" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_5ED948AE1F6B9783BEB774128591921A" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_4917FB441C891725F5FD741285921167" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_D14BE826585B07573C26741285928172" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_5ED948AE1F6B9783BEB774128591921A" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_D14BE826585B07573C26741285928172" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_706BC9FEE7F65268708A7412859273DD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_5ED948AE1F6B9783BEB774128591921A" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_706BC9FEE7F65268708A7412859273DD" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstruments" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_F40690FC5DE5BE82C32F7412861D03B2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_73E02659880127AE79A57412861DF614" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_F40690FC5DE5BE82C32F7412861D03B2" xlink:to="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_73E02659880127AE79A57412861DF614" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_2622413F3D18367B7C2174128570A7A0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_1F721FFCC55D9C3F555C7412857086EF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_2622413F3D18367B7C2174128570A7A0" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_1F721FFCC55D9C3F555C7412857086EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_E256350D4D10EC26D713741285704312" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_1F721FFCC55D9C3F555C7412857086EF" xlink:to="loc_us-gaap_InvestmentTypeAxis_E256350D4D10EC26D713741285704312" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_07ABD2017CF721E7DAB874128570B8B1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_E256350D4D10EC26D713741285704312" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_07ABD2017CF721E7DAB874128570B8B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_5926A2C99DC4B2E701F274128570409E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_07ABD2017CF721E7DAB874128570B8B1" xlink:to="loc_us-gaap_CommercialPaperMember_5926A2C99DC4B2E701F274128570409E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementsMember" xlink:label="loc_us-gaap_RepurchaseAgreementsMember_AE2A18DBD3EC6D4BCAF974128570C971" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_07ABD2017CF721E7DAB874128570B8B1" xlink:to="loc_us-gaap_RepurchaseAgreementsMember_AE2A18DBD3EC6D4BCAF974128570C971" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_46297473E91FFF47EDD6741285700F59" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_07ABD2017CF721E7DAB874128570B8B1" xlink:to="loc_us-gaap_MoneyMarketFundsMember_46297473E91FFF47EDD6741285700F59" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtSecuritiesMember" xlink:label="loc_us-gaap_DebtSecuritiesMember_AC62169F04661A22BB73741285702627" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_07ABD2017CF721E7DAB874128570B8B1" xlink:to="loc_us-gaap_DebtSecuritiesMember_AC62169F04661A22BB73741285702627" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_1DB70DD5DD3D25B62DE6741285700C88" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_1F721FFCC55D9C3F555C7412857086EF" xlink:to="loc_us-gaap_CashAndCashEquivalentsLineItems_1DB70DD5DD3D25B62DE6741285700C88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_E7D62A8A1CE96EBF1FED7412857046E5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_1DB70DD5DD3D25B62DE6741285700C88" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_E7D62A8A1CE96EBF1FED7412857046E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_A7BCD403C336965C9FC17412857045E9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_E7D62A8A1CE96EBF1FED7412857046E5" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_A7BCD403C336965C9FC17412857045E9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_1CF74A6C0599DC73BC4A74128585AE6F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_596407D89492CC68970474128585C4CC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_1CF74A6C0599DC73BC4A74128585AE6F" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_596407D89492CC68970474128585C4CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_F1E3BB0484B23F6355B374128585849E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_596407D89492CC68970474128585C4CC" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_F1E3BB0484B23F6355B374128585849E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_06161575FD6348E04CEF7412858510D5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_F1E3BB0484B23F6355B374128585849E" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_06161575FD6348E04CEF7412858510D5" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_CorporateDebtSecuritiesCurrentMember" xlink:label="loc_biib_CorporateDebtSecuritiesCurrentMember_6CF6A3A250B7A7A9B3547412858645AB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_06161575FD6348E04CEF7412858510D5" xlink:to="loc_biib_CorporateDebtSecuritiesCurrentMember_6CF6A3A250B7A7A9B3547412858645AB" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_CorporateDebtSecuritiesNonCurrentMember" xlink:label="loc_biib_CorporateDebtSecuritiesNonCurrentMember_BB2E8A25CA6755B8582074128586B6BE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_06161575FD6348E04CEF7412858510D5" xlink:to="loc_biib_CorporateDebtSecuritiesNonCurrentMember_BB2E8A25CA6755B8582074128586B6BE" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_GovernmentSecuritiesCurrentMember" xlink:label="loc_biib_GovernmentSecuritiesCurrentMember_00E27231AF31E7477BAF74128586111B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_06161575FD6348E04CEF7412858510D5" xlink:to="loc_biib_GovernmentSecuritiesCurrentMember_00E27231AF31E7477BAF74128586111B" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_GovernmentSecuritiesNonCurrentMember" xlink:label="loc_biib_GovernmentSecuritiesNonCurrentMember_0BFBD90AAAE3A16AF5B07412858638B2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_06161575FD6348E04CEF7412858510D5" xlink:to="loc_biib_GovernmentSecuritiesNonCurrentMember_0BFBD90AAAE3A16AF5B07412858638B2" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_246BCFD4EB74A6553C78741285868DCC" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_06161575FD6348E04CEF7412858510D5" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_246BCFD4EB74A6553C78741285868DCC" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_771D1BCDE326C09FA3DD74128586B467" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_06161575FD6348E04CEF7412858510D5" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_771D1BCDE326C09FA3DD74128586B467" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_MarketableEquitySecuritiesMember" xlink:label="loc_biib_MarketableEquitySecuritiesMember_FA1D45C965E0157B77D37412858685AC" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_06161575FD6348E04CEF7412858510D5" xlink:to="loc_biib_MarketableEquitySecuritiesMember_FA1D45C965E0157B77D37412858685AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6CD19605095FA7A9674D741285868C19" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_596407D89492CC68970474128585C4CC" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6CD19605095FA7A9674D741285868C19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_FFE3243587A7C40D1B96741285863E21" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6CD19605095FA7A9674D741285868C19" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_FFE3243587A7C40D1B96741285863E21" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_8B6EB25C110BDA5A9479741285866C03" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_FFE3243587A7C40D1B96741285863E21" xlink:to="loc_us-gaap_AvailableForSaleSecurities_8B6EB25C110BDA5A9479741285866C03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_58736ABFF3033C279061741285866A88" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_FFE3243587A7C40D1B96741285863E21" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_58736ABFF3033C279061741285866A88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_93884E10312B9D6FCF0474128586BF6E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_FFE3243587A7C40D1B96741285863E21" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_93884E10312B9D6FCF0474128586BF6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_4599C1B6F0250B95BC1D74128586BBB3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_FFE3243587A7C40D1B96741285863E21" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_4599C1B6F0250B95BC1D74128586BBB3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_441E8C80A89D911294A874128862F505" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_50EAD4201C713231F55774128862917E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_441E8C80A89D911294A874128862F505" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_50EAD4201C713231F55774128862917E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_9BD61D05DD67F66FC9827412886207AD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_50EAD4201C713231F55774128862917E" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_9BD61D05DD67F66FC9827412886207AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_717EFF9F6109710071FD74128862009B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_50EAD4201C713231F55774128862917E" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_717EFF9F6109710071FD74128862009B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_CAE91BAF5177044AD5D4741288625D39" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_50EAD4201C713231F55774128862917E" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_CAE91BAF5177044AD5D4741288625D39" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_0204508C72F04343FA0774128867FF95" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_50EAD4201C713231F55774128862917E" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_0204508C72F04343FA0774128867FF95" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_50466D71A427E88FF92F741288683A67" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_50EAD4201C713231F55774128862917E" xlink:to="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_50466D71A427E88FF92F741288683A67" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_FBD1B5C6A46AF42C540274128868D9FA" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_50EAD4201C713231F55774128862917E" xlink:to="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_FBD1B5C6A46AF42C540274128868D9FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_1DB87E3F612961436103741288687D1A" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_50EAD4201C713231F55774128862917E" xlink:to="loc_us-gaap_AvailableForSaleSecurities_1DB87E3F612961436103741288687D1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_B0EAD00535E14A301F2474128868A766" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_50EAD4201C713231F55774128862917E" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_B0EAD00535E14A301F2474128868A766" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_8E46C9BFEAD7B6718C437412887D0DFD" xlink:type="locator" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ProceedsFromMarketableDebtSecuritiesAbstract" xlink:label="loc_biib_ProceedsFromMarketableDebtSecuritiesAbstract_9E5A0952B81FC024BB557412887D6137" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_8E46C9BFEAD7B6718C437412887D0DFD" xlink:to="loc_biib_ProceedsFromMarketableDebtSecuritiesAbstract_9E5A0952B81FC024BB557412887D6137" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_B909BBB1C1E1A293CFC17412887D6CC3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ProceedsFromMarketableDebtSecuritiesAbstract_9E5A0952B81FC024BB557412887D6137" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_B909BBB1C1E1A293CFC17412887D6CC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedGains" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_4441DF522A524225764D7412887DD2FC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ProceedsFromMarketableDebtSecuritiesAbstract_9E5A0952B81FC024BB557412887D6137" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_4441DF522A524225764D7412887DD2FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_BD090D05B53C3C3020137412887D41EA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ProceedsFromMarketableDebtSecuritiesAbstract_9E5A0952B81FC024BB557412887D6137" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_BD090D05B53C3C3020137412887D41EA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_485DE7797D31372FACE5F4AB00379CEF" xlink:type="locator" />
    <link:loc xlink:href="biib-20161231.xsd#biib_FinancialInstrumentsTextualAbstract" xlink:label="loc_biib_FinancialInstrumentsTextualAbstract_84051641C72F24ACD2A6F4AB0037FA0C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_485DE7797D31372FACE5F4AB00379CEF" xlink:to="loc_biib_FinancialInstrumentsTextualAbstract_84051641C72F24ACD2A6F4AB0037FA0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentMaturityDateDescription" xlink:label="loc_us-gaap_DebtInstrumentMaturityDateDescription_F7D6028B7E3F34C65CB7F4AB0037C598" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FinancialInstrumentsTextualAbstract_84051641C72F24ACD2A6F4AB0037FA0C" xlink:to="loc_us-gaap_DebtInstrumentMaturityDateDescription_F7D6028B7E3F34C65CB7F4AB0037C598" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_Overnightreverserepurchaseagreementspercentoftotalassets" xlink:label="loc_biib_Overnightreverserepurchaseagreementspercentoftotalassets_FD80643A04A2853980A3F4AB0038ACBC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FinancialInstrumentsTextualAbstract_84051641C72F24ACD2A6F4AB0037FA0C" xlink:to="loc_biib_Overnightreverserepurchaseagreementspercentoftotalassets_FD80643A04A2853980A3F4AB0038ACBC" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_AverageMaturityOfMarketableSecurities" xlink:label="loc_biib_AverageMaturityOfMarketableSecurities_B3753617F7991C0BDF7AF4AB0038D869" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FinancialInstrumentsTextualAbstract_84051641C72F24ACD2A6F4AB0037FA0C" xlink:to="loc_biib_AverageMaturityOfMarketableSecurities_B3753617F7991C0BDF7AF4AB0038D869" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_4D0D2A245D8BABE11C4B7412892D1F7B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_19DAD7DC54B2DC0DF9C17412892D15C3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_4D0D2A245D8BABE11C4B7412892D1F7B" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_19DAD7DC54B2DC0DF9C17412892D15C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_239F68ED15E0CEFF272F7412892D9E9C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_19DAD7DC54B2DC0DF9C17412892D15C3" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_239F68ED15E0CEFF272F7412892D9E9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_3FD54EFB30E9436DB6897412892DEBE2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_239F68ED15E0CEFF272F7412892D9E9C" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_3FD54EFB30E9436DB6897412892DEBE2" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_StrategicInvestmentsMember" xlink:label="loc_biib_StrategicInvestmentsMember_3A56DF22F59F5DDF8DA27412892D5151" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_3FD54EFB30E9436DB6897412892DEBE2" xlink:to="loc_biib_StrategicInvestmentsMember_3A56DF22F59F5DDF8DA27412892D5151" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_4B2010F92FBE1938FF967412892D594C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_19DAD7DC54B2DC0DF9C17412892D15C3" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_4B2010F92FBE1938FF967412892D594C" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_StrategicInvestmentPortfolio" xlink:label="loc_biib_StrategicInvestmentPortfolio_9CD6A3EA0986DD668F157412892D8E5F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4B2010F92FBE1938FF967412892D594C" xlink:to="loc_biib_StrategicInvestmentPortfolio_9CD6A3EA0986DD668F157412892D8E5F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_84A048E966ABA67439C1741285DE2C3A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_7912E4FF9ADB36C54777741285DE0A6B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_84A048E966ABA67439C1741285DE2C3A" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_7912E4FF9ADB36C54777741285DE0A6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_A68A284FAE15909FA237741285DE9D01" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_84A048E966ABA67439C1741285DE2C3A" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_A68A284FAE15909FA237741285DE9D01" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_44308A501203545369B5741285DE88A0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_84A048E966ABA67439C1741285DE2C3A" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_44308A501203545369B5741285DE88A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RealizedGainLossOnInvestmentsTableTextBlock" xlink:label="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_DAA6813D3BA140507BBC741285DE1217" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_84A048E966ABA67439C1741285DE2C3A" xlink:to="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_DAA6813D3BA140507BBC741285DE1217" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Guarantees" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GuaranteesAbstract" xlink:label="loc_us-gaap_GuaranteesAbstract_6B7A961749CF64535CCB7412862FAF48" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GuaranteesTextBlock" xlink:label="loc_us-gaap_GuaranteesTextBlock_A2B7DA4C9C169A7B96477412862F11C1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteesAbstract_6B7A961749CF64535CCB7412862FAF48" xlink:to="loc_us-gaap_GuaranteesTextBlock_A2B7DA4C9C169A7B96477412862F11C1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_85926A9E78A5C070DBA574128552EFA8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_1B19D95009801A545C74741285521463" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_85926A9E78A5C070DBA574128552EFA8" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_1B19D95009801A545C74741285521463" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_12EE56DDB72B0C92BAD4741287C8BD9A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsAbstract" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsAbstract_27B31ABAAAEE4BC3BA00741287C8ACF2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_12EE56DDB72B0C92BAD4741287C8BD9A" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsAbstract_27B31ABAAAEE4BC3BA00741287C8ACF2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_11AD9491DDD4750AB7D1741287C80BE5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsAbstract_27B31ABAAAEE4BC3BA00741287C8ACF2" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_11AD9491DDD4750AB7D1741287C80BE5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_62ACE3D9AE5F3E13B65E741287C8395E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_11AD9491DDD4750AB7D1741287C80BE5" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_62ACE3D9AE5F3E13B65E741287C8395E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_063DAC2307739C134EAC741287C800C6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_11AD9491DDD4750AB7D1741287C80BE5" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_063DAC2307739C134EAC741287C800C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_72A0F2C3E21979479F43741287C81212" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_11AD9491DDD4750AB7D1741287C80BE5" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_72A0F2C3E21979479F43741287C81212" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_253906626C54F6F2AE12741287C838B7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsAbstract_27B31ABAAAEE4BC3BA00741287C8ACF2" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_253906626C54F6F2AE12741287C838B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_3C22CFDDAE006CC90693741287C88981" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_253906626C54F6F2AE12741287C838B7" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_3C22CFDDAE006CC90693741287C88981" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_D813E68252FF3AEB55D1741287C98092" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_3C22CFDDAE006CC90693741287C88981" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_D813E68252FF3AEB55D1741287C98092" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_C9DDFC92B11C6E3D99ED741287C9F510" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_3C22CFDDAE006CC90693741287C88981" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_C9DDFC92B11C6E3D99ED741287C9F510" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_4844BD8AE816E27F5F4E741287C94D15" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_3C22CFDDAE006CC90693741287C88981" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_4844BD8AE816E27F5F4E741287C94D15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_E58354977A86488070A2741287C99E97" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_3C22CFDDAE006CC90693741287C88981" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_E58354977A86488070A2741287C99E97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_5094EE50E8A66A199E0A741287C9EA89" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_253906626C54F6F2AE12741287C838B7" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_5094EE50E8A66A199E0A741287C9EA89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_2BC0DE047EEA4B058E1F741287C93110" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_5094EE50E8A66A199E0A741287C9EA89" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_2BC0DE047EEA4B058E1F741287C93110" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_C06395115D97EEF0C26F741287C90DA9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_5094EE50E8A66A199E0A741287C9EA89" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_C06395115D97EEF0C26F741287C90DA9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_5120469C3498ACE3CE6B741287C9C099" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_5094EE50E8A66A199E0A741287C9EA89" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_5120469C3498ACE3CE6B741287C9C099" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_61FF8A76906EE8FD39D6741287CA3409" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_5094EE50E8A66A199E0A741287C9EA89" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_61FF8A76906EE8FD39D6741287CA3409" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_3C280754D761BD17CAFD741287CA37CD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsAbstract_27B31ABAAAEE4BC3BA00741287C8ACF2" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_3C280754D761BD17CAFD741287CA37CD" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_6BF51B4EF5CF4C23727A741285BC798A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_29D8FB4DE8FB45613543741285BC94F4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6BF51B4EF5CF4C23727A741285BC798A" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_29D8FB4DE8FB45613543741285BC94F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_976232192BFB527D4BAB741285BCD225" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_29D8FB4DE8FB45613543741285BC94F4" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_976232192BFB527D4BAB741285BCD225" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_6EAAE85FA1B930E14FA1741285BD74F5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_29D8FB4DE8FB45613543741285BC94F4" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_6EAAE85FA1B930E14FA1741285BD74F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_F4F6EF72CB966621B9FC741285BD7154" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_29D8FB4DE8FB45613543741285BC94F4" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_F4F6EF72CB966621B9FC741285BD7154" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_AD7997AEA0D71912DC93741285BD41D6" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_29D8FB4DE8FB45613543741285BC94F4" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_AD7997AEA0D71912DC93741285BD41D6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_E6EF74F7B76A7485DD7F741285BD6D8B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_29D8FB4DE8FB45613543741285BC94F4" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_E6EF74F7B76A7485DD7F741285BD6D8B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_36F0BC779783F9883E7E741285BD6642" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_29D8FB4DE8FB45613543741285BC94F4" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_36F0BC779783F9883E7E741285BD6642" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_D85C2B8AE911B4459102741285BDF10C" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_29D8FB4DE8FB45613543741285BC94F4" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_D85C2B8AE911B4459102741285BDF10C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_074AC8687960D447536F741285BD4822" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_29D8FB4DE8FB45613543741285BC94F4" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_074AC8687960D447536F741285BD4822" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_583B3255D0C7527E0BB3741285BD1BD2" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_29D8FB4DE8FB45613543741285BC94F4" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_583B3255D0C7527E0BB3741285BD1BD2" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_DeferredTaxLiabilitiesDepreciationAmortizationOther" xlink:label="loc_biib_DeferredTaxLiabilitiesDepreciationAmortizationOther_64B0E38F7245D7C08C25741285BDE65D" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_29D8FB4DE8FB45613543741285BC94F4" xlink:to="loc_biib_DeferredTaxLiabilitiesDepreciationAmortizationOther_64B0E38F7245D7C08C25741285BDE65D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_AA759D6CB7AE73DAEE36741285BD48FC" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_29D8FB4DE8FB45613543741285BC94F4" xlink:to="loc_us-gaap_DeferredTaxLiabilities_AA759D6CB7AE73DAEE36741285BD48FC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_DE47BD3E94FA0D53063BFCCBDBB11D55" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_C2DFF3E3118DF58C9D9BFCCBDBB19441" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_DE47BD3E94FA0D53063BFCCBDBB11D55" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_C2DFF3E3118DF58C9D9BFCCBDBB19441" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_160FE3F0D351623EBA00FCCBDBB1F09F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_C2DFF3E3118DF58C9D9BFCCBDBB19441" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_160FE3F0D351623EBA00FCCBDBB1F09F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_C363BC7FBCE94DDD6B36FCCBDBB1A74A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_C2DFF3E3118DF58C9D9BFCCBDBB19441" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_C363BC7FBCE94DDD6B36FCCBDBB1A74A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_BEE896DA696F9EA4DA72FCCBDBB1C75C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_C2DFF3E3118DF58C9D9BFCCBDBB19441" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_BEE896DA696F9EA4DA72FCCBDBB1C75C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_BB4E62F1443136934D4BFCCBDBB131E1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_C2DFF3E3118DF58C9D9BFCCBDBB19441" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_BB4E62F1443136934D4BFCCBDBB131E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_CCFEF370E37CD7EB9A8EFCCBDBB10FB3" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_C2DFF3E3118DF58C9D9BFCCBDBB19441" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_CCFEF370E37CD7EB9A8EFCCBDBB10FB3" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction" xlink:label="loc_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_F689E5F4ED03AB68A094FCCBDBB1C033" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_C2DFF3E3118DF58C9D9BFCCBDBB19441" xlink:to="loc_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_F689E5F4ED03AB68A094FCCBDBB1C033" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_443C4121CE014887BEC2FCCBDBB1AC0E" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_C2DFF3E3118DF58C9D9BFCCBDBB19441" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_443C4121CE014887BEC2FCCBDBB1AC0E" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_EffectiveIncomeTaxRateReconciliationContingentConsideration" xlink:label="loc_biib_EffectiveIncomeTaxRateReconciliationContingentConsideration_D830CC20EA0B9986027AFCCBDBB1D409" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_C2DFF3E3118DF58C9D9BFCCBDBB19441" xlink:to="loc_biib_EffectiveIncomeTaxRateReconciliationContingentConsideration_D830CC20EA0B9986027AFCCBDBB1D409" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1B6847EE7F34AD39A0ADFCCBDBB1C3F0" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_C2DFF3E3118DF58C9D9BFCCBDBB19441" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1B6847EE7F34AD39A0ADFCCBDBB1C3F0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails3" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_10F852276B1D588CAB60F15B085346C9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract_A147A3BED54DF704CA43F15B085360CE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_10F852276B1D588CAB60F15B085346C9" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract_A147A3BED54DF704CA43F15B085360CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_4767749A06685A276054F15B0853742A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract_A147A3BED54DF704CA43F15B085360CE" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_4767749A06685A276054F15B0853742A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_3C391CFCC6B5A43B423EF15B0853E013" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract_A147A3BED54DF704CA43F15B085360CE" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_3C391CFCC6B5A43B423EF15B0853E013" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_E0963A3C083530F8A83AF15B08538927" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract_A147A3BED54DF704CA43F15B085360CE" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_E0963A3C083530F8A83AF15B08538927" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_B0617FE81610C5FFD16AF15B0853EA32" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract_A147A3BED54DF704CA43F15B085360CE" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_B0617FE81610C5FFD16AF15B0853EA32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_C6E6A72E332904A0B1E5F15B08537CE5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract_A147A3BED54DF704CA43F15B085360CE" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_C6E6A72E332904A0B1E5F15B08537CE5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_F91CD49D9C388E76FAD3F15B0853A3C3" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract_A147A3BED54DF704CA43F15B085360CE" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_F91CD49D9C388E76FAD3F15B0853A3C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_3930ABAD8EED3AD61816F15B0853B35A" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract_A147A3BED54DF704CA43F15B085360CE" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_3930ABAD8EED3AD61816F15B0853B35A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_D26FA65FB34DD7193CFBFB6C3A93A4FC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxCreditCarryforwardTable" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_D57276560D19C41D50F7FB6C3A9367D1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_D26FA65FB34DD7193CFBFB6C3A93A4FC" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_D57276560D19C41D50F7FB6C3A9367D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_E11EC0C22E1883BEC9AEFB6C3A93B7EB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_D57276560D19C41D50F7FB6C3A9367D1" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_E11EC0C22E1883BEC9AEFB6C3A93B7EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_2B58F2608EBA3640FA55FB6C3A93193C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_E11EC0C22E1883BEC9AEFB6C3A93B7EB" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_2B58F2608EBA3640FA55FB6C3A93193C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralBusinessMember" xlink:label="loc_us-gaap_GeneralBusinessMember_2543008807CF7B4EF9A1FB6C3A9498A8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_2B58F2608EBA3640FA55FB6C3A93193C" xlink:to="loc_us-gaap_GeneralBusinessMember_2543008807CF7B4EF9A1FB6C3A9498A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaap_ResearchMember_4DBDF5E2704A4CE40BA7FB6C3A943A1D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_2B58F2608EBA3640FA55FB6C3A93193C" xlink:to="loc_us-gaap_ResearchMember_4DBDF5E2704A4CE40BA7FB6C3A943A1D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_07A5337131E57B86ACE7FB6C3A94B15F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_D57276560D19C41D50F7FB6C3A9367D1" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_07A5337131E57B86ACE7FB6C3A94B15F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_26593EAF62DE347B1BBCFB6C3A9423E2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_07A5337131E57B86ACE7FB6C3A94B15F" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_26593EAF62DE347B1BBCFB6C3A9423E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_2AB747F1F5878B670DE6FB6C3A9434B7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_26593EAF62DE347B1BBCFB6C3A9423E2" xlink:to="loc_us-gaap_DomesticCountryMember_2AB747F1F5878B670DE6FB6C3A9434B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_663494817860BFA82613FB6C3A9484E6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_26593EAF62DE347B1BBCFB6C3A9423E2" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_663494817860BFA82613FB6C3A9484E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember_64F033248F252C04694DFB6C3A94EC7B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_26593EAF62DE347B1BBCFB6C3A9423E2" xlink:to="loc_us-gaap_ForeignCountryMember_64F033248F252C04694DFB6C3A94EC7B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_9234C749B3FF2908F622FB6C3A945D4D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_D57276560D19C41D50F7FB6C3A9367D1" xlink:to="loc_us-gaap_RangeAxis_9234C749B3FF2908F622FB6C3A945D4D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_8B9AC74B131A1D034804FB6C3A946CE9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_9234C749B3FF2908F622FB6C3A945D4D" xlink:to="loc_us-gaap_RangeMember_8B9AC74B131A1D034804FB6C3A946CE9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_E7207E82EF97ED817AEEFB6C3A94D0EF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_8B9AC74B131A1D034804FB6C3A946CE9" xlink:to="loc_us-gaap_MinimumMember_E7207E82EF97ED817AEEFB6C3A94D0EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_8CC9083D6471A8848333FB6C3A94DB6B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_8B9AC74B131A1D034804FB6C3A946CE9" xlink:to="loc_us-gaap_MaximumMember_8CC9083D6471A8848333FB6C3A94DB6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_00E0B3716ACF582B5EA0FB6C3A9493FA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_D57276560D19C41D50F7FB6C3A9367D1" xlink:to="loc_us-gaap_TaxCreditCarryforwardLineItems_00E0B3716ACF582B5EA0FB6C3A9493FA" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_Totaldeferredchargesandprepaidtaxes" xlink:label="loc_biib_Totaldeferredchargesandprepaidtaxes_2E0ADAB25257D49EB115FB6C3A957FB2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_00E0B3716ACF582B5EA0FB6C3A9493FA" xlink:to="loc_biib_Totaldeferredchargesandprepaidtaxes_2E0ADAB25257D49EB115FB6C3A957FB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_38AFF590486AB590C0B9FB6C3A956F3D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_00E0B3716ACF582B5EA0FB6C3A9493FA" xlink:to="loc_us-gaap_OperatingLossCarryforwards_38AFF590486AB590C0B9FB6C3A956F3D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_8610CCAFA874187D1B4BFB6C3A955530" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_00E0B3716ACF582B5EA0FB6C3A9493FA" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_8610CCAFA874187D1B4BFB6C3A955530" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_0D009D03ECAED24684B2FB6C3A956205" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_00E0B3716ACF582B5EA0FB6C3A9493FA" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_0D009D03ECAED24684B2FB6C3A956205" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_EstimatedTaxLiabilityOnUndistributedEarningsOfForeignSubsidiaries" xlink:label="loc_biib_EstimatedTaxLiabilityOnUndistributedEarningsOfForeignSubsidiaries_E54A5FDFD81D0E0D90E3FB6C3A9502EF" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_00E0B3716ACF582B5EA0FB6C3A9493FA" xlink:to="loc_biib_EstimatedTaxLiabilityOnUndistributedEarningsOfForeignSubsidiaries_E54A5FDFD81D0E0D90E3FB6C3A9502EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_6B106CD6D6215CB73F9CFB6C3A9512C6" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_00E0B3716ACF582B5EA0FB6C3A9493FA" xlink:to="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_6B106CD6D6215CB73F9CFB6C3A9512C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForOtherTaxes" xlink:label="loc_us-gaap_PaymentsForOtherTaxes_AA28A789123BF1CD05C6FB6C3A959E3E" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_00E0B3716ACF582B5EA0FB6C3A9493FA" xlink:to="loc_us-gaap_PaymentsForOtherTaxes_AA28A789123BF1CD05C6FB6C3A959E3E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_D60AD832F51E83D8A8EDFB6C3A9521FE" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_00E0B3716ACF582B5EA0FB6C3A9493FA" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_D60AD832F51E83D8A8EDFB6C3A9521FE" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_IncomeTaxesTextualAbstract" xlink:label="loc_biib_IncomeTaxesTextualAbstract_9D57ADF06678AF6C508CFB6C3A95CBD1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_D26FA65FB34DD7193CFBFB6C3A93A4FC" xlink:to="loc_biib_IncomeTaxesTextualAbstract_9D57ADF06678AF6C508CFB6C3A95CBD1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UndistributedEarningsOfForeignSubsidiaries" xlink:label="loc_us-gaap_UndistributedEarningsOfForeignSubsidiaries_FE677785951A64866093FB6C3A95FB34" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_IncomeTaxesTextualAbstract_9D57ADF06678AF6C508CFB6C3A95CBD1" xlink:to="loc_us-gaap_UndistributedEarningsOfForeignSubsidiaries_FE677785951A64866093FB6C3A95FB34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_1482ED81FE2CEE029BCEFB6C3A957588" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_IncomeTaxesTextualAbstract_9D57ADF06678AF6C508CFB6C3A95CBD1" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_1482ED81FE2CEE029BCEFB6C3A957588" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_FCF8EE553950DD812519FB6C3A950230" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_IncomeTaxesTextualAbstract_9D57ADF06678AF6C508CFB6C3A95CBD1" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_FCF8EE553950DD812519FB6C3A950230" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_69A3D7A0BED79C843304FB6C3A95B9F8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_IncomeTaxesTextualAbstract_9D57ADF06678AF6C508CFB6C3A95CBD1" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_69A3D7A0BED79C843304FB6C3A95B9F8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_3D2E4F8752B2AC23B24E741285688A2A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_367A2BFD273EBF00AF7B741285683182" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3D2E4F8752B2AC23B24E741285688A2A" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_367A2BFD273EBF00AF7B741285683182" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_8DA5E4F7EFE6DA231EA6741285687E13" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3D2E4F8752B2AC23B24E741285688A2A" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_8DA5E4F7EFE6DA231EA6741285687E13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_982811AC6F51690EA967741285689D74" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3D2E4F8752B2AC23B24E741285688A2A" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_982811AC6F51690EA967741285689D74" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_1768E1E533026D7B638A741285681D83" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3D2E4F8752B2AC23B24E741285688A2A" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_1768E1E533026D7B638A741285681D83" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Indebtedness" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_E24F27CB6D4EA6D3D2267412863BA195" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_7FC3DA7A2E04CF9278727412863B6686" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_E24F27CB6D4EA6D3D2267412863BA195" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_7FC3DA7A2E04CF9278727412863B6686" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IndebtednessDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_737A10FCC294779FEC8A741288A99625" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_23F9140F38F65B1DDB2E741288A9EE20" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_737A10FCC294779FEC8A741288A99625" xlink:to="loc_us-gaap_DebtInstrumentTable_23F9140F38F65B1DDB2E741288A9EE20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_B430770893D0DB9F3C13741288A97DE2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_23F9140F38F65B1DDB2E741288A9EE20" xlink:to="loc_us-gaap_DebtInstrumentAxis_B430770893D0DB9F3C13741288A97DE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4FFF00931BE31D2A41B6741288A9B039" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_B430770893D0DB9F3C13741288A97DE2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4FFF00931BE31D2A41B6741288A9B039" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" xlink:label="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_5A34F004F545210CD412741288A9369A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4FFF00931BE31D2A41B6741288A9B039" xlink:to="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_5A34F004F545210CD412741288A9369A" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_4806B7808167A366B9EB741288AAA67C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4FFF00931BE31D2A41B6741288A9B039" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_4806B7808167A366B9EB741288AAA67C" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_EF8D4829394D0B581ABC741288AA5501" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4FFF00931BE31D2A41B6741288A9B039" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_EF8D4829394D0B581ABC741288AA5501" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_81E00D5E1B6671A18FBB741288AAFDE7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4FFF00931BE31D2A41B6741288A9B039" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_81E00D5E1B6671A18FBB741288AAFDE7" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_566786B39A46B984EFE1741288AA18D3" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4FFF00931BE31D2A41B6741288A9B039" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_566786B39A46B984EFE1741288AA18D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_4717E0D33EA9E282914D741288AAD767" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_23F9140F38F65B1DDB2E741288A9EE20" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_4717E0D33EA9E282914D741288AAD767" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_09E296E8F6ED8F373242741288AAD493" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_4717E0D33EA9E282914D741288AAD767" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_09E296E8F6ED8F373242741288AAD493" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_F23C5DB4BBDFE5956646741288AAEC7A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_09E296E8F6ED8F373242741288AAD493" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_F23C5DB4BBDFE5956646741288AAEC7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_BC28B9D17ECAB81729CC741288AA5DA2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_23F9140F38F65B1DDB2E741288A9EE20" xlink:to="loc_us-gaap_DebtInstrumentLineItems_BC28B9D17ECAB81729CC741288AA5DA2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtCurrentAbstract" xlink:label="loc_us-gaap_LongTermDebtCurrentAbstract_A6EE826FFB2C467AA233741288AA0965" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_BC28B9D17ECAB81729CC741288AA5DA2" xlink:to="loc_us-gaap_LongTermDebtCurrentAbstract_A6EE826FFB2C467AA233741288AA0965" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent_C31B1000A917B2A5C089741288AA281D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtCurrentAbstract_A6EE826FFB2C467AA233741288AA0965" xlink:to="loc_us-gaap_NotesPayableCurrent_C31B1000A917B2A5C089741288AA281D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_6DFFAFF1E404547E719A741288AA4E43" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtCurrentAbstract_A6EE826FFB2C467AA233741288AA0965" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_6DFFAFF1E404547E719A741288AA4E43" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_3C7D1573FDEBA5ED8472741288AB984F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtCurrentAbstract_A6EE826FFB2C467AA233741288AA0965" xlink:to="loc_us-gaap_DebtCurrent_3C7D1573FDEBA5ED8472741288AB984F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtNoncurrentAbstract" xlink:label="loc_us-gaap_LongTermDebtNoncurrentAbstract_93443A2C22ECD0C39F07741288ABCDDA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_BC28B9D17ECAB81729CC741288AA5DA2" xlink:to="loc_us-gaap_LongTermDebtNoncurrentAbstract_93443A2C22ECD0C39F07741288ABCDDA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaap_LongTermNotesPayable_FD3ABB6E93C3F750EEE4741288AB5B0F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtNoncurrentAbstract_93443A2C22ECD0C39F07741288ABCDDA" xlink:to="loc_us-gaap_LongTermNotesPayable_FD3ABB6E93C3F750EEE4741288AB5B0F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_FAFDE133BE7A727291CE741288ABB2AC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtNoncurrentAbstract_93443A2C22ECD0C39F07741288ABCDDA" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_FAFDE133BE7A727291CE741288ABB2AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_1BF3B6344A87BA76F58D741288AB31AA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtNoncurrentAbstract_93443A2C22ECD0C39F07741288ABCDDA" xlink:to="loc_us-gaap_LongTermDebt_1BF3B6344A87BA76F58D741288AB31AA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IndebtednessDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_8FC9014DD3F7FBD10B7DD13AF2F666AA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtByMaturityAbstract" xlink:label="loc_us-gaap_LongTermDebtByMaturityAbstract_3460EC8D39E5918E957CD13AF2F6BA07" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_8FC9014DD3F7FBD10B7DD13AF2F666AA" xlink:to="loc_us-gaap_LongTermDebtByMaturityAbstract_3460EC8D39E5918E957CD13AF2F6BA07" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_2BFE0615A33D5D4CE90AD13F815CAD83" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_3460EC8D39E5918E957CD13AF2F6BA07" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_2BFE0615A33D5D4CE90AD13F815CAD83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_322850FE789B539075B2D13FEEDCF142" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_3460EC8D39E5918E957CD13AF2F6BA07" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_322850FE789B539075B2D13FEEDCF142" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_3DCC9AFE2E9DD541B35AD1404F15BBA2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_3460EC8D39E5918E957CD13AF2F6BA07" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_3DCC9AFE2E9DD541B35AD1404F15BBA2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_9F436DC06146B076AF56D140A48E24FC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_3460EC8D39E5918E957CD13AF2F6BA07" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_9F436DC06146B076AF56D140A48E24FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_2488AC957999C343CE9BD13AF2F66FBB" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_3460EC8D39E5918E957CD13AF2F6BA07" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_2488AC957999C343CE9BD13AF2F66FBB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_28E1592F4C825515435CD13AF2F61DE4" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_3460EC8D39E5918E957CD13AF2F6BA07" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_28E1592F4C825515435CD13AF2F61DE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaap_LongTermNotesPayable_2763671CF633C0C4CA4CD13AF2F66364" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_3460EC8D39E5918E957CD13AF2F6BA07" xlink:to="loc_us-gaap_LongTermNotesPayable_2763671CF633C0C4CA4CD13AF2F66364" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IndebtednessDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_8800ED0923E9FDDB8DD0FB6C3B2BA592" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_D02E8ABC39633BDC6620FB6C3B2BC381" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_8800ED0923E9FDDB8DD0FB6C3B2BA592" xlink:to="loc_us-gaap_DebtInstrumentTable_D02E8ABC39633BDC6620FB6C3B2BC381" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_A17D36DD43378FDA977AFB6C3B2B1A64" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_D02E8ABC39633BDC6620FB6C3B2BC381" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_A17D36DD43378FDA977AFB6C3B2B1A64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F0E0D0B2A3072779215EFB6C3B2CAA86" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_A17D36DD43378FDA977AFB6C3B2B1A64" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F0E0D0B2A3072779215EFB6C3B2CAA86" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_EisaiMember" xlink:label="loc_biib_EisaiMember_862C7250210EF6500D67FB6C3B2CA88E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F0E0D0B2A3072779215EFB6C3B2CAA86" xlink:to="loc_biib_EisaiMember_862C7250210EF6500D67FB6C3B2CA88E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_348D41DAD7599358180DFB6C3B2C2C50" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_D02E8ABC39633BDC6620FB6C3B2BC381" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_348D41DAD7599358180DFB6C3B2C2C50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_2554A9C66B380B3904E4FB6C3B2C8D98" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_348D41DAD7599358180DFB6C3B2C2C50" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_2554A9C66B380B3904E4FB6C3B2C8D98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember_34748199695F03984D23FB6C3B2C68D6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_2554A9C66B380B3904E4FB6C3B2C8D98" xlink:to="loc_us-gaap_InterestRateSwapMember_34748199695F03984D23FB6C3B2C68D6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_9F4E5C22383D81478732FB6C3B2CCCF1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_D02E8ABC39633BDC6620FB6C3B2BC381" xlink:to="loc_us-gaap_DebtInstrumentAxis_9F4E5C22383D81478732FB6C3B2CCCF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4966CEBD113955EC117DFB6C3B2C4CC1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_9F4E5C22383D81478732FB6C3B2CCCF1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4966CEBD113955EC117DFB6C3B2C4CC1" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" xlink:label="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_F460B26AD7CCE0039BC4FB6C3B2D2BF7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4966CEBD113955EC117DFB6C3B2C4CC1" xlink:to="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_F460B26AD7CCE0039BC4FB6C3B2D2BF7" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_922BBC27FB74C86B3203FB6C3B2C95AC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4966CEBD113955EC117DFB6C3B2C4CC1" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_922BBC27FB74C86B3203FB6C3B2C95AC" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_11AE3B411779C35DC2D1FB6C3B2C38AD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4966CEBD113955EC117DFB6C3B2C4CC1" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_11AE3B411779C35DC2D1FB6C3B2C38AD" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_7696055F354DD5BBB4C2FB6C3B2C1E1B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4966CEBD113955EC117DFB6C3B2C4CC1" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_7696055F354DD5BBB4C2FB6C3B2C1E1B" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_E141CCBD9CD21A414615FB6C3B2DE27F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4966CEBD113955EC117DFB6C3B2C4CC1" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_E141CCBD9CD21A414615FB6C3B2DE27F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_4D512F1DE9CC41220EC3FB6C3B2D7AAE" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_D02E8ABC39633BDC6620FB6C3B2BC381" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_4D512F1DE9CC41220EC3FB6C3B2D7AAE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_E0EE637A77F1FD013EB4FB6C3B2DBB5D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_4D512F1DE9CC41220EC3FB6C3B2D7AAE" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_E0EE637A77F1FD013EB4FB6C3B2DBB5D" xlink:type="arc" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_E0EE637A77F1FD013EB4FB6C3B2DBB5D" xlink:to="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_F460B26AD7CCE0039BC4FB6C3B2D2BF7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_C377AD0DACDA89BDFF77FB6C3B2DD741" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_E0EE637A77F1FD013EB4FB6C3B2DBB5D" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_C377AD0DACDA89BDFF77FB6C3B2DD741" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_5752CFAD9689FE6191B7FB6C3B2D530F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_D02E8ABC39633BDC6620FB6C3B2BC381" xlink:to="loc_us-gaap_DebtInstrumentLineItems_5752CFAD9689FE6191B7FB6C3B2D530F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_B5B9DD9F22A0B43D16EDFB6C3B2D5AA9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5752CFAD9689FE6191B7FB6C3B2D530F" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_B5B9DD9F22A0B43D16EDFB6C3B2D5AA9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7996C1D6E355B21926FEFB6C3B2D9D04" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5752CFAD9689FE6191B7FB6C3B2D530F" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7996C1D6E355B21926FEFB6C3B2D9D04" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_PercentageParValueOfSeniorNotes" xlink:label="loc_biib_PercentageParValueOfSeniorNotes_E17B1A73F4DD56062176FB6C3B2D1F28" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5752CFAD9689FE6191B7FB6C3B2D530F" xlink:to="loc_biib_PercentageParValueOfSeniorNotes_E17B1A73F4DD56062176FB6C3B2D1F28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_7EE34F6F1CEF32E9E451FB6C3B2DF9A8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5752CFAD9689FE6191B7FB6C3B2D530F" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_7EE34F6F1CEF32E9E451FB6C3B2DF9A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_6EE391E5E954B296E080FB6C3B2D47C7" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5752CFAD9689FE6191B7FB6C3B2D530F" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_6EE391E5E954B296E080FB6C3B2D47C7" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage" xlink:label="loc_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_EE511399A391A897CE62FB6C3B2DA09E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5752CFAD9689FE6191B7FB6C3B2D530F" xlink:to="loc_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_EE511399A391A897CE62FB6C3B2DA09E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_A2269BFCD9DFFAE512CFFB6C3B2DAE9E" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5752CFAD9689FE6191B7FB6C3B2D530F" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_A2269BFCD9DFFAE512CFFB6C3B2DAE9E" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_IncreasedCarryingAmountOfSeniorNotes" xlink:label="loc_biib_IncreasedCarryingAmountOfSeniorNotes_A6F9FEA410774AB1EDE8FB6C3B2D91E5" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5752CFAD9689FE6191B7FB6C3B2D530F" xlink:to="loc_biib_IncreasedCarryingAmountOfSeniorNotes_A6F9FEA410774AB1EDE8FB6C3B2D91E5" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_DebtInstrumentUnamortizedInterestOnDebt" xlink:label="loc_biib_DebtInstrumentUnamortizedInterestOnDebt_71176A85CAD91D7BC8ABFB6C3B2EC1FA" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5752CFAD9689FE6191B7FB6C3B2D530F" xlink:to="loc_biib_DebtInstrumentUnamortizedInterestOnDebt_71176A85CAD91D7BC8ABFB6C3B2EC1FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaap_LongTermNotesPayable_D86392754D2EA82DEA91FB6C3B2E8DB1" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5752CFAD9689FE6191B7FB6C3B2D530F" xlink:to="loc_us-gaap_LongTermNotesPayable_D86392754D2EA82DEA91FB6C3B2E8DB1" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ParValueOfNotesPayable" xlink:label="loc_biib_ParValueOfNotesPayable_5B4F5A729633222018C4FB6C3B2E5127" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5752CFAD9689FE6191B7FB6C3B2D530F" xlink:to="loc_biib_ParValueOfNotesPayable_5B4F5A729633222018C4FB6C3B2E5127" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_E9CD763E2F6FE6E78D65FB6C3B2E7DFB" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5752CFAD9689FE6191B7FB6C3B2D530F" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_E9CD763E2F6FE6E78D65FB6C3B2E7DFB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:label="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_990D5D30089F47B7C6CAFB6C3B2EE2F4" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5752CFAD9689FE6191B7FB6C3B2D530F" xlink:to="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_990D5D30089F47B7C6CAFB6C3B2EE2F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" xlink:label="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_62720ECD59E7A105B580FB6C3B2E9D4D" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5752CFAD9689FE6191B7FB6C3B2D530F" xlink:to="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_62720ECD59E7A105B580FB6C3B2E9D4D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalLeaseObligations" xlink:label="loc_us-gaap_CapitalLeaseObligations_24683F64C9594DEE4071FB6C3B2E9B9C" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5752CFAD9689FE6191B7FB6C3B2D530F" xlink:to="loc_us-gaap_CapitalLeaseObligations_24683F64C9594DEE4071FB6C3B2E9B9C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IndebtednessTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_9516F4B18AC4C884EF307412858BA364" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_37EC383BF4A289CFD77F7412858B5CE5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_9516F4B18AC4C884EF307412858BA364" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_37EC383BF4A289CFD77F7412858B5CE5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_CB335014BEB5A8D720207412858BF906" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_9516F4B18AC4C884EF307412858BA364" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_CB335014BEB5A8D720207412858BF906" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8BFD620DEB5980B42CAC741287ED5EDE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_CBEF66339F5F537A2CFB741287EDB2C3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8BFD620DEB5980B42CAC741287ED5EDE" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_CBEF66339F5F537A2CFB741287EDB2C3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_43D49CCE297C1372A032FA4EA566D521" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_D482A3637939C6007F8DFA4EA5662371" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_43D49CCE297C1372A032FA4EA566D521" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_D482A3637939C6007F8DFA4EA5662371" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:label="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_9571EB206C38718E9A32FA4EA566847A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_D482A3637939C6007F8DFA4EA5662371" xlink:to="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_9571EB206C38718E9A32FA4EA566847A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:label="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_4D521F71344B6FA0A530FA4EA566F134" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_9571EB206C38718E9A32FA4EA566847A" xlink:to="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_4D521F71344B6FA0A530FA4EA566F134" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_RodinTherapeuticsMember" xlink:label="loc_biib_RodinTherapeuticsMember_D47F17B4A3B4ED539DAAFA4EA566E194" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_4D521F71344B6FA0A530FA4EA566F134" xlink:to="loc_biib_RodinTherapeuticsMember_D47F17B4A3B4ED539DAAFA4EA566E194" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_AtaxionMember" xlink:label="loc_biib_AtaxionMember_45D4F6F4E9C1F53ADDF0FA4EA5668E55" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_4D521F71344B6FA0A530FA4EA566F134" xlink:to="loc_biib_AtaxionMember_45D4F6F4E9C1F53ADDF0FA4EA5668E55" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_D729CC80798A0C1AF420FA4EA566A740" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_D482A3637939C6007F8DFA4EA5662371" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_D729CC80798A0C1AF420FA4EA566A740" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_755DA58CD94666FFF0E5FA4EA56617E9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_D729CC80798A0C1AF420FA4EA566A740" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_755DA58CD94666FFF0E5FA4EA56617E9" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ConvergencePharmaceuticalsMember" xlink:label="loc_biib_ConvergencePharmaceuticalsMember_B4AA3F1C7F5BC186F547FA4EA5662E50" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_755DA58CD94666FFF0E5FA4EA56617E9" xlink:to="loc_biib_ConvergencePharmaceuticalsMember_B4AA3F1C7F5BC186F547FA4EA5662E50" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_FumapharmAgMember" xlink:label="loc_biib_FumapharmAgMember_718F7CFAED742A741E4DFA4EA567F58A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_755DA58CD94666FFF0E5FA4EA56617E9" xlink:to="loc_biib_FumapharmAgMember_718F7CFAED742A741E4DFA4EA567F58A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_B99380799C21A0B54886FA4EA567FE44" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_D482A3637939C6007F8DFA4EA5662371" xlink:to="loc_us-gaap_ProductOrServiceAxis_B99380799C21A0B54886FA4EA567FE44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_88D951F6EB60560F5A28FA4EA5677E4A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductOrServiceAxis_B99380799C21A0B54886FA4EA567FE44" xlink:to="loc_us-gaap_ProductsAndServicesDomain_88D951F6EB60560F5A28FA4EA5677E4A" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_AVONEXMember" xlink:label="loc_biib_AVONEXMember_7870E220AA7EAE6E577EFA4EA56761DA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_88D951F6EB60560F5A28FA4EA5677E4A" xlink:to="loc_biib_AVONEXMember_7870E220AA7EAE6E577EFA4EA56761DA" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_TysabriProductMember" xlink:label="loc_biib_TysabriProductMember_B4BA9D2D422AA49F85B6FA4EA5679D1D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_88D951F6EB60560F5A28FA4EA5677E4A" xlink:to="loc_biib_TysabriProductMember_B4BA9D2D422AA49F85B6FA4EA5679D1D" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_SPINRAZAMember" xlink:label="loc_biib_SPINRAZAMember_E6C645BEAE1F3AA442CAFA4EA567F477" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_88D951F6EB60560F5A28FA4EA5677E4A" xlink:to="loc_biib_SPINRAZAMember_E6C645BEAE1F3AA442CAFA4EA567F477" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_BiosimilarsMember" xlink:label="loc_biib_BiosimilarsMember_E12D59C42DA0F0715779FA4EA567955E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_88D951F6EB60560F5A28FA4EA5677E4A" xlink:to="loc_biib_BiosimilarsMember_E12D59C42DA0F0715779FA4EA567955E" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ZINBRYTAMember" xlink:label="loc_biib_ZINBRYTAMember_5461BBCC6A5B80477BFFFA4EA5673C4B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_88D951F6EB60560F5A28FA4EA5677E4A" xlink:to="loc_biib_ZINBRYTAMember_5461BBCC6A5B80477BFFFA4EA5673C4B" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ALPROLIXMember" xlink:label="loc_biib_ALPROLIXMember_7BEEC76BE0B4D5A4F5E0FA4EA5673A0A" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_88D951F6EB60560F5A28FA4EA5677E4A" xlink:to="loc_biib_ALPROLIXMember_7BEEC76BE0B4D5A4F5E0FA4EA5673A0A" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_0B13F5CFBAA3BC5F6A0CFA4EA5675070" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_88D951F6EB60560F5A28FA4EA5677E4A" xlink:to="loc_biib_TecfideraMember_0B13F5CFBAA3BC5F6A0CFA4EA5675070" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_DF6DB2AD6DE068351AC8FA4EA567EE67" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_D482A3637939C6007F8DFA4EA5662371" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_DF6DB2AD6DE068351AC8FA4EA567EE67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_FA7F0C10BBC676532FD0FA4EA567DF98" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_DF6DB2AD6DE068351AC8FA4EA567EE67" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_FA7F0C10BBC676532FD0FA4EA567DF98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_883C2E327BC7EAFD2020FA4EA568E9AA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_FA7F0C10BBC676532FD0FA4EA567DF98" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_883C2E327BC7EAFD2020FA4EA568E9AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_A069B136347BACE6EF79FA4EA5689F22" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_FA7F0C10BBC676532FD0FA4EA567DF98" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_A069B136347BACE6EF79FA4EA5689F22" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3A77B573F189966822CAFA4EA568479A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_D482A3637939C6007F8DFA4EA5662371" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3A77B573F189966822CAFA4EA568479A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4CFF285E3BED4B15CE9DFA4EA5682C9B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3A77B573F189966822CAFA4EA568479A" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4CFF285E3BED4B15CE9DFA4EA5682C9B" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_OutLicensedPatentsMember" xlink:label="loc_biib_OutLicensedPatentsMember_B0AE17218424D421D4F4FA4EA568F926" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4CFF285E3BED4B15CE9DFA4EA5682C9B" xlink:to="loc_biib_OutLicensedPatentsMember_B0AE17218424D421D4F4FA4EA568F926" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_EC4FE92223CD4ACE0E8FFA4EA568338A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4CFF285E3BED4B15CE9DFA4EA5682C9B" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_EC4FE92223CD4ACE0E8FFA4EA568338A" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_InLicensedPatentsMember" xlink:label="loc_biib_InLicensedPatentsMember_4F03EF38B05FBF13C07FFA4EA5689712" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4CFF285E3BED4B15CE9DFA4EA5682C9B" xlink:to="loc_biib_InLicensedPatentsMember_4F03EF38B05FBF13C07FFA4EA5689712" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_9570C071FC13D3C8A406FA4EA56892A6" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_D482A3637939C6007F8DFA4EA5662371" xlink:to="loc_us-gaap_RangeAxis_9570C071FC13D3C8A406FA4EA56892A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_10376B02C73034E9AC1EFA4EA56977D1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_9570C071FC13D3C8A406FA4EA56892A6" xlink:to="loc_us-gaap_RangeMember_10376B02C73034E9AC1EFA4EA56977D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_198B75AFA09405F8212FFA4EA569478E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_10376B02C73034E9AC1EFA4EA56977D1" xlink:to="loc_us-gaap_MinimumMember_198B75AFA09405F8212FFA4EA569478E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_1B1F0E0106FFFE7F90A3FA4EA56913CC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_10376B02C73034E9AC1EFA4EA56977D1" xlink:to="loc_us-gaap_MaximumMember_1B1F0E0106FFFE7F90A3FA4EA56913CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_C95FCA0A99D01B9DF1A7FA4EA5692355" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_D482A3637939C6007F8DFA4EA5662371" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_C95FCA0A99D01B9DF1A7FA4EA5692355" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_238640EE7A862943D437FA4EA569696D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_C95FCA0A99D01B9DF1A7FA4EA5692355" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_238640EE7A862943D437FA4EA569696D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_A29B57FC344DCAC48CE6FA4EA5691754" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_C95FCA0A99D01B9DF1A7FA4EA5692355" xlink:to="loc_us-gaap_Goodwill_A29B57FC344DCAC48CE6FA4EA5691754" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_C5638768CFA6E40E605AFA4EA569C628" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_C95FCA0A99D01B9DF1A7FA4EA5692355" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_C5638768CFA6E40E605AFA4EA569C628" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_9F7FB4B9002A04739509FA4EA5695DA5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_C5638768CFA6E40E605AFA4EA569C628" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_9F7FB4B9002A04739509FA4EA5695DA5" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_IndefiniteLivedIntangibleAssetsUsefulLife" xlink:label="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_EABE525958F1D684A851FA4EA5697F53" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_C5638768CFA6E40E605AFA4EA569C628" xlink:to="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_EABE525958F1D684A851FA4EA5697F53" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_09AFB774F9270418D372FA4EA5698256" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_C5638768CFA6E40E605AFA4EA569C628" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_09AFB774F9270418D372FA4EA5698256" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_B28F4E22F8595B80D9DEFA4EA56AB87D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_C5638768CFA6E40E605AFA4EA569C628" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_B28F4E22F8595B80D9DEFA4EA56AB87D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_016DD484F130E93016A9FA4EA56A7B50" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_C5638768CFA6E40E605AFA4EA569C628" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_016DD484F130E93016A9FA4EA56A7B50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9A75AC0F6DB0FE13818CFA4EA56A6641" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_C5638768CFA6E40E605AFA4EA569C628" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9A75AC0F6DB0FE13818CFA4EA56A6641" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_9D42B46898876CD1B454FA4EA56A84FA" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_C5638768CFA6E40E605AFA4EA569C628" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_9D42B46898876CD1B454FA4EA56A84FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_D1A76CD50BA8CB402E03FA4EA56ADFCE" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_C5638768CFA6E40E605AFA4EA569C628" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_D1A76CD50BA8CB402E03FA4EA56ADFCE" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract" xlink:label="loc_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_29FD9B87D1DD80B3CB79FA4EA56AEBBC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_C95FCA0A99D01B9DF1A7FA4EA5692355" xlink:to="loc_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_29FD9B87D1DD80B3CB79FA4EA56AEBBC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_08608861291CC0CADB77FA4EA56ABD03" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_29FD9B87D1DD80B3CB79FA4EA56AEBBC" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_08608861291CC0CADB77FA4EA56ABD03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_25BA715290654A34933CFA4EA56A2953" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_29FD9B87D1DD80B3CB79FA4EA56AEBBC" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_25BA715290654A34933CFA4EA56A2953" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_E726D53C151763F6DC85FA4EA56ABE9E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_29FD9B87D1DD80B3CB79FA4EA56AEBBC" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_E726D53C151763F6DC85FA4EA56ABE9E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_EB71C2D975CE7DC733E7FA4EA56A551E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_29FD9B87D1DD80B3CB79FA4EA56AEBBC" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_EB71C2D975CE7DC733E7FA4EA56A551E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_3063EF10D969D201069FFA4EA56A164F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_29FD9B87D1DD80B3CB79FA4EA56AEBBC" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_3063EF10D969D201069FFA4EA56A164F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_43E1686ECC9C1656DA43FA4EA56A3C50" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_C95FCA0A99D01B9DF1A7FA4EA5692355" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_43E1686ECC9C1656DA43FA4EA56A3C50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_EC4D94D43C4F25DB9DC7FA4EA56A6E5C" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_C95FCA0A99D01B9DF1A7FA4EA5692355" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_EC4D94D43C4F25DB9DC7FA4EA56A6E5C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_AF511DF43B9C4BA90E88FA4EA56A75A8" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_C95FCA0A99D01B9DF1A7FA4EA5692355" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_AF511DF43B9C4BA90E88FA4EA56A75A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_6445ECC3E6EE14771830FA4EA56A2905" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_C95FCA0A99D01B9DF1A7FA4EA5692355" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_6445ECC3E6EE14771830FA4EA56A2905" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_MilestonePaymentsMadeDuringPeriod" xlink:label="loc_biib_MilestonePaymentsMadeDuringPeriod_518533EDC445F5CE2D71FA4EA56AF71A" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_C95FCA0A99D01B9DF1A7FA4EA5692355" xlink:to="loc_biib_MilestonePaymentsMadeDuringPeriod_518533EDC445F5CE2D71FA4EA56AF71A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_4184BF8ACCE7F88664D2FA4EA56AD3ED" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_C95FCA0A99D01B9DF1A7FA4EA5692355" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_4184BF8ACCE7F88664D2FA4EA56AD3ED" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_C545F76C4E9F7CBAC36F87BF3B29A7EA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_EA940FBA93144EFE1E7487BF3B29D862" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_C545F76C4E9F7CBAC36F87BF3B29A7EA" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_EA940FBA93144EFE1E7487BF3B29D862" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1D4C47B303104186CDD987BF3B2979BF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_EA940FBA93144EFE1E7487BF3B29D862" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1D4C47B303104186CDD987BF3B2979BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_969D8966B6BFB1C0262287BF3B2A80B7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1D4C47B303104186CDD987BF3B2979BF" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_969D8966B6BFB1C0262287BF3B2A80B7" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_FumapharmAgMember" xlink:label="loc_biib_FumapharmAgMember_BD8A0BD79ED07843716B87BF3B2A1185" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_969D8966B6BFB1C0262287BF3B2A80B7" xlink:to="loc_biib_FumapharmAgMember_BD8A0BD79ED07843716B87BF3B2A1185" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ConvergencePharmaceuticalsMember" xlink:label="loc_biib_ConvergencePharmaceuticalsMember_81CCFAAC11B5E2B2B25787BF3B2A5B1A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_969D8966B6BFB1C0262287BF3B2A80B7" xlink:to="loc_biib_ConvergencePharmaceuticalsMember_81CCFAAC11B5E2B2B25787BF3B2A5B1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_E5EA64CCE23D194102EA87BF3B2A0B07" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_EA940FBA93144EFE1E7487BF3B29D862" xlink:to="loc_us-gaap_ProductOrServiceAxis_E5EA64CCE23D194102EA87BF3B2A0B07" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_2A7C3E518EA8DD65BD5887BF3B2AC2EA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductOrServiceAxis_E5EA64CCE23D194102EA87BF3B2A0B07" xlink:to="loc_us-gaap_ProductsAndServicesDomain_2A7C3E518EA8DD65BD5887BF3B2AC2EA" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_1118904958EDA2238F7687BF3B2A4B9F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_2A7C3E518EA8DD65BD5887BF3B2AC2EA" xlink:to="loc_biib_TecfideraMember_1118904958EDA2238F7687BF3B2A4B9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillLineItems" xlink:label="loc_us-gaap_GoodwillLineItems_8AEA97134254380E3CEA87BF3B2AE537" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_EA940FBA93144EFE1E7487BF3B29D862" xlink:to="loc_us-gaap_GoodwillLineItems_8AEA97134254380E3CEA87BF3B2AE537" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_F0528CC32E758AB7A44387BF3B2ADD4B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_8AEA97134254380E3CEA87BF3B2AE537" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_F0528CC32E758AB7A44387BF3B2ADD4B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_2C5F2DB47884536A4FFD87BF3B2ADFDE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_8AEA97134254380E3CEA87BF3B2AE537" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_2C5F2DB47884536A4FFD87BF3B2ADFDE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillRollForward" xlink:label="loc_us-gaap_GoodwillRollForward_F42EEE2993604665D2F387BF3B2A6BCA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_C545F76C4E9F7CBAC36F87BF3B29A7EA" xlink:to="loc_us-gaap_GoodwillRollForward_F42EEE2993604665D2F387BF3B2A6BCA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_097E00B64063F9CC41F987BF3B2A7189" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_F42EEE2993604665D2F387BF3B2A6BCA" xlink:to="loc_us-gaap_Goodwill_097E00B64063F9CC41F987BF3B2A7189" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_35BBF5D516E49D800AF787BF3B2A5C66" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_F42EEE2993604665D2F387BF3B2A6BCA" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_35BBF5D516E49D800AF787BF3B2A5C66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillOtherIncreaseDecrease" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_C7021BCFD0F9EB3A933E87BF3B2A6860" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_F42EEE2993604665D2F387BF3B2A6BCA" xlink:to="loc_us-gaap_GoodwillOtherIncreaseDecrease_C7021BCFD0F9EB3A933E87BF3B2A6860" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_734F832DE97B917DB97787BF3B2A6072" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_F42EEE2993604665D2F387BF3B2A6BCA" xlink:to="loc_us-gaap_Goodwill_734F832DE97B917DB97787BF3B2A6072" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5873F0DA646157AE07F4741285DA250F" xlink:type="locator" />
    <link:loc xlink:href="biib-20161231.xsd#biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:label="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_C1937652D8054560F4ED741285DAAD7F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5873F0DA646157AE07F4741285DA250F" xlink:to="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_C1937652D8054560F4ED741285DAAD7F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_3311B4AD738F881B814C741285DA6C0E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5873F0DA646157AE07F4741285DA250F" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_3311B4AD738F881B814C741285DA6C0E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_04E78B019CC94BDB82A5741285DA6135" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5873F0DA646157AE07F4741285DA250F" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_04E78B019CC94BDB82A5741285DA6135" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Inventory" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_788F506B12EAA48381EA7412892AB72D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_5D086E97061320707C8C7412892AD231" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_788F506B12EAA48381EA7412892AB72D" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_5D086E97061320707C8C7412892AD231" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_28A1BB26CB8EB5805CD5741287D33F64" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNetAbstract" xlink:label="loc_us-gaap_InventoryNetAbstract_7638E650219C0D7BC906741287D3662E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_28A1BB26CB8EB5805CD5741287D33F64" xlink:to="loc_us-gaap_InventoryNetAbstract_7638E650219C0D7BC906741287D3662E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_51BDE1562471CCE8691F741287D37F78" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_7638E650219C0D7BC906741287D3662E" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_51BDE1562471CCE8691F741287D37F78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_27513D91F545418F1C48741287D38075" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_7638E650219C0D7BC906741287D3662E" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_27513D91F545418F1C48741287D38075" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_19AC6750A5A43A805F22741287D30B21" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_7638E650219C0D7BC906741287D3662E" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_19AC6750A5A43A805F22741287D30B21" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_Inventorynetcurrentandnoncurrent" xlink:label="loc_biib_Inventorynetcurrentandnoncurrent_CCF031A5E78C60AEAD6D741287D36754" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_7638E650219C0D7BC906741287D3662E" xlink:to="loc_biib_Inventorynetcurrentandnoncurrent_CCF031A5E78C60AEAD6D741287D36754" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_A25D533272BCC66D806E741287D386CA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_28A1BB26CB8EB5805CD5741287D33F64" xlink:to="loc_us-gaap_InventoryNet_A25D533272BCC66D806E741287D386CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNoncurrent" xlink:label="loc_us-gaap_InventoryNoncurrent_5852560715BFF17C5B46741287D3F0D2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_28A1BB26CB8EB5805CD5741287D33F64" xlink:to="loc_us-gaap_InventoryNoncurrent_5852560715BFF17C5B46741287D3F0D2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InventoryDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_D6CABC076FEE928429E7FA4EA574CBC3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AirlineProductsAndServicesTable" xlink:label="loc_us-gaap_AirlineProductsAndServicesTable_F9BE3E575610995DFE86FA4EA5747988" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_D6CABC076FEE928429E7FA4EA574CBC3" xlink:to="loc_us-gaap_AirlineProductsAndServicesTable_F9BE3E575610995DFE86FA4EA5747988" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_B4FCFC950B150F3BADB9FA4EA5744761" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AirlineProductsAndServicesTable_F9BE3E575610995DFE86FA4EA5747988" xlink:to="loc_us-gaap_ProductOrServiceAxis_B4FCFC950B150F3BADB9FA4EA5744761" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_745DA2D409B793DA4F46FA4EA574DF6D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductOrServiceAxis_B4FCFC950B150F3BADB9FA4EA5744761" xlink:to="loc_us-gaap_ProductsAndServicesDomain_745DA2D409B793DA4F46FA4EA574DF6D" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ZINBRYTAMember" xlink:label="loc_biib_ZINBRYTAMember_5B5607FF8AFAB5049888FA4EA5750FF1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_745DA2D409B793DA4F46FA4EA574DF6D" xlink:to="loc_biib_ZINBRYTAMember_5B5607FF8AFAB5049888FA4EA5750FF1" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_FLIXABIMember" xlink:label="loc_biib_FLIXABIMember_2306DB88289A58D8113EFA4EA5751589" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_745DA2D409B793DA4F46FA4EA574DF6D" xlink:to="loc_biib_FLIXABIMember_2306DB88289A58D8113EFA4EA5751589" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_BENEPALIMember" xlink:label="loc_biib_BENEPALIMember_B09D4C84C9A62C145A5DFA4EA575E81B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_745DA2D409B793DA4F46FA4EA574DF6D" xlink:to="loc_biib_BENEPALIMember_B09D4C84C9A62C145A5DFA4EA575E81B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryLineItems" xlink:label="loc_us-gaap_InventoryLineItems_305528DEBE90E366EF97FA4EA575481F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AirlineProductsAndServicesTable_F9BE3E575610995DFE86FA4EA5747988" xlink:to="loc_us-gaap_InventoryLineItems_305528DEBE90E366EF97FA4EA575481F" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_Preapprovalinventory" xlink:label="loc_biib_Preapprovalinventory_9AFB9E710795E7A71CDEFA4EA5752B17" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_305528DEBE90E366EF97FA4EA575481F" xlink:to="loc_biib_Preapprovalinventory_9AFB9E710795E7A71CDEFA4EA5752B17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="loc_us-gaap_InventoryWriteDown_515486300E3C8EF55E7BFA4EA575F043" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_D6CABC076FEE928429E7FA4EA574CBC3" xlink:to="loc_us-gaap_InventoryWriteDown_515486300E3C8EF55E7BFA4EA575F043" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InventoryTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_57E8649F300B45EF26F57412863CE0C4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_2E12FE2E286790A29E7A7412863C2652" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_57E8649F300B45EF26F57412863CE0C4" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_2E12FE2E286790A29E7A7412863C2652" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities" xlink:type="extended">
    <link:loc xlink:href="biib-20161231.xsd#biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:label="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_344E893259392665568B7412856C6381" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_C4F3FECEAA13F25C1B507412856C4E64" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_344E893259392665568B7412856C6381" xlink:to="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_C4F3FECEAA13F25C1B507412856C4E64" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails" xlink:type="extended">
    <link:loc xlink:href="biib-20161231.xsd#biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:label="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_83538BA663E4AFAE1C06FB6C3A6EE9AD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_A9511272C46777E782BAFB6C3A6EE6B3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_83538BA663E4AFAE1C06FB6C3A6EE9AD" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_A9511272C46777E782BAFB6C3A6EE6B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_F9D984D2409EB6869042FB6C3A6EE9A0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_A9511272C46777E782BAFB6C3A6EE6B3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_F9D984D2409EB6869042FB6C3A6EE9A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_77F973F31DFF86B3C4E1FB6C3A6FC0FE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_F9D984D2409EB6869042FB6C3A6EE9A0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_77F973F31DFF86B3C4E1FB6C3A6FC0FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_B10D2936A3C04D38EC9BFB6C3A6FB17A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_77F973F31DFF86B3C4E1FB6C3A6FC0FE" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_B10D2936A3C04D38EC9BFB6C3A6FB17A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:label="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_02E2121797B058EAA30DFB6C3A6F7A5F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_A9511272C46777E782BAFB6C3A6EE6B3" xlink:to="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_02E2121797B058EAA30DFB6C3A6F7A5F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:label="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_90D8249C6B9956EF840BFB6C3A6F9A60" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_02E2121797B058EAA30DFB6C3A6F7A5F" xlink:to="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_90D8249C6B9956EF840BFB6C3A6F9A60" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_NeurimmuneMember" xlink:label="loc_biib_NeurimmuneMember_9DD675C4915E938A271EFB6C3A6F23EF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_90D8249C6B9956EF840BFB6C3A6F9A60" xlink:to="loc_biib_NeurimmuneMember_9DD675C4915E938A271EFB6C3A6F23EF" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_RodinTherapeuticsMember" xlink:label="loc_biib_RodinTherapeuticsMember_4895BE54026B721A9706FB6C3A6F5AB3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_90D8249C6B9956EF840BFB6C3A6F9A60" xlink:to="loc_biib_RodinTherapeuticsMember_4895BE54026B721A9706FB6C3A6F5AB3" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_AtaxionMember" xlink:label="loc_biib_AtaxionMember_A2AC2BBB54308E41566EFB6C3A6F71CD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_90D8249C6B9956EF840BFB6C3A6F9A60" xlink:to="loc_biib_AtaxionMember_A2AC2BBB54308E41566EFB6C3A6F71CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableInterestEntityLineItems" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_D749D4FC817F1D4B08E8FB6C3A6F2AF7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_A9511272C46777E782BAFB6C3A6EE6B3" xlink:to="loc_us-gaap_VariableInterestEntityLineItems_D749D4FC817F1D4B08E8FB6C3A6F2AF7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_DE19D1C78A0A7ADA62CAFB6C3A6FAD3B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_D749D4FC817F1D4B08E8FB6C3A6F2AF7" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_DE19D1C78A0A7ADA62CAFB6C3A6FAD3B" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_InvestmentInVariableInterestEntitiesTextualAbstract" xlink:label="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_077D275A6430BD65E4B1FB6C3A6FBFF2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_D749D4FC817F1D4B08E8FB6C3A6F2AF7" xlink:to="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_077D275A6430BD65E4B1FB6C3A6FBFF2" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement" xlink:label="loc_biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement_E51BC98ADC77575FBE8EFB6C3A709C63" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_077D275A6430BD65E4B1FB6C3A6FBFF2" xlink:to="loc_biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement_E51BC98ADC77575FBE8EFB6C3A709C63" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement" xlink:label="loc_biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement_CDC4BD9DA9249EC557E1FB6C3A703CA7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_077D275A6430BD65E4B1FB6C3A6FBFF2" xlink:to="loc_biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement_CDC4BD9DA9249EC557E1FB6C3A703CA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_B9B2E0F8F520ED2F8788FB6C3A7052DD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_077D275A6430BD65E4B1FB6C3A6FBFF2" xlink:to="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_B9B2E0F8F520ED2F8788FB6C3A7052DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_CB74C091903190AA71FCFB6C3A70124C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_077D275A6430BD65E4B1FB6C3A6FBFF2" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_CB74C091903190AA71FCFB6C3A70124C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NoncontrollingInterestInVariableInterestEntity" xlink:label="loc_us-gaap_NoncontrollingInterestInVariableInterestEntity_8CDA4892E5DFFF9798B6FB6C3A704EDF" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_077D275A6430BD65E4B1FB6C3A6FBFF2" xlink:to="loc_us-gaap_NoncontrollingInterestInVariableInterestEntity_8CDA4892E5DFFF9798B6FB6C3A704EDF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_7AE815B77CF6B967F862FB6C3A700A97" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_077D275A6430BD65E4B1FB6C3A6FBFF2" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_7AE815B77CF6B967F862FB6C3A700A97" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:label="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_3C3C50D7A085BD91B647FB6C3A7023D4" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_077D275A6430BD65E4B1FB6C3A6FBFF2" xlink:to="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_3C3C50D7A085BD91B647FB6C3A7023D4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Litigation" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:label="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_D5BEFA375996064EEB5974128890BF8D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_CFE7BF3D427C0D89F572741288912A24" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_D5BEFA375996064EEB5974128890BF8D" xlink:to="loc_us-gaap_LegalMattersAndContingenciesTextBlock_CFE7BF3D427C0D89F572741288912A24" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/LitigationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:label="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_74E5CD62BA87DB8CFA1FFCCAD8EFCA7D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_CE23F5EB8675F207A859FCCAD8F1EFDB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_74E5CD62BA87DB8CFA1FFCCAD8EFCA7D" xlink:to="loc_us-gaap_LossContingenciesTable_CE23F5EB8675F207A859FCCAD8F1EFDB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_9871C956DAEBAF712F29FCCAD8F11184" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_CE23F5EB8675F207A859FCCAD8F1EFDB" xlink:to="loc_us-gaap_StatementGeographicalAxis_9871C956DAEBAF712F29FCCAD8F11184" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_C721FDD84A1313C1DFA5FCCAD8F1DF5A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementGeographicalAxis_9871C956DAEBAF712F29FCCAD8F11184" xlink:to="loc_us-gaap_SegmentGeographicalDomain_C721FDD84A1313C1DFA5FCCAD8F1DF5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd#country_IT" xlink:label="loc_country_IT_6C56232AED5E0666E7A7FCCAD8F1F8B4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_C721FDD84A1313C1DFA5FCCAD8F1DF5A" xlink:to="loc_country_IT_6C56232AED5E0666E7A7FCCAD8F1F8B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_E1218D3754D6593F72E7FCCAD8F24890" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_CE23F5EB8675F207A859FCCAD8F1EFDB" xlink:to="loc_us-gaap_LossContingenciesLineItems_E1218D3754D6593F72E7FCCAD8F24890" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ReimbursementLimitStatedInResolution" xlink:label="loc_biib_ReimbursementLimitStatedInResolution_9ECCB5AAD6F7CF31DFC9FCCAD8F24F60" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_E1218D3754D6593F72E7FCCAD8F24890" xlink:to="loc_biib_ReimbursementLimitStatedInResolution_9ECCB5AAD6F7CF31DFC9FCCAD8F24F60" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_C4083F241F0D1BD03A9DFCCAD8F27140" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_E1218D3754D6593F72E7FCCAD8F24890" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_C4083F241F0D1BD03A9DFCCAD8F27140" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_05722C04D156C5F12BEF7412876890D5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_29A3EF5CC10644D90B057412876898FE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_05722C04D156C5F12BEF7412876890D5" xlink:to="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_29A3EF5CC10644D90B057412876898FE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_CA15C1024614414B8AC2FB6C3A8497B2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_F5018EEA7FAE61CF11CFFB6C3A85EDEE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_CA15C1024614414B8AC2FB6C3A8497B2" xlink:to="loc_us-gaap_StatementTable_F5018EEA7FAE61CF11CFFB6C3A85EDEE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_DA5CA3A0DB2A65F331DFFB6C3A85B94A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_F5018EEA7FAE61CF11CFFB6C3A85EDEE" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_DA5CA3A0DB2A65F331DFFB6C3A85B94A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_85FBA75FE9291149FD8CFB6C3A851BE4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_DA5CA3A0DB2A65F331DFFB6C3A85B94A" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_85FBA75FE9291149FD8CFB6C3A851BE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_6BAAB45C376C946753E2FB6C3A856C14" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_85FBA75FE9291149FD8CFB6C3A851BE4" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_6BAAB45C376C946753E2FB6C3A856C14" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_A42FA2D960549E2AB32EFB6C3A854558" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_F5018EEA7FAE61CF11CFFB6C3A85EDEE" xlink:to="loc_us-gaap_StatementLineItems_A42FA2D960549E2AB32EFB6C3A854558" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_4342839C9E9EB11919FDFB6C3A853624" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_A42FA2D960549E2AB32EFB6C3A854558" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_4342839C9E9EB11919FDFB6C3A853624" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_401A5A7A0772D376535AFB6C3A85D57F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_CA15C1024614414B8AC2FB6C3A8497B2" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_401A5A7A0772D376535AFB6C3A85D57F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_40B5B122F87E1F10FF32FB6C3A85BBD5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_401A5A7A0772D376535AFB6C3A85D57F" xlink:to="loc_us-gaap_InterestPaidNet_40B5B122F87E1F10FF32FB6C3A85BBD5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_619DE04A88276891C555FB6C3A85111D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_401A5A7A0772D376535AFB6C3A85D57F" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_619DE04A88276891C555FB6C3A85111D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_B2D7A1719DDC0DC86B2AFB6C3A85F734" xlink:type="locator" />
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_CA15C1024614414B8AC2FB6C3A8497B2" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_B2D7A1719DDC0DC86B2AFB6C3A85F734" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_4830AFF7636950969FCBFB6C3A8500AE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_B2D7A1719DDC0DC86B2AFB6C3A85F734" xlink:to="loc_us-gaap_InvestmentIncomeInterest_4830AFF7636950969FCBFB6C3A8500AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_61DA2F09D53281FDC87AFB6C3A862B6D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_B2D7A1719DDC0DC86B2AFB6C3A85F734" xlink:to="loc_us-gaap_InterestExpense_61DA2F09D53281FDC87AFB6C3A862B6D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnSaleOfInvestments" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments_990B6444814F3DE87296FB6C3A86A56F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_B2D7A1719DDC0DC86B2AFB6C3A85F734" xlink:to="loc_us-gaap_GainLossOnSaleOfInvestments_990B6444814F3DE87296FB6C3A86A56F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_A89D6F73061AC9B88A47FB6C3A8600AE" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_B2D7A1719DDC0DC86B2AFB6C3A85F734" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_A89D6F73061AC9B88A47FB6C3A8600AE" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_OtherIncomeExpenseNet" xlink:label="loc_biib_OtherIncomeExpenseNet_01AC010B6F8DD062F390FB6C3A868CAB" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_B2D7A1719DDC0DC86B2AFB6C3A85F734" xlink:to="loc_biib_OtherIncomeExpenseNet_01AC010B6F8DD062F390FB6C3A868CAB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_32D3E7B0194FA8F2B604FB6C3A86B24F" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_B2D7A1719DDC0DC86B2AFB6C3A85F734" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_32D3E7B0194FA8F2B604FB6C3A86B24F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_65965AD395E0BFE79CD4FB6C3A865D83" xlink:type="locator" />
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_CA15C1024614414B8AC2FB6C3A8497B2" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_65965AD395E0BFE79CD4FB6C3A865D83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_35C5BDE1D363DDF837C7FB6C3A86F383" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_65965AD395E0BFE79CD4FB6C3A865D83" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_35C5BDE1D363DDF837C7FB6C3A86F383" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationReserve" xlink:label="loc_us-gaap_LitigationReserve_C095AB38E5F7A2E6F241FB6C3A86750E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_65965AD395E0BFE79CD4FB6C3A865D83" xlink:to="loc_us-gaap_LitigationReserve_C095AB38E5F7A2E6F241FB6C3A86750E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_2D60653B7294B1261D94FB6C3A86FDCB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_65965AD395E0BFE79CD4FB6C3A865D83" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_2D60653B7294B1261D94FB6C3A86FDCB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_4374CE5FB5DDEA44FA79FB6C3A86ED55" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_65965AD395E0BFE79CD4FB6C3A865D83" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_4374CE5FB5DDEA44FA79FB6C3A86ED55" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConstructionPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent_02746E28D90BFFFB8120FB6C3A86AA61" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_65965AD395E0BFE79CD4FB6C3A865D83" xlink:to="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent_02746E28D90BFFFB8120FB6C3A86AA61" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_Collaborationexpensesaccrual" xlink:label="loc_biib_Collaborationexpensesaccrual_E5A3341D74D9E65A64DCFBC387FDF5F8" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_65965AD395E0BFE79CD4FB6C3A865D83" xlink:to="loc_biib_Collaborationexpensesaccrual_E5A3341D74D9E65A64DCFBC387FDF5F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_7F9DB389DB03A2A40D20FB6C3A873723" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_65965AD395E0BFE79CD4FB6C3A865D83" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_7F9DB389DB03A2A40D20FB6C3A873723" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_B2E02A1EA03CF1B90BC1FB6C3A873A6B" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_65965AD395E0BFE79CD4FB6C3A865D83" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_B2E02A1EA03CF1B90BC1FB6C3A873A6B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_FAEFCE55AC12BAC28EC2FB6C3A7AF340" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_C6C4AA17ADE20EB1DE6CFB6C3A7A249B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_FAEFCE55AC12BAC28EC2FB6C3A7AF340" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_C6C4AA17ADE20EB1DE6CFB6C3A7A249B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_0C528E6E7E6A74EDD0DCFB6C3A7A1265" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_C6C4AA17ADE20EB1DE6CFB6C3A7A249B" xlink:to="loc_us-gaap_StatementGeographicalAxis_0C528E6E7E6A74EDD0DCFB6C3A7A1265" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_F8CC8DB532DAD514734FFB6C3A7ADBC2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementGeographicalAxis_0C528E6E7E6A74EDD0DCFB6C3A7A1265" xlink:to="loc_us-gaap_SegmentGeographicalDomain_F8CC8DB532DAD514734FFB6C3A7ADBC2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd#country_IT" xlink:label="loc_country_IT_A3D617FBC9AE3E88202AFB6C3A7A76A7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_F8CC8DB532DAD514734FFB6C3A7ADBC2" xlink:to="loc_country_IT_A3D617FBC9AE3E88202AFB6C3A7A76A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_6D5C446F1C15A7800AF3FB6C3A7B9206" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_C6C4AA17ADE20EB1DE6CFB6C3A7A249B" xlink:to="loc_us-gaap_ProductOrServiceAxis_6D5C446F1C15A7800AF3FB6C3A7B9206" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_3026F79808E98109B16EFB6C3A7B498B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductOrServiceAxis_6D5C446F1C15A7800AF3FB6C3A7B9206" xlink:to="loc_us-gaap_ProductsAndServicesDomain_3026F79808E98109B16EFB6C3A7B498B" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_DC6B9DBCB0C99121CF87FB6C3A7B37A0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_3026F79808E98109B16EFB6C3A7B498B" xlink:to="loc_biib_TecfideraMember_DC6B9DBCB0C99121CF87FB6C3A7B37A0" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_CumulativeSalesLevelAxis" xlink:label="loc_biib_CumulativeSalesLevelAxis_307D3D3893BBBAF6C9ECFB6C3A7B8756" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_C6C4AA17ADE20EB1DE6CFB6C3A7A249B" xlink:to="loc_biib_CumulativeSalesLevelAxis_307D3D3893BBBAF6C9ECFB6C3A7B8756" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_CumulativeSalesLevelDomain" xlink:label="loc_biib_CumulativeSalesLevelDomain_4FB6EEB520BB1657F312FB6C3A7BF198" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CumulativeSalesLevelAxis_307D3D3893BBBAF6C9ECFB6C3A7B8756" xlink:to="loc_biib_CumulativeSalesLevelDomain_4FB6EEB520BB1657F312FB6C3A7BF198" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ElevenbillionMember" xlink:label="loc_biib_ElevenbillionMember_9F9AC15002436D034960FB6C3A7B568D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CumulativeSalesLevelDomain_4FB6EEB520BB1657F312FB6C3A7BF198" xlink:to="loc_biib_ElevenbillionMember_9F9AC15002436D034960FB6C3A7B568D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_C5F8E25C7C340703C061FB6C3A7BAD75" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_C6C4AA17ADE20EB1DE6CFB6C3A7A249B" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_C5F8E25C7C340703C061FB6C3A7BAD75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_AB37326A5FE5473795CBFB6C3A7BA6B1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_C5F8E25C7C340703C061FB6C3A7BAD75" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_AB37326A5FE5473795CBFB6C3A7BA6B1" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_FumapharmAgMember" xlink:label="loc_biib_FumapharmAgMember_D2B1B793D81F312FA855FB6C3A7C4106" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_AB37326A5FE5473795CBFB6C3A7BA6B1" xlink:to="loc_biib_FumapharmAgMember_D2B1B793D81F312FA855FB6C3A7C4106" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ConvergencePharmaceuticalsMember" xlink:label="loc_biib_ConvergencePharmaceuticalsMember_D99BA0E8217D8EA15DA0FB6C3A7C524F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_AB37326A5FE5473795CBFB6C3A7BA6B1" xlink:to="loc_biib_ConvergencePharmaceuticalsMember_D99BA0E8217D8EA15DA0FB6C3A7C524F" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_FacilityLocationAxis" xlink:label="loc_biib_FacilityLocationAxis_6357BD1E932CB5C1E74CFB6C3A7CA068" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_C6C4AA17ADE20EB1DE6CFB6C3A7A249B" xlink:to="loc_biib_FacilityLocationAxis_6357BD1E932CB5C1E74CFB6C3A7CA068" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_64D750ECCACBD74194B9FB6C3A7C9CE5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityLocationAxis_6357BD1E932CB5C1E74CFB6C3A7CA068" xlink:to="loc_biib_FacilityLocationDomain_64D750ECCACBD74194B9FB6C3A7C9CE5" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_SolothurnMember" xlink:label="loc_biib_SolothurnMember_35273543728AA07E2BDDFB6C3A7C2074" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityLocationDomain_64D750ECCACBD74194B9FB6C3A7C9CE5" xlink:to="loc_biib_SolothurnMember_35273543728AA07E2BDDFB6C3A7C2074" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_818E713A0D6967D4B9D4FB6C3A7CF643" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_C6C4AA17ADE20EB1DE6CFB6C3A7A249B" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_818E713A0D6967D4B9D4FB6C3A7CF643" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationSettlementExpense" xlink:label="loc_us-gaap_LitigationSettlementExpense_4524B2A259A0974CC6EBFB6C3A7CA717" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_818E713A0D6967D4B9D4FB6C3A7CF643" xlink:to="loc_us-gaap_LitigationSettlementExpense_4524B2A259A0974CC6EBFB6C3A7CA717" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_502880A06042CF43D120FB6C3A7C510C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_818E713A0D6967D4B9D4FB6C3A7CF643" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_502880A06042CF43D120FB6C3A7C510C" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_CumulativeSalesLevel" xlink:label="loc_biib_CumulativeSalesLevel_8EFDC8FC90D214139B9DFB6C3A7DEE48" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_818E713A0D6967D4B9D4FB6C3A7CF643" xlink:to="loc_biib_CumulativeSalesLevel_8EFDC8FC90D214139B9DFB6C3A7DEE48" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConstructionPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent_1D736EE70810393C06D4FBBFB7A802BD" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_818E713A0D6967D4B9D4FB6C3A7CF643" xlink:to="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent_1D736EE70810393C06D4FBBFB7A802BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_173FF5BE27589843D7E1FB6C3A7DE364" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_818E713A0D6967D4B9D4FB6C3A7CF643" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_173FF5BE27589843D7E1FB6C3A7DE364" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidTaxes" xlink:label="loc_us-gaap_PrepaidTaxes_16BCC52584BEED3645FBFB6C3A7DA321" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_818E713A0D6967D4B9D4FB6C3A7CF643" xlink:to="loc_us-gaap_PrepaidTaxes_16BCC52584BEED3645FBFB6C3A7DA321" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_22F8E760669A78A5DC89FB6C3A7D9597" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_818E713A0D6967D4B9D4FB6C3A7CF643" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_22F8E760669A78A5DC89FB6C3A7D9597" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ReimbursementLimitStatedInResolution" xlink:label="loc_biib_ReimbursementLimitStatedInResolution_6E8014F8D75FCB28EB30FB6C3A7DAB05" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_818E713A0D6967D4B9D4FB6C3A7CF643" xlink:to="loc_biib_ReimbursementLimitStatedInResolution_6E8014F8D75FCB28EB30FB6C3A7DAB05" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_CCFE86255E01399D9E5FFB6C3A7D30BC" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_818E713A0D6967D4B9D4FB6C3A7CF643" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_CCFE86255E01399D9E5FFB6C3A7D30BC" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_LossContingencyAdjustmentRelatedToClaimAmountPercent" xlink:label="loc_biib_LossContingencyAdjustmentRelatedToClaimAmountPercent_E53392492F4F75200048FB6C3A7D1749" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_818E713A0D6967D4B9D4FB6C3A7CF643" xlink:to="loc_biib_LossContingencyAdjustmentRelatedToClaimAmountPercent_E53392492F4F75200048FB6C3A7D1749" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_46110BB3A1600EBDE0E5FB6C3A7D621E" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_818E713A0D6967D4B9D4FB6C3A7CF643" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_46110BB3A1600EBDE0E5FB6C3A7D621E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_C90D4BB660FE9CBDF6A0FB6C3A7DDACA" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_818E713A0D6967D4B9D4FB6C3A7CF643" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_C90D4BB660FE9CBDF6A0FB6C3A7DDACA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5C8820174FFA19EDA1BAD6D80CA4BA1F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_4C1A22F2310E33F4645CD6D80CA4B913" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5C8820174FFA19EDA1BAD6D80CA4BA1F" xlink:to="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_4C1A22F2310E33F4645CD6D80CA4B913" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_463E2ABAB28F8474B7A6D6D80CA47F8E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5C8820174FFA19EDA1BAD6D80CA4BA1F" xlink:to="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_463E2ABAB28F8474B7A6D6D80CA47F8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_3728B5EE5AD5FECB26E9D6D80CA4F3A2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5C8820174FFA19EDA1BAD6D80CA4BA1F" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_3728B5EE5AD5FECB26E9D6D80CA4F3A2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipment" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_17F5F4CBDA1134B693A6741289475CB8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_57B95B6C9BB26B78810E741289472C8E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_17F5F4CBDA1134B693A6741289475CB8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_57B95B6C9BB26B78810E741289472C8E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_A716CF5AD670A1CA3FDA741285AD7121" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Land" xlink:label="loc_us-gaap_Land_DB98DD13CE2844966A5A741285AD0E6D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_A716CF5AD670A1CA3FDA741285AD7121" xlink:to="loc_us-gaap_Land_DB98DD13CE2844966A5A741285AD0E6D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BuildingsAndImprovementsGross" xlink:label="loc_us-gaap_BuildingsAndImprovementsGross_896444DCD382CCC964B5741285ADBDC1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_A716CF5AD670A1CA3FDA741285AD7121" xlink:to="loc_us-gaap_BuildingsAndImprovementsGross_896444DCD382CCC964B5741285ADBDC1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="loc_us-gaap_LeaseholdImprovementsGross_5B1DE702061BE3B2AECC741285ADC99B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_A716CF5AD670A1CA3FDA741285AD7121" xlink:to="loc_us-gaap_LeaseholdImprovementsGross_5B1DE702061BE3B2AECC741285ADC99B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MachineryAndEquipmentGross" xlink:label="loc_us-gaap_MachineryAndEquipmentGross_88E85845253AD50A0AE9741285AD11AD" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_A716CF5AD670A1CA3FDA741285AD7121" xlink:to="loc_us-gaap_MachineryAndEquipmentGross_88E85845253AD50A0AE9741285AD11AD" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ComputerSoftwareAndHardware" xlink:label="loc_biib_ComputerSoftwareAndHardware_A0836A8A58508A60D1FE741285AD54BB" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_A716CF5AD670A1CA3FDA741285AD7121" xlink:to="loc_biib_ComputerSoftwareAndHardware_A0836A8A58508A60D1FE741285AD54BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FurnitureAndFixturesGross" xlink:label="loc_us-gaap_FurnitureAndFixturesGross_DCC6EEC10FE5ECA2A0C0741285AE0DC7" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_A716CF5AD670A1CA3FDA741285AD7121" xlink:to="loc_us-gaap_FurnitureAndFixturesGross_DCC6EEC10FE5ECA2A0C0741285AE0DC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConstructionInProgressGross" xlink:label="loc_us-gaap_ConstructionInProgressGross_F3B033946DAE7A28B5A2741285AE3DC1" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_A716CF5AD670A1CA3FDA741285AD7121" xlink:to="loc_us-gaap_ConstructionInProgressGross_F3B033946DAE7A28B5A2741285AE3DC1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_C2E1774E2A90A7B4E83E741285AE6DF4" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_A716CF5AD670A1CA3FDA741285AD7121" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_C2E1774E2A90A7B4E83E741285AE6DF4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_5177FFE974E9FBD96B34741285AECD5D" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_A716CF5AD670A1CA3FDA741285AD7121" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_5177FFE974E9FBD96B34741285AECD5D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_273ED9F81EE043739078741285AEBCEF" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_A716CF5AD670A1CA3FDA741285AD7121" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_273ED9F81EE043739078741285AEBCEF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_9FD403698DBD81386ED9FA4EA4BEBFCB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_06817BABE672F9B4C485FA4EA4BEA452" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_9FD403698DBD81386ED9FA4EA4BEBFCB" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_06817BABE672F9B4C485FA4EA4BEA452" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrencyAxis" xlink:label="loc_us-gaap_CurrencyAxis_89E315A9DE4ABD0FEAA0FA4EA4BE27DC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_06817BABE672F9B4C485FA4EA4BEA452" xlink:to="loc_us-gaap_CurrencyAxis_89E315A9DE4ABD0FEAA0FA4EA4BE27DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_DF848F43B464F2E7C07AFA4EA4BEA272" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrencyAxis_89E315A9DE4ABD0FEAA0FA4EA4BE27DC" xlink:to="loc_currency_AllCurrenciesDomain_DF848F43B464F2E7C07AFA4EA4BEA272" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd#currency_CHF" xlink:label="loc_currency_CHF_1422E3ABF05D9928DDE7FA4EA4BE1A85" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_DF848F43B464F2E7C07AFA4EA4BEA272" xlink:to="loc_currency_CHF_1422E3ABF05D9928DDE7FA4EA4BE1A85" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd#currency_USD" xlink:label="loc_currency_USD_5DCBBF9C02779CC13F8BFA4EA4BEC338" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_DF848F43B464F2E7C07AFA4EA4BEA272" xlink:to="loc_currency_USD_5DCBBF9C02779CC13F8BFA4EA4BEC338" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_A8DE4DA358BA42F02131FA4EA4BE06E0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_06817BABE672F9B4C485FA4EA4BEA452" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_A8DE4DA358BA42F02131FA4EA4BE06E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_20FEF50E048C85BD0526FA4EA4BE80C7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_A8DE4DA358BA42F02131FA4EA4BE06E0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_20FEF50E048C85BD0526FA4EA4BE80C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BuildingMember" xlink:label="loc_us-gaap_BuildingMember_EF2AD1EA31FA14BC7DD9FA4EA4BE95E4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_20FEF50E048C85BD0526FA4EA4BE80C7" xlink:to="loc_us-gaap_BuildingMember_EF2AD1EA31FA14BC7DD9FA4EA4BE95E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_69FD1E648E437808EF2EFA4EA4BF4A37" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_20FEF50E048C85BD0526FA4EA4BE80C7" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_69FD1E648E437808EF2EFA4EA4BF4A37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LandMember" xlink:label="loc_us-gaap_LandMember_894D830F5CD78D669735FA4EA4BFD82B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_20FEF50E048C85BD0526FA4EA4BE80C7" xlink:to="loc_us-gaap_LandMember_894D830F5CD78D669735FA4EA4BFD82B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_01F7CB7AF10A096C9A36FA4EA4BF0643" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_06817BABE672F9B4C485FA4EA4BEA452" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_01F7CB7AF10A096C9A36FA4EA4BF0643" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_66C0C7DEC4DDCF9593A7FA4EA4BF64AE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_01F7CB7AF10A096C9A36FA4EA4BF0643" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_66C0C7DEC4DDCF9593A7FA4EA4BF64AE" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_EisaiMember" xlink:label="loc_biib_EisaiMember_7284362A5D52773CACB7FA4EA4BF7A69" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_66C0C7DEC4DDCF9593A7FA4EA4BF64AE" xlink:to="loc_biib_EisaiMember_7284362A5D52773CACB7FA4EA4BF7A69" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_FacilityLocationAxis" xlink:label="loc_biib_FacilityLocationAxis_74D61367D05743380EF1FA4EA4BF0B74" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_06817BABE672F9B4C485FA4EA4BEA452" xlink:to="loc_biib_FacilityLocationAxis_74D61367D05743380EF1FA4EA4BF0B74" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_94BC43AE99B5AF6925C4FA4EA4BF36F6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityLocationAxis_74D61367D05743380EF1FA4EA4BF0B74" xlink:to="loc_biib_FacilityLocationDomain_94BC43AE99B5AF6925C4FA4EA4BF36F6" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_SolothurnMember" xlink:label="loc_biib_SolothurnMember_F226F2D866627C19B19CFA4EA4BF5E5D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityLocationDomain_94BC43AE99B5AF6925C4FA4EA4BF36F6" xlink:to="loc_biib_SolothurnMember_F226F2D866627C19B19CFA4EA4BF5E5D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_EC0C8926DE2938ADB2F3FA4EA4BF5D26" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_06817BABE672F9B4C485FA4EA4BEA452" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_EC0C8926DE2938ADB2F3FA4EA4BF5D26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_E917D5DCDAE6C53D41F7FA4EA4BFA2F9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_EC0C8926DE2938ADB2F3FA4EA4BF5D26" xlink:to="loc_us-gaap_Depreciation_E917D5DCDAE6C53D41F7FA4EA4BFA2F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestCostsCapitalized" xlink:label="loc_us-gaap_InterestCostsCapitalized_01359CEC34A7EE743104FA4EA4BF65DE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_EC0C8926DE2938ADB2F3FA4EA4BF5D26" xlink:to="loc_us-gaap_InterestCostsCapitalized_01359CEC34A7EE743104FA4EA4BF65DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAdditions" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAdditions_FDAC12C5DC82EDB3C9BDFA4EA4BF4275" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_EC0C8926DE2938ADB2F3FA4EA4BF5D26" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAdditions_FDAC12C5DC82EDB3C9BDFA4EA4BF4275" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConstructionInProgressGross" xlink:label="loc_us-gaap_ConstructionInProgressGross_5C51B16F78EBD6F3D08DFA4EA4C0C18E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_EC0C8926DE2938ADB2F3FA4EA4BF5D26" xlink:to="loc_us-gaap_ConstructionInProgressGross_5C51B16F78EBD6F3D08DFA4EA4C0C18E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:label="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_A169EC780FFBB76DCA2CFA4EA4C0B98F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_EC0C8926DE2938ADB2F3FA4EA4BF5D26" xlink:to="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_A169EC780FFBB76DCA2CFA4EA4C0B98F" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_TermOfLease" xlink:label="loc_biib_TermOfLease_4684C66542187739F454FA4EA4C0B882" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_EC0C8926DE2938ADB2F3FA4EA4BF5D26" xlink:to="loc_biib_TermOfLease_4684C66542187739F454FA4EA4C0B882" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalLeaseObligations" xlink:label="loc_us-gaap_CapitalLeaseObligations_6DDC589EBC8E538467CCFA4EA4C023D2" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_EC0C8926DE2938ADB2F3FA4EA4BF5D26" xlink:to="loc_us-gaap_CapitalLeaseObligations_6DDC589EBC8E538467CCFA4EA4C023D2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_EBE03422AF83FC606749D6D80DED3B2A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_7BDEE2B8F885C6CD7AE8D6D80DED445D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_EBE03422AF83FC606749D6D80DED3B2A" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_7BDEE2B8F885C6CD7AE8D6D80DED445D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/QuarterlyFinancialDataUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_5CE1E71C24F0C85875DD74128945DBE2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock_D6A9AB60E31A1DC3A7B174128945023F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_5CE1E71C24F0C85875DD74128945DBE2" xlink:to="loc_us-gaap_QuarterlyFinancialInformationTextBlock_D6A9AB60E31A1DC3A7B174128945023F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_0E2F52D8E60C054CF8B1FCCBDAA9ABFA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SelectedQuarterlyFinancialInformationAbstract" xlink:label="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_B2B82078E3250991C858FCCBDAA90A2F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_0E2F52D8E60C054CF8B1FCCBDAA9ABFA" xlink:to="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_B2B82078E3250991C858FCCBDAA90A2F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_5EA5103ED73D055501EDFCCBDAA9DAA4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_B2B82078E3250991C858FCCBDAA90A2F" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_5EA5103ED73D055501EDFCCBDAA9DAA4" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_RevenuesfromantiCD20therapeuticprograms" xlink:label="loc_biib_RevenuesfromantiCD20therapeuticprograms_369BC0F2B7DF31718B69FCEA3E55532F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_B2B82078E3250991C858FCCBDAA90A2F" xlink:to="loc_biib_RevenuesfromantiCD20therapeuticprograms_369BC0F2B7DF31718B69FCEA3E55532F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherSalesRevenueNet" xlink:label="loc_us-gaap_OtherSalesRevenueNet_14F500372F6CE80D3747FCCBDAA92B6C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_B2B82078E3250991C858FCCBDAA90A2F" xlink:to="loc_us-gaap_OtherSalesRevenueNet_14F500372F6CE80D3747FCCBDAA92B6C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_FDDD39B8961D98D36F15FCCBDAA93423" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_B2B82078E3250991C858FCCBDAA90A2F" xlink:to="loc_us-gaap_Revenues_FDDD39B8961D98D36F15FCCBDAA93423" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_8ED741BFCFAC58431C46FCCBDAA9BE5C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_B2B82078E3250991C858FCCBDAA90A2F" xlink:to="loc_us-gaap_GrossProfit_8ED741BFCFAC58431C46FCCBDAA9BE5C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_9CB8F1542C9BE69C64E5FCCBDAA9DE9C" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_B2B82078E3250991C858FCCBDAA90A2F" xlink:to="loc_us-gaap_ProfitLoss_9CB8F1542C9BE69C64E5FCCBDAA9DE9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_E860CBA5718194256389FCCBDAAE5A13" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_B2B82078E3250991C858FCCBDAA90A2F" xlink:to="loc_us-gaap_NetIncomeLoss_E860CBA5718194256389FCCBDAAE5A13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_083D348A269100D3B748FCCBDAAE063A" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_B2B82078E3250991C858FCCBDAA90A2F" xlink:to="loc_us-gaap_EarningsPerShareBasic_083D348A269100D3B748FCCBDAAE063A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_459999EA0B0F03ABFDEDFCCBDAAE3CE2" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_B2B82078E3250991C858FCCBDAA90A2F" xlink:to="loc_us-gaap_EarningsPerShareDiluted_459999EA0B0F03ABFDEDFCCBDAAE3CE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_349EB7C899F11549B28FFCCBDAAEA643" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_B2B82078E3250991C858FCCBDAA90A2F" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_349EB7C899F11549B28FFCCBDAAEA643" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5EF47B49601F12D3DFE3FCCBDAAE20E1" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_B2B82078E3250991C858FCCBDAA90A2F" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5EF47B49601F12D3DFE3FCCBDAAE20E1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_044C5C253184537B43B4FCCBDA962932" xlink:type="locator" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable" xlink:label="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_DD90BBCBFD70B10B3C91FCCBDA9677F8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_044C5C253184537B43B4FCCBDA962932" xlink:to="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_DD90BBCBFD70B10B3C91FCCBDA9677F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_842679059329E7BC7E03FCCBDA961A46" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_DD90BBCBFD70B10B3C91FCCBDA9677F8" xlink:to="loc_us-gaap_ProductOrServiceAxis_842679059329E7BC7E03FCCBDA961A46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_C228479EF900150D1EBCFCCBDA978CB6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductOrServiceAxis_842679059329E7BC7E03FCCBDA961A46" xlink:to="loc_us-gaap_ProductsAndServicesDomain_C228479EF900150D1EBCFCCBDA978CB6" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_SPINRAZAMember" xlink:label="loc_biib_SPINRAZAMember_A597A5BB090FCE733603FCCBDA97A7BE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_C228479EF900150D1EBCFCCBDA978CB6" xlink:to="loc_biib_SPINRAZAMember_A597A5BB090FCE733603FCCBDA97A7BE" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_FacilityLocationAxis" xlink:label="loc_biib_FacilityLocationAxis_0FD623E7A2F2978A7BB3FCCBDA9748F4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_DD90BBCBFD70B10B3C91FCCBDA9677F8" xlink:to="loc_biib_FacilityLocationAxis_0FD623E7A2F2978A7BB3FCCBDA9748F4" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_F5FBF2E48B4F457F79E3FCCBDA97A499" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityLocationAxis_0FD623E7A2F2978A7BB3FCCBDA9748F4" xlink:to="loc_biib_FacilityLocationDomain_F5FBF2E48B4F457F79E3FCCBDA97A499" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_CambridgeMAMember" xlink:label="loc_biib_CambridgeMAMember_9F7A0D3D9DFED50D21C6FCCBDA97E788" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityLocationDomain_F5FBF2E48B4F457F79E3FCCBDA97A499" xlink:to="loc_biib_CambridgeMAMember_9F7A0D3D9DFED50D21C6FCCBDA97E788" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringPlanAxis" xlink:label="loc_us-gaap_RestructuringPlanAxis_9E3C71DF67BEA010D6C9FCCBDA974768" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_DD90BBCBFD70B10B3C91FCCBDA9677F8" xlink:to="loc_us-gaap_RestructuringPlanAxis_9E3C71DF67BEA010D6C9FCCBDA974768" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringPlanDomain" xlink:label="loc_us-gaap_RestructuringPlanDomain_4A6E345E0224F5483195FCCBDA976257" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_9E3C71DF67BEA010D6C9FCCBDA974768" xlink:to="loc_us-gaap_RestructuringPlanDomain_4A6E345E0224F5483195FCCBDA976257" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_A2015RestructuringChargesMember" xlink:label="loc_biib_A2015RestructuringChargesMember_EB06A8254A161B8B1EA3FCCBDA97C4F0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_4A6E345E0224F5483195FCCBDA976257" xlink:to="loc_biib_A2015RestructuringChargesMember_EB06A8254A161B8B1EA3FCCBDA97C4F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:label="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_517001ABA83BD333B12DFCCBDA98971F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_DD90BBCBFD70B10B3C91FCCBDA9677F8" xlink:to="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_517001ABA83BD333B12DFCCBDA98971F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:label="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_895A00F3D4AB3BD88309FCCBDA98D490" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_517001ABA83BD333B12DFCCBDA98971F" xlink:to="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_895A00F3D4AB3BD88309FCCBDA98D490" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_NeurimmuneMember" xlink:label="loc_biib_NeurimmuneMember_87A6135A4C1A251156ACFCCBDA98D7CE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_895A00F3D4AB3BD88309FCCBDA98D490" xlink:to="loc_biib_NeurimmuneMember_87A6135A4C1A251156ACFCCBDA98D7CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_653F5C675DA02922DFB5FCCBDA98EFD9" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_DD90BBCBFD70B10B3C91FCCBDA9677F8" xlink:to="loc_us-gaap_TypeOfArrangementAxis_653F5C675DA02922DFB5FCCBDA98EFD9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ABEFCDBDC21F0533DC69FCCBDA984AEF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_653F5C675DA02922DFB5FCCBDA98EFD9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ABEFCDBDC21F0533DC69FCCBDA984AEF" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_IonisPharmaceuticalsInc.Member" xlink:label="loc_biib_IonisPharmaceuticalsInc.Member_029D1FC1B26E6FB2597BFCCBDA9DEA6E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ABEFCDBDC21F0533DC69FCCBDA984AEF" xlink:to="loc_biib_IonisPharmaceuticalsInc.Member_029D1FC1B26E6FB2597BFCCBDA9DEA6E" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_EisaiMember" xlink:label="loc_biib_EisaiMember_A737BCB44D1537AF7D96FCCBDA9D7E0D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ABEFCDBDC21F0533DC69FCCBDA984AEF" xlink:to="loc_biib_EisaiMember_A737BCB44D1537AF7D96FCCBDA9D7E0D" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_AGTCMember" xlink:label="loc_biib_AGTCMember_B6F3FE2551930753DC63FCCBDA98D175" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ABEFCDBDC21F0533DC69FCCBDA984AEF" xlink:to="loc_biib_AGTCMember_B6F3FE2551930753DC63FCCBDA98D175" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_MitsubishiTanabePharmaCorporationMember" xlink:label="loc_biib_MitsubishiTanabePharmaCorporationMember_26F6B8E4E4F33FCDCBBEFCCBDA9DC3B0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ABEFCDBDC21F0533DC69FCCBDA984AEF" xlink:to="loc_biib_MitsubishiTanabePharmaCorporationMember_26F6B8E4E4F33FCDCBBEFCCBDA9DC3B0" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems" xlink:label="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_8D61436B050E51C22A74FCCBDA9EDFA0" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_DD90BBCBFD70B10B3C91FCCBDA9677F8" xlink:to="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_8D61436B050E51C22A74FCCBDA9EDFA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_8F6728B08721A77F9C1EFCCBDA9ECECA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_8D61436B050E51C22A74FCCBDA9EDFA0" xlink:to="loc_us-gaap_RestructuringCharges_8F6728B08721A77F9C1EFCCBDA9ECECA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:label="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_9C667E06869B8B51983BFCCBDA9E7DAD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_8D61436B050E51C22A74FCCBDA9EDFA0" xlink:to="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_9C667E06869B8B51983BFCCBDA9E7DAD" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_LicenseFee" xlink:label="loc_biib_LicenseFee_2B82C6267B65D2B2F27EFCCBDA9EAB75" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_8D61436B050E51C22A74FCCBDA9EDFA0" xlink:to="loc_biib_LicenseFee_2B82C6267B65D2B2F27EFCCBDA9EAB75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_8CA086F2C3B2A0583B4EFCCBDA9E31E3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_8D61436B050E51C22A74FCCBDA9EDFA0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_8CA086F2C3B2A0583B4EFCCBDA9E31E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationSettlementExpense" xlink:label="loc_us-gaap_LitigationSettlementExpense_56E62808A3F2885A7425FCCBDA9EAF06" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_8D61436B050E51C22A74FCCBDA9EDFA0" xlink:to="loc_us-gaap_LitigationSettlementExpense_56E62808A3F2885A7425FCCBDA9EAF06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_7A33040AF70ACFB45EF5FCCBDA9E2F66" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_8D61436B050E51C22A74FCCBDA9EDFA0" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_7A33040AF70ACFB45EF5FCCBDA9E2F66" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_D54FA488B601909845C8741286EB942C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_ACF66F1417A596214540741286EBC6FB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_D54FA488B601909845C8741286EB942C" xlink:to="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_ACF66F1417A596214540741286EBC6FB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RestructuringRestructuring" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_4A77240A8DBB670733187412872288FD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_5600D24BBB4CCD7FAFF4741287224D53" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_4A77240A8DBB670733187412872288FD" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_5600D24BBB4CCD7FAFF4741287224D53" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RestructuringRestructuringDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_7DC161CD49A2CB8F2118FA4EA5C36F94" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8846F3EA4F344CC8EB24FA4EA5C33A90" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_7DC161CD49A2CB8F2118FA4EA5C36F94" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8846F3EA4F344CC8EB24FA4EA5C33A90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_D12C194F276AEACBF7B0FA4EA5C45A09" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8846F3EA4F344CC8EB24FA4EA5C33A90" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_D12C194F276AEACBF7B0FA4EA5C45A09" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_B97E74C8BAF2E4A1E822FA4EA5C4AD56" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_D12C194F276AEACBF7B0FA4EA5C45A09" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_B97E74C8BAF2E4A1E822FA4EA5C4AD56" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="loc_us-gaap_EmployeeSeveranceMember_892B946708C514E5728CFA4EA5C49DF4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_B97E74C8BAF2E4A1E822FA4EA5C4AD56" xlink:to="loc_us-gaap_EmployeeSeveranceMember_892B946708C514E5728CFA4EA5C49DF4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractTerminationMember" xlink:label="loc_us-gaap_ContractTerminationMember_1C7835881F9C8BB4C3C2FA4EA5C42FEC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_B97E74C8BAF2E4A1E822FA4EA5C4AD56" xlink:to="loc_us-gaap_ContractTerminationMember_1C7835881F9C8BB4C3C2FA4EA5C42FEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_4D4ADC8CE5D34B08C7C8FA4EA5C47B04" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8846F3EA4F344CC8EB24FA4EA5C33A90" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_4D4ADC8CE5D34B08C7C8FA4EA5C47B04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve_F98E011F465E7C6E1F06FA4EA5C456B5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_4D4ADC8CE5D34B08C7C8FA4EA5C47B04" xlink:to="loc_us-gaap_RestructuringReserve_F98E011F465E7C6E1F06FA4EA5C456B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringCosts" xlink:label="loc_us-gaap_RestructuringCosts_8C8A6227327B7F4CE4DFFA4EA5C5DA64" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_4D4ADC8CE5D34B08C7C8FA4EA5C47B04" xlink:to="loc_us-gaap_RestructuringCosts_8C8A6227327B7F4CE4DFFA4EA5C5DA64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForRestructuring" xlink:label="loc_us-gaap_PaymentsForRestructuring_1DAC998E1EC73EF1021CFA4EA5C4EEC3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_4D4ADC8CE5D34B08C7C8FA4EA5C47B04" xlink:to="loc_us-gaap_PaymentsForRestructuring_1DAC998E1EC73EF1021CFA4EA5C4EEC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringReserveAccrualAdjustment1" xlink:label="loc_us-gaap_RestructuringReserveAccrualAdjustment1_7437DEE17F0945E2D236FA4EA5C432AD" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_4D4ADC8CE5D34B08C7C8FA4EA5C47B04" xlink:to="loc_us-gaap_RestructuringReserveAccrualAdjustment1_7437DEE17F0945E2D236FA4EA5C432AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve_2D4129A94F11085DC892FA854417BA72" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_4D4ADC8CE5D34B08C7C8FA4EA5C47B04" xlink:to="loc_us-gaap_RestructuringReserve_2D4129A94F11085DC892FA854417BA72" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RestructuringRestructuringDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_743D37E640CD3A4604B3FA4EA5BDD34B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_087A087A8E3CC64BB59AFA4EA5BD2D35" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_743D37E640CD3A4604B3FA4EA5BDD34B" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_087A087A8E3CC64BB59AFA4EA5BD2D35" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_FacilityLocationAxis" xlink:label="loc_biib_FacilityLocationAxis_D88BF99C7DD80632BFE8FA4EA5BE494B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_087A087A8E3CC64BB59AFA4EA5BD2D35" xlink:to="loc_biib_FacilityLocationAxis_D88BF99C7DD80632BFE8FA4EA5BE494B" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_D0B46BE437119D940BE6FA4EA5BEC9B4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityLocationAxis_D88BF99C7DD80632BFE8FA4EA5BE494B" xlink:to="loc_biib_FacilityLocationDomain_D0B46BE437119D940BE6FA4EA5BEC9B4" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_CambridgeMAMember" xlink:label="loc_biib_CambridgeMAMember_70B30548757135BB71F0FA4EA5BEDC28" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityLocationDomain_D0B46BE437119D940BE6FA4EA5BEC9B4" xlink:to="loc_biib_CambridgeMAMember_70B30548757135BB71F0FA4EA5BEDC28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringPlanAxis" xlink:label="loc_us-gaap_RestructuringPlanAxis_F0EF9EF6AE038BD6A0BFFA4EA5BE8FD7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_087A087A8E3CC64BB59AFA4EA5BD2D35" xlink:to="loc_us-gaap_RestructuringPlanAxis_F0EF9EF6AE038BD6A0BFFA4EA5BE8FD7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringPlanDomain" xlink:label="loc_us-gaap_RestructuringPlanDomain_4773AB87B787A78453D2FA4EA5BE9A0C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_F0EF9EF6AE038BD6A0BFFA4EA5BE8FD7" xlink:to="loc_us-gaap_RestructuringPlanDomain_4773AB87B787A78453D2FA4EA5BE9A0C" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_A2015RestructuringChargesMember" xlink:label="loc_biib_A2015RestructuringChargesMember_35527C5B4B6B83711063FA4EA5BEAE85" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_4773AB87B787A78453D2FA4EA5BE9A0C" xlink:to="loc_biib_A2015RestructuringChargesMember_35527C5B4B6B83711063FA4EA5BEAE85" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_A2016RestructuringChargesMember" xlink:label="loc_biib_A2016RestructuringChargesMember_939EF3D923298797CFE6FA4EA5BE45B4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_4773AB87B787A78453D2FA4EA5BE9A0C" xlink:to="loc_biib_A2016RestructuringChargesMember_939EF3D923298797CFE6FA4EA5BE45B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_EC5C3494D051AFB0CF82FA4EA5BFF493" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_087A087A8E3CC64BB59AFA4EA5BD2D35" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_EC5C3494D051AFB0CF82FA4EA5BFF493" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_Restructuringandrelatedcostexpectedpercentageofpositionseliminated" xlink:label="loc_biib_Restructuringandrelatedcostexpectedpercentageofpositionseliminated_A7963B3270BA73D76483FA4EA5BF9007" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_EC5C3494D051AFB0CF82FA4EA5BFF493" xlink:to="loc_biib_Restructuringandrelatedcostexpectedpercentageofpositionseliminated_A7963B3270BA73D76483FA4EA5BF9007" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_RestructuringandRelatedCostExpectedCashPayments" xlink:label="loc_biib_RestructuringandRelatedCostExpectedCashPayments_9AD883F3037E741C1C08FA4EA5BF94FE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_EC5C3494D051AFB0CF82FA4EA5BFF493" xlink:to="loc_biib_RestructuringandRelatedCostExpectedCashPayments_9AD883F3037E741C1C08FA4EA5BF94FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringReserveAccrualAdjustment1" xlink:label="loc_us-gaap_RestructuringReserveAccrualAdjustment1_F792AC8F0796450B7A7EFA4EA5BFFA77" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_EC5C3494D051AFB0CF82FA4EA5BFF493" xlink:to="loc_us-gaap_RestructuringReserveAccrualAdjustment1_F792AC8F0796450B7A7EFA4EA5BFFA77" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_38BE0210DFD11C5640CDFA4EA5BF5F5A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_EC5C3494D051AFB0CF82FA4EA5BFF493" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_38BE0210DFD11C5640CDFA4EA5BF5F5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_204BC0BD4E63BF5CFAA3FA4EA5BFCDF2" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_EC5C3494D051AFB0CF82FA4EA5BFF493" xlink:to="loc_us-gaap_RestructuringCharges_204BC0BD4E63BF5CFAA3FA4EA5BFCDF2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:label="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_99B935F2C070CC4CCCD0FA4EA5BFBF9C" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_EC5C3494D051AFB0CF82FA4EA5BFF493" xlink:to="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_99B935F2C070CC4CCCD0FA4EA5BFBF9C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RestructuringRestructuringTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_3D6A3B7DAC9A3AEC9C2CFA4EA5C7412C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_E73DE8F1400F988F6C05FA4EA5C76E44" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_3D6A3B7DAC9A3AEC9C2CFA4EA5C7412C" xlink:to="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_E73DE8F1400F988F6C05FA4EA5C76E44" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenueReserves" xlink:type="extended">
    <link:loc xlink:href="biib-20161231.xsd#biib_ReservesForDiscountsAndAllowancesAbstract" xlink:label="loc_biib_ReservesForDiscountsAndAllowancesAbstract_7BBDCA9A6D4DCA49E6DE7412853A84AF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:label="loc_us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_E41E7A8D8B861F809BE07412853AE111" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ReservesForDiscountsAndAllowancesAbstract_7BBDCA9A6D4DCA49E6DE7412853A84AF" xlink:to="loc_us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_E41E7A8D8B861F809BE07412853AE111" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenueReservesDetails" xlink:type="extended">
    <link:loc xlink:href="biib-20161231.xsd#biib_ReservesForDiscountsAndAllowancesAbstract" xlink:label="loc_biib_ReservesForDiscountsAndAllowancesAbstract_593D4D09D84AB9296BE37412860F499D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_F22B8E0CDA4C75DE58FA7412860F7902" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ReservesForDiscountsAndAllowancesAbstract_593D4D09D84AB9296BE37412860F499D" xlink:to="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_F22B8E0CDA4C75DE58FA7412860F7902" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_6C3AEB43EC27BF0E6E597412860FA81D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_F22B8E0CDA4C75DE58FA7412860F7902" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_6C3AEB43EC27BF0E6E597412860FA81D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_2E67798B5F6F9E086F7C7412860FFF43" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_6C3AEB43EC27BF0E6E597412860FA81D" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_2E67798B5F6F9E086F7C7412860FFF43" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReserveForCashDiscountMember" xlink:label="loc_us-gaap_ReserveForCashDiscountMember_BC7C0170ACC231ACADD97412860F2087" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_2E67798B5F6F9E086F7C7412860FFF43" xlink:to="loc_us-gaap_ReserveForCashDiscountMember_BC7C0170ACC231ACADD97412860F2087" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ContractualAdjustmentsMember" xlink:label="loc_biib_ContractualAdjustmentsMember_760BA8657469537B49AD7412860F41A4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_2E67798B5F6F9E086F7C7412860FFF43" xlink:to="loc_biib_ContractualAdjustmentsMember_760BA8657469537B49AD7412860F41A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember_FE0DC58AD709CDABE5C27412860FACFA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_2E67798B5F6F9E086F7C7412860FFF43" xlink:to="loc_us-gaap_SalesReturnsAndAllowancesMember_FE0DC58AD709CDABE5C27412860FACFA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_C97D500E00A90B8F27387412860F9DDB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_F22B8E0CDA4C75DE58FA7412860F7902" xlink:to="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_C97D500E00A90B8F27387412860F9DDB" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract" xlink:label="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_518129311F902B2564A67412860F3F49" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_C97D500E00A90B8F27387412860F9DDB" xlink:to="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_518129311F902B2564A67412860F3F49" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_0AB80A908396C2913C477412860FEFA8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_518129311F902B2564A67412860F3F49" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_0AB80A908396C2913C477412860FEFA8" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:label="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_70C3699B3A02F341F710741286109150" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_518129311F902B2564A67412860F3F49" xlink:to="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_70C3699B3A02F341F710741286109150" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:label="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_569B038F3DDF3940872374128610336B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_518129311F902B2564A67412860F3F49" xlink:to="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_569B038F3DDF3940872374128610336B" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_54882D79CC37482823DD74128610D2CB" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_518129311F902B2564A67412860F3F49" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_54882D79CC37482823DD74128610D2CB" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_389E80FE308C3DC0B06074128610C2A1" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_518129311F902B2564A67412860F3F49" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_389E80FE308C3DC0B06074128610C2A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_C55244427442ED04BFD7741286105CC5" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_518129311F902B2564A67412860F3F49" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_C55244427442ED04BFD7741286105CC5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenueReservesDetails1" xlink:type="extended">
    <link:loc xlink:href="biib-20161231.xsd#biib_ReservesForDiscountsAndAllowancesAbstract" xlink:label="loc_biib_ReservesForDiscountsAndAllowancesAbstract_13958EFE8FF68DB747ED7412856A1479" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_427F5F77EB7F27AC13F77412856B5E0B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ReservesForDiscountsAndAllowancesAbstract_13958EFE8FF68DB747ED7412856A1479" xlink:to="loc_us-gaap_StatementTable_427F5F77EB7F27AC13F77412856B5E0B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_6661E1B537003DFBEDE97412856BB501" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_427F5F77EB7F27AC13F77412856B5E0B" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_6661E1B537003DFBEDE97412856BB501" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_C8BE19C77706966D6F427412856B97F2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_6661E1B537003DFBEDE97412856BB501" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_C8BE19C77706966D6F427412856B97F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_201986558ECDB33345607412856B30B6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_C8BE19C77706966D6F427412856B97F2" xlink:to="loc_us-gaap_AccountsReceivableMember_201986558ECDB33345607412856B30B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_9F3EAFCAECEBF769D40E7412856B5086" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_C8BE19C77706966D6F427412856B97F2" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_9F3EAFCAECEBF769D40E7412856B5086" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_E4AE9B8C3471305904FE7412856BCC04" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_427F5F77EB7F27AC13F77412856B5E0B" xlink:to="loc_us-gaap_StatementLineItems_E4AE9B8C3471305904FE7412856BCC04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_2E891048FD0FC444334C7412856B5C92" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_E4AE9B8C3471305904FE7412856BCC04" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_2E891048FD0FC444334C7412856B5C92" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenueReservesTables" xlink:type="extended">
    <link:loc xlink:href="biib-20161231.xsd#biib_ReservesForDiscountsAndAllowancesAbstract" xlink:label="loc_biib_ReservesForDiscountsAndAllowancesAbstract_965A2AD9B860E847938E74128969E42E" xlink:type="locator" />
    <link:loc xlink:href="biib-20161231.xsd#biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:label="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_6062B72096C355CD7F50741289698D2F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ReservesForDiscountsAndAllowancesAbstract_965A2AD9B860E847938E74128969E42E" xlink:to="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_6062B72096C355CD7F50741289698D2F" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:label="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_563BBDB65902B3FC4329741289698C87" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ReservesForDiscountsAndAllowancesAbstract_965A2AD9B860E847938E74128969E42E" xlink:to="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_563BBDB65902B3FC4329741289698C87" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SegmentInformation" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_C80BC235D2A1D18B179E7412887E1443" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_102AF70286EE64762A887412887EBEA8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_C80BC235D2A1D18B179E7412887E1443" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_102AF70286EE64762A887412887EBEA8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SegmentInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_2021F7D0CE65F042E861D6253303C36D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_E72281390FDBEAEF0D33D6253303FCEB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_2021F7D0CE65F042E861D6253303C36D" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_E72281390FDBEAEF0D33D6253303FCEB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_0F24FA10BF0E2218A04AD6253303C5DF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_E72281390FDBEAEF0D33D6253303FCEB" xlink:to="loc_us-gaap_ProductOrServiceAxis_0F24FA10BF0E2218A04AD6253303C5DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_7BB229E8315B32F01391D6253303898A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductOrServiceAxis_0F24FA10BF0E2218A04AD6253303C5DF" xlink:to="loc_us-gaap_ProductsAndServicesDomain_7BB229E8315B32F01391D6253303898A" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_15C54AA4E0531D12CAE7D6253303170D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_7BB229E8315B32F01391D6253303898A" xlink:to="loc_biib_TecfideraMember_15C54AA4E0531D12CAE7D6253303170D" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_AVONEXMember" xlink:label="loc_biib_AVONEXMember_A5BFAECC376C2C81987AD6253303C48C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_7BB229E8315B32F01391D6253303898A" xlink:to="loc_biib_AVONEXMember_A5BFAECC376C2C81987AD6253303C48C" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_PLEGRIDYMember" xlink:label="loc_biib_PLEGRIDYMember_E0F2867121121025D50DD6253303324B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_7BB229E8315B32F01391D6253303898A" xlink:to="loc_biib_PLEGRIDYMember_E0F2867121121025D50DD6253303324B" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_TysabriMember" xlink:label="loc_biib_TysabriMember_FAD340642C25E4B77D63D6253303F27C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_7BB229E8315B32F01391D6253303898A" xlink:to="loc_biib_TysabriMember_FAD340642C25E4B77D63D6253303F27C" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_FAMPYRAMember" xlink:label="loc_biib_FAMPYRAMember_84620BD3AE6BF6F8F39BD625330314E7" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_7BB229E8315B32F01391D6253303898A" xlink:to="loc_biib_FAMPYRAMember_84620BD3AE6BF6F8F39BD625330314E7" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ZINBRYTAMember" xlink:label="loc_biib_ZINBRYTAMember_6E9313E6CFD79283560AD62533034FBB" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_7BB229E8315B32F01391D6253303898A" xlink:to="loc_biib_ZINBRYTAMember_6E9313E6CFD79283560AD62533034FBB" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ELOCTATEMember" xlink:label="loc_biib_ELOCTATEMember_932ED9441F65ADA90FE3D62533039E8D" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_7BB229E8315B32F01391D6253303898A" xlink:to="loc_biib_ELOCTATEMember_932ED9441F65ADA90FE3D62533039E8D" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ALPROLIXProductMember" xlink:label="loc_biib_ALPROLIXProductMember_48E09595890D1E5A5905D6253303EBA3" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_7BB229E8315B32F01391D6253303898A" xlink:to="loc_biib_ALPROLIXProductMember_48E09595890D1E5A5905D6253303EBA3" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_FUMADERMMember" xlink:label="loc_biib_FUMADERMMember_B1930264832021B16508D62533034645" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_7BB229E8315B32F01391D6253303898A" xlink:to="loc_biib_FUMADERMMember_B1930264832021B16508D62533034645" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_SPINRAZAMember" xlink:label="loc_biib_SPINRAZAMember_12C191FF1826722F7B57D6253303E598" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_7BB229E8315B32F01391D6253303898A" xlink:to="loc_biib_SPINRAZAMember_12C191FF1826722F7B57D6253303E598" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_BENEPALIMember" xlink:label="loc_biib_BENEPALIMember_DC6CDDF5CEF0600A66DCD6253303965D" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_7BB229E8315B32F01391D6253303898A" xlink:to="loc_biib_BENEPALIMember_DC6CDDF5CEF0600A66DCD6253303965D" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_FLIXABIMember" xlink:label="loc_biib_FLIXABIMember_0A7D1DDE9C9E279DEB88D641DB278DF0" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_7BB229E8315B32F01391D6253303898A" xlink:to="loc_biib_FLIXABIMember_0A7D1DDE9C9E279DEB88D641DB278DF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_C5A46EC3601644616EAED62533030D78" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_E72281390FDBEAEF0D33D6253303FCEB" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_C5A46EC3601644616EAED62533030D78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_C833D7DB5645675FE15BD6253303188C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_C5A46EC3601644616EAED62533030D78" xlink:to="loc_us-gaap_SegmentDomain_C833D7DB5645675FE15BD6253303188C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd#country_US" xlink:label="loc_country_US_9737309753D323FCA3B4D625330302F9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_C833D7DB5645675FE15BD6253303188C" xlink:to="loc_country_US_9737309753D323FCA3B4D625330302F9" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_RestOfWorldMember" xlink:label="loc_biib_RestOfWorldMember_79B1664F14E3F27452DCD62533030BA1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_C833D7DB5645675FE15BD6253303188C" xlink:to="loc_biib_RestOfWorldMember_79B1664F14E3F27452DCD62533030BA1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_F4B182F3456C3DA39C30D6253303538E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_E72281390FDBEAEF0D33D6253303FCEB" xlink:to="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_F4B182F3456C3DA39C30D6253303538E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNetAbstract" xlink:label="loc_us-gaap_SalesRevenueGoodsNetAbstract_2E0EFA6AC25B666C97F1D6253303E494" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_F4B182F3456C3DA39C30D6253303538E" xlink:to="loc_us-gaap_SalesRevenueGoodsNetAbstract_2E0EFA6AC25B666C97F1D6253303E494" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_5AC660AC0AEED2B78CAED6253303FA8A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SalesRevenueGoodsNetAbstract_2E0EFA6AC25B666C97F1D6253303E494" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_5AC660AC0AEED2B78CAED6253303FA8A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SegmentInformationDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_96F9798F62D6F8AA57C1FCCBDAD76FF2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_92D3F3966936A27A585CFCCBDAD7C583" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_96F9798F62D6F8AA57C1FCCBDAD76FF2" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_92D3F3966936A27A585CFCCBDAD7C583" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_CB2D09A6E40FCB4CFDC4FCCBDAD7EA6F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_92D3F3966936A27A585CFCCBDAD7C583" xlink:to="loc_us-gaap_StatementGeographicalAxis_CB2D09A6E40FCB4CFDC4FCCBDAD7EA6F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_64AF6D8AD308C7498449FCCBDAD7F7CC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementGeographicalAxis_CB2D09A6E40FCB4CFDC4FCCBDAD7EA6F" xlink:to="loc_us-gaap_SegmentGeographicalDomain_64AF6D8AD308C7498449FCCBDAD7F7CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd#country_US" xlink:label="loc_country_US_2070A85DA878947C21D3FCCBDAD757DB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_64AF6D8AD308C7498449FCCBDAD7F7CC" xlink:to="loc_country_US_2070A85DA878947C21D3FCCBDAD757DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EuropeMember" xlink:label="loc_us-gaap_EuropeMember_287DD1D37D55C3F9BB16FCCBDAD7926C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_64AF6D8AD308C7498449FCCBDAD7F7CC" xlink:to="loc_us-gaap_EuropeMember_287DD1D37D55C3F9BB16FCCBDAD7926C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd#country_DE" xlink:label="loc_country_DE_33ED03D7F031EF18B13BFCCBDAD84518" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_64AF6D8AD308C7498449FCCBDAD7F7CC" xlink:to="loc_country_DE_33ED03D7F031EF18B13BFCCBDAD84518" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AsiaMember" xlink:label="loc_us-gaap_AsiaMember_3D02FA0D16C77E390DB6FCCBDAD8B98E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_64AF6D8AD308C7498449FCCBDAD7F7CC" xlink:to="loc_us-gaap_AsiaMember_3D02FA0D16C77E390DB6FCCBDAD8B98E" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember" xlink:label="loc_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember_2B71F906AE0E6DC5B173FCCBDAD8E0C7" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_64AF6D8AD308C7498449FCCBDAD7F7CC" xlink:to="loc_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember_2B71F906AE0E6DC5B173FCCBDAD8E0C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_0D4046DFB38E0125FC38FCCBDAD8870C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_92D3F3966936A27A585CFCCBDAD7C583" xlink:to="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_0D4046DFB38E0125FC38FCCBDAD8870C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentsGeographicalAreasAbstract" xlink:label="loc_us-gaap_SegmentsGeographicalAreasAbstract_85F38EC10D32DCF3A0E4FCCBDAD8125A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_0D4046DFB38E0125FC38FCCBDAD8870C" xlink:to="loc_us-gaap_SegmentsGeographicalAreasAbstract_85F38EC10D32DCF3A0E4FCCBDAD8125A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_9F56E840AF7CF4A87CBAFCCBDAD8F7DE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentsGeographicalAreasAbstract_85F38EC10D32DCF3A0E4FCCBDAD8125A" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_9F56E840AF7CF4A87CBAFCCBDAD8F7DE" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_RevenuesfromantiCD20therapeuticprograms" xlink:label="loc_biib_RevenuesfromantiCD20therapeuticprograms_35A3EFD597512058F4C1FCE261DA5FA4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentsGeographicalAreasAbstract_85F38EC10D32DCF3A0E4FCCBDAD8125A" xlink:to="loc_biib_RevenuesfromantiCD20therapeuticprograms_35A3EFD597512058F4C1FCE261DA5FA4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherSalesRevenueNet" xlink:label="loc_us-gaap_OtherSalesRevenueNet_E5031EDA988972BCD522FCCBDAD8EF75" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentsGeographicalAreasAbstract_85F38EC10D32DCF3A0E4FCCBDAD8125A" xlink:to="loc_us-gaap_OtherSalesRevenueNet_E5031EDA988972BCD522FCCBDAD8EF75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NoncurrentAssets" xlink:label="loc_us-gaap_NoncurrentAssets_8E874CC2DD3FA532A570FCCBDAD83975" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentsGeographicalAreasAbstract_85F38EC10D32DCF3A0E4FCCBDAD8125A" xlink:to="loc_us-gaap_NoncurrentAssets_8E874CC2DD3FA532A570FCCBDAD83975" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SegmentInformationDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_452352E9EF70C33B4454FCCBDAC998D4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_9BD4DBCFCBD52B1929B2FCCBDAC9889D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_452352E9EF70C33B4454FCCBDAC998D4" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_9BD4DBCFCBD52B1929B2FCCBDAC9889D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_A2E8E8C54EBF49DE76B1FCCBDAC98AF2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_9BD4DBCFCBD52B1929B2FCCBDAC9889D" xlink:to="loc_us-gaap_StatementGeographicalAxis_A2E8E8C54EBF49DE76B1FCCBDAC98AF2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_6F87343CA8C5F1A54E66FCCBDAC913AE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementGeographicalAxis_A2E8E8C54EBF49DE76B1FCCBDAC98AF2" xlink:to="loc_us-gaap_SegmentGeographicalDomain_6F87343CA8C5F1A54E66FCCBDAC913AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd#country_DK" xlink:label="loc_country_DK_37D00F9C0B052EE7CBBEFCCBDAC96594" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_6F87343CA8C5F1A54E66FCCBDAC913AE" xlink:to="loc_country_DK_37D00F9C0B052EE7CBBEFCCBDAC96594" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_SolothurnMember" xlink:label="loc_biib_SolothurnMember_4E07644CE08344D83290FCCBDAC9ACE9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_6F87343CA8C5F1A54E66FCCBDAC913AE" xlink:to="loc_biib_SolothurnMember_4E07644CE08344D83290FCCBDAC9ACE9" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_MajorDistributorAxis" xlink:label="loc_biib_MajorDistributorAxis_4CE345720BAD7FAF95F2FCCBDAC9C69B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_9BD4DBCFCBD52B1929B2FCCBDAC9889D" xlink:to="loc_biib_MajorDistributorAxis_4CE345720BAD7FAF95F2FCCBDAC9C69B" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_MajorDistributorDomain" xlink:label="loc_biib_MajorDistributorDomain_732AB2608F8CC55B7B07FCCBDAC98BA5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MajorDistributorAxis_4CE345720BAD7FAF95F2FCCBDAC9C69B" xlink:to="loc_biib_MajorDistributorDomain_732AB2608F8CC55B7B07FCCBDAC98BA5" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_DistributorOneMember" xlink:label="loc_biib_DistributorOneMember_F178FF845BE66F5A057FFCCBDAC9478C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MajorDistributorDomain_732AB2608F8CC55B7B07FCCBDAC98BA5" xlink:to="loc_biib_DistributorOneMember_F178FF845BE66F5A057FFCCBDAC9478C" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_DistributorTwoMember" xlink:label="loc_biib_DistributorTwoMember_884E0803F9274A505BF0FCCBDAC9172B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MajorDistributorDomain_732AB2608F8CC55B7B07FCCBDAC98BA5" xlink:to="loc_biib_DistributorTwoMember_884E0803F9274A505BF0FCCBDAC9172B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_C00646353A7BBA92F040FCCBDAC9FDAE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_9BD4DBCFCBD52B1929B2FCCBDAC9889D" xlink:to="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_C00646353A7BBA92F040FCCBDAC9FDAE" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms" xlink:label="loc_biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms_1BBECB4198EE9ACB6956FCE69BFAFF51" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_C00646353A7BBA92F040FCCBDAC9FDAE" xlink:to="loc_biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms_1BBECB4198EE9ACB6956FCE69BFAFF51" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:label="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_258A6514AF60758796C1FCCBDAC97752" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_C00646353A7BBA92F040FCCBDAC9FDAE" xlink:to="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_258A6514AF60758796C1FCCBDAC97752" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NoncurrentAssets" xlink:label="loc_us-gaap_NoncurrentAssets_546F5ACCDE8D8EFF0914FCCBDACA4BDC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_C00646353A7BBA92F040FCCBDAC9FDAE" xlink:to="loc_us-gaap_NoncurrentAssets_546F5ACCDE8D8EFF0914FCCBDACA4BDC" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_SegmentInformationTextualAbstract" xlink:label="loc_biib_SegmentInformationTextualAbstract_1FD70DFF1534541CEB1FFCCBDACA2707" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_452352E9EF70C33B4454FCCBDAC998D4" xlink:to="loc_biib_SegmentInformationTextualAbstract_1FD70DFF1534541CEB1FFCCBDACA2707" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaap_NumberOfReportableSegments_5E9147CB31329628DAE3FCCBDACA2721" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SegmentInformationTextualAbstract_1FD70DFF1534541CEB1FFCCBDACA2707" xlink:to="loc_us-gaap_NumberOfReportableSegments_5E9147CB31329628DAE3FCCBDACA2721" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SegmentInformationTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_059891D465F0E2B1AA037412858024B9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_2824576FE30FF765D7E274128580453B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_059891D465F0E2B1AA037412858024B9" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_2824576FE30FF765D7E274128580453B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:label="loc_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_79934338A91A46E766C17412858125F5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_059891D465F0E2B1AA037412858024B9" xlink:to="loc_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_79934338A91A46E766C17412858125F5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPayments" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_FE42284964746602E2E3741287AA8764" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_B30DC78CB621AD1EBB5B741287AA35EC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_FE42284964746602E2E3741287AA8764" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_B30DC78CB621AD1EBB5B741287AA35EC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8D61CFBA4363948A1C38FB6C3AF4AF62" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_F51E8C4065F378FB4403FB6C3AF48C3B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8D61CFBA4363948A1C38FB6C3AF4AF62" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_F51E8C4065F378FB4403FB6C3AF48C3B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_A61B9E7665CC3749D8AFFB6C3AF4BCAC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_F51E8C4065F378FB4403FB6C3AF48C3B" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_A61B9E7665CC3749D8AFFB6C3AF4BCAC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8B753C9D7E38F6C098B9FB6C3AF46075" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_A61B9E7665CC3749D8AFFB6C3AF4BCAC" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8B753C9D7E38F6C098B9FB6C3AF46075" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_C1BBB5E5A84FB1E4EE65FB6C3AF4DB6C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8B753C9D7E38F6C098B9FB6C3AF46075" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_C1BBB5E5A84FB1E4EE65FB6C3AF4DB6C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_AB5A9E1AF72E880E5071FB6C3AF4E91D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8B753C9D7E38F6C098B9FB6C3AF46075" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_AB5A9E1AF72E880E5071FB6C3AF4E91D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringChargesMember" xlink:label="loc_us-gaap_RestructuringChargesMember_861D34FD216488DE6A06FB6C3AF40ACC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8B753C9D7E38F6C098B9FB6C3AF46075" xlink:to="loc_us-gaap_RestructuringChargesMember_861D34FD216488DE6A06FB6C3AF40ACC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaap_ParentMember_853662D2FFA4CE3A0451FB6C3AF4A819" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8B753C9D7E38F6C098B9FB6C3AF46075" xlink:to="loc_us-gaap_ParentMember_853662D2FFA4CE3A0451FB6C3AF4A819" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3673719AA25E849D2CEBFB6C3AF449AB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_F51E8C4065F378FB4403FB6C3AF48C3B" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3673719AA25E849D2CEBFB6C3AF449AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_C7EF5191E5F2FE25056AFB6C3AF44AEA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3673719AA25E849D2CEBFB6C3AF449AB" xlink:to="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_C7EF5191E5F2FE25056AFB6C3AF44AEA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_BA6D979ACACEB4E62C82FB6C3AF552C1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_C7EF5191E5F2FE25056AFB6C3AF44AEA" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_BA6D979ACACEB4E62C82FB6C3AF552C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_28847CE0E13B593D63B2FB6C3AF5A1DE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_C7EF5191E5F2FE25056AFB6C3AF44AEA" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_28847CE0E13B593D63B2FB6C3AF5A1DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_16D86BEA17B7C9154F18FB6C3AF56008" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_C7EF5191E5F2FE25056AFB6C3AF44AEA" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_16D86BEA17B7C9154F18FB6C3AF56008" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_23B7ED9669D453AB7CC8FB6C3AF53405" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_C7EF5191E5F2FE25056AFB6C3AF44AEA" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_23B7ED9669D453AB7CC8FB6C3AF53405" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_F3CDEEA12A6D67B5FF1CFB6C3AF5871F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_C7EF5191E5F2FE25056AFB6C3AF44AEA" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_F3CDEEA12A6D67B5FF1CFB6C3AF5871F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D80C185DC8059E40D880FCCBDBF8D218" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_ED4F42753DB211D679D2FCCBDBF932F0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D80C185DC8059E40D880FCCBDBF8D218" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_ED4F42753DB211D679D2FCCBDBF932F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_526C5F4D461F6E8F64E7FCCBDBF9750A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_ED4F42753DB211D679D2FCCBDBF932F0" xlink:to="loc_us-gaap_PlanNameAxis_526C5F4D461F6E8F64E7FCCBDBF9750A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_BBA12AB6B3E3D2008B1EFCCBDBF90E80" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_526C5F4D461F6E8F64E7FCCBDBF9750A" xlink:to="loc_us-gaap_PlanNameDomain_BBA12AB6B3E3D2008B1EFCCBDBF90E80" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_5BE8DDDE9284359E782BFCCBDBF97D56" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_BBA12AB6B3E3D2008B1EFCCBDBF90E80" xlink:to="loc_biib_MarketStockUnitsMember_5BE8DDDE9284359E782BFCCBDBF97D56" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_2CF622EA7C88A4E9CDC2FCCBDBF9178D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_BBA12AB6B3E3D2008B1EFCCBDBF90E80" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_2CF622EA7C88A4E9CDC2FCCBDBF9178D" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_CashSettledPerformanceSharesMember" xlink:label="loc_biib_CashSettledPerformanceSharesMember_07DB1ED188101A2572AEFCCBDBF9FE15" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_BBA12AB6B3E3D2008B1EFCCBDBF90E80" xlink:to="loc_biib_CashSettledPerformanceSharesMember_07DB1ED188101A2572AEFCCBDBF9FE15" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_PerformanceUnitsMember" xlink:label="loc_biib_PerformanceUnitsMember_0B35579AF2D99A91D3F9FCCBDBF9B11A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_BBA12AB6B3E3D2008B1EFCCBDBF90E80" xlink:to="loc_biib_PerformanceUnitsMember_0B35579AF2D99A91D3F9FCCBDBF9B11A" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_EmployeeStockPurchasePlanMember" xlink:label="loc_biib_EmployeeStockPurchasePlanMember_420AB1F2642296763C40FCCBDBF95CEF" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_BBA12AB6B3E3D2008B1EFCCBDBF90E80" xlink:to="loc_biib_EmployeeStockPurchasePlanMember_420AB1F2642296763C40FCCBDBF95CEF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5327E5FA35DE914A0418FCCBDBF9AB7A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_ED4F42753DB211D679D2FCCBDBF932F0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5327E5FA35DE914A0418FCCBDBF9AB7A" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:label="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_4C5DB6279FA0D67FA030FCCBDBF9BB4B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5327E5FA35DE914A0418FCCBDBF9AB7A" xlink:to="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_4C5DB6279FA0D67FA030FCCBDBF9BB4B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_FD0AD41CD2C18315A39AFCCBDBF9E79E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_4C5DB6279FA0D67FA030FCCBDBF9BB4B" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_FD0AD41CD2C18315A39AFCCBDBF9E79E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_B59F0208579375A23CE4FCCBDBF97B57" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_4C5DB6279FA0D67FA030FCCBDBF9BB4B" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_B59F0208579375A23CE4FCCBDBF97B57" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_CE72565E6683CE0D2336FCCBDBF9F6C0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_4C5DB6279FA0D67FA030FCCBDBF9BB4B" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_CE72565E6683CE0D2336FCCBDBF9F6C0" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_68A457065EA3B81A3828FCCBDBFAAC0B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_4C5DB6279FA0D67FA030FCCBDBF9BB4B" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_68A457065EA3B81A3828FCCBDBFAAC0B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_65F9BB373E78DC3593E1741285501F34" xlink:type="locator" />
    <link:loc xlink:href="biib-20161231.xsd#biib_StockOptionActivityAbstract" xlink:label="loc_biib_StockOptionActivityAbstract_63FFD68403502708E7D174128550C563" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_65F9BB373E78DC3593E1741285501F34" xlink:to="loc_biib_StockOptionActivityAbstract_63FFD68403502708E7D174128550C563" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_D04CBCACD8673358DA44741285501914" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_StockOptionActivityAbstract_63FFD68403502708E7D174128550C563" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_D04CBCACD8673358DA44741285501914" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_D457F3D198DA02C474E7741285504A00" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_StockOptionActivityAbstract_63FFD68403502708E7D174128550C563" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_D457F3D198DA02C474E7741285504A00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_4411824CB83C23E1D088741285502061" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_StockOptionActivityAbstract_63FFD68403502708E7D174128550C563" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_4411824CB83C23E1D088741285502061" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_D6242A16E59967BB739074128550AD7C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_StockOptionActivityAbstract_63FFD68403502708E7D174128550C563" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_D6242A16E59967BB739074128550AD7C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6898291F4B1AB630FA7274128550EFE9" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_StockOptionActivityAbstract_63FFD68403502708E7D174128550C563" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6898291F4B1AB630FA7274128550EFE9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_0B59B0D59B87C40E9E8F74128550B90B" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_StockOptionActivityAbstract_63FFD68403502708E7D174128550C563" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_0B59B0D59B87C40E9E8F74128550B90B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2409E4B93EFCF98A6522741285501AC6" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_StockOptionActivityAbstract_63FFD68403502708E7D174128550C563" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2409E4B93EFCF98A6522741285501AC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_8F6586DA4A1FE2A61ABC741285511758" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_StockOptionActivityAbstract_63FFD68403502708E7D174128550C563" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_8F6586DA4A1FE2A61ABC741285511758" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_EBCBC870FFD6D440968074128551B58E" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_StockOptionActivityAbstract_63FFD68403502708E7D174128550C563" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_EBCBC870FFD6D440968074128551B58E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_38B7568935F828AC060074128551D302" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_StockOptionActivityAbstract_63FFD68403502708E7D174128550C563" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_38B7568935F828AC060074128551D302" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails3" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_54A085C6BCAEDE1EDE607412885E9AA6" xlink:type="locator" />
    <link:loc xlink:href="biib-20161231.xsd#biib_TaxBenefitAndCashReceivedFromStockOptionAbstract" xlink:label="loc_biib_TaxBenefitAndCashReceivedFromStockOptionAbstract_FE69185DC09BA2C8BF9B7412885EE90F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_54A085C6BCAEDE1EDE607412885E9AA6" xlink:to="loc_biib_TaxBenefitAndCashReceivedFromStockOptionAbstract_FE69185DC09BA2C8BF9B7412885EE90F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions_29A59EF6EAEDDF20F4FF7412885E26C2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_TaxBenefitAndCashReceivedFromStockOptionAbstract_FE69185DC09BA2C8BF9B7412885EE90F" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions_29A59EF6EAEDDF20F4FF7412885E26C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions_C54135149F619543D6D07412885EB409" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_TaxBenefitAndCashReceivedFromStockOptionAbstract_FE69185DC09BA2C8BF9B7412885EE90F" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions_C54135149F619543D6D07412885EB409" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails4" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3130897F6B64A77B8D7A7412882CB522" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_18801415804C0709608D7412882CE0F9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3130897F6B64A77B8D7A7412882CB522" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_18801415804C0709608D7412882CE0F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_68BDA0B0AED75AC406657412882C99C1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_18801415804C0709608D7412882CE0F9" xlink:to="loc_us-gaap_AwardTypeAxis_68BDA0B0AED75AC406657412882C99C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6B5FEE71662A7AFABDC27412882C8CE7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_68BDA0B0AED75AC406657412882C99C1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6B5FEE71662A7AFABDC27412882C8CE7" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_9FE60F77DB962B5CD1D27412882C770B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6B5FEE71662A7AFABDC27412882C8CE7" xlink:to="loc_biib_MarketStockUnitsMember_9FE60F77DB962B5CD1D27412882C770B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_10FA2251D793D993B5D67412882D1DED" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_18801415804C0709608D7412882CE0F9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_10FA2251D793D993B5D67412882D1DED" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_MarketStockUnitsActivityAbstract" xlink:label="loc_biib_MarketStockUnitsActivityAbstract_EB0B9D4F3BA062C2AD067412882DAEE2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_10FA2251D793D993B5D67412882D1DED" xlink:to="loc_biib_MarketStockUnitsActivityAbstract_EB0B9D4F3BA062C2AD067412882DAEE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4BB21F8CE6F0C63187D37412882D5626" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_EB0B9D4F3BA062C2AD067412882DAEE2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4BB21F8CE6F0C63187D37412882D5626" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6063B783674D6381F89C7412882D400B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_EB0B9D4F3BA062C2AD067412882DAEE2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6063B783674D6381F89C7412882D400B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2062511BC52E337205867412882D7309" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_EB0B9D4F3BA062C2AD067412882DAEE2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2062511BC52E337205867412882D7309" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_D3B73801144B40130E437412882DCD0A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_EB0B9D4F3BA062C2AD067412882DAEE2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_D3B73801144B40130E437412882DCD0A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_54EEAF6623742D53F7497412882D7C9F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_EB0B9D4F3BA062C2AD067412882DAEE2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_54EEAF6623742D53F7497412882D7C9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_F5A2A4A6D44F141A03077412882D970A" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_EB0B9D4F3BA062C2AD067412882DAEE2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_F5A2A4A6D44F141A03077412882D970A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_C2050BC33A50C40072537412882DDB10" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_EB0B9D4F3BA062C2AD067412882DAEE2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_C2050BC33A50C40072537412882DDB10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_6492CF2A6FEB1AF9D75F7412882D852F" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_EB0B9D4F3BA062C2AD067412882DAEE2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_6492CF2A6FEB1AF9D75F7412882D852F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_C8BB8547164C1CFABF057412882D8571" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_EB0B9D4F3BA062C2AD067412882DAEE2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_C8BB8547164C1CFABF057412882D8571" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_736E02A77E9315FF92107412882E92E2" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_EB0B9D4F3BA062C2AD067412882DAEE2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_736E02A77E9315FF92107412882E92E2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails5" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1D1A98F5722FC97CAE82FB6C3ADA73C6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_641BF024B801A2A15CF6FB6C3ADA4EBF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1D1A98F5722FC97CAE82FB6C3ADA73C6" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_641BF024B801A2A15CF6FB6C3ADA4EBF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_06DC7333E17FE1485B53FB6C3ADAD803" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_641BF024B801A2A15CF6FB6C3ADA4EBF" xlink:to="loc_us-gaap_AwardTypeAxis_06DC7333E17FE1485B53FB6C3ADAD803" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_913CF6D82CA7E2A4CBD7FB6C3ADAF552" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_06DC7333E17FE1485B53FB6C3ADAD803" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_913CF6D82CA7E2A4CBD7FB6C3ADAF552" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_9ADFE3A9AC8E8D5132D8FB6C3ADAF787" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_913CF6D82CA7E2A4CBD7FB6C3ADAF552" xlink:to="loc_biib_MarketStockUnitsMember_9ADFE3A9AC8E8D5132D8FB6C3ADAF787" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_5E20694293916A4CA961FB6C3ADA361D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_641BF024B801A2A15CF6FB6C3ADA4EBF" xlink:to="loc_us-gaap_RangeAxis_5E20694293916A4CA961FB6C3ADA361D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_102BD134AD4882E977B9FB6C3ADA8F1F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_5E20694293916A4CA961FB6C3ADA361D" xlink:to="loc_us-gaap_RangeMember_102BD134AD4882E977B9FB6C3ADA8F1F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_89665EFA87A0227E56D0FB6C3ADA5EBB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_102BD134AD4882E977B9FB6C3ADA8F1F" xlink:to="loc_us-gaap_MinimumMember_89665EFA87A0227E56D0FB6C3ADA5EBB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_57F5F80375041EE3600FFB6C3ADA2277" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_102BD134AD4882E977B9FB6C3ADA8F1F" xlink:to="loc_us-gaap_MaximumMember_57F5F80375041EE3600FFB6C3ADA2277" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8EF275847D972757B64AFB6C3ADA4A2D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_641BF024B801A2A15CF6FB6C3ADA4EBF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8EF275847D972757B64AFB6C3ADA4A2D" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ValuationOfGrantedStockUnitsAbstract" xlink:label="loc_biib_ValuationOfGrantedStockUnitsAbstract_FB2EC3965B7896849E93FB6C3ADB8E00" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8EF275847D972757B64AFB6C3ADA4A2D" xlink:to="loc_biib_ValuationOfGrantedStockUnitsAbstract_FB2EC3965B7896849E93FB6C3ADB8E00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_61CB6AD25C6385BDF790FB6C3ADBAABC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ValuationOfGrantedStockUnitsAbstract_FB2EC3965B7896849E93FB6C3ADB8E00" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_61CB6AD25C6385BDF790FB6C3ADBAABC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_5CBB127508B0202ECF86FB6C3ADBACE4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ValuationOfGrantedStockUnitsAbstract_FB2EC3965B7896849E93FB6C3ADB8E00" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_5CBB127508B0202ECF86FB6C3ADBACE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_B296757E39549928EB1BFB6C3ADBD156" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ValuationOfGrantedStockUnitsAbstract_FB2EC3965B7896849E93FB6C3ADB8E00" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_B296757E39549928EB1BFB6C3ADBD156" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_0C126A384E819793B300FB6C3ADB8383" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ValuationOfGrantedStockUnitsAbstract_FB2EC3965B7896849E93FB6C3ADB8E00" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_0C126A384E819793B300FB6C3ADB8383" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_AverageStockPriceOnGrantDateInDollarsMinimum" xlink:label="loc_biib_AverageStockPriceOnGrantDateInDollarsMinimum_31DCF42228DC7E3F4957FB6C3ADBB518" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ValuationOfGrantedStockUnitsAbstract_FB2EC3965B7896849E93FB6C3ADB8E00" xlink:to="loc_biib_AverageStockPriceOnGrantDateInDollarsMinimum_31DCF42228DC7E3F4957FB6C3ADBB518" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_AverageStockPriceOnGrantDateInDollarsMaximum" xlink:label="loc_biib_AverageStockPriceOnGrantDateInDollarsMaximum_FD5C768ECF8625BFB681FB6C3ADBCEA9" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ValuationOfGrantedStockUnitsAbstract_FB2EC3965B7896849E93FB6C3ADB8E00" xlink:to="loc_biib_AverageStockPriceOnGrantDateInDollarsMaximum_FD5C768ECF8625BFB681FB6C3ADBCEA9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_C3CF65BAB3363B652D06FB6C3ADB6678" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ValuationOfGrantedStockUnitsAbstract_FB2EC3965B7896849E93FB6C3ADB8E00" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_C3CF65BAB3363B652D06FB6C3ADB6678" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails6" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_061CFA32784BE16EE629741286F45102" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_52C766BF8869984412AD741286F424FF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_061CFA32784BE16EE629741286F45102" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_52C766BF8869984412AD741286F424FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_30CA20BB01B9775C0187741286F42BB2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_52C766BF8869984412AD741286F424FF" xlink:to="loc_us-gaap_AwardTypeAxis_30CA20BB01B9775C0187741286F42BB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3E397BC6F4D662901608741286F4E683" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_30CA20BB01B9775C0187741286F42BB2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3E397BC6F4D662901608741286F4E683" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_CashSettledPerformanceSharesMember" xlink:label="loc_biib_CashSettledPerformanceSharesMember_528682C21A819A76A6AE741286F5BDCE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3E397BC6F4D662901608741286F4E683" xlink:to="loc_biib_CashSettledPerformanceSharesMember_528682C21A819A76A6AE741286F5BDCE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B037F8FE4018249D6562741286F5BF5A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_52C766BF8869984412AD741286F424FF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B037F8FE4018249D6562741286F5BF5A" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_CashSettledPerformanceSharesAbstract" xlink:label="loc_biib_CashSettledPerformanceSharesAbstract_C8B0513E210CDCD3A606741286F5A57C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B037F8FE4018249D6562741286F5BF5A" xlink:to="loc_biib_CashSettledPerformanceSharesAbstract_C8B0513E210CDCD3A606741286F5A57C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_EAF171D1AD935D09BF1A741286F54506" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CashSettledPerformanceSharesAbstract_C8B0513E210CDCD3A606741286F5A57C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_EAF171D1AD935D09BF1A741286F54506" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_B8B02B2E5353C727629A741286F58965" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CashSettledPerformanceSharesAbstract_C8B0513E210CDCD3A606741286F5A57C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_B8B02B2E5353C727629A741286F58965" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_FDD2AF720A28E86A873F741286F539F9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CashSettledPerformanceSharesAbstract_C8B0513E210CDCD3A606741286F5A57C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_FDD2AF720A28E86A873F741286F539F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_EF47A5BE56FC6379F104741286F52E5A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CashSettledPerformanceSharesAbstract_C8B0513E210CDCD3A606741286F5A57C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_EF47A5BE56FC6379F104741286F52E5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_063A4CBC3BD4B5A2378B741286F521B9" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CashSettledPerformanceSharesAbstract_C8B0513E210CDCD3A606741286F5A57C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_063A4CBC3BD4B5A2378B741286F521B9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails8" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D7DC95964E84D217FB107412873E214F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5046C72D39C35117E7357412873E7E14" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D7DC95964E84D217FB107412873E214F" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5046C72D39C35117E7357412873E7E14" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_667671D70CAD4E446BE07412873EFB28" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5046C72D39C35117E7357412873E7E14" xlink:to="loc_us-gaap_AwardTypeAxis_667671D70CAD4E446BE07412873EFB28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_33E397BBFF5436C22D227412873F7416" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_667671D70CAD4E446BE07412873EFB28" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_33E397BBFF5436C22D227412873F7416" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_E67F7C3572C4F46D1A7B7412873F2D8A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_33E397BBFF5436C22D227412873F7416" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_E67F7C3572C4F46D1A7B7412873F2D8A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_251C89B8F19660BEF5897412873FC80C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5046C72D39C35117E7357412873E7E14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_251C89B8F19660BEF5897412873FC80C" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_RestrictedStockUnitsActivityAbstract" xlink:label="loc_biib_RestrictedStockUnitsActivityAbstract_F27C758B5D2570FBFF197412873F3509" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_251C89B8F19660BEF5897412873FC80C" xlink:to="loc_biib_RestrictedStockUnitsActivityAbstract_F27C758B5D2570FBFF197412873F3509" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8466604ABA6CB2DF63057412873FA437" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_F27C758B5D2570FBFF197412873F3509" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8466604ABA6CB2DF63057412873FA437" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6FE2C5F528C471B40D1E7412873F6923" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_F27C758B5D2570FBFF197412873F3509" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6FE2C5F528C471B40D1E7412873F6923" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_8C0B20A50D4F82FE9EC074128740BAE5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_F27C758B5D2570FBFF197412873F3509" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_8C0B20A50D4F82FE9EC074128740BAE5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_36BDB20C404FB45E3733741287403541" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_F27C758B5D2570FBFF197412873F3509" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_36BDB20C404FB45E3733741287403541" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_DC4690F6FC8AFF60799A741287404FD7" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_F27C758B5D2570FBFF197412873F3509" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_DC4690F6FC8AFF60799A741287404FD7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_2CFD9C1EC8C55AB37E71741287406675" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_F27C758B5D2570FBFF197412873F3509" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_2CFD9C1EC8C55AB37E71741287406675" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_CDA41B0670AA14519C66741287403329" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_F27C758B5D2570FBFF197412873F3509" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_CDA41B0670AA14519C66741287403329" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_F679596BE59C9EC7B7BC741287409B0E" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_F27C758B5D2570FBFF197412873F3509" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_F679596BE59C9EC7B7BC741287409B0E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5F5DCBF71E10B8060790741287409237" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_F27C758B5D2570FBFF197412873F3509" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5F5DCBF71E10B8060790741287409237" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2D314A9CAD8E4488871574128740264B" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_F27C758B5D2570FBFF197412873F3509" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2D314A9CAD8E4488871574128740264B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails9" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_79B596B5316D0DC7E092886F7665B7BF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_D0E2863E35C7BD077131886F76652E6A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_79B596B5316D0DC7E092886F7665B7BF" xlink:to="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_D0E2863E35C7BD077131886F76652E6A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_936C2D906EC05AB3CD22886F76655298" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_D0E2863E35C7BD077131886F76652E6A" xlink:to="loc_us-gaap_PlanNameAxis_936C2D906EC05AB3CD22886F76655298" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_24B094D3E1C41F11157C886F76658D07" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_936C2D906EC05AB3CD22886F76655298" xlink:to="loc_us-gaap_PlanNameDomain_24B094D3E1C41F11157C886F76658D07" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_A2015ESPPMember" xlink:label="loc_biib_A2015ESPPMember_A211A5E6775E8F7601E4886F7665FD00" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_24B094D3E1C41F11157C886F76658D07" xlink:to="loc_biib_A2015ESPPMember_A211A5E6775E8F7601E4886F7665FD00" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_A1995ESPPMember" xlink:label="loc_biib_A1995ESPPMember_47480A7C219297A899A3886F76655F6D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_24B094D3E1C41F11157C886F76658D07" xlink:to="loc_biib_A1995ESPPMember_47480A7C219297A899A3886F76655F6D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_4AB6710A9DE9758EEDA8886F76652946" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_D0E2863E35C7BD077131886F76652E6A" xlink:to="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_4AB6710A9DE9758EEDA8886F76652946" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_AB912E158D0F3D191D51886F766B1BF9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_4AB6710A9DE9758EEDA8886F76652946" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_AB912E158D0F3D191D51886F766B1BF9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_A8A79E123689DBA46648886F766B403B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_4AB6710A9DE9758EEDA8886F76652946" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_A8A79E123689DBA46648886F766B403B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_700A232E783CD765B583FB6C3ABCADA9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_73C35A5BDE91FDEDB644FB6C3ABCDB25" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_700A232E783CD765B583FB6C3ABCADA9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_73C35A5BDE91FDEDB644FB6C3ABCDB25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_13FC1BD3227FED52E914FB6C3ABCE306" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_73C35A5BDE91FDEDB644FB6C3ABCDB25" xlink:to="loc_us-gaap_VestingAxis_13FC1BD3227FED52E914FB6C3ABCE306" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_320AE8B6E933D76CE29EFB6C3ABC7229" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_13FC1BD3227FED52E914FB6C3ABCE306" xlink:to="loc_us-gaap_VestingDomain_320AE8B6E933D76CE29EFB6C3ABC7229" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_DBD87A2CFE74972CED60FB6C3ABC17E3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_320AE8B6E933D76CE29EFB6C3ABC7229" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_DBD87A2CFE74972CED60FB6C3ABC17E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_6877531E0B7D765B3954FB6C3ABC65D1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_73C35A5BDE91FDEDB644FB6C3ABCDB25" xlink:to="loc_us-gaap_TitleOfIndividualAxis_6877531E0B7D765B3954FB6C3ABC65D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_172857DB172052692648FB6C3ABCF04B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_6877531E0B7D765B3954FB6C3ABC65D1" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_172857DB172052692648FB6C3ABCF04B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DirectorMember" xlink:label="loc_us-gaap_DirectorMember_54D488B4764A8620FB33FB6C3ABCB917" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_172857DB172052692648FB6C3ABCF04B" xlink:to="loc_us-gaap_DirectorMember_54D488B4764A8620FB33FB6C3ABCB917" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ShareBasedCompensationPlanAxis" xlink:label="loc_biib_ShareBasedCompensationPlanAxis_693C1B162F6843BB9BF4FB6C3ABC9981" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_73C35A5BDE91FDEDB644FB6C3ABCDB25" xlink:to="loc_biib_ShareBasedCompensationPlanAxis_693C1B162F6843BB9BF4FB6C3ABC9981" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ShareBasedCompensationPlanDomain" xlink:label="loc_biib_ShareBasedCompensationPlanDomain_0661520A83D58ADD79EDFB6C3ABDA209" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ShareBasedCompensationPlanAxis_693C1B162F6843BB9BF4FB6C3ABC9981" xlink:to="loc_biib_ShareBasedCompensationPlanDomain_0661520A83D58ADD79EDFB6C3ABDA209" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_DirectorsPlanMember" xlink:label="loc_biib_DirectorsPlanMember_9FA25E1B95FAB2302BBDFB6C3ABDBF74" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ShareBasedCompensationPlanDomain_0661520A83D58ADD79EDFB6C3ABDA209" xlink:to="loc_biib_DirectorsPlanMember_9FA25E1B95FAB2302BBDFB6C3ABDBF74" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_OmnibusPlansMember" xlink:label="loc_biib_OmnibusPlansMember_A7FF3A038E92A3ACB5A9FB6C3ABD2724" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ShareBasedCompensationPlanDomain_0661520A83D58ADD79EDFB6C3ABDA209" xlink:to="loc_biib_OmnibusPlansMember_A7FF3A038E92A3ACB5A9FB6C3ABD2724" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_AttainmentOfPerformanceCriteriain2013Member" xlink:label="loc_biib_AttainmentOfPerformanceCriteriain2013Member_EBF663E1E30148C70E48FB6C3ABDE2E3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ShareBasedCompensationPlanDomain_0661520A83D58ADD79EDFB6C3ABDA209" xlink:to="loc_biib_AttainmentOfPerformanceCriteriain2013Member_EBF663E1E30148C70E48FB6C3ABDE2E3" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_AttainmentOfPerformanceCriteriain2012Member" xlink:label="loc_biib_AttainmentOfPerformanceCriteriain2012Member_FE978AD1E2853A5EC6AEFB6C3ABD3F2C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ShareBasedCompensationPlanDomain_0661520A83D58ADD79EDFB6C3ABDA209" xlink:to="loc_biib_AttainmentOfPerformanceCriteriain2012Member_FE978AD1E2853A5EC6AEFB6C3ABD3F2C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_80B6F04B1E582FE480B2FB6C3ABEB31F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_73C35A5BDE91FDEDB644FB6C3ABCDB25" xlink:to="loc_us-gaap_AwardTypeAxis_80B6F04B1E582FE480B2FB6C3ABEB31F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_92811D27273A1D199FFAFB6C3ABEFAF1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_80B6F04B1E582FE480B2FB6C3ABEB31F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_92811D27273A1D199FFAFB6C3ABEFAF1" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_01DB996B3E072ECC5EC4FB6C3ABE5FF0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_92811D27273A1D199FFAFB6C3ABEFAF1" xlink:to="loc_biib_MarketStockUnitsMember_01DB996B3E072ECC5EC4FB6C3ABE5FF0" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_CashSettledPerformanceSharesMember" xlink:label="loc_biib_CashSettledPerformanceSharesMember_5788B0B8E876590EF60FFB6C3ABEDDF0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_92811D27273A1D199FFAFB6C3ABEFAF1" xlink:to="loc_biib_CashSettledPerformanceSharesMember_5788B0B8E876590EF60FFB6C3ABEDDF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_BE37102DA20E931910BFFB6C3ABE955C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_92811D27273A1D199FFAFB6C3ABEFAF1" xlink:to="loc_us-gaap_PerformanceSharesMember_BE37102DA20E931910BFFB6C3ABE955C" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_F1CD908540A804D55240FB6C3ABEDCAC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_92811D27273A1D199FFAFB6C3ABEFAF1" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_F1CD908540A804D55240FB6C3ABEDCAC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8642D524F792DB30754EFB6C3ABED5B7" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_73C35A5BDE91FDEDB644FB6C3ABCDB25" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8642D524F792DB30754EFB6C3ABED5B7" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_NumberOfSharesOfCommonStockForIssuance" xlink:label="loc_biib_NumberOfSharesOfCommonStockForIssuance_9385B2452E59EC90DA0EFB6C3ABE9279" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8642D524F792DB30754EFB6C3ABED5B7" xlink:to="loc_biib_NumberOfSharesOfCommonStockForIssuance_9385B2452E59EC90DA0EFB6C3ABE9279" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_RatioOfNumberOfSharesReservedUnderPlan" xlink:label="loc_biib_RatioOfNumberOfSharesReservedUnderPlan_EF9774C4143A5FC116B0FB6C3ABEBAD7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8642D524F792DB30754EFB6C3ABED5B7" xlink:to="loc_biib_RatioOfNumberOfSharesReservedUnderPlan_EF9774C4143A5FC116B0FB6C3ABEBAD7" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_NumberOfEqualAnnualIncrements" xlink:label="loc_biib_NumberOfEqualAnnualIncrements_FED7351DD2CF1D71E8BBFB6C3ABE0AA3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8642D524F792DB30754EFB6C3ABED5B7" xlink:to="loc_biib_NumberOfEqualAnnualIncrements_FED7351DD2CF1D71E8BBFB6C3ABE0AA3" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" xlink:label="loc_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_93F1735E18862861C0D6FB6C3ABE4733" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8642D524F792DB30754EFB6C3ABED5B7" xlink:to="loc_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_93F1735E18862861C0D6FB6C3ABE4733" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" xlink:label="loc_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_012D665CA003490616B2FB6C3ABFBE61" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8642D524F792DB30754EFB6C3ABED5B7" xlink:to="loc_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_012D665CA003490616B2FB6C3ABFBE61" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5A1F588ECE37683E6921FB6C3ABFCC36" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8642D524F792DB30754EFB6C3ABED5B7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5A1F588ECE37683E6921FB6C3ABFCC36" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_EmployeeServiceSharebasedCompensationSharesUsedtoSettleAwards" xlink:label="loc_biib_EmployeeServiceSharebasedCompensationSharesUsedtoSettleAwards_A867212FFCB6FD1AFC02FB6C3ABFB492" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8642D524F792DB30754EFB6C3ABED5B7" xlink:to="loc_biib_EmployeeServiceSharebasedCompensationSharesUsedtoSettleAwards_A867212FFCB6FD1AFC02FB6C3ABFB492" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_NumberOfDaysForCalculationOfAverageClosingStockPrice" xlink:label="loc_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice_29E946ED3485878ED861FB6C3ABFA5E2" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8642D524F792DB30754EFB6C3ABED5B7" xlink:to="loc_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice_29E946ED3485878ED861FB6C3ABFA5E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_C9A2D292A3C6BC70D612FB6C3ABF3CAF" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8642D524F792DB30754EFB6C3ABED5B7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_C9A2D292A3C6BC70D612FB6C3ABF3CAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_ED8CF59300C2A24F2B5FFB6C3ABF8960" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8642D524F792DB30754EFB6C3ABED5B7" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_ED8CF59300C2A24F2B5FFB6C3ABF8960" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_C965FABDE23F547930BDFB6C3ABFEC00" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8642D524F792DB30754EFB6C3ABED5B7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_C965FABDE23F547930BDFB6C3ABFEC00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_EF43722CBE330ACF957CFB6C3ABFABC5" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8642D524F792DB30754EFB6C3ABED5B7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_EF43722CBE330ACF957CFB6C3ABFABC5" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ShareBasedPaymentsTextualAbstract" xlink:label="loc_biib_ShareBasedPaymentsTextualAbstract_15496D6D0235C502459EFB6C3ABF2F73" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_700A232E783CD765B583FB6C3ABCADA9" xlink:to="loc_biib_ShareBasedPaymentsTextualAbstract_15496D6D0235C502459EFB6C3ABF2F73" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_WindfallTaxBenefitsFromVestingOfStockAwardsExercisesOfStockOptionsAndEsppParticipation" xlink:label="loc_biib_WindfallTaxBenefitsFromVestingOfStockAwardsExercisesOfStockOptionsAndEsppParticipation_B758B8655DEF6C2C54CAFB6C3ABF1845" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ShareBasedPaymentsTextualAbstract_15496D6D0235C502459EFB6C3ABF2F73" xlink:to="loc_biib_WindfallTaxBenefitsFromVestingOfStockAwardsExercisesOfStockOptionsAndEsppParticipation_B758B8655DEF6C2C54CAFB6C3ABF1845" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_0E973089056F76FC2010FB6C3ABFBB78" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ShareBasedPaymentsTextualAbstract_15496D6D0235C502459EFB6C3ABF2F73" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_0E973089056F76FC2010FB6C3ABFBB78" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards" xlink:label="loc_biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards_DB646783595BD4B6FA37FB6C3ABF4EDB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ShareBasedPaymentsTextualAbstract_15496D6D0235C502459EFB6C3ABF2F73" xlink:to="loc_biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards_DB646783595BD4B6FA37FB6C3ABF4EDB" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade" xlink:label="loc_biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade_92A015FC5A6BB10A3C19FB6C3AC089D2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ShareBasedPaymentsTextualAbstract_15496D6D0235C502459EFB6C3ABF2F73" xlink:to="loc_biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade_92A015FC5A6BB10A3C19FB6C3AC089D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_6AC4960BF1C9A3AE6609FB6C3AC0CCE1" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ShareBasedPaymentsTextualAbstract_15496D6D0235C502459EFB6C3ABF2F73" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_6AC4960BF1C9A3AE6609FB6C3AC0CCE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_C7DB8E7F29D6C642EF6CFB6C3AC08941" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ShareBasedPaymentsTextualAbstract_15496D6D0235C502459EFB6C3ABF2F73" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_C7DB8E7F29D6C642EF6CFB6C3AC08941" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_C29A18095AAABCB46C3EFB6C3AC05391" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ShareBasedPaymentsTextualAbstract_15496D6D0235C502459EFB6C3ABF2F73" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_C29A18095AAABCB46C3EFB6C3AC05391" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_281DC2A06026F7A88730FB6C3AC0EFC1" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ShareBasedPaymentsTextualAbstract_15496D6D0235C502459EFB6C3ABF2F73" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_281DC2A06026F7A88730FB6C3AC0EFC1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedPaymentsDetails7" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_85AF11B5E1888073E105741285C6E646" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_737368393D87DBC9DE8E741285C6913F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_85AF11B5E1888073E105741285C6E646" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_737368393D87DBC9DE8E741285C6913F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2D6E4801F5DEDD51C91C741285C69561" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_737368393D87DBC9DE8E741285C6913F" xlink:to="loc_us-gaap_AwardTypeAxis_2D6E4801F5DEDD51C91C741285C69561" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2A23EE2FA3B0D63C59B3741285C61499" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2D6E4801F5DEDD51C91C741285C69561" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2A23EE2FA3B0D63C59B3741285C61499" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_256F088A5EF62C5A3B9A741285C6240B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2A23EE2FA3B0D63C59B3741285C61499" xlink:to="loc_us-gaap_PerformanceSharesMember_256F088A5EF62C5A3B9A741285C6240B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A157320CEE791243E1B3741285C79024" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_737368393D87DBC9DE8E741285C6913F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A157320CEE791243E1B3741285C79024" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5AED1D7A81C904DBCE80741285C74715" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A157320CEE791243E1B3741285C79024" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5AED1D7A81C904DBCE80741285C74715" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_CFB86F0FFA5CC3D781EF741285C7AF05" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A157320CEE791243E1B3741285C79024" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_CFB86F0FFA5CC3D781EF741285C7AF05" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_432CCB86D89DBA20487F741285C7B256" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A157320CEE791243E1B3741285C79024" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_432CCB86D89DBA20487F741285C7B256" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_DDEC41701D2A3974EF72741285C762F9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A157320CEE791243E1B3741285C79024" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_DDEC41701D2A3974EF72741285C762F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_983ABA5A9D07653504D2741285C776E7" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A157320CEE791243E1B3741285C79024" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_983ABA5A9D07653504D2741285C776E7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B5FF1395BDB3C59024E67412884D3476" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_2888EB03FA2E01B02F5D7412884D03D5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B5FF1395BDB3C59024E67412884D3476" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_2888EB03FA2E01B02F5D7412884D03D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_F8E1177C68655A3DABAC7412884D4999" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B5FF1395BDB3C59024E67412884D3476" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_F8E1177C68655A3DABAC7412884D4999" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_F09BA77671235D9A07A97412884DE7B5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B5FF1395BDB3C59024E67412884D3476" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_F09BA77671235D9A07A97412884DE7B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCashProceedsReceivedFromShareBasedPaymentAwardsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashProceedsReceivedFromShareBasedPaymentAwardsTableTextBlock_0A3DE9C6D60261AC97E47412884D08B8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B5FF1395BDB3C59024E67412884D3476" xlink:to="loc_us-gaap_ScheduleOfCashProceedsReceivedFromShareBasedPaymentAwardsTableTextBlock_0A3DE9C6D60261AC97E47412884D08B8" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ScheduleOfMarketStockUnitsActivityTableTextBlock" xlink:label="loc_biib_ScheduleOfMarketStockUnitsActivityTableTextBlock_E09E95E30AED98E4CF237412884DF243" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B5FF1395BDB3C59024E67412884D3476" xlink:to="loc_biib_ScheduleOfMarketStockUnitsActivityTableTextBlock_E09E95E30AED98E4CF237412884DF243" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock" xlink:label="loc_biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock_1CC208B869C71CCF07537412884D0016" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B5FF1395BDB3C59024E67412884D3476" xlink:to="loc_biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock_1CC208B869C71CCF07537412884D0016" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock" xlink:label="loc_biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock_08E0B6873219E6A0F2AD7412884D6ECA" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B5FF1395BDB3C59024E67412884D3476" xlink:to="loc_biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock_08E0B6873219E6A0F2AD7412884D6ECA" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_PerformanceunitsactivityTableTextBlock" xlink:label="loc_biib_PerformanceunitsactivityTableTextBlock_4305236B8E5A1C8037497412884DE645" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B5FF1395BDB3C59024E67412884D3476" xlink:to="loc_biib_PerformanceunitsactivityTableTextBlock_4305236B8E5A1C8037497412884DE645" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock_9F487BC84A6571B12E257412884EF2A0" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B5FF1395BDB3C59024E67412884D3476" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock_9F487BC84A6571B12E257412884EF2A0" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock" xlink:label="loc_biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock_5ED042AEA7BA2576FF767412884E93E8" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B5FF1395BDB3C59024E67412884D3476" xlink:to="loc_biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock_5ED042AEA7BA2576FF767412884E93E8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SubsequentEventsNotes" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_69A827D5E992A87FD89FFCCBDA7FFCB7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_1980AA37463A6D680C6DFCF6322304BF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_69A827D5E992A87FD89FFCCBDA7FFCB7" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_1980AA37463A6D680C6DFCF6322304BF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1E78396BE0876AC2616F74128573A54C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_E870D908C4AEAB07C9897412857491DB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1E78396BE0876AC2616F74128573A54C" xlink:to="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_E870D908C4AEAB07C9897412857491DB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_D383F0ACCCC9CCC07981FD6455B5B498" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_FFC379CA953923695574FD6455B52934" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_D383F0ACCCC9CCC07981FD6455B5B498" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_FFC379CA953923695574FD6455B52934" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_MajorDistributorAxis" xlink:label="loc_biib_MajorDistributorAxis_0C617459372D0287C764FD6455B53D20" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_FFC379CA953923695574FD6455B52934" xlink:to="loc_biib_MajorDistributorAxis_0C617459372D0287C764FD6455B53D20" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_MajorDistributorDomain" xlink:label="loc_biib_MajorDistributorDomain_618A118D84C9D3C6979AFD6455B5B322" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MajorDistributorAxis_0C617459372D0287C764FD6455B53D20" xlink:to="loc_biib_MajorDistributorDomain_618A118D84C9D3C6979AFD6455B5B322" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_DistributorOneMember" xlink:label="loc_biib_DistributorOneMember_22E99E9D740EDFB6B6BEFD6455B6E07C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MajorDistributorDomain_618A118D84C9D3C6979AFD6455B5B322" xlink:to="loc_biib_DistributorOneMember_22E99E9D740EDFB6B6BEFD6455B6E07C" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_DistributorTwoMember" xlink:label="loc_biib_DistributorTwoMember_5A50F69B599D584F1C04FD6455B67FFE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MajorDistributorDomain_618A118D84C9D3C6979AFD6455B5B322" xlink:to="loc_biib_DistributorTwoMember_5A50F69B599D584F1C04FD6455B67FFE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_FA6775DA937575ABDDE9FD6455B6550D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_FFC379CA953923695574FD6455B52934" xlink:to="loc_us-gaap_RangeAxis_FA6775DA937575ABDDE9FD6455B6550D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_7AB54C06CE2BD698E040FD6455B622FC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_FA6775DA937575ABDDE9FD6455B6550D" xlink:to="loc_us-gaap_RangeMember_7AB54C06CE2BD698E040FD6455B622FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_B002776E3D783143D648FD6455B62FC3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_7AB54C06CE2BD698E040FD6455B622FC" xlink:to="loc_us-gaap_MinimumMember_B002776E3D783143D648FD6455B62FC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_E50660221DD02361D2F0FD6455B6FF0B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_7AB54C06CE2BD698E040FD6455B622FC" xlink:to="loc_us-gaap_MaximumMember_E50660221DD02361D2F0FD6455B6FF0B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5EC3A36315AF9FBB018EFD6455B68766" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_FFC379CA953923695574FD6455B52934" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5EC3A36315AF9FBB018EFD6455B68766" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_F19D4C59A615F3586A34FD6455B6F1B5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5EC3A36315AF9FBB018EFD6455B68766" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_F19D4C59A615F3586A34FD6455B6F1B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BuildingMember" xlink:label="loc_us-gaap_BuildingMember_36B74441F3065935CA3CFD6455B62F30" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_F19D4C59A615F3586A34FD6455B6F1B5" xlink:to="loc_us-gaap_BuildingMember_36B74441F3065935CA3CFD6455B62F30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_F43F3E47CD3075DDB6B5FD6455B6B77D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_F19D4C59A615F3586A34FD6455B6F1B5" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_F43F3E47CD3075DDB6B5FD6455B6B77D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_02C03DA302A7E2EC3DA9FD6455B6AB21" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_F19D4C59A615F3586A34FD6455B6F1B5" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_02C03DA302A7E2EC3DA9FD6455B6AB21" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_6DD451FA08BDA8CE0645FD6455B7FF52" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_F19D4C59A615F3586A34FD6455B6F1B5" xlink:to="loc_us-gaap_ComputerEquipmentMember_6DD451FA08BDA8CE0645FD6455B7FF52" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_C340C1736CFB9C480174FD6455B7FD73" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_FFC379CA953923695574FD6455B52934" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_C340C1736CFB9C480174FD6455B7FD73" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables" xlink:label="loc_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables_0213699FEAA841A1133CFD6455B7064C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_C340C1736CFB9C480174FD6455B7FD73" xlink:to="loc_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables_0213699FEAA841A1133CFD6455B7064C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_E82E394D507DA2A5F92EFD6455B7211E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_C340C1736CFB9C480174FD6455B7FD73" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_E82E394D507DA2A5F92EFD6455B7211E" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_BusinessTextualAbstract" xlink:label="loc_biib_BusinessTextualAbstract_F2F790AB569569D52FACFD6455B7B738" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_D383F0ACCCC9CCC07981FD6455B5B498" xlink:to="loc_biib_BusinessTextualAbstract_F2F790AB569569D52FACFD6455B7B738" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_InterestInSubsidiary" xlink:label="loc_biib_InterestInSubsidiary_85A64598858CA72579F2FD6455B723C9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BusinessTextualAbstract_F2F790AB569569D52FACFD6455B7B738" xlink:to="loc_biib_InterestInSubsidiary_85A64598858CA72579F2FD6455B723C9" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_PaymentTermsOfAccountsReceivable" xlink:label="loc_biib_PaymentTermsOfAccountsReceivable_3024DF3BCF6143708E66FD6455B72294" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BusinessTextualAbstract_F2F790AB569569D52FACFD6455B7B738" xlink:to="loc_biib_PaymentTermsOfAccountsReceivable_3024DF3BCF6143708E66FD6455B72294" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_EstimatedUsefulLivesOfLeaseholdImprovements" xlink:label="loc_biib_EstimatedUsefulLivesOfLeaseholdImprovements_870271B4C148845B3851FD6455B7D37D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BusinessTextualAbstract_F2F790AB569569D52FACFD6455B7B738" xlink:to="loc_biib_EstimatedUsefulLivesOfLeaseholdImprovements_870271B4C148845B3851FD6455B7D37D" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_PurchasePriceOfCommonStockUnderEspp" xlink:label="loc_biib_PurchasePriceOfCommonStockUnderEspp_87CAB256082CBC5D11F2FD6455B72CF3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BusinessTextualAbstract_F2F790AB569569D52FACFD6455B7B738" xlink:to="loc_biib_PurchasePriceOfCommonStockUnderEspp_87CAB256082CBC5D11F2FD6455B72CF3" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_PercentageOfMarketValuePerShareOfCommonStock" xlink:label="loc_biib_PercentageOfMarketValuePerShareOfCommonStock_17F2E1E1E771AC0D430EFD6455B759F7" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BusinessTextualAbstract_F2F790AB569569D52FACFD6455B7B738" xlink:to="loc_biib_PercentageOfMarketValuePerShareOfCommonStock_17F2E1E1E771AC0D430EFD6455B759F7" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_CompensationExpenseOverPurchasePeriod" xlink:label="loc_biib_CompensationExpenseOverPurchasePeriod_B91C5A91FFCE90C1D2F8FD6455B7AB5A" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BusinessTextualAbstract_F2F790AB569569D52FACFD6455B7B738" xlink:to="loc_biib_CompensationExpenseOverPurchasePeriod_B91C5A91FFCE90C1D2F8FD6455B7AB5A" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_DiscountRateRecognizedInCompensationExpense" xlink:label="loc_biib_DiscountRateRecognizedInCompensationExpense_B868EDE20548C7CC7946FD6455B7657C" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BusinessTextualAbstract_F2F790AB569569D52FACFD6455B7B738" xlink:to="loc_biib_DiscountRateRecognizedInCompensationExpense_B868EDE20548C7CC7946FD6455B7657C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdvertisingExpense" xlink:label="loc_us-gaap_AdvertisingExpense_E4F0DE0E609A8569A20AFD6455B7ABF8" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BusinessTextualAbstract_F2F790AB569569D52FACFD6455B7B738" xlink:to="loc_us-gaap_AdvertisingExpense_E4F0DE0E609A8569A20AFD6455B7ABF8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_9E898ED8FF6E0233F250FA4EA5F12D53" xlink:type="locator" />
    <link:loc xlink:href="biib-20161231.xsd#biib_BusinessOverviewPolicyTextBlock" xlink:label="loc_biib_BusinessOverviewPolicyTextBlock_0C66D3DE0492CF21543AFA4EA5F1B30A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9E898ED8FF6E0233F250FA4EA5F12D53" xlink:to="loc_biib_BusinessOverviewPolicyTextBlock_0C66D3DE0492CF21543AFA4EA5F1B30A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_AD3BA4B53FC32530B02DFA4EA5F2FB0C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9E898ED8FF6E0233F250FA4EA5F12D53" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_AD3BA4B53FC32530B02DFA4EA5F2FB0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_99A969F1682B8F034EF0FA4EA5F2E511" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9E898ED8FF6E0233F250FA4EA5F12D53" xlink:to="loc_us-gaap_UseOfEstimates_99A969F1682B8F034EF0FA4EA5F2E511" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_7AD9BDDD6B306F362656FA4EA5F229BE" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9E898ED8FF6E0233F250FA4EA5F12D53" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_7AD9BDDD6B306F362656FA4EA5F229BE" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_CollaborativeandOtherRelationshipsPolicyTextBlock" xlink:label="loc_biib_CollaborativeandOtherRelationshipsPolicyTextBlock_B5AD5C9FBBB12E210C11FA4EA5F23561" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9E898ED8FF6E0233F250FA4EA5F12D53" xlink:to="loc_biib_CollaborativeandOtherRelationshipsPolicyTextBlock_B5AD5C9FBBB12E210C11FA4EA5F23561" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_C6167CA2E65167BD8523FA4EA5F243E7" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9E898ED8FF6E0233F250FA4EA5F12D53" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_C6167CA2E65167BD8523FA4EA5F243E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_A2E3533CC6D77782AD04FA4EA5F22B39" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9E898ED8FF6E0233F250FA4EA5F12D53" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_A2E3533CC6D77782AD04FA4EA5F22B39" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock_47010DDB6425AA410848FA4EA5F2B68B" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9E898ED8FF6E0233F250FA4EA5F12D53" xlink:to="loc_us-gaap_ReceivablesPolicyTextBlock_47010DDB6425AA410848FA4EA5F2B68B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_539D186664ADBA562802FA4EA5F2265B" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9E898ED8FF6E0233F250FA4EA5F12D53" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_539D186664ADBA562802FA4EA5F2265B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_7905AE6274F095ABB806FA4EA5F2D71B" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9E898ED8FF6E0233F250FA4EA5F12D53" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_7905AE6274F095ABB806FA4EA5F2D71B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityMethodInvestmentsPolicy" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy_283B5D89A6B5A8382134FA4EA5F25927" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9E898ED8FF6E0233F250FA4EA5F12D53" xlink:to="loc_us-gaap_EquityMethodInvestmentsPolicy_283B5D89A6B5A8382134FA4EA5F25927" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_79546CC2596F29419D7FFA4EA5F3C940" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9E898ED8FF6E0233F250FA4EA5F12D53" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_79546CC2596F29419D7FFA4EA5F3C940" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_428B3D918160E8A020C8FA4EA5F3D06A" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9E898ED8FF6E0233F250FA4EA5F12D53" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_428B3D918160E8A020C8FA4EA5F3D06A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_A2C37BFB65CC4EA1D81AFA4EA5F37AD7" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9E898ED8FF6E0233F250FA4EA5F12D53" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_A2C37BFB65CC4EA1D81AFA4EA5F37AD7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentPolicy_81A53C16AC7ACFC08867FA4EA5F37B69" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9E898ED8FF6E0233F250FA4EA5F12D53" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentPolicy_81A53C16AC7ACFC08867FA4EA5F37B69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_336971FF93DCF2C0E541FA4EA5F3F551" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9E898ED8FF6E0233F250FA4EA5F12D53" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_336971FF93DCF2C0E541FA4EA5F3F551" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_65ABCD5004CED5C5010EFA4EA5F34FCA" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9E898ED8FF6E0233F250FA4EA5F12D53" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_65ABCD5004CED5C5010EFA4EA5F34FCA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_EF825907F05187C98951FA4EA5F330CB" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9E898ED8FF6E0233F250FA4EA5F12D53" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_EF825907F05187C98951FA4EA5F330CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_44640B7F8B8B6F5B1D21FA4EA5F37DA3" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9E898ED8FF6E0233F250FA4EA5F12D53" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_44640B7F8B8B6F5B1D21FA4EA5F37DA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_9030579F663589326000FA4EA5F37B4C" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9E898ED8FF6E0233F250FA4EA5F12D53" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_9030579F663589326000FA4EA5F37B4C" xlink:type="arc" />
    <link:loc xlink:href="biib-20161231.xsd#biib_RoyaltyCostofSalesPolicyTextBlock" xlink:label="loc_biib_RoyaltyCostofSalesPolicyTextBlock_96F5FB333FFEE77F1DACFA4EA5F3FB27" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9E898ED8FF6E0233F250FA4EA5F12D53" xlink:to="loc_biib_RoyaltyCostofSalesPolicyTextBlock_96F5FB333FFEE77F1DACFA4EA5F3FB27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_6D735E2E558A5F9E638CFA4EA5F3BEA2" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9E898ED8FF6E0233F250FA4EA5F12D53" xlink:to="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_6D735E2E558A5F9E638CFA4EA5F3BEA2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_F2C983F9508734B978EFFA4EA5F4BC60" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9E898ED8FF6E0233F250FA4EA5F12D53" xlink:to="loc_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_F2C983F9508734B978EFFA4EA5F4BC60" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_F8AE32562D9B06E76E2CFA4EA5F46C9A" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9E898ED8FF6E0233F250FA4EA5F12D53" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_F8AE32562D9B06E76E2CFA4EA5F46C9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_36A115D6637679A4222DFA4EA5F49539" xlink:type="locator" />
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9E898ED8FF6E0233F250FA4EA5F12D53" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_36A115D6637679A4222DFA4EA5F49539" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_EADD7AB6BE8085EC7ECEFA4EA5F46221" xlink:type="locator" />
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9E898ED8FF6E0233F250FA4EA5F12D53" xlink:to="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_EADD7AB6BE8085EC7ECEFA4EA5F46221" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_44E584C92EF1EA17530DFA4EA5F417CF" xlink:type="locator" />
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9E898ED8FF6E0233F250FA4EA5F12D53" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_44E584C92EF1EA17530DFA4EA5F417CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_5B0BD681D0AE71C31A82FA4EA5F49F11" xlink:type="locator" />
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9E898ED8FF6E0233F250FA4EA5F12D53" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_5B0BD681D0AE71C31A82FA4EA5F49F11" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_01629867B8D6A34FCCBC7412884330B3" xlink:type="locator" />
    <link:loc xlink:href="biib-20161231.xsd#biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" xlink:label="loc_biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_3C390512AB33B60D48FD74128843AE5A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_01629867B8D6A34FCCBC7412884330B3" xlink:to="loc_biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_3C390512AB33B60D48FD74128843AE5A" xlink:type="arc" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>alprolixchart.jpg
<TEXT>
begin 644 alprolixchart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $R 3T# 2(  A$! Q$!_\0
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MI=]\I^&_^"._PC\$^$='\*>"_%7A_P /6O@ZX\"Z7X4BM/V=OV?H=*\4> O
M&G>(-)T;P=^T/I>F^#-*D_:0C-OKUIJ[WWCS4;2S@\;^"O 'Q$LM!M_&VA:C
MK6N^A?!W_@EK\-_@AX?^)7AOP1\2O%EGIWQ"^#?B#X-)'+X)^$EY8:!H6O\
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MC:>'%M?BUXATX?"SX<Z7#JWB^VALI=#\(6T;Z"?$6N>*?$VN>G?M=_LO>/\
M]IQ/ 6CZ-\<S\//A_P"&KK6-2\;_  LU3X5^%OB;X ^,>HS'36\*I\2=-UO6
M-!U#6?#G@RXM;[4[3P.VIMX+\3:Q>VEYXYT+Q+;Z%I%C;@'@3_\ !2^UU;P?
MJ/QA\)?"26?X)?#+X1?LX?&+]H;7/%WC>'PQ\1/AIH7[2'A;2O']AI.@> K+
MPUXATKQ9KWPL^'&MZ1X\^*%KK7C7P1 -(U*WT[P1<^*]=2YLH/6+O]MJ_L/V
M@/VC?@MJ?P5\3Z#I/P%_9C_X:,TWQGXB\0Z)I\WQ-M;7QI\4?!FIZ=X>\,6:
MZG>:'X96\^&LKZ)XN\3ZAIU]XB6_FO;7PE;:#;:9K>O5/&_["</Q%U'6;CQ1
M\7_$R:/\8/"GPI\.?M7^%= \+>%=(\/_ +0<_P )!LTO5 MQ'JFJ_#%O%FF[
M?!OCZS\*:I>0Z[\/K73?#VG2:'JM@GB>2-_V./BM/^UGXU_:;E_:=U.TL_&W
MPPE^"%SX#T7X2>$]+N-%^%=GXD\>^,_"]GH/CF37]0U&U\:^&_%7CZ^U2'QE
M=Z'?6^H1:=IUI>>&MHN)I@#J/V,OVI?$/[2NE>*;GQ:/@1IFLZ)IO@;6;;P[
M\'OBAX_^(>HVND>,],U"_MM6\0)X_P#@Y\()5T#49[*6S\'>+O"MOXI\(>,F
MTSQ ^F:XCZ1+ VWXS_;Q_9C^',_CZ/X@>-]>\$6GPZ\)_$CQSK&L^+?AG\4/
M#OA_6O"OP>NK:T^*>L> =>U?P=9Z3\2;7P$]Y:W/B,^ [OQ ;;2Y'UJW%UHU
MM=ZA;]!\'_V=-8\"_$'7/BW\2?BUXD^,WQ+U'P+H/PKTKQ#J_AKPEX)L=$^'
MOAS7M3\36]C'X?\ !5A8:;?^(]>UW4VU/Q9XBNR+>]GL;"V\.:#X2TM+K3KO
MX$^(/_!&7X7?$BZ\9WWB'XN>+9]7\2>'/VH_!]IXQ?P)\-IOB9/X<_:KT35-
M-\5V_P 0OB>VC)XU^*U[X+GU*&'X?77BG58K/1?#FCZ+X?N=+OY;$:TX!]N7
M'[=?[.$+36">)_%L_BF#QOKWP^F\ 1?"3XOR?$BUU[PUX2T/Q]J^H:A\.XO
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MNN^+;W3K2[L_!7A)X_"VLV4?BSQ5/I6@/J=K)9+?%X+U[, ^EZ*^=[3]J[X
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MBY^F[P8,_A2C_@M3HY&1^SIJQ!Z$?%#32#]"/!>#^%']LY;_ -!*_P#!5?\
M^5>?Y]F'_$/^+_\ H3R_\+<N_P#FP_<BBOPX_P"'U&D?]&YZO_X<_3O_ )BZ
M_2S]DW]I"W_:F^%3?$^V\'W'@B)?%.O^&?[%NM;AU^4MH1L@U[]O@T[2X]MU
M]L&V#[-NB\LYEDW#;OA\QP>*J>RH5O:5.5RY?9U8^[&UW><(K3F76^ODSSLS
MX4S_ ";#?7,RR]X;#>TA2]J\3@ZO[R:DX1Y:&(JSU49:\O*K:M71]-T445VG
MSP4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^RFR?_U'S(_H%;Q3H05C]OCX4G_577I_U[U_!-_P6%_;N\0_"[_@H_\ M,>
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MO^"]/_*6;]KW_L-_"O\ ]45\,:^R\2O^1)A/^QG2_P#47%GX-]$S_DX.??\
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M8&I6A"4IT:>-P52K&$,7AY56_!G_ )+'\'_^RN_"G_U8OABO]@R/[I_WY/\
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M6-S'_P -7>#@J6NFSV;AS\)OB]M8R2ZI?*RA0X*")2Q92'4(5?[ _P""D_\
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MJ(-?)<IJFD*AEF**VAWCLJ^:^U6<:^@9@, L$0,1D*N<#_(+^#/_ "6/X/\
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M,(^"O_9V'@S_ -5+\8:^=XM_Y)S-_P#L%?\ Z<@?J7@G_P G6X'_ .QU3_\
M3%<_@7HHHK^<3_58**** "BBB@ K_0R_X-AO^4:,O_9R'QL_]"\(U_GFU_H9
M?\&PW_*-&7_LY#XV?^A>$:^[\._^2A?_ & 8G_TN@?SG]*3_ )-<O^RFR?\
M]1\R/Z)'^XW^ZW\C7^9-_P %Z?\ E+-^U[_V&_A7_P"J*^&-?Z;+_<;_ '6_
MD:_S)O\ @O3_ ,I9OVO?^PW\*_\ U17PQK[+Q*_Y$F$_[&=+_P!1<6?@WT3/
M^3@Y]_V1F._]7G#Y^05%%%?B1_H*%%%% !1110!Z3\&?^2Q_!_\ [*[\*?\
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M+\-_B/')<S)#+<O#;(_A-7N)4MX)KAXH0\BP0S3LHBBD=9O^$GL?^@5XX_\
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MG8WXU&W:]D\5^'?BU\4_%NJ6CZ:'^VQVT6B^*='GCOW46\TLTMM&QEMY5'U
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MM8''UP33J &[1ZM_WV__ ,51M'JW_?;_ /Q5.HH ;M'JW_?;_P#Q5&T>K?\
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M2.VHWE[!<W%[(?-N9)955P ?GQ^VM^T;\:_#/QM_: TWP]K'Q;\"_##]D/\
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M\2_M%Z#\?O"ESH^EZMI_A;QA/';Z)X$\"Z?\//$-_P"*?%FF7MM9^%KCX@^
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MZMKZRNHEGMKNSGBNK6XA<926"X@>2&:)QRLD;LC#D$U_"FEK:;E_T2T^\/\
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M;1E1)<6ES A<D*'F@DB4L0&(4,X+$ D#. 3Q5RBC<:;BTUNFFO5.Z/X 9_\
M@UI_X*$2332#XH?LF[9)YY%SX]^*0(629Y%! ^#I&0K '!/.>3U/Z=?\$A/^
M"&O[6_[!7[9NC_M"_&'QO\ ]=\$Z?\,/B3X,GT_X>^*O'.K^)&U7Q>GAY=,F
MCL]>^'?AO3VL8CI5Q]ME;4UFB#P^3!/N<)_6)17R&#X(R+ XJAC,/#%*MAJL
M*U)RQ,I14X24H\T7'WE=:IO7[K?N&=_2%\1N(,GS+(LQQ&3RP&:X*O@,7&CE
M5.E5>'Q%-TZBIU55;A/E;Y96?*];!1117UY^''!_$;X6_#;XO^'3X1^*G@+P
M?\1O"YO[35!X?\;>'=)\3:3'JFGF0Z?JD%CJ]K=P6^IV#32M9:C;K%>VC2R&
MWGC\QPW+77[.OP"O=+O]$N_@I\*;C1=5^&3_  6U+2)/ 'A8Z7??""2ZN[Y_
MA==:>NEK9S?#YKR^O;IO"#PG03<7=S,;'S)Y&;V6B@#QN\_9W^ VH7&CWE[\
M&OAA<W?A[Q?XZ^(&AW4W@;PW)<Z3XW^*$VHW'Q)\5:?.VG&6VUWX@SZOJ<WC
M?4(V$WBN6_NI->:_:4FL.R_91_9CT[P.GPSL/V>_@M9?#V/Q/9>-H_!-K\,O
M!L'A=/&&FHD.G>*%T2/1UL!K]A:QQV-EJXA^W6FG1IIEO/'IRBU'T!10!YTO
MP@^%"_#M_A$OPT\!?\*JEL)M*E^&Q\(Z _@.32[F]DU*XTZ3PB^GMH#V$VH2
MRWTEHVGF W<C7(C$QWCCK7]E[]G&R\):%X"L_@3\)+3P7X9\8VGQ$\/>&+?X
M?>%H=%T7Q]8J$MO&VFV":6(;7Q:D6ZW?Q%&HU>>TDEL[B\EM)9(']VHH ^<K
M/]C_ /92T[P[XA\(Z?\ LV_ NQ\+^+-"F\,>)O#]G\*_!-MH^O>')]=3Q.VA
M:KI\.BI;7ND1^(HH=<M=/GC>UL=5M[:_L8[:YM;>2+>M/V9_V=K#6/&7B&U^
M!?PBBUWXB>'[CPGX^UC_ (5UX1DU/QKX7O+2TL;_ ,/>++V72))_$.C:E9:?
MI]KJFG:J]U:ZK!I]A'J4=VMC:B'V^B@#SWX:_"7X7_!KP_)X4^$WP]\%_#;P
MU-J$^K3Z%X'\-:1X8TNXU6ZB@@N-3NK/1[2TBNM0FM[6UMI+VY66Y:VM;6V\
MWR+:"./T*BB@ K\QO^"AG[&OQ1_:LU#X4W?PZUCP3I4?@>S\9V^K#Q=J>L:>
M\[^(;CPS+9&P&E:#K0E6-='NA<F<VY0O!Y8E#.4_3FBL,1AZ>*HRH54W3GR\
MW*^5^[)35GZQ5_(]'*<TQ>38^AF6"=..)PZJJFZL%4A:M2G1GS0;2=Z=226N
MCL^A_-0O_!'[]IL,"?%WP7X(/_(R^+NQ_P"Q&K]Z_P!G#X<ZY\(_@5\*?AGX
MEN-,N]>\$>"-#\.:M<Z/-<7.ESWVFVYBGDL)[NUL;F6U9CF)Y[2WD8<M$AXK
MVRBN?"9;AL%.52@IJ4H<CYI\RY;I[66MXK7U/5SSBW..(:%'#9E/#RI4*WMZ
M:HT(TFJG)*G=M-W7+)Z=]0H(!Z@'D'GGD'(/U! (]",T45WGS)Y7;_ SX,6F
MA>%_"]I\*?AW;>&O!.H>*-5\(>'X/!OA^/1?#.H^-]-\4:/XRO=#TQ;#[%IE
MQXLTGQOXQTSQ*]I!%_;MAXI\0V>J"ZM]7OXY^);]D/\ 96;P)!\,#^SC\#_^
M%=6OB)_%]KX)'PM\%CPQ:^*I+(:8_B6VT<:,+2#7FTE5T=M6BC2_.C :.;C^
MRP+2OHJB@#SC2/@]\*- \5Z5XZT'X;>!M#\9:%X$M?A=HWB?1O"NB:5KFF?#
M:PN;>\T[P%8ZC865O<V_@[3+JVAGTSPY&ZZ1ILBLUA:6WF2A^<O?V;OV?=2U
MCXC^(-0^"'PGO==^,'AK5_!OQ6UFZ^'WA2?5/B1X3\0V,&F>(/#?CB_DTHW7
MB?0]>TZUL['6],UB6[M-8M+&Q@U**ZCL;18/:J* .>UOPCX6\2Z78Z)XA\-Z
M%KNCZ9JWAK7M.TK6-)L=2TZPUOP9K>F^)?".L6=G>036]MJGA?Q%HVD:[X?O
MX8TNM'UC3-/U+3Y;>\L[>:/SOQ1^SM\ _&WA>T\$>,?@M\*O%/@VP\5Z[XZL
MO"OB#P!X5UCP]:>,_%&K:UKWB;Q5;:/J&E7%A!X@\2:QXD\1:EX@U:.!;W7+
MOQ!KDNJRW9U;4!<>RT4 >83_  3^#UU?7&IW/PM^'UQJ-WX]\+?%.ZOIO!^@
MR7=Q\2O _AW1O"'@WQ]-.UCYDGC'PIX5\.Z#X;\.^(V8ZKHNAZ+I>E:?<V]E
M86L,5#P#^S_\#/A5K-]XB^&?P=^&/P^U[4X-3M=0UGP7X%\->&=4O;36M6M]
M=U6TN;[1M-L[F:TU#6K6VU:ZM'D-M)J,$5WY0G0/7KU% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
=10 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>amortizationchart.jpg
<TEXT>
begin 644 amortizationchart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #P 3T# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /-?C-\0_P#A4?PA
M^*?Q4_L>3Q#_ ,*U^''CKQ__ &##=BPEUO\ X0OPKJWB;^R(KXVUX+.34_[+
M^PI=&UN1;M.)OL\^SRG^#/V?/^"COA/X@?"KPK\6/BMK7P$MK#XCV/AJ?P%X
M0_94^*/Q%_; ^("ZK>> [CXD>-?#?C3P;X"^".C>(= U?X?^$VL=4\0?V9IF
MO6MC:-=W&K3:0&T>/6/OCXO_  [M/B[\*/B;\*K_ %.[T6Q^)?P]\;?#^\UC
M3X;>XOM*M/&GAC5?#-SJ5E!=@VLUW80ZH]W;17(,$DT*),#&S5\O:M^Q5:V7
MAG]FM?A?\4==^%_Q+_9B\ W?PR\'?$K3/!_@K7VUWPAXB\%>#_!?C2Q\4>#=
M<L'\/7MUKO\ P@7@_P 4V&H6[6]UH7BCPUI3*VI>')=:\-ZR >Q_"[]J;X%?
M&SQ;KW@OX3^.8_'VK^&/#WA'Q3KUWX;T+Q-?^&-.T+X@>"?!OQ&\!WTOC1=&
M7PBY\:>"/'GAWQ)X5M(=:DO]>TQ]5FTZUG_X1[7AIWPGX9_X*\?!_P 0ZW\.
M'OOAA\8O!?@7QIJW[=^AZSK_ (P^&OQ,M_&&@WG[#?Q*\&> ?$5_I'PQT+P#
MKGBCQCX=\3V?B75_$VJ:QI21+\-8?"FN>'/&,$/BG2M?TK1/JC]DK]B[P!^Q
MVOQ(TWX<>(?$NJ>&?'+?!F#3=&\2?V;<3^&=-^"WP"^''P#T>W35;&VLYM9N
M]=TOX=6OB?7=1OK:"237M7U&.T@MM.CM+>+QK0O^"<.@:%X\;Q+;_%SQ7)X8
MTB+]NJ'P5X0/AKPU%)X=A_;^\:^'?B=\6XK_ ,2PE=0\2KX=^(FDZGJW@22^
MM+6XT_1=8C\.ZO/K":19:BX!]+>&OVO?V>_&/C?2/ 7A;Q^NO:EK]YI.D:)K
M^E^&O&%W\.=5\2Z]\/[/XK:-X,T_XKQZ ?AG=^.]4^&E_9>.[+P-#XK?Q5/X
M6NH-672?)E0'S;XR_MCO\%_B[<_!;7OAQ->^,/'WA/PYJ_[+JVWB9+>S^/OB
MV[U\>&/B!X $UQHG_%&ZK\'WO_#/Q"\?WX_X22"R^"NN:G\2K6WFM? _C#3M
M-\%_9P_X)/?!C]FWX@?#WQOX<U+0_$4_@:R\&:G)J7B7X,?"'4/B)JOQ \)_
M![P]\'+CQ%:?%J[\.WOC;PKX;U[3_#L'C&[\&>&[FRDTWQE?:FNC>*++P=?W
M/@^3[%^,W[-'ACXV?$_]GKXC^(]9U&V3X Z_\5=:M?#5K:V<FG>+X?BO\%_&
M/P5UC3-8O9-FHZ;!9:+XSOM2M;C1Y8+J6[@CMII!:RR@@')Z/^W9^S;K^CW.
ML:#XI\8>($6QT'5]$L/#_P &_C1K&M>/O#WB<ZM'H'C/X5Z!9?#Z76_BE\/M
M7GT+54LOB%X$L->\$^5;1WMQKT%A>Z==WF'>?\%&/V-;&R?4KCXT6*Z=;?#A
M_BUJE\GA+Q_-;^'O ,7C'Q[\.)]8\5&'PI)+X5N[?XE_#7Q;\,KGP[XABTWQ
M-!\2K.P^'[Z/_P );KFB:1?_ "5X8_X(Y?"?P+X2T;PGX*\8:%H-EX+NO!>G
M^$K6/]GOX%'2/%/@7P1I/B#0],\(?M%Z98^&=,N/VCTEM==LM;GNO&FK:;I2
M>/?!'@'XB6WAJ+Q;H-YJ.L>B?!G_ ()9_#_X&Z)\3O#_ (,^*7BF+3?B+\'O
M$'P>CM;OX??!N^TCP_H^O_M1_M)?M1SRP>"M3\#:E\-M5TL:Y^TEX@\"R>"]
M0\$?\(>_@;0].L+32=/N+N>6  ^]_!7QJ^'WCKP5K?Q T_4-:\.>&O"\NKP>
M*Y?B5X-\9_"75?"DF@:;!K&M-XG\/?$_0/"6O:%:Z?I5S#JDFHZCIT.F3:7(
MFIVE[<6#K<GPM/V_/V6/[$T?7KGQ[X@TZ#Q'XJ^'_@[PUI>K?"CXOZ/XI\3Z
MQ\6M.\5:I\)YO#/@W5/ EGXL\1:#\4+;P3XHB^'WBG1M%OO#GBW4]%O]%T?4
M[C6;6?3XZ/PB_8G\'^ /@3\:O@+XM\4:KXX\%_'L>,;/QEX;TS3K7X>^ /"O
MAWQS\/=,^&NO^#/@]X T"[OM.^%?A&_T;3KG7[K1M$U&ZCE\=^(O%/BN-[>;
M639V_@GPZ_X)8?#;X>0?#@:5XNTS2K[X<?'3X'_&&WOO GP1^#/PMF\6V?P"
MT/XDZ)X0\/\ CN3P'X;TJ\\4:KJZ_$_7]2\4>*[Z^*-J?[WPGX:\(6^HZW:Z
MD =+\?O^"HW[/GPH^!?C+XN?#ZXU7XQZYX:^'(^(EMX'T?PQ\2-%^RV<OQ#U
MCX566D_$OQ&?A]J]K\$]9U'XA>%_&7@K3](^)UEX?UJ[\7>#?%'A^+2S?:#J
MRV?O=Q^W%^S'8IXZNM3^)#:3I7P_T_QSJFJ^(M5\&^/]-\*Z_9_#/Q=8> /'
M_P#PK?Q1>>%8=!^+5WX0\=ZMI'@G7M-^%]_XNU&S\7ZOI7AQ;6;5-3L;>X^.
MM2_X)+^&_P#A"OC/X#\+?'_XC>$M$_:-D\>M\<#:>%O FJ7?BU=;_:&^,O[0
MO@+^RKC5;"=O"T_@?4OC7XC\!ZG-8_:1XW\"Z;HD-]'HWB*VFU^;2T+_ ()%
M? 3PZ/B/8Z+>Z?X?T_Q++KNI^ M<\,?";X1:)\5?A_XCU?XQ^'/CUI.NW_Q?
M/A6^\9_$1O ?Q'\)>'Y?!NC^*9H]#N?#=A%H7Q#L/B#/%9ZO9@'O_P -_P!M
MO1?B;;_MHZEHG@+7['2OV1M>L-#"^)(/$?@_Q)XTFN/V:OA[^T'>1:QX.\8^
M$_#_ (D^'FI:?-XY;P?)I>LV&H32#3(_$2N+?4HK"'R/X6_\%$[^'PA\"_'?
M[5/P[\$? OP9^T;\!;CX]?#;QAX+^*.O_%;0;.VT_P &>%/B%J7PV\:6FI_"
MKX<^)=/^(<GA#Q=:ZCX7M?"FB^--+\8WFC^(-!TZZM/$$6@:9XD]S^''[(3^
M$M,_:J;Q=\5O$GQ \5_M=:A8ZS\1?$ESX;\,>&8=&U2S^ ?@W]G]4\'Z#HD1
ML=/TB+PUX)TK4K/3]2N-5NXM2DNS>ZKJ7GO.WR]!_P $I=$\;_!KP1\%_P!H
MSXY^)?C5X=^#WP9T;X+_  2AMOAS\/O >D^ [/0C\.S8^/\ 5?#L4'BRP\?_
M !%\OX6>$=*FN_%,LO@UO#4GBKP['X*AL?&7B!KD ^MM5_;H_9JT31;/6-5\
M8>)[&ZN-3\5:5>>#YOA+\7S\3/#D_@/1/#_B?QW>^,_A7%X$D^(O@G0?!?AC
MQ9X4\3>)?$_BOPSI/AS3/#_BOPGJ\FJ/9>*_#LNIR:S^W1^RYX?E^(1U?XFB
MRTKX8^'?B3XF\3^*Y/"'CL^ Y[+X.>'[OQ5\5]/\(_$!?#!\$_$#Q+\.O#UA
M?ZIXQ\)^!=?\0^)=#@TW5X[O2UN-#UR'3?!/"'_!./3/AK%X:\1_"3XK1_!7
MXJZ9'\4M$UWQI\'?@9\$/ 7AW5/!/QCB^%<?C#P_I?PVL/"TWA[2M7T^Y^"?
MPTUSP=XWU>\\6>)M%US0[B+5[GQ-X3U!O"-MP>L?\$B/@G?+^T98:5K>G:#I
MOQ[\%?M/:"FM6_P;^#FH?%?PIXF_:T\.^-=%^*/B=_C3J/A:7XA>)[2VOOB%
MXOUKPOX=O=2TR.R;7+G0-:U?Q!X5M]+T73@#W_Q1_P %&/V9-(LO%-KH?B_4
M=;\:Z!=:UX=M/".H^!_B7X56Y\>Q?#B_^*/@?PAK?B#7?!$&C^#W^+GA*R75
MOA)K7B*:TTCXG6$K3?#^X\3W$36C9WPB_P""D'[._P 2?A!X$^)&M:QK/@[Q
M/XO^%_P$^(Y^&#^"OB7K/B[4_P#AH31OM7@C3_A3I4?@2QU_XY:9J.OV7B+P
MQIGB?X8^']<TN_O?#.LW-P--M;2=XN#^(G_!,CP5\1-6^)6J7_Q5\:V/_"R_
MBQ^S%\5=0MK;1_#DL6GW?[,WPKM?A9I.B6KSQF2:P\76%L-6UJYN";RQOW\O
M3&2!%KA-<_X)%_#/Q?X:\!:1\0/B7KGQ-U7X%>!?A'\,?V=M0^(GP^^&WB?0
MO '@3X/VFI6=AI/C/P1<:/#X<^+EYXYL]4DTWXB:GXBBTIK_ $_2_#TWA*V\
M&>(-,N/$&I 'W!X1_:^_9]\>^.O"?PT\'>-[SQ#XY\9^$;GQWI'ANP\%>/3J
M-EX4T_Q5XO\  FM:MXLCG\,0+X#'AOQSX&\2>!_%5EXX;P[J/A?QI:6WA+7;
M.Q\0:IIFG7?E_P :_P!KOQ+\%_C3X!^'&I?#GP/J&@?$/Q_\-/A[X4MG^.GA
MRR^//CV3Q_K^@:!K_CGX6_ *#PUJE]XL^'GP>DUN36/BMJNL^,_"6LZ-X4\.
M^-/%>GZ'>Z/X=L9O$<G[/W[#?@K]GKXG:3\2_"_B-B^G?L_6GP*;PEHW@3X?
M_#_P:H/QK\?_ !TUCQ7I7ASP!H?A_1]"NM3\4_$36+,:186'V9+""WO=0OM8
M\0W.JZUJ&C\9_P!D75/C?XPB?Q9\</&S?"2?QW\-_B7?_"]?#/@9]2TSQ-\+
M/$7A#Q9X<T[P%\4TT>V\<^!?!^J>)/!&CZSXITBUEU77;VZOO$46@>+/#%EK
M'V.T +_P#_:LO_C;\>?VF_@K?_"+Q/\ #-/V>S\(9M,UCQ?K.D2ZWX_TGXK:
M/XTU&VU^3PCI/VQ_!-A#<>"[R/2-/UO6KGQ%JNDW=CK6JZ/X:>ZBTL>R_%KQ
M?\5/#4/A?3_A%\++#XE>(_$NMW.G7=UXF\<1?#WP%X)TBST;4-3G\1>,?$5K
MX>\:^)F@N[RVL?#^B:3X3\#^)M4U'6]6M6O5T;0K75-;L?D#P9^QU^T!X$^-
M?[2GQVTW]JVTO_$W[0G@?3/#3Z,WP"\%:5I_A+6/A]X5\:^'_@YKND:D?$NM
M2W4GA"Z\8R:EK]MK>F:M9>+GT^WMY[72[.2XMY?6_P!IG]G3XK?'_P"%'@_X
M9:/^T3J?PWCMKK36^+5Y8?#O0]=L/C=H5KH;V.J^"/%>G1Z[X8U+0/!7BG66
M35_%.D^#?$6B7.NZ;$_@S4+^7PCJ6N:3JH!\QZ?_ ,%,]3\5?#W5_B5X#^ D
MFN:!\)/@3/\ M$?M'0ZG\5M!TR\\(> +7XA?&?X=A/@]/IOAO7M,^-.H:Z?V
M>OB]X]\$:I=WOPX\(>,/A[H_@_5K/Q#9WWQ!TRQTSZ A_;2TV3]J1/@-=?#K
M6M&^'$O[,?Q&_:4T_P#: US7M&M/#/B71?AOXE^"NDZU;>$_"EG_ &AX@U#P
MU#I'QHTS59_'&LR>'[2:_P!'U'1=!T?75M[_ %2PX;Q#^P5J7BOPZ=&O_CAJ
M7A>7QW\#],_9G_:"A^&?PM^'_@KPO\5?@;X<U/QW)X0\+>&_"<Z>(K?X/:QX
M4\,?$CQIX%T;Q)X/U&\:W\,^)M4$>E1:O8^$=4\*7_$W[%WC_P 0?M2^%OCY
M%\>-)T_X?^$_A9XM^ =C\"Q\#?"]UH=S\$/B)KOPI\0^._!MYXR/BV#77U/4
M[SX2:%9Z-XABT^*+0-)O]4LUT/49I(+R( O?LD?MNQ_M4>)KZPT_PS\.-'\/
MWWPX\/\ Q6\-#PY\=_"_COXDZ-X8\6W%@_A?3?B_\+K?0=!U3P)XBUO1-1MM
M8BE\*:M\2O!NEZC;>(/!&O>+M+\7:"EEK'NOQT^)WQ;^'Z6 ^%_PD\-^.[>+
MP[XM\7>+O%WQ%^+-A\'?ASX/T;PC#IMP=,O_ !+_ ,(IX]U>7Q/XFBO+V;1$
M?PM:^#]*TO0=?UGQAXPT"*UTJQUSYA\!?L$>(OA)HNDQ_#S]H#Q,GB3X,?LX
M^)OV7/V1-3UKP%\-S9_ ?X9>([GX=7(_MVSL- BB^,'B#3E^$GPVL(=4\7Q6
MU@^D^%=JZ%'K_B'Q/XBU?T[]K[]EWXB?M.)X"T70_CJGP\^'GAR\U74_'7PI
MUGX4>'/B=X ^,M^[::_A:#XD:=J?B'PQJ6L>%_"4UK?Z@G@1]5D\%^+-4O;2
MX\;Z)XAM-$TVP0 \'_X>8V&L>#=1^,7A#X17MU\$OAK\(OV<?C)^T%K_ (L\
M:6OA7XA?#+P_^T;X6TKX@V.E:+\/K;P[X@L/%NO_  M^&VN:/X]^*%GJWC+P
M7"FCZE;:;X%N/&'B!;G38/6KO]MNYL/CW^T9\&-3^"GBW0-.^ ?[-$G[1=CX
MS\2:]H>F2?$VQM/&/Q,\'7^G^&_"]L-1OM$\-"\^&]S)HGC+Q-?:?<>)4U"2
M\L?"T&@V=AK>N9WC?]A"+XBZAKT_B?XO:_#H_P 9O"GPL\-_M8^%?#O@[PKH
M_A_X^3?">%;?3=1LTN3JVJ?"X>+])"^"?']EX=U/5TUOX=VFE>'M*N/#^KZ<
MOBF6.7]CGXNW/[6OCC]IN3]J&[L+#QO\+1\$)_ 6A?!CP;IE[H7PQTWQ+X^\
M8^%HM \?76OZKJ-OXW\/^)/']]?_ /"6W^@:C8:FNFZ=#=^%5(N)9@#L/V-_
MVIM8_:6TOQ5=>)'^ =AJNAV/@[5;;P_\&OBWXY^)FI6VE>++'4KNVU7Q#%XZ
M^#/P<G@T/4'L6MO"'BKPS;>*?"?C"2P\0'2];#:-+'+J^,/V]/V7OAY<>.HO
M'WC[6/!-O\/?"GQ&\<:WJWBSX:?%+P[H.I^$_A#>167Q1UOP1K^K^#+/1_B+
M9^ I+B&X\2/X$O?$!L].=]5B%QI=O<WL._\ "']G77?!/Q$USXO_ !.^+OB'
MXS?$W4? NB?"S3-?U'PKX/\  >F:+\/O#_B#4_%%O91^'/!5C::??>(];US4
MVO\ Q1X@N)([*Y:QTZU\-^'?">GI>V5]^?WQ&_X(P_#?XES>,[O7OC1XR;6?
M$GAK]J7P=:^-W\!?#6[^*%WX=_:IT37=-\1P?$;XG7.DGQE\5KSP!<ZX(_AI
M+XDU*UTWP_X;TO3/#D^CWAMDU< 'W5<_MS_LV0/-8+XQ\13^)H?&VM?#^;P+
M!\*_BY<?$2TU_P />#]!^(>KWNI?#RU\"7'CC2_!UAX \5^%?&]Q\0+[P_!X
M(7PKXH\.:M'KTD>NZ5%=YGPJ_:>^('QQ_9"_9R_:0^%OP2&O^+OVC/A[\(O'
M6F_#Z[^(.GZ3X6\!6GQ/\,V7BO4-3\9_$2?09M0E\*>#=-GG2YU'PSX"U[Q-
MXAOSI6GZ+X1:;56ET_@M<_8'MV_:5^(W[5?@3XT>,? 'Q6^(OB.RFN[ZR\+^
M#?$.FZ9X!O/A)\)/A5XS\ 6NG^(;.[@N(?$#_!7P)X[TKQ)<+_:WACQAI86.
M+6/#-YJOA[4M>]_8S\7>'OV*OA#^QQ\%/VC/''PBMOA1X'^&/PQ/Q5L/#.A:
MWXV\4_#[X>:%;^'[[P_?%+_0&\.W?C?3K&TL_$'B?P;JN@^*=-M9-1/A35]
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MH7A-='=K[3_"6H_$[2[#5O&S>(HK<>--&\5^";?1);OPSJFHQ_:M?GK\+_\
M@FO\ /@O^TSX#_:1^&-Y\2_#=S\/_A!\3?A/I'P[N_BY\7O%O@;R_B?XT\(^
M,=5UX:9XU^(?B*VM?LL_AJ^CB\+VUDOA6[U37G\676F-XIT+P[JFG?H50 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 45^/W_  4"^*OQ+\&?MX_\$=?AWX0\?^+_  MX&^,O[2/[0WAKXK>%
M?#WB#4='T7XA:#X<_9:\:^+-!TCQ;9Z?/ -9T[2/$EA9ZW86ETS00:E;Q700
MRQHR_K"GAS3"B$K?9*J?^0QK7< ]]1)_,D^] '045@_\(WI?I??^#C6O_EC1
M_P (WI?I??\ @XUK_P"6- &]16#_ ,(WI?I??^#C6O\ Y8T?\(WI?I??^#C6
MO_EC0!O45@_\(WI?I??^#C6O_EC1_P (WI?I??\ @XUK_P"6- &]16#_ ,(W
MI?I??^#C6O\ Y8T?\(WI?I??^#C6O_EC0!O45@_\(WI?I??^#C6O_EC1_P (
MWI?I??\ @XUK_P"6- &]16#_ ,(WI?I??^#C6O\ Y8T?\(WI?I??^#C6O_EC
M0!O45@_\(WI?I??^#C6O_EC1_P (WI?I??\ @XUK_P"6- &]16#_ ,(WI?I?
M?^#C6O\ Y8T?\(WI?I??^#C6O_EC0!O45@_\(WI?I??^#C6O_EC1_P (WI?I
M??\ @XUK_P"6- &]17#^([+2] T/5-:^S7UU_9MI)=?9O[<UF'SO+ _=^;]M
MD\O=G[WEOC^Z:\._X6SI0_YE6_\ _"PUG_XFO S?BC(\BK4L/FF-^K5JU+VU
M.'U?%UN:FYRI\W-AZ%6*]Z,E:4E+2]K-,#ZIHKY6'Q9TLD*OA34&9CA57Q?K
M)9C@G"@+DG )P.< TJ_%C3)#B/PGJ,AVLY">+M:<A$!9W(53A$4%G8_*J@EB
M ,UY/_$0^$/^AM_Y8YEY?]0?G^'K8/JBBOEG_A:VG>7YW_"(ZGY)<QB;_A+=
M;\HR 9,?F[-GF <E-VX#G&.:1_BMIL>T2>$=2C+HLB"3Q;K:;XV^[(FY!OC;
M!VNN4;!P3BC_ (B)P@_^9M_Y8YEY7_Y@^E_\^M@^IZ*^6?\ A:VG>6)O^$1U
M/R2YC$W_  ENM^49 ,F,2[-GF <E-V_'.,<TS_A;6E?]"K?_ /A8:S_\31_Q
M$/A#_H;?^6.9>7_4'YO[O6P?5-%>+> ?$&E^.)]3@&CW^F_V=#:R[SXEUF[\
M[[2\Z;=OGV^S9Y.<Y?=NQ@8R?6K'3;73_--L)QYNS?YUY>W?W-VW;]LN;CR_
MO'/E[-W&[=A<?3Y;F6"S?!TL?E];V^%K.HJ=7V=6ES.E4E2J+DK4Z=1<M2$H
MWE!7M=733 OT445W %%%% !1110 4444 %%%% 'X@?\ !2?_ )22?\$*?^SK
M?VH/_6.?B#7[>1_ZN/\ W%_]!%?B'_P4G_Y22?\ !"G_ +.M_:@_]8Y^(-?M
MY'_JX_\ <7_T$4 /HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@#B_B+_P B-XG_ .P3<?R6OAQNI^I_G7W'\1?^1&\3_P#8)N/Y+7PXW4_4
M_P Z_!/%G_D<Y;_V+/\ W:Q ^B]7^43\P?\ @K?JESIO[(7BCR?B=IOP[MKF
M758]0TO7?%/C;X=:#\2X8_#FI-:>"KWXH^!D2]\$ZA9:D]GXTT"TU>\M?#_C
MB_\ #$GA?4(]09X+9?E']IK]I;XBZY\$?@-K>B^ _P!M'P?\/?"_Q3_9"U^V
M\96>E^+?B)??%CQ?KG[:W@SP!?\ AGQ!\:_#=QHDGCOP%I_P_P!.UD>$Y=<L
M=/N?VC;[XI?#6]U72[FVTZ=-5_=77M!T/Q5H>K>&?$^C:7XC\-Z]9MI^N>']
M=L+;5=$UFP:6*=K'5=+O8YK+4+,SP03FVNX983-##+LWQ(RZ-Y!!J+.VH00:
M@TD\=U(=0@AOM]S#,MS#<N+M)@UQ!<I'<V\Y!FM[F..XA>.:..1?AL)FU'#8
M;"49X)5YX7%U,3SRK*,7&HJ<90C3C2<>><8N#JUE6G!*+@U:DJ)?^NO]/;3Y
MGX3:C\2_BG?_ +1WB/6?"_Q$MO#VI_$O]J;]H+X7?#_5?$'Q3\8WO[2'PLL[
M+X7_ !&\.>!O"?Q2_8EDO[CX?:%^RAX!^(GA>;Q\?']CI\OQ&'PYL/ OQ%U7
MPH-7\7:MXF;TC]D/XT6_AOXHWE]J7C;1?"GP T7]CCX9ZY\=_&?C']K#3/V@
M/!7_  U!X@^+7AWP=X5^(Y^)\WBOQ-X5\&ZA\:=(U;Q>L7ARYUOPCXI\46MA
MX6UCQ7\*_!-\/#EKJ/[&+86":D^LII^GIK,EI'I\FM)86::U)I\+B2'3Y-86
M :G)I\,BK)#8/=M9Q2*KQP*RJ17&BZ*+2ZL!HNBK87UY+J-]8+HVEK87^HSS
M17,^HW]@MF+.^U&>Y@@NI]0NX)KR:Y@@N)9WG@BD32MG5"M0E0E@%%2P]'#<
MT:[NHTIR?-;V:C.482Y:*G%PHU5[:G"#E.$W=-6LTUUT\KZ:=M.KZO1'XP^#
M?B9XR7]L[1=9OO$QOM'\>_MO?%7X76.EW/QE\7#]IWPWX.T3POXS\.:;\+?B
M!^Q_-JA^'7A']EO1?%?A#5_$FG?%:RME^(5IX!/P[^*.K^&[75/%NL>*Q^UZ
MG*J>>5!Y&#R.X['U'8U5%A8#49=8&GZ>-8GM$T^?61860UJ?3XW$D>G3ZP(/
M[3FTZ.0"2.PENWLXW =(%8 BW7GYAC88V6'E"@J'L,/##M*?/SJ$IN+^""CR
MQDH6BE'W;QC"_*DW>WHE]R_K^M#Z!^ 7_']XF_Z]-,_]'7M?2]?-'P"_X_O$
MW_7IIG_HZ]KZ7K^B/#G_ ))'+?\ KYC_ /U/Q(@HHHK[@ HHHH **** "BBB
M@ HKR>]^//P/TWQ(W@W4?C'\*K#Q>EW]@;PK>_$3P?:^(UO?,6'[(VB3ZS'J
M2W1E=8A;-;+.9"$$98@5ZQ0!^'7_  4N69_^"CW_  0L6WE2"8_M6_M/[)7A
M^T*N/V._B 6S%YL._<H*_P"M7:2'&[;M/[,7<^H:9;Q3ZEXIT73X'*1)->Z7
M':Q/(R,ZQJTNM*AD*([!%).U6(X4FOQM_P""D_\ RDD_X(4_]G6_M0?^L<_$
M&OU2^.'_ "*&E_\ 8;M/_3?J%>1GV8SRC*,?F5.G"M/!T'5C2FW&$WS1C:3C
MJE[U] 6K2[G7?\)':_\ 10/"7_?JS_\ E]1_PD=K_P!% \)?]^K/_P"7U?$U
M?!'[4W[8OB/X!?&O]GGX1>'_  /X&U7_ (7!XEMK*^USXH_$R/X1Z/K5I=Z!
M\4[E/"'PR\4:IH&I^$+OXCVFL>!-#_M"V\9:SHNGQQ^-O!&AVEG>7'C)O$'A
M3\IPOBAG.-J^PP^38"=3DJ5+2Q52FN2E!SFW.I*,%:,6]9+ST38'[H?\)':_
M]% \)?\ ?JS_ /E]1_PD=K_T4#PE_P!^K/\ ^7U?BYKG[3OB[PU^TEX6^ ^I
M^!/A_JT_CC5O&]KX?\'^#?BH^O?M":=X/\)>!?%/C+2_C)XO^'EUX;TSP;HO
MPW\9:AX73P98Z;%XYE\4>&O$'BSP<^LO??;=<T[P]\R^!?\ @I;=_$/X:^+/
M&WA[P[\$;O5=$\+?!O7[_3])^)7Q#\2:9\$_$7Q>^,?AKX31?"C]IF*R^&>G
M^*="^)?ALZMXCURXL/AGHGBB#7)/ /BK1M/M+8?\(YJWB7KI^(/$=6$9T\AP
M$X2CAI*4<8Y1Y<96G0P[;C4=E4JTJL$_YHVZQYG;S7W^G;M?7T9_1[_PD=K_
M -% \)?]^K/_ .7U'_"1VO\ T4#PE_WZL_\ Y?5^47PF^.%IXK^$/BCXG^.?
M$'PY"^ 9_'DGQ ?X;6_Q-@T[P=:> -'_ .$CUW3-?\-?%[PQX*^)>@^,=)\/
M*=6U3PWXB\,Z3</:7FCW>F"YL-4M+R7S+]EO]K"[_:,U?4;6;2OA7I%E/\-?
M!WQ6T/3/!_Q3U'Q7X\T+0?&UXT6E:)\0?#&L>#/#%E>7L5E);F^\??"O6?&W
MPOL_%MKXA^',^MIX@T2TOM?P_P"(EYZH8JI_8>#Y,&XQQ$G7K1]G*;2BK3<9
M2;U=HIM)J^KBI#6_6W5;=/\ -'[5?\)':_\ 10/"7_?JS_\ E]6M92ZEJ4/V
MG3O$^C7]OO:/S[/2TN8?,3&^/S(M:=-Z9&Y<Y7(R!FOA"OKKX)?\B6W_ &&M
M2_\ :%>UPEQ[C.(LV_LZO@,-AX?5:V(]I2JU93YJ4Z,5&T]+/VC;ZZ+YKI?T
M_&_^1Z!]D\0_]!JQ_P#!&W_RXJ!QK$;%)/$6E(ZXRKZ2JL,@$95M9!&001D=
M"#72U\3_ !4 /C[Q#D#_ %MCV'_0+L:^EXNXDEPQE]#'1P:QKK8VGA/9.N\.
MHJ=&O6<^=4:UVO8<O+RJ_-?F5K,/K'=JO_0R:1_X*D_^75&[5?\ H9-(_P#!
M4G_RZKX/2,.Z( ,NZ(/E9N78*/E17=N3]U$=VZ(C,0I^#/@A^V]+\>],^./B
M+P)^SY\2=:\,?"_7=)TCP5K&C>*OA-?K\2'U?PE\-O$\6F:XLOC>UB^#OBRQ
MMOB&-7U[0?'LJ0^&?"'AWQ+>Z[J-IXT\+^)/ 6G_  M#Q2QN(A5J4N'J4J=!
MT55G+-X4XP=:<:=--U<'!-SGS:1ORQ3G*T(RE$/WCW:K_P!#)I'_ (*D_P#E
MU1NU7_H9-(_\%2?_ "ZK\&+K]NW0;/1[%+KX936GC&]^/6K?L[BWO_BY\-;'
MX*1^,M(^%=I\8FUH?M03,?AE<>$]1\*WL.A:/)#IW_"47WQ/AU3X82^%K/Q'
MHFJM;:^N_MI1:-\+E^.2? /XIW/P:T#P!HGQ(^)?CNZU?P/HT?A'P_J_B74_
M#-U'X(T>]U.2?XZ7GA[^RV\3:M+X O;71]2\'ZQX2U+P=JWBK6_%NC^&WZ?^
M(CYLN1OAFFE4J1I0;SF@E4J2:C&,)/"I3]I)2C2<6U5DU&DYRLAV?]>EVO57
MU['[H;M5_P"ADTC_ ,%2?_+JC=JO_0R:1_X*D_\ EU7Y+?'SX\>'_@-%X2LM
M2L-.UGQ3X\UWQ#HGAC1]7\;^%?ACX;BMO!N@W/B?QMXL\9?$7QS)#X<\$>"_
M"6C0VAU/6+^WO[^[UG7?#7AS1]&U#5M<AC@]%^'GBU_'W@3PEXVE\-ZIX1D\
M5:#8ZXWAK6]0\,ZQJ6CB]5F6VFUKP9K7B/PCKEO(BK>:7KWAG7M5T/7='NM/
MUC3KLV]\L47(_%7&1H4\3+AZFJ%63C3F\UC>;BVI.,/J7M'!2A4BZG)[/G3A
MS<R:2L][:=_N_P U]Z/TE!U8D >)-())P -*0DD] !_;7)-6/LGB'_H-6/\
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MF>"M1BN+P_"4V[Z,FE^#M+DL[5;".2*]>^E>[F$R10G_ !"7-O\ H:9=_P"
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MJ/\ P68_\33T'_YS5'_#C_2O^DJ/_!9C_P 33T'_ .<U7YI_Q"7-O^AIEO\
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M +Z'^-?*O_#C_2O^DJ/_  68_P#$T]!_^<U1_P ./]*_Z2H_\%F/_$T]!_\
MG-4?\0ES;_H:9;_X#BO_ )5_5GY7#]*_@$Z?;O$WS+_QZ:9_$/\ GM>^]?3
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)%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>avonex.jpg
<TEXT>
begin 644 avonex.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" !5 .(# 2(  A$! Q$!_\0
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M0JJ.PJ6N&M5=27,Q-B8HI:*R$(.E+2#I6=X@U-='T.ZO6(!B0E<]V[4TFW9
M>1_$75QJGBF1(VS%:KY2_7O^M=I\*](^QZ%)?2+B2[;Y2>NT<#^M>1R2--*\
MDARSDL3[FNXL/BE=:?8P6D.FP>7"@1?G/05ZM:E+V2IP*:T'?%;1_LFM0ZC&
MN$NUVO\ [Z_XC'Y5I?"75RR7>ER'A?WT?/X$?RKG/$OCN;Q+IHM+BQACVN'5
MU8DJ:RO"VK'1/$5I>9(C#[9,=U/!H]E*5#DEN@MH=/\ $#0_[,UK[5$I\B[R
MWT?N/ZURE>U>*=(37_#\D<?,@'FPD>H''YUXL058AA@@X(-?/U(\LC[+*,5[
M>@HO>.G^0E>K^ M&&CZ$]_<KMFN!YAS_  H.G^-<%X4T0Z[KD4+*3!&=\Q_V
M1V_&O8=2B+:1=11@ F!U4#_=-71C=W9Q9YB[16'CUU?Z'@_B76Y=?UN>[D8E
M-VV)?[JCI79>%OADEY91WFM/(OF@,D"'! ]2:\[B(BF0N.$<;A]#7T=97$=U
M903PL&CD0,I'3&*]O%3E2BHPT/FGH<%KGPJM&LWDT:62.X09$<C95_;/8UYM
M97ESHVI)<0EHKBW?D>XZ@U]&$A023@#J:^>?$-Q%=>(=1G@QY3W#LI'0C-+"
M595+QEJ"9[#K]^FJ?#N[O8QA9[0N!Z9%>&UZ]'&T7P></U-F3^!KS?PM&LOB
M?3XY%#(TP!4C@BJPUH1G;HP1N_#_ ,8'0[P6%ZY^P3MP3_RR8]_IZUVOQ.(;
MP;(00094P1]:X'QUX2;P]J'GVZDV%PQ*'^X?[I_I4<OBR2]\%OHUXS/+$Z&%
MSW4=C]*3IJ<HU8?,+=23X;?\CM:_[DG_ *#74_%__CPT[_KJW\JY;X;?\CK:
M_P"Y)_Z#74?%_P#X\-._ZZM_*BI_O,?Z[AU.5\":)IFMW]S%JS[4CC#)^\V9
M.:]'T;P=X>TW4DNM/;=<1CY?WV[]*\<T[2;[5I7CT^WDG=!E@G85VW@'PUJ^
MF>*([B]LI8H1&P+-TS3Q$=WSV\@9ZM7+_$)M/'A2X&H]R/) ^]YG;%=++*D,
M3RRL%1 69CT %>&>-/$[^)-7+(2+. E85]?5C[FN/#4G.=^PDCG>WO7L_P ,
MO[/_ .$87[%_Q\;C]IS][=_ACI7GZ^![YO"1UG#;L[A#CDQ_WO\ /:JWA#Q'
M)X<UI)B2;63Y)T'<>OU%=]9*M!J+V*>I[U14<,T=Q"DL+!XW 96'0BI*\<@*
M*** $'2O./BUJVV"TTN-N7/G2 >@X'ZYKT?M7.:OX$TK6]0>\O?/:5@!Q)@
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M&JS<?$;48,7;>'[A=-)XF?()'KTQ6TJ4IPAR]@/0**Q7\5Z:GAO^V_,)M2.
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>avonexchart.jpg
<TEXT>
begin 644 avonexchart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $R 3T# 2(  A$! Q$!_\0
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MI=]\I^&_^"._PC\$^$='\*>"_%7A_P /6O@ZX\"Z7X4BM/V=OV?H=*\4> O
M&G>(-)T;P=^T/I>F^#-*D_:0C-OKUIJ[WWCS4;2S@\;^"O 'Q$LM!M_&VA:C
MK6N^A?!W_@EK\-_@AX?^)7AOP1\2O%EGIWQ"^#?B#X-)'+X)^$EY8:!H6O\
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MC:>'%M?BUXATX?"SX<Z7#JWB^VALI=#\(6T;Z"?$6N>*?$VN>G?M=_LO>/\
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M'[=?[.$+36">)_%L_BF#QOKWP^F\ 1?"3XOR?$BUU[PUX2T/Q]J^H:A\.XO
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M/X>\!Z!X\^*/BC5+^RL[#X;>#/AOI/B[P_XVT*^OO$/B"_FBG\-:=\//%OQ
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MP+X7U+QE\1K^&;2;4MK'BO6?"O\ AYW\3?\ HF?@/_P;>(_\:/\ AYW\3?\
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M_!"IY72-!^U=^T\"\C*B@O\ L=_$!%!9B "S,JJ,Y9B%&20#^U<>MZ/Y:?\
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MM,CUK61J'X">:_\ >;_OM_\ XJCS7_O-_P!]O_\ %4?\2^S_ .BLA_X8W_\
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M ,I)/^"%/_9UO[4'_K'/Q!KZE_X*6_\ )#?!O_93-'_]1?Q57RM_P4L61O\
M@I#_ ,$*1%((G_X:O_:<(=H_,&U?V/?'[2*4WIGS(PT>X,"F[>N2H!^EO^"D
M%OJ</P1\'M>ZDEY&?B3I(6-;".U*N?#/B<A]Z7$I("AEV[0#NR3\HS]OX;_\
MESPU_P!C&/\ Z:JGQWB#_P D9Q#_ -@$O_3M(_%2MS2?#'B/7K76+[1-"U?5
M[/P_8KJ6N76FZ==7L&E6#3Q6RW5]);Q2"",RS)@-\_EB6XV?9K:YFAPZ^N?V
M>O%'A_3?!_C?2O$WC'2O#^D1J^K3+;ZWXL\)^.M'>;6O 5K/KWA/5-$@OM,\
M13366GM'!H%WIUU?P:GIEM:@VNA>(]:ND_M3.<?7R[ O%8?#2Q515\-3]C"%
M2<W"K7A3FXPIJ\I*,GRJ4H1YFM9RY:53^0LJP5''XQ8>OB(X6FZ->I[6<Z<(
MJ5*E*<%*51V47)+F<8SERIZ0CS5:?S')X6\3PZ'#XGE\.:_%X:N)%AM_$,FC
M:DFASRO*\*)#JS6PL)"\T<D$92X*R3H\,;-*C(,V[L+ZPBL9[ZRN[*#5+%=4
MTR>[MIK:'4=,>:>W34;&2=(TN[!Y[6YA2]MVDMGEMYT64M$X7Z[U[Q9X%N_A
M[JUC9ZOX6FNH_A+X)\%>'?%C^([U?B'KUUHNK:!?GP3XH^&DEH_AK0/#]G)#
M<VMWXAA@AN8-+\/Z;??\)1K\NK7EO<4/%>N>'YM7^$7BWXB^+]#\<R^%_ U[
MI6NP>&->\,^-=1;QI!XM\=:YX9BU'08]6T>WO/!^GQ:CH5Q?P6%U9Z=]B@@\
M.6R002211>51S_&2LZV6S@I8K%T8TK58XFI"C@EBJ#HT>2?-[6J_JLW7EAJU
M.LX4ZN#I5)RA3]&MDN%CI2S"G.V&PM5U;TY8>$ZN,^K5E5J\\'%4Z?\ M,%1
MCB*52CSSI8JK""G4^6-4TG5=$NOL.M:9J&D7OV:TO?L>J65SI]U]CU"UCO;"
M[-O=Q0S"VO;*:&[M)B@CN+:6.>)GB=6-S6?#/B7PX+(^(?#NNZ -3@-UIQUO
M1]1TH7]L-A:>R-_;6_VF)1+$7:'?L$L1?:)(]WN'Q0US0M=\;>'_ !SX=\;6
M?B.[\->!O@]J.KS^,;>"RO=<\1Z-:Z!8WEE;Z=8ZAKAUW48+J-]1\8:4)[0:
M;;1:I;64NI);Q2S;7QB\4>#)_!.KZ+I&H66KZ]XL^,=[\2YI+'QW<?$"#3+6
MXT'5++4Y8=2E\/\ AX:-::YJ.JVBV&B7]M/XJ>ST@7'BB6"2UTV$[TLXQM26
M4+^SYMXV$5C4H5:;PM9TZ,YIQQ"HU(4Z<:KJJ4Z4W4A'DM2FXN6-3*\)!9J_
MKL$L')O".4Z4UBJ7/5A!J5!U:<ZE25/V3C"I!4YOGO4BI*/RS7[P_P#!.+_D
MW9O^R@^,?_0M+K\'J_<[_@G?;ZG-^ST6L]22SC'Q \8 QM81W1+9TK+>8]Q$
M0"<G&WC/7 %?!>-__)%+_L<8#_TWBC[;P=_Y+'_ND8[_ -/X(_0ENA^A_E7\
MZ7[;?_)T/Q4_Z_/#7_J&>'*_H.-CKV#_ ,3V+H?^8/!_\F5_/7^VDD\?[3?Q
M12XF%Q,+SPYOF6(0!\^#O#Q7$2NX3:I5?O'.W<<$D#\M\!O^2MS/_LG<3_ZL
M\J/TKQL_Y)G+?^Q[0_\ 5?F)\M@$\*"S-\J*HW,SGA553@,Q8@*I(#$@$@&O
MMS6/AE\)'C^'6IZ9I6FQ^%&L-:M=2UN\\<ZKH-WJ'B-O^%D#P9X8^*6F:]IF
MF7W@RY\1^(/"T.D7OBS3I+'1],?3=?T!)X[6STK68OB/_/\ G_$<CM7I^H?&
M?XI:H?"[WWC?79Y?!R2C0IY+D22Q33'4$EO;\S)*FLWTEGJ=YI<MWJ\=[+-I
M$KZ;,9+>6X$_]*YU@,QQL\%+ 8J6%]B\8J[^MXG#1DJ^%G1I2Y,-3<JM6G4:
ME1G.HH8:3E65'$34::_GO*<;@,''%K'858GVRPCH_P"RX?$2@Z&)A5J1Y\1.
M*ITZM-.-6G"$I8E*-%U</!RF_9-3\&?"_P ,:?I'BGQ3#X,T*;Q)\.H]7;P\
M^I^-O&_A+2/$^G_$F]\+:H-(O/!FOR:K?R7WA[3);N#3;GQ;>:78:HFL0P:O
M>_84MH.3G\$>$M/M/CE8:SIB-XM\+^$;/QAX:NM"U:^@\#Z7H>I:_P##L:/>
MZ39ZK+-XEU2;6M%\7RRB+Q/<QC1;5HXIK:\U9WET_P WC^*7Q!BU:ZUM/%%Y
M]NO=*LM"N4>TTB;2I=$TV59]-T<^'9M-D\-II>F7"BZTVQBTA+;3[LO>6<<-
MU++-)8T[XN?$72WUR6U\2M)/XEN;BZ\0W6I:+X:UR\UJ6ZFL[B==2O=<T74K
MRZMFGT^QG6PDG.GPRV=M);VL30H1P4\JSRFFWC_;2=2E5<)YEC(TH^SQF$KK
M#T7]2JUXT*>'HUL+4G6JXBICU.-3$*DI5Z=;LJ9GDU1I+ NE&-.K2C*.7X.=
M63J83$47B*R>,IT9UIXBI1Q,(T:="G@G3E"@ZKC0G2TOA'\/YO'&M7]]+HNK
M^(?#GA%=/U#Q!I6@1W,^J:O)J&H1Z?HWARU-BDMU9G6;QG.I:HB :+H-EJVI
METN8;))L?XL^&$\&?$[X@>%H--N=(L=$\8>(K#2K"[6[$L.BPZM=KHK*]\SW
M<\$^EBUFM;J>262[MWCN#-+YGF-RU]X@UG4FT=[V_>9] L+?2]'80VMN;"PM
M;ZZU*WMH_LMO )5BOKVZN%DN?/G)E\MI6ACACCK:KJFH:YJFI:UJUW+?ZKJ]
M_>:IJ=]/L\Z\U"_N)+J\NI?+2.,27%Q+)*XCC2,,Y"(JX4>S2PV/68RQ=;%0
M>$EAIT(8*'M6J4U.A*G5<Y2C3K5)<N)<ZGU>C.$:M.@G4C2=6IY53$8+ZA'"
MTL-4^LQQ$:TL9/V2=2#A5C.DH1BZE*"O04(>WJPE*G4KM4Y5?90T?"7_ "-O
MA/\ [&KPS_Z?=/K^K<=/Q;^9K^4?PH"?%?A4*=K'Q1X;"MC=M8ZY8!6VY&[:
M<'!(!QC-?U-FRUTLQ77(E4NY5?[(@.T%C@9-YDX'&3R>IK^>_I ?[SPO_P!>
MLW_]*RP_=/ W^%Q)_P!?,K_])QYXK^UI_P FV_&?_L0]9_\ 08J_FQ"EGV@J
M"S!1N<1KEFVC=(Q C7)&Z0D"-<N2 N1_1M^U7::Q'^SE\96N=7CN(1X$U@O$
M-,B@+ >22!(ETY4E05SM.-V<9 K^<ANI^I_G7T/@)_R3N<?]CJ7_ *@X(\+Q
MM_Y*#*O^Q0O_ %,Q.FW^>_R/N3XV>'8['PM\-?$-G\---BM-,\W2[;X;ZKX-
MGT;Q)+-/>_$.\M=+T[Q%X)U"5OB+X/TX:=;ZAK$MLW]IW$7]A:]/J4,'C6_
M\6^,?A,VOQS\=6TWAV\\/^%+?Q;:7NHG3M N=(TK1/"=S>Z%8:EJEA##9PV=
MCHUG-J)MK>XMU%C;WDUO9K)]H=$?Q8:WK(;2W35]4BDT.T?3]%EAU"[@FTBQ
MDN+J[DL],F@FCEL+9[F]O)WAM7B1I+F<L")"*G?Q'X@FCO(KC6]6O$O[!=+N
M_MVHWE^TNFK?VFI_8!)>S7$D5HVH6-I=R00M''+- C2*W(/Z?EN28[+I4?\
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M7&=NW:<9W<?R-XQ?\E_G/_7K*O\ U48 _J7PH_Y(;*?^OV9_^K/%E^BBBOS
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MK_L8Q_\ 354^.\0?^2,XA_[ )?\ IVD?BK1_GZ<$9'H<$C([$CH357[=8_\
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M ."/Q)_\J*/^&H/@5_T/D/\ X(_$G_RHH_L[,/\ H!QG_A-7_P#D _M'+_\
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M%8(8 @CR[?@@@@_B*_@/>&'>W[F'[S?\LH_4_P"S7]^'_!3,@_L#?M88(/\
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ME=[OVA/#*;+VY6>-=WP[^(QW*JPQX<;,*<G"LXP=V1VO_!2?_E))_P $*?\
MLZW]J#_UCGX@USO_  <"_P#)H/PL_P"SA_"__JN?B37Z5X._\G.X,_['$/\
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M5_>1_$(4444 %%%% ':_#4;OB3\-UR5W?$;X?KN4X9=WC+0QN4\X89RIP<$
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MW_\ !NW_ ,E"_:F_[$OX1_\ J0^/Z_J@K_.+Z0G_ "=;B+SH9'_ZH,L/]!O
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M!%%EJ-Y*&8,2I:-4PC;G!VANQ_X*3_\ *23_ ((4_P#9UO[4'_K'/Q!KG?\
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M[VO&DXXG'*7L)3<[0ITI.*A&52<)UZLO986%>I"K&G^8=%>Q?LZ?#K1_B_\
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MT[4M+U2QNK.]LKN>"6+YPZ_36H_MH?%#4/B]8_&1_"OPB;7O#DES-\/]!NO
M,<OA+X:7&H7]UJFLZCX.T;2]4T)$USQ#J-]>7?B/7M>DUO4M:>9%NY"EG8BW
M^1:*_P!+,9D^5YA55?&8'#8BLL-6P?M:E.,JGU7$6]M0Y_B]G4CS0E&^M.K7
MIJU/$5HU/\Z\)FV98"G['!XW$8>E]9HXMTJ=1JF\30_@U^3X?:4VHRC*UU.G
M1J?'0HRAZ[:?%F/2Y;"_T;X9?"/2M4L/'4_B^.%/ 6G:KX6.D2^"[7P=_P (
M"_AGQ+-KPN?!<VR_\076EW^IWC+XBOO[8TN?2]2@ANX^MN_VG?B#J=K-H&L^
M'OA1KWP[;2_#NDV?P=UKX;Z;>_"718O"E[XEU/0[[0O"XOH=3TW7[?4O&GC&
M_P!0\2CQ'-K_ (BN/%>OKXGU#6K>_P#(B^=:*4\FRRJX2JX.E6G345"I6YJU
M2#A/VE.<*E24JD*E*=YT:L)1J4I2G*G*+G)MT\WS*DI*CBZM&,V^>%%JE3J*
M4%3G&I3IJ,)TZD$H5:<HN%6,8J<9*,4OIN#]KSXV1ZMJWB"\U#P=K/B&\\77
MGCWP[KNM^ O#M_J/PQ\9WWA;2_!,OB'X1E(+:S\ 7<7A+0?#FA6-I8V=WH^F
MP^&?#6I6&F6^O:%IVKP\%H?QDU70[(Z0W@+X,Z_X?G\+^%?#&J^&O%7PNT;6
M]&\0R>#;G5;G1/%^NDW%IK5QX_=M:U&WUOQ99:UIUSXEL)DT[Q#;:E90Q0)Y
M#12ADF44HRA2R["482C0BXT:,*,5'#.^&C!4E!06'FW4H<G+[&K*=6GRU)RD
MZEG.:U)1G4S#%590E6DI5:TZK<L0DL0Y.;DYO$0C&G7<F_:THPI5.:G&,%UG
MCKQQXF^)/B_7_'?C+4$U3Q-XEO8[W5+N&RLM,M<V]G:Z;86>GZ7IL%KIVE:5
MI6E6%AI&D:7I]M!9:;I=A9V5M$L4"U_8-_P0:/\ Q@O)U_Y+?\4^Q/\ %X=]
M!7\9M?V1?\$)M(TO4/V&GDOM/M+J1?C=\5 KSP)(X!/AL8W,"<850!G QP!S
M7X;])*E3H>&%&A0IPI4:.?9-2I4J<5"G2I4\-CH4Z=.$4HPA"$8PA"*48Q22
M222/V?Z/-6I6\2*U:M4G5K5LCS6K5JU)2G4JU:F*P$ZE2I.3<ISG-N4YR;E*
M3;;;;9^VC$8/7H>Q]/I7\)7_  5U_P"4BG[2/_83^'W_ *J;P'7]S+>&/#V#
M_P 2;3NA_P"76+T_W:_A@_X*W6\%K_P4/_:/@MH8X(4U3P 4BB0)&N_X4^!9
M'VHH"KN=V8@ #)-?B?T6O^2\SK_LD<;_ .KG(C]D^DQ_R1&3_P#9583_ -5&
M='R;\-_VB/C1\(O#/B[P?\.OB!KGA?P_XUM6@U6QL9D)L+N6[T:YN==\,W$J
M/<>%?$UW#H.GZ7=^(=!DL=3N-*C%O).9[;3+O3SQ9^T)\6/'7A32?!7B[7="
MUSP]H'A;1/!&A1W'PZ^&-MK&A^$O#LL4^D:#HOBJQ\%VOBO2+*VFB\^5M/UN
M"XOKF>\NM2FO;G4+^6Z\6HK^X7D^4O$RQCRO+WBY5HXEXIX/#O$O$0A&G"O[
M=T_:JM"G",(U%)3C&*2:/XP6;9HL/'"+,L>L+&C+#K#+&8A8=4)S=2='V*J*
MFZ4IRE*5-Q<)2;;3N>\#]I?XS6>I>/;_ ,/^+Y/"L'Q$\3Z]XOUC2]!TGP_#
M9:1KWB73KC0]7U+P9)<Z1<WO@/4[WPY</X:O=9\$W7AW5]0T()I]Y>2P10I%
MC7'QW^)MS\-8_A#+J?AK_A7D*#R=!B^&OPNMYX;H:=9Z.VKQ>(K;P7#XJB\1
M2Z186>ES^)TUQ?$5S86\=K<ZI+"&1O(**4<GRF+IM97E_-2G0J0F\'AW4C5P
MT/9X>K[1TW/VM"G>%*HY<].+<822;0Y9MFLE.+S+'\M2%:G."QF(4)4\1-5*
M])P511]E6FE.K32Y*DDG.+:/0E^*WQ 7Q79>.&\0F?Q3IWA2T\#6.J7FD>']
M06W\*6'@<_#:QT9=,O\ 2;G1WAL_!)&A6MQ+I\E_;JL>I0W::S%'J2;FI?'O
MXP:QX)/P\U+QUJ-UX5ET/0O"][;MIWAV/6M7\*^%WM9/#7A37_&<&BP^./$7
MA?P^]AIQTCP[KWB34M'LAINEI'9^5I>G):^0T5K++<NG*C.>7X&<\,J"PTI8
M3#REAUAI2GAE0E*FW16'G*4J'LW'V4I2E3Y7)MYQS',(QK0CC\;&&(=9XB,<
M57C&N\1&,,0ZT542JNO",8UO:*7M8QC&IS**2[;X9_\ )2_AK_V4CX??^IGH
M=?Z3ZD8/7[S]C_?;VK_-?^&JAOB5\-E8 JWQ&^'ZLIY#*WC+0U92.X()!'<$
MBO\ 2&_X1K0'9W?1].9WDD=F-K%DLTC%B<+CDDFOX_\ I7_[WP1_UXX@_P#2
M\E/ZO^B]_NW&7_7_ "/_ --YH?&7_!3,Y_8&_:PZ_P#)&/%?8C_EG;^HK^!7
M>\<PDC=HY(Y1)'(C%'CDCD#QR(PY5XW571ARKJ&'(K^]7_@I7H6C6?[!7[5T
M]KI=C!,OP8\5;98K>-74J+5P58+E2&16!!!R.M?P4/\ ?;_>;^9KZSZ+&O"/
M$5_^BCEIW7]F9?\ \'0^6^DSIQ9D+6_^KZ^3_M'&'TWXV_:Q^(WQ$TGP?H'B
M[PY\*]7T#PTINM=\/M\.]$TG0OB=XACO_'E]9>*/B38^%!X8N-<U/2V^(WBB
M32[2SO\ 3-'LM7U;5_$D6G_VWK^LW-US?Q ^/FJ?%#Q#X^\9>+_A_P#"T>,?
M'N@IIMYKWAKPBVB26NN_\)/X8UV7QPEO?:IKJ+XM&E^&W\*07]@VFVZZ!J^H
MV5S:7,4\R3>#45_15#(<HPTJ<\-@*&&E1=1T_JZE14?;5Z6)K)1IRC'EJUJ-
M&52+3C.-&C3DG3HTH0_ JV>9MB(U(8C'5L0JJIJI[=QK.7L:$\/1;E4C*7-2
MHU:T:<TU*$JU:I%JI5J3E])M^U9\4HA%:Z/I?PL\*Z%//XAN?%7@_P )?"SP
MQH7@GXCS^+/#LGA'Q&?B/X6BCFTWQ+::CX:GN]'M]&MUTC0/#T%_J%QX1TGP
M]?WUS>29-U^TW\94O/#DOA/Q7-\*M'\(Z7::+X<\'?!N35/AEX*T[2[7Q'J?
MB^2UET+P]J\<NM-J7B;6M8UK5[WQ%J.L:CJ-[JM]YMXL$JPIX%13CD.2Q::R
MO NR:M+#TI)M\ZYI*46I5%&K5A&I).<(5:M.,E"I*+4L[S>2:>98U:I^[B*L
M6K>S]V+C).,'*C2G*$;0G4IPJ2BYPC)>]:Q^T?\ $;Q'XUU#XB>);7P)XH\9
MZUXW\:^-M?U[Q7X&TCQ5>>)/^$]T>+0-:\$^(&\1OJ9U+X:6.E1R6WA3P8QC
M@\'275Q>>'+_ $^^6UN;7A/B!\2?$/Q'NM!?6+7PYHVD^$]"'AKPCX4\&Z!;
M>&/"/A70VU/4-;NK+1='MY;F59-3US5M3UK6=3U*_P!3UG6=5OI[S4M1N6$"
M0<!16]#*\NPTZ%3#X+#T9X:DJ.'=.E&/L:24XQA225H1A&I5A!1MR0JU81M"
MK-2PK9EF&(C6A7QF(JQQ%1UJZG5E+VU5N#E.K=WG*4J5*<W*_/.E3G*\Z<)1
M_HX_X-VSCXA?M3?]B7\(^Q/_ #,7C[TK^J#.?7\01_.OY4_^#>;3['4/B!^U
M(E[:6]VJ^"OA*%6>))0N[Q'X[9MH8':6,49)&"=@&<<5_4[9:7IVF^9]@LK:
MT\[9YOV>)8_,\O=LW;0,[=[8STW'UK_/'Z0G_)UN(O\ KQD?_JARP_OGP%_Y
M-?D'_81G?_J[S OT445^*'[$%%%% !1110 4444 %%%% 'X@?\%)_P#E))_P
M0I_[.M_:@_\ 6.?B#7._\' O_)H/PL_[.'\+_P#JN?B36]_P4M,P_P""D'_!
M"HP+&TG_  U?^TYA97=$*_\ #'OC\29=$D8,(]Y3Y&&\*&PI)''_ /!?A]7;
M]D7X6C4(=.CB_P"&A?#.UK.XNI9"_P#PKOXC;0RSVD"A=ID+$.3D( I&XC]*
M\'O^3G<&?]CBG_Z9K'YWXL_\FXXM_P"Q6_\ U(H'\C5%%%?Z?'^;84444 %%
M%% !7]F?_!!K_DQ>3_LM_P 4_P#T+P[7\9E?V0?\$)GU=?V&G&GPZ=)'_P +
MO^*FYKRXNXGZ^&L!4@M)UX;?DE^1MP 0U?S[])C_ )-JO^RBRK_TQF!^[_1U
M_P"3AR_[$&9?^I&7G[;MT/T/\J_A)_X*Z_\ *13]I'_L)_#[_P!5-X#K^Y=I
M?$^#_HNA=#_R^ZEZ?]@ZOX8O^"MIN#_P4/\ VCS=+"D_]J> =ZV[O)$!_P *
MI\"[-KR1Q.Q,>PN3&H#E@N5 )_#_ *+7_)>9U_V2.-_]7.1'[/\ 28_Y(C)_
M^RJPG_JHSH_.2BBBO[R/XA"BBB@ HHHH [;X9_\ )2_AK_V4CX??^IGH=?Z4
M"]#_ +S_ /H;5_FO?#7=_P +)^&^W!?_ (6-\/\ 8&)"E_\ A,M#VAB 2%+8
MW$ D#) )XK_2$,GB3<_EVNB>7YDNS?>ZAOV>8VW?MTXKNVXW;21G.#BOXR^E
M?_O?!'_7CB#_ -+R4_KOZ+W^[<9?]?\ (_\ TWFA\:_\%,_^3!?VL/\ LC'B
MO_T7;U_ D_WV_P!YOYFO[UO^"E3ZZ?V"OVKQ>6^DI#_PICQ3EK:ZO7E'%IN(
M26QB1OW>_:"ZY?;DA=QK^"E_OM_O-_,U]9]%?_DD>(O^RCE_ZK,O/EOI,_\
M)69#_P!D^O\ U8XP;1117]0G\VA1110 4444 ?T<?\&[?_)0OVIO^Q+^$?\
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M))DW_P VA_J'QS_T1G%?_B.YQ_\ ,9]"T5X!_P -0?!?_H-^,?\ PS?QK_\
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MDR;_ .;3^._]0^.?^B,XL_\ $=SC_P"8_-?>>_T5X!_PT_\ !<D :WXR))
M'P;^-9))X  'P[R23P .2:AM_P!J?X(74$5S:^(O%5U;3H)(+FV^$7QFN;>>
M-ONR07$'P^DAFC;^&2*1T;G#&C_B(' ?_1;<(_\ B29-_P#-H?ZA\<_]$9Q7
M_P"([G'E_P!0?FOO7<^A:*\ _P"&H/@O_P!!OQC_ .&;^-?_ ,[NC_AJ#X+_
M /0;\8_^&;^-?_SNZ/\ B(' ?_1;<(_^))DW_P VA_J'QS_T1G%G_B.YQ_\
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M_P#\53@01D'(/((Z$>M% #=H]6_[[?\ ^*I0 .F?Q)/\R:6B@ HHHH ****
M"BBB@ HHHH **** "BBB@ K.U>'4[C2M2@T6^M-,UB:PO(M*U&_T^35K*PU*
M2VE2PO;S2X;[2Y=2M;6[:&XN-/BU+3Y+V&-[5+VT:47$>C69K6C:5XBTC5-
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MH1JEC;16EZ)K=?+(!^17CGXW?MA^'?A[\:/$7Q=^*>K?"[XW_L7_ +!O[/\
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M&OGP+X/T'PL=7>S-PUC'?'1K&S,]MIYO+PZ;9,?L6G&\O#8V]O\ :KCS/5J
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M2> /"QTN^^$$EU=WS_"ZZT]=+6SF^'S7E]>W3>$'A.@FXN[F8V/F3R,WLM%
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M?!(^%O@L>&+7Q5)9#3'\2VVCC1A:0:\VDJNCMJT4:7YT8#1S<?V6!:5]%44
M><:1\'OA1H'BO2O'6@_#;P-H?C+0O EK\+M&\3Z-X5T32M<TSX;6%S;WFG>
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
4B@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>benepalia02.jpg
<TEXT>
begin 644 benepalia02.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" !S -\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#V:BBB@ HH
MJG?:I;:>/WSY<]$7DFHJ5(TX\TW9";MN7**Y:X\3W,A(MXTB7U/S'_"J3:Q?
ML<FZ<?3 KRYYSAXNT4W_ %YD.JCMJ*XN/6]0C.1<LWLP!K0M?%#@A;N$$?WH
M^OY55+.,/-VE=>O_   56+.DHJ&VNX;R+S+>0.O?'4?45-7J1DI*\7=&@444
M4P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***J:E>BPLGFZMT
M0>I/2IG.,(N4MD#=BCK6M?8\V]N09R.6_N#_ !KEF9G<L[%F8Y))R32N[2.S
MNQ9F.23W--KXS%XN>)GS2VZ(Y92<F%3VUE<7AQ;PL_N.@_&MC2/#_FJL]Z#M
M/*Q>ON?\*Z)$6-0J*%4= !@"N["91.JE.J[+\?\ @%1IWU9R\?AB[89DDB3V
MY-/;PM< ?+<1$^X(KIZ*]191A;6L_O-/9Q.0^P:GI,OGQH>.K1G<"/<>E=%I
MFI1ZE;[U^61>'3T/^%7:J/81BZ6YAQ',.&(Z./0C^M51P<L+*]*5XO=/\T-1
MY=BW1117HEA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<SXHN"
MUQ#;@\(N\_4__JKIJXW7V)UF;V"C]!7E9Q-QPUEU:7Z_H9U7[IG5L>']-%W<
M&>5<Q1'@'^)O_K5C]*[C2[86FFPQXYV[F^IY->/E6&5:M>6T=?\ (RIQNRW7
M.^+?%?\ PC"6I%K]H:X+#!DV[<8]CZUT5>:?%67.H:=%_=B=OS(']*^SP\%.
MHHO8Z13\5;G/&EPX]YC_ (5O^'/'UIKMVMG- UK<O]P%MRN?0'UK-\%^%M)U
M+PM'<7]G'++*S_O"2" &(&#VZ5Q&B)M\4V"0,6"WB!&]0'Z_E77[*C/FC%6:
M ]THJ*YN8;.W>>YE2*&,99W. !7,R_$C08Y2BRW$@!^^D)Q^M<,:<I_"K@=7
M15'2M8L=:MC/I]PLR X8#@J?0@\BJ4OC#1X=6.FR7+"Z$@B*^6V-Q]\8[TE"
M3=K ;=%<Q>?$+0K.X:'SY)BIP6AC+*#]>_X5M:7J]GK5F+FPF$L><'C!4^A!
MZ&G*G.*NT!=HK-U?7].T.-6U"Y6,O]U "S-] .:QX/B-H,TH1IIX@3]^2(A?
MS%.-*<E=(#JJ*KSWUO;6#WLD@-LD9D+K\PVXSD8ZUDVWC70[J">9+T+'  7+
MHR]>F,CD\=!4J$FKI ;U%<O;?$/0;BY$/GRQ;C@/)$57\^WXUTX.1D=*)0E#
MXE8!:*Y[4O'.AZ9.T,ET994.&6%"^#Z9Z?K5>#XC:!*V'GFA]Y(3C],U2HU&
MK\K V]9U(:/I%S?M'Y@@3=LSC=[9K#\,>-O^$DU*2T%@8 D1D+F7=W QC ]:
MD\=72-X(NI(V#),(PK#N"P/\JYCX5Q9U34)?[L*K^;'_  K:%*+HRFUJ!O\
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M/7H?I5*'Q/!)>0PS6MU;I<'$,TJ860]OSK*U(.? NGK,I#;H58,,'KBM'QD
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MZ3)O.-PQSBMVWM8+1&6WB2-68NP48R3U-0WVE66I;?MEM',5Z%AR/QH STU
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21D=#4U%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>biogenlogostandarda06.jpg
<TEXT>
begin 644 biogenlogostandarda06.jpg
M_]C_X  02D9)1@ ! @$ E@"6  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M4D]&24Q%  $!   ,2$QI;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8 ,0
M86-S<$U31E0     245#('-21T(                  /;6  $     TRU(
M4" @
M       18W!R=    5     S9&5S8P   80   !L=W1P=    ?     48FMP
M=    @0    4<EA96@   A@    49UA96@   BP    48EA96@   D     4
M9&UN9    E0   !P9&UD9    L0   "(=G5E9    TP   "&=FEE=P   ]0
M   D;'5M:0   _@    4;65A<P  ! P    D=&5C:   !#     ,<E120P
M!#P   @,9U120P  !#P   @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG
M:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD  &1E<V,
M    $G-21T(@245#-C$Y-C8M,BXQ               2<U)'0B!)14,V,3DV
M-BTR+C$
M             %A96B        #S40 !     1;,6%E:(
M      !865H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:
M6%E:(        "2@   /A   ML]D97-C         !9)14,@:'1T<#HO+W=W
M=RYI96,N8V@              !9)14,@:'1T<#HO+W=W=RYI96,N8V@
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M"58 4    %<?YVUE87,          0                        */
M G-I9R      0U)4(&-U<G8        $      4 "@ / !0 &0 > ", *  M
M #( -P [ $  10!* $\ 5 !9 %X 8P!H &T <@!W 'P @0"& (L D "5 )H
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MQQMEM;KJT---(4XZZXI*&VVT)-2UK6HR2A"$D9F9GH1#Z 7$-:*N*^$@"IV
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MC)(CTM-?,>D'L-"L[%<JI 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
M1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
M1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
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MIH;9K7%C2 YW$]K-A.S>ZOF4*_\ 2'=FOF[;G?QIQ7^]#87]E74'TK9_BY%
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MUOC/M9\HF/";O#S[T[+U-S[!ZAKGY[LKSUUO[9BI!#HNN?R B B B B B B
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M_81+HOR9]V6)]5)[>52("*E)Z B B B B B B B B B B B B B B B B B
MB B B B B B B B B B B B B B B B B B B B B B B B B B B B B B
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MMO.ZN1LZ1OV[2VGX-_G:.$G>7-<3O6LO,+!'"9UT\+:6-U61G4'5_"-\SCQ
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M>V9ME0EXR"U[6]>U7K6D>,_A1NF_]-G(WFGRK0LV]&ZX?L[?J%>T/B@MG?\
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MJZZZ^ZX^^XX\\\XMUYYU:G'777%&MQQQQ9FM;BUF9F9F9F9ZF)3:T- :T -
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M;3#'3W>/?/9MWR6Y$[:=)+6?A6@;R71M%.G?22]/<X.7^I'M@M;]D%V[='<
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M6S;N9$QK&^4AH%2>EQJ2=I)*U?R>6RF:NG7V7N)KF\=O?(]SW>0%Q- .@"@
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MCY.\.'3#DC[K,/ZF3V\JYS\Y?>;EO71^QB4=XE51B@(KE_D+?R'[;_3KGO\
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M>J'$NQW'F'(^YB<N<)S$PQL,@!'D8P3!<  OB?\ 4XHW?+C)HX;06O#7#/-
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M"*RTN::TG.I-*3-,9E]6BR,M=%]OOC_$#RNOY.Z??26[R:#O8)6@_P )K'M
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MH.:&;K<D^;4FHV-TGJ22N<C9^ E<=MPQHVM>>F9@VUWR,!)]-KB^? :QK8]
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M]KFU-*KFD9>L40$4AOEB<JY_%/E=@M[-LE1=M]Q)\';?=*(ZZ2(!8YD4]B-
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M6.4V2YTJ.I78:6)DV46&1DOH(U$OP?A#9*3HE:R/N* \EXI],P3%F*QM[<1
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M/.YSYWN+G.<27.<34N<3M))VDG:3M*WXBBB@B;#"UK(6-#6M: &M:!0  ;
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MCJ=):QLH'8XJ ?$7A(\AH9N6#1\XL+ICN*FT1S'NGM[ Y[HB>UH5-D;^K1=
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M+*,/<=[I(QW;W'[9["?.N9?,/$1X+7&4Q<(#;>.\D+ -S6//>,:/(UP'F7*
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M /@KOI_R6 ?CB+3^RSJ_Z1QO_'_JE=/VF=)_^0R/_!_K4_I"?&?_ ,%=]/\
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MI_+UQ_\ T8[D?Y.AB!?$A[LI?[9!_**G#P]^\>+^R3_R0KJPYZ+?9 1 1 1
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M_P XB_PUVMAO#3_WU=_Y3+_B+57"!H8MX$!$!$!$!%1<\X[Z1_D9_JB^0C;
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MQ)FRW&X[*W%$VA1DA"E'T(S$F\F[NUL>9F*N[V6.&U9-(7/>X,8VL,H%7.(
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M)\1QY:42K1Y"'GTH2W'CQ^>?-;FOD^9&1;&UKK?3EN\F&&NUQW=[+389"W8
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M@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(HT>=_P#@3OT;?^"L?RX?^*1^P?\
MZ?\ \T2_RT_G!_W=\8__ (C_ %__ .7G44<Q?YL_]J[A_P#EO)T?ZO,JE')O
M_"+7^15_<OY,G^#_ /O*'_[J_P#2_P#9O$&\FCOBL_[AZ?\ \AO^*?C?ZOLJ
M+2W5OQG_ /X#^X;OC#XO^GQ:KBH2$L"0$0$6Q-KO^M\#_N\_N?\ WH_]4/\
M#(G^'_\ I?\  ^(+5F?^@=_U?]W_ )W<?B_Z;Z*YXC_KF_\ 2_WC^:WC?_IN
MJK,? S_"<?\ H9_\*K_^I'_?S^QI_9O_ &K_ -1_PWBC3_F9\27W@;G?SW_1
M>;LZ^SA6V/+GX\?_ &)O;_-?]9Y^WJ[:JQ<Q^PL_L7[$W^P?L/O"_8?^"_L?
MM#5%WQCOW]._S]JVA;\4;MW1N\R^4?E?4!$!$!$!$!$!$!$!$!$!$!$!$!$!
C$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!%__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>biosimilarschart.jpg
<TEXT>
begin 644 biosimilarschart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $R 3T# 2(  A$! Q$!_\0
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MI=]\I^&_^"._PC\$^$='\*>"_%7A_P /6O@ZX\"Z7X4BM/V=OV?H=*\4> O
M&G>(-)T;P=^T/I>F^#-*D_:0C-OKUIJ[WWCS4;2S@\;^"O 'Q$LM!M_&VA:C
MK6N^A?!W_@EK\-_@AX?^)7AOP1\2O%EGIWQ"^#?B#X-)'+X)^$EY8:!H6O\
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MC:>'%M?BUXATX?"SX<Z7#JWB^VALI=#\(6T;Z"?$6N>*?$VN>G?M=_LO>/\
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M'[=?[.$+36">)_%L_BF#QOKWP^F\ 1?"3XOR?$BUU[PUX2T/Q]J^H:A\.XO
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M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _$#_@I/_P I)/\
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M1&LO"PTGQGXS3QI\./A[+XM\4^-=*U%?&F@>"M'\/ZKH\5OJ'BNX\2?SN?\
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M?VAY'J/S%+D'H<U_%W_P]%_;Q_Z. U3_ ,(GX8__ #$U_11_P2X^-_Q2^/\
M^S&_CSXO>+)_&7BT?$OQSH0UBXTW1=*D&DZ2VD?V?9_9=!TW2K';;?:9\2_9
M?/D\P^;+)M7;YF:\+8[*,+];Q%?"5*?M84N6C.M*?--2:=JE"G'E7*[OFOM9
M.[M[&2<:99GV.^H83#XZE6]A4K\V(IX>-/DING&2O2Q-67,W45O<M9.[6Q^C
ME%%%?-'UX4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% 'X@?\%)_^4DG_  0I_P"SK?VH/_6.?B#6U_P7
M#_Y-8^&__9=?#O\ Z@/Q K!_X*6-*O\ P4@_X(5&&-99/^&K_P!IP!'D\I=K
M?L>^/U=B^R0C9&6? 0ERNP8+!A<_X+;W&IR_LM_#A;W3H;2,?'/P^5DCU!;M
MBX\!>/0JE!:P8# N=V\X*X*G<"/;X;_Y'N6?]A,?_29'SO%O_)-YO_V"O_TY
M _EVHHHK]U/YI"BBB@ HHHH *_K._P""*O\ R9I)_P!EB^)7_H6@5_)C7]7G
M_!&*?4XOV-V%EIT-Y&?C#\2MSR:@+1E.?#_\#6DX()+ $/GY<D#(KX_CC_D2
M+_L,P_\ Z35/O?#C_DHW_P!B[%_^G,,?L)16!]M\0?\ 0#MO_!U'_P#*ZC[;
MX@_Z =M_X.H__E=7X^?O9OT5@?;?$'_0#MO_  =1_P#RNH^V^(/^@';?^#J/
M_P"5U &_16!]M\0?] .V_P#!U'_\KJ/MOB#_ * =M_X.H_\ Y74 ;]%8'VWQ
M!_T [;_P=1__ "NH^V^(/^@';?\ @ZC_ /E=0!OT5@?;?$'_ $ [;_P=1_\
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M*_'S]["BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^"D__*23_@A3_P!G6_M0?^L<_$&MK_@N'_R:Q\-_^RZ^'?\ U ?B!7M\-_\
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M^"D__*23_@A3_P!G6_M0?^L<_$&MK_@N'_R:Q\-_^RZ^'?\ U ?B!7M\-_\
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MK*6T\SS-0OK[S-F/MKVK>5MW9\O[-:6N-^X;M^_[J[=O.Z_10 4444 %%%%
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M_P"G,,?KE1117X^?O84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P"G,,?KE1117X^?O84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\)%H'_0;TC_P9V/_ ,D5J>1!_P \8O\ OVG^%'D0?\\8O^_:?X5^/G[V9?\
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M\ZT5]K_\.:?^"RW_ $+/_!.+_P 2,_:-_P#H<Z/^'-/_  66_P"A9_X)Q?\
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MQ'Q*^%/PS&ABR$?A_P#L(Z.=9.HFZU;[>+#[%:?:P#['HHHH **** "BBB@
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M2-6TZZMK_3=1L9Y[.^LKB&ZMII894=MF@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *YGQHFF2>#_%4>M:)>^)='?PWKJ:KX>TVPEU74==TUM*NUO\
M1K#3('BGU&]U2T,UA:6,,D<MY<7$=M'(CRJPZ:CKUH _GKG\">-/VG]&\?\
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ML;"QD\-VO@.PUF#QW=>&4N/A#>:O%X+O/AC=W5U<^-+B;],J0*JYVJJY.3@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
)HHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>collabprofitsharingchart.jpg
<TEXT>
begin 644 collabprofitsharingchart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #P 3T# 2(  A$! Q$!_\0
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MWXV\4_#[X>:%;^'[[P_?%+_0&\.W?C?3K&TL_$'B?P;JN@^*=-M9-1/A35]
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MH7A-='=K[3_"6H_$[2[#5O&S>(HK<>--&\5^";?1);OPSJFHQ_:M?GK\+_\
M@FO\ /@O^TSX#_:1^&-Y\2_#=S\/_A!\3?A/I'P[N_BY\7O%O@;R_B?XT\(^
M,=5UX:9XU^(?B*VM?LL_AJ^CB\+VUDOA6[U37G\676F-XIT+P[JFG?H50 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6O\ Y8T?\(WI?I??^#C6O_EC0!O45@_\(WI?I??^#C6O_EC1_P (WI?I??\
M@XUK_P"6- &]16#_ ,(WI?I??^#C6O\ Y8U?L=-M=/\ --L)QYNS?YUY>W?W
M-VW;]LN;CR_O'/E[-W&[=A< %^BBB@ HHHH **** "BBB@ HHHH _$#_ (*3
M_P#*23_@A3_V=;^U!_ZQS\0:_;R/_5Q_[B_^@BOQ#_X*3_\ *23_ ((4_P#9
MUO[4'_K'/Q!K]O(_]7'_ +B_^@B@!]%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%>3WOQY^!^F^)&\&ZC\8_A58>+TN_L#>%;WXB>#[7Q&M[YBP_9&T2?
M68]26Z,KK$+9K99S(0@C+$"O6* /Q _X*3_\I)/^"%/_ &=;^U!_ZQS\0:_;
MR/\ U<?^XO\ Z"*_$/\ X*3_ /*23_@A3_V=;^U!_P"L<_$&OV\C_P!7'_N+
M_P"@B@!]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:<TZ=12;2AR4DE5A3E5E4FJ<7'#2G,:MZ_HU?;?^E=79]J?\+N\:?\\]$_\
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M ((4_P#9UO[4'_K'/Q!K]4OCA_R*&E_]ANT_]-^H5^5O_!2?_E))_P $*?\
MLZW]J#_UCGX@U^J7QP_Y%#2_^PW:?^F_4*^7XU_Y)7._^P-_^G*8X[KU7YGR
MI1117\KB"BBB@ HHHH *^NO@E_R);?\ 8:U+_P!H5\BU]=?!+_D2V_[#6I?^
MT*_1/##_ )*=_P#8MQ?_ *>PH^C]5^4CUZBBBOZ,$%%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^('_
M  4G_P"4DG_!"G_LZW]J#_UCGX@U^J7QP_Y%#2_^PW:?^F_4*_*W_@I/_P I
M)/\ @A3_ -G6_M0?^L<_$&OU2^.'_(H:7_V&[3_TWZA7R_&O_)*YW_V!O_TY
M3''=>J_,^5****_E<04444 %%%% !7UU\$O^1+;_ +#6I?\ M"OD6OKKX)?\
MB6W_ &&M2_\ :%?HGAA_R4[_ .Q;B_\ T]A1]'ZK\I'KU%%%?T8(**** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@#\0/\ @I00/^"D?_!"DD@#_AJW]J#D\#_DSGX@U^J'QP=/^$0TOYE_
MY#=I_$/^@?J'O7SI^W#_ ,$\_AK^W5=_ [7?%WQ?_:.^!GCC]G7QAXI\<?"O
MXD_LR_$G2_AAX_T#7/&?A*7P/X@9-?U+PCXMVV][X:N;S3&6TMK.?[/?7L+7
M#P74L+?(]Y_P17_M")8;[_@K#_P6BNX5<2K'/^VMH#()%5E5P!\&!\P5W4'T
M8UY&?9=4S?)\?EM&I"E4QE!TH5*JDZ<&YQE>2@G*UH]$WY#3LT^SN?3&]/[R
M_P#?0_QHWI_>7_OH?XU\J_\ #C_2O^DJ/_!9C_Q-/0?_ )S5'_#C_2O^DJ/_
M  68_P#$T]!_^<U7X[_Q"7-O^AIEO_@.*_\ E7]6?E='U5O3^\O_ 'T/\:-Z
M?WE_[Z'^-?*O_#C_ $K_ *2H_P#!9C_Q-/0?_G-5\W:=_P $G+Z[_:W\5_ J
M3_@J5_P5^'A'0_V=/ /Q8M)T_;*T@>(6\2>*/BE\3/!6HQ7%X?A*;=]&32_!
MVER6=JMA')%>O?2O=S"9(H3_ (A+FW_0TR[_ ,!Q7_RH#].]Z?WE_P"^A_C1
MO3^\O_?0_P :^5?^''^E?])4?^"S'_B:>@__ #FJ/^''^E?])4?^"S'_ (FG
MH/\ \YJC_B$N;?\ 0TRW_P !Q7_RK^K/RN'U5O3^\O\ WT/\:^NO@DZ?\(6W
MS+_R&M2_B'_3#WK\F_\ AQ_I7_25'_@LQ_XFGH/_ ,YJM.T_X(LM80BWLO\
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M?XU^+/\ PYEO?^DM?_!:C_Q-C0/_ )R]'_#F6]_Z2U_\%J/_ !-C0/\ YR]
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MXRU/0_"FK7JV$=[?>%-,\3?88.?U_P _YY]<'B@ HHHH **** "BBO$OB_\
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M'C[5_".A_ SP'XJT8OI7P6\%W&@026VIZ_?W_BB^\<>*?$_CO5ZGQZ_8)_:
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# /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>costofsaleschart.jpg
<TEXT>
begin 644 costofsaleschart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $R 3T# 2(  A$! Q$!_\0
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MI=]\I^&_^"._PC\$^$='\*>"_%7A_P /6O@ZX\"Z7X4BM/V=OV?H=*\4> O
M&G>(-)T;P=^T/I>F^#-*D_:0C-OKUIJ[WWCS4;2S@\;^"O 'Q$LM!M_&VA:C
MK6N^A?!W_@EK\-_@AX?^)7AOP1\2O%EGIWQ"^#?B#X-)'+X)^$EY8:!H6O\
M[3?[1G[3ES);>$-4\$ZE\-]2T\Z[^T;XB\%S>$+_ ,#GP?+X*T;3].M]'L6N
M)3  ?=W@GXV?#_QUX'USXAV5YKOACPUX6GUNW\5R?$WP;XP^$NJ>%9/#=A%J
MNN2>)-"^)FA>%=9T:RT_2YHM4?5;RQ329]+==2L[^YL6%Q7A*?\ !0']ELZ+
MI6MS^-?%%A'X@\6?#WP7X:T?5OA)\7M'\6>*-8^+FG>*]3^$UQX9\&:KX%L_
M%>OZ!\3[?P1XIA\ >)]*T:[\/^*=2T2_T;3-1FUBWEL4B^$/[%7@OX>_ WXT
M? CQ/X@OO&7@SX\OXS@\9>&M(TG3OAQ\/_#'A_QUX!TSX<:_X,^$'P\\+RRZ
M-\+/"%]HVG7&N76D:'=W/VCQQX@\4>+&G2[UE[>#P?X;_P#!+/X8?#JW^'BZ
M9XFTG3;OX<_'#X'_ !?LKKP'\$/@G\)V\2P? #0OB+H/@O1/&_\ PKCPGH-S
MXJU;4X_B5KNI>*?%>J7DPFU7]]X5\.^$+6_U6SO@#<^/O_!4;X!?"OX$^,OB
M[\/&UKXO:[X;^&J?$BU\$:=X2^)NAK9VD_Q'U+X3V>C?$WQ'_P *\U>T^"FN
M7_Q \-^-?"%EHWQ.L_#^MW7BCP/XLT.'2WO=!U);;WJ?]N7]F2R'CR?4OB'<
MZ5I?P]T_QQJFI>(M5\$?$'3O"WB2S^&GBZP^'_C[_A67B>[\*Q:)\7+SPEX\
MU?1O!&M:;\+[WQ;J-OXOUG2/#L-K<:GJ=E!/\B:G_P $FO"+>#?C%X$\,?'/
MXA^$_#W[1+>-C\<(++PUX&U*X\9C5_VA_C!^T3X%>PN]6TVXN?#%QX'UGXS^
M)?!-Y+ILTL?C'P/9Z1;W]OI/B"T/B!]+1/\ @D=\ - 3XG:?H\VE>']+\6'Q
M+?>!-5\+_"'X,Z%\3_AWK_B'XR^'?C[8Z[<_&%?!EYX\^(LW@GXE^%-!N/!V
MF^,K^;1I_#MDNA_$&P^(,Z6FKV@![M\-?VW-'^)]M^VCJFB> M?T[2_V1]=T
M[1$C\46OB;P9XF\92W7[,WP[_:&O(M;\&^,O"7A_Q)\/-2T^;QVWA"33-6L-
M2FE33(O$22?9]3BL(?(OA3_P41U6#P9\"/'G[5WP^\ _ [PA^T=\ KGX]_#G
MQ;X&^*'B+XIZ)91:=X+\'_$+4_AGXNL=6^%?P[\2VWQ D\)>,K:^\)P>$M(\
M96'C6_T77O#]BVG>(O\ A'-*\3>]?#;]D0>$-+_:D;Q=\4O$?Q"\6_M;ZC9Z
MW\2_$]WX?\.>&X]/U:U^!'@_X!@>$]!T2,V.F:1#X8\%:3>V.G7T^IW4%Z9_
MMNJZF\LER_R_;_\ !*?P_P"-/@UX+^"_[17QN\3_ !L\-_"/X*Z/\$O@M;+\
M/?AYX+T;P'IVB)\.EL_'>H^'/L7BVP\?_$.2+X5^$-,N;OQA->^#9/#G_"2^
M'8O!,-CXQ\2-?@'U;J?[=?[-NC:'9:UJGBCQA9W5UJ_BS1;[P:_PA^+\GQ-\
M,S^ =$\.>)_'E]XT^%MOX%F^(7@O0/!GACQAX0\2^)?$GB;PWIF@:;H'B_PA
MJKZE):^*O#SZE)K/[=?[+WA^;XB?VO\ $EK+2OAAX>^)GB3Q)XM?P?XY;P'>
M6GP8\/7GBOXLZ;X-\?KX:/@SX@^)OAUX>T_4-3\6^$_ VN^(/$>DPZ9K$<VF
MFXT+7(=-\)\+?\$XM'^'D/AGQ#\)_BDOP5^*FE#XJZ1K/C7X,_ [X%_#KP_J
M'@SXSP_#*'QIX=TKX;:)X/'AS2-1L+CX._#O7?!GC/5+GQ5XIT3Q!H;-K5[X
MJ\,W;^%(N+U?_@D=\#;YOVAK32]1TK0=-^/'@S]IO0/[8M/@W\&;OXK^&->_
M:R\.^+M$^*.OR?&^]\)2?$WQ186MWXY\5:SX5\.ZCK=BNGRZ[?:)K>L>(O"]
MOHNB:0 >Y^)?^"C'[-6EV?BBTT+Q/J^K^,]!O->\.6WA;5_ ?Q+\(0R^.K?X
M;:E\4O WA;7_ !#K_@FVTGP@GQ>\*V U'X0Z[K\MMI/Q1M)2_P /I_$]VGV)
M\SX0_P#!2/\ 9Z^(_P (? OQ%UW4?$'@SQ5XN^%_P#^(O_"KY/ ?Q0U;Q;K!
M_:$\/Q:CX)L?A)IA\!:=KOQUTF_UVW\0>&;#Q3\,-!UW2;J\\-:O=7K:7:6T
MSQ\C\0?^"9G@#XA:K\1]4U#XC^,;(_$CXJ_LS_%/4K>VTS0GBL;W]FGX6V_P
MLT31[1I5\Q[#Q/ID']I:S/,?M5I>NT>GD0!:\_UC_@D;\+_%?AKP-I'Q ^(F
MK_$_5?@?X(^#WPS_ &=[WXD?#GX7^+/#WP[\!?!FVU&WTK0O%O@6\T!/#7Q:
MD\9PZM<6/Q U'Q/#87%_I^F^'Y/":>#/$.E3>)-1 /MGP9^V!\ /B%XZ\(_#
M3P7XPU+Q%XX\:>#[KQ[I?AVP\$>._MVF^$]-\6>+_ 6N:KXP^T>&H(_ ?_"-
M>/? WB/P+XILO&KZ!J/AOQK;6GA/6;2SU_5=+L+OS'XV_M=^)?@O\;?AW\-=
M1\ _#Z]T+XC_ ! ^&OP^\)6-Q\<]!T_X]_$(^/==T+0/$?CKX5_ >#PSJEWX
MI^'_ ,&Y]<&K?%/5-;\8^%-5TKPKX?\ &GBBSTF;2M TN3Q19_9__8=\#?L]
M_$C2/B/X6U]S<:9\ ;;X%'PSH_@?X??#_P 'K;M\:/'GQQU;Q+I7A?X=Z!X9
M\/Z!<ZCXI^(.KVHTG2])CM([""VNKZ[U;79]3U>_U/C#^R;JGQH\9)-XI^-O
MC=_A%<^/_AG\3-1^$W_"/^"II+/Q)\*/$'@_Q7X=TWP5\2SI$/COP/X1U7Q/
MX'T?7O%&DZ?=WVN7&H76N#PSXJ\)V>L7%H@!-\ OVK-2^-OQ[_:>^"NH_"/Q
M%\-8_P!GMO@]-I&L^*M;TBXUKX@Z-\6-"\8ZK:^(7\*Z0+T>#-/CN/!UVNC:
M?J^N7?B/4M)N[/5=;T;PK=S_ -BQ^R_%OQ=\5O#D'A;3?A!\,-+^(OB3Q-KE
MQIUW>>+/&X^'W@'P5I%EHNHZM<:_XO\ $%CX<\;>)Y$O;JSLO#N@Z3X5\$^(
M;_4->U>S?47T30;35-;L_D3P?^QU\?/ WQJ_:3^.^F?M7"_\5_M"^"M/\.W.
MEO\  SP5IMAX8UCX?^%/&GASX+:YH][+X@USS9?!4OC&;4=>M=7TG5+'QE<6
M-LEW::;9-<64_K/[2W[.?Q3_ &@/A5X+^&>F?M#ZM\.HK.\TV3XMW-A\/?#N
MOZ=\<M"M= FT_5? OC#3&U7P[>Z+X'\4ZW)'K7BK1O!VMZ%-XATZ!O!>I7DW
M@S5->T75@#Y?T[_@IGJWB[X>ZI\2_ 'P&76O#_PG^ DO[1_[1D6J_%31]+NO
M"?P]@^('QD\ QQ_!^XT_POK>G?&'4-?B_9]^+?C_ ,$ZGJMS\,_"WBWP!I7A
M#4K?6;&_\=6MEHWT)#^VA8/^U/'\!;OX>:MHOPVG_9@^(O[2^G?'_6M>TJW\
M.>)M%^'7B;X+:3J]OX3\*6*ZAKE[X:M](^,VG:G=^,];F\/I)J6CW^C:%H6N
M6\-UK-MPWB+]@B_\6>'4T?5/CCK/A^X\;? _3?V:?V@/^%;_  U^'_@?PY\6
M?@AX>UCQK=^$_"^A>$_L^N6/PDU?POX<^(/C+P'I'B/P?=W3V_A#Q3K5O%I<
M6KVWA+5_">EXG_8O\>>(?VIO"_[0$?QZM-/\#^%/A?XI^ EA\$!\%O"MUX?F
M^!?Q USX8>(_'G@:Z\5OXFAUIM0UC4?A5H5OI?B6&PA?0=(NM0T^/2;Z22*\
MC )?V1?VX%_:I\57NG67AKX;Z-X?U#X9^&_BWX77PY\<?#_C?XCZ3X6\7W-D
MWAG3_BO\-(_#V@7WA#7M7T34;/53=>#=8^)7@W1=7M_$'@/Q!XLTWQ=H45KK
M/O'QX^)_Q;^'D5B_PP^%7A7QK9VWAKQEXR\9>,/B1\5K;X1?#OP?HG@VWTRY
M_LN]\0P^$?'VL3>)O$\=]>3Z-N\,6WA+2-(\/>(M9\6>*]&^S:1IFO?-'@;]
M@OQ!\)M$TU/AU\?O%D/B7X._LX>)/V7/V2M3UCP3\-VM/@1\,]?N_ -W'_:]
MC:>'%M?BUXATX?"SX<Z7#JWB^VALI=#\(6T;Z"?$6N>*?$VN>G?M=_LO>/\
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M'[=?[.$+36">)_%L_BF#QOKWP^F\ 1?"3XOR?$BUU[PUX2T/Q]J^H:A\.XO
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M8R1V[CUIQ_;G\6#;GX;^%QO"LF?$OC4%U?[C*/MWS!_X"N0W\)-'_$,N+?\
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M->*;"UTL>)/"/BSP/XR\.>(-"U:\T'PYJB_:K[2-:\/Z1K.DW]E& >_T444
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M**\H]X**** "BBB@ HHJ.82&*412+%)Y;^7(\?FK&Y1@CM'OC\Q4;#%/,3>
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M$6<_^&O'>7_3CS1Q5%=K_P *V^(/_0E>)?\ P57/_P 31_PK;X@_]"5XE_\
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MB[:GHO\ X([[_P":&O@_3/\ D):=_P!A"P_]+(*_0JOU_P (OX6??]?,M_\
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MZA-=M?5]R/\ 8K^&/C/P+K/Q!GO[O0(1J6E>'(8C%]JU?<UK>ZQ(X9$FTDP
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M7UU\$O\ D2V_[#6I?^T*^1:^NO@E_P B6W_8:U+_ -H5^B>&'_)3O_L6XO\
M]/84?1^J_*1Z]7Q1\5/^1^\0_P#76Q_]-=C7VO7Q1\5/^1^\0_\ 76Q_]-=C
M7WGBQ_R(,#_V.*/_ *A8\1Y]1117\_@%%%% !1110!>TS_D):=_V$+#_ -+(
M*_0JOSUTS_D):=_V$+#_ -+(*_0JOVSPB_A9]_U\RW_TG&CZ+U?Y1.+^(O\
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M-)M'JW_?;_\ Q5.HH ;M'JW_ 'V__P 51M'JW_?;_P#Q5.HH ;M'JW_?;_\
MQ5?,.F_"_P 76W[8_B_XQ2VEN/ FK_LT?#OX:6-\-1MVO9/%GA[XM?%/Q;JE
MJ^FA_MD5M%HOBG1YX[]U%O/+-+;1L9;>51]/@@YP0<'!P0<$=0?0CWHW+C=N
M&W&=V1C'KGIB@!-H]6_[[?\ ^*HVCU;_ +[?_P"*I20,9(&3@9.,GT'J:6@!
MNT>K?]]O_P#%4;1ZM_WV_P#\53J* &[1ZM_WV_\ \51M'JW_ 'V__P 53J*
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M;>'Q+XT\4?#7QO\ "^^MIPYU#4_$7P7\3:2NGQ?$F3PSH8!^MI( R2 !U)X
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M))T2:2W$;RJ'+ :- !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
&444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>eloctatechart.jpg
<TEXT>
begin 644 eloctatechart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $R 3T# 2(  A$! Q$!_\0
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MI=]\I^&_^"._PC\$^$='\*>"_%7A_P /6O@ZX\"Z7X4BM/V=OV?H=*\4> O
M&G>(-)T;P=^T/I>F^#-*D_:0C-OKUIJ[WWCS4;2S@\;^"O 'Q$LM!M_&VA:C
MK6N^A?!W_@EK\-_@AX?^)7AOP1\2O%EGIWQ"^#?B#X-)'+X)^$EY8:!H6O\
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MC:>'%M?BUXATX?"SX<Z7#JWB^VALI=#\(6T;Z"?$6N>*?$VN>G?M=_LO>/\
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M'[=?[.$+36">)_%L_BF#QOKWP^F\ 1?"3XOR?$BUU[PUX2T/Q]J^H:A\.XO
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M+/-/HQU4VUAJVCZPNB^-O"MSJ6BQ^+_"?A\Z[HWVX ^GJ*** "BBB@ HHHH
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M_P#L Q/_ *70/YR^E)_R:Y?]E-D__J/F7^2^X_HFHHHK]U/\XPHHHH ****
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M?P+T445_.)_JL%%%% !1110 5_H9?\&PW_*-&7_LY#XV?^A>$:_SS:_T,O\
M@V&_Y1HR_P#9R'QL_P#0O"-?=^'?_)0O_L Q/_I= _G/Z4G_ ":Y?]E-D_\
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M>^\#_''X[:G8IX9L_$WC&'S+KP?9^!/ 7@O]HZ?2_ OBW41\.I/'FC_"*\\
M>+-9UB#Q#>_$_P #+:>&: /T0^-?Q=O/@WX:MO%%O\*OB7\4K,W=U'J]O\.!
M\.HI_"^E66FWFIWGB7Q'=_$OXC?#71;'P]:16;17-Y!J]Y<022QRR6:V2W%Y
M!N?![XEV7QD^%W@+XJZ9X:\7>$-,^(/A;2/%VF^&_'NEV>B>,-*TW7+5+[3X
M/$&D:?JNMVFG:C)92P7,EI%JEYY4<\0>42%T3PKXN?"+XQ?&GX/?%/X.:_/\
M./"VA>)_BCX'\/>'I?#FN^,-0DUW]EJS\3_#"\^(^B>-CJ6@VTFG?$?QEX+L
M?BKX)_LG19-7\+-8ZGX;N+KQ$DFH:T--^O$18U"( JJ,*H& J_PJH' 51A54
M8"J    !0 ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D
M/0]^#ZG^63^0S2U5O;J*QL[N]G$Y@L[:XNIA:VMU?7/E6\3S2?9[*RAN;R[G
MV(WDVMI;SW-Q)MAMX99G2-@#\1?&OAJ/5_VY?B9JWB/0_&O@/4;SXR? N&PN
M/ /_  3>^)'Q4\.?%GPS\.XOA_XE\#^)_&W[2MW\.]9T:;4O#'C?[?#>^)M,
MU+2?"?PO;0?"NI27%YJOA&W\20_N&.GXGMCN?\Y[]>]?@C\2?#^B^(?VNKW5
M+#PR;O6?'?QU^ /Q+\/_ +2^O?LM?MJR_M!?!CPSING?#"[E^"G@'Q'8?LPZ
MC\,;3P'X@LM(OM'U34=0^-7@+P;X-L?B5X_L?BU\//$FN:3XI;6_WN7@?G^'
M)X' X'0''(P: /Q!_P""D_\ RDD_X(4_]G6_M0?^L<_$&OD[_@ZA.?V"/@KU
M_P"3L/!G8C_FDOQ@]:^K?^"ED,4__!2#_@A5%-&LL9_:O_:<8HX#*6C_ &/?
M'\J$J>#MD16 .1D#((XKY!_X.EM(TS3_ -@OX+265E!;2']J[P<A>)-K%7^$
MWQ=+*3DD@F-#@\94$<YS\[Q;_P DYF__ &"O_P!.0/U+P3_Y.MP/_P!CJG_Z
M8KG\%%%%%?SB?ZK!1110 4444 %?Z&7_  ;#''_!-&7K_P G(?&SH"?XO"/I
M7^>;7^A#_P &R6D:9J/_  33=[VRM[ET_:0^-VUI4W,-Q\'J1G@XQ&@P>!CC
M&3G[OP[_ .2A?_8!B?\ TN@?SG]*3_DUR_[*;)__ %'S(_HU+  GG@$]#V_"
MOY\_VSO^"S=_^R]^TQ\4/@1#KO[.MI'X N_#ELMOXVU'78/%$7]M^#O#WB8C
M58K3Q9IMNCL=:+VWEV4 -DULS!W+2/\ O<_A?P_L;_B4V?W6_P"6?L?>O\S_
M /X+PP0VO_!6']KN&WC6&)=<^%Q6.,;44R? WX9R/A1P-SLS$#C).,5^C\99
MQBLERW#XG"6]I4QU.A*[:7)*AB*CU6M^:G'39J]S^4_ 3@?)^/N+<TRC.HRE
MA<+PYB<RIJ,8R?MZ69Y3A8Z25K.GBZNJLUIYG]&7_$0QJG_0R_LE_P#@V\2_
M_-U5^S_X. _$VH6NL7MAJO[+%[9^'=-CUGQ!=VEWXLN;70M'FU.PT2'5M:N(
M?&[Q:5I<NLZKIFD1:A?O;VDFJ:C8:>DQNKN")_X1\GU/YFOW2_X);>++:V_9
M\_:4\(ZO\4O#/P<\)W$#:WXP^*7AKXO^!?"'Q(^'6E:GXZ_9Z\+W/B/XH_!W
MXG:+>^&OCK\'K71EU>?PUHVFOJ6IW%Q)\4?A9;6EGXH^+'A5KCX/+^,\WQN)
M5"=6-%.G5FII2FVZ<')1LY023Y?>DY*,8\TI-14I+^E>)? ;@7(,K>8TLOJ8
MV4<5@L/*C*5.@E#%8JE0G4YXT<1.4H*;=.E3HU*M:I*%*C3JU94Z4_W;_P"(
MA/63$9AXA_9/,(F^SF8:EXI,*W!B6<6[3#QQY0N# ZSBW+B8P,LWE^4RN4;_
M (.%-818I'\0_LGK'/&98)&U+Q0L<\2RR0-+ [>. D\2SPS0-+"SQK/#- 6$
ML,J)_-9XR\-_%OQ5_P $VO@WI-[HO@%M&^&?[2^N>-_"OAO0]3^$/AFYG^$'
MB#X'?#[PY9_$/Q#X5T[Q5:>,]<U'XA>.([F/Q1K/BN*\\9W=XITW4ETFPTFU
MLM/O_MM_#+X\?%JV_8ZU?7])^'47BO2OV4[GP'XLL-$\??L^>"?"/@WQ3X%^
M*'[3OQ'3X<6>C^&_&UGX6\&P:'\)+;0[CPMH=K;6]E>6=QX?T'3+C5O%NLVE
MAJ/14XISV-.<X.I4E'#X2O""HU/WGUB482A=3E9PF_<M&7M8QDVJ;3B>?0\&
M?#BIB,-1K4\%0A5S/.,OKU'F6$E*A'+*56O2K.G/#TE*-:C3B\2I5*<<%4K4
MZ<:F+C)53^DA/^#@_7)()KI-=_93>VMY(8KBY2^\6/;6\MSYGV:.XN5\;&"W
MDN?)F%M'-)')<F&;R%D\F79!_P 1#&J?]#+^R7_X-O$O_P W5?SK2^(?V=$_
MX)N?''X6?#7X]^'II; _LB_$'5_">L?#KX@>&?'7Q"^.USXC^(&H_$*\D?5M
M(CL;_3="L+G2OAIX'N=*U#4O#OA'P;X4'B'Q'/I>K?$+49+K\?R3D_,3[Y//
MO7-C.,\XPGU:U>C6=>@JTO9U%*-.7M*E.5/FA.?-RNG?F:AS<VD7&TI>KDW@
M'P'FW]J<^68_ _V?FD\!3CB\).A5Q-%8+ 8RGB_98G#8>=-55BY15)*KR*"Y
MZGM'*G3_ +Q_"G_!P!J?B'Q5X6\/'Q)^RFP\0>)_#>@%;35?$ANV&N:YI^DE
M;0-XWD5KIA>$6JM&ZM<&,,CJ2I_J.#9!Z_>8< _PL1Z>W-?X^/P;&_XP_"%&
M^96^+?PK5@>05;XA^&58'V*D@^QK_7R_X1O096DEDTJS:22::1V,?+.\SLS'
M! R6)/  YXK[+@K/<9G=/,98NU\//#1IV;>E2-9RWV^"/KU/P#Z07ASD/A]B
M.%J>1QE&.:4<XGB>:,(WE@Y98J5E!:_[S4O=Z:6ZF[D>_P"1_P *,CW_ "/^
M%87_  B_A_\ Z!-G_P!^_P#Z]'_"+^'_ /H$V?\ W[_^O7W)_.ANY'O^1_PH
MR/?\C_A6%_PB_A__ *!-G_W[_P#KT?\ "+^'_P#H$V?_ '[_ /KT ;N1[_D?
M\*,CW_(_X5A?\(OX?_Z!-G_W[_\ KT?\(OX?_P"@39_]^_\ Z] &[D>_Y'_"
MC(]_R/\ A6%_PB_A_P#Z!-G_ -^__KT?\(OX?_Z!-G_W[_\ KT ;N1[_ )'_
M  I<Y]?Q!'\ZP?\ A%_#_P#T";/_ +]__7J_9:7I^F^9]@M(;7SMGF^4NW?L
MW;-W)SMWMC_>- %^BBB@ HHHH **** "L;Q$-V@:V,2'.D:F,0V>J:A,<V-P
M,16.B36^LWLG/R6FE3PZE<OB"PECNY(779I&^ZWT/0X/3U[?7M0!_.IX(^!^
ML^"_B]\.-/U"Y\375QIGC/X::G+-HG[&'_!:>7P\T6H7OASQ! C>.M?_ &M?
M%?PNT=XK6_AAUV]\:VNM>&_!^J1ZG8?$/29AH?B+2%_HK']3ZCN?7_\ 4>HX
MQ7\]/CF3X22?\% _B6OCFV_8G;QE'^T5\*5\.3?M%>&_B=\4/V@GB_X1CX6I
MI#_#'Q9H36G@WP'HL>IQRP_#;P*HOT\'^*HM4\1^(KHW/BJ:PLOZ%AT[=3T^
MI_7U]3F@#\0?^"D__*23_@A3_P!G6_M0?^L<_$&OD[_@ZB_Y,(^"O_9V'@S_
M -5+\8:^L?\ @I/_ ,I)/^"%/_9UO[4'_K'/Q!KY._X.HO\ DPCX*_\ 9V'@
MS_U4OQAKYWBW_DG,W_[!7_Z<@?J7@G_R=;@?_L=4_P#TQ7/X%Z**_3K]A?\
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M #.<"EHHH)/2?@S_ ,EC^#__ &5WX4_^K%\,5_L&1_=/^_)_Z,:O\?/X,_\
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MB_\ 3F2#Z***_4S^-0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_9X@U+X_:1/\8+RSU*\UOXR^$/@K\3/!=@FB3^+OVC]7U;3?VNOA%X8\4_\
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MO_'9;/PU\$OA3\"M&^,W[$&I>!M%UC0OA;\6_B1H7PPM_'NN6_Q.U.TO-/\
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MF?:+6VVX^39LWYRV[;@9T** "BBB@ HHHH **** "BBB@ HHHH _$#_@I/\
M\I)/^"%/_9UO[4'_ *QS\0:^3O\ @ZB_Y,(^"O\ V=AX,_\ 52_&&OK'_@I/
M_P I)/\ @A3_ -G6_M0?^L<_$&OD[_@ZB_Y,(^"O_9V'@S_U4OQAKYWBW_DG
M,W_[!7_Z<@?J7@G_ ,G6X'_['5/_ -,5S^!>BBBOYQ/]5@HHHH **** "O\
M0R_X-AO^4:,O_9R'QL_]"\(U_GFU_H9?\&PW_*-&7_LY#XV?^A>$:^[\._\
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M>7_4?YHZ*O\ 0R_X-AO^4:,O_9R'QL_]"\(U_G5_\)/8_P#0*\<?^&Q^)?\
M\R-?V8?\$'O^"N7_  3^_8\_89D^$7[1_P ;/$'PR^(K?&[XI^+!X:OO@'^T
MCKDY\/>(3X<.C:E]M\*_"#7=,\N^%C=;(3>BYB\EA/!$2H;[3@/*\SP>>.MB
M\NQV%I?4L1#VN(PF(H4^>4J+C'GJTXQYI)-J-[M)M+0_!/I(<8<)9WX<+ Y+
MQ3PYF^-_UARJM]3RO/,LS#%>QIT,>JE;ZOA,56K>RINI!3J<G)%SBI-.2O\
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M7]_:VR;29)D'-?P+R>*;!I)&&E>."&=B/^+8_$OH6)'_ #*->;XA9=F&-S'
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MVN#I^J6VAZCX,U+0?#W@ZQ^"NN_LG6U]\";;2O!NH>)_%'AFT\-_!F\^%_\
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M/$>L_#'0/@=;Z1X-UCPYX>TSQCK/C'7/ ]RNJWO@B[\/_4NB_%'X^Z;_ ,%
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M- \8>'-9U%K:V"&XN%L=,U.ZNF@@\R/SI1"8XMZ>8R[ES_CQW=AI_P!JNO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
&444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>equitinlossofinvesteechart.jpg
<TEXT>
begin 644 equitinlossofinvesteechart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #P 3T# 2(  A$! Q$!_\0
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MWXV\4_#[X>:%;^'[[P_?%+_0&\.W?C?3K&TL_$'B?P;JN@^*=-M9-1/A35]
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MH7A-='=K[3_"6H_$[2[#5O&S>(HK<>--&\5^";?1);OPSJFHQ_:M?GK\+_\
M@FO\ /@O^TSX#_:1^&-Y\2_#=S\/_A!\3?A/I'P[N_BY\7O%O@;R_B?XT\(^
M,=5UX:9XU^(?B*VM?LL_AJ^CB\+VUDOA6[U37G\676F-XIT+P[JFG?H50 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6O\ Y8T?\(WI?I??^#C6O_EC0!O45@_\(WI?I??^#C6O_EC1_P (WI?I??\
M@XUK_P"6- &]16#_ ,(WI?I??^#C6O\ Y8U?L=-M=/\ --L)QYNS?YUY>W?W
M-VW;]LN;CR_O'/E[-W&[=A< %^BBB@ HHHH **** "BBB@ HHHH _$#_ (*3
M_P#*23_@A3_V=;^U!_ZQS\0:_;R/_5Q_[B_^@BOQ#_X*3_\ *23_ ((4_P#9
MUO[4'_K'/Q!K]O(_]7'_ +B_^@B@!]%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]1^8HR/4?F*P_P"P+?\ Z"&N_P#@]U3_ .2:/[ M_P#H(:[_ .#W5/\ Y)H
MW,CU'YBC(]1^8K#_ + M_P#H(:[_ .#W5/\ Y)H_L"W_ .@AKO\ X/=4_P#D
MF@#<R/4?F*,CU'YBL/\ L"W_ .@AKO\ X/=4_P#DFC^P+?\ Z"&N_P#@]U3_
M .2: -S(]1^8HR/4?F*P_P"P+?\ Z"&N_P#@]U3_ .2:/[ M_P#H(:[_ .#W
M5/\ Y)H W,CU'YBC(]1^8K#_ + M_P#H(:[_ .#W5/\ Y)H_L"W_ .@AKO\
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MJWQJ\6:?X8U+3=(UBPU"XB^"(NKK2=?,7]BZC%H":4_B?['J:S12VD[:(J/
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MO4!I]LMM/J6AWEW?7,44S?B9'\,8O#_A[X2_#_XU^ ]2\!1^+_%'Q&\5^/\
M4;'XFW7BOQU\3Y?!EY:)XL\1:!)X!L_^$6T&_ALO^$*\%Z!IE_XEU6VU'Q)-
MXF^(&M7,MY?7.@?'V3C&3CT[4N3ZG\ZQC@5&2:K54HU*M512HJ//4V;2HIOV
M3<G3C)RBI2YI1G)1<=Y9E*47&6'H.3I4:$JG-B>=TJ+CS0NZ[4?;*,8UI049
MN,5"$H0E.,_K_P 0^/?A[KGPHOXO$WB'X8>*M5/P>^'OA#X?>'="^#5SX5^+
M?A#XA^%SX6TS^V?%?Q!?2'AO=$T+POI7B#0]1NX?'_B'2_'UC?:(NG^#/#-Y
M'</H_P ?G&3CIGCZ445O0H1H*<8RE)3GS6ER)1]V,;14(0BE:*;;3DY-MMWT
MYL3B9XF5.4X0BZ=-4[Q=1N?O2ES3E4G4DW[W*DFHQBHQC%):]?\ #W_DH/P^
M_P"Q_P# O_J7:+7^@<I&#R/O/W']]J_S\/A\,_$#P N67=X^\#KN4X9<^+=&
M&Y3SAAG*G!P0#BO[\AH1.3_;&N_>;_F)'^\?^G?IZ#L.*_.O$#^+EG^'&?\
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M?A]_V/\ X%_]2[1:_P! ]>A_WG_]#:OS/Q _BY9_AQG_ +JGZ_X6_P /.?\
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MD62VNHYK:XC9)&5X+B&6"528YHY(V9&MT4 ?FCIG[ _ACPQXCTFY\*?L_?\
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M16#_ &-<_P#0P:Y_W]TS_P"5-']C7/\ T,&N?]_=,_\ E30!O45@_P!C7/\
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MI6DZ990+M@L]/TVPAM[*RM85^6*WMH(H8UX1 *_/R3_@I1\)K_PGHOQ)\&^
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; %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>fampyra.jpg
<TEXT>
begin 644 fampyra.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1"  C 'X# 2(  A$! Q$!_\0
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MM@''\S110T@N%I:01VT>V-1\H_EBG?8;<.7\I=Q&,_Y^@HHH458&W<<;2!@
M8EP.F.,=_P"M2A0%VXXQC%%%.PC#U#PIHMR&EDTZ'>3DE<K_ "(K.M_!VAM,
M U@I&>AD?_&BBLY15]C*45?8WK70=,LHFCM[&!$?AAMSG\34,GAS26<$V,0/
MMD#\J**)PBUJC>$G'X78M6>E65B=UM:Q1M_> Y_.KE%%:122T$VV[L****8@
&HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>financialhighlightschart.jpg
<TEXT>
begin 644 financialhighlightschart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &J 3T# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#QC]H[XN'X
M ?L]?'?X[#0#XK/P6^#7Q0^+0\+KJ/\ 8[>)#\-_ ^N^,AH(U866I?V6=8.B
M_P!G#4?[.O\ [$;G[3]BNO*\B3XW^$'_  43\%ZQ\.-/^(WQ@\5_ "ZM/%2/
M<>#M+_9 ^(_Q)_;"U,6GA_P;I/C;XE2>,M-\#?!?2-7\,)\.-'\1^&KWQ+?)
MIFHZ5I=AKNDSZQ?Z7=:UH-AJOVK\?/A+IOQ\^!?QH^!FL:M?:#I'QG^$_P 1
MOA/JFN:9#;W.I:-IWQ&\':UX.OM5T^WO/]$GOM.M=:EO+2&Z_P!'EN(8TG_=
M,U>%_$W]D%/%C?"/7/AY\4_$GP?^('PD^&WC7X-Z?XT\.^%_!?B!]8^&7Q+T
MCP%IOCC1M0T'Q/I=WI4>L2WWPQ\"^)O"^OPDMX=\0>'K=;S3O$/AR^U?PYJ(
M!ZI\-_VFO@O\7_%7C7P?\,?%TGCC4OA[;Z)<^+M0\.^'O$VH^%M,7Q/X,\#_
M !%\+00^,X=';PGJM]XI\!_$7PEXO\-:=I&L7]_KOA[4SJFFVUQ:6MU+%^?O
MP_\ ^"P_P4\:?\*O\1ZQ\//BK\/_ (:>/_AK^V1\0-7\1^+/A[\2W\6^$$_8
M^^.'PR^$'B5[OX=Z%\/M4US4O".IZ=X]U/QSKOCNTD70?A[8>%=1T/Q*_P#;
M5KKD.A?:/[+'[)'@#]DC2OB3X;^&^H:O-X6\=^+?A]XBTW1-5,$H\):=\-OV
M=?@?^SCX?T"ROD NM5A/AGX&Z'K5]J.HXO+C6=8U0!4M4M47YBT#_@F#X0T%
M/%6D1?%KQ?<>$;WX/?MQ_!#P-H4GA[P\EYX)\%?MU_$7P7\6?'Z3ZY'()O%.
MH^#O'/AG4YO!MYJ%E8,=!UR+2-=&IW>D1ZS?@'U]X<_:N^!/B[XE)\*O#?C2
M76?$EQJEUX>T[5;'PQXNF^'VM>+-/\)+X]U+P1X>^*8T$?#7Q#X[TOP2S^*M
M3\%Z+XKOO$EAH=KJ5[<:<@TC5TL/(?BS^V<?A%\8->^!OB'P#"GCOQ-I'@;7
M_P!FR.?Q2]EI/QQT?5-0;1_B_=S:C)X>DC\'+^S=]EN?'?QD8#Q!#HOPBU'P
MWXWM99[K5+O0M,\T_9[_ ."8/P:_9V^+>A?%#PJ_AF_E\/W=WXHLI-2^#'PB
ME^(+^/\ 6_ %OX \3ZR_QHG\-7GQ,MO#6K0_VKXDM/!^EZSIS:1KNO:KID'B
M.Y\!FS\%6OT=\</V4O!'Q[^)WPC^(7C34M4:R^%WA'X_>"9O"5HD,6F^+-!_
M:$\":3\/_%5MJ>I(\>JZ:]CH^F.UA-I4L4K37<IE=?*B8 &-HW[<_P"SQXDT
M9]:\.:K\1O$/G0^&=1T30]%^!7QQU'Q=XO\ #/C6T\17_@[QYX(\'6_P\;Q+
MXP^&WB>T\*>(9M'^)7A_3+[P'=#2KI/^$A20VZ7&+/\ \%$?V08;-M1B^+*Z
MCI\7PZ\&_%:YOM&\%_$'6K6Q\$_$/Q-XI\"^!KW4)-+\*73:?J_BSXA^#/$/
MPUT+PE>QP>+M1^)=@?A_;:')XME323\I>&O^"0'PM\'>&_#F@^&?%OAG2AX/
MU3P=:Z=9VO[-W[/=GX4\<^!_!/ACQ7X3T7P_\>_!^E>#],T_X[:Y:VOBV?Q/
MIWBCQG=QV?A[XCZ#X:\>>&?">C:K;Z]%XC[[X-?\$M_AU\#?AU\4/AMX*^)/
MB3^Q_B-\&/ 'P5C_ +;\!_";Q%I^D>&_AY\=OVE/CG817/@SQ#X/U;X>>(-*
MUV]_:3U_P7XB\,7_ (1M]"D\'Z+9VNA6_A^^NEO-- /NOPU\<?AQXF^&VN_%
MD:MJ?A;P1X4MO%%WXOO_ (C^%?%GPNU#P=;^"H;FY\5S^+= ^(>B>&=?\.V^
MB6EI<7UU=ZGIL%E+IJ+JEE<W>FS6]W+XD_[?'[,4.DZ+J=WXO\6:=>>)/'.@
M_#CP]X0U7X0_&#2?B/KOBWQ?X&\9?$GP18:3\,M3\"VGC^^M?'?@WX?^+]5\
M$:O;^''T?Q3-H=]I&DWUQK=O/IT6?\/_ -B+P-X=_9I^,_[,7C7Q)K7C;P'\
M>XOB79>-=)L;+3O!/A/PKH'Q3\*6O@[Q!X*^#7@?2?[0T?X5> [/3[:;5M%\
M+:9/JEI8>*=9\0^('EN)]9N(%\E^&G_!,[X<_#K4?A5KUGK_ (?T_7?A?\?_
M  A\=%N/AU\#/@O\&M-\67'@/X,_&3X+^'=$\4:7\-/#&B-JEU/IGQI\2>)]
M=\1W]_?33^)$*^'-)\*:!>W&B* 6_CA_P4]^ WPZ^$LOQ&^&#ZG\:]5ET;X-
M>([/P_H/A[XA:9H^GZ-\:OC3HGP6\+1^/O&J> =8T/X6>)+[7;KQ,ND>#/B#
M_8'BK6-5\&:WH(TJSNH99H?:V_;M_9@CL?&FJ3_$*\MM+\%6>J:@^K7/@3XC
M0:5XVL-'\>:3\+;Z[^#^HR>$EM/C;"GQ+\0>'/ $)^$<OC1KWQAXG\+:%IZW
M=WXG\/C4_D&P_P""2/A'0O 'B?X8>&OCIX_T/P5\2=1\*Z]\6M,B\+^";V?Q
MWXC^''[0'B#X\_#K5UU"^M)KSPW_ &9+KT7@'Q19:3*UOXL\(>'?#LD1\/:]
M'K>JZ[K>$?\ @D=\#O ^E>*='\)ZIIGA-8Y]$O\ X2>)?"'P:^"?A[XC_#K6
M/"?QF\*?'OP5K/B+XEP^"[GQ?\7;WPC\0/ WA.VL8/&NH1Z5KWA/2$TSQOIW
MBKQ%,_C! #V7PS^WAI'BWX0_MW?%_1_A[JZ:5^Q=XL^)'AB'1M=EU_PGKWC]
MOAU^S+\,OVAKQM7T/Q7X0T7Q#\-]2N+KX@W'@FXT;6-%U.[T]]$77G:XCU*/
M3K?E_ O[?&I^&[3X:W'[6G@7P/\ !>S^,?P+G^.?PV\2?#KXC>)/B]X?UB#2
M[CX<P:[\,KS3+[X7?#_QV/BE'_PMKP&/"&@>&O"?BV#XASW^HZ7H%S!XAT^W
MT35/2/"_[%MEIGPD_:^^&WBKXH>)O&.K_MH:UXY\3?$[QG/H7AW1+K2==\?_
M +/W@+]GW5F\)Z%I<?\ 9ECI&G>'_ &EZCH6FW\NH7%M-(UKJ6J:NZ2:C=>!
MZM_P2ZT?XI_#OP]X)_:2^-6M_&FY^&_PV\*_#7X-SGX9?#GPMX5^'=MX2\6?
M#'QO;^*;CP#=6GC'1_'OBKQ#KGP;^'=AXN;QO>:IX9U7PAHVH>$=,\,Z%IWB
MCQ1-JP!]0W_[<W[-^F:/HVKWGBOQ2DNJW'CB&]\-Q?"CXLW?CCP;!\,I/#D?
MQ)U?XE^ K/P3<>,OACX=\ ?\)AX0F\7^)?'FB:!H&BV?BSPO?W&HFQ\0Z1<7
MD>L_MX?LM^'H/B1?ZW\1[G3-"^%GA[XE>*/$WBR\\#_$"'P5?:-\&;Q=/^+T
M_@CQH_A9?"OQ(G^%]\S6?CVQ^'^L>)+SPQ<07T6I00G3=2-GXGX3_P""<VC_
M  X?PAXC^$GQ2;X*_$73-*^)?A/Q=XF^#WP5^"'@'P[K_@?XL>(O!'BCQ)HG
MA[X=:5X1;PQX/UK0=8^'GAFY\"^-IO\ A*O$^E;-0C\57?CB&>PATOS?4?\
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M\0ZK=:'H=[X@U/4-:N-*L+B&PDU2\N+TV_GRL] '[945@?\ ",Z3_P \[O\
M\&NK_P#R?1_PC.D_\\[O_P &NK__ "?0!OT5@?\ ",Z3_P \[O\ \&NK_P#R
M?1_PC.D_\\[O_P &NK__ "?0!OT5@?\ ",Z3_P \[O\ \&NK_P#R?1_PC.D_
M\\[O_P &NK__ "?0!OT5@?\ ",Z3_P \[O\ \&NK_P#R?1_PC.D_\\[O_P &
MNK__ "?0!OT5@?\ ",Z3_P \[O\ \&NK_P#R?1_PC.D_\\[O_P &NK__ "?0
M!OT5@?\ ",Z3_P \[O\ \&NK_P#R?1_PC.D_\\[O_P &NK__ "?0!OT5@?\
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MXSIU(SIU:<E&=*I"=.I&,XRBM^BL#_A&=)_YYW?_ (-=7_\ D^C_ (1G2?\
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M33],MQ*+:T0_LJ_#"Z*1!I&<+Y]_=R8+D!IWP H4* ?O)D>_Y'_"C(]_R/\
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M_0,M_P#R)_\ %T?\(QH'_0,M_P#R)_\ %T ;N1[_ )'_  HR/?\ (_X5A?\
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MNTM[GX/:3K7Q)\)WFAZ_(;B\L?WC'3OU/7ZGI[>GMB@!:*** "BBB@ HHHH
MCF_U4O\ US?_ -!-?B3_ ,$OO^3YO^"X?_9]WPR_]9-^$M?MM-_JI?\ KF__
M *":_$G_ ()??\GS?\%P_P#L^[X9?^LF_"6@#]NJ*** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBO&O&G[0?P<^'>O3>&/&OCO2O#NNP6UK>R:=?V^J"7
M[)>HSVMPCP:?-!+#,(Y%62*5U$D4L3E98W10#V6BO*O /QN^%GQ1U&^TKP#X
MQT[Q-?Z99)J%_!I\&I+]DLY)UMHYII;JQMX%\V=O+BC\TRR%9&C1EBE9/5:
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MVYJY;_L]?!VW!'_"$V=UN4(3J>I:[J[$ Y)9M5U6\9GD_P"6TA/F3#B5G'%
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M>$O"UW!-:W7AS0KFVN(GAN+>XTJQF@GAD4K)%-#) T<L4BDJ\;JRLI(8$'%
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M$)SG@Z\ERUJ$XSC)0YI5:#;I5;VC5JE%%%?,'VX4444 %%%% !1110 4444
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MI0A"4X^S4ZKIA_YB%C_X&VP_E-2?VII?_01LO_ ZW_\ CU']D:7_ - ZP_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]X;E\)WGQ>A\*G2O[17Q9/I,]S<G3F\0MX'C\5W5S\0X?"$7Q$GD\5-]7@
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M]GO0O&'B$6%_8'QM-XPU8?&3Q1\<?"'B=_%]K=:5X,\'>'-%;1IM C\7GQ
M?LGD9(R,CJ.XSTS]:0$$9!!'J#D?I7X9>)OVK/VGO@CX1_X*V^(/%_Q @^)_
MBC]G7QC\ +7X8GP_\/\ 2M)\+_#+2OB[\$?A!JFM7/AOPC>:E=7NN:!X U+Q
MQJWC^]'COQCJ]]KT^EZ@=6UK2=!N8-)TC[/_ &,/''CD^.?VC?@A\3O$_P 6
M=;\;_";7OAWKPTWXK:W\+?&]WI7@[XH>&M5OO"][HWQ$^%OAGP7::O%XAN_"
MOB+4M;\'^)O#%GKOP]\0)J&E:'J&N?#;4/ >J3 'W_1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7R_P"//V*_V4OB
M?\1KWXO>/?@)\-O$_P 3]2A\+6VI^.]2\/Q'Q/JEMX'>:3P=;:GJUO)!<ZC;
M>%Y+F[DT&WO6GATI[R]>S2)KRY,OU!10!X[)^SW\#9?'OB/XIM\)?AZ/B1XN
MT2\\.>)O'2>$]&B\6:WHVHZ?;Z1J-EJ&O16B:C.NHZ19Z?I.H3FX%U?:7IFE
MZ==W$UEIFGP6WE?@G]@S]C7X<Z?XWTCP5^S3\'O#^D_$JPAT[X@Z7:>"],ET
MWQI;6^H6&JP/XFL+R.ZM-9O8=3TK2K^+4[V&74XKS2]-N8[Q9M/LW@^MJ* .
M*^'WPW\ _"CPQ9^#/AKX.\-^!?"MA+=7%KH'A71[+1=,2[OIFN=0OGM;&&))
M]0U&Z=[O4=1N?.OM0NY)+J]N)YW:0]K110 4444 %%%% !1110!\U?%[]CK]
ME[X]^+[7X@?&+X&_#KXA>.++PK'X%M?%WB/08KKQ'#X,AU:[U^+PHNL1207Q
M\/)KE_=ZPND/,UB-4F:_\G[4J2KW'_"@?@E_PL31/BX?A1\/V^*'AO1[?0="
M^(#^%-&D\7Z7I5GI]QI%E:6>OR6C:E%]BTB]O])L9_M!N[+2M2U/3+6XAL-2
MO[>Y]=HH ^5? /[#W[(OPN\3>*/&/@#]G?X4^%_$WCC1M8\/>--9TWPG8B[\
M8:'K]M!8ZQI7BDW(N(O$-AJ&GVT&FSVVKQ7D1TR)--55L1]GKV#X7?!OX4_!
M+0;KPQ\(OAWX.^&_A^_U.76;_2?!GA_3= M+_5IK>VLWU*_33[>%KZ^6PLK'
M38KF\>>6WTS3]/TRW:*PL;2VA]*HH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBDW#UX]>WY]/;KUXH 6BBB@ HHIOF)NV[TW9QMW#=GTQG.: '44
M49 P"1D]!Z]^/7CF@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/%IJWBZ19VOGV^E075Q;Z39N39Z3;3S6^FV]I!+)&P!ZQ1110 4444 %%%%
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MG:22:1V8YK8/[1_A< G_ (0/XX<>GP4^(6?_ $S5]!X'O^9_QHP/?\S_ (T
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M\&1:G-XS\*1_LT^--(\/:=X;"Z7X[U7Q9X7L(M0T)=)UN]N>D^#_ .VM\2/
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
..**** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>flixabi.jpg
<TEXT>
begin 644 flixabi.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" !U .H# 2(  A$! Q$!_\0
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M^BBBMC **** "O,?C1 IL=*GP-RRR)GV*@_TKTZO+_C3<@6NDVV?F:220CV
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MI6IZ)=>(-5MM/MD74;,@7;K %9B>1\W\72N=^#?_ "+&H?\ 82F_DM-\%?\
M)3/&G_72+^1H ZSP_P")=/\ $UK-/IKR%893#(LB%&5AV(/UJO8>*=(U^TU0
MV^^>ULBT=P7B.QL [@,_>X'ZCUK@?$=_-\//%6NO;(_V?7+0RVP4<+<YP?U8
MG\177:#X?_X1GX:O8,!Y_P!DDDG/K(RDG\NGX4 :6AZSH]QX7_M728A#IBK)
M(%2'R\!<[CM'T-8LOQ<\+QK"PN+F19%#,4@8^5D\;O0^U4/ O_)$V_Z];K^;
MU-\.K"UD^$D*/;QLMS#,9@5_UAW,,G\ /RH OZE\4_#.G2(GVN2ZW()"UM$9
M @/3<>WTZUTNF:I::QI\5]I\ZSVTHRKK^H]C[5Q'P=L;9_ !+P1L;F>03%E!
M\P9Q@^HQ3/A;:?:/!&KV*2-$C7MQ C#DQ@@#(^G6@#2N_BOX9M+V2W-Q<2K$
M^R2>&!GB4_[P_I6[JMW!?>$KZYM95E@ELI'213D,"AP:P[;3/#_A3P?-X>GO
M[(YAD$GGR(CRE@3DKGKTQ]!6=X$9F^##!B3MMKD#/89>@#-\%_$70?#O@O2+
M"]EG:>.+][Y,)=8LNV Q'0XYQ7IUG>6^H6<5U9RI-;S*'CD0Y# UQ?PYTJTN
M/A3:P/!&4O(9#/E<[R689/X ?E2_!V9I? <<;,6$%Q+&N?3.?ZT =U1110 4
M444 %%%% !1110 4444 5-0L(M0MC%)P>JL.JGUK)T=YM+OGT^ZX63YHV[$^
MWUKH:@N;6*ZCV2KD Y!'!4^H/8UR5L-S5%6AI)?BNS)<=;DU<3\8/^2=WO\
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M[DDF@#1HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
>**** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>fumaderm.jpg
<TEXT>
begin 644 fumaderm.jpg
M_]C_X  02D9)1@ !  $ 8 !@  #__@ ?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$  4%!0@%" P'!PP,"0D)# T,# P,#0T-#0T-#0T-#0T-
M#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T!!0@("@<*# <'# T,
M"@P-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-
M#0T-#0T-#?_$ :(   $% 0$! 0$!           ! @,$!08'" D*"P$  P$!
M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1  (! @0$ P0'!00$  $"=P ! @,1
M! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_  !$( "L ;0,!$0 "$0$#$0'_V@ ,
M P$  A$#$0 _ /KO4-4M]+57N&91(VQ0B22,6VLV L:NWW58DXP .36-2K"B
ME*H[)NRT;ULWLDWLF9SG&FKS=E>W5_D9O_"56'_3Q_X"7?\ \8KF^N4?YG_X
M!/\ ^1,?K%+^;\)?Y!_PE5A_T\?^ EW_ /&*/KE'^9_^ 3_^1#ZQ2_F_"7^0
M?\)58?\ 3Q_X"7?_ ,8H^N4?YG_X!/\ ^1#ZQ2_F_"7^0?\ "56'_3Q_X"7?
M_P 8H^N4?YG_ . 3_P#D0^L4OYOPE_D'_"56'_3Q_P" EW_\8H^N4?YG_P"
M3_\ D0^L4OYOPE_D'_"56'_3Q_X"7?\ \8H^N4?YG_X!/_Y$/K%+^;\)?Y!_
MPE5A_P!/'_@)=_\ QBCZY1_F?_@$_P#Y$/K%+^;\)?Y!_P )58?]/'_@)=__
M !BCZY1_F?\ X!/_ .1#ZQ2_F_"7^0?\)58?]/'_ ("7?_QBCZY1_F?_ (!/
M_P"1#ZQ2_F_"7^0?\)58?]/'_@)=_P#QBCZY1_F?_@$__D0^L4OYOPE_D'_"
M56'_ $\?^ EW_P#&*/KE'^9_^ 3_ /D0^L4OYOPE_D'_  E5A_T\?^ EW_\
M&*/KE'^9_P#@$_\ Y$/K%+^;\)?Y&U:W45Y$EQ VZ.55=#@C*L RG! (R"#@
M@$=QFNV,E-*<=4TFO1ZHZ4U)*2V:NOF<9XID*W5H.PF8_P#DO<#^M>9COX</
M\:_])F<&+^!?XE^3*GFBO!/&#S10 >:* #S10 >:* #S10 >:* #S10 >:*
M#S10 >:* #S10!J^#Y"VF6^>T,0_)!7U5#^#3_P0_P#24?24O@A_AC^2,KQF
M_E3VK>DS?^B)JXL?I3C_ (U_Z3,Y,7I37^)?DSG_ +:/6OGKGAW-_P /2I<2
MR!@C;8F8>8 4!!')ST [GTS7J85*4:LFH7BE9S7NK??LNYV89*53E:37++1J
MZZ%PJE[,(6-MA8GDS:$=1CAR0?P'ZT2@JGM&^3]W2<U[+X6[[2\_NT:.CD52
M<*;]G9\W\+?1=?T^9'8V$-S'"[LX\Y96;!''E],?+^?7\*I8>G92DY)>Q=1V
MMNG%::;6;T_$SHT8U%!MN\IRCI;HFUT\B6*RLY?)*R3 7081@A,AESDMVQZ
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MT4 'V2+^Z* #[)%_=% !]DB_NB@ ^R1?W10 ?9(O[HH /LD7]T4 'V2+^Z*
C#[)%_=% !]DB_NB@ ^R1?W10 HM(O[HH O1(J#"C H __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>gainlossfairvaluechart.jpg
<TEXT>
begin 644 gainlossfairvaluechart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #P 3T# 2(  A$! Q$!_\0
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MWXV\4_#[X>:%;^'[[P_?%+_0&\.W?C?3K&TL_$'B?P;JN@^*=-M9-1/A35]
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MH7A-='=K[3_"6H_$[2[#5O&S>(HK<>--&\5^";?1);OPSJFHQ_:M?GK\+_\
M@FO\ /@O^TSX#_:1^&-Y\2_#=S\/_A!\3?A/I'P[N_BY\7O%O@;R_B?XT\(^
M,=5UX:9XU^(?B*VM?LL_AJ^CB\+VUDOA6[U37G\676F-XIT+P[JFG?H50 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6O\ Y8T?\(WI?I??^#C6O_EC0!O45@_\(WI?I??^#C6O_EC1_P (WI?I??\
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M>ZI_\DT ;F1ZC\Q7Q3\5/^1^\0_]=;'_ --=C7UU_8%O_P!!#7?_  >ZI_\
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M^#W5/_DFC^P+?_H(:[_X/=4_^2:_9!&YD>H_,49'J/S%8?\ 8%O_ -!#7?\
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MM9)/(MY]T#V5Y*R;+F*5!F2*-MP4-\N <$@_DE_P4G_Y22?\$*?^SK?VH/\
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MV=TD;]%%%>J 4444 %%%% !2'H<=<''^3Q^=+378*K,6"A59BS$!5 !)8DD
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M^E '045@_P!C7/\ T,&N?]_=,_\ E31_8US_ -#!KG_?W3/_ )4T ;U%8/\
M8US_ -#!KG_?W3/_ )4T?V-<_P#0P:Y_W]TS_P"5- &]16#_ &-<_P#0P:Y_
MW]TS_P"5-']C7/\ T,&N?]_=,_\ E30!O45@_P!C7/\ T,&N?]_=,_\ E31_
M8US_ -#!KG_?W3/_ )4T ;U%8/\ 8US_ -#!KG_?W3/_ )4T?V-<_P#0P:Y_
MW]TS_P"5- &]16#_ &-<_P#0P:Y_W]TS_P"5-']C7/\ T,&N?]_=,_\ E30!
MO45@_P!C7/\ T,&N?]_=,_\ E31_8US_ -#!KG_?W3/_ )4T ;U%8/\ 8US_
M -#!KG_?W3/_ )4T?V-<_P#0P:Y_W]TS_P"5- &]16#_ &-<_P#0P:Y_W]TS
M_P"5-']C7/\ T,&N?]_=,_\ E30!D_$7_D1O$_\ V";C^2U\.-U/U/\ .OLO
MQ[I=Q!X-\1ROK6KW"QZ7<,8)Y-/,,H 'R2B/38I"A_B"2(Q' 85\:-U/U/\
M.OP3Q9_Y'.6_]BS_ -VL0/HO5_H)1117Y4(**** "BBB@#Z!^ 7_ !_>)O\
MKTTS_P!'7M?2]?+?P0LY+N\\1+'?WUB4MM-):R>V4RAI;P8D^TVMT"%(RFP(
M06;<6! 'TK8V4MIYOF:A?7WF;-OVU[5O*V[L^7]FM+7&_<-^_?\ =7;MYS_3
M'AS_ ,DCEO\ U\Q__J?B0+]%%%?< %%%% !1110 4444 %%%% 'X@?\ !2?_
M )22?\$*?^SK?VH/_6.?B#7[>1_ZN/\ W%_]!%?B'_P4G_Y22?\ !"G_ +.M
M_:@_]8Y^(-?MY'_JX_\ <7_T$4 /HHHH **** "BBB@ HHHH **** "BBB@
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M^'?P]UW4?A[X9\0>+=;^)A]GTCX>?$O6?V+_  9\!O&WP>^*_ACXF_"OP_\
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; 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>gazyva.jpg
<TEXT>
begin 644 gazyva.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M P$  A$#$0 _ /LN@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@!"
M0HR> * \D<MJ7C;1])RL]S'O7^!2"WY9 _6I;2/6HY=BL19TZ4K=VK(XNX^-
M6A6QVA+N3'=$A(_6=:GG1[4.'<9/7FI1]937Y4V0Q_'#0I#CR;U?=HX /TN#
M2YUYEOAO&1^W1?I*?_RLZ;3OB7H6H<"<0$]!+M7_ -!9JI21YE7)\91_Y=\W
M^"[_ #2.VMKN&\020.LB'H5.15^AX<Z<J3Y:D7%KHU8L4&84 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % '$^+?'5AX3C/G-YEP1\L2\DG_:Q]T5#DHGN8#+
M*V82_=KEAUD]OEW/F/Q-\2=5\0LR>8;> GY8XSC'U88)K!R;/U'!Y/AL$D^7
MGJ=92V^X\^>1G.YB23U)))_,U!] O=TBK+LM!E PZ4"%R:!W-[2/$VHZ'();
M.9T*]B25_P"^2<4TVMC@KX.ABH\E:FGYI6?WGT/X-^+T&IE;35@()C@"4?<8
M^_9:WC/HS\ZS#()X=.MA/?ANX]5Z=SVY'5P&4@J1D$<@CVK4^&:<79Z-=!U
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MH0!V/>L)QMJC]1R+,_:Q^IXF7O17N2;W7:YXC_9]S_SRD_[X;_"LC[?VE/\
MGC]Z.C\*W5[H&I0WD<<GR. PV-RIX(Z>AS36CN>?C:=+%X>I0E..J;6JW6I]
MQ6\PN(UE7HZ@C\:ZS\*E%PDX/=.Q+00% !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % %'4[P:?:RW
M+=(49_R&:3T-Z-/VU2%)?:DE]Y\#:G=M?74MPQR9)&;GT+$C]*Y#^@*--4:<
M*25N6*7W%$#-(W/L;X4^'5T724N& $UWB1CCD*>B_2NF"LC\:SS%O%8ETT_<
MI^ZETOU9Z?6A\L% !0 4 % !0 R2-95VN RGL1D4%)N+O%V?D5?[-M?^>4?_
M 'R*5C7VU3^>7WL/[.MA_P LD_[Y%%@]M4_FE][+BJ$&U1@#H*9BW?5BT""@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@#AOB/>&RT*Y(XWH4_[ZJ):(]W*:?M,9279W^X^(SUKE
M/W%[FAI-N;J\AA SOE0?AN&?TS31SUI^SI5)]HR^^Q]^VENMK"D*#"QJ% ^@
MKLV/Y]G)SE*;W;;+%!F% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0!YA\7<C09,?WU_K6<]CZC(O]\CZ,^.37,?LQT_@T#^U[;/3S5JEN>7F&F%J
MV_E9]W#I76?@H4 % $<RNR,L9V.0=I(R >QQ05&R:<E=7U7D?-'BGQUXL\*7
M;6MR\6W),;B$;77L0<CGU%8.4HZ'Z?@<LRW'TE5I*=_M1YM4SF?^%Q^(?^>D
M7_?E?\:GG9Z?^K^!_EG_ .!,/^%Q^(?^>D7_ 'Y7_&CG8?ZOX'^6?_@3#_A<
M?B'_ )Z1?]^5_P :.=A_J_@?Y9_^!,V-"^,^IQW:?VF4EMB<.$0(1G^($$].
MN*:F^IQ8GA[#RI/ZIS1J+57=T_+YGT]87\&IP)=6K"2*095A_G@^HK=>1^75
M:4Z$W2JKEE%V:+=,Q"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H X/XE6AN]"N0/^6:[_ ,JB
M6Q[^45/9XRG?J[?>?$QX-<I^WO<T]%N#:7L$PXV2H?PW#/Z4UH<V(A[2C4AW
MA+\C[]MYEGC65#E74$'V(KL/Y]E%PDXO=-HEH("@ H YGQ5X6M?%5FUK<@!@
M"8Y,?,C=B/;U%2U?0]3!8VIE]55:3T^U'HT?%_B+PY=>&[M[.Z4@J?E;LZ]F
M%<S7+H?M>$Q=/&TE7HM:[KJGV,'8?2I._P"[[PV'TH#[OO$QM]J!?-?>>G_#
MSX@2^%IQ;7!+V,A 9<_ZLG^)?ZUI&7+IT/F,URN&/@ZM*RK16CT][R9]>V=W
M#?1+<6["2.0 JP.00:Z?0_':E.5&3IU%:479HLT&84 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M_P!V/)_I5G@2WT.OH)"@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M?$;7=/4)#<O@>H#?SJ^9H\:IE."JN\Z6OD[%UOBKXA88-R1]%4?THYF8K),
MO^77_DS.<U#Q9JFI_P#'Q<2,/0,5'Z8I79Z-+ X;#_PJ<5ZI,YYG+G+$DGKF
MI/0VT6B[(85S03*-]#IO"7@B[\6W2PPJ5A!_>2D?*H[\^OM6D5?8^7S'$4\#
M!RFUSOX8]3[7\/Z#;>'+-+&S4*D8Y/0L>['W-="5M#\DK595YNI/=_@;5,YP
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M2^=CIHWO>]/0X]2[&;GO2T*U+J&3O2 G%(84 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 &* # H ,"@ QB@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M^A4]?TS7H+5'F[.W8^SO VO#Q!I4-P3F55"2?[X'-<$X\KL>C!W5SKZS- H
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MES+S.2<>1V6QZ9\%O$7^LTB4_P#32/)Z8X*C\>:QJQ^T;4I?9/H6N4ZPH *
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M/S'^\.2,>E>EBY^QKQFDG9;'S&3T'C,!4P[DX\TOBZHD_P"%=X_Y>3_WS_\
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MA^-?+SBX2<'T=C]6HU57IQK1VDDRU4'0% !0 4 % !0 4 % !0 4 % !0 4
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M_(T_'O\ R"G_ -]/YUA@?XR]&>AGW^XS_P 4?U(/ G_()/\ UTE_G5X[^/\
M)&&0_P"X?]O3.1\,?\AQ_J_\S7H8G_=H^B/G,K_Y&53U9Z?XA_Y!UQ_US/\
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MTB5[BY5WD(PN%)QZG/J:Z<51J5DH4](K<\S*L;A\#.5?$:S>WEYG>CX@6?\
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
8 * "@ H * "@ H * "@ H * "@ H __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>geographicsaleschart.jpg
<TEXT>
begin 644 geographicsaleschart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" '\ 3T# 2(  A$! Q$!_\0
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M#]C:Z/A[POK]I\*?%7B7XJ:O?>-I],^(]QX!\%^*8/B%#K-]XF8^"/$$GAP
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M_P $*?\ LZW]J#_UCGX@U^J7QP_Y%#2_^PW:?^F_4*_*W_@I/_RDD_X(4_\
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MC#X\>%]:^(/[._PH^'/Q!'P\^%=C\3_BO\9KWQ7X]U/]J[X3_LG7-EX-\/\
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MTQX<_P#)(Y;_ -?,?_ZGXD HHHK[@ HHHH **** "BBB@ HHHH _$#_@I/\
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M]XF_Z]-,_P#1U[7TO7],>'/_ "2.6_\ 7S'_ /J?B0"BBBON "BBB@ HHHH
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M4JR<YX912A3C.I)R:C&G"4Y-1C)K]NO^$I\,?]#+X>_\'>F?_)5'_"4^&/\
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MO/$991RYY9/!1BJ.)GB%5^MQQ+DY<]*DX\GU=6M?FYG>UM>,^(O_ "(WB?\
M[!-Q_):^'&ZGZG^=?<?Q%_Y$;Q/_ -@FX_DM?#C=3]3_ #K^>/%G_D<Y;_V+
M/_=K$'ZCT7J_RB)1117Y4(**** "BBB@#Z!^ 7_']XF_Z]-,_P#1U[7TO7S1
M\ O^/[Q-_P!>FF?^CKVOI>OZ8\.?^21RW_KYC_\ U/Q(!1117W !1110 444
M4 %%%% !1110!^('_!2?_E))_P $*?\ LZW]J#_UCGX@U]F?\% O^2.^$_\
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M"/+"$(K<\,?\C/X9_P"QD\/_ /IYL:_I3'3\6_F:_FL\,?\ (S^&?^QD\/\
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M=5TCPO\ #K16\+_%#P?X>^$NDZ1;7?ASQ5KUOH>FMX4U/QA9?$'P^;&"YL?
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MCP^(KVWNH]/TGPQ+:K!86MF4>ZOM:CF+-;QH9 RP1@!R0I!*X+'/Z.U^5O\
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M]^_VF?\ D@7Q8_[$O5O_ $".OP$;J?J?YU[/A'_R(\R_[&LO_43"GSOT@?\
MDI<F_P"Q(O\ U.Q0E(0",$ CT(X]?YTM%?JY^""8 Z #\!WZ_G0%4=% ^@ I
M:* "BBB@#]'O^"=?_(P_%3_L"^$?_3CX@K]4J_*W_@G7_P C#\5/^P+X1_\
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M0'_)(Y5_V4>&_P#59FI\YT445_0I_(@4444 %%%% &YX8_Y&?PS_ -C)X?\
M_3S8U_2F.GXM_,U_-7X956\2^&U8!E;Q'H"LK %65M8L0RL#D$$$@@\$$@\5
M_1V/#OA\]="T;J?^879>I_Z85^'^,/\ %R#_ *]YE_Z5@3^G?H[_ ,#BO_K[
MD_\ Z1F1Y+^TS_R0+XL?]B7JW_H$=?@(W4_4_P Z_>?]I/0]$MO@/\59[?1]
M+@FB\&ZJ\<T.GVD4L;A8\,DB0JZ,.S*01V-?@PW4_4_SKV?"/_D1YE_V-9?^
MHF%/G?I _P#)2Y-_V)%_ZG8H2BBBOU<_! HHHH **** /T>_X)U_\C#\5/\
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M*OYZ;7XQU^SG[!?_ "0IO^QX\5?STVOSCQ3_ .25_P"ZG@O_ $WB3]D\"_\
MDN7_ -B7,/\ T_@3[4K\(?VO/^3BOB1_U]:!_P"HGH-?N]7X0_M>?\G%?$C_
M *^M _\ 43T&O@?"3_DH<?\ ]B:O_P"IV /U?Z0'_)(Y5_V4>&_]5F:GS;11
M17]"G\B!1110 4444 ;GAC_D9_#/_8R>'_\ T\V-?TICI^+?S-?S6>&/^1G\
M,_\ 8R>'_P#T\V-?TICI^+?S-?A_C#_%R#_KWF7_ *5@3^G?H[_P.*_^ON3_
M /I&9'AG[3/_ "0+XL?]B7JW_H$=?@(W4_4_SK]^_P!IG_D@7Q8_[$O5O_0(
MZ_ 1NI^I_G7L^$?_ "(\R_[&LO\ U$PI\[]('_DI<F_[$B_]3L4)1117ZN?@
M@4444 %%%% 'Z/?\$Z_^1A^*G_8%\(_^G'Q!7ZI5^5O_  3K_P"1A^*G_8%\
M(_\ IQ\05^J5?S'XE?\ )7YE_P!>\!_ZKL(?V[X,?\F[R7_K_F__ *M\:%%%
M%?!GZF%%%% !1110 4C?=;DC@\C&1QU&>,_7BEJ"ZEE@MKB>"UEO9H8)I8K.
M![>.:[ECC9X[:&2[FM[5);AU6&-[B>&!7=6FEBB#2* ?SY?$N&UU[_@HMXK@
M/[4_[-G@+5+3QGX8\(ZDGQ,_:$OO O[2>@6UY\0OV4_BKX*\#_#GX+W,-YX8
M\<^%)8_A3XV\+?#N^TOQ3X7L]4O_ (Y?$"V\;>#M<UK1M9L?'O\ 0DHP ,YQ
MGIT')X'LO0=^.>:_+_4OV_/"N@?&+PK\)OB?^S?)\,/B3XK\0>%=/MM'^(7[
M27_!/33O&=NWBF_M++2M93P9'^U5>?$/64=66YLK;P[X<U?6]72T\C0-/U.]
M-M;2?J$#G\R.W8X[?_K]<'B@#\0/^"D__*23_@A3_P!G6_M0?^L<_$&OLS_@
MH%_R1WPG_P!E!TK_ -1WQ)7QG_P4G_Y22?\ !"G_ +.M_:@_]8Y^(-?9G_!0
M+_DCOA/_ +*#I7_J.^)*^JX(_P"2LR+_ +#H?^D3/A?$S_D@N)_^Q;+_ -/4
MC\@J***_JX_@D**** "BBB@ K]G/V"_^2%-_V/'BK^>FU^,=?LY^P7_R0IO^
MQX\5?STVOSCQ3_Y)7_NIX+_TWB3]D\"_^2Y?_8ES#_T_@3[4K\(?VO/^3BOB
M1_U]:!_ZB>@U^[U?A#^UY_R<5\2/^OK0/_43T&O@?"3_ )*''_\ 8FK_ /J=
M@#]7^D!_R2.5?]E'AO\ U69J?-M%%%?T*?R(%%%% !1110!N>&/^1G\,_P#8
MR>'_ /T\V-?TICI^+?S-?S6>&/\ D9_#/_8R>'__ $\V-?TICI^+?S-?A_C#
M_%R#_KWF7_I6!/Z=^CO_  .*_P#K[D__ *1F1X9^TS_R0+XL?]B7JW_H$=?@
M(W4_4_SK]^_VF?\ D@7Q8_[$O5O_ $".OP$;J?J?YU[/A'_R(\R_[&LO_43"
MGSOT@?\ DI<F_P"Q(O\ U.Q0E%%%?JY^"!1110 4444 ?H]_P3K_ .1A^*G_
M &!?"/\ Z<?$%?JE7Y6_\$Z_^1A^*G_8%\(_^G'Q!7ZI5_,?B5_R5^9?]>\!
M_P"J["']N^#'_)N\E_Z_YO\ ^K?&A1117P9^IA1110 4444 %-?[C9R1@CC@
M\\=>WU[=:=36X5LDC@\CJ/I[^@[F@#^<35;.^^,'[17C+QK\)O@9^UKX3\;3
M_M7Z=H.O3^/?V5+CP_%K/@[3?'?[+GBGQ!X@\,?'[7O$ND6?@'1] U#X3WVK
MZ+XRUW2/&"6?P^\0^,_A[I/A#4]6NO >H:=_1XN<<^I_F<?08Z#L..U?S:^+
M_BQ^RY\3_P!J#QMX@^'?QQ_94^(_C.^_:X^$=EI?Q*TR7Q5XG_;I^&NM^"]9
M^%GA_4_@+\"/"&E^'[JW\3?#G5)[6XL)_$^B>.O"W@'P_P"%/'?Q*U#QOX"\
M=/H?BJ^\1?TDKT'X_EDXQ[>GJ,&@#\0O^"D__*23_@A3_P!G6_M0?^L<_$&O
MLS_@H%_R1WPG_P!E!TK_ -1WQ)7QG_P4G_Y22?\ !"G_ +.M_:@_]8Y^(-?9
MG_!0+_DCOA/_ +*#I7_J.^)*^JX(_P"2LR+_ +#H?^D3/A?$S_D@N)_^Q;+_
M -/4C\@J***_JX_@D**** "BBB@ K]G/V"_^2%-_V/'BK^>FU^,=?LY^P7_R
M0IO^QX\5?STVOSCQ3_Y)7_NIX+_TWB3]D\"_^2Y?_8ES#_T_@3[4K\(?VO/^
M3BOB1_U]:!_ZB>@U^[U?A#^UY_R<5\2/^OK0/_43T&O@?"3_ )*''_\ 8FK_
M /J=@#]7^D!_R2.5?]E'AO\ U69J?-M%%%?T*?R(%%%% !1110!N>&/^1G\,
M_P#8R>'_ /T\V-?TICI^+?S-?S6>&/\ D9_#/_8R>'__ $\V-?TICI^+?S-?
MA_C#_%R#_KWF7_I6!/Z=^CO_  .*_P#K[D__ *1F1X9^TS_R0+XL?]B7JW_H
M$=?@(W4_4_SK]^_VF?\ D@7Q8_[$O5O_ $".OP$;J?J?YU[/A'_R(\R_[&LO
M_43"GSOT@?\ DI<F_P"Q(O\ U.Q0E%%%?JY^"!1110 4444 ?H]_P3K_ .1A
M^*G_ &!?"/\ Z<?$%?JE7Y6_\$Z_^1A^*G_8%\(_^G'Q!7ZI5_,?B5_R5^9?
M]>\!_P"J["']N^#'_)N\E_Z_YO\ ^K?&A1117P9^IA1110 4444 %9NLS:G;
M:3JEQHMC;:GK$&G7LVE:=>WK:;9W^I1VLKV%E=ZBMK>M86UU=K#;W%ZMG=&U
MAD>X%M.8Q"^E2'H><<'D<$>^: /S+^"'[;VL^(_$VK^"]?\ V"/VH/@SXQU#
MXF/H?B1#X/\ A?)H>L:U_9_@^T\4_$Q]6M/B)HVI>*O"%AJFIR:;<>/M%T3Q
M/9ZGHGAV'4H]1GED&CV/Z:__ %^OL?Z]1[5^7'Q"_85\9>*_V@/$'CRPF^!$
MF@>-?C/\+OC5<?&?Q%\/];U7]K#X9?\ "M!X$)^%OPM\<QW/]D6'@[68_ DF
MEZ3J4FHZ+;>$_#WCGQGI-WX+\:/J-Y>ZK^HP& !_^KZ#V'0#L,"@#\0?^"D_
M_*23_@A3_P!G6_M0?^L<_$&OLS_@H%_R1WPG_P!E!TK_ -1WQ)7Q=_P4NF%O
M_P %'O\ @A9,T<T@3]JW]I\E+>&2XF.?V._B OR0Q*TCXSN;:IVH&8\*:^P/
MV]]2BO/A%X6B2UU. IX_TMBU[IEY91D#P]XC7:)+B)$,ASD1ABQ4.P&$)KZK
M@C_DK,B_[#H?^D3/A?$S_D@N)_\ L6R_]/4C\DZ***_JX_@D**** "BBB@ K
M]G/V"_\ DA3?]CQXJ_GIM?C'7[$_L+:I%9? ]HGM-4F;_A-?%#[[33+V[APQ
MT\ >=;PR1[QMY3=N7/('&?SCQ3_Y)7_NIX+_ --XD_9/ K_DN7_V)<P_]/X(
M^YZ_"']KS_DXKXD?]?6@?^HGH-?N#_;]O_T#]=_\$6J?_(U?AQ^UI.MS^T)\
M1)UCGB62YT B.Y@EMIUQX4T)?G@F5)$SC<NY1N0JX^5A7P/A)_R4./\ ^Q-7
M_P#4[ 'ZO](#_DD<J_[*/#?^JS-3YSHHHK^A3^1 HHHH **** -SPQ_R,_AG
M_L9/#_\ Z>;&OZ4QT_%OYFOYJ_#)V^)?#;$,0OB/0&(52S$#6+$X51RS'&%4
M<L< <FOZ-QK]O_T#]=ZG_F!:IZG_ *=J_#_&'^+D'_7O,O\ TK G]._1W_@<
M5_\ 7W)__2,R/*?VF?\ D@7Q8_[$O5O_ $".OP$;J?J?YU^\G[26LP7'P(^*
MD*V6L1M)X-U50\^CZA!"I*(<R32P+'&HQRSL% R2>*_!MNI^I_G7L^$?_(CS
M+_L:R_\ 43"GSOT@O^2ER;_L2+_U.Q:$HHHK]7/P0**** "BBB@#]'O^"=?_
M ",/Q4_[ OA'_P!./B"OU2K\H/\ @GQ?1V.O_%!I+>^G$FC>$P!96-S>E2NH
M:^<R"VCD,8.?E+@!L-MSM(K]4++4([[S/+M[^#RMF?MMA=66[?NQY?VF*/S,
M;3OV;MF5W8W#/\Q^)7_)7YE_U[R__P!5V$_R/[=\&/\ DW>2_P#7_-__ %;X
MTOT445\&?J84444 %%%% !69K4QM]'U6X6VU*]:'3KZ46>C,JZO=&.UE<6VE
MLT]LHU&XV^38EKBW473PDSPC,J:=% 'XT^"-%^-'QW\9^#_'_BFR^(6N^"_A
MMXE\,Z'I]UH]U:P_$SPU'=:GI_B265K_ ,=^"_A/IU[XA\,7-K_PA_QG\0^
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M?Z0'_)(Y5_V4>&_]5F:GS;1117]"G\B!1110 4444 ;GAC_D9_#/_8R>'_\
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M'_7UH'_J)Z#7[O5^$/[7G_)Q7Q(_Z^M _P#43T&O@?"3_DH<?_V)J_\ ZG8
M_5_I ?\ )(Y5_P!E'AO_ %69J?-M%%%?T*?R(%%%% !1110!N>&/^1G\,_\
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M]NX%2@D+%"' #!OD3_@I/_RDD_X(4_\ 9UO[4'_K'/Q!K[,_X*!?\D=\)_\
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M>'__ $\V-?TICI^+?S-?S6>&/^1G\,_]C)X?_P#3S8U_2F.GXM_,U^'^,/\
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M_@A3_P!G6_M0?^L<_$&OLS_@H%_R1WPG_P!E!TK_ -1WQ)7U7!'_ "5F1?\
M8=#_ -(F?"^)G_)!<3_]BV7_ *>I'Y!4445_5Q_!(4444 %%%% !7[.?L%_\
MD*;_ +'CQ5_/3:_&.OV<_8+_ .2%-_V/'BK^>FU^<>*?_)*_]U/!?^F\2?LG
M@7_R7+_[$N8?^G\"?:E?A#^UY_R<5\2/^OK0/_43T&OW>K\(?VO/^3BOB1_U
M]:!_ZB>@U\#X2?\ )0X__L35_P#U.P!^K_2 _P"21RK_ +*/#?\ JLS4^;:*
M**_H4_D0**** "BBB@#<\,?\C/X9_P"QD\/_ /IYL:_I3'3\6_F:_FL\,?\
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M4 %%%% !1110 4444 ?A]_P4J=8_^"D/_!"R21E2-/VK/VH&=W941 ?V.OB
M 6=RJKDD*,D98A1DD _8O[?]Y9R?![PH$N[1BOQ!TK(%W;'_ )EWQ(,C]]R/
M<9'(YY&?5?VI_P!B3]E#]MOPYX9\)?M6? CX??'/P_X-UFZ\0>%=/\=Z5-?K
MX?UB^LUT^]OM*N;2[L;RSEO;)([>[6*Y$5S'# )XW,$13X?_ .' /_!' ?\
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M\$<0./\ @GU^S^?F0?\ ('\2="P!/'B;L"3Z>O%?-'[&G_!"#_@EGXH_97^
MGB#XL_\ !/OX/M\2M7^&'A>^\;OXK\->,M-\2R>(YK('4Y-<L-2\06U]::G)
M.#)=P7-M;R1RLR^3&NU%/^(Q?]4[_P"9?_\ !8?\2ZK_ *+!_P#B/^G_ %.O
M7TTW/*?/@_Y^+;_P*MO_ (]1Y\'_ #\6W_@5;?\ QZON_P#X<!?\$</^D?7[
M/_\ X*/$?_S34?\ #@+_ ((X?](^OV?_ /P4>(__ )IJ/^(Q?]4[_P"9?_\
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M-^ZK2TMK"UM[*SACM[2T@AMK:WA4)%!;V\:PP0Q(.$BAB1(XT'"HJJ.E6**
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MOAO#/^V?[5Q_]I?VI[+^S_W?U_ZW[/VGUBA\'UCW>?DO\/O<M^EQ]%ZO]/\
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MA]\%M3L_&NL>"?A[I/Q^\,VL.H^*W.I>)/!?[2L_B'4OBAX(\5ZA9Z=:/?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
J**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>incometaxchart.jpg
<TEXT>
begin 644 incometaxchart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %2 3T# 2(  A$! Q$!_\0
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M=-XH\/:!J_@S5?#.G:SX!\;6%Y)>:+K4FI3ZOH_B/3-8U;1[VEXJ_8+\6_\
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M$%E:16VH:!?F'PO:V*>%IM5UV7Q5-I@\3:/H6I6'Z"4 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !112'.#@9.#@=,GL,T
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M^*-0\/WNFZQ8>&_$G@^1X_%F@Z]>6&L3VVD:KX9>*7^WK._EMY=+CBDFO!%
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MJ?\ @AUW_P"5M'_"1:;_ '=4_P#!#KO_ ,K: -RBL/\ X2+3?[NJ?^"'7?\
MY6T?\)%IO]W5/_!#KO\ \K: -RBL/_A(M-_NZI_X(==_^5M'_"1:;_=U3_P0
MZ[_\K: -RBJMI>0WT1F@$X0.R?Z1:75G)N4 G]S>0P2E?F&'";&Y"L2#BU0
M4444 %%%% !2-T/L,],].<8[YZ$9&1W'6EI#T. "<' /0^Q]CWH _G_T7X8?
M%X?M)?%CX<'XP_''XM_"W2?VK/#7B/QKX?\ C-^UU\&/A ]Y/JA^%OQ$M]+T
M+X6^&OV;-?\ B'X@^&.BR0:4/"UK8_%'X8CXBW&CZ]X>_L2PT"]U'5_%']
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M\#]5T_3;?Q(+ZY2W,T^EF,,LC;PD=Z&(V(W0L!SCKQ7VWAW_ ,E?E7^''_\
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M[51Y)U,13]G[25.=2,:[A!NC4C%:=G]Z_P NQ^S_ /PNWP7_ '=:_P#!;_\
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MTJ_\'6T%EJ%I=3#5M/D,4$R2.$6WNPSE5).U2P!., D ]17S7&/_ "2^>?\
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M_P!5V+&MI>GZH^E:^6OCS_R,.A_]@:7_ -+I*^B/^$G\/?\ 09T[_P "HO\
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M^OC2?_15]7R)_8?B'_H>]5_\)_PI_P#*NO;_ (.Z%J*0^(#=?&#Q-H#M-IQ
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MDG@G0[74+&*2Y_60?CU/7'K[=O3OCKSF@#\0/^"D_P#RDD_X(4_]G6_M0?\
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M4 )@>_YG_&C ]_S/^-+10 F![_F?\:,#W_,_XTM% "8'O^9_QKY:'PM\8?\
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M&UW$!<P;X2&KZDW+C.X8'4Y&!CKSTXHR, Y&#C!SP<],>N>WK0 8'O\ F?\
M&C ]_P S_C02!C) R<#)ZG!.!ZG )QZ TM "8'O^9_QHP/?\S_C2T4 &,?\
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MXG6.D_$'2/[$N[^\\-W[:YI<=CK3Z=:^)?#]W+I>M)8Z9]>T %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
@B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>noncontrollinginterestchart.jpg
<TEXT>
begin 644 noncontrollinginterestchart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #P 3T# 2(  A$! Q$!_\0
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MWXV\4_#[X>:%;^'[[P_?%+_0&\.W?C?3K&TL_$'B?P;JN@^*=-M9-1/A35]
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MH7A-='=K[3_"6H_$[2[#5O&S>(HK<>--&\5^";?1);OPSJFHQ_:M?GK\+_\
M@FO\ /@O^TSX#_:1^&-Y\2_#=S\/_A!\3?A/I'P[N_BY\7O%O@;R_B?XT\(^
M,=5UX:9XU^(?B*VM?LL_AJ^CB\+VUDOA6[U37G\676F-XIT+P[JFG?H50 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6O\ Y8T?\(WI?I??^#C6O_EC0!O45@_\(WI?I??^#C6O_EC1_P (WI?I??\
M@XUK_P"6- &]16#_ ,(WI?I??^#C6O\ Y8U?L=-M=/\ --L)QYNS?YUY>W?W
M-VW;]LN;CR_O'/E[-W&[=A< %^BBB@ HHHH **** "BBB@ HHHH _$#_ (*3
M_P#*23_@A3_V=;^U!_ZQS\0:_;R/_5Q_[B_^@BOP]_X*73PVO_!1[_@A9/._
MEQ1_M6_M/[G*NV-W['?Q 11MC5V.YF51A2 3DD*"1^T<?B;1/+3_ $T'Y%Y%
MO>X/ YYM0?S /M0!T5%8'_"3Z+_S^C_P'O/_ )&H_P"$GT7_ )_1_P" ]Y_\
MC4 ;]%8'_"3Z+_S^C_P'O/\ Y&H_X2?1?^?T?^ ]Y_\ (U &_16!_P )/HO_
M #^C_P ![S_Y&H_X2?1?^?T?^ ]Y_P#(U &_16!_PD^B_P#/Z/\ P'O/_D:C
M_A)]%_Y_1_X#WG_R-0!OU\H?$3QKXKTOQGK=AIVNW]G9V\EF(+:%H1%$'TZT
ME<*&A=OFD=W.6/S,>W ^D/\ A)]%_P"?T?\ @/>?_(U?('Q+N8+SQOKMS;2"
M6&62R*.%=-P&F62GY9$1QAE93E1DC(RI!/YMXH8K%83(L%4PF)Q&%J2S:C"5
M3#5JE"<H/!XV3@YTI0DXN48R<6[-QB[72 A_X6)XW_Z&;5/^^[?_ .1Z\'^+
M7[</P]^!?B;X>^#_ (L_'&U\$^(/BAJ\FC^$[+5#-)&6CTS7M3&K>(KZSTVY
ML?!WAB8>&M6TVV\4^*;C2M"N-;B72XKYIDNVM/1*_+O]NCX'_M$>//C!\ /'
M7[-OA:31O'&BZ]<V!^-FB_%&/P_8>#UL_A-^T7IVB1_'GX5>(_#?B+PE\1/A
M/HOB7XAV3:;=:3IFL^-KVR\9?$7X8V*>%SX\TWQ/#^-9;F688G%*EBL\S2C2
M=*M)5'F]?#Q52--RI\]6M4G&,.9+FY:=2I)+EA3E)H=_ZMZ>G;O^;/TQU7]J
M'3=$^+/@[X%:I\5OLGQ=\?\ A;Q?XV\(^ G\^36M8\*> Y;*#Q7K@D@TJ73=
M.L]*GOX(D75[_3[G5'COO['@U!=*U4V6)\-OVQ?"/Q@U?5M"^&OQD/BO5='T
M>U\236UK8ZYIL>I^%+[5K[0+'QIX4O=?\-Z1IWCKP->:]INH:):^-_ ]WXC\
M)SZM:26,>LM-);"X_+[Q]^QC^U1XI_:4\+^.;OXK_"/5_!GBG1_VXM(\?>/]
M(^&_B[PO\0?!.B_'CX0>$OA9\)O#FGPW_P 9];M=8A\#>'=&M?#_ ()E\.Z#
M::;X8N-#\0^*_$^FZMK/CZ\NAW7[.WP[_:G^"2>&+NZ\ ^-=<T?P/^SS\*/@
MUXM^&^M_M(>%/%^E_%#XR:+XS^'_ (:U+XW_  =;6M2NO#OP5^&G@7X5Z;XN
MU.X\'I9^ -1^(&FS>%_!>G_"W2O$?@G3=:U3MEBJ_P!452EQ1F%7%.A2?(\W
MQ&'IQKRKUZ=1..(E3JNFX4J7LXKEE34X8C$RIX>JG3JRLM[W71;66NW?3_/5
M/] ='_;-\%>(/B)+\*=&^-4=_P".TU7Q/X?M]*CM-:ATS5O$W@>WDN_''A/P
MYXQNO#EOX&\5>,/!%K#/<>,O"/ACQ/J_B7PO%::@VM:79G2M6%C[1_PL3QO_
M -#-JG_?=O\ _(]?FGHFG?&GQ_\ M,^';WXH_LY^*_!'P:^"7C_X@7_[/[^&
M_&OP$O? 9U_5O#OB_P +7'[1WQ,M-'^(_P#PL6Z\3^*M \5>,-)^'_PV\/?#
MZ"S^'R?$+6O$_C^_\6^-]3GOO!OWQ^E>=C,TS*A*C&CG6:3<J$*E5+.:N)C"
MK*<_<57#U(P35-4G*FU*5.;E'GJ149N=NW3HNR?]=]?,[^P^('C66^L8G\2Z
MFR27UG'(I>##H]U"CH<6X.&5BIYZ$U]LU^>FFL%U"P9CA5OK)F/)PJW<))P
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MOF+#]D;1)]9CU);HRNL0MFMEG,A"",L0*]8H _$#_@I.2/\ @I)_P0IP<?\
M&5O[4 _ _L<_$$$?B.#[5^W<8S&A)))1226;).!R>:_$3_@I/_RDD_X(4_\
M9UO[4'_K'/Q!K]O(_P#5Q_[B_P#H(H =@>_YG_&C ]_S/^-+10 F![_F?\:,
M#W_,_P"-+10 F![_ )G_ !HP/?\ ,_XTM% "8'O^9_QHP/?\S_C2T4 )@>_Y
MG_&OBGXJ?\C]XAY)_>V Y))P-*L0!D^@X'H.*^UZ^*/BI_R/WB'_ *ZV/_IK
ML:_+_%C_ )$&!_['%'_U"QX'GU&!QQTY'L<$9'X$CZ$T45_/X!1110 4444
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MXA_Z!>C?^#V^_P#F<H\_Q#_T"]&_\'M]_P#,Y6S10!C>?XA_Z!>C?^#V^_\
MF<KX[^)C7#>.=>:ZBAAG,MEYD<$[W,*G^S+(+LGDM[5Y 5VDEK>/#$J P 9O
MMVOBCXJ?\C]XA_ZZV/\ Z:[&OR_Q8_Y$&!_['%'_ -0L>!Y]1117\_@%%%%
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M;_A(_#W_ $'=&_\ !I8__'Z/^$C\/?\ 0=T;_P &EC_\?H V:*QO^$C\/?\
M0=T;_P &EC_\?H_X2/P]_P!!W1O_  :6/_Q^@#9HK&_X2/P]_P!!W1O_  :6
M/_Q^C_A(_#W_ $'=&_\ !I8__'Z -FBL;_A(_#W_ $'=&_\ !I8__'Z/^$C\
M/?\ 0=T;_P &EC_\?H V:^*/BI_R/WB'_KK8_P#IKL:^OO\ A(_#W_0=T;_P
M:6/_ ,?KX[^)EQ;W7CG7KBUGAN8));(QSP2I-#(%TRR5BDD;,C ,K*=K'# @
M\@BOR_Q8_P"1!@?^QQ1_]0L>!PE%%%?S^ 4444 %%%% %[3/^0EIW_80L/\
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M1+$QE3H*:I)4<35HQY54G4GK&FG*\G[S=K*R2"BBBOH@"BBB@ HHHH ****
M"BBB@#\-/^"F\]Y;?\%%_P#@AC/86/\ :5W'^U7^T^8;+[7!8>>Q_8\\?AA]
MJN5>&+8A:7#J3)L\I,.ZD?K?K7Q$U_PQ8PWVM^!KBVM)9H[2)[;Q+HUY(T[Q
M22HIC5(OD,<,A,@)4,%&/G!'Y.?\%)_^4DG_  0I_P"SK?VH/_6.?B#7ZI?'
M#_D4-+_[#=I_Z;]0KP^),?B,LR+,\?A'".(PN'=2BZD%."GSPC[T&TI*S>ET
M-:M+NT8O_"_[3_H4M5_\&FD?_'*/^%_VG_0I:K_X--(_^.5\W5P'Q4U;Q[H7
MP\\5:M\+O#EIXN^(5G8VK>$_#5X(98M8U&?5]-M+B"&QGUOPS#K.I6^E7&HZ
MAHOAJ3Q+X:7Q9K=EIWA<^(M"_MG^U;3\.I^)7%=2I"FJ^ 3J3A!.>$A&"<Y*
M*<I.=HQ3=Y2>D5J]$[BMV_'T_.S^_P D?:'_  T!:?\ 0I:K_P"#32/_ (Y1
M_P +_M/^A2U7_P &FD?_ !ROPC_8;_:P\>_'#P/\#/"7BWXFZ)XR^*6NZ+\2
M/%GQ0U*[^$6K?"OQWX8\-^$/"/@V[\/Z3XM\ ZS=W.@MKOBG7_BIX/\ $7A[
MQQX06#P5XK^'>FR#1K:;51K=^/I7]G:[^,FL?$3XXV_BKXU7GQ?^'GP\\16G
MPBT&74?A'\,OA[JE]\6/#=K9Z]\5M1LKOX;V%F;OPUX177=!^'D-G?QW$EYX
MPT[QU>B6&UT;3H[GOQ/'/&&$GB(5L5ED98>/.T\#5BZL7B'ADZ2G2C\4XN<8
MU?92E1:JQ4H*33T72_S?]U_?O==+^A^H_P#PO^T_Z%+5?_!II'_QRC_A?]I_
MT*6J_P#@TTC_ ..5^6/A7XH?&74_VX/'WP&\52> M(^%R?LP:+\6OAS%X:L=
M1U?Q?!J=_P#'G6?A6_B?QGX@UA+&RFO=0TVP^VVW@/1=*;0O#\=O;+=^(_$V
MHWU[<6GLWP.\?WGQ.^%/A#QEJL5G#KMY'X@T+Q-'IR21Z:/%G@/QCXC^'?BR
M738YB9(]-N_$OA'5;[3H79S;V5U;VYDE,7FOSUO$+BZA!3E7RZ46L.VX86$K
M?6:52K35^:S?+2J*5FU&4;7:LV:+IV[_ -W_ (/W]-#[H_X7_:?]"EJO_@TT
MC_XY78:)\0?$7B2R_M+1? L]Q9>=+;^9<>)=&M9/.A($J^44E(4;EVL6&X'.
M!7Q]7UU\$O\ D2V_[#6I?^T*^EX(XTSS/<[^HYA4PTL/]2Q%>U+#QI2]I3G0
MC%\RDW9>TE===.UQ:6VV:_%?YJ_S-[_A(?''_1/O_+MT7_XQ7D7B7X9^-/%>
MMWWB V6EZ2=1,#G3[G5Q=36Y@MH;0AY[2Q-O)YGD>:OED[5D5&)=6KZ=HK]&
MSW(,!Q%A*6#S#VWL:.(CB8>PJ*G/VD:=6DKR<9WCR5IZ6WL[Z6:/D;_A2/C3
M_GIHG_@?<?\ R#1_PI'QI_STT3_P/N/_ )!KZYHKY3_B%_#/?,?_  JC_P#*
M?7^EJ'R-_P *1\:?\]-$_P# ^X_^0:/^%(^-/^>FB?\ @?<?_(-?7-%'_$+^
M&>^8_P#A5'_Y3Z_TM0^1O^%(^-/^>FB?^!]Q_P#(-'_"D?&G_/31/_ ^X_\
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M_G0T?\.:[C_I*]_P6=_\3=L/_G0T ?L[O3^\O_?0_P :4$'H0?H0?Y5^,/\
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61110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>otherincomeexpensechart.jpg
<TEXT>
begin 644 otherincomeexpensechart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #P 3T# 2(  A$! Q$!_\0
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MWXV\4_#[X>:%;^'[[P_?%+_0&\.W?C?3K&TL_$'B?P;JN@^*=-M9-1/A35]
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MH7A-='=K[3_"6H_$[2[#5O&S>(HK<>--&\5^";?1);OPSJFHQ_:M?GK\+_\
M@FO\ /@O^TSX#_:1^&-Y\2_#=S\/_A!\3?A/I'P[N_BY\7O%O@;R_B?XT\(^
M,=5UX:9XU^(?B*VM?LL_AJ^CB\+VUDOA6[U37G\676F-XIT+P[JFG?H50 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6RML;?*^R7\][OSNW^9YVG:?Y>WY=NWS=V6SLVC=<HH **** "BBB@ HHHH
M*S=9O)M/TC5+ZWC@EGL].OKJ".Z>[CMI)K:UFGC2XDL;+4;U('>-5F>TL+VZ
M6,LUO9W4P2"32K-UF"YNM(U2VL_*-W<:=?06OG7E]I\/VB6UFC@\V^TQEU*R
MC\UD\R[L&6]MDS/:,+B.,T ?SZWGQ6\(?$[]HW0-0L=$TA_!?Q#^*'P@\6>-
M?A]!\6_V^_"GPY\:?$S2W\#6Z^-?$/PDNOV!8O"&I:SH'B#0M-DTVUO/BKX*
M\ ^/F\*>%_$7Q3TFUO+C6S;?T-KTX[$C\B>3D#D]2?7N>I_ 2UTW6/#7[2>F
M>!?"\7Q'\8VG@#XC_##PUXVU'PS\??\ @MG\9- \,>+IM+\#>)/$_A_Q%XFT
M1/%_[/;W&DOKZWUQH?CCQ0V@V7AN]TC_ (6?!I$%YK-G;_OV/ZGU]3Z__J].
M,4 ?B#_P4G_Y22?\$*?^SK?VH/\ UCGX@U^J7QP_Y%#2_P#L-VG_ *;]0K\K
M?^"D_P#RDD_X(4_]G6_M0?\ K'/Q!K]4_CB#_P (AI?!XURT!]C_ &?J'!]^
M#^5?+\:_\DKG?_8&_P#TY3''=>J_,^4Z***_E<04444 %%%% !7UU\$O^1+;
M_L-:E_[0KY%KZZ^"7_(EM_V&M2_]H5^B>&'_ "4[_P"Q;B__ $[A1]'ZK\I'
MKU?%'Q4_Y'[Q#_UUL?\ TUV-?:]?%'Q4_P"1^\0_]=;']=*L<?G7WGBQ_P B
M# _]CBC_ .H6/$>?=> "3V &2?8 <D^PHR/7W_#UK\\/^"GGB[XF>$/V6?%5
MY\*?B&G@'Q#/;>)'O8M'\?>'OAG\3?%FC:5X,U_4I-(^$GBWQ+INJ65OXIT?
M6(]$\5:[I-@FF>(==\#:-XCLM#\2>'IOM%U/U7[-OQ7\7?M&IXUMOA]\2O%5
MN/#'A#X7^"- \6?%+X?>$;[6W\<>)/'7Q-MOB)XS\5>#? VH:-\//&'B;PPG
M@5?A]HFH^#]5/POUW4M#U#QCI0U[PSXFDMKW\1CEM26 CF/MJ,:#JRI3O[1R
MI)5*5)3FHTY:2G5T4>9N,).'/*%2%-I7TZZ67>_GLOF?<FY<;MR[?[V1C\^E
M!91@$@$] 2.?IZ_A7Y<? OXDZ_XQ_8(_9"^*_P </VB_C-HMYXA\-:A-XXO_
M (:16 _: _:+\:7OB/QGX=\$^#/!5]X>T"YUZX\6WMWIHU,>%?AKX4MKKQ9=
M6&GV6IWOA?P%I'B,W/'_ !H\5?M3?#O]EW3OB-XN^,'CC3OCS\'?@WX<\4_&
M[3?!/CKX):3X8^!877]6\1_\+9^//PKMM..K_M#76M_#B)=$\3_#KP3+9^&_
M$^O>!/&:_!JPT[5?$NG:]9;0R>I.LZ/UK#PFL;4P/OJM&,JL*LZ/-"4J48S@
MIQA[247^[6)PM-<^(KQH(M;?M=?A_G;KJGTU/UV9E499E4'@%B ,^G)%*"",
M@@@\@@@@CUR*^7?VN-;TJQ^"OB_QEI7C'XEZ7J?A+4=-LO"&D_!WXL:Q\+]9
M\4_$CQYK6A^ ?AG\/_%>L^'A/JT6F:OXO\:^%(]3T:_6WU'3;*[DU=H/M4%O
MNM>!(O%_PM^)GPR^"'B'X@^,/BLEW^S;KFJ:YXT\9W8U;6=6\?\ PC\?^!?#
MFN>-+S5/*@DB_P"%A6WQ7>,V$JNL</A#0XXF:YM=0N+SBAA7/#JNII2<J\52
ME&2E+ZM2A6K.,E>/[NE5IR:GR7<U&'.U+E&K?Y/1]//;L_)Z'U/IG_(2T[_L
M(6'_ *605^A5?GKIG_(2T[_L(6'_ *605^A5?L/A%_"S[_KYEO\ Z3C0Z+U?
MY1"BBBOV004444 %%%% !1110 4444 %%%% !1110 4444 %(>AQUP<?Y/'Y
MTM-=@JLQ8*%5F+,0%4 $EB20 !U)) QU('- 'Y/:_P# S]H"#]JSQMXW7P!\
M5/%?@;Q-\7/!/B?1O$_A?]O;QI\#?"6C>%=,T/P9I%W9ZI^SC\/=$TGPIXQ7
M2;G1=4OM2F\7W>O>)/B/:W7]B>)-671[31=.L?UB']3WSW/^<=NG:OR9UZ_^
M.6L?M2^*9_$-Q^V_J'@*#XI^"8_AA?? OQW^QEX:_9W/P\&E>$GN;/Q7X<\3
M?$T?&C78[;Q-_P )//X\U:YTEM?US3+QK'PCI5O;V6FZ7#^LP_'J>N/4^G;T
M[XQGF@#\._\ @I?!'<_\%'O^"%D$H8QO^U;^T]N"2RPM\O['?Q <8D@DBE7#
M*#\KKD?*V5)4_J-\9-)LK#PKILULMP'?6+6,^;?ZC=*$-C?L0L=W=W$:G*K\
MX3S,# ?!8'\O_P#@I/\ \I)/^"%/_9UO[4'_ *QS\0:_5+XX?\BAI?\ V&[3
M_P!-^H5\OQK_ ,DKG?\ V!O_ -.4QQW7JOS/E2BBBOY7$%%%% !1110 5]3?
M![1[*^\(M/<"Y\S^U]0C_<ZAJ-LFU/)V_NK6[@BW8."VS<W&YC@5\LU]=?!+
M_D2V_P"PUJ7_ +0K]$\,/^2G?_8MQ?\ Z=PH^C]5^IZ!_P (WI?I??\ @XUK
M_P"6-><:Y\&=)UK5;O4_[9U*T^U&(_9U6.[$?E010?\ 'Q>--<R;O*WDRRL5
M+%%PBJH]EHK]ZS3*,NSFA##9GA8XNA3K1KPIRG5@HU8PG34[TITY-J%2<;-N
M+4M4VE9'R/\ $[]C+X1_&GP-X@^&?Q8TO3_B%X!\4VHL]>\*^*M!TK5=)U"%
M'$D3^5-%YMI>6[@M::EI\UIJ5FS2&TNX?-DWX^N?L+_!;Q++KD6O:79:KH'B
M?P-X<^'7B3P1=^'?#S> M;\+>#-?O?$?@RSO/"4=A'I2-X2O]4U:#P\+.*UM
M=/TW4IM/2T:"VTT6/VA17CPX*X8IQ4898H14G*,8XS'J,9MP;G&*Q5E-NE2?
M.DI<U.F[WA%H/SGC_P""5O[$L.@:9X5A_9Y^"4/AG1=8O_$&C>'X?A!X$AT?
M1]=U32TT34]9TBPBTM(-*U+4M%C72-0N]/6VFO=,!L+EI;9GB;MQ_P $]_V9
MA'X)B;X6_#26/X:V\=I\/5N?A?X%O#X)LX-2N-9M[/PS)>:/<2Z59VNLW=UK
M%G:0.+:RU>XGU6SB@U"5KD_<-%:/@_AV5G+ 5)6;:YL?F4K.5U)J^,=G)2DF
M^JE).Z;N7_R_K[CY,B_8X^$4 \2"#0M A'C'Q]8_%;Q=Y7A#PW'_ ,)3\4--
MG\/7.G?$;Q$5L@=9\<V-SX1\*3V?BO4/M&MV\WAK0)8KU7TFQ:'0B_95\(Q^
M-K[X@MX@UVX\27OA+3O \4UQ'826NF>&[#7-0\2SV.E6P@3[*^M:[?Q:CKMP
M\D\VHR:/H$1:&WTFWAKZCHK+_4?A:S7]DPLURN^*QSO%\B:UQ6S5."?=12>F
M@7/"(?@3I4,T,P\0:FWDS12[?LUFH<12+)L+(JNH;;M+(P=<[E(8 UZS_P (
MWI?I??\ @XUK_P"6-;U%>KE6193DBKQRO!PPBQ+INNHU*U3VCI*:IM^VJ5+<
MJJ3^&U^9WOH!@_\ "-Z7Z7W_ (.-:_\ EC1_PC>E^E]_X.-:_P#EC6]17K 8
M/_"-Z7Z7W_@XUK_Y8T?\(WI?I??^#C6O_EC6]10!@_\ "-Z7Z7W_ (.-:_\
MEC1_PC>E^E]_X.-:_P#EC6]10!@_\(WI?I??^#C6O_EC1_PC>E^E]_X.-:_^
M6-;U% &#_P (WI?I??\ @XUK_P"6-7['3;73_--L)QYNS?YUY>W?W-VW;]LN
M;CR_O'/E[-W&[=A<7Z* "BBB@ HHHH **** "JE_9Q:A97EA.L;P7MK<6DR3
M0074317,+P2+);74<UM<1LDC*\%Q#+!*I,<T<D;,C6Z* /S1TS]@?PQX8\1Z
M3<^%/V?O^"=>G2:'?:?JFA_$B/\ 8W\/:7X^T+4M,N8+O3=6M-'T'5K#2/\
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MT?VZ?^@/KO\ X+3_ /'Z -^BL#^W3_T!]=_\%I_^/T?VZ?\ H#Z[_P""T_\
MQ^@#?HK _MT_] ?7?_!:?_C]']NG_H#Z[_X+3_\ 'Z -^BL#^W3_ - ?7?\
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M]J=.:E*+A-2A\<7%J4=5'WDU>/O2BM4M9);M ='7US\$P#X+;(!_XG6I=O\
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MI?&+Q/\ 'OX-^#?'?[/WQ:\$Z7\4="\/_LM? /PW!:6FL?$OP]:OK_CGQO\
M%?P5XET:XT_Q%JES\0?$NJ?VCXJNQ?1W7]KS_P!$7_"I_#9)/D6>222?[&T<
MDD\DDFS)))/)))/<U\M:9:3W'[:/C'X/RWFGMX%TG]E[X<?$>RT0>&_#0DA\
M7>(/C!\6/"VJ:N;Q=.&HNESH?AC1M.%I)<-I\?V-KF&W2[EGEDN?AUG<Z<Z4
ML;ESISP^'H.G+%X^4+T<1]:E5E_L*G4J5*TJLG*<W*"JU84I1IRA"F-W7];6
M27Y'QQ\+-/U[X)?!_P"$'@:/P=KOBOXM?$30M?\ $'BO78O#&H+X*D^/VM^
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MC^RM4_Z&.^_\ -%_^5] &]16#_96J?\ 0QWW_@!HO_ROH_LK5/\ H8[[_P
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MQI?ACXE:C\5?&7@SP1J?@7Q_JOAB30]4\7:/<W6KS:99^)[WP]F_$S_@H_X
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M%P+:"&W$]W,]Q=3"&-8A-<W$GSSW$H3S)YG^::9GD;YG-6:* "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
C%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>otherrevenueschart.jpg
<TEXT>
begin 644 otherrevenueschart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $R 3T# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /-/C/\ $,_"/X0_
M%/XJ#1W\0GX:_#CQUX_&@QW?V"36CX+\*ZMXF&DI?"VO39OJ7]E_8ENA9W7V
M9IQ-]FG\ORG^!/V=O^"D?A?XA_"3PM\7/BKK7P$:S^(VG>%+CP%X._9(^)?Q
M&_;!\?+K&H_#P?$_QKX:\8^$/ GP8TGQ!H>I^ /"5YIFJZW+I^F:Q:VMC+)=
M:N^C&ZT2#5OT#^+GP\LOBW\*_B5\*]2U"[TG3OB5X \:> +_ %2PCAFO=-LO
M&GAG5/#5U?V<5R#;RW5E;ZI)<V\<X,+S1(DH\LM7S)KW[&%NGAK]FQ/AK\5/
M$OPQ^)/[,'@.Y^&?@?XE:;X9\'^))]2\&:]X \(?#[QAIOB#PGXDL+KP_=3Z
MS9^ _!WB'3;VW%O-H7B;POHKXU3PW_;/AG6@#UKX6?M3? WXV^+M>\%_"CQH
M?'>J^&/#W@_Q5KM_X?\ #_B>[\*Z=H7Q"\#^#/B1X!O)?&AT>/PF[^-? _CW
MP]XD\*V4.L2:AKFFMJ\UA:2CP]KHT_X/\*_\%>OA+XEUGX<37GPN^+W@_P "
M^,]5_;ST/6=;\4_#CXGKXST.^_89^(7@KP/K][H_PRT/X>ZQXG\7Z!XJM_$V
MKZ[J6KZ7''%\.O\ A%M7\.^*E7Q%IVO6.B_67[)W[&7P]_8_7XB:=\-M:\0W
M_A[QP/@U;66D>(#I\\OAW3O@O\!OAW\!M$MX]1LK:SDU6YUC2/AY:>)-;OKJ
MVMVEU[5M1%K!;V(MX(_&= _X)P>%] \=W/B6+XI^*[GPSI\O[<;>!_"$N@>'
MHV\*6_[?7BOPQ\1?C!97'B*$K?\ B.WT7XAZ+JNN>!Y-0M+>]TW2==;P[JUW
MK,6EV5^P!]'^&OVP/V>_&/CK2/ 'A?QV^NZEK]WI.D:)XBTWPMXQN?AMJWB;
M7OA_:?%;1O!.G_%=- _X5K=>/=2^&E_9^.K/P/#XI;Q1-X8N8=3&EA)%2O-?
MC1^V-<?!;XO7'P5UGX</J7C'XB>$_#&J?LKI:>)?L]K\>?&5WXB/A?XA^ )9
M;G0U'A#5/A M_P"&_B/XZO8#XF@M?@KJ^K?$2"!X?!7BO3M/\2_9V_X)2?!+
M]G'XA> /'/A>YT#6I/ ]KX,U9KSQ#\&/@[J/Q"U3XA^$_@SX=^"D_B>W^,%]
MX6O_ (B^&]!U[1_#=MXLO?!GAW5K%;#QC=Z@-&\16'@R]N?!DOV'\8?V;?"W
MQG^)GP ^(WB35-1A'P%UWXI:Q9>';:"W;3?%<'Q5^#GB[X-:UIFLW3-'?V5M
M:Z)XOO=0MIM+EAN7O((8G=8&<T <7H?[=7[.?B;2KK5?#.O^.O$H6TT#5="T
M[P_\%OC/JVN^/_#?BJXU.S\.>.?A?H%GX"FU?XE?#G6;O1]0BM/B+X+M-:\$
M1I';W5YK]K9:CI=U?8<__!1?]CRWM/M[_%V-[*'X;-\6]3N8/!?Q!NH_#W@.
M/QCX^^'$^J^*5MO"DLWAB^MOB5\-/%WPSN/#FNPV'B:+XCV=AX$_L=O%&MZ-
MI=]\I^&_^"._PC\$^$='\*>"_%7A_P /6O@ZX\"Z7X4BM/V=OV?H=*\4> O
M&G>(-)T;P=^T/I>F^#-*D_:0C-OKUIJ[WWCS4;2S@\;^"O 'Q$LM!M_&VA:C
MK6N^A?!W_@EK\-_@AX?^)7AOP1\2O%EGIWQ"^#?B#X-)'+X)^$EY8:!H6O\
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MC:>'%M?BUXATX?"SX<Z7#JWB^VALI=#\(6T;Z"?$6N>*?$VN>G?M=_LO>/\
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M'[=?[.$+36">)_%L_BF#QOKWP^F\ 1?"3XOR?$BUU[PUX2T/Q]J^H:A\.XO
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M74M5TC5(KW3_ !3:6>L^%M/T^[\1>--,\-^&('UL 'V/17SOXU_:F^#/P_\
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M/(J$?'C5F<1KX9LFE9_+6);V\:5I-VWRQ&+(N9-WR[ I;=\N,\4O^(D<(/\
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MGT?_ )[W'_@MU7_Y!H_X2?1_^>]Q_P""W5?_ )!KH** .?\ ^$GT?_GO<?\
M@MU7_P"0:/\ A)]'_P">]Q_X+=5_^0:Z"B@#G_\ A)]'_P">]Q_X+=5_^0:/
M^$GT?_GO<?\ @MU7_P"0:Z"B@#S+Q[K^F77@WQ';PRSM++I<Z(&L-1C4LVT#
M=)+:1QH,GEG=5'<BOC4\D_4U]Q_$7_D1O$__ &";C^2U\.-U/U/\Z_!/%G_D
M<Y;_ -BS_P!VL0/HO5_H(6V N%D<H"X2%4>:0H-PCA217BDG?&R&.5'BDE9$
MD1T8J?YC?AUXN\=>&+?]NGPY\-'\7_$ZXO\ XK_"&]^,7QTTKQ'^TKX)U*R^
M%B:A^QCX?^-@^._PS\51:SJ_PY^,>H?#7Q%\0M:O?$7PSU:X^(^F^'/"7Q_T
MK2/#_@;P9I'PXGM?Z<NO6HK>""TFO+FTABM;G4+Y=3O[FUC2WN+[4TL;'2TU
M*]G@6.:[U%-,TO3--2^N7ENUT[3=.L%F%G86<$'P&5YFLN6(4L/]9C7>&E[-
MU?94V\-B(5TJG+3E4FGRM**J1IJ34JE.MRP4!.W1;WVUZ?Y;>OR_"J*_\$6>
MBZ0^MCX#>*/V6?AW^U7\0]"O-#MOBI\5_@W^R7^T8GC;X!^"M8T7Q=\-M?\
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M&Z G!Q]*V.J6>I>;]D>1_)V;_,MKNWQOW;<?:8(=^=ASLW;>-V,C/SQ\ O\
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MFUM+>>YN)-L-O#+,Z1L ?B+XU\-1ZO\ MR_$S5O$>A^-? >HWGQD^!<-A<>
M?^";WQ(^*GASXL^&?AW%\/\ Q+X'\3^-OVE;OX=ZSHTVI>&/&_V^&]\3:9J6
MD^$_A>V@^%=2DN+S5?"-OXDA_<,=/Q/;'<_YSWZ]Z_!'XD^']%\0_M=7NJ6'
MADW>L^._CK\ ?B7X?_:7U[]EK]M67]H+X,>&=-T[X87<OP4\ ^([#]F'4?AC
M:> _$%EI%]H^J:CJ'QJ\!>#?!MC\2O']C\6OAYXDUS2?%+:W^]R\#\_PY/ X
M' Z XY&#0!^(/_!2?_E))_P0I_[.M_:@_P#6.?B#7ZI?'#_D4-+_ .PW:?\
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MO?\ A'[6R$$7]LW&@6]L=1O])TZ0176K:>EQ[%_PL#QS_P!#CXG_ /!W??\
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MO]IG_D@7Q8_[$O5O_0(Z_ 1NI^I_G7]R^$?_ "),R_[&LO\ U$PI_)/T@?\
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MJG['_P"P;JEKXGET>_TZ<6U[\9?#G[.VG>&;*VU*&SBM6UNU^)WAC7-/L_\
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M5,/B*N&J1CCL0VIT9PI2GR7]HJ,ZTE0A5<%#VW/2FX5*%>-+^BW_ (3WP/\
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MVFBYL[A[D30F71M.GC#A+9U!>*6.08<_*XS@Y _0FOPB_:\)_P"&B?B1R?\
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M)0A3A*6O-+EIQG.'[W_\+8^&W_0ZZ'_W\N__ )#H_P"%L?#;_H==#_[^7?\
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ML4)1117ZN?@@4444 %%%% 'Z/?\ !.O_ )&'XJ?]@7PC_P"G'Q!7ZI5^5O\
MP3K_ .1A^*G_ &!?"/\ Z<?$%?JE7\Q^)7_)7YE_U[P'_JNPA_;O@Q_R;O)?
M^O\ F_\ ZM\:%%%%?!GZF%%%% !1110 4444 %%%% 'X@?\ !2?_ )22?\$*
M?^SK?VH/_6.?B#7V9_P4"_Y([X3_ .R@Z5_ZCOB2OSD_X+,?&3X>_LX?M>_\
M$:_VA/C'JVI^%_@_\*OVG_VB-2^(/C*Q\)>,?&4/AFPU[]ECQAX8TBYO=(\#
M:!XE\03)?:[JUAI\*V6DW4GF3F9T6VM[F>'R[]L/_@NC_P $M_BA\-?#V@^!
MOVE-9UW5K'QCI^J75I#^SE^U3;-%80Z+K=I+<&2]^"%M$P2XN[>,JKLY,@(4
MJ&(^EX.KT<-Q/DM?$5J6'H4L9&52M7J0I4J<5"=Y3J5)1A".RO*25VD?&>(>
M%Q.-X*XCPN#P]?%XFOE\H4</AJ52O7K3]K2?)2HTHSJ5)63?+"+=DW;0SJR-
M>T:W\0Z3=Z/<WVNZ7'=-:2+J?A?7+_PUXBTVYL+ZUU*RO]%U[376[TS4+2]L
M[>>"95GMY/+:VU"SO].GN[&Y^!_^'K7[!?\ T6GQ#_X8#]I;_P"<[1_P]:_8
M+_Z+3XA_\,!^TM_\YVOZ9EQ#PY.,HRSW))1E%QE%YI@&I1DK-->WU34K-=4[
M/J?Q/#A#C&$X3APMQ+&<)1G"2R+-$XRBU*,D_JNCB[-/HUY,]!\)?L'_  !T
MGX;6_@+QQX?;XNZP-'O-+O?B/X_2&X\8/)=>&+?P9#=:.--^QZ7X;@TSPUI^
MD:=INDZ;:/IX?2K6\U)-3NVED;:L?V,OA1H?@K2/AYX3U7QUX*\(Q?!OPO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
910 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>plegridy.jpg
<TEXT>
begin 644 plegridy.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" "6 /H# 2(  A$! Q$!_\0
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MMO#:P+%;":2<'!9L!<>W?K66FL^,[E4ECTRW2*3!''8_C5/XH_\ 'QIOT?\
MF*[O3O\ D&VO_7%/Y"@#G?&GB&]\/6]B;80N\Q8.73(X Z<\=:Z+3;A[K3+2
MXDQOEA1VP,#)4$UQ7Q3_ -1IO^^_\A6Y>7;V/P]%Q&2'6Q0 CJ,J!_6@"AJW
MCEQJ1T[0K3[;<@[2W5<]\8Z_6LOQ!=>+)- N1J=E;):,!YC(1N7YAC^+UQ5O
MX86,:Z?=7Q ,LDGEACU ')_,FMSQO_R*%_\ [J_^A"@#+^'GFGPA<?9RHF\Y
M]A89&=HQFCPAXMO-7U6XL-32))44E-BE>0<$5)\-/^19?_KX;^2UA>)(CX:\
M=VVIQ@B&=A(<?DX_SZT >C75PEI:RW$IPD2%V^@%<SX-U_4O$,EU-=+"MK'\
MJ!$())]\]A_.H_B'JHM_#R6\+9:]8 8[J.3_ $K7\*Z4-'\/VUN1B1E\R3_>
M//\ @/PI#-BBBB@ K$\2:(=5MA)"!]HB'R_[0]*VZ*&KB:NK,X;1/$,ND2?8
M[Y7,(.,$?-&?\*[2WNH;N(2V\BR(>ZFH+W2K/4?^/F!7;^]T/YU1M_#%I:2[
M[:>ZB/\ L28_I4I-$Q4HZ&U6?J6LV^GH06#S=HP>?Q]*GFL_.B"-<3@ 8RK
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M@>QR*W:* .-3X9:4'!>XNV4?P[@/Z5T^FZ7::3:BWL85BCZG'4GU)[U;I"<
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M]MCTSXA7;78D1;N"-(6"$ACQZ?2@#-@N],URYO[G6=3>&19FCMXA,4\I1T8
M=:CGU>\N_ -O*+E_M$=ZL/G \L!T)]>"*M:5>:=X<;4+'680LJSM+"SP[O-4
M] IQST_6EUK[9<>#+62ZM4@FDNT?RHDQM7G&1ZT 6]=T5=+\):O(;F>XGN(U
M,KR-D%LCH.U5=1D&B>&M-MX+R: 7[1B29WSY:[06P>U;WC!6?PGJ"JI9C&,
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>principalproductschart.jpg
<TEXT>
begin 644 principalproductschart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" )] 3T# 2(  A$! Q$!_\0
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MG0:+I>BPSZA-IL-O#HOVO4)[,W4X!Y_^RS_P45_9M_:4^!_PF^*5U\3OA/\
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MO 7Q%^$_A_2O"EE:W=[KGC/XY6VC:5X>T*\O+JX30=+\(V?AW6O$UYX@N+:
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M:7<KC&TLQ&!T&,XP*910!Z!\)@3\5?A: Q4GXH?#4!@ 2I/CSPZ P# J2IY
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M)T8Q_:?QOQQ@?\*4U[ P<C _M#'!_P \4H_X.(_^"=(Z:I\<.>O_ !977^>
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MB_Y-V;_LH/C'_P!"TS_ U^/^-_\ R1*_['& _P#3>*/U/P=_Y+'_ +I&._\
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M35.FT^:S52Z?(E*:3Y;-PC*,IK[*:<K)GP517Z&?\,7/_8T/B/\ X1+XP?\
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MM[/]T]'IOKY_@R/]7<R5KQHJZNOWRV>W3S/VV_X-@_\ DIG[7_\ V(7P5_\
M4G^)5?V%U_+7_P &\GPQT#P!\0OVI)]$N-6N'U+P7\)(;@:C<6\Z(EKX@\?2
MQF(06=L58F>3>6+@JJX P2?ZE*_F[Q"Q%/%<69E7I<W).G@4N9<LO=P&&B[K
MIJF?UEX6X:KA."<JH5E%5(5,Q;Y7S+WLRQ<E9Z=&@HHHKXH_00HHHH ****
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M:L,D95M<L%(!!!!()P5(8=000#7]3(\-:2?^6=WU/35=7]3_ -/]?RS^$O\
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MU'QUXC^%NG_"*Z\56NFZ+IVG_M58VEK86=M8V-M;V=E9P1VUI:6D$5M;6MM
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M^9MMRS',)*2ECL8XR4U*/UFLH.-1<LX\BGR\LXI0E%+E<$H-<J2/2]0^+WQ
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MM^,__8AZS_Z#%7\V!R6( )))  !))SP !DDD\  $DX !)%?0^ G_ "3N<?\
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M2*QU*QO)5^+^A2-':W4,[K&/!WC-2Y6-V(4,RJ6(P"RCJ<5^B^$G_)R.$?\
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M*YNCA(QABXJ&%7M*D9X:'+1JTZE2E5A.E-P>[S[-)5J>(G6HU*]*O7Q4*M3
MX"I4^M8E05;%2E+"MSQ,O9TY1KS<JM.=.%2E.%2*FM;7K^WU76]6U2T&L>1J
M6H75^K>(=737]>DDO)#<7$^L:VECIJZMJ5Q=23W%WJ'V"U:YEE,DD7F%W?\
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M_P#P5X_Y-S\!?]EBT'_U#?&E>0?\%)_^4DG_  0I_P"SK?VH/_6.?B#7K_\
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M-"BBBOQT_5PHHHH **** "BBB@! H'K^+,?3U)P..0.#WI:** /Q _X*3_\
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M7\D;_?;_ 'F_F:_K<_;@_P"32OV@/^R9^(/_ $"&OY(W^^W^\W\S7T?T9?\
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M_DQ>3_LM_P 4_P#T+P[7\^_27_Y-JO\ LHLI_P#3.//W?Z.O_)PY?]B#,O\
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MKQ3YA@FU!I@GEP;O+$END9;'W0[ ;L9.W=7\%3_?;_>;^9KZSZ*__)(\0_\
M91R_]5F7GRWTFO\ DK,A_P"R?7_JQQHVBBBOZA/YM"BBB@ HHHH _HX_X-V_
M^2A?M3?]B7\(_P#U(?']?U05_*E_P;T-J(^('[4?]G)8NY\%_";S/MKW* #_
M (2#Q]L\O[-%*22=V[?MP0F,@OC^IVQ;5#YO]I)8)C9Y/V%[E\_>\SS/M$46
M,?)LV;LY;=C S_G%](7_ ).MQ%_UXR/_ -4.6'^@W@+_ ,FOR#_L(SO_ -7>
M8&A1117XH?L04444 %%%% !1110 4444 ?B!_P %)_\ E))_P0I_[.M_:@_]
M8Y^(-<[_ ,' O_)H/PL_[.'\+_\ JN?B371?\%)_^4DG_!"G_LZW]J#_ -8Y
M^(-<[_P<"_\ )H/PL_[.'\+_ /JN?B37Z5X/?\G.X,_['%/_ -,UC\[\6?\
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M ';?#/\ Y*7\-?\ LI'P^_\ 4ST.O]*!>A_WG_\ 0VK_ #7_ (9_\E+^&O\
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M_HX7_@HG_P")=ZI_\Q%?UI_Q-7P[_P!$IG?_ (5X#_/^K/RO_+?_ !+%GO\
MT5&4?^$>-\O/S?W>9_+E17]1O_$+M^PC_P!'"_\ !1/_ ,2[U3_YB*^;-._X
M-T?V-+O]KOQ9\#)/V@_V_P#_ (1'1/V<?A]\5K,I^UGJ8UO_ (2/Q-\5/B?X
M,U(SWG_"'$R:6=+\(:5]DM1;H(;H7LAFE:?$2_XFKX=_Z)3._P#PKP'_ ,D'
M_$L6>_\ 1491_P"$>-\O/U^[S/P%HK^HW_B%V_81_P"CA?\ @HG_ .)=ZI_\
MQ%'_ !"[?L(_]'"_\%$__$N]4_\ F(I_\35\._\ 1*9W_P"%> _S_JS\KG_$
ML6>_]%1E'_A'C?+S\W]WF?RY5_9G_P $&^/V%Y,@_P#);_BGV/\ >\.^WL:^
M6?\ B%V_81_Z.%_X*)_^)=ZI_P#,17MGP_\ ^"!?P;^$V@GPK\+?V_/^"N'P
MY\,&_N]5/AWP1^WWXY\,Z)_:=_Y7V[4/[,TGPQ:VGVR\\B$W5SY7FSF)#(S%
M17YKXJ^.64>(7"JX?P619EEU;^T\'C_K&*Q&%J4N3#4\1"5/EHMSYI.NFGLN
M5WW1^A^&/@MFG ?$SSW%YW@,PI/+L5@?J^&P^)I5%/$5,-4C4YJKY>6/L)1:
MW=TT?NZ3P>O0_P )_P *_A*_X*Z_\I%/VD>O_(3^'W4$?\TF\!^M?T(?\.6-
M#_Z2<_\ !9__ ,6-_$S_ .4-> ^,?^#:O]D+XB>)-3\9>/\ ]K#_ (*:>-O%
MVM/;R:QXH\5_MH^(==U_57L[.WT^T?4-5U'P=<7EVUK86EK96YGF<Q6EM! F
M(XD4? >$7B#@O#?B+'YUCLOQ694L7DM?*XT,)4HTJD*E;'9?BU5E*LU%PC'!
MR@TO><IQ:T3/N?%7@/%^(608')\'C\-EU3"9Q1S*5;%4JM6$Z=+!8["NE&-'
MWE-RQ<9IOW>6$ENT?RF45_4;_P 0NW["/_1PO_!1/_Q+O5/_ )B*/^(7;]A'
M_HX7_@HG_P")=ZI_\Q%?T3_Q-7P[_P!$IG?_ (5X#_/^K/RO^!_\2Q9[_P!%
M1E'_ (1XWR\_-_=YG\N5%?U&-_P:[_L(J ?^&A?^"B9^9!C_ (:[U3^)@O\
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M1^IQQ<9J?MOBYWB8\KCMR2ONK_7W_!3,Y_8&_:PX/_)&/%?8_P#/.W/I[5_
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MS:PME;+JDVEVMS<WMMILNHB(7DEA;WEY=W<%D\S6T-S=7$\<2RSRN_Y^7?\
MP4(T[PC-XDT7XL_ /XN_#3QS%X!\#?$KX>?#Z[N? 7B;Q/\ $31OB=\5_#?P
M-\">$P_AWQ5/HG@?XGZA\6/&?@[P;JOA/QGJ^G:/I=UXE@O[7Q?K&F:%XONO
M#F=\4?\ @H]X:^"_P/\ C/\ $SXA?!'XMIX_^ 'B6T\*?%'X-^$(O#GC/5O#
M]QJ7A7PMX]TOQ;/X]TO5(OA[8_#:_P# _C'1_$-OXR\0:QH4D]S'J?@NST*[
M^(5@?"<P!^DM%?%7QR_;/T3X1?%"P^$VA?#[6_B;XNMK#P7K7BW3-&\;_"OP
M7?:78?$36O%&B>!O#_A.S^)OC/PBWQ+^)WBU_!'C'5M"^&GA&:76KC1/#=Q<
M75W9:AK?@[2O$WVH#D9P1UX/7K[9_+J.X!R* %HHHH **** "BBO#_C'\4?'
M'@"7PQI/P[^"7CCXS^)/$[:S.+;P]J?A?PIX8\.Z5X>CTV2^O/%7CCQEJ6G:
M%I-]JDVJV6F>$?#\0OM:\3ZF]W)!:V>@:'XE\0:* >X?Y_+I6?I.D:5H.FV6
MC:)INGZ/I&FV\=IIVEZ596VG:=8VL(VQ6UG8V<4%K:V\2\1PP0QQ(.%0"OSI
MD_X*6_#G5?!^E?%'P'\,?B9XS^%.D? CX=_M*_&KQ?%_PB.AWOP1^$7Q/?Q=
M_P (]JFO>%=5\1#6/&&NZ1IW@'QOXL\7Z!X&.K_V1X)\,S>(-*U'Q#-K_@W2
MO$OL>B?ME>"]<_:/^+/[.\/@CXC:?=?"/X)VOQLU+Q[KF@?V'X4\5Z0_C'Q1
MX+U+3? EIJLMKXD\1II&I^%;T2>*H](M_!NM--%'X5UO7TM[ZYM@#[#HKXK_
M &/?VM-0_:ITWQ!K$W@KP/X.LM)T?P;JT%GX8_:#^&'QJU^U;QA97VI0:5XT
MT;X="1O FL65C;0.UGJUU<K?3R7D.GS3+IEQ,_VI0 4444 %%%% !103@$X)
MP,X'4^PS@9_&OC#7/VP1X,^*/ASPI\1?@Q\2?A_\-/''Q(\6_"#P-\8_$UQX
M3MM(UWQUX+\&_$#Q]J=[=^!XM;E\>Z#\-]5\,_"[QU=^%OB)J>D#3];31(]6
METS3?"6M:!XHU0 ^P+O2],O[G3+V^TZQO+S1+R74-'NKJSM[BYTF_GTZ]TB>
M]TV>:)Y;"[FTK4M1TV6YM'AGDT^_O;)Y&MKJXBDOU\$_#?\ ;RT#QG;65[XC
M^#7Q?\%0>.OA!#^T%\#;%-&T[Q]XD^,OPBNM<\&^'8=0T3PM\/+[7]8\.>-+
M/4/B1\-;CQ!X'\30V<WAS2/B%X<U35=:AAL/&B>$=?P;^W'X*\8_L7^"/VQ[
M?P3XOLK'XD>!+/Q1X)^$4USX<NOB3XB\3ZS]O@\._#3338:K<>&+KQ=JVH6+
MV;W-OK,WAO2K:+4-?U+68?#6CZEK$ !]OT5Y)\ ?BWIGQ]^!/P6^.NBZ5>Z%
MH_QI^$WPY^+&E:)J5Q9WFHZ-IWQ&\':-XPLM)U"[TYY=/N;[3K;68K.[N+&2
M2SFN(9)+9VA9&/K= !1110 4444 %%%% !1110 4444 %%%% !1110 5F:W'
MK$VCZK%X>N].L->DTV^CT6^U>PN=5TJSU9[29=-NM3TRSU#2;O4=/M[XP37U
MC:ZIIMS>6J36\&H64TJ746G10!^4G@O]@OXW:GX/^*6D?'GXV_"OQS\3/B)J
MOPI^(7_#0'A'X.^,='^)"_%_X$_$W0OBO\&M4OM&\;_&'QUX)L_A!\//%6A1
MOX=^!G@S2?"/AZRL+_7"-9?Q-XG\5>+M=K_'7]@'XU?%[X'?M,^ [/XU_"+2
M?BE^V3K>E7'QT^(FH?!'QA>>&]+\,^%/!'A7P/X&\,?"_P %:;\:=-U72U\.
M6/A2&^N=4\9^,_%\^LZQKGB*]%OIEG<Z9I.D_K'10!^57QE_X)W>+/CK>_$S
MQ-XM^(OP@TKQG^TM\ _"W[._[3.IV'P'U#Q#;W'A7P1K/Q+O_"_C#]GZ3Q3\
M4KO4_A)\1K+2?B9JVE2:SXFN_B5I;:MI?@OQ;#I$5_X*L]/U3]3+.U6RM+:S
M22>5+6"&W26YGDN;F188UB5[BYF9IKB=U0--/*S232EY9&+NQ-FB@ HHHH *
M*** "OC?]L?X'?'KX_>%_"_@;X2_&#P5\,_ UU?:N/C1X;\4^"/'.O7GQ7\,
M3V5O!I7@:V\9?#SXI_#'Q5X$\+W%VU]-XZ3P_??VYXSTG[+X8AUWP]HMQK\.
MN?9%% 'YE^,OV"/%7B_2?&NBZ=\1_AK\-M!_:%^ 'P]_9O\ VH_"?@#X*RVW
MAO6_A[\/;+QKX>L5^ ]MJ'Q!D_X5)?7OP]\?>(OAFT/B>W^)VCZ5X>_X1O5-
M#TS3]6\,%=;WH_V5OVAA^V9XF_:0'Q;^"EC\/_$'P3L_V<[;X?:9\%O&+>+M
M&^&6A>,/&7C?PYJ5KXNU?XO:KX/O/&MKJOBQ;34&U'X<7/A&]TW3$A7PU#]I
ME5?T6HH ^,/@=^S%XQ\!?$S2OBG\2?'?P^\2ZYX.^"EM^S_X'TOX3_!JT^"_
MAN+P+'XET;Q3=:GXJTJ/Q?XS_M37Y-0\.Z1%H&DZ%/X;\#^!;.;Q-#X7\.0M
MXLU&2'[/HHH **** "BBB@ /MQ7YQM^R7\>/%W[27BKXK?&OXF_ [XN?#358
M_'W@KP3X'U/X1?$;2?$'PD^"WCG2+G0]3\(> ;Z'XV7O@6V^('B;3GCM?B1\
M8M2\"WWBKQ?IL][X9TR'PKX,%EX9MOT<HH _.?X:_L=?&'X6+X0US3_C1\/_
M !AXT^ O[/\ )^S/^S'=^*?@[JMAH'ACX=:MK_PTU'Q7K?Q:LO#OQ,M-8^('
MC_Q#HGPC^'V@2ZCX/UCX9^%[27PY<:Q9^%HO^$EU'2[3R?X3?\$S_%&E?LP_
M!;]GOXO_ !_UZXU?]G#1/%7AKX0?$3]G23Q[\!KE=-\7>$[CPMJ6I>.O#NI^
M/_B18>)O$"VFI:W96=]:SZ7%INB:WK.EZ;%:)K6L27OZX44 ?.W[(_P$?]EO
M]F'X"_LYR>-M<^(\GP4^%7@KX;R>-_$32C4O$<GA30K/29+]+6:YO9-*THO;
M&+0=!-]?CP]H46G:&FH7R:>MW-]$T44 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?S]_
M\%:_^"BW[2W['?QT^&_@#X*W_@.T\.^)_A*GC#58_%7@O_A);YM:/C+Q#HA>
MWO/[:TWR+3[!IML/LWDR?OA)+YG[S:OY4W'_  7/_;ZCM[F5=:^#>^*WGE3/
MPIR-\<+NN1_PE0R-RC(R,CC->W?\'!Z.W[5'P7*I(P'[/L8)5'89_P"%D^,>
M,J#SWQUQS7X&W<<IL[P>5-_QYW?_ "QE_P"?>3_8K_0CPG\/N!LU\/>%,PS/
MA7(L=CL5@)5,3B\5EV&K5Z\_KE>*G5J3@Y3ERPC&\G\,;;+3^#/%'CSC3*^/
M>*,!EW$V=X+!87'QAAL+ALPQ%*C1@\)A9N-*G"HHPCSR;M%+63>]V?Z2GP9\
M4:MXW^$'PK\9Z\UL^M^+?AOX%\3:P]G;_9+1]5U_PMI.K:BUK:^9+]FMVO+R
M8P6_FR>3$4C\Q]NX^E5XG^S7Q^SM\!000?\ A2_PKR",$?\ %!Z!P0>0?8U[
M97\"YI3A2S+,*=.,84Z>-Q4(0BDHPA&M-1C%+11BDDDM$E9:']S9;.=3+L!4
MJ2E.I4P6%G.<FW*<Y4*<I2DWJY2;;;>K;N9NLW6H66D:I>:3IRZQJEIIU]<Z
M=I3WT.F)J=_;VLTMGI[ZC<1S06"WMRD5JU[-%+#:"4W$L;I&RG\@;3_@J7\0
MVTLW.K_LCW/A[4KW]KCQ'^Q=H=OK/[2'PEL=&O/B[X&\'_$[QQXVN]5\376F
MV^FZ!X/TS1?A?JD.BZI=QSZKXDU;5-)TVUT.UEG9Q^QSKO1ESC<K+GKC<",X
MXSC/K7Y*_$7_ ()HZQXG\)+I&E>/_A5XBU"T_P""B7Q0_;RM]$^-/P1N?B5\
M,=7A^)7@;XI^!V^%GBKP3;_$#P_/K":!'\33KNG^+(]8M0VL^'M/F'A^#?N@
MX3M/=+_]LOQS:2Z9X7TK]F?QI\0/BEI/PIL/CE\5O OPP^('P]\5VO@3X:^(
M?$_C/P[X$'A_QA?7OAW1_B=X\^):> ?%NI> _!7AFWM5U"'PYJ\&L:_H<K:$
MVO>+:[_P4YO=-D_:Y\2:;^S_ 'VH_"_]CJS^,US\0M>OOC'\/O#OQ%UMO@Q\
M"-/^..KIX;^#&JV8\61IJMIK.D>%[5]?OM'ETW5YKZXUBWM+33I%E]7C_91^
M.FC:E;^._AO\9/A%\'?B7XI^!F@?L]_$_P#X0/X 74GPU@\'?#KQ+X^UGX,^
M)O@UX*U3XGK>_#WQK\+=-^)?C+2M,M?$NO\ C_P!K)U>UDU3P:+'0-,TUN&N
MO^"9/@6\^&'[?7A:ZUKPC?\ Q/\ VUX_C[I]A\<M4^%7A^\^(OPVT3XV_ /P
MQ\$!I=YKXO(-?\7PZ,WA^Z\4:E#::WX3TS7I]8NM,ATS1H$6=@#5TG_@HFUS
MXD^+.IZQ\!/&&D? ;X-?';PW^SWXW^-47C?P)J;:'XM\26'PNFC\5:M\.4N[
M/Q/;?#71]2^+?A33O$7BBQN]6U'0[0ZEXEOO#B>&=+O]4MO+[+_@J?JTWP'^
M-W[3%U^S?=P?"7X/Z5\5[F**U^._PLU/XDZ_JWPS^*NJ?"&'2=1^'UI#YW@M
M/$OB31K^XM]4UW6I+32=-6"744-Q,;>/J-._X)[_ !+.H?'+P#KOQO\  U[^
MS=\>_P!HKP]^T'X[\&V/P@UN#XJ:K'I&E_!ZTU3X4M\0;[XJ7W@^S\%>*[OX
M/Z5%XAU:U^&<GB=_"^L:YX?TJ[TG4[JT\4:?X[I?_!*7QQ%^SG^T)^R[J/CW
M]F:#PA\=].^+UIJWQ7\-?LN:KH?QWUB3XF_&G6/B_:0?$CQ5)\8+W1O'VCZ,
M^OW_ (=O=,ET;3!JEI!874$VF&&6VE /J6?]O34O#GAK]H&R\<_L_P#C*R^-
MWP)\!?#;QW;?!OP+XV\"?$F7XHCXV^(O&?@CX-^$? GCG2KO2]"M_''C7QYX
M&U?PP_AWQA8^&I](-WHVNO)?>'=274HON#X<^//#OQ3^'_@?XF>$+IK[PI\0
MO"'AKQOX9OF3RVO- \5Z+8Z]I%RR9)1Y=/U"W:2,\QR%XV^937P5_P .U_A=
MI_C+Q=I_@^[L?AK^SKXX^*_P]^/6M? SX2:5K'P9DL?B[X#^&^N?#LZOX6\?
M?!_Q1X$U[PMH&MRVGPK\<W>BZ/':30>-?AS?WZ7\UKX[UVVA^J/V8O@3!^S5
M\']$^"NE>(;KQ%X2\$ZWXV@^'SZA_:DVJ>'OAQK/C7Q!XC\#>!=1U36M:UW5
M/$,WP]\.ZS9>";?Q)J%\=0U[3=!L-1U&)-0FNFD /H"BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH JSV
M-G=.'N;2VN'5=BO/;PS,JY)VAI$9@N23@$#))QDFH/[(TK_H&V'_ (!6O_QF
MM&BJ4YI64I)+9*32_,EP@W=QBWW<4W]]O)?<(JJBJBJ%55"JJ@*JJHP%50
M      !P!BEHHJ2@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\A?^"A7[
M97QN_9R^*O@KPC\,KWPI;:-KGP]'B2_37O#"ZY=-J9\3:QI>Z&Y.I67E0?9+
M* >1Y;?O TF_YMH^!)O^"I_[6Z0S.-6^'&Y(977/P]3&Y(V9<_\ $^Y&0,CO
MTKU/_@L CGX]_#,JCL/^%/@91&;G_A-O$7'R@\\BOR5N$D^SW/[J;_CWG_Y8
MR_\ /)_]BO[T\+^!."\SX"X7Q^8\,9)C,;BL"ZF(Q6)R_#5:]>?UJO'GJU)P
M<IRY81C=N]DNRM_$GB1QKQ=EW&_$F"P'$F<X/"8;'*&'PV'Q^(I4:,/JN'GR
MTZ<)J,5S-RLDM7<_M6^&NNZAXH^'7@'Q+JS0MJGB'P5X5US4FMH?L]NU_J^@
MV&H7C00;Y/)A-S<2F*+>_EQ[4WMMW'MJ\Q^"G_)&_A-V_P"+9^ NO!_Y%32>
MHKTZOX9S.$*68X^G3C&%.GC,3"$(JT8QC6FHQBEHHQ2226B2LC^S\NG.IE^!
MJ5).<YX/#3G.3;E*<J,)2E)O5N3;;;U;=PKX/^!?_!13]FKXS?#WX*^++_QQ
MH?PW\7?&CP'\)?'.F_"OQ9K5E/XS\/1?&W1KO5_AKI.NG2$N=*AO_&36%YI/
MA.0726WBG7X5\/Z"]]KEQ:Z;-]X5^-_PM_X)07GPS^%$_P -X/CM#J5X_@O_
M ()>^$H/$*_#F33S%)_P3A^+EC\4S?M8Q^-9I9(_BR]H^D160U!/^$&:XDU%
M;CQ*Q:V;A.P^G?@S_P %+/V/?CA\.O"/Q-\.?%&'PSH/C?Q;X[\'Z!8_$/2=
M3\&^(9+OX=>,I/ WB/6[_1]0MWET?PA%K;:6B>,=6ELO#-L?$.A:;JVJZ9XB
MNYM$M<+X]_\ !2[]G/X.>(O!'PZ\/^(K7XI_%GX@_'.']GG1? _A2YO1:Z'\
M1[:7Q')XCTSQ]XKBT/5M'\%OX=T_PAXAGN=/ODN-<O;F+3H['2I-,OY-:LOD
MRX_X(W6LVJZF]U\7/#WB7P_J.E_%CX:2Z-XN\%_%9X;KX(?$[XU_$OX_1^'-
M=L? G[1?P]T#Q7XUT/QA\9OB+X9O]5\6:/KGPZ\9>$'\)'7?AC%J6@:D?$?T
MQI__  3U^R7^C74WQ6D:"P_X*#?'/]N#4H['PK<:5>:EIGQK^#_QL^$5S\+H
M]1M/% N+*^T+3OC!]NA\?+YTUR/#T-I'X=LA=QSV(!]'P_MF_LM3:#XC\4CX
MY_#N/PUX4UWPUX>UO7Y]=6WT:"^\::]+X6\'3VNIW$,5GJVC>+/$D%SX?\,^
M)-&FU#PUKVM6EYIFE:Q=WEI<Q15Y_P!M?]E.TU'Q/I-]\=_AWI^I>#/ FM_$
MCQ39ZCK1L)]!\)>%_"-KX_\ %-]J27EO +>_\*^![ZR\7^*?#I)\3>&_#5Y:
M:UKFBZ?I]Q%.WP5\,_\ @D?IGPZ\%^$?!D'Q,\/7"_#OQ;^QG)X1\2IX,^)&
MI>)[SX<?L@_'[X>?'.Q\)^*KGX@_'GXAZ2FH>-Y_AWI.DW*?#O1OAYX \,ZR
M]QXLT?P!(LUOX?T_J_C1_P $P]9^+OA'XQ?"M_CQ;:)\)?''BW]KCXN^ =%_
MX5BU_P"-/!WQF_:]^#?QM^%'BO5/%'C0>/;2S\;_  Z\'W/Q_P#B3XK\.>"[
M;PIX7UR_;4]!\,:QXSFT'PI!'JP!^B'PX^/GP:^+NG>+=6^&OQ(\)^,M/\":
MK)H_B^YT35(KA?#]XNF0:W$VI+((9(+*^T.ZM]<TG5 CZ7K6B3PZMH][?Z?(
MEP?G?QC^W1X1\(7W[)MA+\,_BAJ0_:U\>>#?"?AC5K318+?PSX&TKXA:+XQ\
M1>"=?\<^)]1FM=&CU#Q!I/A&66'P'X<N->\;6#WJW&KZ3INCV=QJ[:'@/]CR
MV\)_$+]I?QAJ?CB76M'_ &BOA%\"_A-/X=M=$DTB7PI9?!_P!X_\!W^J6NJ+
MK-VMZ_B>W\<M?PVL-CIG]B/IJ0"YU'[0LUOX3\3OV2?VGOBE\/\ ]BW0O#GQ
M)^"_PMO/V5/$OPM^(]_I?C+X8>-/BE+XJ^)?PD\'^+?AS:-::WX8^,_P[M=/
M\ >(]&\0OK<5C+IEQXIMYA9QWNI6\GVK3H #]"/"'Q&TKQ;XG^(G@^.UNM.U
M[X<:[I.EZK:7;1L+[3?$7AW3O$OASQ%ISQ_ZS2M6M+R\L%,JQSVVLZ%KFGR(
MPLDGG]$KYV^%/PU\3Z)\5_C?\4?%R6%O?^/$^%OA'1X--=Q;7GAKX7>$K]%U
MY[-M2U,Z7+K7C+QOXX-EILMU<7UOX>L=!;4KF2^FEBM_HF@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH @EM
M;>=@TT$,K ;0TD4<C!<DX!=6(&23@<9)-1?V?8_\^=K_ . T'_QNKE%4IS2L
MI226R4FE^9+C%ZN,6^[2_P A  H"J JJ %4    8  '  '  X I:**DH****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:T2_CDTW]FWQEH>M^$+C1-&\8Z+=ZKX6UZ32[GPEX@TC7-0^0M*_X(W:K>?
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M[):?\^UO_P!^8_\ XFK%%/FDMI-?-_UT7W$N,6[M)O\ X;_)?<(
M!@ #@  <  < #I2T44B@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\-_^
M"H/[>7[0O[*OQG^'_@CX0ZEX-LM!\1?"]?%6IQ^(_"$?B&[?5SXMUW1R\%V^
MIV1@MOL5A;+]G$3CS0\OF?/M'YH3_P#!9+]MV."XD77OA;NC@GD7/PQ@(W1Q
M.ZY'_"0#(RHR,\]*]G_X+FQ2O^TI\)&2*5U'P-4$QQ2. ?\ A8'BHX)16 /3
M@D'G.*_$RZAG-K=C[/<<VET/^/>;_GA)Z1U^P</Y1E6(R? 5L1@,)5JU*3<J
MDZ%.4YOVC5Y2<6V]$KM[:'X'Q3GN=87/\TH8;-,=0H4L0HTZ5+$U80A'V5)V
MC&,DDKN]DMW?T_T ?A)XCU/QA\*_AKXLUMX)-9\3^ /!GB'5GM8!;6SZGK?A
MK3-4OWM[8/(+>!KNZF:& .XBC*Q[VV[CZ%7D/[/H(^ _P5!!!'PD^&P(((((
M\%:'D$'D$=P>17KU?DE=*->M&*24:M1)+9)3DDEY):'[KAI2EAL/*3<I2H4I
M2DW=N3IQ;;?5MN[93U"_L]*L;S4]1N8+*PT^UN+V]O+F5(;:TL[2%[BZNKB9
MR$B@MX(Y)II&(6.*-W/ K\QM9_X*E?#7X??#B;XV_&;X4_%#X:?!GQ/\"_B#
M^T9\%O&##PQXOU?XL_#CX;^%=-\=ZK8IX+\,:Q<ZWX&^('B/P+K&G>.?!?@[
MQ4\:W_A7^U;GQ)K7A+5O#OB'1=-_3+6='TWQ#I&J:#K-I#J&D:UIU]I.J6%P
MI:"]TW4K66RO[.=05+0W5I/-!* P)21L$'!'Y<WW_!,VZ\;?"W3/@?\ %GXX
M2>+?AC\,OV:/C3^RY\!8_#_PXL?"?C7PCX3^,GPH7X'R^.OB#XCF\5^(-*\?
M?$CP=\)S/X+\/7OA[PS\.?#-\FI>(=>\0>'-1U76+)- R-SV'X,?\%&_V<OC
M+\4O%?PILO$L7A/7;'Q?\._"GP]'C&9M#NOBI+\2?V?_ (??M!:)/X?TC4+2
MTU+0KR30?'-SH=GX>\61Z3X@US5_"/B630;#4+6R8IZU#^V?^RS/H'B'Q4GQ
MS^'P\,^%];\+Z!J_B&;6&M]%2[\;Z^_A7P7=V&IW%O%9ZUH7B_Q-#<>'O"_B
MC1)=2\,:_K5K=Z9I6L7=Y:W$,7QM;?\ !-7Q5K4/BN^^('QRT35?$OCK]K#]
ME+]I?Q3>^$?AEJ_A72I[3]F/X3?"OX0MX)TVTO\ XF>)=:L9O'.B_"^WU9O$
MUQXAOYO"^KZU<&STW4HK&W\SD/AE_P $C](^''@SPCX,MOB7X>F3X>>+/V,Y
M?"/B6+P/\0;[Q3>?#O\ 9!^/OP[^.EAX3\6W?CSX[?$'3#J7CFY^'.CZ3>-\
M/-(^'7@'PWK+7'BW1OAZQEM] L #]+?$OQP\,Z')\/(M-T[Q!XKG^(^A>)O&
M&BV7AW1M1N]6_P"$,\)>$H_%>L>(!HCVB:Q=.6U/PMX=T_0X+$:Y?^(_%^AZ
M:EG$[7;6WS7I/[=(T_7?$OA?XM_ SXA_"#Q'H/PS\,_'<:1K>L^#O%$\7P2U
MSQY;> M<\3>(IO!VJ:K;>%?%GPZOKC^TO'/@:_EN&_LN&\E\&^(_&,^D:_%I
M'N7Q1^'?CC4_BS\*?B?X!FT6+5?"_@KXV_#.\N->MI]0L-#L/BIIO@KQ%I/B
MR?1H=9T.7Q%;:)XZ^$O@ZQU;0K75--U._P!$U[4Y-/U.Q>UE=OC#PS^QI^TC
MH?PG_:)\'_$KXE_!_P"-_P 0/VFO"5KX ^(7Q<TOX9^-_AW\0M6B\173>%=6
MUG5K_P 0?&OQ]X>T;X>?#CP)XD\87GPY^#GPZ\/>%]#\/ZC*_P#9C7.N^(?$
M^O:X ?JR#D9]R/Q!(/ZCKWZTM-1=JJHZ*, <G"CA02222%P"222>>].H ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@""6UMIV#300RLHVAI(8Y&"YSM!=&(&23@$#))J+^S['_GSM?_
M  &@_P#C=7**=WW?WBLNR^X0 * J@!0      !@  <  < #@"EHHI#"BBB@
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M/'OA6S\2_!_QUHWP6\;_ !-T?X.>$OCI>ZIX4CT?Q!XS\0>'[[Q%HOB+2O!
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
AHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>rdpiechart2014.jpg
<TEXT>
begin 644 rdpiechart2014.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $9 3T# 2(  A$! Q$!_\0
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M\_9^2T\3>%]0U71+.YMM9\)?$'6+^X;3]7M)[/5H+*6VE>".2.0 CT/_ (*
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MC\*[C7_A;K_P9^-WASX9^ -!\2^&O!?Q\\6?%[Q#!XQT+5;F[^(>H>/?A?\
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M#X](^(?Q4T?P_87>NZSX<M/A_P""[G4=>TZQAEU>[MIH]:UB;0M*NN!^$/\
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M>CZCX@O[2V\-6>KZ1\.KG_A8$VEW&L1W]QX&M-4\7V-O=>'='U;4K+F/@/\
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MH4HK\</VM_VX/B]\&OVE/B/\*?!/BKX8V9^'?P%_90^,G@+X6>)/#4VJ^/\
M]H_QC\8OCG\=?A9XG^"_@?4$\4Z--;:[K6D^ /#@\*W&BZ1K^L:1XHU&SU.]
MTK4?#D>K:;?^<67[<O[0FH>#/ 7B7Q?\8?@A\#?#7Q.^(/[>VDZ?\6_''P\%
MYX!\(I^QO\;?%OPK^'?PQO#>_$7P]9ZWX\^..F:-J?Q!U&[.L::T/A?X;^,?
M#O@;1Y=:NQXNTP _=8G'KR<< G^70>YXHK^:[QO^VM^T5\;KW]F_4_$^L^'_
M (&>.$_;?_9 T!_V0[>RUG3OBX_AO7O@;9?%"Z\:^+-8@\<VNLZK\//'GCSQ
MFWAN'2=1\'VGA2/1- LO"FJ:D/B(FM?9^^\"?\%./C/\0+3X1Z1_PG'PA\'Z
M3XT_9W_X)UZK\8OC=<>';;4O!7[.OQ?_ &@M!_:XOOCZ_BZ&Y\6V&B6ESI_C
M7X&_#GX->'O"WB/6;6T^&_Q#^(-G%XV?5+F:U\/7H!_0G_G_ #^1HK^>'Q;^
MUE^TGX*^.WQ2\91?M7_!J^\+^+?V+_V)_%WPJ\*>*=(T_P"'GPD\3:GXN_:#
M^-O@/XX?%#X+CXD>,M$D;Q3#X+T#1-:TF/QUX@L/A])KGCWX6:1\2O'NF?#_
M $[PSXCU[]#_ -D7]I:]^.]Q\,;G4_CQX%O-7N?!O[1&F:Y\(+OX<>&?"?Q
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M-N[1117Y"?JX4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M#"&0@@CD$$ @CD$ CFOYW/ZP+7^?3^=&1G&1G&<=\>N/3@U^#_P#_;G;P_\
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M%^(GC34-.TW09/%,=AI\NKQ>&=._,/6_V[OVDO&T_P"S-!<?'KX<?#:_\/\
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M:.UFU*W:XU66Z\50ZAH'B:T7[7JUGK%M!%)%K_"+X._L_P#PUT+PKX;\(_\
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MI5KK>O6NFVL&L:O;:9"6BTZWU/4H[J^AL(R8[.*X2V0E8@: .@HHHH ****
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MOWMU N.!;ZD4U2# Z !+P  =-HQ@BN>L;SSQY4I_?*#M8XS*H]>F9 /O8^\
M6Z[J_*/H>_2CJ+.*OT>O%?,W_K'P_F6,X;X(XHS"LW+.EE6*J8"'"V;XFJ[_
M -L4'A_9Y%C:TG_:U",<KJSCFE' _P!K_P 8>(G!$L#7Q6<952?L:=:JLSPE
M-?P)PFXSQE"$5;V$I1OB812]C+]]%.C*I[#1R3U.:***_P!-=MC\?#C^ZO\
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M\URVFWE5:?[ZC!-_V?6F[)62TPE63M2EM2J-4)<JE1Y[-%%%?Z#'YL%?H?\
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M?L2_LC>'7CDT+]GCX4Z4\-UIUU:M9>$+&W-@-%^(/@GXK:%96&Q%&FZ-X?\
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M+HG@7X@^(/&?B+4-!\8GP!JOAS2/ .@^%-2\;W?C"S\7Q:EH[^#8O#Y\3[]
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M)M,U6V:VNH#GNT,T9/R3VTNU5F@D_@D4#!RCJDBNBY5 !1110 4444 >+_M
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MGQ-@*<J6&I\19+AHN$'5KUZE&AF^6X=1A@,?6IU:4*&7XW#4Z'X3G'AMF_\
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M3PI\7]?^,>J?L3_"?P]H'BFV_:$CMY?V<O\ @H!:WETOQ#^.'Q>O'^*&E?\
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MI_V3[!J<JRPN)-0LOL%B;2]<-=6QL[0P2QFV@\L TT8,BL-V" 1N#*V.VY6
M96_O*P#*<A@""*=110 4444 <SXH\)Z/XML?L6J0G?&2UI>P;4O+*1L;F@E9
M'&UP )89%>&8 "1"51E^4/%OP]U_PF\DL\!OM*#'R]6M$9H%3=A?ML?+V4F"
MNXR;K<L2([AONC[5IK*KJR.JNC*596 965AAE92""I'!!!!'!H _/&BOKKQ'
M\(?#&MO)<V(DT&\?<S-IZH;*20DG?+I[@1+S][[*]J6'WB3@CQG6/@]XPTW<
M]G%::U .0UA,(;G;ZFSO#$<^T4\YZ$9!X /*Z*U;S0=<TXD7^BZK9[2%)N-/
MNT0,<X'F>48SG!VD.0W8GBLL@CJ".<<@CDG '/?/&.N>*  ':0W7:0V/7:0V
M/TK\H?B+HXT#QWXOTA5VQV7B'4U@4< 6UQ<->VV!V'V>ZB '8"OU@2*61@L<
M4LC''RQQ22-R<#Y8U9N20.!R2!U(KY ^,7[/7Q;\9_$ZYOO!GP\\2ZQ;:SI>
MD7$U^+)-.TR&^@A?3[B.XU+5I=/LHI?+M+>9E,S2&.17"D'-?R5]+_A#,N)N
M!^',9DN5X_-\TRCB>%&&$RW!XC'8QX'-L!BJ>)=/#X6G5KS3QF"RQ2Y8-+W7
M*R5SYGBC"U,1A*$J5.=6I2Q"2C3A*<N2K"2E:,4V_>A3O9>OE\5U9L[.[U&[
MM=/T^UN;Z_OIX[6RL;*WFN[V\N96"Q6UI:6Z27%S/(Q 2&".21NRD U^C'P]
M_P""=/C/4IH+OXE^+M)\-6&Y6FTCPPK:]K<D>W+1'4[R&UT>PDR=A=+;6%&U
MF4'*$_9OA;X%?#G]G75?"WB/PAHI-G,[>%?%NOZU,=5UM/[:GCCT;Q =0G1(
M],CAU,QZ3J,6E1:?9-8ZG&\EN1:[S_+O 7T3_$GBJM0K\0X>GP5D[E&5:MFO
M+6S>I2O%M87)J%3VT*K3:Y<RK9<H6<U[2T83^>P7#>/Q,DZ\5A*6C<JEG5:Z
M\M).Z?\ U\</GL?'O[//[!^K:S-9^+/C=;SZ+HR-;W5CX"BG5-8U4!C+M\4S
MP[_[(T^11&DFD6<YU:X5I([VXTP!H)?UHT[3K#2+"STO2[*UT[3=/MH;.QL+
M&"*UL[.TMHUBM[:UMH52*"W@B58XHHT5$10J@"K@]N/\^U%?Z'^&WA5PAX69
M2\MX9P4OK&(C#^T\YQCA6S;-:E.[@\5B(PIQA1IN4G0P>&IT<)1<ISA1]K5K
M5:GW& RW"Y=3=/#P]Z5O:59V=6HUMS225HKI"*45=M*[;91117Z0=X4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 5&T,3<-%&PR#AD4\@@@\CJ" 0>H(!'-244 -"(O*JJDC&0
M #CZC!IV >HZ<CV/K110 5F:UI%CK^DZEHNIPB>PU2RN+"[BX#-!<Q-$YC;#
M%)4#>9#(HW1RHDBD,H(TZ* . ^'>KWUYHUQHNM3>=XB\(W\WAK6I6RLEX]DD
M;Z;K!1CO\O7-(ELM35L!#+/.BDF)@._KRSQ+_P 4EXRT;QE'^[T?Q!]C\'^+
ML?+%#+-._P#PB6N38VHOV34KB70[F:1OEM=7MV<[+5=OJ61[_D?Y]/UH \+^
M(O[4/[-WPA\8:9\/?BI\?/@U\-_'>M:1::_I7@[QW\2_!_A/Q-?Z%J&H7^DV
M&M6VBZ[J]C?OI%_JFE:IIEEJ?DBQNM0TV_LX)WN+.XCC]S#J1G<,8SU'3&[Z
M?=()] 0>A%?B3^VG^SA^U;\0OVB/VQO'7P1UG7_#OA7Q+_P3G^!_PT.@6O@S
MP1KUA^T#K&@?%C]KS6O'_P &=$\2>+[#5F\'^-)_A]XT@T?0=:M["73M*U[X
MC^&=;URVU33M,ETZ;@?AM\+/VW=,^*'Q)TVV\5_M >#O!]AI/[0&D?#CP]X.
M\%Z_<6NF?L\-\'M;\.?LD^'/"/BOXR?M*P?L_P"G_%WP;</\.[NXCNO@EI_Q
M0?XO^%/%5M\8/%I^'WB;5?&^I@'[Z[E]1UQU'7&?Y<_3GI1N7U';N._3\^WK
MVK^<B3PS^WS+X6\->'])@_: T[X)^'_B>^I>/_&.KV_[56J_%;XB3ZM\%9]/
MT:PTOX3/^U?I?[3'@CP7X,^*^F@^,;CPA^TAX@\"^*?%?BG0?%FAZ#/\.=#\
M7B/O/$VB?\%$(/B-\"VM(OCC<^,/AYXI_8'M/&7BMK;QC<>#?B_\+KOQ'\)=
M._:X\3ZYH7A7]HV/]GWX7:S8:1KWQ)T;QG\/=6\ _'OX@ZI?^%IOB!X%\;VW
MAO4/#VI>$ #]^]PXY'/Y]A_,@?4@=2*P/#GBSPMXQLKO4O"7B30?$^GV&N^(
M_#%[?>'M7L-9L[/Q)X/UV_\ #'BSP_=7.GSW$,&M>&/$FE:GX?\ $&ERNM[H
M^M:=?:7J$-O>VL\*?@Y\&OAU^V9H'@W]FFY^.T7[:OBZ[UWX&+=ZG!\._BOK
M%GX]\-_M<GXI6-H+_P"+LFM^+H/"UAX!LO@UIGAZS\,Z=XRTS6O@G&=.^)6I
M>/\ P_K7Q&\9Z1?>(_2_V8?@Q^TS\'OCK\--:L]+^+FE>!OB)^UO_P %9=5^
M-N@:GX@UBZ^&MC\,_&WQ^^*?Q/\ V;?$UIX%NM4E\+>&)_%.I7&DZWX:\8:3
MHMOXOUO3_%5_IGB#5;K3+N"PL0#]M]PSC//3\<9Q]<<XZXYQ2;E_O#J!U'5N
M /Q/ ]2"!R*_ G]H#3_V_P#5OVAO%FO?"KPW\<_"^FV_Q8^+O@_7-&L-:^)/
MB'PGKWP(UC]E_P"+6E?#+Q[X3\6GXWZ7\'-'N-3^,-K\/-9TSP7X#^ $7Q3^
M''B@1OXR^)82ZN[KQ!5T'P%^VQX3\1?!RS\:']K7Q1\ 9/@]^PS\0OVG[7P[
M\1_B'J?QDUKXPW/PS_:@\,_&C3O NM6/C;3_ !IH5CIWQ6TO]F+Q3\;/AS\)
MM1T"V.C1R7_AK03I>J^/=-UD _>#POXO\*>-]&3Q%X-\3:!XL\/R:AK>E)KG
MAO6-/US2'U3PUKFH^&?$6G+J.FW%S9M?:#XCTC5M UFT$QGTS6=,U#3+V.&]
ML[B&/#TSXJ_#'6_%=YX$T;XB>!]6\;:=<^);+4/"&F^*M#OO$UC>>#;7P7>^
M+K2\T*VOI=3M;GPO9_$CX>W?B"":V271[;QSX0GU!+>+Q'I#7?Y,_!_X0?M+
M_#;_ ()@Z+\.=)\-_%7PO\2+3]H/XD>)_B#X6T;7;*R^/=]\ ?%7[??CSXB_
M$O3_  9XGTG7[*UB^*OB_P#9ZU[5)]!UG0_$4&K7FH:NTGA/6K3Q/=Z+J4'S
M-\.O@A^UOX>^)7[3^I^!-"_:V^&WPV^*L/\ P4!\9>#M6M]1L]=^*KZMXS\
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M8VO]K:5I^I?9S<>5]H,'VVWG\DS^1#YQBV^;Y47F;O+3;MT4 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
3 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>rdpiechart2015.jpg
<TEXT>
begin 644 rdpiechart2015.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $9 3T# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***0
MD*,G/IPK,?R4$_CTH _-#QA^WCK>E_ML>+OV2-)MOV8O"\7@3PQ\"/%E_K'Q
MO_:5O/AG\0_'>G?&"3XCW>L0_"7X8VOPM\3)XONO!&A_#;4KJX\_Q5IMOJ%_
M?V]M=S:+9V]QJ%>KP?\ !0[]D^XTRQU5?'_B&&+6M6^'6D^%;&\^$WQ?L-=\
M<CXPVGB^[^$6L_#_ ,.7W@2WU[Q[X6^*9\!^*[#X>>*_"&G:SX=\7ZUI$VA:
M)J-WJ\UI9W'8Q_LG> ;KXM?M,?%#Q#=WOB2#]I_X:?"[X6>,O"EY;VUMI^F>
M'/AKX>^*OA>1=)U2S:/5UG\3:1\6-<MM3=IHGLUMX?L+J9IS7S/H/_!,_1+?
MQ%\'?%OC'XW^//'?B3X$^(/V>;?X=ZIJ?ACP-H[V?PL_9I;XBW'@7X?:K!X>
MTS3H-4U/7-1^(MYJ?CGQRR6]YK%WH>@IHV@^&[.&^M;X ]%_:H_;Y\)_LQ^.
MO"GPTN_AK\1O&'BSQS^S?^T]^T1X<O+#PUXCL? UI8_LT^$?#_BC4?#'C'QH
MGA[4]-\)7WB9_$-KIHO[Y6@\+7#:>/$,$%SXF\*VFL6?AW_P44_9V\;^ /#/
MBF[U7Q3I?B[7=$^$%Z_PMT[X:?%KQ'\0+[5/C/\ #K5?B5X1M? 'A*Q^'T7B
MWXI^'M2\/^%O'M]IGCGP-X=U7PIJ&F?#[QKJIU*UM/#6LFQW_P!JO]C71_VG
M-5\&>('\?:YX#UOPM\,?VAO@G>SZ=HVD:_8:[\+?VF_!OA[PK\2='FL=2DM)
M=.UZ"Y\%^#=>\+>)+*^SI-[HUU97^EZQI>L7=JGSE\0/^"3GPB\?>(?"OC/5
M_$L&N>*_A_\ #']F[X<^!8OB%\,_ /Q-\"V8_9Z\'?'KP ^I^)?A[XNM;G1/
M%D?C[PK\?O$$.KV,LVE7GAO6/#WAK7?">MZ;>6UXMX ?8GQ0_:4TOPO^SJW[
M3/PPT)_C1\/].L/#_C?6H?"M[<0:Z_PF&L6:_$?Q7X;TF72[B^UGQ3\/_"']
MO^*3\/+NVTC7-;O?#.H>#C)I7B.6*!?*?#O_  4,^ >IP7/B#5M=-EX#UR\U
MW6?ACXQ\-Z;XG^(NE^+?@OX6N=*\-:S^T9XFO/ ?AS7]'^&/P*U#Q_/KNA>#
MOB7XSU>Q\'>*_#FB+XZL-<30KZ4Z=](_"_X+^&?A/\%_#7P3\,"UM?#GAKPE
M+X5M9=,\->$/"5NR74-Y]NOK;POX&T+PQX-T4W5[?WE]_9OA_0-*TF"69D@M
M$4LS_G]J?_!)3X(ZEX?_ &;='N]0T+Q'?? 7]F;X5_LF:CK7Q)^"_P '?BX_
MC'X4_"@03:'=Z9H_Q*\,^)-#^'WCB6^?73/X@T*QU'3+G3/%&K:7J_AO6C9>
M&[W0@#Z?\5?MY?LP^!)_&L7CKQUK7@BV\">'/&?C#5-7\8?#7XG^%_#^L>%/
MASXCT;PI\0/$G@;Q#KG@ZPT;XAZ'X*UOQ#HD/B35?!%[KUEI]CJ=KK?GRZ$Y
MU-?3_&'[1?PQ\">#/!_C?Q-/XSL[3X@ZQ%X>\#>&+;X8?$K5/B9XLUZ;3=9U
ML:-H7PGTKPG>?$J^U.'P_P"'=<\2WUFOA99M+\-:3J'B#5%LM)M)[M/S.\7_
M /!%_P"%WC63Q'<:U\7/%4^K:IX/_:#^'UCXR/@'X<-\2M0\)_M!ZKX<US65
M^)OQ*&EIXQ^+OB#PE?\ AG3[#PCK?BO4XK>Q\.06NES:-+?P2ZW=?=/[6G['
M_P /_P!K'1_AS'XKA\/?\))\(?'%]X_\!WOB_P"'WA/XK^#TU36?"7B3P)KV
MF^*OAQXXM;CPYXHTC5/#/BG4HXU\W2=;T?6+;1]<T76[&YL7BO "O+^WQ^RF
MFO:!X>B^)[7MUXBT3X-^);?4--\%?$#4O#ND^'?V@/%7B3P'\(M>\7>*+'PK
M<>'_  /I'C#QYX3UWP+#?>,M1T*#2O&5HOAG76TO5YDM:\EUW_@IM\ =,^,/
M@;P%87>H:A\/_$GPX_:)\>:O\7+GP[\0=(T);CX$^/\ X%?#*QT?X8V=[X$$
M?QTA^('C?XT?\(GX?U3X6:IX@2[\5:%9>'O#]KXEOO%&F!,74?\ @F/\,KOP
MA\1O!>E^--8\/:/\0?A+^QW\*)K70/!/@'PUI>BV/[(/QH^(/QMT35M(\,>%
M-$\,^$=.E\=^(OB)JUGXCT;1M!T?0M,LXDET6RBN9[AWX+Q?_P $C_AQ\0=*
M\%^#_&WQ8\6^)/AS\&O"'C_P+\!/ .I^#/AUJ&B_#;PWXL^*'P5^,/AJTU==
M3T34(/B<W@/Q9\"_!NC:=!XYL+S2O$?P_@D\->*M+U/5;K5O%6K@'TOX^_;^
M^ '@[X?:CXQL=5\3Z]K\'AGXQZ];?#I/AO\ %:V\<Z;<? [0+#6?'T'Q&\)P
M^ K_ ,5_"31_#D^O^#M/\0>*?B#X>T30M'?QOX1N7NKBW\1Z,U]R'C+]L[Q\
MOP/_ &$_B)\,_A+X0UOQW^W#XM^%7A71/"GCKXFZSX4\)_#^3XA_LW?$?]HS
M4+S5?&'AWX;^-M7UU-#TSX<7WABSBLO!]E_:]_J5KJ,TNEVT,L!XNQ_X)F>$
M_#VAV,7P_P#B)#\)_%>I^"_C3\,?B-J_PG^"GP9^'_A7Q7\-?CQ<^%K_ ,7^
M&]%^'F@^&;?0/"6IZ'J7@GPW=^"O&$EUXF\46"PZC:>*[_QI:7UI'I?IWCS]
MBNZU?X+_ +'GPO\ AO\ %S4OAYXB_8M\4?#7Q1\-O'%_X(T?QO'K5S\.O@/X
M\_9^2T\3>%]0U71+.YMM9\)?$'6+^X;3]7M)[/5H+*6VE>".2.0 CT/_ (*
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M*8/CIJ/Q7^(&O^ OC%XA\'Z;XY_:=N_'NF:/\.K[P_JFB> 8/@IX;_:2\/\
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M%:5O;P6D$-K:PQ6]M;0QV]O;P1I#!!!"BQPPPPQ*D<444:JD<<:JB(JHBA0
M ":BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\P1^AYHK^7OX#?M1_M5_#+]D#X*>$K_X\_$+4/BCX _8ZU[Q!HC>/OAYX?\
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M+ZQK.J^)-/\ ">D>))H-4TG1K_7;W5H=/MH[6;4I;G]^>>\,_"3QA\._A_\
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M06&H2:U-:Z?<VL8^T;/0-,\)^+;/4+.ZO/B9XAU6TMYUDN--NM$\(P07L0#
MV\T]EHT%U$C$@L]M+%("N%8 D'_/U_9E_:J^-7[(WQ"C^(OP5\4?V+?7(M[;
MQ/X>U&W&H^$?'&DP3+,='\6:*S1B\APK+::I936.OZ.SM+I&J6F^:.;^U_\
M86_;[^$G[<?@2?5O"C?\(K\2_#5M:'XB?"K5;Q+C6O#,UR3%%JFEWGDVJ>)?
M"&H7"/'IOB.RMXE2;&FZQ::7JZ-9'^&_%+P3SKP^<\TP-2IG7"\JBBL?&FEB
M\M=248TZ6:T::Y(QE.2I4\?12PU:IRQJ0PE6M1P\_P"TO#3QCR?CM0RS&PIY
M/Q)"G=X&51O"YBH1;J5<LJS]YRC&+JU,%5;Q%&GS2ISQ5*C6KP]$^.?[6'A#
MX%_%']GSX3ZSX/\ B%XBUK]H/XHZ'\,-+U[0/#TJ^"?!=YX@\/\ CW7](U/Q
MAXNU5]/T0-J3?#W6M-L?#/AZXUSQC/,T6IW.A67AN&YUJ'SK3OV[/!MY\3]$
M\*WOP^\;:3\,?%O[0OC/]D[P;\<+[4?" \*^(?VAO 0\9V_B+P6OA6'Q$_CW
M3]$DU_X?>-?!6@^+[W0!INJ^,?#MU9O9:=H>I>'/$>MT?VS?V<OVB?C[XP_9
MXUGX1?$GX+^!=#^ 7Q>\,_'FUL?B/\-_'GC;5?$GC[PKX=^(OA&RT>>^\+_$
MKP79:=X1N]$^(,UQ=K'87.M+JFF1-'>&SN3!!Q4O_!/BW\0?M*:+\:_%VJ_"
MU?#'AWXSZ;^T79^&_!WPU\4:!XFU?XN:5X+U7PMI>I^(-4U'XHZY\/8&L=1U
MB;Q#K/C3P?\ "WPG\3_B-_8O@K0?'WBW4M,\-ZHWBO\ $#]F/H;XX_M8^#_@
M;\4OV>OA/J_@_P"(?B+6?VA?BAHGPTTK7] \/3CP1X+O/$'AOQ]XATC4_&'B
M_59+#10=3_X5WK>FV'A?P]<:YXOEF:+5KK0K'PY%<ZW%RG@']MGP/\0OB->?
M##0_"'B[_A*F\92:!HEE/_9J-J/AO2?%WQ-\&>+O&FJ0M=++X6L_"6I_"'Q9
M=:EHVO1PZU+I>K?#R2SA>_\ '6G:;:>0?M _LQ_MF?&BS_9+NH?C7^S99>*_
MV=/B'X.^./BG5KSX&_%!-%\??%SPIX7^)/@Q[;1= L?CDUSX-^'FI:-\0Y+K
M^RKO7/%/B.TU/2HR=?N[2Z,,'6_&?]B;7?B]XFUCQR/BC'X-\77^H:/8Z7=^
M&/#MUIUEX?\ "X\ W6B:[J=I'8ZY8W]_\3H?B3J,7Q8\+^-=3OYX=/U;P#\)
M=$U;2M6LO!:7ET ?H.%'7!!ZXW-W'0C)! R<+RH/(%+M&<\\^YQSUXSCGJ>.
M3R>>: ,?F3^9)_K_ /JZ4M '+Z'X)\(>&=7\8^(/#OAK1-$UOXA:]9^*?'6K
M:7IUM8W_ (O\2:?X8T#P78Z[XCNK>-)=7U:S\)>%?#?ANVO[UI;B'1-"TK3H
MW6VL;>-.F*@XSGCC[S<CIAN?F')X;/4GK3J* &A%&<9YSQEL<\' S@ ]2  ,
M\]>:-BXQ\W_?39[=\YP<#<,X8\L":=10 THIR>1D8X9EQ]-I&#V)&"1P3BE
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M#P.*_P#DEN)O^R>SO_U68H_"1NI^I_G24K=3]3_.DK_66.R]%^1_EL%%%%,
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MIQ'CX6D\1G;A7PRFK-^RRNG&&!]FVKQCBZ>-J0Z5F]3F?!_@KP=\/=$A\->
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M  5.\1^$;76?"WC^ZN]%;_@F9\?KWX=3VGBC[#\2K"+79?C;X5N-*L'72O\
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M!HVNW/A[X:>'O _P^?6]8LOACX2\'>%;K3=<\3:7J.IV^J7'[D%5)R0I/')
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MY\<K;Q3H&A_#F^L]3OO"/@:XUGPWJ%KXH2SN?UBV+@CG!_VFXZ<#GY1P,JN
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' 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>rdpiechart2016.jpg
<TEXT>
begin 644 rdpiechart2016.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $9 3T# 2(  A$! Q$!_\0
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M\_9^2T\3>%]0U71+.YMM9\)?$'6+^X;3]7M)[/5H+*6VE>".2.0 CT/_ (*
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M<D#) ->BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX?>"/#/CCQOX,\+:9\%?CUX0TSXPV?Q\^"FH_&CP5X,\::]^S=XC\2Z!X?\
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M_4_AW\2KRQ^&WBCQ?X!^,^B>.KWX0>.?C'XL\:_"WQ?X?T?X >+O@-HVH?\
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MQ7P;7A4R+-\3AZ$9\U3+JTY8C*ZZ;3FJN!JN5%2FERRK452Q,8_PZ\'9K_1
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M%^-K6SM[F_T[?GS+W1+^&XBU3PQK)1!JNC7,#S1V^I6^HV5I]@U_!S_P2_\
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MUW-F1].D7?8.V3DB("6T4XQMMD[DU\BUZI\'M8.E^,K:U=RMOK-M/ISCJIG
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M_".ZSJK^+/@5XM@\#>%OBOJO[.?BSQ1X0\5:+XTUJ#]HS2?A5=?%>3X>^%_
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ML6\=Q)J?B'7]9WI/!=_-Y.J:C>6T<GFK&HF2&.4)F-7VNRO]#5Y_\4=/;4/
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M=>E=&$P\L7B\+A()N>*Q%##P25VYUZL:44E_BDAK=7[H^[47:B*3G:JKGUP
M,TK#<,>ZG_OE@WZXQ2T5_8Z5DEV27W"/S*^%/_!/?]CGP]HWQ ^"'BN>P^,?
MC*_?XL>+?'FAZWX\\1VNN:'X*_:<_:/\8?'Z7[+\.M%\;M9_#G2_%7C+1K31
M+KQAX:T?PWJ/Q53X4V(\0ZGK3:#/8V77>(?V>?V._P!K!/C1XK^%7C;PEJ?C
M[Q/:>+?#7B7XA_"/XCV/CJP\!_$_Q-\*=2^$DGQ%G^'4?B+Q%\(+?XU:7\-]
M4E\*P>--?\$MXVE\'A?#TFL?V-Y<<?Y_?$;X<>+_ !+^T?\ \%,?!O[.OP1^
M-?PQ\1?M2?L0Z;\&_ GQA\0_!;XB^'_AUXK_ &G/"OB']M37O%.L>)OBEJUG
M#!%HFI6/Q'^'6C^&?'M]K%MHDNE:EH^B^!]2AM= LK&P^G_V7=8^*/PV\;^/
M/%=]\%_CEJ'PFU_PU^R3\)M!@\6? KX4>"?C%X7^(5SXT\7^#O%WA?1]+^&^
MC^#9KW]D_P#9_P##_BKPMKG_  D'B2Y\2:3X)AN/B+JGPQ\1^.?"\MZ8F!:_
M9T_9S_9N^&'BS6?#?C3]H3X5_%#Q%^SYJ6F_$?0OA-H?CWQKIWAS]G/4O#G@
M;XH_#3Q)\0=1\!_$S]I'X\^+M!U;Q5X!^-?B'PIX^GU_Q'IW@"\TX>'KK_A#
M-/\ $5LFN7?M'A#]B_\ 82U7_A"F\+^$]!\5_P!A^#O!4OPW/_"W?B%XS'A_
MX8^!OB[\-_C!\/-%\"#4/B#K(T+X4>$?BU\'_AWKO@_PEX>^Q^ ]"NO#*Z!I
M&DV^C7^MZ1?_ !MI7@[P9^TG\=[#P5XG_9N_: _9Z^#7P0D_:2TGX2:-!^SQ
MX]\+7'CCQIXVNKJ[^(/QT\2_%*'0K_P1H_ACQ3J6GZGXB^%'PX74?$&N_%'Q
M9J&E?$'XGI#JC^'? -E[;^R/X2_:'^&?Q@N[37_AK?VW@SXMV.I_$CQ/K_B<
M"\\0^$[#Q1/XM^(6E^&=4\56%U8^&(?%7A[XC^,=?L?%GPT\/>%M/TY_%OC_
M ,?>/O#4UIX/@TK2X0#ZFU3]B#]EK63,VI?"73;IYO%?QV\<L\GB'QFI7Q=^
MTOYQ^->OQ&+Q)$8+_P 92SM=QO T2>&+^.VU#P<GA^^M+6XAZ'PE^RC\$/!.
MKZ%XAT'0/%7_  DF@_$2]^*R^)]:^*_Q<\4>)_$?CR]^&=U\'/[<^(GB/Q1X
MZUG6OBDNG?#2Z_X1/0-)^)-]XJT+PS86.B3>'=+TO4/#^AWFG_1E% !THHHH
M **** "ORE^)G[7?Q;\+_M%?'7P?I/B'P3!J'PA$-A\)OV5+SP9J6H?%C]J_
M2[K]FJZ^,S^./ GB>PUJ34=)M)_B+#J7PLT?4[7PW>>"-!G^'GC6T\9W4WB'
MQ%H/_"-_JU4!M;9KA+MH(C=1Q201W)C0W$<$S1O+"DV/,2&5X8GDB5A'(\4;
MNK-&A4 _ 4_M^_'Z?PL/[!^/?[//CGPO?V7[-'BWQ'\=-'T7P;\/K#PIK7QC
M\-_&[5/B-^SCX(F^)7Q*C^#$GQ>\$W?P]\ ^*]%T_P"-/CGP;>:=\/?%VM>&
MO%=WJGQ+N/ 3Z_Q&G_ME?M"3?$?XP_%_3OVFO".CZ%XW_81_8Q\=?"#X9_&[
MPGH/PE^';^+M3_:&^-'PO_:.^('@?2-1\>^+[>PUK0-'\-V^HVVN77Q!\4?"
M*>_\??![4_B+\3_^%+V_A;Q9=?T4/I6F26MS926%F]G>/-)=VCVL#VUU)<.9
M+A[FW:,PW#SRL99VF1VFD/F2%GPU/FTZPN9(9;BSM9Y+:*X@MY)K>*62"&Z1
M8[J&%Y$9HHKF-$CN(XRJ3QHD<RNBJH /SG_9*_:=O/CC>?"E=4_: \+-J[0_
MM-^&]1^%^M?#?P)H/C'XV2?"[Q;\+K*S^)7@+Q1X"^,_Q*\"ZSX8^$.D>+-,
MT+Q_XE^$NJ^,? 'C?Q-\1=,<O\,M5\.W/@E?G?\ ;>\4>$=#_:$\#>(/ WQ%
M$GQ9\,?&[]G#3?&/A"R^-7Q0TC]HG2?#NH>//AJ(O#/[,'[/,\-O\-?BCX)^
M(_A;7M87XU7MQ'?:#J.@/XY;4KS5O$G@6UTSPS^T,&G6%J+46]G:P"QMVM;(
M0VT,0M+9A$&M[4(BBV@800@P0>7$1%'E#L3:][*SEN8;V2UMY+RWCEBM[IX8
MVN8(IS&9XH)V4RPQ3^5'YT<;JDVQ?,5MHP ?@'\*/VF?'%O_ ,%0-1\<?M!^
M%OCI\$_#5]^PS^TWXM\6:;\4H(/#7P5^$7PT^#GQ\^&EWX2\27US#XRU7PD/
M[.\$VWB77/'7Q/6*6:_\2^//[#@O4\':3HJV,W[>'[1GQ*OOVG?V.+W1_!'[
M0"?!KP[^V?\ LI:7\,O%OPUM8[OX8_&^U^*W@7QUJWC7QG<Z]H/BRWMO%WA^
MVT/7M$\)>$?"6O:>MA9WFB?$+QG?6>I"]\%7.G_OK)8V<Q=I;2VD:2WEM',E
MO"Y>VG(,UNQ=&+02D RPL3%(0"Z,0*5K.T<0AK:W86[Q20!H(B(9(%*PO$"A
M$;Q*2L;)M:-20A4'% 'XB?!?QEXM^ /QQ\)?#SQAXJ\8?%_P/:_$0^ /#6OV
M>H:KIFE^(_C%"OP6^ /Q7\96MMJU[JVI^.]=TC7?&D?C/QOX6BO+;1=,\2:U
M^T[XVTZ*XF^%5K)K7[B#D9_ER*J_8;/,!^RV^;:>:ZMCY,>;>YN!,)YX?E_=
M33"XN!++'MDD6><.S":0/:H *BGACN8)K>5=T4\4D,JG&&CE1HW4Y!!RK$8(
M(]14M% 'P%K6E3Z'JVHZ1< B73[N:VRW5XD8FWE&.")K=HI@1QB0<"LROH#X
MV>%FCN+;Q7:19BG6.QU8J/N3( MC=/C)Q*F;1VX4,EJI.7%?/] !1110 445
MG:QJUCH.E:CK6IRB#3]*LKB_O)2<%;>VC:1PO()DDP(HE'+RNBCEA66(KT,+
M0K8K$U:>'PV&I5*^(KUI*%*A0HPE4JUJLY-1A3I4XRG4G)J,(1<I-)-BE)1B
MY2:C&*<I2;LDDKMMO1)+5M[(^4/VH_&ZQP:7X!L9?WDYAUW7MC'Y8(RXT:QD
MP<'SI1+J4B-_!#9,1\X-?%];WB?Q#?>*_$&K^(]28M>:O?37DBD_+!&Y"V]I
M&.=L5G;)#:Q*#@)"#U)-8-?XK^+O']?Q*X^SWBB3J+ U:ZP624*B<98;(\"Y
M4<OIN#O[.K6ASX[%TTW%8[%XJ4'RR2/R?,\;+'XVMB'?D<N2C%_9HPT@K=&U
M[\E_/*1+!(894D'\+ D>J]&'4=5)'UKJ\@@%3E6 93ZJP!!_(BN/KHM/E\RW
M"$Y:$[3SD[#S'[8'*]ONU_>?[-;Q3>5<6<5^$68XCEP7%6$EQ3PY3G*T(\09
M+0C1SC"T(7]ZMFF0QIXVH[6A1X:LM:C/QCQ2RCVV#P>=4H7G@Y_5,4TM?JU>
M3="<GTC2Q+=-+K+%>1>JY8:C?Z5=PW^F7ESI]];-N@N[.:2WN(F[[)8V5PIZ
M,A)1QE75E)!IT5_L?5I4J].I1K4Z=:C5A*G5I581J4JM.<7&=.I3FI0G"<6X
MSA).,HMJ2:;1^)4ZDZ4X5:4YTZE.49TZE.3A.$X-2C.$XM2C*,DG&46FFDTT
MT?57@?\ :'8>3IWCNWWK\L:^(=.@_>#H-^IZ;$ K\_-)<Z<JL<DFQ."X^H=.
MU+3]8LH=1TJ^M=1L+@9AN[.9)X).,E0Z$[77H\3A)4/#HIXK\M*Z;PQXP\1>
M#[TWOA_4IK)W(^T6Q FL+U1QLO;&0^1<#' D*K/'P8IHSR?Y=\1OHQ\/Y_[?
M,^":M'AG-I<U2665%4EP_C*CUY:=.G&=?*)R;WPD*^"BE&$,OI7E57[IP;XX
M9OE/LL#Q/"KG>7QY81QT'!9OAX+2\YSE"EF,8K=8B5+%2;<IXRI90?Z95[U\
M"M#:?5-4\02I^YL+?^SK5CCF[O#'+<%>O^JMHXU)R,?:2,'G'PI\//C=H_C"
MZL-"U6T;1O$E_/;V-C%%YEQIFK7US*L%M;6<N'FM+JYF=(XK6\RCR.J17<C$
M)7ZO>"O#<?A7PYI^D@*;E8_M&H2K_P MM0N 'N6R"=RQMBWB/_/"&/C-?S'P
M_P"&W$W#G&*P_%&3XG+'E$'C(2K1C/"XVI)SI82>"Q=*4\-C*2FIU_:8>K-4
MIT/95E"K>FOZ?R'B+)N)<"LPR3'T<=AI6A4]FW&MAZC2E[+%8>HHU\/52U4*
MU.#E&TX<U-QD^KHHHK]I/:&B- VX(@;).X* V3U.<9R<G/KF@(@& B@9#8"@
M#<.0>!U! P>O%.HH 8(XP<A$!YY"J#SUY SSW]:=@#H!TQT[>GT]J6B@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"AJFFVFL:=>:7?Q^
M;9WT#V\Z="5<<,C8.V2-@LD3CE)$5QR*^(/%/AJ^\*ZQ<Z3>AG$9\RTN]A2.
M^LV_U5S'U7)_U<Z*S>3.KQG@*3]W5Q_C3P?8>,=*-G<8@O;??+IU^%!DM9RN
M"K8!9[6?"I<P@C>H5UQ+%$R@'P_16KK6B:GX?U";3-5MFMKJ Y[M#-&3\D]M
M+M59H)/X)% P<HZI(KHN50 5\D?M1>-VM;#3/ =C+B74Q'K6N[&&5L+>9ETN
MR< Y N[R.2]=6 W164&04D-?5.J:E9:-INH:OJ4PM]/TRSN;^]F/_+.UM8FF
MF8=,N579&O5I&1!RPK\HO&'B:]\8^)=8\2W^5GU6\>=(221:6B@16-BG. EG
M9QPP #@NKOU<D_R=]+;Q&_U5X%APCE^(=/.N-G5PM94Y6J8;AW#2@\TJRM=Q
M683E1RN,)I0Q&&KYDHRYL.T?-<38_P"K8-86$K5<7>+L]8T(V]H_^XC:IV>D
MHRJ6UB<U1117^7!^>!5_3YO*N I/RRCRSDX ).4/MAAC_@1^M4*4$@\''OZ>
MA_ \]^G0U]GX=\:YGX<<=<*<=9,W_:'"V>8#-Z5)3]G'%TL-6B\9EU:>ZPV9
MX*6(R[%VUEA<56C]HX<SP%'-,OQF75_X6,P]2A)VNX.2]RJE_-2J*-6':<(O
MH=?14-O*)H8Y.[+AL]G7Y7&?J,^V<5-7_4+P]GN6<49#DG$N2XA8K)^(<IR[
M.\KQ*5O;Y?FF$HX[!U7&[Y93P]>G*4&^:$FX2M)-'\EXG#UL)B*^$Q$>2OAJ
MU7#UH?RU:,Y4YKS2E%V>S5FM&%%%?6_[,G[,NJ_&+5K?Q)XCMKG3OAGIMT3>
M7A+6]QXHNK5T+:+I!*[S9,Q,>KZO'B."-9;&RD:_=Y+/IS/,\%D^"K8_,*T:
M&'HQNVVN>I-WY*-&#:=2M4:M""=V[MN,8RDO0R3),RXBS+#93E.&EB<9B9J,
M4KJG1IW2J8C$5$FJ.'HI\U6K+2*LHJ4Y1A+>_9X\/_#[X/>#]=_:\_:"\0Z;
MX$^%?P_6+^Q=:\10W:V U+4=4T_PW;>)&2VM;NZNX1J^L6OAWPW!96=U<:EX
M@O\ ?9HTEM:&;]0OA#\;_AI\=?#VH>*?AAKUSXAT32M<N/#=]=3^&_%GAN2W
MUBTM+.]N+0V'BW0= U&016U_:NUS#9R6>Z1H5N#/%/%%\H?\%,/@MX]^+?["
M_P 4?A+\$?"FNZWXNFO?@I=>&/"_@&_\)^'O$Z:9X"^.GPL\9ZLO@J[\9:AH
M_@ZQU_1O"OA?5K_PW%KE];:4^I6%E:S"591!+\@_&_X:?M-_&OX;_#GP/X<^
M%G[4\ND:<WQWL=3\:_'3Q-\%KSXT:7\0M=MO"%_\)?$T_AGP%\>_A_\ !V/X
M>Z<VH^*X--^)5SIGCOXE?#C4_"MC8^&?A_IK>([WQA=?RKQ)G^)XCS6MF.(3
MIP:5+"8>_-'#86#;ITD[)2DW*52K.RYZLYR24>6*_N_@SA/!<&Y%ALHPC56J
MF\1C\6X\L\9CJD81K5VKMQ@E"%*A3O+V="G3C*4YJ4Y?LAXT^(_@;X=KX8?Q
MOXGTGPRGC3QIX;^'?A5M6G:W77?&WB^XEM/#/AK3B$<3ZKK5S#+!80?*LLD;
M*77%=J&5@&!R" P/;!&0<_3GU QGJ*_G.\/_ +(7[8_BOP]X+\9_M':#XHUS
MQUI_[5__  3E\<^-M0\0_%C0Y-)T'X3?#7]CC]GC0_VL/%NE+:>,H-)T)[?X
M^:)\5[[Q!J.D1V/BW7M5T\^(M$6\TJ32[V;]#?V&=-^)OB[]F[Q1XZ\8^*]1
M\4^)_%NDW_PQ^'OBOP_XZ::R\7?#?X(:7K'PE^''Q9\+>(;JQU&PTV\^.%]I
M>N_'&W\2KI^J1"/X@:).PUC3])L?-\ ^K/T&UWQ7X8\+KI3^)?$.B>'5UW7=
M,\+Z&VNZI9:0-9\2ZU*\&C>'M*_M":W_ +1UO5YT>'2]*L_.O]0E1X[.WF=6
M W0ZGH3Z@X;!'7*G&'SVVDYK^:NX_8>_:%\4?#OP-I?C7]GWQQXP\+_ /]IK
M]BOX_P!GI/CKQSH2?&SXGZG\+-<\=Z%\=+DZ3;_M1?$WX,^*O&<_@_4_"WB;
M6?BGINJ? =_C;XCDUR._^',M[I'AZ\K@?CSX$_;D^&.D?$GXQ^(=$^(GP9\/
M^.?A[\<OAI\98O#GQ%T(>%KOXD?$;XW_  ,;]G36M.^)>J?'SQ5X[UKP4^F3
M>./"OB'XK^/M4_9[T_X<>"]?\1Z%%J'P0\,7YU'P< ?U&17=M.TZ0SQ2O;3?
M9[E(W5WMI_)BN/)N44EK>7R)X)O+F"/Y,T4N-DB,UBOY7?A[\$/VB_BMX;L;
MWX :SXSG^'FGZU\<].O].^%Z?"WQ%:_"C]I;XA>,/"7Q(T3XA^!/'UG^V%I?
MA#Q?X6\"?#'6_"W@/X??%:?XC_M$:]X U+PQXU\%:Y\._#VFWEOX!M/ZF+&*
MY@L[6&\N3>7<5M!'=79CCA-U<1Q(D]R8H42*+SY5>;RXD2./?L1%154 %JBB
MB@ HHHH **** "BBB@ HHH) ZD#ZT %%%% !1110 4444 %%%% !1110!S/B
MCPGH_BVQ^Q:I"=\9+6E[!M2\LI&QN:"5D<;7  EAD5X9@ )$)5&7Y0\6_#W7
M_";R2SP&^TH,?+U:T1F@5-V%^VQ\O928*[C)NMRQ(CN&^Z/M6FLJNK(ZJZ,I
M5E8!E96&&5E((*D<$$$$<&@#\1?VGO'/]GZ-8^!K&;%WKVS4M9V-\T6BVLW^
MB6KX.1_:=_%YK*?O6U@004FY^&Z_=OXT?L6?#+XM:E=^)+.[U;P3XKNH4CEO
M]':*\T:[>"(0VSWWA^^)MT6%$1"-&N='>1=QD9Y6\ROSU\=_L(?'3PD9KC0K
M/1OB!IT9#))X;OULM6,9X+2:'K;6;[E/#)9ZCJ#<@J&!(7_-'Z27AAXQ<0\=
MYQQ;4X;Q.></J-/ Y%+AV<LWG@<EP<6\/1KY=2BLTHXBM4J8C'X[EP=7"4\9
MBL3"CBJM&-.3^ S[+\TK8VKB7AY5J%E"BZ#]KR4H+12@DJD9-N4Y^XXJ4I)2
M<4CXNHKMM>^&OQ%\+/(GB3P#XTT,Q2+%(^I>%];MX!(Y81J+HV36CF3:WEF.
M=UDP2A88SQ3*R9#HZ$':0Z,A#9V[<, =VXA=O7<0N-Q /\@8O 8[ 594,?@\
M5@J\+\]#%X>KAJT6G9J5*M"$XM.Z:<4TTT]4[?,2A.#<9PE"2W4HN+7JFDT)
M15FWLKV[D$-I97MU,Q 6*UL[JZE)9@JXBMX99#EF51A3EF51EF /K'AG]GWX
MW>,)%30?A;XTG1G"?:K_ $:?0;!6.T_/?^(#I5J %96)65SM.0#@XZ<MR/.L
MZK1P^3Y/FF;8B348T,LR_%X^M*3V2I82E5FV^B4;Z/LRJ=&M5?+2I5*K>B5.
MG.;^Z*;/-M+FYD@/0CS$YZ$##CGU7#=>J]*Z"TM+N_NK:QL+6XO;Z\F2VL[*
MS@ENKR[N)"%CM[6U@22>YGD) 2&&-Y&/13S7W9\./^"=OC:]NK6_^)'B_2?#
M-DDBO+I'AA6U[6I8]N7A;4[N&UT>P<EO+9X[;6% #,G5"?T5^%OP ^%_P@A1
MO"7AZ(ZP8C%<>)]79=3\1W08,K@ZC-&OV*&13A[32X;"S.!F G+'_;_Z(7''
M%_!?@A@N$O$+AS-<%FW#N:YCA.&*.-J8>G5Q7#6,=/,L*L:O;5<7@9Y?F.+S
M+!4\/B,-"K' 4L!2I4E3@YQ^'S?P;S?B/B)YA"MA\IRW%TJ-3'5:R=3%+$4_
MW53ZO@X.*E*K2A2FW6JT(JHZLFY.T9?!GP#_ &(-4UB6T\4_&:"?1](1H+FR
M\#QS*FKZF ?,V^)IH@W]E6#J$632K2?^U+A6>.\GTT!H)?U.T_3['2K&TTW3
M+.VT_3K"WAL[&QLX([:TL[2WC6*"VMK>%4B@@AC58XHHT5$4 * *N45^B9_Q
M+FO$F)5?,*W[NG?ZOA*5X87#1E;F]G3;DW.5ESU:DIU962<^2,(Q_<.$^"\C
MX-P3PF4X=^VJJ/US'UW&IC<9*-^5UJJC%1IP;?LZ%*-.C3;E*-/GG.<O'/CY
M\<O O[.'PMU[XO\ Q(;65\'^'=2\':5J)\/Z1-KVKF[\<^./#7P^T);/2+:2
M.ZOR_B#Q7I230VOFW7V9IGMK>ZG2.VE^7KG_ (*1? +1]>D\(^*-%^*'@[QC
MH9^-MW\1O"_B/P?I]I?_  DT+]GG2?A+XM^*OBSXAWMEXDU#0+'PKHGPW^-O
MP[^)NF:]X>UKQ+9^*?".MQP>%SJ_B]K?PG<^I_MO?L[:O^U9^S;XU^!FA>);
M;PAJ/BSQ!\*-43Q%<OJ<1TZV\ ?&3X>_$G43:7&CD:C::I=:;X.N['1[ZV(:
MQU:YLKQV6*"0CA;3_@GG\![CQ3X@\;>-KOQY\3/%/CGPG^TEX+^*&J^-M>TD
MM\4]#_:BTCX*^%/B##XPL_"WASPMI]JND^ ?V?\ X:?#_P $6?@VT\)Z3X9\
M*Z7>PKIU]JVH3:N/ /K#&G_X**?"6-+?0+KX9?'F#XI:WJ/A*U\+? J^^'.F
MV?Q5\::!X\^'GQ'^*7AGQEH6E7GBR'PJOA74/ /P@^*6J7LVO^+M$U?0-4\#
MZUX(\2Z)I'CUM.\+7^%X*_X*5?![Q7X4DUG1/ 7Q.U(Z'\(O@7\7_$L/AO2/
M#=UX9\*^%?VBO"=IXP^$46J^./$'B7P;X0TW^W-#EN1J&JZG?Z5X4\*S:/J<
MOB37])T8:3JVK^+_ +0W_!,'4?'.F^##X4\>ZW\6-0L?$7@^7X@'X]^.M-TO
MQ1XR\&?"OP'XW\'?!3P98>/M)^!WQ+\':+X<^&%Y\2OB%XFN+#6O@#XL\2?$
M/Q+XPOO$GB/Q]9^*+9=:O/5_#?\ P3@\,ZUX;;7OC!\0O%6I_'?Q#>_LY^+O
M$WQ"\!0^#-#T31O'_P"S'I?BK0OAAK?A+P-K'@"_^'UY'IOA[Q;>Z1K>G^*_
MA_J'A#Q#?6EIXFTWP%X,OX-+L=& *Q_X*U?LG-X27QO:W/CS5O#.G>!_&'Q(
M\=:KX<\.Z+XKL?AOX)^&?QJF^ ?Q9U_Q7>^&/%>L6&H6?PQ\?P[?$G_"!W7C
M:35O#LD?B?P(GC+1R]PG5Z__ ,%)?@?HNIS^#=0\&?%Y_B3;?$/XA_#36?A/
M+X3\,V/C?3M4^&_@GX=?$K7KAXM:\<Z9X8UQ-6^''Q<^&OC'P=X7\+>)O$/Q
M#\>Z7XK33O"?@?5_$.A>+=$T#GKK_@E)^S1>Z%\7] NM;^+DT'QP^''QY^&?
MCN\D\8:-+J,^E?M'?%Z+XX?$S6--N9?"3I9>(+KQ\LUWHUPT$^EZ/IMU+I<&
MD/;1V?V7T;XE?\$__A3\2M3^-&IW/C?XJ^'O^&@/'5QXZ^*6D:3J/@#7/"?B
M*XNO@S\+O@9/HTO@KXB_#CQWX0^PKX-^$?AJXTK7I=#F\?>%M<U#Q1>^$?&6
M@V?B*_TU@#Z<\$>.[;Q!XC\:^#=/^'GQ \)Z;X"7P:NG^(O$OA%/#/@WQC;^
M+?#<7B-3X FDO/MU_'X6$HT+Q=;7^BZ%<:%XD2;2C;7+H\U?GU=_\%!_'O@R
MY_X*(W_Q0^#ND>&=-_8Z\/\ PC\0?#[PO9^+QJGBKQU#\6O"6N7_ (8L_'>M
M:=;:EX7\*ZCKGBBQTFT,/AA?%5AX6\/ZJE[?:KK^J0W>GVGW=\)?@II?P<_M
M2P\-^-OB1J_A&70/AMX7\*>!/&'B>'Q+X9^&^@_#/P58>!]/L?!4]YI:>*-_
MB.STZWUKQCJ'BOQ+XJU37/$AFU5;VS$TEL?FG2_^"?/@I?''[0_C'QO\;OCS
M\5M-_:F\)V/@GXT_#_QS+\$;/P9XET#0O"^L>#?!T-C-\/?@AX#\;^&[WP3X
M?UV_M_#^J^'?&FFZE-?"TUWQ#=:[K]A9ZG" >C? 7XQ_$_6OBG\7/V?_ (WV
M/@#_ (6=\*_"/PA^):^(_AA'XDL_!GB3P)\9Y?B%I&C+%HWBR_UC7-'UWPUX
MQ^$_CWP[J FUG4+77M)M_#?BNVAT*;7+[PMH/@;?'7]L/0/B5\</#4Q^!7Q:
M\-?"'PEX1FUV3X<?"CXM^'/$/A'QK\3O&GAY_#6F7MO?_%SQ\_Q#3X>?!&ZU
M[XP_$GP]X6T?P[XCU6RF\":+X5>"]\8.-(]\\)?LD:5X1U6/Q3!\;/C[JWCZ
M]\<_#GQ5XT^(6L>+?"4OBGXD^%_A5X?\0>'O!?P=\:KIW@'2_#DGPFL8?$^L
MZK?Z+X;\/>&_$>O>*+_4/%FN>+-0\1:SKNHZGZSX3^#6@>"#\9;CPYKGBJSU
M7XW>/-8^)'B?6YM0T^\U/2O%&J>!_"'P^MY_#376DRVEE::#X?\  WAQ-!L]
M2M-7BLY[+]^;NT9;1 #Q;]E[]IN^^/5[KVF:[8^&?"6N^%]*M]/U'PDVHO#X
MSU#Q/H>NZUHOCGQ':^%;^^.N:-\/;2X'AK2M+DUBQ.K6_BN?Q3X9U:X6\\,&
M2^^QJ^6OAE^R!\(/A)XVT;QOX.@\0V]UH'AE?#^E:1>ZRM[H\&H3>$? _@36
M/&,V^R35[[Q9XC\)_#GPCINOW=_K%UI=]=Z?=^(5TB#Q/KFNZSJ/U+0 4444
M %%%% !7Y+_\%!_C]\5?A;^T-^R3\/\ P?XM_:,\/_#SQU\./VN_'WQ+TS]E
MOX>?"'X@_%+69?@OIGP+U#PM.++XM^!_'%M%X<TJW\:>*_M]EX:L8M=UO5=1
MT/3X([YO)MJ_6BN(U;X<>!]=\>>#/B=J_AO3K_Q[\/=&\9^'_!?B>=9CJ7A[
M1OB$WAA_&>GZ>RS+ L'B%O!OA@WXF@F=CHUGY+PXE\P _(+]G'_@IO\ $;Q%
M+\(_AKXV^$WB+XG^)9-,_9VMOBM\4/ 'A3XDZC8VQ_:@>T\2_"?Q':1?#;X/
M^-/@GM\/_![Q7\.?'_QXU#5?C'\.O#FA7NI^,E^%]AXMT?PW:PWW8ZO_ ,%4
M=5\'Z;KL/Q%_9ZU7P+\0=1\6> ?!WPL^#^IZU\3[WXI^(]4^('Q3D^&%IJ'B
MGP9IG[/USK=SX/T&3['XCU_Q]^SO9_M+>"VL]0L=!T#6=;\1ZKX;L_$/W1H?
M[&_[,WAK6_!'B'0?A!X7TG4?AU!IMMX1%DVKPZ?IL&@Z[K'B7PK'/HHU3^Q=
M87P/KOB#6M3^'W]NZ=JA^'MSJ5R?!!\/HX1<JR_8;_90T^U\3V-G\$?!T-EX
MJT\:1<6H75WM] TE/%&G>.8=*\ 12:JZ?"_3+?QQH^C>-;73_AH/"%I:>,-%
MT;Q1:PPZ[I&G7]J ?$WQ-_X*LWOPV^#MS\5[S]GSQ%/=>"?A_P#&'XH_%KX>
MW47QVL/B#H?@'X->*M:\.:GXT\(^#$_9EO\ Q@O@+QG:^'=<UOP!\1_CQX<_
M9\\#:O#I\^DZCK6F:KIWB1/#O<Z'_P %%O%WCWQY??#?X:_ O0=5\3ZI^T%\
M;O@-\.&\7?%O4/"FB>*9?V??"#?$'X@^-_$6IZ=\*?%<OA#0;GPQJ?A+2_".
MEV]EXF\1:WXVUO4]/U#3-"\&>&KGQU?_ $[X@_87_9,\5Z1I&@^(_@?X.UC2
M=(\'^*O #6E\-8F&O>#?&U]JNK^*O#GC2;^UA<_$#3-;\0:[K?BJ]@\>3>)2
MWB_5M2\7Q/%XGO;G5I-_6OV/_P!FSQ!X5U+P9JGPD\,S>']6^(FK?%F[MX6U
M>QOD^(_B#37T3Q!XOL=;T_5+37M*UC7M!FN_#^N2Z3JEC%K'A[4-4T'4H;K1
M]5U*RN@#X"\(?M^_%[P_^T;\:/#_ ,2/ <>H_!R7]J[]C/\ 9[\,!/%_A%?%
M'P>UG]J+]EOX)>+M-T*PL/"7AK6-(^*FE6GQA\;WC^,?%5U\1;&+2],\11W?
M@B7Q7HVEC3+7W#]J'_@H3IO[-/Q%3PY<^ 8O'/@SP[J?P+TWXI:YX7U7Q_KO
MBOP!_P +Y^(EK\/?#=WJVA>#/@]XT^'_ (4M+)]1L/$2GXQ_%OX2W7BK1?M[
M>#;76'M(9;WZ@C_95_9W@EN9;7X1>#+$77Q!^$_Q3D@T[3GTZRC\>_ OP]X5
M\*?"+Q%::?87%M8V-S\/_#?@CPGHOANULK:WTVRT_0=/MS92K$V^E\0_V1OV
M;_BMXNO?'7Q!^$?A/Q/XGU33_#.G:QJ%]#?QQ:['X)U:/7/!-YX@TRRO[32-
M?UGP3JD?VKP;X@UG3[[7O"9EN(?#VIZ;;W5S#* ?G^G_  5<U2UTCP1JFM_L
M]I92_&N]^-?@[X"Z9IWQ5&I7OBOXF?!7]L#P!^QSJ&A>/99_AQI^F?#CPEXD
M\8_%/P9XOT;QI#?^,;BU\(P^*EUKPO8Z[IFB:3XB]2^$'[7WQ$\.^!_^"F_Q
M7_:.TY!I/['/QO\ &-M8^"O =UIOBH:'\.O G[&W[.WQJU3PYX4\1IX9\#WO
MC!M7\2^,?%^M:3J_C#1M'UF)_$,6EZNNEZ;I-O;V7U/??L>?LRZIH>E^&M2^
M#/@J_P!!T31OC%X?TG2;VRN;JRL-)^/WC32?B+\7K2WAGO) A\;>.M"T7Q9J
M%QDW=GKVE:?J6C7&F7%I Z=A\/?V>_@O\+?#/C+P=X(^'?AW2?#?Q%U&YUCX
M@Z5<07&N0>.]8O\ PIHO@C5=6\9OXBN=7N/%&J:WX6\/:1H^O:AKDU_=Z];V
M8DUF:_N9[J>< _*]?VV/VE--_;?T+X-_%/PW_P (;HWB/4/V*]*T7X8_#+QW
MX$\<:/:ZK\9/A#_P4P^(GC&35?'GBCX0>'==\06FOO\ LV> -"NM MF\#'2/
M%7AO2M6\/^/D\'7OBB'Q=ZEX(_X*1>-_&$W@[P#<_ +1/"?[0?Q2\7>!/#'P
M^^"GC/XF^-_!FNZ%%XL\ _%SXDZ[JWQIC\:_ #PMXK\%:5X+T#X,>+]*D\4?
M#[P1\7?AYX\\9BS\-?#;QQXB,>K7VE_7'A+]B#]E3P/J6CZUX:^"GA"PUC0=
M4\,ZQI>JR_VQJ>HP7W@OPY\3O!O@\R7NKZMJ%Q>6GA;P?\9?B7X2\/:;?27.
MFZ-X7\5WOA[3[.WT>VTRRL*-C^PC^R9IGA_5O#-C\%/"]MIFJ-X4\J1+OQ)_
M:WARV\!WNI:AX%TWP+XB?7F\1?#G1? ]YK6M7'@W0OA_JWAC1O"SZUK(T*PL
M$U74%N #P76?V_?&FG:QK,$'[/T/]B_#OQ=^S1\(OC%<WOQ<TB37/"GQN_:J
MB\%6?P]\,>#-*\.>$?$>B_$GP+H'B'XH_#"P\<?$&T\5:!<6VE^)]4U/PMX2
M\2W_ (0UG09/-/$W_!5NVA?X1:3X#^!GB+Q?XI^*W@>R\2'2XW^)^N67@[Q5
MX>\%VOC3XS_#SQ*?@W\#OC3XP37_ (6)XH^&_AFZN;3P/-IMUXF\9RQ:_/X1
MTW09KS4OJ33_ (4_L'1^.-7\4:7H?P(L_%G[(^C^"- \7M8:IH>FV7P1L/!G
MA2Y\5?#5?B#HMOJEMX:\.W_@/P7KM[XD\ ZKXUTW^V? WA_7;S6/#=_HUGJT
M]S<4_ ?PB_80_:&\$:^/A;H_PG\?>%%^,7CKXC^(-2^'/B">&_TKXQ_$57U/
MXAZQ>:YX3UK3_$WA_7O'FF:X9?$VG"^TZT\5^%M<BAO-/U'PSJL$5P >1>&?
M^"CFI>)]8\;7W_"A]5\(?#7X5S?LAS?%/Q'\0_&,GA+QMX)T;]KCP9X \5Z?
M?ZM\/)_!UR=-N?@Z?'!3XP6/B#Q+H(\/Z7I-QJEA/J,L>KV.A_8'P<^*OQ'^
M*S:/XGO?A7I/A7X3>*OA[8>,?"OBVX\>RZAXNU'5M5\8^*;73-#U+X?MX-L(
MM)TR\^&EGX)\?1>(3XLO)SJGBZ_\'R:!$/#2^(M;^3O&.C_L,_%/X=?M-?#'
MX7?%KX%>"[#QSX:\)^"?VG9/!%UX*\1W%W\)?#6D6WP6G\(3:%=:A<Z)I-G<
M^";6Z^#GA[6M*T;4+7P[JI_LO3-.O_%.FQ:>GV#X&\.? C4OB OQ,\ )X6U'
MQU=_!;X>^$XM<\/:M->$_!--?\7:_P##>S@L;6_DT6'P]-K=QXON=!U"*PBN
M[]H=1@%[<6U@L%L >Y8'O^9QZ=,X_2O,]3L[.X^*/AB)K2VE$'@OQ=<3(\$+
M*A;6_""V\I#H06\Z.0HP!974MQP3V/B"XU^VT_S?#>FZ=JNI>?"OV75-4FTB
MU^SL6\^7[7!8Z@_FQ@*8XOL^V0DYD3:">+\/:=XSOO&2^)?%&DZ%HT%GX8OM
M#MH-)URYUJ2YFU#5M.U!II&GTK3!;QP1Z?Y>/WS2M*""@0AIE"$U:<(R6JM*
M*DK/1JS3W6C[A9/='I:001DF.&*,D;2T<:HQ!YQE0#C(!Z]0#VJ3 ^N#D9YP
M?QI:*:22LDDNR22UWV ****8!1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %(<'J,\C\P00?P//X4M%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
%HH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>researchanddevelopment.jpg
<TEXT>
begin 644 researchanddevelopment.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #& 3T# 2(  A$! Q$!_\0
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MOX3+7'B#P=IVC72V^B>-=/M_%\(!ZY\8?^"H?[+OPI^'GQU\;6FI^-O'>I?
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M^(=S>>)=1MO!D/A^+4/H73?^"EG[5=Y!^T#K2^!/ >ES>#K+XNM?>#?$-_\
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M/^QDTY=<\?7VI>)K[5M?U#ZC_;E^*W[,GAGX5_#7Q5\=?BKJ]OX&\4>+;/\
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M6%GY,5U=Q6H4M!!)<.D"2/N^5I65!CDU\*']OSX3 D?\*;\3\''_ !_^'?\
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MC8J3KP)PZLIX&"".U 'D=%<3_P +,^&O_12?AO\ ^'#\$_\ R^H_X69\-?\
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M^'.'_!*#_I&_^Q)_XC3\*/\ YF:_2>B@#\V/^'.'_!*#_I&_^Q)_XC3\*/\
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MI:^")M<\7>+SXHO+#Q1J'@I_A[8^/[VPA\0Z.GB74/'>E^']1@TU?HCX8_\
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MPYX;^.MCX=T71='\5V5CK&O>())9=!TWPC>ZCI'B/Q+X0U2[O?!7B+6O#E[
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
8% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>41
<FILENAME>researchanddevelopmentchart.jpg
<TEXT>
begin 644 researchanddevelopmentchart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" +: 3T# 2(  A$! Q$!_\0
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MK>@?"3X$7'[1/[1T.J?%?0]-O/"7@"V^(/QH^'BI\')]-\-:[IGQHO\ 7_\
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M8:4!"FK>&KS5?#VI:][^QEXK\/\ [%7PB_8W^"W[1?COX16GPI\#_#+X8_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 &1Z]>GO17Y"?M]?%OXH> OV^/^"./@3P7X_\ %OA7P7\8/VDO
MVB/#?Q3\*Z#K=YIN@_$+0?#_ .RSXU\5:%I'B_3;>1+?7=.TCQ'86FM:?:7J
MR0VNIP17D:B>.-U_7F,DHA/)**2?4D"@!U%%% !1110 4444 %%%% !1110
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M/[/_ -H:[S_Q(4X)'_(8M.QQ_P ^_P"G;I0!T-%<]_:&N_\ 0!3_ ,'%I_\
M(]']H:[_ - %/_!Q:?\ R/0!T-%<]_:&N_\ 0!3_ ,'%I_\ (]']H:[_ - %
M/_!Q:?\ R/0!T-%<]_:&N_\ 0!3_ ,'%I_\ (]']H:[_ - %/_!Q:?\ R/0!
MT-%<]_:&N_\ 0!3_ ,'%I_\ (]']H:[_ - %/_!Q:?\ R/0!T-%<]_:&N_\
M0!3_ ,'%I_\ (]:-A<7\_F_;; 6.W9Y>+R*[\W.[?_JHX_+V87[V=V[C&TY
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M%]933VD@6:**\MI'0+-&67PI_P %(OBOX\.JKX'^-WP]\9-H5S'9ZTOA;3_
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M/_9UO[4'_K'/Q!KZ]_X*)_\ )%_"/_91M)_]1KQ/0!^--'XGD8//49!P?49
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M ."EQG'_  4?_P""%AMDADG'[5O[3VQ)Y7@B;_C#OX@;M\L<-PZX3<5Q"^6
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M]?!7@K]HG]HOXI2_LF>!?AOX!^(P\':9X=TS]G+P;JWQ!3X<P:KX/\*2>'_
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MTL6@CPQ90& #-]KU\7?%'_D?/$'_ %UL?_378T <!EARNP,.4,JEX@XY3S4
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M_D9/BQ_V _!__IR\0U^M% !1110 4444 %%%% !1110 4444 ?B!_P %)_\
ME))_P0I_[.M_:@_]8Y^(-?JI\;O^12TK_L-VO_INU&ORE_X*7BX/_!1[_@A8
M+4P"?_AJS]I_RS<"5H0?^&._B!NWB%DD)V;MFU@ ^TME=P/ZD?&%=8'A?3?[
M0?2VA_MFV\L64=ZDH?[!J&,FYGD0Q;=V<J)-VS! W@@'S91110 4444 %%%%
M !7UK\%?^1,;_L,ZE_."ODJOJ#X1+K1\)$Z?)I:V_P#:VH<7D5X\WF9AW\P3
MQQ[>FWY<^I- 'N%?%WQ1_P"1\\0?]=;'_P!-=C7UCL\4?\]M!_[\:E_\EU\C
M_$D7(\:ZX+PV[7/F67FFU658"?[-L\;%F=Y1\NW=N8C?N*X7:  </1110 44
M44 %%%% %W3?^0CI_P#U_P!C_P"ED%?H$.GXM_,U^?FG[OM]CMV[_MMELW E
M=WVJ';N"D,5W8W $'&<'.*^XPGBC_GMH/4_\L-2]3G_EZH Y#XT^'[7Q5\*O
M'GAR^FN+>TUCPW?V-Q/:&(7,44H0,\)FCEB$@Q\OF1NOJIK\IF_97\#Y/_%0
M^+.I_P"6FC>O_8+K]7?'2^(!X0\1&ZET8V_]E7/FB"'4%F*;1D1&2X>,/TVE
MU*@XR,9KX\;J?J?YT ?)VO?LZ_"OPMHNI^)/$_CO5O#GAW1+4WVM:_K^K>&=
M&T31[$2Q0&\U35M2LK:PT^T$\\,/VB[N(8O.FABW^9*BME:]\%/@7X5U6'0?
M%7Q=T_PMKMQ%%-;Z%XH\>?#GPWKEQ#/))#!/;Z-KLVGZI<03S0S103PVDD,\
ML,L<+R/%(J^#?\%<?"=GXI_9 \537VG>-;^+PP^J^(('\/\ PP@^,_@RTO9/
M#NHZ!;R?%;X<K-_;-]X8ECUJY7PWXK\/6-[J7@7QW'H&KR3:5:74M\;UG\+%
M^*.C?L:_#[XE_LL^ / $%W>?$?Q=\5-'3X8V.I:?X3\"_L^ZI=:K\(?AK!J7
MC&S\1>+/AQX?^*_CCQ-\/?B'#\)-:\4SZSX5\.:)XH^%=W<WJZ5XBW@'MR_
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M^NMC_P"FNQK[1KXN^*/_ "/GB#_KK8_^FNQH X"BBB@ HHHH **** +NF_\
M(1T__K_L?_2R"OT"'3\6_F:_/W3?^0CI_P#U_P!C_P"ED%?H$.GXM_,T <;\
M0_\ D2O$W_8(NOY)7Q&W4_4_SK[<^(?_ ")7B;_L$77\DKXC;J?J?YT )@<<
M=.1['!&1^!(^A- ) V@D*<$J#A21G!('!(R<''&3CJ:** %R2H0LQ0,7"%CL
M#L,,X3.T.PX9@-Q'!)'%.\R3<K>9)N1!&C;VW)& 0(T;.50 D!%(4 D 8)IE
M% "Y8J$+,45F=4+$HKL,,ZIG:K,  S !F  )(I*** /?/@-_R$/$O_7GI?\
MZ/OJ^E*^:_@-_P A#Q+_ ->>E_\ H^^KZ4H **** "BBB@ HHHH **** "BB
MB@#\0/\ @I/_ ,I)/^"%/_9UO[4'_K'/Q!K]5/C=_P BEI7_ &&[7_TW:C7Y
M5_\ !2?_ )22?\$*?^SK?VH/_6.?B#7ZJ?&[_D4M*_[#=K_Z;M1H ^6J***
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M"%/_ &=;^U!_ZQS\0:_53XW?\BEI7_8;M?\ TW:C0!\M4444 %%%% !1110
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M'^S;,@F*!4B4JI"911NV[F&YF- '#T444 %%%% !1110!=TW_D(Z?_U_V/\
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MNIO+@B>63R;:TBGNKB78A\N"VAEGF?;'#')*R(P!^=>L_L;^(;/]HCQ5\6]
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M+_Y.5^)O_7UX<_\ 4.\/5_2/TU/^39\/?]ES@/\ U0\1'O<6?\B^A_V&0_\
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M_85Q+_ZTV;'Z/PY_R*,-_BK_ /I^H7Z***_H@]P**** "BBB@ HHHH ****
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M7_(WSG?W;K_D8??_ -O'Z%_\,QZ@2 /&=@22  -#O"22<  "_)))(  !))
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MP\,"X8#+L#[&.,C5>(367X3"JI[1X6B[U5-QY;0<>:7-]5PWP=P]PE#%QR#
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M_P"O> _]5V$/[=\&/^3=Y+_U_P W_P#5OC0HHHKX,_4PHHHH **** "BBB@
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M(X+>")%5(H88TBB152-%10HEHJ;ONP+VF?\ (2T[_L(6'_I9!7Z%5^>NF?\
M(2T[_L(6'_I9!7Z%5^V>$7\+/O\ KYEO_I.-'T7J_P HGA?[3/\ R0+XL?\
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M2?\ TB/^C?K_ ,2K@OR_ZJ+S_JZN?\1R\+;V_P!:%?33^QN(+J]K7_X2O/\
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M"_$;PY<K??#CQGI37-SLUFXL-1TO6O#][KGAN^;2VO[?4$\O\<? []K^V?\
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M-;#T91P^=\-<T/K%:G1]K4GB.&L/AZ-"ES.I6K5ZU.G3IQDY2OI+^6,H\?\
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M'_9&/%?_ *+MZ_@2?[[?[S?S-?6?18_Y)'B'_LHY?^JS+SY;Z3+?^MF0Z_\
M-/K_ -6.,/JG]CKX,^!?CM\8]/\  _C[7[^QL7M(;O3O"NAZ]X8\,>*/B#>O
MJECI]SH'AO7?%]Y::/9W6DZ;>77BB_MX(]2U_4M,TBXLM TJ\NI)I+7T7X4?
MLQ_#OQ]\0O&'PKU'_A?NE>)/#^M^(K?6-0UW2/AGX'OOA5X7TWPG)KNCZWXV
M^&^I:MX@\8?$_P 47NIVFJ66K>!_A3);7*:1866K^&;W79O$>FV-I\X_ _XS
MZS\#?&UKXPTOPUX,\96H:S&J^%O'?A^SUS1=5CT^Y-[I\D-S)&-6\/:I87N)
M[/6_#U[8:@L3W6GW#W.FWUW:2=W8?M9_$JV\2:;XZU'PY\(_$7Q&\,ZW#XB\
M ?$+6?AKIZ>*/AIJEEH^B:%H8\$-HFH:-I":3X0T[PWH,7@30?%>D>+=)\%/
MI5I)H-M:_P"D+<?M>;X'BJMF.:SR[%0IX&OE>%I9=>O&,L-F4'77M?8^RC>E
M&<HU,1SU+N+I3E_:="$LGI?C^58WAFE@,LAF&&E/&T<RQ%3,+4)36(RZ4:'[
MKVSJ2Y:DH1G3PZA3LI>UA'^S:TUFU3/TKP?\)+_]G_5OB-J6F?$KPYXL3Q#X
M7^'7A;4[OQKX8U+P=XH^(=];6WB/QG<#PK;?#BW\2:=X/\#>"735]8EB\5:G
MJR:KXA\(:-;"]EU*[>WI?'SX7^!_AE)\(IOA]XQ\0>.=!^(OP;T?XBS^(M=T
M"/PP;K5;KQU\1/!VHMHGA\37.HZ9X;E/@B*]T2WUZZF\1-:W7GZPEC=3'2[#
MSB_^(6NZGX,\#^ KZ#2KCP[X"\3>-O%NF1-:7"7FJ:O\0+CPM-XD?Q%>Q7J2
M:E%/#X/T>PM3;K87-I8?:X4N6DF2:'U+Q1^T5)XL_P"%<KJ'P3^ T-M\+O#K
M^#_"^GP^&?'EWILGA+?XRO;;P[K5EK?Q,U>'5K'3]>\<ZQXHL+J00ZQ#K]MI
M$SZI-ING_P!ES]ZPV<8?%T:U-XFO0EC\TKU\)]:H5,/'"NBZ& IQJ8N^*4YS
MHT<4J=*I&C0J8K%PE&=.EAE3X?K&55\+6HS6'HUHX++*5#%/#5J==XE5X5L?
M4<,-_LSC"%6MAO:5*;K5Z>&PM2,H3J8AS[O5?V>O!-EX3UO1+;7O&;_&3PM^
MS)X7_:GUF:X/A_\ X5I>^&_$%AX9\6:C\/-+LXK%?%,'B+0?AYXRT3Q!'XMN
MM9N=)UGQ!::UX:3P]IUL-.UB;X[)8$@D\$CJ>U>XW/[0GCVZ^'Y\!2VGA'SI
MOA[HGPAU#X@KX>9?B=J_PD\.:M:ZUHOPVU3Q1_:)LI_#=G>:?I=L]Q%H-OXD
MOM"TG2O"^H:_=>'+"'3*\,)R23U/)KMR:AFE"&*6:5HUI2Q'-1:E&=U[*DJM
M2GRTZ?L:%6LIU*&%ESSP\7RNJTXTZ7'F]?+:T\*\MI2HQCA[58N,H6;J3E2I
MSO4J>UKT:3A"OB8N$:\TI*FG&52I_1S_ ,&[9)^(7[4N23_Q1?PCZ_\ 8P^/
MJ_J?K^5__@W;_P"2A?M3?]B7\(__ %(?']?U05_GY](3_DZW$/\ UXR/_P!4
M.6']W> O_)K\@_[",[_]7>8!1117XH?L04444 %%%% !1110 4444 ?B!_P4
MG_Y22?\ !"G_ +.M_:@_]8Y^(-<[_P ' O\ R:#\+/\ LX?PO_ZKGXDUT/\
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MG_@KK_RD4_:1_P"PG\/O_53> Z_NM-Y9X/\ I=MT/_+>+_XNOX4/^"N;*_\
MP42_:09&5U.I_#XAD8,I_P"+3> ^C*2#@\'G@@@\@U^'_1:_Y+S.O^R1QO\
MZN<B/V?Z3'_)$9/_ -E5A/\ U49T?G!1117]Y'\0A1110 4444 =M\,_^2E_
M#7_LI'P^_P#4ST.O]*!>A_WG_P#0VK_-?^&?'Q+^&I)  ^)'P^)).  /&>AD
MDD\  <DG@"O])=;RT .;JV^\_P#RWB_O'_;K^,OI7_[WP1_UXX@_]+R4_KOZ
M+W^[<9?]?\C_ /3>:'Q#_P %,_\ DP7]K#_LC'BO_P!%V]?P)/\ ?;_>;^9K
M^^;_ (*8W-M)^P/^U>J7$#L?@SXJ 59HV8DQV^ %#$DGL /:OX&7^^W^\W\S
M7UGT5_\ DD>(?^RCE_ZK,O/EOI,_\E9D/_9/K_U8XP;1117]0G\VA1110 44
M44 ?T<?\&[?_ "4+]J;_ +$OX1_^I#X_K^J"OY7/^#=Z6*+X@_M2F66.('P7
M\),&21$!QXA\?DXW$9P.N/4>HK^I^.:&;/E2Q2[<;O+D5]N<XSM)QG!QGK@U
M_G%](7_DZW$/_7C(_P#U0Y8?Z#> O_)K\@_[",[_ /5WF!)1117XH?L04444
M %%%% !1110 4444 ?AY_P %+(8I_P#@I!_P0KBGBCFB?]JW]I\/'-&DL;8_
M8Z^(##<DBLAVL RDJ2K ,N& (Y3_ (+^:=I]G^R)\+I+2PLK61OVA?#"L]M9
MVUNY4_#OXD,4+PQ(VPL 2F=I*J2,JN.O_P""D_\ RDD_X(4_]G6_M0?^L<_$
M&N=_X.!?^30?A9_V</X7_P#5<_$FOTKP>_Y.=P9_V.*?_IFL?G?BS_R;CBW_
M +%;_P#4B@?R$4445_I\?YMA1110 4444 %?V2_\$(],TZ\_8:DEN["RN9?^
M%V_%)?,N+2VGDVJWA["^9+$[[1DX7=CVK^-JO[,_^"#7_)B\G_9;_BG_ .A>
M':_GWZ2__)M5_P!E%E/_ *9QY^[_ $=?^3AR_P"Q!F?_ *D9>?L<=!T3!_XE
M&E]#_P PZR_^,5_"U_P5OAAM_P#@H?\ M'0V\44$*:E\/PD4,:0Q(#\)_ C'
M;'&JHN6)9L*-S$L<L23_ '=MT/T/\J_A)_X*Z_\ *13]I'_L)_#[_P!5-X#K
M\/\ HM?\EYG7_9(XW_U<Y$?L_P!)C_DB,G_[*K"?^JC.C\WJ***_O(_B$***
M* "BBB@#M?AH WQ*^&RL RM\1_A^K*P!5E;QEH896!R"K D$$$$$@C!K_2,7
M0M%.2=(TLDL^3_9UES\S<G]QU/<]2>3S7^;I\,_^2E_#7_LI'P^_]3/0Z_TH
M%Z'_ 'G_ /0VK^,OI7_[WP1_UXX@_P#2\E/Z[^B]_NW&7_7_ "/_ --YH? _
M_!2W2-*MOV"OVK9H-,T^&5/@SXJ9)8K&TCD1A';X9)$A5U(/(*L"" >H&/X(
MW^^W^\W\S7]]O_!3/_DP7]K#_LC'BO\ ]%V]?P)/]]O]YOYFOK/HK_\ )(\0
M_P#91R_]5F7GRWTF?^2LR'_LGU_ZL<8-HHHK^H3^;0HHHH **** /Z+_ /@W
MDLK.]^('[4:WEI:W2IX,^$I07-O#<!"WB'Q\&*"9'"EL+DK@G:I/W1C^IZUL
M+&QW_8[.UM/-V^9]FMH+?S-F=N_R8TW[=S;=V=N3C&3G^6K_ (-V_P#DH7[4
MW_8E_"/_ -2'Q_7]4%?YQ?2%_P"3K<0_]>,C_P#5#EA_H-X"_P#)K\@_[",[
M_P#5WF 4445^*'[$%%%% !1110 4444 %%%% 'X@?\%)_P#E))_P0I_[.M_:
M@_\ 6.?B#7._\' O_)H/PL_[.'\+_P#JN?B371?\%)_^4DG_  0I_P"SK?VH
M/_6.?B#7._\ !P+_ ,F@_"S_ +.'\+_^JY^)-?I7@]_R<[@S_L<4_P#TS6/S
MOQ9_Y-QQ;_V*W_ZD4#^0BBBBO]/C_-L**** "BBB@ K^S/\ X(-?\F+R?]EO
M^*?_ *%X=K^,RO[,_P#@@U_R8O)_V6_XI_\ H7AVOY]^DO\ \FU7_9193_Z9
MQY^[_1U_Y.'+_L09E_ZD9>?M(W0_0_RK^$G_ (*Z_P#*13]I'_L)_#[_ -5-
MX#K^[9NA^A_E7\)/_!77_E(I^TC_ -A/X??^JF\!U^'_ $6O^2\SK_LD<;_Z
MN<B/V?Z3'_)$9/\ ]E5A/_51G1^;U%%%?WD?Q"%%%% !1110!VWPS_Y*7\-?
M^RD?#[_U,]#K_2@7H?\ >?\ ]#:O\U_X9_\ )2_AK_V4CX??^IGH=?Z4"]#_
M +S_ /H;5_&7TK_][X(_Z\<0?^EY*?UW]%[_ ';C+_K_ )'_ .F\T/AC_@IG
M_P F"_M8?]D8\5_^B[>OX$G^^W^\W\S7]]O_  4S_P"3!?VL/^R,>*__ $7;
MU_ D_P!]O]YOYFOK/HK_ /)(\0_]E'+_ -5F7GRWTF?^2LR'_LGU_P"K'&#:
M***_J$_FT**** "BBB@#^CC_ (-V_P#DH7[4W_8E_"/_ -2'Q_7]4%?RO_\
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M //SU_I:_E?_ !+1P/\ ]#CBO_PLRC_YR'^5/_PU'\$_^A@\5_\ AH?C-SZ
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M,4*B2[NK>!3@R2HN6'\@#?M1_!(LQ'B'Q7@L2/\ BT/QFZ$_]D]K_57P/?\
M,_XT8'O^9_QKT?#_ ,8>(_#C+<;EF39?DF+H8['/'U9YG0Q]6M&JZ%'#\E.6
M%S'!P5/DH1:4J<I<[D^=JT5P<=^$O#OB#F.#S+.,=G6%KX+!_4:4,MKX&E2E
M2]M5K\U2.*R_&3=3GJR5XSC'E45R73D_\J?_ (:C^"?_ $,'BO\ \-#\9O\
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M3>'M$NIX?M$-OJ^MZ7ID\T&]H_.BAOKNWEDA\Q&C\U%:/>K)NW*0,@_%#X;
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M(?\ A'O@-XC?Q?\ !/0R%L 6TGX2^*I9?$?PXT]F-KX-UR:;5-!BL;R:25^
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M^(K:#2TCU+^S=;DFUW2UF79I6NW%QK6FI:ZK<37C@'YU?##]LSXO?#?]BO\
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MCH'AG3X=(\-:5X>O[;2H[C2K/PYI,$>E>'TM71]#TPR:?I3VEG+)"WT'TZ4
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M8T3P6O[1OQML/BGX/^,_Q$^-_AW0->U#Q'\*/AC\!= \7>+-)UV^>2\US1/
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M\._"_P )>&_B#XMN]?\ !5_H]_86^FW$T.O>-LZ'::I#\/K^Y\5WG@_BX?\
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M>.TL=/T^PLXH;2RLK.UABMK2TMH8K>VMXHX88TC15 !?HHHH **** "BBB@
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M9OE685\QQ=6E@ZM2G.HG&<8IQDN2"NM=KJWR/UQ^%H ^&?P\   '@7PB
M /#VG8  X '8#@5W=<SX+T>Z\/>#_"F@7SP27NB>&]"TB[DMF=[=[K3-*M+*
MX>W>2.*1X6F@=HF>*-VC*EHT8E1TU?Z=9-1J8?)\JH5H.G5HY;@:-6G)6E3J
M4\+2A.$ET<91<6NZ/T&BG&E2BU9JG!-/=-12:?HS"\3W,]EX=UZ[M9C;W-KH
MVK7$$Z@$PS0:=<S12@%6!,<B*X!5@2N"IZ'^8+]FK]N+]I/X/_!O]G?XM^*X
M?VG?'FH^-/V(_@?\6_B#X3_:'\:^ ?B1;_M"_$C]HSXA?L]?!3X:_$/]G6S^
M$,GC?QAX1\(^"OB1\1]6\2?&71)].T'5O#?@+QQX!TF/X7:MXF\4^'+KPW_4
MK/!#<PRV]Q%'/!/%)#-#*BR12PRHT<L4B,"KQR1LR.C JRL5(()%>47'P!^!
MUWX=\*^$+OX/_#*\\)>!O >I_"SP?X7N_ _ANZ\.^&OAEK6F:'HNL?#S1=%N
M-.ETW3_ ^K:3X9\-Z;J?A6WMDT.^LO#^B07-C(FE6 M_2-#\TM>_X*$_M#Z1
M\/M'\27'[.<7AV70-1^-+?$SQ/XUT?XPZ?I=EH'PDTCX:Z]HGB*#X0^&/!7B
MW]HSP?X,^(-AX_U2VUGXA^(OAQKV@_!W5_ E]9^*=/\ $-MXT\ WVN5M#_X*
MJ7NN^,?B5XBM?A,]K^S9X$U3XW>'6^-FNP_$30_ 5A;_  1^%OBCXEW?Q:\2
M?%;_ (034OAZ_P +?&4OA.]T70-(\%Q^+OB5!X<U?PM\1T\.ZSIVJ:KX<\/_
M *#W_P"R%^RKJGA7POX&U+]F_P"!FH>#?!5[J&H^$_"U[\*O!%UH7AZ_UB2U
MFUN\TK3)M$>UM+G7YK*TE\0RQQ[M?D@B;6C?E$(Z:;]G7X!7/C'6/B'<_!3X
M3W/COQ#X>E\)Z]XPN/AYX2F\2:UX9GT1?#-QH.J:O+I#7E_I-UX:CA\.7=C<
MRRP77A^WM=$N4ETJUM[.( _*G0?^"G7QRU'XJZ?^SI?? ?P_I'QEUCXS_ OX
M?65_XP;XA?#?PK;^%/VA_@O^UU\3O"WB:Z\+^*='F^(R7?A+4?V4-<TW4[#4
M=-T2Y\6V&NV<UCIWA._2>WM*?Q$_;B_:&^(O[/?PE^,?@6S^&WPZL/C'^T%^
MP[JOPGT71?B;=7/Q*?X:_$C]M[X2_![Q9X"^.'A_4?"%R/#EOXI\+>(+C2/&
MNM^#;?5X?"NK:GXE^&J++XFT;2_$>M?J=X3_ &6OV;/ ESH=[X+^ GP?\*7O
MAG5-'UOP]>>'OAUX4TB\T76/#MAXXTK0-5TVZL=+AGM-1T33/B9\0]-TF]BD
M6YT_3_&_BJRM)8K77=0BGT+7]F_]GRQOO$.IV7P0^$UGJ7BWQGX8^(GBB_M/
MA[X4M;SQ%X\\%>)X/&WA#QAK5S!I4<VI>)/#'C2VC\8Z#K%V\M[I?BLR^)+.
M:+6IY[Z4 ^3O"?[<>I7'[,'QS^+_ (YT#P/X7\>_ 7XV_$K]G/7M/;7/&MS\
M/_%'Q,\&?%/3OA3X8D\,W.B>"?%'Q$N(/B)K?B+PM;>'?"EGX-UGQ1<>*=:A
M\&V3:C)):Z]/\K^&/^"G/Q\\8_$ ? ?2/@?X(T7XP:)X\_:'^'WBV^^(NI^.
M_ _ARVNO@W^SK^SU^TMX?\0VWA*#3?$_C+3[+Q7X7^.L'A:[T+4+VXU73=0T
MN'Q/'<3:=>'1%_7>;X,_".X\+^-O!-Q\,/ %SX.^).M>(?$?Q!\*W'A#0;CP
M[XWU_P 6W27WBC6O%FBS6,FG:_JOB&]BCN]9O]3M[FZU&ZCCN+J629$=><\,
M?LT_L\^"KO3=0\'_  .^$WA>_P!'35TTN^T#X?\ A?2;RQ'B#PSH?@O7FMKJ
MQTR">.76_"/AKP]X:UB8/YVIZ'H>DZ9?//:6%M'& ?CGJG_!1OXS?M%^&/V9
MOBO\)=)T?X-?!_Q?^VY^P9\'-?M;WQ==7/Q<\30_&OP/\*?C;XVT*?1[CPJ/
M#$_@+4O"WQ7TSPC:QV5[;^)/$&DZ/JGQ%L+[3M%N;#2#Z[_P4>_;!^.?@CP-
M^UEX.^!?]A_#^X_9X^"_P*\=^*_BEK?B&^TCQQ-JOQ\^(VM^&_"T?PJT27PY
MJWAR^M]"L? NMQ:MJ'B2Y,/B?7]9C\%Z'#IFH:5J&JM^D5C^RQ^S3IFJ^%-=
MT[X ?!JQUKP)H_@;P_X*U:T^&OA"WU+PEHGPQ%BOPYTKPW?1:2ESHMCX$CTW
M3X/",&GR0+X>MK.VM=+^S6T*0C?^('P!^!WQ7U;3M>^)_P '_AE\0];TC2KS
M0]*U;QKX&\-^)]2T[1]0E%Q>:797NL:==W-O83W*K=-:12+ MVHNHT2XS*0#
M\I]*_P""A'Q;\)>$;+Q(?AWHK_"_0?B3^VA>_%/XL_$7QQX^\;Z?X/\ #7P6
M_;?^./P7M[#Q%)\+?AQXK\7_  I\'0^!_ .H^,K'XH>// MW\)O!FBZ)_P *
M^O-=N/\ A'M2\50>IM_P4&^),G@&^^+MI\-_A5_P@?Q"^)^J_!SX#Z/K'Q1U
MK0O'EOXITS]KCPE^Q[!XH^,6DR^$+Z#2_A_+XM\6V_CCQEJG@U=6O?A=I$6D
M>#M9@U[Q'XMTN^M/N/7/V4_V9/$W]@_\)%^SW\%M=/A?7/%7B3PXVK_#+P;J
M+:)KOCGQ5JGCKQKJFFM>:/,UK=>+O&VM:KXP\2M&0FN>*;ZX\0:FESJK_:QK
MR_LY?L_SZE\1-8N/@E\)KG5/BY8SZ9\4[^Y^'GA.XNOB-IMU)'-=Z?XWEFTE
MV\3V5[-##/>VVL&[BO9X8;B[6:XABE0 _/;2O^"B?Q&L/%WB[X6^,OAAX(D^
M(>D>*/&?P1\'77@_Q;KVH^$_B'^T%X&\2_!T:AX?\//JNCV6K/HU[\-_V@/!
M'CBZTF)+SQ+X:U+X<_'KPS>3ZI;^ H/$%[Y)X6_X*O\ Q=\3_")?C!;_ ++V
MK6&@>/(OV9O$7PCE\6Q>/_AYHDVA_M'_ +2WP<^ NB^&/%/B3QCX2LDU[Q+8
MZ'\8='\?GQ3\,M)\2>"0VFZ_X:G8S:?HVI>*OUXT3X&_!CPWI?P_T30/A/\
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MZRFW55%Y5"X_9+_9;NY_$UU<_LY? V:Y\9W'B&Z\6W$GPJ\$-/XEN/%RV_\
MPE<NMS?V*)-2/B>2U@N/$(NFE76KN/[9J*W-VSSL ?FK^T;^V?\ M(P?L\_M
M\:MH=G\*OAS-^SS\,_VF/A'_ ,)?I?CO7=&^*%G^T#X%_8ZU;]HO2/'OPK\.
M^+O#3:3X@T'1SJNAV7A[PWJ>WQ/KVF:-K7Q:C$7A.P7PU<?6/[,/[5/C+QMX
MD^/OPP^-.B>#?#/B?]GSPC\%/'VH^+/#OB?5M2\+ZKX%^,WP\UWQCI-QKEWK
MVB:/=Z?XC\,2^#?$UKXJO+2TET&_M/[,US3$L6NKW1=.^F?%'[/'P%\;^(_$
M7B_QC\%_A9XJ\5>+O!VK?#WQ3XD\1> ?"^L:[XC\":]I%SX?UOP?KFJW^ESW
MVJ>&]6T&]O-$U'1[V>:RO-'N[G2IXGT^>2V;L]&^'O@3P[K?B'Q+H'@WPOHO
MB+Q;IWAO2/%&N:7H6FV.K>(M*\'65]IWA/3M;U"VMH[K5+'PU8:GJ-EH5K>2
M30:5:WUW;V20Q7$JN ?BCI__  5K^)DWB/1O""?!SPEJVJ?$RS_9'\<?!WQ%
M]L^(W@OP%XG^&O[4/[4_PR_9E35K74O&GAFS\9Z]IF@S_%#1/&OASQU'X"\+
MV/C73(-0L8_!>CSP6\U[RWQU_P""DO[07BS]G?\ ;C\._#GP_P##OX7_ !7_
M &5OV:?VS]>^)WQ(N?&WB'3;2+Q?\'M?^,GPD\(Z]^SQ'J/A74!J.IV^M_#V
M+Q[J<GCN.33_  EK&K^"_ 5W#KC^)#XIL?V'T+]E#]F#PPUJ_AO]G?X): ]C
MJ>EZS9OHOPN\%Z6]IJNA>,M!^(>A7]L]CHT#07.A>._"WAKQ?HDD97^Q_$?A
M_1=7TT6M[IEG+#8\0?LM_LU^+!(OBCX ?!GQ&LNN^.?$\JZ[\,_!VK"7Q#\3
M@O\ PL?6I1?Z/<>9J7CUTAF\8W;YE\1W%O:W6K-=7-I;31 'C/Q/_:%^(GA#
MQ5^S+\(? .B^"-6\;?&KP5X^\?:KXM^*GB76/"_A#2?"WP;\/?#O4?%]DDWA
M[1]5O[[QSXGN?B)I4NB6+):Z=I7AW2?&_C'4#J%OX670]4_,+]A#_@I;^T9\
M5OA7^S9X4/PJ\6?%'56^&_[,GP\^)/QC\4^'_&AB\1_&'XS_ +/OPY^*EQ\3
MM1\<:+X=TWX6VG@+P_J/Q*\+6^O:8-3A\:>,=,;Q-XC\&Z9;OI^@^'_$?[L^
M-/A)\+?B/H^A^'_B#\./ WCC0O#.J:;KGAS1_%WA30_$6FZ#K&CPR6NF:IH]
MEJ]C=P:;?V5G-/8V]U9I#,MC<W5B6-I<W$$G*Z9^S7^SQHOB7P=XRTCX%_"'
M2_%WP]\/V7A3P'XGL/AQX0M/$'@SPSID$UKI7A_POJ\.D)?Z%H^DVEU>VFDV
M&FW%O;Z59W^H6FGI;6U_>13@'Y=:W_P53\>ZTWP@T3X6? B\\1^)?B?X0DNM
M62ST;XD_$"/P'\3_ (:^#?#_ (H_:"^%&LZ!\,O#6L>);G7/ FN_$/X<_#];
MOR+&'1]6;Q_K>OQSP^$;70]:R_AA^W#\=O$7QM^+'AW3-(@M]>^-GQE_9&^'
M_P &?A[\9/$BVWA#]GRY^(O_  3LD_:N\?Z1XHO_  +H^H:CKE^UUX*\4Z/9
MZ/HU]CQ/\0M8L$L=;TO0!=3P?JUXB_9L_9Y\7>';OPCXI^!GPA\1>%K_ ,=:
MW\4+_P .:U\./"&IZ)>_$CQ-?WVJ>)?'MWIEYI$UG/XP\1W^J:I=>(/$<D3:
MMK<FIZE_:EW=I?WB32:U^SG\ /$>E^*=$U_X)?"?6M'\;W'A2\\8:7JGP^\*
MWMAXFO/ FCV/A[P/>:W:7&E/!J%YX-T/2],TGPI=3QM<>'=.TZQL](DLX+6!
M$ /RO\-_\%4/B1XI3Q;X@LO@]\/K?PO\(?#7[,'B;XHZ8/B!XAU+Q5XA@^.?
M[2?QX_9;\30_!?[+X6@L/&5CHWB_X*S^,?AEKVJVNDV_Q4T#7M \.1V.@:WK
M7]I:1RP_X*M?'!?A]XC^(9^"OPEDT[1OV6OVJ_VMK:Q;XB>,K>XG\$?L1_'&
M/X1?&#PC=W"^$+R&#Q)\1[;5=#USX6ZO;_:M%\.S1:W9>.+:X2+39[W]-M(_
M8L_9QTCXT:C\=E^&OAC4?&+^$?@EX+\*6.J^&_"MYX9^%VE_L_S?$B7X>7'P
MIT?^P(V\!ZC:?\+/UN.[GT>[2 II?AIM-M=,FT6.67T!?V;OV?4T:7PZOP1^
M$ZZ!/X$\?_"Z?11X \+C2IOAM\5=:@\1_$WP#+8?V9]FD\'?$'7[6VUKQIX;
M:,Z3XEU6"&_U>TN[F-)  ?E3K_\ P5>^)EIX7_:5^*&A_LR^)Y_AA\)? 7[:
M.N^#-5\1Z-XZ\*0W6N?L=Z)\0KF23QAXOUS0[#P7?:3\5-=^'&MZ/I^D?#V\
MU[Q/X!-WH$_B&/5(M0UB7PR>*_VZ/VLM6_:A^ W[/WAS3O@GX#O8OVNOACX&
M^,1<>,?&VD^,_@S\;/V-OVB/VBO!FAZ)J-QI^A:GX=\8>';WX,Z]9:UJUI:F
MQU?Q!I7@:]M9]/\ "FM^-/"\?ZH7_P"S+^SGJFL^.O$>I? ?X/7_ (@^)_A;
M5/ _Q'UV\^&_A"XUCQYX.UO2UT/6_#'B_4I=(:]\1:%K>B1P:/K.F:K-=6NK
MZ5:V>GZC'=6EE:0PW?$?[//P'\7S:W<>*?@W\,?$%SXDO_!.J:]=:QX'\.:A
M=ZOJ?PV@N;7X>ZEJ%W<Z?)<W.H>![6]O+;PG>O*;GP_;7EW;Z7+;0W,\<@!X
M-X[_ &E?B!8?M(:G\%_!'AOX9Q>'OAGX1^ ?CGXJ>(?BEX[U/P-J.N:/^T5\
M3/'OPS\,:9\+!'H5]HE]K'ANX^'6LW]^_B&]CM/%/B;5_"?PUT*.QUC6KG7=
M*^1(?^"E'QJU/0/#/B7PS\!/!GBB+X^>!OBCXX_9Z\*:=\0M2M/'6B6?PC^.
MOPN^"_B/2_C+I&KZ)I]D?%][I_Q2M?%NE>!? ^H-XBO?'7AG4_V>]*CUKQYK
M?AS7+W]4?$_P?^%'C;Q5X2\=>,?AKX"\5>-/ -PUUX(\6^(O".@ZSXD\(W#7
M$5XTWAO6]1L+C4M&<WL%O? V%Q!MO[:UODVWEM!/'R\G[-'[.TTWQ"N)O@1\
M'IIOBTSM\4I9OAKX-F?XBE]236I/^$V,FC-_PDPDUI/[:D75_M2R:TSZPX;4
MW>[(!^5-K^WO^TYXD^.?PNL_!G_"BO$7A'P]^S?_ ,% _$_QL^#;I\0_AEXL
MUCXT_LM:W^SG)X/\,W_BOXY^&O 5U\!-9U30?C1X3N;K3_B'I]WX.\-:%XU\
M1>)-;\3^-M&MOA_XEB^]/V0/VE/$WQTB^(_A;XDZ;X9\*?%;X8ZEX4_X2GP+
MIVC?%7PAXHT#1?'7A^36O#5WXH\%_%GP?X=U+3H[V]TWQ1H^B>(/#&O>.?!O
MB^'PQ?ZKI6O6%Y%J?AO1_6(OV7/V;8/#_A'PI!\!/@[!X:\ W^JZKX*T*'X;
M^$8]*\+:EK]F^G^(-0T2Q321!87GB&RDDMO$-Q$@DUZ&1TUAKU6Q77?#+X,_
M"/X*Z3?:%\(/AAX ^%VBZG?MJFI:7\/_  AH/A"PU#4F7R_MU];:%86,=W=1
MP;+6":X$KV]G%#9VYBM88H4 /2J*** "BBB@ HHHH **** "BBB@ HHHH **
MQ]1\0Z!I$R6^K:WI&F3RQ^='#J&IV-E+)%N9/-2.ZGB=X]ZLF]5*[E*YR"!G
M_P#";^#!U\6^&?\ P?Z1_P#)E '444R*6.>*.:&1)89HTEBEB=9(Y8Y%#I)'
M(A9'1U(9'4E64AE)!!I] !112;EP#N&#@ Y&"2<  ]#D\#'4T +12!E/1@>,
M\$'C)&>.V01]01VI: "BBB@ HHHH *** 00"""",@CD$'H0>X- !112 @D@$
M$CJ 02,],CMGWH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** /QK_X*.11/\6O Q>*-R/AS@%XT<@?\)1K)P"RD@9Y
MQTS7YY300>3-_H\'^IE_Y8Q?\\V_V*_:7]K+]EGX@_'7QQX<\2^$=6\)6%CI
M'A/^PKF+7[[5;6Z>[_MG4-1\R%+#1M1B:W\BZC7<\J2>8''E[0K-\KR?\$Z_
MC8T<BCQ)\-<O&Z#_ (F_B3JR%1G_ (I;ID\T ?K3\+0!\,_AX   / WA$  8
M  \/:=@ #@ =@.E=W7->#-&NO#OA#PKH%Z\$MYH?AO0M'NY+9G>WDN=,TJTL
M;A[=Y(XI&A>6!VB:2*-VC*EXT8E1TM '.>,+^YTOPIXEU.R<)>:?X?UN^M7/
M1;FSTN[N8&.>RRQ(WX5_-!X;_;2_:9G_ &4/V:OA1+\;_%EU\>_AG\5OV$/'
MGQO^+]R="D\6_$S]G+]H/XV_LM6?PL/B2TCT.WTZ-?C/8_M%:I\-_$>I6%EI
MXUR^_9_^,UKITUK<0SO'_3Y<6\%W!-:W4,5S;7,4L%Q;SQI+#/!,C130RQ.&
M22*6-VCD1U*NC,K J2*\R/P.^"[:?%I1^$OPU.FPZ5\+]"BL?^$(\-BV31/@
MEX@;Q7\&]'$0T[;_ &5\*/%#R>(OAQIY!M/!6N2RZKX<BTZ]EDG8 _GX^'G_
M  4I^,OAGQ_J=_;Z5X^\?VWCCP3\-/AUX!^&]U>>*?BQIOACXB^*/V^/^"F'
MPUUOXFZL?"_AFU\>:[&_PY_9ST+3;#PGI-O%-?7.E^"_A_I5_IT*7/B=OM/7
M_P#@HO\ &CPYHWP^\:>,?@=X?^%/PZL/#.I^(?CGXS^(UY\1KJU\&KH'QJ\9
M_"?59/$&@?#_ ,'^,?'/P(\+7WAKP1=?%?P]X_\ C3X+_P"$7>UU27X>^*KC
MPGXA\%>.=8T;]%)OV8OV<;C2=>T&?X#?!Z71/%.C0>'?$FDR?#CPB^G:[H5K
MXX\2_$VTTC5K-M),%_I]G\1_&?BWQ]9VUPCQVGC3Q-KWBBV$6MZK>7LT6H?L
MM?LT:J/ ZZG^SY\$K]?AG EI\.EO/A7X&N$\"VD=W-J$5GX2270F30+*+4IW
MU..STU;>U35 FIK"+^-+E0#\N/@1^VM^V'KOVGX9^+6_9Z\5?%KQI^U+_P %
M$O"7@;Q9XAE\9?#3X8^$OA-^QI\8K_P>?#/B1],L-=U;6?&-_;:EH5GX7N+&
M*&2/X>Z-XH^(7BR?Q'K7AC4M/U_.\-?\%=_&'B#3(_B[/\#=)TWX%VGQ)_9>
M^'NK:3%XEU[5?C9+/^U1^R9\)_VA_#DNBZ#;Z!!X8O;SP=XA^(W_  BUY93W
MMO\ \)IHAM=:T-])O($LM:_5GQ%^RY^S9XOE\3S>*_@#\&O$S^-?$^F>-?%_
M_"0?#3P=K">*/&&C6%[I.F>*=?CU#1[B/5?$5II.I:CI":U>)+J+Z5?WVF37
M,MC=W$$O3S?!+X.W%W=W\_PK^'<U]?\ C3P9\1[Z\E\&>'GN;OX@?#K2-%\/
M^ /&]Q,=/WR^+/!.A>&_#VC^%/$#DZIX?TO0](L-*N;6UTZTBB /CS]A7]LG
MXD_M3VVI7GCWX*:W\-=.U#X;?##XN^$-=N-$\7Z%HUUHWQ277)(O!,1\=6.C
MZMXPU+PI#I5E='XE^&-*@^'_ (WM=9SH4&EW.C7UI)\2?%;_ (+">,_AJOC?
M7=*^%7A+X@^"M6^$G[1OQ4^!/B[1;SQ[X?\ !/C6/]FOX@> _"7B#11XV\6:
M)I4_B^V\2:9XT:\D\6^%/ ^E^&_"FMV%OIMC=_$#1-6M/$H_:#X<_!3X/?!_
M^WO^%4?"SX=_#7_A*+V/4?$G_"!^#/#OA+^WKZ%KAH+K5_[!TZP_M"6W:[NC
M;FY\Q;8W-R;=8O/FW\9/^R=^R]=3>);FX_9T^!LUQXRGU^Z\6W$GPJ\#F?Q+
M<>+%MQXIEUR7^PQ)J;>)6M8)O$ NVE76;F-;K45N+DM,P!\!:E^WA\==3^,/
MQ8_96TKP1\'=#^+WPBOOB]J_C'X@:[XW\9Z/\+KOX>> ?@Y^S;\7M.@\'SR^
M&)];'Q-O=,_:D\+Z=JEIJV[P_P"&M.\!>+/'TRZGINHZ1X;@Z7X1?M:?$GPK
M^Q1_P28\>>(K=/B9XO\ VKK#]B[X=_%+QCXGU"6VU*.]^,G[/U]XR\2_$.:;
M2+&.PO/$-_XIT.VC%K+!I^DWM]X@DCA\F5K*V?[Y\3?L^? CQK>:GJ'C#X,?
M"SQ5?ZSXPTKXA:M>^(_ 'A;6[K4O'FA^&=+\%:/XSOKC4M+N9;GQ1IO@W1-)
M\(V>NRLVHP^%]-LO#XN/[)MHK1=O5?A!\*-=^'MC\)-<^&G@+6?A;IFFZ#H^
MF_#G5?".@ZAX&T_2_"KV4GAC3['PK=V$VB6EIX;ETW3IM!@M[*--'FT^RFT\
M6\EK \8!^*GA;_@KI\5?%?@CQ;\0K#X2?"5M"^%?[/VB?M+^/-,'Q%\1CQ#X
MK\#7/[6W[5G[-^I>&?A9!#H5Y;ZGXLNM%_9_T+Q-X8O-5SHNK>+?%-KX'=$B
MUO2M>T[C?A'^WE^U)\+]5^*NO?&"#PG\8KC6O'/_  5+^(FIP^'M<\:Z;9>!
M/@Y_P3'^.'A/X5W?P_\ A?X O+>\L)O%_CKP[XBN+;1)/M]O'?:W#IGB/QMJ
MFIZBNJ6-W^MMG^PY^S!9_&5/C<OPD\%3^)-/\#^ / _A?0;KPCX0G\$^!(_A
MS\1_BW\5]#\4^!/#C^'MGA3QK=>-OC3XQUC6/$.E744E]=)HMY';VNI:6E]-
M[=I7P>^$^A:Q9^(-$^&?@+2-=T^X^)=W8ZSIOA+0K+5+.Z^,WB/3_&'Q<N;6
M^M[&.Y@G^)_BS2=+\2_$"6.17\7Z]IUEJVO&^OK6&9 #\N+W_@H)^T%I7Q)^
M%/P%NOAM\!]4^*?QC\7_  /AT#Q/X5^(_C77OA1H'@O]H3X%_M>?%'PT=6U(
M^%[+7=3\8^#-9_94OHKW3=.BM=-^(/@;Q?H'BS0Y_"4MY/8Z6?L+_MK_ +0O
M[6'[3?B==<7X:^&O@/'^R#\'OB-:_#S3;#7-0\7Z)\6[W]H/]J[X%?$'4].\
M<W,=A#K7AC5?$/[/VHO:VVL:79RVWA=/!,]EI>E^(;KQK+J/Z3>%/V</V??
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M_%>J^&KS1'\,W>@ZAX@GTM]4N])NO#DC^'[FRFNGAGT(_P!C2JVF!;09NO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
)44 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>42
<FILENAME>reserveschart.jpg
<TEXT>
begin 644 reserveschart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %( 3T# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /-?C-\0_P#A4?PA
M^*?Q4_L>3Q#_ ,*U^''CKQ__ &##=BPEUO\ X0OPKJWB;^R(KXVUX+.34_[+
M^PI=&UN1;M.)OL\^SRG^#/V?/^"COA/X@?"KPK\6/BMK7P$MK#XCV/AJ?P%X
M0_94^*/Q%_; ^("ZK>> [CXD>-?#?C3P;X"^".C>(= U?X?^$VL=4\0?V9IF
MO6MC:-=W&K3:0&T>/6/OCXO_  [M/B[\*/B;\*K_ %.[T6Q^)?P]\;?#^\UC
M3X;>XOM*M/&GAC5?#-SJ5E!=@VLUW80ZH]W;17(,$DT*),#&S5\O:M^Q5:V7
MAG]FM?A?\4==^%_Q+_9B\ W?PR\'?$K3/!_@K7VUWPAXB\%>#_!?C2Q\4>#=
M<L'\/7MUKO\ P@7@_P 4V&H6[6]UH7BCPUI3*VI>')=:\-ZR >Q_"[]J;X%?
M&SQ;KW@OX3^.8_'VK^&/#WA'Q3KUWX;T+Q-?^&-.T+X@>"?!OQ&\!WTOC1=&
M7PBY\:>"/'GAWQ)X5M(=:DO]>TQ]5FTZUG_X1[7AIWPGX9_X*\?!_P 0ZW\.
M'OOAA\8O!?@7QIJW[=^AZSK_ (P^&OQ,M_&&@WG[#?Q*\&> ?$5_I'PQT+P#
MKGBCQCX=\3V?B75_$VJ:QI21+\-8?"FN>'/&,$/BG2M?TK1/JC]DK]B[P!^Q
MVOQ(TWX<>(?$NJ>&?'+?!F#3=&\2?V;<3^&=-^"WP"^''P#T>W35;&VLYM9N
M]=TOX=6OB?7=1OK:"237M7U&.T@MM.CM+>+QK0O^"<.@:%X\;Q+;_%SQ7)X8
MTB+]NJ'P5X0/AKPU%)X=A_;^\:^'?B=\6XK_ ,2PE=0\2KX=^(FDZGJW@22^
MM+6XT_1=8C\.ZO/K":19:BX!]+>&OVO?V>_&/C?2/ 7A;Q^NO:EK]YI.D:)K
M^E^&O&%W\.=5\2Z]\/[/XK:-X,T_XKQZ ?AG=^.]4^&E_9>.[+P-#XK?Q5/X
M6NH-672?)E0'S;XR_MCO\%_B[<_!;7OAQ->^,/'WA/PYJ_[+JVWB9+>S^/OB
MV[U\>&/B!X $UQHG_%&ZK\'WO_#/Q"\?WX_X22"R^"NN:G\2K6WFM? _C#3M
M-\%_9P_X)/?!C]FWX@?#WQOX<U+0_$4_@:R\&:G)J7B7X,?"'4/B)JOQ \)_
M![P]\'+CQ%:?%J[\.WOC;PKX;U[3_#L'C&[\&>&[FRDTWQE?:FNC>*++P=?W
M/@^3[%^,W[-'ACXV?$_]GKXC^(]9U&V3X Z_\5=:M?#5K:V<FG>+X?BO\%_&
M/P5UC3-8O9-FHZ;!9:+XSOM2M;C1Y8+J6[@CMII!:RR@@')Z/^W9^S;K^CW.
ML:#XI\8>($6QT'5]$L/#_P &_C1K&M>/O#WB<ZM'H'C/X5Z!9?#Z76_BE\/M
M7GT+54LOB%X$L->\$^5;1WMQKT%A>Z==WF'>?\%&/V-;&R?4KCXT6*Z=;?#A
M_BUJE\GA+Q_-;^'O ,7C'Q[\.)]8\5&'PI)+X5N[?XE_#7Q;\,KGP[XABTWQ
M-!\2K.P^'[Z/_P );KFB:1?_ "5X8_X(Y?"?P+X2T;PGX*\8:%H-EX+NO!>G
M^$K6/]GOX%'2/%/@7P1I/B#0],\(?M%Z98^&=,N/VCTEM==LM;GNO&FK:;I2
M>/?!'@'XB6WAJ+Q;H-YJ.L>B?!G_ ()9_#_X&Z)\3O#_ (,^*7BF+3?B+\'O
M$'P>CM;OX??!N^TCP_H^O_M1_M)?M1SRP>"M3\#:E\-M5TL:Y^TEX@\"R>"]
M0\$?\(>_@;0].L+32=/N+N>6  ^]_!7QJ^'WCKP5K?Q T_4-:\.>&O"\NKP>
M*Y?B5X-\9_"75?"DF@:;!K&M-XG\/?$_0/"6O:%:Z?I5S#JDFHZCIT.F3:7(
MFIVE[<6#K<GPM/V_/V6/[$T?7KGQ[X@TZ#Q'XJ^'_@[PUI>K?"CXOZ/XI\3Z
MQ\6M.\5:I\)YO#/@W5/ EGXL\1:#\4+;P3XHB^'WBG1M%OO#GBW4]%O]%T?4
M[C6;6?3XZ/PB_8G\'^ /@3\:O@+XM\4:KXX\%_'L>,;/QEX;TS3K7X>^ /"O
MAWQS\/=,^&NO^#/@]X T"[OM.^%?A&_T;3KG7[K1M$U&ZCE\=^(O%/BN-[>;
M639V_@GPZ_X)8?#;X>0?#@:5XNTS2K[X<?'3X'_&&WOO GP1^#/PMF\6V?P"
MT/XDZ)X0\/\ CN3P'X;TJ\\4:KJZ_$_7]2\4>*[Z^*-J?[WPGX:\(6^HZW:Z
MD =+\?O^"HW[/GPH^!?C+XN?#ZXU7XQZYX:^'(^(EMX'T?PQ\2-%^RV<OQ#U
MCX566D_$OQ&?A]J]K\$]9U'XA>%_&7@K3](^)UEX?UJ[\7>#?%'A^+2S?:#J
MRV?O=Q^W%^S'8IXZNM3^)#:3I7P_T_QSJFJ^(M5\&^/]-\*Z_9_#/Q=8> /'
M_P#PK?Q1>>%8=!^+5WX0\=ZMI'@G7M-^%]_XNU&S\7ZOI7AQ;6;5-3L;>X^.
MM2_X)+^&_P#A"OC/X#\+?'_XC>$M$_:-D\>M\<#:>%O FJ7?BU=;_:&^,O[0
MO@+^RKC5;"=O"T_@?4OC7XC\!ZG-8_:1XW\"Z;HD-]'HWB*VFU^;2T+_ ()%
M? 3PZ/B/8Z+>Z?X?T_Q++KNI^ M<\,?";X1:)\5?A_XCU?XQ^'/CUI.NW_Q?
M/A6^\9_$1O ?Q'\)>'Y?!NC^*9H]#N?#=A%H7Q#L/B#/%9ZO9@'O_P -_P!M
MO1?B;;_MHZEHG@+7['2OV1M>L-#"^)(/$?@_Q)XTFN/V:OA[^T'>1:QX.\8^
M$_#_ (D^'FI:?-XY;P?)I>LV&H32#3(_$2N+?4HK"'R/X6_\%$[^'PA\"_'?
M[5/P[\$? OP9^T;\!;CX]?#;QAX+^*.O_%;0;.VT_P &>%/B%J7PV\:6FI_"
MKX<^)=/^(<GA#Q=:ZCX7M?"FB^--+\8WFC^(-!TZZM/$$6@:9XD]S^''[(3^
M$M,_:J;Q=\5O$GQ \5_M=:A8ZS\1?$ESX;\,>&8=&U2S^ ?@W]G]4\'Z#HD1
ML=/TB+PUX)TK4K/3]2N-5NXM2DNS>ZKJ7GO.WR]!_P $I=$\;_!KP1\%_P!H
MSXY^)?C5X=^#WP9T;X+_  2AMOAS\/O >D^ [/0C\.S8^/\ 5?#L4'BRP\?_
M !%\OX6>$=*FN_%,LO@UO#4GBKP['X*AL?&7B!KD ^MM5_;H_9JT31;/6-5\
M8>)[&ZN-3\5:5>>#YOA+\7S\3/#D_@/1/#_B?QW>^,_A7%X$D^(O@G0?!?AC
MQ9X4\3>)?$_BOPSI/AS3/#_BOPGJ\FJ/9>*_#LNIR:S^W1^RYX?E^(1U?XFB
MRTKX8^'?B3XF\3^*Y/"'CL^ Y[+X.>'[OQ5\5]/\(_$!?#!\$_$#Q+\.O#UA
M?ZIXQ\)^!=?\0^)=#@TW5X[O2UN-#UR'3?!/"'_!./3/AK%X:\1_"3XK1_!7
MXJZ9'\4M$UWQI\'?@9\$/ 7AW5/!/QCB^%<?C#P_I?PVL/"TWA[2M7T^Y^"?
MPTUSP=XWU>\\6>)M%US0[B+5[GQ-X3U!O"-MP>L?\$B/@G?+^T98:5K>G:#I
MOQ[\%?M/:"FM6_P;^#FH?%?PIXF_:T\.^-=%^*/B=_C3J/A:7XA>)[2VOOB%
MXOUKPOX=O=2TR.R;7+G0-:U?Q!X5M]+T73@#W_Q1_P %&/V9-(LO%-KH?B_4
M=;\:Z!=:UX=M/".H^!_B7X56Y\>Q?#B_^*/@?PAK?B#7?!$&C^#W^+GA*R75
MOA)K7B*:TTCXG6$K3?#^X\3W$36C9WPB_P""D'[._P 2?A!X$^)&M:QK/@[Q
M/XO^%_P$^(Y^&#^"OB7K/B[4_P#AH31OM7@C3_A3I4?@2QU_XY:9J.OV7B+P
MQIGB?X8^']<TN_O?#.LW-P--M;2=XN#^(G_!,CP5\1-6^)6J7_Q5\:V/_"R_
MBQ^S%\5=0MK;1_#DL6GW?[,WPKM?A9I.B6KSQF2:P\76%L-6UJYN";RQOW\O
M3&2!%KA-<_X)%_#/Q?X:\!:1\0/B7KGQ-U7X%>!?A'\,?V=M0^(GP^^&WB?0
MO '@3X/VFI6=AI/C/P1<:/#X<^+EYXYL]4DTWXB:GXBBTIK_ $_2_#TWA*V\
M&>(-,N/$&I 'W!X1_:^_9]\>^.O"?PT\'>-[SQ#XY\9^$;GQWI'ANP\%>/3J
M-EX4T_Q5XO\  FM:MXLCG\,0+X#'AOQSX&\2>!_%5EXX;P[J/A?QI:6WA+7;
M.Q\0:IIFG7?E_P :_P!KOQ+\%_C3X!^'&I?#GP/J&@?$/Q_\-/A[X4MG^.GA
MRR^//CV3Q_K^@:!K_CGX6_ *#PUJE]XL^'GP>DUN36/BMJNL^,_"6LZ-X4\.
M^-/%>GZ'>Z/X=L9O$<G[/W[#?@K]GKXG:3\2_"_B-B^G?L_6GP*;PEHW@3X?
M_#_P:H/QK\?_ !TUCQ7I7ASP!H?A_1]"NM3\4_$36+,:186'V9+""WO=0OM8
M\0W.JZUJ&C\9_P!D75/C?XPB?Q9\</&S?"2?QW\-_B7?_"]?#/@9]2TSQ-\+
M/$7A#Q9X<T[P%\4TT>V\<^!?!^J>)/!&CZSXITBUEU77;VZOO$46@>+/#%EK
M'V.T +_P#_:LO_C;\>?VF_@K?_"+Q/\ #-/V>S\(9M,UCQ?K.D2ZWX_TGXK:
M/XTU&VU^3PCI/VQ_!-A#<>"[R/2-/UO6KGQ%JNDW=CK6JZ/X:>ZBTL>R_%KQ
M?\5/#4/A?3_A%\++#XE>(_$NMW.G7=UXF\<1?#WP%X)TBST;4-3G\1>,?$5K
MX>\:^)F@N[RVL?#^B:3X3\#^)M4U'6]6M6O5T;0K75-;L?D#P9^QU^T!X$^-
M?[2GQVTW]JVTO_$W[0G@?3/#3Z,WP"\%:5I_A+6/A]X5\:^'_@YKND:D?$NM
M2W4GA"Z\8R:EK]MK>F:M9>+GT^WMY[72[.2XMY?6_P!IG]G3XK?'_P"%'@_X
M9:/^T3J?PWCMKK36^+5Y8?#O0]=L/C=H5KH;V.J^"/%>G1Z[X8U+0/!7BG66
M35_%.D^#?$6B7.NZ;$_@S4+^7PCJ6N:3JH!\QZ?_ ,%,]3\5?#W5_B5X#^ D
MFN:!\)/@3/\ M$?M'0ZG\5M!TR\\(> +7XA?&?X=A/@]/IOAO7M,^-.H:Z?V
M>OB]X]\$:I=WOPX\(>,/A[H_@_5K/Q#9WWQ!TRQTSZ A_;2TV3]J1/@-=?#K
M6M&^'$O[,?Q&_:4T_P#: US7M&M/#/B71?AOXE^"NDZU;>$_"EG_ &AX@U#P
MU#I'QHTS59_'&LR>'[2:_P!'U'1=!T?75M[_ %2PX;Q#^P5J7BOPZ=&O_CAJ
M7A>7QW\#],_9G_:"A^&?PM^'_@KPO\5?@;X<U/QW)X0\+>&_"<Z>(K?X/:QX
M4\,?$CQIX%T;Q)X/U&\:W\,^)M4$>E1:O8^$=4\*7_$W[%WC_P 0?M2^%OCY
M%\>-)T_X?^$_A9XM^ =C\"Q\#?"]UH=S\$/B)KOPI\0^._!MYXR/BV#77U/4
M[SX2:%9Z-XABT^*+0-)O]4LUT/49I(+R( O?LD?MNQ_M4>)KZPT_PS\.-'\/
MWWPX\/\ Q6\-#PY\=_"_COXDZ-X8\6W%@_A?3?B_\+K?0=!U3P)XBUO1-1MM
M8BE\*:M\2O!NEZC;>(/!&O>+M+\7:"EEK'NOQT^)WQ;^'Z6 ^%_PD\-^.[>+
MP[XM\7>+O%WQ%^+-A\'?ASX/T;PC#IMP=,O_ !+_ ,(IX]U>7Q/XFBO+V;1$
M?PM:^#]*TO0=?UGQAXPT"*UTJQUSYA\!?L$>(OA)HNDQ_#S]H#Q,GB3X,?LX
M^)OV7/V1-3UKP%\-S9_ ?X9>([GX=7(_MVSL- BB^,'B#3E^$GPVL(=4\7Q6
MU@^D^%=JZ%'K_B'Q/XBU?T[]K[]EWXB?M.)X"T70_CJGP\^'GAR\U74_'7PI
MUGX4>'/B=X ^,M^[::_A:#XD:=J?B'PQJ6L>%_"4UK?Z@G@1]5D\%^+-4O;2
MX\;Z)XAM-$TVP0 \'_X>8V&L>#=1^,7A#X17MU\$OAK\(OV<?C)^T%K_ (L\
M:6OA7XA?#+P_^T;X6TKX@V.E:+\/K;P[X@L/%NO_  M^&VN:/X]^*%GJWC+P
M7"FCZE;:;X%N/&'B!;G38/6KO]MNYL/CW^T9\&-3^"GBW0-.^ ?[-$G[1=CX
MS\2:]H>F2?$VQM/&/Q,\'7^G^&_"]L-1OM$\-"\^&]S)HGC+Q-?:?<>)4U"2
M\L?"T&@V=AK>N9WC?]A"+XBZAKT_B?XO:_#H_P 9O"GPL\-_M8^%?#O@[PKH
M_A_X^3?">%;?3=1LTN3JVJ?"X>+])"^"?']EX=U/5TUOX=VFE>'M*N/#^KZ<
MOBF6.7]CGXNW/[6OCC]IN3]J&[L+#QO\+1\$)_ 6A?!CP;IE[H7PQTWQ+X^\
M8^%HM \?76OZKJ-OXW\/^)/']]?_ /"6W^@:C8:FNFZ=#=^%5(N)9@#L/V-_
MVIM8_:6TOQ5=>)'^ =AJNAV/@[5;;P_\&OBWXY^)FI6VE>++'4KNVU7Q#%XZ
M^#/P<G@T/4'L6MO"'BKPS;>*?"?C"2P\0'2];#:-+'+J^,/V]/V7OAY<>.HO
M'WC[6/!-O\/?"GQ&\<:WJWBSX:?%+P[H.I^$_A#>167Q1UOP1K^K^#+/1_B+
M9^ I+B&X\2/X$O?$!L].=]5B%QI=O<WL._\ "']G77?!/Q$USXO_ !.^+OB'
MXS?$W4? NB?"S3-?U'PKX/\  >F:+\/O#_B#4_%%O91^'/!5C::??>(];US4
MVO\ Q1X@N)([*Y:QTZU\-^'?">GI>V5]^?WQ&_X(P_#?XES>,[O7OC1XR;6?
M$GAK]J7P=:^-W\!?#6[^*%WX=_:IT37=-\1P?$;XG7.DGQE\5KSP!<ZX(_AI
M+XDU*UTWP_X;TO3/#D^CWAMDU< 'W5<_MS_LV0/-8+XQ\13^)H?&VM?#^;P+
M!\*_BY<?$2TU_P />#]!^(>KWNI?#RU\"7'CC2_!UAX \5^%?&]Q\0+[P_!X
M(7PKXH\.:M'KTD>NZ5%=YGPJ_:>^('QQ_9"_9R_:0^%OP2&O^+OVC/A[\(O'
M6F_#Z[^(.GZ3X6\!6GQ/\,V7BO4-3\9_$2?09M0E\*>#=-GG2YU'PSX"U[Q-
MXAOSI6GZ+X1:;56ET_@M<_8'MV_:5^(W[5?@3XT>,? 'Q6^(OB.RFN[ZR\+^
M#?$.FZ9X!O/A)\)/A5XS\ 6NG^(;.[@N(?$#_!7P)X[TKQ)<+_:WACQAI86.
M+6/#-YJOA[4M>]_8S\7>'OV*OA#^QQ\%/VC/''PBMOA1X'^&/PQ/Q5L/#.A:
MWXV\4_#[X>:%;^'[[P_?%+_0&\.W?C?3K&TL_$'B?P;JN@^*=-M9-1/A35]
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MH7A-='=K[3_"6H_$[2[#5O&S>(HK<>--&\5^";?1);OPSJFHQ_:M?GK\+_\
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M.GZK>^&B=?T.6YM;>9-'\4:/!?ZCX2UW^R_$]KI6KS:0NEW?XQ_L_P#[/O\
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M/VCOAK\+=137-6O9=:TJT\"?#;1].B\-^._C7X4\.Z9H7Q$N?AKX(TJ;Q!J
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M:[;>'](EO[HWGS;X6_:%_:4\=:':>)O _P 1/@/XU\-7[W$=CXB\'7>C>*M
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M;LK]%%%<IWA1110 4444 %(>A^A[X_7M]:6@@$$'D$8(]0: /QD^+7B.XO\
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MA:?XA\*Z5#HEGX2BMKO1OA+\+].T;P]X*N/#O]K2@'Z+Z;_R$=/_ .O^Q_\
M2R"OT"'3\6_F:_/O3B$OK L3A+VR+'!9L+=0DG"@LQP,X526/"@D@5]S#Q)I
M>/O7W4_\P?6O4_\ 4.H R_B'_P B5XF_[!%U_)*^(VZGZG^=?8GCO7=.N?"'
MB*"-KOS)=*ND3S-+U:%-Q"XW2S6,<48XQNDD11D985\=MU/U/\Z &EG0%HU#
MNH9D1I6@5W4$I&9U(>W$C (;A"'@W><A#("/Y\_@#\$/'FC:Y^UUX+M?@/\
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MBT_LB\-QI>EW6K3F55M+0W=VRPM\6?L[?L@?';]G[XU?M%_';1O%?P-?Q/\
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MM'U]#](-RYQN&<9QD9QZX]*,CU'YBOSV\>^-OBMX'_:3^!U[:?$GQ_K'P?\
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M5_X78GR_Z>>3^_R"_DON]/\ +\7W/YT?^&ROVO\ _I#/_P %#O\ PH_V2O\
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M3MV?KZG\Z/\ PV5^U_\ ](9_^"AW_A1_LE?_ #\J7_ALO]L X!_X(T?\%#R
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M47GPS\"Z%X/N?$-KIDFDV^L3:/;F![^'39[O4)K*.X/S+;R7MT\8X,S]:/\
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M$?!>N:B=9\:_"3P)XJU?POK_ (GF&CVGPL^&-O\ "W0?#'P_3Q!X_N?%&O\
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M/$P]GB,+EN!P]>'-&?)5HX6E3J1YH2E"7+.,ES1E*+M=-IIB(Y?]5+_US?\
M]!-?S0?#^3X7KXX_:0C^'4FFI_P4&E_X*W^)AX)'AS_A(S\8S\*5_:1\"?\
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M)7(R,$Z- !112;AG'.?7:V/^^L;?;KUXZ\4 +111GG'X]#C\^GX=: "BBB@
MHHH_S_G_ #_(T %%%)GMS^1[Y[XQV_#C/44 +1110 4444 %%'^?\_Y_F**
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ML:E_0-M'^U_WTW'.>.>/3C'''3BE  Z9_%F/IZD^G\_4Y /P%_:%_;Y_:N\
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MTC5CX'\=VVI^,=+OHKW]W, ^OKU/T]?R]#R,'F@*!TSZ\LQ[8[D_ETSSUYH
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M/?& /<G![&LS46BC_/\ G_/'>B@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _.7_@HF
M2/"WPQP2/^*GUWIQ_P P..ORJR?4_F:_H,^,'P.\&?&ZQT33_&4NN10:!?76
MH6)T/4H].D,]Y:BSF%P\EG>"6/R@"B!4*O\ ,6(XKPC_ (8&^!__ #^>/O\
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? %%%% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>43
<FILENAME>restructuringchargeschart.jpg
<TEXT>
begin 644 restructuringchargeschart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #P 3T# 2(  A$! Q$!_\0
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MWXV\4_#[X>:%;^'[[P_?%+_0&\.W?C?3K&TL_$'B?P;JN@^*=-M9-1/A35]
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MH7A-='=K[3_"6H_$[2[#5O&S>(HK<>--&\5^";?1);OPSJFHQ_:M?GK\+_\
M@FO\ /@O^TSX#_:1^&-Y\2_#=S\/_A!\3?A/I'P[N_BY\7O%O@;R_B?XT\(^
M,=5UX:9XU^(?B*VM?LL_AJ^CB\+VUDOA6[U37G\676F-XIT+P[JFG?H50 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@;U%8/\ PC>E^E]_X.-:_P#EC1_PC>E^E]_X.-:_^6-,#>HK!_X1O2_2^_\
M!QK7_P L:/\ A&]+]+[_ ,'&M?\ RQH WJ*P?^$;TOTOO_!QK7_RQH_X1O2_
M2^_\'&M?_+&@#>HK!_X1O2_2^_\ !QK7_P L:/\ A&]+]+[_ ,'&M?\ RQH
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M(?"7@:73X/%WB.PL8]-D0:3H,^J6,-Y<W<]KYLLSQV*W;6E\+7O?^%G>//\
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M_P#VCK?_ $ ?_*M9?_&Z/[1UO_H _P#E6LO_ (W7[((Z"BN?_M'6_P#H _\
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M?_(U'_"3Z+_S^C_P'O/_ )&K>P/?\S_C1@>_YG_&@#!_X2?1?^?T?^ ]Y_\
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M_=\\>?WH0G./NIZQA.2WC"32BTOZ_K^O5'R'\,_VNO&/Q(_9[^'GQO@_9O\
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M')RHYZY_+_\ X*3_ /*23_@A3_V=;^U!_P"L<_$&OU2^.'_(H:7_ -ANT_\
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M_P" Z?X5NT5^R",+_A&/#W_0'L/_  '3_"C_ (1CP]_T![#_ ,!T_P *W:*
M,+_A&/#W_0'L/_ =/\*/^$8\/?\ 0'L/_ =/\*W:* ,+_A&/#W_0'L/_  '3
M_"C_ (1CP]_T![#_ ,!T_P *W:* ,+_A&/#W_0'L/_ =/\*O66EZ=IOF&PL[
M>T\[9YOD1B/S-F[9NQUV[FQGIDU?HH **** "BBB@ HHHH **** "BBB@#\0
M/^"E! _X*1_\$*22 /\ AJW]J#D\#_DSGX@U^J'QP=/^$0TOYE_Y#=I_$/\
MH'ZA[U\Z?MP_\$\_AK^W5=_ [7?%WQ?_ &CO@9XX_9U\8>*?''PK^)/[,OQ)
MTOX8>/\ 0-<\9^$I? _B!DU_4O"/BW;;WOAJYO-,9;2VLY_L]]>PM</!=2PM
M\CWG_!%?^T(EAOO^"L/_  6BNX5<2K'/^VMH#()%5E5P!\&!\P5W4'T8UY&?
M9=4S?)\?EM&I"E4QE!TH5*JDZ<&YQE>2@G*UH]$WY#3LT^SN?3&]/[R_]]#_
M !HWI_>7_OH?XU\J_P##C_2O^DJ/_!9C_P 33T'_ .<U1_PX_P!*_P"DJ/\
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M)M?LGAW2)I;V[TC0+?3=,O=3U:[M)M3N_HZBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
AHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>44
<FILENAME>rituxan.jpg
<TEXT>
begin 644 rituxan.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_X0!<17AI9@  34T *@    @ ! ,"  (
M   6    /E$0  $    ! 0   %$1  0    !   7$E$2  0    !   7$@
M  !0:&]T;W-H;W @24-#('!R;V9I;&4 _^(,6$E#0U]04D]&24Q%  $!   ,
M2$QI;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8 ,0  86-S<$U31E0
M245#('-21T(               $  /;6  $     TRU(4" @
M                                                   18W!R=
M 5     S9&5S8P   80   !L=W1P=    ?     48FMP=    @0    4<EA9
M6@   A@    49UA96@   BP    48EA96@   D     49&UN9    E0   !P
M9&UD9    L0   "(=G5E9    TP   "&=FEE=P   ]0    D;'5M:0   _@
M   4;65A<P  ! P    D=&5C:   !#     ,<E120P  !#P   @,9U120P
M!#P   @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG:'0@*&,I(#$Y.3@@
M2&5W;&5T="U086-K87)D($-O;7!A;GD  &1E<V,         $G-21T(@245#
M-C$Y-C8M,BXQ               2<U)'0B!)14,V,3DV-BTR+C$
M                                                         %A9
M6B        #S40 !     1;,6%E:(                     !865H@
M    ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(        "2@
M   /A   ML]D97-C         !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M         !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M                                        9&5S8P         N245#
M(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M           N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A
M8V4@+2!S4D="                             &1E<V,         +%)E
M9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M         "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y
M-C8M,BXQ                                  !V:65W       3I/X
M%%\N !#/%  #[<P !!,+  -<G@    %865H@      !,"58 4    %<?YVUE
M87,          0                        */     G-I9R      0U)4
M(&-U<G8        $      4 "@ / !0 &0 > ", *  M #( -P [ $  10!*
M $\ 5 !9 %X 8P!H &T <@!W 'P @0"& (L D "5 )H GP"D *D K@"R +<
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MCPFD";H)SPGE"?L*$0HG"CT*5 IJ"H$*F JN"L4*W KS"PL+(@LY"U$+:0N
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M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R_\  $0@
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M,"#P?4'U![BK_LZ,H7C*_P"1'UZ2E:4;'UA/J%E:S1PW%Y;PRR?<224*S=N
M3S5FN"\0>$]0UO5&O[5H&AN8E.V9B,9"C:P Y4!2PP1RQ!XZ]S!&8;>.(NSE
M%"EFZM@=37G3C%)-/4[XRDV[HDHHHK,L**** "O&/CGJ&;C2--7/RH]P_ODA
M5_DU>SU\U_%+4?[1^(&H;7W1VVVW3VV@;A_WT6KNR^'-6OV.3&RM2MW.=T/2
M9==UNSTN!@DES($#$9"^I_ <UWNJ?!C4].TJZO4U."X-O$TGE)$P9\#.![U7
M^#&G_:O&CW9 VV=LS G^\V%'Z%J^@" P((!!&"#WKIQ>+G2JJ,#GPN&A4I\T
MCXZKZ%^%FA^'T\-6>LV%J#?RH4GFE;<ZN#A@.R@]>.<$9S7B_C'1/^$>\6:C
MIP7$22EH?^N;?,OY @?4&NZ^">O>1J=YH4K_ +NY7SX0?[ZCYA^*\_\  :VQ
MB=2AS0?G\C+"VA6Y9(]DU2]33=)O+Z0X2WA>4_\  037R-)(\LKR2,6=V+,Q
M[D]:^C_BMJ1T[P#>*C8>Z9+<<^IR?_'0:^;U4NP51EB< #O6>6PM!R[FF/E>
M:B?17PBTX6/@*WGP0]Y*\[9^NT?HH/XU@_'+4-FE:7IP?F:9IF4>BC S_P!]
M'\J]*T2P_LK0M/T_C_1K>.(D=RJ@$_G7E'QKT;4;B_L-3@MI9K.. Q2/&I;R
MVW$_-CH"#U]JY,/)3Q7,^[.BM%PP_*O(\T\-6(U/Q/I=DWW)KJ-&_P!W<,_I
MFOK&OCR&:6VG2>"5XIHV#)(C%64CH01T-?1/PGFU&\\'F^U*^N+N2XN',;3R
MERJ+A<9/N&KIS*FVE.^QA@)I-PL>=_&F_P#M/C""T!.VTM5!'^TQ+']-M4OA
M#;QS_$"W>3&889)$!_O8Q_)C6Y\9?#%VFL)X@MX7DM98E2=E&?+=> 3Z C'/
MJ/I7EMM=7%G<)<6L\L$Z'*21.593[$<BNBC%5,,HQ?0PJMPQ'-)=3ZH\4Z]!
MX<\.WFHS.H=(R(5)^_(1\H'X_I7RF26)))))R2:W]6M_$EYHL6LZU<7DEJ9!
M%;M>2LQ<D$_(&[8'7I6):V\EY=PVT(W2S2+&@]23@482@J,7K<,36=62TL?2
MGPSTTZ;X TQ6&'G0W#>^\Y7_ ,=VUOZMK%AH>G27^HW"P6\8Y+=2?0#N?:LO
M7?$6D>!]!A^TOA8XQ%;6Z'YY-HP !Z=,GH*^>?%/BW4_%FH_:;Z3;$F1#;H?
MDB'MZGU/>O.I8>6)FYO17.ZK7C0@H+5D7BK5[77?$EYJ5G9"TAG?<(\\D]V/
M;)ZG'K^-9^GFS&HV_P#: E-GYB^<(B ^S/.,]\5Z1\/?A>VK"/5]>B>.Q(W0
MVQRK3>C'N%_G].O)>-_"LWA+Q#+9G<UI)^\MI#_$A/0^XZ'\^]>K"M3<O8Q>
MQYTZ511]K);GTIHUOIMMH]K'I"1)8>6&@\K[I4C(/OGU/)KS/XB_$^]TC59-
M&T(QQS0@>?<LH<ACSM4'C@=20?3M69\(?&OV2X7PWJ$N()6)LW8_=<]4^A[>
M_P!:Y_XG>%[_ $CQ3>Z@T,CV%[*9DG RH9N2I/8YSCVKSZ.&C'$.-77MYG;5
MKRE04J>G?R*>G:EXX\7ZB;6RU/4KB;&Y@EP8T0>IP0H%=*WP]^( @>6YUU88
MT!9C+J,F !U)(!%<!H?B#5/#E\;O2KIH)2NUN P8>A!X-='>:IXZ\9Z7<SSR
M74FF6\32S,J"*$JHR<D !CQTYKMJ0FI>[91.2G*#7O7;..N)));B1Y9C.Y/,
MA8G=[Y/->N_ W3\?VOJCX"@) I_\>;_V6O':]I\+7,6B? O4+^-MDLPFRPZ^
M8Q\M?_9:6,O[+E75I#PMO:<SZ)L\EUO4#JNNW^H<_P"DW$DH![!F) _*O9/@
MEHZ0:'>ZN\?[ZXF\E&/_ #S4#I]6)_[YKPROJ/P%IPTOP-I%N!AFMQ,^1SN?
MYS^6['X5GCY<E%174TP4>:JY,X[XXW:)X?TRS(7?+=&49Z@*I!_]#%>-:1I[
M:KK5EIZ'#7,Z19]-Q S7=_&G4/M/C&&S4G;:6R@C_:8EC^FVJ'PET[[?X^M9
M"FY+2-YVSVXVC]6%5A_W6%YO*Y-;]YB.7Y'T8    , =*6BBO"/8"BBB@ HH
MHH **:ZED*AV0G^)<9'YU#]GE_Y_9_\ OE/_ (FI;:Z#23ZEBBJ_V>7_ )_9
M_P#OE/\ XFC[/+_S^S_]\I_\31S/M^7^8^5=_P RQ15?[/+_ ,_L_P#WRG_Q
M-'V>7_G]G_[Y3_XFCF?;\O\ ,.5=_P RQ15?[/+_ ,_L_P#WRG_Q-'V>7_G]
MG_[Y3_XFCF?;\O\ ,.5=_P RQ15?[/+_ ,_L_P#WRG_Q-'V>7_G]G_[Y3_XF
MCF?;\O\ ,.5=_P RQ15?[/+_ ,_L_P#WRG_Q-'V>7_G]G_[Y3_XFCF?;\O\
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HB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>45
<FILENAME>sellinggeneraladminchart.jpg
<TEXT>
begin 644 sellinggeneraladminchart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #P 3T# 2(  A$! Q$!_\0
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MWXV\4_#[X>:%;^'[[P_?%+_0&\.W?C?3K&TL_$'B?P;JN@^*=-M9-1/A35]
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MH7A-='=K[3_"6H_$[2[#5O&S>(HK<>--&\5^";?1);OPSJFHQ_:M?GK\+_\
M@FO\ /@O^TSX#_:1^&-Y\2_#=S\/_A!\3?A/I'P[N_BY\7O%O@;R_B?XT\(^
M,=5UX:9XU^(?B*VM?LL_AJ^CB\+VUDOA6[U37G\676F-XIT+P[JFG?H50 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MPG_T'?&__@'H_P#\BT?ZX<+_ /0]R[_PHCY?YH#WVBO O^%J^$_^@[XW_P#
M/1__ )%KO_#-Y;^*]-.JZ5KWB9;47,]KB[&E02^;;[=YV+ILHV?.-K;LGG(&
M*[,#Q!DF95_JV S/!XNOR2J>RHU5.?)'EYI671<\;OS0'?5X9XM^,%UX:\0Z
MEH<>A6]XE@]NHN'U"2%I/.M(+DDQ+:2!=IF*##MD*#P20/5?[&N?^A@US_O[
MIG_RIKY ^)<+0>.-=A>XGNF22Q!GN6B:>3.F61RYAA@C^7.U0L2815!W$%F^
M9\0\XS+)<GPF)RS$O"UZF9TJ$ZBIT:KE2>%Q=5PY:].K%)SI0E=14O=LG9M,
M/1_^%^WO_0LVO7'_ "%9>H1Y"!_H/)$<<DA R1''(^-D;LLI^.VJ+$EPWA*-
M;>1BD=PU_=+!(Z[MR),=/$3NNUMR*Y8;6R!M./YQ?^"G?BN/P3\?_P!D_P 4
MW.O>)?%LGA_Q//J7A_X"Z!XO^,GPE\<>(=:L?A3^TQ?/KW[//CKP!;WGA/QC
M\7/%,JZ-X(F\#Z]H^L:Q!KFF?##0[K4_"?P^^)'C"ZU#UCP5XW^ WCC]M;0-
M(^!_QJTZ;QWX"^*/Q?D_:,\3^*?CM97WC'XNZ]J'A/Q?I:?LD>#?A#-XL*>)
M]"^#OB'4M(\1ZUJWAWP-IW@WX(Q_"?3O!W@SQ!XI\;:Q\0+W3_S=<2<8_4Z&
M,_MW$<E7"8C%-K*L![*F\/)I4IU)4822J.%.$:OLN656K&%&-:$:E6F[);OM
M^-G^OE\MG^[P^/=^P8KX6MV"+O<KJ4["--RIO<K8$(F]E3>V%W,JYW,H)_PO
MN_V[_P#A%K?R]Q3S/[2G\O>%#E/,^P;-X0ARF[<$(8C:0:_!_P#:J^/GP2M/
MCA_P3@^)<'[6/AO2O"/B7X]:3KT'AC_A=/A+PG\,]:^$WB3]G3]J&:+XO:WH
M4EYHU]XHT/7/$5IX5\/Z-XI\9WNH>"=%OK"QLO#&GZ;XGUC4+V^N>&OB[\,=
M#_X*5_&CPY<_M+GQ=<^(?V+M$DB\#'XK:%KU_P"$O'.D?M!?$J:^^'7PJ^&G
MA>7S;#QOX;\#:?;ZFOA[2/#>M?%;7B\&M>(I_$5Q=:>L>4>*.-'1C56<XAMX
M.>*Y%E6%NI4L5]7G1;>#6L(Q52<VE9OV:C)6J,MM^5M>GYWTVO8_=B7X[:I!
ML\_PBD E3S(C/?74(ECX_>1&33E\Q.1\Z;EY'/(J/_A?=_MW_P#"+6^S<4\S
M^TI_+WA0QCW_ &#9Y@4ABF=P4AB-I!/X"?LZ_$OX0?"_]H+XEZSI?Q8\")^S
M_J7P)\ 75GXL\(?&#XA_$;P)!XMUWXY:5X&\$:O^TSK7Q4N+W4O"?[7GQ0D\
M;:%X>T32M(E2X\5:=!XT@\96PO\ 1/"WV+OO _Q.^'NE?\%2OBWX%D_:.L/%
M^M^)OV3O".GV_P .M?\ BYX5U"+PG\2]+_:7^)5M??"OP/\ #S3+ZQL]!\2>
M&O".GVESK.AQZ/=_$?4+-Y=?\::EJJRV\]LZW$_&5*6(2SO$2C0PD,5&3RO!
M0E/_ '=U*4XK#3C2G155.I>I.UHNUJB<2V]M=MO.W^9^X=K\=[VYNK:W/AJU
M47%S;P%O[4E)43S1Q%@/L/)7?N )&<8R,YKZ/K\]--^;4-/ 8KNOK$!U(W+N
MNX0&0D,-RYW*2&&0"01P?NW^QKK_ *&#7/\ O[IG_P J:^]\-\^S;/*>;O-,
M9+%O#3P*H.5+#TN158XKVG\"E24N;V</B3MRZ6N[G3YO7[OR_4R?B+_R(WB?
M_L$W'\EKX;9HT+/*Z)$FYY7E8I$D2 O(\KK\R1(BL\KJ"R1AG4$@"OLSQ[I=
MQ!X-\1ROK6KW"QZ7<,8)Y-/,,H 'R2B/38I"A_B"2(Q' 85\:'(8D<$$X/H<
MU\CXL_\ (YRW_L6?^[6(#HNUW^E^Q^.7[-WQQ_:*\:^._P!IWX6_%S]H0_#7
MXC1:O!XP\/3>(?AG\+/$?PH\'_##PAX _9D\1_&/QM^SC\6- U^X\$ZQX3T#
M1OBE]HTC3?B[%K4?AVW^)?P\^+GBN/4+M_'/A2X^[/V8?$7Q6\8^!OB%J_B'
M5=<\6^%Y?B)XD@_9M^(GQ$\&Q>$O&/Q*^#Z^&/"X\->.O'/AGPYH/@N*XT;4
M/B3/XST_P=XCL/"W@S5_B'\+M.\+>+I-%L+W7[/4]2R7_8._8]DT?XM^'I/V
M?/AZ= ^.?B/0?%'Q.T:WL;[2+#Q!?^&#X6GT"PM1X>O]%N_#OAC3-5\&:!XC
M@\'>'+O2_"[^*+:;Q!<:5-?W4CCO-*_9E^"^A6/AW2]'\*7]IIOACQQK/Q&T
MVUO/''Q&\2S'Q=KWP]\2_"[4M3FUCQAXQ\1>(%2?P=XMUO3_ +#;:M;V$=Q<
M)J4-M%J40NS\/C<=EN(C-4*+H2G['2.7X.%*FZ5"DI.BZ595X>UJT^3V=2I6
MIQ@ZE63G4KVPYI_P?GUZZ:_@?-_@S6?V@]6\:?$GP-X>_:%U;XA^%=#^&>CZ
M'XN^-UW\)/A9;:7X9_:V;Q]ID&L_!_\ 9RM8M/\ "G@SQA<:A\/X_$]A=^#/
M&&J?$JW^#OC^[^&VFZ_XK\5>*+WQMX/BX_P-\5?B?J_A#XP1_%O]H+X@_ O0
M?@7\?-2\*^*U\2_#+X5ZI^V#'X.\4_"WX<^)_@QX"UBR\*^%/&GP:USQYXW\
M2^*=?\2>$(_A3X$\<^*?BGX&NOA[X(LO[*\;MXZ>+Z6\&?L3_LJ?#_PU>^"O
M"7P4\/:;X+O_  _8>%I?!MWXB^(OB/PC;:#I6LV'B/2++1O"_BSQMKVA>&9M
M'\0:7I^N:+J_A?3]%UW1=7M(]1TG5;*Z:66276?V+?V6=?TKPGHVI_!?P])9
M^!O%>O>._"MQ9^(/B'HVO:5XX\4:':>&/$/C1_%VA>-=+\8ZQXMU?PW86?AV
MZ\2>(/$&KZRF@VZ:+:WEOIADM'OZ_E;=2,J,^1NGR3AE>60KQY(052I;VLJ$
M95FI15)4W3H-PKP<ZD*D,07733;;[^W1][O3KNK?@>7]H3Q#^RYX$N/B=J*?
M"7]HOQ#X,T"+Q7=Z=X0\*W^J:5XPO-169M"T3P3XCUA? MM\5/$OAE;/2H/#
M%WJ>M>%O"GQ-UV>VM[+Q%H6AV]A>\M^R+\1/B#XSL_CIX8^)NH>+W\2?"?XW
M7'@W3O#WQ4T/P7H7QP\*>"-9^''P_P#'/A"U^,B?#""+X6:OX@UX>(M:\2>$
MO$/P_DN]/U/X<ZAX5B\17 \:V/B.VM_1Q^S'\ 6L;[3;KX5^'-6L]3\!^%?A
MEJ$?B*\\3>*9KSP-X&\7:SX^\&:'-?>)O$&L:B9?"OC7Q!J_BGP_XA2\3Q;I
M6M74=Y:>((SI^E+8=Y\/?AC\/OA1H=QX<^''A+2O".CWNJ76NZE;Z<;ZZN]8
MUV]@M;6\UW7];UB]U3Q!XCURYM+"PLYM8\0:MJ>I-96%C8BZ6RLK2WAX:F)P
MCH8NG&DO:8BO[6BUA*%%89.<)RA3J*O6JQI**G2CAUS1BN2HJJ;JTZ@[=/+?
MIW_+?3?;M]=_ +_C^\3?]>FF?^CKVOI>OEOX(6<EW>>(ECO[ZQ*6VFDM9/;*
M90TMX,2?:;6Z!"D938$(+-N+ @#Z5L;*6T\WS-0OK[S-FW[:]JWE;=V?+^S6
MEKC?N&_?O^ZNW;SG^AO#G_DD<M_Z^8__ -3\2(OT445]P 4444 %%%% !111
M0 45Y/>_'GX'Z;XD;P;J/QC^%5AXO2[^P-X5O?B)X/M?$:WOF+#]D;1)]9CU
M);HRNL0MFMEG,A"",L0*]8H _$#_ (*3_P#*23_@A3_V=;^U!_ZQS\0:_5+X
MX?\ (H:7_P!ANT_]-^H5^5O_  4G_P"4DG_!"G_LZW]J#_UCGX@U^J7QP_Y%
M#2_^PW:?^F_4*^7XU_Y)7._^P-_^G*8X[KU7YGP;\7=1\=:5\-O%=[\,6\/#
MXABUTRU\')XIO=#L-(N=;U/Q#HVEQ6*W'B>]TWPR^N:A:WMW8^#['Q+?V?AW
M5O&EQX=TG7KB+2+Z]:OQM\._M4?M+WG_  2_^*7Q5\&?&W5;[X\? SPMI/B3
MXEZY\9O@GHL'Q:\*:3X@M/#^O^$=(M+'P]>R?"SQI+X\T[5O[4T'XN7VF3Z?
M:^"[R\TT>%=5\9:#;ZG#^X6O^'O#_BS1=3\->*]!T3Q1X;UJU:QUKP[XDTJR
MUO0=9L)'222QU72=1AN+&_M)'CC=H;B%U62..:,I/%%(GR]'^PA^R0OP4T7]
MG:;X(^';KX-:)->7:>"9-:\9V-IK=]J$4,%]J'C34- \3:'JOC^^NK>UL;:2
M;QM>Z\BVVG:9!!%#'IUD(?YPR[&8##T/9XO#^UFL?A<3S+"X:NW0I)JM1E+$
M5(\T)J\8T8^SBYS=2I5G"#H5!6[?U_P/G?:W4])_:OU?XK^"OA'XYU3X,Z1K
M-WXUT_Q+X/TP'0_"L7C3Q9H/@C4/B3X:TCXE^*?!/@34(Y;?Q[X_\'?#"\\4
M>*/!7@>YM[]O$WB#3-.LDTG7IY(="U7\R?%O[>FN_#SPW^T_\)]=^+%_X4\5
M>'O'.H>$OV?/CY^T!X.\._#CQ1%X(F_9=\)?'CQ1XM\:>#=2\+^"M%U/Q[\/
MM9\36?A'X:^'_$GP_P#!>M_$34?'GPMOO%/@A]%MO$NI7OZ7#]F?X(M;W6G7
MO@2RUK0[WX7Q?!V[T#Q+JOB3Q7I]UX"B\>7_ ,3!I=[<^*-;UG6K^['C6_.N
M6VMWVK7&NZ;=VMD^E:G8FU@\OM_"/PJ^''@+P9JOP\\'>#M(\/>"]?/B.3Q#
MH-FVH3IXDNO&%M+9>+-1\3:IJ-_?:]XEUGQ):3R6VM:]K^K:EKFH0&.*?46C
MM[983"8O+<-0=.MA98V:K>TA*='#T))7PTHN=63Q4YJ#H3C]5<'AZD,17YY2
M;A)--)Z:[/5+?M?]>O5'YYZ%\0OB)\=O@?\ L#^-? '[4GQ-\/\ Q$_::^'G
MP?MM4E^&Z_!34/A[+=^&OA=;?%']ICXF:[I?B/X0^*=0N];T.WTS7_!BZ#HN
MO^']!A\=:YX3TM=-TRVL]5\_Z@_:1U_XK:;XT^!V@>%K[XK^"/A5XQU/XBP_
M%+X@_ [X7VWQB^*7AO6++0M"E^#?A^Q\+7W@;XD'3O!?C#7;WQ/%XF\<)X%U
MB"#5?#_A/PEJFI^$=*\:7FOI[AI'PO\ AYH"_#==&\'Z)IH^#_A"\\ _"X6T
M,X_X03P7J&@>&_"U[X9\/&2YD-MI=SX<\'^%M&ECN#<S&PT+3XEG4I*\O#^(
M/V9?@#XJL=9TWQ#\*O#>J6OB#XB>*?BUJYEN?$=K>W/Q'\<:7:Z%XT\5PZOI
MVO66LZ;=^+=#L[?0_$FFZ1J.G^']:T9&TK4-&GL9IX)96-P;KT9N@X4*7UMN
M"PN$JS;Q$ZT:;O)TH5/JU!X:5'VL90AB:=2:AR3<9)-)]=+->NE_Z]#F?V,O
MB[XS^//[+'P0^+WQ$TFWT;QQXV\(7=SXHM;.UL[&QNM6T'Q9XE\'RZ]86&GZ
MAJNG6%AXKA\-P>*[2PTW5-1TRQBUM;32[ZZTZ&UGD_53X)?\B6W_ &&M2_\
M:%?&FCZ/I'A[2-*\/Z!I6FZ%H.A:98:+H>AZ-8VNEZ/HVC:5:0V&EZ3I.F6,
M4%EIVF:;8V\%E86-G!#:VEK!%!!%'%&JC[+^"7_(EM_V&M2_]H5]GX<3IU>+
M\15HTU1I5,'F%2E16U&G/$X>5.DNZIP:@GU4;AT?K'\F>O5\4?%3_D?O$/\
MUUL?_378U]KU\4?%3_D?O$/_ %UL?_378U]MXL?\B# _]CBC_P"H6/$>9W-A
M97D^F7-W9VMU<:)J$FK:-<7%O#//H^JS:9J&B2ZII4TJ/)INI2Z+JVJZ/+?V
M307<FDZIJ6F/,UC?W<$R+INFI<?;$TW3$O 21>QZ=8QWRDAE++?1VZW:L59E
MWK,'PS#=ACFY17X!=]WM;?I>]O2[;MW8[ONS'M?#OA^RLK'3;;0M&CL--L+;
M2K"U;2K":*TTVS18[6P@^T6\SK:0*B^7 6*;QYK!I69S=73].2<7*:=IJ72R
MF=;I-.L4NEG(VF=;E+<7 G*_*9Q()2ORER.*MT4.4FVVVV[MMMMMO=MO>_6^
MXKOOY_/N-*J1(K(C+-.]U,K1HRS74FTR7<ZE2LUW(40R74H>X<HA:4E$*UAI
M^G+/]J73M-6Z\UI_M2Z=8K=>>XP\_P!J6W%QY[KE7G\WS74E6<@D&W12 O:9
M_P A+3O^PA8?^ED%?H57YZZ9_P A+3O^PA8?^ED%?H57[9X1?PL^_P"OF6_^
MDXT?1>K_ "B<7\1?^1&\3_\ 8)N/Y+7PXW4_4_SK[C^(O_(C>)_^P3<?R6OA
MQNI^I_G7D>+/_(YRW_L6?^[6(#HO5_E$2BBBORH04444 %%%% 'T#\ O^/[Q
M-_UZ:9_Z.O:^EZ^:/@%_Q_>)O^O33/\ T=>U]+U_3'AS_P DCEO_ %\Q_P#Z
MGXD HHHK[@ HHHH **** "HIX8[B":":-9HIHI(I(G&4DCD1D>-A_==6*M[$
MU+2-T/..#SG&..N>V/7M0!^//Q*^(7[2UC\6M8^#'P[^ FE:/\(? _Q>\*VM
MUX8M_P!FG6M7\"_$[X;>-=;_ &?_  AX:\/P^.[@#P)+!K%AXM_:5^*/C_QI
MX2T^0?!JS^$G@WP_X_MK0:G<GQM^O&EZ;8:/IMCI.E65MIVF:;:6]AIVGV4*
M6]G96-I$L%I:VMO&%C@MX((XXH8$54BC58T554 ?@UX_TKPG8?MU?$'7O$?P
MJ_9L^+&GR_M"_"6T?XW_ !4^%_[2WC76/@KXDU+1_A9IFA?#-OC;9_"_Q!\%
M_ 6O6UY<^']5\ ^#[/Q-HWASPSXE\4Z3!XLUC3_$GBR)KK]\QR.W4]/J>O3G
MU'8YH _#S_@I=,+?_@H]_P $+)FCFD"?M6_M/DI;PR7$QS^QW\0%^2&)6D?&
M=S;5.U S'A37ZC?&74XKSPKIT26NIP,FLVKEKW3+RRB(%A?KM$EQ%&AE).1&
M"6*AVZ*:_+[_ (*3_P#*2/\ X(4_]G6_M0?^L<_$&OU1^.  \(:7@ ?\3NT[
M?]0_4*^7XU_Y)7._^P-_^G*8X[KU7YGRK1117\KB"BBB@ HHHH *^I_@]JL5
MEX1:%[35)F_M?4'WVFF7MW#AO)P!-;PR1[QCYDW;E/4#(S\L5]<_!, ^"VR
M?^)UJ7;_ *X5^B>%_P#R4[_[%N+_ /3N%'T?JORD>A?V_;_] _7?_!%JG_R-
M7Q_\3)UN?'&NSK'<1+))8D1W4$MK.N-,LA\\$RI*F<;EWJ-R%7 VL*^W,#T'
MY"OBGXJ?\C]XA_ZZV/\ Z:[&OO/%C_D08'_L<4?_ %"QXCSZBBBOY_ ****
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M-XD\3^'_ !%XFT1/%_[/;W&DOKZWUQH?CCQ0V@V7AN]TC_A9\&D07FLV=O\
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M$-U'I:1J387Y$BFRTVSE+@ J TK)AFRA;:R_EY_P4G_Y22?\$*?^SK?VH/\
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MC/PE+X'\0,FOZEX1\6[;>]\-7-YIC+:6UG/]GOKV%KAX+J6%OD>\_P""*_\
M:$2PWW_!6'_@M%=PJXE6.?\ ;6T!D$BJRJX ^# ^8*[J#Z,:\C/LNJ9OD^/R
MVC4A2J8R@Z4*E52=.#<XRO)03E:T>B;\AIV:?9W/IC>G]Y?^^A_C1O3^\O\
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M *VQ_B'_ $"['WKXP_X<RWO_ $EK_P""U'_B;&@?_.7K*N?^")%E>3/<W?\
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M]F7X'_&+Q?\ \%2_^"O\'B?XC_#CPYXMUV'P]^V5H]GH<>I:O:^=<II=I/\
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M2OX!.GV[Q-\R_P#'IIG\0_Y[7OO7TP"#T(/T(/\ *OQ)LO\ @BC%IQE.G_\
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MI?ACXE:C\5?&7@SP1J?@7Q_JOAB30]4\7:/<W6KS:99^)[WP]F_$S_@H_P"
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MM-1^''Q,L=(^)U[9'5/$J^);-/$?AOX?^,8(TF\%+HFN_K%9VPL[2VM!-<7
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M)8_;U%% !1110 4444 !SC@X/KC/Z<5^:MU^RO\ M$^/?VE?$OQ+^.OB_P"
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H0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>46
<FILENAME>spinrazalogonewa01.jpg
<TEXT>
begin 644 spinrazalogonewa01.jpg
M_]C_X  02D9)1@ ! 0$ 2 !(  #_[@ .061O8F4 9      !_^$0C$5X:68
M $U- "H    (  <!$@ #     0 !   !&@ %     0   &(!&P %     0
M &H!*  #     0 "   !,0 "    )    '(!,@ "    %    ):':0 $
M 0   *H   $N  K\@   )Q  "OR    G$$%D;V)E(%!H;W1O<VAO<"!#0R R
M,#$U("A-86-I;G1O<V@I #(P,38Z,3 Z,C@@,#@Z-# Z-#,   >0 P "
M%    020!  "    %    1B2D0 "     S P  "2D@ "     S P  "@ 0 #
M     0 !  "@ @ $     0   >"@ P $     0   /      ,C Q-CHQ,#HR
M." P.#HT,#HP,  R,#$V.C$P.C(X(# X.C0P.C P      8! P #     0 &
M   !&@ %     0   7P!&P %     0   80!*  #     0 "   " 0 $
M 0   8P" @ $     0  #O<         2     $   !(     ?_8_^T #$%D
M;V)E7T--  '_[@ .061O8F4 9(     !_]L A  ," @("0@,"0D,$0L*"Q$5
M#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,
M# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,# P,$0P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" !0 * # 2(  A$! Q$!_]T
M!  *_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$!
M 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$  A$#!"$2
M,05!46$3(G&!,@84D:&Q0B,D%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D23
M5&1%PJ-T-A?25>)E\K.$P]-UX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&
MUN;V-T=79W>'EZ>WQ]?G]Q$  @(! @0$ P0%!@<'!@4U 0 "$0,A,1($05%A
M<2(3!3*!D12AL4(CP5+1\#,D8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C
M%V1%539T9>+RLX3#TW7C\T:4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W
M1U=G=X>7I[?'_]H # ,!  (1 Q$ /P#U5))))2DDDDE*22224I))))2DDDDE
M*22224I))))2DDDDE*22224I))))3__0]5227'_XR>K9&!TJO'H=L^UEPL</
MW6[&[#_(W7;W_P#%^G]!.A'BD(]UF2?!$RJ]@!_6D>&+IW?7#I?VH86"VSJ6
M27%@9C .;N&I;ZUCJZ_:WW/>SV5_X1:N);F6U[\JAN,XZBL6>HX?UX8QF[^H
M^Q<9]3L6[IGU3;UBBIK\W* ],V@P*C9])WT;/UAV[(_E_J_^C76])ZK5U*@O
M#35=60+J7&2TGB'?GUO_ ,'9_P!_3\D8B^$6!H97K;'BG(RK)*I&S& %1X.G
M^$WDE&RQE;'66.#&,!<][C  &KG.<?HM:L%OUY^KSKA4+;(<=K;/2?M)/$>W
M?_T%!*<8_,0/-N8N7S903BQRR</S<$3*GH$E0ZIUK Z557;F.<UESMK"QI?J
M!O\ S)_-"#TWZS]$ZG>,?$R)O();6]KF%T:NV>HUK7^WW;&I<<+KB%^:AR^8
MXSE&.9QC>8B>#3?U.JDJ5O5\*GJ=72WN<,J]GJ,&TENWW\V?0;_-N4,GKG3L
M7J5/3+WEF1D .K):=GN+F5M-GT6N>^O8Q(Y("[D--]=D#!E- 0D;C[@TWQC]
M/^ZZ"2I9_5L+I]N-5E.<UV6_TJ=K2X%TM'NV_1^FA]5Z[T[I'I'-<YHOW>F6
M,<_Z&W=.P';]-(SB"09#TU>NW%LJ.#+,Q$82E[E\%#Y^#YN'^ZZ*2S.F?63H
MW5;#3AW[K@"?3>US'$#G;ZC6[]O\A7,W-Q\#%LR\EVRFH2X@$GG:T-:/SG..
MU$2B18(([JEARPF,<H2CD-5"42)^KY?2G253IO4\3J>*,K$<75DEON&UP+3M
M(<T_15+J'ULZ+TW,?A95KVWUAI<UK'.^D-S=6A#CA7%Q"CUM,>7S2G+'''*6
M2-\4!&YQX=[B["2S^E==Z=U8VC"<YQIV[][',^E.V-X'[J;J77^F=,R*<?+L
M+;+_ *(#2X $AF^PCZ#-Q2]R%&7$.$;FU?=\WN>U[<O<WX.'U[<7RNBDA')J
M%PI,[W?1]I(X+OI@;6_1_.14X$'9C((W%7J__]'U54>J]'Z?U2IK,S'JR'52
M:?6:'M:XQKM=[?S6J\DD"1J$$ BB\[T_J!9U%W2\INF3N:6.Y#PTO+?ZEE3%
M@9WUI_8WUG_9N!0V]]9%65<\F(<&W^E4ROZ5C&;-]KW?SGZ/TUT77NL]'P;F
M7-;7E=9J:ZO%J9[[&EPC]**_?77[O^K]%<]]6/J?GW]6=USK#'5 O]2NNS2U
M[@=WJ6L_P7J6M]9^_P#XK8K$!$#CD*%;']*7@TS=^W$\4Q?#*/\ D^+AX>/_
M )\WM^HX8SL#(PG.+!D5NJW@3&X;=T?G+DZ,WJGU9J9A=9PJ\CIH=#,JJ#&O
MJ?1=]/\ ?V6MIL_EWKK\S'.5BVX[;7T&UA9ZM9 >V1&YA,^Y<Z[ZGYV2^MG4
M^K6YV+4X.%#F[08_TCM[]W_GS_A%G<S&ZD(&<A\M",OI4G=Y'+AC"4,\X^T9
M<1QF.3W>(1^?#DQ_+/\ OL/KPX#'Z6^H;P,IKF-;^=#2YK&_U_HJLVGJ76NM
MX>:>G.Z=5A:O>_2RQWYN[VL_.^C[?T;/6_2?I/36[UKH/[4JQ*VW>C]CM;</
M;NW1^;RW8M5@(: >0 #"BER\\DR) 0N $I1%_P!Z&/\ =3'G88N7QQ@!+*!E
M@92X_P!7'*>WR3XH/,]1_P#%WT__ ,*G\MZJ?67I[>I_6FO!)V.MP?T;_P!V
MQMESJW.C\W]Y;V5T1U_7L;K#;MOV>KTC06\R7G?ZD_\ "_N)9'176]?HZR+H
M]&GT306\C<]^_P!2?^$_<1R8\A.6HG4PX?'YEV/F\<)8IQG4L?+2Q['3/Q2E
M"+R>3U7(SCTC&SALZCT_-%.4P\F#6&W:>WW;??\ R_\ @WL6I]='OKS>BV5L
M-MC+7N94#!>X&@MK#OY:T>K?5BG/ZE1U*JWT+Z7,=:W:"+?3<'U[OH[7Z>GZ
MG^C_ .+1NL=#=U+(P,@7>D[ >;-FW<'R:W;=TC9_-)L\.0#,.$SN$8Q_K\)V
M9!S?+>YRTQZ(PCF]S'4N''/-&?H]/Z$IS]#S_3W6]8^M8RG4-Z=;@,&_&)_2
MN)#F>H_VU[MC;O\ ,]'_ $RM?7KJ%3?L73;'[*K;&WY9$DBICAM;M'TO4?[F
M?\0M/J7U?.3U3&ZMB7_9<S'T>=N]MC1^98-S/S'65_\ JJM.WH+CUY_6;[A;
MNK%5=&W2MH G:^3OW.W_ )O^&L1./)$9(B)E*?!$$>F'!_W/#^FM'-<N<N+,
M34<.*H8?5Q0S1^6'N2X_WO>AD<3ZG=2Q6=7SL'&?NQ,EQOQ="V"(]2O8[W-V
ML<UG_65I?6WJIQ:*\##:']3S_P!'3$;F,/M?;/YG[E7_ &]_@+%9ZE]7QE=2
MP^IXUPQLC#T(#9%C9_FW:MV^UUK/^NJGU+ZIY.9U6WJ=747X]EFT,#626 -%
M>QEF]OM^F[_KB7!DACGCX.+4&/Z4?5O_ "_KJ]WE,G,PSSEP#@N<)B4_U^/T
M0&0XX>J,_P"<DW_J]T>KI6 RINMA&ZQ_[SC&YW_1]G_!>FN+ZQU#IW4NH]5M
MR[]A+!1T[VEX/HN+OI,'Z-F18QWO_<R5U_3^C=5Q*LJNWJMN2_(KV566"34Z
M' 6,;N]WT_\ H(W0>AU=(P6XFX7%I+C86Q)/YT:[?;[/^MI>W,PQXX0D/5<Y
M3]-R'KXY?WY(Q<UCPY,V>63W\LS$0./BQ^F_=R2_6X_WHPQ_*M]6.HGJ/1J+
M7F;JQZ5WCO9[=W]O^<6JLCHO07='R,LTW;\3*?ZC*-NWTCK[6.EV]NS;7_UM
M:ZLX.(0$9"C#T_X,?E:/->T<TSB-XY'BCI7#Q>K@_P #Y7__TO54Q (((D'0
M@ITDE(ZJ*:6[::VUM.I# &B?[*(DDDK9S^O9-^-TQ[L=_I76V48[+0 2PY%U
M6'ZS6N]KGT^OZK-ZH9V;U7&MS,3IKJ&U=+PZ<@'*%MS[)^U-]!]WKLL]S<-G
MZW9Z]G_!7K7ZAA59^'9B6N<QM@!;8PP]CVD6575EP<WU*;6,MKW-^F@CI5=G
MVBS)>7WYN-7BY3JY8PBL7>^BISK74[G95W^%M_,3@16J-6D[KF0YG4K*F,VX
MF#5F8X<#)=8S(MV7;7>YOZ"OZ"&_K74!U3&Q[7TX6->V@TONJL<W(?9N=?11
MF-NKHQLEFW]!C7,MMN_G/TG^#L9/U:PL@%OK7U5V8PPLFNMX OI:'MJ;>7,=
M8U]7JV_I<9^/9^D_2^I6BW=#INNK>_)R#0QU+W8F]II<_'+;,:PAS'75;+:Z
MK=F-=15:^O\ 35V?I$;BK5R\'J'4G##P<!N/C_:G=1<^RQME@9]GR?28YE7K
M-?:ZWUOTC'7U_P#!_P W]GL3OK%U%U.%3-.-E6G+&5D&JW(J'V&YN!::,:E]
M5WZUD65V5^K?^@I_TMBU\;HN)C7475FPOQ_M.S<Z0?M=C<K(W:?Z5GZ+]Q#=
MT'&#*_L]UV-?3;?;5DU%OJ#[58[)RJHNKMHLHLL?_-74V?S5%G\]37:EQ1O;
M^7J51:6#UKJ^=EX.,VFJCU:'W9;[&V2/1N;BO^S5V&BUU>9[GXEES6>E5^GM
M]7^CH5'UDS*L7J&5G>D+\*JRUW2O3LIO86DMI'VFRRZO,Q;=OI_;\;&]"Q_\
MW_H*]C'Z511D59/J6VW4T'&WVOWES2YMKGV3]*USV*O7]7<2;?M=U^<VRBS$
M:S)>';*+BTY%#'UMJML];TZ=]V39?D?H6?IDKCV5JYQ^L/4\?%SC8*LN[&QQ
M?5<S'NQZ=^[T[,6[[0^W^0^JVNW^;]3]!^@_3ESK^IO;U+ OR&MR<7&9G8>5
MC-=3M<79&RJZI]U_KMK?B-]3W>CE56OIMH_TET= 8[$OQ,K-R\NO(K;5-SVD
ML8R2T5^E75NL]WZ3(N]7)M_PMR?J?11FG(?5>['MS*68E[P-Q]!KK'V-HU;Z
M618S(NK;D?I/2^GZ7L2N-JU8VY/VK'Q,GU#CLOQS:]K2?4AXI</3<QCW^Q[V
M[]J@*^H/!VWM!>#MK%@;N!>][H](/V_:*1ZE.17^EK5_(P:[JA4USJ6M;L'I
MP/;+)9#FN;M<VOT_^+0[>DXEAL<X>^SET 'BIGYH:[Z..Q"PIIVLR:X++A^F
M<]S(L>XNW%KV>G:VJUU;*G.9^B;^CLV?N66*WBB['?<<O(:\$;C+N"'6N<[8
M?YIGH'']G\C_ *]; ='8<9]%MKG&PRY[6M;^<^T[&[7^F[U+;'>HS]*BV]*Q
M;7/>9;8\DE[0W<"0X?2+'?OI$A3<246-+6!KG%Y U<8D^?M#6J2:E__3]522
M224I))))2DDDDE*22224I))))2DDDDE*22224I))))2DDDDE*22224__V0#_
M[1AB4&AO=&]S:&]P(#,N,  X0DE-!"4      !
M.$))300Z      $+    $     $       MP<FEN=$]U='!U=     4
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M8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M     $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^            !"
M<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M  !2<VQT56YT1B-0>&Q 4@            IV96-T;W)$871A8F]O; $
M4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M         %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O
M='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R;W!2
M96-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#
M[0      $ !(     0 ! $@    !  $X0DE-!"8       X
M/X   #A"24T$#0      !    '@X0DE-!!D       0    >.$))30/S
M   )           ! #A"24TG$       "@ !          $X0DE- _4
M $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $
M6@    8       $ -0    $ +0    8       $X0DE- _@      '   /__
M__________________________\#Z     #_________________________
M____ ^@     _____________________________P/H     /__________
M__________________\#Z   .$))300        "   X0DE-! (       (
M #A"24T$,        0$ .$))300M       &  $    ".$))300(       0
M     0   D    )      #A"24T$'@      !      X0DE-!!H      U<
M   &              #P   !X    !$ 4P!0 $D 3@!2 $$ 6@!! %\ ; !O
M &< ;P!? &X 90!W     0                         !
M  '@    \                      !                         !
M   !        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL
M;VYG    \     !29VAT;&]N9P   >     &<VQI8V5S5FQ,<P    %/8FIC
M     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O
M=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN
M#6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !)
M;6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO
M;F<          $QE9G1L;VYG          !"=&]M;&]N9P   /      4F=H
M=&QO;F<   '@     W5R;%1%6%0    !        ;G5L;%1%6%0    !
M    37-G951%6%0    !       &86QT5&%G5$585     $       YC96QL
M5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z
M06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E
M<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +
M8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4
M   )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M#&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P
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M# P,# P,# P,# P,# P,# P,# P,_\  $0@ 4 "@ P$B  (1 0,1 ?_=  0
M"O_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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M300A      !=     0$    / $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@
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M   ,2$QI;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8 ,0  86-S<$U31E0
M    245#('-21T(               $  /;6  $     TRU(4" @
M                                                       18W!R
M=    5     S9&5S8P   80   !L=W1P=    ?     48FMP=    @0    4
M<EA96@   A@    49UA96@   BP    48EA96@   D     49&UN9    E0
M  !P9&UD9    L0   "(=G5E9    TP   "&=FEE=P   ]0    D;'5M:0
M _@    4;65A<P  ! P    D=&5C:   !#     ,<E120P  !#P   @,9U12
M0P  !#P   @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG:'0@*&,I(#$Y
M.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD  &1E<V,         $G-21T(@
M245#-C$Y-C8M,BXQ               2<U)'0B!)14,V,3DV-BTR+C$
M
M %A96B        #S40 !     1;,6%E:(                     !865H@
M        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(
M "2@   /A   ML]D97-C         !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M             !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M                                            9&5S8P         N
M245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M               N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@
M<W!A8V4@+2!S4D="                             &1E<V,
M+%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M             "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#
M-C$Y-C8M,BXQ                                  !V:65W       3
MI/X %%\N !#/%  #[<P !!,+  -<G@    %865H@      !,"58 4    %<?
MYVUE87,          0                        */     G-I9R
M0U)4(&-U<G8        $      4 "@ / !0 &0 > ", *  M #( -P [ $
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M P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#_\
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M>W/Z>QY[ZC_D+;5_TL4_ZLS]9(_W9'_3[>>/_%1N/^[EM?5.'\I_CY-[T_\
M$#[I_P#>HVM[YQ?>*QR%M?\ TMXO^K4O6?7WX?\ ISG+_P#XLMO_ -H]QUN,
M];_\>%M+_M1T/_6H>^D_W??^G)>UW_2FMO\ C@ZX%<V_\K-OG_/2_P#AZH5_
MX4!_\>=\8/\ P^]^_P#O'I[#_OU_N)RQ_P UY?\ JWUTV_NN?^5@]Y/^E99?
M]I1ZKP_E,TE%6=P=U"OQ^.R*0]/8*6*+(X^BR,,<G]_J9/)'#705$22%#I+*
M UO?.O[QLTUORQRP\,SH3N,M2K,I(%LQ )4@TJ.LJ_ORSW,/(?MW]-=2PLV_
MS F-WC)'T3&A*%217-">MF#-_"OX]=M;,I,9V#L' ;DQ69Q=-4U-%58#;U/)
M3S5=*LC38S)T&)I,QBJB!Y2T4M/412(P!!N/>5GMW]T;DR?E[E;FVQYXYGM-
MSO+"WG81WB^&&EB5V7PWA=6CJ2-+AJCC7KC_ +=]X7W4Y%YAGO.5.:+JSO;>
M9E5UGG8,JL122-Y6BD5@.Y71E()%*'K39^6G3V$^/?R:[JZ4VQE:O-;=ZXWC
M38O 9+(3)4Y.3%97;&WMUT-'DZA$2.IR>'BW!]G-(%4RO3ZV 9B DYIV>/8.
M8=UV2.X\6.VD5=9 !:L<;U(7 /=0@8!& /+Z /8SGW<?=3V=]N_<3>;)+?=M
MVL&DFC0%8Q+%<3VSO&IKICE,'BHM3I#Z02%'6P[_ "<-[YJ#XZ]68RJDD_A?
M]\>T]B00.6\7\(QNX:C)826$-]#1U];)"I'IT.PMP+1%[;<[W_)/WM+/:;6Y
M/[DYA@@@NXZG3XTEJ[PS4\I%E@C0-YI,X8'M*\IOO^\N;?)[L\ZW<*CZW]W[
M=>L12OBR0+',#_IT16/GJ -<FM['OJCUS5Z2V^-XX+KS9>[=^[GJA1;<V5MK
M-[KSU78$T^(V_C:G*Y&55)77(E+2OI6]V:P')]I;V[@V^SN[ZY;3;PQL['T5
M 6/\AT=<N;!N7-7,.Q\L;-#XF[;C>0VT*_Q2SR+&@)\@685/D,]?/_WKNS>?
MR0[PS>[JV-9-]]\=L)6+1.7,-)DM\[BIZ'$X96+3NE!MS%34]!"=3Z:>D3DV
M)]X \P;WX\N_<S[JU$I-=24_"%5GTC_2JJH,\% Z^HCE[9>7_:/VVV[8[9BO
M+/+.QE=7F\=G;L\LIH!5YY0\S8%9)3@8'2J^5_3%-T7W[V?U%3+.^W,+74<^
MV):IY9I:S:&X\139#%SR5$EFJRAGGIVD^CM 3Q]/8']N^:'YNY.V'F1R/K94
M(E QIFB<J]!Y<%:GD&'1/['^X4_N7[7<F\]3LHW>XB=;D*  MU!*R2@*,+P1
MPOD''6TA_*>^0,G;O0FRVS%?]UN3'XV;KS=[RR*]1+O+K>.#'09"I<E-53N'
M9\]%4G2I!*6!N#[$GW9MZ7V[]]>?/;.7]/8>8(5W&R& HE6I=%J?Q(9$I0D_
M3KP\^+GWW_:U.0_<[F%+"VT;3+,+ZU &!:7Y+E%X]L%T)H\D<>%*=6W^^CG6
M#'6"JI:6NIIZ.MIX*NCJH9*>II:J*.>GJ()5*2PSPRJT<L4B$AE8$$'GVS<6
M]O=V\UK=0)+:R(5=& 965A1E934%2#0@BA&#T[#--;317%O*T<Z,&5E)5E(R
M""*$$'((R.@'R7QHZGKZR6K@VYB\7'*=7V6/P6VUI(FYU&%*C#3O&K<>D-I%
MN />)',?W*_:;?MWNMTM=PWK;89:'Z>UNRD"'S\-'1R@..Q6T"G:!4]279^[
M_.]K;I#)NTTSC\;S7&H_;IF4$_.E3Y]58?S3-Z]8?$_HR?;FQ100]Y=O13;=
MV2?X!M>HEVIMG[BFCWMOFH6+#0/1RTF$EFH<7(6UME:J)T5D@G:.+.<_NK>U
M/M^NV7T/,._W>[F='BMYKL-"XC8,YG58U8QT&D*&!9R!E0U,U/N6<N\Y^^'N
M3%N_,K2M[;;"RSWGZ]RHN;BC&SLU)E;4&F"S7"TH+:-U8AI(@VLKTYU'NGNW
ML?:'4>PXM&:W14- V2G5YJ+;&WL>BU&XMWY=_K_#]OXT-,USJGJ#'"MWE'LE
MYGYCL.5=CW/F3=C_ (K;K\(H&ED8TCA3^E*]!C"KJ;@O78GW Y\V7VXY1WWG
MKF5J[=9)41@@-<3N=,%K%_3GDHHIA$U.:!#UN)_%[H/:VT\-LWKG96/EQO6_
M5V/HZ> NP^\RE7'.*Z6NRDZB]1GMT99I*ZNE^OK900NCW!'W=O;'>O?KW8GY
MLYG9FV*PNHKR]D4T5I497M;*,\0M47 H1;QDU#2*3P(]Y?<[>M]W+F#FWF*[
M$W-V]2LS4^"-2- 2,?AAMXM,,*T\@34ZNK)??:'K$GH)^]^U\'T7TSV=W!N.
M:*'$]=;*W!NJ99'C0UD^*QT\]!C*=9'C$]=E:]8J:GB!#332JB^IA[*M\W6#
M8]GW/=[@@16\+N?GI!( ]2QH /,D =#CVTY(W+W*]P>3>0MIC+7V[;C!; @$
MZ1+(%>1J T2)-4CMP5%9C@'K0SV#A-R=^]\[0P68E>LW1W-VQ1R[HJ84D8&H
MW=N.3/;UK[(S214]-12UL@<&T:J#< >^>/-F_-M6R<S<SWK?JPV\]PQK2LI!
M91G^*5@ //AU]-'-&Y;1[7^V._[C8*(]FY?V-A;J2/AMK<0VB9XEG$*TXM4B
MAZB]]];5'5'<W;?51ED@_N1OG,8O UC,TDPP,E2,QLG*&7TO)+_!:NDD)X+.
MA/Y]I>4-\3F/E?EOF'2#]5:(T@I_HE-$ZT]-8<#T!IT_[8<W1<\^WO(W.I0/
M^\=MBDG6E!XP7PKN.G #QDE4#@ 1UN)_RX/D"O>G1VS-R5<NK+9_;D4F>B+H
M[4N^]IO%M;?E)((W\<+5&0I8:Z-%4?M58/XO[$GW/][?DSGOW,]D[MS]$)/W
MEM]2U#"^A9%&HXHC0$!1W,)2>'7 K[VOM:WMK[D<Q;/ G^(6MV1":$:K.Y!N
M+)A45-$9X2Q/Q1'JQK2O' X)(X'!/U(_Q/OH3UB=4^O78 'T%OJ>/ZDW)_V)
M]^ZUQZ][]U[KWOW7NO>_=>Z__]3?X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW14?E
M5UW/N/:U/O'$PZ\IM2*H.11!>2JV^X,\Q4+$[R28ZI02*-2JL<DI-S8>S+;9
M@DOA-\+</M_U?Y.HP]S>7WW';8]VM5K=6H.KYQ')\B24.1P%"WRZJ6W#DEC1
M[MI/J)_U_P _7^GL7VD19M1X=8VS/0%@<])OJKY&Y'H;LG%;LC>:IVZT\=!N
M[$QRS:*S;M3/ ,C/!3QL8Y<ECH8_-3W1BTD>@6UD@XGV0;I9O"U!,<H?1APK
M\CP/VU\NEG+/.$W*6\P;@K%K,G3*N:,A(U$ <64#4M1Q%!2M>MBK$Y7&Y_$X
MW-XBKI\CB<S04N2QU=32)-35M!7P)4TM3#(A9)(9X)592"00?<4R1O#(\4BD
M2*2"#Q!&".LS[>>&[MX;FWD#V\B!E89#*PJ"#Y@@]5L_)'J1=L[P_C&*B(P^
MZY*JNCU^&"DQ^0C!GR<$]4[1PTU+''JJ?+,R*L>LDE8V8'5E=ZHM+G*_F:>5
M/7R%/6G6.ON)RVNT;HU[ M+*Y)88PK?B7\ZZEKDU(%:5ZU)_FE_.@I,/NC<'
M6GPQPNUMTTN!K:K#9?Y%;UH)<[MO*96BG:GR*=0[':2CH\Y@J:>)X4SV7=H:
MMAY*2E,8$KS?RYR"[6\5YOTKH7 80(0" >'BOFA_H**KP9JXZ(=NY56=%N-S
M+J#GPUPU/Z;?AKQTC(\R.C5_RN?YHWS%[)[?^)-%W)W;F]Z;.W%OE^K-S;7F
MP^U\)A:^CRIR>R\#5U%/@<)C':HPE77453&Q>[24P+EBS$GO,W(/*Z<F[Y>V
M&TI'N,<+2"2KEJHP<@:F([E!!H.!\NHK;W6YWY;^\ILG)+[_ "R<DF6TA2U.
MD(L=S;!!4A=;F.0AU+,3@5)ZW9/>*W70+KWOW7NB5_//X?X;YH]#U_6LF3I]
MN;VP.6I=Y]8[MJ8)*BEP.\L;2UE$D64@A_?J=O[@Q&1JL?7HEW6"I\L8\T49
M -YYY2AYQV.3;C(([V-A)#(14)( 1W>95E+(U,T-1D#K(;[LOOUN'W>_<RUY
MO2S>[Y=N8&M-PME(5IK61E<F,GM6>"5(YX2<%X]#'PW?K2S[V^/?<'QSW7-L
M'O+K[*[*RDT]5!BZK(4[U>T]W14,UGK]E;J2)<1N6C%EE"Q.M; C(T\$#,H]
MX=[OL6]<MWOTFZV4D%PM2IH2K@&A:-QAUR*D9%1K J ?H7]M/=7D+W8V5.9O
M;;FF#<+-54R*C!;JV9Q4)=VU?%MVXK5@8G8,(Y9 #T:[XZ_S0?EY\<Z;"X'%
M;ZA['V#A5BI:;8G:%*V?I8,7&TK''8O<],])N[%@&4B%WJJN. !1X7C41^Q'
MRW[C\T<L16]I:7$<FU1 *L,B#0JC\*%=+(!Y $JO +04ZA'W7^YG[$>[4M_N
M=YRTVT\T7!+->[<W@LTA 'B26[!K63AW@1Q,]2=:L2_6R-\(OYG72WS%<;,J
M*>3JKNRGI34R]:[BR4%7#N2E@@22MRO7VXUAI*;=-#22:Q-3-%392E11)-2I
M$Z2-D3R?[G;%S2%MIV%GN]0/"D84<GAX+X#U.--!(/-!4$\COO&?<Y]PO8)3
MS!%,-[]NW?2-P@C*M;LQ(2*^MZNUL["FF0-);R,2D<S.K*++/<E=8@]56?SH
M/^W?W9G_ (?/2/\ [^+97N+O>/\ Y4+<O^:]M_VD1]9K_P!WO_XE'R=_TKMW
M_P"[5=]:HGQI[5P_1O?/77;FX,1EL_A=E56=J*_#8%Z./,UR9;;N1PT*T+Y"
M2*B#13UJN_D8#0IM<V'O!7GKEVYYMY0WKERSN8H;JZ6,*\FK0NB17.K2"V0"
M!3SIY==N_>#DF_\ <GVQYLY%VJ_@M=RW".%4EGU&)/"N$E.O0"^50@4'$BN.
MKW]N?SS^G-C]>'"[9Z$[?S6[HILK44E/G,EL7"[5\]7-+/2&OSU+N#*9I(-3
M 2B#$3.B_I#GW+?L/S-#[.>UUCR1>V;7V\Q7-U*9(B$@;QYGD05D/B JK!6
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MYD_Y[I?^/=?3U]WG_IQ?LQ_XKMA_U:7K:(_EL?\ ,H?C7_X@7$?^X-'[Q_\
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M\BYID<ZQ2HH/*M;'O[O-CO'NU]Y;:N:ELVCL;.Y>_G\Q!;PQ-#:Q,PQK:0Q
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MK(6=_EZ]S^4;?EC>9_H!_B1N9XOD'AD9"1Z!U :G &M,4 )5_.@_[=_=F?\
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M2]0K -)FV*$#[$&3%WWBYQ_>E]_5C;Y0=OM7K,0?CF'X/]+#Y^LF*=F>V?\
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M2/\ [^+97O/+WC_Y4+<O^:]M_P!I$?4T_P!WO_XE'R=_TKMW_P"[5=]:R?\
M+_\ ^RSNB?\ M8;R_P#>&SOOGK[R5_UL.;?])#_U?3KL1]Z3_P 1[]RO^:-I
M_P!IL/6ZQT'_ ,RZHOZ#*YNW^'^Y"4\?[$^\H?N0$_ZP6T GAN>X?]I3_P"7
MKYX?<W_E:YZ\? A_ZMCH9_>774?=>]^Z]U[W[KW6@K\T_P#LK;Y0_P#B;>R?
M_=W4C_>_>"?-W_*W<R?\]TO_ !X]?3[]WK_IQ?LQ_P"*[8?]65ZVB/Y;'_,H
MOC7_ .(%P_\ [@TGO'_[M/\ XE[S"?+P=V_X];]<7_O<_P#*^^\'_BSR_P#'
MVZMB]];.L(NOGC_(/_F<'?/_ (D_M7_WJ\]_Q3W@/NG_ "L.Y_\ /=+_ -76
MZ^JWVM_Y4+VS_P"E+MO_ &C0];E/P@_XL76W_B =F?\ NFV5[A7[E]/^".Y^
M_P"E1N?_ '<[#KY^OO%U_>G-W_BSW?\ U>N^C4?(3HK8WR3Z@WKTUV%2-/M[
M>&,:F6L@ &0P&9IG6KP6YL1(2OBRVW\M#%50$G0[1Z'#1LZGJ5O^R67,6TWN
MS[@M;>9:5'%6&5=?Z2M0C[*'!/4,>UGN5S)[1<^<O>X'*LX7=;";5H;X)HF&
MF:WE'G%/$6C?S ;4I#!2-$/O7I;?'QW[;WOTUV)2&FW1LG+/125<4$T..W#A
MJC5-M_=V#,X#S8+<^,TU,!NQA<R4[GRP2 8.;YLM[R_NU[L^X+2YA:E:4#KQ
M21?577(]#53E3U]+_MK[A\N>Z_(O+GN!RG/JV;<8 P4L&>"5<36LU.$UO)5'
MX!AHE4:)$).I_*?_ .RF]Z?X=#[I_P!@!NC:W^\ >\<OO%?\J%M9_P"DO%_U
M:EZQV^_#_P!.<Y>_\66W_P"T>XZW&>M_^/"VE_VHZ'_K4/?2?[OO_3DO:[_I
M36W_ !P=<"N;?^5FWS_GI?\ P]4*_P#"@/\ X\_XP?\ A][^_P#>.7_B?9![
M\_[B<L_\UY?^K8ZZ;?W7/_*P>\G_ $K++_M*/5?/\I _\9A[O_\ $-8('_7_
M -(%*??.?[RW_*K\LD\/WC-_VC-UE+]^JO\ 4+VZ_P#%@F_[0FZVULEL3:W:
M'3]3UUO?%0YS:.]MB#;6XL5.71*W$Y?#K1U<2RQ,DU/.(Y=4<L;+)%(%=&#*
M".J/MY8VNY^U')>W7L0>TFV.U1U/FK6Z _8?0C(.1GKAI:<R[UR;S[#S7R[>
MM;;]MVY?402"A*2Q2ZU-#4,*BC*P*LI*L""1UHJ?+#XX;F^+7>&_.C=X--7P
MX2H^^VIN"51 =Y=>YJ6HDVINN,0,5@K:BFII*:M1+"GRM)4*GH6-CBSS+L%W
MRIOUYM-RQ)B;5&Y_T2)JZ'(_I95QP#*PX4Z^E3V/]W-G]Z/;?ECW(V$+%+<+
MHN8!W?2WL047-L:Y9 S+)"3F2WEB+=Q<#9/_ )1/S6?NWK>3J7L#-?==H=;P
M8_&9*IK'7[K<^$FO2;9WF&+WEFRL4'V.2-O3E8!(QO6)[3>Q?. ]KN?F]M]Q
MD\/D'F.=YMJ)^"TW$]]S8%JT1+FIFMA2FO5&#K< \A_OV_=W7VYYO7GGE;;@
MG)F[M))&J?#;S#NN+3A@1EO&MQYVSE1BW;JS/Y0=TXWX[_'WMON?)Z6386S,
MIE,=2LY0Y+<50BXW:V'B8*_^49G<E=2TL0L;R3 >\V>9MYCY?V#=MYEX00LP
M'J_!%^UG*J/F>L/?9KV]N_=7W2Y&]OK.H;<]PCCD:E?#@!\2XE/#MB@221OZ
M*GK09QN*W7V-NW'82.IGS>^^R-VTF,-;*WGJLMN[>N:"U>1F:0ZI9)LID9*J
M0L;E W/O :_W*.QM=PWK=)JQ0123S,?/2#(Y/^F((KZGKZ>[R]V/E+8;O<6A
M6VY:VBQ:30  L5M:152, <*1HL8^9'6Y_P#'WH?:,6*P76N/Q]#3;2ZVV;A=
MN4]?28; R5U4V)IJ?&4M1)55V(K4FFRL]-4U4CNK.;\\F_O&/[OGM+)]XGG_
M )JFYGW?<;798H7N[B2VD"2":XF_Q>%#*DL2@J)21H)"PT6FJO7SV>Z7N;OL
MM_N7-UU=ROOF[W\L[*TLP1?$8R,H5)4H(PR1J!0#^71G$^->P(Y$D#UA:-U<
M7Q.RB"4-P&']T[%3^1[S,_X 7VLI3^O/-G_959_]L'4/-[N\T.K*0E"*?VMW
M_P!M/6G5_,9^-]-\6_EEV!L7!1U$>Q]U1T7:/7XF"6I<%O&HKFRN(B:*"G@9
M,#N['Y"&-57T4KP W/);YLY.'(FYV_+<=Y/<VL5K$(IIBIEE0+HU2LB1QF6J
M$,41 : Z02>N^GW3?=N;WI]CN5^9-T=3S%9,VVWU*]TUJJ>%*02QK-;/ S$G
M,@DI08%PO\E+OE<OUS)U;DZTODNJ\W-M(022$R?W!WK4U&?V+5A>%2DPNXEK
M\8I)9M+J386]Q9R#O9]LOO+\O[O(Q3EWG"T-E/Y*+Q"OANV::BZQY(P+ASZ]
M8#_WB'MDVW\W+SI9V]+/>[<7.H#'UMHJP7BUXEIH/!N#3%0?.O5C?\ROY*;I
M^+7Q1WCO[8M.3OC<&3P_76TLNXIWI=J9C=[5-,=VU5/4!UK#M^@IYYZ>#0ZS
MUBPI)IB9W7H%[C\QW/+'*UY?V*_X[(RPQMBB-)4>(0>.@ D#S:@.*GK$W[H7
MM#LOO1[W<O\ +',LO_(;M8I;ZZB[@US%:Z6^E5EH4\=V1)'J"D1D9:N%4Z/4
MAEE\I-1.\\OFDDK*F0U57-53L\LU94S3$O5U<\\C22NY)DD8L3S[PL4YU,"<
MUSFM>))XU.:G\^OH]70ACTQ*(EH J@*H4"@10/A4* J@?"H '#JSGIC^9?DN
MDMD[$ZUVW\;.MZC8VR*6*F./;L#>5'E=P/-.:S/Y7+90X6L@.=W/D9)*BIJ&
MIIE!?0$,:*ON&KKV5V;>>;QS;S3S!=[BKW22SVK1Q1PS1(PI::@6>. H/".@
M%@A8\6)ZPV]P?N>V?N+S)S+SAN_N_NZ\R;BY;Q/H;1HX !I@CBC\92(;= J1
MH)$)"ZBP9B>CM)_PH#WLB*D?Q+V='&BA(XU[VS2JB+Z4557I<!551P!;CWF[
M%[ZW%O'';P\H0)"BA55;@A54"@4 6X  %  !0>76.S?W7'+KDLWOG?EB:DG9
MHJD^I_W:]'Y^"O\ -#J?EM6]EIO3J'&=58K8#[4@BRF&WW7;Z6NJ=R0Y>HD^
M^@JME;1?'P44&-!U1_<EM1)"@<A_>?O9\M<G[SR_9<\;,]EM%^DQ^IBD,ZP&
M(H"TR>&C^$0Q)=-;+IRA4DKC!]Y7[FD/L7!R>>7N?)M[O=T%RQCELDLRBVYB
M4:"MW="0N9"*-X8%!0DGHU7SW^0)^-WQ+[;[1Q=9'3[G.W#MCK^4QM.&WQO1
MDV_MBJ6%'C:6/&5F0%;(+@>&F8GWD'SKS''L?*&X[S:S R/"!"W$%Y:+&P]0
M-0?[!U"GW8_:[_7;]\>1>3+RW+[-]7]1>BM/\3M 9[A:T-#(B>"N#W2#K1]Z
MQZZR7:W8G7?4^(,[UV_MUX':*U!>62H@QU94QKFLA--:2:0T6$@J)Y7-VLA8
M_D^\#M]WF#EO8=WY@N?[&RM7ESFK*I\,9\V<J/F2.OH[YSYKM.1^4N:^>+[2
M+;:[*>Y*BBJSJI\)%& -4Q1%'#( QUNI=/=.[3W0*S$Q8NAQ>U-I8S%83#+C
ML+M\SF.D@%'CZ<U-=A:U)D@QM$K.2/(S.I)Y-\?_ +LOL3![][KS??\ -N^[
MI;;19)&6EM90DDEW<.[E-4T4\6A$4LX50]7CR%X_/#SYS]OFS>!?/>R3;W?3
M2S2ZYI]-6.MVTI,A!+N0/P@ BGH.0^,_7?TD6JGB97CE@EQ.S#%-#*C1302A
M=J*QCFB<J;$&QX(//O+_ /X ;VNP1SWS:&!J"+NSJ".!'^(<>HX/N_S53L**
MXR");NH(-01_C-*@Y&*>M>M*SYJ?')OBQ\E>T.F(EJY=KXS)19_8E97MY9LA
MU_NZ#^+[?9IA3TR5$F+:2HQ<TBJ%-5CY;<>V>;.7IN5-_N]E>=Y4A"%)7"ZY
M8RHTN^E4362"'T*J:PVE0,=?0Y]WCW:'O7[0\F>X$C(-ZEA,%XJ"@2]M3X4P
M JQ4242Y4$U$<R=;#/\ )N[_ 'WWT?MO9V8KFJ,_U[-4]19E7=?(U)@X&S?7
M&2DA5BR1UFU*F2D25_7*](U[VXC_ -D=\'MK]Y3<N7I&9.7><[/Q8^.@7L6M
MR*< 2PG!(X>+&N12G*G[_P![7#ECW(W??MOM@FU;JJ[G%0&@:8B*_C!/$K<J
M)2HPJRBG'J\#WTKZYR]>]^Z]U[W[KW7O?NO=?__7W^/?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U0?_.'_F$8WKO:&;^*/3V>IJSLK>N-?&]M
MYO&3>9>OMD96E=:K;*5E-.JT^]MW4<H1H3K:BQ<KRR*CSTVJ;_:;D.3<;N'F
M;=H2NW0M6!6QXL@.'H>,:'-?Q. !@-UA?]ZCWPM^7=HN_;GEB]1^8KQ-%VZF
MOTUNX.J.H(I-*#32<K$2Q'<O6F)\E,M75&W-M]7;:HILKNOL7+P&EPM"O^4G
M X"5:BHGE (CI\?/DA#')))ICCCB=R;+[R/W%F9(X$4F>1N ]%XU^T^OV]8K
M?=RVJQM-^W[W)Y@NXK3E7E^T96GDP@NKI="*OFTB0ZV1$J[.Z(!W='?_ )='
M\N?M'O+<T/7G6U+$U=7UE))W'W-6XRMJ=C[ H88OO/X6DT7@;*U&/IY/]Q^)
MCFAJ,I6RI).]-3,:B(.<P\R[/R3MCW=_)KO''9$I&N0^06OPH#\3D8 ) 8T4
MGUQ;<[?>EY[M;/8;.6RY%L'*1/*"4@C/]I<SZ:*]Y,H 2%3V+HBU(NN3K?>^
M.GQ_Z^^,'4&TNF.LZ2IAVUM2FFU5V1>";-;@S%?.];F=QYZJIJ>D@JLSF:^9
MYIG2.-!<(BJBJHP\W_?+_F/=;K=]Q<&YE/ 5TJH%%502:*HP,GU.2>NEW(_)
M>R>W_+.V<J[!$5V^V4BK4+R.QJ\CD  N[$DD #R   '0W>R?H6]>]^Z]T53Y
M,_"SXZ?+;&4U-W-L"BRN>QE&U!@-]X>63 []V]2-,]2*3&;HQQBKVQJU4C2_
M95!GHFD9F:$EB2"><N1-HYSM=%T[V^YHI$=S$%\1/.A#JR2)6M8Y%9<DKI8U
MZFSV>^\-[L>Q=Y+-[?<T20;9-('FLY0)K*=@ NJ2WDJGB:0%\5-$P4 "0 "E
M,W87\@W'4];-4=9]\[QBQ%M4=!N';NVMQY5;?6/[G[C;,;_X&Y)_I[Q&YK]K
M_?+EJ2XEV3EO9^9-N4$J8+E]ONC_ $6MI_%@)I^)+H:C6D2#KH%RM_>>WLEO
M'%S?[8[>U]P+P3W$$9^>G3<$?ZL](W;7\C;[.M$F]^R^T]R4 /JQVU=J[1VC
M/)<>D/F*K*[C94O]=,0X_/T]P]N,7WE67PMK]@)8)^&J2=)U_8DL8_/50>?0
M@W?^\B-Q 4Y=Y0V6SN?]^7-S=72C[(EB@J1\VSZ=6A?'_P"#&W.F<%+MCKG9
M&*ZSP61G@GW'EJZL;/[TW144=E@K,_EY)ZG(9B2%6;[>*6>&EIB;QP@?4/[3
M]U;[PGNQN]KN7N1=1;1MR,5!G:.1XDJ-0M;*V9HP7%>Z66,D@%]8P<,_=+[R
M6[>X.YKO7-O,<^\[G$A6"-$\"TME;)2"(*J1 FFME1I)*=SGRL3VOMC%[1P]
M/A<3&4IX2TDLLA#3U=3);S550X URRE1_@J@*. /?33VV]NN6_:SE.PY0Y7M
MRMC#5G=J&2:9J>)-*P J[T'  *H5% 50!BEO.\7N^7\NX7SUE;  X*HX*H\@
M/YFI.3T!GRV^-&W?EST;N3HW=.Y=P[1Q.X<IM7,MG=L?P\Y6EK=G[EQ>ZL;&
M$R=)6TLE'4Y#$QQU"Z%=H68(Z-9PMYZY;N>;>6-QV2ROH[:]DTM'))&98P\;
MAT\2,/&S(64!@LB-0G2P/4D^QGO!NWL5[D;1[D;+M%K?7]I#<Q"&XU^&R75O
M);2&L;(P=4E9D-2 X!966JFIWJ+^3YCN@^W=J]J;5W/VANO,[%JLI+BZ3*Y+
M8*[;RIR^'K,/,U4(XL9E_'%35[,HM&PE4 W7Z\V^?O;#[T6]V&_\FO[5;=<;
M9,57ZJUN[<*ZHZR*T0N;N.0 D ,)8E([@ 0 QS>Y\^_K>>Y_(F]\D[SLVS6-
MAN21B1XX[TW$?A2K* M3)%ED /Q=I)%#PNFZ?P&8VULFEQ>=HFQ^03(96=Z5
MYJ:=DBJ*V62%C)233P'7&00 Q(!YL>/>8GW4^2.:_;WV>VWEOG3:&L=^2_O9
M&A,D4A"2W#O&=4$DL9U*0U Y(K1J&H'/7GO=+'=^89KW;KCQ;4Q1@-1AE4 (
MHP4X..'V8Z%#WD?T#>O>_=>Z][]U[JASO_\ DI[$[([/[ [2I.S^VZRI[+WA
MN'>&6Q&/JMBTYP]?N.MEKJJDH3D,-11S8NF>8I 7D,Z(JAS(UW]X1>\GMY[V
M[=OUSO?MOR_M>_;7=SLYB=_I[J!V.JC&2>."6*M:.K1R*  8W)U]=,?:_P#O
M#^9N4>3>5^2Y^3=BCAVBP@M8Y76\/BI H17?PY6(D8"KT 4DDJ$';T?[XM=!
M[DZ-H^OMER8_*R;8Z_V)_<W'9S,UV"J,G6P4,--#1SY*/$UCQFMJ0C%S%$L8
M(_'N,?NZ>S?O-R[[^R^X?/G(C;;MES:7YD=;BSEC26<PE$58KF66C:6 .DTI
MW$5ZQ=]Y_<[:O<BXYJYA6ZA&\[KN?U<D,2S"-&<L76,RJ#H6HIJ8M3C7H\OO
MI7UCAUK\=N_R-.O]R[OW=NG&]I]R95-\;AW'N*MIJ2KV#!58RKW'D:O)U<"F
MOPN/IY:6*:M98F!+Z5 9;^HX)>ZWMU[Z[%O[W_MWRSM7,.RW,SR ,XMKJ%BV
MLK,)KB*&136BR1.K&E&B7XFZD\B_WDG-6S[#L6R7?)7+\+;;:P0(S+>E9%MX
MTC4]DLC!B$!8'%34&F!:9\<^I=T=85.'Q64Q=93X7;G7F/V9C\C75N)J*NM7
M"K@*&BEJX\;5SJ*NIH\69)"J+&'N!86'L)?=1]F/=KD;W?YDYPY]Y-;;=LO-
MHNT#_46DJ^//>6<XC58+B9Z:8Y""PH H!-3UA5[K\\[/SE%?WUG>(VX7>ZO=
MNB+*JJ93.[A3(H.E7D 4$EJ<:GHW?OHUU!?5>?SA_ES=2?-N;:6XMS9G<NQ]
M^[)HZ_&8_=.T)<;!4YS UK"I&VMQQ9+'Y&"KQ])D :BDE55GI99)-+&.66-X
MF]U?;^_YQVOZSEN>UAYLMD;P3<(SP2CCX,VAE=5+?#*I8QDDZ'4LARI^[C][
M'GK[NB;[M6S;?9[CRSN+I(]M="0K#,G;]1 8W0J[IV2J24E54J Z(ZD_^.O\
MK>/XO]@9CL'9-=V9NK,93:.4V//2;KR^Q'PRXS(Y+'Y&6NI%QG\.K?O5FQB"
M,N0FAFU+>UN<?/WM/]Z+GC;AR_N7M%;I907@E62WNK.KM&'0$>+>U\-@U15%
M:E,+D=3S[L??1D]YN5K#E7F.UV>RL8;^.\#6T5Z)?$2-T"-XFM-%)#JH*U H
M:5K=#L6@K<7L_;F.R-.U)7T6)I*>KIG>*1H9XH]+H9())87((^JL1[Z4>S&R
M;MRU[4\@;!OU@UKO-GMD,4T19&,<B+1E+1LZ-0^:LP/D3USXYDNK>]W[=KNU
ME#VTD[,K $5!.#0@$?F!T33YV_ _:?SBV_L+&[DWSN[9E5UOELUF\+_=EL0*
M?+5&:QJ8NII<M_%,;D'6..G4F%HBFB0W8.OI]HO=[DGF'G'88?ZJ7EI'O]HS
M/$ETCM!-J6AC=HV5XB?PR .%/Q1L#C('[M/WF-\^[ANO,UYL_+=AN$.[P10R
M_4"75$L4AD5HO#D05+'N#5JN!I.>B;?&S^6-4?%K=&\-U;+KNQ-VUV[]K4VT
M*^EW;D]B#'TU#C\VF<AKL?\ PN6BJ#5S5,00^2Z^(_I#>^;ON![/?>AY]L+7
M:=R]GX(H;2XDD5[>\LOU&*&+_1+[X".Y>U6X5 X=3][O??&B]ZMEV#9>8K;:
MK&WL+UKI&M8[S6SO$82DGBAUT!37MSJ\Z=72[;IJBCV]@Z2KB:"JI<3CZ>HA
M9HW:*>&EBCEC9XGDC8HZD75B#^#[ZE^WNW7VT<A\F;5NEL8=RMMKMHI8R58I
M(D**ZED9D)5@15693Q!(SUSVW>:*XW3<9X'U0O.[*<BH+$@T(!R/4 ]$E^<'
M\O[JOYP8S9<F\,UN79F\.OI\H=O;MVC+C(:^JQ&9AC&3VOFTRF-R4-9A*BMI
M:>K30L<]/4P QN$DGCE(_<WD.XYSVE'V>XMX.9+8,8'F1GA8-\44P1E?0Q (
M9#J1@" P+*V17W<?O1\[?=QO.8DV#;[/<-AW58_'M;H2%%EA)\.XA,<D9694
M:2(U+(\;D,I98V2O_I?^4A6?'GM7;_:O7>_^Y7W!MF2LI9:2JR77;;?W3@ZY
M!%DMO9F-(J&NEQ-<R1S(Z".>"HACEC*NH]\\>;/;G[T>_P!C?\O7?LY8O"LR
M-%<V]Y;JT4\+AXKJV>6\C8.C+5&>-20>Y!PZR@]POOT0^ZO).Z<D\U\K\OC:
M[Q58,L=\)[:9,QSQ$EU$J592#J1XV='JK=6%_*;XK9'YL=#X3JKL'=N\^K9,
M5NK%;IS,&UY=M3Q[NKMNTM?'B*3*S5%+F8UPXR%7%D%2(Q21UU+"S:ECTMF3
M%MGN[[A^SVVV/,6U1;-[D6K#QHKLQ3VUX\*D*^NSG;PTF)60$$M#**-$ZJ*X
MK^ROO7:_=V]S-QYVY7V+;]Z6:RDMHC<"<&U2=D,K1!6B/BZ%: EM2M#)(!1F
MJ*[.F_Y/N%Z0[5VIVKB,EV?O',;%J\C6X+%;FRO7PV_)EJG'U6+I,Q,M */(
M/-B4JGGI>4M*59AQ;WAGS?[=_>MYEV;>.6)O:*UCLK@A'F@O+/4R(X8B/Q;X
M=DND5+(K%3E5)(&5ON#]_7<O<CDC>^2-PL]FL-OW)(UFEMX[[QQ&KK(\0UZD
MI*5"2'-5J <UZN>Z9V97;0VQ.,Q2?99K*Y":JK:=I*>9Z>"G I*& S4LU1 X
M,,1E]+$!IB/K?WEM]TCVCWGVI]NKY>:]K^DYNW._DFGB+12-%''^C;QF2&26
M-AX:&;M<Z6G8'->N?//_ #!;[]O$1L)O$V^"(*C48!F/<[48*1DZ<C@HZ%[W
ME1T!>J\OG3_+OZV^;[[%SFY=S[KV9N[KJCS^.Q.3VK-B(5S>(STF.JIL/G/X
MGB<FS0T==C5EI)(]!@>::X<2&T/^[W(>^\W[3%><HSV2<TVBOX2W2N8)E:A,
M3O&0\1U*"DH$@2K:HW!QE5]VO[UO-_W<EYEVW9]GL=PV/=I())8[D2GP98 Z
MB6'PY(Z%TD*RJU=86.A4H*E"^-_\L&N^+6_LKV!U[G^V,W7YC;=1M;)X?<^8
MV"^ KJ0Y"ERE!D6BQWV-6N4PV0HUEI9;^@.ZE;,??.OG3VN^]-SG96FWW?M!
M!;RVEXMQ!<6]W9B6.2.H4H9+TT4X.4!JJFE1U.ONW]\F#WIY8LN5^:MKV.WM
MK>\6YCEMHKT3HVAHWCK)K4Q2QN5D6F:*:U'5@_RN^+&+^:G0N-ZIW]N#=/7<
MHSVV]Y3U6VGPD]?#G-OQ5B)CJQJVBRE'/C)Y:UV?P&.0E4*N!J5NBNY;)S;[
MA>UNSP;E;IM'.SV\,LL-P%N(X[I%I)'+]/( T9;51X9, JPK0J<6_9'WJO?N
M\^YMWSMROM=ENJ?37%JJW F"&&<K61-#QN) $ &NJY8%3@BGNH_D5;5AFEA3
M?7=54L;Z!44V3ZT^WFTBQD@-324M08F/TUQHW]0/>$-[RI][&SO+FUB]F]KN
M8XV*B6*\@\*2GXH_&O(92IX@R11MZJ.L]H_[RO?)8TD;EGEU"PKI:/<*CY'2
MS+7[&(^?6'_AB[;'_/9=X?\ GSZM_P"C/:;^KGWM/_"'V/\ V66?_>PZM_R<
MGWO_ *9_EO\ YQ[EU[_AB[;'_/9=X?\ GSZM_P"C/?OZN?>T_P#"'V/_ &66
M?_>PZ]_R<GWO_IG^6_\ G'N71L_C'_+OR'Q8Q^^<7L]-[[KA["R^WLGF:K>.
M4V3]QCQM^@J\73TV-_@U52**:>"ODDEUAGU@:;>X[Y\]COO,>Y%QLK;[[1I;
MP6JO%2&\L,QS.ID9M5\34 &FGR^?4&^\?WK+;WKNN6[S?_W;8OM4$\<2VL=Y
MI?QW61FD\56.H,@5:4&DFM3T:SYR_"7'?-;8NRMGYOL7>6R,9L?.3;HAP>U_
MX"E#N+,'%38JB;+U.4Q.2JHVQ--5S_;>)UB$DQ:17*H4Z1^[?)O.7,W*-E;<
MDW%BF[V8UK;78?P)V$>D1F:-M<++D(^F1*GO0BC"%?NW?>*NON\<R<P[]MW*
M>W[C=[E;"V,UQXQ>"+Q!(_A+'(BGQ65/$U*6TK12H+!B%?'_ /E.T'QU[-I.
MU-MU'96[]PXO"Y["8BEW;EMA+B<:^?IDH*S-TZ8F2CJGRD..$D,!9@B+.Y(O
M;WSYYS]L?O5<Z;)/R[>>T,%O823([O#>66MQ$Q94.N_/Z;-1B* G2 :=9->Z
M'WX;OW8Y/GY)WB':+#:Y[F&65[6.]\200,72)C(&41F32[T%3H4<*]7,=3[3
MGVALZCH:^G^URU;//DLK"7BE:*IG*QQ0-)!)-"QIZ.&)#H9EU V)O[SG^[![
M7WOM5[4;7M&]V!M^:+V:2[O4+([)-)1$C+QL\9,4$<2'0[+J#$$UJ>?O.^^1
M;]O\]S:RZ[*-1'&:$549)H0#W.6.0#0C'0E^\AN@AU6A\Z_Y:O6WS4W'M'L+
M,;JWCL[>VR]MY#:RMM2HPE/3;IP53D8\O0T68.7Q.19:K!UK51H9$>.-!7U
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M]1-!-63N7UL"3<RCN/-G*NQ1".]WBUB5!I$:,'84'PB./45]!4 #UZQAY?\
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MIIV9HB8G4 %0205!^*F:4X'UQY]<?DIOW([GVW\+_DG+U+WCB]B==?),;V[
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M\KAG;^6I\!6=F=S\./CCJ9F+,3_HCVI]6:Y/MCFT4YIYB X?73?]7&ZMM/\
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M3PTE'3P4M+31)#3TU-%'!3P0QJ%CBAAB58XHHU%@J@ #Z>VB2Q)8U)ZL
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..[KW7O?NO=>]^Z]U__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>47
<FILENAME>stockperformancechart.jpg
<TEXT>
begin 644 stockperformancechart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" '@ F4# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M3[/^!?P.\<^#OB+\5OCA\8/&?A+QE\7/BSH/PS\#:BWP^\&ZEX(\#^'OA_\
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M1O2_2^_\'&M?_+&C_A&]+]+[_P '&M?_ "QK>HH P?\ A&]+]+[_ ,'&M?\
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M/O[0G[.?COXBZU\8]/\ A?X)^ /Q.\-?$GQ3H/@G0?%J_P#"Y_\ A;.B:_X
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M_P"$YXA_^5= &S16-_;MC_SPUG_PG/$/_P JZ/[=L?\ GAK/_A.>(?\ Y5T
M;-<AI'_(V>+/^N'AO_TBOZUO[=L?^>&L_P#A.>(?_E77)Z5K5FOBGQ4YAU;#
MP>'0 - UUG&RSO@=\:Z<7C!)&TNJAQDIN ) !Z+16-_;MC_SPUG_ ,)SQ#_\
MJZ/[=L?^>&L_^$YXA_\ E70!LT5C?V[8_P#/#6?_  G/$/\ \JZ/[=L?^>&L
M_P#A.>(?_E70!LT5C?V[8_\ /#6?_"<\0_\ RKH_MVQ_YX:S_P"$YXA_^5=
M&S16-_;MC_SPUG_PG/$/_P JZ/[=L?\ GAK/_A.>(?\ Y5T ;-(>GXK_ #%8
M_P#;MC_SPUG_ ,)SQ#_\JZ0Z[8_\\-9ZC_F7/$/J/^H70!E>!/\ D5]._P!_
M4?\ T[7]=?7G7@C6K./PSIZ-#JQ(?4,F/0-=E7G5+YAAXM.=#P1G#'!RIPP(
M'6?V[8_\\-9_\)SQ#_\ *N@#9HK&_MVQ_P">&L_^$YXA_P#E71_;MC_SPUG_
M ,)SQ#_\JZ -FBL;^W;'_GAK/_A.>(?_ )5T?V[8_P#/#6?_  G/$/\ \JZ
M-FBL;^W;'_GAK/\ X3GB'_Y5T?V[8_\ /#6?_"<\0_\ RKH V:*QO[=L?^>&
ML_\ A.>(?_E71_;MC_SPUG_PG/$/_P JZ ,KQU_R*VJ?[MI_Z<;.NM'3\6_F
M:\\\;ZU9R>&=318=6!*VF#)H&NQ+QJ%H>7ETY$7@'&YADX49) /5#7;'_GAK
M/4_\RYXA]3_U"Z -JBL;^W;'_GAK/_A.>(?_ )5T?V[8_P#/#6?_  G/$/\
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M<:L-+62:]T*1)K>Y65=4L#<Q6B",.-22Q<.$#JX!WVBD?\)/XPY'^MT#N/\
MH#BNPK\!OAY\8OVE/B%XYT+PAX<^*WC!=8\8ZK8Z>UT)+%Q;P*A^TZI=K_9K
M;;?2-+BN;V?Y5_=VQ1@9&4'][--M&L-.L;%[R[U![.SMK1K^_D66^O6MX$A:
M[O)52-9+JY*&>X=8T5I9'*HHPH +M%%% !1110 4444 %%%% "'I^*_S%<EX
M$_Y%/1?^O5__ $JN*ZT]/Q7^8KDO G_(IZ+_ ->K_P#I5<4 ==1110 4444
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MMXV>32AXR7X[1Z0-:>Q#VR:^? IL8[MDO6\.2PH;)@#ZN_X)\_\ )AG[$_\
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MCH\CQ#_T%-&_\$5]_P#-'0!LT5C>1XA_Z"FC?^"*^_\ FCH\CQ#_ -!31O\
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M_)AG[$__ &:/^S7_ .J6\$5]?5\@_P#!/G_DPS]B?_LT?]FO_P!4MX(KZ^H
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M!/\ D4]%_P"O5_\ TJN* .NHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "OSN_X*[?\ **K_ (*3_P#9B'[67_JC/'%?HC7YW?\ !7;_ )15?\%)
M_P#LQ#]K+_U1GCB@#U/_ ()\_P#)AG[$_P#V:/\ LU_^J6\$5]?5\@_\$^?^
M3#/V)_\ LT?]FO\ ]4MX(KZ^H **** "N0TC_D;/%G_7#PW_ .D5_77UR&D?
M\C9XL_ZX>&__ $BOZ .OHHHH **** "BBB@ HHHH *0]/Q7^8I:0]/Q7^8H
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M^1C]9P_M)T?;T?;4H\]2E[6G[6G!VM.=/FYX0=U:4DHN^C.SKS+XM?&;X6?
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M+\3?V]/ J11^-/V8_A%\:+42GS]:_9^^.C^%=?DMPK$R)\.OCOX7\,:1!.2
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M"G_80_8JEETJRDED_9)_9L>21X59G9O@OX()9B<Y)[U]=?\ ",>'O^@/8?\
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M1CP]_P! >P_\!T_PH W,CW_(_P"%&1[_ )'_  K#_P"$8\/?] >P_P# =/\
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M416D _=:9HUBEOI.DVP6"RM4P\DGI^1[_D?\*P_^$8\/?] >P_\  =/\*/\
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MI$5_X@N0_B#72KRWES#!+]C3W>@!D<<<4:11(L<<:JD<:*$1$0!51%4!515
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M:*T3Q1KEGI\&J>(5M8F:*V75[N\6"-BD85214_@CX?> _AIH@\-?#GP5X2\
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M'_#!G[$_ _Y-'_9K[?\ 5%O!%?7V!Z#\A0!@_P!NG_H#Z[_X+3_\?H_MT_\
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M-/J?^F]4/'0'_"+:IP/NVG;_ *B-G76@#'0=6[#U- &%_;I_Z ^N_P#@M/\
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M9A0Q=*E'%4E5CA:]7#K&TTY./+5P]&M6DIW5^6+GHUK=V/2?[=/_ $!]=_\
M!:?_ (_1_;I_Z ^N_P#@M/\ \?KS8_$OQM>H&T7X$_$*3.0)/$&K_#CPW!G'
M!=)/&FI:BBAB-Y&G.X0.R1R,HC8&O_'74$/V/X:_#[0P3E7\0_$W5+V=5.2
M]GX>^']U!OV@*ZIJCHCDE9)47<WF_P!CXM:SJY;35[24\XRE3C_BI+&NK\E!
MR\CT/[6PK=HT\PF[73CE69N,MK<M1X14G>ZUY[>9Z3_;I_Z ^N_^"T__ !^C
M^W3_ - ?7?\ P6G_ ./UYJFF?'^^#+<^*_A-X>5A@_V;X(\5^)+A!PIV7&I>
M-=!MBQ&74OI[*I(C9) ID=8O 'Q0N7)U7XYZ[ CY+0^%? O@+1(USE@(Y-=T
MKQA=(JOM"YN7<Q+L=W=C-3_L[#QNJF<Y73DMXI9G5?313H9;5I2>O2HXO7WA
M+'XB23AE&93C+:3EEM)>KA6S"G52]:5[=.AZ3_;Q_P"@/KO_ (+3_P#'Z3^W
MST_L;7O_  6-_,SX_6O-U^"\$\F_6?B9\9-<4D;XI?B'?Z!#(O *O%X*M?"R
M[60!&"[<C<^1,S2LC?L]?".=_-U+PM-XADZL_BOQ)XL\6%V.XEG7Q)KNJ1LQ
M=WD/R8$DDC@!I'++ZOE$-*F9XN<K;X7*X5:=^REB<QP52WFZ2?D@]OFLM:>7
M86"OMB<RE3G;3=8? 8N%[7VJ->;V.JU7XE>%-!4MKNI6FB*H);^V-2T/2RH
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MPGGF#P5+#2Q6(PL84,)A56K8BK/V]"7+2Q-2K@J=.249-RG0DK)KEU1^)/\
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M ./T?VZ?^@/KO_@M/_Q^M[ ]!^0HP/0?D*_E4_IY;+H8/]NG_H#Z[_X+3_\
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M<:*J(JJ *F5510J@*J@*JJ   !@  8            IU>6>R%%%% '(^.O\
MD5M4_P!VT_\ 3C9UUHZ?BW\S7)>.O^16U3_=M/\ TXV==:.GXM_,T +1110
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M."5'@A20#@D!E)&0",Y$8_X7_@9_X4_G'/\ R/!_GS^=>7_:D7\.!S.6U_\
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MY,,_8G_[-'_9K_\ 5+>"*^OJ "BBB@ KD-(_Y&SQ9_UP\-_^D5_77UR&D?\
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M3J2;C.5-2C0>&IIN4HNT95H17,N:I%)R/Z"2RJ"6( 498DX"@#)+'H  ,DG
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MC53QDKJ2GF=:>84TXVY9++*-+ 991JPMI6HTW46GOR=V_*K?XJ7ES EC\/\
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MS\,M3\1^#O$7A[X@:KJD;:?]^_L\^#_B7JWQ^_:&_:*\=_#C6O@WIOQ0\$?
M'X:>'?AMXH\0>"-?\5R7/P9/Q;U?Q'\0-?D^'>N^+O"MFWB&_P#BY!X.T*&W
M\6:OJ5WX>^'ECK&HQZ5#JFFZ39_:M% !7Y _\%=? OQB_P"'<?\ P4GUY?CE
MY7@[_AB[]K/4#X(_X53X-N,Z%_PI3QQ*WAS_ (26:_755\VUS8?VZL)U&V\S
M^T(8FNH8T/Z_5^=W_!7;_E%5_P %)_\ LQ#]K+_U1GCB@#N/V +'5W_81_8J
M:+6_*C;]DG]FTI'_ &59OY:GX+^"2$WM(&?:"!N8 GIT KZY_L[6_P#H/?\
ME)LO_CE?,/\ P3Y_Y,,_8G_[-'_9K_\ 5+>"*^OJ .?_ +.UO_H/?^4FR_\
MCE']G:W_ -![_P I-E_\<KH** .?_L[6_P#H/?\ E)LO_CE<KI=CK!\3^*%7
M7,.L'A[>_P#9-E\X:TO2HQYF%V@'IG.<&O2JY#2/^1L\6?\ 7#PW_P"D5_0!
M?_L[6_\ H/?^4FR_^.4?V=K?_0>_\I-E_P#'*Z"B@#G_ .SM;_Z#W_E)LO\
MXY1_9VM_]![_ ,I-E_\ '*Z"B@#G_P"SM;_Z#W_E)LO_ (Y1_9VM_P#0>_\
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M1%2I3HPG5JSA2IPBY3J5)*$(16\ISDU&,4M7)M)+5L=_9VM_]![_ ,I-E_\
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M@]_Y2;+_ ..5T%% '/\ ]G:W_P!![_RDV7_QRC^SM;_Z#W_E)LO_ (Y7044
M<_\ V=K?_0>_\I-E_P#'*/[.UO\ Z#W_ )2;+_XY7044 <__ &=K?_0>_P#*
M39?_ !RN4U:QU@>)O"JMKF79=?V/_9-E\FW3X"W'F8;<"!SC&.*]+KC]9_Y&
MOPA_N^(__3;;T :']G:W_P!![_RDV7_QRC^SM;_Z#W_E)LO_ (Y7044 <_\
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M9?\ QRC^SM;_ .@]_P"4FR_^.5T%% '/_P!G:W_T'O\ RDV7_P <H_L[6_\
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M/'%?HC7YJ_\ !7;Q'X?_ .'6_P#P4GTTZ[HHU#_AA?\ :RM?L+:MIZWAN?\
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MFZN#R3+L/6DN26,S+-<1BLRE"R?+5JQP6+JUHIVM"69.*M:+2M; U?\ ;/\
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M:E"<JU&C-)SDI**NKJ[L[$]%0?:K;_GX@_[_ $?_ ,51]JMO^?B#_O\ 1_\
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M[5;?\_$'_?Z/_P"*H GHJ#[5;?\ /Q!_W^C_ /BJ/M5M_P _$'_?Z/\ ^*H
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M6?,TW?W[7M:QX[^RI\);'X4?LS_ ;X7WOA\6%SX ^$O@/PA=V6KV-@=3BNM
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MC^P-#_Z VE?^"VR_^,5KT4 9']@:'_T!M*_\%ME_\8H_L#0_^@-I7_@MLO\
MXQ6O10!D?V!H?_0&TK_P6V7_ ,8H_L#0_P#H#:5_X+;+_P",5KT4 9']@:'_
M - ;2O\ P6V7_P 8H_L#0_\ H#:5_P""VR_^,5KT4 >>^-M$T:+PSJ<D>DZ6
MCJMIM9=.LU89U"T4X(@!&02#@\YKJAH&A_\ 0&TKJ?\ F&V7J?\ IA63XZ_Y
M%;5/]VT_].-G76CI^+?S- &3_8&A_P#0&TK_ ,%ME_\ &*/[ T/_ * VE?\
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MP_ZZZ!_Z9Q77T %%%% !1110 4444 %%%% "'I^*_P Q7)>!/^13T7_KU?\
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M%!9V4'C#2==OO#C6>H?\,KS#4'N[32[^2YC%K:FR,<2DW(F$J '[W45^-?\
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M_P"&K_\ @L__ -(COV=?_%H^A?\ T)='_#5__!9__I$=^SK_ .+1]"_^A+H
M_6;QU_R*VJ?[MI_Z<;.NM'3\6_F:_!/XX_MU_P#!7+X9_"_Q1XV\<_\ !)OX
M :=X7T1-(;5+RQ_X*<:%JEW"-0\0Z1I-F8; ?LKV!GWZA?V<4F+J+RHY&E)?
M8(I/6!^UA_P6>(X_X)'?LZ]6''_!4?0CR&(/3]DP]P<^AX(!X !^RM%?C7_P
MU?\ \%G_ /I$=^SK_P"+1]"_^A+H_P"&K_\ @L__ -(COV=?_%H^A?\ T)=
M'[*45^-?_#5__!9__I$=^SK_ .+1]"_^A+H_X:O_ ."S_P#TB._9U_\ %H^A
M?_0ET ?LI17XU_\ #5__  6?_P"D1W[.O_BT?0O_ *$NC_AJ_P#X+/\ _2([
M]G7_ ,6CZ%_]"70!^RE%?C7_ ,-7_P#!9_\ Z1'?LZ_^+1]"_P#H2Z/^&K_^
M"S__ $B._9U_\6CZ%_\ 0ET ?LI7'ZS_ ,C7X0_W?$?_ *;;>OR;_P"&K_\
M@L__ -(COV=?_%H^A?\ T)=>2^+_ -NO_@KCH'Q2^$?@C5_^"3G[/\'BGQ]'
M\0G\(V4/_!3C0KBTOE\)^'[#5?$)O;__ (98A&FFUT^ZMY;<-:W?VQV:,?9@
MGFL ?O=17XU_\-7_ /!9_P#Z1'?LZ_\ BT?0O_H2Z/\ AJ__ (+/_P#2([]G
M7_Q:/H7_ -"70!^RE%?C7_PU?_P6?_Z1'?LZ_P#BT?0O_H2Z/^&K_P#@L_\
M](COV=?_ !:/H7_T)= '[*45^-?_  U?_P %G_\ I$=^SK_XM'T+_P"A+H_X
M:O\ ^"S_ /TB._9U_P#%H^A?_0ET ?LI17XU_P##5_\ P6?_ .D1W[.O_BT?
M0O\ Z$NC_AJ__@L__P!(COV=?_%H^A?_ $)= '[*45^-?_#5_P#P6?\ ^D1W
M[.O_ (M'T+_Z$NC_ (:O_P""S_\ TB._9U_\6CZ%_P#0ET ?K+HO_(S^,/\
MKKH'_IG%=?7X(^#?V[/^"N/B+XF?&#P7HW_!)S]G^X\3_#Z[\"0>,+.;_@IQ
MH5M:V,OBCPBFOZ"+&^_X98G&IK<Z0ZSSNMK:"UFW6^+C:9AZU_PU?_P6?_Z1
M'?LZ_P#BT?0O_H2Z /V4HK\:_P#AJ_\ X+/_ /2([]G7_P 6CZ%_]"71_P -
M7_\ !9__ *1'?LZ_^+1]"_\ H2Z /V4HK\:_^&K_ /@L_P#](COV=?\ Q:/H
M7_T)='_#5_\ P6?_ .D1W[.O_BT?0O\ Z$N@#]E**_&O_AJ__@L__P!(COV=
M?_%H^A?_ $)='_#5_P#P6?\ ^D1W[.O_ (M'T+_Z$N@#]E**_&O_ (:O_P""
MS_\ TB._9U_\6CZ%_P#0ET?\-7_\%G_^D1W[.O\ XM'T+_Z$N@#]DST_%?YB
MN2\"?\BGHO\ UZO_ .E5Q7Y,']K#_@L\!S_P2._9UZJ.?^"H^A#DL .O[)@[
MD8]3P 3P?*/@;^W7_P %<OB;\*?!GCOP+_P2;^ &H^%/$>FSWFBWM_\ \%.-
M"TN\N+:+4K^R=[C3S^RO?FU<7-K.GEFZF.%#%@28T /WLHK\:_\ AJ__ (+/
M_P#2([]G7_Q:/H7_ -"71_PU?_P6?_Z1'?LZ_P#BT?0O_H2Z /V4HK\:_P#A
MJ_\ X+/_ /2([]G7_P 6CZ%_]"71_P -7_\ !9__ *1'?LZ_^+1]"_\ H2Z
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MK7/A_681NETG6X-/N[F72-3B )DT_44MKQ "6A !( .CHHHH **** "BBB@
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M6UW1M(N-!T7PYXFL/$VH_%"/1?%B7[C]H?\ /^?\\]J3'U_,_P"-+0 4444
M%%%% !1110!\ _M[>-_ ?P^\/?#'Q%KW[/7B/]H3XA+XMUG3?A)IR?"WXI_$
M[X:^ /$>K^&;O3M:^(OQ:3X;^!_B0WA?PKI'ANXO=,36O^$(\1^,M2DU>Z\)
M_#S39=6\0ZC+!^8NI_LZV?@SX1>(_!MM\-?BO^T1H_CW_@G5IGP._9,\6_\
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M ,'_ !*\2:+H_B;X9>,]$\9V/AO4/%WC/PEI>N6VF_O/COS^9_EG%& !@#'
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ML/"_PE^!>L>*/@_\;+BYT3_@J5X*_:+_ &<OA[X;^ /[0?BL_!7]EZQ_;/\
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MGU/-+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MLK0>4;F']V9Q*^_]VC;6Q[[7\\/[$A\>'XYP?\*Z/A$^)?\ A#?$_E_\)O\
MVW_87V#S='^V[O[ _P")C]MSY'V;'[C;Y_F_-Y5?L9_QEW_U;C_YE&N+CS@3
M+^&\[AEV6YK0AAW@:&(:SC'48XOVE2=:,FE0PE&'LK4X\GN<U^:\GHEU\$\:
MX[B#)Y8[,,LK2Q$<96PZEE.#K2POLZ<*$HINMBJT_:WJ2<USVY>5I)WO])5S
MGB+QAX2\(#1#XL\3^'?# \2^(M*\(>'#XAUO3-%_M_Q7KKRQZ)X8T3^T[JU_
MM7Q#K#P3II6B6'VC4]1>&5;.UF:-P,/X?_\ "TOL6H?\+2_X0'^T?MJ?V5_P
M@/\ PD?V+^S_ +-'YO\ :'_"1_O_ +9]K\W9]F_<?9]F[][NKY#_ &]_@./V
MBM-_9G^'^H>%-=\2^$U_:A\-:]XRU#P]')'J?@+2M+^#OQRBT3XF6&L0H\WA
MC6O GCV^\&Z[X2\4P 3:%XU@\-7D1,BJK?FN(H_5ZTZ/M:-?D:7M</4]K1G>
M*E>$[1YDKV>BM)-=#]"H5?;TH5?95J/.F_95X>SK0LVK3A=\K=KI7>C3ZGV5
MJ_Q#\ ^'[+7=2UWQOX0T73O#&NZ)X8\2W^K>)M$TVR\/>)/$S>'T\.>']<NK
MV^@@TC6]??Q9X671=)U"2WU#56\2: MA;W#:SIHNJNM_%+X:>&?%OA[P#XB^
M(7@;0?'/BU/,\*^#-:\7>'M*\5^)D\Z:W+^'_#E_J5OK.M()X)X2VF65T/-A
MEB!,D;JOX1:]^SU^V-^T5X5_:#^"'CGX4>%-.\3>/?VH/$?B?XE^-OBG:^*/
M#_P:^)6D?"+]B[]FWX'^ /BU\/+OP'I^O7XN_&7Q@N]/^.WPWT>\M8'\(>)?
M@YXAT#49[;4?!5K<W4WBOPO\=]6NM/\ C+IOP(^,/_#4GQ5^&_[+[?%#X._%
M']GGPG\8_P!F/XW?$WX4VEM8213_ !%F2T\7_LK:GX%\:IXF\KQQJWC3PYX5
MTVQM?"/QH\(> O'NL7M[;:UB;'[;^$/C[\"_B#XLU[P%X"^,_P )_&_CCPK<
M:I9^*/!WA#XC>#?$OBKPW=Z'?OI>M6NO^'=%UJ]UG1[C2=31]/U.'4+*WDT^
M^1[2\6&X5HQU/_"Q? !T[QGJX\<>#SI7PYU#4-)^(&ICQ-HAT_P-JFDZ58:[
MJNF^,;W[=]E\,7^F:)JNF:QJ%GKDMA<V6EZC8:A<Q16=Y;32_A)\,/!_C.?X
M>?"[X5Z7^SK\<-!^,WP3_P""DG[2W[1GB+XEZO\ !'Q;X1TGPU\&HOVV_P!H
MCXQ:_J7A#XCZUHNB:5\3KW]HCX$>)%^%OAWPQ\.-2\37_B1?B[;OX@T_2]"T
M_7+W2^,LOV:/VO\ PGK%OJGQ-^#.@>(_!OQ2^(?[./[8'QR\&_!9/$_BS_A.
MO&?PC^+6K7OQIT[XEZ%XRL='T[4?BIJN@?%;X-^+?#?A#0)-4M/&NB?L@ZEX
M;T./4M:M]$TJ_ /Z&?"_C;P;XW\,V/C3P9XL\,^+?!VJ6T]YIOBOPSK^DZ_X
M:U&SM99H+F[L=>TF\O-*N[:WFMKB&>>WNY(X98)HY&5XG5?._!G[2G[.WQ&T
MR?6_A]\>O@OXZT6VUKPSX;N-8\&_%/P)XHTN#Q%XTU./1/!^@37^AZ_?VL6M
M^*]9FBTGPWI4DJWVO:G+'8:5!=W;K"?BS]CX0?$+0_VVOC-\.;"XT_X-_'SX
MGS>(OA%X,;1+7POKDMUHG[/_ ,/_ (>>/O%FK>!4V:QX!UWXB_$/PYJE[-X0
M\6Z5H'C-S80>*O$_A_3=5\5S1R?G#X2_X)^_'FW_ &,_V O$GCJ77[_XP^$?
M"_\ P2D^$-S\//A=\&K;X2^)O@K\-/!7[2W[+/Q4^+5_\1VE\4>/=8\7_$#X
M30?#A6N_&.JG0=$^'MKHOC;6_#_@O2-4\2ZU<T ?TM;TX^=><X^8<X.#CGG!
MX/OQ2EE'5E&.N2*_FA^,]U_P4HT[P#\;_!OP^TO]JRW\:?"6[_;(N/V2_&]Q
M'\6?'C_$V[\)_%/Q=?? 7PGXF@\'^*_!5AK=TG@NR\.?\(_\2/VH/$_C#X?^
M/?"VKZ-H6G>!/'/B[2O%MWJOTOX4\$?ME>-?BGX+B\<^)/VJM!\%?$#_ (*
M?MB^$_B NE^*?%/A'3?"?[)FG_ KX_ZS\#;C1KK2I;2?PEX4OOBG=>!H_"GC
MFT:/Q-=:HWA;P_:ZS!I5AI.G68!^XV]/[R\8S\PXST[]^WKVHW+Q\R\].1SS
MCCGGGCCOQ7\W?A?5_P#@HW9>#?A0/B/I'[66LP_%[]D[]COQ5^T+KHC^($6H
M?";X]R>*_BEI'QDN]*\'_""#1_BA8N?#^G_#W3_'_P '/@-J'@K6)+K4] \<
M3:OX>TNS^(&JZYZ;^SG<?MVRZGX;L?VG8_VO&N/#^M:WX9_9YO?A?I=WH6BZ
MS>^'?VOOC9IE[KO[4-KK_B'QA:R>%M6_9OA_9\N])O/C#XN\6IJ7PU;Q]=^&
M?$.M_M!R27\X!^_&Y3G#*<=>1QDX&?3GCZ\5C:[XD\/>%]-O]9\2Z[HWA[2-
M*TW4]9U35=<U2QTC3=-T?1+.34=9U6_OM0N+>UL]-TG3X9;[4[ZXECM;"SBD
MNKN6&!&D'\[_ (0T7_@J->_ 3XS7.M^,OC(?C-IOP\^%GB+Q[X=T;P?\4M"N
M[KXR>%?CYX!\7_%:U^"?C#XA^-KSPQJMAJGPGT;XI>$=%\&_L[^'[3X2^,_#
M^K^#[>*_T_Q7++87_D/Q]^&/[9WC_P"('BS]H^;P9^V#>7/AKQ7_ ,%1_"/[
M.=EIR?$3_A(/"VC_ !G_ &:/@K)^RDLOPLT:ZD?3_ 6N?$#0?&]F9?%N@2:/
MX9U\:;H?Q&AT:6WBL]. /ZB[#4=/U6RM-2TR_L]1T[4+2WO["_L+J"\LKVQN
MX([FTO;2ZMY)(+FTN;:6*XM[F&1X9H)(Y8G:-U8T=0\2^'=)U+P_H^J:]HNF
MZMXLO[S2O"^EZAJMA9ZCXDU33]'U#Q#?Z;H%C<W$5UK-_9:!I.J:Y=V>G17-
MQ;:/INH:G/&EE9W,\7XE>&M1_:]\/>%_C-J6O^$?VT_&'QYT?X>^-G^'/@[P
M?KNG>$/@?K?PKC^ G@Z#X<:;9:[XNTO5_"6B_&E?',NH7.H7&B:'J?QLB^+]
MGXIM]6T^Y^$#Z#:S>;? OP3^V!K?[8'[/US\2/#WQ=\:? [X6?M7O\1/AE\0
M/&_@CXO:,_ACP7\1/^"=O[7/@?Q^VH3?'?QS\0/C!INA6OQ>E\$^&HD\?ZOI
MMU:^)?&-I;Z'X9\.^'O$>E64@!_0S11]*\6\4?\ #0_]O:C_ ,(9_P *8_X1
MCS(?[)_X2;_A.O[=\K[+!]H_M#^R?^)=YGVS[3Y/V;Y?LWD>9^]\RN7%XKZI
M3C4^K8K$\TU#DPE'VU2-U)\\H\T;07+9ROHW%6U,:];V,5+V5:K>2CRT8>TD
MKIOFDKJT5:S?=I=3VFL/6_$N@^&SHZZ[JEII9\0:W8^&]&%TY3^T==U)9WL=
M,ML*VZZNEMIS$AV@^6P+ D9\3_XRN_ZM[_\ ,EU^4_[6GQH^(_BKX@V?A#Q%
MJOA6.Y^%.K2_9[KX>G78M)7Q:RV-Q/?";76-]+JGA^2%--2146WMKI-0CAWE
MYF/Q'%?'M#AG*GCJF69@L14K4J&$HXS#_5Z=>I*49U8NI[5N/L\-&M5346G.
M$8-KG1X&<\1T\IP;Q$L)B?:3J0IT*=>G[*%23:E-<RDVN6DIRO9KFBHNW,C]
MX**^)/@U\5/VC/C'X"TOQKX;D^ YMIY;K3;^VU)/B#%JMAJVF2""\MM2AL7D
MLHKF4&&_06KM;O:WMO+"?+< >I_\97?]6]_^9+KWL)Q+A\?A</C<)EV<5\+B
MJ-/$8>M3P*E"I2JQC.$XM5MG&2;6Z::=FFCT:&:TL31I8BAA<=4HUH1J4YQP
M]U*$TG&2]_JGZJS3U1]$5POCOXG_  V^%UCI^I_$OX@>"/A[INK:C'I&EZAX
MY\6^'_"-CJ6K3(TD.EZ?=^(=1TVWO=1FC1WBLK:26Y=$9EB*J2-;PE_PEW]@
M67_"=?\ ".?\)/NN?[1_X1/^U/[!V_:IOL?V/^V?^)CN^Q?9_M/G\?:O.\K]
MSLK\Y?V\OAS/K?Q$^%/Q&T;2?CAH_BOPO\._BYX$T?XB?#CX$>$?VK/AZ^D?
M$?5?AW>^)/AA\5_@)K&F:WXKFL?&4W@?P]J>D>//!B>$)--L]!\1>&/$'Q&\
M/:5XA&EZ[[]*I[6E3J\E2G[2$9^SJQY*L.:*ER5(7?+.-[2C=VDFKL]*$N>$
M9\LH\T8RY9KEG'F2?+*.MI*]I*[LTT?HGJ7COP3H_B/PSX/U?QAX6TOQ9XTB
MU2;P?X8U'Q#H]CXB\50Z);)>ZS+X;T2ZO8M3UV/2+.2.[U.32K6[2PMI$GNS
M#$RN>4TGX[?!'7_B#JWPET+XQ?"S6OBIH,MQ!KOPTTCXA^$-2^(&BS6=JM[=
MQ:MX,L]9F\2:=);6;I=7$=YID+P6SK<2JD+!S^"'C*']KW3_ !-\)/BCXM_8
M^UW2/B)\+/@_\ ="\+_ 7X-_"[4O%/P1DBT?X<1^)=.^(E_X_P##E]KVK:#J
M?[)/[0?B'Q='!^S;I/B;2-1\5_".RU2V\(M\=O&^I> ;>S^D?V8_V-/B?XQ^
M-/QN^(?Q6U&?P%\.?"G_  4F^(G[3GPS\'M\'SX6^(GCK58OACX6\.Z!XS?X
MLZEXMN[^/X8>(Y]:UEKCPGH_@72-7OH]*OO!^M^+[_0)]=TO4="C]6?&_P ?
MO@3\,_%.@^!OB/\ &KX2_#_QKXICLIO#'A#QM\1_!OA3Q1XCBU+4I=&TZ70?
M#^O:U8:OJ\=_J\$VE63Z?9W"W6I126,!DNHWB7J;/XB^ -1\:ZO\-]/\<>$+
M[XA^'],M=:U[P)9^)M#NO&>B:/?"V-EJVK^%H+^37M-TV\^V6GV6_O=/@M;C
M[3;^3*_GQ;_SA_:RT+XDZ%\7/''C3X*V'[32_&CQ)\*/AAH?PIM/!7PM^%?C
M/]G[Q[XR\#>(/BA=Z%X<^+/C?7_#FO:UX*\,07OCMX_B$/%WB7X8:1I_A:^3
MQ1\,=8USQ[#<?V+\T:E^S[\</$+:1\'/!OP\\7^ /VA/"G[4'[>OQB\4_M07
M7@>PTSP3JOPV^/W@K]JW3_A9J>E?%JWN&D\6:CKG_"X_V?\ PG<^!;2YO/%?
M@M_A3)>Z[H6DZ7\./!]_? '[9^#_ (C_  ^^(/\ ;H\!^.O!WC7_ (1;6;GP
M[XF_X1+Q1H7B7_A'O$%GD7>AZ[_8E_??V1K%J0?M.F:C]FOH,'S(%P<;&B>)
M_#?B6+49_#GB#0]?ATC6]7\-:M-HNK:?JL6F>(O#]Y)IVO:#J$EA<7"66M:)
MJ$4ECJ^E7)BO]-O(WM;VW@G1HQ^6G[&?P\\4P_&'X<>*=$^"OC/X"^"/A=^P
MSX*_9V^*'A[Q;X,B\"Q^*?C#H/B[PWJ7AK1M C@;[-X\T?X,Z+HWQ'M;?X@Z
M(=4\#:JGQ<CB\&>)]=,WB*/3/CNP^#O[8&F:W\7M \(Z?^TA\,_">M>+O^"W
MOQ@A'PVN-4\%IXI^*&I_'WX#^*/V.M9N]3T^$W.H3^+K&Z^(^M?#>R$B6?C3
M2T\26.J0ZKX<N-8T?4 #^@_6/$_AOP]-HEMK_B#1-#N/$NMP>&O#D&L:MI^F
M3:_XBNK*_P!2MM!T6*]N()-5UJXT_2]3OX-*L%N+^:STZ^NH[=H+2XDCV@Z,
M,JRL#T(8$'C/4'TY^G/2OYF/B5X4_P""@?Q;T[X*>+M0\#?'?4_VN/"W[2NB
M_%_PW8^)-#U&Q_97\ >$I?V)?BQHWPDU0Z-/Y?@W0M9T7XS>,=+T7XH6^T_$
M#3/B%>^)XO&3)\)D\,D>R^!=/_X*$#X)^)7\)^)?CWK7Q.7Q+\*[WX?:1XR\
M+?%;P5!:ZQI?@3XA/^TS;>.O$OQ\\3>*]:UBP\8^#I['1/AI::9I&G?!OPE^
MTVGPV\1_#.?4?!#^*QH0!_0)17*>!+R'4?!/A#4+>T\56-O?>%_#]Y;V7CJ'
M4+;QM9V]SI%G-#:^,+;5WDU6W\4VT3I#XA@U-WU"/6$O5O'>X$C-U= !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7@/[0_[+?[/_ .U?
MX/MO G[0OPL\,?%#PWI]\=4TFWUZ"Z@U'0]2:+R9-0\/>(-)NM.\0>'[V: "
M"XN-'U.R>ZMP(+KSX0(Q[]16M&O6PU6%?#UJM"O2DI4JU&I.E5IR6TH5(.,X
M271Q:?F8XC#X?%T:F&Q5"CB</6CR5:&(IPK4:L+IN-2E4C*$XMI7C*+3MJCY
M+_9G_86_9._8^_MR;]G;X*^%_AWJ?B6"&TU_Q%#-K/B'Q7JMC;S?:(=-NO%?
MBO4]<\0_V3'<!+A=)AU&'3#<1Q7#VCW$:2K]:4456)Q6)QE:>(Q>(KXJO.W/
M7Q%6I7K3Y4HQYJE24IRLDDKMV226B(PF#PF H0PN!PN'P>&IW]GA\+1IX>A#
MF;E+DI4HPIQYI-RE:*O)MN[84$ \$9'H:**P.D3:HY"C.<YP.HX!^H'%<=XY
M^'7P_P#B=X>N/"7Q)\#>#_B#X5NYH+B[\,^-_#&A^+/#]U/;;_L\USHOB"PU
M'39I8"[F&22V:2+<WELNYL]E10!CZ#X>T'PMHVF>'?#.B:1X>T#1;.'3]'T3
M0],L=(TC2K"V&VVLM-TS3H+:QL+2W7Y8+:T@AAB7A$45KX'H.,XXZ9Z_GW]:
M6B@ P.N!GU_3^7%-VKG.U<XQG SC&,=.F.,>G%.HH .G2BBB@ HHHH ****
M"BBB@ HHHH *^3/%7[$O[/7C+Q+KWBW7O"VL7.M^)=7OM<U>XA\8>)[2*?4=
M1G:XNY8[6VU*.WMT>5V988(TBC!VHH4 5]9T5Z66YQFN35*E;*<RQN6U:T%3
MJU,#BJV%G4IQDIJ$Y49PE**DE)1;:OK:YY^893EF;4Z=+-,OP>84Z4W4I4\9
MAJ.)A3FURN<(UH349.-XN22=G:Y\X?##]E'X*_!_Q4GC/P+X>U/3=?CTV^TE
M+J[\3:_JL0LM1:V:[C^R:C?7%L6<VL.V4Q^9'M(1@&;/T?116>89GF.;5UBL
MSQV+S#$JG&DJ^,Q%7$UE2@Y.--5*TIS4(N4FHWLG*32U9> R[ 970>&RW!87
M X=SE5=#"4*6'I.I)14I^SI1A'GDHQ4I6N[)-V2L4445PG:&!Z#_ #_^H?E3
M2JGJJG&,9 /0Y';L>1Z'FG44 )M7.=HSSS@9YZ\^_?UH*J1@@$8Q@@$8],'M
MP./:EHH QM&\.>'_  [_ &K_ &!H>CZ)_;NLWWB+6O[(TNQTS^U]?U/RO[1U
MS5/L-O;_ -H:Q?\ D0?;=3O/.OKOR8OM%Q)Y:;=G QC P,8'88Z?EVHHH :5
M4]54]>H'?KV[]Z7 ]!U)Z=SU/U/>EHH 0JIZJ#T'('0=!^';TI-J\?*O'3@<
M<YXXXYYX[\TZB@!NU>?E7GKP.?KQS^-+M7IM7 Z# XSP?S'%+10 W:N2=JY(
MP3@9(QC!XZ8 &/08I0JCHH'.> !SZ\=^3^=+10 4444 (1D$<C(QD'!'N#V(
M['L>:^7+G]B_]FZ\N;F\N_AZ]S=WEQ/=W5S/XL\:237%U=2O/<W$TC>(2TDL
M\\DDLKL27D=F)R:^I**\['Y1E6:JDLTRW 9BJ#FZ*QV#P^+5)U.3VCI+$4ZG
MLW-0@IN%N91C>_*K<V)P6#QG(L7A,-BE3YG36(H4JR@Y<O,X*I&7+S<L>:UK
MV2=['F/PT^#OP\^$%KJMC\/-#ET"RUNZM[W4;0ZQK6IP37EM ;:*YCCU?4+]
M;:8VY6&9[80FXCA@6?S/(BV>G445TX7"87 X>GA,%AJ&$PM%-4L/AJ-.A0I*
M4I3DJ=&E&%."E.4IM1BDY2E)ZMLTHT:.'IQHT*5.C1@FH4J4(TZ<$VY-1A!*
M,4Y-MV2NVWNPI"JM]Y0<=,@'KUZTM%=!J-*(>2BD\#)4'@=!T[9./2G  = !
M]*** $*J2"5!(Z$@$CG/![<\_6C:N=V!GUP,]N_7L/R%+10 @55Z #/7  _E
M1@>@[]O7K^??UI:* &[5SG:N?7 SV'7'H /P%*%4=%4?0 =L?RX^G%+10 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445P?CO_A9OV73
M_P#A6G_""?;/M4O]J_\ "<_\)#]F^Q^0?(_L_P#X1[]]]I^TX\W[3^Z\C[G[
MS% '>5XI\1/VA_A%\*=;@\.^/O%$OA_5KK3XM5M;>30/$=['<V$TT]NMQ!=Z
M;I-Y:2!9[::&6-9S+"Z 2HF^,MB?\95_]6^_^9*KY6_:O^$/QT^(?@1_%7BN
MQ^$UQ/\ #BVU/7(CX)'C3_A([K2)(8SK5A$NM(UC<6T<,$6L/"Y2</IA%HWF
M3213 'U9X0_:F^!OCSQ'I?A+PEXSEUGQ#K4TD&G:=!X:\5PO,T-O-=SN\]UH
MD%M;P06UO-///<310Q1QDNX)4'Z#K\@/V+_A%\6K2QN?C+X+L_AS_P 3B+4/
M#6B2>/\ _A*#.EA;74/]JZKHR:!%Y(@U"\@_LPW,\IF9-,N4@5+>XD:;[Y_X
MRK_ZM]_\R50!]#5@>*?%?A?P-X=UGQ?XU\1Z#X0\)^'-/N=6\0>)_%&L:=X?
M\/:%I5FGF7>IZSK>KW-GIFEZ?:Q_/<7M]=06T"?-+*B\UQW@;_A<W]HWG_"R
M?^%8_P!E?8E_L_\ X0?_ (2S^T/[1^T)N^V?\)!_HWV+[+YFWR/W_P!HV9_=
M[J\%_P""@O@+6_BA^QS\>/A_X>\'7'Q!U3Q;X0MM%3P3;Z0NOGQ1:77B70/[
M4T6XT217BU:POM*2^BU/3YD>"[TXW<,RM$S@@'U-?^,O".E7&J6FJ>*?#FG7
M6A^&V\8ZU;7^N:79W&D>$DDO8G\4:I#<7<<FG^'4ETW48VUR[6'2UDL+U#=!
MK6<1\MXA^-/P>\(^'_"_BSQ5\5OAMX:\+>-AIY\&>)?$'COPKHN@>+?[7LXM
M1TG_ (1C6=3U:UTW7_[4L)X+[3O[)N;P7MG-%=6WF02I(WXP>)OV?_VGO#WQ
M9^-_P4\*?#V^\9>$[SX$_ OX!?!_XF^./[:F^%OBGX#>)?VB_BYX\\2?#7XA
M>)M$BU7Q/IE[\(?@M:^(/@MXHN9K?4=6\0Z7K7PD\5>;>:GXYUA-/X^'X&_%
M/PCX(^%>B>/_ (=_&'X?_%']G?1OVE?V;O!GC+X/? /3OVN_V<O$7P.\9>.?
M _C;X>_"O4_@SXWT9_'^J^!+KX;0?#3PAH7Q$\/1?#YK.\^&'Q"\">,?B!H5
MJ;73=3 /W!N?C]\"[/XC#X/7?QG^$]M\6R=/7_A5MQ\1O!L/Q&SJMG;ZCI@_
MX0>76E\3DZCI]W:WU@!I9:\L[FWN;82P31NW?0^*/#5SXDU'P;;^(=#G\7:1
MHND>(]5\+0ZOI\OB/3/#WB"]UC3=!UW4-#CN6U2RT;6M1\/:_8:3JES:16.I
M7NB:O:V5Q//IE['!_.'H_P /_C#K'PX_;^^#WQ!_8U\;^&_VA?VH_!O[,B?"
M+1_ 7P@UZX^!/PU^*5O^P;^SK\+K/Q%X:^/TEM=?#_P+X;_9O^-GAB\U2/4'
M\=R>+_"8^'3R>"X?%.O6NAOK'>_M!?LY?ML^.O''Q^^*?@WP3X=BF_::^&O[
M3/[)5CJVF-XRT?XS6_@^/X91Z7\"M?\ B1#?:98>$?"/P^U7XB? O6;G0-:L
M-<>7P5_PUWJNOWEMI<=UKUQ:@'[R^!_B9\.?B;9:EJ7PX\>^"_'^G:/JD^B:
MO?\ @GQ5H'BRRTO6K54>ZTC4;K0-0U&"QU2V22-KC3[J2*[A5T9X55@3QNF_
MM(?L\ZSXR\0?#K2/CO\ !G5?B!X2?74\5^!M-^*/@6^\8^&7\+I._B5?$/AB
MUUZ76]%;P\EK<MKJZE8VS:0MO.VHBV6&0K\+_LP7OAOXE_MC>/OB9\'? >J_
M!SX:_#K]F_P=^S[\2?A]XE\$V/PG\37'Q6TOQHGCCP9X?N_AI&;?4H=,^"OP
M[U75-%TGQDNFMX&\0V_Q1^P?#;Q+XITG1]6GT_\ -/1/@W^T!#\1O&>EV'@/
MX^:WK7AK_@HO^W)\:_#'P\U3]F*7P+\-_"OA?X@>*_VEIO"GQ^\,?M2#PQIL
MGCO4?^$=\>V?BKPAX'3Q;XKC\;ZQXCL/ %YX333O+U/0 #^FC1==T3Q)H^D^
M(?#NL:7KV@:_IEAK6A:YHNH6>JZ/K6C:K:17^EZMI.IV$UQ9:EIFI6,\%[87
M]G/-:7EI-%<VTTD,B.UZ"ZMKJ&*XMKB">"=0\,T,T<T4J$X#12QL\<BD\!D9
M@3P#7X _"#1/VY-4T[X"^&O'H_:YT?XH7.F_L)Z/9^1>WWACX(:?^S;=_L\_
M![3OVT%^+^I:++I^D:)^T%9>/I/VCA8W>J7%E\8-&\<Q?!"\^%TEKX>M];E3
MYM_9^^%O[?/PB^#_ .R=\%O!DG[1/POT+X2_L[_#KX>P6>N>#/CY\1;S3?VM
M=!^)/B:+XU-K<NE^-_#O@SQ-\(K;P8?A='\+KSXL:W>_LSZEX6F\>P^"+^Q\
M0V,L4(!_3UXC\4>&?!^D77B#Q;XAT+POH-B]I'?:WXBU?3]$TBSDO[ZUTRQ2
MZU+4[BULK=[W4KVST^T6:=&N;Z[MK2$/<3Q1OM[T(R'7&2,[AC*G!&<]0>".
MQZU_/'^TE\//VF_BU^SK^U1X#\3^&?VN?%/QYU_QAKXUG0].T]M8_9R/A32_
MVX/A?K7P%U#X(:?K%O<Z/=:YH/[/^G6^OZ;<?#RRN?(L],\?7/[1]O-XZC\,
M6[=/XE\!?MP:A\=OBE\+[/Q3^U]8? ;P??\ [=DOPU\4:5XP\2P:IX@A/[/_
M .P/X_\ @!#<?$MEF\3>([6V^//B?]IG2OAJ+S4)I)H]!\4_#J>74?!VB7N@
MW0!^]E[?V.FVEU?ZC>VEA8V-M/>WM[>W,-K:6=G:PO<7-U=7,[QPV]M;V\4D
M\\\SI%##&\LCJB,PKZ-K6C^(M)TK7M U;3-<T/7=-L=8T76='O[34]*UC2=3
MM8K[3=4TO4;&:>SU#3M0LIX;RQOK2::UN[66*XMY9(9$<_S\PS?M]?$70--D
M^(GA_P#:4B^,?C+2_AA/K?A=-#U+2_V<3^S7XH_8G\-O\;O#WBGP]9)'X/L_
MC</V@;WXEZ;;:),B_&&P^* \%66@I'\$X[H' ^%3?M;? _X4_!1O%A_:+^%>
ML?!KX9_L4S:(^JV4>G_LJ?#S]D3X?_LG?";_ (:Z_P"%Y:>\D'@Z#XK^$/&6
MC_M"D:9XOGM_B3!XDT[X*V_@B>U\$_\ "27,8!_1L&4]"#[CD'KP#T)P,X!R
M!SC%.K^8+]GGXW_'CP3X(_X7GK?C/XN>*/V@;#0?V0M8O?@'\3M7^)%[XJ^,
M/A[X@6/Q"^!GB7Q=HFN_$"P\*^!E\(_$CXQ?%WP]\5?#GP8^'-O=Z#\.->^$
M\T?AK6]8L?&=AIEE_2;\/?#^K>%/ G@[PQKWB+4?%^N>'O#&A:+K7BO5YI)]
M4\3:OI>EVMEJGB"_EE9G>ZUF_AN-2FZ*K7)1%1$5% .PHHHH **** "BBB@
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M0 W:N<[5STS@9QC&,X]./IQ39(894>.6*.1'1HW21$='C92C(RL"K(RLRLK
MJ5)4@@D5)10!X_X8_9[^ O@IH7\'?!/X1^$WM_$UOXU@?PU\-?!6@O#XRM;/
M5-.MO%L3:3H=FT7B:#3]<UJQAUZ,KJL-GJ^IVT5VD.H7:3>P=.E%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
A110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>48
<FILENAME>tecfidera.jpg
<TEXT>
begin 644 tecfidera.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" !2 7(# 2(  A$! Q$!_\0
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M.BJO:4XJ75HYW5]=U/Q7JBF>1W:1]L,(.%3/8"NMM/A',]INNM2BCG(SL7D
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$% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>49
<FILENAME>tecfiderachart.jpg
<TEXT>
begin 644 tecfiderachart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $R 3T# 2(  A$! Q$!_\0
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MI=]\I^&_^"._PC\$^$='\*>"_%7A_P /6O@ZX\"Z7X4BM/V=OV?H=*\4> O
M&G>(-)T;P=^T/I>F^#-*D_:0C-OKUIJ[WWCS4;2S@\;^"O 'Q$LM!M_&VA:C
MK6N^A?!W_@EK\-_@AX?^)7AOP1\2O%EGIWQ"^#?B#X-)'+X)^$EY8:!H6O\
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MC:>'%M?BUXATX?"SX<Z7#JWB^VALI=#\(6T;Z"?$6N>*?$VN>G?M=_LO>/\
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M'[=?[.$+36">)_%L_BF#QOKWP^F\ 1?"3XOR?$BUU[PUX2T/Q]J^H:A\.XO
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MB;J7PU\<_#?Q5\8O GAOX>>$H-*^%/@OXV3?$S7OCEJMO;Z#I/PLN_A_\1O
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M\+:_HG[3OPZ\%ZZ/VW_A/HGPUU3P'\;/#WPOU[PS\.]$^%:>'/BWXFO'TY?
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M8;!O+Y8.--8>=67M/K,<2Y.?M6[<KHKEY;?$[WT%HHHK\Q/T<**** "BBB@
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M9O\ OU)_\37X/?\ "8^,/^AN\5_^%-KO_P L*/\ A,?&'_0W>*__  IM=_\
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M /*23_@A3_V=;^U!_P"L<_$&N=_X.!?^30?A9_V</X7_ /5<_$FNB_X*3_\
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M+8-'_#<7@W_H0?%W_@UT#_XJOS;HK^E/]6LI_P"?%3_PHK>7]_R_%]S^>?\
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MI^TC_P!A/X??^JF\!U^(?1:_Y+S.O^R1QO\ ZN<B/V?Z3'_)$9/_ -E5A/\
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M]&?^(@<!_P#1;<(_^))DW_S:?Y_?ZA\<_P#1&<6?^([G'_S'YK[SW^BO /\
MAJ#X+_\ 0;\8_P#AF_C7_P#.[J$?M3_! SM:CQ%XJ-TL*7+6P^$7QF-RMM)(
M\*7+6P^'WGK;/-')"EPT8@>:.2%)&DC=5/\ B(' ?_1;<(_^))DW_P VA_J'
MQS_T1G%?_B.YQ_\ ,9]"T5X!_P -0?!?_H-^,?\ PS?QK_\ G=T?\-0?!?\
MZ#?C'_PS?QK_ /G=T?\ $0. _P#HMN$?_$DR;_YM#_4/CG_HC.+/_$=SC_YC
M\U]Y[_7]F?\ P0:_Y,7D_P"RW_%/_P!"\.U_";_PU!\%_P#H-^,?_#-_&O\
M^=W7]-__  2._P""S?\ P3@_9J_9.?X<?&WX^Z]X%\:'XJ_$#Q$-#N_V>_VG
M-4F_L;63HATR]^TZ#\&=5L@EU]EN-L1N?/3RSYL:$J#^&?2&XKX7SGP^6#RC
MB3(,UQ?]O996^JY;G&78[$^RIT<<IU?887$U:OLX.<5.?+RQ<HIM75_VGP%X
M7XFRCCMXO-N'<]RO"/),PHK%9CE&88+#^UG7P,H4O;XG#TJ7M)QA.48<W-)1
MDTFDS^N=NA^A_E7\)/\ P5U_Y2*?M(_]A/X??^JF\!U_0<?^#AS_ ()!$'_C
M*[5.A_YMJ_:V_P#G#U_);_P4<_;X_96^.7[:7QO^*GPK\>^*O%G@'Q9?^#IO
M#WB&V^"'Q\L(-2BTOX=^$=$OGCM-6^%]AJ$(M]4TV]M&%S:0EF@9XP\31R/^
M.?1MSG*,DXUS?%9SFN6Y1AJG"V+P]/$9GCL+@*%2O+-LFJ1HPK8NK2IRJRIT
MJE14XR<W"G.2CRPDU^M_2%RC-LZX/RK#9/E>8YMB:?$N%KU,/EN"Q./KTZ$<
MKS>G*M.EA:56I&DJE6G3=245!3J0BWS3BGY%17@'_#4'P7_Z#?C'_P ,W\:_
M_G=T?\-0?!?_ *#?C'_PS?QK_P#G=U_:W_$0. _^BVX1_P#$DR;_ .;3^._]
M0^.?^B,XL_\ $=SC_P"8_-?>>_T5X!_PT_\ !<D :WXR))  'P;^-9))X  '
MP[R23P .2:AM_P!J?X(74$5S:^(O%5U;3H)(+FV^$7QFN;>>-ONR07$'P^DA
MFC;^&2*1T;G#&C_B(' ?_1;<(_\ B29-_P#-H?ZA\<_]$9Q7_P"([G'E_P!0
M?FOO7<^A:*\ _P"&H/@O_P!!OQC_ .&;^-?_ ,[NC_AJ#X+_ /0;\8_^&;^-
M?_SNZ/\ B(' ?_1;<(_^))DW_P VA_J'QS_T1G%G_B.YQ_\ ,?FOO/K7X9_\
ME+^&O_92/A]_ZF>AU_I0+T/^\_\ Z&U?Y:?@7]K#X%Z/XY\#:OJ/B+QA;:=I
M'C?P;JVHW+?!GXW.MMI^E^)])U"_N62+X<O*ZV]G;33%(D>5PA2-'D*J?[A1
M_P '#?\ P2"&0?VKM4^\W_-M7[6IX+$CI\!R.GO7\E?2:S[(L\Q7!TLDSK*<
MXCAJ.>+$2RK,<'F"P[JSRGV2KO"5JRI.I[.HZ:J<KFH3<;\KM_4OT<LBSO),
M/Q9'.<GS7*)8FMD[PZS/+\7@'75*&8^T=%8NC2=54_:4^=PYE#GAS6YHW^P/
M^"F?_)@O[6'_ &1CQ7_Z+MZ_@2?[[?[S?S-?T^_MU?\ !=3_ ();?%_]D']H
M;X9_#K]I/6?$OCCQK\,/$.@>%]!@_9T_:GLIM5U>]2%;6RCNM4^"-C80-*5;
M$EU=P0KC+R*.:_D";]J#X+%F(UOQC@L2/^+-_&OH3_V3NOI_HU\3<.9)PMGM
M#.N(,DRBO6S^5:E1S3-L!@*U6E_9V!A[6G2Q>(I3G3YX2ASQBX\T91O>+2^;
M^D/PWQ%G7$^2U\GR'.LVH4LC5*K6RS*\=CZ5.K]?Q<_95*F%H580J<DHRY)2
M4N6496M)-^_45X!_PU!\%_\ H-^,?_#-_&O_ .=W1_PU!\%_^@WXQ_\ #-_&
MO_YW=?T=_P 1 X#_ .BVX1_\23)O_FT_G[_4/CG_ *(SBS_Q'<X_^8_-?>>_
MT5\]R?M3?!")X(Y?$7BJ*2YD:&VCE^$/QFBDN9DADN'AMHY/A\KW$J6\,UP\
M4"R2);PS3LHAAE=)?^&H/@O_ -!OQC_X9OXU_P#SNZ/^(@<!_P#1;<(_^))D
MW_S:'^H?'/\ T1G%?_B.YQY?]0?FOO7<]_HKP#_AJ#X+_P#0;\8_^&;^-?\
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MQ^&K8/%4XU<WQU6FZF'Q$*=6"J4YPJ0<H)3A*,XWC)-_:U%%%?D)^K!1110
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MT>K?]]O_ /%4;1ZM_P!]O_\ %4ZB@!NT>K?]]O\ _%4;1ZM_WV__ ,53J0D
M9) 'J3@?K0 QDR!C=D,AY=NBNK'J<'@=.]?-'[&OPQ\5_!O]ECX"_"SQU:6]
MAXP\!?#+PSX9\1V=EJ,&IVMMJVF6ABNXH-0LW>UO(DD.$N(&:-QRAP!7TT2
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%H ?N^"#T(/)''J.H^H[T5_/=?\ _!0S]H7X:?%OQKXR%A:>*/V;OA5\/?\
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M/_@R_P!;T30K^^F\7Z'\;/B;K/P@MEAM([+1+'X9?$CQUJ<>L?\ "-Q^%M4
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M>'O#%O\ #[PM#HNB^/K%0EMXVTVP32Q#:^+4BW6[^(HU&KSVDDMG<7DMI+)
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M=6CR&VDU&"*[\H3H'KUZB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
+ "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>50
<FILENAME>teclitigationchart.jpg
<TEXT>
begin 644 teclitigationchart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #P 3T# 2(  A$! Q$!_\0
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MWXV\4_#[X>:%;^'[[P_?%+_0&\.W?C?3K&TL_$'B?P;JN@^*=-M9-1/A35]
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MH7A-='=K[3_"6H_$[2[#5O&S>(HK<>--&\5^";?1);OPSJFHQ_:M?GK\+_\
M@FO\ /@O^TSX#_:1^&-Y\2_#=S\/_A!\3?A/I'P[N_BY\7O%O@;R_B?XT\(^
M,=5UX:9XU^(?B*VM?LL_AJ^CB\+VUDOA6[U37G\676F-XIT+P[JFG?H50 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 9'KUZ>]%?D-^WS\7OBAX!_;V_X(Y^ O!7C_P 6>%O!7QC_ &D?VA_#
M7Q4\+:%K-UI^A?$+0/#W[+/C7Q7H6D>+=/@80ZUI^D>(["TUK3[6[#Q6VI01
M7:*)HXW7](/BYK6K:)X9TZ[TB_N-/N9=6MH9)K<H)'A:QO9&C8R)(-K/&C'
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MXW*ISC=P/FP2#\OQK_R2N=_]@;_].4QQW7JOS/F>OR\_;M^!_P"T-X_^*_P
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M\+_^2G?_ &+<7_Z=PH='ZK\I'N.1[_D?\*,CW_(_X5@_\(QHO_/D/_ B\_\
MDFC_ (1C1?\ GR'_ ($7G_R37]&"-[(]_P C_A1D>_Y'_"L'_A&-%_Y\A_X$
M7G_R31_PC&B_\^0_\"+S_P"2: -[(]_R/^%&1[_D?\*P?^$8T7_GR'_@1>?_
M "31_P (QHO_ #Y#_P "+S_Y)H WLCW_ "/^%&1[_D?\*P?^$8T7_GR'_@1>
M?_)-'_",:+_SY#_P(O/_ ))H WLCW_(_X49'O^1_PK!_X1C1?^?(?^!%Y_\
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MUG_O_P"'O_E[1_:E]_T+FL_]_P#P]_\ +VMFB@#&_M2^_P"A<UG_ +_^'O\
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M "DD_P""%/\ V=;^U!_ZQS\0:_5+XX?\BAI?_8;M/_3?J%?E;_P4G_Y21_\
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M>/SI::[!59BP4*K,68@*H )+$D@ #J22!CJ0.: /R>U_X&?M 0?M6>-O&Z^
M/BIXK\#>)OBYX)\3Z-XG\+_M[>-/@;X2T;PKIFA^#-(N[/5/V<?A[HFD^%/&
M*Z3<Z+JE]J4WB^[U[Q)\1[6Z_L3Q)JRZ/::+IUC^L0_J>^>Y_P X[=.U?DSK
MU_\ '+6/VI?%,_B&X_;?U#P%!\4_!,?PPOO@7X[_ &,O#7[.Y^'@TKPD]S9^
M*_#GB;XFCXT:[';>)O\ A)Y_'FK7.DMK^N:9>-8^$=*M[>RTW2X?UF'X]3UQ
MZGT[>G?&,\T ?AY_P4NA%Q_P4>_X(60M)-&'_:M_:?!>WFDMYAC]COX@-\DT
M3+(F<;6VL-R%E/#&OU&^,NF16?A73I4NM3G9]9M4*WNIWE[$ ;"_;<([B61!
M*","0 ,%+KT8U^7W_!2?_E))_P $*?\ LZW]J#_UCGX@U^J7QP_Y%#2_^PW:
M?^F_4*^7XU_Y)7._^P-_^G*8X[KU7YGRI1117\KB"BBB@ HHHH *^I_@]I45
M[X1:9[O5(6_M?4$V6FIWMI#A?)P1#;S1Q[SGYGV[F/4G Q\L5]=?!+_D2V_[
M#6I?^T*_1/"__DIW_P!BW%_^G<*/H_5?E(]!_L"W_P"@AKO_ (/=4_\ DFC^
MP+?_ *"&N_\ @]U3_P"2:W:*_HP1A?V!;_\ 00UW_P 'NJ?_ "31_8%O_P!!
M#7?_  >ZI_\ )-;M% &%_8%O_P!!#7?_  >ZI_\ )-']@6__ $$-=_\ ![JG
M_P DUNT4 87]@6__ $$-=_\ ![JG_P DT?V!;_\ 00UW_P 'NJ?_ "36[10!
MA?V!;_\ 00UW_P 'NJ?_ "31_8%O_P!!#7?_  >ZI_\ )-;M% &%_8%O_P!!
M#7?_  >ZI_\ )-']@6__ $$-=_\ ![JG_P DUNT4 87]@6__ $$-=_\ ![JG
M_P DT?V!;_\ 00UW_P 'NJ?_ "36[10!A?V!;_\ 00UW_P 'NJ?_ "31_8%O
M_P!!#7?_  >ZI_\ )-;M% &%_8%O_P!!#7?_  >ZI_\ )-']@6__ $$-=_\
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M (+,?^)IZ#_\YJC_ (<?Z5_TE1_X+,?^)IZ#_P#.:H_XA+FW_0TRW_P'%?\
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M ?T8[T_O+_WT/\:-Z?WE_P"^A_C7XL_\.9;W_I+7_P %J/\ Q-C0/_G+T?\
M#F6]_P"DM?\ P6H_\38T#_YR] '[3;T_O+_WT/\ &C>G]Y?^^A_C7XL_\.9;
MW_I+7_P6H_\ $V- _P#G+T?\.9;W_I+7_P %J/\ Q-C0/_G+T ?M-O3^\O\
MWT/\:-Z?WE_[Z'^-?BS_ ,.9;W_I+7_P6H_\38T#_P"<O1_PYEO?^DM?_!:C
M_P 38T#_ .<O0!^TV]/[R_\ ?0_QHWI_>7_OH?XU^+/_  YEO?\ I+7_ ,%J
M/_$V- _^<O1_PYEO?^DM?_!:C_Q-C0/_ )R] '[3;T_O+_WT/\:-Z?WE_P"^
MA_C7\[?Q<_X);^+? GQ._98\&:/_ ,%9O^"R3Z7\:_C-XN^'WBM]0_;0T6>^
MAT30?V<?CG\6[.30I8_A# EGJ3>)?AKH$5Q//#>QOHTFJVJVR37$5Y:>_?\
M#F6]_P"DM?\ P6H_\38T#_YR] '[3;T_O+_WT/\ &C>G]Y?^^A_C7XL_\.9;
MW_I+7_P6H_\ $V- _P#G+T?\.9;W_I+7_P %J/\ Q-C0/_G+T ?M-O3^\O\
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MOC;6-+\,?$K4?BKXR\&>"-3\"^/]5\,2:'JGB[1[FZU>;3+/Q/>^'LWXF?\
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M?"CQ5XGNO VN:?IL=G<76F>)VM)IVNWBL3<_8;MT^QZ "BBB@ HHHH **"<
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MW[+?[/\ ^SMJ?CG5_B5J'P5^$G@;X;7?C?6HXK>Z\03^$O#]CH[W5K9Q(O\
M9NBPFU^R>'=(FEO;O2- M]-TR]U/5KNTFU.[^CJ** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
D* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>51
<FILENAME>tysabri.jpg
<TEXT>
begin 644 tysabri.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" !W -@# 2(  A$! Q$!_\0
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M)T!2444 +2444 +2444 +2444 +1110 E+110 E+110 4E%% !1110 M%%%
M!4%X\J6<S6Z!Y@AV*3C)[444UN)['/>!M->ST^>XG&)KB0YYS@+D?SS1116E
..>3E4DV8X:"IT8Q78_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>52
<FILENAME>tysabrichart.jpg
<TEXT>
begin 644 tysabrichart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $R 3T# 2(  A$! Q$!_\0
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MI=]\I^&_^"._PC\$^$='\*>"_%7A_P /6O@ZX\"Z7X4BM/V=OV?H=*\4> O
M&G>(-)T;P=^T/I>F^#-*D_:0C-OKUIJ[WWCS4;2S@\;^"O 'Q$LM!M_&VA:C
MK6N^A?!W_@EK\-_@AX?^)7AOP1\2O%EGIWQ"^#?B#X-)'+X)^$EY8:!H6O\
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MC:>'%M?BUXATX?"SX<Z7#JWB^VALI=#\(6T;Z"?$6N>*?$VN>G?M=_LO>/\
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M'[=?[.$+36">)_%L_BF#QOKWP^F\ 1?"3XOR?$BUU[PUX2T/Q]J^H:A\.XO
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M:;X=^-/CM?>*?'.L^ 1\*?V6O"47@?Q5#\7/B]H6K66@?VUX4U'7?"/DW?Q
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M_#SQ?\0;O3;C6+;PCH=YK<VF6D\-M<WL=H%+6\-Q<!H8I'W?*\@*#'(.:_/
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M/XP^(?VF76_B+IOCCQ=H_AY?B%X[B\*Z'KUAI4/B*" 1>&?#OS1_P]#\*?\
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MT] **** "BBB@ HHHH **** /Q _X*4$#_@I'_P0IR<?\96_M/CGU/['7Q!
M'XG@>]?4G_!2QE;X&^#=K*?^+F:/T(/_ #*_BGT^H_.OE?\ X*60Q3_\%(/^
M"%44\4<T3?M7?M/%HY461&*?L=_$!T)1P5)5U5U)'RLH88(!KZ;_ ."D>EZ9
M8_!'P?+9:=86<K?$K2$:2UM+>WD9#X9\4,49XHT8J656*DD$JI(R!7V_AO\
M\ESPU_V,8_\ IJJ?'>(/_)&<0_\ 8!+_ -.TC\3Z***_ND_C **** "BBB@
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M )(%?U-GQ)I2,RM+<AE=U(_LS5>"&((XL2.".Q(]Z_G7Z0'^\\+_ /7K./\
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M'HL>IQRP_#;P*HOT\'^*HM4\1^(KHW/BJ:PLOZ%AT[=3T^I_7U]3F@#\0?\
M@I/_ ,I)/^"%/_9UO[4'_K'/Q!KG?^#@7_DT'X6?]G#^%_\ U7/Q)K>_X*6^
M;_P\@_X(5>1Y?F?\-7_M.8\W?LV?\,>^/_,SL^;=Y>_9VW[=WRYKCO\ @OO_
M &O_ ,,B?"[^T1IWE?\ #0GAG;]C-V7W_P#"N_B-MW?: %V;?,SCG.W'&ZOT
MKP=_Y.=P9_V.(?\ IBL?G?BS_P FXXM_[%;_ /4B@?R-T445_I\?YMA1110
M4444 %?V9_\ !!K_ ),7D_[+?\4__0O#M?QF5_8__P $)_[7_P"&&G_L\:=Y
M?_"[_BIN^V&\#Y_XIK&W[."N-V_.>VW'.ZOY]^DQ_P FU7_9195_Z8S _=_H
MZ_\ )PY?]B#,O_4C+S]N&Z'Z'^5?PD_\%=?^4BG[2/\ V$_A]_ZJ;P'7]RK?
M\)/@\:%T/?4_3Z5_#)_P5M^T?\/#OVC_ +5Y/G_VIX!W^1YGE8_X53X%V;?,
MP^?+V[L\;]VWY<5^'_1:_P"2\SK_ +)'&_\ JYR(_9_I,?\ )$9/_P!E5A/_
M %49T?G)1117]Y'\0A1110 4444 =M\,_P#DI?PU_P"RD?#[_P!3/0Z_TH%Z
M'_>?_P!#:O\ ->^&N[_A9/PWV8W_ /"QOA_LW9V[_P#A,M#V[L<[=V-V.<9Q
MS7^D&W_"2;Y/+&B>7YLOE[SJ6_9YC;-^T;=VW&[;\N<XXQ7\9?2O_P![X(_Z
M\<0?^EY*?UW]%[_=>,_^O^1_^F\T/EC_ (*#^)]2\&?L5?M+^*M'6T?4]"^$
MWB74;%+Z%KBS:X@C@\L7$"2P/+%\QW(LT9/9QUK^*)_VS?B]O;_0_ _WF_YE
M^]]3_P!1NO[(_P#@I3_;O_#!?[5_VP:3Y/\ PICQ3G[,;[S?^73=CS@$_P!7
MYFW_ &]F?EW5_!4_WV_WF_F:^A^B_@<'B^$^()8G#TJTH<12C&52*;4?[-R^
M5DWTNW\[G@_21QV+PG%610P^(J4HSR!2E&$FDY+,,8KM+K9)>ECZP_X;-^+W
M_/GX'_\ "?O?_EU1_P -F_%[_GS\#_\ A/WO_P NJ^3:*_IG^QLK_P"@'#_^
M"UY?Y?U96_G3^V,S_P"@W$?^!O\ K_AWY6^LO^&S?B]_SY^!_P#PG[W_ .75
M'_#9OQ>_Y\_ _P#X3][_ /+JODVBC^QLK_Z </\ ^"UY?Y?U96/[8S/_ *#<
M1_X&_P"O^'?E;ZR_X;-^+W_/GX'_ /"?O?\ Y=4?\-F_%[_GS\#_ /A/WO\
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M(QFDP<9QQTSVSZ4 =M\,_P#DI?PU_P"RD?#[_P!3/0Z_TH%Z'_>?_P!#:O\
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MT'PY8ZSJL_\ PCGAK2[.22SMQ)>ZQK.MZI>S7,7F&I?'#XU:SJ.C:OK'Q?\
MBAJVK>';#6M+T#4]2\?>*;Z_T73_ !)I4V@^(K32[NZU26:SB\0:'<3Z-KQA
M=)=9TF:33M2DN;1C%1/\;_C+<^"D^&UQ\5_B'/\ #R/3(-%3P++XMUA_"*:1
M:Q006^FIX?:Y.F+9P06MM!%"+<*D-O!$/W<2*-<+D^;X:GE]-XF-983,YXV3
MGF>.4OJ]=XJ-7"3<,+&GC:5&%:G+#0KT:5.\8JI%XF@L?7RQ6;95B*N-J+#N
MD\3EL,'%0RW!./MZ/U25+%04\3*I@ZE6=&I'$RH5:DVI2=*4</6^I4,/X: G
MXE?#8 E2?B/\/P&&-RD^,M# 9=P9=RGD;E9<@;E89!_TB!I=Z2Q'B'65!>0A
M5BT':H+L=J[M$9L#H-S,<#DD\U_F\?#/_DI?PU_[*1\/O_4ST.O]*!>A_P!Y
M_P#T-J_E_P"E?_O?!'_7CB#_ -+R4_I+Z+W^[<9?]?\ (_\ TWFA\"?\%+-/
MNH?V"OVKI)-;U2Z5?@SXJ)AN(]'$3@+;$AC;:3;S , 5.R5#M8X(;##^"63A
MG/'#-U95'4]7=E1!ZN[*BCYG95!8?WW?\%,_^3!?VL/^R,>*_P#T7;U_ INV
MR[]L;[)0^R52\4FUPWERH&0O%)C9*@="\;,H="0P^L^BQ_R2/$5M_P#6.7W_
M -F9>?+?29_Y*S(?^R?7_JQQA]??&/\ 9%O?@_?_  R\.:G\6/AZWC+QKI>H
M7WB?0?$Z>)OAU8>"H]+U;QK9:CXCC\3^--!TS1?%/P[LK?P9=HWBW1)IKW4M
M4GT^/P[X?UO2_$WA#4=:\2^*OPFUCX8?&3QA\%EU"T\7Z]X5\9Q^"+74=$M;
MNRL_$NIW;:='IDFEV>J>7?6L>J3:I9PVL.H^3<(TJ_:DMVWQQ_17Q4_:I\"_
M%#X6_"KX,7/PM\5:'\.O".-4\1:/8_%74-=U'1]7M;WXGM8Z)\&=5\=Z'XLA
M\!>#Y;?X@6TNM1ZMIWB+6M9L] \,^%+FZ_L[P7HVL7_"_%GXS?#;XF?%?XC?
M&O1_"'CSP1XS\0'3O&/A2UO/'&C>*[#1OBKIWB[P5<:?JRO8>!O# E\+:=X4
MT36B^BZH+B\N?$$VGW<6JBWA.G/^U9/B>+(3PT<VPN)J1E1S:G5G.&4I+%/-
M,)#*J]>.!Q'/2HO!2Q?/1P\<5'#T(0J5\7BZ]2,J?X_F^'X7E&O+*\3AX35;
M*YTX0GFC_P!F66XB>:4:+QE#EJU5C(X90KXAX>5:M4G3HX7#48-3U-=_94L]
M%O-54_'/X=3:)X"^(&L_"WXT>)KK1/%^E:7\,_'&B>&?$?B9M-TVWNK.34?B
MA9^(CX-\7^%_ ][X2MK:Z\5^-?#\^AQZ7IMKJ&EZO=ZGA_\ 8[U+Q/=K>>'_
M !QJGBKP9JGPJ\*_%OPEKW@7X.^-_%_BSQ%H?BOXCZO\+8=.N_AA#J.FZYX<
MU'1_%/ASQ$NL7MUK&H:!_9FFQ:GI.K:K::E;.ERX_:?^$VKZYJDOB+]GO4-2
M\'?$'XN3?'?XT>"HOBS<6]GXW^(EIHGBNS\,Z-X?U%?!27GA/X5:)XB\<>+?
M%-]X1N7\0>(O$#:R/#MQXSLM(TZVDDXWQ9\=/A]XY\6^,]6\7^#/BSKWA[QU
MX5\->'-0LHOC)HGA/6O#Z>$=3^T>']&\)6O@WX7:5\,K7X;:9I$-CH6D_#G5
M_AKJFG^&ELK;6?"^HZ3JT!FN.>G/C27+"7UZ@U1HRE7G1X;Q#;=:A[>$:$,1
M1A+&1E];<:KKTL##+8X&"H8S,\1BZV"Z)QX/C)SBL%73K58QHQK<0T$DJ57V
M,W7GAZLXX22^JJ5-4*F,GF$\;/V^#R[#X:EC/%6\"2S?$34/ %KK-CI/V#6]
M8TJ;7_B3"_PIL]+MM"CN[C5-3\8:?XDN+F]\'26%M87DE]H=W)J.MQW<*Z18
MVFI:S<V=A<7?C'\-;SX.?%;X@?"K4-8L/$-[\/\ Q->>&KC7M+M;RRTW6'M(
M;:==1L+/40-0M;6ZBNHWA@OE2[1>+B.*7=$G:?$7XJ^ OBYXUU'QMXZ^'_BF
MVU'7_$ES-KZ^$OB/!"\G@/3/ ?ASP7X&\,:;<^+/!OB63_A*M#E\/KJ_B?XA
MZXNL7?C9[V>.70]%NT%^U/\ :*^*/A/XT_%?Q5\4O#/A'Q)X+N?'&J76O^)-
M'\0>+])\801ZQ<+;6Z?V%=Z9X0\(266F1V=I$KVNHPZG=R7323"^2$I;K]!A
M*^<SQV6K%86M1PM3)Z_]H1D\OG&AF\:N!]E^^H5_:U83IK'*+H8:G02=*=2,
M)5(TZ'@XJAE$,'F#PV*HU<3#-:'U!Q6/IRK95*EC/:VHUJ'LJ4Z=1X)R]OB*
ME=OVD*<I1IRJ5OV[_P"#>:VFN?B!^U(L5_=V)'@OX2Y>T6R9GSXB\>$;OMMG
M>*-NTA=JKQ(^[<=A3^IZSM)[;S/.U*]U#?MV_;$T]/*V[L^7]AL++._<-WF^
M9C:NS9\V[^6S_@W;_P"2A?M3?]B7\(__ %(?']?U05_ /TA/^3K<1?\ 7C(_
M_5#EA_=7@+_R:_(/^PC._P#U=Y@%%%%?BA^Q!1110 4444 %%%% !1110!^(
M'_!2?_E))_P0I_[.M_:@_P#6.?B#7._\' O_ ":#\+/^SA_"_P#ZKGXDUO?\
M%+8DG_X*0?\ !"J.3=M/[5_[3C_)))$P:/\ 8]\?R(0\3HZX=%/# $ JP*DJ
M>/\ ^"_&DV5A^R+\+9;99U=OVA?#*'S+V^N%VM\._B,QPES<S(#F-?F"A@!@
M$ L#^E>#W_)SN#/^QQ3_ /3-8_._%G_DW'%O_8K?_J10/Y&J***_T^/\VPHH
MHH **** "O[,_P#@@U_R8O)_V6_XI_\ H7AVOXS*_L@_X(3:397_ .PT\ERL
M[,OQO^*F/*O;ZV49/AI2=EM=0H20BY)7)QZY)_GWZ2__ ";5?]E%E/\ Z9QY
M^[_1U_Y.'+_L09E_ZD9>?MNW0_0_RK^$G_@KK_RD4_:1_P"PG\/O_53> Z_N
M7;PSI.#^[N^A_P"8KJ_I_P!?]?PQ?\%;8([;_@H?^T?!%O$::IX!*^9++,^7
M^%/@61MTL[R2MEG)^9S@85<* H_#_HM?\EYG7_9(XW_U<Y$?L_TF/^2(R?\
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M1110 4444 ?B!_P4G_Y22?\ !"G_ +.M_:@_]8Y^(-<[_P ' O\ R:#\+/\
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M'A2Y:V'P^\];9YHY(4N&C$#S1R0I(TD;JI_Q$#@/_HMN$?\ Q),F_P#FT/\
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M97:IT/\ S;5^UM_\X>OY+?\ @HY^WQ^RM\<OVTOC?\5/A7X]\5>+/ /BR_\
M!TWA[Q#;?!#X^6$&I1:7\._".B7SQVFK?"^PU"$6^J:;>VC"YM(2S0,\8>)H
MY'_'/HVYSE&2<:YOBLYS7+<HPU3A;%X>GB,SQV%P%"I7EFV35(T85L75I4Y5
M94Z52HJ<9.;A3G)1Y82:_6_I"Y1FV=<'Y5ALGRO,<VQ-/B7"UZF'RW!8G'UZ
M=".5YO3E6G2PM*K4C252K3INI**@IU(1;YIQ3\BHKP#_ (:@^"__ $&_&/\
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M@?\ !3/_ ),%_:P_[(QXK_\ 1=O7\"3_ 'V_WF_F:_I]_;J_X+J?\$MOB_\
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M !5&T>K?]]O_ /%4I(&,D#)P,G&3Z#U-+0 W:/5O^^W_ /BJ-H]6_P"^W_\
MBJ=10 W:/5O^^W_^*HVCU;_OM_\ XJG44 -VCU;_ +[?_P"*HVCU;_OM_P#X
MJG4A( R2 /4G _6@!C)D#&[(9#R[=%=6/4X/ Z=Z^:/V-?ACXK^#?[+'P%^%
MGCJTM[#QAX"^&7AGPSXCL[+48-3M;;5M,M#%=Q0:A9N]K>1)(<)<0,T;CE#@
M"OIHD @$@$\ $@$GK@>O'I2Y&<9&<9QWQZX]* &[1ZM_WV__ ,51M'JW_?;_
M /Q5"NCYVNK8Z[6!Q]<$TZ@!NT>K?]]O_P#%4;1ZM_WV_P#\53J* &[1ZM_W
MV_\ \51M'JW_ 'V__P 53J* &[1ZM_WV_P#\51M'JW_?;_\ Q5.I,C.,C.,X
MSSCUQUQ0!\Y_&7X<>)_&7Q6_9(\5Z%:P3Z-\)/C?XS\;^-)YK^&VFLO#^M?L
MQ_'WX96-Q:6\SB;49Y/%GC[PW:/:6@>>*VN;B_91;6=PR_1>T>K?]]O_ /%4
MH(.<$'!P<$'!]#Z'V-&1C.1C&<YXQZYZ8H 3:/5O^^W_ /BJ-H]6_P"^W_\
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M:3P=X<\+7-SXHGCL;OQ-KFB?#_PYXNM]9^Q*\-^,O[,W[/\ ^T-/X3N_C?\
M!WX>_%.]\!OKTG@J^\;>&=/UR_\ ";^*;2SL/$I\.WUU&;O1_P#A(+#3[*PU
MH6,T(U2QMHK2]$UNOED _(KQS\;OVP_#OP]^-'B+XN_%/5OA=\;_ -B_]@W]
MG_X^-X'\-0_#J+P5\;?CAXOL_C-JOCBQ\<:<MAJ$7BO0/$>L_#'0/@=;Z1X-
MUCPYX>TSQCK/C'7/ ]RNJWO@B[\/_4NB_%'X^Z;_ ,% /CM\/?%?Q1L+GX?#
M]A?PU\:?A]X /A[1O"_A3X9>(+CXR?%+PI'?:[K=[?ZKJ>O^(I-)T'2X_&GB
M/5O$%GX55-/C&@^&?#=C;ZA<ZI]E_P##+_[.AB^&$,WP0^%MTOP6M[2T^$S7
MW@G0-0F^'EK87%O>V-MX2N;^QN;G1H+/4+.QU*TBM9ECMM4L+#5(%CU&QM+J
M#G[3]C;]E:Q^,,W[05G\ /A7;?&^XU2\UF?XK0^$-,3Q[-J.H"]^V3R^)1'_
M &E(EP^HZA+);/,UH9[VZN! )YY9& /DG]A;7?B7X*\<V?PF^.?B/XG^*_B/
M\0_V=_!/QPTC6O$O[1>@_'[PI<Z/I>K:?X6\83QV^B>!/ NG_#SQ#?\ BGQ9
MIE[;6?A:X^(/@#Q1X?DB?PIXXN&\,ZE81?J;7E/PR^!7P7^"YUQOA'\*?AY\
M,SXEGM[C7SX%\'Z#X6.KO9FX:QCOCHUC9F>VT\WEX=-LF/V+3C>7AL;>W^U7
M'F>K4 %%%% !1110 'H><<=>./?G(X]P17Y8>._%OQP\(_M+1Q_"?XL_$OX]
MZ_X=UKXF^.?CY\++/P[X1L_@7\-/@7#\,/'6K?"?X402VVE'5-*_:#USQP?A
M8GA7[/XWU#QYXPTN_P#''CKQCX;T?X8S>%]'T[]3Z^9M"_8S_95\,?$^Z^-/
MAS]G_P"%6@_%:]\8^(/B%>^/='\(:;IOB6]\=^*Q<KXG\8WNH6D<3W?B;Q"M
MW<#6M;N%DU#4_,_TR>79'L /@;]FWXF?M"^)=4^ 'A_1_P!HBX\=ZW^UI^PJ
MW[3_ (H\0>//#7A/Q?H/P6^)5MXM^ =C)?\ @;PQX0N/ L]AX*\9:1\8O'/A
M[PCX(U75=:T73M9^$^CZC)>ZC/'\03XD\M\)_MP^.]!_X)=?LE^*?B'\5O$M
MK\;/VCO@]K\&J_M WW@^]UJY\)MX6\,^(-;\:_$R]M_!_@FZ\'P>/+BTM--T
M?X>Z!=:1I.@:AX[\0:7J T>;PKX;\06,?ZR#]E/]FM-!^(WABW^!7PJL= ^+
MMU;7OQ/TO3/ ^@:5:^.[FRU-];LY?$ZZ996;ZJ;769KG6+=+AVB@U6]U#4HH
MUO=0OI[C0^$?[-/P ^ G@_6/A]\%O@]\/?A=X&U^>:YUCP?X&\,:=X=\-7\M
MQIJ:1/Y^BZ=%#I_ERZ9&ME) D"0-;@H8SN8D \L_X)[_ !>OOCY^PK^Q_P#&
M/6/$MUXQ\1_$']FWX,^(?&'B>^MY;:]UOQS<_#_0$\<W]Y%+8:9FZF\71ZT;
MB:"QM[*YFWW-@ALI;=V^PZP?"OA;PWX&\,>'/!7@W0M)\+>$/!^@Z1X7\*^&
M= L+;2M"\.^&_#^GV^DZ'H6BZ79QQ6FFZ1I&F6EKI^FZ?:Q16UE96\%M;QI%
M$BC>H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "D) !)(  )))P !R22>  .23TI:HZGSIU]G_GSN__
M $GEIQ5VEW:7WL3=DWV3?W*YQ'_"WOA2"0?B9\/@02"/^$U\,9!'!!_XFO4'
M@UK:+\0? GB.^73/#_C3PEKFHM%+.MAH_B71-4O6@@VF:9;6QOKBX,46]/-D
M$92/>N]EW#/^:C-967GW'^@V7_'Q<?\ +G;#_EM(>T5?K_\ \$,K:VC_ &^]
M!:*UMHG'P>^+ #Q6\,;X:/PQN&]$5L' R,X.!D5_5_%7T:\%PYPSGF?PXNQ.
M+GE&5XO,(X662TJ,:\L-1=54I55F=5TU-Q:<U3FXWORNUC^8.&/I#8SB'B/)
M<AGPKAL+'-<RPF EB8YQ4K2H1Q-:G2=6-)Y;351P4G+D=2">W,K7/[7J***_
MD\_J 3(! ) )Z#/)QR<>N!2Y!Z'/4?B#@C\#P?>OAO\ :-^(/Q#\)?M5_P#!
M/SPIX<U_5-(\"?$[XJ_'KPS\1]-MA -+\31:+^RW\3_&_@_2-4DF@DD,EMXE
M\-)KNFV]K-!<37&DRN1-!!/'7P)KO_!2/XR_"*R^/ 3PGX6^)^A_ _P'^V!^
MUCXI\0^*?%FJ:1K.H_!OX4?M[?M _!W3/ASX)BT#0]1T^348_A5X$TN7P/KN
MJE]+CETZVM-9COK>_P#[0M #]WP0>A!Y(X]1U'U'>BOY[K__ (*&?M"_#3XM
M^-?&0L+3Q1^S=\*OA[_P6%^(OC_X<7DFM>+?BMXS\0_L9?M>> ?A/X-@\&^+
MDT>W@\+:2;/QQI%IH7AG^SM1T?PEX0U'Q6VLCQ1=Z!X3O8/JOP3^W7\?O%_B
M?X=?!R;X':;X6^*_Q ^+NJ^$=.\4?$32?BM\+_AI=^#_  C\(5^,_C&XTW0?
M&7A>#XG2>,+:W2;P-H.G:EI&G:)XFC@U'XG:3J-SH.C:EX2B /UER,;LC;C.
M<C&!U.>F* 0P!4@@]"""#]".*_&+X(?&7]HSXM_\$C_@K\3='^,&@Z9^T1\3
M=-\#6T7C;QEXR\->%I?&%_KGQV&BZOX$\)_$#6O"6O\ AG0O'WQ#\&0ZC\._
MA1XNO_ >MV=MXQU?PSJ9\//+M\CR/3OVO_VA_A[\=/V=OA-'XO\ %/@WP9X=
M^.O[0/A?]K'PE^UNOP^\5^//!OA/PG^QO9_M-^"=%T3XW?!R]\0>%_$W@]?#
MR:CXWTCQU?7MSX^LOM=MX;^(NGSP:%=Z1>@'[]45_//\1/\ @IC^U?XI&B_#
MSX6>%OA]\/OB1JWCO_@GA\1M!\8^*/!_Q'_X07Q7^S]^UK^UOIG[.FLZ'8:-
MXWTW0O&]R?[1GT\)\1[GPWX+N-7\(:WK-YH7A'P;XMTG2[A_HKPY_P %+/B_
MXNG^+VK^%?V7_$>L^'-!TG]I^W^%\.OP^*?A9:ZOXO\ V:O'&I?#JSTOQ=\4
M?B1HNC?"WR?B_P"(]%UI-'MO!FIZU?\ PZN8-(T/Q;)J=WK<FH:. ?L=17RC
M^R=\?]5^.?ASQW:>,%\.:=\1/AEXY'@_Q=X=T?P]\5O!&L:5'J7A7PYXR\.7
M7BGX>_&?P?X2\:>"]3U?1?$4=S:64<WC'PWJNE0V>O:#XUU./4KG3-%^KJ "
MLK4M=T71C"-7U?2]+-P', U'4+.Q,PBV"0PBZFB,HC,B!RF[9O7=C<N=6OR
M_P""H\<;ZG\%M\<;XL?'V"Z(Y&;KPEG!8'&<#..N*^HX-X>AQ5Q'@,BJ8J6"
MAC5BY/$PHK$2I_5L'B,6DJ3JT5+G=#V;_>1Y5+FUMROYOBW/I\,Y!CLZAAHX
MR>#EA$L/*JZ$:GUG&X?"N]54ZKCR*NYZ4WS./+I?F7ZK_P#";^#?^AL\,_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
F%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>53
<FILENAME>unconsoljointbusinesschart.jpg
<TEXT>
begin 644 unconsoljointbusinesschart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $R 3T# 2(  A$! Q$!_\0
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MI=]\I^&_^"._PC\$^$='\*>"_%7A_P /6O@ZX\"Z7X4BM/V=OV?H=*\4> O
M&G>(-)T;P=^T/I>F^#-*D_:0C-OKUIJ[WWCS4;2S@\;^"O 'Q$LM!M_&VA:C
MK6N^A?!W_@EK\-_@AX?^)7AOP1\2O%EGIWQ"^#?B#X-)'+X)^$EY8:!H6O\
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MC:>'%M?BUXATX?"SX<Z7#JWB^VALI=#\(6T;Z"?$6N>*?$VN>G?M=_LO>/\
M]IQ/ 6CZ-\<S\//A_P"&KK6-2\;_  LU3X5^%OB;X ^,>HS'36\*I\2=-UO6
M-!U#6?#G@RXM;[4[3P.VIMX+\3:Q>VEYXYT+Q+;Z%I%C;@'@3_\ !2^UU;P?
MJ/QA\)?"26?X)?#+X1?LX?&+]H;7/%WC>'PQ\1/AIH7[2'A;2O']AI.@> K+
MPUXATKQ9KWPL^'&MZ1X\^*%KK7C7P1 -(U*WT[P1<^*]=2YLH/6+O]MJ_L/V
M@/VC?@MJ?P5\3Z#I/P%_9C_X:,TWQGXB\0Z)I\WQ-M;7QI\4?!FIZ=X>\,6:
MZG>:'X96\^&LKZ)XN\3ZAIU]XB6_FO;7PE;:#;:9K>O5/&_["</Q%U'6;CQ1
M\7_$R:/\8/"GPI\.?M7^%= \+>%=(\/_ +0<_P )!LTO5 MQ'JFJ_#%O%FF[
M?!OCZS\*:I>0Z[\/K73?#VG2:'JM@GB>2-_V./BM/^UGXU_:;E_:=U.TL_&W
MPPE^"%SX#T7X2>$]+N-%^%=GXD\>^,_"]GH/CF37]0U&U\:^&_%7CZ^U2'QE
M=Z'?6^H1:=IUI>>&MHN)I@#J/V,OVI?$/[2NE>*;GQ:/@1IFLZ)IO@;6;;P[
M\'OBAX_^(>HVND>,],U"_MM6\0)X_P#@Y\()5T#49[*6S\'>+O"MOXI\(>,F
MTSQ ^F:XCZ1+ VWXS_;Q_9C^',_CZ/X@>-]>\$6GPZ\)_$CQSK&L^+?AG\4/
M#OA_6O"OP>NK:T^*>L> =>U?P=9Z3\2;7P$]Y:W/B,^ [OQ ;;2Y'UJW%UHU
MM=ZA;]!\'_V=-8\"_$'7/BW\2?BUXD^,WQ+U'P+H/PKTKQ#J_AKPEX)L=$^'
MOAS7M3\36]C'X?\ !5A8:;?^(]>UW4VU/Q9XBNR+>]GL;"V\.:#X2TM+K3KO
MX$^(/_!&7X7?$BZ\9WWB'XN>+9]7\2>'/VH_!]IXQ?P)\-IOB9/X<_:KT35-
M-\5V_P 0OB>VC)XU^*U[X+GU*&'X?77BG58K/1?#FCZ+X?N=+OY;$:TX!]N7
M'[=?[.$+36">)_%L_BF#QOKWP^F\ 1?"3XOR?$BUU[PUX2T/Q]J^H:A\.XO
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M7_@H=^WM>_LVR^&_!WPQ\7?"O2O'&A^/_P!FC7/C!+\0=3TN9?#_ ,)/B_\
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M70]=U5;@^,M)BLOC_P#X7WIW_0O:K_X,[+_XQ5(?M;?M'2_"KQK\%]4^,/Q
M\1?#_P >6'@32-:TGQ-XO\3ZZUOH?P\DO3H>@Z,U]K+VVF:%=P7D>GZ[I*V<
MUEJNF:9HU@8K>WTNW0?.9))))R3R2>I/J:]C ^(''-)XQXS-:%1U<6ZU#DPF
M"G"G0EAL-#V4(RP5/V485J=9Q@N=M2YY5)3E)OY[,O!#PDK1R^. X=Q-)8?
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MT:_N0IX3$*5/V=:'O.47S)KELKO[;Q8^D9X=^#.;Y9DG&,<_>-S7+O[4PO\
M9&64<=1^J_6JN$_>U*F.PKA5]K1F^10DN3E?-=M+]OO@1^P%\:_@3\9_VG?V
MB-(^+WPDU7XL?%G4+JW\&7,7P>N_!WA3Q98:KX;_ &?=/OO&/[27AGP#XL\.
MQ>.?B-I&H_"'Q*?!S^#9O"OA_P -W7Q#^(7BFS@0_$G4O"/ACUW]C3]G+]I3
M]E3X!_ ']GS6/B5\'/'NA_"G7_\ A'-<\3:'\,_&'A:^USX/6W@;QQ/;6D5A
MK'Q0\1)IGC^3XIZCX1NWURWDU'0_^$,L]9T<^'8]4O[?7M-_GB_X?6?MR_\
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M#GCO]I'X1^ ;O3],^'_BWQA-J>J^)+FTL==TKPCK6NG]9=+@O+73=/MM1O\
M^U-0MK.VM[[4OLL-C_:%W!"D5S>_8K=G@M#=3(\YMH&,,)D,<7[M5  /Q/\
M^"D__*23_@A3_P!G6_M0?^L<_$&O%/\ @Y5_Y,D^$'_9SGA+_P!5?\5:]K_X
M*3_\I)/^"%/_ &=;^U!_ZQS\0:\4_P"#E7_DR3X0?]G.>$O_ %5_Q5KZO@;_
M )*W(O\ L-7_ *:J'Q?B)_R1/$?_ &+Y?^G:1_$31117]:G\1A1110 4444
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M-<#0X<R/ZOF]'#4<53CEN#HPFL+6]M2<XT:$/:.#<^3F:492O+G@YTJG[+^
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M "5N1?\ 8:O_ $U4/B_$3_DB>(_^Q?+_ -.TC^)RBBBOZU/XC"BBB@ HHHH
M*_NX_P"#<S_E'E-_V<%\8?\ T/PS7\(]?W3?\&[3:N/^">C_ -G)IS)_PT%\
M8MYO7NE;[WA7 46\3C[WF9)/*[, $-7YKXK_ /)*?]U3!?\ IO%'ZSX+_P#)
M9O\ [%&._P#3V#/WY;H?H?Y5_G8?\%L?^4G_ .U1_P!ACX;?^J7^'%?Z%[/X
MHP?W>@]#_P M=2]/^O>O\\K_ (+4FX/_  4Y_:E^U"$3_P!L_#C>("[1 ?\
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MR1,KL ?B=_P4G_Y22?\ !"G_ +.M_:@_]8Y^(->*?\'*O_)DGP@_[.<\)?\
MJK_BK7LW_!2V1HO^"D'_  0J=8I)V'[5_P"TXHCB\O>=_P"Q[X_0D>;)$@5
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M.HHH _$#_@I/_P I)/\ @A3_ -G6_M0?^L<_$&O%/^#E7_DR3X0?]G.>$O\
MU5_Q5KVO_@I/_P I)/\ @A3_ -G6_M0?^L<_$&O%/^#E7_DR3X0?]G.>$O\
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MC?\ @K+_ ,HWOVS/^R#>,_\ T5:U_FY3?ZV7_KH__H1KV?!__D2YE_V-)?\
MJ)A3P/'3_DH<I_[$Z_\ 4S$D=%%%?KA^(A1110 4444 ?U*_\&P?_)3/VO\
M_L0O@K_ZD_Q*K^PNOX]/^#8/_DIG[7__ &(7P5_]2?XE5_877\M^)?\ R66:
M?]>\O_\ 5?A3^Q_"3_D@\G_Z^YG_ .K3&!1117P9^DA1110 4444 %%%% !1
M110!^('_  4G_P"4DG_!"G_LZW]J#_UCGX@UXI_P<J_\F2?"#_LYSPE_ZJ_X
MJUL_\%FOC1\-_P!FW]K_ /X(T?M!?&C7;KP?\'_A=^U!^T3J/C_QI%X;\5>*
M+7PU8Z[^RMXP\,Z3<7NF^#M$\0ZY*M[KFJV%A"MGI=R_F3F5U2W@N)H?R_\
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M>?Y]F?Q[_JEQ7_T3/$/_ (9<R_\ F;S7WGJ]%>4?\+N^&W_03\2_^&S^*?\
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M_AUP'_S1Y_GV9_-?^J7%?_1,\0_^&7,O_F;S7WGJ]%>4?\+N^&Y( U/Q*22
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M&?";Q)HGB'Q?8>/]<TK6OA_X7U*PU7QOI?@[1?AW8>++ZUN],E@G\06OP_\
M#NA^!8M49/M7_"&Z79>%FD;0H18'YNM_^"<WP<M/VAIOVA+77_$\.LS_ !#T
MKXH-H_\ 8?PO>_M_$>A>'=+\)Z-X?TWXK/\ #T_'#2_A5I_AW2++2K;X067Q
M(B\!PZ4DWAN'3(O!US<>&I/T%HH \"\*_LK?LT^![>PM/!WP#^#_ (7MM+\;
MZ1\2=-AT#X=>%-(CT_Q]X?M-3T_P_P"+[);#2X!:^(- T_6M7T_0M2@\N;1;
M#4[ZQTLVEI<RPMV,GP7^$4O@#6OA3-\,? ,_PR\1W_B;5-?^'UQX1T*Y\%ZU
MJ7C/Q5J/CGQ9?ZKX9N+&71[^\\2>,]7U3Q7K=S<V<DVH^(M0O-:N'?49WN#Z
M910!YEX5^"WPB\#^ ;[X5^$/AEX#\.?#;5;76+/5_ FD^$]#M/">L6WB&!K7
MQ!%K.@I9?V;K*Z];R20ZV=4M[Q]7B=X]1:Y1F!YKP1^S+^SQ\-9/#DWP_P#@
MA\*_!D_@_7M=\4>%KCPUX%\.:/<^'_$?B;PZW@_Q!KFD7-C80W%EJNK^$6'A
M6^OH91<3>&TBT'>-*AAM$]RHH ^<M*_9 _96T/4O#FLZ/^SG\$]+U7PAIO@;
M1_"VHV'PR\(6EYX=TWX8WVF:E\.K31;B'24ETV/P-?:+I%QX3:U:.703I>GQ
MZ;);P6D$2:>I?LL_LV:QHOPU\.:M\!?@_J6@?!NSMM-^%.BW_P .O"EYI?P[
MTRS6Q6VTOP;8W&ER6_A_2X3I>ER)IFG1PV FTK2[@VQGTVQEM_>J* /-OB;\
M'/A/\:=&L?#OQ=^&O@;XFZ#IFJ1ZWIVC^._"VB^*M.L-7CMKFR&HV=IK5E>0
MVUV]A>WVG3S0JCW.FW]]IMR9K&]NK>;6\/?#KP%X1U?Q+X@\*^#?#'AO7/&4
MGAV7Q;J^A:'INDZCXED\):':>&/##:W=6-M!+J7_  C_ (;L++0-&%TT@TW1
M[6WTZS$-I#'$O9T4 ?&GP@_8#_93^#7@.[\ Z/\ "/P;XLM-5GOYO$?B/Q]X
M2\'^(?%_BU+KXNZU\<=/M?%6N0^'=-;6[7PW\1M9_MSPY'=6Y;3I](T"Y9[C
M4=(MK\>[K\#?@RGQ1D^-J?"KX>K\8)K'^SI?B</!^@#QW)9_V:=&\E_% L/[
M88_V*1HIF-W]H;1E72&F.F*MH/5** /!?'/[+7[-_P 3-?UCQ5\0O@5\)_&G
MB3Q#:^&[/7=<\2^ _#FL:KK$'@ZXFN?"@U*^O-/EN+V7PW)<7*:'<W#O=:9;
M75U96<T5E<SV\FKHG[.WP&\,QVT7ASX-_#+0(K/Q3I?C:RBT7P3X>TN.R\6Z
M)J6O:SI'B*RCL;"!++5]-U;Q3XFU&QO+589;:\\1Z_/$5?6=2-S[+10!\Q7'
M['_P%U/]H/Q%^TUXE\$Z5XR^*.MZ)\'=&TN^\8:1X=\06/@67X'7WQ,U'P7K
M_@!;W1&U3PUXC>[^*OB";5=3BU6X\Z?3O#EUIT&F7FDBYN.FUG]EW]F_Q%X.
M\,?#W7_@/\(M:\">"]8U77_"7@[5?AYX5U#PUX;UG7;[4=2UW4M$T6\TN:PT
MVZUR]U?5;C6WM8(QK#:GJ"ZFMU'>7"2>[T4 >:'X,_"5O$7_  EY^&O@8^*?
M^$^LOBI_PD7_  B^C_VU_P +*T[X:M\&]/\ 'O\ :7V3[5_PE]E\)W?X;6OB
M#S/[2@\#,WA>*X71R;6O--._8T_9-TC4/"VJZ7^S;\#[#4?!%_<ZGX.N[3X8
M>#X)O"]Y=:[=>*&DT(II(&F1P>);VZ\0V%M:B.UTO6YY=5TN"ROW-Q7TM10
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MQI.FSSRN,/)-+9022R,!P&=V9F X!)H UZ*** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
=10 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>54
<FILENAME>zinbryta.jpg
<TEXT>
begin 644 zinbryta.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" !: /$# 2(  A$! Q$!_\0
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M0O.*G$5*=&3YG;6QGAY.=*,GNTOR+-%,65'9E1U9E.& .2/K3Z9JG?8****
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MN\,BJ#(2Q4@<L,<^]5?B3IMWJ'C#3X;6)R\\2HC8.,[CW[8K)_!\ROM'J0
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MV8*^#].CU&.^ADNXKA%V,R3MF49S\YZFGWOA:VOM734Y+N^2YC&(S'-M"#N
M,=#6W11RKL%V8^J>&K;5KVVNI[F\26V_U1BEVA3W.,=33=4\,6NKR6DEU<WH
M>TP8C'-MPP_BZ?>]ZVJ*.5!=F)J'A6SU&:VGEGO([JV38MQ%-MD*^A..::O@
M_3HM0BO87NXIT38S).V91G/SGJ:W:*.5=@NS'O\ PW;WVJ#45N;RVNA'Y6^W
MEVY7.<$$&K&FZ+:Z6\LL7F2W$V/,GF??(^.@)]/85H44^57N%V96FV,YU"YU
C*_55N)1Y448.1%$#P,^I/)_"M6BBA*P@HHHI@)1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>55
<FILENAME>zinbrytachart.jpg
<TEXT>
begin 644 zinbrytachart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $R 3T# 2(  A$! Q$!_\0
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MI=]\I^&_^"._PC\$^$='\*>"_%7A_P /6O@ZX\"Z7X4BM/V=OV?H=*\4> O
M&G>(-)T;P=^T/I>F^#-*D_:0C-OKUIJ[WWCS4;2S@\;^"O 'Q$LM!M_&VA:C
MK6N^A?!W_@EK\-_@AX?^)7AOP1\2O%EGIWQ"^#?B#X-)'+X)^$EY8:!H6O\
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MC:>'%M?BUXATX?"SX<Z7#JWB^VALI=#\(6T;Z"?$6N>*?$VN>G?M=_LO>/\
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M'[=?[.$+36">)_%L_BF#QOKWP^F\ 1?"3XOR?$BUU[PUX2T/Q]J^H:A\.XO
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M=LW^9<W=QG9NVX^U3S;,;VSLV[N-V<# !H4444 %%%% !1110 4444 %%%%
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MBBB@ HHHH **** /Q _X*3_\I)/^"%/_ &=;^U!_ZQS\0:_;R/\ U<?^XO\
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MCQ#_ - K1_\ P?7G_P SM;5%?Q^?U:8OVCQ#_P! K1__  ?7G_S.T?:/$/\
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M?;^&_P#R7/#7_8QC_P"FJI\=X@_\D9Q#_P!@$O\ T[2/Q!I1U'UI**_ND_C
M^U;'39;O]EB>:.STWPQ;Z5.-:.JWFD>#=>T'Q3J%E97=Q'<67B*%X?%7A7XC
M7<TEOI-KI]TVJW45YIZZ3]DL/#NI.8?+_B)?>-_$\'PT^';2:EXP\1W?AZQ\
M>7T<5G97&KWVM^--*DUNQTFS^R6EM(+'0/!45@RV:MY;ZA>ZW?3AY#!Y/S_Y
MTWV<VGFR?93="]-MO;[.;U;<VBWAASY9NEM6:U%P5\X6S- '$1*%F]@P;<VX
M  -N8, !@ ,"&  X !  X''%?.X7(7A\17Q$J^'JSEC\=F&&3P23H5\71C17
M/5=>5>M&/[R59.K'VTG2Y/J\</2BO>Q.=+$4*.'C2Q%*"P."P&)<<8_W]'"U
MG5ERTU1C0I2E:G&BU2E[&,:G/[=UZKE]NWND:>WP1FL8[?4DCTWX'Z=KG]J0
M>'_#K?!G5-<NM6L]8;4+'QB+,>*IOC']BOQH;VINVL9/$]I?Z*$BTN$6[?$)
MZGZG^=+N;:$R=@<R!,G8)"-ID"9V>:5^4R;?,*_+NQQ3:[<JRR66QQ:EB?K'
MUK%U,6W[)4N256,5-.U2?M)2E%R<W9ZJ-DHHY,SS".8/"N.'^K_5L+#"I>U=
M52C3<N1J\(<D8Q?*H+FVO=ML*_>'_@G%_P F[-_V4'QC_P"A:77X/5^\/_!.
M+_DW9O\ LH/C'_T+2Z_-/&__ )(E?]CC ?\ IO%'Z!X._P#)8_\ =(QW_I_!
M'WO1117\?G]6A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^2&^#?\ LIFC_P#J+^*J^"_^"S'QD^'O[.'[7O\ P1K_ &A/C'JVI^%_@_\
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M1?\ 17/$?_AA?VC_ /YT5'_#SO\ 8B_Z*YXC_P##"_M'_P#SHJ_LW_6_A/\
MZ*CAW_P]Y;_\TG\C_P"J_$W_ $3F??\ AGS'R_ZAO-'WO17P1_P\[_8B_P"B
MN>(__#"_M'__ #HJC_X>@_L.&8VP^,6NFX6%;AK<? K]HHW"V[R/"EPUN/A)
MYZV[S1R0I<-&(7FCDA21I(W13_6_A/\ Z*CAW_P]Y;_\TA_JMQ,_^:<S[_PS
MYCY?]0WFC[[HKX(_X>=_L1?]%<\1_P#AA?VC_P#YT5'_  \[_8B_Z*YXC_\
M#"_M'_\ SHJ/];^$_P#HJ.'?_#WEO_S2'^J_$W_1.9]_X9\Q\O\ J&\T?>]?
MO#_P3B_Y-V;_ +*#XQ_]"TNOY)_^'G?[$7_17/$?_AA?VC__ )T5?K9^Q/\
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MX)!?]'7:I_XC5^UM_P#.'H_XB'/^"07_ $==JG_B-7[6W_SAZ /VHHK\5_\
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M_P#A'=A^*7@+P2-6_M#_ (1S6=W]B'4C9?9!_:'V3[59_: #[6HHHH ****
M"BBB@ HHHH **** $(!QG/'HS#\\$9_&DVCU;_OM_P#XJG44 -VCU;_OM_\
MXJC:/5O^^W_^*IU% #=H]6_[[?\ ^*KYATWX7^+K;]L?Q?\ &*6TMQX$U?\
M9H^'?PTL;X:C;M>R>+/#WQ:^*?BW5+5]-#_;(K:+1?%.CSQW[J+>>6:6VC8R
MV\JCZ?!!S@@X.#@@X(Z@^A'O1N7&[<-N,[LC&/7/3% ";1ZM_P!]O_\ %4;1
MZM_WV_\ \52D@8R0,G R<9/H/4TM #=H]6_[[?\ ^*HVCU;_ +[?_P"*IU%
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MNX634-3\S_3)Y=D>P ^!OV;?B9^T+XEU3X >']'_ &B+CQWK?[6G["K?M/\
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M\/Z+=W4,L^FVCQ>8Z1^S-^SMX?\ $?@OQ?H?P,^$FD^*_ASH%EX4\ >)-/\
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6904943424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Jan. 27, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BIOGEN INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000875045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">215,951,945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,843,669,823<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Document and Entity Information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6905461600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Income - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="nump">$ 9,817.9<span></span>
</td>
<td class="nump">$ 9,188.5<span></span>
</td>
<td class="nump">$ 8,203.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RevenuesfromantiCD20therapeuticprograms', window );">Revenues from anti-CD20 therapeutic programs</a></td>
<td class="nump">1,314.5<span></span>
</td>
<td class="nump">1,339.2<span></span>
</td>
<td class="nump">1,195.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSalesRevenueNet', window );">Other</a></td>
<td class="nump">316.4<span></span>
</td>
<td class="nump">236.1<span></span>
</td>
<td class="nump">304.5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">11,448.8<span></span>
</td>
<td class="nump">10,763.8<span></span>
</td>
<td class="nump">9,703.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Cost and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsSold', window );">Cost of sales, excluding amortization of acquired intangible assets</a></td>
<td class="num">(1,478.7)<span></span>
</td>
<td class="num">(1,240.4)<span></span>
</td>
<td class="num">(1,171.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="num">(1,973.3)<span></span>
</td>
<td class="num">(2,012.8)<span></span>
</td>
<td class="num">(1,893.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="num">(1,947.9)<span></span>
</td>
<td class="num">(2,113.1)<span></span>
</td>
<td class="num">(2,232.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of acquired intangible assets</a></td>
<td class="num">(385.6)<span></span>
</td>
<td class="num">(382.6)<span></span>
</td>
<td class="num">(489.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="num">(33.1)<span></span>
</td>
<td class="num">(93.4)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Loss (gain) on fair value remeasurement of contingent consideration</a></td>
<td class="nump">14.8<span></span>
</td>
<td class="nump">30.5<span></span>
</td>
<td class="num">(38.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationProfitSharing', window );">Collaboration profit (loss) sharing</a></td>
<td class="num">(10.2)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">TECFIDERA litigation settlement and license charges</a></td>
<td class="nump">454.8<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total cost and expenses</a></td>
<td class="nump">6,298.4<span></span>
</td>
<td class="nump">5,872.8<span></span>
</td>
<td class="nump">5,747.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GainOnSaleOfRights', window );">Gain on sale of rights</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">16.8<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="nump">5,150.4<span></span>
</td>
<td class="nump">4,891.0<span></span>
</td>
<td class="nump">3,972.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="num">(217.4)<span></span>
</td>
<td class="num">(123.7)<span></span>
</td>
<td class="num">(25.8)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before income tax expense and equity in loss of investee, net of tax</a></td>
<td class="nump">4,933.0<span></span>
</td>
<td class="nump">4,767.3<span></span>
</td>
<td class="nump">3,946.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">1,237.3<span></span>
</td>
<td class="nump">1,161.6<span></span>
</td>
<td class="nump">989.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in loss of investee, net of tax</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">12.5<span></span>
</td>
<td class="nump">15.1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">3,695.7<span></span>
</td>
<td class="nump">3,593.2<span></span>
</td>
<td class="nump">2,941.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net (loss) income attributable to noncontrolling interests, net of tax</a></td>
<td class="num">(7.1)<span></span>
</td>
<td class="nump">46.2<span></span>
</td>
<td class="nump">6.8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">$ 3,702.8<span></span>
</td>
<td class="nump">$ 3,547.0<span></span>
</td>
<td class="nump">$ 2,934.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net income per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">$ 16.96<span></span>
</td>
<td class="nump">$ 15.38<span></span>
</td>
<td class="nump">$ 12.42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">$ 16.93<span></span>
</td>
<td class="nump">$ 15.34<span></span>
</td>
<td class="nump">$ 12.37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average shares used in calculating:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">218.4<span></span>
</td>
<td class="nump">230.7<span></span>
</td>
<td class="nump">236.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">218.8<span></span>
</td>
<td class="nump">231.2<span></span>
</td>
<td class="nump">237.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CollaborationProfitSharing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments are made to Elan for their share of rest of world net operating profits to effect an equal sharing of collaboration operating profit. These payments include the reimbursement of our portion of third-party royalties that Elan pays on behalf of the collaboration, relating to sales outside of the U.S. These amounts are reflected in the collaboration profit sharing line in our consolidated statement of income. As sales of TYSABRI outside the U.S. increase, our collaboration profit sharing expense will increase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CollaborationProfitSharing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_GainOnSaleOfRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain on sale of our royalty and other rights related to future sales of BENLYSTA recognized in our consolidated statement of income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_GainOnSaleOfRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RevenuesfromantiCD20therapeuticprograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenues from anti-CD20 therapeutic programs consists of our share of pre-tax co-promotion profits in the U.S.; reimbursement of selling and development expense in the U.S.; and revenue on sales of RITUXAN outside the U.S., which consist of our share of pre-tax co-promotion profits in Canada.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RevenuesfromantiCD20therapeuticprograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs related to goods produced and sold during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=65016374&amp;loc=d3e4984-109258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized on the income statement for financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the entity's proportionate share for the period of the net income (loss) of its investee (such as unconsolidated subsidiaries and joint ventures) to which the equity method of accounting is applied. This item includes income or expense related to stock-based compensation based on the investor's grant of stock to employees of an equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66022249&amp;loc=d3e33749-111570<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Income Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4591551-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSalesRevenueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after sales adjustments, returns, allowances, and discounts, of revenue classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSalesRevenueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4569616-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4591551-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Research and Development<br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140864-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Weighted-Average Number of Common Shares Outstanding<br> -URI http://asc.fasb.org/extlink&amp;oid=6528421<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6826087872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Income - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">$ 3,702.8<span></span>
</td>
<td class="nump">$ 3,547.0<span></span>
</td>
<td class="nump">$ 2,934.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gains (losses) recognized during the period, net of tax</a></td>
<td class="num">(10.6)<span></span>
</td>
<td class="num">(1.7)<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax', window );">Less: reclassification adjustment for (gains) losses included in net income, net of tax</a></td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
<td class="num">(6.4)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gains (losses) on securities available for sale, net of tax</a></td>
<td class="num">(10.0)<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
<td class="num">(6.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax', window );">Unrealized gains (losses) recognized during the period, net of tax</a></td>
<td class="nump">51.6<span></span>
</td>
<td class="nump">110.8<span></span>
</td>
<td class="nump">101.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax', window );">Less: reclassification adjustment for (gains) losses included in net income, net of tax</a></td>
<td class="num">(4.0)<span></span>
</td>
<td class="num">(172.3)<span></span>
</td>
<td class="num">(6.3)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax', window );">Unrealized gains (losses) on cash flow hedges, net of tax</a></td>
<td class="nump">47.6<span></span>
</td>
<td class="num">(61.5)<span></span>
</td>
<td class="nump">95.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax', window );">Unrealized gains (losses) on pension benefit obligation</a></td>
<td class="nump">5.1<span></span>
</td>
<td class="num">(6.2)<span></span>
</td>
<td class="num">(12.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Currency translation adjustment</a></td>
<td class="num">(138.6)<span></span>
</td>
<td class="num">(96.4)<span></span>
</td>
<td class="num">(109.2)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive income (loss), net of tax</a></td>
<td class="num">(95.9)<span></span>
</td>
<td class="num">(164.5)<span></span>
</td>
<td class="num">(31.8)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income attributable to Biogen Inc.</a></td>
<td class="nump">3,606.9<span></span>
</td>
<td class="nump">3,382.5<span></span>
</td>
<td class="nump">2,903.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive income (loss) attributable to noncontrolling interests, net of tax</a></td>
<td class="num">(7.1)<span></span>
</td>
<td class="nump">46.2<span></span>
</td>
<td class="nump">6.8<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive income</a></td>
<td class="nump">$ 3,599.8<span></span>
</td>
<td class="nump">$ 3,428.7<span></span>
</td>
<td class="nump">$ 2,909.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831223<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4613674-111683<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4569643-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4569616-111683<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b,c)<br> -URI http://asc.fasb.org/extlink&amp;oid=64808268&amp;loc=d3e32211-110900<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=SL4573702-111684<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4569616-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of (increase) decrease in accumulated other comprehensive (income) loss related to pension and other postretirement defined benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27357-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e689-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustment from accumulated other comprehensive income of accumulated gain (loss) realized from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's deferred hedging gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph c<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=d3e41638-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6441202&amp;loc=d3e80720-113993<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6903251152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 2,326.5<span></span>
</td>
<td class="nump">$ 1,308.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">2,568.6<span></span>
</td>
<td class="nump">2,120.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">1,441.6<span></span>
</td>
<td class="nump">1,227.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DueFromUnconsolidatedJointBusiness', window );">Due from anti-CD20 therapeutic programs, net</a></td>
<td class="nump">300.6<span></span>
</td>
<td class="nump">314.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">1,001.6<span></span>
</td>
<td class="nump">893.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">1,093.3<span></span>
</td>
<td class="nump">836.9<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">8,732.2<span></span>
</td>
<td class="nump">6,700.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesNoncurrent', window );">Marketable securities</a></td>
<td class="nump">2,829.4<span></span>
</td>
<td class="nump">2,760.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">2,501.8<span></span>
</td>
<td class="nump">2,187.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">3,808.3<span></span>
</td>
<td class="nump">4,085.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">3,669.3<span></span>
</td>
<td class="nump">2,663.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Investments and other assets</a></td>
<td class="nump">1,335.8<span></span>
</td>
<td class="nump">1,107.6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">22,876.8<span></span>
</td>
<td class="nump">19,504.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Current portion of notes payable and other financing arrangements</a></td>
<td class="nump">4.7<span></span>
</td>
<td class="nump">4.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Taxes payable</a></td>
<td class="nump">231.9<span></span>
</td>
<td class="nump">208.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">279.8<span></span>
</td>
<td class="nump">267.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Accrued expenses and other</a></td>
<td class="nump">2,903.5<span></span>
</td>
<td class="nump">2,096.8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">3,419.9<span></span>
</td>
<td class="nump">2,577.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Notes payable and other financing arrangements</a></td>
<td class="nump">6,512.7<span></span>
</td>
<td class="nump">6,521.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNoncurrent', window );">Deferred tax liability</a></td>
<td class="nump">93.1<span></span>
</td>
<td class="nump">124.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">722.5<span></span>
</td>
<td class="nump">905.8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">10,748.2<span></span>
</td>
<td class="nump">10,129.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Biogen Idec Inc. shareholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, par value $0.001 per share</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value $0.0005 per share</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(319.9)<span></span>
</td>
<td class="num">(224.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">15,071.6<span></span>
</td>
<td class="nump">12,208.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, at cost; 22.6 million shares, respectively</a></td>
<td class="num">(2,611.7)<span></span>
</td>
<td class="num">(2,611.7)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Biogen Inc. shareholders&#8217; equity</a></td>
<td class="nump">12,140.1<span></span>
</td>
<td class="nump">9,372.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="num">(11.5)<span></span>
</td>
<td class="nump">2.1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">12,128.6<span></span>
</td>
<td class="nump">9,374.9<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">$ 22,876.8<span></span>
</td>
<td class="nump">$ 19,504.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DueFromUnconsolidatedJointBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Receivable from unconsolidated joint business for our share of the pre-tax co-promotion profits generated from our co-promotion arrangement for sales of RITUXAN.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DueFromUnconsolidatedJointBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e681-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as trading securities nor held-to-maturity securities and intended be sold or mature one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65884222&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=66010992&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments in debt and equity securities which are categorized neither as held-to-maturity nor trading and which are intended to be sold or mature more than one year from the balance sheet date or operating cycle, if longer. Such securities are reported at fair value; unrealized gains (losses) related to Available-for-sale Securities are excluded from earnings and reported in a separate component of shareholders' equity (other comprehensive income), unless the Available-for-sale security is designated as a hedge or is determined to have had an other than temporary decline in fair value below its amortized cost basis. All or a portion of the unrealized holding gain (loss) of an Available-for-sale security that is designated as being hedged in a fair value hedge is recognized in earnings during the period of the hedge, as are other than temporary declines in fair value below the cost basis for investments in equity securities and debt securities that an entity intends to sell or it is more likely than not that it will be required to sell before the recovery of its amortized cost basis. Other than temporary declines in fair value below the cost basis for debt securities categorized as Available-for-sale that an entity does not intend to sell and for which it is not more likely than not that the entity will be required to sell before the recovery of its amortized cost basis are bifurcated into credit losses and losses related to all other factors. Other than temporary declines in fair value below cost basis related to credit losses are recognized in earnings, and losses related to all other factors are recognized in other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Available-for-Sale Securities<br> -URI http://asc.fasb.org/extlink&amp;oid=6505594<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=66010992&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting and classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e31958-109318<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=64834752&amp;loc=SL49117168-202975<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6904-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4590271-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4568740-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6898750496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br> shares in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0005<span></span>
</td>
<td class="nump">$ 0.0005<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock at cost, shares</a></td>
<td class="nump">22.6<span></span>
</td>
<td class="nump">22.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6905928272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 3,695.7<span></span>
</td>
<td class="nump">$ 3,593.2<span></span>
</td>
<td class="nump">$ 2,941.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">682.7<span></span>
</td>
<td class="nump">600.4<span></span>
</td>
<td class="nump">688.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">154.8<span></span>
</td>
<td class="nump">161.4<span></span>
</td>
<td class="nump">155.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="num">(175.0)<span></span>
</td>
<td class="num">(145.6)<span></span>
</td>
<td class="num">(308.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="nump">91.2<span></span>
</td>
<td class="nump">82.2<span></span>
</td>
<td class="num">(50.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(241.4)<span></span>
</td>
<td class="nump">29.0<span></span>
</td>
<td class="num">(512.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet', window );">Due from anti-CD20 therapeutic programs</a></td>
<td class="nump">13.9<span></span>
</td>
<td class="num">(31.1)<span></span>
</td>
<td class="num">(30.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(165.6)<span></span>
</td>
<td class="num">(174.4)<span></span>
</td>
<td class="num">(185.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="nump">59.1<span></span>
</td>
<td class="num">(127.0)<span></span>
</td>
<td class="num">(108.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">570.1<span></span>
</td>
<td class="nump">74.2<span></span>
</td>
<td class="nump">244.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income tax assets and liabilities</a></td>
<td class="num">(232.6)<span></span>
</td>
<td class="num">(429.4)<span></span>
</td>
<td class="nump">40.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="nump">69.5<span></span>
</td>
<td class="nump">83.2<span></span>
</td>
<td class="nump">68.7<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash flows provided by operating activities</a></td>
<td class="nump">4,522.4<span></span>
</td>
<td class="nump">3,716.1<span></span>
</td>
<td class="nump">2,942.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from sales and maturities of marketable securities</a></td>
<td class="nump">7,378.9<span></span>
</td>
<td class="nump">4,063.0<span></span>
</td>
<td class="nump">2,718.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(7,913.2)<span></span>
</td>
<td class="num">(6,864.9)<span></span>
</td>
<td class="num">(3,583.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherProductiveAssets', window );">Contingent consideration related to Fumapharm AG acquisition</a></td>
<td class="num">(1,200.0)<span></span>
</td>
<td class="num">(850.0)<span></span>
</td>
<td class="num">(375.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisitions of businesses, net of cash acquired</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(198.8)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="num">(616.1)<span></span>
</td>
<td class="num">(643.0)<span></span>
</td>
<td class="num">(287.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquisitions of intangible assets</a></td>
<td class="num">(111.6)<span></span>
</td>
<td class="num">(15.4)<span></span>
</td>
<td class="num">(28.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other</a></td>
<td class="num">(22.8)<span></span>
</td>
<td class="num">(44.5)<span></span>
</td>
<td class="nump">12.2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash flows used in investing activities</a></td>
<td class="num">(2,484.8)<span></span>
</td>
<td class="num">(4,553.6)<span></span>
</td>
<td class="num">(1,543.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchases of treasury stock</a></td>
<td class="num">(1,000.0)<span></span>
</td>
<td class="num">(5,000.0)<span></span>
</td>
<td class="num">(886.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from issuance of stock for share-based compensation arrangements</a></td>
<td class="nump">43.7<span></span>
</td>
<td class="nump">54.2<span></span>
</td>
<td class="nump">54.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from borrowings</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">5,930.5<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of borrowings</a></td>
<td class="num">(2.7)<span></span>
</td>
<td class="num">(2.1)<span></span>
</td>
<td class="num">(2.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities', window );">Excess tax benefit from share-based compensation</a></td>
<td class="nump">12.6<span></span>
</td>
<td class="nump">78.2<span></span>
</td>
<td class="nump">96.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Contingent consideration payments</a></td>
<td class="num">(38.6)<span></span>
</td>
<td class="num">(13.1)<span></span>
</td>
<td class="num">(20.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other</a></td>
<td class="num">(2.8)<span></span>
</td>
<td class="num">(61.3)<span></span>
</td>
<td class="nump">2.8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash flows provided by (used in) financing activities</a></td>
<td class="num">(987.8)<span></span>
</td>
<td class="nump">986.4<span></span>
</td>
<td class="num">(755.9)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net increase in cash and cash equivalents</a></td>
<td class="nump">1,049.8<span></span>
</td>
<td class="nump">148.9<span></span>
</td>
<td class="nump">643.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="num">(31.3)<span></span>
</td>
<td class="num">(45.8)<span></span>
</td>
<td class="num">(40.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, beginning of the year</a></td>
<td class="nump">1,308.0<span></span>
</td>
<td class="nump">1,204.9<span></span>
</td>
<td class="nump">602.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, end of the year</a></td>
<td class="nump">$ 2,326.5<span></span>
</td>
<td class="nump">$ 1,308.0<span></span>
</td>
<td class="nump">$ 1,204.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49171198&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Deferred Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=63044130<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49171198&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from realized tax benefit related to deductible compensation cost reported on the entity's tax return for equity instruments in excess of the compensation cost for those instruments recognized for financial reporting purposes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=65896087&amp;loc=d3e11374-113907<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3098-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3095-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3291-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire debt and equity securities not classified as either held-to-maturity securities or trading securities which would be classified as available-for-sale securities and reported at fair value, with unrealized gains and losses excluded from earnings and reported in a separate component of shareholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3213-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=66010992&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total cash inflow associated with the amount received from holders to acquire the entity's shares under incentive and share awards, including stock option exercises. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3095-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3098-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale or maturity (principal being due) of securities not classified as either held-to-maturity securities or trading securities which are classified as available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3179-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=66010992&amp;loc=d3e26853-111562<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4569616-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4591551-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6908352576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Equity - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Preferred stock</div></th>
<th class="th"><div>Common stock</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><div>Accumulated other comprehensive income (loss)</div></th>
<th class="th"><div>Retained earnings</div></th>
<th class="th"><div>Treasury stock</div></th>
<th class="th"><div>Noncontrolling interests</div></th>
<th class="th"><div>Parent</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance at Dec. 31, 2013</a></td>
<td class="num">$ (8,620.8)<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">$ (0.1)<span></span>
</td>
<td class="num">$ (4,023.6)<span></span>
</td>
<td class="nump">$ 27.7<span></span>
</td>
<td class="num">$ (6,349.1)<span></span>
</td>
<td class="num">$ (1,724.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2013</a></td>
<td class="nump">8,620.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Beginning Balance at Dec. 31, 2013</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning Balance, shares at Dec. 31, 2013</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(256,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19,700,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">2,934.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,934.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net (loss) income attributable to noncontrolling interests, net of tax</a></td>
<td class="nump">6.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">2,941.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(31.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(31.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(31.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distribution or Capital contribution to noncontrolling interests</a></td>
<td class="num">(9.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9.1)<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Noncontrollinginterestincreasedecreaseother', window );">Noncontrolling interest, increase (decrease) other</a></td>
<td class="nump">6.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.7<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock, at cost</a></td>
<td class="num">$ (886.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (886.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost, shares</a></td>
<td class="num">(2,900,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,900,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans</a></td>
<td class="nump">$ 54.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">54.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock under stock award plan</a></td>
<td class="num">(140.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">(140.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock under stock award plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation expense related to share-based payments</a></td>
<td class="nump">165.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">165.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation', window );">Tax benefit from share-based payments</a></td>
<td class="num">(93.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(93.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Dec. 31, 2014</a></td>
<td class="num">(10,814.0)<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">$ (0.1)<span></span>
</td>
<td class="num">(4,196.2)<span></span>
</td>
<td class="num">(59.5)<span></span>
</td>
<td class="num">(9,283.9)<span></span>
</td>
<td class="num">$ (2,611.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2014</a></td>
<td class="nump">10,809.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Ending Balance at Dec. 31, 2014</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending Balance, shares at Dec. 31, 2014</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(257,100,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22,600,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">3,547.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,547.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net (loss) income attributable to noncontrolling interests, net of tax</a></td>
<td class="nump">46.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">3,593.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(164.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(164.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">164.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination', window );">Acquisition of noncontrolling interests</a></td>
<td class="num">(10.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10.9)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distribution or Capital contribution to noncontrolling interests</a></td>
<td class="num">(60.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock, at cost</a></td>
<td class="num">$ (5,000.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,000.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost, shares</a></td>
<td class="num">(16,800,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,800,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredCostMethodAmount', window );">Retirement of common stock pursuant to the 2016 Share Repurchase Program, at cost</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">(4,377.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(622.5)<span></span>
</td>
<td class="num">$ (5,000.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Retirement of common stock pursuant to the 2015 Share Repurchase Program, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,800,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,800,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans</a></td>
<td class="nump">54.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">54.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock under stock award plan</a></td>
<td class="num">(125.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">(125.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock under stock award plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation expense related to share-based payments</a></td>
<td class="nump">183.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">183.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation', window );">Tax benefit from share-based payments</a></td>
<td class="num">(69.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(69.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Dec. 31, 2015</a></td>
<td class="num">(9,374.9)<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">$ (0.1)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(224.0)<span></span>
</td>
<td class="num">(12,208.4)<span></span>
</td>
<td class="num">$ (2,611.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2015</a></td>
<td class="nump">9,372.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Ending Balance at Dec. 31, 2015</a></td>
<td class="nump">2.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending Balance, shares at Dec. 31, 2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(241,200,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22,600,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">3,702.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,702.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net (loss) income attributable to noncontrolling interests, net of tax</a></td>
<td class="num">(7.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">3,695.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(95.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(95.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(95.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination', window );">Acquisition of noncontrolling interests</a></td>
<td class="num">(0.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distribution or Capital contribution to noncontrolling interests</a></td>
<td class="num">(1.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation', window );">Deconsolidation of noncontrolling interests</a></td>
<td class="num">(7.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7.5)<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock, at cost</a></td>
<td class="num">$ (1,000.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,000.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost, shares</a></td>
<td class="num">(3,300,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,300,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredCostMethodAmount', window );">Retirement of common stock pursuant to the 2016 Share Repurchase Program, at cost</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">(164.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(835.1)<span></span>
</td>
<td class="num">$ (1,000.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Retirement of common stock pursuant to the 2015 Share Repurchase Program, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,300,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,300,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans</a></td>
<td class="nump">43.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">43.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock under stock award plan</a></td>
<td class="num">$ (52.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">(47.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock under stock award plan</a></td>
<td class="nump">41,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation expense related to share-based payments</a></td>
<td class="nump">$ 169.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation', window );">Tax benefit from share-based payments</a></td>
<td class="num">(0.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Dec. 31, 2016</a></td>
<td class="num">(12,128.6)<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">$ (0.1)<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">$ (319.9)<span></span>
</td>
<td class="num">$ (15,071.6)<span></span>
</td>
<td class="num">$ (2,611.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2016</a></td>
<td class="nump">12,140.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Ending Balance at Dec. 31, 2016</a></td>
<td class="num">$ (11.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (11.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending Balance, shares at Dec. 31, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(238,500,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22,600,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Noncontrollinginterestincreasedecreaseother">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling interest, increase (decrease) other</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Noncontrollinginterestincreasedecreaseother</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from a tax benefit associated with share-based compensation plan other than an employee stock ownership plan (ESOP). Includes, but is not limited to, excess tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 740<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65880886&amp;loc=d3e23524-113945<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4591551-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the reduction or elimination during the period of a noncontrolling interest resulting from the parent's loss of control and deconsolidation of the entity in which one or more outside parties had a noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=SL4573702-111684<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in noncontrolling interest from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=73530397&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=66004921&amp;loc=d3e1436-108581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=SL4573702-111684<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4569616-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4569616-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4591551-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of treasury shares (units) reissued during the period, excluding reissuance of shares (units) held in treasury used to satisfy equity-based compensation obligations exercised by the holders of such rights. Upon reissuance of shares (units) from treasury, either the common or preferred stock (unit) reissued is outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of treasury stock (units) reissued during the period, excluding reissuance of shares (units) held in treasury used to satisfy equity-based compensation obligations exercised by the holders of such rights. Upon reissuance of shares (units) from treasury, either the common or preferred stock (unit) reissued is outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4590271-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4568740-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockRetiredCostMethodAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockRetiredCostMethodAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_ParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_ParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6895537648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Summary of Significant Accounting Policies</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Business Overview</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen is a global biopharmaceutical company focused on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). We also have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other potential anti-CD20 therapies under a collaboration agreement with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group (Roche Group).</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities, particularly within areas of our scientific, manufacturing and technical capabilities. Our research is currently focused on additional improvements in the treatment of MS, solving some of the most challenging and complex diseases, including Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis (ALS), and employing innovative technologies to discover potential treatments for rare and genetic disorders, including new ways of treating diseases through gene therapy.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our innovative drug development and commercialization activities are complemented by our biosimilar therapies that expand access to medicines and reduce the cost burden for healthcare systems. We are leveraging our manufacturing capabilities and know-how to develop, manufacture and market biosimilars through Samsung Bioepis, our joint venture with Samsung BioLogics Co. Ltd. (Samsung Biologics). Under this agreement, we are currently manufacturing and commercializing BENEPALI, an etanercept biosimilar referencing ENBREL, and FLIXABI, an infliximab biosimilar referencing REMICADE, in the European Union (E.U.).</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Hemophilia Spin-Off</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2016 we announced our intention to spin off our hemophilia business, Bioverativ Inc. (Bioverativ), as an independent, publicly traded company. Bioverativ, will focus on the discovery, development and commercialization of therapies for treatment of hemophilia and other blood disorders, including ELOCTATE for the treatment of hemophilia A and ALPROLIX for the treatment of hemophilia B. Bioverativ will also assume all of our rights and obligations under our collaboration agreement with Swedish Orphan Biovitrum AB (Sobi) and our collaboration and license agreement with Sangamo Biosciences Inc. (Sangamo).</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On February 1, 2017, we completed the distribution of all the then outstanding shares of common stock of Bioverativ to Biogen stockholders, who received one share of Bioverativ common stock for every two shares of Biogen common stock. As a result of the distribution, Bioverativ is now an independent public company whose shares of common stock are trading under the symbol "BIVV" on the Nasdaq Global Select Market.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The financial results of Bioverativ are reflected in our consolidated results of operations and financial position included in these audited consolidated financial statements for the periods presented in this Form 10-K. The financial results of Bioverativ will be excluded from our consolidated results of operations and financial position commencing February 1, 2017. For additional information regarding the separation of Bioverativ, please read Note 26, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Subsequent Events</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Consolidation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the economics, we record net income (loss) attributable to noncontrolling interests in our consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In determining whether we are the primary beneficiary of an entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The preparation of our consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an on-going basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates under different assumptions or conditions.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Revenue Recognition</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognize revenue when all of the following criteria are met: persuasive evidence of an arrangement exists; delivery has occurred or services have been rendered; our price to the customer is fixed or determinable; and collectability is reasonably assured.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Product Revenues</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from product sales are recognized when title and risk of loss have passed to the customer, which is typically upon delivery. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Reserves for Discounts and Allowances</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from product sales are recorded net of reserves established for applicable discounts and allowances, including those associated with the implementation of pricing actions in certain of the international markets in which we operate. These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer). Our estimates take into consideration our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Actual amounts may ultimately differ from our estimates. If actual results vary, we adjust these estimates, which could have an effect on earnings in the period of adjustment. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenue reserves are categorized as follows: discounts, contractual adjustments and returns.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Discounts include trade term discounts and wholesaler incentives. Trade term discounts and wholesaler incentives primarily relate to estimated obligations for credits to be granted to wholesalers for remitting payment on their purchases within established incentive periods and credits to be granted to wholesalers for compliance with various contractually-defined inventory management practices, respectively. We determine these reserves based on our historical experience, including the timing of customer payments.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contractual adjustments primarily relate to Medicaid and managed care rebates, co-payment (copay) assistance, Veterans Administration (VA) and Public Health Service (PHS) discounts, specialty pharmacy program fees and other governmental rebates or applicable allowances.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Medicaid rebates relate to our estimated obligations to states under established reimbursement arrangements. Rebate accruals are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a liability which is included in other current liabilities. Our liability for Medicaid rebates consists of estimates for claims that a state will make for the current quarter, claims for prior quarters that have been estimated for which an invoice has not been received, invoices received for claims from the prior quarters that have not been paid, and an estimate of potential claims that will be made for inventory that exists in the distribution channel at period end.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Governmental rebates or chargebacks, including VA and PHS discounts, represent our estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices we charge to wholesalers which provide those products. The wholesaler charges us for the difference between what the wholesaler pays for the products and the ultimate selling price to the qualified healthcare providers. Rebate and chargeback reserves are established in the same period as the related revenue is recognized, resulting in a reduction in product revenue and accounts receivable. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider from the wholesaler, and we generally issue credits for such amounts within a few weeks of the wholesaler notifying us about the resale. Our reserves for VA, PHS and chargebacks consist of amounts that we expect to issue for inventory that exists at the wholesalers that we expect will be sold to qualified healthcare providers and chargebacks that wholesalers have claimed for which we have not issued a credit.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Managed care rebates represent our estimated obligations to third parties, primarily pharmacy benefit managers. Rebate accruals are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a liability which is included in accrued expenses and other current liabilities. These rebates result from performance-based goals, formulary position and price increase limit allowances (price protection). The calculation of the accrual for these rebates is based on an estimate of the customer&#8217;s buying patterns and the resulting applicable contractual rebate rate(s) to be earned over a contractual period.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Copay assistance represents financial assistance to qualified patients, assisting them with prescription drug co-payments required by insurance. The calculation of the accrual for copay is based on an estimate of claims and the cost per claim that we expect to receive associated with inventory that exists in the distribution channel at period end.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other governmental rebates or applicable allowances primarily relate to mandatory rebates and discounts in international markets where government-sponsored healthcare systems are the primary payors for healthcare.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product returns are established for returns expected to be made by wholesalers and are recorded in the period the related revenue is recognized, resulting in a reduction to product sales. In accordance with contractual terms, wholesalers are permitted to return product for reasons such as damaged or expired product. The majority of wholesaler returns are due to product expiration. Expired product return reserves are estimated through a comparison of historical return data to their related sales on a production lot basis. Historical rates of return are determined for each product and are adjusted for known or expected changes in the marketplace specific to each product.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition to the discounts, rebates and product returns described above and classified as a reduction of revenue, we also maintain certain customer service contracts with distributors and other customers in the distribution channel that provide us with inventory management, data and distribution services, which are generally reflected as a reduction of revenue. To the extent we can demonstrate a separable benefit and fair value for these services, we classify these payments in selling, general and administrative expenses.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Revenues from Anti-CD20 Therapeutic Programs</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs consist of:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(i)&#160;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our share of pre-tax profits and losses in the U.S. for RITUXAN and GAZYVA; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(ii)&#160; </font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">reimbursement of our selling and development expenses in the U.S. for RITUXAN; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(iii)&#160;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">revenues on sales in the rest of world for RITUXAN, which consist of our share of pre-tax co-promotion profits on RITUXAN in Canada and royalty revenue on RITUXAN sales outside the U.S. and Canada by the Roche Group and its sublicensees. </font></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pre-tax co-promotion profits on RITUXAN and GAZYVA are calculated and paid to us by Genentech in the U.S. Pre-tax co-promotion profits on RITUXAN are calculated and paid to us by the Roche Group in Canada. Pre-tax co-promotion profits consist of U.S. and Canadian net sales to third-party customers less applicable costs to manufacture, third-party royalty expenses, distribution, selling and marketing expenses, and joint development expenses incurred by Genentech, the Roche Group and us. We record our share of the pre-tax co-promotion profits on RITUXAN in Canada and royalty revenues on RITUXAN sales outside the U.S. on a cash basis as we do not have the ability to estimate these profits or royalty revenue in the period incurred. Our share of the pre-tax profits on RITUXAN and GAZYVA in the U.S. includes estimates made by Genentech and those estimates are subject to change. Actual results may differ from our estimates. For additional information related to our collaboration with Genentech, please read Note&#160;19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Royalty Revenues</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We receive royalty revenues on sales by our licensees of other products covered under patents that we own. We do not have future performance obligations under these license arrangements. We record these revenues based on estimates of the sales that occurred during the relevant period as a component of other revenues. The relevant period estimates of sales are based on interim data provided by licensees and analysis of historical royalties that have been paid to us, adjusted for any changes in facts and circumstances, as appropriate. Differences between actual and estimated royalty revenues are adjusted for in the period in which they become known, typically the following quarter. Historically, adjustments have not been material when compared to actual amounts paid by licensees. If we are unable to reasonably estimate royalty revenue or do not have access to the information, then we record royalty revenues on a cash basis. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Multiple-Element Revenue Arrangements</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We may enter into transactions that involve the sale of products and related services under multiple element arrangements.&#160;In accounting for these transactions, we assess the elements of the contract and whether each element has standalone value and allocate revenue to the various elements based on their estimated selling price as a component of total revenues.&#160;The selling price of a revenue generating element can be based on current selling prices offered by us or another party for current products or management&#8217;s best estimate of a selling price. Revenue allocated to an individual element is recognized when all other revenue recognition criteria are met for that element.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Collaborative and Other Relationships</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our development and commercialization arrangements with Sobi and AbbVie Inc. (AbbVie) represent collaborative arrangements as each party is an active participant and exposed to significant risks and rewards of the arrangements. Where we are the principal on sales transactions with third parties, we recognize revenue, cost of sales and operating expenses on a gross basis in their respective lines in our consolidated statements of income. Where we are not the principal on sales transactions with third parties, we record our share of the revenues, cost of sales and operating expenses on a net basis in collaborative and other relationships included in other revenue in our consolidated statements of income. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information related to our collaborations with Sobi and AbbVie, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Fair Value Measurements</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have certain financial assets and liabilities recorded at fair value which have been classified as Level&#160;1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Level&#160;1</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#8212; Fair values are determined utilizing quoted prices (unadjusted) in active markets for identical assets or liabilities that we have the ability to access;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Level&#160;2</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#8212; Fair values are determined by utilizing quoted prices for identical or similar assets and liabilities in active markets or other market observable inputs such as interest rates, yield curves and foreign currency spot rates;&#160;and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Level&#160;3</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#8212; Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The majority of our financial assets have been classified as Level&#160;2. Our financial assets (which include our cash equivalents, derivative contracts, marketable debt securities and plan assets for deferred compensation) have been initially valued at the transaction price and subsequently valued, at the end of each reporting period, utilizing third-party pricing services or other market observable data. The pricing services utilize industry standard valuation models, including both income and market-based approaches and observable market inputs to determine value. These observable market inputs include reportable trades, benchmark yields, credit spreads, broker/dealer quotes, bids, offers, current spot rates and other industry and economic events.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We validate the prices provided by our third-party pricing services by reviewing their pricing methods and matrices, obtaining market values from other pricing sources and analyzing pricing data in certain instances. After completing our validation procedures, we did not adjust or override any fair value measurements provided by our pricing services as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Other Assets and Liabilities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The carrying amounts reflected in the consolidated balance sheets for current accounts receivable, due from anti-CD20 therapeutic programs, other current assets, accounts payable and accrued expenses and other, approximate fair value due to their short-term maturities.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Cash and Cash Equivalents</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We consider only those investments which are highly liquid, readily convertible to cash and that mature within three months from date of purchase to be cash equivalents. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, cash equivalents were comprised of money market funds and commercial paper, overnight reverse repurchase agreements and other debt securities with maturities less than 90 days from the date of purchase.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accounts Receivable</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The majority of our accounts receivable arise from product sales and primarily represent amounts due from our wholesale distributors, public hospitals and other government entities. We monitor the financial performance and creditworthiness of our customers so that we can properly assess and respond to changes in their credit profile. We provide reserves against trade receivables for estimated losses that may result from a customer&#8217;s inability to pay. Amounts determined to be uncollectible are charged or written-off against the reserve. To date, our historical reserves and write-offs of accounts receivable have not been significant.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In countries where we have experienced a pattern of payments extending beyond our contractual payment term and we expect to collect receivables greater than one year from the time of sale, we have discounted our receivables and reduced related revenues over the period of time that we estimate those amounts will be paid using the country&#8217;s market-based borrowing rate for such period. The related receivables are classified at the time of sale as non-current assets. We accrete interest income on these receivables, which is recognized as a component of other income (expense), net in our consolidated statements of income.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Concentration of Credit Risk</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Financial instruments that potentially subject us to concentrations of credit risk include cash and cash equivalents, investments, derivatives and accounts receivable. We attempt to minimize the risks related to cash and cash equivalents and investments by investing in a broad and diverse range of financial instruments as previously defined by us. We have established guidelines related to credit ratings and maturities intended to safeguard principal balances and maintain liquidity. Our investment portfolio is maintained in accordance with our investment policy, which defines allowable investments, specifies credit quality standards and limits the credit exposure of any single issuer. We minimize credit risk resulting from derivative instruments by choosing only highly rated financial institutions as counterparties.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Concentrations of credit risk with respect to receivables, which are typically unsecured, are somewhat mitigated due to the wide variety of customers and markets using our products, as well as their dispersion across many different geographic areas. The majority of our accounts receivable arise from product sales in the U.S. and Europe and have standard payment terms which generally require payment within </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30 to 90 days</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We monitor the financial performance and creditworthiness of our customers so that we can properly assess and respond to changes in their credit profile. We continue to monitor these conditions and assess their possible impact on our business. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, two wholesale distributors individually accounted for approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.2%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">19.2%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35.4%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">23.1%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, of accounts receivable, net, respectively. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Marketable Securities and Other Investments</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Marketable Debt Securities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Available-for-sale debt securities are recorded at fair market value and unrealized gains and losses are included in accumulated other comprehensive income (loss) in equity, net of related tax effects, unless the security has experienced a credit loss, we have determined that we have the intent to sell the security or we have determined that it is more likely than not that we will have to sell the security before its expected recovery. Realized gains and losses are reported in other income (expense), net, on a specific identification basis.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Marketable Equity Securities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our marketable equity securities represent investments in publicly traded equity securities and are included in investments and other assets in our consolidated balance sheet. When assessing whether a decline in the fair value of a marketable equity security is other-than-temporary, we consider the fair market value of the security, the duration of the security&#8217;s decline and prospects for the underlying business, including favorable or adverse clinical trial results, new product initiatives and new collaborative agreements with the companies in which we have invested.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Non-Marketable Equity Securities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also invest in equity securities of companies whose securities are not publicly traded and where fair value is not readily available. These investments are recorded using either the cost method or the equity method of accounting, depending on our ownership percentage and other factors that suggest we have significant influence. We monitor these investments to evaluate whether any decline in their value has occurred that would be other-than-temporary, based on the implied value of recent company financings, public market prices of comparable companies and general market conditions and are included in investments and other assets in our consolidated balance sheet.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Evaluating Investments for Other-than-Temporary Impairments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We conduct periodic reviews to identify and evaluate each investment that has an unrealized loss, in accordance with the meaning of other-than-temporary impairment and its application to certain investments. An unrealized loss exists when the current fair value of an individual security is less than its amortized cost basis. Unrealized losses on available-for-sale securities that are determined to be temporary, and not related to credit loss, are recorded, net of tax, in accumulated other comprehensive income.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For available-for-sale debt securities with unrealized losses, management performs an analysis to assess whether we intend to sell or whether we would more likely than not be required to sell the security before the expected recovery of the amortized cost basis. Where we intend to sell a security, or may be required to do so, the security&#8217;s decline in fair value is deemed to be other-than-temporary and the full amount of the unrealized loss is reflected in earnings as an impairment loss.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Regardless of our intent to sell a security, we perform additional analysis on all securities with unrealized losses to evaluate losses associated with the creditworthiness of the security. Credit losses are identified where we do not expect to receive cash flows sufficient to recover the amortized cost basis of a security.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For equity securities, when assessing whether a decline in value is other-than-temporary, we consider the fair market value of the security, the duration of the security&#8217;s decline, and the financial condition of the issuer. We then consider our intent and ability to hold the equity security for a period of time sufficient to recover our carrying value. Where we have determined that we lack the intent and ability to hold an equity security to its expected recovery, the security&#8217;s decline in fair value is deemed to be other-than-temporary and is reflected in earnings as an impairment loss.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Equity Method of Accounting</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In circumstances where we have the ability to exercise significant influence over the operating and financial policies of a company in which we have an investment, we utilize the equity method of accounting for recording investment activity.&#160;In assessing whether we exercise significant influence, we consider the nature and magnitude of our investment, the voting and protective rights we hold, any participation in the governance of the other company, and other relevant factors such as the presence of a collaboration or other business relationship.&#160;Under the equity method of accounting, we record in our results of operations our share of income or loss of the other company. If our share of losses exceeds the carrying value of our investment, we will suspend recognizing additional losses and will continue to do so unless we commit to providing additional funding. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Inventory</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventories are stated at the lower of cost or market with cost based on the first-in, first-out (FIFO) method. We classify our inventory costs as long-term when we expect to utilize the inventory beyond our normal operating cycle and include these costs in investments and other assets in our consolidated balance sheets. Inventory that can be used in either the production of clinical or commercial products is expensed as research and development costs when identified for use in a clinical manufacturing campaign.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Capitalization of Inventory Costs</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We capitalize inventory costs associated with our products prior to regulatory approval, when, based on management&#8217;s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized. We consider numerous attributes in evaluating whether the costs to manufacture a particular product should be capitalized as an asset. We assess the regulatory approval process and where the particular product stands in relation to that approval process, including any known safety or efficacy concerns, potential labeling restrictions and other impediments to approval. We evaluate our anticipated research and development initiatives and constraints relating to the product and the indication in which it will be used. We consider our manufacturing environment including our supply chain in determining logistical constraints that could hamper approval or commercialization. We consider the shelf life of the product in relation to the expected timeline for approval and we consider patent related or contract issues that may prevent or delay commercialization. We also base our judgment on the viability of commercialization, trends in the marketplace and market acceptance criteria. Finally, we consider the reimbursement strategies that may prevail with respect to the product and assess the economic benefit that we are likely to realize. We expense previously capitalized costs related to pre-approval inventory upon a change in such judgment, due to, among other potential factors, a denial or significant delay of approval by necessary regulatory bodies.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Obsolescence and Unmarketable Inventory</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We periodically review our inventories for excess or obsolescence and write-down obsolete or otherwise unmarketable inventory to its estimated net realizable value. If the actual net realizable value is less than that estimated by us, or if it is determined that inventory utilization will further diminish based on estimates of demand, additional inventory write-downs may be required. Additionally, our products are subject to strict quality control and monitoring which we perform throughout the manufacturing process. In the event that certain batches or units of product no longer meet quality specifications, we will record a charge to cost of sales to write-down any unmarketable inventory to its estimated net realizable value. In all cases, product inventory is carried at the lower of cost or its estimated net realizable value. Amounts written-down due to unmarketable inventory are charged to cost of sales.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Property, Plant and Equipment</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Property, plant and equipment are carried at cost, subject to review for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. The cost of normal, recurring, or periodic repairs and maintenance activities related to property, plant and equipment are expensed as incurred. The cost for planned major maintenance activities, including the related acquisition or construction of assets, is capitalized if the repair will result in future economic benefits.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest costs incurred during the construction of major capital projects are capitalized until the underlying asset is ready for its intended use, at which point the interest costs are amortized as depreciation expense over the life of the underlying asset. We also capitalize certain direct and incremental costs associated with the validation effort required for licensing by regulatory agencies of new manufacturing equipment for the production of a commercially approved drug. These costs primarily include direct labor and material and are incurred in preparing the equipment for its intended use. The validation costs are either amortized over the life of the related equipment or expensed as cost of sales when the product produced in the validation process is sold.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we capitalize certain internal use computer software development costs. If the software is an integral part of production assets, these costs are included in machinery and equipment and are amortized on a straight-line basis over the estimated useful lives of the related software, which generally range from </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three to five years</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We generally depreciate or amortize the cost of our property, plant and equipment using the straight-line method over the estimated useful lives of the respective assets, which are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="2" rowspan="1"></td></tr><tr><td style="width:50%;" rowspan="1" colspan="1"></td><td style="width:50%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Asset Category</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Useful Lives</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Land</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Not depreciated</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Buildings</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">15 to 40&#160;years</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Leasehold Improvements</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Lesser of the useful life or the term of the respective lease</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Furniture and Fixtures</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5 to 7&#160;years</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Machinery and Equipment</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5 to 20&#160;years</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Computer&#160;Software&#160;and&#160;Hardware</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3 to 5&#160;years</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">When we dispose of property, plant and equipment, we remove the associated cost and accumulated depreciation from the related accounts on our consolidated balance sheet and include any resulting gain or loss in our consolidated statement of income.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Intangible Assets</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our intangible assets consist of acquired and in-licensed rights and patents, developed technology, out-licensed patents, in-process research and development acquired after January&#160;1, 2009, trademarks and trade names. Our intangible assets are recorded at fair value at the time of their acquisition and are stated in our consolidated balance sheets net of accumulated amortization and impairments, if applicable.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets related to acquired and in-licensed rights and patents, developed technology and out-licensed patents are amortized over their estimated useful lives using the economic consumption method if anticipated future revenues can be reasonably estimated. The straight-line method is used when revenues cannot be reasonably estimated. Amortization is recorded as amortization of acquired intangible assets in our consolidated statements of income.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired and in-licensed rights and patents primarily relate to our acquisition of all remaining rights to TYSABRI from Elan Pharma International, Ltd (Elan), an affiliate of Elan Corporation, plc. Developed technology primarily relates to our AVONEX product, which was recorded in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003. We amortize the intangible assets related to TYSABRI and AVONEX using the economic consumption method based on revenue generated from the products underlying the related intangible assets. An analysis of the anticipated lifetime revenues of TYSABRI and AVONEX is performed annually during our long range planning cycle, which is generally updated in the third quarter of each year, and whenever events or changes in circumstances would significantly affect the anticipated lifetime revenues of TYSABRI or AVONEX.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets related to trademarks, trade names and in-process research and development prior to commercialization are not amortized because they have indefinite lives; however, they are subject to review for impairment. We review our intangible assets with indefinite lives for impairment annually, as of October&#160;31, and whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Acquired In-process Research and Development (IPR&amp;D)</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired IPR&amp;D represents the fair value assigned to research and development assets that have not reached technological feasibility. The value assigned to acquired IPR&amp;D is determined by estimating the costs to develop the acquired technology into commercially viable products, estimating the resulting revenue from the projects and discounting the net cash flows to present value. The revenue and costs projections used to value acquired IPR&amp;D are, as applicable, reduced based on the probability of success of developing a new drug. Additionally, the projections consider the relevant market sizes and growth factors, expected trends in technology and the nature and expected timing of new product introductions by us and our competitors. The rates utilized to discount the net cash flows to their present value are commensurate with the stage of development of the projects and uncertainties in the economic estimates used in the projections. Upon the acquisition of IPR&amp;D, we complete an assessment of whether our acquisition constitutes the purchase of a single asset or a group of assets. We consider multiple factors in this assessment, including the nature of the technology acquired, the presence or absence of separate cash flows, the development process and stage of completion, quantitative significance and our rationale for entering into the transaction.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">If we acquire a business as defined under applicable accounting standards, then the acquired IPR&amp;D is capitalized as an intangible asset. If we acquire an asset or group of assets that do not meet the definition of a business, then the acquired IPR&amp;D is expensed on its acquisition date. Future costs to develop these assets are recorded to research and development expense as they are incurred. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">When performing our impairment assessment, we calculate the fair value using the same methodology as described above. If the carrying value of our acquired IPR&amp;D exceeds its fair value, then the intangible asset is written-down to its fair value. Certain IPR&amp;D programs have a fair value that is not significantly in excess of carrying value, including our program for the treatment of trigeminal neuralgia (TGN). Such programs could become impaired if assumptions used in determining the fair value change.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Goodwill</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill represents the difference between the purchase price and the fair value of the identifiable tangible and intangible net assets when accounted for using the purchase method of accounting. Goodwill is not amortized, but reviewed for impairment. Goodwill is reviewed annually, as of October&#160;31, and whenever events or changes in circumstances indicate that the carrying value of the goodwill might not be recoverable.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We compare the fair value of our reporting unit to its carrying value. If the carrying value of the net assets assigned to the reporting unit exceeds the fair value of our reporting unit, then we would need to determine the implied fair value of our reporting unit&#8217;s goodwill. If the carrying value of our reporting unit&#8217;s goodwill exceeds its implied fair value, then we would record an impairment loss equal to the difference. As described in Note&#160;24, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Segment Information</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements, we operate in one operating segment which we consider our only reporting unit.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Impairment of Long-Lived Assets</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-lived assets to be held and used, including property, plant and equipment and definite-lived intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets or asset group may not be recoverable.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written-down to their fair values. Long-lived assets to be disposed of are carried at fair value less costs to sell.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Consideration</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The consideration for our acquisitions often includes future payments that are contingent upon the occurrence of a particular event. For acquisitions completed before January 1, 2009, we record contingent consideration resulting from a business combination when the contingency is resolved. For acquisitions that qualify as business combinations completed after January&#160;1, 2009, we record an obligation for such contingent payments at fair value on the acquisition date. We estimate the fair value of contingent consideration obligations through valuation models that incorporate probability-adjusted assumptions related to the achievement of the milestones and thus likelihood of making related payments. We revalue these contingent consideration obligations each reporting period. Changes in the fair value of our contingent consideration obligations are recognized in our consolidated statements of income. Changes in the fair value of the contingent consideration obligations can result from changes to one or multiple inputs, including adjustments to the discount rates, changes in the amount or timing of expected expenditures associated with product development, changes in the amount or timing of cash flows and reserves associated with products upon commercialization, changes in the assumed achievement or timing of any cumulative sales-based and development milestones, changes in the probability of certain clinical events and changes in the assumed probability associated with regulatory approval. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Discount rates in our valuation models represent a measure of the credit risk associated with settling the liability. The period over which we discount our contingent obligations is based on the current development stage of the product candidates, our specific development plan for that product candidate adjusted for the probability of completing the development step, and when the contingent payments would be triggered. In estimating the probability of success, we utilize data regarding similar milestone events from several sources, including industry studies and our own experience. These fair value measurements are based on significant inputs not observable in the market. Significant judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, changes in assumptions could have a material impact on the amount of contingent consideration expense we record in any given period.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Derivative Instruments and Hedging Activities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognize all derivative instruments as either assets or liabilities at fair value in our consolidated balance sheets. Changes in the fair value of derivatives are recorded each period in current earnings or accumulated other comprehensive income (loss), depending on whether a derivative is designated as part of a hedge transaction and, if so, the type of hedge transaction. We classify the cash flows from these instruments in the same category as the cash flows from the hedged items. We do not hold or issue derivative instruments for trading or speculative purposes.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We assess, both at inception and on an ongoing basis, whether the derivatives that are used in hedging transactions are highly effective in offsetting the changes in cash flows or fair values of the hedged items. We also assess hedge ineffectiveness on a quarterly basis and record the gain or loss related to the ineffective portion to current earnings. If we determine that a forecasted transaction is no longer probable of occurring, we discontinue hedge accounting for the affected portion of the hedge instrument, and any related unrealized gain or loss on the contract is recognized in current earnings.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Translation of Foreign Currencies</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The functional currency for most of our foreign subsidiaries is their local currency. For our non-U.S. subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the average foreign exchange rates for the period. Adjustments resulting from the translation of the financial statements of our foreign operations into U.S.&#160;dollars are excluded from the determination of net income and are recorded in accumulated other comprehensive income, a separate component of equity. For subsidiaries where the functional currency of the assets and liabilities differ from the local currency, non-monetary assets and liabilities are translated at the rate of exchange in effect on the date assets were acquired while monetary assets and liabilities are translated at current rates of exchange as of the balance sheet date. Income and expense items are translated at the average foreign currency rates for the period. Translation adjustments of these subsidiaries are included in other income (expense), net, in our consolidated statements of income.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Royalty Cost of Sales</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We make royalty payments to a number of third parties under license or purchase agreements associated with our acquisition of intellectual property. These royalty payments are typically calculated as a percentage (royalty rate) of the sales of our products in a particular year.&#160;That royalty rate may remain constant, increase or decrease within each year based on the total amount of sales during the annual period. Each quarterly period, we estimate our total royalty obligation for the full year and recognize the proportional amount as cost of sales based on actual quarterly sales as a percentage of full year estimated sales. For example, if the level of net sales in any calendar year increases the royalty rate within the year, we will record our cost of sales at an even rate over the year, based on the estimated blended royalty rate. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accounting for Share-Based Compensation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our share-based compensation programs grant awards that have included stock options, restricted stock units which vest based on stock performance known as market stock units (MSUs), performance-vested restricted stock units which settle in cash (CSPUs), time-vested restricted stock units (RSUs), performance-vested restricted stock units which can be settled in cash or shares of our common stock (PUs) at the sole discretion of the Compensation and Management Development Committee of the Board of Directors and shares issued under our employee stock purchase plan (ESPP). We charge the estimated fair value of awards against income over the requisite service period, which is generally the vesting period. Where awards are made with non-substantive vesting periods (for instance, where a portion of the award vests upon retirement eligibility), we estimate and recognize expense based on the period from the grant date to the date on which the employee is retirement eligible.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair values of our stock option grants are estimated as of the date of grant using a Black-Scholes option valuation model. The estimated fair values of the stock options are then expensed over the options&#8217; vesting periods.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair values of our MSUs are estimated using a lattice model with a Monte Carlo simulation. We apply an accelerated attribution method to recognize share-based compensation expense over the applicable service period, net of estimated forfeitures, when accounting for our MSUs. The probability of actual shares expected to be earned is considered in the grant date valuation, therefore the expense is not adjusted to reflect the actual units earned.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair values of our RSUs are based on the market value of our stock on the date of grant. Compensation expense for RSUs is recognized straight-line over the applicable service period.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We apply an accelerated attribution method to recognize share-based compensation expense when accounting for our CSPUs and PUs and the fair value of the liability is remeasured at the end of each reporting period through expected settlement. Compensation expense associated with CSPUs and PUs are based upon the stock price and the number of units expected to be earned after assessing the probability that certain performance criteria will be met and the associated targeted payout level that is forecasted will be achieved, net of estimated forfeitures. Cumulative adjustments are recorded each quarter to reflect changes in the stock price and estimated outcome of the performance-related conditions until the date results are determined and settled.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The purchase price of common stock under our ESPP is equal to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">85%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the lesser of (i)&#160;the fair market value per share of the common stock on the first business day of an offering period and (ii)&#160;the fair market value per share of the common stock on the purchase date. The fair value of the discounted purchases made under our ESPP is calculated using the Black-Scholes model. The fair value of the look-back provision plus the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> discount is recognized as compensation expense over the 90 day purchase period. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Research and Development Expenses</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development expenses consist of upfront fees and milestones paid to collaborators and expenses incurred in performing research and development activities, which include compensation and benefits, facilities and overhead expenses, clinical trial expenses and fees paid to contract research organizations (CROs), clinical supply and manufacturing expenses, write-offs of inventory that was previously capitalized in anticipation of product launch and determined to no longer be realizable, and other outside expenses. Research and development expenses are expensed as incurred. Payments we make for research and development services prior to the services being rendered are recorded as prepaid assets on our consolidated balance sheets and are expensed as the services are provided. We also accrue the costs of ongoing clinical trials associated with programs that have been terminated or discontinued for which there is no future economic benefit at the time the decision is made to terminate or discontinue the program.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">From time to time, we enter into development agreements in which we share expenses with a collaborative partner. We record payments received from our collaborative partners for their share of the development costs as a reduction of research and development expense, except as discussed in Note&#160;19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements. Because an initial indication has been approved for both RITUXAN and GAZYVA, expenses incurred by Genentech in the ongoing development of RITUXAN and GAZYVA are not recorded as research and development expense, but rather reduce our share of profits recorded as a component of revenues from anti-CD20 therapeutic programs.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For collaborations with commercialized products, if we are the principal, we record revenue and the corresponding operating costs in their respective line items in our consolidated statements of income. If we are not the principal, we record operating costs as a reduction of revenue.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Selling, General and Administrative Expenses</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative expenses are primarily comprised of compensation and benefits associated with sales and marketing, finance, human resources, legal, information technology and other administrative personnel, outside marketing, advertising and legal expenses and other general and administrative costs.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Advertising costs are expensed as incurred. For the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, advertising costs totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$106.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$108.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$92.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Income Taxes</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The provision for income taxes includes federal, state, local and foreign taxes. Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences of temporary differences between the financial statement carrying amounts and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which the temporary differences are expected to be recovered or settled. We evaluate the realizability of our deferred tax assets and establish a valuation allowance when it is more likely than not that all or a portion of deferred tax assets will not be realized.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">All tax effects associated with intercompany transfers of assets in our consolidated group, both current and deferred, are recorded as a prepaid tax or deferred charge and recognized through the consolidated statement of income when the asset transferred is sold to a third party or otherwise recovered through amortization of the asset's remaining economic life.&#160;If the asset transferred becomes impaired, for example through the discontinuation of a research program, we will expense any remaining deferred charge or prepaid tax.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We account for uncertain tax positions using a &#8220;more-likely-than-not&#8221; threshold for recognizing and resolving uncertain tax positions. We evaluate uncertain tax positions on a quarterly basis and consider various factors including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, information obtained during in process audit activities and changes in facts or circumstances related to a tax position. We also accrue for potential interest and penalties related to unrecognized tax benefits in income tax expense.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingencies</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are currently involved in various claims and legal proceedings. Loss contingency provisions are recorded if the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount can be reasonably estimated or a range of loss can be determined. These accruals represent management&#8217;s best estimate of probable loss. Disclosure also is provided when it is reasonably possible that a loss will be incurred or when it is reasonably possible that the amount of a loss will exceed the recorded provision. On a quarterly basis, we review the status of each significant matter and assess its potential financial exposure.&#160;Significant judgment is required in both the determination of probability and the determination as to whether an exposure is reasonably estimable. Because of uncertainties related to these matters, accruals are based only on the best information available at the time. As additional information becomes available, we reassess the potential liability related to pending claims and litigation and may change our estimates. These changes in the estimates of the potential liabilities could have a material impact on our consolidated results of operations and financial position.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Earnings per Share</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share is computed by dividing undistributed net income attributable to Biogen Inc. by the weighted-average number of common shares outstanding during the period. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">New Accounting Pronouncements</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed, we do not believe that the impact of recently issued standards that are not yet effective will have a material impact on our financial position or results of operations upon adoption.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2014 the FASB issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers (Topic 606), which supersedes all existing revenue recognition requirements, including most industry-specific guidance. The new standard requires a company to recognize revenue when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. The FASB has subsequently issued the following amendments to ASU 2014-09 which have the same effective date and transition date of January 1, 2018:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2015 the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date, which delayed the effective date of the new standard from January 1, 2017 to January 1, 2018. The FASB also agreed to allow entities to choose to adopt the standard as of the original effective date. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2016 the FASB issued ASU No. 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations, which clarifies the implementation guidance on principal versus agent considerations. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In April 2016 the FASB issued ASU No. 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing, which clarifies certain aspects of identifying performance obligations and licensing implementation guidance. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2016 the FASB issued ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients related to disclosures of remaining performance obligations, as well as other amendments to guidance on collectability, non-cash consideration and the presentation of sales and other similar taxes collected from customers. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2016 the FASB issued ASU No. 2016-20, Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers, which amends certain narrow aspects of the guidance issued in ASU 2014-09 including guidance related to the disclosure of remaining performance obligations and prior-period performance obligations, as well as other amendments to the guidance on loan guarantee fees, contract costs, refund liabilities, advertising costs and the clarification of certain examples. </font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are currently evaluating the method of adoption and the potential impact that Topic 606 may have on our financial position and results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In April 2015 the FASB issued ASU No. 2015-05, Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Customer's Accounting for Fees Paid in a Cloud Computing Arrangement. Under this standard, if a cloud computing arrangement includes a software license, the software license element of the arrangement should be accounted for consistent with the acquisition of other software licenses. If a cloud computing arrangement does not include a software license, the arrangement should be accounted for as a service contract. We adopted this standard as of January 1, 2016, which did not have an impact on our financial position or results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2015 the FASB issued ASU No. 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory. The new standard applies only to inventory for which cost is determined by methods other than last-in, first-out and the retail inventory method, which includes inventory that is measured using first-in, first-out or average cost. Inventory within the scope of this standard is required to be measured at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. We adopted this standard as of January 1, 2016, which did not have an impact on our financial position or results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In September 2015 the FASB issued ASU No. 2015-16, Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments. The new standard requires that an acquirer recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined and sets forth new disclosure requirements related to the adjustments. We adopted this standard as of January 1, 2016, which did not have an impact on our financial position or results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2016 the FASB issued ASU No. 2016-01, Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. This new standard amends certain aspects of accounting and disclosure requirements of financial instruments, including the requirement that equity investments with readily determinable fair values be measured at fair value with changes in fair value recognized in our results of operations. This new standard does not apply to investments accounted for under the equity method of accounting or those that result in consolidation of the investee. Equity investments that do not have readily determinable fair values may be measured at fair value or at cost minus impairment adjusted for changes in observable prices. A financial liability that is measured at fair value in accordance with the fair value option is required to be presented separately in other comprehensive income for the portion of the total change in the fair value resulting from change in the instrument-specific credit risk. In addition, a valuation allowance should be evaluated on deferred tax assets related to available-for-sale debt securities in combination with other deferred tax assets. This new standard will be effective for us on January 1, 2018. The adoption of this standard is not expected to have a material impact on our financial position or results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2016 the FASB issued ASU No. 2016-02, Leases (Topic 842). This new standard requires that all lessees recognize the assets and liabilities that arise from leases on the balance sheet and disclose qualitative and quantitative information about its leasing arrangements. This new standard will be effective for us on January 1, 2019. The adoption of this standard is not expected to have a material impact on our net financial position, but will impact the amount of our assets and liabilities. We are currently evaluating the potential impact that this standard may have on our results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2016 the FASB issued ASU No. 2016-06, Derivatives and Hedging (Topic 815): Contingent Put and Call Options in Debt Instruments. This new standard simplifies the embedded derivative analysis for debt instruments containing contingent call or put options by removing the requirement to assess whether a contingent event is related to interest rates or credit risks. This new standard will be effective for us on January 1, 2017. The adoption of this standard is not expected to have an impact on our financial position or results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2016 the FASB issued ASU No. 2016-07, Investments - Equity Method and Joint Ventures (Topic 323): Simplifying the Transition to the Equity Method of Accounting. This new standard eliminates the requirement that when an investment qualifies for use of the equity method as a result of an increase in the level of ownership interest or degree of influence, an adjustment must be made to the investment, results of operations and retained earnings retroactively on a step-by-step basis as if the equity method had been in effect during all previous periods that the investment has been held. This new standard will be effective for us on January 1, 2017. The adoption of this standard is not expected to have a material impact on our financial position or results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2016 the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. This new standard requires recognition of the income tax effects of vested or settled awards in the income statement and involves several other aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities and classification on the statement of cash flows. This new standard will be effective for us on January 1, 2017. The adoption of this standard is not expected to have a material impact on our financial position, results of operations or statements of cash flows upon adoption.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2016 the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. This new standard changes the impairment model for most financial assets and certain other instruments. Under the new standard, entities holding financial assets and net investment in leases that are not accounted for at fair value through net income to be presented at the net amount expected to be collected. An allowance for credit losses will be a valuation account that will be deducted from the amortized cost basis of the financial asset to present the net carrying value at the amount expected to be collected on the financial asset. This new standard will be effective for us on January 1, 2020. The adoption of this standard is not expected to have a material impact on our financial position or results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2016 the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. This new standard clarifies certain aspects of the statement of cash flows, including the classification of debt prepayment or debt extinguishment costs or other debt instruments with coupon interest rates that are insignificant in relation to the effective interest rate of the borrowing, contingent consideration payments made after a business combination, proceeds from the settlement of insurance claims, proceeds from the settlement of corporate-owned life insurance policies, distributions received from equity method investees and beneficial interests in securitization transactions. This new standard also clarifies that an entity should determine each separately identifiable source of use within the cash receipts and payments on the basis of the nature of the underlying cash flows. In situations in which cash receipts and payments have aspects of more than one class of cash flows and cannot be separated by source or use, the appropriate classification should depend on the activity that is likely to be the predominant source or use of cash flows for the item. This new standard will be effective for us on January 1, 2018. The adoption of this standard is not expected to have a material impact on our statements of cash flows upon adoption.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2016 the FASB issued ASU No. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfer of Assets Other Than Inventory. This new standard eliminates the exception for an intra-entity transfer of an asset other than inventory. Under the new standard, entities should recognize the income tax consequences on an intra-entity transfer of an asset other than inventory when the transfer occurs. This new standard will be effective for us on January 1, 2018 and will be applied on a modified retrospective basis through a cumulative-effect adjustment directly to retained earnings as of the beginning of the period of adoption. We are currently evaluating the potential impact this standard may have on our financial position and results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2017 the FASB issued ASU No. 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business. This new standard clarifies the definition of a business and provides a screen to determine when an integrated set of assets and activities is not a business. The screen requires that when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the set is not a business. This new standard will be effective for us on January 1, 2018. However, we have adopted this standard as of January 1, 2017, with prospective application to any business development transaction.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6824505856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock', window );">Acquisitions</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">&#160;&#160;&#160;&#160;Acquisitions</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Convergence Pharmaceuticals</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On February 12, 2015, we completed our acquisition of all of the outstanding stock of Convergence Pharmaceuticals (Convergence), a clinical-stage biopharmaceutical company with a focus on developing product candidates for neuropathic pain. Convergence&#8217;s lead candidate was a Phase 2 clinical candidate BIIB074 (CNV1014802), which had demonstrated clinical activity in proof-of-concept studies for TGN. Additionally, BIIB074 had potential applicability in several other neuropathic pain states, including lumbosacral radiculopathy and erythromelalgia. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The purchase price consisted of a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$200.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> cash payment at closing, plus contingent consideration in the form of development and approval milestones up to a maximum of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$450.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, of which </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$350.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was associated with the development and approval of BIIB074 for the treatment of TGN. The acquisition was funded from our existing cash on hand and was accounted for as the acquisition of a business. In addition to obtaining the rights to BIIB074 and additional product candidates in preclinical development, we retained the services of key employees of Convergence. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisition of Convergence, we recorded a liability of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$274.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> representing the fair value of the contingent consideration.&#160;This amount was estimated through a valuation model that incorporated industry-based probability adjusted assumptions relating to the achievement of these milestones and thus the likelihood of making the contingent payments. This fair value measurement was based upon significant inputs not observable in the market and therefore represented a Level 3 measurement. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The purchase price, as adjusted, consisted of the following:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash portion of consideration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">200.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">274.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total purchase price</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">474.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the second quarter of 2015 we adjusted our preliminary estimate of the fair value of the assets acquired and contingent consideration as of the date of acquisition as a result of finalizing the purchase price accounting. This resulted in an increase in the value of our estimated contingent consideration and goodwill by </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$36.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Our revised purchase price allocation is reflected in the chart below. Our purchase price allocation is complete.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subsequent changes in the fair value of the contingent consideration obligation will be recognized as adjustments to contingent consideration and reflected in our consolidated statements of income. In the fourth quarter of 2016 a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$50.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> milestone related to BIIB074 in an additional neuropathic pain indication was earned and paid, resulting in a reduction to the contingent consideration. For additional information related to the fair value of this obligation, please read Note 7,&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Fair Value Measurements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the estimated fair values of the separately identifiable assets acquired and liabilities assumed as of February&#160;12, 2015, as adjusted:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In-process research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">424.6</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">128.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferred tax liability</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(84.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total purchase price</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">474.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our estimate of the fair value of the IPR&amp;D programs acquired was determined through a probability adjusted discounted cash flow analysis utilizing a discount rate of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This valuation was primarily driven by the value associated with the lead candidate, BIIB074, which is in development for the treatment of TGN and was expected to be completed no earlier than 2020, at a remaining cost of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$145.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The fair value associated with BIIB074 for the treatment of TGN was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$200.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We recorded additional IPR&amp;D assets related to the use of BIIB074 in two additional neuropathic pain indications, with a total estimated value of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$220.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The remaining cost of development for these two indications was approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$415.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, with an expected completion date of no earlier than 2021. These fair value measurements were based on significant inputs not observable in the market and thus represented Level 3 fair value measurements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We attributed the goodwill recognized to the Convergence workforce's expertise in chronic pain research and clinical development and to establishing a deferred tax liability for the acquired IPR&amp;D intangible assets which had no tax basis. The goodwill was not tax deductible.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pro forma results of operations would not be materially different as a result of the acquisition of Convergence and therefore are not presented. Subsequent to the acquisition date, our results of operations include the results of operations of Convergence.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures.  This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6895528576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Restructuring<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Restructuring, Business Transformation and Other Cost Saving Initiatives</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">2015 Cost Saving Initiatives</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">2015 Restructuring Charges</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On October 21, 2015, we announced a corporate restructuring, which included the termination of certain pipeline programs and an </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> reduction in workforce. Under this restructuring, cash payments were estimated to total approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$120.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, of which </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> were related to previously accrued 2015 incentive compensation, resulting in net restructuring charges totaling approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$102.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. These amounts were substantially paid by the end of 2016.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized total net restructuring charges of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$8.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We previously recognized </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$93.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of restructuring charges in our consolidated statements of income during the fourth quarter of 2015.&#160;Our restructuring reserve is included in accrued expenses and other in our consolidated balance sheets.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the charges and spending related to our 2015 restructuring program during 2016:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Workforce</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Reduction</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Pipeline</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Programs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restructuring reserve as of December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">33.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">37.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(31.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(9.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(40.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments to previous estimates, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(5.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(2.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restructuring reserve as of December 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">2016 Organizational Changes and Cost Saving Initiatives</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">2016 Restructuring Charges</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the third quarter of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> we initiated cost saving measures primarily intended to realign our organizational structure due to the changes in roles and workforce resulting from our decision to spin off our hemophilia business, and to achieve further targeted cost reductions. For the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized charges totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$17.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to this effort, which are in addition to, and separate from, the 2015 corporate restructuring described above. These amounts, which were substantially incurred and paid by the end of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, are primarily related to severance and are reflected in restructuring charges in our consolidated statements of income.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Cambridge, MA Manufacturing Facility</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2016 following an evaluation of our current and future manufacturing capabilities and capacity needs, we determined that we intend to vacate and cease manufacturing in our 67,000 square foot small-scale biologics manufacturing facility in Cambridge, MA and also vacate our 46,000 square foot warehouse space in Somerville, MA.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December&#160;2016 we subleased our rights to the manufacturing facility in Cambridge, MA to Brammer Bio MA,&#160;LLC (Brammer). Brammer also purchased from us certain manufacturing equipment, leasehold improvements and other assets in exchange for shares of Brammer common LLC interests and assumed manufacturing operations effective January 1, 2017. In December 2016 we also closed and vacated our warehouse space in Somerville, MA.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our departure from these facilities shortened the expected useful lives of certain leasehold improvements and other assets at these facilities. As a result, we recorded additional depreciation expense to reflect the assets' new shorter useful lives. For the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$45.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of this additional depreciation, which was recorded as cost of sales in our consolidated statements of income.</font></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the terms of the agreement, Brammer will also provide manufacturing and other transition and support services to us.</font></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the fourth quarter of 2016 we recognized charges totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$7.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for severance costs related to certain employees separated from Biogen in connection with this transaction. These amounts will be substantially incurred and paid by the end of first quarter of 2017 and are reflected in restructuring charges in our consolidated statements of income.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140864-122747<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6824465360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Reserves<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ReservesForDiscountsAndAllowancesAbstract', window );"><strong>Reserves for Discounts and Allowances [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock', window );">Reserves for Discounts and Allowances</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Reserves for Discounts and Allowances</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">An analysis of the change in reserves for discounts and allowances is summarized as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Discounts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Returns</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Beginning balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">56.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">548.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">57.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">662.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current provisions relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">592.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,044.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">30.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,668.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments relating to prior years</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(16.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(16.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/returns relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(522.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1,576.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(2,099.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/returns relating to sales in prior years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(53.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(536.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(19.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(609.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Ending balance</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">71.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">482.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">51.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">605.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Discounts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Returns</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">2015</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Beginning balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">47.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">387.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">483.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current provisions relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">459.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,732.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,229.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments relating to prior years</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(16.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(14.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(32.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/returns relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(405.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1,258.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1,666.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/returns relating to sales in prior years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(44.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(296.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(11.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(351.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Ending balance</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">56.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">548.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">57.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">662.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Discounts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Returns</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">2014</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Beginning balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">47.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">345.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">33.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">426.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current provisions relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">347.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,265.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">39.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,651.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments relating to prior years</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(28.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(16.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/returns relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(299.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(933.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1,237.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/returns relating to sales in prior years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(46.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(261.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(33.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(341.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Ending balance</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">47.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">387.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">483.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The total revenue-related reserves above, included in our consolidated balance sheets, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Reduction of accounts receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">166.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">144.6</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Component of accrued expenses and other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">438.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">518.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenue-related reserves</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">605.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">662.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ReservesForDiscountsAndAllowancesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ReservesForDiscountsAndAllowancesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for any allowance and reserve accounts (their beginning and ending balances, as well as a reconciliation by type of activity during the period). Alternatively, disclosure of the required information may be within the footnotes to the financial statements or a supplemental schedule to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6895460208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">&#160;&#160;&#160;&#160;Inventory</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The components of inventory are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Raw materials</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">170.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">213.0</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Work in process</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">698.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">577.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Finished goods</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">170.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">143.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total inventory</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,039.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">933.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Balance Sheet Classification:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,001.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">893.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">37.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">40.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total inventory</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,039.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">933.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-term inventory, which primarily consists of work in process, is included in investments and other assets in our consolidated balance sheets.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our inventory included </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$24.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> associated with our ZINBRYTA program, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$24.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> associated with our FLIXABI program and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$18.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> associated with our BENEPALI program, which had been capitalized in advance of regulatory approval. The European Commission (EC) approved the marketing authorization applications for BENEPALI and FLIXABI, two anti-tumor necrosis factor (TNF) biosimilars, for marketing in the E.U. in January 2016 and May 2016, respectively. In addition, ZINBRYTA was approved for the treatment of relapsing forms of MS in the U.S. in May 2016 and in the E.U. in July 2016. For information on our pre-approval inventory policy, please read Note 1,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"> Summary of Significant Accounting Policies</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory amounts written down as a result of excess, obsolescence, unmarketability or other reasons are charged to cost of sales, and totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$48.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$41.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$50.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6824478928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Intangible Assets and Goodwill</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">&#160;&#160;&#160;&#160;Intangible Assets and Goodwill</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Intangible Assets</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets, net of accumulated amortization, impairment charges and adjustments, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="26" rowspan="1"></td></tr><tr><td style="width:21%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">As of December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated Life</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Out-licensed patents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13-23 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">543.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(523.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">19.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">543.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(506.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Developed technology</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15-23 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,005.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(2,634.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">371.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,005.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2,552.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">452.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In-process research and development</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indefinite until commercialization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">648.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">648.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">730.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">730.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Trademarks and trade names</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indefinite</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">64.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">64.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired and in-licensed rights and patents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6-18 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,481.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(776.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,705.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,303.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(502.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,800.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total intangible assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7,742.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(3,934.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,808.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7,646.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3,561.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,085.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amortization of acquired intangible assets totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$385.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$382.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$489.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Amortization of acquired intangible assets during 2016 included impairment charges of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$12.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to two of our IPR&amp;D intangible assets. Amortization of acquired intangible assets during </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> included impairment charges of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$34.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to one of our out-licensed patents and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$16.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to one of our IPR&amp;D intangible assets. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Out-licensed Patents</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Out-licensed patents to third-parties primarily relate to patents acquired in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003. During 2014 we recorded a charge of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$34.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to the impairment of one of our out-licensed patents to reflect a change in its estimated fair value due to a change in the underlying competitive market for that product. The charge was included in amortization of acquired intangible assets in our consolidated statements of income. The fair value of the intangible asset was based on a discounted cash flow calculated using Level 3 fair value measurements and inputs including estimated revenues. There were no impairment charges related to our out-licensed patents during </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> or </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Developed Technology</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Developed technology primarily relates to our AVONEX product, which was recorded in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003. The net book value of this asset as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$363.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">IPR&amp;D</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">IPR&amp;D represents the fair value assigned to research and development assets that we acquire and have not reached technological feasibility at the date of acquisition. Upon commercialization, we will determine the estimated useful life. In connection with our acquisition of Convergence in February 2015, we acquired IPR&amp;D programs with an estimated fair value of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$424.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This amount has and will be adjusted for foreign exchange rate fluctuations. For a more detailed description of this transaction, please read Note 2, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">An analysis of anticipated lifetime revenues and anticipated development costs is performed annually during our long- range planning cycle, which was updated in the third quarter of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.&#160;This analysis is based upon certain assumptions that we evaluate on a periodic basis, including anticipated future product sales, the expected impact of changes in the amount of development costs and the probabilities of our programs succeeding, the introduction of new products by our competitors and changes in our commercial and pipeline product candidates.&#160;&#160; </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the fourth quarter of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> we terminated our collaboration agreements with Rodin Therapeutics, Inc. and Ataxion Inc., resulting in impairment losses of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$8.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, reflecting the full value of the assets recorded upon entering into the collaboration agreements. These impairment losses are included in amortization of acquired intangible assets in our consolidated statements of income.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the third quarter of 2014 we updated the probabilities of success related to the early stage programs acquired through our recent acquisitions.&#160;The change in probability of success, combined with a delay in one of the projects, resulted in an impairment loss of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$16.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in one of our IPR&amp;D assets during 2014.&#160;This impairment is included in amortization of acquired intangible assets in our consolidated statements of income.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Acquired and In-licensed Rights and Patents</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired and in-licensed rights and patents primarily relate to our acquisition of all remaining rights to TYSABRI from Elan Corporation plc (Elan). The net book value of this asset as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2,493.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The net change in acquired and in-licensed rights and patents during the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, reflects:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$60.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> milestone payment due to Ionis Pharmaceuticals, Inc. (Ionis) for the approval of SPINRAZA in the U.S. in December 2016;</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$50.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in total milestone payments due to Samsung Bioepis, which became payable upon the approval of BENEPALI and FLIXABI in the E.U. in January 2016 and May 2016, respectively;</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$32.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in total milestone payments due to AbbVie, Inc. (AbbVie), which became payable upon the approval of ZINBRYTA in the U.S. in May 2016 and the E.U. in July 2016; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$26.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> upon the approval of ALPROLIX in the E.U. in May 2016 which is comprised of a </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$20.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> contingent payment due to the former owners of Syntonix Pharmaceuticals, Inc. (Syntonix) and </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$6.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to the establishment of a corresponding deferred tax liability.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our relationships with Samsung Bioepis, AbbVie and Ionis, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Estimated Future Amortization of Intangible Assets</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;"> </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our amortization expense is based on the economic consumption of intangible assets. Our most significant intangible assets are related to our AVONEX and TYSABRI products. Annually, during our long-range planning cycle, we perform an analysis of anticipated lifetime revenues of AVONEX and TYSABRI. This analysis is also updated whenever events or changes in circumstances would significantly affect the anticipated lifetime revenues of either product.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our most recent long range planning cycle was completed in the third quarter of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Based upon this analysis, the estimated future amortization of acquired intangible assets is expected to be as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:81%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">As of December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">334.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">312.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">295.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">259.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">242.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Goodwill</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table provides a roll forward of the changes in our goodwill balance:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill, beginning of year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,663.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,760.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Increase to goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,026.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">908.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(21.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill, end of year</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,669.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,663.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The increase in goodwill during </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was related to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.2 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in contingent milestones achieved (exclusive of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$173.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in tax benefits) and payable to the former shareholders of Fumapharm AG or holders of their rights. Other includes changes related to foreign exchange rate fluctuations. The increase in goodwill during </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was related to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$900.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in contingent milestones achieved (exclusive of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$120.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in tax benefits) and payable to the former shareholders of Fumapharm AG or holders of their rights and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$128.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to our acquisition of Convergence.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information related to future contingent payments to the former shareholders of Fumapharm AG or holders of their rights, please read Note 21, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Commitments and Contingencies</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements. For additional information related to our acquisition of Convergence, please read Note 2, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">no</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> accumulated impairment losses related to goodwill.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final.  May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6895460208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Fair Value Measurements</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br clear="none"/>December 31, <br clear="none"/>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quoted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Prices in</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Active</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level&#160;1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Observable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level&#160;2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level&#160;3)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,039.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,039.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable debt securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,663.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,663.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,172.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,172.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">561.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">561.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">24.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">24.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">61.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">61.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Plan assets for deferred compensation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">34.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">34.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7,558.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">24.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7,533.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">13.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">13.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration obligations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">467.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">467.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">481.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">13.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">467.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br clear="none"/>December 31, <br clear="none"/>2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quoted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Prices</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">in&#160;Active</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Observable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">909.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">909.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable debt securities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,510.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,510.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,875.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,875.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">494.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">494.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">27.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">27.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Plan assets for deferred compensation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">40.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">40.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,895.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,857.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">14.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">14.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration obligations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">506.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">506.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">520.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">14.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">506.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair value of Level 2 instruments classified as cash equivalents and marketable debt securities were determined through third-party pricing services. For a description of our validation procedures related to prices provided by third-party pricing services, refer to Note 1, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies: Fair Value Measurements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Debt Instruments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes payable to Fumedica</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.875% Senior Notes due March 1, 2018</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">583.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">602.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.900% Senior Notes due September 15, 2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,521.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,497.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.625% Senior Notes due September 15, 2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,026.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,014.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.050% Senior Notes due September 15, 2025</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,796.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,764.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.200% Senior Notes due September 15, 2045</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,874.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,757.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6,808.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,645.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair value of our notes payable to Fumedica was estimated using market observable inputs, including current interest and foreign currency exchange rates. The fair values of each of our series of Senior Notes were determined through market, observable, and corroborated sources. For additional information related to our debt instruments, please read Note 11, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Indebtedness</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Consideration Obligations</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table provides a roll forward of the fair values of our contingent consideration obligations which includes Level 3 measurements:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As&#160;of&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value, beginning of year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">506.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">215.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Additions</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">274.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Changes in fair value</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">14.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments and other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(53.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(14.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value, end of year</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">467.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">506.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$246.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$301.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, of the fair value of our total contingent consideration obligations was reflected as a component of other long-term liabilities in our consolidated balance sheets with the remaining balance reflected as a component of accrued expenses and other. Payments and other for 2016 includes </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$7.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of a Convergence milestone converted to a short-term obligation under the terms of the acquisition agreement.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">There were </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">no</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> changes in valuation techniques or transfers between fair value measurement levels during the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The fair values of the intangible assets and contingent consideration liabilities were based on a probability-adjusted discounted cash flow calculation using Level 3 fair value measurements and inputs including estimated revenues and probabilities of success. For additional information related to the valuation techniques and inputs utilized in valuation of our financial assets and liabilities, please read Note 1, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Convergence</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisition of Convergence in February 2015 we recorded a contingent consideration obligation of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$274.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This valuation was based on probability weighted net cash outflow projections of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$450.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, discounted using a rate of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.0%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which was the estimated cost of debt financing for market participants. This liability reflected the revised estimate from the date of acquisition for our initial clinical development plans, resulting probabilities of success and the timing of certain milestone payments. For a more detailed description of this transaction, please read Note 2, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the fair value of this contingent consideration obligation was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$258.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$297.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Our most recent valuation was determined based upon probability weighted net cash flow projections of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$400.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, discounted using a rate of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.7%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which is a measure of the credit risk associated with settling the liability. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the net decrease in the fair value of this obligation was primarily due to achievement of a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$50.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> milestone related to a second indication, partially offset by changes in the discount rate and an increase in the probability of success related to the achievement of certain developmental milestones. Approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$148.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> is reflected as a component of accrued expenses and other in our consolidated balance sheets as we expect to make the payment within one year.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Stromedix Inc.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisition of Stromedix Inc. (Stromedix) in March 2012 we recorded a contingent consideration obligation of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$122.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the fair value of this contingent consideration obligation was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$133.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$131.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Our most recent valuation was determined based upon probability weighted net cash outflow projections of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$419.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, discounted using a rate of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.2%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which is a measure of the credit risk associated with settling the liability. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the net increase in the fair value of this obligation was primarily due to changes in the discount rate, partially offset by changes in the expected timing related to the achievement of certain remaining developmental milestones. Approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$56.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> is reflected as a component of accrued expenses and other in our consolidated balance sheets as we expect to make the payment within one year.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Biogen Idec International Neuroscience GmbH</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisition of Biogen Idec International Neuroscience GmbH (BIN), formerly Panima Pharmaceuticals AG (Panima), in December 2010 we recorded a contingent consideration obligation of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$81.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the fair value of this contingent consideration obligation was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$75.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$77.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Our most recent valuation was determined based upon probability weighted net cash outflow projections of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$361.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, discounted using a rate of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.7%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which is a measure of the credit risk associated with settling the liability. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the net decrease in the fair value of this obligation was primarily due to payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in developmental milestones, partially offset by changes in the discount rate. Approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> is reflected as a component of accrued expenses and other in our consolidated balance sheets as we expect to make the payment within one year.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Acquired IPR&amp;D</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisition of Convergence, we also allocated </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$424.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the total purchase price to acquired IPR&amp;D, which was capitalized as an intangible asset. The amount allocated to acquired IPR&amp;D was based on significant inputs not observable in the market and thus represented a Level 3 fair value measurement. This estimate was also adjusted from our preliminary estimate as of the date of acquisition to reflect revised estimates to our initial clinical development plans, resulting probabilities of success and the timing of certain milestone payments. These assets will be tested for impairment annually until commercialization, after which time the IPR&amp;D will be amortized over its estimated useful life. For a more detailed description of this transaction, please read Note 2, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14172-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13537-108611<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13504-108611<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6895548112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Investments, All Other Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock', window );">Financial Instruments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Financial Instruments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our financial assets with maturities of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">less than 90&#160;days</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> from the date of purchase included in cash and cash equivalents on the accompanying consolidated balance sheet:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Commercial paper</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">31.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Overnight reverse repurchase agreements</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">134.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Money market funds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">741.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">673.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Short-term debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,266.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">79.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,039.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">909.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The carrying values of our commercial paper, including accrued interest, overnight reverse repurchase agreements, money market funds and our short-term debt securities approximate fair value due to their short term maturities. Our overnight reverse repurchase agreements were collateralized with agency-guaranteed mortgage-backed securities and represented approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.7%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of total assets as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables summarize our marketable debt and equity securities, classified as available for sale:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2016 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,408.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(0.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,409.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,255.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(4.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,258.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,156.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,156.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,016.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(3.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,019.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">557.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(2.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">559.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total marketable debt securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5,398.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(11.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5,406.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities, non-current</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">24.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(9.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">33.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2015 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">394.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">394.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,116.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,120.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,723.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,724.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,152.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,155.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">491.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">493.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total marketable debt securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,880.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(10.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,891.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities, non-current</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">28.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Summary of Contractual Maturities: Available-for-Sale Securities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">As of December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair&#160; Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair&#160; Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due in one year or less</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,568.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,569.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,120.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,122.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due after one year through five years</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,552.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,559.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,575.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,583.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due after five years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">276.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">277.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">184.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">185.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total available-for-sale securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5,398.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5,406.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,880.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,891.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The average maturity of our marketable debt securities available-for-sale as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;months and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Proceeds from Marketable Debt Securities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Proceeds from maturities and sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7,378.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,063.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,718.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Realized gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Realized losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Realized losses for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, primarily relate to sales of corporate bonds, agency mortgage-backed securities and other asset-backed securities. Realized losses for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, primarily relate to sales of corporate bonds, agency mortgage-backed securities and other asset-backed securities. Realized losses for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, primarily relate to sales of agency mortgage-backed securities and government securities.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Strategic Investments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our strategic investment portfolio was comprised of investments totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$99.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$96.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, which are included in investments and other assets in our consolidated balance sheets. Our strategic investment portfolio includes investments in equity securities of certain biotechnology companies and investments in venture capital funds where the underlying investments are in equity securities of biotechnology companies.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6703090864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Derivative Instruments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Derivative Instruments</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Foreign Currency Forward Contracts - Hedging Instruments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due to the global nature of our operations, portions of our revenues and operating expenses are recorded in currencies other than the U.S.&#160;dollar. The value of revenues and operating expenses measured in U.S.&#160;dollars is therefore subject to changes in foreign currency exchange rates. In order to mitigate these changes we use foreign currency forward contracts to lock in exchange rates associated with a portion of our forecasted international revenues and operating expenses.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign currency forward contracts in effect as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, had durations of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18 months</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. These contracts have been designated as cash flow hedges and accordingly, to the extent effective, any unrealized gains or losses on these foreign currency forward contracts are reported in accumulated other comprehensive income (loss) (referred to as AOCI in the tables below). Realized gains and losses for the effective portion of such contracts are recognized in revenue when the sale of product in the currency being hedged is recognized and, beginning in the fourth quarter of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, in operating expenses when the expense in the currency being hedged is recorded. To the extent ineffective, hedge transaction gains and losses are reported in other income (expense), net.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenues and operating expenses is summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Notional Amount</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As&#160;of&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Foreign Currency: (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Euro</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">871.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">945.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Swiss francs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">80.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Canadian dollar</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">76.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total foreign currency forward contracts</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">871.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,103.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The portion of the fair value of these foreign currency forward contracts that was included in accumulated other comprehensive income (loss) in total equity reflected net gains of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$49.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$72.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. We expect all contracts to be settled over the next </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18 months</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and any amounts in accumulated other comprehensive income (loss) to be reported as an adjustment to revenue or operating expense. We consider the impact of our and our counterparties&#8217; credit risk on the fair value of the contracts as well as the ability of each party to execute its contractual obligations. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, credit risk did not change the fair value of our foreign currency forward contracts.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the effect of foreign currency forward contracts designated as hedging instruments on our consolidated statements of income:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="27" rowspan="1"></td></tr><tr><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="27" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December 31,</font></div></td></tr><tr><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Reclassified from AOCI into Net Income</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;">(Effective Portion)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized into Net Income</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;">(Ineffective Portion)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">173.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.8</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Interest Rate Contracts - Hedging Instruments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have entered into interest rate lock contracts or interest rate swap contracts on certain borrowing transactions to manage our exposure to interest rate changes and to reduce our overall cost of borrowing. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Interest Rate Lock Contracts</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> we entered into treasury rate locks, with an aggregated notional amount of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.1 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which were designated as cash flow hedges to hedge against changes in the 10-year and 30-year U.S. treasury interest rates that could have impacted our anticipated debt offering. In connection with the issuance of our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.05%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.20%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes, as described in Note 11, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Indebtedness</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we settled the treasury rate locks and realized an </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$8.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> gain. As the hedging relationship was effective, the gain was recorded in AOCI and will be recognized in other income (expense), net over the life of the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.05%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.20%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Interest Rate Swap Contracts</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the issuance of our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.90%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes, as described in Note 11, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Indebtedness</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we entered into interest rate swaps with an aggregate notional amount of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$675.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which expire on September 15, 2020. The interest rate swap contracts are designated as hedges of the fair value changes in the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.90%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes attributable to changes in interest rates. Since the specific terms and notional amount of the swaps match the debt being hedged, it is assumed to be a highly effective hedge and all changes in the fair value of the swaps are recorded as a component of the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.90%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes with no net impact recorded in income. Any net interest payments made or received on the interest rate swap contracts are recognized as a component of interest expense in our consolidated statements of income.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Foreign Currency Forward Contracts - Other Derivatives</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also enter into other foreign currency forward contracts, usually with durations of one month or less, to mitigate the foreign currency risk related to certain balance sheet positions. We have not elected hedge accounting for these transactions.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The aggregate notional amount of these outstanding foreign currency contracts was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$902.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$721.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Net losses of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$29.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$23.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to these contracts were recognized as a component of other income (expense), net, for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Summary of Derivatives</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">While certain of our derivatives are subject to netting arrangements with our counterparties, we do not offset derivative assets and liabilities in our consolidated balance sheets.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the fair value and presentation in our consolidated balance sheets of our outstanding derivatives including those designated as hedging instruments:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.61013645224172%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance&#160;Sheet&#160;Location</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">Fair Value<br clear="none"/>As of December 31, 2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hedging Instruments:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">50.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Other Derivatives:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued&#160;expenses&#160;and&#160;other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">9.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.61013645224172%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance Sheet Location</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value<br clear="none"/>As of December 31, 2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hedging Instruments:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued&#160;expenses&#160;and&#160;other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Other Derivatives:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued&#160;expenses&#160;and&#160;other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6441202&amp;loc=d3e80720-113993<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624171-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=d3e41620-113959<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624163-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5579240-113959<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4D<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624177-113959<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=35736893&amp;loc=d3e80784-113994<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=d3e41641-113959<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5579245-113959<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4H<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624258-113959<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35736893&amp;loc=d3e80748-113994<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5708775-113959<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5708773-113959<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5618551-113959<br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5580258-113959<br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4E<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624181-113959<br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 25<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6886632&amp;loc=d3e76258-113986<br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=d3e41638-113959<br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6824465360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Property, Plant and Equipment</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Property, plant and equipment are recorded at historical cost, net of accumulated depreciation. Components of property, plant and equipment, net are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Land</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">137.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">74.7</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Buildings</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,107.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,035.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Leasehold improvements</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">123.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">166.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Machinery and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,105.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,079.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Computer software and hardware</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">746.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">647.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Furniture and fixtures</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">60.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">72.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Construction in progress</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">658.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">441.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total cost</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,941.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,517.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Less: accumulated depreciation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1,439.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1,330.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total property, plant and equipment, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,501.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,187.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Depreciation expense totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$309.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$217.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$198.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we capitalized interest costs related to construction in progress totaling approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$12.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$6.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Solothurn, Switzerland Facility</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the first quarter of 2016 we closed on the purchase of land in Solothurn, Switzerland for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Swiss Francs (approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$62.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">). We are building a biologics manufacturing facility on this land in the Commune of Luterbach over the next several years. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$481.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$99.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, capitalized as construction in progress related to the construction of this facility. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Research Triangle Park Facility Purchase</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On August 24, 2015, we purchased from Eisai, Inc. (Eisai) its drug product manufacturing facility and supporting infrastructure in Research Triangle Park (RTP), North Carolina for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$104.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The purchase price consisted of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$58.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for buildings, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$25.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for machinery and equipment and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$20.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for land.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On August 24, 2015, we also amended our existing </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">-year lease related to Eisai's oral solid dose products manufacturing facility in RTP, North Carolina where we manufacture our and Eisai's oral solid dose products. As amended, the lease provides for a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">-year term and our agreement to purchase the facility upon expiration of the lease term and Eisai's completion of certain activities. Accordingly, we recorded the assets along with a corresponding financing obligation on our consolidated balance sheet for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$20.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the net present value of the future minimum lease payments. The assets were recorded as a component of buildings and machinery and equipment. We expect to complete the purchase of the oral solid products manufacturing facility at the end of the lease term in the third quarter of 2018.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13-14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=d3e1361-107760<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64862545&amp;loc=d3e2921-110230<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6895514976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Indebtedness<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Indebtedness</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Indebtedness</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our indebtedness is summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Current portion:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes payable to Fumedica</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Financing arrangement for the purchase of the RTP facility</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current portion of notes payable and other financing arrangements</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Non-current portion:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.875% Senior Notes due March 1, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">558.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">565.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.900% Senior Notes due September 15, 2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,485.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,485.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.625% Senior Notes due September 15, 2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">993.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">992.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.050% Senior Notes due September 15, 2025</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,734.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,733.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.200% Senior Notes due September 15, 2045</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,721.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,721.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes payable to Fumedica</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Financing arrangement for the purchase of the RTP facility</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">16.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current portion of notes payable and other financing arrangements</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6,512.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,521.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following is a summary of our principal indebtedness as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$550.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> aggregate principal amount of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">6.875%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes due March 1, 2018, valued at </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">99.184%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of par;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> aggregate principal amount of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2.90%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes due September 15, 2020, valued at </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">99.792%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of par;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> aggregate principal amount of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">3.625%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes due September 15, 2022, valued at </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">99.920%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of par;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1.75 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> aggregate principal amount of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">4.05%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes due September 15, 2025, valued at </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">99.764%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of par; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1.75 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> aggregate principal amount of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">5.20%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes due September 15,&#160;2045, valued at </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">99.294%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of par.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The costs associated with these offerings of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$52.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> have been recorded as a reduction to the carrying amount of the debt on our consolidated balance sheet. These costs along with the discounts will be amortized as additional interest expense using the effective interest rate method over the period from issuance through maturity. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These notes are senior unsecured obligations. The notes may be redeemed at our option at any time at </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the principal amount plus accrued interest and a specified make-whole amount. The </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.875%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes due in 2018 contain a change of control provision that may require us to purchase the notes under certain circumstances. There is also an interest rate adjustment feature that requires us to pay interest at an increased rate on the notes if the credit rating on the notes declines below investment grade. The remaining Senior Notes contain a change of control provision that may require us to purchase the notes at a price equal to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">101%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the principal amount plus accrued and unpaid interest to the date of purchase under certain circumstances.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.90%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes offering due in 2020, we entered into interest rate swap contracts. The carrying value of the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.90%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes includes approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$4.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to changes in the fair value of these contracts. For additional information, please read Note 9, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Derivative Instruments, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.875%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;Senior Notes due in 2018, we entered into interest rate swap contracts where we received a fixed rate and paid a variable rate. These contracts were terminated in December 2008. Upon termination of these swaps, the carrying amount of the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.875%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;Senior Notes due in 2018 was increased by </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$62.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and is being amortized using the effective interest rate method over the remaining life of the Senior Notes and is being recognized as a reduction of interest expense. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$9.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> remains to be amortized. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Notes Payable to Fumedica</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our 2006 distribution agreement with Fumedica, we issued notes totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">61.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Swiss Francs which were payable to Fumedica in varying amounts from June 2008 through June 2018. Our remaining note payable to Fumedica had a carrying value of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Swiss Francs (</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$6.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Swiss Francs (</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$9.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Credit Facility</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2015 we entered into a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">five</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">-year senior unsecured revolving credit facility under which we are permitted to draw funds for working capital and general corporate purposes. The terms of the revolving credit facility include a financial covenant that requires us not to exceed a maximum consolidated leverage ratio. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">no</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> outstanding borrowings and were in compliance with all covenants under this facility.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Financing Arrangement</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During 2015 we recorded a financing obligation in relation to the amendment of our lease agreement of Eisai's oral solid dose products manufacturing facility in RTP, North Carolina where we manufacture our and Eisai's oral solid dose products. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the financing obligation totaled approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$18.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$19.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. For additional information, please read Note 10, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Property, Plant and Equipment</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Debt Maturity</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The total gross payments, excluding our financing arrangement, due under our debt arrangements are as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.4375%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:80%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">As of December 31, 2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">553.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,500.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2022 and thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4,500.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6,556.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair value of our debt is disclosed in Note&#160;7, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Fair Value Measurements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20,22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6824465360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Equity</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Preferred Stock</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;shares of Preferred Stock authorized, of which </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.75 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares are authorized as Series A, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares are authorized as Series X junior participating and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.25 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares are undesignated. Shares may be issued without a vote or action of stockholders from time to time in classes or series with the designations, powers, preferences, and the relative, participating, optional or other special rights of the shares of each such class or series and any qualifications, limitations or restrictions thereon as set forth in the instruments governing such shares. Any such Preferred Stock may rank prior to common stock as to dividend rights, liquidation preference or both, and may have full or limited voting rights and may be convertible into shares of common stock. No shares of Preferred Stock were issued and outstanding during </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Common Stock</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table describes the number of shares authorized, issued and outstanding of our common stock as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18" rowspan="1"></td></tr><tr><td style="width:24%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">As of December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Authorized</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Issued</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Authorized</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Issued</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Outstanding</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Common stock</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,000.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">238.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">215.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,000.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">241.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">218.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Share Repurchases</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2016 our Board of Directors authorized a program to repurchase up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of our common stock (2016 Share Repurchase Program). This authorization does not have an expiration date. Repurchased shares will be retired. As of December 31, 2016, we repurchased and retired </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of common stock at a cost of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> under our 2016 Share Repurchase Program.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2015 our Board of Directors authorized a program to repurchase up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of our common stock (2015 Share Repurchase Program), which was completed as of December&#160;31, 2015. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we repurchased and retired approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of common stock at a cost of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> under our 2015 Share Repurchase Program.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2011 our Board of Directors authorized a program to repurchase up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">20.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of our common stock (2011 Share Repurchase Program), which has been used principally to offset common stock issuances under our share-based compensation plans. The 2011 Share Repurchase Program does not have an expiration date. We did not repurchase any shares of common stock under our 2011 Share Repurchase Program during the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. During </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> we purchased approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of common stock at a cost of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$886.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> under our 2011 Share Repurchase Program. We have approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares remaining available for repurchase under this authorization.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74567-122707<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Preferred Stock<br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6895482832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Loss)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNoteTextBlock', window );">Comprehensive Income (Loss) Note</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Accumulated Other Comprehensive Income (Loss)</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the changes in accumulated other comprehensive income (loss), net of tax by component:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:26%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Translation Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(0.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(37.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(195.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(224.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(10.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">51.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(138.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(92.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(4.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(3.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(10.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">47.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(138.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(95.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(10.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">57.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(32.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(334.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(319.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:26%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Translation Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">71.7</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(31.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(99.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(59.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">110.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(6.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(96.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(172.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(171.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(61.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(6.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(96.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(164.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(37.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(195.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(224.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:26%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Translation Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.6</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(23.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(19.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.0</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(27.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">101.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(12.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(109.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(19.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(6.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(6.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(12.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(6.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">95.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(12.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(109.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(31.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2014</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">71.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(31.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(99.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(59.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the amounts reclassified from accumulated other comprehensive income:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:28%;" rowspan="1" colspan="1"></td><td style="width:25%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Income Statement Location</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amounts Reclassified from</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated Other Comprehensive Income</font></div></td></tr><tr><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended December&#160;31,</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on securities available for sale</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(0.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on cash flow hedges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">173.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total reclassifications, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">171.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e640-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e716-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e709-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e637-108580<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e681-108580<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Reclassification Adjustments<br> -URI http://asc.fasb.org/extlink&amp;oid=6522872<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6824465360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings per Share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Earnings&#160;per Share</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic and diluted earnings per share are calculated as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Numerator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,702.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,547.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,934.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Denominator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted average number of common shares outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">218.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">230.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">236.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effect of dilutive securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Stock options and employee stock purchase plan</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Time-vested restricted stock units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Market stock units</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Dilutive potential common shares</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Shares used in calculating diluted earnings per share</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">218.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">231.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">237.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts excluded from the calculation of net income per diluted share because their effects were anti-dilutive were insignificant.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Earnings per share for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, reflects, on a weighted average basis, the repurchase of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares, respectively, of our common stock under our share repurchase authorizations.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1278-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1252-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=65016374&amp;loc=d3e4984-109258<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6821481984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Payments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-based Payments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Share-based Payments</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Share-based Compensation Expense</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes share-based compensation expense included in our consolidated statements of income:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:55%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">84.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">88.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">102.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">121.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">127.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">150.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restructuring charges</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(8.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">204.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">207.3</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">252.4</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capitalized share-based compensation costs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(14.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(11.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(10.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in total cost and expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">189.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">196.3</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">242.4</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax effect</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(54.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(55.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(72.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">135.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">140.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">170.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:55%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Market stock units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">38.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">38.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Time-vested restricted stock units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">120.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">119.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">115.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash settled performance units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">16.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">22.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">65.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">18.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee stock purchase plan</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">11.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">204.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">207.3</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">252.4</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capitalized share-based compensation costs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(14.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(11.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(10.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in total cost and expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">189.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">196.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">242.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Windfall tax benefits from vesting of stock awards, exercises of stock options and ESPP participation were </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$12.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$78.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$96.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. These amounts have been calculated under the alternative transition method. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, unrecognized compensation cost related to unvested share-based compensation was approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$189.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, net of estimated forfeitures. We expect to recognize the cost of these unvested awards over a weighted-average period of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.9</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> years.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Share-Based Compensation Plans</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> share-based compensation plans pursuant to which awards are currently being made: (i)&#160;the Biogen Inc. 2006 Non-Employee Directors Equity Plan (2006&#160;Directors Plan); (ii)&#160;the Biogen Inc. 2008 Amended and Restated Omnibus Equity Plan (2008 Omnibus Plan); and (iii)&#160;the Biogen Inc. 2015 Employee Stock Purchase Plan (ESPP). </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Directors Plan</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2006 our stockholders approved the 2006&#160;Directors Plan for share-based awards to our directors. Awards granted from the 2006&#160;Directors Plan may include stock options, shares of restricted stock, restricted stock units, stock appreciation rights and other awards in such amounts and with such terms and conditions as may be determined by a committee of our Board of Directors, subject to the provisions of the plan. We have reserved a total of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of common stock for issuance under the 2006&#160;Directors Plan. The 2006&#160;Directors Plan provides that awards other than stock options and stock appreciation rights will be counted against the total number of shares reserved under the plan in a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.5-to-1</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> ratio. In June 2015 our stockholders approved an amendment to extend the term of the 2006 Directors Plan until June 2025.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Omnibus Plans</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2008 our stockholders approved the 2008 Omnibus Plan for share-based awards to our employees. Awards granted from the 2008 Omnibus Plan may include stock options, shares of restricted stock, restricted stock units, performance shares, shares of phantom stock, stock appreciation rights and other awards in such amounts and with such terms and conditions as may be determined by a committee of our Board of Directors, subject to the provisions of the plan. Shares of common stock available for issuance under the 2008 Omnibus Plan consist of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares reserved for this purpose, plus shares of common stock that remained available for issuance under our 2005 Omnibus Equity Plan on the date that our stockholders approved the 2008 Omnibus Plan, plus shares that were subject to awards under the 2005 Omnibus Equity Plan that remain unissued upon the cancellation, surrender, exchange or termination of such awards. The 2008 Omnibus Equity Plan provides that awards other than stock options and stock appreciation rights will be counted against the total number of shares available under the plan in a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.5-to-1</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> ratio.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have not made any awards pursuant to the 2005 Omnibus Equity Plan since our stockholders approved the 2008 Omnibus Plan, and do not intend to make any awards pursuant to the 2005 Omnibus Equity Plan in the future, except that unused shares under the 2005 Omnibus Equity Plan have been carried over for use under the 2008 Omnibus Plan.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Stock Options</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We currently do not grant stock options to our employees or directors. Outstanding stock options previously granted to our employees and directors generally have a ten-year term and vest over a period of between one and four years, provided the individual continues to serve at Biogen through the vesting dates. Options granted under all plans are exercisable at a price per share not less than the fair market value of the underlying common stock on the date of grant. The estimated fair value of options, including the effect of estimated forfeitures, is recognized over the options&#8217; vesting periods. The fair value of the stock options granted in 2010 was estimated as of the date of grant using a Black-Scholes option valuation model. There were </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">no</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> grants of stock options made in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, all outstanding options were exercisable.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The expected life of options granted is derived using assumed exercise rates based on historical exercise patterns and represents the period of time that options granted are expected to be outstanding. Expected stock price volatility is based upon implied volatility for our exchange-traded options and other factors, including historical volatility. After assessing all available information on either historical volatility, implied volatility, or both, we have concluded that a combination of both historical and implied volatility provides the best estimate of expected volatility. The risk-free interest rate used is determined by the market yield curve based upon risk-free interest rates established by the Federal Reserve, or non-coupon bonds that have maturities equal to the expected term. The dividend yield of zero is based upon the fact that we have not historically granted cash dividends, and do not expect to issue dividends in the foreseeable future. Stock options granted prior to January&#160;1, 2006 were valued based on the grant date fair value of those awards, using the Black-Scholes option pricing model, as previously calculated for pro-forma disclosures.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our stock option activity:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Exercise</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Price</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Outstanding at December 31, 2015</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">107,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">53.94</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(41,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">53.75</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cancelled</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Outstanding at December 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">66,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">54.06</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The total intrinsic values of options exercised in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$38.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$42.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. The aggregate intrinsic values of options outstanding as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The weighted average remaining contractual term for options outstanding as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.0</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;years. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the amount of tax benefit realized for stock options and cash received from the exercise of stock options:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Tax benefit realized for stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash received from the exercise of stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Market Stock Units (MSUs)</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">MSUs awarded to employees prior to 2014 vested in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">four</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> equal annual increments beginning on the first anniversary of the grant date. Participants may ultimately earn between </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">150%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the target number of units granted based on actual stock performance. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">MSUs awarded to employees in 2014, 2015 and 2016 vest in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> equal annual increments beginning on the first anniversary of the grant date, and participants may ultimately earn between </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">200%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the target number of units granted based on actual stock performance. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The vesting of these awards is subject to the respective employee&#8217;s continued employment. The number of MSUs granted represents the target number of units that are eligible to be earned based on the attainment of certain market-based criteria involving our stock price. The number of MSUs earned is calculated at each annual anniversary from the date of grant over the respective vesting periods, resulting in multiple performance periods. Accordingly, additional MSUs may be issued or currently outstanding MSUs may be cancelled upon final determination of the number of awards earned. Compensation expense, including the effect of forfeitures, is recognized over the applicable service period.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our MSU activity:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Grant&#160;Date</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2015</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">269,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">339.89</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Granted (a)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">168,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">328.03</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(155,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">244.68</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(52,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">371.62</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">230,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">355.60</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">MSUs granted in 2016 include approximately </font><font style="font-family:Franklin Gothic Book;font-size:9pt;">15,000</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"> and </font><font style="font-family:Franklin Gothic Book;font-size:9pt;">20,000</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"> MSUs issued in 2016 based upon the attainment of performance criteria set for 2013 and 2012, respectively, in relation to awards granted in those years. The remainder of MSUs granted during 2016 include awards granted in conjunction with our annual awards made in February 2016 and MSUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We value grants of MSUs using a lattice model with a Monte Carlo simulation. This valuation methodology utilizes several key assumptions, including the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">60</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> calendar day average closing stock price on grant date for MSUs awarded prior to 2014, the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> calendar day average closing stock price on the date of grant for MSUs awarded in 2014, 2015 and 2016, expected volatility of our stock price, risk-free rates of return and expected dividend yield.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> The assumptions used in our valuation are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:44%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Range of expected stock price volatility</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">38.2% - 40.7%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31.0% - 33.2%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31.7% - 35.1%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Range of risk-free interest rates</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.6% - 0.9%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2% - 1.0%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1% - 0.7%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30 calendar day average stock price on grant date</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$260.67 - $304.86</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$277.35 - $426.27</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$280.88 - $335.65</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted-average per share grant date fair value</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$328.03</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$493.43</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$395.22</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The total fair values of MSUs vested in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$39.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$109.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$117.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Cash Settled Performance Units (CSPUs)</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">CSPUs awarded to employees vest in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> equal annual increments beginning on the first anniversary of the grant date. The vesting of these awards is subject to the respective employee&#8217;s continued employment with such awards settled in cash. The number of CSPUs granted represents the target number of units that are eligible to be earned based on the attainment of certain performance measures established at the beginning of the performance period, which ends on December&#160;31 of each year. Participants may ultimately earn between </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">200%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the target number of units granted based on the degree of actual performance metric achievement. Accordingly, additional CSPUs may be issued or currently outstanding CSPUs may be cancelled upon final determination of the number of units earned. CSPUs awarded prior to 2014 are settled in cash based on the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">60</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> calendar day average closing stock price through each vesting date once the actual vested and earned number of units is known. CSPUs awarded in 2014, 2015 and 2016 will be settled in cash based on the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> calendar day average closing stock price through each vesting date, once the actual vested and earned number of units is known. Since no shares are issued, these awards do not dilute equity. Compensation expense, including the effect of forfeitures, is recognized over the applicable service period.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our CSPU activity:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:82%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2015</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">192,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Granted (a)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">86,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(117,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(39,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">122,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">CSPUs granted in 2016 include awards granted in conjunction with our annual awards made in February 2016 and CSPUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The total cash paid in settlement of CSPUs vested in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$31.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$79.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$92.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.&#160; </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Performance-vested Restricted Stock Units (PUs)</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2014 we revised our long term incentive program to include a new type of award granted to certain employees in the form of restricted stock units that may be settled in cash or shares of our common stock at the sole discretion of the Compensation and Management Development Committee of our Board of Directors. These awards are structured and accounted for the same way as the cash settled performance units, and vest in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> equal annual increments beginning on the first anniversary of the grant date. The number of PUs granted represents the target number of units that are eligible to be earned based on the attainment of certain performance measures established at the beginning of the performance period, which ends on December 31 of each year. Participants may ultimately earn between </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">200%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the target number of units granted based on the degree of actual performance metric achievement. Accordingly, additional PUs may be issued or currently outstanding PUs may be cancelled upon final determination of the number of units earned. PUs settling in cash are based on the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> calendar day average closing stock price through each vesting date once the actual vested and earned number of units is known. Compensation expense, including the effect of forfeitures, is recognized over the applicable service period.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our PU activity:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:82%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2015</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">103,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Granted (a)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">55,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(31,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(17,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">110,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(a)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">PUs granted in 2016 include awards granted in conjunction with our annual awards made in February 2016 and PUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">32,000</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> PU were converted to share settlements, of which approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11,000</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares were vested and issued. All other PUs that vested in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> were settled in cash totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$12.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">All PUs that vested in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> were settled in cash totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$8.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Time-Vested Restricted Stock Units (RSUs)</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">RSUs awarded to employees generally vest no sooner than </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">one-third per year over three years</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> on the anniversary of the date of grant, or upon the third anniversary of the date of the grant, provided the employee remains continuously employed with us, except as otherwise provided in the plan. Shares of our common stock will be delivered to the employee upon vesting, subject to payment of applicable withholding taxes. RSUs awarded to directors for service on our Board of Directors vest on the first anniversary of the date of grant, provided in each case that the director continues to serve on our Board of Directors through the vesting date. Shares of our common stock will be delivered to the director upon vesting and are not subject to any withholding taxes. The fair value of all RSUs is based on the market value of our stock on the date of grant. Compensation expense, including the effect of forfeitures, is recognized over the applicable service period.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our RSU activity:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Grant&#160;Date</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2015</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">810,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">323.87</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Granted (a)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">649,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">268.52</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(406,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">285.13</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(165,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">310.30</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">888,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">303.49</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">RSUs granted in 2016 primarily represent RSUs granted in conjunction with our annual awards made in February 2016 and awards made in conjunction with the hiring of new employees. RSUs granted in 2016 also include approximately </font><font style="font-family:Franklin Gothic Book;font-size:9pt;">11,000</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"> RSUs granted to our Board of Directors.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">RSUs granted in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> had weighted average grant date fair values of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$388.88</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$321.72</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The total fair values of RSUs vested in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$104.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$239.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$281.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.&#160; </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Employee Stock Purchase Plan (ESPP)</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2015 our stockholders approved the Biogen Inc. 2015 ESPP (2015 ESPP). The 2015 ESPP, which became effective on July 1, 2015, replaced the Biogen Idec Inc. 1995 ESPP (1995 ESPP), which expired on June&#160;30, 2015. The maximum aggregate number of shares of our common stock that may be purchased under the 2015 ESPP is </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our ESPP activity:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except share amounts)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Shares issued under the 2015 ESPP</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">190,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">78,000</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">**</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Shares issued under the 1995 ESPP</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">98,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">180,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash received under the 2015 ESPP</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">41.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">19.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">**</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash received under the 1995 ESPP</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">46.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65895303&amp;loc=d3e17540-113929<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68057994&amp;loc=d3e25284-112666<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5444-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6824517776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">&#160;&#160;&#160;&#160;Income Taxes</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Income Tax Expense</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income before income tax provision and the income tax expense consist of the following:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Income before income taxes (benefit):</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Domestic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,655.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,386.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,557.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,277.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,380.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,389.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4,933.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,767.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,946.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Income tax expense (benefit):</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Federal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,304.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,214.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,159.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">State</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">55.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">38.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">65.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">52.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">54.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">73.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,412.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,307.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,298.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferred:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Federal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(125.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(129.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(280.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">State</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(3.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(21.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(45.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(14.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(6.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(175.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(145.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(308.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total income tax expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,237.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,161.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">989.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Deferred Tax Assets and Liabilities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Significant components of our deferred tax assets and liabilities are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As&#160;of&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Deferred tax assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Tax credits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">201.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">189.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory, other reserves and accruals</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">250.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">243.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangibles, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">459.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">328.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net operating loss</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">65.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">61.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">63.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">49.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(16.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(14.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total deferred tax assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,071.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">871.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Deferred tax liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchased intangible assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(376.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(440.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Depreciation, amortization and other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(113.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(102.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total deferred tax liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(490.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(542.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition to deferred tax assets and liabilities, we have recorded prepaid tax and deferred charges related to intercompany transactions. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the total deferred charges and prepaid taxes were </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$989.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$697.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Tax Rate</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:55%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Statutory rate</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">35.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">State taxes</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Taxes on foreign earnings</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(9.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(10.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(9.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Credits and net operating loss utilization</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchased intangible assets</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Manufacturing deduction</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other permanent items</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effective tax rate</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">25.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">25.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our effective tax rate for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> increased primarily due to a net state tax benefit in 2015 resulting from the remeasurement of one of our uncertain tax positions, described below, and a higher relative percentage of our earnings being attributed to the U.S., a higher tax jurisdiction.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our effective tax rate for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> benefited from lower taxes on foreign earnings and reflects a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$27.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> benefit from the 2015 remeasurement of one of our uncertain tax positions.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had net operating losses and general business credit carry forwards for federal income tax purposes of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$22.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$140.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, which begin to expire in 2020. Additionally, for state income tax purposes, we had net operating loss carry forwards of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$86.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which begin to expire in 2017. For state income tax purposes, we also had research and investment credit carry forwards of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$126.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which begin to expire in 2017. For foreign income tax purposes, we had </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$489.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of net operating loss carryforwards, which begin to expire in 2021.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In assessing the realizability of our deferred tax assets, we have considered whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. In making this determination, under the applicable financial reporting standards, we are allowed to consider the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies. Our estimates of future taxable income take into consideration, among other items, our estimates of future income tax deductions related to the exercise of stock options. Based upon the level of historical taxable income and income tax liability and projections for future taxable income over the periods in which the deferred tax assets are utilizable, we believe it is more likely than not that we will realize the net benefits of the deferred tax assets of our wholly owned subsidiaries. In the event that actual results differ from our estimates or we adjust our estimates in future periods, we may need to establish a valuation allowance, which could materially impact our financial position and results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, undistributed foreign earnings of non-U.S.&#160;subsidiaries included in consolidated retained earnings and other basis differences aggregated approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$7.6 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We intend to reinvest these earnings indefinitely in operations outside the U.S.&#160;The residual U.S. tax liability, if cumulative amounts were repatriated, would be between </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.8 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.3 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accounting for Uncertainty in Income Taxes</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A reconciliation of the beginning and ending amount of our unrecognized tax benefits is summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance at January&#160;1,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">67.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">131.5</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">110.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Additions based on tax positions related to the current period</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">20.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Additions for tax positions of prior periods</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">36.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">19.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">86.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Reductions for tax positions of prior periods</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(13.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(49.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(23.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Statute expirations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Settlements</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(64.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(42.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(60.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance at December&#160;31,</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">32.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">67.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">131.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We and our subsidiaries are routinely examined by various taxing authorities. We file income tax returns in the U.S.&#160;federal jurisdiction, various U.S. states, and foreign jurisdictions. With few exceptions, including the proposed disallowance we discuss below, we are no longer subject to U.S.&#160;federal tax examination for years before 2013 or state, local, or non-U.S.&#160;income tax examinations for years before 2005. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Included in the balance of unrecognized tax benefits as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> are </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$26.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$53.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> (net of the federal benefit on state issues), respectively, of unrecognized tax benefits that, if recognized, would affect the effective income tax rate in future periods. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognize potential interest and penalties accrued related to unrecognized tax benefits in income tax expense. In </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> we recognized a net interest expense of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$9.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. In </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> we recognized net interest expense of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. In </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> we recognized a net interest expense of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$4.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We have accrued approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$25.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$12.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the payment of interest as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2015 we received a final assessment from the Danish Tax Authority (SKAT) for fiscal 2009 regarding withholding taxes and the treatment of certain intercompany transactions involving a Danish affiliate and another of our affiliates.&#160;In April 2016 we received final assessments from the SKAT for 2011 and 2013 regarding withholding taxes for similar intercompany transactions. The total amount assessed for 2009, 2011 and 2013 is estimated to be </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$58.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, including interest. For the assessments related to 2011 and 2013 we have made payments to SKAT totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$12.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We continue to dispute the assessments for all of these periods and believe that the positions taken in our historical filings are valid. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Federal Uncertain Tax Positions</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the year ended December 31, 2015, the net effect of adjustments to one of our uncertain tax positions was a net benefit of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$27.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, primarily related to the state impact of a federal uncertain tax item.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">It is reasonably possible that we will adjust the value of our uncertain tax positions related to our revenues from anti-CD20 therapeutic programs and certain transfer pricing issues as we receive additional information from various taxing authorities, including reaching settlements with the authorities. In addition, the IRS and other national tax authorities routinely examine our intercompany transfer pricing with respect to intellectual property related transactions and it is possible that they may disagree with one or more positions we have taken with respect to such valuations.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32718-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6895554304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock', window );">Other Consolidated Financial Statement Detail</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Other Consolidated Financial Statement Detail</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Supplemental Cash Flow Information</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Supplemental disclosure of cash flow information for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, is as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:51%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash paid during the year for:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">281.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">39.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">41.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,642.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,674.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,163.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Non-cash Operating, Investing and Financing Activity</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2016 we accrued </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$454.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to the recent settlement and license agreement with Forward Pharma A/S (Forward Pharma). For additional information related to this transaction, please read Note 21, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Commitment and Contingencies</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the fourth quarter of 2016 we accrued </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$300.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> upon reaching </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$11.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in total cumulative sales of Fumapharm Products. The amount, net of tax benefit, was accounted for as an increase to goodwill in accordance with the accounting standard applicable to business combinations when we acquired Fumapharm and is expected to be paid in the first quarter of 2017. For additional information related to this transaction, please read Note 21, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Commitments and Contingencies</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the construction of our manufacturing facility in Solothurn, Switzerland, we accrued charges related to processing equipment and engineering services of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$100.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in our consolidated balance sheet. For additional information related to this transaction, please read Note 10,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"> Property, Plant and Equipment</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2015 upon completion of our acquisition of Convergence, we recorded a contingent consideration obligation of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$274.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as part of the purchase price. For additional information related to this transaction, please read Note 2, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Income (Expense), Net</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Components of other income (expense), net, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">63.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">22.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(260.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(95.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(29.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gain (loss) on investments, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign exchange gains (losses), net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(9.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(32.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(11.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(17.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(13.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(8.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other income (expense), net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(217.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(123.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(25.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Current Assets</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets include prepaid taxes totaling approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$817.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$550.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accrued Expenses and Other</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other consists of the following:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current portion of contingent consideration obligations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">580.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">504.7</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued TECFIDERA litigation settlement and license charges</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">454.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenue-related reserves for discounts and allowances</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">438.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">518.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee compensation and benefits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">282.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">270.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Royalties and licensing fees</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">195.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">167.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Construction in progress</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">134.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">87.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Collaboration expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">130.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">685.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">516.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total accrued expenses and other</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,903.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,096.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Pricing of TYSABRI in Italy - AIFA</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the fourth quarter of 2011 Biogen Italia SRL, our Italian subsidiary,&#160;received a notice from the Italian National Medicines Agency (Agenzia Italiana del Farmaco or AIFA) that sales of TYSABRI after mid-February 2009 through mid-February 2011 exceeded by EUR</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> a reimbursement limit established pursuant to a Price Determination Resolution granted by AIFA in December 2006. In January 2012 we filed an appeal against AIFA in administrative court in Rome, Italy seeking a ruling that the reimbursement limit in the Price Determination Resolution should apply as written to only &#8220;the first </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months&#8221; of TYSABRI sales, which ended in mid-February 2009. That appeal is still pending. Since being notified in the fourth quarter of 2011 that AIFA believed a reimbursement limit was still in effect, we deferred revenue on sales of TYSABRI as if the reimbursement limit were in effect for each biannual period beginning in mid-February 2009. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2013 we negotiated an agreement in principle with AIFA's Price and Reimbursement Committee that would have resolved all of AIFA's claims relating to sales of TYSABRI in excess of the reimbursement limit for the periods from February 2009 through January 2013 for an aggregate repayment of EUR</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">33.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. As a result of this agreement in principle, we recorded a liability and reduction to revenue of EUR</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> at June 30, 2013, which approximated </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the claim related to the period from mid-February 2009 through mid-February 2011. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we have approximately EUR</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">79 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> recorded as accrued expenses and other in our consolidated balance sheets for the periods mid-February 2009 through January 2013, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2014 AIFA approved a resolution affirming that there is no reimbursement limit from and after February 2013. As a result, we recognized </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$53.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of TYSABRI revenues related to the periods February 2013 through June 2014 that were previously deferred. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2017 we negotiated an agreement in principle with AIFA's Price and Reimbursement Committee to settle all of AIFA's existing claims relating to sales of TYSABRI in excess of the reimbursement limit for the periods from February 2009 through January 2013 for an aggregate repayment of EUR</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The agreement is subject to ratification by AIFA. If this most recent settlement agreement is accepted, we will recognize approximately EUR</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">42 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in revenue upon final resolution of this matter.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalFinancialInformationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6895547424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Variable Interest Entities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InvestmentsInVariableInterestEntitiesAbstract', window );"><strong>Investments in Variable Interest Entities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityDisclosureTextBlock', window );">Investments in Variable Interest Entities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Investments in Variable Interest Entities</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Consolidated Variable Interest Entities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our consolidated financial statements include the financial results of variable interest entities in which we are the primary beneficiary. The following are our significant variable interest entities.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Neurimmune SubOne AG</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2007 we entered into a collaboration agreement with Neurimmune SubOne AG (Neurimmune), a subsidiary of Neurimmune AG, for the development and commercialization of antibodies for the treatment of Alzheimer&#8217;s disease. Neurimmune conducts research to identify potential therapeutic antibodies and we are responsible for the development, manufacturing and commercialization of all products. Our anti-amyloid beta antibody, aducanumab, for the treatment of Alzheimer&#8217;s disease resulted from this collaboration. In September 2015 we announced that the first patient had been enrolled in a Phase 3 trial for aducanumab, which triggered a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$60.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> milestone payment due to Neurimmune. As we consolidate the financial results of Neurimmune, we recognized this payment as a charge to noncontrolling interest in the third quarter of 2015. Based upon our current development plans for aducanumab, we may pay Neurimmune up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$275.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in remaining milestone payments. We may also pay royalties in the low-to-mid-teens on sales of any resulting commercial products.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We determined that we are the primary beneficiary of Neurimmune because we have the power through the collaboration to direct the activities that most significantly impact the entity&#8217;s economic performance and are required to fund </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the research and development costs incurred in support of the collaboration agreement. Accordingly, we consolidate the results of Neurimmune.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are required to reimburse Neurimmune for amounts that are incurred by Neurimmune for research and development expenses in support of the collaboration. Amounts reimbursed are reflected in research and development expense in our consolidated statements of income. During the years ending </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, these amounts were immaterial. Future milestone payments and royalties, if any, will be reflected in our consolidated statements of income as a charge to noncontrolling interest, net of tax, when such milestones are achieved. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The assets and liabilities of Neurimmune are not significant to our financial position or results of operations as it is a research and development organization. We have provided no financing to Neurimmune other than previously contractually required amounts.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Rodin Therapeutics, Inc.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2015 we paid </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$8.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for preferred stock in Rodin Therapeutics, Inc. (Rodin) and entered into an option and collaboration agreement which gave us the right to purchase all remaining outstanding shares of Rodin at any time until 35 days after acceptance of an Investigational New Drug (IND) application by the FDA. As we determined that we were the primary beneficiary of Rodin, we consolidated the results of Rodin and recorded an IPR&amp;D intangible asset of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$8.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and assigned approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to noncontrolling interest.  </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the fourth quarter of 2016 we terminated our collaboration agreement with Rodin. Upon termination of the collaboration agreement, we deconsolidated the results of Rodin and impaired the IPR&amp;D asset, resulting in an impairment loss of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$8.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to the IPR&amp;D asset recorded upon entering into the collaboration agreement. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The assets and liabilities of Rodin were not significant to our financial position or results of operations as Rodin is a research and development organization. We had provided no financing to Rodin other than the contractually required amounts disclosed above.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Ataxion Inc.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2014 we paid </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for preferred stock in Ataxion, Inc. (Ataxion) and entered into an option and collaboration agreement which gave us the right to purchase all outstanding shares of Ataxion at any time until 30 days after delivery of a Phase 1 clinical trial study report. As we determined that we were the primary beneficiary of Ataxion, we consolidated the results of Ataxion and recorded an IPR&amp;D intangible asset of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and assigned that amount to noncontrolling interest.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the fourth quarter of 2016 we terminated our option agreement with Ataxion. Upon termination of the collaboration agreement, we deconsolidated the results of Ataxion and impaired the IPR&amp;D asset, resulting in an impairment loss of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to the IPR&amp;D asset recorded upon entering into the collaboration agreement.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The assets and liabilities of Ataxion were not significant to our financial position or results of operations as Ataxion is a research and development organization. We had provided no financing to Ataxion other than the contractually required amounts disclosed above.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Unconsolidated Variable Interest Entities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have relationships with other variable interest entities that we do not consolidate as we lack the power to direct the activities that significantly impact the economic success of these entities. These relationships include investments in certain biotechnology companies and research collaboration agreements. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the total carrying value of our investments in biotechnology companies totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$47.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$29.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Our maximum exposure to loss related to these variable interest entities is limited to the carrying value of our investments.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have also entered into research collaboration agreements with certain variable interest entities where we are required to fund certain development activities. These development activities are included in research and development expense in our consolidated statements of income, as they are incurred. We have provided no financing to these variable interest entities other than previously contractually required amounts.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InvestmentsInVariableInterestEntitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments In Variable Interest Entities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InvestmentsInVariableInterestEntitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -URI http://asc.fasb.org/extlink&amp;oid=64801991&amp;loc=SL6759159-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=64801991&amp;loc=d3e5728-111685<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64801991&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6821481984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborative and Other Relationships</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Collaborative and Other Relationships</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our business strategy, we have entered into various collaboration agreements which provide us with rights to develop, produce and market products using certain know-how, technology and patent rights maintained by our collaborative partners. Terms of the various collaboration agreements may require us to make milestone payments upon the achievement of certain product research and development objectives and pay royalties on future sales, if any, of commercial products resulting from the collaboration.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Depending on the collaborative arrangement, we may record funding receivable or payable balances with our partners, based on the nature of the cost-sharing mechanism and activity within the collaboration. Our significant collaboration arrangements are discussed below.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Genentech (Roche Group)</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other potential anti-CD20 therapies under a collaboration agreement with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group. The Roche Group and its sub-licensees maintain sole responsibility for the development, manufacturing and commercialization of GAZYVA in the U.S. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our collaboration agreement will continue in effect until we mutually agree to terminate the collaboration, except that if we undergo a change in control, as defined in the collaboration agreement, Genentech has the right to present an offer to buy the rights to RITUXAN and we must either accept Genentech&#8217;s offer or purchase Genentech&#8217;s rights on the same terms as its offer. Genentech will also be deemed concurrently to have purchased our rights to any other anti-CD20 products in development in exchange for a royalty and our rights to GAZYVA in exchange for the compensation described in the table below. Our collaboration with Genentech was created through a contractual arrangement and not through a joint venture or other legal entity.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">RITUXAN</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Genentech is responsible for the worldwide manufacturing of RITUXAN. Development and commercialization rights and responsibilities under this collaboration are divided as follows:</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">U.S.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We share with Genentech co-exclusive rights to develop, commercialize and market RITUXAN in the U.S.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Canada</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We and Genentech have assigned our rights under our collaboration agreement with respect to Canada to the Roche Group.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">GAZYVA</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognize our share of the development and commercialization expenses of GAZYVA as a reduction of our share of pre-tax profits in revenues from anti-CD20 therapeutic programs. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Commercialization of GAZYVA impacts our percentage of the co-promotion profits for RITUXAN, as summarized in the table below.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">OCREVUS (Ocrelizumab)</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Genentech is solely responsible for development and commercialization of OCREVUS, a humanized anti-CD20 monoclonal antibody currently in development for MS, and funding future costs. Genentech cannot develop OCREVUS in CLL, NHL or Rheumatoid Arthritis (RA). We will receive tiered royalties between </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.5%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> on U.S. net sales of OCREVUS if approved for commercial sale by the FDA. The FDA has accepted for review the Biologics License Application for OCREVUS for the treatment of relapsing multiple sclerosis (RMS) and primary-progressive multiple sclerosis (PPMS), and has granted the application Priority Review Designation. There will be a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> reduction to these royalties if a biosimilar to OCREVUS is approved in the U.S. In addition, we will receive a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> royalty on net sales of OCREVUS outside the U.S., with the royalty period lasting </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> years from the first commercial sale of OCREVUS on a country-by-country basis. In June 2016 the European Medicines Agency (EMA) validated its marketing authorization application (MAA) of OCREVUS for the treatment of RMS and PPMS in the E.U. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Commercialization of OCREVUS will not impact the percentage of the co-promotion profits we receive for RITUXAN or GAZYVA.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Profit-sharing Formulas</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">RITUXAN Profit Share</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our current pretax co-promotion profit-sharing formula for RITUXAN provides for a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> share on the first </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$50.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of co-promotion operating profits earned each calendar year. Our share of annual co-promotion profits in excess of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$50.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> varies, as summarized in the table below, upon the following events:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:82%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Until GAZYVA First Non-CLL FDA Approval</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">40.0</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">After GAZYVA First Non-CLL FDA Approval until First GAZYVA Threshold Date</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">39.0</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">After First GAZYVA Threshold Date until Second GAZYVA Threshold Date</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">37.5</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">After Second GAZYVA Threshold Date</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">35.0</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;">First Non-CLL GAZYVA FDA Approval</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> means the FDA&#8217;s first approval of GAZYVA in an indication other than CLL.</font></div><div style="line-height:120%;padding-top:12px;padding-left:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;">First GAZYVA Threshold Date</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> means the earlier of (1)&#160;the date of the First Non-CLL GAZYVA FDA approval if U.S. gross sales of GAZYVA for the preceding consecutive 12 month period were at least </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$150.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> or (2)&#160;the first day of the calendar quarter after the date of the First Non-CLL GAZYVA FDA Approval that U.S. gross sales of GAZYVA within any consecutive 12 month period have reached </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$150.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;">Second GAZYVA Threshold Date</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> means the first day of the calendar quarter after U.S. gross sales of GAZYVA within any consecutive 12 month period have reached </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$500.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The Second GAZYVA Threshold Date can be achieved regardless of whether GAZYVA has been approved in a non-CLL indication.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our share of RITUXAN pre-tax profits in the U.S. decreased to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">39%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> from </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">40%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as GAZYVA was approved by the FDA in follicular lymphoma in February 2016. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, should the FDA approve an anti-CD20 product other than OCREVUS or GAZYVA that is acquired or developed by Genentech and subject to the collaboration agreement, our share of the co-promotion operating profits would be between </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">38%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> based on certain events.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">GAZYVA Profit Share</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our current pretax profit-sharing formula for GAZYVA provides for a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> share on the first </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$50.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of operating profits earned each calendar year. Our share of annual profits in excess of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$50.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> varies, as summarized in the table below, upon the following events:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:82%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Until First GAZYVA Threshold Date</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">39.0</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">After First GAZYVA Threshold Date until Second GAZYVA Threshold Date</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">37.5</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">After Second GAZYVA Threshold Date</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">35.0</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our share of operating losses on GAZYVA was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Revenues from Anti-CD20 Therapeutic Programs</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,249.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,269.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,117.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenue on sales in the rest of world for RITUXAN</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">65.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">69.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">78.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues from anti-CD20 therapeutic programs</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,314.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,339.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,195.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">39%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> profit-sharing threshold was met during the first quarter. In </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">40%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> profit-sharing threshold was met during the first quarter.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Prior to regulatory approval, we record our share of the expenses incurred by the collaboration for the development of anti-CD20 products in research and development expense in our consolidated statements of income. After an anti-CD20 product is approved, we record our share of the development expenses related to that product as a reduction of our share of pre-tax profits in revenues from anti-CD20 therapeutic programs. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Acorda</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2009 we entered into a collaboration and license agreement with Acorda Therapeutics, Inc. (Acorda) to develop and commercialize products containing fampridine in markets outside the U.S, including FAMPYRA.&#160;We also have responsibility for regulatory activities and the future clinical development of related products in those markets. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the terms of the collaboration and license agreement, we pay Acorda tiered royalties based on the level of ex-U.S. net sales. We may pay up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$375.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of additional milestone payments to Acorda based on the successful achievement of certain regulatory and commercial milestones. The next expected milestone would be </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, due if ex-U.S. net sales reach </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$100.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> over a period of four consecutive quarters. We will capitalize these additional milestones as intangible assets upon achievement of the milestone which will then be amortized utilizing an economic consumption model and recognized as amortization of acquired intangible assets. Royalty payments are recognized as a cost of goods sold.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the collaboration and license agreement, we have also entered into a supply agreement with Acorda for the commercial supply of FAMPYRA. This agreement is a sublicense arrangement of an existing agreement between Acorda and Alkermes, who acquired Elan Drug Technologies, the original party to the license with Acorda. During the years ending </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, total cost of sales related to royalties and commercial supply of FAMPRYA reflected in our consolidated statements of income were </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$31.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$30.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$29.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">AbbVie</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have a collaboration agreement with AbbVie aimed at advancing the development and commercialization of ZINBRYTA in MS, which was approved for the treatment of relapsing forms of MS in the U.S. in May 2016 and the E.U. in July 2016. We made milestone payments totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$32.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to these approvals, which were capitalized as intangible assets, net in our consolidated balance sheets. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the agreement, we and AbbVie conduct ZINBRYTA co-promotion activities in the U.S., E.U. and Canadian territories (Collaboration Territory), where development and commercialization costs and profits are shared equally. Outside of the Collaboration Territory, we are solely responsible for development and commercialization of ZINBRYTA and will pay a tiered royalty to AbbVie as a percentage of net sales in the low to high teens.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> We are responsible for manufacturing and research and development activities in both the Collaboration Territory and outside the Collaboration Territory and will record these activities within their respective lines in our consolidated statements of income, net of any reimbursement of research and development expenditures received from AbbVie.&#160;For the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the collaboration incurred </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$48.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$113.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$117.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for research and development activities, for which we recognized </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$24.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$60.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$67.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in our consolidated statements of income. During </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> we made milestone payments of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$16.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the development of ZINBRYTA as a result of filing for regulatory approval in the U.S. and E.U. during the year. These payments were recorded as research and development expense in our consolidated statements of income.  </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Prior to regulatory approval, we also recognized </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$22.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of pre-commercialization expenses within our selling, general and administrative expense, which represents </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the collaboration's pre-commercialization costs for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. After ZINBRYTA was approved by the FDA and EMA in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we began to recognize our share of the collaboration activities within the U.S., E.U. and Canadian territories as described below.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Co-promotion Profits and Losses</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the U.S., AbbVie recognizes revenues on sales to third parties and we recognize our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> share of the co-promotion profits or losses as a component of total revenues in our consolidated statements of income. The collaboration began selling ZINBRYTA in the U.S. in the third quarter of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. For the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized a net reduction in revenue of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$21.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to reflect our share of an overall net loss within the collaboration.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table provides a summary of the U.S. collaboration and our share of the co-promotion losses on ZINBRYTA in the U.S.:</font></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:84%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Year Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Costs and expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">50.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Co-promotion losses in the U.S.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">43.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of co-promotion losses in the U.S.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">21.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the E.U. and Canada, we recognize revenues on sales to third parties in product revenues, net in our consolidated statements of income. We also record the related cost of revenues and sales and marketing expenses to their respective line items in our consolidated statements of income as these costs are incurred. We reimburse AbbVie for their </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> share of the co-promotion profits or losses in the E.U. and Canada. This reimbursement is recognized in collaboration profit (loss) sharing in our consolidated statements of income. We began to recognize product revenues on sales of ZINBRYTA in the E.U. in the third quarter of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. For the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized income of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$4.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to reflect AbbVie's </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> sharing of the net collaboration losses in the E.U. and Canada. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Swedish Orphan Biovitrum AB (publ)</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2007 we acquired </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the stock of Syntonix. Syntonix, now known as Bioverativ Therapeutics Inc. (formerly Biogen Hemophilia Inc.), had previously entered into a collaboration agreement with Swedish Orphan Biovitrum AB (publ) (Sobi) to jointly develop and commercialize Factor VIII and Factor IX hemophilia products, including ELOCTATE and ALPROLIX. Under an amended and restated collaboration agreement, we have commercial rights for North America (the Biogen North America Territory) and for rest of the world markets outside of the Sobi Territory, as defined below (the Biogen Direct Territory).&#160;Subject to the exercise of an option right that Sobi controls, Sobi has commercial rights in substantially all of Europe, Russia and certain countries in Northern Africa and the Middle East (the Sobi Territory). The collaboration agreement was amended and restated in April 2014. (References to the collaboration agreement refer to the amended and restated collaboration agreement).</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2014 Sobi exercised its option to assume final development and commercialization activities in the Sobi Territory for ELOCTA (the trade name for ELOCTATE in the E.U.). In July 2015 Sobi exercised its option to assume final development and commercialization of ALPROLIX in the Sobi Territory. Upon each exercise of opt-in right under the terms of the collaboration agreement, Sobi made a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> payment in escrow. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ELOCTA was approved by the EC in November 2015 and Sobi had its first commercial sale of ELOCTA in January 2016. In March 2016 the EC approved the transfer of the marketing authorization for ELOCTA in the E.U. from Biogen to Sobi, making Sobi the marketing authorization holder of ELOCTA in the E.U. As the marketing authorization holder, Sobi assumes full legal responsibility for ELOCTA, from a regulatory perspective, during its entire life cycle in the E.U. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$144.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in expenditures for ELOCTA, net of the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> escrow payment and other royalty adjustments as described in the table and its footnote (3) below, are reimbursable by Sobi under the collaboration agreement due to its election to assume final development and commercialization of ELOCTA within the Sobi Territory, which is the Opt-In Consideration for ELOCTA. This reimbursement will be recognized by us as royalty revenue in proportion to collaboration revenues, over a ten-year period, consistent with the initial patent term of the product.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ALPROLIX was approved in the E.U. by the EC in May 2016 and Sobi had its first commercial sale in June 2016. In September 2016 the EC approved the transfer of the marketing authorization for ALPROLIX in the E.U. from Biogen to Sobi, making Sobi the marketing authorization holder of ALPROLIX in the E.U. As the marketing authorization holder, Sobi assumes full legal responsibility for ALPROLIX, from a regulatory perspective, during its entire life cycle in the E.U. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$123.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in expenditures for ALPROLIX, net of the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> escrow payment and other royalty adjustments as described in the table and its footnote (3) below, are reimbursable to us by Sobi under the collaboration agreement due to Sobi's election to assume final development and commercialization of ALPROLIX in the Sobi Territory, which is the Opt-In Consideration for ALPROLIX. This reimbursement will be recognized by us as royalty revenue in proportion to collaboration revenues, over a ten-year period, consistent with the initial patent term of the product. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The Opt-In Consideration for each product will be paid by Sobi using a cross-royalty cash payment structure for sales in each company&#8217;s respective territories as an adjustment to the Base Rate in the table below. Under the collaboration agreement, cash payments are as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:51%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rates post Sobi Opt-In</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(3)</sup></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Royalty and Net Revenue Share Rates:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Method</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Base Rate following</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">1st&#160;commercial&#160;sale&#160;in</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">the Sobi Territory:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rate during the</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Reimbursement</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Period:</font></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Sobi rate to Biogen on net sales in the Sobi Territory</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Royalty</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">12%</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Base&#160;Rate<br clear="none"/>plus 5%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Biogen rate to Sobi on net sales in the Biogen North America Territory</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Royalty</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">12%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Base Rate<br clear="none"/>less 5%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Biogen rate to Sobi on net sales in the Biogen Direct Territory</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Royalty</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">17%</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Base Rate<br clear="none"/>less 5%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Biogen rate to Sobi on net revenue</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">from the Biogen Distributor Territory</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(2)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Net<br clear="none"/>Revenue<br clear="none"/>Share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">50%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Base Rate<br clear="none"/>less 15%</font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Net revenue represents Biogen&#8217;s pre-tax receipts from third-party distributors, less expenses incurred by Biogen in the conduct of commercialization activities supporting the distributor activities.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">The Biogen Distributor Territory represents Biogen territories where sales are derived utilizing a third-party distributor.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">A credit will be issued to Sobi against its reimbursement of the Opt-in Consideration for each product in an amount equal to the difference in the rate paid by Biogen to Sobi on sales in the Biogen territories for certain periods prior to the first commercial sale in the Sobi Territory versus the rate that otherwise would have been payable on such sales.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are recording revenue at the effective royalty rate expected over the term of the agreement of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">14%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and recording cost of sales at the effective royalty rate expected over the term of the agreement of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">If the reimbursement of the Opt-in Consideration has not been achieved within </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six years</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the first commercial sale of such product, we maintain the right to require Sobi to pay any remaining balances due to us within </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">90 days</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the six-year anniversary date of the first commercial sale.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Following the spin-off of our hemophilia business, this collaboration agreement with Sobi will continue with Bioverativ, an independent public company. For additional information about the spin-off, please see Note 1, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">and Note 26, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Subsequent Events </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Ionis Pharmaceuticals, Inc. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Long-Term Strategic Research Collaboration</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In September 2013 we entered into a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">-year research collaboration with Ionis, formerly known as Isis Pharmaceuticals Inc. under which both companies collaborate to perform discovery level research and then develop and commercialize antisense or other therapeutics for the treatment of neurological disorders.&#160;Under the collaboration, Ionis will perform research on a set of neurological targets identified within the agreement. Once the research has reached a specific stage of development, we will make the determination whether antisense is the preferred approach to develop a therapeutic candidate or whether another modality is preferred. If antisense is selected, Ionis will continue development and identify a product candidate. If another modality is used, we will assume the responsibility for identifying a product candidate and developing it. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the terms of this agreement, we paid Ionis an upfront amount of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$100.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.&#160;Of this payment, we recorded prepaid research and discovery services of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$25.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing the value of the Ionis full time equivalent employee resources which are required by the collaboration to provide research and discovery services to us over the term.&#160;The remaining </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$75.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the upfront payment was recorded as research and development expense as it represented the purchase of intellectual property that had not reached technological feasibility.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Ionis is also eligible to receive milestone payments, license fees and royalty payments for all product candidates developed through this collaboration, with the specific amount dependent upon the modality of the product candidate advanced by us. During the years ending </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we triggered milestones of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$20.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$20.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, related to the advancement of IONIS-SOD1</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">Rx</sub></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the treatment of ALS and other neurological targets identified.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For non-ALS antisense product candidates, Ionis will be responsible for global development through the completion of a Phase 2 trial and we will provide advice on the clinical trial design and regulatory strategy. For ALS antisense product candidates, we are responsible for global development, clinical trial design and regulatory strategy. We have an option to license a product candidate until completion of the Phase 2 trial. If we exercise our option, we will pay Ionis up to a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$70.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> license fee and assume global development, regulatory and commercialization responsibilities. Ionis could receive additional milestone payments upon the achievement of certain regulatory milestones of up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$130.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, plus additional amounts related to the cost of clinical trials conducted by Ionis under the collaboration, and royalties on future sales if we successfully develop the product candidate after option exercise. &#160;&#160;</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For product candidates using a different modality, we will be responsible for global development through all stages and will pay Ionis up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$90.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> upon the achievement of certain regulatory milestones and royalties on future sales if we successfully develop the product candidate. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Product Collaborations </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2012 we entered into three separate exclusive worldwide option and collaboration agreements with Ionis under which both companies will develop and commercialize SPINRAZA (nusinersen) for the treatment of SMA, antisense therapeutics for up to three gene targets and IONIS-DMPK</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">RX</sub></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the treatment of myotonic dystrophy type 1 (DM1), respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">SPINRAZA (nusinersen)</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2012 we entered into an exclusive worldwide option and collaboration agreement with Ionis under which both companies will develop and commercialize the antisense investigational drug candidate, SPINRAZA, for the treatment of SMA. Under the terms of this agreement, we paid Ionis </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$29.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as an upfront payment. During 2014 we amended the agreement to adjust the amount of potential additional payments and terms of the exercise of our opt-in right to license SPINRAZA, which included providing for additional opt-in scenarios, based on the filing or acceptance of a new drug application (NDA) or marketing authorization application with the FDA or EMA. Consistent with the initial agreement, Ionis remained responsible for conducting the pivotal/Phase 3 trials and we provided input on the clinical trial design and regulatory strategy for the development of SPINRAZA.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we triggered clinical trial payments of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$35.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$42.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$57.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, related to the advancement of the program. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2016 we and Ionis announced that SPINRAZA met the primary endpoint for the interim analysis of the Phase 3 trial evaluating SPINRAZA in infantile-onset SMA. In November 2016 we and Ionis announced that SPINRAZA met the primary endpoint for the interim analysis of the Phase 3 trial evaluating SPINRAZA in later-onset SMA. During the third quarter of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> we exercised our option to develop and commercialize SPINRAZA and paid Ionis a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$75.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> license fee in connection with the option exercise. This amount was recognized as research and development expense in our consolidated statements of income. In December 2016 SPINRAZA was approved by the FDA for the treatment of SMA in pediatric and adult patients in the U.S. During the fourth quarter of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> we accrued a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$60.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> milestone payment due to Ionis for the approval of SPINRAZA in the U.S. This amount was capitalized in intangible assets, net in our consolidated balance sheets.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the years ending </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$257.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$74.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$27.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, were reflected in research and development expense in our consolidated statements of income related to the advancement of the program. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We may pay Ionis up to approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$90.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in additional milestone payments upon the achievement of certain regulatory milestones as well as a royalty rate in the mid-teens on future sales of SPINRAZA.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Antisense Therapeutics</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the terms of the December 2012 agreement relating to the development and commercialization of up to three gene targets we provided Ionis with an upfront payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$30.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and agreed to make potential additional payments, prior to licensing, of up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> based on the development of the selected product candidate as well as a mark-up of the cost estimate of the Phase 1 and Phase 2 trials. During </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> we triggered a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> milestone payment. Ionis will be responsible for global development of any product candidate</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt"> </sub></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">through the completion of a Phase 2 trial and we will provide advice on the clinical trial design and regulatory strategy. We have an option to license the product candidate</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt"> </sub></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">until completion of the Phase 2 trial. If we exercise our option, we will pay Ionis up to a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$70.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> license fee and assume global development, regulatory and commercialization responsibilities. Ionis could receive up to another </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$130.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in milestone payments upon the achievement of certain regulatory milestones as well as royalties on future sales</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt"> </sub></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">if we successfully develop the product candidate after option exercise. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">IONIS-DMPK</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">Rx</sub>&#160;</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the terms of the June 2012 agreement for the DM1 candidate, we provided Ionis with an upfront payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$12.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and agreed to make potential additional payments, prior to licensing, of up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$59.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> based on the development of the selected product candidate. During </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> we amended the agreement to adjust the amount of potential additional payments by an additional </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$4.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> due to changes in the clinical trial design. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> we terminated the development of the IONIS-DMPK</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">Rx </sub></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">product candidate to treat DM1 and returned the product to Ionis. During the years ending </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.1 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$9.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, were reflected in research and development expense in our consolidated statements of income. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Eisai Co., Ltd. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">BAN2401 and E2609 Collaboration</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2014 we entered into a collaboration agreement with Eisai Co., Ltd. (Eisai) (Eisai Collaboration Agreement) to jointly develop and commercialize two Eisai product candidates for the treatment of Alzheimer&#8217;s disease, BAN2401, a monoclonal antibody that targets amyloid-beta aggregates, and E2609, a BACE inhibitor.&#160;Under the Eisai Collaboration Agreement, Eisai serves as the global operational and regulatory lead for both compounds and all costs, including research, development, sales and marketing expenses, will be shared equally by us and Eisai. Following marketing approval in major markets, such as the U.S., the E.U. and Japan, we will co-promote BAN2401 and E2609 with Eisai and share profits equally. In smaller markets, Eisai will distribute these products and pay us a royalty. The Eisai Collaboration Agreement also provides the parties with certain rights and obligations in the event of a change in control of either party. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The Eisai Collaboration Agreement also provides Eisai an option to jointly develop and commercialize aducanumab, our anti-amyloid beta antibody candidate for Alzheimer&#8217;s disease (Aducanumab Option) and an option to jointly develop and commercialize one of our anti-tau monoclonal antibodies (Anti-Tau Option). Upon exercise of each of the Aducanumab Option and the Anti-Tau Option, we will execute a separate collaboration agreement with Eisai on terms and conditions that mirror the Eisai Collaboration Agreement.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Aducanumab Option</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Eisai may exercise the Aducanumab Option after either (i) the Phase 1b clinical trial for aducanumab and the Phase 2 clinical trial for BAN2401 (Post-Phase 2 Aducanumab Option), or (ii) completion of the Phase 3 clinical trial for aducanumab (Post-Phase 3 Aducanumab Option) under certain conditions. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The consideration we will receive if Eisai exercises the Post-Phase 2 Aducanumab Option depends on the development status of BAN2401. If BAN2401 is then determined to advance to Phase 3, we will be entitled to receive a single payment from Eisai upon regulatory approval of aducanumab and we will no longer be required to pay Eisai any milestone payments for products containing BAN2401 under the Eisai Collaboration Agreement. If the development of BAN2401 has instead been terminated, we will receive development and commercial milestone payments from Eisai (Post-Phase 2 Aducanumab Milestone Payments). If Eisai does not exercise its Post-Phase 2 Aducanumab Option, we may elect to terminate the Eisai Collaboration Agreement with respect to BAN2401 but, under certain conditions, will have the option to reinstate the Eisai Collaboration Agreement after completion of a BAN2401 Phase 3 clinical trial.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">If Eisai exercises its Post-Phase 3 Aducanumab Option, Eisai will be required to pay us all Phase 3 development and commercialization costs plus a mark-up and an amount equal to any unpaid Post-Phase 2 Aducanumab Milestone Payments that would have been payable if Eisai had exercised its Post-Phase 2 Aducanumab Option. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Anti-Tau Option</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Eisai may exercise the Anti-Tau Option after completion of the Phase 1 clinical trial of such anti-tau monoclonal antibody. If Eisai exercises its Anti-Tau Option, we will receive an upfront payment from Eisai and will be entitled to additional development and commercial milestone payments.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Upon the effective date of the Eisai Collaboration Agreement, we paid Eisai </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$100.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and recorded </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$17.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, reflecting the fair value of the options granted under the Eisai Collaboration Agreement, both of which were classified as research and development expense in our consolidated statements of income. During the second quarter of 2014 Eisai exercised its option under the Eisai Collaboration Agreement to expand the joint development and commercialization activities to include Japan. Upon such exercise, we paid Eisai an additional </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$35.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and recorded </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$21.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as research and development expense in our consolidated statements of income, which represented the difference between the payment made upon exercise of the option and the fair value of that option recorded as research and development expense upon closing of the agreement in the first quarter of 2014. During the fourth quarter of 2016 we recognized a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$50.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> milestone payment related to the initiation of a phase 3 trial for E2609, which is included in research and development expense in our consolidated statements of income. We could pay Eisai up to an additional </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> under the Eisai Collaboration Agreement based on the future achievement of certain development, regulatory and commercial milestones.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition to our arrangements with Eisai, Neurimmune is entitled to milestone and royalty payments related to the development and commercialization of aducanumab and certain anti-tau antibodies. For additional information regarding our agreement with Neurimmune, please see Note 18, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Investments in Variable Interest Entities</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A summary of activity related to our collaboration with Eisai is as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total development expense incurred by the collaboration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">95.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">84.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">57.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen&#8217;s share of development expense, excluding upfront and milestone payments, reflected in our consolidated statements of income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">50.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">40.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">29.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Applied Genetic Technologies Corporation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2015 we announced a collaboration and license agreement to develop gene-based therapies for multiple ophthalmic diseases with Applied Genetic Technologies Corporation (AGTC). The collaboration will focus on the development of a portfolio of AGTC&#8217;s therapeutic programs, including both a clinical-stage candidate for X-linked Retinoschisis (XLRS) and a pre-clinical candidate for the treatment of X-Linked Retinitis Pigmentosa (XLRP). The agreement also includes options for early stage discovery programs in two ophthalmic diseases and one non-ophthalmic condition, as well as an equity investment in AGTC.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the third quarter of 2015 we made an upfront payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$124.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which included a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$30.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> equity investment in AGTC, prepaid research and development expenditures of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$58.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and total licensing and other fees of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$35.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$58.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of prepaid research and development expenditures were recorded in investments and other assets in our consolidated balance sheets and will be expensed as the services are provided. During </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> we recorded </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$54.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as research and development expense associated with AGTC in our consolidated statements of income, including the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$35.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> total licensing and other fees, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$6.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in research and development services, a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$7.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> premium on our equity investment and a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> clinical development milestone related to XLRS. During </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> we recorded </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$26.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in research and development services in research and development expense in our consolidated statements of income.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">AGTC is eligible to receive development, regulatory and commercial milestone payments aggregating in excess of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.1 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which includes up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$472.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> collectively for the two lead programs and up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$592.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> across the discovery programs. AGTC is also eligible to receive royalties in the mid-single digit to mid-teen percentages of annual net sales. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We were granted worldwide commercialization rights for the XLRS and XLRP programs. AGTC has an option to share development costs and profits after the initial clinical trial data are available, and an option to co-promote the second of these products to be approved in the U.S. AGTC will lead the clinical development programs of XLRS through product approval and of XLRP through the completion of first-in-human trials. We will support the clinical development costs, subject to certain conditions, following the first-in-human study for XLRS and IND-enabling studies for XLRP. Under the manufacturing license, we have received an exclusive license to use AGTC&#8217;s proprietary technology platform to make AAV vectors for up to six genes, three of which are in AGTC&#8217;s discretion, in exchange for payment of milestones and royalties.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">University of Pennsylvania</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2016 we entered into a collaboration and alliance with the University of Pennsylvania (UPenn) to advance gene therapy and gene editing technologies. The collaboration will primarily focus on the development of therapeutic approaches that target the eye, skeletal muscle and the central nervous system. The alliance is also expected to focus on the research and validation of next-generation gene transfer technology using adeno-associated virus gene delivery vectors and exploring the expanded use of genome editing technology as a potential therapeutic platform.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the second quarter of 2016 we paid Penn an upfront fee of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$20.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which was recorded as research and development expense in our consolidated statements of income, and prepaid research and development expenditures of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which was recorded in investments and other assets in our consolidated balance sheets. We also expect to fund an additional </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$47.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the aggregate in research and development costs extending over the next three to five years in seven preclinical research and development programs, as well as the exploration of genome-editing technology.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">If all of the collaborations programs are successful and we exercise all of our options under the Penn collaboration and alliance, we may be required to make future payments of over </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in research funding, options and milestone payments, in addition to royalties payable on net sales of products.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Sangamo BioSciences, Inc. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2014 we completed an exclusive worldwide research, development and commercialization collaboration and license agreement with Sangamo under which both companies will develop and commercialize product candidates for the treatment of two inherited blood disorders, sickle cell disease and beta-thalassemia.&#160;The collaboration is currently in the research stage of development.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the terms of the agreement, we paid Sangamo an upfront payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$20.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in cash, with additional payments of up to approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$300.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> based on the achievement of certain development, regulatory and commercial milestones, plus royalties based on sales.&#160;We recorded the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$20.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> upfront payment as research and development expense in our consolidated statements of income. Under this arrangement, Sangamo will be responsible for identifying a product candidate for the treatment of beta-thalassemia and advancing that candidate through a completed Phase 1 human clinical trial, at which point we would assume responsibility for development.&#160;We will jointly develop a sickle cell disease candidate through the potential filing of an investigative new drug application, after which we would assume clinical responsibilities. We will lead the global development and commercialization efforts and Sangamo will have the option to assume co-promotion responsibilities in the U.S.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the years ending </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$13.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$13.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$28.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, of expense was reflected in our consolidated statements of income.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Following the spin-off of our hemophilia business, this collaboration and license agreement with Sangamo will continue with Bioverativ, an independent public company. For additional information about the spin-off, please see Note 1, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and Note 26, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Subsequent Events </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Mitsubishi Tanabe Pharma Corporation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In September 2015 we announced an agreement with Mitsubishi Tanabe Pharma Corporation (MTPC) to exclusively license amiselimod (MT-1303), a late stage experimental medicine with potential in multiple autoimmune indications. Amiselimod is an oral compound that targets the sphingosine 1-phosphate receptor. During the fourth quarter of 2015 the agreement became effective and we made an upfront payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$60.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which was recorded as research and development expense in our consolidated statements of income. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the third quarter of 2016 we discontinued our development of amiselimod. We expect to formally terminate the agreement and return the program to MTPC in the first quarter of 2017. We will have no further license to or continuing involvement in the development of this compound. For the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$22.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was reflected in research and development expense in our consolidated statements of income.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Research and Discovery Arrangements </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we entered into several research, discovery and other related arrangements that resulted in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$9.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$40.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, recorded as research and development expense in our consolidated statements of income. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These additional arrangements include the potential for future milestone payments based on clinical and commercial development over a period of several years. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Samsung Bioepis</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Joint Venture Agreement</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2012 we entered into a joint venture agreement with Samsung BioLogics Co. Ltd. (Samsung Biologics), establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar pharmaceuticals.&#160;Samsung Biologics contributed </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">280.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> South Korean won (approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$250.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) for an </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">85%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> stake in Samsung Bioepis and we contributed approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> South Korean won (approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$45.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) for the remaining </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> ownership interest.&#160;Under the joint venture agreement, we have no obligation to provide any additional funding and our ownership interest may be diluted due to financings in which we do not participate. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our ownership interest is approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.5%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which reflects the effect of additional equity financings in which we did not participate. We maintain an option to purchase additional stock in Samsung Bioepis that would allow us to increase our ownership percentage up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49.9%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.&#160;The exercise of this option is within our control and is based on paying for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49.9%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the total investment made by Samsung Biologics into Samsung Bioepis in excess of what we have already contributed under the agreement plus a rate that will represent their return on capital. If we do not exercise this option by a date in 2018 determined pursuant to the joint venture agreement, this option will expire and Samsung Biologics will have the right to purchase all of Samsung Bioepis&#8217; shares then held by us.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Samsung Biologics has the power to direct the activities of Samsung Bioepis which will most significantly and directly impact its economic performance.&#160;We account for this investment under the equity method of accounting as we maintain the ability to exercise significant influence over Samsung Bioepis through a presence on the entity&#8217;s Board of Directors and our contractual relationship.&#160;Under the equity method, we recorded our original investment at cost and subsequently adjust the carrying value of our investment for our share of equity in the entity&#8217;s income or losses according to our percentage of ownership. We recognize our share of the results of operations related to our investment in Samsung Bioepis one quarter in arrears when the results of the entity become available, which is reflected as equity in loss of investee, net of tax in our consolidated statements of income. During the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized a loss on our investment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$12.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. During </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, as our share of losses exceeded the carrying value of our investment, we suspended recognizing additional losses and will continue to do so unless we commit to providing additional funding.</font></div><div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Commercial Agreement</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2013 pursuant to our rights under the joint venture agreement with Samsung Biologics, we entered into an agreement with Samsung Bioepis to commercialize, over a 10-year term, three anti-tumor necrosis factor (TNF) biosimilar product candidates in Europe and in the case of one anti-TNF biosimilar, Japan.&#160;Under the terms of this agreement, we have made total upfront and clinical development milestone payments of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$46.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, all of which have been recorded as research and development expense in our consolidated statements of income as the programs they relate to had not achieved regulatory approval. We also agreed to make additional milestone payments of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$25.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> upon regulatory approval in the E.U. for each of the three anti-TNF biosimilar product candidates. During the year ended December 31, 2016, we paid </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$50.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in milestone payments, which have been capitalized in intangible assets, net in our consolidated balance sheets as BENEPALI received regulatory approval in the E.U. in January 2016 and FLIXABI received regulatory approval in the E.U. in May 2016. In July 2016 the EMA accepted Samsung Bioepis' MAA for SB5, an adalimumab biosimilar candidate referencing HUMIRA.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We began to recognize revenue on sales of BENEPALI in the E.U. in the first quarter of 2016 and FLIXABI in the E.U. in the third quarter of 2016. We reflect revenues on sales of BENEPALI and FLIXABI to third parties in product revenues, net in our consolidated statements of income and record the related cost of revenues and sales and marketing expenses in our consolidated statements of income to their respective line items when these costs are incurred. We share </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the profit or loss related to our commercial agreement with Samsung Bioepis. This profit sharing with Samsung Bioepis is recognized in collaboration profit (loss) sharing in our consolidated statements of income. For the year ended December 31, 2016, we recognized a net expense of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to the collaboration profit share. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Other Services</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Simultaneous with the formation of Samsung Bioepis, we also entered into a license agreement, a technical development services agreement and a manufacturing agreement with Samsung Bioepis. Under the terms of the license agreement, we granted Samsung Bioepis an exclusive license to use, develop, manufacture and commercialize biosimilar products created by Samsung Bioepis using Biogen product-specific technology. In exchange, we will receive single digit royalties on all biosimilar products developed and commercialized by Samsung Bioepis. Under the terms of the technical development services agreement, we provide Samsung Bioepis technical development and technology transfer services, which include, but are not limited to, cell culture development, purification process development, formulation development and analytical development. Under the terms of our manufacturing agreement, we manufacture clinical and commercial quantities of bulk drug substance of biosimilar products for Samsung Bioepis pursuant to contractual terms.&#160;Under limited circumstances, we may also supply Samsung Bioepis with quantities of drug product of biosimilar products for use in clinical trials through arrangements with third-party contract manufacturers. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$20.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$62.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$58.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in revenues in relation to these services, which is reflected as a component of other revenues in our consolidated statements of income.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6711925696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Litigation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract', window );"><strong>Loss Contingency, Information about Litigation Matters [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalMattersAndContingenciesTextBlock', window );">Litigation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Litigation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are currently involved in various claims and legal proceedings, including the matters described below. For information as to our accounting policies relating to claims and legal proceedings, including use of estimates and contingencies, please read Note 1, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">With respect to some loss contingencies, an estimate of the possible loss or range of loss cannot be made until management has further information, including, for example, (i) which claims, if any, will survive dispositive motion practice; (ii) information to be obtained through discovery; (iii) information as to the parties' damages claims and supporting evidence; (iv) the parties&#8217; legal theories; and (v) the parties' settlement positions. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The claims and legal proceedings in which we are involved also include challenges to the scope, validity or enforceability of the patents relating to our products, pipeline or processes, and challenges to the scope, validity or enforceability of the patents held by others. These include claims by third parties that we infringe their patents. An adverse outcome in any of these proceedings could result in one or more of the following and have a material impact on our business or consolidated results of operations and financial position: (i) loss of patent protection; (ii) inability to continue to engage in certain activities; and (iii) payment of significant damages, royalties, penalties and/or license fees to third parties.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Loss Contingencies </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Forward Pharma German Patent Litigation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On November 18, 2014, Forward Pharma A/S (Forward Pharma) filed suit against us in the Regional Court of D&#252;sseldorf, Germany (the German Infringement Litigation) alleging that TECFIDERA infringes German Utility Model DE&#160;20 2005 022 112&#160;U1 (the utility model), which was issued in April 2014 and expired in October 2015. Forward Pharma subsequently&#160;extended its allegations&#160;to assert that TECFIDERA infringes Forward Pharma's European Patent No. 2,801,355 (the '355 patent), which was issued in May 2015 and expires in October 2025. We have entered a settlement and license agreement with Forward Pharma that will provide us an irrevocable license to all intellectual property owned by Forward Pharma and result in the termination of the German Infringement Litigation. For more information on the settlement and license agreement please read Note 21, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Commitments and Contingencies</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Italian National Medicines Agency</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the fourth quarter of 2011 Biogen Italia SRL&#160;received notice from the Italian National Medicines Agency (Agenzia Italiana del Farmaco or AIFA) that sales of TYSABRI after mid-February 2009 exceeded a reimbursement limit established pursuant to a Price Determination Resolution (Price Resolution) granted by AIFA in December 2006. On January&#160;12, 2012, we filed an appeal in the Regional Administrative Tribunal of Lazio (Il Tribunale Amministrativo Regionale per il Lazio) in Rome, Italy seeking a ruling that the reimbursement limit in the Price Resolution should apply as written to only &#8220;the first </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months&#8221; of TYSABRI sales, which ended in mid-February 2009. The appeal is still pending. In June 2014 AIFA approved a resolution affirming that there is no reimbursement limit from and after February 2013. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#231f20;">In January 2017 we negotiated an agreement in principle with AIFA's Price and Reimbursement Committee to settle all of AIFA's existing claims relating to sales of TYSABRI in excess of the reimbursement limit for the periods from February 2009 through January 2013 for an aggregate repayment of EUR</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#231f20;">. The agreement is subject to ratification by AIFA.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information regarding this matter, please read Note 17, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Other Consolidated Financial Statement Detail </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Qui Tam Litigation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On July 6, 2015, a qui tam action filed on behalf of the United States and certain states were unsealed by the U.S. District Court for the District of Massachusetts. The action alleges sales and promotional activities in violation of the federal False Claims Act and state law counterparts, and seeks single and treble damages, civil penalties, interest, attorneys&#8217; fees and costs. Our motion to dismiss is pending. The United States has not made an intervention decision. An estimate of the possible loss or range of loss cannot be made at this time.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Securities Litigation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We and certain current and former officers are defendants in In re Biogen Inc. Securities Litigation, filed by a shareholder on August 18, 2015 in the U.S. District Court for the District of Massachusetts. The amended complaint alleges violations of federal securities laws under 15 U.S.C. &#167;78j(b) and &#167;78t(a) and 17 C.F.R. &#167;240.10b-5. The lead plaintiff sought a declaration of the action as a class action, certification as a representative of the class and its counsel as class counsel, and an award of damages, interest and attorneys' fees. On July 1, 2016, the U.S. District Court dismissed the case and in September 2016 denied the plaintiff's motion to vacate the order of dismissal. The plaintiff has appealed. An estimate of the possible loss or range of loss cannot be made at this time.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We and certain current and former officers are also defendants in an action filed by another shareholder on October 20, 2016 in the U.S. District Court for the District of Massachusetts, related to the matter described above. The complaint alleges violations of federal securities laws under 15 U.S.C. &#167;78j(b) and &#167;78t(a) and 17 C.F.R. &#167;240.10b-5 and seeks a declaration of the action as a class action and an award of damages, interest and attorney's fees. An estimate of the possible loss or range of loss cannot be made at this time.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Matters</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Interference Proceeding with Forward Pharma</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In April 2015 the U.S. Patent and Trademark Office (USPTO) declared an interference between Forward Pharma&#8217;s pending U.S. Patent Application No. 11/576,871 and our U.S. Patent No. 8,399,514 (the '514 patent). The '514 patent includes claims covering the treatment of multiple sclerosis with 480 mg of dimethyl fumarate as provided for in our TECFIDERA label. We are awaiting a decision in this matter.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Inter Partes Review Proceeding</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On March 22, 2016, the USPTO instituted </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">inter partes</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> review of the '514 patent on the petition of the Coalition for Affordable Drugs V LLC, an entity associated with a hedge fund. We are awaiting a decision in this matter.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On April 18, 2016, Swiss Pharma International AG filed petitions in the USPTO for inter partes review of U.S. Patent Nos. 8,349,321 and 8,900,577, relating to specific formulations of natalizumab (TYSABRI), and U.S. Patent No. 8,815,236, relating to methods for treating MS and Crohn's disease using specific formulations of natalizumab (TYSABRI). In October 2016 the USPTO declined to institute proceedings under all three petitions. Swiss Pharma filed requests for rehearing, which are pending.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">European Patent Office Oppositions</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2016 the European Patent Office issued a written decision confirming its earlier revocation of our European patent number 2 137 537 (the '537 patent), which we have appealed. The '537 patent includes claims covering the treatment of MS with 480 mg of dimethyl fumarate as provided for in our TECFIDERA label.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Patent Revocation Matter</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2015 Swiss Pharma International AG brought an action in the Patents Court of the United Kingdom to revoke the UK counterpart of our European Patent Number 1 485 127&#160;(&#8220;Administration of agents to treat inflammation&#8221;) (the '127 patent), which was issued in June 2011 and concerns administration of natalizumab (TYSABRI) to treat MS. The patent expires in February 2023.&#160;Subsequently, the same entity brought an actions in the District Court of The Hague (on January 11, 2016) and the German Patents Court (on March 3, 2016) to invalidate the Dutch and German counterparts of the '127 patent. In September 2016 we resolved the UK action by agreeing to revocation of the UK patent. A hearing has been scheduled in the Dutch action for early 2017 and the German action for early 2018.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">'755 Patent Litigation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On May&#160;28, 2010, Biogen MA Inc. (formerly Biogen Idec MA Inc.) filed a complaint in the U.S.&#160;District Court for the District of New Jersey alleging infringement by Bayer Healthcare Pharmaceuticals Inc. (Bayer) (manufacturer, marketer and seller of BETASERON and manufacturer of EXTAVIA), EMD Serono, Inc. (EMD Serono) (manufacturer, marketer and seller of REBIF), Pfizer Inc. (co-marketer of REBIF) and Novartis Pharmaceuticals Corp. (Novartis) (marketer and seller of EXTAVIA) of our U.S. Patent No. 7,588,755 ('755 Patent), which claims the use of interferon beta for immunomodulation or treating a viral condition, viral disease, cancers or tumors. The complaint seeks monetary damages, including lost profits and royalties. Bayer had previously filed a complaint against us in the same court, on May 27, 2010, seeking a declaratory judgment that it does not infringe the '755 Patent and that the patent is invalid, and seeking monetary relief in the form of attorneys' fees, costs and expenses. The court has consolidated the two lawsuits, and we refer to the two actions as the &#8220;Consolidated '755 Patent Actions.&#8221;</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Bayer, Pfizer, Novartis and EMD Serono have all filed counterclaims in the Consolidated '755 Patent Actions seeking declaratory judgments of patent invalidity and non-infringement, and seeking monetary relief in the form of costs and attorneys' fees, and EMD Serono and Bayer have each filed a counterclaim seeking a declaratory judgment that the '755 Patent is unenforceable based on alleged inequitable conduct. Bayer has also amended its complaint to seek such a declaration. Trial has been set for September 2017.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Government Matters</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have learned that state and federal governmental authorities are investigating our sales and promotional practices and have received related subpoenas. We are cooperating with the government. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On March 4, 2016, we received a subpoena from the federal government for documents relating to our relationship with non-profit organizations that provide assistance to patients taking drugs sold by Biogen. We are cooperating with the government.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On July 1, 2016, we received a civil investigative demand from the federal government for documents and information relating to our treatment of certain service agreements with wholesalers when calculating and reporting Average Manufacturer Prices in connection with the Medicaid Drug Rebate Program. We are cooperating with the government.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On December 5, 2016, we received a subpoena from the federal government for documents relating to government price reporting, rebate payments and Biogen's co-pay assistance programs for AVONEX, TECFIDERA, TYSABRI and PLEGRIDY. We are cooperating with the government.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On December 29, 2016, we received a civil investigative demand from the federal government for documents and information relating to our relationships with entities providing clinical education and reimbursement support services. We are cooperating with the government.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Product Liability and Other Legal Proceedings</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are also involved in product liability claims and other legal proceedings generally incidental to our normal business activities. While the outcome of any of these proceedings cannot be accurately predicted, we do not believe the ultimate resolution of any of these existing matters would have a material adverse effect on our business or financial condition.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalMattersAndContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalMattersAndContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyInformationAboutLitigationMattersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6895548112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Commitments and Contingencies</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">TECFIDERA Litigation Settlement and License Agreement</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2017 we agreed to enter into a settlement and license agreement with Forward Pharma that will provide us an irrevocable license to all intellectual property owned by Forward Pharma and results in the termination of the German Infringement Litigation. Under the terms of the settlement and license agreement with Forward Pharma, we have agreed to pay Forward Pharma </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.25 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in cash. Under certain circumstances outlined in the agreement, we will pay Forward Pharma royalties on net sales of our products for the treatment of multiple sclerosis that are covered by a Forward Pharma patent and have dimethyl fumarate (&#8220;DMF&#8221;) as an active pharmaceutical ingredient.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the fourth quarter of 2016 we recognized a pre-tax charge of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$454.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to this matter. This amount represents the fair value of estimated royalties on our sales of TECFIDERA during the period April 2014 through December 31, 2016. When the cash payment is made following approval of the settlement and license agreement, we will recognize assets of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$656.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$138.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, reflecting the estimated fair value of the license acquired that is attributable to the U.S. and E.U., respectively. If Forward Pharma does not receive a patent in either the Interference Proceeding pending in the U.S. or the pending European Opposition Proceeding (which proceedings are defined in the settlement and license agreement), we would likely recognize an immediate impairment charge equal to the value of the license that is attributable to that jurisdiction as additional litigation expense and we would not be obligated to pay Forward Pharma royalties in such jurisdiction. If Forward Pharma receives a patent in either the U.S. Interference Proceeding or the E.U. Opposition Proceeding, we would amortize the assets related to a license of intellectual property in the related jurisdiction utilizing an economic consumption model and we may be obligated to royalties on a country by country basis in Europe and other ex-U.S. markets. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information with respect to the terms of this agreement, including potential royalties payable, please read the Settlement and License Agreement dated January 17, 2017,&#160;between Biogen Swiss Manufacturing GmbH, Biogen International Holding Ltd, Forward Pharma A/S and the other parties thereto which is filed as Exhibit 10.41 to this 2016 Form 10-K. For additional information related to the ongoing Interference Proceeding with Forward Pharma in the U.S. or the European Office Opposition in the E.U., please read Note 20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Litigation</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">TYSABRI Contingent Payments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2013 we acquired from Elan full ownership of all remaining rights to TYSABRI that we did not already own or control. Under the terms of the acquisition agreement, we are obligated to make contingent payments to Elan of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> on annual worldwide net sales up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">25%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> on annual worldwide net sales that exceed </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Royalty payments to Elan and other third parties are recognized as cost of sales in our consolidated statements of income. Elan was acquired by Perrigo Company plc (Perrigo) in December 2013. Following that acquisition, we began making these royalty payments to Perrigo.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Consideration related to Business Combinations</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisitions of Convergence, Stromedix and Biogen International Neuroscience GmbH (BIN), we agreed to make additional payments based upon the achievement of certain milestone events. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As the acquisitions of Convergence, Stromedix and BIN, formerly Panima Pharmaceuticals AG, occurred after January&#160;1, 2009, we record contingent consideration liabilities at their fair value on the acquisition date and revalue these obligations each reporting period. We may pay up to approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.2 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in remaining milestones related to these acquisitions. For additional information related to our acquisition of Convergence please read Note 2, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Fumapharm AG</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2006 we acquired Fumapharm AG. As part of this acquisition we acquired FUMADERM and TECFIDERA (together, Fumapharm Products). We paid </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$220.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> upon closing of the transaction and agreed to pay an additional </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> if a Fumapharm Product was approved for MS in the U.S.&#160;or E.U. In the second quarter of 2013 we paid this </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> contingent payment as TECFIDERA was approved in the U.S. for MS by the FDA. We are also required to make additional contingent payments to former shareholders of Fumapharm AG or holders of their rights based on the attainment of certain cumulative sales levels of Fumapharm Products and the level of total net sales of Fumapharm Products in the prior twelve month period, as defined in the acquisition agreement. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> we paid </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.2 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in contingent payments as we reached the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$7.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$8.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$9.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> cumulative sales levels related to the Fumapharm Products in the fourth quarter of 2015 and the first, second and third quarters of 2016, respectively, and accrued </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$300.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> upon reaching </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$11.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in total cumulative sales of Fumapharm Products in the fourth quarter of 2016.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We will owe an additional </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$300.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> contingent payment for every additional </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in cumulative sales level of Fumapharm Products reached if the prior 12 months sales of the Fumapharm Products exceed </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, until such time as the cumulative sales level reaches </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$20.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, at which time no further contingent payments shall be due. If the prior 12 months sales of Fumapharm Products are less than </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, contingent payments remain payable on a decreasing tiered basis. These payments will be accounted for as an increase to goodwill as incurred, in accordance with the accounting standard applicable to business combinations when we acquired Fumapharm. Any portion of the payment which is tax deductible will be recorded as a reduction to goodwill. Payments are due within 60&#160;days following the end of the quarter in which the applicable cumulative sales level has been reached. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Development, Regulatory and Commercial Milestone Payments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based on our development plans as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we could make potential future milestone payments to third parties of up to approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.1 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, including approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$0.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in development milestones, approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$0.8 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in regulatory milestones and approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.8 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in commercial milestones as part of our various collaborations, including licensing and development programs. Payments under these agreements generally become due and payable upon achievement of certain development, regulatory or commercial milestones. Because the achievement of these milestones had not occurred as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, such contingencies have not been recorded in our financial statements. Amounts related to contingent milestone payments are not considered contractual obligations as they are contingent on the successful achievement of certain development, regulatory approval and commercial milestones. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Funding Commitments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we have several on-going clinical studies in various clinical trial stages. Our most significant clinical trial expenditures are to contract research organizations (CROs). The contracts with CROs are generally cancellable, with notice, at our option. We have recorded accrued expenses of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$21.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> on our consolidated balance sheet for expenditures incurred by CROs as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We have approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$500.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in cancellable future commitments based on existing CRO contracts as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Tax Related Obligations</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We exclude liabilities pertaining to uncertain tax positions from our summary of contractual obligations as we cannot make a reliable estimate of the period of cash settlement with the respective taxing authorities. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we have approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$47.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of net liabilities associated with uncertain tax positions.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Solothurn, Switzerland Facility</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On December 1, 2015, we purchased land in Solothurn, Switzerland where we are building a biologics manufacturing facility over the next several years. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had contractual commitments of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$176.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the construction of this facility.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Leases</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We rent laboratory and office space and certain equipment under non-cancelable operating leases. These lease agreements contain various clauses for renewal at our option and, in certain cases, escalation clauses typically linked to rates of inflation. Rental expense under these leases, net of amounts recognized in relation to exiting our manufacturing facility in Cambridge, Massachusetts and our Weston, Massachusetts facility, which terminate at various dates through 2028, amounted to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$68.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$68.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$62.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. In addition to rent, the leases may require us to pay additional amounts for taxes, insurance, maintenance and other operating expenses.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, minimum rental commitments under non-cancelable leases, net of income from subleases, for each of the next five years and total thereafter were as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="28" rowspan="1"></td></tr><tr><td style="width:31%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2021</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Thereafter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Minimum lease payments </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">75.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">69.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">69.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">65.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">64.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">331.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">676.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Less: income from subleases (1)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(8.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(15.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(15.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(15.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(16.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(55.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(126.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net minimum lease payments</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">66.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">54.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">53.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">50.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">48.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">276.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">549.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Represents sublease income expected to be received for the vacated manufacturing facility in Cambridge, MA, the vacated portion of our Weston, Massachusetts facility and other facilities throughout the world. For additional information related to the sublease of the vacated manufacturing facility in Cambridge, MA, please read Note 3, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-style:italic;">Restructuring, Business Transformation and Other Cost Savings Initiatives</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"> to these consolidated financial statements.</font></div></td></tr></table><div style="line-height:120%;padding-left:4px;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under certain of our lease agreements, we are contractually obligated to return leased space to its original condition upon termination of the lease agreement. At the inception of a lease with such conditions, we record an asset retirement obligation liability and a corresponding capital asset in an amount equal to the estimated fair value of the obligation. In subsequent periods, for each such lease, we record interest expense to accrete the asset retirement obligation liability to full value and depreciate each capitalized asset retirement obligation asset, both over the term of the associated lease agreement. Our asset retirement obligations were not significant as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> or </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-left:4px;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Eisai Financing Arrangement</font></div><div style="line-height:120%;padding-left:4px;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During 2015 we amended our existing lease related to Eisai's oral solid dose products manufacturing facility in RTP, North Carolina where we manufacture our and Eisai's oral solid dose products. For additional information, please read Note 10, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Property, Plant and Equipment</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the net present values of the future minimum lease payments were as follows:</font></div><div style="line-height:120%;padding-left:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:79%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">As of December 31, 2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">16.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">18.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Less: interest</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(0.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net present value of the future minimum lease payments</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">18.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68068213&amp;loc=d3e12565-110249<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=73718637&amp;loc=d3e25287-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6895482832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Guarantees<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GuaranteesAbstract', window );"><strong>Guarantees [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GuaranteesTextBlock', window );">Guarantees</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Guarantees</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we did not have significant liabilities recorded for guarantees.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We enter into indemnification provisions under our agreements with other companies in the ordinary course of business, typically with business partners, contractors, clinical sites and customers. Under these provisions, we generally indemnify and hold harmless the indemnified party for losses suffered or incurred by the indemnified party as a result of our activities. These indemnification provisions generally survive termination of the underlying agreement. The maximum potential amount of future payments we could be required to make under these indemnification provisions is unlimited. However, to date we have not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. As a result, the estimated fair value of these agreements is minimal. Accordingly, we have no liabilities recorded for these agreements as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for each guarantee obligation, or each group of similar guarantee obligations, including (a) the nature of the guarantee, including its term, how it arose, and the events or circumstances that would require the guarantor to perform under the guarantee; (b) the maximum potential amount of future payments (undiscounted) the guarantor could be required to make under the guarantee; (c) the current carrying amount of the liability, if any, for the guarantor's obligations under the guarantee; and (d) the nature of any recourse provisions under the guarantee, and any assets held either as collateral or by third parties, and any relevant related party disclosure. Excludes disclosures about product warranties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6895364240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Compensation and Retirement Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employee Benefit Plans</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Employee Benefit Plans</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We sponsor various retirement and pension plans. Our estimates of liabilities and expenses for these plans incorporate a number of assumptions, including expected rates of return on plan assets and interest rates used to discount future benefits.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">401(k) Savings Plan</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We maintain a 401(k) Savings Plan, which is available to substantially all regular employees in the U.S. over the age of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Participants may make voluntary contributions. We make matching contributions according to the 401(k) Savings Plan&#8217;s matching formula. All matching contributions and participant contributions vest immediately. The 401(k) Savings Plan also holds certain transition contributions on behalf of participants who previously participated in the Biogen, Inc. Retirement Plan. The expense related to our 401(k) Savings Plan primarily consists of our matching contributions.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Expense related to our 401(k) Savings Plan totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$45.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$51.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$49.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Deferred Compensation Plan</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We maintain a non-qualified deferred compensation plan, known as the Supplemental Savings Plan (SSP), which allows a select group of management employees in the U.S. to defer a portion of their compensation. The SSP also provides certain credits to highly compensated U.S. employees, which are paid by the company. These credits are known as the Restoration Match. The deferred compensation amounts are accrued when earned. Such deferred compensation is distributable in cash in accordance with the rules of the SSP. Deferred compensation amounts under such plan as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, totaled approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$128.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$126.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, and are included in other long-term liabilities in our consolidated balance sheets. The SSP also holds certain transition contributions on behalf of participants who previously participated in the Biogen, Inc. Retirement Plan. The Restoration Match and participant contributions vest immediately. Distributions to participants can be either in one lump sum payment or annual installments as elected by the participants.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Pension Plans</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our retiree benefit plans include defined benefit plans for employees in our affiliates in Switzerland and Germany as well as other insignificant defined benefit plans in certain other countries in which we maintain an operating presence.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our Swiss plan is a government-mandated retirement fund that provides employees with a minimum investment return. The minimum investment return is determined annually by the Swiss government and was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.25%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in 2016 and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.75%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Under the Swiss plan, both we and certain of our employees with annual earnings in excess of government determined amounts are required to make contributions into a fund managed by an independent investment fiduciary. Employer contributions must be in an amount at least equal to the employee&#8217;s contribution. Minimum employee contributions are based on the respective employee&#8217;s age, salary and gender. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the Swiss plan had an unfunded net pension obligation of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$39.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$42.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, and plan assets which totaled approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$68.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$63.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. In </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized expense totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$12.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$9.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, related to our Swiss plan.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The obligations under the German plans are unfunded and totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$35.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$27.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Net periodic pension cost related to the German plans totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$4.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$4.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for pension and other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 80<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=65877416&amp;loc=SL14450702-114947<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65897934&amp;loc=d3e2410-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39675-114964<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66047640&amp;loc=d3e39622-114963<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6824661312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Information</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Segment Information</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We operate as </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">one</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> operating segment, which is discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. Our Chief Executive Officer (CEO), as the chief operating decision-maker, manages and allocates resources to the operations of our company on a total company basis. Our research and development organization is responsible for the research and discovery of new product candidates and supports development and registration efforts for potential future products. Our pharmaceutical, operations and technology organization manages the development of the manufacturing processes, clinical trial supply, commercial product supply, distribution, buildings and facilities. Our commercial organization is responsible for U.S. and international development of our commercial products. The company is also supported by corporate staff functions. Managing and allocating resources on a total company basis enables our CEO to assess the overall level of resources available and how to best deploy these resources across functions, therapeutic areas, and research and development projects that are in line with our long-term company-wide strategic goals. Consistent with this decision-making process, our CEO uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Enterprise-wide disclosures about product revenues, other revenues and long-lived assets by geographic area and information relating to major customers are presented below. Revenues are primarily attributed to individual countries based on location of the customer or licensee.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenue by product is summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="36" rowspan="1"></td></tr><tr><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="35" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">States</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">World</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">States</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">World</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">States</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">World</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Multiple Sclerosis (MS):</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">TECFIDERA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">3,169.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">798.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">3,968.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">2,908.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">730.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">3,638.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">2,426.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">482.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">2,909.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">AVONEX</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">1,675.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">638.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">2,313.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,790.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">840.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">2,630.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,956.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,056.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">3,013.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">PLEGRIDY</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">305.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">176.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">481.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">227.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">111.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">338.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">27.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">16.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">44.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">TYSABRI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">1,182.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">780.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">1,963.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,103.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">783.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,886.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,025.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">934.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,959.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">FAMPYRA</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">84.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">84.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">89.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">89.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">80.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">80.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">ZINBRYTA</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">7.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">7.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Hemophilia:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">ELOCTATE</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">445.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">68.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">513.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">308.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">11.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">319.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">58.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">58.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">ALPROLIX</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">268.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">65.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">333.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">208.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">25.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">234.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">72.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">3.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">76.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Other product revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">FUMADERM</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">45.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">45.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">51.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">51.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">62.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">62.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">SPINRAZA</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">4.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">4.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">BENEPALI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">100.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">100.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">FLIXABI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total product revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">7,050.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">2,767.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">9,817.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">6,545.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">2,642.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">9,188.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">5,566.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">2,636.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">8,203.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Geographic Information</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables contain certain financial information by geographic area:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="24" rowspan="1"></td></tr><tr><td style="width:29%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">December 31, 2016 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Europe</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Germany</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Asia</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues from external customers</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7,050.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,533.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">703.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">217.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">313.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">9,817.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,249.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">63.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,314.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues from external customers</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">224.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">70.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">20.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">316.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-lived assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,272.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,219.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,501.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">December 31, 2015 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Europe</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Germany</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Asia</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues from external customers</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,545.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,497.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">668.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">143.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">333.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9,188.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,269.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">65.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,339.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues from external customers</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">142.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">29.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">62.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">236.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-lived assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,296.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">879.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,187.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">December 31, 2014 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Europe</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Germany</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Asia</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues from external customers</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,566.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,383.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">811.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">112.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">328.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8,203.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,117.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">70.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,195.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues from external customers</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">212.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">58.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">304.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-lived assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,055.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">701.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,765.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Represents amounts related to Europe less those attributable to Germany.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Revenues from Anti-CD20 Therapeutic Programs</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of our total revenues in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, are derived from our collaboration agreement with Genentech. For additional information related to our collaboration with Genentech, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Significant Customers</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recorded revenue from two wholesalers accounting for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">22%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of gross product revenues in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">34%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">26%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of gross product revenues in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">33%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">27%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of gross product revenues in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$643.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$684.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$676.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, of our long-lived assets were related to our manufacturing facilities in Denmark. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$545.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$161.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, of our long-lived assets were related to the construction of a biologics manufacturing facility in Solothurn, Switzerland.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information related to our manufacturing facility in Solothurn, Switzerland, please read Note 10, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Property, plant and equipment</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8981-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e9038-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 33<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8971-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8595-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8380-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 35<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8984-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e9031-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8538-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8864-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8924-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6895364240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Financial Data (Unaudited)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">Quarterly Financial Data (Unaudited)</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">&#160;&#160;&#160;&#160;Quarterly Financial Data (Unaudited)</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:36%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except per share amounts)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">First</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Second</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Third</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fourth</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Year</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2016</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(a)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(b)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(b) (c)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(b) (d) (e)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,309.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,466.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,539.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,502.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">9,817.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">329.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">349.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">317.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">318.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,314.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">87.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">79.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">98.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">50.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">316.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,726.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,894.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,955.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,872.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">11,448.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gross profit (1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,413.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,523.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,538.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,493.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">9,970.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">969.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,048.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,030.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">647.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,695.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">970.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,049.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,032.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">649.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,702.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income per share:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.44</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.79</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.72</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.00</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">16.96</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.43</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.79</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.71</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2.99</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">16.93</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted-average shares used in calculating:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share attributable to Biogen Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">218.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">219.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">218.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">216.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">218.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">219.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">219.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">219.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">217.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">218.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:36%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except per share amounts)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">First</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Second</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Third</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fourth</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Year</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">2015</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(f) (g)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(a) (h)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,172.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,198.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,391.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,425.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9,188.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">330.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">337.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">337.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">333.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,339.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">52.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">55.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">79.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">236.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,555.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,591.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,777.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,839.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10,763.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gross profit (1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,242.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,305.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,467.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,507.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9,523.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">820.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">924.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,019.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">828.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,593.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">822.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">927.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">965.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">831.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,547.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income per share:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.50</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.94</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.16</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.77</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15.38</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.49</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.93</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.15</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.77</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15.34</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted-average shares used in calculating:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share attributable to Biogen Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">235.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">235.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">232.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">220.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">230.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">235.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">235.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">232.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">220.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">231.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(1) Gross profit is calculated as total revenues less cost of sales, excluding amortization of acquired intangible assets.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc., for the first quarter of 2016 and the fourth quarter of 2015, includes pre-tax restructuring charges totaling </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$9.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$93.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively related to the 2015 corporate restructuring program.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for the second, third and fourth quarters of 2016 includes pre-tax additional depreciation expense totaling </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$15.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$15.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$14.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, as part of our determination to cease manufacturing in our small-scale biologics manufacturing facility in Cambridge, MA as well as vacate our warehouse space in Somerville, MA. Our departure from these facilities has shortened the expected useful lives of certain leasehold improvements and other assets at these facilities.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for the third quarter of 2016 includes a pre-tax charge to research and development expense of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$75.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for a license fee paid to Ionis as we exercised our option to develop and commercialize SPINRAZA.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for the fourth quarter of 2016 includes a pre-tax charge to research and development expense of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$50.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for a milestone payment due to Eisai related to the initiation of a phase 3 trial for E2609.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(e)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for the fourth quarter of 2016 includes a pre-tax charge of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$454.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to the January 2017 settlement and license agreement with Forward Pharma.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(f)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for the third quarter of 2015 includes a pre-tax charge to research and development expense of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$48.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> recorded upon entering into the collaboration agreement with AGTC.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(g)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc. for the third quarter of 2015 reflects the attribution of a </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$60.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> charge to noncontrolling interests, net of tax, related to a milestone payment due Neurimmune upon the enrollment of the first patient in a Phase 3 trial for aducanumab.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(h)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for the fourth quarter of 2015 includes a pre-tax charge to research and development expense of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$60.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> recorded upon entering into the collaboration agreement with MTPC.</font></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68076893&amp;loc=d3e1570-108306<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=68064558&amp;loc=d3e765-108305<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=68064558&amp;loc=d3e725-108305<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6713514784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Notes)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Subsequent Events</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On February 1, 2017, we completed the distribution of the issued and outstanding common stock of Bioverativ to Biogen stockholders. For additional information related to the distribution of Bioverativ, please read Note 1, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the distribution, we entered into a separation and distribution agreement and various other agreements (including a transition services agreement, a tax matters agreement, a manufacturing and supply agreement, an employee matters agreement, an intellectual property matters agreement and certain other commercial agreements). These agreements govern the separation and distribution and the relationship between the two companies going forward. They also provide for the performance of services by each company for the benefit of the other for a period of time (including under the manufacturing and supply agreement pursuant to which we will manufacture and supply certain products and materials to Bioverativ).</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6826731824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_BusinessOverviewPolicyTextBlock', window );">Business Overview</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen is a global biopharmaceutical company focused on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). We also have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other potential anti-CD20 therapies under a collaboration agreement with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group (Roche Group).</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities, particularly within areas of our scientific, manufacturing and technical capabilities. Our research is currently focused on additional improvements in the treatment of MS, solving some of the most challenging and complex diseases, including Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis (ALS), and employing innovative technologies to discover potential treatments for rare and genetic disorders, including new ways of treating diseases through gene therapy.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our innovative drug development and commercialization activities are complemented by our biosimilar therapies that expand access to medicines and reduce the cost burden for healthcare systems. We are leveraging our manufacturing capabilities and know-how to develop, manufacture and market biosimilars through Samsung Bioepis, our joint venture with Samsung BioLogics Co. Ltd. (Samsung Biologics). Under this agreement, we are currently manufacturing and commercializing BENEPALI, an etanercept biosimilar referencing ENBREL, and FLIXABI, an infliximab biosimilar referencing REMICADE, in the European Union (E.U.).</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Hemophilia Spin-Off</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2016 we announced our intention to spin off our hemophilia business, Bioverativ Inc. (Bioverativ), as an independent, publicly traded company. Bioverativ, will focus on the discovery, development and commercialization of therapies for treatment of hemophilia and other blood disorders, including ELOCTATE for the treatment of hemophilia A and ALPROLIX for the treatment of hemophilia B. Bioverativ will also assume all of our rights and obligations under our collaboration agreement with Swedish Orphan Biovitrum AB (Sobi) and our collaboration and license agreement with Sangamo Biosciences Inc. (Sangamo).</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On February 1, 2017, we completed the distribution of all the then outstanding shares of common stock of Bioverativ to Biogen stockholders, who received one share of Bioverativ common stock for every two shares of Biogen common stock. As a result of the distribution, Bioverativ is now an independent public company whose shares of common stock are trading under the symbol "BIVV" on the Nasdaq Global Select Market.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The financial results of Bioverativ are reflected in our consolidated results of operations and financial position included in these audited consolidated financial statements for the periods presented in this Form 10-K. The financial results of Bioverativ will be excluded from our consolidated results of operations and financial position commencing February 1, 2017. For additional information regarding the separation of Bioverativ, please read Note 26, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Subsequent Events</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the economics, we record net income (loss) attributable to noncontrolling interests in our consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In determining whether we are the primary beneficiary of an entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The preparation of our consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an on-going basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates under different assumptions or conditions.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognize revenue when all of the following criteria are met: persuasive evidence of an arrangement exists; delivery has occurred or services have been rendered; our price to the customer is fixed or determinable; and collectability is reasonably assured.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Product Revenues</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from product sales are recognized when title and risk of loss have passed to the customer, which is typically upon delivery. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Reserves for Discounts and Allowances</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from product sales are recorded net of reserves established for applicable discounts and allowances, including those associated with the implementation of pricing actions in certain of the international markets in which we operate. These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer). Our estimates take into consideration our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Actual amounts may ultimately differ from our estimates. If actual results vary, we adjust these estimates, which could have an effect on earnings in the period of adjustment. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenue reserves are categorized as follows: discounts, contractual adjustments and returns.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Discounts include trade term discounts and wholesaler incentives. Trade term discounts and wholesaler incentives primarily relate to estimated obligations for credits to be granted to wholesalers for remitting payment on their purchases within established incentive periods and credits to be granted to wholesalers for compliance with various contractually-defined inventory management practices, respectively. We determine these reserves based on our historical experience, including the timing of customer payments.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contractual adjustments primarily relate to Medicaid and managed care rebates, co-payment (copay) assistance, Veterans Administration (VA) and Public Health Service (PHS) discounts, specialty pharmacy program fees and other governmental rebates or applicable allowances.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Medicaid rebates relate to our estimated obligations to states under established reimbursement arrangements. Rebate accruals are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a liability which is included in other current liabilities. Our liability for Medicaid rebates consists of estimates for claims that a state will make for the current quarter, claims for prior quarters that have been estimated for which an invoice has not been received, invoices received for claims from the prior quarters that have not been paid, and an estimate of potential claims that will be made for inventory that exists in the distribution channel at period end.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Governmental rebates or chargebacks, including VA and PHS discounts, represent our estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices we charge to wholesalers which provide those products. The wholesaler charges us for the difference between what the wholesaler pays for the products and the ultimate selling price to the qualified healthcare providers. Rebate and chargeback reserves are established in the same period as the related revenue is recognized, resulting in a reduction in product revenue and accounts receivable. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider from the wholesaler, and we generally issue credits for such amounts within a few weeks of the wholesaler notifying us about the resale. Our reserves for VA, PHS and chargebacks consist of amounts that we expect to issue for inventory that exists at the wholesalers that we expect will be sold to qualified healthcare providers and chargebacks that wholesalers have claimed for which we have not issued a credit.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Managed care rebates represent our estimated obligations to third parties, primarily pharmacy benefit managers. Rebate accruals are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a liability which is included in accrued expenses and other current liabilities. These rebates result from performance-based goals, formulary position and price increase limit allowances (price protection). The calculation of the accrual for these rebates is based on an estimate of the customer&#8217;s buying patterns and the resulting applicable contractual rebate rate(s) to be earned over a contractual period.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Copay assistance represents financial assistance to qualified patients, assisting them with prescription drug co-payments required by insurance. The calculation of the accrual for copay is based on an estimate of claims and the cost per claim that we expect to receive associated with inventory that exists in the distribution channel at period end.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other governmental rebates or applicable allowances primarily relate to mandatory rebates and discounts in international markets where government-sponsored healthcare systems are the primary payors for healthcare.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product returns are established for returns expected to be made by wholesalers and are recorded in the period the related revenue is recognized, resulting in a reduction to product sales. In accordance with contractual terms, wholesalers are permitted to return product for reasons such as damaged or expired product. The majority of wholesaler returns are due to product expiration. Expired product return reserves are estimated through a comparison of historical return data to their related sales on a production lot basis. Historical rates of return are determined for each product and are adjusted for known or expected changes in the marketplace specific to each product.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition to the discounts, rebates and product returns described above and classified as a reduction of revenue, we also maintain certain customer service contracts with distributors and other customers in the distribution channel that provide us with inventory management, data and distribution services, which are generally reflected as a reduction of revenue. To the extent we can demonstrate a separable benefit and fair value for these services, we classify these payments in selling, general and administrative expenses.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Revenues from Anti-CD20 Therapeutic Programs</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs consist of:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(i)&#160;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our share of pre-tax profits and losses in the U.S. for RITUXAN and GAZYVA; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(ii)&#160; </font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">reimbursement of our selling and development expenses in the U.S. for RITUXAN; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(iii)&#160;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">revenues on sales in the rest of world for RITUXAN, which consist of our share of pre-tax co-promotion profits on RITUXAN in Canada and royalty revenue on RITUXAN sales outside the U.S. and Canada by the Roche Group and its sublicensees. </font></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pre-tax co-promotion profits on RITUXAN and GAZYVA are calculated and paid to us by Genentech in the U.S. Pre-tax co-promotion profits on RITUXAN are calculated and paid to us by the Roche Group in Canada. Pre-tax co-promotion profits consist of U.S. and Canadian net sales to third-party customers less applicable costs to manufacture, third-party royalty expenses, distribution, selling and marketing expenses, and joint development expenses incurred by Genentech, the Roche Group and us. We record our share of the pre-tax co-promotion profits on RITUXAN in Canada and royalty revenues on RITUXAN sales outside the U.S. on a cash basis as we do not have the ability to estimate these profits or royalty revenue in the period incurred. Our share of the pre-tax profits on RITUXAN and GAZYVA in the U.S. includes estimates made by Genentech and those estimates are subject to change. Actual results may differ from our estimates. For additional information related to our collaboration with Genentech, please read Note&#160;19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Royalty Revenues</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We receive royalty revenues on sales by our licensees of other products covered under patents that we own. We do not have future performance obligations under these license arrangements. We record these revenues based on estimates of the sales that occurred during the relevant period as a component of other revenues. The relevant period estimates of sales are based on interim data provided by licensees and analysis of historical royalties that have been paid to us, adjusted for any changes in facts and circumstances, as appropriate. Differences between actual and estimated royalty revenues are adjusted for in the period in which they become known, typically the following quarter. Historically, adjustments have not been material when compared to actual amounts paid by licensees. If we are unable to reasonably estimate royalty revenue or do not have access to the information, then we record royalty revenues on a cash basis. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Multiple-Element Revenue Arrangements</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We may enter into transactions that involve the sale of products and related services under multiple element arrangements.&#160;In accounting for these transactions, we assess the elements of the contract and whether each element has standalone value and allocate revenue to the various elements based on their estimated selling price as a component of total revenues.&#160;The selling price of a revenue generating element can be based on current selling prices offered by us or another party for current products or management&#8217;s best estimate of a selling price. Revenue allocated to an individual element is recognized when all other revenue recognition criteria are met for that element.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborativeandOtherRelationshipsPolicyTextBlock', window );">Collaborative and Other Relationships</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our development and commercialization arrangements with Sobi and AbbVie Inc. (AbbVie) represent collaborative arrangements as each party is an active participant and exposed to significant risks and rewards of the arrangements. Where we are the principal on sales transactions with third parties, we recognize revenue, cost of sales and operating expenses on a gross basis in their respective lines in our consolidated statements of income. Where we are not the principal on sales transactions with third parties, we record our share of the revenues, cost of sales and operating expenses on a net basis in collaborative and other relationships included in other revenue in our consolidated statements of income. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information related to our collaborations with Sobi and AbbVie, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value Measurements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have certain financial assets and liabilities recorded at fair value which have been classified as Level&#160;1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Level&#160;1</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#8212; Fair values are determined utilizing quoted prices (unadjusted) in active markets for identical assets or liabilities that we have the ability to access;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Level&#160;2</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#8212; Fair values are determined by utilizing quoted prices for identical or similar assets and liabilities in active markets or other market observable inputs such as interest rates, yield curves and foreign currency spot rates;&#160;and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Level&#160;3</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#8212; Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The majority of our financial assets have been classified as Level&#160;2. Our financial assets (which include our cash equivalents, derivative contracts, marketable debt securities and plan assets for deferred compensation) have been initially valued at the transaction price and subsequently valued, at the end of each reporting period, utilizing third-party pricing services or other market observable data. The pricing services utilize industry standard valuation models, including both income and market-based approaches and observable market inputs to determine value. These observable market inputs include reportable trades, benchmark yields, credit spreads, broker/dealer quotes, bids, offers, current spot rates and other industry and economic events.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We validate the prices provided by our third-party pricing services by reviewing their pricing methods and matrices, obtaining market values from other pricing sources and analyzing pricing data in certain instances. After completing our validation procedures, we did not adjust or override any fair value measurements provided by our pricing services as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Other Assets and Liabilities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The carrying amounts reflected in the consolidated balance sheets for current accounts receivable, due from anti-CD20 therapeutic programs, other current assets, accounts payable and accrued expenses and other, approximate fair value due to their short-term maturities.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We consider only those investments which are highly liquid, readily convertible to cash and that mature within three months from date of purchase to be cash equivalents. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, cash equivalents were comprised of money market funds and commercial paper, overnight reverse repurchase agreements and other debt securities with maturities less than 90 days from the date of purchase.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Accounts Receivable</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The majority of our accounts receivable arise from product sales and primarily represent amounts due from our wholesale distributors, public hospitals and other government entities. We monitor the financial performance and creditworthiness of our customers so that we can properly assess and respond to changes in their credit profile. We provide reserves against trade receivables for estimated losses that may result from a customer&#8217;s inability to pay. Amounts determined to be uncollectible are charged or written-off against the reserve. To date, our historical reserves and write-offs of accounts receivable have not been significant.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In countries where we have experienced a pattern of payments extending beyond our contractual payment term and we expect to collect receivables greater than one year from the time of sale, we have discounted our receivables and reduced related revenues over the period of time that we estimate those amounts will be paid using the country&#8217;s market-based borrowing rate for such period. The related receivables are classified at the time of sale as non-current assets. We accrete interest income on these receivables, which is recognized as a component of other income (expense), net in our consolidated statements of income.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Financial instruments that potentially subject us to concentrations of credit risk include cash and cash equivalents, investments, derivatives and accounts receivable. We attempt to minimize the risks related to cash and cash equivalents and investments by investing in a broad and diverse range of financial instruments as previously defined by us. We have established guidelines related to credit ratings and maturities intended to safeguard principal balances and maintain liquidity. Our investment portfolio is maintained in accordance with our investment policy, which defines allowable investments, specifies credit quality standards and limits the credit exposure of any single issuer. We minimize credit risk resulting from derivative instruments by choosing only highly rated financial institutions as counterparties.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Concentrations of credit risk with respect to receivables, which are typically unsecured, are somewhat mitigated due to the wide variety of customers and markets using our products, as well as their dispersion across many different geographic areas. The majority of our accounts receivable arise from product sales in the U.S. and Europe and have standard payment terms which generally require payment within </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30 to 90 days</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We monitor the financial performance and creditworthiness of our customers so that we can properly assess and respond to changes in their credit profile. We continue to monitor these conditions and assess their possible impact on our business. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, two wholesale distributors individually accounted for approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.2%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">19.2%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35.4%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">23.1%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, of accounts receivable, net, respectively. </font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Marketable Securities and Other Investments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Marketable Debt Securities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Available-for-sale debt securities are recorded at fair market value and unrealized gains and losses are included in accumulated other comprehensive income (loss) in equity, net of related tax effects, unless the security has experienced a credit loss, we have determined that we have the intent to sell the security or we have determined that it is more likely than not that we will have to sell the security before its expected recovery. Realized gains and losses are reported in other income (expense), net, on a specific identification basis.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Marketable Equity Securities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our marketable equity securities represent investments in publicly traded equity securities and are included in investments and other assets in our consolidated balance sheet. When assessing whether a decline in the fair value of a marketable equity security is other-than-temporary, we consider the fair market value of the security, the duration of the security&#8217;s decline and prospects for the underlying business, including favorable or adverse clinical trial results, new product initiatives and new collaborative agreements with the companies in which we have invested.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Non-Marketable Equity Securities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also invest in equity securities of companies whose securities are not publicly traded and where fair value is not readily available. These investments are recorded using either the cost method or the equity method of accounting, depending on our ownership percentage and other factors that suggest we have significant influence. We monitor these investments to evaluate whether any decline in their value has occurred that would be other-than-temporary, based on the implied value of recent company financings, public market prices of comparable companies and general market conditions and are included in investments and other assets in our consolidated balance sheet.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Evaluating Investments for Other-than-Temporary Impairments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We conduct periodic reviews to identify and evaluate each investment that has an unrealized loss, in accordance with the meaning of other-than-temporary impairment and its application to certain investments. An unrealized loss exists when the current fair value of an individual security is less than its amortized cost basis. Unrealized losses on available-for-sale securities that are determined to be temporary, and not related to credit loss, are recorded, net of tax, in accumulated other comprehensive income.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For available-for-sale debt securities with unrealized losses, management performs an analysis to assess whether we intend to sell or whether we would more likely than not be required to sell the security before the expected recovery of the amortized cost basis. Where we intend to sell a security, or may be required to do so, the security&#8217;s decline in fair value is deemed to be other-than-temporary and the full amount of the unrealized loss is reflected in earnings as an impairment loss.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Regardless of our intent to sell a security, we perform additional analysis on all securities with unrealized losses to evaluate losses associated with the creditworthiness of the security. Credit losses are identified where we do not expect to receive cash flows sufficient to recover the amortized cost basis of a security.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For equity securities, when assessing whether a decline in value is other-than-temporary, we consider the fair market value of the security, the duration of the security&#8217;s decline, and the financial condition of the issuer. We then consider our intent and ability to hold the equity security for a period of time sufficient to recover our carrying value. Where we have determined that we lack the intent and ability to hold an equity security to its expected recovery, the security&#8217;s decline in fair value is deemed to be other-than-temporary and is reflected in earnings as an impairment loss.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsPolicy', window );">Equity Method of Accounting</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In circumstances where we have the ability to exercise significant influence over the operating and financial policies of a company in which we have an investment, we utilize the equity method of accounting for recording investment activity.&#160;In assessing whether we exercise significant influence, we consider the nature and magnitude of our investment, the voting and protective rights we hold, any participation in the governance of the other company, and other relevant factors such as the presence of a collaboration or other business relationship.&#160;Under the equity method of accounting, we record in our results of operations our share of income or loss of the other company. If our share of losses exceeds the carrying value of our investment, we will suspend recognizing additional losses and will continue to do so unless we commit to providing additional funding. </font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventories are stated at the lower of cost or market with cost based on the first-in, first-out (FIFO) method. We classify our inventory costs as long-term when we expect to utilize the inventory beyond our normal operating cycle and include these costs in investments and other assets in our consolidated balance sheets. Inventory that can be used in either the production of clinical or commercial products is expensed as research and development costs when identified for use in a clinical manufacturing campaign.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Capitalization of Inventory Costs</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We capitalize inventory costs associated with our products prior to regulatory approval, when, based on management&#8217;s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized. We consider numerous attributes in evaluating whether the costs to manufacture a particular product should be capitalized as an asset. We assess the regulatory approval process and where the particular product stands in relation to that approval process, including any known safety or efficacy concerns, potential labeling restrictions and other impediments to approval. We evaluate our anticipated research and development initiatives and constraints relating to the product and the indication in which it will be used. We consider our manufacturing environment including our supply chain in determining logistical constraints that could hamper approval or commercialization. We consider the shelf life of the product in relation to the expected timeline for approval and we consider patent related or contract issues that may prevent or delay commercialization. We also base our judgment on the viability of commercialization, trends in the marketplace and market acceptance criteria. Finally, we consider the reimbursement strategies that may prevail with respect to the product and assess the economic benefit that we are likely to realize. We expense previously capitalized costs related to pre-approval inventory upon a change in such judgment, due to, among other potential factors, a denial or significant delay of approval by necessary regulatory bodies.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Obsolescence and Unmarketable Inventory</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We periodically review our inventories for excess or obsolescence and write-down obsolete or otherwise unmarketable inventory to its estimated net realizable value. If the actual net realizable value is less than that estimated by us, or if it is determined that inventory utilization will further diminish based on estimates of demand, additional inventory write-downs may be required. Additionally, our products are subject to strict quality control and monitoring which we perform throughout the manufacturing process. In the event that certain batches or units of product no longer meet quality specifications, we will record a charge to cost of sales to write-down any unmarketable inventory to its estimated net realizable value. In all cases, product inventory is carried at the lower of cost or its estimated net realizable value. Amounts written-down due to unmarketable inventory are charged to cost of sales.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Property, plant and equipment are carried at cost, subject to review for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. The cost of normal, recurring, or periodic repairs and maintenance activities related to property, plant and equipment are expensed as incurred. The cost for planned major maintenance activities, including the related acquisition or construction of assets, is capitalized if the repair will result in future economic benefits.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest costs incurred during the construction of major capital projects are capitalized until the underlying asset is ready for its intended use, at which point the interest costs are amortized as depreciation expense over the life of the underlying asset. We also capitalize certain direct and incremental costs associated with the validation effort required for licensing by regulatory agencies of new manufacturing equipment for the production of a commercially approved drug. These costs primarily include direct labor and material and are incurred in preparing the equipment for its intended use. The validation costs are either amortized over the life of the related equipment or expensed as cost of sales when the product produced in the validation process is sold.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we capitalize certain internal use computer software development costs. If the software is an integral part of production assets, these costs are included in machinery and equipment and are amortized on a straight-line basis over the estimated useful lives of the related software, which generally range from </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three to five years</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We generally depreciate or amortize the cost of our property, plant and equipment using the straight-line method over the estimated useful lives of the respective assets, which are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="2" rowspan="1"></td></tr><tr><td style="width:50%;" rowspan="1" colspan="1"></td><td style="width:50%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Asset Category</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Useful Lives</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Land</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Not depreciated</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Buildings</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">15 to 40&#160;years</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Leasehold Improvements</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Lesser of the useful life or the term of the respective lease</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Furniture and Fixtures</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5 to 7&#160;years</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Machinery and Equipment</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5 to 20&#160;years</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Computer&#160;Software&#160;and&#160;Hardware</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3 to 5&#160;years</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">When we dispose of property, plant and equipment, we remove the associated cost and accumulated depreciation from the related accounts on our consolidated balance sheet and include any resulting gain or loss in our consolidated statement of income.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy', window );">Intangible Assets</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our intangible assets consist of acquired and in-licensed rights and patents, developed technology, out-licensed patents, in-process research and development acquired after January&#160;1, 2009, trademarks and trade names. Our intangible assets are recorded at fair value at the time of their acquisition and are stated in our consolidated balance sheets net of accumulated amortization and impairments, if applicable.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets related to acquired and in-licensed rights and patents, developed technology and out-licensed patents are amortized over their estimated useful lives using the economic consumption method if anticipated future revenues can be reasonably estimated. The straight-line method is used when revenues cannot be reasonably estimated. Amortization is recorded as amortization of acquired intangible assets in our consolidated statements of income.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired and in-licensed rights and patents primarily relate to our acquisition of all remaining rights to TYSABRI from Elan Pharma International, Ltd (Elan), an affiliate of Elan Corporation, plc. Developed technology primarily relates to our AVONEX product, which was recorded in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003. We amortize the intangible assets related to TYSABRI and AVONEX using the economic consumption method based on revenue generated from the products underlying the related intangible assets. An analysis of the anticipated lifetime revenues of TYSABRI and AVONEX is performed annually during our long range planning cycle, which is generally updated in the third quarter of each year, and whenever events or changes in circumstances would significantly affect the anticipated lifetime revenues of TYSABRI or AVONEX.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets related to trademarks, trade names and in-process research and development prior to commercialization are not amortized because they have indefinite lives; however, they are subject to review for impairment. We review our intangible assets with indefinite lives for impairment annually, as of October&#160;31, and whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InProcessResearchAndDevelopmentPolicy', window );">Acquired In-process Research and Development (IPR&amp;D)</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired IPR&amp;D represents the fair value assigned to research and development assets that have not reached technological feasibility. The value assigned to acquired IPR&amp;D is determined by estimating the costs to develop the acquired technology into commercially viable products, estimating the resulting revenue from the projects and discounting the net cash flows to present value. The revenue and costs projections used to value acquired IPR&amp;D are, as applicable, reduced based on the probability of success of developing a new drug. Additionally, the projections consider the relevant market sizes and growth factors, expected trends in technology and the nature and expected timing of new product introductions by us and our competitors. The rates utilized to discount the net cash flows to their present value are commensurate with the stage of development of the projects and uncertainties in the economic estimates used in the projections. Upon the acquisition of IPR&amp;D, we complete an assessment of whether our acquisition constitutes the purchase of a single asset or a group of assets. We consider multiple factors in this assessment, including the nature of the technology acquired, the presence or absence of separate cash flows, the development process and stage of completion, quantitative significance and our rationale for entering into the transaction.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">If we acquire a business as defined under applicable accounting standards, then the acquired IPR&amp;D is capitalized as an intangible asset. If we acquire an asset or group of assets that do not meet the definition of a business, then the acquired IPR&amp;D is expensed on its acquisition date. Future costs to develop these assets are recorded to research and development expense as they are incurred. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">When performing our impairment assessment, we calculate the fair value using the same methodology as described above. If the carrying value of our acquired IPR&amp;D exceeds its fair value, then the intangible asset is written-down to its fair value. Certain IPR&amp;D programs have a fair value that is not significantly in excess of carrying value, including our program for the treatment of trigeminal neuralgia (TGN). Such programs could become impaired if assumptions used in determining the fair value change.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill represents the difference between the purchase price and the fair value of the identifiable tangible and intangible net assets when accounted for using the purchase method of accounting. Goodwill is not amortized, but reviewed for impairment. Goodwill is reviewed annually, as of October&#160;31, and whenever events or changes in circumstances indicate that the carrying value of the goodwill might not be recoverable.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We compare the fair value of our reporting unit to its carrying value. If the carrying value of the net assets assigned to the reporting unit exceeds the fair value of our reporting unit, then we would need to determine the implied fair value of our reporting unit&#8217;s goodwill. If the carrying value of our reporting unit&#8217;s goodwill exceeds its implied fair value, then we would record an impairment loss equal to the difference. As described in Note&#160;24, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Segment Information</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements, we operate in one operating segment which we consider our only reporting unit.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-lived assets to be held and used, including property, plant and equipment and definite-lived intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets or asset group may not be recoverable.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written-down to their fair values. Long-lived assets to be disposed of are carried at fair value less costs to sell.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Contingent Consideration</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The consideration for our acquisitions often includes future payments that are contingent upon the occurrence of a particular event. For acquisitions completed before January 1, 2009, we record contingent consideration resulting from a business combination when the contingency is resolved. For acquisitions that qualify as business combinations completed after January&#160;1, 2009, we record an obligation for such contingent payments at fair value on the acquisition date. We estimate the fair value of contingent consideration obligations through valuation models that incorporate probability-adjusted assumptions related to the achievement of the milestones and thus likelihood of making related payments. We revalue these contingent consideration obligations each reporting period. Changes in the fair value of our contingent consideration obligations are recognized in our consolidated statements of income. Changes in the fair value of the contingent consideration obligations can result from changes to one or multiple inputs, including adjustments to the discount rates, changes in the amount or timing of expected expenditures associated with product development, changes in the amount or timing of cash flows and reserves associated with products upon commercialization, changes in the assumed achievement or timing of any cumulative sales-based and development milestones, changes in the probability of certain clinical events and changes in the assumed probability associated with regulatory approval. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Discount rates in our valuation models represent a measure of the credit risk associated with settling the liability. The period over which we discount our contingent obligations is based on the current development stage of the product candidates, our specific development plan for that product candidate adjusted for the probability of completing the development step, and when the contingent payments would be triggered. In estimating the probability of success, we utilize data regarding similar milestone events from several sources, including industry studies and our own experience. These fair value measurements are based on significant inputs not observable in the market. Significant judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, changes in assumptions could have a material impact on the amount of contingent consideration expense we record in any given period.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivative Instruments and Hedging Activities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognize all derivative instruments as either assets or liabilities at fair value in our consolidated balance sheets. Changes in the fair value of derivatives are recorded each period in current earnings or accumulated other comprehensive income (loss), depending on whether a derivative is designated as part of a hedge transaction and, if so, the type of hedge transaction. We classify the cash flows from these instruments in the same category as the cash flows from the hedged items. We do not hold or issue derivative instruments for trading or speculative purposes.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We assess, both at inception and on an ongoing basis, whether the derivatives that are used in hedging transactions are highly effective in offsetting the changes in cash flows or fair values of the hedged items. We also assess hedge ineffectiveness on a quarterly basis and record the gain or loss related to the ineffective portion to current earnings. If we determine that a forecasted transaction is no longer probable of occurring, we discontinue hedge accounting for the affected portion of the hedge instrument, and any related unrealized gain or loss on the contract is recognized in current earnings.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Translation of Foreign Currencies</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The functional currency for most of our foreign subsidiaries is their local currency. For our non-U.S. subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the average foreign exchange rates for the period. Adjustments resulting from the translation of the financial statements of our foreign operations into U.S.&#160;dollars are excluded from the determination of net income and are recorded in accumulated other comprehensive income, a separate component of equity. For subsidiaries where the functional currency of the assets and liabilities differ from the local currency, non-monetary assets and liabilities are translated at the rate of exchange in effect on the date assets were acquired while monetary assets and liabilities are translated at current rates of exchange as of the balance sheet date. Income and expense items are translated at the average foreign currency rates for the period. Translation adjustments of these subsidiaries are included in other income (expense), net, in our consolidated statements of income.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RoyaltyCostofSalesPolicyTextBlock', window );">Royalty Cost of Sales</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We make royalty payments to a number of third parties under license or purchase agreements associated with our acquisition of intellectual property. These royalty payments are typically calculated as a percentage (royalty rate) of the sales of our products in a particular year.&#160;That royalty rate may remain constant, increase or decrease within each year based on the total amount of sales during the annual period. Each quarterly period, we estimate our total royalty obligation for the full year and recognize the proportional amount as cost of sales based on actual quarterly sales as a percentage of full year estimated sales. For example, if the level of net sales in any calendar year increases the royalty rate within the year, we will record our cost of sales at an even rate over the year, based on the estimated blended royalty rate.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Accounting for Share-Based Compensation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our share-based compensation programs grant awards that have included stock options, restricted stock units which vest based on stock performance known as market stock units (MSUs), performance-vested restricted stock units which settle in cash (CSPUs), time-vested restricted stock units (RSUs), performance-vested restricted stock units which can be settled in cash or shares of our common stock (PUs) at the sole discretion of the Compensation and Management Development Committee of the Board of Directors and shares issued under our employee stock purchase plan (ESPP). We charge the estimated fair value of awards against income over the requisite service period, which is generally the vesting period. Where awards are made with non-substantive vesting periods (for instance, where a portion of the award vests upon retirement eligibility), we estimate and recognize expense based on the period from the grant date to the date on which the employee is retirement eligible.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair values of our stock option grants are estimated as of the date of grant using a Black-Scholes option valuation model. The estimated fair values of the stock options are then expensed over the options&#8217; vesting periods.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair values of our MSUs are estimated using a lattice model with a Monte Carlo simulation. We apply an accelerated attribution method to recognize share-based compensation expense over the applicable service period, net of estimated forfeitures, when accounting for our MSUs. The probability of actual shares expected to be earned is considered in the grant date valuation, therefore the expense is not adjusted to reflect the actual units earned.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair values of our RSUs are based on the market value of our stock on the date of grant. Compensation expense for RSUs is recognized straight-line over the applicable service period.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We apply an accelerated attribution method to recognize share-based compensation expense when accounting for our CSPUs and PUs and the fair value of the liability is remeasured at the end of each reporting period through expected settlement. Compensation expense associated with CSPUs and PUs are based upon the stock price and the number of units expected to be earned after assessing the probability that certain performance criteria will be met and the associated targeted payout level that is forecasted will be achieved, net of estimated forfeitures. Cumulative adjustments are recorded each quarter to reflect changes in the stock price and estimated outcome of the performance-related conditions until the date results are determined and settled.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The purchase price of common stock under our ESPP is equal to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">85%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the lesser of (i)&#160;the fair market value per share of the common stock on the first business day of an offering period and (ii)&#160;the fair market value per share of the common stock on the purchase date. The fair value of the discounted purchases made under our ESPP is calculated using the Black-Scholes model. The fair value of the look-back provision plus the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> discount is recognized as compensation expense over the 90 day purchase period. </font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock', window );">Research and Development Expenses</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development expenses consist of upfront fees and milestones paid to collaborators and expenses incurred in performing research and development activities, which include compensation and benefits, facilities and overhead expenses, clinical trial expenses and fees paid to contract research organizations (CROs), clinical supply and manufacturing expenses, write-offs of inventory that was previously capitalized in anticipation of product launch and determined to no longer be realizable, and other outside expenses. Research and development expenses are expensed as incurred. Payments we make for research and development services prior to the services being rendered are recorded as prepaid assets on our consolidated balance sheets and are expensed as the services are provided. We also accrue the costs of ongoing clinical trials associated with programs that have been terminated or discontinued for which there is no future economic benefit at the time the decision is made to terminate or discontinue the program.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">From time to time, we enter into development agreements in which we share expenses with a collaborative partner. We record payments received from our collaborative partners for their share of the development costs as a reduction of research and development expense, except as discussed in Note&#160;19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements. Because an initial indication has been approved for both RITUXAN and GAZYVA, expenses incurred by Genentech in the ongoing development of RITUXAN and GAZYVA are not recorded as research and development expense, but rather reduce our share of profits recorded as a component of revenues from anti-CD20 therapeutic programs.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For collaborations with commercialized products, if we are the principal, we record revenue and the corresponding operating costs in their respective line items in our consolidated statements of income. If we are not the principal, we record operating costs as a reduction of revenue.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">Selling, General and Administrative Expenses</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative expenses are primarily comprised of compensation and benefits associated with sales and marketing, finance, human resources, legal, information technology and other administrative personnel, outside marketing, advertising and legal expenses and other general and administrative costs.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Advertising costs are expensed as incurred. For the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, advertising costs totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$106.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$108.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$92.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The provision for income taxes includes federal, state, local and foreign taxes. Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences of temporary differences between the financial statement carrying amounts and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which the temporary differences are expected to be recovered or settled. We evaluate the realizability of our deferred tax assets and establish a valuation allowance when it is more likely than not that all or a portion of deferred tax assets will not be realized.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">All tax effects associated with intercompany transfers of assets in our consolidated group, both current and deferred, are recorded as a prepaid tax or deferred charge and recognized through the consolidated statement of income when the asset transferred is sold to a third party or otherwise recovered through amortization of the asset's remaining economic life.&#160;If the asset transferred becomes impaired, for example through the discontinuation of a research program, we will expense any remaining deferred charge or prepaid tax.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We account for uncertain tax positions using a &#8220;more-likely-than-not&#8221; threshold for recognizing and resolving uncertain tax positions. We evaluate uncertain tax positions on a quarterly basis and consider various factors including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, information obtained during in process audit activities and changes in facts or circumstances related to a tax position. We also accrue for potential interest and penalties related to unrecognized tax benefits in income tax expense.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Contingencies</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are currently involved in various claims and legal proceedings. Loss contingency provisions are recorded if the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount can be reasonably estimated or a range of loss can be determined. These accruals represent management&#8217;s best estimate of probable loss. Disclosure also is provided when it is reasonably possible that a loss will be incurred or when it is reasonably possible that the amount of a loss will exceed the recorded provision. On a quarterly basis, we review the status of each significant matter and assess its potential financial exposure.&#160;Significant judgment is required in both the determination of probability and the determination as to whether an exposure is reasonably estimable. Because of uncertainties related to these matters, accruals are based only on the best information available at the time. As additional information becomes available, we reassess the potential liability related to pending claims and litigation and may change our estimates. These changes in the estimates of the potential liabilities could have a material impact on our consolidated results of operations and financial position.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings per Share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share is computed by dividing undistributed net income attributable to Biogen Inc. by the weighted-average number of common shares outstanding during the period. </font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed, we do not believe that the impact of recently issued standards that are not yet effective will have a material impact on our financial position or results of operations upon adoption.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2014 the FASB issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers (Topic 606), which supersedes all existing revenue recognition requirements, including most industry-specific guidance. The new standard requires a company to recognize revenue when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. The FASB has subsequently issued the following amendments to ASU 2014-09 which have the same effective date and transition date of January 1, 2018:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2015 the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date, which delayed the effective date of the new standard from January 1, 2017 to January 1, 2018. The FASB also agreed to allow entities to choose to adopt the standard as of the original effective date. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2016 the FASB issued ASU No. 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations, which clarifies the implementation guidance on principal versus agent considerations. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In April 2016 the FASB issued ASU No. 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing, which clarifies certain aspects of identifying performance obligations and licensing implementation guidance. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2016 the FASB issued ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients related to disclosures of remaining performance obligations, as well as other amendments to guidance on collectability, non-cash consideration and the presentation of sales and other similar taxes collected from customers. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2016 the FASB issued ASU No. 2016-20, Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers, which amends certain narrow aspects of the guidance issued in ASU 2014-09 including guidance related to the disclosure of remaining performance obligations and prior-period performance obligations, as well as other amendments to the guidance on loan guarantee fees, contract costs, refund liabilities, advertising costs and the clarification of certain examples. </font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are currently evaluating the method of adoption and the potential impact that Topic 606 may have on our financial position and results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In April 2015 the FASB issued ASU No. 2015-05, Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Customer's Accounting for Fees Paid in a Cloud Computing Arrangement. Under this standard, if a cloud computing arrangement includes a software license, the software license element of the arrangement should be accounted for consistent with the acquisition of other software licenses. If a cloud computing arrangement does not include a software license, the arrangement should be accounted for as a service contract. We adopted this standard as of January 1, 2016, which did not have an impact on our financial position or results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2015 the FASB issued ASU No. 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory. The new standard applies only to inventory for which cost is determined by methods other than last-in, first-out and the retail inventory method, which includes inventory that is measured using first-in, first-out or average cost. Inventory within the scope of this standard is required to be measured at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. We adopted this standard as of January 1, 2016, which did not have an impact on our financial position or results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In September 2015 the FASB issued ASU No. 2015-16, Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments. The new standard requires that an acquirer recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined and sets forth new disclosure requirements related to the adjustments. We adopted this standard as of January 1, 2016, which did not have an impact on our financial position or results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2016 the FASB issued ASU No. 2016-01, Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. This new standard amends certain aspects of accounting and disclosure requirements of financial instruments, including the requirement that equity investments with readily determinable fair values be measured at fair value with changes in fair value recognized in our results of operations. This new standard does not apply to investments accounted for under the equity method of accounting or those that result in consolidation of the investee. Equity investments that do not have readily determinable fair values may be measured at fair value or at cost minus impairment adjusted for changes in observable prices. A financial liability that is measured at fair value in accordance with the fair value option is required to be presented separately in other comprehensive income for the portion of the total change in the fair value resulting from change in the instrument-specific credit risk. In addition, a valuation allowance should be evaluated on deferred tax assets related to available-for-sale debt securities in combination with other deferred tax assets. This new standard will be effective for us on January 1, 2018. The adoption of this standard is not expected to have a material impact on our financial position or results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2016 the FASB issued ASU No. 2016-02, Leases (Topic 842). This new standard requires that all lessees recognize the assets and liabilities that arise from leases on the balance sheet and disclose qualitative and quantitative information about its leasing arrangements. This new standard will be effective for us on January 1, 2019. The adoption of this standard is not expected to have a material impact on our net financial position, but will impact the amount of our assets and liabilities. We are currently evaluating the potential impact that this standard may have on our results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2016 the FASB issued ASU No. 2016-06, Derivatives and Hedging (Topic 815): Contingent Put and Call Options in Debt Instruments. This new standard simplifies the embedded derivative analysis for debt instruments containing contingent call or put options by removing the requirement to assess whether a contingent event is related to interest rates or credit risks. This new standard will be effective for us on January 1, 2017. The adoption of this standard is not expected to have an impact on our financial position or results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2016 the FASB issued ASU No. 2016-07, Investments - Equity Method and Joint Ventures (Topic 323): Simplifying the Transition to the Equity Method of Accounting. This new standard eliminates the requirement that when an investment qualifies for use of the equity method as a result of an increase in the level of ownership interest or degree of influence, an adjustment must be made to the investment, results of operations and retained earnings retroactively on a step-by-step basis as if the equity method had been in effect during all previous periods that the investment has been held. This new standard will be effective for us on January 1, 2017. The adoption of this standard is not expected to have a material impact on our financial position or results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2016 the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. This new standard requires recognition of the income tax effects of vested or settled awards in the income statement and involves several other aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities and classification on the statement of cash flows. This new standard will be effective for us on January 1, 2017. The adoption of this standard is not expected to have a material impact on our financial position, results of operations or statements of cash flows upon adoption.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2016 the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. This new standard changes the impairment model for most financial assets and certain other instruments. Under the new standard, entities holding financial assets and net investment in leases that are not accounted for at fair value through net income to be presented at the net amount expected to be collected. An allowance for credit losses will be a valuation account that will be deducted from the amortized cost basis of the financial asset to present the net carrying value at the amount expected to be collected on the financial asset. This new standard will be effective for us on January 1, 2020. The adoption of this standard is not expected to have a material impact on our financial position or results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2016 the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. This new standard clarifies certain aspects of the statement of cash flows, including the classification of debt prepayment or debt extinguishment costs or other debt instruments with coupon interest rates that are insignificant in relation to the effective interest rate of the borrowing, contingent consideration payments made after a business combination, proceeds from the settlement of insurance claims, proceeds from the settlement of corporate-owned life insurance policies, distributions received from equity method investees and beneficial interests in securitization transactions. This new standard also clarifies that an entity should determine each separately identifiable source of use within the cash receipts and payments on the basis of the nature of the underlying cash flows. In situations in which cash receipts and payments have aspects of more than one class of cash flows and cannot be separated by source or use, the appropriate classification should depend on the activity that is likely to be the predominant source or use of cash flows for the item. This new standard will be effective for us on January 1, 2018. The adoption of this standard is not expected to have a material impact on our statements of cash flows upon adoption.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2016 the FASB issued ASU No. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfer of Assets Other Than Inventory. This new standard eliminates the exception for an intra-entity transfer of an asset other than inventory. Under the new standard, entities should recognize the income tax consequences on an intra-entity transfer of an asset other than inventory when the transfer occurs. This new standard will be effective for us on January 1, 2018 and will be applied on a modified retrospective basis through a cumulative-effect adjustment directly to retained earnings as of the beginning of the period of adoption. We are currently evaluating the potential impact this standard may have on our financial position and results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2017 the FASB issued ASU No. 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business. This new standard clarifies the definition of a business and provides a screen to determine when an integrated set of assets and activities is not a business. The screen requires that when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the set is not a business. This new standard will be effective for us on January 1, 2018. However, we have adopted this standard as of January 1, 2017, with prospective application to any business development transaction.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_BusinessOverviewPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes an overview of the company and its operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_BusinessOverviewPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CollaborativeandOtherRelationshipsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative and Other Relationships [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CollaborativeandOtherRelationshipsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RoyaltyCostofSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Cost of Sales [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RoyaltyCostofSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6052-115624<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6049-115624<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=68068213&amp;loc=d3e12565-110249<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18726-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 55<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6875567&amp;loc=d3e14489-108613<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68064133&amp;loc=d3e61082-112788<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28088331&amp;loc=SL29635902-196195<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13537-108611<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13531-108611<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68064133&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=d3e5614-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355100-122828<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355033-122828<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=d3e41620-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5579240-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5579245-113959<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=d3e41675-113959<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=d3e41638-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the equity method of accounting for investments in common stock or other interests including unconsolidated subsidiaries, corporate joint ventures, noncontrolling interests in real estate ventures, limited partnerships, and limited liability companies. The accounting policy may include information such as: (1) initially recording an investment in the stock of an investee at cost; (2) adjusting the carrying amount of the investment to recognize the investor's share of the earnings or losses of the investee after the date of acquisition; and (3) adjustments to reflect the investor's share of changes in the investee's capital (dividends). This disclosure may also include a detailed description of the policy for determining the amount of equity method losses recognized after an investment has been reduced to zero as a result of previous losses, reasons for not using the equity method when the investor company owns 20 percent or more of the voting stock of the investee's company (including identification of the significant investee), reasons for using the equity method when the ownership percentage is less than 20 percent, and discussion of recognition of equity method losses when an investor's total investment in an investee includes, in addition to an investment in common stock, other investments such as preferred stock and loans to the investee. An entity also may describe how such investments are assessed for impairment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66011266&amp;loc=d3e33918-111571<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13279-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=64802544&amp;loc=d3e202-110218<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InProcessResearchAndDevelopmentPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.15)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InProcessResearchAndDevelopmentPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32840-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32809-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e32247-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e32280-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66092785&amp;loc=d3e4492-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66092785&amp;loc=d3e4556-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investments in financial assets, including marketable securities (debt and equity securities with readily determinable fair values), investments accounted for under the equity method and cost method, securities borrowed and loaned, and repurchase and resale agreements. For marketable securities, the disclosure may include the entity's accounting treatment for transfers between investment categories and how the fair values for such securities are determined. Also, for all investments, an entity may describe its policy for assessing, recognizing and measuring impairment of the investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66011266&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27290-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2,12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.M)<br> -URI http://asc.fasb.org/extlink&amp;oid=65877573&amp;loc=d3e87990-122713<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 325<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6872867&amp;loc=d3e40691-111596<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for trade and other accounts receivable, and finance, loan and lease receivables, including those classified as held for investment and held for sale. This disclosure may include (1) the basis at which such receivables are carried in the entity's statements of financial position (2) how the level of the valuation allowance for receivables is determined (3) when impairments, charge-offs or recoveries are recognized for such receivables (4) the treatment of origination fees and costs, including the amortization method for net deferred fees or costs (5) the treatment of any premiums or discounts or unearned income (6) the entity's income recognition policies for such receivables, including those that are impaired, past due or placed on nonaccrual status and (7) the treatment of foreclosures or repossessions (8) the nature and amount of any guarantees to repurchase receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65890831&amp;loc=d3e10133-111534<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66008989&amp;loc=d3e4975-111524<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its research and development and computer software activities including the accounting treatment for costs incurred for (1) research and development activities, (2) development of computer software for internal use, (3) computer software to be sold, leased or otherwise marketed as a separate product or as part of a product or process and (4) in-process research and development acquired in a purchase business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Research and Development<br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 40<br> -Section 30<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6389767&amp;loc=d3e17916-109280<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.15)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 50<br> -Section 25<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=16397303&amp;loc=d3e19347-109286<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.B.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6061-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6143-108592<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6132-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6895537648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock', window );">Property, plant and equipment estimated useful lives</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="2" rowspan="1"></td></tr><tr><td style="width:50%;" rowspan="1" colspan="1"></td><td style="width:50%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Asset Category</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Useful Lives</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Land</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Not depreciated</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Buildings</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">15 to 40&#160;years</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Leasehold Improvements</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Lesser of the useful life or the term of the respective lease</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Furniture and Fixtures</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5 to 7&#160;years</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Machinery and Equipment</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5 to 20&#160;years</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Computer&#160;Software&#160;and&#160;Hardware</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3 to 5&#160;years</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of property plant and equipment useful lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6905846384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions Acquisitions (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock', window );">Purchase price</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash portion of consideration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">200.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">274.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total purchase price</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">474.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Estimated fair values of separately identifiable assets acquired and liabilities assumed</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In-process research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">424.6</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">128.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferred tax liability</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(84.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total purchase price</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">474.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table  does not include leveraged buyouts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=65885119&amp;loc=d3e1486-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65885119&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=73530397&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6807736832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Restructuring (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock', window );">Charges and spending related to our 2015 restructuring program</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Workforce</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Reduction</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Pipeline</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Programs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restructuring reserve as of December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">33.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">37.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(31.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(9.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(40.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments to previous estimates, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(5.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(2.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restructuring reserve as of December 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6825616560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Reserves (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ReservesForDiscountsAndAllowancesAbstract', window );"><strong>Reserves for Discounts and Allowances [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock', window );">Analysis of the change in reserves</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Discounts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Returns</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Beginning balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">56.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">548.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">57.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">662.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current provisions relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">592.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,044.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">30.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,668.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments relating to prior years</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(16.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(16.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/returns relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(522.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1,576.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(2,099.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/returns relating to sales in prior years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(53.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(536.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(19.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(609.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Ending balance</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">71.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">482.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">51.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">605.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Discounts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Returns</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">2015</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Beginning balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">47.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">387.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">483.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current provisions relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">459.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,732.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,229.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments relating to prior years</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(16.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(14.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(32.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/returns relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(405.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1,258.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1,666.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/returns relating to sales in prior years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(44.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(296.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(11.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(351.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Ending balance</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">56.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">548.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">57.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">662.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Discounts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Returns</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">2014</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Beginning balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">47.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">345.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">33.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">426.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current provisions relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">347.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,265.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">39.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,651.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments relating to prior years</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(28.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(16.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/returns relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(299.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(933.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1,237.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/returns relating to sales in prior years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(46.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(261.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(33.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(341.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Ending balance</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">47.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">387.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">483.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock', window );">Total reserves, included in consolidated balance sheets</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Reduction of accounts receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">166.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">144.6</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Component of accrued expenses and other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">438.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">518.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenue-related reserves</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">605.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">662.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Analysis of amount of and change in product revenue reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ReservesForDiscountsAndAllowancesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ReservesForDiscountsAndAllowancesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of total product revenue reserves included in consolidated balance sheets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6887953088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Components of inventory</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Raw materials</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">170.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">213.0</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Work in process</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">698.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">577.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Finished goods</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">170.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">143.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total inventory</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,039.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">933.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Balance Sheet Classification:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,001.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">893.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">37.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">40.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total inventory</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,039.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">933.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6909603584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IntangibleAssetsExcludingGoodwillTableTextBlock', window );">Intangible assets</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="26" rowspan="1"></td></tr><tr><td style="width:21%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">As of December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated Life</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Out-licensed patents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13-23 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">543.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(523.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">19.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">543.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(506.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Developed technology</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15-23 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,005.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(2,634.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">371.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,005.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2,552.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">452.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In-process research and development</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indefinite until commercialization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">648.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">648.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">730.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">730.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Trademarks and trade names</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indefinite</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">64.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">64.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired and in-licensed rights and patents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6-18 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,481.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(776.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,705.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,303.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(502.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,800.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total intangible assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7,742.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(3,934.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,808.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7,646.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3,561.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,085.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Estimated future amortization of intangible assets</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:81%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">As of December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">334.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">312.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">295.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">259.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">242.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Summary of roll forward of the changes in goodwill</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill, beginning of year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,663.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,760.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Increase to goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,026.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">908.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(21.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill, end of year</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,669.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,663.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_IntangibleAssetsExcludingGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intangible assets excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_IntangibleAssetsExcludingGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6826878384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Summary of assets and liabilities recorded at fair value</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br clear="none"/>December 31, <br clear="none"/>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quoted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Prices in</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Active</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level&#160;1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Observable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level&#160;2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level&#160;3)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,039.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,039.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable debt securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,663.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,663.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,172.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,172.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">561.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">561.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">24.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">24.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">61.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">61.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Plan assets for deferred compensation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">34.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">34.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7,558.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">24.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7,533.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">13.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">13.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration obligations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">467.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">467.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">481.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">13.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">467.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br clear="none"/>December 31, <br clear="none"/>2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quoted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Prices</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">in&#160;Active</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Observable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">909.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">909.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable debt securities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,510.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,510.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,875.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,875.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">494.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">494.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">27.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">27.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Plan assets for deferred compensation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">40.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">40.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,895.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,857.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">14.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">14.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration obligations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">506.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">506.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">520.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">14.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">506.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock', window );">Summary of fair and carrying value of debt instruments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes payable to Fumedica</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.875% Senior Notes due March 1, 2018</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">583.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">602.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.900% Senior Notes due September 15, 2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,521.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,497.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.625% Senior Notes due September 15, 2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,026.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,014.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.050% Senior Notes due September 15, 2025</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,796.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,764.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.200% Senior Notes due September 15, 2045</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,874.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,757.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6,808.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,645.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Fair value of contingent consideration obligations</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As&#160;of&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value, beginning of year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">506.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">215.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Additions</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">274.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Changes in fair value</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">14.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments and other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(53.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(14.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value, end of year</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">467.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">506.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13476-108611<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13467-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6447952&amp;loc=d3e13220-108610<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14172-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByBalanceSheetGroupingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19279-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19190-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6887708816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Investments, All Other Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Summary of financial assets with maturities of less than 90 days included within cash and cash equivalents</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Commercial paper</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">31.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Overnight reverse repurchase agreements</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">134.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Money market funds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">741.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">673.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Short-term debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,266.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">79.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,039.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">909.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesTextBlock', window );">Marketable securities including strategic investments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2016 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,408.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(0.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,409.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,255.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(4.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,258.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,156.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,156.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,016.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(3.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,019.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">557.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(2.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">559.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total marketable debt securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5,398.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(11.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5,406.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities, non-current</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">24.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(9.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">33.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2015 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">394.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">394.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,116.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,120.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,723.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,724.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,152.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,155.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">491.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">493.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total marketable debt securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,880.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(10.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,891.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities, non-current</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">28.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Summary of contractual maturities: Available-for-sale securities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">As of December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair&#160; Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair&#160; Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due in one year or less</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,568.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,569.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,120.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,122.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due after one year through five years</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,552.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,559.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,575.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,583.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due after five years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">276.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">277.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">184.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">185.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total available-for-sale securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5,398.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5,406.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,880.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,891.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock', window );">Proceeds from marketable securities, excluding strategic investments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Proceeds from maturities and sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7,378.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,063.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,718.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Realized gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Realized losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957658&amp;loc=d3e62557-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27337-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27198-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6957658&amp;loc=d3e62586-112803<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27161-111563<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27357-111563<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27290-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of realized gains and losses on investments reported in the statement of income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealizedGainLossOnInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6905368368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock', window );">Foreign currency forward contracts that were entered into to hedge forecasted revenue</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Notional Amount</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As&#160;of&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Foreign Currency: (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Euro</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">871.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">945.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Swiss francs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">80.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Canadian dollar</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">76.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total foreign currency forward contracts</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">871.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,103.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock', window );">Summary of the effect of derivatives designated as hedging instruments on our consolidated statements of income</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="27" rowspan="1"></td></tr><tr><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="27" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December 31,</font></div></td></tr><tr><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Reclassified from AOCI into Net Income</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;">(Effective Portion)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized into Net Income</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;">(Ineffective Portion)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">173.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.8</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock', window );">Summary of the fair value for our outstanding derivatives</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.61013645224172%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance&#160;Sheet&#160;Location</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">Fair Value<br clear="none"/>As of December 31, 2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hedging Instruments:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">50.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Other Derivatives:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued&#160;expenses&#160;and&#160;other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">9.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.61013645224172%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance Sheet Location</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value<br clear="none"/>As of December 31, 2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hedging Instruments:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued&#160;expenses&#160;and&#160;other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Other Derivatives:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued&#160;expenses&#160;and&#160;other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624171-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the notional amounts of outstanding derivative positions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6895364240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Components of property, plant and equipment, net</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Land</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">137.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">74.7</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Buildings</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,107.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,035.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Leasehold improvements</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">123.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">166.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Machinery and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,105.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,079.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Computer software and hardware</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">746.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">647.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Furniture and fixtures</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">60.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">72.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Construction in progress</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">658.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">441.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total cost</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,941.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,517.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Less: accumulated depreciation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1,439.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1,330.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total property, plant and equipment, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,501.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,187.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6895438240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Indebtedness (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Summary of Indebtedness</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Current portion:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes payable to Fumedica</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Financing arrangement for the purchase of the RTP facility</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current portion of notes payable and other financing arrangements</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Non-current portion:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.875% Senior Notes due March 1, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">558.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">565.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.900% Senior Notes due September 15, 2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,485.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,485.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.625% Senior Notes due September 15, 2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">993.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">992.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.050% Senior Notes due September 15, 2025</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,734.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,733.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.200% Senior Notes due September 15, 2045</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,721.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,721.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes payable to Fumedica</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Financing arrangement for the purchase of the RTP facility</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">16.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current portion of notes payable and other financing arrangements</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6,512.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,521.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Total debt maturities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.4375%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:80%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">As of December 31, 2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">553.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,500.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2022 and thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4,500.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6,556.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the combined aggregate amount of maturities and sinking fund requirements for all long-term borrowings for each of the five years following the date of the latest balance sheet date presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6824529632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfCommonStockTableTextBlock', window );">Summary of common stock</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18" rowspan="1"></td></tr><tr><td style="width:24%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">As of December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Authorized</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Issued</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Authorized</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Issued</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Outstanding</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Common stock</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,000.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">238.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">215.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,000.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">241.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">218.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryOfCommonStockTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryOfCommonStockTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6895552240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Loss) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of Accumulated Other Comprehensive Income (Loss)</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:26%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Translation Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(0.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(37.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(195.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(224.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(10.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">51.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(138.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(92.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(4.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(3.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(10.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">47.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(138.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(95.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(10.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">57.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(32.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(334.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(319.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:26%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Translation Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">71.7</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(31.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(99.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(59.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">110.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(6.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(96.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(172.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(171.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(61.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(6.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(96.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(164.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(37.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(195.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(224.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:26%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Translation Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.6</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(23.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(19.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.0</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(27.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">101.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(12.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(109.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(19.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(6.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(6.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(12.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(6.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">95.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(12.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(109.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(31.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2014</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">71.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(31.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(99.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(59.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock', window );">Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:28%;" rowspan="1" colspan="1"></td><td style="width:25%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Income Statement Location</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amounts Reclassified from</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated Other Comprehensive Income</font></div></td></tr><tr><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended December&#160;31,</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on securities available for sale</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(0.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on cash flow hedges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">173.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total reclassifications, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">171.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6824517776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Basic and diluted earnings per share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Numerator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,702.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,547.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,934.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Denominator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted average number of common shares outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">218.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">230.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">236.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effect of dilutive securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Stock options and employee stock purchase plan</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Time-vested restricted stock units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Market stock units</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Dilutive potential common shares</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Shares used in calculating diluted earnings per share</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">218.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">231.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">237.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6825707600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Share-based compensation expense included in consolidated statements of income</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:55%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">84.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">88.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">102.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">121.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">127.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">150.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restructuring charges</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(8.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">204.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">207.3</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">252.4</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capitalized share-based compensation costs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(14.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(11.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(10.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in total cost and expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">189.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">196.3</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">242.4</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax effect</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(54.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(55.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(72.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">135.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">140.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">170.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Summary of share-based compensation expense associated with each of our share-based compensating programs</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:55%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Market stock units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">38.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">38.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Time-vested restricted stock units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">120.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">119.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">115.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash settled performance units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">16.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">22.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">65.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">18.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee stock purchase plan</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">11.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">204.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">207.3</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">252.4</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capitalized share-based compensation costs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(14.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(11.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(10.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in total cost and expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">189.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">196.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">242.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Stock option activity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Exercise</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Price</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Outstanding at December 31, 2015</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">107,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">53.94</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(41,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">53.75</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cancelled</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Outstanding at December 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">66,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">54.06</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashProceedsReceivedFromShareBasedPaymentAwardsTableTextBlock', window );">Tax benefit and cash received from stock option exercises</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Tax benefit realized for stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash received from the exercise of stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ScheduleOfMarketStockUnitsActivityTableTextBlock', window );">Market stock units activity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Grant&#160;Date</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2015</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">269,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">339.89</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Granted (a)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">168,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">328.03</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(155,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">244.68</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(52,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">371.62</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">230,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">355.60</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock', window );">Assumptions used in valuation of market based stock units</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:44%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Range of expected stock price volatility</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">38.2% - 40.7%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31.0% - 33.2%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31.7% - 35.1%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Range of risk-free interest rates</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.6% - 0.9%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2% - 1.0%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1% - 0.7%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30 calendar day average stock price on grant date</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$260.67 - $304.86</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$277.35 - $426.27</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$280.88 - $335.65</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted-average per share grant date fair value</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$328.03</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$493.43</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$395.22</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock', window );">Cash settled performance shares activity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:82%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2015</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">192,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Granted (a)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">86,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(117,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(39,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">122,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PerformanceunitsactivityTableTextBlock', window );">Performance units activity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:82%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2015</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">103,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Granted (a)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">55,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(31,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(17,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">110,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock', window );">Time-vested restricted stock units activity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Grant&#160;Date</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2015</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">810,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">323.87</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Granted (a)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">649,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">268.52</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(406,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">285.13</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(165,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">310.30</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">888,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">303.49</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock', window );">Shares issued under employee stock purchase plan</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except share amounts)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Shares issued under the 2015 ESPP</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">190,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">78,000</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">**</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Shares issued under the 1995 ESPP</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">98,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">180,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash received under the 2015 ESPP</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">41.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">19.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">**</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash received under the 1995 ESPP</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">46.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assumptions used in valuation of market based stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PerformanceunitsactivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Performance units activity [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PerformanceunitsactivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Cash Settled Performance Shares Activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ScheduleOfMarketStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Market Stock Units Activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ScheduleOfMarketStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares issued under employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Time Vested Restricted Stock Units Activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashProceedsReceivedFromShareBasedPaymentAwardsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of cash proceeds received from the exercise of stock options and similar instruments granted under share-based payment arrangements and the tax benefit realized from stock options exercised during the period.  Disclosure may also include the intrinsic value of stock options exercised during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashProceedsReceivedFromShareBasedPaymentAwardsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of total share-based compensation cost, including the amounts attributable to each share-based compensation plan and any related tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6895549488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Income before income tax provision and the income tax expense</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Income before income taxes (benefit):</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Domestic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,655.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,386.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,557.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,277.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,380.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,389.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4,933.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,767.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,946.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Income tax expense (benefit):</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Federal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,304.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,214.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,159.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">State</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">55.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">38.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">65.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">52.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">54.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">73.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,412.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,307.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,298.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferred:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Federal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(125.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(129.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(280.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">State</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(3.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(21.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(45.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(14.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(6.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(175.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(145.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(308.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total income tax expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,237.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,161.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">989.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Components of deferred tax assets and liabilities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As&#160;of&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Deferred tax assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Tax credits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">201.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">189.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory, other reserves and accruals</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">250.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">243.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangibles, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">459.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">328.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net operating loss</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">65.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">61.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">63.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">49.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(16.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(14.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total deferred tax assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,071.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">871.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Deferred tax liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchased intangible assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(376.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(440.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Depreciation, amortization and other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(113.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(102.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total deferred tax liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(490.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(542.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation between the U.S. federal statutory tax rate and effective tax rate</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:55%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Statutory rate</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">35.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">State taxes</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Taxes on foreign earnings</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(9.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(10.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(9.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Credits and net operating loss utilization</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchased intangible assets</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Manufacturing deduction</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other permanent items</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effective tax rate</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">25.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">25.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Reconciliation of beginning and ending amount of unrecognized tax benefits</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance at January&#160;1,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">67.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">131.5</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">110.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Additions based on tax positions related to the current period</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">20.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Additions for tax positions of prior periods</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">36.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">19.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">86.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Reductions for tax positions of prior periods</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(13.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(49.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(23.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Statute expirations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Settlements</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(64.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(42.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(60.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance at December&#160;31,</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">32.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">67.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">131.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI http://asc.fasb.org/extlink&amp;oid=75116239&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6825951120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock', window );">Supplementary cash flow information</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:51%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash paid during the year for:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">281.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">39.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">41.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,642.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,674.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,163.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Other income (expense), net</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">63.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">22.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(260.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(95.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(29.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gain (loss) on investments, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign exchange gains (losses), net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(9.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(32.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(11.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(17.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(13.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(8.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other income (expense), net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(217.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(123.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(25.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Accrued expenses and other</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current portion of contingent consideration obligations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">580.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">504.7</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued TECFIDERA litigation settlement and license charges</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">454.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenue-related reserves for discounts and allowances</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">438.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">518.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee compensation and benefits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">282.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">270.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Royalties and licensing fees</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">195.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">167.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Construction in progress</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">134.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">87.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Collaboration expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">130.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">685.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">516.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total accrued expenses and other</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,903.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,096.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information for the periods presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6895480432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CoPromotionProfitSharingFormulaTableTextBlock', window );">Co-promotion profit sharing formula</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:82%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Until GAZYVA First Non-CLL FDA Approval</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">40.0</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">After GAZYVA First Non-CLL FDA Approval until First GAZYVA Threshold Date</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">39.0</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">After First GAZYVA Threshold Date until Second GAZYVA Threshold Date</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">37.5</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">After Second GAZYVA Threshold Date</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">35.0</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;">First Non-CLL GAZYVA FDA Approval</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> means the FDA&#8217;s first approval of GAZYVA in an indication other than CLL.</font></div><div style="line-height:120%;padding-top:12px;padding-left:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;">First GAZYVA Threshold Date</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> means the earlier of (1)&#160;the date of the First Non-CLL GAZYVA FDA approval if U.S. gross sales of GAZYVA for the preceding consecutive 12 month period were at least </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$150.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> or (2)&#160;the first day of the calendar quarter after the date of the First Non-CLL GAZYVA FDA Approval that U.S. gross sales of GAZYVA within any consecutive 12 month period have reached </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$150.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;">Second GAZYVA Threshold Date</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> means the first day of the calendar quarter after U.S. gross sales of GAZYVA within any consecutive 12 month period have reached </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$500.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The Second GAZYVA Threshold Date can be achieved regardless of whether GAZYVA has been approved in a non-CLL indication.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"></font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PretaxProfitSharingFormulaTableTextBlock', window );">Pretax profit sharing formula</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:82%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Until First GAZYVA Threshold Date</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">39.0</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">After First GAZYVA Threshold Date until Second GAZYVA Threshold Date</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">37.5</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">After Second GAZYVA Threshold Date</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">35.0</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RevenuesFromUnconsolidatedJointBusinessTableTextBlock', window );">Revenues from unconsolidated joint business</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,249.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,269.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,117.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenue on sales in the rest of world for RITUXAN</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">65.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">69.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">78.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues from anti-CD20 therapeutic programs</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,314.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,339.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,195.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ReimbursementUnderAmendedAgreementAmountsPayableTableTextBlock', window );">Mechanism for reimbursement, under the amended agreement amounts payable</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:51%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rates post Sobi Opt-In</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(3)</sup></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Royalty and Net Revenue Share Rates:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Method</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Base Rate following</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">1st&#160;commercial&#160;sale&#160;in</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">the Sobi Territory:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rate during the</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Reimbursement</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Period:</font></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Sobi rate to Biogen on net sales in the Sobi Territory</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Royalty</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">12%</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Base&#160;Rate<br clear="none"/>plus 5%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Biogen rate to Sobi on net sales in the Biogen North America Territory</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Royalty</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">12%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Base Rate<br clear="none"/>less 5%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Biogen rate to Sobi on net sales in the Biogen Direct Territory</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Royalty</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">17%</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Base Rate<br clear="none"/>less 5%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Biogen rate to Sobi on net revenue</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">from the Biogen Distributor Territory</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(2)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Net<br clear="none"/>Revenue<br clear="none"/>Share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">50%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Base Rate<br clear="none"/>less 15%</font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Net revenue represents Biogen&#8217;s pre-tax receipts from third-party distributors, less expenses incurred by Biogen in the conduct of commercialization activities supporting the distributor activities.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">The Biogen Distributor Territory represents Biogen territories where sales are derived utilizing a third-party distributor.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">A credit will be issued to Sobi against its reimbursement of the Opt-in Consideration for each product in an amount equal to the difference in the rate paid by Biogen to Sobi on sales in the Biogen territories for certain periods prior to the first commercial sale in the Sobi Territory versus the rate that otherwise would have been payable on such sales.</font></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfActivityRelatedToCollaborationWithCompanySevenTableTextBlock', window );">Summary of activity related to collaboration with AbbVie Inc.</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:84%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Year Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Costs and expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">50.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Co-promotion losses in the U.S.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">43.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of co-promotion losses in the U.S.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">21.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock', window );">Summary of activity related to collaboration with Eisai</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total development expense incurred by the collaboration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">95.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">84.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">57.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen&#8217;s share of development expense, excluding upfront and milestone payments, reflected in our consolidated statements of income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">50.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">40.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">29.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CoPromotionProfitSharingFormulaTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Co-promotion profit sharing formula.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CoPromotionProfitSharingFormulaTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PretaxProfitSharingFormulaTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Pretax Profit Sharing Formula [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PretaxProfitSharingFormulaTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ReimbursementUnderAmendedAgreementAmountsPayableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Mechanism for reimbursement, under the amended agreement amounts payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ReimbursementUnderAmendedAgreementAmountsPayableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RevenuesFromUnconsolidatedJointBusinessTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenues from unconsolidated joint business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RevenuesFromUnconsolidatedJointBusinessTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary Of Activity Related To Collaboration With Company Eight [Table Text Block] [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryOfActivityRelatedToCollaborationWithCompanySevenTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of activity related to collaboration with company seven.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryOfActivityRelatedToCollaborationWithCompanySevenTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6798620144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Minimum rental commitments under non-cancelable leases</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="28" rowspan="1"></td></tr><tr><td style="width:31%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2021</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Thereafter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Minimum lease payments </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">75.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">69.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">69.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">65.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">64.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">331.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">676.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Less: income from subleases (1)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(8.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(15.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(15.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(15.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(16.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(55.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(126.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net minimum lease payments</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">66.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">54.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">53.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">50.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">48.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">276.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">549.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"></font></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock', window );">Future minimum lease payments for capital leases</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-left:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:79%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">As of December 31, 2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">16.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">18.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Less: interest</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(0.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net present value of the future minimum lease payments</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">18.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum lease payments as of the date of the latest balance sheet presented, in aggregate and for each of the five years succeeding fiscal years, with separate deductions from the total for the amount representing executor costs, including any profit thereon, included in the minimum lease payments and for the amount of the imputed interest necessary to reduce the net minimum lease payments to present value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6906241296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock', window );">Revenue by product</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="36" rowspan="1"></td></tr><tr><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="35" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">States</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">World</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">States</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">World</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">States</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">World</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Multiple Sclerosis (MS):</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">TECFIDERA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">3,169.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">798.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">3,968.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">2,908.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">730.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">3,638.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">2,426.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">482.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">2,909.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">AVONEX</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">1,675.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">638.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">2,313.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,790.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">840.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">2,630.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,956.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,056.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">3,013.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">PLEGRIDY</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">305.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">176.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">481.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">227.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">111.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">338.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">27.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">16.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">44.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">TYSABRI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">1,182.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">780.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">1,963.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,103.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">783.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,886.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,025.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">934.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,959.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">FAMPYRA</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">84.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">84.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">89.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">89.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">80.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">80.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">ZINBRYTA</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">7.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">7.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Hemophilia:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">ELOCTATE</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">445.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">68.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">513.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">308.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">11.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">319.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">58.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">58.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">ALPROLIX</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">268.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">65.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">333.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">208.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">25.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">234.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">72.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">3.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">76.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Other product revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">FUMADERM</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">45.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">45.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">51.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">51.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">62.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">62.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">SPINRAZA</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">4.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">4.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">BENEPALI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">100.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">100.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">FLIXABI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total product revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">7,050.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">2,767.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">9,817.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">6,545.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">2,642.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">9,188.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">5,566.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">2,636.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">8,203.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock', window );">Geographic information</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="24" rowspan="1"></td></tr><tr><td style="width:29%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">December 31, 2016 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Europe</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Germany</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Asia</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues from external customers</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7,050.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,533.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">703.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">217.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">313.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">9,817.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,249.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">63.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,314.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues from external customers</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">224.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">70.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">20.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">316.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-lived assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,272.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,219.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,501.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">December 31, 2015 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Europe</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Germany</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Asia</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues from external customers</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,545.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,497.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">668.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">143.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">333.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9,188.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,269.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">65.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,339.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues from external customers</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">142.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">29.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">62.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">236.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-lived assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,296.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">879.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,187.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">December 31, 2014 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Europe</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Germany</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Asia</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues from external customers</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,566.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,383.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">811.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">112.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">328.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8,203.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,117.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">70.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,195.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues from external customers</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">212.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">58.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">304.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-lived assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,055.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">701.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,765.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e9031-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the names of foreign countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6824547200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Financial Data (Unaudited) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock', window );">Quarterly Financial Data (Unaudited)</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:36%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except per share amounts)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">First</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Second</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Third</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fourth</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Year</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2016</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(a)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(b)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(b) (c)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(b) (d) (e)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,309.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,466.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,539.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,502.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">9,817.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">329.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">349.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">317.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">318.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,314.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">87.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">79.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">98.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">50.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">316.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,726.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,894.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,955.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,872.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">11,448.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gross profit (1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,413.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,523.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,538.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,493.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">9,970.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">969.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,048.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,030.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">647.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,695.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">970.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,049.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,032.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">649.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,702.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income per share:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.44</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.79</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.72</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.00</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">16.96</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.43</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.79</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.71</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2.99</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">16.93</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted-average shares used in calculating:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share attributable to Biogen Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">218.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">219.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">218.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">216.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">218.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">219.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">219.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">219.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">217.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">218.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:36%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except per share amounts)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">First</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Second</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Third</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fourth</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Year</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">2015</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(f) (g)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(a) (h)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,172.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,198.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,391.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,425.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9,188.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">330.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">337.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">337.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">333.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,339.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">52.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">55.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">79.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">236.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,555.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,591.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,777.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,839.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10,763.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gross profit (1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,242.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,305.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,467.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,507.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9,523.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">820.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">924.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,019.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">828.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,593.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">822.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">927.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">965.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">831.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,547.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income per share:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.50</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.94</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.16</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.77</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15.38</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.49</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.93</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.15</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.77</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15.34</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted-average shares used in calculating:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share attributable to Biogen Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">235.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">235.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">232.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">220.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">230.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">235.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">235.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">232.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">220.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">231.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(1) Gross profit is calculated as total revenues less cost of sales, excluding amortization of acquired intangible assets.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc., for the first quarter of 2016 and the fourth quarter of 2015, includes pre-tax restructuring charges totaling </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$9.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$93.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively related to the 2015 corporate restructuring program.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for the second, third and fourth quarters of 2016 includes pre-tax additional depreciation expense totaling </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$15.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$15.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$14.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, as part of our determination to cease manufacturing in our small-scale biologics manufacturing facility in Cambridge, MA as well as vacate our warehouse space in Somerville, MA. Our departure from these facilities has shortened the expected useful lives of certain leasehold improvements and other assets at these facilities.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for the third quarter of 2016 includes a pre-tax charge to research and development expense of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$75.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for a license fee paid to Ionis as we exercised our option to develop and commercialize SPINRAZA.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for the fourth quarter of 2016 includes a pre-tax charge to research and development expense of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$50.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for a milestone payment due to Eisai related to the initiation of a phase 3 trial for E2609.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(e)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for the fourth quarter of 2016 includes a pre-tax charge of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$454.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to the January 2017 settlement and license agreement with Forward Pharma.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(f)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for the third quarter of 2015 includes a pre-tax charge to research and development expense of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$48.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> recorded upon entering into the collaboration agreement with AGTC.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(g)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc. for the third quarter of 2015 reflects the attribution of a </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$60.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> charge to noncontrolling interests, net of tax, related to a milestone payment due Neurimmune upon the enrollment of the first patient in a Phase 3 trial for aducanumab.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(h)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for the fourth quarter of 2015 includes a pre-tax charge to research and development expense of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$60.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> recorded upon entering into the collaboration agreement with MTPC.</font></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)-(j)<br> -URI http://asc.fasb.org/extlink&amp;oid=68076893&amp;loc=d3e1280-108306<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6905640384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_BusinessTextualAbstract', window );"><strong>Business (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InterestInSubsidiary', window );">Interest in subsidiary (less than given percentage)</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentTermsOfAccountsReceivable', window );">Payment terms of accounts receivable arising from product sales</a></td>
<td class="text">30 to 90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EstimatedUsefulLivesOfLeaseholdImprovements', window );">Estimated useful lives of leasehold improvements</a></td>
<td class="text">Lesser of the useful life or the term of the respective lease<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PurchasePriceOfCommonStockUnderEspp', window );">Purchase price of common stock under ESPP</a></td>
<td class="text">85% of the lower of (i) the market value per share of the common stock on the participant's entry date into an offering period or (ii) the market value per share of the common stock on the purchase date<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfMarketValuePerShareOfCommonStock', window );">Percentage of market value per share of common stock</a></td>
<td class="nump">$ 0.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CompensationExpenseOverPurchasePeriod', window );">Compensation expense over purchase period</a></td>
<td class="text">The fair value of the look-back provision plus the 15% discount<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DiscountRateRecognizedInCompensationExpense', window );">Discount rate recognized in compensation expense</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising costs</a></td>
<td class="nump">$ 106.3<span></span>
</td>
<td class="nump">$ 108.6<span></span>
</td>
<td class="nump">$ 92.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum | Building</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum | Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum | Machinery and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum | Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum | Building</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">40 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum | Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum | Machinery and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum | Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MajorDistributorAxis=biib_DistributorOneMember', window );">Distributor One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables', window );">Percentage receivables of wholesale distributor accounted in consolidated receivables</a></td>
<td class="nump">37.20%<span></span>
</td>
<td class="nump">35.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MajorDistributorAxis=biib_DistributorTwoMember', window );">Distributor Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables', window );">Percentage receivables of wholesale distributor accounted in consolidated receivables</a></td>
<td class="nump">19.20%<span></span>
</td>
<td class="nump">23.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_BusinessTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_BusinessTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CompensationExpenseOverPurchasePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Compensation expense over purchase period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CompensationExpenseOverPurchasePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DiscountRateRecognizedInCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount rate recognized in compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DiscountRateRecognizedInCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EstimatedUsefulLivesOfLeaseholdImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated useful lives of leasehold improvements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EstimatedUsefulLivesOfLeaseholdImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InterestInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest in subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InterestInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PaymentTermsOfAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment  terms of accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PaymentTermsOfAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfMarketValuePerShareOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of market value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfMarketValuePerShareOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage receivables of wholesale distributor accounted in consolidated receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PurchasePriceOfCommonStockUnderEspp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase Price Of Common Stock Under ESPP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PurchasePriceOfCommonStockUnderEspp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_MajorDistributorAxis=biib_DistributorOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_MajorDistributorAxis=biib_DistributorOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_MajorDistributorAxis=biib_DistributorTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_MajorDistributorAxis=biib_DistributorTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6905201456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions Acquisitions (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2015</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Contingent consideration obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 274.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ConvergencePharmaceuticalsMember', window );">Convergence Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash portion of consideration</a></td>
<td class="nump">$ 200.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Contingent consideration obligation</a></td>
<td class="nump">274.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total purchase price</a></td>
<td class="nump">$ 474.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6578-128477<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6613-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_ConvergencePharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_ConvergencePharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6887767984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Acquisitions Acquisitions (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Feb. 12, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 3,669.3<span></span>
</td>
<td class="nump">$ 2,663.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,760.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ConvergencePharmaceuticalsMember', window );">Convergence Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 424.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Other intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent', window );">Deferred tax liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(84.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets', window );">Other, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 474.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary difference assumed at the acquisition date that are classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=73530397&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=73530397&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=73531372&amp;loc=d3e2207-128464<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=73530397&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=73531372&amp;loc=d3e2207-128464<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=73530397&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=73530397&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=64834752&amp;loc=SL49117168-202975<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_ConvergencePharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_ConvergencePharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6905565008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2015</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Feb. 12, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential future milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100.0<span></span>
</td>
<td class="nump">$ 3,100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Contingent consideration obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">$ 274.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Maximum contingent consideration in the form of development and approval milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200.0<span></span>
</td>
<td class="nump">$ 1,200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ConvergencePharmaceuticalsMember', window );">Convergence Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash portion of consideration</a></td>
<td class="nump">$ 200.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential future milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 450.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Contingent consideration obligation</a></td>
<td class="nump">274.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Increase in contingent consideration liability</a></td>
<td class="nump">$ 36.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsDiscountRate', window );">Discount rate</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Maximum contingent consideration in the form of development and approval milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400.0<span></span>
</td>
<td class="nump">$ 400.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">424.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MilestonePaymentsMadeDuringPeriod', window );">Milestone payment made during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_BIIB074Member', window );">BIIB074 | Convergence Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential future milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsDiscountRate', window );">Discount rate</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Maximum contingent consideration in the form of development and approval milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_NeuropathicpainindicationsMember', window );">Neuropathic pain indications | Convergence Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Maximum contingent consideration in the form of development and approval milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">415.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 220.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_MilestonePaymentsMadeDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payments Made During Period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_MilestonePaymentsMadeDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential future milestone payments commitment to third party approximately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=73530397&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueInputsDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest rate used to find the present value of an amount to be paid or received in the future as an input to measure fair value.  For example, but not limited to, weighted average cost of capital (WACC), cost of capital, cost of equity and cost of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueInputsDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_ConvergencePharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_ConvergencePharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_BIIB074Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_BIIB074Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_NeuropathicpainindicationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_NeuropathicpainindicationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6908416208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Restructuring (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve, beginning period</a></td>
<td class="nump">$ 37.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Expense</a></td>
<td class="nump">10.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments</a></td>
<td class="num">(40.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveAccrualAdjustment1', window );">Adjustments to previous estimates, net</a></td>
<td class="num">(2.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve, ending period</a></td>
<td class="nump">5.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Workforce reduction</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve, beginning period</a></td>
<td class="nump">33.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Expense</a></td>
<td class="nump">4.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments</a></td>
<td class="num">(31.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveAccrualAdjustment1', window );">Adjustments to previous estimates, net</a></td>
<td class="num">(5.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve, ending period</a></td>
<td class="nump">2.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_ContractTerminationMember', window );">Pipeline programs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve, beginning period</a></td>
<td class="nump">3.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Expense</a></td>
<td class="nump">5.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments</a></td>
<td class="num">(9.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveAccrualAdjustment1', window );">Adjustments to previous estimates, net</a></td>
<td class="nump">2.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve, ending period</a></td>
<td class="nump">$ 2.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveAccrualAdjustment1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) which increases (decreases) the restructuring reserve from an adjustment to a previously accrued restructuring liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveAccrualAdjustment1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_ContractTerminationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_ContractTerminationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6904865776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Restructuring (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="5">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveAccrualAdjustment1', window );">Adjustments to previous estimates, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.1<span></span>
</td>
<td class="nump">$ 93.4<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=biib_A2015RestructuringChargesMember', window );">2015 Restructuring Charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Restructuringandrelatedcostexpectedpercentageofpositionseliminated', window );">Restructuring and related cost, expected percentage of positions eliminated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RestructuringandRelatedCostExpectedCashPayments', window );">Previously accrued incentive compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveAccrualAdjustment1', window );">Adjustments to previous estimates, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Total restructuring charges expected</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 102.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.7<span></span>
</td>
<td class="nump">$ 93.4<span></span>
</td>
<td class="nump">8.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=biib_A2016RestructuringChargesMember', window );">2016 Restructuring Charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FacilityLocationAxis=biib_CambridgeMAMember', window );">Cambridge, MA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveAcceleratedDepreciation', window );">Accelerated depreciation</a></td>
<td class="nump">$ 14.0<span></span>
</td>
<td class="nump">$ 15.7<span></span>
</td>
<td class="nump">$ 15.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FacilityLocationAxis=biib_CambridgeMAMember', window );">Cambridge, MA | 2016 Restructuring Charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RestructuringandRelatedCostExpectedCashPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restructuring and Related Cost, Expected Cash Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RestructuringandRelatedCostExpectedCashPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Restructuringandrelatedcostexpectedpercentageofpositionseliminated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restructuring and related cost, expected percentage of positions eliminated</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Restructuringandrelatedcostexpectedpercentageofpositionseliminated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostExpectedCost1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount expected to be recognized in earnings for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostExpectedCost1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140864-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveAcceleratedDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accelerated depreciation charged against earnings associated with exit from or disposal of business activities or restructuring plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveAcceleratedDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveAccrualAdjustment1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) which increases (decreases) the restructuring reserve from an adjustment to a previously accrued restructuring liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveAccrualAdjustment1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=biib_A2015RestructuringChargesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=biib_A2015RestructuringChargesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=biib_A2016RestructuringChargesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=biib_A2016RestructuringChargesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FacilityLocationAxis=biib_CambridgeMAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FacilityLocationAxis=biib_CambridgeMAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6826691744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Reserves (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract', window );"><strong>Analysis of the amount of, and change in, reserves</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning balance</a></td>
<td class="nump">$ 662.7<span></span>
</td>
<td class="nump">$ 483.8<span></span>
</td>
<td class="nump">$ 426.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current provisions relating to sales in current year</a></td>
<td class="nump">2,668.0<span></span>
</td>
<td class="nump">2,229.4<span></span>
</td>
<td class="nump">1,651.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments relating to prior years</a></td>
<td class="num">(16.7)<span></span>
</td>
<td class="num">(32.3)<span></span>
</td>
<td class="num">(16.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/returns relating to sales in current year</a></td>
<td class="num">(2,099.5)<span></span>
</td>
<td class="num">(1,666.6)<span></span>
</td>
<td class="num">(1,237.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/returns relating to sales in prior years</a></td>
<td class="num">(609.0)<span></span>
</td>
<td class="num">(351.6)<span></span>
</td>
<td class="num">(341.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending balance</a></td>
<td class="nump">605.5<span></span>
</td>
<td class="nump">662.7<span></span>
</td>
<td class="nump">483.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ReserveForCashDiscountMember', window );">Discounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract', window );"><strong>Analysis of the amount of, and change in, reserves</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning balance</a></td>
<td class="nump">56.1<span></span>
</td>
<td class="nump">47.6<span></span>
</td>
<td class="nump">47.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current provisions relating to sales in current year</a></td>
<td class="nump">592.6<span></span>
</td>
<td class="nump">459.7<span></span>
</td>
<td class="nump">347.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments relating to prior years</a></td>
<td class="num">(1.4)<span></span>
</td>
<td class="num">(1.3)<span></span>
</td>
<td class="num">(1.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/returns relating to sales in current year</a></td>
<td class="num">(522.5)<span></span>
</td>
<td class="num">(405.9)<span></span>
</td>
<td class="num">(299.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/returns relating to sales in prior years</a></td>
<td class="num">(53.2)<span></span>
</td>
<td class="num">(44.0)<span></span>
</td>
<td class="num">(46.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending balance</a></td>
<td class="nump">71.6<span></span>
</td>
<td class="nump">56.1<span></span>
</td>
<td class="nump">47.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ContractualAdjustmentsMember', window );">Contractual Adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract', window );"><strong>Analysis of the amount of, and change in, reserves</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning balance</a></td>
<td class="nump">548.7<span></span>
</td>
<td class="nump">387.1<span></span>
</td>
<td class="nump">345.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current provisions relating to sales in current year</a></td>
<td class="nump">2,044.5<span></span>
</td>
<td class="nump">1,732.1<span></span>
</td>
<td class="nump">1,265.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments relating to prior years</a></td>
<td class="nump">1.5<span></span>
</td>
<td class="num">(16.3)<span></span>
</td>
<td class="num">(28.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/returns relating to sales in current year</a></td>
<td class="num">(1,576.0)<span></span>
</td>
<td class="num">(1,258.1)<span></span>
</td>
<td class="num">(933.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/returns relating to sales in prior years</a></td>
<td class="num">(536.0)<span></span>
</td>
<td class="num">(296.1)<span></span>
</td>
<td class="num">(261.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending balance</a></td>
<td class="nump">482.7<span></span>
</td>
<td class="nump">548.7<span></span>
</td>
<td class="nump">387.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember', window );">Returns</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract', window );"><strong>Analysis of the amount of, and change in, reserves</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning balance</a></td>
<td class="nump">57.9<span></span>
</td>
<td class="nump">49.1<span></span>
</td>
<td class="nump">33.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current provisions relating to sales in current year</a></td>
<td class="nump">30.9<span></span>
</td>
<td class="nump">37.6<span></span>
</td>
<td class="nump">39.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments relating to prior years</a></td>
<td class="num">(16.8)<span></span>
</td>
<td class="num">(14.7)<span></span>
</td>
<td class="nump">13.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/returns relating to sales in current year</a></td>
<td class="num">(1.0)<span></span>
</td>
<td class="num">(2.6)<span></span>
</td>
<td class="num">(4.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/returns relating to sales in prior years</a></td>
<td class="num">(19.8)<span></span>
</td>
<td class="num">(11.5)<span></span>
</td>
<td class="num">(33.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending balance</a></td>
<td class="nump">$ 51.2<span></span>
</td>
<td class="nump">$ 57.9<span></span>
</td>
<td class="nump">$ 49.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to product revenue reserves relating to sales in prior years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Analysis of the amount of, and change in product revenue reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Current provisions to product revenue reserves relating to sales in current year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments/ returns applied against product revenue reserves relating to current year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments/ returns applied against product revenue reserves relating to prior year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of allowances and reserves, the valuation and qualifying accounts that are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ReserveForCashDiscountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ReserveForCashDiscountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ContractualAdjustmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ContractualAdjustmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6905372864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Revenue Reserves (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Total reserves</a></td>
<td class="nump">$ 605.5<span></span>
</td>
<td class="nump">$ 662.7<span></span>
</td>
<td class="nump">$ 483.8<span></span>
</td>
<td class="nump">$ 426.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember', window );">Reduction of accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Total reserves</a></td>
<td class="nump">166.9<span></span>
</td>
<td class="nump">144.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Component of accrued expenses and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Total reserves</a></td>
<td class="nump">$ 438.6<span></span>
</td>
<td class="nump">$ 518.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of allowances and reserves, the valuation and qualifying accounts that are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6825658640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNetAbstract', window );"><strong>Components of inventories</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 170.4<span></span>
</td>
<td class="nump">$ 213.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in process</a></td>
<td class="nump">698.7<span></span>
</td>
<td class="nump">577.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">170.3<span></span>
</td>
<td class="nump">143.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Inventorynetcurrentandnoncurrent', window );">Total inventory</a></td>
<td class="nump">1,039.4<span></span>
</td>
<td class="nump">933.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, current</a></td>
<td class="nump">1,001.6<span></span>
</td>
<td class="nump">893.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Inventory, noncurrent</a></td>
<td class="nump">$ 37.8<span></span>
</td>
<td class="nump">$ 40.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Inventorynetcurrentandnoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventory, net current and noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Inventorynetcurrentandnoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6888613280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Write-downs on excess, obsolete, unmarketable or other inventory</a></td>
<td class="nump">$ 48.2<span></span>
</td>
<td class="nump">$ 41.9<span></span>
</td>
<td class="nump">$ 50.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_ZINBRYTAMember', window );">ZINBRYTA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Preapprovalinventory', window );">Pre-approval inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_FLIXABIMember', window );">FLIXABI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Preapprovalinventory', window );">Pre-approval inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_BENEPALIMember', window );">BENEPALI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Preapprovalinventory', window );">Pre-approval inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Preapprovalinventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Pre-approval inventory</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Preapprovalinventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=66092785&amp;loc=d3e4542-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 1C<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=SL66093883-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=SL66093879-108312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_ZINBRYTAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_ZINBRYTAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_FLIXABIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_FLIXABIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_BENEPALIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_BENEPALIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6910106576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Feb. 12, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Increase to goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,026.9<span></span>
</td>
<td class="nump">$ 908.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 3,669.3<span></span>
</td>
<td class="nump">3,669.3<span></span>
</td>
<td class="nump">2,663.8<span></span>
</td>
<td class="nump">$ 1,760.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Total intangible assets, gross</a></td>
<td class="nump">7,742.3<span></span>
</td>
<td class="nump">7,742.3<span></span>
</td>
<td class="nump">7,646.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(3,934.0)<span></span>
</td>
<td class="num">(3,934.0)<span></span>
</td>
<td class="num">(3,561.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">3,808.3<span></span>
</td>
<td class="nump">3,808.3<span></span>
</td>
<td class="nump">4,085.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract', window );"><strong>Intangible Assets and Goodwill (Additional Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Expected future amortization expense, 2017</a></td>
<td class="nump">334.8<span></span>
</td>
<td class="nump">334.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Expected future amortization expense, 2018</a></td>
<td class="nump">312.7<span></span>
</td>
<td class="nump">312.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Expected future amortization expense, 2019</a></td>
<td class="nump">295.2<span></span>
</td>
<td class="nump">295.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Expected future amortization expense, 2020</a></td>
<td class="nump">259.7<span></span>
</td>
<td class="nump">259.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">Expected future amortization expense, 2021</a></td>
<td class="nump">242.8<span></span>
</td>
<td class="nump">242.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of acquired intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(385.6)<span></span>
</td>
<td class="num">(382.6)<span></span>
</td>
<td class="num">(489.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Deferred tax liabilities</a></td>
<td class="nump">376.6<span></span>
</td>
<td class="nump">376.6<span></span>
</td>
<td class="nump">440.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember', window );">Out-licensed patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">543.3<span></span>
</td>
<td class="nump">543.3<span></span>
</td>
<td class="nump">543.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(523.6)<span></span>
</td>
<td class="num">(523.6)<span></span>
</td>
<td class="num">(506.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">19.7<span></span>
</td>
<td class="nump">$ 19.7<span></span>
</td>
<td class="nump">37.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract', window );"><strong>Intangible Assets and Goodwill (Additional Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of out-licensed patent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember', window );">Out-licensed patents | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (In Years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">13 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember', window );">Out-licensed patents | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (In Years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">23 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">3,005.3<span></span>
</td>
<td class="nump">$ 3,005.3<span></span>
</td>
<td class="nump">3,005.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(2,634.3)<span></span>
</td>
<td class="num">(2,634.3)<span></span>
</td>
<td class="num">(2,552.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">371.0<span></span>
</td>
<td class="nump">$ 371.0<span></span>
</td>
<td class="nump">452.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (In Years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (In Years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">23 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember', window );">Acquired and in-licensed rights and patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">3,481.7<span></span>
</td>
<td class="nump">$ 3,481.7<span></span>
</td>
<td class="nump">3,303.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(776.1)<span></span>
</td>
<td class="num">(776.1)<span></span>
</td>
<td class="num">(502.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">2,705.6<span></span>
</td>
<td class="nump">$ 2,705.6<span></span>
</td>
<td class="nump">2,800.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember', window );">Acquired and in-licensed rights and patents | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (In Years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember', window );">Acquired and in-licensed rights and patents | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (In Years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IndefiniteLivedIntangibleAssetsUsefulLife', window );">Indefinite lived intangible assets useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Indefinite<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Cost and net</a></td>
<td class="nump">648.0<span></span>
</td>
<td class="nump">$ 648.0<span></span>
</td>
<td class="nump">730.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract', window );"><strong>Intangible Assets and Goodwill (Additional Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of out-licensed patent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember', window );">Trademarks and trade names</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IndefiniteLivedIntangibleAssetsUsefulLife', window );">Indefinite lived intangible assets useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Indefinite<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Cost and net</a></td>
<td class="nump">64.0<span></span>
</td>
<td class="nump">$ 64.0<span></span>
</td>
<td class="nump">64.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_AVONEXMember', window );">AVONEX | Developed technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">363.3<span></span>
</td>
<td class="nump">363.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_TysabriProductMember', window );">TYSABRI | Acquired and in-licensed rights and patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">2,493.2<span></span>
</td>
<td class="nump">2,493.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_SPINRAZAMember', window );">SPINRAZA | Acquired and in-licensed rights and patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract', window );"><strong>Intangible Assets and Goodwill (Additional Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease', window );">Net change in acquired and in-licensed rights and patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_BiosimilarsMember', window );">Biosimilars | Acquired and in-licensed rights and patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract', window );"><strong>Intangible Assets and Goodwill (Additional Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease', window );">Net change in acquired and in-licensed rights and patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_ZINBRYTAMember', window );">ZINBRYTA | Acquired and in-licensed rights and patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract', window );"><strong>Intangible Assets and Goodwill (Additional Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease', window );">Net change in acquired and in-licensed rights and patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_ALPROLIXMember', window );">ALPROLIX | Acquired and in-licensed rights and patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract', window );"><strong>Intangible Assets and Goodwill (Additional Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease', window );">Net change in acquired and in-licensed rights and patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MilestonePaymentsMadeDuringPeriod', window );">Milestone payment made during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Deferred tax liabilities</a></td>
<td class="nump">6.5<span></span>
</td>
<td class="nump">6.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ConvergencePharmaceuticalsMember', window );">Convergence Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 128.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract', window );"><strong>Intangible Assets and Goodwill (Additional Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 424.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MilestonePaymentsMadeDuringPeriod', window );">Milestone payment made during period</a></td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_FumapharmAgMember', window );">Fumapharm AG | TECFIDERA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Increase to goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200.0<span></span>
</td>
<td class="nump">$ 900.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis=biib_RodinTherapeuticsMember', window );">Rodin Therapeutics | In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract', window );"><strong>Intangible Assets and Goodwill (Additional Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of out-licensed patent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis=biib_AtaxionMember', window );">Ataxion | In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract', window );"><strong>Intangible Assets and Goodwill (Additional Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of out-licensed patent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_IndefiniteLivedIntangibleAssetsUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indefinite lived intangible assets useful life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_IndefiniteLivedIntangibleAssetsUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>us-types:durationStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intangible assets and goodwill additional.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_MilestonePaymentsMadeDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payments Made During Period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_MilestonePaymentsMadeDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=73530397&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=68052875&amp;loc=d3e28680-109314<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in carrying value of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=64834752&amp;loc=SL49117168-202975<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_AVONEXMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_AVONEXMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_TysabriProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_TysabriProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_SPINRAZAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_SPINRAZAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_BiosimilarsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_BiosimilarsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_ZINBRYTAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_ZINBRYTAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_ALPROLIXMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_ALPROLIXMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_ConvergencePharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_ConvergencePharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_FumapharmAgMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_FumapharmAgMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_TecfideraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_TecfideraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis=biib_RodinTherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis=biib_RodinTherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis=biib_AtaxionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis=biib_AtaxionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6889278512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">$ 1,237.3<span></span>
</td>
<td class="nump">$ 1,161.6<span></span>
</td>
<td class="nump">$ 989.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Accumulated impairment losses related to goodwill</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Summary of roll forward of the changes in goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, beginning of period</a></td>
<td class="nump">2,663.8<span></span>
</td>
<td class="nump">1,760.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Increase to goodwill</a></td>
<td class="nump">1,026.9<span></span>
</td>
<td class="nump">908.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Other goodwill adjustments</a></td>
<td class="num">(21.4)<span></span>
</td>
<td class="num">(4.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, end of period</a></td>
<td class="nump">3,669.3<span></span>
</td>
<td class="nump">2,663.8<span></span>
</td>
<td class="nump">$ 1,760.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_FumapharmAgMember', window );">Fumapharm AG | TECFIDERA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">173.1<span></span>
</td>
<td class="nump">120.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Summary of roll forward of the changes in goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Increase to goodwill</a></td>
<td class="nump">$ 1,200.0<span></span>
</td>
<td class="nump">$ 900.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=64834752&amp;loc=SL49117168-202975<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a,h)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillOtherIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillOtherIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Income Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_FumapharmAgMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_FumapharmAgMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_TecfideraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_TecfideraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6907176048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">$ 5,398.0<span></span>
</td>
<td class="nump">$ 4,880.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">2,039.6<span></span>
</td>
<td class="nump">909.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments</a></td>
<td class="nump">24.9<span></span>
</td>
<td class="nump">37.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">61.0<span></span>
</td>
<td class="nump">27.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">34.5<span></span>
</td>
<td class="nump">40.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">7,558.0<span></span>
</td>
<td class="nump">5,895.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">13.6<span></span>
</td>
<td class="nump">14.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">467.6<span></span>
</td>
<td class="nump">506.0<span></span>
</td>
<td class="nump">$ 215.5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">481.2<span></span>
</td>
<td class="nump">520.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">2,663.8<span></span>
</td>
<td class="nump">1,510.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">2,172.5<span></span>
</td>
<td class="nump">2,875.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">561.7<span></span>
</td>
<td class="nump">494.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments</a></td>
<td class="nump">24.9<span></span>
</td>
<td class="nump">37.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">24.9<span></span>
</td>
<td class="nump">37.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring | Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">2,039.6<span></span>
</td>
<td class="nump">909.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">61.0<span></span>
</td>
<td class="nump">27.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">34.5<span></span>
</td>
<td class="nump">40.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">7,533.1<span></span>
</td>
<td class="nump">5,857.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">13.6<span></span>
</td>
<td class="nump">14.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">13.6<span></span>
</td>
<td class="nump">14.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">2,663.8<span></span>
</td>
<td class="nump">1,510.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">2,172.5<span></span>
</td>
<td class="nump">2,875.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">561.7<span></span>
</td>
<td class="nump">494.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">467.6<span></span>
</td>
<td class="nump">506.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">467.6<span></span>
</td>
<td class="nump">506.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair values as of the balance sheet date of all assets of deferred compensation plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PlanAssetsForDeferredCompensationFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65884222&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27232-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66010992&amp;loc=d3e26610-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyContractAssetFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Trading Securities<br> -URI http://asc.fasb.org/extlink&amp;oid=6526789<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=27723805&amp;loc=d3e24584-111560<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884222&amp;loc=d3e22054-111558<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Available-for-Sale Securities<br> -URI http://asc.fasb.org/extlink&amp;oid=6505594<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6888689296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfFairAndCarryingValueOfDebtInstrumentsAbstract', window );"><strong>Summary of fair and carrying value of debt instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Total fair value</a></td>
<td class="nump">$ 6,808.4<span></span>
</td>
<td class="nump">$ 6,645.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_NotesPayableToFumedicaMember', window );">Notes Payable to Fumedica</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfFairAndCarryingValueOfDebtInstrumentsAbstract', window );"><strong>Summary of fair and carrying value of debt instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">6.1<span></span>
</td>
<td class="nump">9.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember', window );">6.875% Senior Notes due 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfFairAndCarryingValueOfDebtInstrumentsAbstract', window );"><strong>Summary of fair and carrying value of debt instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">583.7<span></span>
</td>
<td class="nump">602.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember', window );">2.90% Senior Notes due 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfFairAndCarryingValueOfDebtInstrumentsAbstract', window );"><strong>Summary of fair and carrying value of debt instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">1,521.5<span></span>
</td>
<td class="nump">1,497.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember', window );">3.625% Senior Notes due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfFairAndCarryingValueOfDebtInstrumentsAbstract', window );"><strong>Summary of fair and carrying value of debt instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">1,026.6<span></span>
</td>
<td class="nump">1,014.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember', window );">4.05% Senior Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfFairAndCarryingValueOfDebtInstrumentsAbstract', window );"><strong>Summary of fair and carrying value of debt instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">1,796.0<span></span>
</td>
<td class="nump">1,764.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember', window );">5.20% Senior Notes due 2045</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfFairAndCarryingValueOfDebtInstrumentsAbstract', window );"><strong>Summary of fair and carrying value of debt instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">$ 1,874.5<span></span>
</td>
<td class="nump">$ 1,757.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryOfFairAndCarryingValueOfDebtInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of fair and carrying value of debt instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryOfFairAndCarryingValueOfDebtInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13433-108611<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13476-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20,22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_NotesPayableToFumedicaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_NotesPayableToFumedicaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6826497120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Additions</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 274.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Loss (gain) on fair value remeasurement of contingent consideration</a></td>
<td class="nump">14.8<span></span>
</td>
<td class="nump">30.5<span></span>
</td>
<td class="num">$ (38.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Payments</a></td>
<td class="num">(53.2)<span></span>
</td>
<td class="num">(14.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value, beginning of period</a></td>
<td class="nump">506.0<span></span>
</td>
<td class="nump">215.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value, end of period</a></td>
<td class="nump">$ 467.6<span></span>
</td>
<td class="nump">$ 506.0<span></span>
</td>
<td class="nump">$ 215.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionContingentConsiderationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized on the income statement for financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6906452096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2015</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2012</div></th>
<th class="th"><div>Dec. 31, 2010</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Feb. 12, 2015</div></th>
<th class="th"><div>Mar. 04, 2008</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementsChangesInValuationTechniques', window );">Fair value measurements, changes in valuation techniques</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">0<span></span>
</td>
<td class="text">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 274.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential future milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Maximum contingent consideration in the form of development and approval milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ConvergencePharmaceuticalsMember', window );">Convergence Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilities', window );">Milestone converted to short-term obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Additions</a></td>
<td class="nump">$ 274.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential future milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 450.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">258.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">258.9<span></span>
</td>
<td class="nump">297.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Maximum contingent consideration in the form of development and approval milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsDiscountRate', window );">Discount rate used for net cash outflow projections for fair value measurement</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MilestonePaymentsMadeDuringPeriod', window );">Milestone payments made during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 424.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_StromedixMember', window );">Stromedix, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 122.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">133.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 133.2<span></span>
</td>
<td class="nump">131.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Maximum contingent consideration in the form of development and approval milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">419.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 419.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsDiscountRate', window );">Discount rate used for net cash outflow projections for fair value measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_BiogenIdecInternationalNeuroscienceMember', window );">Biogen Idec International Neuroscience GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75.5<span></span>
</td>
<td class="nump">$ 77.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Maximum contingent consideration in the form of development and approval milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 361.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 361.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsDiscountRate', window );">Discount rate used for net cash outflow projections for fair value measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MilestonePaymentsMadeDuringPeriod', window );">Milestone payments made during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember', window );">6.875% Senior Notes due 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.875%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember', window );">2.90% Senior Notes due 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember', window );">3.625% Senior Notes due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember', window );">4.05% Senior Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.05%<span></span>
</td>
<td class="nump">4.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember', window );">5.20% Senior Notes due 2045</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 246.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 246.8<span></span>
</td>
<td class="nump">$ 301.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=us-gaap_AccruedLiabilitiesMember', window );">Accrued expenses and other | Convergence Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">148.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">148.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=us-gaap_AccruedLiabilitiesMember', window );">Accrued expenses and other | Stromedix, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=us-gaap_AccruedLiabilitiesMember', window );">Accrued expenses and other | Biogen Idec International Neuroscience GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_MilestonePaymentsMadeDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payments Made During Period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_MilestonePaymentsMadeDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential future milestone payments commitment to third party approximately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionContingentConsiderationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=73530397&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueInputsDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest rate used to find the present value of an amount to be paid or received in the future as an input to measure fair value.  For example, but not limited to, weighted average cost of capital (WACC), cost of capital, cost of equity and cost of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueInputsDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementsChangesInValuationTechniques">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the changes in valuation technique(s) and related inputs used to measure fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementsChangesInValuationTechniques</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_ConvergencePharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_ConvergencePharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_StromedixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_StromedixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_BiogenIdecInternationalNeuroscienceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_BiogenIdecInternationalNeuroscienceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=us-gaap_AccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=us-gaap_AccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6907914112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 2,039.6<span></span>
</td>
<td class="nump">$ 909.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">31.0<span></span>
</td>
<td class="nump">21.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_RepurchaseAgreementsMember', window );">Overnight Reverse Repurchase Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">134.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">741.7<span></span>
</td>
<td class="nump">673.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember', window );">Short-term Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 1,266.9<span></span>
</td>
<td class="nump">$ 79.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_RepurchaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_RepurchaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6907169504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable Debt and Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">$ 5,398.0<span></span>
</td>
<td class="nump">$ 4,880.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">2.9<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(11.2)<span></span>
</td>
<td class="num">(10.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">5,406.3<span></span>
</td>
<td class="nump">4,891.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_CorporateDebtSecuritiesCurrentMember', window );">Corporate debt securities Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable Debt and Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">1,408.6<span></span>
</td>
<td class="nump">394.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(0.6)<span></span>
</td>
<td class="num">(0.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">1,409.0<span></span>
</td>
<td class="nump">394.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_CorporateDebtSecuritiesNonCurrentMember', window );">Corporate debt securities Non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable Debt and Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">1,255.2<span></span>
</td>
<td class="nump">1,116.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">1.2<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(4.7)<span></span>
</td>
<td class="num">(4.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">1,258.7<span></span>
</td>
<td class="nump">1,120.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_GovernmentSecuritiesCurrentMember', window );">Government securities Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable Debt and Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">1,156.0<span></span>
</td>
<td class="nump">1,723.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(0.3)<span></span>
</td>
<td class="num">(1.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">1,156.1<span></span>
</td>
<td class="nump">1,724.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_GovernmentSecuritiesNonCurrentMember', window );">Government securities Non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable Debt and Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">1,016.5<span></span>
</td>
<td class="nump">1,152.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(3.4)<span></span>
</td>
<td class="num">(3.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">1,019.4<span></span>
</td>
<td class="nump">1,155.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember', window );">Mortgage and other asset backed securities Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable Debt and Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">4.0<span></span>
</td>
<td class="nump">2.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">4.0<span></span>
</td>
<td class="nump">2.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember', window );">Mortgage and other asset backed securities Non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable Debt and Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">557.7<span></span>
</td>
<td class="nump">491.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(2.2)<span></span>
</td>
<td class="num">(1.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">559.1<span></span>
</td>
<td class="nump">493.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_MarketableEquitySecuritiesMember', window );">Marketable equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable Debt and Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">24.9<span></span>
</td>
<td class="nump">37.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">9.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(9.3)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">$ 33.5<span></span>
</td>
<td class="nump">$ 28.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65884222&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27232-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66010992&amp;loc=d3e26610-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_CorporateDebtSecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_CorporateDebtSecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_CorporateDebtSecuritiesNonCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_CorporateDebtSecuritiesNonCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_GovernmentSecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_GovernmentSecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_GovernmentSecuritiesNonCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_GovernmentSecuritiesNonCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_MarketableEquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_MarketableEquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6824383520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract', window );"><strong>Summary of Contractual Maturities: Available-for-Sale Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Due in one year or less, Estimated Fair Value</a></td>
<td class="nump">$ 2,568.6<span></span>
</td>
<td class="nump">$ 2,120.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Due in one year or less, Amortized Cost</a></td>
<td class="nump">2,569.1<span></span>
</td>
<td class="nump">2,122.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Due after one year through five years, Estimated Fair Value</a></td>
<td class="nump">2,552.6<span></span>
</td>
<td class="nump">2,575.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost', window );">Due after one year through five years, Amortized Cost</a></td>
<td class="nump">2,559.7<span></span>
</td>
<td class="nump">2,583.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue', window );">Due after five years, Estimated Fair Value</a></td>
<td class="nump">276.8<span></span>
</td>
<td class="nump">184.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost', window );">Due after five years, Amortized Cost</a></td>
<td class="nump">277.5<span></span>
</td>
<td class="nump">185.3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Total available-for-sale securities, Fair Value</a></td>
<td class="nump">5,398.0<span></span>
</td>
<td class="nump">4,880.9<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Total available-for-sale securities, Amortized Cost</a></td>
<td class="nump">$ 5,406.3<span></span>
</td>
<td class="nump">$ 4,891.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents debt securities, at cost, net of adjustments made for accretion, amortization, other-than-temporary impairments, and hedging, if any, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the fair value of debt securities, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the cost of debt securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65884222&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27232-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66010992&amp;loc=d3e26610-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after adjustments of available-for-sale debt securities at cost, maturing in the second fiscal year through the fifth fiscal year following the latest fiscal year. Adjustments include, but are not limited to, accretion, amortization, collection of cash, previous other-than-temporary impairments (OTTI) recognized in earnings less cumulative-effect adjustments, and fair value hedge accounting adjustments. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of available-for-sale debt securities maturing in the second fiscal year through the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6957658&amp;loc=d3e62586-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27161-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after adjustments of available-for-sale debt securities at cost, maturing in the next fiscal year following the latest fiscal year. Adjustments include, but are not limited to, accretion, amortization, collection of cash, previous other-than-temporary impairments (OTTI) recognized in earnings less cumulative-effect adjustments, and fair value hedge accounting adjustments. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27198-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of available-for-sale debt securities maturing in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27198-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6957658&amp;loc=d3e62586-112803<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6824539568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Details 3) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ProceedsFromMarketableDebtSecuritiesAbstract', window );"><strong>Proceeds from Marketable Debt Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from maturities and sales</a></td>
<td class="nump">$ 7,378.9<span></span>
</td>
<td class="nump">$ 4,063.0<span></span>
</td>
<td class="nump">$ 2,718.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains', window );">Realized gains</a></td>
<td class="nump">3.3<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses', window );">Realized losses</a></td>
<td class="num">$ (4.3)<span></span>
</td>
<td class="num">$ (3.5)<span></span>
</td>
<td class="num">$ (0.5)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ProceedsFromMarketableDebtSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from marketable debt securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ProceedsFromMarketableDebtSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the gross profit realized on the sale of debt or equity securities categorized neither as held-to-maturity nor trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesGrossRealizedGains</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the gross loss realized on the sale of debt or equity securities categorized neither as held-to-maturity nor trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale or maturity (principal being due) of securities not classified as either held-to-maturity securities or trading securities which are classified as available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3179-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=66010992&amp;loc=d3e26853-111562<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6598276016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Details Textual 1)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FinancialInstrumentsTextualAbstract', window );"><strong>Financial Instruments (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDateDescription', window );">Original maturities of commercial paper and short-term debt securities</a></td>
<td class="text">less than 90&#160;days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Overnightreverserepurchaseagreementspercentoftotalassets', window );">Overnight reverse repurchase agreements, percent of total assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.71%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AverageMaturityOfMarketableSecurities', window );">Average maturity of marketable securities, months</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">16 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AverageMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average remaining time to maturity of marketable debt securities, available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AverageMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FinancialInstrumentsTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial Instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FinancialInstrumentsTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Overnightreverserepurchaseagreementspercentoftotalassets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Overnight reverse repurchase agreements, percent of total assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Overnightreverserepurchaseagreementspercentoftotalassets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDateDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDateDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6824403600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Details Textual 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_StrategicInvestmentsMember', window );">Strategic Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_StrategicInvestmentPortfolio', window );">Strategic investment portfolio</a></td>
<td class="nump">$ 99.9<span></span>
</td>
<td class="nump">$ 96.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_StrategicInvestmentPortfolio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Strategic investment portfolio.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_StrategicInvestmentPortfolio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_StrategicInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_StrategicInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>133
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6906364576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Derivative Instruments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="nump">$ 871.7<span></span>
</td>
<td class="nump">$ 1,103.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="nump">902.1<span></span>
</td>
<td class="nump">721.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign Exchange Contract | Other current assets | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueNetAbstract', window );"><strong>Summary of derivatives designated as hedging instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Asset derivatives</a></td>
<td class="nump">50.4<span></span>
</td>
<td class="nump">16.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign Exchange Contract | Other current assets | Not Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueNetAbstract', window );"><strong>Summary of derivatives designated as hedging instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Asset derivatives</a></td>
<td class="nump">4.0<span></span>
</td>
<td class="nump">10.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign Exchange Contract | Investments and other assets | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueNetAbstract', window );"><strong>Summary of derivatives designated as hedging instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Asset derivatives</a></td>
<td class="nump">6.6<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign Exchange Contract | Accrued expenses and other | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueNetAbstract', window );"><strong>Summary of derivatives designated as hedging instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Liability derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign Exchange Contract | Accrued expenses and other | Not Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueNetAbstract', window );"><strong>Summary of derivatives designated as hedging instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Liability derivatives</a></td>
<td class="nump">9.0<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign Exchange Contract | Other long-term liabilities | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueNetAbstract', window );"><strong>Summary of derivatives designated as hedging instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Liability derivatives</a></td>
<td class="nump">4.6<span></span>
</td>
<td class="nump">2.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrencyAxis=currency_EUR', window );">Euro | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="nump">871.7<span></span>
</td>
<td class="nump">945.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrencyAxis=currency_CHF', window );">Swiss francs | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">80.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrencyAxis=currency_CAD', window );">Canadian dollar | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 76.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_invest_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate notional amount specified by the derivative(s). Expressed as an absolute value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 12<br> -Section 13<br> -Sentence Column B<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">invest_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>invest_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetFairValueNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetFairValueNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624163-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=51825145&amp;loc=SL20226000-175313<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=64830801&amp;loc=SL51823488-111719<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=64830801&amp;loc=SL51823488-111719<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624163-113959<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=51825145&amp;loc=SL20226000-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesFairValueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesFairValueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrencyAxis=currency_EUR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrencyAxis=currency_EUR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrencyAxis=currency_CHF">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrencyAxis=currency_CHF</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrencyAxis=currency_CAD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrencyAxis=currency_CAD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>134
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6905455472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments (Details 1) - Foreign Exchange Contract - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsrevenueMember', window );">Cash flows, revenue | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNetAbstract', window );"><strong>Summary of the effect of derivatives designated as hedging instruments on the consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet', window );">Amount Reclassified from Accumulated Other Comprehensive Income into Income Gain/(Loss) (Effective Portion)</a></td>
<td class="nump">$ 5.3<span></span>
</td>
<td class="nump">$ 173.2<span></span>
</td>
<td class="nump">$ 6.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsrevenueMember', window );">Cash flows, revenue | Other income (expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNetAbstract', window );"><strong>Summary of the effect of derivatives designated as hedging instruments on the consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet', window );">Net gains (losses) in earnings of foreign currency forward contracts due to hedge ineffectiveness</a></td>
<td class="nump">2.9<span></span>
</td>
<td class="nump">4.9<span></span>
</td>
<td class="num">(1.5)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsoperatingexpensesMember', window );">Cash flows, operating expenses | Other income (expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNetAbstract', window );"><strong>Summary of the effect of derivatives designated as hedging instruments on the consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet', window );">Net gains (losses) in earnings of foreign currency forward contracts due to hedge ineffectiveness</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsoperatingexpensesMember', window );">Cash flows, operating expenses | Operating Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNetAbstract', window );"><strong>Summary of the effect of derivatives designated as hedging instruments on the consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet', window );">Amount Reclassified from Accumulated Other Comprehensive Income into Income Gain/(Loss) (Effective Portion)</a></td>
<td class="num">$ (1.5)<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The effective portion of net gain (loss) reclassified from accumulated other comprehensive income into income on derivative instruments designated and qualifying as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624171-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624177-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of gains and losses (net) on derivative instruments designated and qualifying as hedging instruments representing (a) the amount of the hedge ineffectiveness and (b) the amount, if any, excluded from the assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624171-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 25<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1),(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6886632&amp;loc=d3e76258-113986<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsrevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsrevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsoperatingexpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsoperatingexpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>135
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6907999328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Gain on treasury rate lock settlement</a></td>
<td class="num">$ (92.5)<span></span>
</td>
<td class="nump">$ 6.5<span></span>
</td>
<td class="num">$ (19.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax', window );">Gain/Loss on fair value of foreign currency forward contracts</a></td>
<td class="num">$ (49.8)<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
<td class="num">(72.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1', window );">Expected settlement time for contracts, in months</a></td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments', window );">Net gains (losses) of other income (expense) related to foreign currency forward contracts</a></td>
<td class="nump">$ 29.2<span></span>
</td>
<td class="nump">23.8<span></span>
</td>
<td class="nump">$ 15.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="nump">871.7<span></span>
</td>
<td class="nump">1,103.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="nump">$ 902.1<span></span>
</td>
<td class="nump">721.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember', window );">Interest rate lock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Gain on treasury rate lock settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember', window );">Interest rate lock | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest rate swap | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 675.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember', window );">4.05% Senior Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on senior notes</a></td>
<td class="nump">4.05%<span></span>
</td>
<td class="nump">4.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember', window );">5.20% Senior Notes due 2045</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on senior notes</a></td>
<td class="nump">5.20%<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember', window );">2.90% Senior Notes due 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on senior notes</a></td>
<td class="nump">2.90%<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeRemainingMaturity1', window );">Derivative, Remaining Maturity</a></td>
<td class="text">1 month<span></span>
</td>
<td class="text">1 month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeRemainingMaturity1', window );">Derivative, Remaining Maturity</a></td>
<td class="text">18 months<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_invest_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate notional amount specified by the derivative(s). Expressed as an absolute value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 12<br> -Section 13<br> -Sentence Column B<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">invest_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>invest_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeRemainingMaturity1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period remaining until the derivative contract matures, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeRemainingMaturity1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesFairValueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesFairValueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624171-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount of time remaining before foreign currency exchange rate derivatives mature or expire, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=66004921&amp;loc=d3e1436-108581<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net unrealized gain (loss) related to the change in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments. Recorded in accumulated other comprehensive income to the extent that the cash flow hedge is determined to be effective.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>136
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6825700432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property, Plant and Equipment (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Land', window );">Land</a></td>
<td class="nump">$ 137.8<span></span>
</td>
<td class="nump">$ 74.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BuildingsAndImprovementsGross', window );">Buildings</a></td>
<td class="nump">1,107.8<span></span>
</td>
<td class="nump">1,035.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseholdImprovementsGross', window );">Leasehold improvements</a></td>
<td class="nump">123.7<span></span>
</td>
<td class="nump">166.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MachineryAndEquipmentGross', window );">Machinery and equipment</a></td>
<td class="nump">1,105.8<span></span>
</td>
<td class="nump">1,079.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ComputerSoftwareAndHardware', window );">Computer software and hardware</a></td>
<td class="nump">746.8<span></span>
</td>
<td class="nump">647.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FurnitureAndFixturesGross', window );">Furniture and fixtures</a></td>
<td class="nump">60.6<span></span>
</td>
<td class="nump">72.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
<td class="nump">658.6<span></span>
</td>
<td class="nump">441.2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total cost</a></td>
<td class="nump">3,941.1<span></span>
</td>
<td class="nump">3,517.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(1,439.3)<span></span>
</td>
<td class="num">(1,330.1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property, plant and equipment, net</a></td>
<td class="nump">$ 2,501.8<span></span>
</td>
<td class="nump">$ 2,187.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ComputerSoftwareAndHardware">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Computer software and hardware</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ComputerSoftwareAndHardware</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BuildingsAndImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BuildingsAndImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FurnitureAndFixturesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FurnitureAndFixturesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Land">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Land</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseholdImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6812-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseholdImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MachineryAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MachineryAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>137
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6890076112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 309.3<span></span>
</td>
<td class="nump">$ 217.9<span></span>
</td>
<td class="nump">$ 198.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestCostsCapitalized', window );">Interest cost capitalization related to construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.9<span></span>
</td>
<td class="nump">10.4<span></span>
</td>
<td class="nump">$ 6.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">658.6<span></span>
</td>
<td class="nump">441.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FacilityLocationAxis=biib_SolothurnMember', window );">Solothurn</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">481.5<span></span>
</td>
<td class="nump">99.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_EisaiMember', window );">Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAdditions', window );">Facility Purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 104.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract', window );">Term of original lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_TermOfLease', window );">Term of amended lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligations', window );">Capital lease obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.3<span></span>
</td>
<td class="nump">$ 18.1<span></span>
</td>
<td class="nump">$ 19.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building | Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAdditions', window );">Facility Purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and Equipment | Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAdditions', window );">Facility Purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Land | Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAdditions', window );">Facility Purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrencyAxis=currency_CHF', window );">Swiss francs | Land | Solothurn</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAdditions', window );">Facility Purchase</a></td>
<td class="nump">$ 64.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrencyAxis=currency_USD', window );">United States of America, Dollars | Land | Solothurn</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAdditions', window );">Facility Purchase</a></td>
<td class="nump">$ 62.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_TermOfLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term Of Lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_TermOfLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal through the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestCostsCapitalized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest capitalized during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Allowance for Funds Used during Construction<br> -URI http://asc.fasb.org/extlink&amp;oid=6504829<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestCostsCapitalized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of the lessee's leasing arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of acquisition of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FacilityLocationAxis=biib_SolothurnMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FacilityLocationAxis=biib_SolothurnMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_EisaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_EisaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrencyAxis=currency_CHF">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrencyAxis=currency_CHF</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrencyAxis=currency_USD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrencyAxis=currency_USD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>138
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6889626976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Indebtedness (Details)<br> SFr in Millions, $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2006 </div>
<div>CHF (SFr)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrentAbstract', window );"><strong>Current portion:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent', window );">Financing arrangement for the purchase of the RTP facility</a></td>
<td class="nump">$ 1.7<span></span>
</td>
<td class="nump">$ 1.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Current portion of notes payable and other financing arrangements</a></td>
<td class="nump">4.7<span></span>
</td>
<td class="nump">4.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-current portion:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Non-current notes payable</a></td>
<td class="nump">6,556.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Financing arrangement for the purchase of the RTP facility</a></td>
<td class="nump">16.4<span></span>
</td>
<td class="nump">18.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Non-current portion of notes payable and other financing arrangements</a></td>
<td class="nump">6,512.7<span></span>
</td>
<td class="nump">6,521.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Note payable to Fumedica</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrentAbstract', window );"><strong>Current portion:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Notes payable to Fumedica</a></td>
<td class="nump">3.0<span></span>
</td>
<td class="nump">3.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-current portion:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Non-current notes payable</a></td>
<td class="nump">3.0<span></span>
</td>
<td class="nump">5.9<span></span>
</td>
<td class="nump">SFr 61.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember', window );">6.875% Senior Notes due 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-current portion:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Non-current notes payable</a></td>
<td class="nump">558.5<span></span>
</td>
<td class="nump">565.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember', window );">2.90% Senior Notes due 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-current portion:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Non-current notes payable</a></td>
<td class="nump">1,485.3<span></span>
</td>
<td class="nump">1,485.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember', window );">3.625% Senior Notes due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-current portion:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Non-current notes payable</a></td>
<td class="nump">993.2<span></span>
</td>
<td class="nump">992.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember', window );">4.05% Senior Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-current portion:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Non-current notes payable</a></td>
<td class="nump">1,734.8<span></span>
</td>
<td class="nump">1,733.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember', window );">5.20% Senior Notes due 2045</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-current portion:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Non-current notes payable</a></td>
<td class="nump">$ 1,721.5<span></span>
</td>
<td class="nump">$ 1,721.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and capital lease obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and capital leases due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>139
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6824680112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Indebtedness (Details 1)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByMaturityAbstract', window );"><strong>Total debt maturities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2017</a></td>
<td class="nump">$ 3.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2018</a></td>
<td class="nump">553.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2019</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2020</a></td>
<td class="nump">1,500.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2021</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">2022 and thereafter</a></td>
<td class="nump">4,500.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Total</a></td>
<td class="nump">$ 6,556.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtByMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtByMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>140
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6906273888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Indebtedness (Details Textual)<br> SFr in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2008 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Sep. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 04, 2008 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2006 </div>
<div>CHF (SFr)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Costs associated with the Senior Notes offerings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemptions percentage of 2015 notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage', window );">Redemption percentage for change in control provision on the 2015 Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Notes payable and other financing arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,556,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Senior unsecured revolving credit facility maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityExpirationPeriod', window );">Term of credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding', window );">Amount outstanding under the credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember', window );">6.875% Senior Notes due 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount of senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 550,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageParValueOfSeniorNotes', window );">Redemption percentage par value of senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.184%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IncreasedCarryingAmountOfSeniorNotes', window );">Increased carrying amount of interest rate swap</a></td>
<td class="nump">$ 62,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DebtInstrumentUnamortizedInterestOnDebt', window );">Interest to be amortized on debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Note payable to Fumedica</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Notes payable and other financing arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="nump">$ 5,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 61.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ParValueOfNotesPayable', window );">Par value of notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000<span></span>
</td>
<td class="nump">9,000,000<span></span>
</td>
<td class="nump">SFr 6.2<span></span>
</td>
<td class="nump">SFr 8.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember', window );">6.875% Senior Notes due 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Notes payable and other financing arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 558,500,000<span></span>
</td>
<td class="nump">565,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember', window );">2.90% Senior Notes due 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount of senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageParValueOfSeniorNotes', window );">Redemption percentage par value of senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.792%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.792%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Notes payable and other financing arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,485,300,000<span></span>
</td>
<td class="nump">$ 1,485,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember', window );">3.625% Senior Notes due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount of senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageParValueOfSeniorNotes', window );">Redemption percentage par value of senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.92%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.92%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Notes payable and other financing arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 993,200,000<span></span>
</td>
<td class="nump">$ 992,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember', window );">4.05% Senior Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount of senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.05%<span></span>
</td>
<td class="nump">4.05%<span></span>
</td>
<td class="nump">4.05%<span></span>
</td>
<td class="nump">4.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageParValueOfSeniorNotes', window );">Redemption percentage par value of senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.764%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.764%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Notes payable and other financing arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,734,800,000<span></span>
</td>
<td class="nump">$ 1,733,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember', window );">5.20% Senior Notes due 2045</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount of senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageParValueOfSeniorNotes', window );">Redemption percentage par value of senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.294%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.294%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Notes payable and other financing arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,721,500,000<span></span>
</td>
<td class="nump">$ 1,721,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest rate swap | 2.90% Senior Notes due 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Fair value of the interest rate swaps</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_EisaiMember', window );">Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligations', window );">Capital lease obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,100,000<span></span>
</td>
<td class="nump">$ 19,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Make Whole Provision Redemption Price, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DebtInstrumentUnamortizedInterestOnDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument unamortized interest on debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DebtInstrumentUnamortizedInterestOnDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_IncreasedCarryingAmountOfSeniorNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increased carrying amount of senior notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_IncreasedCarryingAmountOfSeniorNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ParValueOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Par value of notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ParValueOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageParValueOfSeniorNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage Par Value Of Senior Notes</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageParValueOfSeniorNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal through the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64930739&amp;loc=d3e28878-108400<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28551-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -URI http://asc.fasb.org/extlink&amp;oid=6479336&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624163-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=51825145&amp;loc=SL20226000-175313<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=64830801&amp;loc=SL51823488-111719<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period remaining on line of credit facility before it terminates, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of the amount outstanding under the credit facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13433-108611<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13476-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3291-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_EisaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_EisaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>141
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6895469088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Equity (Details) - shares<br> shares in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Summary of common stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">1,000.0<span></span>
</td>
<td class="nump">1,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">238.5<span></span>
</td>
<td class="nump">241.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">215.9<span></span>
</td>
<td class="nump">218.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>142
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6825419088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Details Textual) - USD ($)<br> shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Mar. 31, 2011</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EquityTextualAbstract', window );"><strong>Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Authorized amount of share repurchases under the 2015 Share Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000.0<span></span>
</td>
<td class="nump">$ 5,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, shares</a></td>
<td class="nump">3,300<span></span>
</td>
<td class="nump">16,800<span></span>
</td>
<td class="nump">2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of common stock, value</a></td>
<td class="nump">$ 1,000.0<span></span>
</td>
<td class="nump">$ 5,000.0<span></span>
</td>
<td class="nump">$ 886.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased', window );">Common stock shares authorized for repurchase</a></td>
<td class="nump">1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">1,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=biib_SeriesXPreferredStockMember', window );">Series X junior participating</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=biib_UndesignatedPreferredStockMember', window );">Undesignated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EquityTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EquityTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3291-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=biib_SeriesXPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=biib_SeriesXPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=biib_UndesignatedPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=biib_UndesignatedPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>143
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6889354848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Loss) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="num">$ (224.0)<span></span>
</td>
<td class="num">$ (59.5)<span></span>
</td>
<td class="num">$ (27.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications</a></td>
<td class="num">(92.5)<span></span>
</td>
<td class="nump">6.5<span></span>
</td>
<td class="num">(19.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income (loss)</a></td>
<td class="num">(3.4)<span></span>
</td>
<td class="num">(171.0)<span></span>
</td>
<td class="num">(12.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Net current period other comprehensive income (loss)</a></td>
<td class="num">(95.9)<span></span>
</td>
<td class="num">(164.5)<span></span>
</td>
<td class="num">(31.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="num">(319.9)<span></span>
</td>
<td class="num">(224.0)<span></span>
</td>
<td class="num">(59.5)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Unrealized Gains (Losses) on Securities Available for Sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="num">(0.8)<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
<td class="nump">5.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications</a></td>
<td class="num">(10.6)<span></span>
</td>
<td class="num">(1.7)<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income (loss)</a></td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
<td class="num">(6.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Net current period other comprehensive income (loss)</a></td>
<td class="num">(10.0)<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
<td class="num">(6.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="num">(10.8)<span></span>
</td>
<td class="num">(0.8)<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember', window );">Unrealized Gains (Losses) on Cash Flow Hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="nump">10.2<span></span>
</td>
<td class="nump">71.7<span></span>
</td>
<td class="num">(23.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications</a></td>
<td class="nump">51.6<span></span>
</td>
<td class="nump">110.8<span></span>
</td>
<td class="nump">101.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income (loss)</a></td>
<td class="num">(4.0)<span></span>
</td>
<td class="num">(172.3)<span></span>
</td>
<td class="num">(6.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Net current period other comprehensive income (loss)</a></td>
<td class="nump">47.6<span></span>
</td>
<td class="num">(61.5)<span></span>
</td>
<td class="nump">95.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="nump">57.8<span></span>
</td>
<td class="nump">10.2<span></span>
</td>
<td class="nump">71.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember', window );">Unfunded Status of Postretirement Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="num">(37.8)<span></span>
</td>
<td class="num">(31.6)<span></span>
</td>
<td class="num">(19.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications</a></td>
<td class="nump">5.1<span></span>
</td>
<td class="num">(6.2)<span></span>
</td>
<td class="num">(12.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income (loss)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Net current period other comprehensive income (loss)</a></td>
<td class="nump">5.1<span></span>
</td>
<td class="num">(6.2)<span></span>
</td>
<td class="num">(12.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="num">(32.7)<span></span>
</td>
<td class="num">(37.8)<span></span>
</td>
<td class="num">(31.6)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Translation Adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="num">(195.6)<span></span>
</td>
<td class="num">(99.2)<span></span>
</td>
<td class="nump">10.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications</a></td>
<td class="num">(138.6)<span></span>
</td>
<td class="num">(96.4)<span></span>
</td>
<td class="num">(109.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income (loss)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Net current period other comprehensive income (loss)</a></td>
<td class="num">(138.6)<span></span>
</td>
<td class="num">(96.4)<span></span>
</td>
<td class="num">(109.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="num">$ (334.2)<span></span>
</td>
<td class="num">$ (195.6)<span></span>
</td>
<td class="num">$ (99.2)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e681-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=66004921&amp;loc=d3e1436-108581<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=SL4573702-111684<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4569616-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669686-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=66004921&amp;loc=d3e1436-108581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>144
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6890536976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Loss) (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (217.4)<span></span>
</td>
<td class="num">$ (123.7)<span></span>
</td>
<td class="num">$ (25.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,237.3<span></span>
</td>
<td class="nump">1,161.6<span></span>
</td>
<td class="nump">989.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="nump">$ 2,502.9<span></span>
</td>
<td class="nump">$ 2,539.6<span></span>
</td>
<td class="nump">$ 2,466.0<span></span>
</td>
<td class="nump">$ 2,309.4<span></span>
</td>
<td class="nump">$ 2,425.9<span></span>
</td>
<td class="nump">$ 2,391.7<span></span>
</td>
<td class="nump">$ 2,198.6<span></span>
</td>
<td class="nump">$ 2,172.3<span></span>
</td>
<td class="nump">9,817.9<span></span>
</td>
<td class="nump">9,188.5<span></span>
</td>
<td class="nump">8,203.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">$ 649.2<span></span>
</td>
<td class="nump">$ 1,032.9<span></span>
</td>
<td class="nump">$ 1,049.8<span></span>
</td>
<td class="nump">$ 970.9<span></span>
</td>
<td class="nump">$ 831.6<span></span>
</td>
<td class="nump">$ 965.6<span></span>
</td>
<td class="nump">$ 927.3<span></span>
</td>
<td class="nump">$ 822.5<span></span>
</td>
<td class="nump">3,702.8<span></span>
</td>
<td class="nump">3,547.0<span></span>
</td>
<td class="nump">2,934.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember', window );">Reclassification out of Accumulated Other Comprehensive Income [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.4<span></span>
</td>
<td class="nump">171.0<span></span>
</td>
<td class="nump">12.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Unrealized Gains (Losses) on Securities Available for Sale | Reclassification out of Accumulated Other Comprehensive Income [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.9)<span></span>
</td>
<td class="num">(2.0)<span></span>
</td>
<td class="nump">9.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="num">(3.5)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember', window );">Unrealized Gains (Losses) on Cash Flow Hedges | Reclassification out of Accumulated Other Comprehensive Income [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(0.8)<span></span>
</td>
<td class="num">(0.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.3<span></span>
</td>
<td class="nump">173.2<span></span>
</td>
<td class="nump">6.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1.5)<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Income Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>145
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6907212944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share (Details) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumeratorAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Idec Inc</a></td>
<td class="nump">$ 649.2<span></span>
</td>
<td class="nump">$ 1,032.9<span></span>
</td>
<td class="nump">$ 1,049.8<span></span>
</td>
<td class="nump">$ 970.9<span></span>
</td>
<td class="nump">$ 831.6<span></span>
</td>
<td class="nump">$ 965.6<span></span>
</td>
<td class="nump">$ 927.3<span></span>
</td>
<td class="nump">$ 822.5<span></span>
</td>
<td class="nump">$ 3,702.8<span></span>
</td>
<td class="nump">$ 3,547.0<span></span>
</td>
<td class="nump">$ 2,934.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DenominatorAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares outstanding</a></td>
<td class="nump">216.6<span></span>
</td>
<td class="nump">218.9<span></span>
</td>
<td class="nump">219.1<span></span>
</td>
<td class="nump">218.9<span></span>
</td>
<td class="nump">220.4<span></span>
</td>
<td class="nump">232.2<span></span>
</td>
<td class="nump">235.3<span></span>
</td>
<td class="nump">235.0<span></span>
</td>
<td class="nump">218.4<span></span>
</td>
<td class="nump">230.7<span></span>
</td>
<td class="nump">236.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Dilutive potential common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used in calculating diluted earnings per share</a></td>
<td class="nump">217.0<span></span>
</td>
<td class="nump">219.4<span></span>
</td>
<td class="nump">219.4<span></span>
</td>
<td class="nump">219.3<span></span>
</td>
<td class="nump">220.8<span></span>
</td>
<td class="nump">232.6<span></span>
</td>
<td class="nump">235.7<span></span>
</td>
<td class="nump">235.6<span></span>
</td>
<td class="nump">218.8<span></span>
</td>
<td class="nump">231.2<span></span>
</td>
<td class="nump">237.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EarningsPerShareTextualAbstract', window );"><strong>Earnings per share (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation', window );">Repurchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">4.6<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_StockOptionsAndEmployeeStockPurchasePlanMember', window );">Stock options and employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock options and employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_TimeVestedRestrictedStockUnitsMember', window );">Time-vested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock options and employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_MarketStockUnitsMember', window );">Market stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock options and employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DenominatorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Denominator.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DenominatorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EarningsPerShareTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EarningsPerShareTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NumeratorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Numerator.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NumeratorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DilutiveSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DilutiveSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1500-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock subject to repurchase or cancellation determined by relating the portion of time within a reporting period that these shares have been outstanding to the total time in that period. Common stock subject to repurchase are outstanding common shares that are contingently returnable (that is, subject to recall).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e2646-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Weighted-Average Number of Common Shares Outstanding<br> -URI http://asc.fasb.org/extlink&amp;oid=6528421<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_StockOptionsAndEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_StockOptionsAndEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_TimeVestedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_TimeVestedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_MarketStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_MarketStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>146
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6906431792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="num">$ (169.4)<span></span>
</td>
<td class="num">$ (183.2)<span></span>
</td>
<td class="num">$ (165.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Subtotal</a></td>
<td class="nump">204.4<span></span>
</td>
<td class="nump">207.3<span></span>
</td>
<td class="nump">252.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Capitalized share-based compensation costs</a></td>
<td class="num">(14.6)<span></span>
</td>
<td class="num">(11.0)<span></span>
</td>
<td class="num">(10.0)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses', window );">Share-based compensation expense included in total costs and expenses</a></td>
<td class="nump">189.8<span></span>
</td>
<td class="nump">196.3<span></span>
</td>
<td class="nump">242.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Income tax effect</a></td>
<td class="num">(54.0)<span></span>
</td>
<td class="num">(55.8)<span></span>
</td>
<td class="num">(72.2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="num">(84.5)<span></span>
</td>
<td class="num">(88.6)<span></span>
</td>
<td class="num">(102.1)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="num">(121.7)<span></span>
</td>
<td class="num">(127.3)<span></span>
</td>
<td class="num">(150.3)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="num">(1.8)<span></span>
</td>
<td class="nump">8.6<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ParentMember', window );">Total share-based compensation expense, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="num">$ (135.8)<span></span>
</td>
<td class="num">$ (140.5)<span></span>
</td>
<td class="num">$ (170.2)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation expense included in costs and expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense, net of income tax, recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the compensation cost capitalized during the period arising from equity-based compensation arrangements (for example, shares of stock, units, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total recognized tax benefit related to compensation cost for equity-based payment arrangements recognized in income during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>147
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6889350528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 169.4<span></span>
</td>
<td class="nump">$ 183.2<span></span>
</td>
<td class="nump">$ 165.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Subtotal</a></td>
<td class="nump">204.4<span></span>
</td>
<td class="nump">207.3<span></span>
</td>
<td class="nump">252.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Capitalized share-based compensation costs</a></td>
<td class="num">(14.6)<span></span>
</td>
<td class="num">(11.0)<span></span>
</td>
<td class="num">(10.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses', window );">Share-based compensation expense included in total costs and expenses</a></td>
<td class="nump">189.8<span></span>
</td>
<td class="nump">196.3<span></span>
</td>
<td class="nump">242.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=biib_MarketStockUnitsMember', window );">Market stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">38.4<span></span>
</td>
<td class="nump">38.1<span></span>
</td>
<td class="nump">37.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=biib_TimeVestedRestrictedStockUnitsMember', window );">Time-vested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">120.0<span></span>
</td>
<td class="nump">119.0<span></span>
</td>
<td class="nump">115.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=biib_CashSettledPerformanceSharesMember', window );">Cash settled performance units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">16.3<span></span>
</td>
<td class="nump">22.4<span></span>
</td>
<td class="nump">65.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=biib_PerformanceUnitsMember', window );">Performance Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">18.6<span></span>
</td>
<td class="nump">13.9<span></span>
</td>
<td class="nump">21.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=biib_EmployeeStockPurchasePlanMember', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 11.1<span></span>
</td>
<td class="nump">$ 13.9<span></span>
</td>
<td class="nump">$ 12.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation expense included in costs and expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of share-based compensation expense associated with different programs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense, net of income tax, recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the compensation cost capitalized during the period arising from equity-based compensation arrangements (for example, shares of stock, units, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=biib_MarketStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=biib_MarketStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=biib_TimeVestedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=biib_TimeVestedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=biib_CashSettledPerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=biib_CashSettledPerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=biib_PerformanceUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=biib_PerformanceUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=biib_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=biib_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>148
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6826861456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details 2)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2016 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_StockOptionActivityAbstract', window );"><strong>Stock Option Activity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning Balance, Outstanding shares | shares</a></td>
<td class="nump">107,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning Balance, Weighted Average Exercise Price | $ / shares</a></td>
<td class="nump">$ 53.94<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Shares, Granted | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted | $ / shares</a></td>
<td class="nump">$ 0.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares, Exercised | shares</a></td>
<td class="num">(41,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised | $ / shares</a></td>
<td class="nump">$ 53.75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Shares, Cancelled | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Cancelled | $ / shares</a></td>
<td class="nump">$ 0.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending Balance, Outstanding shares | shares</a></td>
<td class="nump">66,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending Balance, Weighted Average Exercise Price | $ / shares</a></td>
<td class="nump">$ 54.06<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_StockOptionActivityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock option activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_StockOptionActivityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>149
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6905218304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details 3) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_TaxBenefitAndCashReceivedFromStockOptionAbstract', window );"><strong>Tax benefit and cash received from stock option</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions', window );">Tax benefit realized for stock options</a></td>
<td class="nump">$ 4.0<span></span>
</td>
<td class="nump">$ 11.9<span></span>
</td>
<td class="nump">$ 13.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions', window );">Cash received from the exercise of stock options</a></td>
<td class="nump">$ 2.2<span></span>
</td>
<td class="nump">$ 6.3<span></span>
</td>
<td class="nump">$ 8.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_TaxBenefitAndCashReceivedFromStockOptionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax benefit and cash received from stock option.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_TaxBenefitAndCashReceivedFromStockOptionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate proceeds received by the entity during the annual period from exercises of stock or unit options and conversion of similar instruments granted under equity-based payment arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the aggregate tax benefit realized from the exercise of stock options and the conversion of similar instruments during the annual period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>150
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6821578208">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details 4) - Market stock units - $ / shares<br></strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MarketStockUnitsActivityAbstract', window );"><strong>Market stock units activity</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning Balance, Unvested, Shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">269,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning Balance, Weighted Average Grant Date Fair Value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 339.89<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Shares, Granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">168,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 328.03<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 493.43<span></span>
</td>
<td class="nump">$ 395.22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Shares, Vested</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(155,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Vested</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 244.68<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Shares, Forfeited</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(52,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Forfeited</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 371.62<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending Balance, Unvested, Shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">230,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">269,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending Balance, Weighted Average Grant Date Fair Value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 355.60<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 339.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">MSUs granted in 2016 include approximately 15,000 and 20,000 MSUs issued in 2016 based upon the attainment of performance criteria set for 2013 and 2012, respectively, in relation to awards granted in those years. The remainder of MSUs granted during 2016 include awards granted in conjunction with our annual awards made in February 2016 and MSUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_MarketStockUnitsActivityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Market stock units activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_MarketStockUnitsActivityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>151
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6906172928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details 5) - Market stock units - USD ($)<br></strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ValuationOfGrantedStockUnitsAbstract', window );"><strong>Assumptions used in valuation of market based stock units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Minimum range of risk-free interest rates</a></td>
<td class="nump">0.60%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0.20%<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Maximum range of risk-free interest rates</a></td>
<td class="nump">0.90%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AverageStockPriceOnGrantDateInDollarsMinimum', window );">Average stock price on grant date minimum</a></td>
<td class="nump">$ 260.67<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 227.35<span></span>
</td>
<td class="nump">$ 280.88<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AverageStockPriceOnGrantDateInDollarsMaximum', window );">Average stock price on grant date maximum</a></td>
<td class="nump">$ 304.86<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 426.27<span></span>
</td>
<td class="nump">$ 335.65<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value</a></td>
<td class="nump">$ 328.03<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 493.43<span></span>
</td>
<td class="nump">$ 395.22<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ValuationOfGrantedStockUnitsAbstract', window );"><strong>Assumptions used in valuation of market based stock units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Range of expected stock price volatility</a></td>
<td class="nump">38.20%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">31.00%<span></span>
</td>
<td class="nump">31.70%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ValuationOfGrantedStockUnitsAbstract', window );"><strong>Assumptions used in valuation of market based stock units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Range of expected stock price volatility</a></td>
<td class="nump">40.70%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">33.20%<span></span>
</td>
<td class="nump">35.10%<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">MSUs granted in 2016 include approximately 15,000 and 20,000 MSUs issued in 2016 based upon the attainment of performance criteria set for 2013 and 2012, respectively, in relation to awards granted in those years. The remainder of MSUs granted during 2016 include awards granted in conjunction with our annual awards made in February 2016 and MSUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AverageStockPriceOnGrantDateInDollarsMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average stock price on grant date in dollars maximum.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AverageStockPriceOnGrantDateInDollarsMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AverageStockPriceOnGrantDateInDollarsMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average stock price on grant date in dollars minimum.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AverageStockPriceOnGrantDateInDollarsMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ValuationOfGrantedStockUnitsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Valuation of granted stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ValuationOfGrantedStockUnitsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>152
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6824631104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details 6) - Cash settled performance units<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr><th class="th" colspan="2">
<div>Dec. 31, 2016 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CashSettledPerformanceSharesAbstract', window );"><strong>Cash settled performance shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning Balance, Unvested, Shares</a></td>
<td class="nump">192,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Shares, Granted</a></td>
<td class="nump">86,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Shares, Vested</a></td>
<td class="num">(117,000,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Shares, Forfeited</a></td>
<td class="num">(39,000,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending Balance, Unvested, Shares</a></td>
<td class="nump">122,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">CSPUs granted in 2016 include awards granted in conjunction with our annual awards made in February 2016 and CSPUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CashSettledPerformanceSharesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash settled performance shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CashSettledPerformanceSharesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_CashSettledPerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_CashSettledPerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>153
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6717837616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Payments Share-Based Payments (Details 7) - Performance units<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr><th class="th" colspan="2">
<div>Dec. 31, 2016 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning Balance, Unvested, Shares</a></td>
<td class="nump">103,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Shares, Granted</a></td>
<td class="nump">55,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Shares, Vested</a></td>
<td class="num">(31,000,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Shares, Forfeited</a></td>
<td class="num">(17,000,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending Balance, Unvested, Shares</a></td>
<td class="nump">110,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">CSPUs granted in 2016 include awards granted in conjunction with our annual awards made in February 2016 and CSPUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>154
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6890598640">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details 8) - Time-vested restricted stock units - $ / shares<br></strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RestrictedStockUnitsActivityAbstract', window );"><strong>Time-vested restricted stock units</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning Balance, Unvested, Shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">810,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning Balance, Weighted Average Grant Date Fair Value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 323.87<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Shares, Granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">649,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 268.52<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 388.88<span></span>
</td>
<td class="nump">$ 321.72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Shares, Vested</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(406,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Vested</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 285.13<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Shares, Forfeited</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(165,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Forfeited</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 310.30<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending Balance, Unvested, Shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">888,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">810,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending Balance, Weighted Average Grant Date Fair Value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 303.49<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 323.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">RSUs granted in 2016 primarily represent RSUs granted in conjunction with our annual awards made in February 2016 and awards made in conjunction with the hiring of new employees. RSUs granted in 2016 also include approximately 11,000 RSUs granted to our Board of Directors.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RestrictedStockUnitsActivityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restricted stock units activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RestrictedStockUnitsActivityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_TimeVestedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_TimeVestedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>155
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6821465216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details 9) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems', window );"><strong>Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares issued under ESPP</a></td>
<td class="nump">6,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=biib_A2015ESPPMember', window );">2015 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems', window );"><strong>Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares issued under ESPP</a></td>
<td class="nump">190,000<span></span>
</td>
<td class="nump">78,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Cash received under ESPP</a></td>
<td class="nump">$ 41.5<span></span>
</td>
<td class="nump">$ 19.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=biib_A1995ESPPMember', window );">1995 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems', window );"><strong>Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares issued under ESPP</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">98,000<span></span>
</td>
<td class="nump">180,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Cash received under ESPP</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 30.0<span></span>
</td>
<td class="nump">$ 46.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=biib_A2015ESPPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=biib_A2015ESPPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=biib_A1995ESPPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=biib_A1995ESPPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>156
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6889566592">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details Textual)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2">
<div>Dec. 31, 2016 </div>
<div>USD ($) </div>
<div>Plan </div>
<div>Increment </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2013 </div>
<div>Increment</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares issued under ESPP</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,200,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ShareBasedPaymentsTextualAbstract', window );"><strong>Share-Based Payments (Textual)</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_WindfallTaxBenefitsFromVestingOfStockAwardsExercisesOfStockOptionsAndEsppParticipation', window );">Windfall tax benefits from vesting of stock awards, exercises of stock options and ESPP participation | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 12.6<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 78.2<span></span>
</td>
<td class="nump">$ 96.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost related to unvested share-based compensation | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 189.8<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards', window );">Weighted-average period to recognize the cost of unvested awards</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">1 year 11 months<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade', window );">Number of share-based compensation plans pursuant to which awards are currently being made | Plan</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares granted under stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Total intrinsic value of options exercised | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 10.4<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 38.0<span></span>
</td>
<td class="nump">$ 42.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic values of options outstanding | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 15.0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual term for options outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">2 years<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember', window );">Market stock units</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumberOfEqualAnnualIncrements', window );">Number of equal annual increments | Increment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent', window );">Percentage of earnings of the target number of units granted based on actual stock performance (Minimum)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent', window );">Percentage of earnings of the target number of units granted based on actual stock performance (Maximum)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">200.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">168,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice', window );">Number of days for calculation of average closing stock price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">30 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Total fair value of vested awards | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 39.3<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 109.0<span></span>
</td>
<td class="nump">$ 117.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 328.03<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 493.43<span></span>
</td>
<td class="nump">$ 395.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_CashSettledPerformanceSharesMember', window );">Cash settled performance units</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumberOfEqualAnnualIncrements', window );">Number of equal annual increments | Increment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent', window );">Percentage of earnings of the target number of units granted based on actual stock performance (Minimum)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent', window );">Percentage of earnings of the target number of units granted based on actual stock performance (Maximum)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">200.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">86,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice', window );">Number of days for calculation of average closing stock price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">30 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards', window );">Cash in settlement of CSPS awards upon vesting | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 31.9<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 79.8<span></span>
</td>
<td class="nump">$ 92.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance units</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumberOfEqualAnnualIncrements', window );">Number of equal annual increments | Increment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent', window );">Percentage of earnings of the target number of units granted based on actual stock performance (Minimum)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent', window );">Percentage of earnings of the target number of units granted based on actual stock performance (Maximum)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">200.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">55,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EmployeeServiceSharebasedCompensationSharesUsedtoSettleAwards', window );">PUs converted to share settlements</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">32,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice', window );">Number of days for calculation of average closing stock price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">30 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards', window );">Cash in settlement of CSPS awards upon vesting | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 8.1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 12.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_TimeVestedRestrictedStockUnitsMember', window );">Time-vested restricted stock units</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">649,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Total fair value of vested awards | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 104.6<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 239.7<span></span>
</td>
<td class="nump">$ 281.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 268.52<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">$ 388.88<span></span>
</td>
<td class="nump">$ 321.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ShareBasedCompensationPlanAxis=biib_DirectorsPlanMember', window );">Directors Plan</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumberOfSharesOfCommonStockForIssuance', window );">Total number of shares of common stock for issuance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,600,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RatioOfNumberOfSharesReservedUnderPlan', window );">Ratio of total number of shares reserved under the plan</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">1.5-to-1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ShareBasedCompensationPlanAxis=biib_OmnibusPlansMember', window );">Omnibus Plans</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumberOfSharesOfCommonStockForIssuance', window );">Total number of shares of common stock for issuance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">15,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RatioOfNumberOfSharesReservedUnderPlan', window );">Ratio of total number of shares reserved under the plan</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">1.5-to-1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ShareBasedCompensationPlanAxis=biib_AttainmentOfPerformanceCriteriain2013Member', window );">Attainment Of Performance Criteria in 2013 | Market stock units</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">15,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ShareBasedCompensationPlanAxis=biib_AttainmentOfPerformanceCriteriain2012Member', window );">Attainment Of Performance Criteria in 2012 | Market stock units</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">20,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=us-gaap_DirectorMember', window );">Director | Time-vested restricted stock units</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">11,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember', window );">Settlement of PUs | Performance units</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EmployeeServiceSharebasedCompensationSharesUsedtoSettleAwards', window );">PUs converted to share settlements</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">11,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">MSUs granted in 2016 include approximately 15,000 and 20,000 MSUs issued in 2016 based upon the attainment of performance criteria set for 2013 and 2012, respectively, in relation to awards granted in those years. The remainder of MSUs granted during 2016 include awards granted in conjunction with our annual awards made in February 2016 and MSUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">CSPUs granted in 2016 include awards granted in conjunction with our annual awards made in February 2016 and CSPUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">RSUs granted in 2016 primarily represent RSUs granted in conjunction with our annual awards made in February 2016 and awards made in conjunction with the hiring of new employees. RSUs granted in 2016 also include approximately 11,000 RSUs granted to our Board of Directors.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EmployeeServiceSharebasedCompensationSharesUsedtoSettleAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee Service Share-based Compensation, Shares Used to Settle Awards</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EmployeeServiceSharebasedCompensationSharesUsedtoSettleAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum target number of market stock units granted based on stock performance in percent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum target number of market stock units granted based on stock performance in percent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of days for calculation of average closing stock price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NumberOfDaysForCalculationOfAverageClosingStockPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NumberOfEqualAnnualIncrements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of equal annual increments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NumberOfEqualAnnualIncrements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share-based compensation plans pursuant to which awards are currently being made.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NumberOfSharesOfCommonStockForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares of common stock for issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NumberOfSharesOfCommonStockForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RatioOfNumberOfSharesReservedUnderPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio of total number of shares reserved under the plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RatioOfNumberOfSharesReservedUnderPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareBasedPaymentsTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareBasedPaymentsTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period to recognize the cost of nonvested awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_WindfallTaxBenefitsFromVestingOfStockAwardsExercisesOfStockOptionsAndEsppParticipation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Windfall tax benefits from vesting of stock awards, exercises of stock options and ESPP participation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_WindfallTaxBenefitsFromVestingOfStockAwardsExercisesOfStockOptionsAndEsppParticipation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate cash paid by the entity during the period to settle equity instruments granted under equity-based payment arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (k)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_CashSettledPerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_CashSettledPerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_TimeVestedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_TimeVestedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareBasedCompensationPlanAxis=biib_DirectorsPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareBasedCompensationPlanAxis=biib_DirectorsPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareBasedCompensationPlanAxis=biib_OmnibusPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareBasedCompensationPlanAxis=biib_OmnibusPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareBasedCompensationPlanAxis=biib_AttainmentOfPerformanceCriteriain2013Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareBasedCompensationPlanAxis=biib_AttainmentOfPerformanceCriteriain2013Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareBasedCompensationPlanAxis=biib_AttainmentOfPerformanceCriteriain2012Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareBasedCompensationPlanAxis=biib_AttainmentOfPerformanceCriteriain2012Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=us-gaap_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=us-gaap_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>157
<FILENAME>R102.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6891857424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract', window );"><strong>Income before income taxes (benefit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic</a></td>
<td class="nump">$ 3,655.4<span></span>
</td>
<td class="nump">$ 3,386.7<span></span>
</td>
<td class="nump">$ 2,557.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="nump">1,277.6<span></span>
</td>
<td class="nump">1,380.6<span></span>
</td>
<td class="nump">1,389.2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before income tax expense and equity in loss of investee, net of tax</a></td>
<td class="nump">4,933.0<span></span>
</td>
<td class="nump">4,767.3<span></span>
</td>
<td class="nump">3,946.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">1,304.3<span></span>
</td>
<td class="nump">1,214.1<span></span>
</td>
<td class="nump">1,159.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">55.1<span></span>
</td>
<td class="nump">38.6<span></span>
</td>
<td class="nump">65.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">52.9<span></span>
</td>
<td class="nump">54.5<span></span>
</td>
<td class="nump">73.4<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total</a></td>
<td class="nump">1,412.3<span></span>
</td>
<td class="nump">1,307.2<span></span>
</td>
<td class="nump">1,298.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">(125.6)<span></span>
</td>
<td class="num">(129.6)<span></span>
</td>
<td class="num">(280.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="num">(3.8)<span></span>
</td>
<td class="num">(1.9)<span></span>
</td>
<td class="num">(21.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="num">(45.6)<span></span>
</td>
<td class="num">(14.1)<span></span>
</td>
<td class="num">(6.3)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total</a></td>
<td class="num">(175.0)<span></span>
</td>
<td class="num">(145.6)<span></span>
</td>
<td class="num">(308.2)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax expense</a></td>
<td class="nump">$ 1,237.3<span></span>
</td>
<td class="nump">$ 1,161.6<span></span>
</td>
<td class="nump">$ 989.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6509736<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6509736<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6509736<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Deferred Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=63044130<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Deferred Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=63044130<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Deferred Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=63044130<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Deferred Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=63044130<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Income Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>158
<FILENAME>R103.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6891445856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract', window );"><strong>Components of deferred tax assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credits</a></td>
<td class="nump">$ 201.1<span></span>
</td>
<td class="nump">$ 189.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInventory', window );">Inventory, other reserves, and accruals</a></td>
<td class="nump">250.6<span></span>
</td>
<td class="nump">243.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangibles, net</a></td>
<td class="nump">459.8<span></span>
</td>
<td class="nump">328.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss</a></td>
<td class="nump">65.9<span></span>
</td>
<td class="nump">24.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Share-based compensation</a></td>
<td class="nump">61.5<span></span>
</td>
<td class="nump">63.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">49.0<span></span>
</td>
<td class="nump">35.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(16.1)<span></span>
</td>
<td class="num">(14.1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets</a></td>
<td class="nump">1,071.8<span></span>
</td>
<td class="nump">871.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Purchased intangible assets</a></td>
<td class="num">(376.6)<span></span>
</td>
<td class="num">(440.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DeferredTaxLiabilitiesDepreciationAmortizationOther', window );">Depreciation, amortization and other</a></td>
<td class="num">(113.5)<span></span>
</td>
<td class="num">(102.7)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="nump">$ 490.1<span></span>
</td>
<td class="nump">$ 542.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DeferredTaxLiabilitiesDepreciationAmortizationOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities depreciation amortization other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DeferredTaxLiabilitiesDepreciationAmortizationOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=68052875&amp;loc=d3e28680-109314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32621-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=68052875&amp;loc=d3e28680-109314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32621-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32632-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=68052875&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Carryforwards<br> -URI http://asc.fasb.org/extlink&amp;oid=6506874<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=68052875&amp;loc=d3e28680-109314<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=68052875&amp;loc=d3e28680-109314<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>159
<FILENAME>R104.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6801726144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details 2)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Reconciliation between the U.S. federal statutory tax rate and effective tax rate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory rate</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes</a></td>
<td class="nump">0.90%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">1.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Taxes on foreign earnings</a></td>
<td class="num">(9.60%)<span></span>
</td>
<td class="num">(10.00%)<span></span>
</td>
<td class="num">(9.50%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Credits and net operating loss utilization</a></td>
<td class="num">(1.40%)<span></span>
</td>
<td class="num">(1.30%)<span></span>
</td>
<td class="num">(1.10%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization', window );">Purchased intangible assets</a></td>
<td class="nump">1.20%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction', window );">Manufacturing deduction</a></td>
<td class="num">(1.90%)<span></span>
</td>
<td class="num">(1.80%)<span></span>
</td>
<td class="num">(1.80%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther', window );">Permanent items</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EffectiveIncomeTaxRateReconciliationContingentConsideration', window );">Contingent consideration</a></td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
<td class="num">(0.40%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">25.10%<span></span>
</td>
<td class="nump">24.40%<span></span>
</td>
<td class="nump">25.10%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EffectiveIncomeTaxRateReconciliationContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EffectiveIncomeTaxRateReconciliationContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation manufacturing deduction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to depreciation and amortization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>160
<FILENAME>R105.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6826296672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details 3) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract', window );"><strong>Reconciliation of the beginning and ending of unrecognized tax benefits</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at January 1</a></td>
<td class="nump">$ 67.9<span></span>
</td>
<td class="nump">$ 131.5<span></span>
</td>
<td class="nump">$ 110.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions based on tax positions related to the current period</a></td>
<td class="nump">7.2<span></span>
</td>
<td class="nump">10.5<span></span>
</td>
<td class="nump">20.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Additions for tax positions of prior periods</a></td>
<td class="nump">36.3<span></span>
</td>
<td class="nump">19.5<span></span>
</td>
<td class="nump">86.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Reductions for tax positions of prior periods</a></td>
<td class="num">(13.3)<span></span>
</td>
<td class="num">(49.9)<span></span>
</td>
<td class="num">(23.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations', window );">Statute expirations</a></td>
<td class="num">(1.4)<span></span>
</td>
<td class="num">(1.2)<span></span>
</td>
<td class="num">(1.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities', window );">Settlements</a></td>
<td class="num">(64.3)<span></span>
</td>
<td class="num">(42.5)<span></span>
</td>
<td class="num">(60.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at December 31</a></td>
<td class="nump">$ 32.4<span></span>
</td>
<td class="nump">$ 67.9<span></span>
</td>
<td class="nump">$ 131.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=SL6600010-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Unrecognized Tax Benefit<br> -URI http://asc.fasb.org/extlink&amp;oid=6527854<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>161
<FILENAME>R106.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6909662032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Totaldeferredchargesandprepaidtaxes', window );">Total deferred charges and prepaid taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 989.8<span></span>
</td>
<td class="nump">$ 697.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions', window );">Net effect of adjustments to our uncertain tax positions</a></td>
<td class="nump">$ 27.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IncomeTaxesTextualAbstract', window );"><strong>Income Taxes (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UndistributedEarningsOfForeignSubsidiaries', window );">Undistributed Foreign Earnings Of Non Us Subsidiaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,600.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26.9<span></span>
</td>
<td class="nump">15.7<span></span>
</td>
<td class="nump">$ 53.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Net interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.1<span></span>
</td>
<td class="nump">3.1<span></span>
</td>
<td class="nump">$ 4.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued', window );">Unrecognized Tax Benefits, Interest on Income Taxes Accrued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.2<span></span>
</td>
<td class="nump">$ 12.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EstimatedTaxLiabilityOnUndistributedEarningsOfForeignSubsidiaries', window );">Estimated Tax Liability On Undistributed Earnings Of Foreign Subsidiaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EstimatedTaxLiabilityOnUndistributedEarningsOfForeignSubsidiaries', window );">Estimated Tax Liability On Undistributed Earnings Of Foreign Subsidiaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued', window );">Notice of assessment of corporate withholding tax including penalties and interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForOtherTaxes', window );">Payments for Other Taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_GeneralBusinessMember', window );">General Business | Domestic Country</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax Credit Carryforward, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_GeneralBusinessMember', window );">General Business | State and Local Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_GeneralBusinessMember', window );">General Business | Foreign Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">489.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research | State and Local Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax Credit Carryforward, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 126.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EstimatedTaxLiabilityOnUndistributedEarningsOfForeignSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated tax liability on undistributed earnings of foreign subsidiaries.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EstimatedTaxLiabilityOnUndistributedEarningsOfForeignSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_IncomeTaxesTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income Taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_IncomeTaxesTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Totaldeferredchargesandprepaidtaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total deferred charges and prepaid taxes</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Totaldeferredchargesandprepaidtaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32621-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=68052875&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForOtherTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for taxes classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForOtherTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32559-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Carryforwards<br> -URI http://asc.fasb.org/extlink&amp;oid=6506874<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UndistributedEarningsOfForeignSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of undistributed earnings of foreign subsidiaries intended to be permanently reinvested outside the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6487024&amp;loc=d3e29054-158556<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6479915&amp;loc=d3e66715-112838<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 995<br> -SubTopic 740<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6503627&amp;loc=d3e59836-110443<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=68052875&amp;loc=d3e28200-109314<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UndistributedEarningsOfForeignSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense accrued for an underpayment of income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_GeneralBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_GeneralBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>162
<FILENAME>R107.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6891434272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Revenue-related reserves for discounts and allowances</a></td>
<td class="nump">$ 605.5<span></span>
</td>
<td class="nump">$ 662.7<span></span>
</td>
<td class="nump">$ 483.8<span></span>
</td>
<td class="nump">$ 426.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Cash Paid During the Year</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest</a></td>
<td class="nump">281.2<span></span>
</td>
<td class="nump">39.1<span></span>
</td>
<td class="nump">41.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes</a></td>
<td class="nump">1,642.2<span></span>
</td>
<td class="nump">1,674.8<span></span>
</td>
<td class="nump">1,163.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Other Nonoperating Income (Expense) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">63.4<span></span>
</td>
<td class="nump">22.1<span></span>
</td>
<td class="nump">12.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">260.0<span></span>
</td>
<td class="nump">95.5<span></span>
</td>
<td class="nump">29.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfInvestments', window );">Gain (loss) on investments, net</a></td>
<td class="nump">6.0<span></span>
</td>
<td class="num">(3.8)<span></span>
</td>
<td class="nump">11.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange gains (losses), net</a></td>
<td class="num">(9.8)<span></span>
</td>
<td class="num">(32.7)<span></span>
</td>
<td class="num">(11.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_OtherIncomeExpenseNet', window );">Other, net</a></td>
<td class="num">(17.0)<span></span>
</td>
<td class="num">(13.8)<span></span>
</td>
<td class="num">(8.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="num">(217.4)<span></span>
</td>
<td class="num">(123.7)<span></span>
</td>
<td class="num">$ (25.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Current portion of contingent consideration obligations</a></td>
<td class="nump">580.8<span></span>
</td>
<td class="nump">504.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationReserve', window );">Accrued TECFIDERA litigation settlement and license charges</a></td>
<td class="nump">454.8<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee compensation and benefits</a></td>
<td class="nump">282.9<span></span>
</td>
<td class="nump">270.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Royalties and licensing fees</a></td>
<td class="nump">195.8<span></span>
</td>
<td class="nump">167.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionPayableCurrentAndNoncurrent', window );">Accrued construction in progress</a></td>
<td class="nump">134.0<span></span>
</td>
<td class="nump">87.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Collaborationexpensesaccrual', window );">Collaboration expenses</a></td>
<td class="nump">130.9<span></span>
</td>
<td class="nump">31.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">685.7<span></span>
</td>
<td class="nump">516.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Accrued expenses and other</a></td>
<td class="nump">2,903.5<span></span>
</td>
<td class="nump">2,096.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Component of accrued expenses and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Revenue-related reserves for discounts and allowances</a></td>
<td class="nump">$ 438.6<span></span>
</td>
<td class="nump">$ 518.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Collaborationexpensesaccrual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration expenses accrual</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Collaborationexpensesaccrual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_OtherIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of other nonoperating income and expense, which does not qualify for separate disclosure on the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_OtherIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for the acquisition of merchandise, materials, supplies and services pertaining to construction projects such as a housing development or factory expansion not classified as trade payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64836518&amp;loc=d3e30700-110894<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64836518&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for interest during the period net of cash paid for interest that is capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e7018-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6904-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of allowances and reserves, the valuation and qualifying accounts that are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>163
<FILENAME>R108.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6907839568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail (Details Textual)<br> &#8364; in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="10">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 28, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2011 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jun. 30, 2013 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">TECFIDERA litigation settlement and license charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 454.8<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Increase to goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,026.9<span></span>
</td>
<td class="nump">908.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionPayableCurrentAndNoncurrent', window );">Accrued construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 134.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 87.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">134.0<span></span>
</td>
<td class="nump">87.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Contingent consideration obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">274.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidTaxes', window );">Prepaid taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">817.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">550.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">817.0<span></span>
</td>
<td class="nump">550.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,502.9<span></span>
</td>
<td class="nump">$ 2,539.6<span></span>
</td>
<td class="nump">$ 2,466.0<span></span>
</td>
<td class="nump">$ 2,309.4<span></span>
</td>
<td class="nump">2,425.9<span></span>
</td>
<td class="nump">$ 2,391.7<span></span>
</td>
<td class="nump">$ 2,198.6<span></span>
</td>
<td class="nump">$ 2,172.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,817.9<span></span>
</td>
<td class="nump">9,188.5<span></span>
</td>
<td class="nump">8,203.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Accrued expenses and other long-term deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">722.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 905.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">722.5<span></span>
</td>
<td class="nump">905.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FacilityLocationAxis=biib_SolothurnMember', window );">Solothurn</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionPayableCurrentAndNoncurrent', window );">Accrued construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ConvergencePharmaceuticalsMember', window );">Convergence Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Contingent consideration obligation</a></td>
<td class="nump">$ 274.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_TecfideraMember', window );">TECFIDERA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,968.1<span></span>
</td>
<td class="nump">3,638.4<span></span>
</td>
<td class="nump">$ 2,909.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_TecfideraMember', window );">TECFIDERA | Fumapharm AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Increase to goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200.0<span></span>
</td>
<td class="nump">$ 900.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_TecfideraMember', window );">TECFIDERA | Eleven billion | Fumapharm AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Increase to goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevel', window );">Cumulative sales level</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=country_IT', window );">ITALY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Proposed settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (37.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (30.7)<span></span>
</td>
<td class="num">(37.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (33.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ReimbursementLimitStatedInResolution', window );">Reimbursement Limit Stated In Resolution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 days<span></span>
</td>
<td class="text">24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Loss contingency accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_LossContingencyAdjustmentRelatedToClaimAmountPercent', window );">Loss contingency, adjustment related to claim amount, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Accrued expenses and other long-term deferred revenue | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CumulativeSalesLevel">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cumulative sales level</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CumulativeSalesLevel</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_LossContingencyAdjustmentRelatedToClaimAmountPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Adjustment Related To Claim Amount, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_LossContingencyAdjustmentRelatedToClaimAmountPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ReimbursementLimitStatedInResolution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reimbursement limit stated in the resolution.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ReimbursementLimitStatedInResolution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for the acquisition of merchandise, materials, supplies and services pertaining to construction projects such as a housing development or factory expansion not classified as trade payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyEstimateOfPossibleLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyEstimateOfPossibleLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5865-108316<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Assets<br> -URI http://asc.fasb.org/extlink&amp;oid=6509628<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6787-107765<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FacilityLocationAxis=biib_SolothurnMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FacilityLocationAxis=biib_SolothurnMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_ConvergencePharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_ConvergencePharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_TecfideraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_TecfideraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_FumapharmAgMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_FumapharmAgMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CumulativeSalesLevelAxis=biib_ElevenbillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CumulativeSalesLevelAxis=biib_ElevenbillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=country_IT">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=country_IT</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>164
<FILENAME>R109.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6905350176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Variable Interest Entities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Mar. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net (loss) income attributable to noncontrolling interests, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (7.1)<span></span>
</td>
<td class="nump">$ 46.2<span></span>
</td>
<td class="nump">$ 6.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InvestmentInVariableInterestEntitiesTextualAbstract', window );"><strong>Investment in Variable Interest Entities (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities', window );">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities</a></td>
<td class="nump">$ 29.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47.4<span></span>
</td>
<td class="nump">29.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis=biib_NeurimmuneMember', window );">Neurimmune</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net (loss) income attributable to noncontrolling interests, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InvestmentInVariableInterestEntitiesTextualAbstract', window );"><strong>Investment in Variable Interest Entities (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement', window );">Remaining potential development milestone payments and royalties on commercial sales under the terms of collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 275.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement', window );">Percentage of funding for R&amp;D cost required in support of the collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis=biib_RodinTherapeuticsMember', window );">Rodin Therapeutics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InvestmentInVariableInterestEntitiesTextualAbstract', window );"><strong>Investment in Variable Interest Entities (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates', window );">Payments to acquire interest in peferred stock of an affiliates</a></td>
<td class="nump">8.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">In-process research and development</a></td>
<td class="nump">8.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestInVariableInterestEntity', window );">Minority interest in our stockholder's equity</a></td>
<td class="nump">$ 10.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis=biib_AtaxionMember', window );">Ataxion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InvestmentInVariableInterestEntitiesTextualAbstract', window );"><strong>Investment in Variable Interest Entities (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates', window );">Payments to acquire interest in peferred stock of an affiliates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment in biotechnology companies that are determined to be unconsolidated variable interest entities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InvestmentInVariableInterestEntitiesTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment in Variable Interest Entities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InvestmentInVariableInterestEntitiesTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected total payments including upfront and milestone payments as well as the greater of an annual maintenance fee or usage-based royalty payments under the terms of collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development cost in support of the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4591551-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestInVariableInterestEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Portion of equity (net assets) in a variable interest entity (VIE) not attributable, directly or indirectly, to the parent entity. That is, this is the portion of equity in a VIE that is attributable to the noncontrolling interest (previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestInVariableInterestEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of or advances to an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary, affiliate, and joint venture or equity method investment) or the acquisition of an additional interest in a subsidiary (controlled entity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis=biib_NeurimmuneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis=biib_NeurimmuneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis=biib_RodinTherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis=biib_RodinTherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis=biib_AtaxionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis=biib_AtaxionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>165
<FILENAME>R110.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6908098800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RevenuesFromUnconsolidatedJointBusinessAbstract', window );"><strong>Revenues from unconsolidated joint business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenue on sales in the rest of world for RITUXAN</a></td>
<td class="nump">$ 2,502.9<span></span>
</td>
<td class="nump">$ 2,539.6<span></span>
</td>
<td class="nump">$ 2,466.0<span></span>
</td>
<td class="nump">$ 2,309.4<span></span>
</td>
<td class="nump">$ 2,425.9<span></span>
</td>
<td class="nump">$ 2,391.7<span></span>
</td>
<td class="nump">$ 2,198.6<span></span>
</td>
<td class="nump">$ 2,172.3<span></span>
</td>
<td class="nump">$ 9,817.9<span></span>
</td>
<td class="nump">$ 9,188.5<span></span>
</td>
<td class="nump">$ 8,203.4<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RevenuesfromantiCD20therapeuticprograms', window );">Total revenues from anti-CD20 therapeutic programs</a></td>
<td class="nump">$ 318.2<span></span>
</td>
<td class="nump">$ 317.6<span></span>
</td>
<td class="nump">$ 349.2<span></span>
</td>
<td class="nump">$ 329.5<span></span>
</td>
<td class="nump">$ 333.9<span></span>
</td>
<td class="nump">$ 337.2<span></span>
</td>
<td class="nump">$ 337.5<span></span>
</td>
<td class="nump">$ 330.6<span></span>
</td>
<td class="nump">1,314.5<span></span>
</td>
<td class="nump">1,339.2<span></span>
</td>
<td class="nump">1,195.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=country_US', window );">U.S</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RevenuesFromUnconsolidatedJointBusinessAbstract', window );"><strong>Revenues from unconsolidated joint business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenue on sales in the rest of world for RITUXAN</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,050.4<span></span>
</td>
<td class="nump">6,545.8<span></span>
</td>
<td class="nump">5,566.7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RevenuesfromantiCD20therapeuticprograms', window );">Total revenues from anti-CD20 therapeutic programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,249.5<span></span>
</td>
<td class="nump">1,269.8<span></span>
</td>
<td class="nump">1,117.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_RocheGroupGenentechMember', window );">Roche Group - Genentech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RevenuesFromUnconsolidatedJointBusinessAbstract', window );"><strong>Revenues from unconsolidated joint business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RevenuesfromantiCD20therapeuticprograms', window );">Total revenues from anti-CD20 therapeutic programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,314.5<span></span>
</td>
<td class="nump">1,339.2<span></span>
</td>
<td class="nump">1,195.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_RocheGroupGenentechMember', window );">Roche Group - Genentech | U.S</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RevenuesFromUnconsolidatedJointBusinessAbstract', window );"><strong>Revenues from unconsolidated joint business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ShareOfCoPromotionProfits', window );">Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,249.5<span></span>
</td>
<td class="nump">1,269.8<span></span>
</td>
<td class="nump">1,117.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_GAZYVAMember', window );">GAZYVA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract', window );"><strong>After First GA101 Threshold Date</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne', window );">Until First GAZYVA Threshold Date</a></td>
<td class="nump">39.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo', window );">After First Threshold Date and until Second Threshold Date</a></td>
<td class="nump">37.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree', window );">After Second Threshold Date</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_RituxanMember', window );">RITUXAN</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CoPromotionProfitSharingFormulaAbstract', window );"><strong>Co-promotion profit sharing formula</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne', window );">Until GAZYVA First Non-CLL FDA Approval</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract', window );"><strong>After First GA101 Threshold Date</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne', window );">Until First GAZYVA Threshold Date</a></td>
<td class="nump">39.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo', window );">After First Threshold Date and until Second Threshold Date</a></td>
<td class="nump">37.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree', window );">After Second Threshold Date</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_RituxanMember', window );">RITUXAN | Roche Group - Genentech | Outside the U.S</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RevenuesFromUnconsolidatedJointBusinessAbstract', window );"><strong>Revenues from unconsolidated joint business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenue on sales in the rest of world for RITUXAN</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65.0<span></span>
</td>
<td class="nump">$ 69.4<span></span>
</td>
<td class="nump">$ 78.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CoPromotionProfitSharingFormulaAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Co-promotion profit sharing formula.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CoPromotionProfitSharingFormulaAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of co promotion operating profits greater than first fifty million option one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of co promotion operating profits greater than first fifty million option two.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of co promotion operating profits greater than first fifty million option two sub option one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of co promotion operating profits greater than first fifty million option two sub option three.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of co promotion operating profits greater than first fifty million option two sub option two.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RevenuesFromUnconsolidatedJointBusinessAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenues from unconsolidated joint business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RevenuesFromUnconsolidatedJointBusinessAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RevenuesfromantiCD20therapeuticprograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenues from anti-CD20 therapeutic programs consists of our share of pre-tax co-promotion profits in the U.S.; reimbursement of selling and development expense in the U.S.; and revenue on sales of RITUXAN outside the U.S., which consist of our share of pre-tax co-promotion profits in Canada.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RevenuesfromantiCD20therapeuticprograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareOfCoPromotionProfits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share of co promotion profits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareOfCoPromotionProfits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_RocheGroupGenentechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_RocheGroupGenentechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_GAZYVAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_GAZYVAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_RituxanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_RituxanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>166
<FILENAME>R111.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6906123776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 2,872.0<span></span>
</td>
<td class="nump">$ 2,955.8<span></span>
</td>
<td class="nump">$ 2,894.2<span></span>
</td>
<td class="nump">$ 2,726.8<span></span>
</td>
<td class="nump">$ 2,839.3<span></span>
</td>
<td class="nump">$ 2,777.9<span></span>
</td>
<td class="nump">$ 2,591.6<span></span>
</td>
<td class="nump">$ 2,555.0<span></span>
</td>
<td class="nump">$ 11,448.8<span></span>
</td>
<td class="nump">$ 10,763.8<span></span>
</td>
<td class="nump">$ 9,703.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_AbbVieMember', window );">AbbVie</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ExpenseIncurredByCollaboration', window );">Total expense incurred by collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Copromotionprofitsandlosses', window );">Co-promotion profits and losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ShareOfCoPromotionProfits', window );">Biogen's share of co-promotion losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Copromotionprofitsandlosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Co-promotion profits and losses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Copromotionprofitsandlosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ExpenseIncurredByCollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total expense incurred by collaboration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ExpenseIncurredByCollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareOfCoPromotionProfits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share of co promotion profits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareOfCoPromotionProfits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_AbbVieMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_AbbVieMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>167
<FILENAME>R112.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6825480832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships (Details 2)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr><th class="th" colspan="2"><div>Dec. 31, 2016</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis=biib_SobiRateToBiogenOnNetSalesInSobiTerritoryMember', window );">Sobi rate to Biogen on net sales in the Sobi Territory [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ReimbursementUnderAmendedAgreementAmountsPayableAbstract', window );"><strong>Mechanism for reimbursement, under the amended agreement amounts payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ReimbursementUnderAmendedAgreementMethod', window );">Reimbursement, under the amended agreement, Method</a></td>
<td class="text">Royalty<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_BaseRateAfterFirstCommercialSale', window );">Base rate following first commercial sale in the territory</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RateDuringReimbursementPeriod', window );">Rate during the reimbursement period</a></td>
<td class="text">Base&#160;Rate
plus 5%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis=biib_BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember', window );">Biogen rate to sobi on net sales in the Biogen North America Territory [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ReimbursementUnderAmendedAgreementAmountsPayableAbstract', window );"><strong>Mechanism for reimbursement, under the amended agreement amounts payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ReimbursementUnderAmendedAgreementMethod', window );">Reimbursement, under the amended agreement, Method</a></td>
<td class="text">Royalty<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RateDuringReimbursementPeriod', window );">Rate during the reimbursement period</a></td>
<td class="text">Base Rate
less 5%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis=biib_BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember', window );">Biogen rate to sobi on net sales in the Biogen North America Territory [Member] | Sobi Territory [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ReimbursementUnderAmendedAgreementAmountsPayableAbstract', window );"><strong>Mechanism for reimbursement, under the amended agreement amounts payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_BaseRateAfterFirstCommercialSale', window );">Base rate following first commercial sale in the territory</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis=biib_BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember', window );">Biogen rate to sobi on net sales in the Biogen direct Territory [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ReimbursementUnderAmendedAgreementAmountsPayableAbstract', window );"><strong>Mechanism for reimbursement, under the amended agreement amounts payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ReimbursementUnderAmendedAgreementMethod', window );">Reimbursement, under the amended agreement, Method</a></td>
<td class="text">Royalty<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RateDuringReimbursementPeriod', window );">Rate during the reimbursement period</a></td>
<td class="text">Base Rate
less 5%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis=biib_BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember', window );">Biogen rate to sobi on net sales in the Biogen direct Territory [Member] | Sobi Territory [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ReimbursementUnderAmendedAgreementAmountsPayableAbstract', window );"><strong>Mechanism for reimbursement, under the amended agreement amounts payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_BaseRateAfterFirstCommercialSale', window );">Base rate following first commercial sale in the territory</a></td>
<td class="nump">17.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis=biib_BiogenRateToSobiOnNetRevenueFromBiogenDistributorTerritoryMember', window );">Biogen rate to Sobi on net revenue from the Biogen distributor Territory [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ReimbursementUnderAmendedAgreementAmountsPayableAbstract', window );"><strong>Mechanism for reimbursement, under the amended agreement amounts payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ReimbursementUnderAmendedAgreementMethod', window );">Reimbursement, under the amended agreement, Method</a></td>
<td class="text">Net
Revenue
Share<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2],[3]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RateDuringReimbursementPeriod', window );">Rate during the reimbursement period</a></td>
<td class="text">Base Rate
less 15%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1],[2],[3]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis=biib_BiogenRateToSobiOnNetRevenueFromBiogenDistributorTerritoryMember', window );">Biogen rate to Sobi on net revenue from the Biogen distributor Territory [Member] | Sobi Territory [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ReimbursementUnderAmendedAgreementAmountsPayableAbstract', window );"><strong>Mechanism for reimbursement, under the amended agreement amounts payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_BaseRateAfterFirstCommercialSale', window );">Base rate following first commercial sale in the territory</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1],[2],[3]</sup></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">A credit will be issued to Sobi against its reimbursement of the Opt-in Consideration for each product in an amount equal to the difference in the rate paid by Biogen to Sobi on sales in the Biogen territories for certain periods prior to the first commercial sale in the Sobi Territory versus the rate that otherwise would have been payable on such sales.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Net revenue represents Biogen&#8217;s pre-tax receipts from third-party distributors, less expenses incurred by Biogen in the conduct of commercialization activities supporting the distributor activities.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">The Biogen Distributor Territory represents Biogen territories where sales are derived utilizing a third-party distributor.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_BaseRateAfterFirstCommercialSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Base rate after first commercial sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_BaseRateAfterFirstCommercialSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RateDuringReimbursementPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rate during the reimbursement period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RateDuringReimbursementPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ReimbursementUnderAmendedAgreementAmountsPayableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Mechanism for reimbursement, under the amended agreement amounts payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ReimbursementUnderAmendedAgreementAmountsPayableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ReimbursementUnderAmendedAgreementMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reimbursement, under the amended agreement, method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ReimbursementUnderAmendedAgreementMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis=biib_SobiRateToBiogenOnNetSalesInSobiTerritoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis=biib_SobiRateToBiogenOnNetSalesInSobiTerritoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis=biib_BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis=biib_BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=biib_SobiTerritoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=biib_SobiTerritoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis=biib_BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis=biib_BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis=biib_BiogenRateToSobiOnNetRevenueFromBiogenDistributorTerritoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis=biib_BiogenRateToSobiOnNetRevenueFromBiogenDistributorTerritoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>168
<FILENAME>R113.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6895495248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships Collaborative and Other Relationships (Details 3) - Eisai - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ExpenseIncurredByCollaboration', window );">Total expense incurred by collaboration</a></td>
<td class="nump">$ 95.1<span></span>
</td>
<td class="nump">$ 84.1<span></span>
</td>
<td class="nump">$ 57.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ExpenseReflectedWithinStatementsOfIncome', window );">Biogen's share of expense reflected within our consolidation statements of income</a></td>
<td class="nump">$ 50.5<span></span>
</td>
<td class="nump">$ 40.4<span></span>
</td>
<td class="nump">$ 29.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ExpenseIncurredByCollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total expense incurred by collaboration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ExpenseIncurredByCollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ExpenseReflectedWithinStatementsOfIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Biogen Idec's share of expense reflected within our consolidated statements of income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ExpenseReflectedWithinStatementsOfIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_EisaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>169
<FILENAME>R114.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6933158064">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships (Details Textual)<br> $ in Millions, &#8361; in Billions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="14">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 29, 2012 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2013 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2013 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2012 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2012 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2012 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 29, 2012 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th"><div>Jan. 31, 2007</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenue on sales in the rest of world for RITUXAN</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,502.9<span></span>
</td>
<td class="nump">$ 2,539.6<span></span>
</td>
<td class="nump">$ 2,466.0<span></span>
</td>
<td class="nump">$ 2,309.4<span></span>
</td>
<td class="nump">$ 2,425.9<span></span>
</td>
<td class="nump">$ 2,391.7<span></span>
</td>
<td class="nump">$ 2,198.6<span></span>
</td>
<td class="nump">$ 2,172.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,817.9<span></span>
</td>
<td class="nump">$ 9,188.5<span></span>
</td>
<td class="nump">$ 8,203.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,973.3<span></span>
</td>
<td class="nump">2,012.8<span></span>
</td>
<td class="nump">1,893.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSalesRevenueNet', window );">Other revenues from external customers</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.9<span></span>
</td>
<td class="nump">$ 98.6<span></span>
</td>
<td class="nump">79.0<span></span>
</td>
<td class="nump">$ 87.9<span></span>
</td>
<td class="nump">79.5<span></span>
</td>
<td class="nump">49.0<span></span>
</td>
<td class="nump">$ 55.6<span></span>
</td>
<td class="nump">$ 52.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">316.4<span></span>
</td>
<td class="nump">236.1<span></span>
</td>
<td class="nump">304.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Prepaid research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,335.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,107.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,335.8<span></span>
</td>
<td class="nump">1,107.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential future milestone payments commitment, approximately</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (Loss) from Equity Method Investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(12.5)<span></span>
</td>
<td class="num">(15.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_BiogenIdecHemophiliaMember', window );">Biogen Hemophilia</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Stock acquired in acquisition</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_AcordaMember', window );">Acorda</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ExpectedAdditionalMilestonePaymentsOnSuccessfulAchievementOfRegulatoryAndCommercialSalesMilestones', window );">Expected additional milestone payments for successful achievement of regulatory and commercial sales milestones</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">375.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">375.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold', window );">Expected additional milestone payments when certain sales threshold is met</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ForeignSalesRequiredToTriggerMilestone', window );">Foreign sales required to trigger milestone</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ExpenseReflectedWithinStatementsOfIncome', window );">Biogen's share of expense reflected within our consolidation statements of income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31.5<span></span>
</td>
<td class="nump">30.6<span></span>
</td>
<td class="nump">29.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_AbbVieMember', window );">AbbVie</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ShareOfCoPromotionProfits', window );">Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ExpenseIncurredByCollaboration', window );">Total expense incurred by collaboration</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Biogenshareofcopromotionprofitsorlosses', window );">Biogen share of co-promotion profits or losses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SwedishOrphanBiovitrumMember', window );">Swedish Orphan Biovitrum</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ConsiderationPerProductDeveloped', window );">Consideration per product</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ReimbursementCostAchievingPeriod', window );">Reimbursement cost achieving period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_TimePeriodForPayingRemainingBalanceDue', window );">Time period for paying remaining balance due</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_IonisPharmaceuticalsMember', window );">Ionis Pharmaceuticals, Inc.</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75.0<span></span>
</td>
<td class="nump">$ 30.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.5<span></span>
</td>
<td class="nump">20.0<span></span>
</td>
<td class="nump">20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Termofcollaborationagreement', window );">Term of collaboration agreement</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Total upfront and milestone payments made to collaborative partner</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssets', window );">Prepaid research and discovery services</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_LicenseFee', window );">License Fee</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments', window );">Expected License Fee And Regulatory Milestone Payments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Additionalmilestonepaymentsforproductcandidateusingadifferentmodality', window );">Additional milestone payments for product candidate using a different modality</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Additional milestone payment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember', window );">Eisai</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ExpenseReflectedWithinStatementsOfIncome', window );">Biogen's share of expense reflected within our consolidation statements of income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.5<span></span>
</td>
<td class="nump">40.4<span></span>
</td>
<td class="nump">29.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ExpenseIncurredByCollaboration', window );">Total expense incurred by collaboration</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95.1<span></span>
</td>
<td class="nump">84.1<span></span>
</td>
<td class="nump">57.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Total upfront and milestone payments made to collaborative partner</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Additional milestone payment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MilestonePaymentsMadeDuringPeriod', window );">Milestone payment made during period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_AGTCMember', window );">AGTC</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26.5<span></span>
</td>
<td class="nump">54.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Total upfront and milestone payments made to collaborative partner</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssets', window );">Prepaid research and discovery services</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Additional milestone payment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Purchaseofcommonstock', window );">Purchase of common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicenseCosts', window );">Total licensing and other fees</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Researchanddevelopmentservices', window );">Research and development services</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Premiumonequityinvestment', window );">Premium on equity investment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_UniversityofPennsylvaniaMember', window );">University of Pennsylvania</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Prepaid research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Futureresearchanddevelopmentcommitment', window );">Future research and development commitment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential future milestone payments commitment, approximately</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SangamoBioSciencesMember', window );">Sangamo BioSciences</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ExpenseReflectedWithinStatementsOfIncome', window );">Biogen's share of expense reflected within our consolidation statements of income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.4<span></span>
</td>
<td class="nump">13.6<span></span>
</td>
<td class="nump">28.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Total upfront and milestone payments made to collaborative partner</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Additional milestone payment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_MitsubishiTanabePharmaCorporationMember', window );">Mitsubishi Tanabe Pharma Corporation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_OtherresearchanddiscoveryMember', window );">Other research and discovery</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.3<span></span>
</td>
<td class="nump">$ 9.7<span></span>
</td>
<td class="nump">$ 40.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Biosimilar Agreement</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Collaborationprofitlosssharing', window );">Collaboration profit (loss) sharing</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EquityMethodInvestmentsExpectedProfitShare', window );">Equity Method Investments, Expected Profit Share</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_RituxanMember', window );">RITUXAN</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion', window );">Percentage of Co promotion Operating Profits first fifty million</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillion', window );">Percentage of share of Co promotion profits exceeding $50 million</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne', window );">Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Sub Option One</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne', window );">Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option One</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_GAZYVAMember', window );">GAZYVA</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion', window );">Percentage of Co promotion Operating Profits first fifty million</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment', window );">Co-promotion operating profit threshold for Rituxan in U S and Canada to determine share of co promotion operating profit prior to amendment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne', window );">Limit of gross sale of GAZYVA to be achieved in preceding 12 months under option one</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne', window );">Limit of gross sale of GAZYVA to be achieved in any 12 months under option one</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SalesTriggerGrossSalesThreshold', window );">Sales Trigger Gross Sales Threshold</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingLosses', window );">Percentage Of Co Promotion Operating Losses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne', window );">Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Sub Option One</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_NewAntiCd20Member', window );">New Anti-CD20 | Minimum</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Futurepercentageofcopromotionoperatingprofits', window );">Future percentage of co-promotion operating profits</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_NewAntiCd20Member', window );">New Anti-CD20 | Maximum</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Futurepercentageofcopromotionoperatingprofits', window );">Future percentage of co-promotion operating profits</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_OcrelizumabMember', window );">Ocrelizumab</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Reductioninroyaltyrate', window );">Reduction in royalty rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PeriodOfCollaborationAgreement', window );">Period of collaboration agreement</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">11 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_OcrelizumabMember', window );">Ocrelizumab | Minimum</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct', window );">Future royalties percentage to be received on sale of ocrelizumab</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_OcrelizumabMember', window );">Ocrelizumab | Maximum</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct', window );">Future royalties percentage to be received on sale of ocrelizumab</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_ZINBRYTAMember', window );">ZINBRYTA</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenue on sales in the rest of world for RITUXAN</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.8<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_ZINBRYTAMember', window );">ZINBRYTA | AbbVie</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ExpenseReflectedWithinStatementsOfIncome', window );">Biogen's share of expense reflected within our consolidation statements of income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.3<span></span>
</td>
<td class="nump">60.8<span></span>
</td>
<td class="nump">67.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_ELOCTATEMember', window );">ELOCTATE</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenue on sales in the rest of world for RITUXAN</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">513.2<span></span>
</td>
<td class="nump">319.7<span></span>
</td>
<td class="nump">58.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_ELOCTATEMember', window );">ELOCTATE | Swedish Orphan Biovitrum</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_ALPROLIXMember', window );">ALPROLIX | Swedish Orphan Biovitrum</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">123.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_SPINRAZAMember', window );">SPINRAZA</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenue on sales in the rest of world for RITUXAN</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.6<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_SPINRAZAMember', window );">SPINRAZA | Ionis Pharmaceuticals, Inc.</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ExpenseReflectedWithinStatementsOfIncome', window );">Biogen's share of expense reflected within our consolidation statements of income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">257.8<span></span>
</td>
<td class="nump">74.9<span></span>
</td>
<td class="nump">27.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.3<span></span>
</td>
<td class="nump">42.8<span></span>
</td>
<td class="nump">57.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones', window );">Estimated additional payments upon achievement of development and commercial milestones.</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_SOD1Member', window );">SOD1 | Ionis Pharmaceuticals, Inc.</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_DMPKMember', window );">DMPK | Ionis Pharmaceuticals, Inc.</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ExpenseReflectedWithinStatementsOfIncome', window );">Biogen's share of expense reflected within our consolidation statements of income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.1<span></span>
</td>
<td class="nump">9.0<span></span>
</td>
<td class="nump">10.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Additional milestone payment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_LeadprogramsMember', window );">Lead programs | AGTC</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Additional milestone payment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">472.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">472.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_DiscoveryprogramsMember', window );">Discovery programs | AGTC</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Additional milestone payment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">592.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">592.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Biosimilar Agreement</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSalesRevenueNet', window );">Other revenues from external customers</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.2<span></span>
</td>
<td class="nump">62.9<span></span>
</td>
<td class="nump">58.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Additional milestone payment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement', window );">Investments By Third Party In Joint Venture As Per Agreement.</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 250.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8361; 280.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_JointVentureOwnerShipPercentageByThirdParty', window );">Joint Venture Owner Ship Percentage By Third Party.</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity Method Investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 45.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8361; 49.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Percentage of equity interest to the portion of total capital stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EquityMethodInvestmentOwnershipPercentageMaximum', window );">Equity Method Investment Ownership Percentage Maximum</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesRevenueNetMember', window );">Revenue | Swedish Orphan Biovitrum</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Biogeneffectiveroyaltyrate', window );">Biogen effective royalty rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">0.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of sales | Swedish Orphan Biovitrum</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Biogeneffectiveroyaltyrate', window );">Biogen effective royalty rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">0.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | AbbVie</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ExpenseIncurredByCollaboration', window );">Total expense incurred by collaboration</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48.6<span></span>
</td>
<td class="nump">113.8<span></span>
</td>
<td class="nump">117.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | Eisai</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_LiabilityForFairValueOfOptionsGrantedUnderAgreement', window );">Amount recorded to reflect fair value of options granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative | ZINBRYTA | AbbVie</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ExpenseReflectedWithinStatementsOfIncome', window );">Biogen's share of expense reflected within our consolidation statements of income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=country_US', window );">U.S</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenue on sales in the rest of world for RITUXAN</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,050.4<span></span>
</td>
<td class="nump">6,545.8<span></span>
</td>
<td class="nump">5,566.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSalesRevenueNet', window );">Other revenues from external customers</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">224.7<span></span>
</td>
<td class="nump">142.0<span></span>
</td>
<td class="nump">212.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=country_US', window );">U.S | Roche Group - Genentech</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ShareOfCoPromotionProfits', window );">Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,249.5<span></span>
</td>
<td class="nump">1,269.8<span></span>
</td>
<td class="nump">1,117.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=country_US', window );">U.S | AbbVie</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSalesRevenueNet', window );">Other revenues from external customers</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=us-gaap_ForeignCountryMember', window );">Outside the U.S | RITUXAN | Roche Group - Genentech</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenue on sales in the rest of world for RITUXAN</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65.0<span></span>
</td>
<td class="nump">69.4<span></span>
</td>
<td class="nump">78.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=us-gaap_ForeignCountryMember', window );">Outside the U.S | Ocrelizumab</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct', window );">Future royalties percentage to be received on sale of ocrelizumab</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=us-gaap_EuropeMember', window );">Europe</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenue on sales in the rest of world for RITUXAN</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,533.5<span></span>
</td>
<td class="nump">1,497.6<span></span>
</td>
<td class="nump">1,383.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSalesRevenueNet', window );">Other revenues from external customers</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.0<span></span>
</td>
<td class="nump">$ 29.6<span></span>
</td>
<td class="nump">$ 31.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=us-gaap_EuropeMember', window );">Europe | AbbVie</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Collaborationprofitlosssharing', window );">Collaboration profit (loss) sharing</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember', window );">Acquired and in-licensed rights and patents | ZINBRYTA</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease', window );">Net change in acquired and in-licensed rights and patents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember', window );">Acquired and in-licensed rights and patents | ALPROLIX</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease', window );">Net change in acquired and in-licensed rights and patents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MilestonePaymentsMadeDuringPeriod', window );">Milestone payment made during period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember', window );">Acquired and in-licensed rights and patents | SPINRAZA</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease', window );">Net change in acquired and in-licensed rights and patents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember', window );">Acquired and in-licensed rights and patents | Biosimilars</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease', window );">Net change in acquired and in-licensed rights and patents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="24"></td></tr>
<tr><td colspan="24"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Represents amounts related to Europe less those attributable to Germany.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AdditionalMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AdditionalMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Additionalmilestonepaymentsforproductcandidateusingadifferentmodality">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional milestone payments for product candidate using a different modality</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Additionalmilestonepaymentsforproductcandidateusingadifferentmodality</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Biogeneffectiveroyaltyrate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Biogen effective royalty rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Biogeneffectiveroyaltyrate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Biogenshareofcopromotionprofitsorlosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Biogen share of co-promotion profits or losses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Biogenshareofcopromotionprofitsorlosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Co promotion operating profit threshold to determine share of co promotion operating profit prior to amendment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Collaborationprofitlosssharing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration profit (loss) sharing</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Collaborationprofitlosssharing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CollaborationsTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CollaborationsTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ConsiderationPerProductDeveloped">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Consideration Per Product Developed</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ConsiderationPerProductDeveloped</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EquityMethodInvestmentOwnershipPercentageMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity method investment ownership percentage maximum.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EquityMethodInvestmentOwnershipPercentageMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EquityMethodInvestmentsExpectedProfitShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investments, Expected Profit Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EquityMethodInvestmentsExpectedProfitShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated additional payments upon achievement of development and commercial milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ExpectedAdditionalMilestonePaymentsOnSuccessfulAchievementOfRegulatoryAndCommercialSalesMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected additional milestone payments on successful achievement of regulatory and commercial sales milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ExpectedAdditionalMilestonePaymentsOnSuccessfulAchievementOfRegulatoryAndCommercialSalesMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected additional milestone payments when meeting certain sales threshold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected license fee and regulatory milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ExpenseIncurredByCollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total expense incurred by collaboration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ExpenseIncurredByCollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ExpenseReflectedWithinStatementsOfIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Biogen Idec's share of expense reflected within our consolidated statements of income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ExpenseReflectedWithinStatementsOfIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ForeignSalesRequiredToTriggerMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Foreign sales required to trigger milestone.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ForeignSalesRequiredToTriggerMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future royalties percentage to be received on sale of product.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Futurepercentageofcopromotionoperatingprofits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future percentage of co-promotion operating profits</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Futurepercentageofcopromotionoperatingprofits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Futureresearchanddevelopmentcommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future research and development commitment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Futureresearchanddevelopmentcommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments by third party in joint venture as per agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_JointVentureOwnerShipPercentageByThirdParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Joint venture owner ship percentage by third party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_JointVentureOwnerShipPercentageByThirdParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_LiabilityForFairValueOfOptionsGrantedUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability For Fair Value Of Options Granted Under Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_LiabilityForFairValueOfOptionsGrantedUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_LicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_LicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_MilestonePaymentsMadeDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payments Made During Period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_MilestonePaymentsMadeDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfCoPromotionOperatingLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Co Promotion Operating Losses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfCoPromotionOperatingLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of co promotion operating profits first fifty million.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of co promotion operating profits greater than first fifty million.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of co promotion operating profits greater than first fifty million option one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of co promotion operating profits greater than first fifty million option two sub option one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PeriodOfCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PeriodOfCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential future milestone payments commitment to third party approximately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Premiumonequityinvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Premium on equity investment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Premiumonequityinvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Purchaseofcommonstock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase of common stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Purchaseofcommonstock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Reductioninroyaltyrate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduction in royalty rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Reductioninroyaltyrate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ReimbursementCostAchievingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reimbursement cost achieving period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ReimbursementCostAchievingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Researchanddevelopmentservices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development services</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Researchanddevelopmentservices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SalesTriggerGrossSalesThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sales trigger gross sales threshold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SalesTriggerGrossSalesThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareOfCoPromotionProfits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share of co promotion profits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareOfCoPromotionProfits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Termofcollaborationagreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of collaboration agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Termofcollaborationagreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold of gross sales of to be achieved in preceding twelve consecutive months under option one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold of gross sales to be achieved in any twelve consecutive months under option one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_TimePeriodForPayingRemainingBalanceDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Time period for paying remaining balance due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_TimePeriodForPayingRemainingBalanceDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total upfront and milestone payments made to collaborative partner.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=65885119&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66011266&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66022249&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in carrying value of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the entity's proportionate share for the period of the net income (loss) of its investee (such as unconsolidated subsidiaries and joint ventures) to which the equity method of accounting is applied. This item includes income or expense related to stock-based compensation based on the investor's grant of stock to employees of an equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66022249&amp;loc=d3e33749-111570<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicenseCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Costs incurred and are directly related to generating license revenue. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LicenseCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSalesRevenueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after sales adjustments, returns, allowances, and discounts, of revenue classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSalesRevenueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Research and Development<br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_BiogenIdecHemophiliaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_BiogenIdecHemophiliaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_AcordaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_AcordaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_AbbVieMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_AbbVieMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_SwedishOrphanBiovitrumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_SwedishOrphanBiovitrumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_IonisPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_IonisPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_EisaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_AGTCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_AGTCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_UniversityofPennsylvaniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_UniversityofPennsylvaniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_SangamoBioSciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_SangamoBioSciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_MitsubishiTanabePharmaCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_MitsubishiTanabePharmaCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_OtherresearchanddiscoveryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_OtherresearchanddiscoveryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_RituxanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_RituxanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_GAZYVAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_GAZYVAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_NewAntiCd20Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_NewAntiCd20Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_OcrelizumabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_OcrelizumabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_ZINBRYTAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_ZINBRYTAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_ELOCTATEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_ELOCTATEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_ALPROLIXMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_ALPROLIXMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_SPINRAZAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_SPINRAZAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_SOD1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_SOD1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_DMPKMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_DMPKMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_LeadprogramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_LeadprogramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_DiscoveryprogramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_DiscoveryprogramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_RocheGroupGenentechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_RocheGroupGenentechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=us-gaap_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=us-gaap_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_BiosimilarsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_BiosimilarsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>170
<FILENAME>R115.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6821483184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Litigation (Details) - ITALY - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2014</div></th>
<th class="th"><div>Dec. 31, 2011</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Jun. 30, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ReimbursementLimitStatedInResolution', window );">Reimbursement Limit Stated In Resolution</a></td>
<td class="text">24 days<span></span>
</td>
<td class="text">24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Proposed settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.7<span></span>
</td>
<td class="nump">$ 37.4<span></span>
</td>
<td class="nump">$ 33.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ReimbursementLimitStatedInResolution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reimbursement limit stated in the resolution.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ReimbursementLimitStatedInResolution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyEstimateOfPossibleLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyEstimateOfPossibleLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=country_IT">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=country_IT</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>171
<FILENAME>R116.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6888070112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract', window );"><strong>Minimum rental commitments under non-cancelable leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">Minimum lease payments, 2017</a></td>
<td class="nump">$ 75.3<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">Minimum lease payments, 2018</a></td>
<td class="nump">69.8<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">Minimum lease payments, 2019</a></td>
<td class="nump">69.1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">Minimum lease payments, 2020</a></td>
<td class="nump">65.7<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears', window );">Minimum lease payments, 2021</a></td>
<td class="nump">64.6<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter', window );">Minimum lease payments, Thereafter</a></td>
<td class="nump">331.9<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Minimum lease payments, Total</a></td>
<td class="nump">676.4<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear', window );">Less: income from subleases, 2017</a></td>
<td class="num">(8.9)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears', window );">Less: income from subleases, 2018</a></td>
<td class="num">(15.2)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears', window );">Less: income from subleases, 2019</a></td>
<td class="num">(15.5)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears', window );">Less: income from subleases, 2020</a></td>
<td class="num">(15.7)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears', window );">Less: income from subleases, 2021</a></td>
<td class="num">(16.2)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter', window );">Less: income from subleases, Thereafter</a></td>
<td class="num">(55.4)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions', window );">Less: income from subleases, Total</a></td>
<td class="num">(126.9)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NetMinimumLeasePaymentsWithInOneYear', window );">Net minimum lease payments, 2017</a></td>
<td class="nump">66.4<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NetMinimumLeasePaymentsWithInTwoYear', window );">Net minimum lease payments, 2018</a></td>
<td class="nump">54.6<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NetMinimumLeasePaymentsWithInThreeYear', window );">Net minimum lease payments, 2019</a></td>
<td class="nump">53.6<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NetMinimumLeasePaymentsWithInFourYear', window );">Net minimum lease payments, 2020</a></td>
<td class="nump">50.0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NetMinimumLeasePaymentsWithInFiveYear', window );">Net minimum lease payments, 2021</a></td>
<td class="nump">48.4<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NetMinimumLeasePaymentsThereafter', window );">Net minimum lease payments, Thereafter</a></td>
<td class="nump">276.5<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NetMinimumLeasePayments', window );">Net minimum lease payments, Total</a></td>
<td class="nump">$ 549.5<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">(1)</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum rental commitments under noncancellable leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NetMinimumLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net minimum lease payments total.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NetMinimumLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NetMinimumLeasePaymentsThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net minimum lease payments thereafter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NetMinimumLeasePaymentsThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NetMinimumLeasePaymentsWithInFiveYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net minimum lease payments with in five year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NetMinimumLeasePaymentsWithInFiveYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NetMinimumLeasePaymentsWithInFourYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net minimum lease payments with in four year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NetMinimumLeasePaymentsWithInFourYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NetMinimumLeasePaymentsWithInOneYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net minimum lease payments with in one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NetMinimumLeasePaymentsWithInOneYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NetMinimumLeasePaymentsWithInThreeYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net minimum lease payments with in three year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NetMinimumLeasePaymentsWithInThreeYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NetMinimumLeasePaymentsWithInTwoYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net minimum lease payments with in two year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NetMinimumLeasePaymentsWithInTwoYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum sublease rentals to be received by the seller-lessee for sale-leaseback transactions accounted for using the deposit method or as a financing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 40<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6456377&amp;loc=d3e50824-112756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum sublease rentals for sale-leaseback transactions accounted for using the deposit method or as a financing to be received by the seller-lessee after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 40<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6456377&amp;loc=d3e50824-112756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum sublease rentals for sale-leaseback transactions accounted for using the deposit method or as a financing to be received by the seller-lessee in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 40<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6456377&amp;loc=d3e50824-112756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum sublease rentals for sale-leaseback transactions accounted for using the deposit method or as a financing to be received by the seller-lessee in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 40<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6456377&amp;loc=d3e50824-112756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum sublease rentals for sale-leaseback transactions accounted for using the deposit method or as a financing to be received by the seller-lessee in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 40<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6456377&amp;loc=d3e50824-112756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum sublease rentals for sale-leaseback transactions accounted for using the deposit method or as a financing to be received by the seller-lessee in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 40<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6456377&amp;loc=d3e50824-112756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum sublease rentals for sale-leaseback transactions accounted for using the deposit method or as a financing to be received by the seller-lessee in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 40<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6456377&amp;loc=d3e50824-112756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>172
<FILENAME>R117.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6799167472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies Commitments and Contingencies (Details 1)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent', window );">Capital leases, future minimum payments due in 2017</a></td>
<td class="nump">$ 2.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears', window );">Capital leases, future minimum payments due in 2018</a></td>
<td class="nump">16.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDue', window );">Capital leases, future minimum payments due total</a></td>
<td class="nump">18.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments', window );">Less: interest on capital lease</a></td>
<td class="num">(0.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments', window );">Net present value of the future minimum lease payments</a></td>
<td class="nump">$ 18.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount necessary to reduce net minimum lease payments to present value for capital leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of minimum lease payments for capital leases net of executory costs, including amounts paid by the lessee to the lessor for insurance, maintenance and taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>173
<FILENAME>R118.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6891767152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2006</div></th>
<th class="th"><div>Jun. 30, 2013</div></th>
<th class="th"><div>Apr. 02, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmount', window );">Litigation settlement and license agreement amount</a></td>
<td class="nump">$ 1,250.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">TECFIDERA litigation settlement and license charges</a></td>
<td class="nump">454.8<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Maximum contingent consideration in the form of development and approval milestones</a></td>
<td class="nump">1,200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Increase to goodwill</a></td>
<td class="nump">1,026.9<span></span>
</td>
<td class="nump">908.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential future milestone payments commitment, approximately</a></td>
<td class="nump">3,100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Cancellable future commitments</a></td>
<td class="nump">500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CommitmentsAndContingenciesTextualAbstract', window );"><strong>Commitments And Contingencies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch', window );">Accrued expenses</a></td>
<td class="nump">21.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUncertainTaxPositionsCurrent', window );">Liabilities associated with uncertain tax positions</a></td>
<td class="nump">47.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Lease rent expense which terminates at various dates through 2028</a></td>
<td class="nump">68.7<span></span>
</td>
<td class="nump">68.6<span></span>
</td>
<td class="nump">$ 62.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_TysabriProductMember', window );">TYSABRI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion', window );">Future contingent payment for annual worldwide net sales up to $2.0 billion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FutureContingentPaymentThreshold', window );">Future contingent payment threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion', window );">Future contingent payment for annual worldwide net sales that exceed $2.0 billion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_FumapharmAgMember', window );">Fumapharm AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Amount paid in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 220.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FacilityLocationAxis=biib_SolothurnMember', window );">Solothurn</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Cancellable future commitments</a></td>
<td class="nump">176.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_TecfideraMember', window );">TECFIDERA | Fumapharm AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Maximum contingent consideration in the form of development and approval milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Increase to goodwill</a></td>
<td class="nump">1,200.0<span></span>
</td>
<td class="nump">$ 900.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevelAxis=biib_TenbillionMember', window );">Ten billion | TECFIDERA | Fumapharm AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Increase to goodwill</a></td>
<td class="nump">1,200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevel', window );">Cumulative sales level</a></td>
<td class="nump">10,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevelAxis=biib_SevenbillionMember', window );">Seven billion | TECFIDERA | Fumapharm AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevel', window );">Cumulative sales level</a></td>
<td class="nump">7,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevelAxis=biib_EightbillionMember', window );">Eight billion | TECFIDERA | Fumapharm AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevel', window );">Cumulative sales level</a></td>
<td class="nump">8,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevelAxis=biib_NinebillionMember', window );">Nine billion | TECFIDERA | Fumapharm AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevel', window );">Cumulative sales level</a></td>
<td class="nump">9,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevelAxis=biib_ElevenbillionMember', window );">Eleven billion | TECFIDERA | Fumapharm AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Increase to goodwill</a></td>
<td class="nump">300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevel', window );">Cumulative sales level</a></td>
<td class="nump">11,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevelAxis=biib_OneBillionMember', window );">One billion | TECFIDERA | Fumapharm AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevel', window );">Cumulative sales level</a></td>
<td class="nump">1,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevelAxis=biib_EachAdditionalOneBillionUpToTwentyBillionMember', window );">Each additional one billion up to twenty billion | TECFIDERA | Fumapharm AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Increase to goodwill</a></td>
<td class="nump">300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevel', window );">Cumulative sales level</a></td>
<td class="nump">20,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevelAxis=biib_ThreeBillionMember', window );">Three billion | TECFIDERA | Fumapharm AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevel', window );">Cumulative sales level</a></td>
<td class="nump">3,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=country_US', window );">U.S</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">TECFIDERA litigation settlement and license charges</a></td>
<td class="nump">656.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=us-gaap_EuropeanUnionMember', window );">European Union</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">TECFIDERA litigation settlement and license charges</a></td>
<td class="nump">138.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FutureContingentMilestoneTypesAxis=biib_DevelopmentMilestonesMember', window );">Development Milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential future milestone payments commitment, approximately</a></td>
<td class="nump">500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FutureContingentMilestoneTypesAxis=biib_RegulatoryMilestonesMember', window );">Regulatory Milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential future milestone payments commitment, approximately</a></td>
<td class="nump">800.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FutureContingentMilestoneTypesAxis=biib_CommercialMilestonesMember', window );">Commercial Milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential future milestone payments commitment, approximately</a></td>
<td class="nump">$ 1,800.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued expenses on funding commitment related to clinical research.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CommitmentsAndContingenciesTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments And Contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CommitmentsAndContingenciesTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CumulativeSalesLevel">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cumulative sales level</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CumulativeSalesLevel</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future contingent payment for annual worldwide net sales that exceed $2.0 billion</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future contingent payment for annual worldwide net sales up to $2.0 billion</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FutureContingentPaymentThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future contingent payment threshold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FutureContingentPaymentThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential future milestone payments commitment to third party approximately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUncertainTaxPositionsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for uncertainty in income taxes classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUncertainTaxPositionsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of judgment or settlement awarded to (against) the entity in respect of litigation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_TysabriProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_TysabriProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_FumapharmAgMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_FumapharmAgMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FacilityLocationAxis=biib_SolothurnMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FacilityLocationAxis=biib_SolothurnMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_TecfideraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_TecfideraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CumulativeSalesLevelAxis=biib_TenbillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CumulativeSalesLevelAxis=biib_TenbillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CumulativeSalesLevelAxis=biib_SevenbillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CumulativeSalesLevelAxis=biib_SevenbillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CumulativeSalesLevelAxis=biib_EightbillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CumulativeSalesLevelAxis=biib_EightbillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CumulativeSalesLevelAxis=biib_NinebillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CumulativeSalesLevelAxis=biib_NinebillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CumulativeSalesLevelAxis=biib_ElevenbillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CumulativeSalesLevelAxis=biib_ElevenbillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CumulativeSalesLevelAxis=biib_OneBillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CumulativeSalesLevelAxis=biib_OneBillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CumulativeSalesLevelAxis=biib_EachAdditionalOneBillionUpToTwentyBillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CumulativeSalesLevelAxis=biib_EachAdditionalOneBillionUpToTwentyBillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CumulativeSalesLevelAxis=biib_ThreeBillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CumulativeSalesLevelAxis=biib_ThreeBillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=us-gaap_EuropeanUnionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=us-gaap_EuropeanUnionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FutureContingentMilestoneTypesAxis=biib_DevelopmentMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FutureContingentMilestoneTypesAxis=biib_DevelopmentMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FutureContingentMilestoneTypesAxis=biib_RegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FutureContingentMilestoneTypesAxis=biib_RegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FutureContingentMilestoneTypesAxis=biib_CommercialMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FutureContingentMilestoneTypesAxis=biib_CommercialMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>174
<FILENAME>R119.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6824718576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans Employee Benefit Plans (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanTypeAxis=us-gaap_UnitedStatesPostretirementBenefitPlansOfUSEntityDefinedBenefitMember', window );">401k</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MinimumQualifyingAgeForEmployeeBenefitPlan', window );">Minimum Qualifying Age For Employee Benefit Plan</a></td>
<td class="text">21 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Expenses related to savings plan</a></td>
<td class="nump">$ 45.2<span></span>
</td>
<td class="nump">$ 51.8<span></span>
</td>
<td class="nump">$ 49.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Deferred Compensation Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent', window );">Deferred compensation liability</a></td>
<td class="nump">$ 128.5<span></span>
</td>
<td class="nump">$ 126.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_MinimumQualifyingAgeForEmployeeBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum qualifying age for employee benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_MinimumQualifyingAgeForEmployeeBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable beyond one year (or the operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the cost recognized during the period for defined contribution plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanTypeAxis=us-gaap_UnitedStatesPostretirementBenefitPlansOfUSEntityDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanTypeAxis=us-gaap_UnitedStatesPostretirementBenefitPlansOfUSEntityDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>175
<FILENAME>R120.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6825666224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans (Details 1) - Foreign Pension Plan - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis=us-gaap_ForeignPensionPlansDefinedBenefitMember', window );">SWITZERLAND</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EmployeeBenefitPlansTextualAbstract', window );"><strong>Employee Benefit Plans (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfMinimumInvestmentReturn', window );">Percentage of minimum investment return</a></td>
<td class="nump">1.25%<span></span>
</td>
<td class="nump">1.75%<span></span>
</td>
<td class="nump">1.75%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan', window );">Unfunded net pension</a></td>
<td class="nump">$ 39.1<span></span>
</td>
<td class="nump">$ 42.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Employee Benefit Plan obligations</a></td>
<td class="nump">68.6<span></span>
</td>
<td class="nump">63.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionExpense', window );">Pension Expense</a></td>
<td class="nump">15.3<span></span>
</td>
<td class="nump">12.9<span></span>
</td>
<td class="nump">$ 9.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis=us-gaap_ForeignPensionPlansDefinedBenefitMember', window );">GERMANY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EmployeeBenefitPlansTextualAbstract', window );"><strong>Employee Benefit Plans (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Employee Benefit Plan obligations</a></td>
<td class="nump">35.4<span></span>
</td>
<td class="nump">27.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Periodic pension cost</a></td>
<td class="nump">$ 4.2<span></span>
</td>
<td class="nump">$ 4.0<span></span>
</td>
<td class="nump">$ 3.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EmployeeBenefitPlansTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EmployeeBenefitPlansTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfMinimumInvestmentReturn">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of minimum investment return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfMinimumInvestmentReturn</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>1) For defined benefit pension plans, the benefit obligation is the projected benefit obligation, which is the actuarial present value as of a date of all benefits attributed by the pension benefit formula to employee service rendered prior to that date.  2) For other postretirement defined benefit plans, the benefit obligation is the accumulated postretirement benefit obligation, which is the actuarial present value of benefits attributed to employee service rendered to a particular date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=65897934&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Projected Benefit Obligation<br> -URI http://asc.fasb.org/extlink&amp;oid=6522206<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Accumulated Postretirement Benefit Obligation<br> -URI http://asc.fasb.org/extlink&amp;oid=6503904<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The funded status is measured as the difference between the fair value of plan assets and the benefit obligation. Will normally be the same as the net Defined Benefit Plan, Amounts Recognized in Balance Sheet, Total.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=65897934&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64852052&amp;loc=d3e1703-114919<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFundedStatusOfPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of net periodic benefit cost for defined benefit plans for the period. Periodic benefit costs include the following components: service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) due to settlements or curtailments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=65897934&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=65897934&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of pension benefit costs recognized during the period for (1) defined benefit plans and (2) defined contribution plans. For defined benefit plans, pension expense includes the following components: service cost, interest cost, expected return on plan assets, gain (loss) on plan assets, prior service cost or credit, transition asset or obligation, and gain (loss) due to settlements or curtailments. For defined contribution plans, the pension expense generally equals the firm's contribution to employees' accounts (if the firm contributes) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65897934&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=65897934&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis=us-gaap_ForeignPensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis=us-gaap_ForeignPensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=country_CH">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=country_CH</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=country_DE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=country_DE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>176
<FILENAME>R121.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6920930576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="nump">$ 2,502.9<span></span>
</td>
<td class="nump">$ 2,539.6<span></span>
</td>
<td class="nump">$ 2,466.0<span></span>
</td>
<td class="nump">$ 2,309.4<span></span>
</td>
<td class="nump">$ 2,425.9<span></span>
</td>
<td class="nump">$ 2,391.7<span></span>
</td>
<td class="nump">$ 2,198.6<span></span>
</td>
<td class="nump">$ 2,172.3<span></span>
</td>
<td class="nump">$ 9,817.9<span></span>
</td>
<td class="nump">$ 9,188.5<span></span>
</td>
<td class="nump">$ 8,203.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=country_US', window );">U.S</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,050.4<span></span>
</td>
<td class="nump">6,545.8<span></span>
</td>
<td class="nump">5,566.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=biib_RestOfWorldMember', window );">Rest of world</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,767.5<span></span>
</td>
<td class="nump">2,642.7<span></span>
</td>
<td class="nump">2,636.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_TecfideraMember', window );">TECFIDERA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,968.1<span></span>
</td>
<td class="nump">3,638.4<span></span>
</td>
<td class="nump">2,909.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_TecfideraMember', window );">TECFIDERA | U.S</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,169.4<span></span>
</td>
<td class="nump">2,908.2<span></span>
</td>
<td class="nump">2,426.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_TecfideraMember', window );">TECFIDERA | Rest of world</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">798.7<span></span>
</td>
<td class="nump">730.2<span></span>
</td>
<td class="nump">482.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_AVONEXMember', window );">AVONEX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,313.5<span></span>
</td>
<td class="nump">2,630.2<span></span>
</td>
<td class="nump">3,013.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_AVONEXMember', window );">AVONEX | U.S</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,675.3<span></span>
</td>
<td class="nump">1,790.2<span></span>
</td>
<td class="nump">1,956.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_AVONEXMember', window );">AVONEX | Rest of world</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">638.2<span></span>
</td>
<td class="nump">840.0<span></span>
</td>
<td class="nump">1,056.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_PLEGRIDYMember', window );">PLEGRIDY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">481.7<span></span>
</td>
<td class="nump">338.5<span></span>
</td>
<td class="nump">44.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_PLEGRIDYMember', window );">PLEGRIDY | U.S</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">305.0<span></span>
</td>
<td class="nump">227.1<span></span>
</td>
<td class="nump">27.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_PLEGRIDYMember', window );">PLEGRIDY | Rest of world</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">176.7<span></span>
</td>
<td class="nump">111.4<span></span>
</td>
<td class="nump">16.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_TysabriMember', window );">TYSABRI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,963.8<span></span>
</td>
<td class="nump">1,886.1<span></span>
</td>
<td class="nump">1,959.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_TysabriMember', window );">TYSABRI | U.S</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,182.9<span></span>
</td>
<td class="nump">1,103.1<span></span>
</td>
<td class="nump">1,025.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_TysabriMember', window );">TYSABRI | Rest of world</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">780.9<span></span>
</td>
<td class="nump">783.0<span></span>
</td>
<td class="nump">934.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_FAMPYRAMember', window );">FAMPYRA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84.9<span></span>
</td>
<td class="nump">89.7<span></span>
</td>
<td class="nump">80.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_FAMPYRAMember', window );">FAMPYRA | U.S</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_FAMPYRAMember', window );">FAMPYRA | Rest of world</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84.9<span></span>
</td>
<td class="nump">89.7<span></span>
</td>
<td class="nump">80.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_ZINBRYTAMember', window );">ZINBRYTA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.8<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_ZINBRYTAMember', window );">ZINBRYTA | U.S</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_ZINBRYTAMember', window );">ZINBRYTA | Rest of world</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.8<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_ELOCTATEMember', window );">ELOCTATE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">513.2<span></span>
</td>
<td class="nump">319.7<span></span>
</td>
<td class="nump">58.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_ELOCTATEMember', window );">ELOCTATE | U.S</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">445.2<span></span>
</td>
<td class="nump">308.3<span></span>
</td>
<td class="nump">58.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_ELOCTATEMember', window );">ELOCTATE | Rest of world</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68.0<span></span>
</td>
<td class="nump">11.4<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_ALPROLIXProductMember', window );">ALPROLIX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">333.7<span></span>
</td>
<td class="nump">234.5<span></span>
</td>
<td class="nump">76.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_ALPROLIXProductMember', window );">ALPROLIX | U.S</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">268.0<span></span>
</td>
<td class="nump">208.9<span></span>
</td>
<td class="nump">72.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_ALPROLIXProductMember', window );">ALPROLIX | Rest of world</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65.7<span></span>
</td>
<td class="nump">25.6<span></span>
</td>
<td class="nump">3.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_FUMADERMMember', window );">FUMADERM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.9<span></span>
</td>
<td class="nump">51.4<span></span>
</td>
<td class="nump">62.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_FUMADERMMember', window );">FUMADERM | U.S</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_FUMADERMMember', window );">FUMADERM | Rest of world</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.9<span></span>
</td>
<td class="nump">51.4<span></span>
</td>
<td class="nump">62.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_SPINRAZAMember', window );">SPINRAZA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.6<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_SPINRAZAMember', window );">SPINRAZA | U.S</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.6<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_SPINRAZAMember', window );">SPINRAZA | Rest of world</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_BENEPALIMember', window );">BENEPALI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.6<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_BENEPALIMember', window );">BENEPALI | U.S</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_BENEPALIMember', window );">BENEPALI | Rest of world</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.6<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_FLIXABIMember', window );">FLIXABI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_FLIXABIMember', window );">FLIXABI | U.S</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_FLIXABIMember', window );">FLIXABI | Rest of world</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=biib_RestOfWorldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=biib_RestOfWorldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_TecfideraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_TecfideraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_AVONEXMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_AVONEXMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_PLEGRIDYMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_PLEGRIDYMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_TysabriMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_TysabriMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_FAMPYRAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_FAMPYRAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_ZINBRYTAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_ZINBRYTAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_ELOCTATEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_ELOCTATEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_ALPROLIXProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_ALPROLIXProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_FUMADERMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_FUMADERMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_SPINRAZAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_SPINRAZAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_BENEPALIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_BENEPALIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_FLIXABIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_FLIXABIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>177
<FILENAME>R122.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6893623904">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentsGeographicalAreasAbstract', window );"><strong>Geographic information</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2,502.9<span></span>
</td>
<td class="nump">$ 2,539.6<span></span>
</td>
<td class="nump">$ 2,466.0<span></span>
</td>
<td class="nump">$ 2,309.4<span></span>
</td>
<td class="nump">$ 2,425.9<span></span>
</td>
<td class="nump">$ 2,391.7<span></span>
</td>
<td class="nump">$ 2,198.6<span></span>
</td>
<td class="nump">$ 2,172.3<span></span>
</td>
<td class="nump">$ 9,817.9<span></span>
</td>
<td class="nump">$ 9,188.5<span></span>
</td>
<td class="nump">$ 8,203.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RevenuesfromantiCD20therapeuticprograms', window );">Revenues from anti-CD20 therapeutic programs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">318.2<span></span>
</td>
<td class="nump">317.6<span></span>
</td>
<td class="nump">349.2<span></span>
</td>
<td class="nump">329.5<span></span>
</td>
<td class="nump">333.9<span></span>
</td>
<td class="nump">337.2<span></span>
</td>
<td class="nump">337.5<span></span>
</td>
<td class="nump">330.6<span></span>
</td>
<td class="nump">1,314.5<span></span>
</td>
<td class="nump">1,339.2<span></span>
</td>
<td class="nump">1,195.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSalesRevenueNet', window );">Other revenues from external customers</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">50.9<span></span>
</td>
<td class="nump">$ 98.6<span></span>
</td>
<td class="nump">$ 79.0<span></span>
</td>
<td class="nump">$ 87.9<span></span>
</td>
<td class="nump">79.5<span></span>
</td>
<td class="nump">$ 49.0<span></span>
</td>
<td class="nump">$ 55.6<span></span>
</td>
<td class="nump">$ 52.0<span></span>
</td>
<td class="nump">316.4<span></span>
</td>
<td class="nump">236.1<span></span>
</td>
<td class="nump">304.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,501.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,187.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,501.8<span></span>
</td>
<td class="nump">2,187.6<span></span>
</td>
<td class="nump">1,765.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=country_US', window );">U.S</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentsGeographicalAreasAbstract', window );"><strong>Geographic information</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,050.4<span></span>
</td>
<td class="nump">6,545.8<span></span>
</td>
<td class="nump">5,566.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RevenuesfromantiCD20therapeuticprograms', window );">Revenues from anti-CD20 therapeutic programs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,249.5<span></span>
</td>
<td class="nump">1,269.8<span></span>
</td>
<td class="nump">1,117.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSalesRevenueNet', window );">Other revenues from external customers</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">224.7<span></span>
</td>
<td class="nump">142.0<span></span>
</td>
<td class="nump">212.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,272.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,296.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,272.3<span></span>
</td>
<td class="nump">1,296.5<span></span>
</td>
<td class="nump">1,055.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=us-gaap_EuropeMember', window );">Europe</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentsGeographicalAreasAbstract', window );"><strong>Geographic information</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,533.5<span></span>
</td>
<td class="nump">1,497.6<span></span>
</td>
<td class="nump">1,383.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RevenuesfromantiCD20therapeuticprograms', window );">Revenues from anti-CD20 therapeutic programs</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.9<span></span>
</td>
<td class="nump">3.5<span></span>
</td>
<td class="nump">7.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSalesRevenueNet', window );">Other revenues from external customers</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.0<span></span>
</td>
<td class="nump">29.6<span></span>
</td>
<td class="nump">31.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,219.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">879.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,219.3<span></span>
</td>
<td class="nump">879.4<span></span>
</td>
<td class="nump">701.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=country_DE', window );">Germany</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentsGeographicalAreasAbstract', window );"><strong>Geographic information</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">703.7<span></span>
</td>
<td class="nump">668.1<span></span>
</td>
<td class="nump">811.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RevenuesfromantiCD20therapeuticprograms', window );">Revenues from anti-CD20 therapeutic programs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSalesRevenueNet', window );">Other revenues from external customers</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
<td class="nump">2.3<span></span>
</td>
<td class="nump">2.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=us-gaap_AsiaMember', window );">Asia</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentsGeographicalAreasAbstract', window );"><strong>Geographic information</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">217.3<span></span>
</td>
<td class="nump">143.7<span></span>
</td>
<td class="nump">112.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RevenuesfromantiCD20therapeuticprograms', window );">Revenues from anti-CD20 therapeutic programs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSalesRevenueNet', window );">Other revenues from external customers</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.2<span></span>
</td>
<td class="nump">62.9<span></span>
</td>
<td class="nump">58.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.0<span></span>
</td>
<td class="nump">7.7<span></span>
</td>
<td class="nump">2.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentsGeographicalAreasAbstract', window );"><strong>Geographic information</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">313.0<span></span>
</td>
<td class="nump">333.3<span></span>
</td>
<td class="nump">328.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RevenuesfromantiCD20therapeuticprograms', window );">Revenues from anti-CD20 therapeutic programs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63.1<span></span>
</td>
<td class="nump">65.9<span></span>
</td>
<td class="nump">70.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSalesRevenueNet', window );">Other revenues from external customers</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="nump">$ 1.7<span></span>
</td>
<td class="nump">$ 3.2<span></span>
</td>
</tr>
<tr><td colspan="13"></td></tr>
<tr><td colspan="13"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Represents amounts related to Europe less those attributable to Germany.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RevenuesfromantiCD20therapeuticprograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenues from anti-CD20 therapeutic programs consists of our share of pre-tax co-promotion profits in the U.S.; reimbursement of selling and development expense in the U.S.; and revenue on sales of RITUXAN outside the U.S., which consist of our share of pre-tax co-promotion profits in Canada.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RevenuesfromantiCD20therapeuticprograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSalesRevenueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after sales adjustments, returns, allowances, and discounts, of revenue classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSalesRevenueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentsGeographicalAreasAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentsGeographicalAreasAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=us-gaap_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=us-gaap_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=country_DE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=country_DE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=us-gaap_AsiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=us-gaap_AsiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>178
<FILENAME>R123.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6893871600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Details Textual)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms', window );">Revenues from unconsolidated joint business in percentage</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets related to operations in Denmark</a></td>
<td class="nump">$ 2,501.8<span></span>
</td>
<td class="nump">$ 2,187.6<span></span>
</td>
<td class="nump">$ 1,765.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SegmentInformationTextualAbstract', window );"><strong>Segment Information (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segment | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MajorDistributorAxis=biib_DistributorOneMember', window );">Distributor One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EntityWidePercentageOfRevenueFromMajorDistributors', window );">Entity wide percentage of revenue from major distributors</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MajorDistributorAxis=biib_DistributorTwoMember', window );">Distributor Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EntityWidePercentageOfRevenueFromMajorDistributors', window );">Entity wide percentage of revenue from major distributors</a></td>
<td class="nump">22.00%<span></span>
</td>
<td class="nump">26.00%<span></span>
</td>
<td class="nump">27.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=country_DK', window );">DENMARK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets related to operations in Denmark</a></td>
<td class="nump">$ 643.6<span></span>
</td>
<td class="nump">$ 684.9<span></span>
</td>
<td class="nump">$ 676.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=biib_SolothurnMember', window );">Solothurn</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets related to operations in Denmark</a></td>
<td class="nump">$ 545.5<span></span>
</td>
<td class="nump">$ 161.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EntityWidePercentageOfRevenueFromMajorDistributors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity wide percentage of revenue from major distributors.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EntityWidePercentageOfRevenueFromMajorDistributors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenues In Percentage From Anti-CD20 Therapeutic Programs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SegmentInformationTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Segment Information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SegmentInformationTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_MajorDistributorAxis=biib_DistributorOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_MajorDistributorAxis=biib_DistributorOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_MajorDistributorAxis=biib_DistributorTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_MajorDistributorAxis=biib_DistributorTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=country_DK">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=country_DK</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=biib_SolothurnMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=biib_SolothurnMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>179
<FILENAME>R124.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6888835600">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Quarterly Financial Data (Unaudited) (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SelectedQuarterlyFinancialInformationAbstract', window );"><strong>Selected Quarterly Financial Information [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2,502.9<span></span>
</td>
<td class="nump">$ 2,539.6<span></span>
</td>
<td class="nump">$ 2,466.0<span></span>
</td>
<td class="nump">$ 2,309.4<span></span>
</td>
<td class="nump">$ 2,425.9<span></span>
</td>
<td class="nump">$ 2,391.7<span></span>
</td>
<td class="nump">$ 2,198.6<span></span>
</td>
<td class="nump">$ 2,172.3<span></span>
</td>
<td class="nump">$ 9,817.9<span></span>
</td>
<td class="nump">$ 9,188.5<span></span>
</td>
<td class="nump">$ 8,203.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RevenuesfromantiCD20therapeuticprograms', window );">Revenues from anti-CD20 therapeutic programs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">318.2<span></span>
</td>
<td class="nump">317.6<span></span>
</td>
<td class="nump">349.2<span></span>
</td>
<td class="nump">329.5<span></span>
</td>
<td class="nump">333.9<span></span>
</td>
<td class="nump">337.2<span></span>
</td>
<td class="nump">337.5<span></span>
</td>
<td class="nump">330.6<span></span>
</td>
<td class="nump">1,314.5<span></span>
</td>
<td class="nump">1,339.2<span></span>
</td>
<td class="nump">1,195.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSalesRevenueNet', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">50.9<span></span>
</td>
<td class="nump">98.6<span></span>
</td>
<td class="nump">79.0<span></span>
</td>
<td class="nump">87.9<span></span>
</td>
<td class="nump">79.5<span></span>
</td>
<td class="nump">49.0<span></span>
</td>
<td class="nump">55.6<span></span>
</td>
<td class="nump">52.0<span></span>
</td>
<td class="nump">316.4<span></span>
</td>
<td class="nump">236.1<span></span>
</td>
<td class="nump">304.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,872.0<span></span>
</td>
<td class="nump">2,955.8<span></span>
</td>
<td class="nump">2,894.2<span></span>
</td>
<td class="nump">2,726.8<span></span>
</td>
<td class="nump">2,839.3<span></span>
</td>
<td class="nump">2,777.9<span></span>
</td>
<td class="nump">2,591.6<span></span>
</td>
<td class="nump">2,555.0<span></span>
</td>
<td class="nump">11,448.8<span></span>
</td>
<td class="nump">10,763.8<span></span>
</td>
<td class="nump">9,703.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross Profit</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2,493.5<span></span>
</td>
<td class="nump">2,538.9<span></span>
</td>
<td class="nump">2,523.9<span></span>
</td>
<td class="nump">2,413.8<span></span>
</td>
<td class="nump">2,507.5<span></span>
</td>
<td class="nump">2,467.9<span></span>
</td>
<td class="nump">2,305.5<span></span>
</td>
<td class="nump">2,242.6<span></span>
</td>
<td class="nump">9,970.1<span></span>
</td>
<td class="nump">9,523.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">647.9<span></span>
</td>
<td class="nump">1,030.2<span></span>
</td>
<td class="nump">1,048.4<span></span>
</td>
<td class="nump">969.2<span></span>
</td>
<td class="nump">828.7<span></span>
</td>
<td class="nump">1,019.5<span></span>
</td>
<td class="nump">924.8<span></span>
</td>
<td class="nump">820.2<span></span>
</td>
<td class="nump">3,695.7<span></span>
</td>
<td class="nump">3,593.2<span></span>
</td>
<td class="nump">2,941.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Idec Inc</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 649.2<span></span>
</td>
<td class="nump">$ 1,032.9<span></span>
</td>
<td class="nump">$ 1,049.8<span></span>
</td>
<td class="nump">$ 970.9<span></span>
</td>
<td class="nump">$ 831.6<span></span>
</td>
<td class="nump">$ 965.6<span></span>
</td>
<td class="nump">$ 927.3<span></span>
</td>
<td class="nump">$ 822.5<span></span>
</td>
<td class="nump">$ 3,702.8<span></span>
</td>
<td class="nump">$ 3,547.0<span></span>
</td>
<td class="nump">$ 2,934.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic earnings per share attributable to Biogen Inc.</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="nump">$ 4.72<span></span>
</td>
<td class="nump">$ 4.79<span></span>
</td>
<td class="nump">$ 4.44<span></span>
</td>
<td class="nump">$ 3.77<span></span>
</td>
<td class="nump">$ 4.16<span></span>
</td>
<td class="nump">$ 3.94<span></span>
</td>
<td class="nump">$ 3.50<span></span>
</td>
<td class="nump">$ 16.96<span></span>
</td>
<td class="nump">$ 15.38<span></span>
</td>
<td class="nump">$ 12.42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted earnings per share attributable to Biogen Inc.</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2.99<span></span>
</td>
<td class="nump">$ 4.71<span></span>
</td>
<td class="nump">$ 4.79<span></span>
</td>
<td class="nump">$ 4.43<span></span>
</td>
<td class="nump">$ 3.77<span></span>
</td>
<td class="nump">$ 4.15<span></span>
</td>
<td class="nump">$ 3.93<span></span>
</td>
<td class="nump">$ 3.49<span></span>
</td>
<td class="nump">$ 16.93<span></span>
</td>
<td class="nump">$ 15.34<span></span>
</td>
<td class="nump">$ 12.37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic earnings per share attributable to Biogen Inc.</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">216.6<span></span>
</td>
<td class="nump">218.9<span></span>
</td>
<td class="nump">219.1<span></span>
</td>
<td class="nump">218.9<span></span>
</td>
<td class="nump">220.4<span></span>
</td>
<td class="nump">232.2<span></span>
</td>
<td class="nump">235.3<span></span>
</td>
<td class="nump">235.0<span></span>
</td>
<td class="nump">218.4<span></span>
</td>
<td class="nump">230.7<span></span>
</td>
<td class="nump">236.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted earnings per share attributable to Biogen Inc.</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">217.0<span></span>
</td>
<td class="nump">219.4<span></span>
</td>
<td class="nump">219.4<span></span>
</td>
<td class="nump">219.3<span></span>
</td>
<td class="nump">220.8<span></span>
</td>
<td class="nump">232.6<span></span>
</td>
<td class="nump">235.7<span></span>
</td>
<td class="nump">235.6<span></span>
</td>
<td class="nump">218.8<span></span>
</td>
<td class="nump">231.2<span></span>
</td>
<td class="nump">237.2<span></span>
</td>
</tr>
<tr><td colspan="12"></td></tr>
<tr><td colspan="12"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">(1) Gross profit is calculated as total revenues less cost of sales, excluding amortization of acquired intangible assets.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RevenuesfromantiCD20therapeuticprograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenues from anti-CD20 therapeutic programs consists of our share of pre-tax co-promotion profits in the U.S.; reimbursement of selling and development expense in the U.S.; and revenue on sales of RITUXAN outside the U.S., which consist of our share of pre-tax co-promotion profits in Canada.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RevenuesfromantiCD20therapeuticprograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=65016374&amp;loc=d3e4984-109258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSalesRevenueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after sales adjustments, returns, allowances, and discounts, of revenue classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSalesRevenueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4569616-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4591551-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SelectedQuarterlyFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SelectedQuarterlyFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Weighted-Average Number of Common Shares Outstanding<br> -URI http://asc.fasb.org/extlink&amp;oid=6528421<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>180
<FILENAME>R125.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6909652720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Financial Data (Unaudited) (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="7">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems', window );"><strong>Schedule Of Development Milestone And Collaboration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33.1<span></span>
</td>
<td class="nump">$ 93.4<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,973.3<span></span>
</td>
<td class="nump">2,012.8<span></span>
</td>
<td class="nump">1,893.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">TECFIDERA litigation settlement and license charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">454.8<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net (loss) income attributable to noncontrolling interests, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7.1)<span></span>
</td>
<td class="nump">46.2<span></span>
</td>
<td class="nump">$ 6.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember', window );">Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems', window );"><strong>Schedule Of Development Milestone And Collaboration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.6<span></span>
</td>
<td class="nump">50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_AGTCMember', window );">AGTC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems', window );"><strong>Schedule Of Development Milestone And Collaboration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26.5<span></span>
</td>
<td class="nump">$ 54.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_MitsubishiTanabePharmaCorporationMember', window );">Mitsubishi Tanabe Pharma Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems', window );"><strong>Schedule Of Development Milestone And Collaboration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis=biib_NeurimmuneMember', window );">Neurimmune</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems', window );"><strong>Schedule Of Development Milestone And Collaboration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net (loss) income attributable to noncontrolling interests, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=biib_A2015RestructuringChargesMember', window );">2015 Restructuring Charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems', window );"><strong>Schedule Of Development Milestone And Collaboration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.7<span></span>
</td>
<td class="nump">$ 93.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FacilityLocationAxis=biib_CambridgeMAMember', window );">Cambridge, MA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems', window );"><strong>Schedule Of Development Milestone And Collaboration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveAcceleratedDepreciation', window );">Accelerated depreciation</a></td>
<td class="nump">$ 14.0<span></span>
</td>
<td class="nump">$ 15.7<span></span>
</td>
<td class="nump">$ 15.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_SPINRAZAMember', window );">SPINRAZA | Ionis Pharmaceuticals, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems', window );"><strong>Schedule Of Development Milestone And Collaboration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_LicenseFee', window );">License Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_LicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_LicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Development Milestone And Collaboration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4591551-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Research and Development<br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140864-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveAcceleratedDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accelerated depreciation charged against earnings associated with exit from or disposal of business activities or restructuring plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveAcceleratedDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_EisaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_AGTCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_AGTCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_MitsubishiTanabePharmaCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_MitsubishiTanabePharmaCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis=biib_NeurimmuneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis=biib_NeurimmuneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=biib_A2015RestructuringChargesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=biib_A2015RestructuringChargesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FacilityLocationAxis=biib_CambridgeMAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FacilityLocationAxis=biib_CambridgeMAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_SPINRAZAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_SPINRAZAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_IonisPharmaceuticalsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_IonisPharmaceuticalsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>181
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M?_A=A7UOW=[]8^.+H&[@U[_07U!+ P04    "  S@T)*F5R<(Q &  "<)P
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M$J-U[,7$LZ +HE!17<9U2>1F!R;O?W(/8K$',7\[(CD^$>,3G@'B>)<PQU]
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M7@]'P\-%6UW&8V__=O:^_1]02P,$%     @ ,X-"2HD:?8=: P  L T  !@
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MJ3K\F=9_[XYOB1\_5.5K> -^<GH-_^H_4$L#!!0    ( #.#0DK.6UHBM0$
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MA,:%XZT_FVG,)L-A/_\@MGSC\@]02P,$%     @ ,X-"2J8SB9VT 0  T@,
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MV4YC-AG>]/,/8LLW+G\"4$L#!!0    ( #.#0DIG67+QM@$  -(#   9
M>&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;&U386_;(!#]*X@?4!+';:/(MM1T
MFCIIDZ)6VSX3^VRC N<"CKM_7\"NZW;^ MQQ[]V[X\@&-,^V!7#D54EM<]HZ
MUQT8LV4+BMLK[$#[FQJ-XLZ;IF&V,\"K"%*2)9O-#5-<:%IDT7<R18:]DT+#
MR1#;*\7-OR-(''*ZI>^.1]&T+CA8D76\@2=PO[N3\1:;62JA0%N!FABH<WJW
M/1S3$!\#_@@8[.),0B5GQ.=@_*ARN@F"0$+I @/WVP7N0<I Y&6\3)QT3AF
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M_[*Q_XW6#KR4Y,J/4.<_V&((:%PXWOBSF<9L,ISNYQ]$EF]<_@502P,$%
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M4]MNW" 0_17$!X0UZZ:KE6TIFRI*I59:I6KSS-IC&X6+"WB=_GT!$\=MK;X
M,\PY<V88BDF;%]L#./0JA;(E[IT;CH38N@?)[(T>0/F;5AO)G#=-1^Q@@#41
M) 6AN]TMD8PK7!71=S95H4<GN(*S07:4DIE?)Q!Z*G&&WQQ/O.M=<)"J&%@'
MW\!]'\[&6V1A:;@$9;E6R$!;XKOL>,I#? SXP6&RJS,*E5RT?@G&YZ;$NR (
M!-0N,#"_7>$>A A$7L;/Q(F7E &X/K^Q/\3:?2T79N%>BV?>N+[$!XP::-DH
MW).>'B'5\P&C5/P7N(+PX4&)SU%K8>.*ZM$Z+1.+ER+9Z[QS%?<IW1P2;!M
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M^,$60T'MP_$MGNTT9I/A33__(+9\X^(W4$L#!!0    ( #.#0DH1]JGGLP$
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MX^/Q-ISM-&:3X;&??Q!;OG'Y"U!+ P04    "  S@T)*E<\&DK0!  #2 P
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M?S;3F$V&PW[^06SYQL4?4$L#!!0    ( #.#0DIC;QARL0$  -(#   9
M>&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;'U3VV[;, S]%4$?4"5*NG:!;:!I
M,6S !@0=MCTK-FT+U<63Y+C[^U&RXWF=L1>+I'D.#RDJ&ZQ[\2U (*]:&9_3
M-H3NP)@O6]#"W]@.#/ZIK=,BH.L:YCL'HDH@K1C?;-XQ+:2A199B)U=DM@]*
M&C@YXGNMA?MU!&6'G&[I-? LFS;$ "NR3C3P%<*W[N308S-+)348+ZTA#NJ<
M/FP/QWW,3PG?)0Q^89/8R=G:E^A\JG*ZB8) 01DB@\#C H^@5"1"&3\G3CJ7
MC,"E?67_D'K'7L["PZ-5/V05VIS>4U)!+7H5GNWP$:9^;BF9FO\,%U"8'I5@
MC=(JG[ZD['VP>F)!*5J\CJ<TZ1PF_BML'< G '\#8&.AI/Q)!%%DS@[$C;/O
M1+SB[8'C;,H83*-(_U"\Q^BEX/PN8Y=(-.4<QQR^R-G.&0S9YQ)\K<21_P/G
MZ_#=JL)=@N_^4GB_3K!?)=@G@OU_6US+>?^F"%O,5(-KTC9Y4MK>I$U>1.>%
M?>#I3OZDC]O^1;A&&D_.-N#-IOG7U@9 *9L;7*$6']CL**A#-._0=N.:C4ZP
MW?2"V/R,B]]02P,$%     @ ,X-"2I]C8;JS 0  T@,  !D   !X;"]W;W)K
M<VAE971S+W-H965T,C4N>&UL?5-A;]P@#/TKB!]0<N3:5:<D4J_3U$J;=.JT
M]3.7. DJQ"F02_?O!R3-LBW;%\#&[_G9F&Q$\V); $?>M.IL3EOG^@-CMFQ!
M"WN%/73^ID:CA?.F:9CM#8@J@K1B/$ENF!:RHT46?2=39#@X)3LX&6('K87Y
M<02%8TYW]-WQ))O6!0<KLEXT\!7<M_YDO,46EDIJZ*S$CABH<WJW.QSW(3X&
M?)<PVM69A$K.B"_!>*QRF@1!H*!T@4'X[0+WH%0@\C)>9TZZI S ]?F=_5.L
MW==R%A;N43W+RK4YO:6D@EH,RCWA^ !S/=>4S,5_A@LH'QZ4^!PE*AM74@[6
MH9Y9O!0MWJ9==G$?IYOK=(9M _@,X O@-N9A4Z*H_*-PHL@,CL1,O>]%>.+=
M@?O>E,$96Q'OO'CKO9>"ITG&+H%HCCE.,7P5LULBF&=?4O"M%$?^%YQOP]--
MA6F$I[\I_$?^_2;!/A+L_UOB5LR?*MFJIQI,$Z?)DA*'+D[RRKL,[!V/;_(K
M?)KV+\(TLK/DC,Z_;.Q_C>C 2TFN_ BU_H,MAH+:A>,'?S;3F$V&PW[^06SY
MQL5/4$L#!!0    ( #.#0DJ:[38 L $  -(#   9    >&PO=V]R:W-H965T
M<R]S:&5E=#(V+GAM;'U3VVZ<,!#]%<L?$.\:FD8K0,JFJE*IE5:IVCQ[8;@H
MOE#;+.G?=VQ8@A+4%SPSG'/FXG$V&OOB6@!/7I74+J>M]_V!,5>VH(2[,3UH
M_%,;JX1'US;,]19$%4E*,K[;W3(E.DV++,9.MLC,X&6GX62)&Y02]N\1I!ES
MNJ?7P%/7M#X$6)'UHH&?X'_U)XL>6U2J3H%VG='$0IW3^_WAF 9\!/SN8'0K
MFX1.SL:\!.=;E=-=* @DE#XH"#PN\ !2!B$LX\^L29>4@;BVK^I?8^_8RUDX
M>##RN:M\F],[2BJHQ2#]DQD?8>[G$R5S\]_A A+AH1+,41KIXI>4@_-&S2I8
MBA*OT]GI>(ZS_I6V3> S@;\CL"E1K/R+\*+(K!F)G6;?BW#%^P/'V90A&$<1
M_V'Q#J.7@B=)QBY!:,8<)PQ?8?8+@J'ZDH)OI3CR#W2^34\V*TPB/5G3^=VV
M0+HID$:!]+\M;F'2=TG8:J8*;!.WR9'2##IN\BJZ+.P]CW?R!I^V_8>P3:<=
M.1N/-QOG7QOC 4O9W> *M?C %D="[8/Y&6T[K=GD>-//+X@MS[CX!U!+ P04
M    "  S@T)*\AQC\+4!  #2 P  &0   'AL+W=O<FMS:&5E=',O<VAE970R
M-RYX;6Q]4V%OVR 0_2N('U 2DJ959%MJ6E6;M$E1IVV?B7VV48'S ,?=OQ]@
MU_,V:U^ .^Z]>W<<V8#VU;4 GKQI95Q.6^^[(V.N;$$+=X,=F'!3H]7"!],V
MS'461)5 6C&^V1R8%M+0(DN^LRTR[+V2!LZ6N%YK87^>0.&0TRU]=[S(IO71
MP8JL$PU\ ?^U.]M@L9FEDAJ,DVB(A3JG#]OC:1_C4\ W"8-;G$FLY(+X&HV/
M54XW41 H*'UD$&&[PB,H%8F"C!\3)YU31N#R_,[^G&H/M5R$@T=4WV7EVYS>
M4U)!+7KE7W#X %,]MY1,Q7^"*Z@0'I6$'"4JEU92]LZCGEB"%"W>QEV:M _C
MS>$PP=8!? +P&7"?\K Q45+^)+PH,HL#L6/O.Q&?>'ODH3=E=*96I+L@W@7O
MM>"[VXQ=(]$4<QIC^")F.T>PP#ZGX&LI3OP?.%^'[U85[A)\]X?"PSK!?I5@
MGPCV_RUQ+>;NKR1LT5,-MDG3Y$B)O4F3O/#. _O TYO\#A^G_;.PC32.7-"'
METW]KQ$]!"F;FS!";?A@LZ&@]O%X%\YV'+/1\-A-/XC-W[CX!5!+ P04
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M_:^-\8!2DAL<H18_V&)(J'TXOL>SG<9L,KSIYQ_$EF]<_ %02P,$%     @
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M,8<_DK!53S6X-DV3)Y4=3)KDE7<9V+OTB.PU?)KV+\*UTGARL0%?-O6_L38
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M@\V&@LJ'XS6>[3AFH^%--_T@-G_C_!502P,$%     @ ,X-"2E)V/-2S 0
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M_.+/9ARST7#833^(S=\X_P=02P,$%     @ ,X-"2KDL*Z0E P  N@X  !D
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MVV=BCR]:,"[@>/OW!>RXKLN^!&9\+C.$(9N$?%4M@$9OG/4JQZW6PXD05;;
MJ7H0 _3F2RTDI]J$LB%JD$ K1^*,1$%P))QV/2XRE[O((A.C9ET/%XG4R#F5
MO\_ Q)3C$-\3+UW3:IL@13;0!KZ!_CY<I(G(JE)U''K5B1Y)J'/\%)[.J<4[
MP(\.)K79(]O)58A7&WRN<AS8@H!!J:T"-<L-GH$Q*V3*^+5HXM72$K?[N_I'
MU[OIY4H5/ OVLZMTF^-'C"JHZ<CTBY@^P=+/ :.E^2]P V;@MA+C40JFW"\J
M1Z4%7U1,*9R^S6O7NW5:].\T/R%:"-&.0&8C5_D'JFF123$A.9_]0.U?')XB
M<S:E3;JC<-],\<ID;T6<!!FY6:$%<YXQT083K@ABU%>+R&=QCOZC1WYZ[*TP
M=O1X2P_>\4^\ HD32/YI,=RUZ,.\4^7!:W+P",0[$Q\F\9L<O29'C\!A9^+#
M'/TFJ=<D]0BD.Q,?YG%G0C97D(-LW/ I5(JQ=X._R:[S_12Y*_P7/C\.7ZEL
MNEZAJ]!F$-QUK8708$H)'LRIMN8]6@,&M;;;U.SE/)5SH,6P/#AD??6*/U!+
M P04    "  S@T)*'6LG+<X!  "<!   &0   'AL+W=O<FMS:&5E=',O<VAE
M970T,RYX;6QU5&V/G" 0_BN$'W"XJ-MVHR:WUS1MTB:;:WK]S.KXD@.Q@.OU
MWQ?0M<;2+PLS/B\S+$,V2?6J6P"#W@3O=8Y;8X83(;IL03#]( ?H[9=:*L&,
M#55#]*" 59XD.*%1="2"=3TN,I^[J"*3H^%=#Q>%]"@$4[_/P.64XP.^)YZ[
MIC4N08IL8 U\!_-CN"@;D56EZ@3TNI,]4E#G^/%P.A\=W@->.ICT9H]<)U<I
M7UWPI<IQY H"#J5Q"LPN-W@"SIV0+>/7HHE72T?<[N_JGWSOMI<KT_ D^<^N
M,FV.WV-40<U&;I[E]!F6?E*,EN:_P@VXA;M*K$<IN?:_J!RUD6)1L:4(]C:O
M7>_7:=&_T\($NA#HCD!F(U_Y1V98D2DY(36?_<#<7WPX47LVI4OZH_#?;/':
M9F]%G'S(R,T)+9CSC*$;S&%%$*N^6M"0Q9G^0Z=A>ARL,/;T>$N/DK! $A1(
MO$"R;3&-=BV&,/]I,@V:I $!NC,)8>*PR3%H<@P()#N3$";=F9#-[1"@&C\7
M&I5R[/U,;K+KZ#U2?[O^PN>Y_<94T_4:7:6Q=]3?I%I* [:4Z,$VW-JG8@TX
MU,9MW]F]F@=F#HP<EK> K ]2\0=02P,$%     @ ,X-"2OPA5=6X 0  T@,
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MJ%TX[OS9C&,V&DYWTP\B\S<N_@!02P,$%     @ ,X-"2I\TF\O& 0  -P0
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M"@HQ=&[P5]EEOA^)N\)_X=/C\(W*NNU4<!':#(*[KI40&DPIX9TYU<:\1TO
MH-)VFYB]G*9R"K3HYP<'+Z]>_@=02P,$%     @ ,X-"2JQ3@E?3 0  F@0
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MNW%[W<^7/K"J'48G'>=W_@=02P,$%     @ ,X-"2@48"3W$ 0  -P0  !D
M  !X;"]W;W)K<VAE971S+W-H965T-3,N>&UL;53_;YP@%/]7"'] N4-MNXN:
M]-HT6[(EER[K?N;TJ:0@#O#L_OL!6N=N_"+P^'QY#WCFD])OI@.PZ%V*WA2X
MLW8X$&*J#B0S-VJ WNTT2DMFW5*WQ P:6!U(4A"ZV]T2R7B/RSS$3KK,U6@%
M[^&DD1FE9/KW$82:"KS''X$7WG;6!TB9#ZR%[V!_#"?M5F15J;F$WG#5(PU-
M@1_VAV/F\0'PRF$RFSGRE9R5>O.++W6!=SXA$%!9K\#<<(%'$,(+N31^+9IX
MM?3$[?Q#_3G4[FHY,P./2OSDM>T*?(]1#0T;A7U1TV=8ZLDP6HK_"A<0#NXS
M<1Z5$B9\434:J^2BXE*1['T>>1_&:=[)LH46)]"%0%?"?? ALU'(_(E95N9:
M34C/9S\P?\7[ W5G4_E@.(JPYY(W+GHI4YKDY.*%%LQQQM -9K\BB%-?+6C,
MXDC_H],X/8EFF 1ZLJ4GG^(":50@#0+I/R6F5R7&,%G<)(N:9!&!VRN3&.;N
MRH1L+DZ";L.3-:A28Q_:91-=N^*!AHO_"Y];ZAO3+>\-.BOKGD^XY$8I"RZ5
MW8W+I7-=O"X$--9/[]Q<SV]Y7E@U+&U*UG]%^0=02P,$%     @ ,X-"2@]N
MU][% 0  -P0  !D   !X;"]W;W)K<VAE971S+W-H965T-30N>&UL;53MCIP@
M%'T5P@,LRCCM[$1-=G;3M$F;3+9I^YO1JY(%L8#C]NT+Z%H[RQ_A7LXY]P.N
M^:3TB^D +'J5HC<%[JP=CH28J@/)S)T:H'<GC=*266?JEIA! ZL#20I"D^0#
MD8SWN,R#[ZS+7(U6\![.&IE12J;_G$"HJ< I?G,\\[:SWD'*?& M? ?[8SAK
M9Y%5I>82>L-5CS0T!7Y(CZ>]QP? 3PZ3V>R1K^2BU(LWOM0%3GQ"(*"R7H&Y
MY0J/((07<FG\7C3Q&M(3M_LW]4^A=E?+A1EX5.(7KVU7X -&-31L%/9939]A
MJ6>/T5+\5[B"<'"?B8M1*6'"%U6CL4HN*BX5R5[GE?=AG>83>K_0X@2Z$.A*
M.(0X9 X4,G]BEI6Y5A/2<^\'YJ\X/5+7F\H[0RO"F4O>..^US.@A)U<OM&!.
M,X9N,.F*($Y]#4%C(4[T'9W&Z;MHAKM WVWIV2$ND$4%LB"0_5?B_4V)$<PN
MB0?91X/L(P+I39 8YK859'-Q$G0;GJQ!E1K[,"X;[SH5#S1<_#_X/%+?F&YY
M;]!%6?=\PB4W2EEPJ21W+I?.3?%J"&BLWWYT>SV_Y=FP:EC&E*S_BO(O4$L#
M!!0    ( #.#0DI39,X!N $  -(#   9    >&PO=V]R:W-H965T<R]S:&5E
M=#4U+GAM;'53VVZ<,!#]%<L?$+.&;:,5(&4318W42*M4;9^],( 57XAMEN3O
M:QM":4)?;,_XG#,7C_-1FV?; 3CT*H6R!>Z<ZP^$V*H#R>R5[D'YFT8;R9PW
M34ML;X#5D20%H4GRA4C&%2[SZ#N9,M>#$US!R2 [2,G,VQ&$'@N\P^^.)]YV
M+CA(F?>LA1_@?O8GXRVRJ-1<@K)<*V2@*?#-[G#, CX"?G$8[>J,0B5GK9^#
M\5 7. D)@8#*!07FMPO<@A!!R*?Q,FOB)60@KL_OZO>Q=E_+F5FXU>(WKUU7
MX&N,:FC8(-R3'K_!7,\>H[GX[W !X>$A$Q^CTL+&%56#=5K.*CX5R5ZGG:NX
MC]/-/IMIVP0Z$^A"N(YQR!0H9G[''"MSHT=DIM[W+#SQ[D!];ZK@C*V(=SYY
MZ[V7,DO3G%R"T(PY3ABZPNP6!/'J2PBZ%>)(/]'I-CW=S#"-]'1-W_\G?K8I
MD$6![!^!Y$.)GS%9FGT(0E8]E6#:.$T657I0<9)7WF5@;VA\D[_P:=H?F6FY
MLNBLG7_9V/]&:P<^E>3*CU#G/]AB"&A<.'[U9S.-V60XW<\_B"S?N/P#4$L#
M!!0    ( #.#0DK&NOK5> ,  $\1   9    >&PO=V]R:W-H965T<R]S:&5E
M=#4V+GAM;)58VX[:,!3\E2@?0&([5P1("ZAJI59:;=7V.0L&HDUBFAC8_GT=
M)YN",ZZ !Q*;.6<\)G-L9W81]5MSX%PZ[V51-7/W(.5QZGG-YL#+K)F((Z_4
M+SM1EYE4S7KO-<>:9UL=5!8>]?W(*[.\<A<SW?=<+V;B)(N\XL^UTYS*,JO_
M+'DA+G.7N!\=+_G^(-L.;S$[9GO^G<L?Q^=:M;PARS8O>=7DHG)JOIN[3V2Z
M#G2 1OS,^:6YNG=:*:]"O+6-+]NYZ[<CX@7?R#9%IBYGON)%T692X_C=)W4'
MSC;P^OXC^R<M7HEYS1J^$L6O?"L/<S=QG2W?9:="OHC+9]X+"EVG5_^5GWFA
MX.U(%,=&%(W^=C:G1HJRSZ*&4F;OW36O]/72Y_\(PP&T#Z#W!K ^@ T!)/AO
M0- '!$: UTG1<[/.9+:8U>+BU-W?>\S:IXA, S7[F[933[;^34U/HWK/BX"%
M,^_<)NHQRPY#KS!D0'@J^T!!$<62CL+I+<%JC&#^+60-()9!,*B3Z7AVHS/"
M"0*8(- )@IL$L3%1")-@DA"2A"!!:I  3.!CD@B21" !,4@0AF*2&)+$( $S
M2! FP"0))$E  O/A[3"IQE0:XT^2$+.DD"4%+)'!@C Q)B$^-J(/4B2F$Q$H
MM?!8#$_&*4+?Y.E \=6L$3^:&'_@"L*2B3$Y:P!+Z23UKSX6+Q-849X(!1IL
M*7 ](.."0'U+02"X(A!@]Y":,XE S,*#BP(!C@\M/B'8\B1Z0"TV- %N':M%
M((O9"/8T :8.;4/%AB7I_6HI=B,%1ANIA2"+6HK=2)$;+86#8C-0^H!:; ;*
M[E&+0);5C6+'4&0&2_FBV PT?$ M-@,%B]M8+0!%EF668L=08(;(MG/"9J#)
M VJQ&2A8FL9J 2BRK/<,.X8!,T260L>P&1BY7RW#9F!H93#5(E!D*:C,LIT$
M9H@LUF?8#"QX0"TV T,KPT@M MF&BAW#D!EL0\5F8/$#:K$9&%@9(G,+#D'&
M-FH%098ZQ+"M&'!,;*D/ 79,X-\_)0%V3 "6C]&4(%!L;/A7$&16 ._J5%GR
M>J]/[(VS$:=*MH>SJ][AK< 3;4^E1O^23-?=V?Y?FNY5P[>LWN=5X[P*J<Z\
M^F2Z$T)R-49_HI[D \^V0Z/@.]G>QNJ^[H[X74.*8__ZPAO>H2S^ E!+ P04
M    "  S@T)*S)UG<38"  "2!@  &0   'AL+W=O<FMS:&5E=',O<VAE970U
M-RYX;6R-5>V.FS 0?!7$ \0$") 30;HDJEJIE:*KVOYVR":@LS&UG7!]^_J#
MD 3<Z_T)]C(S.[NQE[QC_%54 -)[HZ01*[^2LGU"2)054"QFK(5&O3DR3K%4
M6WY"HN6 #X9$"0J#($$4UXU?Y":VXT7.SI+4#>RX)\Z48OYG#81U*W_N7P,O
M]:F2.H"*O,4G^ [R1[OC:H<&E4--H1$U:SP.QY7_/'_:+C7> '[6T(F[M:<K
MV3/VJC=?#BL_T(: 0"FU E:/"VR $"VD;/SN-?TAI2;>KZ_JGTSMJI8]%K!A
MY%=]D-7*SWSO $=\)O*%=9^AKV?A>WWQ7^$"1,&U$Y6C9$287Z\\"\EHKZ*L
M4/QFGW5CGIU]DUQI;D+8$\*!H'*_1XAZ0G0C).\2XIX0WPBQZ98MQ?1FBR4N
M<LXZC]M_M\7Z$,V?8M7]4@=-L\T[U1ZAHI<B3J,<7;10CUE;3/B B1\QFREF
M/B"0<C#8"%TVUJ$CQ6*48HH)'Q';*2(*W"XB9S,BPX\>7"1N@=@I$!N!^$$@
M'95A,8G!- 83C,JPB/0.$:;Q;.$VLG :63B,9&Z!Q"F0?+P5J5,@=3A8C@Y6
M.BTT"&;_.#B9,TWV_XZO+2;[6#^7SC3+:9IL]+>MEY-JU#69C9N&[FXF!7XR
M4T]X)3LW4I_=N^@P6)]#?;-'\8T:N'8^WF3LM/Z&^:ENA+=G4LT-<[N/C$E0
M)H.9.AF5^D ,&P)'J9>I6G,[)NU&LK;_ J#A,U3\!5!+ P04    "  S@T)*
MUDSB_E0"  ">!P  &0   'AL+W=O<FMS:&5E=',O<VAE970U."YX;6R-55MO
MFS 4_BN(]W$Q!DQ$D-:DTR9M4M5JV[.3. $5,+.=T/W[V88R@ITM>0B^?)=S
MCF]Y3]DK+PD1SEM3MWSMED)T*]_G^Y(TF'NT(ZV<.5+68"&[[.3SCA%\T*2F
M]D$0)'Z#J]8M<CWVQ(J<GD5=M>2).?S<-)C]?B U[==NZ+X//%>G4J@!O\@[
M?"(O1'SOGICL^9/*H6I(RRO:.HP<U^['</48:H)&_*A(SV=M1Z6RH_15=;X<
MUFZ@(B(UV0LE@>7G0C:DKI62C./7*.I.GHHX;[^K?]+)RV1VF),-K7]6!U&N
M7>0Z!W+$YUH\T_XS&1.*76?,_BNYD%K"52328T]KKO^=_9D+VHPJ,I0&OPW?
MJM7??IA)P$BS$\!( !,AA/\D1",ANI< 1P*\EQ"/A'A!\(?<=3&W6. B9[1W
MV+ ?.JRV7;B*Y7+MU:!>'3TGZ\GEZ*6 *,S]BQ(:,0\#!LPPX!JQ,1%1< W9
MFA"(%C*/%IF_L?@RCRD98$T&:'XT]T@3NT!D%8BT )P)(+@HQ@!)-:0=8DR2
MS(L6%3%A($DB#RTR-F%AF@0>L <-K4%#(VB8(KM ;!6([R];8A5(S C0HB#;
MQ,@4 NC=L$FM-JG%9K$\VP&#9C;I+1-D-4'_W0);9'B$ ,UVP)5+9G7)#)=L
MZ9(9+A\0]+)@]KMQ.,+ ?M0#2_WBY3$=0/'<]I;-C1LEM-@8MT%H;H?4W [^
M[!I3+]<WS$Y5RYT=%?)&U/?6D5)!I&3@R9A+^5A.G9H<A6JFLLV&%V/H"-J-
MKZ$_/<G%'U!+ P04    "  S@T)*!8'Z)% #  !'#@  &0   'AL+W=O<FMS
M:&5E=',O<VAE970U.2YX;6R55VUOVC 0_BM1?@")'><- 5(I19NT256G;9]3
M,! UB5EBH/OWLQ.3)O:YL"\D-L^=GSO?/;%G%U:_-0=*N?->%E4S=P^<'Z>>
MUVP.M,R:"3O22ORS8W69<3&L]UYSK&FV;8W*PL.^'WEEEE?N8M;./=>+&3OQ
M(J_H<^TTI[+,ZK]+6K#+W$7N=>(EWQ^XG/ 6LV.VIS\H_WE\KL7(Z[UL\Y)6
M3<XJIZ:[N?N IFL<28,6\2NGEV;P[LA07AE[DX.OV[GK2T:TH!LN763B<::/
MM"BD)\'CCW+J]FM*P^'[U?NZ#5X$\YHU])$5O_,M/\S=Q'6V=)>="O["+E^H
M"BAT'17]-WJFA8!+)F*-#2N:]M?9G!K.2N5%4"FS]^Z95^WSHOQ?S6 #K QP
M;R#6_LP@4 ;!O09$&9 /@^A3@U 9A!\&Y%.#2!E$FH'7):O-_BKCV6)6LXM3
M=P5TS&2=HFDD]G<C)]OM;/\3&]"(V?.")-',.TM'"K/L,'B(B<D8\PA@DGB,
M69D8U",\P;*GBB&J2PS0"#4:)@9K)&XBGDQ$X(\A:X!*@N%8 C#M0>L@&,42
MP0X(Z("T#LB(0:(EH\-$+:;J D&^%LKJ!FA$)02IA":56-_Z#A,.5M%X/'6(
M>(# ,9F$,)$()!(!.4FUG$0&$82-G$1&3D:@$948I!(#.4E@!PGH(+F_0%+0
M00HPT)*Q3,V<^_[$TI3(AP7$OUV):P4:9I2$EH0BBU"AVV6V5*#DOBI"H,X\
M(&RNE/KZ2MCL&\O^(%@"4  L@_1E() N:2 HL)"!Y01!>J+WC@(-FX<8O8-,
M02&VWD&PH"! 49) +ZG0V&J"R<2V![!B($ R4N/39LJ!M79A-4" '*2VHH3U
M /V'("!8$1 @"6:GIL8>![9H,:P(&% $H[!!D"4>#"L"!A1!K]FU HT$GUA2
MCV$]P( >&.6H0.%82RWKP(* H3:.+2[@-L;D_BK!</-AJ/F,K)K?<X)L685;
M#T-?:R.K9NMAK&?5&YQU2UKOVYM*XVS8J>+RD#:8[6]##UB>E;7Y%9H^=7>:
M#S?=%>M[5N_SJG%>&1<G\?:\O&.,4\'1GX@L',2MKA\4=,?E:RS>Z^YJTPTX
M.ZIKF]??'1?_ %!+ P04    "  S@T)*!-R?3[0"  "+"@  &0   'AL+W=O
M<FMS:&5E=',O<VAE970V,"YX;6R55M&.FS 0_!7$>P$;"$F41$JNJEJIE:*K
MKGUVB!/0 ::VDUS_OK;Q40+K*GT)MIG=V34SRJYNC+^*@E+IO=55(]9^(66[
M#$.1%[0F(F M;=2;$^,UD6K+SZ%H.25'$U17(8ZB65B3LO$W*W.VYYL5N\BJ
M;.B>>^)2UX3_WM&*W=8^\M\/GLMS(?5!N%FUY$R_4_G2[KG:A7V68UG31I2L
M\3@]K?TM6NXPU@$&\:.D-S%8>[J5 V.O>O/EN/8C71&M:"YU"J(>5_I$JTIG
M4G7\LDG]GE,'#M?OV3^9YE4S!R+H$ZM^ED=9K/VY[QWIB5PJ^<QNGZEM*/4]
MV_U7>J65@NM*%$?.*F%^O?PB)*MM%E5*3=ZZ9]F8YZU[DV(;!@=@&X#[ -SU
MTA&9RC\2238KSFX>[RZ_)?H;HR56=Y/K0W,5YITJ7JC3ZR99S%?A52>RF%V'
MP0,,ZA&ARMY38(ABAR?AR6(!)XC!&F.3(!XD2*,(3I" "1*3(+E+@$9-=IC,
M8!J#B;,@AEE2D"4%6/"(I</,!RPH<K',0)89P!*/6&83E@])%&"8)@-I,H F
M&=%D4QKL:F8.LLP!EG3$,I^PI(%#?PN09 &0S. $*()-$CVN0.3P&7I @Q8T
M[#6.@\Q!!+IMB_ #,K2@(5$2.#R)8%.B^ $A6M"=1&+D4B*"W8L@^XZU:$%W
M3*F3"#8P@AP\EB.:6A@[>6 +(\C#KJ\,VQ-E_Z%(V'L(,M]$D5/WQ8'+/+#]
M$.2_B2 7@,L3Q[\,;%(</2!("TJ',G'H'L-&QI"1QVK$4R-CE[\P[&,,^7@L
M1@O*_LD3#F:!FO*SF8*$E[-+8T:PP6D_:6W-\!'^A7=CVC?"SV4CO .3:B(Q
M<\.),4E5+5&@+K50DV&_J>A)ZF6FUKP;C[J-9*T=_<)^_MS\ 5!+ P04
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MMTS<&+LRK[O_B]VU;LIBR.*H%-FW_O-T[CYO_3>A&L)P@!P"Y#U F)\&J"%
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M+J-?D#8LL!()+),VOO$.(^JS6X#2"9]TCG+OZHP72RSI$NW/F:[Q3;4*.&F
MXIM,A$KFYEMA$U'(1*BB*2[[K5C1G\D0IME["F!"S4F:PAZBD(=021M ,SO#
M@3/WA0>V@4X12L]V&GN'0MY!I4PA6TAXIQ&,F4R*8.ZUGN,]<W*$W(,JV0 :
M']>XG\!TAXE0;,6F *7Y:^V/3O@*6QVZT]-ZL2NOYZ8]*!L]O9_0/LOVA) \
MWXC'M#]G_9&F/_;],ZL.IW.]>"V;IBRZ4\*WLFRL(QEX[JTZVFQ_O\GM6]->
M1NZZZH];^YNFO Q'R?[]/'O]/U!+ P04    "  S@T)*L0W/2! "   D!@
M&0   'AL+W=O<FMS:&5E=',O<VAE970V,RYX;6R-E=N.FS 417\%\0&8FPF-
M *G)3-5*K11-->VSDYP$- 93VPG3OZ]M/(@0J\I+?%M[<[;!3C$P_B9J .F]
MM[03I5]+V:\1$H<:6B("UD.G5DZ,MT2J(3\CT7,@1R-J*8K#,$,M:3J_*LS<
MCE<%NTC:=+#CGKBT+>%_-T#94/J1_S'QTIQKJ2=05?3D##]!OO8[KD9H<CDV
M+72B89W'X53ZGZ/U<Z9Y _QJ8!"SOJ>3[!E[TX-OQ](/=4% X2"U U'-%;9
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M*]7GX\4U#B3K[9V,IC^&ZA]02P,$%     @ ,X-"2GC=U_@S @  D08  !D
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MUD1Y&"16*D:5+51Q!-THB1,E<: 4%HK1%(M-LDT16,#U6I7F>?"D+JD3)G7
M;"R8=+6-J@NT8(PJ7:J2)W7)G"C9&B4)+91LC1+"S>J,UK(-A,\*DSMI<@=-
M9-'D#IHP6NQC:-:R8@,7S \TA9.F<-!8_[%]L?I\81Y8'U:]%B5A$%LH8'$Y
MJ,OZ!V+7MN?>D0IYS^C;X$*IP-(P#.2)-_)]F <$7X3JYK+/S"UI!H(.TP,
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M#YVFOVQT[-T+YO+%!.\Y[#U'O:?"RQ /CJY>E5 +9C/KL?T\M1\9CW>=R(Q
MFL<6]6"R\EP5V*(>35;,$/#8?!Y=(PAG9T_-%XLH7.YYNG[U$9<0]J@''O5<
M0MA9?L*<YK&S/#IV"B'@Z3[5+8SO_6/>BLWHP13GN=M"V&9^@LT\<^-HS%;2
M4YM) L#ER6W,;5:\MG=IR]E3_KZKFKN&)T^/]W5O17.;,WB^BB_O#[=N?U5S
MN 3\9UJ\KG?E[%M>5?FVO='YDN=55L<8+>IQ\):ES\</F^RE:GYM%CW%X?+M
MX4.5[[N+Q<OC[>:;_P%02P,$%     @ ,X-"2JVFHB/$ @  T0D  !D   !X
M;"]W;W)K<VAE971S+W-H965T-C<N>&ULC591;YLP$/XKB/>!;<! E41J$DV;
MM$E5IVW/;N(DJ( SXR3=OY]M*"7VI>L+V.;[[KX[F_/-+D(^=P?.5?#2U&TW
M#P]*'>_BN-L<>,.Z2!QYJ[_LA&R8TE.YC[NCY&QK24T=$X1HW+"J#1<SN_8@
M%S-Q4G75\@<9=*>F8?+ODM?B,@]Q^+KP6.T/RBS$B]F1[?D/KGX>'Z2>Q:.5
M;=7PMJM$&TB^FX?W^&Z-,T.PB%\5OW23<6!">1+BV4R^;N<A,HIXS3?*F&#Z
M=>8K7M?&DM;Q9S :CCX-<3I^M?[9!J^#>6(=7XGZ=[55AWE8A,&6[]BI5H_B
M\H4/ 65A,$3_C9]YK>%&B?:Q$75GG\'FU"G1#%:TE(:]].^JM>]+_X7F PTF
MD(% 1@*F[Q*2@9"\$=)W">E 2!U"W(=B<[-FBBUF4EP"V6_OD9E3A.]2G?V-
M6;3)MM]T>CJ]>EYD93*+S\;0@%GV&#+!X!$1:^NC"P*Y6!*/3JX=K'Q$@JXA
M:P!R0T0"QIE8?G(59PH;2$$#J3603@U@)T\])+>0ML\32?+(2><*@&&*(^I$
M[,/*HHQ*6',&:LY\S67FB.XQV<0-@EU0T 7U\IK<VI@<-) #&IU4+'M,,=%(
M*$VBPDFL#\,Y11&!Y12@G,*7DSG'=5GX?A"ADZWIY?BP$A71C>24H)H22$[N
MJ"D]-Y\(CE)'#(!*HPS6@A%<*A"@IG!K!?(<)926WD\ X* ]70^X_(.;BF]4
M.0Q(OW'.,5C%[C'Y> 7!< W"R?]KR("Y/L1)A-WT 3!R.RMP2</IQW]>#%<8
M#)08[W\90/1:+')#\E$E<O<HGMQK#9=[VS-TP4:<6F6NA\GJV)?<$W,O.NM+
MTZ_8^_+-3-_L?&=R7[5=\"24OG7MW;@30G&M$45:XT'W5^.DYCMEAKD>R[[)
MZ"=*'(<&*AZ[N,4_4$L#!!0    ( #.#0DI#6=0 M 4  .(E   9    >&PO
M=V]R:W-H965T<R]S:&5E=#8X+GAM;)5:[6ZK1A1\%<L/ .SW$CF6&D=5*[52
M=*O>_B;Q)K8N-BZ0Y/;MRU<L8&?7RQ_;X-GCV0-G/)S=S6=1_J@.QM2KGZ?\
M7-VO#W5]N8OCZN5@3ED5%1=S;KYY+<I35C>'Y5M<74J3[;M!ISRF22+C4W8\
MK[>;[MQ3N=T4[W5^/)NG<E6]GTY9^=^#R8O/^S59?YWX=GP[U.V)>+NY9&_F
M+U/_?7DJFZ/X&F5_/)ES=2S.J]*\WJ]_(7>/FK4#.L3WH_FL1I]7[52>B^)'
M>_#[_GZ=M(Q,;E[J-D36O'V8G<GS-E+#X]\AZ/KZF^W \>>OZ+]VDV\F\YQ5
M9E?D_QSW]>%^K=>KO7G-WO/Z6_'YFQDF)-:K8?9_F ^3-_"62?,;+T5>=:^K
ME_>J+DY#E(;**?O9OQ_/W?OG$/]K&!Y AP'T.H!P[P V#&"A _@P@,\&Q/U4
MNMP\9G6VW93%YZKL+^\E:^\B<L>;[+^T)[MD=]\UZ:F:LQ];D::;^*,--& >
M>@P=8>@4L;,1+)E"'@&$7"%QP_%*E$*BM!O/1N-EDN  # 9@70 ^"4!F,^TQ
MLL.<^VRP5,\FVX/4",2U3J(4D^&0# =D* X@8  1G@X) TC @,W2T6/T:*8T
M86DD9PFQ86F21@*S49"- FSXC(VRV?!H=J_N;!!3+BH:4M& BIA1Z3%B]"MR
M=BOMM,U618Y+G$(B*2 R2_U#:D^71S.V.QO$D\A1?"3!,I%89(A(YCJ16&E1
M0LS+9T"-Z0B="E=NB$.W""@ Y0B!%870@"L]@,9L";,J *%XY**#]8D@@=)S
M.LR^EE+9?)AU)<3\WGDDMI!1(ES%0K"0$5O)P(W!;=::1-:_B T3-'&F$0LC
M$2"-#FTF6!J)#!=7@O6,($&;_]L0H&A2LLBJ&!M'!''^XQ"L:P0(&W'-"BL2
M2<,30[&04%M([,106R(H4=02-H332K@20[&44 (2X_(F#G.RP)U07/XTQ)]0
MN_R%)*,*&?("5"+E+LFGN+(I\"C$(=(4UR)=X%(HKD4:XE,&T%CNDGE*?) I
M$5S1-,2BT""/ E!NDT)Q-=,0FT)MGV+EQ0>9$L&:0$-LR@#R$O%!IO8>*PL+
ML2@,*(9]@0#*?8$85A6VP* PK"HLQ* ,(%]JO9 I$<>C4X@U8;;GL(CX(%,B
M6)-8B-L80%XB/LB4"%8V!EP&88X06-G8 I?!L":Q$)<Q@+SI\$&F1+ :,>0M
MN",$UA&VP%MPK  \Q%MP^R%EG@XO9$H$USY'CL(A'QS7/E_@*#BN6A[B*/CM
MJO5"ID0<S0[D)*0C!*XWOL!)<%QO/,1)\,"6!\!Y>AX<ER\/L13\=OEZ(5,B
MN'QYB)G@ 4T/OJ3KP;$0\!!#P8,:'P#E[GP(+"HBQ%8(VS HP5@TSP_ "2V4
MZQ%78'D1"ZR%P/(B0JR%".I]()2S]R&P5(D0@R%N2Y47,B6"I4J$& QA]RE0
M7@#*G1='EQ?9#%<(+'MB@<T06*=$B,T0@<T,@/,U,P16+($,AW:$P#HC%A@.
MB;5!AA@.&=C,0#A/,T-B;9#(>KA"8&V0"ZR'Q/4L0ZR'#&MF )BGF2%Q74M@
M0:AK3K@6Y9(E%\>:2]"BR^UFAA<R)8(K6H8X#WG;>7@A4R*XCF6(\Y"WVQA>
MR)0(5@,9XCKD[3:&%S)=",.:HD+\AKK]$..%3(E@)5$+7(;"2J)"7(:ZW<#P
M0J9$L!ZI$'^APM96E']M94H'JY$*<1D*+)H@.G8KPTT'*YL"+H,Z]%5A95,+
M7(9R+ &'N QU6Y.\D"D1K$D*:!)U/,,HK"9J@;?06 =TB+?0MW7 "YD2P3J@
M@:.@CE:7QCJ@%S@*C2M8AS@*;>_?L-+A@_1$XM'>F7;WTY]9^78\5ZOGHJZ+
M4[=9YK4H:M.$2Z(FKP>3[:\'N7FMVX]M397]KJ/^H"XNPXZJ^+JM:_L_4$L#
M!!0    ( #.#0DK.L9 VH (  %,*   9    >&PO=V]R:W-H965T<R]S:&5E
M=#8Y+GAM;)56VXZ;,!3\%<0' #;W%8G4356U4BM%6W7[["1.0 N8VD[8_GUM
M0Q"!0\6^!-O,&>8,3.RL9?Q-Y)1*Z[TJ:[&Q<RF;)]<5QYQ61#BLH;6Z<V:\
M(E)-^<45#:?D9(JJTL6>%[D5*6I[FYFU/=]F["K+HJ9[;HEK51'^]YF6K-W8
MR+XOO!277.H%=YLUY$)_4OFKV7,U<P>64U'16A2LMC@];^Q/Z&F'38%!O!:T
M%:.QI5LY,/:F)]].&]O3BFA)CU)3$'6YT1TM2\VD=/SI2>WAF;IP/+ZS?S'-
MJV8.1- =*W\7)YEO[,2V3O1,KJ5\8>U7VC<4VE;?_7=ZHZ6":R7J&4=6"O-K
M':]"LJIG45(J\MY=B]I<V^Y.="^#"W!?@(<"%/RWP.\+_$F!VRDSK7XFDFPS
MSEJ+=V^K(?JC0$^^,O.H%XUWYI[J5JC5VS;"0>;>-%&/>>XP>(3!CXC='.%[
M \15 @85&%2!3;T_KO<CF, '"7Q#$#RT$4[:Z#"QP=0=)O$29]+M#H!%0>BD
ML)P E!, <A;Z"4&"<+TA$4@0 0KBB2$=)AEWZJ")&W-,.G+L04@,"HD!(0E,
MD( $R7HK4I @76%%.FLS3'QG@MK-49&'G04QR(,#YP%R%CXNM)!9M-X2! <.
MX16F]*!QORC$R FGZ0=P01J/<(^2X @C(,-+_R((CAT*/F ,'#P4KC$FG#?L
MX6CT)?3&0#@4.'A!$AQE!&391PL4< A1_ %CX!BB9(TQ'2@<-QRG,UN2N2UQ
M%"P&"8XU G+M+SB+X2QB;[TM&,XB1BMLZ4'C/04E<3 +$H2+PWAFC#O:W?5Q
MZP?AEZ(6UH%)=5 PV_F9,4D5I^>HEY&K$]XP*>E9ZF&LQKP[YG03R9K^".<.
MY\CM/U!+ P04    "  S@T)*M_%-M'$"  "W!P  &0   'AL+W=O<FMS:&5E
M=',O<VAE970W,"YX;6R-5=N.FS 4_!7$^V(NYI*((&T25:W42M%6VSX[B1/0
M J:V$[9_7U]8EA@GZ@O89F8\YV"?D_>$OK$28^Z\-W7+5F[)>;<$@!U*W"#F
MD0ZWXLN)T 9Q,:5GP#J*T5&1FAJ$OI^ !E6M6^1J;4>+G%QX7;5X1QUV:1I$
M_ZYQ3?J5&[@?"R_5N>1R 11YA\[X)^:OW8Z*&1A5CE6#6U:1UJ'XM'*?@^4V
M\"5!(7Y5N&>3L2-#V1/R)B??CBO7EXYPC0]<2B#QNN(-KFNI)'S\&43=<4])
MG(X_U+^HX$4P>\3PAM2_JR,O5V[F.D=\0I>:OY#^*QX"BEUGB/X[ON):P*43
ML<>!U$P]G<.%<=(,*L)*@][UNVK5N]=?DFR@V0GA0 A'0I \)$0#(?HDP(<$
M.!"@00 Z%)6;+>*HR"GI':I_;X?D*0J64&3_(!=5LM4WD1XF5J]%$D4YN$JA
M ;/6F'"""48$$.KC%J%MBW4XHX>W&VSFB,B_A6PMD#LF(FN<D>)'-W%"NP"T
M"D E &\$8B-1&I,H3*LP1A@;C4@GB#"%7FPW$EN-Q#,CT/QA&I)-=@F@EQE6
MYJ#(]XR(MO',[U.4>0N[W\3J-YGYC7W3<#+S\A1'GGE,+*C@;O)2JYET_A?]
MT"Z0606R_S]'"ZO PG*.$B,=&A-/ HU] [-9S)(1!O&]9(C*;+W\OL5,:MY^
M?W8&8))ZII\!ECPRO;5HV5R#2?5J,#VKSL"< [FT7!:!R>K8?9Y#6?V,];7L
M2JHJ?LKHEO8#T7/5,F=/N*BMJ@*>".%8N!2WP'5*T47'28U/7 Y3,::ZE>@)
M)]W0)L'8JXM_4$L#!!0    ( #.#0DJCM/XE*04  !0=   9    >&PO=V]R
M:W-H965T<R]S:&5E=#<Q+GAM;)59VVZK.!3]E2@? /C&I4HCM6E#*\U(U3F:
MF6>:N$UT(&2 -F?^?KBX*=C+@;PT@:Z]O;S9:V''BU->_"IW4E:SWUEZ*&_G
MNZHZWKANN=G)+"F=_"@/]7_>\B)+JOJR>'?+8R&3;1N4I2[U/-_-DOUAOERT
M]UZ*Y2+_J-+]0;X4L_(CRY+BOWN9YJ?;.9E_W?BQ?]]5S0UWN3@F[_*GK/XZ
MOA3UE7O.LMUG\E#N\\.LD&^W\SMR\RR")J!%_+V7I[+W?=9,Y37/?S47S]O;
MN=<PDJG<5$V*I/[XE"N9IDVFFL>_*NG\/&83V/_^E7W=3KZ>S&M2RE6>_K/?
M5KO;>3B?;>5;\I%6/_+3DU03$O.9FOT?\E.F-;QA4H^QR=.R_3O;?)15GJDL
M-94L^=U][@_MYTGE_PK# 50%T'- /?:E *8"V-0 K@+X=P"_&"!4@)@:X*L
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M-7G/J9_&3B;;\T4JWZKF:U!_+[ISNNZBRH_J#-(]'X0N_P=02P,$%     @
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MWA]=_42R=CB6P?C?H/@+4$L#!!0    ( #.#0DK-(4=\EP0  -$8   9
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M?S-Z_<B"6,!Q^_8%=%W7(?TC<#GGW'L0;CIR\2(; (5>&>UDYC5*]4>,9=$
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M&IDI1VBL?F 8 H"89SD@,.Q.AMQIZ:H,>XK%\_LJPYYBJ)U-.VL/&E>+#AH
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M:$P<[5AN.E0X0"4)SH1X>$'RD-6()UQ,U#1R_WH0M!X]$D!8:"NR4J"1;KS
MF2*+%POBFY&H7OI0T$1-(GA-(4A1H:#',4'!Y.+CA8 @E8#Z>AQ3P.#IQ6N-
MH$CL$.W$8:AD<A/P<D"0>D G"@K!14RB3QPZ7,8DON?0Q88.1U5I' B7.T'T
M3D/<!> R!>_^= &7*9 [TE6@8;H0.A,E!7 Q R)F.L455RE\XDX'7(" W>I&
MNLB%/13&.!"N0, 4.'&? *X'H)](%]<#8+>:ENY2@487>> $WN!OZF<D+B%
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M/0VX30#F$_-=;4 ?5D.M:EB0SUUQ  &9[@((7(QQ/P';4!+B< + K0!N\ +
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M_NO_Y(YQ.7M>% C-@K,2LIBEP40=S#LBD.KM$A&TQ#)RZ%%_@96+B,,^9 U
M!C:_N) TG/0Q=RZF0 ,W]Q FA@..P9S&6B#N"22P0 (*)%H@Z0FD@TTQF%1C
M&H,)PQ!>)05720&;&2R0@0(98#,?;(K!9!V;:=>FV97_@'I6<M!*#E@I!AG+
MG8S%\=#*R@6AK!BBUBXJFHP9+D##!6!X<%B7A9,6Y.1NY8+<!*\-*.\>EB*[
M*6##$]#PQ#4<#9993MSD.1F^=T'RXAQ+'@KAJA4";D:*$AHI?.CZKQ2!A>T6
M15=\IQ;42TJ>CH4+%Q04 ^%&(Q)P24'))\*%ZP5*KPDW=<,=WUVXKB"@L$0C
M%1C!]0#EGP@7_D(1](DZX19.N&GD[&[0N8UKPO:Z^>+>AIX:H6Z:SFS;X-U&
MZC8?S"_1=&W:M'<9TS7^P&Q?-MQ[ID+V"OI&WU$JB#09WDA[!]FHMH.*[(1Z
MS>4[,]V:&0AZM)UHT+;#BW]02P,$%     @ ,X-"2N09J<"D!   %A@  !D
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M @(,S4PL*&N 2V-;7YI"0+Z#>:AZ&%C'!1K)3640=(XVE>%S2/8A1.>*&X9
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MISRON,A=3+&N77AT["\2?JKJ4T^<%^W'DO:BRJ_=AR"S_QJU_!]02P,$%
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M.AHP:8_!$PP:$:[P/H; 4(@4&^9X'F!K(GQO#LD R ()'\S35_;^+,\(=D!
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M36,Y9Z8/F(6@W=#CP-AH\[]02P,$%     @ ,X-"2KIDFF<+ @  A04  !D
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M-BYX;6R55NV.FS 0?!7$ P V7R9*(H4D52NUTNFJMK]]B9.@ YS:3G)]^]K
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MVW3/N6+:;Q1HOT?=\@V#BNV5>9WI=]'U/=U \;;OZ<*AL5S] U!+ P04
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M3 A'PJ2[$@4MQ4D]3# Z<SF,Q9CVQU4_X:351[$S? _D_P%02P,$%     @
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MFU=WG_><F5&$[JG._LXTMLENW^GT-+KUNDHY7X17XZAGUAV#1PP:B%!['[K
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M*$F7,A.#,+$+DR$+)G:FB:,@0[.?O62N!6%! G,E(%?B<&%L)REQN7 062B
MB,X2^822@BBI@T*M27:#))HOEP6;I^Y:14L<&<B1 4ME)7Z7.;-\P+&SHR 5
MFZF>8#""CRD$X!#[G$+.3!@EV"ED0)=JV4+%X(6#$P-$U";";NPTB9U]#ND8
M0XM)@D]13  D9B,18#DP=2H9U"&RF"7X7,; P9S9]8S=,Y=ER*DC0!8QXE1U
M./OTF;O(=]Z>B[KS]E+IKVC_K3M)J81VB0*]B2[Z^C-U2G%2IIGH=CO< 8:.
MDLUXOPFG2];V'U!+ P04    "  S@T)*E8$GNZ "  !M"@  &@   'AL+W=O
M<FMS:&5E=',O<VAE970Q,#0N>&ULC9;=CMHP$(5?)<H#;'X)! $2 56MU$IH
MJVZO33 0K1.GMH'MV]=V0C89!N@-B<TWQV<F3CRS"Q?O\DBI<CY*5LFY>U2J
MGGJ>S(^T)/*%U[32_^RY*(G20W'P9"THV=F@DGFA[R=>28K*7<SLW$8L9ORD
M6%'1C7#DJ2R)^)M1QB]S-W"O$Z_%X:C,A+>8U>1 ?U+UJ]X(/?(ZE5U1TDH6
MO'($W<_=93!=!Z$)L,1;02^R=^^85+:<OYO!M]W<]8TCRFBNC 31ES-=4<:,
MDO;QIQ5UNS5-8/_^JO[%)J^3V1))5YS]+G;J.'<GKK.C>W)BZI5?OM(VH9'K
MM-E_IV?*-&Z<Z#5RSJ3]=?*35+QL5;25DGPTUZ*RUTNK?PW# \(V(.P"@N1A
M0-0&1)\!\<. N V(08#7I&)KLR:*+&:"7QS1/-Z:F%T43&-=_=Q,VF+;_W1Y
MI)X]+](TF7EG(]0R6<.$/2;H"$^K=TN$V!)9>!,>#A=8W1*1/T36"'+'1(3F
M&=GXJ!<?^W<$8E0@M@+QH%!C4"B,F8!<_X-9/V8&9D>HV1$BD *S"..#A%:W
M3.#[\-&@T)W:)JC=!%, FR1#H0@81J$8&$:A$6YXC!H>8PKPM4$A6&$4@OL!
MA5+<\ 0U/$$V!*A==LL,GF/C%Q&ZL?M$:& W1>VFB$( ]EV&0M O"H&MM7X"
M#0P'/OX=]3$-6&*4@B_4"J%2'[R^ZV=20]-W/OX!9CJ&IE%J!$VC5 )=H]3X
MCFOT/%D&(:8Q@:Y1*H6N,2J$7[AG6HUKKW?FEE0<;#\CG9R?*F6.KMYLUS,M
M;<L$YC/32]FS_%.F:<1^$'$H*NELN=(=@3VW]YPKJDWZ+_H[?-2]7S=@=*_,
M[5C?BZ8!:@:*UVUSYW4=YN(?4$L#!!0    ( #.#0DHM'Q?9J (  #L)   :
M    >&PO=V]R:W-H965T<R]S:&5E=#$P-2YX;6R%EMN.FS 0AE\%<5\.QN$0
MD4B;1%4KM=)JJ[;73N(D: %3VTFV;U_;L"S8LULN C;_S'PS.!Z7=\:?Q852
MZ;TT=2M6_D7*;AF&XG"A#1$!ZVBKWIP8;XA40WX.1<<I.1JCI@Y1%*5A0ZK6
M7Y=F[I&O2W:5==721^Z):],0_G=#:W9?^;'_.O%4G2]23X3KLB-G^H/*G]TC
M5Z-P]'*L&MJ*BK4>IZ>5_Q O=W&D#8SB5T7O8O+LZ53VC#WKP=?CRH\T$:WI
M06H71-UN=$OK6GM2''\&I_X84QM.GU^]?S;)JV3V1- MJW]71WE9^;GO'>F)
M7&OYQ.Y?Z)#0PO>&[+_1&ZV57).H& =6"_/K':Y"LF;PHE :\M+?J];<[_V;
M# UFL $:#-!H$*<?&B2#0?)F@#\TP(,!M@S"/A53FQV19%UR=O=X_WD[HE=1
MO,2J^@<]:8IMWJGR"#5[6\<1BLOPICT-HDTO0E/1J B5^S$&@F)LD&..Y@&V
MKB*)YI(=('D'(@$338Q],D\4P1XPZ $;#WCN(;%*U8LR(VJ-*,V"(II<5G&W
MKD6<Q,'"2A]0Q5'P3@46(/\"XL<6?R_*)W&RP/Y:KD:AV,"N"$5!#O.F(&\*
M\5IA-JD3)DD#ZZ-L75%<.,"N*$^#J)A>,'T&TF<0?6K19T[,3W'BX ,J7 2%
MQ0^H4!)@F#D'F7.(.;.8<X YL);1%A19ZV@'BE(8N "!"P@XMX +-TR*G2(#
M*HR<10+YFJ[]&;/JA^"6&T'4A;WG1LX_/D%.G0'5?_:;'6 RWW#Z',))!VDH
M/YON++P#N[92[\.3V?$$\&":HC6_T2<#TYG>W/3'BN^$GZM6>'LF57\S7>C$
MF*2*4M74]R[J)#,.:GJ2^C%3S[QOY_U LFXXJH3C>6G]#U!+ P04    "  S
M@T)*PG8RRXT#  "R#P  &@   'AL+W=O<FMS:&5E=',O<VAE970Q,#8N>&UL
ME5=M;YLP$/XKB!\ ^ 4P51*I33-MTB95F[9]IHF3H )FX"3=OY\-E!+[7"W]
M4,!Y[NZYP\^96UQ$^](=.9?>:U76W=(_2MG<A6&W/?(J[P+1\%K]LA=ME4OU
MV!["KFEYONN-JC+$492$55[4_FK1KSVUJX4XR;*H^5/K=:>JRMN_#[P4EZ6/
M_+>%[\7A*/5"N%HT^8'_X/)G\]2JIW#RLBLJ7G>%J+V6[Y?^/;K;$*(->L2O
M@E^ZV;VG4WD6XD4_?-DM_4@SXB7?2NTB5Y<S7_.RU)X4CS^C4W^*J0WG]V_>
M/_7)JV2>\XZO1?F[V,GCTF>^M^/[_%3*[^+RF8\)Q;XW9O^5GWFIX)J)BK$5
M9=?_][:G3HIJ]**H5/GK<"WJ_GH9_;^9P09X-,"3@8K]D0$9#<B[0?*A 1T-
MZ+L!_= @'@UBPR <<N^+^9C+?+5HQ<5KA_W0Y'K;H;M8O:ZM7NS?3O^;JF>G
M5L\K%)%H$9ZUIQ'T,(#P#$19>HU9VQ@T(4)%8>*!(1X/V#)G)#%"V!A\C7BT
M$68N&P#B($K @I'>GEP7S.&!@AYH[X%>>S R60^@M ?5/2AC6<",?&U4DJ5!
M!K.)038QQ(88&V  );,X.(6#)&"0!"H:A3VDH(<4HAD;11M \8QFFD01'(:!
M81@4QMR' XC-JY',BCZ\&AN$XL 0S899[R\F00(3SD#"&438U&9F<<D"9/"U
M,<3$;#*++@T<6Q]%<+N)(+[,["617>$X,,4^HN9T$ YB!Q]'^T,6GPP1APNP
M<]TC?$-'0'!3000J2V:6A5C[&S'7_D9P\T%V]\D0<[B .P:*;TD8;@@H^:^$
M$RMA3)P)PXT#09V#NGS 70&Q6S*&A8H@I5)D9FS+,&:!8T-B6&,8TA@U#QAL
M:TRI!SLBP>K!MGI4)!=;6#[X%OE@6#X8D@^E9L;$[BK.?H%A^6#H\*;F.32B
MKH3JVG(8%AF&SF7J.!HP+#(,'KNNTL+RP:!\S -F1,U+RY* 1K,_5UA8<1@Z
MB*FC3V%8<3B[(7T":XF 6C)W%K&U1-77FN,#A\!B(J"8'-]R!!83N45,Q/&!
M"XK)W.(CZOKP3:QOEW VAU2\/?1#8>=MQ:F6^BM\MCH-GO=8SS'&^EH-I,/X
M^.YFF&:_Y>VAJ#OO64@U)?6SS%X(R17+*% J.JH!>GHH^5[JVU3=M\,4.3Q(
MT8P3<CB-Z:M_4$L#!!0    ( #.#0DK%#7W&[ ,   X1   :    >&PO=V]R
M:W-H965T<R]S:&5E=#$P-RYX;6R-6&V/HS80_BN([POV&!M8)9$VR9U:J956
M5[7]S"9.@@YP#LCF^N]K7C8'GN%T? C@/#-^9FS/8[.ZF_IK<]&Z];Z71=6L
M_4O;7I_#L#E<=)DU@;GJROYS,G69M?:U/H?-M=;9L3<JBQ 84V&9Y96_6?5M
MK_5F96YMD5?ZM?::6UEF]7];79C[VN?^1\.7_'QINX9PL[IF9_V7;O^^OM;V
M+7QX.>:EKIK<5%ZM3VO_A3]_@J@SZ!'_Y/K>3)Z]+I0W8[YV+[\?US[K&.E"
M']K.169O[WJGBZ+S9'E\&YWZCSX[P^GSA_?/?? VF+>LT3M3_)L?V\O:3WSO
MJ$_9K6B_F/MO>@Q(^MX8_1_Z71<6WC&Q?1Q,T?2_WN'6M*8<O5@J9?9]N.=5
M?[^/_C_,: ,8#>!AP-5/#<1H('X81#\UB$:#Z%<-Y&@@'8-PB+U/YCYKL\VJ
M-G>O'N;#->NF'7^6=K@.76,_.OU_-I^-;7W?<";9*GSO/(V@[0""*>B!"*W[
M1Q] ];$%9 [S#G88(1P.>P+"YY!/&"+% E%!)D/T#J)Y,IQ>M@,H[D%5#U),
M!M*)B$ I"&(G*(R*$A$D3EP$"E0 =&01&5G4NQ#SR!8\2-*#I'(CG-P,H&3"
M%!(>N*.-42(-G#3O,2CB2S$KDK&B&$<.8X6ZX2H"1)F"Q9$[4GL"QI58HAV3
MM&-JJ"3M(2$])%3@R@D\050M42<[.PP"0".%01R60DY)PBE%V%DKVP$DIUR4
M4R1V*:*2HJ6YQR!(@X4$<T97348Q3MRRR1!E9Q1V(V1*Y@D5@#V!XGR"FE->
M*/2<HIRZE#GFDP8)FU[<C8&P$;C643 ;A5J(@I22%PXHBBB1;A" \O[$8Y<U
M$'2(U!.P)%#I[%H(@1893JF,.Y.W(VK6+_ 8K5 *QT'@[&,1>0*Y.(=H%>&4
MC*@%B>6TCG!*2!2XX>/R+Q/FCLZ.@K%H$OR<$:T3G!(*Y4H;Q[4]DD@!=B-L
M.O?8 ANZ_/.88N/*UHB:*RT$J<N&@,5L<=1I.>&4GBBTZ @92"7.#P%3<;"T
MA&B]X)1@*%?A.%8,+M#ZP6J06#ITO9OO=6EI $H:E"MF0%1TP=#X$3"QN L"
MNO #+OS"'3S M5DETBTB.P(F^>).%.@2#KB$I^X>&W#5A90)M,NF<"Q52Q,<
MZ(H,N"++R429NZ K(T2_<G084;.=O$@"=U- P"1/ G<>AI,S7JGK<W_@;KR#
MN55M=PR:M#X.]2_0G1&=]BU_W@]'\Q]NAB\%?V;U.:\:[\VT]@3:GQ-/QK3:
MLF2!75@7G1T?+X4^M=UC;)_KX80^O+3F.GY]"!^?0#;_ U!+ P04    "  S
M@T)*Q[6E.0 %   ,&0  &@   'AL+W=O<FMS:&5E=',O<VAE970Q,#@N>&UL
ME5G;4N,X$/V55-[7=DN^4B%5$(;+@ /,UNX^&R)(:NPX:QLR\_<KVTK6;K5
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MROY.O(M<PMM(Y!K/95YW_R?/;W53%LJ+#*7(?O6OFVWWNE?^#V:T 5,&[&C
MX$,#K@RXK8&O#'Q;@T 9!+8&H3((;0TB91#9&L3*(+8U2)1!8FL WJ%SGK7)
ML=E@;7)H-UCW&PX-!^N.PZ'E8-US.#0=K+L.A[:#==_AT'C G7=[7G5$O<B:
M;#ZKROVDZK5FE[62!B?22CIO[W;4[SZ49*WEW?<Y>&$\<]];5PITWH/8 .1'
M_ABS(#!Q-,:D.@:."%?&>0R6D<&>,]W>"Q,4B [R$X2YH!Q%WACTC03!&'1)
M@M@8=*6#(KS:-8&)@S'FAER,CT'?21#JUBT)0LO=D: 0]=2BW$N+_._)Q=
M/9 @-*V/)"BA!XW3K."="SX:^)#VX-,>_,Z#/_2 RIOVD*B#;!7$=U VRQX5
M#E"X<A\A1J$&=*B!%FH0H E.>TP\6 ,\%CJXT3HL\6+'0/*0#B?4PI$D1U.W
M"+6<@:,9OPJU^L:1DWB#/T3FM+<(/O*Z#+44S5Y'Z49TNI$^*'CLTTB+"\W
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M-I+OJ_[Y?'_1E#OUVX-[_ %D_A]02P,$%     @ ,X-"2H]6=LT5 P  5PP
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M)Z:'. @AN4I2^*1$>5)M93_(^4'JQZEZKMO>JAU(475]8] WKZM_4$L#!!0
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M5A&**BK5Z?-'4-J";K<@%RLWT<Z(8#Y/%%.]>H35N[!0*]"/H"Y?Y8D:Z0L
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M8D$=&D &9H0D,8 +3(8D,51"^"!H"ATA2Q]TFC_J*VJ#+L(&L(_AU(@%7&H
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M1(8#:L^#[O<C1(8'S>\S1(9GGGMH36X6,#"E#;E5Y1DM C85'CUPY32&0TY
M[_L1&L.#UO<9&J/!M->K:-U1O:"JIHUI[IC'(FHF8OL?OX( B"=P&L.A)\F
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M1IO'M4BE[1H=_K) N%L$&F52?(5&\E9/T"EN!XOK?>9:H 8L8>%"1P4*@F4
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MJ6J;IW6/9/-7D2JYO?Z[:-<LM9^,WE=B5#MA@RY1LX[?K>;8U+"#_5DG.@O
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M1*K@AM!9H$U*F4X"&RST,Y)J123OG*_D(?&I,OK>;$T@4@#]ZV138B%9'U/
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MJ!%X")-G(/XOASHMJ[AP-+IO,\5PM$AYE31:"8H)ERYS?=P*+$AN5YS I#=
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MW")))?8B4O3)OZJ-1RL8VJ^KMOI^N\+]RHL7Q!]D-ZK)^-I%"1,18-4ZT]Z
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MNZ,9/?RR*6 &6@NNR_+1:\2U"[]*1E8N>$)&HK%EY&3CE*E/34N@CP55<)N
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M>8LO!)C(.&K)?*A="7L5 ZE_B8IXP+XOB5?U%EZ=/LE1@X+25<W^<HNUAK7
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MD5JLMR<J;W7)G62C=\ER#I(]U0%G'[VCGG,"%%'TXW"=\0%&'%'4X]1*+7!
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M&=YY@  A8J&8WHG/KG>F/T@K$41Z,MMD3K<5!BZVC6HN*H."<G4PZ^QX$*.
M6]LEW[A(@.37=!DTD16DF+52L" S23.(] 9.$QRXL%0+=5YM3!O&X#H@T /P
M+))U-P/A"*!_T-.[@50?AZ=FN'FV(D1Q<!DLG'&!3:Z/3T9$MF85Z1OGZL%5
M0[ 9WD$H_=20?]7\MJ"<_IP\"2O:'D'\5\ .Q$&6HK/;RS]WR$UPA'U"""LV
M9>O/^:98\U!DS?"*X#**#V0'\.#Z 6B[E.J$;KP*G_[!G,ULXS;&8Q),]O[8
M4"I\R%;F3LKO5(*M6"DKNZY44!!X47:T_IO/G/2GA0U*\K3:?N$"4D@:5U$^
M3Q@(LB6,YU7Z7#-T-%U:H'$YYG*9?+9(363-\AOH,F2MR"8:=<.Y.#&:_HD@
M@B0_R:A&4*1P%=%D?!P#@H:XSZLS2_-5X+VM4I?.>JMR'=$+4F5"*(3ST"G@
M@L(J<$ S"&(PRNP"6=1VWQQO1GSJE+V,'2E:X=@I^8N[H$X"S6[](H4LN751
M-USGDC;@A%+:6A"\I.O;Y\XZ _Z1(A:0Y56WQ9)P*F]+<"<N+&K\I[7R'[@K
MYZ?,&OS8CPM&/T]>D$)5('B5%#%>;9S"MY8(UX+?;3,K7GX!"7NG>U>H2JQX
MV2 V,%W1]N"3K/==" 04!F3%GO$-=)0*9QO%"! TVN1W[!4+?&5N)U'LD51R
M*/4%Y:L19![11!YJDJ"7&6 S=?WL)&G4K4]9-1R==.;V#3@HWGU>2:0G'F]#
M-[CJ"1U",J?3!<F:E5AK&/A'4/Q\KLK7$&I)>(8^6U.N+1N:;C$N'^2<=4Z2
MO9S =8%")"00&!'-196P/R]UV:FXF*PII JXTL\Y R1+1TQP(7XEZ9!5:D&E
M'1V+EF9 G#%*1-X@B+?I1F(G)1H21\]!(C43T'&4U64(E/Y+KMS<Q803SI8T
M!,39G)M,SP*:ZFJZX4.-F4G.N@#B((09"S@Y(:1*E(1O(Y"RK$08GNKE6R11
MED(:MV9:M*6X%!^9**D/$'( EGA4)0'@UGD?8* JC"HC=5C5L_'8\K[UT0*^
M0\FP T)PW17 *"TIGJ:FTRH(M8PA79C>&&.0*SAM-TX#D?!\)#=WO>22@ ES
ME1,B)5]J1&FI; 1N-M&L0L"%Z@!H3MPW+-<_,F$P>D"@U*^J/ES:4ZH0L20C
M7KY5D7 [*(N*$)H(.XO(+6*$4\-$[ )K3L5D0W.;@BX#8Y2+V%J4M&A5'8R3
M:92F).R*JR*Q'DJ9(BC]Q=0G%']<5@J5W'56_;M"P#G0F>U=M49Y6HMI"SS1
M%6G54E\%(5<H0@E:*]$Q8 \WNWM7"*GT(,M%K>89HBU'XA,)DD'Y%8DD$,86
M\+:$,/QQ5?>13H1:$+=UK%V['8SNE)P'UPWCM\G9\]F]]<8)9Z:?+I>FFC%$
M3@X >O6 W4C #&F!P1!7J*"#96D'@=EE<;?]0CZWBG)O90W[""6L0SOW&XP&
MWVS5_8>A>GRVM;&CZMM]3!?@Q9 L,,>9>+_4JF(X#*@I]P_;8]05V.D@R^WN
M(C.IN]T*"J,[(!:+,<$3Z(:A>BBC<C@ZI,88_GD'UDD(4^<@/0U=S(>4HC5X
MG"ZR@&UNS0S8!9C[,Q.+8MNIV31Z67,7O5GN'N&45*M'8")7YY1J2SQW/E&S
M[[#9=S#(#\56S7'9>;/+5TLTQR<C6)EAC]?E':2*HP?A0A>@?F=(TM7^ML.^
MRR38 LUKX0PH\_SM;@-V9+8JO\U_@=_+#O8\X8[?>[1S;A<5'^K+\$Z%N*^%
M<N'I/Z>;)?XQ@(='_.Q/;.R#>%.N7]BX?VSD?2S$/^"8*-( AXI;+[/'V&W>
M@[LJ.?JPV&?Q\VR)( NZJ.)[K)##]N/&F/V&D'USCYJS@,&;E/ 7@\W(W4-L
MJ=2HU@N^*&BDQPQUL]1E<1FRR18'SI:NVC<*_%OWFGW6M"7\KM8>XSK'7,N_
MF/O'EO3LS;H47P2RIQ2>@02B=?HH=0S"F47C+#G TL_:H @<+?4(*V.S]GYS
MKL0I:,IA_N)J_#IY%1;E3@'1H1A4&;^2"+]Z9\B,%MF<*L-FYN5!WGCLRW$_
M*\O!LG"A,F&",#EEA6/IS^;YL*T[ I;$8FR4L^8E6<?QGM5M6>D\UMQ<[T*N
MT2=*?X?T"0BIJ3VLQ[S]9D5AD2GJ74G@5*O9L"S.<^9VS*,W/U_/WUQ=$%LZ
MA^S]2P17)Z%:<).[4)"]<P3?O\:JY^G='13&II1)?.VTV#RQ*PV8YN*D<Q:C
MHNIP2QGO_,>/'\[_*H*$7&5?4K7<5(MT32#D.F9J<T]7#A5\[A(L#RS2Q=GY
M*4]H@0G#D ZI1@I-&N8P( %:7^;A]JG#)(N&V"DT[G9$;6TE%?"F;*DKB["U
M0TGY^KX(1H;A71K$#>\D=7;@^D5&Y;+D[F)S@&)B9"-!TEM3D#UK48C+5V"R
M&\A+J!Q:+Y?*-'.BTNYI*:P/624"\#"\FD5J@!NX*QZ$UOHWA4(ID^#**XO9
M>O*%T-T>[NFNCJZ^-^1\[KV:K",J!C)%8;".@]YFBQ3D\RV UG%<+J8SY1 A
M!"ST3YV'X@NL59<>JMC%HO8-AC%4YLSJ?!D>V>^J:B41LN@RE,#'Q;:0-(Y#
M=['!BJ(#$!MM*&&6-K/."[<M5WI;SM2V'%U<7OU[^OCTI[/7]>W((QU5"< &
M'[$P4 (I9HR"7B>>T"K[E8(V< @TAT3/S)VYAG)R05@-M-)-&H[/M^/>VBO,
MV4!* 0S!4;$160+V'(_FBH!*'?],]7Q=KE:E:2>("F/3[(QM*VN'S"_O@<BC
MXL[(H8"I"0[*Q#9)/C8R 6";!-_)"&F\1.&RH-*7:LS>KDT?]F((R'EK'3_E
MCE 5T9B-"X;V%K1MD%7"MU2KR>+ *OX=CDIA[U!I3CH'16^*+^;<69^'\XTY
M+Y,OA%5B;[0SC4.'_22!K=7-2X;Z2VU>]^.388[0,2\UWL@<ZD!!G+QC-=NU
M97@5M6ED1 /JP2(66Q7=7$K)<WTNG+O0T<ENS18+@83R+E95[[9T]XM:^Y/.
MIZ=B[>C;B4&6+-@%AW LF7"9LI01B5>]*DFA'1%2+S,.*!(X"HJ!I&108E@8
MVW>/V,O6XNG[32W0I80JX4P0#UG&4K6O\K[SFFG"8,(7.I0XIPV4+Y>0)T*:
MW^I83XZ0].XJY]6W&R; -2#<F2L<L",HP\3=P5*.&4*>6&PDOVZ&,+08C<;^
M2@7N9#%0:?R0YRSA5V@2I:1E @;5=4$B.&P,=NIQ-8\[AJ$.U4LP&,W:;69E
M*XF1<S0M.GMH(?'RM$9-E^^S9VS6)EAP0+TBNB6BY+Z5$)20BY=QC;7I-A+[
M,@7&/7M64L[)8EE0A#\M!"CZ_*)PVJOWHK)S0<DE5^N[ JZ'Y22LK3$>Q199
M-@E]P\)>ME>UU-7MA87V7%+L-7,OGW1.V53JNK'5#"@T4T^0G*64F^1+HQ"D
M\XO<'_Z,])EF6R&5M!0+&>!E6-9H5+4,*E6#H]>PT]5]GG:.;G[X\/JD<[VC
MNAY2:X$B>C"4D#:+7"JZ"+@P3!T24MDTAB>O"D0_%,62/3*>&!0ICN<Q1@?>
M5NE'XJDY<HQPR.QVK3U%!RX>D5(QC-Q+_'5D9GN-Q6:>=.P<>,NLS-TU!W7+
MTC$WJB5G_9Y]Z/>6A+<8!\L#>418I)A/\:=,,*@C"T[QJ(*-!]YK.0+5V/+:
MLRAR@# <)9.R[TZWKJ-3]PW%@563>K?.6 31-7)MAMJ^UFP0GZS9'OZRYVV/
MV81CJ(Y='/M!_#I8D2&KLZ@<'LR+]^!&$8"U/^QVKC.*3KI0Z*[MP5:[JB0Z
MFJ#6.CJ]Y+9MD(07<(88%/["A$9C-S^SDN\@@O8=5DV-FY#Q@14^(/<HAC\^
M9"LR=P&'TAQRCRL;KS526+G9.C-N]&S_AEY_0M3&:X=$A[HH@#.F;VM#M-^2
M+M)0V UBJRU.DL2H.@&]@CK"'AD_-D'2"''^0)KD!<E9. NB8#"22_4A]HM*
M.&M]"E'CFG7U^D'3U>N:% YW\(Q(74=2[,ZA6\ /"5', \.DK% %65XQ*"-8
M1)C+*1\/W*L8_-M"/X#$5E$AX*[8(O I5Q.1\A2"P&4S(!>NVYVH,YS9:U,8
M5+ M[A&G+>KN1,E92A)@X!AQ*0NJ2W\B%4I24KII_E9HUR632CN+9[HS2Z@$
ML(R,#F=+!111*(RUJ^=0X]MQ4P",,5O=PX%RJ9G9E?8)(:(PDN#]DX<:5KW'
M:I?,*V;*M>:J<+ L0*X7;)+VC!#'MK*%EN"T51*'^Y!GGS.M23_FAJ:WQ9H-
M#-L'H_%CM&?^4)!,])C^DVPUU)0K$T\F0A9M^7K9/[LHY"Z6 =;5Z<(+NU7C
MHM$P>EE[)TIC]QZ1-G4/?B8-'2B7 W@MUJA?6RV>X'6] '95-*12:D\@JBLE
M_(0G;I0UQW)6U-F6.?G$JY$[8N]12EZKUC4K)XP@AB&,MU\2+XI$15?[ II%
M][8B4-TQ5HLA3R<:$B  1L"/*\JJH^B@FXK1SM85E+P3OM;1=A@?H&ZA.NE(
MU@.4J]%;*!09'&V%WBD@O9;R%!I7M4MS@6U7HL_8FL$,/,V9HG"56HG-4E3E
M2&DJSOUR)#;97R^RM?7H^"-#_DL\926%XEI@&L]B!/X_6W,C>-6OT!/;-(>*
M7#5&F=>>G#I5/;:6DUN("U"7[S.T85RLJU;JN('72Z]$!.<-IH&C>,Q8]98
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M:D+F>%N 4QM#+FK1IFUZ+@IL#/D1+6?1E<AM!2WLQ^[G6#D1$4 P$'7_&[:
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M. QF[C/DW7U#-@'3U-%>=+^?>MB (IN#_/ZZ?@$71DO9K3*&4&K?8C,9!19
MJT84@$EKC0K6Z(-GZ!I,#HVO6IP#E-LRL"F"^=T\>VW+;%V:.VZ3;07?Z0T7
M_@:YI*2<7$[XUV&_1(8L+G:CZ1Q'/32VL60&(503_N HF8W8CG;4[U/8U<=Z
MN,:C%6[);09Z*<3/>-&1I;7*833V",U\&)@*P<(4\3]_M#&O%0U/W^(-B)$\
M!.CGB,9;-3JR#1RT/,NK.(=U;[,P 6@38XLK$Z"0]MJ%'K-5DA9V1&(9!-%/
M:'DA2*S/OR8SBG'^_YKRAD1Y0YPSFR@@48C);3:3Y1A1OL=7T1VY57#YC\:<
MBS3&OL$U\JVH#JS71Q"[-(C173*A2/6741ZMU-&8,QK\21PE8W*:?L-S_O\W
M]0W0&H.'$I4<7@7QT_50_#WJ3_"KKR"]'B;#81QLTN>DH]Z,'=TS5#B^%?4=
M,2V,:\B/6,W+J(^"HV>08!+.8T#.FF]UTL/TO"JNSF[;_E;?EVF*TW200]:2
M(KL2L36VDR;V&C8K5D(^&RMW-I2/(O6.%7HP:JU[1SV\/8!\.4X:KA-73%U*
MRJJ7>NAVF\#=B$&XP5 LQ@C9TTNQ:99HTB2#)IHS0Q,E&RBK]%@S?'9F)^J-
MQI%;\B;>QBY3R7&IG$;2VPNJ1PPR_Q"ML10UD42R7<YUI4B$)ZR5-ZFT)&$"
MK[!:9%AF\O=P]WPPFIW9@F+S/1[U%N4J(;AZTNNC0#+HCC@_K8]Q]E/3\QKA
M<K#%G[BD9>>0DI8@Y \!M@N<>0-@4N?.QP!K176=7? D 4@*?BU:7@0BDA0+
MEY$-D81 +?+O)G_,CAGC$9.F\P4Y(N"UW1I@EX'"B-Y'[!2N?"VM]3MG,CH'
M6.)/LX>>]!'&.ES31[N2\\;2U6+'66WU%(&+,S7+@MH0I,<%>DP(BME@2E*8
MDUXPI50YK\UL:^&J^4W(]:H^OQ_=N.8'.9:3'F2O7E/IDV['4"\B<2+FR?(1
M,KK P0J;E?31[M3'K,@1;+6?+[[@K'N.,3@B 5X8"99VH 1."(KH]Z"9/F;P
MG*9/^98EF;)NI0G*#8+8QIR!RI<E_CQH@[;.LHF'0#AJ,H6TY60&%SWDBPPU
MBV3_W=&(I;C1B&8YH5"<@P;0LMXMF)E'E/TQ)(\_I-2%E.Q,&K6K)Z,P;+M@
M$!$,PT.,-$86C[_L<!%^%Z]ZA'- KBG>*(,I^M?,:1ZV84@0)M$SRLD,_Q\A
MH94/%I]6%W7C%W#C8=_'8(F\#!\ DDX@6 )# <^;N&<"]D%\-@$*^7^ _%_Q
M 7C%1^ 5'8* W-0M8G'AVI$&LW)[V\WYMCO_!0(NRXQ2%CS#5[J-J%Q);P+F
M+E US (;$0\+ZBTCKEII>=DY&J*)C*P$1C,901S PK"]Z'M[AC#NC,<R L,/
M E/;C9*I;-"JCY=8ZF7,>)B_RQ'3@[,:)(J_GGQ 3M570,B8& T6[=-P'H0V
MQ_L'+*C22)]=\D!/T[I05>_<?AN:0IK LKG:>?MIS3PC2E?]\8QW=3 P)V%F
M">LH?6VXPU2^[$]/>H/.C]3243(:6<KJ0_KX%#;H+LOQVU'??@F)K.-^XQC&
M(,])-Q 2&/A-YP#TPZLK,I&#X 6H2%I18@9J7;\1:56(Z5S %;&T.\23/^?9
MRAZI[R*_7"&XBQFI!69D_HF'_W,!PATZ0 R_[W_7.88DE<EW&(0-?PT&\*GY
M:X)_C4X2U2042SB^ WC\"IQK[V0,CQL5[CL00>%W;*\'K\/GT$,/I,L,<,@@
M"-T*XWIX9HWOD;*PW/*K/CA5)Z:!5P/#UZ=&H()8N<$(/D'H":.3]R'J:(K/
M@%-X9&G5%K!W8JMJ6X6%O&**>P5QFT/S<P#Y.8$@4'N]L53]HH/5?&*2&9&W
M/BA38HWV>"03/@'J5 QF_%GS84CZV'P0.Q#<S+_%U'J#8&I\TF5J@R2<F9WM
MGIDEO=C,6H@U_WWL<9I8UM0?G$PGWM*,A\([^V/#Y_MVD8:]L6./D#4^\)9K
M[)CG ,)+>GL6;CJU;+AG#D.0ZL,39E!**DG6I.;^!C=NE^%7^4QS%<#@'HZ-
M%/J@F,;KRTMSNFC!)S3E__D_:]])9C-^1R28&;V33*D)_^:.=6;N>PH]32!T
MP_15]XKK2\>Z#<BT.QR'$F,%_;8.-@,?8H.O I"UF#VV8JFN0$'"Z^\A-M4-
M$.;$XM3K[SMGYM-RFR_0YC,>C4AQZ0ZF8S3/0O UJ"\2W)IT^PB=DI@G>OQS
M9H-O(&H8H$EP8;N3\83"?[NS(46159=!#X1C0[[OO,V6J-%#H"I<4A@IV>TG
M0U2F(/, K,-HJ37\#:)\0,L90^J,C!+Q-D9@-IB ;8\&EW2'21\#-P8]R$(U
M;<Y 01,T0-WS4=*W?I"D/[,ND2F95*GSHP$#G)&3KD\JCHSA:#ABU8=AC\@<
M3V,Q7'?$"I$\-NA-43$7\(M@K7 5!A->CV1,D#(SL_P!3_&CSF+EZ"H8!]\\
MQN@L[/-[%.2I*@,*VKV$=G0*Y]<"YG39#6&!B C-=K'9 ;Q/?P14UQ\.T))M
MZVN301< SJ8H[0[0YEE8(S18L(%$,+5_4J]^HE<-D0K(+#T$71QM&C]&RO\!
M.E:BMEBB4<+E1NR>"86(41AV%(,2K9Z" [J,(J <#29C(<?AD SD9RJ8K>MC
MF*BTRB09,)A>CSQ D>'ZT9='PQEU "X9P".)^F2*-<3_4'>WV?9+QJC7GTZN
M3SIW?*3 K+BC8LRF&\R 0EW>!E7+Q[^-U']MN\>N!W#XOJO\H$--#!*..5BP
M,*X0/R%D<CS9UGI[-.,33D:-(_)/GS*%2Y64"A7N0%GX/Q)XR%Y;CCW$Q6[:
M_P3S WL=2F1:[^Y2,68N+628\*-$N-/4>B[-2(P0"E950+,OV60]P9_T!!FR
M!^*F.P_VQYQ ,\KO.I@I]AW_M8<J#--P&<2X[6RHL(4"=VM5\E4Y>/;$<E5V
M66*AC1RF\)B-,C]ABP#+"PE0M<M8)CX L,QP>Q>"TULI95SQE>(- NO6[R&^
MGC2&D7)>.QCW"Y%Z4C-L #=! L0R!?YAP=Y:O7R4#(A8AAP;TJ<P%J)P,&T\
MY1L7[L#D16YFI-9K6TK#/# ><F.,LSGNZ>B!0* %09K2UM6*5K=(7*'*J>!R
ML9V#]8S*N-?'O3T]T3"QE+EU.ZH2FK^'$$5 RVGN5=K&C+4[\(-=B-(.J@+A
MG@P87S A\",G=,$=,!Z2><G\-ADR3E)B[INJ:OP;"80\6!8N7L%-ATAY?;J(
M^SAD?LB*:& RZ'%D$Q))?V:=PQ(74.C"@GP;0Z@ BT@),"$1C(RN07"Y]YYW
MF3%^&8B5XZ' ;CSN5""9)RPY#<1MXRZS(NI,EC!M(Z)-./K@*''1'OU1Y&;[
MYF'6;8$<P$2+:5^0P +"BB0JW)R?OKTX.[^:=^""ON?B)ZXP#HET",EF75O#
MT5"EVU[583W>$5X_XTRBP"5"3NEA1EH/@B<UN9(Y /<R!>&[/X$I7!7/Z<KF
M&-+@L*(8%-J!4*-I)T%64AO@GR#&VY2>6:W2VV+C.0K@";BLT6]*G&=L=/:)
M&>_8JB4-@)CHW^X-.#VU-QN'@&*J7Z[I2_U<<5DEJ'=9KR:>%H#V]UA0V:1-
M 49L4+.Y.B#$CU1?^82(?S_,__;SCW/#.C?F,$) ]>F[=YVW9_/.'$KA?#;3
M&O90;IECM/'^QPE(D![@IV\>S")CN@<:5@8SU6#3@]34-=SRR[JV( -7VFI^
MDL0O?^0R'3V!QPSBO+",Q]D<:7KR)T.[^%XJ#YE3QN_F7"1C:<.%7)$6T\5)
MXPQ=7X;5KG(*;3A*7E/Q#E4MJW;8=D3Y'8G"5"J#$FW=*&UD/1@NEES&%X(@
MV(7=>30\XT&D#LQL-;<R%#HP' V\VCUA/I"&?=1_S67C8%1@$Q9H0+$3_Y<1
MB[!:%VY,Z]G83< $VX;Y,/P)E+=HF@@6U-B -]><R\H\3IKIQ6U-VUE^Z^%2
M7+\;+E13:1SR(EUCL9[%0YY]1L9[GVZ6F#-OAB(EE_E=6SZ6*"CC:BEKWA1'
MT$%YD$LHV//+05SF7Y4=U$#S<_+Z;NW%K/P#"RU+-97?0Y2BJ(<_E&PQ12D]
M.W:+;\O(DA)L^KJZN/GTU_D'@N3%B5>+!AKIZ/%VMREMF;N28ER"B!CM ._V
MAP1&![ [,Y$HDPGJ%91M#%*"0&ESO11L_DNQ62V]L8UAZ<< "#.96LR$C;?R
M4!7H^/2LW\-,E_0IVX'M4 (NR&:7#'E$X)0D:1?N^L#,^CX#03 O'W$0WO2[
MRGR;F@\0?5.PBL1 +9E$[3;\"MUJ3Q!%<%W<YE"H_=AL\='@-8LIE- (=B-9
M.0KTPQ>_ET+<$("%'YE!@XP$&Y246P702U&9O-C8U4VVV>1@??B>WE2JQ)6W
MZ9?(;;ZGMU#;=A$V!87A>%OIMV[GD?2_4^/D]Z4Y?"?6&#_WP8BK#YVYF0RD
MA7WCQL^PNEBLU4G+5ID<\2ZV_GS;.I=[-.3DNH [$785TNU<%_#^!]7>)N.Z
MK26W9@4,.=FV\"%WFV^6QT_FFGEV92:+C=%]D*W;,VK.^ [-:[?/,DPIW&AX
MX&ZQE9A)']U9E>\JC28,*@13C.I,/76"T[S9MQ;!+*&2$GX'/7V!Y#7>-Z!\
M3)<&5PJ:K) 5U<W[! _27(KN2J$M]OO('J:H\H'UJ0S9'4P.#B64;O64(^ .
M&/=EV RN&$EV4D$7RMB+D6:9W]UE@(!A#R#2$"KP;@,42<6(5"\)%A+F6K!B
M@B&##/=(,DBKT]\!^+5=Z8:%LA1*I5\@&.4+%B9$40/O?TF4A&'NH#0HC+6I
M)I@M>JE,5PM/:\(8NOGM[8\YAJ=7&VMQ5[:\*B]YJ^3V$!5\C&6I2M8R[2E!
M^<]3E1A"1E^CKSIH]@_OWL7>%R'\[>L7[CPOT_QWB7ABRWQPYWOLA)B('N4K
MR,Q(*&0VH>RR496=V56+-*]QBG9/AL^Q6<$,U @- -8D!5^A_OH=EZK.6R*^
MH$4#18,A5VB8A9#LD#B:*Z@)"[K:6-7N?;[.'W>/'3"X<'"V-$*"!.)Z8?P<
M'BFJ5;[7N#RA5&"":4> =DCZO7$YOK11TCN5G[,U<5]U)H3SPH(9XV&-1Y31
M/*2R) ,*5QM/("">@ IXN2CL;G?+A=7AQCJ:LFU_Q"9=-LDE(S:7<3H8^G'A
M;X19IYONL6Z4XS'NQH@&-!HPIB9Y<2F2%6"U,%M^&$%O?$O8^37M(P>EB-%6
MR[XG/[N/J=<)&(XL^E$RM1@/-HJ*H19AXE*0W2M<>=<XZ%>8QQYPC.R>JS-8
M&W0M18H,:<XI7UN_C6>KFIV'42IH92\QW!WF^Q-*^K16W^*)][O5-G\RQ^AZ
ML<J,6IT;XGQ__?I[9:($KW\RIF(EDQD551IT9^,I0\+-T-O]"FM4]"GV@(.F
M^]TA(O52L:TQ/PV*Q/S'CQ_._XJV<SA7\$+??#E OR:@]$)34[2*03&.'OKX
M9Z,Q%KWJC8#*!]U> FG]E^_.?[BZ./NY,^B!SI,@E!:5J>CW07E*$O"=#"AA
M'1%2\ DLF_CS]?S-U05H-6CJG&!0@.D)_<8$KI683P>(&3Q%'P_ #P-GAE2:
M(8X*M+:W\_>7/YO%LFA?@/(TU=CS4P"^P_\4(EB?_OO;Q8<W5S_?N-=AF),(
MNN*^GW_.'HNG!_#6?=\Y?_?Q]&9^<VZF"BP&"[^-$LCJ&F"%#5H6+)HR@OVR
M -?PQ_S=Y=7'=Q=_Q8BJ'C&Z =:UZO> <6%,11]1[B=8@@Q6#]P$[)VLR S?
M=]Y^>C\WY/3>(8R""W^H <]',"#\SZ+P@R\+_[N^O/AP-?_;'-&:'$AIB&"_
M[^>;\P_GE_-W%PXDMX?!+_C_H8V]-2LT?^/:DD2C0]NQ^#3>HL&9,L3.%RS&
MX""$97>:<$VS[F@X8JP:<$<A ITA989#Z8[&$ODS'M!OTVX?(M>J'.Z'#)1^
M0SB+!J?<?^S#XT4!#0#QGD@G^P%=U,_F&LA3*2:.$ZU*E'0]9K\8?@^X?(N=
M$5",#.XO0(*U$F!BDQ[55P,7$ 8E)12F) MS=:B9PQI><%7#B'STKB7*(O*1
MPUKV#K_?)XR;"5W!Y+3N]RH@I .$6WD'P%DKU-)4J$E_TK=A4S,&:43T)VZ0
M:(,PB_:A@/P6&^1HD*#<QRB%T-T ];>H6 [!2PIM'KY!+'8-*N4;U :-R(O-
MAJK6&Y0,^Y0:29#6%(@U[E<( 5(<D[H-FI$\-9W0%4G;124+$CY^""05R:'^
M[;?',0$([QO@O*8)D5"2<()HGRYP9@Z';P\9*672L>V9]&AYR7IXP/E)2&X8
M)+P]Z$N=5L@ 0@M'-=O3&XV8:=#I[M,1I%;9I#F!ZZW*[?Z3_ ZK9Q7R<)9N
MT\[1IW5J]"HC6-4CU41#<EVHO0W+)5,\=R7&=/GS!NPS]J^W1C$SBJO]$BD!
MU7ABQ:D9S2W_6_!/&&'VNE:#-P)7;R:2VIAK !@V.Q/8WQX=A!<RUD&?V.I@
M2+;C0<+E&Y,I+WR4F[XB'S$(F\36IZ+%S"ROK-BS\7KLC_DJG,Z&5!S8R&9R
M/4XG?<XHZ@Z'D)Y+*-_L7X'3AHN0#/AYJ"HWX^68\F^0 4$7\&P"M[S*Q38?
MCL5 WF-%"X#XB-,#--Z,).,9"%*MD[BAGQDW*AZ!WH V92RKRHG>JE%+:-]W
M*(4]DJ3<W+$1;8?X8T*(I1/LZ01CW\T&S,:41QW/?][;],!K&K6(D]F,FQZ$
M.2IE;1KV"R?81Q#D/H)UR.^@J%!:^PNG1O=S'U'XY7^XI2D=_/?F".;NOS.G
M__XU<8:')BZ0L(QA?IL)Y/=@)I?7L#]B+O"BVQLP&,DZ,N'BN!.BV\&@Z<J&
MTCH$WTV0+D-B!A-B*70A1[C :#02-C9+>"J3R81/\'3 (E3/\/Q!'1> U%->
M!"Z;"NQ1VACU1 P?8;R>QP6F+-O-^A(2UDMHQ-.^:,XCA YLS0.F?;JR9GV2
M=F=C6I IWXD"[_!-S[]A=(05.2,VD-!U.4%!PFCLTY>??TB<H::)#5#U>=?T
M\/<X_^B9AO_-@1U K%R_W[. %B\]_P/2B4>(B8%P]QA02D 0*-!I:LM+.Q&4
M6#@WVE(S^IXP4QK\Q^G*AYZO5K=,I:!G$&A\@@Q DQL',^^GOJX-:2'7B(1B
MF/Y0YI"DF#MB1/[7(UMS6?O=8J -.''XX!78(B06 \%NL<BN? *&ZO*)@IA7
MGH'?9A,M;%$.OROF1R<H%KUH+>Q2E,B2N^0](Y1;;_JE79Y@^BF'%J-#0('6
MBD? +40"<HN;]RLT"GLKDPQ5W(J_,EV@)G#K";K",@,\9@!\@8?!(8(FTD<O
MZIQ-_^5CNEH=EQ!^T[G-H4ANOB@KCUJ84/#OI8^WFWQYGW4[[^?0\9=L!>66
M.I_3!48CF38!)?BA,,>W@T92>.T:)/S/9OCXWDGG(PX3!@VF7/$&EYGT!1X#
MB*8IH5I1MLZ6G/S-6;RF[;O=JK-".&AP([&?;Q4'00Z K]-MT-T)BM%?1RM$
M(]5C8^DBM91!1P&:J:TC+$1B6GF%&4>R^=!9:L-%[S+VD9JV+HJUX3*X)S9/
M?DD@[T]""MP%004HWW5F36XGJ$=\W4)$.<2W6 DOVHQ6(O!P(:*N:1!]?E6V
M 36376Z#&0=F9PXZ6ZA!CBV>]\=&2T)%ZG=>!)@@A?W*#"N#E]0(=*C4Q ^[
M6!MT?+[E:A*7IHO'] 2EQ&]/Y*-OL+5#,"*YB7/AWMT3,$QP#1'3DI0.SWE:
MF?/\AYO3$Y2%6TI=S5-C=REY_Z492T"OQIHDW9S7Q1HK>!04"2;>+0_ K*LW
MN(Z2/V2&"S\^[LS'N!C("-?0K@Z_H!O[R:P'Y@A!V.%E0-JI40@,"3VFMR>H
M(OP&]/TM*,%;T:^BA/<WEZ=-81>ZS.Q\@4'TT/AE84X3.JTIU<7H:<>=3]=G
MG:-7H#+\4214L\S@<BLAO<;\_I[UO0!7CL,;.T<WV2]06RJ2D6SS.\!M7.;+
M'$9XY(H5WINK#N-8%N GO\^")L"CT>L%T9>,-P:1,8\E28X+BU69Y514-]WD
M%-P/]["X)5 &K38WZ,$N<N7$^IKLU?LY?B]7WP<_,!$2;*QMXR[KR/F$,A/\
MM9. J/5@XC;SGL T?!!NCBV U/+JB]/1=]+'JOC"X>,Y!6<SX FYHYV:(#',
MN@,^J2#B&%IZ,A3VAQ+(UVPKAFTC :? 1.Z(H@7)<V-Z>WEW,NMEF) )6!9,
M/0J\)=)X UHYYB<'D$]0KDY!'>!$ K@)O_R,7>'BG\=0<4[EWC^M.-(J,3LA
MN2V!<XH_[[#TK^K_1&&I@N,RBIV6^=+,9$N' 6&PZJ)5?K65..J+C42K3BBJ
M#H=$E=#J^_2K;;SE:AO5Y_<VX]<!L950ZE^P!4%JGQW4])G^LF>YAKU];[:;
M]&1?,RTGW=\[GOV+H0,X/ZZ;CJ'CP9Q.4)C?0!7S0T61TB.(C^KU8$,F)_V0
MO@>CDV'XJ1=P^J4(Z'(6:ZH_.$DB!PCL$I(!Z_T1OTH;;LT$*MEN'SB2)HA<
MRHP,TY^2W[/VPE4CZ/S]G?FL<P'9T_\[Y&I[L_LBKQA><8\!JR1<+] 6FJZ"
MF5 FJI=+Z+J(U\5X\FZOPU>YD[1>9US)I!]?R8LUQ&<N8"WK1+=X$G%@EXH^
M%BN<]!_Q"8GHU'9:@T;RN;1HL#::K!HG6<<!:C-!.6X5XBFJ09J8EVF3X:2K
MH LC7F_05$,'/=Z- #U449G\*S$XKK'KKG\R"3]\'V@AC^G29C[$+_<W%Q=O
M>I,A<L?6QP* )</N0=TIC!X#P2E/8--Q65/E8>W[D+'^7XX;-1+166;T'0E_
M8;)K[N94L"ZO*"ZPD>WXKW(DH:[9'E_M\[A(<UE#N!I2W\B<1BG[G!=&Q,I8
M7"^CI[!F;(S_$!_83\7FGX;\%W"Q,3)",,C\*5O!BM0@O;;:M8.9P77V9/:Q
M1_L8P85TFQS* \FH,HI3LF,W#QQ(0)1[D"2[SGCYY(GA#C#"K L:;2/<BK=L
M]6P3HHV6#0SLLY_/';],XF9X&4]DQN-V,_9LP2$77V0KX%F97[*ML1%SP-MW
M+W&Z5Y(+?["(,5^GJV>(@65MQ**:=,D^2F '^;IK\^T#QF>/ZBT!;P33$R@!
M46\8G01S@@J7Q"(8)2!\-AU@_3)ELT3%5>$%?]QD9A%?TFF[%AJ&<$Z<HF9=
MY+(*B4J5X%83#S<?1]6:)@X0B#33#XJ%VQ,5)0<+"%-C:8EITXCVQ<_78!V$
M<@(C;AU.\CZ^6,X-14JO7:5?H#!;!L;#X$M@] SVL CS=O_C+6"Y0[[U?5$L
M@V\%)HWG4#NYKM!GPQ-@9=WST,MO#==$TR7^TR;?9L?+XLL:H:8@U*,T5VIQ
M:_2T;)M!/JRJ+ Y5=UE KIF_!(='+H%CATQ0]S:'* =\BL.@(X9'$=/G#E[N
M![-MF =X,'G!SIO5>(=A>6'C3>MHA5_#7^YY '6D4]$MN@01$+F";)67N7*@
M'[H(<^?'K3/@6FQB5B<\?[U-T0*_S8O?#-!-6K\9Y,^U?;,?@,:V?C/(P*E#
MS0OTPMWVF'U92_!GQ)@_"-FAWA"R@$>C0&S$2U*$#;?I&TQ'9 BK-W>#-8_R
M C'W)[3-UYC'ZOHC33.TN,1;.2-%$Y8V6SRLP8<?ZH:19^IG5O=T?%QSB46!
M4Y.OW8PV$-=#AZEF(P]XM7ZTX_BR'-AV?&[)--XX5/F]0U[7H1#D$/"OP=+K
MWHY1MOCB N:W,7HX7"4T]BW\V5FGC^$9XG2K7SMM2$.2HG[M?,5&VGR=KVH%
M"YN)T.UBG YOZ$UNM*K'? 6)>%\U(INI]56MV.RJKVKE[>XQ?0*31V?^@VG)
M9NP%DEMA!&],=>7P3%B#%QCRYH93 UM_T<LM!8L#Q'+[;I,0H:_\W+%_SBQ7
MWO8Z"4-ZT588T-*C]@XR=4I3G;1>77'-0MV"V@85/OI[(POM-H+V>+!F2[B]
M$5.'"*)8>=F5[*H?2=<;2A>JZ1F).^+*03,WN+H^ Y93N 87#F8PO' VYBTV
M9Y#^%ZJT4.J&>2NBWHE T60 >:?@>6.:YCY(OQ<L"QHI)2SQZU?9-/<#^%?7
M2,A?V]1[(Z[=@^6I$A+7 1\L)/_7MO^?NP*.#I;-0=5_3LYW(BFH" K, ,[S
MKYT7$,\W;OZ03?CV7;?:L&_?[<LW5\?!$%/[> L6#N04%^NGG1M/_X4;_!MT
M<<@F_S;=M]KHWZ;K;[/9G]9%W5@&WV"COT'S+]WD;]/UP1O\;;I]^>;NDR .
M$+C(V.)B=@)IO0"4B4N&.C(RE1%0,_#5Q1]D3*1N0XOCD^ED]%WG.EN#59E>
M@Q#(F/6C?S+K11\-C1:#DW$_WFQ8V&AXTJMY-/"-CR L(O;H,,19V;<K_=:[
M$HMMZ':4+.,C<#4*RP)]'AWN9R+2%F*P?ORKQ-N#+;3:=1=LI;;C!S2!;_:&
M\&4OH"TW(8 L56>4E-/2+X2&JG7^7[OP,#I7^@+=UJQ[8%+#,04SUL:7^ %N
MF L%4B_$Z"*D>K';(JJZ4<S^D2D0^KOHV.M'9H%S]GOYK[>; D[X+]T8 IDY
MD9$P(0D<7F8+ BBGK!3#6-#17RYR=.7_\'C[YX@*Z<JJ43%M/&IK.&IQUA%E
M$G%V$#WXT2,>T3'K,*D/BD]H;&?/6C>^^Q5K[G+?+Q#6^X7JIPJQOK,MLNZ&
M@=G%)C=L!8)ATJT42,<X88EWYA!CB29?"MPOTKZM<]F@;9XZ7+_+]"GTH7V$
MBQUL+IC@N@%PR<Q&7<TEC#P\TN;,/$OIV+>[=>C>NG:G^PS$E>OZN[IQL0^X
MJ95:CUU*A./VN:EWRXP#8P7F+7Y:VXJ=6$Q^[U/OT,@24"IY"+)E)V:UKQ7M
M!(.__0L ?5WC"XQ*<74]Q!]N:+V]L%;7Y0$M-(W#44%&F]\@)C:37GMQ1)UT
M[;E_;X_U]YWY9],F#.O8W$_'UQ#>6D^59SNT_<+-A+4Z#+]?H3_5>5OJ";?V
MY68BA-<(%-"^N7W8%+O[!\.]/M,G!XR@15-MQ_/R[MOWQH46O$W"&&1'/=V&
M+EN]WCR"/<0X:$V,EV"DSI8,55#EBO5$Y[^GKB0XC]$\F"MA>O<QUFB_7459
MXI[YLA!L^'_+%^N<TA_CEZQ"O'V"FY%FZ6ZM/4JVOJ/__7\DX]Z?8KE [GK=
M\/6Z<=>KS=(RI,'1<!B"1:04#1?NG4R24!)CP ">W[-+:\%=UQ2(-0'"$-1^
MW1?CFB]:[MT!#'0+M]E]ON@TV,?=0ZY6#T:4WQ6FT09K^E=)<6=9F=^O!:_@
MS]GR'G0#UV1]OQ[':-9![^^AI(*YS]<%"ZD4A1<Q(G0.'9#4+3J7ND5R11DA
MF2QQ$@''LNFO!W>A[K^EF[[Y73?SP,WD;C>B#AO=Q#>8R[=>,D6@84K]X4O7
MU%6C?G-H1^($>G[I^C:.YK<AS!6@FR$[UH4=#Y\[X,N]A*R_Y"5<AX;7O:37
MTW2=+G-S12PA._<E>[:'AY%R5+^,;:,AI3@=HF)3Z.BO@GC4<-0Q!QL++!Y\
M\"53<R_F=D21 G/05;98F2.7W^5@$0)Y1?N\I8+?X],F>X"27;A^F-*-":?\
M.RAT?SQZAP7@CERER$O*40HK846721)]_(IM =\V;,TO%P<;8K%VP$+ NTC\
M:_$,'R!F@74%"Z(#+"=,Q-8>C12-\0;K"GC:H]MVW/N;L1_6Y&/L(^%#C9U8
MM0^H9X-V/2Z(NH+L7X<%$7OIC[#16 ;5R[_=O^X!,Y'H/X4]8922C)#"Y2T
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M5!=8:/ 'R1DQ;"0ZEYK\]KK'X1C6?5<1_OC1VJ7UJPZ8^7(%JF[G#*6_-FU
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M*FUF<0P?6>2Y+38;J@-H;A[S97@\A8576JC1S8K=UFARE/?HJB#N>??2+#L
M!*U<^FFCISN^N$^IDNR;7I_-3I+I,%@]R;X"Q^IF\\R8HSR</!!F:^]Q<^YO
M;5H0H ^NT9X<3%H/MY&GF?%.9OU@O.;C^*>3<3@Y\W%_%IMS1$8_(*[HK:=.
M$;I@M<50AR+7G):;&4W,@8HU)&]:8*:N/)_NM@]&/OD_829W]'&JZ]?J447.
M>V81$QS==&X #-2TL^_^_LMN72]-ZE"?L/08F$00T W!L)H,SI<;B1MONXPR
MUSHWR]R^J4\P@FDYGT>I& )Q.*I0ZIPBEP2($!YW+4XL(OMTR!O1L#N]^>%R
M<(G7IQH1^3K#:HM!%@I__M?./W9XE"P0VC9"3I_6SFX6+&\[\Y98LP[.E#BH
M^;:Y)R1@+;R6Q(X!!H[7&@92Q=C59,M_W-_<;0:V$,@U9_/@(I[!,'^T2>D5
M.V)ZR/AC!APK>C*2W:%MO'P!LT:L@6HD"VTFVIC6RBOL A60Y"%0X:"6T&+X
M%F+RP+(3GLM/Z[L=ZH&@*>V075T:X6R3;7,*TNN\R=898(6#CAYJDT9$+U>D
M&3< ([SLN!P6;.2DVY#W^.2G1@K7"6J'[0;8=-+:67"#L1PX@!I[V,NI"5T+
MO_^8JG3YVPTC,(F'TH_&V*<K,,:Q0U%HC^CPP>@^INMB$RK/^T%M*4YR$2I6
MZP(!>2*M2LV"CM0L6.^PU).Z</?+4,Z!!!4(8'U=Q$+0XYD\\V2AR[R>@ONW
MMH@"=9?%"AXT;A>)-+5B4+W8$0R-$$M9J43CY>/3JGC.,I9!'/J=880!'\P?
MLV-P1*.*!\B%Y))@6-<\9A_&:,V&)W"QCM^@_B/ -R^(>L56;K$5#R?UW)4
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M:6<M @"^BCD<;,FEP'*H(S=WK&/46_ BS0<E@=FEB!7DN%_.HJ""N;87FF5
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M !;MSS@D*;.W/J_X5V'X&U!+ P04    "  S@T)*VJM$WW4'  #D4   #P
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MV$-I9XYJ0V:[2]4I<?)OK?HEQ43&B)B-,>OGK?[1#X-X];B].$X^-YUN_Z"
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MGU^H:G%CQ/#CZ9].ABGDKJ^J"_O<E_ICHX;GMY^QVW7P_#]02P,$%     @
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MF0$  &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ ,X-"2IE<G",0!@
MG"<  !,              ( !M@(  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"
M% ,4    "  S@T)*:@F_T* "  "D"0  &               @ 'W"   >&PO
M=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ ,X-"2C['/3SN!
MAQ<  !@              ( !S0L  'AL+W=O<FMS:&5E=',O<VAE970R+GAM
M;%!+ 0(4 Q0    ( #.#0DJ)&GV'6@,  + -   8              "  ?$0
M  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    "  S@T)*AFMY
M$: $  !Z%@  &               @ &!%   >&PO=V]R:W-H965T<R]S:&5E
M=#0N>&UL4$L! A0#%     @ ,X-"2@IX*__@ 0  \@0  !@
M ( !5QD  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( #.#
M0DJE<_] L@4  -8<   8              "  6T;  !X;"]W;W)K<VAE971S
M+W-H965T-BYX;6Q02P$"% ,4    "  S@T)*J<O6D=P'  "2+P  &
M        @ %5(0  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%
M  @ ,X-"2LY;6B*U 0  T@,  !@              ( !9RD  'AL+W=O<FMS
M:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( #.#0DJF,XF=M $  -(#   8
M              "  5(K  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"
M% ,4    "  S@T)*9UER\;8!  #2 P  &0              @ $\+0  >&PO
M=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( #.#0DJ (X/8MP$
M -(#   9              "  2DO  !X;"]W;W)K<VAE971S+W-H965T,3$N
M>&UL4$L! A0#%     @ ,X-"2A\RA8FV 0  T ,  !D              ( !
M%S$  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    "  S@T)*
M7XT I[4!  #2 P  &0              @ $$,P  >&PO=V]R:W-H965T<R]S
M:&5E=#$S+GAM;%!+ 0(4 Q0    ( #.#0DHG%20;M0$  -(#   9
M      "  ? T  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%
M  @ ,X-"2HN6S+FS 0  T@,  !D              ( !W#8  'AL+W=O<FMS
M:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    "  S@T)*V1C*GK4!  #2 P
M&0              @ '&.   >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+
M 0(4 Q0    ( #.#0DK?9>8*M0$  -(#   9              "  ;(Z  !X
M;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ ,X-"2KVN) ZT
M 0  T@,  !D              ( !GCP  'AL+W=O<FMS:&5E=',O<VAE970Q
M."YX;6Q02P$"% ,4    "  S@T)*)9>/P+,!  #2 P  &0
M@ &)/@  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( #.#
M0DKY ^LJMP$  -(#   9              "  7-   !X;"]W;W)K<VAE971S
M+W-H965T,C N>&UL4$L! A0#%     @ ,X-"2FV*[ZFT 0  T@,  !D
M         ( !84(  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4
M    "  S@T)*$?:IY[,!  #2 P  &0              @ %,1   >&PO=V]R
M:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( #.#0DJ5SP:2M $  -(#
M   9              "  39&  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL
M4$L! A0#%     @ ,X-"2F-O&'*Q 0  T@,  !D              ( !(4@
M 'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    "  S@T)*GV-A
MNK,!  #2 P  &0              @ $)2@  >&PO=V]R:W-H965T<R]S:&5E
M=#(U+GAM;%!+ 0(4 Q0    ( #.#0DJ:[38 L $  -(#   9
M  "  ?-+  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @
M,X-"2O(<8_"U 0  T@,  !D              ( !VDT  'AL+W=O<FMS:&5E
M=',O<VAE970R-RYX;6Q02P$"% ,4    "  S@T)*/F($F[8!  #2 P  &0
M            @ '&3P  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4
M Q0    ( #.#0DJJ8#0RLP$  -(#   9              "  ;-1  !X;"]W
M;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ ,X-"2BK._76T 0
MT@,  !D              ( !G5,  'AL+W=O<FMS:&5E=',O<VAE970S,"YX
M;6Q02P$"% ,4    "  S@T)*'/]M.K4!  #2 P  &0              @ &(
M50  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( #.#0DI2
M=CS4LP$  -(#   9              "  717  !X;"]W;W)K<VAE971S+W-H
M965T,S(N>&UL4$L! A0#%     @ ,X-"2EAG#"6W 0  T@,  !D
M     ( !7ED  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( #.#0DHK*J-7Q@$  #<$   9              "
M 7YD  !X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @ ,X-"
M2CQ.20VW 0  T@,  !D              ( !>V8  'AL+W=O<FMS:&5E=',O
M<VAE970S.2YX;6Q02P$"% ,4    "  S@T)*!C4!I]0!  "<!   &0
M        @ %I:   >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0
M   ( #.#0DILCU[BTP$  )P$   9              "  71J  !X;"]W;W)K
M<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ ,X-"2I'D6=O: 0   04
M !D              ( !?FP  'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q0
M2P$"% ,4    "  S@T)*'6LG+<X!  "<!   &0              @ &/;@
M>&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( #.#0DK\(575
MN $  -(#   9              "  91P  !X;"]W;W)K<VAE971S+W-H965T
M-#0N>&UL4$L! A0#%     @ ,X-"2I\TF\O& 0  -P0  !D
M ( !@W(  'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"% ,4    "  S
M@T)* $2KL;8!  #2 P  &0              @ & =   >&PO=V]R:W-H965T
M<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( #.#0DKF+CZVQ0$  #<$   9
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M970U,2YX;6Q02P$"% ,4    "  S@T)*#R<3??0!  #+!0  &0
M    @ ';@   >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    (
M #.#0DH%& D]Q $  #<$   9              "  0:#  !X;"]W;W)K<VAE
M971S+W-H965T-3,N>&UL4$L! A0#%     @ ,X-"2@]NU][% 0  -P0  !D
M             ( ! 84  'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6Q02P$"
M% ,4    "  S@T)*4V3. ;@!  #2 P  &0              @ ']A@  >&PO
M=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    ( #.#0DK&NOK5> ,
M $\1   9              "  >R(  !X;"]W;W)K<VAE971S+W-H965T-38N
M>&UL4$L! A0#%     @ ,X-"2LR=9W$V @  D@8  !D              ( !
MFXP  'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q02P$"% ,4    "  S@T)*
MUDSB_E0"  ">!P  &0              @ $(CP  >&PO=V]R:W-H965T<R]S
M:&5E=#4X+GAM;%!+ 0(4 Q0    ( #.#0DH%@?HD4 ,  $<.   9
M      "  9.1  !X;"]W;W)K<VAE971S+W-H965T-3DN>&UL4$L! A0#%
M  @ ,X-"2@3<GT^T @  BPH  !D              ( !&I4  'AL+W=O<FMS
M:&5E=',O<VAE970V,"YX;6Q02P$"% ,4    "  S@T)*UXR0)4(#  "8#0
M&0              @ $%F   >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+
M 0(4 Q0    ( #.#0DJ8W_)QK@0  -L6   9              "  7Z;  !X
M;"]W;W)K<VAE971S+W-H965T-C(N>&UL4$L! A0#%     @ ,X-"2K$-ST@0
M @  ) 8  !D              ( !8Z   'AL+W=O<FMS:&5E=',O<VAE970V
M,RYX;6Q02P$"% ,4    "  S@T)*>-W7^#,"  "1!@  &0
M@ &JH@  >&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+ 0(4 Q0    ( #.#
M0DH@[!%O4 (  * '   9              "  12E  !X;"]W;W)K<VAE971S
M+W-H965T-C4N>&UL4$L! A0#%     @ ,X-"2I:JF])0!P  Z2P  !D
M         ( !FZ<  'AL+W=O<FMS:&5E=',O<VAE970V-BYX;6Q02P$"% ,4
M    "  S@T)*K::B(\0"  #1"0  &0              @ $BKP  >&PO=V]R
M:W-H965T<R]S:&5E=#8W+GAM;%!+ 0(4 Q0    ( #.#0DI#6=0 M 4  .(E
M   9              "  1VR  !X;"]W;W)K<VAE971S+W-H965T-C@N>&UL
M4$L! A0#%     @ ,X-"2LZQD#:@ @  4PH  !D              ( !"+@
M 'AL+W=O<FMS:&5E=',O<VAE970V.2YX;6Q02P$"% ,4    "  S@T)*M_%-
MM'$"  "W!P  &0              @ '?N@  >&PO=V]R:W-H965T<R]S:&5E
M=#<P+GAM;%!+ 0(4 Q0    ( #.#0DJCM/XE*04  !0=   9
M  "  8>]  !X;"]W;W)K<VAE971S+W-H965T-S$N>&UL4$L! A0#%     @
M,X-"2IAC0OE8 @  )P@  !D              ( !Y\(  'AL+W=O<FMS:&5E
M=',O<VAE970W,BYX;6Q02P$"% ,4    "  S@T)*S2%'?)<$  #1&   &0
M            @ %VQ0  >&PO=V]R:W-H965T<R]S:&5E=#<S+GAM;%!+ 0(4
M Q0    ( #.#0DIONA[-8P(  +P'   9              "  43*  !X;"]W
M;W)K<VAE971S+W-H965T-S0N>&UL4$L! A0#%     @ ,X-"2NS9KX8R @
M/@8  !D              ( !WLP  'AL+W=O<FMS:&5E=',O<VAE970W-2YX
M;6Q02P$"% ,4    "  S@T)*GXR/R?(!   L!0  &0              @ %'
MSP  >&PO=V]R:W-H965T<R]S:&5E=#<V+GAM;%!+ 0(4 Q0    ( #.#0DH'
MU,B;P@$  !X$   9              "  7#1  !X;"]W;W)K<VAE971S+W-H
M965T-S<N>&UL4$L! A0#%     @ ,X-"2C#YQ;0I P  I X  !D
M     ( !:=,  'AL+W=O<FMS:&5E=',O<VAE970W."YX;6Q02P$"% ,4
M"  S@T)*3-C77GL"  "U"   &0              @ ')U@  >&PO=V]R:W-H
M965T<R]S:&5E=#<Y+GAM;%!+ 0(4 Q0    ( #.#0DK]1=O_F@,   ,1   9
M              "  7O9  !X;"]W;W)K<VAE971S+W-H965T.# N>&UL4$L!
M A0#%     @ ,X-"2J%@>3F, @  [ @  !D              ( !3-T  'AL
M+W=O<FMS:&5E=',O<VAE970X,2YX;6Q02P$"% ,4    "  S@T)*IB%@BGD#
M   \#P  &0              @ $/X   >&PO=V]R:W-H965T<R]S:&5E=#@R
M+GAM;%!+ 0(4 Q0    ( #.#0DH5?.+@+ ,  /$-   9              "
M ;_C  !X;"]W;W)K<VAE971S+W-H965T.#,N>&UL4$L! A0#%     @ ,X-"
M2D&BAK8  @  P 4  !D              ( !(N<  'AL+W=O<FMS:&5E=',O
M<VAE970X-"YX;6Q02P$"% ,4    "  S@T)*RRHHN"4%  #_'   &0
M        @ %9Z0  >&PO=V]R:W-H965T<R]S:&5E=#@U+GAM;%!+ 0(4 Q0
M   ( #.#0DIC2Q]IY $  .P$   9              "  ;7N  !X;"]W;W)K
M<VAE971S+W-H965T.#8N>&UL4$L! A0#%     @ ,X-"2H4)66[9 @  &@L
M !D              ( !T/   'AL+W=O<FMS:&5E=',O<VAE970X-RYX;6Q0
M2P$"% ,4    "  S@T)*Y!FIP*0$   6&   &0              @ '@\P
M>&PO=V]R:W-H965T<R]S:&5E=#@X+GAM;%!+ 0(4 Q0    ( #.#0DHXE/]$
M, 0  ,@2   9              "  ;OX  !X;"]W;W)K<VAE971S+W-H965T
M.#DN>&UL4$L! A0#%     @ ,X-"2LM!M_7X P  F1(  !D
M ( !(OT  'AL+W=O<FMS:&5E=',O<VAE970Y,"YX;6Q02P$"% ,4    "  S
M@T)*QB1RAB<#  "H#   &0              @ %1 0$ >&PO=V]R:W-H965T
M<R]S:&5E=#DQ+GAM;%!+ 0(4 Q0    ( #.#0DJM3IZ](@,  !8-   9
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M970Y-BYX;6Q02P$"% ,4    "  S@T)*"E48&4 "  #"!@  &0
M    @ $?$P$ >&PO=V]R:W-H965T<R]S:&5E=#DW+GAM;%!+ 0(4 Q0    (
M #.#0DHNKK'W/P(  ,$&   9              "  985 0!X;"]W;W)K<VAE
M971S+W-H965T.3@N>&UL4$L! A0#%     @ ,X-"2FX*SU?D @  9 H  !D
M             ( !#!@! 'AL+W=O<FMS:&5E=',O<VAE970Y.2YX;6Q02P$"
M% ,4    "  S@T)*_$=1SVD"   ;"   &@              @ $G&P$ >&PO
M=V]R:W-H965T<R]S:&5E=#$P,"YX;6Q02P$"% ,4    "  S@T)*T_(Z$^$%
M   M(0  &@              @ '('0$ >&PO=V]R:W-H965T<R]S:&5E=#$P
M,2YX;6Q02P$"% ,4    "  S@T)*F]L?H& #  !-#0  &@
M@ 'A(P$ >&PO=V]R:W-H965T<R]S:&5E=#$P,BYX;6Q02P$"% ,4    "  S
M@T)*T92=KZ8"  !P"0  &@              @ %Y)P$ >&PO=V]R:W-H965T
M<R]S:&5E=#$P,RYX;6Q02P$"% ,4    "  S@T)*E8$GNZ "  !M"@  &@
M            @ %7*@$ >&PO=V]R:W-H965T<R]S:&5E=#$P-"YX;6Q02P$"
M% ,4    "  S@T)*+1\7V:@"   ["0  &@              @ $O+0$ >&PO
M=V]R:W-H965T<R]S:&5E=#$P-2YX;6Q02P$"% ,4    "  S@T)*PG8RRXT#
M  "R#P  &@              @ $/, $ >&PO=V]R:W-H965T<R]S:&5E=#$P
M-BYX;6Q02P$"% ,4    "  S@T)*Q0U]QNP#   .$0  &@
M@ '4,P$ >&PO=V]R:W-H965T<R]S:&5E=#$P-RYX;6Q02P$"% ,4    "  S
M@T)*Q[6E.0 %   ,&0  &@              @ 'X-P$ >&PO=V]R:W-H965T
M<R]S:&5E=#$P."YX;6Q02P$"% ,4    "  S@T)*CU9VS14#  !7#   &@
M            @ $P/0$ >&PO=V]R:W-H965T<R]S:&5E=#$P.2YX;6Q02P$"
M% ,4    "  S@T)*$@ )8&D$   $%@  &@              @ %]0 $ >&PO
M=V]R:W-H965T<R]S:&5E=#$Q,"YX;6Q02P$"% ,4    "  S@T)*Y_\#>/D"
M   W"P  &@              @ $>10$ >&PO=V]R:W-H965T<R]S:&5E=#$Q
M,2YX;6Q02P$"% ,4    "  S@T)*[I2O#B8#  #(#@  &@
M@ %/2 $ >&PO=V]R:W-H965T<R]S:&5E=#$Q,BYX;6Q02P$"% ,4    "  S
M@T)*?UKHU!("  "K!0  &@              @ &M2P$ >&PO=V]R:W-H965T
M<R]S:&5E=#$Q,RYX;6Q02P$"% ,4    "  S@T)*C@AW6M,.   [90  &@
M            @ 'W30$ >&PO=V]R:W-H965T<R]S:&5E=#$Q-"YX;6Q02P$"
M% ,4    "  S@T)*0\L6GA4"  #(!0  &@              @ $"70$ >&PO
M=V]R:W-H965T<R]S:&5E=#$Q-2YX;6Q02P$"% ,4    "  S@T)*GH3=H5$#
M  #K#0  &@              @ %/7P$ >&PO=V]R:W-H965T<R]S:&5E=#$Q
M-BYX;6Q02P$"% ,4    "  S@T)*H^)X!M\!  #V!   &@
M@ '88@$ >&PO=V]R:W-H965T<R]S:&5E=#$Q-RYX;6Q02P$"% ,4    "  S
M@T)*^IF:(Q %  !S'   &@              @ 'O9 $ >&PO=V]R:W-H965T
M<R]S:&5E=#$Q."YX;6Q02P$"% ,4    "  S@T)*FU*N#"\"  ";!@  &@
M            @ $W:@$ >&PO=V]R:W-H965T<R]S:&5E=#$Q.2YX;6Q02P$"
M% ,4    "  S@T)*!,^'WY "  #-"   &@              @ &>; $ >&PO
M=V]R:W-H965T<R]S:&5E=#$R,"YX;6Q02P$"% ,4    "  S@T)*.J>P&9<(
M  !8.   &@              @ %F;P$ >&PO=V]R:W-H965T<R]S:&5E=#$R
M,2YX;6Q02P$"% ,4    "  S@T)*K>?*MS0&  #.(0  &@
M@ $U> $ >&PO=V]R:W-H965T<R]S:&5E=#$R,BYX;6Q02P$"% ,4    "  S
M@T)*?'@#P-<"   0"P  &@              @ &A?@$ >&PO=V]R:W-H965T
M<R]S:&5E=#$R,RYX;6Q02P$"% ,4    "  S@T)*U(R<J=8%   R'0  &@
M            @ &P@0$ >&PO=V]R:W-H965T<R]S:&5E=#$R-"YX;6Q02P$"
M% ,4    "  S@T)*TZ1W&>D#  "0$0  &@              @ &^AP$ >&PO
M=V]R:W-H965T<R]S:&5E=#$R-2YX;6Q02P$"% ,4    "  S@T)*0E,?G7UF
M 0"QC@4 %               @ '?BP$ >&PO<VAA<F5D4W1R:6YG<RYX;6Q0
M2P$"% ,4    "  S@T)*JH-&,9L"  !B$   #0              @ &.\@(
M>&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( #.#0DK:JT3?=0<  .10   /
M          "  53U @!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  S@T)*
M6H!A4(4#  #C20  &@              @ 'V_ ( >&PO7W)E;',O=V]R:V)O
M;VLN>&UL+G)E;'-02P$"% ,4    "  S@T)*1O9?SK "  #%1@  $P
M        @ &S  , 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     A@"& /8D
(  "4 P,    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>182
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>183
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>185
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.6.0.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>730</ContextCount>
  <ElementCount>611</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>200</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001000 - Statement - Consolidated Statements of Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ConsolidatedStatementsOfIncome</Role>
      <ShortName>Consolidated Statements of Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002000 - Statement - Consolidated Statements of Comprehensive Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ConsolidatedStatementsOfComprehensiveIncome</Role>
      <ShortName>Consolidated Statements of Comprehensive Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003000 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003501 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1004000 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1005000 - Statement - Consolidated Statements of Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ConsolidatedStatementsOfEquity</Role>
      <ShortName>Consolidated Statements of Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101100 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2102100 - Disclosure - Acquisitions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Acquisitions</Role>
      <ShortName>Acquisitions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2106100 - Disclosure - Restructuring Restructuring</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RestructuringRestructuring</Role>
      <ShortName>Restructuring Restructuring</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2107100 - Disclosure - Revenue Reserves</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenueReserves</Role>
      <ShortName>Revenue Reserves</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2108100 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2109100 - Disclosure - Intangible Assets and Goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill</Role>
      <ShortName>Intangible Assets and Goodwill</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2110100 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2111100 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2112100 - Disclosure - Derivative Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstruments</Role>
      <ShortName>Derivative Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2113100 - Disclosure - Property, Plant and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/PropertyPlantAndEquipment</Role>
      <ShortName>Property, Plant and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2114100 - Disclosure - Indebtedness</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Indebtedness</Role>
      <ShortName>Indebtedness</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2115100 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Equity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2116100 - Disclosure - Accumulated Other Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLoss</Role>
      <ShortName>Accumulated Other Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2117100 - Disclosure - Earnings per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EarningsPerShare</Role>
      <ShortName>Earnings per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2118100 - Disclosure - Share-based Payments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPayments</Role>
      <ShortName>Share-based Payments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2119100 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2120100 - Disclosure - Other Consolidated Financial Statement Detail</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail</Role>
      <ShortName>Other Consolidated Financial Statement Detail</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2121100 - Disclosure - Investments in Variable Interest Entities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities</Role>
      <ShortName>Investments in Variable Interest Entities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2122100 - Disclosure - Collaborative and Other Relationships</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeAndOtherRelationships</Role>
      <ShortName>Collaborative and Other Relationships</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2123100 - Disclosure - Litigation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Litigation</Role>
      <ShortName>Litigation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2124100 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2125100 - Disclosure - Guarantees</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Guarantees</Role>
      <ShortName>Guarantees</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2126100 - Disclosure - Employee Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EmployeeBenefitPlans</Role>
      <ShortName>Employee Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2127100 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2128100 - Disclosure - Quarterly Financial Data (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/QuarterlyFinancialDataUnaudited</Role>
      <ShortName>Quarterly Financial Data (Unaudited)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2129100 - Disclosure - Subsequent Events (Notes)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.biogenidec.com/role/SubsequentEventsNotes</Role>
      <ShortName>Subsequent Events (Notes)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2201201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2301302 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2302301 - Disclosure - Acquisitions Acquisitions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AcquisitionsAcquisitionsTables</Role>
      <ShortName>Acquisitions Acquisitions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2306301 - Disclosure - Restructuring Restructuring (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RestructuringRestructuringTables</Role>
      <ShortName>Restructuring Restructuring (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/RestructuringRestructuring</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2307301 - Disclosure - Revenue Reserves (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenueReservesTables</Role>
      <ShortName>Revenue Reserves (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/RevenueReserves</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2308301 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Inventory</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2309301 - Disclosure - Intangible Assets and Goodwill (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables</Role>
      <ShortName>Intangible Assets and Goodwill (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2310301 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurements</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2311301 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstruments</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2312301 - Disclosure - Derivative Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstrumentsTables</Role>
      <ShortName>Derivative Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/DerivativeInstruments</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2313301 - Disclosure - Property, Plant and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/PropertyPlantAndEquipmentTables</Role>
      <ShortName>Property, Plant and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/PropertyPlantAndEquipment</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2314301 - Disclosure - Indebtedness (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IndebtednessTables</Role>
      <ShortName>Indebtedness (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Indebtedness</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2315301 - Disclosure - Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EquityTables</Role>
      <ShortName>Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Equity</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2316301 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables</Role>
      <ShortName>Accumulated Other Comprehensive Income (Loss) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLoss</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2317301 - Disclosure - Earnings per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EarningsPerShareTables</Role>
      <ShortName>Earnings per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/EarningsPerShare</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2318301 - Disclosure - Share-Based Payments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsTables</Role>
      <ShortName>Share-Based Payments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2319301 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IncomeTaxes</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2320301 - Disclosure - Other Consolidated Financial Statement Detail (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables</Role>
      <ShortName>Other Consolidated Financial Statement Detail (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2322301 - Disclosure - Collaborative and Other Relationships (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables</Role>
      <ShortName>Collaborative and Other Relationships (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/CollaborativeAndOtherRelationships</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2324301 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2327301 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/SegmentInformation</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2328301 - Disclosure - Quarterly Financial Data (Unaudited) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedTables</Role>
      <ShortName>Quarterly Financial Data (Unaudited) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/QuarterlyFinancialDataUnaudited</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2401403 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2402402 - Disclosure - Acquisitions Acquisitions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AcquisitionsAcquisitionsDetails</Role>
      <ShortName>Acquisitions Acquisitions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/AcquisitionsAcquisitionsTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2402403 - Disclosure - Acquisitions Acquisitions (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AcquisitionsAcquisitionsDetails1</Role>
      <ShortName>Acquisitions Acquisitions (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/AcquisitionsAcquisitionsTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2402404 - Disclosure - Acquisitions (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AcquisitionsDetailsTextual</Role>
      <ShortName>Acquisitions (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/AcquisitionsAcquisitionsTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Restructuring Restructuring (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RestructuringRestructuringDetails</Role>
      <ShortName>Restructuring Restructuring (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/RestructuringRestructuringTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2406403 - Disclosure - Restructuring Restructuring (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RestructuringRestructuringDetailsTextual</Role>
      <ShortName>Restructuring Restructuring (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/RestructuringRestructuringTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2407402 - Disclosure - Revenue Reserves (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenueReservesDetails</Role>
      <ShortName>Revenue Reserves (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/RevenueReservesTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Revenue Reserves (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenueReservesDetails1</Role>
      <ShortName>Revenue Reserves (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/RevenueReservesTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2408402 - Disclosure - Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InventoryDetails</Role>
      <ShortName>Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/InventoryTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - Inventory (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InventoryDetailsTextual</Role>
      <ShortName>Inventory (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/InventoryTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2409402 - Disclosure - Intangible Assets and Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails</Role>
      <ShortName>Intangible Assets and Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2409403 - Disclosure - Intangible Assets and Goodwill (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1</Role>
      <ShortName>Intangible Assets and Goodwill (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2410402 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2410403 - Disclosure - Fair Value Measurements (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetails1</Role>
      <ShortName>Fair Value Measurements (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - Fair Value Measurements (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetails2</Role>
      <ShortName>Fair Value Measurements (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2410405 - Disclosure - Fair Value Measurements (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual</Role>
      <ShortName>Fair Value Measurements (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>2411402 - Disclosure - Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails</Role>
      <ShortName>Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>2411403 - Disclosure - Financial Instruments (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails1</Role>
      <ShortName>Financial Instruments (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>2411404 - Disclosure - Financial Instruments (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails2</Role>
      <ShortName>Financial Instruments (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>2411405 - Disclosure - Financial Instruments (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails3</Role>
      <ShortName>Financial Instruments (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>2411406 - Disclosure - Financial Instruments (Details Textual 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual1</Role>
      <ShortName>Financial Instruments (Details Textual 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>76</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>2411407 - Disclosure - Financial Instruments (Details Textual 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual2</Role>
      <ShortName>Financial Instruments (Details Textual 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>77</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>2412402 - Disclosure - Derivative Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstrumentsDetails</Role>
      <ShortName>Derivative Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/DerivativeInstrumentsTables</ParentRole>
      <Position>78</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>2412403 - Disclosure - Derivative Instruments (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstrumentsDetails1</Role>
      <ShortName>Derivative Instruments (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/DerivativeInstrumentsTables</ParentRole>
      <Position>79</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>2412404 - Disclosure - Derivative Instruments (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstrumentsDetailsTextual</Role>
      <ShortName>Derivative Instruments (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/DerivativeInstrumentsTables</ParentRole>
      <Position>80</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>2413402 - Disclosure - Property, Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails</Role>
      <ShortName>Property, Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/PropertyPlantAndEquipmentTables</ParentRole>
      <Position>81</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>2413403 - Disclosure - Property, Plant and Equipment (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetailsTextual</Role>
      <ShortName>Property, Plant and Equipment (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/PropertyPlantAndEquipmentTables</ParentRole>
      <Position>82</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>2414402 - Disclosure - Indebtedness (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IndebtednessDetails</Role>
      <ShortName>Indebtedness (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IndebtednessTables</ParentRole>
      <Position>83</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>2414403 - Disclosure - Indebtedness (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IndebtednessDetails1</Role>
      <ShortName>Indebtedness (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IndebtednessTables</ParentRole>
      <Position>84</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>2414404 - Disclosure - Indebtedness (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IndebtednessDetailsTextual</Role>
      <ShortName>Indebtedness (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IndebtednessTables</ParentRole>
      <Position>85</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>2415402 - Disclosure - Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EquityDetails</Role>
      <ShortName>Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/EquityTables</ParentRole>
      <Position>86</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>2415403 - Disclosure - Equity (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EquityDetailsTextual</Role>
      <ShortName>Equity (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/EquityTables</ParentRole>
      <Position>87</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>2416402 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails</Role>
      <ShortName>Accumulated Other Comprehensive Income (Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables</ParentRole>
      <Position>88</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>2416403 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails1</Role>
      <ShortName>Accumulated Other Comprehensive Income (Loss) (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables</ParentRole>
      <Position>89</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>2417402 - Disclosure - Earnings per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EarningsPerShareDetails</Role>
      <ShortName>Earnings per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/EarningsPerShareTables</ParentRole>
      <Position>90</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>2418402 - Disclosure - Share-Based Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetails</Role>
      <ShortName>Share-Based Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>91</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>2418403 - Disclosure - Share-Based Payments (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetails1</Role>
      <ShortName>Share-Based Payments (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>92</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>2418404 - Disclosure - Share-Based Payments (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetails2</Role>
      <ShortName>Share-Based Payments (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>93</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>2418405 - Disclosure - Share-Based Payments (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetails3</Role>
      <ShortName>Share-Based Payments (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>94</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>2418406 - Disclosure - Share-Based Payments (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetails4</Role>
      <ShortName>Share-Based Payments (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>95</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>2418407 - Disclosure - Share-Based Payments (Details 5)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetails5</Role>
      <ShortName>Share-Based Payments (Details 5)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>96</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>2418408 - Disclosure - Share-Based Payments (Details 6)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetails6</Role>
      <ShortName>Share-Based Payments (Details 6)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>97</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>2418409 - Disclosure - Share-based Payments Share-Based Payments (Details 7)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedPaymentsDetails7</Role>
      <ShortName>Share-based Payments Share-Based Payments (Details 7)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>98</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>2418410 - Disclosure - Share-Based Payments (Details 8)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetails8</Role>
      <ShortName>Share-Based Payments (Details 8)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>99</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>2418411 - Disclosure - Share-Based Payments (Details 9)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetails9</Role>
      <ShortName>Share-Based Payments (Details 9)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>100</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>2418412 - Disclosure - Share-Based Payments (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetailsTextual</Role>
      <ShortName>Share-Based Payments (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>101</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R102.htm</HtmlFileName>
      <LongName>2419402 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IncomeTaxesTables</ParentRole>
      <Position>102</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R103.htm</HtmlFileName>
      <LongName>2419403 - Disclosure - Income Taxes (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesDetails1</Role>
      <ShortName>Income Taxes (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IncomeTaxesTables</ParentRole>
      <Position>103</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R104.htm</HtmlFileName>
      <LongName>2419404 - Disclosure - Income Taxes (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesDetails2</Role>
      <ShortName>Income Taxes (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IncomeTaxesTables</ParentRole>
      <Position>104</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R105.htm</HtmlFileName>
      <LongName>2419405 - Disclosure - Income Taxes (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesDetails3</Role>
      <ShortName>Income Taxes (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IncomeTaxesTables</ParentRole>
      <Position>105</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R106.htm</HtmlFileName>
      <LongName>2419406 - Disclosure - Income Taxes (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesDetailsTextual</Role>
      <ShortName>Income Taxes (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IncomeTaxesTables</ParentRole>
      <Position>106</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R107.htm</HtmlFileName>
      <LongName>2420402 - Disclosure - Other Consolidated Financial Statement Detail (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails</Role>
      <ShortName>Other Consolidated Financial Statement Detail (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables</ParentRole>
      <Position>107</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R108.htm</HtmlFileName>
      <LongName>2420403 - Disclosure - Other Consolidated Financial Statement Detail (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetailsTextual</Role>
      <ShortName>Other Consolidated Financial Statement Detail (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables</ParentRole>
      <Position>108</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R109.htm</HtmlFileName>
      <LongName>2421401 - Disclosure - Investments in Variable Interest Entities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails</Role>
      <ShortName>Investments in Variable Interest Entities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities</ParentRole>
      <Position>109</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R110.htm</HtmlFileName>
      <LongName>2422402 - Disclosure - Collaborative and Other Relationships (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetails</Role>
      <ShortName>Collaborative and Other Relationships (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables</ParentRole>
      <Position>110</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R111.htm</HtmlFileName>
      <LongName>2422403 - Disclosure - Collaborative and Other Relationships (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetails1</Role>
      <ShortName>Collaborative and Other Relationships (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables</ParentRole>
      <Position>111</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R112.htm</HtmlFileName>
      <LongName>2422404 - Disclosure - Collaborative and Other Relationships (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetails2</Role>
      <ShortName>Collaborative and Other Relationships (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables</ParentRole>
      <Position>112</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R113.htm</HtmlFileName>
      <LongName>2422405 - Disclosure - Collaborative and Other Relationships Collaborative and Other Relationships (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsDetails3</Role>
      <ShortName>Collaborative and Other Relationships Collaborative and Other Relationships (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>113</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R114.htm</HtmlFileName>
      <LongName>2422406 - Disclosure - Collaborative and Other Relationships (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual</Role>
      <ShortName>Collaborative and Other Relationships (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables</ParentRole>
      <Position>114</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R115.htm</HtmlFileName>
      <LongName>2423401 - Disclosure - Litigation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/LitigationDetails</Role>
      <ShortName>Litigation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Litigation</ParentRole>
      <Position>115</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R116.htm</HtmlFileName>
      <LongName>2424402 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CommitmentsAndContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>116</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R117.htm</HtmlFileName>
      <LongName>2424403 - Disclosure - Commitments and Contingencies Commitments and Contingencies (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CommitmentsAndContingenciesCommitmentsAndContingenciesDetails1</Role>
      <ShortName>Commitments and Contingencies Commitments and Contingencies (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>117</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R118.htm</HtmlFileName>
      <LongName>2424404 - Disclosure - Commitments and Contingencies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CommitmentsAndContingenciesDetailsTextual</Role>
      <ShortName>Commitments and Contingencies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>118</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R119.htm</HtmlFileName>
      <LongName>2426401 - Disclosure - Employee Benefit Plans Employee Benefit Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EmployeeBenefitPlansEmployeeBenefitPlansDetails</Role>
      <ShortName>Employee Benefit Plans Employee Benefit Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>119</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R120.htm</HtmlFileName>
      <LongName>2426402 - Disclosure - Employee Benefit Plans (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EmployeeBenefitPlansDetails1</Role>
      <ShortName>Employee Benefit Plans (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/EmployeeBenefitPlans</ParentRole>
      <Position>120</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R121.htm</HtmlFileName>
      <LongName>2427402 - Disclosure - Segment Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SegmentInformationDetails</Role>
      <ShortName>Segment Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/SegmentInformationTables</ParentRole>
      <Position>121</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R122.htm</HtmlFileName>
      <LongName>2427403 - Disclosure - Segment Information (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SegmentInformationDetails1</Role>
      <ShortName>Segment Information (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/SegmentInformationTables</ParentRole>
      <Position>122</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R123.htm</HtmlFileName>
      <LongName>2427404 - Disclosure - Segment Information (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SegmentInformationDetailsTextual</Role>
      <ShortName>Segment Information (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/SegmentInformationTables</ParentRole>
      <Position>123</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R124.htm</HtmlFileName>
      <LongName>2428402 - Disclosure - Quarterly Financial Data (Unaudited) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetails</Role>
      <ShortName>Quarterly Financial Data (Unaudited) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedTables</ParentRole>
      <Position>124</Position>
    </Report>
    <Report instance="biib-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R125.htm</HtmlFileName>
      <LongName>2428403 - Disclosure - Quarterly Financial Data (Unaudited) (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetailsTextual</Role>
      <ShortName>Quarterly Financial Data (Unaudited) (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedTables</ParentRole>
      <Position>125</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>biib-20161231.xml</File>
    <File>biib-20161231.xsd</File>
    <File>biib-20161231_cal.xml</File>
    <File>biib-20161231_def.xml</File>
    <File>biib-20161231_lab.xml</File>
    <File>biib-20161231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies/>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>187
<FILENAME>0000875045-17-000009-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000875045-17-000009-xbrl.zip
M4$L#!!0    ( #.#0DK?]C"1>SD$ -E*2P 1    8FEI8BTR,#$V,3(S,2YX
M;6SLO5MWXS;R+_J\]Z?HD[7.V^F$  A>LF:R%PB2&>_I;KMM=S+)RRQ:@FU.
M)-)#2MWM_Z<_!4K4C91$RKKP@KDDW2)%L0J_NJ*J\+?_\WT\>O=5)&D81W__
M ?VH_?!.1(-X&$9/?__AR]U[=L>OKG[X/[_\[[_]/^_?_\NY_?#.C0?3L8@F
M[W@B@HD8OOL63I[?_3X4Z5_O'I-X_.[W./DK_!J\?S_[TLO/^B,9!-K0'&@Z
MT2W;M ;Z@T#6X-$D@18$]O_W_>?A,+#@VM#0*-*I%M@V-@*#ZM@4IF5B/7O8
M]X=D%/XL__D.WCI*?WX(PX>___ \F;S\_--/W[Y]^_$AC)]$% [%X,=!//X)
M:\A F* ?YO</XFDT25X77Y&/^C&%FY_BKS_-+V9?>J^A]RM?FR8),&7;]^97
M2[XX%&'Y=^""O%U?OUU\'SR7WR^OE#P_C+Z*=%+^E=DU^26R\:4TUC$RU_B6
M?3-.GN!VC?PTOR/_PBB,_MIQM[S\$*0BOST*PD%:_D[9)?E*:/V5HCB*IN/R
MWQA.DI\FKR_B)[CI/=PEDG"P^-[^+ZU_(1&/6RDQ?H*K^8UI."@G 2Z4$)!.
M7I(M]\.5DB],T_=/0?"R^,YCD#YD+S*_4++8<"6)1R(M_4YVI?Q+D@_E7\JN
ME'UIDHBGK7RR?X+K^:WRPG #Y M^SBZNW3HIO97.;IVLWAKN FB43H)HL(#<
M]P)$OY'L;F3;]D_9U<6MZ;#L1G@L^NE?'S_<#9[%.%C>'.Z_^?WB;7[YW__K
M;_*W?DZS"[?B\5WVVS\_9[B3VNI]KI)^A!?Y87Y9KL/??TC#\<L(2/I)/F:F
MZ@9Q-!'?)^]">&??E5_]K/]Q[\H?RF\!11Q.7N4'^2>@_>"SQU D[[+W$&LD
MY+CD5__\X1<-_F.95-/IWW[:_'+V&S]M_LC\-UY J.+AZJ\""Y*)"_;@EQQ/
M&LJ_OKRV\@41#9>W(PSP6_[:,+\Y_VCQ>_D'<\[L8!5M!ZMH/5;1([/J:@:J
M)K)I)E832;4IF83-Q2/G5PX'R(QLW'"R08R,]T0['ME2+O1VR(5>3R[T8ZN0
MJYD*:2*?5A"RH0Z.)1A-)]LX!=FD\6234Y"M-YYL_=AD+SVI?\_=[7_?34!=
MR*C6^^\47HW'XY<X@K^F['N8+NZZ"2#2FWP4XP>1G(UI"_4HGN0+9A_-/AO"
M+W]_&86#</Y.[X8AW#(+Y>?O_/-.RG[X);]ME;2__53Z]-G+_%1XFS9[B0?!
M #X>Q]'=)![\U4DL%.CK"2#F-K\F&MAP&$Z S<'H)@B'5Q$/7L)),.HD,G;2
M>CJ4G-+C.5@+W"<B2*?):W?U0 F%/=($1FU-<"LF01B)H1<D41@]I9T$13F1
M9Y']D[C]]16^6N:^J'BUTGU0]/4U@ H 6B'WAUGQFT0\BB01P^ZN;QF)[;7@
M]9?X4QS)IR3Q: 0:[PJ>EXBTFWF=7:2V<\D/MN8J4#]YH-XXVUY?-RC;W@HM
M<-CBJIQ-JQ:XOF>NG+>6^>?UEU@Y;RU>\H.=-[7J?7/=ZFL&9=U;HP<.<]_8
M8# =3T>RZ^!Z\BP2>5LBGB4SOXHKD)JQZ.2R5Z:[3ZZ> D,3P- 4S:!R.VW6
M (?G])02N)02:)S#J*M0LFE!Q:FK>*G:!VBDK6A2B]/A0%%; 0H0JAY(04.Y
M$@UP)1H%D\/<3;4YU0OW4H6DC0A)VZDC5'!RSD16<[2&VKM2FD AHJ52?Z"J
M5XY" S:P&@(&E5IHV3(?;.G5$ EEVU5FN14R/A\+I%1YHU3Y2<8@U5]FE?%M
M\9(O)^$IS=V(/<%+S_L[&!!*#?0))H>9"J4TNFT45-+^O!5%[=0"*J';?4V@
MDCM=DO.#8:!$78%"Y87.7CUX:6@<YA>HLK 6>0:'+;':ZFW"5F]SW$2%AV;4
M"+;38*ATPSEK!$]B0F2'LSP/[-\?@__$B1NFDR1\F$[B)%OH[,K*A_??XG8L
MKGSQG\M(^N&7[%(936=9Q)/-+*B^B-=12W1ZC45<T'2613S9K &UB+V21*5.
M&R>))0,@;I(8'C)YO1G!HUDTE'["BWQMY_7^]45L;K"]3"<B6=PS(WJ9>@FB
MI_5O? RC<#P=MP,'RS!Z+TO6-N7*>+(+'S5>9<'1Y0^NL?1,#OREYTZ\$;?^
M-(G"R301<)\??I=_2A5T?][.%H7>!J'7F88C>5#\?L0&WSN.V'56G!"EJYQ4
M*#V1;]!YN)[?-U"XK8O;C\'@.8Q$\KIZG\+NSSOXHO#;?OQVWKF]#'Z5=WN>
MV*SSZO<BL9G2OJ>+S3JO<,\6F_5/Q\Z:H-$*ZE(P;6G*!K @:;9QN\S \SCZ
M*I(G$0W$S7.0C(.!F$["03!J627<%B+G.?E]5)X)&/2]AFOU1</MV#JZ^OJ\
MHKX4.)H"#E #V@6UQFS'#A68<1RDK)K+X70PN4[N1/(U'(CE(YRK*T<S=86L
MVF:OC*?S-UACZIEV(4%I(7RT7<C3XE+AK*<+7T$A?1)3\&B#R7,X> G C8R&
M\'WY*PH[1]51^_C<2O0>U0E7UK/3UK.),8),<63 \H-!. (*/L0SH5Q!;3!^
M2,+AD_C(-A,:(ITDP--I A&^3 <LO\3DX]>N<UC;)]$2G9K!HHPE.68W>7*L
MS$891^>_N8>E_4AZE*7F]L"0MA>&56&Q@\0>P8*NISP4+"X/"UHOV7&2"8&K
MIQLJ3%P$$V>N7NZN7Z+\A#/XMTT'P5&=TVXN>:DFX'$J]ROA,X@ -^L4HTD2
M#";W(AF'4<;0=F"A5"$4"5VM/MQ"J0+)/I!XXY=1_"K$G?@JDB :M*0;K39$
MMM#9$X#L=!D5.LZ/CG,>>*T6NSF+?9)FU4,66SD'+5[P0U2Y6O"6JO.2<T%^
M"T;368 T&L7?I I+E\Q("Z6;\PM^G/ @?7;#=!!/VS93LAK)JV/CMM-\OMVP
MIAT]6Q$X^<9N)D;38,2&_YFF$\F/EJ64JJ(FW[/=2G!/(+-I7&HJFKM@)-);
M 2HZDO<MO]1-U"PF3^TFNYUFYXU04#;G7#:G@2!0]N-\]J/9KJ>R".>U"(WS
M)G3E3;0%.^<\PU09DB8;DJ8LOW(F+^A,GN2 6T,ELEJ!@T;M7AX.'&4_+I3(
M:B]DE/?9@,CETO#9W%55=JJA=NJ<6^O*YC3.YC1P^97]N'CVXN0U%TXPDC3=
M/0LQ6:N]SF^8G44S3>0!AQ_"X$%6-8=M6_IM5"X7>R>9[4QY;TK]WJ5F@\S0
M >8'(OP:/(Q:5C:W?Y6W4=@3658+W'$)5LJZK;)<<ER><M(;YZ0WZH"\PR&C
M'/L&)(;:#Q^5&[K('L:E@;-Y,*=2.HU6.N<\\5DID(8JD :"0/FM%TDNGV3Y
M5[,0VX?C_7GUR;G]X[XE8QPJ#*9;)ZB].89JR^=XG[P;]N&J,\NW3E#7E\__
M</4OYG1G]=;H:>?BE91V^&$43L2'\*L87D7P^*?P8218FHI)ZKQFQ]WR49"F
MRV6]BCX 7Z)4#&_ K5_8DBKR',9I. Y'0=(R@UN#1W.L;&'2+M0<2<5L\KBG
M52=U8)U_QQ5?Q2A^$<-[,7B.XE'\]'H;/CW70#C[[?J3]Z\.@SO_TAY6G1[G
MJYSN3 +^*AJ*QP. >Q4!IR *2&4,$"2#9P@'YBLDB6X7'FLR88G)2ESH2<JL
MQ-#OG$3N3\?!BQRVS38/J=JN[$#T'V'EDZ!=^-H]?+S B-.KL@T^]L1@7]85
M;6=FH$5^Z+DR%0K32^?SP\WM-<2H"M.G\CG7&-Q?3"LWM2MN:A/ I;]185Y/
M)Z7ZH"U JJ\ MU'<W]CFC%;V[N;JTRW[4WF.I[*RZPSND2*D*EY7\?I6A%YZ
M(,VY_<"5ZHXDE'7U\'B1B'3B2<:% AZ?/1E@-JO8OG[,KKRN!$23X'OK1K5>
MSJ^L58%2?TWR(&IU47JBW=^R.:62 LUV5\Z5%#CU5E3+=/MM/ RC^V>PPB_9
MZ: M"_JZKN6W+(_2]Z?6]_>O:?"0A/,;VB44+=+Z96QNI^[?K.<[5/'?)\%0
MC(/D+UF+G/WE4S!N6X_%P6IY)_7MK!4\0T556V!Q[A*I]FB+8UFV3B+A4!/5
M'IV@=@);O!-XS@%0RJMHIU?16'=3:9!F:9!&N9^J+N#\OL;)38AR-9OL:C8O
MTE#RW_Y8XU  J/Q#,_(/36M@K=OI=PN/6Y\@\A%^;3P=*_P<*<>^X/#RA]=8
MW),=HV/4-&Y3_[O0''SO.)H/-HQOQ/ J8Q6&C[;QV5L(GW:G4R'XHEJX\S[%
MI;2P\B0NX"%W7B%?WD-6NOE<WD4_5//YO0NEF=6V:,NV11L%IL+N2! F<BZH
M<%X7?_P'K)/<%'S]( W5&H 6]UQ%+]-)FMU -K3ARB,_BB"=)D(RS4_$?Z<B
M&KR6/V_E3GDFQC1)PNBI7;BLQLHE''?P\D@*M,)*E+S.CJ5H[Y;0D3&/%>:/
MAGFL,-\*S".%^:-A'BG,GQ7SF6M8](>SCYU@\)<8WDD.K)S.I"3GI)*SOB K
MYZ)M7Y'C"XL2WY:(;U^E1,&ACC;G<?(2)Q ?N^)A4D6?]Q56VY3O3@8J9=<R
M=*O8MFL"HT+L=HOPF<(-E9#M6+BALL)]$E]E?SLFOLKZME%\E:Q=4-84LNL@
M^\O=?9)QX95%PU_CKR*)EFV\RC1=1%QVKHDR3DJ$+R3"*CCLG BK\+ 1(GRV
M!*W:3NY<@E9M*#="A&M;825O%S69"MV-]#&5@6JJP"@#U6X1/IN/J<+$SOF8
M*DP\P[BQG:=OW4V2>"R&X?=VR<#ND[0VB#K+,IY\:N3.9>1Q!';Z"6 N;N01
M8L$@.ZLB&+6LD7+WNNZCL@?RZH0QT'\U%(/L*),H.[4D&'T2TR1.!Z%D39=6
MO#*Y/9!QI:J;+,&5EU%)\ 4E^+)+OP'VE1 *B(B 31/X4YH=R"F_Z+S>O[ZL
M#_%@@T$R%<,/8? 0CE9\^FY@I88RJ/&;>[F[4E"RA;WMQ&;)E YE8$ZVDHV;
MJ5'9IU3!0WL]2"GC^#/ZK&3\[#*.Z\DXW$Y..C?G33*N?)$CJ@OEG-1';W7<
M74^>1?(ICF2J%FYO+?YJ+/T^DKL!@>.$S4J3G2("5RJMOM.M5%K35=I)W''M
MLU[9'5?)P',G ]=<>.T]_*^Z"Z^=88ZJ@DMSX7+IK$Y=N*C$3H_ L>E]R-*?
M*S!HR512MI(!$E$8@^6=B/3^6WP3A]'D$W#W1B0#N,^=BOMO\._7V3_;A9,B
MR7F"J#[-[?0_-D.J"B"X"[]G#/'DO/\[\55$?OBUP)KLJA!1]P!Q"/WMC4]J
M@L./ITG&G3]%$I?Q9?9/>:5[R*A-?&]@<?^<")&Q!J0'-.IVYL#%[@'C /+;
M"XTJ/D7&E9O@-7@8B?O8G\K-F$'0D87?15QOO(0,XA+QTG_:@+H?)YTU =7)
M[K:$*X>Q^0YC$_2$"BDO'%(V04,H]["1[N'%](-R#[LN\2I/T+@\P4FDO2XL
M5-30A*CAY%!0 QK444X-:ZL^)^;544X-DYQ&#(Q5XML2\54#22YOLM0DD'9@
M7HU;/A[FU9SC\V*^KP!5<%!']G5W^)A"=R.G]2E'H:D"H_R5=HNPF@C=K@&W
M"MT-3)HJ\]2QI*DR3FT47R5K%Y0UA6QU5$&[Q44=5:!$N(G)#[4SV+GDA]J@
M;(0(JT,IFR?";;'"2H0;(<+J4,KFB7!;K+!RI!LAPF=*TBH;W,S$D;+ [1;?
MLSG1:I>E<TZTVF<YD0CKJFBQI7#03]U7?15]%>E$OF1A<O#'.!*O'X/D+S'Q
MI]&P98,=BX0ME[><LK,LZ,E';.U84!Z/QR(9A,'H)H!?Z<YZEA+6WN6DU9:S
M+)[NPFK6S1,TV_96E,U;\3(%5RE(!7M*Q,S@=&=)MU/7>2E5"]M1B57JMT-2
MJERC=LAFQ>54H4M;%G15V7X,_A,GDN3T^E%J(18-O?].X0V7ZFAE%-!$[BD]
MA8,EMUJVS!7)71Y$N(7>;BAGM?C-7?QF2?Z6#64^.^VIRS"H0GE[M<'!@%AN
M:?0*#7O)5E#(KGZ*HYZB89/R'@)BB\KL!R8J$M]#6'R,D\E3\"3@INRTR-(:
MEQX@I#X?%%C*F=0/C7(0*_H(F2Q#(^=V;][3:73LH;J]0#@X4Z&"U8L'JR=/
M1"MCTC5CTBS(J*#VXD%MLP"AO(N+>1?- H+*;C0DN]$L6*B$N'(W5:*K#8FN
MDX/%"49!-!!WST),/L2#8 (\7"N5R;A1V%9>J7)+PJ_PK:]B>3+1;9C^M=XG
M$B<B?(J\[X/G('H2'%XH"0:;35__$,.G,'IR10KW%E\D_UP,63J_=?F3[8+F
M-J8ORWC*N;X+<C5^?M>:K?2X[%JT([U)^9*OUAKN7?,^B>%<_V2ZZ7*"" [4
M<+$NG12\$C[W3O1*5KE/H@;D#V8H^! &#^&H;,R LGVG$\$=_.^=*"HKN!C^
M,1@D4S%L@DAVV@INXW/O1*^_5K!!HM8KZZ=$3UF]YL9^O1)%%0MV713=60W7
M'_?N*62I[%'IKT$8?8C3U'F=<_)6C#*6I\_AR\K.79 ^/X[B;VDBOHIH*C8>
M?14-XK&XF\":R*>6JHV[8-2V#=_FB,1A:Y?O/)8NWI'>;,?2+UFTLO:GDTR0
MOF3BPGO,RNHT!/];/'%Q;>4+(AHN;U\3Y?Q*IT4Y!I+@.OS*]Q=8U8)'746H
MK_-G>+-G*/F^I'QO6=%S2GHY('HD]%0)O1)Z)?3G$WI:3^CI*81>;[;0'^ZT
MYYL?"Y#-OJ0$OP&"?S%OO@HHSB3\>CWAUY7%/\SB*S706#70!/O?'(6@O &5
MPNNRM/<HA:=LNW+LE8PK.WXQ.]Y9X5=VO+\R?GX[W@11;KA+KF+T;DN[BM&;
MYMCW86]>*02E$%JA$)JP;]\'#T'MVRL5T)A]>^4%J/1>+P5?I?<N;_$WIZ6J
M+NPV-+^H+NSF-<&<?)"Q&@G47(%4(X&4&*Z)83/:0CL]#$&U@<ZO7VH8PN5%
MK4'#$#HM:FKX0>]%K4%6K7_NI;)R/7(P9XL]>,TP/YC_Y=^<N3V4CU5>_/!+
MSHR?@1D*=<=%77\PI99\MZ+YA]]#4&Q3-/_PE:(Y[E@M9=Z4>2N@[N0GE9>C
MSOMRJU"7HPZ8T3/4G5S7]0=3;5GRDT^-5(I&*9JFH$ZY\KUVY4\REO.07L K
M>$8BTLDM\&0]=]@63%5+DVZG\TS59)?N,*OI_[1XSZRI&T4GMS1O%/@>VJ-3
MZ@YEM8Z>Z59*J?EQ=DG+PJW<F%Q;R(_!]W \';=K"1=D+%=MC8XS.1)-*$M_
MD]6Y^Q:\*(M3V>(LV:6LS3E44QAU0S6MTM$3U502!*L%[E(06VV!E7/1V@7.
M X*LQ]0/!K*D]76MZ#&[<A>/XLGS-(G:L<A9;V49-?.VRPURVNOXT\_D\XIL
M.M,TC$2:LL%_IV$:KJ^A%Z9!N.$'WB2R[W/R>C."=YF?/O\BZ71>Y;'T:V+N
M3$/@4?34#@@LJDK+63('P@I/CN3L5>#H4N.LL_1\*L>LI7(T^SW1CFM3C,](
MXK:>UMFSP_/ESCT(UQ^"J"6YC2.JM;?O(0&[+R$RR]5JJH^MD1.X8 >I^:;C
M^:@ZND,:<I;Q(6J]SY3V6%N^8Z4]CF_@5DL8E($[N8$[7I&$,G!5\MLJ!&UE
M@O><(>C'8/ ,3T]>5^]K!QY:$8_NX&]/7*]S([H]MKD5 #Z[\;PT7C<WAS_$
MT=-$)&-7/$P*8/L43T1Z$[P&#R.1]5+/_]RRL?]E-*X6=NPDLIV&=G.95438
MIN6#U=,,):3-$E+MV!LRX#IHUF>TDH4N7>=9,".B,$XR+MR%WV_B,)IXX=/S
MY$Z. ?7#K^)&) ,@QYV*^V_P[]?LJA M"7YV@V 6_[R- ^<Q[YHE,5+9O,]N
M/^5(4H6H%B+JG',,E&EI@&DY^C)?*=/2+44 ED(C[S7]A B1C%F6D?8.'T7R
M>XR.XH@[%3^V2/V7M #LE>W[;W&&[4_ ETU$S_ZYD;5\0UM!6U!212=4Y=N1
MLING:D]H;"ZDH(H6YU/P49"FUX]WDWCPURJDDU"D_[I)Q*-($C',+K<+=ELI
M7*!O*XGM55?&9W*V]3F4["/7?=1$]I>5!L0NPWL?G6W&>)7%7MR1B3GKZ%(O
M;ME.97L7FG[&#5=F]+UF'%V9H<^HX62C]6*DXY"MEXFUW':>O/)X_!)'\-=T
M<_;^=#P=20UWGP11.COKBPW_,YT=A-)2*2^C>6T0?@6BSR+T^BD*FS8._ZR-
MA$]B\B5*1# *_T<,EX?BY$?#=1T3E<@_4Y5&$XZ5?"N<7/$((>G0$1'\82*K
M8=+^*)@*Q"LHU=%,N1CZ23Q>SA^X3CY/06 ?7\/H21Y-Z8_B;W(B0=MVB [2
M5H>Q1,%.N4:-<XT:!9TWN]3*\EW*\IW2Q7XS+)05:X,5:SJ$5(AVL1#MU- @
MRNBTW.B0QL%"&9V6&9WF04B%04J3*-^C.;['T:%1-O92#.2.*;![U@A^/9U<
M/ZYP8W:R*7 M$<^2M[(<:!"/U\NW#WW(1J&7LGF%68!O6)TEN-^V/+N@WC?S
MW;@9IWJWI+D[=J?ODJMV6'<,JE52JJ1426F3I@UW4$J59]QER6VT9ZRDN0PN
M2K2.(UH= VK'0CAE=I39Z7$I6L?2JRK4ZXKD-B;44VE3Y1RVPCE4YD0!M15
M;8)&I:J)J*55;8T+B-\*I<X'H=V+W"X-N\TQ1@ISG<3<Z4^<4(W9'8E2NZ"1
M%)::4,792$VC2KU[Z5Z_6:NH,*T!S4<G/\1#J9/&JI-3&Q9#!=\]"(0:ESX\
M NR4M]N,R*D+<%)N3B.RT5V DG*->@F=K5-XE2/5)4?J(H.<E5/4!J>HT=!0
M#DX#\CC-@X5R5KH @Y(*1P9O- Q'4WF>RYT83)-P$HK4^SX838=B**VI9-1T
M,BMR>O2") );FMZ(Y.XY2(3S6OZ Y9D1][ 2OX&&%<-;^&<2#B;S"?M?HG#2
M,E-S0F;-3YZHPJTS.<I-J'(\-U@S5E^_R*^G\N#V\<LH?A4B^_AFF@R>@U1(
MLZ!@NP[;>GSK$8 -I6T;#-L&:=M+IR5*:@<46!58R\%ZZ6J%2[@&'X/D+S%1
M\-P&SW+^*%.O -E'0/;1G"M -AB033#9Y]:0*IKO4#3?1XVJ -PA #=! V\
M>-:2O-@8^1#/>IDWFL)3$0#+@(^N^"I&\4NVA_+]!9:U99W?.\A=;>S>2Z\"
MS![ 3)+I8 )B&3UQD-C6%:!4Q<D6,GL$#[T^/.[$: 0<^U5$(@E&(&5L. ZC
M$)@92'T^%[0N(J86Y3U*G!R@8Q2(F@2BEFJB&W FVU;$4@DCJX3U2(\8"@*7
MA$ 3 O0#(*!,29-,21- =( I43%/?\S, >ZJ,C/=<C8/,#-*0R@#HK*L#<RR
M-L&D'*9/%& N I@&:ABYE_4IF$_SS78.&;)MZMW=W+0+"JN$S/?R-BCIKU8H
M663IWW1CD=<IZ9$D[U]D)<FM7V2J)+G[0>'^15:2W/I%WNPZ^!8DP_O7EY55
M;GD5["I!3:A;;9 C-BO)RTK0@E0,99$:L"^+5:2,K CZ9!*$D:3\^O%&)(]Q
M,@ZB@>!).($?ATOP3#QC5_>0-"O V\FE7(M49],NL+49W4UP3LA>E28GY]R)
MR60DABOKE*UQ2T"Y"P#[J3L3&$@],)"VJ#JB5%T--BE5=[:T60D0.]627 *!
M!C41-\BS*P?$(I+KE,U;A'47M75-T :;W3Q*&_1\I,!.;: \X7YIA_U@:*?3
MJAS$-YD$I0&4.5#^03^U0]WDB!LF8C")D[0]/=K54QHEQ/4("OL-A?(..F<0
M]F?*U:)W+B.^4]+WI(@6UZ41#:.G]<:C4BT[>WX"3WH6UU'+*CF/EVJJ\:,K
MO%WI;:K.W!XIL+H.S/4X"A^FF85OB2JK[K\4:>N1^[)_(T3%N6<!0^,W02K'
MN8OOWX? UNO'JV@8?@V'TV"T9O7RL*']&'IK<%SCYTM9NC1VZSSMD1I[BV_6
M4N@U8_ONTL[,YGDV:N5;>B+-Y@'3:B%;>D3T;HE4+F5')50M;&LEME+/2D=&
MSI;TL*BAL)6;B5=@W\*L=LG:EQ/4HY!_[Y*W>R.C9,E[W\2T5]4K*>^:8M_;
M6]ZE^I42 *CRE7IP4,Y>]T&PUPPHR]\U,[!WR;L3OY<L?V.V^IH A;TF0$E_
MUQ3^WE!/6?WN!W][Y5Z9 *4/%!1ZIA7V.H8J/Z"<0Y4A[+,Q4!J@+P:APCY_
ME\#0O';'"U?GJ,5M<X7.GL5M=UJG"7UI%RZQ4@O89/7ZEH[@Y8D.0?2T7O;Z
M,8S"\73<Q[6N\8,+OBTK:]<8U]\([B@8#+XK#!Z$P57&]3>D5!CL&08O'<>>
MRA8K#+8'@TVPQ:?0@\H?;(\_V 0]> I_4&&P/1AL@C](/R/ X-F0<C:3H9&3
M=C1W1/(N)PCGS+C.3K"\#[ZSZ>0Y3N#5UF=>P,5T$@YX/(TFR>N&CH6O\40,
MPPD/DN3U,4ZDLEK[_OR$=F>:AI%(6Y;[*^?-RO"*,N8<20UO9>WRYTMYVPM4
M9@>NLF@HSUL=_=]I$J;#<" ')=7&9WXV:[> N8<_YX/H.GM[@4T_3D3X%"F%
M68++,MXH?7D93/854\U=U*W'J:MU/?FZ-BKVK!!0M3&E>[D,:X-4\?%<UTY[
M"HWQ8#OD-,Q2^_CSBGW)V"Q?\U<1/R7!RW,XF ^]',ST[K^O[ML"J:VT_/#+
MG)B?K^[/ET'7:V70->,]T4YG0=0ZMT)"K[))_5@MVTF7C:Q+V_%<@%D/VG0\
M'063\*NX"T8B_2"^BM%*Q^H(_AX]A*-1T>3G-H8-_CL-TS";^K[XHC\= \^"
M9,R>-KYVD\3#Z6!RG=R)Y&LX6*V+%H-'6,,D:(=O,.MRV\*^O"^VR+\C^0);
MN#__W0+[C_2K98N75WVOKUX[-5I)3*N46C>CULU3&I0B5(JP78JP4>(DG0JD
M7/@3&SQTHGZ*U2#[MR )@X>1N(+;$I%.//F&H4B=5SX*TA28.LA.>;E^S*Z\
M+O76;3P,H_MG@/Z+F$["0<N2/(<0/I?Y+92?2?;I>Z1=N@ASPVLZ'$2?Q#0)
MQ^-IVT[D>@-Z-DGNB<F8Z1YR'-VC8'/&DF^S7OV>?=1DX2POC(X#&S8)OB\\
MTAY@9HW>\V67Z]5GGZ#@<[7I5SDX+7!PSCFC87LD?AM.IM];-Y]O>VRZ1D_K
M4W1SF7P-1H#5:/A)3&YEEF$ZFS)V"UH#H'TODB2<Q,F*&-_%#Z&\>A\[8?PD
MHNL(OIJE+:XB>6WQE7:L^UQ :[!ACH::?.B16_I&@,W8.6.M9.0J8V?7/L7)
MY)F-X<T&05_@]B:N*/"=!7P5\G<+%:IP^T;<'B<%N5#E2F*.*3'SK_I)/)Y=
M=T,YS.IA"M_M-?)K,$9!\'A*>W;T<*^1MY\?"G G!ISR#\Z"5>49-%A*:AA
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M%%L%'THY*>74:D-Z4(MYIYR[2[25]S+@..@ @PX [ );7:U:;C4DJ@=#HIJ
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M>!^[ H1J'$8S37#]N/U+6<+O/@:=&@W?4BGY*_OSC]_8GH2FK\NJ6%"@F&K
M+KGW.G=)?5\S75*H 5VOHCDQZ2LL!O?N(4XR"9G=*Q\&7ZQ=.P,>)\4F&&S7
MMS BR- 751\6$%VHG5F2NNT5#GK+/3OBCJ=C2GR7NPC9'&D0,OB+M(W-M#.]
MY9Z-+D"/[ADR(VQZIFXXCN_1?,=95@L7"S_P.GKJO:R8E_$'LJH_&-7+9GH6
MMI%)?-/E!'2_QEQ'=Y$!JZYQ9+ "T@G:_JX;+W+@V^Y*0^J.9E'L,=T'M!)
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M#()\"P(D2DW*=<LESMS(NY9%.-I\65#E5OV7C=+L6.],E\,"S/P2%WS7$>B
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M3F)]C4WUJ&\%Z[:5[ZTVL!$'&1XW(#9U&6$<:R9#.>L<RRDOXD:$=HIW^T^
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MT>AEU)X4$Q#)EW(3 C<:#3C0"FQN B/\ATBWGMSI7[\N/9 WQ:8J GDC2R:
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MTXYCPZ0+,J"*5I3>OJB9K-U%O':R[<;2W,2M9'H?L>QQ^'0DTZZ%LQ09RI3
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M\>+=(FCG/0'0;H$1K'Y1$MO# RXEAAL$H%!:226<(=^G FD5SS$%)R%!MY#
MGG0+JF>Q5,O:E+0T,65;J@UH"[J$O!IPG0.R5;;J)<GI*:9J65H&$)5-D%2Y
M>!<8N:YECYH\WPK+?F)CM:.XGHJ[EJ</4'3&2TYB) OE'7I=RT22\DNC !_(
M2QG]D@1V4.M>RBV\INUH/$3IO2&$-3^7$I ,GJ=UWU5B>UCW93$Y)THZB2W7
M<AR="Z%6=9#Y$N!6V?<3":D-@9YA(SXR713[1<U%E%+Z$*T'+DH$%$40+HL5
ML.'P6_'GWFVI=OP:Z1=B?W(Q'MR4O(/5QX4/RCT%>LZEHQA66><8T3U?<^"2
MML8?K_N3R0^WGWK#'RS[;_^%*_8_+WM?)ZOH7T'):M)_[5_V/T_?\VX\N.BO
MVA#=9YV/W*Y"30J+)57>&T>1N66\G*)[I;V%KFW.5_&QDJQE3F8S*THN7W\X
M>33UYKHWF0RN!OU-F40/U/>*]NZT6&^:[U<>?MT;=D];>3<B4ONW@UF/DODY
M;'G[9/XQ\Q]MZCE@(Y-$1\18YI.5GO3SI(R$@1:[H_RU#8MWE,*!1:A.+,(0
M$T\4-EAO.09(WM6T&Q*A]!TB;"J>#B+"^2WSH:X"K6'1Z50FPS 7#+-&+UK>
M9;/D-&?)\N0U5JG&>M(.P<RFJT&O*)9C42AIM JH--9AW8&C;L[N7G%H"OF?
MCYD-ESK9)AML"IH1\$O&R52K1X%T2W8Q@P=D9G8K?2@U2Z#0*Q&B)RIYB8YD
MS<37@.U]PROU^-9S.\(.P<JFCD(\,Q$P6143DQ3&A#ITD$DOL66ES7=Y/EXV
MZ)A+3D6#0K! X490,O":/B(0VIG7K^1J%=N9EX.9L!ABE( QN53R.+7C-1/#
M)<M:$R:8>7PCO8&F)Y&_09\4RSRH',A@)=*?&%&+>IVN/6LN;TF?5B[",<C?
MH$+&I8S9)P!CDU(.TKWTA0Z-7WRUN#][$OE+-]6'TB0A!?!0+GZ<@>P"FII:
MP@EILI87:#)K=Z'O<'QM-%F";"^SM,'!&FM2,*DZ>>D[MGG3<NHT;&VT7H)%
M<B;!9LX99I:MK:5NAK>=J5\U;9:>RE:IB9L.-"G)P+\-KJ_I,]9.MMIX@X6)
M,#JF9,C%$+E)0>WK!M)$;&MIP:SRE-L0=SBFU@X=T"Q(H1!U\#H2-"/O4G&9
M0=7F?&!32'4PIDJSF>'M:-PQAW?MNLAL0L@E\4QQ4SQ([>;.G>]H( 12K-I#
M+2G[$KQ.YD@X*\1<FLVIG.B/D LLS'(+4P#9*J^R(\&/QT]ME&VFR"-ICHH\
MB3')F^PKHB(@WS:C*L'K)E(?37O:CLAU\B0$[DHM@P52V62D4ZDFYK,439NY
MQS3?J,2;J'Q[,QUJ.OSXTV@RF38CNAJ-?^N-+W>T*J',^$DY4VR4!6CA$\Z=
M-,/HVQH?Z$ARVIJT@W&T=CFTY@25O,>,B: 3.;>:2%DJ?=L>>QWW_,?F:,FK
M;&J!-?<Y\R8SM\L-:Y<^Z?^[&P\FEX-IS=&C)L'T 8%H&]P^I&/ID_Y$SHPB
MP3J):>,0,1\4_9^G?U-L+?V\_4CR"GE;Y:;:#(7]Q+5>Y.5<9T<;(S-%!Z75
M"V$YF23!5+LX&NC(&A:X<?-.J=B'SG5Z;9@5A  "EH2'TJB$ZWG3-J^U"$T&
MBVQ*5?>@LU-M=C0Q97@:F43,TI6R#V-UKMU?I ;=%E89NQ&X=--U$%;6K0$X
ME[D/-E"H8H*R:=[PO>B*U:)UG8ROBO"?R$K]V1R)/CPXI(TR!Z:3:4\?WYLL
MGRR6&J8=O00%H898C_07BXQ\W<*F&J/;D@:U$D\?DH?GE]%:6"6%1.%BS 33
M W?6LONV>10M-C)JJI:?748E)6SV4=?7H]]ZPXL=D^K(\B1)]I ,4?(I6 ZJ
MFB2?);:],U>>=ZTAZ<D<K%NTDMRMH_8EJU7:3(XKI<H!=VV#(JX.Q\&#89B[
MB5T N"RM):"F!46!,M;HUMM@6\R&LJFS["9C'T+7]BK@-IJ$PE(((17MC^#G
MT5T09$$:LT$N:XUX=R)T31#XM##<B,2A5.<@EX R1&/DHFFU:><X2[DE3SM0
M?&3VU\ZK),7S09;VY.7:F#1QT1$9,X2V-996:X+'<V7_?A[$ZA'9_NO/O7\;
MC:>W<_>I!J^'/PTNBJ6^?$>8==&3=HO)XNZG=[^^_>GU_]K40CR6>[FHG74E
M"];P%!0GO=-.@]'MY4\S<>T9Q+]OZPS,I1^3]RE&VF(LHT^U!%]PT9Y,<&CF
M^VTBZ&G$K_7_D2)FFZTJ]@!YB8Q"G5<0I&Y'A(GM[,)*VA_<4)=+Z_FW]Z-K
MMTHV6+KU7@P7F72\NCPG97:G\ZZT+YI=L7?>F2^'J>66_4_]T<=Q[^93&50]
M_<2+DNX__OI_PI]7.VE$%S$I$"&3I0&?39T$$2BT:.OVNP[8-DGKFQ9NZ52_
M,CHSY*&"!9F$D-R$F*'VYM2BQ7"@.^SYT87;D>-Q-L)=I[D$?'),VBBAK"I%
M'6H.@%*Y#FLJR%131_J]"W>-YK) +C!1!&*-S,8JIVU%E]IDZ#BXZ3B">IIP
M2[/]V1W1W>3M5?G)R[(+:U374Y2?4A F)<DA>:^#J:I;NG,U.!<V2[<5U]/%
M>\[*NTZ\405DEKR734RB#ZAU%:\B5]<H;S/[YNGB?=._G8UT&ES,?]J>>MS?
MC9^ME->8""= VU*E2BY.<#0Q2%5-!/ 64(H.L+R5T XC:'RQ@C99*LLD$TX'
M#\'Z+*LZ8XJM.C>-XIY7T.K%"AJM)=DEBK5S%)E4ADE;[4;VK-%HV9'/M*^@
M'V?5EK?]VK\8?1RVHQA6VXV-N;E_*2'W+/%BLCI%]^W57]ZGX6U)->\0]NJ>
MACS&9 (C=;6@HK6V#C=)(;*.YI)==Q&;A7$ Z74;@]-*+Y&<RL@!! IN#?/T
M;[&0'O(FKP:[+KJ?17K=._RTTI/H7!GLIW6.G'R2YACKG2FAI_;HL&F/LX?T
M;L9$3 ?PWR9]TF<02F7@5F) 2?37PCP5LVX3V]MV>0^?OSU=&Y+62'2).<+Z
M@@M5NN+1O^L9I BB21H"WK18W8^N#5EG 0*]!S(7X#$X:;1>3(O#T*8R"]9A
M7#;31=]?]^<70.YS:1']G_NMKV8B&@J5/$:OB6@G%OFEUOMV<K@R3:^O;>AZ
M.A^;DOL%SUZ$Z(2*.B4K3*Y\Z&3;\8(48Z_3T^/QL4%_.,6QWFHC12I]!UTV
MO-9B671M)IDRT";C[,K'>/"%?OJEOV@1\?;J_H?3 ]_U(:WO79<[KO>?^OW;
MI8:[]0W3)(/:^G9Z@/P(#]T_[D'YU6#R[UT@*_U^\:DW_-B?6D"2V:./^G/_
M\N-@^#'V)_3>EI3Z\_ZEF\S?^J!R;;WQ=F IE(#LP$B7;(1<SZ:3"%FV=YT=
M]QZ;9?W]KLV;$06O=7DV#?(+'$,DMQ3*7"%R4L[5M<!@.C)*6&MGSW,M[@<>
MOLQ=(KT+M X$#X1.VDF;>:HKXVW'L<;)U^6 E=6[K=52I>]OO9M-<UEYZ:$K
M(]J45"!;)$P%CYE 3QNXG,;\J!=J?IZB]+0,OD!2I;B*3,AR+5L3W,B1-TN#
M'?#C'VMS&-<0.1<Q2BSSC2A\RAC\(MF0J;;HJ.,@ZCR7XJ5[!A0Y,&=M#I%%
MRQ03HK94E<$^'GE:&K ==V$6Y=5/=-ONXF)\U[]\<&'_(I='16-YCK0\/LJ8
MHB-XQ8U"35M(F=11Q-">36PG[^][C7:Q92D%BO PIUAJO*107BR:]Q( :(<^
M[FC+3KDD4YMVG]IR#DOSE.U3+O.U]<D9'FEK.&7\=/L$&2F:#VT617O1])Q+
MM9/[>:&[A[GD.%+([H(W(GBO4W4X0J4V4;.C7.)LE^0;VSW:9@U,@TU >#G3
M7HHU!TE8Y]N#\1VQP8:ENJ=S\J?>8%C*CW[M7RRZKN3QZ#/M@;O/=]>%O;?A
M-85NHUE=5KJZZE_<3GL&3D?U-<6#G?=@!UN3M3SXK_-U^+5_/5VOR:?!S7V
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M\J>+UM:=:Q$8&9)_ X9N'/,6M(RQ.GSD%S3']FK1Y=W%]Y%9N8BT>BH<=!7
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M30JM\C5L#,9XTV#\<KN?V[ /)SN+Z\/@C^4FK'(&#_]FF;/=6<OPC,"1V<"
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MII5P+&BO8O(D77+!LF(K1$.FFI2$<DLTON<FUF,]WV*=Z-UBV<TA I+'EJI
M#-FYIOWA%==/<R'GXJ0ODTF/)2BE&3E=]&S*'$FL>5\#[8MYQ443ZIR)DYY+
M&C4HXD"2^6'11QU#KMM2A96IR6 ?S@%=TO3'X,MH/+^_[X;CP4V)@.;7='EC
MKZZF=T]#MG:9SO*;X1W]R&F-E599K64_X.1N?#O]UC=7*8+P'ITJ?7HV AUN
MYG19<R27.OIV*6;3EK,C:VND,E]:X8?C86>JL>=UH95*D+>@F3!8^MZ@@G_2
M%[-V.-25\M]:+AZ2<@"U]TMIAU>/ ]P["BL?%!#G1:TP^?)U.OQ,WW?>N%E^
MTJ-#W?>;/ G"?[ZE#Y?;N;BSY0LFXW)9'_VP!]_WS?"V]@66JW[?1/IV^M/=
MX&;T\1NIY#"8?<XWD]]+6VGO<B9O$R,C2K?.*U5 TDCEU'FZ&&,3O;[J5A]_
M'57'4?TRG@[I4/YG^$ /U>/K0T$J8:;)":(V+K( H:[B89JC:MI'7[49K".>
M2X\1BM9GQ9-CY/PRY5/4MD[_":*K\2\XAV;4]/CD7KXW*&6/: 39,>8M!4KD
M0_#295FFBXM/UM&DT1TTGT0L+_UU'5D1*NN"UU(&E#Q2M&98L!7%R:)H?<*G
ME=>_CNH4BA SN8)&6$_G(JV"(&.=>!3EM\UD\0E/I<>#Y<)'RU2B)YXHW$I9
M0:W\*NE81]=:N[KC^.1>7@UJ[HQTB7,3LHO".&>@3M<8Q=IZF)'=T=9)Q/+2
MW]:1U:!1CDN%IN!#:7"*K):L7?<H69/I_>N03JP P2>7;0@6HL\Y<]2\[HER
M$EA;9SG@Z0QG[P:CZV;QQ#89%9. )] 1>,0H#:F["JE@R!=L!THX-$M56C)V
M);+'3^61XFN'G#OZOY1#9':5T*=HIYGL*8)>:^7W)K+'BD@Z8Q-B\?;)/ 25
MDJS=5D!N<POI *KM'^@C\E''YNLQ7=:2GBC .</1;Z4LO'N%2$<Z=B8B"D?^
M$A'L>46BB S:_8B\V="T#5V'\]$7RT3)D7L@0T[.NXH 4/T-ZWEN47.62"9G
MYZ.OCD.AEPQ6:"Q =73=?5K&9&1>T33.B%!-F^]1^"A)ID?7\=M>U\N0V^#+
MZ++6@5%H3&<"E1V-[;8\Q3KTX+;4'8VIGKOFP&/VV@<7359>.VDJC@,=61LW
MET3^5H=T8K9ZKE[!=2^GE#TPFRW33F$%)C"0VDA*R*9S^]AL54"NT7#W:D&)
MV*5((@>M.$;N@ZI "R#(CK1/26U]^1[0=3@?/=>-F>A8 "P6.8LD7<[UNI&C
M!PT?1G78E3.PT7.]R#%%[AR]&D[&G+RBE%?7*ZK06''=-K(>SD=QX\:WD^D^
M]PE]02860<C$F0T@95VMS%7NP##B5G?DQ]<3= #E?0Z4#%)CT$"!@$A)<2>J
MD8<,L4WT&=6OKXY#><^ET49J;DG 6)::.YLA^$IY-!V@0=!L33R \GEDL:R4
MCC\M.M=V[S/#X"/3Y&&5L0!/M\)7M,("-=#VX+"VDVXKRH[!2]]LMY7&.C)X
M=(\,O0%O_.HX.+8XW77_^D5XZ4-ZX,:2_-%&H",1UJ"LYL'1.V\'JK3KUT>'
M\A(&7T>W@YM]0CG0A@**+%ST<RA[>C#+LZ&OY2WTOV2[7K-[XH[%4I]3+Q-:
M,G&>"\Q)80"]LGP46#?73?)=3^CX+/7<.C3$$9.)85*1)V7U/4M,QZ923+J[
MWX@<@Z=#/"U R(("2.[)M@<>1 9USY1I6H5A9PVWM8'?@:F^1EEKM$T@&)V0
M2!13:E\A"PM:6V/N;5=BY.Q,]2F]Q*,E59>LB4J <!BK$T:N&38^/KB.^N3>
M3'V98Y2%R9<OD_'/GP?3X0QO;Z>C7^]N2T#P83+_,S^8SP5]*Q_&Z70P_C3<
MV"UTG[H;WXZN1S=W\WGY B4\)R+]<75S=SV\7K0_??E*/VO9'S^8CHG>LAEO
M\7._=7^#^\3YCX/IOX:W/]].KO[U"TFI-R5;MCP[QTQ@+(8$V9OEK'=$(?)#
M[36;"X-"D"YA'R2U[^T,YM)_^W7>N8;CZ_3EZ\WDVW X_^-W=].KST3YNYM!
MWZ )Y.*RHRXW/V@9G!)8SX9EY3K.IM.T_'4V#\[FP^C+\!_#V>WP^CW]=SJZ
MHE]M_5H\YZB1+$/B.9,%B8Q7V" O&9J.$^E43<_Z1/3SUEA)TJM(X 20E2@+
MM(.O9X R/,H O=Q7<>XS.)+&\F6=>8P&DG4@Z*0"+&$W(AGSSO?QU]F<5&.9
M['40WG(;#1D0!)=7-L28V&5#.O.+S_I$X'EK+%GP*$+Q8A7/UJB(WE6KX9G^
M/C36N<_@2!J+*X:,PG0!5KAL(E<K_]=35!O_.IMS:RPK+)/&^(19D'EW=!9U
M_(EBOPP7B$@VSDPOY$8"VHA/>F'8 /*SN60:HBJ "YDKY5;="2+9)K]KZ,.-
M4'<3P_,3X8?IX'KXA71W41CSW[P9?.EM6I)D.TDU1),,BPYBJ4PL.\P2U^TL
M,J@VFWQ)R<'%+U\$8+*TF\OL!9.\ML:4B2C'V]Y%6#;&?%<BW._RY>1M\D&:
MDML+SA4 OMK>"*QMU3_VY7O\X3E&SW:/=?US<I[\H629\R"$@[2$,"IK]NB)
M-14- PI:CW0;NH[!R28L9TON,WD-VJ*5&:VW*JQTJI'MV9!?(8[/R9OA[8$G
M0A$!G40L<U(JI21$YK!J3N\ PROP9JT/U$_5X5QLW-K!$(/A#M&"RH:Q!+41
M6"!=L:8,8UG'?-O.7,SGW<)D=CM;5C1*'^;.M0E><+*3"H&764NOLDZL7J60
M8M,] 6WENYN2_:CM*3KH4KV3""S&9 +W7'-3P=%$5.T8/SLMN;UH^2$HYDBN
M+&BMZ!^1*[DA= &^ML6L[<E==L+N7IZRMH"Z.><+(A;+P4NQHE**1JBBH^CQ
MB(*=B.OK[@EDD3.3*JMHC4E09HV6@Q)<80N7WL!2'D)<WVA$]AQ4\)F":\EX
M(&[J^F&3P34.VK(?;$?J]FU>]M%*'[++PAN&95FULRLKX;#QO!5OHYE'%.Q$
M7.^YTL/PGH@#6:J=QNM[],74L8Z@H[M@?^)ZNTPI,E>@/8E0>4U?<=^LS'R[
MB4K8W42WZ*_Y5E">9I^'UT7!%XW_]F-Q<J>_/2U<]IE1X5P"3%*6=8N1JQ!Q
M!=Y#P5;; *XZ<!!Z:3J8A4TVU%D)CF5=_(!(7B?@/2@-(F\;[4U')^Q^+#07
MI$_<048I$H=B*D7.,L98,9+IE<D6^<LU**L/?_CV1&U<_DAA8H[T2G1F#BG*
M\:GB'V?-0T<;%>L85NVC:C*^FB\ VE%B3NI$1L,%$IDNAPO9U<<.6C<75'4,
MC#8D[$SAQNTHW@9R0,E>"\^+RA3:K71E3NT> =-.4&Q'X?O![S\.2#>,B(@#
MWKR.64@3#=U%B@2D$YK'U9O/IL5CY>O?_%J2#F5@8PRC%>E2\H^LEM%RE+C*
M"U'@%1M@#'KQ:U_1;@S\YV3ZKU5:X8 CH'?F)$L^,NZ%5G00@/=JUW5T['9
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M+X5_JEP=';3*Y$X((SB+:*-)M9G#>M=VFG0+M,]5O:QP+Q9UVLQ(L@(Y10$
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M,O3K)KYK5ND<A\_-C9>:*YV<0=3:&H-<JFJ.!:BVJ55K.,T]A L8I)@Q<QW
M\ !<"+G<]%*J+\:QMH70K,]BG)?YHQDDF2R%A3R2!UU@NS"#6L:Z3.I@6[^3
M7F^31+R$"(YJD.B99A55(G_-HG.9HHJZP:^@NK8+(K5]%O?@F :)/+.874(9
MM$U6*J4XJYYK%- DSYQK=H%<1@:'&J2 C =55N\X%Y,CB\3J$_#:AO8)%+"+
MDW-^$H/$DLZ1">6E%DSZ@M3#:CT]>M><<8,V<C"?Q"8[/9LFE2PDIBB00DH'
M4B^O<LI2P4/_\NKS1S)JS7K1?CYGL])B/QI_FC=ME U]@QN\#8/IM*RUGM>)
MVP.6/XD=ZB*O/ZR/(Y3,TFBCZ=(:;EF*.5N+I,1-EJYMU^*ZY7 +#C:PG&:W
M1-CMD*)1^HN">?A#Y]0'?W#8![%,?DGRX%3VWG,T/((&:UV.6M(IAZ;DT*[^
MVHJ#([!\M%/F!2]-.&1.<DL!LTS1EE,6T?%24VU8EJU>.@_+<*Q3)MW*.()T
MD<R+S=I!#M%842ZX4!V(<J;G8O>S_./@ZC/9CNFW @/_[[O1'))XCZ&K)&SQ
M'H5+,HN,R4959YA,6176,9#BGG;SK*=E7XHW.?_:RX(W!SXI>EHL.=(=%2K=
M06@3,ISII\[?MA3/.TS>#[\,1@4,?IG7^O;V(_GJP]&G\:)N</4M#J>CWP8%
M&'[&UQ?$'^#?1"LYO0?%+'GLREB^3)L62!P6RQ"5_?$AM7O0\8B1T7A2OJ ;
MJF7Q^CN>PF+(I<#B3\8EA_?$S(W+=YE.;FZ(I/J=^];8T&$0VUH$B!0_V^P8
MUN8F9EM0DN:F/6%D-R;5>9ADJC3_0;:,-(%#I_TJ8T@6OHU.]%-_Y3 N-[UV
M%91V**RQ2FI9FA3U:H3'DV%NH=N.3=HY#L )RP!9X #6>/(B^*H_,5G13A$?
MF<O-O:&990802,T&+EB&"B!&Q'7LS7S%F]C]8.+.<01*>)Z<YMQ -H8K [$V
M-:3LV\+7@7S6E8=EC4<<S18;+TIE]\.DF_R_+\;X=NX,<Q%\<"%2*$*/6FO2
M9?5J9=$!;-M QQZ+\G-*XQP7QB,W1@IN<^#<98B,IXID#KE]&']&P;X;E"Z%
M/A-KHE#.:N,E!@L:K0\50H&<O$VP22]+A'UX[5Q(7UHB-=,L2.,5<!LMY.@0
M50OKV^)COT1QG..I!EDV[^H$0#]69)YL<$6RQI,)D^V(QJL_I6BW>JQ!&Z[G
MH"$JDC/,'=-I+LI WC#]_KMYK'U0D#%DGK--0B3FF7<):^Z+ E395IC[G(67
M((USO%4=5%9*@!>E$3_3M9++@"L)$U*3F7CU9Y3L5D\U.PKHHO<4K3LM(*55
M%II9QF(CR1.+\,WP-@QFG]]-)[^-KH?7_MLOL[+G*(_&@_%5P5JYNAW]MM_.
M^ !2D,]N@'0["Z!B-LNF2TYJOVVZ?%7\X">W9GORCL54'RRRIB<0;=DJ M(5
MJ']=EWD _4GK7]JFW??\//5H34Q9@T207)-'$[.%NN.%0^)M7\XK9YM1PZ,R
MM<!-.^SV*2MC29EG],DS%^9HEQ7'3K<5/=)8[4Z)[>D[%E=]UT^%K(66,?*D
MD^,FU,897LJX3='^E=*ZF:<^/U<]%S )AD+D"$ALR)!DR"O,P7)H#5="V:80
M?U2N5K!2!]Q AX(T1$A<N41*4(>D8N6*B=1"!SG59)"V)^]83/5<0$\\1,L3
M:0COA!$.8IW:*$TC'24*#I=GJN?^0399T ,J"[=EDKD4)U9,B=C$NDJ+!C!P
M;Z86D.-M96D;F$.CR/,/#$32S"?P*=46'JY4"\HG7-N_\HB"G4E;^3[OAU=E
M:^/HX^AJL?GV[O;M1[RZNOMR=T.^T_6\@EW\INGP\W \&_TV7'SS1P[4OM^D
M;XVW,\9(R:S2F:/!D'DM_)?_=.PP>UH\/9*0MG,CWP_+F/[PNJX.[N-.DTO"
M7,0H71G045A;5S*/O.VS.^8ET#_QC>_*1T'16*;'E2++SB?C5@/^J8T:K!!/
MPX;]*1,_;?(.C& ZJY)09BGPB%A'^,IB#M'4TTG5/:TN[T^9W$29YY I>$J.
M7!832AL:+!.8P7OM&EWDH$%%V)\RM8DR[8DN"X8!*1T3 /,"I;Z<)OVJZ5VU
MLEG/= !E&[TB+TEC<XX449%5XJY G]4^3I8;IUSJ)3;7T4A[$7I0JAQ3C$CW
MG@(SF069C67HB4J:%J[7\!-)Z22*, MDTBO2@E#:7WAF;EE3\1A8V\U[S%L
M/_&-3R=F!B[Q0IV)(62A[OO=&6\LD#.L(Q+>D[*-BC!%<-P'+BV/266)/E?K
MD0*V,"&<*7<LZP&;-:%%34&.YLP*C\[1K_ER?;.W1K2&C3/9+!_=G[2-JM )
M'8-A9"FRE]EG2Z=;S]/H=O,7*/>T7?0 RC:I0JF4CN37T%N(@:(,D]UJ"CS'
M=AFN-$P<[SQ?C"H$R\B6.0S&2L]S=ASKT+8WS'=@D)Y&1J?Q"!%U]@%=S(8+
M)2UZ5VN@S'< K.Y]!_!VD70L':+KDHX[1S5,(M"K5YB-=9D#,5,7MN@RJ]!"
MC6^B?1L23\+?64IHZ*7U64E2RL&3>>=UL1BI)E3/7U1/\,3^,9B.RC=8K10>
MW\Y#9O\M/-8"'^=_\^V^)_[-\&XZ^O+E;MSW\KWQPAOTT8M$M@X]NU]H;5(+
MJ-D6'2\OL\W/)SJ5E;$ZEKU]&*PQL28%DHQ-,DTU(TW/@\%SO!\*2<LJUQA
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MN\ZOQK3>:P:C'1I(T2/C/KF$-;>BM)*-U]Q6>\_)QW^LCP2S=):A(N<M<);
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M@B]3^XH,. )WWHE4]X_2_>U(J.VGF#>0? ;N+Y-B$I932)7)'P)/@649(JH
MQAZAK0'MV#SPTD5[_&23X1 C0XB:B\S)U>)BV<''K,;<]'SN%M!^!_(^I)=
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M^U4$[@4Y_LX:3"'RLJ&M]FUFW4(:6MOT@/=3=2@/'1?./LP)H[*L@!'F0/J
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MJ(&.=,?"//M\16L#1^=:W(IH"KGLLZJZ.HZMM[+'E8\EN1]=TS,%6$?P5JR
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MHQ/]^$A:A]@X+A>U/91M_R1MJ0_Q7J**-D41/TVOKVY^G5Y]G+X_N3CY=3$
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M]S[@2%"WW8)6GFKQC6UZ5-"-H:8Z.>1%#4/WE ]]"0CYD7?8+1>TTE2K&L4
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MD4/:!Z+MZ:%.4:B8&OMA](YR05L'O2#H+L"U! ^KBUZ%6C8X]*"56'4QV+5
M(FVL5DM5F$I]D8P%=VQ=?+DZ^76VCK\FJXRE3:N@-D+ <]$Y#=4_E$I?N1$P
M'!DHWA-L3S@1+=C82NM\< DS13T,A1:OQYV5#\8>.9WY%*5L<.Y]:]D@$PW[
M&L6X5PYIX/O,V8\1/G1M60?6Q(9DKTH +632!152<#%F8$T1D]C_'%Y2@N>^
M0/LY\ @2$A9 <>B-LB 4E7/3AA.@TUH_7[DV-CCIR6C((*<:LV,Q?EA,:1I0
MN:2"\># [N%TO+<WLI4;C,>[%_T\]8<\IMSCS=%TAA,[HB@>M^U.<GFPR)28
MNG?4KD1U+YNTV]#":D^EE0]4%;,!Q!*'F+SJO@2Q%34?)#WQ[+O5PF$2?(W9
M%L;BP05> NS8%T5@F]!^4,FZ_,%M"'4KY]TOSE,"5V\_W"84II.K^5_,[]$Z
MI!5,0JRN6"8 ,I;(#KDG44C?6P]TD"!C?;UIXT9[+.FAQ30JTYK8M&^)M0R+
M?I*88NUK^1J/Q<L0:L5Q51+_ <<VLU=.KBJYD5,L;(TIV)<X'/^X+FWPU5J&
M:##*9N1@LFULLH)M[5![Y2O8SI+J?D[(D80K-[/+SVL;S9P@T.!() Q< TE
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M&\NFJC 6PQ1"S8ES'L(]HY7N<BY'5,!&)?M)3!FZD$T-Q9E<"\N_."L7&T
MZ_Z?[9XFSYX@C-BP7!BMM=DWEL$06V$2)*B)1]*VKTL9F]0P.Y=<=1*7BGMK
ME*)6-=)%\,59%C_V@A2P6<E^+,PQIH(H08C@TN++,@$AY[M+Z.&Q??4A2O;%
MA'LC87G612-5YJ:)(65%I1]'_2J5LL%QE]B\Y6^+!.@NB/S5T-!_);&I?4&
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MW5+[*M%S[P=?L6XV@;$8)/9PJLK=Y0P57!P::[D ]N-27#?=_- *V:1N7_!
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ME%ARP%!Y49S7:)9C&+M6^L]-W''4K"RDXCESD8@L%NT$OR]V08O)&]L%[&O
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M9..S'3I&<@8SUHRU6]5\O#P_F\RN;@4:;8=\W&RVRO! UF7(-F)I]49#9B
M='E8$DP\&A3>6\.V*[0K5BBNK$#5#FK"JH(RG./P (4X\J2B:&3,X;.7B"N6
MJ)V* NY,H^3 XH-697$W<C0)N[@Z& ^C1N-9*USE'1F-S4HB0,$&V4D<Z(<.
M2/DK*EV&3(-N@.]Y2WQS<7I^TYJQWUW.YHW<U]>SZ:\WUXWT[OWEWRXOF@BS
MR_/S6S:?.17E=J<W6?%;(:50R(A%JMG'.K3B!N6Z6H5V>M<K_BGK/I FM@U_
M3T]O/MV<RT?/YN.QVL=FDX^3BZOI[Q-9U.6GR;I06 YJ)*L-*4,.L\"%N&RP
M"MBA_[^ 'XV%OU4%/RF_0.0\Y:BCKTQ)C)HWP]N.(#'NWM2M C/Z_/6-:G5S
M5!*R0XI4),Z6F >*+FY9F8(*1IS#]Z/%K5I#6P^R\K$H"EEE;XHX@*4B7?]X
M_9WH<,O$3TZN.I]93J&V1H<,PVQ2 ('+G;5TQH;OZ4AN@ZJSJ>+3/9N,@6*R
M@"H-.<8435]XY&'\6>]5Z'(5 B9#.I!)QKF211$4!PJ5R!GL"-,I:;L> ;]@
M51P<YC16]HI0E#-9XIN$A1</I#$8[HM>,8S6$WRK^GT2RJD!H[,>G0[!0.#J
MP R/:5[E[C'-ZC#>C?N-:G6+!DQ#T:>DDF8&A8W_?C  8@^H<\ZOUZ7LF0@(
M74:)9;@@JBH^)"; 9;5 -[7XE:*<[76X)<K1QOM4G03<VH@"B2CPH$4YFYUG
M#D#F57OF?9*):4BM=MQR:%/J//B!4KE$P%Z7(,CR]0;8JY)HCM&%4"LY6UQP
M7)(9,I'>Q=[(M0E.K_=4;4_-]'R0(UK-G".)0BMZ#<'')055Y=@Y9(!7C"*?
MH. GH1R+1;%78'3)657(:3"&)1:_OI[]&U7F%@T!QKK@"R0K1M +VM;+6I)&
M9?<-@9L],\Q!S% RA>PH:R-G3]'0#EW9N>XIYSO1X9;@II0<D5QDXRQ6$XM;
M-I77X%3?&0B@:+2-^AO5YS;H!JH5)Q,,>:K!(Z5J8.C0%U?4>YQ7C6Y6/<!E
M(W[!BI%#CCX74"4LLEDYZ%K[%DK00*\WY[\]Z]_SX8W1WI?,D3SD]FIEB8>;
MFW11'90V.KQ>_/@$!3^MM4*1D?-9LW8::RL>YCR80R\(\IMP*OND$[6Z5$#-
MXE*@\1 [/7#2*4/6]C-SOJ,CN16\(8&%13=B!K2!M/%D87BABHF[(HOO1(=;
MPAN6&%#+C:;L52%6;#,NN9>,ZL(5C<KK[\D/;?5$)?$>N9)," B1P#DSU,05
M4MR]/A\&WKP_^2/)G9I>IY/9[,N'RUF;D'!;E;Q:0;=>5KY]4>-Z_>6>9K)\
M\>IZ>IK:3YI]N=7-5[V-_M:[W__7R<5D=G(>;Z[DO%ZM.ZC(B1)J@4?*&E=K
M(;,LJD/'W;#)X<7KCFI7*.(0^IJ?-[XX^_'R].3\_[N93:_.IJ=M0[?6W,^3
MJ\G)[/3C.LXPG3/7@"H2D2914EFJS&GJJMLUN(<W>W.53:[>G7QI1S+=B 7?
M8%;M_524^,10T_PAPS 4MF%AAG+5(XEXB;$>7IR1-6R]Q)4E<R4ZLNU_V@ 8
MP>P<%K, Q8]3ZB^WT0_AY+HEWN_GF%=[ILNKZY\F<IQ&3^ &#9&)0G'52GPA
M%Z<2!PVM]P1"S.1#_UA\=[D;K&=7ZS],;LYGK7RB(@",5%(16;=*=U%#3-#W
MX5CC_<-WW1>LE"V8\H*84>!*@N)5BE$11U$$.E4JE[*JNN<%R[\E]/':&V16
M;5XL<2&Y&ZWO01=K5<ZFZ^IS *_H,&PUN4&9G-K\G1R@!J,"Y])LA&/6+NHN
M+3/6!G485:SI:A4QHO$!DTIM6)<!FX9N)R>(K+/11UK_08R=IS9&&M%42U['
M;'.V@_?G,5H_USV?O6"=;&[K<L[50<Z0 Q6G6I:"!E#N0:]ZD'G!\F_[1)\4
M18-!&[D97"$9&A*O!5SI#@.9CH?J!2MC&UL7N>I@Q/LS,+5>=U0XO,]EU;>O
MZEW;NK&VI'7P."6@ZA-8  HZ$7H8ZDA1/-5FXYU&5K'U(E<!9$O5N.S:X W?
MQGTZB3D6B]1MY,2>%LFG<C1F3Z#4J1)]&V8Y DY\OISW["1.PIBLS=[ET=;8
ME1;R_GJ>N>P]7H%BBQ%G:%P09Y_8R&5W0[L!Q-'Q9P<1?$TD4UK]"WNG6D-O
M"%SKO/$\:O'W0&9T/D/7B[F_=>]QP] YD=$K+<&Q:NW<(E9#J@K;A",[-H;^
M,)*O@6/5,D?%RE<E_L1JSC')CB4QNM'P:&=QUPBYOV7O<<.4386-89=5\,X$
M2FI@_6_O>V,;MA/!Y[00V[D6MD69(F80M&)C)0*R>IEY0>@>(L=REOT:MEWA
MRDY^1=9Y\7-:&9]2%?"Z,%=9@O;:9?YVL<)!TU^]^M;N); 3#Y,BEGE_90Q+
MQ59H1>4=Y*+55_:1=>U*CGW>!MFZPM4*O#*%)(JF@8H!(-O091N.IHDU#LBU
MQB<D2U&N<'%)OJ.982A1H0EU(^:30PJRQRWU[ VQV#?4!#&56$O+I&E,*8"'
MGF'O:*I8XZ)4M"C^M :Q),G)(6V9Y=N,@<WD^O>O(PNRQST53Q4YMEKNH@45
M(\0R%-X5U-B7I.Q %?^X.)M>W3YG?8UEWWZHE[/)]+>+7VY^O9J>34]FTTUB
MD;O$/C9*@)=#KB&A$ZRKQ.T.R0\P?;/8@DWVGBR;K^V^1**"\\8'\U<)T'^\
MO+IZ>['XEMN4_^F7/)E-?S^YGOX^N?K;Y#I./LB7WY_\L;6'D=W**C5322G(
M,?8T#"RKSLN?.B$[@N&G+W9?(J\QP2UBEW^JRT$%)0=6#R^LU8DUZNS.7_1#
M3_+R1%YCH: BH+&V5!.Y-"J:89)8=0KZ%WH;]B?RZ>5O%W.JHY,_XN1B\F%Z
M/7(O5Q$T<.6L:JHEAE(X)9$*%^-7Q*]B5Y.J=<<Z\<@ZGK3455V61054SDJ8
M696X-!<!%IY!^QA5WV5INL$7NUSJ*@R?K<4LO]P#) L>:Z(T:-5CZ$IAG'\8
MSN]RI:NPO!QAN:@9J[.I:K')"I?[[U2?E#;PL)3VZ2O-D]/FG297/T^N;LZO
MQ9K7V>6GQ3OL+9^.?/K=Y=4\V3[*-J774&KZ*F%NLKYX@0Y*@JKLQ'."$C.=
MNN=V\+W'V<7"GZR*=_*39ILH8HU?RA2LHNR!)+#4<X*>8?9NB+D_CF VW.2M
MEKU_-:SQ54;IQC\M![PV2C61$6$XZ['XGM*^*S]]'6I8]R87DP%=17Q38F2.
M7R=N4<21;O4N$W)4-?PRN;X^GP/MJW]-KS_*Y^4+0X%/ATLWN!T4T*# LU K
M!H@^N3#HPZ>L.@CCU(9NY6GK/Z!BUMP7ZUB<@XVZ&*YM%!FR7_J&$5)RVSW'
MOU;%K+E!L<@Y$4>B!0JVB7Z:6 TGIHPHQMEGW: =*&99"?=N<G%RWKZ)+\Z&
MVL3RQ^?)Q=5D^XN32%N@6L#Y%IV;2D-G7;')=V[%;H@<-UGLWF1>1V?/(5&
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M.Q1P3 '=W_7*(UH]%9,4-X*\!#KZ/$PG0D&&HP+J\+#FZK@"KC0R+B/[S.C
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M3_(J&!06^H++XTAQ226 X02)3QS^9P3_!)YO<[P7'W_[]?KS3>=_.QON!!T
M?1E'@14YW&<\]$&7INSL]E/GIRK['8;1"3PV @>564"['(353Y L'S^$^UW+
MAF=(#@UBM?!%@*D6J#0WUW??_J?S>?WK7<\]_Y<WN/]NN_\(F#,=3T: S@JS
M1K[GPH#$WUC3$/\6T7<QMCD[N_SX\2?Y<@_5$YEC8$N"JK /G?_]X[<.#,<
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M#Z(%Q0]]/A"#61!333T)4&([3FP#T0*B*J;,^LN4%EN]A*>D;Y@VDJE^++S
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ML40HA1FK[0@THU$2'-H3I^B=Z3\ME>B.M^HD:V0;U6H^H/:0?:O>5AGX&$'
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M8%ER6/XF#2\A4D5NE7X02)9MOGB?Y"B"]098]SQ_*&Q"MAIDZTU"]G$AN[3
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M'LYW,<<+ CREP941T[?J;34;%31!!0=>A#,_^T1 Q3\^JDA>STLCL(];E(7
M<RL%;%;;^0N],"I,O)QC9M<_4OE<5LF9>LVK"CQ(9:!J=1+/BZL-O6!<G;,2
MEVM!=\VBZ^H2+EP[]EQ99&KG]=EZKZ&UNIK9NZKWS$N]W=,['2S^U-5T0^]V
M.E3\*<_B3RTEZZW&O@N>QUV!Z+A;KQUUZX];]M1Z2G/(.<VA=:23QD59SNW(
MW3FS= =FZA5&A7VRJ:JRKZJ60"-WT<&M=^Q0NDUATFWV7<(K95;-!J6/PI'G
MPS7/UT,DKGT5UY(B;JV(<3UN4D)2PAR5\$L4!B%WL>FDB:2)9)=)$4]=$<DN
MDQ+FKH2OL,N4)+LIC0Y7(>%IGO5=%:J5SEZ6*4-+KT"C%:;'GG0.UD&UL&1&
MYW"".S*$&F:+BC(54Y,(@B<"0;VN,#?NU"%(2%,OGR(#*@L_D[!"6"DM5HR:
M7C4(*8040LI+2-%;564I6&5!BK+-!1NW ZSN'$@*==S$=3IN! S9@PBN7:R0
M+0;7[F6JX/4%=[AKB=N1$&&P^R'3]4:[>Z5UM+;1;#>ZW9IN=.)#IB]KX*>;
MM,]@MWT&[7:UI=6U1LLP&M"_5EW=K@,UFPX:S5,J\E:PVZG"W4[D7\S4[R;E
MTVY(85C)IWV%C:546JI<=SRKUZHKUQ6/G0L7EE&ET6P/+*8\BO7!\8W D PK
M7("1XY8%%!<&S =K9S_(L#!'B!<_3Z!(-2RHFE"\AM!H'& 9KC :2+.IY9I-
M+8QB%?V,DJ/EK)BE:C5U<]*%T9GBE"X['0<.2_> ,.&!L0/G1V)1.%96D85G
M"?\UH0B5D-VUD*'"A::3KR%+WL?AD%H&0,KGU?66P@KL+TBM+$C;T[3JI;6M
M=U[(G=FY$N=^7#X//L<+U]FH6=8%0 LL\Z,M\5GD<&.-4!M:7>%F@5<+MBST
M28Y* ?FOP#1W8&([<OZ*&:MA5)L'DUA9B$E9CI^BQ+UY1B#FG/TF K@:GA7Z
MM@5_R0S";ZX=!K-RQ3MG_=7JYE6G?6&"?;NX;'2-3EOKQ5E_W:[1;5]0UE]A
MLOZ:Q<CZJQ]UWAVE[9V ZZ1\CN?8\_%N\7P.9<$W:1BE'KU""7^77[Q04*AH
MC>[ L/+[YU-ZBM;F#_",<*'65^!B'E7[>]SVV6_<B;;.I**%SO4QX#?W088,
MC(>OKVY,!0PV3PNV= WW7V<NRK*$UU1%I$AY4T70MB*M=YS.<H9IF-66NMG!
M(B@2K?;FX&!(5Q/\BS.^RQ8C<B<VK3+6VN1.D#M![@2Y$T?%6T:C5:TKJZQ3
M"$4B=R('=R)>X"PD^Q\9(L]J6N,@KL2JDAUWILD:61;3M25WA-P1<D?6NR.M
M>E4WR1TA=V0_=Z3G^4-AJ_1(<MO]57S0GNF-NE*/95]9DT=#'@UY-.31%($<
M35VKFC0O?""/IK0.S7/Y(!GMPG[-MK$2>SFM5BL[)X=VDI&'0AX*>2BY>"B:
M6:W163ZO\%!>M<_L-=O!<"]9%)S?<SYYUP%]PQ*&W.G9+G<MFSO7[A#W3N&W
M5W9@.5X0^3OM)>NV+WN7=;/1N^SV&F:CH]?-*]Q+UM5T4V_76YGO)5O:](48
M2CW$4 P#8P&#>K.EMQL;DIF_8"4AEM[MQ^829[<A?#'&0D17(N2V\ZSV[-3S
MI[J?WC*GMY9%DSU#Q#_B0]_9(;3*VB"LVV@R<:1 0#B7/!BQ'MA+EM),)1)J
MO" @T\A>0*O]'<Q!AV6I+.P]>@O,7O2>P5\,%(I-@78")J"Y [8B$I4MG$4)
M"_]B8[B@\K65;'NU-OU=Y0MD$;&LNU#+> CL@/$ 5,X!+0S>O1IY6S Y[?"-
MO1A#R1;?^DEMDBW8[>91M_ZH1OY(MD<?VZDFNE[LRG@Y;DST4GX0N&&+#W^@
M/[;XV$7'++4#<YT3E<U<=G[;CHN$@O7#1R>BT(DHY9[0I;($V9Z(0BI(*IB-
M"J[&\K2TO5M-=YPOFW!0H$'D0]/GTV0X9_;\Y,5K%3A?:UXXY!,S*E(LTA_2
M']*?W>1#.>P;[.(U.C4B"/,$8B%6\RDM))^M.'J5-@:3%2RNEU!@#E++.D=.
M+G&665O=435$&D0:1!HG0!HUA2Y(64B#XJ6-\9+EC04+^8]\"V87PM>EF"D/
MF>F51LV@J(D<('* R %2(0P@E&:MVB(?B'B#>(-X8P?>T!LFQ4[/Q$Z;]^X=
MK&&[;PL[_#:PNMDRS'KR(SYTM@U,ON^SYY[+[4Y?)L+G(32XPJYEI0+,X\"=
M-,F..?@TV]FH1"2%V0=V[2[*,6!*)'L4C%N6'V6]O>OOM3HX!K.LV$Q?Q69G
M08>>S,WQ!29<L4"$8;P%3HXT*(5P ^C]O2_B;Q_M<,1ZGO_(_0'[.N+^F+/.
MS[?L;/F[GZIX$>/S?:U+^^:6WFT'+(0.!-S"WRIL G@+L$%\P#Y[H6"&GMW^
MLPT8N/3&8SN<B^$2K@(M%:#T:Z8AE Y+/!S0?RN]1W4XWZ,:S/:H!M55H1P[
MZE 1AU[D@XK]&7$_!/QYPP-#T-2TJG88"$83B05NC9!+L^V6KD.O^H?H%5P>
MRE/GK6@< <[M!\$"[H@ Q[(7C?D$&8(E)[*"&M_!J/.Q%[EAA;DBQ,M"_H/U
MA2N&-GSWR ,<>[P H8"T E^X\"++EU0!F+GWO,$C] [?CM?Z SS"-68KU*KD
M?I0S(,@=(%/QR00 +W<GPA/Z40 P"0( WK@/<$,R"MCC2+BQ[OT9V3[N%I]W
M (D!N$O\F @K(;.^B',>[425;3\(GVARLRS$&)2>&5_<N7](:H1.NT(JPD*I
M41"A'\7?@GH!<[(Q=Z,A:$R<=0M_V0[X9ZB1M^#\A:/(!TVZA4?\)7P'1K"2
M9E8+%/L>@)I2PXGO68 *?)@ "$SF-E&X]R \(5^#IRF#IR 1#JCRO1\V*+1P
MIEF3VN&X&BY'\2[I7C\^*)H%>%*T0ESKVNIVM&QAC6P,WGXXK;"OT*=XA+NS
M\29<9X?KGNC[8""F\@S V",  P0JD0:UM#Z!/?L*2!=">B1=(>$+OCONW@"+
M)LO"2#X.I3CM@0SA\+8^])7/GI M+(UFK5H_#"S!$YB >94^ S#B)/*!PT"7
M)C[PD4I3>W!+VUF,>7$,ZV'P5]R*.''YH&11^JP+KA]$QS]5V&?Q?$;OT05C
MX.<!%4DW#SE(=MM.NBWFW09OO<*X#Q8P&H^Y#X\84(V2HZQ1DG.=C),NTT&=
MIQHEVRZW4(T2JE%"-4JH1DDY]^-3C9*7Y$D%(@I ZE2CA%0P?Q6D&B5[S[[&
M>[&3B8T\$;W1S"<J+V<L5O2]P (NZMZ#+.29V_'T9G5K#GBU3 NC@)1Z7*[4
MX\(H5M'SDH^6LF)'Q5"W1;PP*D-<1%Q$7'1T7*2KW,99%)4I\+;T\D>.R5+X
M:R8[C$/6L]QA3B.W Z>-AE;-_DS5564[[FUR:R2I[#AI<C6VAVL94!GCL%VO
M*I_=+@O:"%^$KWWQ9;0)7VKP1>[I>@%^X'#]F>,%P4_,PWU2N'E7)O#*E$WR
M5A7,O1_ 52U+%$EFD,S@JADTU57 .6TK2/ B>*U.=>I48(K<Q>UTI>?Y E[(
MQ ]KQ-U[P>[!?PQB!U($/Y'/J&J&LZT.DS2_29:1+./K'$^CVB3/DSQ/PE<V
M^ +74_D&C=/$%SFLZP4H=^%GYY8><DM6T2"\SFW5FPHG._<5;EF8@/S:8MC=
MG'<F'](N*YQQW59J94$KX9/PF34^6^K"4H)GAFYU>0];NI-E6Y\I]I2-?IJ@
MGP,OP@I,^Z"Z^%O8BK2'\J41H$V6LW0M"'_4;;/<6^P[47:)-)^<+W7.5P[<
M?*2*>&#2+3.W)D&H86;EYCXCSY,@3:))HDFBR7+0I%'/:JZ.6/*54P5'>;;8
MD1;8OHQ\'TO8=X) A,^?^[RM3 I363ONH97TD,L>XFR+$PVP;+V0!\C(\Z[C
M8W1L/'3M@&=JM'"Y[T#%^]VL#W.JU[5JXV G$61]L,+:HK!L;4',XQJGM045
M5;Z@PGP1X#E-]@,@Z.2/,>@DY_TD!QC$1SE)8BH7U\[Z*=+]C.>WY>DH07R\
M07SL')Y9 #V@4PNR/[6@I>30@D8SW]+UM:,NO']4G:>Z_9G4[6\6>_$]O_*Z
M'6D7J @_%>%7GO'YPG#DCP@JPG_PF6:J@)YM$7Y*I-]PRELR"S7Q_-G)D%L<
M(/G\A!Q52B]0E@\E\<BGUUO: ;;>%D8#J9A+<=>-:5F8RA-OD%1=JRG/C<E?
M9ZBBQ^$Q-YOWONM>]JZONC<=YMCA[/CO0(2A(\]SEM/ACFWAW#BS1MR_%[OX
M=E3H8X.[4:O7#N!NE 7$Y%&H0UH9 )424\O0#65Z5!:\D-%;KS(WXD&XD3CW
MA<-#,'Z^@&L?!!Y'[[.!'5C H6&\!,QQK9>[%ID[)>;.;*FK^$'FCLS=Z9F[
MNMY2=TQ669!"AFZ]LG3'$\>;"@C9O#'F-<5A'=JUOG#%T'XA8Y:LVE96S6@9
MU399-;)J9-5>G=;;5+CL4A:DD%7;$+YY4^Z$=I*D&\]*XMZ'H: H384]T]LJ
M]Y21/2-[=G+V3&\TU;F$94$*V;,-N56>&X1^9,G@#&Z=^-Z]+P*R92ILF5FC
M\Y?(EI$M>ST]M<B4D2G;VI0Y#N][22+P;#,E&3(5ADRC248R9&3(7D].IEXU
MR)"1(=NZ]DHF=HO.C%@^'K=5/UPU:[)[9/>HGOQJ2DE#G6%\26IE01J5AG^V
M-#S?6$\G&T6CRO!4&;X8E+HN0:C2ULSJUGO0LY-[8;28?*#B[CNE>L69;4RE
M>L5&16LW#EBQN#!Z=R!?E&H/O\I:U\V68=:3'_&ALZJ8\GU??1MK)&+1D[L_
M;CL7-]>X3'\-5TS9.>M<]SI*!/)B,4PM>WG(YUV[2:'+R ]'[,^(^Z'PL?>&
MINOLPO;N1=Q]F[/;FX\5!A<FGUT61/W 'MC<GU86MLD7EK ?(![@S/4 Q_!P
MWQO+M\SN^RS7C"!T^"0&*&Z(&3KP'FO*SO#?O^!=R:6<#83#>MP?<\MCGB]'
MX"=X& <)<$<$Z8'B0VS[V!Z<]T3?AZY,H1=:&ZX&!^E^]/07Z)_X80DQ@+;V
MIZS[[69E:)5.26O5YH&*#C-?V.-^Y ?QAF[''MLA$P'RA1V,H+L3^"WB\%/H
MP=6H\X)="9#>V';C];P; ?P9R3_OH0UA+".4/N)A5@,/Y=NH,E"B_^+N3*P&
M>X0QMQU4 1>K5 L,$N^Y[0;A_ E\ *^R@Q"7#Q]PTP+H'WY_XXU%)<%;(,1W
MQ"+T)Y(5K^6PHR*MZY\=:_(+G0E&7N0,L%7P AZP1^##$%0<!.&Y6$8[V6)J
M:.\E+FP?&IWI<!FKYT@IU88Q?#D*YOW2WZ<A(S%488_PM!$3+D+!=E<A5&5W
M*/ID+.T &@>*S"#>1T:KLEO;!:'W!0X2@GYHQP]ZAEKD6$IMZ O'%C%AK!O7
M1SY['3Q0#(?""BNH80,Q%+XOMW3*+9X,1W>%$@)F#S>JS*/PQ>*I<DNHX""(
M/C /J#-VT+<]W$%S;[LN=FZ]< YC(P]I$_XK<B26392T*^YA3.7V603TO2]B
M(<K\-1AY>P)>V*,-@XSC^8\@P2!. ]TL2?W2&X\1;B(>_4<)Q1%_P-$!A$H=
M@'&&\4L>9#G<'@=,;MZ5!."M#C&.']!X,"_:O&ZD<6CQMWA @]@DK;<2*28S
MY7VRS]#I>Y  PU+\4_E@>%OF)L.LF@<Q&576"23\@L@)8SD"R->/M 0?&'GT
MMA&S8*;[MF.'4SG@ ,@DNQ'&:H[,[$6EUZNU UG7$-#A"F9JLLJ^.6//U'$,
M&1?&KVMOL^UB B2)/C;;.0_CN4!0#* =7"VI824]"D$B0M+8\I$<6>M\LWT8
MC5^ /7AFLA]) H,#+!")H;=4FCYWL*("N%T"3S1Y2L.;%2C-PKF<TW!8:PM\
M CVMQ0Z1U**90S3W7/D0G-%QV@U&YR4 ?VN]Q4. RK(6,BI*@]%<HOLYG]^[
MT+#,SUXQJ_7#:&W*14CL4+">RX)EX2Q4<#XJL;>"\I[ HVPO"@#=,_^SE.[?
M GW-K#Q +ZDY]L3E$S\@*D0M/W7?KWD@AP9C.Y$>TP#G=?Z- 1&Z<!RC.2N.
MHY,9  CX$P]Q[$%TC!,^V)Q4!;GTP\!BB EHCN291XSCYF1S8'M9,P[#/'#Y
MS/.-)B"VH8US72DJGSG8T&_@YN<-VNSO?_X<!>?WG$_>=8 TXOFS'CP8P,>=
M:W>(Q\+@MU=V8#E>$/GB#LCCPO&L[[_^YW_\<W[S [<=G#?N>?XMP.E66)%O
MXP[;^>6RVC-\N!'#7][TKM!]^N_:'W=7;Y@]@"^X%9[W+CIFJ]&NM1O=-ORO
M?E5K=9LU7;_J]6J-*]-X\^L3ZDO+](5S9M;-R-.I.J\^54=O*#E6IY;SR3+&
M49^+0YVGSA]!Y^ETFFR."F*S:0B6^ZDU&8S&\R.0WUD@/6YO?7)A(1K\&W<B
ML8-24.H3@4:U#G[PO1>J$12MQ=]<7T ;_A*#HVKV!UP/)[ 3V GLY0?[1Y#S
M3GOC">V$=N4QR1@/=#LVZ%QZ0;BM8M .YTVE.OP)%NK I*D^SM3/YGPS05R^
MYZ(6CJH*(ZSR<CQI'&D<:1QI'&G<:6@<;<A__NCF/ /-0M1=*=+.^3TVQA=Y
MB^>ZNG65FD:'/H5D.//V.(BWB+=VD)FFL"12$;2(.(LXBSBKW)QUIAW T5K%
M7W:"S$GW=DG"(N(CXB/B*T"0V:9S/FBN;-^YLL^>>V[M/%]&AQ9LQ*51KU,@
M18'4(5=-"(1/0$@ )  2 ',,RVL*3SB@L)Q03"C.R9=M'0#(93&EE'>[/L3\
M@)!WQW%U#,JY+<B$(YD$TCC2N*((CC2.-(XTKOB"HW4$93FW%'=MC+OT>H/6
M]L@*T.0'94,2  F )PG ,ZUJTAH"K2$0BH\9Q;$OJY,II?B2\M0*A4M-;R@\
MH+?LN"3C2,8Q@QB3 $@ ) #F%V.:U=5C)RG&I!B34'Q$*$9?MGT ()?%E%*>
MVOH0\Y/GA_?\7J0.\^-!($*&&B$&E+QV4+HKC+".UDZ0QI'&D<8567"%$19I
MW"EH'"TN4/):UL%8C1+7R +0;$A^ (REV3)T(WL])" 2$ F(!$0"(@&QN$ D
ME_1@:P/E#1&SSC][X8"V4\-LO=Y46'GBM<(M"ZK)K!["K!*$GV2WM0C !& "
M\+$"^,Q0N =R7]E2]ARQ +% +IYX6^'^K5,WY/OFWFEEC:_OO) [;,S][R+D
M?6>?,YIWT$ 3-'#@1?B^?8Y"+X3:%ND@AI>$?$(G-=0K9KNE< ;RU:(M"X62
M%Y15PME!J3%Y&]ZZZ@<0;ZKGS2P$GA>I&M5V_C(OC 83VQ+;DB-*CN@+TWFZ
MRG-1]A8L3>@1N1*Y$KF6@USKE9K64%BP[N2C?-JDO&&3\F*&5/P9V>$T-4=:
M8>ZKLI2(2HE*BT.E1JT(P7U9>)1<3'(QB1?+P(M:5@FQ1(M$BT2+1(O'28MG
M[2*$W32K2=Q*W$K<6BYN-4V%%8I/WN=,36G^+&?PUEZ?^CO5+QA&<3X2DN1T
M0WN[L8&I>Y;8 !-'I7!L%X@N_IQ^J.OY8^XLZ;".U\P?',\Y6L)QDFM^>:.]
MD9]A.*S9YS4BO;/'(F"?Q2.[\<9\A6,?[4$X>M=N5UM:76NT#*,!_6O5W\X4
M!L;;X9- O)O]\?[I&"^:F)XH7NA)8VV6]?9SS7$+:_K;ES5Q+1[B^_>]W<CW
M]=1YZGSY.[_;JM.6FQJ*M##54NLXX./DI\?8BO0]9Q _OQ,P;\BNA"7&?>$S
M4Z\P0]/K[.S:9? 2Q_;<8)>(8M[A%RO^'7XTGA\!"\RM\/,8@QZW_6=%7+0&
M_\:=2*AR."F:)-"\0@<_^%[P_&ZCHK7XF^L+:,-?8G!4S?[ ;5?9MBX".X&=
MP%[<9G\$.:O;Q$EH)[2_)B89>R"A8X/.I1=LG<Q'69,;"GQ[_L3S>;C/MO*M
M$7<81!6.D8BQ27](?TA_2'^**1_2G^P<I_+6O=W]:!3ENE5T$2E+/3GR!)(X
M9:1=4Y>/5Y;,#[).Q!K$&L\((X.S,H@[B#N(.TZ .\XT=4FJ94OC5YNX3U1#
M5'/25(/!C;)##<KBH-#423Y'!NW--D5!E5[1]4:U0;@B:YQ54?_28$535XN?
M<$(X*2U.SFKJ@$)!(<&+X/7493,T<MD4AT*EC80^(&3=L7 I]>XX9J7*2M"D
M/Z0_I#^D/Z0_Q9$/S1\K2[T[Q4"D:9C5&@4BQ,D4M-/<,>&$<++_W+%.<\<T
M=TSPRM!EJY'+1F$0I=&H7I.I&^I28<N"*[)!A!7:;T)X(;SL$Q*9%!)12$3P
MRM!UJU,ZC>*0J+01T2?/#^_YO6#<'3"X3?B,!X$(&1ZA( :48T-KW+3&733Y
MD/Z0_I#^D/Y0CDV17"G*L7E91@;M>28^IBB>)I4)+X07P@OAA?!"?E@Q<$)Q
M33Y),UD<*E)(S-7:>E;'RZ]*K2RH).M%2,MS=P+AC'!&.-N\NT&9&[FMT"C5
MA^!)\-S2X32K&AG"PR8*M<H:!MYY(7?8F/O?1<C[SC['W^V@:"8HVL"+\'W*
M\%E X2HKC;RU](ZY=G*MTFIIU?;!9%86;B,O@JB)J"GCJ8>,IOB(EHB6B):(
MEEX[4Z.PQ.K6$J.Y&J(SHC.BLRP"P+9>-<C3HEUP2O3ITV)62_P9V>$T-:]5
M8>ZK$B"(XXCC]CH@K*FN ,O)$!SY7L1+Q$N92JM-?A?1$M$2T5*Q:"F#'2!$
M3T1/1$]$3RJD9;1H87"?Z:J?Y>S,VNO7_/W/GZ/@_)[SR;O. [<=O+7G^;?<
M$;?S>9T[Z/B%XUG??_W/__CG[/*+*+!=$027WKAONSRT/3?XZCFV-04QNBBK
M&S'\Y4WORM#TQG_7_KB[>L/L 7S!K?#\LM%IU%H-K=EK:W7M4K_03:-9T_6K
MWM5EL]/HOOGUB>S3<KRSQR)@G\4CN_'&?#/CI6X'%13G(R$)5C>TMTM :0 J
MGHZM_&R[0*CA.Q-A<PC-OQL)E%U@@\Y*@;*AYS,O\AFW_HSLP)9"9MXP%"ZS
M7<N)!B"(811&OF 3/L6CW@(6CGC(N"\?%4(?\?RW: (/"^'QGA5/SUGPYY!Q
MN MA$SG<9^(!KJPR&/WEUUG>>.*(4 Q87T![!/LO[D;<GS*]P@Q-:U?8HV"^
ML !JZ5<N=\070>3@3VSH>V-X<3]1'WS\3'_8XTC$S9P_![3)#O!NSWD0@S6M
MD[W],X*A&TX9#]8^-]T'#L+S9UU8V+<U?>$N\_J@$8N1"")KE.[B7.30A"&W
M??; G0@$&_<AU4PVX*&HLM\%$T%HC^&#O")]SW"S[!:MP.[Z7G0_DG?%OXZ]
M@7 2.8!.>/[$\_$%$]_K\[[MV.'TG _^'06R]T$0C2?QHWSA</PN])+FCFQ0
M 7E<(+0&OP)%AO8"%P6RYEDXB@+FV-^%8X\\;X!7C?EW'-/9HV8"D5WU1=PU
M>%(@MNN=@$; ?= #J2H30(H'@WXYXG!G -U;(S:$QU8/1TC@T-Z[@+H!/BRY
M56;GRO8'(?P3#RD\&:4Y%B^\?DE;GWN]Q6<HB"%@)4\%\8.$&:C7&!$":@HO
MFD1A4$D@CI*(!S#!=SQ> SNPO A>B:,-%UO+K>1C^2,\%A0.'P%M%3\FPL)^
MXA_NP$;>"% G/,N6_7^TPQ$JSB"R0C8 ;7"\";YTJZ=;/!@Q]$1C;8%'"_]A
M\_.#F)1 Q&/AP^^._9>4U.J[4&=1=],*FGXQ=\'D1" ]N/]!L !L5W#>YP'>
M PU)]2.ET2NO2>%%]@;\"0X_6<#AZ%?$]!AW;4,#TT]XVFE?W&/[/*!-/H$+
M07^J[%GCOJWUDKMI"V&^KI8T<@:P%:8"?*-NP'6<C04/T'C-@.0+T$KFV\'W
M%0D&(@P=''&\T+$305<9&LV8*!B&0F!#;""1QQ1 GC!$&I1@6V)%23@[6;M:
MTAD@A?MY"V?@ #0/)&F (N'S T"6/01!I>^<.#PV')*<5VYE<UJ.KUG5P=AJ
MS3J]W"@QJ4AE7+69*</TZ$4.VFT6@O]^+WPTH=?NS K-'OSDM6#F++"@TA9&
M(7S]ET #QE&)N2_Y* #PH<\PQ],,'I+: OC@ V0"D(PEEH@,=!*Z#"@(0O@B
M,2PH0._1E;3DV^B<R&$-EK@V497$X(+.S <N +5'V7,W3*B3N1Z.,Q*07*E,
M@!IGY%?9;>J&?T>#>RE14 4!XO:FL6T8@+?@ \/,9"11._%1(:5[$>M#()9,
M*I]]OV+\93]QF*6)"R)HVY^1'*K$QG4L=#K@;<YTB9K2C[?D:(XXD!Q !YX*
MS7&8/9Z 2SWW.A)F?L:?D.P/+5^X.O@>(-%[H$]WUJ+G(X^5Z&%S.) .&B[!
M1G3< ?[3!0'!R.)PQM?-HXPMX@>ST;W4:H9>:YF7S>[%5:]9;R3Q0T_O7G5.
M,W[X?1$^@#HX4U (+T#M!S.<. \Q.R)\1M 9N,2Q81P&%= $/H#WX@-D*(VP
M 4]#&O78^0,* YU#MD8^EI#R!8 *&C)*@"\U'51O K@? 3SQ"4 ^\B%B,=Z@
M[1(H*RJFU!H)2XS[PE_X^*9T\O75Y#Z5KY7"RO0-T(75U6Z5+ZBL#!A0A8PG
MQT" DG2'..QBFC JA*#N('&-YNX<&"%@DHHTRBX"!P,"X0=(.G/]X/>@0N.Y
M8Q5757ZR6RHV_U+UXL\.\B_HH\O:&JC<-%$^:2*?*."N++85/STEM"=7P_V+
M))DUDRC;T-N5UFYV+FK=BYIY5>_5.[W&54QOO6Y+[^D'I3?]"7T9BND+GV=Y
MCN>_^UN]V=+;C?C'Q[@Y?<\9Q*_K@5EQI69=N^!"1%)ME+C0A2%P]&6'G@,Q
ME'0[I.\"YA]0!M<%TD\:SJ4@BX^OHB-K7DVC;\&M",-L>74CQF<S8=*-F=NK
M%0J;S\H@C8&W@Q)>"O[['-QU"P0^$B)\]VK%V@)N2VL<VDSY$F7#S^F'NIX_
MYLXR(O&:^8-C-;&$XR37_/)&>R,_!^ 8SC[O3A2/]B <O6NWJRVMKC5:AM&
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MV&3#K8-U=7RLC3(K@\%E4:3S^XB#D$,!7X_A9??P]3D:?RQBDVJLK,.2E-O
M<BB+QCO3;+<):M7FVTQ?("LMR(,6DXV0/,<]Y=ENR'Y^%_-Q8OW)-M=@L<]5
M(O#IX9FHR6O.&[ <&'Q[:,O25HS/*MC%U;JX(V@;9_;;./6&DGV<M9RW,AI'
MO1&3.D^=/X+.T[[([/:FRMHV+/?]DB>T"ZT'_O^V#D8A&OP;QBHTU:9^[8]
ML[4.?O"]8.NR/85H\3?7%W$(?E3-_L!M=Y>D$P([@9W ?J1@_PARWBG%C-!.
M:%<>D^!4]-%!Y](+MCZLE+)>-]62F!T[H"#I]47$Y5N1IW!451AAE9?C2>-(
MXTCC2.-(XTY#XR@=>Y.C%Q^0DF>@68@<UR+E6Y]..K5>J6DMA>G41="D/+.E
MR7 2;Q%O92\SK6H09Q%G$6<19QT-9YUI!W"T5O%WW-N-ULAQER0L(CXB/B*^
M @29[0-4EBZ+PT9S91OFRCY[[KFU\WP95;+;7-NG7J= B@*I0ZZ:$ B?@)
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M!95DO0AI>>Y.()P1S@AGFW<W*',CMQ4:I?H0/ F>6SJ<9E4C0WC81*%66</
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M9]'BMG%:(5K=@\AVP8+L-XQQR5:HMQ4$I.VMQVQVY:B =.D%RC+""#@$'+)
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M"ID$)A_8C7QO(KC+/HF!;>&2">O$B8IGW4^=G]@#GZ6WV'*Y%V-E.0$?A2.
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MEN?,E3&>5EY%[3;ONLN0ADH'H;MG\K ]@&L#6@Y'J^42^P]9@Y)[C))HRF5
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M*B+_U%%ZV[[_-SE1.9LY#)2IE*LRRQW#!%X!2GCN')S(A_"@3S5.0KE^YD'
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M>8<F[]\ [[G2'>280\>-<!! SY+WVL/X8> 'MB>ZDH!I- D<V0@R+3B?+[W
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M':&%.:JF8(@CD&%)Y)4;5J@?(:4[]*\B.-00=S4E)>TWS<06"%3K)[U3/S#
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M%>B4AZA3+M,SZ9!M+G&\,::MZRFF *R]GO\.!M1J]G,-^J-.E&R=C!IJ6]1
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M$?%+AT]UZ?44#;SM99W:/?<;5K=IQ "ZSQS;%U(]RGP!$!8#K00KY'^0.U+
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M"JY/J\U!FXDM_@><7Q$R$($[%SC%W!#HV$M2HLY>U@=\1YJ/X+>XC05<2.#
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M(<7$.U\)1GY1&)ECSE(!2<68QG;\5;[2STMF!7.\>5J>N+5$05080H; .D3
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MTZXWPOA3C-.N2Y_7_JT=$W;(#V=B;.%P-/CQSX^-3<R?7%LEQ[RPX0:MXOK
ME\5G_35^$,Z9E[O,(3Z3+DQGL&SN>?*9O[X9O*'/<%^V^EP"\Z_NG$?6)_Y@
M?0GF;$4DS%EXY_IBDRR) _4'@6#TEP?7B6?OSL_[9X/QX.1L-#H!H)R-?U1X
M!=?DL47$WZE__+F()]DI]&!OE@DQ*,TPV#Q>+'8X.OGQ:6PNI5+Q^^$+?S[:
M[>O-X<WAS>$[??AG%9+M8/+PL]6(QF80']SX%BSF85_R9]63F7G/&\/Z5S_D
ML(=_<\?Z&W/]R#KX.8@B'KVU M^ZY78"%J<+.LK%/7,]4G.F06C=,M#9*M*W
MC2%N$+=JQ+UDT<SZ %=L_9T[=WR;Z08&5PVN5H^KTP1,2\>ZC5F<1%8PM3X'
M41SRV WY'*NKWW.?3]W8^NRQK69Q&&PUV%HUMGZ%-2*/QL)8%\[O210CBAJL
M-%BY4ZP,8N8]P\'XW"Z\SP7FOOIS'R]QJ*QG3;WU3RT$:67AH"X'=839/ZBN
M-=*K"L54&S$W\MEP,,/!G@6ITV'E"9^[1YE=ILD;7F1XD>%%S].FCBH<8VC4
M*</"# LS+*QA%G9^7ETNMF%AAH49%F986,,L;'Q>W0 ^P\+J=/AW=NS>+T^U
M[+8F?!J$7)O+9U/T;YN0W\:=TY[#+-O6XTR0=H7.GF=1=MOQSN@?-42,7PUY
M#:ML,&7\I892.DLI!R<[MI*-(#+DU6'R.C_9<5Z"H2]#7]VEKY/J'"1=4?.,
M-V,]NES,@\2/(\U9P1UK&@9SB]EV,D\\%O-=C2FK(5NWE20[[!]51;)/P:PK
M)&U$GZ&S9[@83T?-D9K130V!&@+="KMV,);;"$1#;X;>#+T9>C.^ERH4S&%U
MDZ9?MP)I!LGOP2#Y&@3E7DWG$U1?8:%E+4;EZ\A9,Q+9$';5F0##ZH(IAK(-
M91O*;@UEUS65P!"V(6Q#V-W(+C*4;2C;4'9;*'MX<FRT\1:0]@Z;P;4=AFO[
MO=6$MQ6-$6H[6)L; 50?L!IU1S8WEOAUQRC:Q_5:I^48;F:XV8MR8P<-SH\T
MR0F&+QF^9/C21OW@3HV:9=0LP\[:BEV&G6WG73L?5]??TO SP\\,/S/\;(?\
M;#0ZKBX3U_"S32,"9OZTF3]=MNA^SZ)MV<_-X?=V]^;P^W)X,W_:S)]>#_7'
M(=W2,;YF_K291[F7B&OF3QM<;16NFOG3!EOW!5O-_&F#E2W$2C-_>H?YR)4U
M0:NW]J"%(#6S>C:%5/7QY-UCC$G::V]4V+ BPXK61H./=CQ<:*\1S22V&!9F
M6-C.$_3,_&G#P@P+:QMF&1:V12E7U1EYNT<98Q$:7F1XT=[QHH/1J;$(]Z-9
M2&='+YE!TK6 M<)NO$:1>#6*Q.NCD^&@PHGKAE(,I7264@Z&(S/5P;C7#'W5
M1E^#<S-SW1"8(; :@T=#0U_&H5$O$,TLZ1:0>MO[G[<=B8VDW8&D?4WD:090
M&_(TY-E.\C0#<8WGU-";H3=#;Z^*WCI#3QBIV&U:2V?T1S-_VLR?WI/)6"=U
M=;HT<[&,P=D9!7C_"/M\W)POMS4T:G1F0Z+[0Z*5I@89X6N$KZ'LUE!VE4E)
MAK0-:1O2;@MI'PWKFMUE*-M,DJX"AFL[M]5D$)HA.C5!;Z^'Z%182F=&Z!@E
MI\92?\/-##=[ EJG%98[FDG2AB\9OF3X4E76J)F\:M0LP\Y:BEV&G6W%SLYK
M<YL;=F;8F6%GAITURL[&Y_VQ86?MF2/=F!6L06UE2+5^*Y3F6X2K/G_Z" N^
MFP#TUQF.<_2 _<+>+#'%.DKF<Q;"<Y$5P]?LA27:[YX-,@U".(/*G2[7PD1;
M)L> 6SO86PZ8'0RJF],]/*IF3O?9RX;FCL:[G?E[M-<3B\WA]^7PZX@I7:$M
MH]TZ.^W90'I;2-^(\AH<0BJFCOX<B/ZP6T ].^2PW36INYM4J+K:?"FJ3)NJ
M0NTXA:;>B<;#ESGU3B#3,S3U->J+0:<U%_$A"$D3_Q?8(I%U37.$59)/YN$X
M&O8JNXN7,M0)L[_=A4 $#JJU0?CNOQSZ7T6<MJK\P2:N5)Y_-#X]FK U%SP:
M#"L?U-.2&::M\^ZU;/+N/J'R6N2MS-MED-<@;]/(NW&^HADI_3P?X]^8ZT>B
MI)]';ZW MR)N)T 7+H\L=L]<CWQL4]!R(N9MK% :R&\X+D3U5.#?%Z"Y\YV&
M"M<JAOL*Y[QZ5W&T["DMNHNSEDH >C#HGS<&TU=1=%,"9)-!T% &0;T%<^W"
MLVKY89?9GF!TNQX:LM=X9CB8X6"&@^VX_U"%FEI;,*;.8ID]J6?N/G]Z&7QV
MP91D+#=FWZT)]_G4C9]EXF_>"*+*F$[;FCR4&$2#"MONKP-=5]A8^RBR=1SK
M]746'IA9H89.#)UL4,U97;F J0;80VU:YJ*/GI/TWW7-NM6PVCP<7V\^U%-L
MK=5 - A7 \(9O#)X9?"J>ECMB8;1CC0?FT4S"^_1FG'GCD?[2[R[@.<7?L_]
M9"NH&5_>&E_>V/CR.B0ZVR,N7XV/8GAZ5%V+%D,IAE(Z2RDGU?4)[PJ=[(G2
MW#KB:1E\=I+!ON ABV'/E@QM&W6XBH3J884-BBI-J&XQ/IJ<::,I5,K;:IAD
MW16-P="+H1=#+T;#-AIV^VM$C9:]-H&TNJ;&QNG\ZGG5ZQ/X!X/^L&H$ZHHU
M:NQ/0UY&GS;Z=+N(J&7P,659>\ZG2K3J&KB6T:X-YWI]XA^TZ\HBU4:[-N1E
MR*M(7J:JRU1UM2%IW<#*5'49A&LOK$SUC<$K@U>FJJN-6MK7(&:>-OM-C(N)
M>I;/8RN8HI^K.]2[<XI]7-VH8_2H:<A<Y0V8CLUB]:/^QEWUZX-Y:S#8N'9?
M&U-M"^;M_;#GO66*M-[P=%A=0^>G&6%;L,[P.\/O#+][C?QN5%W+1\/N"IZ)
M]?/MR_[]EY^2Z/".L<6[W-!.D9WR*8CY5SCU>R^PO_WW?_['7[)G?9S%%9*1
M_\6-OEV&W'%C_!< T4=(?>'3O[[Y<(4C"__W^%]?K]Y8K@-_8'9\./AP,1X<
M#:ZOKX:GX]/WIU='5^/3X^'PZL/5U?79]>C-?Q<@KT/QB7GI91>W,C!>)["3
MQ?>5 >KZ)/BCT3/<3L\AB@^NSWS;99[E^E$<)CAW-[+B&8NM!=R#'\-7WM**
MDLGOW(ZM!+X+$-C9143H:+'I)JP0K\+U;2]QN&BPPWQ'_(/_D;CWS,/E>_#(
M/8_BN?@ = +?Q'#_$3W.;%L,J VYS>$;P*N^]1NW6!SS^2+&#<Q=WYW#06CP
M*+X4'Q:S8'%[ZUY,?]3>;4V6\B/<"_S+8M8D#)A#S\%5\C""Y9E_Q_&,TU)0
ML<@"!+YW@R0".#D<GH)=P,))1+N>L7MNP1O@&&XT@Z_N$M?AB!SY/4L 4CFQ
MV.B<Q6H.F0O(38-5X<F(3?E=PD('W@N@=A>PH0GS8&M<_0X>A_^S/!>.#JLN
M^]8O2:@='*XVC*? D@++C=+GN4,@ .B'#JYF/;CQS J*O_1<>]FS'@#!9O*X
M\%H/5 R:DY:[V6C!;1PO'*GC_9$ OL> 3C%L%(X@-NS!71+2<?4<_[X(HB0D
ML#,?G@>@X.)1E/"0P)IB@(YY(8\2C^X2QQEKB)6[,;@;>Q8$N*85^'!I,Z!1
M^$](=Y&_93=.!([#-1-6\G#!0KR3_J-,<E,^,!RUA1%</DK3A H W@4R 4#"
MC#0CA0L,KBM>+E!6 C 3G\;H<:='7T3 UQ^0J<!-NW<$:"?AN!+>^@-0A'7/
M0I<#;N";DPC$*E"?Q.?P&X=[2\2- 3XNPL!);,0PN)8'[GGX7UC(#8%J88]A
M!&< 3 Z#"-$;$,AQIU,>(@+?\> N9 L$"VR, 9%^A1W,V>]!Z(JWXQM*>! \
M[@([(,R2&Z")@$B==(I?^[=]VO!U$@8+3O\DZE?8;BW8DH@(L&@>2;#=<9^'
M!+(0.17 2CV%,(>E5_"LREL_&N =G \LARU7FQ=4^29!M8'OQG)>=$9H<&'3
M()P3SR&V38CW #QJAMPE4I>2H444"!'U@%+&Q^N -0"$#+N[":Q!9 U\P5MG
MR,+5/0&22,R&GTU=*5Q0?W!]@9+:+B/Z!AX63 "EDWB%6 BX5.02VYLO0,?
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MPO[UC?841%29QMP56C$B;FU:Y,FHS/9?$7$C(^)>+N+.SX_ZVP#2"#@CX(R
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M,JNPD02;9#< @F Z+*E)8JG*RJVR,I^4_AM>)!)S\]B:8FO"@AC,*'@>Q.>
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MX(UE%QTKY<QB1H3U2%Z&;:+%Q)0_(V!L[L-(Q,S$C*7DB<<^B!8TOFC1MM9
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M%?DD&SDDP"-RZ4,/KHQA6K=FG3PQL(F+A>]]L^=PE[.LV@IB:+$F,^CR$)D
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M_?:YL,];JKS1;YF#FO$..#<[+=6J_[/#//'8YWG>/*T]LF2;E,?0EO?GG[,
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MA1P5<E2.K]?Z/54KSX(T@8^H0T>SJ\PD>I'MAK[M!G"?*. +\M6]266N1?
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ME<0&/>+8GLQO)>974P?(PYHZ)OU(^K%4D=:D8X<F^'1)1ZS53-;2I=;:?\M
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M&'(-$^0-GR_@K6*&A1 :D6#F<,9"40!>#*4A$4T*\4Q,\+CAXPJNR9RS(!+
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MO1#31]$&.>/IWD1P8?Z*O*8RO0"W-K#KYSXPY5S AKH1<\!+BG<CJ!(<#T@
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MZ5Z9^MY<N87]S$I@=N&8REO\]AW%9BO6<$:G-^[6I.1*C\X>VR0GO)F9/7:
M"%F90<>TQ%9G)<:>9O#^60X0R=:P?W><>+U_>*.]$9\#V%\GG^-!;;!$?I1?
M[#DX/3_#WOB3-V<N)H 6LT,1Q-V3;84SR44[4]I7D^OWO_A@E+U#DNLWQ&=M
M]BL5)VA^*I&._XE;C!F#U]?2(,S@JRA019U+L48=:*I6C\\(=_(@1+=QP9;"
M^8OS2^X]%\SCVM%GO)%_*WY\EV9$LP6XVV!7T8A^_GC_\Z?+_W>91*]^43^K
M^'>B-H2F>'T9Q:L4_0KOUJ;IO^O7MJI(>X$TN;&\0;*^GV&+%H'IN+(]OL#
MI8P 3[C)YN)JH4?%9GU]B:]N?[[]>/GCO;!$=S_>_]_+J_MDN6_57\1R_YNY
MR?G20%SW$Y,?5N,'SS,"Z7+2Y2>OR[M&@Z3^<C+YU>:)&I>?WATB^__O_N>K
M3[]_V5#OB7BG)Q*I(H@<^8L(@KY:[Y-*()5P\BK!&-04K"^6X<L?/W[Z &9[
MW6:G,BS5 ;A_> CHVR(;=ZJPU^TKMY"B-I_(A"^!H]'%77-UY:F=/\<X^)/+
M?1$,^KQT08/:W[:YP,GO[UY_MK-E#U 7CZS'\@/4L78P2Q+8&9#.1Z?-<\6Y
MML6GW!=Q??9-<>PX0O]\1+<:E[[N6(U(YH&!8(!1P+@CU\1A<3<^WG!DYL_,
M7L3'H1N.MK2Z,C*,^ZB"?!]]7'O"SW5V_O8H!_<!N,%7/N5G5"TC'B\3J&G'
M![=IDMV=3!Q9KU6\STY>+HL[")0[W,%PS,S)MN&6$Y-MS!G&!SR#R!,<<W1<
M/(/.U:8(50F,ZLWAJ<BP<9Z0/./:*+/#9\Z] ,8(<[.G8$KPG&WC_ S/M-=J
M3.*\=I3(Y,0CR=51E<LXS:NSD>>U)<V+)SEB>!:Z?_89>@T;XTA2)7,I5& @
MO?0$^6G&77B K^!3\/3/SV<1F;9O1G.0:=>$+YZ\R+'RQ(%= YM.L2I*N"^[
M1L=MH:V2\J::#@GJY$C!/?'Q.:YP82*?..U!K\WA+<[A4ZZR3+TPSX*=M43I
M..WND /L(,O( P'$E-\ G$/'@7W%\P</>VXM,'_8GBZWLDWN,2M[,&W-5N'G
M_'M<=$6<5?[5\ONV@W;.SVV4UT8NM\*Z!M.,D7U$*L\BX.^3/S:$J'AOG>[7
M>H6]GO;?&LLAC?3O#]V<K]S_VMN'M;[^L&A!A8WRJFK*-"I7N8X25_A)RL_$
M<RSY_+?W;K+Q"@Y!N$LGUGUE>\(ZP=Z?7P)3Y.E5NPBK2-C%2W(I;'QZA+3U
MP+F4=F2E8A(V!NSLA99\^.JXW"O(V7R$\B;A[!.,OGAZM]M31Y43M3$<V)PV
MCD?#<CV2:CR$R?9O75RF[6]:R]0B:=4-M30;T_KN;B20SPGD(6UX22"W"*0Q
M[I<(BTX"><8":1S2@8X$<IM ]L=D(4D@2Q'(0T#>22"W"63/J&&#V4*!/$D@
M_"0U8%!;:D ^$KIRUEX<&_V7YUD(3U/*O-?.X)/#JJ,<>@K$2''R)DJ<Q/$5
M)K'9%A9_@W@X#J9M/3'?2JI^UT J'F+2*!/FX#'SRP_P6G9:-QZK(ZVO#3#S
M$N8WZI=W=C<JY>QN4._AV<;MO>.^_IPF?_(>6P5G8KGDZ /;2*63&+[R$+)B
MYZV.D\5]SQ(KW5O0$?L9'K'O?SIT?"G9Y_S]D,/V$SM7;UPCP-)X_/Q8>2OS
M;B*-EZ+BL>2H2?J[NKU8LLGL*!/^8,N$4["BB#EQ3+W0_.-Y2A!I7ORN,QAT
M*46DG/!>\S9JC3/HY6N]IC#641OWMEEKB>?IG>% *[U%^?&YICG'?QO^F]Y:
M!^[>-7U19!IZ:5C\)9L2.@Q<=2;TCF8,U$,RC\[[.)#\A?)DK0TB)9XWUD;E
M]9]OBZ20*=M6#(N5OI78KCJ#QDT3Q +;]M;0U<V6Q*]S/U].W(Q!#Z5NLWBX
M@-"''(&0]:Q)VML@U%*,>^K>\>^R3C/;(JR'B2>='NPZ/>"N5?:YP2I+=H$E
M+2_"Y*G7"'+S@[I-.EC8M0)T\A 7NW4&@[':/3[=&\/%%&IH[M%$-8JU*9QW
MU+.+O4G;1L58R2'L3E78%+ZC6HO=>)YU5AC8R<$(W)K6"\1@>AO3*U4"JF_<
MR%8:M57ZLN]TU5 F-:&<YZ!\4ZAS[#<WL_DCS/4M_V8Z48 XIM5W=QMV5;T^
M>'?V39EPET_M,'@7-P*28.VK,,;!C/E\YCE6#&9\%\W9 G&,E<M_(0QC[B>X
MR_;CUD)JC/D:-W\+TGJ:'!?MT_3ZV'*U&>XX7;D::W5V#6F29!E:C8T3*Y:L
M&AK ZL9([=:.&%[0K^_:<\%) QXRJVKS6)N#\ S@=UXE2I3138#YH!SF*0 (
M-_0C (3/YW8HIX7<?)U,U[1Y<X#!E?V6['FV+2)X[?2^S+7(;0QY2Y;G8^,J
M7[:Y[R=79JQBH^-ZU7(F,\UH'DFIW6P GI/GQ,/<T84B_OL??XN"BP?&%N^3
MDXE+U\H@]26B_HT=F/ BT.Q?@#6O',_\^L^__N4?>]R9_/019,E<"KL 3_C$
MIS^\N;O!E?]/[_<O-V\4VX(OF!E>W/7ZHZO^U94^TOK&<&#H_:OQL*?K-W<W
M=]I0Z[_YYYIXY0F[H^"[*(9Q&C#\"1EAG1<^J"=A3\&86O9TRGW4T^"QA4^<
M2Y#S1>3#CB1 C #;Y/\_>^_>G#B2[8O^?<ZG4/2=CG9%8#9@8^/N,R>"\J/'
ML^MURJ[NF?U?(A)0EY 8/4S3G_ZN1V8J!<+&-F",\YZ[I\NVE,K'>J^5ZV=P
MJ 9 -&5 ^@"7$0P"MNY,_^^HU X\(E1@:@F.;>R1$N,\(KD("@9,8(6Z:KXZ
MEMDH9IP<?A2>J'MF#4'J17&F.Y'+?LWKY=C._2Z04S5H0>#E]\Q#PC3[9[SB
MSWX6+T@67,=C&N_#J08^@2^/!/?:]T62S'!]I5TS/MP8R886TT,%Z6-0&[=R
MWW3#[Y(:Z2,BPR(=,=;+! \3-BJ/@@RE$/@.<[M7]ZX']VRJ167P'UAO <,S
M-SHX7E+VTY6F0EWP(U0 C*H021ZV+S.9C&'WF0W&DS! TGM@-(W1U3S])2WD
M[/)UK3B"61%NVN)<YM> A)8@"\SK 4_^!YA"[UHA&^H>*/>^3/TDZ#$2 MIQ
M!:^TCK=NT=W((4W[NK!)=\6P(W,AGD@*YF#WE$C_B(>8JHDS+MB4QP,QFM!A
MQQ$AN-LGOD8U7%:F*VK@^9]7UL075YV3\]/6Y>5IX_SHY++9/(7_CS7QY>G[
MD\NWJ8D1?F01*H.((,U*@!H/0Y;7@"GO9 C$!3))^J,H#N,AJ+0XSXK7S+,P
MUB2)04^A&DRE &5+@ZDQB"J+CP\0WD0ASQ:<3N9VXPPD2B+Z<BR2[SPA^M&+
M!!P:X_,L@^-!R8/#9[:L5,J2@&B,OVZ[E/@)?)^8K*];$I4X4;4E\M*1Q*^A
M-F#[P1B])>02VEPC_7!W!HCK![NVC_KW>N$T+'O_V01'3U31')V9,=,\M&[4
MX1:P,GDJ!WGHA<$=\'MA"U;"02F[,"@C+*F0D4$P\D&QD3DETCB"TYP57^-P
M>@K4BDL[Q-,S@^+7%=!2:2QCG54-5\(2(_M2$WCZ**2<"H(N% K#8($!M7=T
MV5V=]- 5 7D3D'X,R<BN##T)<G+&(J![]6H<>%3C?0V2>.Q=@JQ08)0(_R:3
M2'",J^9]R/K> ?[]78U@O0:#( SP<S VO78>)Q."]HLCC&WY=>^BBB?FIYO.
M89 I="V-%\QY$$4\G#R($-@;%D7(A\@38PRI$>;4^R >RDC!9Q+XX<7E^3RZ
MICU3'!($]U'=^[W@2#9=[Q,->M/P$VK>J[&H@793G.3!=,D@ZO,!D+NGD-?
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MX/#USQ5;?AN,80L^R:GW-1Z+!?4_#?K9Z.>SLWJGT6Z<=%JM$UA?I_VCEEY
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MHM7 \1(QD7D&LP6:&R9BS'+1C(H*>P!D#X?GDVZB>".:[X7YX.'.XG<I1#9
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MY'/MT!EXL>((SW$WU[(?.\/BR'+&A:U@N$67V-#@) G0@HBK/-T:T5RMD !
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M:M8[AY&>@;42F. 22W"48@@ZK(RF(4@>]A#"&(TS&L$N00%3,1_GRK@E"8W
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M$RK52F59AMAV24XRP4K@D%'.F2Q/L9::N?[E .T05<E3 ZX$Q<@1119%X 8
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MB9P=%6*W< HM@<YIK*3L\U!*SY(V9&+$F1TZ+[E>MO V?AWX<[75_<-]NXF
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M?D-UF>W:T5EG?>403]_:?9&BSKG?4&66$XU.-&Y9-!XW3C9E1CK1Z%RYG9"
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MHXJ QYI]G*/F (A BQW%(/CM4V2)2 Y!DI#>0;XPFCG 4!,XZ0&H:+9.<#_
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M!L+ST9-F-4*,Q%1E2HC+=O?<O;D*3*"0+ITB:4PCF:2C8%+0.G$@EA,S3LH
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M[^TU\Y*YY6J:YF.IPVQ4:,Y&-\W6ZD#"MBD^<*]U>C,%F9R.O,_)!*/K^,T
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M,.TGD<AA]+>65_K"546Z%?J:]>E+D[->%<LY54&E41J24@<Y+O(/LI#U ;9
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ME7DIFT!K<7RRAENJH-2T@+YH/@^(URE>1_.D'9YQKL8F \-$A81$-Z$.N]O
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MZ_+K;A[]J3$4N3YYNUU!NO.Y&QEX^$U[L^?:F]TO2Q]+IFW$^EK9= W12OS
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M#7UI\J3(R0!3$@?%\[ #8PO*=F:"_9+N"Z,L"/1H&*--H@> \9/D/MW7WAF
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MLI>A(B/?J"P/W(%$9+)!BU)F.@\+/POJ4:78*U-GPW=U#4-4LZ1F1K%SRI
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M9$A3CDSB@DGY<-5LJ4,W3@(Y">0D4$T"J4:8!<10#^R2;]@O15+C OL1 V,
M5 0,L+N61 O*+F6-D- PIDA"0LRV2 B&3LD2N4[XH!WL-(%C_<':.!4CW182
M;EP)A= $AQ(3Y[E2L+)ZD&9QZJ.-Y".FFQ"$.=$R8!/4GH)] Z.R6OS<U,6B
M.T79G@NTN%1G*:LK5R$(5Y<*Z6RK;DF6(:J,JX1_P_(6F0PRZL=4QG&:B<+Z
MFL"INH$BZ_/33[(Z<C;_M(<9)^WG/!$P[0Q:WHT>/I][A_">-*3TGH$ .,2/
MB"P!0?M'+KROZ:BXQWL\^%H."[J!_J!S>-0!>T>)DG_+O1JX]C4BN7S&8E^"
MKK^(TY)1MDOZR'E&]5P,G/>';*[ >FD9WJ1^;1_X"K\6Z*_YYFNFQ\/W<K5$
MB?7/M:'UWWHBKLP#MA^6C]5HR6K?AT3?P8^0[&04S<IT &D/U5[&8Z$>WT&8
M"L;K5+@Z\W:RR$JISEU!2BIIQE6GR%P4R+8.6,:/J]'I8QW[AGNCH6J4\TV>
MG^O=0U[[KS)^6"0WT4564_A"TDOH]Y%KOJ*_+AU\?,9OU9IH_:V&'"O!AZ)[
MD'!;C4$P,L U-#" !OQI-**AZE;*[:%)L9_C";88ENX0(1V5_,T$J*_8>CQ_
MO08$E=<1E+ SIMH>Q(^NO@2I5=;HX%K;UCE9 Q%R<J)XJ(=%MW8U(5>'UQ$\
MX_1>E?W(@FHL)#( 3(Q%UP9/8/:W<F*5/0""6^P9 E&7R]%P4V0<8,&,JPL5
MJE^+< ,KA9TX!SB0CHS",%+3<!',%TPCX"39F$;Y8&P>LD"0'0>ODH._"CA-
M98$_Q<9PHA\57B/HKZ$L1=6._VEGT,#2-6UH<?CA9[9FK2%?C]52<%5.HN9%
M958]16V*NBX!UD-1K)H>&5.,3*]#O1G##"!E_J\AWU::],R;37=A(S J@2LA
M2#_LS;+_[9J3NIO@V^?B:'_EVDL>V0(I,#A54^UF#Q$^]#[11.S8,@E/>\ K
MJ-R^6+5%-+RBJMRL^CG3>&E^^:OQMY K$'VMHOZJGJKEHEHU?-0,.(?8<,J/
M?IDU&=:N?&+ZUU]B)N*)=*3O%,^100AB/D0X%5VGCD+>!B"O*2@+#)7QBNR6
M(OVGZLA-I-IF^FPX(FU4ZM9;>\WSNIKE]BR/S)RG+I:2I5>X$$_.E>(Z;ZM/
MD5\F0+U>S9X8/4#-ZT7F?/+TT,^;?X)H2+#'[L&72]7:R(+)GD9OG;(U1YU5
M>ML[MVC"5-O/&#0S\Z!]&G+.K<'*.;!7-U7S7FL&BXRMDG'!TP^II^>QR<YZ
MSEYU; F/T3)#!VLKJ V/K'[.4+^I[@O04H$[CO+O:)7I_H76G(YHXXRH#D/"
MUF_J=[8[XU3;PR%LZQ CR_"-(2)2!J";J/J%R$LK6SF9C8ZGX=E-;*#:;DQ-
M#!$\=3HVEN3H$$23Q8D$:_<DKJP6=@\US+489HNJF%[+^Y5'HREKZJCWONDZ
M:_80W"V!<PL+9-ET/<_B%D@[" NFB1-B?JEJZ*F,R;34A\ ^*GB$ 4F$G[%
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MX'_+**/JWL)/;B.,%/AY+HK\\1 !QQ0"$<?RB/[ZKO..?@:R"=3/\@CL4Z1
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MD\O66?0ALEZ?^>:@JTANG<B7?S"K3*.%,3F8G]VRU:Y=NE"ET< Z!['#FI?
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M^DX<>Q,JJJ(#2M&::*OOI<KJ>DFLN/"N9.__<&(PMC3,YD$('@BL$8'B)OL
M@  @ %C<DZUD0!U<6> 8."X3QP-=8+L=P!C1J:-FK$_3>;*KX!,9*Y,HG+(N
M:8NN&6ESM+=B6*40 [J1KNF[R$ 6>I'"LI=OV0'@=<LO<L_J6-G",0 +@ 5J
MT,Y4VK:NZ>*L%<PY@ P@ \@ ,H ,(!<O>.B:M2,8?KG(@%U[1QA\(8GBSJ.(
MM<Z9T5^%=47G3HTD-%76C%.)51:K<]E]@1.#L=E'(AF\<2 0B60 ( !XD@!$
M(AE<V5;BN,JPUOY5?I*2P, 2.+*]TJ 7"BQWO9;3&86]M:5G2:E2&.6)49[R
M<KHFLBOHT5('J<,K;-.44' V.%M\-$QDKSW,7@;=@FY!MZ#;[:D^>K<OC]3A
M(H.SP=F-4EUP=O6<;9@"N_.#M$':(&V0-DB[7-+6!F5M,(*TR]UA_"EATZXW
M_C[W=^XQZ1V2CP_IV$)-5]___-;8Q/4GSYUEC;Q8PPU^%B^@O)Q^SE\F"*.I
MXZ^]3(W]9GEB_@R*2WP_^\TO[]1W_#-]7^[B\P:9WWI3$BM?R)-R$TZ=5R9A
MZD3W7I#>I#-/PL47J8+Q;YZ\<?+P:3#HVJJE]FQ=[U&AV-;[A5[1U^0[LYA\
M6OSQ\TL]63U%?K-WE0FA;LPPV'^_.+U#O?=^MS9O1&EZO';DX7J]E\?#X^'Q
M\*U^^(,*R6J8/'RP&U'9#.*SZT"A)_-97_*#ZLDP[WEO6?\MB B]AW^3L?*K
MXP6Q<O8YC&,2?U#"0/E.W#E=<7K41QD^.I[/W9Q)&"G?'>JS"?*WL1"'XHI6
MW LG?E"NZ"M6_D+&]Z3(= /H*G15O*Y.YG1I.5:^)TXRCY5PHGP+XR0BB1>1
M*:NN/B<!F7B)\LUW"LWB@+9"6T5KZRT]1^SSL3#*</S/>9PP%8560BMKU<HP
M<?P# HR'=N$]5)A-C>>^7>(@K&=-N?5/$HI4V'90FS=UTF6_*JXUTDEMQ8C=
M,8=]!H.!P0Z25%\3GO!9O\K4F28/+@(7@8L.\Z8,@6,,X4Z!PD!AH+"**6PP
M$)>+#0H#A8'"0&$54Y@U$#> #Q169L"_M6/WONYJV:W<D4D8D=Q</I?O_A79
M\MN[<]HA9"E;C[,4V@*#/0<A6W:]@_]1PH[QR<!+$]E@"O%2(*6U2#GKU;Q*
MAB$"O%H,KT&OYKP$X OX:B^^>N(")&UQ\Q#-V*XNPVDX#Y(X%ZP@8V42A5/%
M<=WY=.X[":EK3%D)V;I20E;K&J(@NTMF;8$T3!]P=D"(L:]7!S7XI@ H %I(
MNVH8RPV#"+P!;\ ;\(;8BP@'4Q,W:?JT'4@,DF_ (/D2#&6CIO.EJ!=8:%G*
MHO(T<M9@D0%LT9D FKC-%" ;R :RI4%V65,) &P &\!N1W81D UD ]FR(%OK
MF?#&)8!VC<W@9)?AUGYO)>FMH#%"LHNUNA% Y0FKTG!D=6.)3WN/0C[6D\[+
M 9N!S8[*C54KG!^)Y 3P$G@)O+17/[@^W"RX6: S6;4+=%8LNC:PQ/6W!)^!
MS\!GX+,:^4S737&9N."S?7<$,'\:\Z<WG;39LV@E.QP/W]B[Q\,WY>$Q?QKS
MI[=+_6U)2SK&%_.G,8^RD8J+^=/05:ET%?.GH:U-T5;,GX962JB5F#]=8SZR
ML"9HY=8>2"A2S.K95U+B]Y/KUQ@D[<F[*PPJ A5MW0TV:AXNU&A%0V(+* P4
M5GN"'N9/@\) 8;)I%BBL0"F7Z(R\^E4&*T)P$;BH<5QTIO>Q(FQ&LY#6CE["
M(.E2Q"JP&R\<B9-Q)$X/)YHJ<.(ZD *DM!8I9YJ.J0X(KP%?I>%+'6#F.@ &
M@)6X>:0!7PAHE"M$S)*6 .JR]S^778EA:6NPM*<$3PR@!CP!3SGAB8&XB)P"
M;\ ;\'92>&L-GMA.1;UI+:WQ'S%_&O.G&S(9JU=6ITO,Q<*"LS4.</. /;"J
MB^5*@U'XS(!H<R J-#4(QA?&%\B6!MDBDY( ;4 ;T)8%VH96UNPN(!N3I$7(
M<&OGMI(6A!BB4Y+T&CU$1V I'4;HP,DIL=0?; 8VVR&MOL!R1TR2!B^!E\!+
MHE:CF+P*-PMT)JEV@<X*T=F@M+ YZ QT!CH#G55*9]:@:X'.Y)PCO?C[3S_-
MXX_WCC/[]-U](..Y3[Y.AJN28]YH[2*?FGK-,U/9A+E;=IU;*I5S/W3_^/-_
M_L>?7I_J?!Y[ 8GCH?NON1=[O 7;^7/NT_)X*OV B?B&3'YY=S725<WZJ_G[
M[>B=XHWI%XZ;?.P/+\ZMD6I>F;VA<7DU,M2K\[ZI::.K\\'5E:&^^_.+5Y87
M_XX!TYO>^%L#MMDP*&_RO,]IUIA0V@G;I8_/-H5,S[;[]4[2K7:0+R;I8I+N
M=JE+[T064U\J"*ETLSRSSH>RSL*(#Q8,)\STQ1[5'MZBM,X53*.3)]#">5])
MZ:HJKJF1-#I3YF8.F&P+D]'OZ!VS:K9#20REW:_@V3?+6C@#H5L0VMZ*4SXN
M5IG-(_?!B8DRBSR72!T%E,:@-#Y$V&POQ:0T6-WNKC1:5Q%)'A\FW#^VMSDV
MR%9!PV#,_G-)CWET?#9<?3VJ^#HJV'L9%1P:JC6\M%7#/A\.SK6KJU%OR**"
MEZIFG5_VK-*C@@@![AL"M(6$ 'LUAP#->B]_2@_?^#*'$N*;AV_H+A^B+_=*
MRZ6L2*(ZHL3#F(7C\H4CY2P_$*F7.%)_Y[A_W$?A/!@SBQ=&G_YKS/]740B_
M8B!DCZA;?>/.V?)*F-M59UBZ98DU#=M3DH*963X @K7'!FNG4Q*Y'@L'.3,2
MU0GIK20KS3J\H(37>51P+&B716IC#&B#0 U-8,<8Z140Q4GRIK\BKHW-]6V[
M=UIW(#AJ7;_*2+QSUUIW[2M]\H#=K1(1^F?,IADOM_&<^XB0*0N8'[+PV+G5
M+G()+-L>^P;'HHQFZMM$V!;8PH40A[<VP(J?3S-,3$:&@=M/67ZCDGQ6ID[T
M!TF4"65*V#(!MJQOBNS6 2L&*W9R5JS7-\1U.6P+4F#%-BO+]X<P2CXF))HJ
M8W)'3TO<.7T''BG'FE6Y>2D;.#=8.ZVC]WK" R[%Q=L6E,,>5H?5-D R=3D%
MSDA'O0+J%1R_'&T25: @@Q&0:7MZ9V[]$?O7,N_W;!"JWE&-095E"S+H(AP2
M>7>JT:BI$NDUE,'X^09JE8V:VD),0FNI]JF%VEY%=479Z/M\-O/YCK#CC[S8
M]<-X'I'BY517Y_;5N=X?]:]&%T/#.C?-P7E63F48QODERJFD*:?2="'U5-9)
ME11)=KC1Z+MOU)M',5DIQ62:)G<8K+Z:A:LP6HDV>2"K#[]3GR->?;RDEFN\
M^KBH/UM]@T*T&EX?"M%0B-;NP $*T<HM1(,*0@7+4<&]A\LA:^.M%IP.5:#Q
M/**WKE#_3'FF;IDRH5:H% 6NUYI+AWPPHR#%@OY ?Z _E7:F;F_VQ35S:DB<
MU E$*?:T9<JO.*'T"5L3. )+!CU";D2[O 2).4@LZS2<7/CY#(&)J2 -D 9(
MXP1(PQ3H@K2%-+!>VKI>8N/PE,3Y4:C>"VLFK)G$E<#U3!VK)CA <(#@ (D0
M!B64OHD">/ &> .\48@WM)Z!M=,;:R<QA2)[EWMLKQCY%H4N(>/XAKC$>R3C
MJRB<?G]P(G+NQ&3\S7EF9QX^.=&X> 7)^>CJ_.KB_-Q2ASU#&YCGH\M%!8DU
M,"ZO4$'2N@J2FJL83KJ( @^/"I)]C2$J2%!!@@H25)"T,UL:%225+_B1OH\*
M$JA@$U40%21'1KMNG1_*'0G(Q&,#&NC%_TW&K'B$GI_%2<(9'XA<)]"EV,G#
MGG =,C,K&)35EO@L;&SU\I&8@;"O\VI?1^!$*Y &2 .D<0JD88AS0=I"&EA*
MO5&,'V5;T<HD"J>\')_\8-.*8Z*$$RRJL*BJ?5&%)%OX1_"/X!\)$4:O:\ ]
M F> ,\ 9>PO#%M>FO2V<(3RY]N#,V"W)MN%T1H+88>N6BS!.KL+H]=DBJ@OW
MZ33OH4_/Q7_]=;+ZX<NSQ.?/WWPG*)R:V[O03=6V>E<7NM&[N.KW!E>]-#57
MUP=7 QNIN:U+S;7J3=#4&YU>BH=':FYSDQ*1FBM$C/P34G.;BH+-KP^IN4C-
M;7>H 'F12,V%"C91!9&:>V2<[#<G^H,DV9[Q// 2[!ACQ[@.F1EV=V\P8\L8
M!K5R^4A,0=C^>7D^RB;H9@O2 &F - J01E^<"](6TL"Z:4M)HS<E'Q])G)"Q
MPH: 1)[+_CQL';5\/+W*P5@%UOBU]6O5553GP<"7$&;;A;0V "J%D#9 =0F0
M J3L@10+_A_\OP)U6#%)$I]Z?3.*799=%[@$OI\PWT]@VC]</QBTTS-HN@Y[
M!J  *+L+S"Q4B\#QVT]7OL'7*\'7L[O"\AGAZ\&$G9X)TPPTG@)0 )3=BR)T
M:(.OMZ>N7$YG?OA,2+:M.YM'[H,3$V7F.T$I;E^5A3"RH7.36ZB)R^(Z6+9M
M 3FL875 ;0,>A;N5NX0&H %HIPLTD1WS3@1H1[JM6FO]UN_SNR1,'%_ZT&2F
MJ;P7S=MJ*@%.-[6Y5,T*JI;VEU*#P0RK66^PIE%0S,#7%Y@A HP!8\#8*XQ9
M G-(3@)CB*5N2YB<>=0E]=CHKYAU:_QXQ]HUTCM=]6ND'^*2-M0165US7,\T
M4^".^['"76EQLTLJ-PBZ2,,LV&9$C8J1ZIFF":R/VU-J;4$K\ E\EHY/D?6K
MP">"P0<$@[<YV^0'^YLH7N#Z\S']5WI>'C;F;KCB!./%3X3U!%M788.J\#B<
MLZ[CQR!?_KBI3!W%=KV!8UJ.E2'P^E*2!UV[?JE+H\.(2\K;F:@<6I5%\VKM
M:[2W:-M(BRD1#D06XNXD0EFT#GP'O@/?G2#?Z:;X+:\3YSNQD\>J&Q.V?4X9
M%0$]]=?)=4"7U.36^7&9KI3/24 F7E)XVIC1TT::K5_T+R[,T6#0ZU^J S9M
M;'1U>6$8UA#3QEHW;:S:H4\USYR2[' \/*:-[6L^,6WLD#T63!O#M#%,&]OU
M.NK'D(MI8U6'-H1I:BL5<JL*8MH85!#3QAJ;BY!^9*?YQ/. W?0*:0!%N2.3
M,.*I".Q3XOR@2_RSNS28\N%3*9I=KYF7CA) F8(4"_H#_8'^%),/DO>V;$:-
MJ#F,Z;/7"40I.N/(E$)W0D,Y.SU+X% $*30)B1WM\A,D9B&QO--P>LD(Q;![
MW;XHD8 WP!O@C1/@#;UC69C.B773OOIR%4:$7O"0]3E:"10LE.GH_;X$S03:
M@FGX M5AM0V0S$!HV&IU( 36@+63QMH W5JK;HQEM]57O2W8JO6X@A.A.P#2
M5*_(M#V "OO])&YV!H915GL4U-C#U4'-:3,"E*@Y-3O]GOAFQB=>=0K& ^.!
M\21E/*,S,'ME!:Q.E?&0=EXP[3QQ?BS;X"'=7!K+ \N,=&'H#_1'TG3S-MI)
M?KZ+>12Q9BXP@""PNN4# H/^0'_D-( MSALD8Q*)VXU%N96 T,[IE%MI'4,U
M!6X#R*!)B/"WRTV0F(50-O$Z54W7S*XF2B3@#? &>.,D>$.S!EUA';?:PAM8
M-FV;,94X"3ED<;XSJ?S$BJDL2YRUAOL/,[XWT-J IS2QQ!:750*@ "BM!4K/
M$E?#U!:@P,%#/7WM+J#>'0AS 5%,#\M7%5#;@,<4@::XT,>I5/<": !:8:#U
MC;(F[;47:"BC%U1&+Z>#NG^=B@0@WIC"8&IZ696,!61_$O4^,+IR&]U&@7F9
M@=2OKK<-4 J4 J6'I/4,;($;A4#I\7YU6]WJ$9F0*")C% 4U,>NJK78"11W0
M'^@/BH*JV?Q$41"*@FJ+J)UINB6P4<XNP:U@V>RD[@V2+#).'):T8OE(K$JH
M#WAY/LI) W&<U#;J =F ;$ VXLA&MU5Q*7&G3398XZ&"J>3EBM&UL5C!8D4F
M_^'TBCO.-%A,N.> 5VDNJ29N<,EIXPL>:0TE5Z?FDYJ(H,,IA=6LVVJ*[$75
M-K0!7\#7L?CJB2N\.&UXH<@*15:R0'MC2DC?*FMPY@&B+\01TB23PQMNI+5&
M!4CF2HM<TNXITY, .J -:-<*;4.UJZO !+01F3YH$:!XKT8HEJ.SH@;/2M\I
M0*;T^IWC5(_(OV_LX-J-[2YTH]+!W=)K,2KIY4V5Q43OTA)M,=%;ZV@]#1.]
MP7A@/##>23#>P!Z4U:KW5/DNM^;^*7'HXV_\_8:___33//YX[SBS3]_=!S*>
M^^3KY"*<SN@=!$G\=7+-5ZNWSH_+=*UZ3@(R\9);=HU;*I!S/W3_^/-__L>?
M7I]F1.Y>_(X*.&!2O"&37]Y=C715Z_W5_/UV]$[QQO0+QTT^#K1>[^I<U36K
M9YF7([5W<:GW34T;75U>75[8%^_^_.*MY"5\ZTU)K'PA3\I-.'6V<VSN<*JZ
MY.,#X92NZ>K[?8Y9XSZ5PI%KAA>,V0QH]CE_TB",IHZ_!FJ-_69Y8OZZ%)?X
M?O:;7]ZI[_AGJHONXG/QIWWRQLD#_9,^4P8!JMZ^,XO)I\4?/[]4Z=5-Y0,W
M2UC8&P-_^X=^TEOJ]=_OQMU&!L@>Z<C#S7HO?TH/7RP46)MOMIW9;;$VT#[*
M8UL^1%_N1L@NY4$2E2M%_NDII=B[T!^GYQ_&2CA11L0ETSL2K81L:)URHM<E
M"KQ!*KWY99Q=!PH]F>^%05QD7W#_+FA5YK[L>!WU(V(]RKKYE3"/"TMH\3NT
MQVIJ*Q5RJPKN/20"O25?+:#3C^PTG[R$7M9-KW QCR+Z2I592$42!F@Z67<
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M;@M68.*VID7V]$UK_U<FKDA[3YBX+29N,# $]DF%@8.!.SD#-QCHXB#4%J3
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MH6-8NV/MOE5F(N<AR*!%,'_MHB:)&0BN,UQG< >X ]P![BB5.P2/%!$R#Z3
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M 4K]#F*%(E5[4$&H8#DJN'<3>FS>[[MY_V4^)9&34!M4BOJBCR!XL0S%@OY
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M9Z43\63&^@875[?$Y4L?+^BV< *:@,IGR@6-WY(9WRFBS;)L^1L2; MP 55
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M'G5)6;FX$K/:\H]W?(*EFZLNIQ_B0B,L$=H].+1K5A<50FP7MAG!HU)BNYK
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MBS <8%BT[:8E;E,<^ /^@#_@#]DJ#8!9\]%4EAL)M  M+46+A=9_@ E@ I@
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M\:G_+JRYYD%)AS(,.2HHQ%(;^1S1IT=0;F%5,M,[JC'H"MLQE4*3,*U.0D,
MW@)O"919"3W-I= F<!>X"]S5;NZ"SP7> F^!MYK&6_"Y*A\PT][X5YH(R4NQ
MQN2.GI:5L?'2-FQUUFT78%"A<= X600'C8/&0>/D%]RQ*6UV6UV]BS":A9&3
MO/+T#E')7=,YA:IDZ6,[1023>CU#8"/XMB_(8!<$V 6 $)$1 !% E Z(L(8
M(4 (:]@X(&+QN&7Q^"O#?3 E 1:.HDVEUM<%3GIH.T)A*F$J82H!1 "QC4"$
M-00( 4)8P\8!$0O';0EF893<._=$<8*Q$K+.6XK#6FDH3"7(&*M)H="U>IK
MZ2YM!RVL)ZPGK"> """V$8BPA8 @( A;V# @HE1I=ZD2:]B3/&/M*#;V:G8'
M0"G,)<PE$ @$ H&GB$ XK  B@ @@-A*(6#EN63F.Z+\\.FQ(&9_$'#ENH4:O
M .D6D/:TK@ITPDS"3,), H@ X@D#$:80" 0"80J;!42L&+>L&+_Y3I#FJ<;*
M)(R4,9F0*"(,?M,9"6*ZF S?'M)]*&IW3+X\-50;IL!JD$-EVQ:XP^Y687>!
MX-+M,H ,( /(,,5 ,! ,!,,4-W<);9IM74+?AHGCEZ-F!E6S<3AGF< +/3L$
ML5+HIDPS5'8)^82&K/0[EF4+#.D?+-JV\"0<GL,='E CJ%$>:A2:I0Y>!"^V
M@1>SJ[%#7R^"0)KB2;,,@=?H;!I&5ZM?[M)H,1@7C M/%)YHS?',4W1(C^UD
MU\)X9OJ1G>:3E]#+NND5/GO.G>=C6*H<Q@=6&QH'C9-$<- X:!PT3G[!(0&\
MG)+A-S40R^ *J+ ]JUS-Z/9*%UM;5J\PH27Y'B MD!:J\<!=X"YP5\NY"PX7
M2 ND!=)J%&G!X4+[ V'1KPOZ';UC-NW9#8/8&Y.(=SQ0PCMZ(_S/<AKHH6!K
M#=1FKR_0%3GU4BVX*@*V5P#A^NTR@ P@ \@ ,H ,( /(<*H;O(9&_X,#U RE
M%2BM*)LD;:VKUR_8MK D')VR4F)!C"#&5BT#08^@1] CZ+&9]"@T=P:\"%X$
M+X(76\"+)08=3Y$8<U''GQ*'/OK&W^?^SCT7?8_DXP/A+*?IZONM-Y@[9HT.
M5*I^7#A>0)DN_9P_:1!&4\=?4V*-_69Y8G['BDM\/_O-+^_4=_PS?1WNXO,&
MD=YZ4Q(K7\B3<A-.G5<D^^2-DX=/@T'75BVU9^MZCSZ?;;U?* Q]W[XSB\FG
MQ1\_OWS'JUO,QW)7>M+;&-_?/QR<WJ%);VFG)F[$0WJ\=N3AQQ[?Z,.;??=X
M^*8\?+&-H3VWTZKW:[=;05NLYV O&LT\I5;D+O3'Z?G/K@.%GLQG69<?"O@0
M^Y?$5R_UMR7M4K-*HCID/8R5<*)L<T]&Q"73.Q(IAM;9^B-=U83-R< Z#EI\
M@!;_=1XF9/RFD&6[Y6^1YY*WD\IENV4O6"GTT&6](AIU^[\YT1]D1U<+V>[Y
M[#-Y)+ZB%3&#(%@0K&@]_$XO[TVHB*B FX2?KPE5GF;=\1W][2,/\33IMJ^#
MV;R9W*J#6\&MX-;B]_VW( 175<M5QMY<A:[&^W8U'O*IYZ4T-*Z&Q*0S C"2
MT!_H#_0'^B.G?* _Y3E.+>Z1XL0/"OG7W'MT?.H'U]H=6'99"4LI:WAB&#_?
M0!UTA6T0MB6A"V8*K '6>$,8)=0=@3O '>".$^ .>!Q@#; &6 ,>AQQ-;]H;
M%$ESRGAYRYC<T=,2=QZ5-R'S% -RL%O0'^@/] ?Z(ZU\H#_E^4ZZW5;?Z2*,
M9F'D)*]<IT,T;U=3T*-7;[*L4K2.I:G= 58H8.FR&NBV!BM8T0,OP ML"[ "
MK,"V-"5:W-X5SZ\,M\&4C1G#:F<OB>D=NV_!(L$BP2+!(@$OP ML"[ "K,"V
MR(,7K':VY<:$47+OW!/%"<9*R!JQ* ZKM598MUXRQA)H/S&: [.K 70P4C!2
M,%+ "_ "RP*D "FP+'+@!:4!NTL#6->$Y!D+GOT$9_11O >K!*L$H  H  K<
M-^ %> %>),$+ECM;=&9$_^7184-!Z,T%2>2XA5K$G1[(]'Y7![I@C6"-8(V
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M^0/>@#?@#7@#WH"WVO$&3Q(%KBAPE4>"2(DNQ%ZZBEH-. JHU0 QR45,J-4
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M(]L(7"/I?EM<6C.$MP^N7V<DSE-LK;?VCS#Z0Z&'S*+0)7$1?PW)]EM<B-[
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M?ZULS2YPWB#)(AL5<#4$P;4-J$QQ.!!8']XVM %?P->Q^-('P)<8?,$]W2S
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MZ*5%>=18N@$W!VCA=^*&P1C  7  G$):>/O@1< -< /<%'34PGF4/  X  Z
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M8SGT,CY[T(?0IRN,*;6(CV1*@B3F[YM*E[I%Z6J#<L"KR\%RPG*N64X7EO,
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M@%HOT5&#,E%85.M95"\'GZJI5)6;'P %0 '08P&J:2A4#'P"GXW%IUYBS!D
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MNQ8!R%V +!+F!T!N :3J&.6E4 <@+QF0:I&TA@#D-D :)9:] B O&I!%0F$
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M80'\I0_!$W_TED4QC7@Q"Y[Y\Q%;?V 2!M3LJMN=#.E"47C>))>G3_*GVS%
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M3=&ZI17RN'@( FF'(ZW]@,K,2,O!4320 J3L0XJMRUT9. %.@),][D 3P4U
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M=P7LX@-QX8 #  L"T+3+*]H!_ %_P%\Q_!F*A@40^QG$J+S7%M=DNZN5I3_
M"7!RICA1%%0( 4P DWW+B8)\@, )<+(/)X:-Y00P 4P000^T "U85)IZT>1<
MCV![OWR]_O++Y_^I DV7Y8%6<014XJJ%(R  L.@1K%&>QP'X _Z OV+XTS0-
M ,2V#=NV]]KBJFR75]@0. %.SA4G1M<$3  3P&0W3#2]:P GP EPLA,GEMI5
M !/ !##9'=&#O0E0 I3L6TS,\@Z!S@4FR/&7U]R7F"0N+<)@FDQB*62/S$]8
MA'Q_-9!28X356C:'QD'CH'%-%AP,TY(4"_H#_8'^0'^@/]"?!LD'^@/]@?Y
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M8IK<2?J7-P7:?F;!?>@N>/N?_;L@G+NQ%_BE2,%<"F%-M]:%HJG5"R6]%_'
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M(BE^""(FN7$<>K=)JNCTC:S.XL%5<[?B=9=8UOE;X6PMY.3YM"S3-[A&5,S
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MI!F[=V>=#:SSHRR?4^*S:"80IT>O^DPXB@+?9_1HD,21-V7KKW.G(K@FXN3
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MZT:.J^Z  :H-&F E*JHU:(!D\- #I,^&9M*C(U59&O>:H=&6NC$J6N10<WV
MMJS)HY$^&HQ' WEHVN,Q@=92%6>H]TW5-!LSP"*GI*T<8)%CUU:N@T7.<=NX
M3!0Z&&[C#!8Z:6[G  L<7:\/<-0?&$.G1SK='ZD#V1X.1NIJ-Z'FQ0"=:(!%
MSL);B<$BA^MMG,%"I_5MW \6.OYOY0"+Q!.TT9(I%*#01I(I%/'0QADL%$+1
MR@$6B<EHHXH6"O)HY0"+1(VT444+A:&T<08+Q;6TT2]:*%"FC6[#=P^P+6[#
M=P^P+6[#0K%3K531]PZP+3-8*-JLC<M$H?"U-B[TA>+AVCB#A0+LVN@V+!2Q
MU\H!%@D!;*-/IE!,81MMT4)!BFTDF4)1CVU<)@J%4;9R@$7B,MNHHH4"/=MX
M-E$H<K2-*EHH%+6-*EHHMK4:2R;[TC+B=K7A+!"O>4B2D=="2#L5LBA(P@G_
MZWQ&??#O__:!^5>_??OPT^#;U]\BZ3YT_:SJC4C+N4QZYCZYX73CXTG@_SOQ
M)R*_39K?313!]'D)[>S;<U>D2]M('VR*+#-O7O:F-9Y8Z,$3622#.XG-%[/@
MF;VDMA&/1LLR/6D^*UYY)Y;\1-3DH(>R]+ELYJ5Y9=-ZY,P-106!["&>29>^
M*]KK_OC#QE0=/GD%O 653!Y//-GW@GOF2T,OBD/O-HF#4+IA8>C1#R+;+T_S
MPV66?2_./GM)-I36,^2I>PA^WB//YAE[,^\_HA!J6GCR:N&&,2^+OGK'NV56
MA!,KD=E'Y7OIYY"GOUJ$P5U:)&CBSB9)F@O+S=*;O52+G_%D@;Q4GE N+JR.
MQ/[@^! 2F@=AO%XA=I*E(WJ=V3AZM\B*&..5B*PG36A$7KPJD^5%49*FI?H6
MW'J2>^]Z/J]5NEYQ;EGCEL/MRX)GZY)X]7!OFB4R%0FXF3MY6);+S!+J9DF2
MV?]R1LE2C4V]NSM255ZX)2O,&?+TD"(=^>WS2K6S[JQJ=&;?S=%\_NYE,JT%
M:7TPY>K@!>'RC6G%W+6:GKS%98/B+2\@>V1AM$SNG19 ))81J:N>/%[M,DAF
MTS03EJBZNW"?1;JK("L!)OKZ;N4HXM"K1#E^%7F !5;>TLW_LZR[27^_BMT_
M>,9@YBWH\V5-XSQR(8 )T*W5.WPIEIC-IK=*3RMTAQ3M;<%F]R7Y658N<9F-
M>NUEZPG4WCT)!?P!E4S"W[_M6L0WJN8H1D>69;$<J[+X43R<07KY[.U+86&1
M937F4%E">KUVZH1 P*ON23P?-(<5/:YEK2OJ9CK"3IIV;K:J[/K6O(@?@B@K
M(IE6NT\K/TW3I7UCF-,TN7B5]LIKL;;;7"FRWZI$2Z_SM#0M,^#-UHP5Z?47
MCYK$5U_8,X<^>UJ?Q]PNBP206]"E"$AM/);E^.X'U _^BJ'(7DPT]^Z9++(M
MJ<J(>G_?#]\S5J.%+XN4NRJ3NTJ$.DK"8,'2]2<E(^(^L52X&3I_9ISZGG,F
M[]5??J%??OK3CS_P3GN?^/__]/\#4$L#!!0    ( #.#0DJF^8SX7R8  .SJ
M 0 1    8FEI8BTR,#$V,3(S,2YX<V3M/=MVVSB2[_,56C_UGK-NWY)T)Z?3
M<^1;1KNVI;&5I'M>]D D)&&; M0 :5OS]0N =Q( "4H>P4._)#*)*M8%0%4!
MA<(O?WU>!8-'2!DB^//!R8_'!P.(/>(CO/A\\/7A</AP,1H=_/77O_SR'X>'
MOYW?WPPNB1>M( X'%Q2"$/J#)Q0N!]]]R/X8S"E9#;X3^@=Z!(>',=! _GAF
M_B?F+>$*#$ 84C2+0GA-Z.H2SD$4A)\/(OQG! (T1]#G) 10?*+4H/ Z!'0!
MPSNP@FP-//CY8!F&ZT]'1T]/3S_.$%E C'SH_>B1U='I\<F'D].SDX,!9Q2S
M3S.$9C;M X3_*+5_GM'@1T(7O.7QV9%X/0,,ILTQP3A:J0'\D!Z%FS4\XHT.
M>2M(D9?!-0.5 2)V*!ZS#&H.V$Q"I&\D*X?')X<Y,P*K'V8@15;>'\4OBTV1
M@7&$60BPES'^7!/4TYEL??+QX\<C^39KRGQ50X[VY.BWVYL'V4L.?OW+8"![
M#5JM"0T'N*;M(L<+ -8EAN.^=D,\$,J>7619"7@$@Y"E3PYS5#]R&@X&1W;D
M4!)4%-"='HEK6X+J/:([01)7%X),O4A#3AU$_'68PAV*1X<GI]M1D0]B.RI2
MN%U0\?$(4$^HFJO-"P_A\SH &(2$;J[YW^TH"R@M8;G*D0@2/PH23SYL0:+$
MC.%"3/OM22I"[90."[&D$%M_7SV)MR&C"'D7 ^Z0FFZ4="=#;3M:CI\40'SX
MO=TG&;?3"_)XY)$(AW33>DI3P:5_=)G+RD@C2KG7U(&:(F#VU];T^! )C.]L
M2$EAQ(_#'+@; ?#96UH+(P.2O[86 L*/D(4"X9D-%06PY/=ACJ(;)1@@3QK?
M$QM"<JCXYV&.H!L9#'G61*0PXL?V!(1K:D]!"B1_&6@ &)-0(A*/TH?K-<)S
M$C_ASX3)_I3:[7LX'TC/]%-B-<W^Z]&:DC6D(>*>5,'OEPB6%,X_'XC@XC"-
M(/[7 \&/W.--F]0^4/8HI(7B(%X42"9N<B)3#&+._GS N+ #F'#^+V?*AW-;
MIC@(PLAAG@(PL^6)@\# 47;6%-JRPT$8C[<[=3R!8,H;#! /ZX:>%ZU$#X;^
M.%Q">D%6'/<28H8>X0CS"!O>$,8.!@+JZ_W(%(I+RMHB3&E*J<H[W:^G)UPP
MQ\>#P\$E8EY 6$0A_Z. >2!1#TJX!S'RP0\"_7_^<E3%6OE>Q#B!^%?YNRK-
M!#AI8@"L#/_6<.41I@1+'J;*VEZ%ES $*-B])E.\)H6^._GP[OAT*X4.?D@^
M]*9:G0I.7DJW)\W*/=N-<@<G;^JM:6$*9@'<_<!-T)I4>W;RX>SX9$O5QM_I
MEU[_C!"3V*S45H RFL?C4Z5YS,%[*NOB[P[FSHS(. 4>GRKM6XZE_$<_;9E1
MOE;&JP%3HZH4UJI)57VS3&H1VYLB(QZC[3D^5=H>K:+Z;6>2;CJ%SV$$@FX:
MJN!H'$;OC-K)1DZ"KT^:N2!! &:$<C(>X1#'?M@]C,EB2[2V&$,M<!F]A5.5
MMU!".@ X]>1*>-\45A!&<XNDOY_M4K467S4.UU,^7-]WZ@0M6V6C_>QMG"O4
ML\L^T<HC/55YI':J?%.D0NH6?JH%SD95UCQ6RU'9*^^UM>!/7T"9I\W*K/E-
MELH\?5.F0O#6KJ\UYD;%?MA2L6^>LD()MC%G:XS&Z/-4%7VV5&?_(M$+LEJA
M4*0 ,R[Q"X)#A+EB/&2G.#T2<X3S3AGA9-BDIDKXWE0CI&!XU<7;V>H[YKGU
MG=(#,BBXX6U?_:(F/>Q$W>WBDW?*^*2-TMY45A1S![>G+<I&!2H<V5:CKI=^
MCE;J]@Y.$RJS9_-.Z=D8%=='CP8S$B!?['*?@T <7GA80AA:Z4F'PJ ?[LF<
M'4MOYH&+3IZJDNK)40T27(,8V9M.0C8!E'.UA"'R[&;"5O@:M/5>CJ:6VAK\
M4,+=UQ&528N-YQ> +:\#\M1Q9*E1F77VKF&$Y3@'9#X06 <2[9NVYHIDHAWH
M38'4K,%3.PTJ\I/>=#F_^C-"X69[]25XS!I[;Z6Q&.6;CN:[&F*M1M6)E8YZ
M-XXN(46/<NUOA%E(Y:EZ"ZNE!C>N;)VH]NYS/(,"HK[KP7H%PXC%&/J>J/96
MU5KIY:*%2;(6*XIF-(T:JBT8-FBH7VN!)N%:+RFU0=:HK]IB4I.^>KB*I!2T
M[?J1"8EQY>A$M2>FTU+_EHS20CM#[%_AD+NO(SPG="6ILM"."8M!/<>9^Y85
M_"G\%&MZ,;I! 5^/E',%*$9XP2:0/BP!M?"H:Y!FC^TGA<>6HABL(1U()#V6
MO+6CID-@MB@_*7RTNAYZZ9]5!6IK0#3P9MOQD\)VJ/31/[MQM5H'9 /A.<0<
M;3@)@,VQ,26T.5U"=;HZ13-(\ PDHIYKP3YF,6(Q[Z>JCDBKM=+3D$4E6X.\
MMU.:"7&C'NL3G5J/#>KME7(MUZ*;UYRY+_9>-='U;64Y9MA^4)3 S+[6>]74
M)>%[W)>[+J8HH1OE7UOMJLB_CZLEL0BLO=LBE-FG?:_R:1.Y]\^/O0:(?@-!
M!&\A$,*PW!Y1@YLG^&/%!"_P#"2B01%3WQ5A;0",6,SST;'"'FC4TDL#81*M
M1;!A1M.HHIK):%)1O\(-DW0M#HZ9T30JJ;8KTJBD7IT.,TG7VO-J@ZQ18;53
MUHT*ZZ%GII2TK:-F0F+VVXX5?IM633UTY! &V$,@Z)3FHH0VNW$G*C<N1=/3
M)!>5&.U]. ,2\TQVHG+A5"KIIP.GEZN-_V;"TJB>NOMF5$_/G#>]:&U\-Q.6
M1@7573>S@OKEN.E%:U% QXBE44%U5\VLH%Z5MC&(-G%8=S/39<@:U56KKM"@
MK@3SV\17EO1NYK\,6:/:?NJHMMY/A];QD!Z'.1PZ485#:B7U+QCZ$@$*< AM
M-%& ,6=BJ#8H<^ >23D^2S(%SS9B+@*9 \R/"CDG9:HE>#\E;1U.*F#-T_]'
M1119E'LO@\>Z%"T\*15PHPYJH:)2!_URE.J"M'",5,"-6JC%@VHM],KOJ0O2
M(OI3 3=JH1;TJ;70JUBO+DCKO1,]BD:-U.(ZM49ZN$U2$*IM,% '-<< 'Q4Q
M0%D/_7/]1]B'LQ#Z&-K<@%6",KNEJKIU1?">RKJ#7UH'-D\[JNIC12P]=4QK
M8K3R3!70C5I0N*8*+?3--:U)LH,]UN)HU(G"457II)<&.1>$O46NP9I-LJI.
M6UD3?33)(< +Q-D>,@9E ;POA/A/*+ :&WHD1H-]K%Y'2K$-8G3RL&V*\$TW
M0@H=+'HC+N,T=JQ>>3)IJJ<FOTG.5AY ,[)&K2D<@E9:ZYN+H!6UO5UJ0F4T
M4\?JR-&LLSX:KD=./*$61]QR$+-1^EEIE!+8/HJX@[6I0)IGJ9^5MB5!T5,S
M4A9@AW!%C:!1$0IS455$/P.51 KVUJ ,:)[[?U;._9D"^CG-L[B.]@A_ Q0)
M"7!K"#E7H2S 8W4E1CMTYAP#57)U >\ X4&*>9"B'J2XWU17EG4GT](:JW&V
M.SU1%!9HK<A>FJ4;CFAA67^K &,>5V>*<94#]U+*UJ.C#FH> F>*(9#CZ&4?
MES=0%:OT9IE[6;7>6"KMM=(>I7F$J$YGQQ=FE:H*YZF&>>'A&/^;&NLRMQYC
MUIC-0U!UMMM*J6^CM(42K .HKA]H5'8MP.JF[#X&8:UU8ANDV2(V!G&GJM.P
MEDKN7Z WH60-:;@1%;MDK=8_([06,FFO13T*<]:(RO%,<?V7+"&6U'M-\;VI
M)1T/%F.L$9-Y&_U,82:-2NJE66P2LK49;(NP47DUL]=.>7TT<UJ9VYJU)D3F
M=(DSA1EK4%K_S-;?(T!#2(--9LTO00B^8A#YB!OY]KIJ0F2.#%5;5AG&@J<A
M< Y^R+"^:2H3A;4]:XG/' ^H=K[:Z*V7QJV=Q*U-G!W:1GW6#)V5/OMH[QH4
M8&OUVJ$SAW"J?;AV>NR?";R'XCRS%T84X47IC_8Z,^ PYVJH2J^7X,M_O:F%
M_V%MZII1F=,*5)78#4KJI7%KE+&U76N-L5%Y-9/61GE]M&1ZD=L:L49,YCR2
M#PK[951:'\W6(\01Y'* ]-%.-65 LX%275^48!BD*/HK]0ZF2 EOGL)45Q=5
M==!3HZ.2ID6&N@Y!HSX4)D6CCW[EH5<$:F\V5.!F6Z&Z2*JNC?X9B >X$*N:
MG2X=5,":%_!49B)!TM,+!NLBM#86>A3F51R5O5 HHY<F0RM3"ZMAP-&HF)KA
M,"FF7[9#*U;KT+$14Z.::D>>C6KJ8:A8%[&MK==B,"]MJLR]4CD]M/CBQLQS
MP*$G8&-9I5T!:\XZ46W9222',X%ED*+IM?SM3;X6A3E#0;41%VOCO*2-?MI\
MG5!M;+X>1Z-FZC;?I)F>&7V=7"VJ[QEP-.JF;NB-NNE5,3ZM7"UJ\AEP-.JF
M5IK/K)M>E>C3RO7=#G3SKEDWM2)]9MV\>],-%\/['>CF?;-N:A76S;IY_Z8;
M+H8/.]#-AV;=_&RGFP]ONN%B^'D'NOFY43<GFGA&IYN?WW3#Q?!Q![KYV*R;
M>LQOU,W'-]UT6CAKPM2H)[LHM)<K9S49:Z7^TS::,V!MM%(?VZSL-*CVIWXK
MU7HY5(?!N!QZHLKT5.NEA^NAT8S!/R/.P)4H0</N2&BE$26X>1]451 RQS.(
M$0U^D*CZI8K5"M#->/Z %AC-D2=.]'@>B7"(\&)" N19%<)IB<^HK&-5)9P$
M\8#,!P74@QSW($7^IKV*M.T7NZW0&HW6L>H"S/:Z[.>R>"OQO]38;#5&3X]%
MU9!M])K^>E-L50'6#HH-5J/3<GQRIMBMLE#JO[4K\\O1,_,_@?4:X3D1CY('
M&).8>OE,/()!7'4!S%A(@1=^/@AI! ]D'Y@A-/O?X<G'C^^O'B:36[B:07HP
MP& %/Q_4'Z,@$")-$3#NL80HC,37OE 2K3\?/,]H@#ZA$*X.!B&G]?,!)AA'
MJT\^60&$1_R%8.%@$#=<0XJ(/Y4-_8@FZ6='%J3S<:\BO?;84=)+^>D7W"%?
M0*9@Q=C,3=8^M&/-W,Q!UKY,+RI<%)\X2/#-Y'Y\,_JM0G3UJ;N$3RCQ>?]0
MTU]]Z2 ;W\9W5U7IEY\Y2/1L]@W!"M'E9WLC.B?2\_BG_:OG-<0,LC&^CK O
M)A&R6B%9W/(>!J(&T91<< /*'85 )'H#ZBTSGK9"T44$\9,5P3R0H)NJ#&8@
M -CCS3P*?12J1(,P"X&H%V24#*$^J*BO_,P!]?F^='M <(NXFQ9RD22K4!G)
MIA:N"5\_EC(NDLF*#9\1J_-8>=N./S_\Y"/^?<8?CVJ<<HIX9][][%"C^5)V
M"3U/V7N7NMTJ[53K9/%S3N@Z)IC'%+ZL7Q8Q+D#@H_D<4MYD17P0H'!3YW0[
M9"_8F7TX4_?EEM+ZOR@I%#PEB38KIV_D#"E.;)('P&4PPA/^#?H[GR0+G7Q+
M+*[)1S\T>%?8,,3&\^%*!*3\?^QSKQ8OH&!)Q?DPP94):RL4W26UW62QC01D
MG"ZV^,X#XOVQA1QJB+:8;L(4S?8282Q:K44S]I7']:*>=Q!)L/'\%M _8"CW
M8!Y"_K&O&(4Z>6R-9I_2T(^8$#QSF(JS4GGHH(<<AARM:#.>3R"5!PKX?')!
M.0D4\5=B3;+*E W(ZV3YS)[EL_VSG+/X")"DX9I088<>H!=Q6N7VPBR\!6'R
MUW#.Z;]&CU :*#X_T1#]$_H7A.73^$Y0[</PM8HP.G%W#1 5LQ;<3DA%-.X*
M"%*P@ D+FW2*%K3F3.9B:->X.[-I[]_!")&D2BO#730/COFGN3 NN7\[PI>$
M4TC9+9^]5]&JPEY;&-></4O>$;;G/8-QC7>M,3B_NKN:#&]&Y?F^]M0]*W8^
M&IT?__2N0G?EX?XMD?#E[GD?268^RD*Q)@6IK-;-9\J,\N9VG9CAG'":/7'R
M<N<:  QYW)>_1$$40O\*4,P##\;] YF15(V'VC??>^QS+O=#1S[T_@979+U$
M :JLPAE;.-#K,O+D34 8Q(L;=S"BA'D(\HE$QT\S@(-S@:1>#)\I>2 S-,9W
M,(TIKRE9Q>\OD>@>LR@D= HI-\:$;E12V K/*Q%.LCB3,D2A%]K(I!7X:Q3%
M'7?;ET,^[R(/=!:(&8DKLP.<S[G:N"].R08$X88#PC*/FA:.3,],6 TR]\B:
MCTPB@/B/.0H9H0%A+/?*VS=WSL(BPM *2=>RV@=K+QSH5V)A'#(VYCWF$<$G
MF<&SJ2V -3=S<H$K)3LYPU!S;[2O]S5>M)Q<@-6,(I\'JL-RMU*]<&\6OP!L
M^0##,(!^82U*.I&U1?B6;1U4D9[NJLY:M'13B?. /#%Q0X/<,8+)YGV=O89V
M#C-'8]]1PU+U[?YG\ NQJQ=;QW$J[XDTD],E[T]+$OA3<@EYA+#BDYWL9..Y
M'DCN_4T)=X6P7TP(>/G/O)JL@@)7,3."6\[9-1_(40!J\UGKYGOWTAI(56^.
MV0(YL3%X(5;_9B1N62([9\O0PK6U0C5?Z;0+1*J5.&2JX*S>QK5QJ.8MC@1$
M&, ,>E.U<DUWAGFFP(G.AVUJY,"<DA'X" 'VY3V%<<H))WB)UDP3<W0!=#(*
MR5>%LURZJL=D:N&@KY2E:#*1%T+DX0^(Y>$272^U@'"@RZ[$I"@;)OFI(O"=
M1-1; @8G$E^!M5:-G> JXO[9 YF'3V+U'OM_ ]07/XN\Z)NXNM\K[CQ%/DPL
M-1=]G*!TR5WU@(<@!4TUMGM%M@'+%V+DY!E^U5G%V,;%>07SD2/F!3CAYGH%
M/,C)\4!09ZRIG0MQ6775DMNP\BJGN<DKZHMT+<PT%(DC>=+$141%JFU5=:W:
MNM@WE83?$6S#IZ*Y STU6LG3DX]0;HG<B/DPXT/]SK480:\V!?W%,P"&]PZ?
M E!173X'8&SA0I>3@X!;X$?$9.#2-C<]@13):#FONT&VET[=2?^7MY/_*<\W
MI2?[UZ^8]498G"X5SV_!'_#[D@0P4]$]]&&<4"T3LR;Q9AQ89)[H-@CVM"6H
M8?XK9RA)+)5Y&CR\&V/11,VJJ;FK#O@EG$,^D/PI>+Y!8(:")(UT32&/:05Y
M26YMG#(OXOB<^2Z@K\;\7$),5@B#D-!J2*Q^Y=RN5A(=R5&H6;TP-W'/E8N3
M7PAEXH;Q"BO*5P[,IXC)(ALBA>4>>F2!XPE"L?B0LV(#XEH:A:2>!WD;'A@M
M*%A5NYSVM8O=+<L]&V-8XT/USFDFID]$RT3QG8-,$$_:V"'VKS"G95.XC:0V
M/;=KN_=5O<LXS?$K]KCC2P)YV-7_;X)PF&:W9!RU:>F8BZ%5Y=7-^&(ZG%Z5
M>V+MJ7M]\ IXR_SH,A_TYYQ&_OOK>DJF3QQTDSRH<&8-YB+KY?1QS5Y!<[.]
M#[JK-,MRQ ?3"G+G-;6RV!-IY0)!MLD1EM:=,RZW0K'O$*<-];< 1W.070@M
MXG%+_K487/-6KM!B&<Z4XU;UQL&AB1A 5<J+CQPD.1"+.VJA*U\YR,)J'9 -
MA.<B;QN%(N;0;:"V:[K_B3$A\T&D"2<IC;(D=3'JB!,=Q4'ZD,1ID,,G0'U6
MY;4KDBVD()&^F)[CDXCIQG M^&QNMO] -/:%OW-;E"^YC>>%\S:WX/\(+40$
MN5:[0.[=SOT9<:)O8;@D/'1^A/$>ZO@)0RHR4').*L=N.\"YR2H32P0>#Q3R
M##AH9E(#X9S)EL3K9EO-R_W/K_Q[*Q&W%>H\)46/OJYY8.HM$1]0<=&'PK*<
MS+FIIQAE[.X:JV-19%U\A>7FS1A_Q7XZ[>2'7,?S:T(A6F!1'![Y"%"DD-@6
MB)P7$C>N\RBXX3XZY^$&<F,DLKQ'JS4E<6^HBZ,5R/Y'43)#Z8O<L3'7EN=!
MQC@[I?Y_#Q=B8Y703:G[RPU%Q<CZ5WS)V8[4S/SW)>3>#111[@6DHF"-9"\[
M4F AQQ:H7!?4#?=V,8/74"3>Y>JOL5J5B@6<RR+@+(RP)[;D_?--*:^YR+"Q
ME6LY4U7^[N$\D"K[CL(E[Z$AGS3C66 >KX-4.&W3WC6>M2[7]?!V\OM]Y?QB
M]:%[4?KUS>BWX7FEVDKUH8-D?[T=7E[=WU;HKCYUD'#@27?JAGCQ;DLA74OS
MSN%4K2K%Y30M[5L'U8(PGQ2X Y+GJN@6J]HUW;L;F+KEPDVXASSD$WDH9$K1
M8@%I9CPSIMJV?CWS<;0":Y$_/5Q4)@G%"P<[9!1&%.9[))D.!,Y2H>=6+5V>
M0XST5V:4=FWWOY)8)31Q4ODP&_+/@. [X=)^0CY,2[5,ER"\>O8@]$^/D\U.
M'=,=<;W@&E4;']B:"['YN[TLJEC<E$(M)&S1SK4TP0J/][)$C[AH*UL.GI)S
ML0<*T:.XA$BH9SQ/<IG+?%O#[GMY.29[G5%;*NN3%8I(CL&4>6T/Y :3-+FF
M F#?SU=+O>P(9)F[%JT="]JU=NK+\!^_?ZO$=Y5G^[<[7SB2='C<B]WYK+<I
MW[R>0P%?1$*D+/C<< :K34/WW#T5U;K35RW;NL?D""=K>?X$A+!VHE/_VD56
MDKP>[:%P8XN]1X><.@IEU@&@=,,QIE<A/$","$UN*LXX:=/6N;FDP&QR%R(4
M>S?BY G "\1I'3(&0Y9NZ\QASG%[@"YL1^Q0_&!9]>R'EPFMJH0/L?^%$.X?
M!T&^UZ#MOYU@'>C99;IY(!1$XNJME'IUG1][,"<J_:2GJ$;Y_NNFP)+JW;[=
M2)%,@<4.#A_T7FRSN'?()9/\D9/?V,XQU['$8IPO(BNPAM!;8A*0Q4;D> &,
MXA!]2&%64LP7\4TY>?T;H$APEZI1IABAXK3\LA]Q3+B&22Z7@XX=[1S7!=2!
M*2Y+1SK?3)>(<H>)BC,<\KS#-_Z<1UY#$3P/%Q3"5650V8.^OJ[ ] K5=X)V
M0,X=8AP1C%BE5 CWV7ZL>-=-K1QTLA4D-S.U?X8R!HJ#2J9'/I32(XLC,.7(
M#L2UO,,;"'SUF4;EF_UK*$MONR8TN_UG/!_'UZ')"U6@_Y6' _6IM!NHLZNV
M>9I-SF#AB6O[?CG=A+&\Y-HFKP55N& 7H%4<LR8#*>.P&^Q^]A"T@ZZ:6E[<
M'-2\<W@[L$IQ>0-0^]8]ZQ5?M97?FC@4!\+X=%'U/UJT<\[EJ-)<GNNU;UU5
MDB JSHK/5U15+!G;[=^8)<<MIH N8'@7";K2&]]R922&25[I.<;Q:9R\3/L(
M5Z;('>/<]^)#+6OT%OCP4A[!G)0*7[9IZ*Q-3*Y]^SN/6]%<KM@NQ$6(BF-V
M.;L6$-WYWO:V0/TXCNF_%UYR4*C'*OVO.X(](=:8;)FX7XL"MT&P]P6!A/C=
M#OS=XG0M4KGEU$<SQ)9H"C"8):4VT\*&J'KHMGUS!VT<H>&"QX[#I,JT7. ^
M!]X?T&_82^T$^4H%H-MM[0J\?W?@#H;)()8S5O5\A?ZULS&JAN0I5PL$XI[*
M!MY*#5\;E^*0Q BG=Q4W<%IK_$JY)1%MSVW>^'5R.\;M59NW?9V\BDS&]MP6
M6[]2?I](>VZSMJ[QJC6QXEY6M%I%U1)PBN?N^0?R4MDU")?(6W/\"/LH/K#"
MZLPTM'.1N:<A#M&%?WI<Y:;^PD'R$8;*,CBJ%P[X7$1LKX>4<,+P B6[B"C-
MH(+Q_Z18)-8.Q+DL*[WF1%X8G]ADW@RYCE90#)>*$LUM'-!G$OA>@@V[)O0"
M!%X4W]$SG@\?(>6!P45 &%=<'/R*<LT9<]U@][>Z4N/ZZD^1^2 /5L@DP'+\
MT-"H.Q]B#"P@W1D;LDK+>;7&DJPR-8DHB[BQFY+O?%9?QE66AA0FT5RP.8=<
M/V+MK\KVKI Z)B8F[C5<K4B\F,.[[8@)7NJ]NK&U<X6J..7B3$6]6+7JA7-;
M+F,^M +TSV@%9N4Y5/7"/3L^7F$TBV3EZ8I7I7SC( -95=(*^?7G^S=;<J4J
MSD!/:BWP@".C6//R];@6DH/BT:*T8'9%-8W-'.QF46@\)&%X[T"W$P=3Q-DB
M<9$P9=R172>%_D": L.2!7TR#TG(NX=,MLZ8ZP[O6$[&Y.;JR_WH\O>R\FI/
M]Z^R"4@3EXJ^>$:P[JUK"Q,%?N*#LI"NN',R].0M 2P^.5KFK+'=WK?UTE6A
M>QA&%+/A>AT@Z \70 BBZ1(@Q55".\3G[-;W5CS*>[MW)K$B-G?E52A7JKK0
M_*9TIU_KUOO.\V@B-"[?R:X19>$UFH>BG%BQSL 6\'NN,-"2\B\4<O>!3KE?
MM*T0&E"]?GG$*;WCO%K.CG&ZYKOLBKOI$ZF&VB^$>_^F>H=\/42SE^MQ=?S_
M+N.SR)G<+WQ1V:5?^+>4WA-Y6=E)_ Y)+DYKDY'.)+F7I;2PJ9)&"Y@M.)3X
M=CHK)=O-^6FWV*=5LJ9MZHY;ET>FBHH%S<V<Z7QYQ,G#4'D+* ,!+)[8B$/3
M^'*[_.!N :[.]6Z0NN>6I(FEBC,'VK<.++'DI$6"-) <\% 7(FC=VHGZ W$N
MO)CX"J6*:T?E&ELYL.<I]A_BT@_7A*87MQ:W]K(S?N)ZQH"P*+\KHB.L8\>J
M<U$0L;",0!#7\*H=A<C3XZ<D/XXZ7*\I>9:5\H/L..MN4+F[VLC]'D'K(PA0
M6JXB8UW]SEFE4[A"D?B&/."$,N-?X$?;P-WE+<JQ/^>7M7"7E0]1<7N\9O9M
MWWZ?\Z_>2%(BZGZR^,JA],R:N&$[3U:OQ>1V,/N/M=/+HT3"3,GGEH=UKMAZ
MG;'6JJDS'(D*D()"5@HZ-"^=VZ[-V!%W'<9'Y>XA6LTBRF2#[-R<9*NIT=Z5
M<B^:C.?E?)=DE3\^UU\\0->Z]?[Y2J^:1)C*.JL;#I2Y,MJWKAW@4MP$4@D)
MC"WV'Q:4NOT%86%\/T[M)&J+=@ZXSR4J;Q!WZN1U'CS Y(. !%%8V%=HV=;!
M8Z8ERN/:'OR7+[8$DV FKA61[I173>T6\ [,&W:TJQVLK;$X$?8V<Q%?'-B>
MZZR] WI>R<,-BRQV*]R*5PO@Q)U,:;7N,:Y<Y"4Y35(LS"L$_^J/.NP\)?EJ
MG,>"",2\+^HXKM>$ALW"W ;%OM=X[Y4EPUE\72ZK\JAMY5I(:K I<>+(M2QL
M$^<A<<T-@X \B>_5XC4; .?2F#GQO//):QJJWEK]A7OIF8)*'DMR9Z6YL$_+
MM@Y,^.(>H^0B>B#NV)/%K\1\D=[!=P'8LGI^W![,V66\*BLT9L7CK,"$E77A
MFH8U8;+^,8,!=UZQ:*H32B=,[H5:,L--+A"5R\?*:H7G$4,\M%+,4[9@#@R%
M5B3K7-MNP(YXM#'Q6<T6WC\%(_*(Z.7IL2B= -:RQN8D*>-8Y=L.=/]N1DSU
MG%,*$DK#G-*UALGFYLZYEOIQS<EZ!I7S+-6'#MI@XBVA_/87B'E+Z"TK+!@:
MN,B.CW!AC%17L;2O761%KAAR9_0.IGG1<B54+/:*@M.04B3O?"Z4J+0%<KAV
M96M6RD4M[<$<6+V,:1;>'IG+N'O"K9VWJ5O%%@V=W$I[&%^>E(=BZ8E[H^]A
M,KJ['_ZC<D55[>G^^TY\26%\MRC_)&/J:]&;F[T>4_O ?8,(+\X1=_A7* "T
ML/!7TE9S.P<['N"QSHIPHA\\!,4*1)4I[7L'.B/W%?Q(W(HFHM4'&(8!] M)
M6/%.WM"8L[4E#C>GOXPGU4HLMU6E!<0;'MH($EA=)+;@SBU9V;$R+9XR[ ;:
MVL-9;D0T%,W@KCT<!>^Z,M5-(Z(UG!-A<$XW#U4Y=+@1V_8AUY2H^RS5E][^
M]0@UZP!;XG!S-H +T> +%&'N>BDNVI#$R#V6"//.!IE\(,_<5Z;_;K .VKF8
MD1&6\[H<L>I[A=HT=&^:RQ/D1=W(B5BSFCZ19$WG,H+3)_Z_N.V"_\,;5)7<
M$=I%->>LD(A*5OX!*9%\5?A)N#**HP,.IX7R@)XE/U>B4L.#"%=57,FW$&*M
M7#JB<5HT\E28Y(ISQ[N_7MW\I58RW;"X+1@^%0B&1-4^-2MZ:;0'=2":@,*:
M_3:AR2$ Z?=463,U<5&+?&@J2S JWSB@ V5EMJ34T0B+>SWC@T],[ILG+_+(
MI3/XJTDYT->N*R[,-K9R>"563WMYZ;5%.P='9$9T5MA<XX>V:+CW/=?LZ&QV
MNC@Y5%SB0M/ N17 ,EM,U$-,\K_3NU3B8I_IP03^,4T4V1W>S0B2S)#8SYB*
M=< %Q&-\!T.YHCO"XEVVR5&Q,=9@#HY7,WNO@X6 A,N(5CV VF,'21?C)2X\
MH,O4,C=Q+U+/R94>B&YBJ.C*%LH!3RX4AT\6R,M+$4P(#>>$>YPY6\8VCAVW
M-.BTQD9U%\74PL5AQZTUMZ#/-2XJCQWH9M%JQ14MR@#&@S^__K.X/"\N9XCO
M5H]7)<IV5V/%7P2U&TOEUJS)>'%7<E(C<TLRA?.F#6R;6KKISJ64B](&8B,+
M4"KN#4RJK8C3PR,L<F'C QM5@]L5>O_12DJYNOIC<7T@S_\\CTW&PQ+"4+=I
MM'N\;O<;XS++D#'B(<&B&/&7:#Z'HOAHFCZJ[4X[0NJ>Q_?$329;CNEZ"3 /
MA/@,R<=&Q;*:V[CG(4S!<W*OJ)P!V#(N/P1]D3Q<=,DKVNX YYQ"I]";(Q[4
M5^Y#J3]V4&V:U6#%\_V[=N(<X'@N[]C*Z2P^<N#HM"!(%'<H^#F@>J2OH8V#
M1Z7E)I;RQ@3E&P>Z2II8.)[GV8;C^92<P_C$O;"^$\KG&E^4=WZ"P2,4QAAZ
MG,I'>$MPN(P/G]:J=[X,:G?7/I7\EKD=XLWV(NR,TF'1H16,ZSI<$SH!&UD?
M)3D;G;A[EU$NE;:M79CF.*W?()-E!O4'(]7><4=8)SU@,R^5J;)=6P<F3W$9
MAY_L:'M+<6DX ]A?4[@&R _!<[Z_VJZI8^MV.:,;!F845=14>>B@TQ93F 27
M2NJK[_;?J<2TS=!"'HLU952T:.>>1O@(%G?<\&F+S"<08[8)'@%&H,I:0RL'
MM+2>4R+36VMU.L05=Z45O$=1D#?$!?XZ CLV/6BU+!:TI B%VP)PV6Q5XMJ6
M;?>^!/8=RIP\/[G#,O8_IH1'X62!T3^AR(P1%P;);0K>3%Y_F#+9%=@!!^8[
MPOX<!$&^_B"/>G^3M[4NQG.IK9C@JV=1D(8))[^Z[<;6:]&-D8?6R2<3P;P4
M=N=\7>U@^<?H[OS^]VGE %OMZ;]NROOE2-#-O"7WJ7_]R_\#4$L#!!0    (
M #.#0DI8ZTRX5#,  #1* @ 5    8FEI8BTR,#$V,3(S,5]C86PN>&UL[7U;
MEQLWDN;[_ JM]SG:N%_F3,\<69)[M,>V-)+</?.4!]<2MRE2S8LN\^LW0+*D
M*A4O268FDO*L'^0J*0,(!#X$(@*!P+_\VZ=WTT<?TF(YF<_^_ /]$_GA49J%
M>9S,;O[\P^^OX?'K)\^?__!O__I/__*_ /[SIU>_/'HZ#^MW:;9Z]&21W"K%
M1Q\GJ[>/_A;3\N^/\F+^[M'?YHN_3SXX@"W1H\T/T\GL[_]<_O!NF1Y]6D[^
M>1G>IG?NEWEPJTW?;U>K]__\XX\?/W[\TR>_F/YIOKCYD1'"?_Q"=?"+\AO<
M?@;EKX RX/1/GY;QAT<XPMERTW>+3FX___3@^X]\\S6UUOZX^=<OGRXG^S[$
M9NF/__GK+Z\WXX3);+ERLY!^^-=_>O1H*X[%?)I>I?RH_/_W5\_O->(G\YLT
MF\04_A3F[WXLG_SX.*#DU],B]!>KMVGQ9/[N_2*]3;/EY$-ZCK/V+OTR7RZ1
MKTWS;Q<I__D'/YEX% E5E&T%\K_/;&;U^7WZ\P_+R;OW4Y3.CX.S_S2MW&3:
MURB^:6VDP=!^1T/'&LX;YZ>IKZFYWUB/0_G'>K*<%*72@M.'WP["R-V?6P.\
M%7DM=EM N!W]X RW!6D;ZD&8W4GD3?JT6KOI.8SNI^R-R2?SZ=3Y^0)WY _I
M\6R[>E^EZ6:'7KZ=O#\IU?8M5&3Z]!<[N?+NPSN_KXJ":*EYSFZH_A!.:J/S
M6ZH_"-;;(-AX@VBIQ2YMK^* VNT;Y[;3XP#>O9NLBN>UQ&Z?S&<K]-'05YNT
MX?DD:0TVC_Q3^V7=1^LU!MM:U[9MH2+3K=?TF0W5&$+;5=RR@1Y9GBWGTTDL
M7M%/;EI" :_?IK1JP>H)PN%9?.D6**FW:34);5!Q3BN#,/]ZA7]N)O=%?N*6
M;W^>SC^>)>>C#0S/\D-_^6+F#S<U^#">H=^R^GPIY_>I!V>VFY@'DNS3M)A\
MV!@:SV?+U6(3=CV)XZ-$P[+6<L]K0UN%T9/F1BOB*JRVW)+/:&)8MMMMPRU(
M^V-S=VZ!^_TSW.Y7GY_/\GSQ;F.WG^2S!6UOC#YSBQE:(\N7:?'Z+>Z9IY@[
M]/U@#+5<YB?(!F.O'?2.4_7''+8P_YS23VF6\F3U$NVATZP=H1F4L;9JL0WM
MH(P>8> 2WELTU]]P6EE% UD_VV;;2FK?Q\.PTG)W.T;3,V,ME<B>;WMCY&<W
M6?S53=?IU^26ZT5J9?T=)1J6M9:P:D-;A=&3:JX5<1563T:*6Q%78;7E4CZC
MB6'9;K?06Y#VQ^9DYF9AXJ9G.'W': 9EK.VB/TU:@\W32[X%;0U&3R_X%K0U
M&#UY9-J&M@:C.Z72!0'?-E&1[2YX^+:)0=ENJ4Y/4O;&Y%_6;N%FJW2:J8=?
M]L;$-C[XQGTZS<6>3X=@HZ7>/DPQ(%,GU^@1D@'9.KD&CY ,R-9)#7R$9$"V
M6MJ!)PF'8+&=DCI(T"-+,?E5BK-T.FMWW[>#,-):,QPD&9*M%KKA,,V0C+7&
M^RG*09ALB_A#%#TRM7*SFPFV_7BY3)O3][_,Y_'C9-I"="=):[#9>GVT;:$B
MTRU63^LF:K#=%K8M&^B1Y0]HLLX7)^.X#S[LGX76>-S__6 ,M5:(1\GZ9Z\M
MIO9^WBL[RVT"TO/97]UB4KI!(*<%_O7FC+%%7M]9C=1E_0Q4GMM6;P/Y!5N_
M:77^^_#+ 9AH*;*#!+VQM+NT\S75Y8N[_B7G9=OU*5;/;JC^$%H*_=+V1AM0
M2^W;L=GZPVNGO2]LKK?AO%S,WZ?%ZG,Y2=XDC?QC/7E?>CW%^$G"X5ELN2+:
MTE=CN"7BSVQF>/;;(;HE>6_L_L?:+7 7GG[^LG*>NI7[?>;6<8+KZ12[+<EK
ML=L2T^>U4IGYEOB^J+%:0VF'];,:Z8WU5ZD<1835>C&9W=S[Y12_IRDK,-D2
MXJT;J,=R2V"?VTZ% ;2#<UOZ'AE&WW6-),NT^-"&O[V?#\5.:Z >HQJ8N9-Q
MLA-D0['7%G!'B'IC[76Z*?;'&5G4ARD&9*HEW$X2#L_B2="=IAR>R9;*NBW]
M@ RW6RNGZ/ICL"29_^26*;YTGUOE=!VF&)"IMLOE%.'P+)Y>+B<IAV?R9,[
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MM'^42A+-7BUIA\C'J-<UAH1;1QG60@HJ]9V&?Y%/U #_]M-&1W1\HDT(?:G
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MQ;SXS6KJ^P7 397E_[GY=511S##Z^/TBOML*.AU=Q=.__1R$BNIV%5ECF,-
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MZH?6*JNV:6CM.+3^(*$U;C0FS&E.H3?4YB4*<0&*H;UF4W4;6JNL_8JAM>.
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MT.<;V\FF=\K[8.,%GY13AR2'BID"$,]AGP;QJ=/2*G.C4C;]<<"^_<SG8']
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M >*DY\*:8(58H4*'I+!L$"8-CNAVMLW<LIH:H'&*D**F3DNGN$$$4!;L4BE
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MUE@L'/*>"8<YM,JH0D**<8,\MW,);C3%I*\ _V5XV\7UDWVODDW"G<]'TG%
M@M&KK?98>^C=-G"#N>/U0\3'^P/GNDO8!K!]D>8U/J/=D)2>?SBRIT@[S0P6
MF%OHF*<*.[W%@S")AKVEV%#'Z2FP^Y-3@]R5'#:5VMJL3,/\_&N6+N_SHSZS
M13R^+=FXW-<@0DH*112C%!L"!;7>;YT6"=$ -S$[TTG: 6#UPX_C@..H)/CX
MY)G( T.]@3Z,U&-OE/28;"D.Z !/T_:BR 88U=?=U=7OR?X3L:^>B3P-D]#J
M%D.)+39:,UN<&A'6P &>>^U'=_4QJA^>_!Y/DOGM179_.\HO-/V6+++E74G
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MV]%01^KO/[5>5ZASY3="YG33P:=X$=;!_Y^]-]UR&U>RA=^E'Z ;\_"M[_[
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M@W:D55#(>.<TXI1X)!$!QOMFGMK2"<6SYA#6LQLAN8#I[0*[&\)_=)1H6Y-
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M MO3FAUN%:25!E/F@?-&2^R,LWLT5?QG>N;K2'(\Q);!F)V3&Z@7-W:M@M5
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M%-I"3_?/I%N4P*0\)P9BBXU0!+#]')#JO_2??D(X-:.E+TA%!=VZMC]X*D"
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M ,,44\R,M;(!A4O=W\-W.CUZIEGH*>2.Y5M/PZ>T;3U.2<[DF122,<VTU]
MQ!!J/CP!-)]V-H;!DCRY-F<_O'X-KIR'(SW+MYZ/(IE,R0%%/;45"FC+I;.
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M%!F'FD2M'E-IG,%$<>?BZ@7!_E-@U/8W4<H[-X?+/A-*9S\"4Y>7=VG8^IR
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M>J*'9'G$UKE&:C^0?DY"3.J4;6(\R'7<]N'-NX_JOU3+:=NCIX*BDBNJ-9#
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MO*O6;Q87]4V5ZFRK]7HY_[)9)R?^YSK5TTVY*")$D??-F<\1XIS<5^ *8T!
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M[3&J-,WHE1-3/TCI(X=3<MB=!L\@X;)^PCW2+$@<B8ZM1!A)P24W_E[M(72
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MA!^++\M5>6:_\A)3),@7OCU(9+''DC&)F4)<44'- 3MNJ!@R4VM#P7%'MM!
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M)<M+3F155PUANMO<VRYI%R1V D;Z,=7*T2]'A0_;U<WGZ.67S3K-X)G' D%
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M(/ *(0IMG/:ME%C3V$D(1$(@"ZUKM,W;M[SB;#/7Q]K97%+1\AL!"@$@@50
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MRN5Z+U4#S+WPC@ H$)&64;9/T,1\'"MI%C?L3D&Y3%&<9)CV0C I!8D(*GO
MD2#B7Y-RN;')]*9<O@SL5ZA<QL H!+0&4$O.J8E,\!H K8<4UXVDI&EL B>5
MRY?AF(UO. 'Y)W98<FTBCI8Q)&-#@:B0=4S@O/4]B58RA XT#=@WT^T.X2SE
M2Q.VV(ZV8WJ],97&V@ID$%0"2L698LK5/H\U&5UWE@>5%]Z[>AF\O9C(.3E.
MDV>#$1I0B!V"P%ACL6*'H\BQ'8KRC+0,(ZX'^H(SFSGN5:6,=<I##BU45F)J
M@=0>JHH#0D%N*6.[M:O1TL9>AOKT+3^_?)>Z%(YHY"BFV'#$XW17,R D2[\C
MO1_!SD3MOA7HTS?[_++S>6N1\AP!A8033 F.?<4 EBVNLNI'M3-1LV\%^O3-
M/M=<8LX3KJAVE'G#,)<> E+Q$ >EW-*U3M3XV^(^9B#Q64SS+9!8KP(1A49(
M+3R4C 'MR@E[QV$<RXP C9:^;X'$(E! 6'1]+)8&4PBYXY@><'3<P72A>'Z!
MQ,8FTU\@\2*P7V$@D3'.XCJ3 Z,L<80P[4 %@-<H75@SG4!B4Q,X?9?D13AF
MX\%-(1JSWW/6WE."F4'((E0-$O%/-J5 8F,K&20LDP3LF^EVA_ $ HF3LMB.
MHD37$:O] OUC_+F:WSS1;YX.)39Y-CC&/8^S#4>&>,(L5%Q7[4!6I"\S)Q9,
M;$KGLE^ DPWEI1HTO7FRR;/!(VXX%9I:1#GP$2E8.\B8MKAS*>=PXJ6K@K[@
MS&:F>U7A1$%89)4HK9C1R'J&0>5N>T5P1JGA>K"KT<*)EZ'^BBP_S^,OEUQ\
MZ!TRU%,D#.%0$V"AJYAC$J6+T?H)0TZ]OW1-R/2[4GZ1>6& 1D!18(D7R#OI
MS&%-0H!6+CTRWT^(<J)=HA7HK\WL\YQ&+CVOAYFVD41# /&:4(<YQA6'F!*8
MW''Z"6^^BH[3-2O3[UGY:5ZL(4P"S^+R4GG/ )<'U1$O.;'I:Y)^LBQ,M%^T
M OVUF7V>$\JE=R BXZTTT!EA*%4:<\=AQ2%C/-T3ZR<AQ:OH.%VS,OV>E:N:
MS%A%H :, Z4@H5 :QNJ)':/TW=M^DE9,M'>TQ?W5V/\KN9W2,RZI9-I1:>(B
MDVNN3<6>U"#]I%T_MU-.N]?T0<F8\LQG?7M >:9[^'*__%;L<U)=_;DH5NO/
M\R]EQ-/]>O7!SM>E8*R$^^<&<LS+7Q:(THQ#H*1U,IJ:<U8)(9CGC%$D22.M
M0=_RR\;-:JZVO.R5P0*'!,,.TVC%%G .,:Q1<FS(R/M)<66?!G!43-DKEEEK
M)RMAPAGIY.-B09:2!2L!<P:47K:Q"%7-CX!/0#G9%]_+SE ;RC=K+!-[IF!!
M1 -)+';0$.@AA)2;JC4B0I2W-C&-F"/LMD)DZCQG*>0;@]Z.A%4J_HJZ7S]\
M."VV>U8L_AM"11WCG#H1ZP2@(U7MO,WQ,I14>)>=H9#.$92R"4=/BP7"B0"*
M&P0EDEP)*16N#=&S(>\ ')*C5B@,MD51.@+OUNMM<6NWJ_GBTWY#97^@\(FW
M\&&[NOD<UU\E-B?/E:6],2@M(7*P!-1C"R6TM/(URH3V&0H?A_38!P%U9*/;
M[3P<;<SE)G?Z?4$)Q:6+(QP3TFI%&",5%YH G'['76_#TO@&URFD8^X:7<=U
MYW9V_[1";T=[O]^WQ@BR%!'/);(: TZ)V^=YULY2W<C]?3O:6P2.#::*ZMC]
MH+?.:D;( 4=C-4H/E^9WM+>QR?1VM/<RL+/>GBH#P''4/;,[]:A4@-@;J"U&
MB/N(-XH8U(UW>-"D72,=ZVU,_[(K%(=RF XU/+N'\:1<P @H)S1S$F/+F7%(
M5AW2<(1DWEM52:R\S&PK/*;-<9;;5,-3FU7\?S=BQ4$M#GQ7B_/7K%_PEF"U
M%5PAXQTGDB/C+ ,5#I"[0?,8-UO3)/+8+&K> 49#V<KU?%/.@>\6M^75K7%I
M<F;J?[%\8()SBJ$#FD?XJ"[O!*S:QJA-EWM?OJ:=F!/0!9ZCV<KO\\WGC\7]
M#JIR2^!ZZ1:;^>;;V<GDPC<%R)&@W.KX)Z"(2107^!4>'A"=MTO1DN-S%M,+
M=F\VE:4+D[<IC6-"=KXJ;B(W9SV:IP4#)98(H0EG1 F&XF2,<=4:+6%&Y\-[
MYVO9(5#)8;Z7I^!R@_>(3]+@J< DCGX^9,@S0;#64ONZ:T@ITCV3RT]P3L0S
MZ1[5'BSBZ&S0Z+D &(,T^OP"6RJ4M5PZ>ZB_50ADND71*3/-V&Z%U_1XSVK.
MSY?NCFBNIIEU^>G3VHX7B@;I%:(.:DF]T@@#I'5=2^WYD.E+F\CWNT-]V2DP
MR?1=/2SF?VQW'SZ3JNS'DD%Q[[$"6#B)%%9&4R6K.B*.TLGK)]E(/^2UQB5=
M4K79Q%J7GL+5W:.$WF8UWQ2K>?Q?\1%\1F[5_!7!:<\8=M!A (DP'+C:$;4.
MM=@?[">/1C]L]P=8KV: VIO!X17!.\DC7-#%90E6U!FFJFU6BSU*O[.JGZP0
MXYE!&F!#+;C3\C\+H%FYZ(2.EEE=2/PWJN+T&L/T:XLO)W\B*[$N<,SFS.D$
MDNA*)" L9UF.%;102N]5A6S\&\QS5=C22H;(IIL&[)OI=H=P5@O;5V"Q'?E?
MO\Q6_R@V33,^OUPZ &BUE$QC!SARQD0WH9I6'/4^P[,HXU*V[!K29/K[O4>8
M"Z&!%DYP1B5PG@%?ZR)M"[/H36>>CUET#N]@QPX;F]&9)X)VF$. RG6,DQA*
M"'3=/DEI^EJM\R5[5N;3+:S)(TOO%PMX:*P$@I*X^@7$4HH(J,W?J(R6\EF9
M1U\ )QO*/FOW86V[OKJ+V#PL%[O:^.6J/(E3FO Q4VGV=)!84(U(><&>=$8"
MJT MT9>(9WC&;H1S"?T!FFP<'\M67]T]K52TV6+UM;C];1$I.')"[H*G@_.2
M<V(()%A1;R!DNC9TK5JDQ!S/3^G).'H!M/7(X?Y9RI 6B_CSW>)FM1]*SPT8
M+SX4O+,<4V@M,AY:#IW0NJHY4"JC,,'8IM ECNFKUPCTP_;A>K;Z5&RJ&CU?
M4>V2?!6W.P"N]B/9(]]HETGO9G>ZZ<B:M\-OQ&'3PPB,*\\B(\&@ 995N!".
MT^UK/*>E)_L:$?86FRE_]6^.'7XC (@L8]0H #"1@,6!NMKQ\MJQ]$V[SI-!
MCVZ.X\&>S2[T*[I6@RKHJ1#.Q,4P$]@QB6#%@#$X_<QHY\F<<SBGG"<KR<-T
MG<8ANJWSP^[('\^;M_=M?XN_W2SW&W&[)AWU*UN]-"C!.(+(>Z.9MU!Y [Z/
M"$2B9'OL/'WRV /QD#BW7IG8V;<R^ZR9W=]L]QKYJ[M#ZEESOUS/%Y_VD\1J
M?GZ'XY)W!22=),Q93 057#@;G9ZJG8JZ='OJ/+'PV/8T +S3G\"?9N6_7FYF
M]SE=WO"T0L%(A2PJU8N&:<.CKP_K3HZ-2M?YR%=D_)/B:*@>]-+D\@,V96C.
MWR__='=WQ<VF_%<YT5R?\Q(Z_T:(PX[Q5&( #%*1>:1I%<GQ0K(687?P"@U]
M+-RG/_J_QNOAC&3EV03K$/:4\$AF?4+!.],F?>IKB@A-G;?!^EXVR42=)Y@C
M9+3#&"CC)>6F]DRU:9%V[34%LX9%^;L5#ICN\6@"R&?1M[?4C[45*4@Y1L X
MQR5$!#NH]Y=34L,E:'8BK"?D)I;ZD6,FL,16<*N-M$ZX XY,0IR^_LHO]6-C
MD^DQ]>,E8,]R3OV8=JH'659*M:&GUEE+H9'0U #0%C&L":5_;&@")T_U7(9C
M-JN:"1R-B(M$[!SR"FM@&394UH,$@T1FFNNAI94,<48B#=@WT^T.X0F<ZIF4
MQ4Y=LX\H\T (19UGR-#8S,-%U[%]B(!!4YJ-*,IN3'-#S?YEL&8SP"7O"KU?
M+K[NH@?[Z-PH.XK/ZA"H<A9:KD0<00")?I83H'+U"8=#)K0?;F,E>7V3*2W3
M[QKY::F,UR(.3]XK:@RV7$#G*P:4!^D=(^<=Q_PZ1BM6IM\OGD:;,Q E!(*1
M,9$$N[L2" $B>,V CC/ZJSQ+D%^_:,7*]/O%X?+SD;O&#[4(UCI#( ?0(H4E
M)W%T0A4/#+6X]2[GDQ#Y]8ZVQ(P2V]IM>ZZ?5J2.8QUJT_:CVS_6Q3^W\6ON
M:_G)]\M-[U]\>)BMOEW=_3K_M)C?S6_B=*YN;I;;17E-Q(?E_?QFGD45#G'$
MT<*('U;++\5J\ZU<<V_BVKNT\2^E730)$YY_.!A,@($<L^A"25-N'7'B+2.4
M:NXM;W1&J^\PX-%F-(_RG7Y%\-Y@+HV2%$N$F:2T1H$BB8?,;7HRB-<EH4>#
M=)UBU5,,[NB9M/]=KNR\/.7_QS92="J3^4ME S LXD4EYL@")'B<!>K&88N&
M3.Z3&%_KBKUEMU"U.&;X]-NG4U*_7#HP*!2$P@IBI,6&22Y555>-$<HS*-4!
M]J=8;(5-WGQF%:G)@\:.Z'OTX5.WFATM&Q!R4CII.0&[[*WQ/W>H)W. IV>R
MZ2>->%NTE]WBT05OUW\N&_-6EPU44>"9U%1*2P7QT(#*5AGWWN6S\=DG;ZEX
M#+6U\K%<(Y]1%-5E@E>,<VI5'( HITK'U;"LVD IL -RFH>WTQ:B06D^&[=^
M5"IPI2DQH+QK45LFA0,$5.U R)L\/: 6?+S$:"LLILMM5M[0.)2.0^4AK<M9
M,I^4"QH Q#ES91P+0X)M>8U8U98XH.7C(;5B8MD=!H/QN<^+<I[/Q^6"HX Q
M@!"TT<G'#%KD:T2\;R$3ZBUDW F?+3 83 IVS'O0WQHHLQL\':@S6&&&(55>
M>JT!%+5W+S@;,BR:EX?5/7BC&TU9[[/"U09/!P^E)89*Q2#UF JF<+VT\%#3
MO'VU3IEM:C6MT?O7L9XLO<'<C68<8]';^?WM?/'IK,/QM&# 3'-""/08,"HQ
M-0J;[]X3SO"*@DXY6G8(SE!4^^TJHKU=E?IJ/_^K_-MY8?KQAX(GV&-'N+'E
M 6%K-=.T:J7F?,BMG0Q,H#.@AEMIW'R>+XK5M\= -%AW''TJ &0 M@H#I+A#
M<2B-"^ZJG4JC(6]FSL @ND-J*(LHM5#;3;%J;@U'G@C,6D*A5T!HJX1Q(#:M
M5@AXFAX\ZTV,UJ<E=(-2<ESFD"5U]JGX6-P4\Z\[L=?5W>^?(SSKV7WQ.&2X
M%R>5ZC6S7*R7]_/;V>Y2@_JY8P&=3C\2^P>,"SWIG5*"0 4AKB=0'E'**(+7
MHVQF=%Q'7[#\MB[NMO<_S^].*; :/!V<0 Y+8BG@5B%%O4257\\1A!E%%@>0
M874/V!"BU492RHQ4G6<UM0>HRA]EOM7__+?_!U!+ P04    "  S@T)*>=C+
M&LC) 0![]1< %0   &)I:6(M,C Q-C$R,S%?;&%B+GAM;.R]^W/<.)8F^OO^
M%;B]$7>Z(^0JOD'VSLP&"!*UNF&7O;:JN^=6W,B@4Y3$KA2I)C-MJ__Z"_"5
MF9(RA2=)5V_,5)?MDGF^\P'X< X>!__^/[_=;\"7O&Z*JOR//]@_6'\ >;FN
MKHOR]C_^\,NG-^@3OKS\P__\S__V[__7FS=_BS^^!4FUWMWGY1;@.L^V^37X
M6FSOP%^O\^8W<%-7]^"O5?U;\25[\Z;[2Z#]Q:8H?_LS^Y_/69.#;TWQYV9]
ME]]G;ZMUMFUMWVVW#W_^\<>O7[_^\.USO?FAJF]_="S+_7'\6R=_@OWNS?!C
M;]@?O;&=-Z[]P[?F^@^ >E@VK6T.(\./?WOV\U_=]J?M*(I^;/_K^*--\=(/
MTL_:/_[MW=M/K9]OBK+99N4Z_\-__C< .CKJ:I-_S&\ ^_<O'R]/HHM^9#_Q
M8YG?,KX_Y'5177_:9O7V;?8YWU 8[=?NZOSFY4]LZOKH"XRAB#%D!XRA__[*
MA[>/#_E__*$I[A\VE)X?%?!+ -X^!VL*74O"SS(@S['Z](.:\5[1H9OK1?S\
MDYHQ=QTM+:]-]-^GG]6,72]DHSVCVF8;S3WCV2=/8MZPGWI+?]7_(/OZ&?EM
MC?>B>O#A_-LV+Z_SZU8TCSX-BNO_^ /]U6K7O+G-LH?5Q[S9UKOU=E?3J0N5
MUQ_S#8.,UMOB2[$M\@9]IC^0K;<KZ+F)"]/ LW#B(B^PO-@ER$N1'R>)Z\6K
MUL J+]_\\FF T_Z1*8-_$.'H.?MUWE2[>MU-710IF[D[\/]YA!%DY37H48(]
M3/#K /3_^_<?]\X>,5ZM7^I"+;R;K/G<8NQYH5CMX,=\LVV&/WG#_N2-9?<3
M\G\7)O!I(U1K@XW0<;IA84E5]UWZJ.>A>@VJ^CJO:;@T_*6L7K_2>/U/_+BN
M: SPL'USU(XL;#+N5V6Z^W;,44=?8NW9>&5AT?5ND[^_.8$$5\VVN<H^;_*5
M%4+$_@E3%^/ BV,_0@,")W']U7:<LEX=MCKMB@S<[8E9]<SH':""Z@:<'LDM
M7O!KB_CT"#;?!GRJ.1?]8KJIDWDCVBE XQGU--$8R]!/(YY5YKLRGX9^+HK/
M*Y*MBTVQ?1PR:/2M:%9)&,8DBC!,DM *7"<F:=C;2;V(QC8<2BG_=<-Z.& "
M R@:NE!8G**G0-IY:9N&+S$!FXVJZWYUJ/TK,U-VA(6;NC=OP,]5F?] _Q<<
M?0'D%" 5_)NJ!MN[H@'Y)F?_\0?PY@VO^C/'6TVWG5[13U+Q@FZKTS:O.FO
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MW/*EFZ]P<"KYU$7= E)1;:Y4!KJ6H*0'9TQ&+HU;W21R7"<*800QV:\<>K[
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M>@R8AXA3IX*UDKB 0\)Z_:E,=3?-B<NI*>SM>+7-\6T<1G%(["@(K#@E?E^
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M F@A9'N^'6&*>UBU<)UH*6F_./+),O\1VE(""8E6GCM4,-2\"P\&1J]_?ZL
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MX12Z=HJ< (WF<$P$SW%+FS$>)#!D[5&+H1Z7X J7/(%\FC )<V(:T4)J.1M
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M]*5,(4R:=/8A(6-\"4T>KO>;*E_7^39;5]53L;]K*RN>+RK#B*:4P,!SXSB
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M$+WN5HVO]PT@N-_VI7HKX*.8X#2*4AR$/F1XL@&*'[CAJLF4+P<JJP"DHM"
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M2CT? YA1]O^Z!J+0)7*B*O'!UL62#]EBORD?A'?LS R_$P<7AI4"4<L8+BK
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M.(H2ZH5]>PD)J=@M//KMR PJI2MW7@O<SF./3R\+DJ!3+8FTPZ-^&NE\GIQ
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ML[QGGM$TID9@#"DQN:R1HV;"F?&BP8?9]985FXQ@XOD^(C%DV05(O8STC2,
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M3<T8'V2K/DV1JQXA+/%J+#K,Q:A^2+#$K/%P<!AP6HH#%\M4#3.X7/U7,49
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M*V>@\<LE&NT6R_S,D4BUBP:SRY!((Y:<JS?19L=NJO^%?_7I]M/QP*:[>=U
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M?"6YDF5WN7(E;8F 7*FQ8_2QP81F7!N96(8 96&4!%[6-QTP(/JO!4@W:5W
M=!X<?+=OX8FROK 1:,0DE;?PY/A2V-1KMAVSW;JNFV5UG :Q&T%*6(82(^0U
M4M#/LE B]>*=>BN3+5_S)]P;;$X#3G?[3I9,Z1T[BSS*90L2I-G>FGO.B=AN
MG"*/"U,E=3O.[[EI,:-8M/9*F4-3U_#3S>W/+VX?@^W6M%T_RD*"F4RZ68:R
M+/)Q7P,1$.QY&C5LTX&<OJ3M]1*V[K&'GR=7/ST0\5)%]?;[)N\4DC*\Y/Z@
MH>+S;AX:)E6\UFUZ/RXLBLQ&P^5*N+G\(AK#LK)Z+/F%*#B_.7SE$+N2O29O
MC^(D22$)0)1XD4M=%D!QUV88AP#+36CUVK(^DQW@.5N&SZD'@'(!0)-1,16?
MCDHY*3YQR($Y)V0S+;Y=Y.F"NIKA=QD2:<B6TD8/E!.K/[]^JQH]?8+[[>\E
M&^5[OMS0[U,0ZF4H1$%,7?9U%$19OT\1DA0D<F*EUY9UL3HA4A8J33;%A&HZ
M&N6$ZL^O3@^L.2 QXG,>I;I(U 6E,D/P,I3*D"VEC2XHIU1-]H;6FW_FVY^T
M,::AFX*(8N)#Y&6$ID/%6IA0(%D_IM.2=97ZHZP.=^N[O!EB95.1L6XF:S<-
M8&7ITJ)73+BFXE5AJOM;Q][LV=4%CBXHE@EFEZ%71BPIS?>[Z<_>?BCV^?4A
M?ZA7V$4>R#Q*?!PD61;X*.FW>L* 1O'4YV_%D4V_8*EW!I=;YC2FS7 05\+A
M2NN2"_*U>@'*9&Y>[(G=P2/B*YD3>7X9$60FVRV<WE7U@*THU8""-_6A6F\.
MJX!XD! O2R(_3#W"UU#1*<N/7<7*'"M8[-<<'A\>UFS>6]ZVV7BK4+N10C'7
M\JZ_==8'YW9XI-ANE)%TF)VH8L]3NE'DZED(X0[[>B@W_[PO=TRBZO_7(?]U
M+ Y/E_9 G;]ZPQ8>2)XYP6#@4'/N^PP4BK9J!@8=AJ665D[G ?F%Y;N2 QG:
M#6G&[Z#S/#>%&(0P)JX[!*  4(4%%JWVK MZ"_%?%-90]'B46$F9C$"%]93G
M![Y/^&83S#<9>VMUQ0C;RQ ^@_:\MM)BD"GA+?=U?<^4E/^'!VV66CT[X'S"
ML?+<#.($LIPYA,@E%+)4NF\?A@&4W'XWUJ[]K7B&T<E/("5WX,T1++@;/PNS
MDCOSG%*>-C9?C&">$;^)]^E%&;RT9V_<"\M00 MVO=S+M\2<<$KW?5WL>"44
M+:NOK/'3PO<*DCC -/ @#8,X#5) 3CED ERI]QHUFK&\-MS>I]"4IHK6'ME)
M/,XR="GCT*=U&0/-A"$O<PQ3W(@.I>O]][P^/)P;OQ"'Q(M=',($^0E*TSCN
MKQ\( 8T]N8Q"LS'K:<0(GUP&H<NB6-HP(7URN<((V"*R@\M$79 F0PPO0YY,
M&5-:Z862J_EEE1=W^^Q85?E^\\0? .(SKF9*]AH*$A!"PQ@&.* DAFZ, ]*C
M2"&57-(QW;IU(<-YQ;*RYNJE30=64M&,$RZX_CXCTY(K[BU2IX?J]%B[!?A%
M"*$DG9?6SBTY9AE2:<VZE^OC5ED4>C+E,^O%W4I66>'\-F=0MEGY\)COZ^8H
MR6LXLB3S$'(ACJCKICX,/#1LT29A)K@=:J]]ZX+*4?>;G[=EQ69=+7 FKR?D
M$F^!V/'"98U=!OUR*MOPWI7%,,!.C]@90Y94VJF\(?%8R^Q>47N_A0Y;_34;
M'+P^@#\/>[-F?[3)G?H^SP_.EA_NX94#NUT_@)JG8U\9/\XC^X>U[GLO*ER^
M$OCL^V4!K\+8M:^<JH<;VA!>(<!F+ZP%-G=)8.![24J']A ,)4\$J;=C/9Q]
M*P_KG:'MW[=9T]SV-4J7P>W>A>SQJNSM"E.ZC/3<@!VB>[F2S(AJSJ@,YM(&
MLN=1/Z,Q2$/@D2@,HPB=\OU8]D(P0XU:5Z,13LF:%%.TBBG4#'S*R=4(X-)*
M5,2XNZ!EALE?AK"9-JJTVF&-+-G6/:BGU]0W "AP$Q+Y-()>%+E,C?N+EUB^
M%_I&UFWU(+S?Q5M-ZK56<*?CW- R[JB ^FD1": *L?(+NF;\M QUM6NBV-*N
M23Y%E?>51[TYG&)_E^\/[*NZ8,0W/Q[ K6B,@C#Q8^3Z41#B. ->.&S;I4CR
MD+D-!/:+" >$7'=/$)WR9E?<-5].7%ZC0..%$6_3*<L8\%8M+*?KXB;GEBOL
M>:0Y3Y$%409CZOG#A#8BKA^N#GPQR,2,\LVFI*KB!E0V5[5TN3,Q<31*FV3V
MPWKN?E.L=_UIXMOA!V_/)9<T@52>. J3OPR%,V6,U$11DB-1W?J]++=_%[L=
MW&^O]P?6+8N;77=P[)5):N#C(,TR M(X\_P80-<'% 8$LNDJ9A-7P:%HME%[
M([/'V0S,$])^+W0!*SI23%X8GW8\LHSA:LFV<HH^+3>8OV[N\^UQEW^Z93&E
M..0?BN_Y3VC:%[MQD+0OV*9^FD6N&],$]P" 'TO=5FVP6:GD1+YDOT?*=[];
MK+\U8%\9W'\U@"4O:3'I #$IG8E[.1TU2+L5%14G\8*$6O#$,O33AF&E]5XL
M48U'CP_KQ_MU]0#[IT]B+Z%Q1B'!<0#X0T0DZ!N):9@('6!2_&C+"C@ <N#O
M$L59"A1=UJ\)V)&<A8V(>?MF/B,,2=2FV65*L?!,BC&QNK&?[#Q7%*9.R (J
MOC3 ET8ZA80XPG_]])'\?_WG)[%+ ' AC DD$0GCF/2?'WE87!>E/M6R)+98
M)(:Z'"4".FB-#3D);&&HB)\<(Q*Z9XT9-<E[HZN(:=S8IG/RIF3W I1-#7>I
MZW$)/?OV5*]OJN)S56Z/F_X^:10@F&*  P @#%*:A"CJVTFQAX5U3>G3+>O;
MMW__"M&7:XGAK,:1@-!9IT=.\#IFG,<6CXKRJ5$EH8#6*5-30FGJQ+3Q-6O/
M::06,PO02CW\I:D^(J&=J"CKXJ'8K:O^<FOB 1RF60 P=*D;>TR@TZ&1,"3"
MPBG_T995<P1(0@X4&!*03;ODR&GF"(N*7BH0)"&6=HE24THIPL14\B<SSTFD
M.A\+T$<-\*61/B&AC/]Q_1%]^?=OL&LA#"(/\>?>8(@2-XAC1&G?@I\%2%@6
M)3_7LB;V:"3&NRPQ FIHD1,Y*>R!J.B@+"\2(FB1'S4%%.=)3/Z>&WA.^Q1I
M6(#PJ2(O]3N!S,+@A\]?/GVX'J;JB) LCA!Q48!#&-"0N$,+4.S.-Y7/M;TX
MV*&160R3)$9D@= >)Y)+A!T0I45"25YDE@GM\:.X4"C,D^":X3,#SZX:JM&P
M ,E315[J=P*9M<-\<]M4%'=-N,CS:9A1!*&/LI!&T,WZ)D(W=L67#24_V/:*
M(<GH-29?9!(]:6Y$E@LMTB*Y4M@SHK1&*$N-S/*@18H45P;%J1)<$WQNXMGE
M0$4F%J!^RM!+ SU!]JK2;7Y[OD8'/?VQ_L^R:IY AS^*>H5IA/EI_@@3-TK\
MT(-9TJ,@1.YE.=-M6U;1$]S?=F>JW6Z>G :STX!V_N*P)4L.C3ODLBXOP1=R
MTBW@AC=XMW0]JA2!KZB>;5<LH_K0FG4_W:AJDT5#\GK"\'']D./R85WL5Q3&
MU,T\E\WOHS@*?4#QD.ABFB8&)5:I_=EE]NJ9R'+DSE\M=K-:J^8=(WIKW3&F
M-5?%)W/H\&O$JFNQEIO>A1[K62BGR0;8%-?ESU6YR>OZ2U[G[!_QES=P_CW?
ME8^C9^F3Q,\ \4&,LIA BH$+^K83DD+)IW_,M"DSR!7OZ__ML<7I5!W0YKS<
M]@1UZA$MP-O%,6R2]Z6,6J,V_31.S3,F.C*_5>MM_K"N_LD?.FR^X6+0;_5"
M-TK9/#CR@QC!C$2$#EN]24H!D!N1>FU9'XDG>,T //!OG3U'*)?F:%(JEM!,
MQZ7D2M]S$IMOF_Q$OGK#C)Q=).J"C)DA>!GR9<B6TD87E-@_^'0\?"@V^;[.
MMY_7!_YX1U^KYT+BQ<!+ A#@ '@XH$'?%DU!)+R1H-R"Y4D:P\5F BTPY[%%
M)K&"KDZ<P"[#))S)B1"#Y/28G Z4RLZ#.F\26Q"3\*>V%_%:M].]VOR<N>?V
M);3I6< &A;X-I<D.(Y<A=IEHOOV6;^[WY:Z\>_I2W-T/K9(LH"0% /@9#IC2
MNR3I:V,2WQ<[[&NJ+<LR/,!S#@,^N=Q0FTRQ['!*'N6D^43A"9K38ILI07R#
MJPLIHBF6EY$D&K.FM-,7)1+%Z_WK AE0UR?43Y ;4D0]/W/CH:DT]H!PGJC:
M@.UJN\U_'0O^(@F?>A7[4^RNV@'&?RR?/2JS*9 \3D&D[-J[D=11F32)S'$*
M\M02Q^N]\;SQC+'GTD9=;A:0-6J;4!KL*Y+WII_?=?A0[//K0_Y0K[(TI!ET
M89IBUT,IIAZ,NZ93X(>A3.)HI$'+ZOS6U4T<J-,@E=Q7-<.V6&8Y.=%RZFV"
M8SLWGPOP=B'5-$K[,O)-LR:]O,G</%_25X)VR1@^5L7^[G->%>5V!?PD"EQ"
M8IA$(.77&/I#D^S_A&Y*,-*0]:J2396OZ]PYE,Y=AU-.U/1H%!.SR1B4$[$>
MUI4S)/0M,J>%-M,=J:^0=$&QC'"[#*4R8\JY"T_U^9%5IA4$*0ICFOE!@#.8
M!4E&^KL-4B\. Q45>O-#+2O.[UHJ\S8E<HIBE TU]9A')00409B;98U^<=AG
M1KJDW>*U5<_SFX_Y@?S8[(Y;)B>#R/07)V=AY"=QE&041H0I3.2&L(>014#R
M=5"C34]0:35,!]I'?&6K5TWR+"8GLQ$LNV;V4WDJ0^K\,F!U>K"_SG;5NPR5
M%ZO;+'AD&4)GQ[2?:MVL\:>_./5GG=\>=Q^*VWR5TIBB *6N"Z ;Q'X:NGWY
M2AIB&$H^XF>B2>L"2>I#\; ^L.G&CN&Y<GZYWCO_GJ^K^E=3ZU$R!.NN1UEB
MUN!ZU)738G0XR*4L1YUH4UJ.4F!]&>IGUB3AY2AEO@0W0B^> !@U3B B(0C3
M,*$>CI( )J'7-Q[3T)?8&C75I/4EJAZHTQZR*5[FA\ZQ'9Z[2\/3*NE".ZAS
M\"V;'PY4GUN9%U%"JU1+[;O.0;GJ3JQ,+]??I!5DYORVK6EJ%[&1:]RHTFIW
M-+;9^WM5UO7*32%%<1S0%,1NX"78C_O7FM($A)&I7%JP.>MY=%;6Y\]L6:)0
M>_?6/'<F=VZOG ;?4I+DEBVU_5HYHI>>',N:([Y/J\*3H7L"?EJ16"&0T(
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M719?]^MU5E6W^VVW-<:_?WG[);O;;[DKGW"Q(>7# S,Q3[?-ZNGP*=7*<=P
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MQE$J)C+3<0D3G",2KSH2.VAS/2IWCJ@S4J2&X&7(DB);7K[OII AB<<]W[E
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M_5MO::L9_=]>ZL4Y/M[0#27TS:L?:DPH%78GH)Z0OR8KT[&LF-^98+@T#*V
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MA7CKM.([8;MV#T%V+5BSAZ&+Q,MQK?SJ<6_#\$XX^]Z1&>A@!QH,F5WY%;E
M:,5Y&B<O(V),;O7)->HI68='F@."#P7+0ILS(54? C^T5[KR[UW>)OVFVE6V
M:ZH]F!\..#W7C;'M>#:FD6_'AA6$3H\S,2/@FPC3XYMR?8<_KM,^G,/_MADL
MK-C7%8M0_ X_E%9-S.'"E1\LYXDK:Z$Y5%-N\TWSJU5/0B-Y[<D<V;@T67^
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M$EIMFB6U87W=Z?%[@WM-/ $DV#1?:JI[Y$V'S+[AXSEE'4/' L1T%/Q24[.
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M1!_FXQA0FL[ M5IYJM"ZQ\X\R'%SKES5S.P"2E;='I7FVB$@H7P2[?#Z[CF
M[AGQS6\[3JC8A+-*TM#WW<BU7(=Z:619A/6WYB2,QCX@H6BR:#RA-#A%#]N_
MW?>J#C*O>3EFM/^:-WO% (*GBWN)I#(#Z;"DTK+-,\FK[-*C1 U,Z%YX71P#
MDLH,7*LE%<46/C:QR/%S+K%H9G<!B46W1Z6YMJ@P4DG^+>Y%VNWX/S_LUE5S
M1V*]2I/8=SPKCNTHM6+?2@+&>H.84LD7Y#08,IY&?AUZ52X HJQ!B(H!HD*%
MK,@I8/!AGDS5,4>##+70T(<96%087IAG4RT!O-LV=8TAWB3@O:'#.-86(.R:
M''EKH*"#&[EM(\6N>#@\?,FJ^WS?6W^YL/ISE>WV^:8Y$WK=#EM.YL0^[/@W
M:_$R5^BD%@>86$% [(!8$8Y)C\_U'8CJ3XK+>)+H@&3WS;V0>5;MBMU],[P7
M1=>^<?*D/FMFV=%]ZUUW@+K<H6R]%]VWG0HX7</Z6\?6WR';."8-O$1J6FS$
M89FL<P.U?IP,=][8?=-YT]U!<-W/KYTN('S8H<ZGQ<86LK%GJ3%6W [4Q?I5
M!WYXM4_H=6]^W8V+G?A6^#9Z5Y%&GL_N19HCE@O(^O/X7<[=BT!;4;_KPX<M
M.R;$BRB/DQMBPH>N=H<O90FQ0!M8)\3UX]<4+5N@FF+2P,O4%$N-.+"F:-V8
MMZ:8-+:@S<(+C;'J%N/O"ZTI-/)\?G_S#+%<0DTQB]_EW+U(RS-%%0=UWTR0
ML*?CG]QD3^)'S1LA[=N*'W;UOFHZ9-V\+/[E:[:[?FSNJ6[\JAO\1;E9>=1*
MO2!(HL3Q2> D)+2M'GX4.:"W$!<#VO FP>-48[>XU&G3(A[KT<[VA2UTBPOX
M,O;D+8\6N3>&YHZ;U( K>7C<ED]Y_CFOOA7=)L7;EZZT:X._\9_NRW8+=0._
M7M& ^+9EIVG$2!I;-(WP4:W=T)8^N6(6ANE=SK_5B+=E/A03%=6^;'6L.S(
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M5_YPP\/MKG\<02&!2DZ%U F[K.B3< 43<"!-$JN1W$E1FKGB"Z$R[DE%=HZ
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M]@+N5QQ#I5SQ.A&+,+E7(M#,_=IGZ;E0K&K@=!F%J@Y'7EZ*K8N;<6?/'L3
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M)?L#KY#K51Q%)'$P"U*<\$8DGIOV>AA!0&Q%==1CW+!.GO;I=W?TH]\%;M0
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M(M5N!FL)+5M"LP[?/\9>>W3>Y3?T7QM+2[CZ2(<;I>;6 RR_Q75++*OSC9@
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M+ I\+(Z@Q2ZO-4C0KS99S L2Z%VXTR.$;X0'WY:;M >W5$YS+7*,,>_9'MF
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MHGXLZVQ[??>QW-U_++[EF],"]CAK0#S*HMC#V(V2V(L\;.&DA^*F$6A*TP@
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M_4^5_ESGZW_<E]_^H_.C[<[=-R][\M'7-_JO A'S]EH5P*5RT&&)B-9%UDF
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M>Q'5;[ F #O"$8E<;#G4*EE2^XVG/S @$E4%/Q91)D&UY%\_"1 @60O)O+F
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M FT"%87+Y$)K"Q:;:QJ"[=Q+E7J#=58-"XJG\,R"*(_R@'J1"%*?Y'GD1>&
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MHI0E@@@1=5"2((A8'$+V=CL!X'@GV3/,, UUP[>:DEZ=:IB>/H/;*>JP5G]
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M8,[1\%_-<)!8R3FLV(7Y9KN$:2\".)<G]FH5S+P:UM0172YFV 1:2YD.]JN
M  AI?>!0R2GN6(RQ/T"HMJ3L]<CQH6/SJ-(8-W"BB&=$"2RM$IPZCZ$V);<
M8OV8(KWALQ]@M83F1A(:.IZ/*@AQ R<XJ%(.4*V!@D) 'Z3%2VZ%\[+77(/A
MXOE4:+6$Z$8R.A>BG]+)ZD[O;8V4K1:_DA@BE$.( FRQE8)0#I_$!W4,U@<8
MQ>U(M^A/ +V&:'_/9T5)[%%1AV-#MOOR$&9QR*M]N&-BPHH-:Q9[:!RATBE$
M:#E;BV!,\N KV%I[P<FNR&M; ND+?M7#<%LRMSG@!W"WIT<B&81* D8%U<IZ
M9]63PH6H,I=E.PT!<.U(HK?@S&B:+K;E?(LGK8JX[J&8S([FB>&62(ZA$0([
M80V6DE2Z".8Q'L\!GJ%#P%@+8NCM)"WWW>UR.*38O6B;8,.\ 1AS[RC#7!-C
M2PW%ZO";7A*2CI45ND2$Q8JB+W@%X+\LW[,#6E^U"]83Q01XR!7""!$,O%!5
MV$""6ND3;:4/?1\[5@S_AY4SM*L2WRO(&")2$VJT@(IPY#5DTKM-=1^..**U
M=M*.5)#Q73I93=-Z2"PE4*>05.3(B:#28^$,A8)8C0)D%2]YAJ"C$=O$ *VU
MIH#Y5C?IE>E#]]76QFH['TB@8)99R6G8G[6&EM'PEY)[5,>DT0W0WFL)LF?A
M?6^G6N#1(EO? CK;H:57BZQX\COP\%,VVUQ)JG&$'>J6&*PPD(X:S)T(FX5E
MRJ^YS8A4E->ZJ]#-;-^E\]L _>><5[.)S18/^?:OX>?Q-%^L@ESK[ W-!DP8
M 5(B:J F3"('"VUMPR&J.#"]IM3V<9NC';CD9^#]&?:"YS^?NWIB%]N#H!XC
M9A3!5 MOM?02>D6<"INRTZH6^+O6=\L)/)>%?GSVMZ,Y]"<.E0!I@><: VT,
M#&O!4BRW7%$"N@LKGM8.0/;JMYWPO"^%=@?Q1W*X]O1(O QZCPYJ%S="<0DE
M,J"<'P3NPM)?NA-_W@6[SPFGXL=Y>CS]ZFC?A#$D!1&(( <(E11**LHY!WW[
MPHK*1DN^!I)B^'L<4R]?N2A^DYA\]KE0IV;C]/W=:'X_&J>K9;"YIOMSGFOU
M2Z0!@C#.A3$*>AS^PGE)/P#^PNYWM"C/O#LNGW'G>5LCB>A0MX08)8FW&&K(
MB]P8"82J9DIM#)X&Z$4YYY'6E.=]H:MZ."O?+K%R#NGBM_GAD-.QKHGS%"*I
MI3+6!K,0:?[$1L!]KXI3G_9YG/CS3KG<%Z[\*)O_;31=I>_24>$Z*.;P]VQY
M]\<L_U0\JERLLS>SA]5R\2$=Y[-Q-LW6,@Y_6\V+E[WU:)$MWF:C3^%?EH_O
M5_/QW>AP=+VK3R9<*X<H 119ZI2AB%I<;0=:Q!B5 ]PM.T'Q0&33]YG]S# /
MVL<BFZR3#L(Q4U2DW$@=UCC#ZPR3> L]H-PCPP$ 1".B4,D);*,NC \P2ZD3
ME';([V%X0,]7"*0+%RBT,%B)15ZW4A0@;3E$WAAM+2!*D3-&2,[I H4(6&6\
MHII(J(-BX(DKN6(UN+"@?CL B76!GL;SU^<"Y49CPISF%'I#;?'Z!B[G9^BE
MW9CJ3OPU7:"GL?LR7*!%P5FO #:2,$ U%Q;;[9RI%>A"MZW&DC_9!7H:?X?G
M K6&,*:*+$SMG8$**EG1+TR4$?9*\-%0GB>Y0$_C\FMV@5K$L4;(^:"L4X1H
MV+MI.5-%HLRE 1KUYSS2FO+\C,9ZX82XG:TK\TP"=[.;K&"*6BS2Y6*[#B=J
M-BG]$5FZ"/^VNB\*^4R*5TVR9?HV^US\=3F:W695W],LG:ZH2()9C)%AG%"F
ML1386@)*.>"@,5_\7MH DL==!0,1U^M<-N64^ULBU1<3[#PB6&OMJ:+>*H]4
M=>@5#Q!>UE'P"I9#4]'T!?WB2N*?V71Z *MEDP1 ;:@&V@0]7@O%@>6LG $2
M43?B7YM;MBFX&O+R-6Z$=BO.Z]&79__X>SX;;^K_][0['B,C 0Q@I1!PW$L#
MC+405)((5D,_+Y/U?6]U\#MGRV)[C0OH:;*]:MS??C9!1C&FJ8/*0X^%AI97
M!Q?E(,9=4?\&[H\%TJZ87N6".%COHN4O)=0IQ;03113>0*>QYJ;DI[<ZINHJ
M^TZTG?.*Y,QQZC-?/N\B2LV!=M(*QQT/'P4<%:\HKV]-"J49K_5:\/FCU"?=
M1J\_7&(I"YR C$@GB250%E43MMPI^'29KJ@XH$1$JQORO;=J3=547FYY88L[
MON$U*)W0RI<2S;'U2GGB8+!2E3<*^Y*?S+L+>S6W8QR?0R1G./BV25D%Q:O1
M]*(./4(1L1 1K@$"0:_FF@5E ULC$2)2#Z(:RSE2LU2 (A00*PV]"*8&=ENN
M$&?XA=TD; <@\:E9I_"\MVL7\WRR&B^OYA_3^>=L?.QY@5W-$Q=V66^-4E!R
M3XBWU+#MS*B'Z,)JK78G^&\O7,3SNF<4%04;ML0NCF9B[>V3.(8ULUPBQ1BR
MW&,=#LWM'*G&,<]0#!!/<6+>C9EHIC9.N])OWNB@9!W.L?JJ4:*0TU89&(P
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M9WYL#^WB6XFF#&$/@A9%K?&>(2-XR2>*=8P1,R@M]17!M[EX!@'CCZM/_>W
MWWPOL=!J;Z%"@H75;X5&H H 4LY[C9AW#N?S(JXK[$?(<UCX#S_WBO_P<X(Y
MT$PZ") S4B-+/2US8[1Q@E_4=G[A^#]=G@/#?_ADOR? ^HL)94 %XT<[H@E"
M4@FK2,DS"J,>&CTY,/1C#?0OT>;Q[O1S.ENE"Q]H_R/8WF7J=3KY]SR;+:LJ
M4T?T]!.'2;#C!% EN"1 8^"PX;2<G?(Z)I YJ#U[.#Z/;B74&'^%-?+UXMFN
MF7U(V]LAX;Z(^2NH?3@ZL(.&L'(%:PE8K[?Q.]\#.Q-GW@&O>XMZCZ;I8LN9
MW_)\LO@]/70%:E?S!(9]GXA@_ 8%Q"HL#<>5]H%XOZ_>O7H4M<CIZ!.NF/IH
MMLR,1:"X[3=Z6#]D]# O8G<[(U"G=$^,AIYKH<*$@K9 #83$>%MXX" H7D7J
M-34G7XZFKQ<U'?)]:-=+X=?D_;A?^LV-/D(MP%HSI*1CP?R3!MG-Y6%,F62#
M>#'^==XOM41 CWCQ\ ;BE'@*"2TY*W&_V:FOY7YI;31V?[_T-/&]KEL?3GD?
MM,M@B7/JD.10,5/.S7-X866US@F.6K<^3A/'Y=_Z"%H+M$6*.L>>8R>E17C+
M#Z8,N+!ZF9&8B+SU<1JO&]L(ZM.GOV7IX8L>S]LD&&M6I.+)H&]JYCTJGKO<
MTN6AO)B86^=RR]OA\(^<Q_WN0FB4QLH'H2L@N= <:U?) A 8@=7OXQ)ET^/T
MC%+L:SV45OH!+)=-$LF-H"I8Z,X:Z:$15H%R!E1$Y=X.\-P\C_#S5G@_K,*!
MSG)',(144Q$F+V'A-=K2+AF/N64[P/WKK+AI7QP1R=</9=#A81-T&,TFTWRQ
M^PW98UT2+ C!0@2MQ!I-";.<P9)J#4V,6W^ -R?/#Z+V9#&$T"(66#(*@L%#
MM0?( RY(2;$!).99F %>&SD_>MJ2Q-#<_=]D;?QP]W_C8,5A*R!,!5M1"ZB$
M $**3:0(.P]LK77VP]V_TX:Q8OTRB25AP5@+BN!]Q5GO+JRL5L]H[,'=?Y+X
M(JJ?/(ZFR\>"NG2Y-1[6>W'Q<O!"/UX'(6<!&(][_/JG#Y((ID5@,8*(6>N!
M1\J!<F:&NPOSIIX3&GE/,NH>?7M+6309)L&8 !AT%(P#2=HJ#ZTJ9U<D(5\&
M KL4>R-D->)^<V,@_Y05%%SG>JW 7<T">>NTI#>SXM\JL@X' 4X<)J%>. .U
M% @Z65S+\[AB(1.D5VQUGTW6E>CSWB30&%\;8C:$%60\)VOS;[_G\^6=ND_G
MV7A4$VU1@R8\6%R,*J*#H62 0 8Z4LY<&G4Q.=;]8:]/>72(1)O-T_&R-0SN
M'"[Q*JPS)*75)!PAR"#KMI>1@SK-8,PEV^'=2!D(^MJ01+NXV_*BR!0M20S&
M5?9I%>B+ > )XR:H>)(N&&Z.0PH9YTS@4D'V')(8))[LO+M@)'8GDE=:JY%3
MZR6FU#F@C(#6JM)[X+$T,44R!ABV&H!AV[9(7F>M1F$U1U!:[*@QC'DC "OG
M:#7KM4+?66LUUI5U[5J-IW$VRE(]P1K]=FLEG!FJC<;<$<B4HDBBDDI#=$RH
M:E 69XOR^M:\C&/ICU2T_<' 8/XHJ(5A7@!.L)<*5YQ44,04DAU@%'Y 9^(9
MI1AQ<2^[_[0*0BHH^6,6I!P,ZR)<JF[GZ285^;XHD[EX/WHLF'/\CGJS\1+,
M*6) ,(0-%T#*,%-3SE<RU>LCSZ_NLGIML.3]BZI#:+Y+EW?YI#D4-_T3QQBA
MP0RS##"DI?.4V>H,8Z[7G,D>;B-W+?73,-9(!LW])Z/%VDA7-^%D6I<),?G]
M?3I?!Z='._,%:O5++"&B."?"?X.^XBC6]LG8IJ#7_.\+PU#+O&^^'P4:[*HH
MZ_?5_-^G\^S )G2H4\(-$9YP'79O6B0_< >?*)<J)F%D@/[;?G>>%AD_M RW
MZ_3+<C6:?DWDCSRW;R\20R<9"BJ\ D [0J5T/$ 6$6N4<JJ6;_!'GMLN TE@
M#Z&22B$'-:+($JA+SC*'+BR=J&<T=I_G=IKX^G*U!.9ER_1M('[R)G!T=IL5
M9\!BD2X7^O'=Z/_E<S,=+19'0@4GC))([0LF:("#*+PS03YHRP?-O(RIYS=
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MBZF-JI<XP"V_@?QV(: 1[_K"P+MLEMT?<&KO;)<($0X?Y;5E/AC/U(2U4>G
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M(<';]#K7Z8=TG!9O%U_-BN=#KFZV5Z;V :S)6 FFB%N+L46$ ,:M@*;20+"
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M&,P9C[FTA'ZX^7= KSOA]&6$N+6M]"Y=WA7WJZJ%=, ,V=,C(=X+Q#""@'N
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M;I?,2"=KOU]97[H>W!H-EG@H89B7A08"0 IGM2;E3!4@,;=2!E7W<@#HZT-
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M"EX/3EI@9:\905_-^EA2T%>-$VAPL!Q@L"<<<-XRR@4N9X5UU(O4)^?HOSZ
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M,=O-(!UU'2"G'=:>3Q4^205.(&4"8\L5$=(@!1P!U:PT C'^F=.K*'9NE'<
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M:]S].QF=PBB>O6?05BJ.+*YNBLK;?IK_.8AW+RIB3E-07G1+$+ 4<0\$AXA
M0(K+)3Z(ERGN,5:U7&?=S+8H'AS(?3_//P<!3?3C'XMT\F96/0>DQLOL\T85
M/LZ#TP=+(!460HTQXT6Z,B6>N UG1/%FVB6_EQ$!D[QGOO>7/93?9,LBIG=0
M%2X;)90'HTMH$W8TB"U2QH?_;6?!*(A) 1DD>KH4],OZ>LVXW%]2R/];+389
MR-?YAW2<AY-T70S]*3!\G;>WMW7QN<0QA2GAEG&%H?*&"PA+SG(1E>LV2!6Z
M1_P.0%[]W0,,D@YJ9(& \/,T74-A-E'WA=?TO]>_/X#L.MT3#C$%4@KON=)A
MUDP"6XG!1%5;'^1.>U[XO+@[V+J$>@OX%#:('@76%,D[Z6QQ#(V[.R2<8$P%
M9MYQ0AB"+"S^<G:(Z1@;<9 [Y:#PUXI,^KX5O6'4]>C+]A5EG<[2FX.Y5D=Z
M)H5F3H+U#+ @FD)-B$'E?"VG%W<G>E 8;%<XO5Z?+N*4@4L;RH^_M+ZW3R*0
M)<XHZX(&+@B#BEE>SA%['Z,NUD\I_3I;Z[IS?]F@4-B6;/K"7Z"Q\ BF-MW\
M^8PKV[SM&J9/_4$2@@RRV%N%)&"(8JZ<J/AJ5:U'T%]3+NJ@P-F9G,Z'UI>O
MG9V$TY?=$T"@5L(Z9IST5"G&'*G."6]B#O'ZADR/&:]=@.(H[J+Y?L;]L=CA
MOV71L6?)Z@Z2&"8148!@ +UVUA37$K9<".ISO0>OH\V8OD_PLT"P)1&<#XCE
M"VV'BUX<[)<@2! TVDD&3+#-,-"4ENR$@9^]6"S?!=R:<WTH6]W1QP'J#9!@
M)87F!@''-4=>0 O(D_9"^WF!YKO 7 OL/ZMF-U\%,=:J!E6G>T*<1EYB)#UW
MUBG(':P<H-:1B[L'=R[-+H[O9T=<Y4"J2E4W =[+41)-J,5: ,*H+#Q1@JJG
M;5^#F-S+DVM,=9_&=$[T13-_*&=NT]UO[RB)U*ZXG5I<O! 4J+#^=!FKAT9%
M%20__9+>98*P+>;W!<+Z0?=64KL2:H46''N-!,;>,,@1J;@ :0P$3]\'NW\]
M:D@>P,ZD=&:L%M;5HJUTQ .#)5Y+91F "'KC%2U.$EER)9PN,6?X(,/,?:8C
MML?W'M,1QVDZ6?C M^*E8C6;O!LMB\>*'Z]N]C]C?#AWL<F("09& TP<H,0A
M%T2AH'M:K3QF3QUD^DV7$'J9Z-B#2'J#[.AQ>Q:I\3]7V3QM!M/ZHR1& 68-
MM!1J6=Q#8094_M1PL/2S9?884.D3FIV)X6QP7"O/@7>35<&F]*C3L=X B<%
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M,@(BYVI_A)=R75^XY"-:]$+_]_EL_G+$IVV0XPV#%8QS900B%'&&-91J-R\
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M;&?Y(9&5M_S\!RP7MS3E@%F*&/65WX=JL7XQV2#8^%"3H#WRV#D1=UXBH\-
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M3!16$X"9AE8RAX1R!M>K.=8>%HT/&_YA8E/%G_4P\3R(2]'IP-)]8K\\TBI
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M6=[@8\V"$3;N"Q(PCS&-/Q/)=I)*J'/LWQ&ZM>,@67O\AS"/MW%\%V<E2RB
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M@F_)YZI/_O])[NS[>%"&(<BD!X0QJ!#2FN_V_NBAY-REG?W,Y<)7GP[P+68
M[?4G?FWP'/]$RP"MYL!::BVVB&J&K'N:*4;DU-49X0O1?CVT;K$NR:WGIY4K
M,UDL?DQG]YL[YM.':LTZ""ZEG59"0>,D<]I#[^S..F0N)[OH*,WOSMBPAV6=
MPST.LK4F65!<&TL -A@SR:B1WNP.YPC-2O$X6G)U28*S.'8FVL-?6+SR%J[P
MQ@)&VX>D9S$T>=\<:T.V=\V"*L<:G=CW?6.AOD==I W6SQ>?)B^NPAK?6ISH
M(U#)".!62"*1,4S(2,@:A_2L[5K/!KLAQ\&;BVYA+^:M3_Y[ODANP_+]73+V
MXVZ<%K54R[<>_HDKC88]! \=UAH0033"GF%*-:[E%Z3LT6))*[HS7KQVZWO!
M?42\.YD(MG$? 3#((.746X:)<""5EZHQ@, 6M:O[YU[GS#B?>:UP;_U>RLP7
MW^:+R:IZ>5QA-IF$3B6+/=TV,..9P@I1H+GBZX+1]1QEA*J<PENC-)U[T/"\
M7\R[YL[O\UD.?5XW#UHC)Z(P1C$>YUD4 H%:&LUTSNXWRAN181B4"7MK$OTR
MCYC.DD5YYNISLF$ P"$>OTQY#!TGG&M5P\,@A#E+SRACEWLF3M> =TJ9IHM.
MD[8!:*^M!$HIAQ5DRJ=7!5LYL&@6T'M)MR #$"<3\_;OP^>+U?WDOHHBKAW:
M]2,G/;GYL[H]<_TYOZ> "-/&6^)T<I@IQ8:+6D9ALXX/1IE6JV=>]:Z!?EG6
M=,EJU5G@'%JHC748,9/2?V)K=]LWR7H5>78>K)^%:YE*:$^W7?S_:Y%/,.M$
MN^ 5M(0:R:@#$;*4$13OI@M5.0O6V9FIKH%$W>)=ZL"IR8'<KPV"!<[J)SJQ
M%DH&*$CEQZ,3RSC9S1UA8,Z=VZA#!_HZ].P3_5),/#SR!G==IQL'[^-*33 5
M7'%#0%R[)=L9H0X5C?TNL=[UQ(EYS\ /3[=6- M",Z<1-1 ";155DG!92QGM
M WQM].I2\8TY=2;*PW-)W=P\?GU\2'4H?EG,E\M_SA;5Y"%E_?DE6AJZNILO
MJL^3O]JM;,WZ#A%_S)3V'@.,#>(RVC<[S%39.+VK968_RA@S@7^-O_5%X!=]
M!XF%( X"#)&6EGGC=U81TSZKQE/SLUZY(?"LND_C_9D(G*.,$1#X:_3NDQAF
MOFQI03[O(1 JI8&:>9"NX"35!CZY_5KG[/,C+!8Q#!4S !\^8O#5:?851@P2
M ITP B@AK8002:(V!ZV"(4]!H["1TLM .O'Y;;+JPJ/<WU6@P"E+XL ,AQAA
MZ"GE-2H2\BM^(]H-61HO#YW@/_S&]%*,5"5D.GL_J_Y/-5GL<DIUP,_]'0>I
M;4I'0]/K-L_B-BX%JM$"/"_A\1C9VA^=6O*V$[V,FL7YEE?3S@./"O%>>@:!
MY!  #K<Y*1-J0.9$@UR8BSL&-N?H9FR,5G?1R(YR??ZRF#_>?_'3[VL1EUTN
MT2>_(QCE9*K^1"'G@!!EJ24UAM3BHH^^?TI^=ZVB2Z%YUVMXH^\)  %"@3 <
M>4 PP5Z!6IL\+B4Y<>FCC-&Z&+KGJ*EU!,19@VZT0'?1;=0!82E_DB*(.R&B
MP-LTCX()K+*"<$89\-4[20?02F%.GEI-N^HZ>&VAIH8IPI0GR% ":B]"6.ES
MJLZ-,D!LS-S,T<SP9D*[RW!HM> .1YL?208)CK8_KJ7DMED9C,ZJ'LY7DX?+
M9E_GB _%JY?/4E[,C'6"]#/8=JJKH!/( %!,'20*IXQRM4$N%&<L@X/G5R>\
M7@YVK(?A[V]>72A=X?V-<(09J7W4"]>,0V'(=JW@%EC?Z.RWH9WT83&_J:K;
MI8^$?8J0?<69PX*=W4=(9:^ I$@+Z U 1&M*:]D8Q%=7,*AKE<_+ %]J WHN
M0EJMU@GUUVOACV-QD4?F6,L>@Y9 :JVA@0XJ)+&I$]\D?(PI&A_87]Q C[R9
M#Z&'X0WP=3#.QV>Q9.U,\K?=!$((M)XBI"@B"%'.MB&_$0F+?,X#D%%=FI3C
M9(_PCXR(*2:LI7.XIY^@+9#  JHI-O'_0!S<;GLBT.7XBZ.*\!L=%5OA/[R-
MG@K@/$X>KC\Y&Q'4.LXEMSAJ!'EE'/5$Z4@Y+DVS<BH-3?5]<&]Q/F6A-V@:
M! $4,@+3;0$BREBD6"V)5^#G3*_66+WS7M$NM;FD->YIT+6Y9M?Y2I8WB^FW
MI-@CDZ91^^#CR@B0T.DX#!/#J-&\EMU0F?/>850N8/=DV)/ENFNX6]^XO$]Y
M)J;W7U:+ZGN:OHM= 8#)K@# MVIQ$_\[OUN?MTT.%5?/ZB]X*P C6 &BD*!8
M"J#P5EZAC"YJ-O?LR/5!KI+@9USO58O)??7D4.ZKPG?X J]!XZ QIYA![KF4
MT !M/5>U)%:PJPGIZ9=(?6 ]&O/V)WA)8$%4,R+4"JVT@] 0O?8[)++0\T9Q
MFWWG1="/R^FL6B[5S?\\3I?3I.JE_O'LM^8IB)MU%:"TRG)K*-'(&F"]W!Y1
M)53HM1P5]D65@ZD1>D&_E.E<+B$QPM(SX:*L#D07Q".^C:")\DLGK\Q1ZX\>
M+?,2GP?_B.C785YB["TESFL,G"2869TRH6PQ<-I=6>W/SIG1.B_Q>;BWMJX_
MK5**TOOIS;-U_G@RJ\,M E:468^0I])3:[VP"M5CII!>64G/'G0Y[P/G4NO2
MGD7[UP;9JHXU"W%A!Q"DP-%H9DB<8DC93E))KL3!+[X!=HAYERO/A_EB=3=_
MF,[/6'MV;8(TEBGL%)""6<N8\)#6XQ:.%BUW7B+<I!LEGEARVL([H..^GAK+
ME\.Y0G]=$ 6(<)(QI574+:[G/K4.&=SHGK9O?_U(>;YTKJ+C]__9R%MOTE'@
M$B)'(M.5U9C%19%S7B,"%+NZ$@A=$^6@M]X#^L/'4#0A8(/603&AD"!>.4AE
MRCV+\$YN:<$5%Y+NA77=0UZ*:L]0,.F.9'HWK6[U#S.?K1%YG#P\O[9KO CF
M=!L(P4 H"B "F!**F=2T1DH(!:[E9J,0.0OJHA1KGP?"I0BD][-G0C8FZ1F]
M!*OB_(788JT@ 11PK4V- T3PBFM?]\+)_J O9,/_\CA93&:K:D";_6D(#>SS
MMQ\.3*<TO5%=TG@6IS8U9G,API!7GC0*<^E;LB;3>,^G@T*:6T5,I".3BFO)
M"*]E@]!<7:[F'/7.NX:ST!1\-XL_II22@_K-VS'8Z?+F8;Y\7#2I6GZD51!4
M(J:DXW'7-8 #J]5VPZ7(>37@K-PSZF:FX.%F 6HHK:0 2 &@B@9&7-EK:2%A
M5Y?TNA/-O['O.@.X_,S=!JQ<T02&R#G*K-4<:6 DTFJ;QX<;H:T<\(AK,^ID
M;J67 \G^G\X>I[/[]]^JQ5J/S0[ZFG82$-<81KM0*>>(-M%^ Z!&0AE_9;>P
MG7!B[]3N >QRQPNG!-@DAGZV(OPVG<V3,_HNVB!1^>F&\F4OF_O*WZK5E_GM
MN8?4Q4<3(%16$@FMC2JG0$5#"M9Z =I=68GD/@A[]IP86HDCGEPV_K!<36^Z
MG21UKX$A91R."YJC'CN(-:.NQ@E+>F6UZ$?-Q/Q9TU*K(V:_C[].[X^%F+7O
M- "&K3(( \[3*1@F3IF=9H#)21<SPJB/*^=^.Z6.F/IMP1^'-14X4L CD\I!
M2)YJ-OEM^I&H!XA@CBMQ]I50_[F8KGQR%6)!V=D8)7-_?:MFRTI7L^INNLKR
MK\_J+2"*)6 ,I0 &SSQ2#J+=!BUTSN7416X]'?D8?2JA%#FW)8>[Y6C[3@,V
M"!EOK7( ,&,B8G(WA8445Q9MW2N/Y@,II3!U?16U.WEX(]%I?AYJ&:R V#&!
M*/(>*Z<IW>UU4@!Y90>3)8BQGXL=*: PX3Y%I:9L8+]&O;>AW?'VP4AK?3H#
MAM"PY%9+9VO9/84YT4TCW*R'(U^G:BB]YFW<SS9KWH&6@0A"M!7*"<@<XIYZ
M4A_B2&)ASCGT^1[4%=.N(P6,PSYL;0,&1P6F1'*N!"-"  Y4;<7$F2:+QLOU
M[[ /1[=N\"^7OVFCMF[=D8Q> P62.$>!$XHQ!2,V0-4X.25RLJB,<#<NZ8^4
MTTII]F[-VO/7S&8=!*0-L X0[IPB&E#AH*^EQS#+0ARA>U*$)P>XV:DB2M/P
MA8';GHQ-N@D&,"PIA-3*"(8'!K$=$L"J*ULFAZ1D#^HHOCYN3.",]?%H!X%"
M! B3!A,ITLVT<4S7TAL@BV8^NVXR=JJ(D1B9[0W)P*#WJ>1(M(><$]YB:=E6
M7H4)R"'>")V:(8G7C08&O@$\_Y8O>8/15Z/$<@:UA5$J;W?R<9-35?LB[[G[
MNLD[$^C!XN*'3%#>=6 \TYY"39RGQA.#,$=\LR90;7C<0(8+C#?SK]_FLQ1B
MD)(B;:9(E$&M4\8F6VPZ^6/Z<*K64$9O 4DKO";6I3\I@YAN(QLB-I)X<ETN
M7R<L>7T>UCOJI>V7W>CC#R;^'K?<R6+QXVZ^^/=D<7LL,JMA#T%RAC""$FFO
M*>*6:*5K^2U"5Q:;WBM##M@QW6I@, :F(*Q9U/V/<TBW:Q28B]NVH%Y!+3%P
MD,2?ME+&3=?G\&R$IP>#\JPMZ(-1ZY?Y_/;?TX>'=1#@:C*[G_[Q4*E#F??;
M=!,\\<QYCHR6C#$4\?!FAP2D.9OK",\+!J5?=VH8C)!;YV-VG_R2UCONX5Z"
MLEQ*KIP"46P)D36R!ML2:',>"IQ_BG#==.Q,"T/:?O7?;3W8!&C\[T;UL]NM
M0[O\]"6J0T^6J7+NTP<.U(GO\^N"2[.<>*XYBY:[H-9R7R/+K,C):$?_YO?
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M$ZU [U6$(<*^E]PET:U]ENZ[H=N $'=>PS[,KQ=5<<\;,UDL'N(^O3UK-C+
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M1"OH=AHGNKGI6*KYS=_*\N;/Z>Q\13_K"<2YO)Q>J_VDU7M"5()E"-BH'2F
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MZ=1)]8=XU!>^V5GUSW+Q[P_S+XORNEBVI]7AT0%Q"K&-PL;S/H'"0T-$+;<
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M@W$'7(3Z@C@7D?Z81*SFQ>+A*0RGB'1X4!#""2H(113',Q)00#E92PFANK
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M&0YSPFO8D&8I)3-&>7^89RWJ >I<)*H_@2/$J1\)WEJ+I1:202N%Q<Q#6DN
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M3 I9F\<&7RQ9SZ2F\]!V_Y4-0MK]VP,6THEH]& @#+8&:,#V>XM!*B6\HWD
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M_1M+*,("//%\-?@^R'],1CN0P0)5AC&@#%#.6:2Y,/<FHU?G%M/6#\@M..=
MNAX[Q+]+A:WQQ?A+YB67PC-DF1=*46Z@-T9;93GS[:K%E(OQWW*,_O'KY+_G
MBP<;;+.PVK?K$M%_X-N#1!9[+!F3F"G$%174U+0S5)Q9NZQ\%FH1OS\L!,7/
M!G^IYE\6DV]?IY>3F[;G@D_'!*.1!5(Q1X WFAAO#:G7Z!1[!7'[@W'%KA/
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ME&JN 6]6K57."<J(]H,>L'H)]4ZT[(S[@P]?S':'U>U\-GC(A?>"4)UT(E6
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M*-0HFF^,:^I]"IC84$]PF-,1L7U'D==G5!\%O6/'RAVOS>]8@^6L  8*:HT
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MQ?8$J>\?&85=,($,@DI J3A33+GM&JBV)J>#]@B9Z;AL,!\2FM%HT",'EVF
MN1?>D:@:$)&6488:JGF:4V1K1)>WX]GUBT,VB![=%US69FPJ"@$HQ Y!8*RQ
M6+%M)GU<AZ+\;&)KC@%]6]W9$8S1:\^3K&OCE(<\95M;B:D%4GNH:@P(!>?7
MYZ%?SCQ:=9O#<#M]V1E?B7F=PIDT<A13;#CBT:YL$!"2T9)6S. 7:2<J-5F0
MG;[0C*^DM;<6*<\14$@XP93@V-<(8)G5);A])%JI.J G*C19D)V^T(RUA*[S
MA"NJ'67>,,REAX#4.$255J:_PIOH#(K:Z4O/&'T<P'"J4&&PMD13A3 7NL$
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M_*M:M6U9\?S3 4"KI60:.\"1,R:J]EJH'?6^:*;!*(JJ#PKXO&] .C//2_T
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M;>*<>;DX1MF^G)W\2,7VS>3F\FZ3RW%QO:U1;&[FR^GLRV9S6DSWGT<=\JZ
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MF_$AKAI3C(UAEG,ND+* - I;XYP A1&=T UI@P] YG+F5A.\=XB=M6M0(!Q
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M<[*L_O__^5]02P$"% ,4    "  S@T)*W_8PD7LY! #92DL $0
M    @ $     8FEI8BTR,#$V,3(S,2YX;6Q02P$"% ,4    "  S@T)*IOF,
M^%\F  #LZ@$ $0              @ &J.00 8FEI8BTR,#$V,3(S,2YX<V10
M2P$"% ,4    "  S@T)*6.M,N%0S   T2@( %0              @ $X8 0
M8FEI8BTR,#$V,3(S,5]C86PN>&UL4$L! A0#%     @ ,X-"2HD]-_DQR0
MYA * !4              ( !OY,$ &)I:6(M,C Q-C$R,S%?9&5F+GAM;%!+
M 0(4 Q0    ( #.#0DIYV,L:R,D! 'OU%P 5              "  2-=!0!B
M:6EB+3(P,38Q,C,Q7VQA8BYX;6Q02P$"% ,4    "  S@T)*VCJ(]I<L 0"3
M8 \ %0              @ $>)P< 8FEI8BTR,#$V,3(S,5]P<F4N>&UL4$L%
3!@     &  8 B@$  .A3"     $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
